Torsade O O 0.9987460374832153
de O O 0.9997530579566956
pointes O O 0.9986408352851868
ventricular O O 0.9999065399169922
tachycardia O O 0.9999420642852783
during O O 0.9997420907020569
low O O 0.9998047947883606
dose O O 0.9981784820556641
intermittent O O 0.9804136157035828
dobutamine B B 0.9998123049736023
treatment O O 0.9997368454933167
in O O 0.9999698400497437
a O O 0.999988317489624
patient O O 0.9999949932098389
with O O 0.9999781847000122
dilated O O 0.9999148845672607
cardiomyopathy O O 0.9999945163726807
and O O 0.9999620914459229
congestive O O 0.9929242134094238
heart O O 0.9999899864196777
failure O O 0.9999842643737793
. O O 0.999968409538269

The O O 0.9999932050704956
authors O O 0.9999985694885254
describe O O 0.9999980926513672
the O O 0.9999974966049194
case O O 0.9999957084655762
of O O 0.9999932050704956
a O O 0.9999938011169434
56 O O 0.9999958276748657
- O O 0.9999873638153076
year O O 0.9999963045120239
- O O 0.9999939203262329
old O O 0.9999958276748657
woman O O 0.9999979734420776
with O O 0.9999725818634033
chronic O O 0.9999641180038452
, O O 0.9999901056289673
severe O O 0.999977707862854
heart O O 0.9999969005584717
failure O O 0.9999980926513672
secondary O O 0.9999825954437256
to O O 0.9998650550842285
dilated O O 0.9999194145202637
cardiomyopathy O O 0.9999932050704956
and O O 0.9999513626098633
absence O O 0.9999821186065674
of O O 0.9999829530715942
significant O O 0.9999632835388184
ventricular O O 0.9999727010726929
arrhythmias O O 0.9998643398284912
who O O 0.9999613761901855
developed O O 0.9999785423278809
QT O O 0.9850589036941528
prolongation O O 0.9996353387832642
and O O 0.9999604225158691
torsade O O 0.9997119307518005
de O O 0.9999257326126099
pointes O O 0.9996448755264282
ventricular O O 0.9999315738677979
tachycardia O O 0.9998581409454346
during O O 0.9999525547027588
one O O 0.9999942779541016
cycle O O 0.9999709129333496
of O O 0.9998893737792969
intermittent O O 0.9998482465744019
low O O 0.9998581409454346
dose O O 0.9993776679039001
( O O 0.9997344613075256
2 O O 0.9998767375946045
. O O 0.9999914169311523
5 O O 0.9999626874923706
mcg O O 0.9999803304672241
/ O O 0.9999790191650391
kg O O 0.9999923706054688
per O O 0.9999738931655884
min O O 0.9999490976333618
) O O 0.9964436888694763
dobutamine B B 0.9997184872627258
. O O 0.9999483823776245

This O O 0.9999860525131226
report O O 0.999992847442627
of O O 0.9999606609344482
torsade O O 0.9996495246887207
de O O 0.999845027923584
pointes O O 0.9998841285705566
ventricular O O 0.9998294115066528
tachycardia O O 0.9999139308929443
during O O 0.9995573163032532
intermittent O O 0.9993647933006287
dobutamine B B 0.9992234706878662
supports O O 0.9998716115951538
the O O 0.9999943971633911
hypothesis O O 0.9999852180480957
that O O 0.9999614953994751
unpredictable O O 0.9364169836044312
fatal O O 0.9998816251754761
arrhythmias O O 0.9999388456344604
may O O 0.9999721050262451
occur O O 0.9999945163726807
even O O 0.9998973608016968
with O O 0.9999562501907349
low O O 0.9999537467956543
doses O O 0.9999039173126221
and O O 0.9999901056289673
in O O 0.9999712705612183
patients O O 0.999994158744812
with O O 0.9999892711639404
no O O 0.9999831914901733
history O O 0.9999945163726807
of O O 0.9999864101409912
significant O O 0.9999792575836182
rhythm O O 0.9999676942825317
disturbances O O 0.9999948740005493
. O O 0.9999874830245972

The O O 0.9999533891677856
mechanisms O O 0.9999136924743652
of O O 0.9998874664306641
proarrhythmic O O 0.9948779344558716
effects O O 0.9998900890350342
of O O 0.9992827773094177
Dubutamine B B 0.9994986057281494
are O O 0.9997695088386536
discussed O O 0.9999493360519409
. O O 0.9999781847000122

Positive O O 0.9999088048934937
skin O O 0.9999473094940186
tests O O 0.9999936819076538
in O O 0.9999476671218872
late O O 0.9991644620895386
reactions O O 0.9999876022338867
to O O 0.9998038411140442
radiographic O O 0.999783456325531
contrast B O 0.9395499229431152
media I O 0.9811314344406128
. O O 0.9999253749847412

In O O 0.999969482421875
the O O 0.9999921321868896
last O O 0.9999938011169434
few O O 0.9999955892562866
years O O 0.99998939037323
delayed O O 0.9999592304229736
reactions O O 0.9999728202819824
several O O 0.9999923706054688
hours O O 0.9999926090240479
after O O 0.9999614953994751
the O O 0.99998939037323
injection O O 0.9999822378158569
of O O 0.9999419450759888
radiographic O O 0.9998098015785217
and O O 0.9997556805610657
contrast B O 0.9305912256240845
materials I O 0.999828577041626
( O O 0.9992774128913879
PRC B O 0.623822808265686
) O O 0.9998007416725159
have O O 0.9999860525131226
been O O 0.9999916553497314
described O O 0.9999934434890747
with O O 0.9999903440475464
increasing O O 0.9999933242797852
frequency O O 0.9999960660934448
. O O 0.9999785423278809

The O O 0.9999828338623047
authors O O 0.999997615814209
report O O 0.9999961853027344
two O O 0.9999960660934448
observations O O 0.9999985694885254
on O O 0.9999746084213257
patients O O 0.9999892711639404
with O O 0.9999839067459106
delayed O O 0.9998983144760132
reactions O O 0.9999890327453613
in O O 0.9999282360076904
whom O O 0.9999417066574097
intradermoreactions O O 0.9968069791793823
( O O 0.9977860450744629
IDR O O 0.5627809166908264
) O O 0.9998544454574585
and O O 0.999940037727356
patch O O 0.9997355341911316
tests O O 0.9999897480010986
to O O 0.999247670173645
a O O 0.9998151659965515
series O O 0.9537644386291504
of O O 0.9975983500480652
ionic O O 0.7137904763221741
and O O 0.999154806137085
non O O 0.9754205346107483
ionic O O 0.6920992136001587
PRC B O 0.7379921674728394
were O O 0.9997174143791199
studied O O 0.999933123588562
. O O 0.9999295473098755

After O O 0.999962568283081
angiography O O 0.9999827146530151
by O O 0.9999524354934692
the O O 0.9999839067459106
venous O O 0.9998981952667236
route O O 0.9999878406524658
in O O 0.9999227523803711
patient O O 0.9999557733535767
n O O 0.978008508682251
degree O O 0.9929232597351074
1 O O 0.9998737573623657
a O O 0.9998832941055298
biphasic O O 0.9970622658729553
reaction O O 0.9999933242797852
with O O 0.9999065399169922
an O O 0.9998914003372192
immediate O O 0.9999607801437378
reaction O O 0.9999978542327881
( O O 0.9999521970748901
dyspnea O O 0.9999984502792358
, O O 0.9999821186065674
loss O O 0.9999991655349731
of O O 0.9999936819076538
consciousness O O 0.9999967813491821
) O O 0.9999747276306152
and O O 0.9999518394470215
delayed O O 0.9998806715011597
macro O O 0.9995784163475037
- O O 0.9973581433296204
papular O O 0.9957131147384644
rash O O 0.9999887943267822
appeared O O 0.9999911785125732
, O O 0.9999704360961914
whilst O O 0.9999657869338989
patient O O 0.9999687671661377
n O O 0.9810749888420105
degree O O 0.996207594871521
2 O O 0.9997285008430481
developed O O 0.9999799728393555
a O O 0.9999842643737793
generalised O O 0.9999728202819824
sensation O O 0.9999979734420776
of O O 0.9999668598175049
heat O O 0.9661253094673157
, O O 0.9999697208404541
persistent O O 0.99997878074646
pain O O 0.9999936819076538
at O O 0.9999847412109375
the O O 0.9999922513961792
site O O 0.999993085861206
of O O 0.9999358654022217
injection O O 0.9998462200164795
immediately O O 0.9999340772628784
and O O 0.9999738931655884
a O O 0.9999804496765137
generalised O O 0.9999226331710815
macro O O 0.9998863935470581
- O O 0.9984258413314819
papular O O 0.9985730648040771
reaction O O 0.9999948740005493
after O O 0.9999545812606812
24 O O 0.9999836683273315
hours O O 0.9999896287918091
. O O 0.9999774694442749

The O O 0.9999738931655884
skin O O 0.9999754428863525
tests O O 0.9999843835830688
revealed O O 0.9999560117721558
positive O O 0.9999064207077026
delayed O O 0.999817430973053
reactions O O 0.9999910593032837
of O O 0.9999240636825562
24 O O 0.9999593496322632
hours O O 0.9999929666519165
and O O 0.9999185800552368
48 O O 0.9999908208847046
hours O O 0.9999909400939941
by O O 0.999903678894043
IDR O O 0.6634561419487
and O O 0.9996566772460938
patch O O 0.9989456534385681
tests O O 0.9999363422393799
to O O 0.9997912049293518
only O O 0.9996256828308105
some O O 0.998948872089386
PRC B O 0.9801787734031677
with O O 0.9998812675476074
common O O 0.9833889603614807
chains O O 0.9981721639633179
in O O 0.9999573230743408
their O O 0.9999575614929199
structures O O 0.9999943971633911
. O O 0.9999626874923706

The O O 0.9999815225601196
positive O O 0.9999600648880005
skin O O 0.9998914003372192
tests O O 0.9999816417694092
are O O 0.9999650716781616
in O O 0.9999486207962036
favour O O 0.9998974800109863
of O O 0.9998026490211487
immunological O O 0.9987282156944275
reactions O O 0.9999663829803467
and O O 0.99993896484375
may O O 0.9999679327011108
help O O 0.9999818801879883
in O O 0.999990701675415
diagnosis O O 0.9999957084655762
of O O 0.9999579191207886
allergy O O 0.9996638298034668
in O O 0.9999604225158691
the O O 0.9999827146530151
patients O O 0.9999864101409912
. O O 0.9999656677246094

Risk O O 0.9999864101409912
of O O 0.999976634979248
transient O O 0.9999860525131226
hyperammonemic O O 0.9996271133422852
encephalopathy O O 0.9999392032623291
in O O 0.9999499320983887
cancer O O 0.9996209144592285
patients O O 0.9999814033508301
who O O 0.9999645948410034
received O O 0.9999333620071411
continuous O O 0.999804675579071
infusion O O 0.9999411106109619
of O O 0.9971936345100403
5 B B 0.9588460922241211
- I I 0.9959591031074524
fluorouracil I I 0.9999903440475464
with O O 0.9996687173843384
the O O 0.9999897480010986
complication O O 0.9999938011169434
of O O 0.999974250793457
dehydration O O 0.9999619722366333
and O O 0.99994957447052
infection O O 0.9999946355819702
. O O 0.9999765157699585

From O O 0.9999470710754395
1986 O O 0.9999203681945801
to O O 0.9999675750732422
1998 O O 0.9999903440475464
, O O 0.999982476234436
29 O O 0.9995984435081482
cancer O O 0.999872088432312
patients O O 0.9999834299087524
who O O 0.9999220371246338
had O O 0.9999715089797974
32 O O 0.999985933303833
episodes O O 0.9999924898147583
of O O 0.9999781847000122
transient O O 0.9999788999557495
hyperammonemic O O 0.9993528723716736
encephalopathy O O 0.9998948574066162
related O O 0.9999850988388062
to O O 0.9998369216918945
continuous O O 0.9996798038482666
infusion O O 0.9999068975448608
of O O 0.9969062209129333
5 B B 0.9759045243263245
- I I 0.9937048554420471
fluorouracil I I 0.9999845027923584
( O O 0.9891743659973145
5 B B 0.9786433577537537
- I I 0.9730969071388245
FU I I 0.9999839067459106
) O O 0.9979312419891357
were O O 0.9999828338623047
identified O O 0.9999921321868896
. O O 0.9999730587005615

None O O 0.9997988343238831
of O O 0.9999613761901855
the O O 0.9999779462814331
patients O O 0.99997878074646
had O O 0.9999566078186035
decompensated O O 0.9999221563339233
liver O O 0.9925222992897034
disease O O 0.9999958276748657
. O O 0.99994957447052

Onset O O 0.9999861717224121
of O O 0.9999771118164062
hyperammonemic O O 0.9991360306739807
encephalopathy O O 0.9999121427536011
varied O O 0.999996542930603
from O O 0.9999885559082031
0 O O 0.9999865293502808
. O O 0.999994158744812
5 O O 0.9999911785125732
to O O 0.9999775886535645
5 O O 0.999984622001648
days O O 0.9999946355819702
( O O 0.9999692440032959
mean O O 0.99998939037323
: O O 0.9999896287918091
2 O O 0.99997878074646
. O O 0.9999933242797852
6 O O 0.9999910593032837
+ O O 0.9999921321868896
/ O O 0.9999856948852539
- O O 0.9999673366546631
1 O O 0.9999898672103882
. O O 0.9999948740005493
3 O O 0.9999939203262329
days O O 0.9999969005584717
) O O 0.9999889135360718
after O O 0.9999905824661255
the O O 0.9999957084655762
initiation O O 0.9999909400939941
of O O 0.9999527931213379
chemotherapy O O 0.9993934631347656
. O O 0.9999758005142212

Plasma O O 0.9990748167037964
ammonium B B 0.9985925555229187
level O O 0.999413013458252
ranged O O 0.9999669790267944
from O O 0.9999754428863525
248 O O 0.9869312644004822
to O O 0.9999728202819824
2387 O O 0.5374982357025146
microg O O 0.9714637398719788
% O O 0.9998364448547363
( O O 0.9999617338180542
mean O O 0.9999803304672241
: O O 0.9999890327453613
626 O O 0.9999908208847046
+ O O 0.999990701675415
/ O O 0.9999513626098633
- O O 0.9999521970748901
431 O O 0.9998787641525269
microg O O 0.9986164569854736
% O O 0.999891996383667
) O O 0.9999710321426392
. O O 0.9999778270721436

Among O O 0.9998767375946045
the O O 0.9999802112579346
32 O O 0.999983549118042
episodes O O 0.9999822378158569
, O O 0.9999297857284546
26 O O 0.9999843835830688
( O O 0.9999425411224365
81 O O 0.9999672174453735
% O O 0.9999954700469971
) O O 0.9999566078186035
had O O 0.9999715089797974
various O O 0.9999674558639526
degrees O O 0.999996542930603
of O O 0.999971866607666
azotemia O O 0.9981459379196167
, O O 0.9999669790267944
18 O O 0.9998601675033569
( O O 0.9999312162399292
56 O O 0.9999895095825195
% O O 0.9999954700469971
) O O 0.9999463558197021
occurred O O 0.9999912977218628
during O O 0.9999294281005859
bacterial O O 0.9991053938865662
infections O O 0.9999673366546631
and O O 0.9999481439590454
14 O O 0.9999706745147705
( O O 0.9999377727508545
44 O O 0.9999924898147583
% O O 0.9999947547912598
) O O 0.9999568462371826
without O O 0.9999250173568726
infection O O 0.9999827146530151
occurred O O 0.9999855756759644
during O O 0.9998761415481567
periods O O 0.9999829530715942
of O O 0.9999675750732422
dehydration O O 0.9998828172683716
. O O 0.9999591112136841

Higher O O 0.9999144077301025
plasma O O 0.9996019005775452
ammonium B B 0.9986628293991089
levels O O 0.9998975992202759
and O O 0.9999796152114868
more O O 0.9999793767929077
rapid O O 0.999996542930603
onset O O 0.9999967813491821
of O O 0.9999765157699585
hyperammonemia O O 0.9994427561759949
were O O 0.999981164932251
seen O O 0.9999943971633911
in O O 0.9999407529830933
18 O O 0.9999352693557739
patients O O 0.9999948740005493
with O O 0.9999779462814331
bacterial O O 0.9999197721481323
infections O O 0.9999927282333374
( O O 0.9999704360961914
p O O 0.9998070597648621
= O O 0.9998169541358948
0 O O 0.9999886751174927
. O O 0.999997615814209
003 O O 0.9999176263809204
and O O 0.99996018409729
0 O O 0.9999890327453613
. O O 0.9999986886978149
0006 O O 0.9998437166213989
, O O 0.9999921321868896
respectively O O 0.9999843835830688
) O O 0.9999821186065674
and O O 0.9999747276306152
in O O 0.9999517202377319
nine O O 0.9999878406524658
patients O O 0.999992847442627
receiving O O 0.9998430013656616
high O O 0.9999157190322876
daily O O 0.99997878074646
doses O O 0.9999792575836182
( O O 0.9999632835388184
2600 O O 0.9995506405830383
or O O 0.9999552965164185
1800 O O 0.9999899864196777
mg O O 0.9999871253967285
/ O O 0.9999897480010986
m2 O O 0.9999960660934448
) O O 0.99998939037323
of O O 0.9986959099769592
5 B B 0.8705030679702759
- I I 0.9830526113510132
FU I I 0.9999474287033081
( O O 0.9994184970855713
p O O 0.999921441078186
= O O 0.999976634979248
0 O O 0.9999920129776001
. O O 0.9999957084655762
0001 O O 0.9998849630355835
and O O 0.9999831914901733
< O O 0.9999935626983643
0 O O 0.9999958276748657
. O O 0.9999960660934448
0001 O O 0.9999284744262695
, O O 0.9999927282333374
respectively O O 0.9999850988388062
) O O 0.9999823570251465
. O O 0.9999804496765137

In O O 0.9999376535415649
25 O O 0.9999898672103882
out O O 0.9999922513961792
of O O 0.9999818801879883
32 O O 0.9999804496765137
episodes O O 0.9999750852584839
( O O 0.9999585151672363
78 O O 0.9999947547912598
% O O 0.9999946355819702
) O O 0.9999723434448242
, O O 0.9999704360961914
plasma O O 0.9799548983573914
ammonium B B 0.9981719255447388
levels O O 0.9995025396347046
and O O 0.9999700784683228
mental O O 0.9999978542327881
status O O 0.9999971389770508
returned O O 0.9999903440475464
to O O 0.9999951124191284
normal O O 0.9999939203262329
within O O 0.9999948740005493
2 O O 0.9999885559082031
days O O 0.999997615814209
after O O 0.9999909400939941
adequate O O 0.9999457597732544
management O O 0.9999896287918091
. O O 0.9999748468399048

In O O 0.9999241828918457
conclusion O O 0.9999650716781616
, O O 0.9998877048492432
hyperammonemic O O 0.999864935874939
encephalopathy O O 0.9998551607131958
can O O 0.9999518394470215
occur O O 0.9999938011169434
in O O 0.9999603033065796
patients O O 0.9999874830245972
receiving O O 0.9998447895050049
continuous O O 0.9997827410697937
infusion O O 0.9999550580978394
of O O 0.9988555908203125
5 B B 0.9315409064292908
- I I 0.9767533540725708
FU I I 0.9999672174453735
. O O 0.9997308850288391

Azotemia O O 0.998149037361145
, O O 0.999862551689148
body O O 0.9998968839645386
fluid O O 0.9672746062278748
insufficiency O O 0.999901533126831
and O O 0.9996639490127563
bacterial O O 0.9997755885124207
infections O O 0.9999642372131348
were O O 0.9999537467956543
frequently O O 0.9999721050262451
found O O 0.9999836683273315
in O O 0.9999551773071289
these O O 0.9999425411224365
patients O O 0.9999852180480957
. O O 0.9999446868896484

It O O 0.999984622001648
is O O 0.9999830722808838
therefore O O 0.9999901056289673
important O O 0.9999903440475464
to O O 0.9999934434890747
recognize O O 0.9999903440475464
this O O 0.9999626874923706
condition O O 0.9999896287918091
in O O 0.9999628067016602
patients O O 0.9999891519546509
receiving O O 0.9998433589935303
continuous O O 0.9997687935829163
infusion O O 0.9999663829803467
of O O 0.9983237385749817
5 B B 0.8939050436019897
- I I 0.9748224020004272
FU I I 0.9999614953994751
. O O 0.9997231364250183

The O O 0.999936580657959
effects O O 0.9999357461929321
of O O 0.9985635876655579
quinine B B 0.9987467527389526
and O O 0.7695232629776001
4 B B 0.9199318289756775
- I I 0.9988595247268677
aminopyridine I I 0.9999644756317139
on O O 0.9996463060379028
conditioned O O 0.9965102076530457
place O O 0.9999713897705078
preference O O 0.9999912977218628
and O O 0.9999669790267944
changes O O 0.999994158744812
in O O 0.9999834299087524
motor O O 0.9999910593032837
activity O O 0.9999946355819702
induced O O 0.999985933303833
by O O 0.9999217987060547
morphine B B 0.9998059868812561
in O O 0.9998733997344971
rats O O 0.9999552965164185
. O O 0.9999402761459351

1 O O 0.9998971223831177
. O O 0.9998472929000854

The O O 0.9999667406082153
effects O O 0.9999712705612183
of O O 0.9998990297317505
two O O 0.9990705847740173
unselective O O 0.9695739150047302
potassium B B 0.9764440059661865
( O O 0.5115599632263184
K B B 0.91631680727005
( O O 0.5158780217170715
+ O O 0.9761530160903931
) O O 0.990696907043457
- O O 0.979413628578186
) O O 0.9655747413635254
channel O O 0.9863424897193909
blockers O O 0.971947968006134
, O O 0.9995243549346924
quinine B B 0.9990750551223755
( O O 0.9991195797920227
12 O O 0.9973467588424683
. O O 0.9999680519104004
5 O O 0.9998307228088379
, O O 0.9988622665405273
25 O O 0.9972549080848694
and O O 0.9989452958106995
50 O O 0.9998924732208252
mg O O 0.9998308420181274
/ O O 0.9999061822891235
kg O O 0.9999624490737915
) O O 0.9999115467071533
and O O 0.9945433139801025
4 B B 0.9541603922843933
- I I 0.9989790916442871
aminopyridine I I 0.9999397993087769
( O O 0.9991911053657532
1 O O 0.9990474581718445
and O O 0.9997842907905579
2 O O 0.9998927116394043
mg O O 0.9998487234115601
/ O O 0.9999595880508423
kg O O 0.9999761581420898
) O O 0.9999685287475586
, O O 0.9999808073043823
on O O 0.9998238682746887
conditioned O O 0.9889984726905823
place O O 0.9999819993972778
preference O O 0.9999939203262329
and O O 0.9999736547470093
biphasic O O 0.9939403533935547
changes O O 0.9999957084655762
in O O 0.999988317489624
motor O O 0.9999964237213135
activity O O 0.999996542930603
induced O O 0.9999910593032837
by O O 0.9998854398727417
morphine B B 0.9997650980949402
( O O 0.9998775720596313
10 O O 0.9996466636657715
mg O O 0.9996986389160156
/ O O 0.9998186230659485
kg O O 0.999948263168335
) O O 0.9999830722808838
were O O 0.9999841451644897
tested O O 0.9999853372573853
in O O 0.9999731779098511
Wistar O O 0.9993970394134521
rats O O 0.9999960660934448
. O O 0.9999735355377197

Quinine B B 0.9995043277740479
is O O 0.9998177886009216
known O O 0.9996763467788696
to O O 0.9997809529304504
block O O 0.9989479184150696
voltage O O 0.5210000276565552
- O O 0.9904526472091675
, O O 0.99882572889328
calcium B B 0.9897330403327942
- O O 0.9804114103317261
and O O 0.9976651668548584
ATP B B 0.9803050756454468
- O O 0.997266411781311
sensitive O O 0.9929037690162659
K B O 0.8464945554733276
( O O 0.8219040036201477
+ O O 0.7402345538139343
) O O 0.7050526142120361
- O O 0.9540626406669617
channels O O 0.9997507929801941
while O O 0.9993682503700256
4 B B 0.995225191116333
- I I 0.9969844222068787
aminopyridine I I 0.9999676942825317
is O O 0.9997487664222717
known O O 0.9998623132705688
to O O 0.9998921155929565
block O O 0.9995459914207458
voltage O B 0.9185642600059509
- O O 0.9976264834403992
sensitive O O 0.993648111820221
K B B 0.9148178696632385
( O O 0.7200168371200562
+ O O 0.9526945352554321
) O O 0.9608631134033203
- O O 0.9909707307815552
channels O O 0.9998586177825928
. O O 0.9998698234558105

2 O O 0.9993448853492737
. O O 0.9999009370803833

In O O 0.999900221824646
the O O 0.9999428987503052
counterbalanced O O 0.9986879229545593
method O O 0.9999881982803345
, O O 0.9996380805969238
quinine B B 0.9995765089988708
attenuated O O 0.9997183680534363
morphine B B 0.9997816681861877
- O O 0.9999209642410278
induced O O 0.9999480247497559
place O O 0.9999873638153076
preference O O 0.9999970197677612
, O O 0.9999537467956543
whereas O O 0.9999130964279175
4 B B 0.9964691400527954
- I I 0.999314546585083
aminopyridine I I 0.9999673366546631
was O O 0.999786913394928
ineffective O O 0.9998224377632141
. O O 0.9999691247940063

In O O 0.9999524354934692
the O O 0.999945878982544
motor O O 0.9999170303344727
activity O O 0.999843955039978
test O O 0.9999761581420898
measured O O 0.9999830722808838
with O O 0.9999393224716187
an O O 0.8110029101371765
Animex O O 0.7121376991271973
- O O 0.7370423078536987
activity O O 0.6505330204963684
meter O O 0.9994876384735107
neither O O 0.9997195601463318
of O O 0.9970663189888
the O O 0.998702883720398
K B B 0.8648181557655334
( O O 0.6825041174888611
+ O O 0.6706762909889221
) O O 0.6982876658439636
- O O 0.8132434487342834
channel O O 0.9239130020141602
blockers O O 0.8973383903503418
affected O O 0.9994105100631714
morphine B B 0.999723494052887
- O O 0.9999127388000488
induced O O 0.9999326467514038
hypoactivity O O 0.9998794794082642
, O O 0.9999476671218872
but O O 0.9996695518493652
both O O 0.9912294149398804
K B O 0.8576722145080566
( O O 0.4970918595790863
+ O O 0.9327800869941711
) O O 0.9286713004112244
- O O 0.9434419274330139
channel O O 0.9636123776435852
blockers O O 0.956078290939331
prevented O O 0.9997419714927673
morphine B B 0.9998326301574707
- O O 0.9999258518218994
induced O O 0.9999425411224365
secondary O O 0.999862551689148
hyperactivity O O 0.9999336004257202
. O O 0.9999409914016724

3 O O 0.9850600361824036
. O O 0.9998869895935059

These O O 0.9999758005142212
results O O 0.9999747276306152
suggest O O 0.9998791217803955
the O O 0.9999734163284302
involvement O O 0.9999282360076904
of O O 0.9997290968894958
quinine B B 0.9981313347816467
- O O 0.9993098974227905
sensitive O O 0.9988633394241333
but O O 0.9999325275421143
not O O 0.9998095631599426
4 B B 0.9047950506210327
- I I 0.9703733921051025
aminopyridine I I 0.9999375343322754
- O O 0.9984421133995056
sensitive O O 0.9948379397392273
K B B 0.9655762910842896
( O O 0.5730462670326233
+ O O 0.9874861836433411
) O O 0.9891003966331482
- O O 0.9878708720207214
channels O O 0.9974270462989807
in O O 0.9997971653938293
morphine B B 0.9997910857200623
reward O O 0.9998875856399536
. O O 0.9999433755874634

It O O 0.9999905824661255
is O O 0.9999792575836182
also O O 0.9999839067459106
suggested O O 0.999992847442627
that O O 0.9997921586036682
the O O 0.9998886585235596
blockade O O 0.9996433258056641
of O O 0.9991693496704102
K B B 0.8897587656974792
( O O 0.6248512268066406
+ O O 0.8770158290863037
) O O 0.9282847046852112
- O O 0.9753300547599792
channels O O 0.9997181296348572
sensitive O O 0.9998396635055542
to O O 0.9991275668144226
these O O 0.6906841993331909
blockers O O 0.6644498109817505
is O O 0.9999388456344604
not O O 0.9999548196792603
sufficient O O 0.9999197721481323
to O O 0.9999353885650635
prevent O O 0.999584972858429
morphine B B 0.9998134970664978
- O O 0.999521017074585
induced O O 0.9998949766159058
hypoactivity O O 0.999913215637207
whereas O O 0.9992547631263733
morphine B B 0.9998846054077148
- O O 0.9997527003288269
induced O O 0.9999221563339233
hyperactivity O O 0.9996373653411865
seems O O 0.9999444484710693
to O O 0.9998489618301392
be O O 0.9999446868896484
connected O O 0.9999709129333496
to O O 0.9997078776359558
both O O 0.9987859129905701
quinine B B 0.9947709441184998
- O O 0.997356653213501
and O O 0.9987978935241699
4 B B 0.9266085028648376
- I I 0.9828760027885437
aminopyridine I I 0.9999518394470215
- O O 0.9987953901290894
sensitive O O 0.9869411587715149
K B B 0.913925051689148
( O O 0.5806017518043518
+ O O 0.9803124070167542
) O O 0.9926748871803284
- O O 0.995331346988678
channels O O 0.9997044205665588
. O O 0.9999547004699707

Nociceptin B B 0.9977638721466064
/ O O 0.6805468797683716
orphanin B B 0.8175562620162964
FQ I I 0.9466969966888428
and O O 0.808588981628418
nocistatin B B 0.9942838549613953
on O O 0.9996984004974365
learning O O 0.999988317489624
and O O 0.9999281167984009
memory O O 0.9999935626983643
impairment O O 0.9999909400939941
induced O O 0.9999668598175049
by O O 0.9998738765716553
scopolamine B B 0.9993574023246765
in O O 0.9997944235801697
mice O O 0.9999691247940063
. O O 0.9998410940170288

1 O O 0.9998971223831177
. O O 0.9998472929000854

Nociceptin B B 0.9995330572128296
, O O 0.9998589754104614
also O O 0.9998582601547241
known O O 0.9998689889907837
as O O 0.9972854852676392
orphanin B O 0.7587964534759521
FQ I O 0.6677507162094116
, O O 0.9997237324714661
is O O 0.9998384714126587
an O O 0.9995812773704529
endogenous O O 0.9997184872627258
ligand O O 0.9716607928276062
for O O 0.9981985688209534
the O O 0.9992590546607971
orphan O O 0.7857828140258789
opioid O O 0.8809754848480225
receptor O O 0.9907388687133789
- O O 0.9982990622520447
like O O 0.9888818860054016
receptor O O 0.9992627501487732
1 O O 0.9980596899986267
( O O 0.998794674873352
ORL1 O O 0.9668475389480591
) O O 0.9998559951782227
and O O 0.9999115467071533
involves O O 0.9986103773117065
in O O 0.9998156428337097
various O O 0.9995788931846619
functions O O 0.9998998641967773
in O O 0.9998921155929565
the O O 0.9999077320098877
central O O 0.9995576739311218
nervous O O 0.9999912977218628
system O O 0.9999899864196777
( O O 0.999873161315918
CNS O O 0.970174252986908
) O O 0.9999457597732544
. O O 0.9999547004699707

On O O 0.9999580383300781
the O O 0.9999827146530151
other O O 0.9999761581420898
hand O O 0.9999926090240479
, O O 0.9996241331100464
nocistatin B B 0.9961709380149841
is O O 0.9997240900993347
recently O O 0.9998860359191895
isolated O O 0.9995852112770081
from O O 0.9997455477714539
the O O 0.9999728202819824
same O O 0.9997771382331848
precursor O O 0.9950050711631775
as O O 0.9991114735603333
nociceptin B B 0.9998093247413635
and O O 0.9998100399971008
blocks O O 0.9962561130523682
nociceptin B B 0.9997560381889343
- O O 0.9998266100883484
induced O O 0.9999161958694458
allodynia O O 0.9999876022338867
and O O 0.9999473094940186
hyperalgesia O O 0.9997966885566711
. O O 0.999955415725708

2 O O 0.9993448853492737
. O O 0.9999009370803833

Although O O 0.9889659285545349
ORL1 O O 0.6578919887542725
receptors O O 0.9993822574615479
which O O 0.9997749924659729
display O O 0.9998922348022461
a O O 0.9999791383743286
high O O 0.9999449253082275
degree O O 0.9999942779541016
of O O 0.9999666213989258
sequence O O 0.9999140501022339
homology O O 0.9998897314071655
with O O 0.9998706579208374
classical O O 0.9745231866836548
opioid O O 0.7015348672866821
receptors O O 0.9960122108459473
are O O 0.9998599290847778
abundant O O 0.9995935559272766
in O O 0.9995049238204956
the O O 0.9997745156288147
hippocampus O O 0.9991710186004639
, O O 0.9999505281448364
little O O 0.999990701675415
is O O 0.9999873638153076
known O O 0.9999899864196777
regarding O O 0.9999845027923584
their O O 0.9997650980949402
role O O 0.9999812841415405
in O O 0.9999295473098755
learning O O 0.9999915361404419
and O O 0.9999535083770752
memory O O 0.9999924898147583
. O O 0.9999803304672241

3 O O 0.9850601553916931
. O O 0.9998869895935059

The O O 0.9999914169311523
present O O 0.9999898672103882
study O O 0.9999881982803345
was O O 0.9999905824661255
designed O O 0.999996542930603
to O O 0.999995231628418
investigate O O 0.9999849796295166
whether O O 0.9999555349349976
nociceptin B B 0.9985697269439697
/ O O 0.7617926001548767
orphanin B B 0.7681014537811279
FQ I I 0.9792371988296509
and O O 0.915477454662323
nocistatin B B 0.9955776929855347
could O O 0.9998939037322998
modulate O O 0.9999746084213257
impairment O O 0.9999912977218628
of O O 0.9999333620071411
learning O O 0.9999918937683105
and O O 0.9999384880065918
memory O O 0.9999969005584717
induced O O 0.9999880790710449
by O O 0.9999068975448608
scopolamine B B 0.9997811913490295
, O O 0.9998778104782104
a O O 0.9992504715919495
muscarinic O O 0.8005817532539368
cholinergic O O 0.5358471274375916
receptor O O 0.9727920889854431
antagonist O O 0.9370821118354797
, O O 0.9999730587005615
using O O 0.9999549388885498
spontaneous O O 0.9999792575836182
alternation O O 0.999992847442627
of O O 0.9999583959579468
Y O O 0.9811111092567444
- O O 0.998573899269104
maze O O 0.9993422627449036
and O O 0.999916672706604
step O O 0.9999107122421265
- O O 0.9999799728393555
down O O 0.9997721314430237
type O O 0.9999527931213379
passive O O 0.9935163259506226
avoidance O O 0.9999699592590332
tasks O O 0.9999699592590332
in O O 0.9998788833618164
mice O O 0.9999423027038574
. O O 0.9999675750732422

4 O O 0.9273311495780945
. O O 0.9998733997344971

While O O 0.9994301199913025
nocistatin B B 0.9969921112060547
( O O 0.9963464140892029
0 O O 0.999724805355072
. O O 0.9999234676361084
5 O O 0.9997652173042297
- O O 0.9950732588768005
5 O O 0.9995501637458801
. O O 0.9999566078186035
0 O O 0.9973552227020264
nmol O O 0.998653769493103
mouse O O 0.9759212136268616
- O O 0.9877869486808777
1 O O 0.9938779473304749
, O O 0.9984776377677917
i O O 0.9975728392601013
. O O 0.9999912977218628
c O O 0.9999526739120483
. O O 0.9999940395355225
v O O 0.9998063445091248
. O O 0.9999833106994629
) O O 0.9999147653579712
administered O O 0.9998413324356079
30 O O 0.9999490976333618
min O O 0.9999802112579346
before O O 0.9999723434448242
spontaneous O O 0.9999827146530151
alternation O O 0.9990248680114746
performance O O 0.9999791383743286
or O O 0.9999864101409912
the O O 0.9999886751174927
training O O 0.9999898672103882
session O O 0.9999960660934448
of O O 0.9999779462814331
the O O 0.999976634979248
passive O O 0.9990528225898743
avoidance O O 0.9998286962509155
task O O 0.999967098236084
, O O 0.9999516010284424
had O O 0.9999644756317139
no O O 0.9999687671661377
effect O O 0.9999830722808838
on O O 0.9999432563781738
spontaneous O O 0.9999576807022095
alternation O O 0.9998842477798462
or O O 0.9998612403869629
passive O O 0.9998268485069275
avoidance O O 0.999961256980896
behaviours O O 0.9999749660491943
, O O 0.9999538660049438
a O O 0.9999233484268188
lower O O 0.9998507499694824
per O O 0.9999904632568359
cent O O 0.9999929666519165
alternation O O 0.9997362494468689
and O O 0.9998801946640015
shorter O O 0.9998692274093628
median O O 0.9929314851760864
step O O 0.9998785257339478
- O O 0.9999743700027466
down O O 0.9999494552612305
latency O O 0.9999793767929077
in O O 0.9999490976333618
the O O 0.9999185800552368
retention O O 0.9998788833618164
test O O 0.9999831914901733
were O O 0.999983549118042
obtained O O 0.9999911785125732
in O O 0.9997425675392151
nociceptin B B 0.9947255253791809
( O O 0.9946188926696777
1 O O 0.9993565678596497
. O O 0.999843955039978
5 O O 0.9997841715812683
and O O 0.999943733215332
/ O O 0.9999159574508667
or O O 0.9999750852584839
5 O O 0.9997815489768982
. O O 0.9999850988388062
0 O O 0.9978679418563843
nmol O O 0.9989677667617798
mouse O O 0.9675485491752625
- O O 0.9812912940979004
1 O O 0.9894695281982422
, O O 0.9994082450866699
i O O 0.9994077682495117
. O O 0.9999922513961792
c O O 0.9999823570251465
. O O 0.9999951124191284
v O O 0.9999362230300903
. O O 0.999984860420227
) O O 0.9921475052833557
- O O 0.9995958209037781
treated O O 0.9997158646583557
normal O O 0.9999191761016846
mice O O 0.9999977350234985
. O O 0.999962329864502

5 O O 0.9164367318153381
. O O 0.999748170375824

Administration O O 0.9999192953109741
of O O 0.9998711347579956
nocistatin B B 0.9942348599433899
( O O 0.9960648417472839
1 O O 0.9935850501060486
. O O 0.997887909412384
5 O O 0.998629093170166
and O O 0.9997227787971497
/ O O 0.9997720122337341
or O O 0.9999794960021973
5 O O 0.9995796084403992
. O O 0.9999557733535767
0 O O 0.9995478987693787
nmol O O 0.9994333386421204
mouse O O 0.9494240880012512
- O O 0.9920144081115723
1 O O 0.9906986355781555
, O O 0.9998910427093506
i O O 0.999891996383667
. O O 0.9999953508377075
c O O 0.9999990463256836
. O O 0.9999966621398926
v O O 0.9999992847442627
. O O 0.9999932050704956
) O O 0.9999735355377197
30 O O 0.9999629259109497
min O O 0.9999779462814331
before O O 0.9999738931655884
spontaneous O O 0.9999864101409912
alternation O O 0.9995986819267273
performance O O 0.9999841451644897
or O O 0.9999890327453613
the O O 0.9999886751174927
training O O 0.9999903440475464
session O O 0.9999949932098389
of O O 0.9999812841415405
the O O 0.999987006187439
passive O O 0.9996582269668579
avoidance O O 0.9998531341552734
task O O 0.9999761581420898
, O O 0.9999390840530396
attenuated O O 0.9997830986976624
the O O 0.9999654293060303
scopolamine B B 0.9993804693222046
- O O 0.9998005032539368
induced O O 0.9999485015869141
impairment O O 0.9999967813491821
of O O 0.999974250793457
spontaneous O O 0.9999679327011108
alternation O O 0.9997995495796204
and O O 0.9999130964279175
passive O O 0.9998449087142944
avoidance O O 0.9999698400497437
behaviours O O 0.9999806880950928
. O O 0.9999521970748901

6 O O 0.9358000755310059
. O O 0.9996689558029175

These O O 0.9999809265136719
results O O 0.9999899864196777
indicated O O 0.9999582767486572
that O O 0.999601423740387
nocistatin B B 0.9934797286987305
, O O 0.9997327923774719
a O O 0.9997832179069519
new O O 0.9996533393859863
biologically O O 0.9993739724159241
active O O 0.9975829124450684
peptide O O 0.9272438287734985
, O O 0.9998887777328491
ameliorates O O 0.9999667406082153
impairments O O 0.9999877214431763
of O O 0.9999321699142456
spontaneous O O 0.9999394416809082
alternation O O 0.9988250136375427
and O O 0.9998828172683716
passive O O 0.9993798732757568
avoidance O O 0.9999445676803589
induced O O 0.9999701976776123
by O O 0.99986732006073
scopolamine B B 0.9987286925315857
, O O 0.9992285966873169
and O O 0.9999662637710571
suggested O O 0.9999899864196777
that O O 0.9998805522918701
these O O 0.9442718625068665
peptides O O 0.9025453925132751
play O O 0.999862551689148
opposite O O 0.9959691762924194
roles O O 0.9999431371688843
in O O 0.9998044371604919
learning O O 0.999990701675415
and O O 0.9999425411224365
memory O O 0.999993085861206
. O O 0.9999752044677734

Meloxicam B B 0.9993994235992432
- O O 0.9989539384841919
induced O O 0.9998466968536377
liver O O 0.9959419369697571
toxicity O O 0.9999186992645264
. O O 0.9999289512634277

We O O 0.9999842643737793
report O O 0.9999971389770508
the O O 0.9999977350234985
case O O 0.9999963045120239
of O O 0.9999899864196777
a O O 0.999990701675415
female O O 0.9999960660934448
patient O O 0.999991774559021
with O O 0.9999690055847168
rheumatoid O O 0.9998688697814941
arthritis O O 0.9998676776885986
who O O 0.9999551773071289
developed O O 0.9999910593032837
acute O O 0.9999649524688721
cytolytic O O 0.9929088354110718
hepatitis O O 0.9995524287223816
due O O 0.9999141693115234
to O O 0.9801223874092102
meloxicam B B 0.9993759989738464
. O O 0.9999027252197266

Recently O O 0.999811589717865
introduced O O 0.9999427795410156
in O O 0.999890923500061
Belgium O O 0.9995633959770203
, O O 0.9985872507095337
meloxicam B B 0.9998470544815063
is O O 0.9974451065063477
the O O 0.9995046854019165
first O O 0.999024510383606
nonsteroidal O O 0.6017696261405945
antiinflammatory O O 0.3940710723400116
drug O O 0.9854243397712708
with O O 0.9995633959770203
selective O O 0.9987789988517761
action O O 0.9997778534889221
on O O 0.9995336532592773
the O O 0.9991876482963562
inducible O O 0.9981902241706848
form O O 0.9996480941772461
of O O 0.9968022108078003
cyclooxygenase O O 0.5560631155967712
2 O O 0.5169078707695007
. O O 0.9990112781524658

The O O 0.9999845027923584
acute O O 0.9999632835388184
cytolytic O O 0.9951401948928833
hepatitis O O 0.9998078942298889
occurred O O 0.9999885559082031
rapidly O O 0.9999959468841553
after O O 0.9999330043792725
meloxicam B B 0.9998365640640259
administration O O 0.999829888343811
and O O 0.9999750852584839
was O O 0.9999711513519287
associated O O 0.9999853372573853
with O O 0.9999780654907227
the O O 0.9999905824661255
development O O 0.9999932050704956
of O O 0.9999514818191528
antinuclear O O 0.87089604139328
antibodies O O 0.9999544620513916
suggesting O O 0.9999103546142578
a O O 0.9999306201934814
hypersensitivity O O 0.9982655644416809
mechanism O O 0.9999394416809082
. O O 0.9999626874923706

This O O 0.9999819993972778
first O O 0.9999967813491821
case O O 0.9999929666519165
of O O 0.9998915195465088
meloxicam B B 0.999796450138092
related O O 0.9993013143539429
liver O O 0.9919453263282776
toxicity O O 0.9999576807022095
demonstrates O O 0.9999468326568604
the O O 0.9999855756759644
potential O O 0.9999933242797852
of O O 0.9998459815979004
this O O 0.9977306723594666
drug O O 0.9970930814743042
to O O 0.9998975992202759
induce O O 0.9999662637710571
hepatic O O 0.9999727010726929
damage O O 0.9999949932098389
. O O 0.9999669790267944

Induction O O 0.9999567270278931
of O O 0.9999359846115112
apoptosis O O 0.9998254179954529
by O O 0.9998125433921814
remoxipride B B 0.991664707660675
metabolites O O 0.9202656745910645
in O O 0.9997552037239075
HL60 O O 0.6328965425491333
and O O 0.9988774657249451
CD34 O O 0.553193986415863
+ O O 0.9995853304862976
/ O O 0.9920641779899597
CD19 O O 0.5208733081817627
- O O 0.9906708002090454
human O O 0.9984197616577148
bone O O 0.9999011754989624
marrow O O 0.9999977350234985
progenitor O O 0.9998034834861755
cells O O 0.9999758005142212
: O O 0.9999521970748901
potential O O 0.9999839067459106
relevance O O 0.9999986886978149
to O O 0.99993896484375
remoxipride B B 0.9996787309646606
- O O 0.9995549321174622
induced O O 0.9999659061431885
aplastic O O 0.9996576309204102
anemia O O 0.9999696016311646
. O O 0.9999698400497437

The O O 0.9992675185203552
antipsychotic O O 0.653114914894104
agent O O 0.9273801445960999
, O O 0.9922975897789001
remoxipride B B 0.9994879961013794
[ O I 0.9296067953109741
( B I 0.5964740514755249
S I I 0.905634880065918
) I I 0.8596450686454773
- I I 0.9958166480064392
( I I 0.9309206604957581
- I I 0.9986503720283508
) I I 0.9698975682258606
- I I 0.9963866472244263
3 I I 0.9318987727165222
- I I 0.9980012774467468
bromo I I 0.9977933168411255
- I I 0.9729612469673157
N I I 0.9845196008682251
- I I 0.9984303116798401
[ I I 0.9998235106468201
( I I 0.9079535007476807
1 I I 0.9750595688819885
- I I 0.9928895235061646
ethyl I I 0.9994140863418579
- I I 0.9808163046836853
2 I I 0.9980313181877136
- I I 0.9937897324562073
pyrrolidinyl I I 0.9993533492088318
) I I 0.955425500869751
methyl I I 0.9994014501571655
] I I 0.9472492337226868
- I I 0.995820164680481
2 I I 0.9992859959602356
, I I 0.9966111779212952
6 I I 0.9952051639556885
- I I 0.9988885521888733
dimethoxybenz I I 0.999891996383667
amide I I 0.999591052532196
] O O 0.6203400492668152
has O O 0.9999393224716187
been O O 0.9999725818634033
associated O O 0.9999629259109497
with O O 0.9999849796295166
acquired O O 0.99997878074646
aplastic O O 0.9970414042472839
anemia O O 0.9999452829360962
. O O 0.9999635219573975

We O O 0.9999579191207886
have O O 0.9999889135360718
examined O O 0.9999663829803467
the O O 0.9999750852584839
ability O O 0.9999856948852539
of O O 0.999382495880127
remoxipride B B 0.9998396635055542
, O O 0.9930869936943054
three O O 0.8814377784729004
pyrrolidine B B 0.9829036593437195
ring O O 0.5506408214569092
metabolites O O 0.7757832407951355
and O O 0.9994586110115051
five O O 0.9642040729522705
aromatic O O 0.6734621524810791
ring O O 0.7521083950996399
metabolites O O 0.9697940349578857
of O O 0.9840996265411377
the O O 0.9974521994590759
parent O O 0.9545652866363525
compound O O 0.65889972448349
to O O 0.9999392032623291
induce O O 0.999948263168335
apoptosis O O 0.9997443556785583
in O O 0.9998770952224731
HL60 O O 0.8296713829040527
cells O O 0.9999316930770874
and O O 0.9998956918716431
human O O 0.9985315799713135
bone O O 0.9984803795814514
marrow O O 0.9999951124191284
progenitor O O 0.9994675517082214
( O O 0.9999583959579468
HBMP O O 0.9236219525337219
) O O 0.9999067783355713
cells O O 0.9999674558639526
. O O 0.9999649524688721

Cells O O 0.9999295473098755
were O O 0.9999442100524902
treated O O 0.9998974800109863
for O O 0.9999377727508545
0 O O 0.9997463822364807
- O O 0.9996684789657593
24 O O 0.9999889135360718
h O O 0.9996353387832642
with O O 0.9998216032981873
each O O 0.9286367297172546
compound O O 0.9736184477806091
( O O 0.9997507929801941
0 O O 0.995641827583313
- O O 0.995191216468811
200 O O 0.9984673857688904
microM O O 0.9994688630104065
) O O 0.9998701810836792
. O O 0.9999604225158691

Apoptosis O O 0.99800044298172
was O O 0.9999673366546631
assessed O O 0.9999850988388062
by O O 0.9999876022338867
fluorescence O O 0.999863862991333
microscopy O O 0.9999803304672241
in O O 0.9999269247055054
Hoechst B O 0.7584009170532227
33342 I O 0.7187752723693848
- O O 0.9784265160560608
and O O 0.9957483410835266
propidium B B 0.9995282888412476
iodide I I 0.9996609687805176
stained O O 0.999042809009552
cell O O 0.9999643564224243
samples O O 0.9999864101409912
. O O 0.9999759197235107

Results O O 0.9999887943267822
were O O 0.9999879598617554
confirmed O O 0.9999903440475464
by O O 0.9999942779541016
determination O O 0.9999872446060181
of O O 0.9999229907989502
internucleosomal O O 0.9878473281860352
DNA O O 0.48378342390060425
fragmentation O O 0.9998592138290405
using O O 0.9999527931213379
gel O O 0.9998886585235596
electrophoresis O O 0.9998854398727417
for O O 0.9999383687973022
HL60 O O 0.614276647567749
cell O O 0.9997283816337585
samples O O 0.9999610185623169
and O O 0.9999345541000366
terminal O O 0.4671858549118042
deoxynucleotidyl O O 0.5080108046531677
transferase O O 0.7052297592163086
assay O O 0.9995717406272888
in O O 0.9999237060546875
HBMP O O 0.5317453145980835
cells O O 0.9998898506164551
. O O 0.9999758005142212

The O O 0.9975130558013916
catechol B B 0.9885857701301575
and O O 0.8579615354537964
hydroquinone B B 0.913885772228241
metabolites O O 0.8780826330184937
, O O 0.9996143579483032
NCQ436 B B 0.8836609125137329
and O O 0.9599319100379944
NCQ344 B B 0.8849846720695496
, O O 0.9997230172157288
induced O O 0.9998503923416138
apoptosis O O 0.9998606443405151
in O O 0.9997445940971375
HL60 O O 0.6761207580566406
and O O 0.999242901802063
HBMP O O 0.6137443780899048
cells O O 0.9998196959495544
in O O 0.9999521970748901
a O O 0.9999603033065796
time O O 0.9997338652610779
- O O 0.9999798536300659
and O O 0.9999783039093018
concentration O O 0.9998152852058411
dependent O O 0.9999542236328125
manner O O 0.999982476234436
, O O 0.9999855756759644
while O O 0.9999216794967651
the O O 0.9994361996650696
phenols B B 0.9298599362373352
, O O 0.996773898601532
NCR181 O B 0.8667033910751343
, O O 0.9417591094970703
FLA873 O B 0.9559747576713562
, O O 0.9711281657218933
and O O 0.9952638149261475
FLA797 B B 0.9473410248756409
, O O 0.9995569586753845
and O O 0.9997366070747375
the O O 0.9985883831977844
derivatives O O 0.9871094226837158
formed O O 0.9994971752166748
by O O 0.9998419284820557
oxidation O O 0.4927448630332947
of O O 0.9882144927978516
the O O 0.9995571970939636
pyrrolidine B B 0.9592097997665405
ring O O 0.8076655268669128
, O O 0.9981777667999268
FLA838 O B 0.9874417781829834
, O O 0.9520134925842285
NCM001 O O 0.7504528164863586
, O O 0.9852767586708069
and O O 0.9968183040618896
NCL118 O O 0.791304886341095
, O O 0.9996117949485779
had O O 0.9999673366546631
no O O 0.9999667406082153
effect O O 0.9999786615371704
. O O 0.9999688863754272

No O O 0.9997212290763855
necrosis O O 0.9998096823692322
was O O 0.9999698400497437
observed O O 0.9999778270721436
in O O 0.9998538494110107
cells O O 0.9999831914901733
treated O O 0.9999103546142578
with O O 0.999718964099884
NCQ436 B B 0.9548493027687073
but O O 0.997900128364563
NCQ344 B B 0.9754744172096252
had O O 0.9998173117637634
a O O 0.9999345541000366
biphasic O O 0.9843340516090393
effect O O 0.9999265670776367
in O O 0.9998158812522888
both O O 0.9992602467536926
cell O O 0.9999563694000244
types O O 0.9999717473983765
, O O 0.9999580383300781
inducing O O 0.9999369382858276
apoptosis O O 0.998816967010498
at O O 0.999862790107727
lower O O 0.9998577833175659
concentrations O O 0.9991697072982788
and O O 0.9998270869255066
necrosis O O 0.9996384382247925
at O O 0.9998307228088379
higher O O 0.9996975660324097
concentrations O O 0.9997226595878601
. O O 0.9999618530273438

These O O 0.9999769926071167
data O O 0.9999845027923584
show O O 0.9998225569725037
that O O 0.9996238946914673
the O O 0.9992712140083313
catechol B B 0.9890168905258179
and O O 0.982579231262207
hydroquinone B B 0.9111252427101135
metabolites O O 0.7943726181983948
of O O 0.9746431112289429
remoxipride B B 0.999262273311615
have O O 0.9998427629470825
direct O O 0.9998059868812561
toxic O O 0.9997156262397766
effects O O 0.9999470710754395
in O O 0.999727189540863
HL60 O O 0.7280218005180359
and O O 0.9992979764938354
HBMP O O 0.6051691174507141
cells O O 0.9998276233673096
, O O 0.9999659061431885
leading O O 0.999958872795105
to O O 0.9999520778656006
apoptosis O O 0.9998565912246704
, O O 0.9999744892120361
while O O 0.9999523162841797
the O O 0.9994943141937256
phenol B B 0.9857428073883057
metabolites O O 0.871969997882843
were O O 0.99992835521698
inactive O O 0.9994551539421082
. O O 0.999963641166687

Similarly O O 0.9808005094528198
, O O 0.9978005290031433
benzene B B 0.997273862361908
- O O 0.7136472463607788
derived O O 0.8531420826911926
catechol B B 0.9248614311218262
and O O 0.9851492643356323
hydroquinone B B 0.9890615940093994
, O O 0.9992971420288086
but O O 0.9997633099555969
not O O 0.9978419542312622
phenol B B 0.9962926506996155
, O O 0.9998416900634766
induce O O 0.9999017715454102
apoptosis O O 0.9997438788414001
in O O 0.9999039173126221
HBMP O O 0.6823049783706665
cells O O 0.9998618364334106
[ O O 0.9988923668861389
Moran O O 0.7215938568115234
et O O 0.9988569021224976
al O O 0.999813973903656
. O O 0.9999860525131226
, O O 0.9961332082748413
Mol O O 0.9732930064201355
. O O 0.9992519021034241
Pharmacol O O 0.9895092248916626
. O O 0.9998774528503418
, O O 0.9921139478683472
50 O O 0.991497814655304
( O O 0.996206521987915
1996 O O 0.9869967699050903
) O O 0.9977301955223083
610 O O 0.8060659170150757
- O O 0.7126168608665466
615 O O 0.923956573009491
] O O 0.9958881735801697
. O O 0.9999165534973145

We O O 0.999980092048645
propose O O 0.999990701675415
that O O 0.9998134970664978
remoxipride B B 0.9997522234916687
and O O 0.9750714302062988
benzene B B 0.9992239475250244
may O O 0.9999097585678101
induce O O 0.9999446868896484
aplastic O O 0.9985610842704773
anemia O O 0.9999241828918457
via O O 0.9999123811721802
production O O 0.9999260902404785
of O O 0.9998416900634766
similar O O 0.9974501729011536
reactive O O 0.9832670092582703
metabolites O O 0.9984672665596008
and O O 0.9999599456787109
that O O 0.9999600648880005
the O O 0.999958872795105
ability O O 0.9999628067016602
of O O 0.999478280544281
NCQ436 B O 0.5729925632476807
and O O 0.9892233610153198
NCQ344 B O 0.7948280572891235
to O O 0.9997573494911194
induce O O 0.9999051094055176
apoptosis O O 0.9989221096038818
in O O 0.9998292922973633
HBMP O O 0.6193320751190186
cells O O 0.9998378753662109
may O O 0.9999254941940308
contribute O O 0.9999568462371826
to O O 0.9999672174453735
the O O 0.9999785423278809
mechanism O O 0.9999914169311523
underlying O O 0.999984860420227
acquired O O 0.999985933303833
aplastic O O 0.999650239944458
anemia O O 0.9999657869338989
that O O 0.9999877214431763
has O O 0.999990701675415
been O O 0.9999959468841553
associated O O 0.9999920129776001
with O O 0.9997194409370422
remoxipride B B 0.9994910955429077
. O O 0.9999045133590698

Synthesis O O 0.9998745918273926
and O O 0.9999682903289795
preliminary O O 0.9999855756759644
pharmacological O O 0.9999631643295288
investigations O O 0.9999936819076538
of O O 0.9996380805969238
1 B B 0.8948737382888794
- I I 0.9920124411582947
( I I 0.9965940117835999
1 I I 0.8994430303573608
, I I 0.9892138838768005
2 I I 0.9978229999542236
- I I 0.9938724040985107
dihydro I I 0.9971475005149841
- I I 0.9820004105567932
2 I I 0.9951409101486206
- I I 0.9953966736793518
acenaphthylenyl I I 0.9998561143875122
) I I 0.9833365082740784
piperazine I I 0.9971088767051697
derivatives O I 0.9957970380783081
as O O 0.9997431635856628
potential O O 0.9999688863754272
atypical O O 0.9994903802871704
antipsychotic O O 0.4986882209777832
agents O O 0.9891952276229858
in O O 0.9999390840530396
mice O O 0.9999613761901855
. O O 0.9999716281890869

In O O 0.9999655485153198
research O O 0.9999856948852539
towards O O 0.9999779462814331
the O O 0.9999951124191284
development O O 0.9999897480010986
of O O 0.9999631643295288
new O O 0.9999279975891113
atypical O O 0.9962685108184814
antipsychotic O O 0.6426452398300171
agents O O 0.9858559370040894
, O O 0.9999382495880127
one O O 0.9999122619628906
strategy O O 0.9999911785125732
is O O 0.9999773502349854
that O O 0.9999794960021973
the O O 0.9998856782913208
dopaminergic O B 0.9560377597808838
system O O 0.9988111257553101
can O O 0.999904990196228
be O O 0.9999704360961914
modulated O O 0.9999666213989258
through O O 0.9999551773071289
manipulation O O 0.9999834299087524
of O O 0.99985671043396
the O O 0.9998455047607422
serotonergic O O 0.5324276685714722
system O O 0.9959568381309509
. O O 0.9999494552612305

The O O 0.9999688863754272
synthesis O O 0.9998729228973389
and O O 0.9999550580978394
preliminary O O 0.9999732971191406
pharmacological O O 0.9999775886535645
evaluation O O 0.99998939037323
of O O 0.9998043179512024
a O O 0.9998985528945923
series O O 0.9993739724159241
of O O 0.9998086094856262
potential O O 0.9998793601989746
atypical O O 0.9976860284805298
antipsychotic O O 0.6452102065086365
agents O O 0.975576639175415
based O O 0.9998536109924316
on O O 0.9996212720870972
the O O 0.9999158382415771
structure O O 0.9991200566291809
of O O 0.9848918914794922
1 B B 0.8407421112060547
- I I 0.9849646687507629
( I I 0.996062695980072
1 I I 0.8941283226013184
, I I 0.9883169531822205
2 I I 0.9966367483139038
- I I 0.9910402894020081
dihydro I I 0.9973184466362
- I I 0.9797955751419067
2 I I 0.995991051197052
- I I 0.9967232346534729
acenaphthylenyl I I 0.9998847246170044
) I I 0.9710168838500977
piperazine I I 0.9993091821670532
( O I 0.9135110974311829
7 O I 0.792561948299408
) O O 0.8798246383666992
is O O 0.9999649524688721
described O O 0.9999815225601196
. O O 0.9999741315841675

Compound O O 0.9155028462409973
7e O B 0.7676585912704468
, O O 0.677802324295044
5 B B 0.8956301212310791
- I I 0.9426746368408203
{ I I 0.9873414635658264
2 I I 0.9764816164970398
- I I 0.9872729182243347
[ I I 0.9973364472389221
4 I I 0.9697180390357971
- I I 0.993035078048706
( I I 0.9855437278747559
1 I I 0.9195540547370911
, I I 0.9867101311683655
2 I I 0.9973278045654297
- I I 0.9906901121139526
dihydro I I 0.9921516180038452
- I I 0.9731151461601257
2 I I 0.9907271862030029
- I I 0.9968215227127075
acenaphthylenyl I I 0.9998175501823425
) I I 0.9933537244796753
piperazinyl I I 0.9991900324821472
] I I 0.97740638256073
ethyl I I 0.9997772574424744
} I I 0.999645471572876
- I I 0.9562968015670776
2 I I 0.997831404209137
, I I 0.9869029521942139
3 I I 0.96860271692276
- I I 0.9953172206878662
dihy I I 0.9903415441513062
dro I I 0.5650883913040161
- I I 0.5319120287895203
1H I I 0.897328794002533
- I I 0.9895227551460266
indol I I 0.9898588061332703
- I I 0.9329462647438049
2 I I 0.9821028709411621
- I I 0.964472770690918
one I I 0.9998481273651123
, O O 0.9988486766815186
from O O 0.9999732971191406
this O O 0.9999269247055054
series O O 0.9997255206108093
showed O O 0.999943733215332
significant O O 0.9998014569282532
affinities O O 0.9982725381851196
at O O 0.9997721314430237
the O O 0.9997847676277161
5 O O 0.6200594305992126
- O O 0.917626678943634
HT1A O O 0.8021591305732727
and O O 0.9992528557777405
5 O O 0.7487462162971497
- O O 0.9421178698539734
HT2A O O 0.8572969436645508
receptors O O 0.9998863935470581
and O O 0.9999387264251709
moderate O O 0.999818742275238
affinity O O 0.9999369382858276
at O O 0.9997164607048035
the O O 0.9991857409477234
D2 O O 0.8232306838035583
receptor O O 0.9999057054519653
. O O 0.9999537467956543

7e O B 0.9231095910072327
exhibits O O 0.9990935325622559
a O O 0.9999252557754517
high O O 0.9996777772903442
reversal O O 0.9999440908432007
of O O 0.9998552799224854
catalepsy O O 0.999861478805542
induced O O 0.9999291896820068
by O O 0.9998210072517395
haloperidol B B 0.9994309544563293
indicating O O 0.9995688796043396
its O O 0.999618649482727
atypical O O 0.9992061257362366
antipsychotic O O 0.4905995726585388
nature O O 0.9998723268508911
. O O 0.9999110698699951

Sub O O 0.9901036024093628
- O O 0.999790608882904
chronic O O 0.9994458556175232
inhibition O O 0.9997534155845642
of O O 0.9980459213256836
nitric B B 0.8682498335838318
- I I 0.7152796983718872
oxide I I 0.9974308609962463
synthesis O O 0.8717005252838135
modifies O O 0.9999256134033203
haloperidol B B 0.9998323917388916
- O O 0.9998852014541626
induced O O 0.9999440908432007
catalepsy O O 0.9999862909317017
and O O 0.9999700784683228
the O O 0.9999915361404419
number O O 0.9999754428863525
of O O 0.9999555349349976
NADPH B B 0.8707740306854248
- O O 0.7621587514877319
diaphorase O O 0.786350667476654
neurons O O 0.9999449253082275
in O O 0.9999202489852905
mice O O 0.9999823570251465
. O O 0.9999483823776245

RATIONALE O O 0.8432363271713257
: O O 0.9712423086166382
NG B B 0.7058470845222473
- I I 0.9011170864105225
nitro I I 0.9602895975112915
- I I 0.9576348066329956
L I I 0.9847077131271362
- I I 0.9949007034301758
arginine I I 0.999902606010437
( O O 0.9785937070846558
L B B 0.7987293601036072
- I I 0.8926754593849182
NOARG I I 0.9919354915618896
) O O 0.9731138348579407
, O O 0.9999096393585205
an O O 0.9834859371185303
inhibitor O O 0.888332188129425
of O O 0.9940177202224731
nitric B O 0.7979499101638794
- I O 0.5006303191184998
oxide I O 0.710018515586853
synthase O O 0.652137041091919
( O O 0.9978173971176147
NOS O O 0.8491733074188232
) O O 0.9497057199478149
, O O 0.9999147653579712
induces O O 0.9999096393585205
catalepsy O O 0.9999426603317261
in O O 0.9999140501022339
mice O O 0.9999523162841797
. O O 0.9998093247413635

This O O 0.999854326248169
effect O O 0.9997963309288025
undergoes O O 0.9999918937683105
rapid O O 0.9999532699584961
tolerance O O 0.9999938011169434
, O O 0.9999871253967285
showing O O 0.9999911785125732
a O O 0.9999923706054688
significant O O 0.9999911785125732
decrease O O 0.9999940395355225
after O O 0.9999747276306152
2 O O 0.9999536275863647
days O O 0.9999923706054688
of O O 0.9999388456344604
sub O O 0.9992375373840332
- O O 0.9998413324356079
chronic O O 0.9997417330741882
L B B 0.8107176423072815
- I I 0.9029252529144287
NOARG I I 0.9969823956489563
treatment O O 0.9993674159049988
. O O 0.9999730587005615

Nitric B B 0.9913239479064941
oxide I I 0.9995704293251038
( O O 0.9643725156784058
NO B B 0.9941615462303162
) O O 0.7070552110671997
has O O 0.9999345541000366
been O O 0.9999775886535645
shown O O 0.9999514818191528
to O O 0.9994082450866699
influence O O 0.7214306592941284
dopaminergic O O 0.48744943737983704
neurotransmission O O 0.9999315738677979
in O O 0.9997442364692688
the O O 0.9997618794441223
striatum O O 0.9930526614189148
. O O 0.9998936653137207

Neuroleptic O O 0.925530731678009
drugs O O 0.9973921775817871
such O O 0.9996161460876465
as O O 0.9994173049926758
haloperidol B B 0.999734103679657
, O O 0.9997279047966003
which O O 0.999420166015625
block O O 0.9972055554389954
dopamine B B 0.9859251379966736
receptors O O 0.9995798468589783
, O O 0.999923825263977
also O O 0.9998927116394043
cause O O 0.9998717308044434
catalepsy O O 0.99997878074646
in O O 0.9999436140060425
rodents O O 0.9999698400497437
. O O 0.9999172687530518

OBJECTIVES O O 0.9997391104698181
: O O 0.9999934434890747
To O O 0.9999939203262329
investigate O O 0.9999551773071289
the O O 0.9999768733978271
effects O O 0.9999713897705078
of O O 0.9999123811721802
subchronic O O 0.9969191551208496
L B B 0.8244579434394836
- I I 0.8428884744644165
NOARG I I 0.9574398398399353
treatment O O 0.9961162805557251
in O O 0.9997206330299377
haloperidol B B 0.9997761845588684
- O O 0.9996470212936401
induced O O 0.9999328851699829
catalepsy O O 0.999990701675415
and O O 0.9999662637710571
the O O 0.9999891519546509
number O O 0.9999606609344482
of O O 0.999924898147583
NOS O O 0.5389686822891235
neurons O O 0.9999083280563354
in O O 0.9997105002403259
areas O O 0.9998573064804077
related O O 0.9999768733978271
to O O 0.9999243021011353
motor O O 0.9998947381973267
control O O 0.9999858140945435
. O O 0.9999710321426392

METHODS O O 0.9955949187278748
: O O 0.9999585151672363
Male O O 0.999924898147583
albino O O 0.9983630776405334
Swiss O O 0.9861788749694824
mice O O 0.9999443292617798
were O O 0.9999600648880005
treated O O 0.9999659061431885
sub O O 0.9993952512741089
- O O 0.9996753931045532
chronically O O 0.9999679327011108
( O O 0.9999436140060425
twice O O 0.9999862909317017
a O O 0.9999947547912598
day O O 0.9999961853027344
for O O 0.9999874830245972
4 O O 0.9998644590377808
days O O 0.9999963045120239
) O O 0.9999818801879883
with O O 0.9998795986175537
L B B 0.743937611579895
- I I 0.8948940634727478
NOARG I I 0.9956424236297607
( O O 0.995488703250885
40 O O 0.99980229139328
mg O O 0.9999384880065918
/ O O 0.9999791383743286
kg O O 0.9999943971633911
i O O 0.9982485771179199
. O O 0.9999951124191284
p O O 0.9999980926513672
. O O 0.9999951124191284
) O O 0.9999324083328247
or O O 0.9973415732383728
haloperidol B B 0.9994754195213318
( O O 0.9997885823249817
1 O O 0.9999845027923584
mg O O 0.9999758005142212
/ O O 0.9999853372573853
kg O O 0.9999960660934448
i O O 0.9990264177322388
. O O 0.9999951124191284
p O O 0.9999983310699463
. O O 0.999995231628418
) O O 0.9999794960021973
. O O 0.9999679327011108

Catalepsy O O 0.9994169473648071
was O O 0.9999206066131592
evaluated O O 0.9999605417251587
at O O 0.9998620748519897
the O O 0.9999740123748779
beginning O O 0.9999887943267822
and O O 0.9999754428863525
the O O 0.9999923706054688
end O O 0.9999920129776001
of O O 0.9999731779098511
the O O 0.999919056892395
treatments O O 0.9999624490737915
. O O 0.9999693632125854

Reduced O O 0.8728755116462708
nicotinamide B B 0.9709895849227905
adenine I I 0.6681751608848572
dinucleotide I I 0.9249559044837952
phosphate I I 0.8241379857063293
- O I 0.8341332077980042
diaphorase O I 0.950735330581665
( O O 0.989997148513794
NADPH B B 0.9876275062561035
- O I 0.6298204660415649
d O I 0.9068393111228943
) O O 0.9995176792144775
histochemistry O O 0.9996380805969238
was O O 0.9999796152114868
also O O 0.9999876022338867
employed O O 0.9999910593032837
to O O 0.9999885559082031
visualize O O 0.9999494552612305
NOS O O 0.7964363098144531
as O O 0.9999656677246094
an O O 0.999984860420227
index O O 0.9999786615371704
of O O 0.9999454021453857
enzyme O O 0.9252564311027527
expression O O 0.9999016523361206
in O O 0.9998137354850769
mice O O 0.9535167813301086
brain O O 0.9999643564224243
regions O O 0.9999738931655884
related O O 0.9999858140945435
to O O 0.9999678134918213
motor O O 0.9999314546585083
control O O 0.9999916553497314
. O O 0.9999744892120361

RESULTS O O 0.999754011631012
: O O 0.9997826218605042
L B B 0.7562552690505981
- I I 0.8895610570907593
NOARG I I 0.9943482279777527
sub O O 0.9935463070869446
- O O 0.9997218251228333
chronic O O 0.9956632256507874
administration O O 0.9998264908790588
produced O O 0.9991395473480225
tolerance O O 0.9999372959136963
of O O 0.9995985627174377
L B B 0.7665460705757141
- I I 0.864780068397522
NOARG I I 0.9850209951400757
and O O 0.998773992061615
of O O 0.9998427629470825
haloperidol B B 0.9997205138206482
- O O 0.9997285008430481
induced O O 0.9999390840530396
catalepsy O O 0.9999916553497314
. O O 0.9999755620956421

It O O 0.9989719390869141
also O O 0.9999183416366577
induced O O 0.9999411106109619
an O O 0.999981164932251
increase O O 0.9999938011169434
in O O 0.9999854564666748
the O O 0.9999903440475464
number O O 0.9999876022338867
of O O 0.9999563694000244
NADPH B B 0.974586009979248
- O O 0.5611124634742737
d O O 0.4367612302303314
- O O 0.9981643557548523
positive O O 0.9994669556617737
cells O O 0.9999778270721436
in O O 0.9995853304862976
the O O 0.9998382329940796
dorsal O O 0.9946407079696655
part O O 0.9999850988388062
of O O 0.9998995065689087
the O O 0.9999129772186279
caudate O O 0.9811491966247559
and O O 0.9993546605110168
accumbens O O 0.9933285713195801
nuclei O O 0.999980092048645
compared O O 0.9999426603317261
with O O 0.9997069239616394
haloperidol B B 0.9995042085647583
and O O 0.9998062252998352
in O O 0.999749481678009
the O O 0.9999375343322754
pedunculopontine O O 0.992595374584198
tegmental O O 0.9978410005569458
nucleus O O 0.9999760389328003
compared O O 0.9999818801879883
with O O 0.9999345541000366
saline O O 0.9997391104698181
. O O 0.9999361038208008

In O O 0.999915599822998
contrast O O 0.999942421913147
, O O 0.999935507774353
there O O 0.9999076128005981
was O O 0.9999581575393677
a O O 0.999971866607666
decrease O O 0.9999881982803345
in O O 0.9999217987060547
NADPH B B 0.9530695080757141
- O O 0.979900062084198
d O O 0.9506505727767944
neuron O O 0.9998641014099121
number O O 0.9991239905357361
in O O 0.9996899366378784
the O O 0.9999154806137085
substantia O O 0.9989149570465088
nigra O O 0.9998784065246582
, O O 0.9989688396453857
pars O O 0.9988240599632263
compacta O O 0.999360978603363
in O O 0.9998551607131958
both O O 0.9997352957725525
haloperidol B B 0.9992594122886658
- O O 0.9994028806686401
treated O O 0.9997658133506775
and O O 0.999679446220398
L B B 0.8676962852478027
- I I 0.9348331093788147
NOARG I I 0.993528425693512
- O O 0.9940033555030823
treated O O 0.9998160004615784
animals O O 0.9999725818634033
. O O 0.9999778270721436

CONCLUSIONS O O 0.9987432360649109
: O O 0.9999958276748657
The O O 0.9999842643737793
results O O 0.9999794960021973
give O O 0.9999785423278809
further O O 0.9999758005142212
support O O 0.9999915361404419
to O O 0.9999402761459351
the O O 0.9999724626541138
hypothesis O O 0.9999637603759766
that O O 0.9998340606689453
NO B B 0.969907283782959
plays O O 0.9995846152305603
a O O 0.999491810798645
role O O 0.9998310804367065
in O O 0.9997774958610535
motor O O 0.9998509883880615
behavior O O 0.9999276399612427
control O O 0.999950647354126
and O O 0.9999489784240723
suggest O O 0.9999233484268188
that O O 0.9999485015869141
it O O 0.9985972046852112
may O O 0.9999063014984131
take O O 0.9998396635055542
part O O 0.9999734163284302
in O O 0.9999417066574097
the O O 0.9999573230743408
synaptic O O 0.999570906162262
changes O O 0.9999938011169434
produced O O 0.9999922513961792
by O O 0.9998548030853271
antipsychotic O O 0.5824562907218933
treatment O O 0.9998447895050049
. O O 0.9999594688415527

Prolonged O O 0.9998356103897095
left O O 0.999971866607666
ventricular O O 0.9999927282333374
dysfunction O O 0.9999899864196777
occurs O O 0.999967098236084
in O O 0.999955415725708
patients O O 0.9999864101409912
with O O 0.999954104423523
coronary O O 0.999895453453064
artery O O 0.9998674392700195
disease O O 0.999995231628418
after O O 0.9996881484985352
both O O 0.99725741147995
dobutamine B B 0.9994181394577026
and O O 0.9975180625915527
exercise O O 0.9988999366760254
induced O O 0.9999724626541138
myocardial O O 0.9999960660934448
ischaemia O O 0.9999822378158569
. O O 0.9999819993972778

OBJECTIVE O O 0.9998849630355835
: O O 0.9999960660934448
To O O 0.999992847442627
determine O O 0.9999954700469971
whether O O 0.999982476234436
pharmacological O O 0.9991604089736938
stress O O 0.997103750705719
leads O O 0.9999583959579468
to O O 0.9999685287475586
prolonged O O 0.9999524354934692
but O O 0.9998412132263184
reversible O O 0.999970555305481
left O O 0.9999831914901733
ventricular O O 0.9999963045120239
dysfunction O O 0.9999967813491821
in O O 0.9999518394470215
patients O O 0.9999938011169434
with O O 0.9999706745147705
coronary O O 0.9999043941497803
artery O O 0.9996817111968994
disease O O 0.9999945163726807
, O O 0.9999864101409912
similar O O 0.999995231628418
to O O 0.9999821186065674
that O O 0.999992847442627
seen O O 0.999992847442627
after O O 0.9999610185623169
exercise O O 0.9999860525131226
. O O 0.9999781847000122

DESIGN O O 0.9999711513519287
: O O 0.9999957084655762
A O O 0.9999884366989136
randomised O O 0.9999890327453613
crossover O O 0.9999209642410278
study O O 0.9999908208847046
of O O 0.9999765157699585
recovery O O 0.9999786615371704
time O O 0.9999799728393555
of O O 0.999944806098938
systolic O O 0.9940472841262817
and O O 0.9996293783187866
diastolic O O 0.9997439980506897
left O O 0.9999768733978271
ventricular O O 0.9999939203262329
function O O 0.9999790191650391
after O O 0.9998728036880493
exercise O O 0.9997649788856506
and O O 0.9996106028556824
dobutamine B B 0.9997692704200745
induced O O 0.9999016523361206
ischaemia O O 0.9999890327453613
. O O 0.9999847412109375

SUBJECTS O O 0.9994014501571655
: O O 0.9999901056289673
10 O O 0.9999834299087524
patients O O 0.9999945163726807
with O O 0.9999864101409912
stable O O 0.9999911785125732
angina O O 0.9999314546585083
, O O 0.9999821186065674
angiographically O O 0.9999817609786987
proven O O 0.9999905824661255
coronary O O 0.9999366998672485
artery O O 0.999528169631958
disease O O 0.9999974966049194
, O O 0.9999268054962158
and O O 0.9999589920043945
normal O O 0.9999853372573853
left O O 0.9999860525131226
ventricular O O 0.999996542930603
function O O 0.999993085861206
. O O 0.9999783039093018

INTERVENTIONS O O 0.9996380805969238
: O O 0.9998830556869507
Treadmill O O 0.9151507019996643
exercise O O 0.9979138970375061
and O O 0.9997900128364563
dobutamine B B 0.9994361996650696
stress O O 0.999640941619873
were O O 0.9999837875366211
performed O O 0.9999816417694092
on O O 0.9999780654907227
different O O 0.999964714050293
days O O 0.9999947547912598
. O O 0.9999817609786987

Quantitative O O 0.9998888969421387
assessment O O 0.9999929666519165
of O O 0.9999712705612183
systolic O O 0.9989410042762756
and O O 0.9997472167015076
diastolic O O 0.9999008178710938
left O O 0.9999769926071167
ventricular O O 0.9999926090240479
function O O 0.9999864101409912
was O O 0.9999847412109375
performed O O 0.9999967813491821
using O O 0.9999728202819824
transthoracic O O 0.9999560117721558
echocardiography O O 0.9998544454574585
at O O 0.9999570846557617
baseline O O 0.9999810457229614
and O O 0.9999865293502808
at O O 0.9999799728393555
regular O O 0.9999921321868896
intervals O O 0.9999951124191284
after O O 0.9999915361404419
each O O 0.9999916553497314
test O O 0.9999964237213135
. O O 0.9999785423278809

RESULTS O O 0.9994860887527466
: O O 0.9999198913574219
Both O O 0.9998655319213867
forms O O 0.9999637603759766
of O O 0.9998852014541626
stress O O 0.999365508556366
led O O 0.9999479055404663
to O O 0.9999743700027466
prolonged O O 0.9999237060546875
but O O 0.9999144077301025
reversible O O 0.9999366998672485
systolic O O 0.9995710253715515
and O O 0.9998249411582947
diastolic O O 0.9999079704284668
dysfunction O O 0.9999933242797852
. O O 0.999976634979248

There O O 0.9999446868896484
was O O 0.999944806098938
no O O 0.9999817609786987
difference O O 0.9999924898147583
in O O 0.9999850988388062
the O O 0.9999704360961914
maximum O O 0.9875146150588989
double O O 0.9823966026306152
product O O 0.9979183077812195
( O O 0.9999362230300903
p O O 0.9986703395843506
= O O 0.9998993873596191
0 O O 0.999963641166687
. O O 0.9999809265136719
53 O O 0.9999921321868896
) O O 0.9999501705169678
or O O 0.9998779296875
ST O O 0.9343951344490051
depression O O 0.9999711513519287
( O O 0.9999268054962158
p O O 0.9989333748817444
= O O 0.9999064207077026
0 O O 0.9999585151672363
. O O 0.9999793767929077
63 O O 0.9999934434890747
) O O 0.9999672174453735
with O O 0.9999338388442993
either O O 0.9999319314956665
form O O 0.99994957447052
of O O 0.999847412109375
stress O O 0.9931573271751404
. O O 0.9999035596847534

After O O 0.9998974800109863
exercise O O 0.9999706745147705
, O O 0.9999018907546997
ejection O O 0.9998353719711304
fraction O O 0.9999898672103882
was O O 0.9999511241912842
reduced O O 0.9999920129776001
at O O 0.9999337196350098
15 O O 0.999995231628418
and O O 0.9999638795852661
30 O O 0.9999924898147583
minutes O O 0.9999926090240479
compared O O 0.9999949932098389
with O O 0.9999934434890747
baseline O O 0.9999686479568481
( O O 0.9999555349349976
mean O O 0.9999932050704956
( O O 0.9999138116836548
SEM O O 0.99979168176651
) O O 0.9999725818634033
, O O 0.9999651908874512
- O O 0.9998306035995483
5 O O 0.9999423027038574
. O O 0.9999884366989136
6 O O 0.9999861717224121
( O O 0.9995494484901428
1 O O 0.999970555305481
. O O 0.9999762773513794
5 O O 0.9999743700027466
) O O 0.9998608827590942
% O O 0.9999865293502808
, O O 0.9999626874923706
p O O 0.9999412298202515
< O O 0.9999740123748779
0 O O 0.9999876022338867
. O O 0.9999955892562866
05 O O 0.9999874830245972
; O O 0.9999624490737915
and O O 0.9998140931129456
- O O 0.9997438788414001
6 O O 0.9999191761016846
. O O 0.9999904632568359
1 O O 0.9999880790710449
( O O 0.9995563626289368
2 O O 0.9999639987945557
. O O 0.9999780654907227
2 O O 0.9999698400497437
) O O 0.999873161315918
% O O 0.9999924898147583
, O O 0.9999632835388184
p O O 0.9999243021011353
< O O 0.9999703168869019
0 O O 0.99998939037323
. O O 0.9999963045120239
01 O O 0.9999942779541016
) O O 0.9999701976776123
, O O 0.9999628067016602
and O O 0.9999445676803589
at O O 0.9999567270278931
30 O O 0.9999929666519165
and O O 0.9999713897705078
45 O O 0.9999960660934448
minutes O O 0.9999980926513672
after O O 0.999896764755249
dobutamine B B 0.9996997117996216
( O O 0.9998249411582947
- O O 0.9998739957809448
10 O O 0.9999445676803589
. O O 0.999991774559021
8 O O 0.9999803304672241
( O O 0.9998251795768738
1 O O 0.9999856948852539
. O O 0.9999686479568481
8 O O 0.9999734163284302
) O O 0.9999194145202637
% O O 0.9999945163726807
and O O 0.9999394416809082
- O O 0.9997063279151917
5 O O 0.999907374382019
. O O 0.9999868869781494
5 O O 0.999987006187439
( O O 0.9997667670249939
1 O O 0.9999769926071167
. O O 0.9999786615371704
8 O O 0.999975323677063
) O O 0.9999256134033203
% O O 0.9999932050704956
, O O 0.999984622001648
both O O 0.999962568283081
p O O 0.9997861981391907
< O O 0.9999595880508423
0 O O 0.9999794960021973
. O O 0.9999957084655762
01 O O 0.9999847412109375
) O O 0.9999774694442749
. O O 0.9999730587005615

Regional O O 0.9985042810440063
analysis O O 0.999964714050293
showed O O 0.999910831451416
a O O 0.9999508857727051
reduction O O 0.9999868869781494
in O O 0.9999508857727051
the O O 0.9999328851699829
worst O O 0.9992333650588989
affected O O 0.9999639987945557
segment O O 0.9999790191650391
15 O O 0.9999232292175293
and O O 0.9999340772628784
30 O O 0.99998939037323
minutes O O 0.9999885559082031
after O O 0.9999551773071289
exercise O O 0.9999406337738037
( O O 0.9999496936798096
- O O 0.9998892545700073
27 O O 0.99998939037323
. O O 0.9999862909317017
9 O O 0.9999788999557495
( O O 0.9997978806495667
7 O O 0.9999876022338867
. O O 0.9999884366989136
2 O O 0.9999706745147705
) O O 0.9998527765274048
% O O 0.99998939037323
and O O 0.9998929500579834
- O O 0.9997561573982239
28 O O 0.9999890327453613
. O O 0.9999840259552002
6 O O 0.9999788999557495
( O O 0.9998239874839783
5 O O 0.9999656677246094
. O O 0.9999881982803345
7 O O 0.9999880790710449
) O O 0.9999264478683472
% O O 0.999990701675415
, O O 0.9999868869781494
both O O 0.9999350309371948
p O O 0.9989249110221863
< O O 0.9999607801437378
0 O O 0.9999618530273438
. O O 0.9999954700469971
01 O O 0.9999853372573853
) O O 0.9999707937240601
, O O 0.9999470710754395
and O O 0.9999339580535889
at O O 0.999961256980896
30 O O 0.9999767541885376
minutes O O 0.9999967813491821
after O O 0.9998788833618164
dobutamine B B 0.9997101426124573
( O O 0.9996483325958252
- O O 0.9998648166656494
32 O O 0.9999816417694092
( O O 0.9998830556869507
5 O O 0.9999532699584961
. O O 0.9999881982803345
3 O O 0.9999786615371704
) O O 0.9998732805252075
% O O 0.9999927282333374
, O O 0.9999582767486572
p O O 0.9998717308044434
< O O 0.9999812841415405
0 O O 0.999985933303833
. O O 0.9999966621398926
01 O O 0.9999878406524658
) O O 0.999957799911499
. O O 0.9999759197235107

The O O 0.999977707862854
isovolumic O O 0.9995304346084595
relaxation O O 0.9999282360076904
period O O 0.9999494552612305
was O O 0.9999622106552124
prolonged O O 0.9999798536300659
45 O O 0.9999648332595825
minutes O O 0.9999971389770508
after O O 0.9999685287475586
each O O 0.9999417066574097
form O O 0.9998428821563721
of O O 0.9997977614402771
stress O O 0.9996453523635864
( O O 0.9999252557754517
p O O 0.9996390342712402
< O O 0.99997878074646
0 O O 0.999992847442627
. O O 0.9999961853027344
05 O O 0.9999934434890747
) O O 0.9999690055847168
. O O 0.9999725818634033

CONCLUSIONS O O 0.9992960691452026
: O O 0.999976396560669
In O O 0.9999266862869263
patients O O 0.9999892711639404
with O O 0.9999648332595825
coronary O O 0.9998927116394043
artery O O 0.9997784495353699
disease O O 0.9999967813491821
, O O 0.9997960925102234
dobutamine B B 0.999646782875061
induced O O 0.9997039437294006
ischaemia O O 0.9999265670776367
results O O 0.999964714050293
in O O 0.9999715089797974
prolonged O O 0.9998971223831177
reversible O O 0.9999209642410278
left O O 0.9999754428863525
ventricular O O 0.9999949932098389
dysfunction O O 0.9999932050704956
, O O 0.9999774694442749
presumed O O 0.9999659061431885
to O O 0.9999376535415649
be O O 0.9998784065246582
myocardial O O 0.9999934434890747
stunning O O 0.9999700784683228
, O O 0.9999830722808838
similar O O 0.9999948740005493
to O O 0.9999874830245972
that O O 0.9999946355819702
seen O O 0.999993085861206
after O O 0.9999700784683228
exercise O O 0.9999895095825195
. O O 0.9999746084213257

Dobutamine B B 0.997660756111145
induced O O 0.9996461868286133
ischaemia O O 0.99996018409729
could O O 0.9999531507492065
therefore O O 0.9999755620956421
be O O 0.9999887943267822
used O O 0.9999887943267822
to O O 0.9999903440475464
study O O 0.9999862909317017
the O O 0.9999862909317017
pathophysiology O O 0.9999620914459229
of O O 0.9999843835830688
this O O 0.9999662637710571
phenomenon O O 0.9999959468841553
further O O 0.9999948740005493
in O O 0.9999873638153076
patients O O 0.999995231628418
with O O 0.9999858140945435
coronary O O 0.9998937845230103
artery O O 0.9998315572738647
disease O O 0.9999945163726807
. O O 0.9999608993530273

Anorexigens O O 0.6591082811355591
and O O 0.9997459053993225
pulmonary O O 0.9999196529388428
hypertension O O 0.9986935257911682
in O O 0.9998812675476074
the O O 0.9999581575393677
United O O 0.9955500364303589
States O O 0.9999754428863525
: O O 0.9999761581420898
results O O 0.9999958276748657
from O O 0.9998950958251953
the O O 0.9999799728393555
surveillance O O 0.9999823570251465
of O O 0.9999051094055176
North O O 0.9343159198760986
American O B 0.8853565454483032
pulmonary O O 0.998908519744873
hypertension O O 0.9911400675773621
. O O 0.9999649524688721

BACKGROUND O O 0.9803857803344727
: O O 0.9999537467956543
The O O 0.999982476234436
use O O 0.9998509883880615
of O O 0.9993496537208557
appetite O B 0.7948715686798096
suppressants O I 0.9969258904457092
in O O 0.6817337274551392
Europe O O 0.4633983373641968
has O O 0.9998227953910828
been O O 0.9999533891677856
associated O O 0.9999704360961914
with O O 0.9999867677688599
the O O 0.9999920129776001
development O O 0.9999964237213135
of O O 0.9999866485595703
primary O O 0.9998892545700073
pulmonary O O 0.9999134540557861
hypertension O O 0.9960758090019226
( O O 0.9998112320899963
PPH O O 0.9811490178108215
) O O 0.9999237060546875
. O O 0.9999662637710571

Recently O O 0.9999231100082397
, O O 0.9995779395103455
fenfluramine B B 0.9971936941146851
appetite O I 0.5084502100944519
suppressants O I 0.9742887020111084
became O O 0.9996122717857361
widely O O 0.9999719858169556
used O O 0.9998750686645508
in O O 0.9998399019241333
the O O 0.9999322891235352
United O O 0.9938265681266785
States O O 0.9999426603317261
but O O 0.9998980760574341
were O O 0.9999637603759766
withdrawn O O 0.9998944997787476
in O O 0.999943733215332
September O O 0.9971597194671631
1997 O O 0.9982628226280212
because O O 0.9999924898147583
of O O 0.9999791383743286
concerns O O 0.9999945163726807
over O O 0.9999904632568359
adverse O O 0.9999489784240723
effects O O 0.9999804496765137
. O O 0.9999562501907349

MATERIALS O O 0.999983549118042
AND O O 0.9999945163726807
METHODS O O 0.9999984502792358
: O O 0.9999932050704956
We O O 0.9999923706054688
conducted O O 0.9999969005584717
a O O 0.9999947547912598
prospective O O 0.9999891519546509
surveillance O O 0.9999642372131348
study O O 0.9999920129776001
on O O 0.9999737739562988
patients O O 0.9999920129776001
diagnosed O O 0.9999938011169434
with O O 0.999984622001648
pulmonary O O 0.9999035596847534
hypertension O O 0.9948169589042664
at O O 0.9999215602874756
12 O O 0.9999755620956421
large O O 0.9999661445617676
referral O O 0.9999920129776001
centers O O 0.9999945163726807
in O O 0.9999731779098511
North O O 0.9928814172744751
America O O 0.9990962743759155
. O O 0.9999406337738037

Data O O 0.999976396560669
collected O O 0.99998939037323
on O O 0.9999666213989258
patients O O 0.9999945163726807
seen O O 0.9999961853027344
from O O 0.9999765157699585
September O O 0.9976734519004822
1 O O 0.9998134970664978
, O O 0.9995403289794922
1996 O O 0.9995250701904297
, O O 0.9999876022338867
to O O 0.999976634979248
December O O 0.9989915490150452
31 O O 0.9998438358306885
, O O 0.9999685287475586
1997 O O 0.999849796295166
, O O 0.9999819993972778
included O O 0.9999635219573975
the O O 0.9999823570251465
cause O O 0.9999808073043823
of O O 0.9999788999557495
the O O 0.9999840259552002
pulmonary O O 0.9999710321426392
hypertension O O 0.9998812675476074
and O O 0.9999480247497559
its O O 0.9999864101409912
severity O O 0.9999971389770508
. O O 0.9999649524688721

Patients O O 0.9999403953552246
with O O 0.9999823570251465
no O O 0.9999898672103882
identifiable O O 0.9999960660934448
cause O O 0.999985933303833
of O O 0.9999568462371826
pulmonary O O 0.999940037727356
hypertension O O 0.9994165897369385
were O O 0.9999099969863892
classed O O 0.9998898506164551
as O O 0.989267110824585
PPH O O 0.6612059473991394
. O O 0.999909520149231

A O O 0.9999580383300781
history O O 0.9999629259109497
of O O 0.9995417594909668
drug O O 0.9970890879631042
exposure O O 0.9999039173126221
also O O 0.9999537467956543
was O O 0.9999512434005737
taken O O 0.9999730587005615
with O O 0.9999775886535645
special O O 0.9999556541442871
attention O O 0.9999860525131226
on O O 0.9996211528778076
the O O 0.9999102354049683
use O O 0.9997566342353821
of O O 0.9988970756530762
antidepressants O B 0.8426835536956787
, O O 0.8686169981956482
anorexigens O O 0.7251619100570679
, O O 0.8632497787475586
and O O 0.9680694937705994
amphetamines B B 0.8840494155883789
. O O 0.9997873902320862

RESULTS O O 0.999790608882904
: O O 0.9999798536300659
Five O O 0.9999990463256836
hundred O O 0.9999979734420776
seventy O O 0.9999967813491821
- O O 0.9999674558639526
nine O O 0.9999949932098389
patients O O 0.9999921321868896
were O O 0.9999661445617676
studied O O 0.9998422861099243
, O O 0.9999815225601196
205 O O 0.9996333122253418
with O O 0.998608410358429
PPH O O 0.6038255095481873
and O O 0.9998171925544739
374 O O 0.9999278783798218
with O O 0.9999575614929199
pulmonary O O 0.9998606443405151
hypertension O O 0.9929195046424866
from O O 0.9997976422309875
other O O 0.999482274055481
causes O O 0.9999673366546631
( O O 0.9992918968200684
secondary O O 0.9997939467430115
pulmonary O O 0.9991777539253235
hypertension O O 0.9857261180877686
[ O O 0.9986624717712402
SPH O O 0.6684986352920532
] O O 0.9994932413101196
) O O 0.9999234676361084
. O O 0.9999672174453735

The O O 0.9999085664749146
use O O 0.999810516834259
of O O 0.9993701577186584
anorexigens O O 0.6579146385192871
was O O 0.9997337460517883
common O O 0.9996703863143921
in O O 0.9997902512550354
both O O 0.9992509484291077
groups O O 0.999927282333374
. O O 0.9999287128448486

However O O 0.9999806880950928
, O O 0.9999617338180542
of O O 0.9963956475257874
the O O 0.9995001554489136
medications O O 0.998823344707489
surveyed O O 0.9919260144233704
, O O 0.9998601675033569
only O O 0.9997479319572449
the O O 0.9995728135108948
fenfluramines B B 0.9928538203239441
had O O 0.9998733997344971
a O O 0.9999586343765259
significant O O 0.9999691247940063
preferential O O 0.9999624490737915
association O O 0.9999792575836182
with O O 0.9997323155403137
PPH O B 0.8996752500534058
as O O 0.9999419450759888
compared O O 0.9999536275863647
with O O 0.9993042945861816
SPH O B 0.9777102470397949
( O O 0.9997193217277527
adjusted O O 0.999969482421875
odds O O 0.999922513961792
ratio O O 0.9999871253967285
for O O 0.9999597072601318
use O O 0.9999457597732544
> O O 0.9999107122421265
6 O O 0.9999867677688599
months O O 0.9999971389770508
, O O 0.9999842643737793
7 O O 0.9999386072158813
. O O 0.9999861717224121
5 O O 0.9999858140945435
; O O 0.9999881982803345
95 O O 0.9999959468841553
% O O 0.9999966621398926
confidence O O 0.9999957084655762
interval O O 0.9999953508377075
, O O 0.9999815225601196
1 O O 0.9999949932098389
. O O 0.9999953508377075
7 O O 0.999995231628418
to O O 0.9999808073043823
32 O O 0.9999966621398926
. O O 0.9999964237213135
4 O O 0.9999902248382568
) O O 0.9999788999557495
. O O 0.9999755620956421

The O O 0.9999707937240601
association O O 0.9999678134918213
was O O 0.9999685287475586
stronger O O 0.9999915361404419
with O O 0.9999822378158569
longer O O 0.9999349117279053
duration O O 0.9999467134475708
of O O 0.9997275471687317
use O O 0.9973641037940979
when O O 0.9999758005142212
compared O O 0.9999897480010986
to O O 0.9999529123306274
shorter O O 0.9999716281890869
duration O O 0.9999600648880005
of O O 0.9997144341468811
use O O 0.9988219141960144
and O O 0.9999706745147705
was O O 0.9999661445617676
more O O 0.9999767541885376
pronounced O O 0.9999946355819702
in O O 0.9999412298202515
recent O O 0.9996557235717773
users O O 0.9999041557312012
than O O 0.9999850988388062
in O O 0.9999417066574097
remote O O 0.9994062185287476
users O O 0.9998773336410522
. O O 0.9999736547470093

An O O 0.9999557733535767
unexpectedly O O 0.9999781847000122
high O O 0.9999803304672241
( O O 0.999956488609314
11 O O 0.9999867677688599
. O O 0.9999948740005493
4 O O 0.999994158744812
% O O 0.9999943971633911
) O O 0.9999823570251465
number O O 0.9999868869781494
of O O 0.9999487400054932
patients O O 0.9999761581420898
with O O 0.9997997879981995
SPH O O 0.6362192034721375
had O O 0.9998167157173157
used O O 0.9977585077285767
anorexigens O B 0.9190751910209656
. O O 0.9998010993003845

CONCLUSION O O 0.9999370574951172
: O O 0.9999936819076538
The O O 0.9999934434890747
magnitude O O 0.9999939203262329
of O O 0.9999880790710449
the O O 0.9999911785125732
association O O 0.9999884366989136
with O O 0.9999387264251709
PPH O O 0.6035671234130859
, O O 0.9999308586120605
the O O 0.9999945163726807
increase O O 0.999995231628418
of O O 0.9999916553497314
association O O 0.9999885559082031
with O O 0.9999949932098389
increasing O O 0.99998939037323
duration O O 0.9999885559082031
of O O 0.999930739402771
use O O 0.999882698059082
, O O 0.9999234676361084
and O O 0.9999617338180542
the O O 0.9999785423278809
specificity O O 0.9999746084213257
for O O 0.9998440742492676
fenfluramines B B 0.9791766405105591
are O O 0.9997947812080383
consistent O O 0.9999885559082031
with O O 0.9999942779541016
previous O O 0.9999532699584961
studies O O 0.999985933303833
indicating O O 0.9999417066574097
that O O 0.9998819828033447
fenfluramines B B 0.9841660261154175
are O O 0.999679684638977
causally O O 0.999969482421875
related O O 0.9999797344207764
to O O 0.99981290102005
PPH O O 0.5570496320724487
. O O 0.9999654293060303

The O O 0.9999914169311523
high O O 0.9999868869781494
prevalence O O 0.9999817609786987
of O O 0.9997268319129944
anorexigen O B 0.9749041795730591
use O O 0.9922426342964172
in O O 0.9999001026153564
patients O O 0.9999834299087524
with O O 0.9999135732650757
SPH O O 0.7186002731323242
also O O 0.999953031539917
raises O O 0.999958872795105
the O O 0.999993085861206
possibility O O 0.9999864101409912
that O O 0.9999186992645264
these O O 0.9761366844177246
drugs O O 0.9873991012573242
precipitate O O 0.9998277425765991
pulmonary O O 0.9999300241470337
hypertension O O 0.9997676014900208
in O O 0.9999411106109619
patients O O 0.9999918937683105
with O O 0.9999812841415405
underlying O O 0.9999685287475586
conditions O O 0.999995231628418
associated O O 0.9999889135360718
with O O 0.9999674558639526
SPH O O 0.7804372906684875
. O O 0.999931812286377

Clinical O O 0.9998412132263184
aspects O O 0.9999943971633911
of O O 0.9999351501464844
heparin B B 0.9987454414367676
- O O 0.9993411898612976
induced O O 0.9999269247055054
thrombocytopenia O O 0.9999593496322632
and O O 0.9999024868011475
thrombosis O O 0.9997205138206482
and O O 0.9999470710754395
other O O 0.9999512434005737
side O O 0.9999831914901733
effects O O 0.9999935626983643
of O O 0.999910831451416
heparin B B 0.998275637626648
therapy O O 0.9989116191864014
. O O 0.9999691247940063

Heparin B B 0.9981537461280823
, O O 0.9997068047523499
first O O 0.9999736547470093
used O O 0.9998701810836792
to O O 0.9998266100883484
prevent O O 0.9993508458137512
the O O 0.9999774694442749
clotting O O 0.9997792840003967
of O O 0.9999345541000366
blood O O 0.9998483657836914
in O O 0.9998458623886108
vitro O O 0.9999682903289795
, O O 0.9999507665634155
has O O 0.999923825263977
been O O 0.9999862909317017
clinically O O 0.999985933303833
used O O 0.9999649524688721
to O O 0.9998984336853027
treat O O 0.9998615980148315
thrombosis O O 0.9999279975891113
for O O 0.9999650716781616
more O O 0.9999912977218628
than O O 0.9999964237213135
50 O O 0.9999945163726807
years O O 0.9999939203262329
. O O 0.999915599822998

Although O O 0.9999803304672241
several O O 0.999818742275238
new O O 0.9998899698257446
anticoagulant O O 0.5266130566596985
drugs O O 0.940794050693512
are O O 0.9999256134033203
in O O 0.9999678134918213
development O O 0.999984860420227
, O O 0.9997232556343079
heparin B B 0.9937519431114197
remains O O 0.9997413754463196
the O O 0.9999430179595947
anticoagulant O O 0.49200838804244995
of O O 0.9997885823249817
choice O O 0.9999586343765259
to O O 0.999914288520813
treat O O 0.999936580657959
acute O O 0.9999713897705078
thrombotic O O 0.9999436140060425
episodes O O 0.9999943971633911
. O O 0.9999760389328003

The O O 0.9999574422836304
clinical O O 0.9999717473983765
effects O O 0.9999892711639404
of O O 0.9998334646224976
heparin B B 0.9958299994468689
are O O 0.9995453953742981
meritorious O O 0.9999810457229614
, O O 0.999954342842102
but O O 0.9995622038841248
side O O 0.9998602867126465
effects O O 0.9999661445617676
do O O 0.9999552965164185
exist O O 0.9999853372573853
. O O 0.9999754428863525

Bleeding O O 0.9998544454574585
is O O 0.9999475479125977
the O O 0.9999748468399048
primary O O 0.9999656677246094
untoward O O 0.9999725818634033
effect O O 0.9999809265136719
of O O 0.9998453855514526
heparin B B 0.9963712692260742
. O O 0.9997696280479431

Major O O 0.9999301433563232
bleeding O O 0.9998781681060791
is O O 0.9999740123748779
of O O 0.9999797344207764
primary O O 0.9999591112136841
concern O O 0.9999911785125732
in O O 0.9999487400054932
patients O O 0.9999822378158569
receiving O O 0.9997567534446716
heparin B B 0.9948098659515381
therapy O O 0.9987290501594543
. O O 0.9999793767929077

However O O 0.9999456405639648
, O O 0.9998868703842163
additional O O 0.9999411106109619
important O O 0.9999723434448242
untoward O O 0.9999619722366333
effects O O 0.9999902248382568
of O O 0.99985671043396
heparin B B 0.9994338154792786
therapy O O 0.9991390705108643
include O O 0.9999234676361084
heparin B B 0.9987844824790955
- O O 0.9991980195045471
induced O O 0.9999322891235352
thrombocytopenia O O 0.9997908473014832
, O O 0.9999321699142456
heparin B B 0.9976328611373901
- O O 0.9992245435714722
associated O O 0.999825656414032
osteoporosis O O 0.9978280663490295
, O O 0.9999526739120483
eosinophilia O O 0.9993877410888672
, O O 0.9999412298202515
skin O O 0.9999063014984131
reactions O O 0.999997615814209
, O O 0.999937891960144
allergic O O 0.9970219731330872
reactions O O 0.9999812841415405
other O O 0.9999333620071411
than O O 0.9999579191207886
thrombocytopenia O O 0.9957725405693054
, O O 0.9999556541442871
alopecia O O 0.9927277565002441
, O O 0.9999176263809204
transaminasemia O O 0.7834596037864685
, O O 0.9999189376831055
hyperkalemia O O 0.9498802423477173
, O O 0.99992835521698
hypoaldosteronism O O 0.9110959768295288
, O O 0.9993491768836975
and O O 0.9993011951446533
priapism O O 0.9924314022064209
. O O 0.999937891960144

These O O 0.9997966885566711
side O O 0.9998965263366699
effects O O 0.9999744892120361
are O O 0.9999549388885498
relatively O O 0.9999856948852539
rare O O 0.9999868869781494
in O O 0.9999167919158936
a O O 0.9999459981918335
given O O 0.9998476505279541
individual O O 0.9998899698257446
, O O 0.999961256980896
but O O 0.9999542236328125
given O O 0.9999923706054688
the O O 0.9999954700469971
extremely O O 0.9999845027923584
widespread O O 0.9999759197235107
use O O 0.9999598264694214
of O O 0.9998718500137329
heparin B B 0.9798840284347534
, O O 0.999677300453186
some O O 0.9998794794082642
are O O 0.9999642372131348
quite O O 0.9999614953994751
common O O 0.9999622106552124
, O O 0.9999836683273315
particularly O O 0.9997859597206116
HITT O O 0.89020174741745
and O O 0.9997177720069885
osteoporosis O O 0.9845455884933472
. O O 0.999945878982544

Although O O 0.9999616146087646
reasonable O O 0.9999712705612183
incidences O O 0.9999842643737793
of O O 0.9999547004699707
many O O 0.999910831451416
of O O 0.9998946189880371
these O O 0.9996519088745117
side O O 0.9999208450317383
effects O O 0.9999815225601196
can O O 0.9999769926071167
be O O 0.999994158744812
" O O 0.9999748468399048
softly O O 0.9997960925102234
" O O 0.9999951124191284
deduced O O 0.9999977350234985
from O O 0.9999938011169434
current O O 0.9999942779541016
reports O O 0.9999984502792358
dealing O O 0.999976396560669
with O O 0.9998513460159302
unfractionated O O 0.9557756781578064
heparin B B 0.9560999870300293
, O O 0.9998306035995483
at O O 0.9999786615371704
present O O 0.9999865293502808
the O O 0.9999922513961792
incidences O O 0.9999940395355225
of O O 0.9999690055847168
these O O 0.9999086856842041
side O O 0.9999586343765259
effects O O 0.9999951124191284
with O O 0.9999094009399414
newer O O 0.9976673722267151
low O O 0.9974825978279114
molecular O O 0.9996881484985352
weight O O 0.9839052557945251
heparins B B 0.9523025155067444
appear O O 0.9998750686645508
to O O 0.9999902248382568
be O O 0.9999939203262329
much O O 0.9999953508377075
less O O 0.9999887943267822
common O O 0.9999947547912598
. O O 0.9999786615371704

However O O 0.9999655485153198
, O O 0.9999438524246216
only O O 0.999919056892395
longer O O 0.9996845722198486
experience O O 0.9999545812606812
will O O 0.9999644756317139
more O O 0.9999731779098511
clearly O O 0.9999847412109375
define O O 0.9999860525131226
the O O 0.9999806880950928
incidence O O 0.9999924898147583
of O O 0.9999608993530273
each O O 0.9995856881141663
side O O 0.9998729228973389
effect O O 0.9999749660491943
with O O 0.9999591112136841
low O O 0.9994833469390869
molecular O O 0.9999774694442749
weight O O 0.9980823993682861
preparations O O 0.9998346567153931
. O O 0.9999533891677856

A O O 0.9999696016311646
case O O 0.999994158744812
of O O 0.999977707862854
bilateral O O 0.999902606010437
optic O O 0.9998769760131836
neuropathy O O 0.9999955892562866
in O O 0.9999594688415527
a O O 0.9999879598617554
patient O O 0.9999853372573853
on O O 0.9994279742240906
tacrolimus B B 0.9996471405029297
( O O 0.9517797827720642
FK506 B B 0.9981915354728699
) O O 0.9106816053390503
therapy O O 0.9998741149902344
after O O 0.9999620914459229
liver O O 0.9990398287773132
transplantation O O 0.9999511241912842
. O O 0.9999736547470093

PURPOSE O O 0.9999376535415649
: O O 0.9999927282333374
To O O 0.9999977350234985
report O O 0.9999985694885254
a O O 0.9999966621398926
case O O 0.9999970197677612
of O O 0.999987006187439
bilateral O O 0.9999651908874512
optic O O 0.9999442100524902
neuropathy O O 0.9999978542327881
in O O 0.9999727010726929
a O O 0.9999926090240479
patient O O 0.9999899864196777
receiving O O 0.9994082450866699
tacrolimus B B 0.9996675252914429
( O O 0.9687665700912476
FK B B 0.9952280521392822
506 I I 0.9989985823631287
, O O 0.6122812032699585
Prograf O O 0.41497501730918884
; O O 0.9410301446914673
Fujisawa O B 0.8835170865058899
USA O O 0.5193232893943787
, O O 0.8000909686088562
Inc O B 0.8583377599716187
, O O 0.6497551798820496
Deerfield O O 0.7910834550857544
, O O 0.5798242688179016
Illinois O O 0.43417179584503174
) O O 0.9997859597206116
for O O 0.9999649524688721
immunosuppression O O 0.9999161958694458
after O O 0.9999579191207886
orthotropic O O 0.9646658897399902
liver O O 0.9990955591201782
transplantation O O 0.9999688863754272
. O O 0.9999778270721436

METHOD O O 0.9999526739120483
: O O 0.9999810457229614
Case O O 0.9999608993530273
report O O 0.9999912977218628
. O O 0.9999697208404541

In O O 0.9999843835830688
a O O 0.9999953508377075
58 O O 0.9999973773956299
- O O 0.9999921321868896
year O O 0.9999978542327881
- O O 0.9999954700469971
old O O 0.999997615814209
man O O 0.9999969005584717
receiving O O 0.9986898303031921
tacrolimus B B 0.9996788501739502
after O O 0.99951171875
orthotropic O O 0.9673720002174377
liver O O 0.9953462481498718
transplantation O O 0.9999462366104126
, O O 0.9999855756759644
serial O O 0.9999814033508301
neuro O O 0.9999967813491821
- O O 0.9998533725738525
ophthalmologic O O 0.9999788999557495
examinations O O 0.9999963045120239
and O O 0.999984622001648
laboratory O O 0.9999765157699585
studies O O 0.9999946355819702
were O O 0.9999861717224121
performed O O 0.9999954700469971
. O O 0.9999794960021973

RESULTS O O 0.9995668530464172
: O O 0.9999381303787231
The O O 0.9999905824661255
patient O O 0.9999831914901733
had O O 0.9999606609344482
episodic O O 0.9999760389328003
deterioration O O 0.9999992847442627
of O O 0.9999932050704956
vision O O 0.999997615814209
in O O 0.9999649524688721
both O O 0.9998266100883484
eyes O O 0.9999939203262329
, O O 0.9999715089797974
with O O 0.9999737739562988
clinical O O 0.9999892711639404
features O O 0.999997615814209
resembling O O 0.9999094009399414
ischemic O O 0.9998646974563599
optic O O 0.9996907711029053
neuropathies O O 0.9999886751174927
. O O 0.9999696016311646

Deterioration O O 0.9999871253967285
of O O 0.9999918937683105
vision O O 0.999996542930603
occurred O O 0.9999867677688599
despite O O 0.9999079704284668
discontinuation O O 0.9999686479568481
of O O 0.9997933506965637
the O O 0.9995347261428833
tacrolimus B B 0.9995560050010681
. O O 0.9999067783355713

CONCLUSION O O 0.9894993305206299
: O O 0.9981846213340759
Tacrolimus B B 0.9997628331184387
and O O 0.9985809326171875
other O O 0.9987215399742126
immunosuppressive O O 0.9855834245681763
agents O O 0.991157054901123
may O O 0.9998522996902466
be O O 0.9999047517776489
associated O O 0.9999381303787231
with O O 0.9999116659164429
optic O O 0.9995155334472656
nerve O O 0.9981371164321899
toxicity O O 0.9999418258666992
. O O 0.9999593496322632

Hypercalcemia O O 0.9206191301345825
, O O 0.9994626641273499
arrhythmia O O 0.9941942095756531
, O O 0.9950954914093018
and O O 0.9958117008209229
mood O O 0.7642598152160645
stabilizers O O 0.9421442151069641
. O O 0.9995736479759216

Recent O O 0.9999924898147583
findings O O 0.9999960660934448
in O O 0.9999889135360718
a O O 0.9999871253967285
bipolar O O 0.9770190119743347
patient O O 0.9999736547470093
receiving O O 0.99965500831604
maintenance O O 0.9970574378967285
lithium B B 0.9996216297149658
therapy O O 0.9942546486854553
who O O 0.9999717473983765
developed O O 0.9999878406524658
hypercalcemia O O 0.9993773102760315
and O O 0.999957799911499
severe O O 0.9999755620956421
bradyarrhythmia O O 0.9999537467956543
prompted O O 0.999991774559021
the O O 0.9999978542327881
authors O O 0.999996542930603
to O O 0.9999972581863403
conduct O O 0.9999980926513672
a O O 0.9999970197677612
retrospective O O 0.999985933303833
study O O 0.9999947547912598
of O O 0.9999853372573853
bipolar O O 0.9722646474838257
patients O O 0.9999589920043945
with O O 0.9999632835388184
lithium B B 0.9996836185455322
- O O 0.999574601650238
associated O O 0.9999094009399414
hypercalcemia O O 0.9981517195701599
. O O 0.999946117401123

A O O 0.9999077320098877
printout O O 0.9999405145645142
of O O 0.9999650716781616
all O O 0.9999390840530396
cases O O 0.9999895095825195
of O O 0.999954342842102
hypercalcemia O O 0.8429250717163086
that O O 0.9999672174453735
presented O O 0.9999926090240479
during O O 0.9999738931655884
a O O 0.9999814033508301
1 O O 0.9999700784683228
- O O 0.9999878406524658
year O O 0.9999942779541016
period O O 0.9999933242797852
was O O 0.9999508857727051
generated O O 0.9997201561927795
. O O 0.9999654293060303

After O O 0.999980092048645
eliminating O O 0.999779999256134
spurious O O 0.9999368190765381
hypercalcemias O O 0.9991080164909363
or O O 0.999944806098938
those O O 0.9999806880950928
associated O O 0.9999866485595703
with O O 0.999904990196228
intravenous O O 0.999923586845398
fluids O O 0.9994766116142273
, O O 0.9999656677246094
the O O 0.9999895095825195
authors O O 0.9999935626983643
identified O O 0.99998939037323
18 O O 0.9999884366989136
non O O 0.9958624839782715
- O O 0.9992497563362122
lithium B B 0.9976053237915039
- O O 0.998988687992096
treated O O 0.9998098015785217
patients O O 0.9999938011169434
with O O 0.9999586343765259
hypercalcemias O O 0.9995759129524231
related O O 0.9999806880950928
to O O 0.9999289512634277
malignancies O O 0.9999938011169434
and O O 0.9999405145645142
other O O 0.999921441078186
medical O O 0.9999927282333374
conditions O O 0.9999970197677612
( O O 0.9999392032623291
group O O 0.9999363422393799
A O O 0.9990424513816833
) O O 0.9999656677246094
and O O 0.9999487400054932
12 O O 0.9999902248382568
patients O O 0.9999949932098389
with O O 0.9999719858169556
lithium B B 0.999656081199646
- O O 0.9992530941963196
associated O O 0.9999122619628906
hypercalcemia O O 0.9148414731025696
( O O 0.9999493360519409
group O O 0.9999076128005981
B O O 0.9995610117912292
) O O 0.9999781847000122
. O O 0.9999724626541138

Patients O O 0.9999771118164062
in O O 0.9999054670333862
group O O 0.9998534917831421
B O O 0.9953359961509705
were O O 0.9999809265136719
not O O 0.9999954700469971
comparable O O 0.9999938011169434
to O O 0.9999624490737915
those O O 0.999985933303833
in O O 0.9999513626098633
group O O 0.9999678134918213
A O O 0.9962599277496338
, O O 0.9999624490737915
as O O 0.9999948740005493
the O O 0.9999908208847046
latter O O 0.9999908208847046
were O O 0.9999902248382568
medically O O 0.9999934434890747
compromised O O 0.9999967813491821
and O O 0.9999840259552002
were O O 0.999991774559021
receiving O O 0.9998780488967896
multiple O O 0.9998986721038818
pharmacotherapies O O 0.9936023354530334
. O O 0.9999618530273438

Thus O O 0.9999442100524902
, O O 0.9999123811721802
two O O 0.9999027252197266
control O O 0.9999071359634399
groups O O 0.9999662637710571
were O O 0.9999486207962036
generated O O 0.9998984336853027
: O O 0.9999382495880127
group O O 0.9998701810836792
C1 O O 0.9928109049797058
, O O 0.9999774694442749
which O O 0.9999501705169678
included O O 0.9999362230300903
age O O 0.9985621571540833
- O O 0.9999802112579346
and O O 0.9999674558639526
sex O O 0.9995379447937012
- O O 0.9999794960021973
comparable O O 0.9555231928825378
lithium B B 0.9997864365577698
- O O 0.9989511966705322
treated O O 0.9995021820068359
bipolar O O 0.6089143753051758
normocalcemic O O 0.9767351746559143
patients O O 0.9999669790267944
, O O 0.9999480247497559
and O O 0.999923825263977
group O O 0.9997140765190125
C2 O O 0.9953376054763794
, O O 0.9999663829803467
which O O 0.9998842477798462
included O O 0.9999539852142334
bipolar O O 0.6804998517036438
normocalcemic O O 0.9726100564002991
patients O O 0.9999734163284302
treated O O 0.9999464750289917
with O O 0.9998950958251953
anticonvulsant O O 0.545626699924469
mood O O 0.6026563048362732
stabilizers O O 0.6883648633956909
. O O 0.9999397993087769

The O O 0.999985933303833
electrocardiographic O O 0.9999468326568604
( O O 0.9998723268508911
ECG O O 0.9988344311714172
) O O 0.999961256980896
findings O O 0.9999964237213135
for O O 0.9999523162841797
patients O O 0.9999880790710449
in O O 0.9998469352722168
group O O 0.9997259974479675
B O O 0.9964746832847595
were O O 0.9999638795852661
compared O O 0.9999874830245972
with O O 0.9999725818634033
those O O 0.9999889135360718
of O O 0.9999759197235107
patients O O 0.9999833106994629
in O O 0.9998624324798584
groups O O 0.9995519518852234
C1 O O 0.9979240894317627
and O O 0.9997395873069763
C2 O O 0.9984661340713501
. O O 0.999963641166687

It O O 0.9999873638153076
was O O 0.999972939491272
found O O 0.9999945163726807
that O O 0.9999587535858154
these O O 0.9997767806053162
groups O O 0.9999594688415527
did O O 0.9999806880950928
not O O 0.9999871253967285
differ O O 0.9999904632568359
in O O 0.9999871253967285
their O O 0.9999850988388062
overall O O 0.9999673366546631
frequency O O 0.9999959468841553
of O O 0.9999631643295288
ECG O O 0.9986116886138916
abnormalities O O 0.9999790191650391
; O O 0.9999315738677979
however O O 0.9999761581420898
, O O 0.9999659061431885
there O O 0.9999475479125977
were O O 0.9999411106109619
significant O O 0.9999592304229736
differences O O 0.9999942779541016
in O O 0.9999865293502808
the O O 0.9999853372573853
frequency O O 0.9999934434890747
of O O 0.9999727010726929
conduction O O 0.9999771118164062
defects O O 0.9999966621398926
. O O 0.9999585151672363

Patients O O 0.9999599456787109
with O O 0.9999401569366455
hypercalcemia O O 0.9509971737861633
resulting O O 0.999934196472168
from O O 0.9997552037239075
medical O O 0.999904990196228
diseases O O 0.9999947547912598
and O O 0.9998736381530762
bipolar O O 0.8890831470489502
patients O O 0.9999558925628662
with O O 0.9998822212219238
lithium B B 0.9999070167541504
- O O 0.9994204044342041
associated O O 0.9998840093612671
hypercalcemia O O 0.9959314465522766
had O O 0.9999797344207764
significantly O O 0.9999929666519165
higher O O 0.9999845027923584
frequencies O O 0.9999979734420776
of O O 0.999985933303833
conduction O O 0.9999874830245972
defects O O 0.9999979734420776
. O O 0.9999760389328003

Patients O O 0.9999665021896362
in O O 0.9998199343681335
group O O 0.9996222257614136
A O O 0.9817764163017273
had O O 0.9999709129333496
significant O O 0.9999806880950928
mortality O O 0.9999922513961792
at O O 0.9999867677688599
2 O O 0.9998898506164551
- O O 0.9999879598617554
year O O 0.9999945163726807
follow O O 0.9999940395355225
- O O 0.9999897480010986
up O O 0.9999973773956299
( O O 0.9999765157699585
28 O O 0.9999891519546509
% O O 0.9999971389770508
) O O 0.9999754428863525
, O O 0.9999676942825317
in O O 0.9999665021896362
contrast O O 0.999962568283081
to O O 0.9999595880508423
zero O O 0.9999282360076904
mortality O O 0.9999830722808838
in O O 0.9998584985733032
the O O 0.9999457597732544
other O O 0.9999595880508423
three O O 0.999935507774353
groups O O 0.999977707862854
. O O 0.9999730587005615

The O O 0.9999891519546509
clinical O O 0.9999935626983643
implications O O 0.9999991655349731
of O O 0.9999973773956299
these O O 0.9999955892562866
findings O O 0.9999960660934448
are O O 0.9999847412109375
discussed O O 0.999993085861206
. O O 0.999983549118042

Attenuation O O 0.9998020529747009
of O O 0.9996508359909058
nephrotoxicity O O 0.9991877675056458
by O O 0.999811589717865
a O O 0.9990610480308533
novel O O 0.9989556074142456
lipid O O 0.7702738642692566
nanosphere O O 0.8540111184120178
( O O 0.9935088157653809
NS O B 0.7571741342544556
- O I 0.7825788855552673
718 O I 0.9859345555305481
) O O 0.6721182465553284
incorporating O O 0.943406879901886
amphotericin B B 0.9969569444656372
B I I 0.9999372959136963
. O O 0.9994444251060486

NS O B 0.8859168291091919
- O I 0.9608781933784485
718 O I 0.9999661445617676
, O O 0.9953061938285828
a O O 0.9948217868804932
lipid O O 0.5119339227676392
nanosphere O O 0.62751704454422
incorporating O O 0.8722981810569763
amphotericin B B 0.984814465045929
B I I 0.9999513626098633
, O O 0.9936431646347046
is O O 0.9998433589935303
effective O O 0.9993056058883667
against O O 0.9988534450531006
pathogenic O O 0.9999754428863525
fungi O O 0.9999572038650513
and O O 0.9999642372131348
has O O 0.9998983144760132
low O O 0.9998992681503296
toxicity O O 0.9999668598175049
. O O 0.9997987151145935

We O O 0.999976634979248
compared O O 0.9999772310256958
the O O 0.9999737739562988
toxicity O O 0.9999657869338989
of O O 0.9989582300186157
NS O B 0.9863508343696594
- O I 0.9824899435043335
718 O I 0.9999856948852539
with O O 0.9976645708084106
that O O 0.9998488426208496
of O O 0.9976383447647095
Fungizone B B 0.9997182488441467
( O O 0.978199303150177
amphotericin B B 0.9975199103355408
B I I 0.9999287128448486
- I I 0.8647528886795044
sodium I I 0.9543241858482361
deoxycholate I I 0.9993532299995422
; O O 0.9101607799530029
D B B 0.8608903884887695
- I I 0.8980008959770203
AmB I I 0.9998366832733154
) O O 0.9995014667510986
in O O 0.9999474287033081
vitro O O 0.9999945163726807
using O O 0.9999088048934937
renal O O 0.9999690055847168
cell O O 0.9999690055847168
cultures O O 0.9999673366546631
and O O 0.9999263286590576
in O O 0.9998098015785217
vivo O O 0.9999468326568604
by O O 0.9999868869781494
biochemical O O 0.9996662139892578
analysis O O 0.9999901056289673
, O O 0.9999707937240601
histopathological O O 0.9999850988388062
study O O 0.9999951124191284
of O O 0.9999788999557495
the O O 0.9999872446060181
kidney O O 0.9999493360519409
and O O 0.9999756813049316
pharmacokinetic O O 0.9998663663864136
study O O 0.9999887943267822
of O O 0.9978435039520264
amphotericin B B 0.9995889067649841
B I I 0.9999582767486572
following O O 0.9995618462562561
intravenous O O 0.9999834299087524
infusion O O 0.9999808073043823
of O O 0.9998798370361328
the O O 0.9149265289306641
formulation O O 0.6791890859603882
in O O 0.9991320967674255
rats O O 0.9998173117637634
. O O 0.9999730587005615

Incubation O O 0.9999653100967407
with O O 0.9996800422668457
NS O B 0.769807755947113
- O I 0.7569248080253601
718 O I 0.9998444318771362
resulted O O 0.9996813535690308
in O O 0.9999915361404419
significantly O O 0.999993085861206
less O O 0.9999833106994629
damage O O 0.9999927282333374
of O O 0.9999712705612183
cultured O O 0.9999537467956543
human O O 0.9997532963752747
renal O O 0.999895453453064
proximal O O 0.9997345805168152
tubular O O 0.9999842643737793
epithelial O O 0.9996378421783447
cells O O 0.9999806880950928
compared O O 0.999977707862854
with O O 0.9999057054519653
D B B 0.6025991439819336
- I I 0.780170202255249
AmB I I 0.9961279034614563
. O O 0.9997873902320862

Serum O O 0.9998031258583069
blood O O 0.9643921852111816
urea B B 0.6855502128601074
and O O 0.9995920062065125
creatinine B B 0.9971076846122742
concentrations O O 0.9993809461593628
increased O O 0.9999624490737915
significantly O O 0.9999910593032837
in O O 0.9999442100524902
rats O O 0.9995880722999573
given O O 0.9999274015426636
an O O 0.9999849796295166
iv O O 0.9997178912162781
infusion O O 0.9999744892120361
of O O 0.9995834231376648
D B B 0.7753610610961914
- I I 0.8570243120193481
AmB I I 0.999723494052887
3 O O 0.975851833820343
mg O O 0.999842643737793
/ O O 0.9999703168869019
kg O O 0.9999773502349854
but O O 0.9999769926071167
not O O 0.999962568283081
in O O 0.9999499320983887
those O O 0.9999804496765137
given O O 0.9999520778656006
the O O 0.9999954700469971
same O O 0.9999903440475464
dose O O 0.9998834133148193
of O O 0.9997798800468445
NS O B 0.9676607251167297
- O I 0.947766900062561
718 O I 0.9999836683273315
. O O 0.9998378753662109

Histopathological O O 0.999933123588562
examination O O 0.9999942779541016
of O O 0.9999752044677734
the O O 0.9999849796295166
kidney O O 0.9998782873153687
showed O O 0.9999239444732666
tubular O O 0.9999802112579346
necrosis O O 0.9999865293502808
in O O 0.9998356103897095
D B B 0.8973435759544373
- I I 0.8733064532279968
AmB I I 0.9995984435081482
- O O 0.9967677593231201
treated O O 0.9998530149459839
rats O O 0.9999896287918091
but O O 0.9999639987945557
no O O 0.9999692440032959
change O O 0.9999954700469971
in O O 0.9998806715011597
NS O B 0.6649515628814697
- O I 0.5489047765731812
718 O I 0.9993137121200562
- O O 0.9936701059341431
treated O O 0.9998877048492432
rats O O 0.999992847442627
. O O 0.9999755620956421

Amphotericin B B 0.9887304902076721
B I I 0.9998252987861633
concentrations O O 0.9928680658340454
in O O 0.9998456239700317
the O O 0.9999756813049316
kidney O O 0.999936580657959
in O O 0.9998513460159302
NS O B 0.71827632188797
- O I 0.6780579090118408
718 O I 0.9996829032897949
- O O 0.9914571642875671
treated O O 0.9998939037322998
rats O O 0.9999939203262329
were O O 0.9999713897705078
higher O O 0.9998261332511902
than O O 0.9999678134918213
those O O 0.9999802112579346
in O O 0.9999110698699951
D B B 0.8326326012611389
- I I 0.8156601786613464
AmB I I 0.9995335340499878
- O O 0.9929431080818176
treated O O 0.999915361404419
rats O O 0.9999926090240479
. O O 0.9999734163284302

Our O O 0.9999713897705078
in O O 0.9999169111251831
vitro O O 0.9999910593032837
and O O 0.9999136924743652
in O O 0.9998706579208374
vivo O O 0.9999866485595703
results O O 0.9999923706054688
suggest O O 0.9999754428863525
that O O 0.9998964071273804
incorporation O O 0.9999361038208008
of O O 0.9991087317466736
amphotericin B B 0.9979338645935059
B I I 0.999974250793457
into O O 0.998327910900116
lipid O O 0.9288169145584106
nanospheres O O 0.9928007125854492
of O O 0.9988645315170288
NS O B 0.782529354095459
- O I 0.816548764705658
718 O I 0.992339015007019
attenuates O O 0.9948845505714417
the O O 0.9999657869338989
nephrotoxicity O O 0.9999470710754395
of O O 0.9997754693031311
amphotericin B B 0.9991307854652405
B I I 0.9999693632125854
. O O 0.9998651742935181

Patterns O O 0.9668728113174438
of O O 0.9790937304496765
sulfadiazine B B 0.9983229041099548
acute O O 0.9991737008094788
nephrotoxicity O O 0.7189222574234009
. O O 0.9982380867004395

Sulfadiazine B B 0.997229278087616
acute O O 0.9996871948242188
nephrotoxicity O O 0.5651633739471436
is O O 0.9998212456703186
reviving O O 0.9990631937980652
specially O O 0.9997302889823914
because O O 0.9999775886535645
of O O 0.9999290704727173
its O O 0.9986335635185242
use O O 0.9998384714126587
in O O 0.9997376799583435
toxoplasmosis O O 0.8404048085212708
in O O 0.9991341233253479
HIV O O 0.6918805241584778
- O O 0.9990430474281311
positive O O 0.9997121691703796
patients O O 0.999981164932251
. O O 0.9999219179153442

We O O 0.9998674392700195
report O O 0.999994158744812
4 O O 0.9995563626289368
cases O O 0.999991774559021
, O O 0.9999901056289673
one O O 0.9999901056289673
of O O 0.9999313354492188
them O O 0.9999949932098389
in O O 0.9999489784240723
a O O 0.9999827146530151
previously O O 0.9999579191207886
healthy O O 0.9999778270721436
person O O 0.9999977350234985
. O O 0.9999567270278931

Under O O 0.9996644258499146
treatment O O 0.9999675750732422
with O O 0.9991915822029114
sulfadiazine B B 0.9989449381828308
they O O 0.9999309778213501
developed O O 0.9999946355819702
oliguria O O 0.9999500513076782
, O O 0.9999885559082031
abdominal O O 0.9999905824661255
pain O O 0.9999972581863403
, O O 0.9999842643737793
renal O O 0.9999879598617554
failure O O 0.9999927282333374
and O O 0.9999890327453613
showed O O 0.9999910593032837
multiple O O 0.9999397993087769
radiolucent O O 0.98117595911026
renal O O 0.9903658628463745
calculi O O 0.9984209537506104
in O O 0.9999593496322632
echography O O 0.9986751675605774
. O O 0.9999818801879883

All O O 0.9997386336326599
patients O O 0.9999692440032959
recovered O O 0.9999707937240601
their O O 0.9999923706054688
previous O O 0.9999924898147583
normal O O 0.9999932050704956
renal O O 0.9999873638153076
function O O 0.9999938011169434
after O O 0.9999276399612427
adequate O O 0.9998977184295654
hydration O O 0.995162844657898
and O O 0.9997195601463318
alcalinization O B 0.9767636060714722
. O O 0.9999316930770874

A O O 0.9999746084213257
nephrostomy O O 0.9895243048667908
tube O O 0.9996787309646606
had O O 0.9999442100524902
to O O 0.9999879598617554
be O O 0.9999879598617554
placed O O 0.9999760389328003
in O O 0.9999675750732422
one O O 0.9999871253967285
of O O 0.9999797344207764
the O O 0.99998939037323
patients O O 0.9999864101409912
for O O 0.9999645948410034
ureteral O O 0.9993877410888672
lithiasis O O 0.9993269443511963
in O O 0.9999109506607056
a O O 0.9999693632125854
single O O 0.9999487400054932
functional O O 0.9998018145561218
kidney O O 0.9999510049819946
. O O 0.9999603033065796

None O O 0.9999673366546631
of O O 0.9999704360961914
them O O 0.9999902248382568
needed O O 0.9999686479568481
dialysis O O 0.9997660517692566
or O O 0.9999785423278809
a O O 0.9999922513961792
renal O O 0.9999793767929077
biopsy O O 0.999987006187439
because O O 0.9999842643737793
of O O 0.9999886751174927
a O O 0.9999915361404419
typical O O 0.9999943971633911
benign O O 0.9999890327453613
course O O 0.9999963045120239
. O O 0.9999700784683228

Treatment O O 0.9999606609344482
with O O 0.9993805885314941
sulfadiazine B B 0.9988589286804199
requires O O 0.9998743534088135
exquisite O O 0.9997338652610779
control O O 0.999985933303833
of O O 0.9999651908874512
renal O O 0.999976634979248
function O O 0.9999895095825195
, O O 0.9999749660491943
an O O 0.9999881982803345
increase O O 0.9999794960021973
in O O 0.9998664855957031
water O B 0.867493748664856
ingestion O O 0.999203622341156
and O O 0.999962568283081
possibly O O 0.9999796152114868
the O O 0.9999877214431763
alcalinization O O 0.5706366896629333
of O O 0.9997369647026062
the O O 0.9999926090240479
urine O O 0.9999434947967529
. O O 0.9999740123748779

We O O 0.9996949434280396
communicate O O 0.9999929666519165
a O O 0.9999876022338867
case O O 0.999987006187439
in O O 0.9999573230743408
a O O 0.9999667406082153
previously O O 0.9999527931213379
healthy O O 0.9999825954437256
person O O 0.9999963045120239
, O O 0.999984622001648
a O O 0.9999915361404419
fact O O 0.9999949932098389
not O O 0.9999947547912598
found O O 0.9999977350234985
in O O 0.9999897480010986
the O O 0.9999948740005493
recent O O 0.9999948740005493
literature O O 0.9999957084655762
. O O 0.9999715089797974

Probably O O 0.9999809265136719
many O O 0.999975323677063
more O O 0.9999649524688721
cases O O 0.9999741315841675
are O O 0.9999725818634033
not O O 0.9999830722808838
detected O O 0.9999850988388062
. O O 0.9999535083770752

We O O 0.9999749660491943
think O O 0.9999849796295166
that O O 0.9999945163726807
a O O 0.9999920129776001
prospective O O 0.999968409538269
study O O 0.9999912977218628
would O O 0.9999860525131226
be O O 0.9999969005584717
useful O O 0.9999971389770508
. O O 0.9999828338623047

Downbeat O O 0.9993355870246887
nystagmus O O 0.9999785423278809
associated O O 0.9999841451644897
with O O 0.9999494552612305
intravenous O O 0.9999607801437378
patient O O 0.9877007007598877
- O O 0.9999703168869019
controlled O O 0.9999415874481201
administration O O 0.999970555305481
of O O 0.9978201389312744
morphine B B 0.9996463060379028
. O O 0.9999274015426636

IMPLICATIONS O O 0.9993914365768433
: O O 0.9999793767929077
This O O 0.9999911785125732
case O O 0.9999923706054688
documents O O 0.9999734163284302
a O O 0.9999921321868896
patient O O 0.9999908208847046
who O O 0.9998989105224609
developed O O 0.999987006187439
dizziness O O 0.999966025352478
with O O 0.9999697208404541
downbeating O O 0.9996185302734375
nystagmus O O 0.9999850988388062
while O O 0.9999110698699951
receiving O O 0.9996592998504639
a O O 0.9999638795852661
relatively O O 0.9999607801437378
large O O 0.9999380111694336
dose O O 0.9991582632064819
of O O 0.9992079138755798
IV O O 0.9531502723693848
patient O O 0.9630374312400818
- O O 0.9998867511749268
controlled O O 0.9818939566612244
analgesia O O 0.6012532114982605
morphine B B 0.9980795383453369
. O O 0.9999076128005981

Although O O 0.9999488592147827
there O O 0.999963641166687
have O O 0.9999912977218628
been O O 0.9999939203262329
case O O 0.9999544620513916
reports O O 0.9999934434890747
of O O 0.9999068975448608
epidural O O 0.4502074420452118
morphine B B 0.9848381280899048
with O O 0.9996453523635864
these O O 0.9999511241912842
symptoms O O 0.9999951124191284
and O O 0.9999922513961792
signs O O 0.999992847442627
, O O 0.9999691247940063
this O O 0.9999858140945435
has O O 0.999984622001648
not O O 0.9999920129776001
been O O 0.9999954700469971
previously O O 0.9999685287475586
documented O O 0.9999957084655762
with O O 0.9998914003372192
IV O O 0.9300011992454529
or O O 0.9998507499694824
patient O O 0.9960681200027466
- O O 0.9999760389328003
controlled O O 0.999380350112915
analgesia O O 0.9620123505592346
morphine B B 0.9971977472305298
. O O 0.999894380569458

Hemodynamic O O 0.9991208910942078
and O O 0.9998412132263184
antiadrenergic O O 0.6307548880577087
effects O O 0.9998646974563599
of O O 0.9997562766075134
dronedarone B B 0.9999040365219116
and O O 0.9563776254653931
amiodarone B B 0.999756395816803
in O O 0.9999494552612305
animals O O 0.9999899864196777
with O O 0.9999898672103882
a O O 0.999991774559021
healed O O 0.9999916553497314
myocardial O O 0.9999988079071045
infarction O O 0.9999926090240479
. O O 0.9999713897705078

The O O 0.9999384880065918
hemodynamic O O 0.9991428852081299
and O O 0.9998443126678467
antiadrenergic O O 0.7427223920822144
effects O O 0.9999182224273682
of O O 0.999749481678009
dronedarone B B 0.9999332427978516
, O O 0.9998599290847778
a O O 0.9981766939163208
noniodinated O O 0.5843790173530579
compound O O 0.8456347584724426
structurally O O 0.9984496831893921
related O O 0.9999313354492188
to O O 0.9989570379257202
amiodarone B B 0.9994624257087708
, O O 0.999915361404419
were O O 0.9999799728393555
compared O O 0.9999876022338867
with O O 0.9999816417694092
those O O 0.9999781847000122
of O O 0.9998327493667603
amiodarone B B 0.9997846484184265
after O O 0.9997966885566711
prolonged O O 0.9998950958251953
oral O O 0.9961125254631042
administration O O 0.9999686479568481
, O O 0.999987006187439
both O O 0.9999462366104126
at O O 0.9999746084213257
rest O O 0.9999908208847046
and O O 0.9999723434448242
during O O 0.9999468326568604
sympathetic O O 0.9946008920669556
stimulation O O 0.9999823570251465
in O O 0.9999498128890991
conscious O O 0.9999856948852539
dogs O O 0.9999920129776001
with O O 0.9999899864196777
a O O 0.9999924898147583
healed O O 0.9999909400939941
myocardial O O 0.999998927116394
infarction O O 0.9999938011169434
. O O 0.9999747276306152

All O O 0.9998243451118469
dogs O O 0.9999840259552002
( O O 0.9999442100524902
n O O 0.9999735355377197
= O O 0.9999716281890869
6 O O 0.9999939203262329
) O O 0.9999871253967285
randomly O O 0.999983549118042
received O O 0.9999768733978271
orally O O 0.9987616539001465
dronedarone B B 0.9998705387115479
( O O 0.9991193413734436
10 O O 0.9996864795684814
and O O 0.9997407793998718
30 O O 0.9999454021453857
mg O O 0.9998987913131714
/ O O 0.9999769926071167
kg O O 0.9999953508377075
) O O 0.999748170375824
, O O 0.9983602166175842
amiodarone B B 0.9997649788856506
( O O 0.998595654964447
10 O O 0.9972906708717346
and O O 0.9993147850036621
30 O O 0.9997507929801941
mg O O 0.9998552799224854
/ O O 0.999915361404419
kg O O 0.9999926090240479
) O O 0.9997739195823669
, O O 0.9994680285453796
and O O 0.9992401599884033
placebo O O 0.998256266117096
twice O O 0.9997668862342834
daily O O 0.9999709129333496
for O O 0.9999668598175049
7 O O 0.9999638795852661
days O O 0.9999932050704956
, O O 0.9999884366989136
with O O 0.9999915361404419
a O O 0.9999939203262329
3 O O 0.9999457597732544
- O O 0.9999897480010986
week O O 0.9999963045120239
washout O O 0.9999856948852539
between O O 0.9999803304672241
consecutive O O 0.9993658661842346
treatments O O 0.9999723434448242
. O O 0.9999839067459106

Heart O O 0.9999306201934814
rate O O 0.9999921321868896
( O O 0.9999682903289795
HR O O 0.9894058108329773
) O O 0.9999700784683228
, O O 0.9999467134475708
mean O O 0.9999737739562988
arterial O O 0.9989722967147827
pressure O O 0.9999487400054932
( O O 0.9998857975006104
MBP O O 0.99962317943573
) O O 0.9999687671661377
, O O 0.9999363422393799
positive O O 0.9999605417251587
rate O O 0.9999939203262329
of O O 0.9999734163284302
increase O O 0.9998390674591064
of O O 0.9998779296875
left O O 0.9999456405639648
ventricular O O 0.9999792575836182
pressure O O 0.9996964931488037
( O O 0.9998225569725037
+ O O 0.999818742275238
LVdP O O 0.9031863808631897
/ O O 0.9992338418960571
dt O O 0.9720180630683899
) O O 0.9999587535858154
, O O 0.9999183416366577
echocardiographically O O 0.9998369216918945
assessed O O 0.9999685287475586
left O O 0.99967360496521
ventricular O O 0.9999812841415405
ejection O O 0.9993002414703369
fraction O O 0.9999927282333374
( O O 0.9998998641967773
LVEF O O 0.9657382369041443
) O O 0.9999364614486694
, O O 0.9998372793197632
and O O 0.999756395816803
fractional O O 0.999977707862854
shortening O O 0.9999915361404419
( O O 0.9999258518218994
FS O O 0.9998898506164551
) O O 0.9999810457229614
, O O 0.9999171495437622
as O O 0.9999145269393921
well O O 0.9999184608459473
as O O 0.9999673366546631
chronotropic O O 0.9742804169654846
response O O 0.999984860420227
to O O 0.999714195728302
isoproterenol B B 0.9991214871406555
and O O 0.9971020817756653
exercise O O 0.9170424342155457
- O O 0.9998176693916321
induced O O 0.9999446868896484
sympathetic O O 0.9991807341575623
stimulation O O 0.9999608993530273
were O O 0.9999775886535645
evaluated O O 0.9999829530715942
under O O 0.9999417066574097
baseline O O 0.9999853372573853
and O O 0.9999668598175049
posttreatment O O 0.9995458722114563
conditions O O 0.9999926090240479
. O O 0.9999821186065674

Resting O O 0.9998737573623657
values O O 0.9999638795852661
of O O 0.9998326301574707
LVEF O O 0.9037114977836609
, O O 0.9990346431732178
FS O O 0.9952032566070557
, O O 0.9998200535774231
+ O O 0.99937504529953
LVdP O O 0.8986958861351013
/ O O 0.9982025623321533
dt O O 0.9832555055618286
, O O 0.9988431930541992
and O O 0.9986838698387146
MBP O O 0.9362841844558716
remained O O 0.9999580383300781
unchanged O O 0.9999891519546509
whatever O O 0.9982372522354126
the O O 0.9999626874923706
drug O O 0.999875545501709
and O O 0.9999792575836182
the O O 0.9999861717224121
dosing O O 0.999907374382019
regimen O O 0.9997764229774475
, O O 0.9999648332595825
whereas O O 0.9999669790267944
resting O O 0.9998430013656616
HR O O 0.8714891076087952
was O O 0.999964714050293
significantly O O 0.9999721050262451
and O O 0.9999715089797974
dose O O 0.9997057318687439
- O O 0.9999829530715942
dependently O O 0.9999772310256958
lowered O O 0.9999912977218628
after O O 0.9997918009757996
dronedarone B B 0.9999016523361206
and O O 0.9998568296432495
to O O 0.9999716281890869
a O O 0.999977707862854
lesser O O 0.9999701976776123
extent O O 0.9999862909317017
after O O 0.9997773766517639
amiodarone B B 0.9997039437294006
. O O 0.9998918771743774

Both O B 0.9968736171722412
dronedarone B B 0.9670494794845581
and O O 0.9771768450737
amiodarone B B 0.9998205304145813
significantly O O 0.9999408721923828
reduced O O 0.9999806880950928
the O O 0.9999761581420898
exercise O O 0.7808109521865845
- O O 0.9999518394470215
induced O O 0.999982476234436
tachycardia O O 0.9999912977218628
and O O 0.9999467134475708
, O O 0.9999918937683105
at O O 0.9999867677688599
the O O 0.9999960660934448
highest O O 0.9999767541885376
dose O O 0.9999566078186035
, O O 0.999971866607666
decreased O O 0.9999581575393677
the O O 0.9999603033065796
isoproterenol B B 0.9987620115280151
- O O 0.9998867511749268
induced O O 0.9999430179595947
tachycardia O O 0.9999725818634033
. O O 0.9999487400054932

Thus O O 0.9999620914459229
, O O 0.9990898370742798
dronedarone B B 0.9999175071716309
and O O 0.9480733275413513
amiodarone B B 0.999799907207489
displayed O O 0.9998899698257446
a O O 0.9999675750732422
similar O O 0.9999563694000244
level O O 0.9999775886535645
of O O 0.9999009370803833
antiadrenergic O O 0.645080029964447
effect O O 0.9998663663864136
and O O 0.9999499320983887
did O O 0.999956488609314
not O O 0.999962329864502
impair O O 0.9999858140945435
the O O 0.999980092048645
resting O O 0.9999856948852539
left O O 0.9999886751174927
ventricular O O 0.9999949932098389
function O O 0.999994158744812
. O O 0.9999707937240601

Consequently O O 0.9999760389328003
, O O 0.9998051524162292
dronedarone B B 0.999887228012085
might O O 0.9998458623886108
be O O 0.9999819993972778
particularly O O 0.9999514818191528
suitable O O 0.999951958656311
for O O 0.9999239444732666
the O O 0.9999494552612305
treatment O O 0.9999667406082153
and O O 0.9999724626541138
prevention O O 0.9999862909317017
of O O 0.999974250793457
various O O 0.999950647354126
clinical O O 0.9999679327011108
arrhythmias O O 0.9999728202819824
, O O 0.999977707862854
without O O 0.999968409538269
compromising O O 0.9999886751174927
the O O 0.9999868869781494
left O O 0.999984860420227
ventricular O O 0.9999945163726807
function O O 0.9999948740005493
. O O 0.999975323677063

Phase O O 0.9999449253082275
2 O O 0.9998058676719666
trial O O 0.999962568283081
of O O 0.9971323013305664
liposomal O B 0.9945429563522339
doxorubicin B I 0.6747540235519409
( O O 0.9974167346954346
40 O O 0.9996479749679565
mg O O 0.9999305009841919
/ O O 0.9997977614402771
m O O 0.9999376535415649
( O O 0.9994927644729614
2 O O 0.9412298202514648
) O O 0.8371726274490356
) O O 0.9998586177825928
in O O 0.9997712969779968
platinum B O 0.8043962717056274
/ O O 0.6956760883331299
paclitaxel B B 0.9925082325935364
- O O 0.999380350112915
refractory O O 0.9997580647468567
ovarian O O 0.97940593957901
and O O 0.9994757771492004
fallopian O O 0.9977721571922302
tube O O 0.996290922164917
cancers O O 0.999903678894043
and O O 0.9999531507492065
primary O O 0.9999866485595703
carcinoma O O 0.999976634979248
of O O 0.9999837875366211
the O O 0.99998939037323
peritoneum O O 0.9999792575836182
. O O 0.9998966455459595

BACKGROUND O O 0.9983586668968201
: O O 0.9999873638153076
Several O O 0.9999866485595703
studies O O 0.9999834299087524
have O O 0.9999852180480957
demonstrated O O 0.9999595880508423
liposomal O O 0.9401575326919556
doxorubicin B B 0.9129093289375305
( O O 0.9777160286903381
Doxil B B 0.9998075366020203
) O O 0.9990748167037964
to O O 0.9999262094497681
be O O 0.9999274015426636
an O O 0.9996453523635864
active O O 0.999110996723175
antineoplastic O O 0.8762605786323547
agent O O 0.9988008737564087
in O O 0.9999099969863892
platinum B B 0.9220067262649536
- O O 0.995093822479248
resistant O O 0.9998051524162292
ovarian O O 0.9954150915145874
cancer O O 0.9999700784683228
, O O 0.99997878074646
with O O 0.9999775886535645
dose O O 0.999923586845398
limiting O O 0.9999833106994629
toxicity O O 0.9999910593032837
of O O 0.9999618530273438
the O O 0.9999805688858032
standard O O 0.9999628067016602
dosing O O 0.9998997449874878
regimen O O 0.998518168926239
( O O 0.9998020529747009
50 O O 0.9998836517333984
mg O O 0.9999274015426636
/ O O 0.9996044039726257
m O O 0.9999475479125977
( O O 0.9994075298309326
2 O O 0.972047746181488
) O O 0.9990776777267456
q O O 0.9998310804367065
4 O O 0.999889612197876
weeks O O 0.9999946355819702
) O O 0.9999679327011108
being O O 0.9999715089797974
severe O O 0.9999815225601196
erythrodysesthesia O O 0.9999864101409912
( O O 0.9999712705612183
" O O 0.9999909400939941
hand O O 0.999218225479126
- O O 0.9998717308044434
foot O O 0.9996554851531982
syndrome O O 0.9999910593032837
" O O 0.9999949932098389
) O O 0.9999856948852539
and O O 0.9999587535858154
stomatitis O O 0.9977389574050903
. O O 0.9999680519104004

We O O 0.9999716281890869
wished O O 0.9999974966049194
to O O 0.9999982118606567
develop O O 0.999996542930603
a O O 0.9999896287918091
more O O 0.999969482421875
tolerable O O 0.9999951124191284
liposomal O O 0.97801673412323
doxorubicin B B 0.8487860560417175
treatment O O 0.9996849298477173
regimen O O 0.9992527365684509
and O O 0.9999865293502808
document O O 0.9999899864196777
its O O 0.9999628067016602
level O O 0.9999649524688721
of O O 0.9999816417694092
activity O O 0.9999184608459473
in O O 0.9999547004699707
a O O 0.9999619722366333
well O O 0.9998422861099243
- O O 0.9999868869781494
defined O O 0.9999794960021973
patient O O 0.9999892711639404
population O O 0.9999872446060181
with O O 0.9999918937683105
platinum B O 0.6820913553237915
/ O O 0.8983941674232483
paclitaxel B B 0.9994064569473267
- O O 0.9993268251419067
refractory O O 0.9998981952667236
disease O O 0.9999977350234985
. O O 0.9999868869781494

METHODS O O 0.999886155128479
AND O O 0.9999926090240479
MATERIALS O O 0.9999854564666748
: O O 0.9999959468841553
Patients O O 0.9999972581863403
with O O 0.9999916553497314
ovarian O O 0.9928120970726013
or O O 0.9997732043266296
fallopian O O 0.9994458556175232
tube O O 0.9963476061820984
cancers O O 0.9999555349349976
or O O 0.9999649524688721
primary O O 0.9999858140945435
peritoneal O O 0.999988317489624
carcinoma O O 0.9999909400939941
with O O 0.9999186992645264
platinum B O 0.6826933026313782
/ O O 0.5833792090415955
paclitaxel B B 0.9845967888832092
- O O 0.9983789920806885
refractory O O 0.9990604519844055
disease O O 0.9999977350234985
( O O 0.9999880790710449
stable O O 0.9999982118606567
or O O 0.9999904632568359
progressive O O 0.999992847442627
disease O O 0.999998927116394
following O O 0.9999712705612183
treatment O O 0.9999884366989136
with O O 0.9999375343322754
these O O 0.9971262812614441
agents O O 0.9942910671234131
or O O 0.9999780654907227
previous O O 0.9999921321868896
objective O O 0.999994158744812
response O O 0.999998927116394
< O O 0.9999957084655762
3 O O 0.999991774559021
months O O 0.9999986886978149
in O O 0.9999958276748657
duration O O 0.9999953508377075
) O O 0.9999887943267822
were O O 0.9999915361404419
treated O O 0.9999886751174927
with O O 0.9998506307601929
liposomal O O 0.9243476986885071
doxorubicin B B 0.8074823617935181
at O O 0.999915599822998
a O O 0.9999916553497314
dose O O 0.9999865293502808
of O O 0.9999539852142334
40 O O 0.9997435212135315
mg O O 0.9999837875366211
/ O O 0.9998698234558105
m O O 0.9999881982803345
( O O 0.9997109770774841
2 O O 0.8983335494995117
) O O 0.9980705380439758
q O O 0.9999663829803467
4 O O 0.9999390840530396
weeks O O 0.9999984502792358
. O O 0.9999895095825195

RESULTS O O 0.9999680519104004
: O O 0.9999802112579346
A O O 0.9999890327453613
total O O 0.9999891519546509
of O O 0.9999943971633911
49 O O 0.9999954700469971
patients O O 0.999997615814209
( O O 0.9999830722808838
median O O 0.9999896287918091
age O O 0.9999712705612183
: O O 0.9999933242797852
60 O O 0.9999986886978149
; O O 0.999993085861206
range O O 0.9999959468841553
41 O O 0.9999854564666748
- O O 0.9993025064468384
81 O O 0.996453046798706
) O O 0.9999788999557495
entered O O 0.9999914169311523
this O O 0.9999825954437256
phase O O 0.9999772310256958
2 O O 0.9947360157966614
trial O O 0.9999536275863647
. O O 0.9999765157699585

The O O 0.9999847412109375
median O O 0.9999771118164062
number O O 0.9999896287918091
of O O 0.9999586343765259
prior O O 0.9998517036437988
regimens O O 0.9909507036209106
was O O 0.9999492168426514
2 O O 0.9994111061096191
( O O 0.9999555349349976
range O O 0.9999867677688599
: O O 0.9999781847000122
1 O O 0.9999849796295166
- O O 0.9988310933113098
6 O O 0.9999666213989258
) O O 0.9999771118164062
. O O 0.9999752044677734

Six O O 0.999861478805542
( O O 0.9999092817306519
12 O O 0.9999927282333374
% O O 0.999994158744812
) O O 0.9999473094940186
and O O 0.9999349117279053
4 O O 0.996768593788147
( O O 0.9998268485069275
8 O O 0.9999831914901733
% O O 0.9999934434890747
) O O 0.9999189376831055
patients O O 0.99998939037323
experienced O O 0.9999808073043823
grade O O 0.9999314546585083
2 O O 0.9996331930160522
hand O O 0.9971766471862793
- O O 0.9997984766960144
foot O O 0.9996511936187744
syndrome O O 0.9999719858169556
and O O 0.9999533891677856
stomatitis O O 0.9984594583511353
, O O 0.9999655485153198
respectively O O 0.9998983144760132
( O O 0.9999622106552124
no O O 0.999976396560669
episodes O O 0.9999972581863403
of O O 0.9999829530715942
grade O O 0.9997666478157043
3 O O 0.9972870349884033
) O O 0.9999692440032959
. O O 0.999969482421875

One O O 0.9999762773513794
patient O O 0.9999904632568359
developed O O 0.9999781847000122
grade O O 0.9999581575393677
3 O O 0.9967898726463318
diarrhea O O 0.9988855719566345
requiring O O 0.9999343156814575
hospitalization O O 0.9999326467514038
for O O 0.9999001026153564
hydration O O 0.7861377000808716
. O O 0.9999357461929321

Six O O 0.9995793700218201
( O O 0.9998674392700195
12 O O 0.9999920129776001
% O O 0.9999918937683105
) O O 0.9999254941940308
individuals O O 0.9999436140060425
required O O 0.9999572038650513
dose O O 0.9982002973556519
reductions O O 0.9999358654022217
. O O 0.9999392032623291

The O O 0.9999874830245972
median O O 0.9999871253967285
number O O 0.9999945163726807
of O O 0.9999717473983765
courses O O 0.9999539852142334
of O O 0.999848484992981
liposomal O O 0.9068743586540222
doxorubicin B B 0.9089385867118835
administered O O 0.9998670816421509
on O O 0.9999850988388062
this O O 0.9999837875366211
protocol O O 0.9999842643737793
was O O 0.9999748468399048
2 O O 0.999708354473114
( O O 0.9999661445617676
range O O 0.9999877214431763
: O O 0.999961256980896
1 O O 0.999988317489624
- O O 0.9991480112075806
12 O O 0.9999756813049316
) O O 0.9999845027923584
. O O 0.9999821186065674

Four O O 0.9999709129333496
of O O 0.999988317489624
44 O O 0.9999969005584717
patients O O 0.9999957084655762
( O O 0.9999715089797974
9 O O 0.9999898672103882
% O O 0.9999940395355225
) O O 0.999954104423523
evaluable O O 0.9999426603317261
for O O 0.9999701976776123
response O O 0.9999853372573853
exhibited O O 0.9999706745147705
objective O O 0.9999405145645142
and O O 0.9999451637268066
subjective O O 0.9999954700469971
evidence O O 0.9999938011169434
of O O 0.9999858140945435
an O O 0.9999775886535645
antineoplastic O O 0.9761928915977478
effect O O 0.9999724626541138
of O O 0.9996918439865112
therapy O O 0.9998165965080261
. O O 0.9999599456787109

CONCLUSION O O 0.9999228715896606
: O O 0.9999740123748779
This O O 0.999984622001648
modified O O 0.9999537467956543
liposomal O O 0.9717939496040344
doxorubicin B B 0.9483954310417175
regimen O O 0.986422598361969
results O O 0.9999738931655884
in O O 0.9999834299087524
less O O 0.9999299049377441
toxicity O O 0.9999819993972778
( O O 0.9998736381530762
stomatitis O O 0.9979485869407654
, O O 0.9999501705169678
hand O O 0.9991945624351501
- O O 0.9999459981918335
foot O O 0.9995133876800537
syndrome O O 0.9999867677688599
) O O 0.9999692440032959
than O O 0.9999829530715942
the O O 0.9999886751174927
standard O O 0.9999487400054932
FDA O B 0.9037961363792419
- O O 0.999250590801239
approved O O 0.9817705750465393
dose O O 0.9997773766517639
schedule O O 0.999924898147583
. O O 0.9999768733978271

Definite O O 0.9995168447494507
, O O 0.9999696016311646
although O O 0.999992847442627
limited O O 0.9999880790710449
, O O 0.9998992681503296
antineoplastic O O 0.8617517948150635
activity O O 0.9995230436325073
is O O 0.9999043941497803
observed O O 0.9999428987503052
in O O 0.999904990196228
patients O O 0.999987006187439
with O O 0.9999747276306152
well O O 0.9997275471687317
- O O 0.9999860525131226
defined O O 0.9999911785125732
platinum B O 0.7836405634880066
- O O 0.98487788438797
and O O 0.994657039642334
paclitaxel B B 0.9992572665214539
- O O 0.9993427395820618
refractory O O 0.9998067021369934
ovarian O O 0.9983052015304565
cancer O O 0.9999696016311646
. O O 0.9999728202819824

Efficacy O O 0.9996755123138428
of O O 0.9977413415908813
olanzapine B B 0.9997361302375793
in O O 0.9997673630714417
acute O O 0.9998934268951416
bipolar O O 0.9443014860153198
mania O O 0.9977328777313232
: O O 0.9999858140945435
a O O 0.9999889135360718
double O O 0.9999771118164062
- O O 0.9999837875366211
blind O O 0.9999963045120239
, O O 0.999977707862854
placebo O O 0.9998841285705566
- O O 0.9999370574951172
controlled O O 0.9999550580978394
study O O 0.9999924898147583
. O O 0.9999806880950928

The O O 0.9998668432235718
Olanzipine B B 0.9989131689071655
HGGW O O 0.497986763715744
Study O O 0.9996464252471924
Group O O 0.9999749660491943
. O O 0.999957799911499

BACKGROUND O O 0.9997056126594543
: O O 0.999993085861206
We O O 0.9999637603759766
compared O O 0.9999597072601318
the O O 0.9999902248382568
efficacy O O 0.9999932050704956
and O O 0.999992847442627
safety O O 0.999997615814209
of O O 0.9996211528778076
olanzapine B B 0.9997711777687073
vs O O 0.995020866394043
placebo O O 0.999758780002594
for O O 0.9999533891677856
the O O 0.9999908208847046
treatment O O 0.9999842643737793
of O O 0.9999876022338867
acute O O 0.9999643564224243
bipolar O O 0.9871692657470703
mania O O 0.9992184638977051
. O O 0.9999638795852661

METHODS O O 0.9998949766159058
: O O 0.9999860525131226
Four O O 0.9999375343322754
- O O 0.999984622001648
week O O 0.9999935626983643
, O O 0.9999903440475464
randomized O O 0.99998939037323
, O O 0.9999890327453613
double O O 0.9999662637710571
- O O 0.9999775886535645
blind O O 0.999994158744812
, O O 0.9999849796295166
parallel O O 0.9999785423278809
study O O 0.9999945163726807
. O O 0.9999899864196777

A O O 0.9999881982803345
total O O 0.9999957084655762
of O O 0.999995231628418
115 O O 0.9999953508377075
patients O O 0.9999967813491821
with O O 0.9999786615371704
a O O 0.9999853372573853
DSM O O 0.7769825458526611
- O O 0.99947589635849
IV O O 0.9980344176292419
diagnosis O O 0.9999951124191284
of O O 0.9999632835388184
bipolar O O 0.995755672454834
disorder O O 0.9999895095825195
, O O 0.999981164932251
manic O O 0.9999786615371704
or O O 0.9998489618301392
mixed O O 0.9316615462303162
, O O 0.9999845027923584
were O O 0.9999821186065674
randomized O O 0.9999969005584717
to O O 0.9998152852058411
olanzapine B B 0.9996969699859619
, O O 0.9996657371520996
5 O O 0.9989994168281555
to O O 0.9993682503700256
20 O O 0.9999328851699829
mg O O 0.9999358654022217
/ O O 0.9996944665908813
d O O 0.9998377561569214
( O O 0.9999630451202393
n O O 0.999854564666748
= O O 0.999852180480957
55 O O 0.9972150325775146
) O O 0.9999195337295532
, O O 0.9998934268951416
or O O 0.9998612403869629
placebo O O 0.999927282333374
( O O 0.9999641180038452
n O O 0.9999303817749023
= O O 0.9999802112579346
60 O O 0.9999860525131226
) O O 0.9999812841415405
. O O 0.9999847412109375

The O O 0.9999712705612183
primary O O 0.9999250173568726
efficacy O O 0.9999749660491943
measure O O 0.9999599456787109
was O O 0.999963641166687
the O O 0.9999040365219116
Young O O 0.9194837808609009
- O O 0.993113100528717
Mania O O 0.9953985810279846
Rating O O 0.9999346733093262
Scale O O 0.9989919066429138
( O O 0.9998244643211365
Y O O 0.9836816787719727
- O O 0.9995173215866089
MRS O O 0.9961899518966675
) O O 0.9999213218688965
total O O 0.9962475895881653
score O O 0.9999556541442871
. O O 0.9999639987945557

Response O O 0.9968048334121704
and O O 0.9997459053993225
euthymia O O 0.9999229907989502
were O O 0.9999508857727051
defined O O 0.9999830722808838
, O O 0.9999921321868896
a O O 0.9999731779098511
priori O O 0.9999942779541016
, O O 0.999993085861206
as O O 0.9999935626983643
at O O 0.9999961853027344
least O O 0.999994158744812
a O O 0.9999955892562866
50 O O 0.9999951124191284
% O O 0.9999977350234985
improvement O O 0.9999986886978149
from O O 0.999996542930603
baseline O O 0.9999896287918091
to O O 0.9999589920043945
end O O 0.9999681711196899
point O O 0.9997013211250305
and O O 0.9999672174453735
as O O 0.99998939037323
a O O 0.9999958276748657
score O O 0.9999923706054688
of O O 0.9999892711639404
no O O 0.9999932050704956
less O O 0.9999926090240479
than O O 0.9999943971633911
12 O O 0.9999947547912598
at O O 0.9999659061431885
end O O 0.9999518394470215
point O O 0.999931812286377
in O O 0.9999837875366211
the O O 0.9999821186065674
Y O O 0.9965587258338928
- O O 0.9999585151672363
MRS O O 0.9821955561637878
total O O 0.9998703002929688
score O O 0.999962329864502
, O O 0.9999806880950928
respectively O O 0.9999611377716064
. O O 0.9999825954437256

Safety O O 0.9998437166213989
was O O 0.9999775886535645
assessed O O 0.9999940395355225
using O O 0.9999812841415405
adverse O O 0.9999375343322754
events O O 0.999998927116394
, O O 0.9999836683273315
Extrapyramidal O O 0.9024459719657898
Symptom O O 0.9721941947937012
( O O 0.9998233914375305
EPS O O 0.9864234328269958
) O O 0.9999330043792725
rating O O 0.9999551773071289
scales O O 0.9971006512641907
, O O 0.9999877214431763
laboratory O O 0.9999946355819702
values O O 0.9999959468841553
, O O 0.9999908208847046
electrocardiograms O O 0.9999586343765259
, O O 0.999982476234436
vital O O 0.9999936819076538
signs O O 0.9999957084655762
, O O 0.9999456405639648
and O O 0.9999819993972778
weight O O 0.9999949932098389
change O O 0.9999958276748657
. O O 0.9999759197235107

RESULTS O O 0.9999604225158691
: O O 0.9997305274009705
Olanzapine B B 0.9998824596405029
- O O 0.9995162487030029
treated O O 0.9998321533203125
patients O O 0.9999872446060181
demonstrated O O 0.9999690055847168
a O O 0.9999902248382568
statistically O O 0.9999797344207764
significant O O 0.9999958276748657
greater O O 0.9999878406524658
mean O O 0.9999972581863403
( O O 0.9999667406082153
+ O O 0.9999948740005493
/ O O 0.9999911785125732
- O O 0.9999909400939941
SD O O 0.9999587535858154
) O O 0.9999688863754272
improvement O O 0.9999959468841553
in O O 0.9999828338623047
Y O O 0.9835424423217773
- O O 0.9999299049377441
MRS O O 0.9847437739372253
total O O 0.9980980753898621
score O O 0.9998524188995361
than O O 0.9999386072158813
placebo O O 0.9996159076690674
- O O 0.9994688630104065
treated O O 0.9999125003814697
patients O O 0.999990701675415
( O O 0.9999629259109497
- O O 0.9999397993087769
14 O O 0.9999953508377075
. O O 0.9999877214431763
8 O O 0.9999700784683228
+ O O 0.9999760389328003
/ O O 0.9999706745147705
- O O 0.9999501705169678
12 O O 0.9999940395355225
. O O 0.9999865293502808
5 O O 0.9999841451644897
and O O 0.999919056892395
- O O 0.9997749924659729
8 O O 0.9999117851257324
. O O 0.9999904632568359
1 O O 0.9999901056289673
+ O O 0.9999837875366211
/ O O 0.9999634027481079
- O O 0.9999731779098511
12 O O 0.9999791383743286
. O O 0.9999938011169434
7 O O 0.9999916553497314
, O O 0.9999904632568359
respectively O O 0.9999855756759644
; O O 0.9999849796295166
P O O 0.9999920129776001
< O O 0.9999862909317017
. O O 0.9999971389770508
001 O O 0.9999347925186157
) O O 0.9999760389328003
, O O 0.999982476234436
which O O 0.9999856948852539
was O O 0.9999829530715942
evident O O 0.9999954700469971
at O O 0.9999834299087524
the O O 0.9999963045120239
first O O 0.9999957084655762
postbaseline O O 0.9999140501022339
observation O O 0.9999934434890747
1 O O 0.9999728202819824
week O O 0.9999978542327881
after O O 0.9999910593032837
randomization O O 0.9999915361404419
and O O 0.9999759197235107
was O O 0.9999786615371704
maintained O O 0.9999933242797852
throughout O O 0.9999873638153076
the O O 0.9999971389770508
study O O 0.9999972581863403
( O O 0.9999853372573853
last O O 0.9999966621398926
observation O O 0.9999988079071045
carried O O 0.9999977350234985
forward O O 0.9999978542327881
) O O 0.9999868869781494
. O O 0.9999799728393555

Olanzapine B B 0.9996846914291382
- O O 0.9997726082801819
treated O O 0.9998741149902344
patients O O 0.9999897480010986
demonstrated O O 0.9999681711196899
a O O 0.999985933303833
higher O O 0.999976634979248
rate O O 0.999996542930603
of O O 0.9999850988388062
response O O 0.9999929666519165
( O O 0.9999785423278809
65 O O 0.9999978542327881
% O O 0.9999983310699463
vs O O 0.9999570846557617
43 O O 0.9999943971633911
% O O 0.9999974966049194
, O O 0.9999896287918091
respectively O O 0.9999909400939941
; O O 0.9999798536300659
P O O 0.9999302625656128
= O O 0.9998236298561096
. O O 0.9999974966049194
02 O O 0.9999715089797974
) O O 0.999964714050293
and O O 0.9999626874923706
euthymia O O 0.9999579191207886
( O O 0.9999786615371704
61 O O 0.9999954700469971
% O O 0.9999984502792358
vs O O 0.9999523162841797
36 O O 0.999990701675415
% O O 0.999996542930603
, O O 0.9999890327453613
respectively O O 0.999992847442627
; O O 0.9999808073043823
P O O 0.9999324083328247
= O O 0.9998921155929565
. O O 0.9999959468841553
01 O O 0.999995231628418
) O O 0.9999738931655884
than O O 0.999962329864502
placebo O O 0.9990448355674744
- O O 0.9996040463447571
treated O O 0.9998811483383179
patients O O 0.9999916553497314
. O O 0.9999812841415405

There O O 0.9999431371688843
were O O 0.9999607801437378
no O O 0.9999784231185913
statistically O O 0.9999605417251587
significant O O 0.999984860420227
differences O O 0.9999929666519165
in O O 0.9999730587005615
EPSs O O 0.9897065162658691
between O O 0.9991562366485596
groups O O 0.9999403953552246
. O O 0.9999306201934814

However O O 0.9999783039093018
, O O 0.9998856782913208
olanzapine B B 0.9998881816864014
- O O 0.9996329545974731
treated O O 0.9998072981834412
patients O O 0.99998939037323
had O O 0.9999873638153076
a O O 0.9999924898147583
statistically O O 0.9999902248382568
significant O O 0.9999971389770508
greater O O 0.9999934434890747
mean O O 0.999998927116394
( O O 0.9999686479568481
+ O O 0.999997615814209
/ O O 0.9999935626983643
- O O 0.9999926090240479
SD O O 0.999992847442627
) O O 0.9999843835830688
weight O O 0.999996542930603
gain O O 0.9999991655349731
than O O 0.9999819993972778
placebo O O 0.9986445307731628
- O O 0.999556839466095
treated O O 0.9999138116836548
patients O O 0.9999951124191284
( O O 0.9999809265136719
2 O O 0.9999804496765137
. O O 0.9999964237213135
1 O O 0.999994158744812
+ O O 0.9999945163726807
/ O O 0.999991774559021
- O O 0.9998562335968018
2 O O 0.9999823570251465
. O O 0.9999960660934448
8 O O 0.9999898672103882
vs O O 0.9998995065689087
0 O O 0.9999873638153076
. O O 0.9999953508377075
45 O O 0.9999920129776001
+ O O 0.9999948740005493
/ O O 0.9999858140945435
- O O 0.9999740123748779
2 O O 0.9999916553497314
. O O 0.9999982118606567
3 O O 0.999991774559021
kg O O 0.9999991655349731
, O O 0.9999954700469971
respectively O O 0.9999949932098389
) O O 0.9999881982803345
and O O 0.9999949932098389
also O O 0.9999953508377075
experienced O O 0.999991774559021
more O O 0.999975323677063
treatment O O 0.9989965558052063
- O O 0.9999746084213257
emergent O O 0.9999920129776001
somnolence O O 0.9999700784683228
( O O 0.9999849796295166
21 O O 0.9999698400497437
patients O O 0.9999911785125732
[ O O 0.9999886751174927
38 O O 0.9999864101409912
. O O 0.9999948740005493
2 O O 0.9999910593032837
% O O 0.999984622001648
] O O 0.9999638795852661
vs O O 0.999830961227417
5 O O 0.9999538660049438
[ O O 0.9999382495880127
8 O O 0.9999526739120483
. O O 0.9999953508377075
3 O O 0.9999819993972778
% O O 0.999990701675415
] O O 0.9999781847000122
, O O 0.9999896287918091
respectively O O 0.9999939203262329
) O O 0.9999874830245972
. O O 0.9999887943267822

CONCLUSION O O 0.9976465106010437
: O O 0.9991733431816101
Olanzapine B B 0.9997904896736145
demonstrated O O 0.9999281167984009
greater O O 0.9999231100082397
efficacy O O 0.9999897480010986
than O O 0.9998666048049927
placebo O O 0.9998496770858765
in O O 0.9999011754989624
the O O 0.9999696016311646
treatment O O 0.999970555305481
of O O 0.9999501705169678
acute O O 0.9999555349349976
bipolar O O 0.9696980714797974
mania O O 0.9979410767555237
and O O 0.9999618530273438
was O O 0.9999698400497437
generally O O 0.9999959468841553
well O O 0.9999730587005615
tolerated O O 0.9999901056289673
. O O 0.9999841451644897

The O O 0.9999533891677856
effect O O 0.9999749660491943
of O O 0.9999438524246216
pupil O O 0.9999371767044067
dilation O O 0.9999037981033325
with O O 0.9997931122779846
tropicamide B B 0.9989392161369324
on O O 0.999653697013855
vision O O 0.9999955892562866
and O O 0.9999419450759888
driving O O 0.999783456325531
simulator O O 0.9998737573623657
performance O O 0.9999942779541016
. O O 0.9999754428863525

PURPOSE O O 0.9999208450317383
: O O 0.9999929666519165
To O O 0.9999853372573853
assess O O 0.9999771118164062
the O O 0.9999759197235107
effect O O 0.9999750852584839
of O O 0.9999277591705322
pupil O O 0.9996148347854614
dilation O O 0.9993914365768433
on O O 0.9998037219047546
vision O O 0.9999929666519165
and O O 0.999944806098938
driving O O 0.9999629259109497
ability O O 0.9999939203262329
. O O 0.9999797344207764

METHODS O O 0.9998964071273804
: O O 0.9999815225601196
A O O 0.999991774559021
series O O 0.9999794960021973
of O O 0.9999715089797974
tests O O 0.999992847442627
on O O 0.9999574422836304
various O O 0.9999188184738159
parameters O O 0.9999815225601196
of O O 0.9999747276306152
visual O O 0.9998915195465088
function O O 0.9999969005584717
and O O 0.999962329864502
driving O O 0.999631404876709
simulator O O 0.9992513060569763
performance O O 0.9999710321426392
were O O 0.9999802112579346
performed O O 0.9999927282333374
on O O 0.9999678134918213
12 O O 0.9999903440475464
healthy O O 0.999708354473114
drivers O O 0.9999357461929321
, O O 0.9999727010726929
before O O 0.9998394250869751
and O O 0.9999445676803589
after O O 0.9998636245727539
pupil O O 0.9992722868919373
dilation O O 0.9998014569282532
using O O 0.9997825026512146
guttae O O 0.579971194267273
tropicamide B B 0.9502021670341492
1 O O 0.9833289384841919
% O O 0.999158501625061
. O O 0.999941349029541

A O O 0.9999217987060547
driving O O 0.9998660087585449
simulator O O 0.9998966455459595
( O O 0.9999055862426758
Transport O O 0.9999250173568726
Research O O 0.9999860525131226
Laboratory O O 0.9999947547912598
) O O 0.9999465942382812
was O O 0.9999629259109497
used O O 0.9999792575836182
to O O 0.9999743700027466
measure O O 0.999970555305481
reaction O O 0.999993085861206
time O O 0.9999949932098389
( O O 0.9999600648880005
RT O O 0.9992276430130005
) O O 0.9999772310256958
, O O 0.9999552965164185
speed O O 0.9999595880508423
maintenance O O 0.9999879598617554
and O O 0.9999181032180786
steering O O 0.9999881982803345
accuracy O O 0.9999985694885254
. O O 0.9999761581420898

Tests O O 0.9999748468399048
of O O 0.9999746084213257
basic O O 0.9998605251312256
visual O O 0.9999814033508301
function O O 0.9999964237213135
included O O 0.9999650716781616
high O O 0.9891842603683472
- O O 0.9998094439506531
and O O 0.9998494386672974
low O O 0.9994638562202454
- O O 0.9999346733093262
contrast O O 0.9998024106025696
visual O O 0.9999721050262451
acuity O O 0.999889612197876
( O O 0.9998140931129456
HCVA O O 0.9408626556396484
and O O 0.999782145023346
LCVA O O 0.9760463833808899
) O O 0.999916672706604
, O O 0.9998670816421509
Pelli O O 0.9498675465583801
- O O 0.9919658899307251
Robson O O 0.959153413772583
contrast O O 0.9909288287162781
threshold O O 0.9999114274978638
( O O 0.999386191368103
CT O O 0.9523067474365234
) O O 0.9999533891677856
and O O 0.9998998641967773
Goldmann O O 0.8253002166748047
perimetry O O 0.9998346567153931
( O O 0.999847412109375
FIELDS O O 0.9998480081558228
) O O 0.9999794960021973
. O O 0.9999761581420898

Useful O O 0.9996084570884705
Field O O 0.9999947547912598
of O O 0.9999914169311523
View O O 0.9999910593032837
( O O 0.9999222755432129
UFOV O O 0.7387654781341553
- O O 0.9852075576782227
- O O 0.999866247177124
a O O 0.9999732971191406
test O O 0.9999805688858032
of O O 0.999943733215332
visual O O 0.9999743700027466
attention O O 0.9999951124191284
) O O 0.9999768733978271
was O O 0.9999896287918091
also O O 0.9999936819076538
undertaken O O 0.9999947547912598
. O O 0.9999700784683228

The O O 0.9999816417694092
mean O O 0.9999830722808838
differences O O 0.999996542930603
in O O 0.999984622001648
the O O 0.9999762773513794
pre O O 0.9998369216918945
- O O 0.9999343156814575
and O O 0.9998846054077148
post O O 0.9996615648269653
- O O 0.9996192455291748
dilatation O O 0.9997294545173645
measurements O O 0.9999850988388062
were O O 0.9999767541885376
tested O O 0.999992847442627
for O O 0.9999736547470093
statistical O O 0.9999810457229614
significance O O 0.9999961853027344
at O O 0.9999896287918091
the O O 0.9999949932098389
95 O O 0.9999793767929077
% O O 0.9999613761901855
level O O 0.9999887943267822
using O O 0.9999634027481079
one O O 0.9998993873596191
- O O 0.999977707862854
tail O O 0.9999843835830688
paired O O 0.9999904632568359
t O O 0.9999597072601318
- O O 0.9999908208847046
tests O O 0.9999948740005493
. O O 0.9999799728393555

RESULTS O O 0.9994902610778809
: O O 0.9995599389076233
Pupillary O O 0.9997187256813049
dilation O O 0.999901533126831
resulted O O 0.9999462366104126
in O O 0.9999858140945435
a O O 0.9999827146530151
statistically O O 0.9999494552612305
significant O O 0.9999936819076538
deterioration O O 0.9999967813491821
in O O 0.9999377727508545
CT O O 0.9896796941757202
and O O 0.9998462200164795
HCVA O O 0.7970796227455139
only O O 0.9998216032981873
. O O 0.9999638795852661

Five O O 0.9999344348907471
of O O 0.9999587535858154
12 O O 0.9999649524688721
drivers O O 0.9989211559295654
also O O 0.9999667406082153
exhibited O O 0.9999758005142212
deterioration O O 0.9999942779541016
in O O 0.9999517202377319
LCVA O O 0.9920578598976135
, O O 0.9998894929885864
CT O O 0.9923021793365479
and O O 0.9997993111610413
RT O O 0.9936228394508362
. O O 0.9999252557754517

Little O O 0.9998935461044312
evidence O O 0.9999829530715942
emerged O O 0.9998088479042053
for O O 0.9999662637710571
deterioration O O 0.9999946355819702
in O O 0.9999452829360962
FIELDS O O 0.99996018409729
and O O 0.9999645948410034
UFOV O O 0.6466869711875916
. O O 0.9998843669891357

Also O O 0.9999679327011108
, O O 0.999954342842102
7 O O 0.9984704852104187
of O O 0.9999724626541138
12 O O 0.9999872446060181
drivers O O 0.9999797344207764
appeared O O 0.9999644756317139
to O O 0.9999338388442993
adjust O O 0.9999551773071289
their O O 0.9999815225601196
driving O O 0.9999703168869019
behaviour O O 0.9999790191650391
by O O 0.9999624490737915
reducing O O 0.9999759197235107
their O O 0.9999825954437256
speed O O 0.9999854564666748
on O O 0.9999449253082275
the O O 0.9999881982803345
driving O O 0.9999474287033081
simulator O O 0.9998884201049805
, O O 0.999966025352478
leading O O 0.999987006187439
to O O 0.9999841451644897
improved O O 0.9999842643737793
steering O O 0.9999872446060181
accuracy O O 0.999998927116394
. O O 0.9999747276306152

CONCLUSIONS O O 0.9387198686599731
: O O 0.999846339225769
Pupillary O O 0.9999271631240845
dilation O O 0.9999655485153198
may O O 0.9999343156814575
lead O O 0.9999853372573853
to O O 0.9999731779098511
a O O 0.9999805688858032
decrease O O 0.9999929666519165
in O O 0.9999784231185913
vision O O 0.9999959468841553
and O O 0.9999486207962036
daylight O O 0.9922935962677002
driving O O 0.9999642372131348
performance O O 0.9999947547912598
in O O 0.9999794960021973
young O O 0.9999936819076538
people O O 0.9999964237213135
. O O 0.9999487400054932

A O O 0.9999613761901855
larger O O 0.9999619722366333
study O O 0.9999872446060181
, O O 0.9999887943267822
including O O 0.9999690055847168
a O O 0.9999697208404541
broader O O 0.9999358654022217
spectrum O O 0.9998294115066528
of O O 0.9998487234115601
subjects O O 0.9997275471687317
, O O 0.9999886751174927
is O O 0.9999887943267822
warranted O O 0.9999912977218628
before O O 0.9999958276748657
guidelines O O 0.9999902248382568
can O O 0.9999961853027344
be O O 0.999997615814209
recommended O O 0.9999960660934448
. O O 0.9999834299087524

A O O 0.9999568462371826
case O O 0.9999858140945435
of O O 0.9999457597732544
isotretinoin O O 0.6123260855674744
embryopathy O O 0.99972003698349
with O O 0.9999635219573975
bilateral O O 0.9998564720153809
anotia O O 0.9992291927337646
and O O 0.9999068975448608
Taussig O O 0.9966722726821899
- O O 0.9988552331924438
Bing O O 0.9288331270217896
malformation O O 0.99998939037323
. O O 0.9999622106552124

We O O 0.9999624490737915
report O O 0.9999960660934448
a O O 0.9999955892562866
newborn O O 0.9999973773956299
infant O O 0.9999982118606567
with O O 0.9999864101409912
multiple O O 0.9999535083770752
congenital O O 0.9998650550842285
anomalies O O 0.9999926090240479
( O O 0.9997766613960266
anotia O O 0.998765230178833
and O O 0.9999138116836548
Taussig O O 0.9977772831916809
- O O 0.9985047578811646
Bing O O 0.9377477169036865
malformation O O 0.9999915361404419
) O O 0.9999862909317017
due O O 0.9999833106994629
to O O 0.9991402626037598
exposure O O 0.9999032020568848
to O O 0.9899470210075378
isotretinoin B B 0.9970507621765137
within O O 0.9993964433670044
the O O 0.9999948740005493
first O O 0.9999957084655762
trimester O O 0.9999948740005493
. O O 0.9999839067459106

In O O 0.9999849796295166
this O O 0.9999867677688599
paper O O 0.9999849796295166
we O O 0.9999637603759766
aim O O 0.9999922513961792
to O O 0.9999934434890747
draw O O 0.9999985694885254
to O O 0.9999908208847046
the O O 0.999995231628418
fact O O 0.9999860525131226
that O O 0.9999876022338867
caution O O 0.9999779462814331
is O O 0.9999849796295166
needed O O 0.9999890327453613
when O O 0.9999897480010986
prescribing O O 0.9999784231185913
vitamin B B 0.8764419555664062
A I I 0.9996119141578674
- O O 0.8128500580787659
containing O O 0.6918889880180359
drugs O O 0.9621749520301819
to O O 0.9999574422836304
women O O 0.9999958276748657
of O O 0.9999908208847046
childbearing O O 0.9999539852142334
years O O 0.9999517202377319
. O O 0.9999821186065674

Effect O O 0.9999135732650757
of O O 0.997960090637207
methoxamine B B 0.9996472597122192
on O O 0.9994577765464783
maximum O O 0.9998990297317505
urethral O O 0.9996427297592163
pressure O O 0.9999136924743652
in O O 0.9999381303787231
women O O 0.9999980926513672
with O O 0.9999697208404541
genuine O O 0.9931800365447998
stress O O 0.980077862739563
incontinence O O 0.9998729228973389
: O O 0.9999833106994629
a O O 0.9999841451644897
placebo O O 0.9998624324798584
- O O 0.9999246597290039
controlled O O 0.9999613761901855
, O O 0.9999749660491943
double O O 0.9999105930328369
- O O 0.999975323677063
blind O O 0.9999909400939941
crossover O O 0.9999880790710449
study O O 0.9999940395355225
. O O 0.9999830722808838

The O O 0.999991774559021
aim O O 0.9999979734420776
of O O 0.9999945163726807
the O O 0.9999947547912598
study O O 0.9999827146530151
was O O 0.9999954700469971
to O O 0.9999957084655762
evaluate O O 0.9999878406524658
the O O 0.9999905824661255
potential O O 0.9999880790710449
role O O 0.9999842643737793
for O O 0.999906063079834
a O O 0.9990196228027344
selective O O 0.9602407217025757
alpha1 O O 0.9558162689208984
- O O 0.9878231287002563
adrenoceptor O O 0.8301998376846313
agonist O O 0.7914949059486389
in O O 0.9999288320541382
the O O 0.9999775886535645
treatment O O 0.9999759197235107
of O O 0.9999783039093018
urinary O O 0.999984860420227
stress O O 0.9774413704872131
incontinence O O 0.9999492168426514
. O O 0.9999692440032959

A O O 0.9999656677246094
randomised O O 0.9999854564666748
, O O 0.9999747276306152
double O O 0.999934196472168
- O O 0.999971866607666
blind O O 0.9999958276748657
, O O 0.9999760389328003
placebo O O 0.9998981952667236
- O O 0.9999017715454102
controlled O O 0.9999271631240845
, O O 0.9999681711196899
crossover O O 0.9999712705612183
study O O 0.9999872446060181
design O O 0.9999898672103882
was O O 0.9999837875366211
employed O O 0.9999926090240479
. O O 0.9999738931655884

Half O O 0.9994217157363892
log O O 0.9999094009399414
incremental O O 0.9999737739562988
doses O O 0.9999445676803589
of O O 0.9999046325683594
intravenous O O 0.9994699358940125
methoxamine B B 0.999657154083252
or O O 0.9985647797584534
placebo O O 0.9990630745887756
( O O 0.9976499676704407
saline O O 0.9962261915206909
) O O 0.9999449253082275
were O O 0.9999701976776123
administered O O 0.9999538660049438
to O O 0.9999550580978394
a O O 0.9999926090240479
group O O 0.9999923706054688
of O O 0.9999905824661255
women O O 0.9999978542327881
with O O 0.9999688863754272
genuine O O 0.9996140599250793
stress O O 0.9985322952270508
incontinence O O 0.9999598264694214
while O O 0.9999418258666992
measuring O O 0.9999523162841797
maximum O O 0.9996509552001953
urethral O O 0.9989751577377319
pressure O O 0.9997836947441101
( O O 0.999903678894043
MUP O O 0.9969357252120972
) O O 0.9999672174453735
, O O 0.9999674558639526
blood O O 0.9998540878295898
pressure O O 0.9995015859603882
, O O 0.9999628067016602
heart O O 0.9999810457229614
rate O O 0.9999918937683105
, O O 0.9999455213546753
and O O 0.999909520149231
symptomatic O O 0.9999748468399048
side O O 0.999974250793457
effects O O 0.9999886751174927
. O O 0.9999749660491943

Methoxamine B B 0.9991693496704102
evoked O O 0.9990050196647644
non O O 0.9994799494743347
- O O 0.9999535083770752
significant O O 0.9999825954437256
increases O O 0.9999746084213257
in O O 0.9999383687973022
MUP O O 0.9953373670578003
and O O 0.9997856020927429
diastolic O O 0.9999330043792725
blood O O 0.9996476173400879
pressure O O 0.9994994401931763
but O O 0.9998120665550232
caused O O 0.9999511241912842
a O O 0.9999794960021973
significant O O 0.9999833106994629
rise O O 0.9999943971633911
in O O 0.9999687671661377
systolic O O 0.9991070628166199
blood O O 0.999721109867096
pressure O O 0.9994556307792664
and O O 0.9999674558639526
significant O O 0.9999873638153076
fall O O 0.999998927116394
in O O 0.9999842643737793
heart O O 0.9999905824661255
rate O O 0.9999954700469971
at O O 0.9998515844345093
maximum O O 0.9996868371963501
dosage O O 0.9999468326568604
. O O 0.999904990196228

Systemic O O 0.9980701804161072
side O O 0.9998868703842163
effects O O 0.9999793767929077
including O O 0.9999276399612427
piloerection O O 0.703206479549408
, O O 0.9999096393585205
headache O O 0.9999808073043823
, O O 0.9998127818107605
and O O 0.9998940229415894
cold O O 0.9990721940994263
extremities O O 0.9999886751174927
were O O 0.9999390840530396
experienced O O 0.9999783039093018
in O O 0.9998778104782104
all O O 0.9992510676383972
subjects O O 0.9996678829193115
. O O 0.9999337196350098

The O O 0.9999830722808838
results O O 0.9999905824661255
indicate O O 0.9999672174453735
that O O 0.9999773502349854
the O O 0.999991774559021
clinical O O 0.9999914169311523
usefulness O O 0.9999958276748657
of O O 0.9999685287475586
direct O O 0.9993481040000916
, O O 0.9998290538787842
peripherally O O 0.9996182918548584
acting O O 0.9979763627052307
sub O O 0.8151252269744873
- O O 0.9984051585197449
type O O 0.9881646633148193
- O O 0.996306300163269
selective O O 0.9366809129714966
alpha1 O O 0.9570730924606323
- O O 0.9915476441383362
adrenoceptor O O 0.9188714623451233
agonists O O 0.8935195207595825
in O O 0.9999189376831055
the O O 0.9999804496765137
medical O O 0.999984860420227
treatment O O 0.9999862909317017
of O O 0.9999614953994751
stress O O 0.9990633130073547
incontinence O O 0.999924898147583
may O O 0.9999529123306274
be O O 0.9999814033508301
limited O O 0.9999873638153076
by O O 0.9999593496322632
associated O O 0.999954342842102
piloerection O O 0.9978756904602051
and O O 0.9999127388000488
cardiovascular O O 0.9999786615371704
side O O 0.9999755620956421
effects O O 0.9999951124191284
. O O 0.9999808073043823

Hyperglycemic O O 0.9904128909111023
effect O O 0.9999086856842041
of O O 0.9991298317909241
amino B O 0.5085839033126831
compounds O O 0.878948986530304
structurally O O 0.9972392320632935
related O O 0.9999674558639526
to O O 0.9987167119979858
caproate B B 0.9957204461097717
in O O 0.9998480081558228
rats O O 0.9998975992202759
. O O 0.99988853931427

The O O 0.999956488609314
chronic O O 0.9998663663864136
feeding O O 0.9999334812164307
of O O 0.9998924732208252
small O O 0.9999678134918213
amounts O O 0.9996620416641235
( O O 0.9999202489852905
0 O O 0.9999581575393677
. O O 0.9999825954437256
3 O O 0.9999661445617676
- O O 0.9997321963310242
3 O O 0.9999730587005615
% O O 0.9999945163726807
of O O 0.9999949932098389
diet O O 0.9999815225601196
weight O O 0.9999847412109375
) O O 0.9999350309371948
of O O 0.9980474710464478
certain O O 0.973712146282196
amino B O 0.8997348546981812
derivatives O O 0.6081289052963257
of O O 0.6487825512886047
caproate B B 0.5021666288375854
resulted O O 0.9998667240142822
in O O 0.9999721050262451
hyperglycemia O O 0.9999774694442749
, O O 0.9999798536300659
an O O 0.9999922513961792
elevated O O 0.9999829530715942
glucose B O 0.48801007866859436
tolerance O O 0.999914288520813
curve O O 0.99996018409729
and O O 0.9999575614929199
, O O 0.9999831914901733
occasionally O O 0.9999922513961792
, O O 0.9999721050262451
glucosuria O O 0.9951853156089783
. O O 0.999943733215332

Effective O O 0.8015544414520264
compounds O O 0.9789830446243286
included O O 0.9988449811935425
norleucine B B 0.9925850033760071
, O O 0.9083176851272583
norvaline B B 0.9984503984451294
, O O 0.8751230835914612
glutamate B B 0.9974831938743591
, O I 0.885202944278717
epsilon B I 0.5068155527114868
- I I 0.9536307454109192
aminocaproate I I 0.9997650980949402
, O O 0.619292140007019
methionine B B 0.9981757402420044
, O O 0.8289582133293152
and O O 0.960556149482727
leucine B B 0.9905475974082947
. O O 0.9998500347137451

Toleration O O 0.9999622106552124
of O O 0.9999610185623169
high O O 0.9995657801628113
doses O O 0.9999265670776367
of O O 0.9995585083961487
angiotensin B B 0.9728922843933105
- I O 0.6437399983406067
converting I O 0.631977915763855
enzyme I O 0.5437315106391907
inhibitors I O 0.6811141967773438
in O O 0.9998481273651123
patients O O 0.9999942779541016
with O O 0.9999932050704956
chronic O O 0.9999792575836182
heart O O 0.9999967813491821
failure O O 0.9999970197677612
: O O 0.9999850988388062
results O O 0.9999980926513672
from O O 0.9999089241027832
the O O 0.9999889135360718
ATLAS O B 0.9264699220657349
trial O O 0.9995949864387512
. O O 0.9999778270721436

The O O 0.9999837875366211
Assessment O O 0.9999947547912598
of O O 0.9999586343765259
Treatment O O 0.9999511241912842
with O O 0.9993778467178345
Lisinopril B B 0.9986892342567444
and O O 0.9997574687004089
Survival O O 0.9982386827468872
. O O 0.9999822378158569

BACKGROUND O O 0.9991967082023621
: O O 0.9998680353164673
Treatment O O 0.9999195337295532
with O O 0.9997296929359436
angiotensin B B 0.939025342464447
- I O 0.7283211946487427
converting I O 0.7945499420166016
enzyme I O 0.8398525714874268
( I O 0.5183283686637878
ACE I O 0.41060328483581543
) I O 0.7137745022773743
inhibitors I O 0.49426737427711487
reduces O O 0.9993751645088196
mortality O O 0.9999986886978149
and O O 0.999994158744812
morbidity O O 0.9999945163726807
in O O 0.9999593496322632
patients O O 0.9999960660934448
with O O 0.9999912977218628
chronic O O 0.9998119473457336
heart O O 0.999993085861206
failure O O 0.9999909400939941
( O O 0.9999419450759888
CHF O O 0.993151068687439
) O O 0.9999675750732422
, O O 0.9999446868896484
but O O 0.9999781847000122
most O O 0.9999288320541382
affected O O 0.999944806098938
patients O O 0.9999933242797852
are O O 0.9999899864196777
not O O 0.999990701675415
receiving O O 0.9999068975448608
these O O 0.9971545934677124
agents O O 0.9972612857818604
or O O 0.9999364614486694
are O O 0.9999858140945435
being O O 0.9999924898147583
treated O O 0.9999794960021973
with O O 0.9999666213989258
doses O O 0.9999405145645142
lower O O 0.9999840259552002
than O O 0.9999967813491821
those O O 0.9999953508377075
found O O 0.9999966621398926
to O O 0.9999858140945435
be O O 0.9999818801879883
efficacious O O 0.9999849796295166
in O O 0.9999797344207764
trials O O 0.9996083378791809
, O O 0.9999878406524658
primarily O O 0.9999902248382568
because O O 0.9999953508377075
of O O 0.9999898672103882
concerns O O 0.9999982118606567
about O O 0.9999954700469971
the O O 0.9999946355819702
safety O O 0.9999969005584717
and O O 0.9999945163726807
tolerability O O 0.9999994039535522
of O O 0.9999709129333496
these O O 0.9979664087295532
agents O O 0.9935200810432434
, O O 0.9999886751174927
especially O O 0.9999895095825195
at O O 0.9999847412109375
the O O 0.9999970197677612
recommended O O 0.9999953508377075
doses O O 0.9999821186065674
. O O 0.9999833106994629

The O O 0.9999910593032837
present O O 0.9999898672103882
study O O 0.9999830722808838
examines O O 0.9998520612716675
the O O 0.9999814033508301
safety O O 0.9999939203262329
and O O 0.9999881982803345
tolerability O O 0.9999978542327881
of O O 0.9999415874481201
high O O 0.9745420813560486
- O O 0.9993056058883667
compared O O 0.9785726070404053
with O O 0.9997511506080627
low O O 0.9997027516365051
- O O 0.9999576807022095
dose O O 0.9951423406600952
lisinopril B B 0.9994449019432068
in O O 0.9997603297233582
CHF O O 0.9501764178276062
. O O 0.9999102354049683

METHODS O O 0.9999470710754395
: O O 0.9999945163726807
The O O 0.9999960660934448
Assessment O O 0.9999680519104004
of O O 0.9994243383407593
Lisinopril B B 0.9991917014122009
and O O 0.999645471572876
Survival O O 0.9999421834945679
study O O 0.9999903440475464
was O O 0.9999970197677612
a O O 0.9999959468841553
multicenter O O 0.9999806880950928
, O O 0.9999836683273315
randomized O O 0.9999895095825195
, O O 0.9999860525131226
double O O 0.9998844861984253
- O O 0.999966025352478
blind O O 0.9999895095825195
trial O O 0.9999868869781494
in O O 0.9999829530715942
which O O 0.9999854564666748
patients O O 0.9999959468841553
with O O 0.9999901056289673
or O O 0.9999889135360718
without O O 0.999995231628418
previous O O 0.9992604851722717
ACE B O 0.45766356587409973
inhibitor I O 0.70250004529953
treatment O O 0.9995983242988586
were O O 0.9999903440475464
stabilized O O 0.9999878406524658
receiving O O 0.9999444484710693
medium O O 0.9988896250724792
- O O 0.9999479055404663
dose O O 0.9948111772537231
lisinopril B B 0.9985163807868958
( O O 0.9949599504470825
12 O O 0.99666827917099
. O O 0.9999382495880127
5 O O 0.9998103976249695
or O O 0.9997925162315369
15 O O 0.9999772310256958
. O O 0.9999948740005493
0 O O 0.9999665021896362
mg O O 0.9998633861541748
once O O 0.9855058193206787
daily O O 0.9998736381530762
[ O O 0.9994195699691772
OD O O 0.6863886713981628
] O O 0.9999264478683472
) O O 0.999975323677063
for O O 0.9999794960021973
2 O O 0.9999871253967285
to O O 0.9999978542327881
4 O O 0.9999912977218628
weeks O O 0.9999984502792358
and O O 0.9999885559082031
then O O 0.9999911785125732
randomized O O 0.9999972581863403
to O O 0.9999614953994751
high O O 0.9991288781166077
- O O 0.9998687505722046
( O O 0.9998708963394165
35 O O 0.9998822212219238
. O O 0.9999929666519165
0 O O 0.9999828338623047
or O O 0.9998805522918701
32 O O 0.9999784231185913
. O O 0.999995231628418
5 O O 0.9999885559082031
mg O O 0.9998447895050049
OD O O 0.8908929824829102
) O O 0.9999707937240601
or O O 0.9999634027481079
low O O 0.9999265670776367
- O O 0.9999619722366333
dose O O 0.999853253364563
( O O 0.999625563621521
5 O O 0.9999088048934937
. O O 0.9999890327453613
0 O O 0.999729573726654
or O O 0.9997900128364563
2 O O 0.9999483823776245
. O O 0.9999912977218628
5 O O 0.9999767541885376
mg O O 0.9996520280838013
OD O O 0.8488801121711731
) O O 0.9999631643295288
groups O O 0.9999878406524658
. O O 0.9999898672103882

Patients O O 0.999975323677063
with O O 0.9999791383743286
New O O 0.9999880790710449
York O O 0.9975900650024414
Heart O O 0.9999631643295288
Association O O 0.9999620914459229
classes O O 0.9992983341217041
II O O 0.9987461566925049
to O O 0.998380184173584
IV O O 0.8309965133666992
CHF O O 0.8410501480102539
and O O 0.9996398687362671
left O O 0.9999755620956421
ventricular O O 0.999995231628418
ejection O O 0.9996592998504639
fractions O O 0.9999916553497314
of O O 0.999976396560669
no O O 0.9999909400939941
greater O O 0.9999895095825195
than O O 0.9999910593032837
0 O O 0.9999587535858154
. O O 0.9999978542327881
30 O O 0.9999977350234985
( O O 0.9999728202819824
n O O 0.999937891960144
= O O 0.9999732971191406
3164 O O 0.9999251365661621
) O O 0.999980092048645
were O O 0.9999823570251465
randomized O O 0.999993085861206
and O O 0.9999890327453613
followed O O 0.9999945163726807
up O O 0.9999980926513672
for O O 0.9999902248382568
a O O 0.999995231628418
median O O 0.9999978542327881
of O O 0.9999953508377075
46 O O 0.9999991655349731
months O O 0.999998927116394
. O O 0.9999902248382568

We O O 0.9999191761016846
examined O O 0.9999892711639404
the O O 0.9999923706054688
occurrence O O 0.9999971389770508
of O O 0.9999902248382568
adverse O O 0.9999518394470215
events O O 0.999998927116394
and O O 0.9999864101409912
the O O 0.9999926090240479
need O O 0.9999935626983643
for O O 0.9999864101409912
discontinuation O O 0.9999465942382812
and O O 0.9999635219573975
dose O O 0.9996709823608398
reduction O O 0.9999854564666748
during O O 0.9999392032623291
treatment O O 0.9999839067459106
, O O 0.9999761581420898
with O O 0.9999699592590332
a O O 0.9999673366546631
focus O O 0.999984622001648
on O O 0.9999241828918457
hypotension O O 0.9998030066490173
and O O 0.999911904335022
renal O O 0.9999816417694092
dysfunction O O 0.9999938011169434
. O O 0.9999762773513794

RESULTS O O 0.9994737505912781
: O O 0.9999284744262695
Of O O 0.9999028444290161
405 O O 0.998379111289978
patients O O 0.9999865293502808
not O O 0.9999825954437256
previously O O 0.999975323677063
receiving O O 0.9998195767402649
an O O 0.9991644620895386
ACE B O 0.637130081653595
inhibitor I O 0.7392350435256958
, O O 0.9994571805000305
doses O O 0.9998067021369934
in O O 0.9999408721923828
only O O 0.9999607801437378
4 O O 0.9816779494285583
. O O 0.9999654293060303
2 O O 0.9999442100524902
% O O 0.9999369382858276
could O O 0.9999809265136719
not O O 0.9999948740005493
be O O 0.9999958276748657
titrated O O 0.9999841451644897
to O O 0.9999672174453735
the O O 0.9999841451644897
medium O O 0.9999279975891113
doses O O 0.999936580657959
required O O 0.9999827146530151
for O O 0.9999889135360718
randomization O O 0.9999794960021973
because O O 0.9999878406524658
of O O 0.9999860525131226
symptoms O O 0.9999974966049194
possibly O O 0.9999878406524658
related O O 0.9999921321868896
to O O 0.9999470710754395
hypotension O O 0.9999175071716309
( O O 0.9999490976333618
2 O O 0.9999136924743652
. O O 0.9999831914901733
0 O O 0.999990701675415
% O O 0.999971866607666
) O O 0.999947190284729
or O O 0.999955415725708
because O O 0.9999871253967285
of O O 0.9999614953994751
renal O O 0.9999798536300659
dysfunction O O 0.9999951124191284
or O O 0.9999464750289917
hyperkalemia O O 0.8544231057167053
( O O 0.9999285936355591
2 O O 0.9991819262504578
. O O 0.9999669790267944
3 O O 0.9999786615371704
% O O 0.9999840259552002
) O O 0.9999655485153198
. O O 0.9999769926071167

Doses O O 0.9998437166213989
in O O 0.9998743534088135
more O O 0.9999873638153076
than O O 0.9999940395355225
90 O O 0.999994158744812
% O O 0.9999954700469971
of O O 0.9999812841415405
randomized O O 0.9999881982803345
patients O O 0.9999958276748657
in O O 0.9999065399169922
the O O 0.9999604225158691
high O O 0.9958034157752991
- O O 0.9999593496322632
and O O 0.9996951818466187
low O O 0.9989834427833557
- O O 0.9999653100967407
dose O O 0.99932861328125
groups O O 0.9999167919158936
were O O 0.9999637603759766
titrated O O 0.9999798536300659
to O O 0.9999839067459106
their O O 0.9999880790710449
assigned O O 0.9999734163284302
target O O 0.999980092048645
, O O 0.9999628067016602
and O O 0.9999862909317017
the O O 0.9999951124191284
mean O O 0.9999784231185913
doses O O 0.9999808073043823
of O O 0.999909520149231
blinded O O 0.943489670753479
medication O O 0.999850869178772
in O O 0.9998248219490051
both O O 0.9996285438537598
groups O O 0.999944806098938
remained O O 0.9999901056289673
similar O O 0.9999940395355225
throughout O O 0.9999758005142212
the O O 0.9999955892562866
study O O 0.9999947547912598
. O O 0.9999837875366211

Withdrawals O O 0.999230146408081
occurred O O 0.9999827146530151
in O O 0.9999557733535767
27 O O 0.9999642372131348
. O O 0.9999744892120361
1 O O 0.999994158744812
% O O 0.99997878074646
of O O 0.9999585151672363
the O O 0.9999542236328125
high O O 0.9907087087631226
- O O 0.9996583461761475
and O O 0.9998051524162292
30 O O 0.9998106360435486
. O O 0.9999657869338989
7 O O 0.9999946355819702
% O O 0.9999796152114868
of O O 0.9999550580978394
the O O 0.9999513626098633
low O O 0.9990236759185791
- O O 0.9999260902404785
dose O O 0.9945907592773438
groups O O 0.9998964071273804
. O O 0.9999520778656006

Subgroups O O 0.9985232949256897
presumed O O 0.9999769926071167
to O O 0.9999676942825317
be O O 0.9999874830245972
at O O 0.999975323677063
higher O O 0.9999517202377319
risk O O 0.9999959468841553
for O O 0.99996018409729
ACE B B 0.7157145738601685
inhibitor I I 0.9506750106811523
intolerance O O 0.9982789754867554
( O O 0.9999229907989502
blood O O 0.9999390840530396
pressure O O 0.9999779462814331
, O O 0.9999679327011108
< O O 0.9999960660934448
120 O O 0.9999988079071045
mm O O 0.9999985694885254
Hg O O 0.750812292098999
; O O 0.9998842477798462
creatinine B B 0.9868416786193848
, O O 0.9988189339637756
> O O 0.999980092048645
or O O 0.9999748468399048
= O O 0.9999927282333374
132 O O 0.9998477697372437
. O O 0.9999982118606567
6 O O 0.9999878406524658
micromol O O 0.9995738863945007
/ O O 0.999964714050293
L O O 0.999874472618103
[ O O 0.9997832179069519
> O O 0.999985933303833
or O O 0.9999661445617676
= O O 0.9999873638153076
1 O O 0.9999905824661255
. O O 0.9999955892562866
5 O O 0.9999785423278809
mg O O 0.9999951124191284
/ O O 0.9999889135360718
dL O O 0.999996542930603
] O O 0.9999710321426392
; O O 0.9999798536300659
age O O 0.9999039173126221
, O O 0.9999805688858032
> O O 0.9999967813491821
or O O 0.9999909400939941
= O O 0.9999974966049194
70 O O 0.9999971389770508
years O O 0.9999977350234985
; O O 0.9999825954437256
and O O 0.999982476234436
patients O O 0.9999947547912598
with O O 0.9999911785125732
diabetes O O 0.9999226331710815
) O O 0.9999837875366211
generally O O 0.9999833106994629
tolerated O O 0.9999898672103882
the O O 0.9999949932098389
high O O 0.9998094439506531
- O O 0.9999871253967285
dose O O 0.9998179078102112
strategy O O 0.9998615980148315
. O O 0.9999722242355347

CONCLUSIONS O O 0.9956747889518738
: O O 0.9999948740005493
These O O 0.9999918937683105
findings O O 0.9999921321868896
demonstrate O O 0.9999711513519287
that O O 0.9998968839645386
ACE B O 0.619855523109436
inhibitor I O 0.6977686882019043
therapy O O 0.9995892643928528
in O O 0.9999456405639648
most O O 0.9999279975891113
patients O O 0.9999926090240479
with O O 0.9999688863754272
CHF O O 0.9716435670852661
can O O 0.9999080896377563
be O O 0.999994158744812
successfully O O 0.9999760389328003
titrated O O 0.9999872446060181
to O O 0.9999648332595825
and O O 0.9999897480010986
maintained O O 0.9999854564666748
at O O 0.9999667406082153
high O O 0.9999456405639648
doses O O 0.9999691247940063
, O O 0.9999531507492065
and O O 0.999987006187439
that O O 0.9999872446060181
more O O 0.9999786615371704
aggressive O O 0.9999712705612183
use O O 0.9999908208847046
of O O 0.9999198913574219
these O O 0.991168737411499
agents O O 0.9942318797111511
is O O 0.9999815225601196
warranted O O 0.9999854564666748
. O O 0.9999853372573853

Cocaine B B 0.9917669892311096
, O O 0.9192581176757812
ethanol B B 0.9840505719184875
, O O 0.8838797211647034
and O O 0.9946235418319702
cocaethylene B B 0.9975124597549438
cardiotoxity O O 0.9999161958694458
in O O 0.9999632835388184
an O O 0.9999653100967407
animal O O 0.9999806880950928
model O O 0.9999929666519165
of O O 0.9998886585235596
cocaine O B 0.9923896193504333
and O O 0.9641939401626587
ethanol O B 0.9673762321472168
abuse O O 0.9978638291358948
. O O 0.9999632835388184

OBJECTIVES O O 0.9687383770942688
: O O 0.9998397827148438
Simultaneous O O 0.9894826412200928
abuse O O 0.9977438449859619
of O O 0.9948458671569824
cocaine O B 0.9977275729179382
and O O 0.8722375631332397
ethanol O B 0.9940251708030701
affects O O 0.9997466206550598
12 O O 0.9999862909317017
million O O 0.9998458623886108
Americans O O 0.9991902709007263
annually O O 0.9999306201934814
. O O 0.9999051094055176

In O O 0.9997585415840149
combination O O 0.9996356964111328
, O O 0.9998935461044312
these O O 0.9964667558670044
substances O O 0.9881356954574585
are O O 0.9998210072517395
substantially O O 0.9999780654907227
more O O 0.9998176693916321
toxic O O 0.9996894598007202
than O O 0.9998862743377686
either O O 0.9989449381828308
drug O O 0.9976081848144531
alone O O 0.9998977184295654
. O O 0.9999301433563232

Their O O 0.9999507665634155
combined O O 0.9997243285179138
cardiac O O 0.9998708963394165
toxicity O O 0.9999731779098511
may O O 0.9998910427093506
be O O 0.9999140501022339
due O O 0.9999502897262573
to O O 0.9996610879898071
independent O O 0.9997114539146423
effects O O 0.9999496936798096
of O O 0.9998775720596313
each O O 0.9990434050559998
drug O O 0.9976206421852112
; O O 0.9998946189880371
however O O 0.9999610185623169
, O O 0.9999427795410156
they O O 0.9999549388885498
may O O 0.9999009370803833
also O O 0.9998825788497925
be O O 0.9999454021453857
due O O 0.9999759197235107
to O O 0.9989104270935059
cocaethylene B B 0.9988633394241333
( O O 0.9944353103637695
CE B B 0.9981162548065186
) O O 0.9570515155792236
, O O 0.999970555305481
a O O 0.9990110397338867
cocaine B B 0.9735369682312012
metabolite O O 0.9675338864326477
formed O O 0.9998624324798584
only O O 0.9999302625656128
in O O 0.9999439716339111
the O O 0.9999557733535767
presence O O 0.9998893737792969
of O O 0.9995899796485901
ethanol B B 0.9940273761749268
. O O 0.9999223947525024

The O O 0.9999878406524658
purpose O O 0.9999964237213135
of O O 0.9999949932098389
this O O 0.9999879598617554
study O O 0.9999833106994629
was O O 0.9999938011169434
to O O 0.9999923706054688
delineate O O 0.9999833106994629
the O O 0.9999514818191528
role O O 0.9999382495880127
of O O 0.9987095594406128
CE B B 0.9918957352638245
in O O 0.9995587468147278
the O O 0.9999572038650513
combined O O 0.9992319345474243
cardiotoxicity O O 0.9999819993972778
of O O 0.9995939135551453
cocaine B B 0.9989369511604309
and O O 0.9520550966262817
ethanol B B 0.9962343573570251
in O O 0.9998868703842163
a O O 0.9998809099197388
model O O 0.9999822378158569
simulating O O 0.9999059438705444
their O O 0.9963335990905762
abuse O O 0.9999548196792603
. O O 0.9999788999557495

METHODS O O 0.9996458292007446
: O O 0.9999951124191284
Twenty O O 0.9999206066131592
- O O 0.99996018409729
three O O 0.9999954700469971
dogs O O 0.9999953508377075
were O O 0.9999923706054688
randomized O O 0.9999959468841553
to O O 0.999980092048645
receive O O 0.9999722242355347
either O O 0.9999805688858032
1 O O 0.999976396560669
) O O 0.9999263286590576
three O O 0.9979217648506165
intravenous O O 0.999961256980896
( O O 0.9995668530464172
IV O O 0.998715877532959
) O O 0.9999531507492065
boluses O O 0.9999849796295166
of O O 0.9993723034858704
cocaine B B 0.998618483543396
7 O O 0.9409108757972717
. O O 0.9999610185623169
5 O O 0.9996029734611511
mg O O 0.9992716908454895
/ O O 0.9994530081748962
kg O O 0.9999768733978271
with O O 0.9980623126029968
ethanol B B 0.998740017414093
( O O 0.9996013045310974
1 O O 0.9998181462287903
g O O 0.9990370273590088
/ O O 0.999981164932251
kg O O 0.9999861717224121
) O O 0.9998977184295654
as O O 0.9999260902404785
an O O 0.9992316961288452
IV O O 0.9842830300331116
infusion O O 0.9996941089630127
( O O 0.9998317956924438
C O O 0.9169137477874756
+ O O 0.9993467926979065
E O O 0.9985213875770569
, O O 0.9999707937240601
n O O 0.9997350573539734
= O O 0.9998995065689087
8 O O 0.9906159043312073
) O O 0.9999600648880005
, O O 0.9999785423278809
2 O O 0.9999792575836182
) O O 0.9999127388000488
three O O 0.9589038491249084
cocaine B B 0.9927428960800171
boluses O O 0.9971394538879395
only O O 0.9998358488082886
( O O 0.9997995495796204
C O O 0.9938111901283264
, O O 0.9999469518661499
n O O 0.99996018409729
= O O 0.9999706745147705
6 O O 0.9999854564666748
) O O 0.999953031539917
, O O 0.9999769926071167
3 O O 0.9999221563339233
) O O 0.9998015761375427
ethanol B B 0.989933431148529
infusion O O 0.996947705745697
only O O 0.999859094619751
( O O 0.9997783303260803
E O O 0.9884754419326782
, O O 0.9999212026596069
n O O 0.9997428059577942
= O O 0.9999641180038452
5 O O 0.999970555305481
) O O 0.9999639987945557
, O O 0.999948263168335
or O O 0.9999740123748779
4 O O 0.9999688863754272
) O O 0.9998584985733032
placebo O O 0.9631041288375854
boluses O O 0.9998670816421509
and O O 0.9998223185539246
infusion O O 0.999190628528595
( O O 0.9999392032623291
n O O 0.9969856142997742
= O O 0.9999090433120728
4 O O 0.9995716214179993
) O O 0.9999735355377197
. O O 0.9999802112579346

Hemodynamic O O 0.999967098236084
measurements O O 0.9999963045120239
, O O 0.9999865293502808
electrocardiograms O O 0.9999575614929199
, O O 0.9999740123748779
and O O 0.9999895095825195
serum O O 0.9994074106216431
drug O O 0.9975171089172363
concentrations O O 0.9998981952667236
were O O 0.999974250793457
obtained O O 0.9999958276748657
at O O 0.99997878074646
baseline O O 0.9999791383743286
, O O 0.9999591112136841
and O O 0.9999513626098633
then O O 0.9999816417694092
at O O 0.9999680519104004
fixed O O 0.9999485015869141
time O O 0.999985933303833
intervals O O 0.9999971389770508
after O O 0.9999724626541138
each O O 0.9998960494995117
drug O O 0.9981021285057068
was O O 0.9999597072601318
administered O O 0.9999513626098633
. O O 0.9999749660491943

RESULTS O O 0.9998645782470703
: O O 0.9999483823776245
Two O O 0.9999953508377075
of O O 0.9999853372573853
eight O O 0.9999972581863403
dogs O O 0.9999963045120239
in O O 0.9999215602874756
the O O 0.9998992681503296
C O O 0.6965243220329285
+ O O 0.9870522618293762
E O O 0.9498023986816406
group O O 0.9999266862869263
experienced O O 0.9999563694000244
cardiovascular O O 0.9999885559082031
collapse O O 0.9999963045120239
. O O 0.9999765157699585

The O O 0.9999773502349854
most O O 0.9999704360961914
dramatic O O 0.9999886751174927
hemodynamic O O 0.9999217987060547
changes O O 0.9999915361404419
occurred O O 0.9999737739562988
after O O 0.9998922348022461
each O O 0.9996840953826904
cocaine B B 0.9939717650413513
bolus O O 0.9993168115615845
in O O 0.99985671043396
the O O 0.9998220801353455
C O O 0.5741052031517029
+ O O 0.9956713914871216
E O O 0.9845426082611084
and O O 0.9992314577102661
C O O 0.8148167133331299
only O O 0.7423651218414307
groups O O 0.9996546506881714
; O O 0.9999178647994995
however O O 0.9999487400054932
, O O 0.9999481439590454
persistent O O 0.9999555349349976
hemodynamic O O 0.9999489784240723
changes O O 0.9999923706054688
occurred O O 0.9999749660491943
in O O 0.9998331069946289
the O O 0.9998301267623901
C O O 0.631502091884613
+ O O 0.9980816841125488
E O O 0.989343523979187
group O O 0.9997943043708801
. O O 0.999955415725708

Peak O O 0.9610580801963806
CE B B 0.9925593137741089
levels O O 0.9996219873428345
were O O 0.999953031539917
associated O O 0.999982476234436
with O O 0.9999798536300659
a O O 0.9999746084213257
45 O O 0.9999929666519165
% O O 0.9999939203262329
( O O 0.999850869178772
SD O O 0.8602483868598938
+ O O 0.9999686479568481
/ O O 0.9998799562454224
- O O 0.9998070597648621
22 O O 0.9999873638153076
% O O 0.9999853372573853
, O O 0.9998472929000854
95 O O 0.9999144077301025
% O O 0.999622106552124
CI O O 0.9927448034286499
= O O 0.9998983144760132
22 O O 0.9999963045120239
% O O 0.9999834299087524
to O O 0.9998865127563477
69 O O 0.9999984502792358
% O O 0.9999938011169434
) O O 0.9999645948410034
decrease O O 0.9999958276748657
in O O 0.9999772310256958
cardiac O O 0.9999154806137085
output O O 0.9999970197677612
( O O 0.9999721050262451
p O O 0.9999737739562988
< O O 0.9999815225601196
0 O O 0.9999946355819702
. O O 0.9999963045120239
05 O O 0.999992847442627
) O O 0.9999685287475586
, O O 0.9999794960021973
a O O 0.999976396560669
56 O O 0.9999963045120239
% O O 0.9999949932098389
( O O 0.999900221824646
SD O O 0.9212775826454163
+ O O 0.9999661445617676
/ O O 0.9996225833892822
- O O 0.9998453855514526
23 O O 0.9999861717224121
% O O 0.9999879598617554
, O O 0.9998056292533875
95 O O 0.999774158000946
% O O 0.9994193315505981
CI O O 0.9896877408027649
= O O 0.999945878982544
32 O O 0.9999915361404419
% O O 0.9999876022338867
to O O 0.9999040365219116
80 O O 0.9999839067459106
% O O 0.999995231628418
) O O 0.9999653100967407
decrease O O 0.9999938011169434
in O O 0.9999144077301025
dP O O 0.9381214380264282
/ O O 0.9989988207817078
dt O O 0.9836720824241638
( O O 0.9993634819984436
max O O 0.9983281493186951
) O O 0.9999680519104004
( O O 0.9999436140060425
p O O 0.9998282194137573
< O O 0.9999738931655884
. O O 0.9999984502792358
006 O O 0.9999831914901733
) O O 0.9999657869338989
, O O 0.9999545812606812
and O O 0.9999638795852661
a O O 0.9999631643295288
23 O O 0.9999940395355225
% O O 0.9999935626983643
( O O 0.9998739957809448
SD O O 0.8855001926422119
+ O O 0.9999734163284302
/ O O 0.9997162222862244
- O O 0.9999172687530518
15 O O 0.9999912977218628
% O O 0.9999867677688599
, O O 0.9998606443405151
95 O O 0.9998922348022461
% O O 0.9997503161430359
CI O O 0.990542471408844
= O O 0.9999455213546753
7 O O 0.9999899864196777
% O O 0.999975323677063
to O O 0.9998466968536377
49 O O 0.9999885559082031
% O O 0.9999936819076538
) O O 0.9999637603759766
decrease O O 0.9999908208847046
in O O 0.9997181296348572
SVO O O 0.6152566075325012
( O O 0.9995044469833374
2 O O 0.9883805513381958
) O O 0.9997989535331726
( O O 0.9999765157699585
p O O 0.9999755620956421
< O O 0.9999866485595703
0 O O 0.9999939203262329
. O O 0.9999958276748657
025 O O 0.9996179342269897
) O O 0.9999502897262573
. O O 0.999972939491272

Ventricular O O 0.999302864074707
arrhythmias O O 0.9999507665634155
were O O 0.9999518394470215
primarily O O 0.9999734163284302
observed O O 0.999974250793457
in O O 0.9997753500938416
the O O 0.9998328685760498
C O O 0.9199796319007874
+ O O 0.9969756603240967
E O O 0.9961674809455872
group O O 0.9998819828033447
, O O 0.9999595880508423
in O O 0.9999127388000488
which O O 0.9999594688415527
four O O 0.9999886751174927
of O O 0.9999709129333496
eight O O 0.999987006187439
dogs O O 0.9999667406082153
experienced O O 0.9999669790267944
ventricular O O 0.9999209642410278
tachycardia O O 0.9999707937240601
. O O 0.999953031539917

CONCLUSIONS O O 0.6206653118133545
: O O 0.997766375541687
Cocaine B B 0.9984519481658936
and O O 0.9700767993927002
ethanol B B 0.9984511137008667
in O O 0.9995680451393127
combination O O 0.998648464679718
were O O 0.9999346733093262
more O O 0.999893307685852
toxic O O 0.999586284160614
than O O 0.9999215602874756
either O O 0.9989497065544128
substance O O 0.9933658242225647
alone O O 0.9998600482940674
. O O 0.999908447265625

Co O O 0.6862488389015198
- O O 0.9097435474395752
administration O O 0.9996160268783569
resulted O O 0.9999668598175049
in O O 0.999991774559021
prolonged O O 0.9999614953994751
cardiac O O 0.9999258518218994
toxicity O O 0.9999829530715942
and O O 0.9999817609786987
was O O 0.9999759197235107
dysrhythmogenic O O 0.9999904632568359
. O O 0.9999728202819824

Peak O O 0.9994328618049622
serum O O 0.9960477948188782
cocaethylene B B 0.9991593360900879
concentrations O O 0.9988777041435242
were O O 0.9999380111694336
associated O O 0.9999819993972778
with O O 0.9999860525131226
prolonged O O 0.999977707862854
myocardial O O 0.9999986886978149
depression O O 0.9999946355819702
. O O 0.9999290704727173

Worsening O O 0.9999182224273682
of O O 0.9999446868896484
Parkinsonism O O 0.9975209832191467
after O O 0.9997058510780334
the O O 0.9999271631240845
use O O 0.9993013143539429
of O O 0.9924302697181702
veralipride B B 0.9994000196456909
for O O 0.9976481795310974
treatment O O 0.999946117401123
of O O 0.9999486207962036
menopause O O 0.8587228655815125
: O O 0.9999839067459106
case O O 0.9999924898147583
report O O 0.9999942779541016
. O O 0.9999843835830688

We O O 0.9999861717224121
describe O O 0.9999957084655762
a O O 0.9999872446060181
female O O 0.9999959468841553
patient O O 0.9999891519546509
with O O 0.9999527931213379
stable O O 0.9999551773071289
Parkinson O O 0.9975292086601257
' O O 0.9999752044677734
s O O 0.9999464750289917
disease O O 0.9999854564666748
who O O 0.9999417066574097
has O O 0.999956488609314
shown O O 0.9999877214431763
a O O 0.9999822378158569
marked O O 0.9999887943267822
worsening O O 0.99998939037323
of O O 0.9999773502349854
her O O 0.9999814033508301
motor O O 0.9999475479125977
functions O O 0.9999969005584717
following O O 0.9998435974121094
therapy O O 0.9998949766159058
of O O 0.999819815158844
menopause O O 0.6587954163551331
related O O 0.9996565580368042
symptoms O O 0.9999948740005493
with O O 0.999180257320404
veralipride B B 0.9993526339530945
, O O 0.9994696974754333
as O O 0.9999746084213257
well O O 0.9999678134918213
as O O 0.9999765157699585
the O O 0.9999951124191284
improvement O O 0.9999969005584717
of O O 0.9999910593032837
her O O 0.9999855756759644
symptoms O O 0.9999957084655762
back O O 0.9999951124191284
to O O 0.9999967813491821
baseline O O 0.9999958276748657
after O O 0.99996018409729
discontinuation O O 0.999984860420227
of O O 0.9999419450759888
the O O 0.9998519420623779
drug O O 0.9984013438224792
. O O 0.9999527931213379

We O O 0.9996507167816162
emphasize O O 0.9836764931678772
the O O 0.9997096657752991
anti O O 0.9170921444892883
- O O 0.998591959476471
dopaminergic O O 0.7883954048156738
effect O O 0.9994335770606995
of O O 0.9988837838172913
veralipride B B 0.9997329115867615
. O O 0.9999032020568848

Viracept B B 0.9966890215873718
and O O 0.9985759258270264
irregular O O 0.9994891881942749
heartbeat O O 0.9999667406082153
warning O O 0.9999819993972778
. O O 0.9986044764518738

A O O 0.999921441078186
group O O 0.9999858140945435
of O O 0.9999102354049683
doctors O O 0.9999833106994629
in O O 0.9999164342880249
Boston O O 0.9931372404098511
warn O O 0.9999761581420898
that O O 0.9999587535858154
the O O 0.9976050853729248
protease O O 0.5845757126808167
inhibitor O O 0.8276442289352417
Viracept B B 0.9013199210166931
may O O 0.9998996257781982
cause O O 0.9999595880508423
an O O 0.9999924898147583
irregular O O 0.9999977350234985
heart O O 0.999995231628418
beat O O 0.9999985694885254
, O O 0.9999895095825195
known O O 0.9999898672103882
as O O 0.9999727010726929
bradycardia O O 0.999993085861206
, O O 0.9999910593032837
in O O 0.999937891960144
people O O 0.9999843835830688
with O O 0.9998859167098999
HIV O O 0.990871012210846
. O O 0.9999334812164307

Bradycardia O O 0.9998873472213745
occurred O O 0.9999911785125732
in O O 0.9999682903289795
a O O 0.9999885559082031
45 O O 0.9999955892562866
- O O 0.9999878406524658
year O O 0.9999964237213135
- O O 0.9999915361404419
old O O 0.9999866485595703
male O O 0.9999921321868896
patient O O 0.9999843835830688
who O O 0.9996222257614136
was O O 0.9980282187461853
Viracept B B 0.9965936541557312
in O O 0.9995170831680298
combination O O 0.9997285008430481
with O O 0.9993767142295837
other O O 0.999218225479126
anti O O 0.7053094506263733
- O O 0.9590740203857422
HIV O O 0.8280940055847168
drugs O O 0.9675654768943787
. O O 0.999935507774353

The O O 0.99997878074646
symptoms O O 0.9999958276748657
ceased O O 0.9999949932098389
after O O 0.9999735355377197
switching O O 0.9999773502349854
to O O 0.9999139308929443
another O O 0.9999799728393555
drug O O 0.9987598657608032
combination O O 0.9882088899612427
. O O 0.9999544620513916

Frequency O O 0.999971866607666
of O O 0.999991774559021
appearance O O 0.9999865293502808
of O O 0.999908447265625
myeloperoxidase O O 0.9744641184806824
- O O 0.9849780797958374
antineutrophil O O 0.9617913961410522
cytoplasmic O O 0.9375196695327759
antibody O O 0.9724453091621399
( O O 0.9997202754020691
MPO O O 0.7475001811981201
- O O 0.9472039937973022
ANCA O O 0.6863533854484558
) O O 0.9999350309371948
in O O 0.9999138116836548
Graves O O 0.9997370839118958
' O O 0.9999878406524658
disease O O 0.9999963045120239
patients O O 0.9999457597732544
treated O O 0.9998441934585571
with O O 0.9988214373588562
propylthiouracil B B 0.9979544878005981
and O O 0.9998557567596436
the O O 0.9999911785125732
relationship O O 0.999997615814209
between O O 0.9999713897705078
MPO O O 0.517408549785614
- O O 0.8952796459197998
ANCA O O 0.47934284806251526
and O O 0.9999103546142578
clinical O O 0.9999895095825195
manifestations O O 0.9999977350234985
. O O 0.9999759197235107

OBJECTIVE O O 0.9964444041252136
: O O 0.9993278980255127
Myeloperoxidase O O 0.9226629734039307
antineutrophil O O 0.9028835296630859
cytoplasmic O O 0.8232091069221497
antibody O O 0.5852862596511841
( O O 0.9981217980384827
MPO O O 0.7168962955474854
- O O 0.9060853719711304
ANCA O O 0.5243220329284668
) O O 0.978825032711029
- O O 0.9994245767593384
positive O O 0.9998644590377808
vasculitis O O 0.9999216794967651
has O O 0.9999772310256958
been O O 0.9999899864196777
reported O O 0.999995231628418
in O O 0.9999572038650513
patients O O 0.9999904632568359
with O O 0.9999814033508301
Graves O O 0.9998272061347961
' O O 0.9999947547912598
disease O O 0.9999979734420776
who O O 0.9999406337738037
were O O 0.9999737739562988
treated O O 0.9999428987503052
with O O 0.999377965927124
propylthiouracil B B 0.9973070621490479
( O O 0.9832823872566223
PTU B B 0.9956128597259521
) O O 0.9993174076080322
. O O 0.9999539852142334

The O O 0.9999864101409912
appearance O O 0.9999933242797852
of O O 0.9999547004699707
MPO O O 0.5530819892883301
- O O 0.866952657699585
ANCA O O 0.488168865442276
in O O 0.9998125433921814
these O O 0.9999607801437378
cases O O 0.9999622106552124
was O O 0.9999657869338989
suspected O O 0.9999572038650513
of O O 0.9998989105224609
being O O 0.9999549388885498
related O O 0.9999837875366211
to O O 0.9996979236602783
PTU B B 0.948688268661499
because O O 0.9998520612716675
the O O 0.9999734163284302
titres O O 0.9993981122970581
of O O 0.9997133612632751
MPO O B 0.8801225423812866
- O I 0.6801407337188721
ANCA O I 0.9508615732192993
decreased O O 0.999293327331543
when O O 0.9998278617858887
PTU B B 0.9866461753845215
was O O 0.9999083280563354
stopped O O 0.9995692372322083
. O O 0.9999570846557617

Nevertheless O O 0.9999375343322754
, O O 0.9999697208404541
there O O 0.9999856948852539
have O O 0.9999938011169434
been O O 0.9999963045120239
no O O 0.9999905824661255
studies O O 0.9999970197677612
on O O 0.9999765157699585
the O O 0.9999892711639404
temporal O O 0.9999890327453613
relationship O O 0.9999978542327881
between O O 0.9999641180038452
the O O 0.9999943971633911
appearance O O 0.9999955892562866
of O O 0.9999754428863525
MPO O O 0.9091603755950928
- O O 0.9957408905029297
ANCA O O 0.9640576839447021
and O O 0.9998668432235718
vasculitis O O 0.9999237060546875
during O O 0.9995123147964478
PTU B O 0.8462343811988831
therapy O O 0.9968156218528748
, O O 0.9999464750289917
or O O 0.9999806880950928
on O O 0.9999511241912842
the O O 0.9999915361404419
incidence O O 0.9999957084655762
of O O 0.9999691247940063
MPO O O 0.8649240732192993
- O O 0.9908876419067383
ANCA O O 0.9468017816543579
in O O 0.9998948574066162
untreated O O 0.9998985528945923
Graves O O 0.9995288848876953
' O O 0.99997878074646
disease O O 0.9999902248382568
patients O O 0.9999630451202393
. O O 0.9999505281448364

Therefore O O 0.9999818801879883
, O O 0.9999815225601196
we O O 0.9999852180480957
sought O O 0.9999958276748657
to O O 0.9999948740005493
address O O 0.9999655485153198
these O O 0.9999483823776245
parameters O O 0.9999685287475586
in O O 0.9999607801437378
patients O O 0.9999922513961792
with O O 0.9999774694442749
Graves O O 0.9992849230766296
' O O 0.9999927282333374
disease O O 0.9999953508377075
. O O 0.9999873638153076

PATIENTS O O 0.999925971031189
: O O 0.9999812841415405
We O O 0.9999345541000366
investigated O O 0.9999792575836182
102 O O 0.9994977712631226
untreated O O 0.9992297887802124
patients O O 0.9999889135360718
with O O 0.9999598264694214
hyperthyroidism O O 0.9199399948120117
due O O 0.9999498128890991
to O O 0.9961897730827332
Graves O O 0.9981476068496704
' O O 0.9999712705612183
disease O O 0.9999643564224243
for O O 0.999935507774353
the O O 0.9999872446060181
presence O O 0.9999669790267944
of O O 0.9997804760932922
MPO O O 0.5265792012214661
- O O 0.7117046117782593
ANCA O O 0.7583521604537964
, O O 0.9965704679489136
and O O 0.9998794794082642
for O O 0.9999630451202393
the O O 0.9999927282333374
development O O 0.9999874830245972
vasculitis O O 0.9999643564224243
after O O 0.9999661445617676
starting O O 0.9995480179786682
PTU B B 0.9747358560562134
therapy O O 0.9897609353065491
. O O 0.9999740123748779

Twenty O O 0.9978352189064026
- O O 0.9999046325683594
nine O O 0.9934250116348267
of O O 0.9999380111694336
them O O 0.9999605417251587
were O O 0.9999675750732422
later O O 0.9999773502349854
excluded O O 0.9999673366546631
because O O 0.9999909400939941
of O O 0.9999780654907227
adverse O O 0.9999494552612305
effects O O 0.9999629259109497
of O O 0.9996424913406372
PTU B B 0.9947938323020935
or O O 0.9990395903587341
because O O 0.9999966621398926
the O O 0.999997615814209
observation O O 0.999994158744812
period O O 0.9999974966049194
was O O 0.999997615814209
less O O 0.9999983310699463
than O O 0.9999985694885254
3 O O 0.9999959468841553
months O O 0.9999986886978149
. O O 0.9999825954437256

The O O 0.9999593496322632
remaining O O 0.9999920129776001
73 O O 0.9999901056289673
patients O O 0.9999966621398926
( O O 0.9999476671218872
55 O O 0.9995558857917786
women O O 0.9998315572738647
and O O 0.9999529123306274
18 O O 0.9997698664665222
men O O 0.99994957447052
) O O 0.9999583959579468
, O O 0.9999828338623047
all O O 0.9999626874923706
of O O 0.9999725818634033
whom O O 0.999981164932251
were O O 0.9999884366989136
examined O O 0.9999967813491821
for O O 0.9999836683273315
more O O 0.9999933242797852
than O O 0.9999971389770508
3 O O 0.9998891353607178
months O O 0.999997615814209
, O O 0.9999881982803345
were O O 0.9999611377716064
adopted O O 0.9999760389328003
as O O 0.9999904632568359
the O O 0.9999942779541016
subjects O O 0.9999932050704956
of O O 0.9999935626983643
the O O 0.9999961853027344
investigation O O 0.9999943971633911
. O O 0.9999727010726929

The O O 0.9999758005142212
median O O 0.9999743700027466
observation O O 0.9999874830245972
period O O 0.9999911785125732
was O O 0.9999898672103882
23 O O 0.9999980926513672
. O O 0.9999983310699463
6 O O 0.9999977350234985
months O O 0.9999983310699463
( O O 0.9999752044677734
range O O 0.9999855756759644
: O O 0.9999760389328003
3 O O 0.9999750852584839
- O O 0.9998879432678223
37 O O 0.9999938011169434
months O O 0.999997615814209
) O O 0.999984860420227
. O O 0.9999845027923584

MEASUREMENTS O O 0.9995453953742981
: O O 0.9997957348823547
MPO O O 0.8827040791511536
- O O 0.9659295082092285
ANCA O O 0.5247620940208435
was O O 0.9999363422393799
measured O O 0.9999263286590576
at O O 0.9999583959579468
intervals O O 0.9999929666519165
of O O 0.999988317489624
2 O O 0.9999792575836182
- O O 0.9997965693473816
6 O O 0.9999921321868896
months O O 0.9999967813491821
. O O 0.9999673366546631

RESULTS O O 0.9998233914375305
: O O 0.9999574422836304
Before O O 0.9998292922973633
treatment O O 0.9999740123748779
, O O 0.9999507665634155
the O O 0.9999488592147827
MPO O O 0.7766621112823486
- O O 0.5965672135353088
ANCA O O 0.4396251440048218
titres O O 0.9927442073822021
of O O 0.9999186992645264
all O O 0.9999638795852661
102 O O 0.999580442905426
untreated O O 0.9995500445365906
Graves O O 0.9998001456260681
' O O 0.9999902248382568
disease O O 0.9999933242797852
patients O O 0.9999685287475586
were O O 0.9999566078186035
within O O 0.9999812841415405
the O O 0.999992847442627
reference O O 0.9999920129776001
range O O 0.9999909400939941
( O O 0.999984860420227
below O O 0.9999963045120239
10 O O 0.9999918937683105
U O O 0.9999923706054688
/ O O 0.9999837875366211
ml O O 0.9999985694885254
) O O 0.9999847412109375
. O O 0.9999852180480957

Three O O 0.9999432563781738
( O O 0.9999440908432007
4 O O 0.9998409748077393
. O O 0.9999854564666748
1 O O 0.9999903440475464
% O O 0.9999943971633911
) O O 0.999984622001648
of O O 0.9999839067459106
the O O 0.9999939203262329
73 O O 0.9999957084655762
patients O O 0.999996542930603
were O O 0.9999756813049316
positive O O 0.9999675750732422
for O O 0.9993984699249268
MPO O O 0.78602135181427
- O O 0.9661149382591248
ANCA O O 0.77182537317276
at O O 0.9999594688415527
13 O O 0.9999785423278809
, O O 0.9998921155929565
16 O O 0.9999865293502808
and O O 0.9999589920043945
17 O O 0.9999680519104004
months O O 0.9999977350234985
, O O 0.9999960660934448
respectively O O 0.9999788999557495
, O O 0.9999946355819702
after O O 0.99998939037323
the O O 0.9999973773956299
start O O 0.9999803304672241
of O O 0.9998987913131714
PTU B B 0.9915703535079956
therapy O O 0.9977559447288513
. O O 0.9999758005142212

In O O 0.999848484992981
two O O 0.9999748468399048
of O O 0.9999581575393677
them O O 0.9999852180480957
, O O 0.9999586343765259
the O O 0.9999654293060303
MPO O O 0.820756733417511
- O O 0.5115465521812439
ANCA O O 0.5286422967910767
titres O O 0.9986804127693176
transiently O O 0.9999841451644897
increased O O 0.9999591112136841
to O O 0.9999860525131226
12 O O 0.9999977350234985
. O O 0.9999947547912598
8 O O 0.9999802112579346
and O O 0.9999678134918213
15 O O 0.9999960660934448
. O O 0.9999971389770508
0 O O 0.9999954700469971
U O O 0.999977707862854
/ O O 0.9999728202819824
ml O O 0.9999979734420776
, O O 0.9999908208847046
respectively O O 0.9999725818634033
, O O 0.9999876022338867
despite O O 0.9999486207962036
continued O O 0.9998694658279419
PTU B B 0.9901463389396667
therapy O O 0.9993908405303955
, O O 0.9999592304229736
but O O 0.9999731779098511
no O O 0.9999842643737793
vasculitic O O 0.9999734163284302
disorders O O 0.9999979734420776
developed O O 0.9999943971633911
. O O 0.9999775886535645

In O O 0.9999678134918213
the O O 0.9999881982803345
third O O 0.9999910593032837
patient O O 0.9999967813491821
, O O 0.9999816417694092
the O O 0.9999754428863525
MPO O B 0.869982898235321
- O I 0.7085252404212952
ANCA O I 0.9664515256881714
titre O O 0.6657823324203491
increased O O 0.9999133348464966
to O O 0.9999741315841675
204 O O 0.9999042749404907
U O O 0.9998407363891602
/ O O 0.9997870326042175
ml O O 0.9999959468841553
and O O 0.9999738931655884
she O O 0.9999929666519165
developed O O 0.9999927282333374
a O O 0.9999927282333374
higher O O 0.9999792575836182
fever O O 0.9999929666519165
, O O 0.9999799728393555
oral O O 0.9942982792854309
ulcers O O 0.9999126195907593
and O O 0.9999614953994751
polyarthralgia O O 0.9999817609786987
, O O 0.9999840259552002
but O O 0.9999752044677734
the O O 0.9999951124191284
symptoms O O 0.9999967813491821
resolved O O 0.9999923706054688
2 O O 0.9999760389328003
weeks O O 0.9999994039535522
after O O 0.999991774559021
stopping O O 0.999883770942688
PTU B B 0.9932000041007996
therapy O O 0.9991719722747803
, O O 0.9999860525131226
and O O 0.9999946355819702
the O O 0.9999877214431763
MPO O B 0.8888145685195923
- O O 0.6267911791801453
ANCA O O 0.8265931010246277
titre O O 0.9372225999832153
decreased O O 0.9999747276306152
to O O 0.9999891519546509
20 O O 0.9999535083770752
. O O 0.9999985694885254
7 O O 0.9999939203262329
U O O 0.9998244643211365
/ O O 0.9999500513076782
ml O O 0.9999953508377075
by O O 0.9999948740005493
4 O O 0.9999228715896606
months O O 0.9999994039535522
after O O 0.9999960660934448
discontinuing O O 0.999980092048645
PTU B B 0.9909735321998596
. O O 0.9999444484710693

CONCLUSIONS O O 0.9714995622634888
: O O 0.9995812773704529
PTU B O 0.6340314149856567
therapy O O 0.9994543194770813
may O O 0.9998457431793213
be O O 0.9999254941940308
related O O 0.9999797344207764
to O O 0.9999815225601196
the O O 0.999994158744812
appearance O O 0.9999951124191284
of O O 0.999962329864502
MPO O O 0.7999891638755798
- O O 0.9916725754737854
ANCA O O 0.9163461327552795
, O O 0.999945878982544
but O O 0.999962568283081
MPO O O 0.7536582350730896
- O O 0.9882090091705322
ANCA O O 0.9090341329574585
does O O 0.9999727010726929
not O O 0.9999630451202393
appear O O 0.9999510049819946
to O O 0.9999780654907227
be O O 0.9999603033065796
closely O O 0.9999616146087646
related O O 0.99998939037323
to O O 0.999962568283081
vasculitis O O 0.9999598264694214
. O O 0.9999605417251587

Prevalence O O 0.9998425245285034
of O O 0.9999525547027588
heart O O 0.9999586343765259
disease O O 0.9999947547912598
in O O 0.9998356103897095
asymptomatic O O 0.9999517202377319
chronic O O 0.9157692193984985
cocaine B B 0.988871157169342
users O O 0.9985641837120056
. O O 0.9998916387557983

To O O 0.9999849796295166
determine O O 0.9999935626983643
the O O 0.999991774559021
prevalence O O 0.9999973773956299
of O O 0.9999867677688599
heart O O 0.9999798536300659
disease O O 0.999997615814209
in O O 0.9999823570251465
outpatient O O 0.999984860420227
young O O 0.9999880790710449
asymptomatic O O 0.9999905824661255
chronic O O 0.9827482104301453
cocaine B B 0.9946224689483643
users O O 0.9993352293968201
, O O 0.9999922513961792
35 O O 0.9970375299453735
cocaine B B 0.9816261529922485
users O O 0.9975468516349792
and O O 0.9999405145645142
32 O O 0.9999727010726929
age O O 0.9975830316543579
- O O 0.9999823570251465
matched O O 0.9999123811721802
controls O O 0.9999951124191284
underwent O O 0.9999655485153198
resting O O 0.9999668598175049
and O O 0.9999443292617798
exercise O O 0.9998070597648621
electrocardiography O O 0.9993925094604492
( O O 0.9999514818191528
ECG O O 0.9987624883651733
) O O 0.9999746084213257
and O O 0.9999388456344604
Doppler O O 0.9990705847740173
echocardiography O O 0.9999346733093262
. O O 0.9999731779098511

Findings O O 0.9999817609786987
consistent O O 0.9999916553497314
with O O 0.9999815225601196
coronary O O 0.9998328685760498
artery O O 0.9999340772628784
disease O O 0.9999957084655762
were O O 0.9999557733535767
detected O O 0.999984860420227
in O O 0.9999340772628784
12 O O 0.999971866607666
( O O 0.9998481273651123
34 O O 0.9999831914901733
% O O 0.9999912977218628
) O O 0.9999264478683472
patients O O 0.9999933242797852
and O O 0.9999303817749023
3 O O 0.9988265633583069
( O O 0.9997851252555847
9 O O 0.9999899864196777
% O O 0.9999903440475464
) O O 0.9998143315315247
controls O O 0.9993284940719604
( O O 0.9999219179153442
p O O 0.9998915195465088
= O O 0.9997376799583435
0 O O 0.9999645948410034
. O O 0.9999971389770508
01 O O 0.9999810457229614
) O O 0.999969482421875
. O O 0.9999700784683228

Decreased O O 0.9999436140060425
left O O 0.9999805688858032
ventricular O O 0.9999940395355225
systolic O O 0.9997132420539856
function O O 0.9999884366989136
was O O 0.9999701976776123
demonstrated O O 0.9999833106994629
in O O 0.9999374151229858
5 O O 0.99782395362854
( O O 0.9998750686645508
14 O O 0.9999969005584717
% O O 0.9999926090240479
) O O 0.9998432397842407
patients O O 0.999991774559021
, O O 0.9999499320983887
but O O 0.9999226331710815
in O O 0.9998964071273804
none O O 0.9999675750732422
of O O 0.9999239444732666
the O O 0.9999576807022095
controls O O 0.9994291663169861
( O O 0.9999312162399292
p O O 0.9999305009841919
= O O 0.9999803304672241
0 O O 0.9999945163726807
. O O 0.9999967813491821
055 O O 0.9997702240943909
) O O 0.9999686479568481
. O O 0.9999676942825317

Finally O O 0.9995887875556946
, O O 0.9998776912689209
resting O O 0.9999402761459351
and O O 0.9997550845146179
peak O O 0.9997963309288025
exercise O O 0.9999502897262573
abnormal O O 0.9999573230743408
left O O 0.9999442100524902
ventricular O O 0.9999817609786987
filling O O 0.9999536275863647
was O O 0.9999487400054932
detected O O 0.9999877214431763
in O O 0.9999139308929443
38 O O 0.999958872795105
and O O 0.9999574422836304
35 O O 0.9999854564666748
% O O 0.9999905824661255
of O O 0.9999693632125854
patients O O 0.9999898672103882
as O O 0.9999821186065674
compared O O 0.9999556541442871
to O O 0.9999505281448364
19 O O 0.9999836683273315
and O O 0.999963641166687
9 O O 0.9999895095825195
% O O 0.9999924898147583
of O O 0.9999525547027588
controls O O 0.9999791383743286
, O O 0.9999799728393555
respectively O O 0.9999748468399048
( O O 0.9999500513076782
p O O 0.9995253086090088
= O O 0.999853253364563
0 O O 0.9999300241470337
. O O 0.9999945163726807
11 O O 0.9999921321868896
and O O 0.9999393224716187
0 O O 0.9997206330299377
. O O 0.9999936819076538
02 O O 0.9999823570251465
, O O 0.9999889135360718
respectively O O 0.9999661445617676
) O O 0.9999762773513794
. O O 0.9999737739562988

We O O 0.99996018409729
conclude O O 0.9999462366104126
that O O 0.9999504089355469
coronary O O 0.9998680353164673
artery O O 0.9994988441467285
or O O 0.9998672008514404
myocardial O O 0.9999972581863403
disease O O 0.9999963045120239
is O O 0.999980092048645
common O O 0.9999911785125732
( O O 0.9999769926071167
38 O O 0.9999946355819702
% O O 0.9999972581863403
) O O 0.9999825954437256
in O O 0.9999338388442993
young O O 0.9998937845230103
asymptomatic O O 0.9999828338623047
chronic O O 0.9978455305099487
cocaine B B 0.9871010780334473
users O O 0.9993448853492737
. O O 0.9999675750732422

Therefore O O 0.9999775886535645
, O O 0.9999860525131226
screening O O 0.9998838901519775
ECG O O 0.9957451224327087
and O O 0.9999687671661377
echocardiography O O 0.9997714161872864
may O O 0.9999806880950928
be O O 0.9999969005584717
warranted O O 0.9999935626983643
in O O 0.9999953508377075
these O O 0.9999794960021973
patients O O 0.9999918937683105
. O O 0.9999809265136719

Cardioprotective O O 0.9997734427452087
effects O O 0.9999306201934814
of O O 0.9991797804832458
Picrorrhiza O B 0.8995686173439026
kurroa O I 0.9957194924354553
against O O 0.9844520092010498
isoproterenol B B 0.9986856579780579
- O O 0.9995704293251038
induced O O 0.9999511241912842
myocardial O O 0.9999977350234985
stress O O 0.999854564666748
in O O 0.9999512434005737
rats O O 0.9999886751174927
. O O 0.9999556541442871

The O O 0.9999783039093018
cardioprotective O O 0.9999856948852539
effect O O 0.9999569654464722
of O O 0.9997535347938538
the O O 0.9962947964668274
ethanol B B 0.7049173712730408
extract O I 0.960549533367157
of O I 0.9465453028678894
Picrorrhiza O I 0.8528189063072205
kurroa O I 0.9448074698448181
rhizomes O O 0.9117434024810791
and O O 0.8224580883979797
roots O O 0.8419080972671509
( O O 0.8236483335494995
PK O B 0.8982051014900208
) O O 0.9407997727394104
on O O 0.9995562434196472
isoproterenol B B 0.9996639490127563
- O O 0.999758780002594
induced O O 0.9999502897262573
myocardial O O 0.9999986886978149
infarction O O 0.9999947547912598
in O O 0.9999513626098633
rats O O 0.9999895095825195
with O O 0.9999890327453613
respect O O 0.9999977350234985
to O O 0.9999607801437378
lipid O B 0.912570595741272
metabolism O O 0.9994322657585144
in O O 0.9998657703399658
serum O O 0.9990058541297913
and O O 0.9998138546943665
heart O O 0.9999405145645142
tissue O O 0.9999897480010986
has O O 0.9999650716781616
been O O 0.9999793767929077
investigated O O 0.9999754428863525
. O O 0.9999709129333496

Oral O O 0.9997082352638245
pre O O 0.9992897510528564
- O O 0.9999024868011475
treatment O O 0.9999569654464722
with O O 0.9996483325958252
PK O B 0.9962940812110901
( O O 0.9962621331214905
80 O O 0.9954401254653931
mg O O 0.999200165271759
kg O O 0.9993552565574646
( O O 0.986799955368042
- O O 0.9960124492645264
1 O O 0.99858558177948
) O O 0.9995676875114441
day O O 0.9997978806495667
( O O 0.9850385785102844
- O O 0.995512068271637
1 O O 0.9972189664840698
) O O 0.9994651675224304
for O O 0.9999558925628662
15 O O 0.9999886751174927
days O O 0.9999908208847046
) O O 0.999895453453064
significantly O O 0.9999712705612183
prevented O O 0.999974250793457
the O O 0.999981164932251
isoproterenol B B 0.9995434880256653
- O O 0.9996641874313354
induced O O 0.9999488592147827
myocardial O O 0.999997615814209
infarction O O 0.999991774559021
and O O 0.9999724626541138
maintained O O 0.9999830722808838
the O O 0.9999871253967285
rats O O 0.9998623132705688
at O O 0.99998939037323
near O O 0.999995231628418
normal O O 0.999995231628418
status O O 0.999997615814209
. O O 0.9999825954437256

Phase O O 0.9991447925567627
2 O O 0.9956764578819275
early O O 0.9992033839225769
afterdepolarization O O 0.9189456105232239
as O O 0.9999587535858154
a O O 0.9999512434005737
trigger O O 0.9999884366989136
of O O 0.999963641166687
polymorphic O O 0.9999823570251465
ventricular O O 0.9999544620513916
tachycardia O O 0.9999933242797852
in O O 0.9998548030853271
acquired O O 0.9985775947570801
long O O 0.9811148047447205
- O O 0.998372495174408
QT O O 0.8825080394744873
syndrome O O 0.999916672706604
: O O 0.9999579191207886
direct O O 0.9999945163726807
evidence O O 0.9999973773956299
from O O 0.9999955892562866
intracellular O O 0.999983549118042
recordings O O 0.9999921321868896
in O O 0.99994957447052
the O O 0.9999839067459106
intact O O 0.9999630451202393
left O O 0.9999725818634033
ventricular O O 0.9999864101409912
wall O O 0.9999765157699585
. O O 0.9999680519104004

BACKGROUND O O 0.9997850060462952
: O O 0.9999874830245972
This O O 0.9999836683273315
study O O 0.9999790191650391
examined O O 0.9999548196792603
the O O 0.9999725818634033
role O O 0.9999672174453735
of O O 0.9998108744621277
phase O O 0.9998217225074768
2 O O 0.9788867235183716
early O O 0.9944422841072083
afterdepolarization O O 0.9571167826652527
( O O 0.999890923500061
EAD O O 0.9977784752845764
) O O 0.999897837638855
in O O 0.9999172687530518
producing O O 0.9999785423278809
a O O 0.9999570846557617
trigger O O 0.9999856948852539
to O O 0.9999852180480957
initiate O O 0.9999819993972778
torsade O O 0.9994049072265625
de O O 0.9999469518661499
pointes O O 0.9999381303787231
( O O 0.9999277591705322
TdP O O 0.9983876943588257
) O O 0.9999665021896362
with O O 0.9999254941940308
QT O O 0.9780713319778442
prolongation O O 0.9998865127563477
induced O O 0.9999804496765137
by O O 0.9998917579650879
dl O B 0.9057540893554688
- O O 0.9613450169563293
sotalol B B 0.5729294419288635
and O O 0.9546396136283875
azimilide B B 0.997267484664917
. O O 0.9999418258666992

The O O 0.9999669790267944
contribution O O 0.9999427795410156
of O O 0.9998470544815063
transmural O O 0.9988588094711304
dispersion O O 0.9998487234115601
of O O 0.9995415210723877
repolarization O O 0.9985132813453674
( O O 0.9996989965438843
TDR O O 0.9645093679428101
) O O 0.9998838901519775
to O O 0.9997275471687317
transmural O O 0.9995390176773071
propagation O O 0.9999728202819824
of O O 0.9995860457420349
EAD O O 0.9358400106430054
and O O 0.9998492002487183
the O O 0.9999513626098633
maintenance O O 0.9999376535415649
of O O 0.9998939037322998
TdP O O 0.7119259238243103
was O O 0.9999560117721558
also O O 0.9999853372573853
evaluated O O 0.9999774694442749
. O O 0.999961256980896

METHODS O O 0.9999862909317017
AND O O 0.9999963045120239
RESULTS O O 0.9999926090240479
: O O 0.9998364448547363
Transmembrane O O 0.9121090173721313
action O O 0.9998552799224854
potentials O O 0.9999885559082031
from O O 0.999935507774353
epicardium O O 0.999305248260498
, O O 0.999863862991333
midmyocardium O O 0.9902896285057068
, O O 0.9993433356285095
and O O 0.9994997978210449
endocardium O O 0.9996597766876221
were O O 0.9999436140060425
recorded O O 0.9999881982803345
simultaneously O O 0.9999493360519409
, O O 0.9999896287918091
together O O 0.999976634979248
with O O 0.9999840259552002
a O O 0.9999793767929077
transmural O O 0.9995483756065369
ECG O O 0.9997379183769226
, O O 0.9999808073043823
in O O 0.9996861219406128
arterially O O 0.9999425411224365
perfused O O 0.9998880624771118
canine O O 0.9985206723213196
and O O 0.9994284510612488
rabbit O O 0.9887789487838745
left O O 0.9999480247497559
ventricular O O 0.9999902248382568
preparations O O 0.9999791383743286
. O O 0.9999610185623169

dl O B 0.9089668989181519
- O O 0.6025205850601196
Sotalol B B 0.9989367127418518
preferentially O O 0.9996722936630249
prolonged O O 0.9996213912963867
action O O 0.9996631145477295
potential O O 0.9999815225601196
duration O O 0.9999513626098633
( O O 0.9995905756950378
APD O O 0.9539846181869507
) O O 0.9999159574508667
in O O 0.9993526339530945
M O O 0.49970030784606934
cells O O 0.9875385761260986
dose O O 0.993730902671814
- O O 0.9999122619628906
dependently O O 0.9999213218688965
( O O 0.9999415874481201
1 O O 0.999872088432312
to O O 0.9999948740005493
100 O O 0.9999823570251465
micromol O O 0.9997603297233582
/ O O 0.9999532699584961
L O O 0.9994487166404724
) O O 0.9999617338180542
, O O 0.9999687671661377
leading O O 0.9999902248382568
to O O 0.9999668598175049
QT O O 0.9753214120864868
prolongation O O 0.9999504089355469
and O O 0.9999862909317017
an O O 0.9999852180480957
increase O O 0.99997878074646
in O O 0.9999552965164185
TDR O O 0.992071807384491
. O O 0.9999276399612427

Azimilide B B 0.9993315935134888
, O O 0.9998980760574341
however O O 0.9999369382858276
, O O 0.9999076128005981
significantly O O 0.9999675750732422
prolonged O O 0.9999698400497437
APD O O 0.996393620967865
and O O 0.9999505281448364
QT O O 0.9891340136528015
interval O O 0.9999880790710449
at O O 0.9949653744697571
concentrations O O 0.9942471981048584
from O O 0.9999071359634399
0 O O 0.9999610185623169
. O O 0.9999892711639404
1 O O 0.9999853372573853
to O O 0.9999349117279053
10 O O 0.9999792575836182
micromol O O 0.9994410872459412
/ O O 0.9999572038650513
L O O 0.9993088245391846
but O O 0.9995949864387512
shortened O O 0.9900437593460083
them O O 0.9999637603759766
at O O 0.999948263168335
30 O O 0.9999816417694092
micromol O O 0.9998326301574707
/ O O 0.9999656677246094
L O O 0.9993439316749573
. O O 0.9999731779098511

Unlike O O 0.9634304046630859
dl O B 0.908008337020874
- O O 0.9285227656364441
sotalol B B 0.9547637701034546
, O O 0.987880289554596
azimilide B B 0.9992281198501587
( O O 0.9998352527618408
> O O 0.9990561604499817
3 O O 0.9985488057136536
micromol O O 0.9966378211975098
/ O O 0.9997270703315735
L O O 0.9876613616943359
) O O 0.9998219609260559
increased O O 0.9996494054794312
epicardial O O 0.9990676045417786
APD O O 0.6470552682876587
markedly O O 0.9997524619102478
, O O 0.999953031539917
causing O O 0.9999545812606812
a O O 0.9999830722808838
diminished O O 0.9999878406524658
TDR O O 0.9772527813911438
. O O 0.9999591112136841

Although O O 0.9999765157699585
both O O 0.9987504482269287
dl O B 0.9922587275505066
- O O 0.9750322699546814
sotalol B B 0.5998125076293945
and O O 0.9684323072433472
azimilide B B 0.9979502558708191
rarely O O 0.9998602867126465
induced O O 0.9999501705169678
EADs O O 0.9984575510025024
in O O 0.999882698059082
canine O O 0.9999675750732422
left O O 0.9999681711196899
ventricles O O 0.9999936819076538
, O O 0.9998974800109863
they O O 0.9996726512908936
produced O O 0.9999768733978271
frequent O O 0.9999532699584961
EADs O O 0.9964358806610107
in O O 0.9996463060379028
rabbits O O 0.9617790579795837
, O O 0.9999771118164062
in O O 0.9998236298561096
which O O 0.9999330043792725
more O O 0.9999572038650513
pronounced O O 0.9999871253967285
QT O O 0.9943485856056213
prolongation O O 0.9999707937240601
was O O 0.9999897480010986
seen O O 0.9999958276748657
. O O 0.9999799728393555

An O O 0.9999363422393799
increase O O 0.999889612197876
in O O 0.9998270869255066
TDR O O 0.568386435508728
by O O 0.9980975985527039
dl O B 0.9938490986824036
- O O 0.8704841136932373
sotalol B B 0.979377031326294
facilitated O O 0.9997709393501282
transmural O O 0.9998487234115601
propagation O O 0.9999819993972778
of O O 0.999638557434082
EADs O O 0.6611889600753784
that O O 0.9999135732650757
initiated O O 0.9999881982803345
multiple O O 0.9999778270721436
episodes O O 0.999995231628418
of O O 0.9999806880950928
spontaneous O O 0.9999722242355347
TdP O O 0.9273549318313599
in O O 0.9998107552528381
3 O O 0.9946856498718262
of O O 0.999923825263977
6 O O 0.9979367256164551
rabbit O O 0.9922040700912476
left O O 0.9999120235443115
ventricles O O 0.999985933303833
. O O 0.9999436140060425

Of O O 0.9999464750289917
note O O 0.9999891519546509
, O O 0.9999585151672363
although O O 0.9998946189880371
azimilide B B 0.9996092915534973
( O O 0.9995390176773071
3 O O 0.9965687990188599
to O O 0.9998038411140442
10 O O 0.9999474287033081
micromol O O 0.9956446886062622
/ O O 0.9995689988136292
L O O 0.965707540512085
) O O 0.999743640422821
increased O O 0.9991990923881531
APD O O 0.7098987698554993
more O O 0.9996225833892822
than O O 0.999566376209259
dl O O 0.7896052002906799
- O O 0.8899486660957336
sotalol B B 0.8264470100402832
, O O 0.9997319579124451
its O O 0.9995976090431213
EADs O O 0.9707027077674866
often O O 0.9999648332595825
failed O O 0.999981164932251
to O O 0.9999772310256958
propagate O O 0.9999698400497437
transmurally O O 0.999919056892395
, O O 0.9999790191650391
probably O O 0.9999808073043823
because O O 0.9999841451644897
of O O 0.9999738931655884
a O O 0.9999804496765137
diminished O O 0.9999780654907227
TDR O O 0.9140039086341858
. O O 0.999954104423523

CONCLUSIONS O O 0.9999399185180664
: O O 0.9999936819076538
This O O 0.999992847442627
study O O 0.9999872446060181
provides O O 0.9999831914901733
the O O 0.9999954700469971
first O O 0.9999971389770508
direct O O 0.9999971389770508
evidence O O 0.9999909400939941
from O O 0.9999920129776001
intracellular O O 0.9999756813049316
action O O 0.9999672174453735
potential O O 0.9999959468841553
recordings O O 0.9999914169311523
that O O 0.9999072551727295
phase O O 0.9979155659675598
2 O O 0.9697377681732178
EAD O O 0.9940829873085022
can O O 0.9996153116226196
be O O 0.9999444484710693
generated O O 0.9999712705612183
from O O 0.9997890591621399
intact O O 0.9993287324905396
ventricular O O 0.9999147653579712
wall O O 0.9998821020126343
and O O 0.999906063079834
produce O O 0.9999470710754395
a O O 0.9999226331710815
trigger O O 0.9999547004699707
to O O 0.9999613761901855
initiate O O 0.9999821186065674
the O O 0.9999911785125732
onset O O 0.9999865293502808
of O O 0.9999301433563232
TdP O O 0.9259313344955444
under O O 0.9965219497680664
QT O O 0.8173237442970276
prolongation O O 0.9998471736907959
. O O 0.9999688863754272

A O O 0.9999504089355469
pilot O O 0.9999923706054688
study O O 0.999992847442627
to O O 0.9999943971633911
assess O O 0.9999932050704956
the O O 0.9999972581863403
safety O O 0.9999983310699463
of O O 0.9998639822006226
dobutamine B B 0.9998015761375427
stress O O 0.9997071623802185
echocardiography O O 0.9995691180229187
in O O 0.9999724626541138
the O O 0.9999973773956299
emergency O O 0.9999890327453613
department O O 0.9999970197677612
evaluation O O 0.999995231628418
of O O 0.9999741315841675
cocaine B B 0.9951459765434265
- O O 0.9977155923843384
associated O O 0.9999537467956543
chest O O 0.9999927282333374
pain O O 0.9999960660934448
. O O 0.9999792575836182

STUDY O O 0.9993380904197693
OBJECTIVE O O 0.9999419450759888
: O O 0.9999667406082153
Chest O O 0.9999619722366333
pain O O 0.9999936819076538
in O O 0.9999809265136719
the O O 0.9999927282333374
setting O O 0.9999610185623169
of O O 0.999863862991333
cocaine B B 0.9946972131729126
use O O 0.9985489249229431
poses O O 0.9999663829803467
a O O 0.9999821186065674
diagnostic O O 0.9999967813491821
dilemma O O 0.9999949932098389
. O O 0.9999865293502808

Dobutamine B B 0.995223343372345
stress O O 0.9927116632461548
echocardiography O O 0.9998351335525513
( O O 0.9999009370803833
DSE O O 0.5149862170219421
) O O 0.9999690055847168
is O O 0.9999821186065674
a O O 0.9999850988388062
widely O O 0.9999767541885376
available O O 0.9999904632568359
and O O 0.9999611377716064
sensitive O O 0.9999772310256958
test O O 0.9999891519546509
for O O 0.9999809265136719
evaluating O O 0.9999772310256958
cardiac O O 0.9999855756759644
ischemia O O 0.9999943971633911
. O O 0.9999804496765137

Because O O 0.9999945163726807
of O O 0.9999874830245972
the O O 0.9999966621398926
theoretical O O 0.9999972581863403
concern O O 0.9999985694885254
regarding O O 0.9999772310256958
administration O O 0.999885082244873
of O O 0.998301088809967
dobutamine B B 0.9996645450592041
in O O 0.9998916387557983
the O O 0.9999948740005493
setting O O 0.9999796152114868
of O O 0.9999047517776489
cocaine B B 0.9970033764839172
use O O 0.9997304081916809
, O O 0.999982476234436
we O O 0.9999809265136719
conducted O O 0.9999980926513672
a O O 0.9999946355819702
pilot O O 0.9999936819076538
study O O 0.9999964237213135
to O O 0.9999961853027344
assess O O 0.9999953508377075
the O O 0.9999973773956299
safety O O 0.9999980926513672
of O O 0.9999735355377197
DSE O B 0.9910749197006226
in O O 0.9998471736907959
emergency O O 0.9999791383743286
department O O 0.999996542930603
patients O O 0.9999974966049194
with O O 0.9999914169311523
cocaine B B 0.9965012073516846
- O O 0.9996813535690308
associated O O 0.9999440908432007
chest O O 0.9999942779541016
pain O O 0.9999961853027344
. O O 0.9999855756759644

METHODS O O 0.9999387264251709
: O O 0.999993085861206
A O O 0.9999915361404419
prospective O O 0.9999915361404419
case O O 0.9999914169311523
series O O 0.9999954700469971
was O O 0.9999873638153076
conducted O O 0.9999957084655762
in O O 0.9999576807022095
the O O 0.9999799728393555
intensive O O 0.9999372959136963
diagnostic O O 0.9999977350234985
and O O 0.999972939491272
treatment O O 0.999964714050293
unit O O 0.9999959468841553
in O O 0.999944806098938
the O O 0.9999887943267822
ED O O 0.9999216794967651
of O O 0.9999887943267822
an O O 0.9999903440475464
urban O O 0.9986293315887451
tertiary O O 0.9999082088470459
- O O 0.9999821186065674
care O O 0.999962329864502
teaching O O 0.9999852180480957
hospital O O 0.9999860525131226
. O O 0.9999744892120361

Patients O O 0.9999165534973145
were O O 0.9999772310256958
eligible O O 0.9999761581420898
for O O 0.9996575117111206
DSE O B 0.9054453372955322
if O O 0.9999452829360962
they O O 0.9999895095825195
had O O 0.9999924898147583
used O O 0.9992400407791138
cocaine B B 0.9976065158843994
within O O 0.9997708201408386
24 O O 0.999972939491272
hours O O 0.9999935626983643
preceding O O 0.9999967813491821
the O O 0.9999982118606567
onset O O 0.9999992847442627
of O O 0.9999979734420776
chest O O 0.9999972581863403
pain O O 0.9999982118606567
and O O 0.9999856948852539
had O O 0.9999915361404419
a O O 0.9999948740005493
normal O O 0.9999463558197021
ECG O O 0.9883434772491455
and O O 0.9998931884765625
tropinin O O 0.6313942074775696
I O O 0.7135540843009949
level O O 0.9982829093933105
. O O 0.9999735355377197

Patients O O 0.9999357461929321
exhibiting O O 0.9998130202293396
signs O O 0.999976634979248
of O O 0.9999762773513794
continuing O O 0.9996976852416992
cocaine B B 0.9960408210754395
toxicity O O 0.9995585083961487
were O O 0.9999765157699585
excluded O O 0.9999808073043823
from O O 0.999987006187439
the O O 0.9999951124191284
study O O 0.9999815225601196
. O O 0.9999734163284302

All O O 0.9999629259109497
patients O O 0.9999908208847046
were O O 0.9999911785125732
admitted O O 0.9999889135360718
to O O 0.999994158744812
the O O 0.9999963045120239
hospital O O 0.9999923706054688
for O O 0.9999880790710449
serial O O 0.9998394250869751
testing O O 0.9999959468841553
after O O 0.9999721050262451
the O O 0.9999524354934692
DSE O O 0.7316681146621704
testing O O 0.9991869330406189
in O O 0.999921441078186
the O O 0.9999865293502808
intensive O O 0.9999686479568481
diagnostic O O 0.9999974966049194
and O O 0.9999797344207764
treatment O O 0.9999758005142212
unit O O 0.9999948740005493
. O O 0.9999864101409912

RESULTS O O 0.9999260902404785
: O O 0.999994158744812
Twenty O O 0.9997019171714783
- O O 0.9999849796295166
four O O 0.9999908208847046
patients O O 0.9999953508377075
were O O 0.9999912977218628
enrolled O O 0.9999842643737793
. O O 0.9999725818634033

Two O O 0.9999443292617798
patients O O 0.999990701675415
had O O 0.9999816417694092
inadequate O O 0.9999929666519165
resting O O 0.9999898672103882
images O O 0.9999966621398926
, O O 0.9999618530273438
one O O 0.999868631362915
DSE O O 0.4986066520214081
was O O 0.9998158812522888
terminated O O 0.9999148845672607
because O O 0.9999876022338867
of O O 0.9999597072601318
inferior O O 0.9999743700027466
hypokinesis O O 0.999927282333374
, O O 0.999927282333374
another O O 0.9999113082885742
DSE O O 0.547911524772644
was O O 0.9998213648796082
terminated O O 0.999953031539917
because O O 0.9999904632568359
of O O 0.9999784231185913
a O O 0.9999696016311646
rate O O 0.9955050945281982
- O O 0.9999443292617798
related O O 0.9999783039093018
atrial O O 0.9998179078102112
conduction O O 0.9999884366989136
deficit O O 0.999990701675415
, O O 0.9999287128448486
and O O 0.9999710321426392
1 O O 0.9995573163032532
patient O O 0.9999915361404419
did O O 0.9999858140945435
not O O 0.9999932050704956
reach O O 0.9999895095825195
the O O 0.9999947547912598
target O O 0.9999793767929077
heart O O 0.9999908208847046
rate O O 0.9999784231185913
. O O 0.9999582767486572

Thus O O 0.9999781847000122
, O O 0.9999769926071167
19 O O 0.9990819692611694
patients O O 0.999987006187439
completed O O 0.9999417066574097
a O O 0.9997573494911194
DSE O O 0.5862347483634949
and O O 0.9999233484268188
reached O O 0.999994158744812
their O O 0.9999940395355225
target O O 0.9999767541885376
heart O O 0.9999767541885376
rates O O 0.9999760389328003
. O O 0.9999663829803467

None O O 0.9999500513076782
of O O 0.9999693632125854
the O O 0.9999736547470093
patients O O 0.9999841451644897
experienced O O 0.9999536275863647
signs O O 0.9999806880950928
of O O 0.9999662637710571
exaggerated O O 0.9917531609535217
adrenergic O O 0.9408484697341919
response O O 0.9999618530273438
, O O 0.999982476234436
which O O 0.999988317489624
was O O 0.9999831914901733
defined O O 0.9999961853027344
as O O 0.999990701675415
a O O 0.9999864101409912
systolic O O 0.9998314380645752
blood O O 0.9999406337738037
pressure O O 0.9999107122421265
of O O 0.9999566078186035
greater O O 0.9999922513961792
than O O 0.9999942779541016
200 O O 0.9999909400939941
mm O O 0.9999960660934448
Hg O O 0.5772715210914612
or O O 0.999956488609314
the O O 0.9999902248382568
occurrence O O 0.9999915361404419
of O O 0.9999525547027588
tachydysrhythmias O O 0.9999594688415527
( O O 0.9999723434448242
excluding O O 0.9999105930328369
sinus O O 0.9999716281890869
tachycardia O O 0.9999796152114868
) O O 0.9999748468399048
. O O 0.9999771118164062

Further O O 0.9999786615371704
suggesting O O 0.9999594688415527
lack O O 0.9999704360961914
of O O 0.9999505281448364
exaggerated O O 0.992424726486206
adrenergic O O 0.8969702124595642
response O O 0.9999154806137085
, O O 0.9999197721481323
13 O O 0.9999579191207886
( O O 0.9999233484268188
65 O O 0.9999955892562866
% O O 0.9999971389770508
) O O 0.9999855756759644
of O O 0.9999810457229614
20 O O 0.9999927282333374
patients O O 0.9999960660934448
required O O 0.9999444484710693
supplemental O O 0.9998307228088379
atropine B B 0.9996110796928406
to O O 0.9999433755874634
reach O O 0.9999898672103882
their O O 0.999994158744812
target O O 0.9999639987945557
heart O O 0.9999920129776001
rates O O 0.9999901056289673
. O O 0.9999734163284302

CONCLUSION O O 0.9968690276145935
: O O 0.9999291896820068
No O O 0.9998212456703186
exaggerated O O 0.9863349199295044
adrenergic O O 0.9293466210365295
response O O 0.9999158382415771
was O O 0.9999655485153198
detected O O 0.9999911785125732
when O O 0.9997397065162659
dobutamine B B 0.9998669624328613
was O O 0.9999644756317139
administered O O 0.9998791217803955
to O O 0.9999527931213379
patients O O 0.9999933242797852
with O O 0.9999806880950928
cocaine B B 0.9954989552497864
- O O 0.9990658164024353
related O O 0.9999403953552246
chest O O 0.9999871253967285
pain O O 0.9999938011169434
. O O 0.9999796152114868

Prenatal O O 0.9992836117744446
cocaine B B 0.9970138072967529
exposure O O 0.9989967942237854
and O O 0.9999589920043945
cranial O O 0.9999263286590576
sonographic O O 0.999916672706604
findings O O 0.9999945163726807
in O O 0.9999866485595703
preterm O O 0.9999979734420776
infants O O 0.9999986886978149
. O O 0.999976396560669

PURPOSE O O 0.9971933960914612
: O O 0.999935507774353
Prenatal O O 0.9999878406524658
cocaine B B 0.9977841973304749
exposure O O 0.9994524121284485
has O O 0.9999709129333496
been O O 0.9999878406524658
linked O O 0.9999719858169556
with O O 0.9999825954437256
subependymal O O 0.9999022483825684
hemorrhage O O 0.999991774559021
and O O 0.9999794960021973
the O O 0.9999953508377075
formation O O 0.9999959468841553
of O O 0.9999697208404541
cysts O O 0.9992610812187195
that O O 0.9999760389328003
are O O 0.99998939037323
detectable O O 0.9999973773956299
on O O 0.9999935626983643
cranial O O 0.9999810457229614
sonography O O 0.9999889135360718
in O O 0.9999703168869019
neonates O O 0.9999985694885254
born O O 0.9999977350234985
at O O 0.9999942779541016
term O O 0.9999994039535522
. O O 0.9999816417694092

We O O 0.9999489784240723
sought O O 0.9999961853027344
to O O 0.9999967813491821
determine O O 0.9999970197677612
if O O 0.9999473094940186
prenatal O O 0.9999663829803467
cocaine B B 0.9986692667007446
exposure O O 0.999309778213501
increases O O 0.9999009370803833
the O O 0.9999973773956299
incidence O O 0.9999979734420776
of O O 0.9999872446060181
subependymal O O 0.9998270869255066
cysts O O 0.9997968077659607
in O O 0.9999775886535645
preterm O O 0.9999980926513672
infants O O 0.999998927116394
. O O 0.9999792575836182

METHODS O O 0.9999613761901855
: O O 0.9999946355819702
We O O 0.9999942779541016
retrospectively O O 0.999990701675415
reviewed O O 0.9999964237213135
the O O 0.9999969005584717
medical O O 0.999997615814209
records O O 0.9999979734420776
and O O 0.9999911785125732
cranial O O 0.9999477863311768
sonograms O O 0.9999806880950928
obtained O O 0.9999966621398926
during O O 0.9999837875366211
a O O 0.9999831914901733
1 O O 0.9999760389328003
- O O 0.9999921321868896
year O O 0.9999979734420776
period O O 0.9999967813491821
on O O 0.999987006187439
122 O O 0.9996857643127441
premature O O 0.9999983310699463
( O O 0.9999637603759766
< O O 0.9999943971633911
36 O O 0.999998927116394
weeks O O 0.9999990463256836
of O O 0.9999963045120239
gestation O O 0.9999955892562866
) O O 0.9999704360961914
infants O O 0.9999978542327881
. O O 0.9999837875366211

Infants O O 0.9999892711639404
were O O 0.9999788999557495
categorized O O 0.9999932050704956
into O O 0.999971866607666
1 O O 0.999859094619751
of O O 0.9999728202819824
2 O O 0.9999740123748779
groups O O 0.9998793601989746
: O O 0.9999724626541138
those O O 0.9999840259552002
exposed O O 0.9997640252113342
to O O 0.9983789920806885
cocaine B B 0.9921467900276184
and O O 0.9994706511497498
those O O 0.9999727010726929
not O O 0.9998515844345093
exposed O O 0.9998742341995239
to O O 0.9989826083183289
cocaine B B 0.9850900173187256
. O O 0.9999089241027832

Infants O O 0.9999916553497314
were O O 0.9999934434890747
assigned O O 0.9999939203262329
to O O 0.9998573064804077
the O O 0.9998960494995117
cocaine B B 0.9961202144622803
- O O 0.9933068156242371
exposed O O 0.9987762570381165
group O O 0.9999326467514038
if O O 0.9999963045120239
there O O 0.9999960660934448
was O O 0.9999933242797852
a O O 0.9999974966049194
maternal O O 0.9999979734420776
history O O 0.9999953508377075
of O O 0.9999322891235352
cocaine O B 0.9917144179344177
abuse O O 0.9945573806762695
during O O 0.9999675750732422
pregnancy O O 0.9999985694885254
or O O 0.9999908208847046
if O O 0.999997615814209
maternal O O 0.9999916553497314
or O O 0.9999903440475464
neonatal O O 0.9999977350234985
urine O O 0.8767486810684204
toxicology O O 0.6223115921020508
results O O 0.9999651908874512
were O O 0.9999896287918091
positive O O 0.9999885559082031
at O O 0.9999977350234985
the O O 0.9999990463256836
time O O 0.9999990463256836
of O O 0.9999982118606567
delivery O O 0.9999988079071045
. O O 0.9999881982803345

RESULTS O O 0.9997279047966003
: O O 0.999980092048645
Five O O 0.9999933242797852
of O O 0.9999881982803345
the O O 0.9999977350234985
122 O O 0.9999971389770508
infants O O 0.9999980926513672
were O O 0.9999933242797852
excluded O O 0.9999958276748657
from O O 0.9999923706054688
the O O 0.9999972581863403
study O O 0.9999946355819702
because O O 0.9999897480010986
of O O 0.9999887943267822
insufficient O O 0.9999842643737793
medical O O 0.9999923706054688
and O O 0.9999673366546631
drug O O 0.9997432827949524
histories O O 0.9999908208847046
. O O 0.9999750852584839

The O O 0.9999929666519165
incidence O O 0.9999971389770508
of O O 0.9999831914901733
subependymal O O 0.9997960925102234
cysts O O 0.999404788017273
in O O 0.9998619556427002
the O O 0.9999762773513794
117 O O 0.9999823570251465
remaining O O 0.99998939037323
infants O O 0.9999936819076538
was O O 0.9999644756317139
14 O O 0.9999971389770508
% O O 0.9999973773956299
( O O 0.9999667406082153
16 O O 0.999997615814209
of O O 0.9999669790267944
117 O O 0.9997872710227966
) O O 0.9999703168869019
. O O 0.9999771118164062

The O O 0.9999933242797852
incidence O O 0.9999967813491821
of O O 0.9999823570251465
subependymal O O 0.9997017979621887
cysts O O 0.9992885589599609
in O O 0.9999593496322632
infants O O 0.9999970197677612
exposed O O 0.9998403787612915
to O O 0.9932540059089661
cocaine B B 0.9950897693634033
prenatally O O 0.9999387264251709
was O O 0.9999778270721436
44 O O 0.9999957084655762
% O O 0.9999983310699463
( O O 0.9999706745147705
8 O O 0.9954649806022644
of O O 0.9998983144760132
18 O O 0.9999877214431763
) O O 0.9999585151672363
compared O O 0.999982476234436
with O O 0.9999914169311523
8 O O 0.9999924898147583
% O O 0.9999977350234985
( O O 0.9999853372573853
8 O O 0.9999945163726807
of O O 0.9999748468399048
99 O O 0.9999141693115234
) O O 0.9999743700027466
in O O 0.9999616146087646
the O O 0.9999914169311523
unexposed O O 0.9991775155067444
group O O 0.999985933303833
( O O 0.9999521970748901
p O O 0.9999533891677856
< O O 0.999970555305481
0 O O 0.9999959468841553
. O O 0.9999985694885254
01 O O 0.9999954700469971
) O O 0.9999805688858032
. O O 0.9999825954437256

CONCLUSIONS O O 0.9992982149124146
: O O 0.9999873638153076
We O O 0.9999361038208008
found O O 0.9999920129776001
an O O 0.9999916553497314
increased O O 0.9999940395355225
incidence O O 0.9999963045120239
of O O 0.9999821186065674
subependymal O O 0.9998030066490173
cyst O O 0.9988954067230225
formation O O 0.9999959468841553
in O O 0.9999635219573975
preterm O O 0.9999984502792358
infants O O 0.9999992847442627
who O O 0.9999524354934692
were O O 0.9999682903289795
exposed O O 0.9994252920150757
to O O 0.9825824499130249
cocaine B B 0.9947499632835388
prenatally O O 0.9997949004173279
. O O 0.9999680519104004

This O O 0.9999841451644897
result O O 0.9999921321868896
is O O 0.999977707862854
consistent O O 0.9999897480010986
with O O 0.9999959468841553
results O O 0.9999951124191284
of O O 0.9999938011169434
similar O O 0.9999773502349854
studies O O 0.9999908208847046
in O O 0.9999865293502808
term O O 0.9999982118606567
infants O O 0.9999983310699463
. O O 0.999975323677063

Thalidomide B B 0.9897980690002441
neuropathy O O 0.9978336691856384
in O O 0.9999465942382812
patients O O 0.9999731779098511
treated O O 0.9999403953552246
for O O 0.9999524354934692
metastatic O O 0.9999804496765137
prostate O O 0.997822642326355
cancer O O 0.9994644522666931
. O O 0.999958872795105

We O O 0.999958872795105
prospectively O O 0.9999881982803345
evaluated O O 0.999977707862854
thalidomide B B 0.9998751878738403
- O O 0.9998719692230225
induced O O 0.9999282360076904
neuropathy O O 0.9999918937683105
using O O 0.9999880790710449
electrodiagnostic O O 0.9997572302818298
studies O O 0.9999960660934448
. O O 0.9999847412109375

Sixty O O 0.9990081191062927
- O O 0.9999669790267944
seven O O 0.9999393224716187
men O O 0.9999954700469971
with O O 0.9999732971191406
metastatic O O 0.9999746084213257
androgen B O 0.605178952217102
- O O 0.9957889914512634
independent O O 0.9954583644866943
prostate O O 0.9995806813240051
cancer O O 0.9999263286590576
in O O 0.9999421834945679
an O O 0.9999725818634033
open O O 0.9982940554618835
- O O 0.9999586343765259
label O O 0.9999542236328125
trial O O 0.9999309778213501
of O O 0.9989370703697205
oral O O 0.6235275268554688
thalidomide B B 0.9803998470306396
underwent O O 0.9999136924743652
neurologic O O 0.9999946355819702
examinations O O 0.999995231628418
and O O 0.9999852180480957
nerve O O 0.9977657794952393
conduction O O 0.9999648332595825
studies O O 0.9999897480010986
( O O 0.9999561309814453
NCS O O 0.9801592826843262
) O O 0.9999822378158569
prior O O 0.9999812841415405
to O O 0.9999834299087524
and O O 0.9999756813049316
at O O 0.9999734163284302
3 O O 0.9996562004089355
- O O 0.9999858140945435
month O O 0.999997615814209
intervals O O 0.999996542930603
during O O 0.9999698400497437
treatment O O 0.9999855756759644
. O O 0.9999819993972778

NCS O O 0.8641206622123718
included O O 0.9999600648880005
recording O O 0.9999769926071167
of O O 0.9999336004257202
sensory O O 0.998461127281189
nerve O O 0.9994089603424072
action O O 0.9994375109672546
potentials O O 0.9999897480010986
( O O 0.9997966885566711
SNAPs O O 0.986628532409668
) O O 0.9999315738677979
from O O 0.9998654127120972
median O O 0.9972298741340637
, O O 0.9994822144508362
radial O O 0.9986090064048767
, O O 0.9993072748184204
ulnar O O 0.9983360171318054
, O O 0.9959171414375305
and O O 0.9977776408195496
sural O O 0.9999064207077026
nerves O O 0.9999502897262573
. O O 0.9999176263809204

SNAP O O 0.9968716502189636
amplitudes O O 0.9997425675392151
for O O 0.9998264908790588
each O O 0.9998387098312378
nerve O O 0.9998002648353577
were O O 0.9999704360961914
expressed O O 0.9999914169311523
as O O 0.9999942779541016
the O O 0.9999940395355225
percentage O O 0.9999951124191284
of O O 0.9999896287918091
its O O 0.9999755620956421
baseline O O 0.9999740123748779
, O O 0.9999475479125977
and O O 0.9999377727508545
the O O 0.9999734163284302
mean O O 0.9999754428863525
of O O 0.9999687671661377
the O O 0.9999699592590332
four O O 0.9999233484268188
was O O 0.9999619722366333
termed O O 0.9999860525131226
the O O 0.9999805688858032
SNAP O O 0.9997116923332214
index O O 0.9999817609786987
. O O 0.9999754428863525

A O O 0.9999552965164185
40 O O 0.999958872795105
% O O 0.999991774559021
decline O O 0.9999942779541016
in O O 0.9999833106994629
the O O 0.9999525547027588
SNAP O O 0.94797682762146
index O O 0.9999748468399048
was O O 0.9999819993972778
considered O O 0.9999915361404419
clinically O O 0.9999901056289673
significant O O 0.9999960660934448
. O O 0.9999790191650391

Thalidomide B B 0.9993301630020142
was O O 0.9996911287307739
discontinued O O 0.999704897403717
in O O 0.9999698400497437
55 O O 0.9997956156730652
patients O O 0.9999970197677612
for O O 0.9999901056289673
lack O O 0.9999986886978149
of O O 0.9999959468841553
therapeutic O O 0.9999758005142212
response O O 0.9999970197677612
. O O 0.9999465942382812

Of O O 0.999947190284729
67 O O 0.9999897480010986
patients O O 0.9999929666519165
initially O O 0.9999784231185913
enrolled O O 0.9999889135360718
, O O 0.9999728202819824
24 O O 0.9998599290847778
remained O O 0.999983549118042
on O O 0.9991556406021118
thalidomide B B 0.9998592138290405
for O O 0.9998438358306885
3 O O 0.9994986057281494
months O O 0.9999910593032837
, O O 0.9999703168869019
8 O O 0.9996102452278137
remained O O 0.9999814033508301
at O O 0.9999618530273438
6 O O 0.9999616146087646
months O O 0.9999980926513672
, O O 0.9999624490737915
and O O 0.9999474287033081
3 O O 0.9992831349372864
remained O O 0.9999731779098511
at O O 0.9999548196792603
9 O O 0.9999749660491943
months O O 0.9999985694885254
. O O 0.9999827146530151

Six O O 0.9999064207077026
patients O O 0.9999817609786987
developed O O 0.9999724626541138
neuropathy O O 0.9999785423278809
. O O 0.999954104423523

Clinical O O 0.9999685287475586
symptoms O O 0.9999977350234985
and O O 0.9999665021896362
a O O 0.9999737739562988
decline O O 0.9999915361404419
in O O 0.9999797344207764
the O O 0.9999188184738159
SNAP O O 0.9351814985275269
index O O 0.9999313354492188
occurred O O 0.9999767541885376
concurrently O O 0.9999626874923706
. O O 0.9999750852584839

Older O O 0.9998879432678223
age O O 0.9999874830245972
and O O 0.9997473359107971
cumulative O O 0.8928936123847961
dose O O 0.9935316443443298
were O O 0.9998886585235596
possible O O 0.999674916267395
contributing O O 0.9998949766159058
factors O O 0.9999796152114868
. O O 0.999946117401123

Neuropathy O O 0.9998313188552856
may O O 0.9999375343322754
thus O O 0.999988317489624
be O O 0.9999866485595703
a O O 0.9999783039093018
common O O 0.9999845027923584
complication O O 0.9999926090240479
of O O 0.999788224697113
thalidomide B B 0.9996547698974609
in O O 0.99985671043396
older O O 0.999957799911499
patients O O 0.9999940395355225
. O O 0.9999794960021973

The O O 0.9999443292617798
SNAP O O 0.9121202230453491
index O O 0.9997994303703308
can O O 0.9999321699142456
be O O 0.9999860525131226
used O O 0.9999762773513794
to O O 0.9999715089797974
monitor O O 0.9999274015426636
peripheral O O 0.999880313873291
neuropathy O O 0.9999673366546631
, O O 0.9999802112579346
but O O 0.9999828338623047
not O O 0.9999889135360718
for O O 0.9999687671661377
early O O 0.999987006187439
detection O O 0.9999953508377075
. O O 0.9999783039093018

Overexpression O O 0.9894790053367615
of O O 0.998349666595459
copper B B 0.9828668236732483
/ O O 0.6479955911636353
zinc B B 0.9227304458618164
- O O 0.7306970357894897
superoxide B B 0.7347825169563293
dismutase O O 0.7072011828422546
protects O O 0.9998016953468323
from O O 0.9997949004173279
kanamycin B B 0.999737560749054
- O O 0.999653697013855
induced O O 0.9999649524688721
hearing O O 0.9999973773956299
loss O O 0.9999986886978149
. O O 0.9999030828475952

The O O 0.9999650716781616
participation O O 0.9999791383743286
of O O 0.9998424053192139
reactive O O 0.9939495325088501
oxygen B B 0.906287670135498
species O O 0.9820351600646973
in O O 0.9998445510864258
aminoglycoside B B 0.9988364577293396
- O O 0.9996694326400757
induced O O 0.9999386072158813
ototoxicity O O 0.9987689852714539
has O O 0.9999717473983765
been O O 0.9999922513961792
deduced O O 0.999987006187439
from O O 0.9999741315841675
observations O O 0.9999879598617554
that O O 0.999821126461029
aminoglycoside B B 0.9886985421180725
- O O 0.7932139039039612
iron B O 0.7832699418067932
complexes O O 0.6080706119537354
catalyze O O 0.999687910079956
the O O 0.9999711513519287
formation O O 0.9999003410339355
of O O 0.9994872808456421
superoxide B B 0.9361820816993713
radicals O O 0.9630824327468872
in O O 0.9999533891677856
vitro O O 0.9999909400939941
and O O 0.9999517202377319
that O O 0.9997285008430481
antioxidants O O 0.49147072434425354
attenuate O O 0.9996839761734009
ototoxicity O O 0.9958028197288513
in O O 0.9999693632125854
vivo O O 0.9999829530715942
. O O 0.9999754428863525

We O O 0.9999711513519287
therefore O O 0.9999874830245972
hypothesized O O 0.9999648332595825
that O O 0.9999366998672485
overexpression O O 0.9996906518936157
of O O 0.9992430210113525
Cu B B 0.8900249600410461
/ O O 0.42065438628196716
Zn B O 0.687340497970581
- O O 0.5019842982292175
superoxide B B 0.7997389435768127
dismutase O O 0.6498754024505615
( O O 0.9987932443618774
h O O 0.47836950421333313
- O O 0.7620474100112915
SOD1 O O 0.7530243396759033
) O O 0.9999215602874756
should O O 0.9999456405639648
protect O O 0.9999655485153198
transgenic O O 0.9999041557312012
mice O O 0.9999953508377075
from O O 0.999812662601471
ototoxicity O O 0.9991331696510315
. O O 0.9999710321426392

Immunocytochemistry O O 0.9999339580535889
confirmed O O 0.9999109506607056
expression O O 0.999954342842102
of O O 0.9997250437736511
h O O 0.7570475339889526
- O O 0.9263823628425598
SOD1 O O 0.7492470741271973
in O O 0.9996844530105591
inner O O 0.9999136924743652
ear O O 0.9999960660934448
tissues O O 0.9999953508377075
of O O 0.9999735355377197
transgenic O O 0.9995803236961365
C57BL O O 0.996987521648407
/ O O 0.9985610842704773
6 O O 0.9712655544281006
- O O 0.9944920539855957
TgN O O 0.9398577213287354
[ O O 0.9658107161521912
SOD1 O O 0.6755853891372681
] O O 0.9897156357765198
3Cje O O 0.9140231013298035
mice O O 0.9999665021896362
. O O 0.9999624490737915

Transgenic O O 0.9866076707839966
and O O 0.9998939037322998
nontransgenic O O 0.9914711117744446
littermates O O 0.999962568283081
received O O 0.9999135732650757
kanamycin B B 0.9996309280395508
( O O 0.9996376037597656
400 O O 0.9999139308929443
mg O O 0.9999741315841675
/ O O 0.9999676942825317
kg O O 0.9999977350234985
body O O 0.9999970197677612
weight O O 0.9999964237213135
/ O O 0.9997808337211609
day O O 0.9999966621398926
) O O 0.9999632835388184
for O O 0.9999642372131348
10 O O 0.9999837875366211
days O O 0.9999942779541016
beginning O O 0.9999895095825195
on O O 0.9999970197677612
day O O 0.9999991655349731
10 O O 0.9999945163726807
after O O 0.9999985694885254
birth O O 0.9999985694885254
. O O 0.9999847412109375

Auditory O O 0.9996428489685059
thresholds O O 0.9999513626098633
were O O 0.9999819993972778
tested O O 0.9999886751174927
by O O 0.9999879598617554
evoked O O 0.9999237060546875
auditory O O 0.9999833106994629
brain O O 0.999981164932251
stem O O 0.9999884366989136
responses O O 0.9999876022338867
at O O 0.9999891519546509
1 O O 0.9999896287918091
month O O 0.9999991655349731
after O O 0.9999988079071045
birth O O 0.9999980926513672
. O O 0.9999866485595703

In O O 0.9999489784240723
nontransgenic O O 0.9996111989021301
animals O O 0.9999970197677612
, O O 0.9999679327011108
the O O 0.999970555305481
threshold O O 0.999976634979248
in O O 0.9999556541442871
the O O 0.9999287128448486
kanamycin B B 0.9998132586479187
- O O 0.9995763897895813
treated O O 0.9998273849487305
group O O 0.9999828338623047
was O O 0.9999773502349854
45 O O 0.9999831914901733
- O O 0.9998958110809326
50 O O 0.9999805688858032
dB O O 0.9999938011169434
higher O O 0.9999041557312012
than O O 0.9999923706054688
in O O 0.999950647354126
saline O O 0.999118983745575
- O O 0.999497652053833
injected O O 0.9998251795768738
controls O O 0.9999629259109497
. O O 0.9999822378158569

In O O 0.9997633099555969
the O O 0.9999316930770874
transgenic O O 0.9998121857643127
group O O 0.9999910593032837
, O O 0.9997374415397644
kanamycin B B 0.9996896982192993
increased O O 0.9998838901519775
the O O 0.9999899864196777
threshold O O 0.9999905824661255
by O O 0.9999909400939941
only O O 0.9999924898147583
15 O O 0.9999006986618042
dB O O 0.9987390637397766
over O O 0.9999597072601318
the O O 0.9999781847000122
respective O O 0.9999610185623169
controls O O 0.9999803304672241
. O O 0.9999725818634033

The O O 0.9998822212219238
effects O O 0.999944806098938
were O O 0.9999526739120483
similar O O 0.999970555305481
at O O 0.9998549222946167
12 O O 0.9998821020126343
and O O 0.9998983144760132
24 O O 0.999947190284729
kHz O O 0.9984221458435059
. O O 0.9999396800994873

The O O 0.9999685287475586
protection O O 0.9999880790710449
by O O 0.999927282333374
overexpression O O 0.9997227787971497
of O O 0.9986788630485535
superoxide B B 0.9815801978111267
dismutase O O 0.552004337310791
supports O O 0.9998220801353455
the O O 0.9999860525131226
hypothesis O O 0.99997878074646
that O O 0.9998476505279541
oxidant O O 0.5305696129798889
stress O O 0.9811632037162781
plays O O 0.9999046325683594
a O O 0.9998893737792969
significant O O 0.9999594688415527
role O O 0.9999619722366333
in O O 0.9999271631240845
aminoglycoside B B 0.9979174733161926
- O O 0.9995998740196228
induced O O 0.999923586845398
ototoxicity O O 0.998708963394165
. O O 0.9999581575393677

The O O 0.9999854564666748
results O O 0.9999898672103882
also O O 0.9999861717224121
suggest O O 0.9999278783798218
transgenic O O 0.9997135996818542
animals O O 0.9999946355819702
as O O 0.9999698400497437
suitable O O 0.9999873638153076
models O O 0.9999967813491821
to O O 0.9999833106994629
investigate O O 0.9999297857284546
the O O 0.9999837875366211
underlying O O 0.9999748468399048
mechanisms O O 0.9999850988388062
and O O 0.9999791383743286
possible O O 0.9999407529830933
strategies O O 0.9999852180480957
for O O 0.999974250793457
prevention O O 0.9999722242355347
. O O 0.9999758005142212

Fatty O O 0.9997209906578064
liver O O 0.999695897102356
induced O O 0.9999610185623169
by O O 0.9999021291732788
tetracycline B B 0.9993137121200562
in O O 0.9998142123222351
the O O 0.9999855756759644
rat O O 0.9999854564666748
. O O 0.999954342842102

Dose O O 0.9903616905212402
- O O 0.9998977184295654
response O O 0.999961256980896
relationships O O 0.9999591112136841
and O O 0.9999504089355469
effect O O 0.9999508857727051
of O O 0.9999161958694458
sex O O 0.991211473941803
. O O 0.9999574422836304

Dose O O 0.9962748289108276
- O O 0.9999129772186279
response O O 0.9999861717224121
relationships O O 0.9999912977218628
, O O 0.9999721050262451
biochemical O O 0.9996746778488159
mechanisms O O 0.9999898672103882
, O O 0.9999730587005615
and O O 0.9999599456787109
sex O O 0.9999741315841675
differences O O 0.9999980926513672
in O O 0.9999842643737793
the O O 0.9999850988388062
experimental O O 0.9999676942825317
fatty O O 0.9994068145751953
liver O O 0.999646782875061
induced O O 0.9999856948852539
by O O 0.9998323917388916
tetracycline B B 0.9995549321174622
were O O 0.9999552965164185
studied O O 0.9999884366989136
in O O 0.9999587535858154
the O O 0.9999778270721436
intact O O 0.9999562501907349
rat O O 0.9999972581863403
and O O 0.9999806880950928
with O O 0.9999816417694092
the O O 0.9999576807022095
isolated O O 0.9991808533668518
perfused O O 0.9991633892059326
rat O O 0.9999849796295166
liver O O 0.9989410042762756
in O O 0.999927282333374
vitro O O 0.9999834299087524
. O O 0.9999738931655884

In O O 0.9997343420982361
the O O 0.9999390840530396
intact O O 0.9998086094856262
male O O 0.9999822378158569
and O O 0.9999568462371826
female O O 0.9999557733535767
rat O O 0.9999833106994629
, O O 0.9999433755874634
no O O 0.9999717473983765
direct O O 0.9999918937683105
relationship O O 0.9999881982803345
was O O 0.999982476234436
observed O O 0.9999969005584717
between O O 0.9998052716255188
dose O O 0.9995489716529846
of O O 0.9962844848632812
tetracycline B B 0.999705970287323
and O O 0.9996353387832642
hepatic O O 0.999923825263977
accumulation O O 0.9999536275863647
of O O 0.9790573120117188
triglyceride B B 0.983858048915863
. O O 0.9999456405639648

With O O 0.999922513961792
provision O O 0.9999548196792603
of O O 0.9999128580093384
adequate O O 0.9984139204025269
oleic B B 0.6847822666168213
acid I I 0.9995777010917664
as O O 0.998900294303894
a O O 0.9997151494026184
substrate O O 0.9993725419044495
for O O 0.9997933506965637
the O O 0.9999501705169678
isolated O O 0.9851223230361938
perfused O O 0.9997499585151672
liver O O 0.9996887445449829
, O O 0.9999505281448364
a O O 0.9999792575836182
direct O O 0.9999922513961792
relationship O O 0.9999953508377075
was O O 0.9999885559082031
observed O O 0.9999978542327881
between O O 0.9997490048408508
dose O O 0.9990645051002502
of O O 0.9940375089645386
tetracycline B B 0.9998421669006348
and O O 0.9998212456703186
both O O 0.9998743534088135
accumulation O O 0.9999904632568359
of O O 0.999891996383667
triglyceride B B 0.9688333868980408
in O O 0.9996756315231323
the O O 0.9999912977218628
liver O O 0.999884843826294
and O O 0.9999665021896362
depression O O 0.9999887943267822
of O O 0.999948263168335
output O O 0.9999895095825195
of O O 0.9991624355316162
triglyceride B B 0.9513831734657288
by O O 0.9998047947883606
livers O O 0.9990686774253845
from O O 0.9999630451202393
male O O 0.9999581575393677
and O O 0.9999253749847412
female O O 0.9999703168869019
rats O O 0.9999897480010986
. O O 0.9999631643295288

Marked O O 0.9995120763778687
differences O O 0.9999889135360718
were O O 0.999984860420227
observed O O 0.9999924898147583
between O O 0.9998972415924072
female O O 0.9999598264694214
and O O 0.9998908042907715
male O O 0.9999226331710815
rats O O 0.9999758005142212
with O O 0.9999902248382568
regard O O 0.9999938011169434
to O O 0.9999289512634277
base O O 0.9981653094291687
line O O 0.9850122928619385
( O O 0.9873101711273193
control O O 0.9978256821632385
) O O 0.9998389482498169
hepatic O O 0.9992732405662537
concentration O O 0.999167799949646
of O O 0.9528607726097107
triglyceride B B 0.9739000201225281
and O O 0.999294638633728
output O O 0.9811689853668213
of O O 0.9881436228752136
triglyceride B B 0.981734573841095
. O O 0.99994957447052

Accumulation O O 0.9999349117279053
of O O 0.999811589717865
hepatic O O 0.9905231595039368
triglyceride B B 0.972093939781189
, O O 0.9998929500579834
as O O 0.9999940395355225
a O O 0.9999916553497314
per O O 0.9999954700469971
cent O O 0.9999990463256836
of O O 0.9999704360961914
control O O 0.999672532081604
values O O 0.9999732971191406
, O O 0.9999884366989136
in O O 0.9999780654907227
response O O 0.9999750852584839
to O O 0.9999587535858154
graded O O 0.99992835521698
doses O O 0.9999257326126099
of O O 0.9992355108261108
tetracycline B B 0.9995419979095459
, O O 0.9999233484268188
did O O 0.999982476234436
not O O 0.9999932050704956
differ O O 0.9999910593032837
significantly O O 0.9999909400939941
between O O 0.9998972415924072
male O O 0.999971866607666
, O O 0.9998362064361572
female O O 0.9999443292617798
and O O 0.9998189806938171
pregnant O O 0.9992190599441528
rat O O 0.9999686479568481
livers O O 0.9995020627975464
. O O 0.9999606609344482

However O O 0.9999347925186157
, O O 0.9999339580535889
livers O O 0.9995846152305603
from O O 0.9999490976333618
female O O 0.9995662569999695
, O O 0.9998818635940552
and O O 0.9999344348907471
especially O O 0.9998884201049805
pregnant O O 0.9999839067459106
female O O 0.9999822378158569
rats O O 0.9999939203262329
, O O 0.9999849796295166
were O O 0.9999562501907349
strikingly O O 0.9999712705612183
resistant O O 0.9999825954437256
to O O 0.9998717308044434
the O O 0.9999123811721802
effects O O 0.9998264908790588
of O O 0.9994268417358398
tetracycline B B 0.9998051524162292
on O O 0.9995571970939636
depression O O 0.999808132648468
of O O 0.998708963394165
output O O 0.9639785885810852
of O O 0.9704595804214478
triglyceride B B 0.9412912726402283
under O O 0.9998817443847656
these O O 0.9999794960021973
experimental O O 0.9999767541885376
conditions O O 0.9999957084655762
. O O 0.9999828338623047

These O O 0.9999796152114868
differences O O 0.9999914169311523
between O O 0.9998664855957031
the O O 0.9999634027481079
sexes O O 0.9990352392196655
could O O 0.9999547004699707
not O O 0.9999264478683472
be O O 0.9999343156814575
related O O 0.9999791383743286
to O O 0.9999226331710815
altered O O 0.9999812841415405
disposition O O 0.9999735355377197
of O O 0.9994691014289856
tetracycline B B 0.9991342425346375
or O O 0.9997797608375549
altered O O 0.9999790191650391
uptake O O 0.9999265670776367
of O O 0.9998589754104614
oleic B B 0.9206269383430481
acid I I 0.9998433589935303
. O O 0.9998118281364441

Depressed O O 0.9984850287437439
hepatic O O 0.9992209672927856
secretion O O 0.998364269733429
of O O 0.9954348206520081
triglyceride B B 0.9593069553375244
accounted O O 0.9996877908706665
only O O 0.9999754428863525
for O O 0.9999557733535767
30 O O 0.9999572038650513
to O O 0.999991774559021
50 O O 0.9999964237213135
% O O 0.9999935626983643
of O O 0.999957799911499
accumulated O O 0.9845408201217651
hepatic O O 0.998794674873352
triglyceride B B 0.9897659420967102
, O O 0.9998784065246582
indicating O O 0.9999070167541504
that O O 0.9999483823776245
additional O O 0.9997004270553589
mechanisms O O 0.9997196793556213
must O O 0.9998600482940674
be O O 0.9999532699584961
involved O O 0.9999551773071289
in O O 0.9999489784240723
the O O 0.9999371767044067
production O O 0.9999622106552124
of O O 0.9999136924743652
the O O 0.9999194145202637
triglyceride B B 0.9339366555213928
- O O 0.9914814233779907
rich O O 0.9857044219970703
fatty O O 0.9993742108345032
liver O O 0.9994670748710632
in O O 0.9999552965164185
response O O 0.9999687671661377
to O O 0.9996273517608643
tetracycline B B 0.9996926784515381
. O O 0.999794065952301

Prednisone B B 0.9955374002456665
induces O O 0.9992641806602478
anxiety O O 0.9944003224372864
and O O 0.9998185038566589
glial O O 0.9979609251022339
cerebral O O 0.9999780654907227
changes O O 0.9999912977218628
in O O 0.9999444484710693
rats O O 0.9999372959136963
. O O 0.9999001026153564

OBJECTIVE O O 0.9998321533203125
: O O 0.9999920129776001
To O O 0.9999897480010986
assess O O 0.9999881982803345
whether O O 0.9999477863311768
prednisone B B 0.9994693398475647
( O O 0.9945287108421326
PDN B B 0.9962738752365112
) O O 0.999496579170227
produces O O 0.9997848868370056
anxiety O O 0.9988021850585938
and O O 0.9999349117279053
/ O O 0.9998080134391785
or O O 0.9999806880950928
cerebral O O 0.9999269247055054
glial O O 0.9985721111297607
changes O O 0.9999951124191284
in O O 0.9999089241027832
rats O O 0.9998321533203125
. O O 0.9999749660491943

METHODS O O 0.9999420642852783
: O O 0.9999886751174927
Male O O 0.9999653100967407
Wistar O O 0.9994445443153381
rats O O 0.9999921321868896
were O O 0.9999663829803467
studied O O 0.9999743700027466
and O O 0.9999610185623169
3 O O 0.9993908405303955
groups O O 0.9999839067459106
were O O 0.9999843835830688
formed O O 0.9999972581863403
( O O 0.9999336004257202
8 O O 0.999942421913147
rats O O 0.9999953508377075
per O O 0.9998812675476074
group O O 0.999980092048645
) O O 0.9999619722366333
. O O 0.9999713897705078

The O O 0.9999840259552002
moderate O O 0.9938669800758362
- O O 0.9999593496322632
dose O O 0.9993839263916016
group O O 0.999984860420227
received O O 0.9999638795852661
5 O O 0.9999077320098877
mg O O 0.9999780654907227
/ O O 0.999990701675415
kg O O 0.9999980926513672
/ O O 0.9999768733978271
day O O 0.9999880790710449
PDN B O 0.8630256056785583
released O O 0.9994000196456909
from O O 0.9996428489685059
a O O 0.9999725818634033
subcutaneous O O 0.9998772144317627
implant O O 0.999996542930603
. O O 0.9999562501907349

In O O 0.9998810291290283
the O O 0.9999649524688721
high O O 0.9994562268257141
- O O 0.9999653100967407
dose O O 0.9990766048431396
group O O 0.9999691247940063
, O O 0.9999145269393921
implants O O 0.9999815225601196
containing O O 0.9979934692382812
PDN B B 0.8697631359100342
equivalent O O 0.9985191226005554
to O O 0.9999737739562988
60 O O 0.9999473094940186
mg O O 0.9999699592590332
/ O O 0.9999887943267822
kg O O 0.9999982118606567
/ O O 0.9999778270721436
day O O 0.9999926090240479
were O O 0.9999645948410034
applied O O 0.9999837875366211
. O O 0.99997878074646

In O O 0.999812662601471
the O O 0.9998582601547241
control O O 0.9998704195022583
group O O 0.999940037727356
implants O O 0.999203622341156
contained O O 0.9998624324798584
no O O 0.974648654460907
PDN B O 0.5962592363357544
. O O 0.9995977282524109

Anxiety O O 0.9997797608375549
was O O 0.9999818801879883
assessed O O 0.999991774559021
using O O 0.9999862909317017
an O O 0.9999485015869141
open O O 0.9999271631240845
field O O 0.9999759197235107
and O O 0.9999130964279175
elevated O O 0.9998395442962646
plus O O 0.9986221790313721
- O O 0.9998946189880371
maze O O 0.9994634985923767
devices O O 0.9999814033508301
. O O 0.9999834299087524

The O O 0.9999545812606812
number O O 0.9999361038208008
of O O 0.9998869895935059
cells O O 0.9999710321426392
and O O 0.9999339580535889
cytoplasmic O O 0.9998154044151306
transformation O O 0.9999858140945435
of O O 0.9996236562728882
astrocytes O O 0.9973684549331665
and O O 0.9994487166404724
microglia O O 0.9972854852676392
cells O O 0.9999616146087646
were O O 0.9999756813049316
assessed O O 0.9999834299087524
by O O 0.9999809265136719
immunohistochemical O O 0.9999494552612305
analyses O O 0.9999793767929077
. O O 0.9999700784683228

RESULTS O O 0.9995021820068359
: O O 0.9997674822807312
Anxiety O O 0.9952037334442139
was O O 0.999890923500061
documented O O 0.9999562501907349
in O O 0.9996652603149414
both O O 0.9994034767150879
groups O O 0.9999221563339233
of O O 0.999880313873291
PDN B B 0.9926745295524597
treated O O 0.9988222718238831
rats O O 0.9999712705612183
compared O O 0.99996018409729
with O O 0.9999469518661499
controls O O 0.9999240636825562
. O O 0.9999668598175049

The O O 0.9999744892120361
magnitude O O 0.9999610185623169
of O O 0.9999508857727051
transformation O O 0.9998408555984497
of O O 0.9997585415840149
the O O 0.999797523021698
microglia O O 0.9988534450531006
assessed O O 0.999890923500061
by O O 0.9999808073043823
the O O 0.9999903440475464
number O O 0.9999406337738037
of O O 0.9998713731765747
intersections O O 0.9657572507858276
was O O 0.9999308586120605
significantly O O 0.999969482421875
higher O O 0.9998947381973267
in O O 0.9995208978652954
the O O 0.9992020726203918
PDN B O 0.7192042469978333
groups O O 0.9945447444915771
than O O 0.9999083280563354
in O O 0.9996578693389893
controls O O 0.9994603991508484
in O O 0.999226450920105
the O O 0.9997196793556213
prefrontal O O 0.9890717267990112
cortex O O 0.9999773502349854
( O O 0.9997586607933044
moderate O O 0.9948394894599915
- O O 0.9991320967674255
dose O O 0.9887209534645081
, O O 0.9995449185371399
24 O O 0.9986472725868225
. O O 0.9997101426124573
1 O O 0.9999886751174927
; O O 0.9993951320648193
high O O 0.9661909341812134
- O O 0.9993575215339661
dose O O 0.9889463782310486
, O O 0.9995193481445312
23 O O 0.9997979998588562
. O O 0.9998844861984253
6 O O 0.9999538660049438
; O O 0.9995388984680176
controls O O 0.9997963309288025
18 O O 0.9985879063606262
. O O 0.9999626874923706
7 O O 0.9999889135360718
; O O 0.9999717473983765
p O O 0.9999386072158813
< O O 0.9999788999557495
0 O O 0.9999809265136719
. O O 0.9999958276748657
01 O O 0.9999938011169434
) O O 0.9999315738677979
and O O 0.9997445940971375
striatum O O 0.9949541687965393
( O O 0.9998559951782227
moderate O O 0.9947620034217834
- O O 0.9995706677436829
dose O O 0.9962074756622314
25 O O 0.9995922446250916
. O O 0.9999731779098511
6 O O 0.9999812841415405
; O O 0.9996551275253296
high O O 0.9534409642219543
- O O 0.9994540810585022
dose O O 0.9884435534477234
26 O O 0.9998238682746887
. O O 0.9998924732208252
3 O O 0.9999291896820068
; O O 0.9992296695709229
controls O O 0.9996181726455688
18 O O 0.9992656111717224
. O O 0.9999827146530151
9 O O 0.9999904632568359
; O O 0.9999746084213257
p O O 0.9999589920043945
< O O 0.9999747276306152
0 O O 0.9999797344207764
. O O 0.9999946355819702
01 O O 0.9999877214431763
) O O 0.9999510049819946
, O O 0.9999263286590576
but O O 0.9999727010726929
not O O 0.9999402761459351
in O O 0.9994383454322815
hippocampus O O 0.996956467628479
. O O 0.9999306201934814

The O O 0.9999817609786987
number O O 0.9999582767486572
of O O 0.9999146461486816
stained O O 0.9780924320220947
microglia O O 0.9974573254585266
cells O O 0.9999462366104126
was O O 0.9999507665634155
significantly O O 0.9999488592147827
higher O O 0.9999397993087769
in O O 0.9995231628417969
the O O 0.999194324016571
PDN B B 0.9728004336357117
treated O O 0.994976818561554
groups O O 0.9994877576828003
in O O 0.9993371367454529
the O O 0.9998273253440857
prefrontal O O 0.9855003952980042
cortex O O 0.9999607801437378
than O O 0.9999675750732422
in O O 0.9998679161071777
controls O O 0.9998859167098999
( O O 0.9998620748519897
moderate O O 0.9960271120071411
- O O 0.9994044303894043
dose O O 0.9972363114356995
, O O 0.9999130964279175
29 O O 0.9998880624771118
. O O 0.9999499320983887
1 O O 0.999985933303833
; O O 0.9998328685760498
high O O 0.9902474284172058
- O O 0.9995762705802917
dose O O 0.9975842237472534
, O O 0.9999042749404907
28 O O 0.9999477863311768
. O O 0.9999796152114868
4 O O 0.9999091625213623
; O O 0.9997909665107727
control O O 0.9996867179870605
, O O 0.9999463558197021
17 O O 0.9999916553497314
. O O 0.9999920129776001
7 O O 0.999984622001648
cells O O 0.9999942779541016
per O O 0.9999574422836304
field O O 0.9999958276748657
; O O 0.9999676942825317
p O O 0.9999537467956543
< O O 0.9999744892120361
0 O O 0.9999902248382568
. O O 0.9999959468841553
01 O O 0.9999967813491821
) O O 0.9999669790267944
. O O 0.999975323677063

Stained O O 0.8259980082511902
microglia O O 0.9909167885780334
cells O O 0.9998601675033569
were O O 0.9998905658721924
significantly O O 0.9999266862869263
more O O 0.9998049139976501
numerous O O 0.9937833547592163
striatum O O 0.9059286713600159
and O O 0.9989203214645386
hippocampus O O 0.9983598589897156
in O O 0.9998753070831299
the O O 0.9999293088912964
high O O 0.9816398024559021
- O O 0.999767005443573
dose O O 0.8787626624107361
group O O 0.999853253364563
compared O O 0.999970555305481
to O O 0.9998998641967773
controls O O 0.9999306201934814
. O O 0.9999619722366333

CONCLUSION O O 0.9587424397468567
: O O 0.9997629523277283
Subacute O O 0.9990215301513672
exposure O O 0.9995725750923157
to O O 0.9879732131958008
PDN B B 0.9955742359161377
induced O O 0.9992971420288086
anxiety O O 0.9923728108406067
and O O 0.9998977184295654
reactivity O O 0.9998472929000854
of O O 0.9998917579650879
microglia O O 0.9996738433837891
. O O 0.9999330043792725

The O O 0.999984622001648
relevance O O 0.9999967813491821
of O O 0.9999866485595703
these O O 0.9997674822807312
features O O 0.9999868869781494
for O O 0.9998805522918701
patients O O 0.9999715089797974
using O O 0.9979793429374695
PDN B O 0.6176304221153259
remains O O 0.9999226331710815
to O O 0.9999901056289673
be O O 0.9999939203262329
elucidated O O 0.9999868869781494
. O O 0.999970555305481

Phase O O 0.9999314546585083
II O O 0.9988596439361572
study O O 0.9999746084213257
of O O 0.9931873083114624
carboplatin B B 0.9996838569641113
and O O 0.8805039525032043
liposomal O O 0.905052661895752
doxorubicin B B 0.877866804599762
in O O 0.9999399185180664
patients O O 0.9999961853027344
with O O 0.9999905824661255
recurrent O O 0.9999890327453613
squamous O O 0.9996669292449951
cell O O 0.999458372592926
carcinoma O O 0.9998879432678223
of O O 0.9999626874923706
the O O 0.9999456405639648
cervix O O 0.9816733598709106
. O O 0.9999053478240967

BACKGROUND O O 0.9996757507324219
: O O 0.9999904632568359
The O O 0.9999850988388062
activity O O 0.9998149275779724
of O O 0.9997760653495789
the O O 0.9998061060905457
combination O O 0.9388296604156494
of O O 0.992984414100647
carboplatin B B 0.9997418522834778
and O O 0.9473614692687988
liposomal O O 0.6008455157279968
doxorubicin B B 0.9702651500701904
was O O 0.9999052286148071
tested O O 0.9999624490737915
in O O 0.9999902248382568
a O O 0.9999911785125732
Phase O O 0.9999731779098511
II O O 0.9998069405555725
study O O 0.9999938011169434
of O O 0.999985933303833
patients O O 0.999995231628418
with O O 0.999994158744812
recurrent O O 0.9999979734420776
cervical O O 0.9966050386428833
carcinoma O O 0.9999198913574219
. O O 0.9999788999557495

METHODS O O 0.9999213218688965
: O O 0.9999735355377197
The O O 0.9999802112579346
combination O O 0.9985206723213196
of O O 0.9992349147796631
carboplatin B B 0.9998039603233337
( O O 0.9977124929428101
area O O 0.6645815372467041
under O O 0.8030818104743958
the O O 0.9973527193069458
concentration O O 0.9999455213546753
curve O O 0.9998869895935059
[ O O 0.994424045085907
AUC O O 0.96568363904953
] O O 0.9997952580451965
, O O 0.9969748258590698
5 O O 0.9683472514152527
) O O 0.9982672929763794
and O O 0.9977123737335205
liposomal O O 0.8787433505058289
doxorubicin B B 0.873663604259491
( O O 0.998414158821106
Doxil B B 0.9998177886009216
; O O 0.9996453523635864
starting O O 0.9999790191650391
dose O O 0.9999576807022095
, O O 0.9999696016311646
40 O O 0.9997037053108215
mg O O 0.999889612197876
/ O O 0.999607264995575
m O O 0.9999561309814453
( O O 0.9997327923774719
2 O O 0.9485302567481995
) O O 0.9835712909698486
) O O 0.9999674558639526
was O O 0.999980092048645
administered O O 0.9999598264694214
intravenously O O 0.9999840259552002
every O O 0.9999724626541138
28 O O 0.9999979734420776
days O O 0.9999954700469971
to O O 0.9999799728393555
37 O O 0.9999837875366211
patients O O 0.9999978542327881
with O O 0.9999939203262329
recurrent O O 0.9999978542327881
squamous O O 0.999901294708252
cell O O 0.9998273253440857
cervical O O 0.9972875118255615
carcinoma O O 0.9999078512191772
to O O 0.9999916553497314
determine O O 0.9999829530715942
antitumor O O 0.9918758869171143
activity O O 0.9999071359634399
and O O 0.9999663829803467
toxicity O O 0.9998250603675842
profile O O 0.9999781847000122
. O O 0.999963641166687

RESULTS O O 0.9998934268951416
: O O 0.999969482421875
Twenty O O 0.9993131160736084
- O O 0.9999513626098633
nine O O 0.9999841451644897
patients O O 0.9999910593032837
were O O 0.9999351501464844
assessable O O 0.9999722242355347
for O O 0.9999328851699829
response O O 0.9999505281448364
, O O 0.9998610019683838
and O O 0.9999251365661621
35 O O 0.9999043941497803
patients O O 0.999988317489624
were O O 0.9999450445175171
assessable O O 0.9999656677246094
for O O 0.9999164342880249
toxicity O O 0.999963641166687
. O O 0.9999728202819824

The O O 0.9999650716781616
overall O O 0.9999161958694458
response O O 0.9999905824661255
rate O O 0.9999948740005493
was O O 0.9999767541885376
38 O O 0.9999955892562866
% O O 0.9999988079071045
, O O 0.9999908208847046
the O O 0.9999936819076538
median O O 0.9999723434448242
time O O 0.9999974966049194
to O O 0.9999967813491821
response O O 0.9999946355819702
was O O 0.9999852180480957
10 O O 0.9999973773956299
weeks O O 0.9999988079071045
, O O 0.9999912977218628
the O O 0.9999934434890747
median O O 0.9999698400497437
duration O O 0.9999951124191284
of O O 0.9999895095825195
response O O 0.9999885559082031
was O O 0.9999847412109375
26 O O 0.9999958276748657
weeks O O 0.999998927116394
, O O 0.9999654293060303
and O O 0.9999761581420898
the O O 0.9999864101409912
median O O 0.9998953342437744
survival O O 0.9999948740005493
was O O 0.9999927282333374
37 O O 0.9999983310699463
weeks O O 0.9999991655349731
. O O 0.9999841451644897

The O O 0.9999713897705078
main O O 0.9999587535858154
toxic O O 0.9996582269668579
effect O O 0.9999744892120361
was O O 0.999914288520813
myelosuppression O O 0.9999942779541016
, O O 0.9999769926071167
with O O 0.999967098236084
Grade O O 0.9999622106552124
3 O O 0.9981158971786499
and O O 0.999665379524231
4 O O 0.9982684850692749
neutropenia O O 0.9999784231185913
in O O 0.9999736547470093
16 O O 0.9999790191650391
patients O O 0.9999911785125732
, O O 0.9999573230743408
anemia O O 0.9993748068809509
in O O 0.9999727010726929
12 O O 0.9999935626983643
patients O O 0.999992847442627
, O O 0.9999545812606812
thrombocytopenia O O 0.998145341873169
in O O 0.9999722242355347
11 O O 0.9999681711196899
patients O O 0.999993085861206
, O O 0.9999163150787354
and O O 0.9998666048049927
neutropenic O O 0.999764621257782
fever O O 0.9999408721923828
in O O 0.9999485015869141
3 O O 0.9996540546417236
patients O O 0.9999865293502808
. O O 0.999970555305481

Four O O 0.9998703002929688
patients O O 0.9999866485595703
had O O 0.9999533891677856
five O O 0.9994540810585022
infusion O O 0.9995115995407104
- O O 0.9998742341995239
related O O 0.9999703168869019
reactions O O 0.999997615814209
during O O 0.9999279975891113
the O O 0.9999591112136841
infusion O O 0.9999769926071167
of O O 0.9981663823127747
liposomal O O 0.9896285533905029
doxorubicin B B 0.5679509043693542
, O O 0.9994625449180603
leading O O 0.9999899864196777
to O O 0.9999880790710449
treatment O O 0.9999535083770752
discontinuation O O 0.9999775886535645
in O O 0.9999864101409912
three O O 0.999984622001648
patients O O 0.9999964237213135
. O O 0.9999790191650391

Grade O O 0.9997579455375671
> O O 0.9995495676994324
or O O 0.999904990196228
= O O 0.9983695149421692
2 O O 0.9998971223831177
nonhematologic O O 0.9964990615844727
toxicity O O 0.9999485015869141
included O O 0.9999520778656006
nausea O O 0.999921441078186
in O O 0.9999618530273438
17 O O 0.9999855756759644
patients O O 0.9999896287918091
, O O 0.9999105930328369
emesis O O 0.9999872446060181
in O O 0.9999830722808838
14 O O 0.9999934434890747
patients O O 0.9999902248382568
, O O 0.9999464750289917
fatigue O O 0.9999864101409912
in O O 0.9999803304672241
9 O O 0.9999607801437378
patients O O 0.9999914169311523
, O O 0.9999488592147827
mucositis O O 0.9999099969863892
and O O 0.9999247789382935
/ O O 0.9999332427978516
or O O 0.9999743700027466
stomatitis O O 0.995231568813324
in O O 0.9999812841415405
8 O O 0.9998892545700073
patients O O 0.9999938011169434
, O O 0.9999499320983887
constipation O O 0.9628599286079407
in O O 0.999983549118042
6 O O 0.9999619722366333
patients O O 0.9999927282333374
, O O 0.9999592304229736
weight O O 0.999887228012085
loss O O 0.9999955892562866
in O O 0.999984860420227
5 O O 0.9999703168869019
patients O O 0.9999916553497314
, O O 0.9999651908874512
hand O O 0.9971480965614319
- O O 0.9998005032539368
foot O O 0.9969057440757751
syndrome O O 0.9999847412109375
in O O 0.9999717473983765
2 O O 0.9999687671661377
patients O O 0.999981164932251
, O O 0.9998949766159058
and O O 0.9999033212661743
skin O O 0.9999492168426514
reactions O O 0.9999946355819702
in O O 0.9999692440032959
3 O O 0.9992750287055969
patients O O 0.9999723434448242
. O O 0.9999608993530273

CONCLUSIONS O O 0.9970670342445374
: O O 0.9999091625213623
The O O 0.999308705329895
combination O O 0.9860585331916809
of O O 0.9946720004081726
carboplatin B B 0.9997238516807556
and O O 0.9592771530151367
liposomal O O 0.7598986029624939
doxorubicin B B 0.9679797291755676
has O O 0.9997828602790833
modest O O 0.999976634979248
activity O O 0.9999113082885742
in O O 0.9999178647994995
patients O O 0.999992847442627
with O O 0.9999915361404419
recurrent O O 0.9999948740005493
cervical O O 0.9955667853355408
carcinoma O O 0.9999048709869385
. O O 0.9999712705612183

Antimicrobial O O 0.6540008783340454
- O O 0.9804031848907471
induced O O 0.9998847246170044
mania O O 0.999897837638855
( O O 0.999651312828064
antibiomania O O 0.5108348727226257
) O O 0.9998443126678467
: O O 0.9999768733978271
a O O 0.9999966621398926
review O O 0.9999889135360718
of O O 0.9999772310256958
spontaneous O O 0.999872088432312
reports O O 0.9999957084655762
. O O 0.9999769926071167

The O O 0.9999754428863525
authors O O 0.999996542930603
reviewed O O 0.9999874830245972
reported O O 0.9999853372573853
cases O O 0.9999932050704956
of O O 0.999972939491272
antibiotic O O 0.7173693776130676
- O O 0.9994563460350037
induced O O 0.9999145269393921
manic O O 0.9999675750732422
episodes O O 0.9999885559082031
by O O 0.999987006187439
means O O 0.9999939203262329
of O O 0.9999926090240479
a O O 0.9999651908874512
MEDLINE O O 0.9973426461219788
and O O 0.9998939037322998
PsychLit O O 0.999839186668396
search O O 0.9998093247413635
for O O 0.999884843826294
reports O O 0.9999924898147583
of O O 0.999950647354126
antibiotic O O 0.7080504894256592
- O O 0.9995573163032532
induced O O 0.999923825263977
mania O O 0.9999606609344482
. O O 0.9999512434005737

Unpublished O O 0.9999521970748901
reports O O 0.9999923706054688
were O O 0.9999908208847046
requested O O 0.9999963045120239
from O O 0.9999871253967285
the O O 0.9999873638153076
World O O 0.9996383190155029
Health O O 0.9965002536773682
Organization O O 0.9999905824661255
( O O 0.9999465942382812
WHO O O 0.9965818524360657
) O O 0.999961256980896
and O O 0.9999403953552246
the O O 0.9999786615371704
Food O O 0.9895456433296204
and O O 0.9989533424377441
Drug O O 0.9989228844642639
Administration O O 0.999910831451416
( O O 0.9998974800109863
FDA O O 0.8220353722572327
) O O 0.9999637603759766
. O O 0.9999672174453735

Twenty O O 0.9643397331237793
- O O 0.9999555349349976
one O O 0.9999823570251465
reports O O 0.9999821186065674
of O O 0.9998987913131714
antimicrobial O O 0.6547773480415344
- O O 0.9979498982429504
induced O O 0.9998816251754761
mania O O 0.9996484518051147
were O O 0.9999592304229736
found O O 0.9999884366989136
in O O 0.9999880790710449
the O O 0.9999933242797852
literature O O 0.9999902248382568
. O O 0.999944806098938

There O O 0.9999297857284546
were O O 0.9999252557754517
6 O O 0.999765932559967
cases O O 0.999945878982544
implicating O O 0.9999163150787354
clarithromycin B B 0.9992283582687378
, O O 0.9997987151145935
13 O O 0.9997735619544983
implicating O O 0.9999490976333618
isoniazid B B 0.9995558857917786
, O O 0.9995844960212708
and O O 0.9999531507492065
1 O O 0.9998548030853271
case O O 0.9999767541885376
each O O 0.999915361404419
implicating O O 0.9999310970306396
erythromycin B B 0.9966475367546082
and O O 0.9603728652000427
amoxicillin B B 0.9979922771453857
. O O 0.9999483823776245

The O O 0.9998412132263184
WHO O O 0.999972939491272
reported O O 0.999983549118042
82 O O 0.999911904335022
cases O O 0.9999864101409912
. O O 0.9999359846115112

Of O O 0.9978947043418884
these O O 0.9999796152114868
, O O 0.9995335340499878
clarithromycin B B 0.999718964099884
was O O 0.9999116659164429
implicated O O 0.9985861778259277
in O O 0.9999368190765381
23 O O 0.9999855756759644
( O O 0.9999414682388306
27 O O 0.999991774559021
. O O 0.9999926090240479
6 O O 0.9999940395355225
% O O 0.9999914169311523
) O O 0.9999494552612305
cases O O 0.9999892711639404
, O O 0.9993659853935242
ciprofloxacin B B 0.9994403719902039
in O O 0.9998960494995117
12 O O 0.9999972581863403
( O O 0.9999200105667114
14 O O 0.9999977350234985
. O O 0.9999957084655762
4 O O 0.9999862909317017
% O O 0.9999920129776001
) O O 0.9999563694000244
cases O O 0.999985933303833
, O O 0.9996421337127686
and O O 0.8430524468421936
ofloxacin B B 0.9997997879981995
in O O 0.9998865127563477
10 O O 0.9999855756759644
( O O 0.9998890161514282
12 O O 0.9999979734420776
% O O 0.9999911785125732
) O O 0.9999542236328125
cases O O 0.9999762773513794
. O O 0.9999756813049316

Cotrimoxazole B B 0.9909851551055908
, O O 0.9701305031776428
metronidazole B B 0.9987117052078247
, O O 0.9566080570220947
and O O 0.9942949414253235
erythromycin B B 0.9948049187660217
were O O 0.9998213648796082
involved O O 0.9995661377906799
in O O 0.9999641180038452
15 O O 0.9997647404670715
reported O O 0.9999899864196777
manic O O 0.9998757839202881
episodes O O 0.99998939037323
. O O 0.9999430179595947

Cases O O 0.9999465942382812
reported O O 0.999988317489624
by O O 0.9999816417694092
the O O 0.9999663829803467
FDA O O 0.9989776611328125
showed O O 0.99978107213974
clarithromycin B B 0.9996011853218079
and O O 0.9658932685852051
ciprofloxacin B B 0.9991832375526428
to O O 0.999884843826294
be O O 0.9999500513076782
the O O 0.9998548030853271
most O O 0.9999122619628906
frequently O O 0.9999555349349976
associated O O 0.9999521970748901
with O O 0.9999853372573853
the O O 0.9999933242797852
development O O 0.9999974966049194
of O O 0.9999880790710449
mania O O 0.9994199275970459
. O O 0.9999725818634033

Statistical O O 0.99997878074646
analysis O O 0.9999978542327881
of O O 0.9999899864196777
the O O 0.9999914169311523
data O O 0.9999812841415405
would O O 0.9999909400939941
not O O 0.9999932050704956
have O O 0.999996542930603
demonstrated O O 0.9999802112579346
a O O 0.9999834299087524
significant O O 0.9999825954437256
statistical O O 0.9999147653579712
correlative O O 0.9999707937240601
risk O O 0.999971866607666
and O O 0.9999791383743286
was O O 0.9999889135360718
therefore O O 0.999997615814209
not O O 0.9999946355819702
undertaken O O 0.9999947547912598
. O O 0.9999688863754272

Patients O O 0.999798595905304
have O O 0.9999793767929077
an O O 0.9999749660491943
increased O O 0.9999799728393555
risk O O 0.9999953508377075
of O O 0.9999905824661255
developing O O 0.9999762773513794
mania O O 0.9989400506019592
while O O 0.9999197721481323
being O O 0.9999765157699585
treated O O 0.9999494552612305
with O O 0.9997994303703308
antimicrobials O O 0.8300623297691345
. O O 0.9999411106109619

Although O O 0.9999821186065674
this O O 0.9999774694442749
is O O 0.9999772310256958
not O O 0.9999924898147583
a O O 0.9999817609786987
statistically O O 0.9999791383743286
significant O O 0.9999890327453613
risk O O 0.9999903440475464
, O O 0.999945878982544
physicians O O 0.9999847412109375
must O O 0.9999752044677734
be O O 0.9999901056289673
aware O O 0.9999818801879883
of O O 0.9999680519104004
the O O 0.9999319314956665
effect O O 0.9999395608901978
and O O 0.9999587535858154
reversibility O O 0.9999946355819702
. O O 0.9999790191650391

Further O O 0.9999762773513794
research O O 0.9999933242797852
clearly O O 0.9999908208847046
is O O 0.9999921321868896
required O O 0.999993085861206
to O O 0.9999949932098389
determine O O 0.9999901056289673
the O O 0.9999924898147583
incidence O O 0.9999933242797852
of O O 0.9999629259109497
antimicrobial O O 0.6121765375137329
- O O 0.9987521171569824
induced O O 0.999914288520813
mania O O 0.9999130964279175
, O O 0.9999808073043823
the O O 0.9999872446060181
relative O O 0.9999611377716064
risk O O 0.9999918937683105
factors O O 0.9999947547912598
of O O 0.9999853372573853
developing O O 0.9999947547912598
an O O 0.9999836683273315
antimicrobial O O 0.72176593542099
- O O 0.998588502407074
induced O O 0.9998382329940796
manic O O 0.999896764755249
episode O O 0.9999830722808838
among O O 0.9998335838317871
various O O 0.9998866319656372
demographic O O 0.9768834114074707
populations O O 0.9999719858169556
, O O 0.9999569654464722
and O O 0.9999712705612183
the O O 0.9999856948852539
incidence O O 0.9999918937683105
of O O 0.9999825954437256
patients O O 0.9999918937683105
who O O 0.9999771118164062
continue O O 0.9999903440475464
to O O 0.9999690055847168
have O O 0.999977707862854
persistent O O 0.9998749494552612
affective O O 0.9991318583488464
disorders O O 0.9999960660934448
once O O 0.9999547004699707
the O O 0.9999889135360718
initial O O 0.9999939203262329
episode O O 0.9999945163726807
, O O 0.9999916553497314
which O O 0.9999892711639404
occurs O O 0.9999923706054688
while O O 0.9999440908432007
the O O 0.9999954700469971
patient O O 0.9999914169311523
is O O 0.999976634979248
taking O O 0.9995112419128418
antibiotics O O 0.919829249382019
, O O 0.9999871253967285
subsides O O 0.9999762773513794
. O O 0.9999780654907227

The O O 0.9999756813049316
authors O O 0.9999967813491821
elected O O 0.999984860420227
to O O 0.9999769926071167
name O O 0.9998879432678223
this O O 0.9998286962509155
syndrome O O 0.9996205568313599
" O O 0.999430239200592
antibiomania O O 0.6288899183273315
. O O 0.9998874664306641
" O O 0.9999701976776123

Levodopa B B 0.9976995587348938
- O O 0.999042809009552
induced O O 0.9997871518135071
ocular O O 0.9999145269393921
dyskinesias O O 0.9999963045120239
in O O 0.9998660087585449
Parkinson O O 0.997425377368927
' O O 0.9999889135360718
s O O 0.9999566078186035
disease O O 0.9999891519546509
. O O 0.9998611211776733

Levodopa B B 0.9976062774658203
- O O 0.999687910079956
induced O O 0.9997174143791199
ocular O O 0.9999597072601318
dyskinesias O O 0.9999963045120239
are O O 0.9999655485153198
very O O 0.9999825954437256
uncommon O O 0.9999550580978394
. O O 0.9999619722366333

Usually O O 0.9998161196708679
they O O 0.9999713897705078
occur O O 0.9999681711196899
simultaneously O O 0.9999419450759888
with O O 0.9999492168426514
limb O O 0.9997296929359436
peak O O 0.8961625099182129
- O O 0.9997829794883728
dose O O 0.9995259046554565
choreatic O O 0.9944654107093811
dyskinesias O O 0.9999934434890747
. O O 0.9999579191207886

We O O 0.9999319314956665
report O O 0.9999901056289673
on O O 0.9999703168869019
a O O 0.9999841451644897
patient O O 0.9999920129776001
with O O 0.9999728202819824
leftward O O 0.9999713897705078
and O O 0.9999722242355347
upward O O 0.9999833106994629
deviations O O 0.9999994039535522
of O O 0.9999958276748657
gaze O O 0.9999959468841553
during O O 0.999833345413208
the O O 0.9999212026596069
peak O O 0.9990032315254211
effect O O 0.9999035596847534
of O O 0.998915433883667
levodopa B B 0.9993298053741455
, O O 0.9996022582054138
and O O 0.9999500513076782
hypothesize O O 0.9997274279594421
that O O 0.9999071359634399
a O O 0.9998335838317871
severe O O 0.9994307160377502
dopaminergic O O 0.6581849455833435
denervation O O 0.9060306549072266
in O O 0.9996901750564575
the O O 0.9998854398727417
caudate O O 0.9952980875968933
nucleus O O 0.9999706745147705
is O O 0.9999507665634155
needed O O 0.9993273019790649
for O O 0.9999840259552002
the O O 0.9999951124191284
appearance O O 0.9999899864196777
of O O 0.9999698400497437
these O O 0.9999253749847412
levodopa B B 0.9996421337127686
- O O 0.9997212290763855
induce O O 0.9996232986450195
ocular O O 0.9999687671661377
dyskinesias O O 0.999998927116394
. O O 0.9999792575836182

A O O 0.9999704360961914
comparison O O 0.9998782873153687
of O O 0.9976412057876587
glyceryl B B 0.998763918876648
trinitrate I I 0.999815046787262
with O O 0.9513071179389954
diclofenac B B 0.9975443482398987
for O O 0.9998267292976379
the O O 0.9999798536300659
treatment O O 0.9999685287475586
of O O 0.9999884366989136
primary O O 0.9999555349349976
dysmenorrhea O O 0.9999550580978394
: O O 0.9999784231185913
an O O 0.9999927282333374
open O O 0.9999958276748657
, O O 0.9999933242797852
randomized O O 0.9999940395355225
, O O 0.9999866485595703
cross O O 0.9998015761375427
- O O 0.9999841451644897
over O O 0.9999773502349854
trial O O 0.9999951124191284
. O O 0.9999865293502808

Primary O O 0.9996691942214966
dysmenorrhea O O 0.9998385906219482
is O O 0.9999567270278931
a O O 0.9999741315841675
syndrome O O 0.9999923706054688
characterized O O 0.9999865293502808
by O O 0.9999744892120361
painful O O 0.9998688697814941
uterine O O 0.9998756647109985
contractility O O 0.9999837875366211
caused O O 0.9999608993530273
by O O 0.999896764755249
a O O 0.9998658895492554
hypersecretion O O 0.9969720840454102
of O O 0.9961581826210022
endometrial O O 0.9872738122940063
prostaglandins B O 0.8756805658340454
; O O 0.9998658895492554
non O O 0.7428523302078247
- O O 0.9653639197349548
steroidal O O 0.46914854645729065
anti O O 0.38669171929359436
- O O 0.9314357042312622
inflammatory O O 0.9789243340492249
drugs O O 0.9943291544914246
are O O 0.9998237490653992
the O O 0.9999535083770752
first O O 0.9999841451644897
choice O O 0.9999774694442749
for O O 0.9999566078186035
its O O 0.9999656677246094
treatment O O 0.9999661445617676
. O O 0.999964714050293

However O O 0.9999407529830933
, O O 0.9999551773071289
in O O 0.9999271631240845
vivo O O 0.9999752044677734
and O O 0.9999520778656006
in O O 0.9998712539672852
vitro O O 0.9999814033508301
studies O O 0.9999862909317017
have O O 0.9999781847000122
demonstrated O O 0.9999803304672241
that O O 0.9998608827590942
myometrial O O 0.9999687671661377
cells O O 0.9999425411224365
are O O 0.9998691082000732
also O O 0.9998505115509033
targets O O 0.9969843029975891
of O O 0.9994316697120667
the O O 0.9997599720954895
relaxant O O 0.9962725639343262
effects O O 0.9998288154602051
of O O 0.9996581077575684
nitric B B 0.9854481816291809
oxide I I 0.9994021654129028
( O O 0.9950492978096008
NO B B 0.9795200824737549
) O O 0.9947695136070251
. O O 0.9999650716781616

The O O 0.9999915361404419
aim O O 0.9999974966049194
of O O 0.9999959468841553
the O O 0.9999973773956299
present O O 0.999992847442627
study O O 0.9999879598617554
was O O 0.9999959468841553
to O O 0.9999948740005493
determine O O 0.9999896287918091
the O O 0.9999791383743286
efficacy O O 0.9999738931655884
of O O 0.9974863529205322
glyceryl B B 0.9985371828079224
trinitrate I I 0.9997991919517517
( O O 0.9829035401344299
GTN B B 0.9978062510490417
) O O 0.9991971850395203
, O O 0.9998970031738281
an O O 0.8186804056167603
NO B O 0.5960860848426819
donor O O 0.9044916033744812
, O O 0.999974250793457
in O O 0.9999425411224365
the O O 0.9999822378158569
resolution O O 0.9999892711639404
of O O 0.9999701976776123
primary O O 0.9999314546585083
dysmenorrhea O O 0.9999865293502808
in O O 0.9999756813049316
comparison O O 0.9999535083770752
with O O 0.9990488886833191
diclofenac B B 0.9986905455589294
( O O 0.9949867725372314
DCF B B 0.9849777221679688
) O O 0.9997231364250183
. O O 0.9999256134033203

A O O 0.9999810457229614
total O O 0.9999904632568359
of O O 0.999988317489624
24 O O 0.9999879598617554
patients O O 0.9999958276748657
with O O 0.999982476234436
the O O 0.9999959468841553
diagnosis O O 0.9999955892562866
of O O 0.9999873638153076
severe O O 0.9999380111694336
primary O O 0.9999626874923706
dysmenorrhea O O 0.9999713897705078
were O O 0.9999573230743408
studied O O 0.9999837875366211
during O O 0.9999361038208008
two O O 0.9999808073043823
consecutive O O 0.9999889135360718
menstrual O O 0.9992775321006775
cycles O O 0.9999449253082275
. O O 0.9999626874923706

In O O 0.9999806880950928
an O O 0.9999836683273315
open O O 0.9999129772186279
, O O 0.9999680519104004
cross O O 0.9989957213401794
- O O 0.9999716281890869
over O O 0.9999825954437256
, O O 0.9999330043792725
controlled O O 0.999972939491272
design O O 0.9999961853027344
, O O 0.9999853372573853
patients O O 0.9999951124191284
were O O 0.999996542930603
randomized O O 0.9999973773956299
to O O 0.9999743700027466
receive O O 0.9999008178710938
either O O 0.9993975162506104
DCF B O 0.7189358472824097
per O O 0.9452825784683228
os O O 0.9779136776924133
or O O 0.9994088411331177
GTN B B 0.9172919392585754
patches O O 0.998124897480011
the O O 0.9999947547912598
first O O 0.9999966621398926
days O O 0.9999964237213135
of O O 0.9999892711639404
menses O O 0.9999376535415649
, O O 0.9999899864196777
when O O 0.9999960660934448
menstrual O O 0.9995983242988586
cramps O O 0.9989221096038818
became O O 0.9999924898147583
unendurable O O 0.9998810291290283
. O O 0.999985933303833

In O O 0.9999402761459351
the O O 0.9999935626983643
subsequent O O 0.9999932050704956
cycle O O 0.9999673366546631
the O O 0.9995349645614624
other O O 0.9989670515060425
treatment O O 0.999566376209259
was O O 0.9999160766601562
used O O 0.9999221563339233
. O O 0.9999638795852661

Patients O O 0.9999256134033203
received O O 0.999958872795105
up O O 0.9999943971633911
to O O 0.9999969005584717
3 O O 0.9998655319213867
doses O O 0.9999587535858154
/ O O 0.999987006187439
day O O 0.9999957084655762
of O O 0.9997604489326477
50 O O 0.9962670207023621
mg O O 0.9986176490783691
DCF B B 0.9345239996910095
or O O 0.9969018697738647
2 O O 0.9998031258583069
. O O 0.9999815225601196
5 O O 0.9999241828918457
mg O O 0.9998750686645508
/ O O 0.9999552965164185
24 O O 0.9999725818634033
h O O 0.9968089461326599
transdermal O O 0.9990274906158447
GTN B B 0.9316214323043823
for O O 0.999636173248291
the O O 0.999991774559021
first O O 0.9999973773956299
3 O O 0.9999686479568481
days O O 0.9999974966049194
of O O 0.9999862909317017
the O O 0.9999895095825195
cycle O O 0.9999754428863525
, O O 0.9999814033508301
according O O 0.999997615814209
to O O 0.9999955892562866
their O O 0.9999905824661255
needs O O 0.9999935626983643
. O O 0.9999856948852539

The O O 0.9999368190765381
participants O O 0.9999886751174927
recorded O O 0.9999732971191406
menstrual O O 0.9950847029685974
symptoms O O 0.9999898672103882
and O O 0.999976396560669
possible O O 0.9999583959579468
side O O 0.9999449253082275
- O O 0.9999634027481079
effects O O 0.9999938011169434
at O O 0.9999649524688721
different O O 0.9999700784683228
times O O 0.9999865293502808
( O O 0.9999717473983765
0 O O 0.9999759197235107
, O O 0.99996018409729
30 O O 0.9999908208847046
, O O 0.9999454021453857
60 O O 0.999987006187439
, O O 0.9999103546142578
120 O O 0.9999884366989136
minutes O O 0.9999967813491821
) O O 0.9999932050704956
after O O 0.9999600648880005
the O O 0.9999895095825195
first O O 0.9999914169311523
dose O O 0.999954342842102
of O O 0.9998764991760254
medication O O 0.9998725652694702
on O O 0.9999523162841797
the O O 0.9999929666519165
first O O 0.9999977350234985
day O O 0.999995231628418
of O O 0.9999809265136719
the O O 0.9999924898147583
cycle O O 0.9999947547912598
, O O 0.9999929666519165
with O O 0.9998654127120972
both O O 0.9932069182395935
drugs O O 0.9958248138427734
. O O 0.999911904335022

The O O 0.9999809265136719
difference O O 0.9999914169311523
in O O 0.9999873638153076
pain O O 0.9998884201049805
intensity O O 0.9998880624771118
score O O 0.9999488592147827
( O O 0.9998384714126587
DPI O O 0.9979743361473083
) O O 0.9999439716339111
was O O 0.9999467134475708
the O O 0.9999690055847168
main O O 0.9999736547470093
outcome O O 0.9999899864196777
variable O O 0.999996542930603
. O O 0.9999778270721436

Both O O 0.9992627501487732
treatments O O 0.9997755885124207
significantly O O 0.9999631643295288
reduced O O 0.9999645948410034
DPI O O 0.8923038244247437
by O O 0.9999831914901733
the O O 0.9999939203262329
30th O O 0.9999908208847046
minute O O 0.9999977350234985
( O O 0.9997957348823547
GTN B O 0.8516384363174438
, O O 0.9996383190155029
- O O 0.9998342990875244
12 O O 0.9999918937683105
. O O 0.9999902248382568
8 O O 0.9999761581420898
+ O O 0.9999802112579346
/ O O 0.9999191761016846
- O O 0.9998453855514526
17 O O 0.9999946355819702
. O O 0.9999884366989136
9 O O 0.999987006187439
; O O 0.9998559951782227
DCF B O 0.7814054489135742
, O O 0.9990143775939941
- O O 0.9995383024215698
18 O O 0.9998917579650879
. O O 0.9999908208847046
9 O O 0.9999891519546509
+ O O 0.9999839067459106
/ O O 0.9998378753662109
- O O 0.9998879432678223
16 O O 0.9999949932098389
. O O 0.9999876022338867
6 O O 0.9999895095825195
) O O 0.9999645948410034
. O O 0.999975323677063

However O O 0.9999496936798096
, O O 0.9990450739860535
DCF B B 0.9650789499282837
continued O O 0.9997501969337463
to O O 0.9999409914016724
be O O 0.999904990196228
effective O O 0.9993706345558167
in O O 0.999889612197876
reducing O O 0.999935507774353
pelvic O O 0.9999722242355347
pain O O 0.9999862909317017
for O O 0.9999067783355713
two O O 0.9999878406524658
hours O O 0.9999847412109375
, O O 0.9999738931655884
whereas O O 0.9992282390594482
GTN B O 0.6532368063926697
scores O O 0.9989981055259705
remained O O 0.9999817609786987
more O O 0.999990701675415
or O O 0.999993085861206
less O O 0.9999903440475464
stable O O 0.9999899864196777
after O O 0.9999579191207886
30 O O 0.9999785423278809
min O O 0.9999454021453857
and O O 0.9999862909317017
significantly O O 0.9999892711639404
higher O O 0.9999572038650513
than O O 0.9999890327453613
those O O 0.9999616146087646
for O O 0.9987586736679077
DFC O O 0.679958164691925
( O O 0.9998626708984375
after O O 0.9998806715011597
one O O 0.9999909400939941
hour O O 0.9999818801879883
: O O 0.9996069073677063
GTN B O 0.6200615167617798
, O O 0.9838203191757202
- O O 0.9995613694190979
12 O O 0.9999979734420776
. O O 0.9999951124191284
8 O O 0.9999885559082031
+ O O 0.9999805688858032
/ O O 0.9996659755706787
- O O 0.9997108578681946
17 O O 0.9999889135360718
. O O 0.9999864101409912
9 O O 0.9999769926071167
; O O 0.9997755885124207
DFC O O 0.739668071269989
, O O 0.9923921227455139
- O O 0.9995458722114563
18 O O 0.9999575614929199
. O O 0.9999971389770508
9 O O 0.999990701675415
+ O O 0.9999860525131226
/ O O 0.9993316531181335
- O O 0.9997718930244446
16 O O 0.9999959468841553
. O O 0.999992847442627
6 O O 0.9999873638153076
and O O 0.9999556541442871
after O O 0.9999105930328369
two O O 0.9999934434890747
hours O O 0.9999830722808838
: O O 0.9996854066848755
GTN B O 0.6935559511184692
, O O 0.9872061014175415
- O O 0.9992114305496216
23 O O 0.9999951124191284
. O O 0.9999971389770508
7 O O 0.9999954700469971
+ O O 0.9999808073043823
/ O O 0.9996777772903442
- O O 0.9996984004974365
20 O O 0.9999862909317017
. O O 0.9999934434890747
5 O O 0.9999966621398926
; O O 0.9997854828834534
DFC O O 0.6640729308128357
, O O 0.9850448966026306
- O O 0.9994737505912781
59 O O 0.9999889135360718
. O O 0.9999964237213135
7 O O 0.999995231628418
+ O O 0.9999797344207764
/ O O 0.9980812072753906
- O O 0.9996985197067261
17 O O 0.9999915361404419
. O O 0.9999922513961792
9 O O 0.9999876022338867
, O O 0.9999816417694092
p O O 0.9999778270721436
= O O 0.9999678134918213
0 O O 0.9999920129776001
. O O 0.9999953508377075
0001 O O 0.9995161294937134
) O O 0.999977707862854
. O O 0.9999792575836182

Low O O 0.9999154806137085
back O O 0.9994885921478271
pain O O 0.9999686479568481
was O O 0.999943733215332
also O O 0.9999434947967529
relieved O O 0.9999686479568481
by O O 0.9998434782028198
both O O 0.9798101186752319
drugs O O 0.9849951863288879
. O O 0.999914288520813

Headache O O 0.9998693466186523
was O O 0.9999334812164307
significantly O O 0.9999750852584839
increased O O 0.999982476234436
by O O 0.9996150732040405
GTN B B 0.9868994951248169
but O O 0.9998434782028198
not O O 0.9999328851699829
by O O 0.9993849992752075
DCF B O 0.7088498473167419
. O O 0.9999079704284668

Eight O O 0.9995546936988831
patients O O 0.9999912977218628
stopped O O 0.9999158382415771
using O O 0.9982882142066956
GTN B B 0.9969698786735535
because O O 0.9992545247077942
headache O O 0.9998795986175537
- O O 0.9912541508674622
- O O 0.9899351000785828
attributed O O 0.9999979734420776
to O O 0.9997181296348572
its O O 0.9950173497200012
use O O 0.9996615648269653
- O O 0.9771446585655212
- O O 0.9701675176620483
became O O 0.9999880790710449
intolerable O O 0.9999862909317017
. O O 0.9999830722808838

These O O 0.999977707862854
findings O O 0.9999916553497314
indicate O O 0.9999457597732544
that O O 0.9996953010559082
GTN B B 0.9983870983123779
has O O 0.9998424053192139
a O O 0.9999735355377197
reduced O O 0.9999802112579346
efficacy O O 0.9999790191650391
and O O 0.9999706745147705
tolerability O O 0.9999915361404419
by O O 0.9999955892562866
comparison O O 0.9999706745147705
with O O 0.9996241331100464
DCF B B 0.9685802459716797
in O O 0.9997287392616272
the O O 0.9999634027481079
treatment O O 0.9999428987503052
of O O 0.9999810457229614
primary O O 0.999921441078186
dysmenorrhea O O 0.9999575614929199
. O O 0.9999347925186157

Temocapril B B 0.9993550181388855
, O O 0.9994977712631226
a O O 0.993596076965332
long O O 0.9627898335456848
- O O 0.9995891451835632
acting O O 0.9935981035232544
non O O 0.45885613560676575
- O O 0.9345460534095764
SH O O 0.8480583429336548
group O O 0.9738860130310059
angiotensin B B 0.9215359091758728
converting O O 0.6892555356025696
enzyme O O 0.5825239419937134
inhibitor O O 0.7658975124359131
, O O 0.9974300265312195
modulates O O 0.9998996257781982
glomerular O O 0.9986037611961365
injury O O 0.9999914169311523
in O O 0.9998834133148193
chronic O O 0.9986231327056885
puromycin B B 0.9780383110046387
aminonucleoside I I 0.9964256882667542
nephrosis O O 0.9547148942947388
. O O 0.999491810798645

The O O 0.9999908208847046
purpose O O 0.9999963045120239
of O O 0.9999949932098389
the O O 0.9999967813491821
present O O 0.9999939203262329
study O O 0.9999921321868896
was O O 0.9999945163726807
to O O 0.9999945163726807
determine O O 0.9999949932098389
whether O O 0.9999520778656006
chronic O O 0.9997784495353699
administration O O 0.9998874664306641
of O O 0.9989363551139832
temocapril B B 0.9998507499694824
, O O 0.999789297580719
a O O 0.9991434812545776
long O O 0.940274715423584
- O O 0.9996342658996582
acting O O 0.9856449365615845
non O O 0.5277979373931885
- O O 0.9115321636199951
SH O O 0.5895103216171265
group O O 0.9501500725746155
angiotensin B B 0.9277862310409546
converting O O 0.6352307200431824
enzyme O O 0.5484219789505005
( O O 0.8908034563064575
ACE O O 0.7325909733772278
) O O 0.5651168823242188
inhibitor O O 0.6241437196731567
, O O 0.997260570526123
reduced O O 0.9997833371162415
proteinuria O O 0.9998478889465332
, O O 0.9994853734970093
inhibited O O 0.999840259552002
glomerular O O 0.9997300505638123
hypertrophy O O 0.9990156888961792
and O O 0.9999306201934814
prevented O O 0.9999080896377563
glomerulosclerosis O O 0.9991826415061951
in O O 0.99988853931427
chronic O O 0.9996528625488281
puromycin B B 0.9980912804603577
aminonucleoside I I 0.9998358488082886
( O O 0.9521359205245972
PAN B B 0.9911125302314758
) O O 0.5666830539703369
- O O 0.9996802806854248
induced O O 0.9999563694000244
nephrotic O O 0.9999247789382935
rats O O 0.9997451901435852
. O O 0.9999727010726929

Nephrosis O O 0.999271810054779
was O O 0.9999735355377197
induced O O 0.9999890327453613
by O O 0.9999426603317261
injection O O 0.9999644756317139
of O O 0.9998164772987366
PAN B B 0.9954909682273865
( O O 0.9971486926078796
15mg O O 0.9994682669639587
/ O O 0.999957799911499
100g O O 0.9998799562454224
body O O 0.9999854564666748
weight O O 0.9999297857284546
) O O 0.9998453855514526
in O O 0.9999617338180542
male O O 0.9999673366546631
Sprague O O 0.9727396368980408
- O O 0.9992558360099792
Dawley O O 0.9948242902755737
( O O 0.9998387098312378
SD O O 0.9490633606910706
) O O 0.9999206066131592
rats O O 0.9999868869781494
. O O 0.9999734163284302

Four O O 0.9977701902389526
groups O O 0.9998898506164551
were O O 0.9999475479125977
used O O 0.9999305009841919
, O O 0.9998986721038818
i O O 0.999976634979248
) O O 0.9998579025268555
the O O 0.9997715353965759
PAN B O 0.8379468321800232
group O O 0.5077382922172546
( O O 0.9485211372375488
14 O O 0.9854028224945068
) O O 0.9992897510528564
, O O 0.9997159838676453
ii O O 0.9999885559082031
) O O 0.9982268214225769
PAN B B 0.9563393592834473
/ O O 0.7700551152229309
temocapril B B 0.9970371723175049
( O O 0.9783742427825928
13 O O 0.9996206760406494
) O O 0.9996322393417358
, O O 0.999758780002594
iii O O 0.9996408224105835
) O O 0.9987755417823792
temocapril B B 0.9988058805465698
( O O 0.9668598771095276
14 O O 0.994563639163971
) O O 0.9997640252113342
and O O 0.9998699426651001
iv O O 0.999942421913147
) O O 0.9997947812080383
untreated O O 0.9997081160545349
controls O O 0.9999779462814331
( O O 0.9996473789215088
15 O O 0.9999610185623169
) O O 0.9999030828475952
. O O 0.9999786615371704

Temocapril B B 0.9994695782661438
( O O 0.9996092915534973
8 O O 0.9993487000465393
mg O O 0.9998787641525269
/ O O 0.9999194145202637
kg O O 0.9999977350234985
/ O O 0.9998067021369934
day O O 0.9999549388885498
) O O 0.9999175071716309
was O O 0.9999673366546631
administered O O 0.9999512434005737
to O O 0.9999550580978394
the O O 0.9999772310256958
rats O O 0.9999715089797974
which O O 0.9999814033508301
were O O 0.9999871253967285
killed O O 0.9999722242355347
at O O 0.9999898672103882
weeks O O 0.9999983310699463
4 O O 0.999982476234436
, O O 0.9999172687530518
14 O O 0.9999985694885254
or O O 0.9999692440032959
20 O O 0.9999879598617554
. O O 0.9999853372573853

At O O 0.9998955726623535
each O O 0.9999333620071411
time O O 0.999958872795105
point O O 0.9999892711639404
, O O 0.9999669790267944
systolic O O 0.9983737468719482
blood O O 0.999691367149353
pressure O O 0.9983280301094055
( O O 0.9998977184295654
BP O O 0.9873325228691101
) O O 0.9999704360961914
, O O 0.9999376535415649
urinary O O 0.9981057643890381
protein O O 0.44252875447273254
excretion O O 0.9993715882301331
and O O 0.9998818635940552
renal O O 0.9999443292617798
histopathological O O 0.9999696016311646
findings O O 0.9999960660934448
were O O 0.9999728202819824
evaluated O O 0.9999885559082031
, O O 0.9999547004699707
and O O 0.9999772310256958
morphometric O O 0.9999653100967407
image O O 0.9999756813049316
analysis O O 0.9999775886535645
was O O 0.9999829530715942
done O O 0.9999912977218628
. O O 0.9999806880950928

Systolic O O 0.999697208404541
BP O O 0.8731269240379333
in O O 0.9998660087585449
the O O 0.9998748302459717
PAN B O 0.8517575263977051
group O O 0.9975263476371765
was O O 0.999941349029541
significantly O O 0.9999804496765137
high O O 0.9999663829803467
at O O 0.9999514818191528
4 O O 0.9999244213104248
, O O 0.9999370574951172
14 O O 0.9999959468841553
and O O 0.9999555349349976
20 O O 0.9999583959579468
weeks O O 0.9999936819076538
, O O 0.9999614953994751
but O O 0.9999135732650757
was O O 0.9999700784683228
normal O O 0.999968409538269
in O O 0.9998546838760376
the O O 0.9996542930603027
PAN B B 0.9012137055397034
/ O O 0.8190733790397644
temocapril B B 0.9994540810585022
group O O 0.9996432065963745
. O O 0.9999810457229614

Urinary O O 0.9699549674987793
protein O O 0.73027104139328
excretion O O 0.9970941543579102
in O O 0.9998733997344971
the O O 0.9998908042907715
PAN B O 0.6914863586425781
group O O 0.9588442444801331
increased O O 0.9999408721923828
significantly O O 0.9999897480010986
, O O 0.9999927282333374
peaking O O 0.9999966621398926
at O O 0.9999796152114868
8 O O 0.9999574422836304
days O O 0.9999946355819702
, O O 0.9999886751174927
then O O 0.9999445676803589
decreased O O 0.999963641166687
at O O 0.999962568283081
4 O O 0.9999657869338989
weeks O O 0.9999964237213135
, O O 0.9999823570251465
but O O 0.9999501705169678
rose O O 0.9999716281890869
again O O 0.9999872446060181
significantly O O 0.9999927282333374
at O O 0.9999562501907349
14 O O 0.9999955892562866
and O O 0.9999704360961914
20 O O 0.9999872446060181
weeks O O 0.9999966621398926
. O O 0.9999785423278809

Temocapril B B 0.9995928406715393
did O O 0.9999035596847534
not O O 0.9999613761901855
attenuate O O 0.9998917579650879
proteinuria O O 0.9997931122779846
at O O 0.9999687671661377
8 O O 0.9999024868011475
days O O 0.9999938011169434
, O O 0.9999735355377197
but O O 0.9999538660049438
it O O 0.9997290968894958
did O O 0.9999653100967407
markedly O O 0.9999845027923584
lower O O 0.9999812841415405
it O O 0.9999730587005615
from O O 0.9999479055404663
weeks O O 0.9999948740005493
4 O O 0.9999521970748901
to O O 0.9999326467514038
20 O O 0.9998452663421631
. O O 0.9999747276306152

The O O 0.9999744892120361
glomerulosclerosis O O 0.9921030402183533
index O O 0.9999040365219116
( O O 0.9997174143791199
GSI O O 0.9822118878364563
) O O 0.9999449253082275
was O O 0.9999512434005737
6 O O 0.9999665021896362
. O O 0.9999914169311523
21 O O 0.9999966621398926
% O O 0.9999948740005493
at O O 0.9999855756759644
4 O O 0.9999562501907349
weeks O O 0.9999983310699463
and O O 0.9999668598175049
respectively O O 0.9999490976333618
25 O O 0.9999762773513794
. O O 0.9999880790710449
35 O O 0.9999970197677612
% O O 0.9999940395355225
and O O 0.9999387264251709
30 O O 0.9999798536300659
. O O 0.9999896287918091
49 O O 0.9999970197677612
% O O 0.9999943971633911
at O O 0.9999740123748779
14 O O 0.9999979734420776
and O O 0.999974250793457
20 O O 0.9999933242797852
weeks O O 0.9999985694885254
in O O 0.9999526739120483
the O O 0.9999613761901855
PAN B O 0.5774122476577759
group O O 0.9998804330825806
. O O 0.9999743700027466

There O O 0.9999666213989258
was O O 0.9999439716339111
a O O 0.9999793767929077
significant O O 0.9999780654907227
correlation O O 0.9999808073043823
between O O 0.9997618794441223
urinary O O 0.9977942705154419
protein O O 0.8032400608062744
excretion O O 0.9988402724266052
and O O 0.9997186064720154
GSI O B 0.8925452828407288
( O O 0.9997139573097229
r O O 0.9997652173042297
= O O 0.9999570846557617
0 O O 0.9999868869781494
. O O 0.9999942779541016
808 O O 0.999798595905304
, O O 0.9999681711196899
p O O 0.9999701976776123
< O O 0.9999816417694092
0 O O 0.9999924898147583
. O O 0.9999951124191284
0001 O O 0.9999779462814331
) O O 0.9999649524688721
. O O 0.9999619722366333

The O O 0.9999872446060181
ratio O O 0.999956488609314
of O O 0.9999195337295532
glomerular O O 0.9800461530685425
tuft O O 0.9985446929931641
area O O 0.999743640422821
to O O 0.9999046325683594
the O O 0.9999709129333496
area O O 0.999880313873291
of O O 0.9998470544815063
Bowman O O 0.9621655941009521
' O O 0.9999918937683105
s O O 0.9997593760490417
capsules O O 0.9975616931915283
( O O 0.999743640422821
GT O O 0.8614590167999268
/ O O 0.999707043170929
BC O O 0.5795446634292603
) O O 0.9999479055404663
in O O 0.999861478805542
the O O 0.9996901750564575
PAN B B 0.9018062353134155
group O O 0.9984696507453918
was O O 0.9999544620513916
significantly O O 0.9999675750732422
increased O O 0.9999555349349976
, O O 0.9999536275863647
but O O 0.9999558925628662
it O O 0.999981164932251
was O O 0.9999719858169556
significantly O O 0.9999814033508301
lower O O 0.9999793767929077
in O O 0.9996058344841003
the O O 0.9994838237762451
PAN B B 0.9288060069084167
/ O O 0.8510843515396118
temocapril B B 0.9995037317276001
group O O 0.9997857213020325
. O O 0.9999755620956421

It O O 0.9999831914901733
appears O O 0.9998742341995239
that O O 0.9988816380500793
temocapril B B 0.9998249411582947
was O O 0.9998700618743896
effective O O 0.9991806149482727
in O O 0.9998761415481567
retarding O O 0.9992915391921997
renal O O 0.9999533891677856
progression O O 0.9999868869781494
and O O 0.9998960494995117
protected O O 0.9992413520812988
renal O O 0.999943733215332
function O O 0.9999722242355347
in O O 0.9998387098312378
PAN B O 0.8407752513885498
neprotic O O 0.9972999691963196
rats O O 0.9995224475860596
. O O 0.9999487400054932

Pulmonary O O 0.9995176792144775
hypertension O O 0.9976670742034912
after O O 0.9992212057113647
ibuprofen B B 0.9897973537445068
prophylaxis O O 0.7571920156478882
in O O 0.9999481439590454
very O O 0.9999817609786987
preterm O O 0.9999991655349731
infants O O 0.9999991655349731
. O O 0.9999653100967407

We O O 0.9999732971191406
report O O 0.9999957084655762
three O O 0.9999924898147583
cases O O 0.9999979734420776
of O O 0.9999903440475464
severe O O 0.9999779462814331
hypoxaemia O O 0.9999434947967529
after O O 0.9997547268867493
ibuprofen B B 0.9820630550384521
administration O O 0.9996781349182129
during O O 0.9999364614486694
a O O 0.9999879598617554
randomised O O 0.9999918937683105
controlled O O 0.9999946355819702
trial O O 0.9999887943267822
of O O 0.99993896484375
prophylactic O O 0.9998612403869629
treatment O O 0.9999852180480957
of O O 0.9999723434448242
patent O O 0.9999699592590332
ductus O O 0.9999980926513672
arteriosus O O 0.9983036518096924
with O O 0.9998493194580078
ibuprofen B B 0.9683359265327454
in O O 0.999805748462677
premature O O 0.9999980926513672
infants O O 0.999998927116394
born O O 0.9999986886978149
at O O 0.9999983310699463
less O O 0.9999992847442627
than O O 0.9999988079071045
28 O O 0.9999994039535522
weeks O O 0.9999997615814209
of O O 0.9999985694885254
gestation O O 0.9999982118606567
. O O 0.9999858140945435

Echocardiography O O 0.9998879432678223
showed O O 0.9999393224716187
severely O O 0.9999867677688599
decreased O O 0.9999892711639404
pulmonary O O 0.9999496936798096
blood O O 0.9999271631240845
flow O O 0.9999921321868896
. O O 0.9999529123306274

Hypoxaemia O O 0.9996682405471802
resolved O O 0.9999692440032959
quickly O O 0.9999920129776001
on O O 0.999804675579071
inhaled O O 0.9985950589179993
nitric B B 0.9900789260864258
oxide I I 0.9994414448738098
therapy O O 0.9992663264274597
. O O 0.9999759197235107

We O O 0.9999685287475586
suggest O O 0.9999661445617676
that O O 0.999969482421875
investigators O O 0.9999816417694092
involved O O 0.9999948740005493
in O O 0.9999884366989136
similar O O 0.9999699592590332
trials O O 0.9999833106994629
pay O O 0.9999839067459106
close O O 0.9999892711639404
attention O O 0.9999890327453613
to O O 0.9999492168426514
pulmonary O O 0.9999275207519531
pressure O O 0.99977046251297
if O O 0.999975323677063
hypoxaemia O O 0.9999697208404541
occurs O O 0.9999915361404419
after O O 0.9999222755432129
prophylactic O O 0.9998403787612915
administration O O 0.9999552965164185
of O O 0.9992203712463379
ibuprofen B B 0.9954547882080078
. O O 0.9999415874481201

Hyponatremia O O 0.9996610879898071
and O O 0.9999169111251831
syndrome O O 0.9998784065246582
of O O 0.9996843338012695
inappropriate O O 0.9980207681655884
anti O O 0.8201101422309875
- O O 0.9895630478858948
diuretic O O 0.9800612926483154
hormone O O 0.992456316947937
reported O O 0.9999830722808838
with O O 0.999944806098938
the O O 0.9999583959579468
use O O 0.9998216032981873
of O O 0.9977511763572693
Vincristine B B 0.9974640607833862
: O O 0.9997914433479309
an O O 0.999718964099884
over O O 0.9987708926200867
- O O 0.9999654293060303
representation O O 0.9999598264694214
of O O 0.9992457628250122
Asians O O 0.8948400020599365
? O O 0.9999057054519653

PURPOSE O O 0.9999755620956421
: O O 0.9999942779541016
This O O 0.9999945163726807
retrospective O O 0.9999865293502808
study O O 0.9999945163726807
used O O 0.9999575614929199
a O O 0.9999583959579468
pharmaceutical O O 0.9971416592597961
company O O 0.9999688863754272
' O O 0.9999837875366211
s O O 0.9999879598617554
global O O 0.9997231364250183
safety O O 0.9999589920043945
database O O 0.9999778270721436
to O O 0.9999837875366211
determine O O 0.9999918937683105
the O O 0.9999886751174927
reporting O O 0.9999785423278809
rate O O 0.9999877214431763
of O O 0.9999454021453857
hyponatremia O O 0.9898320436477661
and O O 0.9999336004257202
/ O O 0.9999758005142212
or O O 0.9999760389328003
syndrome O O 0.9999487400054932
of O O 0.9999449253082275
inappropriate O O 0.9996469020843506
secretion O O 0.9996383190155029
of O O 0.9960570335388184
anti O O 0.45344406366348267
- O O 0.838401198387146
diuretic O O 0.6223673224449158
hormone O O 0.6863763332366943
( O O 0.9995693564414978
SIADH O O 0.5599926114082336
) O O 0.9998581409454346
among O O 0.9997950196266174
vincristine B B 0.9990713596343994
- O O 0.9996693134307861
treated O O 0.9998779296875
patients O O 0.9999901056289673
and O O 0.9999892711639404
to O O 0.9999896287918091
explore O O 0.9999885559082031
the O O 0.9999934434890747
possibility O O 0.9999947547912598
of O O 0.999985933303833
at O O 0.9984172582626343
- O O 0.9999505281448364
risk O O 0.9999914169311523
population O O 0.9999796152114868
subgroups O O 0.9999842643737793
. O O 0.9999641180038452

METHOD O O 0.9996064305305481
: O O 0.9999691247940063
We O O 0.9999322891235352
searched O O 0.9999693632125854
the O O 0.9999483823776245
Eli O O 0.9762542247772217
Lilly O O 0.9985118508338928
and O O 0.9996095299720764
Company O O 0.999182403087616
' O O 0.999983549118042
s O O 0.9999864101409912
computerized O O 0.9999501705169678
adverse O O 0.9998829364776611
event O O 0.999996542930603
database O O 0.9999722242355347
for O O 0.9998883008956909
all O O 0.99993896484375
reported O O 0.9999837875366211
cases O O 0.9999864101409912
of O O 0.9999438524246216
hyponatremia O O 0.9456385970115662
and O O 0.9999074935913086
/ O O 0.9997610449790955
or O O 0.9999783039093018
SIADH O O 0.9809014201164246
as O O 0.9984014630317688
of O O 0.9999219179153442
1 O O 0.9993543028831482
November O O 0.9966161847114563
1999 O O 0.7699822187423706
that O O 0.9999704360961914
had O O 0.9999899864196777
been O O 0.9999934434890747
reported O O 0.9999912977218628
during O O 0.9998966455459595
the O O 0.9999712705612183
use O O 0.9998904466629028
of O O 0.9986415505409241
vincristine B B 0.9984133243560791
. O O 0.9999103546142578

RESULTS O O 0.9996837377548218
: O O 0.9999581575393677
A O O 0.9999669790267944
total O O 0.9999657869338989
of O O 0.9999821186065674
76 O O 0.9999421834945679
cases O O 0.9999874830245972
of O O 0.9999449253082275
hyponatremia O O 0.9971956014633179
and O O 0.9998779296875
/ O O 0.99983811378479
or O O 0.9999698400497437
SIADH O O 0.981313943862915
associated O O 0.9999551773071289
with O O 0.999804675579071
vincristine B B 0.9988971948623657
use O O 0.9997338652610779
were O O 0.9999688863754272
identified O O 0.9999854564666748
. O O 0.9999650716781616

The O O 0.9999799728393555
overall O O 0.9999352693557739
reporting O O 0.9999630451202393
rate O O 0.9999805688858032
was O O 0.9999593496322632
estimated O O 0.999968409538269
to O O 0.9999724626541138
be O O 0.9999862909317017
1 O O 0.9999673366546631
. O O 0.9999938011169434
3 O O 0.9999897480010986
/ O O 0.9999918937683105
100 O O 0.9999972581863403
, O O 0.9999986886978149
000 O O 0.9999887943267822
treated O O 0.9999639987945557
patients O O 0.9999839067459106
. O O 0.9999686479568481

The O O 0.9999874830245972
average O O 0.9999858140945435
age O O 0.9999839067459106
of O O 0.9999905824661255
patients O O 0.999992847442627
was O O 0.9999873638153076
35 O O 0.9999988079071045
. O O 0.9999973773956299
6 O O 0.9999964237213135
+ O O 0.9999969005584717
/ O O 0.9999876022338867
- O O 0.9999524354934692
28 O O 0.9999974966049194
. O O 0.9999980926513672
3 O O 0.999996542930603
years O O 0.9999978542327881
, O O 0.9999470710754395
and O O 0.9999685287475586
62 O O 0.9999960660934448
% O O 0.9999936819076538
were O O 0.9999797344207764
males O O 0.9998226761817932
. O O 0.9999732971191406

Approximately O O 0.9999756813049316
75 O O 0.9999911785125732
% O O 0.9999923706054688
of O O 0.9999803304672241
the O O 0.9999872446060181
patients O O 0.9999938011169434
were O O 0.9999755620956421
receiving O O 0.9999322891235352
treatment O O 0.9999833106994629
for O O 0.9999281167984009
leukemia O O 0.9999558925628662
or O O 0.9997528195381165
lymphoma O O 0.9999537467956543
. O O 0.999950647354126

Among O O 0.9999048709869385
the O O 0.9999669790267944
39 O O 0.9998841285705566
reports O O 0.9999861717224121
that O O 0.9999247789382935
included O O 0.9998966455459595
information O O 0.9999525547027588
on O O 0.9998760223388672
race O O 0.9572705626487732
, O O 0.9999432563781738
the O O 0.9999788999557495
racial O O 0.9999550580978394
distribution O O 0.9999911785125732
was O O 0.9999728202819824
: O O 0.9999489784240723
1 O O 0.9997110962867737
Black O O 0.9994158744812012
, O O 0.9999363422393799
3 O O 0.999575674533844
Caucasian O O 0.9914777874946594
, O O 0.9997490048408508
and O O 0.9998493194580078
35 O O 0.9892635941505432
Asian O O 0.9842230677604675
. O O 0.9999641180038452

CONCLUSION O O 0.999721348285675
: O O 0.999991774559021
Our O O 0.9998477697372437
data O O 0.9999914169311523
suggest O O 0.9999650716781616
that O O 0.999886155128479
Asian O O 0.8497377634048462
patients O O 0.9998581409454346
may O O 0.9999560117721558
be O O 0.9999772310256958
at O O 0.9999629259109497
increased O O 0.9999715089797974
risk O O 0.9999933242797852
of O O 0.9999380111694336
hyponatremia O O 0.9983709454536438
and O O 0.9998507499694824
/ O O 0.9997991919517517
or O O 0.999958872795105
SIADH O O 0.9928612112998962
associated O O 0.999980092048645
with O O 0.9997723698616028
vincristine B B 0.9988254904747009
use O O 0.9998027682304382
. O O 0.999957799911499

Although O O 0.9999839067459106
the O O 0.9999911785125732
overall O O 0.9999748468399048
reported O O 0.9999948740005493
rate O O 0.9999866485595703
of O O 0.9999134540557861
SIADH O O 0.9893112182617188
associated O O 0.9999452829360962
with O O 0.9995539784431458
vincristine B B 0.9989439845085144
is O O 0.9998717308044434
very O O 0.9999890327453613
low O O 0.9999916553497314
, O O 0.9999545812606812
physicians O O 0.9999951124191284
caring O O 0.9999943971633911
for O O 0.9999752044677734
Asian O O 0.9807977080345154
oncology O O 0.9998897314071655
patients O O 0.9999665021896362
should O O 0.999970555305481
be O O 0.9999940395355225
aware O O 0.9999895095825195
of O O 0.9999862909317017
this O O 0.9999778270721436
potential O O 0.9999905824661255
serious O O 0.999992847442627
but O O 0.9999788999557495
reversible O O 0.9999747276306152
adverse O O 0.999958872795105
event O O 0.9999984502792358
. O O 0.9999802112579346

Delayed O O 0.9997465014457703
toxicity O O 0.9999325275421143
of O O 0.9981935620307922
cyclophosphamide B B 0.9989374279975891
on O O 0.9996114373207092
the O O 0.9999630451202393
bladder O O 0.9997376799583435
of O O 0.9997889399528503
DBA O O 0.9557490944862366
/ O O 0.9998922348022461
2 O O 0.999556839466095
and O O 0.9996846914291382
C57BL O O 0.9944097399711609
/ O O 0.9984795451164246
6 O O 0.9986448884010315
female O O 0.9996541738510132
mouse O O 0.9999736547470093
. O O 0.9996016621589661

The O O 0.9999942779541016
present O O 0.9999895095825195
study O O 0.9999926090240479
describes O O 0.9999736547470093
the O O 0.9999886751174927
delayed O O 0.9999861717224121
development O O 0.9999971389770508
of O O 0.999984622001648
a O O 0.9999815225601196
severe O O 0.9999635219573975
bladder O O 0.9998799562454224
pathology O O 0.9999963045120239
in O O 0.9999545812606812
a O O 0.9999406337738037
susceptible O O 0.9999740123748779
strain O O 0.9999969005584717
of O O 0.9999759197235107
mice O O 0.9999891519546509
( O O 0.9998533725738525
DBA O O 0.9229074120521545
/ O O 0.999876856803894
2 O O 0.999530553817749
) O O 0.9999498128890991
but O O 0.9999479055404663
not O O 0.9999251365661621
in O O 0.9999402761459351
a O O 0.9999253749847412
resistant O O 0.9999390840530396
strain O O 0.9999891519546509
( O O 0.9998914003372192
C57BL O O 0.9966337084770203
/ O O 0.999896764755249
6 O O 0.999914288520813
) O O 0.999976634979248
when O O 0.9999173879623413
both O O 0.999896764755249
were O O 0.999985933303833
treated O O 0.9999736547470093
with O O 0.9999314546585083
a O O 0.9999761581420898
single O O 0.9999449253082275
300 O O 0.9993767142295837
mg O O 0.9999445676803589
/ O O 0.9999840259552002
kg O O 0.9999958276748657
dose O O 0.9998738765716553
of O O 0.9964112639427185
cyclophosphamide B B 0.9990235567092896
( O O 0.9935051202774048
CY B B 0.9984197616577148
) O O 0.9995286464691162
. O O 0.9999696016311646

Inbred O O 0.9987103939056396
DBA O O 0.9955637454986572
/ O O 0.9999028444290161
2 O O 0.9986000657081604
and O O 0.9996477365493774
C57BL O O 0.9940391778945923
/ O O 0.9998420476913452
6 O O 0.9998676776885986
female O O 0.9999910593032837
mice O O 0.9999914169311523
were O O 0.9999805688858032
injected O O 0.9999595880508423
with O O 0.9997382760047913
CY B B 0.9951767921447754
, O O 0.9797514081001282
and O O 0.9999785423278809
the O O 0.999992847442627
effect O O 0.9999736547470093
of O O 0.9999700784683228
the O O 0.999975323677063
drug O O 0.9986987113952637
on O O 0.9998887777328491
the O O 0.9999785423278809
bladder O O 0.999964714050293
was O O 0.9999927282333374
assessed O O 0.9999963045120239
during O O 0.9999597072601318
100 O O 0.9999638795852661
days O O 0.99998939037323
by O O 0.9999908208847046
light O O 0.9999698400497437
microscopy O O 0.9999853372573853
using O O 0.9999630451202393
different O O 0.999970555305481
staining O O 0.9999744892120361
procedures O O 0.9999897480010986
, O O 0.9999587535858154
and O O 0.9999637603759766
after O O 0.9999618530273438
30 O O 0.9999845027923584
days O O 0.9999911785125732
by O O 0.9999896287918091
conventional O O 0.9999945163726807
electron O O 0.9999481439590454
microscopy O O 0.9999890327453613
. O O 0.9999879598617554

Early O O 0.7883313894271851
CY B B 0.855952799320221
toxicity O I 0.9372749328613281
caused O O 0.9993187189102173
a O O 0.9999852180480957
typical O O 0.999984860420227
haemorrhagic O O 0.9993689656257629
cystitis O O 0.9996682405471802
in O O 0.9999502897262573
both O O 0.9998327493667603
strains O O 0.9999815225601196
that O O 0.9999727010726929
was O O 0.9999790191650391
completely O O 0.9999845027923584
repaired O O 0.9999973773956299
in O O 0.9999898672103882
about O O 0.9999958276748657
7 O O 0.9999433755874634
- O O 0.9999151229858398
10 O O 0.999994158744812
days O O 0.9999961853027344
. O O 0.9999539852142334

After O O 0.9999608993530273
30 O O 0.9999754428863525
days O O 0.9999854564666748
of O O 0.9999439716339111
CY B O 0.7729622721672058
injection O O 0.9665101170539856
ulcerous O O 0.9991198182106018
and O O 0.9995898604393005
non O O 0.9884993433952332
- O O 0.999634861946106
ulcerous O O 0.9998154044151306
forms O O 0.9999752044677734
of O O 0.9999483823776245
chronic O O 0.9988161325454712
cystitis O O 0.9942386150360107
appeared O O 0.999976634979248
in O O 0.9999555349349976
86 O O 0.9999649524688721
% O O 0.9999914169311523
of O O 0.9999557733535767
DBA O O 0.9502468109130859
/ O O 0.9991708993911743
2 O O 0.9949135780334473
mice O O 0.9999481439590454
but O O 0.9999673366546631
only O O 0.9999773502349854
in O O 0.9999635219573975
4 O O 0.9999366998672485
% O O 0.9999927282333374
of O O 0.9999587535858154
C57BL O O 0.9936049580574036
/ O O 0.9989781379699707
6 O O 0.9993618130683899
mice O O 0.999968409538269
. O O 0.9999599456787109

Delayed O O 0.996434211730957
cystitis O O 0.9990020394325256
was O O 0.9999583959579468
characterized O O 0.9999902248382568
by O O 0.9999610185623169
infiltration O O 0.9996315240859985
and O O 0.9999551773071289
transepithelial O O 0.9992992877960205
passage O O 0.99998939037323
into O O 0.9999659061431885
the O O 0.9999648332595825
lumen O O 0.9998134970664978
of O O 0.9998607635498047
inflammatory O O 0.9997448325157166
cells O O 0.9999908208847046
and O O 0.9999570846557617
by O O 0.9999457597732544
frequent O O 0.9998620748519897
exfoliation O O 0.9999058246612549
of O O 0.9999486207962036
the O O 0.9999692440032959
urothelium O O 0.9999086856842041
. O O 0.9999697208404541

Mast O O 0.9869019985198975
cells O O 0.9999752044677734
appeared O O 0.999937891960144
in O O 0.9997702240943909
the O O 0.9998903274536133
connective O O 0.9985828399658203
and O O 0.9991536140441895
muscular O O 0.9997953772544861
layers O O 0.9999797344207764
of O O 0.9999306201934814
the O O 0.9999643564224243
bladder O O 0.9994226694107056
at O O 0.9999696016311646
a O O 0.999988317489624
much O O 0.9999939203262329
higher O O 0.9999856948852539
number O O 0.9999923706054688
in O O 0.9999264478683472
DBA O O 0.9310421943664551
/ O O 0.9996147155761719
2 O O 0.9927319884300232
mice O O 0.9999538660049438
than O O 0.999948263168335
in O O 0.999908447265625
C57BL O O 0.9951156377792358
/ O O 0.9996446371078491
6 O O 0.9992855191230774
mice O O 0.9999738931655884
or O O 0.9999014139175415
untreated O O 0.9998533725738525
controls O O 0.9999796152114868
. O O 0.9999489784240723

Electron O O 0.9999357461929321
microscopy O O 0.9999730587005615
disclosed O O 0.9999457597732544
the O O 0.999987006187439
absence O O 0.9999707937240601
of O O 0.9999665021896362
the O O 0.9999759197235107
typical O O 0.9999097585678101
discoidal O O 0.9708946943283081
vesicles O O 0.9995734095573425
normally O O 0.9999532699584961
present O O 0.9999676942825317
in O O 0.9999157190322876
the O O 0.9999576807022095
cytoplasm O O 0.9998750686645508
of O O 0.9999023675918579
surface O O 0.9914344549179077
cells O O 0.9999867677688599
. O O 0.9999487400054932

Instead O O 0.9995812773704529
, O O 0.9999570846557617
numerous O O 0.9999412298202515
abnormal O O 0.9996713399887085
vesicles O O 0.9998364448547363
containing O O 0.9997945427894592
one O O 0.9998658895492554
or O O 0.9999806880950928
several O O 0.9998642206192017
dark O O 0.9963220357894897
granules O O 0.9964489936828613
were O O 0.9999493360519409
observed O O 0.9999902248382568
in O O 0.9998241066932678
the O O 0.9999414682388306
cytoplasm O O 0.9999285936355591
of O O 0.9998477697372437
cells O O 0.9999715089797974
from O O 0.9996435642242432
all O O 0.9992038607597351
the O O 0.9998890161514282
epithelial O O 0.999901294708252
layers O O 0.9999856948852539
. O O 0.9999442100524902

Delayed O O 0.9984136819839478
cystitis O O 0.9974539875984192
still O O 0.9999434947967529
persisted O O 0.9999644756317139
in O O 0.9998743534088135
DBA O O 0.9682726860046387
/ O O 0.9991163611412048
2 O O 0.9952380657196045
mice O O 0.999962329864502
100 O O 0.9999665021896362
days O O 0.9999977350234985
after O O 0.9999772310256958
treatment O O 0.9999655485153198
. O O 0.9999674558639526

These O O 0.999982476234436
results O O 0.9999911785125732
indicate O O 0.9999428987503052
that O O 0.9999121427536011
delayed O O 0.9995349645614624
toxicity O O 0.9997192025184631
of O O 0.9985223412513733
CY B B 0.9988831877708435
in O O 0.9994613528251648
female O O 0.9998503923416138
DBA O O 0.9318962097167969
/ O O 0.9988893866539001
2 O O 0.990217387676239
mice O O 0.9999618530273438
causes O O 0.999879002571106
a O O 0.9999697208404541
bladder O O 0.999929666519165
pathology O O 0.9999936819076538
that O O 0.9999858140945435
is O O 0.9999920129776001
not O O 0.9999920129776001
observed O O 0.9999938011169434
in O O 0.9999690055847168
C57BL O O 0.9957362413406372
/ O O 0.9997859597206116
6 O O 0.9996453523635864
mice O O 0.9999821186065674
. O O 0.9999727010726929

This O O 0.9998747110366821
pathology O O 0.999991774559021
resembles O O 0.9999624490737915
interstitial O O 0.9931058287620544
cystitis O O 0.999092698097229
in O O 0.9999498128890991
humans O O 0.9999309778213501
and O O 0.9999693632125854
could O O 0.9999779462814331
perhaps O O 0.9999947547912598
be O O 0.9999934434890747
used O O 0.9999923706054688
as O O 0.9999892711639404
an O O 0.9999815225601196
animal O O 0.9999890327453613
model O O 0.9999966621398926
for O O 0.9999891519546509
studies O O 0.9999948740005493
on O O 0.9999722242355347
the O O 0.9999858140945435
disease O O 0.9999922513961792
. O O 0.9999703168869019

High O O 0.9992069602012634
- O O 0.9999220371246338
dose O O 0.9987503290176392
5 B B 0.963320255279541
- I I 0.9950234889984131
fluorouracil I I 0.9999927282333374
/ O O 0.7978230118751526
folinic B B 0.7797873616218567
acid I I 0.9999414682388306
in O O 0.9997825026512146
combination O O 0.9999462366104126
with O O 0.9998155236244202
three O O 0.9958738684654236
- O O 0.9993520379066467
weekly O O 0.9981038570404053
mitomycin B B 0.9996868371963501
C I I 0.9999227523803711
in O O 0.9997155070304871
the O O 0.9999743700027466
treatment O O 0.9999902248382568
of O O 0.9999918937683105
advanced O O 0.9999948740005493
gastric O O 0.999204695224762
cancer O O 0.9999711513519287
. O O 0.9997847676277161

A O O 0.9999490976333618
phase O O 0.9998893737792969
II O O 0.9993822574615479
study O O 0.9999839067459106
. O O 0.9999732971191406

BACKGROUND O O 0.9994248151779175
: O O 0.9999768733978271
The O O 0.9999839067459106
24 O O 0.9999382495880127
- O O 0.9999666213989258
hour O O 0.999964714050293
continuous O O 0.9998488426208496
infusion O O 0.9999406337738037
of O O 0.9995991587638855
5 B B 0.982569694519043
- I I 0.99836665391922
fluorouracil I I 0.9999918937683105
( O O 0.9850334525108337
5 B B 0.9771528244018555
- I I 0.9793624877929688
FU I I 0.999980092048645
) O O 0.9665158987045288
and O O 0.9940701127052307
folinic B B 0.9879876375198364
acid I I 0.9999572038650513
( O O 0.9581013917922974
FA B B 0.9960558414459229
) O O 0.9981240630149841
as O O 0.9999868869781494
part O O 0.9999856948852539
of O O 0.999974250793457
several O O 0.999984860420227
new O O 0.9999555349349976
multidrug O O 0.9819434285163879
chemotherapy O O 0.997288703918457
regimens O O 0.9992071986198425
in O O 0.9999382495880127
advanced O O 0.9999237060546875
gastric O O 0.9980169534683228
cancer O O 0.9998741149902344
( O O 0.9995150566101074
AGC O B 0.9648805856704712
) O O 0.989355742931366
has O O 0.9999755620956421
shown O O 0.999993085861206
to O O 0.9999651908874512
be O O 0.999964714050293
effective O O 0.9999158382415771
, O O 0.9999918937683105
with O O 0.9999960660934448
low O O 0.999954342842102
toxicity O O 0.9999932050704956
. O O 0.9999834299087524

In O O 0.9999818801879883
a O O 0.9999951124191284
previous O O 0.9999902248382568
phase O O 0.9999524354934692
II O O 0.9991224408149719
study O O 0.9999922513961792
with O O 0.9999299049377441
3 O O 0.9580296277999878
- O O 0.9949501752853394
weekly O O 0.9910913109779358
bolus O O 0.9997606873512268
5 B B 0.9326854944229126
- I I 0.9816212058067322
FU I I 0.9999687671661377
, O O 0.6285600066184998
FA B B 0.9958608746528625
and O O 0.9021553993225098
mitomycin B B 0.9994997978210449
C I I 0.9997043013572693
( O O 0.9627686142921448
MMC B B 0.9930585622787476
) O O 0.9994578957557678
we O O 0.9999833106994629
found O O 0.9999961853027344
a O O 0.9999942779541016
low O O 0.999987006187439
toxicity O O 0.9999798536300659
rate O O 0.9999895095825195
and O O 0.9999631643295288
response O O 0.9999871253967285
rates O O 0.9999872446060181
comparable O O 0.9999828338623047
to O O 0.9999662637710571
those O O 0.9999911785125732
of O O 0.9998776912689209
regimens O O 0.9993187189102173
such O O 0.9997590184211731
as O O 0.9989593029022217
ELF O O 0.8390877842903137
, O O 0.5480456948280334
FAM O B 0.9825904965400696
or O O 0.7782188653945923
FAMTX O B 0.9592307209968567
, O O 0.9994533658027649
and O O 0.9999816417694092
a O O 0.999994158744812
promising O O 0.9999982118606567
median O O 0.9999966621398926
overall O O 0.9999966621398926
survival O O 0.999995231628418
. O O 0.9999902248382568

In O O 0.9999854564666748
order O O 0.9999960660934448
to O O 0.9999957084655762
improve O O 0.9999641180038452
this O O 0.9999693632125854
MMC B B 0.9903696179389954
- O O 0.9986415505409241
dependent O O 0.9998794794082642
schedule O O 0.9999803304672241
we O O 0.9999619722366333
initiated O O 0.999993085861206
a O O 0.9999946355819702
phase O O 0.9999691247940063
II O O 0.9997294545173645
study O O 0.9999923706054688
with O O 0.999930739402771
high O O 0.9993756413459778
- O O 0.9999167919158936
dose O O 0.9991410970687866
5 B B 0.9550631642341614
- I I 0.969692051410675
FU I I 0.9999748468399048
/ O I 0.7826159000396729
FA B I 0.7521166801452637
and O O 0.9971786737442017
3 O O 0.9363951683044434
- O O 0.9975829124450684
weekly O O 0.996773898601532
bolus O O 0.9998339414596558
MMC B B 0.9948884844779968
. O O 0.9999197721481323

PATIENTS O O 0.999944806098938
AND O O 0.9999716281890869
METHODS O O 0.9997445940971375
: O O 0.9999943971633911
From O O 0.9999805688858032
February O O 0.9998137354850769
, O O 0.9999182224273682
1998 O O 0.9383014440536499
to O O 0.9996227025985718
September O O 0.9448997974395752
, O O 0.9999746084213257
2000 O O 0.9999650716781616
we O O 0.9999778270721436
recruited O O 0.999889612197876
33 O O 0.9999717473983765
patients O O 0.9999951124191284
with O O 0.9998587369918823
AGC O O 0.6237759590148926
to O O 0.9999432563781738
receive O O 0.999936580657959
weekly O O 0.9998862743377686
24 O O 0.9994992017745972
- O O 0.9998948574066162
hour O O 0.9983166456222534
5 B B 0.7848078012466431
- I I 0.8301783800125122
FU I I 0.998561441898346
2 O O 0.6301196217536926
, O O 0.6556873321533203
600 O O 0.826472282409668
mg O O 0.9995003938674927
/ O O 0.9993815422058105
m O O 0.999764621257782
( O O 0.9988721013069153
2 O O 0.9697198271751404
) O O 0.9994958639144897
preceded O O 0.9998493194580078
by O O 0.9998658895492554
2 O O 0.9961793422698975
- O O 0.9998225569725037
hour O O 0.9913285374641418
FA B B 0.8876757621765137
500 O O 0.8868743777275085
mg O O 0.9995039701461792
/ O O 0.9986710548400879
m O O 0.9993492960929871
( O O 0.9989951252937317
2 O O 0.9426766633987427
) O O 0.9995006322860718
for O O 0.9999817609786987
6 O O 0.9999717473983765
weeks O O 0.9999974966049194
, O O 0.9999904632568359
followed O O 0.9999573230743408
by O O 0.9999902248382568
a O O 0.9999880790710449
2 O O 0.9999672174453735
- O O 0.9999886751174927
week O O 0.9999957084655762
rest O O 0.9999852180480957
period O O 0.9999881982803345
. O O 0.9999822378158569

Bolus O O 0.9575345516204834
MMC B B 0.9988873600959778
10 O O 0.9868053197860718
mg O O 0.999846339225769
/ O O 0.9994435906410217
m O O 0.9993141889572144
( O O 0.996093213558197
2 O O 0.9486538171768188
) O O 0.9954110980033875
was O O 0.9999486207962036
added O O 0.9999597072601318
in O O 0.9999771118164062
3 O O 0.9947475790977478
- O O 0.9999538660049438
weekly O O 0.9999886751174927
intervals O O 0.9999964237213135
. O O 0.999957799911499

Treatment O O 0.999790370464325
given O O 0.9999383687973022
on O O 0.9999926090240479
an O O 0.9999969005584717
outpatient O O 0.9999927282333374
basis O O 0.9999936819076538
, O O 0.9999912977218628
using O O 0.9999709129333496
portable O O 0.9985566735267639
pump O O 0.9994924068450928
systems O O 0.999875545501709
, O O 0.9999784231185913
was O O 0.9999821186065674
repeated O O 0.9999896287918091
on O O 0.9999868869781494
day O O 0.9999942779541016
57 O O 0.9999977350234985
. O O 0.9999833106994629

Patients O O 0.999971866607666
' O O 0.9999953508377075
characteristics O O 0.9999988079071045
were O O 0.9999938011169434
: O O 0.9999542236328125
male O O 0.9999790191650391
/ O O 0.9999440908432007
female O O 0.9999957084655762
ratio O O 0.9999330043792725
20 O O 0.9997298121452332
/ O O 0.9998447895050049
13 O O 0.9998931884765625
; O O 0.9999842643737793
median O O 0.9999822378158569
age O O 0.999963641166687
57 O O 0.9999988079071045
( O O 0.999968409538269
27 O O 0.9999934434890747
- O O 0.9996180534362793
75 O O 0.9999575614929199
) O O 0.9999878406524658
years O O 0.9999990463256836
; O O 0.9999732971191406
median O O 0.9912930130958557
WHO O O 0.9196893572807312
status O O 0.9999560117721558
1 O O 0.9998489618301392
( O O 0.9995086193084717
0 O O 0.9999324083328247
- O O 0.9980237483978271
2 O O 0.9999760389328003
) O O 0.9999063014984131
. O O 0.9999806880950928

18 O O 0.9999433755874634
patients O O 0.9999897480010986
had O O 0.9999798536300659
a O O 0.9999672174453735
primary O O 0.9999192953109741
AGC O O 0.7871559858322144
, O O 0.9998818635940552
and O O 0.9999724626541138
15 O O 0.9999479055404663
showed O O 0.9999673366546631
a O O 0.9999731779098511
relapsed O O 0.999982476234436
AGC O O 0.8883625864982605
. O O 0.9999638795852661

Median O O 0.999953031539917
follow O O 0.9999891519546509
- O O 0.9999901056289673
up O O 0.9999947547912598
was O O 0.999994158744812
11 O O 0.9999744892120361
. O O 0.9999985694885254
8 O O 0.9999880790710449
months O O 0.9999982118606567
( O O 0.9999780654907227
range O O 0.9999666213989258
of O O 0.9999656677246094
those O O 0.9984452128410339
surviving O O 0.9999121427536011
: O O 0.9999856948852539
2 O O 0.999992847442627
. O O 0.9999963045120239
7 O O 0.9999933242797852
- O O 0.999461829662323
11 O O 0.9999626874923706
. O O 0.9999969005584717
8 O O 0.9999898672103882
months O O 0.9999977350234985
) O O 0.9999738931655884
. O O 0.9999853372573853

RESULTS O O 0.9999030828475952
: O O 0.9999730587005615
32 O O 0.9999794960021973
patients O O 0.999984860420227
were O O 0.9999494552612305
evaluable O O 0.999903678894043
for O O 0.9999357461929321
response O O 0.9999552965164185
- O O 0.9998180270195007
complete O O 0.9974168539047241
remission O O 0.9999822378158569
9 O O 0.9999439716339111
. O O 0.9999841451644897
1 O O 0.9999938011169434
% O O 0.9999932050704956
( O O 0.9999485015869141
n O O 0.999629020690918
= O O 0.9996708631515503
3 O O 0.9999657869338989
) O O 0.9998902082443237
, O O 0.9999157190322876
partial O O 0.9996721744537354
remission O O 0.9999661445617676
45 O O 0.9999573230743408
. O O 0.9999856948852539
5 O O 0.9999945163726807
% O O 0.9999959468841553
( O O 0.9999679327011108
n O O 0.9996386766433716
= O O 0.9998719692230225
15 O O 0.9999933242797852
) O O 0.9999338388442993
, O O 0.9999619722366333
no O O 0.9999775886535645
change O O 0.9999982118606567
27 O O 0.9999918937683105
. O O 0.9999891519546509
3 O O 0.9999920129776001
% O O 0.9999961853027344
( O O 0.9999618530273438
n O O 0.9997808337211609
= O O 0.9999338388442993
9 O O 0.99997878074646
) O O 0.9999352693557739
, O O 0.9999184608459473
progressive O O 0.9999814033508301
disease O O 0.9999966621398926
15 O O 0.999985933303833
. O O 0.9999881982803345
1 O O 0.9999961853027344
% O O 0.999995231628418
( O O 0.9999628067016602
n O O 0.9997001886367798
= O O 0.9998936653137207
5 O O 0.9999858140945435
) O O 0.9999433755874634
. O O 0.9999737739562988

Median O O 0.9999328851699829
overall O O 0.9999402761459351
survival O O 0.9999690055847168
time O O 0.9999876022338867
was O O 0.999987006187439
10 O O 0.9999978542327881
. O O 0.9999980926513672
2 O O 0.9999947547912598
months O O 0.9999988079071045
[ O O 0.9999666213989258
95 O O 0.9999768733978271
% O O 0.9998568296432495
confidence O O 0.9982858300209045
interval O O 0.999976634979248
( O O 0.9988287091255188
CI O O 0.998619794845581
) O O 0.9999768733978271
: O O 0.9999134540557861
8 O O 0.9999876022338867
. O O 0.9999961853027344
7 O O 0.9999912977218628
- O O 0.9985712766647339
11 O O 0.9999852180480957
. O O 0.9999977350234985
6 O O 0.9999923706054688
] O O 0.9999853372573853
, O O 0.9999667406082153
and O O 0.9999704360961914
median O O 0.9999301433563232
progression O O 0.9996628761291504
- O O 0.9999746084213257
free O O 0.9999912977218628
survival O O 0.9999818801879883
time O O 0.9999909400939941
was O O 0.9999855756759644
7 O O 0.9999964237213135
. O O 0.9999973773956299
6 O O 0.9999940395355225
months O O 0.999998927116394
( O O 0.9999381303787231
95 O O 0.9998480081558228
% O O 0.9995280504226685
CI O O 0.998225748538971
: O O 0.9999195337295532
4 O O 0.999985933303833
. O O 0.9999704360961914
4 O O 0.9999688863754272
- O O 0.9982940554618835
10 O O 0.9999864101409912
. O O 0.9999939203262329
9 O O 0.9999895095825195
) O O 0.9999853372573853
. O O 0.9999856948852539

The O O 0.9999641180038452
worst O O 0.9999405145645142
toxicities O O 0.999819815158844
( O O 0.999790608882904
% O O 0.9999128580093384
) O O 0.9999678134918213
observed O O 0.9999382495880127
were O O 0.9999489784240723
( O O 0.995820164680481
CTC O O 0.8938167691230774
- O O 0.9733432531356812
NCI O O 0.7272868752479553
1 O O 0.9992086291313171
/ O O 0.9963012933731079
2 O O 0.9996821880340576
/ O O 0.9941436648368835
3 O O 0.9949775338172913
) O O 0.9998804330825806
: O O 0.9997124075889587
leukopenia O O 0.9994145631790161
45 O O 0.9999234676361084
. O O 0.9999867677688599
5 O O 0.9999872446060181
/ O O 0.9984831213951111
18 O O 0.999484658241272
. O O 0.9999929666519165
2 O O 0.9994860887527466
/ O O 0.993833065032959
6 O O 0.9998694658279419
. O O 0.9999897480010986
1 O O 0.9999916553497314
, O O 0.9998542070388794
thrombocytopenia O O 0.9989256262779236
33 O O 0.9999673366546631
. O O 0.9999940395355225
3 O O 0.9999781847000122
/ O O 0.9995225667953491
9 O O 0.9998865127563477
. O O 0.9999963045120239
1 O O 0.999993085861206
/ O O 0.9983471632003784
6 O O 0.9999619722366333
. O O 0.9999934434890747
1 O O 0.9999963045120239
, O O 0.9998244643211365
vomitus O O 0.9930844306945801
24 O O 0.9999566078186035
. O O 0.9999836683273315
2 O O 0.9996558427810669
/ O O 0.9970391988754272
9 O O 0.999535083770752
. O O 0.999996542930603
1 O O 0.9999953508377075
/ O O 0.9983592629432678
0 O O 0.9998282194137573
, O O 0.999890923500061
diarrhea O O 0.9999170303344727
36 O O 0.9999910593032837
. O O 0.9999939203262329
4 O O 0.9999542236328125
/ O O 0.997157096862793
6 O O 0.9997171759605408
. O O 0.9999942779541016
1 O O 0.9999853372573853
/ O O 0.994259238243103
3 O O 0.9999666213989258
. O O 0.9999921321868896
0 O O 0.999968409538269
, O O 0.9998688697814941
stomatitis O O 0.9872239828109741
18 O O 0.9979755282402039
. O O 0.9999779462814331
2 O O 0.9998935461044312
/ O O 0.996673583984375
9 O O 0.999115526676178
. O O 0.9999909400939941
1 O O 0.9999867677688599
/ O O 0.9970819354057312
0 O O 0.9998936653137207
, O O 0.9998134970664978
hand O O 0.9796063303947449
- O O 0.9993962049484253
foot O O 0.9966757297515869
syndrome O O 0.9999772310256958
12 O O 0.9998610019683838
. O O 0.9999436140060425
1 O O 0.9999910593032837
/ O O 0.9960249662399292
0 O O 0.9999812841415405
/ O O 0.9919226169586182
0 O O 0.9999450445175171
. O O 0.9999275207519531

Two O O 0.9999734163284302
patients O O 0.9999889135360718
developed O O 0.9999779462814331
hemolytic O O 0.989976704120636
- O O 0.9982609152793884
uremic O O 0.9908483028411865
syndrome O O 0.9999638795852661
( O O 0.9998430013656616
HUS O O 0.9747353196144104
) O O 0.9999436140060425
. O O 0.9999607801437378

CONCLUSIONS O O 0.9991983771324158
: O O 0.9999616146087646
High O O 0.9958434700965881
- O O 0.9998112320899963
dose O O 0.9991612434387207
5 B B 0.9838778972625732
- I I 0.9833139181137085
FU I I 0.9999653100967407
/ O O 0.534741222858429
FA B B 0.5486302375793457
/ O O 0.7089598178863525
MMC B B 0.998786985874176
is O O 0.9999384880065918
an O O 0.9999696016311646
effective O O 0.9999301433563232
and O O 0.9999923706054688
well O O 0.9999550580978394
- O O 0.9999946355819702
tolerated O O 0.999997615814209
outpatient O O 0.9999954700469971
regimen O O 0.9995187520980835
for O O 0.9998466968536377
AGC O B 0.8704943656921387
( O O 0.9998083710670471
objective O O 0.9999809265136719
response O O 0.9999949932098389
rate O O 0.999995231628418
54 O O 0.9999809265136719
. O O 0.9999978542327881
6 O O 0.9999983310699463
% O O 0.9999977350234985
) O O 0.9999822378158569
. O O 0.9999864101409912

It O O 0.9996318817138672
may O O 0.9999315738677979
serve O O 0.9999194145202637
as O O 0.9999617338180542
an O O 0.9999394416809082
alternative O O 0.9999867677688599
to O O 0.9997668862342834
cisplatin B B 0.9981971383094788
- O O 0.9992365837097168
containing O O 0.9984756112098694
regimens O O 0.999555766582489
; O O 0.9999696016311646
however O O 0.9999837875366211
, O O 0.999987006187439
it O O 0.9999940395355225
has O O 0.999987006187439
to O O 0.9999963045120239
be O O 0.9999969005584717
considered O O 0.9999927282333374
that O O 0.9999735355377197
possibly O O 0.9884761571884155
HUS O O 0.5111872553825378
may O O 0.9999328851699829
occur O O 0.9999865293502808
. O O 0.9999575614929199

Persistent O O 0.9999161958694458
sterile O O 0.9996527433395386
leukocyturia O O 0.9999386072158813
is O O 0.9999419450759888
associated O O 0.9999865293502808
with O O 0.9999802112579346
impaired O O 0.9999889135360718
renal O O 0.9999903440475464
function O O 0.9999891519546509
in O O 0.999940037727356
human O O 0.9877839684486389
immunodeficiency O O 0.9995641112327576
virus O O 0.9948503375053406
type O O 0.9982278943061829
1 O O 0.9799919724464417
- O O 0.9991647005081177
infected O O 0.9997137188911438
children O O 0.9999775886535645
treated O O 0.9999109506607056
with O O 0.9991880059242249
indinavir B B 0.9989920258522034
. O O 0.9999175071716309

BACKGROUND O O 0.9986805319786072
: O O 0.999977707862854
Prolonged O O 0.9999297857284546
administration O O 0.9999665021896362
of O O 0.9992450475692749
indinavir B B 0.999123752117157
is O O 0.9996806383132935
associated O O 0.9999873638153076
with O O 0.9999946355819702
the O O 0.9999942779541016
occurrence O O 0.9999961853027344
of O O 0.9999877214431763
a O O 0.9999855756759644
variety O O 0.99998939037323
of O O 0.9999682903289795
renal O O 0.9999679327011108
complications O O 0.999996542930603
in O O 0.9999791383743286
adults O O 0.9999874830245972
. O O 0.9999690055847168

These O O 0.9998772144317627
well O O 0.9996914863586426
- O O 0.9999845027923584
documented O O 0.9999690055847168
side O O 0.9999465942382812
effects O O 0.9999877214431763
have O O 0.9999692440032959
restricted O O 0.9999890327453613
the O O 0.9999758005142212
use O O 0.9999701976776123
of O O 0.9998525381088257
this O O 0.9961877465248108
potent O O 0.7769332528114319
protease O O 0.6996280550956726
inhibitor O O 0.6660346388816833
in O O 0.9994156360626221
children O O 0.9985870122909546
. O O 0.9999210834503174

DESIGN O O 0.9999872446060181
: O O 0.9999971389770508
A O O 0.9999914169311523
prospective O O 0.9999916553497314
study O O 0.9999923706054688
to O O 0.999995231628418
monitor O O 0.9999597072601318
indinavir B B 0.9995645880699158
- O O 0.9996540546417236
related O O 0.9998910427093506
nephrotoxicity O O 0.9999293088912964
in O O 0.9999620914459229
a O O 0.9999868869781494
cohort O O 0.9999834299087524
of O O 0.9999866485595703
30 O O 0.9999405145645142
human O O 0.9959482550621033
immunodeficiency O O 0.9990482926368713
virus O O 0.9946808218955994
type O O 0.9976671934127808
1 O O 0.9881711006164551
- O O 0.9997400641441345
infected O O 0.999911904335022
children O O 0.9999877214431763
treated O O 0.9999674558639526
with O O 0.9995230436325073
indinavir B B 0.9991059899330139
. O O 0.9999431371688843

METHODS O O 0.9985076785087585
: O O 0.99981290102005
Urinary O O 0.99564528465271
pH O O 0.9494564533233643
, O O 0.9999042749404907
albumin O O 0.976579487323761
, O O 0.9997945427894592
creatinine B B 0.9950030446052551
, O O 0.9997449517250061
the O O 0.9999947547912598
presence O O 0.9999879598617554
of O O 0.9999374151229858
erythrocytes O O 0.9997971653938293
, O O 0.999868631362915
leukocytes O O 0.9992877840995789
, O O 0.9998302459716797
bacteria O O 0.9972833395004272
and O O 0.9997922778129578
crystals O O 0.996417760848999
, O O 0.9999486207962036
and O O 0.9998526573181152
culture O O 0.9997983574867249
were O O 0.9999825954437256
analyzed O O 0.9999939203262329
every O O 0.9999885559082031
3 O O 0.9999653100967407
months O O 0.9999977350234985
for O O 0.9999892711639404
96 O O 0.9999831914901733
weeks O O 0.9999985694885254
. O O 0.9999895095825195

Serum O O 0.9990216493606567
creatinine B B 0.996966540813446
levels O O 0.9998651742935181
were O O 0.9999828338623047
routinely O O 0.999982476234436
determined O O 0.9999947547912598
at O O 0.9999629259109497
the O O 0.9999905824661255
same O O 0.9999756813049316
time O O 0.9999843835830688
points O O 0.9999958276748657
. O O 0.9999768733978271

Steady O O 0.9965589642524719
- O O 0.9999756813049316
state O O 0.9999665021896362
pharmacokinetics O O 0.999779999256134
of O O 0.9996689558029175
indinavir B B 0.9985169768333435
were O O 0.9998905658721924
done O O 0.9999926090240479
at O O 0.9999797344207764
week O O 0.9999991655349731
4 O O 0.9999933242797852
after O O 0.9999920129776001
the O O 0.9999959468841553
initiation O O 0.9999788999557495
of O O 0.9998493194580078
indinavir B B 0.9991849064826965
. O O 0.9999532699584961

RESULTS O O 0.9999356269836426
: O O 0.9999691247940063
The O O 0.9999939203262329
cumulative O O 0.9999887943267822
incidence O O 0.9999959468841553
of O O 0.9999858140945435
persistent O O 0.9999622106552124
sterile O O 0.9995423555374146
leukocyturia O O 0.9998420476913452
( O O 0.9999724626541138
> O O 0.9999613761901855
or O O 0.9999829530715942
= O O 0.9999897480010986
75 O O 0.999988317489624
cells O O 0.9999979734420776
/ O O 0.9999617338180542
micro O O 0.9999619722366333
L O O 0.9999823570251465
in O O 0.9999812841415405
at O O 0.999991774559021
least O O 0.9999946355819702
2 O O 0.9999847412109375
consecutive O O 0.9999914169311523
visits O O 0.9999938011169434
) O O 0.9999786615371704
after O O 0.999970555305481
96 O O 0.9999927282333374
weeks O O 0.9999967813491821
was O O 0.999970555305481
53 O O 0.999997615814209
% O O 0.9999979734420776
. O O 0.9999861717224121

Persistent O O 0.9999384880065918
sterile O O 0.9997292160987854
leukocyturia O O 0.9999125003814697
was O O 0.9999301433563232
frequently O O 0.9999756813049316
associated O O 0.9999802112579346
with O O 0.9999734163284302
a O O 0.999977707862854
mild O O 0.9999955892562866
increase O O 0.9999961853027344
in O O 0.9999897480010986
the O O 0.9999892711639404
urine O O 0.9996746778488159
albumin O O 0.8660524487495422
/ O O 0.9971166849136353
creatinine B B 0.9959167838096619
ratio O O 0.9984591007232666
and O O 0.999929666519165
by O O 0.9999650716781616
microscopic O O 0.9997572302818298
hematuria O O 0.9999743700027466
. O O 0.9999812841415405

The O O 0.9999880790710449
cumulative O O 0.9999779462814331
incidence O O 0.9999954700469971
of O O 0.9999805688858032
serum O O 0.999569833278656
creatinine B B 0.9981972575187683
levels O O 0.9998353719711304
> O O 0.999855637550354
50 O O 0.9999938011169434
% O O 0.9999920129776001
above O O 0.9999758005142212
normal O O 0.9999792575836182
was O O 0.9999861717224121
33 O O 0.9999947547912598
% O O 0.9999971389770508
after O O 0.9999773502349854
96 O O 0.9999916553497314
weeks O O 0.9999982118606567
. O O 0.9999783039093018

Children O O 0.9999853372573853
with O O 0.9999568462371826
persistent O O 0.9999606609344482
sterile O O 0.9956089854240417
leukocyturia O O 0.9997311234474182
more O O 0.9999500513076782
frequently O O 0.9999809265136719
had O O 0.9999690055847168
serum O O 0.9977971315383911
creatinine B B 0.9977831244468689
levels O O 0.9998793601989746
of O O 0.9999725818634033
50 O O 0.9999949932098389
% O O 0.9999973773956299
above O O 0.9999713897705078
normal O O 0.9999384880065918
than O O 0.9999809265136719
those O O 0.9999778270721436
children O O 0.9999905824661255
without O O 0.9999790191650391
persistent O O 0.9999890327453613
sterile O O 0.9977124929428101
leukocyturia O O 0.9997989535331726
. O O 0.9999814033508301

In O O 0.9998964071273804
children O O 0.9999964237213135
younger O O 0.9999966621398926
than O O 0.9999970197677612
5 O O 0.9999961853027344
. O O 0.9999984502792358
6 O O 0.9999715089797974
years O O 0.9999915361404419
, O O 0.9999642372131348
persistent O O 0.9999479055404663
sterile O O 0.9979131817817688
leukocyturia O O 0.9995046854019165
was O O 0.9999617338180542
significantly O O 0.9999799728393555
more O O 0.9999849796295166
frequent O O 0.9999923706054688
than O O 0.999990701675415
in O O 0.999957799911499
older O O 0.9999569654464722
children O O 0.9999959468841553
. O O 0.9999772310256958

A O O 0.9999538660049438
higher O O 0.9999426603317261
cumulative O O 0.9999840259552002
incidence O O 0.9999945163726807
of O O 0.9999823570251465
persistent O O 0.9999505281448364
leukocyturia O O 0.9999145269393921
was O O 0.9999681711196899
found O O 0.9999862909317017
in O O 0.9998723268508911
children O O 0.9999730587005615
with O O 0.9999556541442871
an O O 0.9999886751174927
area O O 0.9995274543762207
under O O 0.9999825954437256
the O O 0.9999923706054688
curve O O 0.9999945163726807
> O O 0.9999516010284424
19 O O 0.9999781847000122
mg O O 0.9999903440475464
/ O O 0.999975323677063
L O O 0.9995548129081726
x O O 0.9995120763778687
h O O 0.9880528450012207
or O O 0.999937891960144
a O O 0.9999792575836182
peak O O 0.9999393224716187
serum O O 0.9998464584350586
level O O 0.9998212456703186
of O O 0.9985602498054504
indinavir B B 0.9993855953216553
> O O 0.9996651411056519
12 O O 0.999984622001648
mg O O 0.999957799911499
/ O O 0.9999219179153442
L O O 0.994809627532959
. O O 0.9999626874923706

In O O 0.9998809099197388
4 O O 0.999043881893158
children O O 0.9999394416809082
, O O 0.999658465385437
indinavir B B 0.9997461438179016
was O O 0.9987521171569824
discontinued O O 0.9995191097259521
because O O 0.9999829530715942
of O O 0.9999665021896362
nephrotoxicity O O 0.9994903802871704
. O O 0.9999405145645142

Subsequently O O 0.9999778270721436
, O O 0.9999774694442749
the O O 0.9999939203262329
serum O O 0.9992783665657043
creatinine B B 0.9967638254165649
levels O O 0.9996417760848999
decreased O O 0.9999828338623047
, O O 0.9999908208847046
the O O 0.9999929666519165
urine O O 0.9991515874862671
albumin O O 0.8419787287712097
/ O O 0.9972374439239502
creatinine B B 0.9964855909347534
ratios O O 0.9313121438026428
returned O O 0.9999812841415405
to O O 0.9999880790710449
zero O O 0.9999725818634033
, O O 0.9999738931655884
and O O 0.9999910593032837
the O O 0.9999933242797852
leukocyturia O O 0.9999334812164307
disappeared O O 0.999982476234436
within O O 0.9999927282333374
3 O O 0.9999207258224487
months O O 0.9999977350234985
. O O 0.9999836683273315

CONCLUSIONS O O 0.9964718818664551
: O O 0.9999698400497437
Children O O 0.9999909400939941
treated O O 0.9997482895851135
with O O 0.9990682005882263
indinavir B B 0.9984826445579529
have O O 0.9998512268066406
a O O 0.9999865293502808
high O O 0.9999674558639526
cumulative O O 0.9999945163726807
incidence O O 0.9999977350234985
of O O 0.9999899864196777
persistent O O 0.9999831914901733
sterile O O 0.999711811542511
leukocyturia O O 0.9999392032623291
. O O 0.9999721050262451

Children O O 0.999951958656311
with O O 0.9999513626098633
persistent O O 0.9999635219573975
sterile O O 0.9977105855941772
leukocyturia O O 0.9997311234474182
more O O 0.9998835325241089
frequently O O 0.9999778270721436
had O O 0.9999752044677734
an O O 0.9999918937683105
increase O O 0.9999963045120239
in O O 0.9999872446060181
serum O O 0.9985314607620239
creatinine B B 0.9990432858467102
levels O O 0.9998132586479187
of O O 0.9999758005142212
> O O 0.9999632835388184
50 O O 0.9999966621398926
% O O 0.9999978542327881
above O O 0.9999890327453613
normal O O 0.9999704360961914
. O O 0.9999862909317017

Younger O O 0.9992006421089172
children O O 0.9999407529830933
have O O 0.9999617338180542
an O O 0.9999587535858154
additional O O 0.9999561309814453
risk O O 0.9999927282333374
for O O 0.9999822378158569
renal O O 0.9999176263809204
complications O O 0.9999943971633911
. O O 0.9999563694000244

The O O 0.9999804496765137
impairment O O 0.9999936819076538
of O O 0.9999663829803467
the O O 0.9999740123748779
renal O O 0.9999287128448486
function O O 0.9999648332595825
in O O 0.9998410940170288
these O O 0.9998941421508789
children O O 0.9998464584350586
occurred O O 0.999984622001648
in O O 0.9999754428863525
the O O 0.99998939037323
absence O O 0.9999815225601196
of O O 0.9999778270721436
clinical O O 0.9999895095825195
symptoms O O 0.9999979734420776
of O O 0.9999836683273315
nephrolithiasis O O 0.9999558925628662
. O O 0.9999618530273438

Indinavir B B 0.9993478655815125
- O O 0.9994008541107178
associated O O 0.9998713731765747
nephrotoxicity O O 0.9996742010116577
must O O 0.9999629259109497
be O O 0.9999949932098389
monitored O O 0.9999858140945435
closely O O 0.9999927282333374
, O O 0.9999862909317017
especially O O 0.9999871253967285
in O O 0.999984622001648
children O O 0.9999963045120239
with O O 0.9999898672103882
risk O O 0.9999704360961914
factors O O 0.999997615814209
such O O 0.9999904632568359
as O O 0.9999897480010986
persistent O O 0.9999856948852539
sterile O O 0.9998660087585449
leukocyturia O O 0.9999955892562866
, O O 0.999991774559021
age O O 0.9999979734420776
< O O 0.9999971389770508
5 O O 0.9999990463256836
. O O 0.9999994039535522
6 O O 0.9999980926513672
years O O 0.9999966621398926
, O O 0.9999920129776001
an O O 0.999996542930603
area O O 0.9995015859603882
under O O 0.9999189376831055
the O O 0.999995231628418
curve O O 0.999935507774353
of O O 0.9996750354766846
indinavir B B 0.9995285272598267
> O O 0.9987475872039795
19 O O 0.9998810291290283
mg O O 0.9999521970748901
/ O O 0.9999186992645264
L O O 0.9989596605300903
x O O 0.9995276927947998
h O O 0.9928079843521118
, O O 0.9999421834945679
and O O 0.999962329864502
a O O 0.9999650716781616
C O O 0.9526624083518982
( O O 0.9987962245941162
max O O 0.9894564747810364
) O O 0.9999734163284302
> O O 0.9999860525131226
12 O O 0.9999978542327881
mg O O 0.9999967813491821
/ O O 0.9999749660491943
L O O 0.9988620281219482
. O O 0.9999845027923584

Utility O O 0.9998881816864014
of O O 0.9996115565299988
troponin O B 0.9887463450431824
I O I 0.9968699812889099
in O O 0.9997798800468445
patients O O 0.9999903440475464
with O O 0.9999672174453735
cocaine B B 0.9935507774353027
- O O 0.9987044334411621
associated O O 0.9999325275421143
chest O O 0.9999891519546509
pain O O 0.9999955892562866
. O O 0.999972939491272

Baseline O O 0.9998156428337097
electrocardiogram O O 0.9999549388885498
abnormalities O O 0.999991774559021
and O O 0.9999086856842041
market O O 0.9972389936447144
elevations O O 0.9999866485595703
not O O 0.9999815225601196
associated O O 0.9999895095825195
with O O 0.9999576807022095
myocardial O O 0.9999630451202393
necrosis O O 0.9999673366546631
make O O 0.9999873638153076
accurate O O 0.9999960660934448
diagnosis O O 0.9999974966049194
of O O 0.9999735355377197
myocardial O O 0.9999822378158569
infarction O O 0.9997701048851013
( O O 0.9998558759689331
MI O O 0.9983546137809753
) O O 0.9999850988388062
difficult O O 0.9999961853027344
in O O 0.9999843835830688
patients O O 0.9999932050704956
with O O 0.9999735355377197
cocaine B B 0.9931633472442627
- O O 0.9993390440940857
associated O O 0.9999333620071411
chest O O 0.999988317489624
pain O O 0.9999939203262329
. O O 0.999984860420227

Troponin O O 0.7337614893913269
sampling O O 0.8650317192077637
may O O 0.999966025352478
offer O O 0.9999878406524658
greater O O 0.999982476234436
diagnostic O O 0.9999979734420776
utility O O 0.9999982118606567
in O O 0.9999932050704956
these O O 0.9999854564666748
patients O O 0.9999934434890747
. O O 0.999984622001648

OBJECTIVE O O 0.9999725818634033
: O O 0.9999961853027344
To O O 0.999995231628418
assess O O 0.9999951124191284
outcomes O O 0.9999963045120239
based O O 0.9999949932098389
on O O 0.9998911619186401
troponin O B 0.9810319542884827
positivity O O 0.9962659478187561
in O O 0.9999797344207764
patients O O 0.9999951124191284
with O O 0.9999858140945435
cocaine B O 0.9997257590293884
chest O O 0.9999862909317017
pain O O 0.9999885559082031
admitted O O 0.9999686479568481
for O O 0.999990701675415
exclusion O O 0.9999468326568604
of O O 0.9996565580368042
MI O O 0.5027338266372681
. O O 0.9999750852584839

METHODS O O 0.999687671661377
: O O 0.9999773502349854
Outcomes O O 0.999954104423523
were O O 0.9999876022338867
examined O O 0.9999747276306152
in O O 0.9999673366546631
patients O O 0.9999889135360718
admitted O O 0.9999083280563354
for O O 0.9999642372131348
possible O O 0.9998779296875
MI O O 0.9963874816894531
after O O 0.9981745481491089
cocaine B B 0.9960026144981384
use O O 0.9980114698410034
. O O 0.9999731779098511

All O O 0.9999805688858032
patients O O 0.9999914169311523
underwent O O 0.999985933303833
a O O 0.9999897480010986
rapid O O 0.9999761581420898
rule O O 0.9998834133148193
- O O 0.9999780654907227
in O O 0.9999574422836304
protocol O O 0.9999927282333374
that O O 0.999984622001648
included O O 0.9999686479568481
serial O O 0.9999408721923828
sampling O O 0.9999783039093018
of O O 0.9998194575309753
creatine B B 0.8728162050247192
kinase O O 0.8195838332176208
( O O 0.9992363452911377
CK O O 0.8670343160629272
) O O 0.9999148845672607
, O O 0.9990713596343994
CK O O 0.9006097316741943
- O O 0.9825512766838074
MB O O 0.9900249242782593
, O O 0.9994661211967468
and O O 0.9997677206993103
cardiac O O 0.9985005855560303
troponin O O 0.599707841873169
I O O 0.7773284912109375
( O O 0.9982047080993652
cTnI O O 0.873505175113678
) O O 0.9999573230743408
over O O 0.9999752044677734
eight O O 0.999994158744812
hours O O 0.999992847442627
. O O 0.9999821186065674

Outcomes O O 0.9993740916252136
included O O 0.9998840093612671
CK O O 0.7031747102737427
- O O 0.92717444896698
MB O O 0.8592158555984497
MI O O 0.9932429194450378
( O O 0.998239278793335
CK O O 0.7880404591560364
- O O 0.9709845185279846
MB O O 0.968690037727356
> O O 0.9998272061347961
or O O 0.9999216794967651
= O O 0.9999535083770752
8 O O 0.9994495511054993
ng O O 0.9998810291290283
/ O O 0.999964714050293
mL O O 0.999994158744812
with O O 0.9999681711196899
a O O 0.9999830722808838
relative O O 0.9999313354492188
index O O 0.999961256980896
[ O O 0.9995637536048889
( O O 0.9966500401496887
CK O O 0.870801568031311
- O O 0.9934884309768677
MB O O 0.9956017732620239
x O O 0.9997240900993347
100 O O 0.9513189792633057
) O O 0.9993717074394226
/ O O 0.9999374151229858
total O O 0.9335214495658875
CK O O 0.7212821245193481
] O O 0.9999600648880005
> O O 0.9999350309371948
or O O 0.9999688863754272
= O O 0.9999843835830688
4 O O 0.9999650716781616
, O O 0.9999791383743286
cardiac O O 0.9999644756317139
death O O 0.999994158744812
, O O 0.9999386072158813
and O O 0.9999738931655884
significant O O 0.9999885559082031
coronary O O 0.9999551773071289
disease O O 0.999997615814209
( O O 0.9999916553497314
> O O 0.9999942779541016
or O O 0.9999927282333374
= O O 0.9999953508377075
50 O O 0.9999929666519165
% O O 0.9999979734420776
) O O 0.999982476234436
. O O 0.999963641166687

RESULTS O O 0.9999284744262695
: O O 0.9998675584793091
Of O O 0.9999525547027588
the O O 0.9999865293502808
246 O O 0.9999923706054688
admitted O O 0.9999866485595703
patients O O 0.9999959468841553
, O O 0.9999480247497559
34 O O 0.9999737739562988
( O O 0.9999527931213379
14 O O 0.9999918937683105
% O O 0.999993085861206
) O O 0.9999392032623291
met O O 0.9999141693115234
CK O O 0.7900686860084534
- O O 0.9892701506614685
MB O O 0.9629430174827576
criteria O O 0.999966025352478
for O O 0.9999107122421265
MI O O 0.976262629032135
and O O 0.9999076128005981
38 O O 0.9998962879180908
( O O 0.9999285936355591
16 O O 0.9999932050704956
% O O 0.999995231628418
) O O 0.9999462366104126
had O O 0.9999420642852783
cTnI O O 0.7783876061439514
elevations O O 0.9999277591705322
. O O 0.9999669790267944

Angiography O O 0.9999634027481079
was O O 0.9999809265136719
performed O O 0.9999935626983643
in O O 0.9999586343765259
29 O O 0.9999909400939941
of O O 0.9999852180480957
38 O O 0.9999911785125732
patients O O 0.9999951124191284
who O O 0.9999411106109619
were O O 0.9999121427536011
cTnI O O 0.7724533081054688
- O O 0.9985373020172119
positive O O 0.9992040991783142
, O O 0.9999572038650513
with O O 0.99997878074646
significant O O 0.9999444484710693
disease O O 0.999988317489624
present O O 0.9999765157699585
in O O 0.9999604225158691
25 O O 0.998869001865387
( O O 0.9999524354934692
86 O O 0.9999887943267822
% O O 0.9999966621398926
) O O 0.9999501705169678
. O O 0.9999734163284302

Three O O 0.9998784065246582
of O O 0.9999771118164062
the O O 0.9999885559082031
four O O 0.9999885559082031
patients O O 0.999995231628418
without O O 0.9999871253967285
significant O O 0.9999881982803345
disease O O 0.9999942779541016
who O O 0.9999151229858398
had O O 0.9998470544815063
cTnI O O 0.8693642020225525
elevations O O 0.999450147151947
met O O 0.9998683929443359
CK O O 0.8317899107933044
- O O 0.9892461895942688
MB O O 0.9549972414970398
criteria O O 0.9999638795852661
for O O 0.9998677968978882
MI O O 0.8807927966117859
, O O 0.9998435974121094
and O O 0.9998648166656494
the O O 0.9999598264694214
other O O 0.9999662637710571
had O O 0.9999749660491943
a O O 0.9999892711639404
peak O O 0.9998540878295898
CK O O 0.7767237424850464
- O O 0.94386887550354
MB O O 0.8454525470733643
level O O 0.999961256980896
of O O 0.9999818801879883
13 O O 0.9999711513519287
ng O O 0.9999120235443115
/ O O 0.9999806880950928
mL O O 0.9999971389770508
. O O 0.9999767541885376

Sensitivities O O 0.9998213648796082
, O O 0.9999438524246216
specificities O O 0.9999850988388062
, O O 0.9999439716339111
and O O 0.9999665021896362
positive O O 0.9999696016311646
and O O 0.9999610185623169
negative O O 0.9999657869338989
likelihood O O 0.9999868869781494
ratios O O 0.9999966621398926
for O O 0.9999755620956421
predicting O O 0.9999921321868896
cardiac O O 0.9999909400939941
death O O 0.9999973773956299
or O O 0.9999818801879883
significant O O 0.9999793767929077
disease O O 0.9999970197677612
were O O 0.9999635219573975
high O O 0.9999686479568481
for O O 0.9996336698532104
both O O 0.9978761672973633
CK O O 0.6524109244346619
- O O 0.9210304617881775
MB O O 0.8790298104286194
MI O O 0.5257912874221802
and O O 0.998103141784668
cTnI O O 0.6111998558044434
and O O 0.9999455213546753
were O O 0.9999769926071167
not O O 0.9999970197677612
significantly O O 0.999995231628418
different O O 0.9999951124191284
. O O 0.9999778270721436

CONCLUSIONS O O 0.998167872428894
: O O 0.9999749660491943
Most O O 0.9999397993087769
patients O O 0.9999884366989136
with O O 0.9999231100082397
cTnI O O 0.8435459136962891
elevations O O 0.9998440742492676
meet O O 0.9999250173568726
CK O O 0.8703352808952332
- O O 0.992661714553833
MB O O 0.9862511157989502
criteria O O 0.9999654293060303
for O O 0.9998964071273804
MI O O 0.9464921951293945
, O O 0.9999648332595825
as O O 0.9999592304229736
well O O 0.9999589920043945
as O O 0.9999620914459229
have O O 0.9999741315841675
a O O 0.9999864101409912
high O O 0.9999678134918213
incidence O O 0.9999974966049194
of O O 0.9999886751174927
underlying O O 0.9999563694000244
significant O O 0.9999706745147705
disease O O 0.9999966621398926
. O O 0.9999619722366333

Troponin O B 0.9869261980056763
appears O O 0.9998677968978882
to O O 0.999954342842102
have O O 0.9999641180038452
an O O 0.9999849796295166
equivalent O O 0.9999586343765259
diagnostic O O 0.9999963045120239
accuracy O O 0.9999979734420776
compared O O 0.9999939203262329
with O O 0.9999154806137085
CK O O 0.5833666324615479
- O O 0.844989001750946
MB O O 0.43395885825157166
for O O 0.9999462366104126
diagnosing O O 0.9999912977218628
necrosis O O 0.99982750415802
in O O 0.9999486207962036
patients O O 0.9999935626983643
with O O 0.9999728202819824
cocaine B B 0.9918321371078491
- O O 0.9988414645195007
associated O O 0.9999383687973022
chest O O 0.9999873638153076
pain O O 0.9999942779541016
and O O 0.9999669790267944
suspected O O 0.9998981952667236
MI O O 0.99857497215271
. O O 0.9999537467956543

Acute O O 0.9999366998672485
interstitial O O 0.9996622800827026
nephritis O O 0.9999643564224243
due O O 0.9999487400054932
to O O 0.9854977130889893
nicergoline B B 0.9974117875099182
( O O 0.9963080883026123
Sermion B O 0.5934721827507019
) O O 0.9996154308319092
. O O 0.9998958110809326

We O O 0.9999512434005737
report O O 0.9999940395355225
a O O 0.999990701675415
case O O 0.9999933242797852
of O O 0.9999833106994629
acute O O 0.9999275207519531
interstitial O O 0.9993938207626343
nephritis O O 0.999972939491272
( O O 0.9999154806137085
AIN O O 0.992274820804596
) O O 0.9999856948852539
due O O 0.9999440908432007
to O O 0.9581668376922607
nicergoline B B 0.9949125051498413
( O O 0.9968982934951782
Sermion B O 0.4887095093727112
) O O 0.9998950958251953
. O O 0.9999600648880005

A O O 0.9999830722808838
50 O O 0.9999927282333374
- O O 0.9999934434890747
year O O 0.9999966621398926
- O O 0.9999951124191284
old O O 0.9999960660934448
patient O O 0.9999903440475464
admitted O O 0.9999589920043945
to O O 0.9999922513961792
our O O 0.9999916553497314
hospital O O 0.9999957084655762
for O O 0.9999732971191406
fever O O 0.9998840093612671
and O O 0.9999796152114868
acute O O 0.9999871253967285
renal O O 0.9999935626983643
failure O O 0.9999887943267822
. O O 0.999971866607666

Before O O 0.9999479055404663
admission O O 0.999990701675415
, O O 0.9999285936355591
he O O 0.9999275207519531
had O O 0.9999663829803467
been O O 0.9999674558639526
taking O O 0.9959241151809692
nicergoline B B 0.9992908239364624
and O O 0.8688287138938904
bendazac B B 0.9985498785972595
lysine I I 0.9978252649307251
due O O 0.9998676776885986
to O O 0.999977707862854
retinal O O 0.9999605417251587
vein O O 0.9997711777687073
occlusion O O 0.9999833106994629
at O O 0.9999703168869019
ophthalmologic O O 0.9999872446060181
department O O 0.9999916553497314
. O O 0.999962329864502

Thereafter O O 0.9999332427978516
, O O 0.9999881982803345
he O O 0.9999762773513794
experienced O O 0.9999889135360718
intermittent O O 0.9999840259552002
fever O O 0.999901294708252
and O O 0.9999829530715942
skin O O 0.9999762773513794
rash O O 0.9999136924743652
. O O 0.9999781847000122

On O O 0.9999347925186157
admission O O 0.9999897480010986
, O O 0.9999847412109375
clinical O O 0.9999914169311523
symptoms O O 0.9999980926513672
( O O 0.9999654293060303
i O O 0.999961256980896
. O O 0.9999750852584839
e O O 0.9999874830245972
. O O 0.9999655485153198
arthralgia O O 0.9999704360961914
and O O 0.999971866607666
fever O O 0.9999954700469971
) O O 0.9999866485595703
and O O 0.9999877214431763
laboratory O O 0.999983549118042
findings O O 0.999996542930603
( O O 0.9999598264694214
i O O 0.9998646974563599
. O O 0.9999818801879883
e O O 0.9999850988388062
. O O 0.9999723434448242
eosinophilia O O 0.9985975623130798
and O O 0.9999533891677856
renal O O 0.9999722242355347
failure O O 0.9999912977218628
) O O 0.9999833106994629
suggested O O 0.9999681711196899
AIN O O 0.9588252902030945
, O O 0.999962329864502
and O O 0.9999634027481079
which O O 0.999982476234436
was O O 0.9999847412109375
confirmed O O 0.9999867677688599
by O O 0.9999959468841553
pathologic O O 0.9999957084655762
findings O O 0.9999977350234985
on O O 0.9999922513961792
renal O O 0.9999890327453613
biopsy O O 0.9999817609786987
. O O 0.9999802112579346

A O O 0.9999014139175415
lymphocyte O O 0.9967141151428223
transformation O O 0.9997342228889465
test O O 0.9999779462814331
demonstrated O O 0.9999439716339111
a O O 0.9999042749404907
positive O O 0.9998717308044434
result O O 0.9999388456344604
against O O 0.9961354732513428
nicergoline B B 0.9965577721595764
. O O 0.9999315738677979

Treatment O O 0.9999419450759888
was O O 0.9999903440475464
consisted O O 0.9999768733978271
of O O 0.9998038411140442
withdrawal O O 0.9995760321617126
of O O 0.992438018321991
nicergoline B B 0.9992367029190063
and O O 0.9923059344291687
intravenous O O 0.9999215602874756
methylprednisolone B B 0.9989296793937683
, O O 0.9992673993110657
and O O 0.9999831914901733
his O O 0.9999891519546509
renal O O 0.9999628067016602
function O O 0.9999828338623047
was O O 0.9999806880950928
completely O O 0.9999911785125732
recovered O O 0.9999940395355225
. O O 0.9999796152114868

To O O 0.9999892711639404
our O O 0.9999872446060181
knowledge O O 0.9999936819076538
, O O 0.9999779462814331
this O O 0.999991774559021
is O O 0.999991774559021
the O O 0.9999932050704956
first O O 0.9999960660934448
report O O 0.9999958276748657
of O O 0.9999278783798218
nicergoline B B 0.9990826845169067
- O O 0.999411940574646
associated O O 0.9997561573982239
AIN O O 0.999893069267273
. O O 0.9999754428863525

Neuroleptic O O 0.9995934367179871
malignant O O 0.9999933242797852
syndrome O O 0.999987006187439
complicated O O 0.9999630451202393
by O O 0.9999651908874512
massive O O 0.9999308586120605
intestinal O O 0.9999663829803467
bleeding O O 0.999982476234436
in O O 0.9999784231185913
a O O 0.9999891519546509
patient O O 0.9999914169311523
with O O 0.9999716281890869
chronic O O 0.9997792840003967
renal O O 0.9999327659606934
failure O O 0.999984622001648
. O O 0.9999712705612183

A O O 0.9999592304229736
patient O O 0.9999808073043823
with O O 0.9999181032180786
chronic O O 0.9979901313781738
renal O O 0.9999808073043823
failure O O 0.9999855756759644
( O O 0.9999312162399292
CRF O O 0.9766303300857544
) O O 0.9999656677246094
developed O O 0.999961256980896
neuroleptic O O 0.9999148845672607
malignant O O 0.9999946355819702
syndrome O O 0.9999886751174927
( O O 0.9999493360519409
NMS O O 0.9972736239433289
) O O 0.9999842643737793
after O O 0.9998987913131714
administration O O 0.9998807907104492
of O O 0.99962317943573
risperidone B B 0.9972538352012634
and O O 0.9600896835327148
levomepromazine B B 0.998176097869873
. O O 0.9999210834503174

In O O 0.999943733215332
addition O O 0.9999613761901855
to O O 0.9999611377716064
the O O 0.9999736547470093
typical O O 0.9999680519104004
symptoms O O 0.9999932050704956
of O O 0.9999688863754272
NMS O O 0.9931742548942566
, O O 0.9999274015426636
massive O O 0.9999436140060425
intestinal O O 0.9999643564224243
bleeding O O 0.9998995065689087
was O O 0.9999581575393677
observed O O 0.9999926090240479
during O O 0.9999423027038574
the O O 0.9999862909317017
episode O O 0.9999933242797852
. O O 0.9999657869338989

This O O 0.9999842643737793
report O O 0.999994158744812
suggests O O 0.9999641180038452
that O O 0.9997484087944031
NMS O O 0.8962686657905579
in O O 0.9999415874481201
a O O 0.9999879598617554
patient O O 0.9999895095825195
with O O 0.9998995065689087
CRF O O 0.8711974024772644
may O O 0.9998735189437866
be O O 0.9999566078186035
complicated O O 0.9999706745147705
by O O 0.9999254941940308
intestinal O O 0.9998875856399536
bleeding O O 0.9999282360076904
and O O 0.9999755620956421
needs O O 0.9999725818634033
special O O 0.9999791383743286
caution O O 0.999924898147583
for O O 0.999923586845398
this O O 0.9999358654022217
complication O O 0.9999855756759644
. O O 0.9999784231185913

Blood O O 0.9906988739967346
brain O O 0.9999539852142334
barrier O O 0.9999269247055054
in O O 0.9999030828475952
right O O 0.9945886135101318
- O O 0.9997301697731018
and O O 0.9998108744621277
left O O 0.9894921779632568
- O O 0.9992570281028748
pawed O O 0.995784342288971
female O O 0.9995755553245544
rats O O 0.999980092048645
assessed O O 0.9999760389328003
by O O 0.9999899864196777
a O O 0.9999886751174927
new O O 0.9999890327453613
staining O O 0.9999707937240601
method O O 0.9999899864196777
. O O 0.9999681711196899

The O O 0.999987006187439
asymmetrical O O 0.9999786615371704
breakdown O O 0.9999805688858032
of O O 0.9999681711196899
the O O 0.9999583959579468
blood O O 0.9880810976028442
- O O 0.9994691014289856
brain O O 0.9999470710754395
barrier O O 0.9999819993972778
( O O 0.9998890161514282
BBB O O 0.9837108254432678
) O O 0.9999547004699707
was O O 0.9999796152114868
studied O O 0.9999748468399048
in O O 0.9999834299087524
female O O 0.9999758005142212
rats O O 0.9999949932098389
. O O 0.999956488609314

Paw O O 0.9969136714935303
preference O O 0.9999072551727295
was O O 0.9999746084213257
assessed O O 0.9999890327453613
by O O 0.9999920129776001
a O O 0.9999740123748779
food O O 0.9692555069923401
reaching O O 0.999884843826294
test O O 0.9999792575836182
. O O 0.9999719858169556

Adrenaline B B 0.9036574959754944
- O O 0.996369481086731
induced O O 0.9999078512191772
hypertension O O 0.9993646740913391
was O O 0.9999490976333618
used O O 0.9999309778213501
to O O 0.9999473094940186
destroy O O 0.9994990825653076
the O O 0.9997518658638
BBB O O 0.8005037903785706
, O O 0.9999418258666992
which O O 0.9999181032180786
was O O 0.9999688863754272
evaluated O O 0.9999971389770508
using O O 0.999963641166687
triphenyltetrazolium B B 0.9982567429542542
( O O 0.9941679239273071
TTC B B 0.9304379224777222
) O O 0.9988813996315002
staining O O 0.9999616146087646
of O O 0.9999449253082275
the O O 0.9999825954437256
brain O O 0.9999504089355469
slices O O 0.9999815225601196
just O O 0.9999713897705078
after O O 0.9999645948410034
giving O O 0.9994920492172241
adrenaline B B 0.9956130981445312
for O O 0.9994137287139893
30 O O 0.9998651742935181
s O O 0.9954747557640076
. O O 0.999968409538269

In O O 0.9998979568481445
normal O O 0.9995675683021545
rats O O 0.9999864101409912
, O O 0.9999537467956543
the O O 0.9999884366989136
whole O O 0.9996938705444336
brain O O 0.9999548196792603
sections O O 0.9999841451644897
exhibited O O 0.99991774559021
complete O O 0.996364176273346
staining O O 0.9999213218688965
with O O 0.9991845488548279
TTC B O 0.6415608525276184
. O O 0.9999125003814697

After O O 0.9999125003814697
adrenaline B B 0.9960307478904724
infusion O O 0.9992204904556274
for O O 0.9999271631240845
30 O O 0.9998800754547119
s O O 0.9942309856414795
, O O 0.999931812286377
there O O 0.9999401569366455
were O O 0.9999675750732422
large O O 0.9999712705612183
unstained O O 0.9998700618743896
areas O O 0.9999538660049438
in O O 0.9999256134033203
the O O 0.9999687671661377
left O O 0.9999536275863647
brain O O 0.999992847442627
in O O 0.9999080896377563
right O O 0.9944527745246887
- O O 0.9966038465499878
pawed O O 0.989825427532196
animals O O 0.9999717473983765
, O O 0.9998732805252075
and O O 0.9995748400688171
vice O O 0.9982718229293823
versa O O 0.9999915361404419
in O O 0.9999171495437622
left O O 0.9935465455055237
- O O 0.9941457509994507
pawed O O 0.9907909631729126
animals O O 0.9999741315841675
. O O 0.9999704360961914

Similar O O 0.9999581575393677
results O O 0.9999818801879883
were O O 0.9999749660491943
obtained O O 0.999995231628418
in O O 0.9993715882301331
seizure O O 0.988165020942688
- O O 0.9995409250259399
induced O O 0.999815046787262
breakdown O O 0.9985975623130798
of O O 0.9963866472244263
BBB O B 0.8675526976585388
. O O 0.999748170375824

These O O 0.9999744892120361
results O O 0.9999918937683105
were O O 0.9999411106109619
explained O O 0.9999854564666748
by O O 0.9999573230743408
an O O 0.9999325275421143
asymmetric O O 0.9999767541885376
cerebral O O 0.9999673366546631
blood O O 0.9997977614402771
flow O O 0.9999715089797974
depending O O 0.9999498128890991
upon O O 0.9999721050262451
the O O 0.9999642372131348
paw O O 0.9981936812400818
preference O O 0.9999366998672485
in O O 0.9998881816864014
rats O O 0.9997099041938782
. O O 0.9999587535858154

It O O 0.9999887943267822
was O O 0.999980092048645
suggested O O 0.9999911785125732
that O O 0.9999771118164062
this O O 0.9999890327453613
new O O 0.9999767541885376
method O O 0.9999904632568359
and O O 0.9999910593032837
the O O 0.9999963045120239
results O O 0.9999932050704956
are O O 0.9999574422836304
consistent O O 0.9999686479568481
with O O 0.999896764755249
contralateral O O 0.996921956539154
motor O O 0.9994305968284607
control O O 0.9999165534973145
that O O 0.9999245405197144
may O O 0.9999328851699829
be O O 0.999964714050293
important O O 0.9999041557312012
in O O 0.9999669790267944
determining O O 0.9999713897705078
the O O 0.9999691247940063
dominant O O 0.9998230338096619
cerebral O O 0.999961256980896
hemisphere O O 0.9999816417694092
in O O 0.9998064637184143
animals O O 0.9991270899772644
. O O 0.9999467134475708

Carvedilol B B 0.9984136819839478
protects O O 0.9971369504928589
against O O 0.9981995820999146
doxorubicin B B 0.9996225833892822
- O O 0.9997110962867737
induced O O 0.9999350309371948
mitochondrial O O 0.9999557733535767
cardiomyopathy O O 0.9999890327453613
. O O 0.9995328187942505

Several O O 0.9992425441741943
cytopathic O O 0.9996160268783569
mechanisms O O 0.9998515844345093
have O O 0.9999629259109497
been O O 0.9999759197235107
suggested O O 0.9999381303787231
to O O 0.9998477697372437
mediate O O 0.9999322891235352
the O O 0.9999674558639526
dose O O 0.9990191459655762
- O O 0.9999560117721558
limiting O O 0.9999469518661499
cumulative O O 0.9992510676383972
and O O 0.9999023675918579
irreversible O O 0.9999762773513794
cardiomyopathy O O 0.9999958276748657
caused O O 0.9999947547912598
by O O 0.9998445510864258
doxorubicin B B 0.9995912909507751
. O O 0.9999183416366577

Recent O O 0.9999808073043823
evidence O O 0.9999819993972778
indicates O O 0.9998985528945923
that O O 0.9998237490653992
oxidative O O 0.9542869329452515
stress O O 0.9988934397697449
and O O 0.9995662569999695
mitochondrial O O 0.9984288811683655
dysfunction O O 0.9999743700027466
are O O 0.9998877048492432
key O O 0.9996935129165649
factors O O 0.9999897480010986
in O O 0.9999812841415405
the O O 0.9999638795852661
pathogenic O O 0.9999935626983643
process O O 0.9999973773956299
. O O 0.9999692440032959

The O O 0.9999918937683105
objective O O 0.9999979734420776
of O O 0.9999932050704956
this O O 0.9999920129776001
investigation O O 0.9999908208847046
was O O 0.9999945163726807
to O O 0.9999884366989136
test O O 0.9999830722808838
the O O 0.9999923706054688
hypothesis O O 0.999981164932251
that O O 0.9997554421424866
carvedilol B B 0.9998001456260681
, O O 0.9998030066490173
a O O 0.998126208782196
nonselective O O 0.635961651802063
beta O O 0.8805403709411621
- O O 0.9616842269897461
adrenergic O O 0.9533934593200684
receptor O O 0.9900376796722412
antagonist O O 0.8984898924827576
with O O 0.9996840953826904
potent O O 0.997635006904602
antioxidant O O 0.5260915756225586
properties O O 0.9996844530105591
, O O 0.9999428987503052
protects O O 0.9998955726623535
against O O 0.9994924068450928
the O O 0.9999421834945679
cardiac O O 0.9999576807022095
and O O 0.9997316002845764
hepatic O O 0.9997085928916931
mitochondrial O O 0.999529242515564
bioenergetic O O 0.988775372505188
dysfunction O O 0.9999932050704956
associated O O 0.9999802112579346
with O O 0.9999607801437378
subchronic O O 0.9783785343170166
doxorubicin B B 0.999749481678009
toxicity O O 0.9998615980148315
. O O 0.9999850988388062

Heart O O 0.9615485072135925
and O O 0.9997267127037048
liver O O 0.9988641738891602
mitochondria O O 0.9913977384567261
were O O 0.9999668598175049
isolated O O 0.9999425411224365
from O O 0.9999403953552246
rats O O 0.999645471572876
treated O O 0.9999622106552124
for O O 0.9999736547470093
7 O O 0.9999728202819824
weeks O O 0.9999964237213135
with O O 0.9998558759689331
doxorubicin B B 0.9996985197067261
( O O 0.9991487264633179
2 O O 0.9995436072349548
mg O O 0.9998086094856262
/ O O 0.9999496936798096
kg O O 0.9999816417694092
sc O O 0.9281585812568665
/ O O 0.9999312162399292
week O O 0.9999932050704956
) O O 0.9998587369918823
, O O 0.9968602657318115
carvedilol B B 0.9996046423912048
( O O 0.9995279312133789
1 O O 0.999906063079834
mg O O 0.9998891353607178
/ O O 0.999984622001648
kg O O 0.9999896287918091
ip O O 0.9792997241020203
/ O O 0.9999547004699707
week O O 0.9999955892562866
) O O 0.9999173879623413
, O O 0.9995063543319702
or O O 0.9998550415039062
the O O 0.9999914169311523
combination O O 0.9989374279975891
of O O 0.9996465444564819
the O O 0.9997926354408264
two O O 0.999760091304779
drugs O O 0.9985607266426086
. O O 0.9999676942825317

Heart O O 0.9979546070098877
mitochondria O O 0.9976020455360413
isolated O O 0.999951958656311
from O O 0.9998840093612671
doxorubicin B B 0.9997957348823547
- O O 0.9997408986091614
treated O O 0.9998683929443359
rats O O 0.999992847442627
exhibited O O 0.9999244213104248
depressed O O 0.9999754428863525
rates O O 0.9999908208847046
for O O 0.9998458623886108
state O O 0.9941630959510803
3 O O 0.9959582686424255
respiration O O 0.9998056292533875
( O O 0.9999209642410278
336 O O 0.9999634027481079
+ O O 0.9999841451644897
/ O O 0.999869704246521
- O O 0.999768078327179
26 O O 0.9999752044677734
versus O O 0.9999431371688843
425 O O 0.9988798499107361
+ O O 0.9999796152114868
/ O O 0.9998412132263184
- O O 0.9998832941055298
53 O O 0.9998693466186523
natom O O 0.9998316764831543
O O O 0.9987248778343201
/ O O 0.9999053478240967
min O O 0.9996718168258667
/ O O 0.9998489618301392
mg O O 0.9997519850730896
protein O O 0.9998440742492676
) O O 0.9999687671661377
and O O 0.9999731779098511
a O O 0.9999713897705078
lower O O 0.9999654293060303
respiratory O O 0.9959025979042053
control O O 0.9999098777770996
ratio O O 0.9996938705444336
( O O 0.9997568726539612
RCR O O 0.99442458152771
) O O 0.9999738931655884
( O O 0.9999563694000244
4 O O 0.9986724853515625
. O O 0.9999805688858032
3 O O 0.9998470544815063
+ O O 0.9999853372573853
/ O O 0.9999661445617676
- O O 0.9999425411224365
0 O O 0.9999784231185913
. O O 0.9999759197235107
6 O O 0.9999914169311523
versus O O 0.999945878982544
5 O O 0.9998291730880737
. O O 0.9999936819076538
8 O O 0.9997715353965759
+ O O 0.999993085861206
/ O O 0.999953031539917
- O O 0.999974250793457
0 O O 0.9999912977218628
. O O 0.9999874830245972
4 O O 0.9999929666519165
) O O 0.9999837875366211
compared O O 0.9999897480010986
with O O 0.999991774559021
cardiac O O 0.9998151659965515
mitochondria O O 0.9988886713981628
isolated O O 0.9999821186065674
from O O 0.999931812286377
saline O O 0.9957780838012695
- O O 0.9996674060821533
treated O O 0.9998549222946167
rats O O 0.9999794960021973
. O O 0.9999642372131348

Mitochondrial O O 0.9988328814506531
calcium B B 0.9932538866996765
- O O 0.9841780066490173
loading O O 0.9985713958740234
capacity O O 0.999695897102356
and O O 0.9998693466186523
the O O 0.9999016523361206
activity O O 0.9976939558982849
of O O 0.9990363121032715
NADH O B 0.9774100184440613
- O O 0.6580100655555725
dehydrogenase O O 0.5763540267944336
were O O 0.9999089241027832
also O O 0.9999368190765381
suppressed O O 0.9997969269752502
in O O 0.9998015761375427
cardiac O O 0.9996515512466431
mitochondria O O 0.9984292387962341
from O O 0.9995347261428833
doxorubicin B B 0.9998267292976379
- O O 0.999716579914093
treated O O 0.999863862991333
rats O O 0.9999456405639648
. O O 0.9999747276306152

Doxorubicin B B 0.9995555281639099
treatment O O 0.9998301267623901
also O O 0.9999723434448242
caused O O 0.9999544620513916
a O O 0.999977707862854
decrease O O 0.9999854564666748
in O O 0.9999154806137085
RCR O O 0.9924545288085938
for O O 0.9992659687995911
liver O O 0.997173547744751
mitochondria O O 0.9970965385437012
( O O 0.9999440908432007
3 O O 0.9985851049423218
. O O 0.9999548196792603
9 O O 0.9999474287033081
+ O O 0.9999797344207764
/ O O 0.9999499320983887
- O O 0.999927282333374
0 O O 0.9999792575836182
. O O 0.9999818801879883
9 O O 0.999972939491272
versus O O 0.9999492168426514
5 O O 0.9997783303260803
. O O 0.9999922513961792
6 O O 0.9999760389328003
+ O O 0.9999880790710449
/ O O 0.9999603033065796
- O O 0.9999557733535767
0 O O 0.9999772310256958
. O O 0.999985933303833
7 O O 0.9999933242797852
for O O 0.9998764991760254
control O O 0.9211371541023254
rats O O 0.9812668561935425
) O O 0.9999395608901978
and O O 0.9999502897262573
inhibition O O 0.9999643564224243
of O O 0.9998884201049805
hepatic O O 0.9993665814399719
cytochrome O O 0.7318506836891174
oxidase O O 0.5485059022903442
activity O O 0.9992669224739075
. O O 0.9999599456787109

Coadministration O O 0.9852229356765747
of O O 0.9986717700958252
carvedilol B B 0.9995007514953613
decreased O O 0.999911904335022
the O O 0.9999804496765137
extent O O 0.9999881982803345
of O O 0.9999550580978394
cellular O O 0.9998973608016968
vacuolization O O 0.9999932050704956
in O O 0.9998759031295776
cardiac O O 0.9993411898612976
myocytes O O 0.999987006187439
and O O 0.9999330043792725
prevented O O 0.9998660087585449
the O O 0.9999266862869263
inhibitory O O 0.996935248374939
effect O O 0.9999103546142578
of O O 0.9991182684898376
doxorubicin B B 0.9997861981391907
on O O 0.999575674533844
mitochondrial O O 0.9828610420227051
respiration O O 0.9994505047798157
in O O 0.9997997879981995
both O O 0.9996722936630249
heart O O 0.9999028444290161
and O O 0.9998863935470581
liver O O 0.9996286630630493
. O O 0.9998654127120972

Carvedilol B B 0.9994237422943115
also O O 0.9997887015342712
prevented O O 0.9997572302818298
the O O 0.999980092048645
decrease O O 0.9999833106994629
in O O 0.9999068975448608
mitochondrial O O 0.896691083908081
Ca B B 0.9792419672012329
( O O 0.939540445804596
2 O O 0.9116390347480774
+ O O 0.9936483502388
) O O 0.977418839931488
loading O O 0.9966921806335449
capacity O O 0.9952139854431152
and O O 0.9999361038208008
the O O 0.9999265670776367
inhibition O O 0.9999417066574097
of O O 0.9998941421508789
the O O 0.9998213648796082
respiratory O O 0.9941498041152954
complexes O O 0.9980915188789368
of O O 0.9997641444206238
heart O O 0.6000483632087708
mitochondria O O 0.9944434762001038
caused O O 0.9999490976333618
by O O 0.9996402263641357
doxorubicin B B 0.9998358488082886
. O O 0.9998726844787598

Carvedilol B B 0.9991341233253479
by O O 0.9999662637710571
itself O O 0.9999518394470215
did O O 0.9999591112136841
not O O 0.9999707937240601
affect O O 0.9999719858169556
any O O 0.9999822378158569
of O O 0.9999808073043823
the O O 0.9999767541885376
parameters O O 0.9999829530715942
measured O O 0.9999935626983643
for O O 0.9998980760574341
heart O O 0.9983416795730591
or O O 0.9999278783798218
liver O O 0.992634117603302
mitochondria O O 0.999081015586853
. O O 0.99993896484375

It O O 0.9999922513961792
is O O 0.9999629259109497
concluded O O 0.9999847412109375
that O O 0.9999047517776489
this O O 0.999843955039978
protection O O 0.9997504353523254
by O O 0.999737560749054
carvedilol B B 0.9996315240859985
against O O 0.9988688826560974
both O O 0.9997742772102356
the O O 0.99994957447052
structural O O 0.9999305009841919
and O O 0.9997853636741638
functional O O 0.9999665021896362
cardiac O O 0.9999768733978271
tissue O O 0.9999942779541016
damage O O 0.9999790191650391
may O O 0.9999740123748779
afford O O 0.999974250793457
significant O O 0.9999836683273315
clinical O O 0.9999910593032837
advantage O O 0.9999877214431763
in O O 0.9999818801879883
minimizing O O 0.9999403953552246
the O O 0.9999668598175049
dose O O 0.9986787438392639
- O O 0.999971866607666
limiting O O 0.9999722242355347
mitochondrial O O 0.999127209186554
dysfunction O O 0.9999942779541016
and O O 0.9999336004257202
cardiomyopathy O O 0.9999958276748657
that O O 0.9999867677688599
accompanies O O 0.9999933242797852
long O O 0.9999046325683594
- O O 0.9999890327453613
term O O 0.9999476671218872
doxorubicin B B 0.9996708631515503
therapy O O 0.9996317625045776
in O O 0.9999560117721558
cancer O O 0.9999349117279053
patients O O 0.9999871253967285
. O O 0.999981164932251

Cocaine B B 0.9982336759567261
- O O 0.9994874000549316
induced O O 0.9998700618743896
hyperactivity O O 0.9998466968536377
is O O 0.9999295473098755
more O O 0.9999319314956665
influenced O O 0.9999710321426392
by O O 0.9996129870414734
adenosine B B 0.9697927236557007
receptor O O 0.937346875667572
agonists O O 0.7258557677268982
than O O 0.9997645020484924
amphetamine B B 0.9985256791114807
- O O 0.9998136162757874
induced O O 0.9998944997787476
hyperactivity O O 0.9998257756233215
. O O 0.9999656677246094

The O O 0.9999500513076782
influence O O 0.9999477863311768
of O O 0.9995526671409607
adenosine B B 0.9814806580543518
receptor O O 0.9589577913284302
agonists O O 0.880416750907898
and O O 0.9977411031723022
antagonists O O 0.9743198156356812
on O O 0.9997432827949524
cocaine B B 0.9978983402252197
- O O 0.9992885589599609
and O O 0.9984594583511353
amphetamine B B 0.9988837838172913
- O O 0.9998412132263184
induced O O 0.9998940229415894
hyperactivity O O 0.999745786190033
was O O 0.9999780654907227
examined O O 0.9999693632125854
in O O 0.9999396800994873
mice O O 0.999981164932251
. O O 0.9999656677246094

All O O 0.9662992358207703
adenosine B B 0.9840930700302124
receptor O O 0.8924188613891602
agonists O O 0.8051522374153137
significantly O O 0.9999336004257202
decreased O O 0.999935507774353
the O O 0.9999722242355347
locomotor O O 0.9999397993087769
activity O O 0.9999819993972778
in O O 0.9998437166213989
mice O O 0.9999814033508301
, O O 0.9999485015869141
and O O 0.9999654293060303
the O O 0.9999500513076782
effects O O 0.9999358654022217
were O O 0.9999614953994751
dose O O 0.99980229139328
- O O 0.9999489784240723
dependent O O 0.999984860420227
. O O 0.999981164932251

It O O 0.9999692440032959
seems O O 0.9997908473014832
that O O 0.9986162185668945
adenosine B B 0.9632241129875183
A1 O O 0.8650360107421875
and O O 0.9550304412841797
A2 O O 0.756750762462616
receptors O O 0.9990440011024475
might O O 0.9996342658996582
be O O 0.999734103679657
involved O O 0.999847412109375
in O O 0.99996018409729
this O O 0.9998378753662109
reaction O O 0.9999755620956421
. O O 0.9998726844787598

Moreover O O 0.9998703002929688
, O O 0.9996141195297241
all O O 0.9795355200767517
adenosine B B 0.9799767732620239
receptor O O 0.942328155040741
agonists O O 0.8500200510025024
: O O 0.9990795850753784
2 B B 0.7802035212516785
- I I 0.9197811484336853
p I I 0.996743381023407
- I I 0.9866408705711365
( I I 0.9809989333152771
2 I I 0.8531072735786438
- I I 0.987748920917511
carboxyethyl I I 0.999695897102356
) I I 0.8384209871292114
phenethylamino I I 0.9823237657546997
- I I 0.9774352312088013
5 I I 0.9821203351020813
' I I 0.9881360530853271
- I I 0.9599177837371826
N I I 0.9618437886238098
- I I 0.991473913192749
ethylcarboxamidoadenosine I I 0.9997182488441467
( O O 0.9843024015426636
CGS B B 0.965812087059021
21680 I I 0.9983720183372498
) O O 0.9895904660224915
, O O 0.9967066645622253
A2A O O 0.7139186859130859
receptor O O 0.9807604551315308
agonist O O 0.9368995428085327
, O O 0.9989421963691711
N6 B B 0.6828697919845581
- I I 0.7554113864898682
cyclopentyladenosine I I 0.9078331589698792
( O O 0.9821739196777344
CPA B B 0.9610202312469482
) O O 0.9848878383636475
, O O 0.9958817958831787
A1 O O 0.9156256914138794
receptor O O 0.999395489692688
agonist O O 0.9422814846038818
, O O 0.9994458556175232
and O O 0.9971194267272949
5 B B 0.6684619784355164
' I I 0.6186856031417847
- I I 0.6492876410484314
N I I 0.9136379361152649
- I I 0.9871527552604675
ethylcarboxamidoadenosine I I 0.9999041557312012
( O O 0.9128655195236206
NECA B B 0.9838113188743591
) O O 0.9843085408210754
, O O 0.9981491565704346
A2 O O 0.4874259829521179
/ O O 0.9764416217803955
A1 O O 0.9173872470855713
receptor O O 0.9972975850105286
agonist O O 0.9464746713638306
significantly O O 0.9998705387115479
and O O 0.9999574422836304
dose O O 0.9982800483703613
- O O 0.9999806880950928
dependently O O 0.9999836683273315
decreased O O 0.9999139308929443
cocaine B B 0.9993751645088196
- O O 0.9998039603233337
induced O O 0.9999245405197144
locomotor O O 0.9999547004699707
activity O O 0.9999693632125854
. O O 0.9999229907989502

CPA B B 0.9875519275665283
reduced O O 0.9987195730209351
cocaine B B 0.9979302883148193
action O O 0.9997827410697937
at O O 0.9998108744621277
the O O 0.999884843826294
doses O O 0.9998462200164795
which O O 0.9998799562454224
, O O 0.9999827146530151
given O O 0.9998761415481567
alone O O 0.9987536668777466
, O O 0.9999632835388184
did O O 0.9999648332595825
not O O 0.9999650716781616
influence O O 0.9999351501464844
motility O O 0.9999955892562866
, O O 0.9999326467514038
while O O 0.9995694756507874
CGS B B 0.9475893974304199
21680 I I 0.9958170056343079
and O O 0.9632878303527832
NECA B B 0.9940500259399414
decreased O O 0.9998605251312256
the O O 0.9999716281890869
action O O 0.999954342842102
of O O 0.9998711347579956
cocaine B B 0.998717188835144
at O O 0.999884843826294
the O O 0.9999232292175293
doses O O 0.9998705387115479
which O O 0.9999455213546753
, O O 0.9999897480010986
given O O 0.9998979568481445
alone O O 0.9987515211105347
, O O 0.9999744892120361
decreased O O 0.9998958110809326
locomotor O O 0.9998999834060669
activity O O 0.9999810457229614
in O O 0.9998608827590942
animals O O 0.9999840259552002
. O O 0.9999594688415527

These O O 0.9999756813049316
results O O 0.9999758005142212
suggest O O 0.9998281002044678
the O O 0.9999408721923828
involvement O O 0.9999226331710815
of O O 0.9996336698532104
both O O 0.9962334036827087
adenosine B B 0.9508417248725891
receptors O O 0.9976921081542969
in O O 0.999921441078186
the O O 0.9999275207519531
action O O 0.9998797178268433
of O O 0.9997255206108093
cocaine B B 0.9986652135848999
although O O 0.9994962215423584
agonists O O 0.9863417744636536
of O O 0.9976067543029785
A1 O O 0.6493860483169556
receptors O O 0.9989585876464844
seem O O 0.9999178647994995
to O O 0.9999459981918335
have O O 0.9999463558197021
stronger O O 0.9997633099555969
influence O O 0.9999114274978638
on O O 0.9999054670333862
it O O 0.9999432563781738
. O O 0.9999462366104126

The O O 0.9999091625213623
selective O O 0.9988877177238464
blockade O O 0.9991952776908875
of O O 0.9987867474555969
A2 O O 0.7152690887451172
adenosine B B 0.97188401222229
receptor O O 0.9908223152160645
by O O 0.9996064305305481
DMPX B B 0.9217185974121094
( O O 0.9519681334495544
3 B B 0.9703242182731628
, I I 0.9940192699432373
7 I I 0.9976686835289001
- I I 0.9912193417549133
dimethyl I I 0.9981474876403809
- I I 0.9461198449134827
1 I I 0.9089598059654236
- I I 0.9896876215934753
propargylxanthine I I 0.9998834133148193
) O O 0.9986581802368164
significantly O O 0.9999638795852661
enhanced O O 0.999883770942688
cocaine B B 0.999047577381134
- O O 0.9999104738235474
induced O O 0.9999016523361206
locomotor O O 0.9999524354934692
activity O O 0.9999879598617554
of O O 0.9998451471328735
animals O O 0.9946554899215698
. O O 0.999904990196228

Caffeine B B 0.9992597699165344
had O O 0.999879002571106
similar O O 0.9999173879623413
action O O 0.9999524354934692
but O O 0.9999699592590332
the O O 0.9999545812606812
effect O O 0.9999359846115112
was O O 0.9999591112136841
not O O 0.9999901056289673
significant O O 0.9999674558639526
. O O 0.9999659061431885

CPT B O 0.8376715779304504
( O O 0.6690605878829956
8 B B 0.5140066742897034
- I I 0.9862415790557861
cyclopentyltheophylline I I 0.9999128580093384
) O O 0.7120679616928101
- O O 0.7751093506813049
- O O 0.8134604692459106
A1 O O 0.7468748092651367
receptor O O 0.9952115416526794
antagonist O O 0.9609692096710205
, O O 0.9997215867042542
did O O 0.9999631643295288
not O O 0.9999822378158569
show O O 0.9999723434448242
any O O 0.999976396560669
influence O O 0.9999915361404419
in O O 0.9999806880950928
this O O 0.9999821186065674
test O O 0.9999797344207764
. O O 0.9998418092727661

Similarly O O 0.999652624130249
, O O 0.9996247291564941
all O O 0.9952448010444641
adenosine B B 0.9824948906898499
receptor O O 0.8226432800292969
agonists O O 0.742220938205719
decreased O O 0.9996649026870728
amphetamine B B 0.999450147151947
- O O 0.9998682737350464
induced O O 0.9999068975448608
hyperactivity O O 0.9993537068367004
, O O 0.9999253749847412
but O O 0.9999247789382935
at O O 0.9998719692230225
the O O 0.9999703168869019
higher O O 0.9998205304145813
doses O O 0.9998113512992859
than O O 0.9999098777770996
those O O 0.9998210072517395
which O O 0.9998718500137329
were O O 0.9999003410339355
active O O 0.9983735084533691
in O O 0.9997673630714417
cocaine B B 0.9985345602035522
- O O 0.9997621178627014
induced O O 0.9999234676361084
hyperactivity O O 0.9995623230934143
. O O 0.9999399185180664

The O O 0.999839186668396
selective O O 0.9990745782852173
blockade O O 0.9990474581718445
of O O 0.9989128112792969
A2 O O 0.5317402482032776
adenosine B B 0.882128894329071
receptors O O 0.9743679165840149
( O O 0.9976407289505005
DMPX B B 0.9833458662033081
) O O 0.9978300929069519
and O O 0.9991218447685242
non O O 0.9650477170944214
- O O 0.9998525381088257
selective O O 0.9991835951805115
blockade O O 0.9987823367118835
of O O 0.9981480836868286
adenosine B O 0.8097871541976929
receptors O O 0.995836615562439
( O O 0.998426079750061
caffeine B B 0.9996337890625
) O O 0.9996780157089233
significantly O O 0.9999686479568481
increased O O 0.9999305009841919
the O O 0.9999904632568359
action O O 0.999968409538269
of O O 0.9998396635055542
amphetamine B B 0.999554455280304
in O O 0.9998284578323364
the O O 0.9999675750732422
locomotor O O 0.9998571872711182
activity O O 0.9998377561569214
test O O 0.9999790191650391
. O O 0.9999443292617798

Our O O 0.9999415874481201
results O O 0.9999799728393555
have O O 0.9999779462814331
shown O O 0.9999673366546631
that O O 0.9995678067207336
all O O 0.995664656162262
adenosine B B 0.8994792103767395
receptor O O 0.9055142402648926
agonists O O 0.809054970741272
( O O 0.998838484287262
A1 O O 0.4697788953781128
and O O 0.9813557267189026
A2 O O 0.5273054838180542
) O O 0.9996769428253174
reduce O O 0.9995989203453064
cocaine B B 0.9981377124786377
- O O 0.9993720650672913
and O O 0.9992557168006897
amphetamine B B 0.998940646648407
- O O 0.9998917579650879
induced O O 0.9999102354049683
locomotor O O 0.9999780654907227
activity O O 0.9999667406082153
and O O 0.9999600648880005
indicate O O 0.9999803304672241
that O O 0.9999089241027832
cocaine B B 0.998325526714325
- O O 0.9996053576469421
induced O O 0.9999302625656128
hyperactivity O O 0.999543309211731
is O O 0.9999405145645142
more O O 0.9998828172683716
influenced O O 0.9999676942825317
by O O 0.9995636343955994
adenosine B B 0.9581940770149231
receptor O O 0.9670777916908264
agonists O O 0.7870966196060181
( O O 0.9999115467071533
particularly O O 0.9986947178840637
A1 O O 0.7216402888298035
receptors O O 0.9988691210746765
) O O 0.9999185800552368
than O O 0.9998863935470581
amphetamine B B 0.9993064403533936
- O O 0.999835729598999
induced O O 0.999932050704956
hyperactivity O O 0.9998323917388916
. O O 0.9999654293060303

Amiodarone B B 0.9994706511497498
and O O 0.9998973608016968
the O O 0.9999864101409912
risk O O 0.9999951124191284
of O O 0.9999843835830688
bradyarrhythmia O O 0.9999068975448608
requiring O O 0.9999696016311646
permanent O O 0.9999852180480957
pacemaker O O 0.9998733997344971
in O O 0.9999698400497437
elderly O O 0.9999843835830688
patients O O 0.9999948740005493
with O O 0.9999723434448242
atrial O O 0.9905779361724854
fibrillation O O 0.99993896484375
and O O 0.9999346733093262
prior O O 0.9999852180480957
myocardial O O 0.9999980926513672
infarction O O 0.999981164932251
. O O 0.999972939491272

OBJECTIVES O O 0.999817430973053
: O O 0.9999972581863403
The O O 0.9999979734420776
aim O O 0.9999979734420776
of O O 0.999995231628418
this O O 0.9999916553497314
study O O 0.9999912977218628
was O O 0.9999959468841553
to O O 0.9999959468841553
determine O O 0.9999961853027344
whether O O 0.9999879598617554
the O O 0.9999847412109375
use O O 0.9999289512634277
of O O 0.9989861845970154
amiodarone B B 0.9998658895492554
in O O 0.999840259552002
patients O O 0.9999940395355225
with O O 0.9999840259552002
atrial O O 0.9837188124656677
fibrillation O O 0.9998904466629028
( O O 0.9997180104255676
AF O O 0.7847029566764832
) O O 0.998955488204956
increases O O 0.9999611377716064
the O O 0.9999957084655762
risk O O 0.9999980926513672
of O O 0.9999880790710449
bradyarrhythmia O O 0.999963641166687
requiring O O 0.9999829530715942
a O O 0.9999954700469971
permanent O O 0.999990701675415
pacemaker O O 0.999940037727356
. O O 0.9999769926071167

BACKGROUND O O 0.9983940720558167
: O O 0.9999635219573975
Reports O O 0.9999960660934448
of O O 0.9999842643737793
severe O O 0.9999823570251465
bradyarrhythmia O O 0.9999898672103882
during O O 0.9998494386672974
amiodarone B B 0.9998631477355957
therapy O O 0.9998106360435486
are O O 0.9999841451644897
infrequent O O 0.9999853372573853
and O O 0.9999920129776001
limited O O 0.9999963045120239
to O O 0.9999768733978271
studies O O 0.9999918937683105
assessing O O 0.9999853372573853
the O O 0.9998263716697693
therapy O O 0.999884843826294
' O O 0.9999775886535645
s O O 0.9999823570251465
use O O 0.9999840259552002
in O O 0.9999806880950928
the O O 0.9999914169311523
management O O 0.999990701675415
of O O 0.9999833106994629
patients O O 0.999991774559021
with O O 0.9999879598617554
ventricular O O 0.9999514818191528
arrhythmias O O 0.9999287128448486
. O O 0.9999663829803467

METHODS O O 0.9999247789382935
: O O 0.9999886751174927
A O O 0.9999797344207764
study O O 0.999984622001648
cohort O O 0.9999775886535645
of O O 0.9999827146530151
8 O O 0.9999902248382568
, O O 0.9999978542327881
770 O O 0.9999847412109375
patients O O 0.9999973773956299
age O O 0.9999929666519165
> O O 0.999984622001648
or O O 0.999995231628418
= O O 0.9999953508377075
65 O O 0.9999985694885254
years O O 0.9999980926513672
with O O 0.9999816417694092
a O O 0.9999970197677612
new O O 0.9999980926513672
diagnosis O O 0.9999966621398926
of O O 0.9999617338180542
AF O O 0.8863266706466675
was O O 0.9999476671218872
identified O O 0.9999879598617554
from O O 0.9999639987945557
a O O 0.9999790191650391
provincewide O O 0.9999179840087891
database O O 0.9999897480010986
of O O 0.9999051094055176
Quebec O O 0.8332004547119141
residents O O 0.9998505115509033
with O O 0.9999732971191406
a O O 0.9999867677688599
myocardial O O 0.9999959468841553
infarction O O 0.9998846054077148
( O O 0.9999397993087769
MI O O 0.997800886631012
) O O 0.9999895095825195
between O O 0.9999312162399292
1991 O O 0.9998019337654114
and O O 0.9999468326568604
1999 O O 0.9999282360076904
. O O 0.9999701976776123

Using O O 0.9999779462814331
a O O 0.9999778270721436
nested O O 0.9999700784683228
case O O 0.9999781847000122
- O O 0.9999774694442749
control O O 0.9999895095825195
design O O 0.9999977350234985
, O O 0.9999713897705078
477 O O 0.9999979734420776
cases O O 0.9999967813491821
of O O 0.9999738931655884
bradyarrhythmia O O 0.9998855590820312
requiring O O 0.9999524354934692
a O O 0.9999804496765137
permanent O O 0.9999794960021973
pacemaker O O 0.9997976422309875
were O O 0.9999576807022095
matched O O 0.9999850988388062
( O O 0.9998430013656616
1 O O 0.9998043179512024
: O O 0.9999867677688599
4 O O 0.9995889067649841
) O O 0.9999618530273438
to O O 0.9999455213546753
1 O O 0.9999614953994751
, O O 0.9999915361404419
908 O O 0.9999719858169556
controls O O 0.9999963045120239
. O O 0.9999772310256958

Multivariable O O 0.9990060925483704
logistic O O 0.9999535083770752
regression O O 0.9999443292617798
was O O 0.9999678134918213
used O O 0.9999843835830688
to O O 0.9999910593032837
estimate O O 0.9999873638153076
the O O 0.9999922513961792
odds O O 0.9999939203262329
ratio O O 0.9999967813491821
( O O 0.9999793767929077
OR O O 0.9999963045120239
) O O 0.999994158744812
of O O 0.9999741315841675
pacemaker O O 0.9999504089355469
insertion O O 0.9999951124191284
associated O O 0.999993085861206
with O O 0.9996637105941772
amiodarone B B 0.9999067783355713
use O O 0.9998986721038818
, O O 0.9999830722808838
controlling O O 0.9999178647994995
for O O 0.9998748302459717
baseline O O 0.9999791383743286
risk O O 0.9998705387115479
factors O O 0.9999974966049194
and O O 0.9999785423278809
exposure O O 0.9999700784683228
to O O 0.999032735824585
sotalol B B 0.9988277554512024
, O O 0.9840195178985596
Class O O 0.9730047583580017
I O O 0.8946784734725952
antiarrhythmic O O 0.580458402633667
agents O O 0.9349998235702515
, O O 0.9976751208305359
beta O O 0.9845324158668518
- O O 0.9959977865219116
blockers O O 0.9866266846656799
, O O 0.9969102740287781
calcium B B 0.9357075691223145
channel O O 0.8778461217880249
blockers O O 0.9002938866615295
, O O 0.9986612796783447
and O O 0.9946674108505249
digoxin B B 0.9967617392539978
. O O 0.9999562501907349

RESULTS O O 0.9996098875999451
: O O 0.999373733997345
amiodarone B B 0.9998542070388794
use O O 0.9997269511222839
was O O 0.9999462366104126
associated O O 0.999984860420227
with O O 0.999992847442627
an O O 0.9999942779541016
increased O O 0.999995231628418
risk O O 0.999998927116394
of O O 0.999991774559021
pacemaker O O 0.9999474287033081
insertion O O 0.9999933242797852
( O O 0.9999791383743286
OR O O 0.999796450138092
: O O 0.9999921321868896
2 O O 0.9998992681503296
. O O 0.999995231628418
14 O O 0.999998927116394
, O O 0.9999712705612183
95 O O 0.999985933303833
% O O 0.9999740123748779
confidence O O 0.9996364116668701
interval O O 0.9999833106994629
[ O O 0.9933485388755798
CI O O 0.9908818006515503
] O O 0.9999464750289917
: O O 0.999954104423523
1 O O 0.9999881982803345
. O O 0.9999942779541016
30 O O 0.9999949932098389
to O O 0.9999624490737915
3 O O 0.9999781847000122
. O O 0.9999949932098389
54 O O 0.9999903440475464
) O O 0.9999793767929077
. O O 0.9999840259552002

This O O 0.9999175071716309
effect O O 0.9999376535415649
was O O 0.9999397993087769
modified O O 0.9999803304672241
by O O 0.9999510049819946
gender O O 0.9996774196624756
, O O 0.9999792575836182
with O O 0.9999855756759644
a O O 0.9999858140945435
greater O O 0.9999722242355347
risk O O 0.9999966621398926
in O O 0.9999701976776123
women O O 0.9999903440475464
versus O O 0.9999549388885498
men O O 0.9999781847000122
( O O 0.9999518394470215
OR O O 0.9991075396537781
: O O 0.9999583959579468
3 O O 0.9998863935470581
. O O 0.9999829530715942
86 O O 0.999984622001648
, O O 0.9998979568481445
95 O O 0.9997262358665466
% O O 0.9996533393859863
CI O O 0.9889966249465942
: O O 0.9999134540557861
1 O O 0.9999889135360718
. O O 0.9999890327453613
70 O O 0.9999959468841553
to O O 0.9988834261894226
8 O O 0.9999686479568481
. O O 0.9999938011169434
75 O O 0.9999723434448242
vs O O 0.999823272228241
. O O 0.9999878406524658
OR O O 0.9956348538398743
: O O 0.999954342842102
1 O O 0.9999803304672241
. O O 0.9999850988388062
52 O O 0.9999918937683105
, O O 0.9999064207077026
95 O O 0.9989359974861145
% O O 0.9996730089187622
CI O O 0.9900031089782715
: O O 0.9999246597290039
0 O O 0.9999884366989136
. O O 0.9999918937683105
80 O O 0.9999761581420898
to O O 0.9991167187690735
2 O O 0.9999892711639404
. O O 0.9999884366989136
89 O O 0.9955845475196838
) O O 0.9999676942825317
. O O 0.9999731779098511

Digoxin B B 0.9951672554016113
was O O 0.9998292922973633
the O O 0.9996858835220337
only O O 0.99973064661026
other O O 0.9938799142837524
medication O O 0.9973233342170715
associated O O 0.9999312162399292
with O O 0.9999935626983643
an O O 0.9999946355819702
increased O O 0.9999953508377075
risk O O 0.999998927116394
of O O 0.999992847442627
pacemaker O O 0.999966025352478
insertion O O 0.9999938011169434
( O O 0.9999655485153198
OR O O 0.9996278285980225
: O O 0.9999860525131226
1 O O 0.999984860420227
. O O 0.9999957084655762
78 O O 0.999972939491272
, O O 0.999954104423523
95 O O 0.9999430179595947
% O O 0.999754011631012
CI O O 0.9936184883117676
: O O 0.9999798536300659
1 O O 0.999994158744812
. O O 0.9999966621398926
37 O O 0.9999979734420776
to O O 0.9999349117279053
2 O O 0.9999802112579346
. O O 0.9999949932098389
31 O O 0.9999926090240479
) O O 0.999970555305481
. O O 0.9999576807022095

CONCLUSIONS O O 0.9991474151611328
: O O 0.9999951124191284
This O O 0.9999949932098389
study O O 0.9999943971633911
suggests O O 0.9999693632125854
that O O 0.9999449253082275
the O O 0.9999921321868896
use O O 0.9999226331710815
of O O 0.999455988407135
amiodarone B B 0.9998037219047546
in O O 0.9998219609260559
elderly O O 0.9999873638153076
patients O O 0.9999948740005493
with O O 0.9999717473983765
AF O O 0.9110694527626038
and O O 0.9998618364334106
a O O 0.9998189806938171
previous O O 0.9825603365898132
MI O O 0.9200482368469238
increases O O 0.9999469518661499
the O O 0.9999958276748657
risk O O 0.999997615814209
of O O 0.9999881982803345
bradyarrhythmia O O 0.9999572038650513
requiring O O 0.9999865293502808
a O O 0.999996542930603
permanent O O 0.9999940395355225
pacemaker O O 0.9999099969863892
. O O 0.9999830722808838

The O O 0.9999892711639404
finding O O 0.999993085861206
of O O 0.9999862909317017
an O O 0.9999855756759644
augmented O O 0.9999619722366333
risk O O 0.9999967813491821
of O O 0.9999793767929077
pacemaker O O 0.9987530708312988
insertion O O 0.9999904632568359
in O O 0.9999401569366455
elderly O O 0.9999591112136841
women O O 0.9999982118606567
receiving O O 0.9993458390235901
amiodarone B B 0.9996548891067505
requires O O 0.9999322891235352
further O O 0.9999970197677612
investigation O O 0.9999971389770508
. O O 0.999984622001648

Indomethacin B B 0.998917818069458
- O O 0.999776303768158
induced O O 0.9999103546142578
morphologic O O 0.9999860525131226
changes O O 0.999996542930603
in O O 0.9999613761901855
the O O 0.9999736547470093
rat O O 0.9993508458137512
urinary O O 0.9999779462814331
bladder O O 0.998870313167572
epithelium O O 0.9998098015785217
. O O 0.9999446868896484

OBJECTIVES O O 0.9989655017852783
: O O 0.9999911785125732
To O O 0.9999845027923584
evaluate O O 0.9999849796295166
the O O 0.9999628067016602
morphologic O O 0.9999750852584839
changes O O 0.9999953508377075
in O O 0.9999494552612305
rat O O 0.9957048296928406
urothelium O O 0.9998389482498169
induced O O 0.9999691247940063
by O O 0.9996960163116455
indomethacin B B 0.9988382458686829
. O O 0.9999163150787354

Nonsteroidal O O 0.6423026323318481
anti O O 0.6030347943305969
- O O 0.7903409004211426
inflammatory O O 0.9128497242927551
drug O O 0.9313857555389404
- O O 0.9993083477020264
induced O O 0.9998481273651123
cystitis O O 0.9976356029510498
is O O 0.9999313354492188
a O O 0.9999779462814331
poorly O O 0.9999785423278809
recognized O O 0.9999966621398926
and O O 0.9999918937683105
under O O 0.9999185800552368
- O O 0.9999904632568359
reported O O 0.9999974966049194
condition O O 0.9999942779541016
. O O 0.9999709129333496

In O O 0.9997878670692444
addition O O 0.9998024106025696
to O O 0.9981812238693237
tiaprofenic B B 0.9924578666687012
acid I I 0.9998372793197632
, O O 0.9812425374984741
indomethacin B B 0.9991124272346497
has O O 0.999704897403717
been O O 0.9999654293060303
reported O O 0.9999841451644897
to O O 0.9998482465744019
be O O 0.999891996383667
associated O O 0.999934196472168
with O O 0.9999755620956421
this O O 0.9999790191650391
condition O O 0.9999943971633911
. O O 0.9999573230743408

METHODS O O 0.9996449947357178
: O O 0.9999673366546631
Three O O 0.9998199343681335
groups O O 0.9999905824661255
were O O 0.9999895095825195
established O O 0.9999881982803345
: O O 0.9999781847000122
a O O 0.9998214840888977
control O O 0.9999591112136841
group O O 0.9999915361404419
( O O 0.9999691247940063
n O O 0.9997722506523132
= O O 0.9999485015869141
10 O O 0.9999881982803345
) O O 0.9999319314956665
, O O 0.999969482421875
a O O 0.9999749660491943
high O O 0.9972813129425049
- O O 0.9999626874923706
dose O O 0.9991729855537415
group O O 0.9999850988388062
( O O 0.9999675750732422
n O O 0.9995957016944885
= O O 0.9999597072601318
10 O O 0.9999634027481079
) O O 0.9999520778656006
, O O 0.9999854564666748
treated O O 0.9999911785125732
with O O 0.9999698400497437
one O O 0.999954104423523
intraperitoneal O O 0.9999924898147583
injection O O 0.9999860525131226
of O O 0.9981752634048462
indomethacin B B 0.9989738464355469
20 O O 0.8717104196548462
mg O O 0.9981623291969299
/ O O 0.9998836517333984
kg O O 0.9999908208847046
, O O 0.9999600648880005
and O O 0.9999678134918213
a O O 0.9999810457229614
therapeutic O O 0.999948263168335
dose O O 0.9998204112052917
group O O 0.999974250793457
( O O 0.9999737739562988
n O O 0.9998916387557983
= O O 0.9999806880950928
10 O O 0.9999430179595947
) O O 0.9999781847000122
in O O 0.9999791383743286
which O O 0.9999507665634155
oral O O 0.9768298268318176
indomethacin B B 0.9977631568908691
was O O 0.9998809099197388
administered O O 0.9999492168426514
3 O O 0.9935877323150635
. O O 0.9999943971633911
25 O O 0.999948263168335
mg O O 0.9999631643295288
/ O O 0.9999915361404419
kg O O 0.9999971389770508
body O O 0.9999947547912598
weight O O 0.9999475479125977
daily O O 0.99996018409729
for O O 0.9999804496765137
3 O O 0.9999561309814453
weeks O O 0.9999970197677612
. O O 0.9999886751174927

The O O 0.9999768733978271
animals O O 0.9999924898147583
were O O 0.9999864101409912
then O O 0.9999778270721436
killed O O 0.999976634979248
and O O 0.9999935626983643
the O O 0.9999918937683105
bladders O O 0.9988172054290771
removed O O 0.9999487400054932
for O O 0.9999799728393555
light O O 0.9999556541442871
and O O 0.9999279975891113
electron O O 0.9993425011634827
microscopic O O 0.9999661445617676
studies O O 0.9999960660934448
. O O 0.9999724626541138

RESULTS O O 0.9998399019241333
: O O 0.9999645948410034
The O O 0.9999822378158569
light O O 0.9999716281890869
microscopic O O 0.9999715089797974
findings O O 0.9999827146530151
showed O O 0.9999195337295532
some O O 0.9999610185623169
focal O O 0.9999336004257202
epithelial O O 0.9998549222946167
degeneration O O 0.9999843835830688
that O O 0.9999169111251831
was O O 0.9999659061431885
more O O 0.9999231100082397
prominent O O 0.9999693632125854
in O O 0.9998676776885986
the O O 0.9999387264251709
high O O 0.996248185634613
- O O 0.9998437166213989
dose O O 0.9786903858184814
group O O 0.9998548030853271
. O O 0.9999511241912842

When O O 0.999976634979248
compared O O 0.9999939203262329
with O O 0.9999843835830688
the O O 0.9999525547027588
control O O 0.9998546838760376
group O O 0.9999852180480957
, O O 0.9999310970306396
both O O 0.9978765249252319
indomethacin B B 0.9987080097198486
groups O O 0.9963123202323914
revealed O O 0.9999369382858276
statistically O O 0.9999401569366455
increased O O 0.9999805688858032
numbers O O 0.9999792575836182
of O O 0.9999432563781738
mast O O 0.9990123510360718
cells O O 0.999988317489624
in O O 0.9998513460159302
the O O 0.999958872795105
mucosa O O 0.9999102354049683
( O O 0.9999517202377319
P O O 0.999889612197876
< O O 0.9999758005142212
0 O O 0.999994158744812
. O O 0.9999970197677612
0001 O O 0.9999299049377441
) O O 0.9999490976333618
and O O 0.9999505281448364
penetration O O 0.9999178647994995
of O O 0.9989462494850159
lanthanum B B 0.9956587553024292
nitrate I I 0.996807873249054
through O O 0.9994794726371765
intercellular O O 0.9366355538368225
areas O O 0.999972939491272
of O O 0.9999191761016846
the O O 0.9999459981918335
epithelium O O 0.9999328851699829
. O O 0.9999661445617676

Furthermore O O 0.9998430013656616
, O O 0.9999659061431885
the O O 0.9999902248382568
difference O O 0.9999958276748657
in O O 0.9999833106994629
mast O O 0.9988529682159424
cell O O 0.9999644756317139
counts O O 0.9999277591705322
between O O 0.999636173248291
the O O 0.99991774559021
high O O 0.9984737038612366
and O O 0.9998968839645386
therapeutic O O 0.9998892545700073
dose O O 0.9991095662117004
groups O O 0.9999599456787109
was O O 0.9999667406082153
also O O 0.9999828338623047
statistically O O 0.999981164932251
significant O O 0.9999908208847046
( O O 0.9999551773071289
P O O 0.9995074272155762
< O O 0.9999829530715942
0 O O 0.9999932050704956
. O O 0.9999966621398926
0001 O O 0.9999228715896606
) O O 0.9999715089797974
. O O 0.9999773502349854

CONCLUSIONS O O 0.9354051947593689
: O O 0.9985629916191101
Indomethacin B B 0.9996992349624634
resulted O O 0.9999068975448608
in O O 0.999934196472168
histopathologic O O 0.9999731779098511
findings O O 0.9999949932098389
typical O O 0.9999932050704956
of O O 0.999944806098938
interstitial O O 0.9955483675003052
cystitis O O 0.9995253086090088
, O O 0.9999773502349854
such O O 0.9999861717224121
as O O 0.9999791383743286
leaky O O 0.9999712705612183
bladder O O 0.9993470311164856
epithelium O O 0.99959796667099
and O O 0.9998961687088013
mucosal O O 0.9998962879180908
mastocytosis O O 0.9999079704284668
. O O 0.9999006986618042

The O O 0.9999881982803345
true O O 0.9999877214431763
incidence O O 0.9999943971633911
of O O 0.9999616146087646
nonsteroidal O O 0.5830113291740417
anti O O 0.4908517301082611
- O O 0.9380491971969604
inflammatory O O 0.9698117971420288
drug O O 0.9776921272277832
- O O 0.9995785355567932
induced O O 0.9998509883880615
cystitis O O 0.9976375102996826
in O O 0.9999630451202393
humans O O 0.9999711513519287
must O O 0.9999676942825317
be O O 0.9999955892562866
clarified O O 0.9999939203262329
by O O 0.9999947547912598
prospective O O 0.999987006187439
clinical O O 0.9999895095825195
trials O O 0.9999936819076538
. O O 0.999983549118042

An O O 0.999980092048645
open O O 0.9998279809951782
- O O 0.9999849796295166
label O O 0.9999788999557495
phase O O 0.9999746084213257
II O O 0.9997370839118958
study O O 0.9999877214431763
of O O 0.9993821382522583
low O O 0.9966278672218323
- O O 0.9999079704284668
dose O O 0.9776440262794495
thalidomide B B 0.9996871948242188
in O O 0.9995162487030029
androgen B O 0.7584745287895203
- O O 0.9980650544166565
independent O O 0.9992499947547913
prostate O O 0.9987151622772217
cancer O O 0.9999558925628662
. O O 0.9999735355377197

The O O 0.9999451637268066
antiangiogenic O O 0.953309953212738
effects O O 0.9999051094055176
of O O 0.9994295239448547
thalidomide B B 0.9993738532066345
have O O 0.9996856451034546
been O O 0.9999903440475464
assessed O O 0.9999796152114868
in O O 0.9999909400939941
clinical O O 0.9999793767929077
trials O O 0.9999880790710449
in O O 0.9999655485153198
patients O O 0.9999940395355225
with O O 0.9999899864196777
various O O 0.9998975992202759
solid O O 0.9983763694763184
and O O 0.9998461008071899
haematological O O 0.9995149374008179
malignancies O O 0.999997615814209
. O O 0.9999784231185913

Thalidomide B B 0.9993471503257751
blocks O O 0.9989553689956665
the O O 0.9997209906578064
activity O O 0.9997052550315857
of O O 0.9994514584541321
angiogenic O O 0.9989038705825806
agents O O 0.9974338412284851
including O O 0.9985107779502869
bFGF O B 0.9346044063568115
, O O 0.9314498901367188
VEGF O B 0.9955281615257263
and O O 0.9372649192810059
IL O O 0.6865674257278442
- O O 0.8852819800376892
6 O O 0.6588323712348938
. O O 0.9996398687362671

We O O 0.9999573230743408
undertook O O 0.9999904632568359
an O O 0.9999932050704956
open O O 0.9997755885124207
- O O 0.9999904632568359
label O O 0.9999923706054688
study O O 0.9999899864196777
using O O 0.999875545501709
thalidomide B B 0.9995880722999573
100 O O 0.9368622899055481
mg O O 0.9998645782470703
once O O 0.9994800686836243
daily O O 0.9999510049819946
for O O 0.9999834299087524
up O O 0.9999921321868896
to O O 0.999995231628418
6 O O 0.999985933303833
months O O 0.9999961853027344
in O O 0.9999823570251465
20 O O 0.9999748468399048
men O O 0.9999974966049194
with O O 0.9999785423278809
androgen B O 0.4937857389450073
- O O 0.9987266659736633
independent O O 0.9978358149528503
prostate O O 0.9992561936378479
cancer O O 0.9998375177383423
. O O 0.9999804496765137

The O O 0.9999914169311523
mean O O 0.9999924898147583
time O O 0.9999980926513672
of O O 0.9999951124191284
study O O 0.9999890327453613
was O O 0.9999940395355225
109 O O 0.9999953508377075
days O O 0.9999979734420776
( O O 0.9999836683273315
median O O 0.9999905824661255
107 O O 0.9999821186065674
, O O 0.9999920129776001
range O O 0.9999951124191284
4 O O 0.9999901056289673
- O O 0.9999051094055176
184 O O 0.999954104423523
days O O 0.9999978542327881
) O O 0.9999841451644897
. O O 0.9999839067459106

Patients O O 0.9999613761901855
underwent O O 0.9999805688858032
regular O O 0.9999809265136719
measurement O O 0.9999881982803345
of O O 0.9998979568481445
prostate O O 0.8474944829940796
- O O 0.9904435276985168
specific O O 0.9543729424476624
antigen O O 0.8784847855567932
( O O 0.9994152784347534
PSA O O 0.8710998296737671
) O O 0.9999374151229858
, O O 0.9998121857643127
urea B B 0.9408441781997681
and O O 0.9691914916038513
electrolytes O O 0.6336586475372314
, O O 0.9999247789382935
serum O O 0.9938033819198608
bFGF O O 0.5429477691650391
and O O 0.9944498538970947
VEGF O B 0.9142809510231018
. O O 0.9999161958694458

Three O O 0.9910139441490173
men O O 0.9997523427009583
( O O 0.9998419284820557
15 O O 0.9999817609786987
% O O 0.9999150037765503
) O O 0.9999204874038696
showed O O 0.9999266862869263
a O O 0.9999874830245972
decline O O 0.9999815225601196
in O O 0.9999583959579468
serum O O 0.9973576664924622
PSA O O 0.7934679985046387
of O O 0.9997435212135315
at O O 0.9999852180480957
least O O 0.9999902248382568
50 O O 0.9999818801879883
% O O 0.999953031539917
, O O 0.9999605417251587
sustained O O 0.9999600648880005
throughout O O 0.9997263550758362
treatment O O 0.9999628067016602
. O O 0.9999736547470093

Of O O 0.9998977184295654
16 O O 0.9999815225601196
men O O 0.9999885559082031
treated O O 0.9999642372131348
for O O 0.9999339580535889
at O O 0.9999881982803345
least O O 0.9999910593032837
2 O O 0.9999483823776245
months O O 0.9999910593032837
, O O 0.9999697208404541
six O O 0.9998999834060669
( O O 0.9999434947967529
37 O O 0.9999911785125732
. O O 0.9999924898147583
5 O O 0.9999933242797852
% O O 0.9999872446060181
) O O 0.9999673366546631
showed O O 0.9999842643737793
a O O 0.9999947547912598
fall O O 0.9999945163726807
in O O 0.9999781847000122
absolute O O 0.988742470741272
PSA O O 0.9639664888381958
by O O 0.9999871253967285
a O O 0.9999862909317017
median O O 0.9999607801437378
of O O 0.9999616146087646
48 O O 0.9999959468841553
% O O 0.9999971389770508
. O O 0.9999786615371704

Increasing O O 0.9998847246170044
levels O O 0.9998670816421509
of O O 0.9998891353607178
serum O O 0.9990487694740295
bFGF O O 0.6775029301643372
and O O 0.9978558421134949
VEGF O B 0.9615089893341064
were O O 0.9998252987861633
associated O O 0.9999912977218628
with O O 0.9999887943267822
progressive O O 0.9999905824661255
disease O O 0.9999974966049194
; O O 0.9999676942825317
five O O 0.999992847442627
of O O 0.999980092048645
six O O 0.9999959468841553
men O O 0.9999878406524658
who O O 0.9999535083770752
demonstrated O O 0.9999728202819824
a O O 0.9999932050704956
fall O O 0.9999964237213135
in O O 0.9998999834060669
PSA O O 0.9732639789581299
also O O 0.9999769926071167
showed O O 0.9999631643295288
a O O 0.9999898672103882
decline O O 0.9999979734420776
in O O 0.9999698400497437
bFGF O O 0.469571590423584
and O O 0.9980204105377197
VEGF O B 0.974845290184021
levels O O 0.9997417330741882
, O O 0.9999319314956665
and O O 0.9999685287475586
three O O 0.9999831914901733
of O O 0.9999823570251465
four O O 0.9999904632568359
men O O 0.9999909400939941
with O O 0.999967098236084
a O O 0.9999892711639404
rising O O 0.9999606609344482
PSA O O 0.9891330599784851
showed O O 0.9999558925628662
an O O 0.9999880790710449
increase O O 0.9999794960021973
in O O 0.9999629259109497
both O O 0.959911584854126
growth O O 0.966806173324585
factors O O 0.999492883682251
. O O 0.9999555349349976

Adverse O O 0.9998224377632141
effects O O 0.9999843835830688
included O O 0.9999823570251465
constipation O O 0.9881574511528015
, O O 0.9999728202819824
morning O O 0.9999645948410034
drowsiness O O 0.9999949932098389
, O O 0.9999527931213379
dizziness O O 0.9999840259552002
and O O 0.9999208450317383
rash O O 0.9999926090240479
, O O 0.9999620914459229
and O O 0.9999810457229614
resulted O O 0.9999963045120239
in O O 0.999992847442627
withdrawal O O 0.9999797344207764
from O O 0.9999885559082031
the O O 0.9999939203262329
study O O 0.9999518394470215
by O O 0.9999746084213257
three O O 0.9997921586036682
men O O 0.999934196472168
. O O 0.9999654293060303

Evidence O O 0.9999672174453735
of O O 0.9999692440032959
peripheral O O 0.9997861981391907
sensory O O 0.9993165731430054
neuropathy O O 0.9999876022338867
was O O 0.9999784231185913
found O O 0.999990701675415
in O O 0.9999582767486572
nine O O 0.9999946355819702
of O O 0.999980092048645
13 O O 0.9999932050704956
men O O 0.999987006187439
before O O 0.9998279809951782
treatment O O 0.9999576807022095
. O O 0.9999630451202393

In O O 0.9998624324798584
the O O 0.9999840259552002
seven O O 0.9999852180480957
men O O 0.9999920129776001
who O O 0.9999908208847046
completed O O 0.9999897480010986
six O O 0.9999957084655762
months O O 0.9999963045120239
on O O 0.9997255206108093
thalidomide B B 0.9997016787528992
, O O 0.9998352527618408
subclinical O O 0.9999643564224243
evidence O O 0.9999969005584717
of O O 0.9999816417694092
peripheral O O 0.9999262094497681
neuropathy O O 0.9999955892562866
was O O 0.999987006187439
found O O 0.9999953508377075
in O O 0.9999291896820068
four O O 0.9994481205940247
before O O 0.9999014139175415
treatment O O 0.999984622001648
, O O 0.999976396560669
but O O 0.99994957447052
in O O 0.9999102354049683
all O O 0.999944806098938
seven O O 0.9999312162399292
at O O 0.9999854564666748
repeat O O 0.9999940395355225
testing O O 0.9999990463256836
. O O 0.999988317489624

The O O 0.9999871253967285
findings O O 0.9999959468841553
indicate O O 0.9999697208404541
that O O 0.9999284744262695
thalidomide B B 0.9998151659965515
may O O 0.9999020099639893
be O O 0.9999822378158569
an O O 0.9999583959579468
option O O 0.9999790191650391
for O O 0.9999459981918335
patients O O 0.9999932050704956
who O O 0.9999876022338867
have O O 0.9999970197677612
failed O O 0.9999909400939941
other O O 0.999975323677063
forms O O 0.9999767541885376
of O O 0.9999456405639648
therapy O O 0.9999699592590332
, O O 0.999966025352478
provided O O 0.9999781847000122
close O O 0.999985933303833
follow O O 0.9999920129776001
- O O 0.9999922513961792
up O O 0.9999966621398926
is O O 0.9999946355819702
maintained O O 0.9999958276748657
for O O 0.999993085861206
development O O 0.9999979734420776
of O O 0.9999885559082031
peripheral O O 0.999954104423523
neuropathy O O 0.9999939203262329
. O O 0.9999788999557495

Central O O 0.9993255138397217
nervous O O 0.9999825954437256
system O O 0.9999487400054932
toxicity O O 0.9999608993530273
following O O 0.9999107122421265
the O O 0.999967098236084
administration O O 0.9998859167098999
of O O 0.9971471428871155
levobupivacaine B B 0.9994947910308838
for O O 0.9991596937179565
lumbar O O 0.9983200430870056
plexus O O 0.9985218644142151
block O O 0.999920129776001
: O O 0.9999936819076538
A O O 0.9999973773956299
report O O 0.9999984502792358
of O O 0.999994158744812
two O O 0.9999960660934448
cases O O 0.9999939203262329
. O O 0.9999904632568359

BACKGROUND O O 0.9998214840888977
AND O O 0.9999816417694092
OBJECTIVES O O 0.9998644590377808
: O O 0.9999521970748901
Central O O 0.9991002082824707
nervous O O 0.9999866485595703
system O O 0.9999504089355469
and O O 0.9998881816864014
cardiac O O 0.9989417195320129
toxicity O O 0.999954342842102
following O O 0.9999555349349976
the O O 0.9999809265136719
administration O O 0.9999330043792725
of O O 0.9999489784240723
local O O 0.9978891015052795
anesthetics O O 0.9848119020462036
is O O 0.999966025352478
a O O 0.9999431371688843
recognized O O 0.9998266100883484
complication O O 0.9999887943267822
of O O 0.9998798370361328
regional O O 0.9998651742935181
anesthesia O O 0.996614396572113
. O O 0.9999527931213379

Levobupivacaine B B 0.9991816878318787
, O O 0.9998748302459717
the O O 0.9982298016548157
pure O O 0.9758427739143372
S O O 0.6930408477783203
( O O 0.6830655336380005
- O O 0.596868097782135
) O O 0.8015181422233582
enantiomer O O 0.8400973677635193
of O O 0.9916256070137024
bupivacaine B B 0.9980738162994385
, O O 0.9997518658638
was O O 0.9999617338180542
developed O O 0.9999781847000122
to O O 0.9999650716781616
improve O O 0.999984860420227
the O O 0.9999954700469971
cardiac O O 0.9999873638153076
safety O O 0.9999903440475464
profile O O 0.9999934434890747
of O O 0.999823272228241
bupivacaine B B 0.9995461106300354
. O O 0.9999390840530396

We O O 0.9999198913574219
describe O O 0.999980092048645
2 O O 0.9999631643295288
cases O O 0.9999951124191284
of O O 0.9999845027923584
grand O O 0.9996565580368042
mal O O 0.9999960660934448
seizures O O 0.999988317489624
following O O 0.9998961687088013
accidental O O 0.9998997449874878
intravascular O O 0.9999632835388184
injection O O 0.9999483823776245
of O O 0.995780348777771
levobupivacaine B B 0.9993634819984436
. O O 0.9998971223831177

CASE O O 0.9999504089355469
REPORT O O 0.9999970197677612
: O O 0.9999692440032959
Two O O 0.999995231628418
patients O O 0.9999911785125732
presenting O O 0.9999674558639526
for O O 0.9999926090240479
elective O O 0.9999946355819702
orthopedic O O 0.9999154806137085
surgery O O 0.9999977350234985
of O O 0.9999936819076538
the O O 0.999992847442627
lower O O 0.9999865293502808
limb O O 0.9999977350234985
underwent O O 0.9999599456787109
blockade O O 0.9998509883880615
of O O 0.999902606010437
the O O 0.9999287128448486
lumbar O O 0.9980095028877258
plexus O O 0.996311604976654
via O O 0.9999796152114868
the O O 0.999995231628418
posterior O O 0.9999903440475464
approach O O 0.9999978542327881
. O O 0.9999632835388184

Immediately O O 0.9999898672103882
after O O 0.9999731779098511
the O O 0.9999892711639404
administration O O 0.9999333620071411
of O O 0.9995946288108826
levobupivacaine B B 0.9997677206993103
0 O O 0.9604638814926147
. O O 0.9999638795852661
5 O O 0.99988853931427
% O O 0.9876356720924377
with O O 0.9991507530212402
epinephrine B B 0.9573233127593994
2 O O 0.9954659938812256
. O O 0.9999840259552002
5 O O 0.9999001026153564
microgram O O 0.9997816681861877
/ O O 0.9999444484710693
mL O O 0.9999973773956299
, O O 0.9999749660491943
the O O 0.9999921321868896
patients O O 0.9999896287918091
developed O O 0.9999861717224121
grand O O 0.905966579914093
mal O O 0.9999850988388062
seizures O O 0.9999912977218628
, O O 0.9999860525131226
despite O O 0.9999748468399048
negative O O 0.9998223185539246
aspiration O O 0.9999914169311523
for O O 0.9996904134750366
blood O O 0.9970280528068542
and O O 0.9999752044677734
no O O 0.9999904632568359
clinical O O 0.9999967813491821
signs O O 0.9999972581863403
of O O 0.9999819993972778
intravenous O O 0.9999514818191528
epinephrine B B 0.974886417388916
administration O O 0.9998559951782227
. O O 0.9999135732650757

The O O 0.9999485015869141
seizures O O 0.9999642372131348
were O O 0.9999815225601196
successfully O O 0.999962329864502
treated O O 0.9999539852142334
with O O 0.9997689127922058
sodium B B 0.9964339733123779
thiopental I I 0.9896710515022278
in O O 0.999642014503479
addition O O 0.9999102354049683
to O O 0.9992302656173706
succinylcholine B B 0.9995500445365906
in O O 0.999842643737793
1 O O 0.9994561076164246
patient O O 0.9999909400939941
. O O 0.9999701976776123

Neither O O 0.999896764755249
patient O O 0.9999688863754272
developed O O 0.9999638795852661
signs O O 0.9999920129776001
of O O 0.9999767541885376
cardiovascular O O 0.9995393753051758
toxicity O O 0.9997279047966003
. O O 0.9999545812606812

Both O O 0.9999158382415771
patients O O 0.9999879598617554
were O O 0.999962329864502
treated O O 0.9999426603317261
preoperatively O O 0.9999810457229614
with O O 0.9997655749320984
beta O O 0.927955687046051
- O O 0.98225337266922
adrenergic O O 0.9296935200691223
antagonist O O 0.8184849619865417
medications O O 0.9974654912948608
, O O 0.9999614953994751
which O O 0.9998811483383179
may O O 0.9998358488082886
have O O 0.9999796152114868
masked O O 0.9999626874923706
the O O 0.9999897480010986
cardiovascular O O 0.9999909400939941
signs O O 0.9999978542327881
of O O 0.9999659061431885
the O O 0.9999785423278809
unintentional O O 0.9999845027923584
intravascular O O 0.9999850988388062
administration O O 0.9999579191207886
of O O 0.998271107673645
levobupivacaine B B 0.9997852444648743
with O O 0.9942654967308044
epinephrine B B 0.9932358860969543
. O O 0.9998973608016968

CONCLUSIONS O O 0.9862668514251709
: O O 0.9999639987945557
Although O O 0.9997939467430115
levobupivacaine B B 0.9996024966239929
may O O 0.9999064207077026
have O O 0.9999696016311646
a O O 0.9999775886535645
safer O O 0.9998883008956909
cardiac O O 0.9998949766159058
toxicity O O 0.999937891960144
profile O O 0.9999761581420898
than O O 0.9990532994270325
racemic O O 0.9959516525268555
bupivacaine B B 0.9989175796508789
, O O 0.9997982382774353
if O O 0.9999746084213257
adequate O O 0.9999576807022095
amounts O O 0.9999603033065796
of O O 0.999832034111023
levobupivacaine B B 0.9992510676383972
reach O O 0.9997348189353943
the O O 0.9999094009399414
circulation O O 0.9999008178710938
, O O 0.9999547004699707
it O O 0.999855637550354
will O O 0.999956488609314
result O O 0.9999856948852539
in O O 0.9999840259552002
convulsions O O 0.9999538660049438
. O O 0.9999663829803467

Plasma O O 0.9996095299720764
concentrations O O 0.9998193383216858
sufficient O O 0.9999675750732422
to O O 0.9999841451644897
result O O 0.9999788999557495
in O O 0.9999269247055054
central O O 0.9993675351142883
nervous O O 0.9999712705612183
system O O 0.999764621257782
toxicity O O 0.9998601675033569
did O O 0.9999655485153198
not O O 0.999945878982544
produce O O 0.9999715089797974
manifestations O O 0.9999871253967285
of O O 0.9999724626541138
cardiac O O 0.8625210523605347
toxicity O O 0.9998724460601807
in O O 0.9999363422393799
these O O 0.9999749660491943
2 O O 0.9999096393585205
patients O O 0.9999889135360718
. O O 0.9999711513519287

Amiodarone B B 0.9986212253570557
- O O 0.9989830851554871
induced O O 0.999958872795105
torsade O O 0.9999619722366333
de O O 0.9999915361404419
pointes O O 0.9999434947967529
during O O 0.9999455213546753
bladder O O 0.9978910088539124
irrigation O O 0.999817430973053
: O O 0.9999781847000122
an O O 0.9999953508377075
unusual O O 0.9999866485595703
presentation O O 0.9999966621398926
- O O 0.9983817338943481
- O O 0.9983766078948975
a O O 0.9999921321868896
case O O 0.9999804496765137
report O O 0.9999963045120239
. O O 0.9999887943267822

The O O 0.9999914169311523
authors O O 0.999997615814209
present O O 0.999996542930603
a O O 0.999995231628418
case O O 0.9999953508377075
of O O 0.999984860420227
early O O 0.9999915361404419
( O O 0.9999803304672241
within O O 0.9999966621398926
4 O O 0.9999740123748779
days O O 0.9999955892562866
) O O 0.999988317489624
development O O 0.9999974966049194
of O O 0.9999897480010986
torsade O O 0.9992208480834961
de O O 0.9999402761459351
pointes O O 0.9997612833976746
( O O 0.9999533891677856
TdP O O 0.996871292591095
) O O 0.9999788999557495
associated O O 0.9999814033508301
with O O 0.9999333620071411
oral O O 0.9963484406471252
amiodarone B B 0.9996756315231323
therapy O O 0.9998071789741516
. O O 0.9999816417694092

Consistent O O 0.9999825954437256
with O O 0.9999892711639404
other O O 0.9999693632125854
reports O O 0.999995231628418
this O O 0.9999847412109375
case O O 0.9999822378158569
of O O 0.9999436140060425
TdP O O 0.9650439620018005
occurred O O 0.9999575614929199
in O O 0.9999372959136963
the O O 0.9999758005142212
context O O 0.9999591112136841
of O O 0.9998664855957031
multiple O O 0.9997324347496033
exacerbating O O 0.9999152421951294
factors O O 0.9999827146530151
including O O 0.9998036026954651
hypokalemia O O 0.9910441637039185
and O O 0.9997010827064514
digoxin B B 0.9986512064933777
excess O O 0.9882630705833435
. O O 0.9999533891677856

Transient O O 0.9999606609344482
prolongation O O 0.999970555305481
of O O 0.9999762773513794
the O O 0.9999492168426514
QT O O 0.9795316457748413
during O O 0.9996160268783569
bladder O O 0.985517680644989
irrigation O O 0.9993054866790771
prompted O O 0.9999544620513916
the O O 0.9999911785125732
episode O O 0.9999744892120361
of O O 0.9999550580978394
TdP O O 0.8910759091377258
. O O 0.9999268054962158

It O O 0.9999775886535645
is O O 0.9999644756317139
well O O 0.9999462366104126
known O O 0.9999470710754395
that O O 0.9997950196266174
bradycardia O O 0.9993531107902527
exacerbates O O 0.9999585151672363
acquired O O 0.9989571571350098
TdP O O 0.9691725373268127
. O O 0.9999220371246338

The O O 0.9999697208404541
authors O O 0.9999898672103882
speculate O O 0.9999604225158691
that O O 0.9998918771743774
the O O 0.9999773502349854
increased O O 0.9999233484268188
vagal O O 0.9981335997581482
tone O O 0.999872088432312
during O O 0.9996922016143799
bladder O O 0.994509756565094
irrigation O O 0.9999024868011475
, O O 0.9999614953994751
a O O 0.9998657703399658
vagal O O 0.9880028963088989
maneuver O O 0.9999160766601562
, O O 0.9999616146087646
in O O 0.9999688863754272
the O O 0.9999908208847046
context O O 0.9999579191207886
of O O 0.9998711347579956
amiodarone B B 0.9998366832733154
therapy O O 0.9996994733810425
resulted O O 0.9999830722808838
in O O 0.9999665021896362
amiodarone B B 0.999873161315918
- O O 0.999931812286377
induced O O 0.9999594688415527
proarrhythmia O O 0.9999223947525024
. O O 0.9999710321426392

In O O 0.999974250793457
the O O 0.9999892711639404
absence O O 0.9999743700027466
of O O 0.9998531341552734
amiodarone B B 0.9998136162757874
therapy O O 0.9998262524604797
, O O 0.9999583959579468
a O O 0.9999626874923706
second O O 0.9999834299087524
bladder O O 0.9888342022895813
irrigation O O 0.8859456181526184
did O O 0.9999470710754395
not O O 0.999930739402771
induce O O 0.9999532699584961
TdP O O 0.9409763216972351
despite O O 0.9997355341911316
hypokalemia O O 0.9992328882217407
and O O 0.9999154806137085
hypomagnesemia O O 0.9984958171844482
. O O 0.9999574422836304

Anaesthetic O O 0.9876928925514221
complications O O 0.9999704360961914
associated O O 0.9999725818634033
with O O 0.9999191761016846
myotonia O O 0.9999457597732544
congenita O O 0.9976848363876343
: O O 0.9999759197235107
case O O 0.9999737739562988
study O O 0.999996542930603
and O O 0.9999933242797852
comparison O O 0.999994158744812
with O O 0.9999810457229614
other O O 0.9999465942382812
myotonic O O 0.9999686479568481
disorders O O 0.9999854564666748
. O O 0.9999816417694092

Myotonia O O 0.9999133348464966
congenita O O 0.9977970123291016
( O O 0.9998944997787476
MC O O 0.9979165196418762
) O O 0.9999752044677734
is O O 0.9999294281005859
caused O O 0.999977707862854
by O O 0.9999725818634033
a O O 0.9999516010284424
defect O O 0.9999756813049316
in O O 0.9999332427978516
the O O 0.9999281167984009
skeletal O O 0.9978731870651245
muscle O O 0.9984422326087952
chloride B B 0.9708248376846313
channel O O 0.963129997253418
function O O 0.9998804330825806
, O O 0.9999548196792603
which O O 0.9997851252555847
may O O 0.9998973608016968
cause O O 0.9999194145202637
sustained O O 0.9999017715454102
membrane O O 0.9998791217803955
depolarisation O O 0.9999624490737915
. O O 0.9999653100967407

We O O 0.9999873638153076
describe O O 0.9999966621398926
a O O 0.999992847442627
previously O O 0.9999902248382568
healthy O O 0.9999951124191284
32 O O 0.9999953508377075
- O O 0.9999866485595703
year O O 0.9999963045120239
- O O 0.9999939203262329
old O O 0.9999954700469971
woman O O 0.9999974966049194
who O O 0.9999561309814453
developed O O 0.9999861717224121
a O O 0.999990701675415
life O O 0.9998974800109863
- O O 0.999988317489624
threatening O O 0.9999951124191284
muscle O O 0.9998897314071655
spasm O O 0.9987326264381409
and O O 0.9999558925628662
secondary O O 0.9998979568481445
ventilation O O 0.9969246983528137
difficulties O O 0.9999943971633911
following O O 0.9999624490737915
a O O 0.9999876022338867
preoperative O O 0.9999349117279053
injection O O 0.9999772310256958
of O O 0.9964572787284851
suxamethonium B B 0.9989398121833801
. O O 0.9999405145645142

The O O 0.9999574422836304
muscle O O 0.9997996687889099
spasms O O 0.9993890523910522
disappeared O O 0.999947190284729
spontaneously O O 0.999988317489624
and O O 0.9999889135360718
the O O 0.9999951124191284
surgery O O 0.9999960660934448
proceeded O O 0.9999979734420776
without O O 0.9999967813491821
further O O 0.9999973773956299
problems O O 0.9999984502792358
. O O 0.9999854564666748

When O O 0.9999717473983765
subsequently O O 0.9999921321868896
questioned O O 0.9999934434890747
, O O 0.9999631643295288
she O O 0.9999449253082275
reported O O 0.9999637603759766
minor O O 0.9999798536300659
symptoms O O 0.9999960660934448
suggesting O O 0.9999803304672241
a O O 0.9999414682388306
myotonic O O 0.9999892711639404
condition O O 0.9999899864196777
. O O 0.999967098236084

Myotonia O O 0.999870777130127
was O O 0.9999352693557739
found O O 0.9999794960021973
on O O 0.9999896287918091
clinical O O 0.9999868869781494
examination O O 0.9999983310699463
and O O 0.999961256980896
EMG O O 0.670866072177887
. O O 0.999666690826416

The O O 0.9999557733535767
diagnosis O O 0.9998544454574585
MC O O 0.7995048761367798
was O O 0.9999479055404663
confirmed O O 0.99994957447052
genetically O O 0.9999758005142212
. O O 0.9999651908874512

Neither O O 0.9999613761901855
the O O 0.9999853372573853
patient O O 0.9999878406524658
nor O O 0.999955415725708
the O O 0.9999796152114868
anaesthetist O O 0.9772272706031799
were O O 0.999976396560669
aware O O 0.9999953508377075
of O O 0.9999914169311523
the O O 0.999988317489624
diagnosis O O 0.9999911785125732
before O O 0.999992847442627
this O O 0.9999810457229614
potentially O O 0.9999666213989258
lethal O O 0.9999606609344482
complication O O 0.9999887943267822
occurred O O 0.9999973773956299
. O O 0.9999713897705078

We O O 0.9999620914459229
give O O 0.9999822378158569
a O O 0.9999675750732422
brief O O 0.9999884366989136
overview O O 0.9999850988388062
of O O 0.9998778104782104
ion O O 0.8049662709236145
channel O O 0.9567270874977112
disorders O O 0.9999316930770874
including O O 0.999616265296936
malignant O O 0.999991774559021
hyperthermia O O 0.653182327747345
and O O 0.9999090433120728
their O O 0.9994572997093201
anaesthetic O O 0.9858636260032654
considerations O O 0.9999593496322632
. O O 0.9999622106552124

Respiratory O O 0.9994935989379883
pattern O O 0.9999581575393677
in O O 0.9999358654022217
a O O 0.9999518394470215
rat O O 0.9999669790267944
model O O 0.9999841451644897
of O O 0.9998944997787476
epilepsy O O 0.9998680353164673
. O O 0.9999438524246216

PURPOSE O O 0.9682630300521851
: O O 0.9991999268531799
Apnea O O 0.8397486805915833
is O O 0.9999736547470093
known O O 0.9997870326042175
to O O 0.9999310970306396
occur O O 0.999981164932251
during O O 0.9998898506164551
seizures O O 0.9999531507492065
, O O 0.9999334812164307
but O O 0.9999387264251709
systematic O O 0.999957799911499
studies O O 0.9999939203262329
of O O 0.9999886751174927
ictal O O 0.9999494552612305
respiratory O O 0.9999563694000244
changes O O 0.9999990463256836
in O O 0.9999626874923706
adults O O 0.9999887943267822
are O O 0.9999808073043823
few O O 0.9999924898147583
. O O 0.9999693632125854

Data O O 0.9999744892120361
regarding O O 0.9999513626098633
respiratory O O 0.9998745918273926
pattern O O 0.9999867677688599
defects O O 0.9999933242797852
during O O 0.999832034111023
interictal O O 0.9968156218528748
periods O O 0.999957799911499
also O O 0.999951958656311
are O O 0.9999750852584839
scarce O O 0.9999887943267822
. O O 0.9999605417251587

Here O O 0.9999809265136719
we O O 0.999972939491272
sought O O 0.9999961853027344
to O O 0.9999954700469971
generate O O 0.9999979734420776
information O O 0.999992847442627
with O O 0.9999960660934448
regard O O 0.9999966621398926
to O O 0.9999877214431763
the O O 0.999971866607666
interictal O O 0.9985976815223694
period O O 0.9999886751174927
in O O 0.9999616146087646
animals O O 0.9999933242797852
with O O 0.9999432563781738
pilocarpine B B 0.99972003698349
- O O 0.9997115731239319
induced O O 0.9998888969421387
epilepsy O O 0.9998212456703186
. O O 0.999964714050293

METHODS O O 0.999702513217926
: O O 0.9999939203262329
Twelve O O 0.9999961853027344
rats O O 0.9999964237213135
( O O 0.999964714050293
six O O 0.9999861717224121
chronically O O 0.9997890591621399
epileptic O O 0.9996393918991089
animals O O 0.9999922513961792
and O O 0.9999343156814575
six O O 0.9999058246612549
controls O O 0.9999616146087646
) O O 0.9999121427536011
were O O 0.9999823570251465
anesthetized O O 0.9999779462814331
, O O 0.9999866485595703
given O O 0.9998682737350464
tracheotomies O O 0.9956003427505493
, O O 0.9999347925186157
and O O 0.9999537467956543
subjected O O 0.9999821186065674
to O O 0.9998533725738525
hyperventilation O O 0.9885873794555664
or O O 0.9996713399887085
hypoventilation O O 0.9875308871269226
conditions O O 0.9998773336410522
. O O 0.9999558925628662

Breathing O O 0.9994001388549805
movements O O 0.9998028874397278
caused O O 0.9999717473983765
changes O O 0.9999980926513672
in O O 0.9999899864196777
thoracic O O 0.9990239143371582
volume O O 0.999893069267273
and O O 0.9999110698699951
forced O O 0.9999856948852539
air O O 0.7477895021438599
to O O 0.9999454021453857
flow O O 0.9999699592590332
tidally O O 0.999340832233429
through O O 0.99993896484375
a O O 0.9999827146530151
pneumotachograph O O 0.9999159574508667
. O O 0.9999403953552246

This O O 0.996325671672821
flow O O 0.9999767541885376
was O O 0.9999816417694092
measured O O 0.9999947547912598
by O O 0.9999954700469971
using O O 0.9999862909317017
a O O 0.9999812841415405
differential O O 0.9943456053733826
pressure O O 0.9950392842292786
transducer O O 0.9997989535331726
, O O 0.9999818801879883
passed O O 0.9999972581863403
through O O 0.9999806880950928
a O O 0.9999827146530151
polygraph O O 0.9998382329940796
, O O 0.9999644756317139
and O O 0.9999934434890747
from O O 0.9999934434890747
this O O 0.9999942779541016
to O O 0.9999810457229614
a O O 0.9999858140945435
computer O O 0.9999947547912598
with O O 0.9999879598617554
custom O O 0.9999772310256958
software O O 0.9999959468841553
that O O 0.9999871253967285
derived O O 0.9999850988388062
ventilation O O 0.9999949932098389
( O O 0.999948263168335
VE O O 0.8576757907867432
) O O 0.9999740123748779
, O O 0.9999799728393555
tidal O O 0.9999912977218628
volume O O 0.9999949932098389
( O O 0.9999394416809082
VT O O 0.9870715737342834
) O O 0.9999794960021973
, O O 0.9999527931213379
inspiratory O O 0.9999468326568604
time O O 0.9999947547912598
( O O 0.9999337196350098
TI O O 0.9999580383300781
) O O 0.9999773502349854
, O O 0.999925971031189
expiratory O O 0.9999279975891113
time O O 0.9999850988388062
( O O 0.9999338388442993
TE O O 0.9999741315841675
) O O 0.9999825954437256
, O O 0.9999696016311646
breathing O O 0.9999686479568481
frequency O O 0.9999980926513672
( O O 0.9999533891677856
f O O 0.9999985694885254
) O O 0.9999936819076538
, O O 0.9999489784240723
and O O 0.9999362230300903
mean O O 0.9999721050262451
inspiratory O O 0.9998773336410522
flow O O 0.9999954700469971
( O O 0.9998743534088135
VT O O 0.97412109375
/ O O 0.9999061822891235
TI O O 0.9982957243919373
) O O 0.9999877214431763
on O O 0.9999974966049194
a O O 0.9999961853027344
breath O O 0.9999831914901733
- O O 0.9999934434890747
by O O 0.9999927282333374
- O O 0.999994158744812
breath O O 0.9999935626983643
basis O O 0.9999964237213135
. O O 0.9999771118164062

RESULTS O O 0.9998131394386292
: O O 0.9999475479125977
The O O 0.9999785423278809
hyperventilation O O 0.9922198057174683
maneuver O O 0.9997643828392029
caused O O 0.9999055862426758
a O O 0.9999703168869019
decrease O O 0.9999921321868896
in O O 0.9999822378158569
spontaneous O O 0.9999814033508301
ventilation O O 0.9999947547912598
in O O 0.9998337030410767
pilocarpine B B 0.9998337030410767
- O O 0.9996670484542847
treated O O 0.9997721314430237
and O O 0.9988142251968384
control O O 0.9991682767868042
rats O O 0.9999926090240479
. O O 0.9999679327011108

Although O O 0.9998921155929565
VE O O 0.6238661408424377
had O O 0.9999650716781616
a O O 0.9999829530715942
similar O O 0.9999856948852539
decrease O O 0.9999948740005493
in O O 0.999612033367157
both O O 0.998214840888977
groups O O 0.999900221824646
, O O 0.9999518394470215
in O O 0.9997738003730774
the O O 0.9998475313186646
epileptic O O 0.9979404807090759
group O O 0.9999150037765503
, O O 0.9999229907989502
the O O 0.9999905824661255
decrease O O 0.9999942779541016
in O O 0.999915599822998
VE O O 0.9703622460365295
was O O 0.9999692440032959
due O O 0.999993085861206
to O O 0.9999721050262451
a O O 0.9999836683273315
significant O O 0.9999872446060181
( O O 0.999945878982544
p O O 0.9999768733978271
< O O 0.9999825954437256
0 O O 0.9999921321868896
. O O 0.999996542930603
05 O O 0.9999942779541016
) O O 0.9999548196792603
increase O O 0.9999798536300659
in O O 0.9999641180038452
TE O O 0.6948127150535583
peak O O 0.9998914003372192
in O O 0.9999862909317017
relation O O 0.9999948740005493
to O O 0.9999779462814331
that O O 0.9999878406524658
of O O 0.9999727010726929
the O O 0.999907374382019
control O O 0.9998476505279541
animals O O 0.9999779462814331
. O O 0.9999399185180664

The O O 0.9999781847000122
hypoventilation O O 0.9998824596405029
maneuver O O 0.999817430973053
led O O 0.9999597072601318
to O O 0.9999767541885376
an O O 0.9999876022338867
increase O O 0.999966025352478
in O O 0.9999642372131348
the O O 0.9999363422393799
arterial O O 0.9995846152305603
Paco2 O O 0.8145935535430908
, O O 0.9997780919075012
followed O O 0.9999620914459229
by O O 0.999976634979248
an O O 0.9999814033508301
increase O O 0.9999723434448242
in O O 0.9998363256454468
VE O O 0.8770434856414795
. O O 0.9995958209037781

In O O 0.9995846152305603
the O O 0.9997977614402771
epileptic O O 0.998580813407898
group O O 0.9998663663864136
, O O 0.9999440908432007
the O O 0.9999880790710449
increase O O 0.9999808073043823
in O O 0.999944806098938
VE O O 0.9963569045066833
was O O 0.9999548196792603
mediated O O 0.9999762773513794
by O O 0.999980092048645
a O O 0.9999812841415405
significant O O 0.9999877214431763
( O O 0.9999620914459229
p O O 0.9999896287918091
< O O 0.9999864101409912
0 O O 0.9999895095825195
. O O 0.9999967813491821
05 O O 0.9999951124191284
) O O 0.9999639987945557
decrease O O 0.9999908208847046
in O O 0.9999773502349854
TE O O 0.925321638584137
peak O O 0.9999890327453613
compared O O 0.9999927282333374
with O O 0.9999929666519165
the O O 0.9999780654907227
control O O 0.9998539686203003
group O O 0.9999643564224243
. O O 0.9999641180038452

Systemic O O 0.9997877478599548
application O O 0.9998762607574463
of O O 0.9997691512107849
KCN O B 0.9971503615379333
, O O 0.9998270869255066
to O O 0.999980092048645
evaluate O O 0.999985933303833
the O O 0.9999808073043823
effects O O 0.999958872795105
of O O 0.9999222755432129
peripheral O O 0.998556911945343
chemoreception O O 0.8072802424430847
activation O O 0.907672643661499
on O O 0.9996297359466553
ventilation O O 0.9999390840530396
, O O 0.999980092048645
led O O 0.9999855756759644
to O O 0.999995231628418
a O O 0.9999966621398926
similar O O 0.999996542930603
increase O O 0.9999954700469971
in O O 0.9999828338623047
VE O O 0.9996408224105835
for O O 0.999907374382019
both O O 0.9998492002487183
groups O O 0.9999780654907227
. O O 0.9999788999557495

CONCLUSIONS O O 0.9991716146469116
: O O 0.9999951124191284
The O O 0.9999923706054688
data O O 0.9999881982803345
indicate O O 0.9999512434005737
that O O 0.9998248219490051
pilocarpine B B 0.9998782873153687
- O O 0.999607503414154
treated O O 0.9997528195381165
animals O O 0.9999560117721558
have O O 0.9999544620513916
an O O 0.9999773502349854
altered O O 0.9999876022338867
ability O O 0.9999884366989136
to O O 0.9999814033508301
react O O 0.9999856948852539
to O O 0.9999699592590332
( O O 0.9998977184295654
or O O 0.9999533891677856
compensate O O 0.9999697208404541
for O O 0.9999666213989258
) O O 0.999955415725708
blood O O 0.9993435740470886
gas O O 0.998252809047699
changes O O 0.9999932050704956
with O O 0.9999841451644897
changes O O 0.9999974966049194
in O O 0.9999773502349854
ventilation O O 0.9905986189842224
and O O 0.9999696016311646
suggest O O 0.9999692440032959
that O O 0.9999803304672241
it O O 0.9999876022338867
is O O 0.9999825954437256
centrally O O 0.9999246597290039
determined O O 0.999990701675415
. O O 0.9999837875366211

We O O 0.9999465942382812
speculate O O 0.9999605417251587
on O O 0.9999290704727173
the O O 0.9999868869781494
possible O O 0.9999366998672485
relation O O 0.9999932050704956
of O O 0.9999780654907227
the O O 0.9999967813491821
current O O 0.9999966621398926
findings O O 0.9999942779541016
on O O 0.9998471736907959
treating O O 0.9992632269859314
different O O 0.9998682737350464
epilepsy O O 0.9996379613876343
- O O 0.9998688697814941
associated O O 0.9999605417251587
conditions O O 0.9999874830245972
. O O 0.999957799911499

Fatal O O 0.9983918070793152
myeloencephalopathy O O 0.9999972581863403
due O O 0.9999796152114868
to O O 0.9994956254959106
intrathecal O O 0.9998641014099121
vincristine B B 0.9975002408027649
administration O O 0.999776303768158
. O O 0.9999374151229858

Vincristine B B 0.9985877275466919
was O O 0.9996681213378906
accidentally O O 0.9999083280563354
given O O 0.9999300241470337
intrathecally O O 0.9999723434448242
to O O 0.9999696016311646
a O O 0.9999935626983643
child O O 0.9999985694885254
with O O 0.9999821186065674
leukaemia O O 0.9999828338623047
, O O 0.999963641166687
producing O O 0.9991610050201416
sensory O O 0.999909520149231
and O O 0.999872088432312
motor O O 0.999964714050293
dysfunction O O 0.9999947547912598
followed O O 0.9999603033065796
by O O 0.9999732971191406
encephalopathy O O 0.9999512434005737
and O O 0.9999736547470093
death O O 0.9999860525131226
. O O 0.9999774694442749

Separate O O 0.9997546076774597
times O O 0.9999582767486572
for O O 0.9999724626541138
administering O O 0.999842643737793
vincristine B B 0.9990597367286682
and O O 0.9995361566543579
intrathecal O O 0.9999641180038452
therapy O O 0.9999806880950928
is O O 0.9999887943267822
recommended O O 0.9999856948852539
. O O 0.999982476234436

Progesterone B B 0.9148187637329102
potentiation O O 0.9682710766792297
of O O 0.9995138645172119
bupivacaine B B 0.9995087385177612
arrhythmogenicity O O 0.9992284774780273
in O O 0.9998593330383301
pentobarbital B B 0.9996742010116577
- O O 0.9992249011993408
anesthetized O O 0.9989396929740906
rats O O 0.9999817609786987
and O O 0.9999362230300903
beating O O 0.9992480874061584
rat O O 0.9999750852584839
heart O O 0.9999200105667114
cell O O 0.9999619722366333
cultures O O 0.9999643564224243
. O O 0.9999269247055054

The O O 0.9999805688858032
effects O O 0.9999669790267944
of O O 0.9998596906661987
progesterone B B 0.9925794005393982
treatment O O 0.9991188645362854
on O O 0.9997343420982361
bupivacaine B B 0.9990116357803345
arrhythmogenicity O O 0.9996463060379028
in O O 0.9998284578323364
beating O O 0.9996823072433472
rat O O 0.9999783039093018
heart O O 0.999935507774353
myocyte O O 0.9998875856399536
cultures O O 0.9998075366020203
and O O 0.9999322891235352
on O O 0.999871015548706
anesthetized O O 0.9999781847000122
rats O O 0.9999920129776001
were O O 0.9999858140945435
determined O O 0.9999744892120361
. O O 0.9999768733978271

After O O 0.9999946355819702
determining O O 0.9999535083770752
the O O 0.9998455047607422
bupivacaine B B 0.9990736246109009
AD50 O O 0.8595978021621704
( O O 0.9999436140060425
the O O 0.9999794960021973
concentration O O 0.999322772026062
of O O 0.9996275901794434
bupivacaine B B 0.9991137385368347
that O O 0.9997562766075134
caused O O 0.9999336004257202
50 O O 0.9999692440032959
% O O 0.9999871253967285
of O O 0.9999418258666992
all O O 0.9998613595962524
beating O O 0.9997126460075378
rat O O 0.9982062578201294
heart O O 0.9998262524604797
myocyte O O 0.999923586845398
cultures O O 0.9998795986175537
to O O 0.9999828338623047
become O O 0.9999905824661255
arrhythmic O O 0.9999113082885742
) O O 0.9999699592590332
, O O 0.999968409538269
we O O 0.999975323677063
determined O O 0.9999908208847046
the O O 0.9999867677688599
effect O O 0.999977707862854
of O O 0.9998890161514282
1 O O 0.9974415302276611
- O O 0.9998668432235718
hour O O 0.9995759129524231
progesterone B B 0.9870945811271667
HCl B O 0.7710505127906799
exposure O O 0.9996167421340942
on O O 0.9998948574066162
myocyte O O 0.9999935626983643
contractile O O 0.9999583959579468
rhythm O O 0.9999836683273315
. O O 0.9999692440032959

Each O O 0.9957610964775085
concentration O O 0.9986145496368408
of O O 0.997435986995697
progesterone B B 0.9910942912101746
( O O 0.9989548921585083
6 O O 0.9959347248077393
. O O 0.9996187686920166
25 O O 0.9992167949676514
, O O 0.999087929725647
12 O O 0.9993601441383362
. O O 0.9996340274810791
5 O O 0.9996465444564819
, O O 0.9988635778427124
25 O O 0.9990861415863037
, O O 0.9991279244422913
and O O 0.9989973902702332
50 O O 0.9999624490737915
micrograms O O 0.9995670914649963
/ O O 0.9997387528419495
ml O O 0.999994158744812
) O O 0.999874472618103
caused O O 0.9999514818191528
a O O 0.9999748468399048
significant O O 0.9999799728393555
and O O 0.9999669790267944
concentration O O 0.9987088441848755
- O O 0.9999525547027588
dependent O O 0.9999823570251465
reduction O O 0.9999911785125732
in O O 0.9999750852584839
the O O 0.9999524354934692
AD50 O O 0.998819887638092
for O O 0.9996426105499268
bupivacaine B B 0.9998400211334229
. O O 0.9999617338180542

Estradiol B B 0.9934515953063965
treatment O O 0.9994014501571655
also O O 0.9999648332595825
increased O O 0.999916672706604
the O O 0.9999901056289673
arrhythmogenicity O O 0.999988317489624
of O O 0.9998227953910828
bupivacaine B B 0.9992641806602478
in O O 0.9996459484100342
myocyte O O 0.9999924898147583
cultures O O 0.9999322891235352
, O O 0.9999377727508545
but O O 0.9998569488525391
was O O 0.9999455213546753
only O O 0.9999760389328003
one O O 0.9999881982803345
fourth O O 0.9999518394470215
as O O 0.9999698400497437
potent O O 0.9994624257087708
as O O 0.9988948702812195
progesterone B B 0.9703529477119446
. O O 0.999886155128479

Neither O O 0.9996886253356934
progesterone B B 0.9696424007415771
nor O O 0.9933604598045349
estradiol B B 0.9758604764938354
effects O O 0.999727189540863
on O O 0.9998605251312256
bupivacaine B B 0.9993144273757935
arrhythmogenicity O O 0.9980042576789856
were O O 0.9999599456787109
potentiated O O 0.9998427629470825
by O O 0.9998106360435486
epinephrine B B 0.9985910058021545
. O O 0.9999333620071411

Chronic O O 0.9876216053962708
progesterone B B 0.9954423904418945
pretreatment O O 0.9995737671852112
( O O 0.9999301433563232
5 O O 0.9996923208236694
mg O O 0.9998077750205994
/ O O 0.9999558925628662
kg O O 0.9999974966049194
/ O O 0.9999147653579712
day O O 0.999993085861206
for O O 0.999972939491272
21 O O 0.9999831914901733
days O O 0.9999901056289673
) O O 0.9999508857727051
caused O O 0.9999616146087646
a O O 0.9999866485595703
significant O O 0.9999877214431763
increase O O 0.9999830722808838
in O O 0.9999523162841797
bupivacaine B B 0.9993269443511963
arrhythmogenicity O O 0.9995753169059753
in O O 0.9999057054519653
intact O O 0.9999171495437622
pentobarbital B B 0.9993108510971069
- O O 0.9987514019012451
anesthetized O O 0.9998335838317871
rats O O 0.9999880790710449
. O O 0.9999779462814331

There O O 0.9999680519104004
was O O 0.999981164932251
a O O 0.999990701675415
significant O O 0.9999902248382568
decrease O O 0.9999955892562866
in O O 0.999992847442627
the O O 0.9999959468841553
time O O 0.9999970197677612
to O O 0.9999972581863403
onset O O 0.9999972581863403
of O O 0.9999864101409912
arrhythmia O O 0.9999936819076538
as O O 0.9999831914901733
compared O O 0.9999951124191284
with O O 0.9999886751174927
control O O 0.9999282360076904
nonprogesterone O O 0.7466638088226318
- O O 0.9963902831077576
treated O O 0.9993661046028137
rats O O 0.9998331069946289
( O O 0.9999741315841675
6 O O 0.9999487400054932
. O O 0.999992847442627
2 O O 0.9999854564666748
+ O O 0.9999889135360718
/ O O 0.9999812841415405
- O O 0.9999613761901855
1 O O 0.9999911785125732
. O O 0.9999957084655762
3 O O 0.999990701675415
vs O O 0.9999363422393799
. O O 0.9999957084655762
30 O O 0.9999783039093018
. O O 0.9999954700469971
8 O O 0.9999933242797852
+ O O 0.9999878406524658
/ O O 0.999971866607666
- O O 0.9999772310256958
2 O O 0.9999878406524658
. O O 0.9999935626983643
5 O O 0.9999889135360718
min O O 0.9999945163726807
, O O 0.9999767541885376
mean O O 0.9998955726623535
+ O O 0.9999936819076538
/ O O 0.9999872446060181
- O O 0.9999805688858032
SE O O 0.9999390840530396
) O O 0.9999771118164062
. O O 0.9999756813049316

The O O 0.9999891519546509
results O O 0.9999946355819702
of O O 0.9999947547912598
this O O 0.9999825954437256
study O O 0.999975323677063
indicate O O 0.9999370574951172
that O O 0.9997872710227966
progesterone B B 0.9875872731208801
can O O 0.9997230172157288
potentiate O O 0.9964679479598999
bupivacaine B B 0.9993439316749573
arrhythmogenicity O O 0.9989084005355835
both O O 0.9999314546585083
in O O 0.9999306201934814
vivo O O 0.9999744892120361
and O O 0.9999511241912842
in O O 0.9999195337295532
vitro O O 0.9999876022338867
. O O 0.9999759197235107

Potentiation O O 0.9999125003814697
of O O 0.999796450138092
bupivacaine B B 0.9993884563446045
arrhythmia O O 0.9993940591812134
in O O 0.9996875524520874
myocyte O O 0.9999899864196777
cultures O O 0.9998903274536133
suggests O O 0.9999574422836304
that O O 0.9999562501907349
this O O 0.9998743534088135
effect O O 0.9999014139175415
is O O 0.9999557733535767
at O O 0.9999737739562988
least O O 0.9999821186065674
partly O O 0.9996950626373291
mediated O O 0.9999644756317139
at O O 0.999925971031189
the O O 0.9999161958694458
myocyte O O 0.9999909400939941
level O O 0.9998993873596191
. O O 0.9999701976776123

Increased O O 0.9998202919960022
serum O O 0.9975268244743347
soluble O O 0.7907636165618896
Fas O O 0.7612380385398865
in O O 0.9999208450317383
patients O O 0.999994158744812
with O O 0.9999866485595703
acute O O 0.9999877214431763
liver O O 0.9988235831260681
failure O O 0.9999942779541016
due O O 0.9999699592590332
to O O 0.9996466636657715
paracetamol B B 0.9994082450866699
overdose O O 0.993220329284668
. O O 0.9999485015869141

BACKGROUND O O 0.9995403289794922
/ O O 0.9999638795852661
AIMS O O 0.9999532699584961
: O O 0.9999861717224121
Experimental O O 0.9999605417251587
studies O O 0.9999912977218628
have O O 0.9999797344207764
suggested O O 0.999981164932251
that O O 0.9999074935913086
apoptosis O O 0.9910187721252441
via O O 0.999895453453064
the O O 0.9996634721755981
Fas O O 0.9580993056297302
/ O O 0.9987156391143799
Fas O O 0.8469651341438293
Ligand O O 0.9768075942993164
signaling O O 0.9969252943992615
system O O 0.9992940425872803
may O O 0.9999147653579712
play O O 0.9999432563781738
an O O 0.9999490976333618
important O O 0.9999465942382812
role O O 0.9999828338623047
in O O 0.9999830722808838
the O O 0.9999830722808838
development O O 0.999993085861206
of O O 0.9999812841415405
acute O O 0.999976634979248
liver O O 0.9994779229164124
failure O O 0.9999960660934448
. O O 0.9999865293502808

The O O 0.9999902248382568
aim O O 0.9999966621398926
of O O 0.9999949932098389
the O O 0.9999957084655762
study O O 0.9999823570251465
was O O 0.9999947547912598
to O O 0.9999921321868896
investigate O O 0.9999058246612549
the O O 0.9998935461044312
soluble O O 0.9636216759681702
form O O 0.9961159229278564
of O O 0.9876917004585266
Fas O O 0.7127551436424255
in O O 0.9996733665466309
patients O O 0.9999923706054688
with O O 0.9999874830245972
acute O O 0.9999874830245972
liver O O 0.9989163875579834
failure O O 0.9999918937683105
. O O 0.9999780654907227

METHODOLOGY O O 0.9981995820999146
: O O 0.9999743700027466
Serum O O 0.9995465874671936
levels O O 0.9998843669891357
of O O 0.9958063364028931
sFas O O 0.6347194910049438
( O O 0.9921940565109253
soluble O O 0.8804326057434082
Fas O O 0.7745253443717957
) O O 0.9999134540557861
were O O 0.9999792575836182
measured O O 0.9999743700027466
by O O 0.9999269247055054
ELISA O O 0.9651601314544678
in O O 0.9999134540557861
24 O O 0.9999539852142334
patients O O 0.9999945163726807
with O O 0.9999792575836182
acute O O 0.9999804496765137
liver O O 0.9993711113929749
failure O O 0.9999914169311523
and O O 0.9999364614486694
10 O O 0.9989848732948303
normal O O 0.9988740086555481
control O O 0.9994163513183594
subjects O O 0.9999345541000366
. O O 0.999976396560669

Serum O O 0.999584972858429
levels O O 0.9997407793998718
of O O 0.9986079335212708
tumor O O 0.7664375305175781
necrosis O O 0.9527108073234558
factor O O 0.9371323585510254
- O O 0.9579681158065796
alpha O O 0.7365010976791382
and O O 0.9972426891326904
interferon O O 0.6027798056602478
- O O 0.804450511932373
gamma O O 0.7309999465942383
were O O 0.9998795986175537
also O O 0.9999880790710449
determined O O 0.9999814033508301
by O O 0.999954104423523
ELISA O O 0.9567081928253174
. O O 0.9999148845672607

RESULTS O O 0.999659538269043
: O O 0.9999058246612549
Serum O O 0.994678258895874
sFas O O 0.5486963987350464
was O O 0.9999150037765503
significantly O O 0.9999716281890869
increased O O 0.9999433755874634
in O O 0.999947190284729
patients O O 0.9999943971633911
with O O 0.9999799728393555
acute O O 0.9999707937240601
liver O O 0.9995620846748352
failure O O 0.9999940395355225
( O O 0.9999628067016602
median O O 0.9998987913131714
, O O 0.9999427795410156
26 O O 0.9999926090240479
. O O 0.9999970197677612
8 O O 0.9999880790710449
U O O 0.9994127750396729
/ O O 0.9999642372131348
mL O O 0.9999971389770508
; O O 0.9999790191650391
range O O 0.9999880790710449
, O O 0.999891996383667
6 O O 0.9999648332595825
. O O 0.999990701675415
9 O O 0.9999731779098511
- O O 0.9982013702392578
52 O O 0.9999808073043823
. O O 0.9999966621398926
7 O O 0.9999935626983643
U O O 0.9995263814926147
/ O O 0.9999383687973022
mL O O 0.9999973773956299
) O O 0.9999793767929077
compared O O 0.999990701675415
to O O 0.9999780654907227
the O O 0.9999839067459106
normal O O 0.9998900890350342
controls O O 0.9999947547912598
( O O 0.9999663829803467
median O O 0.9999210834503174
, O O 0.9999713897705078
8 O O 0.9999861717224121
. O O 0.9999961853027344
6 O O 0.9999929666519165
U O O 0.9999364614486694
/ O O 0.9999649524688721
mL O O 0.9999966621398926
; O O 0.9999762773513794
range O O 0.9999738931655884
, O O 0.9998762607574463
6 O O 0.9999805688858032
. O O 0.9999922513961792
5 O O 0.9999899864196777
- O O 0.9996151924133301
12 O O 0.9999978542327881
. O O 0.9999969005584717
0 O O 0.9999914169311523
U O O 0.9997615218162537
/ O O 0.9999568462371826
mL O O 0.9999963045120239
, O O 0.9999710321426392
P O O 0.9999909400939941
< O O 0.9999905824661255
0 O O 0.999995231628418
. O O 0.9999943971633911
0001 O O 0.9999819993972778
) O O 0.9999758005142212
. O O 0.9999816417694092

Levels O O 0.9998699426651001
were O O 0.9999414682388306
significantly O O 0.9999849796295166
greater O O 0.9999287128448486
in O O 0.9999345541000366
patients O O 0.9999934434890747
with O O 0.9999821186065674
acute O O 0.999982476234436
liver O O 0.9997714161872864
failure O O 0.999997615814209
due O O 0.9999808073043823
to O O 0.9996542930603027
paracetamol B B 0.9996209144592285
overdose O O 0.9978588223457336
( O O 0.9999657869338989
median O O 0.9998704195022583
, O O 0.9999688863754272
28 O O 0.9999971389770508
. O O 0.9999959468841553
7 O O 0.999991774559021
U O O 0.9993473887443542
/ O O 0.9999526739120483
mL O O 0.9999974966049194
; O O 0.9999783039093018
range O O 0.999987006187439
, O O 0.9999477863311768
12 O O 0.9999970197677612
. O O 0.9999970197677612
8 O O 0.9997549653053284
- O O 0.9986816048622131
52 O O 0.999977707862854
. O O 0.9999980926513672
7 O O 0.9999936819076538
U O O 0.9994481205940247
/ O O 0.9999525547027588
mL O O 0.9999978542327881
, O O 0.9999865293502808
n O O 0.9999542236328125
= O O 0.9999078512191772
17 O O 0.9999915361404419
) O O 0.999968409538269
than O O 0.999950647354126
those O O 0.9999635219573975
due O O 0.9999842643737793
to O O 0.9997357726097107
non O O 0.7454195618629456
- O O 0.9945946335792542
A O O 0.7965075969696045
to O O 0.9711869955062866
E O O 0.9716796875
hepatitis O O 0.9993663430213928
( O O 0.9999462366104126
median O O 0.9997747540473938
, O O 0.9999754428863525
12 O O 0.9999973773956299
. O O 0.999996542930603
5 O O 0.9999904632568359
U O O 0.999920129776001
/ O O 0.9999698400497437
mL O O 0.9999967813491821
; O O 0.999983549118042
range O O 0.9999909400939941
, O O 0.9999178647994995
6 O O 0.9999955892562866
. O O 0.9999938011169434
9 O O 0.9999585151672363
- O O 0.9995772242546082
46 O O 0.9999942779541016
. O O 0.9999982118606567
0 O O 0.9999935626983643
U O O 0.9991395473480225
/ O O 0.9999178647994995
mL O O 0.9999957084655762
, O O 0.9999864101409912
n O O 0.9999438524246216
= O O 0.9999537467956543
7 O O 0.9999834299087524
, O O 0.9999812841415405
P O O 0.9999884366989136
< O O 0.9999802112579346
0 O O 0.9999910593032837
. O O 0.9999974966049194
01 O O 0.9999958276748657
) O O 0.9999775886535645
. O O 0.9999830722808838

There O O 0.999955415725708
was O O 0.9999562501907349
no O O 0.9999728202819824
relationship O O 0.9999774694442749
of O O 0.9996009469032288
sFas O O 0.7210503816604614
to O O 0.9997586607933044
eventual O O 0.9999819993972778
outcome O O 0.9999903440475464
in O O 0.9999783039093018
the O O 0.9999761581420898
patients O O 0.9999816417694092
. O O 0.9999560117721558

A O O 0.9999411106109619
significant O O 0.9999681711196899
correlation O O 0.999976634979248
was O O 0.9999649524688721
observed O O 0.9999974966049194
between O O 0.9996546506881714
serum O O 0.9975591897964478
sFas O B 0.8863326907157898
levels O O 0.9993770718574524
and O O 0.9996955394744873
aspartate B B 0.9902371764183044
aminotransferase O O 0.7086948156356812
( O O 0.9998694658279419
r O O 0.999509334564209
= O O 0.9999384880065918
0 O O 0.9999865293502808
. O O 0.9999935626983643
613 O O 0.9999949932098389
, O O 0.9999697208404541
P O O 0.9996310472488403
< O O 0.9999477863311768
0 O O 0.9999905824661255
. O O 0.9999971389770508
01 O O 0.999990701675415
) O O 0.9999709129333496
. O O 0.9999637603759766

CONCLUSIONS O O 0.99899822473526
: O O 0.9999749660491943
The O O 0.9999922513961792
increased O O 0.9999649524688721
concentration O O 0.9998925924301147
of O O 0.9938602447509766
sFas O O 0.6447046995162964
in O O 0.9995241165161133
serum O O 0.9995636343955994
of O O 0.999943733215332
patients O O 0.9999932050704956
with O O 0.9999903440475464
acute O O 0.9999909400939941
liver O O 0.9992363452911377
failure O O 0.9999964237213135
may O O 0.9998527765274048
reflect O O 0.9998378753662109
activation O O 0.9997264742851257
of O O 0.9997290968894958
Fas O O 0.6775878667831421
- O O 0.9870971441268921
mediated O O 0.9997827410697937
apoptosis O O 0.995442271232605
in O O 0.9998916387557983
the O O 0.999962329864502
liver O O 0.9992461204528809
and O O 0.9999505281448364
this O O 0.9999556541442871
together O O 0.9999598264694214
with O O 0.999913215637207
increased O O 0.9997742772102356
tumor O O 0.7598729133605957
necrosis O O 0.957612156867981
factor O O 0.9773678183555603
- O O 0.981877326965332
alpha O O 0.8541090488433838
may O O 0.9999263286590576
be O O 0.9999393224716187
an O O 0.9999003410339355
important O O 0.9998942613601685
factor O O 0.99998939037323
in O O 0.9999752044677734
liver O O 0.9975267052650452
cell O O 0.9999707937240601
loss O O 0.9999960660934448
. O O 0.9999715089797974

Bilateral O O 0.9991187453269958
subthalamic O O 0.9943689703941345
nucleus O O 0.9856568574905396
stimulation O O 0.9988390803337097
for O O 0.9997318387031555
Parkinson O O 0.9935384392738342
' O O 0.9999861717224121
s O O 0.999969482421875
disease O O 0.9999822378158569
. O O 0.9997301697731018

High O O 0.9968408346176147
frequency O O 0.999625563621521
stimulation O O 0.9855329394340515
of O O 0.9991143345832825
the O O 0.9997305274009705
subthalamic O O 0.9894692897796631
nucleus O O 0.9995865225791931
( O O 0.9994812607765198
STN O O 0.7109754681587219
) O O 0.999054491519928
is O O 0.999839186668396
known O O 0.999327540397644
to O O 0.999369204044342
ameliorate O O 0.9998018145561218
the O O 0.9999666213989258
signs O O 0.9999918937683105
and O O 0.9999877214431763
symptoms O O 0.999995231628418
of O O 0.99998939037323
advanced O O 0.9999773502349854
Parkinson O O 0.9991872906684875
' O O 0.9999798536300659
s O O 0.9999661445617676
disease O O 0.9999922513961792
. O O 0.999919056892395

AIM O O 0.9999146461486816
: O O 0.9999902248382568
We O O 0.9999531507492065
studied O O 0.9999711513519287
the O O 0.9999822378158569
effect O O 0.9999679327011108
of O O 0.9999526739120483
high O O 0.9990898370742798
frequency O O 0.9997907280921936
STN O O 0.8347983956336975
stimulation O O 0.9953098893165588
in O O 0.9998998641967773
23 O O 0.999822199344635
patients O O 0.9999949932098389
. O O 0.9999749660491943

METHOD O O 0.9999157190322876
: O O 0.9999949932098389
Twenty O O 0.9999598264694214
- O O 0.9999613761901855
three O O 0.9999914169311523
patients O O 0.9999958276748657
suffering O O 0.9999867677688599
from O O 0.999976634979248
severe O O 0.9999536275863647
Parkinson O O 0.9995027780532837
' O O 0.9999852180480957
s O O 0.9999765157699585
disease O O 0.999994158744812
( O O 0.9999301433563232
Stages O O 0.9978025555610657
III O O 0.9971711039543152
- O O 0.9970018267631531
V O O 0.9920756816864014
on O O 0.9999747276306152
Hoehn O O 0.9945153594017029
and O O 0.9997833371162415
Yahr O O 0.9949710369110107
scale O O 0.9999885559082031
) O O 0.9999619722366333
and O O 0.9999316930770874
, O O 0.9999773502349854
particularly O O 0.9998948574066162
bradykinesia O O 0.9999202489852905
, O O 0.9999237060546875
rigidity O O 0.9999902248382568
, O O 0.9998683929443359
and O O 0.9998931884765625
levodopa B B 0.9996026158332825
- O O 0.9996851682662964
induced O O 0.9998918771743774
dyskinesias O O 0.9999973773956299
underwent O O 0.9999687671661377
bilateral O O 0.9999693632125854
implantation O O 0.9999992847442627
of O O 0.9999843835830688
electrodes O O 0.999841570854187
in O O 0.999931812286377
the O O 0.9999604225158691
STN O O 0.9422876238822937
. O O 0.9999779462814331

Preoperative O O 0.9997609257698059
and O O 0.9999535083770752
postoperative O O 0.9998229146003723
assessments O O 0.9999967813491821
of O O 0.9999849796295166
these O O 0.999984622001648
patients O O 0.9999947547912598
at O O 0.9999772310256958
1 O O 0.9999668598175049
, O O 0.9999815225601196
3 O O 0.99996018409729
, O O 0.9999788999557495
6 O O 0.9999902248382568
and O O 0.999988317489624
12 O O 0.9999982118606567
months O O 0.999995231628418
follow O O 0.9999961853027344
- O O 0.9999871253967285
up O O 0.9999963045120239
, O O 0.9999895095825195
in O O 0.9998944997787476
" O O 0.9999632835388184
on O O 0.9864521026611328
" O O 0.9999288320541382
and O O 0.9998294115066528
" O O 0.9999521970748901
off O O 0.9968312382698059
" O O 0.9999746084213257
drug O O 0.9950789213180542
conditions O O 0.9998730421066284
, O O 0.9999920129776001
was O O 0.99998939037323
carried O O 0.9999964237213135
out O O 0.9999971389770508
using O O 0.9999847412109375
Unified O O 0.9989970326423645
Parkinson O O 0.9964126944541931
' O O 0.9999855756759644
s O O 0.9999688863754272
Disease O O 0.9999927282333374
Rating O O 0.9999483823776245
Scale O O 0.9994226694107056
, O O 0.9999755620956421
Hoehn O O 0.9941287040710449
and O O 0.9998632669448853
Yahr O O 0.9981024861335754
staging O O 0.9999898672103882
, O O 0.9999498128890991
England O O 0.9569101929664612
activities O O 0.9995729327201843
of O O 0.9999042749404907
daily O O 0.9999654293060303
living O O 0.9999887943267822
score O O 0.9997484087944031
and O O 0.9999774694442749
video O O 0.9999444484710693
recordings O O 0.9999943971633911
. O O 0.9999786615371704

RESULTS O O 0.9998586177825928
: O O 0.999972939491272
After O O 0.9999806880950928
one O O 0.9999945163726807
year O O 0.9999955892562866
of O O 0.9999396800994873
electrical O O 0.9998539686203003
stimulation O O 0.9997666478157043
of O O 0.9990391731262207
the O O 0.9996329545974731
STN O O 0.6540594100952148
, O O 0.9999324083328247
the O O 0.9999897480010986
patients O O 0.9999899864196777
' O O 0.9999878406524658
scores O O 0.9999849796295166
for O O 0.9999568462371826
activities O O 0.9996887445449829
of O O 0.9999599456787109
daily O O 0.9999775886535645
living O O 0.9999948740005493
and O O 0.9999051094055176
motor O O 0.9998883008956909
examination O O 0.9999833106994629
scores O O 0.9999338388442993
( O O 0.999883770942688
Unified O O 0.9991918206214905
Parkinson O O 0.9971945285797119
' O O 0.9999895095825195
s O O 0.9999837875366211
Disease O O 0.9999874830245972
Rating O O 0.9999574422836304
Scale O O 0.9941639304161072
parts O O 0.9959865212440491
II O O 0.9993708729743958
and O O 0.9997715353965759
III O O 0.9983604550361633
) O O 0.999956488609314
off O O 0.9994827508926392
medication O O 0.9993963241577148
improved O O 0.9999822378158569
by O O 0.9999939203262329
62 O O 0.9999979734420776
% O O 0.9999988079071045
and O O 0.9999785423278809
61 O O 0.9999963045120239
% O O 0.9999980926513672
respectively O O 0.9999845027923584
( O O 0.999972939491272
p O O 0.9999619722366333
< O O 0.9999881982803345
0 O O 0.9999960660934448
. O O 0.999997615814209
0005 O O 0.9999793767929077
) O O 0.999976634979248
. O O 0.9999855756759644

The O O 0.9999616146087646
subscores O O 0.9941457509994507
for O O 0.9998877048492432
the O O 0.9999390840530396
akinesia O O 0.9998500347137451
, O O 0.9997912049293518
rigidity O O 0.9999804496765137
, O O 0.9997932314872742
tremor O O 0.9998844861984253
and O O 0.9998602867126465
gait O O 0.9999401569366455
also O O 0.9999589920043945
improved O O 0.9999687671661377
. O O 0.9999779462814331

( O O 0.9996857643127441
p O O 0.9902749061584473
< O O 0.9999719858169556
0 O O 0.9999905824661255
. O O 0.9999977350234985
0005 O O 0.9999816417694092
) O O 0.999901533126831
. O O 0.9999171495437622

The O O 0.9999836683273315
average O O 0.9999008178710938
levodopa B B 0.9997168183326721
dose O O 0.9999028444290161
decreased O O 0.9999884366989136
from O O 0.9999831914901733
813 O O 0.9608204364776611
mg O O 0.9998196959495544
to O O 0.9998636245727539
359 O O 0.9999746084213257
mg O O 0.99993896484375
. O O 0.9999432563781738

The O O 0.9999459981918335
cognitive O O 0.9999570846557617
functions O O 0.9999947547912598
remained O O 0.9999831914901733
unchanged O O 0.9999858140945435
. O O 0.9999752044677734

Two O O 0.9999581575393677
patients O O 0.9999887943267822
developed O O 0.9999827146530151
device O O 0.9999631643295288
- O O 0.9999287128448486
related O O 0.9999901056289673
complications O O 0.9999982118606567
and O O 0.9999710321426392
two O O 0.9999878406524658
patients O O 0.9999935626983643
experienced O O 0.9999945163726807
abnormal O O 0.9999971389770508
weight O O 0.9999732971191406
gain O O 0.9999971389770508
. O O 0.9999690055847168

CONCLUSION O O 0.9960570335388184
: O O 0.9997015595436096
Bilateral O O 0.997879147529602
subthalamic O O 0.9841188192367554
nucleus O O 0.9877127408981323
stimulation O O 0.9822899699211121
is O O 0.9998248219490051
an O O 0.9997667670249939
effective O O 0.9997274279594421
treatment O O 0.9999558925628662
for O O 0.9999619722366333
advanced O O 0.9999810457229614
Parkinson O O 0.9992146492004395
' O O 0.9999845027923584
s O O 0.9999814033508301
disease O O 0.9999940395355225
. O O 0.9999650716781616

It O O 0.9991579055786133
reduces O O 0.9999284744262695
the O O 0.9999574422836304
severity O O 0.9999899864196777
of O O 0.9999561309814453
" O O 0.9999113082885742
off O O 0.9989443421363831
" O O 0.9999629259109497
phase O O 0.9999402761459351
symptoms O O 0.9999867677688599
, O O 0.9999575614929199
improves O O 0.9999370574951172
the O O 0.9999738931655884
axial O O 0.9998561143875122
symptoms O O 0.9999959468841553
and O O 0.9999767541885376
reduces O O 0.9999433755874634
levodopa B B 0.9997015595436096
requirements O O 0.9999222755432129
. O O 0.9996898174285889

The O O 0.999971866607666
reduction O O 0.9999861717224121
in O O 0.9998350143432617
the O O 0.9988285899162292
levodopa B B 0.9996845722198486
dose O O 0.9996895790100098
is O O 0.99991774559021
useful O O 0.9998668432235718
in O O 0.9999281167984009
controlling O O 0.9999082088470459
drug O O 0.9990019202232361
- O O 0.9999083280563354
induced O O 0.9999395608901978
dyskinesias O O 0.9999969005584717
. O O 0.9999257326126099

Acute O O 0.9999477863311768
renal O O 0.9999905824661255
failure O O 0.9999922513961792
occurring O O 0.9999924898147583
during O O 0.9999388456344604
intravenous O O 0.996239423751831
desferrioxamine B B 0.9985933899879456
therapy O O 0.9995468258857727
: O O 0.9998730421066284
recovery O O 0.9999982118606567
after O O 0.9999579191207886
haemodialysis O O 0.9998688697814941
. O O 0.999972939491272

A O O 0.9999723434448242
patient O O 0.9999908208847046
with O O 0.9999587535858154
transfusion O O 0.9995991587638855
- O O 0.9999368190765381
dependent O O 0.9999567270278931
thalassemia O O 0.9998224377632141
was O O 0.9999676942825317
undergoing O O 0.9999805688858032
home O O 0.9999077320098877
intravenous O O 0.9981052875518799
desferrioxamine B B 0.9992327690124512
( O O 0.9931405186653137
DFX B B 0.9731335639953613
) O O 0.9992586970329285
treatment O O 0.9999706745147705
by O O 0.9999909400939941
means O O 0.9999960660934448
of O O 0.9999935626983643
a O O 0.999993085861206
totally O O 0.9999401569366455
implanted O O 0.9999988079071045
system O O 0.9999955892562866
because O O 0.9999933242797852
of O O 0.9999946355819702
his O O 0.9999924898147583
poor O O 0.9999948740005493
compliance O O 0.999997615814209
with O O 0.9999868869781494
the O O 0.999993085861206
nightly O O 0.9999397993087769
subcutaneous O O 0.9987902045249939
therapy O O 0.9999743700027466
. O O 0.9999699592590332

Due O O 0.9999897480010986
to O O 0.9999849796295166
an O O 0.9999921321868896
accidental O O 0.9999912977218628
malfunctioning O O 0.9999983310699463
of O O 0.9999648332595825
the O O 0.9999799728393555
infusion O O 0.9995798468589783
pump O O 0.9997385144233704
, O O 0.9999651908874512
the O O 0.9999938011169434
patient O O 0.9999898672103882
was O O 0.9999738931655884
inadvertently O O 0.9999860525131226
administered O O 0.9999178647994995
a O O 0.9999809265136719
toxic O O 0.9998466968536377
dosage O O 0.9998953342437744
of O O 0.9981310963630676
the O O 0.9996789693832397
drug O O 0.99783855676651
which O O 0.9999092817306519
caused O O 0.9999144077301025
renal O O 0.9999779462814331
insufficiency O O 0.9999896287918091
. O O 0.9999662637710571

Given O O 0.9999929666519165
the O O 0.9999979734420776
progressive O O 0.9999953508377075
deterioration O O 0.9999985694885254
of O O 0.9999923706054688
the O O 0.9999955892562866
symptoms O O 0.9999980926513672
and O O 0.9999988079071045
of O O 0.9999958276748657
the O O 0.9999979734420776
laboratory O O 0.999994158744812
values O O 0.9999901056289673
, O O 0.9999860525131226
despite O O 0.9999736547470093
adequate O O 0.9999778270721436
medical O O 0.9999904632568359
treatment O O 0.9999920129776001
, O O 0.9999754428863525
a O O 0.9999873638153076
decision O O 0.9999969005584717
was O O 0.999993085861206
made O O 0.9999990463256836
to O O 0.9999921321868896
introduce O O 0.9999053478240967
haemodialytical O O 0.9666088819503784
therapy O O 0.9995482563972473
in O O 0.9999806880950928
order O O 0.9999949932098389
to O O 0.9999699592590332
remove O O 0.9997978806495667
the O O 0.9989665746688843
drug O O 0.9981946349143982
and O O 0.9996110796928406
therapy O O 0.9998639822006226
reduce O O 0.9997405409812927
the O O 0.999916672706604
nephrotoxicity O O 0.9991093277931213
. O O 0.9999408721923828

From O O 0.9999927282333374
the O O 0.999995231628418
results O O 0.9999972581863403
obtained O O 0.9999982118606567
, O O 0.9999451637268066
haemodialysis O O 0.9917892217636108
can O O 0.9999569654464722
therefore O O 0.9999899864196777
be O O 0.9999850988388062
suggested O O 0.9999721050262451
as O O 0.9999794960021973
a O O 0.999980092048645
useful O O 0.9999713897705078
therapy O O 0.9999768733978271
in O O 0.9999814033508301
rare O O 0.9999749660491943
cases O O 0.9999899864196777
of O O 0.9999713897705078
progressive O O 0.9999892711639404
acute O O 0.999982476234436
renal O O 0.9999918937683105
failure O O 0.999990701675415
caused O O 0.9999796152114868
by O O 0.9998321533203125
desferrioxamine B B 0.9993864297866821
. O O 0.9999610185623169

Ocular O O 0.9994372725486755
motility O O 0.9999715089797974
changes O O 0.9999935626983643
after O O 0.999748170375824
subtenon O O 0.5735610723495483
carboplatin B B 0.9714150428771973
chemotherapy O O 0.8987558484077454
for O O 0.9998505115509033
retinoblastoma O O 0.9985221028327942
. O O 0.9999405145645142

BACKGROUND O O 0.8971586227416992
: O O 0.9995498061180115
Focal O O 0.781175971031189
subtenon O O 0.6106340885162354
carboplatin B B 0.999091625213623
injections O O 0.996212363243103
have O O 0.999970555305481
recently O O 0.9999827146530151
been O O 0.9999855756759644
used O O 0.9999679327011108
as O O 0.9999792575836182
a O O 0.999957799911499
presumably O O 0.9995081424713135
toxicity O O 0.999484658241272
- O O 0.999958872795105
free O O 0.9996637105941772
adjunct O O 0.9999527931213379
to O O 0.9998728036880493
systemic O O 0.9998716115951538
chemotherapy O O 0.9998427629470825
for O O 0.9999549388885498
intraocular O O 0.999967098236084
retinoblastoma O O 0.9997257590293884
. O O 0.999962568283081

OBJECTIVE O O 0.9997199177742004
: O O 0.9999966621398926
To O O 0.999997615814209
report O O 0.9999973773956299
our O O 0.999991774559021
clinical O O 0.9999971389770508
experience O O 0.9999988079071045
with O O 0.999992847442627
abnormal O O 0.9999841451644897
ocular O O 0.9999719858169556
motility O O 0.9999961853027344
in O O 0.9999570846557617
patients O O 0.9999897480010986
treated O O 0.9999710321426392
with O O 0.9998288154602051
subtenon O O 0.6083554029464722
carboplatin B B 0.9897578954696655
chemotherapy O O 0.9636223316192627
. O O 0.9999768733978271

METHODS O O 0.9994401335716248
: O O 0.9999806880950928
We O O 0.9999760389328003
noted O O 0.9999943971633911
abnormal O O 0.9999890327453613
ocular O O 0.9999840259552002
motility O O 0.9999970197677612
in O O 0.9999513626098633
10 O O 0.9999690055847168
consecutive O O 0.999984622001648
patients O O 0.9999951124191284
with O O 0.9999771118164062
retinoblastoma O O 0.9991494417190552
who O O 0.9999250173568726
had O O 0.9999839067459106
received O O 0.9999070167541504
subtenon O O 0.5675503015518188
carboplatin B B 0.9989581108093262
. O O 0.9999250173568726

During O O 0.9999345541000366
ocular O O 0.9998893737792969
manipulation O O 0.9999971389770508
under O O 0.999971866607666
general O O 0.9999836683273315
anesthesia O O 0.9999902248382568
, O O 0.9999691247940063
we O O 0.9999510049819946
assessed O O 0.9999920129776001
their O O 0.9999895095825195
eyes O O 0.9999936819076538
by O O 0.9999872446060181
forced O O 0.9926208257675171
duction O O 0.999885082244873
testing O O 0.9999746084213257
, O O 0.9999783039093018
comparing O O 0.9999302625656128
ocular O O 0.9998120665550232
motility O O 0.999964714050293
after O O 0.9997311234474182
tumor O O 0.999811589717865
control O O 0.9999631643295288
with O O 0.999935507774353
ocular O O 0.9997789263725281
motility O O 0.9999730587005615
at O O 0.9998328685760498
diagnosis O O 0.999983549118042
. O O 0.9999781847000122

Eyes O O 0.9995498061180115
subsequently O O 0.9999107122421265
enucleated O O 0.9998843669891357
because O O 0.9999885559082031
of O O 0.9998801946640015
treatment O O 0.9998546838760376
failure O O 0.9999880790710449
( O O 0.9999465942382812
n O O 0.9998053908348083
= O O 0.9998281002044678
4 O O 0.9999055862426758
) O O 0.9999635219573975
were O O 0.9999858140945435
examined O O 0.9999889135360718
histologically O O 0.9999774694442749
. O O 0.9999765157699585

RESULTS O O 0.999826967716217
: O O 0.9998512268066406
Limitation O O 0.9998884201049805
of O O 0.9998792409896851
ocular O O 0.999874472618103
motility O O 0.999981164932251
was O O 0.9999700784683228
detected O O 0.9999877214431763
in O O 0.9998972415924072
all O O 0.9999347925186157
12 O O 0.9999819993972778
eyes O O 0.9999955892562866
of O O 0.9999781847000122
10 O O 0.999954104423523
patients O O 0.9999933242797852
treated O O 0.9999616146087646
for O O 0.9999595880508423
intraocular O O 0.9996252059936523
retinoblastoma O O 0.9994692206382751
with O O 0.9999213218688965
1 O O 0.9997938275337219
to O O 0.9999920129776001
6 O O 0.9999200105667114
injections O O 0.9999514818191528
of O O 0.9995390176773071
subtenon O O 0.6798104047775269
carboplatin B B 0.980548620223999
as O O 0.9999275207519531
part O O 0.9999843835830688
of O O 0.9999731779098511
multimodality O O 0.9984034895896912
therapy O O 0.9999829530715942
. O O 0.9999799728393555

Histopathological O O 0.9998893737792969
examination O O 0.9999910593032837
revealed O O 0.9999485015869141
many O O 0.9997780919075012
lipophages O O 0.9895748496055603
in O O 0.9998177886009216
the O O 0.9999454021453857
periorbital O O 0.9987006187438965
fat O O 0.9999326467514038
surrounding O O 0.9998716115951538
the O O 0.9999679327011108
optic O O 0.9999498128890991
nerve O O 0.999977707862854
in O O 0.9999158382415771
1 O O 0.994446873664856
eye O O 0.9999728202819824
, O O 0.9999676942825317
indicative O O 0.9999822378158569
of O O 0.999902606010437
phagocytosis O O 0.9991883635520935
of O O 0.9997770190238953
previously O O 0.999464213848114
existing O O 0.9998553991317749
fat O O 0.9969996809959412
cells O O 0.9999575614929199
and O O 0.9999467134475708
suggesting O O 0.9999120235443115
prior O O 0.9998231530189514
fat O O 0.9967063069343567
necrosis O O 0.999970555305481
. O O 0.999953031539917

The O O 0.9999781847000122
enucleations O O 0.9999825954437256
were O O 0.9999871253967285
technically O O 0.9999959468841553
difficult O O 0.9999957084655762
and O O 0.9999754428863525
hazardous O O 0.9997636675834656
for O O 0.9999924898147583
globe O O 0.9992226362228394
rupture O O 0.9999572038650513
because O O 0.9999816417694092
of O O 0.9999752044677734
extensive O O 0.9999604225158691
orbital O O 0.9993942975997925
soft O O 0.9994949102401733
tissue O O 0.9999865293502808
adhesions O O 0.9996610879898071
. O O 0.9999673366546631

CONCLUSIONS O O 0.9547019600868225
: O O 0.9979290962219238
Subtenon O O 0.6970091462135315
carboplatin B B 0.9979155659675598
chemotherapy O O 0.976994514465332
is O O 0.9999445676803589
associated O O 0.9999746084213257
with O O 0.9999828338623047
significant O O 0.999958872795105
fibrosis O O 0.9999858140945435
of O O 0.9999567270278931
orbital O O 0.999600350856781
soft O O 0.9998561143875122
tissues O O 0.9999961853027344
, O O 0.9999778270721436
leading O O 0.9999794960021973
to O O 0.99997878074646
mechanical O O 0.9999874830245972
restriction O O 0.9999982118606567
of O O 0.9999823570251465
eye O O 0.9999157190322876
movements O O 0.9999966621398926
and O O 0.9999706745147705
making O O 0.9999902248382568
subsequent O O 0.9999936819076538
enucleation O O 0.9999964237213135
difficult O O 0.9999979734420776
. O O 0.9999843835830688

Subtenon O O 0.9019982218742371
carboplatin B B 0.9804642796516418
is O O 0.9998674392700195
not O O 0.9999788999557495
free O O 0.9998718500137329
of O O 0.9999444484710693
toxicity O O 0.9999650716781616
, O O 0.9999232292175293
and O O 0.9999716281890869
its O O 0.9999451637268066
use O O 0.9999732971191406
is O O 0.9999762773513794
best O O 0.9999806880950928
restricted O O 0.9999957084655762
to O O 0.999958872795105
specific O O 0.9999699592590332
indications O O 0.9999595880508423
. O O 0.9999663829803467

Ethambutol B B 0.9988846182823181
and O O 0.9993278980255127
optic O O 0.9963963627815247
neuropathy O O 0.9999034404754639
. O O 0.9996752738952637

PURPOSE O O 0.9995406866073608
: O O 0.9999935626983643
To O O 0.9999721050262451
demonstrate O O 0.9999290704727173
the O O 0.9999663829803467
association O O 0.9999862909317017
between O O 0.9997840523719788
ethambutol B B 0.9995354413986206
and O O 0.9996583461761475
optic O O 0.9998533725738525
neuropathy O O 0.9999923706054688
. O O 0.9999693632125854

METHOD O O 0.9997840523719788
: O O 0.9999823570251465
Thirteen O O 0.9999804496765137
patients O O 0.9999898672103882
who O O 0.9999620914459229
developed O O 0.9999873638153076
optic O O 0.9997915625572205
neuropathy O O 0.9999957084655762
after O O 0.9999594688415527
being O O 0.9999587535858154
treated O O 0.999913215637207
with O O 0.9992209672927856
ethambutol B B 0.998450517654419
for O O 0.9991369843482971
tuberculosis O O 0.9993360638618469
of O O 0.9999573230743408
the O O 0.9999924898147583
lung O O 0.9998520612716675
or O O 0.9999185800552368
lymph O O 0.9999778270721436
node O O 0.9999926090240479
at O O 0.9999302625656128
Siriraj O O 0.9960787892341614
Hospital O O 0.9999611377716064
between O O 0.9999219179153442
1997 O O 0.9999382495880127
and O O 0.9999175071716309
2001 O O 0.9999943971633911
were O O 0.9999887943267822
retrospectively O O 0.9999881982803345
reviewed O O 0.9999960660934448
. O O 0.9999810457229614

The O O 0.9999701976776123
clinical O O 0.9999847412109375
characteristics O O 0.9999979734420776
and O O 0.9999797344207764
initial O O 0.9999743700027466
and O O 0.9999027252197266
final O O 0.9999808073043823
visual O O 0.9999918937683105
acuity O O 0.9999821186065674
were O O 0.9999723434448242
analyzed O O 0.9999836683273315
to O O 0.9999889135360718
determine O O 0.9999918937683105
visual O O 0.999994158744812
outcome O O 0.9999986886978149
. O O 0.9999814033508301

RESULTS O O 0.9997206330299377
: O O 0.9999563694000244
All O O 0.9999583959579468
patients O O 0.9999920129776001
had O O 0.9999665021896362
optic O O 0.999742329120636
neuropathy O O 0.999991774559021
between O O 0.9999650716781616
1 O O 0.9999821186065674
to O O 0.9999896287918091
6 O O 0.9999948740005493
months O O 0.9999982118606567
( O O 0.9999760389328003
mean O O 0.9999943971633911
= O O 0.9999719858169556
2 O O 0.9999942779541016
. O O 0.9999964237213135
9 O O 0.9999955892562866
months O O 0.9999992847442627
) O O 0.9999914169311523
after O O 0.9999657869338989
starting O O 0.9998313188552856
ethambutol B B 0.9990587830543518
therapy O O 0.9987916350364685
at O O 0.9999628067016602
a O O 0.9999836683273315
dosage O O 0.9999886751174927
ranging O O 0.999988317489624
from O O 0.9999725818634033
13 O O 0.9996209144592285
to O O 0.9999611377716064
20 O O 0.9999902248382568
mg O O 0.9999585151672363
/ O O 0.99997878074646
kg O O 0.9999977350234985
/ O O 0.9999785423278809
day O O 0.9999954700469971
( O O 0.9999768733978271
mean O O 0.9999915361404419
= O O 0.9999881982803345
17 O O 0.9999949932098389
mg O O 0.9999746084213257
/ O O 0.9999932050704956
kg O O 0.9999982118606567
/ O O 0.9999903440475464
day O O 0.9999973773956299
) O O 0.9999849796295166
. O O 0.9999819993972778

Seven O O 0.9989435076713562
( O O 0.9999607801437378
54 O O 0.9999914169311523
% O O 0.9999980926513672
) O O 0.999990701675415
of O O 0.9999810457229614
the O O 0.9999929666519165
13 O O 0.9999936819076538
patients O O 0.9999929666519165
experienced O O 0.9999806880950928
visual O O 0.9999680519104004
recovery O O 0.9999960660934448
after O O 0.9999833106994629
stopping O O 0.999907374382019
the O O 0.9998793601989746
drug O O 0.9978972673416138
. O O 0.9999282360076904

Of O O 0.9998564720153809
6 O O 0.9996820688247681
patients O O 0.9999860525131226
with O O 0.999972939491272
irreversible O O 0.9999111890792847
visual O O 0.9999881982803345
impairment O O 0.9999926090240479
, O O 0.9999661445617676
4 O O 0.9987471103668213
patients O O 0.9999840259552002
had O O 0.9999673366546631
diabetes O O 0.9973374009132385
mellitus O O 0.9999982118606567
, O O 0.9998350143432617
glaucoma O O 0.9836722016334534
and O O 0.9999189376831055
a O O 0.9999539852142334
history O O 0.9999223947525024
of O O 0.9992786049842834
heavy O O 0.730502188205719
smoking O B 0.8987857103347778
. O O 0.9998648166656494

CONCLUSION O O 0.9997636675834656
: O O 0.9999591112136841
Early O O 0.9999864101409912
recognition O O 0.9999972581863403
of O O 0.9999727010726929
optic O O 0.9994174242019653
neuropathy O O 0.9999821186065674
should O O 0.9999191761016846
be O O 0.9999947547912598
considered O O 0.999993085861206
in O O 0.9999897480010986
patients O O 0.9999923706054688
with O O 0.9999268054962158
ethambutol B B 0.9985843896865845
therapy O O 0.9997259974479675
. O O 0.9999798536300659

A O O 0.9999310970306396
low O O 0.9999268054962158
dose O O 0.99989914894104
and O O 0.9999115467071533
prompt O O 0.999810516834259
discontinuation O O 0.9999768733978271
of O O 0.9999415874481201
the O O 0.9999216794967651
drug O O 0.9988939166069031
is O O 0.9999681711196899
recommended O O 0.9999809265136719
particularly O O 0.9999852180480957
in O O 0.9999773502349854
individuals O O 0.9999940395355225
with O O 0.999984860420227
diabetes O O 0.9999175071716309
mellitus O O 0.9999982118606567
, O O 0.9999663829803467
glaucoma O O 0.9961894154548645
or O O 0.9999672174453735
who O O 0.9999634027481079
are O O 0.9999721050262451
heavy O O 0.9615148901939392
smokers O O 0.6819638013839722
. O O 0.999967098236084

Treatment O O 0.9999325275421143
of O O 0.9999518394470215
compensatory O O 0.9996284246444702
gustatory O O 0.9741548299789429
hyperhidrosis O O 0.9986710548400879
with O O 0.9998817443847656
topical O O 0.9998608827590942
glycopyrrolate B B 0.9984839558601379
. O O 0.9991676807403564

Gustatory O O 0.982410192489624
hyperhidrosis O O 0.9992903470993042
is O O 0.9998859167098999
facial O O 0.9827150702476501
sweating O O 0.9999780654907227
usually O O 0.9999135732650757
associated O O 0.9999700784683228
with O O 0.9999616146087646
the O O 0.9999874830245972
eating O O 0.9999585151672363
of O O 0.9998890161514282
hot O O 0.9715138077735901
spicy O O 0.9794674515724182
food O O 0.9988786578178406
or O O 0.9999594688415527
even O O 0.9999243021011353
smelling O O 0.9998818635940552
this O O 0.99835205078125
food O O 0.9983776807785034
. O O 0.9999454021453857

Current O O 0.9999721050262451
options O O 0.9999934434890747
of O O 0.9999847412109375
treatment O O 0.9999861717224121
include O O 0.99994957447052
oral O O 0.9934545755386353
anticholinergic O O 0.5344011187553406
drugs O O 0.98497074842453
, O O 0.9999505281448364
the O O 0.9999860525131226
topical O O 0.999992847442627
application O O 0.9999836683273315
of O O 0.999723494052887
anticholinergics O O 0.5692890286445618
or O O 0.997641921043396
aluminum B B 0.989891529083252
chloride I I 0.9997822642326355
, O O 0.995936393737793
and O O 0.9999021291732788
the O O 0.999985933303833
injection O O 0.9999593496322632
of O O 0.9997840523719788
botulinum O B 0.9904600381851196
toxin O I 0.9979580640792847
. O O 0.9996058344841003

Thirteen O O 0.9991900324821472
patients O O 0.9999847412109375
have O O 0.999984860420227
been O O 0.999988317489624
treated O O 0.9999685287475586
to O O 0.9999972581863403
date O O 0.999993085861206
with O O 0.9998326301574707
1 O O 0.9935277104377747
. O O 0.9999366998672485
5 O O 0.9999487400054932
% O O 0.9993016719818115
or O O 0.9998050332069397
2 O O 0.9995856881141663
% O O 0.9997631907463074
topical O O 0.9998063445091248
glycopyrrolate B B 0.9990480542182922
. O O 0.9999334812164307

All O O 0.9998736381530762
patients O O 0.999984622001648
had O O 0.9999212026596069
gustatory O O 0.9737330675125122
hyperhidrosis O O 0.9985117316246033
, O O 0.9999675750732422
which O O 0.999930739402771
interfered O O 0.9999347925186157
with O O 0.9999547004699707
their O O 0.9999617338180542
social O O 0.9997314810752869
activities O O 0.9999872446060181
, O O 0.9999858140945435
after O O 0.9999198913574219
transthroacic O O 0.9978919625282288
endoscopic O O 0.9997084736824036
sympathectomy O O 0.9950283169746399
, O O 0.9999363422393799
and O O 0.9999752044677734
which O O 0.9999148845672607
was O O 0.9999277591705322
associated O O 0.9999743700027466
with O O 0.9999617338180542
compensatory O O 0.999419093132019
focal O O 0.9999791383743286
hyperhidrosis O O 0.9996980428695679
. O O 0.9999538660049438

After O O 0.9999738931655884
applying O O 0.9998425245285034
topical O O 0.9999241828918457
glycopyrrolate B B 0.9988821148872375
, O O 0.999825656414032
the O O 0.9999817609786987
subjective O O 0.9998756647109985
effect O O 0.9999827146530151
was O O 0.9999752044677734
excellent O O 0.9999111890792847
( O O 0.9999481439590454
no O O 0.9999765157699585
sweating O O 0.9999808073043823
after O O 0.9999537467956543
eating O O 0.9999226331710815
hot O O 0.9952296018600464
spicy O O 0.9754229187965393
food O O 0.9946934580802917
) O O 0.9999629259109497
in O O 0.9999568462371826
10 O O 0.9999887943267822
patients O O 0.9999947547912598
( O O 0.9999434947967529
77 O O 0.999985933303833
% O O 0.9999895095825195
) O O 0.9999600648880005
, O O 0.999957799911499
and O O 0.9999722242355347
fair O O 0.9999816417694092
( O O 0.9998973608016968
clearly O O 0.9999632835388184
reduced O O 0.9999916553497314
sweating O O 0.9999157190322876
) O O 0.9999635219573975
in O O 0.9999536275863647
3 O O 0.9997356534004211
patients O O 0.9999934434890747
( O O 0.9999451637268066
23 O O 0.9999960660934448
% O O 0.9999903440475464
) O O 0.9999549388885498
. O O 0.999984622001648

All O O 0.9998288154602051
had O O 0.999968409538269
reported O O 0.9999886751174927
incidents O O 0.9999966621398926
of O O 0.9999815225601196
being O O 0.9999921321868896
very O O 0.9999817609786987
embarrassed O O 0.9999935626983643
whilst O O 0.9999494552612305
eating O O 0.9995689988136292
hot O O 0.907275378704071
spicy O O 0.9581897258758545
foods O O 0.9994140863418579
. O O 0.9999109506607056

Adverse O O 0.9985839128494263
effects O O 0.999969482421875
included O O 0.9999842643737793
a O O 0.999983549118042
mildly O O 0.9999877214431763
dry O O 0.9999881982803345
mouth O O 0.9999903440475464
and O O 0.9999531507492065
a O O 0.9999817609786987
sore O O 0.9999744892120361
throat O O 0.9999895095825195
in O O 0.9999227523803711
2 O O 0.9998290538787842
patients O O 0.999984622001648
( O O 0.9952768087387085
2 O O 0.9953935146331787
% O O 0.9545790553092957
glycopyrrolate B B 0.9907716512680054
) O O 0.9844141006469727
, O O 0.9996622800827026
a O O 0.9999712705612183
light O O 0.9999364614486694
headache O O 0.9999964237213135
in O O 0.9999654293060303
1 O O 0.9997919201850891
patient O O 0.9999932050704956
( O O 0.9983787536621094
1 O O 0.9994569420814514
. O O 0.9999399185180664
5 O O 0.9999610185623169
% O O 0.973368763923645
glycopyrrolate B B 0.9956570863723755
) O O 0.9978606104850769
. O O 0.9998898506164551

The O O 0.9999837875366211
topical O O 0.9999902248382568
application O O 0.9999865293502808
of O O 0.9997230172157288
a O O 0.9765547513961792
glycopyrrolate B B 0.9915900826454163
pad O O 0.8637624382972717
appeared O O 0.9998247027397156
to O O 0.9999810457229614
be O O 0.9999896287918091
safe O O 0.9999887943267822
, O O 0.9999923706054688
efficacious O O 0.9999895095825195
, O O 0.9999955892562866
well O O 0.9999754428863525
tolerated O O 0.9999972581863403
, O O 0.9999847412109375
and O O 0.9999874830245972
a O O 0.999969482421875
convenient O O 0.9999831914901733
method O O 0.9999951124191284
of O O 0.999977707862854
treatment O O 0.9999830722808838
for O O 0.9999722242355347
moderate O O 0.999969482421875
to O O 0.9999866485595703
severe O O 0.9999805688858032
symptoms O O 0.9999949932098389
of O O 0.9999682903289795
gustatory O O 0.9692180156707764
hyperhidrosis O O 0.9987162351608276
in O O 0.9999474287033081
post O O 0.9998088479042053
transthoracic O O 0.9999065399169922
endoscopic O O 0.9999732971191406
sympathectomy O O 0.998336672782898
or O O 0.9999223947525024
sympathicotomy O O 0.9981884360313416
patients O O 0.9999473094940186
, O O 0.9999881982803345
with O O 0.9999827146530151
few O O 0.9999630451202393
side O O 0.9999866485595703
effects O O 0.9999951124191284
. O O 0.9999693632125854

Neuroleptic B O 0.8671244382858276
- O O 0.9988518953323364
associated O O 0.9998337030410767
hyperprolactinemia O O 0.9947774410247803
. O O 0.9999102354049683

Can O O 0.9999576807022095
it O O 0.9999595880508423
be O O 0.9999760389328003
treated O O 0.9999217987060547
with O O 0.9996975660324097
bromocriptine B B 0.9974779486656189
? O O 0.9999065399169922

Six O O 0.9993277788162231
stable O O 0.9999606609344482
psychiatric O O 0.9999829530715942
outpatients O O 0.9999886751174927
with O O 0.9999784231185913
hyperprolactinemia O O 0.9956551790237427
and O O 0.9998965263366699
amenorrhea O O 0.9829733371734619
/ O O 0.9996687173843384
oligomenorrhea O O 0.9994465708732605
associated O O 0.9999735355377197
with O O 0.9998364448547363
their O O 0.9995018243789673
neuroleptic B O 0.9979121088981628
medications I O 0.998404324054718
were O O 0.9999274015426636
treated O O 0.9999403953552246
with O O 0.9995006322860718
bromocriptine B B 0.9992424249649048
. O O 0.9999285936355591

Daily O O 0.999272882938385
dosages O O 0.9998738765716553
of O O 0.9996645450592041
5 O O 0.947432279586792
- O O 0.9641417860984802
10 O O 0.9973899722099304
mg O O 0.9984917640686035
corrected O O 0.9998749494552612
the O O 0.9999631643295288
hyperprolactinemia O O 0.99973064661026
and O O 0.9999215602874756
restored O O 0.999764621257782
menstruation O O 0.9995137453079224
in O O 0.9999616146087646
four O O 0.9999936819076538
of O O 0.9999845027923584
the O O 0.9999902248382568
six O O 0.9999935626983643
patients O O 0.9999961853027344
. O O 0.9999752044677734

One O O 0.9999290704727173
woman O O 0.9999836683273315
, O O 0.9999825954437256
however O O 0.9999845027923584
, O O 0.9999841451644897
developed O O 0.9999864101409912
worsened O O 0.9999792575836182
psychiatric O O 0.9999786615371704
symptoms O O 0.9999978542327881
while O O 0.9999251365661621
taking O O 0.9984386563301086
bromocriptine B B 0.9990241527557373
, O O 0.9986398816108704
and O O 0.999970555305481
it O O 0.999482274055481
was O O 0.9999449253082275
discontinued O O 0.9999116659164429
. O O 0.9999558925628662

Thus O O 0.9999566078186035
, O O 0.9999674558639526
three O O 0.9999866485595703
of O O 0.9999899864196777
six O O 0.9999971389770508
patients O O 0.9999955892562866
had O O 0.999987006187439
their O O 0.9999934434890747
menstrual O O 0.9988963603973389
irregularity O O 0.9999912977218628
successfully O O 0.9999469518661499
corrected O O 0.9999552965164185
with O O 0.999685525894165
bromocriptine B B 0.9994065761566162
. O O 0.9999405145645142

This O O 0.9999879598617554
suggests O O 0.9999819993972778
that O O 0.9992232322692871
bromocriptine B B 0.9997013211250305
should O O 0.9998341798782349
be O O 0.9999781847000122
further O O 0.9999842643737793
evaluated O O 0.9999693632125854
as O O 0.9999557733535767
potential O O 0.9999465942382812
therapy O O 0.9998983144760132
for O O 0.9997757077217102
neuroleptic B O 0.9984762072563171
- O O 0.9993985891342163
associated O O 0.9999442100524902
hyperprolactinemia O O 0.9991518259048462
and O O 0.9999297857284546
amenorrhea O O 0.9799797534942627
/ O O 0.9997690320014954
galactorrhea O O 0.999728262424469
. O O 0.9999550580978394

Ethacrynic B B 0.996306300163269
acid I I 0.999903678894043
- O O 0.998918890953064
induced O O 0.9999256134033203
convulsions O O 0.9998502731323242
and O O 0.999863862991333
brain O O 0.9996181726455688
neurotransmitters O O 0.9999196529388428
in O O 0.9999459981918335
mice O O 0.9999656677246094
. O O 0.9999116659164429

Intracerebroventricular O O 0.9999614953994751
injection O O 0.9999624490737915
of O O 0.9992289543151855
ethacrynic B B 0.9942581653594971
acid I I 0.9999455213546753
( O O 0.9985509514808655
50 O O 0.9998787641525269
% O O 0.9986212253570557
convulsive O O 0.9683858752250671
dose O O 0.9985623955726624
; O O 0.9998582601547241
50 O O 0.9999450445175171
micrograms O O 0.9995847344398499
/ O O 0.9999115467071533
mouse O O 0.9999454021453857
) O O 0.9999498128890991
accelerated O O 0.9998152852058411
the O O 0.9998443126678467
synthesis O O 0.9998047947883606
/ O O 0.9996668100357056
turnover O O 0.9996281862258911
of O O 0.9994304776191711
5 B B 0.9214625358581543
- I I 0.9788146615028381
hydroxytryptamine I I 0.9984617233276367
( O O 0.9962052702903748
5 B B 0.6580122709274292
- I I 0.8228464722633362
HT I I 0.9990717172622681
) O O 0.9989232420921326
but O O 0.9998520612716675
suppressed O O 0.9999179840087891
the O O 0.9999263286590576
synthesis O O 0.9998241066932678
of O O 0.9997608065605164
gamma B B 0.9660882353782654
- I I 0.980398952960968
aminobutyric I I 0.9997939467430115
acid I I 0.9999085664749146
and O O 0.993731677532196
acetylcholine B B 0.9790226817131042
in O O 0.9997368454933167
mouse O O 0.999980092048645
brain O O 0.9999874830245972
. O O 0.9998431205749512

These O O 0.9998345375061035
effects O O 0.9998722076416016
were O O 0.9999117851257324
completely O O 0.9998785257339478
antagonized O O 0.9999622106552124
by O O 0.9999105930328369
pretreatment O O 0.9998672008514404
with O O 0.9998606443405151
a O O 0.9989950060844421
glutamate B B 0.9945092797279358
/ O O 0.8919089436531067
N B B 0.6721537709236145
- I I 0.8677031397819519
methyl I I 0.9962659478187561
- I I 0.7848799824714661
D I I 0.9242242574691772
- I I 0.9601583480834961
aspartate I I 0.9995536208152771
antagonist O O 0.5132439136505127
, O O 0.9925189018249512
aminophosphonovaleric B B 0.9725698828697205
acid I I 0.9998680353164673
. O O 0.9998346567153931

In O O 0.9997870326042175
ethacrynic B B 0.9954699277877808
acid I I 0.9998860359191895
- O O 0.9992783665657043
induced O O 0.999951958656311
convulsions O O 0.999925971031189
, O O 0.9999573230743408
these O O 0.9996525049209595
neurotransmitter O O 0.9999409914016724
systems O O 0.9986221790313721
may O O 0.999907374382019
be O O 0.9999626874923706
differentially O O 0.9997912049293518
modulated O O 0.9999046325683594
, O O 0.9999822378158569
probably O O 0.9999624490737915
through O O 0.9998995065689087
activation O O 0.999911904335022
of O O 0.9998979568481445
glutaminergic O O 0.6205055117607117
neurons O O 0.999931812286377
in O O 0.9998194575309753
the O O 0.9999639987945557
brain O O 0.9999889135360718
. O O 0.999974250793457

Pharmacology O O 0.9996999502182007
of O O 0.9992197751998901
gamma B B 0.8176171183586121
- I I 0.9290794134140015
aminobutyric I I 0.9985091090202332
acidA I I 0.9995433688163757
receptor O O 0.753508985042572
complex O O 0.5499840974807739
after O O 0.9998873472213745
the O O 0.9999874830245972
in O O 0.9999748468399048
vivo O O 0.9999979734420776
administration O O 0.9999362230300903
of O O 0.9998248219490051
the O O 0.9996115565299988
anxioselective O O 0.8320668935775757
and O O 0.8232805728912354
anticonvulsant O O 0.6749356389045715
beta B B 0.559566855430603
- I I 0.8338829278945923
carboline I I 0.9996013045310974
derivative O O 0.7965586185455322
abecarnil B B 0.9288759231567383
. O O 0.9998722076416016

In O O 0.9999603033065796
rodents O O 0.9999823570251465
, O O 0.9999715089797974
the O O 0.9999656677246094
effect O O 0.999961256980896
of O O 0.9998750686645508
the O O 0.9990948438644409
beta B B 0.4632037580013275
- I I 0.69099360704422
carboline I I 0.998380184173584
derivative O O 0.6011435985565186
isopropyl B B 0.9982806444168091
- I I 0.9837368130683899
6 I I 0.9727487564086914
- I I 0.9967020153999329
benzyloxy I I 0.9988939166069031
- I I 0.9623331427574158
4 I I 0.9549610614776611
- I I 0.9916451573371887
methoxymethyl I I 0.9989342093467712
- I I 0.9177001714706421
beta I I 0.9790447354316711
- I I 0.9902859330177307
carboline I I 0.9998071789741516
- I I 0.9904946088790894
3 I I 0.9705317616462708
- I I 0.997260332107544
carboxylate I I 0.9998328685760498
( O O 0.921879768371582
abecarrnil B B 0.9985393285751343
) O O 0.9986018538475037
, O O 0.9999651908874512
a O O 0.9997847676277161
new O O 0.9943271279335022
ligand O O 0.9297115802764893
for O O 0.9754008054733276
benzodiazepine B B 0.9748989939689636
receptors O O 0.999032735824585
possessing O O 0.9965607523918152
anxiolytic O O 0.9521930813789368
and O O 0.9996291399002075
anticonvulsant O O 0.7063242197036743
properties O O 0.9998887777328491
, O O 0.9999791383743286
was O O 0.9999679327011108
evaluated O O 0.9999761581420898
on O O 0.9999229907989502
the O O 0.9999737739562988
function O O 0.9999643564224243
of O O 0.999683141708374
central O O 0.7093288898468018
gamma B B 0.9516716599464417
- I I 0.9860888123512268
aminobutyric I I 0.9995311498641968
acid I I 0.9998636245727539
( O O 0.9787850975990295
GABA B B 0.9968744516372681
) O O 0.9912030696868896
A O O 0.9779291749000549
receptor O O 0.9988868832588196
complex O O 0.9664467573165894
, O O 0.9999749660491943
both O O 0.9999377727508545
in O O 0.999966025352478
vitro O O 0.9999951124191284
and O O 0.9999607801437378
in O O 0.9999397993087769
vivo O O 0.9999924898147583
. O O 0.9999725818634033

Added O O 0.9998797178268433
in O O 0.9999310970306396
vitro O O 0.999990701675415
to O O 0.9998395442962646
rat O O 0.9511938691139221
cortical O O 0.9973356127738953
membrane O O 0.9998984336853027
preparation O O 0.9999767541885376
, O O 0.9991862177848816
abecarnil B B 0.9993922710418701
increased O O 0.9996609687805176
[ O O 0.6440445780754089
3H O O 0.5666635632514954
] O O 0.9790900945663452
GABA B B 0.9931265115737915
binding O O 0.9999126195907593
, O O 0.9999088048934937
enhanced O O 0.9996125102043152
muscimol B B 0.9995400905609131
- O O 0.9975060820579529
stimulated O O 0.999356210231781
36Cl O B 0.9238495826721191
- O O 0.8315466642379761
uptake O O 0.9960039258003235
and O O 0.9999575614929199
reduced O O 0.99996018409729
the O O 0.9999276399612427
binding O O 0.9999133348464966
of O O 0.9997686743736267
t B B 0.7199303507804871
- I I 0.8866839408874512
[ I I 0.9960030913352966
35S I I 0.9920074939727783
] I O 0.502532422542572
butylbicyclophosphorothionate I O 0.8105000257492065
( O O 0.9989063739776611
[ B O 0.9262628555297852
35S I O 0.9610953330993652
] I O 0.9978341460227966
TBPS I O 0.572942852973938
) O O 0.9998924732208252
. O O 0.9998575448989868

These O O 0.9998316764831543
effects O O 0.9999358654022217
were O O 0.9999253749847412
similar O O 0.9999897480010986
to O O 0.9999643564224243
those O O 0.9999727010726929
induced O O 0.9999775886535645
by O O 0.9997616410255432
diazepam B B 0.9998337030410767
, O O 0.9998928308486938
whereas O O 0.9998134970664978
the O O 0.9997082352638245
partial O O 0.7989832758903503
agonist O O 0.7668191194534302
Ro B B 0.9987769722938538
16 I I 0.994870662689209
- I I 0.9569605588912964
6028 I I 0.9999669790267944
( O O 0.9534615278244019
tert B B 0.9753501415252686
- I I 0.9079965949058533
butyl I I 0.9869383573532104
- I I 0.9709302186965942
( I I 0.8615647554397583
S I I 0.9405217170715332
) I I 0.9720014929771423
- I I 0.9748835563659668
8 I I 0.9880309700965881
- I I 0.9513821005821228
bromo I I 0.9924421310424805
- I I 0.9756259918212891
11 I I 0.9940621256828308
, I I 0.9619458317756653
12 I I 0.9927228093147278
, I I 0.9555394053459167
13 I I 0.9647693634033203
, I I 0.9740327000617981
13a I I 0.9633145928382874
- I I 0.9368332028388977
tetrahydro I I 0.970355749130249
- I I 0.9561236500740051
9 I I 0.9657513499259949
- I I 0.9628831148147583
oxo I I 0.9962946772575378
- I I 0.954652726650238
9H I I 0.9973347783088684
- I I 0.951485276222229
imidazo I I 0.9862819314002991
[ I I 0.9745447039604187
1 I I 0.8043578863143921
, I I 0.9811439514160156
5 I I 0.9618045091629028
- I I 0.982502818107605
a I I 0.9999182224273682
] I I 0.9441376328468323
- I I 0.9784467816352844
pyrrolo I I 0.9871511459350586
- I I 0.9511353969573975
[ I I 0.9785712361335754
2 I I 0.9929646253585815
, I I 0.9859912991523743
1 I I 0.9715868234634399
- I I 0.9683178067207336
c I I 0.9994909763336182
] I I 0.91791832447052
[ I I 0.9073865413665771
1 I I 0.9298693537712097
, I I 0.9803538918495178
4 I I 0.9951823353767395
] I I 0.9764688014984131
benzodiazepine I I 0.7841687202453613
- I I 0.978160560131073
1 I I 0.963780403137207
- I I 0.9932565689086914
carboxylate I I 0.9996763467788696
) O O 0.9981504082679749
showed O O 0.9999810457229614
very O O 0.9999921321868896
weak O O 0.9999741315841675
efficacy O O 0.9999872446060181
in O O 0.9999700784683228
these O O 0.9998958110809326
biochemical O O 0.9995782971382141
tests O O 0.9999924898147583
. O O 0.9999802112579346

After O O 0.9999701976776123
i O O 0.9997588992118835
. O O 0.9999953508377075
p O O 0.9999977350234985
. O O 0.9999902248382568
injection O O 0.9999837875366211
to O O 0.9999754428863525
rats O O 0.9977948665618896
, O O 0.9998493194580078
abecarnil B B 0.9996620416641235
and O O 0.9879913926124573
diazepam B B 0.9997583031654358
decreased O O 0.9999135732650757
in O O 0.9999914169311523
a O O 0.9999619722366333
time O O 0.9998958110809326
- O O 0.9999756813049316
dependent O O 0.99998939037323
and O O 0.9999426603317261
dose O O 0.9996247291564941
- O O 0.9999805688858032
related O O 0.9999920129776001
( O O 0.9998722076416016
0 O O 0.9999665021896362
. O O 0.9999947547912598
25 O O 0.9999864101409912
- O O 0.9993463158607483
20 O O 0.9999929666519165
mg O O 0.9999853372573853
/ O O 0.999994158744812
kg O O 0.9999971389770508
i O O 0.9997159838676453
. O O 0.9999973773956299
p O O 0.9999985694885254
. O O 0.9999951124191284
) O O 0.9999061822891235
manner O O 0.9047961831092834
[ B O 0.9505467414855957
35S I O 0.9893248677253723
] I O 0.997931718826294
TBPS I O 0.5708461403846741
binding O O 0.9993446469306946
measured O O 0.9999638795852661
ex O O 0.9999707937240601
vivo O O 0.9999939203262329
in O O 0.9998691082000732
the O O 0.9999699592590332
cerebral O O 0.9999796152114868
cortex O O 0.999996542930603
. O O 0.9999666213989258

Moreover O O 0.9999603033065796
, O O 0.9998538494110107
both O O 0.997892439365387
drugs O O 0.9968345761299133
at O O 0.9998784065246582
the O O 0.9999803304672241
dose O O 0.9999685287475586
of O O 0.9999343156814575
0 O O 0.9999661445617676
. O O 0.9999939203262329
5 O O 0.9999622106552124
mg O O 0.9999569654464722
/ O O 0.9999790191650391
kg O O 0.9999839067459106
antagonized O O 0.9999192953109741
completely O O 0.9986435770988464
the O O 0.9998356103897095
convulsant O O 0.9994124174118042
activity O O 0.999967098236084
and O O 0.9999501705169678
the O O 0.9999809265136719
increase O O 0.999969482421875
of O O 0.9999339580535889
[ B O 0.9920250177383423
35S I O 0.9986602067947388
] I O 0.999626874923706
TBPS I O 0.5639449954032898
binding O O 0.9997721314430237
induced O O 0.9999803304672241
by O O 0.9999077320098877
isoniazide B B 0.9998685121536255
( O O 0.9997171759605408
350 O O 0.99988853931427
mg O O 0.9999818801879883
/ O O 0.999988317489624
kg O O 0.9999953508377075
s O O 0.9999449253082275
. O O 0.9999964237213135
c O O 0.9999972581863403
. O O 0.9999936819076538
) O O 0.999971866607666
as O O 0.999982476234436
well O O 0.9999698400497437
as O O 0.9999768733978271
the O O 0.999984622001648
increase O O 0.9999831914901733
of O O 0.9999322891235352
[ B O 0.9803481698036194
35S I O 0.9988297820091248
] I O 0.9992721676826477
TBPS I O 0.4913070499897003
binding O O 0.9997887015342712
induced O O 0.999977707862854
by O O 0.9999102354049683
foot O O 0.8059087991714478
- O O 0.9631983637809753
shock O O 0.5409097075462341
stress O O 0.9994853734970093
. O O 0.9999616146087646

To O O 0.9999783039093018
better O O 0.999980092048645
correlate O O 0.9999949932098389
the O O 0.9999419450759888
biochemical O O 0.9962899684906006
and O O 0.9999150037765503
the O O 0.9999589920043945
pharmacological O O 0.9997369647026062
effects O O 0.9999445676803589
, O O 0.9999746084213257
we O O 0.9999644756317139
studied O O 0.9999402761459351
the O O 0.9999538660049438
action O O 0.9998384714126587
of O O 0.998661994934082
abecarnil B B 0.9991127848625183
on O O 0.9994518160820007
[ B O 0.9105938076972961
35S I O 0.9575785994529724
] I O 0.9948840737342834
TBPS I O 0.5459506511688232
binding O O 0.995118260383606
, O O 0.9998291730880737
exploratory O O 0.9996566772460938
motility O O 0.9999790191650391
and O O 0.9999330043792725
on O O 0.9991769194602966
isoniazid B B 0.9998667240142822
- O O 0.9997344613075256
induced O O 0.9999186992645264
biochemical O O 0.9970345497131348
and O O 0.9999271631240845
pharmacological O O 0.9997393488883972
effects O O 0.9999732971191406
in O O 0.9999691247940063
mice O O 0.9999814033508301
. O O 0.9999586343765259

In O O 0.9998795986175537
these O O 0.9999606609344482
animals O O 0.9999953508377075
, O O 0.9997019171714783
abecarnil B B 0.9996291399002075
produced O O 0.9998010993003845
a O O 0.9999608993530273
paralleled O O 0.9998730421066284
dose O O 0.9997500777244568
- O O 0.9999769926071167
dependent O O 0.9999903440475464
( O O 0.9999217987060547
0 O O 0.9999808073043823
. O O 0.9999967813491821
05 O O 0.9999936819076538
- O O 0.9997517466545105
1 O O 0.9999929666519165
mg O O 0.9999868869781494
/ O O 0.9999942779541016
kg O O 0.9999942779541016
i O O 0.9997485280036926
. O O 0.9999954700469971
p O O 0.9999979734420776
. O O 0.9999908208847046
) O O 0.9999655485153198
reduction O O 0.9999840259552002
of O O 0.9999370574951172
both O O 0.9996665716171265
motor O O 0.9999649524688721
behavior O O 0.9999685287475586
and O O 0.9998775720596313
cortical O O 0.9966956377029419
[ O O 0.9996622800827026
35S O O 0.9975965619087219
] O O 0.9965136647224426
TBPS O O 0.6772503852844238
binding O O 0.9991592168807983
. O O 0.9999654293060303

Moreover O O 0.9999409914016724
, O O 0.9997599720954895
0 O O 0.9999006986618042
. O O 0.9999896287918091
05 O O 0.9999780654907227
mg O O 0.9999462366104126
/ O O 0.999980092048645
kg O O 0.999962568283081
of O O 0.9987114667892456
this O O 0.9893496036529541
beta B B 0.4578826427459717
- I I 0.7334335446357727
carboline I I 0.9990936517715454
reduced O O 0.9994708895683289
markedly O O 0.9999514818191528
the O O 0.9999808073043823
increase O O 0.999931812286377
of O O 0.9998732805252075
[ B O 0.9916675686836243
35S I O 0.9991982579231262
] I O 0.9956515431404114
TBPS I O 0.6638367176055908
binding O O 0.98812335729599
and O O 0.9999302625656128
the O O 0.999977707862854
convulsions O O 0.9999788999557495
induced O O 0.9999951124191284
by O O 0.9999176263809204
isoniazid B B 0.999828577041626
( O O 0.9998742341995239
200 O O 0.999765932559967
mg O O 0.999955415725708
/ O O 0.9999802112579346
kg O O 0.9999927282333374
s O O 0.9999508857727051
. O O 0.9999960660934448
c O O 0.9999971389770508
. O O 0.9999934434890747
) O O 0.9999728202819824
. O O 0.9999817609786987
( O O 0.9998698234558105
ABSTRACT O O 0.9999053478240967
TRUNCATED O O 0.9999552965164185
AT O O 0.9999407529830933
250 O O 0.9951611161231995
WORDS O O 0.9999967813491821
) O O 0.9998729228973389

Recurrent O O 0.99991774559021
myocardial O O 0.9999973773956299
infarction O O 0.999984860420227
in O O 0.9999719858169556
a O O 0.999984622001648
postpartum O O 0.9998723268508911
patient O O 0.9999904632568359
receiving O O 0.9971262812614441
bromocriptine B B 0.9985755681991577
. O O 0.9997627139091492

Myocardial O O 0.9999535083770752
infarction O O 0.9999572038650513
in O O 0.9994335770606995
puerperium O O 0.9735060334205627
is O O 0.999951958656311
infrequently O O 0.9999892711639404
reported O O 0.9999853372573853
. O O 0.9999489784240723

Spasm O O 0.9657188057899475
, O O 0.999859094619751
coronary O O 0.9995688796043396
dissection O O 0.9999754428863525
, O O 0.9997624754905701
or O O 0.9995962977409363
atheromatous O O 0.998223602771759
etiology O O 0.999931812286377
has O O 0.9999649524688721
been O O 0.9999821186065674
described O O 0.9999845027923584
. O O 0.9999653100967407

Bromocriptine B B 0.9991689920425415
has O O 0.9996448755264282
been O O 0.9999455213546753
implicated O O 0.999803364276886
in O O 0.9999047517776489
several O O 0.9999923706054688
previous O O 0.9999890327453613
case O O 0.9999884366989136
reports O O 0.9999980926513672
of O O 0.9999656677246094
myocardial O O 0.9999949932098389
infarction O O 0.9999850988388062
in O O 0.999885082244873
the O O 0.9997493624687195
puerperium O O 0.988631546497345
. O O 0.9999159574508667

Our O O 0.9999798536300659
case O O 0.9999816417694092
( O O 0.9999473094940186
including O O 0.9999822378158569
an O O 0.9999850988388062
inadvertent O O 0.9999803304672241
rechallenge O O 0.999994158744812
) O O 0.9999727010726929
suggests O O 0.9999140501022339
such O O 0.9999723434448242
a O O 0.9999860525131226
relationship O O 0.999977707862854
. O O 0.9999735355377197

Although O O 0.9999600648880005
generally O O 0.999940037727356
regarded O O 0.9999567270278931
as O O 0.9999151229858398
" O O 0.9999245405197144
safe O O 0.9999130964279175
, O O 0.9999334812164307
" O O 0.9999464750289917
possible O O 0.9999092817306519
serious O O 0.9999319314956665
cardiac O O 0.9999790191650391
effects O O 0.9999798536300659
of O O 0.9998084902763367
bromocriptine B B 0.9992631077766418
should O O 0.9996091723442078
be O O 0.9999910593032837
acknowledged O O 0.9999873638153076
. O O 0.9999655485153198

Asterixis O O 0.997725784778595
induced O O 0.9999234676361084
by O O 0.999894380569458
carbamazepine B B 0.998994767665863
therapy O O 0.999278724193573
. O O 0.9998800754547119

There O O 0.9999722242355347
are O O 0.9999769926071167
very O O 0.9999948740005493
few O O 0.9999896287918091
reports O O 0.9999966621398926
about O O 0.9998565912246704
asterixis O O 0.989062488079071
as O O 0.9999583959579468
a O O 0.9999423027038574
side O O 0.9999727010726929
effect O O 0.9999876022338867
of O O 0.9999041557312012
treatment O O 0.9999849796295166
with O O 0.9999078512191772
psychopharmacologic O O 0.9990770816802979
agents O O 0.9908469319343567
. O O 0.9999065399169922

In O O 0.9999874830245972
this O O 0.9999861717224121
report O O 0.9999926090240479
we O O 0.9999692440032959
present O O 0.9999786615371704
four O O 0.9999830722808838
patients O O 0.9999943971633911
treated O O 0.9999607801437378
with O O 0.9999308586120605
a O O 0.9999790191650391
combination O O 0.9992092847824097
of O O 0.9998599290847778
different O O 0.9998898506164551
psychotropic O O 0.9997676014900208
drugs O O 0.9980499744415283
, O O 0.999970555305481
in O O 0.9998952150344849
whom O O 0.9999537467956543
asterixis O O 0.9957003593444824
was O O 0.999942421913147
triggered O O 0.9999525547027588
either O O 0.9999659061431885
by O O 0.9999490976333618
adding O O 0.9998676776885986
carbamazepine B B 0.999138355255127
( O O 0.9923096895217896
CBZ B B 0.9962003827095032
) O O 0.9994606375694275
to O O 0.9999010562896729
a O O 0.9999445676803589
treatment O O 0.9999204874038696
regimen O O 0.9996438026428223
, O O 0.9999431371688843
or O O 0.9999547004699707
by O O 0.9999843835830688
increasing O O 0.9999547004699707
its O O 0.9999353885650635
dosage O O 0.999940037727356
. O O 0.9999333620071411

Neither O O 0.9998797178268433
dosage O O 0.999519944190979
nor O O 0.9999663829803467
serum O O 0.9994537234306335
levels O O 0.99994957447052
of O O 0.999651312828064
CBZ B B 0.919691264629364
were O O 0.999788224697113
in O O 0.9999465942382812
a O O 0.9999804496765137
higher O O 0.9999568462371826
range O O 0.9999706745147705
. O O 0.9999682903289795

We O O 0.9999321699142456
consider O O 0.9999443292617798
asterixis O O 0.9957473874092102
to O O 0.9999439716339111
be O O 0.9999817609786987
an O O 0.9999651908874512
easily O O 0.9999370574951172
overlooked O O 0.999988317489624
sign O O 0.9999641180038452
of O O 0.999948263168335
neurotoxicity O O 0.9999746084213257
, O O 0.9999798536300659
which O O 0.999983549118042
may O O 0.99997878074646
occur O O 0.9999926090240479
even O O 0.9999544620513916
at O O 0.9999524354934692
low O O 0.9999719858169556
or O O 0.9999794960021973
moderate O O 0.9999622106552124
dosage O O 0.9999204874038696
levels O O 0.9999521970748901
, O O 0.9999860525131226
if O O 0.9999685287475586
certain O O 0.99988853931427
drugs O O 0.9987468719482422
as O O 0.9998315572738647
lithium B B 0.9997066855430603
or O O 0.9960309863090515
clozapine B B 0.9992005228996277
are O O 0.9999376535415649
used O O 0.999887228012085
in O O 0.9999637603759766
combination O O 0.9998748302459717
with O O 0.9994946718215942
CBZ B B 0.9774845242500305
. O O 0.9999207258224487

Pharmacodynamics O O 0.999518871307373
of O O 0.9999281167984009
the O O 0.9999526739120483
hypotensive O O 0.9999207258224487
effect O O 0.9998830556869507
of O O 0.9993252754211426
levodopa B B 0.999667763710022
in O O 0.9997242093086243
parkinsonian O O 0.9968110918998718
patients O O 0.9999475479125977
. O O 0.9999302625656128

Blood O O 0.9991523027420044
pressure O O 0.9972200393676758
effects O O 0.9999353885650635
of O O 0.9998722076416016
i O O 0.9996005892753601
. O O 0.9999854564666748
v O O 0.9999957084655762
. O O 0.9998334646224976
levodopa B B 0.9993638396263123
were O O 0.9998453855514526
examined O O 0.999942421913147
in O O 0.9998898506164551
parkinsonian O O 0.9986843466758728
patients O O 0.9999661445617676
with O O 0.9999568462371826
stable O O 0.9999784231185913
and O O 0.9999920129776001
fluctuating O O 0.9999927282333374
responses O O 0.999997615814209
to O O 0.9998823404312134
levodopa B B 0.9995477795600891
. O O 0.9999152421951294

The O O 0.9999827146530151
magnitude O O 0.9999843835830688
of O O 0.9999780654907227
the O O 0.9999854564666748
hypotensive O O 0.9999765157699585
effect O O 0.9999434947967529
of O O 0.9996733665466309
levodopa B B 0.9997438788414001
was O O 0.9999043941497803
concentration O O 0.9996764659881592
dependent O O 0.9999611377716064
and O O 0.9999810457229614
was O O 0.9999639987945557
fit O O 0.9999916553497314
to O O 0.9999110698699951
an O O 0.9996953010559082
Emax O O 0.9994708895683289
model O O 0.9998841285705566
in O O 0.9998642206192017
fluctuating O O 0.9999756813049316
responders O O 0.999913215637207
. O O 0.9999680519104004

Stable O O 0.6761491298675537
responders O O 0.9984877109527588
demonstrated O O 0.999950647354126
a O O 0.9999649524688721
small O O 0.9999932050704956
hypotensive O O 0.9999411106109619
response O O 0.999970555305481
. O O 0.9999514818191528

Baseline O O 0.9999027252197266
blood O O 0.9998832941055298
pressures O O 0.9999262094497681
were O O 0.9999583959579468
higher O O 0.9999632835388184
in O O 0.9999359846115112
fluctuating O O 0.9999860525131226
patients O O 0.9999866485595703
; O O 0.999974250793457
a O O 0.999985933303833
higher O O 0.9999672174453735
baseline O O 0.9999868869781494
blood O O 0.9998383522033691
pressure O O 0.9994063377380371
correlated O O 0.9999781847000122
with O O 0.9999866485595703
greater O O 0.9999487400054932
hypotensive O O 0.9999711513519287
effects O O 0.9999651908874512
. O O 0.9999767541885376

Antiparkinsonian O O 0.7784684896469116
effects O O 0.9998206496238708
of O O 0.9997455477714539
levodopa B B 0.9992309808731079
temporally O O 0.9996687173843384
correlated O O 0.9999793767929077
with O O 0.9999860525131226
blood O O 0.9999366998672485
pressure O O 0.9993941783905029
changes O O 0.9999901056289673
. O O 0.999976396560669

Phenylalanine B B 0.998965859413147
, O O 0.9997089505195618
a O O 0.996550440788269
large O O 0.9763832092285156
neutral O O 0.8543931841850281
amino B B 0.721063494682312
acid I I 0.9639330506324768
( O O 0.6681041121482849
LNAA O O 0.5209442377090454
) O O 0.9236505627632141
competing O O 0.9955301880836487
with O O 0.9994978904724121
levodopa B B 0.9997618794441223
for O O 0.9992024302482605
transport O O 0.9999648332595825
across O O 0.9999536275863647
the O O 0.9999749660491943
blood O O 0.9974536299705505
- O O 0.999821126461029
brain O O 0.9999898672103882
barrier O O 0.9999957084655762
, O O 0.9999030828475952
reduced O O 0.9998950958251953
the O O 0.9999682903289795
hypotensive O O 0.9998871088027954
and O O 0.9998495578765869
antiparkinsonian O O 0.6359477639198303
effects O O 0.9998602867126465
of O O 0.9998078942298889
levodopa B B 0.9997915625572205
. O O 0.999880313873291

We O O 0.9999504089355469
conclude O O 0.9999361038208008
that O O 0.9994687438011169
levodopa B B 0.9998618364334106
has O O 0.9999048709869385
a O O 0.9999481439590454
central O O 0.9998958110809326
hypotensive O O 0.9998713731765747
action O O 0.9999436140060425
that O O 0.999946117401123
parallels O O 0.9998703002929688
the O O 0.9999014139175415
motor O O 0.9999182224273682
effects O O 0.9999599456787109
in O O 0.9999707937240601
fluctuating O O 0.9999637603759766
patients O O 0.9999871253967285
. O O 0.9999680519104004

The O O 0.9999663829803467
hypotensive O O 0.9999271631240845
effect O O 0.9999363422393799
appears O O 0.9998956918716431
to O O 0.9998782873153687
be O O 0.9999436140060425
related O O 0.9999780654907227
to O O 0.9999599456787109
the O O 0.9999849796295166
higher O O 0.9999786615371704
baseline O O 0.9999862909317017
blood O O 0.999923586845398
pressure O O 0.9994463324546814
we O O 0.9999817609786987
observed O O 0.9999904632568359
in O O 0.9999309778213501
fluctuating O O 0.9999711513519287
patients O O 0.9999929666519165
relative O O 0.9999669790267944
to O O 0.9999452829360962
stable O O 0.999985933303833
patients O O 0.9999948740005493
. O O 0.9999624490737915

Syndrome O O 0.9999363422393799
of O O 0.9999496936798096
inappropriate O O 0.9998440742492676
secretion O O 0.9999325275421143
of O O 0.999593198299408
antidiuretic O O 0.48033368587493896
hormone O O 0.7852141261100769
after O O 0.9994297623634338
infusional O O 0.9998916387557983
vincristine B B 0.9980515241622925
. O O 0.9998593330383301

A O O 0.9999814033508301
77 O O 0.9999939203262329
- O O 0.9999901056289673
year O O 0.9999977350234985
- O O 0.9999946355819702
old O O 0.9999954700469971
woman O O 0.9999980926513672
with O O 0.9999793767929077
refractory O O 0.9999858140945435
multiple O O 0.9959915280342102
myeloma O O 0.9999958276748657
was O O 0.9999685287475586
treated O O 0.9999839067459106
with O O 0.999982476234436
a O O 0.9999808073043823
4 O O 0.999833345413208
- O O 0.9999871253967285
day O O 0.9999912977218628
continuous O O 0.9999270439147949
intravenous O O 0.9999734163284302
infusion O O 0.9999707937240601
of O O 0.9950828552246094
vincristine B B 0.9969180822372437
and O O 0.9518651962280273
doxorubicin B B 0.999234676361084
and O O 0.9993911981582642
4 O O 0.998246431350708
days O O 0.9999935626983643
of O O 0.9998737573623657
oral O O 0.9770978689193726
dexamethasone B B 0.998779833316803
. O O 0.9999434947967529

Nine O O 0.9999902248382568
days O O 0.9999985694885254
after O O 0.9999947547912598
her O O 0.9999915361404419
second O O 0.9999878406524658
cycle O O 0.9998223185539246
she O O 0.9999704360961914
presented O O 0.9999938011169434
with O O 0.9999829530715942
lethargy O O 0.9999961853027344
and O O 0.9999755620956421
weakness O O 0.9999973773956299
associated O O 0.9999749660491943
with O O 0.9999514818191528
hyponatremia O O 0.9955171942710876
. O O 0.9999550580978394

Evaluation O O 0.9999476671218872
revealed O O 0.9999520778656006
the O O 0.9999712705612183
syndrome O O 0.9999611377716064
of O O 0.9999072551727295
inappropriate O O 0.9998586177825928
secretion O O 0.9999138116836548
of O O 0.9984251260757446
antidiuretic O O 0.5653737783432007
hormone O O 0.5636307001113892
, O O 0.999916672706604
which O O 0.9999475479125977
was O O 0.9999567270278931
attributed O O 0.9999918937683105
to O O 0.9998579025268555
the O O 0.9997530579566956
vincristine B B 0.9979568719863892
infusion O O 0.9996404647827148
. O O 0.9999600648880005

After O O 0.999988317489624
normal O O 0.9999667406082153
serum O O 0.9995967745780945
sodium B B 0.9990383386611938
levels O O 0.9997321963310242
returned O O 0.9999761581420898
, O O 0.9999682903289795
further O O 0.9998325109481812
doxorubicin B B 0.9997637867927551
and O O 0.9533259868621826
dexamethasone B B 0.9975798726081848
chemotherapy O O 0.9968281388282776
without O O 0.9992848038673401
vincristine B B 0.9958219528198242
did O O 0.9999271631240845
not O O 0.9999731779098511
produce O O 0.9999872446060181
this O O 0.9999780654907227
complication O O 0.999992847442627
. O O 0.9999815225601196

Heart O O 0.9983687996864319
failure O O 0.9999427795410156
: O O 0.9999347925186157
to O O 0.9965139031410217
digitalise O O 0.9893381595611572
or O O 0.999942421913147
not O O 0.9998726844787598
? O O 0.9999512434005737

The O O 0.9998037219047546
view O O 0.9981209635734558
against O O 0.9857752323150635
. O O 0.9998301267623901

Despite O O 0.9999537467956543
extensive O O 0.9999830722808838
clinical O O 0.9999881982803345
experience O O 0.9999983310699463
the O O 0.9999891519546509
role O O 0.999945878982544
of O O 0.9996218681335449
digoxin B B 0.9988802075386047
is O O 0.999842643737793
still O O 0.9999939203262329
not O O 0.9999979734420776
well O O 0.9999861717224121
defined O O 0.9999938011169434
. O O 0.9999775886535645

In O O 0.9998047947883606
patients O O 0.9999861717224121
with O O 0.9999815225601196
atrial O O 0.9995256662368774
fibrillation O O 0.9999732971191406
digoxin B B 0.9994056224822998
is O O 0.9997097849845886
beneficial O O 0.9999363422393799
for O O 0.9998948574066162
ventricular O O 0.99997878074646
rate O O 0.9999631643295288
control O O 0.9999673366546631
. O O 0.9999786615371704

For O O 0.9996452331542969
patients O O 0.9999831914901733
in O O 0.9998559951782227
sinus O O 0.9999748468399048
rhythm O O 0.9999827146530151
and O O 0.9998641014099121
heart O O 0.9998818635940552
failure O O 0.9999749660491943
the O O 0.999990701675415
situation O O 0.9999914169311523
is O O 0.9999884366989136
less O O 0.9999948740005493
clear O O 0.9999955892562866
. O O 0.9999815225601196

Digoxin B B 0.998304009437561
has O O 0.9998424053192139
a O O 0.9999561309814453
narrow O O 0.9999321699142456
therapeutic O O 0.9994314312934875
: O O 0.9998481273651123
toxic O O 0.9997782111167908
ratio O O 0.9999233484268188
and O O 0.9999353885650635
concentrations O O 0.999832034111023
are O O 0.9999428987503052
affected O O 0.999981164932251
by O O 0.9999206066131592
a O O 0.9999654293060303
number O O 0.9999523162841797
of O O 0.9995965361595154
drugs O O 0.9991891980171204
. O O 0.9999499320983887

Also O O 0.9998701810836792
, O O 0.9992789626121521
digoxin B B 0.9995483756065369
has O O 0.9996813535690308
undesirable O O 0.9999542236328125
effects O O 0.9999465942382812
such O O 0.9999589920043945
as O O 0.9999797344207764
increasing O O 0.9999078512191772
peripheral O O 0.99980229139328
resistance O O 0.9999964237213135
and O O 0.9999481439590454
myocardial O O 0.9999978542327881
demands O O 0.9999641180038452
, O O 0.999933123588562
and O O 0.9999574422836304
causing O O 0.9999315738677979
arrhythmias O O 0.9999855756759644
. O O 0.999953031539917

There O O 0.9999810457229614
is O O 0.9999854564666748
a O O 0.9999915361404419
paucity O O 0.9999973773956299
of O O 0.9999947547912598
data O O 0.9999902248382568
from O O 0.9999871253967285
well O O 0.9996745586395264
- O O 0.9999836683273315
designed O O 0.9999895095825195
trials O O 0.999947190284729
. O O 0.9999557733535767

The O O 0.9999793767929077
trials O O 0.99996018409729
that O O 0.999991774559021
are O O 0.9999974966049194
available O O 0.9999977350234985
are O O 0.9999889135360718
generally O O 0.9999951124191284
small O O 0.9999958276748657
with O O 0.9999825954437256
limitations O O 0.9999964237213135
in O O 0.9999922513961792
design O O 0.999995231628418
and O O 0.9999783039093018
these O O 0.9999749660491943
show O O 0.999962329864502
variation O O 0.999997615814209
in O O 0.9999842643737793
patient O O 0.9999778270721436
benefit O O 0.9999914169311523
. O O 0.9999769926071167

More O O 0.9999639987945557
convincing O O 0.9999804496765137
evidence O O 0.9999887943267822
is O O 0.9999816417694092
required O O 0.9999940395355225
showing O O 0.9999821186065674
that O O 0.9999033212661743
digoxin B B 0.9987183809280396
improves O O 0.9998212456703186
symptoms O O 0.9999898672103882
or O O 0.9999924898147583
exercise O O 0.9999727010726929
capacity O O 0.999995231628418
. O O 0.9999791383743286

Furthermore O O 0.9996328353881836
, O O 0.9999767541885376
no O O 0.9999656677246094
trial O O 0.9999492168426514
has O O 0.9999790191650391
had O O 0.9999934434890747
sufficient O O 0.9999898672103882
power O O 0.9999970197677612
to O O 0.9999933242797852
evaluate O O 0.9999737739562988
mortality O O 0.9999897480010986
. O O 0.9999678134918213

Pooled O O 0.9995081424713135
analysis O O 0.9996150732040405
of O O 0.9998461008071899
the O O 0.9999041557312012
effects O O 0.9999417066574097
of O O 0.999891996383667
other O O 0.9993822574615479
inotropic O O 0.7541823387145996
drugs O O 0.9835140705108643
shows O O 0.9998369216918945
an O O 0.9999775886535645
excess O O 0.9999511241912842
mortality O O 0.9999924898147583
and O O 0.9999704360961914
there O O 0.9999799728393555
is O O 0.9999793767929077
a O O 0.9999821186065674
possibility O O 0.999990701675415
that O O 0.9998786449432373
digoxin B B 0.9996521472930908
may O O 0.9999104738235474
increase O O 0.9998365640640259
mortality O O 0.9999923706054688
after O O 0.9998929500579834
myocardial O O 0.9999929666519165
infarction O O 0.9998268485069275
( O O 0.999920129776001
MI O O 0.9759781360626221
) O O 0.9999839067459106
. O O 0.9999834299087524

Angiotensin B B 0.9473094344139099
- O O 0.7140724062919617
converting O O 0.7637101411819458
enzyme O O 0.8024397492408752
( O O 0.5792081356048584
ACE O O 0.5227193236351013
) O O 0.5476663112640381
inhibitors O O 0.6904778480529785
should O O 0.9989326596260071
be O O 0.9999549388885498
used O O 0.9998477697372437
first O O 0.9999836683273315
as O O 0.9999954700469971
they O O 0.9999727010726929
are O O 0.9999837875366211
safer O O 0.9999830722808838
, O O 0.9999899864196777
do O O 0.9999959468841553
not O O 0.999996542930603
require O O 0.9999881982803345
blood O O 0.9998047947883606
level O O 0.9996988773345947
monitoring O O 0.9999755620956421
, O O 0.9999709129333496
modify O O 0.9999864101409912
progression O O 0.9999984502792358
of O O 0.9999927282333374
disease O O 0.9999945163726807
, O O 0.9999768733978271
relieve O O 0.9994275569915771
symptoms O O 0.9999961853027344
, O O 0.9999806880950928
improve O O 0.999929666519165
exercise O O 0.9997296929359436
tolerance O O 0.9999943971633911
and O O 0.9999722242355347
reduce O O 0.9999830722808838
mortality O O 0.9999974966049194
. O O 0.9999120235443115

Caution O O 0.999976634979248
should O O 0.999950647354126
be O O 0.9999895095825195
exercised O O 0.9999970197677612
in O O 0.9999781847000122
using O O 0.9998290538787842
digoxin B B 0.9981818199157715
until O O 0.999854326248169
large O O 0.9999364614486694
mortality O O 0.9999309778213501
trials O O 0.9999412298202515
are O O 0.9999933242797852
completed O O 0.9999924898147583
showing O O 0.9999642372131348
either O O 0.9999309778213501
benefit O O 0.9999918937683105
or O O 0.9999805688858032
harm O O 0.9999945163726807
. O O 0.9999616146087646

Until O O 0.9985952973365784
then O O 0.9990591406822205
digoxin B B 0.9991053938865662
should O O 0.9995487332344055
be O O 0.9999783039093018
considered O O 0.9999712705612183
a O O 0.9999251365661621
third O O 0.9998940229415894
- O O 0.9999058246612549
line O O 0.9989432692527771
therapy O O 0.999934196472168
. O O 0.9999511241912842

Isradipine B B 0.998946487903595
treatment O O 0.9989567995071411
for O O 0.9997996687889099
hypertension O O 0.8517603874206543
in O O 0.9999732971191406
general O O 0.9998894929885864
practice O O 0.9999947547912598
in O O 0.999656081199646
Hong O O 0.8334322571754456
Kong O O 0.591152012348175
. O O 0.9965691566467285

A O O 0.9999821186065674
6 O O 0.9999278783798218
- O O 0.9999852180480957
week O O 0.9999948740005493
open O O 0.9999877214431763
study O O 0.9999964237213135
of O O 0.9999706745147705
the O O 0.9999926090240479
introduction O O 0.9999901056289673
of O O 0.9988986253738403
isradipine B B 0.9983565211296082
treatment O O 0.9993574023246765
was O O 0.9999898672103882
conducted O O 0.9999977350234985
in O O 0.9999829530715942
general O O 0.9999333620071411
practice O O 0.9999978542327881
in O O 0.9999334812164307
Hong O O 0.9364343285560608
Kong O O 0.9270316958427429
. O O 0.9999524354934692

303 O O 0.9979960918426514
Chinese O O 0.8777825832366943
patients O O 0.9999382495880127
with O O 0.9999498128890991
mild O O 0.999968409538269
to O O 0.9999878406524658
moderate O O 0.9999710321426392
hypertension O O 0.9910883903503418
entered O O 0.9999523162841797
the O O 0.9999958276748657
study O O 0.9999833106994629
. O O 0.9999501705169678

Side O O 0.999638557434082
effects O O 0.9999614953994751
were O O 0.9999675750732422
reported O O 0.9999897480010986
in O O 0.9999773502349854
21 O O 0.9999786615371704
% O O 0.9999951124191284
of O O 0.9999754428863525
patients O O 0.9999887943267822
and O O 0.9999306201934814
caused O O 0.9999690055847168
withdrawal O O 0.9999834299087524
from O O 0.9999910593032837
the O O 0.9999970197677612
study O O 0.999963641166687
in O O 0.9999312162399292
3 O O 0.9997807145118713
patients O O 0.9999902248382568
. O O 0.999971866607666

The O O 0.9998869895935059
main O O 0.9998905658721924
side O O 0.9999377727508545
- O O 0.9999535083770752
effects O O 0.9999901056289673
were O O 0.9999606609344482
headache O O 0.9999935626983643
, O O 0.9999723434448242
dizziness O O 0.999992847442627
, O O 0.9999688863754272
palpitation O O 0.9999955892562866
and O O 0.9998589754104614
flushing O O 0.9997350573539734
and O O 0.9999514818191528
these O O 0.9999856948852539
were O O 0.9999804496765137
not O O 0.999996542930603
more O O 0.9999791383743286
frequent O O 0.9999957084655762
than O O 0.9999924898147583
reported O O 0.9999912977218628
in O O 0.9999806880950928
other O O 0.9999668598175049
studies O O 0.9999867677688599
with O O 0.999873161315918
isradipine B B 0.9993060827255249
or O O 0.9997429251670837
with O O 0.9998713731765747
placebo O O 0.9997889399528503
. O O 0.9999313354492188

Supine O O 0.9998602867126465
blood O O 0.9990737438201904
pressure O O 0.9985873699188232
was O O 0.9999697208404541
reduced O O 0.9999912977218628
( O O 0.9999427795410156
P O O 0.9921677708625793
less O O 0.9999376535415649
than O O 0.9999921321868896
0 O O 0.9999946355819702
. O O 0.9999982118606567
01 O O 0.9999977350234985
) O O 0.9999793767929077
from O O 0.9999796152114868
170 O O 0.999964714050293
+ O O 0.9999632835388184
/ O O 0.999497652053833
- O O 0.9993321299552917
20 O O 0.9999537467956543
/ O O 0.9997796416282654
102 O O 0.988024890422821
+ O O 0.9999549388885498
/ O O 0.9983384609222412
- O O 0.9998296499252319
6 O O 0.9999483823776245
mmHg O O 0.9997300505638123
to O O 0.9999552965164185
153 O O 0.999972939491272
+ O O 0.9999791383743286
/ O O 0.9994972944259644
- O O 0.9996151924133301
19 O O 0.9999707937240601
/ O O 0.9998791217803955
92 O O 0.9841805696487427
+ O O 0.9999788999557495
/ O O 0.9980921149253845
- O O 0.9998916387557983
8 O O 0.9998730421066284
, O O 0.9999654293060303
147 O O 0.9999889135360718
+ O O 0.9999746084213257
/ O O 0.9977443218231201
- O O 0.9993317723274231
18 O O 0.9999421834945679
/ O O 0.9997530579566956
88 O O 0.9423172473907471
+ O O 0.9999765157699585
/ O O 0.9977426528930664
- O O 0.9997765421867371
7 O O 0.9999351501464844
and O O 0.9999666213989258
144 O O 0.999981164932251
+ O O 0.9999855756759644
/ O O 0.9990496039390564
- O O 0.9997308850288391
14 O O 0.9999899864196777
/ O O 0.9994397759437561
87 O O 0.9974205493927002
+ O O 0.9999756813049316
/ O O 0.9986028075218201
- O O 0.9998703002929688
6 O O 0.9999300241470337
mmHg O O 0.9998829364776611
at O O 0.9999560117721558
2 O O 0.999987006187439
, O O 0.9999516010284424
4 O O 0.999985933303833
and O O 0.9999778270721436
6 O O 0.9999762773513794
weeks O O 0.9999943971633911
respectively O O 0.9999741315841675
in O O 0.9999208450317383
evaluable O O 0.9998353719711304
patients O O 0.9999755620956421
. O O 0.9999642372131348

Similar O O 0.999934196472168
reductions O O 0.9999939203262329
occurred O O 0.9999945163726807
in O O 0.9999762773513794
standing O O 0.9998037219047546
blood O O 0.9998828172683716
pressure O O 0.9982128143310547
and O O 0.9999619722366333
there O O 0.9999749660491943
was O O 0.999976396560669
no O O 0.9999785423278809
evidence O O 0.9999856948852539
of O O 0.9999512434005737
postural O O 0.9994331002235413
hypotension O O 0.9999358654022217
. O O 0.999955415725708

Normalization O O 0.9980448484420776
and O O 0.9998189806938171
responder O O 0.9995582699775696
rates O O 0.9998289346694946
at O O 0.9999779462814331
6 O O 0.9999616146087646
weeks O O 0.9999959468841553
were O O 0.9999719858169556
86 O O 0.9999686479568481
% O O 0.9999936819076538
and O O 0.9999728202819824
69 O O 0.9999957084655762
% O O 0.9999953508377075
respectively O O 0.9999735355377197
. O O 0.9999860525131226

Dosage O O 0.999906063079834
was O O 0.9999804496765137
increased O O 0.9999880790710449
from O O 0.9999914169311523
2 O O 0.9958500862121582
. O O 0.999990701675415
5 O O 0.9999648332595825
mg O O 0.9995802044868469
b O O 0.9996638298034668
. O O 0.9999957084655762
d O O 0.9999990463256836
. O O 0.9999918937683105
to O O 0.9999513626098633
5 O O 0.9999490976333618
mg O O 0.9999405145645142
b O O 0.999434769153595
. O O 0.9999960660934448
d O O 0.9999988079071045
. O O 0.9999895095825195
at O O 0.9999814033508301
4 O O 0.999972939491272
weeks O O 0.9999982118606567
in O O 0.9999704360961914
patients O O 0.9999971389770508
with O O 0.9999912977218628
diastolic O O 0.9999189376831055
blood O O 0.9997082352638245
pressure O O 0.9999234676361084
greater O O 0.9999880790710449
than O O 0.9999929666519165
90 O O 0.9999914169311523
mmHg O O 0.9999978542327881
and O O 0.9999586343765259
their O O 0.9999635219573975
further O O 0.9996134638786316
response O O 0.9999798536300659
was O O 0.9999634027481079
greater O O 0.9999667406082153
than O O 0.9999935626983643
those O O 0.9999896287918091
remaining O O 0.999990701675415
on O O 0.9999271631240845
2 O O 0.993694007396698
. O O 0.9999558925628662
5 O O 0.9997746348381042
mg O O 0.9979433417320251
b O O 0.9955078363418579
. O O 0.9999905824661255
d O O 0.9999969005584717
. O O 0.9999138116836548

Pharmacological O O 0.9995860457420349
characteristics O O 0.9999839067459106
and O O 0.9999505281448364
side O O 0.9999707937240601
effects O O 0.9999847412109375
of O O 0.999915361404419
a O O 0.9999526739120483
new O O 0.9998921155929565
galenic O O 0.5331470966339111
formulation O O 0.9986395239830017
of O O 0.991493821144104
propofol B B 0.9992750287055969
without O O 0.9300544261932373
soyabean O O 0.7658970952033997
oil O O 0.9222685694694519
. O O 0.9997197985649109

We O O 0.9999748468399048
compared O O 0.999975323677063
the O O 0.9999812841415405
pharmacokinetics O O 0.9999743700027466
, O O 0.9999861717224121
pharmacodynamics O O 0.9998776912689209
and O O 0.9999730587005615
safety O O 0.9999837875366211
profile O O 0.9999905824661255
of O O 0.9999171495437622
a O O 0.9999169111251831
new O O 0.9998918771743774
galenic O O 0.6271829009056091
formulation O O 0.9961329698562622
of O O 0.9940018057823181
propofol B B 0.9993427395820618
( O O 0.9892144799232483
AM149 O B 0.9935891628265381
1 O O 0.8928627371788025
% O O 0.6884171366691589
) O O 0.9998447895050049
, O O 0.9999790191650391
which O O 0.9998772144317627
does O O 0.9998540878295898
not O O 0.9989967942237854
contain O O 0.9962701797485352
soyabean O O 0.6120280623435974
oil O O 0.7467206716537476
, O O 0.999937891960144
with O O 0.9998819828033447
a O O 0.9999697208404541
standard O O 0.9999799728393555
formulation O O 0.9999531507492065
of O O 0.9996116757392883
propofol B B 0.9995418787002563
( O O 0.9975294470787048
Disoprivan B B 0.9888829588890076
1 O O 0.9869491457939148
% O O 0.96390300989151
) O O 0.9999561309814453
. O O 0.9999548196792603

In O O 0.9999784231185913
a O O 0.9999878406524658
randomised O O 0.9999862909317017
, O O 0.9999845027923584
double O O 0.9999353885650635
- O O 0.999970555305481
blind O O 0.9999964237213135
, O O 0.9999836683273315
cross O O 0.9997778534889221
- O O 0.9999818801879883
over O O 0.9999735355377197
study O O 0.9999951124191284
, O O 0.9999914169311523
30 O O 0.9999929666519165
healthy O O 0.9999970197677612
volunteers O O 0.9999984502792358
received O O 0.9999641180038452
a O O 0.9999878406524658
single O O 0.9999654293060303
intravenous O O 0.9999878406524658
bolus O O 0.9999668598175049
injection O O 0.9999842643737793
of O O 0.9998798370361328
2 O O 0.9994788765907288
. O O 0.9999778270721436
5 O O 0.9999418258666992
mg O O 0.9999563694000244
. O O 0.9999837875366211
kg O O 0.9949008226394653
- O O 0.9987176656723022
1 O O 0.9981684684753418
propofol B B 0.9993757605552673
. O O 0.9999326467514038

Plasma O O 0.9988344311714172
propofol B B 0.9995766282081604
levels O O 0.9998555183410645
were O O 0.9999817609786987
measured O O 0.9999767541885376
for O O 0.9999616146087646
48 O O 0.9999912977218628
h O O 0.999829888343811
following O O 0.9999551773071289
drug O O 0.9995706677436829
administration O O 0.9999438524246216
and O O 0.9999674558639526
evaluated O O 0.9999922513961792
according O O 0.9999932050704956
to O O 0.9999902248382568
a O O 0.99998939037323
three O O 0.999795138835907
- O O 0.999976396560669
compartment O O 0.9999887943267822
model O O 0.9999949932098389
. O O 0.9999768733978271

The O O 0.9999706745147705
pharmacodynamic O O 0.9999014139175415
parameters O O 0.9999637603759766
assessed O O 0.9999604225158691
included O O 0.9999227523803711
induction O O 0.9999339580535889
and O O 0.9996575117111206
emergence O O 0.9997270703315735
times O O 0.999958872795105
, O O 0.9999539852142334
respiratory O O 0.9999792575836182
and O O 0.9999568462371826
cardiovascular O O 0.9999812841415405
effects O O 0.9999788999557495
, O O 0.9998737573623657
and O O 0.9999088048934937
pain O O 0.9999847412109375
on O O 0.9998118281364441
injection O O 0.9998936653137207
. O O 0.9999635219573975

Patients O O 0.9996378421783447
were O O 0.9999748468399048
monitored O O 0.9999576807022095
for O O 0.999951958656311
side O O 0.9999043941497803
effects O O 0.9999759197235107
over O O 0.9999523162841797
48 O O 0.9999772310256958
h O O 0.9979561567306519
. O O 0.9999512434005737

Owing O O 0.9999943971633911
to O O 0.9999902248382568
a O O 0.9999955892562866
high O O 0.9999885559082031
incidence O O 0.999997615814209
of O O 0.9999817609786987
thrombophlebitis O O 0.9993740916252136
, O O 0.9999780654907227
the O O 0.9999974966049194
study O O 0.9999922513961792
was O O 0.9999964237213135
terminated O O 0.9999982118606567
prematurely O O 0.9999980926513672
and O O 0.9999873638153076
only O O 0.9999816417694092
the O O 0.999992847442627
data O O 0.9999897480010986
of O O 0.9999711513519287
the O O 0.999967098236084
two O O 0.9999520778656006
parallel O O 0.9996914863586426
treatment O O 0.9998984336853027
groups O O 0.9999685287475586
( O O 0.9999649524688721
15 O O 0.9999796152114868
patients O O 0.9999960660934448
in O O 0.9999539852142334
each O O 0.999849796295166
group O O 0.9999682903289795
) O O 0.9999672174453735
were O O 0.9999861717224121
analysed O O 0.9999476671218872
. O O 0.9999827146530151

Plasma O O 0.9993482232093811
concentrations O O 0.9997522234916687
did O O 0.9999678134918213
not O O 0.9999895095825195
differ O O 0.9999850988388062
significantly O O 0.9999872446060181
between O O 0.9994588494300842
the O O 0.999900221824646
two O O 0.9998528957366943
formulations O O 0.9988106489181519
. O O 0.999955415725708

Anaesthesia O O 0.982837438583374
induction O O 0.9999399185180664
and O O 0.9999066591262817
emergence O O 0.9990087747573853
times O O 0.9999411106109619
, O O 0.9999217987060547
respiratory O O 0.9999544620513916
and O O 0.9999336004257202
cardiovascular O O 0.9999735355377197
variables O O 0.9999943971633911
showed O O 0.9999797344207764
no O O 0.9999827146530151
significant O O 0.9999934434890747
differences O O 0.9999946355819702
between O O 0.9999039173126221
the O O 0.9999746084213257
two O O 0.9999580383300781
treatment O O 0.9999189376831055
groups O O 0.9999934434890747
. O O 0.9999655485153198

Pain O O 0.9999582767486572
on O O 0.9996367692947388
injection O O 0.9991145730018616
( O O 0.9999402761459351
80 O O 0.9824122786521912
vs O O 0.9999111890792847
. O O 0.9999957084655762
20 O O 0.999994158744812
% O O 0.9999927282333374
, O O 0.9999696016311646
p O O 0.999954104423523
< O O 0.9999850988388062
0 O O 0.9999902248382568
. O O 0.9999961853027344
01 O O 0.9999979734420776
) O O 0.999936580657959
and O O 0.9999426603317261
thrombophlebitis O O 0.99699866771698
( O O 0.9999518394470215
93 O O 0.9990488886833191
. O O 0.9999920129776001
3 O O 0.9999521970748901
vs O O 0.9998804330825806
. O O 0.9999939203262329
6 O O 0.9999551773071289
. O O 0.999985933303833
6 O O 0.9999927282333374
% O O 0.9999939203262329
, O O 0.9999717473983765
p O O 0.9999467134475708
< O O 0.9999750852584839
0 O O 0.999974250793457
. O O 0.999995231628418
001 O O 0.9997856020927429
) O O 0.9999518394470215
occurred O O 0.999983549118042
more O O 0.9999839067459106
frequently O O 0.9999876022338867
with O O 0.9993497729301453
AM149 O B 0.9985588192939758
than O O 0.9998051524162292
with O O 0.999777615070343
Disoprivan B B 0.9903091788291931
. O O 0.9999390840530396

Although O O 0.9999598264694214
both O O 0.9992467164993286
formulations O O 0.9968478083610535
had O O 0.9999337196350098
similar O O 0.9998503923416138
pharmacokinetic O O 0.9998887777328491
and O O 0.999901533126831
pharmacodynamic O O 0.9998822212219238
profiles O O 0.9999854564666748
the O O 0.999992847442627
new O O 0.9998053908348083
formulation O O 0.9993771910667419
is O O 0.9999628067016602
not O O 0.9999955892562866
suitable O O 0.9999884366989136
for O O 0.9999935626983643
clinical O O 0.9999927282333374
use O O 0.999995231628418
due O O 0.9999873638153076
to O O 0.9999933242797852
the O O 0.9999972581863403
high O O 0.9999896287918091
incidence O O 0.999997615814209
of O O 0.9999812841415405
thrombophlebitis O O 0.9993613362312317
produced O O 0.9999829530715942
. O O 0.9998706579208374

Pure O O 0.9849408268928528
red O O 0.9999457597732544
cell O O 0.9983633160591125
aplasia O O 0.9964278340339661
, O O 0.9999371767044067
toxic O O 0.9986579418182373
dermatitis O O 0.99998939037323
and O O 0.9999200105667114
lymphadenopathy O O 0.999921441078186
in O O 0.9999653100967407
a O O 0.9999809265136719
patient O O 0.9999730587005615
taking O O 0.9982492923736572
diphenylhydantoin B B 0.9968881011009216
. O O 0.9998419284820557

A O O 0.9999767541885376
patient O O 0.9999884366989136
taking O O 0.998754620552063
diphenylhydantoin B B 0.9989903569221497
for O O 0.9991135001182556
3 O O 0.9984671473503113
weeks O O 0.9999697208404541
developed O O 0.999977707862854
a O O 0.9999912977218628
generalized O O 0.9999756813049316
skin O O 0.9999773502349854
rash O O 0.9999525547027588
, O O 0.999969482421875
lymphadenopathy O O 0.9999080896377563
and O O 0.9999521970748901
pure O O 0.9796079397201538
red O O 0.9999333620071411
cell O O 0.9988875985145569
aplasia O O 0.9941096305847168
. O O 0.9999715089797974

After O O 0.9999086856842041
withdrawal O O 0.9998389482498169
of O O 0.9999145269393921
the O O 0.9997739195823669
pharmacon O O 0.7563334107398987
all O O 0.9998569488525391
symptoms O O 0.999994158744812
disappeared O O 0.9999871253967285
spontaneously O O 0.9999961853027344
. O O 0.9999823570251465

Skin O O 0.9997565150260925
rash O O 0.9999698400497437
is O O 0.9999419450759888
a O O 0.9999678134918213
well O O 0.9997580647468567
- O O 0.9999864101409912
known O O 0.9999699592590332
complication O O 0.9999897480010986
of O O 0.9997959733009338
diphenylhydantoin B B 0.9977437257766724
treatment O O 0.9995915293693542
as O O 0.9999394416809082
is O O 0.999954104423523
benign O O 0.9993749260902405
and O O 0.9999254941940308
malignant O O 0.9999935626983643
lymphadenopathy O O 0.9999698400497437
. O O 0.9999692440032959

Pure O O 0.9881463050842285
red O O 0.9999724626541138
cell O O 0.9996812343597412
aplasia O O 0.9992826581001282
associated O O 0.9999761581420898
with O O 0.9996358156204224
diphenylhydantoin B B 0.9947220087051392
medication O O 0.743358314037323
has O O 0.9999696016311646
been O O 0.999992847442627
reported O O 0.9999935626983643
in O O 0.999972939491272
3 O O 0.9994331002235413
patients O O 0.9999879598617554
. O O 0.9999802112579346

The O O 0.9999624490737915
exact O O 0.9999539852142334
mechanism O O 0.9999781847000122
by O O 0.9999725818634033
which O O 0.9999247789382935
diphenylhydantoin B B 0.9991874098777771
exerts O O 0.9998260140419006
its O O 0.9998809099197388
toxic O O 0.9994707703590393
effects O O 0.9999158382415771
is O O 0.9999586343765259
not O O 0.9999954700469971
known O O 0.9999842643737793
. O O 0.9999653100967407

In O O 0.999981164932251
this O O 0.999971866607666
patient O O 0.9999786615371704
the O O 0.9999886751174927
time O O 0.9999735355377197
relation O O 0.9999988079071045
between O O 0.9999707937240601
the O O 0.999984622001648
ingestion O O 0.999866247177124
of O O 0.997722327709198
diphenylhydantoin B B 0.9972411394119263
and O O 0.9997389912605286
the O O 0.9999955892562866
occurrence O O 0.9999978542327881
of O O 0.9999918937683105
the O O 0.9999946355819702
skin O O 0.9999841451644897
rash O O 0.9999735355377197
, O O 0.9999639987945557
lymphadenopathy O O 0.9999649524688721
and O O 0.9999312162399292
pure O O 0.9845720529556274
red O O 0.9999593496322632
cell O O 0.9995412826538086
aplasia O O 0.9977715015411377
is O O 0.9999704360961914
very O O 0.9999765157699585
suggestive O O 0.9999905824661255
of O O 0.9999469518661499
a O O 0.999921441078186
direct O O 0.9999454021453857
connection O O 0.9999954700469971
. O O 0.9999758005142212

Vinorelbine B B 0.9989699125289917
- O O 0.9987260699272156
related O O 0.9999728202819824
cardiac O O 0.9999918937683105
events O O 0.9999982118606567
: O O 0.999984860420227
a O O 0.99998939037323
meta O O 0.9999772310256958
- O O 0.9999841451644897
analysis O O 0.9999555349349976
of O O 0.9999831914901733
randomized O O 0.9999905824661255
clinical O O 0.9999915361404419
trials O O 0.9999953508377075
. O O 0.9999840259552002

Several O O 0.9999514818191528
cases O O 0.9999918937683105
of O O 0.9999682903289795
cardiac O O 0.9997829794883728
adverse O O 0.9997143149375916
reactions O O 0.9999911785125732
related O O 0.9999548196792603
to O O 0.9934545755386353
vinorelbine B B 0.9983024597167969
( O O 0.9673183560371399
VNR B B 0.9706130623817444
) O O 0.9968948364257812
have O O 0.999950647354126
been O O 0.999966025352478
reported O O 0.999984622001648
in O O 0.9999803304672241
the O O 0.9999918937683105
literature O O 0.9999831914901733
. O O 0.9999626874923706

In O O 0.9999679327011108
order O O 0.9999953508377075
to O O 0.9999946355819702
quantify O O 0.9999902248382568
the O O 0.9999957084655762
incidence O O 0.9999983310699463
of O O 0.999992847442627
these O O 0.9999809265136719
cardiac O O 0.9999874830245972
events O O 0.9999990463256836
, O O 0.999976634979248
we O O 0.9999716281890869
performed O O 0.9999946355819702
a O O 0.9999935626983643
meta O O 0.9999750852584839
- O O 0.9999817609786987
analysis O O 0.9999849796295166
of O O 0.9999817609786987
clinical O O 0.9999889135360718
trials O O 0.9999908208847046
comparing O O 0.9994495511054993
VNR B B 0.9906676411628723
with O O 0.9919539093971252
other O O 0.9995484948158264
chemotherapeutic O O 0.9984787106513977
agents O O 0.9944828748703003
in O O 0.9999172687530518
the O O 0.9999706745147705
treatment O O 0.999982476234436
of O O 0.9999825954437256
various O O 0.9999717473983765
malignancies O O 0.9999942779541016
. O O 0.9999632835388184

Randomized O O 0.9999269247055054
clinical O O 0.9999788999557495
trials O O 0.9999822378158569
comparing O O 0.9994654059410095
VNR B B 0.984416663646698
with O O 0.9922268390655518
other O O 0.9990639090538025
drugs O O 0.9968960285186768
in O O 0.9999123811721802
the O O 0.9999635219573975
treatment O O 0.9999803304672241
of O O 0.9999781847000122
cancer O O 0.999951958656311
were O O 0.9999727010726929
searched O O 0.999975323677063
in O O 0.9998987913131714
Medline O O 0.998916506767273
, O O 0.9998905658721924
Embase O O 0.9935150146484375
, O O 0.9999008178710938
Evidence O O 0.9990156888961792
- O O 0.9999581575393677
based O O 0.9991909861564636
Medicine O O 0.999794065952301
Reviews O O 0.9999310970306396
databases O O 0.9999098777770996
and O O 0.999954342842102
the O O 0.9999524354934692
Cochrane O O 0.8730529546737671
library O O 0.9999563694000244
from O O 0.9999830722808838
1987 O O 0.9999514818191528
to O O 0.999971866607666
2002 O O 0.9999852180480957
. O O 0.9999706745147705

Outcomes O O 0.999957799911499
of O O 0.9999746084213257
interest O O 0.9999885559082031
were O O 0.9999891519546509
severe O O 0.9999676942825317
cardiac O O 0.9999819993972778
events O O 0.9999964237213135
, O O 0.9999269247055054
toxic O O 0.9995812773704529
deaths O O 0.9999804496765137
and O O 0.999920129776001
cardiac O O 0.9989162683486938
event O O 0.9987934827804565
- O O 0.9999172687530518
related O O 0.9999743700027466
deaths O O 0.9999775886535645
reported O O 0.9999892711639404
in O O 0.9999803304672241
each O O 0.9999098777770996
publication O O 0.999583899974823
. O O 0.9999672174453735

We O O 0.9999287128448486
found O O 0.999982476234436
19 O O 0.9999772310256958
trials O O 0.999984860420227
, O O 0.999987006187439
involving O O 0.9999808073043823
2441 O O 0.9999639987945557
patients O O 0.9999836683273315
treated O O 0.999956488609314
by O O 0.9990350008010864
VNR B O 0.8003838658332825
and O O 0.9989224672317505
2050 O O 0.9994235038757324
control O O 0.9998805522918701
patients O O 0.9999849796295166
. O O 0.9999632835388184

The O O 0.9999905824661255
incidence O O 0.9999978542327881
of O O 0.9999889135360718
cardiac O O 0.9999926090240479
events O O 0.9999983310699463
with O O 0.9998964071273804
VNR B O 0.9067547917366028
was O O 0.9999589920043945
1 O O 0.9999814033508301
. O O 0.9999961853027344
19 O O 0.9999986886978149
% O O 0.999993085861206
[ O O 0.9998729228973389
95 O O 0.9999666213989258
% O O 0.9999178647994995
confidence O O 0.999942421913147
interval O O 0.9998874664306641
( O O 0.997492790222168
CI O O 0.9962897300720215
) O O 0.9999608993530273
( O O 0.9997240900993347
0 O O 0.9999876022338867
. O O 0.9999901056289673
75 O O 0.9999935626983643
; O O 0.9993293285369873
1 O O 0.9999909400939941
. O O 0.999992847442627
67 O O 0.9999872446060181
) O O 0.9999411106109619
] O O 0.999962329864502
. O O 0.9999780654907227

There O O 0.999962568283081
was O O 0.9999678134918213
no O O 0.9999830722808838
difference O O 0.9999933242797852
in O O 0.9999921321868896
the O O 0.9999899864196777
risk O O 0.9999973773956299
of O O 0.9999918937683105
cardiac O O 0.9999884366989136
events O O 0.999997615814209
between O O 0.9972202777862549
VNR B B 0.9306033253669739
and O O 0.9972835779190063
other O O 0.9981951117515564
drugs O O 0.9973242282867432
[ O O 0.9998037219047546
odds O O 0.9998546838760376
ratio O O 0.9999594688415527
: O O 0.9999686479568481
0 O O 0.9999923706054688
. O O 0.9999929666519165
92 O O 0.9999649524688721
, O O 0.9999665021896362
95 O O 0.999853253364563
% O O 0.9971576929092407
CI O O 0.9631586670875549
( O O 0.9987881779670715
0 O O 0.9998536109924316
. O O 0.9999847412109375
54 O O 0.999991774559021
; O O 0.9977909326553345
1 O O 0.999966025352478
. O O 0.9999891519546509
55 O O 0.9986684322357178
) O O 0.9998451471328735
] O O 0.9999237060546875
. O O 0.9999717473983765

The O O 0.9999614953994751
risk O O 0.9999939203262329
of O O 0.9999687671661377
VNR B O 0.9291771054267883
cardiac O O 0.9999591112136841
events O O 0.9999970197677612
was O O 0.9999414682388306
similar O O 0.9999873638153076
to O O 0.9985048770904541
vindesine B B 0.9972694516181946
( O O 0.9960067868232727
VDS B B 0.9820299744606018
) O O 0.9816438555717468
and O O 0.9993481040000916
other O O 0.9995846152305603
cardiotoxic O O 0.9999642372131348
drugs O O 0.9939743876457214
[ O O 0.9972670078277588
fluorouracil B B 0.9989370703697205
, O O 0.7311093211174011
anthracyclines B B 0.9669732451438904
, O O 0.5324052572250366
gemcitabine B B 0.9892388582229614
( O O 0.9675799012184143
GEM B B 0.9972931742668152
) O I 0.8469211459159851
em O I 0.9996490478515625
leader O I 0.9813184142112732
] O O 0.9975047707557678
. O O 0.9999696016311646

Even O O 0.9999853372573853
if O O 0.9999918937683105
it O O 0.999990701675415
did O O 0.9999837875366211
not O O 0.999993085861206
reach O O 0.9999836683273315
statistical O O 0.9999903440475464
significance O O 0.9999985694885254
because O O 0.9999915361404419
of O O 0.9999904632568359
a O O 0.9999929666519165
few O O 0.9999961853027344
number O O 0.9999958276748657
of O O 0.9999808073043823
cases O O 0.9999946355819702
, O O 0.9999599456787109
the O O 0.9999842643737793
risk O O 0.9999936819076538
was O O 0.999976396560669
lower O O 0.9999722242355347
in O O 0.999902606010437
trials O O 0.9999610185623169
excluding O O 0.9999127388000488
patients O O 0.9999926090240479
with O O 0.9999860525131226
cardiac O O 0.9999703168869019
history O O 0.9999935626983643
, O O 0.9999313354492188
and O O 0.9999334812164307
seemed O O 0.9999536275863647
to O O 0.9999233484268188
be O O 0.9999738931655884
higher O O 0.999819815158844
in O O 0.9998212456703186
trials O O 0.999963641166687
including O O 0.9999557733535767
patients O O 0.9999855756759644
with O O 0.9999873638153076
pre O O 0.9992602467536926
- O O 0.9999822378158569
existing O O 0.999994158744812
cardiac O O 0.9999569654464722
diseases O O 0.9999974966049194
. O O 0.9999874830245972

Vinorelbine B B 0.9992744326591492
- O O 0.9986494183540344
related O O 0.9999644756317139
cardiac O O 0.9999819993972778
events O O 0.999996542930603
concern O O 0.9999933242797852
about O O 0.9999825954437256
1 O O 0.9999756813049316
% O O 0.9999970197677612
of O O 0.9999876022338867
treated O O 0.9999797344207764
patients O O 0.9999959468841553
in O O 0.9999685287475586
clinical O O 0.9999850988388062
trials O O 0.999994158744812
. O O 0.9999746084213257

However O O 0.9999330043792725
, O O 0.999930739402771
the O O 0.9999773502349854
risk O O 0.9999885559082031
associated O O 0.9999892711639404
with O O 0.999672532081604
VNR B B 0.8920465111732483
seems O O 0.9989639520645142
to O O 0.9999372959136963
be O O 0.9999523162841797
similar O O 0.9999867677688599
to O O 0.9999293088912964
that O O 0.999977707862854
of O O 0.9998912811279297
other O O 0.9996321201324463
chemotherapeutic O O 0.9996981620788574
agents O O 0.9932143688201904
in O O 0.9999020099639893
the O O 0.9999867677688599
same O O 0.9999219179153442
indications O O 0.9999459981918335
. O O 0.9999700784683228

MRI O O 0.7613658905029297
findings O O 0.9999730587005615
of O O 0.9999679327011108
hypoxic O O 0.9987167119979858
cortical O O 0.9949851036071777
laminar O O 0.9225218892097473
necrosis O O 0.9999585151672363
in O O 0.999948263168335
a O O 0.9999831914901733
child O O 0.9999957084655762
with O O 0.999941349029541
hemolytic O O 0.9982472658157349
anemia O O 0.99399334192276
crisis O O 0.9999583959579468
. O O 0.9999773502349854

We O O 0.9999912977218628
present O O 0.9999897480010986
magnetic O O 0.9997333884239197
resonance O O 0.9999576807022095
imaging O O 0.9999879598617554
findings O O 0.9999959468841553
of O O 0.9999854564666748
a O O 0.9999895095825195
5 O O 0.9999486207962036
- O O 0.99997878074646
year O O 0.9999960660934448
- O O 0.9999923706054688
old O O 0.9999948740005493
girl O O 0.9999980926513672
who O O 0.9999632835388184
had O O 0.9999604225158691
a O O 0.9999691247940063
rapidly O O 0.9999152421951294
installing O O 0.9998886585235596
hemolytic O O 0.9987497329711914
anemia O O 0.961577296257019
crisis O O 0.9999701976776123
induced O O 0.9999693632125854
by O O 0.9997376799583435
trimethoprim B B 0.9942561984062195
- I I 0.874119758605957
sulfomethoxazole I I 0.9954578876495361
, O O 0.9988977909088135
resulting O O 0.9999713897705078
in O O 0.9999457597732544
cerebral O O 0.9999748468399048
anoxia O O 0.9891385436058044
leading O O 0.9999816417694092
to O O 0.9999756813049316
permanent O O 0.9999618530273438
damage O O 0.9999970197677612
. O O 0.9999781847000122

Magnetic O O 0.9998400211334229
Resonance O O 0.9999939203262329
imaging O O 0.9999839067459106
revealed O O 0.9998877048492432
cortical O O 0.9558467864990234
laminar O O 0.6482226848602295
necrosis O O 0.9999650716781616
in O O 0.9988860487937927
arterial O O 0.9979175925254822
border O O 0.9985268115997314
zones O O 0.9999500513076782
in O O 0.9998540878295898
both O O 0.9995822310447693
cerebral O O 0.9999327659606934
hemispheres O O 0.9999722242355347
, O O 0.9999064207077026
ischemic O O 0.9998946189880371
changes O O 0.9999924898147583
in O O 0.9997239708900452
subcortical O O 0.9920384883880615
white O O 0.9999115467071533
matter O O 0.9999961853027344
of O O 0.9997462630271912
left O O 0.9997829794883728
cerebral O O 0.9999698400497437
hemisphere O O 0.99997878074646
, O O 0.9998277425765991
and O O 0.9995312690734863
in O O 0.9998412132263184
the O O 0.9999821186065674
left O O 0.9998643398284912
putamen O O 0.9993708729743958
. O O 0.9999377727508545

Although O O 0.9999247789382935
cortical O O 0.9922210574150085
laminar O O 0.9444955587387085
necrosis O O 0.999955415725708
is O O 0.9999531507492065
a O O 0.9999569654464722
classic O O 0.9999582767486572
entity O O 0.9999959468841553
in O O 0.9999552965164185
adulthood O O 0.9999667406082153
related O O 0.9999806880950928
to O O 0.999552309513092
conditions O O 0.9999616146087646
of O O 0.9998672008514404
energy O O 0.6893452405929565
depletions O O 0.9575523734092712
, O O 0.9999502897262573
there O O 0.9999778270721436
are O O 0.9999762773513794
few O O 0.9999833106994629
reports O O 0.9999892711639404
available O O 0.9999915361404419
in O O 0.9999792575836182
children O O 0.9999405145645142
. O O 0.9999487400054932

A O O 0.9999724626541138
wide O O 0.9999779462814331
review O O 0.9999903440475464
of O O 0.9999827146530151
the O O 0.9999858140945435
literature O O 0.9999610185623169
is O O 0.9999644756317139
also O O 0.9999852180480957
presented O O 0.9999933242797852
. O O 0.9999631643295288

The O O 0.9999626874923706
natural O O 0.9999926090240479
history O O 0.9999943971633911
of O O 0.9999237060546875
Vigabatrin B B 0.9940618872642517
associated O O 0.9995253086090088
visual O O 0.9999591112136841
field O O 0.9999940395355225
defects O O 0.9999982118606567
in O O 0.9999618530273438
patients O O 0.9999918937683105
electing O O 0.9999924898147583
to O O 0.9999924898147583
continue O O 0.9999113082885742
their O O 0.9989388585090637
medication O O 0.9998931884765625
. O O 0.9999529123306274

PURPOSE O O 0.9999480247497559
: O O 0.9999967813491821
To O O 0.9999966621398926
determine O O 0.9999955892562866
the O O 0.9999946355819702
natural O O 0.9999951124191284
history O O 0.9999971389770508
of O O 0.9999810457229614
visual O O 0.9999326467514038
field O O 0.9999933242797852
defects O O 0.9999980926513672
in O O 0.9999526739120483
a O O 0.999984622001648
group O O 0.9999898672103882
of O O 0.9999817609786987
patients O O 0.9999927282333374
known O O 0.9999842643737793
to O O 0.9999786615371704
have O O 0.999975323677063
Vigabatrin B B 0.9636182188987732
- O O 0.9989612102508545
associated O O 0.9998708963394165
changes O O 0.999992847442627
who O O 0.9999759197235107
elected O O 0.9999840259552002
to O O 0.9999927282333374
continue O O 0.9998706579208374
the O O 0.9998103976249695
medication O O 0.999671220779419
because O O 0.999980092048645
of O O 0.999988317489624
good O O 0.9999676942825317
seizure O O 0.9999866485595703
control O O 0.9999865293502808
. O O 0.9999841451644897

METHODS O O 0.9995740056037903
: O O 0.9999773502349854
All O O 0.9999767541885376
patients O O 0.9999904632568359
taking O O 0.9992778897285461
Vigabatrin B B 0.9972081780433655
alone O O 0.9984995126724243
or O O 0.9999291896820068
in O O 0.9999567270278931
combination O O 0.9998258948326111
with O O 0.9998107552528381
other O O 0.9997106194496155
antiepileptic O O 0.8310718536376953
drugs O O 0.9911603331565857
for O O 0.999930739402771
at O O 0.9999818801879883
least O O 0.9999929666519165
5 O O 0.9999644756317139
years O O 0.9999845027923584
( O O 0.9999715089797974
range O O 0.9999814033508301
5 O O 0.9999818801879883
- O O 0.9987021684646606
12 O O 0.9999947547912598
years O O 0.9999815225601196
) O O 0.9999701976776123
were O O 0.9999781847000122
entered O O 0.9999886751174927
into O O 0.9999656677246094
a O O 0.9999676942825317
visual O O 0.9993593096733093
surveillance O O 0.9999661445617676
programme O O 0.999983549118042
. O O 0.9999668598175049

Patients O O 0.9999232292175293
were O O 0.9999862909317017
followed O O 0.9999845027923584
up O O 0.9999959468841553
at O O 0.9999865293502808
6 O O 0.9991531372070312
- O O 0.9998903274536133
monthly O O 0.9999958276748657
intervals O O 0.9999943971633911
for O O 0.9999836683273315
not O O 0.9999972581863403
less O O 0.9999942779541016
than O O 0.999992847442627
18 O O 0.9999908208847046
months O O 0.9999984502792358
( O O 0.9999810457229614
range O O 0.9999957084655762
18 O O 0.9999622106552124
- O O 0.9979028701782227
43 O O 0.9999969005584717
months O O 0.9999983310699463
) O O 0.9999769926071167
. O O 0.9999839067459106

In O O 0.9998822212219238
all O O 0.9999407529830933
, O O 0.9999843835830688
16 O O 0.9999561309814453
patients O O 0.9999934434890747
with O O 0.999987006187439
unequivocal O O 0.9999866485595703
defects O O 0.99989914894104
continued O O 0.9994747042655945
the O O 0.9984458088874817
medication O O 0.999052107334137
. O O 0.9999161958694458

Following O O 0.9999470710754395
already O O 0.9999825954437256
published O O 0.9999922513961792
methodology O O 0.9999607801437378
( O O 0.9999186992645264
Eye O O 0.9995625615119934
2002 O O 0.999982476234436
; O O 0.9998575448989868
16 O O 0.9999128580093384
; O O 0.9999107122421265
567 O O 0.999479353427887
- O O 0.998056173324585
571 O O 0.9957345128059387
) O O 0.9999252557754517
monocular O O 0.9998157620429993
mean O O 0.9999858140945435
radial O O 0.9999706745147705
degrees O O 0.9998843669891357
( O O 0.9999675750732422
MRDs O O 0.9999673366546631
) O O 0.999984860420227
to O O 0.9998676776885986
the O O 0.9998241066932678
I O O 0.9707150459289551
/ O O 0.9995388984680176
4e O O 0.9808741211891174
isopter O O 0.99280846118927
on O O 0.9999092817306519
Goldmann O O 0.9221158623695374
perimetry O O 0.9997404217720032
was O O 0.9999862909317017
calculated O O 0.9999912977218628
for O O 0.9999483823776245
the O O 0.9999945163726807
right O O 0.9999923706054688
eye O O 0.9999938011169434
at O O 0.999985933303833
the O O 0.9999961853027344
time O O 0.9999960660934448
of O O 0.9999973773956299
discovery O O 0.9999977350234985
of O O 0.9999911785125732
a O O 0.999991774559021
visual O O 0.9999696016311646
field O O 0.9999933242797852
defect O O 0.9999986886978149
and O O 0.9999539852142334
again O O 0.9999920129776001
after O O 0.999991774559021
not O O 0.9999974966049194
less O O 0.9999970197677612
than O O 0.999997615814209
18 O O 0.999997615814209
months O O 0.9999978542327881
follow O O 0.9999970197677612
- O O 0.9999943971633911
up O O 0.9999980926513672
. O O 0.9999804496765137

RESULTS O O 0.9999008178710938
: O O 0.9998441934585571
Mean O O 0.9999829530715942
right O O 0.999969482421875
eye O O 0.9999891519546509
MRD O O 0.9996824264526367
at O O 0.9999855756759644
presentation O O 0.9999948740005493
was O O 0.9999809265136719
36 O O 0.9999973773956299
. O O 0.9999932050704956
98 O O 0.9999967813491821
degrees O O 0.9999979734420776
( O O 0.9999793767929077
range O O 0.9999899864196777
22 O O 0.9999901056289673
. O O 0.9999948740005493
25 O O 0.9999884366989136
- O O 0.998320996761322
51 O O 0.99996018409729
. O O 0.9999961853027344
0 O O 0.999995231628418
) O O 0.9999812841415405
, O O 0.9999864101409912
compared O O 0.9999933242797852
to O O 0.9999876022338867
38 O O 0.999995231628418
. O O 0.9999927282333374
40 O O 0.9999964237213135
degrees O O 0.9999963045120239
( O O 0.9999767541885376
range O O 0.9999880790710449
22 O O 0.9999743700027466
. O O 0.9999904632568359
5 O O 0.99998939037323
- O O 0.9985542893409729
49 O O 0.999626636505127
. O O 0.9999960660934448
75 O O 0.999994158744812
) O O 0.9999889135360718
after O O 0.9999727010726929
follow O O 0.9999914169311523
- O O 0.9999929666519165
up O O 0.9999945163726807
; O O 0.9999850988388062
P O O 0.9999454021453857
= O O 0.9999648332595825
0 O O 0.9999926090240479
. O O 0.9999942779541016
338 O O 0.9999988079071045
unpaired O O 0.9999521970748901
t O O 0.99991774559021
- O O 0.9999289512634277
test O O 0.9999876022338867
. O O 0.999982476234436

Only O O 0.9999768733978271
one O O 0.9999934434890747
patient O O 0.9999910593032837
demonstrated O O 0.999967098236084
a O O 0.9999920129776001
deterioration O O 0.9999982118606567
in O O 0.9999771118164062
visual O O 0.9999831914901733
field O O 0.9999977350234985
during O O 0.9999468326568604
the O O 0.9999934434890747
study O O 0.9999914169311523
period O O 0.9999912977218628
and O O 0.9999790191650391
discontinued O O 0.9999425411224365
treatment O O 0.9999383687973022
. O O 0.9999614953994751

CONCLUSION O O 0.9997674822807312
: O O 0.999921441078186
Established O O 0.998820960521698
visual O O 0.9999666213989258
field O O 0.9999769926071167
defects O O 0.9999951124191284
presumed O O 0.9999560117721558
to O O 0.9999617338180542
be O O 0.9999772310256958
due O O 0.9999792575836182
to O O 0.9995183944702148
Vigabatrin B B 0.9855809807777405
therapy O O 0.9993191957473755
did O O 0.9999918937683105
not O O 0.999994158744812
usually O O 0.9999923706054688
progress O O 0.9999974966049194
in O O 0.9999932050704956
spite O O 0.999971866607666
of O O 0.9999656677246094
continuing O O 0.9999107122421265
use O O 0.9999680519104004
of O O 0.9999138116836548
the O O 0.9997214674949646
medication O O 0.9995831847190857
. O O 0.9999539852142334

These O O 0.9999791383743286
data O O 0.9999897480010986
give O O 0.9999735355377197
support O O 0.999991774559021
to O O 0.9999847412109375
the O O 0.9999886751174927
hypothesis O O 0.9999834299087524
that O O 0.9999618530273438
the O O 0.9999891519546509
pathogenesis O O 0.99998939037323
of O O 0.9999501705169678
Vigabatrin B B 0.9979594945907593
- O O 0.9996401071548462
associated O O 0.9999030828475952
visual O O 0.9999754428863525
field O O 0.9999959468841553
defects O O 0.9999983310699463
may O O 0.999925971031189
be O O 0.9999388456344604
an O O 0.9999251365661621
idiosyncratic O O 0.9999942779541016
adverse O O 0.9998470544815063
drug O O 0.9994433522224426
reaction O O 0.9999880790710449
rather O O 0.9999769926071167
than O O 0.9999587535858154
dose O O 0.9990563988685608
- O O 0.9999376535415649
dependent O O 0.9999409914016724
toxicity O O 0.9999779462814331
. O O 0.9999674558639526

Induction O O 0.9999750852584839
of O O 0.9999699592590332
rosaceiform O O 0.9972977042198181
dermatitis O O 0.9999710321426392
during O O 0.9998351335525513
treatment O O 0.9999760389328003
of O O 0.999981164932251
facial O O 0.9997300505638123
inflammatory O O 0.9999852180480957
dermatoses O O 0.9999834299087524
with O O 0.9996687173843384
tacrolimus B B 0.9994864463806152
ointment O O 0.9926044940948486
. O O 0.9995336532592773

BACKGROUND O O 0.9676514267921448
: O O 0.9971038699150085
Tacrolimus B B 0.999584972858429
ointment O O 0.9855581521987915
is O O 0.9999558925628662
increasingly O O 0.9999849796295166
used O O 0.9999262094497681
for O O 0.9999215602874756
anti O O 0.9277535080909729
- O O 0.9991027116775513
inflammatory O O 0.9998984336853027
treatment O O 0.9999504089355469
of O O 0.9999001026153564
sensitive O O 0.999262273311615
areas O O 0.9999796152114868
such O O 0.9999889135360718
as O O 0.9999912977218628
the O O 0.999992847442627
face O O 0.9999938011169434
, O O 0.9999679327011108
and O O 0.9999865293502808
recent O O 0.9999972581863403
observations O O 0.9999983310699463
indicate O O 0.9999873638153076
that O O 0.9999767541885376
the O O 0.9999641180038452
treatment O O 0.9999568462371826
is O O 0.999956488609314
effective O O 0.9999299049377441
in O O 0.9999080896377563
steroid B B 0.8691012859344482
- O O 0.9988069534301758
aggravated O O 0.9996994733810425
rosacea O O 0.9998601675033569
and O O 0.9999366998672485
perioral O O 0.999323844909668
dermatitis O O 0.9999880790710449
. O O 0.9999632835388184

We O O 0.9999303817749023
report O O 0.999988317489624
on O O 0.9990755319595337
rosaceiform O O 0.9988555908203125
dermatitis O O 0.999983549118042
as O O 0.9999755620956421
a O O 0.9999548196792603
complication O O 0.9999922513961792
of O O 0.9998447895050049
treatment O O 0.9999690055847168
with O O 0.9994789958000183
tacrolimus B B 0.999366819858551
ointment O O 0.9854546785354614
. O O 0.9999401569366455

OBSERVATIONS O O 0.9996336698532104
: O O 0.9999784231185913
Six O O 0.9999895095825195
adult O O 0.9999948740005493
patients O O 0.9999953508377075
with O O 0.9999843835830688
inflammatory O O 0.9999209642410278
facial O O 0.9999717473983765
dermatoses O O 0.9999872446060181
were O O 0.9999489784240723
treated O O 0.9999597072601318
with O O 0.9996498823165894
tacrolimus B B 0.9996013045310974
ointment O O 0.998458981513977
because O O 0.9999887943267822
of O O 0.9999903440475464
the O O 0.9999949932098389
ineffectiveness O O 0.999961256980896
of O O 0.999966025352478
standard O O 0.9995754361152649
treatments O O 0.9999663829803467
. O O 0.999962329864502

Within O O 0.9999830722808838
2 O O 0.9999868869781494
to O O 0.9999972581863403
3 O O 0.9999806880950928
weeks O O 0.9999983310699463
of O O 0.9999873638153076
initially O O 0.9999560117721558
effective O O 0.9999377727508545
and O O 0.9999784231185913
well O O 0.9999351501464844
- O O 0.9999850988388062
tolerated O O 0.9999932050704956
treatment O O 0.999966025352478
, O O 0.9999898672103882
3 O O 0.9998434782028198
patients O O 0.9999949932098389
with O O 0.9999661445617676
a O O 0.999984622001648
history O O 0.9999889135360718
of O O 0.9999613761901855
rosacea O O 0.9990035891532898
and O O 0.9998990297317505
1 O O 0.9996089339256287
with O O 0.9999531507492065
a O O 0.9999786615371704
history O O 0.9999871253967285
of O O 0.9999358654022217
acne O O 0.9902948141098022
experienced O O 0.9999527931213379
sudden O O 0.9999889135360718
worsening O O 0.9999970197677612
with O O 0.9999905824661255
pustular O O 0.9977745413780212
rosaceiform O O 0.9943418502807617
lesions O O 0.9999955892562866
. O O 0.9999728202819824

Biopsy O O 0.99896240234375
revealed O O 0.9999521970748901
an O O 0.9999558925628662
abundance O O 0.997370719909668
of O O 0.9991863369941711
Demodex O B 0.9435356259346008
mites O O 0.5515742301940918
in O O 0.9998769760131836
2 O O 0.9998160004615784
of O O 0.9999834299087524
these O O 0.9999781847000122
patients O O 0.9999909400939941
. O O 0.9999748468399048

In O O 0.9999557733535767
1 O O 0.9996769428253174
patient O O 0.999988317489624
with O O 0.9999346733093262
eyelid O O 0.9998077750205994
eczema O O 0.9997697472572327
, O O 0.9999393224716187
rosaceiform O O 0.9986401200294495
periocular O O 0.9998635053634644
dermatitis O O 0.9999774694442749
gradually O O 0.9999706745147705
appeared O O 0.9999970197677612
after O O 0.9999617338180542
3 O O 0.9997788071632385
weeks O O 0.9999964237213135
of O O 0.9999295473098755
treatment O O 0.999953031539917
. O O 0.9999780654907227

In O O 0.9999563694000244
1 O O 0.9996531009674072
patient O O 0.9999876022338867
with O O 0.9999533891677856
atopic O O 0.9992916584014893
dermatitis O O 0.9999896287918091
, O O 0.9998961687088013
telangiectatic O O 0.9966831803321838
and O O 0.9997770190238953
papular O O 0.9991206526756287
rosacea O O 0.9999575614929199
insidiously O O 0.9999009370803833
appeared O O 0.9999947547912598
after O O 0.999969482421875
5 O O 0.9998723268508911
months O O 0.9999940395355225
of O O 0.999941349029541
treatment O O 0.9999529123306274
. O O 0.9999707937240601

CONCLUSIONS O O 0.9986621141433716
: O O 0.9999963045120239
Our O O 0.9999630451202393
observations O O 0.9999946355819702
suggest O O 0.999972939491272
that O O 0.9999771118164062
the O O 0.9999886751174927
spectrum O O 0.9999895095825195
of O O 0.9999759197235107
rosaceiform O O 0.9997183680534363
dermatitis O O 0.9999874830245972
as O O 0.9999814033508301
a O O 0.9999841451644897
complication O O 0.9999902248382568
of O O 0.9998890161514282
treatment O O 0.9999793767929077
with O O 0.9995993971824646
tacrolimus B B 0.9995219707489014
ointment O O 0.9851529598236084
is O O 0.9999505281448364
heterogeneous O O 0.9999829530715942
. O O 0.9999798536300659

A O O 0.9997262358665466
variety O O 0.9998838901519775
of O O 0.9995976090431213
factors O O 0.9998539686203003
, O O 0.9999370574951172
such O O 0.9998762607574463
as O O 0.9998328685760498
vasoactive O O 0.9895451664924622
properties O O 0.9999102354049683
of O O 0.9991388320922852
tacrolimus B B 0.9992708563804626
, O O 0.9989271759986877
proliferation O O 0.9924730062484741
of O O 0.9659245014190674
Demodex O B 0.9954408407211304
due O O 0.9997686743736267
to O O 0.9995275735855103
local O O 0.9992813467979431
immunosuppression O O 0.998828113079071
, O O 0.9998552799224854
and O O 0.9997108578681946
the O O 0.9998652935028076
occlusive O O 0.9958829879760742
properties O O 0.9999406337738037
of O O 0.9999097585678101
the O O 0.9995798468589783
ointment O O 0.9954125285148621
, O O 0.9999648332595825
may O O 0.9999275207519531
be O O 0.9999499320983887
involved O O 0.9999793767929077
in O O 0.999977707862854
the O O 0.9999903440475464
observed O O 0.9999933242797852
phenomena O O 0.9999969005584717
. O O 0.9999725818634033

Future O O 0.9999536275863647
studies O O 0.9999877214431763
are O O 0.9999865293502808
needed O O 0.9999910593032837
to O O 0.9999909400939941
identify O O 0.9999626874923706
individual O O 0.9999195337295532
risk O O 0.9998396635055542
factors O O 0.9999939203262329
. O O 0.9999579191207886

Intravascular O O 0.9999691247940063
hemolysis O O 0.9998406171798706
and O O 0.9999508857727051
acute O O 0.9999871253967285
renal O O 0.9999964237213135
failure O O 0.999990701675415
following O O 0.9998561143875122
intermittent O O 0.9979152083396912
rifampin B B 0.9838564395904541
therapy O O 0.9993109703063965
. O O 0.9999680519104004

Renal O O 0.999847412109375
failure O O 0.9999876022338867
is O O 0.9999637603759766
a O O 0.9999754428863525
rare O O 0.9999794960021973
complication O O 0.9999935626983643
associated O O 0.9999773502349854
with O O 0.9998525381088257
the O O 0.9999490976333618
use O O 0.9999324083328247
of O O 0.9991437196731567
rifampin B B 0.9856167435646057
. O O 0.9998347759246826

Intravascular O O 0.9999434947967529
hemolysis O O 0.9998395442962646
leading O O 0.9999765157699585
to O O 0.9999809265136719
acute O O 0.9999769926071167
renal O O 0.9999953508377075
failure O O 0.9999923706054688
following O O 0.9998503923416138
rifampin B B 0.9834935665130615
therapy O O 0.9990020394325256
is O O 0.999976396560669
extremely O O 0.9999871253967285
rare O O 0.9999895095825195
. O O 0.9999672174453735

Two O O 0.9999576807022095
patients O O 0.9999876022338867
with O O 0.9999487400054932
leprosy O O 0.9647101163864136
who O O 0.9998955726623535
developed O O 0.9999574422836304
hemolysis O O 0.9995796084403992
and O O 0.999919056892395
acute O O 0.999976634979248
renal O O 0.999993085861206
failure O O 0.9999967813491821
following O O 0.9996997117996216
rifampin B B 0.9870039820671082
are O O 0.9994556307792664
reported O O 0.9999939203262329
. O O 0.9999862909317017

Structural O O 0.9999325275421143
abnormalities O O 0.9999864101409912
in O O 0.999916672706604
the O O 0.9999054670333862
brains O O 0.9999520778656006
of O O 0.9999511241912842
human O O 0.9998264908790588
subjects O O 0.9999915361404419
who O O 0.9997971653938293
use O O 0.9979851245880127
methamphetamine B B 0.9989734888076782
. O O 0.9999017715454102

We O O 0.999909520149231
visualize O O 0.9999428987503052
, O O 0.9999880790710449
for O O 0.9999977350234985
the O O 0.9999954700469971
first O O 0.9999932050704956
time O O 0.9999785423278809
, O O 0.999976396560669
the O O 0.9999397993087769
profile O O 0.9999707937240601
of O O 0.9999552965164185
structural O O 0.999976634979248
deficits O O 0.9999887943267822
in O O 0.9999388456344604
the O O 0.9999685287475586
human O O 0.999962568283081
brain O O 0.999995231628418
associated O O 0.999982476234436
with O O 0.9999614953994751
chronic O O 0.9997288584709167
methamphetamine B B 0.9994243383407593
( O O 0.9371214509010315
MA B B 0.9923650026321411
) O O 0.8537947535514832
abuse O O 0.9995418787002563
. O O 0.9999681711196899

Studies O O 0.9999823570251465
of O O 0.9999629259109497
human O O 0.9998522996902466
subjects O O 0.9999902248382568
who O O 0.9999653100967407
have O O 0.9999878406524658
used O O 0.9998797178268433
MA B B 0.9816910624504089
chronically O O 0.9995317459106445
have O O 0.9999669790267944
revealed O O 0.9999569654464722
deficits O O 0.9999836683273315
in O O 0.9999024868011475
dopaminergic O B 0.9052426815032959
and O O 0.9903786182403564
serotonergic O O 0.6870636940002441
systems O O 0.9989369511604309
and O O 0.9999148845672607
cerebral O O 0.9999010562896729
metabolic O O 0.9990622401237488
abnormalities O O 0.9999861717224121
. O O 0.9999740123748779

Using O O 0.9999679327011108
magnetic O O 0.999972939491272
resonance O O 0.9999685287475586
imaging O O 0.999994158744812
( O O 0.9999277591705322
MRI O O 0.9941603541374207
) O O 0.9999676942825317
and O O 0.999977707862854
new O O 0.9999773502349854
computational O O 0.9959372282028198
brain O O 0.9995449185371399
- O O 0.9996703863143921
mapping O O 0.9997156262397766
techniques O O 0.9999890327453613
, O O 0.9999834299087524
we O O 0.9999767541885376
determined O O 0.9999940395355225
the O O 0.9999929666519165
pattern O O 0.99998939037323
of O O 0.9999743700027466
structural O O 0.9999756813049316
brain O O 0.9999743700027466
alterations O O 0.9999974966049194
associated O O 0.9999884366989136
with O O 0.9999685287475586
chronic O O 0.9989140033721924
MA B O 0.7389334440231323
abuse O O 0.9998476505279541
in O O 0.9999167919158936
human O O 0.9998993873596191
subjects O O 0.9999929666519165
and O O 0.9999814033508301
related O O 0.9999897480010986
these O O 0.9999891519546509
deficits O O 0.9999961853027344
to O O 0.9999796152114868
cognitive O O 0.9999920129776001
impairment O O 0.9999960660934448
. O O 0.9999641180038452

We O O 0.9999803304672241
used O O 0.9999817609786987
high O O 0.9996458292007446
- O O 0.999976634979248
resolution O O 0.99996018409729
MRI O O 0.9846732020378113
and O O 0.9998297691345215
surface O O 0.998206615447998
- O O 0.999935507774353
based O O 0.9999202489852905
computational O O 0.9995231628417969
image O O 0.999954342842102
analyses O O 0.9999608993530273
to O O 0.9999849796295166
map O O 0.9999608993530273
regional O O 0.9999797344207764
abnormalities O O 0.9999947547912598
in O O 0.9999436140060425
the O O 0.9999545812606812
cortex O O 0.9999622106552124
, O O 0.9997822642326355
hippocampus O O 0.9966829419136047
, O O 0.9997350573539734
white O O 0.9999516010284424
matter O O 0.9999980926513672
, O O 0.999901533126831
and O O 0.9997203946113586
ventricles O O 0.999638557434082
in O O 0.9999709129333496
22 O O 0.9999904632568359
human O O 0.9999932050704956
subjects O O 0.9999949932098389
who O O 0.9999488592147827
used O O 0.9994022846221924
MA B O 0.49337950348854065
and O O 0.9999414682388306
21 O O 0.999964714050293
age O O 0.9979641437530518
- O O 0.999977707862854
matched O O 0.9999922513961792
, O O 0.9999856948852539
healthy O O 0.999969482421875
controls O O 0.999996542930603
. O O 0.9999728202819824

Cortical O O 0.9985963702201843
maps O O 0.9999616146087646
revealed O O 0.9999505281448364
severe O O 0.999946117401123
gray O O 0.9963789582252502
- O O 0.9999395608901978
matter O O 0.999996542930603
deficits O O 0.9999802112579346
in O O 0.9997320771217346
the O O 0.9998457431793213
cingulate O O 0.9572158455848694
, O O 0.9993528723716736
limbic O O 0.9941117167472839
, O O 0.9990379810333252
and O O 0.9994397759437561
paralimbic O O 0.9867222309112549
cortices O O 0.9989860653877258
of O O 0.9995245933532715
MA B O 0.7828919887542725
abusers O O 0.5320773720741272
( O O 0.9998805522918701
averaging O O 0.9999550580978394
11 O O 0.9997513890266418
. O O 0.9999821186065674
3 O O 0.999975323677063
% O O 0.9999915361404419
below O O 0.9998680353164673
control O O 0.999916672706604
; O O 0.9999765157699585
p O O 0.9999361038208008
< O O 0.9999741315841675
0 O O 0.999987006187439
. O O 0.9999942779541016
05 O O 0.9999880790710449
) O O 0.999968409538269
. O O 0.9999730587005615

On O O 0.9999728202819824
average O O 0.9999529123306274
, O O 0.9998706579208374
MA B O 0.7414901256561279
abusers O O 0.4251599907875061
had O O 0.9999101161956787
7 O O 0.9999393224716187
. O O 0.9999799728393555
8 O O 0.9999897480010986
% O O 0.9999887943267822
smaller O O 0.9999551773071289
hippocampal O O 0.9991183876991272
volumes O O 0.9999393224716187
than O O 0.9998875856399536
control O O 0.9996293783187866
subjects O O 0.9999891519546509
( O O 0.999940037727356
p O O 0.9998935461044312
< O O 0.999947190284729
0 O O 0.9999696016311646
. O O 0.9999934434890747
01 O O 0.9999924898147583
; O O 0.9999185800552368
left O O 0.999987006187439
, O O 0.9999555349349976
p O O 0.9997311234474182
= O O 0.999893307685852
0 O O 0.9997798800468445
. O O 0.9999904632568359
01 O O 0.999981164932251
; O O 0.9998946189880371
right O O 0.9999725818634033
, O O 0.9999608993530273
p O O 0.9998195767402649
< O O 0.999957799911499
0 O O 0.9999887943267822
. O O 0.9999933242797852
05 O O 0.9999885559082031
) O O 0.9999678134918213
and O O 0.9999566078186035
significant O O 0.9999629259109497
white O O 0.999894380569458
- O O 0.9998735189437866
matter O O 0.9999942779541016
hypertrophy O O 0.9996817111968994
( O O 0.9999783039093018
7 O O 0.9999638795852661
. O O 0.9999905824661255
0 O O 0.9999921321868896
% O O 0.9999949932098389
; O O 0.9999678134918213
p O O 0.9996504783630371
< O O 0.9999257326126099
0 O O 0.999972939491272
. O O 0.999995231628418
01 O O 0.9999856948852539
) O O 0.9999676942825317
. O O 0.9999804496765137

Hippocampal O O 0.9945313930511475
deficits O O 0.9999314546585083
were O O 0.9999376535415649
mapped O O 0.9923549890518188
and O O 0.9999315738677979
correlated O O 0.9999768733978271
with O O 0.9999583959579468
memory O O 0.9999765157699585
performance O O 0.999992847442627
on O O 0.9999845027923584
a O O 0.9999715089797974
word O O 0.9997534155845642
- O O 0.9987693428993225
recall O O 0.9999799728393555
test O O 0.9999852180480957
( O O 0.9999618530273438
p O O 0.9999098777770996
< O O 0.9999772310256958
0 O O 0.9999920129776001
. O O 0.9999949932098389
05 O O 0.9999918937683105
) O O 0.9999639987945557
. O O 0.9999620914459229

MRI O O 0.8445719480514526
- O O 0.9997929930686951
based O O 0.9991550445556641
maps O O 0.9998701810836792
suggest O O 0.9999806880950928
that O O 0.9999191761016846
chronic O O 0.999377965927124
methamphetamine B B 0.9990230798721313
abuse O O 0.9991839528083801
causes O O 0.9998317956924438
a O O 0.9999052286148071
selective O O 0.9998465776443481
pattern O O 0.9999767541885376
of O O 0.9999481439590454
cerebral O O 0.9999856948852539
deterioration O O 0.9999948740005493
that O O 0.9999516010284424
contributes O O 0.9999797344207764
to O O 0.9999855756759644
impaired O O 0.9999808073043823
memory O O 0.9999924898147583
performance O O 0.9999960660934448
. O O 0.9999727010726929

MA B O 0.6931211948394775
may O O 0.9996649026870728
selectively O O 0.9998562335968018
damage O O 0.9997596144676208
the O O 0.9998376369476318
medial O O 0.9999610185623169
temporal O O 0.9999697208404541
lobe O O 0.9999459981918335
and O O 0.9994363188743591
, O O 0.9999798536300659
consistent O O 0.999996542930603
with O O 0.9999638795852661
metabolic O O 0.99891197681427
studies O O 0.9999639987945557
, O O 0.9999381303787231
the O O 0.9997864365577698
cingulate O O 0.9647976756095886
- O O 0.998702883720398
limbic O O 0.9984130859375
cortex O O 0.999942421913147
, O O 0.9999549388885498
inducing O O 0.9999189376831055
neuroadaptation O O 0.9999622106552124
, O O 0.9998941421508789
neuropil O O 0.9998923540115356
reduction O O 0.9990754127502441
, O O 0.9997751116752625
or O O 0.9998455047607422
cell O O 0.9999758005142212
death O O 0.9999853372573853
. O O 0.9999536275863647

Prominent O O 0.9996860027313232
white O O 0.9999206066131592
- O O 0.9998408555984497
matter O O 0.9999933242797852
hypertrophy O O 0.9999244213104248
may O O 0.9999091625213623
result O O 0.9999022483825684
from O O 0.9992627501487732
altered O O 0.9998922348022461
myelination O O 0.999983549118042
and O O 0.9995033740997314
adaptive O O 0.6679521799087524
glial O O 0.9929884076118469
changes O O 0.9999860525131226
, O O 0.999976634979248
including O O 0.9997919201850891
gliosis O O 0.9961428046226501
secondary O O 0.99996018409729
to O O 0.9997392296791077
neuronal O O 0.999969482421875
damage O O 0.9999741315841675
. O O 0.999967098236084

These O O 0.9972420930862427
brain O O 0.9991293549537659
substrates O O 0.9996391534805298
may O O 0.9998152852058411
help O O 0.9998526573181152
account O O 0.9999442100524902
for O O 0.9999099969863892
the O O 0.9999728202819824
symptoms O O 0.9999905824661255
of O O 0.9999394416809082
MA B O 0.8601827621459961
abuse O O 0.995511531829834
, O O 0.9999701976776123
providing O O 0.9999170303344727
therapeutic O O 0.99992835521698
targets O O 0.9999808073043823
for O O 0.9999605417251587
drug O O 0.9889813661575317
- O O 0.9999008178710938
induced O O 0.9999476671218872
brain O O 0.9999730587005615
injury O O 0.9999947547912598
. O O 0.9999648332595825

Disruption O O 0.9999692440032959
of O O 0.9999668598175049
hepatic O O 0.9995431900024414
lipid O O 0.6046927571296692
homeostasis O O 0.9999185800552368
in O O 0.9999244213104248
mice O O 0.9999836683273315
after O O 0.9999123811721802
amiodarone B B 0.9997859597206116
treatment O O 0.9997001886367798
is O O 0.9999481439590454
associated O O 0.9999828338623047
with O O 0.9998997449874878
peroxisome O O 0.9735521078109741
proliferator O O 0.916509211063385
- O O 0.9726783633232117
activated O O 0.9554550647735596
receptor O O 0.97865891456604
- O O 0.9811597466468811
alpha O O 0.9653472304344177
target O O 0.998969554901123
gene O O 0.9994882345199585
activation O O 0.9998131394386292
. O O 0.9999715089797974

Amiodarone B B 0.9994471669197083
, O O 0.999902606010437
an O O 0.9996381998062134
efficacious O O 0.9993749260902405
and O O 0.9999738931655884
widely O O 0.9996252059936523
used O O 0.9997484087944031
antiarrhythmic O O 0.6660336256027222
agent O O 0.9351775646209717
, O O 0.9999074935913086
has O O 0.9998472929000854
been O O 0.999975323677063
reported O O 0.9999877214431763
to O O 0.9999226331710815
cause O O 0.9999126195907593
hepatotoxicity O O 0.9999479055404663
in O O 0.9999334812164307
some O O 0.9999322891235352
patients O O 0.9999825954437256
. O O 0.9999473094940186

To O O 0.9999842643737793
gain O O 0.999996542930603
insight O O 0.9999973773956299
into O O 0.9999926090240479
the O O 0.9999934434890747
mechanism O O 0.999993085861206
of O O 0.9999854564666748
this O O 0.9999755620956421
unwanted O O 0.9988730549812317
effect O O 0.9999780654907227
, O O 0.9999823570251465
mice O O 0.9999957084655762
were O O 0.9999926090240479
administered O O 0.9999241828918457
various O O 0.9999834299087524
doses O O 0.9999473094940186
of O O 0.9991818070411682
amiodarone B B 0.9996922016143799
and O O 0.9998461008071899
examined O O 0.9999866485595703
for O O 0.9999831914901733
changes O O 0.9999969005584717
in O O 0.9999873638153076
hepatic O O 0.9998568296432495
histology O O 0.9999359846115112
and O O 0.9999769926071167
gene O O 0.9996441602706909
regulation O O 0.9999889135360718
. O O 0.9999812841415405

Amiodarone B B 0.9996106028556824
induced O O 0.9998689889907837
hepatomegaly O O 0.9999502897262573
, O O 0.9999266862869263
hepatocyte O O 0.9987323880195618
microvesicular O O 0.6882815957069397
lipid O O 0.6298211216926575
accumulation O O 0.9995740056037903
, O O 0.9998711347579956
and O O 0.9999380111694336
a O O 0.9999774694442749
significant O O 0.9999918937683105
decrease O O 0.9999948740005493
in O O 0.9999580383300781
serum O O 0.9990929365158081
triglycerides B B 0.9656469821929932
and O O 0.999056875705719
glucose B B 0.9967085123062134
. O O 0.999924898147583

Northern O O 0.9584410786628723
blot O O 0.9999910593032837
analysis O O 0.9999699592590332
of O O 0.9997968077659607
hepatic O O 0.996502161026001
RNA O O 0.9706850647926331
revealed O O 0.9999299049377441
a O O 0.9999679327011108
dose O O 0.9990931749343872
- O O 0.9999639987945557
dependent O O 0.9999836683273315
increase O O 0.9999701976776123
in O O 0.9999637603759766
the O O 0.9999569654464722
expression O O 0.9999661445617676
of O O 0.9999003410339355
a O O 0.9999442100524902
number O O 0.9999688863754272
of O O 0.9999213218688965
genes O O 0.99940025806427
critical O O 0.9998897314071655
for O O 0.9995468258857727
fatty B B 0.516222357749939
acid I I 0.9586568474769592
oxidation O O 0.6368074417114258
, O O 0.9998070597648621
lipoprotein O O 0.6273640990257263
assembly O O 0.8568485975265503
, O O 0.9986061453819275
and O O 0.9997139573097229
lipid O O 0.5154128670692444
transport O O 0.9998537302017212
. O O 0.9999685287475586

Many O O 0.9974397420883179
of O O 0.9999129772186279
these O O 0.9998373985290527
genes O O 0.9999206066131592
are O O 0.9998546838760376
regulated O O 0.9999328851699829
by O O 0.999874472618103
the O O 0.9992089867591858
peroxisome O O 0.9320971965789795
proliferator O O 0.8538722395896912
- O O 0.9545639753341675
activated O O 0.9326685070991516
receptor O O 0.9458699226379395
- O O 0.9559158682823181
alpha O O 0.7046205401420593
( O O 0.9959905743598938
PPARalpha O O 0.793723464012146
) O O 0.9824398756027222
, O O 0.9999356269836426
a O O 0.9987432360649109
ligand O O 0.5985193848609924
- O O 0.9937659502029419
activated O O 0.9663368463516235
nuclear O O 0.9160983562469482
hormone O O 0.9697339534759521
receptor O O 0.9991827607154846
transcription O O 0.9959455132484436
factor O O 0.998719334602356
. O O 0.9999008178710938

The O O 0.9999850988388062
absence O O 0.9999769926071167
of O O 0.9999700784683228
induction O O 0.9999485015869141
of O O 0.9998914003372192
these O O 0.9975427389144897
genes O O 0.9997581839561462
as O O 0.9999613761901855
well O O 0.9999288320541382
as O O 0.9999607801437378
hepatomegaly O O 0.9999561309814453
in O O 0.999901533126831
PPARalpha O O 0.6350308060646057
knockout O O 0.9977381229400635
[ O O 0.9928815364837646
PPARalpha O O 0.6699854731559753
- O O 0.9959283471107483
/ O O 0.9988372921943665
- O O 0.9981302618980408
] O O 0.9999347925186157
mice O O 0.9999821186065674
indicated O O 0.9999583959579468
that O O 0.999950647354126
the O O 0.999975323677063
effects O O 0.9999655485153198
of O O 0.9998041987419128
amiodarone B B 0.9997796416282654
were O O 0.9998080134391785
dependent O O 0.9999706745147705
upon O O 0.9999666213989258
the O O 0.999981164932251
presence O O 0.9999749660491943
of O O 0.9999691247940063
a O O 0.9999586343765259
functional O O 0.9998741149902344
PPARalpha O O 0.6779766082763672
gene O O 0.9999111890792847
. O O 0.9999680519104004

Compared O O 0.9999910593032837
to O O 0.9999860525131226
wild O O 0.9999319314956665
- O O 0.9999719858169556
type O O 0.9999955892562866
mice O O 0.9999954700469971
, O O 0.9999496936798096
treatment O O 0.9999475479125977
of O O 0.999963641166687
PPARalpha O O 0.9096665382385254
- O O 0.9995575547218323
/ O O 0.9989442229270935
- O O 0.9998158812522888
mice O O 0.999992847442627
with O O 0.999832272529602
amiodarone B B 0.9997121691703796
resulted O O 0.9999231100082397
in O O 0.9999920129776001
an O O 0.9999940395355225
increased O O 0.999992847442627
rate O O 0.9999978542327881
and O O 0.9999927282333374
extent O O 0.9999958276748657
of O O 0.9999918937683105
total O O 0.9999806880950928
body O O 0.9999974966049194
weight O O 0.999809205532074
loss O O 0.9999948740005493
. O O 0.999982476234436

The O O 0.9999878406524658
inability O O 0.9999948740005493
of O O 0.9998832941055298
amiodarone B B 0.9998093247413635
to O O 0.9999006986618042
directly O O 0.9999396800994873
activate O O 0.9997507929801941
either O O 0.9998780488967896
human O O 0.9980553388595581
or O O 0.9998016953468323
mouse O O 0.9995469450950623
PPARalpha O O 0.6917068958282471
transiently O O 0.9998313188552856
expressed O O 0.9998669624328613
in O O 0.9999021291732788
human O O 0.9994291663169861
HepG2 O O 0.9683371782302856
hepatoma O O 0.9978539347648621
cells O O 0.9999384880065918
indicates O O 0.9999247789382935
that O O 0.9999032020568848
the O O 0.999964714050293
effects O O 0.9999603033065796
of O O 0.9998399019241333
amiodarone B B 0.9997592568397522
on O O 0.9996693134307861
the O O 0.999944806098938
function O O 0.9999622106552124
of O O 0.9998701810836792
this O O 0.995281994342804
receptor O O 0.9999371767044067
were O O 0.9998759031295776
indirect O O 0.9998283386230469
. O O 0.9999693632125854

Based O O 0.9999951124191284
upon O O 0.9999957084655762
these O O 0.9999861717224121
results O O 0.9999964237213135
, O O 0.9999767541885376
we O O 0.9999619722366333
conclude O O 0.9999828338623047
that O O 0.9996170997619629
amiodarone B B 0.999573290348053
disrupts O O 0.9998606443405151
hepatic O O 0.9998176693916321
lipid O O 0.5968873500823975
homeostasis O O 0.9999189376831055
and O O 0.9999455213546753
that O O 0.9999245405197144
the O O 0.999993085861206
increased O O 0.9999462366104126
expression O O 0.9999616146087646
of O O 0.9995007514953613
PPARalpha O O 0.6155499219894409
target O O 0.997704803943634
genes O O 0.9991890788078308
is O O 0.9999357461929321
secondary O O 0.9999936819076538
to O O 0.9999270439147949
this O O 0.9997187256813049
toxic O O 0.9985014200210571
effect O O 0.9999769926071167
. O O 0.9999618530273438

These O O 0.9999741315841675
results O O 0.9999865293502808
provide O O 0.9999644756317139
important O O 0.9999904632568359
new O O 0.9999887943267822
mechanistic O O 0.9999903440475464
information O O 0.9999879598617554
regarding O O 0.9999796152114868
the O O 0.9999597072601318
hepatotoxic O O 0.9999606609344482
effects O O 0.9999494552612305
of O O 0.9997803568840027
amiodarone B B 0.999643087387085
and O O 0.9998828172683716
indicate O O 0.9999204874038696
that O O 0.9989209175109863
PPARalpha O B 0.999284565448761
protects O O 0.9997833371162415
against O O 0.9997255206108093
amiodarone B B 0.9998363256454468
- O O 0.9998749494552612
induced O O 0.9999501705169678
hepatotoxicity O O 0.9999725818634033
. O O 0.9999784231185913

Safety O O 0.9999582767486572
and O O 0.9999572038650513
compliance O O 0.9999840259552002
with O O 0.9998992681503296
once O O 0.9995883107185364
- O O 0.9998453855514526
daily O O 0.9997419714927673
niacin B B 0.9986392855644226
extended I O 0.7334623336791992
- I O 0.9912808537483215
release I O 0.9934305548667908
/ I O 0.956230878829956
lovastatin I B 0.9993329644203186
as O O 0.9999456405639648
initial O O 0.9999889135360718
therapy O O 0.9999829530715942
in O O 0.9999833106994629
the O O 0.9999744892120361
Impact O O 0.9999504089355469
of O O 0.9999477863311768
Medical O O 0.9999493360519409
Subspecialty O O 0.9999527931213379
on O O 0.9999171495437622
Patient O O 0.9999784231185913
Compliance O O 0.9999885559082031
to O O 0.9999692440032959
Treatment O O 0.9999639987945557
( O O 0.9999531507492065
IMPACT O O 0.9999845027923584
) O O 0.9999912977218628
study O O 0.9999958276748657
. O O 0.9999667406082153

Niacin B B 0.9978221654891968
extended I O 0.7620769739151001
- I O 0.9864562749862671
release I O 0.9872065782546997
/ I O 0.9475124478340149
lovastatin I B 0.9995519518852234
is O O 0.9997197985649109
a O O 0.9999065399169922
new O O 0.9997281432151794
combination O O 0.9409521222114563
product O O 0.9687766432762146
approved O O 0.9987573623657227
for O O 0.9995328187942505
treatment O O 0.9999394416809082
of O O 0.9999731779098511
primary O O 0.9998674392700195
hypercholesterolemia O O 0.9684346318244934
and O O 0.9998530149459839
mixed O O 0.9997268319129944
dyslipidemia O O 0.9996696710586548
. O O 0.9999439716339111

This O O 0.9999797344207764
open O O 0.9997586607933044
- O O 0.9999839067459106
labeled O O 0.999990701675415
, O O 0.999976396560669
multicenter O O 0.9998689889907837
study O O 0.9999830722808838
evaluated O O 0.9999724626541138
the O O 0.999994158744812
safety O O 0.9999921321868896
of O O 0.9998480081558228
bedtime O O 0.9998533725738525
niacin B B 0.9993962049484253
extended I O 0.8977041244506836
- I O 0.9973629117012024
release I O 0.9935622215270996
/ I O 0.9527903199195862
lovastatin I B 0.9995255470275879
when O O 0.9999231100082397
dosed O O 0.9997749924659729
as O O 0.9999662637710571
initial O O 0.9999724626541138
therapy O O 0.9999690055847168
and O O 0.9999805688858032
patient O O 0.9999861717224121
compliance O O 0.9999970197677612
to O O 0.9999679327011108
treatment O O 0.9999833106994629
in O O 0.9999916553497314
various O O 0.9999864101409912
clinical O O 0.9999958276748657
practice O O 0.9999983310699463
settings O O 0.9999902248382568
. O O 0.9999818801879883

A O O 0.9999570846557617
total O O 0.9999853372573853
of O O 0.9999871253967285
4 O O 0.9999679327011108
, O O 0.9999971389770508
499 O O 0.9999935626983643
patients O O 0.9999942779541016
with O O 0.9999790191650391
dyslipidemia O O 0.9993995428085327
requiring O O 0.9999258518218994
drug O O 0.9994887113571167
intervention O O 0.9999592304229736
was O O 0.9999740123748779
enrolled O O 0.9999912977218628
at O O 0.9999306201934814
1 O O 0.999992847442627
, O O 0.9999974966049194
081 O O 0.9999216794967651
sites O O 0.9999945163726807
. O O 0.999976634979248

Patients O O 0.9997116923332214
were O O 0.9999909400939941
treated O O 0.9999810457229614
with O O 0.9999063014984131
1 O O 0.9993089437484741
tablet O O 0.9997523427009583
( O O 0.9995742440223694
500 O O 0.999843955039978
mg O O 0.9997496008872986
of O O 0.9992365837097168
niacin B B 0.9972737431526184
extended O O 0.8534494042396545
- O O 0.9947139620780945
release O O 0.9971407651901245
/ O O 0.9941098690032959
20 O O 0.9997816681861877
mg O O 0.9993948936462402
of O O 0.9982503056526184
lovastatin B B 0.9989954829216003
) O O 0.999529242515564
once O O 0.9998412132263184
nightly O O 0.9999604225158691
for O O 0.9999687671661377
4 O O 0.9998395442962646
weeks O O 0.999996542930603
and O O 0.9999740123748779
then O O 0.9999525547027588
2 O O 0.9994599223136902
tablets O O 0.9996694326400757
for O O 0.9999728202819824
8 O O 0.9999097585678101
weeks O O 0.9999966621398926
. O O 0.9999898672103882

Patients O O 0.9999449253082275
also O O 0.9999687671661377
received O O 0.999951958656311
dietary O O 0.999382495880127
counseling O O 0.9999822378158569
, O O 0.9999380111694336
educational O O 0.9999251365661621
materials O O 0.9999914169311523
, O O 0.9999452829360962
and O O 0.9999656677246094
reminders O O 0.9999611377716064
to O O 0.9999945163726807
call O O 0.9999910593032837
a O O 0.9999825954437256
toll O O 0.9994992017745972
- O O 0.9999834299087524
free O O 0.9999719858169556
number O O 0.9999634027481079
that O O 0.9999505281448364
provided O O 0.9999551773071289
further O O 0.9999932050704956
education O O 0.9999902248382568
about O O 0.9998970031738281
dyslipidemia O O 0.929442822933197
and O O 0.9994389414787292
niacin B B 0.9957767128944397
extended I O 0.7939462065696716
- I O 0.9906280040740967
release I O 0.9806663393974304
/ I O 0.9501293301582336
lovastatin I B 0.9989385008811951
. O O 0.9999470710754395

Primary O O 0.9998804330825806
end O O 0.9999904632568359
points O O 0.9999943971633911
were O O 0.9999706745147705
study O O 0.9998024106025696
compliance O O 0.9999964237213135
, O O 0.9999688863754272
increases O O 0.9999911785125732
in O O 0.999967098236084
liver O O 0.9762536883354187
transaminases O O 0.47168391942977905
to O O 0.9999517202377319
> O O 0.999923586845398
3 O O 0.999424934387207
times O O 0.9999837875366211
the O O 0.9999969005584717
upper O O 0.9999767541885376
limit O O 0.9999983310699463
of O O 0.9999690055847168
normal O O 0.9999910593032837
, O O 0.9998960494995117
and O O 0.9999018907546997
clinical O O 0.999911904335022
myopathy O O 0.9999949932098389
. O O 0.9999778270721436

Final O O 0.999924898147583
study O O 0.9999809265136719
status O O 0.9998496770858765
was O O 0.9999815225601196
available O O 0.9999953508377075
for O O 0.9999754428863525
4 O O 0.9999799728393555
, O O 0.9999933242797852
217 O O 0.9999935626983643
patients O O 0.9999936819076538
( O O 0.9999576807022095
94 O O 0.9999139308929443
% O O 0.9999910593032837
) O O 0.999956488609314
. O O 0.9999769926071167

Compliance O O 0.9999628067016602
to O O 0.9993742108345032
niacin B B 0.9990543723106384
extended I O 0.8922554850578308
- I O 0.9967086315155029
release I O 0.9969174861907959
/ I O 0.9286125898361206
lovastatin I B 0.9990012049674988
was O O 0.9999098777770996
77 O O 0.9999916553497314
% O O 0.9999969005584717
, O O 0.9999790191650391
with O O 0.999994158744812
3 O O 0.9999887943267822
, O O 0.9999967813491821
245 O O 0.9999947547912598
patients O O 0.9999922513961792
completing O O 0.9999668598175049
the O O 0.9999964237213135
study O O 0.9999762773513794
. O O 0.9999809265136719

Patients O O 0.9999428987503052
in O O 0.9998482465744019
the O O 0.9997076392173767
southeast O O 0.9954257607460022
and O O 0.9998970031738281
those O O 0.9999611377716064
enrolled O O 0.9999849796295166
by O O 0.9999359846115112
endocrinologists O O 0.9973862767219543
had O O 0.9999148845672607
the O O 0.9999806880950928
lowest O O 0.9999396800994873
compliance O O 0.9999867677688599
and O O 0.9999827146530151
highest O O 0.9999568462371826
adverse O O 0.9999847412109375
event O O 0.9999979734420776
rates O O 0.9999861717224121
. O O 0.999964714050293

Flushing O O 0.9988188147544861
was O O 0.9999628067016602
the O O 0.9999797344207764
most O O 0.9999914169311523
common O O 0.9999887943267822
adverse O O 0.9999313354492188
event O O 0.9999958276748657
, O O 0.9999852180480957
reported O O 0.9999929666519165
by O O 0.99998939037323
18 O O 0.9999736547470093
% O O 0.999995231628418
of O O 0.9999845027923584
patients O O 0.9999914169311523
and O O 0.9999783039093018
leading O O 0.9999943971633911
to O O 0.999991774559021
discontinuation O O 0.9999727010726929
by O O 0.9999896287918091
6 O O 0.9998624324798584
% O O 0.9995784163475037
. O O 0.9999750852584839

Incidence O O 0.9999681711196899
of O O 0.9999692440032959
increased O O 0.9998633861541748
aspartate B B 0.9902065396308899
aminotransferase O O 0.7663334012031555
and O O 0.9995675683021545
/ O O 0.9998995065689087
or O O 0.9999867677688599
alanine B B 0.9840789437294006
aminotransferase O O 0.7825480699539185
> O O 0.9988229870796204
3 O O 0.9994667172431946
times O O 0.999974250793457
the O O 0.9999967813491821
upper O O 0.9999827146530151
limit O O 0.9999979734420776
of O O 0.9999842643737793
normal O O 0.9999849796295166
was O O 0.9999655485153198
< O O 0.9999933242797852
0 O O 0.9999947547912598
. O O 0.9999935626983643
3 O O 0.999996542930603
% O O 0.9999915361404419
. O O 0.9999750852584839

An O O 0.9999691247940063
increase O O 0.9999818801879883
of O O 0.9998995065689087
creatine B B 0.9811996221542358
phosphokinase O O 0.644214391708374
to O O 0.9998890161514282
> O O 0.9999232292175293
5 O O 0.9998891353607178
times O O 0.9999815225601196
the O O 0.9999966621398926
upper O O 0.9999830722808838
limit O O 0.999997615814209
of O O 0.9999741315841675
normal O O 0.9999918937683105
occurred O O 0.9999899864196777
in O O 0.9999803304672241
0 O O 0.9999837875366211
. O O 0.999991774559021
24 O O 0.9999967813491821
% O O 0.999991774559021
of O O 0.9999767541885376
patients O O 0.9999905824661255
, O O 0.9999456405639648
and O O 0.9999759197235107
no O O 0.9999827146530151
cases O O 0.9999961853027344
of O O 0.9999699592590332
drug O O 0.9963132739067078
- O O 0.9999270439147949
induced O O 0.9999575614929199
myopathy O O 0.9999970197677612
were O O 0.9999804496765137
observed O O 0.9999853372573853
. O O 0.9999668598175049

Niacin B B 0.9986439347267151
extended I O 0.8692569732666016
- I O 0.9944248199462891
release I O 0.9948915243148804
/ I O 0.9445076584815979
lovastatin I B 0.9990749359130859
1 O O 0.9714676737785339
, O O 0.9997169375419617
000 O O 0.807848334312439
/ O O 0.9772335290908813
40 O O 0.997893750667572
mg O O 0.998731791973114
, O O 0.9999525547027588
dosed O O 0.9999492168426514
as O O 0.9999793767929077
initial O O 0.999990701675415
therapy O O 0.9999873638153076
, O O 0.9999878406524658
was O O 0.9999697208404541
associated O O 0.9999897480010986
with O O 0.9999933242797852
good O O 0.9999436140060425
compliance O O 0.9999967813491821
and O O 0.9999923706054688
safety O O 0.9999977350234985
and O O 0.9999912977218628
had O O 0.9999920129776001
very O O 0.9999974966049194
low O O 0.9999978542327881
incidences O O 0.9999974966049194
of O O 0.9999938011169434
increased O O 0.9999706745147705
liver O O 0.9969391822814941
and O O 0.9998762607574463
muscle O O 0.9903717041015625
enzymes O O 0.9998028874397278
. O O 0.999957799911499

Protective O O 0.9996210336685181
effect O O 0.9998853206634521
of O O 0.9993500113487244
Terminalia B B 0.9864208698272705
chebula I O 0.8476216197013855
against O O 0.9993002414703369
experimental O O 0.9998620748519897
myocardial O O 0.9999978542327881
injury O O 0.9999887943267822
induced O O 0.9999686479568481
by O O 0.9998266100883484
isoproterenol B B 0.9987615346908569
. O O 0.9994961023330688

Cardioprotective O O 0.9998794794082642
effect O O 0.9999207258224487
of O O 0.9998235106468201
ethanolic B B 0.795498251914978
extract I I 0.9970114231109619
of I I 0.9732317924499512
Terminalia I I 0.9383242726325989
chebula I O 0.650517463684082
fruits I O 0.8975231647491455
( O O 0.9983373880386353
500 O O 0.9998213648796082
mg O O 0.9998316764831543
/ O O 0.9999598264694214
kg O O 0.9999966621398926
body O O 0.9994478821754456
wt O O 0.9172515273094177
) O O 0.9998593330383301
was O O 0.9999784231185913
examined O O 0.9999785423278809
in O O 0.9995197057723999
isoproterenol B B 0.998365581035614
( O O 0.9994996786117554
200 O O 0.999009370803833
mg O O 0.9997571110725403
/ O O 0.9999405145645142
kg O O 0.9999961853027344
body O O 0.9953334927558899
wt O O 0.8579350709915161
) O O 0.9997813105583191
induced O O 0.9998997449874878
myocardial O O 0.999997615814209
damage O O 0.9999935626983643
in O O 0.9999568462371826
rats O O 0.9999923706054688
. O O 0.9999738931655884

In O O 0.9989977478981018
isoproterenol B B 0.999313473701477
administered O O 0.9995129108428955
rats O O 0.9998348951339722
, O O 0.9999443292617798
the O O 0.9999803304672241
level O O 0.9999226331710815
of O O 0.9977262616157532
lipid O O 0.5856382846832275
peroxides B O 0.5189751982688904
increased O O 0.999870777130127
significantly O O 0.9999853372573853
in O O 0.9997872710227966
the O O 0.9999217987060547
serum O O 0.9995168447494507
and O O 0.9998646974563599
heart O O 0.9998670816421509
. O O 0.9999630451202393

A O O 0.9999533891677856
significant O O 0.9999841451644897
decrease O O 0.9999876022338867
was O O 0.9999814033508301
observed O O 0.9999953508377075
in O O 0.9999759197235107
the O O 0.9999710321426392
activity O O 0.9996638298034668
of O O 0.9994638562202454
the O O 0.9997188448905945
myocardial O O 0.999915599822998
marker O O 0.9225966930389404
enzymes O O 0.9711947441101074
with O O 0.9999579191207886
a O O 0.9999847412109375
concomitant O O 0.9999876022338867
increase O O 0.9999550580978394
in O O 0.9999635219573975
their O O 0.9961193799972534
activity O O 0.9994389414787292
in O O 0.9996542930603027
serum O O 0.9973370432853699
. O O 0.999925971031189

Histopathological O O 0.9999268054962158
examination O O 0.9999924898147583
was O O 0.9999668598175049
carried O O 0.999991774559021
out O O 0.9999926090240479
to O O 0.9999856948852539
confirm O O 0.9999692440032959
the O O 0.999981164932251
myocardial O O 0.9999921321868896
necrosis O O 0.9999685287475586
. O O 0.999951958656311

T B O 0.5685927271842957
. I O 0.7449191212654114
chebula I O 0.554924726486206
extract I O 0.8860592246055603
pretreatment O O 0.9912524819374084
was O O 0.9999582767486572
found O O 0.9999724626541138
to O O 0.9998992681503296
ameliorate O O 0.9998975992202759
the O O 0.9999071359634399
effect O O 0.9998987913131714
of O O 0.9997803568840027
isoproterenol B B 0.9994244575500488
on O O 0.9992468357086182
lipid O O 0.5596452951431274
peroxide B O 0.45437881350517273
formation O O 0.9998108744621277
and O O 0.9999538660049438
retained O O 0.9990703463554382
the O O 0.9999233484268188
activities O O 0.999737560749054
of O O 0.9996463060379028
the O O 0.9996471405029297
diagnostic O O 0.9935643076896667
marker O O 0.9957209229469299
enzymes O O 0.9855924248695374
. O O 0.9999394416809082

A O O 0.999940037727356
case O O 0.9999852180480957
of O O 0.9999388456344604
postoperative O O 0.9997771382331848
anxiety O O 0.9994638562202454
due O O 0.9999779462814331
to O O 0.9997872710227966
low O O 0.9993877410888672
dose O O 0.992928683757782
droperidol B B 0.9998369216918945
used O O 0.9997748732566833
with O O 0.999897837638855
patient O O 0.9995328187942505
- O O 0.9999810457229614
controlled O O 0.9999713897705078
analgesia O O 0.9956515431404114
. O O 0.9999525547027588

A O O 0.9999853372573853
multiparous O O 0.9993109703063965
woman O O 0.9999970197677612
in O O 0.9999778270721436
good O O 0.9999932050704956
psychological O O 0.9999945163726807
health O O 0.9999922513961792
underwent O O 0.9999685287475586
urgent O O 0.999985933303833
caesarean O O 0.9740469455718994
section O O 0.9999712705612183
in O O 0.9999487400054932
labour O O 0.9999939203262329
. O O 0.9999736547470093

Postoperatively O O 0.9998548030853271
, O O 0.9999661445617676
she O O 0.999976634979248
was O O 0.9999591112136841
given O O 0.9998515844345093
a O O 0.9999202489852905
patient O O 0.984849214553833
- O O 0.9999626874923706
controlled O O 0.9999566078186035
analgesia O O 0.9996906518936157
device O O 0.9979581832885742
delivering O O 0.9550861716270447
boluses O O 0.9998106360435486
of O O 0.9963456988334656
diamorphine B B 0.9994001388549805
0 O O 0.9557344317436218
. O O 0.9999487400054932
5 O O 0.9997342228889465
mg O O 0.9963347911834717
and O O 0.9899786710739136
droperidol B B 0.9998376369476318
0 O O 0.9539079070091248
. O O 0.9999836683273315
025 O O 0.9976325035095215
mg O O 0.9994200468063354
. O O 0.9999295473098755

Whilst O O 0.9998900890350342
using O O 0.9999583959579468
the O O 0.9999905824661255
device O O 0.9999793767929077
she O O 0.9999756813049316
gradually O O 0.9999920129776001
became O O 0.9999935626983643
anxious O O 0.9999772310256958
, O O 0.9999947547912598
the O O 0.9999980926513672
feeling O O 0.9999955892562866
worsening O O 0.9998843669891357
after O O 0.9999415874481201
each O O 0.9998118281364441
bolus O O 0.9998383522033691
. O O 0.9999831914901733

The O O 0.9999885559082031
diagnosis O O 0.9999885559082031
of O O 0.9998979568481445
droperidol B B 0.9998695850372314
- O O 0.9994939565658569
induced O O 0.9998794794082642
psychological O O 0.9995996356010437
disturbance O O 0.9999871253967285
was O O 0.9999905824661255
not O O 0.999996542930603
made O O 0.9999991655349731
straight O O 0.9999991655349731
away O O 0.9999920129776001
although O O 0.9999750852584839
on O O 0.9999911785125732
subsequent O O 0.9999959468841553
close O O 0.9999948740005493
questioning O O 0.9999972581863403
the O O 0.9999938011169434
patient O O 0.9999914169311523
gave O O 0.9999879598617554
a O O 0.999996542930603
very O O 0.9999966621398926
clear O O 0.9999949932098389
history O O 0.9999939203262329
. O O 0.9999786615371704

After O O 0.999987006187439
she O O 0.9999840259552002
had O O 0.999992847442627
received O O 0.9999125003814697
a O O 0.9999842643737793
total O O 0.9999586343765259
of O O 0.9999383687973022
only O O 0.9999313354492188
0 O O 0.9999387264251709
. O O 0.9999819993972778
9 O O 0.999873161315918
mg O O 0.9984527826309204
droperidol B B 0.999798595905304
, O O 0.9996905326843262
a O O 0.9997770190238953
syringe O O 0.9718068838119507
containing O O 0.9991580247879028
diamorphine B B 0.9984052777290344
only O O 0.9969009160995483
was O O 0.9999440908432007
substituted O O 0.9997051358222961
and O O 0.9999827146530151
her O O 0.9999691247940063
unease O O 0.9952488541603088
resolved O O 0.9999734163284302
completely O O 0.9999947547912598
. O O 0.9999806880950928

We O O 0.9999651908874512
feel O O 0.9999712705612183
that O O 0.9999089241027832
, O O 0.9999827146530151
although O O 0.9999603033065796
the O O 0.9999700784683228
dramatic O O 0.9999247789382935
extrapyramidal O O 0.9872940182685852
side O O 0.9999446868896484
effects O O 0.9999830722808838
of O O 0.9998059868812561
dopaminergic O B 0.9920493960380554
antiemetics O O 0.7669229507446289
are O O 0.9996360540390015
well O O 0.9998863935470581
known O O 0.9999586343765259
, O O 0.9999547004699707
more O O 0.9999182224273682
subtle O O 0.9999803304672241
manifestations O O 0.9999779462814331
may O O 0.9999890327453613
easily O O 0.9999967813491821
be O O 0.999996542930603
overlooked O O 0.9999960660934448
. O O 0.9999841451644897

Accurate O O 0.999683141708374
patient O O 0.9999552965164185
history O O 0.999298095703125
contributes O O 0.9999350309371948
to O O 0.9999741315841675
differentiating O O 0.9999285936355591
diabetes O O 0.9933701753616333
insipidus O O 0.999707043170929
: O O 0.9999798536300659
a O O 0.9999598264694214
case O O 0.9999706745147705
study O O 0.9999951124191284
. O O 0.9999792575836182

This O O 0.9999645948410034
case O O 0.9999575614929199
study O O 0.9999918937683105
highlights O O 0.9998430013656616
the O O 0.9999806880950928
important O O 0.9998668432235718
contribution O O 0.9999814033508301
of O O 0.9998732805252075
nursing O O 0.9998351335525513
in O O 0.9999608993530273
obtaining O O 0.9999969005584717
an O O 0.9999963045120239
accurate O O 0.9999969005584717
health O O 0.99998939037323
history O O 0.9999983310699463
. O O 0.999974250793457

The O O 0.9999809265136719
case O O 0.9999866485595703
discussed O O 0.999994158744812
herein O O 0.9999754428863525
initially O O 0.999970555305481
appeared O O 0.9999748468399048
to O O 0.9999545812606812
be O O 0.9999474287033081
neurogenic O O 0.9996498823165894
diabetes O O 0.9994182586669922
insipidus O O 0.9995785355567932
( O O 0.9997853636741638
DI O O 0.9586573839187622
) O O 0.9999672174453735
secondary O O 0.9999532699584961
to O O 0.9998730421066284
a O O 0.999982476234436
traumatic O O 0.9999943971633911
brain O O 0.9999912977218628
injury O O 0.9999949932098389
. O O 0.9999703168869019

The O O 0.9999877214431763
nursing O O 0.9999790191650391
staff O O 0.9999915361404419
, O O 0.9999943971633911
by O O 0.9999966621398926
reviewing O O 0.999996542930603
the O O 0.9999967813491821
patient O O 0.9999947547912598
' O O 0.9999955892562866
s O O 0.9999963045120239
health O O 0.9999896287918091
history O O 0.9999983310699463
with O O 0.999991774559021
his O O 0.9999774694442749
family O O 0.9999945163726807
, O O 0.9999879598617554
discovered O O 0.9999481439590454
a O O 0.9999704360961914
history O O 0.9999668598175049
of O O 0.9999220371246338
polydipsia O O 0.995310366153717
and O O 0.9997535347938538
long O O 0.9995239973068237
- O O 0.9999887943267822
standing O O 0.999893307685852
lithium B B 0.9996973276138306
use O O 0.9991369843482971
. O O 0.9999678134918213

Lithium B B 0.9973415732383728
is O O 0.9996448755264282
implicated O O 0.999756395816803
in O O 0.9997472167015076
drug O O 0.996803879737854
- O O 0.9998955726623535
induced O O 0.9999496936798096
nephrogenic O O 0.999909520149231
DI O O 0.9942057728767395
, O O 0.9999494552612305
and O O 0.9999759197235107
because O O 0.9999978542327881
the O O 0.9999970197677612
patient O O 0.9999960660934448
had O O 0.9999955892562866
not O O 0.9999922513961792
received O O 0.9999163150787354
lithium B B 0.9995094537734985
since O O 0.999767005443573
being O O 0.9999977350234985
admitted O O 0.9999964237213135
to O O 0.9999929666519165
the O O 0.9999951124191284
hospital O O 0.999995231628418
, O O 0.999982476234436
his O O 0.9999850988388062
treatment O O 0.9999852180480957
changed O O 0.9999951124191284
to O O 0.9999607801437378
focus O O 0.9999688863754272
on O O 0.9994437098503113
nephrogenic O O 0.9991461038589478
DI O O 0.9790678024291992
. O O 0.999962329864502

By O O 0.9999707937240601
combining O O 0.9997325539588928
information O O 0.9999957084655762
from O O 0.9999847412109375
the O O 0.9999897480010986
patient O O 0.9999932050704956
history O O 0.9999911785125732
, O O 0.9999880790710449
the O O 0.9999959468841553
physical O O 0.9999909400939941
examination O O 0.9999985694885254
, O O 0.9999523162841797
and O O 0.9999717473983765
radiologic O O 0.9999536275863647
and O O 0.9999599456787109
laboratory O O 0.9999643564224243
studies O O 0.9999911785125732
, O O 0.9999692440032959
the O O 0.9999915361404419
critical O O 0.9999891519546509
care O O 0.9999973773956299
team O O 0.9999955892562866
demonstrated O O 0.9999868869781494
that O O 0.9999350309371948
the O O 0.9999903440475464
patient O O 0.999984622001648
had O O 0.9999738931655884
been O O 0.9999662637710571
self O O 0.9994864463806152
- O O 0.9999455213546753
treating O O 0.9997801184654236
his O O 0.9999352693557739
lithium B B 0.9998527765274048
- O O 0.999553382396698
induced O O 0.999864935874939
nephrogenic O O 0.9998236298561096
DI O O 0.9997015595436096
and O O 0.9999443292617798
developed O O 0.9999831914901733
neurogenic O O 0.9999829530715942
DI O O 0.9999192953109741
secondary O O 0.9999940395355225
to O O 0.9999558925628662
brain O O 0.9999812841415405
trauma O O 0.9999970197677612
. O O 0.9999786615371704

Thus O O 0.9999604225158691
successful O O 0.9998530149459839
treatment O O 0.9999852180480957
required O O 0.9999868869781494
that O O 0.9999314546585083
nephrogenic O O 0.9996614456176758
and O O 0.9997748732566833
neurogenic O O 0.9999406337738037
DI O O 0.9951625466346741
be O O 0.9999072551727295
treated O O 0.9999018907546997
concomitantly O O 0.9998161196708679
. O O 0.9999644756317139

Factors O O 0.9997550845146179
contributing O O 0.9998815059661865
to O O 0.9998526573181152
ribavirin B B 0.9994683861732483
- O O 0.9996114373207092
induced O O 0.9999361038208008
anemia O O 0.9998049139976501
. O O 0.9998880624771118

BACKGROUND O O 0.9998074173927307
AND O O 0.9999831914901733
AIM O O 0.9996747970581055
: O O 0.9997072815895081
Interferon B B 0.9865505695343018
and O O 0.5597153306007385
ribavirin B B 0.9861225485801697
combination O O 0.8989635109901428
therapy O O 0.9995788931846619
for O O 0.9999449253082275
chronic O O 0.9988358616828918
hepatitis O O 0.9983153343200684
C O O 0.9571669101715088
produces O O 0.9992671608924866
hemolytic O O 0.9997314810752869
anemia O O 0.9999145269393921
. O O 0.999901294708252

This O O 0.9999743700027466
study O O 0.9999884366989136
was O O 0.999980092048645
conducted O O 0.9999957084655762
to O O 0.9999920129776001
identify O O 0.9999470710754395
the O O 0.9998774528503418
factors O O 0.9999598264694214
contributing O O 0.9999837875366211
to O O 0.9999419450759888
ribavirin B B 0.9995183944702148
- O O 0.9997437596321106
induced O O 0.9999598264694214
anemia O O 0.9999364614486694
. O O 0.9999746084213257

METHODS O O 0.9999148845672607
: O O 0.9999938011169434
Eighty O O 0.9973262548446655
- O O 0.9999383687973022
eight O O 0.9998062252998352
patients O O 0.9999964237213135
with O O 0.9999916553497314
chronic O O 0.9995245933532715
hepatitis O O 0.9991399049758911
C O O 0.9733664393424988
who O O 0.9999376535415649
received O O 0.9997395873069763
interferon B B 0.6361998319625854
- I I 0.6605263948440552
alpha I I 0.9271928668022156
- I I 0.9173492193222046
2b I I 0.9993196725845337
at O O 0.9992485642433167
a O O 0.9999831914901733
dose O O 0.9999047517776489
of O O 0.9996360540390015
6 O O 0.9977779984474182
MU O O 0.9989627599716187
administered O O 0.9999074935913086
intramuscularly O O 0.9999657869338989
for O O 0.9999706745147705
24 O O 0.9999669790267944
weeks O O 0.9999959468841553
in O O 0.9999796152114868
combination O O 0.9999046325683594
with O O 0.999745786190033
ribavirin B B 0.9992014765739441
administered O O 0.9997137188911438
orally O O 0.998826801776886
at O O 0.9999563694000244
a O O 0.9999843835830688
dose O O 0.9999827146530151
of O O 0.9999300241470337
600 O O 0.9996048808097839
mg O O 0.9999477863311768
or O O 0.9998688697814941
800 O O 0.9928237199783325
mg O O 0.9998606443405151
participated O O 0.9999946355819702
in O O 0.999990701675415
the O O 0.9999983310699463
study O O 0.9999946355819702
. O O 0.9999758005142212

A O O 0.9999097585678101
hemoglobin O O 0.9777823686599731
concentration O O 0.9996633529663086
of O O 0.9999144077301025
< O O 0.9999837875366211
10 O O 0.9999938011169434
g O O 0.999911904335022
/ O O 0.999974250793457
dL O O 0.9999966621398926
was O O 0.9999651908874512
defined O O 0.999972939491272
as O O 0.9999454021453857
ribavirin B B 0.9992438554763794
- O O 0.9996874332427979
induced O O 0.9999401569366455
anemia O O 0.9998630285263062
. O O 0.999972939491272

RESULTS O O 0.9998241066932678
: O O 0.9997712969779968
Ribavirin B B 0.9996114373207092
- O O 0.9996240139007568
induced O O 0.9999455213546753
anemia O O 0.9998276233673096
occurred O O 0.999982476234436
in O O 0.9999769926071167
18 O O 0.999363362789154
( O O 0.9999563694000244
20 O O 0.9999955892562866
. O O 0.9999939203262329
5 O O 0.9999960660934448
% O O 0.9999957084655762
) O O 0.9999504089355469
patients O O 0.9999949932098389
during O O 0.9998801946640015
treatment O O 0.9999808073043823
. O O 0.9999819993972778

A O O 0.9999728202819824
2 O O 0.9999735355377197
g O O 0.9999842643737793
/ O O 0.9999915361404419
dL O O 0.9999972581863403
decrease O O 0.9999881982803345
in O O 0.9999649524688721
hemoglobin O O 0.983896017074585
concentrations O O 0.969480574131012
in O O 0.9999144077301025
patients O O 0.9999891519546509
with O O 0.9999614953994751
anemia O O 0.9997007846832275
was O O 0.9999781847000122
observed O O 0.999991774559021
at O O 0.9999785423278809
week O O 0.9999994039535522
2 O O 0.9999955892562866
after O O 0.9999948740005493
the O O 0.9999980926513672
start O O 0.9999936819076538
of O O 0.999968409538269
treatment O O 0.9999744892120361
. O O 0.999980092048645

The O O 0.9999812841415405
hemoglobin O O 0.9919803142547607
concentration O O 0.9997391104698181
in O O 0.9998599290847778
patients O O 0.9999943971633911
with O O 0.999981164932251
> O O 0.9999727010726929
or O O 0.9999881982803345
= O O 0.9999890327453613
2 O O 0.99997878074646
g O O 0.9999760389328003
/ O O 0.9999750852584839
dL O O 0.999995231628418
decrease O O 0.9999881982803345
at O O 0.9999154806137085
week O O 0.9999958276748657
2 O O 0.9995390176773071
was O O 0.9999570846557617
observed O O 0.9999908208847046
to O O 0.9999637603759766
be O O 0.9999747276306152
significantly O O 0.9999837875366211
lower O O 0.9999755620956421
even O O 0.9999227523803711
after O O 0.9999552965164185
week O O 0.9999964237213135
2 O O 0.9998934268951416
than O O 0.9999837875366211
in O O 0.9999403953552246
patients O O 0.9999949932098389
with O O 0.9999884366989136
< O O 0.9999921321868896
2 O O 0.9999833106994629
g O O 0.9999943971633911
/ O O 0.9999834299087524
dL O O 0.9999966621398926
decrease O O 0.9999862909317017
( O O 0.9999408721923828
P O O 0.9999823570251465
< O O 0.9999692440032959
0 O O 0.9999936819076538
. O O 0.9999973773956299
01 O O 0.9999971389770508
) O O 0.9999786615371704
. O O 0.9999773502349854

A O O 0.9999572038650513
significant O O 0.9999771118164062
relationship O O 0.9999918937683105
was O O 0.9999877214431763
observed O O 0.9999974966049194
between O O 0.9999113082885742
the O O 0.9999926090240479
rate O O 0.999984622001648
of O O 0.9999822378158569
reduction O O 0.9999891519546509
of O O 0.9999252557754517
hemoglobin O O 0.9882099628448486
concentrations O O 0.9897280335426331
at O O 0.999940037727356
week O O 0.9999954700469971
2 O O 0.9999687671661377
and O O 0.9999722242355347
the O O 0.9999943971633911
severity O O 0.999996542930603
of O O 0.9999868869781494
anemia O O 0.9998038411140442
( O O 0.9999555349349976
P O O 0.9992971420288086
< O O 0.9999473094940186
0 O O 0.9999904632568359
. O O 0.9999971389770508
01 O O 0.9999933242797852
) O O 0.999980092048645
. O O 0.9999676942825317

Such O O 0.9997696280479431
factors O O 0.9999862909317017
as O O 0.999956488609314
sex O O 0.9999698400497437
( O O 0.9999697208404541
female O O 0.9998944997787476
) O O 0.9999823570251465
, O O 0.9999746084213257
age O O 0.9999237060546875
( O O 0.999982476234436
> O O 0.9999942779541016
or O O 0.9999973773956299
= O O 0.9999984502792358
60 O O 0.999998927116394
years O O 0.9999986886978149
old O O 0.9999752044677734
) O O 0.9999762773513794
, O O 0.999950647354126
and O O 0.9999744892120361
the O O 0.9999740123748779
ribavirin B B 0.9978241920471191
dose O O 0.9990170001983643
by O O 0.999975323677063
body O O 0.9999978542327881
weight O O 0.9999909400939941
( O O 0.9999854564666748
12 O O 0.9999980926513672
mg O O 0.9999970197677612
/ O O 0.9999967813491821
kg O O 0.9999994039535522
or O O 0.9999947547912598
more O O 0.9999780654907227
) O O 0.9999854564666748
were O O 0.9999605417251587
significant O O 0.9999741315841675
by O O 0.9999946355819702
univariate O O 0.9999375343322754
analysis O O 0.999991774559021
. O O 0.9999812841415405

CONCLUSIONS O O 0.9977134466171265
: O O 0.9999594688415527
Careful O O 0.9902855753898621
administration O O 0.9999290704727173
is O O 0.9999901056289673
necessary O O 0.9999885559082031
in O O 0.9999737739562988
patients O O 0.9999986886978149
> O O 0.999996542930603
or O O 0.9999945163726807
= O O 0.9999973773956299
60 O O 0.9999991655349731
years O O 0.9999995231628418
old O O 0.9999984502792358
, O O 0.9999879598617554
in O O 0.999968409538269
female O O 0.999990701675415
patients O O 0.9999920129776001
, O O 0.999976634979248
and O O 0.9999794960021973
in O O 0.9999805688858032
patients O O 0.9999896287918091
receiving O O 0.999901533126831
a O O 0.9999891519546509
ribavirin B B 0.9979948997497559
dose O O 0.9995490908622742
of O O 0.9999699592590332
12 O O 0.9999825954437256
mg O O 0.9999814033508301
/ O O 0.9999630451202393
kg O O 0.9999978542327881
or O O 0.9999942779541016
more O O 0.999923825263977
. O O 0.9999808073043823

Patients O O 0.9999804496765137
who O O 0.9999812841415405
experience O O 0.9999954700469971
a O O 0.9999974966049194
fall O O 0.9999984502792358
in O O 0.9999868869781494
hemoglobin O O 0.9907217025756836
concentrations O O 0.9989718198776245
of O O 0.9999781847000122
2 O O 0.9999881982803345
g O O 0.9999486207962036
/ O O 0.9999856948852539
dL O O 0.9999970197677612
or O O 0.999992847442627
more O O 0.9999880790710449
at O O 0.9999755620956421
week O O 0.9999985694885254
2 O O 0.9999891519546509
after O O 0.9999916553497314
the O O 0.9999978542327881
start O O 0.9999914169311523
of O O 0.9999669790267944
treatment O O 0.9999628067016602
should O O 0.9999560117721558
be O O 0.9999927282333374
monitored O O 0.9999896287918091
with O O 0.9999862909317017
particular O O 0.9996459484100342
care O O 0.9999960660934448
. O O 0.9999823570251465

Zidovudine B B 0.9964954257011414
- O O 0.9985093474388123
induced O O 0.9998668432235718
hepatitis O O 0.9998137354850769
. O O 0.9998592138290405

A O O 0.9999759197235107
case O O 0.9999929666519165
of O O 0.9999673366546631
acute O O 0.9998441934585571
hepatitis O O 0.9996228218078613
induced O O 0.9999442100524902
by O O 0.9994410872459412
zidovudine B B 0.9991987347602844
in O O 0.9998045563697815
a O O 0.9999927282333374
38 O O 0.9999971389770508
- O O 0.9999923706054688
year O O 0.9999971389770508
- O O 0.999995231628418
old O O 0.9999936819076538
patient O O 0.9999929666519165
with O O 0.9999513626098633
AIDS O O 0.9012822508811951
is O O 0.999924898147583
presented O O 0.9999909400939941
. O O 0.9999738931655884

The O O 0.9999653100967407
mechanism O O 0.9999803304672241
whereby O O 0.9999834299087524
the O O 0.9999570846557617
hepatitis O O 0.9985848665237427
was O O 0.999929666519165
induced O O 0.9999808073043823
is O O 0.9999551773071289
not O O 0.9999868869781494
known O O 0.9999614953994751
. O O 0.9999501705169678

However O O 0.9999494552612305
, O O 0.9999681711196899
the O O 0.9999926090240479
patient O O 0.9999889135360718
tolerated O O 0.9999681711196899
well O O 0.9999178647994995
an O O 0.9997976422309875
alternative O O 0.9995169639587402
reverse O O 0.8949770927429199
transcriptase O O 0.9857181310653687
inhibitor O O 0.9542551636695862
, O O 0.998871386051178
2 B O 0.9123267531394958
' I O 0.7661993503570557
3 I O 0.7243028879165649
' I O 0.9329512715339661
dideoxyinosine I B 0.9862856268882751
. O O 0.9999322891235352

Physicians O O 0.9999618530273438
caring O O 0.999991774559021
for O O 0.9999700784683228
patients O O 0.9999799728393555
with O O 0.9999393224716187
AIDS O O 0.8565778136253357
should O O 0.9999420642852783
be O O 0.9999918937683105
aware O O 0.999984860420227
of O O 0.999987006187439
this O O 0.9999783039093018
hitherto O O 0.999874472618103
rarely O O 0.9999799728393555
reported O O 0.9999916553497314
complication O O 0.9999911785125732
. O O 0.9999727010726929

Oxidative O O 0.9917353391647339
damage O O 0.9999327659606934
precedes O O 0.9999083280563354
nitrative O O 0.5684666037559509
damage O O 0.9999066591262817
in O O 0.9998109936714172
adriamycin B B 0.9995624423027039
- O O 0.9992044568061829
induced O O 0.999908447265625
cardiac O O 0.9999887943267822
mitochondrial O O 0.9998038411140442
injury O O 0.9999916553497314
. O O 0.9999712705612183

The O O 0.9999914169311523
purpose O O 0.9999955892562866
of O O 0.9999943971633911
the O O 0.9999967813491821
present O O 0.9999927282333374
study O O 0.9999918937683105
was O O 0.9999960660934448
to O O 0.999996542930603
determine O O 0.9999980926513672
if O O 0.9999632835388184
elevated O O 0.9994723200798035
reactive O O 0.9659581780433655
oxygen B B 0.944530725479126
( O O 0.9936220049858093
ROS O O 0.8257716298103333
) O O 0.9993240833282471
/ O O 0.989473283290863
nitrogen B O 0.6678975820541382
species O O 0.9193968176841736
( O O 0.9939760565757751
RNS O O 0.6728870272636414
) O O 0.9998750686645508
reported O O 0.9999228715896606
to O O 0.9999107122421265
be O O 0.9999450445175171
present O O 0.9998308420181274
in O O 0.9997491240501404
adriamycin B B 0.9994397759437561
( O O 0.9881689548492432
ADR B B 0.9969172477722168
) O O 0.9308156967163086
- O O 0.9997106194496155
induced O O 0.9998658895492554
cardiotoxicity O O 0.9999908208847046
actually O O 0.9999663829803467
resulted O O 0.9999725818634033
in O O 0.9999324083328247
cardiomyocyte O O 0.9999955892562866
oxidative O O 0.9734899997711182
/ O O 0.9993060827255249
nitrative O O 0.9884595274925232
damage O O 0.9999814033508301
, O O 0.9999712705612183
and O O 0.9999923706054688
to O O 0.9999954700469971
quantitatively O O 0.9999867677688599
determine O O 0.999995231628418
the O O 0.9999889135360718
time O O 0.9999717473983765
course O O 0.9999924898147583
and O O 0.9999808073043823
subcellular O O 0.9999237060546875
localization O O 0.9999904632568359
of O O 0.9999490976333618
these O O 0.9997965693473816
postulated O O 0.9993640780448914
damage O O 0.9886016249656677
products O O 0.9999641180038452
using O O 0.9999933242797852
an O O 0.9999938011169434
in O O 0.9999667406082153
vivo O O 0.9999940395355225
approach O O 0.9999958276748657
. O O 0.9999805688858032

B6C3 O O 0.9861630797386169
mice O O 0.9999932050704956
were O O 0.9999815225601196
treated O O 0.9999798536300659
with O O 0.9999312162399292
a O O 0.9999791383743286
single O O 0.9999171495437622
dose O O 0.9999152421951294
of O O 0.9995800852775574
20 O O 0.9998237490653992
mg O O 0.9999395608901978
/ O O 0.9999557733535767
kg O O 0.9999681711196899
ADR B B 0.9532158374786377
. O O 0.9996895790100098

Ultrastructural O O 0.8700475692749023
damage O O 0.9999747276306152
and O O 0.9999474287033081
levels O O 0.9997311234474182
of O O 0.9965236783027649
4 B B 0.7155546545982361
- I I 0.874208390712738
hydroxy I I 0.9873305559158325
- I I 0.890896201133728
2 I I 0.9858953356742859
- I I 0.9824528694152832
nonenal I I 0.9999344348907471
( O O 0.9228596687316895
4HNE B B 0.8551856875419617
) O O 0.5997105836868286
- O O 0.6370500922203064
protein O O 0.6055690050125122
adducts O O 0.8985009789466858
and O O 0.9993001222610474
3 B B 0.8425711393356323
- I I 0.9621374607086182
nitrotyrosine I I 0.9982557892799377
( O O 0.9955993890762329
3NT B B 0.9023025035858154
) O O 0.9955586194992065
were O O 0.9999606609344482
analyzed O O 0.9996143579483032
. O O 0.9999175071716309

Quantitative O O 0.9994877576828003
ultrastructural O O 0.9982384443283081
damage O O 0.9999860525131226
using O O 0.9999654293060303
computerized O O 0.9999067783355713
image O O 0.9998942613601685
techniques O O 0.999972939491272
showed O O 0.9999408721923828
cardiomyocyte O O 0.9999881982803345
injury O O 0.999981164932251
as O O 0.9999864101409912
early O O 0.9999933242797852
as O O 0.9999954700469971
3 O O 0.9998962879180908
hours O O 0.999992847442627
, O O 0.9999772310256958
with O O 0.9999240636825562
mitochondria O O 0.9963909983634949
being O O 0.9999418258666992
the O O 0.999883770942688
most O O 0.9999210834503174
extensively O O 0.999815046787262
and O O 0.9998935461044312
progressively O O 0.9999525547027588
injured O O 0.9999728202819824
subcellular O O 0.999291181564331
organelle O O 0.9999300241470337
. O O 0.9999604225158691

Analysis O O 0.9999649524688721
of O O 0.9998390674591064
4HNE B O 0.5290912985801697
protein O O 0.6096489429473877
adducts O O 0.5569100379943848
by O O 0.9999563694000244
immunogold O O 0.9998797178268433
electron O O 0.9997459053993225
microscopy O O 0.9999804496765137
showed O O 0.9999711513519287
appearance O O 0.9999921321868896
of O O 0.9998420476913452
4HNE B O 0.5343232154846191
protein O O 0.6979360580444336
adducts O O 0.8478564620018005
in O O 0.9997586607933044
mitochondria O O 0.9996309280395508
as O O 0.9999792575836182
early O O 0.9999830722808838
as O O 0.9999951124191284
3 O O 0.9999088048934937
hours O O 0.9999868869781494
, O O 0.9999754428863525
with O O 0.9999687671661377
a O O 0.9999889135360718
peak O O 0.9999741315841675
at O O 0.9999797344207764
6 O O 0.9999585151672363
hours O O 0.999991774559021
and O O 0.9999686479568481
subsequent O O 0.999977707862854
decline O O 0.9999932050704956
at O O 0.9999878406524658
24 O O 0.9999886751174927
hours O O 0.9999963045120239
. O O 0.9999778270721436

3NT B O 0.5601593852043152
levels O O 0.9995885491371155
were O O 0.999958872795105
significantly O O 0.9999836683273315
increased O O 0.9999353885650635
in O O 0.9996720552444458
all O O 0.9995620846748352
subcellular O O 0.9995635151863098
compartments O O 0.999954104423523
at O O 0.9999526739120483
6 O O 0.9998772144317627
hours O O 0.9999887943267822
and O O 0.999958872795105
subsequently O O 0.9999837875366211
declined O O 0.9999771118164062
at O O 0.9999691247940063
24 O O 0.9999828338623047
hours O O 0.9999943971633911
. O O 0.9999754428863525

Our O O 0.999972939491272
data O O 0.9999775886535645
showed O O 0.9997773766517639
ADR B B 0.9529424905776978
induced O O 0.9828106164932251
4HNE B O 0.5178202390670776
- O O 0.6350422501564026
protein O O 0.5822160243988037
adducts O O 0.8782536387443542
in O O 0.9996656179428101
mitochondria O O 0.9992412328720093
at O O 0.999924898147583
the O O 0.9999884366989136
same O O 0.9999725818634033
time O O 0.9999740123748779
point O O 0.9999908208847046
as O O 0.9999904632568359
when O O 0.9999841451644897
mitochondrial O O 0.9996918439865112
injury O O 0.9999902248382568
initially O O 0.9999743700027466
appeared O O 0.9999923706054688
. O O 0.999968409538269

These O O 0.9999709129333496
results O O 0.99997878074646
document O O 0.9999716281890869
for O O 0.9999953508377075
the O O 0.9999936819076538
first O O 0.9999867677688599
time O O 0.9999799728393555
in O O 0.9999725818634033
vivo O O 0.9999765157699585
that O O 0.9999381303787231
mitochondrial O O 0.9993739724159241
oxidative O O 0.9487629532814026
damage O O 0.9998456239700317
precedes O O 0.9999716281890869
nitrative O O 0.9336349964141846
damage O O 0.9999608993530273
. O O 0.9999613761901855

The O O 0.999982476234436
progressive O O 0.9999898672103882
nature O O 0.9999878406524658
of O O 0.9999600648880005
mitochondrial O O 0.9994804263114929
injury O O 0.9999814033508301
suggests O O 0.9998996257781982
that O O 0.999779999256134
mitochondria O O 0.9992819428443909
, O O 0.9999574422836304
not O O 0.9999175071716309
other O O 0.9998975992202759
subcellular O O 0.9990484118461609
organelles O O 0.9999010562896729
, O O 0.9999548196792603
are O O 0.9998854398727417
the O O 0.9999593496322632
major O O 0.999967098236084
site O O 0.9999715089797974
of O O 0.9999480247497559
intracellular O O 0.9998714923858643
injury O O 0.9999790191650391
. O O 0.99996018409729

Sotalol B B 0.9995691180229187
- O O 0.9994675517082214
induced O O 0.9999005794525146
coronary O O 0.9999687671661377
spasm O O 0.9893538951873779
in O O 0.9999750852584839
a O O 0.999981164932251
patient O O 0.9999918937683105
with O O 0.999951958656311
dilated O O 0.9999089241027832
cardiomyopathy O O 0.9999959468841553
associated O O 0.9999769926071167
with O O 0.9999806880950928
sustained O O 0.9998874664306641
ventricular O O 0.9999347925186157
tachycardia O O 0.9999079704284668
. O O 0.9999560117721558

A O O 0.9999845027923584
54 O O 0.9999911785125732
- O O 0.9999855756759644
year O O 0.9999963045120239
- O O 0.9999923706054688
old O O 0.9999955892562866
man O O 0.9999964237213135
with O O 0.9999619722366333
severe O O 0.9999815225601196
left O O 0.9999885559082031
ventricular O O 0.9999954700469971
dysfunction O O 0.9999960660934448
due O O 0.9999819993972778
to O O 0.9998699426651001
dilated O O 0.9998430013656616
cardiomyopathy O O 0.9999891519546509
was O O 0.9999724626541138
referred O O 0.9999959468841553
to O O 0.9999947547912598
our O O 0.9999943971633911
hospital O O 0.9999966621398926
for O O 0.9999734163284302
symptomatic O O 0.9999902248382568
incessant O O 0.9996474981307983
sustained O O 0.9997170567512512
ventricular O O 0.9998168349266052
tachycardia O O 0.999841570854187
( O O 0.999854564666748
VT O O 0.9870467185974121
) O O 0.9999792575836182
. O O 0.9999699592590332

After O O 0.999985933303833
the O O 0.9999822378158569
administration O O 0.9998854398727417
of O O 0.9997305274009705
nifekalant B B 0.991358757019043
hydrochloride I I 0.9746173024177551
, O O 0.9992456436157227
sustained O O 0.9994345307350159
VT O O 0.6494784951210022
was O O 0.9999336004257202
terminated O O 0.999961256980896
. O O 0.9999740123748779

An O O 0.9997161030769348
alternate O O 0.99724280834198
class O O 0.7156350016593933
III O O 0.6521462202072144
agent O O 0.595657467842102
, O O 0.9963288903236389
sotalol B B 0.9997265934944153
, O O 0.9998681545257568
was O O 0.9999432563781738
also O O 0.999862551689148
effective O O 0.999819815158844
for O O 0.9999213218688965
the O O 0.9999349117279053
prevention O O 0.999964714050293
of O O 0.9999499320983887
VT O O 0.980209231376648
. O O 0.9998776912689209

However O O 0.9999809265136719
, O O 0.999983549118042
one O O 0.9999932050704956
month O O 0.9999991655349731
after O O 0.9999926090240479
switching O O 0.9998682737350464
over O O 0.9990569949150085
nifekalant B B 0.9953392744064331
to O O 0.9170684218406677
sotalol B B 0.9995442032814026
, O O 0.9999006986618042
a O O 0.999991774559021
short O O 0.9999953508377075
duration O O 0.9999889135360718
of O O 0.9999856948852539
ST O O 0.9962520003318787
elevation O O 0.9999558925628662
was O O 0.9999818801879883
documented O O 0.9999951124191284
in O O 0.9999707937240601
ECG O O 0.9963233470916748
monitoring O O 0.9999741315841675
at O O 0.9999802112579346
almost O O 0.9999920129776001
the O O 0.9999946355819702
same O O 0.9999892711639404
time O O 0.9999955892562866
for O O 0.9999616146087646
three O O 0.9999916553497314
consecutive O O 0.9999914169311523
days O O 0.9999936819076538
. O O 0.9999550580978394

ST O O 0.999777615070343
elevation O O 0.9999971389770508
with O O 0.9999923706054688
chest O O 0.9999814033508301
discomfort O O 0.9999932050704956
disappeared O O 0.9999959468841553
since O O 0.9998593330383301
he O O 0.9999704360961914
began O O 0.9999774694442749
taking O O 0.9993687272071838
long O O 0.9971089959144592
- O O 0.9998306035995483
acting O O 0.9863865375518799
diltiazem B B 0.9991784691810608
. O O 0.9999101161956787

Coronary O O 0.9996345043182373
vasospasm O O 0.9999845027923584
may O O 0.9998836517333984
be O O 0.9999536275863647
induced O O 0.9999794960021973
by O O 0.9998704195022583
the O O 0.9998272061347961
non O O 0.9825690984725952
- O O 0.9998732805252075
selective O O 0.9988960027694702
beta O O 0.990471363067627
- O O 0.9993089437484741
blocking O O 0.9838745594024658
properties O O 0.9998526573181152
of O O 0.9987419247627258
sotalol B B 0.9993500113487244
. O O 0.9999052286148071

Effects O O 0.9998593330383301
of O O 0.9993259906768799
the O O 0.9975426197052002
antidepressant O O 0.8925759196281433
trazodone B B 0.9759277105331421
, O O 0.9993759989738464
a O O 0.9928551316261292
5 B B 0.48828408122062683
- I I 0.677025318145752
HT I I 0.9551445841789246
2A O O 0.7824285626411438
/ O O 0.7611053586006165
2C O O 0.5896609425544739
receptor O O 0.9756189584732056
antagonist O O 0.9066113233566284
, O O 0.9999452829360962
on O O 0.9998263716697693
dopamine B B 0.9952791929244995
- O O 0.9997729659080505
dependent O O 0.9998028874397278
behaviors O O 0.9999864101409912
in O O 0.9999570846557617
rats O O 0.9999721050262451
. O O 0.9999667406082153

RATIONALE O O 0.5921298265457153
: O O 0.9970368146896362
5 B B 0.9800920486450195
- I I 0.993341863155365
Hydroxytryptamine I I 0.9981635212898254
, O O 0.9998008608818054
via O O 0.9997325539588928
stimulation O O 0.9996302127838135
of O O 0.9997535347938538
5 B O 0.5438435077667236
- I O 0.5098954439163208
HT I O 0.8190625309944153
2C O O 0.7721781134605408
receptors O O 0.9960319399833679
, O O 0.999859094619751
exerts O O 0.9998764991760254
a O O 0.9998747110366821
tonic O O 0.9991641044616699
inhibitory O O 0.9992002844810486
influence O O 0.9999494552612305
on O O 0.9998724460601807
dopaminergic O B 0.9890845417976379
neurotransmission O O 0.9999818801879883
, O O 0.9998900890350342
whereas O O 0.9991455078125
activation O O 0.9995762705802917
of O O 0.9992839694023132
5 B O 0.673958957195282
- I O 0.557263195514679
HT I O 0.8375216722488403
2A O O 0.807125985622406
receptors O O 0.9988594055175781
enhances O O 0.9988358616828918
stimulated O O 0.9950531125068665
DAergic O O 0.5437279939651489
neurotransmission O O 0.9999628067016602
. O O 0.9999374151229858

The O O 0.9936395287513733
antidepressant O O 0.8695672154426575
trazodone B B 0.9897806644439697
is O O 0.9985873699188232
a O O 0.9847226738929749
5 B O 0.5455783605575562
- I O 0.7464204430580139
HT I O 0.920401394367218
2A O O 0.7805936336517334
/ O O 0.7804000377655029
2C O O 0.531846284866333
receptor O O 0.9814388155937195
antagonist O O 0.9397600293159485
. O O 0.9998155236244202

OBJECTIVES O O 0.999941349029541
: O O 0.9999948740005493
To O O 0.9999939203262329
evaluate O O 0.9999897480010986
the O O 0.9999898672103882
effect O O 0.9999508857727051
of O O 0.9992702603340149
trazodone B B 0.9996646642684937
treatment O O 0.9984983205795288
on O O 0.9997633099555969
behaviors O O 0.9942677021026611
dependent O O 0.9999701976776123
on O O 0.9998903274536133
the O O 0.9999760389328003
functional O O 0.9999810457229614
status O O 0.9999945163726807
of O O 0.9999481439590454
the O O 0.9999525547027588
nigrostriatal O O 0.9808979630470276
DAergic O O 0.8859132528305054
system O O 0.9998420476913452
. O O 0.9999712705612183

METHODS O O 0.9992212057113647
: O O 0.9999479055404663
The O O 0.9999779462814331
effect O O 0.9999681711196899
of O O 0.9999512434005737
pretreatment O O 0.9999004602432251
with O O 0.9998646974563599
trazodone B B 0.9997407793998718
on O O 0.999345600605011
dexamphetamine B B 0.999114453792572
- O O 0.9993144273757935
and O O 0.996698796749115
apomorphine B B 0.9928718209266663
- O O 0.999798595905304
induced O O 0.9999628067016602
oral O O 0.9948306679725647
stereotypies O O 0.9993571639060974
, O O 0.9999685287475586
on O O 0.9989054203033447
catalepsy O O 0.9998272061347961
induced O O 0.9999715089797974
by O O 0.9998528957366943
haloperidol B B 0.9997842907905579
and O O 0.9677015542984009
apomorphine B B 0.9972135424613953
( O O 0.999674916267395
0 O O 0.9999580383300781
. O O 0.9999955892562866
05 O O 0.999988317489624
mg O O 0.9999493360519409
/ O O 0.9999715089797974
kg O O 0.999996542930603
, O O 0.9999662637710571
i O O 0.9998831748962402
. O O 0.999996542930603
p O O 0.9999985694885254
. O O 0.999995231628418
) O O 0.9999867677688599
, O O 0.9999767541885376
on O O 0.9985132813453674
ergometrine B B 0.9996764659881592
- O O 0.9996997117996216
induced O O 0.9999476671218872
wet O O 0.9968806505203247
dog O O 0.9999641180038452
shake O O 0.9997598528862
( O O 0.9997308850288391
WDS O O 0.9714350700378418
) O O 0.9999382495880127
behavior O O 0.999966025352478
and O O 0.999811589717865
fluoxetine B B 0.999693751335144
- O O 0.9998210072517395
induced O O 0.9999362230300903
penile O O 0.9999651908874512
erections O O 0.9999501705169678
was O O 0.9999791383743286
studied O O 0.9999701976776123
in O O 0.9999635219573975
rats O O 0.9999762773513794
. O O 0.9999650716781616

We O O 0.9999620914459229
also O O 0.9999815225601196
investigated O O 0.9999860525131226
whether O O 0.9999409914016724
trazodone B B 0.9995391368865967
induces O O 0.9998192191123962
catalepsy O O 0.9999728202819824
in O O 0.9999070167541504
rats O O 0.9999871253967285
. O O 0.9999735355377197

RESULTS O O 0.9999618530273438
: O O 0.9993687272071838
Trazodone B B 0.999805748462677
at O O 0.9996292591094971
2 O O 0.9974232912063599
. O O 0.9999816417694092
5 O O 0.9998811483383179
- O O 0.9961926937103271
20 O O 0.9993032217025757
mg O O 0.9999053478240967
/ O O 0.9999750852584839
kg O O 0.9999898672103882
i O O 0.9996565580368042
. O O 0.9999934434890747
p O O 0.9999980926513672
. O O 0.9999855756759644
did O O 0.9999501705169678
not O O 0.9998946189880371
induce O O 0.9999618530273438
catalepsy O O 0.9999808073043823
, O O 0.9999197721481323
and O O 0.9998437166213989
did O O 0.9998939037322998
not O O 0.9992192983627319
antagonize O O 0.9976755976676941
apomorphine B B 0.9964724779129028
( O O 0.9966083765029907
1 O O 0.9993664622306824
. O O 0.9998643398284912
5 O O 0.9992928504943848
and O O 0.9991492033004761
3 O O 0.9990876913070679
mg O O 0.998828113079071
/ O O 0.9998409748077393
kg O O 0.9999279975891113
) O O 0.9991926550865173
stereotypy O O 0.9603433609008789
and O O 0.9992635846138
apomorphine B B 0.9973377585411072
( O O 0.9995102882385254
0 O O 0.9999545812606812
. O O 0.9999959468841553
05 O O 0.9999796152114868
mg O O 0.9997726082801819
/ O O 0.9997779726982117
kg O O 0.999890923500061
) O O 0.9994481205940247
- O O 0.9997610449790955
induced O O 0.999923586845398
catalepsy O O 0.9999897480010986
. O O 0.9999780654907227

However O O 0.9999638795852661
, O O 0.9997422099113464
pretreatment O O 0.9998471736907959
with O O 0.9998331069946289
5 O O 0.9984719157218933
, O O 0.9969754219055176
10 O O 0.998582124710083
and O O 0.9995404481887817
20 O O 0.9999099969863892
mg O O 0.9999301433563232
/ O O 0.9999809265136719
kg O O 0.9999887943267822
i O O 0.9952147006988525
. O O 0.9999915361404419
p O O 0.9999929666519165
. O O 0.9999442100524902
trazodone B B 0.9997195601463318
enhanced O O 0.999461829662323
dexamphetamine B B 0.9979097247123718
stereotypy O O 0.9899703860282898
, O O 0.9999082088470459
and O O 0.9993658661842346
antagonized O O 0.9728747606277466
haloperidol B B 0.9987435936927795
catalepsy O O 0.937202513217926
, O O 0.9998626708984375
ergometrine B B 0.9995506405830383
- O O 0.9997110962867737
induced O O 0.9999217987060547
WDS O O 0.9926137924194336
behavior O O 0.9999791383743286
and O O 0.9997636675834656
fluoxetine B B 0.9996422529220581
- O O 0.9999024868011475
induced O O 0.9999477863311768
penile O O 0.9999699592590332
erections O O 0.9999629259109497
. O O 0.999962568283081

Trazodone B B 0.9994304776191711
at O O 0.9993612170219421
30 O O 0.999887228012085
, O O 0.9991940855979919
40 O O 0.9992672801017761
and O O 0.9996803998947144
50 O O 0.999983549118042
mg O O 0.9999496936798096
/ O O 0.9999773502349854
kg O O 0.9999933242797852
i O O 0.9996539354324341
. O O 0.999996542930603
p O O 0.999997615814209
. O O 0.9999840259552002
induced O O 0.9999446868896484
catalepsy O O 0.9999833106994629
and O O 0.9998053908348083
antagonized O O 0.9912247061729431
apomorphine B B 0.9909143447875977
and O O 0.9915801882743835
dexamphetamine B B 0.9964809417724609
stereotypies O O 0.9937068819999695
. O O 0.9999275207519531

CONCLUSIONS O O 0.9816680550575256
: O O 0.9999920129776001
Our O O 0.9953395128250122
results O O 0.9999819993972778
indicate O O 0.9999356269836426
that O O 0.9994340538978577
trazodone B B 0.9997952580451965
at O O 0.9997883439064026
2 O O 0.9973635077476501
. O O 0.9999743700027466
5 O O 0.9998669624328613
- O O 0.9962790608406067
20 O O 0.9999678134918213
mg O O 0.9999154806137085
/ O O 0.9998792409896851
kg O O 0.9998741149902344
does O O 0.999861478805542
not O O 0.9998419284820557
block O O 0.999464213848114
pre O O 0.9834640622138977
- O O 0.999725878238678
and O O 0.9998113512992859
postsynaptic O O 0.9963234663009644
striatal O O 0.8844782114028931
D2 O O 0.9684367775917053
DA O O 0.8825045228004456
receptors O O 0.9999403953552246
, O O 0.9998836517333984
while O O 0.9997349381446838
at O O 0.9998332262039185
30 O O 0.9999464750289917
, O O 0.998866081237793
40 O O 0.9997492432594299
and O O 0.9993071556091309
50 O O 0.9999850988388062
mg O O 0.9998763799667358
/ O O 0.9999592304229736
kg O O 0.9998230338096619
it O O 0.9985517859458923
blocks O O 0.9994875192642212
postsynaptic O O 0.9974676370620728
striatal O O 0.6911248564720154
D2 O O 0.9149551391601562
DA O O 0.8736224174499512
receptors O O 0.9999322891235352
. O O 0.9999526739120483

Furthermore O O 0.9997610449790955
, O O 0.9998860359191895
at O O 0.9998190999031067
5 O O 0.9983267188072205
, O O 0.9979923963546753
10 O O 0.9991779923439026
and O O 0.9999122619628906
20 O O 0.9998742341995239
mg O O 0.9999779462814331
/ O O 0.9999849796295166
kg O O 0.9999934434890747
, O O 0.9993801116943359
trazodone B B 0.9996591806411743
blocks O O 0.999823272228241
5 B B 0.6526423692703247
- I I 0.6967791318893433
HT I I 0.92982017993927
2A O I 0.9690274596214294
and O O 0.9835247993469238
5 B B 0.6193114519119263
- I I 0.543285608291626
HT I I 0.8792360424995422
2C O I 0.9495161771774292
receptors O O 0.9965221881866455
. O O 0.9999678134918213

We O O 0.9999861717224121
suggest O O 0.999941349029541
that O O 0.9995167255401611
trazodone B B 0.9998420476913452
( O O 0.9987853169441223
5 O O 0.9980267882347107
, O O 0.9972236156463623
10 O O 0.9990804195404053
and O O 0.9994620680809021
20 O O 0.9999371767044067
mg O O 0.9999109506607056
/ O O 0.9998977184295654
kg O O 0.9999716281890869
) O O 0.9999339580535889
, O O 0.9999483823776245
by O O 0.9998847246170044
blocking O O 0.9984070658683777
the O O 0.9996128678321838
5 B B 0.7762270569801331
- I I 0.7558887600898743
HT I I 0.9961967468261719
2C O O 0.559172511100769
receptors O O 0.8616445064544678
, O O 0.9999045133590698
releases O O 0.9997573494911194
the O O 0.9998867511749268
nigrostriatal O O 0.9756752252578735
DAergic O O 0.8481301665306091
neurons O O 0.9999388456344604
from O O 0.9996930360794067
tonic O O 0.9992620348930359
inhibition O O 0.9998493194580078
caused O O 0.9999653100967407
by O O 0.9997749924659729
5 B B 0.7264347076416016
- I I 0.7041714787483215
HT I I 0.9952875375747681
, O O 0.9984726309776306
and O O 0.9998763799667358
thereby O O 0.999893307685852
potentiates O O 0.9995713829994202
dexamphetamine B B 0.9980239868164062
stereotypy O O 0.9787514805793762
and O O 0.9999370574951172
antagonizes O O 0.9999560117721558
haloperidol B B 0.9994671940803528
catalepsy O O 0.9980570673942566
. O O 0.9999452829360962

Swallowing O O 0.9990476965904236
abnormalities O O 0.9999630451202393
and O O 0.9999053478240967
dyskinesia O O 0.9999821186065674
in O O 0.9998558759689331
Parkinson O O 0.9942190647125244
' O O 0.9999774694442749
s O O 0.9999195337295532
disease O O 0.999969482421875
. O O 0.9999412298202515

Gastrointestinal O O 0.9991880059242249
abnormalities O O 0.999964714050293
in O O 0.9999215602874756
Parkinson O O 0.9832305908203125
' O O 0.9999814033508301
s O O 0.9999368190765381
disease O O 0.9999229907989502
( O O 0.999698281288147
PD O O 0.9825383424758911
) O O 0.999948263168335
have O O 0.9999549388885498
been O O 0.9999896287918091
known O O 0.9999716281890869
for O O 0.9999719858169556
almost O O 0.9999942779541016
two O O 0.999995231628418
centuries O O 0.9999874830245972
, O O 0.9999457597732544
but O O 0.9999507665634155
many O O 0.9999189376831055
aspects O O 0.9999938011169434
concerning O O 0.9999805688858032
their O O 0.9999396800994873
pathophysiology O O 0.9999871253967285
have O O 0.9999899864196777
not O O 0.9999951124191284
been O O 0.999995231628418
completely O O 0.9999841451644897
clarified O O 0.9999897480010986
. O O 0.9999741315841675

The O O 0.999990701675415
aim O O 0.9999973773956299
of O O 0.9999957084655762
this O O 0.9999891519546509
study O O 0.9999876022338867
was O O 0.9999942779541016
to O O 0.9999934434890747
characterize O O 0.9999922513961792
the O O 0.9999799728393555
oropharyngeal O O 0.9999037981033325
dynamics O O 0.9999459981918335
in O O 0.9999432563781738
PD O O 0.9909777641296387
patients O O 0.9999837875366211
with O O 0.9999529123306274
and O O 0.9999806880950928
without O O 0.9999834299087524
levodopa B B 0.999749481678009
- O O 0.9997437596321106
induced O O 0.9998775720596313
dyskinesia O O 0.9999973773956299
. O O 0.9999735355377197

Fifteen O O 0.9988579750061035
dyskinetic O O 0.9997832179069519
, O O 0.9998645782470703
12 O O 0.9997537732124329
nondyskinetic O O 0.9787620306015015
patients O O 0.9999618530273438
, O O 0.9998596906661987
and O O 0.9998486042022705
a O O 0.9997900128364563
control O O 0.9997857213020325
group O O 0.9999802112579346
were O O 0.9999685287475586
included O O 0.9999831914901733
. O O 0.9999649524688721

Patients O O 0.9999247789382935
were O O 0.99998939037323
asked O O 0.9999974966049194
about O O 0.999977707862854
dysphagia O O 0.9999417066574097
and O O 0.999967098236084
evaluated O O 0.9999959468841553
with O O 0.9999916553497314
the O O 0.9999717473983765
Unified O O 0.9987419247627258
Parkinson O O 0.9971784353256226
' O O 0.9999845027923584
s O O 0.9999860525131226
Disease O O 0.999993085861206
Rating O O 0.9999450445175171
Scale O O 0.9996926784515381
Parts O O 0.9967586398124695
II O O 0.9993016719818115
and O O 0.9994470477104187
III O O 0.998668909072876
and O O 0.9999197721481323
the O O 0.9999009370803833
Hoehn O O 0.9968307614326477
and O O 0.9998682737350464
Yahr O O 0.996052086353302
scale O O 0.9998621940612793
. O O 0.9999804496765137

Deglutition O O 0.9852821826934814
was O O 0.9999765157699585
assessed O O 0.9999896287918091
using O O 0.9999749660491943
modified O O 0.9999816417694092
barium B O 0.9986466765403748
swallow O O 0.999812662601471
with O O 0.9999756813049316
videofluoroscopy O O 0.9996030926704407
. O O 0.9999719858169556

Nondyskinetic O O 0.9765402674674988
patients O O 0.9999620914459229
, O O 0.999964714050293
but O O 0.9999719858169556
not O O 0.9999614953994751
the O O 0.9999154806137085
dyskinetic O O 0.9999779462814331
ones O O 0.9999685287475586
, O O 0.9999650716781616
showed O O 0.9999393224716187
less O O 0.9999599456787109
oropharyngeal O O 0.9998639822006226
swallowing O O 0.999943733215332
efficiency O O 0.999890923500061
( O O 0.9791728258132935
OPSE O O 0.7515822649002075
) O O 0.999091625213623
for O O 0.9996144771575928
liquid O O 0.9829226732254028
food O O 0.9983311295509338
than O O 0.9996614456176758
controls O O 0.9996544122695923
( O O 0.9991204142570496
Dunnett O O 0.7879661321640015
, O O 0.9994456171989441
P O O 0.9993491768836975
= O O 0.9997918009757996
0 O O 0.9999433755874634
. O O 0.9999837875366211
02 O O 0.9999010562896729
) O O 0.9999626874923706
. O O 0.9999709129333496

Dyskinetic O O 0.9980446100234985
patients O O 0.9999412298202515
tended O O 0.9999700784683228
to O O 0.9999444484710693
have O O 0.9999345541000366
a O O 0.9998528957366943
greater O O 0.9992614388465881
OPSE O O 0.997962474822998
than O O 0.9998542070388794
nondyskinetic O O 0.963913083076477
( O O 0.999583899974823
Dunnett O O 0.826747477054596
, O O 0.9989977478981018
P O O 0.9986060261726379
= O O 0.9998555183410645
0 O O 0.9999475479125977
. O O 0.9999871253967285
06 O O 0.9999794960021973
) O O 0.999950647354126
. O O 0.9999639987945557

Patients O O 0.9999642372131348
who O O 0.999932050704956
were O O 0.9999915361404419
using O O 0.9998657703399658
a O O 0.9999923706054688
higher O O 0.9999631643295288
dose O O 0.9995833039283752
of O O 0.997897744178772
levodopa B B 0.9995672106742859
had O O 0.9998526573181152
a O O 0.9999794960021973
greater O O 0.9999016523361206
OPSE O O 0.9983204007148743
and O O 0.9999821186065674
a O O 0.9999940395355225
trend O O 0.9999972581863403
toward O O 0.9999969005584717
a O O 0.9999954700469971
smaller O O 0.9999895095825195
oral O O 0.9865409731864929
transit O O 0.9999622106552124
time O O 0.9999732971191406
( O O 0.9998431205749512
Pearson O O 0.9893450140953064
' O O 0.9999669790267944
s O O 0.9999691247940063
correlation O O 0.9992824196815491
, O O 0.9999376535415649
P O O 0.9956473708152771
= O O 0.9991912245750427
0 O O 0.9999780654907227
. O O 0.9999901056289673
01 O O 0.9999920129776001
and O O 0.9999439716339111
0 O O 0.9999723434448242
. O O 0.9999942779541016
08 O O 0.9999942779541016
, O O 0.9999890327453613
respectively O O 0.9999167919158936
) O O 0.9999756813049316
. O O 0.9999849796295166

Neither O O 0.9999606609344482
the O O 0.9999821186065674
report O O 0.9999923706054688
of O O 0.9999752044677734
dysphagia O O 0.9999752044677734
nor O O 0.9999680519104004
any O O 0.9999656677246094
of O O 0.9999620914459229
the O O 0.9999655485153198
PD O O 0.9567780494689941
severity O O 0.9985737800598145
parameters O O 0.9999480247497559
correlated O O 0.9999697208404541
to O O 0.9999436140060425
the O O 0.9999927282333374
videofluoroscopic O O 0.9997226595878601
variables O O 0.9999861717224121
. O O 0.9999539852142334

In O O 0.9999755620956421
the O O 0.9999955892562866
current O O 0.9999886751174927
study O O 0.9999896287918091
, O O 0.99986732006073
dyskinetic O O 0.9998137354850769
patients O O 0.9999234676361084
performed O O 0.9999432563781738
better O O 0.9998774528503418
in O O 0.999894380569458
swallowing O O 0.9974073767662048
function O O 0.9999887943267822
, O O 0.9999727010726929
which O O 0.9999810457229614
could O O 0.9999178647994995
be O O 0.9999915361404419
explained O O 0.9999898672103882
on O O 0.9999959468841553
the O O 0.9999949932098389
basis O O 0.9999939203262329
of O O 0.9999716281890869
a O O 0.9999873638153076
greater O O 0.9998277425765991
levodopa B B 0.9997135996818542
dose O O 0.9997933506965637
. O O 0.9999096393585205

Our O O 0.9999699592590332
results O O 0.9999909400939941
suggest O O 0.999901294708252
a O O 0.9999301433563232
role O O 0.9999223947525024
for O O 0.9996961355209351
levodopa B B 0.9996660947799683
in O O 0.9996209144592285
the O O 0.9999123811721802
oral O O 0.9970160722732544
phase O O 0.9999912977218628
of O O 0.9999376535415649
deglutition O O 0.9992747902870178
and O O 0.9999423027038574
confirm O O 0.999956488609314
that O O 0.9999443292617798
dysphagia O O 0.9999527931213379
is O O 0.9999758005142212
not O O 0.9999831914901733
a O O 0.9999425411224365
good O O 0.9999210834503174
predictor O O 0.9999901056289673
of O O 0.9999608993530273
deglutition O O 0.9986557960510254
alterations O O 0.9999343156814575
in O O 0.9998869895935059
PD O O 0.9966378211975098
. O O 0.9998736381530762

Inhibition O O 0.9997479319572449
of O O 0.997822642326355
nuclear O O 0.9150101542472839
factor O O 0.9777066707611084
- O O 0.9819520115852356
kappaB O O 0.9525408148765564
activation O O 0.9979575872421265
attenuates O O 0.9997758269309998
tubulointerstitial O O 0.9999433755874634
nephritis O O 0.9999033212661743
induced O O 0.999975323677063
by O O 0.9998475313186646
gentamicin B B 0.9997541308403015
. O O 0.9998691082000732

BACKGROUND O O 0.9950055480003357
: O O 0.9999585151672363
Animals O O 0.9999196529388428
treated O O 0.9998779296875
with O O 0.9994304776191711
gentamicin B B 0.9995177984237671
can O O 0.9995982050895691
show O O 0.9998921155929565
residual O O 0.9999450445175171
areas O O 0.9999839067459106
of O O 0.9999392032623291
interstitial O O 0.9990559220314026
fibrosis O O 0.9999738931655884
in O O 0.9998775720596313
the O O 0.9999712705612183
renal O O 0.9999171495437622
cortex O O 0.9999924898147583
. O O 0.9999676942825317

This O O 0.9999754428863525
study O O 0.9999765157699585
investigated O O 0.9999319314956665
the O O 0.999966025352478
expression O O 0.999954342842102
of O O 0.9998238682746887
nuclear O O 0.9293727874755859
factor O O 0.9778720736503601
- O O 0.979550838470459
kappaB O O 0.8581629395484924
( O O 0.9995991587638855
NF O O 0.8613541126251221
- O O 0.967221200466156
kappaB O O 0.881787896156311
) O O 0.9998975992202759
, O O 0.9993245601654053
mitogen O O 0.9220597147941589
- O O 0.990502119064331
activated O O 0.9724376797676086
protein O O 0.9856018424034119
( O O 0.977897584438324
MAP O O 0.800888180732727
) O O 0.9698581695556641
kinases O O 0.9778339862823486
and O O 0.9995916485786438
macrophages O O 0.9994044303894043
in O O 0.9995222091674805
the O O 0.9999514818191528
renal O O 0.9999213218688965
cortex O O 0.9999865293502808
and O O 0.9999297857284546
structural O O 0.9999774694442749
and O O 0.9999474287033081
functional O O 0.9999648332595825
renal O O 0.9999679327011108
changes O O 0.9999979734420776
of O O 0.9999566078186035
rats O O 0.9983760118484497
treated O O 0.9999490976333618
with O O 0.9996637105941772
gentamicin B B 0.9998273849487305
or O O 0.9968493580818176
gentamicin B B 0.9998452663421631
+ O O 0.9608723521232605
pyrrolidine B B 0.9892683625221252
dithiocarbamate I I 0.9997261166572571
( O O 0.9858071804046631
PDTC B B 0.997553288936615
) O O 0.9821427464485168
, O O 0.9997871518135071
an O O 0.9969526529312134
NF O O 0.6967516541481018
- O O 0.9469103813171387
kappaB O O 0.8705762624740601
inhibitor O O 0.9333664774894714
. O O 0.9999102354049683

METHODS O O 0.9997867941856384
: O O 0.9999958276748657
38 O O 0.999997615814209
female O O 0.9999974966049194
Wistar O O 0.9998667240142822
rats O O 0.999983549118042
were O O 0.9999854564666748
injected O O 0.9999891519546509
with O O 0.9999297857284546
gentamicin B B 0.9997088313102722
, O O 0.9996827840805054
40 O O 0.9999575614929199
mg O O 0.9999855756759644
/ O O 0.9999860525131226
kg O O 0.9999961853027344
, O O 0.999980092048645
twice O O 0.9999573230743408
a O O 0.9999912977218628
day O O 0.9999923706054688
for O O 0.9999825954437256
9 O O 0.999977707862854
days O O 0.999997615814209
, O O 0.9999861717224121
38 O O 0.9999592304229736
with O O 0.9998722076416016
gentamicin B B 0.9995342493057251
+ O O 0.9933125376701355
PDTC B B 0.976597785949707
, O O 0.997232973575592
and O O 0.9999402761459351
28 O O 0.9998778104782104
with O O 0.9999430179595947
0 O O 0.9993036985397339
. O O 0.9999874830245972
15 O O 0.9999884366989136
M O O 0.9992955923080444
NaCl B B 0.9921877384185791
solution O O 0.9993866682052612
. O O 0.9999659061431885

The O O 0.9999834299087524
animals O O 0.9999966621398926
were O O 0.9999935626983643
killed O O 0.9999922513961792
5 O O 0.9999402761459351
and O O 0.9999890327453613
30 O O 0.9999902248382568
days O O 0.9999974966049194
after O O 0.9999731779098511
these O O 0.9998960494995117
injections O O 0.9998539686203003
and O O 0.9999911785125732
the O O 0.9999895095825195
kidneys O O 0.9999459981918335
were O O 0.9999772310256958
removed O O 0.9999885559082031
for O O 0.9999723434448242
histological O O 0.9999599456787109
and O O 0.9999313354492188
immunohistochemical O O 0.9999126195907593
studies O O 0.9999938011169434
. O O 0.9999767541885376

The O O 0.9999887943267822
results O O 0.9999958276748657
of O O 0.9999837875366211
the O O 0.9999736547470093
immunohistochemical O O 0.9999091625213623
studies O O 0.9999761581420898
were O O 0.9999791383743286
scored O O 0.9999966621398926
according O O 0.9999949932098389
to O O 0.9999929666519165
the O O 0.9999949932098389
extent O O 0.9999885559082031
of O O 0.999976634979248
staining O O 0.9999253749847412
. O O 0.9999715089797974

The O O 0.9999634027481079
fractional O O 0.9999810457229614
interstitial O O 0.9998471736907959
area O O 0.9997149109840393
was O O 0.9999860525131226
determined O O 0.9999960660934448
by O O 0.9999778270721436
morphometry O O 0.9999597072601318
. O O 0.9999761581420898

RESULTS O O 0.9997149109840393
: O O 0.9995779395103455
Gentamicin B B 0.9998397827148438
- O O 0.9991366267204285
treated O O 0.9998419284820557
rats O O 0.9999668598175049
presented O O 0.9999747276306152
a O O 0.999988317489624
transitory O O 0.9999949932098389
increase O O 0.9999945163726807
in O O 0.9999849796295166
plasma O O 0.999853253364563
creatinine B B 0.998609185218811
levels O O 0.999881386756897
. O O 0.9999775886535645

Increased O O 0.9361612796783447
ED O O 0.9176355004310608
- O O 0.9939892292022705
1 O O 0.9807482957839966
, O O 0.9932166934013367
MAP O O 0.5513275861740112
kinases O O 0.8205742239952087
and O O 0.9995829463005066
NF O O 0.8134064674377441
- O O 0.950129508972168
kappaB O O 0.8407477736473083
staining O O 0.9998952150344849
were O O 0.9999666213989258
also O O 0.9999715089797974
observed O O 0.9999872446060181
in O O 0.9996347427368164
the O O 0.9999527931213379
renal O O 0.9999148845672607
cortex O O 0.9999871253967285
from O O 0.9998255372047424
all O O 0.999612033367157
gentamicin B B 0.9998270869255066
- O O 0.9995373487472534
treated O O 0.9997609257698059
rats O O 0.9999858140945435
compared O O 0.9999780654907227
to O O 0.9999161958694458
control O O 0.999908447265625
( O O 0.9999678134918213
p O O 0.9999703168869019
< O O 0.999982476234436
0 O O 0.9999939203262329
. O O 0.9999969005584717
05 O O 0.9999958276748657
) O O 0.9999849796295166
. O O 0.9999834299087524

The O O 0.9999871253967285
animals O O 0.9999822378158569
killed O O 0.9999731779098511
on O O 0.9999916553497314
day O O 0.9999922513961792
30 O O 0.9999749660491943
also O O 0.999970555305481
presented O O 0.9999290704727173
fibrosis O O 0.9999632835388184
in O O 0.9999117851257324
the O O 0.9999765157699585
renal O O 0.9999027252197266
cortex O O 0.9999876022338867
despite O O 0.9998557567596436
the O O 0.9999935626983643
recovery O O 0.9999926090240479
of O O 0.9999744892120361
renal O O 0.9999262094497681
function O O 0.9999808073043823
. O O 0.9999687671661377

Treatment O O 0.999915599822998
with O O 0.999388575553894
PDTC B B 0.9268071055412292
reduced O O 0.9997114539146423
the O O 0.9999574422836304
functional O O 0.9999669790267944
and O O 0.9999548196792603
structural O O 0.9999902248382568
changes O O 0.9999961853027344
induced O O 0.9999929666519165
by O O 0.9998973608016968
gentamicin B B 0.9997805953025818
. O O 0.9998906850814819

CONCLUSIONS O O 0.9735792279243469
: O O 0.9999898672103882
These O O 0.9999855756759644
data O O 0.999982476234436
show O O 0.9998904466629028
that O O 0.9998328685760498
inhibition O O 0.9996744394302368
of O O 0.9977558255195618
NF O O 0.8154739141464233
- O O 0.9513282775878906
kappaB O O 0.8922110199928284
activation O O 0.9986605644226074
attenuates O O 0.9998892545700073
tubulointerstitial O O 0.999948263168335
nephritis O O 0.9998284578323364
induced O O 0.9999725818634033
by O O 0.9998805522918701
gentamicin B B 0.9997314810752869
. O O 0.9999520778656006

Glucose B O 0.518456757068634
metabolism O O 0.9996811151504517
in O O 0.9999133348464966
patients O O 0.9999853372573853
with O O 0.9999735355377197
schizophrenia O O 0.9866691827774048
treated O O 0.9999473094940186
with O O 0.9998749494552612
atypical O O 0.9788936972618103
antipsychotic O O 0.47649696469306946
agents O O 0.8290533423423767
: O O 0.9999426603317261
a O O 0.999976634979248
frequently O O 0.9999778270721436
sampled O O 0.9999841451644897
intravenous O O 0.9999685287475586
glucose B B 0.937543511390686
tolerance O O 0.9953687191009521
test O O 0.9999793767929077
and O O 0.9999732971191406
minimal O O 0.9999089241027832
model O O 0.999829888343811
analysis O O 0.9998530149459839
. O O 0.9999812841415405

BACKGROUND O O 0.9996424913406372
: O O 0.9999837875366211
While O O 0.9999927282333374
the O O 0.9999959468841553
incidence O O 0.9999980926513672
of O O 0.9999889135360718
new O O 0.9999886751174927
- O O 0.9999929666519165
onset O O 0.9999959468841553
diabetes O O 0.9992424249649048
mellitus O O 0.9999971389770508
may O O 0.9999744892120361
be O O 0.9999812841415405
increasing O O 0.9999808073043823
in O O 0.9999428987503052
patients O O 0.9999886751174927
with O O 0.9999608993530273
schizophrenia O O 0.9251428842544556
treated O O 0.999916672706604
with O O 0.9998981952667236
certain O O 0.9993411898612976
atypical O O 0.8799188733100891
antipsychotic O O 0.5050322413444519
agents O O 0.6587777137756348
, O O 0.9999130964279175
it O O 0.9999929666519165
remains O O 0.9999938011169434
unclear O O 0.9999927282333374
whether O O 0.9999713897705078
atypical O O 0.9380477070808411
agents O O 0.9912630319595337
are O O 0.9998955726623535
directly O O 0.9999473094940186
affecting O O 0.9998971223831177
glucose B O 0.6754987239837646
metabolism O O 0.9998036026954651
or O O 0.9999231100082397
simply O O 0.9999709129333496
increasing O O 0.9998936653137207
known O O 0.9999706745147705
risk O O 0.999984860420227
factors O O 0.999997615814209
for O O 0.9999822378158569
diabetes O O 0.9995373487472534
. O O 0.9999748468399048

OBJECTIVE O O 0.9999594688415527
: O O 0.9999942779541016
To O O 0.9999911785125732
study O O 0.9999016523361206
the O O 0.9998526573181152
2 O O 0.9988487958908081
drugs O O 0.998994767665863
most O O 0.9999556541442871
clearly O O 0.9999829530715942
implicated O O 0.9999366998672485
( O O 0.9980859756469727
clozapine B B 0.998984158039093
and O O 0.8698815703392029
olanzapine B B 0.997681736946106
) O O 0.998228132724762
and O O 0.9978700876235962
risperidone B B 0.9976951479911804
using O O 0.9999600648880005
a O O 0.9999904632568359
frequently O O 0.9999867677688599
sampled O O 0.9999918937683105
intravenous O O 0.9999701976776123
glucose B O 0.8439735174179077
tolerance O O 0.9983795881271362
test O O 0.9999841451644897
. O O 0.999984622001648

DESIGN O O 0.9999902248382568
: O O 0.9999955892562866
A O O 0.9999932050704956
cross O O 0.9999778270721436
- O O 0.9999901056289673
sectional O O 0.9999985694885254
design O O 0.9999971389770508
in O O 0.9999816417694092
stable O O 0.999974250793457
, O O 0.9999675750732422
treated O O 0.9997360110282898
patients O O 0.9999951124191284
with O O 0.9999803304672241
schizophrenia O O 0.9975398778915405
evaluated O O 0.9999890327453613
using O O 0.9999819993972778
a O O 0.999984622001648
frequently O O 0.9999904632568359
sampled O O 0.9999945163726807
intravenous O O 0.9999217987060547
glucose B B 0.935845136642456
tolerance O O 0.9972774386405945
test O O 0.9999872446060181
and O O 0.9999818801879883
the O O 0.9999682903289795
Bergman O O 0.9969243407249451
minimal O O 0.9985601305961609
model O O 0.9999943971633911
analysis O O 0.999971866607666
. O O 0.999982476234436

SETTING O O 0.9999057054519653
: O O 0.9999842643737793
Subjects O O 0.9999933242797852
were O O 0.9999940395355225
recruited O O 0.9999939203262329
from O O 0.9999885559082031
an O O 0.999987006187439
urban O O 0.9996176958084106
community O O 0.9999252557754517
mental O O 0.9997952580451965
health O O 0.9996744394302368
clinic O O 0.9999912977218628
and O O 0.9999337196350098
were O O 0.9999879598617554
studied O O 0.9999896287918091
at O O 0.9999644756317139
a O O 0.9999841451644897
general O O 0.9999282360076904
clinical O O 0.999992847442627
research O O 0.9999970197677612
center O O 0.9999964237213135
. O O 0.9999785423278809

Patients O O 0.9999771118164062
Fifty O O 0.9998997449874878
subjects O O 0.9999951124191284
signed O O 0.999993085861206
informed O O 0.9999969005584717
consent O O 0.9999991655349731
and O O 0.9999876022338867
41 O O 0.9999228715896606
underwent O O 0.9999932050704956
the O O 0.9999903440475464
frequently O O 0.9999761581420898
sampled O O 0.999993085861206
intravenous O O 0.9999042749404907
glucose B B 0.9528577327728271
tolerance O O 0.9951066970825195
test O O 0.9999891519546509
. O O 0.9999754428863525

Thirty O O 0.9845240712165833
- O O 0.9998902082443237
six O O 0.9999921321868896
nonobese O O 0.998390793800354
subjects O O 0.9999828338623047
with O O 0.9999728202819824
schizophrenia O O 0.99681156873703
or O O 0.9999210834503174
schizoaffective O O 0.9984945058822632
disorder O O 0.9999910593032837
, O O 0.9999791383743286
matched O O 0.9999865293502808
by O O 0.9999876022338867
body O O 0.9999644756317139
mass O O 0.9997068047523499
index O O 0.9999724626541138
and O O 0.9999809265136719
treated O O 0.9999632835388184
with O O 0.9998145699501038
either O O 0.9995854496955872
clozapine B B 0.9989057779312134
, O O 0.6601123213768005
olanzapine B B 0.9959229230880737
, O O 0.8721495270729065
or O O 0.9937729239463806
risperidone B B 0.9931401610374451
, O O 0.999627947807312
were O O 0.9999687671661377
included O O 0.9999916553497314
in O O 0.999984622001648
the O O 0.9999942779541016
analysis O O 0.9999966621398926
. O O 0.9999830722808838

MAIN O O 0.9998881816864014
OUTCOME O O 0.9999852180480957
MEASURES O O 0.9999942779541016
: O O 0.9999679327011108
Fasting O O 0.9999605417251587
plasma O O 0.9970229268074036
glucose B B 0.9884108304977417
and O O 0.999736487865448
fasting O O 0.9998780488967896
serum O O 0.9515702128410339
insulin O B 0.9914644360542297
levels O O 0.9997816681861877
, O O 0.9999641180038452
insulin O O 0.6391541957855225
sensitivity O O 0.9996706247329712
index O O 0.9999867677688599
, O O 0.9999634027481079
homeostasis O O 0.9998443126678467
model O O 0.999982476234436
assessment O O 0.9999746084213257
of O O 0.9998960494995117
insulin O O 0.4711112976074219
resistance O O 0.9998589754104614
, O O 0.9999198913574219
and O O 0.9998974800109863
glucose B B 0.9422494173049927
effectiveness O O 0.9996726512908936
. O O 0.9999769926071167

RESULTS O O 0.9998464584350586
: O O 0.9999697208404541
The O O 0.9999927282333374
mean O O 0.9999802112579346
+ O O 0.9999949932098389
/ O O 0.9999719858169556
- O O 0.9999712705612183
SD O O 0.9990023970603943
duration O O 0.9999793767929077
of O O 0.999945878982544
treatment O O 0.9999892711639404
with O O 0.9999209642410278
the O O 0.9997491240501404
identified O O 0.9978222846984863
atypical O O 0.9779694080352783
antipsychotic O O 0.4799651503562927
agent O O 0.5523961782455444
was O O 0.999829888343811
68 O O 0.9999977350234985
. O O 0.9999908208847046
3 O O 0.9999920129776001
+ O O 0.9999927282333374
/ O O 0.9999856948852539
- O O 0.9999500513076782
28 O O 0.9999949932098389
. O O 0.9999923706054688
9 O O 0.9999908208847046
months O O 0.9999964237213135
( O O 0.996131181716919
clozapine B B 0.9994660019874573
) O O 0.9978898167610168
, O O 0.9999290704727173
29 O O 0.9999878406524658
. O O 0.9999933242797852
5 O O 0.9999868869781494
+ O O 0.9999924898147583
/ O O 0.9999880790710449
- O O 0.9999493360519409
17 O O 0.9999960660934448
. O O 0.9999959468841553
5 O O 0.9999946355819702
months O O 0.9999988079071045
( O O 0.9983229041099548
olanzapine B B 0.9995811581611633
) O O 0.9986628293991089
, O O 0.9999412298202515
and O O 0.9998759031295776
40 O O 0.9999645948410034
. O O 0.9999939203262329
9 O O 0.9999959468841553
+ O O 0.9999959468841553
/ O O 0.9999794960021973
- O O 0.9999425411224365
33 O O 0.9999972581863403
. O O 0.9999955892562866
7 O O 0.9999918937683105
( O O 0.9957876801490784
risperidone B B 0.9967314004898071
) O O 0.9997221827507019
. O O 0.9999758005142212

Fasting O O 0.9998785257339478
serum O O 0.976385235786438
insulin O B 0.988965630531311
concentrations O O 0.9973379969596863
differed O O 0.9999018907546997
among O O 0.8854407668113708
groups O O 0.9997867941856384
( O O 0.9998805522918701
F O O 0.9998742341995239
( O O 0.9981372356414795
33 O O 0.9993705153465271
) O O 0.99991774559021
= O O 0.999870777130127
3 O O 0.9988963603973389
. O O 0.9999769926071167
35 O O 0.9999887943267822
; O O 0.9999829530715942
P O O 0.9999629259109497
= O O 0.9999507665634155
. O O 0.9999977350234985
047 O O 0.9989921450614929
) O O 0.9999593496322632
( O O 0.9976683259010315
clozapine B B 0.9992477893829346
> O O 0.7643213272094727
olanzapine B B 0.9881200790405273
> O O 0.772224485874176
risperidone B B 0.5914409160614014
) O O 0.9997848868370056
with O O 0.9999680519104004
significant O O 0.999981164932251
differences O O 0.999993085861206
between O O 0.9991735816001892
clozapine B B 0.9998565912246704
and O O 0.9937468767166138
risperidone B B 0.9836041331291199
( O O 0.9999041557312012
t O O 0.9997846484184265
( O O 0.9981820583343506
33 O O 0.9995434880256653
) O O 0.999968409538269
= O O 0.9999470710754395
2 O O 0.999943733215332
. O O 0.9999938011169434
32 O O 0.9999933242797852
; O O 0.9999816417694092
P O O 0.9999699592590332
= O O 0.9999556541442871
. O O 0.9999983310699463
03 O O 0.9999874830245972
) O O 0.9999681711196899
and O O 0.9991114735603333
olanzapine B B 0.9997754693031311
and O O 0.97654128074646
risperidone B B 0.9890754222869873
( O O 0.9998633861541748
t O O 0.999763548374176
( O O 0.9987963438034058
33 O O 0.9993836879730225
) O O 0.99996018409729
= O O 0.9999651908874512
2 O O 0.9998871088027954
. O O 0.9999908208847046
15 O O 0.9999983310699463
; O O 0.9999803304672241
P O O 0.9995833039283752
= O O 0.9998843669891357
. O O 0.9999979734420776
04 O O 0.9999818801879883
) O O 0.9999802112579346
. O O 0.9999614953994751

There O O 0.9999707937240601
was O O 0.9999583959579468
a O O 0.9999880790710449
significant O O 0.9999881982803345
difference O O 0.999995231628418
in O O 0.9999781847000122
insulin O O 0.6284220218658447
sensitivity O O 0.999242901802063
index O O 0.9998947381973267
among O O 0.9195171594619751
groups O O 0.9999477863311768
( O O 0.9998750686645508
F O O 0.9993680119514465
( O O 0.9956247210502625
33 O O 0.9942366480827332
) O O 0.9995686411857605
= O O 0.9993500113487244
10 O O 0.9999529123306274
. O O 0.9999918937683105
66 O O 0.9999954700469971
; O O 0.9999841451644897
P O O 0.9999240636825562
< O O 0.9999710321426392
. O O 0.9999971389770508
001 O O 0.9999133348464966
) O O 0.9998507499694824
( O O 0.998030960559845
clozapine B B 0.9991218447685242
< O O 0.839139461517334
olanzapine B B 0.9895381927490234
< O I 0.8325031399726868
risperidone B I 0.6750518679618835
) O O 0.9995755553245544
, O O 0.9999865293502808
with O O 0.9999822378158569
subjects O O 0.9997596144676208
who O O 0.9999278783798218
received O O 0.999839186668396
clozapine B B 0.9997861981391907
and O O 0.9479730725288391
olanzapine B B 0.9994088411331177
exhibiting O O 0.9998571872711182
significant O O 0.9999657869338989
insulin O O 0.9823827147483826
resistance O O 0.9999847412109375
compared O O 0.9999879598617554
with O O 0.9999879598617554
subjects O O 0.9999537467956543
who O O 0.9999455213546753
were O O 0.9999830722808838
treated O O 0.9999797344207764
with O O 0.999897837638855
risperidone B B 0.9607377648353577
( O O 0.9972811937332153
clozapine B B 0.9994300007820129
vs O O 0.9770068526268005
risperidone B B 0.7238703966140747
, O O 0.9970467686653137
t O O 0.999789297580719
( O O 0.9974833130836487
33 O O 0.9992434978485107
) O O 0.9999270439147949
= O O 0.999444305896759
- O O 0.9990221261978149
4 O O 0.9999586343765259
. O O 0.9999978542327881
29 O O 0.9999978542327881
; O O 0.9999887943267822
P O O 0.9999297857284546
< O O 0.9999852180480957
. O O 0.9999984502792358
001 O O 0.9999881982803345
; O O 0.9999066591262817
olanzapine B B 0.9973871111869812
vs O O 0.9634373784065247
risperidone B B 0.5268121361732483
, O O 0.9758460521697998
t O O 0.9963750243186951
( O O 0.9942184686660767
33 O O 0.9976430535316467
) O O 0.9998956918716431
= O O 0.9973927736282349
- O O 0.998591959476471
3 O O 0.9999915361404419
. O O 0.9999955892562866
62 O O 0.9999974966049194
; O O 0.9999890327453613
P O O 0.999962329864502
= O O 0.9999825954437256
. O O 0.9999983310699463
001 O O 0.9999346733093262
[ O O 0.9997597336769104
P O O 0.9967120885848999
< O O 0.9999711513519287
. O O 0.9999980926513672
001 O O 0.9989983439445496
] O O 0.9998842477798462
) O O 0.9999761581420898
. O O 0.9999737739562988

The O O 0.9999516010284424
homeostasis O O 0.9995156526565552
model O O 0.999767005443573
assessment O O 0.9999052286148071
of O O 0.9998674392700195
insulin O O 0.7444865703582764
resistance O O 0.9993973970413208
also O O 0.9999423027038574
differed O O 0.9999619722366333
significantly O O 0.9999831914901733
among O O 0.9988642930984497
groups O O 0.9999606609344482
( O O 0.9998579025268555
F O O 0.9998468160629272
( O O 0.9980055689811707
33 O O 0.9981980919837952
) O O 0.9998805522918701
= O O 0.9997603297233582
4 O O 0.9999114274978638
. O O 0.9999884366989136
92 O O 0.9998681545257568
; O O 0.9999781847000122
P O O 0.9999167919158936
= O O 0.9998844861984253
. O O 0.9999949932098389
01 O O 0.9999945163726807
) O O 0.9998955726623535
( O O 0.9971768856048584
clozapine B B 0.9994441866874695
> O O 0.6750386953353882
olanzapine B B 0.9887836575508118
> O I 0.7036741971969604
risperidone B I 0.7011990547180176
) O O 0.9992037415504456
( O O 0.9989674091339111
clozapine B B 0.9996691942214966
vs O O 0.9758373498916626
risperidone B B 0.8805374503135681
, O O 0.9985975623130798
t O O 0.9998338222503662
( O O 0.997873067855835
33 O O 0.9998290538787842
) O O 0.9999673366546631
= O O 0.9999465942382812
2 O O 0.9999929666519165
. O O 0.9999939203262329
94 O O 0.9998067021369934
; O O 0.999991774559021
P O O 0.9999771118164062
= O O 0.9999808073043823
. O O 0.9999984502792358
006 O O 0.9999974966049194
; O O 0.9999102354049683
olanzapine B B 0.9984476566314697
vs O O 0.9582247734069824
risperidone B B 0.7982227206230164
, O O 0.9984068274497986
t O O 0.9997965693473816
( O O 0.9975651502609253
33 O O 0.998711109161377
) O O 0.9999361038208008
= O O 0.9999470710754395
2 O O 0.9999802112579346
. O O 0.9999936819076538
42 O O 0.9999963045120239
; O O 0.9999864101409912
P O O 0.9991154074668884
= O O 0.9999223947525024
. O O 0.9999974966049194
02 O O 0.9999872446060181
) O O 0.9999756813049316
. O O 0.9999749660491943

There O O 0.9999580383300781
was O O 0.9999483823776245
a O O 0.9999728202819824
significant O O 0.99996018409729
difference O O 0.9999889135360718
among O O 0.9996201992034912
groups O O 0.9999631643295288
in O O 0.999618411064148
glucose B B 0.9662739634513855
effectiveness O O 0.9899395108222961
( O O 0.9999262094497681
F O O 0.9996929168701172
( O O 0.9980494976043701
30 O O 0.9970880150794983
) O O 0.9999455213546753
= O O 0.9994800686836243
4 O O 0.9988718628883362
. O O 0.9999858140945435
18 O O 0.9999954700469971
; O O 0.9999781847000122
P O O 0.999901294708252
= O O 0.9995142221450806
. O O 0.9999959468841553
02 O O 0.9977027773857117
) O O 0.999915361404419
( O O 0.9983468055725098
clozapine B B 0.9994109869003296
< O O 0.8406893610954285
olanzapine B B 0.9935063123703003
< O O 0.8141449093818665
risperidone B B 0.7451539635658264
) O O 0.9998670816421509
with O O 0.9999712705612183
significant O O 0.9999802112579346
differences O O 0.9999905824661255
between O O 0.9989657402038574
clozapine B B 0.9998881816864014
and O O 0.9950514435768127
risperidone B B 0.9835271239280701
( O O 0.999909520149231
t O O 0.9996933937072754
( O O 0.9992153644561768
30 O O 0.9998726844787598
) O O 0.999974250793457
= O O 0.999840497970581
- O O 0.9997392296791077
2 O O 0.9999611377716064
. O O 0.9999959468841553
59 O O 0.9999978542327881
; O O 0.9999864101409912
P O O 0.9999696016311646
= O O 0.9999164342880249
. O O 0.9999982118606567
02 O O 0.999954342842102
) O O 0.9999628067016602
and O O 0.9989815354347229
olanzapine B B 0.9998257756233215
and O O 0.982459545135498
risperidone B B 0.9881234765052795
( O O 0.9998660087585449
t O O 0.9995294809341431
( O O 0.999352753162384
30 O O 0.9995893836021423
) O O 0.9999737739562988
= O O 0.9994900226593018
- O O 0.9996949434280396
2 O O 0.999755322933197
. O O 0.9999942779541016
34 O O 0.9999971389770508
, O O 0.9999833106994629
P O O 0.9995977282524109
= O O 0.9999090433120728
. O O 0.9999977350234985
03 O O 0.999954342842102
) O O 0.9999773502349854
. O O 0.9999531507492065

CONCLUSIONS O O 0.999161958694458
: O O 0.9999613761901855
Both O O 0.9999284744262695
nonobese O O 0.8561002612113953
clozapine B B 0.9996960163116455
- O O 0.9985217452049255
and O O 0.9990000128746033
olanzapine B B 0.999810516834259
- O O 0.9997933506965637
treated O O 0.9999085664749146
groups O O 0.9999783039093018
displayed O O 0.9999573230743408
significant O O 0.9999704360961914
insulin O O 0.8880059123039246
resistance O O 0.999976634979248
and O O 0.9999573230743408
impairment O O 0.9999949932098389
of O O 0.999935507774353
glucose B B 0.9409433603286743
effectiveness O O 0.9994198083877563
compared O O 0.9999786615371704
with O O 0.999962329864502
risperidone B B 0.9989492297172546
- O O 0.999704897403717
treated O O 0.999894380569458
subjects O O 0.9999750852584839
. O O 0.9999703168869019

Patients O O 0.999925971031189
taking O O 0.998860239982605
clozapine B B 0.9995667338371277
and O O 0.9808496832847595
olanzapine B B 0.9992623925209045
must O O 0.9998056292533875
be O O 0.9999889135360718
examined O O 0.999942421913147
for O O 0.9999256134033203
insulin O O 0.6477972269058228
resistance O O 0.9996916055679321
and O O 0.9999688863754272
its O O 0.9999799728393555
consequences O O 0.9999955892562866
. O O 0.9999840259552002

Thoracic O O 0.9998053908348083
hematomyelia O O 0.9999576807022095
secondary O O 0.9999475479125977
to O O 0.9988961219787598
coumadin B B 0.987794041633606
anticoagulant O O 0.6591020226478577
therapy O O 0.9989560842514038
: O O 0.9999864101409912
a O O 0.9999964237213135
case O O 0.9999885559082031
report O O 0.9999960660934448
. O O 0.9999843835830688

A O O 0.9999443292617798
case O O 0.9999891519546509
of O O 0.9999791383743286
thoracic O O 0.9997984766960144
hematomyelia O O 0.9999403953552246
secondary O O 0.9999607801437378
to O O 0.9975415468215942
anticoagulant O O 0.6844161152839661
therapy O O 0.9943242073059082
is O O 0.9999250173568726
presented O O 0.9999864101409912
. O O 0.9999645948410034

Clinical O O 0.999914288520813
features O O 0.9999943971633911
, O O 0.9999868869781494
similar O O 0.9999933242797852
to O O 0.9999887943267822
2 O O 0.9999539852142334
other O O 0.9999876022338867
previously O O 0.9999792575836182
reported O O 0.9999969005584717
cases O O 0.9999908208847046
, O O 0.9999830722808838
are O O 0.9999849796295166
discussed O O 0.9999897480010986
. O O 0.9999799728393555

A O O 0.9999442100524902
high O O 0.9999607801437378
index O O 0.9999942779541016
of O O 0.9999779462814331
suspicion O O 0.9999749660491943
may O O 0.9999414682388306
lead O O 0.999991774559021
to O O 0.9999896287918091
a O O 0.9999892711639404
quick O O 0.9999767541885376
diagnostic O O 0.9999960660934448
procedure O O 0.9999979734420776
and O O 0.9999892711639404
successful O O 0.9999700784683228
decompressive O O 0.9998630285263062
surgery O O 0.9999942779541016
. O O 0.9999772310256958

Mania O O 0.9991618394851685
associated O O 0.9999786615371704
with O O 0.9998632669448853
fluoxetine B B 0.9993686079978943
treatment O O 0.9988780617713928
in O O 0.9999250173568726
adolescents O O 0.9999146461486816
. O O 0.9999270439147949

Fluoxetine B B 0.9987469911575317
, O O 0.9998379945755005
a O O 0.9979666471481323
selective O O 0.7462843656539917
serotonin B B 0.8181435465812683
reuptake O O 0.7547741532325745
inhibitor O O 0.8335316181182861
, O O 0.9993719458580017
is O O 0.9997085928916931
gaining O O 0.9999927282333374
increased O O 0.9999845027923584
acceptance O O 0.999880313873291
in O O 0.999862790107727
the O O 0.9998544454574585
treatment O O 0.9999043941497803
of O O 0.9999454021453857
adolescent O O 0.9858031272888184
depression O O 0.9997172951698303
. O O 0.9998154044151306

Generally O O 0.9999454021453857
safe O O 0.9999886751174927
and O O 0.9999947547912598
well O O 0.999976396560669
tolerated O O 0.9999892711639404
by O O 0.9999642372131348
adults O O 0.995729386806488
, O O 0.9996275901794434
fluoxetine B B 0.999729335308075
has O O 0.9997594952583313
been O O 0.9999728202819824
reported O O 0.9999692440032959
to O O 0.9999175071716309
induce O O 0.9999234676361084
mania O O 0.999721109867096
. O O 0.9999339580535889

The O O 0.9999806880950928
cases O O 0.9999837875366211
of O O 0.9999628067016602
five O O 0.9998897314071655
depressed O O 0.9998987913131714
adolescents O O 0.9999172687530518
, O O 0.9999864101409912
14 O O 0.9999889135360718
- O O 0.9992051720619202
16 O O 0.9999963045120239
years O O 0.9999983310699463
of O O 0.9999961853027344
age O O 0.9999830722808838
, O O 0.999985933303833
who O O 0.9999223947525024
developed O O 0.999984622001648
mania O O 0.9995347261428833
during O O 0.9997082352638245
pharmacotherapy O O 0.9955354928970337
with O O 0.9995989203453064
fluoxetine B B 0.9967976212501526
, O O 0.9977839589118958
are O O 0.9999806880950928
reported O O 0.999993085861206
here O O 0.999983549118042
. O O 0.9999746084213257

Apparent O O 0.9987905621528625
risk O O 0.9999138116836548
factors O O 0.9999918937683105
for O O 0.9999829530715942
the O O 0.9999932050704956
development O O 0.9999963045120239
of O O 0.9999808073043823
mania O O 0.9999792575836182
or O O 0.99996018409729
hypomania O O 0.9998445510864258
during O O 0.9992140531539917
fluoxetine B B 0.9995112419128418
pharmacotherapy O O 0.9369696974754333
in O O 0.9999690055847168
this O O 0.9999797344207764
population O O 0.9999873638153076
were O O 0.9999756813049316
the O O 0.9999895095825195
combination O O 0.9998908042907715
of O O 0.999915599822998
attention O O 0.9970577955245972
- O O 0.9999121427536011
deficit O O 0.9977134466171265
hyperactivity O O 0.995161235332489
disorder O O 0.999967098236084
and O O 0.9998714923858643
affective O O 0.9982157945632935
instability O O 0.999890923500061
; O O 0.9999657869338989
major O O 0.9999845027923584
depression O O 0.99991774559021
with O O 0.9999555349349976
psychotic O O 0.9998206496238708
features O O 0.9999964237213135
; O O 0.9999775886535645
a O O 0.9999914169311523
family O O 0.9999896287918091
history O O 0.9999884366989136
of O O 0.9998726844787598
affective O O 0.997443675994873
disorder O O 0.9999574422836304
, O O 0.9999861717224121
especially O O 0.9997847676277161
bipolar O O 0.9501628875732422
disorder O O 0.9986469149589539
; O O 0.999936580657959
and O O 0.9999605417251587
a O O 0.9999891519546509
diagnosis O O 0.9999972581863403
of O O 0.9999457597732544
bipolar O O 0.8418520092964172
disorder O O 0.9991157650947571
. O O 0.9999711513519287

Further O O 0.9999634027481079
study O O 0.9999880790710449
is O O 0.9999794960021973
needed O O 0.9999865293502808
to O O 0.9999953508377075
determine O O 0.9999911785125732
the O O 0.9999924898147583
optimal O O 0.9999500513076782
dosage O O 0.9998223185539246
and O O 0.9999837875366211
to O O 0.9999905824661255
identify O O 0.9999663829803467
risk O O 0.9998370409011841
factors O O 0.9999886751174927
that O O 0.9999673366546631
increase O O 0.999893307685852
individual O O 0.9999849796295166
vulnerability O O 0.9999969005584717
to O O 0.9999324083328247
fluoxetine B B 0.9995911717414856
induced O O 0.9997398257255554
mania O O 0.9996874332427979
in O O 0.9999141693115234
adolescents O O 0.9999587535858154
. O O 0.9999803304672241

Acute O O 0.9999821186065674
renal O O 0.9999755620956421
insufficiency O O 0.9999954700469971
after O O 0.9998655319213867
high O O 0.9919867515563965
- O O 0.9999344348907471
dose O O 0.9919431209564209
melphalan B B 0.9987285733222961
in O O 0.9998470544815063
patients O O 0.9999947547912598
with O O 0.9999852180480957
primary O O 0.9999582767486572
systemic O O 0.998528003692627
amyloidosis O O 0.5049259662628174
during O O 0.9998613595962524
stem O O 0.9999854564666748
cell O O 0.9997841715812683
transplantation O O 0.9999765157699585
. O O 0.9999744892120361

BACKGROUND O O 0.9978324770927429
: O O 0.9999785423278809
Patients O O 0.9999877214431763
with O O 0.9999618530273438
primary O O 0.9996041655540466
systemic O O 0.9567520618438721
amyloidosis O O 0.8120843768119812
( O O 0.9954751133918762
AL O O 0.8034251928329468
) O O 0.9989416003227234
have O O 0.9999747276306152
a O O 0.9999887943267822
poor O O 0.9999926090240479
prognosis O O 0.9999960660934448
. O O 0.999975323677063

Median O O 0.9999605417251587
survival O O 0.999972939491272
time O O 0.9999960660934448
from O O 0.9999566078186035
standard O O 0.9980535507202148
treatments O O 0.9999696016311646
is O O 0.9999867677688599
only O O 0.9999974966049194
17 O O 0.9999982118606567
months O O 0.999998927116394
. O O 0.9999834299087524

High O O 0.999279797077179
- O O 0.9999573230743408
dose O O 0.9992126226425171
intravenous O O 0.9954395890235901
melphalan B B 0.9987326264381409
followed O O 0.9981780052185059
by O O 0.9998642206192017
peripheral O O 0.9999188184738159
blood O O 0.9997901320457458
stem O O 0.9998243451118469
cell O O 0.9994096755981445
transplant O O 0.9998980760574341
( O O 0.9997448325157166
PBSCT O O 0.7689079642295837
) O O 0.9998964071273804
appears O O 0.9999624490737915
to O O 0.9999775886535645
be O O 0.999987006187439
the O O 0.9999912977218628
most O O 0.9999916553497314
promising O O 0.9999861717224121
therapy O O 0.9999802112579346
, O O 0.9999632835388184
but O O 0.9999871253967285
treatment O O 0.9999743700027466
mortality O O 0.9999969005584717
can O O 0.9999690055847168
be O O 0.999993085861206
high O O 0.9999834299087524
. O O 0.9999836683273315

The O O 0.9999676942825317
authors O O 0.9999970197677612
have O O 0.9999912977218628
noted O O 0.9999946355819702
the O O 0.999994158744812
development O O 0.999995231628418
of O O 0.9999868869781494
acute O O 0.999969482421875
renal O O 0.9998534917831421
insufficiency O O 0.9999879598617554
immediately O O 0.9999823570251465
after O O 0.9999045133590698
melphalan B B 0.9995582699775696
conditioning O O 0.9992246627807617
. O O 0.9999710321426392

This O O 0.9999823570251465
study O O 0.9999873638153076
was O O 0.9999840259552002
undertaken O O 0.9999939203262329
to O O 0.9999872446060181
further O O 0.9999921321868896
examine O O 0.9999566078186035
its O O 0.9998513460159302
risk O O 0.9998225569725037
factors O O 0.9999957084655762
and O O 0.9999657869338989
impact O O 0.9999866485595703
on O O 0.999974250793457
posttransplant O O 0.9997902512550354
mortality O O 0.999995231628418
. O O 0.9999700784683228

METHODS O O 0.9999748468399048
: O O 0.9999808073043823
Consecutive O O 0.9997339844703674
AL O O 0.9032372236251831
patients O O 0.9999222755432129
who O O 0.99996018409729
underwent O O 0.999968409538269
PBSCT O O 0.9575477838516235
were O O 0.9999634027481079
studied O O 0.9999734163284302
retrospectively O O 0.9999698400497437
. O O 0.9999752044677734

Acute O O 0.9999173879623413
renal O O 0.999992847442627
insufficiency O O 0.9999964237213135
( O O 0.9999785423278809
ARI O O 0.9972710013389587
) O O 0.999990701675415
after O O 0.9999446868896484
high O O 0.9974057078361511
- O O 0.999876856803894
dose O O 0.9948216676712036
melphalan B B 0.9987269043922424
was O O 0.9999076128005981
defined O O 0.9999939203262329
by O O 0.9999954700469971
a O O 0.9999948740005493
minimum O O 0.9999901056289673
increase O O 0.9999953508377075
of O O 0.9999630451202393
0 O O 0.999967098236084
. O O 0.9999886751174927
5 O O 0.9999818801879883
mg O O 0.9999845027923584
/ O O 0.9999746084213257
dL O O 0.9999959468841553
( O O 0.9999469518661499
44 O O 0.9998525381088257
micromol O O 0.9969538450241089
/ O O 0.9999470710754395
L O O 0.999495267868042
) O O 0.9999909400939941
in O O 0.9999942779541016
the O O 0.9999959468841553
serum O O 0.999420166015625
creatinine B B 0.9982409477233887
level O O 0.9998134970664978
that O O 0.9999825954437256
is O O 0.9999861717224121
greater O O 0.9999934434890747
than O O 0.9999951124191284
50 O O 0.9999949932098389
% O O 0.9999974966049194
of O O 0.999994158744812
baseline O O 0.9999860525131226
immediately O O 0.9999856948852539
after O O 0.9999880790710449
conditioning O O 0.9997501969337463
. O O 0.9999798536300659

Urine O O 0.9992871880531311
sediment O O 0.9912860989570618
score O O 0.9998987913131714
was O O 0.9999780654907227
the O O 0.999985933303833
sum O O 0.9999138116836548
of O O 0.9999057054519653
the O O 0.9999656677246094
individual O O 0.9999316930770874
types O O 0.9999822378158569
of O O 0.9999479055404663
sediment O O 0.9998624324798584
identified O O 0.9999819993972778
on O O 0.9999940395355225
urine O O 0.9993865489959717
microscopy O O 0.9999488592147827
. O O 0.9999675750732422

RESULTS O O 0.999906063079834
: O O 0.9999802112579346
Of O O 0.9999340772628784
the O O 0.9999828338623047
80 O O 0.999930739402771
patients O O 0.9999892711639404
studied O O 0.9999736547470093
, O O 0.9999088048934937
ARI O O 0.9766079187393188
developed O O 0.9999774694442749
in O O 0.9999442100524902
18 O O 0.9999773502349854
. O O 0.9999794960021973
8 O O 0.9999918937683105
% O O 0.9999938011169434
of O O 0.9999737739562988
the O O 0.9999887943267822
patients O O 0.9999923706054688
after O O 0.9998730421066284
high O O 0.9987438321113586
- O O 0.999923586845398
dose O O 0.9940628409385681
melphalan B B 0.9993118047714233
. O O 0.999932050704956

Univariate O O 0.9993813037872314
analysis O O 0.9999703168869019
identified O O 0.9999184608459473
age O O 0.9992581009864807
, O O 0.9999247789382935
hypoalbuminemia O O 0.9792317152023315
, O O 0.9997701048851013
heavy O O 0.9940793514251709
proteinuria O O 0.9998165965080261
, O O 0.999592125415802
diuretic O O 0.48338520526885986
use O O 0.9997574687004089
, O O 0.999640703201294
and O O 0.9998668432235718
urine O O 0.9996984004974365
sediment O O 0.9530525803565979
score O O 0.9982638955116272
( O O 0.9999666213989258
> O O 0.9998112320899963
3 O O 0.9971956014633179
) O O 0.9999065399169922
as O O 0.9998279809951782
risk O O 0.99979168176651
factors O O 0.9999939203262329
. O O 0.9999642372131348

Age O O 0.9991133809089661
and O O 0.999901533126831
urine O O 0.9941447377204895
sediment O O 0.7909830808639526
score O O 0.9803110361099243
remained O O 0.9999130964279175
independently O O 0.9998658895492554
significant O O 0.9999322891235352
risk O O 0.9997414946556091
factors O O 0.9999933242797852
in O O 0.9999594688415527
the O O 0.999984860420227
multivariate O O 0.9989826083183289
analysis O O 0.999968409538269
. O O 0.9999650716781616

Patients O O 0.9999762773513794
who O O 0.9999582767486572
had O O 0.999977707862854
ARI O O 0.9999741315841675
after O O 0.9997919201850891
high O O 0.9866002202033997
- O O 0.9996837377548218
dose O O 0.9926822781562805
melphalan B B 0.9984642267227173
underwent O O 0.9998428821563721
dialysis O O 0.9997439980506897
more O O 0.9999744892120361
often O O 0.99998939037323
( O O 0.9999650716781616
P O O 0.9996874332427979
= O O 0.9998871088027954
0 O O 0.9999862909317017
. O O 0.9999977350234985
007 O O 0.9998797178268433
) O O 0.9999676942825317
, O O 0.9999508857727051
and O O 0.999991774559021
had O O 0.9999935626983643
a O O 0.9999964237213135
worse O O 0.9999908208847046
1 O O 0.9999468326568604
- O O 0.9999923706054688
year O O 0.999997615814209
survival O O 0.999993085861206
( O O 0.9999767541885376
P O O 0.999415397644043
= O O 0.9992473125457764
0 O O 0.9998972415924072
. O O 0.9999948740005493
03 O O 0.9999840259552002
) O O 0.9999825954437256
. O O 0.9999871253967285

CONCLUSION O O 0.9989349246025085
: O O 0.9999723434448242
The O O 0.999993085861206
timing O O 0.9999862909317017
of O O 0.9999809265136719
renal O O 0.9998811483383179
injury O O 0.9999852180480957
strongly O O 0.9999449253082275
suggests O O 0.999637246131897
melphalan B B 0.9996726512908936
as O O 0.9997269511222839
the O O 0.9996293783187866
causative O O 0.9997755885124207
agent O O 0.9999393224716187
. O O 0.9999548196792603

Ongoing O O 0.9991714954376221
tubular O O 0.999987006187439
injury O O 0.9999598264694214
may O O 0.9998964071273804
be O O 0.9999208450317383
a O O 0.9999080896377563
prerequisite O O 0.9999305009841919
for O O 0.9999556541442871
renal O O 0.999927282333374
injury O O 0.9999806880950928
by O O 0.9996317625045776
melphalan B B 0.9996132254600525
as O O 0.9999642372131348
evidenced O O 0.9999957084655762
by O O 0.9999958276748657
the O O 0.9999942779541016
active O O 0.9999783039093018
urinary O O 0.9999823570251465
sediment O O 0.9999895095825195
. O O 0.9999434947967529

Development O O 0.9999228715896606
of O O 0.9995993971824646
ARI O O 0.5634398460388184
adversely O O 0.9995923638343811
affected O O 0.999985933303833
the O O 0.9999871253967285
outcome O O 0.9999948740005493
after O O 0.9999215602874756
PBSCT O O 0.9783145785331726
. O O 0.9999083280563354

Effective O O 0.999224066734314
preventive O O 0.9989961981773376
measures O O 0.9998111128807068
may O O 0.9998953342437744
help O O 0.9998668432235718
decrease O O 0.9999202489852905
the O O 0.9999676942825317
treatment O O 0.9999216794967651
mortality O O 0.9999912977218628
of O O 0.9997500777244568
PBSCT O O 0.7931018471717834
in O O 0.999573290348053
AL O B 0.9309490919113159
patients O O 0.9995915293693542
. O O 0.9999334812164307

Focal O O 0.9999104738235474
cerebral O O 0.999987006187439
ischemia O O 0.9999963045120239
in O O 0.999955415725708
rats O O 0.9998522996902466
: O O 0.9998782873153687
effect O O 0.999971866607666
of O O 0.9997896552085876
phenylephrine B B 0.9997723698616028
- O O 0.9997714161872864
induced O O 0.9998795986175537
hypertension O O 0.994748055934906
during O O 0.9997915625572205
reperfusion O O 0.9977549910545349
. O O 0.9999545812606812

After O O 0.9999622106552124
180 O O 0.99997878074646
min O O 0.9999912977218628
of O O 0.9999605417251587
temporary O O 0.9999583959579468
middle O O 0.9999847412109375
cerebral O O 0.9999918937683105
artery O O 0.9978427886962891
occlusion O O 0.999955415725708
in O O 0.9998655319213867
spontaneously O O 0.9997852444648743
hypertensive O O 0.9997184872627258
rats O O 0.9999847412109375
, O O 0.9999525547027588
the O O 0.9999749660491943
effect O O 0.9999630451202393
of O O 0.9997996687889099
phenylephrine B B 0.9998544454574585
- O O 0.9997482895851135
induced O O 0.9998691082000732
hypertension O O 0.9822551012039185
on O O 0.9998219609260559
ischemic O O 0.9999929666519165
brain O O 0.9999678134918213
injury O O 0.9999912977218628
and O O 0.9999253749847412
blood O O 0.9631913900375366
- O O 0.9990757703781128
brain O O 0.9987420439720154
barrier O O 0.9997727274894714
permeability O O 0.9998050332069397
was O O 0.9999737739562988
determined O O 0.9999839067459106
. O O 0.9999675750732422

Blood O O 0.99962317943573
pressure O O 0.9995267391204834
was O O 0.999958872795105
manipulated O O 0.9998422861099243
by O O 0.9998512268066406
one O O 0.9997958540916443
of O O 0.9998667240142822
the O O 0.9999616146087646
following O O 0.9998759031295776
schedules O O 0.9992907047271729
during O O 0.9998855590820312
120 O O 0.9999961853027344
min O O 0.9999938011169434
of O O 0.9999576807022095
reperfusion O O 0.9981221556663513
: O O 0.9994798302650452
Control O O 0.9999486207962036
, O O 0.999909520149231
normotensive O O 0.999477207660675
reperfusion O O 0.9897605776786804
; O O 0.9997281432151794
90 O O 0.9977606534957886
/ O O 0.9989701509475708
hypertension O O 0.7388916015625
( O O 0.9994831085205078
90 O O 0.9985970854759216
/ O O 0.998835027217865
HTN O O 0.9312885999679565
) O O 0.9999547004699707
, O O 0.9999300241470337
blood O O 0.9972389936447144
pressure O O 0.9896436929702759
was O O 0.9999740123748779
increased O O 0.9999560117721558
by O O 0.9999866485595703
35 O O 0.9999955892562866
mm O O 0.9999953508377075
Hg O O 0.4890902638435364
during O O 0.999894380569458
the O O 0.999995231628418
initial O O 0.9999978542327881
90 O O 0.999991774559021
min O O 0.9999951124191284
of O O 0.9999673366546631
reperfusion O O 0.998100221157074
only O O 0.9999406337738037
; O O 0.9999394416809082
15 O O 0.9997000694274902
/ O O 0.9984934329986572
hypertension O O 0.7963682413101196
( O O 0.9998262524604797
15 O O 0.9997010231018066
/ O O 0.9990423321723938
HTN O O 0.9369187951087952
) O O 0.9999606609344482
, O O 0.9999148845672607
normotensive O O 0.9993705153465271
reperfusion O O 0.999078631401062
for O O 0.9999644756317139
30 O O 0.9999914169311523
min O O 0.9999865293502808
followed O O 0.9999523162841797
by O O 0.9999772310256958
15 O O 0.9999936819076538
min O O 0.9999911785125732
of O O 0.9999326467514038
hypertension O O 0.6970271468162537
and O O 0.999907374382019
75 O O 0.9999912977218628
min O O 0.9999860525131226
of O O 0.9999058246612549
normotension O O 0.8990983366966248
. O O 0.9999667406082153

Part O O 0.9940471649169922
A O O 0.9978235960006714
, O O 0.9999600648880005
for O O 0.9998377561569214
eight O O 0.9999004602432251
rats O O 0.9999814033508301
in O O 0.9997504353523254
each O O 0.9992363452911377
group O O 0.9997479319572449
brain O O 0.9998072981834412
injury O O 0.9999721050262451
was O O 0.9999630451202393
evaluated O O 0.9999890327453613
by O O 0.9999898672103882
staining O O 0.9999107122421265
tissue O O 0.9999772310256958
using O O 0.9998584985733032
2 B B 0.7687011361122131
, I I 0.8643863201141357
3 I I 0.9037382006645203
, I I 0.9726905822753906
5 I I 0.9440423250198364
- I I 0.9953124523162842
triphenyltetrazolium I I 0.9998317956924438
chloride I I 0.9993807077407837
and O O 0.9993615746498108
edema O O 0.9999454021453857
was O O 0.9999738931655884
evaluated O O 0.999990701675415
by O O 0.9999865293502808
microgravimetry O O 0.9993334412574768
. O O 0.9999750852584839

Part O O 0.9971922039985657
B O O 0.9988059997558594
, O O 0.9999877214431763
for O O 0.9999474287033081
eight O O 0.9999803304672241
different O O 0.9999741315841675
rats O O 0.9999744892120361
in O O 0.9998830556869507
each O O 0.9997555613517761
group O O 0.9999325275421143
blood O O 0.9397024512290955
- O O 0.9987646341323853
brain O O 0.9995711445808411
barrier O O 0.9997040629386902
permeability O O 0.9997275471687317
was O O 0.9999688863754272
evaluated O O 0.9999908208847046
by O O 0.9999958276748657
measuring O O 0.9999949932098389
the O O 0.9999932050704956
amount O O 0.9999872446060181
and O O 0.9999920129776001
extent O O 0.9999927282333374
of O O 0.9999845027923584
extravasation O O 0.9999862909317017
of O O 0.9997988343238831
Evans O O 0.47994697093963623
Blue O O 0.5959683656692505
dye O O 0.993826687335968
. O O 0.9999673366546631

Brain O O 0.9998440742492676
injury O O 0.9999819993972778
( O O 0.9998899698257446
percentage O O 0.9988033771514893
of O O 0.999916672706604
the O O 0.9999277591705322
ischemic O O 0.9999659061431885
hemisphere O O 0.9999818801879883
) O O 0.9999185800552368
was O O 0.9999463558197021
less O O 0.9999760389328003
in O O 0.9999529123306274
the O O 0.9999395608901978
15 O O 0.9854023456573486
/ O O 0.9820042252540588
HTN O O 0.7007654309272766
group O O 0.9996912479400635
( O O 0.9998596906661987
16 O O 0.9993700385093689
+ O O 0.99996018409729
/ O O 0.9999372959136963
- O O 0.9996446371078491
6 O O 0.999921441078186
, O O 0.9999449253082275
mean O O 0.9996070265769958
+ O O 0.9999752044677734
/ O O 0.999934196472168
- O O 0.9997519850730896
SD O O 0.995532751083374
) O O 0.9999637603759766
versus O O 0.9999511241912842
the O O 0.9996330738067627
90 O O 0.9762227535247803
/ O O 0.9830018877983093
HTN O O 0.7699851393699646
group O O 0.9995373487472534
( O O 0.999913215637207
30 O O 0.9999642372131348
+ O O 0.9999773502349854
/ O O 0.9999374151229858
- O O 0.999731719493866
6 O O 0.9997609257698059
) O O 0.9999686479568481
, O O 0.9999706745147705
which O O 0.999944806098938
was O O 0.9999817609786987
in O O 0.9999977350234985
turn O O 0.9999954700469971
less O O 0.9999836683273315
than O O 0.9999916553497314
the O O 0.9999436140060425
control O O 0.9998859167098999
group O O 0.9999786615371704
( O O 0.9999692440032959
42 O O 0.9999760389328003
+ O O 0.9999865293502808
/ O O 0.9999796152114868
- O O 0.9999287128448486
5 O O 0.9999598264694214
) O O 0.9999722242355347
. O O 0.999977707862854

Specific O O 0.9940898418426514
gravity O O 0.6941153407096863
was O O 0.999921441078186
greater O O 0.9998701810836792
in O O 0.9997941851615906
the O O 0.9998893737792969
15 O O 0.9938376545906067
/ O O 0.9817051887512207
HTN O O 0.6389139294624329
group O O 0.9998113512992859
( O O 0.9999099969863892
1 O O 0.9984910488128662
. O O 0.9999812841415405
043 O O 0.9987512826919556
+ O O 0.9999803304672241
/ O O 0.9996747970581055
- O O 0.9995050430297852
0 O O 0.9999630451202393
. O O 0.9999963045120239
002 O O 0.9998961687088013
) O O 0.9999550580978394
versus O O 0.9999039173126221
the O O 0.9997972846031189
90 O O 0.9935901165008545
/ O O 0.9839821457862854
HTN O O 0.5267966985702515
( O O 0.9998749494552612
1 O O 0.9998915195465088
. O O 0.999977707862854
036 O O 0.9999408721923828
+ O O 0.999982476234436
/ O O 0.9996354579925537
- O O 0.9995244741439819
0 O O 0.9999496936798096
. O O 0.9999953508377075
003 O O 0.9997498393058777
) O O 0.9999300241470337
and O O 0.9994200468063354
control O O 0.9917042255401611
( O O 0.9998584985733032
1 O O 0.9998780488967896
. O O 0.999975323677063
037 O O 0.9999200105667114
+ O O 0.9999861717224121
/ O O 0.9997929930686951
- O O 0.999672532081604
0 O O 0.9999818801879883
. O O 0.9999949932098389
003 O O 0.9996955394744873
) O O 0.9999181032180786
groups O O 0.9999173879623413
. O O 0.9999709129333496

Evans B O 0.9149559736251831
Blue I O 0.9762448072433472
( O O 0.9991821646690369
mug O O 0.6418202519416809
g O O 0.8385657668113708
- O O 0.9007721543312073
1 O O 0.8614553213119507
of O O 0.9993859529495239
brain O O 0.9998533725738525
tissue O O 0.99998939037323
) O O 0.999906063079834
was O O 0.9999470710754395
greater O O 0.9998292922973633
in O O 0.9999277591705322
the O O 0.999954342842102
90 O O 0.9799142479896545
/ O O 0.965137243270874
HTN O O 0.5255905389785767
group O O 0.9998082518577576
( O O 0.9999587535858154
24 O O 0.9999556541442871
. O O 0.9999912977218628
4 O O 0.9999796152114868
+ O O 0.9999886751174927
/ O O 0.9999721050262451
- O O 0.9998672008514404
6 O O 0.9999790191650391
. O O 0.9999899864196777
0 O O 0.9999696016311646
) O O 0.9999774694442749
versus O O 0.9999842643737793
the O O 0.9998227953910828
control O O 0.9998685121536255
group O O 0.999958872795105
( O O 0.999974250793457
12 O O 0.9999979734420776
. O O 0.9999949932098389
3 O O 0.9999880790710449
+ O O 0.9999866485595703
/ O O 0.9999603033065796
- O O 0.999934196472168
4 O O 0.9999673366546631
. O O 0.999990701675415
1 O O 0.9999916553497314
) O O 0.9999738931655884
, O O 0.9999786615371704
which O O 0.9999415874481201
was O O 0.9999780654907227
in O O 0.9999966621398926
turn O O 0.9999940395355225
greater O O 0.9999667406082153
than O O 0.9999934434890747
the O O 0.9999741315841675
15 O O 0.998532772064209
/ O O 0.9853377342224121
HTN O O 0.6643410325050354
group O O 0.9997285008430481
( O O 0.9999711513519287
7 O O 0.9999451637268066
. O O 0.9999927282333374
3 O O 0.9999809265136719
+ O O 0.9999910593032837
/ O O 0.9999518394470215
- O O 0.9999282360076904
3 O O 0.9999852180480957
. O O 0.9999854564666748
2 O O 0.9999833106994629
) O O 0.9999697208404541
. O O 0.9999775886535645

This O O 0.9999747276306152
study O O 0.9999805688858032
supports O O 0.9999200105667114
a O O 0.9999524354934692
hypothesis O O 0.9999672174453735
that O O 0.9999102354049683
during O O 0.9996700286865234
reperfusion O O 0.9812130331993103
, O O 0.9998582601547241
a O O 0.999934196472168
short O O 0.9999527931213379
interval O O 0.9999442100524902
of O O 0.9997805953025818
hypertension O O 0.9377734065055847
decreases O O 0.9995228052139282
brain O O 0.9999544620513916
injury O O 0.9999920129776001
and O O 0.9999312162399292
edema O O 0.9999631643295288
; O O 0.9999276399612427
and O O 0.9999562501907349
that O O 0.9999635219573975
sustained O O 0.9997468590736389
hypertension O O 0.9617007374763489
increases O O 0.9998101592063904
the O O 0.9999853372573853
risk O O 0.9999935626983643
of O O 0.999958872795105
vasogenic O O 0.999930739402771
edema O O 0.9999573230743408
. O O 0.9999524354934692

People O O 0.9999834299087524
aged O O 0.9999955892562866
over O O 0.9999970197677612
75 O O 0.9999758005142212
in O O 0.9999401569366455
atrial O O 0.9958006739616394
fibrillation O O 0.9999439716339111
on O O 0.999372661113739
warfarin B B 0.9993823766708374
: O O 0.9999116659164429
the O O 0.9999945163726807
rate O O 0.9999978542327881
of O O 0.9999924898147583
major O O 0.9999884366989136
hemorrhage O O 0.9999914169311523
and O O 0.9999494552612305
stroke O O 0.9999945163726807
in O O 0.9999819993972778
more O O 0.9999924898147583
than O O 0.9999943971633911
500 O O 0.9999954700469971
patient O O 0.9999837875366211
- O O 0.9999828338623047
years O O 0.9999970197677612
of O O 0.9999951124191284
follow O O 0.9999904632568359
- O O 0.9999904632568359
up O O 0.9999969005584717
. O O 0.999984860420227

OBJECTIVES O O 0.9996998310089111
: O O 0.9999923706054688
To O O 0.9999948740005493
determine O O 0.9999934434890747
the O O 0.9999946355819702
incidence O O 0.9999983310699463
of O O 0.9999895095825195
major O O 0.9999403953552246
hemorrhage O O 0.9999804496765137
and O O 0.9999366998672485
stroke O O 0.9999949932098389
in O O 0.9999613761901855
people O O 0.9999988079071045
aged O O 0.9999963045120239
76 O O 0.9999666213989258
and O O 0.9999963045120239
older O O 0.9998327493667603
with O O 0.9999735355377197
atrial O O 0.9977326393127441
fibrillation O O 0.9999740123748779
on O O 0.9997265934944153
adjusted O O 0.9873886108398438
- O O 0.9997038245201111
dose O O 0.9891600012779236
warfarin B B 0.9990992546081543
who O O 0.9999133348464966
had O O 0.999994158744812
been O O 0.9999964237213135
recently O O 0.9999923706054688
been O O 0.999995231628418
admitted O O 0.9999911785125732
to O O 0.999985933303833
hospital O O 0.999992847442627
. O O 0.9999855756759644

DESIGN O O 0.9999933242797852
: O O 0.9999977350234985
A O O 0.9999967813491821
retrospective O O 0.9999887943267822
observational O O 0.9999916553497314
cohort O O 0.9999805688858032
study O O 0.9999926090240479
. O O 0.9999889135360718

SETTING O O 0.9998351335525513
: O O 0.9999805688858032
A O O 0.9999409914016724
major O O 0.999957799911499
healthcare O O 0.9999611377716064
network O O 0.9999784231185913
involving O O 0.9999232292175293
four O O 0.9998971223831177
tertiary O O 0.9998218417167664
hospitals O O 0.9999923706054688
. O O 0.9999678134918213

PARTICIPANTS O O 0.9999057054519653
: O O 0.9999948740005493
Two O O 0.9999994039535522
hundred O O 0.9999966621398926
thirty O O 0.9999943971633911
- O O 0.9999525547027588
five O O 0.9999945163726807
patients O O 0.9999960660934448
aged O O 0.9999862909317017
76 O O 0.9999864101409912
and O O 0.9999945163726807
older O O 0.9998728036880493
admitted O O 0.9999301433563232
to O O 0.9998621940612793
a O O 0.9999804496765137
major O O 0.9999450445175171
healthcare O O 0.9999681711196899
network O O 0.9999842643737793
between O O 0.9997664093971252
July O O 0.9984760880470276
1 O O 0.9996060729026794
, O O 0.9989808201789856
2001 O O 0.9976688027381897
, O O 0.9998952150344849
and O O 0.9996472597122192
June O O 0.9985321760177612
30 O O 0.9996166229248047
, O O 0.9998494386672974
2002 O O 0.9993174076080322
, O O 0.9999933242797852
with O O 0.9999748468399048
atrial O O 0.9993093013763428
fibrillation O O 0.9999856948852539
on O O 0.9996412992477417
warfarin B B 0.9955114126205444
were O O 0.9996771812438965
enrolled O O 0.9999450445175171
. O O 0.9999468326568604

MEASUREMENTS O O 0.998938262462616
: O O 0.999966025352478
Information O O 0.9999929666519165
regarding O O 0.9999620914459229
major O O 0.9999771118164062
bleeding O O 0.9997854828834534
episodes O O 0.9999939203262329
, O O 0.999981164932251
strokes O O 0.9999750852584839
, O O 0.9999096393585205
and O O 0.9997928738594055
warfarin B B 0.9989047050476074
use O O 0.9994543194770813
was O O 0.9999749660491943
obtained O O 0.9999954700469971
from O O 0.9999849796295166
patients O O 0.9999933242797852
, O O 0.9999817609786987
relatives O O 0.9999947547912598
, O O 0.9999887943267822
primary O O 0.999818742275238
physicians O O 0.9999788999557495
, O O 0.9999533891677856
and O O 0.9999829530715942
medical O O 0.999994158744812
records O O 0.9999867677688599
. O O 0.9999804496765137

RESULTS O O 0.9999380111694336
: O O 0.999994158744812
Two O O 0.9999996423721313
hundred O O 0.9999969005584717
twenty O O 0.9999924898147583
- O O 0.9999734163284302
eight O O 0.9999904632568359
patients O O 0.9999967813491821
( O O 0.9999514818191528
42 O O 0.9999891519546509
% O O 0.9999812841415405
men O O 0.9995710253715515
) O O 0.9999474287033081
with O O 0.9999827146530151
a O O 0.9999920129776001
mean O O 0.9999978542327881
age O O 0.9999511241912842
of O O 0.9999786615371704
81 O O 0.9999983310699463
. O O 0.999998927116394
1 O O 0.9999988079071045
( O O 0.9999847412109375
range O O 0.999996542930603
76 O O 0.9999959468841553
- O O 0.9996039271354675
94 O O 0.9993335604667664
) O O 0.9999849796295166
were O O 0.9999750852584839
included O O 0.9999935626983643
in O O 0.9999839067459106
the O O 0.9999911785125732
analysis O O 0.9999939203262329
. O O 0.9999691247940063

Total O O 0.9999470710754395
follow O O 0.9999933242797852
- O O 0.9999878406524658
up O O 0.9999970197677612
on O O 0.9998431205749512
warfarin B B 0.9984690546989441
was O O 0.9998302459716797
530 O O 0.9999942779541016
years O O 0.9999967813491821
( O O 0.999968409538269
mean O O 0.9999926090240479
28 O O 0.9999958276748657
months O O 0.9999980926513672
) O O 0.9999816417694092
. O O 0.9999798536300659

There O O 0.9999251365661621
were O O 0.9999562501907349
53 O O 0.9999849796295166
major O O 0.9999855756759644
hemorrhages O O 0.9999728202819824
, O O 0.9999794960021973
for O O 0.9999301433563232
an O O 0.99994957447052
annual O O 0.9997156262397766
rate O O 0.9999949932098389
of O O 0.999915599822998
10 O O 0.9999897480010986
. O O 0.9999935626983643
0 O O 0.9999958276748657
% O O 0.9999940395355225
, O O 0.9999886751174927
including O O 0.9999544620513916
24 O O 0.9994673132896423
( O O 0.9999133348464966
45 O O 0.9999772310256958
. O O 0.9999915361404419
3 O O 0.9999850988388062
% O O 0.9999814033508301
) O O 0.9998774528503418
life O O 0.9997177720069885
- O O 0.9999743700027466
threatening O O 0.9998736381530762
and O O 0.9998267292976379
five O O 0.9999481439590454
( O O 0.9998088479042053
9 O O 0.9999924898147583
. O O 0.9999947547912598
4 O O 0.9999860525131226
% O O 0.9999899864196777
) O O 0.9999041557312012
fatal O O 0.9986826777458191
bleeds O O 0.9999853372573853
. O O 0.9999626874923706

The O O 0.9999810457229614
annual O O 0.9999847412109375
stroke O O 0.9999970197677612
rate O O 0.9999955892562866
after O O 0.9999309778213501
initiation O O 0.9999666213989258
of O O 0.9997619986534119
warfarin B B 0.9987865090370178
was O O 0.9998449087142944
2 O O 0.9999862909317017
. O O 0.999993085861206
6 O O 0.9999970197677612
% O O 0.9999969005584717
. O O 0.9999794960021973

CONCLUSION O O 0.9996614456176758
: O O 0.9999682903289795
The O O 0.9999886751174927
rate O O 0.9999959468841553
of O O 0.9999867677688599
major O O 0.9999477863311768
hemorrhage O O 0.999958872795105
was O O 0.9999432563781738
high O O 0.9998728036880493
in O O 0.9999284744262695
this O O 0.9999786615371704
old O O 0.9998918771743774
, O O 0.9999794960021973
frail O O 0.9999310970306396
group O O 0.9999855756759644
, O O 0.9999599456787109
but O O 0.9998645782470703
excluding O O 0.8357752561569214
fatalities O O 0.7958324551582336
, O O 0.9998843669891357
resulted O O 0.9999507665634155
in O O 0.9999785423278809
no O O 0.9999632835388184
long O O 0.9997438788414001
- O O 0.9999855756759644
term O O 0.9999880790710449
sequelae O O 0.9999960660934448
, O O 0.9999340772628784
and O O 0.9999748468399048
the O O 0.9999815225601196
stroke O O 0.9999909400939941
rate O O 0.9999881982803345
on O O 0.9996446371078491
warfarin B B 0.9991384744644165
was O O 0.9999039173126221
low O O 0.9999732971191406
, O O 0.9999877214431763
demonstrating O O 0.9999892711639404
how O O 0.9999816417694092
effective O O 0.9998698234558105
warfarin B B 0.9993754029273987
treatment O O 0.9997462630271912
is O O 0.9999575614929199
. O O 0.9999657869338989

Safety O O 0.9987964630126953
of O O 0.9972768425941467
celecoxib B B 0.9995323419570923
in O O 0.9999294281005859
patients O O 0.9999938011169434
with O O 0.9999861717224121
adverse O O 0.9999632835388184
skin O O 0.9999817609786987
reactions O O 0.9999980926513672
to O O 0.9995881915092468
acetaminophen B B 0.9964509010314941
( O O 0.9164734482765198
paracetamol B B 0.985253632068634
) O O 0.9931643605232239
and O O 0.9975739121437073
nimesulide B B 0.9902004599571228
associated O O 0.9992393255233765
or O O 0.999992847442627
not O O 0.9999309778213501
with O O 0.9997865557670593
common O O 0.9803352355957031
non O O 0.6447861194610596
- O O 0.9798387289047241
steroidal O O 0.5319870114326477
anti O O 0.3958253860473633
- O O 0.9662249088287354
inflammatory O O 0.9978435039520264
drugs O O 0.9974551796913147
. O O 0.9999370574951172

BACKGROUND O O 0.9757456183433533
: O O 0.9975155591964722
Acetaminophen B B 0.9984434247016907
( O O 0.9659869074821472
paracetamol B B 0.9916702508926392
- O I 0.8677399754524231
- O I 0.983669102191925
P B I 0.9998026490211487
) O I 0.9591954350471497
and O O 0.8227519989013672
Nimesulide B B 0.9952051639556885
( O O 0.989323079586029
N B B 0.991872251033783
) O O 0.9037273526191711
are O O 0.998965859413147
widely O O 0.9994083642959595
used O O 0.9995753169059753
analgesic O O 0.7607138156890869
- O O 0.9361419677734375
antipyretic O O 0.5783538818359375
/ O O 0.9898881316184998
anti O O 0.693952202796936
- O O 0.9927917718887329
inflammatory O O 0.9991957545280457
drugs O O 0.993847668170929
. O O 0.9997081160545349

The O O 0.999961256980896
rate O O 0.99998939037323
of O O 0.999976634979248
adverse O O 0.9999223947525024
hypersensitivity O O 0.9989548921585083
reactions O O 0.9999901056289673
to O O 0.9998883008956909
these O O 0.9938644766807556
agents O O 0.9927774667739868
is O O 0.9999037981033325
generally O O 0.9999810457229614
low O O 0.9999722242355347
. O O 0.9999610185623169

On O O 0.999880313873291
the O O 0.999945878982544
contrary O O 0.9998897314071655
non O O 0.6038918495178223
- O O 0.9651563167572021
steroidal O O 0.6534592509269714
anti O O 0.3623667061328888
- O O 0.9070445895195007
inflammatory O O 0.9622827172279358
drugs O O 0.9850971698760986
( O O 0.9986230134963989
NSAIDs O O 0.7376076579093933
) O O 0.9987047910690308
are O O 0.9998476505279541
commonly O O 0.9999282360076904
involved O O 0.9999521970748901
in O O 0.9999582767486572
such O O 0.9999152421951294
reactions O O 0.9999951124191284
. O O 0.9999500513076782

Celecoxib B B 0.9990323781967163
( O O 0.9266667366027832
CE B B 0.998852014541626
) O O 0.9864872097969055
is O O 0.9998418092727661
a O O 0.9994946718215942
novel O O 0.9991042017936707
drug O O 0.9989224672317505
, O O 0.9999253749847412
with O O 0.99989914894104
high O O 0.9995638728141785
selectivity O O 0.9999239444732666
and O O 0.9999327659606934
affinity O O 0.99994957447052
for O O 0.9995118379592896
COX O O 0.8406244516372681
- O O 0.984055757522583
2 O O 0.9741209149360657
enzyme O O 0.9939029812812805
. O O 0.9998775720596313

OBJECTIVE O O 0.9998834133148193
: O O 0.9999954700469971
We O O 0.9999618530273438
evaluated O O 0.9999935626983643
the O O 0.9999932050704956
tolerability O O 0.9999979734420776
of O O 0.9998587369918823
CE B B 0.9969084858894348
in O O 0.9999161958694458
a O O 0.9999878406524658
group O O 0.9999897480010986
of O O 0.999983549118042
patients O O 0.9999938011169434
with O O 0.9999724626541138
documented O O 0.999992847442627
history O O 0.9999923706054688
of O O 0.9999755620956421
adverse O O 0.9999146461486816
cutaneous O O 0.999983549118042
reactions O O 0.9999823570251465
to O O 0.999286949634552
P B B 0.8884381651878357
and O I 0.7456225156784058
N B I 0.8330380320549011
associated O I 0.995701253414154
or O O 0.9997934699058533
not O O 0.9996829032897949
to O O 0.9983878135681152
classic O O 0.8794565200805664
NSAIDs O O 0.6862888336181641
. O O 0.9999557733535767

METHODS O O 0.9995191097259521
: O O 0.9999823570251465
We O O 0.9999498128890991
studied O O 0.9999796152114868
9 O O 0.9999208450317383
patients O O 0.9999910593032837
with O O 0.9999734163284302
hypersensitivity O O 0.9995377063751221
to O O 0.9992139339447021
P B B 0.938784658908844
and O O 0.7085680365562439
N B O 0.4241015911102295
with O O 0.9997259974479675
or O O 0.9999836683273315
without O O 0.9999791383743286
associated O O 0.9999786615371704
reactions O O 0.999987006187439
to O O 0.999687910079956
classic O O 0.9011097550392151
NSAIDs O O 0.8061197400093079
. O O 0.9998806715011597

The O O 0.9999839067459106
diagnosis O O 0.9999942779541016
of O O 0.9999532699584961
P B B 0.9434460401535034
and O I 0.9148024916648865
N B I 0.6177163124084473
- O O 0.8800011277198792
induced O O 0.9999525547027588
skin O O 0.9999560117721558
reactions O O 0.9999957084655762
was O O 0.9999872446060181
based O O 0.9999954700469971
in O O 0.9998832941055298
vivo O O 0.9999929666519165
challenge O O 0.9999933242797852
. O O 0.9999825954437256

The O O 0.9999301433563232
placebo O O 0.9997028708457947
was O O 0.9999393224716187
blindly O O 0.9999498128890991
administered O O 0.9999434947967529
at O O 0.9999545812606812
the O O 0.9999943971633911
beginning O O 0.9999954700469971
of O O 0.9999865293502808
each O O 0.9999419450759888
challenge O O 0.9999706745147705
. O O 0.9999673366546631

After O O 0.9999630451202393
three O O 0.9999836683273315
days O O 0.999990701675415
, O O 0.9999650716781616
a O O 0.9999842643737793
cumulative O O 0.9998192191123962
dosage O O 0.9999232292175293
of O O 0.9998884201049805
200 O O 0.9991033673286438
mg O O 0.9997889399528503
of O O 0.9899487495422363
CE B B 0.9897428154945374
in O O 0.9244549870491028
refracted O O 0.9815571308135986
doses O O 0.9996851682662964
were O O 0.9999690055847168
given O O 0.9999551773071289
. O O 0.9999653100967407

After O O 0.9999645948410034
2 O O 0.9998786449432373
- O O 0.9999068975448608
3 O O 0.9999250173568726
days O O 0.9999909400939941
, O O 0.9999814033508301
a O O 0.9999902248382568
single O O 0.9999357461929321
dose O O 0.999937891960144
of O O 0.9996672868728638
200 O O 0.9888196587562561
mg O O 0.9997561573982239
was O O 0.9999592304229736
administered O O 0.9999656677246094
. O O 0.9999642372131348

All O O 0.9999455213546753
patients O O 0.9999889135360718
were O O 0.9999871253967285
observed O O 0.9999816417694092
for O O 0.9999711513519287
6 O O 0.9999195337295532
hours O O 0.9999845027923584
after O O 0.9999524354934692
each O O 0.9998810291290283
challenge O O 0.9999094009399414
, O O 0.9999028444290161
and O O 0.9998294115066528
controlled O O 0.9999469518661499
again O O 0.9999862909317017
after O O 0.9999313354492188
24 O O 0.9999650716781616
hours O O 0.999982476234436
to O O 0.999992847442627
exclude O O 0.99992835521698
delayed O O 0.9998472929000854
reactions O O 0.9999867677688599
. O O 0.9999696016311646

The O O 0.9999798536300659
challenge O O 0.999950647354126
was O O 0.9999654293060303
considered O O 0.9999657869338989
positive O O 0.9999711513519287
if O O 0.9999957084655762
one O O 0.9999816417694092
or O O 0.9999855756759644
more O O 0.999985933303833
of O O 0.999964714050293
the O O 0.9999885559082031
following O O 0.999983549118042
appeared O O 0.9999908208847046
: O O 0.9998996257781982
erythema O O 0.999981164932251
, O O 0.9999545812606812
rush O O 0.9979711174964905
or O O 0.9999641180038452
urticaria O O 0.9998613595962524
- O O 0.9987524747848511
angioedema O O 0.9901511669158936
. O O 0.9999654293060303

RESULTS O O 0.9995157718658447
: O O 0.9999639987945557
No O O 0.9998703002929688
reaction O O 0.999980092048645
was O O 0.9999781847000122
observed O O 0.999991774559021
with O O 0.9998200535774231
placebo O O 0.997285008430481
and O O 0.9999356269836426
eight O O 0.999985933303833
patients O O 0.999996542930603
( O O 0.9999735355377197
88 O O 0.9999797344207764
. O O 0.999992847442627
8 O O 0.9999805688858032
% O O 0.999995231628418
) O O 0.9999818801879883
tolerated O O 0.9999524354934692
CE B B 0.9823073148727417
. O O 0.9983831644058228

Only O O 0.9999593496322632
one O O 0.9999924898147583
patient O O 0.9999924898147583
developed O O 0.9999817609786987
a O O 0.999984860420227
moderate O O 0.9999759197235107
angioedema O O 0.9994753003120422
of O O 0.99994957447052
the O O 0.9999401569366455
lips O O 0.999940037727356
. O O 0.9999481439590454

CONCLUSION O O 0.9969044327735901
: O O 0.9999370574951172
Only O O 0.9999750852584839
one O O 0.999974250793457
hypersensitivity O O 0.9989375472068787
reaction O O 0.9999732971191406
to O O 0.998819887638092
CE B B 0.9969874024391174
was O O 0.9998493194580078
documented O O 0.9999810457229614
among O O 0.9998677968978882
9 O O 0.9748665690422058
P B O 0.8567788600921631
and O O 0.9913727045059204
N B O 0.6585816740989685
- O O 0.8125290274620056
highly O O 0.7738816738128662
NSAIDs O B 0.8009623885154724
intolerant O O 0.9926744103431702
patients O O 0.9999724626541138
. O O 0.9999624490737915

Thus O O 0.999974250793457
, O O 0.9999778270721436
we O O 0.9999692440032959
conclude O O 0.9999909400939941
that O O 0.9998255372047424
CE B B 0.9979860782623291
is O O 0.9998890161514282
a O O 0.9999781847000122
reasonably O O 0.999991774559021
safe O O 0.9999793767929077
alternative O O 0.9999593496322632
to O O 0.99997878074646
be O O 0.999991774559021
used O O 0.9999315738677979
in O O 0.9999549388885498
subjects O O 0.9998574256896973
who O O 0.9999927282333374
do O O 0.9999964237213135
not O O 0.9999959468841553
tolerate O O 0.9997921586036682
P B O 0.48655617237091064
and O O 0.9265463948249817
N B O 0.9772070050239563
. O O 0.999940037727356

Case O O 0.9973146319389343
- O O 0.9999293088912964
control O O 0.9999414682388306
study O O 0.9999518394470215
of O O 0.9997513890266418
regular O O 0.9477621912956238
analgesic O O 0.8635837435722351
and O O 0.996825098991394
nonsteroidal O O 0.47237297892570496
anti O O 0.5754427909851074
- O O 0.7579399943351746
inflammatory O O 0.9136816263198853
use O O 0.9993777275085449
and O O 0.9999306201934814
end O O 0.9999488592147827
- O O 0.9999722242355347
stage O O 0.9999899864196777
renal O O 0.9999514818191528
disease O O 0.9999877214431763
. O O 0.9999727010726929

BACKGROUND O O 0.9976267218589783
: O O 0.9999746084213257
Studies O O 0.9999816417694092
on O O 0.9999608993530273
the O O 0.9999778270721436
association O O 0.999984622001648
between O O 0.99977046251297
the O O 0.9999536275863647
long O O 0.9995375871658325
- O O 0.9999854564666748
term O O 0.9999583959579468
use O O 0.9998998641967773
of O O 0.9990014433860779
aspirin B B 0.999091386795044
and O O 0.9903669357299805
other O O 0.998723566532135
analgesic O O 0.982508659362793
and O O 0.9955590963363647
nonsteroidal O O 0.5053926110267639
anti O O 0.45940035581588745
- O O 0.9385045766830444
inflammatory O O 0.9714791774749756
drugs O O 0.9900525212287903
( O O 0.9989235997200012
NSAIDs O O 0.6273559331893921
) O O 0.9988853335380554
and O O 0.9998941421508789
end O O 0.99972003698349
- O O 0.9999686479568481
stage O O 0.9999871253967285
renal O O 0.9999878406524658
disease O O 0.999992847442627
( O O 0.999934196472168
ESRD O O 0.9416667819023132
) O O 0.9999589920043945
have O O 0.9999860525131226
given O O 0.9999948740005493
conflicting O O 0.9999971389770508
results O O 0.999996542930603
. O O 0.9999819993972778

In O O 0.999983549118042
order O O 0.999995231628418
to O O 0.999993085861206
examine O O 0.9999825954437256
this O O 0.9999802112579346
association O O 0.9999868869781494
, O O 0.9999773502349854
a O O 0.9999881982803345
case O O 0.9999642372131348
- O O 0.9999829530715942
control O O 0.9999897480010986
study O O 0.9999920129776001
with O O 0.9999877214431763
incident O O 0.9999346733093262
cases O O 0.9999651908874512
of O O 0.9995782971382141
ESRD O O 0.8468706011772156
was O O 0.9999700784683228
carried O O 0.9999899864196777
out O O 0.999990701675415
. O O 0.9999854564666748

METHODS O O 0.9992897510528564
: O O 0.999972939491272
The O O 0.9999822378158569
cases O O 0.9999878406524658
were O O 0.9999884366989136
all O O 0.9999686479568481
patients O O 0.9999921321868896
entering O O 0.9999197721481323
the O O 0.9999866485595703
local O O 0.9999592304229736
dialysis O O 0.9996217489242554
program O O 0.9999719858169556
because O O 0.9999849796295166
of O O 0.9999759197235107
ESRD O O 0.9831897020339966
in O O 0.999956488609314
the O O 0.9999949932098389
study O O 0.9999940395355225
area O O 0.9999933242797852
between O O 0.9998291730880737
June O O 0.9991211295127869
1 O O 0.9998561143875122
, O O 0.9998003840446472
1995 O O 0.9845263957977295
and O O 0.9998873472213745
November O O 0.9841795563697815
30 O O 0.9980692267417908
, O O 0.9999563694000244
1997 O O 0.9995695948600769
. O O 0.9999591112136841

They O O 0.9999223947525024
were O O 0.9999452829360962
classified O O 0.9999877214431763
according O O 0.9999784231185913
to O O 0.9999463558197021
the O O 0.999983549118042
underlying O O 0.9999817609786987
disease O O 0.9999908208847046
, O O 0.9999579191207886
which O O 0.9999494552612305
had O O 0.9999938011169434
presumably O O 0.9999794960021973
led O O 0.9999899864196777
them O O 0.9999879598617554
to O O 0.9999425411224365
ESRD O O 0.9870637655258179
. O O 0.999920129776001

Controls O O 0.9999276399612427
were O O 0.9999934434890747
patients O O 0.999996542930603
admitted O O 0.9999871253967285
to O O 0.9999890327453613
the O O 0.9999959468841553
same O O 0.9999881982803345
hospitals O O 0.9999947547912598
from O O 0.9999924898147583
where O O 0.9999862909317017
the O O 0.9999959468841553
cases O O 0.9999955892562866
arose O O 0.9999982118606567
, O O 0.9999902248382568
also O O 0.9999903440475464
matched O O 0.9999904632568359
by O O 0.9999902248382568
age O O 0.9999395608901978
and O O 0.9999886751174927
sex O O 0.9998775720596313
. O O 0.9999805688858032

Odds O O 0.9996837377548218
ratios O O 0.999980092048645
were O O 0.9999872446060181
calculated O O 0.9999923706054688
using O O 0.9999644756317139
a O O 0.9999667406082153
conditional O O 0.9998427629470825
logistic O O 0.9998751878738403
model O O 0.9999855756759644
, O O 0.9999845027923584
including O O 0.9998260140419006
potential O O 0.9998617172241211
confounding O O 0.999075174331665
factors O O 0.9999709129333496
, O O 0.9999679327011108
both O O 0.9999266862869263
for O O 0.9999470710754395
the O O 0.9999922513961792
whole O O 0.9999328851699829
study O O 0.9999927282333374
population O O 0.9999936819076538
and O O 0.9999462366104126
for O O 0.9997486472129822
the O O 0.9999837875366211
various O O 0.999953031539917
underlying O O 0.9999654293060303
diseases O O 0.9999902248382568
. O O 0.9999810457229614

RESULTS O O 0.9999281167984009
: O O 0.9999788999557495
Five O O 0.9999982118606567
hundred O O 0.9999973773956299
and O O 0.9999957084655762
eighty O O 0.9960798621177673
- O O 0.9999573230743408
three O O 0.99998939037323
cases O O 0.9999890327453613
and O O 0.9999566078186035
1190 O O 0.9999884366989136
controls O O 0.9999876022338867
were O O 0.9999765157699585
included O O 0.9999920129776001
in O O 0.9999850988388062
the O O 0.9999908208847046
analysis O O 0.9999891519546509
. O O 0.9999686479568481

Long O O 0.9992087483406067
- O O 0.999982476234436
term O O 0.9999361038208008
use O O 0.9999575614929199
of O O 0.9998490810394287
any O O 0.9931801557540894
analgesic O O 0.9724825024604797
was O O 0.9999208450317383
associated O O 0.99997878074646
with O O 0.9999914169311523
an O O 0.9999842643737793
overall O O 0.9999759197235107
odds O O 0.9998695850372314
ratio O O 0.9999943971633911
of O O 0.9999769926071167
1 O O 0.9999942779541016
. O O 0.9999971389770508
22 O O 0.9999992847442627
( O O 0.9999537467956543
95 O O 0.9999915361404419
% O O 0.9997487664222717
CI O O 0.9938818216323853
, O O 0.9999188184738159
0 O O 0.9999936819076538
. O O 0.9999942779541016
89 O O 0.9999756813049316
- O O 0.9969082474708557
1 O O 0.9999963045120239
. O O 0.9999936819076538
66 O O 0.9999983310699463
) O O 0.999963641166687
. O O 0.9999792575836182

For O O 0.9985557198524475
specific O O 0.9998784065246582
groups O O 0.9989318251609802
of O O 0.9988110065460205
drugs O O 0.9937320351600647
, O O 0.999954104423523
the O O 0.9999797344207764
risks O O 0.9999876022338867
were O O 0.9999741315841675
1 O O 0.9999798536300659
. O O 0.999994158744812
56 O O 0.9999985694885254
( O O 0.9999306201934814
1 O O 0.9999947547912598
. O O 0.9999966621398926
05 O O 0.9999946355819702
- O O 0.9982795715332031
2 O O 0.9999943971633911
. O O 0.9999973773956299
30 O O 0.9999958276748657
) O O 0.9999548196792603
for O O 0.9951412677764893
aspirin B B 0.9978094696998596
, O O 0.9988138675689697
1 O O 0.9999711513519287
. O O 0.9999909400939941
03 O O 0.9999969005584717
( O O 0.9999496936798096
0 O O 0.9999884366989136
. O O 0.9999898672103882
60 O O 0.999997615814209
- O O 0.99795001745224
1 O O 0.9999957084655762
. O O 0.9999959468841553
76 O O 0.9999852180480957
) O O 0.9999388456344604
for O O 0.9958486557006836
pyrazolones B B 0.9818347096443176
, O O 0.9985435009002686
0 O O 0.9999632835388184
. O O 0.9999780654907227
80 O O 0.9983365535736084
( O O 0.9999091625213623
0 O O 0.9999885559082031
. O O 0.9999939203262329
39 O O 0.9999865293502808
- O O 0.9980267882347107
1 O O 0.9999957084655762
. O O 0.9999933242797852
63 O O 0.9999960660934448
) O O 0.9999505281448364
for O O 0.9929602742195129
paracetamol B B 0.997633695602417
, O O 0.9969185590744019
and O O 0.9997753500938416
0 O O 0.9999668598175049
. O O 0.999976396560669
94 O O 0.9999711513519287
( O O 0.9999591112136841
0 O O 0.9999936819076538
. O O 0.9999889135360718
57 O O 0.9999980926513672
- O O 0.9988245368003845
1 O O 0.9999977350234985
. O O 0.9999954700469971
56 O O 0.9999971389770508
) O O 0.9999744892120361
for O O 0.9973723888397217
nonaspirin O O 0.6334743499755859
NSAIDs O O 0.4355224370956421
. O O 0.9999442100524902

The O O 0.9999853372573853
risk O O 0.9999922513961792
of O O 0.9999605417251587
ESRD O O 0.9948225021362305
associated O O 0.9999855756759644
with O O 0.9995797276496887
aspirin B B 0.9989185333251953
was O O 0.9998282194137573
related O O 0.9999938011169434
to O O 0.9999796152114868
the O O 0.9999885559082031
cumulated O O 0.9999181032180786
dose O O 0.9999626874923706
and O O 0.9999876022338867
duration O O 0.999982476234436
of O O 0.9999817609786987
use O O 0.9999606609344482
, O O 0.9999481439590454
and O O 0.9999679327011108
it O O 0.9999850988388062
was O O 0.9999693632125854
particularly O O 0.9999872446060181
high O O 0.9999855756759644
among O O 0.9999629259109497
the O O 0.9999887943267822
subset O O 0.9999855756759644
of O O 0.9999804496765137
patients O O 0.9999905824661255
with O O 0.9999629259109497
vascular O O 0.9999498128890991
nephropathy O O 0.999948263168335
as O O 0.9998705387115479
underlying O O 0.9999798536300659
disease O O 0.999997615814209
[ O O 0.9999316930770874
2 O O 0.9993842840194702
. O O 0.9999803304672241
35 O O 0.9999896287918091
( O O 0.9998193383216858
1 O O 0.9999147653579712
. O O 0.9999803304672241
17 O O 0.999994158744812
- O O 0.9978613257408142
4 O O 0.9999058246612549
. O O 0.9999953508377075
72 O O 0.9999920129776001
) O O 0.9999285936355591
] O O 0.9999727010726929
. O O 0.9999866485595703

CONCLUSION O O 0.9991796612739563
: O O 0.9999767541885376
Our O O 0.9995705485343933
data O O 0.9999902248382568
indicate O O 0.9999316930770874
that O O 0.9998701810836792
long O O 0.999705970287323
- O O 0.9999833106994629
term O O 0.9999397993087769
use O O 0.9999468326568604
of O O 0.9997777342796326
nonaspirin O O 0.6452013254165649
analgesic O O 0.9242669343948364
drugs O O 0.9957126379013062
and O O 0.9955829977989197
NSAIDs O O 0.8099362254142761
is O O 0.9997782111167908
not O O 0.9999336004257202
associated O O 0.9999818801879883
with O O 0.9999887943267822
an O O 0.9999861717224121
increased O O 0.9999903440475464
risk O O 0.9999961853027344
of O O 0.9999827146530151
ESRD O O 0.9964309930801392
. O O 0.9999502897262573

However O O 0.9998395442962646
, O O 0.9999297857284546
the O O 0.9999858140945435
chronic O O 0.9998681545257568
use O O 0.9998526573181152
of O O 0.9992319345474243
aspirin B B 0.9979343414306641
may O O 0.9997990727424622
increase O O 0.9999486207962036
the O O 0.9999885559082031
risk O O 0.999994158744812
of O O 0.9999778270721436
ESRD O O 0.9967228770256042
. O O 0.9999454021453857

Two O O 0.999961256980896
cases O O 0.9999860525131226
of O O 0.999863862991333
amisulpride B B 0.9995538592338562
overdose O O 0.9988429546356201
: O O 0.9999440908432007
a O O 0.99972003698349
cause O O 0.9999871253967285
for O O 0.9999817609786987
prolonged O O 0.9999134540557861
QT O O 0.9809320569038391
syndrome O O 0.9999828338623047
. O O 0.9999204874038696

Two O O 0.9999758005142212
cases O O 0.9999929666519165
of O O 0.9999680519104004
deliberate O O 0.9998801946640015
self O O 0.9998549222946167
- O O 0.9999217987060547
poisoning O O 0.9997155070304871
with O O 0.999859094619751
5 O O 0.9976481795310974
g O O 0.9876651763916016
and O O 0.9995840191841125
3 O O 0.9991501569747925
. O O 0.9999927282333374
6 O O 0.999953031539917
g O O 0.9971319437026978
of O O 0.9956454038619995
amisulpride B B 0.998916745185852
, O O 0.9996833801269531
respectively O O 0.9996519088745117
, O O 0.9999829530715942
are O O 0.9999668598175049
reported O O 0.9999927282333374
. O O 0.9999723434448242

In O O 0.9998136162757874
both O O 0.9997455477714539
cases O O 0.9999449253082275
, O O 0.9998071789741516
QT O O 0.951737642288208
prolongation O O 0.9996637105941772
and O O 0.9999178647994995
hypocalcaemia O O 0.9996144771575928
were O O 0.9999456405639648
noted O O 0.999972939491272
. O O 0.9999592304229736

The O O 0.9999758005142212
QT O O 0.9889315366744995
prolongation O O 0.9999657869338989
appeared O O 0.9999810457229614
to O O 0.9999746084213257
respond O O 0.9999821186065674
to O O 0.9999303817749023
administration O O 0.9999604225158691
of O O 0.9999085664749146
i O O 0.9998487234115601
. O O 0.9999884366989136
v O O 0.9999979734420776
. O O 0.9999083280563354
calcium B B 0.9983604550361633
gluconate I I 0.9993688464164734
. O O 0.9998722076416016

Growth O O 0.6713935732841492
- O O 0.9812182188034058
associated O O 0.9795337915420532
protein O O 0.9956749081611633
43 O O 0.8528633713722229
expression O O 0.9999288320541382
in O O 0.999784529209137
hippocampal O O 0.9969915151596069
molecular O O 0.9999097585678101
layer O O 0.9999833106994629
of O O 0.9999494552612305
chronic O O 0.9987531900405884
epileptic O O 0.9996767044067383
rats O O 0.9998795986175537
treated O O 0.9998772144317627
with O O 0.9972266554832458
cycloheximide B B 0.9988324046134949
. O O 0.9998136162757874

PURPOSE O O 0.6499795317649841
: O O 0.998992383480072
GAP43 O O 0.9192906618118286
has O O 0.9999192953109741
been O O 0.9999843835830688
thought O O 0.9999425411224365
to O O 0.9999423027038574
be O O 0.9999558925628662
linked O O 0.9999719858169556
with O O 0.9998985528945923
mossy O O 0.9988405108451843
fiber O O 0.9988272786140442
sprouting O O 0.9955822825431824
( O O 0.9999204874038696
MFS O O 0.9947460889816284
) O O 0.9999548196792603
in O O 0.9999222755432129
various O O 0.9999220371246338
experimental O O 0.9999359846115112
models O O 0.9999904632568359
of O O 0.9999570846557617
epilepsy O O 0.999932050704956
. O O 0.9999736547470093

To O O 0.9999927282333374
investigate O O 0.999981164932251
how O O 0.999981164932251
GAP43 O O 0.7209864854812622
expression O O 0.9999463558197021
( O O 0.9998462200164795
GAP43 O O 0.6872583031654358
- O O 0.8948323130607605
ir O O 0.8383966684341431
) O O 0.9997029900550842
correlates O O 0.9999884366989136
with O O 0.9999700784683228
MFS O O 0.9832758903503418
, O O 0.9999781847000122
we O O 0.9999781847000122
assessed O O 0.9999895095825195
the O O 0.9999898672103882
intensity O O 0.9999905824661255
( O O 0.99991774559021
densitometry O O 0.9999687671661377
) O O 0.9999781847000122
and O O 0.9999768733978271
extension O O 0.9999914169311523
( O O 0.9999344348907471
width O O 0.9999970197677612
) O O 0.9999949932098389
of O O 0.9999550580978394
GAP43 O B 0.7872830033302307
- O I 0.5550854802131653
ir O I 0.9896474480628967
in O O 0.9982500672340393
the O O 0.9999545812606812
inner O O 0.9994683861732483
molecular O O 0.9998596906661987
layer O O 0.9999927282333374
of O O 0.9999412298202515
the O O 0.9999725818634033
dentate O O 0.9997835755348206
gyrus O O 0.999295711517334
( O O 0.9999173879623413
IML O O 0.9998078942298889
) O O 0.9999724626541138
of O O 0.9999721050262451
rats O O 0.9999853372573853
subject O O 0.9999923706054688
to O O 0.99997878074646
status O O 0.9999914169311523
epilepticus O O 0.9999791383743286
induced O O 0.9999886751174927
by O O 0.9999096393585205
pilocarpine B B 0.9997331500053406
( O O 0.9975857734680176
Pilo B B 0.9991087317466736
) O O 0.9996001124382019
, O O 0.9999864101409912
previously O O 0.9999492168426514
injected O O 0.9999654293060303
or O O 0.9999812841415405
not O O 0.9999756813049316
with O O 0.9999247789382935
cycloheximide B B 0.9985793828964233
( O O 0.9952913522720337
CHX B B 0.9967601895332336
) O O 0.999327540397644
, O O 0.9999849796295166
which O O 0.9999265670776367
has O O 0.999964714050293
been O O 0.9999896287918091
shown O O 0.9999709129333496
to O O 0.9997765421867371
inhibit O O 0.9996213912963867
MFS O O 0.9781261086463928
. O O 0.9999580383300781

METHODS O O 0.9868019223213196
: O O 0.9988974332809448
CHX B B 0.9883105754852295
was O O 0.9998840093612671
injected O O 0.9998644590377808
before O O 0.9999464750289917
the O O 0.9999799728393555
Pilo B B 0.9886257648468018
injection O O 0.9995847344398499
in O O 0.9999608993530273
adult O O 0.9999936819076538
Wistar O O 0.9997897744178772
rats O O 0.9999984502792358
. O O 0.9999727010726929

The O O 0.9999196529388428
Pilo B O 0.6190385222434998
group O O 0.9993742108345032
was O O 0.9999381303787231
injected O O 0.9998584985733032
with O O 0.9999078512191772
the O O 0.9999823570251465
same O O 0.9999245405197144
drugs O O 0.9573506712913513
, O O 0.9999138116836548
except O O 0.9997968077659607
for O O 0.9799817204475403
CHX B B 0.9592064023017883
. O O 0.998917818069458

Animals O O 0.9999854564666748
were O O 0.9999903440475464
killed O O 0.999994158744812
between O O 0.9999790191650391
30 O O 0.9999892711639404
and O O 0.9999865293502808
60 O O 0.999996542930603
days O O 0.9999974966049194
later O O 0.9999969005584717
, O O 0.9999467134475708
and O O 0.9999772310256958
brain O O 0.9999575614929199
sections O O 0.9999881982803345
were O O 0.9999828338623047
processed O O 0.9999940395355225
for O O 0.9998014569282532
GAP43 O O 0.735476553440094
immunohistochemistry O O 0.9996968507766724
. O O 0.9999798536300659

RESULTS O O 0.9995658993721008
: O O 0.9997233748435974
Densitometry O O 0.9595587253570557
showed O O 0.999941349029541
no O O 0.9999699592590332
significant O O 0.9999921321868896
difference O O 0.9999905824661255
regarding O O 0.9999473094940186
GAP43 O O 0.6358418464660645
- O O 0.7888124585151672
ir O O 0.906582236289978
in O O 0.9989039897918701
the O O 0.9998190999031067
IML O O 0.9996694326400757
between O O 0.9962866306304932
Pilo B O 0.7337235808372498
, O O 0.9981268048286438
CHX B B 0.9616838693618774
+ O O 0.9928886294364929
Pilo B O 0.6900207996368408
, O O 0.9983384609222412
and O O 0.9992313385009766
control O O 0.9997925162315369
groups O O 0.9999512434005737
. O O 0.9999656677246094

However O O 0.9999847412109375
, O O 0.999987006187439
the O O 0.999994158744812
results O O 0.9999963045120239
of O O 0.9999781847000122
the O O 0.9999785423278809
width O O 0.9999812841415405
of O O 0.9999523162841797
the O O 0.9999045133590698
GAP43 O O 0.7070820331573486
- O O 0.9178018569946289
ir O O 0.6935039162635803
band O O 0.9947237968444824
in O O 0.9998996257781982
the O O 0.9997593760490417
IML O O 0.9998341798782349
showed O O 0.9999696016311646
that O O 0.999025821685791
CHX B B 0.9847991466522217
+ O O 0.9908447861671448
Pilo B O 0.8696396350860596
and O O 0.9977701902389526
control O O 0.9413466453552246
animals O O 0.996236264705658
had O O 0.9999548196792603
a O O 0.9999818801879883
significantly O O 0.999983549118042
larger O O 0.9999700784683228
band O O 0.999974250793457
( O O 0.9999778270721436
p O O 0.9999346733093262
= O O 0.9999700784683228
0 O O 0.9999852180480957
. O O 0.999996542930603
03 O O 0.9999861717224121
) O O 0.9999711513519287
as O O 0.9999939203262329
compared O O 0.9999942779541016
with O O 0.9999953508377075
that O O 0.9999878406524658
in O O 0.9999289512634277
the O O 0.9998910427093506
Pilo B O 0.934878945350647
group O O 0.9999512434005737
. O O 0.999976634979248

CONCLUSIONS O O 0.9998805522918701
: O O 0.9999798536300659
Our O O 0.9999934434890747
current O O 0.9999958276748657
finding O O 0.9999955892562866
that O O 0.9999784231185913
animals O O 0.9999926090240479
in O O 0.9998984336853027
the O O 0.9998359680175781
CHX B B 0.9440227746963501
+ O O 0.9741619825363159
Pilo B O 0.8489829897880554
group O O 0.9990505576133728
have O O 0.9999499320983887
a O O 0.9999427795410156
GAP43 O O 0.9671252965927124
- O O 0.9882209300994873
ir O O 0.8899672627449036
band O O 0.999767005443573
in O O 0.9996763467788696
the O O 0.9994725584983826
IML O O 0.9970198273658752
, O O 0.9999675750732422
similar O O 0.9999877214431763
to O O 0.9999827146530151
that O O 0.9999921321868896
of O O 0.9999840259552002
controls O O 0.9998915195465088
, O O 0.999981164932251
reinforces O O 0.9999536275863647
prior O O 0.999982476234436
data O O 0.9999948740005493
on O O 0.9999642372131348
the O O 0.9999505281448364
blockade O O 0.9992268085479736
of O O 0.9990697503089905
MFS O O 0.6266692876815796
in O O 0.9998051524162292
these O O 0.9999570846557617
animals O O 0.9999898672103882
. O O 0.9999688863754272

The O O 0.9999856948852539
change O O 0.9999927282333374
in O O 0.9999251365661621
GAP43 O O 0.5237569808959961
- O O 0.9090608358383179
ir O O 0.9032370448112488
present O O 0.9993354678153992
in O O 0.9995751976966858
Pilo B B 0.9894381761550903
- O O 0.9705589413642883
treated O O 0.9968616962432861
animals O O 0.99910968542099
was O O 0.9999732971191406
a O O 0.9999821186065674
thinning O O 0.9999866485595703
of O O 0.9999837875366211
the O O 0.9999737739562988
band O O 0.9999680519104004
to O O 0.9999697208404541
a O O 0.9999709129333496
very O O 0.9999877214431763
narrow O O 0.9999319314956665
layer O O 0.9999687671661377
just O O 0.999961256980896
above O O 0.9999654293060303
the O O 0.9999624490737915
granule O O 0.997132420539856
cell O O 0.9997977614402771
layer O O 0.9999721050262451
that O O 0.9999713897705078
is O O 0.99997878074646
likely O O 0.999970555305481
to O O 0.9999638795852661
be O O 0.9999842643737793
associated O O 0.9999791383743286
with O O 0.9999731779098511
the O O 0.9999850988388062
loss O O 0.9999823570251465
of O O 0.9999023675918579
hilar O O 0.9992902278900146
cell O O 0.9998475313186646
projections O O 0.9980965256690979
that O O 0.9997971653938293
express O O 0.9997894167900085
GAP O B 0.47980278730392456
- O I 0.5409772396087646
43 O I 0.990334689617157
. O O 0.9995099306106567

Nicotine B B 0.998358428478241
antagonizes O O 0.9987207055091858
caffeine B B 0.9997066855430603
- O O 0.9991045594215393
but O O 0.9998102784156799
not O O 0.9998693466186523
pentylenetetrazole B B 0.9942223429679871
- O O 0.999840497970581
induced O O 0.9999222755432129
anxiogenic O O 0.9520437717437744
effect O O 0.9999592304229736
in O O 0.9999111890792847
mice O O 0.9999703168869019
. O O 0.9990589022636414

RATIONALE O O 0.5218642950057983
: O O 0.9985483288764954
Nicotine B B 0.9983956217765808
and O O 0.9081184267997742
caffeine B B 0.9989069700241089
are O O 0.998961329460144
widely O O 0.9971008896827698
consumed O O 0.9838677644729614
licit O O 0.7284843325614929
psychoactive O O 0.929396390914917
drugs O O 0.9603108167648315
worldwide O O 0.9812785387039185
. O O 0.9998842477798462

Epidemiological O O 0.9997360110282898
studies O O 0.9999918937683105
showed O O 0.9999862909317017
that O O 0.9999452829360962
they O O 0.9959447979927063
were O O 0.9999483823776245
generally O O 0.9999351501464844
used O O 0.999945878982544
concurrently O O 0.9998519420623779
. O O 0.9999340772628784

Although O O 0.9999675750732422
some O O 0.9999010562896729
studies O O 0.9999773502349854
in O O 0.9999370574951172
experimental O O 0.9999321699142456
animals O O 0.9999947547912598
indicate O O 0.9998156428337097
clear O O 0.9996702671051025
pharmacological O O 0.9995025396347046
interactions O O 0.999887228012085
between O O 0.9985098242759705
them O O 0.9996691942214966
, O O 0.9999239444732666
no O O 0.9999204874038696
studies O O 0.999975323677063
have O O 0.9999819993972778
shown O O 0.9999607801437378
a O O 0.9999136924743652
specific O O 0.9998751878738403
interaction O O 0.9997624754905701
on O O 0.9998482465744019
anxiety O O 0.9806163311004639
responses O O 0.999935507774353
. O O 0.9999567270278931

OBJECTIVES O O 0.9998637437820435
: O O 0.9999940395355225
The O O 0.9999969005584717
present O O 0.9999922513961792
study O O 0.9999802112579346
investigates O O 0.9998586177825928
the O O 0.9999469518661499
effects O O 0.9998852014541626
of O O 0.9996620416641235
nicotine B B 0.9990474581718445
on O O 0.9980952143669128
anxiety O O 0.9998495578765869
induced O O 0.9999620914459229
by O O 0.9998540878295898
caffeine B B 0.9997503161430359
and O O 0.9983501434326172
another O O 0.9998722076416016
anxiogenic O O 0.9374884366989136
drug O O 0.9973451495170593
, O O 0.9983452558517456
pentylenetetrazole B B 0.996704638004303
, O O 0.9999167919158936
in O O 0.9998760223388672
mice O O 0.9999665021896362
. O O 0.9999796152114868

The O O 0.9999765157699585
elevated O O 0.9999394416809082
plus O O 0.9998461008071899
- O O 0.9998838901519775
maze O O 0.9999305009841919
( O O 0.9999127388000488
EPM O O 0.9949253797531128
) O O 0.9999372959136963
test O O 0.999984860420227
was O O 0.9999778270721436
used O O 0.9999903440475464
to O O 0.9999873638153076
evaluate O O 0.9999880790710449
the O O 0.9999768733978271
effects O O 0.9999227523803711
of O O 0.9998083710670471
drugs O O 0.9641435146331787
on O O 0.9996115565299988
anxiety O O 0.9960632920265198
. O O 0.9999654293060303

METHODS O O 0.9996830224990845
: O O 0.999982476234436
Adult O O 0.9999940395355225
male O O 0.9999877214431763
Swiss O O 0.9974890947341919
Webster O O 0.9895474910736084
mice O O 0.9911332726478577
( O O 0.999976634979248
25 O O 0.9999804496765137
- O O 0.99811851978302
32 O O 0.9999785423278809
g O O 0.9998670816421509
) O O 0.9999732971191406
were O O 0.9999866485595703
given O O 0.9997416138648987
nicotine B B 0.9992916584014893
( O O 0.9985449314117432
0 O O 0.9997188448905945
. O O 0.9999760389328003
05 O O 0.9999704360961914
- O O 0.9980366826057434
0 O O 0.9999911785125732
. O O 0.999997615814209
25 O O 0.9999938011169434
mg O O 0.9999034404754639
/ O O 0.9999797344207764
kg O O 0.9999951124191284
s O O 0.9999128580093384
. O O 0.999993085861206
c O O 0.9999959468841553
. O O 0.999992847442627
) O O 0.9999109506607056
or O O 0.9996033310890198
saline O O 0.9994264841079712
10 O O 0.9999380111694336
min O O 0.9999655485153198
before O O 0.9997426867485046
caffeine B B 0.9998112320899963
( O O 0.9995412826538086
70 O O 0.999961256980896
mg O O 0.9999784231185913
/ O O 0.9999904632568359
kg O O 0.9999973773956299
i O O 0.9995263814926147
. O O 0.9999970197677612
p O O 0.9999990463256836
. O O 0.9999970197677612
) O O 0.9999237060546875
or O O 0.9985424280166626
pentylenetetrazole B B 0.9885268211364746
( O O 0.9959093332290649
15 O O 0.999734103679657
and O O 0.9998194575309753
30 O O 0.9999921321868896
mg O O 0.9999798536300659
/ O O 0.9999949932098389
kg O O 0.9999967813491821
i O O 0.9994660019874573
. O O 0.9999971389770508
p O O 0.9999985694885254
. O O 0.9999963045120239
) O O 0.9999479055404663
injections O O 0.9999362230300903
. O O 0.9999754428863525

After O O 0.999972939491272
15 O O 0.999993085861206
min O O 0.9999874830245972
, O O 0.9999697208404541
mice O O 0.9994680285453796
were O O 0.9999878406524658
evaluated O O 0.9999922513961792
for O O 0.9999899864196777
their O O 0.9999876022338867
open O O 0.999711811542511
- O O 0.9999595880508423
and O O 0.9999347925186157
closed O O 0.9998764991760254
- O O 0.9999569654464722
arm O O 0.999988317489624
time O O 0.9999773502349854
and O O 0.9999188184738159
entries O O 0.9999020099639893
on O O 0.9999308586120605
the O O 0.9999717473983765
EPM O O 0.9849241971969604
for O O 0.9999275207519531
a O O 0.999983549118042
10 O O 0.9999834299087524
- O O 0.999990701675415
min O O 0.9999756813049316
session O O 0.9999911785125732
. O O 0.999977707862854

Locomotor O O 0.9992362260818481
activity O O 0.99992835521698
was O O 0.9999748468399048
recorded O O 0.9999873638153076
for O O 0.9998927116394043
individual O O 0.9998489618301392
groups O O 0.9999781847000122
by O O 0.9999845027923584
using O O 0.9999815225601196
the O O 0.9999945163726807
same O O 0.9999710321426392
treatment O O 0.9999107122421265
protocol O O 0.9999812841415405
with O O 0.9999914169311523
the O O 0.999975323677063
EPM O O 0.8515527844429016
test O O 0.9999474287033081
. O O 0.9999773502349854

RESULTS O O 0.9999393224716187
: O O 0.997689962387085
Nicotine B B 0.999699592590332
( O O 0.9988658428192139
0 O O 0.9994099140167236
. O O 0.9999604225158691
05 O O 0.9999186992645264
- O O 0.995136559009552
0 O O 0.9999585151672363
. O O 0.9999961853027344
25 O O 0.9999867677688599
mg O O 0.9991531372070312
/ O O 0.9997051358222961
kg O O 0.9999107122421265
) O O 0.9993205070495605
itself O O 0.9988908171653748
did O O 0.9999589920043945
not O O 0.9999717473983765
produce O O 0.9999858140945435
any O O 0.9999740123748779
significant O O 0.9999821186065674
effect O O 0.9999650716781616
in O O 0.9999580383300781
the O O 0.9999697208404541
EPM O O 0.9761101007461548
test O O 0.9999856948852539
, O O 0.9998854398727417
whereas O O 0.8412931561470032
caffeine B B 0.9997264742851257
( O O 0.9997537732124329
70 O O 0.9990492463111877
mg O O 0.9998997449874878
/ O O 0.9999333620071411
kg O O 0.9999903440475464
) O O 0.9997605681419373
and O O 0.9977850914001465
pentylenetetrazole B B 0.9923787117004395
( O O 0.999833345413208
30 O O 0.9999555349349976
mg O O 0.9998749494552612
/ O O 0.9999175071716309
kg O O 0.9999840259552002
) O O 0.9999167919158936
produced O O 0.9999605417251587
an O O 0.9998201727867126
anxiogenic O O 0.9971238970756531
effect O O 0.9999667406082153
, O O 0.9999861717224121
apparent O O 0.9999960660934448
with O O 0.9999905824661255
decreases O O 0.9999966621398926
in O O 0.9999899864196777
open O O 0.999448835849762
- O O 0.9999234676361084
arm O O 0.9999899864196777
time O O 0.9999946355819702
and O O 0.9999567270278931
entry O O 0.9999942779541016
. O O 0.9999735355377197

Nicotine B B 0.9988433122634888
( O O 0.9992355108261108
0 O O 0.999736487865448
. O O 0.9999904632568359
25 O O 0.9999032020568848
mg O O 0.9994685053825378
/ O O 0.999405026435852
kg O O 0.9998903274536133
) O O 0.9996764659881592
pretreatment O O 0.9995446801185608
blocked O O 0.9973344802856445
the O O 0.9999626874923706
caffeine B B 0.9996248483657837
- O O 0.9994285702705383
but O O 0.9999309778213501
not O O 0.9998867511749268
pentylenetetrazole B B 0.9959914088249207
- O O 0.9998770952224731
induced O O 0.9999287128448486
anxiety O O 0.9999167919158936
. O O 0.9999575614929199

Administration O O 0.9999508857727051
of O O 0.9999246597290039
each O O 0.999674916267395
drug O O 0.9989153146743774
and O O 0.9996569156646729
their O O 0.9965701103210449
combinations O O 0.9987475872039795
did O O 0.9999278783798218
not O O 0.9999402761459351
produce O O 0.9999822378158569
any O O 0.9999628067016602
effect O O 0.9999758005142212
on O O 0.9999470710754395
locomotor O O 0.9999597072601318
activity O O 0.9999839067459106
. O O 0.9999527931213379

CONCLUSIONS O O 0.998773992061615
: O O 0.9999939203262329
Our O O 0.9985016584396362
results O O 0.9999839067459106
suggest O O 0.9999363422393799
that O O 0.9999150037765503
the O O 0.9999737739562988
antagonistic O O 0.9996334314346313
effect O O 0.9998843669891357
of O O 0.999711811542511
nicotine B B 0.9992330074310303
on O O 0.9995394945144653
caffeine B B 0.9997009038925171
- O O 0.999477207660675
induced O O 0.9998759031295776
anxiety O O 0.9998451471328735
is O O 0.9999011754989624
specific O O 0.9999262094497681
to O O 0.9986218214035034
caffeine B B 0.9991476535797119
, O O 0.9998132586479187
instead O O 0.9999861717224121
of O O 0.9999706745147705
a O O 0.9999065399169922
non O O 0.9988823533058167
- O O 0.9999663829803467
specific O O 0.9999419450759888
anxiolytic O O 0.7829864025115967
effect O O 0.9999077320098877
. O O 0.999970555305481

Thus O O 0.9999663829803467
, O O 0.9999645948410034
it O O 0.9999701976776123
may O O 0.999945878982544
extend O O 0.9999735355377197
the O O 0.9999943971633911
current O O 0.9999914169311523
findings O O 0.9999938011169434
on O O 0.9997794032096863
the O O 0.9998875856399536
interaction O O 0.999744713306427
between O O 0.9981330037117004
nicotine B B 0.9981458187103271
and O O 0.9862396121025085
caffeine B B 0.998894989490509
. O O 0.9999469518661499

Long O O 0.9995195865631104
term O O 0.99937504529953
hormone O O 0.6597490906715393
therapy O O 0.9982978701591492
for O O 0.9998685121536255
perimenopausal O O 0.9994159936904907
and O O 0.9999110698699951
postmenopausal O O 0.9998372793197632
women O O 0.9999880790710449
. O O 0.9998927116394043

BACKGROUND O O 0.7381356358528137
: O O 0.9213253259658813
Hormone O O 0.6773108243942261
therapy O O 0.5222819447517395
( O O 0.9878147840499878
HT O B 0.9228941202163696
) O O 0.9872727990150452
is O O 0.9998089671134949
widely O O 0.9995162487030029
used O O 0.9998546838760376
for O O 0.9998679161071777
controlling O O 0.9998421669006348
menopausal O O 0.9965358972549438
symptoms O O 0.9999974966049194
. O O 0.9999468326568604

It O O 0.6347121596336365
has O O 0.9997653365135193
also O O 0.9998351335525513
been O O 0.9999356269836426
used O O 0.9998235106468201
for O O 0.9998639822006226
the O O 0.9999487400054932
management O O 0.9999924898147583
and O O 0.9999842643737793
prevention O O 0.9999890327453613
of O O 0.9999707937240601
cardiovascular O O 0.9999905824661255
disease O O 0.9999984502792358
, O O 0.9999697208404541
osteoporosis O O 0.9989458918571472
and O O 0.9998843669891357
dementia O O 0.9999971389770508
in O O 0.9999476671218872
older O O 0.9997928738594055
women O O 0.9999665021896362
but O O 0.9999773502349854
the O O 0.9999983310699463
evidence O O 0.9999970197677612
supporting O O 0.9999909400939941
its O O 0.999895453453064
use O O 0.9999634027481079
for O O 0.9999406337738037
these O O 0.999862551689148
indications O O 0.9998995065689087
is O O 0.9999860525131226
largely O O 0.9999927282333374
observational O O 0.9999927282333374
. O O 0.9999744892120361

OBJECTIVES O O 0.9995788931846619
: O O 0.9999895095825195
To O O 0.9999898672103882
assess O O 0.999980092048645
the O O 0.9999711513519287
effect O O 0.9999722242355347
of O O 0.9999202489852905
long O O 0.9993058443069458
- O O 0.9999891519546509
term O O 0.9999117851257324
HT O O 0.8203549981117249
on O O 0.9746339321136475
mortality O O 0.9996516704559326
, O O 0.9999713897705078
heart O O 0.9999926090240479
disease O O 0.9999967813491821
, O O 0.999944806098938
venous O O 0.9999653100967407
thromboembolism O O 0.9995977282524109
, O O 0.9999176263809204
stroke O O 0.9999927282333374
, O O 0.9999529123306274
transient O O 0.9999802112579346
ischaemic O O 0.9999852180480957
attacks O O 0.9999970197677612
, O O 0.9999818801879883
breast O O 0.9996386766433716
cancer O O 0.9999673366546631
, O O 0.9999481439590454
colorectal O O 0.9990924596786499
cancer O O 0.9998500347137451
, O O 0.9999134540557861
ovarian O O 0.9858684539794922
cancer O O 0.9998935461044312
, O O 0.9999393224716187
endometrial O O 0.9978262782096863
cancer O O 0.9998847246170044
, O O 0.9999629259109497
gallbladder O O 0.9591847658157349
disease O O 0.9999749660491943
, O O 0.9999785423278809
cognitive O O 0.9995730519294739
function O O 0.9999978542327881
, O O 0.9999877214431763
dementia O O 0.9999972581863403
, O O 0.9999845027923584
fractures O O 0.9998788833618164
and O O 0.9999845027923584
quality O O 0.9999871253967285
of O O 0.9998425245285034
life O O 0.9999688863754272
. O O 0.9999822378158569

SEARCH O O 0.9988497495651245
STRATEGY O O 0.9999842643737793
: O O 0.9998602867126465
We O O 0.9998525381088257
searched O O 0.9998922348022461
the O O 0.9999529123306274
following O O 0.9999101161956787
databases O O 0.9999538660049438
up O O 0.9998338222503662
to O O 0.999697208404541
November O O 0.9376944303512573
2004 O O 0.9997867941856384
: O O 0.9999055862426758
the O O 0.9998291730880737
Cochrane O O 0.9602822661399841
Menstrual O O 0.9981862902641296
Disorders O O 0.999901533126831
and O O 0.9995712637901306
Subfertility O O 0.9871777296066284
Group O O 0.9993703961372375
Trials O O 0.999757707118988
Register O O 0.9998692274093628
, O O 0.9998732805252075
Cochrane O O 0.7892611026763916
Central O O 0.9997085928916931
Register O O 0.9998997449874878
of O O 0.997623860836029
Controlled O O 0.9999001026153564
Trials O O 0.9999727010726929
( O O 0.9995213747024536
CENTRAL O O 0.997986912727356
) O O 0.9999420642852783
, O O 0.9998867511749268
MEDLINE O O 0.9942024350166321
, O O 0.9998577833175659
EMBASE O O 0.995573878288269
, O O 0.9998950958251953
Biological O O 0.9996479749679565
Abstracts O O 0.9999772310256958
. O O 0.9999443292617798

Relevant O O 0.9998794794082642
non O O 0.9985101819038391
- O O 0.9999197721481323
indexed O O 0.9999330043792725
journals O O 0.9999752044677734
and O O 0.9999570846557617
conference O O 0.9998762607574463
abstracts O O 0.99997878074646
were O O 0.9999376535415649
also O O 0.9999762773513794
searched O O 0.9999063014984131
. O O 0.9999488592147827

SELECTION O O 0.9999850988388062
CRITERIA O O 0.9999974966049194
: O O 0.9999877214431763
Randomised O O 0.999988317489624
double O O 0.9999053478240967
- O O 0.9999581575393677
blind O O 0.9999685287475586
trials O O 0.9999600648880005
of O O 0.9997439980506897
HT O B 0.882697582244873
( O O 0.8955310583114624
oestrogens B O 0.5385391116142273
with O O 0.9939107894897461
or O O 0.9995318651199341
without O O 0.9997552037239075
progestogens B O 0.6745811104774475
) O O 0.9988054037094116
versus O O 0.9995871186256409
placebo O O 0.9997419714927673
, O O 0.99998939037323
taken O O 0.9999939203262329
for O O 0.9999769926071167
at O O 0.9999951124191284
least O O 0.999995231628418
one O O 0.9999923706054688
year O O 0.9999896287918091
by O O 0.9999886751174927
perimenopausal O O 0.9995846152305603
or O O 0.9999499320983887
postmenopausal O O 0.9998254179954529
women O O 0.9999964237213135
. O O 0.9999889135360718

DATA O O 0.9996359348297119
COLLECTION O O 0.9999960660934448
AND O O 0.99998939037323
ANALYSIS O O 0.9999184608459473
: O O 0.9999752044677734
Fifteen O O 0.9664192795753479
RCTs O O 0.9863727688789368
were O O 0.9998668432235718
included O O 0.9998786449432373
. O O 0.9998884201049805

Trials O O 0.9999420642852783
were O O 0.9999765157699585
assessed O O 0.9999958276748657
for O O 0.999972939491272
quality O O 0.9999959468841553
and O O 0.9999635219573975
two O O 0.9998446702957153
review O O 0.9995909333229065
authors O O 0.9990023970603943
extracted O O 0.9999408721923828
data O O 0.9998530149459839
independently O O 0.9999759197235107
. O O 0.9999843835830688

They O O 0.9999873638153076
calculated O O 0.9999762773513794
risk O O 0.9999864101409912
ratios O O 0.9999903440475464
for O O 0.9999159574508667
dichotomous O O 0.9999656677246094
outcomes O O 0.9999916553497314
and O O 0.9999728202819824
weighted O O 0.9998958110809326
mean O O 0.9999943971633911
differences O O 0.9999978542327881
for O O 0.9999505281448364
continuous O O 0.999982476234436
outcomes O O 0.9999945163726807
. O O 0.9999791383743286

Clinical O O 0.9999703168869019
heterogeneity O O 0.9999988079071045
precluded O O 0.9999902248382568
meta O O 0.9996471405029297
- O O 0.9999715089797974
analysis O O 0.9999538660049438
for O O 0.999961256980896
most O O 0.9997780919075012
outcomes O O 0.9999878406524658
. O O 0.9999693632125854

MAIN O O 0.9998911619186401
RESULTS O O 0.9999456405639648
: O O 0.9999182224273682
All O O 0.9999779462814331
the O O 0.9999920129776001
statistically O O 0.9999716281890869
significant O O 0.9999935626983643
results O O 0.999991774559021
were O O 0.9999920129776001
derived O O 0.9999982118606567
from O O 0.9999819993972778
the O O 0.9999649524688721
two O O 0.999957799911499
biggest O O 0.9998573064804077
trials O O 0.9999521970748901
. O O 0.9999619722366333

In O O 0.9998904466629028
relatively O O 0.9999744892120361
healthy O O 0.9999860525131226
women O O 0.9999876022338867
, O O 0.9999114274978638
combined O O 0.9770448207855225
continuous O O 0.7136069536209106
HT O O 0.4618162214756012
significantly O O 0.9997631907463074
increased O O 0.9999547004699707
the O O 0.9999938011169434
risk O O 0.9999974966049194
of O O 0.9999735355377197
venous O O 0.9999544620513916
thromboembolism O O 0.9999788999557495
or O O 0.9999572038650513
coronary O O 0.9999595880508423
event O O 0.9999983310699463
( O O 0.9999606609344482
after O O 0.9999674558639526
one O O 0.9999966621398926
year O O 0.9999879598617554
' O O 0.9999951124191284
s O O 0.9999713897705078
use O O 0.9999330043792725
) O O 0.999962568283081
, O O 0.9999696016311646
stroke O O 0.9999958276748657
( O O 0.9999740123748779
after O O 0.9999668598175049
3 O O 0.9999629259109497
years O O 0.9999856948852539
) O O 0.9999762773513794
, O O 0.999977707862854
breast O O 0.9995322227478027
cancer O O 0.9999567270278931
( O O 0.9999512434005737
after O O 0.9999456405639648
5 O O 0.9999769926071167
years O O 0.9999639987945557
) O O 0.9999701976776123
and O O 0.9999411106109619
gallbladder O O 0.9988321661949158
disease O O 0.9999880790710449
. O O 0.999963641166687

Long O O 0.9945248365402222
- O O 0.9998960494995117
term O O 0.9995627999305725
oestrogen B B 0.9391796588897705
- O O 0.9605047702789307
only O O 0.9869570732116699
HT O O 0.7430246472358704
also O O 0.9998666048049927
significantly O O 0.9999561309814453
increased O O 0.9999529123306274
the O O 0.9999877214431763
risk O O 0.999996542930603
of O O 0.9999849796295166
stroke O O 0.9999743700027466
and O O 0.9999755620956421
gallbladder O O 0.9994813799858093
disease O O 0.9999867677688599
. O O 0.9999246597290039

Overall O O 0.9999449253082275
, O O 0.9999716281890869
the O O 0.9999779462814331
only O O 0.9999833106994629
statistically O O 0.999876856803894
significant O O 0.9999891519546509
benefits O O 0.9999963045120239
of O O 0.9997740387916565
HT O B 0.9704722762107849
were O O 0.9999103546142578
a O O 0.999995231628418
decreased O O 0.9999953508377075
incidence O O 0.9999979734420776
of O O 0.9999834299087524
fractures O O 0.9999672174453735
and O O 0.9999823570251465
colon O O 0.9994634985923767
cancer O O 0.9999575614929199
with O O 0.9999806880950928
long O O 0.999757707118988
- O O 0.9999867677688599
term O O 0.9999381303787231
use O O 0.9999125003814697
. O O 0.9999779462814331

Among O O 0.9998224377632141
relatively O O 0.9999784231185913
healthy O O 0.9999709129333496
women O O 0.9999948740005493
over O O 0.9999909400939941
65 O O 0.999995231628418
years O O 0.9999866485595703
taking O O 0.9996899366378784
continuous O O 0.9668833017349243
combined O O 0.8608242869377136
HT O O 0.517175555229187
, O O 0.9999228715896606
there O O 0.9999788999557495
was O O 0.999985933303833
a O O 0.9999932050704956
statistically O O 0.9999781847000122
significant O O 0.9999955892562866
increase O O 0.9999969005584717
in O O 0.9999942779541016
the O O 0.999996542930603
incidence O O 0.999997615814209
of O O 0.9999803304672241
dementia O O 0.9999971389770508
. O O 0.9999796152114868

Among O O 0.9991635084152222
women O O 0.9999957084655762
with O O 0.9999752044677734
cardiovascular O O 0.9999690055847168
disease O O 0.9999954700469971
, O O 0.9998527765274048
long O O 0.9997603297233582
- O O 0.9999823570251465
term O O 0.9999496936798096
use O O 0.9999395608901978
of O O 0.9995958209037781
combined O O 0.8039789795875549
continuous O O 0.7032749056816101
HT O O 0.5525814294815063
significantly O O 0.9996837377548218
increased O O 0.9999748468399048
the O O 0.9999959468841553
risk O O 0.9999985694885254
of O O 0.9999936819076538
venous O O 0.9999916553497314
thromboembolism O O 0.9999880790710449
. O O 0.9999746084213257

No O O 0.9995995163917542
trials O O 0.9999797344207764
focussed O O 0.9999749660491943
specifically O O 0.9999793767929077
on O O 0.9999569654464722
younger O O 0.9999909400939941
women O O 0.9999583959579468
. O O 0.9999555349349976

However O O 0.9999669790267944
, O O 0.9999419450759888
one O O 0.9999845027923584
trial O O 0.9999902248382568
analysed O O 0.999569833278656
subgroups O O 0.9997746348381042
of O O 0.9999600648880005
2839 O O 0.9990220069885254
relatively O O 0.999975323677063
healthy O O 0.9999862909317017
50 O O 0.9999877214431763
to O O 0.9999932050704956
59 O O 0.9999973773956299
year O O 0.9999946355819702
- O O 0.9999918937683105
old O O 0.9999639987945557
women O O 0.999992847442627
taking O O 0.9991844296455383
combined O O 0.9801586270332336
continuous O O 0.4861881732940674
HT O O 0.37438642978668213
and O O 0.9986780285835266
1637 O O 0.7764168977737427
taking O O 0.9988895058631897
oestrogen B B 0.8554884791374207
- O O 0.9661101698875427
only O O 0.9944300055503845
HT O O 0.7406017780303955
, O O 0.9998134970664978
versus O O 0.9998836517333984
similar O O 0.9998519420623779
- O O 0.9999864101409912
sized O O 0.9999641180038452
placebo O O 0.9996941089630127
groups O O 0.9997627139091492
. O O 0.9999374151229858

The O O 0.9999784231185913
only O O 0.9999834299087524
significantly O O 0.9999885559082031
increased O O 0.999985933303833
risk O O 0.9999946355819702
reported O O 0.999994158744812
was O O 0.9999827146530151
for O O 0.9999561309814453
venous O O 0.9999384880065918
thromboembolism O O 0.9999432563781738
in O O 0.9999167919158936
women O O 0.999997615814209
taking O O 0.9995166063308716
combined O O 0.9529955387115479
continuous O O 0.6501722931861877
HT O O 0.6385143399238586
; O O 0.9999545812606812
their O O 0.9999891519546509
absolute O O 0.9999783039093018
risk O O 0.9999959468841553
remained O O 0.9999887943267822
very O O 0.9999933242797852
low O O 0.9999933242797852
. O O 0.999984860420227

AUTHORS O O 0.9996460676193237
' O O 0.9998810291290283
CONCLUSIONS O O 0.9999749660491943
: O O 0.9998704195022583
HT O O 0.7314249873161316
is O O 0.9998379945755005
not O O 0.9999707937240601
indicated O O 0.9999415874481201
for O O 0.9999662637710571
the O O 0.9999935626983643
routine O O 0.999976396560669
management O O 0.9999877214431763
of O O 0.999990701675415
chronic O O 0.9998088479042053
disease O O 0.9999933242797852
. O O 0.9999737739562988

We O O 0.9999700784683228
need O O 0.9999794960021973
more O O 0.9999847412109375
evidence O O 0.9999852180480957
on O O 0.9999446868896484
the O O 0.9999887943267822
safety O O 0.9999736547470093
of O O 0.9957898259162903
HT O B 0.9817012548446655
for O O 0.9976782202720642
menopausal O O 0.5903030633926392
symptom O O 0.9995853304862976
control O O 0.9996693134307861
, O O 0.9999768733978271
though O O 0.9999822378158569
short O O 0.999687910079956
- O O 0.9999696016311646
term O O 0.9998782873153687
use O O 0.9999033212661743
appears O O 0.9999741315841675
to O O 0.9999760389328003
be O O 0.9999867677688599
relatively O O 0.999977707862854
safe O O 0.9999690055847168
for O O 0.9999687671661377
healthy O O 0.9999885559082031
younger O O 0.9999966621398926
women O O 0.9999967813491821
. O O 0.9999685287475586

Drug O O 0.6064361333847046
- O O 0.9991951584815979
induced O O 0.9999504089355469
liver O O 0.9985538125038147
injury O O 0.9999852180480957
: O O 0.9999732971191406
an O O 0.9999836683273315
analysis O O 0.9999740123748779
of O O 0.9999797344207764
461 O O 0.9999843835830688
incidences O O 0.999987006187439
submitted O O 0.9999967813491821
to O O 0.9999903440475464
the O O 0.9999947547912598
Spanish O O 0.9999455213546753
registry O O 0.9999951124191284
over O O 0.9999624490737915
a O O 0.9999841451644897
10 O O 0.999974250793457
- O O 0.9999890327453613
year O O 0.9999955892562866
period O O 0.9999948740005493
. O O 0.9999774694442749

BACKGROUND O O 0.9999135732650757
& O O 0.9999510049819946
AIMS O O 0.9999563694000244
: O O 0.999985933303833
Progress O O 0.9999990463256836
in O O 0.9999933242797852
the O O 0.9999957084655762
understanding O O 0.9999955892562866
of O O 0.9999773502349854
susceptibility O O 0.9999877214431763
factors O O 0.9999940395355225
to O O 0.9999724626541138
drug O O 0.9967658519744873
- O O 0.9998478889465332
induced O O 0.99994957447052
liver O O 0.9962956309318542
injury O O 0.9999903440475464
( O O 0.9997819066047668
DILI O O 0.965041995048523
) O O 0.9999417066574097
and O O 0.9999375343322754
outcome O O 0.9999455213546753
predictability O O 0.9999942779541016
are O O 0.9999829530715942
hampered O O 0.9999971389770508
by O O 0.9999860525131226
the O O 0.999993085861206
lack O O 0.9999948740005493
of O O 0.9999910593032837
systematic O O 0.9999513626098633
programs O O 0.999988317489624
to O O 0.9999908208847046
detect O O 0.9999810457229614
bona O O 0.9998570680618286
fide O O 0.9998722076416016
cases O O 0.9999370574951172
. O O 0.9999825954437256

METHODS O O 0.999910831451416
: O O 0.9999527931213379
A O O 0.9999492168426514
cooperative O O 0.9990191459655762
network O O 0.9999918937683105
was O O 0.9999700784683228
created O O 0.9999924898147583
in O O 0.9999769926071167
1994 O O 0.9979904890060425
in O O 0.9998941421508789
Spain O O 0.913920521736145
to O O 0.9999513626098633
identify O O 0.9999655485153198
all O O 0.9999123811721802
suspicions O O 0.9984660148620605
of O O 0.999680757522583
DILI O O 0.923240065574646
following O O 0.999923825263977
a O O 0.9999794960021973
prospective O O 0.9999921321868896
structured O O 0.9999856948852539
report O O 0.9999954700469971
form O O 0.9999915361404419
. O O 0.9999723434448242

The O O 0.9999562501907349
liver O O 0.9990062117576599
damage O O 0.9999804496765137
was O O 0.9999616146087646
characterized O O 0.9999940395355225
according O O 0.9999908208847046
to O O 0.9999336004257202
hepatocellular O O 0.9988666772842407
, O O 0.9997313618659973
cholestatic O O 0.9984868764877319
, O O 0.9995852112770081
and O O 0.9991963505744934
mixed O O 0.9990021586418152
laboratory O O 0.9999868869781494
criteria O O 0.9999843835830688
and O O 0.999984622001648
to O O 0.9999009370803833
histologic O O 0.9999265670776367
criteria O O 0.9999805688858032
when O O 0.9999908208847046
available O O 0.9999948740005493
. O O 0.9999780654907227

Further O O 0.9999603033065796
evaluation O O 0.999984860420227
of O O 0.9999322891235352
causality O O 0.9999542236328125
assessment O O 0.9999812841415405
was O O 0.9999617338180542
centrally O O 0.9999619722366333
performed O O 0.9999898672103882
. O O 0.9999674558639526

RESULTS O O 0.9997385144233704
: O O 0.9998917579650879
Since O O 0.9990423321723938
April O B 0.997614860534668
1994 O O 0.9991737008094788
to O O 0.999384880065918
August O O 0.6524243354797363
2004 O O 0.9038439989089966
, O O 0.9999654293060303
461 O O 0.999992847442627
out O O 0.9999797344207764
of O O 0.9999868869781494
570 O O 0.9999912977218628
submitted O O 0.9999904632568359
cases O O 0.9999393224716187
, O O 0.999976396560669
involving O O 0.9998912811279297
505 O O 0.9822009205818176
drugs O O 0.9946534633636475
, O O 0.9999716281890869
were O O 0.9999179840087891
deemed O O 0.9999876022338867
to O O 0.9999421834945679
be O O 0.9999479055404663
related O O 0.9999749660491943
to O O 0.9994940757751465
DILI O O 0.6745388507843018
. O O 0.9998680353164673

The O O 0.9998898506164551
antiinfective O O 0.7387300729751587
group O O 0.9775935411453247
of O O 0.9962043166160583
drugs O O 0.9945341348648071
was O O 0.9998469352722168
the O O 0.9997106194496155
more O O 0.999798595905304
frequently O O 0.9999244213104248
incriminated O O 0.9955669045448303
, O O 0.9996869564056396
amoxicillin B B 0.998562753200531
- I I 0.8642072081565857
clavulanate I I 0.9991936087608337
accounting O O 0.9998283386230469
for O O 0.9999717473983765
the O O 0.9999881982803345
12 O O 0.9999895095825195
. O O 0.9999823570251465
8 O O 0.9999953508377075
% O O 0.9999942779541016
of O O 0.9999868869781494
the O O 0.999990701675415
whole O O 0.9999524354934692
series O O 0.9999839067459106
. O O 0.9999617338180542

The O O 0.9999649524688721
hepatocellular O O 0.999512791633606
pattern O O 0.9999712705612183
of O O 0.9999103546142578
damage O O 0.9999755620956421
was O O 0.9999626874923706
the O O 0.999990701675415
most O O 0.9999916553497314
common O O 0.9999880790710449
( O O 0.9999687671661377
58 O O 0.9999936819076538
% O O 0.9999973773956299
) O O 0.999969482421875
, O O 0.9999852180480957
was O O 0.9999898672103882
inversely O O 0.9999301433563232
correlated O O 0.9999979734420776
with O O 0.999984860420227
age O O 0.9999483823776245
( O O 0.9999544620513916
P O O 0.9997877478599548
< O O 0.9999881982803345
. O O 0.9999971389770508
0001 O O 0.999919056892395
) O O 0.9999380111694336
, O O 0.9999202489852905
and O O 0.9999686479568481
had O O 0.9999823570251465
the O O 0.9999914169311523
worst O O 0.9999881982803345
outcome O O 0.9999966621398926
( O O 0.9998594522476196
Cox O O 0.8210741877555847
regression O O 0.9997550845146179
, O O 0.9999507665634155
P O O 0.9993141889572144
< O O 0.9999619722366333
. O O 0.9999972581863403
034 O O 0.9999946355819702
) O O 0.9999649524688721
. O O 0.9999686479568481

Indeed O O 0.999970555305481
, O O 0.9999730587005615
the O O 0.9999926090240479
incidence O O 0.9999979734420776
of O O 0.9999862909317017
liver O O 0.9843426942825317
transplantation O O 0.99993896484375
and O O 0.9999407529830933
death O O 0.9999921321868896
in O O 0.9999490976333618
this O O 0.9999544620513916
group O O 0.9999781847000122
was O O 0.9999711513519287
11 O O 0.9999911785125732
. O O 0.9999958276748657
7 O O 0.9999967813491821
% O O 0.9999967813491821
if O O 0.999963641166687
patients O O 0.9999825954437256
had O O 0.9999598264694214
jaundice O O 0.9998619556427002
at O O 0.9999486207962036
presentation O O 0.9999923706054688
, O O 0.9999477863311768
whereas O O 0.9999570846557617
the O O 0.9999872446060181
corresponding O O 0.9999855756759644
figure O O 0.9999895095825195
was O O 0.9999794960021973
3 O O 0.9999619722366333
. O O 0.9999934434890747
8 O O 0.9999947547912598
% O O 0.9999933242797852
in O O 0.9999585151672363
nonjaundiced O O 0.9627783894538879
patients O O 0.9999839067459106
( O O 0.9999402761459351
P O O 0.9999394416809082
< O O 0.9999837875366211
. O O 0.9999972581863403
04 O O 0.9999308586120605
) O O 0.9999706745147705
. O O 0.9999781847000122

Factors O O 0.9999796152114868
associated O O 0.9999837875366211
with O O 0.9999871253967285
the O O 0.9999932050704956
development O O 0.9999948740005493
of O O 0.9999887943267822
fulminant O O 0.999981164932251
hepatic O O 0.999954342842102
failure O O 0.999996542930603
were O O 0.9999613761901855
female O O 0.9997286200523376
sex O O 0.9999009370803833
( O O 0.9999279975891113
OR O O 0.99957674741745
= O O 0.9999433755874634
25 O O 0.999942421913147
; O O 0.9999425411224365
95 O O 0.99970942735672
% O O 0.999430239200592
CI O O 0.9950904846191406
: O O 0.9999505281448364
4 O O 0.9957006573677063
. O O 0.9997687935829163
1 O O 0.9999582767486572
- O O 0.9957727789878845
151 O O 0.9848344326019287
; O O 0.9999767541885376
P O O 0.9992032647132874
< O O 0.9999926090240479
. O O 0.9999984502792358
0001 O O 0.9995539784431458
) O O 0.9999475479125977
, O O 0.999930739402771
hepatocellular O O 0.999609649181366
damage O O 0.9845594763755798
( O O 0.9999338388442993
OR O O 0.9998816251754761
= O O 0.9999598264694214
7 O O 0.9999641180038452
. O O 0.9999899864196777
9 O O 0.9999717473983765
; O O 0.9999462366104126
95 O O 0.9984476566314697
% O O 0.9991461038589478
CI O O 0.9946070313453674
: O O 0.9999473094940186
1 O O 0.999994158744812
. O O 0.9998990297317505
6 O O 0.9999899864196777
- O O 0.9972801208496094
37 O O 0.9997727274894714
; O O 0.999968409538269
P O O 0.9989985823631287
< O O 0.9999575614929199
. O O 0.9999982118606567
009 O O 0.9999961853027344
) O O 0.9999741315841675
, O O 0.9999361038208008
and O O 0.9999501705169678
higher O O 0.9999547004699707
baseline O O 0.9999932050704956
plasma O O 0.49163034558296204
bilirubin B B 0.9707800149917603
value O O 0.9989631175994873
( O O 0.999971866607666
OR O O 0.9998853206634521
= O O 0.9999926090240479
1 O O 0.9999986886978149
. O O 0.999998927116394
15 O O 0.9999995231628418
; O O 0.9999761581420898
95 O O 0.9997435212135315
% O O 0.9994439482688904
CI O O 0.9960414171218872
: O O 0.9999687671661377
1 O O 0.999996542930603
. O O 0.9999980926513672
09 O O 0.9999988079071045
- O O 0.9986397624015808
1 O O 0.9999984502792358
. O O 0.9999992847442627
22 O O 0.9999986886978149
; O O 0.9999890327453613
P O O 0.9997867941856384
< O O 0.9999936819076538
. O O 0.9999985694885254
0001 O O 0.9996322393417358
) O O 0.999982476234436
. O O 0.999984860420227

CONCLUSIONS O O 0.9994022846221924
: O O 0.9999803304672241
Patients O O 0.9999909400939941
with O O 0.9999713897705078
drug O O 0.9976237416267395
- O O 0.999784529209137
induced O O 0.99994957447052
hepatocellular O O 0.9974380731582642
jaundice O O 0.9955044388771057
have O O 0.9999648332595825
11 O O 0.999981164932251
. O O 0.9999953508377075
7 O O 0.9999967813491821
% O O 0.9999977350234985
chance O O 0.9999994039535522
of O O 0.9999960660934448
progressing O O 0.9999977350234985
to O O 0.999984622001648
death O O 0.9999920129776001
or O O 0.9999909400939941
transplantation O O 0.9999587535858154
. O O 0.9999759197235107

Amoxicillin B B 0.9958756566047668
- I I 0.9269274473190308
clavulanate I I 0.9989566802978516
stands O O 0.9921820163726807
out O O 0.9997004270553589
as O O 0.999869704246521
the O O 0.9997912049293518
most O O 0.9999444484710693
common O O 0.9998101592063904
drug O O 0.999087929725647
related O O 0.9999344348907471
to O O 0.9996980428695679
DILI O O 0.7980867624282837
. O O 0.9998823404312134

Morphological O O 0.9998190999031067
evaluation O O 0.9999715089797974
of O O 0.9999579191207886
the O O 0.9999628067016602
effect O O 0.9998762607574463
of O O 0.9986423850059509
d B B 0.9765927791595459
- I I 0.9967247843742371
ribose I I 0.9999771118164062
on O O 0.9986047148704529
adriamycin B B 0.9994651675224304
- O O 0.9997381567955017
evoked O O 0.9998741149902344
cardiotoxicity O O 0.9999960660934448
in O O 0.999933123588562
rats O O 0.9999765157699585
. O O 0.9999762773513794

The O O 0.999981164932251
influence O O 0.9999569654464722
of O O 0.9993878602981567
d B B 0.9461185932159424
- I I 0.9978711605072021
ribose I I 0.9999914169311523
on O O 0.9990574717521667
adriamycin B B 0.9995419979095459
- O O 0.9997538924217224
induced O O 0.9999624490737915
myocardiopathy O O 0.9999984502792358
in O O 0.999963641166687
rats O O 0.9999710321426392
was O O 0.999971866607666
studied O O 0.9999533891677856
. O O 0.9999675750732422

Adriamycin B B 0.9994651675224304
in O O 0.9998282194137573
the O O 0.9999908208847046
cumulative O O 0.9998676776885986
dose O O 0.9999481439590454
of O O 0.9998608827590942
25 O O 0.999922513961792
mg O O 0.9999444484710693
/ O O 0.9999659061431885
kg O O 0.9999909400939941
evoked O O 0.9998109936714172
fully O O 0.9999912977218628
developed O O 0.9999918937683105
cardiac O O 0.9999498128890991
toxicity O O 0.9999822378158569
. O O 0.9999498128890991

D B B 0.9214676022529602
- I I 0.9903832077980042
ribose I I 0.9998611211776733
in O O 0.9994402527809143
the O O 0.9999769926071167
multiple O O 0.9999738931655884
doses O O 0.9999737739562988
of O O 0.9999169111251831
200 O O 0.9987084865570068
mg O O 0.9998094439506531
/ O O 0.999846339225769
kg O O 0.9999498128890991
did O O 0.9999532699584961
not O O 0.9999129772186279
influence O O 0.9915751814842224
ADR B O 0.4846152067184448
cardiotoxicity O O 0.9999712705612183
. O O 0.9999630451202393

In O O 0.9996738433837891
vivo O O 0.9999713897705078
evidences O O 0.9999265670776367
suggesting O O 0.9999250173568726
the O O 0.9999613761901855
role O O 0.9999504089355469
of O O 0.9998296499252319
oxidative O O 0.9631553292274475
stress O O 0.9984517097473145
in O O 0.9998718500137329
pathogenesis O O 0.999987006187439
of O O 0.9998854398727417
vancomycin B B 0.9999221563339233
- O O 0.9996660947799683
induced O O 0.9999227523803711
nephrotoxicity O O 0.9999481439590454
: O O 0.9994333386421204
protection O O 0.9997507929801941
by O O 0.9996751546859741
erdosteine B B 0.9979625940322876
. O O 0.9998923540115356

The O O 0.9999877214431763
aims O O 0.9999955892562866
of O O 0.9999899864196777
this O O 0.999983549118042
study O O 0.999975323677063
were O O 0.9999936819076538
to O O 0.9999895095825195
examine O O 0.9998760223388672
vancomycin B B 0.9998451471328735
( O O 0.9937775135040283
VCM B B 0.9937817454338074
) O O 0.9916912317276001
- O O 0.9997583031654358
induced O O 0.9998496770858765
oxidative O O 0.9745127558708191
stress O O 0.9994637370109558
that O O 0.999321699142456
promotes O O 0.9964520931243896
production O O 0.9998949766159058
of O O 0.9993822574615479
reactive O O 0.9144664406776428
oxygen B B 0.8851843476295471
species O O 0.9069188833236694
( O O 0.9997174143791199
ROS O O 0.9381793737411499
) O O 0.9999645948410034
and O O 0.9999862909317017
to O O 0.9999914169311523
investigate O O 0.9999517202377319
the O O 0.9999736547470093
role O O 0.9999710321426392
of O O 0.9987064599990845
erdosteine B B 0.9994294047355652
, O O 0.9996551275253296
an O O 0.910647988319397
expectorant O O 0.8685671091079712
agent O O 0.9172477722167969
, O O 0.9999665021896362
which O O 0.9990295171737671
has O O 0.9993746876716614
also O O 0.9922868013381958
antioxidant O O 0.5767735838890076
properties O O 0.9983713030815125
, O O 0.999972939491272
on O O 0.9995989203453064
kidney O O 0.9983142614364624
tissue O O 0.9999884366989136
against O O 0.9999040365219116
the O O 0.9999891519546509
possible O O 0.9999697208404541
VCM B B 0.9898098707199097
- O O 0.9994538426399231
induced O O 0.9999592304229736
renal O O 0.9999879598617554
impairment O O 0.9999972581863403
in O O 0.9999657869338989
rats O O 0.9999531507492065
. O O 0.9999781847000122

Rats O O 0.9999321699142456
were O O 0.9999756813049316
divided O O 0.9999812841415405
into O O 0.9999419450759888
three O O 0.9998928308486938
groups O O 0.9999569654464722
: O O 0.9996034502983093
sham O O 0.9715721011161804
, O O 0.9989311099052429
VCM B B 0.9331239461898804
and O O 0.9936568140983582
VCM B B 0.9518274068832397
plus O O 0.9915008544921875
erdosteine B B 0.997205913066864
. O O 0.9999139308929443

VCM B B 0.9830338358879089
was O O 0.9997918009757996
administrated O O 0.9999614953994751
intraperitoneally O O 0.9999834299087524
( O O 0.999930739402771
i O O 0.9999836683273315
. O O 0.999995231628418
p O O 0.9999985694885254
. O O 0.9999973773956299
) O O 0.9999901056289673
with O O 0.9998251795768738
200mgkg O O 0.9885733127593994
( O O 0.9720405340194702
- O O 0.987277090549469
1 O O 0.9805102348327637
) O O 0.9989733695983887
twice O O 0.9996663331985474
daily O O 0.9999699592590332
for O O 0.9999715089797974
7 O O 0.9999711513519287
days O O 0.9999954700469971
. O O 0.9999862909317017

Erdosteine B B 0.9970049262046814
was O O 0.9997594952583313
administered O O 0.9999250173568726
orally O O 0.998826801776886
. O O 0.9999076128005981

VCM B B 0.9962133765220642
administration O O 0.9996403455734253
to O O 0.9997947812080383
control O O 0.9945504069328308
rats O O 0.9998052716255188
significantly O O 0.9999802112579346
increased O O 0.9999518394470215
renal O O 0.9986274242401123
malondialdehyde B B 0.9972236156463623
( O O 0.9988977909088135
MDA B B 0.9783635139465332
) O O 0.9985799789428711
and O O 0.9996975660324097
urinary O O 0.9999730587005615
N O B 0.4876006841659546
- O I 0.557740330696106
acetyl O I 0.9866589307785034
- O I 0.9128991365432739
beta O I 0.9587046504020691
- O I 0.9513667821884155
d O I 0.9801560640335083
- O I 0.9158256649971008
glucosaminidase O I 0.9967628717422485
( O O 0.9984161853790283
NAG O B 0.9721338152885437
, O O 0.9992778897285461
a O O 0.9998037219047546
marker O O 0.9999806880950928
of O O 0.9999483823776245
renal O O 0.9998421669006348
tubular O O 0.9999908208847046
injury O O 0.9999865293502808
) O O 0.9996851682662964
excretion O O 0.9999200105667114
but O O 0.9999101161956787
decreased O O 0.9998313188552856
superoxide B B 0.981613278388977
dismutase O O 0.5581657290458679
( O O 0.9985001087188721
SOD O O 0.5900542140007019
) O O 0.9974910020828247
and O O 0.9988711476325989
catalase O B 0.8581179976463318
( O O 0.9910069108009338
CAT O O 0.7590770721435547
) O O 0.9983097314834595
activities O O 0.9996485710144043
. O O 0.9999314546585083

Erdosteine B B 0.9977007508277893
administration O O 0.999863862991333
with O O 0.9998733997344971
VCM B B 0.924302875995636
injections O O 0.9983533620834351
caused O O 0.9999319314956665
significantly O O 0.999983549118042
decreased O O 0.999981164932251
renal O O 0.9999481439590454
MDA B O 0.9921367168426514
and O O 0.9999361038208008
urinary O O 0.9995290040969849
NAG O B 0.9922205805778503
excretion O O 0.9996614456176758
, O O 0.9999382495880127
and O O 0.9999635219573975
increased O O 0.999744713306427
SOD O O 0.5472646951675415
activity O O 0.9978347420692444
, O O 0.9999572038650513
but O O 0.9999747276306152
not O O 0.9999023675918579
CAT O O 0.5146657824516296
activity O O 0.9876865744590759
in O O 0.9997192025184631
renal O O 0.9997215867042542
tissue O O 0.9999904632568359
when O O 0.9999735355377197
compared O O 0.9999911785125732
with O O 0.9998611211776733
VCM B B 0.9834660887718201
alone O O 0.9994773268699646
. O O 0.9999608993530273

Erdosteine B B 0.9982439279556274
showed O O 0.99982750415802
histopathological O O 0.9997192025184631
protection O O 0.9998902082443237
against O O 0.9988197684288025
VCM B B 0.9915738701820374
- O O 0.9936226010322571
induced O O 0.9999274015426636
nephrotoxicity O O 0.9999520778656006
. O O 0.9999475479125977

There O O 0.9998929500579834
were O O 0.9999494552612305
a O O 0.9999746084213257
significant O O 0.9999736547470093
dilatation O O 0.9999886751174927
of O O 0.9999480247497559
tubular O O 0.9999741315841675
lumens O O 0.9997244477272034
, O O 0.9999479055404663
extensive O O 0.9998409748077393
epithelial O O 0.9998250603675842
cell O O 0.9999412298202515
vacuolization O O 0.9999877214431763
, O O 0.9998364448547363
atrophy O O 0.9998972415924072
, O O 0.9998194575309753
desquamation O O 0.9990424513816833
, O O 0.9998679161071777
and O O 0.999707043170929
necrosis O O 0.9998636245727539
in O O 0.9993008375167847
VCM B B 0.937163770198822
- O O 0.9674734473228455
treated O O 0.9962266683578491
rats O O 0.9965391159057617
more O O 0.9996702671051025
than O O 0.9999126195907593
those O O 0.9999122619628906
of O O 0.9997628331184387
the O O 0.9992461204528809
control O O 0.8647676706314087
and O O 0.9998032450675964
the O O 0.9996562004089355
erdosteine B B 0.998870313167572
groups O O 0.9981260895729065
. O O 0.9999529123306274

Erdosteine B B 0.9973107576370239
caused O O 0.9998812675476074
a O O 0.9999576807022095
marked O O 0.9999805688858032
reduction O O 0.9999934434890747
in O O 0.9999860525131226
the O O 0.9999853372573853
extent O O 0.9999895095825195
of O O 0.9999594688415527
tubular O O 0.9999914169311523
damage O O 0.9999954700469971
. O O 0.9999181032180786

It O O 0.9999816417694092
is O O 0.9999351501464844
concluded O O 0.999963641166687
that O O 0.9996503591537476
oxidative O O 0.986647367477417
tubular O O 0.9999499320983887
damage O O 0.9999552965164185
plays O O 0.999896764755249
an O O 0.9999544620513916
important O O 0.9998428821563721
role O O 0.9999808073043823
in O O 0.9999668598175049
the O O 0.999893069267273
VCM B B 0.945745050907135
- O O 0.9969770908355713
induced O O 0.9998863935470581
nephrotoxicity O O 0.9999704360961914
and O O 0.9998948574066162
the O O 0.999881386756897
modulation O O 0.9998637437820435
of O O 0.9996412992477417
oxidative O O 0.5307061672210693
stress O O 0.9936128258705139
with O O 0.9993732571601868
erdosteine B B 0.9996017813682556
reduces O O 0.999879002571106
the O O 0.9999644756317139
VCM B B 0.9841973185539246
- O O 0.9990253448486328
induced O O 0.999935507774353
kidney O O 0.9998918771743774
damage O O 0.9999943971633911
both O O 0.9999494552612305
at O O 0.9999502897262573
the O O 0.9999562501907349
biochemical O O 0.9994342923164368
and O O 0.9998248219490051
histological O O 0.999977707862854
levels O O 0.9999691247940063
. O O 0.9999632835388184

Gemfibrozil B B 0.9984972476959229
- O O 0.8182610273361206
lovastatin B B 0.9488701224327087
therapy O O 0.999226450920105
for O O 0.9999372959136963
primary O O 0.9999243021011353
hyperlipoproteinemias O O 0.9251133799552917
. O O 0.9992521405220032

The O O 0.999994158744812
specific O O 0.999993085861206
aim O O 0.9999978542327881
of O O 0.9999935626983643
this O O 0.9999847412109375
retrospective O O 0.9999217987060547
, O O 0.9999781847000122
observational O O 0.99998939037323
study O O 0.9999911785125732
was O O 0.9999949932098389
to O O 0.9999977350234985
assess O O 0.999990701675415
safety O O 0.9999963045120239
and O O 0.9999860525131226
efficacy O O 0.9999953508377075
of O O 0.9999587535858154
long O O 0.9998490810394287
- O O 0.9999767541885376
term O O 0.9999679327011108
( O O 0.999919056892395
21 O O 0.9999867677688599
months O O 0.9999979734420776
/ O O 0.9999971389770508
patient O O 0.9999983310699463
) O O 0.9999775886535645
, O O 0.999946117401123
open O O 0.9935349225997925
- O O 0.9996089339256287
label O O 0.9993402361869812
, O O 0.9992095232009888
gemfibrozil B B 0.9990092515945435
- O O 0.5341667532920837
lovastatin B B 0.8754197359085083
treatment O O 0.9997557997703552
in O O 0.9999797344207764
80 O O 0.9999929666519165
patients O O 0.9999967813491821
with O O 0.9999872446060181
primary O O 0.9999395608901978
mixed O O 0.9981909394264221
hyperlipidemia O O 0.9741000533103943
( O O 0.9999816417694092
68 O O 0.999994158744812
% O O 0.9999978542327881
of O O 0.9999809265136719
whom O O 0.9999850988388062
had O O 0.9999687671661377
atherosclerotic O O 0.9994764924049377
vascular O O 0.999956488609314
disease O O 0.9999980926513672
) O O 0.9999748468399048
. O O 0.9999830722808838

Because O O 0.9999771118164062
ideal O O 0.9989946484565735
lipid O O 0.9168187975883484
targets O O 0.9997188448905945
were O O 0.999982476234436
not O O 0.9999964237213135
reached O O 0.9999748468399048
( O O 0.9997703433036804
low O O 0.9978315234184265
- O O 0.9995026588439941
density O O 0.9845731854438782
lipoprotein O O 0.9405838251113892
( O O 0.9972562193870544
LDL O O 0.8446943163871765
) O O 0.9952616691589355
cholesterol B O 0.6345970034599304
less O O 0.9998750686645508
than O O 0.9999873638153076
130 O O 0.9999911785125732
mg O O 0.9999935626983643
/ O O 0.9999822378158569
dl O O 0.9999966621398926
, O O 0.9999043941497803
high O O 0.9689093828201294
- O O 0.999695897102356
density O O 0.9822940230369568
lipoprotein O O 0.8867231011390686
( O O 0.9951425790786743
HDL O O 0.5053750276565552
) O O 0.9930001497268677
cholesterol B O 0.6102761030197144
greater O O 0.9998795986175537
than O O 0.9999935626983643
35 O O 0.9999911785125732
mg O O 0.9999959468841553
/ O O 0.9999887943267822
dl O O 0.9999971389770508
, O O 0.9999163150787354
or O O 0.9999130964279175
total O O 0.7058742046356201
cholesterol B B 0.8578513860702515
/ O O 0.9892982244491577
HDL O O 0.5099501013755798
cholesterol B O 0.8022450804710388
less O O 0.9996023774147034
than O O 0.9999977350234985
4 O O 0.9998776912689209
. O O 0.9999955892562866
5 O O 0.9999812841415405
mg O O 0.9999967813491821
/ O O 0.9999885559082031
dl O O 0.9999972581863403
) O O 0.9999701976776123
with O O 0.9999053478240967
diet O O 0.8456787467002869
plus O O 0.9996752738952637
a O O 0.9999679327011108
single O O 0.9998235106468201
drug O O 0.9995406866073608
, O O 0.9991323351860046
gemfibrozil B B 0.9996092915534973
( O O 0.9983920454978943
1 O O 0.9994237422943115
. O O 0.9999818801879883
2 O O 0.9993125200271606
g O O 0.9993758797645569
/ O O 0.9998471736907959
day O O 0.9999463558197021
) O O 0.9981734752655029
- O O 0.9865018725395203
lovastatin B B 0.9961016178131104
( O O 0.9967897534370422
primarily O O 0.99803227186203
20 O O 0.9766539931297302
or O O 0.9985406398773193
40 O O 0.9992498755455017
mg O O 0.9984288811683655
) O O 0.9997054934501648
treatment O O 0.9999327659606934
was O O 0.9999576807022095
given O O 0.999903678894043
. O O 0.9999297857284546

Follow O O 0.9997530579566956
- O O 0.9999830722808838
up O O 0.9999908208847046
visits O O 0.9999879598617554
were O O 0.9999905824661255
scheduled O O 0.9999945163726807
with O O 0.9999735355377197
2 O O 0.7751631140708923
- O O 0.9125343561172485
drug O O 0.650935709476471
therapy O O 0.999099612236023
every O O 0.9999551773071289
6 O O 0.9999960660934448
to O O 0.9999980926513672
8 O O 0.9999942779541016
weeks O O 0.9999974966049194
, O O 0.9999929666519165
an O O 0.9999955892562866
average O O 0.9999849796295166
of O O 0.999992847442627
10 O O 0.9999958276748657
. O O 0.9999980926513672
3 O O 0.9999957084655762
visits O O 0.9999955892562866
per O O 0.9999964237213135
patient O O 0.999997615814209
, O O 0.9999938011169434
with O O 0.9999961853027344
741 O O 0.9999067783355713
batteries O O 0.9999358654022217
of O O 0.9999511241912842
6 O O 0.9992280006408691
liver O O 0.9871619343757629
function O O 0.9998337030410767
tests O O 0.9999923706054688
and O O 0.9999567270278931
714 O O 0.9998871088027954
creatine B B 0.9820541143417358
phosphokinase O O 0.8360871076583862
levels O O 0.9997605681419373
measured O O 0.999983549118042
. O O 0.9999858140945435

Only O O 0.9999645948410034
1 O O 0.9998327493667603
of O O 0.9999216794967651
the O O 0.9999822378158569
4 O O 0.9999041557312012
, O O 0.99997878074646
446 O O 0.9999246597290039
liver O O 0.993807852268219
function O O 0.999483585357666
tests O O 0.9999644756317139
( O O 0.9998757839202881
0 O O 0.9999756813049316
. O O 0.9999923706054688
02 O O 0.9998266100883484
% O O 0.9999089241027832
) O O 0.9999085664749146
, O O 0.9998224377632141
a O O 0.9652518630027771
gamma O O 0.47951069474220276
glutamyl O O 0.6691194176673889
transferase O O 0.550592303276062
, O O 0.9999485015869141
was O O 0.9999785423278809
greater O O 0.9999938011169434
than O O 0.9999957084655762
or O O 0.9999967813491821
equal O O 0.999997615814209
to O O 0.9999971389770508
3 O O 0.9999229907989502
times O O 0.9999912977218628
the O O 0.9999963045120239
upper O O 0.9999902248382568
normal O O 0.999994158744812
limit O O 0.9999966621398926
. O O 0.9999755620956421

Of O O 0.9996943473815918
the O O 0.999981164932251
714 O O 0.9999642372131348
creatine B B 0.9893383979797363
phosphokinase O O 0.8430335521697998
levels O O 0.9995079040527344
, O O 0.9999639987945557
9 O O 0.9997544884681702
% O O 0.9999746084213257
were O O 0.999975323677063
high O O 0.996199905872345
; O O 0.9999741315841675
only O O 0.9999561309814453
1 O O 0.9997308850288391
( O O 0.9999332427978516
0 O O 0.9999728202819824
. O O 0.9999778270721436
1 O O 0.9999837875366211
% O O 0.9999468326568604
) O O 0.9999219179153442
was O O 0.9999817609786987
greater O O 0.9999945163726807
than O O 0.9999961853027344
or O O 0.9999971389770508
equal O O 0.9999972581863403
to O O 0.9999970197677612
3 O O 0.9999558925628662
times O O 0.9999933242797852
the O O 0.9999966621398926
upper O O 0.9999890327453613
normal O O 0.9999933242797852
limit O O 0.9999959468841553
. O O 0.9999793767929077

With O O 0.9998635053634644
2 O O 0.8191981315612793
- O O 0.9429829120635986
drug O O 0.9218571782112122
therapy O O 0.9998592138290405
, O O 0.9999395608901978
mean O O 0.9999483823776245
total O O 0.5096712708473206
cholesterol B B 0.9866368174552917
decreased O O 0.9998812675476074
22 O O 0.9999922513961792
% O O 0.9999977350234985
from O O 0.9999867677688599
255 O O 0.9995964169502258
to O O 0.9999594688415527
200 O O 0.999889612197876
mg O O 0.9999920129776001
/ O O 0.999977707862854
dl O O 0.9999955892562866
, O O 0.9998277425765991
triglyceride B B 0.9670608639717102
levels O O 0.9997492432594299
decreased O O 0.9999842643737793
35 O O 0.999994158744812
% O O 0.9999979734420776
from O O 0.9999901056289673
236 O O 0.9992074370384216
to O O 0.9999768733978271
154 O O 0.9999223947525024
mg O O 0.999995231628418
/ O O 0.9999852180480957
dl O O 0.9999974966049194
, O O 0.9999488592147827
LDL O O 0.9059667587280273
cholesterol B B 0.9883421063423157
decreased O O 0.9998817443847656
26 O O 0.9999802112579346
% O O 0.9999970197677612
from O O 0.9999905824661255
176 O O 0.9999181032180786
to O O 0.9999667406082153
131 O O 0.9999643564224243
mg O O 0.9999970197677612
/ O O 0.9999847412109375
dl O O 0.9999960660934448
, O O 0.9999598264694214
and O O 0.9999592304229736
the O O 0.9999833106994629
total O O 0.4991858899593353
cholesterol B B 0.9557281732559204
/ O O 0.9979308843612671
HDL O O 0.5024606585502625
cholesterol B O 0.7734308242797852
ratio O O 0.999579131603241
decreased O O 0.9999802112579346
24 O O 0.9999912977218628
% O O 0.9999973773956299
from O O 0.9999709129333496
7 O O 0.9999022483825684
. O O 0.9999920129776001
1 O O 0.9999750852584839
to O O 0.9999442100524902
5 O O 0.9999550580978394
. O O 0.9999916553497314
4 O O 0.9995577931404114
, O O 0.9999897480010986
all O O 0.9999322891235352
p O O 0.999962329864502
less O O 0.9999901056289673
than O O 0.9999953508377075
or O O 0.9999974966049194
equal O O 0.9999969005584717
to O O 0.9999945163726807
0 O O 0.999996542930603
. O O 0.9999974966049194
0001 O O 0.999995231628418
. O O 0.9999740123748779

Myositis O O 0.9999121427536011
, O O 0.999977707862854
attributable O O 0.9999860525131226
to O O 0.9998842477798462
the O O 0.9995391368865967
drug O O 0.9975990653038025
combination O O 0.993654727935791
and O O 0.9999569654464722
symptomatic O O 0.9999886751174927
enough O O 0.9999990463256836
to O O 0.9999938011169434
discontinue O O 0.9997847676277161
it O O 0.9993785619735718
, O O 0.9999885559082031
occurred O O 0.9999967813491821
in O O 0.9999717473983765
3 O O 0.9996768236160278
% O O 0.999993085861206
of O O 0.9999796152114868
patients O O 0.9999914169311523
, O O 0.9999533891677856
and O O 0.9999651908874512
in O O 0.9999814033508301
1 O O 0.9999210834503174
% O O 0.9999899864196777
with O O 0.9999898672103882
concurrent O O 0.9999803304672241
high O O 0.999765932559967
creatine B B 0.981084942817688
phosphokinase O O 0.832417368888855
( O O 0.99958735704422
769 O O 0.9999526739120483
U O O 0.9999923706054688
/ O O 0.9999816417694092
liter O O 0.9999864101409912
) O O 0.9999599456787109
; O O 0.9999845027923584
no O O 0.9999631643295288
patients O O 0.9999722242355347
had O O 0.9999666213989258
rhabdomyolysis O O 0.9999415874481201
or O O 0.9999529123306274
myoglobinuria O O 0.9999784231185913
. O O 0.9999821186065674
( O O 0.9997962117195129
ABSTRACT O O 0.9992984533309937
TRUNCATED O O 0.999901294708252
AT O O 0.9997261166572571
250 O O 0.987704873085022
WORDS O O 0.9999850988388062
) O O 0.9998667240142822

Does O O 0.9985049962997437
domperidone B B 0.999265730381012
potentiate O O 0.9617697596549988
mirtazapine B B 0.9998297691345215
- O O 0.999823272228241
associated O O 0.9999467134475708
restless O O 0.9999971389770508
legs O O 0.9999970197677612
syndrome O O 0.9999949932098389
? O O 0.9999313354492188

There O O 0.9999724626541138
is O O 0.9999732971191406
now O O 0.9999940395355225
evidence O O 0.9999877214431763
to O O 0.9999885559082031
suggest O O 0.9997153878211975
a O O 0.9998894929885864
central O O 0.999812662601471
role O O 0.9999637603759766
for O O 0.99970942735672
the O O 0.9998108744621277
dopaminergic O B 0.8897036910057068
system O O 0.9939646124839783
in O O 0.9998736381530762
restless O O 0.9999368190765381
legs O O 0.999984622001648
syndrome O O 0.999988317489624
( O O 0.9999306201934814
RLS O O 0.9965593218803406
) O O 0.9999712705612183
. O O 0.9999579191207886

For O O 0.9996775388717651
example O O 0.9999306201934814
, O O 0.9999086856842041
the O O 0.9999797344207764
symptoms O O 0.9999945163726807
of O O 0.9999843835830688
RLS O O 0.9922216534614563
can O O 0.9996873140335083
be O O 0.9999557733535767
dramatically O O 0.9999830722808838
improved O O 0.9999779462814331
by O O 0.9996805191040039
levodopa B B 0.9998589754104614
and O O 0.9977638721466064
dopamine B B 0.9922999143600464
agonists O O 0.5524559617042542
, O O 0.9998946189880371
whereas O O 0.9997689127922058
central O O 0.992371678352356
dopamine B B 0.9926387071609497
D2 O O 0.5581008791923523
receptor O O 0.9975572824478149
antagonists O O 0.972149133682251
can O O 0.9999173879623413
induce O O 0.9999663829803467
or O O 0.9999380111694336
aggravate O O 0.999930739402771
RLS O O 0.9894835352897644
symptoms O O 0.999992847442627
. O O 0.9999755620956421

To O O 0.9999881982803345
our O O 0.9999842643737793
knowledge O O 0.999992847442627
, O O 0.9999616146087646
there O O 0.999982476234436
is O O 0.9999829530715942
no O O 0.9999949932098389
previous O O 0.9999908208847046
report O O 0.9999970197677612
regarding O O 0.9999921321868896
whether O O 0.9999077320098877
domperidone B B 0.999842643737793
, O O 0.9998918771743774
a O O 0.9996609687805176
peripheral O O 0.9931890964508057
dopamine B B 0.9867597222328186
D2 O O 0.5204852223396301
receptor O O 0.9908921718597412
antagonist O O 0.9531981348991394
, O O 0.9999537467956543
can O O 0.9999611377716064
also O O 0.9999270439147949
induce O O 0.9999690055847168
or O O 0.9999327659606934
aggravate O O 0.9999523162841797
symptoms O O 0.9999957084655762
of O O 0.9999889135360718
RLS O O 0.9972579479217529
. O O 0.9999589920043945

Mirtazapine B B 0.9995536208152771
, O O 0.9998340606689453
the O O 0.99965500831604
first O O 0.9926254153251648
noradrenergic O O 0.5060818791389465
and O O 0.9576042890548706
specific O O 0.7176161408424377
serotonergic O O 0.8060302138328552
antidepressant O B 0.4962587356567383
( O O 0.9609012007713318
NaSSA O B 0.9991045594215393
) O O 0.9995282888412476
, O O 0.999951958656311
has O O 0.9999009370803833
been O O 0.9999717473983765
associated O O 0.9999434947967529
with O O 0.9999386072158813
RLS O O 0.9922426342964172
in O O 0.9999725818634033
several O O 0.9999908208847046
recent O O 0.9999663829803467
publications O O 0.9999812841415405
. O O 0.999970555305481

The O O 0.9999890327453613
authors O O 0.999996542930603
report O O 0.9999966621398926
here O O 0.9999920129776001
a O O 0.9999808073043823
depressed O O 0.9999741315841675
patient O O 0.9999899864196777
comorbid O O 0.9998528957366943
with O O 0.9998972415924072
postprandial O O 0.9899557828903198
dyspepsia O O 0.9998719692230225
who O O 0.9999567270278931
developed O O 0.9999843835830688
RLS O O 0.9959405660629272
after O O 0.9997972846031189
mirtazapine B B 0.9996891021728516
had O O 0.9999185800552368
been O O 0.9999768733978271
added O O 0.9999337196350098
to O O 0.9996040463447571
his O O 0.9998495578765869
domperidone B B 0.9997202754020691
therapy O O 0.9993314743041992
. O O 0.9999674558639526

Our O O 0.9999171495437622
patient O O 0.9999864101409912
started O O 0.9999947547912598
to O O 0.9999891519546509
have O O 0.9999841451644897
symptoms O O 0.999991774559021
of O O 0.9999850988388062
RLS O O 0.9911017417907715
only O O 0.9999301433563232
after O O 0.9998562335968018
he O O 0.9999570846557617
had O O 0.9999884366989136
been O O 0.9999806880950928
treated O O 0.9999599456787109
with O O 0.9995512366294861
mirtazapine B B 0.9989810585975647
, O O 0.9988207221031189
and O O 0.9999661445617676
his O O 0.9999717473983765
RLS O O 0.9815382957458496
symptoms O O 0.9999825954437256
resolved O O 0.9999865293502808
completely O O 0.9999951124191284
upon O O 0.9999796152114868
discontinuation O O 0.9999827146530151
of O O 0.9998914003372192
his O O 0.999352753162384
mirtazapine B B 0.9994984865188599
. O O 0.9999395608901978

Such O O 0.9999855756759644
a O O 0.9999914169311523
temporal O O 0.9999895095825195
relationship O O 0.9999977350234985
between O O 0.9999680519104004
the O O 0.999987006187439
use O O 0.9999043941497803
of O O 0.999146580696106
mirtazapine B B 0.9995429515838623
and O O 0.9997335076332092
the O O 0.9999966621398926
symptoms O O 0.9999946355819702
of O O 0.9999843835830688
RLS O O 0.9964653253555298
in O O 0.9999592304229736
our O O 0.9999732971191406
patient O O 0.9999847412109375
did O O 0.9999808073043823
not O O 0.9999618530273438
support O O 0.9998704195022583
a O O 0.9999071359634399
potentiating O O 0.9989842772483826
effect O O 0.9998849630355835
of O O 0.9988388419151306
domperione B B 0.999648928642273
on O O 0.9994520545005798
mirtazapine B B 0.9998408555984497
- O O 0.9998192191123962
associated O O 0.9998832941055298
RLS O O 0.995449960231781
. O O 0.999948263168335

However O O 0.9999420642852783
, O O 0.999934196472168
physicians O O 0.9999803304672241
should O O 0.999967098236084
be O O 0.9999933242797852
aware O O 0.9999891519546509
of O O 0.9999778270721436
the O O 0.9999897480010986
possibility O O 0.9999908208847046
that O O 0.9999401569366455
mirtazapine B B 0.999872088432312
can O O 0.9999241828918457
be O O 0.9999645948410034
associated O O 0.9999592304229736
with O O 0.9998356103897095
RLS O O 0.9808427691459656
in O O 0.9996635913848877
some O O 0.9999042749404907
individuals O O 0.9999450445175171
, O O 0.999984622001648
especially O O 0.9999574422836304
those O O 0.9999897480010986
receiving O O 0.9998779296875
concomitant O O 0.9943401217460632
dopamine B B 0.992649257183075
D2 O O 0.5475894212722778
receptor O O 0.9948803186416626
antagonists O O 0.9565410614013672
. O O 0.9999686479568481

Antiandrogenic O O 0.4816950261592865
therapy O O 0.9928258657455444
can O O 0.9990206956863403
cause O O 0.9999228715896606
coronary O O 0.9998887777328491
arterial O O 0.9999388456344604
disease O O 0.999995231628418
. O O 0.9998389482498169

AIM O O 0.9999744892120361
: O O 0.9999884366989136
To O O 0.9999876022338867
study O O 0.9999722242355347
the O O 0.9999779462814331
change O O 0.9999916553497314
of O O 0.9999021291732788
lipid O O 0.6099686026573181
metabolism O O 0.9992184638977051
by O O 0.9996052384376526
antiandrogen O O 0.7828050851821899
therapy O O 0.9947385191917419
in O O 0.9999245405197144
patients O O 0.999991774559021
with O O 0.9999837875366211
prostate O O 0.9990102052688599
cancer O O 0.9998773336410522
. O O 0.9999727010726929

MATERIALS O O 0.999962568283081
AND O O 0.9999924898147583
METHODS O O 0.9999982118606567
: O O 0.9999920129776001
We O O 0.9999779462814331
studied O O 0.9999885559082031
with O O 0.9999948740005493
a O O 0.9999920129776001
2 O O 0.9999876022338867
. O O 0.9999934434890747
5 O O 0.999993085861206
years O O 0.9999960660934448
follow O O 0.9999933242797852
- O O 0.9999879598617554
up O O 0.9999983310699463
the O O 0.9999963045120239
changes O O 0.9999960660934448
in O O 0.9999648332595825
plasma O O 0.9241077303886414
cholesterols B B 0.9323606491088867
( O O 0.9976220726966858
C B O 0.6020271182060242
) O O 0.9911193251609802
, O O 0.9997542500495911
triglycerides B O 0.6450581550598145
( O O 0.9991304278373718
TG B O 0.8283398747444153
) O O 0.9997746348381042
, O O 0.9992314577102661
lipoproteins O O 0.7603546380996704
( O O 0.9992302656173706
LP O O 0.9286019206047058
) O O 0.999715268611908
, O O 0.9966750144958496
and O O 0.9934874773025513
apolipoproteins O O 0.566856324672699
( O O 0.9987075328826904
Apo O O 0.5195687413215637
) O O 0.9989792704582214
B O O 0.9812588095664978
- O O 0.9900319576263428
100 O O 0.7647239565849304
, O O 0.9943130016326904
A O O 0.8800967931747437
- O O 0.9794397950172424
I O O 0.9553618431091309
, O O 0.9976856708526611
and O O 0.9966877102851868
A O O 0.9235947132110596
- O O 0.982725203037262
II O O 0.985080897808075
pro O O 0.8643685579299927
fi O B 0.9134999513626099
les O O 0.9940578937530518
in O O 0.9999561309814453
24 O O 0.9999929666519165
patients O O 0.9999985694885254
of O O 0.9999959468841553
mean O O 0.9999986886978149
age O O 0.9999985694885254
60 O O 0.9999985694885254
years O O 0.9999985694885254
with O O 0.9999909400939941
low O O 0.9999306201934814
risk O O 0.9999845027923584
prostate O O 0.9997681975364685
cancer O O 0.9999765157699585
( O O 0.9999746084213257
stage O O 0.9999967813491821
: O O 0.9999254941940308
T1cN0M0 O O 0.9987472295761108
, O O 0.9999794960021973
Gleason O O 0.9989408850669861
score O O 0.9999288320541382
: O O 0.9999239444732666
2 O O 0.9975152015686035
- O O 0.9976102113723755
5 O O 0.999880313873291
) O O 0.9999829530715942
during O O 0.999883770942688
treatment O O 0.9999845027923584
with O O 0.9997983574867249
cyproterone B B 0.9972088932991028
acetate I I 0.9996706247329712
( O O 0.9872870445251465
CPA B B 0.986061692237854
) O O 0.999482274055481
without O O 0.9999309778213501
surgical O O 0.99998939037323
management O O 0.9999897480010986
or O O 0.999984622001648
radiation O O 0.9999773502349854
therapy O O 0.9999884366989136
. O O 0.999974250793457

RESULTS O O 0.999805748462677
: O O 0.9997403025627136
Significant O O 0.9999141693115234
decreases O O 0.999962329864502
of O O 0.9995962977409363
HDL O O 0.7839844822883606
- O O 0.9686276316642761
C O O 0.942869246006012
, O O 0.9988025426864624
Apo O O 0.6983094215393066
A O O 0.5302011966705322
- O O 0.9054253101348877
I O O 0.9606581330299377
and O O 0.9983780384063721
Apo O O 0.6685835123062134
A O O 0.5841608643531799
- O O 0.9060890674591064
II O O 0.9470681548118591
and O O 0.9999511241912842
an O O 0.9999743700027466
increase O O 0.9999756813049316
of O O 0.9998974800109863
triglyceride B B 0.9200088977813721
levels O O 0.9997393488883972
in O O 0.9989203214645386
VLDL O O 0.520060658454895
were O O 0.9999121427536011
induced O O 0.9999697208404541
by O O 0.9994719624519348
CPA B B 0.9659115076065063
. O O 0.9997544884681702

After O O 0.9999767541885376
a O O 0.9999901056289673
period O O 0.9999926090240479
of O O 0.9999761581420898
2 O O 0.9999890327453613
. O O 0.9999973773956299
5 O O 0.9999926090240479
years O O 0.9999953508377075
on O O 0.9995997548103333
CPA B B 0.9798156023025513
treatment O O 0.9753437638282776
, O O 0.9999750852584839
four O O 0.9999904632568359
patients O O 0.9999974966049194
out O O 0.9999911785125732
of O O 0.9999786615371704
twenty O O 0.9999910593032837
- O O 0.9999527931213379
four O O 0.9999841451644897
were O O 0.9999901056289673
found O O 0.9999951124191284
to O O 0.9999793767929077
be O O 0.9999858140945435
affected O O 0.9999926090240479
by O O 0.9999845027923584
coronary O O 0.9998214840888977
heart O O 0.9999933242797852
disease O O 0.9999953508377075
. O O 0.9999642372131348

CONCLUSIONS O O 0.9974316954612732
: O O 0.9998910427093506
Ischaemic O O 0.9998576641082764
coronary O O 0.9999208450317383
arteriosclerosis O O 0.9992789626121521
with O O 0.9999814033508301
an O O 0.9999886751174927
incidence O O 0.9999159574508667
rate O O 0.9999970197677612
of O O 0.9999439716339111
16 O O 0.9999939203262329
. O O 0.9999946355819702
6 O O 0.9999938011169434
% O O 0.9999963045120239
as O O 0.9999885559082031
caused O O 0.999992847442627
by O O 0.9999222755432129
prolonged O O 0.9994440674781799
CPA B B 0.9739062190055847
therapy O O 0.998863697052002
is O O 0.999894380569458
mediated O O 0.9999759197235107
through O O 0.9998767375946045
changes O O 0.9999737739562988
in O O 0.9998376369476318
HDL O O 0.7533648610115051
cholesterol B B 0.8936732411384583
, O O 0.992909848690033
Apo O O 0.6807428002357483
A O O 0.5169362425804138
- O O 0.8531709313392639
I O O 0.6979292631149292
and O O 0.9982732534408569
Apo O O 0.6339753866195679
A O O 0.5177360773086548
- O O 0.7789225578308105
II O O 0.5443390607833862
pro O O 0.8430956602096558
fi O O 0.7010318040847778
les O O 0.9963234663009644
, O O 0.9999363422393799
other O O 0.9999080896377563
than O O 0.9999693632125854
the O O 0.9999510049819946
well O O 0.9998607635498047
- O O 0.9999822378158569
known O O 0.9999810457229614
hyperglyceridemic O O 0.8545080423355103
effect O O 0.999961256980896
caused O O 0.9999748468399048
by O O 0.9998100399971008
estrogen B B 0.914495050907135
. O O 0.9996211528778076

5 B B 0.908405601978302
- I I 0.9974271655082703
Fluorouracil I I 0.999977707862854
cardiotoxicity O O 0.9996706247329712
induced O O 0.9999544620513916
by O O 0.999871015548706
alpha B B 0.9814797043800354
- I I 0.9695464372634888
fluoro I I 0.9999287128448486
- I I 0.969553530216217
beta I I 0.995554506778717
- I I 0.9976693987846375
alanine I I 0.9998645782470703
. O O 0.9986079335212708

Cardiotoxicity O O 0.9999582767486572
is O O 0.9999388456344604
a O O 0.9999526739120483
rare O O 0.999976396560669
complication O O 0.9999884366989136
occurring O O 0.9999878406524658
during O O 0.999870777130127
5 B B 0.9523985981941223
- I I 0.9944179058074951
fluorouracil I I 0.9999884366989136
( O O 0.9802002906799316
5 B B 0.9742022156715393
- I I 0.9827080368995667
FU I I 0.9999899864196777
) O O 0.9955050945281982
treatment O O 0.9999520778656006
for O O 0.9999293088912964
malignancies O O 0.9999831914901733
. O O 0.9999823570251465

We O O 0.9999841451644897
herein O O 0.99998939037323
report O O 0.9999972581863403
the O O 0.9999970197677612
case O O 0.9999939203262329
of O O 0.9999864101409912
a O O 0.999990701675415
70 O O 0.9999969005584717
- O O 0.9999847412109375
year O O 0.9999948740005493
- O O 0.999991774559021
old O O 0.9999955892562866
man O O 0.9999960660934448
with O O 0.9999488592147827
5 B B 0.9195005297660828
- I I 0.9755771160125732
FU I I 0.9999629259109497
- O O 0.9941306710243225
induced O O 0.9999572038650513
cardiotoxicity O O 0.9999955892562866
, O O 0.9999868869781494
in O O 0.9999502897262573
whom O O 0.9999793767929077
a O O 0.9999756813049316
high O O 0.9998822212219238
serum O O 0.9995917677879333
level O O 0.9997251629829407
of O O 0.9919006824493408
alpha B B 0.9415300488471985
- I I 0.9777206778526306
fluoro I I 0.9996979236602783
- I I 0.9708367586135864
beta I I 0.9910605549812317
- I I 0.9931815266609192
alanine I I 0.9996155500411987
( O O 0.9865823984146118
FBAL B B 0.9832620620727539
) O O 0.9998201727867126
was O O 0.9999810457229614
observed O O 0.9999616146087646
. O O 0.9999707937240601

The O O 0.9999879598617554
patient O O 0.9999918937683105
, O O 0.9999940395355225
who O O 0.9999850988388062
had O O 0.9999827146530151
unresectable O O 0.9998146891593933
colon O O 0.9991957545280457
cancer O O 0.99774569272995
metastases O O 0.9999668598175049
to O O 0.9999053478240967
the O O 0.9999836683273315
liver O O 0.999909520149231
and O O 0.999937891960144
lung O O 0.9999113082885742
, O O 0.9999910593032837
was O O 0.9999868869781494
referred O O 0.9999984502792358
to O O 0.9999966621398926
us O O 0.9999963045120239
for O O 0.9999514818191528
chemotherapy O O 0.9995424747467041
from O O 0.9999719858169556
an O O 0.9999881982803345
affiliated O O 0.9970765113830566
hospital O O 0.999988317489624
; O O 0.9999877214431763
he O O 0.9999842643737793
had O O 0.9999890327453613
no O O 0.9999829530715942
cardiac O O 0.9999349117279053
history O O 0.9999780654907227
. O O 0.999977707862854

After O O 0.9999707937240601
admission O O 0.9999932050704956
, O O 0.9999924898147583
the O O 0.9999974966049194
patient O O 0.9999946355819702
received O O 0.9999313354492188
a O O 0.9999892711639404
continuous O O 0.99992835521698
intravenous O O 0.9999873638153076
infusion O O 0.9999816417694092
of O O 0.9969024062156677
5 B B 0.9339751601219177
- I I 0.9939460158348083
FU I I 0.9999737739562988
( O O 0.9986011385917664
1000 O O 0.9992178678512573
mg O O 0.9999502897262573
/ O O 0.9999328851699829
day O O 0.9998871088027954
) O O 0.999968409538269
, O O 0.9999762773513794
during O O 0.9999425411224365
which O O 0.9999734163284302
precordial O O 0.9998188614845276
pain O O 0.9999960660934448
with O O 0.9999741315841675
right O O 0.9999833106994629
bundle O O 0.9999958276748657
branch O O 0.9999935626983643
block O O 0.9999867677688599
occurred O O 0.9999902248382568
concomitantly O O 0.9999613761901855
with O O 0.9999721050262451
a O O 0.9999924898147583
high O O 0.9998871088027954
serum O O 0.9971675276756287
FBAL B B 0.9961672425270081
concentration O O 0.9999172687530518
of O O 0.9999600648880005
1955 O O 0.9995174407958984
ng O O 0.9999804496765137
/ O O 0.9999628067016602
ml O O 0.9999982118606567
. O O 0.9999765157699585

Both O O 0.9999536275863647
the O O 0.9999667406082153
precordial O O 0.9987001419067383
pain O O 0.9998469352722168
and O O 0.9999490976333618
the O O 0.9999914169311523
electrocardiographic O O 0.9999847412109375
changes O O 0.9999955892562866
disappeared O O 0.9999750852584839
spontaneously O O 0.9999970197677612
after O O 0.9999706745147705
the O O 0.9999831914901733
discontinuation O O 0.9999686479568481
of O O 0.9994957447052002
5 B B 0.9803262948989868
- I I 0.9881699085235596
FU I I 0.9999663829803467
. O O 0.9998266100883484

As O O 0.9999926090240479
the O O 0.999995231628418
precordial O O 0.9999760389328003
pain O O 0.999990701675415
in O O 0.9999767541885376
this O O 0.9999867677688599
patient O O 0.9999904632568359
was O O 0.9999724626541138
considered O O 0.9999635219573975
to O O 0.9999607801437378
have O O 0.9999927282333374
been O O 0.9999879598617554
due O O 0.9999887943267822
to O O 0.9998512268066406
5 B B 0.9791899919509888
- I I 0.9907123446464539
FU I I 0.9999839067459106
- O O 0.9989973902702332
induced O O 0.9999611377716064
cardiotoxicity O O 0.9999871253967285
, O O 0.9999786615371704
the O O 0.999992847442627
administration O O 0.999957799911499
of O O 0.9998317956924438
5 B B 0.9843652248382568
- I I 0.9905261993408203
FU I I 0.9999771118164062
was O O 0.9996728897094727
abandoned O O 0.9999288320541382
. O O 0.9999849796295166

Instead O O 0.9999858140945435
, O O 0.9999802112579346
oral O O 0.9998630285263062
administration O O 0.9999489784240723
of O O 0.9995092153549194
S O O 0.823093056678772
- O O 0.797374427318573
1 O O 0.8336162567138672
( O O 0.988686203956604
a O O 0.9943969249725342
derivative O O 0.9910234212875366
of O O 0.9967034459114075
5 B B 0.9266642928123474
- I I 0.9808000326156616
FU I I 0.999966025352478
) O O 0.9945989847183228
, O O 0.9999886751174927
at O O 0.9999709129333496
200 O O 0.9998944997787476
mg O O 0.9999735355377197
/ O O 0.9999586343765259
day O O 0.9999948740005493
twice O O 0.9999550580978394
a O O 0.9999945163726807
week O O 0.9999946355819702
, O O 0.9999865293502808
was O O 0.9999765157699585
instituted O O 0.9999834299087524
, O O 0.999990701675415
because O O 0.999990701675415
S O B 0.8005291223526001
- O I 0.8173546195030212
1 O I 0.9814459681510925
has O O 0.9953493475914001
a O O 0.9999102354049683
strong O O 0.9996476173400879
inhibitory O O 0.997965931892395
effect O O 0.9998787641525269
on O O 0.9995456337928772
dihydropyrimidine B B 0.9406493902206421
dehydrogenase O O 0.536110520362854
, O O 0.999946117401123
which O O 0.9994382262229919
catalyzes O O 0.9998165965080261
the O O 0.9998418092727661
degradative O O 0.9999204874038696
of O O 0.9975800514221191
5 B B 0.9671775102615356
- I I 0.9913914203643799
FU I I 0.9999783039093018
into O O 0.9854795336723328
FBAL B B 0.9556546807289124
. O O 0.9999430179595947

The O O 0.999977707862854
serum O O 0.9995347261428833
FBAL B B 0.9911726117134094
concentration O O 0.9998730421066284
subsequently O O 0.9999678134918213
decreased O O 0.9999477863311768
to O O 0.9999734163284302
352 O O 0.999985933303833
ng O O 0.9999803304672241
/ O O 0.9999765157699585
ml O O 0.999997615814209
, O O 0.9999908208847046
the O O 0.9999969005584717
same O O 0.99998939037323
as O O 0.9999967813491821
the O O 0.9999949932098389
value O O 0.9999934434890747
measured O O 0.999993085861206
on O O 0.9999890327453613
the O O 0.999996542930603
first O O 0.9999974966049194
day O O 0.9999948740005493
of O O 0.9998087286949158
S O O 0.6679648160934448
- O O 0.5042406320571899
1 O O 0.6011106371879578
administration O O 0.9998679161071777
. O O 0.9999690055847168

Thereafter O O 0.9998952150344849
, O O 0.9999747276306152
no O O 0.9999853372573853
cardiac O O 0.9999847412109375
symptoms O O 0.9999963045120239
were O O 0.9999867677688599
observed O O 0.9999899864196777
. O O 0.9999744892120361

The O O 0.9999693632125854
patient O O 0.9999866485595703
achieved O O 0.9999904632568359
a O O 0.9999955892562866
partial O O 0.9999819993972778
response O O 0.9999926090240479
6 O O 0.999948263168335
months O O 0.9999986886978149
after O O 0.9999926090240479
the O O 0.9999949932098389
initiation O O 0.9999874830245972
of O O 0.9999518394470215
the O O 0.9998311996459961
S O O 0.7034536004066467
- O O 0.8586763739585876
1 O O 0.8041689991950989
treatment O O 0.9994603991508484
. O O 0.9999778270721436

The O O 0.9999884366989136
experience O O 0.9999988079071045
of O O 0.9999959468841553
this O O 0.9999880790710449
case O O 0.9999926090240479
, O O 0.9999920129776001
together O O 0.9999967813491821
with O O 0.9999973773956299
a O O 0.9999947547912598
review O O 0.9999951124191284
of O O 0.999982476234436
the O O 0.9999923706054688
literature O O 0.9999904632568359
, O O 0.9999772310256958
suggests O O 0.9999620914459229
that O O 0.9997690320014954
FBAL B B 0.9741823077201843
is O O 0.9996941089630127
related O O 0.9999815225601196
to O O 0.999840259552002
5 B B 0.9427152872085571
- I I 0.9710753560066223
FU I I 0.9999688863754272
- O O 0.9977502226829529
induced O O 0.9999434947967529
cardiotoxicity O O 0.9999945163726807
. O O 0.9999760389328003

S O B 0.7996563911437988
- O I 0.8787261247634888
1 O I 0.9973304271697998
may O O 0.99968421459198
be O O 0.9999876022338867
administered O O 0.9999682903289795
safely O O 0.9999762773513794
to O O 0.9999667406082153
patients O O 0.9999918937683105
with O O 0.9999804496765137
5 B B 0.9270520806312561
- I I 0.983924388885498
FU I I 0.9999641180038452
- O O 0.9982619881629944
induced O O 0.9999673366546631
cardiotoxicity O O 0.9999938011169434
. O O 0.9999691247940063

Hepatocellular O O 0.9997612833976746
carcinoma O O 0.9994852542877197
in O O 0.999885082244873
Fanconi O O 0.9966493248939514
' O O 0.9999630451202393
s O O 0.9999585151672363
anemia O O 0.9930271506309509
treated O O 0.9999043941497803
with O O 0.9989111423492432
androgen B O 0.7831015586853027
and O O 0.8052220344543457
corticosteroid B B 0.845731794834137
. O O 0.9990028738975525

The O O 0.9999868869781494
case O O 0.9999910593032837
of O O 0.999985933303833
an O O 0.9999903440475464
11 O O 0.9999604225158691
- O O 0.9999798536300659
year O O 0.9999949932098389
- O O 0.9999927282333374
old O O 0.9999912977218628
boy O O 0.9999825954437256
is O O 0.9997920393943787
reported O O 0.9994658827781677
who O O 0.9999561309814453
was O O 0.9999628067016602
known O O 0.9999867677688599
to O O 0.9999706745147705
have O O 0.9999662637710571
Fanconi O O 0.9993451237678528
' O O 0.9999712705612183
s O O 0.999972939491272
anemia O O 0.9999011754989624
for O O 0.9999583959579468
3 O O 0.9997755885124207
years O O 0.9999793767929077
and O O 0.9999520778656006
was O O 0.9999691247940063
treated O O 0.9999756813049316
with O O 0.9998576641082764
androgens B O 0.7498538494110107
, O O 0.9970308542251587
corticosteroids B O 0.6426160335540771
and O O 0.9971555471420288
transfusions O O 0.9994871616363525
. O O 0.999967098236084

Two O O 0.9999867677688599
weeks O O 0.9999977350234985
before O O 0.9999982118606567
his O O 0.9999921321868896
death O O 0.9999936819076538
he O O 0.9999814033508301
was O O 0.9999711513519287
readmitted O O 0.999988317489624
because O O 0.9999938011169434
of O O 0.9999774694442749
aplastic O O 0.9962414503097534
crisis O O 0.9999881982803345
with O O 0.9999724626541138
septicemia O O 0.9999303817749023
and O O 0.999954342842102
marked O O 0.9999657869338989
abnormalities O O 0.9999916553497314
in O O 0.9999741315841675
liver O O 0.9952285289764404
function O O 0.9999748468399048
and O O 0.9999688863754272
died O O 0.9999884366989136
of O O 0.9999332427978516
hemorrhagic O O 0.9990793466567993
bronchopneumonia O O 0.9974290728569031
. O O 0.9999746084213257

At O O 0.9999570846557617
autopsy O O 0.9996898174285889
peliosis O O 0.9100978970527649
and O O 0.9999223947525024
multiple O O 0.9997912049293518
hepatic O O 0.9983235001564026
tumors O O 0.9999845027923584
were O O 0.9999679327011108
found O O 0.9999910593032837
which O O 0.9999490976333618
histologically O O 0.9999961853027344
proved O O 0.9999978542327881
to O O 0.9999675750732422
be O O 0.9999762773513794
well O O 0.9989866614341736
- O O 0.9999786615371704
differentiated O O 0.9999920129776001
hepatocellular O O 0.9945809245109558
carcinoma O O 0.9998663663864136
. O O 0.999980092048645

This O O 0.9999769926071167
case O O 0.9999878406524658
contributes O O 0.999981164932251
to O O 0.9999892711639404
the O O 0.9999936819076538
previous O O 0.9999946355819702
observations O O 0.9999964237213135
that O O 0.9999719858169556
non O O 0.9969735145568848
- O O 0.999826967716217
metastasizing O O 0.999970555305481
hepatic O O 0.9999128580093384
neoplasms O O 0.9998977184295654
and O O 0.9998377561569214
peliosis O O 0.9913864135742188
can O O 0.9999353885650635
develop O O 0.9999932050704956
in O O 0.9999425411224365
patients O O 0.9999796152114868
with O O 0.9999401569366455
androgen B O 0.704450786113739
- O O 0.9952536821365356
and O O 0.9961936473846436
corticosteroid B B 0.8953875303268433
- O O 0.9980518817901611
treated O O 0.9997720122337341
Fanconi O O 0.9994379878044128
' O O 0.9999756813049316
s O O 0.9999778270721436
anemia O O 0.9999006986618042
. O O 0.9999743700027466

The O O 0.9999401569366455
influence O O 0.9999879598617554
of O O 0.999961256980896
the O O 0.999975323677063
time O O 0.9999626874923706
interval O O 0.9999721050262451
between O O 0.9997650980949402
monoHER B B 0.9968748092651367
and O O 0.9882206916809082
doxorubicin B B 0.9997339844703674
administration O O 0.9998669624328613
on O O 0.9999516010284424
the O O 0.9999874830245972
protection O O 0.9999936819076538
against O O 0.9999245405197144
doxorubicin B B 0.9997498393058777
- O O 0.9998247027397156
induced O O 0.9999542236328125
cardiotoxicity O O 0.9999966621398926
in O O 0.9999721050262451
mice O O 0.9999934434890747
. O O 0.9999759197235107

PURPOSE O O 0.9976491332054138
: O O 0.9999614953994751
Despite O O 0.9999583959579468
its O O 0.9999457597732544
well O O 0.999829888343811
- O O 0.9999864101409912
known O O 0.9999852180480957
cardiotoxicity O O 0.9999892711639404
, O O 0.9998241066932678
the O O 0.9973466396331787
anthracyclin O B 0.9637102484703064
doxorubicin B I 0.8953299522399902
( O O 0.9700616598129272
DOX B B 0.999342143535614
) O O 0.9974040389060974
continues O O 0.9999560117721558
to O O 0.9999494552612305
be O O 0.9999430179595947
an O O 0.9998338222503662
effective O O 0.9998657703399658
and O O 0.9999749660491943
widely O O 0.9999549388885498
used O O 0.999929666519165
chemotherapeutic O O 0.9997754693031311
agent O O 0.9997643828392029
. O O 0.9999505281448364

DOX B B 0.998820960521698
- O O 0.9997974038124084
induced O O 0.9999183416366577
cardiac O O 0.9999775886535645
damage O O 0.9999957084655762
presumably O O 0.9999222755432129
results O O 0.9999548196792603
from O O 0.9999092817306519
the O O 0.9999619722366333
formation O O 0.99992835521698
of O O 0.9997280240058899
free O O 0.9947729706764221
radicals O O 0.9602798223495483
by O O 0.9997285008430481
DOX B B 0.9996198415756226
. O O 0.9999485015869141

Reactive O O 0.953886866569519
oxygen B B 0.8932194709777832
species O O 0.8715329170227051
particularly O O 0.9995676875114441
affect O O 0.9996621608734131
the O O 0.999830961227417
cardiac O O 0.9994578957557678
myocytes O O 0.9999775886535645
because O O 0.9999428987503052
these O O 0.9999052286148071
cells O O 0.9999802112579346
seem O O 0.9999586343765259
to O O 0.9999606609344482
have O O 0.9998948574066162
a O O 0.9999278783798218
relatively O O 0.9999738931655884
poor O O 0.9997712969779968
antioxidant O O 0.8133093118667603
defense O O 0.9895991086959839
system O O 0.9997909665107727
. O O 0.9998990297317505

The O O 0.9997379183769226
semisynthetic O O 0.6243374943733215
flavonoid B O 0.9551679491996765
monohydroxyethylrutoside B B 0.8063085079193115
( O O 0.9808642268180847
monoHER B B 0.994776725769043
) O O 0.9991047978401184
showed O O 0.9999412298202515
cardioprotection O O 0.9999493360519409
against O O 0.9993292093276978
DOX B B 0.9997196793556213
- O O 0.9990819692611694
induced O O 0.9999656677246094
cardiotoxicity O O 0.9999945163726807
through O O 0.9998905658721924
its O O 0.9985041618347168
radical O O 0.7211997509002686
scavenging O O 0.6961590051651001
and O O 0.9994064569473267
iron B B 0.9720313549041748
chelating O O 0.9047229290008545
properties O O 0.9999196529388428
. O O 0.9999493360519409

Because O O 0.9999812841415405
of O O 0.9999685287475586
the O O 0.9999881982803345
relatively O O 0.9999865293502808
short O O 0.9999890327453613
final O O 0.9999773502349854
half O O 0.9999439716339111
- O O 0.9999182224273682
life O O 0.999985933303833
of O O 0.9998371601104736
monoHER B B 0.9866263270378113
( O O 0.999716579914093
about O O 0.9999957084655762
30 O O 0.999994158744812
min O O 0.9999921321868896
) O O 0.9999699592590332
, O O 0.9999685287475586
it O O 0.9999858140945435
is O O 0.9999809265136719
expected O O 0.9999953508377075
that O O 0.9999809265136719
the O O 0.9999613761901855
time O O 0.9998902082443237
interval O O 0.9999654293060303
between O O 0.9997428059577942
monoHER B B 0.9949951171875
and O O 0.9940458536148071
DOX B B 0.999697208404541
might O O 0.9997847676277161
be O O 0.9999842643737793
of O O 0.999941349029541
influence O O 0.999975323677063
on O O 0.9999619722366333
the O O 0.9999773502349854
cardioprotective O O 0.9999902248382568
effect O O 0.9999710321426392
of O O 0.9997237324714661
monoHER B B 0.9963207244873047
. O O 0.9998669624328613

Therefore O O 0.9999854564666748
, O O 0.9999898672103882
the O O 0.9999969005584717
aim O O 0.9999974966049194
of O O 0.9999964237213135
the O O 0.9999979734420776
present O O 0.9999943971633911
study O O 0.9999901056289673
was O O 0.9999961853027344
to O O 0.9999938011169434
investigate O O 0.9999521970748901
this O O 0.9998763799667358
possible O O 0.9997246861457825
effect O O 0.999967098236084
. O O 0.9999772310256958

METHODS O O 0.9995550513267517
: O O 0.9999905824661255
Six O O 0.9999929666519165
groups O O 0.9999959468841553
of O O 0.9999871253967285
6 O O 0.999956488609314
BALB O O 0.99993896484375
/ O O 0.9989529848098755
c O O 0.9867542386054993
mice O O 0.9999972581863403
were O O 0.9999638795852661
treated O O 0.999983549118042
with O O 0.9999316930770874
saline O O 0.9999806880950928
, O O 0.9992209672927856
DOX B B 0.9997288584709167
alone O O 0.9847750067710876
or O O 0.9990936517715454
DOX B B 0.9996771812438965
( O O 0.9991639852523804
4 O O 0.999646782875061
mg O O 0.9999531507492065
/ O O 0.9999884366989136
kg O O 0.9999958276748657
i O O 0.9995494484901428
. O O 0.9999971389770508
v O O 0.9999988079071045
. O O 0.9999957084655762
) O O 0.9999837875366211
preceded O O 0.99989914894104
by O O 0.9999287128448486
monoHER B O 0.6204960346221924
( O O 0.99969482421875
500 O O 0.9999874830245972
mg O O 0.9999582767486572
/ O O 0.9999861717224121
kg O O 0.9999957084655762
i O O 0.99934321641922
. O O 0.9999958276748657
p O O 0.9999991655349731
. O O 0.9999969005584717
) O O 0.999981164932251
with O O 0.9999849796295166
an O O 0.9999951124191284
interval O O 0.9999969005584717
of O O 0.9999891519546509
10 O O 0.9999964237213135
, O O 0.9999805688858032
30 O O 0.9999966621398926
, O O 0.9999639987945557
60 O O 0.9999905824661255
or O O 0.9999752044677734
120 O O 0.9999897480010986
min O O 0.9999942779541016
. O O 0.9999816417694092

After O O 0.9999473094940186
a O O 0.9999759197235107
6 O O 0.999911904335022
- O O 0.9999688863754272
week O O 0.9999856948852539
treatment O O 0.9999467134475708
period O O 0.9999512434005737
and O O 0.9999643564224243
additional O O 0.9999622106552124
observation O O 0.9999964237213135
for O O 0.9999450445175171
2 O O 0.9999619722366333
weeks O O 0.9999977350234985
, O O 0.9999902248382568
the O O 0.9999957084655762
mice O O 0.9999963045120239
were O O 0.9999946355819702
sacrificed O O 0.9999964237213135
. O O 0.9999791383743286

Their O O 0.9999305009841919
cardiac O O 0.9999121427536011
tissues O O 0.999994158744812
were O O 0.9999587535858154
processed O O 0.9999946355819702
for O O 0.9999865293502808
light O O 0.9999738931655884
microscopy O O 0.9999734163284302
, O O 0.99996018409729
after O O 0.9999604225158691
which O O 0.999954342842102
cardiomyocyte O O 0.9999841451644897
damage O O 0.9999730587005615
was O O 0.9999690055847168
evaluated O O 0.9999942779541016
according O O 0.9999819993972778
to O O 0.9998326301574707
Billingham O O 0.9960986375808716
( O O 0.9999418258666992
in O O 0.9998038411140442
Cancer O O 0.9989367127418518
Treat O O 0.9986316561698914
Rep O O 0.9929928779602051
62 O O 0.9983477592468262
( O O 0.995560884475708
6 O O 0.9955567717552185
) O O 0.994478702545166
: O O 0.9995274543762207
865 O O 0.9902603030204773
- O O 0.9963973164558411
872 O O 0.9918907880783081
, O O 0.9999699592590332
1978 O O 0.9989268183708191
) O O 0.9999674558639526
. O O 0.9999730587005615

Microscopic O O 0.9994906187057495
evaluation O O 0.9999891519546509
revealed O O 0.9999799728393555
that O O 0.9998875856399536
treatment O O 0.9999629259109497
with O O 0.9994518160820007
DOX B B 0.9997661709785461
alone O O 0.9639885425567627
induced O O 0.9999327659606934
significant O O 0.9999744892120361
cardiac O O 0.9999868869781494
damage O O 0.9999966621398926
in O O 0.9999858140945435
comparison O O 0.9999942779541016
to O O 0.9999701976776123
the O O 0.999966025352478
saline O O 0.9998388290405273
control O O 0.9998427629470825
group O O 0.999964714050293
( O O 0.999962568283081
P O O 0.9988077878952026
< O O 0.9999752044677734
0 O O 0.9999855756759644
. O O 0.9999963045120239
001 O O 0.9997602105140686
) O O 0.999969482421875
. O O 0.9999819993972778

RESULTS O O 0.9998226761817932
: O O 0.9999399185180664
The O O 0.9999918937683105
number O O 0.9999818801879883
of O O 0.9999457597732544
damaged O O 0.9998185038566589
cardiomyocytes O O 0.9999585151672363
was O O 0.9999550580978394
9 O O 0.9999871253967285
. O O 0.999995231628418
6 O O 0.9999864101409912
- O O 0.9999682903289795
fold O O 0.9999954700469971
( O O 0.9998996257781982
95 O O 0.9999921321868896
% O O 0.9998745918273926
CI O O 0.9954408407211304
4 O O 0.9997132420539856
. O O 0.9999067783355713
4 O O 0.9995813965797424
- O O 0.9968531727790833
21 O O 0.9999877214431763
. O O 0.9999927282333374
0 O O 0.999984860420227
) O O 0.9999815225601196
higher O O 0.9999319314956665
in O O 0.9999091625213623
mice O O 0.9999902248382568
treated O O 0.9999128580093384
with O O 0.9995347261428833
DOX B B 0.9998303651809692
alone O O 0.9909586906433105
than O O 0.9999655485153198
that O O 0.9999567270278931
in O O 0.9998619556427002
animals O O 0.9997592568397522
of O O 0.9999629259109497
the O O 0.9999860525131226
control O O 0.999915361404419
group O O 0.9999772310256958
. O O 0.9999717473983765

The O O 0.9999867677688599
ratio O O 0.9999549388885498
of O O 0.9999525547027588
aberrant O O 0.9999881982803345
cardiomyocytes O O 0.9999828338623047
in O O 0.9999046325683594
mice O O 0.9999833106994629
treated O O 0.9998798370361328
with O O 0.9997125267982483
DOX B B 0.9995409250259399
preceded O I 0.9777596592903137
by O O 0.9690820574760437
monoHER B O 0.8256165981292725
and O O 0.9996459484100342
those O O 0.9999674558639526
in O O 0.9999392032623291
mice O O 0.9999896287918091
treated O O 0.9999096393585205
with O O 0.9999064207077026
saline O O 0.9975581169128418
ranged O O 0.9999656677246094
from O O 0.9999804496765137
1 O O 0.9999806880950928
. O O 0.9999916553497314
6 O O 0.9999936819076538
to O O 0.9999655485153198
2 O O 0.9999916553497314
. O O 0.9999903440475464
8 O O 0.9999821186065674
( O O 0.9999682903289795
mean O O 0.9999946355819702
2 O O 0.9999805688858032
. O O 0.9999934434890747
2 O O 0.9999940395355225
, O O 0.9999690055847168
95 O O 0.9999403953552246
% O O 0.999420166015625
CI O O 0.9963588118553162
1 O O 0.9998643398284912
. O O 0.9998918771743774
2 O O 0.9999783039093018
- O O 0.9967562556266785
4 O O 0.999792754650116
. O O 0.9999880790710449
1 O O 0.9999934434890747
, O O 0.9999643564224243
P O O 0.9995796084403992
= O O 0.9999450445175171
0 O O 0.9999945163726807
. O O 0.9999973773956299
019 O O 0.9999967813491821
) O O 0.9999781847000122
. O O 0.9999809265136719

The O O 0.9999728202819824
mean O O 0.9992464780807495
protective O O 0.99937504529953
effect O O 0.9999581575393677
by O O 0.9999395608901978
adding O O 0.9996316432952881
monoHER B B 0.9834180474281311
before O O 0.9715995788574219
DOX B B 0.999562680721283
led O O 0.9999346733093262
to O O 0.9999831914901733
a O O 0.9999874830245972
significant O O 0.9999909400939941
4 O O 0.9999527931213379
. O O 0.9999945163726807
4 O O 0.9999481439590454
- O O 0.9999868869781494
fold O O 0.9999979734420776
reduction O O 0.9999967813491821
( O O 0.999958872795105
P O O 0.9985270500183105
< O O 0.9999773502349854
0 O O 0.9999892711639404
. O O 0.9999972581863403
001 O O 0.9999748468399048
, O O 0.9999421834945679
95 O O 0.9999754428863525
% O O 0.9997854828834534
CI O O 0.9926797151565552
2 O O 0.9998044371604919
. O O 0.9998776912689209
3 O O 0.9999494552612305
- O O 0.9973146319389343
8 O O 0.9971528053283691
. O O 0.9999865293502808
2 O O 0.9999686479568481
) O O 0.9999731779098511
of O O 0.9999744892120361
abnormal O O 0.9999650716781616
cardiomyocytes O O 0.9999815225601196
. O O 0.9999644756317139

This O O 0.9999040365219116
protective O O 0.9992150068283081
effect O O 0.9999071359634399
did O O 0.9999581575393677
not O O 0.9999604225158691
depend O O 0.999991774559021
on O O 0.9999843835830688
the O O 0.999993085861206
time O O 0.9999830722808838
interval O O 0.9999948740005493
between O O 0.9999281167984009
monoHER B B 0.9961353540420532
and O O 0.9925065636634827
DOX B B 0.9996606111526489
administration O O 0.9997789263725281
( O O 0.999977707862854
P O O 0.9997825026512146
= O O 0.9999654293060303
0 O O 0.9999874830245972
. O O 0.9999943971633911
345 O O 0.9999940395355225
) O O 0.9999728202819824
. O O 0.9999600648880005

CONCLUSION O O 0.9985211491584778
: O O 0.9999935626983643
The O O 0.9999949932098389
results O O 0.9999867677688599
indicate O O 0.999957799911499
that O O 0.9999425411224365
in O O 0.9999861717224121
an O O 0.999985933303833
outpatient O O 0.9999794960021973
clinical O O 0.9999922513961792
setting O O 0.9999868869781494
monoHER B B 0.999309778213501
may O O 0.9998282194137573
be O O 0.999974250793457
administered O O 0.9999046325683594
shortly O O 0.9999856948852539
before O O 0.999550998210907
DOX B B 0.9998403787612915
. O O 0.9998301267623901

Clinical O O 0.999947190284729
evaluation O O 0.9999891519546509
of O O 0.9999610185623169
adverse O O 0.9998968839645386
effects O O 0.9999674558639526
during O O 0.999885082244873
bepridil B B 0.9994317889213562
administration O O 0.9997978806495667
for O O 0.9999444484710693
atrial O O 0.9996558427810669
fibrillation O O 0.9999929666519165
and O O 0.9999005794525146
flutter O O 0.9999982118606567
. O O 0.9999850988388062

BACKGROUND O O 0.9871249794960022
: O O 0.9860101938247681
Bepridil B B 0.9981841444969177
hydrochloride I I 0.9973701238632202
( O O 0.9661897420883179
Bpd B B 0.9927688837051392
) O O 0.9985265731811523
has O O 0.9999415874481201
attracted O O 0.9999881982803345
attention O O 0.999974250793457
as O O 0.9999468326568604
an O O 0.9993500113487244
effective O O 0.9985370635986328
drug O O 0.9995660185813904
for O O 0.9996638298034668
atrial O O 0.9994418025016785
fibrillation O O 0.9999827146530151
( O O 0.9991463422775269
AF O O 0.5756734609603882
) O O 0.9998000264167786
and O O 0.9997628331184387
atrial O O 0.9988345503807068
flutter O O 0.999996542930603
( O O 0.9995622038841248
AFL O O 0.8541188836097717
) O O 0.9999476671218872
. O O 0.9998812675476074

However O O 0.9992617964744568
, O O 0.9997889399528503
serious O O 0.9998657703399658
adverse O O 0.9998243451118469
effects O O 0.9999579191207886
, O O 0.9999734163284302
including O O 0.9999200105667114
torsade O O 0.9161126613616943
de O O 0.9990015625953674
pointes O O 0.9993564486503601
( O O 0.9997798800468445
Tdp O O 0.8378757834434509
) O O 0.9998669624328613
, O O 0.9999589920043945
have O O 0.9999672174453735
been O O 0.9999744892120361
reported O O 0.999980092048645
. O O 0.9999446868896484

METHODS O O 0.9998168349266052
AND O O 0.9999645948410034
RESULTS O O 0.9999758005142212
: O O 0.9995778203010559
Adverse O O 0.9998250603675842
effects O O 0.9999668598175049
of O O 0.9997947812080383
Bpd B B 0.8643617033958435
requiring O O 0.9997159838676453
discontinuation O O 0.9999841451644897
of O O 0.9999246597290039
treatment O O 0.99974125623703
were O O 0.9999231100082397
evaluated O O 0.9999593496322632
. O O 0.999958872795105

Bpd B B 0.9678205847740173
was O O 0.9997223019599915
administered O O 0.9999176263809204
to O O 0.9999597072601318
459 O O 0.9999961853027344
patients O O 0.9999969005584717
( O O 0.9999599456787109
361 O O 0.9999920129776001
males O O 0.9987510442733765
, O O 0.9999817609786987
63 O O 0.9999973773956299
+ O O 0.9999972581863403
/ O O 0.9999890327453613
- O O 0.9999595880508423
12 O O 0.999997615814209
years O O 0.9999932050704956
old O O 0.9998509883880615
) O O 0.9999420642852783
comprising O O 0.9996504783630371
378 O O 0.9999692440032959
AF O O 0.8742015957832336
and O O 0.9996559619903564
81 O O 0.994387149810791
AFL O O 0.9447497725486755
cases O O 0.9998916387557983
. O O 0.9999468326568604

Mean O O 0.9999608993530273
left O O 0.999962568283081
ventricular O O 0.9999926090240479
ejection O O 0.9995203018188477
fraction O O 0.9999932050704956
and O O 0.9999427795410156
atrial O O 0.9973112344741821
dimension O O 0.9999872446060181
( O O 0.9999011754989624
LAD O O 0.9982559084892273
) O O 0.9999819993972778
were O O 0.999976634979248
66 O O 0.9999985694885254
+ O O 0.999995231628418
/ O O 0.9999927282333374
- O O 0.9999558925628662
11 O O 0.9999921321868896
% O O 0.9999961853027344
and O O 0.999971866607666
40 O O 0.9999741315841675
+ O O 0.999992847442627
/ O O 0.9999933242797852
- O O 0.9999691247940063
6 O O 0.9999855756759644
mm O O 0.9999983310699463
, O O 0.999990701675415
respectively O O 0.9999833106994629
. O O 0.9999786615371704

Adverse O O 0.9992026686668396
effects O O 0.9999732971191406
were O O 0.9999693632125854
observed O O 0.9999717473983765
in O O 0.9999531507492065
19 O O 0.9999676942825317
patients O O 0.9999933242797852
( O O 0.999968409538269
4 O O 0.9999316930770874
% O O 0.9999886751174927
) O O 0.9999568462371826
during O O 0.9999545812606812
an O O 0.9999918937683105
average O O 0.9999817609786987
follow O O 0.9999940395355225
- O O 0.9999935626983643
up O O 0.9999977350234985
of O O 0.999991774559021
20 O O 0.999994158744812
months O O 0.9999983310699463
. O O 0.9999804496765137

There O O 0.9999371767044067
was O O 0.9999567270278931
marked O O 0.999954104423523
QT O O 0.9814924597740173
prolongation O O 0.9998749494552612
greater O O 0.9999765157699585
than O O 0.9999943971633911
0 O O 0.9999933242797852
. O O 0.9999955892562866
55 O O 0.9999825954437256
s O O 0.9998586177825928
in O O 0.9999681711196899
13 O O 0.9999737739562988
patients O O 0.999994158744812
, O O 0.9999520778656006
bradycardia O O 0.9999456405639648
less O O 0.9999825954437256
than O O 0.9999959468841553
40 O O 0.999990701675415
beats O O 0.999998927116394
/ O O 0.9999904632568359
min O O 0.999967098236084
in O O 0.9999791383743286
6 O O 0.9998329877853394
patients O O 0.9999924898147583
, O O 0.9999493360519409
dizziness O O 0.999971866607666
and O O 0.9999301433563232
general O O 0.9999709129333496
fatigue O O 0.9999909400939941
in O O 0.999947190284729
1 O O 0.9998098015785217
patient O O 0.9999806880950928
each O O 0.9999499320983887
. O O 0.9999573230743408

In O O 0.9999685287475586
4 O O 0.9999396800994873
of O O 0.9999754428863525
13 O O 0.9999908208847046
patients O O 0.9999905824661255
with O O 0.999956488609314
QT O O 0.9636375904083252
prolongation O O 0.9998149275779724
, O O 0.9998883008956909
Tdp O O 0.9496778249740601
occurred O O 0.999972939491272
. O O 0.9999783039093018

The O O 0.9999634027481079
major O O 0.9999334812164307
triggering O O 0.9999822378158569
factors O O 0.9999903440475464
of O O 0.9999628067016602
Tdp O O 0.9887802600860596
were O O 0.9998430013656616
hypokalemia O O 0.997234046459198
and O O 0.9999134540557861
sudden O O 0.9999940395355225
decrease O O 0.9999983310699463
in O O 0.9999904632568359
heart O O 0.9999912977218628
rate O O 0.9999912977218628
. O O 0.9999547004699707

There O O 0.9999767541885376
were O O 0.9999818801879883
no O O 0.9999896287918091
differences O O 0.9999974966049194
in O O 0.9999953508377075
the O O 0.9999945163726807
clinical O O 0.9999957084655762
backgrounds O O 0.9999980926513672
of O O 0.9999873638153076
the O O 0.9999895095825195
patients O O 0.9999924898147583
with O O 0.999966025352478
and O O 0.999972939491272
without O O 0.9999755620956421
Tdp O O 0.847590446472168
other O O 0.9999047517776489
than O O 0.9999393224716187
LAD O O 0.978644609451294
and O O 0.9999489784240723
age O O 0.9924599528312683
, O O 0.9999750852584839
which O O 0.9999315738677979
were O O 0.9999699592590332
larger O O 0.9999768733978271
and O O 0.9999707937240601
older O O 0.9997356534004211
in O O 0.9999305009841919
the O O 0.9999865293502808
patients O O 0.9999910593032837
with O O 0.9999619722366333
Tdp O O 0.8487197756767273
. O O 0.999943733215332

CONCLUSION O O 0.9999282360076904
: O O 0.9999388456344604
Careful O O 0.9999734163284302
observation O O 0.9999929666519165
of O O 0.999963641166687
serum O O 0.9988248944282532
potassium B B 0.998964786529541
concentration O O 0.9998151659965515
and O O 0.9999734163284302
the O O 0.9999715089797974
ECG O O 0.9903659820556641
should O O 0.9999098777770996
always O O 0.9999505281448364
be O O 0.9999969005584717
done O O 0.9999967813491821
during O O 0.9999419450759888
Bpd B B 0.9784345030784607
administration O O 0.9996730089187622
, O O 0.9999866485595703
particularly O O 0.9999890327453613
in O O 0.9999853372573853
elderly O O 0.9998419284820557
patients O O 0.9999927282333374
. O O 0.9999822378158569

Enhanced O O 0.9982695579528809
isoproterenol B B 0.9983847141265869
- O O 0.9992411136627197
induced O O 0.9999333620071411
cardiac O O 0.9999904632568359
hypertrophy O O 0.9998891353607178
in O O 0.9999603033065796
transgenic O O 0.9989646673202515
rats O O 0.9999972581863403
with O O 0.9999275207519531
low O O 0.9996846914291382
brain O O 0.9392249584197998
angiotensinogen O B 0.9124736785888672
. O O 0.9997982382774353

We O O 0.9999407529830933
have O O 0.9999927282333374
previously O O 0.9999607801437378
shown O O 0.9999825954437256
that O O 0.9998828172683716
a O O 0.9998564720153809
permanent O O 0.9997815489768982
deficiency O O 0.9998410940170288
in O O 0.9997170567512512
the O O 0.999722421169281
brain O O 0.9893745183944702
renin O O 0.4662860929965973
- O O 0.9231063723564148
angiotensin B B 0.9066808819770813
system O O 0.614331066608429
( O O 0.9989443421363831
RAS O O 0.7794816493988037
) O O 0.999840497970581
may O O 0.99992835521698
increase O O 0.9996080994606018
the O O 0.9999117851257324
sensitivity O O 0.9999145269393921
of O O 0.9998713731765747
the O O 0.9994503855705261
baroreflex O O 0.7586153149604797
control O O 0.9997186064720154
of O O 0.9998966455459595
heart O O 0.9999570846557617
rate O O 0.9999778270721436
. O O 0.9999492168426514

In O O 0.9999862909317017
this O O 0.9999668598175049
study O O 0.9999617338180542
we O O 0.999958872795105
aimed O O 0.9999867677688599
at O O 0.999972939491272
studying O O 0.9998867511749268
the O O 0.9999454021453857
involvement O O 0.9999709129333496
of O O 0.9998799562454224
the O O 0.999829888343811
brain O O 0.9996433258056641
RAS O O 0.9821994304656982
in O O 0.9998763799667358
the O O 0.9999427795410156
cardiac O O 0.9998725652694702
reactivity O O 0.9999762773513794
to O O 0.9994008541107178
the O O 0.9992043375968933
beta O O 0.8838388323783875
- O O 0.9670413732528687
adrenoceptor O O 0.8672384023666382
( O O 0.9937817454338074
beta O O 0.7380139827728271
- O O 0.890896201133728
AR O O 0.7863005995750427
) O O 0.8263692259788513
agonist O O 0.64615797996521
isoproterenol B B 0.9991010427474976
( O O 0.9971022009849548
Iso B B 0.9702742695808411
) O O 0.9995458722114563
. O O 0.9999480247497559

Transgenic O O 0.9924962520599365
rats O O 0.999984860420227
with O O 0.9999439716339111
low O O 0.9970411658287048
brain O O 0.9687970280647278
angiotensinogen O O 0.8139973282814026
( O O 0.9949020147323608
TGR O O 0.6217193603515625
) O O 0.9996640682220459
were O O 0.9999452829360962
used O O 0.9999665021896362
. O O 0.9999465942382812

In O O 0.9997805953025818
isolated O O 0.9989187717437744
hearts O O 0.9999878406524658
, O O 0.9997569918632507
Iso B B 0.9992990493774414
induced O O 0.9997069239616394
a O O 0.9999854564666748
significantly O O 0.9999890327453613
greater O O 0.9999818801879883
increase O O 0.9999939203262329
in O O 0.9999825954437256
left O O 0.9999520778656006
ventricular O O 0.999993085861206
( O O 0.9995962977409363
LV O O 0.9805597066879272
) O O 0.999863862991333
pressure O O 0.9999572038650513
and O O 0.9999295473098755
maximal O O 0.9999537467956543
contraction O O 0.9999909400939941
( O O 0.9999138116836548
+ O O 0.999853253364563
dP O O 0.9931772947311401
/ O O 0.9996286630630493
dt O O 0.9945949912071228
( O O 0.9983711838722229
max O O 0.9971501231193542
) O O 0.999896764755249
) O O 0.9999662637710571
in O O 0.9998138546943665
the O O 0.9998117089271545
TGR O O 0.7623134851455688
than O O 0.9998607635498047
in O O 0.9998741149902344
the O O 0.999923586845398
Sprague O O 0.9797763228416443
- O O 0.9979678988456726
Dawley O O 0.9959295392036438
( O O 0.9998539686203003
SD O O 0.9687837958335876
) O O 0.9998658895492554
rats O O 0.9996910095214844
. O O 0.9999663829803467

LV O O 0.9370988607406616
hypertrophy O O 0.9996703863143921
induced O O 0.9999558925628662
by O O 0.999922513961792
Iso B B 0.9974274039268494
treatment O O 0.9960383176803589
was O O 0.9999490976333618
significantly O O 0.9999816417694092
higher O O 0.9999639987945557
in O O 0.9998749494552612
TGR O O 0.9332329630851746
than O O 0.9998797178268433
in O O 0.9997503161430359
SD O O 0.873197615146637
rats O O 0.99957674741745
( O O 0.9999468326568604
in O O 0.9998317956924438
g O O 0.8973013162612915
LV O O 0.9652302861213684
wt O O 0.9987720847129822
/ O O 0.999504566192627
100 O O 0.9912145137786865
g O O 0.9343938827514648
body O O 0.6918053030967712
wt O O 0.9019290208816528
, O O 0.9999520778656006
0 O O 0.9998598098754883
. O O 0.9999828338623047
28 O O 0.9999788999557495
+ O O 0.9999746084213257
/ O O 0.9997047781944275
- O O 0.9996495246887207
0 O O 0.999947190284729
. O O 0.9999953508377075
004 O O 0.9999614953994751
vs O O 0.9998606443405151
. O O 0.999988317489624
0 O O 0.9999576807022095
. O O 0.9999878406524658
24 O O 0.9999921321868896
+ O O 0.9999831914901733
/ O O 0.9997166991233826
- O O 0.9998897314071655
0 O O 0.9999818801879883
. O O 0.9999967813491821
004 O O 0.9999513626098633
, O O 0.9999852180480957
respectively O O 0.9999693632125854
) O O 0.9999758005142212
. O O 0.99997878074646

The O O 0.9999544620513916
greater O O 0.9999327659606934
LV O O 0.9244213700294495
hypertrophy O O 0.9998433589935303
in O O 0.9996479749679565
TGR O O 0.5234817266464233
rats O O 0.999861478805542
was O O 0.999927282333374
associated O O 0.9999715089797974
with O O 0.9999480247497559
more O O 0.9999517202377319
pronounced O O 0.9999772310256958
downregulation O O 0.9998420476913452
of O O 0.9997982382774353
beta O O 0.9693037867546082
- O O 0.9906056523323059
AR O O 0.6260170936584473
and O O 0.9998501539230347
upregulation O O 0.9887269735336304
of O O 0.9998264908790588
LV O O 0.8764963150024414
beta O O 0.8251329064369202
- O O 0.9607434272766113
AR O O 0.5859670042991638
kinase O O 0.7590639591217041
- O O 0.9650835990905762
1 O O 0.9444355964660645
mRNA O O 0.9677881598472595
levels O O 0.9998674392700195
compared O O 0.9999715089797974
with O O 0.9999909400939941
those O O 0.9999872446060181
in O O 0.9998865127563477
SD O O 0.8451042771339417
rats O O 0.9999878406524658
. O O 0.9999696016311646

The O O 0.9999873638153076
decrease O O 0.9999921321868896
in O O 0.9999779462814331
the O O 0.9999830722808838
heart O O 0.999983549118042
rate O O 0.9999933242797852
( O O 0.9998756647109985
HR O O 0.9673601984977722
) O O 0.9999665021896362
induced O O 0.9999831914901733
by O O 0.9999125003814697
the O O 0.9998817443847656
beta O O 0.7946699857711792
- O O 0.9338870644569397
AR O O 0.590975284576416
antagonist O O 0.9002230763435364
metoprolol B B 0.9998530149459839
in O O 0.9997692704200745
conscious O O 0.6383056640625
rats O O 0.9999487400054932
was O O 0.9999493360519409
significantly O O 0.9999563694000244
attenuated O O 0.9998806715011597
in O O 0.9997888207435608
TGR O O 0.8481703996658325
compared O O 0.999956488609314
with O O 0.999975323677063
SD O O 0.7074339389801025
rats O O 0.9999783039093018
( O O 0.9999386072158813
- O O 0.9999351501464844
9 O O 0.9999030828475952
. O O 0.9999904632568359
9 O O 0.9999804496765137
+ O O 0.9999839067459106
/ O O 0.9999818801879883
- O O 0.9999456405639648
1 O O 0.9999831914901733
. O O 0.9999715089797974
7 O O 0.99998939037323
% O O 0.9999949932098389
vs O O 0.9999581575393677
. O O 0.9999841451644897
- O O 0.9999381303787231
18 O O 0.999968409538269
. O O 0.999994158744812
1 O O 0.9999921321868896
+ O O 0.9999879598617554
/ O O 0.9999734163284302
- O O 0.9999628067016602
1 O O 0.9999791383743286
. O O 0.9999791383743286
5 O O 0.9999860525131226
% O O 0.9999947547912598
) O O 0.9999759197235107
, O O 0.9999642372131348
whereas O O 0.9999767541885376
the O O 0.9999805688858032
effect O O 0.9999606609344482
of O O 0.9998903274536133
parasympathetic O O 0.9671730399131775
blockade O O 0.9998774528503418
by O O 0.9998562335968018
atropine B B 0.9996311664581299
on O O 0.9997603297233582
HR O O 0.764358639717102
was O O 0.9999617338180542
similar O O 0.9999707937240601
in O O 0.9998959302902222
both O O 0.9982743263244629
strains O O 0.9996329545974731
. O O 0.9999740123748779

These O O 0.9999759197235107
results O O 0.9999871253967285
indicate O O 0.99994957447052
that O O 0.9998086094856262
TGR O O 0.5058273673057556
are O O 0.9998108744621277
more O O 0.9996180534362793
sensitive O O 0.9998900890350342
to O O 0.9997815489768982
beta O B 0.5644693970680237
- O I 0.6171942353248596
AR O I 0.975918173789978
agonist O I 0.9242275357246399
- O O 0.9985626339912415
induced O O 0.9999251365661621
cardiac O O 0.9999840259552002
inotropic O O 0.9998960494995117
response O O 0.9999829530715942
and O O 0.9998537302017212
hypertrophy O O 0.999276340007782
, O O 0.9999741315841675
possibly O O 0.9999563694000244
due O O 0.9999679327011108
to O O 0.999910831451416
chronically O O 0.9999532699584961
low O O 0.9999397993087769
sympathetic O O 0.9857062101364136
outflow O O 0.9986981153488159
directed O O 0.9998428821563721
to O O 0.9998224377632141
the O O 0.9999798536300659
heart O O 0.9999765157699585
. O O 0.9999538660049438

Drug O O 0.9139363765716553
- O O 0.9997075200080872
induced O O 0.9999151229858398
long O O 0.9936882853507996
QT O O 0.9752936363220215
syndrome O O 0.999969482421875
in O O 0.999882698059082
injection O O 0.5171878933906555
drug O O 0.5254523158073425
users O O 0.9996830224990845
receiving O O 0.9991683959960938
methadone B B 0.9997807145118713
: O O 0.9998743534088135
high O O 0.9998881816864014
frequency O O 0.9999895095825195
in O O 0.9999632835388184
hospitalized O O 0.9999761581420898
patients O O 0.9999910593032837
and O O 0.9999600648880005
risk O O 0.9999474287033081
factors O O 0.9999972581863403
. O O 0.9999828338623047

BACKGROUND O O 0.9977940320968628
: O O 0.9998823404312134
Drug O O 0.9690937399864197
- O O 0.9995349645614624
induced O O 0.9999364614486694
long O O 0.9899798631668091
QT O O 0.9764004945755005
syndrome O O 0.9999575614929199
is O O 0.999967098236084
a O O 0.9999724626541138
serious O O 0.9999629259109497
adverse O O 0.99978107213974
drug O O 0.9989816546440125
reaction O O 0.999992847442627
. O O 0.9999337196350098

Methadone B B 0.9991173148155212
prolongs O O 0.9996845722198486
the O O 0.9999842643737793
QT O O 0.9970062375068665
interval O O 0.9999946355819702
in O O 0.9998705387115479
vitro O O 0.999957799911499
in O O 0.9999853372573853
a O O 0.9999698400497437
dose O O 0.9995741248130798
- O O 0.9999520778656006
dependent O O 0.999976634979248
manner O O 0.9999874830245972
. O O 0.999893307685852

In O O 0.99994957447052
the O O 0.9999685287475586
inpatient O O 0.9999054670333862
setting O O 0.9999871253967285
, O O 0.9999765157699585
the O O 0.9999911785125732
frequency O O 0.9999955892562866
of O O 0.9999847412109375
QT O O 0.9957565665245056
interval O O 0.999984860420227
prolongation O O 0.9999890327453613
with O O 0.9999208450317383
methadone B B 0.9998551607131958
treatment O O 0.9998588562011719
, O O 0.9999611377716064
its O O 0.9999744892120361
dose O O 0.9997716546058655
dependence O O 0.9999862909317017
, O O 0.999944806098938
and O O 0.9999277591705322
the O O 0.9999786615371704
importance O O 0.9999549388885498
of O O 0.9998168349266052
cofactors O O 0.7505484223365784
such O O 0.9999258518218994
as O O 0.9999562501907349
drug O O 0.9979946613311768
- O O 0.9998636245727539
drug O O 0.9996474981307983
interactions O O 0.9999442100524902
remain O O 0.9999889135360718
unknown O O 0.9999713897705078
. O O 0.9999732971191406

METHODS O O 0.999954104423523
: O O 0.9999942779541016
We O O 0.9999860525131226
performed O O 0.9999947547912598
a O O 0.9999953508377075
systematic O O 0.9999856948852539
, O O 0.9999934434890747
retrospective O O 0.9999825954437256
study O O 0.9999957084655762
comparing O O 0.9999560117721558
active O O 0.9997543692588806
or O O 0.9998520612716675
former O O 0.9998689889907837
intravenous O O 0.9968841671943665
drug O O 0.9942743182182312
users O O 0.999913215637207
receiving O O 0.9994768500328064
methadone B B 0.9994853734970093
and O O 0.9996188879013062
those O O 0.9999608993530273
not O O 0.9999475479125977
receiving O O 0.9998090863227844
methadone B B 0.9995736479759216
among O O 0.9996912479400635
all O O 0.9999833106994629
patients O O 0.9999957084655762
hospitalized O O 0.9999904632568359
over O O 0.99997878074646
a O O 0.9999903440475464
5 O O 0.9999700784683228
- O O 0.9999902248382568
year O O 0.9999966621398926
period O O 0.9999969005584717
in O O 0.99997878074646
a O O 0.9999912977218628
tertiary O O 0.9999828338623047
care O O 0.9999951124191284
hospital O O 0.9999954700469971
. O O 0.9999804496765137

A O O 0.9999685287475586
total O O 0.9999804496765137
of O O 0.9999868869781494
167 O O 0.9999825954437256
patients O O 0.9999915361404419
receiving O O 0.9994901418685913
methadone B B 0.9996532201766968
fulfilled O O 0.9999473094940186
the O O 0.9999963045120239
inclusion O O 0.9999963045120239
criteria O O 0.9999970197677612
and O O 0.9999821186065674
were O O 0.9999827146530151
compared O O 0.9999935626983643
with O O 0.999963641166687
a O O 0.9999666213989258
control O O 0.999982476234436
group O O 0.9999947547912598
of O O 0.9999692440032959
80 O O 0.9972570538520813
injection O O 0.8838835954666138
drug O O 0.9862150549888611
users O O 0.9998612403869629
not O O 0.9999785423278809
receiving O O 0.9996672868728638
methadone B B 0.9996606111526489
. O O 0.9999529123306274

In O O 0.9999539852142334
addition O O 0.9999675750732422
to O O 0.9998632669448853
methadone B B 0.9997857213020325
dose O O 0.9996482133865356
, O O 0.9999113082885742
15 O O 0.8417842984199524
demographic O O 0.9331587553024292
, O O 0.9997099041938782
biological O O 0.9972629547119141
, O O 0.9997946619987488
and O O 0.9998013377189636
pharmacological O O 0.9992122650146484
variables O O 0.9999504089355469
were O O 0.9998995065689087
considered O O 0.9999433755874634
as O O 0.9999599456787109
potential O O 0.999962329864502
risk O O 0.9999696016311646
factors O O 0.9999946355819702
for O O 0.9999561309814453
QT O O 0.9759697318077087
prolongation O O 0.9999336004257202
. O O 0.9999797344207764

RESULTS O O 0.9999593496322632
: O O 0.9999704360961914
Among O O 0.9999027252197266
167 O O 0.9997387528419495
methadone B B 0.9995261430740356
maintenance O O 0.9922186136245728
patients O O 0.9999411106109619
, O O 0.9999462366104126
the O O 0.9999910593032837
prevalence O O 0.9999856948852539
of O O 0.9999594688415527
QTc O O 0.9891341328620911
prolongation O O 0.9998655319213867
to O O 0.9999847412109375
0 O O 0.9999711513519287
. O O 0.9999945163726807
50 O O 0.9999902248382568
second O O 0.9999923706054688
( O O 0.9991075396537781
( O O 0.9935991764068604
1 O O 0.9998611211776733
/ O O 0.9998660087585449
2 O O 0.9995602965354919
) O O 0.9994372725486755
) O O 0.9999489784240723
or O O 0.999982476234436
longer O O 0.9999755620956421
was O O 0.9999706745147705
16 O O 0.9999927282333374
. O O 0.9999932050704956
2 O O 0.9999954700469971
% O O 0.9999939203262329
compared O O 0.9999853372573853
with O O 0.9999926090240479
0 O O 0.9999877214431763
% O O 0.9999953508377075
in O O 0.9999549388885498
80 O O 0.9904127717018127
control O O 0.9999605417251587
subjects O O 0.9999933242797852
. O O 0.9999808073043823

Six O O 0.9998120665550232
patients O O 0.9999916553497314
( O O 0.9999721050262451
3 O O 0.9998899698257446
. O O 0.9999797344207764
6 O O 0.999992847442627
% O O 0.9999850988388062
) O O 0.9999725818634033
in O O 0.9998385906219482
the O O 0.9998040795326233
methadone B B 0.9997300505638123
group O O 0.9991452693939209
presented O O 0.9999624490737915
torsades O O 0.9999855756759644
de O O 0.999943733215332
pointes O O 0.999808132648468
. O O 0.9999619722366333

QTc O O 0.9551213383674622
length O O 0.9999412298202515
was O O 0.9999405145645142
weakly O O 0.9999334812164307
but O O 0.9999648332595825
significantly O O 0.9999517202377319
associated O O 0.9999942779541016
with O O 0.999854564666748
methadone B B 0.999813973903656
daily O O 0.9994627833366394
dose O O 0.9998300075531006
( O O 0.9999452829360962
Spearman O O 0.9986513257026672
rank O O 0.9998200535774231
correlation O O 0.9995110034942627
coefficient O O 0.9998041987419128
, O O 0.9999762773513794
0 O O 0.9999750852584839
. O O 0.9999966621398926
20 O O 0.9999959468841553
; O O 0.9999655485153198
P O O 0.9997106194496155
< O O 0.9999626874923706
. O O 0.9999963045120239
01 O O 0.9999922513961792
) O O 0.9999723434448242
. O O 0.9999818801879883

Multivariate O O 0.9983691573143005
regression O O 0.9996883869171143
analysis O O 0.9999227523803711
allowed O O 0.9998692274093628
attribution O O 0.9997705817222595
of O O 0.9999555349349976
31 O O 0.999936580657959
. O O 0.999976634979248
8 O O 0.999991774559021
% O O 0.9999938011169434
of O O 0.999964714050293
QTc O O 0.9566293358802795
variability O O 0.9999892711639404
to O O 0.9998393058776855
methadone B B 0.999822199344635
dose O O 0.9993519186973572
, O O 0.9998923540115356
cytochrome O O 0.6829407215118408
P O O 0.7129788398742676
- O O 0.8364017009735107
450 O O 0.8759435415267944
3A4 O O 0.7304840683937073
drug O O 0.9536908864974976
- O O 0.9996774196624756
drug O O 0.9987003803253174
interactions O O 0.9999001026153564
, O O 0.9999387264251709
hypokalemia O O 0.9997065663337708
, O O 0.999889612197876
and O O 0.9999310970306396
altered O O 0.9999923706054688
liver O O 0.999639630317688
function O O 0.9999929666519165
. O O 0.9999675750732422

CONCLUSIONS O O 0.9992125034332275
: O O 0.9999724626541138
QT O O 0.9710808396339417
interval O O 0.9999586343765259
prolongation O O 0.9999812841415405
in O O 0.999953031539917
methadone B B 0.9996899366378784
maintenance O O 0.9970968961715698
patients O O 0.9999446868896484
hospitalized O O 0.999977707862854
in O O 0.9999750852584839
a O O 0.9999855756759644
tertiary O O 0.9999293088912964
care O O 0.9999902248382568
center O O 0.9999895095825195
is O O 0.9999927282333374
a O O 0.999992847442627
frequent O O 0.9999891519546509
finding O O 0.9999960660934448
. O O 0.9999825954437256

Methadone B B 0.999467670917511
dose O O 0.9997809529304504
, O O 0.9999430179595947
presence O O 0.9999302625656128
of O O 0.9995318651199341
cytochrome O O 0.5623316764831543
P O O 0.8041671514511108
- O O 0.9283342361450195
450 O O 0.6366117596626282
3A4 O O 0.49769970774650574
inhibitors O O 0.6591257452964783
, O O 0.9998390674591064
potassium B B 0.9945037364959717
level O O 0.9950394034385681
, O O 0.9997374415397644
and O O 0.9998825788497925
liver O O 0.9934317469596863
function O O 0.9999538660049438
contribute O O 0.9999641180038452
to O O 0.9999822378158569
QT O O 0.9500851631164551
prolongation O O 0.999963641166687
. O O 0.9999817609786987

Long O O 0.9710800647735596
QT O O 0.9831547737121582
syndrome O O 0.999936580657959
can O O 0.9999140501022339
occur O O 0.9999871253967285
with O O 0.9999152421951294
low O O 0.9998332262039185
doses O O 0.9997699856758118
of O O 0.9989911913871765
methadone B B 0.9995514750480652
. O O 0.9998382329940796

Mechanisms O O 0.9997170567512512
of O O 0.9999115467071533
hypertension O O 0.9980530738830566
induced O O 0.9999358654022217
by O O 0.9998340606689453
nitric B B 0.9764177799224854
oxide I I 0.9996713399887085
( O O 0.9956383109092712
NO B B 0.993285596370697
) O O 0.7786643505096436
deficiency O O 0.8440414667129517
: O O 0.9999091625213623
focus O O 0.9999366998672485
on O O 0.9997269511222839
venous O O 0.9999421834945679
function O O 0.9999831914901733
. O O 0.999954342842102

Loss O O 0.9999438524246216
of O O 0.9997226595878601
endothelial O O 0.9976019263267517
cell O O 0.9987143278121948
- O O 0.9989622831344604
derived O O 0.9935649037361145
nitric B B 0.8878928422927856
oxide I I 0.99774569272995
( O O 0.9951406717300415
NO B B 0.9587348699569702
) O O 0.9859123826026917
in O O 0.9996516704559326
hypertension O O 0.9990323781967163
is O O 0.9999494552612305
a O O 0.9999486207962036
hallmark O O 0.9999203681945801
of O O 0.9999635219573975
arterial O O 0.9999544620513916
dysfunction O O 0.9999943971633911
. O O 0.9999723434448242

Experimental O O 0.9992567896842957
hypertension O O 0.9996870756149292
created O O 0.9999418258666992
by O O 0.9999517202377319
the O O 0.99998939037323
removal O O 0.9999439716339111
of O O 0.9974095225334167
NO B B 0.9281978011131287
, O O 0.9998804330825806
however O O 0.9999568462371826
, O O 0.9999793767929077
involves O O 0.9994944334030151
mechanisms O O 0.99973064661026
in O O 0.9999727010726929
addition O O 0.9999620914459229
to O O 0.9999631643295288
decreased O O 0.9999420642852783
arterial O O 0.9993282556533813
vasodilator O O 0.9883432984352112
activity O O 0.9996596574783325
. O O 0.9999579191207886

These O O 0.999927282333374
include O O 0.9999150037765503
augmented O O 0.9994595646858215
endothelin O O 0.7843381762504578
- O O 0.9381698369979858
1 O O 0.9450283050537109
( O O 0.9860253930091858
ET O O 0.9450567364692688
- O O 0.9906876683235168
1 O O 0.983066737651825
) O O 0.9950698614120483
release O O 0.9993840456008911
, O O 0.9999117851257324
increased O O 0.9999407529830933
sympathetic O O 0.9988477230072021
nervous O O 0.9999749660491943
system O O 0.999968409538269
activity O O 0.9999611377716064
, O O 0.9997934699058533
and O O 0.9998929500579834
elevated O O 0.9998741149902344
tissue O O 0.9998495578765869
oxidative O O 0.6289446353912354
stress O O 0.9981845021247864
. O O 0.9999556541442871

We O O 0.9999301433563232
hypothesized O O 0.9999285936355591
that O O 0.9998694658279419
increased O O 0.9998238682746887
venous O O 0.9970968961715698
smooth O O 0.9826563596725464
muscle O O 0.9980332255363464
( O O 0.9845232963562012
venomotor O O 0.9706034064292908
) O O 0.9981953501701355
tone O O 0.9994267225265503
plays O O 0.9999288320541382
a O O 0.9999172687530518
role O O 0.9999674558639526
in O O 0.9999096393585205
Nomega B B 0.7650870084762573
- I I 0.6975929141044617
nitro I I 0.9207319021224976
- I I 0.9313163757324219
L I I 0.9906692504882812
- I I 0.9824498891830444
arginine I I 0.9998667240142822
( O O 0.9685487151145935
LNNA B O 0.8050734996795654
) O O 0.9987612962722778
hypertension O O 0.9999198913574219
through O O 0.9998618364334106
these O O 0.999687910079956
mechanisms O O 0.999901294708252
. O O 0.9999662637710571

Rats O O 0.9997949004173279
were O O 0.9999910593032837
treated O O 0.9999779462814331
with O O 0.9998602867126465
the O O 0.9995546936988831
NO B O 0.648582935333252
synthase O O 0.6251096129417419
inhibitor O O 0.7011210918426514
LNNA B B 0.9360016584396362
( O O 0.9993515610694885
0 O O 0.9999117851257324
. O O 0.9999867677688599
5 O O 0.9999358654022217
g O O 0.9990460276603699
/ O O 0.9999293088912964
L O O 0.9952530860900879
in O O 0.9998594522476196
drinking O O 0.9995561242103577
water O O 0.8717400431632996
) O O 0.9999343156814575
for O O 0.9999338388442993
2 O O 0.9999481439590454
weeks O O 0.9999943971633911
. O O 0.9999874830245972

Mean O O 0.9999785423278809
arterial O O 0.9998200535774231
pressure O O 0.9999172687530518
of O O 0.9998624324798584
conscious O O 0.99733966588974
rats O O 0.9999656677246094
was O O 0.9999674558639526
119 O O 0.9999866485595703
+ O O 0.9999927282333374
/ O O 0.999993085861206
- O O 0.9999803304672241
2 O O 0.9999890327453613
mm O O 0.9999958276748657
Hg O O 0.947309136390686
in O O 0.9997918009757996
control O O 0.9998214840888977
and O O 0.999937891960144
194 O O 0.9944888353347778
+ O O 0.9999920129776001
/ O O 0.9999918937683105
- O O 0.9999582767486572
5 O O 0.99996018409729
mm O O 0.9999947547912598
Hg O O 0.83652263879776
in O O 0.9996944665908813
LNNA B O 0.5703005194664001
rats O O 0.999964714050293
( O O 0.999958872795105
P O O 0.9999810457229614
< O O 0.9999792575836182
0 O O 0.9999910593032837
. O O 0.9999955892562866
05 O O 0.9999908208847046
) O O 0.9999643564224243
. O O 0.999969482421875

Carotid O O 0.9997605681419373
arteries O O 0.9996464252471924
and O O 0.9999221563339233
vena O O 0.9997171759605408
cava O O 0.9919054508209229
were O O 0.9999654293060303
removed O O 0.9999798536300659
for O O 0.9999767541885376
measurement O O 0.9999912977218628
of O O 0.9999473094940186
isometric O O 0.9998193383216858
contraction O O 0.99998939037323
. O O 0.9999085664749146

Maximal O O 0.9997904896736145
contraction O O 0.9999353885650635
to O O 0.9995943903923035
norepinephrine B B 0.9977987408638
was O O 0.9999053478240967
modestly O O 0.9999799728393555
reduced O O 0.9999922513961792
in O O 0.9997614026069641
arteries O O 0.9999741315841675
from O O 0.9984129667282104
LNNA B O 0.6007210612297058
compared O O 0.9998373985290527
with O O 0.9999295473098755
control O O 0.999836802482605
rats O O 0.9998753070831299
whereas O O 0.9999738931655884
the O O 0.999967098236084
maximum O O 0.9996834993362427
contraction O O 0.9999569654464722
to O O 0.9988540410995483
ET O O 0.9136688113212585
- O O 0.9859567880630493
1 O O 0.9878217577934265
was O O 0.9999598264694214
significantly O O 0.9999858140945435
reduced O O 0.9999951124191284
( O O 0.99997878074646
54 O O 0.9999899864196777
% O O 0.99998939037323
control O O 0.9999747276306152
) O O 0.9999818801879883
. O O 0.9999734163284302

Maximum O O 0.999764621257782
contraction O O 0.999990701675415
of O O 0.9999512434005737
vena O O 0.9999130964279175
cava O O 0.9560846090316772
to O O 0.9990881681442261
norepinephrine B B 0.999401330947876
( O O 0.999519944190979
37 O O 0.9995321035385132
% O O 0.9998917579650879
control O O 0.9992390871047974
) O O 0.9999288320541382
also O O 0.9999486207962036
was O O 0.9999569654464722
reduced O O 0.9999828338623047
but O O 0.9999693632125854
no O O 0.9999830722808838
change O O 0.9999963045120239
in O O 0.9999915361404419
response O O 0.9999744892120361
to O O 0.9994121789932251
ET O O 0.8082902431488037
- O O 0.650284469127655
1 O O 0.5087917447090149
was O O 0.9999637603759766
observed O O 0.9999910593032837
. O O 0.999967098236084

Mean O O 0.9997406601905823
circulatory O O 0.9971252083778381
filling O O 0.999931812286377
pressure O O 0.9999256134033203
, O O 0.9999794960021973
an O O 0.9999822378158569
in O O 0.9998409748077393
vivo O O 0.9999748468399048
measure O O 0.9999593496322632
of O O 0.9998569488525391
venomotor O O 0.9951808452606201
tone O O 0.9999396800994873
, O O 0.999970555305481
was O O 0.9999619722366333
not O O 0.9999672174453735
elevated O O 0.999954104423523
in O O 0.999524712562561
LNNA B O 0.577941358089447
hypertension O O 0.999415397644043
at O O 0.9999591112136841
1 O O 0.999961256980896
or O O 0.9999878406524658
2 O O 0.9999730587005615
weeks O O 0.9999986886978149
after O O 0.9999531507492065
LNNA B O 0.6867544054985046
. O O 0.9999352693557739

The O O 0.9989525079727173
superoxide B B 0.9115743637084961
scavenger O O 0.5805532932281494
tempol B B 0.9965971112251282
( O O 0.9971950054168701
30 O O 0.9989367127418518
, O O 0.9980224370956421
100 O O 0.9965511560440063
, O O 0.9971078038215637
and O O 0.9994508624076843
300 O O 0.9995982050895691
micromol O O 0.9942042231559753
kg O B 0.9590174555778503
( O I 0.8593432307243347
- O I 0.8600608706474304
1 O I 0.9416496753692627
) O I 0.9510388970375061
, O O 0.8752769827842712
IV O O 0.9828029870986938
) O O 0.9998598098754883
did O O 0.9999492168426514
not O O 0.9999842643737793
change O O 0.9999797344207764
arterial O O 0.9999672174453735
pressure O O 0.9998435974121094
in O O 0.9997325539588928
control O O 0.9998301267623901
rats O O 0.9999748468399048
but O O 0.9999666213989258
caused O O 0.9999668598175049
a O O 0.9999825954437256
dose O O 0.9994244575500488
- O O 0.9999819993972778
dependent O O 0.9999792575836182
decrease O O 0.9999914169311523
in O O 0.9999600648880005
LNNA B O 0.9618649482727051
rats O O 0.9998892545700073
( O O 0.999971866607666
- O O 0.999866247177124
18 O O 0.9999423027038574
+ O O 0.9999873638153076
/ O O 0.9999899864196777
- O O 0.9999665021896362
8 O O 0.9988508224487305
, O O 0.9998511075973511
- O O 0.9999226331710815
26 O O 0.999983549118042
+ O O 0.9999837875366211
/ O O 0.9999639987945557
- O O 0.9999446868896484
15 O O 0.9999904632568359
, O O 0.9999120235443115
and O O 0.9999082088470459
- O O 0.9999052286148071
54 O O 0.9999860525131226
+ O O 0.9999934434890747
/ O O 0.9999901056289673
- O O 0.999983549118042
11 O O 0.9999955892562866
mm O O 0.999994158744812
Hg O O 0.4800649583339691
) O O 0.9999699592590332
. O O 0.9999771118164062

Similarly O O 0.9998773336410522
, O O 0.999804675579071
ganglionic O O 0.9197081327438354
blockade O O 0.9997140765190125
with O O 0.9998513460159302
hexamethonium B B 0.9995865225791931
caused O O 0.9999099969863892
a O O 0.9999821186065674
significantly O O 0.9999887943267822
greater O O 0.9999819993972778
fall O O 0.9999960660934448
in O O 0.9999712705612183
LNNA B O 0.868710458278656
hypertensive O O 0.9951872825622559
rats O O 0.9999688863754272
( O O 0.9999737739562988
76 O O 0.9998748302459717
+ O O 0.999984860420227
/ O O 0.9999936819076538
- O O 0.9999814033508301
9 O O 0.9999885559082031
mm O O 0.9999934434890747
Hg O O 0.8976472020149231
) O O 0.9999648332595825
compared O O 0.9999768733978271
with O O 0.9999847412109375
control O O 0.9998958110809326
rats O O 0.9999935626983643
( O O 0.9999710321426392
35 O O 0.999983549118042
+ O O 0.9999854564666748
/ O O 0.999993085861206
- O O 0.9999779462814331
10 O O 0.9999842643737793
mm O O 0.9999945163726807
Hg O O 0.9494330286979675
) O O 0.999964714050293
. O O 0.9999762773513794

Carotid O O 0.999016523361206
arteries O O 0.999544084072113
, O O 0.9997485280036926
vena O O 0.9998335838317871
cava O O 0.9943280816078186
, O O 0.9997949004173279
and O O 0.9994447827339172
sympathetic O O 0.9826251268386841
ganglia O O 0.9995684027671814
from O O 0.9998162388801575
LNNA B O 0.7110936641693115
rats O O 0.9998255372047424
had O O 0.9998959302902222
higher O O 0.9997424483299255
basal O O 0.999060332775116
levels O O 0.9995909333229065
of O O 0.9987694621086121
superoxide B B 0.9719251394271851
compared O O 0.9998810291290283
with O O 0.9999822378158569
those O O 0.9999593496322632
from O O 0.9999141693115234
control O O 0.9993351101875305
rats O O 0.999991774559021
. O O 0.9999505281448364

These O O 0.9999852180480957
data O O 0.9999880790710449
suggest O O 0.9999682903289795
that O O 0.9999428987503052
while O O 0.9999556541442871
NO B B 0.957400918006897
deficiency O O 0.8080612421035767
increases O O 0.9971068501472473
oxidative O O 0.9651176929473877
stress O O 0.9989305138587952
and O O 0.9997624754905701
sympathetic O O 0.9976449608802795
activity O O 0.9999200105667114
in O O 0.9997397065162659
both O O 0.999523401260376
arterial O O 0.9998183846473694
and O O 0.9998138546943665
venous O O 0.9999420642852783
vessels O O 0.9999837875366211
, O O 0.9999392032623291
the O O 0.9990302324295044
impact O O 0.9998419284820557
on O O 0.9987358450889587
veins O O 0.9995495676994324
does O O 0.9999730587005615
not O O 0.9999690055847168
make O O 0.999980092048645
a O O 0.9999573230743408
major O O 0.9999657869338989
contribution O O 0.9999814033508301
to O O 0.9999754428863525
this O O 0.99997878074646
form O O 0.9999914169311523
of O O 0.9999681711196899
hypertension O O 0.9999232292175293
. O O 0.9999480247497559

Association O O 0.9999455213546753
of O O 0.999255359172821
DRD2 O O 0.6931928992271423
polymorphisms O O 0.9990324974060059
and O O 0.9997231364250183
chlorpromazine B B 0.9981334805488586
- O O 0.999279797077179
induced O O 0.9999178647994995
extrapyramidal O O 0.9963343143463135
syndrome O O 0.9999885559082031
in O O 0.9999282360076904
Chinese O O 0.9871232509613037
schizophrenic O O 0.9848411679267883
patients O O 0.9999769926071167
. O O 0.9999294281005859

AIM O O 0.9824451804161072
: O O 0.9996248483657837
Extrapyramidal O O 0.935419499874115
syndrome O O 0.9999449253082275
( O O 0.999890923500061
EPS O O 0.9912528395652771
) O O 0.9999587535858154
is O O 0.9999581575393677
most O O 0.9999638795852661
commonly O O 0.9999759197235107
affected O O 0.9999785423278809
by O O 0.9998470544815063
typical O O 0.9982428550720215
antipsychotic O O 0.7432783842086792
drugs O O 0.9952905178070068
that O O 0.999858021736145
have O O 0.9999139308929443
a O O 0.9999462366104126
high O O 0.9988706707954407
affinity O O 0.9998526573181152
with O O 0.9997369647026062
the O O 0.9991469383239746
D2 O O 0.6940527558326721
receptor O O 0.9997716546058655
. O O 0.9999316930770874

Recently O O 0.999970555305481
, O O 0.9999678134918213
many O O 0.9999252557754517
research O O 0.9999767541885376
groups O O 0.9999881982803345
have O O 0.9999829530715942
reported O O 0.9999983310699463
on O O 0.9999442100524902
the O O 0.9999890327453613
positive O O 0.9999758005142212
relationship O O 0.9999958276748657
between O O 0.9999459981918335
the O O 0.999967098236084
genetic O O 0.9999759197235107
variations O O 0.9999841451644897
in O O 0.9998984336853027
the O O 0.9998394250869751
DRD2 O O 0.7912375330924988
gene O O 0.999544084072113
and O O 0.9999483823776245
the O O 0.999974250793457
therapeutic O O 0.9997746348381042
response O O 0.9999924898147583
in O O 0.9999632835388184
schizophrenia O O 0.9893162250518799
patients O O 0.9999786615371704
as O O 0.9999920129776001
a O O 0.9999850988388062
result O O 0.9999892711639404
of O O 0.9998899698257446
the O O 0.9999390840530396
role O O 0.9999500513076782
of O O 0.9997261166572571
variations O O 0.9998756647109985
in O O 0.9994708895683289
the O O 0.9992246627807617
receptor O O 0.9999135732650757
in O O 0.999836802482605
modulating O O 0.9996802806854248
receptor O O 0.9999098777770996
expression O O 0.9999653100967407
. O O 0.9999501705169678

In O O 0.9999767541885376
this O O 0.9999756813049316
study O O 0.9999698400497437
, O O 0.9999492168426514
we O O 0.9999411106109619
evaluate O O 0.9999457597732544
the O O 0.9999502897262573
role O O 0.9998251795768738
DRD2 O B 0.9640483856201172
plays O O 0.9993902444839478
in O O 0.9998723268508911
chlorpromazine B B 0.9995594620704651
- O O 0.9997894167900085
induced O O 0.9999260902404785
EPS O O 0.998327910900116
in O O 0.999849796295166
schizophrenic O O 0.9934545755386353
patients O O 0.9999688863754272
. O O 0.9999489784240723

METHODS O O 0.9997689127922058
: O O 0.9999849796295166
We O O 0.9999772310256958
identified O O 0.9999731779098511
seven O O 0.995640754699707
SNP O O 0.6681939959526062
( O O 0.989188551902771
single O O 0.8847021460533142
nucleotide O O 0.9279009699821472
polymorphism O O 0.9948042035102844
) O O 0.9999285936355591
( O O 0.9984784722328186
- O O 0.9915106892585754
141Cins O O 0.8384711742401123
> O O 0.5894243121147156
del O O 0.7119311690330505
, O O 0.9935625791549683
TaqIB O O 0.6123396158218384
, O O 0.8817843794822693
TaqID O O 0.5966213345527649
, O O 0.8073359727859497
Ser311Cys O O 0.6452062726020813
, O O 0.9759628772735596
rs6275 O O 0.9494224786758423
, O O 0.9973188042640686
rs6277 O O 0.9592893123626709
and O O 0.9978394508361816
TaqIA O O 0.7716359496116638
) O O 0.999653697013855
in O O 0.9999314546585083
the O O 0.9999302625656128
DRD2 O O 0.8912439346313477
gene O O 0.9998395442962646
in O O 0.9999263286590576
146 O O 0.9989080429077148
schizophrenic O O 0.9993636012077332
inpatients O O 0.9999110698699951
( O O 0.9999772310256958
59 O O 0.9999874830245972
with O O 0.9999412298202515
EPS O O 0.9753408432006836
and O O 0.9999743700027466
87 O O 0.9999498128890991
without O O 0.9999622106552124
EPS O O 0.9677746891975403
according O O 0.9999918937683105
to O O 0.9999916553497314
the O O 0.9999932050704956
Simpson O O 0.9920064806938171
- O O 0.9993209838867188
Angus O O 0.9851974844932556
Scale O O 0.9998562335968018
) O O 0.9999852180480957
treated O O 0.9999662637710571
with O O 0.9998175501823425
chlorpromazine B B 0.9991093277931213
after O O 0.9997231364250183
8 O O 0.9999656677246094
weeks O O 0.999996542930603
. O O 0.9999860525131226

The O O 0.9999690055847168
alleles O O 0.9999755620956421
of O O 0.9999008178710938
all O O 0.9994609951972961
loci O O 0.9996310472488403
were O O 0.9999794960021973
determined O O 0.9999955892562866
by O O 0.9999568462371826
PCR O O 0.9840056896209717
( O O 0.9998470544815063
polymerase O O 0.992624044418335
chain O O 0.9814736247062683
reaction O O 0.9922897219657898
) O O 0.9999734163284302
. O O 0.9999717473983765

RESULTS O O 0.9995467066764832
: O O 0.9997429251670837
Polymorphisms O O 0.9941021800041199
TaqID O O 0.6454064249992371
, O O 0.9936696887016296
Ser311Cys O O 0.5440073013305664
and O O 0.9988706707954407
rs6277 O O 0.5258269309997559
were O O 0.9999234676361084
not O O 0.9999363422393799
polymorphic O O 0.9999189376831055
in O O 0.9999568462371826
the O O 0.9999867677688599
population O O 0.9999932050704956
recruited O O 0.9999977350234985
in O O 0.9999958276748657
the O O 0.999997615814209
present O O 0.9999945163726807
study O O 0.9999940395355225
. O O 0.9999744892120361

No O O 0.9999473094940186
statistical O O 0.9999778270721436
significance O O 0.9999969005584717
was O O 0.999984622001648
found O O 0.9999958276748657
in O O 0.9999783039093018
the O O 0.9999821186065674
allele O O 0.9999841451644897
distribution O O 0.9999819993972778
of O O 0.9994901418685913
- O O 0.9646115303039551
141Cins O O 0.8663883209228516
> O O 0.8360062837600708
del O O 0.8834094405174255
, O O 0.9993313550949097
TaqIB O O 0.7779985070228577
, O O 0.88742595911026
rs6275 O O 0.607814610004425
and O O 0.9964585900306702
TaqIA O O 0.7619770169258118
or O O 0.9997479319572449
in O O 0.9999417066574097
the O O 0.9998917579650879
estimated O O 0.9980517625808716
haplotypes O O 0.9844975471496582
( O O 0.9999104738235474
constituted O O 0.9997687935829163
by O O 0.9997661709785461
TaqIB O O 0.7676250338554382
, O O 0.964888870716095
rs6275 O O 0.9449558258056641
and O O 0.9992074370384216
TaqIA O O 0.7903038263320923
) O O 0.9998714923858643
in O O 0.9999130964279175
linkage O O 0.9999938011169434
disequilibrium O O 0.9999904632568359
between O O 0.9999064207077026
the O O 0.9999725818634033
two O O 0.9999556541442871
groups O O 0.9999850988388062
. O O 0.9999692440032959

CONCLUSION O O 0.9998832941055298
: O O 0.9999823570251465
Our O O 0.999963641166687
results O O 0.9999923706054688
did O O 0.9999896287918091
not O O 0.9999935626983643
lend O O 0.9999934434890747
strong O O 0.999982476234436
support O O 0.9999942779541016
to O O 0.9999759197235107
the O O 0.9999829530715942
view O O 0.9999825954437256
that O O 0.999906063079834
the O O 0.9999407529830933
genetic O O 0.9999423027038574
variation O O 0.9999817609786987
of O O 0.9997543692588806
the O O 0.9997795224189758
DRD2 O O 0.8392661809921265
gene O O 0.9993422627449036
plays O O 0.9999321699142456
a O O 0.9998657703399658
major O O 0.9999463558197021
role O O 0.9999488592147827
in O O 0.9999504089355469
the O O 0.9999662637710571
individually O O 0.995757520198822
variable O O 0.9999948740005493
adverse O O 0.9998937845230103
effect O O 0.9999833106994629
induced O O 0.9999885559082031
by O O 0.9999023675918579
chlorpromazine B B 0.999479353427887
, O O 0.999893307685852
at O O 0.9999722242355347
least O O 0.9999892711639404
in O O 0.9999371767044067
Chinese O O 0.9904788732528687
patients O O 0.9999871253967285
with O O 0.9999737739562988
schizophrenia O O 0.9990503191947937
. O O 0.9999713897705078

Our O O 0.9999469518661499
results O O 0.9999791383743286
confirmed O O 0.9999759197235107
a O O 0.9999948740005493
previous O O 0.9999767541885376
study O O 0.9999858140945435
on O O 0.9998531341552734
the O O 0.9999815225601196
relationship O O 0.9999474287033081
between O O 0.9997040629386902
DRD2 O O 0.6462706327438354
and O O 0.9995180368423462
EPS O O 0.7747111320495605
in O O 0.9998656511306763
Caucasians O O 0.9995737671852112
. O O 0.9999567270278931

Physical O O 0.9997498393058777
training O O 0.9999645948410034
decreases O O 0.999862551689148
susceptibility O O 0.9999899864196777
to O O 0.9999728202819824
subsequent O O 0.9999490976333618
pilocarpine B B 0.9998500347137451
- O O 0.999862790107727
induced O O 0.9999337196350098
seizures O O 0.9999855756759644
in O O 0.9999854564666748
the O O 0.9999779462814331
rat O O 0.9999797344207764
. O O 0.99993896484375

Regular O O 0.9975881576538086
motor O O 0.9998944997787476
activity O O 0.9997139573097229
has O O 0.9998555183410645
many O O 0.9999387264251709
benefits O O 0.9999576807022095
for O O 0.9998656511306763
mental O O 0.9999910593032837
and O O 0.9999364614486694
physical O O 0.9999711513519287
condition O O 0.999992847442627
but O O 0.9999316930770874
its O O 0.9999690055847168
implications O O 0.9999957084655762
for O O 0.9999380111694336
epilepsy O O 0.9999018907546997
are O O 0.9999841451644897
still O O 0.9999954700469971
controversial O O 0.9999958276748657
. O O 0.9999803304672241

In O O 0.9999721050262451
order O O 0.9999935626983643
to O O 0.9999915361404419
elucidate O O 0.9999780654907227
this O O 0.9999802112579346
problem O O 0.9999955892562866
, O O 0.9999561309814453
we O O 0.9999581575393677
have O O 0.9999934434890747
studied O O 0.9999629259109497
the O O 0.9999549388885498
effect O O 0.9999704360961914
of O O 0.9999101161956787
long O O 0.999691367149353
- O O 0.9999886751174927
term O O 0.9999455213546753
physical O O 0.9987070560455322
activity O O 0.9970552921295166
on O O 0.9997974038124084
susceptibility O O 0.9999877214431763
to O O 0.9999748468399048
subsequent O O 0.9999755620956421
seizures O O 0.9999797344207764
. O O 0.9999524354934692

Male O O 0.9999414682388306
Wistar O O 0.9994456171989441
rats O O 0.9999896287918091
were O O 0.9999649524688721
subjected O O 0.9999867677688599
to O O 0.9999767541885376
repeated O O 0.9999428987503052
training O O 0.9999892711639404
sessions O O 0.9999847412109375
in O O 0.9999755620956421
a O O 0.999968409538269
treadmill O O 0.9999111890792847
and O O 0.9999338388442993
swimming O O 0.9999581575393677
pool O O 0.9999899864196777
. O O 0.9999687671661377

Thereafter O O 0.9999018907546997
, O O 0.9999264478683472
seizures O O 0.9999805688858032
were O O 0.9999765157699585
induced O O 0.9999945163726807
by O O 0.9999111890792847
pilocarpine B B 0.9996993541717529
injections O O 0.9996820688247681
in O O 0.9998421669006348
trained O O 0.9999464750289917
and O O 0.9998742341995239
non O O 0.999647855758667
- O O 0.9999094009399414
trained O O 0.9998360872268677
control O O 0.9998425245285034
groups O O 0.9999810457229614
. O O 0.9999756813049316

During O O 0.9999277591705322
the O O 0.9999852180480957
acute O O 0.9999850988388062
period O O 0.9999881982803345
of O O 0.9999618530273438
status O O 0.9999765157699585
epilepticus O O 0.999784529209137
, O O 0.9999605417251587
we O O 0.9999332427978516
measured O O 0.9999849796295166
: O O 0.9999892711639404
( O O 0.9998883008956909
1 O O 0.9999966621398926
) O O 0.9999908208847046
the O O 0.9999949932098389
latency O O 0.9999969005584717
of O O 0.9999879598617554
the O O 0.9999911785125732
first O O 0.9999898672103882
motor O O 0.9999644756317139
sign O O 0.999971866607666
, O O 0.999987006187439
( O O 0.9999487400054932
2 O O 0.9999932050704956
) O O 0.9999911785125732
the O O 0.9999909400939941
intensity O O 0.9999957084655762
of O O 0.9999830722808838
seizures O O 0.999981164932251
, O O 0.9999845027923584
( O O 0.9999028444290161
3 O O 0.9999877214431763
) O O 0.9999916553497314
the O O 0.9999969005584717
time O O 0.9999967813491821
when O O 0.9999966621398926
it O O 0.9999926090240479
occurred O O 0.9999958276748657
within O O 0.9999650716781616
the O O 0.9999909400939941
6 O O 0.9999396800994873
- O O 0.9999793767929077
h O O 0.9998524188995361
observation O O 0.9999819993972778
period O O 0.9999561309814453
, O O 0.9999549388885498
and O O 0.9999418258666992
( O O 0.9998229146003723
4 O O 0.9999878406524658
) O O 0.9999890327453613
the O O 0.9999963045120239
time O O 0.9999932050704956
when O O 0.9999927282333374
the O O 0.9999873638153076
acute O O 0.9999562501907349
period O O 0.9999879598617554
ended O O 0.9999953508377075
. O O 0.9999680519104004

All O O 0.9999648332595825
these O O 0.9998903274536133
behavioral O O 0.9999792575836182
parameters O O 0.9999819993972778
showed O O 0.9999186992645264
statistically O O 0.9999364614486694
significant O O 0.9999938011169434
changes O O 0.9999966621398926
suggesting O O 0.9999619722366333
that O O 0.9997758269309998
regular O O 0.9995878338813782
physical O O 0.999862551689148
exercises O O 0.9999735355377197
decrease O O 0.9998121857643127
susceptibility O O 0.9999886751174927
to O O 0.9998993873596191
subsequently O O 0.7585766911506653
induced O O 0.9998728036880493
seizures O O 0.9999687671661377
and O O 0.9999054670333862
ameliorate O O 0.9999481439590454
the O O 0.9999918937683105
course O O 0.9999920129776001
of O O 0.9999798536300659
experimentally O O 0.9999501705169678
induced O O 0.9999898672103882
status O O 0.9999967813491821
epilepticus O O 0.9999802112579346
. O O 0.9999634027481079

Tonic O O 0.998106837272644
dopaminergic O B 0.9782415628433228
stimulation O O 0.9972960352897644
impairs O O 0.999924898147583
associative O O 0.9998844861984253
learning O O 0.9999929666519165
in O O 0.9999736547470093
healthy O O 0.9998917579650879
subjects O O 0.9999958276748657
. O O 0.9999566078186035

Endogenous O O 0.9948714971542358
dopamine B B 0.9974008798599243
plays O O 0.9995453953742981
a O O 0.9998823404312134
central O O 0.9998243451118469
role O O 0.9998852014541626
in O O 0.9997625946998596
salience O O 0.9994524121284485
coding O O 0.9999809265136719
during O O 0.9999115467071533
associative O O 0.9998995065689087
learning O O 0.999995231628418
. O O 0.9999614953994751

Administration O O 0.9998844861984253
of O O 0.9998838901519775
the O O 0.9995057582855225
dopamine B B 0.9962904453277588
precursor O O 0.8355438709259033
levodopa B B 0.9993083477020264
enhances O O 0.9970508813858032
learning O O 0.999984860420227
in O O 0.9999715089797974
healthy O O 0.9999450445175171
subjects O O 0.9999959468841553
and O O 0.9999666213989258
stroke O O 0.9999817609786987
patients O O 0.9999781847000122
. O O 0.9999724626541138

Because O O 0.9998231530189514
levodopa B B 0.999767005443573
increases O O 0.998672604560852
both O O 0.9993520379066467
phasic O O 0.9663143754005432
and O O 0.9996126294136047
tonic O O 0.9992619156837463
dopaminergic O B 0.9077513217926025
neurotransmission O O 0.9999246597290039
, O O 0.9999568462371826
the O O 0.9999583959579468
critical O O 0.9998427629470825
mechanism O O 0.9999521970748901
mediating O O 0.9998934268951416
the O O 0.9999591112136841
enhancement O O 0.9999066591262817
of O O 0.9999196529388428
learning O O 0.9998446702957153
is O O 0.9999630451202393
unresolved O O 0.9999488592147827
. O O 0.9999618530273438

We O O 0.9999357461929321
here O O 0.9999779462814331
probed O O 0.9999843835830688
how O O 0.9999620914459229
selective O O 0.9997885823249817
tonic O O 0.9997240900993347
dopaminergic O B 0.9934388995170593
stimulation O O 0.9997969269752502
affects O O 0.9998304843902588
associative O O 0.9998646974563599
learning O O 0.9999940395355225
. O O 0.9999845027923584

Forty O O 0.9994045495986938
healthy O O 0.9999810457229614
subjects O O 0.9999960660934448
were O O 0.9999887943267822
trained O O 0.9999934434890747
in O O 0.9999587535858154
a O O 0.9999812841415405
novel O O 0.9999791383743286
vocabulary O O 0.999972939491272
of O O 0.9999046325683594
45 O O 0.9995917677879333
concrete O O 0.9999086856842041
nouns O O 0.997384250164032
over O O 0.9999676942825317
the O O 0.9999881982803345
course O O 0.9999853372573853
of O O 0.9999909400939941
5 O O 0.9999501705169678
consecutive O O 0.9999885559082031
training O O 0.9999959468841553
days O O 0.999994158744812
in O O 0.999983549118042
a O O 0.9999890327453613
prospective O O 0.9999849796295166
, O O 0.9999830722808838
randomized O O 0.999985933303833
, O O 0.9999816417694092
double O O 0.9999438524246216
- O O 0.9999778270721436
blind O O 0.9999939203262329
, O O 0.9999772310256958
placebo O O 0.9999319314956665
- O O 0.9999617338180542
controlled O O 0.9999479055404663
design O O 0.9999918937683105
. O O 0.9999819993972778

Subjects O O 0.9999219179153442
received O O 0.9999555349349976
the O O 0.9999287128448486
tonically O O 0.9938822984695435
stimulating O O 0.9708918929100037
dopamine B B 0.9962826371192932
- O O 0.7334620356559753
receptor O O 0.9211453199386597
agonist O O 0.8164241313934326
pergolide B B 0.9997159838676453
( O O 0.9993636012077332
0 O O 0.9993019104003906
. O O 0.9999798536300659
1 O O 0.9999277591705322
mg O O 0.9990543723106384
) O O 0.9997931122779846
vs O O 0.9937942028045654
placebo O O 0.9965136647224426
120 O O 0.9998762607574463
min O O 0.9999662637710571
before O O 0.9999176263809204
training O O 0.9999942779541016
on O O 0.9999709129333496
each O O 0.9999744892120361
training O O 0.9999866485595703
day O O 0.9999876022338867
. O O 0.9999805688858032

The O O 0.9988594055175781
dopamine B B 0.9973012804985046
agonist O O 0.6604726910591125
significantly O O 0.99986732006073
impaired O O 0.9999079704284668
novel O O 0.9820992946624756
word O O 0.9999792575836182
learning O O 0.999981164932251
compared O O 0.9999755620956421
to O O 0.9996657371520996
placebo O O 0.9997532963752747
. O O 0.9998912811279297

This O O 0.9999158382415771
learning O O 0.9999366998672485
decrement O O 0.9999799728393555
persisted O O 0.9999711513519287
up O O 0.9999977350234985
to O O 0.9999974966049194
the O O 0.9999992847442627
last O O 0.9999961853027344
follow O O 0.9999938011169434
- O O 0.9999896287918091
up O O 0.9999966621398926
4 O O 0.9999281167984009
weeks O O 0.9999972581863403
post O O 0.9999678134918213
- O O 0.9999401569366455
training O O 0.9999926090240479
. O O 0.9999746084213257

Subjects O O 0.9997844099998474
treated O O 0.9998645782470703
with O O 0.9992969036102295
pergolide B B 0.9993354678153992
also O O 0.999901533126831
showed O O 0.9999668598175049
restricted O O 0.9999716281890869
emotional O O 0.9993873834609985
responses O O 0.9999878406524658
compared O O 0.9999798536300659
to O O 0.9999657869338989
the O O 0.9999706745147705
PLACEBO O O 0.999792754650116
group O O 0.9999450445175171
. O O 0.999969482421875

The O O 0.9999592304229736
extent O O 0.9999715089797974
of O O 0.9999672174453735
' O O 0.9999258518218994
flattened O O 0.9999500513076782
' O O 0.9999837875366211
affect O O 0.9999734163284302
with O O 0.9996874332427979
pergolide B B 0.9995905756950378
was O O 0.9998493194580078
related O O 0.9999810457229614
to O O 0.9999364614486694
the O O 0.9999676942825317
degree O O 0.9999215602874756
of O O 0.9999363422393799
learning O O 0.999006450176239
inhibition O O 0.9997772574424744
. O O 0.9999427795410156

These O O 0.9999645948410034
findings O O 0.9999887943267822
suggest O O 0.9999274015426636
that O O 0.9997900128364563
tonic O O 0.9996626377105713
occupation O O 0.9994612336158752
of O O 0.999258816242218
dopamine B B 0.9335938692092896
receptors O O 0.9988924860954285
impairs O O 0.999962329864502
learning O O 0.9999895095825195
by O O 0.9999212026596069
competition O O 0.9998799562454224
with O O 0.9999175071716309
phasic O O 0.9158802628517151
dopamine B B 0.9825935959815979
signals O O 0.9997945427894592
. O O 0.9999287128448486

Thus O O 0.9999277591705322
, O O 0.9997095465660095
phasic O O 0.9067385196685791
signaling O O 0.9997730851173401
seems O O 0.9999037981033325
to O O 0.9999263286590576
be O O 0.9999456405639648
the O O 0.999955415725708
critical O O 0.999944806098938
mechanism O O 0.9999500513076782
by O O 0.9999325275421143
which O O 0.9998739957809448
dopamine B B 0.9996830224990845
enhances O O 0.9993898868560791
associative O O 0.9999226331710815
learning O O 0.999984860420227
in O O 0.9999200105667114
healthy O O 0.9998540878295898
subjects O O 0.9999918937683105
and O O 0.9999195337295532
stroke O O 0.9999774694442749
patients O O 0.9999674558639526
. O O 0.999981164932251

Minocycline B B 0.9996603727340698
- O O 0.9992973804473877
induced O O 0.9999197721481323
vasculitis O O 0.9999620914459229
fulfilling O O 0.9999339580535889
the O O 0.9999849796295166
criteria O O 0.9999831914901733
of O O 0.9999427795410156
polyarteritis O O 0.9995622038841248
nodosa O O 0.9999727010726929
. O O 0.9999517202377319

A O O 0.9999878406524658
47 O O 0.9999973773956299
- O O 0.999987006187439
year O O 0.9999963045120239
- O O 0.9999935626983643
old O O 0.9999954700469971
man O O 0.9999949932098389
who O O 0.9999516010284424
had O O 0.999984622001648
been O O 0.9999517202377319
taking O O 0.9919173121452332
minocycline B B 0.9998001456260681
for O O 0.9983861446380615
palmoplantar O O 0.9864426851272583
pustulosis O O 0.9997953772544861
developed O O 0.9999529123306274
fever O O 0.9999740123748779
, O O 0.9999798536300659
myalgias O O 0.999998927116394
, O O 0.9999808073043823
polyneuropathy O O 0.9999856948852539
, O O 0.9999591112136841
and O O 0.9999719858169556
testicular O O 0.999889612197876
pain O O 0.9999914169311523
, O O 0.9999853372573853
with O O 0.9999895095825195
elevated O O 0.9998005032539368
C O O 0.697964072227478
- O O 0.7554883360862732
reactive O O 0.6180486679077148
protein O O 0.5348836779594421
( O O 0.9992446899414062
CRP O O 0.801271378993988
) O O 0.9999316930770874
. O O 0.9999635219573975

Neither O O 0.9997484087944031
myeloperoxidase O O 0.9787116646766663
- O O 0.9924915432929993
nor O O 0.9930936098098755
proteinase O O 0.9218437671661377
- O O 0.9753028154373169
3 O O 0.9606227278709412
- O O 0.9937518239021301
antineutrophil O O 0.934932291507721
cytoplasmic O O 0.8741946816444397
antibody O O 0.9906303286552429
was O O 0.9998934268951416
positive O O 0.9997621178627014
. O O 0.999943733215332

These O O 0.999882698059082
manifestations O O 0.9999804496765137
met O O 0.9999663829803467
the O O 0.9999890327453613
American O O 0.997759222984314
College O O 0.9999591112136841
of O O 0.9998965263366699
Rheumatology O O 0.9997809529304504
1990 O O 0.999933123588562
criteria O O 0.9999871253967285
for O O 0.9999874830245972
the O O 0.9999916553497314
classification O O 0.9999923706054688
of O O 0.9999486207962036
polyarteritis O O 0.9993607401847839
nodosa O O 0.9999793767929077
. O O 0.9999604225158691

Stopping O O 0.9847850799560547
minocycline B B 0.9997732043266296
led O O 0.9999003410339355
to O O 0.9999767541885376
amelioration O O 0.9999798536300659
of O O 0.9999861717224121
symptoms O O 0.9999953508377075
and O O 0.9999904632568359
normalization O O 0.999981164932251
of O O 0.9999468326568604
CRP O O 0.7720893025398254
level O O 0.9992263317108154
. O O 0.9999455213546753

To O O 0.9999891519546509
our O O 0.999983549118042
knowledge O O 0.9999938011169434
, O O 0.9999744892120361
this O O 0.9999843835830688
is O O 0.9999909400939941
the O O 0.9999939203262329
second O O 0.9999977350234985
case O O 0.999996542930603
of O O 0.9999637603759766
minocycline B B 0.9998884201049805
- O O 0.9996353387832642
induced O O 0.9999637603759766
vasculitis O O 0.9999756813049316
satisfying O O 0.9999276399612427
the O O 0.9999772310256958
criteria O O 0.9999940395355225
. O O 0.999980092048645

Differential O O 0.999904990196228
diagnosis O O 0.9999914169311523
for O O 0.999909520149231
drug O O 0.9841930270195007
- O O 0.9996966123580933
induced O O 0.9998968839645386
disease O O 0.9999858140945435
is O O 0.9999749660491943
invaluable O O 0.9999837875366211
even O O 0.9999630451202393
for O O 0.9999442100524902
patients O O 0.999984860420227
with O O 0.9999598264694214
classical O O 0.997574508190155
polyarteritis O O 0.9997572302818298
nodosa O O 0.9999727010726929
. O O 0.9999724626541138

Intramuscular O O 0.9995964169502258
hepatitis O B 0.9146139025688171
B O I 0.9697548151016235
immune O I 0.9658425450325012
globulin O I 0.9776580333709717
combined O O 0.9916171431541443
with O O 0.9983785152435303
lamivudine B B 0.998839795589447
in O O 0.9998893737792969
prevention O O 0.9999765157699585
of O O 0.9999505281448364
hepatitis O O 0.9728912711143494
B O O 0.9593204855918884
recurrence O O 0.9999876022338867
after O O 0.9999597072601318
liver O O 0.9983002543449402
transplantation O O 0.9999696016311646
. O O 0.9991747736930847

BACKGROUND O O 0.9883754253387451
: O O 0.9994046688079834
Combined O O 0.9958125948905945
hepatitis O B 0.6452520489692688
B O I 0.9162431955337524
immune O I 0.9601051807403564
globulin O I 0.9831620454788208
( O O 0.9471622705459595
HBIg O B 0.8569045662879944
) O O 0.9649481773376465
and O O 0.9957973957061768
lamivudine B B 0.9989492297172546
in O O 0.9997114539146423
prophylaxis O O 0.99600750207901
of O O 0.9999488592147827
the O O 0.9999897480010986
recurrence O O 0.9999955892562866
of O O 0.9999189376831055
hepatitis O O 0.6043723821640015
B O O 0.8104904890060425
after O O 0.9994121789932251
liver O O 0.9961978793144226
transplantation O O 0.9999550580978394
has O O 0.9999642372131348
significantly O O 0.9999927282333374
improved O O 0.9999918937683105
the O O 0.9999909400939941
survival O O 0.9999967813491821
of O O 0.9999741315841675
HBsAg B O 0.8052799105644226
positive O O 0.9983055591583252
patients O O 0.9999812841415405
. O O 0.9999749660491943

This O O 0.9999850988388062
study O O 0.9999921321868896
was O O 0.9999904632568359
undertaken O O 0.9999964237213135
to O O 0.999992847442627
evaluate O O 0.9999915361404419
the O O 0.9999951124191284
outcomes O O 0.9999985694885254
of O O 0.9999679327011108
liver O O 0.9623149037361145
transplantation O O 0.9999066591262817
for O O 0.9999399185180664
patients O O 0.9999932050704956
with O O 0.9999769926071167
hepatitis O O 0.9559570550918579
B O O 0.9446921348571777
virus O O 0.9782415628433228
( O O 0.9997021555900574
HBV O O 0.9214264154434204
) O O 0.9999464750289917
. O O 0.9999444484710693

METHODS O O 0.9999556541442871
: O O 0.9999854564666748
A O O 0.9999874830245972
retrospective O O 0.9999879598617554
chart O O 0.9999923706054688
analysis O O 0.9999902248382568
and O O 0.9999899864196777
a O O 0.999984622001648
review O O 0.9999960660934448
of O O 0.9999845027923584
the O O 0.9999911785125732
organ O O 0.9992212057113647
transplant O O 0.9997273087501526
database O O 0.99998939037323
identified O O 0.9999710321426392
51 O O 0.9999872446060181
patients O O 0.9999966621398926
( O O 0.999971866607666
43 O O 0.9999746084213257
men O O 0.9999520778656006
and O O 0.9999831914901733
8 O O 0.9997703433036804
women O O 0.999002993106842
) O O 0.9999799728393555
transplanted O O 0.9999171495437622
for O O 0.999943733215332
benign O O 0.9995469450950623
HBV O O 0.8116872906684875
- O O 0.9940717816352844
related O O 0.9998884201049805
cirrhotic O O 0.9998965263366699
diseases O O 0.9999967813491821
between O O 0.9986924529075623
June O O 0.9945027828216553
2002 O O 0.9991270899772644
and O O 0.9988246560096741
December O O 0.9917676448822021
2004 O O 0.9979840517044067
who O O 0.9999451637268066
had O O 0.9999898672103882
survived O O 0.9999929666519165
more O O 0.9999954700469971
than O O 0.9999979734420776
3 O O 0.9999809265136719
months O O 0.9999966621398926
. O O 0.9999840259552002

HBIg O B 0.9661666750907898
was O O 0.9998142123222351
administered O O 0.9999091625213623
intravenously O O 0.9999712705612183
during O O 0.9999115467071533
the O O 0.9999918937683105
first O O 0.9999949932098389
week O O 0.9999964237213135
and O O 0.9999493360519409
intramuscularly O O 0.9999436140060425
thereafter O O 0.9999781847000122
. O O 0.9999738931655884

RESULTS O O 0.9998724460601807
: O O 0.9999760389328003
At O O 0.9999902248382568
a O O 0.9999879598617554
median O O 0.9999963045120239
follow O O 0.999996542930603
- O O 0.9999948740005493
up O O 0.9999986886978149
of O O 0.9999915361404419
14 O O 0.9999964237213135
. O O 0.9999988079071045
1 O O 0.9999960660934448
months O O 0.9999990463256836
, O O 0.9999792575836182
the O O 0.9999921321868896
overall O O 0.9999659061431885
recurrence O O 0.9999858140945435
rate O O 0.9999935626983643
in O O 0.9999552965164185
the O O 0.9999911785125732
51 O O 0.9999527931213379
patients O O 0.9999932050704956
was O O 0.9999712705612183
3 O O 0.9999629259109497
. O O 0.999993085861206
9 O O 0.9999970197677612
% O O 0.9999972581863403
( O O 0.9999401569366455
2 O O 0.9999885559082031
/ O O 0.9998871088027954
51 O O 0.9999463558197021
) O O 0.9999622106552124
. O O 0.9999821186065674

The O O 0.999976396560669
overall O O 0.999983549118042
patient O O 0.9999910593032837
survival O O 0.9999697208404541
was O O 0.9999865293502808
88 O O 0.9998843669891357
. O O 0.9999972581863403
3 O O 0.999995231628418
% O O 0.999996542930603
, O O 0.9999587535858154
and O O 0.999968409538269
82 O O 0.999970555305481
. O O 0.9999953508377075
4 O O 0.9999947547912598
% O O 0.9999960660934448
after O O 0.9999586343765259
1 O O 0.9999748468399048
and O O 0.9999755620956421
2 O O 0.9999309778213501
years O O 0.9999890327453613
, O O 0.9999903440475464
respectively O O 0.9999784231185913
. O O 0.9999805688858032

A O O 0.9999392032623291
daily O O 0.9999175071716309
oral O O 0.9994193315505981
dose O O 0.9999094009399414
of O O 0.9998557567596436
100 O O 0.9977577328681946
mg O O 0.9985339641571045
lamivudine B B 0.999526858329773
for O O 0.9998793601989746
2 O O 0.9999476671218872
weeks O O 0.9999970197677612
before O O 0.9999957084655762
transplantation O O 0.9999768733978271
for O O 0.9999676942825317
10 O O 0.999903678894043
patients O O 0.9999903440475464
enabled O O 0.999940037727356
57 O O 0.9999945163726807
. O O 0.9999897480010986
1 O O 0.9999943971633911
% O O 0.999994158744812
( O O 0.9999550580978394
4 O O 0.9999160766601562
/ O O 0.9999361038208008
7 O O 0.9999880790710449
) O O 0.9998325109481812
and O O 0.9999397993087769
62 O O 0.9999935626983643
. O O 0.9999836683273315
5 O O 0.9999895095825195
% O O 0.9999947547912598
( O O 0.9999723434448242
5 O O 0.9999818801879883
/ O O 0.9999659061431885
8 O O 0.9999710321426392
) O O 0.9999786615371704
of O O 0.9999727010726929
HBV O O 0.609672486782074
- O O 0.9845727682113647
DNA O O 0.9841192364692688
and O O 0.999750554561615
HBeAg B O 0.8056783676147461
positive O O 0.9994243383407593
patients O O 0.9999706745147705
respectively O O 0.9999629259109497
to O O 0.9999833106994629
convert O O 0.9999943971633911
to O O 0.9999910593032837
be O O 0.9999943971633911
negative O O 0.999984860420227
. O O 0.9999798536300659

Intramuscular O O 0.9999433755874634
HBIg O O 0.7842589020729065
was O O 0.9998842477798462
well O O 0.999966025352478
tolerated O O 0.9999884366989136
in O O 0.9999734163284302
all O O 0.9999562501907349
patients O O 0.9999934434890747
. O O 0.9999740123748779

CONCLUSION O O 0.9977008700370789
: O O 0.9983470439910889
Lamivudine B B 0.999129593372345
combined O O 0.99955815076828
with O O 0.9997116923332214
intramuscular O O 0.9998763799667358
HBIg O B 0.9627571702003479
can O O 0.9996563196182251
effectively O O 0.9998714923858643
prevent O O 0.9998669624328613
allograft O O 0.9998083710670471
from O O 0.9998898506164551
the O O 0.999982476234436
recurrence O O 0.9999934434890747
of O O 0.9998806715011597
HBV O O 0.5915213227272034
after O O 0.9998281002044678
liver O O 0.998514711856842
transplantation O O 0.9999704360961914
. O O 0.9999592304229736

Anticonvulsant O O 0.5278417468070984
effect O O 0.9993523955345154
of O O 0.9945569038391113
eslicarbazepine B B 0.9995089769363403
acetate I I 0.9998444318771362
( O O 0.9765757322311401
BIA B B 0.994212806224823
2 I I 0.9957156777381897
- I I 0.996822714805603
093 I I 0.9999489784240723
) O O 0.9991311430931091
on O O 0.9998217225074768
seizures O O 0.9999821186065674
induced O O 0.9999901056289673
by O O 0.999955415725708
microperfusion O O 0.9529887437820435
of O O 0.9984657764434814
picrotoxin B B 0.9887685775756836
in O O 0.9994447827339172
the O O 0.9998753070831299
hippocampus O O 0.9993904829025269
of O O 0.999914288520813
freely O O 0.9999394416809082
moving O O 0.9999940395355225
rats O O 0.9999912977218628
. O O 0.9997124075889587

Eslicarbazepine B B 0.9990556836128235
acetate I I 0.9996212720870972
( O O 0.9909582138061523
BIA B B 0.9800155758857727
2 I I 0.9891991019248962
- I I 0.9891231656074524
093 I I 0.9998596906661987
, O O 0.8720922470092773
S B B 0.8606396913528442
- I I 0.9272171854972839
( I I 0.9688624739646912
- I I 0.9782055020332336
) I I 0.9700177907943726
- I I 0.9820979237556458
10 I I 0.9810875058174133
- I I 0.9837173223495483
acetoxy I I 0.993500292301178
- I I 0.9203510880470276
10 I I 0.9158551096916199
, I I 0.9959237575531006
11 I I 0.9851213693618774
- I I 0.9872006177902222
dihydro I I 0.9890627264976501
- I I 0.9733118414878845
5H I I 0.9837542176246643
- I I 0.9821898937225342
dibenzo I I 0.9662644267082214
/ I O 0.7900630831718445
b I B 0.5849778652191162
, I I 0.9428367614746094
f I I 0.507175624370575
/ I I 0.9705479741096497
azepine I I 0.9739199280738831
- I I 0.9771865606307983
5 I I 0.9795563220977783
- I I 0.995267391204834
carboxamide I I 0.9997978806495667
) O O 0.9988293051719666
is O O 0.9999682903289795
a O O 0.9998745918273926
novel O O 0.9999417066574097
antiepileptic O O 0.9459142684936523
drug O O 0.9995123147964478
, O O 0.9999747276306152
now O O 0.9999830722808838
in O O 0.9999809265136719
Phase O O 0.999909520149231
III O O 0.9989032745361328
clinical O O 0.9999884366989136
trials O O 0.999993085861206
, O O 0.9999864101409912
designed O O 0.9999865293502808
with O O 0.9999924898147583
the O O 0.9999964237213135
aim O O 0.9999880790710449
of O O 0.9999887943267822
improving O O 0.9999747276306152
efficacy O O 0.9999951124191284
and O O 0.9999935626983643
safety O O 0.9999973773956299
in O O 0.9999943971633911
comparison O O 0.9999927282333374
with O O 0.9999415874481201
the O O 0.9999063014984131
structurally O O 0.9999192953109741
related O O 0.9996821880340576
drugs O O 0.993598461151123
carbamazepine B B 0.9993653893470764
( O O 0.9934678673744202
CBZ B B 0.9865060448646545
) O O 0.9940580129623413
and O O 0.9951642751693726
oxcarbazepine B B 0.9951395988464355
( O O 0.9943326711654663
OXC B B 0.9903656244277954
) O O 0.9994377493858337
. O O 0.9999488592147827

We O O 0.9999700784683228
have O O 0.9999947547912598
studied O O 0.9999858140945435
the O O 0.9999834299087524
effects O O 0.9999823570251465
of O O 0.9999513626098633
oral O O 0.999452531337738
treatment O O 0.9999840259552002
with O O 0.9996609687805176
eslicarbazepine B B 0.9995192289352417
acetate I I 0.9994223117828369
on O O 0.9994831085205078
a O O 0.9999706745147705
whole O O 0.9995966553688049
- O O 0.9999208450317383
animal O O 0.9999644756317139
model O O 0.9999953508377075
in O O 0.9999605417251587
which O O 0.9999760389328003
partial O O 0.9998067021369934
seizures O O 0.9999562501907349
can O O 0.9999558925628662
be O O 0.9999911785125732
elicited O O 0.9999898672103882
repeatedly O O 0.9999727010726929
on O O 0.9999821186065674
different O O 0.9999301433563232
days O O 0.9999911785125732
without O O 0.9999723434448242
changes O O 0.9999963045120239
in O O 0.9999922513961792
threshold O O 0.9999872446060181
or O O 0.9999860525131226
seizure O O 0.9999698400497437
patterns O O 0.9999933242797852
. O O 0.9999798536300659

In O O 0.999862790107727
the O O 0.9999525547027588
animals O O 0.9999784231185913
treated O O 0.9998977184295654
with O O 0.9999066591262817
threshold O O 0.9987857937812805
doses O O 0.9997522234916687
of O O 0.9987290501594543
picrotoxin B B 0.9986295700073242
, O O 0.9997217059135437
the O O 0.9999868869781494
average O O 0.999935507774353
number O O 0.9999971389770508
of O O 0.9999839067459106
seizures O O 0.9999791383743286
was O O 0.9999833106994629
2 O O 0.9999785423278809
. O O 0.9999959468841553
3 O O 0.9999874830245972
+ O O 0.9999910593032837
/ O O 0.9999634027481079
- O O 0.999953031539917
1 O O 0.999992847442627
. O O 0.9999948740005493
2 O O 0.9999897480010986
, O O 0.999954104423523
and O O 0.9999656677246094
average O O 0.9995760321617126
seizure O O 0.99997878074646
duration O O 0.9999918937683105
was O O 0.9999823570251465
39 O O 0.9999972581863403
. O O 0.999996542930603
5 O O 0.9999946355819702
+ O O 0.999994158744812
/ O O 0.9999783039093018
- O O 0.9999727010726929
8 O O 0.9999226331710815
. O O 0.9999954700469971
4s O O 0.9999492168426514
. O O 0.9999878406524658

Pre O O 0.995897650718689
- O O 0.9998579025268555
treatment O O 0.9999630451202393
with O O 0.999944806098938
a O O 0.9999790191650391
dose O O 0.9996424913406372
of O O 0.9998972415924072
30 O O 0.9997170567512512
mg O O 0.9999113082885742
/ O O 0.9999326467514038
kg O O 0.9999840259552002
2h O O 0.9911925196647644
before O O 0.9995225667953491
picrotoxin B B 0.9980296492576599
microperfusion O O 0.5342905521392822
prevented O O 0.9998949766159058
seizures O O 0.9999810457229614
in O O 0.9999436140060425
the O O 0.9999845027923584
75 O O 0.999988317489624
% O O 0.9999936819076538
of O O 0.9999537467956543
the O O 0.9999721050262451
rats O O 0.9998733997344971
. O O 0.9999517202377319

Lower O O 0.9997298121452332
doses O O 0.9999407529830933
( O O 0.9996256828308105
3 O O 0.9470177888870239
and O O 0.9995818734169006
10mg O O 0.9958327412605286
/ O O 0.9996504783630371
kg O O 0.9987162351608276
) O O 0.9999188184738159
did O O 0.9999347925186157
not O O 0.9999257326126099
suppress O O 0.999932050704956
seizures O O 0.9999721050262451
, O O 0.9999551773071289
however O O 0.9999686479568481
, O O 0.9999926090240479
after O O 0.9999099969863892
administration O O 0.9999862909317017
of O O 0.9999514818191528
10mg O O 0.9873656034469604
/ O O 0.9989959597587585
kg O O 0.9973234534263611
, O O 0.9999538660049438
significant O O 0.9999449253082275
reductions O O 0.9999921321868896
in O O 0.999974250793457
seizures O O 0.9999643564224243
duration O O 0.9999854564666748
( O O 0.9999796152114868
24 O O 0.9999583959579468
. O O 0.9999938011169434
3 O O 0.9999858140945435
+ O O 0.9999909400939941
/ O O 0.9999849796295166
- O O 0.999935507774353
6 O O 0.9999808073043823
. O O 0.9999929666519165
8s O O 0.999609649181366
) O O 0.999969482421875
and O O 0.9999632835388184
seizure O O 0.9999830722808838
number O O 0.9999699592590332
( O O 0.9999709129333496
1 O O 0.9999756813049316
. O O 0.9999926090240479
6 O O 0.99998939037323
+ O O 0.9999929666519165
/ O O 0.9999722242355347
- O O 0.9999716281890869
0 O O 0.999994158744812
. O O 0.9999881982803345
34 O O 0.9999945163726807
) O O 0.9999709129333496
were O O 0.9999784231185913
found O O 0.9999868869781494
. O O 0.9999598264694214

No O O 0.9998722076416016
adverse O O 0.9999099969863892
effects O O 0.9999831914901733
of O O 0.9997135996818542
eslicarbazepine B B 0.9995368719100952
acetate I I 0.999041736125946
were O O 0.9997972846031189
observed O O 0.9999855756759644
in O O 0.9998075366020203
the O O 0.9998868703842163
behavioral O O 0.9999319314956665
/ O O 0.9997958540916443
EEG O O 0.9976065158843994
patterns O O 0.9999501705169678
studied O O 0.9999678134918213
, O O 0.9999803304672241
including O O 0.9998555183410645
sleep O O 0.9993650317192078
/ O O 0.9998470544815063
wakefulness O O 0.999907374382019
cycle O O 0.9998010993003845
, O O 0.9999736547470093
at O O 0.9998881816864014
the O O 0.9999309778213501
doses O O 0.9998080134391785
studied O O 0.9999796152114868
. O O 0.9999566078186035

Acute O O 0.9999740123748779
renal O O 0.9999781847000122
failure O O 0.9999874830245972
associated O O 0.9999792575836182
with O O 0.9999430179595947
prolonged O O 0.9998836517333984
intake O O 0.9998859167098999
of O O 0.9991387128829956
slimming O O 0.9219092130661011
pills O O 0.9956106543540955
containing O O 0.9915204644203186
anthraquinones B B 0.9861263632774353
. O O 0.9998045563697815

Chinese B O 0.6004050374031067
herbal I O 0.8931705951690674
medicine O O 0.9351966381072998
preparations O O 0.9911103248596191
are O O 0.999885082244873
widely O O 0.9999698400497437
available O O 0.9999518394470215
and O O 0.9999798536300659
often O O 0.9999635219573975
regarded O O 0.9999805688858032
by O O 0.999988317489624
the O O 0.9999904632568359
public O O 0.9999716281890869
as O O 0.999954104423523
natural O O 0.9998332262039185
and O O 0.9999656677246094
safe O O 0.999907374382019
remedies O O 0.9999198913574219
for O O 0.9999136924743652
a O O 0.9999780654907227
variety O O 0.9999918937683105
of O O 0.9999716281890869
medical O O 0.9999911785125732
conditions O O 0.9999961853027344
. O O 0.9999730587005615

Nephropathy O O 0.9992524981498718
caused O O 0.9999569654464722
by O O 0.9997430443763733
Chinese B O 0.7502303123474121
herbs I O 0.5943317413330078
has O O 0.9998425245285034
previously O O 0.999913215637207
been O O 0.9999840259552002
reported O O 0.9999916553497314
, O O 0.9999840259552002
usually O O 0.9998677968978882
involving O O 0.9999264478683472
the O O 0.9999287128448486
use O O 0.9997648596763611
of O O 0.998455286026001
aristolochic B B 0.7619849443435669
acids I I 0.9993792772293091
. O O 0.9994841814041138

We O O 0.9999891519546509
report O O 0.9999977350234985
a O O 0.9999958276748657
23 O O 0.9999963045120239
- O O 0.9999842643737793
year O O 0.9999959468841553
- O O 0.9999915361404419
old O O 0.9999943971633911
woman O O 0.9999974966049194
who O O 0.9999687671661377
developed O O 0.9999860525131226
acute O O 0.9999849796295166
renal O O 0.9999809265136719
failure O O 0.9999969005584717
following O O 0.9999727010726929
prolonged O O 0.999915599822998
use O O 0.9997870326042175
of O O 0.9996609687805176
a O O 0.9995537400245667
proprietary O O 0.9808355569839478
Chinese B O 0.6852811574935913
herbal I O 0.880355179309845
slimming O O 0.8204081654548645
pill O O 0.6695995330810547
that O O 0.9994304776191711
contained O O 0.9932491779327393
anthraquinone B B 0.9853729605674744
derivatives O I 0.9618131518363953
, O O 0.9984752535820007
extracted O O 0.9885208606719971
from O O 0.9920271039009094
Rhizoma O O 0.9940312504768372
Rhei O O 0.9679513573646545
( O O 0.9991449117660522
rhubarb O O 0.9579083323478699
) O O 0.9999521970748901
. O O 0.9999539852142334

The O O 0.9999595880508423
renal O O 0.9999655485153198
injury O O 0.9999939203262329
was O O 0.9999560117721558
probably O O 0.9999639987945557
aggravated O O 0.9999724626541138
by O O 0.9999001026153564
the O O 0.9999698400497437
concomitant O O 0.9999512434005737
intake O O 0.9997449517250061
of O O 0.9993066787719727
a O O 0.9990023970603943
non O O 0.6535812616348267
- O O 0.9859835505485535
steroidal O O 0.4746318459510803
anti O O 0.5366926789283752
- O O 0.921759843826294
inflammatory O O 0.9900071620941162
drug O O 0.9958023428916931
, O O 0.9956757426261902
diclofenac B B 0.9988574981689453
. O O 0.9999065399169922

Renal O O 0.9998204112052917
pathology O O 0.999994158744812
was O O 0.9999744892120361
that O O 0.9999610185623169
of O O 0.9999022483825684
hypocellular O O 0.995528519153595
interstitial O O 0.997687578201294
fibrosis O O 0.9999749660491943
. O O 0.999954342842102

Spontaneous O O 0.9997170567512512
renal O O 0.9999117851257324
recovery O O 0.9999881982803345
occurred O O 0.9999943971633911
upon O O 0.9999386072158813
cessation O O 0.9999053478240967
of O O 0.9998633861541748
the O O 0.9992995262145996
slimming O O 0.5618312358856201
pills O O 0.6256974339485168
, O O 0.9998637437820435
but O O 0.9999741315841675
mild O O 0.9999628067016602
interstitial O O 0.9976627826690674
fibrosis O O 0.9999747276306152
and O O 0.9997811913490295
tubular O O 0.999976396560669
atrophy O O 0.9999023675918579
was O O 0.9999854564666748
still O O 0.999984622001648
evident O O 0.9999910593032837
histologically O O 0.9999896287918091
4 O O 0.9997528195381165
months O O 0.9999990463256836
later O O 0.9999984502792358
. O O 0.9999873638153076

Although O O 0.9999828338623047
a O O 0.9999754428863525
causal O O 0.9999741315841675
relationship O O 0.999995231628418
between O O 0.9999321699142456
the O O 0.9999878406524658
use O O 0.9999260902404785
of O O 0.9999024868011475
an O O 0.9998137354850769
anthraquinone B B 0.9936097860336304
- O O 0.9980164766311646
containing O O 0.9965498447418213
herbal O O 0.9805988073348999
agent O O 0.980591356754303
and O O 0.9999033212661743
renal O O 0.9999854564666748
injury O O 0.9999971389770508
remains O O 0.9999898672103882
to O O 0.9999945163726807
be O O 0.9999966621398926
proven O O 0.9999959468841553
, O O 0.9999587535858154
phytotherapy O B 0.9419495463371277
- O O 0.9993226528167725
associated O O 0.9998842477798462
interstitial O O 0.9961638450622559
nephropathy O O 0.999955415725708
should O O 0.9999637603759766
be O O 0.9999954700469971
considered O O 0.9999903440475464
in O O 0.9999822378158569
patients O O 0.9999959468841553
who O O 0.9999914169311523
present O O 0.9999971389770508
with O O 0.9999910593032837
unexplained O O 0.99996018409729
renal O O 0.9999873638153076
failure O O 0.9999967813491821
. O O 0.9999879598617554

Chloroacetaldehyde B B 0.9981864094734192
as O O 0.9991368651390076
a O O 0.9803637862205505
sulfhydryl B B 0.9862303137779236
reagent O O 0.6671432852745056
: O O 0.9996238946914673
the O O 0.9999384880065918
role O O 0.9999648332595825
of O O 0.9998979568481445
critical O O 0.9912236928939819
thiol B O 0.801261842250824
groups O O 0.8131237030029297
in O O 0.999496579170227
ifosfamide B B 0.9994509816169739
nephropathy O O 0.9989863038063049
. O O 0.9995872378349304

Chloroacetaldehyde B B 0.9977673292160034
( O O 0.9642874002456665
CAA B B 0.9995586276054382
) O O 0.9976972937583923
is O O 0.9999154806137085
a O O 0.9998369216918945
metabolite O O 0.9990485310554504
of O O 0.9967997074127197
the O O 0.9872612953186035
alkylating O O 0.48823097348213196
agent O O 0.7747870087623596
ifosfamide B B 0.997783362865448
( O O 0.9899717569351196
IFO B B 0.9908985495567322
) O O 0.9993546605110168
and O O 0.9999663829803467
putatively O O 0.9999740123748779
responsible O O 0.999913215637207
for O O 0.9999516010284424
renal O O 0.9999551773071289
damage O O 0.9999960660934448
following O O 0.9998341798782349
anti O O 0.9787478446960449
- O O 0.9996880292892456
tumor O O 0.9999887943267822
therapy O O 0.9999876022338867
with O O 0.9997876286506653
IFO B B 0.9969027638435364
. O O 0.9998594522476196

Depletion O O 0.9997321963310242
of O O 0.9982321858406067
sulfhydryl B B 0.9911485910415649
( O O 0.9818785786628723
SH B B 0.966701328754425
) O O 0.9535067081451416
groups O O 0.8806228637695312
has O O 0.9999767541885376
been O O 0.999980092048645
reported O O 0.9999874830245972
from O O 0.9999740123748779
cell O O 0.9999678134918213
culture O O 0.9999717473983765
, O O 0.9999485015869141
animal O O 0.9999896287918091
and O O 0.9999287128448486
clinical O O 0.9999727010726929
studies O O 0.9999923706054688
. O O 0.9999582767486572

In O O 0.9999692440032959
this O O 0.9999665021896362
work O O 0.999981164932251
the O O 0.9999831914901733
effect O O 0.9999037981033325
of O O 0.9995902180671692
CAA B B 0.9987032413482666
on O O 0.9988376498222351
human O O 0.9992522597312927
proximal O O 0.9992560744285583
tubule O O 0.9996875524520874
cells O O 0.999956488609314
in O O 0.9998633861541748
primary O O 0.9998451471328735
culture O O 0.9999840259552002
( O O 0.9998348951339722
hRPTEC O O 0.6410967707633972
) O O 0.9998711347579956
was O O 0.9999516010284424
investigated O O 0.9999281167984009
. O O 0.9999619722366333

Toxicity O O 0.9990443587303162
of O O 0.9993283748626709
CAA B B 0.9026001691818237
was O O 0.9999147653579712
determined O O 0.9999905824661255
by O O 0.9999797344207764
protein O O 0.9994739890098572
content O O 0.9999430179595947
, O O 0.9999790191650391
cell O O 0.9999825954437256
number O O 0.999996542930603
, O O 0.9999759197235107
LDH O O 0.573668360710144
release O O 0.9998557567596436
, O O 0.9999469518661499
trypan B B 0.988976001739502
blue I O 0.9033501744270325
exclusion O O 0.9960523843765259
assay O O 0.9999290704727173
and O O 0.9999452829360962
caspase O O 0.8863967657089233
- O O 0.9887950420379639
3 O O 0.9934815168380737
activity O O 0.9997804760932922
. O O 0.9999576807022095

Free O O 0.8965387344360352
thiols B O 0.6974396109580994
were O O 0.9998243451118469
measured O O 0.9998757839202881
by O O 0.9999822378158569
the O O 0.9999796152114868
method O O 0.999988317489624
of O O 0.99998939037323
Ellman O O 0.979631245136261
. O O 0.9999117851257324

CAA B B 0.9975371360778809
reduced O O 0.9997363686561584
hRPTEC O O 0.5712029933929443
cell O O 0.9997016787528992
number O O 0.9999384880065918
and O O 0.9999542236328125
protein O O 0.9981608986854553
, O O 0.9973280429840088
induced O O 0.9999251365661621
a O O 0.9999650716781616
loss O O 0.9999868869781494
in O O 0.9999401569366455
free O O 0.9916887879371643
intracellular O O 0.9980311989784241
thiols B O 0.8439375758171082
and O O 0.9998922348022461
an O O 0.9999656677246094
increase O O 0.9999067783355713
in O O 0.9998425245285034
necrosis O O 0.9991301894187927
markers O O 0.9999591112136841
. O O 0.9997087121009827

CAA B B 0.9968199729919434
but O O 0.9926766157150269
not O O 0.980735719203949
acrolein B B 0.9959320425987244
inhibited O O 0.9987636804580688
the O O 0.9998373985290527
cysteine B O 0.6499775648117065
proteases O O 0.9666884541511536
caspase O O 0.6424255967140198
- O O 0.9281739592552185
3 O O 0.9627959132194519
, O O 0.9981178045272827
caspase O O 0.5084677338600159
- O O 0.8738923668861389
8 O O 0.6411267518997192
and O O 0.9990875720977783
cathepsin O O 0.686098039150238
B O O 0.6509286761283875
. O O 0.9983939528465271

Caspase O O 0.6734721064567566
activation O O 0.9995840191841125
by O O 0.9998495578765869
cisplatin B B 0.9991427659988403
was O O 0.9999023675918579
inhibited O O 0.9923250675201416
by O O 0.9987885355949402
CAA B B 0.9990512728691101
. O O 0.9998382329940796

In O O 0.9998251795768738
cells O O 0.9999864101409912
stained O O 0.9999926090240479
with O O 0.9999270439147949
fluorescent O O 0.9998821020126343
dyes O O 0.999104917049408
targeting O O 0.9997109770774841
lysosomes O O 0.9889179468154907
, O O 0.9994248151779175
CAA B B 0.9992781281471252
induced O O 0.9998679161071777
an O O 0.9999895095825195
increase O O 0.9999929666519165
in O O 0.9999880790710449
lysosomal O O 0.9989707469940186
size O O 0.9999855756759644
and O O 0.9999836683273315
lysosomal O O 0.9992546439170837
leakage O O 0.999985933303833
. O O 0.9999775886535645

The O O 0.9999452829360962
effects O O 0.9999009370803833
of O O 0.9993040561676025
CAA B B 0.9995362758636475
on O O 0.9990555644035339
cysteine B O 0.6016117930412292
protease O O 0.8826163411140442
activities O O 0.9989867806434631
and O O 0.9997047781944275
thiols B O 0.7935952544212341
could O O 0.9997541308403015
be O O 0.9999719858169556
reproduced O O 0.9999691247940063
in O O 0.9999464750289917
cell O O 0.9998364448547363
lysate O O 0.9999247789382935
. O O 0.9999650716781616

Acidification O O 0.5695264339447021
, O O 0.9999351501464844
which O O 0.9996110796928406
slowed O O 0.9981495141983032
the O O 0.9998501539230347
reaction O O 0.9999157190322876
of O O 0.9996845722198486
CAA B B 0.9988943934440613
with O O 0.998584508895874
thiol B B 0.7249209880828857
donors O I 0.9774520397186279
, O O 0.9974740147590637
could O O 0.9997511506080627
also O O 0.9999121427536011
attenuate O O 0.9968953132629395
effects O O 0.999940037727356
of O O 0.9997871518135071
CAA B B 0.9994749426841736
on O O 0.9991870522499084
necrosis O O 0.9991635084152222
markers O O 0.9996705055236816
, O O 0.9997768998146057
thiol B B 0.9611192941665649
depletion O O 0.9984252452850342
and O O 0.9998449087142944
cysteine B O 0.6756005883216858
protease O O 0.81028151512146
inhibition O O 0.9998602867126465
in O O 0.999896764755249
living O O 0.9997311234474182
cells O O 0.9999908208847046
. O O 0.9999338388442993

Thus O O 0.999826967716217
, O O 0.9902848601341248
CAA B B 0.9991772770881653
directly O O 0.9996800422668457
reacts O O 0.9992407560348511
with O O 0.9996957778930664
cellular O O 0.9993894100189209
protein O O 0.6081676483154297
and O O 0.9990875720977783
non O O 0.8897377848625183
- O O 0.996982991695404
protein O O 0.9795882701873779
thiols B O 0.6890785694122314
, O O 0.9999512434005737
mediating O O 0.9998892545700073
its O O 0.998711347579956
toxicity O O 0.9998525381088257
on O O 0.9993095397949219
hRPTEC O O 0.7900957465171814
. O O 0.9998168349266052

This O O 0.999840259552002
effect O O 0.9998965263366699
can O O 0.9989122152328491
be O O 0.9998894929885864
reduced O O 0.9999731779098511
by O O 0.9998032450675964
acidification O O 0.6953988671302795
. O O 0.9998160004615784

Therefore O O 0.9999644756317139
, O O 0.9998514652252197
urinary O O 0.9970003962516785
acidification O O 0.8231981992721558
could O O 0.9996973276138306
be O O 0.9999779462814331
an O O 0.9999542236328125
option O O 0.9999462366104126
to O O 0.9999262094497681
prevent O O 0.9960505366325378
IFO B O 0.6924064755439758
nephropathy O O 0.9996688365936279
in O O 0.999919056892395
patients O O 0.9999762773513794
. O O 0.9999707937240601

Stereological O O 0.9991911053657532
methods O O 0.9999963045120239
reveal O O 0.9999645948410034
the O O 0.9999769926071167
robust O O 0.9998431205749512
size O O 0.9999890327453613
and O O 0.9999849796295166
stability O O 0.9999924898147583
of O O 0.9999516010284424
ectopic O O 0.999958872795105
hilar O O 0.9986385703086853
granule O O 0.998256266117096
cells O O 0.9999840259552002
after O O 0.9995449185371399
pilocarpine B B 0.9998502731323242
- O O 0.999733030796051
induced O O 0.9999583959579468
status O O 0.9999964237213135
epilepticus O O 0.9999537467956543
in O O 0.9999747276306152
the O O 0.9999909400939941
adult O O 0.9999943971633911
rat O O 0.9999954700469971
. O O 0.9999736547470093

Following O O 0.9995680451393127
status O O 0.9999834299087524
epilepticus O O 0.9999700784683228
in O O 0.9999716281890869
the O O 0.99996018409729
rat O O 0.9999737739562988
, O O 0.9999219179153442
dentate O O 0.9153436422348022
granule O O 0.972075343132019
cell O O 0.9987053871154785
neurogenesis O O 0.9995176792144775
increases O O 0.9998791217803955
greatly O O 0.9999895095825195
, O O 0.99994957447052
and O O 0.9999732971191406
many O O 0.999871015548706
of O O 0.9998618364334106
the O O 0.9999411106109619
new O O 0.9998569488525391
neurons O O 0.9999654293060303
appear O O 0.9999423027038574
to O O 0.9998530149459839
develop O O 0.9999803304672241
ectopically O O 0.9999681711196899
, O O 0.9999642372131348
in O O 0.9997732043266296
the O O 0.9999171495437622
hilar O O 0.9994144439697266
region O O 0.9999644756317139
of O O 0.9998466968536377
the O O 0.9999122619628906
hippocampal O O 0.99888676404953
formation O O 0.9999818801879883
. O O 0.999968409538269

It O O 0.9999794960021973
has O O 0.9999822378158569
been O O 0.9999858140945435
suggested O O 0.9999790191650391
that O O 0.9998216032981873
the O O 0.999866247177124
ectopic O O 0.9997913241386414
hilar O O 0.9971492886543274
granule O O 0.9811661839485168
cells O O 0.9993625283241272
could O O 0.9998053908348083
contribute O O 0.9999498128890991
to O O 0.9999362230300903
the O O 0.9999613761901855
spontaneous O O 0.9999525547027588
seizures O O 0.9999803304672241
that O O 0.9999849796295166
ultimately O O 0.9999855756759644
develop O O 0.9999940395355225
after O O 0.9999521970748901
status O O 0.9999898672103882
epilepticus O O 0.999981164932251
. O O 0.9999572038650513

However O O 0.9999383687973022
, O O 0.9999649524688721
the O O 0.9998182654380798
population O O 0.9998646974563599
has O O 0.9999909400939941
never O O 0.9999892711639404
been O O 0.9999912977218628
quantified O O 0.9999657869338989
, O O 0.9999347925186157
so O O 0.9999450445175171
it O O 0.9999891519546509
is O O 0.9999831914901733
unclear O O 0.9999855756759644
whether O O 0.999983549118042
it O O 0.9997439980506897
is O O 0.9999094009399414
substantial O O 0.9999511241912842
enough O O 0.9999698400497437
to O O 0.9999631643295288
have O O 0.999915361404419
a O O 0.9999586343765259
strong O O 0.9999206066131592
influence O O 0.9999730587005615
on O O 0.9999669790267944
epileptogenesis O O 0.9999285936355591
. O O 0.9999518394470215

To O O 0.9999428987503052
quantify O O 0.9999641180038452
this O O 0.9997060894966125
population O O 0.9999467134475708
, O O 0.999976396560669
the O O 0.9999865293502808
total O O 0.9999455213546753
number O O 0.9999841451644897
of O O 0.9999632835388184
ectopic O O 0.9999597072601318
hilar O O 0.9991840720176697
granule O O 0.9993005990982056
cells O O 0.9999901056289673
was O O 0.999976634979248
estimated O O 0.9999909400939941
using O O 0.9999576807022095
unbiased O O 0.9998892545700073
stereology O O 0.9997434020042419
at O O 0.9999736547470093
different O O 0.9999713897705078
times O O 0.9999877214431763
after O O 0.9999443292617798
pilocarpine B B 0.9998918771743774
- O O 0.9997972846031189
induced O O 0.9999555349349976
status O O 0.9999972581863403
epilepticus O O 0.999968409538269
. O O 0.9999802112579346

The O O 0.9999831914901733
number O O 0.9999704360961914
of O O 0.9999501705169678
hilar O O 0.9993743300437927
neurons O O 0.9999721050262451
immunoreactive O O 0.9999006986618042
for O O 0.9994823932647705
Prox O O 0.9874073266983032
- O O 0.9988425970077515
1 O O 0.9971401691436768
, O O 0.9999668598175049
a O O 0.999864935874939
granule O O 0.9890043139457703
- O O 0.999442994594574
cell O O 0.9971029162406921
- O O 0.9999127388000488
specific O O 0.9985103011131287
marker O O 0.9999536275863647
, O O 0.9999819993972778
was O O 0.9999841451644897
estimated O O 0.9999946355819702
using O O 0.9999877214431763
the O O 0.9999885559082031
optical O O 0.9998158812522888
fractionator O O 0.9999864101409912
method O O 0.9999904632568359
. O O 0.9999645948410034

The O O 0.9999815225601196
results O O 0.9999877214431763
indicate O O 0.9999557733535767
that O O 0.9999607801437378
the O O 0.9999854564666748
size O O 0.9999769926071167
of O O 0.9999454021453857
the O O 0.9999470710754395
hilar O O 0.9987346529960632
ectopic O O 0.9997523427009583
granule O O 0.9964236617088318
cell O O 0.9997863173484802
population O O 0.9999464750289917
after O O 0.99943608045578
status O O 0.9999675750732422
epilepticus O O 0.9997919201850891
is O O 0.9998792409896851
substantial O O 0.9999594688415527
, O O 0.9999575614929199
and O O 0.9999904632568359
stable O O 0.999994158744812
over O O 0.999995231628418
time O O 0.9999922513961792
. O O 0.9999793767929077

Interestingly O O 0.9999070167541504
, O O 0.9999804496765137
the O O 0.9999901056289673
size O O 0.9999921321868896
of O O 0.9999767541885376
the O O 0.9999172687530518
population O O 0.9999650716781616
appears O O 0.9999666213989258
to O O 0.9999203681945801
be O O 0.999974250793457
correlated O O 0.9999926090240479
with O O 0.999994158744812
the O O 0.9999953508377075
frequency O O 0.9999933242797852
of O O 0.9999841451644897
behavioral O O 0.9999279975891113
seizures O O 0.9999752044677734
, O O 0.9999734163284302
because O O 0.9999724626541138
animals O O 0.9999853372573853
with O O 0.9999644756317139
more O O 0.999813973903656
ectopic O O 0.9996687173843384
granule O O 0.9972798824310303
cells O O 0.9999637603759766
in O O 0.9998676776885986
the O O 0.9997963309288025
hilus O O 0.9988545179367065
have O O 0.9999597072601318
more O O 0.999963641166687
frequent O O 0.9999806880950928
behavioral O O 0.9999512434005737
seizures O O 0.9999799728393555
. O O 0.9999783039093018

The O O 0.9999549388885498
hilar O O 0.9998906850814819
ectopic O O 0.999823272228241
granule O O 0.9988133907318115
cell O O 0.9998307228088379
population O O 0.9999617338180542
does O O 0.9999758005142212
not O O 0.9999898672103882
appear O O 0.999984622001648
to O O 0.9999829530715942
vary O O 0.9999879598617554
systematically O O 0.9999854564666748
across O O 0.9999390840530396
the O O 0.9999688863754272
septotemporal O O 0.9999873638153076
axis O O 0.9999891519546509
, O O 0.9999768733978271
although O O 0.9999533891677856
it O O 0.9999749660491943
is O O 0.9999613761901855
associated O O 0.9999892711639404
with O O 0.9999864101409912
an O O 0.9999867677688599
increase O O 0.9999932050704956
in O O 0.9999849796295166
volume O O 0.9999796152114868
of O O 0.9999289512634277
the O O 0.9999654293060303
hilus O O 0.9998329877853394
. O O 0.9999459981918335

The O O 0.9999779462814331
results O O 0.9999867677688599
provide O O 0.999976634979248
new O O 0.9999845027923584
insight O O 0.9999942779541016
into O O 0.9999784231185913
the O O 0.9999772310256958
potential O O 0.9999759197235107
role O O 0.9999747276306152
of O O 0.9999148845672607
ectopic O O 0.999882698059082
hilar O O 0.9975893497467041
granule O O 0.9931883811950684
cells O O 0.9997014403343201
in O O 0.9998164772987366
the O O 0.9999148845672607
pilocarpine B B 0.9834120273590088
model O O 0.9997264742851257
of O O 0.9999052286148071
temporal O O 0.9993982315063477
lobe O O 0.999903678894043
epilepsy O O 0.9996203184127808
. O O 0.9999667406082153

A O O 0.999890923500061
prospective O O 0.9999685287475586
, O O 0.9999778270721436
open O O 0.9997838139533997
- O O 0.9999860525131226
label O O 0.9999790191650391
trial O O 0.9999284744262695
of O O 0.998274564743042
galantamine B B 0.9998074173927307
in O O 0.9997043013572693
autistic O O 0.9971417784690857
disorder O O 0.9999837875366211
. O O 0.9999641180038452

OBJECTIVE O O 0.9836926460266113
: O O 0.9999775886535645
Post O O 0.9999204874038696
- O O 0.9999274015426636
mortem O O 0.9999961853027344
studies O O 0.9999886751174927
have O O 0.9999799728393555
reported O O 0.9999752044677734
abnormalities O O 0.9999525547027588
of O O 0.9998701810836792
the O O 0.9998700618743896
cholinergic O O 0.7237116098403931
system O O 0.9993977546691895
in O O 0.9980575442314148
autism O O 0.6922009587287903
. O O 0.9997609257698059

The O O 0.9999887943267822
purpose O O 0.9999974966049194
of O O 0.9999958276748657
this O O 0.9999939203262329
study O O 0.9999849796295166
was O O 0.9999948740005493
to O O 0.9999948740005493
assess O O 0.9999808073043823
the O O 0.9999737739562988
use O O 0.9999188184738159
of O O 0.9981828331947327
galantamine B B 0.9998849630355835
, O O 0.9995384216308594
an O O 0.9839929938316345
acetylcholinesterase O B 0.8505937457084656
inhibitor O O 0.8071109652519226
and O O 0.967602550983429
nicotinic O B 0.8629493117332458
receptor O O 0.9703302383422852
modulator O O 0.9838430881500244
, O O 0.9999128580093384
in O O 0.9999575614929199
the O O 0.9999809265136719
treatment O O 0.9999278783798218
of O O 0.999947190284729
interfering O O 0.998383641242981
behaviors O O 0.999962329864502
in O O 0.999932050704956
children O O 0.9999958276748657
with O O 0.9999887943267822
autism O O 0.9998149275779724
. O O 0.9999698400497437

METHODS O O 0.9998570680618286
: O O 0.9999873638153076
Thirteen O O 0.9999018907546997
medication O O 0.9978825449943542
- O O 0.999946117401123
free O O 0.9996262788772583
children O O 0.9999898672103882
with O O 0.9999841451644897
autism O O 0.9996089339256287
( O O 0.9999792575836182
mean O O 0.9999966621398926
age O O 0.9999979734420776
, O O 0.9999929666519165
8 O O 0.9999812841415405
. O O 0.9999963045120239
8 O O 0.9999946355819702
+ O O 0.9999966621398926
/ O O 0.9999957084655762
- O O 0.9999841451644897
3 O O 0.9999946355819702
. O O 0.9999955892562866
5 O O 0.9999945163726807
years O O 0.9999958276748657
) O O 0.999982476234436
participated O O 0.9999887943267822
in O O 0.9999936819076538
a O O 0.9999910593032837
12 O O 0.9999920129776001
- O O 0.999984860420227
week O O 0.9999948740005493
, O O 0.9999887943267822
open O O 0.999871015548706
- O O 0.9999858140945435
label O O 0.9999938011169434
trial O O 0.9999721050262451
of O O 0.9989542961120605
galantamine B B 0.9998267292976379
. O O 0.9999086856842041

Patients O O 0.9998646974563599
were O O 0.9999890327453613
rated O O 0.9999837875366211
monthly O O 0.9999740123748779
by O O 0.9999816417694092
parents O O 0.999995231628418
on O O 0.9999426603317261
the O O 0.9999675750732422
Aberrant O O 0.9977920055389404
Behavior O O 0.9934117197990417
Checklist O O 0.9984815716743469
( O O 0.9997411370277405
ABC O O 0.4923315644264221
) O O 0.9998283386230469
and O O 0.9999648332595825
the O O 0.9999171495437622
Conners O O 0.9395768642425537
' O O 0.9999951124191284
Parent O O 0.9971024394035339
Rating O O 0.9997316002845764
Scale O O 0.9870440363883972
- O O 0.9985191226005554
Revised O O 0.9988059997558594
, O O 0.9999535083770752
and O O 0.9999527931213379
by O O 0.9999840259552002
a O O 0.9999746084213257
physician O O 0.9999951124191284
using O O 0.999972939491272
the O O 0.9999885559082031
Children O O 0.9999929666519165
' O O 0.9999940395355225
s O O 0.999991774559021
Psychiatric O O 0.9999047517776489
Rating O O 0.9999139308929443
Scale O O 0.9977092742919922
and O O 0.9999594688415527
the O O 0.9999853372573853
Clinical O O 0.9999887943267822
Global O O 0.9993870258331299
Impressions O O 0.9998161196708679
scale O O 0.9995569586753845
. O O 0.9999780654907227

RESULTS O O 0.9996052384376526
: O O 0.9998949766159058
Patients O O 0.9999793767929077
showed O O 0.9999516010284424
a O O 0.9999839067459106
significant O O 0.9999815225601196
reduction O O 0.9999915361404419
in O O 0.999954342842102
parent O O 0.7525379061698914
- O O 0.999545156955719
rated O O 0.9947752952575684
irritability O O 0.9999343156814575
and O O 0.9999313354492188
social O O 0.9884881377220154
withdrawal O O 0.9999743700027466
on O O 0.9997971653938293
the O O 0.9992235898971558
ABC O B 0.8830075860023499
as O O 0.9999176263809204
well O O 0.9999397993087769
as O O 0.999957799911499
significant O O 0.9999531507492065
improvements O O 0.9999898672103882
in O O 0.9999700784683228
emotional O O 0.9989834427833557
lability O O 0.9999761581420898
and O O 0.9999086856842041
inattention O O 0.9999313354492188
on O O 0.9999735355377197
the O O 0.9998579025268555
Conners O O 0.6357724070549011
' O O 0.9999805688858032
Parent O O 0.984367311000824
Rating O O 0.999897837638855
Scale O O 0.9992517828941345
- O O 0.992637038230896
- O O 0.9504585266113281
Revised O O 0.6814296841621399
. O O 0.9999464750289917

Similarly O O 0.9998432397842407
, O O 0.999931812286377
clinician O O 0.9999486207962036
ratings O O 0.9999891519546509
showed O O 0.9999706745147705
reductions O O 0.9999747276306152
in O O 0.9999539852142334
the O O 0.999925971031189
anger O O 0.5119431018829346
subscale O O 0.9970102310180664
of O O 0.9999219179153442
the O O 0.9999796152114868
Children O O 0.999974250793457
' O O 0.9999951124191284
s O O 0.9999943971633911
Psychiatric O O 0.9998125433921814
Rating O O 0.9999338388442993
Scale O O 0.9846330881118774
. O O 0.9999699592590332

Eight O O 0.9989294409751892
of O O 0.9999698400497437
13 O O 0.9999661445617676
participants O O 0.99998939037323
were O O 0.9999430179595947
rated O O 0.9999761581420898
as O O 0.9999110698699951
responders O O 0.999803364276886
on O O 0.9999969005584717
the O O 0.9999972581863403
basis O O 0.9999985694885254
of O O 0.9999943971633911
their O O 0.9999912977218628
improvement O O 0.9999916553497314
scores O O 0.9999972581863403
on O O 0.9999939203262329
the O O 0.9999921321868896
Clinical O O 0.9999904632568359
Global O O 0.9998389482498169
Impressions O O 0.9997230172157288
scale O O 0.999958872795105
. O O 0.9999738931655884

Overall O O 0.999945878982544
, O O 0.9996132254600525
galantamine B B 0.9998458623886108
was O O 0.9999171495437622
well O O 0.9999094009399414
- O O 0.9999755620956421
tolerated O O 0.9999641180038452
, O O 0.9999762773513794
with O O 0.9999840259552002
no O O 0.9999825954437256
significant O O 0.9999916553497314
adverse O O 0.999954342842102
effects O O 0.9999732971191406
apart O O 0.9999790191650391
from O O 0.9999862909317017
headaches O O 0.9999649524688721
in O O 0.9999443292617798
one O O 0.999985933303833
patient O O 0.999991774559021
. O O 0.9999693632125854

CONCLUSION O O 0.999800980091095
: O O 0.9999542236328125
In O O 0.9999935626983643
this O O 0.9999905824661255
open O O 0.9999740123748779
trial O O 0.9999881982803345
, O O 0.9992479681968689
galantamine B B 0.999873161315918
was O O 0.9999172687530518
well O O 0.9998248219490051
- O O 0.9999825954437256
tolerated O O 0.9999629259109497
and O O 0.9999613761901855
appeared O O 0.9999697208404541
to O O 0.9999619722366333
be O O 0.9999511241912842
beneficial O O 0.9999189376831055
for O O 0.9998761415481567
the O O 0.9999703168869019
treatment O O 0.9999213218688965
of O O 0.9999488592147827
interfering O O 0.9984412789344788
behaviors O O 0.9999619722366333
in O O 0.9999154806137085
children O O 0.999995231628418
with O O 0.9999877214431763
autism O O 0.999832034111023
, O O 0.9999821186065674
particularly O O 0.9995291233062744
aggression O O 0.9999415874481201
, O O 0.999942421913147
behavioral O O 0.9998960494995117
dyscontrol O O 0.9999946355819702
, O O 0.9997937083244324
and O O 0.9997550845146179
inattention O O 0.99982088804245
. O O 0.9999680519104004

Further O O 0.9998340606689453
controlled O O 0.9999687671661377
trials O O 0.999943733215332
are O O 0.9999665021896362
warranted O O 0.9999781847000122
. O O 0.999968409538269

Randomized O O 0.9999687671661377
comparison O O 0.9999041557312012
of O O 0.9983124732971191
olanzapine B B 0.9997888207435608
versus O O 0.9888864159584045
risperidone B B 0.9990610480308533
for O O 0.9998501539230347
the O O 0.9999854564666748
treatment O O 0.9999738931655884
of O O 0.9999796152114868
first O O 0.9999748468399048
- O O 0.9999252557754517
episode O O 0.9985920786857605
schizophrenia O O 0.9979944229125977
: O O 0.9999611377716064
4 O O 0.9998359680175781
- O O 0.9999756813049316
month O O 0.9999918937683105
outcomes O O 0.999994158744812
. O O 0.999987006187439

OBJECTIVE O O 0.9999182224273682
: O O 0.999995231628418
The O O 0.9999951124191284
authors O O 0.9999966621398926
compared O O 0.9999552965164185
4 O O 0.9996961355209351
- O O 0.9999878406524658
month O O 0.9999955892562866
treatment O O 0.9999783039093018
outcomes O O 0.9999980926513672
for O O 0.9975848197937012
olanzapine B B 0.9997898936271667
versus O O 0.9592899680137634
risperidone B B 0.996485710144043
in O O 0.999875545501709
patients O O 0.999995231628418
with O O 0.9999903440475464
first O O 0.9999523162841797
- O O 0.9999593496322632
episode O O 0.9990471005439758
schizophrenia O O 0.9614301919937134
spectrum O O 0.9995242357254028
disorders O O 0.9999939203262329
. O O 0.9999768733978271

METHOD O O 0.9999444484710693
: O O 0.9999958276748657
One O O 0.9999991655349731
hundred O O 0.9999946355819702
twelve O O 0.9999980926513672
subjects O O 0.999996542930603
( O O 0.9999392032623291
70 O O 0.999996542930603
% O O 0.9999890327453613
male O O 0.999983549118042
; O O 0.9999912977218628
mean O O 0.999997615814209
age O O 0.999995231628418
= O O 0.999990701675415
23 O O 0.9999988079071045
. O O 0.999998927116394
3 O O 0.9999973773956299
years O O 0.9999978542327881
[ O O 0.9999387264251709
SD O O 0.9998503923416138
= O O 0.9999903440475464
5 O O 0.9999966621398926
. O O 0.999996542930603
1 O O 0.9999969005584717
] O O 0.999993085861206
) O O 0.9999788999557495
with O O 0.999961256980896
first O O 0.9998369216918945
- O O 0.9999489784240723
episode O O 0.9995948672294617
schizophrenia O O 0.9947699904441833
( O O 0.999923825263977
75 O O 0.9999899864196777
% O O 0.9999905824661255
) O O 0.999954104423523
, O O 0.9999361038208008
schizophreniform O O 0.9862209558486938
disorder O O 0.9999823570251465
( O O 0.9999421834945679
17 O O 0.9999903440475464
% O O 0.9999804496765137
) O O 0.9999516010284424
, O O 0.9998729228973389
or O O 0.9998542070388794
schizoaffective O O 0.977200448513031
disorder O O 0.9999771118164062
( O O 0.9999480247497559
8 O O 0.9999620914459229
% O O 0.9999825954437256
) O O 0.9999701976776123
were O O 0.9999784231185913
randomly O O 0.9999973773956299
assigned O O 0.9999974966049194
to O O 0.9999096393585205
treatment O O 0.9999790191650391
with O O 0.9997852444648743
olanzapine B B 0.99982088804245
( O O 0.998798131942749
2 O O 0.9970691800117493
. O O 0.9999767541885376
5 O O 0.9999598264694214
- O O 0.9944307208061218
20 O O 0.9981483221054077
mg O O 0.9998623132705688
/ O O 0.999866247177124
day O O 0.9998607635498047
) O O 0.9997629523277283
or O O 0.9959553480148315
risperidone B B 0.9977235198020935
( O O 0.9995262622833252
1 O O 0.9996240139007568
- O O 0.9969884753227234
6 O O 0.999985933303833
mg O O 0.9998441934585571
/ O O 0.9998989105224609
day O O 0.9999533891677856
) O O 0.9999469518661499
. O O 0.9999741315841675

RESULTS O O 0.999649167060852
: O O 0.9998050332069397
Response O O 0.9998834133148193
rates O O 0.9999446868896484
did O O 0.9999690055847168
not O O 0.999990701675415
significantly O O 0.9999918937683105
differ O O 0.9999785423278809
between O O 0.9972604513168335
olanzapine B B 0.9998891353607178
( O O 0.9997827410697937
43 O O 0.9999936819076538
. O O 0.9999849796295166
7 O O 0.999992847442627
% O O 0.9999724626541138
, O O 0.9999284744262695
95 O O 0.999945878982544
% O O 0.9998830556869507
CI O O 0.9929593801498413
= O O 0.9994006156921387
28 O O 0.9999943971633911
. O O 0.9999923706054688
8 O O 0.99998939037323
% O O 0.9999222755432129
- O O 0.9958593249320984
58 O O 0.9999973773956299
. O O 0.9999927282333374
6 O O 0.9999959468841553
% O O 0.9999715089797974
) O O 0.9997981190681458
and O O 0.9955039620399475
risperidone B B 0.9989317059516907
( O O 0.9997938275337219
54 O O 0.9999738931655884
. O O 0.9999878406524658
3 O O 0.9999908208847046
% O O 0.9999454021453857
, O O 0.9999127388000488
95 O O 0.9993687272071838
% O O 0.9996682405471802
CI O O 0.9922621250152588
= O O 0.999808132648468
39 O O 0.9999921321868896
. O O 0.9999911785125732
9 O O 0.9999901056289673
% O O 0.999954104423523
- O O 0.9974330067634583
68 O O 0.9999951124191284
. O O 0.9999909400939941
7 O O 0.999996542930603
% O O 0.999977707862854
) O O 0.9999485015869141
. O O 0.9999599456787109

Among O O 0.9993042945861816
those O O 0.9999648332595825
responding O O 0.9999834299087524
to O O 0.9999294281005859
treatment O O 0.9999490976333618
, O O 0.9999276399612427
more O O 0.9998049139976501
subjects O O 0.9989210367202759
in O O 0.9998341798782349
the O O 0.9996351003646851
olanzapine B B 0.9997779726982117
group O O 0.9996875524520874
( O O 0.9999465942382812
40 O O 0.9999865293502808
. O O 0.9999914169311523
9 O O 0.9999909400939941
% O O 0.9999836683273315
, O O 0.9999254941940308
95 O O 0.9997102618217468
% O O 0.9996546506881714
CI O O 0.9939684867858887
= O O 0.9995458722114563
16 O O 0.999992847442627
. O O 0.9999945163726807
8 O O 0.9999549388885498
% O O 0.9999338388442993
- O O 0.9968919157981873
65 O O 0.9999840259552002
. O O 0.9999958276748657
0 O O 0.999993085861206
% O O 0.9999735355377197
) O O 0.9999403953552246
than O O 0.999945878982544
in O O 0.9999154806137085
the O O 0.9997115731239319
risperidone B B 0.9988858103752136
group O O 0.9998306035995483
( O O 0.9999473094940186
18 O O 0.9999969005584717
. O O 0.9999924898147583
9 O O 0.9999934434890747
% O O 0.9999722242355347
, O O 0.9999392032623291
95 O O 0.9990870952606201
% O O 0.9993865489959717
CI O O 0.9941536784172058
= O O 0.9997723698616028
0 O O 0.9999850988388062
% O O 0.9997957348823547
- O O 0.9980970025062561
39 O O 0.9999963045120239
. O O 0.9999964237213135
2 O O 0.9999914169311523
% O O 0.9999227523803711
) O O 0.9999673366546631
had O O 0.9999649524688721
subsequent O O 0.9999649524688721
ratings O O 0.9999932050704956
not O O 0.9999983310699463
meeting O O 0.9999823570251465
response O O 0.9999749660491943
criteria O O 0.9999953508377075
. O O 0.9999790191650391

Negative O O 0.9992406368255615
symptom O O 0.999930739402771
outcomes O O 0.9962531328201294
and O O 0.9999626874923706
measures O O 0.9999666213989258
of O O 0.9999538660049438
parkinsonism O O 0.9985207915306091
and O O 0.9998693466186523
akathisia O O 0.999291181564331
did O O 0.9999672174453735
not O O 0.9999825954437256
differ O O 0.9999818801879883
between O O 0.9982169270515442
medications O O 0.9997840523719788
. O O 0.999957799911499

Extrapyramidal O O 0.8142938017845154
symptom O O 0.9823121428489685
severity O O 0.9982981085777283
scores O O 0.999951958656311
were O O 0.999940037727356
1 O O 0.999931812286377
. O O 0.9999872446060181
4 O O 0.9999842643737793
( O O 0.9999064207077026
95 O O 0.9999654293060303
% O O 0.9998719692230225
CI O O 0.9957926273345947
= O O 0.9992567896842957
1 O O 0.9999796152114868
. O O 0.9999872446060181
2 O O 0.9999887943267822
- O O 0.9953163862228394
1 O O 0.99998939037323
. O O 0.9999909400939941
6 O O 0.9999946355819702
) O O 0.9999696016311646
with O O 0.9995847344398499
risperidone B B 0.9990782737731934
and O O 0.9996640682220459
1 O O 0.9997630715370178
. O O 0.9999749660491943
2 O O 0.9999874830245972
( O O 0.9999105930328369
95 O O 0.9999399185180664
% O O 0.9998437166213989
CI O O 0.992925763130188
= O O 0.9992290735244751
1 O O 0.9999847412109375
. O O 0.9999915361404419
0 O O 0.9999909400939941
- O O 0.9968693852424622
1 O O 0.9999918937683105
. O O 0.9999924898147583
4 O O 0.9999914169311523
) O O 0.999969482421875
with O O 0.9996577501296997
olanzapine B B 0.9997712969779968
. O O 0.9999337196350098

Significantly O O 0.9999920129776001
more O O 0.9999867677688599
weight O O 0.999969482421875
gain O O 0.9999978542327881
occurred O O 0.9999942779541016
with O O 0.9997273087501526
olanzapine B B 0.9995419979095459
than O O 0.999680757522583
with O O 0.9997950196266174
risperidone B B 0.9942411184310913
: O O 0.9998863935470581
the O O 0.9999969005584717
increase O O 0.9999992847442627
in O O 0.9999966621398926
weight O O 0.9999890327453613
at O O 0.9999881982803345
4 O O 0.9999632835388184
months O O 0.9999979734420776
relative O O 0.999995231628418
to O O 0.999996542930603
baseline O O 0.99998939037323
weight O O 0.9999942779541016
was O O 0.9999853372573853
17 O O 0.9999986886978149
. O O 0.9999960660934448
3 O O 0.9999936819076538
% O O 0.9999983310699463
( O O 0.9999701976776123
95 O O 0.9999362230300903
% O O 0.9997691512107849
CI O O 0.9975796341896057
= O O 0.9998248219490051
14 O O 0.9999955892562866
. O O 0.9999940395355225
2 O O 0.9999915361404419
% O O 0.9999356269836426
- O O 0.998322069644928
20 O O 0.9999961853027344
. O O 0.9999961853027344
5 O O 0.999996542930603
% O O 0.9999954700469971
) O O 0.9999861717224121
with O O 0.9997726082801819
olanzapine B B 0.9997784495353699
and O O 0.9997830986976624
11 O O 0.9999873638153076
. O O 0.999995231628418
3 O O 0.9999938011169434
% O O 0.999997615814209
( O O 0.9999488592147827
95 O O 0.999948263168335
% O O 0.9999525547027588
CI O O 0.998201847076416
= O O 0.9999209642410278
8 O O 0.9999911785125732
. O O 0.9999951124191284
4 O O 0.9999911785125732
% O O 0.9999691247940063
- O O 0.999037504196167
14 O O 0.9999985694885254
. O O 0.9999948740005493
3 O O 0.999992847442627
% O O 0.9999922513961792
) O O 0.9999852180480957
with O O 0.9997318387031555
risperidone B B 0.9973078966140747
. O O 0.9999521970748901

Body O O 0.9916483163833618
mass O O 0.991168737411499
index O O 0.9999256134033203
at O O 0.9999690055847168
baseline O O 0.9999830722808838
and O O 0.9999918937683105
at O O 0.9999666213989258
4 O O 0.9997499585151672
months O O 0.999994158744812
was O O 0.9999762773513794
24 O O 0.9999957084655762
. O O 0.999992847442627
3 O O 0.9999902248382568
( O O 0.999933123588562
95 O O 0.9995757937431335
% O O 0.9996399879455566
CI O O 0.9967592358589172
= O O 0.9996994733810425
22 O O 0.9999918937683105
. O O 0.9999886751174927
8 O O 0.999982476234436
- O O 0.9975207448005676
25 O O 0.9999860525131226
. O O 0.9999912977218628
7 O O 0.9999828338623047
) O O 0.9999575614929199
versus O O 0.9999407529830933
28 O O 0.9999932050704956
. O O 0.9999905824661255
2 O O 0.9999924898147583
( O O 0.9999175071716309
95 O O 0.9997299313545227
% O O 0.9997231364250183
CI O O 0.9969767332077026
= O O 0.9998513460159302
26 O O 0.9999865293502808
. O O 0.9999918937683105
7 O O 0.9999922513961792
- O O 0.9979299306869507
29 O O 0.9999946355819702
. O O 0.9999936819076538
7 O O 0.9999946355819702
) O O 0.9999843835830688
with O O 0.9998112320899963
olanzapine B B 0.9998797178268433
and O O 0.999733030796051
23 O O 0.9999192953109741
. O O 0.9999876022338867
9 O O 0.9999924898147583
( O O 0.999937891960144
95 O O 0.9994970560073853
% O O 0.9994022846221924
CI O O 0.9958123564720154
= O O 0.9995747208595276
22 O O 0.9999872446060181
. O O 0.9999850988388062
5 O O 0.9999841451644897
- O O 0.9974368810653687
25 O O 0.9999916553497314
. O O 0.9999916553497314
3 O O 0.9999668598175049
) O O 0.9999600648880005
versus O O 0.9999208450317383
26 O O 0.999961256980896
. O O 0.9999926090240479
7 O O 0.999995231628418
( O O 0.9999427795410156
95 O O 0.9997029900550842
% O O 0.9997103810310364
CI O O 0.9965469241142273
= O O 0.9998047947883606
25 O O 0.9999877214431763
. O O 0.9999914169311523
2 O O 0.9999850988388062
- O O 0.9974461793899536
28 O O 0.9999973773956299
. O O 0.9999934434890747
2 O O 0.9999949932098389
) O O 0.9999839067459106
with O O 0.9995741248130798
risperidone B B 0.9991996884346008
. O O 0.9999430179595947

CONCLUSIONS O O 0.9986386895179749
: O O 0.9999818801879883
Clinical O O 0.9999911785125732
outcomes O O 0.9999985694885254
with O O 0.999808132648468
risperidone B B 0.9990286827087402
were O O 0.9997578263282776
equal O O 0.9999754428863525
to O O 0.9999821186065674
those O O 0.999995231628418
with O O 0.9998722076416016
olanzapine B B 0.9996302127838135
, O O 0.9994959831237793
and O O 0.9999533891677856
response O O 0.999990701675415
may O O 0.9999843835830688
be O O 0.9999955892562866
more O O 0.9999926090240479
stable O O 0.999991774559021
. O O 0.9999829530715942

Olanzapine B B 0.9994671940803528
may O O 0.999846339225769
have O O 0.9999219179153442
an O O 0.9999260902404785
advantage O O 0.9976803064346313
for O O 0.9994895458221436
motor O O 0.994326651096344
side O O 0.999881386756897
effects O O 0.9999731779098511
. O O 0.9998300075531006

Both O O 0.9996887445449829
medications O O 0.9988594055175781
caused O O 0.9999152421951294
substantial O O 0.9999945163726807
rapid O O 0.9999980926513672
weight O O 0.9999574422836304
gain O O 0.9999959468841553
, O O 0.9999502897262573
but O O 0.9999440908432007
weight O O 0.9999690055847168
gain O O 0.9999940395355225
was O O 0.999967098236084
greater O O 0.9999794960021973
with O O 0.9991044402122498
olanzapine B B 0.999805748462677
. O O 0.9999241828918457

Early O O 0.9999376535415649
paracentral O O 0.9989377856254578
visual O O 0.9999654293060303
field O O 0.9999910593032837
loss O O 0.9999936819076538
in O O 0.9999595880508423
patients O O 0.999971866607666
taking O O 0.998722493648529
hydroxychloroquine B B 0.9966890215873718
. O O 0.9999048709869385

OBJECTIVE O O 0.9998862743377686
: O O 0.9999957084655762
To O O 0.9999955892562866
review O O 0.9999945163726807
the O O 0.9999877214431763
natural O O 0.999993085861206
history O O 0.9999969005584717
and O O 0.9999847412109375
ocular O O 0.9998331069946289
and O O 0.9999531507492065
systemic O O 0.9999266862869263
adverse O O 0.9999604225158691
effects O O 0.9999902248382568
of O O 0.9999709129333496
patients O O 0.9999885559082031
taking O O 0.9988804459571838
hydroxychloroquine B B 0.996657133102417
sulfate I I 0.9974572062492371
who O O 0.9998158812522888
attended O O 0.9999804496765137
an O O 0.999985933303833
ophthalmic O O 0.9999643564224243
screening O O 0.9999926090240479
program O O 0.9999887943267822
. O O 0.9999793767929077

DESIGN O O 0.9999905824661255
: O O 0.999996542930603
Retrospective O O 0.9999717473983765
study O O 0.9999935626983643
. O O 0.9999904632568359

RESULTS O O 0.9996076226234436
: O O 0.9999234676361084
Records O O 0.9999932050704956
of O O 0.9999798536300659
262 O O 0.9991187453269958
patients O O 0.999990701675415
who O O 0.9999412298202515
were O O 0.9999661445617676
taking O O 0.9972720742225647
hydroxychloroquine B B 0.9973472356796265
and O O 0.9988497495651245
screened O O 0.999901533126831
in O O 0.999977707862854
the O O 0.9999933242797852
Department O O 0.9999945163726807
of O O 0.9999828338623047
Ophthalmology O O 0.9999417066574097
were O O 0.9999673366546631
reviewed O O 0.9999946355819702
. O O 0.9999740123748779

Of O O 0.9999008178710938
the O O 0.9999922513961792
262 O O 0.9999772310256958
patients O O 0.9999958276748657
, O O 0.9999326467514038
14 O O 0.9999823570251465
( O O 0.9999411106109619
18 O O 0.999994158744812
% O O 0.9999951124191284
) O O 0.9999818801879883
of O O 0.9999483823776245
76 O O 0.9993991851806641
who O O 0.9999526739120483
had O O 0.9999912977218628
stopped O O 0.9999592304229736
treatment O O 0.9998528957366943
at O O 0.9999918937683105
the O O 0.9999984502792358
time O O 0.999998927116394
of O O 0.9999970197677612
the O O 0.9999980926513672
study O O 0.9999936819076538
experienced O O 0.9999436140060425
documented O O 0.9999589920043945
adverse O O 0.9999351501464844
effects O O 0.999988317489624
. O O 0.9999687671661377

Systemic O O 0.9982603192329407
adverse O O 0.9990932941436768
effects O O 0.999962329864502
occurred O O 0.9999734163284302
in O O 0.999921441078186
8 O O 0.9999145269393921
patients O O 0.9999898672103882
( O O 0.9999412298202515
10 O O 0.9999922513961792
. O O 0.9999860525131226
5 O O 0.9999858140945435
% O O 0.9999650716781616
) O O 0.9997918009757996
and O O 0.9998242259025574
ocular O O 0.9992372989654541
adverse O O 0.9987059831619263
effects O O 0.9999768733978271
, O O 0.9999455213546753
in O O 0.9999648332595825
5 O O 0.9998757839202881
( O O 0.9998712539672852
6 O O 0.9999808073043823
. O O 0.9999854564666748
5 O O 0.9999914169311523
% O O 0.9999892711639404
) O O 0.9999219179153442
. O O 0.9999700784683228

Thirty O O 0.9855465888977051
- O O 0.9999485015869141
five O O 0.9999935626983643
patients O O 0.9999951124191284
( O O 0.99997878074646
13 O O 0.999996542930603
. O O 0.999993085861206
4 O O 0.9999920129776001
% O O 0.9999940395355225
) O O 0.9999673366546631
had O O 0.9999786615371704
visual O O 0.9999852180480957
field O O 0.9999970197677612
abnormalities O O 0.9999984502792358
, O O 0.9999845027923584
which O O 0.999975323677063
were O O 0.999985933303833
attributed O O 0.999995231628418
to O O 0.9996676445007324
hydroxychloroquine B B 0.9988467693328857
treatment O O 0.9995822310447693
in O O 0.9999645948410034
4 O O 0.9994316697120667
patients O O 0.9999948740005493
( O O 0.9999547004699707
1 O O 0.9999760389328003
. O O 0.9999754428863525
5 O O 0.999987006187439
% O O 0.9999935626983643
) O O 0.999951958656311
. O O 0.9999792575836182

Three O O 0.9997764229774475
of O O 0.9999798536300659
the O O 0.9999921321868896
4 O O 0.9997445940971375
patients O O 0.9999885559082031
were O O 0.9999723434448242
taking O O 0.9997921586036682
less O O 0.9999899864196777
than O O 0.9999929666519165
6 O O 0.9998952150344849
. O O 0.9999980926513672
5 O O 0.9999892711639404
mg O O 0.9999798536300659
/ O O 0.999921441078186
kg O O 0.9999982118606567
per O O 0.9999487400054932
day O O 0.9999964237213135
and O O 0.9999611377716064
all O O 0.9998875856399536
patients O O 0.9999920129776001
had O O 0.9999853372573853
normal O O 0.9999891519546509
renal O O 0.9999531507492065
and O O 0.9999568462371826
liver O O 0.9991353154182434
function O O 0.9999402761459351
test O O 0.9999881982803345
results O O 0.99998939037323
. O O 0.9999775886535645

CONCLUSIONS O O 0.9998749494552612
: O O 0.9999926090240479
The O O 0.9999986886978149
current O O 0.9999935626983643
study O O 0.9999943971633911
used O O 0.9999650716781616
a O O 0.9999852180480957
protocol O O 0.9999923706054688
of O O 0.999964714050293
visual O O 0.9999499320983887
acuity O O 0.9999653100967407
and O O 0.9999643564224243
color O O 0.9998626708984375
vision O O 0.9999843835830688
assessment O O 0.9999819993972778
, O O 0.9999808073043823
funduscopy O O 0.9999638795852661
, O O 0.9999299049377441
and O O 0.9999587535858154
Humphrey O O 0.8877561688423157
10 O O 0.9707183241844177
- O O 0.996145486831665
2 O O 0.9634865522384644
visual O O 0.9997954964637756
field O O 0.9999890327453613
testing O O 0.9999785423278809
and O O 0.9999717473983765
shows O O 0.9999438524246216
that O O 0.9998801946640015
visual O O 0.999885082244873
field O O 0.9999703168869019
defects O O 0.9999922513961792
appeared O O 0.9999730587005615
before O O 0.9998342990875244
any O O 0.9999688863754272
corresponding O O 0.9999866485595703
changes O O 0.999996542930603
in O O 0.9999881982803345
any O O 0.9999631643295288
other O O 0.9999651908874512
tested O O 0.999984860420227
clinical O O 0.9999873638153076
parameters O O 0.9999966621398926
; O O 0.9999856948852539
the O O 0.9999934434890747
defects O O 0.9999970197677612
were O O 0.9999727010726929
reproducible O O 0.9999979734420776
and O O 0.9999837875366211
the O O 0.9999912977218628
test O O 0.9999833106994629
parameters O O 0.9999940395355225
were O O 0.9999794960021973
reliable O O 0.9999964237213135
. O O 0.9999903440475464

Patients O O 0.999915361404419
taking O O 0.9993044137954712
hydroxychloroquine B B 0.9983684420585632
can O O 0.9998600482940674
demonstrate O O 0.9999518394470215
a O O 0.9999613761901855
toxic O O 0.9995217323303223
reaction O O 0.9999853372573853
in O O 0.9998527765274048
the O O 0.9999635219573975
retina O O 0.9998633861541748
despite O O 0.9999333620071411
the O O 0.9999945163726807
absence O O 0.9999854564666748
of O O 0.9999752044677734
known O O 0.9999463558197021
risk O O 0.9999169111251831
factors O O 0.9999947547912598
. O O 0.9999749660491943

Screening O O 0.9999648332595825
, O O 0.9999915361404419
including O O 0.9999669790267944
Humphrey O O 0.8616925477981567
10 O O 0.9611167907714844
- O O 0.9933319687843323
2 O O 0.9738644957542419
visual O O 0.9999102354049683
field O O 0.9999839067459106
assessment O O 0.9999748468399048
, O O 0.9999849796295166
is O O 0.9999923706054688
recommended O O 0.9999878406524658
2 O O 0.9999781847000122
years O O 0.9999961853027344
after O O 0.9999926090240479
the O O 0.9999957084655762
initial O O 0.9999939203262329
baseline O O 0.9999693632125854
and O O 0.9999537467956543
yearly O O 0.9999619722366333
thereafter O O 0.9999874830245972
. O O 0.9999812841415405

Peri O O 0.9999678134918213
- O O 0.9999480247497559
operative O O 0.999991774559021
atrioventricular O O 0.9999703168869019
block O O 0.9999932050704956
as O O 0.9999881982803345
a O O 0.9999914169311523
result O O 0.9999852180480957
of O O 0.9998487234115601
chemotherapy O O 0.999850869178772
with O O 0.9995618462562561
epirubicin B B 0.9746009707450867
and O O 0.7488300204277039
paclitaxel B B 0.9981833100318909
. O O 0.9998631477355957

A O O 0.9999822378158569
47 O O 0.9999974966049194
- O O 0.9999916553497314
year O O 0.9999979734420776
- O O 0.9999953508377075
old O O 0.9999938011169434
woman O O 0.9999969005584717
presented O O 0.9999803304672241
for O O 0.9999438524246216
mastectomy O O 0.9999717473983765
and O O 0.9999681711196899
immediate O O 0.9995948672294617
latissimus O O 0.9863328337669373
dorsi O O 0.9981842637062073
flap O O 0.9991670846939087
reconstruction O O 0.9999874830245972
having O O 0.9999886751174927
been O O 0.9999964237213135
diagnosed O O 0.9999983310699463
with O O 0.9999864101409912
carcinoma O O 0.9999574422836304
of O O 0.9999864101409912
the O O 0.9999924898147583
breast O O 0.9999898672103882
6 O O 0.9998829364776611
months O O 0.9999971389770508
previously O O 0.9999967813491821
. O O 0.9999732971191406

In O O 0.9999581575393677
the O O 0.999993085861206
preceding O O 0.999995231628418
months O O 0.9999933242797852
she O O 0.9999688863754272
had O O 0.9999743700027466
received O O 0.9999288320541382
neo O O 0.9831725358963013
- O O 0.9996551275253296
adjuvant O O 0.9998400211334229
chemotherapy O O 0.9999370574951172
with O O 0.9998400211334229
epirubicin B B 0.9781347513198853
, O O 0.6256843209266663
paclitaxel B B 0.9953219294548035
( O O 0.9274311065673828
Taxol B B 0.9971078038215637
) O O 0.9880192875862122
and O O 0.9943917393684387
cyclophosphamide B B 0.9984627962112427
. O O 0.9999048709869385

This O O 0.9999827146530151
had O O 0.9999933242797852
been O O 0.9999958276748657
apparently O O 0.9999898672103882
uncomplicated O O 0.9999717473983765
and O O 0.9999599456787109
she O O 0.9999898672103882
had O O 0.9999892711639404
maintained O O 0.9999922513961792
a O O 0.9999909400939941
remarkably O O 0.9999926090240479
high O O 0.9999867677688599
level O O 0.9999943971633911
of O O 0.9999676942825317
physical O O 0.999099850654602
activity O O 0.9993569254875183
. O O 0.9999635219573975

She O O 0.9999674558639526
was O O 0.999962329864502
found O O 0.9999934434890747
to O O 0.9999617338180542
be O O 0.9999656677246094
bradycardic O O 0.9998984336853027
at O O 0.9999783039093018
pre O O 0.9999511241912842
- O O 0.9999587535858154
operative O O 0.9999904632568359
assessment O O 0.9999947547912598
but O O 0.999936580657959
had O O 0.9999876022338867
no O O 0.9999902248382568
cardiac O O 0.9999809265136719
symptoms O O 0.9999954700469971
. O O 0.9999784231185913

Second O O 0.9999310970306396
degree O O 0.99857497215271
Mobitz O O 0.9996709823608398
type O O 0.9998267292976379
II O O 0.98946613073349
atrioventricular O O 0.9998655319213867
block O O 0.9999661445617676
was O O 0.9999722242355347
diagnosed O O 0.9999955892562866
on O O 0.9999922513961792
electrocardiogram O O 0.9999850988388062
, O O 0.9999401569366455
and O O 0.9999555349349976
temporary O O 0.9999362230300903
transvenous O O 0.9985074400901794
ventricular O O 0.994367778301239
pacing O O 0.9995934367179871
instituted O O 0.9999300241470337
in O O 0.9999727010726929
the O O 0.9999922513961792
peri O O 0.9999916553497314
- O O 0.9999574422836304
operative O O 0.9999909400939941
period O O 0.999995231628418
. O O 0.9999740123748779

We O O 0.9999680519104004
discuss O O 0.9999899864196777
how O O 0.999988317489624
evidence O O 0.9983624815940857
- O O 0.9999747276306152
based O O 0.999552309513092
guidelines O O 0.9999246597290039
would O O 0.9999783039093018
not O O 0.9999932050704956
have O O 0.9999961853027344
been O O 0.9999963045120239
helpful O O 0.9999920129776001
in O O 0.9999901056289673
this O O 0.9999884366989136
case O O 0.9999716281890869
, O O 0.9999691247940063
and O O 0.999992847442627
how O O 0.9999594688415527
chemotherapy O O 0.9976019263267517
can O O 0.9999287128448486
exhibit O O 0.9999626874923706
substantial O O 0.999962329864502
cardiotoxicity O O 0.9999901056289673
that O O 0.9999723434448242
may O O 0.9999819993972778
develop O O 0.9999973773956299
over O O 0.9999945163726807
many O O 0.9999903440475464
years O O 0.9999921321868896
. O O 0.9999771118164062

We O O 0.9999594688415527
suggest O O 0.9999755620956421
that O O 0.9999738931655884
patients O O 0.9999923706054688
who O O 0.9999871253967285
have O O 0.9999973773956299
received O O 0.9999643564224243
chemotherapy O O 0.998087465763092
at O O 0.9999419450759888
any O O 0.999961256980896
time O O 0.9999948740005493
should O O 0.9999864101409912
have O O 0.9999957084655762
a O O 0.9999938011169434
pre O O 0.9999220371246338
- O O 0.9999606609344482
operative O O 0.9999926090240479
electrocardiogram O O 0.9999226331710815
even O O 0.9999243021011353
if O O 0.9999866485595703
they O O 0.9999922513961792
are O O 0.9999911785125732
asymptomatic O O 0.9999929666519165
. O O 0.9999819993972778

Risks O O 0.9999822378158569
and O O 0.9999582767486572
benefits O O 0.9999924898147583
of O O 0.9998869895935059
COX B O 0.7177190780639648
- I O 0.9496604204177856
2 I O 0.930379331111908
inhibitors I O 0.8564742803573608
vs O O 0.9983031749725342
non O O 0.9737710356712341
- O O 0.9996844530105591
selective O O 0.8940287232398987
NSAIDs O O 0.5678617358207703
: O O 0.9999804496765137
does O O 0.9999932050704956
their O O 0.9999861717224121
cardiovascular O O 0.999976634979248
risk O O 0.9999847412109375
exceed O O 0.9999234676361084
their O O 0.9997984766960144
gastrointestinal O O 0.9991945624351501
benefit O O 0.9999774694442749
? O O 0.9999734163284302

A O O 0.999972939491272
retrospective O O 0.9999704360961914
cohort O O 0.9999315738677979
study O O 0.9999892711639404
. O O 0.9999799728393555

OBJECTIVES O O 0.9964377880096436
: O O 0.9999659061431885
The O O 0.9999812841415405
risk O O 0.9999884366989136
of O O 0.9999687671661377
acute O O 0.9999339580535889
myocardial O O 0.9999970197677612
infarction O O 0.9999738931655884
( O O 0.9996784925460815
AMI O O 0.9835878610610962
) O O 0.9999674558639526
with O O 0.9997280240058899
COX B O 0.8600392937660217
- I O 0.9904630780220032
2 I O 0.9846932888031006
inhibitors I O 0.9611523747444153
may O O 0.999916672706604
offset O O 0.9998032450675964
their O O 0.9996839761734009
gastrointestinal O O 0.9958910942077637
( O O 0.9995591044425964
GI O O 0.9817793965339661
) O O 0.9998741149902344
benefit O O 0.9999728202819824
compared O O 0.9999592304229736
with O O 0.9998487234115601
non O O 0.9737513661384583
- O O 0.999661922454834
selective O O 0.9749062061309814
( O O 0.9993090629577637
NS O O 0.9489020109176636
) O O 0.9994919300079346
non B O 0.5318097472190857
- I O 0.9827204346656799
steroidal I O 0.49774304032325745
anti I O 0.48028984665870667
- I O 0.9600370526313782
inflammatory I O 0.9935709238052368
drugs I O 0.9980863332748413
( O O 0.9993864297866821
NSAIDs O O 0.522018313407898
) O O 0.999902606010437
. O O 0.9999641180038452

We O O 0.9999710321426392
aimed O O 0.9999970197677612
to O O 0.9999972581863403
compare O O 0.9999833106994629
the O O 0.9999897480010986
risks O O 0.9999959468841553
of O O 0.9999821186065674
hospitalization O O 0.9999645948410034
for O O 0.9999322891235352
AMI O O 0.9719722270965576
and O O 0.9993873834609985
GI O O 0.8740306496620178
bleeding O O 0.9996601343154907
among O O 0.9999052286148071
elderly O O 0.9996302127838135
patients O O 0.9999958276748657
using O O 0.9996721744537354
COX B O 0.9024445414543152
- I O 0.9914911389350891
2 I O 0.9837955236434937
inhibitors I O 0.974311888217926
, O O 0.9992326498031616
NS O O 0.5504827499389648
- O O 0.7923072576522827
NSAIDs O O 0.5466395020484924
and O O 0.9954225420951843
acetaminophen B B 0.9966410398483276
. O O 0.9999393224716187

METHODS O O 0.9999631643295288
: O O 0.9999922513961792
We O O 0.9999916553497314
conducted O O 0.999997615814209
a O O 0.9999970197677612
retrospective O O 0.9999879598617554
cohort O O 0.9999589920043945
study O O 0.9999967813491821
using O O 0.9999902248382568
administrative O O 0.9999961853027344
data O O 0.999998927116394
of O O 0.9999951124191284
patients O O 0.999998927116394
> O O 0.999997615814209
or O O 0.9999958276748657
= O O 0.9999985694885254
65 O O 0.9999992847442627
years O O 0.9999996423721313
of O O 0.9999992847442627
age O O 0.9999874830245972
who O O 0.999975323677063
filled O O 0.9999818801879883
a O O 0.9999943971633911
prescription O O 0.999915361404419
for O O 0.9988967180252075
NSAID O B 0.8968494534492493
or O O 0.8851678371429443
acetaminophen B B 0.9810632467269897
during O O 0.9997666478157043
1999 O O 0.9504966139793396
- O O 0.9964005947113037
2002 O O 0.9770018458366394
. O O 0.9999841451644897

Outcomes O O 0.9999593496322632
were O O 0.9999908208847046
compared O O 0.9999866485595703
using O O 0.9999595880508423
Cox O O 0.8223961591720581
regression O O 0.997980535030365
models O O 0.9999712705612183
with O O 0.9999489784240723
time O O 0.9989722967147827
- O O 0.99994957447052
dependent O O 0.9999552965164185
exposures O O 0.9999289512634277
. O O 0.9999829530715942

RESULTS O O 0.9993903636932373
: O O 0.9999438524246216
Person O O 0.9998971223831177
- O O 0.9999856948852539
years O O 0.9999815225601196
of O O 0.9999003410339355
exposure O O 0.9998973608016968
among O O 0.9995725750923157
non O O 0.9853680729866028
- O O 0.9998927116394043
users O O 0.977512001991272
of O O 0.9977526068687439
aspirin B B 0.9907141923904419
were O O 0.999510645866394
: O O 0.9997163414955139
75 O O 0.9994069337844849
, O O 0.9998531341552734
761 O O 0.9995793700218201
to O O 0.9984024167060852
acetaminophen B B 0.9975027441978455
, O O 0.9867809414863586
42 O O 0.9998388290405273
, O O 0.9999570846557617
671 O O 0.9999473094940186
to O O 0.9993792772293091
rofecoxib B B 0.9860828518867493
65 O O 0.9246991276741028
, O O 0.9450604319572449
860 O O 0.9370838403701782
to O O 0.9987254738807678
celecoxib B B 0.9979066848754883
, O O 0.9928620457649231
and O O 0.9997647404670715
37 O O 0.9996023774147034
, O O 0.9999480247497559
495 O O 0.9999873638153076
to O O 0.9987260699272156
NS O O 0.6713538765907288
- O O 0.8798059821128845
NSAIDs O O 0.7603086233139038
. O O 0.9999483823776245

Among O O 0.9913284182548523
users O O 0.971293568611145
of O O 0.9987012147903442
aspirin B B 0.996752142906189
, O O 0.9995957016944885
they O O 0.9998759031295776
were O O 0.9999351501464844
: O O 0.9993178844451904
14 O O 0.9999215602874756
, O O 0.9999066591262817
671 O O 0.9999827146530151
to O O 0.9983953833580017
rofecoxib B B 0.9931102991104126
, O O 0.9877981543540955
22 O O 0.9997754693031311
, O O 0.9999669790267944
875 O O 0.9978790283203125
to O O 0.999004065990448
celecoxib B B 0.9976699948310852
, O O 0.9962551593780518
9 O O 0.9998507499694824
, O O 0.9999725818634033
832 O O 0.9996554851531982
to O O 0.9991104006767273
NS O O 0.7377948760986328
- O O 0.8499664664268494
NSAIDs O O 0.7282633781433105
and O O 0.9996882677078247
38 O O 0.9993458390235901
, O O 0.9999905824661255
048 O O 0.9999629259109497
to O O 0.9993081092834473
acetaminophen B B 0.9955874681472778
. O O 0.9999409914016724

Among O O 0.9991999268531799
non O O 0.9921097159385681
- O O 0.9998216032981873
users O O 0.974187970161438
of O O 0.9986473917961121
aspirin B B 0.9918604493141174
, O O 0.9997079968452454
the O O 0.9999719858169556
adjusted O O 0.9999725818634033
hazard O O 0.9999881982803345
ratios O O 0.999992847442627
( O O 0.9999775886535645
95 O O 0.9999969005584717
% O O 0.9999936819076538
confidence O O 0.999994158744812
interval O O 0.9999856948852539
) O O 0.9999918937683105
of O O 0.9999371767044067
hospitalization O O 0.9999427795410156
for O O 0.9992372989654541
AMI O B 0.9636877775192261
/ O O 0.6513623595237732
GI O B 0.9371182322502136
vs O O 0.9914883375167847
the O O 0.9989940524101257
acetaminophen B B 0.9940018057823181
( O O 0.999737560749054
with O O 0.9999306201934814
no O O 0.9905253052711487
aspirin B B 0.9444546103477478
) O O 0.9985948204994202
group O O 0.9989252686500549
were O O 0.9999774694442749
: O O 0.9990154504776001
rofecoxib B B 0.9982495903968811
1 O O 0.9992101192474365
. O O 0.9999866485595703
27 O O 0.9999939203262329
( O O 0.99991774559021
1 O O 0.9999969005584717
. O O 0.999994158744812
13 O O 0.9999964237213135
, O O 0.9986164569854736
1 O O 0.9999977350234985
. O O 0.9999964237213135
42 O O 0.9999964237213135
) O O 0.9999412298202515
, O O 0.9966701865196228
celecoxib B B 0.9965715408325195
0 O O 0.9955130219459534
. O O 0.9999822378158569
93 O O 0.9968282580375671
( O O 0.9997962117195129
0 O O 0.9999897480010986
. O O 0.9999845027923584
83 O O 0.9981132745742798
, O O 0.9968720078468323
1 O O 0.9999725818634033
. O O 0.9999910593032837
03 O O 0.9999873638153076
) O O 0.9999346733093262
, O O 0.9915714263916016
naproxen B B 0.9750423431396484
1 O O 0.9992700219154358
. O O 0.9999825954437256
59 O O 0.9999973773956299
( O O 0.9999451637268066
1 O O 0.9999986886978149
. O O 0.999995231628418
31 O O 0.9999949932098389
, O O 0.9990448355674744
1 O O 0.999995231628418
. O O 0.9999932050704956
93 O O 0.9996685981750488
) O O 0.9999282360076904
, O O 0.9925910234451294
diclofenac B B 0.9930388331413269
1 O O 0.9196284413337708
. O O 0.9997511506080627
17 O O 0.9999983310699463
( O O 0.9999173879623413
0 O O 0.9999948740005493
. O O 0.9999897480010986
99 O O 0.9992884397506714
, O O 0.9990050196647644
1 O O 0.9999954700469971
. O O 0.9999943971633911
38 O O 0.9999977350234985
) O O 0.9999097585678101
and O O 0.999261200428009
ibuprofen B B 0.9443460702896118
1 O O 0.9471047520637512
. O O 0.9999518394470215
05 O O 0.9999972581863403
( O O 0.999948263168335
0 O O 0.9999949932098389
. O O 0.9999816417694092
74 O O 0.9999793767929077
, O O 0.9988540410995483
1 O O 0.999994158744812
. O O 0.999992847442627
51 O O 0.9999977350234985
) O O 0.999966025352478
. O O 0.9999765157699585

Among O O 0.9774860143661499
users O O 0.9428166151046753
of O O 0.995053768157959
aspirin B B 0.9973307847976685
, O O 0.9990181922912598
they O O 0.9983276724815369
were O O 0.9996458292007446
: O O 0.9379227161407471
rofecoxib B B 0.9951741099357605
1 O O 0.9993083477020264
. O O 0.9999555349349976
73 O O 0.9999951124191284
( O O 0.9998173117637634
1 O O 0.9999943971633911
. O O 0.9999887943267822
52 O O 0.9999940395355225
, O O 0.9942052960395813
1 O O 0.999990701675415
. O O 0.9999889135360718
98 O O 0.9991549253463745
) O O 0.9998536109924316
, O O 0.9856411814689636
celecoxib B B 0.9975899457931519
1 O O 0.9660158157348633
. O O 0.9999159574508667
34 O O 0.9999936819076538
( O O 0.9999072551727295
1 O O 0.9999921321868896
. O O 0.9999936819076538
19 O O 0.9999874830245972
, O O 0.9941375255584717
1 O O 0.9999805688858032
. O O 0.9999948740005493
52 O O 0.9999886751174927
) O O 0.999853253364563
, O O 0.9881666302680969
ibuprofen B B 0.9835963249206543
1 O O 0.9913889765739441
. O O 0.9999085664749146
51 O O 0.9999958276748657
( O O 0.9998989105224609
0 O O 0.9999905824661255
. O O 0.9999816417694092
95 O O 0.9982055425643921
, O O 0.99334716796875
2 O O 0.9991963505744934
. O O 0.999950647354126
41 O O 0.9999532699584961
) O O 0.9998664855957031
, O O 0.9884971380233765
diclofenac B B 0.9936336278915405
1 O O 0.9988700747489929
. O O 0.9999743700027466
69 O O 0.9999932050704956
( O O 0.9999262094497681
1 O O 0.9999973773956299
. O O 0.9999834299087524
35 O O 0.9999924898147583
, O O 0.9961057305335999
2 O O 0.9999594688415527
. O O 0.9999532699584961
10 O O 0.999993085861206
) O O 0.9999109506607056
, O O 0.9732601642608643
naproxen B B 0.9546526074409485
1 O O 0.9543420076370239
. O O 0.999396800994873
35 O O 0.9999985694885254
( O O 0.999930739402771
0 O O 0.9999921321868896
. O O 0.9999842643737793
97 O O 0.9982581734657288
, O O 0.9971715807914734
1 O O 0.9999861717224121
. O O 0.9999755620956421
88 O O 0.9930481910705566
) O O 0.9998323917388916
and O O 0.9962283372879028
acetaminophen B B 0.9885715842247009
1 O O 0.9062412977218628
. O O 0.9997619986534119
29 O O 0.9999977350234985
( O O 0.9998051524162292
1 O O 0.9999661445617676
. O O 0.9999548196792603
17 O O 0.9999971389770508
, O O 0.9959560036659241
1 O O 0.9999849796295166
. O O 0.9999915361404419
42 O O 0.9999957084655762
) O O 0.9999444484710693
. O O 0.9999456405639648

CONCLUSION O O 0.9981069564819336
: O O 0.9998751878738403
Among O O 0.9998049139976501
non O O 0.9908778071403503
- O O 0.9998466968536377
users O O 0.9944514632225037
of O O 0.9986051917076111
aspirin B B 0.9900296330451965
, O O 0.9929209351539612
naproxen B B 0.9942511320114136
seemed O O 0.9998812675476074
to O O 0.9999598264694214
carry O O 0.9999710321426392
the O O 0.999972939491272
highest O O 0.9999780654907227
risk O O 0.9999918937683105
for O O 0.9999344348907471
AMI O O 0.9831916689872742
/ O O 0.9991093277931213
GI O O 0.9790549874305725
bleeding O O 0.9999526739120483
. O O 0.9999468326568604

The O O 0.9999583959579468
AMI O O 0.4853517413139343
/ O O 0.9873381853103638
GI O B 0.9316062331199646
toxicity O O 0.9990929365158081
of O O 0.9992875456809998
celecoxib B B 0.9994682669639587
was O O 0.9998893737792969
similar O O 0.9999899864196777
to O O 0.9999572038650513
that O O 0.9999837875366211
of O O 0.999510645866394
acetaminophen B B 0.9978753328323364
and O O 0.99986732006073
seemed O O 0.9999817609786987
to O O 0.999957799911499
be O O 0.9999561309814453
better O O 0.9998785257339478
than O O 0.999934196472168
those O O 0.9999120235443115
of O O 0.9995170831680298
rofecoxib B B 0.9984992742538452
and O O 0.9966790676116943
NS O O 0.49329710006713867
- O O 0.7475696802139282
NSAIDs O O 0.5069432258605957
. O O 0.9999510049819946

Among O O 0.9810327291488647
users O O 0.9863709807395935
of O O 0.9939776659011841
aspirin B B 0.9944010376930237
, O O 0.9985871315002441
both O O 0.9959383010864258
celecoxib B B 0.9984177350997925
and O O 0.9090508818626404
naproxen B B 0.9916971921920776
seemed O O 0.9998342990875244
to O O 0.9999488592147827
be O O 0.9999216794967651
the O O 0.9999256134033203
least O O 0.9999445676803589
toxic O O 0.9998379945755005
. O O 0.9999464750289917

Quinine B B 0.9969835877418518
- O O 0.9989882111549377
induced O O 0.9999551773071289
arrhythmia O O 0.9999731779098511
in O O 0.9999767541885376
a O O 0.9999849796295166
patient O O 0.9999911785125732
with O O 0.9999783039093018
severe O O 0.9999649524688721
malaria O O 0.9999390840530396
. O O 0.999945878982544

It O O 0.9999874830245972
was O O 0.9999692440032959
reported O O 0.9999959468841553
that O O 0.9999797344207764
there O O 0.9999831914901733
was O O 0.9999926090240479
a O O 0.9999933242797852
case O O 0.9999945163726807
of O O 0.9999575614929199
severe O O 0.9885833263397217
malaria O O 0.976599395275116
patient O O 0.9999480247497559
with O O 0.9998379945755005
jaundice O O 0.9989511966705322
who O O 0.9999221563339233
presented O O 0.9999517202377319
with O O 0.9999840259552002
arrhythmia O O 0.9999430179595947
( O O 0.9999116659164429
premature O O 0.9999891519546509
ventricular O O 0.9999874830245972
contraction O O 0.9999971389770508
) O O 0.9999728202819824
while O O 0.9999091625213623
getting O O 0.9989155530929565
quinine B B 0.999390721321106
infusion O O 0.9990278482437134
was O O 0.9999843835830688
reported O O 0.9999964237213135
. O O 0.9999843835830688

A O O 0.9996956586837769
man O O 0.9999973773956299
, O O 0.999983549118042
25 O O 0.9999808073043823
years O O 0.9999924898147583
old O O 0.9998315572738647
, O O 0.9999856948852539
was O O 0.9999854564666748
admitted O O 0.9999884366989136
to O O 0.9999908208847046
hospital O O 0.9999970197677612
with O O 0.9999914169311523
high O O 0.9997836947441101
fever O O 0.9999854564666748
, O O 0.9999786615371704
chill O O 0.9996320009231567
, O O 0.9999686479568481
vomiting O O 0.9999498128890991
, O O 0.99979168176651
jaundice O O 0.9994913339614868
. O O 0.9999680519104004

The O O 0.999988317489624
patient O O 0.9999935626983643
was O O 0.9999861717224121
fully O O 0.99998939037323
conscious O O 0.9999979734420776
, O O 0.9999903440475464
blood O O 0.9994425177574158
pressure O O 0.9998807907104492
120 O O 0.9997785687446594
/ O O 0.9999955892562866
80 O O 0.9992270469665527
mmHg O O 0.9999631643295288
, O O 0.9999790191650391
pulse O O 0.9955416321754456
rate O O 0.999988317489624
100 O O 0.9999665021896362
x O O 0.9999986886978149
/ O O 0.9999963045120239
minute O O 0.9999992847442627
, O O 0.9999837875366211
regular O O 0.9999332427978516
. O O 0.9999902248382568

On O O 0.9999692440032959
admission O O 0.9999934434890747
, O O 0.9999879598617554
laboratory O O 0.999983549118042
examination O O 0.9999955892562866
showed O O 0.9998347759246826
Plasmodium O O 0.6798892021179199
falciparum O O 0.7901937961578369
( O O 0.9995855689048767
+ O O 0.9958643913269043
+ O O 0.9997014403343201
+ O O 0.9998877048492432
+ O O 0.999955415725708
) O O 0.999950647354126
, O O 0.9998586177825928
total O O 0.9768600463867188
bilirubin B B 0.9687900543212891
8 O O 0.9437527060508728
. O O 0.9999936819076538
25 O O 0.9999954700469971
mg O O 0.9999966621398926
/ O O 0.9999873638153076
dL O O 0.999997615814209
, O O 0.9998894929885864
conjugated O O 0.8777948021888733
bilirubin B O 0.7851842641830444
4 O O 0.9739229679107666
. O O 0.9999957084655762
36 O O 0.9999964237213135
mg O O 0.999996542930603
/ O O 0.9999910593032837
dL O O 0.9999982118606567
, O O 0.9998596906661987
unconjugated O O 0.9644036889076233
bilirubin B B 0.9369335770606995
3 O O 0.9787832498550415
. O O 0.9999953508377075
89 O O 0.9999363422393799
mg O O 0.9999971389770508
/ O O 0.9999923706054688
dL O O 0.999996542930603
, O O 0.9960262775421143
potassium B B 0.9959359169006348
3 O O 0.613466739654541
. O O 0.9998735189437866
52 O O 0.9999393224716187
meq O O 0.9999874830245972
/ O O 0.9999642372131348
L O O 0.9999773502349854
Patient O O 0.9999840259552002
was O O 0.9999767541885376
diagnosed O O 0.9999979734420776
as O O 0.9999808073043823
severe O O 0.9982720613479614
malaria O O 0.9999029636383057
with O O 0.9999630451202393
jaundice O O 0.9997583031654358
and O O 0.9999817609786987
got O O 0.9953580498695374
quinine B B 0.9993079900741577
infusion O O 0.9985839128494263
in O O 0.99836665391922
dextrose B B 0.9949637651443481
5 O O 0.9083907604217529
% O O 0.9915687441825867
500 O O 0.9990242719650269
mg O O 0.9998643398284912
/ O O 0.9999208450317383
8 O O 0.9988985061645508
hour O O 0.9996901750564575
. O O 0.9999282360076904

On O O 0.9999731779098511
the O O 0.9999921321868896
second O O 0.9999969005584717
day O O 0.9999908208847046
the O O 0.9999910593032837
patient O O 0.9999933242797852
had O O 0.9999797344207764
vomitus O O 0.9991280436515808
, O O 0.9999686479568481
diarrhea O O 0.9998700618743896
, O O 0.9999630451202393
tinnitus O O 0.9999440908432007
, O O 0.9999523162841797
loss O O 0.9999990463256836
of O O 0.9999887943267822
hearing O O 0.9999940395355225
. O O 0.9999698400497437

After O O 0.9999760389328003
30 O O 0.9999897480010986
hours O O 0.999983549118042
of O O 0.999850869178772
quinine B B 0.9994484782218933
infusion O O 0.9996625185012817
the O O 0.99998939037323
patient O O 0.999991774559021
felt O O 0.9999792575836182
palpitation O O 0.9999957084655762
and O O 0.9999827146530151
electrocardiography O O 0.9999674558639526
( O O 0.9999513626098633
ECG O O 0.9991697072982788
) O O 0.9999654293060303
recording O O 0.9999775886535645
showed O O 0.9999581575393677
premature O O 0.9999688863754272
ventricular O O 0.9999649524688721
contraction O O 0.9999942779541016
( O O 0.999929666519165
PVC O O 0.9973787069320679
) O O 0.9999692440032959
> O O 0.9999181032180786
5 O O 0.9999756813049316
x O O 0.999991774559021
/ O O 0.9999927282333374
minute O O 0.9999991655349731
, O O 0.9997672438621521
trigemini O O 0.9858848452568054
, O O 0.9998278617858887
constant O O 0.9995908141136169
type O O 0.9995538592338562
- O O 0.9914649128913879
- O O 0.9962655901908875
sinoatrial O O 0.9994295239448547
block O O 0.9999874830245972
, O O 0.9997029900550842
positive O O 0.9998229146003723
U O O 0.9992703795433044
wave O O 0.9999953508377075
. O O 0.9999709129333496

He O O 0.999937891960144
was O O 0.9999599456787109
treated O O 0.9999755620956421
with O O 0.9996141195297241
lidocaine B B 0.9996097683906555
50 O O 0.910651445388794
mg O O 0.9993497729301453
intravenously O O 0.99994957447052
followed O O 0.9999246597290039
by O O 0.999910831451416
infusion O O 0.991046130657196
1500 O O 0.9997956156730652
mg O O 0.999974250793457
in O O 0.9989277720451355
dextrose B B 0.9931766986846924
5 O O 0.9924333095550537
% O O 0.9939627051353455
/ O O 0.9996808767318726
24 O O 0.999937891960144
hour O O 0.9985710382461548
and O O 0.9990291595458984
potassium B B 0.9947185516357422
aspartate I I 0.9983752965927124
tablet O O 0.9949997663497925
. O O 0.999966025352478

Quinine B B 0.9980757236480713
infusion O O 0.9979269504547119
was O O 0.9999568462371826
discontinued O O 0.9999287128448486
and O O 0.9999681711196899
changed O O 0.9999222755432129
with O O 0.9997398257255554
sulfate O B 0.998518168926239
quinine B I 0.9880393147468567
tablets O O 0.9933439493179321
. O O 0.9999610185623169

Three O O 0.9999771118164062
hours O O 0.9999966621398926
later O O 0.9999948740005493
the O O 0.9999966621398926
patient O O 0.9999954700469971
felt O O 0.9999957084655762
better O O 0.9999961853027344
, O O 0.9999970197677612
the O O 0.9999972581863403
frequency O O 0.9999939203262329
of O O 0.9999074935913086
PVC O O 0.9119080901145935
reduced O O 0.9999589920043945
to O O 0.9999792575836182
4 O O 0.9996240139007568
- O O 0.9996790885925293
5 O O 0.999975323677063
x O O 0.99997878074646
/ O O 0.9999849796295166
minute O O 0.9999947547912598
and O O 0.9999836683273315
on O O 0.9999961853027344
the O O 0.9999980926513672
third O O 0.9999966621398926
day O O 0.9999816417694092
ECG O O 0.9577394127845764
was O O 0.9999798536300659
normal O O 0.999993085861206
, O O 0.9998923540115356
potassium B B 0.9991353154182434
level O O 0.9982835054397583
was O O 0.999987006187439
3 O O 0.9664280414581299
. O O 0.9999876022338867
34 O O 0.9998270869255066
meq O O 0.9999663829803467
/ O O 0.9998927116394043
L O O 0.9990124702453613
. O O 0.9999769926071167

He O O 0.9999761581420898
was O O 0.9999902248382568
discharged O O 0.9999904632568359
on O O 0.9999912977218628
7th O O 0.9999812841415405
day O O 0.9999868869781494
in O O 0.9999961853027344
good O O 0.9999959468841553
condition O O 0.9999984502792358
. O O 0.9999909400939941

Quinine B B 0.9984071850776672
, O O 0.9993283748626709
like O O 0.9991969466209412
quinidine B B 0.9977637529373169
, O O 0.9996386766433716
is O O 0.9996974468231201
a O O 0.9382609128952026
chincona O O 0.6502925753593445
alkaloid O O 0.5849504470825195
that O O 0.9994446635246277
has O O 0.9997547268867493
anti O O 0.9588647484779358
- O O 0.9992926120758057
arrhythmic O O 0.9998350143432617
property O O 0.9999500513076782
, O O 0.9999433755874634
although O O 0.9999405145645142
it O O 0.9993139505386353
also O O 0.9996412992477417
pro O O 0.8561282157897949
- O O 0.9911125302314758
arrhythmic O O 0.9961256384849548
that O O 0.9998862743377686
can O O 0.9999122619628906
cause O O 0.9999557733535767
various O O 0.9999624490737915
arrhythmias O O 0.999984622001648
, O O 0.9999815225601196
including O O 0.999970555305481
severe O O 0.9998570680618286
arrhythmia O O 0.9999748468399048
such O O 0.9999862909317017
as O O 0.9999903440475464
multiple O O 0.9997168183326721
PVC O O 0.9949172735214233
. O O 0.9998906850814819

Administration O O 0.9998880624771118
of O O 0.9996821880340576
parenteral O O 0.9926028847694397
quinine B B 0.9984349608421326
must O O 0.9998130202293396
be O O 0.9999971389770508
done O O 0.9999971389770508
carefully O O 0.9999946355819702
and O O 0.999995231628418
with O O 0.9999947547912598
good O O 0.9999785423278809
observation O O 0.9999977350234985
because O O 0.9999936819076538
of O O 0.9999885559082031
its O O 0.9998830556869507
pro O O 0.982433557510376
- O O 0.9981566071510315
arrhythmic O O 0.9998824596405029
effect O O 0.9999575614929199
, O O 0.9999861717224121
especially O O 0.9999778270721436
in O O 0.9999704360961914
older O O 0.9999744892120361
patients O O 0.9999958276748657
who O O 0.9999854564666748
have O O 0.9999842643737793
heart O O 0.9999759197235107
diseases O O 0.9999974966049194
or O O 0.9999583959579468
patients O O 0.9999897480010986
with O O 0.9999871253967285
electrolyte O O 0.9894411563873291
disorder O O 0.9999426603317261
( O O 0.9999489784240723
hypokalemia O O 0.9758920669555664
) O O 0.9999830722808838
which O O 0.9999843835830688
frequently O O 0.9999911785125732
occurs O O 0.9999940395355225
due O O 0.9999942779541016
to O O 0.9999761581420898
vomiting O O 0.9999817609786987
and O O 0.9999488592147827
or O O 0.9999688863754272
diarrhea O O 0.99992835521698
in O O 0.9998997449874878
malaria O O 0.8303791284561157
cases O O 0.9999402761459351
. O O 0.9999774694442749

Penicillamine B B 0.9947013854980469
- O O 0.9989005327224731
related O O 0.9998483657836914
lichenoid O O 0.9998410940170288
dermatitis O O 0.9999945163726807
and O O 0.999919056892395
utility O O 0.9998207688331604
of O O 0.9969273209571838
zinc B B 0.997261643409729
acetate I I 0.9999620914459229
in O O 0.9997932314872742
a O O 0.9999785423278809
Wilson O O 0.9982086420059204
disease O O 0.9999639987945557
patient O O 0.999962329864502
with O O 0.9999315738677979
hepatic O O 0.9994649291038513
presentation O O 0.9999850988388062
, O O 0.9999645948410034
anxiety O O 0.993040919303894
and O O 0.9999125003814697
SPECT O O 0.8928975462913513
abnormalities O O 0.9999065399169922
. O O 0.9999685287475586

Wilson O O 0.9834813475608826
' O O 0.9999828338623047
s O O 0.9999948740005493
disease O O 0.9999922513961792
is O O 0.9999583959579468
an O O 0.9999686479568481
autosomal O O 0.9997268319129944
recessive O O 0.9999408721923828
disorder O O 0.9999864101409912
of O O 0.9996613264083862
hepatic O O 0.9775001406669617
copper B B 0.986799418926239
metabolism O O 0.996292769908905
with O O 0.9999657869338989
consequent O O 0.9223209619522095
copper B B 0.993920087814331
accumulation O O 0.9997988343238831
and O O 0.9999408721923828
toxicity O O 0.9999357461929321
in O O 0.9998593330383301
many O O 0.9997870326042175
tissues O O 0.9999873638153076
and O O 0.9999686479568481
consequent O O 0.9692951440811157
hepatic O O 0.9993264675140381
, O O 0.9998801946640015
neurologic O O 0.9999597072601318
and O O 0.9999058246612549
psychiatric O O 0.9999167919158936
disorders O O 0.99998939037323
. O O 0.9999445676803589

We O O 0.9999810457229614
report O O 0.9999935626983643
a O O 0.9999874830245972
case O O 0.999992847442627
of O O 0.9999617338180542
Wilson O O 0.9979795813560486
' O O 0.9999841451644897
s O O 0.9999896287918091
disease O O 0.9999887943267822
with O O 0.9999639987945557
chronic O O 0.99985671043396
liver O O 0.9920859932899475
disease O O 0.9999910593032837
; O O 0.9999682903289795
moreover O O 0.9999896287918091
, O O 0.9999960660934448
in O O 0.9999940395355225
our O O 0.9999867677688599
patient O O 0.9999923706054688
, O O 0.9999874830245972
presenting O O 0.999987006187439
also O O 0.9999890327453613
with O O 0.999975323677063
high O O 0.9998611211776733
levels O O 0.9999755620956421
of O O 0.9999420642852783
state O O 0.998052716255188
anxiety O O 0.9851321578025818
without O O 0.999964714050293
depression O O 0.9999784231185913
, O O 0.999982476234436
99mTc O O 0.7241029143333435
- O O 0.8451164364814758
ECD O O 0.9598451256752014
- O O 0.995430588722229
SPECT O O 0.9682053923606873
showed O O 0.9998993873596191
cortical O O 0.9980771541595459
hypoperfusion O O 0.999858021736145
in O O 0.9990805387496948
frontal O O 0.999614953994751
lobes O O 0.9999665021896362
, O O 0.9999599456787109
more O O 0.9999643564224243
marked O O 0.9999861717224121
on O O 0.9999104738235474
the O O 0.9999825954437256
left O O 0.9999561309814453
frontal O O 0.9999630451202393
lobe O O 0.9999891519546509
. O O 0.9999762773513794

During O O 0.999970555305481
the O O 0.9999971389770508
follow O O 0.9999958276748657
- O O 0.9999953508377075
up O O 0.9999979734420776
of O O 0.9999940395355225
our O O 0.9999901056289673
patient O O 0.9999949932098389
, O O 0.9997063279151917
penicillamine B B 0.9994392991065979
was O O 0.9998739957809448
interrupted O O 0.9996334314346313
after O O 0.9999803304672241
the O O 0.9999960660934448
appearance O O 0.9999988079071045
of O O 0.999994158744812
a O O 0.9999901056289673
lichenoid O O 0.9998183846473694
dermatitis O O 0.9999854564666748
, O O 0.9998801946640015
and O O 0.9997419714927673
zinc B B 0.9986953139305115
acetate I I 0.9999504089355469
permitted O O 0.9996792078018188
to O O 0.9999792575836182
continue O O 0.9999866485595703
the O O 0.9999945163726807
successful O O 0.9999204874038696
treatment O O 0.9999880790710449
of O O 0.9999866485595703
the O O 0.999991774559021
patient O O 0.9999871253967285
without O O 0.9999619722366333
side O O 0.9999227523803711
- O O 0.9999669790267944
effects O O 0.9999830722808838
. O O 0.9999722242355347

In O O 0.999971866607666
our O O 0.999950647354126
case O O 0.9999585151672363
the O O 0.9999505281448364
therapy O O 0.9999345541000366
with O O 0.999755322933197
zinc B B 0.9977856874465942
acetate I I 0.9999428987503052
represented O O 0.999680757522583
an O O 0.9999499320983887
effective O O 0.9997780919075012
treatment O O 0.9999586343765259
for O O 0.9999449253082275
a O O 0.9999537467956543
Wilson O O 0.9997039437294006
' O O 0.9999881982803345
s O O 0.9999927282333374
disease O O 0.9999903440475464
patient O O 0.9999785423278809
in O O 0.9999672174453735
which O O 0.9999735355377197
penicillamine B B 0.9959818124771118
- O O 0.9990423321723938
related O O 0.9998685121536255
side O O 0.9999333620071411
effects O O 0.9999847412109375
appeared O O 0.9999916553497314
. O O 0.9999419450759888

The O O 0.9999732971191406
safety O O 0.9999727010726929
of O O 0.9997981190681458
the O O 0.9958736300468445
zinc B B 0.9930425882339478
acetate I I 0.9999054670333862
allowed O O 0.9995844960212708
us O O 0.999991774559021
to O O 0.9999679327011108
avoid O O 0.9997851252555847
other O O 0.9998974800109863
potentially O O 0.9996862411499023
toxic O O 0.9970802664756775
chelating O O 0.9535424709320068
drugs O O 0.9977781176567078
; O O 0.9999897480010986
this O O 0.9999964237213135
observation O O 0.9999974966049194
is O O 0.99998939037323
in O O 0.9999963045120239
line O O 0.9999964237213135
with O O 0.9999960660934448
the O O 0.9999959468841553
growing O O 0.999996542930603
evidence O O 0.9999946355819702
on O O 0.9999586343765259
the O O 0.9999808073043823
efficacy O O 0.9999791383743286
of O O 0.9998980760574341
the O O 0.9997804760932922
drug O O 0.9981667995452881
in O O 0.9999182224273682
the O O 0.99994957447052
treatment O O 0.9999573230743408
of O O 0.999962329864502
Wilson O O 0.9998319149017334
' O O 0.9999843835830688
s O O 0.9999916553497314
disease O O 0.9999929666519165
. O O 0.9999786615371704

Since O O 0.9999910593032837
most O O 0.9999779462814331
of O O 0.9999701976776123
Wilson O O 0.9965103268623352
' O O 0.9999775886535645
s O O 0.9999850988388062
disease O O 0.9994675517082214
penicillamine B B 0.9992454051971436
- O O 0.9989966750144958
treated O O 0.9997873902320862
patients O O 0.999976634979248
do O O 0.9999949932098389
not O O 0.999990701675415
seem O O 0.9999935626983643
to O O 0.9999885559082031
develop O O 0.9999940395355225
this O O 0.9999735355377197
skin O O 0.9999535083770752
lesion O O 0.9999957084655762
, O O 0.9999790191650391
it O O 0.9999898672103882
could O O 0.9999823570251465
be O O 0.9999961853027344
conceivable O O 0.9998284578323364
that O O 0.9999476671218872
a O O 0.9998565912246704
specific O O 0.9999085664749146
genetic O O 0.9999313354492188
factor O O 0.9999759197235107
is O O 0.9999665021896362
involved O O 0.9999856948852539
in O O 0.9999750852584839
drug O O 0.9997989535331726
response O O 0.9999797344207764
. O O 0.9999690055847168

Further O O 0.9999632835388184
studies O O 0.9999881982803345
are O O 0.9999836683273315
needed O O 0.9999877214431763
for O O 0.9999904632568359
a O O 0.9999897480010986
better O O 0.9999822378158569
clarification O O 0.9999969005584717
of O O 0.9999598264694214
Wilson O O 0.997672975063324
' O O 0.999977707862854
s O O 0.9999620914459229
disease O O 0.9999740123748779
therapy O O 0.9999334812164307
, O O 0.9999759197235107
and O O 0.999984622001648
in O O 0.9999828338623047
particular O O 0.9999886751174927
to O O 0.9999910593032837
differentiate O O 0.9998290538787842
specific O O 0.9998962879180908
therapies O O 0.9999701976776123
for O O 0.9998723268508911
different O O 0.9999513626098633
Wilson O O 0.9993767142295837
' O O 0.9999868869781494
s O O 0.9999833106994629
disease O O 0.9999879598617554
phenotypes O O 0.9999845027923584
. O O 0.999975323677063

A O O 0.9999384880065918
dramatic O O 0.9999780654907227
drop O O 0.9999957084655762
in O O 0.99998939037323
blood O O 0.99992835521698
pressure O O 0.9995452761650085
following O O 0.999908447265625
prehospital O O 0.9990498423576355
GTN B B 0.9977644681930542
administration O O 0.9996731281280518
. O O 0.9999622106552124

A O O 0.9999707937240601
male O O 0.9999972581863403
in O O 0.9999711513519287
his O O 0.9999969005584717
sixties O O 0.9999810457229614
with O O 0.9999502897262573
no O O 0.9999819993972778
history O O 0.999990701675415
of O O 0.9999608993530273
cardiac O O 0.9999619722366333
chest O O 0.999956488609314
pain O O 0.999975323677063
awoke O O 0.9999712705612183
with O O 0.9999938011169434
chest O O 0.999992847442627
pain O O 0.9999945163726807
following O O 0.999969482421875
an O O 0.9999949932098389
afternoon O O 0.9997784495353699
sleep O O 0.999993085861206
. O O 0.999975323677063

The O O 0.9999754428863525
patient O O 0.9999814033508301
did O O 0.9999837875366211
not O O 0.9999856948852539
self O O 0.999870777130127
medicate O O 0.9998944997787476
. O O 0.9999465942382812

The O O 0.9999809265136719
patient O O 0.999992847442627
' O O 0.9999948740005493
s O O 0.9999945163726807
observations O O 0.9994767308235168
were O O 0.9999923706054688
within O O 0.999996542930603
normal O O 0.9999946355819702
limits O O 0.9999961853027344
, O O 0.9999580383300781
he O O 0.9998738765716553
was O O 0.9999638795852661
administered O O 0.9997270703315735
oxygen B B 0.9993656277656555
via O O 0.9997523427009583
a O O 0.9999648332595825
face O O 0.9946081638336182
mask O O 0.9931453466415405
and O O 0.999196469783783
glyceryl B B 0.9976763129234314
trinitrate I I 0.9995579123497009
( O O 0.9794658422470093
GTN B B 0.993959903717041
) O O 0.9992693066596985
. O O 0.9999659061431885

Several O O 0.9999785423278809
minutes O O 0.9999966621398926
after O O 0.9999799728393555
the O O 0.9996793270111084
GTN B O 0.7822182178497314
the O O 0.9999411106109619
patient O O 0.9999845027923584
experienced O O 0.999988317489624
a O O 0.999994158744812
sudden O O 0.9999954700469971
drop O O 0.9999982118606567
in O O 0.9999923706054688
blood O O 0.999944806098938
pressure O O 0.999969482421875
and O O 0.9999806880950928
heart O O 0.999984622001648
rate O O 0.9999935626983643
, O O 0.9999698400497437
this O O 0.9999805688858032
was O O 0.9999605417251587
rectified O O 0.9999697208404541
by O O 0.9997459053993225
atropine B B 0.9996287822723389
sulphate I O 0.9146955609321594
and O O 0.9992577433586121
a O O 0.999964714050293
fluid O O 0.9937295913696289
challenge O O 0.9999198913574219
. O O 0.9999613761901855

There O O 0.9999756813049316
was O O 0.9999866485595703
no O O 0.9999951124191284
further O O 0.9999972581863403
deterioration O O 0.9999994039535522
in O O 0.9999967813491821
the O O 0.9999960660934448
patient O O 0.999994158744812
' O O 0.9999947547912598
s O O 0.9999948740005493
condition O O 0.9999972581863403
during O O 0.9999645948410034
transport O O 0.9999972581863403
to O O 0.9999934434890747
hospital O O 0.9999920129776001
. O O 0.9999709129333496

There O O 0.9999310970306396
are O O 0.9999706745147705
very O O 0.9999889135360718
few O O 0.9999862909317017
documented O O 0.9999889135360718
case O O 0.9999881982803345
like O O 0.999976634979248
this O O 0.9999490976333618
in O O 0.9999539852142334
the O O 0.999988317489624
prehospital O O 0.9981180429458618
scientific O O 0.99998939037323
literature O O 0.9999861717224121
. O O 0.999941349029541

The O O 0.9999352693557739
cause O O 0.999984622001648
appears O O 0.9999487400054932
to O O 0.9999493360519409
be O O 0.9999167919158936
the O O 0.9998774528503418
Bezold O O 0.8530749678611755
- O O 0.9996224641799927
Jarish O O 0.9999836683273315
reflex O O 0.9999624490737915
, O O 0.9994500279426575
stimulation O O 0.996021568775177
of O O 0.9996799230575562
the O O 0.9998241066932678
ventricular O O 0.9998619556427002
walls O O 0.9994558691978455
which O O 0.9998911619186401
in O O 0.9999884366989136
turn O O 0.9999786615371704
decreases O O 0.9998434782028198
sympathetic O O 0.9518333077430725
outflow O O 0.9977726340293884
from O O 0.9997279047966003
the O O 0.9998500347137451
vasomotor O O 0.9988497495651245
centre O O 0.9997630715370178
. O O 0.9999419450759888

Prehospital O O 0.8153970837593079
care O O 0.9999423027038574
providers O O 0.9999538660049438
who O O 0.9999492168426514
are O O 0.9999885559082031
managing O O 0.999977707862854
any O O 0.9999920129776001
patient O O 0.9999908208847046
with O O 0.9999697208404541
a O O 0.9999903440475464
syncopal O O 0.9999650716781616
episode O O 0.9999973773956299
that O O 0.9999876022338867
fails O O 0.9999961853027344
to O O 0.9999933242797852
recover O O 0.9999954700469971
within O O 0.9999878406524658
a O O 0.9999936819076538
reasonable O O 0.9999951124191284
time O O 0.9999905824661255
frame O O 0.9999938011169434
should O O 0.9999620914459229
consider O O 0.9999380111694336
the O O 0.9997469782829285
Bezold O O 0.7973455786705017
- O O 0.9896055459976196
Jarisch O O 0.9970853924751282
reflex O O 0.9997856020927429
as O O 0.9999206066131592
the O O 0.9999414682388306
cause O O 0.9999860525131226
and O O 0.9999567270278931
manage O O 0.9999915361404419
the O O 0.9999958276748657
patient O O 0.999994158744812
accordingly O O 0.999982476234436
. O O 0.9999778270721436

Chronic O O 0.9997960925102234
lesion O O 0.999982476234436
of O O 0.999833345413208
rostral O O 0.9982403516769409
ventrolateral O O 0.9998972415924072
medulla O O 0.9998804330825806
in O O 0.9997673630714417
spontaneously O O 0.9856016039848328
hypertensive O O 0.9732773900032043
rats O O 0.999489426612854
. O O 0.9999295473098755

We O O 0.9999642372131348
studied O O 0.9999767541885376
the O O 0.999968409538269
effects O O 0.9999785423278809
of O O 0.9999239444732666
chronic O O 0.9996548891067505
selective O O 0.9982252717018127
neuronal O O 0.9999250173568726
lesion O O 0.9999624490737915
of O O 0.9996706247329712
rostral O O 0.9993027448654175
ventrolateral O O 0.9998683929443359
medulla O O 0.9998681545257568
on O O 0.9999167919158936
mean O O 0.9999001026153564
arterial O O 0.99564528465271
pressure O O 0.9997695088386536
, O O 0.9999573230743408
heart O O 0.9999639987945557
rate O O 0.9999899864196777
, O O 0.9999157190322876
and O O 0.9998871088027954
neurogenic O O 0.9999691247940063
tone O O 0.9999797344207764
in O O 0.9998966455459595
conscious O O 0.9999566078186035
, O O 0.9999750852584839
unrestrained O O 0.9999908208847046
spontaneously O O 0.9998251795768738
hypertensive O O 0.9947500824928284
rats O O 0.9999881982803345
. O O 0.9999606609344482

The O O 0.9999208450317383
lesions O O 0.9999750852584839
were O O 0.9999752044677734
placed O O 0.9999827146530151
via O O 0.9999676942825317
bilateral O O 0.999872088432312
microinjections O O 0.9998156428337097
of O O 0.9999043941497803
30 O O 0.8889625668525696
nmol O O 0.9658311009407043
/ O O 0.998040497303009
200 O O 0.9960013031959534
nl O O 0.912671685218811
N B B 0.6595718860626221
- I I 0.9213755130767822
methyl I I 0.9975451827049255
- I I 0.9198963046073914
D I I 0.9818551540374756
- I I 0.988652765750885
aspartic I I 0.9997416138648987
acid I I 0.9997909665107727
. O O 0.9998453855514526

The O O 0.9999725818634033
restimulation O O 0.999902606010437
of O O 0.9998362064361572
this O O 0.9999196529388428
area O O 0.9996951818466187
with O O 0.9998564720153809
N B B 0.7177510261535645
- I I 0.9418795108795166
methyl I I 0.9989128112792969
- I I 0.8871147036552429
D I I 0.9832481145858765
- I I 0.9894084930419922
aspartic I I 0.999755322933197
acid I I 0.9995891451835632
15 O O 0.9995194673538208
days O O 0.9999921321868896
postlesion O O 0.9993589520454407
failed O O 0.9999831914901733
to O O 0.9999908208847046
produce O O 0.9999899864196777
a O O 0.9999847412109375
pressor O O 0.9999428987503052
response O O 0.9999768733978271
. O O 0.9999752044677734

One O O 0.9999812841415405
day O O 0.9999933242797852
postlesion O O 0.9999411106109619
, O O 0.9999662637710571
the O O 0.9999862909317017
resting O O 0.9999841451644897
mean O O 0.9999842643737793
arterial O O 0.9998270869255066
pressure O O 0.99989914894104
was O O 0.999957799911499
significantly O O 0.9999862909317017
decreased O O 0.9999855756759644
in O O 0.9998534917831421
lesioned O O 0.99981290102005
rats O O 0.9999920129776001
when O O 0.9999886751174927
compared O O 0.9999964237213135
with O O 0.9999920129776001
sham O O 0.9998718500137329
rats O O 0.9999960660934448
( O O 0.9999643564224243
100 O O 0.9964141249656677
+ O O 0.9999868869781494
/ O O 0.9999889135360718
- O O 0.999870777130127
7 O O 0.9997615218162537
versus O O 0.9999688863754272
173 O O 0.9999023675918579
+ O O 0.999992847442627
/ O O 0.9999939203262329
- O O 0.9999704360961914
4 O O 0.9999589920043945
mm O O 0.9999946355819702
Hg O O 0.5090207457542419
, O O 0.9999499320983887
p O O 0.9995506405830383
less O O 0.9999898672103882
than O O 0.9999924898147583
0 O O 0.9999932050704956
. O O 0.9999961853027344
05 O O 0.9999949932098389
) O O 0.9999814033508301
. O O 0.9999871253967285

Fifteen O O 0.9999535083770752
days O O 0.9999970197677612
later O O 0.9999955892562866
, O O 0.9999797344207764
the O O 0.9999592304229736
lesioned O O 0.999845027923584
group O O 0.9999426603317261
still O O 0.9999804496765137
showed O O 0.9999758005142212
values O O 0.9999873638153076
significantly O O 0.9999914169311523
lower O O 0.999984622001648
than O O 0.9999922513961792
the O O 0.9999837875366211
sham O O 0.9998295307159424
group O O 0.9999836683273315
( O O 0.99996018409729
150 O O 0.9996969699859619
+ O O 0.99997878074646
/ O O 0.9999762773513794
- O O 0.9995042085647583
6 O O 0.9994207620620728
versus O O 0.9999656677246094
167 O O 0.9996317625045776
+ O O 0.9999862909317017
/ O O 0.9999892711639404
- O O 0.9998944997787476
5 O O 0.9999810457229614
mm O O 0.9999912977218628
Hg O O 0.6735826134681702
, O O 0.9997977614402771
p O O 0.9995594620704651
less O O 0.9999845027923584
than O O 0.9999920129776001
0 O O 0.9999891519546509
. O O 0.9999953508377075
05 O O 0.9999902248382568
) O O 0.9999715089797974
. O O 0.9999866485595703

No O O 0.9999324083328247
significant O O 0.9999873638153076
heart O O 0.9999842643737793
rate O O 0.9999885559082031
differences O O 0.9999892711639404
were O O 0.9999876022338867
observed O O 0.999990701675415
between O O 0.9998307228088379
the O O 0.9999656677246094
sham O O 0.9999473094940186
and O O 0.999776303768158
lesioned O O 0.9999706745147705
groups O O 0.9999895095825195
. O O 0.9999616146087646

The O O 0.9996678829193115
ganglionic O O 0.9388934373855591
blocker O O 0.8649117946624756
trimethaphan B B 0.9994418025016785
( O O 0.9997289776802063
5 O O 0.9999552965164185
mg O O 0.9999635219573975
/ O O 0.999977707862854
kg O O 0.9999932050704956
i O O 0.999954342842102
. O O 0.9999977350234985
v O O 0.999998927116394
. O O 0.9999938011169434
) O O 0.9999445676803589
caused O O 0.9999657869338989
similar O O 0.9999912977218628
reductions O O 0.9999979734420776
in O O 0.9999922513961792
mean O O 0.99998939037323
arterial O O 0.999625563621521
pressure O O 0.9998067021369934
in O O 0.9999213218688965
both O O 0.9998908042907715
lesioned O O 0.9999730587005615
and O O 0.9999104738235474
sham O O 0.9999104738235474
groups O O 0.9999898672103882
. O O 0.9999696016311646

The O O 0.9999252557754517
trimethaphan B B 0.9996834993362427
- O O 0.9998635053634644
induced O O 0.9999454021453857
hypotension O O 0.9999786615371704
was O O 0.9999707937240601
accompanied O O 0.9999878406524658
by O O 0.9999744892120361
a O O 0.9999817609786987
significant O O 0.9999802112579346
bradycardia O O 0.9999878406524658
in O O 0.9999370574951172
lesioned O O 0.9997610449790955
rats O O 0.999995231628418
( O O 0.9999414682388306
- O O 0.9999053478240967
32 O O 0.9999886751174927
+ O O 0.9999922513961792
/ O O 0.9999914169311523
- O O 0.9999825954437256
13 O O 0.9999922513961792
beats O O 0.9999967813491821
per O O 0.9999899864196777
minute O O 0.9999974966049194
) O O 0.9999693632125854
but O O 0.9999284744262695
a O O 0.9999796152114868
tachycardia O O 0.9999688863754272
in O O 0.9999219179153442
sham O O 0.9995664954185486
rats O O 0.999996542930603
( O O 0.9999401569366455
+ O O 0.9999890327453613
33 O O 0.9999927282333374
+ O O 0.999990701675415
/ O O 0.9999923706054688
- O O 0.9999856948852539
12 O O 0.9999948740005493
beats O O 0.9999973773956299
per O O 0.9999878406524658
minute O O 0.9999967813491821
) O O 0.999983549118042
1 O O 0.999950647354126
day O O 0.9999957084655762
postlesion O O 0.9999268054962158
. O O 0.9999704360961914

Therefore O O 0.9998118281364441
, O O 0.9996082186698914
rostral O O 0.9917467832565308
ventrolateral O O 0.9996792078018188
medulla O O 0.9982569813728333
neurons O O 0.9982985854148865
appear O O 0.9999182224273682
to O O 0.9998636245727539
play O O 0.9998434782028198
a O O 0.999875545501709
significant O O 0.9998871088027954
role O O 0.9998947381973267
in O O 0.9999088048934937
maintaining O O 0.9998295307159424
hypertension O O 0.9996160268783569
in O O 0.9998170733451843
conscious O O 0.9987518787384033
spontaneously O O 0.9994763731956482
hypertensive O O 0.9929047226905823
rats O O 0.9998947381973267
. O O 0.9999583959579468

Spinal O O 0.996131181716919
or O O 0.9993245601654053
suprabulbar O O 0.9951013922691345
structures O O 0.9999412298202515
could O O 0.9997386336326599
be O O 0.9998775720596313
responsible O O 0.9999164342880249
for O O 0.9999486207962036
the O O 0.9999849796295166
gradual O O 0.9999691247940063
recovery O O 0.999990701675415
of O O 0.9999758005142212
the O O 0.9999637603759766
hypertension O O 0.9995152950286865
in O O 0.9997339844703674
the O O 0.9999420642852783
lesioned O O 0.9999548196792603
rats O O 0.9998600482940674
. O O 0.9999457597732544

Acute O O 0.9999300241470337
encephalopathy O O 0.9999722242355347
and O O 0.999964714050293
cerebral O O 0.9999797344207764
vasospasm O O 0.9999760389328003
after O O 0.9999040365219116
multiagent O O 0.98067307472229
chemotherapy O O 0.9993388056755066
including O O 0.9996100068092346
PEG B B 0.9665407538414001
- I I 0.9498222470283508
asparaginase I I 0.9977651834487915
and O O 0.9603859186172485
intrathecal O O 0.9989901185035706
cytarabine B B 0.9994825124740601
for O O 0.999674916267395
the O O 0.9999812841415405
treatment O O 0.999984622001648
of O O 0.9999842643737793
acute O O 0.9999141693115234
lymphoblastic O O 0.9999759197235107
leukemia O O 0.9999961853027344
. O O 0.9999604225158691

A O O 0.999981164932251
7 O O 0.9999678134918213
- O O 0.9999778270721436
year O O 0.999994158744812
- O O 0.999993085861206
old O O 0.9999955892562866
girl O O 0.9999982118606567
with O O 0.9999454021453857
an O O 0.9999911785125732
unusual O O 0.9999654293060303
reaction O O 0.9999979734420776
to O O 0.9998828172683716
induction O O 0.9999160766601562
chemotherapy O O 0.9983779191970825
for O O 0.9998027682304382
precursor O O 0.9997149109840393
B O O 0.9970645308494568
- O O 0.9997984766960144
cell O O 0.997572124004364
acute O O 0.9980667233467102
lymphoblastic O O 0.9998852014541626
leukemia O O 0.9999617338180542
( O O 0.999884843826294
ALL O O 0.9972960352897644
) O O 0.9999728202819824
is O O 0.9999855756759644
described O O 0.9999927282333374
. O O 0.9999840259552002

The O O 0.9999890327453613
patient O O 0.9999854564666748
developed O O 0.9999783039093018
acute O O 0.9999796152114868
encephalopathy O O 0.999933123588562
evidenced O O 0.9999901056289673
by O O 0.9999905824661255
behavioral O O 0.9999898672103882
changes O O 0.9999978542327881
, O O 0.9999812841415405
aphasia O O 0.9999370574951172
, O O 0.9999620914459229
incontinence O O 0.9999889135360718
, O O 0.9999650716781616
visual O O 0.9998762607574463
hallucinations O O 0.9999964237213135
, O O 0.9999539852142334
and O O 0.9999771118164062
right O O 0.9999144077301025
- O O 0.9999723434448242
sided O O 0.9999951124191284
weakness O O 0.9999978542327881
with O O 0.9999771118164062
diffuse O O 0.9999825954437256
cerebral O O 0.9999929666519165
vasospasm O O 0.9999463558197021
on O O 0.9999862909317017
magnetic O O 0.9995861649513245
resonance O O 0.9992104768753052
angiography O O 0.9999033212661743
after O O 0.9999016523361206
the O O 0.9999842643737793
administration O O 0.9999350309371948
of O O 0.9998577833175659
intrathecal O O 0.9988507032394409
cytarabine B B 0.9994912147521973
. O O 0.9998307228088379

Vincristine B B 0.997588038444519
, O O 0.9839850068092346
dexamethasone B B 0.999163031578064
, O O 0.9928090572357178
and O O 0.9994244575500488
polyethylene B B 0.9636625051498413
glycol I I 0.9913318157196045
- I I 0.9063258171081543
asparaginase I I 0.998751163482666
were O O 0.9993322491645813
also O O 0.9999302625656128
administered O O 0.9999077320098877
before O O 0.9999822378158569
the O O 0.9999957084655762
episode O O 0.9999969005584717
as O O 0.9999897480010986
part O O 0.9999899864196777
of O O 0.9999904632568359
induction O O 0.9999902248382568
therapy O O 0.9999954700469971
. O O 0.9999775886535645

Neurologic O O 0.999958872795105
status O O 0.999995231628418
returned O O 0.9999923706054688
to O O 0.9999957084655762
baseline O O 0.9999938011169434
within O O 0.9999922513961792
10 O O 0.9999949932098389
days O O 0.9999982118606567
of O O 0.9999946355819702
the O O 0.9999966621398926
acute O O 0.9999946355819702
event O O 0.9999990463256836
, O O 0.9999638795852661
and O O 0.9999772310256958
magnetic O O 0.9997547268867493
resonance O O 0.9959700107574463
angiography O O 0.992321789264679
findings O O 0.9999798536300659
returned O O 0.9999922513961792
to O O 0.9999955892562866
normal O O 0.9999933242797852
4 O O 0.9998880624771118
months O O 0.999998927116394
later O O 0.9999983310699463
. O O 0.9999841451644897

Comparison O O 0.9999814033508301
of O O 0.9994701743125916
valsartan B B 0.9997038245201111
/ O O 0.5063459873199463
hydrochlorothiazide B B 0.9338105916976929
combination O O 0.890948474407196
therapy O O 0.9998953342437744
at O O 0.9999306201934814
doses O O 0.999984622001648
up O O 0.999996542930603
to O O 0.9999386072158813
320 O O 0.9696173667907715
/ O O 0.9934828877449036
25 O O 0.9997517466545105
mg O O 0.9996424913406372
versus O O 0.9998809099197388
monotherapy O O 0.9993705153465271
: O O 0.9999873638153076
a O O 0.9999905824661255
double O O 0.9999574422836304
- O O 0.9999812841415405
blind O O 0.9999951124191284
, O O 0.9999778270721436
placebo O O 0.999880313873291
- O O 0.9999279975891113
controlled O O 0.9999525547027588
study O O 0.9999915361404419
followed O O 0.9999756813049316
by O O 0.9999730587005615
long O O 0.9998682737350464
- O O 0.9999909400939941
term O O 0.9999865293502808
combination O O 0.9959783554077148
therapy O O 0.9999592304229736
in O O 0.9999549388885498
hypertensive O O 0.9989408850669861
adults O O 0.9999103546142578
. O O 0.9999818801879883

BACKGROUND O O 0.9988721013069153
: O O 0.9999746084213257
One O O 0.9999645948410034
third O O 0.9999915361404419
of O O 0.9999727010726929
patients O O 0.9999794960021973
treated O O 0.9997909665107727
for O O 0.9993834495544434
hypertension O O 0.9921867847442627
attain O O 0.9998613595962524
adequate O O 0.9999510049819946
blood O O 0.9994170665740967
pressure O O 0.9605613350868225
( O O 0.9998151659965515
BP O O 0.9849559664726257
) O O 0.9999195337295532
control O O 0.9998992681503296
, O O 0.9999411106109619
and O O 0.9999518394470215
multidrug O O 0.933581531047821
regimens O O 0.9991745352745056
are O O 0.9999475479125977
often O O 0.9999885559082031
required O O 0.9999661445617676
. O O 0.999967098236084

Given O O 0.9999866485595703
the O O 0.9999929666519165
lifelong O O 0.9999738931655884
nature O O 0.9999873638153076
of O O 0.9999604225158691
hypertension O O 0.9967848062515259
, O O 0.999956488609314
there O O 0.9999836683273315
is O O 0.9999867677688599
a O O 0.9999897480010986
need O O 0.9999973773956299
to O O 0.9999943971633911
evaluate O O 0.9999920129776001
the O O 0.9999829530715942
long O O 0.9997201561927795
- O O 0.9999881982803345
term O O 0.9999767541885376
efficacy O O 0.9999904632568359
and O O 0.9999868869781494
tolerability O O 0.9999982118606567
of O O 0.999968409538269
higher O O 0.9999605417251587
doses O O 0.9999773502349854
of O O 0.9998712539672852
combination O O 0.986711859703064
anti O O 0.5168679356575012
- O O 0.9283064603805542
hypertensive O O 0.5941017866134644
therapies O O 0.9957045912742615
. O O 0.999937891960144

OBJECTIVE O O 0.9999531507492065
: O O 0.9999946355819702
This O O 0.9999890327453613
study O O 0.9999843835830688
investigated O O 0.9999784231185913
the O O 0.9999916553497314
efficacy O O 0.9999758005142212
and O O 0.9999827146530151
tolerability O O 0.9999979734420776
of O O 0.9997941851615906
valsartan B B 0.9997699856758118
( O O 0.9847871661186218
VAL B B 0.9996843338012695
) O O 0.9206565022468567
or O O 0.9906151294708252
hydrochlorothiazide B B 0.9932403564453125
( O O 0.9911797642707825
HCTZ B B 0.9782642126083374
) O O 0.9965019226074219
- O O 0.9996960163116455
monotherapy O O 0.9998557567596436
and O O 0.999937891960144
higher O O 0.9992782473564148
- O O 0.9999589920043945
dose O O 0.9996798038482666
combinations O O 0.9998666048049927
in O O 0.999954342842102
patients O O 0.999993085861206
with O O 0.9999818801879883
essential O O 0.9998186230659485
hypertension O O 0.9993317723274231
. O O 0.999974250793457

METHODS O O 0.9999744892120361
: O O 0.9999955892562866
The O O 0.9999980926513672
first O O 0.9999988079071045
part O O 0.9999978542327881
of O O 0.999988317489624
this O O 0.9999920129776001
study O O 0.9999953508377075
was O O 0.9999929666519165
an O O 0.9999949932098389
8 O O 0.9999505281448364
- O O 0.9999860525131226
week O O 0.9999954700469971
, O O 0.9999880790710449
multicenter O O 0.999956488609314
, O O 0.9999871253967285
randomized O O 0.9999866485595703
, O O 0.9999880790710449
double O O 0.9997979998588562
- O O 0.999944806098938
blind O O 0.9999938011169434
, O O 0.9999740123748779
placebo O O 0.9998558759689331
controlled O O 0.9999203681945801
, O O 0.9999641180038452
parallel O O 0.9815402626991272
- O O 0.9997451901435852
group O O 0.9999104738235474
trial O O 0.999982476234436
. O O 0.9999802112579346

Patients O O 0.9999896287918091
with O O 0.99997878074646
essential O O 0.9985036849975586
hypertension O O 0.9997913241386414
( O O 0.9999440908432007
mean O O 0.9999666213989258
sitting O O 0.9984151124954224
diastolic O O 0.9994229078292847
BP O O 0.9157819151878357
[ O O 0.99983811378479
MSDBP O O 0.9999256134033203
] O O 0.9999232292175293
, O O 0.9999535083770752
> O O 0.9999792575836182
or O O 0.9999908208847046
= O O 0.9999934434890747
95 O O 0.9999967813491821
mm O O 0.9999951124191284
Hg O O 0.9511591196060181
and O O 0.9999668598175049
< O O 0.9999942779541016
110 O O 0.999998927116394
mm O O 0.9999954700469971
Hg O O 0.8032044172286987
) O O 0.9999885559082031
were O O 0.9999879598617554
randomized O O 0.9999958276748657
to O O 0.9999182224273682
1 O O 0.9998874664306641
of O O 0.9999582767486572
8 O O 0.9999549388885498
treatment O O 0.9999457597732544
groups O O 0.9999849796295166
: O O 0.9999041557312012
VAL B B 0.9989577531814575
160 O I 0.9542272686958313
or O O 0.9773455858230591
320 O O 0.9579823613166809
mg O O 0.9996113181114197
; O O 0.9992395639419556
HCTZ B B 0.8848592042922974
12 O O 0.9205664992332458
. O O 0.9919360876083374
5 O O 0.9995414018630981
or O O 0.9998427629470825
25 O O 0.9999257326126099
mg O O 0.9996439218521118
; O O 0.9995883107185364
VAL B B 0.9979264736175537
/ O O 0.8631844520568848
HCTZ B O 0.7603307366371155
160 O O 0.6089081168174744
/ O O 0.9713293313980103
12 O O 0.9996398687362671
. O O 0.9999924898147583
5 O O 0.9999533891677856
, O O 0.9969879984855652
320 O O 0.9654161334037781
/ O O 0.9950855374336243
12 O O 0.9981398582458496
. O O 0.9999816417694092
5 O O 0.9998471736907959
, O O 0.9993985891342163
or O O 0.9984554052352905
320 O O 0.9465453624725342
/ O O 0.990598738193512
25 O O 0.9997085928916931
mg O O 0.9987769722938538
; O O 0.9997038245201111
or O O 0.9996676445007324
placebo O O 0.9999068975448608
. O O 0.9999638795852661

Mean O O 0.9999622106552124
changes O O 0.9999961853027344
in O O 0.9999679327011108
MSDBP O O 0.9981881976127625
and O O 0.9998546838760376
mean O O 0.9998138546943665
sitting O O 0.9944827556610107
systolic O O 0.9915105700492859
BP O O 0.9351874589920044
( O O 0.9998899698257446
MSSBP O O 0.9956966638565063
) O O 0.999961256980896
were O O 0.9999802112579346
analyzed O O 0.999985933303833
at O O 0.9999754428863525
the O O 0.9999948740005493
8 O O 0.9999220371246338
- O O 0.9999744892120361
week O O 0.999996542930603
core O O 0.9999817609786987
study O O 0.9999942779541016
end O O 0.9999914169311523
point O O 0.9999933242797852
. O O 0.9999802112579346

VAL B B 0.9985018968582153
/ O O 0.6263900995254517
HCTZ B B 0.9242005348205566
320 O I 0.9927811026573181
/ O O 0.6771020889282227
12 O O 0.7144509553909302
. O O 0.9389984011650085
5 O O 0.98874831199646
and O O 0.9934797286987305
320 O O 0.8200730681419373
/ O O 0.9805237054824829
25 O O 0.9998379945755005
mg O O 0.9981354475021362
were O O 0.9999182224273682
further O O 0.9999761581420898
investigated O O 0.9999624490737915
in O O 0.9999839067459106
a O O 0.9999809265136719
54 O O 0.9999738931655884
- O O 0.9999866485595703
week O O 0.9999943971633911
, O O 0.9999825954437256
open O O 0.999745786190033
- O O 0.9999827146530151
label O O 0.9999856948852539
extension O O 0.999984860420227
. O O 0.9999794960021973

Response O O 0.9999643564224243
was O O 0.9999802112579346
defined O O 0.9999933242797852
as O O 0.9999850988388062
MSDBP O O 0.9998430013656616
< O O 0.9999681711196899
90 O O 0.9999988079071045
mm O O 0.9999984502792358
Hg O O 0.8387367725372314
or O O 0.9999599456787109
a O O 0.9999884366989136
> O O 0.9999814033508301
or O O 0.9999924898147583
= O O 0.9999954700469971
10 O O 0.9999903440475464
mm O O 0.9999980926513672
Hg O O 0.780122697353363
decrease O O 0.9999970197677612
compared O O 0.9999982118606567
to O O 0.9999969005584717
baseline O O 0.9999825954437256
. O O 0.9999829530715942

Control O O 0.9999414682388306
was O O 0.999984622001648
defined O O 0.9999929666519165
as O O 0.999990701675415
MSDBP O O 0.9997487664222717
< O O 0.9999698400497437
90 O O 0.9999988079071045
mm O O 0.9999988079071045
Hg O O 0.47327888011932373
compared O O 0.9999868869781494
with O O 0.9999954700469971
baseline O O 0.9999699592590332
. O O 0.9999827146530151

Tolerability O O 0.9999533891677856
was O O 0.9999834299087524
assessed O O 0.9999966621398926
by O O 0.999993085861206
monitoring O O 0.9999727010726929
adverse O O 0.9999688863754272
events O O 0.999997615814209
at O O 0.9999356269836426
randomization O O 0.999984860420227
and O O 0.9999786615371704
all O O 0.9999502897262573
subsequent O O 0.9999864101409912
study O O 0.9999877214431763
visits O O 0.9999954700469971
and O O 0.9999834299087524
regular O O 0.9999854564666748
evaluation O O 0.9999969005584717
of O O 0.9999805688858032
hematology O O 0.9995877146720886
and O O 0.999950647354126
blood O O 0.9964879751205444
chemistry O O 0.9800033569335938
. O O 0.9999803304672241

RESULTS O O 0.9999703168869019
: O O 0.9999877214431763
A O O 0.9999897480010986
total O O 0.9999946355819702
of O O 0.9999920129776001
1346 O O 0.999924898147583
patients O O 0.9999963045120239
were O O 0.9999898672103882
randomized O O 0.9999924898147583
into O O 0.9999756813049316
the O O 0.999988317489624
8 O O 0.9999078512191772
- O O 0.9999779462814331
week O O 0.9999945163726807
core O O 0.9999738931655884
study O O 0.9999904632568359
( O O 0.9999376535415649
734 O O 0.9999972581863403
men O O 0.9999829530715942
, O O 0.9999798536300659
612 O O 0.9999969005584717
women O O 0.9996366500854492
; O O 0.9999799728393555
924 O O 0.9997662901878357
white O O 0.9997331500053406
, O O 0.9998026490211487
291 O O 0.9999915361404419
black O O 0.9974272847175598
, O O 0.9996397495269775
23 O O 0.9990814924240112
Asian O O 0.998752236366272
, O O 0.9997259974479675
108 O O 0.9847981333732605
other O O 0.999589741230011
; O O 0.9999858140945435
mean O O 0.9999959468841553
age O O 0.9999772310256958
, O O 0.999993085861206
52 O O 0.9999982118606567
. O O 0.9999990463256836
7 O O 0.9999977350234985
years O O 0.9999996423721313
; O O 0.9999955892562866
mean O O 0.9999971389770508
weight O O 0.9999672174453735
, O O 0.9999945163726807
92 O O 0.9999992847442627
. O O 0.9999994039535522
6 O O 0.9999982118606567
kg O O 0.9999985694885254
) O O 0.9999784231185913
. O O 0.9999823570251465

All O O 0.9998088479042053
active O O 0.9994428753852844
treatments O O 0.9999005794525146
were O O 0.9999350309371948
associated O O 0.9999558925628662
with O O 0.9999710321426392
significantly O O 0.9999715089797974
reduced O O 0.9999798536300659
MSSBP O O 0.9611000418663025
and O O 0.999593198299408
MSDBP O O 0.9105406403541565
during O O 0.9998936653137207
the O O 0.9999895095825195
core O O 0.9999780654907227
8 O O 0.9998754262924194
- O O 0.9999661445617676
week O O 0.9999920129776001
study O O 0.9999958276748657
, O O 0.9999716281890869
with O O 0.999929666519165
each O O 0.9956588745117188
monotherapy O O 0.9894443154335022
significantly O O 0.9998308420181274
contributing O O 0.9999433755874634
to O O 0.9999784231185913
the O O 0.9999854564666748
overall O O 0.9999288320541382
effect O O 0.9999819993972778
of O O 0.9999362230300903
combination O O 0.9844312071800232
therapy O O 0.9998879432678223
( O O 0.9980435371398926
VAL B B 0.9981850981712341
and O O 0.9667597413063049
HCTZ B B 0.886972188949585
, O O 0.9991139769554138
P O O 0.999864935874939
< O O 0.9999818801879883
0 O O 0.9999918937683105
. O O 0.9999971389770508
001 O O 0.9993513226509094
) O O 0.9999651908874512
. O O 0.9999499320983887

Each O O 0.9989786148071289
combination O O 0.9988620281219482
was O O 0.9998900890350342
associated O O 0.999948263168335
with O O 0.9999803304672241
significantly O O 0.999984622001648
greater O O 0.9999669790267944
reductions O O 0.999991774559021
in O O 0.9999406337738037
MSSBP O O 0.9683995246887207
and O O 0.9996558427810669
MSDBP O O 0.8884142637252808
compared O O 0.9999498128890991
with O O 0.9999028444290161
the O O 0.9997162222862244
monotherapies O O 0.9770812392234802
and O O 0.9995867609977722
placebo O O 0.9993153810501099
( O O 0.9999173879623413
all O O 0.9977099895477295
, O O 0.9999462366104126
P O O 0.9998227953910828
< O O 0.9999721050262451
0 O O 0.9999871253967285
. O O 0.9999963045120239
001 O O 0.9996511936187744
) O O 0.999945878982544
. O O 0.9999643564224243

The O O 0.9999933242797852
mean O O 0.999984860420227
reduction O O 0.9999949932098389
in O O 0.9999657869338989
MSSBP O O 0.9954105019569397
/ O O 0.9997064471244812
MSDBP O O 0.9932357668876648
with O O 0.999774158000946
VAL B B 0.9996858835220337
/ O O 0.6607947945594788
HCTZ B B 0.9475266933441162
320 O O 0.616060733795166
/ O O 0.9449684619903564
25 O O 0.9968410730361938
mg O O 0.9995144605636597
was O O 0.9999754428863525
24 O O 0.9999897480010986
. O O 0.9999942779541016
7 O O 0.9999957084655762
/ O O 0.9999663829803467
16 O O 0.9999986886978149
. O O 0.9999970197677612
6 O O 0.9999958276748657
mm O O 0.999996542930603
Hg O O 0.6523481607437134
, O O 0.9999768733978271
compared O O 0.9999934434890747
with O O 0.9999868869781494
5 O O 0.9999701976776123
. O O 0.9999949932098389
9 O O 0.9999953508377075
/ O O 0.99994957447052
7 O O 0.9999954700469971
. O O 0.9999967813491821
0 O O 0.9999963045120239
mm O O 0.9999974966049194
Hg O O 0.8450120091438293
with O O 0.9999161958694458
placebo O O 0.9996067881584167
. O O 0.9999529123306274

The O O 0.9999855756759644
reduction O O 0.9999918937683105
in O O 0.9999496936798096
MSSBP O O 0.8897267580032349
was O O 0.9999449253082275
significantly O O 0.9999710321426392
greater O O 0.9999589920043945
with O O 0.9997938275337219
VAL B B 0.9996689558029175
/ O O 0.6301450133323669
HCTZ B B 0.8945017457008362
320 O I 0.9801774024963379
/ O O 0.6377090811729431
25 O O 0.9974894523620605
mg O O 0.9989101886749268
compared O O 0.9998778104782104
with O O 0.9995275735855103
VAL B B 0.9993748068809509
/ O O 0.7665311098098755
HCTZ B B 0.9070094227790833
160 O O 0.8721387982368469
/ O O 0.7368053197860718
12 O O 0.9789898991584778
. O O 0.9999449253082275
5 O O 0.9998722076416016
mg O O 0.9993312358856201
( O O 0.9999547004699707
P O O 0.9999692440032959
< O O 0.9999809265136719
0 O O 0.9999949932098389
. O O 0.9999983310699463
002 O O 0.9998942613601685
) O O 0.9999767541885376
. O O 0.9999693632125854

Rates O O 0.9999644756317139
of O O 0.9999722242355347
response O O 0.9999874830245972
and O O 0.9999088048934937
BP O O 0.9081448912620544
control O O 0.9999332427978516
were O O 0.9999536275863647
significantly O O 0.9999804496765137
higher O O 0.9999628067016602
in O O 0.9999285936355591
the O O 0.9999761581420898
groups O O 0.9999862909317017
that O O 0.9999654293060303
received O O 0.9999558925628662
combination O O 0.9604019522666931
treatment O O 0.9998915195465088
compared O O 0.9999731779098511
with O O 0.9999715089797974
those O O 0.9999704360961914
that O O 0.9999580383300781
received O O 0.9998874664306641
monotherapy O O 0.9994558691978455
. O O 0.9999731779098511

The O O 0.999983549118042
incidence O O 0.9999914169311523
of O O 0.9999583959579468
hypokalemia O O 0.9997218251228333
was O O 0.9999388456344604
lower O O 0.9999809265136719
with O O 0.9997355341911316
VAL B B 0.9967218041419983
/ O O 0.7208027839660645
HCTZ B B 0.9075681567192078
combinations O O 0.9970924854278564
( O O 0.9998915195465088
1 O O 0.9999229907989502
. O O 0.9999819993972778
8 O O 0.9999877214431763
% O O 0.9999673366546631
- O O 0.9987779259681702
6 O O 0.9999818801879883
. O O 0.9999916553497314
1 O O 0.9999938011169434
% O O 0.9999823570251465
) O O 0.9999196529388428
than O O 0.999971866607666
with O O 0.9997604489326477
HCTZ B B 0.9358034729957581
monotherapies O O 0.9965858459472656
( O O 0.9999508857727051
7 O O 0.9999724626541138
. O O 0.9999918937683105
1 O O 0.9999932050704956
% O O 0.9999521970748901
- O O 0.999000608921051
13 O O 0.9999947547912598
. O O 0.9999920129776001
3 O O 0.9999918937683105
% O O 0.9999853372573853
) O O 0.9999430179595947
. O O 0.999969482421875

The O O 0.9999709129333496
majority O O 0.9999842643737793
of O O 0.9999721050262451
adverse O O 0.9999499320983887
events O O 0.9999948740005493
in O O 0.9999735355377197
the O O 0.9999825954437256
core O O 0.9999650716781616
study O O 0.9999803304672241
were O O 0.9999485015869141
of O O 0.9999841451644897
mild O O 0.9999920129776001
to O O 0.999984860420227
moderate O O 0.9999890327453613
severity O O 0.9999966621398926
. O O 0.9999703168869019

The O O 0.9999722242355347
efficacy O O 0.9999737739562988
and O O 0.9999740123748779
tolerability O O 0.9999964237213135
of O O 0.9996902942657471
VAL B B 0.9992419481277466
/ O O 0.6713479161262512
HCTZ B B 0.8425537943840027
combinations O O 0.8797620534896851
were O O 0.9999735355377197
maintained O O 0.9999779462814331
during O O 0.9999343156814575
the O O 0.9999856948852539
extension O O 0.9999940395355225
( O O 0.9999909400939941
797 O O 0.9999921321868896
patients O O 0.9999978542327881
) O O 0.9999862909317017
. O O 0.999984622001648

CONCLUSIONS O O 0.9955930113792419
: O O 0.9999762773513794
In O O 0.99997878074646
this O O 0.9999728202819824
study O O 0.999955415725708
population O O 0.9999881982803345
, O O 0.9998630285263062
combination O O 0.9967302083969116
therapies O O 0.9999662637710571
with O O 0.9996590614318848
VAL B B 0.9982860684394836
/ O O 0.777527391910553
HCTZ B B 0.8553997874259949
were O O 0.9997691512107849
associated O O 0.9999697208404541
with O O 0.9999874830245972
significantly O O 0.9999905824661255
greater O O 0.9999642372131348
BP O O 0.963869035243988
reductions O O 0.9999792575836182
compared O O 0.999994158744812
with O O 0.999981164932251
either O O 0.9994800686836243
monotherapy O O 0.9996689558029175
, O O 0.9999682903289795
were O O 0.9999815225601196
well O O 0.9999836683273315
tolerated O O 0.9999949932098389
, O O 0.9999648332595825
and O O 0.9999665021896362
were O O 0.9999661445617676
associated O O 0.9999841451644897
with O O 0.9999873638153076
less O O 0.9999675750732422
hypokalemia O O 0.9995362758636475
than O O 0.999638557434082
HCTZ B B 0.9881707429885864
alone O O 0.9997510313987732
. O O 0.9999829530715942

Succimer B B 0.9977772831916809
chelation O O 0.6902849078178406
improves O O 0.9996968507766724
learning O O 0.9999815225601196
, O O 0.9999352693557739
attention O O 0.9999921321868896
, O O 0.9999120235443115
and O O 0.9999196529388428
arousal O O 0.9958618879318237
regulation O O 0.9999852180480957
in O O 0.9999622106552124
lead B B 0.976813793182373
- O O 0.9992411136627197
exposed O O 0.9999438524246216
rats O O 0.9999797344207764
but O O 0.9998916387557983
produces O O 0.9998890161514282
lasting O O 0.9999247789382935
cognitive O O 0.9999939203262329
impairment O O 0.9999978542327881
in O O 0.9999775886535645
the O O 0.9999836683273315
absence O O 0.9999798536300659
of O O 0.9999347925186157
lead B B 0.960386335849762
exposure O O 0.9993372559547424
. O O 0.9995884299278259

BACKGROUND O O 0.9968457818031311
: O O 0.9999868869781494
There O O 0.9999717473983765
is O O 0.999987006187439
growing O O 0.999994158744812
pressure O O 0.9999948740005493
for O O 0.9999696016311646
clinicians O O 0.999957799911499
to O O 0.9999690055847168
prescribe O O 0.9998393058776855
chelation O B 0.8884182572364807
therapy O O 0.9989914298057556
at O O 0.9999600648880005
only O O 0.9999662637710571
slightly O O 0.9999927282333374
elevated O O 0.9999884366989136
blood O O 0.9838676452636719
lead B O 0.6950920820236206
levels O O 0.9998531341552734
. O O 0.9999772310256958

However O O 0.9999532699584961
, O O 0.9999692440032959
very O O 0.9999926090240479
few O O 0.9999903440475464
studies O O 0.9999837875366211
have O O 0.9999855756759644
evaluated O O 0.9999862909317017
whether O O 0.9999527931213379
chelation O O 0.8215640187263489
improves O O 0.9995959401130676
cognitive O O 0.9999911785125732
outcomes O O 0.9999986886978149
in O O 0.9999583959579468
Pb B B 0.996701180934906
- O O 0.9959017634391785
exposed O O 0.9998559951782227
children O O 0.9999810457229614
, O O 0.999944806098938
or O O 0.9999651908874512
whether O O 0.9999622106552124
these O O 0.9982588887214661
agents O O 0.9951121211051941
have O O 0.9999300241470337
adverse O O 0.9997997879981995
effects O O 0.9999704360961914
that O O 0.9999685287475586
may O O 0.9999779462814331
affect O O 0.9999791383743286
brain O O 0.9999899864196777
development O O 0.9999980926513672
in O O 0.9999855756759644
the O O 0.9999885559082031
absence O O 0.999962329864502
of O O 0.9999037981033325
Pb B B 0.9968963861465454
exposure O O 0.9994175434112549
. O O 0.9999717473983765

OBJECTIVES O O 0.999956488609314
: O O 0.9999955892562866
The O O 0.9999978542327881
present O O 0.999993085861206
study O O 0.9999889135360718
was O O 0.9999918937683105
designed O O 0.9999959468841553
to O O 0.9999938011169434
answer O O 0.9999922513961792
these O O 0.9999890327453613
questions O O 0.9999982118606567
, O O 0.9999901056289673
using O O 0.9999599456787109
a O O 0.9999788999557495
rodent O O 0.99997878074646
model O O 0.9999934434890747
of O O 0.9999545812606812
early O O 0.999980092048645
childhood O O 0.9998886585235596
Pb B B 0.9885679483413696
exposure O O 0.9993547797203064
and O O 0.9999345541000366
treatment O O 0.9999613761901855
with O O 0.9994194507598877
succimer B B 0.9993795156478882
, O O 0.9999140501022339
a O O 0.9998968839645386
widely O O 0.9997856020927429
used O O 0.999687910079956
chelating O O 0.6838763952255249
agent O O 0.8808870315551758
for O O 0.9998114705085754
the O O 0.9999703168869019
treatment O O 0.9999150037765503
of O O 0.9998667240142822
Pb O B 0.963351845741272
poisoning O O 0.9960640072822571
. O O 0.9999624490737915

RESULTS O O 0.9995518326759338
: O O 0.9998675584793091
Pb B B 0.9980124235153198
exposure O O 0.9993122816085815
produced O O 0.9997593760490417
lasting O O 0.999135434627533
impairments O O 0.9999867677688599
in O O 0.9998944997787476
learning O O 0.9999873638153076
, O O 0.9998465776443481
attention O O 0.9999842643737793
, O O 0.9998667240142822
inhibitory O O 0.9995008707046509
control O O 0.9999696016311646
, O O 0.9996775388717651
and O O 0.9998083710670471
arousal O O 0.9714904427528381
regulation O O 0.9999287128448486
, O O 0.999962329864502
paralleling O O 0.999975323677063
the O O 0.9999822378158569
areas O O 0.9999630451202393
of O O 0.9999467134475708
dysfunction O O 0.9999814033508301
seen O O 0.9999898672103882
in O O 0.9999616146087646
Pb B B 0.9955422282218933
- O O 0.9903146624565125
exposed O O 0.9996414184570312
children O O 0.9999072551727295
. O O 0.9999513626098633

Succimer B B 0.999077320098877
treatment O O 0.9998003840446472
of O O 0.9998688697814941
the O O 0.9999629259109497
Pb B B 0.9953330159187317
- O O 0.9983053207397461
exposed O O 0.9998279809951782
rats O O 0.9999431371688843
significantly O O 0.9999418258666992
improved O O 0.9998530149459839
learning O O 0.9999880790710449
, O O 0.9998631477355957
attention O O 0.9999865293502808
, O O 0.9998119473457336
and O O 0.9996523857116699
arousal O O 0.9878525733947754
regulation O O 0.9999432563781738
, O O 0.9999806880950928
although O O 0.9999871253967285
the O O 0.9999911785125732
efficacy O O 0.9999932050704956
of O O 0.9999730587005615
the O O 0.9999737739562988
treatment O O 0.9999604225158691
varied O O 0.9999840259552002
as O O 0.9999896287918091
a O O 0.9999780654907227
function O O 0.999990701675415
of O O 0.9999816417694092
the O O 0.9999749660491943
Pb B B 0.9969057440757751
exposure O O 0.9989598989486694
level O O 0.9998829364776611
and O O 0.9999735355377197
the O O 0.999981164932251
specific O O 0.9999635219573975
functional O O 0.9999912977218628
deficit O O 0.9999964237213135
. O O 0.9999788999557495

In O O 0.99994957447052
contrast O O 0.9999701976776123
, O O 0.9996694326400757
succimer B B 0.9996994733810425
treatment O O 0.9997729659080505
of O O 0.9999226331710815
rats O O 0.9999920129776001
not O O 0.9999918937683105
previously O O 0.9999818801879883
exposed O O 0.9999805688858032
to O O 0.9997369647026062
Pb B B 0.9905049204826355
produced O O 0.9996170997619629
lasting O O 0.99415522813797
and O O 0.9998656511306763
pervasive O O 0.9999736547470093
cognitive O O 0.9999887943267822
and O O 0.9998952150344849
affective O O 0.9997803568840027
dysfunction O O 0.9999943971633911
comparable O O 0.9999773502349854
in O O 0.9999953508377075
magnitude O O 0.9999924898147583
to O O 0.9999737739562988
that O O 0.9999816417694092
produced O O 0.9999923706054688
by O O 0.9999241828918457
the O O 0.9999781847000122
higher O O 0.9989885687828064
Pb B B 0.9949466586112976
exposure O O 0.9990391731262207
regimen O O 0.9992303848266602
. O O 0.999977707862854

CONCLUSIONS O O 0.9999160766601562
: O O 0.9999940395355225
These O O 0.999994158744812
are O O 0.9999970197677612
the O O 0.999996542930603
first O O 0.9999985694885254
data O O 0.9999978542327881
, O O 0.9999939203262329
to O O 0.9999974966049194
our O O 0.9999948740005493
knowledge O O 0.9999921321868896
, O O 0.9999910593032837
to O O 0.9999920129776001
show O O 0.999984860420227
that O O 0.9998422861099243
treatment O O 0.9999644756317139
with O O 0.9998944997787476
any O O 0.99349445104599
chelating O O 0.5010634660720825
agent O O 0.8699998259544373
can O O 0.9998503923416138
alleviate O O 0.9998482465744019
cognitive O O 0.9999904632568359
deficits O O 0.9999977350234985
due O O 0.9999899864196777
to O O 0.9992807507514954
Pb B B 0.9962856769561768
exposure O O 0.9980635046958923
. O O 0.9999649524688721

These O O 0.9999783039093018
findings O O 0.9999927282333374
suggest O O 0.999981164932251
that O O 0.9999783039093018
it O O 0.9999885559082031
may O O 0.9999752044677734
be O O 0.9999943971633911
possible O O 0.9999897480010986
to O O 0.9999921321868896
identify O O 0.9999443292617798
a O O 0.9998871088027954
succimer B B 0.9990839958190918
treatment O O 0.9988076686859131
protocol O O 0.9998214840888977
that O O 0.9999353885650635
improves O O 0.9999544620513916
cognitive O O 0.9999963045120239
outcomes O O 0.9999986886978149
in O O 0.9999748468399048
Pb B B 0.9916742444038391
- O O 0.9592886567115784
exposed O O 0.9997490048408508
children O O 0.9999871253967285
. O O 0.9999724626541138

However O O 0.9999666213989258
, O O 0.9999849796295166
they O O 0.9999955892562866
also O O 0.9999933242797852
suggest O O 0.999987006187439
that O O 0.999862790107727
succimer B B 0.9993614554405212
treatment O O 0.9997276663780212
should O O 0.999941349029541
be O O 0.9999864101409912
strongly O O 0.999970555305481
discouraged O O 0.9999779462814331
for O O 0.9999066591262817
children O O 0.9999915361404419
who O O 0.9999829530715942
do O O 0.9999938011169434
not O O 0.999982476234436
have O O 0.9999712705612183
elevated O O 0.9998434782028198
tissue O O 0.9996402263641357
levels O O 0.9998072981834412
of O O 0.9974664449691772
Pb B B 0.9697785973548889
or O O 0.996607780456543
other O O 0.9990807771682739
heavy O O 0.5559187531471252
metals O O 0.5974841713905334
. O O 0.9999353885650635

Caffeine B B 0.9975225329399109
challenge O O 0.9863449335098267
test O O 0.9998213648796082
in O O 0.9999428987503052
panic O O 0.9938509464263916
disorder O O 0.9999481439590454
and O O 0.9998641014099121
depression O O 0.9999873638153076
with O O 0.9999442100524902
panic O O 0.9988447427749634
attacks O O 0.9999833106994629
. O O 0.9998798370361328

Our O O 0.9999812841415405
aim O O 0.9999966621398926
was O O 0.9999963045120239
to O O 0.9999951124191284
observe O O 0.9999945163726807
if O O 0.9999798536300659
patients O O 0.9999872446060181
with O O 0.9999780654907227
panic O O 0.9956508278846741
disorder O O 0.9999622106552124
( O O 0.9995673298835754
PD O O 0.9933445453643799
) O O 0.9999498128890991
and O O 0.999832034111023
patients O O 0.9999821186065674
with O O 0.999981164932251
major O O 0.999916672706604
depression O O 0.9999780654907227
with O O 0.999921441078186
panic O O 0.990204930305481
attacks O O 0.9998840093612671
( O O 0.999695897102356
MDP O O 0.994473397731781
) O O 0.9999514818191528
( O O 0.9999345541000366
Diagnostic O O 0.999982476234436
and O O 0.9999784231185913
Statistical O O 0.9999668598175049
Manual O O 0.9998648166656494
of O O 0.9998308420181274
Mental O O 0.9999806880950928
Disorders O O 0.9999914169311523
, O O 0.9999692440032959
Fourth O O 0.9978963136672974
Edition O O 0.9998384714126587
criteria O O 0.9999284744262695
) O O 0.9999524354934692
respond O O 0.9999750852584839
in O O 0.999990701675415
a O O 0.9999892711639404
similar O O 0.9999818801879883
way O O 0.9999935626983643
to O O 0.9999414682388306
the O O 0.9999737739562988
induction O O 0.9999923706054688
of O O 0.9999575614929199
panic O O 0.9967905879020691
attacks O O 0.9999905824661255
by O O 0.9999864101409912
an O O 0.9999725818634033
oral O O 0.9967305660247803
caffeine B B 0.9989473223686218
challenge O O 0.9928458333015442
test O O 0.9999796152114868
. O O 0.9999871253967285

We O O 0.9999544620513916
randomly O O 0.9999794960021973
selected O O 0.9999855756759644
29 O O 0.9999825954437256
patients O O 0.9999926090240479
with O O 0.9999401569366455
PD O O 0.991888701915741
, O O 0.9999600648880005
27 O O 0.999972939491272
with O O 0.9998999834060669
MDP O O 0.9828254580497742
, O O 0.999963641166687
25 O O 0.9999641180038452
with O O 0.9999674558639526
major O O 0.9998809099197388
depression O O 0.9998830556869507
without O O 0.999860405921936
panic O O 0.9877567291259766
attacks O O 0.999915361404419
( O O 0.9996566772460938
MD O O 0.979225218296051
) O O 0.9999555349349976
, O O 0.999937891960144
and O O 0.9999760389328003
28 O O 0.9999847412109375
healthy O O 0.9999659061431885
volunteers O O 0.9999977350234985
. O O 0.9999710321426392

The O O 0.9999606609344482
patients O O 0.9999885559082031
had O O 0.9999315738677979
no O O 0.9994797110557556
psychotropic O O 0.9172050356864929
drug O O 0.9816235303878784
for O O 0.999910831451416
at O O 0.9999784231185913
least O O 0.9999878406524658
a O O 0.9999829530715942
4 O O 0.9998799562454224
- O O 0.999984622001648
week O O 0.9999853372573853
period O O 0.9999814033508301
. O O 0.9999665021896362

In O O 0.9999889135360718
a O O 0.9999911785125732
randomized O O 0.99998939037323
double O O 0.9999505281448364
- O O 0.9999701976776123
blind O O 0.999995231628418
experiment O O 0.9999963045120239
performed O O 0.9999922513961792
in O O 0.999995231628418
2 O O 0.9999418258666992
occasions O O 0.9999929666519165
7 O O 0.9999817609786987
days O O 0.999995231628418
apart O O 0.9999940395355225
, O O 0.9999521970748901
480 O O 0.9937545657157898
mg O O 0.9993166923522949
caffeine B B 0.999377965927124
and O O 0.9989768266677856
a O O 0.9999109506607056
caffeine B B 0.9958422780036926
- O O 0.9258294105529785
free O O 0.9943615198135376
( O O 0.999201238155365
placebo O O 0.9998855590820312
) O O 0.9999227523803711
solution O O 0.9999455213546753
were O O 0.9999680519104004
administered O O 0.999962329864502
in O O 0.9999638795852661
a O O 0.9999831914901733
coffee O O 0.9947180151939392
form O O 0.9999780654907227
and O O 0.9999537467956543
anxiety O O 0.999460756778717
scales O O 0.9997913241386414
were O O 0.9999589920043945
applied O O 0.9999703168869019
before O O 0.9999704360961914
and O O 0.9999852180480957
after O O 0.9999836683273315
each O O 0.9999948740005493
test O O 0.9999969005584717
. O O 0.999981164932251

A O O 0.9999562501907349
total O O 0.9999840259552002
of O O 0.9999752044677734
58 O O 0.9999958276748657
. O O 0.9999850988388062
6 O O 0.9999896287918091
% O O 0.9999934434890747
( O O 0.9999692440032959
n O O 0.9998103976249695
= O O 0.9999690055847168
17 O O 0.9999967813491821
) O O 0.999968409538269
of O O 0.9999803304672241
patients O O 0.9999892711639404
with O O 0.9998550415039062
PD O O 0.9558257460594177
, O O 0.9999363422393799
44 O O 0.9999932050704956
. O O 0.9999845027923584
4 O O 0.9999808073043823
% O O 0.9999868869781494
( O O 0.9999558925628662
n O O 0.999788224697113
= O O 0.9999692440032959
12 O O 0.9999935626983643
) O O 0.9999653100967407
of O O 0.9999631643295288
patients O O 0.9999793767929077
with O O 0.999882698059082
MDP O O 0.9692930579185486
, O O 0.999946117401123
12 O O 0.9999943971633911
. O O 0.9999830722808838
0 O O 0.9999871253967285
% O O 0.999984860420227
( O O 0.9999544620513916
n O O 0.9998904466629028
= O O 0.9999659061431885
3 O O 0.9999679327011108
) O O 0.9999653100967407
of O O 0.9999442100524902
patients O O 0.9999817609786987
with O O 0.9998699426651001
MD O O 0.959648847579956
, O O 0.9998975992202759
and O O 0.9999328851699829
7 O O 0.9999799728393555
. O O 0.9999802112579346
1 O O 0.999990701675415
% O O 0.999984860420227
( O O 0.9999642372131348
n O O 0.9999129772186279
= O O 0.9999721050262451
2 O O 0.999985933303833
) O O 0.9999748468399048
of O O 0.999824583530426
control O O 0.9811076521873474
subjects O O 0.9999216794967651
had O O 0.9999783039093018
a O O 0.9999878406524658
panic O O 0.9995850920677185
attack O O 0.9999947547912598
after O O 0.9999508857727051
the O O 0.9999586343765259
480 O O 0.9104332327842712
- O O 0.9994045495986938
mg O O 0.9962354302406311
caffeine B B 0.9991827607154846
challenge O O 0.9587268829345703
test O O 0.99989914894104
( O O 0.9999326467514038
chi O O 0.9967315196990967
( O O 0.999914288520813
2 O O 0.994687557220459
) O O 0.9999146461486816
( O O 0.9994173049926758
3 O O 0.9996534585952759
) O O 0.9998946189880371
= O O 0.999333918094635
16 O O 0.9999499320983887
. O O 0.9999960660934448
22 O O 0.99997878074646
, O O 0.9999804496765137
P O O 0.9993183612823486
= O O 0.9999217987060547
. O O 0.9999977350234985
001 O O 0.9992892742156982
) O O 0.9999760389328003
. O O 0.9999747276306152

The O O 0.9999556541442871
patients O O 0.9999876022338867
with O O 0.9999258518218994
PD O O 0.9661489129066467
and O O 0.9995359182357788
MDP O O 0.7782723307609558
were O O 0.999839186668396
more O O 0.9997991919517517
sensitive O O 0.9999011754989624
to O O 0.9996155500411987
caffeine B B 0.999600350856781
than O O 0.9998044371604919
were O O 0.9999663829803467
patients O O 0.9999871253967285
with O O 0.9999117851257324
MD O O 0.9132872223854065
and O O 0.9999077320098877
healthy O O 0.999457061290741
volunteers O O 0.9999945163726807
. O O 0.9999619722366333

No O O 0.999923825263977
panic O O 0.9996700286865234
attack O O 0.9999880790710449
was O O 0.9999756813049316
observed O O 0.9999880790710449
after O O 0.9997137188911438
the O O 0.9996682405471802
caffeine B B 0.9978346228599548
- O O 0.9647635817527771
free O O 0.9862572550773621
solution O O 0.995402455329895
intake O O 0.9997071623802185
. O O 0.9999582767486572

The O O 0.99997878074646
patients O O 0.9999878406524658
with O O 0.9998857975006104
MD O O 0.9881377816200256
had O O 0.9999614953994751
a O O 0.9999854564666748
lower O O 0.9999847412109375
heart O O 0.9999929666519165
rate O O 0.9999927282333374
response O O 0.9999843835830688
to O O 0.9999833106994629
the O O 0.9999918937683105
test O O 0.9999808073043823
than O O 0.9999022483825684
all O O 0.9999005794525146
the O O 0.9999830722808838
other O O 0.9999018907546997
groups O O 0.9999876022338867
( O O 0.999944806098938
2 O O 0.9998974800109863
- O O 0.9999818801879883
way O O 0.999987006187439
analysis O O 0.99998939037323
of O O 0.9999774694442749
variance O O 0.9999960660934448
, O O 0.9998685121536255
group O O 0.999936580657959
by O O 0.9999688863754272
time O O 0.9999759197235107
interaction O O 0.9999895095825195
with O O 0.9999544620513916
Greenhouse O O 0.9554997086524963
- O O 0.999376118183136
Geisser O O 0.9993267059326172
correction O O 0.9999750852584839
: O O 0.9999518394470215
F O O 0.9999637603759766
( O O 0.9994169473648071
3 O O 0.9994556307792664
, O O 0.9998338222503662
762 O O 0.9944714307785034
) O O 0.9999512434005737
= O O 0.9999116659164429
2 O O 0.9999732971191406
. O O 0.9999932050704956
85 O O 0.999980092048645
, O O 0.9999570846557617
P O O 0.9999339580535889
= O O 0.9999761581420898
. O O 0.9999980926513672
026 O O 0.9999748468399048
) O O 0.9999740123748779
. O O 0.9999797344207764

Our O O 0.9999761581420898
data O O 0.9999880790710449
suggest O O 0.9999494552612305
that O O 0.9999595880508423
there O O 0.9999336004257202
is O O 0.999933123588562
an O O 0.9999635219573975
association O O 0.999988317489624
between O O 0.9998323917388916
panic O O 0.9929748773574829
attacks O O 0.9999622106552124
, O O 0.9999842643737793
no O O 0.999994158744812
matter O O 0.9999960660934448
if O O 0.9999798536300659
associated O O 0.9999743700027466
with O O 0.9998608827590942
PD O O 0.9210153818130493
or O O 0.9997642636299133
MDP O O 0.96965092420578
, O O 0.999950647354126
and O O 0.9998612403869629
hyperreactivity O O 0.9997909665107727
to O O 0.9998509883880615
an O O 0.9999192953109741
oral O O 0.989413857460022
caffeine B B 0.9985581040382385
challenge O O 0.9908213019371033
test O O 0.9999392032623291
. O O 0.9999651908874512

Mitral O O 0.9885870814323425
annuloplasty O O 0.8087937831878662
as O O 0.9996336698532104
a O O 0.9998055100440979
ventricular O O 0.9984562397003174
restoration O O 0.9981372356414795
method O O 0.9999856948852539
for O O 0.9999653100967407
the O O 0.9999885559082031
failing O O 0.9999905824661255
left O O 0.9999915361404419
ventricle O O 0.9999935626983643
: O O 0.9999886751174927
a O O 0.999988317489624
pilot O O 0.9999910593032837
study O O 0.9999980926513672
. O O 0.9999918937683105

BACKGROUND O O 0.9999635219573975
AND O O 0.9999909400939941
AIM O O 0.9999920129776001
OF O O 0.9999951124191284
THE O O 0.9999977350234985
STUDY O O 0.9999902248382568
: O O 0.9999474287033081
Undersized O O 0.7851366996765137
mitral O O 0.9980131387710571
annuloplasty O O 0.43756017088890076
( O O 0.9995490908622742
MAP O O 0.9825897216796875
) O O 0.999961256980896
is O O 0.999958872795105
effective O O 0.9999150037765503
in O O 0.999919056892395
patients O O 0.9999923706054688
with O O 0.999971866607666
dilated O O 0.9999291896820068
cardiomyopathy O O 0.9999977350234985
and O O 0.9998902082443237
functional O O 0.9999376535415649
mitral O O 0.9998569488525391
regurgitation O O 0.9998471736907959
( O O 0.9998915195465088
MR O O 0.999347984790802
) O O 0.9999569654464722
since O O 0.9997734427452087
, O O 0.9999873638153076
as O O 0.9999756813049316
well O O 0.9999494552612305
as O O 0.9999772310256958
addressing O O 0.9999147653579712
the O O 0.9999479055404663
MR O O 0.9868944883346558
, O O 0.9999648332595825
the O O 0.9999403953552246
MAP O O 0.9907392263412476
may O O 0.9999309778213501
also O O 0.9999220371246338
reshape O O 0.9999450445175171
the O O 0.9999808073043823
dilated O O 0.9998806715011597
left O O 0.999957799911499
ventricular O O 0.9999939203262329
( O O 0.9998242259025574
LV O O 0.9860388040542603
) O O 0.9999126195907593
base O O 0.9999889135360718
. O O 0.999968409538269

However O O 0.9999592304229736
, O O 0.9999731779098511
the O O 0.9999710321426392
direct O O 0.9999567270278931
benefits O O 0.9999924898147583
of O O 0.9999676942825317
this O O 0.9999563694000244
possible O O 0.9998168349266052
reshaping O O 0.9998968839645386
on O O 0.9997473359107971
LV O O 0.9735621809959412
function O O 0.9999605417251587
in O O 0.9999641180038452
the O O 0.9999686479568481
absence O O 0.9999295473098755
of O O 0.9999538660049438
underlying O O 0.9998044371604919
MR O O 0.9598866701126099
remain O O 0.9999626874923706
incompletely O O 0.9999914169311523
understood O O 0.999993085861206
. O O 0.9999725818634033

The O O 0.9999809265136719
study O O 0.999991774559021
aim O O 0.9999926090240479
was O O 0.9999960660934448
to O O 0.9999923706054688
identify O O 0.9999628067016602
these O O 0.9998127818107605
benefits O O 0.9998631477355957
in O O 0.9999785423278809
a O O 0.9999614953994751
canine O O 0.9998564720153809
model O O 0.9999935626983643
of O O 0.9999752044677734
acute O O 0.999984860420227
heart O O 0.9999942779541016
failure O O 0.9999921321868896
. O O 0.9999769926071167

METHODS O O 0.9998031258583069
: O O 0.9999977350234985
Six O O 0.999998927116394
dogs O O 0.9999983310699463
underwent O O 0.9999897480010986
MAP O O 0.9999097585678101
with O O 0.9999948740005493
a O O 0.9999468326568604
prosthetic O O 0.9992921352386475
band O O 0.9999144077301025
on O O 0.9999529123306274
the O O 0.99998939037323
posterior O O 0.9999639987945557
mitral O O 0.9999644756317139
annulus O O 0.9992432594299316
, O O 0.9999856948852539
using O O 0.9999712705612183
four O O 0.9941335320472717
mattress O O 0.9995467066764832
sutures O O 0.9988671541213989
. O O 0.9999688863754272

The O O 0.9999669790267944
sutures O O 0.9949772953987122
were O O 0.999946117401123
passed O O 0.99997878074646
individually O O 0.9999752044677734
through O O 0.9998949766159058
four O O 0.9945796728134155
tourniquets O O 0.9901553392410278
and O O 0.9999560117721558
exteriorized O O 0.999847412109375
untied O O 0.9835288524627686
via O O 0.9999749660491943
the O O 0.9999955892562866
left O O 0.9999949932098389
atriotomy O O 0.9999648332595825
. O O 0.9999701976776123

Sonomicrometry O O 0.9950405955314636
crystals O O 0.999937891960144
were O O 0.9999741315841675
implanted O O 0.9999927282333374
around O O 0.9999312162399292
the O O 0.9999781847000122
mitral O O 0.999929666519165
annulus O O 0.9992201328277588
and O O 0.9998610019683838
left O O 0.9999810457229614
ventricle O O 0.9999915361404419
to O O 0.9999672174453735
measure O O 0.9998998641967773
geometry O O 0.9764418601989746
and O O 0.9999068975448608
regional O O 0.9999608993530273
function O O 0.9999927282333374
. O O 0.999974250793457

Acute O O 0.9999707937240601
heart O O 0.9999964237213135
failure O O 0.9999974966049194
was O O 0.9999843835830688
induced O O 0.9999951124191284
by O O 0.9999074935913086
propranolol B B 0.999792754650116
and O O 0.998479425907135
volume O O 0.9814808368682861
loading O O 0.9998212456703186
after O O 0.9999428987503052
weaning O O 0.999997615814209
from O O 0.9999796152114868
cardiopulmonary O O 0.999995231628418
bypass O O 0.9999831914901733
; O O 0.9999879598617554
an O O 0.9999951124191284
absence O O 0.9999074935913086
of O O 0.999570906162262
MR O O 0.9329984784126282
was O O 0.9999881982803345
confirmed O O 0.9999951124191284
by O O 0.9999974966049194
echocardiography O O 0.9999514818191528
. O O 0.9999792575836182

MAP O O 0.9997363686561584
was O O 0.9999829530715942
accomplished O O 0.9999905824661255
by O O 0.9999632835388184
cinching O O 0.9785471558570862
the O O 0.9999655485153198
tourniquets O O 0.9958692193031311
. O O 0.9999338388442993

Data O O 0.9999498128890991
were O O 0.9999903440475464
acquired O O 0.999994158744812
at O O 0.9999831914901733
baseline O O 0.999992847442627
, O O 0.9999872446060181
after O O 0.9998748302459717
induction O O 0.9999936819076538
of O O 0.9999827146530151
acute O O 0.9999758005142212
heart O O 0.9999921321868896
failure O O 0.9999810457229614
, O O 0.9999274015426636
and O O 0.9998626708984375
after O O 0.9997230172157288
MAP O O 0.642227828502655
. O O 0.9999725818634033

RESULTS O O 0.9997723698616028
: O O 0.9992530941963196
MAP O O 0.9998182654380798
decreased O O 0.9999818801879883
mitral O O 0.9999212026596069
annular O O 0.9955592155456543
dimensions O O 0.9999792575836182
in O O 0.9999561309814453
both O O 0.9998595714569092
commissure O O 0.9939801692962646
- O O 0.9985003471374512
commissure O O 0.9979764819145203
and O O 0.9998502731323242
septal O O 0.9984560012817383
- O O 0.9995892643928528
lateral O O 0.9997499585151672
directions O O 0.9999445676803589
. O O 0.9999637603759766

Concomitantly O O 0.9997583031654358
, O O 0.9999691247940063
the O O 0.999980092048645
diastolic O O 0.999895453453064
diameter O O 0.9998931884765625
of O O 0.9998779296875
the O O 0.9998936653137207
LV O O 0.9709779620170593
base O O 0.9999518394470215
and O O 0.9995697140693665
LV O O 0.9148457646369934
sphericity O O 0.9991496801376343
decreased O O 0.9999676942825317
( O O 0.999967098236084
i O O 0.9999890327453613
. O O 0.9999843835830688
e O O 0.9999922513961792
. O O 0.9999935626983643
, O O 0.999983549118042
improved O O 0.9999464750289917
) O O 0.9999871253967285
from O O 0.9999908208847046
37 O O 0.9999973773956299
. O O 0.9999948740005493
4 O O 0.9999783039093018
+ O O 0.999988317489624
/ O O 0.9999744892120361
- O O 0.9999392032623291
9 O O 0.9999144077301025
. O O 0.9999940395355225
3 O O 0.9999502897262573
to O O 0.9999613761901855
35 O O 0.9999915361404419
. O O 0.9999964237213135
9 O O 0.9999908208847046
+ O O 0.9999852180480957
/ O O 0.9999754428863525
- O O 0.9999772310256958
10 O O 0.9999881982803345
mm O O 0.9999984502792358
( O O 0.9999756813049316
p O O 0.9999608993530273
= O O 0.9999704360961914
0 O O 0.9999939203262329
. O O 0.999997615814209
063 O O 0.9999858140945435
) O O 0.9999780654907227
, O O 0.9999644756317139
and O O 0.9999760389328003
from O O 0.999988317489624
67 O O 0.9999960660934448
. O O 0.9999949932098389
9 O O 0.9999892711639404
+ O O 0.999981164932251
/ O O 0.9999154806137085
- O O 0.9999270439147949
18 O O 0.9999548196792603
. O O 0.999983549118042
6 O O 0.9999942779541016
% O O 0.9999948740005493
to O O 0.999915599822998
65 O O 0.9999954700469971
. O O 0.9999947547912598
3 O O 0.9999839067459106
+ O O 0.999981164932251
/ O O 0.9997959733009338
- O O 0.9999332427978516
18 O O 0.9999408721923828
. O O 0.9999902248382568
9 O O 0.9999923706054688
% O O 0.9999940395355225
( O O 0.9999672174453735
p O O 0.9999009370803833
= O O 0.9998981952667236
0 O O 0.9999854564666748
. O O 0.9999945163726807
016 O O 0.9999939203262329
) O O 0.9999786615371704
, O O 0.9999836683273315
respectively O O 0.9999709129333496
. O O 0.9999648332595825

Decreases O O 0.9998502731323242
were O O 0.9999819993972778
evident O O 0.9999955892562866
in O O 0.9999603033065796
both O O 0.9997995495796204
LV O O 0.9196878671646118
end O O 0.9988012313842773
- O O 0.9976494908332825
diastolic O O 0.999930739402771
pressure O O 0.9998052716255188
( O O 0.9999711513519287
from O O 0.9999874830245972
17 O O 0.9999221563339233
+ O O 0.999985933303833
/ O O 0.9999915361404419
- O O 0.9998902082443237
7 O O 0.9998949766159058
to O O 0.9999505281448364
15 O O 0.9999918937683105
+ O O 0.999984622001648
/ O O 0.9999735355377197
- O O 0.9999514818191528
6 O O 0.9999651908874512
mmHg O O 0.9999901056289673
, O O 0.9999712705612183
p O O 0.9999605417251587
= O O 0.9998853206634521
0 O O 0.9999926090240479
. O O 0.9999970197677612
0480 O O 0.9998326301574707
and O O 0.999701201915741
Tau O O 0.9872516393661499
( O O 0.9999397993087769
from O O 0.9999860525131226
48 O O 0.9999735355377197
+ O O 0.9999879598617554
/ O O 0.9999836683273315
- O O 0.9998658895492554
8 O O 0.9951613545417786
to O O 0.9999611377716064
45 O O 0.9999823570251465
+ O O 0.9999911785125732
/ O O 0.9999740123748779
- O O 0.9999610185623169
8 O O 0.999184787273407
ms O O 0.9999978542327881
, O O 0.9999681711196899
p O O 0.9999593496322632
< O O 0.9999793767929077
0 O O 0.9999908208847046
. O O 0.9999940395355225
01 O O 0.9999959468841553
) O O 0.9999562501907349
, O O 0.9999613761901855
while O O 0.9999474287033081
fractional O O 0.999992847442627
shortening O O 0.9999914169311523
at O O 0.9999642372131348
the O O 0.9999634027481079
LV O O 0.9771807193756104
base O O 0.999983549118042
increased O O 0.9999275207519531
from O O 0.9999860525131226
7 O O 0.9999575614929199
. O O 0.9999903440475464
7 O O 0.9999858140945435
+ O O 0.9999783039093018
/ O O 0.9999713897705078
- O O 0.999945878982544
4 O O 0.9999392032623291
. O O 0.9999830722808838
5 O O 0.9999818801879883
% O O 0.9999955892562866
to O O 0.9999816417694092
9 O O 0.9999910593032837
. O O 0.999995231628418
4 O O 0.9999871253967285
+ O O 0.9999896287918091
/ O O 0.9999847412109375
- O O 0.9999610185623169
4 O O 0.9999440908432007
. O O 0.9999873638153076
5 O O 0.9999881982803345
% O O 0.9999963045120239
( O O 0.999977707862854
p O O 0.9999393224716187
= O O 0.9999756813049316
0 O O 0.9999833106994629
. O O 0.9999971389770508
045 O O 0.9924430251121521
) O O 0.9999750852584839
. O O 0.9999711513519287

After O O 0.9992788434028625
MAP O O 0.9964828491210938
, O O 0.9999055862426758
increases O O 0.9999812841415405
were O O 0.9999839067459106
identified O O 0.9999970197677612
in O O 0.999961256980896
both O O 0.9998120665550232
cardiac O O 0.999847412109375
output O O 0.9999691247940063
( O O 0.9999822378158569
from O O 0.9999887943267822
1 O O 0.9999668598175049
. O O 0.9999940395355225
54 O O 0.9999884366989136
+ O O 0.9999840259552002
/ O O 0.999884843826294
- O O 0.999943733215332
0 O O 0.9999475479125977
. O O 0.9999967813491821
57 O O 0.9999948740005493
to O O 0.9999555349349976
1 O O 0.999987006187439
. O O 0.9999942779541016
65 O O 0.9999896287918091
+ O O 0.9999755620956421
/ O O 0.9996053576469421
- O O 0.9998534917831421
0 O O 0.999845027923584
. O O 0.9999936819076538
57 O O 0.9999773502349854
1 O O 0.9996036887168884
/ O O 0.9999791383743286
min O O 0.9999861717224121
) O O 0.9999555349349976
and O O 0.9997547268867493
Emax O O 0.9922582507133484
( O O 0.9999659061431885
from O O 0.9999899864196777
1 O O 0.9999693632125854
. O O 0.9999817609786987
86 O O 0.9998194575309753
+ O O 0.9999803304672241
/ O O 0.9999524354934692
- O O 0.9999649524688721
0 O O 0.9999731779098511
. O O 0.999984622001648
9 O O 0.9999909400939941
to O O 0.9999616146087646
2 O O 0.9999831914901733
. O O 0.999993085861206
41 O O 0.9999833106994629
+ O O 0.9999867677688599
/ O O 0.9999734163284302
- O O 0.9999715089797974
1 O O 0.9999903440475464
. O O 0.9999951124191284
31 O O 0.9999886751174927
mmHg O O 0.9999942779541016
/ O O 0.9999587535858154
ml O O 0.9999969005584717
) O O 0.9999667406082153
. O O 0.9999738931655884

CONCLUSION O O 0.9997370839118958
: O O 0.99997878074646
The O O 0.9999942779541016
data O O 0.9999879598617554
acquired O O 0.9999722242355347
suggest O O 0.9999743700027466
that O O 0.9998692274093628
isolated O O 0.8610270619392395
MAP O B 0.9612326622009277
may O O 0.9998086094856262
have O O 0.9999113082885742
certain O O 0.9996904134750366
benefits O O 0.9999120235443115
on O O 0.9997979998588562
LV O O 0.911575436592102
dimension O O 0.999852180480957
/ O O 0.9997796416282654
function O O 0.9999805688858032
in O O 0.999948263168335
acute O O 0.9999644756317139
heart O O 0.9999879598617554
failure O O 0.9999867677688599
, O O 0.9999821186065674
even O O 0.9999477863311768
in O O 0.9999886751174927
the O O 0.999990701675415
absence O O 0.9999557733535767
of O O 0.9997850060462952
MR O O 0.5178667306900024
. O O 0.999864935874939

However O O 0.9999635219573975
, O O 0.9999771118164062
further O O 0.9999867677688599
investigations O O 0.99998939037323
are O O 0.9999891519546509
warranted O O 0.9999858140945435
in O O 0.9999842643737793
a O O 0.9999426603317261
model O O 0.9999898672103882
of O O 0.9999728202819824
chronic O O 0.9999434947967529
heart O O 0.9999866485595703
failure O O 0.9999878406524658
. O O 0.999976396560669

Piperacillin B B 0.9987906813621521
/ I O 0.8865357637405396
tazobactam I B 0.8186731338500977
- O O 0.9997792840003967
induced O O 0.9999567270278931
seizure O O 0.9999852180480957
rapidly O O 0.9999728202819824
reversed O O 0.9999829530715942
by O O 0.9999500513076782
high O O 0.9978686571121216
flux O O 0.9979210495948792
hemodialysis O O 0.9992406368255615
in O O 0.9999691247940063
a O O 0.9999853372573853
patient O O 0.9999898672103882
on O O 0.9999130964279175
peritoneal O O 0.9998103976249695
dialysis O O 0.9993857145309448
. O O 0.999966025352478

Despite O O 0.999937891960144
popular O O 0.9985395669937134
use O O 0.9998629093170166
of O O 0.9992392063140869
piperacillin B B 0.9952415227890015
, O O 0.9998375177383423
the O O 0.9999791383743286
dire O O 0.9993091821670532
neurotoxicity O O 0.9999879598617554
associated O O 0.9999791383743286
with O O 0.9997197985649109
piperacillin B B 0.9968133568763733
still O O 0.999796450138092
goes O O 0.9999887943267822
unrecognized O O 0.99998939037323
, O O 0.9999871253967285
leading O O 0.9999966621398926
to O O 0.999995231628418
a O O 0.9999951124191284
delay O O 0.9999991655349731
in O O 0.9999969005584717
appropriate O O 0.9999904632568359
management O O 0.9999960660934448
. O O 0.9999855756759644

We O O 0.9999867677688599
report O O 0.9999982118606567
a O O 0.9999967813491821
57 O O 0.9999984502792358
- O O 0.9999866485595703
year O O 0.9999963045120239
- O O 0.9999935626983643
old O O 0.9999963045120239
woman O O 0.9999984502792358
with O O 0.9999790191650391
end O O 0.9999493360519409
- O O 0.9999682903289795
stage O O 0.9999890327453613
renal O O 0.9999899864196777
disease O O 0.9999961853027344
receiving O O 0.9999271631240845
continuous O O 0.9996552467346191
ambulatory O O 0.9978718757629395
peritoneal O O 0.9730263352394104
dialysis O O 0.9962499737739563
( O O 0.9996566772460938
CAPD O O 0.8253004550933838
) O O 0.9999687671661377
, O O 0.999984860420227
who O O 0.9999749660491943
developed O O 0.999995231628418
slurred O O 0.999994158744812
speech O O 0.9999992847442627
, O O 0.999980092048645
tremor O O 0.9999446868896484
, O O 0.9999752044677734
bizarre O O 0.9999852180480957
behavior O O 0.999997615814209
, O O 0.9999784231185913
progressive O O 0.9999889135360718
mental O O 0.9999960660934448
confusion O O 0.9999984502792358
, O O 0.9999814033508301
and O O 0.9999839067459106
2 O O 0.9999641180038452
episodes O O 0.9999967813491821
of O O 0.9999876022338867
generalized O O 0.999906063079834
tonic O O 0.999962568283081
- O O 0.9985412359237671
clonic O O 0.9997065663337708
seizure O O 0.9999947547912598
( O O 0.9999470710754395
GTCS O O 0.9951466917991638
) O O 0.9999868869781494
after O O 0.9999767541885376
5 O O 0.9987102746963501
doses O O 0.9998760223388672
of O O 0.9991820454597473
piperacillin B B 0.9974973797798157
/ I O 0.8981770277023315
tazobactam I B 0.6284950971603394
( O O 0.9938272833824158
2 O O 0.9985697269439697
g O O 0.9795274138450623
/ O O 0.9994598031044006
250 O O 0.9945730566978455
mg O O 0.9993417859077454
) O O 0.9998990297317505
were O O 0.9999775886535645
given O O 0.9998509883880615
for O O 0.9999120235443115
bronchiectasis O O 0.9997491240501404
with O O 0.999976634979248
secondary O O 0.9999549388885498
infection O O 0.9999947547912598
. O O 0.999974250793457

The O O 0.9999854564666748
laboratory O O 0.9999744892120361
data O O 0.9999889135360718
revealed O O 0.9999679327011108
normal O O 0.9999203681945801
plasma O O 0.9893325567245483
electrolyte O B 0.8601767420768738
and O O 0.9966145157814026
ammonia B B 0.9990449547767639
levels O O 0.9998216032981873
but O O 0.9996525049209595
leukocytosis O O 0.9993547797203064
. O O 0.9999672174453735

Neurologic O O 0.9999659061431885
examinations O O 0.9999940395355225
showed O O 0.9999481439590454
dysarthria O O 0.9999936819076538
and O O 0.999942421913147
bilateral O O 0.9994035959243774
Babinski O O 0.9973258972167969
sign O O 0.9999659061431885
. O O 0.9999643564224243

Computed O O 0.9998028874397278
tomography O O 0.9997219443321228
of O O 0.9998152852058411
brain O O 0.9999840259552002
and O O 0.9999639987945557
electroencephalogram O O 0.9999562501907349
were O O 0.9999483823776245
unremarkable O O 0.9999740123748779
. O O 0.9999700784683228

Despite O O 0.9999258518218994
the O O 0.9999823570251465
use O O 0.9998632669448853
of O O 0.9997900128364563
antiepileptic O O 0.8642992973327637
agents O O 0.9854397177696228
, O O 0.9999353885650635
another O O 0.999988317489624
GTCS O O 0.9958176016807556
episode O O 0.9999914169311523
recurred O O 0.9999853372573853
after O O 0.9998233914375305
the O O 0.9999743700027466
sixth O O 0.9995755553245544
dose O O 0.9995875954627991
of O O 0.9972612857818604
piperacillin B B 0.997538685798645
/ I O 0.8090444207191467
tazobactam I B 0.8750206828117371
. O O 0.9999234676361084

Brain O O 0.9999579191207886
magnetic O O 0.9999139308929443
resonance O O 0.9999604225158691
imaging O O 0.9999860525131226
did O O 0.999974250793457
not O O 0.9999769926071167
demonstrate O O 0.9999200105667114
acute O O 0.999756395816803
infarction O O 0.9999481439590454
and O O 0.9998359680175781
organic O O 0.9332725405693054
brain O O 0.9999436140060425
lesions O O 0.9999905824661255
. O O 0.9999638795852661

Initiation O O 0.9999674558639526
of O O 0.9999215602874756
high O O 0.9861229658126831
- O O 0.9997730851173401
flux O O 0.9756041169166565
hemodialysis O O 0.8875681161880493
rapidly O O 0.9998877048492432
reversed O O 0.9999592304229736
the O O 0.999991774559021
neurologic O O 0.9999972581863403
symptoms O O 0.9999978542327881
within O O 0.9999880790710449
4 O O 0.9998297691345215
hours O O 0.9999953508377075
. O O 0.9999778270721436

Piperacillin B B 0.9993919134140015
- O O 0.9995414018630981
induced O O 0.9998682737350464
encephalopathy O O 0.9998558759689331
should O O 0.9999357461929321
be O O 0.9999874830245972
considered O O 0.999982476234436
in O O 0.9999749660491943
any O O 0.9999752044677734
uremic O O 0.9982919096946716
patients O O 0.9999723434448242
with O O 0.9999653100967407
unexplained O O 0.999442994594574
neurological O O 0.9999946355819702
manifestations O O 0.9999945163726807
. O O 0.999980092048645

CAPD O B 0.9745094180107117
is O O 0.9995474219322205
inefficient O O 0.9999219179153442
in O O 0.9999293088912964
removing O O 0.9997730851173401
piperacillin B B 0.9981648325920105
, O O 0.9993765950202942
whereas O O 0.9995645880699158
hemodialysis O O 0.9985681772232056
can O O 0.9998558759689331
rapidly O O 0.9999741315841675
terminate O O 0.9999469518661499
the O O 0.999987006187439
piperacillin B B 0.9988396763801575
- O O 0.999885082244873
induced O O 0.9999622106552124
encephalopathy O O 0.99997878074646
. O O 0.9999680519104004

Frequency O O 0.999983549118042
of O O 0.9999854564666748
transient O O 0.9999911785125732
ipsilateral O O 0.9999741315841675
vocal O O 0.9999659061431885
cord O O 0.9999635219573975
paralysis O O 0.9999312162399292
in O O 0.9999514818191528
patients O O 0.9999910593032837
undergoing O O 0.9999256134033203
carotid O O 0.9879807829856873
endarterectomy O O 0.9946696162223816
under O O 0.9999556541442871
local O O 0.999866247177124
anesthesia O O 0.998514711856842
. O O 0.999944806098938

BACKGROUND O O 0.9956543445587158
: O O 0.9999873638153076
Especially O O 0.9999935626983643
because O O 0.9999984502792358
of O O 0.9999935626983643
improvements O O 0.9999982118606567
in O O 0.9999961853027344
clinical O O 0.9999940395355225
neurologic O O 0.9999974966049194
monitoring O O 0.9999971389770508
, O O 0.9999401569366455
carotid O O 0.9994304776191711
endarterectomy O O 0.9986478686332703
done O O 0.9999759197235107
under O O 0.9999570846557617
local O O 0.9997416138648987
anesthesia O O 0.9993545413017273
has O O 0.9999815225601196
become O O 0.999996542930603
the O O 0.999990701675415
technique O O 0.9999955892562866
of O O 0.9999840259552002
choice O O 0.9999879598617554
in O O 0.999977707862854
several O O 0.9999850988388062
centers O O 0.999985933303833
. O O 0.9999802112579346

Temporary O O 0.9996392726898193
ipsilateral O O 0.9999581575393677
vocal O O 0.9997261166572571
nerve O O 0.9999591112136841
palsies O O 0.9999902248382568
due O O 0.9999572038650513
to O O 0.9994691014289856
local O O 0.9862288236618042
anesthetics O O 0.9385936260223389
have O O 0.9999388456344604
been O O 0.9999831914901733
described O O 0.9999699592590332
, O O 0.9999685287475586
however O O 0.9999520778656006
. O O 0.9999662637710571

Such O O 0.9998332262039185
complications O O 0.999983549118042
are O O 0.9999817609786987
most O O 0.9999759197235107
important O O 0.9999827146530151
in O O 0.9999662637710571
situations O O 0.9999569654464722
where O O 0.999941349029541
there O O 0.9999701976776123
is O O 0.9999734163284302
a O O 0.9999716281890869
pre O O 0.999550998210907
- O O 0.9999810457229614
existing O O 0.9999915361404419
contralateral O O 0.9998775720596313
paralysis O O 0.9999279975891113
. O O 0.9999599456787109

We O O 0.9999568462371826
therefore O O 0.9999939203262329
examined O O 0.9999767541885376
the O O 0.9999847412109375
effect O O 0.9999692440032959
of O O 0.999909520149231
local O O 0.9995131492614746
anesthesia O O 0.7879557609558105
on O O 0.999785840511322
vocal O O 0.9998941421508789
cord O O 0.999970555305481
function O O 0.9999905824661255
to O O 0.9999891519546509
better O O 0.9999923706054688
understand O O 0.9999891519546509
its O O 0.9999773502349854
possible O O 0.999983549118042
consequences O O 0.9999957084655762
. O O 0.999976396560669

METHODS O O 0.9998602867126465
: O O 0.9999845027923584
This O O 0.9999927282333374
prospective O O 0.9999909400939941
study O O 0.9999933242797852
included O O 0.9999909400939941
28 O O 0.9999852180480957
patients O O 0.9999958276748657
undergoing O O 0.9999808073043823
carotid O O 0.9997814297676086
endarterectomy O O 0.9996669292449951
under O O 0.9999736547470093
local O O 0.9999375343322754
anesthesia O O 0.9999533891677856
. O O 0.9999728202819824

Vocal O O 0.9983933568000793
cord O O 0.9999216794967651
function O O 0.9999818801879883
was O O 0.9999774694442749
evaluated O O 0.9999887943267822
before O O 0.9999246597290039
, O O 0.9998559951782227
during O O 0.9999498128890991
, O O 0.9999415874481201
and O O 0.9999125003814697
after O O 0.9999309778213501
surgery O O 0.9999955892562866
( O O 0.9999597072601318
postoperative O O 0.9999923706054688
day O O 0.999998927116394
1 O O 0.9999980926513672
) O O 0.9999924898147583
using O O 0.999991774559021
flexible O O 0.9999898672103882
laryngoscopy O O 0.9999810457229614
. O O 0.9999812841415405

Anesthesia O O 0.9999617338180542
was O O 0.9999772310256958
performed O O 0.9999943971633911
by O O 0.9999816417694092
injecting O O 0.9999903440475464
20 O O 0.999984860420227
to O O 0.9999966621398926
40 O O 0.9999915361404419
mL O O 0.9999934434890747
of O O 0.9998894929885864
a O O 0.9999662637710571
mixture O O 0.9922575950622559
of O O 0.9983401298522949
long O O 0.9785264730453491
- O O 0.9998445510864258
acting O O 0.9942981600761414
( O O 0.9941762685775757
ropivacaine B B 0.998623251914978
) O O 0.9952405691146851
and O O 0.9983787536621094
short O O 0.9822788238525391
- O O 0.9995536208152771
acting O O 0.9905357956886292
( O O 0.9948167204856873
prilocaine B B 0.9978850483894348
) O O 0.9981449842453003
anesthetic O O 0.7980342507362366
. O O 0.9999710321426392

RESULTS O O 0.9990536570549011
: O O 0.9998868703842163
All O O 0.9998593330383301
patients O O 0.9999903440475464
had O O 0.9999823570251465
normal O O 0.9999856948852539
vocal O O 0.9998338222503662
cord O O 0.999828577041626
function O O 0.9999921321868896
preoperatively O O 0.9999481439590454
. O O 0.9999793767929077

Twelve O O 0.999870777130127
patients O O 0.9999933242797852
( O O 0.9999775886535645
43 O O 0.9999926090240479
% O O 0.9999942779541016
) O O 0.9999716281890869
were O O 0.9999898672103882
found O O 0.9999958276748657
to O O 0.9999827146530151
have O O 0.9999775886535645
intraoperative O O 0.9999878406524658
ipsilateral O O 0.9999421834945679
vocal O O 0.9999270439147949
cord O O 0.9999790191650391
paralysis O O 0.9998594522476196
. O O 0.9999737739562988

It O O 0.9999600648880005
resolved O O 0.9999485015869141
in O O 0.9998995065689087
all O O 0.9998739957809448
cases O O 0.9999667406082153
< O O 0.999981164932251
or O O 0.9999573230743408
= O O 0.9999649524688721
24 O O 0.9999865293502808
hours O O 0.9999788999557495
. O O 0.9999613761901855

There O O 0.9999827146530151
were O O 0.9999858140945435
no O O 0.99998939037323
significant O O 0.9999951124191284
differences O O 0.9999978542327881
in O O 0.9999948740005493
operating O O 0.9999967813491821
time O O 0.9999984502792358
or O O 0.9999908208847046
volume O O 0.999963641166687
or O O 0.9999877214431763
frequency O O 0.9999924898147583
of O O 0.9999152421951294
anesthetic O O 0.8616200685501099
administration O O 0.9999004602432251
in O O 0.999925971031189
patients O O 0.9999949932098389
with O O 0.9999762773513794
temporary O O 0.9999443292617798
vocal O O 0.9998968839645386
cord O O 0.9999122619628906
paralysis O O 0.9998432397842407
compared O O 0.9999737739562988
with O O 0.9999921321868896
those O O 0.9999833106994629
without O O 0.9999607801437378
. O O 0.9999666213989258

CONCLUSION O O 0.9987584352493286
: O O 0.9997939467430115
Local O O 0.9946867227554321
anesthesia O O 0.9490070343017578
led O O 0.9999656677246094
to O O 0.9999761581420898
temporary O O 0.9999479055404663
ipsilateral O O 0.9999644756317139
vocal O O 0.9999562501907349
cord O O 0.9999802112579346
paralysis O O 0.9999734163284302
in O O 0.9999562501907349
almost O O 0.999991774559021
half O O 0.999993085861206
of O O 0.9999823570251465
these O O 0.9999799728393555
patients O O 0.9999951124191284
. O O 0.9999752044677734

Because O O 0.9998942613601685
pre O O 0.9985092282295227
- O O 0.9999558925628662
existing O O 0.9999659061431885
paralysis O O 0.99954754114151
is O O 0.9999514818191528
of O O 0.9999686479568481
a O O 0.999950647354126
relevant O O 0.9997088313102722
frequency O O 0.9999948740005493
( O O 0.9999721050262451
up O O 0.9999914169311523
to O O 0.9999929666519165
3 O O 0.9999169111251831
% O O 0.9999887943267822
) O O 0.9999738931655884
, O O 0.999975323677063
a O O 0.9999896287918091
preoperative O O 0.9999523162841797
evaluation O O 0.9999947547912598
of O O 0.9999699592590332
vocal O O 0.9998151659965515
cord O O 0.9999465942382812
function O O 0.9999847412109375
before O O 0.999679446220398
carotid O O 0.9979231953620911
endarterectomy O O 0.998784601688385
under O O 0.999955415725708
local O O 0.9998403787612915
anesthesia O O 0.9998825788497925
is O O 0.9999768733978271
recommended O O 0.9999886751174927
to O O 0.999983549118042
avoid O O 0.9999638795852661
intraoperative O O 0.9999854564666748
bilateral O O 0.9999756813049316
paralysis O O 0.9999220371246338
. O O 0.9999809265136719

In O O 0.9999655485153198
patients O O 0.9999923706054688
with O O 0.9999866485595703
preoperative O O 0.9999239444732666
contralateral O O 0.9996509552001953
vocal O O 0.9998371601104736
cord O O 0.9998216032981873
paralysis O O 0.9999152421951294
, O O 0.9999772310256958
surgery O O 0.9999939203262329
under O O 0.9999797344207764
general O O 0.9999873638153076
anesthesia O O 0.9999804496765137
should O O 0.999983549118042
be O O 0.9999978542327881
considered O O 0.9999964237213135
. O O 0.9999841451644897

Impaired O O 0.9999475479125977
fear O O 0.9998441934585571
recognition O O 0.9999598264694214
in O O 0.9998562335968018
regular O O 0.9930499792098999
recreational O O 0.5068108439445496
cocaine B B 0.8895027041435242
users O O 0.9987150430679321
. O O 0.9998551607131958

INTRODUCTION O O 0.9914491772651672
: O O 0.9999576807022095
The O O 0.9999778270721436
ability O O 0.9999878406524658
to O O 0.9999933242797852
read O O 0.9999854564666748
facial O O 0.999848484992981
expressions O O 0.9998923540115356
is O O 0.9999474287033081
essential O O 0.9999725818634033
for O O 0.9999651908874512
normal O O 0.999954104423523
human O O 0.9999872446060181
social O O 0.9998835325241089
interaction O O 0.999995231628418
. O O 0.9999659061431885

The O O 0.9999886751174927
aim O O 0.9999972581863403
of O O 0.9999940395355225
the O O 0.9999958276748657
present O O 0.9999897480010986
study O O 0.9999854564666748
was O O 0.9999949932098389
to O O 0.9999942779541016
conduct O O 0.9999980926513672
the O O 0.9999946355819702
first O O 0.9999969005584717
investigation O O 0.9999954700469971
of O O 0.999970555305481
facial O O 0.9997714161872864
expression O O 0.992429792881012
recognition O O 0.9999551773071289
performance O O 0.9999858140945435
in O O 0.9999260902404785
recreational O O 0.8556196689605713
cocaine B B 0.987555205821991
users O O 0.9994729161262512
. O O 0.999947190284729

MATERIALS O O 0.9999423027038574
AND O O 0.999988317489624
METHODS O O 0.9999936819076538
: O O 0.9999803304672241
Three O O 0.9998559951782227
groups O O 0.9999691247940063
, O O 0.9999825954437256
comprised O O 0.9999781847000122
of O O 0.9999005794525146
21 O O 0.9993109703063965
cocaine B B 0.9511314034461975
naive O O 0.780930757522583
participants O O 0.9963943362236023
( O O 0.9965527057647705
CN O O 0.6140082478523254
) O O 0.9990063309669495
, O O 0.9999134540557861
30 O O 0.9999219179153442
occasional O O 0.9796485304832458
cocaine B B 0.9835575819015503
( O O 0.9876229763031006
OC O O 0.6580684781074524
) O O 0.9993178844451904
, O O 0.9998239874839783
and O O 0.9998753070831299
48 O O 0.9997721314430237
regular O O 0.9926509261131287
recreational O O 0.8680353164672852
cocaine B B 0.9798768162727356
( O O 0.9706494808197021
RC O O 0.6456105709075928
) O O 0.9871858954429626
users O O 0.9998606443405151
, O O 0.9999618530273438
were O O 0.9999717473983765
compared O O 0.9999613761901855
. O O 0.9999641180038452

An O O 0.9999716281890869
emotional O O 0.999344527721405
facial O O 0.999575674533844
expression O O 0.9999001026153564
( O O 0.99989914894104
EFE O O 0.9934576153755188
) O O 0.9999215602874756
task O O 0.9999899864196777
consisting O O 0.9999638795852661
of O O 0.9999642372131348
a O O 0.9999656677246094
male O O 0.999826967716217
and O O 0.9999252557754517
female O O 0.999929666519165
face O O 0.9999744892120361
expressing O O 0.9998865127563477
six O O 0.9978657364845276
basic O O 0.9999449253082275
emotions O O 0.9998472929000854
( O O 0.9998679161071777
happiness O O 0.9954724907875061
, O O 0.9997913241386414
surprise O O 0.9999861717224121
, O O 0.9998351335525513
sadness O O 0.9948306679725647
, O O 0.9996935129165649
anger O O 0.8805845975875854
, O O 0.9993294477462769
fear O O 0.9999293088912964
, O O 0.9997501969337463
and O O 0.9990672469139099
disgust O O 0.9997696280479431
) O O 0.9999685287475586
was O O 0.9999628067016602
administered O O 0.9999746084213257
. O O 0.999954342842102

Mean O O 0.9999109506607056
percent O O 0.9999847412109375
accuracy O O 0.9999960660934448
and O O 0.9999710321426392
latencies O O 0.9999935626983643
for O O 0.9999768733978271
correct O O 0.999985933303833
responses O O 0.9999933242797852
across O O 0.9999734163284302
eight O O 0.9999579191207886
presentations O O 0.9999881982803345
of O O 0.9999164342880249
each O O 0.999880313873291
basic O O 0.9995695948600769
emotion O O 0.978344202041626
were O O 0.9999594688415527
derived O O 0.9999915361404419
. O O 0.999968409538269

Participants O O 0.9998446702957153
were O O 0.9999903440475464
also O O 0.9999809265136719
assessed O O 0.999991774559021
with O O 0.9999802112579346
the O O 0.9999344348907471
" O O 0.9998788833618164
Eyes O O 0.9988258481025696
task O O 0.9999828338623047
" O O 0.9999890327453613
to O O 0.9999804496765137
investigate O O 0.9999650716781616
their O O 0.9999880790710449
ability O O 0.9999903440475464
to O O 0.9999909400939941
recognize O O 0.9999945163726807
more O O 0.999969482421875
complex O O 0.9999897480010986
emotional O O 0.9997909665107727
states O O 0.9999936819076538
and O O 0.9998979568481445
the O O 0.99992835521698
Symptom O O 0.9862745404243469
CheckList O O 0.998571515083313
- O O 0.9931540489196777
90 O O 0.8919358849525452
- O O 0.9757997393608093
Revised O O 0.6473950743675232
to O O 0.9999692440032959
measure O O 0.9999611377716064
psychopathology O O 0.9999313354492188
. O O 0.9999829530715942

RESULTS O O 0.9996752738952637
: O O 0.9999319314956665
There O O 0.9999794960021973
were O O 0.9999710321426392
no O O 0.9999620914459229
group O O 0.9998925924301147
differences O O 0.9999970197677612
in O O 0.9999886751174927
psychopathology O O 0.9999743700027466
or O O 0.9999771118164062
" O O 0.9999388456344604
eyes O O 0.9799811244010925
task O O 0.9999721050262451
" O O 0.9999620914459229
performance O O 0.9999837875366211
, O O 0.9999358654022217
but O O 0.9999148845672607
the O O 0.9999452829360962
RC O O 0.959753155708313
group O O 0.9999022483825684
, O O 0.9999896287918091
who O O 0.9999500513076782
otherwise O O 0.9998866319656372
had O O 0.9999271631240845
similar O O 0.999914288520813
illicit O O 0.9162008762359619
substance O O 0.9084586501121521
use O O 0.9956595301628113
histories O O 0.999731719493866
to O O 0.9999217987060547
the O O 0.9998596906661987
OC O O 0.8913755416870117
group O O 0.999847412109375
, O O 0.9999563694000244
exhibited O O 0.9998949766159058
impaired O O 0.9999697208404541
fear O O 0.999426007270813
recognition O O 0.9999451637268066
accuracy O O 0.9999802112579346
compared O O 0.9999778270721436
to O O 0.9999392032623291
the O O 0.9998629093170166
OC O O 0.9150893092155457
and O O 0.9995580315589905
CN O O 0.8406771421432495
groups O O 0.999937891960144
. O O 0.9999474287033081

The O O 0.999934196472168
RC O O 0.9606824517250061
group O O 0.9999583959579468
also O O 0.9999438524246216
correctly O O 0.9999765157699585
identified O O 0.9999725818634033
anger O O 0.4958500564098358
, O O 0.9994435906410217
fear O O 0.999944806098938
, O O 0.9994352459907532
happiness O O 0.989463210105896
, O O 0.9994551539421082
and O O 0.9990054965019226
surprise O O 0.9999579191207886
, O O 0.9999676942825317
more O O 0.9999454021453857
slowly O O 0.9999583959579468
than O O 0.999901294708252
CN O O 0.7169021368026733
, O O 0.9999215602874756
but O O 0.9999903440475464
not O O 0.999910831451416
OC O O 0.8945223689079285
participants O O 0.9999781847000122
. O O 0.9999653100967407

The O O 0.9999275207519531
OC O O 0.9153093695640564
group O O 0.9999468326568604
was O O 0.9999358654022217
slower O O 0.9999680519104004
than O O 0.9996863603591919
CN O O 0.6932991743087769
when O O 0.9999641180038452
correctly O O 0.9999819993972778
identifying O O 0.9999773502349854
disgust O O 0.8624449372291565
. O O 0.9999351501464844

The O O 0.9999648332595825
selective O O 0.9998472929000854
deficit O O 0.9999829530715942
in O O 0.9998904466629028
fear O O 0.9977974891662598
recognition O O 0.9998828172683716
accuracy O O 0.9999762773513794
manifested O O 0.9999330043792725
by O O 0.9998773336410522
the O O 0.9996531009674072
RC O O 0.7827238440513611
group O O 0.9988334774971008
cannot O O 0.999909520149231
be O O 0.9999573230743408
explained O O 0.9999493360519409
by O O 0.9998987913131714
the O O 0.9998607635498047
subacute O O 0.999757707118988
effects O O 0.9999524354934692
of O O 0.9998077750205994
cocaine B B 0.9977608919143677
, O O 0.9742690920829773
or O O 0.9958602786064148
ecstasy B B 0.990057647228241
, O O 0.9998027682304382
because O O 0.9999516010284424
recent O O 0.9999455213546753
and O O 0.9998835325241089
less O O 0.9999722242355347
recent O O 0.9999861717224121
users O O 0.9999399185180664
of O O 0.9995999932289124
these O O 0.9984449744224548
drugs O O 0.9851672053337097
within O O 0.999863862991333
this O O 0.9999269247055054
group O O 0.9996594190597534
were O O 0.9999468326568604
similarly O O 0.9999476671218872
impaired O O 0.9999892711639404
. O O 0.9999760389328003

Possible O O 0.9999537467956543
parallels O O 0.9999855756759644
between O O 0.9995263814926147
RC O O 0.7947751879692078
users O O 0.9118859767913818
and O O 0.9993277788162231
psychopaths O O 0.9994984865188599
with O O 0.999974250793457
respect O O 0.9999940395355225
to O O 0.9999333620071411
impaired O O 0.9999681711196899
fear O O 0.9923436045646667
recognition O O 0.9999732971191406
, O O 0.9999281167984009
amygdala O O 0.9800755977630615
dysfunction O O 0.9999717473983765
, O O 0.9998726844787598
and O O 0.9998321533203125
etiology O O 0.9999014139175415
are O O 0.9999662637710571
discussed O O 0.9999899864196777
. O O 0.9999828338623047

Damage O O 0.9996939897537231
of O O 0.9999208450317383
substantia O O 0.9963066577911377
nigra O O 0.9990768432617188
pars O O 0.9994553923606873
reticulata O O 0.9906514883041382
during O O 0.9995778203010559
pilocarpine B B 0.9998538494110107
- O O 0.9997381567955017
induced O O 0.9999692440032959
status O O 0.9999982118606567
epilepticus O O 0.9999130964279175
in O O 0.9999822378158569
the O O 0.9999938011169434
rat O O 0.9999947547912598
: O O 0.999980092048645
immunohistochemical O O 0.9998859167098999
study O O 0.9999786615371704
of O O 0.9998300075531006
neurons O O 0.9999748468399048
, O O 0.9998378753662109
astrocytes O O 0.9991463422775269
and O O 0.9998965263366699
serum O O 0.5247929692268372
- O O 0.7077972888946533
protein O O 0.6191938519477844
extravasation O O 0.9996771812438965
. O O 0.9999024868011475

The O O 0.9998730421066284
substantia O O 0.9969162940979004
nigra O O 0.9997215867042542
has O O 0.9998137354850769
a O O 0.9997301697731018
gating O O 0.996905505657196
function O O 0.9998780488967896
controlling O O 0.9998902082443237
the O O 0.9999725818634033
spread O O 0.9999829530715942
of O O 0.9999419450759888
epileptic O O 0.9998266100883484
seizure O O 0.9999629259109497
activity O O 0.9999821186065674
. O O 0.9999469518661499

Additionally O O 0.999972939491272
, O O 0.9999550580978394
in O O 0.9998637437820435
models O O 0.9998201727867126
of O O 0.9999403953552246
prolonged O O 0.9999409914016724
status O O 0.9999929666519165
epilepticus O O 0.99997878074646
the O O 0.9999072551727295
pars O O 0.9977923631668091
reticulata O O 0.9977362155914307
of O O 0.9995328187942505
substantia O O 0.9966161847114563
nigra O O 0.999582827091217
( O O 0.9997406601905823
SNR O O 0.9548805952072144
) O O 0.9998852014541626
suffers O O 0.9999182224273682
from O O 0.9999440908432007
a O O 0.9999473094940186
massive O O 0.9998118281364441
lesion O O 0.9999951124191284
which O O 0.9999701976776123
may O O 0.9998952150344849
arise O O 0.999980092048645
from O O 0.9999053478240967
a O O 0.9999370574951172
massive O O 0.9997586607933044
metabolic O O 0.9994663596153259
derangement O O 0.9999803304672241
and O O 0.9998577833175659
hyperexcitation O O 0.996548593044281
developing O O 0.9994552731513977
in O O 0.9994755387306213
the O O 0.9998019337654114
activated O O 0.9971113204956055
SNR O O 0.7090477347373962
. O O 0.9999340772628784

In O O 0.9999709129333496
this O O 0.9999734163284302
study O O 0.9999833106994629
, O O 0.9998805522918701
status O O 0.9999880790710449
epilepticus O O 0.9999605417251587
was O O 0.9999622106552124
induced O O 0.9999934434890747
by O O 0.9999383687973022
systemic O O 0.999783456325531
injection O O 0.9999477863311768
of O O 0.9995449185371399
pilocarpine B B 0.9997702240943909
in O O 0.9997590184211731
rats O O 0.9999549388885498
. O O 0.9999645948410034

The O O 0.9999822378158569
neuropathology O O 0.9999885559082031
of O O 0.9998903274536133
SNR O O 0.9628186821937561
was O O 0.9999518394470215
investigated O O 0.9999786615371704
using O O 0.9999535083770752
immunohistochemical O O 0.9999277591705322
techniques O O 0.9999918937683105
with O O 0.9999858140945435
the O O 0.999994158744812
major O O 0.999997615814209
emphasis O O 0.9999955892562866
on O O 0.999980092048645
the O O 0.9999892711639404
time O O 0.9999167919158936
- O O 0.9999866485595703
course O O 0.9999951124191284
of O O 0.9999798536300659
changes O O 0.9999899864196777
in O O 0.9999160766601562
neurons O O 0.9999748468399048
and O O 0.9998096823692322
astrocytes O O 0.9998821020126343
. O O 0.9999614953994751

Animals O O 0.9996194839477539
surviving O O 0.9999146461486816
20 O O 0.9999696016311646
, O O 0.9999213218688965
30 O O 0.9999772310256958
, O O 0.9996054768562317
40 O O 0.9995396137237549
, O O 0.999351441860199
60 O O 0.9999352693557739
min O O 0.9999560117721558
, O O 0.9999586343765259
2 O O 0.9999240636825562
, O O 0.9998812675476074
3 O O 0.9999500513076782
, O O 0.9999363422393799
6 O O 0.999975323677063
hours O O 0.9999797344207764
, O O 0.9999939203262329
1 O O 0.9998925924301147
, O O 0.999854564666748
2 O O 0.9999804496765137
, O O 0.999836802482605
and O O 0.9999394416809082
3 O O 0.9999412298202515
days O O 0.999990701675415
after O O 0.99998939037323
induction O O 0.9999955892562866
of O O 0.9999865293502808
status O O 0.9999922513961792
epilepticus O O 0.9998278617858887
were O O 0.9999752044677734
perfusion O O 0.9966312050819397
- O O 0.99954754114151
fixed O O 0.9999252557754517
, O O 0.9999258518218994
and O O 0.9999409914016724
brains O O 0.9999606609344482
processed O O 0.9999810457229614
for O O 0.9999675750732422
immunohistochemical O O 0.9999635219573975
staining O O 0.9999581575393677
of O O 0.999213457107544
SNR O O 0.8103609085083008
. O O 0.9999593496322632

Nissl O O 0.6743850111961365
- O O 0.9768696427345276
staining O O 0.9996160268783569
and O O 0.9997097849845886
antibodies O O 0.9999417066574097
against O O 0.9989635944366455
the O O 0.9997702240943909
neuron O O 0.9998770952224731
- O O 0.9996744394302368
specific O O 0.9922690987586975
calcium B B 0.9834312796592712
- O O 0.9018166065216064
binding O O 0.9424120187759399
protein O O 0.9544587135314941
, O O 0.9871072173118591
parvalbumin O B 0.9756174087524414
, O O 0.9993230104446411
served O O 0.9999728202819824
to O O 0.9999608993530273
detect O O 0.9999476671218872
neuronal O O 0.9998999834060669
damage O O 0.9999810457229614
in O O 0.9995681643486023
SNR O O 0.7694499492645264
. O O 0.9999363422393799

Antibodies O O 0.9999502897262573
against O O 0.9986012578010559
the O O 0.9992368221282959
astroglia O O 0.9884109497070312
- O O 0.9990206956863403
specific O O 0.9902073740959167
cytoskeletal O O 0.9817281365394592
protein O O 0.9928953051567078
, O O 0.9976194500923157
glial O O 0.5480325818061829
fibrillary O O 0.9574978351593018
acidic O O 0.8962767124176025
protein O O 0.938637912273407
( O O 0.9946079254150391
GFAP O O 0.5699166059494019
) O O 0.9964206218719482
, O O 0.9997724890708923
and O O 0.9996743202209473
against O O 0.9983697533607483
the O O 0.9994741082191467
glial O O 0.6186193227767944
calcium B B 0.9585494995117188
- O O 0.8846690654754639
binding O O 0.9699074029922485
protein O O 0.9797056317329407
, O O 0.9654932618141174
S O O 0.8427190184593201
- O O 0.9296349883079529
100 O O 0.7735451459884644
protein O O 0.5483187437057495
, O O 0.9997723698616028
were O O 0.9999562501907349
used O O 0.9999662637710571
to O O 0.9999865293502808
assess O O 0.9999940395355225
the O O 0.999992847442627
status O O 0.9999936819076538
of O O 0.9999746084213257
astrocytes O O 0.9998051524162292
. O O 0.9999247789382935

Immunohistochemical O O 0.9998461008071899
staining O O 0.9999665021896362
for O O 0.9994743466377258
serum O O 0.6938456892967224
- O O 0.7105275392532349
albumin O O 0.8447489738464355
and O O 0.990504801273346
immunoglobulins O O 0.9647000432014465
in O O 0.9998213648796082
brain O O 0.9999475479125977
tissue O O 0.9999954700469971
was O O 0.9999659061431885
taken O O 0.9999840259552002
as O O 0.9999759197235107
indicator O O 0.9999675750732422
of O O 0.9999685287475586
blood O O 0.9821242690086365
- O O 0.9997376799583435
brain O O 0.9979105591773987
barrier O O 0.9999589920043945
disturbances O O 0.9999803304672241
and O O 0.9999067783355713
vasogenic O O 0.9997498393058777
edema O O 0.9999704360961914
formation O O 0.9999850988388062
. O O 0.9999544620513916

Immunohistochemical O O 0.9999055862426758
staining O O 0.9999514818191528
indicated O O 0.9999438524246216
loss O O 0.9999905824661255
of O O 0.9998810291290283
GFAP O O 0.7551477551460266
- O O 0.9086964130401611
staining O O 0.9990476965904236
already O O 0.999976396560669
at O O 0.9999887943267822
30 O O 0.9999837875366211
min O O 0.999991774559021
after O O 0.9999703168869019
induction O O 0.9999927282333374
of O O 0.9999750852584839
seizures O O 0.9999107122421265
in O O 0.9997518658638
an O O 0.9999029636383057
oval O O 0.9685705900192261
focus O O 0.999962568283081
situated O O 0.9999642372131348
in O O 0.9999574422836304
the O O 0.9999626874923706
center O O 0.9999809265136719
of O O 0.9997525811195374
SNR O O 0.8105831742286682
while O O 0.9995922446250916
sparing O O 0.9996557235717773
medial O O 0.9998082518577576
and O O 0.9997562766075134
lateral O O 0.9996500015258789
aspects O O 0.9999784231185913
. O O 0.9999637603759766

At O O 0.9996836185455322
1 O O 0.9998027682304382
h O O 0.9999194145202637
there O O 0.9998670816421509
was O O 0.9999700784683228
additional O O 0.999915599822998
vacuolation O O 0.9999344348907471
in O O 0.9925967454910278
S O O 0.7627242207527161
- O O 0.9150218367576599
100 O O 0.7961352467536926
protein O O 0.9892622828483582
staining O O 0.9998480081558228
. O O 0.9999573230743408

By O O 0.9999316930770874
2 O O 0.9997701048851013
hours O O 0.9999806880950928
, O O 0.9999127388000488
parvalbumin O B 0.9722795486450195
- O O 0.9037955403327942
staining O O 0.9986507296562195
changed O O 0.9999103546142578
in O O 0.9998648166656494
the O O 0.99986732006073
central O O 0.9996578693389893
SNR O O 0.9531282186508179
indicating O O 0.9998507499694824
neuronal O O 0.9999005794525146
damage O O 0.9999667406082153
, O O 0.9998759031295776
and O O 0.9997393488883972
Nissl O O 0.7637975215911865
- O O 0.8043859601020813
staining O O 0.9929850697517395
visualized O O 0.9999064207077026
some O O 0.9998459815979004
neuronal O O 0.9997926354408264
distortion O O 0.9997503161430359
. O O 0.9999685287475586

Staining O O 0.9999028444290161
for O O 0.9987838864326477
serum O O 0.7340278625488281
- O O 0.8947528004646301
proteins O O 0.8449563980102539
occurred O O 0.9999722242355347
in O O 0.9999899864196777
a O O 0.9999881982803345
patchy O O 0.9999740123748779
manner O O 0.9999914169311523
throughout O O 0.9998475313186646
the O O 0.9999659061431885
forebrain O O 0.9999823570251465
during O O 0.999897837638855
the O O 0.9999884366989136
first O O 0.9999934434890747
hours O O 0.9999904632568359
. O O 0.9999700784683228

By O O 0.9999051094055176
6 O O 0.999617338180542
h O O 0.9797693490982056
, O O 0.9999266862869263
vasogenic O O 0.9992148876190186
edema O O 0.9999368190765381
covered O O 0.999935507774353
the O O 0.999961256980896
lesioned O O 0.9999313354492188
SNR O O 0.934826672077179
. O O 0.9999420642852783

By O O 0.9998904466629028
24 O O 0.9999059438705444
h O O 0.9978066086769104
, O O 0.999884843826294
glial O O 0.9933538436889648
and O O 0.9995135068893433
neuronal O O 0.9999308586120605
markers O O 0.9998735189437866
indicated O O 0.9999316930770874
a O O 0.9999711513519287
massive O O 0.9999361038208008
lesion O O 0.9999804496765137
in O O 0.9999114274978638
the O O 0.9999632835388184
center O O 0.9999843835830688
of O O 0.9995437264442444
SNR O O 0.8642001748085022
. O O 0.9999542236328125

By O O 0.9999767541885376
48 O O 0.9999656677246094
- O O 0.999448835849762
72 O O 0.9997188448905945
h O O 0.9996981620788574
, O O 0.999923586845398
astrocytes O O 0.9992886781692505
surrounding O O 0.9999032020568848
the O O 0.9999881982803345
lesion O O 0.9999918937683105
increased O O 0.9999700784683228
in O O 0.9999954700469971
size O O 0.9999933242797852
, O O 0.999909520149231
and O O 0.9999134540557861
polymorphic O O 0.9976834058761597
phagocytotic O O 0.9981721639633179
cells O O 0.9999681711196899
invaded O O 0.9997956156730652
the O O 0.9999667406082153
damaged O O 0.9998584985733032
area O O 0.9999756813049316
. O O 0.9999630451202393

In O O 0.9999262094497681
a O O 0.999980092048645
further O O 0.9999817609786987
group O O 0.9999823570251465
of O O 0.999970555305481
animals O O 0.9999927282333374
surviving O O 0.9999332427978516
1 O O 0.9999339580535889
to O O 0.9999933242797852
5 O O 0.9999576807022095
days O O 0.9999805688858032
, O O 0.9999805688858032
conventional O O 0.9999785423278809
paraffin O O 0.9999464750289917
- O O 0.9997256398200989
sections O O 0.9999957084655762
confirmed O O 0.9999445676803589
the O O 0.9999539852142334
neuronal O O 0.9998658895492554
and O O 0.9996886253356934
glial O O 0.997722327709198
damage O O 0.9999804496765137
of O O 0.9987629652023315
SNR O O 0.4766791760921478
. O O 0.9999436140060425

Additional O O 0.9997813105583191
pathology O O 0.9999550580978394
of O O 0.9999392032623291
similar O O 0.9998286962509155
quality O O 0.9999982118606567
was O O 0.9999510049819946
found O O 0.9999840259552002
in O O 0.999872088432312
the O O 0.9999359846115112
globus O O 0.9895527362823486
pallidus O O 0.9987959861755371
. O O 0.9999300241470337

Since O O 0.9999655485153198
astrocytes O O 0.9961739182472229
were O O 0.9998960494995117
always O O 0.9997292160987854
damaged O O 0.9999479055404663
in O O 0.9999734163284302
parallel O O 0.9999549388885498
with O O 0.999875545501709
neurons O O 0.9999555349349976
in O O 0.9988356232643127
SNR O O 0.5472905039787292
it O O 0.9999842643737793
is O O 0.9999774694442749
proposed O O 0.9999885559082031
that O O 0.9999121427536011
the O O 0.9999611377716064
anatomical O O 0.999966025352478
and O O 0.9999133348464966
functional O O 0.9999426603317261
interrelationship O O 0.999852180480957
between O O 0.9998536109924316
neurons O O 0.9999339580535889
and O O 0.9997954964637756
astrocytes O O 0.9989966750144958
is O O 0.9999110698699951
particularly O O 0.9999244213104248
tight O O 0.9998123049736023
in O O 0.9985344409942627
SNR O O 0.6148006916046143
. O O 0.9999290704727173

Both O O 0.9890297055244446
cell O O 0.999715268611908
elements O O 0.9999661445617676
may O O 0.9998462200164795
suffer O O 0.9999648332595825
in O O 0.9999182224273682
common O O 0.9994757771492004
from O O 0.9996218681335449
metabolic O O 0.9983981251716614
disturbance O O 0.9999556541442871
and O O 0.9997572302818298
neurotransmitter O O 0.9999364614486694
dysfunction O O 0.9999690055847168
as O O 0.9999701976776123
occur O O 0.99997878074646
during O O 0.9999308586120605
massive O O 0.9998472929000854
status O O 0.9999935626983643
epilepticus O O 0.9999810457229614
. O O 0.999956488609314

Neuroprotective O O 0.9995799660682678
effects O O 0.9999233484268188
of O O 0.9993380904197693
melatonin B B 0.9997748732566833
upon O O 0.9995386600494385
the O O 0.9999387264251709
offspring O O 0.9419648051261902
cerebellar O O 0.9994646906852722
cortex O O 0.9999798536300659
in O O 0.9999490976333618
the O O 0.9999825954437256
rat O O 0.999984860420227
model O O 0.9999834299087524
of O O 0.9998499155044556
BCNU B B 0.9827531576156616
- O O 0.999110996723175
induced O O 0.9999315738677979
cortical O O 0.9997342228889465
dysplasia O O 0.9999946355819702
. O O 0.9999696016311646

Cortical O O 0.9970646500587463
dysplasia O O 0.999964714050293
is O O 0.9999594688415527
a O O 0.9999386072158813
malformation O O 0.9999946355819702
characterized O O 0.9999843835830688
by O O 0.9999617338180542
defects O O 0.9999756813049316
in O O 0.999923825263977
proliferation O O 0.999981164932251
, O O 0.9999266862869263
migration O O 0.999985933303833
and O O 0.9999110698699951
maturation O O 0.9999198913574219
. O O 0.9999687671661377

This O O 0.9999774694442749
study O O 0.9999860525131226
was O O 0.9999885559082031
designed O O 0.999994158744812
to O O 0.9999923706054688
evaluate O O 0.9999754428863525
the O O 0.9999686479568481
alterations O O 0.9999929666519165
in O O 0.9999598264694214
offspring O O 0.9898556470870972
rat O O 0.9997264742851257
cerebellum O O 0.999663233757019
induced O O 0.9999676942825317
by O O 0.9999432563781738
maternal O O 0.999924898147583
exposure O O 0.9999271631240845
to O O 0.9914228320121765
carmustine B B 0.9987248778343201
- O I 0.8433797955513
[ O I 0.9705589413642883
1 B I 0.8867619037628174
, I I 0.9830392599105835
3 I I 0.9667890071868896
- I I 0.9789510369300842
bis I I 0.9917650818824768
( I I 0.9417733550071716
2 I I 0.9871556758880615
- I I 0.9878575801849365
chloroethyl I I 0.9990886449813843
) I I 0.8874768614768982
- I I 0.9430319666862488
1 I I 0.9373602271080017
- I I 0.9645972847938538
nitrosoure I I 0.9925310015678406
] O O 0.8298132419586182
( O O 0.9786126613616943
BCNU B B 0.950930655002594
) O O 0.999886155128479
and O O 0.9999922513961792
to O O 0.999995231628418
investigate O O 0.9999808073043823
the O O 0.9999823570251465
effects O O 0.9999696016311646
of O O 0.9999089241027832
exogenous O O 0.9994980096817017
melatonin B B 0.9995991587638855
upon O O 0.9996751546859741
cerebellar O O 0.9060332775115967
BCNU B B 0.9636656045913696
- O O 0.9996871948242188
induced O O 0.9999302625656128
cortical O O 0.9981776475906372
dysplasia O O 0.999995231628418
, O O 0.9999890327453613
using O O 0.9999836683273315
histological O O 0.9999885559082031
and O O 0.999971866607666
biochemical O O 0.9998763799667358
analyses O O 0.9999920129776001
. O O 0.9999557733535767

Pregnant O O 0.9998776912689209
Wistar O O 0.9994924068450928
rats O O 0.9999963045120239
were O O 0.9999793767929077
assigned O O 0.999988317489624
to O O 0.9999583959579468
five O O 0.9999622106552124
groups O O 0.9999858140945435
: O O 0.9999457597732544
intact O O 0.9993641972541809
- O O 0.999300479888916
control O O 0.9998377561569214
, O O 0.9997400641441345
saline O O 0.9981380701065063
- O O 0.998789370059967
control O O 0.9944124817848206
, O O 0.9996610879898071
melatonin B B 0.999698281288147
- O O 0.9939867258071899
treated O O 0.9997859597206116
, O O 0.9997043013572693
BCNU B B 0.9118641018867493
- O O 0.9550383687019348
exposed O O 0.9998237490653992
and O O 0.9995573163032532
BCNU B B 0.9282253384590149
- O O 0.8070574998855591
exposed O O 0.9985314607620239
plus O O 0.9983090162277222
melatonin B B 0.9991222023963928
. O O 0.9999300241470337

Rats O O 0.9998940229415894
were O O 0.9999877214431763
exposed O O 0.9998805522918701
to O O 0.9972892999649048
BCNU B B 0.9753844738006592
on O O 0.9996368885040283
embryonic O O 0.9999983310699463
day O O 0.9999991655349731
15 O O 0.9999657869338989
and O O 0.9998202919960022
melatonin B B 0.9993195533752441
was O O 0.9999004602432251
given O O 0.9997932314872742
until O O 0.9999510049819946
delivery O O 0.9999982118606567
. O O 0.99998939037323

Immuno O O 0.9995835423469543
/ O O 0.9989677667617798
histochemistry O O 0.9994207620620728
and O O 0.9999293088912964
electron O O 0.9996157884597778
microscopy O O 0.9999798536300659
were O O 0.9999781847000122
carried O O 0.9999901056289673
out O O 0.9999884366989136
on O O 0.9999244213104248
the O O 0.9999420642852783
offspring O O 0.9966817498207092
cerebellum O O 0.9995090961456299
, O O 0.9999395608901978
and O O 0.999954342842102
levels O O 0.9997044205665588
of O O 0.9977771639823914
malondialdehyde B B 0.9970824122428894
and O O 0.988565981388092
superoxide B B 0.9723191857337952
dismutase O O 0.5311407446861267
were O O 0.9999353885650635
determined O O 0.9999747276306152
. O O 0.9999673366546631

Histopathologically O O 0.9998717308044434
, O O 0.999908447265625
typical O O 0.9999260902404785
findings O O 0.9999889135360718
were O O 0.9999560117721558
observed O O 0.9999759197235107
in O O 0.9997004270553589
the O O 0.9999009370803833
cerebella O O 0.998609185218811
from O O 0.9985126852989197
the O O 0.9994804263114929
control O O 0.9987592697143555
groups O O 0.9999382495880127
, O O 0.9998871088027954
but O O 0.9998692274093628
the O O 0.9999713897705078
findings O O 0.9999884366989136
consistent O O 0.999987006187439
with O O 0.999975323677063
early O O 0.9999159574508667
embryonic O O 0.9999951124191284
development O O 0.9999964237213135
were O O 0.9999443292617798
noted O O 0.9999849796295166
in O O 0.9995754361152649
BCNU B O 0.4790591895580292
- O O 0.9949525594711304
exposed O O 0.9965195655822754
cortical O O 0.9890060424804688
dysplasia O O 0.999919056892395
group O O 0.9997833371162415
. O O 0.9999520778656006

There O O 0.9999336004257202
was O O 0.9999661445617676
a O O 0.9999881982803345
marked O O 0.9999858140945435
increase O O 0.99998939037323
in O O 0.9999853372573853
the O O 0.999988317489624
number O O 0.9999773502349854
of O O 0.9999109506607056
TUNEL O O 0.5439181923866272
positive O O 0.9986506104469299
cells O O 0.9999723434448242
and O O 0.9998264908790588
nestin O O 0.9883953332901001
positive O O 0.9997054934501648
cells O O 0.9999829530715942
in O O 0.9995400905609131
BCNU B B 0.9867333769798279
- O O 0.9145113825798035
exposed O O 0.983898937702179
group O O 0.999717652797699
, O O 0.9999505281448364
but O O 0.99985671043396
a O O 0.9999586343765259
decreased O O 0.9999536275863647
immunoreactivity O O 0.9999386072158813
to O O 0.9993605017662048
glial O O 0.9086893200874329
fibrillary O O 0.9978653788566589
acidic O O 0.9897657036781311
protein O O 0.997786283493042
, O O 0.996722400188446
synaptophysin O O 0.7577887177467346
and O O 0.9984143972396851
transforming O O 0.9824939370155334
growth O O 0.9633250832557678
factor O O 0.9964388608932495
beta1 O O 0.9716019034385681
was O O 0.9999606609344482
observed O O 0.9999620914459229
, O O 0.9999755620956421
indicating O O 0.999889612197876
a O O 0.9999634027481079
delayed O O 0.9999797344207764
maturation O O 0.9999934434890747
, O O 0.999964714050293
and O O 0.9992775321006775
melatonin B B 0.9998745918273926
significantly O O 0.9999058246612549
reversed O O 0.9999487400054932
these O O 0.9999837875366211
changes O O 0.9999971389770508
. O O 0.9999747276306152

Malondialdehyde B B 0.9986000657081604
level O O 0.9972885847091675
in O O 0.999243974685669
BCNU B B 0.9826667308807373
- O O 0.9774968028068542
exposed O O 0.9815838932991028
group O O 0.9995937943458557
was O O 0.9999427795410156
higher O O 0.9998114705085754
than O O 0.999957799911499
those O O 0.9999527931213379
in O O 0.999884843826294
control O O 0.9992945194244385
groups O O 0.9999754428863525
and O O 0.998971700668335
melatonin B B 0.9998664855957031
decreased O O 0.9994620680809021
malondialdehyde B B 0.998969554901123
levels O O 0.999624490737915
in O O 0.999284565448761
BCNU B B 0.910422682762146
group O O 0.9984413981437683
( O O 0.9999006986618042
P O O 0.9930800795555115
< O O 0.9998019337654114
0 O O 0.9999806880950928
. O O 0.9999972581863403
01 O O 0.9999918937683105
) O O 0.9999408721923828
, O O 0.9999544620513916
while O O 0.9999836683273315
there O O 0.999984622001648
were O O 0.9999822378158569
no O O 0.9999796152114868
significant O O 0.9999915361404419
differences O O 0.9999934434890747
in O O 0.9999901056289673
the O O 0.9998100399971008
superoxide B B 0.9833411574363708
dismutase O O 0.579169750213623
levels O O 0.9997151494026184
between O O 0.9997971653938293
these O O 0.9997944235801697
groups O O 0.9999502897262573
. O O 0.9999464750289917

These O O 0.9999895095825195
data O O 0.9999945163726807
suggest O O 0.9999555349349976
that O O 0.9998598098754883
exposure O O 0.9999581575393677
of O O 0.9999775886535645
animals O O 0.9999799728393555
to O O 0.997369647026062
BCNU B B 0.89055997133255
during O O 0.9979789853096008
pregnancy O O 0.9999921321868896
leads O O 0.9999662637710571
to O O 0.9999581575393677
delayed O O 0.9999619722366333
maturation O O 0.9999954700469971
of O O 0.9999431371688843
offspring O O 0.959478497505188
cerebellum O O 0.9993201494216919
and O O 0.999618649482727
melatonin B B 0.998332679271698
protects O O 0.9993727803230286
the O O 0.9999502897262573
cerebellum O O 0.997905969619751
against O O 0.9997150301933289
the O O 0.9999326467514038
effects O O 0.9999499320983887
of O O 0.999847412109375
BCNU B B 0.9612051844596863
. O O 0.9998897314071655

Reduced O O 0.9999066591262817
cardiotoxicity O O 0.9999910593032837
of O O 0.9974114298820496
doxorubicin B B 0.999860405921936
given O O 0.9998362064361572
in O O 0.999971866607666
the O O 0.999983549118042
form O O 0.9999710321426392
of O O 0.9998106360435486
N B B 0.6689421534538269
- I I 0.9801385402679443
( I I 0.9976735711097717
2 I I 0.9622737765312195
- I I 0.9884786009788513
hydroxypropyl I I 0.994492769241333
) I I 0.9436964988708496
methacrylamide I I 0.9993276596069336
conjugates O I 0.9907264709472656
: O O 0.9904719591140747
and O O 0.9999417066574097
experimental O O 0.9999839067459106
study O O 0.9999942779541016
in O O 0.9999856948852539
the O O 0.9999819993972778
rat O O 0.9999921321868896
. O O 0.999963641166687

A O O 0.9999159574508667
rat O O 0.9999663829803467
model O O 0.9999945163726807
was O O 0.9999831914901733
used O O 0.9999836683273315
to O O 0.999985933303833
evaluate O O 0.9999736547470093
the O O 0.9999721050262451
general O O 0.9997754693031311
acute O O 0.9997431635856628
toxicity O O 0.9999768733978271
and O O 0.999969482421875
the O O 0.9999865293502808
late O O 0.9999574422836304
cardiotoxicity O O 0.9999951124191284
of O O 0.9997716546058655
4 O O 0.9980213642120361
mg O O 0.9998109936714172
/ O O 0.9991844296455383
kg O O 0.9994251728057861
doxorubicin B B 0.9996751546859741
( O O 0.9731960296630859
DOX B B 0.9998248219490051
) O O 0.9894295334815979
given O O 0.999922513961792
either O O 0.9998631477355957
as O O 0.9997538924217224
free O O 0.9997034668922424
drug O O 0.9999549388885498
or O O 0.9999152421951294
in O O 0.9999697208404541
the O O 0.9999817609786987
form O O 0.9999678134918213
of O O 0.9998682737350464
three O O 0.9866394400596619
N B B 0.5955749154090881
- I I 0.9522143006324768
( I I 0.9930237531661987
2 I I 0.9644731879234314
- I I 0.9849147796630859
hydroxypropyl I I 0.9935258626937866
) I I 0.9772473573684692
methacrylamide I I 0.999022364616394
( O O 0.7353671789169312
HPMA B B 0.9300586581230164
) O O 0.623477041721344
copolymer O O 0.5595584511756897
conjugates O O 0.6129279732704163
. O O 0.9999392032623291

In O O 0.9979366064071655
these O O 0.9975472092628479
HPMA B O 0.789581298828125
copolymers O O 0.614723265171051
, O O 0.9992621541023254
DOX B B 0.9997506737709045
was O O 0.9998096823692322
covalently O O 0.49368634819984436
bound O O 0.9998942613601685
via O O 0.9998615980148315
peptide O O 0.7449399828910828
linkages O O 0.9912132620811462
that O O 0.9999364614486694
were O O 0.9999504089355469
either O O 0.9999366998672485
non O O 0.9996738433837891
- O O 0.9997770190238953
biodegradable O O 0.9951169490814209
( O O 0.9992455244064331
Gly O B 0.9476674199104309
- O I 0.7610645294189453
Gly O I 0.9038552045822144
) O O 0.9915379285812378
or O O 0.9999169111251831
degradable O O 0.9997255206108093
by O O 0.9999128580093384
lysosomal O O 0.9730715155601501
proteinases O O 0.9917850494384766
( O O 0.9991883635520935
Gly B B 0.9389259815216064
- I I 0.6968861222267151
Phe I I 0.92447829246521
- I I 0.7391554713249207
Leu I I 0.8965107202529907
- I I 0.8053705096244812
Gly I I 0.9426460266113281
) O O 0.9992433786392212
. O O 0.9999550580978394

In O O 0.9999383687973022
addition O O 0.9999711513519287
, O O 0.9999469518661499
one O O 0.9982810020446777
biodegradable O O 0.8792912364006042
conjugate O O 0.5809035897254944
containing O O 0.9813719987869263
galactosamine B B 0.9991315007209778
was O O 0.9998090863227844
used O O 0.9999117851257324
; O O 0.999985933303833
this O O 0.9998962879180908
residue O O 0.9706712365150452
was O O 0.9999539852142334
targeted O O 0.9999654293060303
to O O 0.9998003840446472
the O O 0.9999639987945557
liver O O 0.9996769428253174
. O O 0.9999514818191528

Over O O 0.9999728202819824
the O O 0.9999934434890747
first O O 0.9999954700469971
3 O O 0.9999746084213257
weeks O O 0.9999973773956299
after O O 0.9999738931655884
the O O 0.9999884366989136
i O O 0.9999160766601562
. O O 0.9999916553497314
v O O 0.9999969005584717
. O O 0.9999914169311523
administration O O 0.999945878982544
of O O 0.9997883439064026
free O O 0.9929149150848389
and O O 0.9976450800895691
polymer O O 0.6129298806190491
- O O 0.9989323019981384
bound O O 0.9912803769111633
DOX B B 0.9994063377380371
, O O 0.9998387098312378
all O O 0.9999617338180542
animals O O 0.9999951124191284
showed O O 0.9999902248382568
a O O 0.9999927282333374
transient O O 0.9999966621398926
reduction O O 0.999998927116394
in O O 0.9999979734420776
body O O 0.9999963045120239
weight O O 0.9999828338623047
. O O 0.9999868869781494

However O O 0.9999709129333496
, O O 0.9999703168869019
the O O 0.999994158744812
maximal O O 0.9999934434890747
reduction O O 0.9999984502792358
in O O 0.9999911785125732
body O O 0.9999967813491821
weight O O 0.9999964237213135
seen O O 0.999993085861206
in O O 0.9999555349349976
animals O O 0.9999977350234985
that O O 0.9999682903289795
received O O 0.9998918771743774
polymer O O 0.4906502366065979
- O O 0.9706444144248962
bound O O 0.6835210919380188
DOX B B 0.9657724499702454
( O O 0.9995502829551697
4 O O 0.9987953901290894
mg O O 0.9999362230300903
/ O O 0.9999736547470093
kg O O 0.9999951124191284
) O O 0.9999680519104004
was O O 0.9999743700027466
significantly O O 0.9999914169311523
lower O O 0.9999879598617554
than O O 0.9999868869781494
that O O 0.9999924898147583
observed O O 0.9999963045120239
in O O 0.9999678134918213
those O O 0.99998939037323
that O O 0.9999891519546509
received O O 0.9999289512634277
free O O 0.6412729620933533
DOX B B 0.8642430305480957
( O O 0.9994285702705383
4 O O 0.9972520470619202
mg O O 0.9999420642852783
/ O O 0.9999655485153198
kg O O 0.9999971389770508
) O O 0.999943733215332
or O O 0.9999239444732666
a O O 0.9999639987945557
mixture O O 0.9990109205245972
of O O 0.9998001456260681
the O O 0.9999397993087769
unmodified O O 0.9958557486534119
parent O B 0.8559306263923645
HPMA B I 0.9313414096832275
copolymer O O 0.833957314491272
and O O 0.9917353391647339
free O O 0.8162711262702942
DOX B B 0.9869487285614014
( O O 0.9996337890625
4 O O 0.9988389611244202
mg O O 0.9999440908432007
/ O O 0.9999836683273315
kg O O 0.9999960660934448
; O O 0.9999580383300781
P O O 0.9998804330825806
less O O 0.9999943971633911
than O O 0.999996542930603
0 O O 0.9999959468841553
. O O 0.9999982118606567
01 O O 0.999997615814209
) O O 0.9999809265136719
. O O 0.9999774694442749

Throughout O O 0.9998745918273926
the O O 0.9999943971633911
study O O 0.9999916553497314
( O O 0.9999710321426392
20 O O 0.9999852180480957
weeks O O 0.9999954700469971
) O O 0.9999727010726929
, O O 0.9999651908874512
deaths O O 0.9995338916778564
related O O 0.9999899864196777
to O O 0.9998594522476196
cardiotoxicity O O 0.9999781847000122
were O O 0.9999877214431763
observed O O 0.99997878074646
only O O 0.9999635219573975
in O O 0.9999419450759888
animals O O 0.9999963045120239
that O O 0.9999722242355347
received O O 0.9999376535415649
either O O 0.9997404217720032
free O O 0.5721471905708313
DOX B B 0.9738261699676514
or O O 0.9991787075996399
the O O 0.9999440908432007
mixture O O 0.9982894062995911
of O O 0.9957690238952637
HPMA B B 0.8897340893745422
copolymer O O 0.6982690691947937
and O O 0.9915364980697632
free O O 0.6291847825050354
DOX B B 0.9129316210746765
; O O 0.9999244213104248
in O O 0.9999656677246094
these O O 0.9999772310256958
cases O O 0.9999819993972778
, O O 0.9999630451202393
histological O O 0.9999666213989258
investigations O O 0.9999959468841553
revealed O O 0.9999644756317139
marked O O 0.9999771118164062
changes O O 0.9999966621398926
in O O 0.9999779462814331
the O O 0.999990701675415
heart O O 0.9999876022338867
that O O 0.9999806880950928
were O O 0.9999786615371704
consistent O O 0.9999942779541016
with O O 0.9999645948410034
DOX B B 0.99931800365448
- O O 0.9997546076774597
induced O O 0.9999614953994751
cardiotoxicity O O 0.9999947547912598
. O O 0.9999889135360718

Sequential O O 0.9999760389328003
measurements O O 0.9999926090240479
of O O 0.9999775886535645
cardiac O O 0.9997724890708923
output O O 0.9999735355377197
in O O 0.9999164342880249
surviving O O 0.9991372227668762
animals O O 0.9999916553497314
that O O 0.9999746084213257
received O O 0.9999374151229858
either O O 0.9998064637184143
free O O 0.4736945331096649
DOX B B 0.9143080115318298
or O O 0.9988052845001221
the O O 0.9999459981918335
mixture O O 0.997420072555542
of O O 0.995760977268219
HPMA B B 0.9089134931564331
copolymer O O 0.7084144353866577
and O O 0.9944932460784912
free O O 0.4891526997089386
DOX B B 0.958480954170227
showed O O 0.9999496936798096
a O O 0.9999921321868896
reduction O O 0.9999980926513672
of O O 0.9999780654907227
approximately O O 0.9999963045120239
30 O O 0.999995231628418
% O O 0.9999980926513672
in O O 0.9999850988388062
function O O 0.9999960660934448
beginning O O 0.9999939203262329
at O O 0.9999967813491821
the O O 0.9999984502792358
4th O O 0.999997615814209
week O O 0.9999992847442627
after O O 0.9999755620956421
drug O O 0.9997757077217102
administration O O 0.9999654293060303
. O O 0.9999814033508301

The O O 0.9999856948852539
heart O O 0.9999868869781494
rate O O 0.9999761581420898
in O O 0.9998778104782104
these O O 0.9999617338180542
animals O O 0.9999856948852539
was O O 0.9999762773513794
approximately O O 0.9999940395355225
12 O O 0.9999977350234985
% O O 0.9999974966049194
lower O O 0.999988317489624
than O O 0.9999934434890747
that O O 0.9999890327453613
measured O O 0.9999910593032837
in O O 0.9999657869338989
age O O 0.9995800852775574
- O O 0.9999775886535645
matched O O 0.9999884366989136
control O O 0.9999654293060303
rats O O 0.9999955892562866
( O O 0.9999651908874512
P O O 0.9997161030769348
less O O 0.9999885559082031
than O O 0.999993085861206
0 O O 0.9999929666519165
. O O 0.9999953508377075
05 O O 0.9999927282333374
) O O 0.9999698400497437
. O O 0.9999749660491943

Animals O O 0.9999079704284668
that O O 0.9999750852584839
were O O 0.9999933242797852
given O O 0.9998483657836914
the O O 0.9983305335044861
HPMA B B 0.9521220922470093
copolymer O O 0.6357430219650269
conjugates O O 0.6455221176147461
containing O O 0.9856145977973938
DOX B B 0.9994010925292969
exhibited O O 0.9998701810836792
no O O 0.999976634979248
significant O O 0.999996542930603
change O O 0.9999974966049194
in O O 0.9999915361404419
cardiac O O 0.9998617172241211
output O O 0.999990701675415
throughout O O 0.9999486207962036
the O O 0.9999963045120239
study O O 0.9999934434890747
( O O 0.9999600648880005
P O O 0.9984802603721619
less O O 0.9999858140945435
than O O 0.999994158744812
0 O O 0.9999910593032837
. O O 0.9999961853027344
05 O O 0.9999955892562866
) O O 0.9999843835830688
. O O 0.9999785423278809

In O O 0.9999516010284424
addition O O 0.9999836683273315
, O O 0.9999759197235107
no O O 0.9999624490737915
significant O O 0.9999896287918091
histological O O 0.9999841451644897
change O O 0.9999978542327881
was O O 0.9999880790710449
observed O O 0.999994158744812
in O O 0.9998888969421387
the O O 0.9999699592590332
heart O O 0.9998264908790588
of O O 0.9998784065246582
animals O O 0.9999909400939941
that O O 0.9999215602874756
received O O 0.9996916055679321
DOX B B 0.9995958209037781
in O O 0.9998501539230347
the O O 0.9999896287918091
form O O 0.9999686479568481
of O O 0.9977445602416992
HPMA B O 0.8309624791145325
copolymer O O 0.6602745056152344
conjugates O O 0.5563705563545227
and O O 0.9997740387916565
were O O 0.9999585151672363
killed O O 0.9999099969863892
at O O 0.999984622001648
the O O 0.9999977350234985
end O O 0.9999972581863403
of O O 0.9999926090240479
the O O 0.9999970197677612
study O O 0.9999946355819702
. O O 0.999980092048645

However O O 0.9999631643295288
, O O 0.9999444484710693
these O O 0.9999797344207764
animals O O 0.9999785423278809
had O O 0.9999889135360718
shown O O 0.999991774559021
a O O 0.9999908208847046
significant O O 0.9999924898147583
increase O O 0.9999963045120239
in O O 0.9999903440475464
heart O O 0.9999831914901733
rate O O 0.9999920129776001
beginning O O 0.9999908208847046
at O O 0.9999958276748657
8 O O 0.9999868869781494
weeks O O 0.9999991655349731
after O O 0.9999747276306152
drug O O 0.9985277652740479
administration O O 0.9999305009841919
( O O 0.9999147653579712
P O O 0.9924139380455017
less O O 0.9999749660491943
than O O 0.9999934434890747
0 O O 0.9999934434890747
. O O 0.9999977350234985
01 O O 0.9999967813491821
) O O 0.9999639987945557
. O O 0.9999827146530151
( O O 0.9996498823165894
ABSTRACT O O 0.9999418258666992
TRUNCATED O O 0.9999639987945557
AT O O 0.9998533725738525
400 O O 0.9970269799232483
WORDS O O 0.9999897480010986
) O O 0.9998998641967773

Corneal O O 0.9997020363807678
ulcers O O 0.9998944997787476
associated O O 0.9999681711196899
with O O 0.999911904335022
aerosolized O O 0.5716562271118164
crack B B 0.8197243213653564
cocaine I I 0.9985927939414978
use O O 0.9983672499656677
. O O 0.9999371767044067

PURPOSE O O 0.9977707862854004
: O O 0.9999641180038452
We O O 0.9997829794883728
report O O 0.9999933242797852
4 O O 0.9996755123138428
cases O O 0.999993085861206
of O O 0.9999788999557495
corneal O O 0.9999665021896362
ulcers O O 0.9999560117721558
associated O O 0.9999788999557495
with O O 0.9999072551727295
drug O O 0.989080011844635
abuse O O 0.997911274433136
. O O 0.9999526739120483

The O O 0.9999716281890869
pathogenesis O O 0.9999868869781494
of O O 0.9999728202819824
these O O 0.9999313354492188
ulcers O O 0.9998666048049927
and O O 0.9999622106552124
management O O 0.9999816417694092
of O O 0.9999877214431763
these O O 0.9999734163284302
patients O O 0.9999765157699585
are O O 0.99997878074646
also O O 0.9999908208847046
reviewed O O 0.9999942779541016
. O O 0.9999791383743286

METHODS O O 0.9994590878486633
: O O 0.9999803304672241
Review O O 0.9999821186065674
of O O 0.9999806880950928
all O O 0.9999707937240601
cases O O 0.9999918937683105
of O O 0.9999828338623047
corneal O O 0.999970555305481
ulcers O O 0.999954104423523
associated O O 0.9999734163284302
with O O 0.9999243021011353
drug O O 0.9935551285743713
abuse O O 0.9993200302124023
seen O O 0.9999794960021973
at O O 0.9999819993972778
our O O 0.9999881982803345
institution O O 0.9999934434890747
from O O 0.9999499320983887
July O O 0.9962258338928223
2006 O O 0.9957369565963745
to O O 0.9992456436157227
December O O 0.9871044158935547
2006 O O 0.9989232420921326
. O O 0.9999597072601318

RESULTS O O 0.9988376498222351
: O O 0.999955415725708
Four O O 0.9999711513519287
patients O O 0.9999871253967285
with O O 0.9999698400497437
corneal O O 0.9999308586120605
ulcers O O 0.9999358654022217
associated O O 0.9999732971191406
with O O 0.9998481273651123
crack B B 0.967863917350769
cocaine I I 0.9967743754386902
use O O 0.9929019808769226
were O O 0.9999527931213379
reviewed O O 0.9999866485595703
. O O 0.9999661445617676

All O O 0.9995797276496887
corneal O O 0.9999229907989502
ulcers O O 0.9999377727508545
were O O 0.9999798536300659
cultured O O 0.999832034111023
, O O 0.9999141693115234
and O O 0.9999837875366211
the O O 0.9999948740005493
patients O O 0.9999929666519165
were O O 0.9999943971633911
admitted O O 0.9999940395355225
to O O 0.999996542930603
the O O 0.999997615814209
hospital O O 0.9999951124191284
for O O 0.9999756813049316
intensive O O 0.9999374151229858
topical O O 0.9999630451202393
antibiotic O O 0.9791476726531982
treatment O O 0.9999600648880005
. O O 0.9999761581420898

Each O O 0.999890923500061
patient O O 0.9999886751174927
received O O 0.9999567270278931
comprehensive O O 0.9999390840530396
health O O 0.999947190284729
care O O 0.9999899864196777
, O O 0.9999836683273315
including O O 0.9999269247055054
medical O O 0.9999682903289795
and O O 0.9999080896377563
substance O O 0.9685990214347839
abuse O O 0.9988137483596802
consultations O O 0.9999758005142212
. O O 0.9999724626541138

Streptococcal O O 0.797500491142273
organisms O O 0.9998668432235718
were O O 0.9999028444290161
found O O 0.9999309778213501
in O O 0.9998856782913208
3 O O 0.9980180263519287
cases O O 0.9999591112136841
and O O 0.9998776912689209
Capnocytophaga O O 0.9727758765220642
and O O 0.9987541437149048
Brevibacterium O O 0.9458611607551575
casei O O 0.999029278755188
in O O 0.9999334812164307
1 O O 0.9997507929801941
patient O O 0.9999902248382568
. O O 0.9999555349349976

The O O 0.9999305009841919
infections O O 0.9999890327453613
responded O O 0.9999805688858032
to O O 0.9998769760131836
antibiotic O O 0.9961404204368591
treatment O O 0.9998778104782104
. O O 0.9999608993530273

Two O O 0.9999556541442871
patients O O 0.9999951124191284
needed O O 0.9999737739562988
a O O 0.9999020099639893
lateral O O 0.9962329268455505
tarsorrhaphy O O 0.9796608686447144
for O O 0.9999217987060547
persistent O O 0.9999712705612183
epithelial O O 0.9999152421951294
defects O O 0.9999924898147583
. O O 0.9999535083770752

CONCLUSIONS O O 0.7959080934524536
: O O 0.9995878338813782
Aerosolized O O 0.796019971370697
crack B B 0.9206583499908447
cocaine I I 0.9902327060699463
use O O 0.9991064667701721
can O O 0.9998880624771118
be O O 0.9999340772628784
associated O O 0.9999746084213257
with O O 0.9999833106994629
the O O 0.9999916553497314
development O O 0.9999972581863403
of O O 0.9999874830245972
corneal O O 0.9999876022338867
ulcers O O 0.9999792575836182
. O O 0.9999585151672363

Drug O O 0.9784290194511414
abuse O O 0.9996727705001831
provides O O 0.9998806715011597
additional O O 0.9999613761901855
challenges O O 0.9999861717224121
for O O 0.9999798536300659
management O O 0.9999804496765137
. O O 0.9999793767929077

Not O O 0.9997308850288391
only O O 0.9998130202293396
treatment O O 0.9998469352722168
of O O 0.9998897314071655
their O O 0.9998401403427124
infections O O 0.9999525547027588
but O O 0.9998904466629028
also O O 0.9999327659606934
the O O 0.9999924898147583
overall O O 0.9999858140945435
poor O O 0.9999960660934448
health O O 0.9999982118606567
of O O 0.9999905824661255
the O O 0.9999878406524658
patients O O 0.9999918937683105
and O O 0.9999758005142212
increased O O 0.9999868869781494
risk O O 0.9999970197677612
of O O 0.9999638795852661
noncompliance O O 0.9989030361175537
need O O 0.999971866607666
to O O 0.9999802112579346
be O O 0.9999866485595703
addressed O O 0.99998939037323
. O O 0.9999698400497437

Comprehensive O O 0.9989732503890991
care O O 0.9999793767929077
may O O 0.999924898147583
provide O O 0.9999686479568481
the O O 0.9999908208847046
patient O O 0.9999924898147583
the O O 0.999993085861206
opportunity O O 0.9999954700469971
to O O 0.9999876022338867
discontinue O O 0.9998238682746887
their O O 0.9999097585678101
substance O O 0.9282768964767456
abuse O O 0.9888858795166016
, O O 0.9999690055847168
improve O O 0.9999512434005737
their O O 0.9999840259552002
overall O O 0.9999747276306152
health O O 0.9999977350234985
, O O 0.9999587535858154
and O O 0.999963641166687
prevent O O 0.9999338388442993
future O O 0.9999852180480957
corneal O O 0.9999814033508301
complications O O 0.9999967813491821
. O O 0.9999754428863525

Topical O O 0.9975866079330444
0 O O 0.9974011182785034
. O O 0.9999430179595947
025 O O 0.9865660071372986
% O O 0.9753095507621765
capsaicin B B 0.9990315437316895
in O O 0.9998025298118591
chronic O O 0.9999569654464722
post O O 0.9990870952606201
- O O 0.9995207786560059
herpetic O O 0.9995067119598389
neuralgia O O 0.9999972581863403
: O O 0.9999431371688843
efficacy O O 0.9999045133590698
, O O 0.999977707862854
predictors O O 0.9999812841415405
of O O 0.9999901056289673
response O O 0.9999878406524658
and O O 0.9999854564666748
long O O 0.9999421834945679
- O O 0.9999912977218628
term O O 0.9999899864196777
course O O 0.9999942779541016
. O O 0.9999759197235107

In O O 0.9999690055847168
order O O 0.9999953508377075
to O O 0.9999936819076538
evaluate O O 0.9999877214431763
the O O 0.9999831914901733
efficacy O O 0.9999895095825195
, O O 0.9999903440475464
time O O 0.9999476671218872
- O O 0.9999805688858032
course O O 0.9999945163726807
of O O 0.9999730587005615
action O O 0.9999804496765137
and O O 0.9999843835830688
predictors O O 0.9999957084655762
of O O 0.9999909400939941
response O O 0.9999971389770508
to O O 0.9999539852142334
topical O O 0.9999794960021973
capsaicin B B 0.9958351850509644
, O O 0.9999572038650513
39 O O 0.9999918937683105
patients O O 0.9999970197677612
with O O 0.9999773502349854
chronic O O 0.9999645948410034
post O O 0.9981884360313416
- O O 0.9993903636932373
herpetic O O 0.9978553652763367
neuralgia O O 0.9999985694885254
( O O 0.9999629259109497
PHN O O 0.9977310299873352
) O O 0.9999692440032959
, O O 0.9999529123306274
median O O 0.9992637038230896
duration O O 0.9999885559082031
24 O O 0.9999810457229614
months O O 0.9999970197677612
, O O 0.9999909400939941
were O O 0.9999827146530151
treated O O 0.9999860525131226
with O O 0.9999291896820068
0 O O 0.9998268485069275
. O O 0.9999885559082031
025 O O 0.991526186466217
% O O 0.9991550445556641
capsaicin B B 0.9758648872375488
cream O O 0.9690937399864197
for O O 0.9999738931655884
8 O O 0.9999532699584961
weeks O O 0.9999977350234985
. O O 0.999987006187439

During O O 0.9991353154182434
therapy O O 0.9999659061431885
the O O 0.9999809265136719
patients O O 0.9999896287918091
rated O O 0.9999889135360718
their O O 0.9999889135360718
pain O O 0.9999700784683228
on O O 0.999947190284729
a O O 0.9999666213989258
visual O O 0.9991220831871033
analogue O O 0.9998911619186401
scale O O 0.9999359846115112
( O O 0.9990670084953308
VAS O O 0.9762559533119202
) O O 0.9999449253082275
and O O 0.9999284744262695
a O O 0.9999555349349976
verbal O O 0.9998965263366699
outcome O O 0.9999945163726807
scale O O 0.9998549222946167
. O O 0.9999732971191406

A O O 0.9999520778656006
follow O O 0.9999790191650391
- O O 0.9999886751174927
up O O 0.9999932050704956
investigation O O 0.9999761581420898
was O O 0.999984860420227
performed O O 0.999996542930603
10 O O 0.9999097585678101
- O O 0.9999175071716309
12 O O 0.9999884366989136
months O O 0.9999990463256836
after O O 0.999990701675415
study O O 0.9999263286590576
onset O O 0.9999911785125732
on O O 0.9998890161514282
the O O 0.99998939037323
patients O O 0.9999938011169434
who O O 0.9999847412109375
had O O 0.999996542930603
improved O O 0.9999972581863403
. O O 0.9999793767929077

Nineteen O O 0.9996203184127808
patients O O 0.9999915361404419
( O O 0.9999376535415649
48 O O 0.9999971389770508
. O O 0.9999923706054688
7 O O 0.9999957084655762
% O O 0.9999948740005493
) O O 0.9999747276306152
substantially O O 0.9999927282333374
improved O O 0.9999978542327881
after O O 0.9999912977218628
the O O 0.9999964237213135
8 O O 0.9999364614486694
- O O 0.9999819993972778
week O O 0.9999934434890747
trial O O 0.9999731779098511
; O O 0.9999858140945435
5 O O 0.9998750686645508
( O O 0.9999204874038696
12 O O 0.9999933242797852
. O O 0.9999889135360718
8 O O 0.9999886751174927
% O O 0.9999927282333374
) O O 0.999916672706604
discontinued O O 0.9999850988388062
therapy O O 0.9999819993972778
due O O 0.9999855756759644
to O O 0.9999358654022217
side O O 0.9998732805252075
- O O 0.9998842477798462
effects O O 0.9999629259109497
such O O 0.999970555305481
as O O 0.9999579191207886
intolerable O O 0.999985933303833
capsaicin B B 0.9919247031211853
- O O 0.9984562397003174
induced O O 0.9999322891235352
burning O O 0.9996743202209473
sensations O O 0.9999634027481079
( O O 0.9998173117637634
4 O O 0.9945502877235413
) O O 0.9986262321472168
or O O 0.9999388456344604
mastitis O O 0.9999845027923584
( O O 0.9999263286590576
1 O O 0.9988627433776855
) O O 0.9998492002487183
; O O 0.999976634979248
15 O O 0.9999580383300781
( O O 0.9999217987060547
38 O O 0.9999934434890747
. O O 0.9999880790710449
5 O O 0.9999942779541016
% O O 0.9999892711639404
) O O 0.9999760389328003
reported O O 0.9999929666519165
no O O 0.9999909400939941
benefit O O 0.9999960660934448
. O O 0.9999864101409912

The O O 0.9999712705612183
decrease O O 0.999981164932251
in O O 0.9999144077301025
VAS O O 0.9990053772926331
ratings O O 0.9991382360458374
was O O 0.9999593496322632
significant O O 0.9999792575836182
after O O 0.9999529123306274
2 O O 0.9999485015869141
weeks O O 0.9999933242797852
of O O 0.9999532699584961
continuous O O 0.9964721202850342
application O O 0.9998942613601685
. O O 0.9999737739562988

Of O O 0.9976869821548462
the O O 0.9998121857643127
responders O O 0.9956055283546448
72 O O 0.9998868703842163
. O O 0.9999184608459473
2 O O 0.999510645866394
% O O 0.9997438788414001
were O O 0.9999406337738037
still O O 0.9999901056289673
improved O O 0.9999866485595703
at O O 0.9999849796295166
the O O 0.9999959468841553
follow O O 0.9999895095825195
- O O 0.9999938011169434
up O O 0.9999972581863403
; O O 0.9999872446060181
only O O 0.9999902248382568
one O O 0.9999797344207764
- O O 0.9999865293502808
third O O 0.9999935626983643
of O O 0.9998335838317871
them O O 0.9994686245918274
had O O 0.9999593496322632
continued O O 0.9999833106994629
application O O 0.9999769926071167
irregularly O O 0.9998841285705566
. O O 0.9999724626541138

Treatment O O 0.999637246131897
effect O O 0.9999082088470459
was O O 0.9999281167984009
not O O 0.9999539852142334
dependent O O 0.9999842643737793
on O O 0.9999701976776123
patient O O 0.9999940395355225
' O O 0.9999943971633911
s O O 0.9999933242797852
age O O 0.9999957084655762
, O O 0.9999808073043823
duration O O 0.999974250793457
or O O 0.9999847412109375
localization O O 0.9999665021896362
of O O 0.9999244213104248
PHN O O 0.9482853412628174
( O O 0.9999070167541504
trigeminal O O 0.9921241402626038
involvement O O 0.9999301433563232
was O O 0.999968409538269
excluded O O 0.9998238682746887
) O O 0.9999268054962158
, O O 0.9999305009841919
sensory O O 0.9999809265136719
disturbance O O 0.9999858140945435
or O O 0.9998751878738403
pain O O 0.9987877011299133
character O O 0.999925971031189
. O O 0.999962329864502

Treatment O O 0.99953293800354
response O O 0.9999788999557495
was O O 0.9999568462371826
not O O 0.9999802112579346
correlated O O 0.9999953508377075
with O O 0.9999861717224121
the O O 0.999987006187439
incidence O O 0.9999949932098389
, O O 0.999988317489624
time O O 0.9999213218688965
- O O 0.999984860420227
course O O 0.9999929666519165
or O O 0.9999856948852539
severity O O 0.9999881982803345
of O O 0.9999573230743408
capsaicin B B 0.9992166757583618
- O O 0.9995930790901184
induced O O 0.9999498128890991
burning O O 0.9999806880950928
. O O 0.999981164932251

If O O 0.9999661445617676
confirmed O O 0.9999961853027344
in O O 0.9999904632568359
controlled O O 0.9999581575393677
trials O O 0.9999810457229614
, O O 0.9999866485595703
the O O 0.9999955892562866
long O O 0.9998151659965515
- O O 0.9999850988388062
term O O 0.9999945163726807
results O O 0.9999984502792358
of O O 0.9999946355819702
this O O 0.9999909400939941
open O O 0.9999853372573853
, O O 0.9999933242797852
non O O 0.9999662637710571
- O O 0.9999616146087646
randomized O O 0.9999940395355225
study O O 0.999990701675415
might O O 0.9999666213989258
indicate O O 0.9999634027481079
that O O 0.9999551773071289
the O O 0.9999693632125854
analgesic O O 0.9998410940170288
effect O O 0.9998981952667236
of O O 0.9996310472488403
capsaicin B B 0.9993201494216919
in O O 0.9995742440223694
PHN O O 0.7126561999320984
is O O 0.9998593330383301
mediated O O 0.9999444484710693
by O O 0.9998058676719666
both O O 0.9993846416473389
interference O O 0.9997923970222473
with O O 0.9998456239700317
neuropeptide O O 0.9998179078102112
metabolism O O 0.9987866282463074
and O O 0.9998922348022461
morphological O O 0.9999798536300659
changes O O 0.9999960660934448
( O O 0.9999725818634033
perhaps O O 0.9999402761459351
degeneration O O 0.999889612197876
) O O 0.9999792575836182
of O O 0.9998900890350342
nociceptive O O 0.9721570611000061
afferents O O 0.9936298727989197
. O O 0.9999480247497559

Myo B B 0.9633662700653076
- I I 0.8560519218444824
inositol I I 0.9409064054489136
- I I 0.8866456151008606
1 I I 0.9125466346740723
- I I 0.9658632278442383
phosphate I I 0.9987441301345825
( O O 0.7643659114837646
MIP B B 0.9383409023284912
) O O 0.5704806447029114
synthase O O 0.7864154577255249
inhibition O O 0.9998151659965515
: O O 0.9999614953994751
in O O 0.9998316764831543
- O O 0.9999219179153442
vivo O O 0.9999920129776001
study O O 0.999987006187439
in O O 0.9999470710754395
rats O O 0.9998766183853149
. O O 0.9999794960021973

Lithium B B 0.9992600083351135
and O O 0.9446001052856445
valproate B B 0.9988723397254944
are O O 0.9995597004890442
the O O 0.9998646974563599
prototypic O O 0.9892855286598206
mood O O 0.6139005422592163
stabilizers O O 0.7085079550743103
and O O 0.9996719360351562
have O O 0.9999066591262817
diverse O O 0.9996209144592285
structures O O 0.9999905824661255
and O O 0.9999524354934692
targets O O 0.9999622106552124
. O O 0.9999145269393921

Both O O 0.9457756280899048
drugs O O 0.9451210498809814
influence O O 0.9989711046218872
inositol B B 0.9838036894798279
metabolism O O 0.9988743662834167
. O O 0.9997217059135437

Lithium B B 0.9994297623634338
inhibits O O 0.9597959518432617
IMPase O O 0.5485559105873108
and O O 0.9978348612785339
valproate B B 0.9994051456451416
inhibits O O 0.9787818789482117
MIP B O 0.7809520363807678
synthase O O 0.7156294584274292
. O O 0.99504554271698

This O O 0.999961256980896
study O O 0.9999582767486572
shows O O 0.9999274015426636
that O O 0.9997286200523376
MIP B B 0.9418628215789795
synthase O O 0.49517154693603516
inhibition O O 0.9981278777122498
does O O 0.9999294281005859
not O O 0.9998100399971008
replicate O O 0.9985016584396362
or O O 0.9999130964279175
augment O O 0.9998217225074768
the O O 0.9999074935913086
effects O O 0.9999334812164307
of O O 0.9998047947883606
lithium B B 0.999910831451416
in O O 0.9996627569198608
the O O 0.9999290704727173
inositol B B 0.9974207878112793
sensitive O O 0.5024949312210083
pilocarpine B B 0.9981928467750549
- O O 0.9998239874839783
induced O O 0.9999370574951172
seizures O O 0.9999691247940063
model O O 0.9999861717224121
. O O 0.9999830722808838

This O O 0.9999735355377197
lack O O 0.9999791383743286
of O O 0.9999659061431885
effects O O 0.9999459981918335
may O O 0.9998829364776611
stem O O 0.9999890327453613
from O O 0.9999474287033081
the O O 0.999951958656311
low O O 0.9998898506164551
contribution O O 0.9999732971191406
of O O 0.9996084570884705
de O O 0.9351744055747986
- O O 0.9854176044464111
novo O O 0.9274966716766357
synthesis O O 0.999009370803833
to O O 0.9996432065963745
cellular O O 0.9997448325157166
inositol B B 0.9951028823852539
supply O O 0.9995887875556946
or O O 0.9999514818191528
to O O 0.9999533891677856
the O O 0.9999245405197144
inhibition O O 0.9998424053192139
of O O 0.9998419284820557
the O O 0.9998956918716431
de O O 0.9237660765647888
- O O 0.9849076271057129
novo O O 0.9115856289863586
synthesis O O 0.9996845722198486
by O O 0.9995822310447693
lithium B B 0.999911904335022
itself O O 0.9998527765274048
. O O 0.9999396800994873

Non O O 0.4959629476070404
- O O 0.7074949741363525
steroidal O O 0.5784357190132141
anti O O 0.4313117563724518
- O O 0.5745734572410583
inflammatory O O 0.5910250544548035
drugs O O 0.550786554813385
- O O 0.9994803071022034
associated O O 0.9999350309371948
acute O O 0.9999797344207764
interstitial O O 0.9998276233673096
nephritis O O 0.9999887943267822
with O O 0.9999734163284302
granular O O 0.9562028646469116
tubular O O 0.9994220733642578
basement O O 0.9971490502357483
membrane O O 0.9916757345199585
deposits O O 0.9999678134918213
. O O 0.9999653100967407

Acute O O 0.9985675811767578
tubulo O O 0.9999358654022217
- O O 0.996982753276825
interstitial O O 0.9875510334968567
nephritis O O 0.9999183416366577
( O O 0.9997478127479553
ATIN O O 0.9797714352607727
) O O 0.9999206066131592
is O O 0.999920129776001
an O O 0.9999301433563232
important O O 0.999861478805542
cause O O 0.9999825954437256
of O O 0.99993896484375
acute O O 0.9999758005142212
renal O O 0.9999932050704956
failure O O 0.9999923706054688
resulting O O 0.9999728202819824
from O O 0.99988853931427
a O O 0.999929666519165
variety O O 0.9999701976776123
of O O 0.9998388290405273
insults O O 0.9999632835388184
, O O 0.9999517202377319
including O O 0.9997158646583557
immune O O 0.9973480701446533
complex O O 0.9259535670280457
- O O 0.9994732737541199
mediated O O 0.9999173879623413
tubulo O O 0.9999525547027588
- O O 0.9990150928497314
interstitial O O 0.9979885816574097
injury O O 0.9999864101409912
, O O 0.9999486207962036
but O O 0.9988886713981628
drugs O O 0.9997376799583435
such O O 0.9997856020927429
as O O 0.9996984004974365
non O O 0.5443930625915527
- O O 0.9141026139259338
steroidal O O 0.6629697680473328
anti O O 0.5585778951644897
- O O 0.8920844197273254
inflammatory O O 0.941725492477417
drugs O O 0.9661524295806885
( O O 0.9989137649536133
NSAIDs O O 0.6300219297409058
) O O 0.9998133778572083
are O O 0.999922513961792
a O O 0.9999443292617798
far O O 0.9999821186065674
more O O 0.9999707937240601
frequent O O 0.9999634027481079
cause O O 0.9999876022338867
. O O 0.9999665021896362

Overall O O 0.9999569654464722
, O O 0.9999852180480957
as O O 0.9999932050704956
an O O 0.9997578263282776
entity O O 0.9999322891235352
, O O 0.9999288320541382
ATIN O O 0.9404973387718201
remains O O 0.9999715089797974
under O O 0.9999520778656006
- O O 0.999987006187439
diagnosed O O 0.9999963045120239
, O O 0.999955415725708
as O O 0.9999737739562988
symptoms O O 0.9999967813491821
resolve O O 0.9999948740005493
spontaneously O O 0.9999982118606567
if O O 0.9999690055847168
the O O 0.9999104738235474
medication O O 0.9994325041770935
is O O 0.9999593496322632
stopped O O 0.9997922778129578
. O O 0.9999651908874512

We O O 0.9999840259552002
report O O 0.9999988079071045
on O O 0.9999922513961792
a O O 0.9999963045120239
14 O O 0.9999958276748657
- O O 0.9999822378158569
year O O 0.9999960660934448
- O O 0.9999922513961792
old O O 0.9999943971633911
boy O O 0.9999942779541016
who O O 0.9999690055847168
developed O O 0.9999898672103882
acute O O 0.9999816417694092
renal O O 0.9999420642852783
failure O O 0.999994158744812
2 O O 0.9999531507492065
weeks O O 0.9999984502792358
after O O 0.9999819993972778
aortic O O 0.9988288283348083
valve O O 0.999913215637207
surgery O O 0.9999884366989136
. O O 0.9999669790267944

He O O 0.9999579191207886
was O O 0.9999599456787109
put O O 0.9999759197235107
on O O 0.9977198243141174
aspirin B B 0.9989089965820312
following O O 0.9998205304145813
surgery O O 0.9999974966049194
and O O 0.9999475479125977
took O O 0.9985122084617615
ibuprofen B B 0.9957180619239807
for O O 0.9993770718574524
fever O O 0.9995805621147156
for O O 0.9999728202819824
nearly O O 0.9999967813491821
a O O 0.9999964237213135
week O O 0.999998927116394
prior O O 0.9999995231628418
to O O 0.9999991655349731
presentation O O 0.9999992847442627
. O O 0.9999790191650391

He O O 0.9999674558639526
then O O 0.9999915361404419
presented O O 0.9999961853027344
to O O 0.9999985694885254
the O O 0.9999990463256836
emergency O O 0.999993085861206
department O O 0.9999991655349731
feeling O O 0.9999978542327881
quite O O 0.9999957084655762
ill O O 0.9999974966049194
and O O 0.9999890327453613
was O O 0.9999905824661255
found O O 0.9999971389770508
to O O 0.9999916553497314
have O O 0.9999867677688599
a O O 0.9999731779098511
blood B B 0.4786224067211151
urea I I 0.9299017190933228
nitrogen I I 0.9994470477104187
( O O 0.9284458160400391
BUN B O 0.8156460523605347
) O O 0.9932125806808472
concentration O O 0.9995995163917542
of O O 0.9997584223747253
of O O 0.9999586343765259
147 O O 0.999983549118042
mg O O 0.9999960660934448
/ O O 0.9999847412109375
dl O O 0.9999972581863403
, O O 0.9997385144233704
creatinine B B 0.9958257675170898
of O O 0.9995393753051758
15 O O 0.9999985694885254
. O O 0.9999985694885254
3 O O 0.9999837875366211
mg O O 0.9999958276748657
/ O O 0.9999889135360718
dl O O 0.9999959468841553
and O O 0.9999141693115234
serum O O 0.9976661205291748
potassium B B 0.9979111552238464
of O O 0.9995179176330566
8 O O 0.9735360741615295
. O O 0.9999855756759644
7 O O 0.9996538162231445
mEq O O 0.9999927282333374
/ O O 0.9998633861541748
l O O 0.9996579885482788
. O O 0.9999773502349854

Dialysis O O 0.992854654788971
was O O 0.9999585151672363
immediately O O 0.9999834299087524
initiated O O 0.9999891519546509
. O O 0.999969482421875

A O O 0.999953031539917
kidney O O 0.9999350309371948
biopsy O O 0.999962568283081
showed O O 0.999895453453064
inflammatory O O 0.9988729357719421
infiltrate O O 0.999925971031189
consistent O O 0.9999632835388184
with O O 0.9998451471328735
ATIN O O 0.6430858373641968
. O O 0.9996744394302368

However O O 0.9998832941055298
, O O 0.9999430179595947
in O O 0.9998168349266052
the O O 0.9999080896377563
tubular O O 0.9999033212661743
basement O O 0.9999252557754517
membrane O O 0.9998561143875122
( O O 0.999721109867096
TBM O O 0.9612917900085449
) O O 0.9998621940612793
, O O 0.9998738765716553
very O O 0.9998568296432495
intense O O 0.9998040795326233
granular O O 0.9950096607208252
deposits O O 0.9999617338180542
of O O 0.9997311234474182
polyclonal O O 0.9970042109489441
IgG O O 0.9442955255508423
and O O 0.9955428242683411
C3 O O 0.9837805032730103
were O O 0.9999279975891113
noted O O 0.9999631643295288
. O O 0.9999501705169678

He O O 0.9999686479568481
needed O O 0.9999452829360962
dialysis O O 0.9993452429771423
for O O 0.9999333620071411
2 O O 0.9999513626098633
weeks O O 0.9999942779541016
and O O 0.9999539852142334
was O O 0.9999808073043823
treated O O 0.9999854564666748
successfully O O 0.9999868869781494
with O O 0.9998489618301392
steroids B B 0.9633404612541199
for O O 0.9988070726394653
6 O O 0.9998210072517395
months O O 0.9999961853027344
. O O 0.9999747276306152

His O O 0.9999566078186035
renal O O 0.9999356269836426
recovery O O 0.9999918937683105
and O O 0.9999867677688599
disappearance O O 0.9999849796295166
of O O 0.9999680519104004
proteinuria O O 0.9963858127593994
took O O 0.9999876022338867
a O O 0.9999954700469971
year O O 0.9999970197677612
. O O 0.9999806880950928

In O O 0.9999656677246094
conclusion O O 0.9999867677688599
, O O 0.9999759197235107
this O O 0.999992847442627
is O O 0.9999908208847046
a O O 0.9999898672103882
first O O 0.9999978542327881
report O O 0.9999947547912598
of O O 0.9999141693115234
NSAIDs O O 0.8188809156417847
- O O 0.9976716637611389
associated O O 0.9998701810836792
ATIN O O 0.9895498752593994
, O O 0.9999575614929199
showing O O 0.999882698059082
deposits O O 0.9998835325241089
of O O 0.9993519186973572
granular O O 0.8669136166572571
immune O O 0.9887657761573792
complex O O 0.9068180918693542
present O O 0.9998962879180908
only O O 0.9998862743377686
in O O 0.9996473789215088
the O O 0.9998315572738647
TBM O O 0.8857304453849792
and O O 0.9999228715896606
not O O 0.9998643398284912
in O O 0.9997155070304871
the O O 0.9998960494995117
glomeruli O O 0.9956344962120056
. O O 0.9999188184738159

Rifampicin B B 0.9855747222900391
- O O 0.9989075660705566
associated O O 0.9998107552528381
segmental O O 0.9999746084213257
necrotizing O O 0.9999206066131592
glomerulonephritis O O 0.9997871518135071
in O O 0.999879002571106
staphylococcal O O 0.7950422763824463
endocarditis O O 0.9989676475524902
. O O 0.999945878982544

Segmental O O 0.9995734095573425
necrotising O O 0.9999191761016846
glomerulonephritis O O 0.9997400641441345
has O O 0.9999688863754272
been O O 0.9999899864196777
reported O O 0.9999920129776001
as O O 0.9999712705612183
complication O O 0.9999916553497314
of O O 0.9998127818107605
rifampicin B B 0.9964001178741455
therapy O O 0.995864987373352
in O O 0.9999322891235352
patients O O 0.9999845027923584
receiving O O 0.9998401403427124
treatment O O 0.9999687671661377
for O O 0.9997323155403137
tuberculosis O O 0.9968650937080383
. O O 0.9999717473983765

Changing O O 0.9997711777687073
epidemiology O O 0.9999812841415405
of O O 0.9999032020568848
infections O O 0.9999688863754272
such O O 0.9999438524246216
as O O 0.9999325275421143
infective O O 0.9995594620704651
endocarditis O O 0.9999768733978271
( O O 0.9999485015869141
IE O O 0.9992953538894653
) O O 0.9999740123748779
has O O 0.9999748468399048
led O O 0.9999966621398926
to O O 0.9999840259552002
an O O 0.9999909400939941
increase O O 0.9999897480010986
in O O 0.9999691247940063
the O O 0.9999638795852661
use O O 0.9999165534973145
of O O 0.9983227849006653
rifampicin B B 0.9973154664039612
for O O 0.9987196922302246
Staphylococcal O O 0.6834604740142822
infections O O 0.9999473094940186
. O O 0.9999699592590332

We O O 0.9999802112579346
describe O O 0.9999960660934448
a O O 0.9999934434890747
case O O 0.9999971389770508
of O O 0.999990701675415
a O O 0.9999908208847046
patient O O 0.9999932050704956
with O O 0.9999390840530396
Staphylococcal O O 0.7155506610870361
IE O O 0.8397274613380432
who O O 0.9999212026596069
developed O O 0.9999853372573853
acute O O 0.9999781847000122
renal O O 0.9999934434890747
failure O O 0.9999961853027344
secondary O O 0.9999805688858032
to O O 0.9999551773071289
a O O 0.9999774694442749
segmental O O 0.9999501705169678
necrotising O O 0.9999332427978516
glomerulonephritis O O 0.999062716960907
while O O 0.9998776912689209
being O O 0.9999639987945557
treated O O 0.9999608993530273
with O O 0.9996641874313354
rifampicin B B 0.8576669692993164
, O O 0.9992901086807251
and O O 0.9999487400054932
review O O 0.9999938011169434
the O O 0.9999977350234985
literature O O 0.9999970197677612
regarding O O 0.9999910593032837
this O O 0.9999809265136719
complication O O 0.9999977350234985
of O O 0.9998764991760254
rifampicin B B 0.9952357411384583
therapy O O 0.9993170499801636
. O O 0.9999760389328003

Rate O O 0.9972334504127502
of O O 0.9987674951553345
YMDD O O 0.48945993185043335
motif O O 0.9069152474403381
mutants O O 0.9914719462394714
in O O 0.9998130202293396
lamivudine B B 0.997350811958313
- O O 0.9981073141098022
untreated O O 0.9989137649536133
Iranian O O 0.5352698564529419
patients O O 0.9999569654464722
with O O 0.9999727010726929
chronic O O 0.9997621178627014
hepatitis O O 0.796700656414032
B O O 0.5424025058746338
virus O O 0.624543309211731
infection O O 0.9999033212661743
. O O 0.9999678134918213

BACKGROUND O O 0.7910641431808472
: O O 0.9972836971282959
Lamivudine B B 0.9989392161369324
is O O 0.9987009763717651
used O O 0.9994906187057495
for O O 0.9998619556427002
the O O 0.9999357461929321
treatment O O 0.999954104423523
of O O 0.9999693632125854
chronic O O 0.9996497631072998
hepatitis O O 0.9968397617340088
B O O 0.9663295149803162
patients O O 0.9999661445617676
. O O 0.9998798370361328

Recent O O 0.9999771118164062
studies O O 0.99998939037323
show O O 0.9999765157699585
that O O 0.9998886585235596
the O O 0.9997699856758118
YMDD O O 0.6662582159042358
motif O O 0.8909454941749573
mutants O O 0.9995088577270508
( O O 0.9996044039726257
resistant O O 0.9994207620620728
hepatitis O O 0.7462162971496582
B O O 0.5162984132766724
virus O O 0.7028722167015076
) O O 0.9991727471351624
occur O O 0.9999687671661377
as O O 0.999950647354126
natural O O 0.9999732971191406
genome O O 0.9999819993972778
variability O O 0.999991774559021
in O O 0.9998815059661865
lamivudine B B 0.9991834759712219
- O O 0.9994863271713257
untreated O O 0.9987069368362427
chronic O O 0.9997665286064148
hepatitis O O 0.9306342005729675
B O O 0.858869731426239
patients O O 0.9999690055847168
. O O 0.9999732971191406

In O O 0.9999872446060181
this O O 0.9999779462814331
study O O 0.9999706745147705
we O O 0.9999616146087646
aimed O O 0.9999942779541016
to O O 0.9999953508377075
determine O O 0.9999889135360718
the O O 0.999984860420227
rate O O 0.9999617338180542
of O O 0.9999446868896484
YMDD O O 0.666581928730011
motif O O 0.9187524914741516
mutants O O 0.99932861328125
in O O 0.9998457431793213
lamivudine B B 0.9992103576660156
- O O 0.9991093277931213
untreated O O 0.9987758994102478
chronic O O 0.9982611536979675
hepatitis O O 0.9732485413551331
B O O 0.8897839188575745
patients O O 0.9999616146087646
in O O 0.9998231530189514
Iran O O 0.977371871471405
. O O 0.999944806098938

PATIENTS O O 0.9999456405639648
AND O O 0.9999808073043823
METHODS O O 0.9999665021896362
: O O 0.9999920129776001
A O O 0.9999921321868896
total O O 0.9999802112579346
of O O 0.9999873638153076
77 O O 0.9999831914901733
chronic O O 0.9996680021286011
hepatitis O O 0.9938410520553589
B O O 0.9708223342895508
patients O O 0.9999779462814331
who O O 0.9999672174453735
had O O 0.9999943971633911
not O O 0.9999886751174927
been O O 0.9999897480010986
treated O O 0.9999337196350098
with O O 0.999656081199646
lamivudine B B 0.9965182542800903
were O O 0.9998723268508911
included O O 0.999994158744812
in O O 0.9999904632568359
the O O 0.9999951124191284
study O O 0.9999943971633911
. O O 0.9999725818634033

Serum O O 0.9998555183410645
samples O O 0.9999760389328003
from O O 0.9999697208404541
patients O O 0.9999839067459106
were O O 0.9999690055847168
tested O O 0.9999717473983765
by O O 0.9999487400054932
polymerase O O 0.9919517040252686
chain O O 0.9888288378715515
reaction O O 0.980994462966919
- O O 0.9853260517120361
restriction O O 0.9619889259338379
fragment O O 0.9414465427398682
length O O 0.9638780951499939
polymorphism O O 0.9888152480125427
( O O 0.9997838139533997
PCR O O 0.9417281150817871
- O O 0.986009955406189
RFLP O O 0.9571993350982666
) O O 0.9999535083770752
for O O 0.9999706745147705
detection O O 0.9999728202819824
of O O 0.9999098777770996
YMDD O O 0.5644266605377197
motif O O 0.9887714982032776
mutants O O 0.9998219609260559
. O O 0.9999496936798096

All O O 0.9999526739120483
patients O O 0.9999823570251465
were O O 0.9999760389328003
also O O 0.9999603033065796
tested O O 0.999916672706604
for O O 0.9990857839584351
liver O O 0.8639065623283386
enzymes O O 0.9538691639900208
, O O 0.9996306896209717
anti O O 0.6882188320159912
- O O 0.9093245267868042
HCV O O 0.5252854824066162
, O O 0.978226363658905
HBeAg B O 0.7751479148864746
, O O 0.8962298035621643
and O O 0.9938226938247681
anti O O 0.49370768666267395
- O O 0.7475154995918274
HBe O O 0.691483736038208
. O O 0.9998947381973267

RESULTS O O 0.9998283386230469
: O O 0.9999234676361084
Of O O 0.9999527931213379
the O O 0.9999934434890747
77 O O 0.999990701675415
patients O O 0.9999946355819702
enrolled O O 0.9999969005584717
in O O 0.9999910593032837
the O O 0.9999961853027344
study O O 0.9999788999557495
, O O 0.9999450445175171
73 O O 0.999991774559021
% O O 0.9999940395355225
were O O 0.999943733215332
male O O 0.9999305009841919
and O O 0.9999303817749023
27 O O 0.999977707862854
% O O 0.9999899864196777
were O O 0.9999423027038574
female O O 0.9999910593032837
. O O 0.9999738931655884

Mean O O 0.9998406171798706
ALT O O 0.8351134657859802
and O O 0.9991968274116516
AST O O 0.4881628453731537
levels O O 0.9998348951339722
were O O 0.9999696016311646
124 O O 0.997380793094635
. O O 0.99998939037323
4 O O 0.9999662637710571
+ O O 0.9999892711639404
/ O O 0.9998736381530762
- O O 0.9995538592338562
73 O O 0.999976396560669
. O O 0.9999927282333374
4 O O 0.9996199607849121
and O O 0.9998284578323364
103 O O 0.9968281388282776
. O O 0.999991774559021
1 O O 0.9999911785125732
+ O O 0.9999890327453613
/ O O 0.9998045563697815
- O O 0.9998431205749512
81 O O 0.9996548891067505
IU O O 0.9996533393859863
/ O O 0.9998247027397156
l O O 0.9978941082954407
, O O 0.9999772310256958
respectively O O 0.9999622106552124
. O O 0.99997878074646

HBeAg B B 0.8501541018486023
was O O 0.9997087121009827
positive O O 0.9998351335525513
in O O 0.9999517202377319
40 O O 0.999948263168335
% O O 0.9999878406524658
and O O 0.999367892742157
anti O O 0.49373942613601685
- O O 0.8739470839500427
HBe O O 0.474901407957077
in O O 0.9999088048934937
60 O O 0.999987006187439
% O O 0.9999957084655762
of O O 0.9999855756759644
the O O 0.999980092048645
patients O O 0.999991774559021
. O O 0.9999696016311646

Anti O O 0.9037820100784302
- O O 0.981913149356842
HCV O O 0.6471730470657349
was O O 0.9998481273651123
negative O O 0.9994903802871704
in O O 0.9998167157173157
all O O 0.9998185038566589
of O O 0.9999122619628906
them O O 0.9999240636825562
. O O 0.999954104423523

YMDD O O 0.6274696588516235
motif O O 0.7617650032043457
mutants O O 0.916690468788147
were O O 0.9999029636383057
not O O 0.9999362230300903
detected O O 0.9999450445175171
in O O 0.9998959302902222
any O O 0.9998944997787476
of O O 0.9999738931655884
the O O 0.9999779462814331
patients O O 0.9999815225601196
despite O O 0.9998297691345215
the O O 0.9999796152114868
liver O O 0.9711020588874817
enzyme O O 0.9866158962249756
levels O O 0.9998522996902466
and O O 0.9999750852584839
the O O 0.9999938011169434
presence O O 0.9999426603317261
of O O 0.9997451901435852
HBeAg B B 0.8503097891807556
or O O 0.9302577972412109
anti O O 0.4562050402164459
- O O 0.8578699231147766
HBe O O 0.7420985698699951
. O O 0.9997836947441101

CONCLUSION O O 0.9998534917831421
: O O 0.9999425411224365
Although O O 0.9999843835830688
the O O 0.9999920129776001
natural O O 0.9999915361404419
occurrence O O 0.9999892711639404
of O O 0.9998595714569092
YMDD O O 0.5646884441375732
motif O O 0.9527420401573181
mutants O O 0.9978474378585815
in O O 0.9999011754989624
lamivudine B B 0.9821112751960754
- O O 0.9915058016777039
untreated O O 0.9948598146438599
patients O O 0.9999866485595703
with O O 0.999977707862854
chronic O O 0.999778687953949
hepatitis O O 0.996673583984375
B O O 0.9808743596076965
has O O 0.9999731779098511
been O O 0.9999916553497314
reported O O 0.9999927282333374
, O O 0.9999758005142212
these O O 0.9997186064720154
mutants O O 0.9997788071632385
were O O 0.9999706745147705
not O O 0.9999827146530151
detected O O 0.999985933303833
in O O 0.9999215602874756
Iranian O O 0.7914284467697144
lamivudine B B 0.9956467747688293
- O O 0.9892190098762512
untreated O O 0.9806898236274719
chronic O O 0.9990110397338867
hepatitis O O 0.9695357084274292
B O O 0.9442197680473328
patients O O 0.9999699592590332
. O O 0.9999765157699585

Branch O O 0.9987006187438965
retinal O O 0.9995228052139282
vein O O 0.9982207417488098
occlusion O O 0.9997798800468445
and O O 0.9970502853393555
fluoxetine B B 0.999164342880249
. O O 0.9994710087776184

A O O 0.9999585151672363
case O O 0.9999808073043823
of O O 0.9999477863311768
branch O O 0.9909018278121948
retinal O O 0.999908447265625
vein O O 0.9998471736907959
occlusion O O 0.9999356269836426
associated O O 0.9999141693115234
with O O 0.9998811483383179
fluoxetine B B 0.9996980428695679
- O O 0.9996278285980225
induced O O 0.9998952150344849
secondary O O 0.9997270703315735
hypertension O O 0.997312068939209
is O O 0.9999622106552124
described O O 0.9999914169311523
. O O 0.999977707862854

Although O O 0.9999418258666992
an O O 0.9999810457229614
infrequent O O 0.9999648332595825
complication O O 0.9999904632568359
of O O 0.9998247027397156
selective O O 0.9525608420372009
serotonin B B 0.9396450519561768
reuptake O O 0.7696639895439148
inhibitor O O 0.9039918780326843
therapy O O 0.9964763522148132
, O O 0.9999275207519531
it O O 0.9999836683273315
is O O 0.9999765157699585
important O O 0.9999902248382568
that O O 0.999987006187439
ophthalmologists O O 0.9998629093170166
are O O 0.9999829530715942
aware O O 0.9999890327453613
that O O 0.9999709129333496
these O O 0.9977374076843262
agents O O 0.9934439659118652
can O O 0.9999392032623291
cause O O 0.9999116659164429
hypertension O O 0.9997836947441101
because O O 0.999963641166687
this O O 0.9998501539230347
class O O 0.991926908493042
of O O 0.9950130581855774
drugs O O 0.9923580288887024
is O O 0.999956488609314
widely O O 0.9997683167457581
prescribed O O 0.9998719692230225
. O O 0.9999731779098511

The O O 0.9999547004699707
differential O O 0.9997435212135315
effects O O 0.9999474287033081
of O O 0.9997490048408508
bupivacaine B B 0.9997265934944153
and O O 0.9599591493606567
lidocaine B B 0.9998151659965515
on O O 0.9997617602348328
prostaglandin B O 0.6330633163452148
E2 I O 0.7309004664421082
release O O 0.9890762567520142
, O O 0.9998677968978882
cyclooxygenase O O 0.6443839073181152
gene O O 0.9985461235046387
expression O O 0.9999587535858154
and O O 0.9999202489852905
pain O O 0.9999750852584839
in O O 0.9999850988388062
a O O 0.9999828338623047
clinical O O 0.9999474287033081
pain O O 0.9998387098312378
model O O 0.9999923706054688
. O O 0.9999822378158569

BACKGROUND O O 0.9924039244651794
: O O 0.9999157190322876
In O O 0.9999732971191406
addition O O 0.9998912811279297
to O O 0.9998983144760132
blocking O O 0.999377965927124
nociceptive O O 0.9904363751411438
input O O 0.9999717473983765
from O O 0.9999129772186279
surgical O O 0.9999876022338867
sites O O 0.9999918937683105
, O O 0.9995263814926147
long O O 0.9985930323600769
- O O 0.9999288320541382
acting O O 0.9974110722541809
local O O 0.9873064756393433
anesthetics O O 0.7308695316314697
might O O 0.9998078942298889
directly O O 0.9998862743377686
modulate O O 0.9999611377716064
inflammation O O 0.9999874830245972
. O O 0.9999750852584839

In O O 0.9999833106994629
the O O 0.9999958276748657
present O O 0.9999879598617554
study O O 0.9999867677688599
, O O 0.999962329864502
we O O 0.9999333620071411
describe O O 0.999937891960144
the O O 0.9998984336853027
proinflammatory O O 0.9855799674987793
effects O O 0.9999291896820068
of O O 0.9995898604393005
bupivacaine B B 0.9996559619903564
on O O 0.9991768002510071
local O O 0.9178500771522522
prostaglandin B O 0.45160436630249023
E2 I O 0.8999488949775696
( O O 0.9782325029373169
PGE2 B O 0.531241238117218
) O O 0.9948875308036804
production O O 0.9996323585510254
and O O 0.9997963309288025
cyclooxygenase O O 0.632442831993103
( O O 0.9628950953483582
COX O O 0.4859134256839752
) O O 0.9988731741905212
gene O O 0.9993929862976074
expression O O 0.9999176263809204
that O O 0.9999183416366577
increases O O 0.9996875524520874
postoperative O O 0.9999467134475708
pain O O 0.9998781681060791
in O O 0.999829888343811
human O O 0.99842369556427
subjects O O 0.9999517202377319
. O O 0.9999780654907227

METHODS O O 0.9996256828308105
: O O 0.9999833106994629
Subjects O O 0.9998458623886108
( O O 0.9999798536300659
n O O 0.9999864101409912
= O O 0.9999873638153076
114 O O 0.9960636496543884
) O O 0.9999905824661255
undergoing O O 0.9999876022338867
extraction O O 0.9999865293502808
of O O 0.9999755620956421
impacted O O 0.999923825263977
third O O 0.9960225820541382
molars O O 0.9995995163917542
received O O 0.9999215602874756
either O O 0.9998002648353577
2 O O 0.9985270500183105
% O O 0.9988480806350708
lidocaine B B 0.9996248483657837
or O O 0.9973307847976685
0 O O 0.9998470544815063
. O O 0.9999872446060181
5 O O 0.9999840259552002
% O O 0.9996181726455688
bupivacaine B B 0.999045193195343
before O O 0.9997124075889587
surgery O O 0.9999980926513672
and O O 0.9998971223831177
either O O 0.9906595945358276
rofecoxib B B 0.9980061650276184
50 O O 0.9493935704231262
mg O O 0.9988409876823425
or O O 0.9995388984680176
placebo O O 0.9835947155952454
orally O O 0.9991645812988281
90 O O 0.99992835521698
min O O 0.9999735355377197
before O O 0.9999897480010986
surgery O O 0.9999974966049194
and O O 0.9999885559082031
for O O 0.9999619722366333
the O O 0.9999947547912598
following O O 0.9999967813491821
48 O O 0.9999970197677612
h O O 0.9999493360519409
. O O 0.9999744892120361

Oral O O 0.998975396156311
mucosal O O 0.9998220801353455
biopsies O O 0.9998636245727539
were O O 0.9999805688858032
taken O O 0.9999947547912598
before O O 0.9999649524688721
surgery O O 0.9999947547912598
and O O 0.9999748468399048
48 O O 0.9999769926071167
h O O 0.998187243938446
after O O 0.9999606609344482
surgery O O 0.9999942779541016
. O O 0.9999767541885376

After O O 0.9999090433120728
extraction O O 0.9999719858169556
, O O 0.9999706745147705
a O O 0.99998939037323
microdialysis O O 0.9943833351135254
probe O O 0.9999769926071167
was O O 0.9999555349349976
placed O O 0.9999723434448242
at O O 0.9999626874923706
the O O 0.9999943971633911
surgical O O 0.9999927282333374
site O O 0.9999922513961792
for O O 0.9999618530273438
PGE2 B O 0.6271113157272339
and O O 0.9989731311798096
thromboxane B O 0.7744065523147583
B2 I O 0.783935010433197
( O O 0.9982628226280212
TXB2 B O 0.49781689047813416
) O O 0.9998352527618408
measurements O O 0.9999485015869141
. O O 0.9999808073043823

RESULTS O O 0.9999344348907471
: O O 0.9999778270721436
The O O 0.9999107122421265
bupivacaine B B 0.9995755553245544
/ O O 0.9215748906135559
rofecoxib B B 0.9940236210823059
group O O 0.9998482465744019
reported O O 0.999987006187439
significantly O O 0.9999961853027344
less O O 0.9999872446060181
pain O O 0.9999864101409912
, O O 0.9999933242797852
as O O 0.9999980926513672
assessed O O 0.999998927116394
by O O 0.9999955892562866
a O O 0.9999922513961792
visual O O 0.9999761581420898
analog O O 0.9999959468841553
scale O O 0.9999967813491821
, O O 0.9999912977218628
compared O O 0.9999812841415405
with O O 0.9999697208404541
the O O 0.9999501705169678
other O O 0.999945878982544
three O O 0.9997488856315613
treatment O O 0.9998099207878113
groups O O 0.9999542236328125
over O O 0.9999517202377319
the O O 0.9999923706054688
first O O 0.9999959468841553
4 O O 0.999964714050293
h O O 0.9999608993530273
. O O 0.9999526739120483

However O O 0.9999728202819824
, O O 0.999923825263977
the O O 0.9999474287033081
bupivacaine B B 0.9995287656784058
/ O O 0.9921362400054932
placebo O O 0.9997319579124451
group O O 0.999920129776001
reported O O 0.9999885559082031
significantly O O 0.999993085861206
more O O 0.999980092048645
pain O O 0.9999877214431763
at O O 0.9999586343765259
24 O O 0.9999815225601196
h O O 0.9998328685760498
and O O 0.9999551773071289
PGE2 B O 0.8692570924758911
levels O O 0.9989595413208008
during O O 0.9998464584350586
the O O 0.9999871253967285
first O O 0.9999896287918091
4 O O 0.9996422529220581
h O O 0.9962013363838196
were O O 0.9999568462371826
significantly O O 0.9999681711196899
higher O O 0.9998756647109985
than O O 0.9999637603759766
the O O 0.9999678134918213
other O O 0.9999244213104248
three O O 0.9997796416282654
treatment O O 0.9997757077217102
groups O O 0.9999666213989258
. O O 0.999976634979248

Moreover O O 0.9999454021453857
, O O 0.9995909333229065
bupivacaine B B 0.9998432397842407
significantly O O 0.9998834133148193
increased O O 0.999886155128479
COX O O 0.961676299571991
- O O 0.9963226318359375
2 O O 0.9917633533477783
gene O O 0.9997718930244446
expression O O 0.999985933303833
at O O 0.999957799911499
48 O O 0.9999819993972778
h O O 0.99982088804245
as O O 0.9999271631240845
compared O O 0.9999849796295166
with O O 0.9999852180480957
the O O 0.999954342842102
lidocaine B B 0.999524712562561
/ O O 0.9931349754333496
placebo O O 0.9992539286613464
group O O 0.9999452829360962
. O O 0.9999700784683228

Thromboxane B O 0.6616780161857605
levels O O 0.9996787309646606
were O O 0.9999374151229858
not O O 0.9999393224716187
significantly O O 0.9999784231185913
affected O O 0.9999886751174927
by O O 0.9999443292617798
any O O 0.9997490048408508
of O O 0.9993149042129517
the O O 0.9995261430740356
treatments O O 0.9999210834503174
, O O 0.999951958656311
indicating O O 0.9998557567596436
that O O 0.9998905658721924
the O O 0.9999719858169556
effects O O 0.9999632835388184
seen O O 0.9999935626983643
were O O 0.9999368190765381
attributable O O 0.9999759197235107
to O O 0.9994816184043884
inhibition O O 0.9972941279411316
of O O 0.9983662962913513
COX O O 0.7540504336357117
- O O 0.9415448307991028
2 O O 0.9190849661827087
, O O 0.9997854828834534
but O O 0.9999605417251587
not O O 0.9997184872627258
COX O O 0.7645545601844788
- O O 0.975293755531311
1 O O 0.9924206137657166
. O O 0.99991774559021

CONCLUSIONS O O 0.9971332550048828
: O O 0.999995231628418
These O O 0.9999948740005493
results O O 0.9999878406524658
suggest O O 0.9999136924743652
that O O 0.9998356103897095
bupivacaine B B 0.9997139573097229
stimulates O O 0.9988388419151306
COX O O 0.9279738664627075
- O O 0.9943670630455017
2 O O 0.9904492497444153
gene O O 0.9997376799583435
expression O O 0.9999457597732544
after O O 0.9998716115951538
tissue O O 0.9999779462814331
injury O O 0.9999959468841553
, O O 0.9999749660491943
which O O 0.9999274015426636
is O O 0.9999676942825317
associated O O 0.9999842643737793
with O O 0.999955415725708
higher O O 0.999316930770874
PGE2 B O 0.5176888704299927
production O O 0.9998273253440857
and O O 0.9999334812164307
pain O O 0.9999901056289673
after O O 0.9999731779098511
the O O 0.999966025352478
local O O 0.9994977712631226
anesthetic O O 0.9943585991859436
effect O O 0.9999076128005981
dissipates O O 0.9999666213989258
. O O 0.9999713897705078

p75NTR O O 0.6468424797058105
expression O O 0.9997407793998718
in O O 0.9998495578765869
rat O O 0.9998626708984375
urinary O O 0.9999030828475952
bladder O O 0.9994640946388245
sensory O O 0.9455859661102295
neurons O O 0.999929666519165
and O O 0.9997597336769104
spinal O O 0.9999881982803345
cord O O 0.9999966621398926
with O O 0.9999679327011108
cyclophosphamide B B 0.9986502528190613
- O O 0.9992108345031738
induced O O 0.9998852014541626
cystitis O O 0.995324969291687
. O O 0.9999513626098633

A O O 0.999910831451416
role O O 0.9998984336853027
for O O 0.9993477463722229
nerve O O 0.9855374693870544
growth O O 0.9814538955688477
factor O O 0.9870375394821167
( O O 0.9986339211463928
NGF O O 0.5293177962303162
) O O 0.9997197985649109
in O O 0.9998949766159058
contributing O O 0.9999707937240601
to O O 0.9999806880950928
increased O O 0.9999842643737793
voiding O O 0.9999934434890747
frequency O O 0.9999972581863403
and O O 0.9999774694442749
altered O O 0.999984860420227
sensation O O 0.9999936819076538
from O O 0.9999668598175049
the O O 0.999985933303833
urinary O O 0.9999685287475586
bladder O O 0.9983068704605103
has O O 0.9999792575836182
been O O 0.9999934434890747
suggested O O 0.9999854564666748
. O O 0.9999715089797974

Previous O O 0.9999113082885742
studies O O 0.9999793767929077
have O O 0.9999631643295288
examined O O 0.9999252557754517
the O O 0.9999632835388184
expression O O 0.9999582767486572
and O O 0.9999105930328369
regulation O O 0.999945878982544
of O O 0.999497652053833
tyrosine B O 0.4973444938659668
kinase O O 0.7312957644462585
receptors O O 0.9961387515068054
( O O 0.9996540546417236
Trks O O 0.9455400109291077
) O O 0.9999172687530518
in O O 0.999754011631012
micturition O O 0.9999774694442749
reflexes O O 0.9999333620071411
with O O 0.9999606609344482
urinary O O 0.9998900890350342
bladder O O 0.9958726763725281
inflammation O O 0.9999496936798096
. O O 0.9999727010726929

The O O 0.9999887943267822
present O O 0.999976634979248
studies O O 0.9999867677688599
examine O O 0.9999310970306396
the O O 0.9999586343765259
expression O O 0.9999659061431885
and O O 0.9999409914016724
regulation O O 0.9999648332595825
of O O 0.9997943043708801
another O O 0.9997848868370056
receptor O O 0.9995492100715637
known O O 0.9998291730880737
to O O 0.9995935559272766
bind O O 0.9984537363052368
NGF O O 0.799592137336731
, O O 0.9998112320899963
p75 O O 0.8917824029922485
( O O 0.9991047978401184
NTR O O 0.8765805959701538
) O O 0.9999068975448608
, O O 0.9999779462814331
after O O 0.9998212456703186
various O O 0.9999421834945679
durations O O 0.9999173879623413
of O O 0.9999479055404663
bladder O O 0.988918125629425
inflammation O O 0.9999436140060425
induced O O 0.9999691247940063
by O O 0.999880313873291
cyclophosphamide B B 0.9988330006599426
( O O 0.9931960105895996
CYP B B 0.9892703294754028
) O O 0.999288022518158
. O O 0.9999597072601318

CYP B B 0.9272246360778809
- O O 0.9954664707183838
induced O O 0.9997789263725281
cystitis O O 0.9880338311195374
increased O O 0.9989720582962036
( O O 0.9995947480201721
P O O 0.9930478930473328
< O O 0.9999861717224121
or O O 0.999997615814209
= O O 0.9999852180480957
0 O O 0.9999837875366211
. O O 0.999996542930603
001 O O 0.9998236298561096
) O O 0.9992875456809998
p75 O O 0.6012458801269531
( O O 0.991869330406189
NTR O O 0.9335827827453613
) O O 0.9995757937431335
expression O O 0.9998416900634766
in O O 0.9997368454933167
the O O 0.9998664855957031
superficial O O 0.9997567534446716
lateral O O 0.9996134638786316
and O O 0.9996621608734131
medial O O 0.999945878982544
dorsal O O 0.9998950958251953
horn O O 0.9999784231185913
in O O 0.9996469020843506
L1 O O 0.9978016018867493
- O O 0.997757613658905
L2 O O 0.9990091323852539
and O O 0.9996834993362427
L6 O O 0.9965002536773682
- O O 0.9942861199378967
S1 O O 0.995900571346283
spinal O O 0.9996465444564819
segments O O 0.9999653100967407
. O O 0.9999418258666992

The O O 0.9999890327453613
number O O 0.9999853372573853
of O O 0.9999547004699707
p75 O O 0.6825730800628662
( O O 0.9945908784866333
NTR O O 0.9082623720169067
) O O 0.9642653465270996
- O O 0.9984419941902161
immunoreactive O O 0.9995315074920654
( O O 0.9010356068611145
- O O 0.9688754677772522
IR O O 0.7718880772590637
) O O 0.9997175335884094
cells O O 0.9999797344207764
in O O 0.99960857629776
the O O 0.9999369382858276
lumbosacral O O 0.996317982673645
dorsal O O 0.9999399185180664
root O O 0.9995235204696655
ganglia O O 0.9998725652694702
( O O 0.9997798800468445
DRG O O 0.9881532788276672
) O O 0.99993896484375
also O O 0.9999699592590332
increased O O 0.9999420642852783
( O O 0.9999516010284424
P O O 0.9999476671218872
< O O 0.9999872446060181
or O O 0.9999945163726807
= O O 0.9999712705612183
0 O O 0.9999902248382568
. O O 0.9999945163726807
05 O O 0.9999970197677612
) O O 0.9999922513961792
with O O 0.9999744892120361
CYP B B 0.989058792591095
- O O 0.9982213377952576
induced O O 0.9998832941055298
cystitis O O 0.9989356398582458
( O O 0.9998947381973267
acute O O 0.9999140501022339
, O O 0.999826967716217
intermediate O O 0.9832417964935303
, O O 0.9996277093887329
and O O 0.9997908473014832
chronic O O 0.9996812343597412
) O O 0.9999685287475586
. O O 0.9999624490737915

Quantitative O O 0.9998094439506531
, O O 0.9999468326568604
real O O 0.9998461008071899
- O O 0.9999675750732422
time O O 0.9988276362419128
polymerase O O 0.9915426969528198
chain O O 0.9940472841262817
reaction O O 0.9990463852882385
also O O 0.9999730587005615
demonstrated O O 0.9999532699584961
significant O O 0.9999767541885376
increases O O 0.999923825263977
( O O 0.9999345541000366
P O O 0.999661922454834
< O O 0.9999918937683105
or O O 0.999997615814209
= O O 0.9999890327453613
0 O O 0.9999899864196777
. O O 0.9999961853027344
01 O O 0.9999963045120239
) O O 0.9999817609786987
in O O 0.9998074173927307
p75 O O 0.8253471255302429
( O O 0.9981496334075928
NTR O O 0.969639778137207
) O O 0.9973262548446655
mRNA O O 0.9505307674407959
in O O 0.9995001554489136
DRG O O 0.9252511262893677
with O O 0.9999605417251587
intermediate O O 0.9945018291473389
and O O 0.9999183416366577
chronic O O 0.9998390674591064
CYP B B 0.9445359706878662
- O O 0.9970830082893372
induced O O 0.9999344348907471
cystitis O O 0.9986276626586914
. O O 0.9999761581420898

Retrograde O O 0.9999021291732788
dye O O 0.9699093103408813
- O O 0.9994483590126038
tracing O O 0.9987545013427734
techniques O O 0.9999853372573853
with O O 0.9998481273651123
Fastblue O O 0.6028392910957336
were O O 0.9998866319656372
used O O 0.9999665021896362
to O O 0.9999747276306152
identify O O 0.9999562501907349
presumptive O O 0.999894380569458
bladder O O 0.878086507320404
afferent O O 0.9875449538230896
cells O O 0.9999746084213257
in O O 0.9997971653938293
the O O 0.9999215602874756
lumbosacral O O 0.9985793828964233
DRG O O 0.9981514811515808
. O O 0.9999431371688843

In O O 0.9994136095046997
bladder O O 0.9118857979774475
afferent O O 0.9749544858932495
cells O O 0.999967098236084
in O O 0.9988048076629639
DRG O O 0.9501183032989502
, O O 0.9993129968643188
p75 O O 0.5250590443611145
( O O 0.9974783062934875
NTR O O 0.9236850142478943
) O O 0.980175793170929
- O O 0.9808821082115173
IR O O 0.8547737002372742
was O O 0.999956488609314
also O O 0.999963641166687
increased O O 0.9999028444290161
( O O 0.9999226331710815
P O O 0.9965044260025024
< O O 0.9999785423278809
or O O 0.9999947547912598
= O O 0.9998618364334106
0 O O 0.9999597072601318
. O O 0.9999954700469971
01 O O 0.9999784231185913
) O O 0.9999829530715942
with O O 0.99997878074646
cystitis O O 0.9929829835891724
. O O 0.9999517202377319

In O O 0.999936580657959
addition O O 0.9999477863311768
to O O 0.9999282360076904
increases O O 0.9998928308486938
in O O 0.9998900890350342
p75 O O 0.7999267578125
( O O 0.9925974607467651
NTR O O 0.9755054116249084
) O O 0.9758962392807007
- O O 0.9865309596061707
IR O O 0.8909862637519836
in O O 0.9994674324989319
DRG O O 0.9663136005401611
cell O O 0.9999010562896729
bodies O O 0.9999227523803711
, O O 0.9998420476913452
increases O O 0.999771773815155
( O O 0.9997949004173279
P O O 0.9992367029190063
< O O 0.9999904632568359
or O O 0.999994158744812
= O O 0.9999827146530151
0 O O 0.999980092048645
. O O 0.9999953508377075
001 O O 0.9998890161514282
) O O 0.9999076128005981
in O O 0.9997760653495789
pericellular O O 0.99303138256073
( O O 0.996306300163269
encircling O O 0.9977760910987854
DRG O O 0.9658041596412659
cells O O 0.9999628067016602
) O O 0.9997105002403259
p75 O O 0.5581868290901184
( O O 0.9709312319755554
NTR O O 0.9406548142433167
) O O 0.9325496554374695
- O O 0.9724180698394775
IR O O 0.7736098170280457
in O O 0.9952204823493958
DRG O O 0.9126393795013428
also O O 0.9999178647994995
increased O O 0.9997383952140808
. O O 0.99997878074646

Confocal O O 0.9997087121009827
analyses O O 0.9999905824661255
demonstrated O O 0.9999821186065674
that O O 0.999826967716217
pericellular O O 0.9957872033119202
p75 O O 0.5320227742195129
( O O 0.9943607449531555
NTR O O 0.918764054775238
) O O 0.959072470664978
- O O 0.9834554195404053
IR O O 0.7736056447029114
was O O 0.9999178647994995
not O O 0.9999595880508423
colocalized O O 0.9995893836021423
with O O 0.9999325275421143
the O O 0.9998966455459595
glial O O 0.998630940914154
marker O O 0.9999537467956543
, O O 0.9940571784973145
glial O O 0.7405381798744202
fibrillary O O 0.9850283861160278
acidic O O 0.9750814437866211
protein O O 0.9934659600257874
( O O 0.9989572763442993
GFAP O O 0.600054144859314
) O O 0.9998621940612793
. O O 0.9999357461929321

These O O 0.9999672174453735
studies O O 0.9999830722808838
demonstrate O O 0.9999734163284302
that O O 0.9997500777244568
p75 O O 0.805061399936676
( O O 0.9964828491210938
NTR O O 0.9020888209342957
) O O 0.9993089437484741
expression O O 0.9998044371604919
in O O 0.9997299313545227
micturition O O 0.9999465942382812
reflexes O O 0.9996470212936401
is O O 0.999859094619751
present O O 0.999824583530426
constitutively O O 0.9859189987182617
and O O 0.9999465942382812
modified O O 0.9999463558197021
by O O 0.9999547004699707
bladder O O 0.9815695285797119
inflammation O O 0.99994957447052
. O O 0.9999560117721558

The O O 0.999972939491272
functional O O 0.9999598264694214
significance O O 0.9999886751174927
of O O 0.9998856782913208
p75 O O 0.7171046733856201
( O O 0.9968687891960144
NTR O O 0.8436692953109741
) O O 0.9969645142555237
expression O O 0.9998694658279419
in O O 0.9996634721755981
micturition O O 0.9999902248382568
reflexes O O 0.9998999834060669
remains O O 0.9999438524246216
to O O 0.99998939037323
be O O 0.9999949932098389
determined O O 0.9999951124191284
. O O 0.9999725818634033

Azathioprine B B 0.998762845993042
- O O 0.999363362789154
induced O O 0.9998612403869629
suicidal O O 0.9963846206665039
erythrocyte O O 0.9999860525131226
death O O 0.9999492168426514
. O O 0.999817430973053

BACKGROUND O O 0.9585614204406738
: O O 0.9985467791557312
Azathioprine B B 0.999649167060852
is O O 0.9991992115974426
widely O O 0.9988480806350708
used O O 0.9996626377105713
as O O 0.9999014139175415
an O O 0.9966424703598022
immunosuppressive O O 0.9992771744728088
drug O O 0.9980944991111755
. O O 0.9997554421424866

The O O 0.999890923500061
side O O 0.9999037981033325
effects O O 0.9999414682388306
of O O 0.9997941851615906
azathioprine B B 0.9991907477378845
include O O 0.9996777772903442
anemia O O 0.9997212290763855
, O O 0.9999759197235107
which O O 0.9999706745147705
has O O 0.999964714050293
been O O 0.9999873638153076
attributed O O 0.9999911785125732
to O O 0.9997407793998718
bone O O 0.9998584985733032
marrow O O 0.9999961853027344
suppression O O 0.9998795986175537
. O O 0.9999479055404663

Alternatively O O 0.9999434947967529
, O O 0.9999411106109619
anemia O O 0.9997249245643616
could O O 0.999887228012085
result O O 0.9999799728393555
from O O 0.9999232292175293
accelerated O O 0.9998608827590942
suicidal O O 0.9954068660736084
erythrocyte O O 0.9997740387916565
death O O 0.999942421913147
or O O 0.9998664855957031
eryptosis O O 0.9994984865188599
, O O 0.9999774694442749
which O O 0.9999663829803467
is O O 0.9999489784240723
characterized O O 0.9999815225601196
by O O 0.9999395608901978
exposure O O 0.9997710585594177
of O O 0.9925347566604614
phosphatidylserine B B 0.9757314324378967
( O O 0.9762997031211853
PS B B 0.9122715592384338
) O O 0.9847849607467651
at O O 0.9999423027038574
the O O 0.9999706745147705
erythrocyte O O 0.9998706579208374
surface O O 0.9999642372131348
and O O 0.9999473094940186
by O O 0.9999198913574219
cell O O 0.9999585151672363
shrinkage O O 0.9999896287918091
. O O 0.9999704360961914

METHODS O O 0.9999110698699951
: O O 0.999963641166687
The O O 0.9999903440475464
present O O 0.9999836683273315
experiments O O 0.9999445676803589
explored O O 0.9999707937240601
whether O O 0.9998881816864014
azathioprine B B 0.9997331500053406
influences O O 0.9997969269752502
eryptosis O O 0.9999281167984009
. O O 0.999962568283081

According O O 0.9999891519546509
to O O 0.9990063309669495
annexin O O 0.5672882199287415
V O O 0.8613147735595703
binding O O 0.9746854901313782
, O O 0.9999048709869385
erythrocytes O O 0.999930739402771
from O O 0.9999232292175293
patients O O 0.9999847412109375
indeed O O 0.9999867677688599
showed O O 0.9999738931655884
a O O 0.9999902248382568
significant O O 0.9999927282333374
increase O O 0.9999711513519287
of O O 0.9998824596405029
PS B O 0.8329833745956421
exposure O O 0.9997853636741638
within O O 0.9999756813049316
1 O O 0.9999840259552002
week O O 0.9999943971633911
of O O 0.9999291896820068
treatment O O 0.9999804496765137
with O O 0.999718964099884
azathioprine B B 0.9991788268089294
. O O 0.9999239444732666

In O O 0.9999316930770874
a O O 0.9999344348907471
second O O 0.999988317489624
series O O 0.9999337196350098
, O O 0.9999697208404541
cytosolic O O 0.9985193610191345
Ca2 B B 0.9759359955787659
+ O O 0.9918730854988098
activity O O 0.9997637867927551
( O O 0.9998292922973633
Fluo3 B O 0.7257829904556274
fluorescence O O 0.9996500015258789
) O O 0.9999566078186035
, O O 0.9999518394470215
cell O O 0.9999423027038574
volume O O 0.9999182224273682
( O O 0.9999154806137085
forward O O 0.997385561466217
scatter O O 0.9996422529220581
) O O 0.9999768733978271
, O O 0.9999282360076904
and O O 0.999900221824646
PS B O 0.4907858669757843
- O O 0.8946794271469116
exposure O O 0.9550853371620178
( O O 0.9994921684265137
annexin O B 0.7805733680725098
V O I 0.9794211387634277
binding O O 0.9287511706352234
) O O 0.9999662637710571
were O O 0.9999796152114868
determined O O 0.9999927282333374
by O O 0.9999914169311523
FACS O O 0.9975399971008301
analysis O O 0.999964714050293
in O O 0.9999711513519287
erythrocytes O O 0.999981164932251
from O O 0.9999816417694092
healthy O O 0.9999874830245972
volunteers O O 0.9999973773956299
. O O 0.9999735355377197

RESULTS O O 0.9998098015785217
: O O 0.9997500777244568
Exposure O O 0.9999487400054932
to O O 0.998971700668335
azathioprine B B 0.9996955394744873
( O O 0.9997265934944153
> O O 0.999504566192627
or O O 0.9999816417694092
= O O 0.999976634979248
2 O O 0.9999382495880127
microg O O 0.9999551773071289
/ O O 0.9999147653579712
mL O O 0.9999949932098389
) O O 0.9999147653579712
for O O 0.999894380569458
48 O O 0.9999393224716187
hours O O 0.9999234676361084
increased O O 0.9998748302459717
cytosolic O O 0.9763978719711304
Ca2 B B 0.9912378191947937
+ O O 0.9939008951187134
activity O O 0.9995989203453064
and O O 0.9998645782470703
annexin O O 0.475369930267334
V O O 0.7134679555892944
binding O O 0.9993371367454529
and O O 0.9999761581420898
decreased O O 0.9999719858169556
forward O O 0.9974760413169861
scatter O O 0.9998852014541626
. O O 0.9999798536300659

The O O 0.999970555305481
effect O O 0.9999569654464722
of O O 0.999756395816803
azathioprine B B 0.9997716546058655
on O O 0.9996906518936157
both O O 0.9996340274810791
annexin O O 0.5416815876960754
V O O 0.8647913336753845
binding O O 0.9993809461593628
and O O 0.9997965693473816
forward O O 0.9989857077598572
scatter O O 0.9995717406272888
was O O 0.9999324083328247
significantly O O 0.9999743700027466
blunted O O 0.9999366998672485
in O O 0.9999697208404541
the O O 0.9999783039093018
nominal O O 0.9998517036437988
absence O O 0.9999656677246094
of O O 0.9999401569366455
extracellular O O 0.9996256828308105
Ca2 B B 0.9994992017745972
+ O O 0.8785664439201355
. O O 0.9999524354934692

CONCLUSIONS O O 0.9799413084983826
: O O 0.999488353729248
Azathioprine B B 0.9992541670799255
triggers O O 0.9993385672569275
suicidal O O 0.9992109537124634
erythrocyte O O 0.9999881982803345
death O O 0.9999619722366333
, O O 0.9999607801437378
an O O 0.9999479055404663
effect O O 0.9999442100524902
presumably O O 0.9999281167984009
contributing O O 0.9999691247940063
to O O 0.9998934268951416
azathioprine B B 0.9997456669807434
- O O 0.9997614026069641
induced O O 0.9999483823776245
anemia O O 0.9999704360961914
. O O 0.9999452829360962

Levetiracetam B B 0.9994213581085205
as O O 0.9999337196350098
an O O 0.9999277591705322
adjunct O O 0.9999418258666992
to O O 0.9996877908706665
phenobarbital B B 0.9993875026702881
treatment O O 0.9997840523719788
in O O 0.9999725818634033
cats O O 0.9999964237213135
with O O 0.9999898672103882
suspected O O 0.999972939491272
idiopathic O O 0.9999967813491821
epilepsy O O 0.9999092817306519
. O O 0.9997559189796448

OBJECTIVE O O 0.9999538660049438
: O O 0.9999966621398926
To O O 0.9999951124191284
assess O O 0.9999856948852539
pharmacokinetics O O 0.9999536275863647
, O O 0.9999822378158569
efficacy O O 0.9999902248382568
, O O 0.9999803304672241
and O O 0.9999886751174927
tolerability O O 0.9999984502792358
of O O 0.9998633861541748
oral O O 0.9946056008338928
levetiracetam B B 0.999247670173645
administered O O 0.9994726777076721
as O O 0.999987006187439
an O O 0.9999856948852539
adjunct O O 0.9999650716781616
to O O 0.999785840511322
phenobarbital B B 0.9995080232620239
treatment O O 0.999891996383667
in O O 0.9999768733978271
cats O O 0.9999959468841553
with O O 0.9999899864196777
poorly O O 0.9999638795852661
controlled O O 0.9999932050704956
suspected O O 0.9999651908874512
idiopathic O O 0.9999970197677612
epilepsy O O 0.9999128580093384
. O O 0.9999816417694092

DESIGN O O 0.9999786615371704
- O O 0.9999634027481079
Open O O 0.9999001026153564
- O O 0.9999920129776001
label O O 0.999985933303833
, O O 0.9999897480010986
noncomparative O O 0.9999669790267944
clinical O O 0.9999790191650391
trial O O 0.9999847412109375
. O O 0.9999836683273315

ANIMALS O O 0.9952918291091919
: O O 0.9999517202377319
12 O O 0.9999233484268188
cats O O 0.9999951124191284
suspected O O 0.9999836683273315
to O O 0.999976634979248
have O O 0.9999656677246094
idiopathic O O 0.9999862909317017
epilepsy O O 0.9999712705612183
that O O 0.9999608993530273
was O O 0.9999698400497437
poorly O O 0.9999879598617554
controlled O O 0.9999946355819702
with O O 0.9997102618217468
phenobarbital B B 0.9989031553268433
or O O 0.9993023872375488
that O O 0.9999338388442993
had O O 0.9999622106552124
unacceptable O O 0.9996298551559448
adverse O O 0.9999337196350098
effects O O 0.9999858140945435
when O O 0.9999732971191406
treated O O 0.9999815225601196
with O O 0.9997052550315857
phenobarbital B B 0.9995312690734863
. O O 0.9998773336410522

PROCEDURES O O 0.9993758797645569
: O O 0.999988317489624
Cats O O 0.9997642636299133
were O O 0.9999927282333374
treated O O 0.9999724626541138
with O O 0.9994381070137024
levetiracetam B B 0.9992953538894653
( O O 0.9989272952079773
20 O O 0.9994787573814392
mg O O 0.9998795986175537
/ O O 0.9998759031295776
kg O O 0.9999911785125732
[ O O 0.9934646487236023
9 O O 0.9917157292366028
. O O 0.9996281862258911
1 O O 0.9996813535690308
mg O O 0.9998821020126343
/ O O 0.9996055960655212
lb O O 0.996441662311554
] O O 0.9988671541213989
, O O 0.9998480081558228
PO O O 0.9994730353355408
, O O 0.9999394416809082
q O O 0.9979288578033447
8 O O 0.9999133348464966
h O O 0.9979315996170044
) O O 0.9999703168869019
. O O 0.9999614953994751

After O O 0.9999679327011108
a O O 0.9999889135360718
minimum O O 0.9999958276748657
of O O 0.9999849796295166
1 O O 0.9999842643737793
week O O 0.999996542930603
of O O 0.9999737739562988
treatment O O 0.9999837875366211
, O O 0.9999722242355347
serum O O 0.9994854927062988
levetiracetam B B 0.9993398785591125
concentrations O O 0.9999066591262817
were O O 0.9999852180480957
measured O O 0.9999810457229614
before O O 0.9999192953109741
and O O 0.9999692440032959
2 O O 0.9999462366104126
, O O 0.99994957447052
4 O O 0.9999743700027466
, O O 0.9999215602874756
and O O 0.9999741315841675
6 O O 0.9999825954437256
hours O O 0.9999920129776001
after O O 0.9999792575836182
drug O O 0.9997890591621399
administration O O 0.9999617338180542
, O O 0.9999732971191406
and O O 0.9999669790267944
maximum O O 0.9998505115509033
and O O 0.9998551607131958
minimum O O 0.9999539852142334
serum O O 0.9996002316474915
concentrations O O 0.9999139308929443
and O O 0.9999616146087646
elimination O O 0.9895988702774048
half O O 0.9999456405639648
- O O 0.9999359846115112
life O O 0.999983549118042
were O O 0.9999773502349854
calculated O O 0.9999880790710449
. O O 0.9999818801879883

Seizure O O 0.9998831748962402
frequencies O O 0.9999946355819702
before O O 0.99992835521698
and O O 0.9999691247940063
after O O 0.9999678134918213
initiation O O 0.9999456405639648
of O O 0.9989705085754395
levetiracetam B B 0.9993496537208557
treatment O O 0.9979503750801086
were O O 0.9999701976776123
compared O O 0.9999294281005859
, O O 0.9999537467956543
and O O 0.9999421834945679
adverse O O 0.9999325275421143
effects O O 0.9999897480010986
were O O 0.9999711513519287
recorded O O 0.9999837875366211
. O O 0.999981164932251

RESULTS O O 0.9999600648880005
: O O 0.9999312162399292
Median O O 0.9997546076774597
maximum O O 0.9988874793052673
serum O O 0.9955299496650696
levetiracetam B B 0.9985513091087341
concentration O O 0.9986132383346558
was O O 0.9999632835388184
25 O O 0.9999853372573853
. O O 0.9999915361404419
5 O O 0.9999796152114868
microg O O 0.9995682835578918
/ O O 0.9999542236328125
mL O O 0.9999936819076538
, O O 0.9999681711196899
median O O 0.9998267292976379
minimum O O 0.9997829794883728
serum O O 0.970457911491394
levetiracetam B B 0.9989060163497925
concentration O O 0.999237060546875
was O O 0.9999774694442749
8 O O 0.9999051094055176
. O O 0.9999948740005493
3 O O 0.9999310970306396
microg O O 0.9997820258140564
/ O O 0.9999536275863647
mL O O 0.9999947547912598
, O O 0.9999570846557617
and O O 0.999948263168335
median O O 0.9690198302268982
elimination O O 0.9271615147590637
half O O 0.9999105930328369
- O O 0.999862790107727
life O O 0.9999794960021973
was O O 0.9999692440032959
2 O O 0.9999912977218628
. O O 0.999996542930603
9 O O 0.9999964237213135
hours O O 0.999996542930603
. O O 0.9999798536300659

Median O O 0.9999418258666992
seizure O O 0.9999700784683228
frequency O O 0.9999963045120239
prior O O 0.9999938011169434
to O O 0.9999691247940063
treatment O O 0.9999872446060181
with O O 0.9997839331626892
levetiracetam B B 0.999113142490387
( O O 0.9997870326042175
2 O O 0.9999215602874756
. O O 0.9999903440475464
1 O O 0.9999908208847046
seizures O O 0.9999910593032837
/ O O 0.9999731779098511
mo O O 0.9999974966049194
) O O 0.9999793767929077
was O O 0.9999804496765137
significantly O O 0.9999945163726807
higher O O 0.9999804496765137
than O O 0.9999793767929077
median O O 0.9999427795410156
seizure O O 0.9999727010726929
frequency O O 0.9999973773956299
after O O 0.9999434947967529
initiation O O 0.9999871253967285
of O O 0.9998899698257446
levetiracetam B B 0.9996427297592163
treatment O O 0.9997352957725525
( O O 0.9999773502349854
0 O O 0.9999884366989136
. O O 0.9999977350234985
42 O O 0.9999966621398926
seizures O O 0.9999924898147583
/ O O 0.9999854564666748
mo O O 0.9999978542327881
) O O 0.9999852180480957
, O O 0.9999732971191406
and O O 0.999988317489624
7 O O 0.9999879598617554
of O O 0.9999866485595703
10 O O 0.9999860525131226
cats O O 0.9999179840087891
were O O 0.9999829530715942
classified O O 0.9999946355819702
as O O 0.999988317489624
having O O 0.9999920129776001
responded O O 0.9999939203262329
to O O 0.999935507774353
levetiracetam B B 0.9995831847190857
treatment O O 0.9998723268508911
( O O 0.9999779462814331
ie O O 0.9999847412109375
, O O 0.9999858140945435
reduction O O 0.9999978542327881
in O O 0.999991774559021
seizure O O 0.9999772310256958
frequency O O 0.9999978542327881
of O O 0.999975323677063
> O O 0.9999889135360718
or O O 0.9999935626983643
= O O 0.9999951124191284
50 O O 0.9999959468841553
% O O 0.9999974966049194
) O O 0.9999837875366211
. O O 0.9999788999557495

Two O O 0.9991614818572998
cats O O 0.9999773502349854
had O O 0.9999449253082275
transient O O 0.9999926090240479
lethargy O O 0.999974250793457
and O O 0.9999121427536011
inappetence O O 0.9999551773071289
. O O 0.9999645948410034

CONCLUSIONS O O 0.9998916387557983
AND O O 0.9999712705612183
CLINICAL O O 0.9999892711639404
RELEVANCE O O 0.9999992847442627
: O O 0.9999566078186035
Results O O 0.9999876022338867
suggested O O 0.9999775886535645
that O O 0.9995587468147278
levetiracetam B B 0.9997900128364563
is O O 0.9999266862869263
well O O 0.9999302625656128
tolerated O O 0.999985933303833
in O O 0.9999501705169678
cats O O 0.9999210834503174
and O O 0.9999691247940063
may O O 0.999976634979248
be O O 0.9999884366989136
useful O O 0.9999816417694092
as O O 0.9999788999557495
an O O 0.9999723434448242
adjunct O O 0.9999074935913086
to O O 0.9998606443405151
phenobarbital B B 0.9996223449707031
treatment O O 0.9998270869255066
in O O 0.9999728202819824
cats O O 0.9999954700469971
with O O 0.9999855756759644
idiopathic O O 0.9999949932098389
epilepsy O O 0.9999058246612549
. O O 0.9999752044677734

Serotonin B B 0.9553389549255371
reuptake O O 0.7401800751686096
inhibitors O O 0.7970331907272339
, O O 0.9986031651496887
paranoia O O 0.9446694254875183
, O O 0.9997351765632629
and O O 0.9997928738594055
the O O 0.9999394416809082
ventral O O 0.9999548196792603
basal O O 0.9998788833618164
ganglia O O 0.9999898672103882
. O O 0.9998592138290405

Antidepressants O O 0.7777265906333923
have O O 0.9993788003921509
previously O O 0.9995187520980835
been O O 0.9999321699142456
associated O O 0.9999133348464966
with O O 0.9999489784240723
paranoid O O 0.9992103576660156
reactions O O 0.9999920129776001
in O O 0.9998884201049805
psychiatric O O 0.999948263168335
patients O O 0.9999898672103882
. O O 0.9999408721923828

Five O O 0.9999319314956665
cases O O 0.9999885559082031
of O O 0.9999531507492065
paranoid O O 0.9873946905136108
exacerbation O O 0.9999876022338867
with O O 0.9997389912605286
the O O 0.9992929697036743
serotonin B B 0.8438640832901001
reuptake O O 0.8101469874382019
inhibitors O O 0.9007039666175842
fluoxetine B B 0.9515754580497742
and O O 0.9529830813407898
amitriptyline B B 0.9991045594215393
are O O 0.9998214840888977
reported O O 0.9999866485595703
here O O 0.9999593496322632
. O O 0.9999847412109375

Elements O O 0.9998871088027954
common O O 0.9999850988388062
to O O 0.9999630451202393
these O O 0.9999703168869019
cases O O 0.9999827146530151
included O O 0.9999597072601318
a O O 0.999974250793457
history O O 0.9999721050262451
of O O 0.9999135732650757
paranoid O O 0.9981212019920349
symptomatology O O 0.9999785423278809
and O O 0.9999418258666992
the O O 0.9999886751174927
concomitant O O 0.9999563694000244
occurrence O O 0.9999895095825195
of O O 0.9999690055847168
depressive O O 0.9968166947364807
and O O 0.9997820258140564
psychotic O O 0.9996852874755859
symptoms O O 0.9999769926071167
. O O 0.9999598264694214

Complicated O O 0.9568967819213867
depressive O O 0.9960030913352966
disorders O O 0.9999233484268188
( O O 0.9999489784240723
including O O 0.9998679161071777
atypicality O O 0.9995700716972351
of O O 0.9999356269836426
course O O 0.9999799728393555
and O O 0.9999711513519287
symptomatology O O 0.9999760389328003
, O O 0.9998736381530762
chronicity O O 0.9998974800109863
, O O 0.9998807907104492
psychosis O O 0.9995458722114563
, O O 0.9998511075973511
bipolarity O O 0.9950436353683472
, O O 0.9998016953468323
and O O 0.9996249675750732
secondary O O 0.9998183846473694
onset O O 0.9999938011169434
in O O 0.9999891519546509
the O O 0.9999830722808838
course O O 0.9999678134918213
of O O 0.999957799911499
a O O 0.9999430179595947
primary O O 0.9996376037597656
psychosis O O 0.9984412789344788
) O O 0.9999359846115112
may O O 0.9999427795410156
present O O 0.9998674392700195
particular O O 0.9997764229774475
vulnerability O O 0.9999904632568359
to O O 0.999778687953949
paranoid O O 0.9956282377243042
exacerbations O O 0.9999831914901733
associated O O 0.9998974800109863
with O O 0.9996504783630371
serotonin B B 0.9239090085029602
reuptake O O 0.7935686111450195
inhibitors O O 0.908689022064209
. O O 0.9993932247161865

Although O O 0.999967098236084
the O O 0.9999701976776123
pharmacology O O 0.999915599822998
and O O 0.9999276399612427
neurobiology O O 0.999976634979248
of O O 0.999937891960144
paranoia O O 0.9992626309394836
remain O O 0.9999275207519531
cryptic O O 0.9997077584266663
, O O 0.9999361038208008
several O O 0.999790370464325
mechanisms O O 0.9998726844787598
, O O 0.9999765157699585
including O O 0.999778687953949
5HT3 O O 0.8192819356918335
receptor O O 0.8861417770385742
- O O 0.9967280626296997
mediated O O 0.9998610019683838
dopamine B B 0.9988627433776855
release O O 0.9997822642326355
, O O 0.9998955726623535
beta O O 0.8606194257736206
- O O 0.936030924320221
noradrenergic O O 0.7101966738700867
receptor O O 0.9998788833618164
downregulation O O 0.9985101819038391
, O O 0.9998855590820312
or O O 0.9996604919433594
GABAB O B 0.9289175868034363
receptor O O 0.9994452595710754
upregulation O O 0.9886570572853088
acting O O 0.9998569488525391
in O O 0.9998891353607178
the O O 0.999945878982544
vicinity O O 0.9999101161956787
of O O 0.9999457597732544
the O O 0.9999598264694214
ventral O O 0.999961256980896
basal O O 0.9999747276306152
ganglia O O 0.9999960660934448
( O O 0.999968409538269
possibly O O 0.9999126195907593
in O O 0.9998462200164795
lateral O O 0.9985103011131287
orbitofrontal O O 0.9992371797561646
or O O 0.9998039603233337
anterior O O 0.9944515824317932
cingulate O O 0.9983550906181335
circuits O O 0.9995200634002686
) O O 0.999962329864502
, O O 0.9999833106994629
might O O 0.999953031539917
apply O O 0.9999904632568359
to O O 0.9999853372573853
this O O 0.9999798536300659
phenomenon O O 0.9999949932098389
. O O 0.9999747276306152

These O O 0.9999732971191406
cases O O 0.9999866485595703
call O O 0.9999803304672241
attention O O 0.9999836683273315
to O O 0.9999469518661499
possible O O 0.9998691082000732
paranoid O O 0.9958009123802185
exacerbations O O 0.9999856948852539
with O O 0.9998764991760254
serotonin B B 0.9586594104766846
reuptake O O 0.7343704104423523
blockers O O 0.8221068978309631
in O O 0.9997939467430115
select O O 0.9999545812606812
patients O O 0.9999854564666748
and O O 0.9999654293060303
raise O O 0.9999754428863525
neurobiological O O 0.9999897480010986
considerations O O 0.9999967813491821
regarding O O 0.9999662637710571
paranoia O O 0.9996498823165894
. O O 0.9999722242355347

Clinical O O 0.9999774694442749
comparison O O 0.9999895095825195
of O O 0.9999614953994751
cardiorespiratory O O 0.999922513961792
effects O O 0.9999748468399048
during O O 0.9997949004173279
unilateral O O 0.9996335506439209
and O O 0.999812662601471
conventional O O 0.999967098236084
spinal O O 0.9998903274536133
anaesthesia O O 0.9996494054794312
. O O 0.9999730587005615

BACKGROUND O O 0.9749465584754944
: O O 0.9998635053634644
Spinal O O 0.8765423893928528
anaesthesia O O 0.9661969542503357
is O O 0.9999542236328125
widely O O 0.9999500513076782
employed O O 0.9999868869781494
in O O 0.9999542236328125
clinical O O 0.999988317489624
practice O O 0.9999948740005493
but O O 0.9999508857727051
has O O 0.9999490976333618
the O O 0.9999946355819702
main O O 0.9999831914901733
drawback O O 0.9999945163726807
of O O 0.9999785423278809
post O O 0.9993938207626343
- O O 0.9998538494110107
spinal O O 0.9994810223579407
block O O 0.9999843835830688
hypotension O O 0.9999001026153564
. O O 0.9999724626541138

Efforts O O 0.9999759197235107
must O O 0.9999674558639526
therefore O O 0.9999970197677612
continue O O 0.9999953508377075
to O O 0.9999861717224121
be O O 0.9999973773956299
made O O 0.9999992847442627
to O O 0.9999864101409912
obviate O O 0.9999438524246216
this O O 0.9999648332595825
setback O O 0.9999836683273315
OBJECTIVE O O 0.9999886751174927
: O O 0.9999761581420898
To O O 0.9999866485595703
evaluate O O 0.9999898672103882
the O O 0.9999809265136719
cardiovascular O O 0.9999719858169556
and O O 0.9999148845672607
respiratory O O 0.9999843835830688
changes O O 0.999997615814209
during O O 0.9995471835136414
unilateral O O 0.9993674159049988
and O O 0.9997103810310364
conventional O O 0.9999227523803711
spinal O O 0.9996867179870605
anaesthesia O O 0.9998506307601929
. O O 0.9999566078186035

METHODS O O 0.9999363422393799
: O O 0.9999908208847046
With O O 0.9999939203262329
ethical O O 0.9999794960021973
approval O O 0.9999973773956299
, O O 0.9999749660491943
we O O 0.9999771118164062
studied O O 0.9999711513519287
74 O O 0.9996895790100098
American O O 0.9997020363807678
Society O O 0.9999358654022217
of O O 0.9963104128837585
Anesthesiologists O O 0.9934213757514954
( O O 0.9998224377632141
ASA O O 0.9921295046806335
) O O 0.9999659061431885
, O O 0.9999649524688721
physical O O 0.9994995594024658
status O O 0.9999349117279053
class O O 0.9996758699417114
1 O O 0.9995890259742737
and O O 0.9991092085838318
2 O O 0.9985643029212952
patients O O 0.9999876022338867
scheduled O O 0.9999891519546509
for O O 0.9999927282333374
elective O O 0.9999960660934448
unilateral O O 0.9999947547912598
lower O O 0.9999905824661255
limb O O 0.9999980926513672
surgery O O 0.9999980926513672
. O O 0.999985933303833

Patients O O 0.9999637603759766
were O O 0.9999908208847046
randomly O O 0.9999934434890747
allocated O O 0.9999949932098389
into O O 0.9999232292175293
one O O 0.9999862909317017
of O O 0.9999836683273315
two O O 0.9999963045120239
groups O O 0.9999890327453613
: O O 0.9999498128890991
lateral O O 0.999087929725647
and O O 0.9998550415039062
conventional O O 0.999954342842102
spinal O O 0.999942421913147
anaesthesia O O 0.9917140603065491
groups O O 0.9999263286590576
. O O 0.9999831914901733

In O O 0.9999442100524902
the O O 0.9999929666519165
lateral O O 0.9999871253967285
position O O 0.9999967813491821
with O O 0.9999911785125732
operative O O 0.9999189376831055
side O O 0.999984622001648
down O O 0.9999926090240479
, O O 0.999990701675415
patients O O 0.9999755620956421
recived O O 0.9999886751174927
10 O O 0.9999017715454102
mg O O 0.9998836517333984
( O O 0.9998584985733032
2mls O O 0.9994574189186096
) O O 0.9999611377716064
of O O 0.9998138546943665
0 O O 0.9989795088768005
. O O 0.9999362230300903
5 O O 0.999935507774353
% O O 0.9993165731430054
hyperbaric O O 0.8979648351669312
bupivacaine B B 0.9870801568031311
through O O 0.9998787641525269
a O O 0.9999963045120239
25 O O 0.9999856948852539
- O O 0.9999955892562866
gauge O O 0.9998856782913208
spinal O O 0.9999914169311523
needle O O 0.9999911785125732
. O O 0.9999556541442871

Patients O O 0.9999582767486572
in O O 0.9999275207519531
the O O 0.9999449253082275
unilateral O O 0.9998161196708679
group O O 0.9999686479568481
were O O 0.9999806880950928
maintained O O 0.9999958276748657
in O O 0.9999868869781494
the O O 0.9999924898147583
lateral O O 0.999992847442627
position O O 0.9999983310699463
for O O 0.9999840259552002
15 O O 0.9999926090240479
minutes O O 0.9999966621398926
following O O 0.9999837875366211
spinal O O 0.9945673942565918
injection O O 0.9999504089355469
while O O 0.9998600482940674
those O O 0.9999754428863525
in O O 0.9999129772186279
the O O 0.9999608993530273
conventional O O 0.9996631145477295
group O O 0.9999786615371704
were O O 0.9999903440475464
turned O O 0.999994158744812
supine O O 0.9999862909317017
immediately O O 0.9999908208847046
after O O 0.9999746084213257
injection O O 0.9999759197235107
. O O 0.9999808073043823

Blood O O 0.9998156428337097
pressure O O 0.9999042749404907
, O O 0.999975323677063
heart O O 0.9999794960021973
rate O O 0.9999901056289673
, O O 0.9999638795852661
respiratory O O 0.9999269247055054
rate O O 0.9999498128890991
and O O 0.9999090433120728
oxygen B B 0.873528003692627
saturation O O 0.9937500357627869
were O O 0.9999680519104004
monitored O O 0.9999805688858032
over O O 0.9999818801879883
1 O O 0.9999856948852539
hour O O 0.9999954700469971
. O O 0.9999773502349854

RESULTS O O 0.9999321699142456
: O O 0.9999701976776123
Three O O 0.9999921321868896
patients O O 0.9999954700469971
( O O 0.9999384880065918
8 O O 0.9998047947883606
. O O 0.9999814033508301
1 O O 0.9999918937683105
% O O 0.9999914169311523
) O O 0.9999521970748901
in O O 0.999885082244873
the O O 0.9999510049819946
unilateral O O 0.9998794794082642
group O O 0.9999778270721436
and O O 0.9999228715896606
5 O O 0.9996167421340942
( O O 0.9999263286590576
13 O O 0.9999914169311523
. O O 0.9999854564666748
5 O O 0.9999874830245972
% O O 0.9999942779541016
) O O 0.9999611377716064
in O O 0.9998772144317627
the O O 0.999920129776001
conventional O O 0.9987911581993103
group O O 0.999964714050293
developed O O 0.9999758005142212
hypotension O O 0.999962568283081
, O O 0.9999709129333496
P O O 0.9951192140579224
= O O 0.9997280240058899
0 O O 0.9999836683273315
. O O 0.999995231628418
71 O O 0.9999885559082031
. O O 0.9999803304672241

Four O O 0.9998132586479187
( O O 0.9998948574066162
10 O O 0.9999845027923584
. O O 0.9999911785125732
8 O O 0.9999903440475464
% O O 0.9999932050704956
) O O 0.9999549388885498
patients O O 0.999995231628418
in O O 0.9998741149902344
the O O 0.9999027252197266
conventional O O 0.9934957027435303
group O O 0.9999659061431885
and O O 0.9999212026596069
1 O O 0.9972800016403198
( O O 0.9998785257339478
2 O O 0.9999657869338989
. O O 0.9999812841415405
7 O O 0.9999927282333374
% O O 0.9999951124191284
) O O 0.9999768733978271
in O O 0.9998645782470703
the O O 0.9999734163284302
unilateral O O 0.9998583793640137
group O O 0.9999833106994629
, O O 0.999950647354126
P O O 0.9897013902664185
= O O 0.997802197933197
0 O O 0.9998661279678345
. O O 0.9999940395355225
17 O O 0.9996753931045532
required O O 0.9998389482498169
epinephrine B B 0.9973601698875427
infusion O O 0.9997721314430237
to O O 0.9999538660049438
treat O O 0.9999427795410156
hypotension O O 0.9999638795852661
. O O 0.9999164342880249

Patients O O 0.999954104423523
in O O 0.9998660087585449
the O O 0.9993195533752441
conventional O B 0.878251314163208
group O O 0.999729573726654
had O O 0.9999289512634277
statistically O O 0.9999682903289795
significant O O 0.9999936819076538
greater O O 0.9999862909317017
fall O O 0.9999986886978149
in O O 0.9999929666519165
the O O 0.9999868869781494
systolic O O 0.9998762607574463
blood O O 0.9999386072158813
pressures O O 0.9999595880508423
at O O 0.9999289512634277
15 O O 0.9999963045120239
, O O 0.9999388456344604
30 O O 0.9999908208847046
and O O 0.9999009370803833
45 O O 0.999987006187439
minutes O O 0.9999953508377075
when O O 0.9999880790710449
compared O O 0.9999895095825195
to O O 0.9999847412109375
the O O 0.9999923706054688
baseline O O 0.999963641166687
( O O 0.9999161958694458
P O O 0.992819607257843
= O O 0.999743640422821
0 O O 0.9998695850372314
. O O 0.9999949932098389
003 O O 0.9999047517776489
, O O 0.9989867806434631
0 O O 0.9994392991065979
. O O 0.9999949932098389
001 O O 0.9989783763885498
and O O 0.9998045563697815
0 O O 0.9996633529663086
. O O 0.9999920129776001
004 O O 0.9991200566291809
) O O 0.9999715089797974
. O O 0.9999668598175049

The O O 0.9999867677688599
mean O O 0.9999927282333374
respiratory O O 0.9999911785125732
rate O O 0.9999947547912598
and O O 0.9999697208404541
oxygen B O 0.7079500555992126
saturations O O 0.9992167949676514
in O O 0.9998701810836792
the O O 0.9999649524688721
two O O 0.9999513626098633
groups O O 0.9999891519546509
were O O 0.9999715089797974
similar O O 0.9999876022338867
. O O 0.999980092048645

CONCLUSION O O 0.9994958639144897
: O O 0.99994957447052
Compared O O 0.9999940395355225
to O O 0.9999399185180664
conventional O O 0.9999351501464844
spinal O O 0.9962040781974792
anaesthesia O O 0.9993422627449036
, O O 0.9998341798782349
unilateral O O 0.9999709129333496
spinal O O 0.9994474053382874
anaesthesia O O 0.9862810373306274
was O O 0.9999464750289917
associated O O 0.9999545812606812
with O O 0.9999804496765137
fewer O O 0.9999146461486816
cardiovascular O O 0.9999663829803467
perturbations O O 0.9999902248382568
. O O 0.9999685287475586

Also O O 0.9999353885650635
, O O 0.9999195337295532
the O O 0.9999576807022095
type O O 0.9999821186065674
of O O 0.9998370409011841
spinal O O 0.988190770149231
block O O 0.9929715991020203
instituted O O 0.9886401891708374
affected O O 0.9999516010284424
neither O O 0.9999727010726929
the O O 0.999983549118042
respiratory O O 0.9999856948852539
rate O O 0.999992847442627
nor O O 0.9999781847000122
the O O 0.9999805688858032
arterial O O 0.9916278123855591
oxygen B B 0.9949472546577454
saturation O O 0.9995554089546204
. O O 0.999967098236084

Spectrum O O 0.9999281167984009
of O O 0.999961256980896
adverse O O 0.999786913394928
events O O 0.9999918937683105
after O O 0.9995787739753723
generic O O 0.5988902449607849
HAART O O 0.5900658965110779
in O O 0.9909024834632874
southern O O 0.5914515256881714
Indian O O 0.9349619150161743
HIV O O 0.8023253679275513
- O O 0.99748295545578
infected O O 0.9998761415481567
patients O O 0.9999606609344482
. O O 0.9999387264251709

To O O 0.9999774694442749
determine O O 0.9999932050704956
the O O 0.9999943971633911
incidence O O 0.9999973773956299
of O O 0.9999884366989136
clinically O O 0.9999874830245972
significant O O 0.9999934434890747
adverse O O 0.9999853372573853
events O O 0.9999991655349731
after O O 0.9999582767486572
long O O 0.9997331500053406
- O O 0.9999725818634033
term O O 0.9999817609786987
, O O 0.9999333620071411
fixed O O 0.9988993406295776
- O O 0.999863862991333
dose O O 0.9996672868728638
, O O 0.9996622800827026
generic O O 0.9956071972846985
highly O O 0.8841904997825623
active O O 0.7378817796707153
antiretroviral O O 0.6602199673652649
therapy O O 0.911023736000061
( O O 0.9774201512336731
HAART O B 0.8816449046134949
) O O 0.9945462942123413
use O O 0.9998658895492554
among O O 0.9998800754547119
HIV O O 0.713137149810791
- O O 0.9988778233528137
infected O O 0.9999576807022095
individuals O O 0.999984860420227
in O O 0.9999271631240845
South O O 0.9989812970161438
India O O 0.995817244052887
, O O 0.9999874830245972
we O O 0.9999758005142212
examined O O 0.9999947547912598
the O O 0.9999912977218628
experiences O O 0.9999953508377075
of O O 0.999990701675415
3154 O O 0.9999772310256958
HIV O O 0.798448920249939
- O O 0.9996324777603149
infected O O 0.9999710321426392
individuals O O 0.9999897480010986
who O O 0.9999485015869141
received O O 0.9999665021896362
a O O 0.9999884366989136
minimum O O 0.9999920129776001
of O O 0.9999712705612183
3 O O 0.9999293088912964
months O O 0.9999960660934448
of O O 0.9999275207519531
generic O O 0.9895535707473755
HAART O B 0.9564979076385498
between O O 0.9635173082351685
February O O 0.9858657121658325
1996 O O 0.99839848279953
and O O 0.9985981583595276
December O O 0.7329888343811035
2006 O O 0.9927079081535339
at O O 0.9999411106109619
a O O 0.9999788999557495
tertiary O O 0.9999176263809204
HIV O O 0.9680721759796143
care O O 0.9999760389328003
referral O O 0.9999912977218628
center O O 0.9999936819076538
in O O 0.9999732971191406
South O O 0.999112069606781
India O O 0.9993996620178223
. O O 0.9999749660491943

The O O 0.9999871253967285
most O O 0.9999914169311523
common O O 0.9999634027481079
regimens O O 0.9973512887954712
were O O 0.9997914433479309
3TC B B 0.9659522175788879
+ O O 0.8188295364379883
d4T B O 0.41543006896972656
+ O O 0.9771696925163269
nevirapine B B 0.9988889098167419
( O O 0.9907061457633972
NVP B O 0.8141993284225464
) O O 0.9497588276863098
( O O 0.9998689889907837
54 O O 0.9999339580535889
. O O 0.999984860420227
8 O O 0.999977707862854
% O O 0.9999521970748901
) O O 0.9997214674949646
, O O 0.9990137815475464
zidovudine B B 0.999861478805542
( O O 0.9967014193534851
AZT B B 0.9925210475921631
) O O 0.9957116842269897
+ O O 0.9979851245880127
3TC B B 0.9702685475349426
+ O O 0.9824851751327515
NVP B O 0.7220638394355774
( O O 0.9994526505470276
14 O O 0.9999948740005493
. O O 0.9999951124191284
5 O O 0.9999961853027344
% O O 0.9999713897705078
) O O 0.9999302625656128
, O O 0.9992978572845459
3TC B B 0.9697298407554626
+ O O 0.9595990777015686
d4T B O 0.6323992609977722
+ O O 0.9920185208320618
efavirenz B B 0.9119755029678345
( O O 0.9861197471618652
EFV B O 0.45253100991249084
) O O 0.9985027313232422
( O O 0.9999237060546875
20 O O 0.9999498128890991
. O O 0.9999935626983643
1 O O 0.9999970197677612
% O O 0.9999823570251465
) O O 0.999919056892395
, O O 0.9994574189186096
and O O 0.9991564750671387
AZT B B 0.9615352749824524
+ O O 0.9917576909065247
3TC B O 0.7718100547790527
+ O O 0.9787812829017639
EFV B O 0.4728357791900635
( O O 0.9998477697372437
5 O O 0.9999356269836426
. O O 0.9999934434890747
4 O O 0.9999781847000122
% O O 0.9999866485595703
) O O 0.999954342842102
. O O 0.9999665021896362

The O O 0.9999794960021973
most O O 0.9999903440475464
common O O 0.9999867677688599
adverse O O 0.9999668598175049
events O O 0.9999955892562866
and O O 0.9999433755874634
median O O 0.988331139087677
CD4 O O 0.717707633972168
at O O 0.9999642372131348
time O O 0.9999963045120239
of O O 0.9999938011169434
event O O 0.9999977350234985
were O O 0.9999393224716187
rash O O 0.9999756813049316
( O O 0.9999480247497559
15 O O 0.9999949932098389
. O O 0.9999916553497314
2 O O 0.9999948740005493
% O O 0.9999905824661255
; O O 0.9998468160629272
CD4 O O 0.6746023297309875
, O O 0.9994897842407227
285 O O 0.9999459981918335
cells O O 0.9999934434890747
/ O O 0.9999468326568604
microL O O 0.9999346733093262
) O O 0.9999375343322754
and O O 0.999923825263977
peripheral O O 0.999956488609314
neuropathy O O 0.9999970197677612
( O O 0.9999561309814453
9 O O 0.9999895095825195
. O O 0.999988317489624
0 O O 0.9999924898147583
% O O 0.999993085861206
and O O 0.9999417066574097
348 O O 0.9999945163726807
cells O O 0.999997615814209
/ O O 0.9999703168869019
microL O O 0.9999909400939941
) O O 0.9999551773071289
. O O 0.999967098236084

Clinically O O 0.99981290102005
significant O O 0.9999809265136719
anemia O O 0.9958341121673584
( O O 0.999940037727356
hemoglobin O O 0.9921576976776123
< O O 0.99994957447052
7 O O 0.9999922513961792
g O O 0.9999933242797852
/ O O 0.9999775886535645
dL O O 0.9999974966049194
) O O 0.999957799911499
was O O 0.9999661445617676
observed O O 0.9999866485595703
in O O 0.9999591112136841
5 O O 0.9999501705169678
. O O 0.9999916553497314
4 O O 0.9999842643737793
% O O 0.9999903440475464
of O O 0.9999799728393555
patients O O 0.9999911785125732
( O O 0.9997050166130066
CD4 O O 0.8393029570579529
, O O 0.9998106360435486
165 O O 0.9992152452468872
cells O O 0.9999808073043823
/ O O 0.9999428987503052
microL O O 0.9997571110725403
) O O 0.9999595880508423
and O O 0.9998844861984253
hepatitis O O 0.9987393021583557
( O O 0.9998459815979004
clinical O O 0.9999747276306152
jaundice O O 0.9999850988388062
with O O 0.999915361404419
alanine B B 0.9289447665214539
aminotransferase O I 0.9326930642127991
> O O 0.9918448328971863
5 O O 0.999916672706604
times O O 0.9999866485595703
upper O O 0.9999606609344482
limits O O 0.9999980926513672
of O O 0.999982476234436
normal O O 0.9999887943267822
) O O 0.9999741315841675
in O O 0.9999532699584961
3 O O 0.9998470544815063
. O O 0.9999841451644897
5 O O 0.9999866485595703
% O O 0.9999933242797852
of O O 0.999981164932251
patients O O 0.9999935626983643
( O O 0.9998492002487183
CD4 O O 0.8450844287872314
, O O 0.9998776912689209
260 O O 0.9994282126426697
cells O O 0.9999929666519165
/ O O 0.9999624490737915
microL O O 0.9999539852142334
) O O 0.9999734163284302
. O O 0.9999804496765137

Women O O 0.9997416138648987
were O O 0.9999631643295288
significantly O O 0.9999673366546631
more O O 0.9999799728393555
likely O O 0.9999927282333374
to O O 0.9999901056289673
experience O O 0.9999798536300659
lactic O O 0.9957981705665588
acidosis O O 0.9620506167411804
, O O 0.9999221563339233
while O O 0.9999171495437622
men O O 0.9975800514221191
were O O 0.9999750852584839
significantly O O 0.9999711513519287
more O O 0.9999817609786987
likely O O 0.9999942779541016
to O O 0.9999914169311523
experience O O 0.9999798536300659
immune O O 0.9992558360099792
reconstitution O O 0.9998914003372192
syndrome O O 0.9999856948852539
( O O 0.9999610185623169
p O O 0.9994775652885437
< O O 0.9999715089797974
0 O O 0.9999935626983643
. O O 0.999996542930603
05 O O 0.9999926090240479
) O O 0.999970555305481
. O O 0.9999806880950928

Among O O 0.9998774528503418
the O O 0.9999849796295166
patients O O 0.9999949932098389
with O O 0.9999920129776001
1 O O 0.9999719858169556
year O O 0.9999977350234985
of O O 0.9999946355819702
follow O O 0.9999927282333374
- O O 0.9999909400939941
up O O 0.999997615814209
, O O 0.9997254014015198
NVP B B 0.9109236001968384
therapy O O 0.9984912872314453
was O O 0.9999463558197021
significantly O O 0.9999650716781616
associated O O 0.9999849796295166
with O O 0.9999854564666748
developing O O 0.9999854564666748
rash O O 0.9999876022338867
and O O 0.9997220635414124
d4T B B 0.9458388686180115
therapy O O 0.998880922794342
with O O 0.9999734163284302
developing O O 0.9999886751174927
peripheral O O 0.9999769926071167
neuropathy O O 0.999996542930603
( O O 0.9999711513519287
p O O 0.9998193383216858
< O O 0.9999827146530151
0 O O 0.9999934434890747
. O O 0.9999969005584717
05 O O 0.9999939203262329
) O O 0.9999740123748779
. O O 0.9999868869781494

Anemia O O 0.9989292025566101
and O O 0.999841570854187
hepatitis O O 0.9991689920425415
often O O 0.9999260902404785
occur O O 0.9999910593032837
within O O 0.9999895095825195
12 O O 0.9999948740005493
weeks O O 0.9999971389770508
of O O 0.9999897480010986
initiating O O 0.999977707862854
generic O B 0.9233595728874207
HAART O O 0.5583527088165283
. O O 0.9998388290405273

Frequent O O 0.9999357461929321
and O O 0.9999707937240601
early O O 0.9999760389328003
monitoring O O 0.9999934434890747
for O O 0.999971866607666
these O O 0.9961536526679993
toxicities O O 0.9921724796295166
is O O 0.9999762773513794
warranted O O 0.9999799728393555
in O O 0.9999805688858032
developing O O 0.9999947547912598
countries O O 0.9999966621398926
where O O 0.9999858140945435
generic O O 0.8371605277061462
HAART O O 0.9141576886177063
is O O 0.9999511241912842
increasingly O O 0.9999852180480957
available O O 0.9999029636383057
. O O 0.9999725818634033

Thalidomide B B 0.9993176460266113
and O O 0.9994736313819885
sensory O O 0.8060139417648315
neurotoxicity O O 0.999760091304779
: O O 0.9999775886535645
a O O 0.9999796152114868
neurophysiological O O 0.9999908208847046
study O O 0.9999961853027344
. O O 0.9999858140945435

BACKGROUND O O 0.9959975481033325
: O O 0.999982476234436
Recent O O 0.9999685287475586
studies O O 0.9999819993972778
confirmed O O 0.9999713897705078
a O O 0.999984622001648
high O O 0.9999833106994629
incidence O O 0.9999954700469971
of O O 0.9999747276306152
sensory O O 0.9997144341468811
axonal O O 0.9997636675834656
neuropathy O O 0.999994158744812
in O O 0.9999450445175171
patients O O 0.9999918937683105
treated O O 0.9999637603759766
with O O 0.9999494552612305
different O O 0.9999687671661377
doses O O 0.9998868703842163
of O O 0.9965910911560059
thalidomide B B 0.9991937279701233
. O O 0.9999352693557739

The O O 0.9999890327453613
study O O 0.9999932050704956
' O O 0.9999892711639404
s O O 0.9999980926513672
aims O O 0.9999979734420776
were O O 0.9999969005584717
to O O 0.9999905824661255
measure O O 0.9999730587005615
variations O O 0.9999908208847046
in O O 0.9999326467514038
sural O O 0.9996554851531982
nerve O O 0.9994803071022034
sensory O O 0.9948753714561462
action O O 0.9971469044685364
potential O O 0.999961256980896
( O O 0.9997033476829529
SAP O O 0.9579501748085022
) O O 0.9998985528945923
amplitude O O 0.9999130964279175
in O O 0.9999493360519409
patients O O 0.9999927282333374
with O O 0.9999741315841675
refractory O O 0.9999185800552368
cutaneous O O 0.999337375164032
lupus O O 0.9988201260566711
erythematosus O O 0.9990867376327515
( O O 0.9998713731765747
CLE O O 0.9870867729187012
) O O 0.9999706745147705
treated O O 0.9999016523361206
with O O 0.9995507597923279
thalidomide B B 0.9994732737541199
and O O 0.9998959302902222
use O O 0.999990701675415
these O O 0.9999921321868896
findings O O 0.9999960660934448
to O O 0.9999955892562866
identify O O 0.9999815225601196
the O O 0.999984860420227
neurotoxic O O 0.9999823570251465
potential O O 0.9999915361404419
of O O 0.9997921586036682
thalidomide B B 0.9995833039283752
and O O 0.9998592138290405
the O O 0.9999688863754272
recovery O O 0.9999666213989258
capacity O O 0.9999943971633911
of O O 0.9997994303703308
sensory O O 0.9972206354141235
fibres O O 0.9999856948852539
after O O 0.999955415725708
discontinuation O O 0.9999860525131226
of O O 0.9999374151229858
treatment O O 0.9999351501464844
. O O 0.999962329864502

PATIENTS O O 0.9999297857284546
AND O O 0.999966025352478
METHODS O O 0.9998806715011597
: O O 0.9999905824661255
Clinical O O 0.999994158744812
and O O 0.9999805688858032
electrophysiological O O 0.9999886751174927
data O O 0.999997615814209
in O O 0.9999856948852539
12 O O 0.9999855756759644
female O O 0.999995231628418
patients O O 0.9999921321868896
with O O 0.9999691247940063
CLE O O 0.9742228388786316
during O O 0.9973587393760681
treatment O O 0.9999347925186157
with O O 0.9993415474891663
thalidomide B B 0.9993699193000793
and O O 0.9997994303703308
up O O 0.9999790191650391
to O O 0.9999966621398926
47 O O 0.999998927116394
months O O 0.9999986886978149
after O O 0.9999901056289673
discontinuation O O 0.9999895095825195
of O O 0.9999386072158813
treatment O O 0.9997314810752869
were O O 0.9999784231185913
analysed O O 0.9999549388885498
. O O 0.9999793767929077

Sural O O 0.9975557327270508
nerve O O 0.9974797368049622
SAP O O 0.6901458501815796
amplitude O O 0.969548225402832
reduction O O 0.9999151229858398
> O O 0.9998425245285034
or O O 0.9999748468399048
= O O 0.9999814033508301
40 O O 0.9999667406082153
% O O 0.9999772310256958
was O O 0.9999825954437256
the O O 0.9999947547912598
criteria O O 0.9999982118606567
for O O 0.9999954700469971
discontinuing O O 0.9999797344207764
therapy O O 0.9999512434005737
. O O 0.9999655485153198

RESULTS O O 0.99978107213974
: O O 0.9999456405639648
During O O 0.9998154044151306
treatment O O 0.9999690055847168
, O O 0.9999585151672363
11 O O 0.9996243715286255
patients O O 0.9999856948852539
showed O O 0.9999678134918213
a O O 0.999981164932251
reduction O O 0.9999911785125732
in O O 0.9999603033065796
sural O O 0.9999651908874512
nerve O O 0.9963685274124146
SAP O O 0.9825612902641296
amplitude O O 0.99994957447052
compared O O 0.9999771118164062
to O O 0.9999850988388062
baseline O O 0.9999767541885376
values O O 0.9999895095825195
( O O 0.9999744892120361
9 O O 0.999038815498352
with O O 0.9999352693557739
a O O 0.9999697208404541
reduction O O 0.999992847442627
> O O 0.9999622106552124
or O O 0.9999762773513794
= O O 0.9999927282333374
50 O O 0.999984622001648
% O O 0.9999910593032837
and O O 0.9999343156814575
2 O O 0.9985557198524475
< O O 0.9999581575393677
50 O O 0.9999945163726807
% O O 0.9999887943267822
) O O 0.9999688863754272
. O O 0.9999806880950928

One O O 0.9999567270278931
patient O O 0.9999845027923584
showed O O 0.999953031539917
no O O 0.9999721050262451
changes O O 0.9999924898147583
in O O 0.9999502897262573
SAP O O 0.8285186290740967
amplitude O O 0.9871288537979126
. O O 0.9999278783798218

Five O O 0.9998103976249695
patients O O 0.9999896287918091
complained O O 0.9999805688858032
of O O 0.9999047517776489
paresthesias O O 0.9997172951698303
and O O 0.9999263286590576
leg O O 0.9998866319656372
cramps O O 0.998747706413269
. O O 0.9999579191207886

After O O 0.9999361038208008
thalidomide B B 0.9996415376663208
treatment O O 0.999752938747406
, O O 0.9999388456344604
sural O O 0.9995899796485901
SAP O O 0.9837718605995178
amplitude O O 0.9995217323303223
recovered O O 0.9999735355377197
in O O 0.9999418258666992
3 O O 0.9996323585510254
patients O O 0.9999887943267822
. O O 0.9999783039093018

At O O 0.9998738765716553
detection O O 0.9999808073043823
of O O 0.9999723434448242
reduction O O 0.9999874830245972
in O O 0.99994957447052
sural O O 0.999971866607666
nerve O O 0.9993026256561279
SAP O O 0.9172338247299194
amplitude O O 0.9996746778488159
, O O 0.9999607801437378
the O O 0.9999818801879883
median O O 0.999416708946228
thalidomide B B 0.9994949102401733
cumulative O O 0.9976199269294739
dose O O 0.9998883008956909
was O O 0.9999842643737793
21 O O 0.9992614388465881
. O O 0.9999709129333496
4 O O 0.9984353184700012
g O O 0.9999518394470215
. O O 0.9999642372131348

The O O 0.9999690055847168
threshold O O 0.9997561573982239
neurotoxic O O 0.9987744688987732
dosage O O 0.9995855689048767
is O O 0.9999184608459473
lower O O 0.9999223947525024
than O O 0.9999936819076538
previously O O 0.9999632835388184
reported O O 0.9999868869781494
. O O 0.9999572038650513

CONCLUSIONS O O 0.9964452385902405
: O O 0.9997242093086243
Sural O O 0.9996048808097839
nerve O O 0.9994737505912781
SAP O O 0.738250195980072
amplitude O O 0.9976678490638733
reduction O O 0.9996960163116455
is O O 0.9999221563339233
a O O 0.9999067783355713
reliable O O 0.9999585151672363
and O O 0.9999253749847412
sensitive O O 0.999967098236084
marker O O 0.9999500513076782
of O O 0.9999121427536011
degeneration O O 0.9999592304229736
and O O 0.999889612197876
recovery O O 0.9999725818634033
of O O 0.9999269247055054
sensory O O 0.9994864463806152
fibres O O 0.999976634979248
. O O 0.9999486207962036

This O O 0.9999649524688721
electrophysiological O O 0.9999769926071167
parameter O O 0.9999836683273315
provides O O 0.9999234676361084
information O O 0.9999854564666748
about O O 0.9999345541000366
subclinical O O 0.9998818635940552
neurotoxic O O 0.9999889135360718
potential O O 0.999988317489624
of O O 0.997885525226593
thalidomide B B 0.9996315240859985
but O O 0.9998762607574463
is O O 0.9999761581420898
not O O 0.9999890327453613
helpful O O 0.9999885559082031
in O O 0.9999896287918091
predicting O O 0.9999953508377075
the O O 0.9999966621398926
appearance O O 0.9999958276748657
of O O 0.999985933303833
sensory O O 0.999980092048645
symptoms O O 0.9999977350234985
. O O 0.9999781847000122

Five O O 0.9999444484710693
cases O O 0.9999934434890747
of O O 0.9999639987945557
encephalitis O O 0.9991533756256104
during O O 0.9997352957725525
treatment O O 0.9999449253082275
of O O 0.9998784065246582
loiasis O O 0.9970529079437256
with O O 0.9993314743041992
diethylcarbamazine B B 0.9976558685302734
. O O 0.9998548030853271

Five O O 0.9999202489852905
cases O O 0.999993085861206
of O O 0.9999725818634033
encephalitis O O 0.9999405145645142
following O O 0.9999033212661743
treatment O O 0.9999635219573975
with O O 0.9993695616722107
diethylcarbamazine B B 0.9980320334434509
( O O 0.939958393573761
DEC B B 0.9988580942153931
) O O 0.9608606100082397
were O O 0.9999778270721436
observed O O 0.9999866485595703
in O O 0.9998965263366699
Congolese O O 0.9737356305122375
patients O O 0.9999799728393555
with O O 0.9999494552612305
Loa O O 0.9886154532432556
loa O O 0.9975252747535706
filariasis O O 0.9998108744621277
. O O 0.9999730587005615

Two O O 0.9999301433563232
cases O O 0.9999723434448242
had O O 0.9999707937240601
a O O 0.9999790191650391
fatal O O 0.9999836683273315
outcome O O 0.9999959468841553
and O O 0.9998670816421509
one O O 0.9996484518051147
resulted O O 0.9999666213989258
in O O 0.9999690055847168
severe O O 0.999893307685852
sequelae O O 0.9999905824661255
. O O 0.9999507665634155

The O O 0.9999896287918091
notable O O 0.9999982118606567
fact O O 0.999996542930603
was O O 0.999994158744812
that O O 0.9999898672103882
this O O 0.9999842643737793
complication O O 0.9999953508377075
occurred O O 0.9999970197677612
in O O 0.9999796152114868
three O O 0.9999784231185913
patients O O 0.9999934434890747
hospitalized O O 0.999985933303833
before O O 0.999977707862854
treatment O O 0.9999873638153076
began O O 0.9999932050704956
, O O 0.9999881982803345
with O O 0.9999775886535645
whom O O 0.9998441934585571
particularly O O 0.9999493360519409
strict O O 0.9998083710670471
therapeutic O O 0.9998190999031067
precautions O O 0.9999455213546753
were O O 0.9999727010726929
taken O O 0.9999828338623047
, O O 0.9999842643737793
i O O 0.9999711513519287
. O O 0.9999908208847046
e O O 0.9999916553497314
. O O 0.9999901056289673
, O O 0.9999809265136719
initial O O 0.9999722242355347
dose O O 0.9999644756317139
less O O 0.9999815225601196
than O O 0.9999938011169434
10 O O 0.999984860420227
mg O O 0.9999589920043945
of O O 0.9928412437438965
DEC B B 0.994942843914032
, O O 0.9995707869529724
very O O 0.9999638795852661
gradual O O 0.9999773502349854
dose O O 0.999729335308075
increases O O 0.9999703168869019
, O O 0.9999241828918457
and O O 0.9999359846115112
associated O O 0.9999414682388306
anti O O 0.69146728515625
- O O 0.9848830103874207
allergic O O 0.9859223365783691
treatment O O 0.9999499320983887
. O O 0.9999748468399048

This O O 0.9999697208404541
type O O 0.9999722242355347
of O O 0.9999520778656006
drug O O 0.99783855676651
- O O 0.999860405921936
induced O O 0.9999253749847412
complication O O 0.999984622001648
may O O 0.9999657869338989
not O O 0.9999889135360718
be O O 0.9999898672103882
that O O 0.999993085861206
uncommon O O 0.9999860525131226
in O O 0.9999653100967407
highly O O 0.9996987581253052
endemic O O 0.999984860420227
regions O O 0.999994158744812
. O O 0.9999642372131348

It O O 0.9999790191650391
occurs O O 0.9999707937240601
primarily O O 0.999906063079834
, O O 0.9999860525131226
but O O 0.999990701675415
not O O 0.9999845027923584
exclusively O O 0.9999430179595947
, O O 0.9999871253967285
in O O 0.9999508857727051
subjects O O 0.9999821186065674
presenting O O 0.9999741315841675
with O O 0.9999815225601196
a O O 0.9999874830245972
high O O 0.999925971031189
microfilarial O O 0.9962737560272217
load O O 0.9999511241912842
. O O 0.9999854564666748

The O O 0.9999672174453735
relationship O O 0.9999921321868896
between O O 0.999955415725708
the O O 0.9999810457229614
occurrence O O 0.9999922513961792
of O O 0.9999606609344482
encephalitis O O 0.9990800619125366
and O O 0.999947190284729
the O O 0.9999866485595703
decrease O O 0.999988317489624
in O O 0.999934196472168
microfilaremia O O 0.9895355105400085
is O O 0.9999096393585205
evident O O 0.9999830722808838
. O O 0.99996018409729

The O O 0.9999227523803711
pathophysiological O O 0.9999064207077026
mechanisms O O 0.999974250793457
are O O 0.9999598264694214
discussed O O 0.9999818801879883
in O O 0.9999918937683105
the O O 0.9999960660934448
light O O 0.9999963045120239
of O O 0.9999891519546509
these O O 0.9999895095825195
observations O O 0.9999969005584717
and O O 0.9999810457229614
the O O 0.9999973773956299
few O O 0.9999909400939941
other O O 0.9999781847000122
comments O O 0.9999716281890869
on O O 0.9999438524246216
this O O 0.9999803304672241
subject O O 0.9999845027923584
published O O 0.9999755620956421
in O O 0.9999861717224121
the O O 0.9999915361404419
literature O O 0.999984860420227
. O O 0.9999674558639526

Amiodarone B B 0.9996521472930908
- O O 0.999409556388855
related O O 0.9998729228973389
pulmonary O O 0.9999186992645264
mass O O 0.9999954700469971
and O O 0.9999270439147949
unique O O 0.9160993099212646
membranous O O 0.9999518394470215
glomerulonephritis O O 0.9982055425643921
in O O 0.9999809265136719
a O O 0.9999816417694092
patient O O 0.9999904632568359
with O O 0.9999693632125854
valvular O O 0.9997664093971252
heart O O 0.9999629259109497
disease O O 0.9999927282333374
: O O 0.9999662637710571
Diagnostic O O 0.9999839067459106
pitfall O O 0.9998970031738281
and O O 0.9999910593032837
new O O 0.9999943971633911
findings O O 0.9999967813491821
. O O 0.9999889135360718

Amiodarone B B 0.9994606375694275
is O O 0.9987666606903076
an O O 0.9960229396820068
anti O O 0.7113890647888184
- O O 0.9856719970703125
arrhythmic O O 0.9923015832901001
drug O O 0.9975494742393494
for O O 0.9996577501296997
life O O 0.9999135732650757
- O O 0.9999803304672241
threatening O O 0.9999918937683105
tachycardia O O 0.999945878982544
, O O 0.9999088048934937
but O O 0.9999499320983887
various O O 0.9999463558197021
adverse O O 0.99996018409729
effects O O 0.9999887943267822
have O O 0.9999686479568481
been O O 0.9999860525131226
reported O O 0.999993085861206
. O O 0.9999569654464722

Reported O O 0.9999686479568481
herein O O 0.9999860525131226
is O O 0.9999933242797852
an O O 0.9999963045120239
autopsy O O 0.9999449253082275
case O O 0.9999984502792358
of O O 0.9999791383743286
valvular O O 0.9999498128890991
heart O O 0.9999964237213135
disease O O 0.9999977350234985
, O O 0.9999903440475464
in O O 0.9999860525131226
a O O 0.9999910593032837
patient O O 0.9999926090240479
who O O 0.9999656677246094
developed O O 0.999995231628418
a O O 0.9999904632568359
lung O O 0.9997517466545105
mass O O 0.9999934434890747
( O O 0.9999843835830688
1 O O 0.9999867677688599
. O O 0.9999970197677612
5 O O 0.9999897480010986
cm O O 0.9999946355819702
in O O 0.9999947547912598
diameter O O 0.999969482421875
) O O 0.9999668598175049
and O O 0.9999624490737915
proteinuria O O 0.999784529209137
( O O 0.999968409538269
2 O O 0.9997459053993225
. O O 0.9999949932098389
76 O O 0.9999725818634033
g O O 0.9999947547912598
/ O O 0.9999897480010986
day O O 0.9999977350234985
) O O 0.9999785423278809
after O O 0.9999094009399414
treatment O O 0.9999674558639526
with O O 0.9995967745780945
amiodarone B B 0.9996888637542725
for O O 0.9998564720153809
a O O 0.9999942779541016
long O O 0.9999889135360718
time O O 0.9999920129776001
. O O 0.9999755620956421

The O O 0.9999781847000122
lung O O 0.9997232556343079
mass O O 0.9999943971633911
was O O 0.9999744892120361
highly O O 0.9999915361404419
suspected O O 0.9999954700469971
to O O 0.9999758005142212
be O O 0.9999462366104126
lung O O 0.9937275648117065
cancer O O 0.9999319314956665
on O O 0.9999822378158569
CT O O 0.985425591468811
and O O 0.9998631477355957
positron O O 0.9389934539794922
emission O O 0.9439737796783447
tomography O O 0.9947382807731628
, O O 0.9999336004257202
but O O 0.9999703168869019
histologically O O 0.9999935626983643
the O O 0.9999768733978271
lesion O O 0.9999966621398926
was O O 0.9999464750289917
composed O O 0.9999809265136719
of O O 0.9995768666267395
lymphoplasmacytic O O 0.9879974126815796
infiltrates O O 0.999859094619751
in O O 0.9996999502182007
alveolar O O 0.9788757562637329
walls O O 0.9999480247497559
and O O 0.9998793601989746
intra O O 0.9996966123580933
- O O 0.9997215867042542
alveolar O O 0.9969484210014343
accumulation O O 0.999956488609314
of O O 0.9996227025985718
foamy O O 0.9975098371505737
macrophages O O 0.9998651742935181
containing O O 0.9998341798782349
characteristic O O 0.9962420463562012
myelinoid O O 0.998357355594635
bodies O O 0.9971561431884766
, O O 0.9999793767929077
indicating O O 0.9999456405639648
that O O 0.9999374151229858
it O O 0.9999653100967407
was O O 0.999948263168335
an O O 0.9999260902404785
amiodarone B B 0.9998689889907837
- O O 0.9996200799942017
related O O 0.9998952150344849
lesion O O 0.9999951124191284
. O O 0.9999791383743286

In O O 0.9999186992645264
addition O O 0.999976396560669
, O O 0.9999854564666748
the O O 0.999981164932251
lung O O 0.9996412992477417
tissue O O 0.9999957084655762
had O O 0.9999324083328247
unevenly O O 0.9995049238204956
distributed O O 0.9999644756317139
hemosiderin O O 0.5497556924819946
deposition O O 0.9998905658721924
, O O 0.9999115467071533
and O O 0.9999221563339233
abnormally O O 0.9998723268508911
tortuous O O 0.9999911785125732
capillaries O O 0.999626636505127
were O O 0.9999477863311768
seen O O 0.9999810457229614
in O O 0.9997387528419495
the O O 0.9999598264694214
mass O O 0.9999606609344482
and O O 0.9998098015785217
in O O 0.9997299313545227
heavily O O 0.9989318251609802
hemosiderotic O O 0.9009277820587158
lung O O 0.9994450211524963
portions O O 0.9999769926071167
outside O O 0.9999542236328125
the O O 0.9999903440475464
mass O O 0.9999853372573853
. O O 0.9999634027481079

In O O 0.9992221593856812
the O O 0.9999279975891113
kidneys O O 0.9997223019599915
, O O 0.9998764991760254
glomeruli O O 0.9927152991294861
had O O 0.9998619556427002
membrane O O 0.9992153644561768
spikes O O 0.9999517202377319
, O O 0.9999465942382812
prominent O O 0.9999145269393921
swelling O O 0.9999536275863647
of O O 0.9998098015785217
podocytes O O 0.9987536668777466
and O O 0.9998031258583069
subepithelial O O 0.9969192743301392
deposits O O 0.9997730851173401
, O O 0.9999659061431885
which O O 0.9999067783355713
were O O 0.9999600648880005
sometimes O O 0.9999885559082031
large O O 0.9999653100967407
and O O 0.9999746084213257
hump O O 0.9979075193405151
- O O 0.9999673366546631
like O O 0.9999560117721558
. O O 0.9999603033065796

Autoimmune O O 0.9919455647468567
diseases O O 0.9999651908874512
, O O 0.9998559951782227
viral O O 0.9998100399971008
hepatitis O O 0.9996886253356934
, O O 0.999890923500061
malignant O O 0.9999880790710449
neoplasms O O 0.9999366998672485
or O O 0.9998579025268555
other O O 0.9998568296432495
diseases O O 0.999976634979248
with O O 0.9999654293060303
a O O 0.9999712705612183
known O O 0.9999797344207764
relationship O O 0.9999959468841553
to O O 0.9999700784683228
membranous O O 0.9999608993530273
glomerulonephritis O O 0.9996917247772217
were O O 0.9999592304229736
not O O 0.999975323677063
found O O 0.999974250793457
. O O 0.9999206066131592

The O O 0.9999957084655762
present O O 0.9999945163726807
case O O 0.9999902248382568
highlights O O 0.9999154806137085
the O O 0.9999858140945435
possibility O O 0.9999884366989136
that O O 0.9999806880950928
differential O O 0.9999680519104004
diagnosis O O 0.9999971389770508
between O O 0.9998780488967896
an O O 0.9999243021011353
amiodarone B B 0.9997690320014954
- O O 0.9997408986091614
related O O 0.9999219179153442
pulmonary O O 0.9999393224716187
lesion O O 0.9999973773956299
and O O 0.9998179078102112
a O O 0.9998781681060791
neoplasm O O 0.9999284744262695
can O O 0.9999752044677734
be O O 0.999997615814209
very O O 0.999995231628418
difficult O O 0.9999980926513672
radiologically O O 0.9999850988388062
, O O 0.9999740123748779
and O O 0.999974250793457
suggests O O 0.9999855756759644
that O O 0.999924898147583
membranous O O 0.9999262094497681
glomerulonephritis O O 0.9995786547660828
might O O 0.9999433755874634
be O O 0.9999877214431763
another O O 0.999982476234436
possible O O 0.999983549118042
complication O O 0.9999970197677612
of O O 0.9998743534088135
amiodarone B B 0.9998477697372437
treatment O O 0.9997559189796448
. O O 0.9999810457229614

Risk O O 0.9999896287918091
of O O 0.9999754428863525
coronary O O 0.9999361038208008
artery O O 0.9999711513519287
disease O O 0.9999979734420776
associated O O 0.9999814033508301
with O O 0.9999473094940186
initial O O 0.9998513460159302
sulphonylurea B B 0.9980567097663879
treatment O O 0.9998010993003845
of O O 0.9999405145645142
patients O O 0.9999916553497314
with O O 0.9999871253967285
type O O 0.9999452829360962
2 O O 0.9991785883903503
diabetes O O 0.9926194548606873
: O O 0.9999903440475464
a O O 0.9999918937683105
matched O O 0.9999969005584717
case O O 0.9999821186065674
- O O 0.9999855756759644
control O O 0.9999940395355225
study O O 0.999995231628418
. O O 0.9999871253967285

AIMS O O 0.9999697208404541
: O O 0.9999953508377075
This O O 0.999994158744812
study O O 0.9999939203262329
sought O O 0.9999943971633911
to O O 0.9999949932098389
assess O O 0.9999940395355225
the O O 0.9999933242797852
risk O O 0.9999983310699463
of O O 0.9999951124191284
developing O O 0.9999914169311523
coronary O O 0.9997326731681824
artery O O 0.9994014501571655
disease O O 0.9999961853027344
( O O 0.9998937845230103
CAD O O 0.9834102988243103
) O O 0.9999878406524658
associated O O 0.9999885559082031
with O O 0.9999597072601318
initial O O 0.999966025352478
treatment O O 0.9999884366989136
of O O 0.9999812841415405
type O O 0.9999728202819824
2 O O 0.9992701411247253
diabetes O O 0.9980230331420898
with O O 0.9998966455459595
different O O 0.9968485236167908
sulphonylureas B B 0.9781162738800049
. O O 0.999901294708252

METHODS O O 0.9994533658027649
: O O 0.9999840259552002
In O O 0.9999797344207764
type O O 0.9996681213378906
2 O O 0.9977080821990967
diabetic O O 0.9986382126808167
patients O O 0.9999785423278809
, O O 0.9999524354934692
cases O O 0.9999923706054688
who O O 0.9999780654907227
developed O O 0.999971866607666
CAD O O 0.9336720108985901
were O O 0.9999734163284302
compared O O 0.9999778270721436
retrospectively O O 0.9999611377716064
with O O 0.9999322891235352
controls O O 0.9999754428863525
that O O 0.999896764755249
did O O 0.9999814033508301
not O O 0.9999904632568359
. O O 0.9999768733978271

The O O 0.999971866607666
20 O O 0.9999377727508545
- O O 0.9999845027923584
year O O 0.9999946355819702
risk O O 0.9999840259552002
of O O 0.9998931884765625
CAD O O 0.6232684850692749
at O O 0.9997615218162537
diagnosis O O 0.9999816417694092
of O O 0.9999402761459351
diabetes O O 0.8810989260673523
, O O 0.9999773502349854
using O O 0.9999626874923706
the O O 0.999904990196228
UKPDS O O 0.6893705725669861
risk O O 0.9856268763542175
engine O O 0.9988514184951782
, O O 0.9999594688415527
was O O 0.9999465942382812
used O O 0.9999560117721558
to O O 0.9999845027923584
match O O 0.9999834299087524
cases O O 0.9999914169311523
with O O 0.999987006187439
controls O O 0.9999884366989136
. O O 0.9999686479568481

RESULTS O O 0.999904990196228
: O O 0.9999260902404785
The O O 0.9999849796295166
76 O O 0.999947190284729
cases O O 0.9999922513961792
of O O 0.9999140501022339
CAD O O 0.4880395829677582
were O O 0.9998986721038818
compared O O 0.9999523162841797
with O O 0.9999077320098877
152 O O 0.9693779349327087
controls O O 0.999980092048645
. O O 0.999955415725708

The O O 0.9999785423278809
hazard O O 0.9998832941055298
of O O 0.9999576807022095
developing O O 0.9767072200775146
CAD O B 0.9416612982749939
( O O 0.9993849992752075
95 O O 0.9999281167984009
% O O 0.9992893934249878
CI O O 0.9754998683929443
) O O 0.9999074935913086
associated O O 0.999985933303833
with O O 0.9999285936355591
initial O O 0.9999656677246094
treatment O O 0.9999815225601196
increased O O 0.999977707862854
by O O 0.9999955892562866
2 O O 0.9999896287918091
. O O 0.9999916553497314
4 O O 0.9999703168869019
- O O 0.9999703168869019
fold O O 0.9999942779541016
( O O 0.9998996257781982
1 O O 0.9999881982803345
. O O 0.9999915361404419
3 O O 0.9999847412109375
- O O 0.9977485537528992
4 O O 0.999879002571106
. O O 0.9999957084655762
3 O O 0.9999885559082031
, O O 0.9999635219573975
P O O 0.9999490976333618
= O O 0.9998757839202881
0 O O 0.9999934434890747
. O O 0.9999955892562866
004 O O 0.9999943971633911
) O O 0.9999862909317017
with O O 0.999555766582489
glibenclamide B B 0.9993829727172852
; O O 0.999748170375824
2 O O 0.9997397065162659
- O O 0.999967098236084
fold O O 0.999997615814209
( O O 0.99993896484375
0 O O 0.9999876022338867
. O O 0.9999866485595703
9 O O 0.9999783039093018
- O O 0.9981618523597717
4 O O 0.999933123588562
. O O 0.9999936819076538
6 O O 0.9999911785125732
, O O 0.9999626874923706
P O O 0.9999570846557617
= O O 0.9999357461929321
0 O O 0.9999936819076538
. O O 0.9999955892562866
099 O O 0.9999927282333374
) O O 0.9999873638153076
with O O 0.9998242259025574
glipizide B B 0.9996322393417358
; O O 0.9998904466629028
2 O O 0.9999833106994629
. O O 0.9999911785125732
9 O O 0.9999905824661255
- O O 0.9999825954437256
fold O O 0.9999969005584717
( O O 0.9999302625656128
1 O O 0.9999918937683105
. O O 0.9999872446060181
6 O O 0.9999897480010986
- O O 0.9975626468658447
5 O O 0.9999886751174927
. O O 0.9999940395355225
1 O O 0.9999963045120239
, O O 0.9999715089797974
P O O 0.9999593496322632
= O O 0.9999680519104004
0 O O 0.9999933242797852
. O O 0.9999942779541016
000 O O 0.9999982118606567
) O O 0.9999896287918091
with O O 0.9990667700767517
either O B 0.9959422945976257
, O O 0.9992558360099792
and O O 0.9999768733978271
was O O 0.9999862909317017
unchanged O O 0.9999982118606567
with O O 0.9996356964111328
metformin B B 0.9995090961456299
. O O 0.999934196472168

The O O 0.998977541923523
hazard O O 0.9972761273384094
decreased O O 0.999955415725708
0 O O 0.9998860359191895
. O O 0.9999274015426636
3 O O 0.9999610185623169
- O O 0.9999650716781616
fold O O 0.9999936819076538
( O O 0.9999105930328369
0 O O 0.999948263168335
. O O 0.9999759197235107
7 O O 0.9999819993972778
- O O 0.9991858601570129
1 O O 0.9999874830245972
. O O 0.9999908208847046
7 O O 0.9999936819076538
, O O 0.9999536275863647
P O O 0.999977707862854
= O O 0.9998027682304382
0 O O 0.9999542236328125
. O O 0.9999710321426392
385 O O 0.9999502897262573
) O O 0.9999773502349854
with O O 0.9995700716972351
glimepiride B B 0.999376118183136
, O O 0.9997718930244446
0 O O 0.9998632669448853
. O O 0.9999384880065918
4 O O 0.9999325275421143
- O O 0.9999657869338989
fold O O 0.9999958276748657
( O O 0.9999387264251709
0 O O 0.9999779462814331
. O O 0.999984860420227
7 O O 0.9999686479568481
- O O 0.9991463422775269
1 O O 0.9999866485595703
. O O 0.9999947547912598
3 O O 0.9999912977218628
, O O 0.9999500513076782
P O O 0.9999392032623291
= O O 0.9997851252555847
0 O O 0.9999738931655884
. O O 0.999984622001648
192 O O 0.9999818801879883
) O O 0.999977707862854
with O O 0.9997609257698059
gliclazide B B 0.9996458292007446
, O O 0.9994285702705383
and O O 0.9999361038208008
0 O O 0.9998910427093506
. O O 0.9999330043792725
4 O O 0.9999397993087769
- O O 0.9999747276306152
fold O O 0.9999959468841553
( O O 0.9999450445175171
0 O O 0.9999769926071167
. O O 0.9999799728393555
7 O O 0.9999920129776001
- O O 0.9990682005882263
1 O O 0.9999871253967285
. O O 0.9999935626983643
1 O O 0.999996542930603
, O O 0.9999587535858154
P O O 0.9999265670776367
= O O 0.9997978806495667
0 O O 0.9999864101409912
. O O 0.9999914169311523
09 O O 0.9999905824661255
) O O 0.9999855756759644
with O O 0.9997183680534363
either O B 0.9871416091918945
. O O 0.9999327659606934

CONCLUSIONS O O 0.9969936609268188
: O O 0.9999761581420898
Initiating O O 0.9999934434890747
treatment O O 0.9999861717224121
of O O 0.9999665021896362
type O O 0.9999573230743408
2 O O 0.9989445805549622
diabetes O O 0.996904194355011
with O O 0.9998821020126343
glibenclamide B B 0.9989218711853027
or O O 0.8316650390625
glipizide B B 0.9986222982406616
is O O 0.9999294281005859
associated O O 0.9999823570251465
with O O 0.999988317489624
increased O O 0.9999812841415405
risk O O 0.9999970197677612
of O O 0.9999650716781616
CAD O O 0.8052744269371033
in O O 0.9999558925628662
comparison O O 0.9999631643295288
to O O 0.9989686012268066
gliclazide B B 0.9995598196983337
or O O 0.9585743546485901
glimepiride B B 0.9973822236061096
. O O 0.9999392032623291

If O O 0.9999299049377441
confirmed O O 0.999976634979248
, O O 0.9999810457229614
this O O 0.9999818801879883
may O O 0.9999728202819824
be O O 0.9999915361404419
important O O 0.9999886751174927
because O O 0.9999778270721436
most O O 0.9998962879180908
Indian O O 0.9987962245941162
patients O O 0.9999732971191406
receive O O 0.9997074007987976
the O O 0.9998290538787842
cheaper O O 0.9479336738586426
older O O 0.9501297473907471
sulphonylureas B B 0.9936664700508118
, O O 0.999701201915741
and O O 0.9999446868896484
present O O 0.9999468326568604
guidelines O O 0.9999847412109375
do O O 0.9999939203262329
not O O 0.999994158744812
distinguish O O 0.9999914169311523
between O O 0.9997174143791199
individual O O 0.9998028874397278
agents O O 0.9987432360649109
. O O 0.9999606609344482

Reduced O O 0.9999561309814453
progression O O 0.9999909400939941
of O O 0.9999128580093384
adriamycin B B 0.9985733032226562
nephropathy O O 0.9949240684509277
in O O 0.9998505115509033
spontaneously O O 0.9940720200538635
hypertensive O O 0.991640567779541
rats O O 0.9998064637184143
treated O O 0.9998412132263184
by O O 0.9992431402206421
losartan B B 0.9994882345199585
. O O 0.9998095631599426

BACKGROUND O O 0.9996675252914429
: O O 0.9999935626983643
The O O 0.9999972581863403
aim O O 0.9999971389770508
of O O 0.9999933242797852
the O O 0.9999947547912598
study O O 0.9999833106994629
was O O 0.9999939203262329
to O O 0.9999927282333374
investigate O O 0.9999185800552368
the O O 0.9999101161956787
antihypertensive O O 0.7825369238853455
effects O O 0.9997640252113342
of O O 0.9986934065818787
angiotensin B B 0.9977337121963501
II I O 0.6603041291236877
type O O 0.5822044014930725
- O O 0.8070158958435059
1 O O 0.7632683515548706
receptor O O 0.9422865509986877
blocker O O 0.8739638328552246
, O O 0.9805291295051575
losartan B B 0.9997454285621643
, O O 0.999552309513092
and O O 0.9999226331710815
its O O 0.9995502829551697
potential O O 0.9999412298202515
in O O 0.9999638795852661
slowing O O 0.9999816417694092
down O O 0.9998950958251953
renal O O 0.999971866607666
disease O O 0.9999933242797852
progression O O 0.9999971389770508
in O O 0.9999455213546753
spontaneously O O 0.9978804588317871
hypertensive O O 0.9966110587120056
rats O O 0.9997736811637878
( O O 0.9998338222503662
SHR O O 0.9549227952957153
) O O 0.9999598264694214
with O O 0.9999032020568848
adriamycin B B 0.9961357712745667
( O O 0.9922466278076172
ADR B B 0.8845747113227844
) O O 0.994559109210968
nephropathy O O 0.9997274279594421
. O O 0.9999809265136719

METHODS O O 0.9996894598007202
: O O 0.9999934434890747
Six O O 0.9999954700469971
- O O 0.9999897480010986
month O O 0.9999979734420776
- O O 0.9999957084655762
old O O 0.9999970197677612
female O O 0.999994158744812
SHR O O 0.9986615180969238
were O O 0.9999939203262329
randomly O O 0.9999815225601196
selected O O 0.9999877214431763
in O O 0.9999457597732544
six O O 0.9999717473983765
groups O O 0.9999936819076538
. O O 0.9999806880950928

Two O O 0.9992039799690247
control O O 0.9999102354049683
groups O O 0.999954104423523
( O O 0.9996867179870605
SH O O 0.8525416851043701
( O O 0.9947752952575684
6 O O 0.999915361404419
) O O 0.9997559189796448
, O O 0.9991714954376221
SH O O 0.6290841102600098
( O O 0.9976866245269775
12 O O 0.9992716908454895
) O O 0.9995827078819275
) O O 0.9999289512634277
received O O 0.9998819828033447
vehicle O O 0.9767390489578247
. O O 0.999940037727356

Groups O O 0.9992517828941345
ADR B O 0.6928477883338928
( O O 0.9992423057556152
6 O O 0.9999427795410156
) O O 0.9999003410339355
, O O 0.9998897314071655
ADR B O 0.6963266134262085
+ O O 0.9987038373947144
LOS B B 0.9478871822357178
( O O 0.9907288551330566
6 O O 0.9999057054519653
) O O 0.9999445676803589
and O O 0.9995450377464294
ADR B O 0.65737384557724
( O O 0.9997473359107971
12 O O 0.9998062252998352
) O O 0.9999158382415771
, O O 0.9999580383300781
and O O 0.9999037981033325
ADR B O 0.7636339664459229
+ O O 0.9986783862113953
LOS B B 0.9403018951416016
( O O 0.9851481914520264
12 O O 0.9984602928161621
) O O 0.9999897480010986
received O O 0.9999480247497559
ADR B B 0.9268733859062195
( O O 0.9982301592826843
2 O O 0.9998912811279297
mg O O 0.9999668598175049
/ O O 0.9999915361404419
kg O O 0.9999978542327881
/ O O 0.9997314810752869
b O O 0.9999533891677856
. O O 0.999996542930603
w O O 0.99998939037323
. O O 0.9999961853027344
i O O 0.9999843835830688
. O O 0.9999970197677612
v O O 0.9999986886978149
. O O 0.9999954700469971
) O O 0.9999802112579346
twice O O 0.9999819993972778
in O O 0.9999939203262329
a O O 0.9999943971633911
3 O O 0.9999631643295288
- O O 0.9999920129776001
week O O 0.9999977350234985
interval O O 0.9999969005584717
. O O 0.9999830722808838

Group O O 0.9965378046035767
ADR B O 0.8590330481529236
+ O O 0.9980954527854919
LOS B B 0.9818705320358276
( O O 0.9915905594825745
6 O O 0.9996721744537354
) O O 0.9999839067459106
received O O 0.9999402761459351
losartan B B 0.9996048808097839
( O O 0.9996953010559082
10 O O 0.9999822378158569
mg O O 0.999962568283081
/ O O 0.9999918937683105
kg O O 0.9999983310699463
/ O O 0.9999401569366455
b O O 0.9999523162841797
. O O 0.9999966621398926
w O O 0.999997615814209
. O O 0.9999979734420776
/ O O 0.9999825954437256
day O O 0.9999959468841553
by O O 0.9999300241470337
gavages O O 0.9978132247924805
) O O 0.9999798536300659
for O O 0.9999817609786987
6 O O 0.9999791383743286
weeks O O 0.9999973773956299
and O O 0.9999595880508423
group O O 0.965319812297821
ADR B O 0.7125076651573181
+ O O 0.9956299066543579
LOS B B 0.9682719111442566
( O O 0.9561090469360352
12 O O 0.945598304271698
) O O 0.9996751546859741
for O O 0.999968409538269
12 O O 0.9999972581863403
weeks O O 0.9999982118606567
after O O 0.9999891519546509
second O O 0.9999954700469971
injection O O 0.9999845027923584
of O O 0.9991381168365479
ADR B B 0.8965721726417542
. O O 0.9998884201049805

Animals O O 0.9999723434448242
were O O 0.9999760389328003
killed O O 0.9999798536300659
after O O 0.9999845027923584
6 O O 0.9999629259109497
or O O 0.9999674558639526
12 O O 0.9999922513961792
weeks O O 0.9999960660934448
, O O 0.9999874830245972
respectively O O 0.9999608993530273
. O O 0.999976396560669

Haemodynamic O O 0.9996871948242188
measurements O O 0.9999908208847046
were O O 0.9999943971633911
performed O O 0.9999954700469971
on O O 0.9999619722366333
anaesthetized O O 0.9999847412109375
animals O O 0.9999839067459106
, O O 0.9999786615371704
blood O O 0.9998518228530884
and O O 0.9999078512191772
urine O O 0.9998503923416138
samples O O 0.9999539852142334
were O O 0.9999731779098511
taken O O 0.9999934434890747
for O O 0.9999586343765259
biochemical O O 0.9984928369522095
analysis O O 0.9999847412109375
and O O 0.9999585151672363
the O O 0.9999828338623047
left O O 0.9999775886535645
kidney O O 0.9999743700027466
was O O 0.9999572038650513
processed O O 0.9999945163726807
for O O 0.9999673366546631
morphological O O 0.9999842643737793
studies O O 0.9999969005584717
. O O 0.9999709129333496

RESULTS O O 0.9999135732650757
: O O 0.9998540878295898
Short O O 0.9997321963310242
- O O 0.9999490976333618
term O O 0.9996351003646851
losartan B B 0.9997795224189758
treatment O O 0.999690055847168
, O O 0.9999603033065796
besides O O 0.9967026114463806
antihypertensive O O 0.6920676827430725
effect O O 0.9986159801483154
, O O 0.9999383687973022
improved O O 0.9999268054962158
glomerular O O 0.99720299243927
filtration O O 0.9999366998672485
rate O O 0.9999889135360718
and O O 0.9999430179595947
ameliorated O O 0.9999319314956665
glomerulosclerosis O O 0.9992445707321167
resulting O O 0.9999860525131226
in O O 0.9999945163726807
decreased O O 0.9999885559082031
proteinuria O O 0.9999462366104126
. O O 0.9999747276306152

Prolonged O O 0.9997005462646484
treatment O O 0.9999463558197021
with O O 0.9994288086891174
losartan B B 0.9996912479400635
showed O O 0.9998302459716797
further O O 0.9999332427978516
reduction O O 0.9999921321868896
of O O 0.9998987913131714
glomerulosclerosis O O 0.9988328814506531
associated O O 0.9999042749404907
with O O 0.9999395608901978
reduced O O 0.9999372959136963
progression O O 0.9999923706054688
of O O 0.9999151229858398
tubular O O 0.9999889135360718
atrophy O O 0.9999493360519409
and O O 0.9998764991760254
interstitial O O 0.997677743434906
fibrosis O O 0.9999837875366211
, O O 0.9999475479125977
thus O O 0.9999392032623291
preventing O O 0.9999188184738159
heavy O O 0.9993521571159363
proteinuria O O 0.9997270703315735
and O O 0.9999525547027588
chronic O O 0.9999409914016724
renal O O 0.9999932050704956
failure O O 0.9999915361404419
. O O 0.9999744892120361

Losartan B B 0.9994760155677795
reduced O O 0.9997954964637756
uraemia O O 0.9779054522514343
and O O 0.9999501705169678
increased O O 0.9998804330825806
urea B B 0.9907054305076599
clearance O O 0.9994891881942749
in O O 0.9998433589935303
advanced O O 0.9995792508125305
ADR B O 0.5788125395774841
nephropathy O O 0.9989473223686218
in O O 0.9998241066932678
SHR O O 0.8163090348243713
. O O 0.9999278783798218

Histological O O 0.9999494552612305
examination O O 0.9999901056289673
showed O O 0.9999358654022217
that O O 0.9995375871658325
losartan B B 0.9997767806053162
could O O 0.9998385906219482
prevent O O 0.998433530330658
tubular O O 0.9999792575836182
atrophy O O 0.9999743700027466
, O O 0.999915599822998
interstitial O O 0.9977523684501648
infiltration O O 0.9999736547470093
and O O 0.9998650550842285
fibrosis O O 0.9999536275863647
in O O 0.9987097978591919
ADR B O 0.5748996734619141
nephropathy O O 0.9992836117744446
. O O 0.9999580383300781

CONCLUSION O O 0.9990322589874268
: O O 0.9991788268089294
Losartan B B 0.999752938747406
reduces O O 0.99937903881073
the O O 0.9999737739562988
rate O O 0.9999938011169434
of O O 0.999984622001648
progression O O 0.9999932050704956
of O O 0.9999403953552246
ADR B B 0.9636504650115967
- O O 0.9926989674568176
induced O O 0.9999128580093384
focal O O 0.9999375343322754
segmental O O 0.9999788999557495
glomerulosclerosis O O 0.9992666840553284
to O O 0.9999520778656006
end O O 0.9999411106109619
- O O 0.999976396560669
stage O O 0.9999923706054688
renal O O 0.9999668598175049
disease O O 0.9999912977218628
in O O 0.9998328685760498
SHR O O 0.9032595753669739
. O O 0.9999300241470337

The O O 0.9999394416809082
risks O O 0.9999719858169556
of O O 0.9995192289352417
aprotinin O B 0.9918501973152161
and O O 0.8637689352035522
tranexamic B B 0.9597964882850647
acid I I 0.9995647072792053
in O O 0.999495267868042
cardiac O O 0.9999831914901733
surgery O O 0.9999938011169434
: O O 0.999985933303833
a O O 0.999993085861206
one O O 0.999994158744812
- O O 0.9999960660934448
year O O 0.999997615814209
follow O O 0.9999964237213135
- O O 0.9999966621398926
up O O 0.9999969005584717
of O O 0.9999946355819702
1188 O O 0.9999496936798096
consecutive O O 0.9999866485595703
patients O O 0.9999972581863403
. O O 0.9999915361404419

BACKGROUND O O 0.9996376037597656
: O O 0.9999934434890747
Our O O 0.9999872446060181
aim O O 0.9999970197677612
was O O 0.9999969005584717
to O O 0.9999966621398926
investigate O O 0.9999563694000244
postoperative O O 0.9998997449874878
complications O O 0.9999967813491821
and O O 0.9999922513961792
mortality O O 0.9999958276748657
after O O 0.9999054670333862
administration O O 0.9998905658721924
of O O 0.9991720914840698
aprotinin O B 0.9941923022270203
compared O O 0.9976658821105957
to O O 0.9924949407577515
tranexamic B B 0.9913555979728699
acid I I 0.9993962049484253
in O O 0.9998026490211487
an O O 0.9999936819076538
unselected O O 0.999963641166687
, O O 0.9999887943267822
consecutive O O 0.9998651742935181
cohort O O 0.9999881982803345
. O O 0.9999889135360718

METHODS O O 0.9999539852142334
: O O 0.9999892711639404
Perioperative O O 0.9999810457229614
data O O 0.9999966621398926
from O O 0.999990701675415
consecutive O O 0.9999524354934692
cardiac O O 0.9999842643737793
surgery O O 0.9999904632568359
patients O O 0.999994158744812
were O O 0.9999899864196777
prospectively O O 0.999995231628418
collected O O 0.9999967813491821
between O O 0.9998553991317749
September O O 0.9979110360145569
2005 O O 0.9924705028533936
and O O 0.9997815489768982
June O O 0.9994515776634216
2006 O O 0.999956488609314
in O O 0.9999403953552246
a O O 0.9999849796295166
university O O 0.99261474609375
- O O 0.9999687671661377
affiliated O O 0.9999749660491943
clinic O O 0.9999953508377075
( O O 0.9999791383743286
n O O 0.9999836683273315
= O O 0.9999862909317017
1188 O O 0.9999706745147705
) O O 0.9999798536300659
. O O 0.9999816417694092

During O O 0.999862551689148
the O O 0.9999873638153076
first O O 0.9999825954437256
5 O O 0.9998950958251953
mo O O 0.9999558925628662
, O O 0.9999498128890991
596 O O 0.9993979930877686
patients O O 0.9999754428863525
received O O 0.9994117021560669
aprotinin O B 0.9956973791122437
( O O 0.998970627784729
Group O O 0.9991239905357361
A O O 0.9762582182884216
) O O 0.9998947381973267
; O O 0.9999151229858398
in O O 0.999936580657959
the O O 0.9999916553497314
next O O 0.9999860525131226
5 O O 0.9997327923774719
mo O O 0.9999724626541138
, O O 0.9999656677246094
592 O O 0.9970418810844421
patients O O 0.9999746084213257
were O O 0.9999719858169556
treated O O 0.9999600648880005
with O O 0.9996016621589661
tranexamic B B 0.9956343770027161
acid I I 0.9996697902679443
( O O 0.9993139505386353
Group O O 0.9995916485786438
T O O 0.9286813735961914
) O O 0.9998987913131714
. O O 0.9999725818634033

Except O O 0.9999098777770996
for O O 0.9992007613182068
antifibrinolytic O O 0.7390440702438354
therapy O O 0.9987290501594543
, O O 0.9999507665634155
the O O 0.9999828338623047
anesthetic O O 0.999822199344635
and O O 0.9999567270278931
surgical O O 0.9999895095825195
protocols O O 0.9999961853027344
remained O O 0.999988317489624
unchanged O O 0.9999932050704956
. O O 0.9999812841415405

RESULTS O O 0.999755322933197
: O O 0.9999688863754272
The O O 0.9999903440475464
pre O O 0.9998849630355835
- O O 0.9999575614929199
and O O 0.9999552965164185
intraoperative O O 0.9999614953994751
variables O O 0.9999939203262329
were O O 0.9999468326568604
comparable O O 0.9999802112579346
between O O 0.9997463822364807
the O O 0.9999406337738037
treatment O O 0.999674916267395
groups O O 0.9999821186065674
. O O 0.9999741315841675

Postoperatively O O 0.9997363686561584
, O O 0.9999544620513916
a O O 0.9999861717224121
significantly O O 0.9999737739562988
higher O O 0.9999854564666748
incidence O O 0.9999942779541016
of O O 0.9999779462814331
seizures O O 0.9999690055847168
was O O 0.999971866607666
found O O 0.999994158744812
in O O 0.9998086094856262
Group O O 0.9990940093994141
T O O 0.9903374910354614
( O O 0.999953031539917
4 O O 0.9997090697288513
. O O 0.9999760389328003
6 O O 0.9999876022338867
% O O 0.99998939037323
vs O O 0.9999213218688965
1 O O 0.9999556541442871
. O O 0.9999747276306152
2 O O 0.9999862909317017
% O O 0.9999916553497314
, O O 0.9999740123748779
P O O 0.9999526739120483
< O O 0.9999749660491943
0 O O 0.9999885559082031
. O O 0.9999969005584717
001 O O 0.9998113512992859
) O O 0.9999732971191406
. O O 0.9999608993530273

This O O 0.9999748468399048
difference O O 0.9999897480010986
was O O 0.9999557733535767
also O O 0.9999874830245972
significant O O 0.999988317489624
in O O 0.9999493360519409
the O O 0.9999620914459229
primary O O 0.9996209144592285
valve O O 0.9990072846412659
surgery O O 0.9999194145202637
and O O 0.9998652935028076
the O O 0.999940037727356
high O O 0.9996899366378784
risk O O 0.9999549388885498
surgery O O 0.999985933303833
subgroups O O 0.9998894929885864
( O O 0.9999343156814575
7 O O 0.9999650716781616
. O O 0.9999861717224121
9 O O 0.9999903440475464
% O O 0.9999910593032837
vs O O 0.9998908042907715
1 O O 0.9999799728393555
. O O 0.9999853372573853
2 O O 0.9999799728393555
% O O 0.9999927282333374
, O O 0.999966025352478
P O O 0.9999270439147949
= O O 0.9996376037597656
0 O O 0.9999864101409912
. O O 0.9999957084655762
003 O O 0.9999381303787231
; O O 0.9999380111694336
7 O O 0.9999524354934692
. O O 0.9999874830245972
3 O O 0.9999773502349854
% O O 0.9999926090240479
vs O O 0.9998168349266052
2 O O 0.999968409538269
. O O 0.9999816417694092
4 O O 0.9999655485153198
% O O 0.9999933242797852
, O O 0.9999630451202393
P O O 0.9998435974121094
= O O 0.9998997449874878
0 O O 0.9999887943267822
. O O 0.9999972581863403
035 O O 0.9999227523803711
, O O 0.9999878406524658
respectively O O 0.9999796152114868
) O O 0.9999794960021973
. O O 0.9999819993972778

Persistent O O 0.9999759197235107
atrial O O 0.9993830919265747
fibrillation O O 0.9999679327011108
( O O 0.9999657869338989
7 O O 0.9999673366546631
. O O 0.999987006187439
9 O O 0.9999833106994629
% O O 0.9999942779541016
vs O O 0.9998316764831543
2 O O 0.999969482421875
. O O 0.999984860420227
3 O O 0.9999821186065674
% O O 0.9999970197677612
, O O 0.9999828338623047
P O O 0.9999542236328125
= O O 0.9998698234558105
0 O O 0.9999872446060181
. O O 0.9999927282333374
020 O O 0.9999808073043823
) O O 0.9999440908432007
and O O 0.9999200105667114
renal O O 0.999966025352478
failure O O 0.9999860525131226
( O O 0.9999785423278809
9 O O 0.9999780654907227
. O O 0.999993085861206
7 O O 0.9999951124191284
% O O 0.9999972581863403
vs O O 0.999882698059082
1 O O 0.999982476234436
. O O 0.9999810457229614
7 O O 0.999993085861206
% O O 0.9999980926513672
, O O 0.9999762773513794
P O O 0.9998387098312378
= O O 0.999702513217926
0 O O 0.9999679327011108
. O O 0.9999926090240479
002 O O 0.9999169111251831
) O O 0.9999599456787109
were O O 0.9999727010726929
also O O 0.9999904632568359
more O O 0.999984622001648
common O O 0.9999934434890747
in O O 0.9999390840530396
Group O O 0.9986379742622375
T O O 0.9947028756141663
, O O 0.9999685287475586
in O O 0.9999340772628784
the O O 0.9999746084213257
primary O O 0.9996495246887207
valve O O 0.999723494052887
surgery O O 0.9999790191650391
subgroup O O 0.999869704246521
. O O 0.9999761581420898

On O O 0.9999574422836304
the O O 0.9999828338623047
contrary O O 0.9999929666519165
, O O 0.9999591112136841
among O O 0.9996034502983093
primary O O 0.9998716115951538
coronary O O 0.9915876984596252
artery O O 0.9801076650619507
bypass O O 0.9998352527618408
surgery O O 0.999963641166687
patients O O 0.9999629259109497
, O O 0.999954104423523
there O O 0.9999581575393677
were O O 0.9999703168869019
more O O 0.9999545812606812
acute O O 0.9999792575836182
myocardial O O 0.9999978542327881
infarctions O O 0.9999654293060303
and O O 0.9999052286148071
renal O O 0.9999532699584961
dysfunction O O 0.9999887943267822
in O O 0.9998842477798462
Group O O 0.9995027780532837
A O O 0.9937683343887329
( O O 0.9999487400054932
5 O O 0.999943733215332
. O O 0.9999821186065674
8 O O 0.9999791383743286
% O O 0.9999858140945435
vs O O 0.9998862743377686
2 O O 0.9999617338180542
. O O 0.9999815225601196
0 O O 0.9999837875366211
% O O 0.9999877214431763
, O O 0.9999676942825317
P O O 0.9999001026153564
= O O 0.9997989535331726
0 O O 0.9999915361404419
. O O 0.9999943971633911
027 O O 0.999963641166687
; O O 0.9999551773071289
22 O O 0.9999676942825317
. O O 0.9999899864196777
5 O O 0.9999899864196777
% O O 0.9999911785125732
vs O O 0.9998873472213745
15 O O 0.9999932050704956
. O O 0.9999922513961792
2 O O 0.9999887943267822
% O O 0.9999939203262329
, O O 0.9999655485153198
P O O 0.9998688697814941
= O O 0.9998735189437866
0 O O 0.9999918937683105
. O O 0.999996542930603
036 O O 0.999958872795105
, O O 0.9999899864196777
respectively O O 0.9999691247940063
) O O 0.999975323677063
. O O 0.9999815225601196

The O O 0.9999728202819824
1 O O 0.9998231530189514
- O O 0.9999722242355347
yr O O 0.9982518553733826
mortality O O 0.9999243021011353
was O O 0.9999752044677734
significantly O O 0.9999916553497314
higher O O 0.9999873638153076
after O O 0.9998034834861755
aprotinin O B 0.9976710677146912
treatment O O 0.9996046423912048
in O O 0.9999502897262573
the O O 0.9999822378158569
high O O 0.9998427629470825
risk O O 0.9999788999557495
surgery O O 0.9999706745147705
group O O 0.9999548196792603
( O O 0.9999585151672363
17 O O 0.9999803304672241
. O O 0.9999908208847046
7 O O 0.9999938011169434
% O O 0.9999927282333374
vs O O 0.9999452829360962
9 O O 0.9999814033508301
. O O 0.999992847442627
8 O O 0.9999891519546509
% O O 0.9999942779541016
, O O 0.9999833106994629
P O O 0.9999393224716187
= O O 0.9999372959136963
0 O O 0.9999866485595703
. O O 0.9999972581863403
034 O O 0.9997422099113464
) O O 0.9999819993972778
. O O 0.9999833106994629

CONCLUSION O O 0.9895590543746948
: O O 0.9998624324798584
Both O O 0.9950957894325256
antifibrinolytic O O 0.5782933235168457
drugs O O 0.9844774007797241
bear O O 0.9999377727508545
the O O 0.999987006187439
risk O O 0.9999940395355225
of O O 0.9999842643737793
adverse O O 0.9999711513519287
outcome O O 0.9999977350234985
depending O O 0.9999881982803345
on O O 0.9999842643737793
the O O 0.9999936819076538
type O O 0.9999966621398926
of O O 0.9999881982803345
cardiac O O 0.9999783039093018
surgery O O 0.9999947547912598
. O O 0.9999613761901855

Administration O O 0.9997988343238831
of O O 0.999255359172821
aprotinin O B 0.9754722714424133
should O O 0.9990503191947937
be O O 0.9999878406524658
avoided O O 0.9999333620071411
in O O 0.9999681711196899
coronary O O 0.9997120499610901
artery O O 0.9992204904556274
bypass O O 0.9999526739120483
graft O O 0.9999830722808838
and O O 0.9999265670776367
high O O 0.9998526573181152
risk O O 0.9999840259552002
patients O O 0.9999943971633911
, O O 0.9999816417694092
whereas O O 0.9999109506607056
administration O O 0.999906063079834
of O O 0.9994066953659058
tranexamic B B 0.9957549571990967
acid I I 0.9993767142295837
is O O 0.9998440742492676
not O O 0.9999842643737793
recommended O O 0.9999843835830688
in O O 0.9999567270278931
valve O O 0.9999130964279175
surgery O O 0.999990701675415
. O O 0.9999774694442749

Delirium O O 0.9998778104782104
in O O 0.9999662637710571
an O O 0.9999920129776001
elderly O O 0.9999345541000366
woman O O 0.9999963045120239
possibly O O 0.9999752044677734
associated O O 0.9999867677688599
with O O 0.9999415874481201
administration O O 0.9998465776443481
of O O 0.9992085099220276
misoprostol B B 0.9991075396537781
. O O 0.9999227523803711

Misoprostol B B 0.99922776222229
has O O 0.9991852641105652
been O O 0.9999169111251831
associated O O 0.9999165534973145
with O O 0.9998413324356079
adverse O O 0.9998773336410522
reactions O O 0.9999945163726807
, O O 0.9999872446060181
including O O 0.9999572038650513
gastrointestinal O O 0.999927282333374
symptoms O O 0.9999957084655762
, O O 0.9999798536300659
gynecologic O O 0.999957799911499
problems O O 0.9999960660934448
, O O 0.9999418258666992
and O O 0.9999408721923828
headache O O 0.9999876022338867
. O O 0.9999370574951172

Changes O O 0.9999881982803345
in O O 0.9999908208847046
mental O O 0.9999949932098389
status O O 0.9999901056289673
, O O 0.9999856948852539
however O O 0.9999830722808838
, O O 0.9999868869781494
have O O 0.9999854564666748
not O O 0.9999842643737793
been O O 0.9999910593032837
reported O O 0.9999905824661255
. O O 0.999961256980896

We O O 0.9999895095825195
present O O 0.9999966621398926
a O O 0.9999959468841553
case O O 0.9999966621398926
in O O 0.999993085861206
which O O 0.9999816417694092
an O O 0.9999933242797852
89 O O 0.9992495179176331
- O O 0.9999866485595703
year O O 0.9999942779541016
- O O 0.9999921321868896
old O O 0.9999921321868896
woman O O 0.9999959468841553
in O O 0.9999188184738159
a O O 0.9999823570251465
long O O 0.9997105002403259
- O O 0.9999821186065674
term O O 0.9999873638153076
care O O 0.9999821186065674
facility O O 0.9999916553497314
became O O 0.9999746084213257
confused O O 0.9999961853027344
after O O 0.999929666519165
the O O 0.9999927282333374
initiation O O 0.9999569654464722
of O O 0.999756395816803
misoprostol B B 0.9993535876274109
therapy O O 0.9682387113571167
. O O 0.9999747276306152

The O O 0.9999847412109375
patient O O 0.99998939037323
' O O 0.9999933242797852
s O O 0.9999959468841553
change O O 0.9999986886978149
in O O 0.999996542930603
mental O O 0.9999974966049194
status O O 0.9999967813491821
was O O 0.9999953508377075
first O O 0.999998927116394
reported O O 0.9999985694885254
nine O O 0.999996542930603
days O O 0.9999985694885254
after O O 0.9999970197677612
the O O 0.9999966621398926
initiation O O 0.9999924898147583
of O O 0.9999606609344482
therapy O O 0.9999667406082153
. O O 0.9999620914459229

Her O O 0.999977707862854
delirium O O 0.9999786615371704
significantly O O 0.9999886751174927
improved O O 0.9999949932098389
after O O 0.9998811483383179
misoprostol B B 0.9997479319572449
was O O 0.9998964071273804
discontinued O O 0.9997920393943787
and O O 0.9999884366989136
her O O 0.9999899864196777
mental O O 0.9999980926513672
status O O 0.9999978542327881
returned O O 0.9999957084655762
to O O 0.9999969005584717
normal O O 0.9999960660934448
within O O 0.9999955892562866
a O O 0.9999945163726807
week O O 0.9999982118606567
. O O 0.9999805688858032

Because O O 0.9999489784240723
no O O 0.9999009370803833
other O O 0.9998722076416016
factors O O 0.9999817609786987
related O O 0.9999891519546509
to O O 0.9999659061431885
this O O 0.9999353885650635
patient O O 0.9999796152114868
changed O O 0.9999761581420898
significantly O O 0.9999885559082031
, O O 0.9999208450317383
the O O 0.9999798536300659
delirium O O 0.9999576807022095
experienced O O 0.9999629259109497
by O O 0.9999752044677734
this O O 0.9999610185623169
patient O O 0.999984860420227
possibly O O 0.9998984336853027
resulted O O 0.9999755620956421
from O O 0.9996265172958374
misoprostol B B 0.9992590546607971
therapy O O 0.9961663484573364
. O O 0.999967098236084

The O O 0.999874472618103
biological O O 0.9998775720596313
properties O O 0.9999774694442749
of O O 0.9997566342353821
the O O 0.9980785846710205
optical O O 0.6572146415710449
isomers O O 0.8799582123756409
of O O 0.9717472195625305
propranolol B B 0.9989776611328125
and O O 0.9998437166213989
their O O 0.9995244741439819
effects O O 0.9999264478683472
on O O 0.999953031539917
cardiac O O 0.9999874830245972
arrhythmias O O 0.9999778270721436
. O O 0.9999650716781616

1 O O 0.9998971223831177
. O O 0.9998472929000854

The O O 0.9941461086273193
optical O O 0.7285951375961304
isomers O O 0.9162962436676025
of O O 0.985633909702301
propranolol B B 0.9994543194770813
have O O 0.999772846698761
been O O 0.9999748468399048
compared O O 0.9993477463722229
for O O 0.9999504089355469
their O O 0.999757707118988
beta O O 0.9570326209068298
- O O 0.9948468208312988
blocking O O 0.9819067120552063
and O O 0.9995119571685791
antiarrhythmic O O 0.7204787135124207
activities O O 0.9996641874313354
. O O 0.9999599456787109
2 O O 0.9999077320098877
. O O 0.9999597072601318

In O O 0.9997244477272034
blocking O O 0.9994617104530334
the O O 0.9997797608375549
positive O O 0.9986760020256042
inotropic O O 0.996455729007721
and O O 0.9993481040000916
chronotropic O O 0.9631397128105164
responses O O 0.999956488609314
to O O 0.9996612071990967
isoprenaline B B 0.9995338916778564
, O O 0.9996150732040405
( O O 0.9911531805992126
+ O O 0.9998778104782104
) O O 0.975182294845581
- O O 0.9572163820266724
propranolol B B 0.9871593713760376
had O O 0.9998499155044556
less O O 0.9999853372573853
than O O 0.9999916553497314
one O O 0.9999985694885254
hundredth O O 0.9999220371246338
the O O 0.9999876022338867
potency O O 0.9997188448905945
of O O 0.9998001456260681
( O O 0.9421048164367676
- O O 0.9667873382568359
) O O 0.9137285947799683
- O O 0.8459592461585999
propranolol B B 0.8557802438735962
. O O 0.9998942613601685

At O O 0.9991390705108643
dose O O 0.9985393285751343
levels O O 0.9999011754989624
of O O 0.9990642666816711
( O O 0.8926896452903748
+ O O 0.9962109327316284
) O O 0.983871340751648
- O O 0.9199122190475464
propranolol B B 0.9920899868011475
which O O 0.9993281364440918
attenuated O O 0.998195469379425
the O O 0.9999618530273438
responses O O 0.9999924898147583
to O O 0.9995632767677307
isoprenaline B B 0.9995139837265015
, O O 0.9998718500137329
there O O 0.9999405145645142
was O O 0.9999881982803345
a O O 0.999990701675415
significant O O 0.9999877214431763
prolongation O O 0.9999895095825195
of O O 0.9999885559082031
the O O 0.9999905824661255
PR O O 0.994627058506012
interval O O 0.9999934434890747
of O O 0.9999877214431763
the O O 0.9999943971633911
electrocardiogram O O 0.9999630451202393
. O O 0.9999712705612183
3 O O 0.9996976852416992
. O O 0.9999749660491943

The O O 0.9999403953552246
metabolic O O 0.999806821346283
responses O O 0.9999926090240479
to O O 0.999834418296814
isoprenaline B B 0.9991633892059326
in O O 0.9927113056182861
dogs O O 0.9400408864021301
( O O 0.999903678894043
an O O 0.9999767541885376
increase O O 0.9999626874923706
in O O 0.9999481439590454
circulating O O 0.9968870282173157
glucose B B 0.9829496145248413
, O O 0.9974985718727112
lactate B B 0.9827427864074707
and O O 0.9980162382125854
free O O 0.9604663848876953
fatty B O 0.979790210723877
acids I O 0.8153605461120605
) O O 0.9999520778656006
were O O 0.9999306201934814
all O O 0.9998761415481567
blocked O O 0.9997244477272034
by O O 0.9995765089988708
( O O 0.9422550201416016
- O O 0.8296326994895935
) O O 0.8323035836219788
- O O 0.7597166895866394
propranolol B B 0.9431163668632507
. O O 0.9999219179153442

( O O 0.977264404296875
+ O O 0.9997097849845886
) O O 0.9840347766876221
- O O 0.9470250606536865
Propranolol B B 0.9979311227798462
had O O 0.9998399019241333
no O O 0.9999561309814453
effect O O 0.9999727010726929
on O O 0.9998658895492554
fatty B B 0.5764927268028259
acid I I 0.995032787322998
mobilization O O 0.9990888833999634
but O O 0.999818742275238
significantly O O 0.9999319314956665
reduced O O 0.9999809265136719
the O O 0.9999854564666748
increments O O 0.9999916553497314
in O O 0.9999620914459229
both O O 0.9996380805969238
lactate B B 0.9948771595954895
and O O 0.9991284012794495
glucose B B 0.9951506853103638
. O O 0.9999533891677856
4 O O 0.9988908171653748
. O O 0.9999614953994751

Both O O 0.9373233318328857
isomers O O 0.8971636891365051
of O O 0.9826571345329285
propranolol B B 0.9994215965270996
possessed O O 0.999626636505127
similar O O 0.9998030066490173
depressant O O 0.7154991030693054
potency O O 0.9973366856575012
on O O 0.9997647404670715
isolated O O 0.9999299049377441
atrial O O 0.9999322891235352
muscle O O 0.9999581575393677
taken O O 0.9999790191650391
from O O 0.9999353885650635
guinea O O 0.9966566562652588
- O O 0.9985730648040771
pigs O O 0.9750537872314453
. O O 0.9999305009841919
5 O O 0.9996542930603027
. O O 0.9998874664306641

The O O 0.9994992017745972
isomers O O 0.7397066950798035
of O O 0.9918344020843506
propranolol B B 0.9993072748184204
exhibited O O 0.9998334646224976
similar O O 0.9999101161956787
local O O 0.9990885257720947
anaesthetic O O 0.9582124948501587
potencies O O 0.9990103244781494
on O O 0.9997500777244568
an O O 0.9997661709785461
isolated O O 0.9997288584709167
frog O O 0.9641866683959961
nerve O O 0.9998816251754761
preparation O O 0.9999451637268066
at O O 0.9999098777770996
a O O 0.9999691247940063
level O O 0.9999723434448242
approximately O O 0.9999860525131226
three O O 0.999991774559021
times O O 0.9999885559082031
that O O 0.999994158744812
of O O 0.9998270869255066
procaine B B 0.9422999024391174
. O O 0.9999171495437622

The O O 0.9999243021011353
racemic O O 0.7670043110847473
compound O O 0.8287844657897949
was O O 0.9999303817749023
significantly O O 0.9999755620956421
less O O 0.9999333620071411
potent O O 0.9995970129966736
than O O 0.9995512366294861
either O O 0.9835579991340637
isomer O O 0.8494210839271545
. O O 0.99991774559021
6 O O 0.9993875026702881
. O O 0.9999812841415405

Both O O 0.9600200057029724
isomers O O 0.8879064321517944
of O O 0.9955565333366394
propranolol B B 0.9988376498222351
were O O 0.9998725652694702
capable O O 0.9998745918273926
of O O 0.9999394416809082
preventing O O 0.999806821346283
adrenaline B B 0.9661288857460022
- O O 0.9979166388511658
induced O O 0.9999830722808838
cardiac O O 0.9999972581863403
arrhythmias O O 0.9999971389770508
in O O 0.9999450445175171
cats O O 0.9999880790710449
anaesthetized O O 0.9999810457229614
with O O 0.9997751116752625
halothane B B 0.9972817897796631
, O O 0.9998749494552612
but O O 0.999981164932251
the O O 0.9999908208847046
mean O O 0.9999006986618042
dose O O 0.9999152421951294
of O O 0.9997759461402893
( O O 0.9358770847320557
- O O 0.9385799169540405
) O O 0.8618157505989075
- O O 0.7887226343154907
propranolol B B 0.8923612236976624
was O O 0.9996908903121948
0 O O 0.9999665021896362
. O O 0.9999939203262329
09 O O 0.999988317489624
+ O O 0.9999915361404419
/ O O 0.9999569654464722
- O O 0.9999772310256958
0 O O 0.9999964237213135
. O O 0.9999985694885254
02 O O 0.999997615814209
mg O O 0.999961256980896
/ O O 0.999981164932251
kg O O 0.9999954700469971
whereas O O 0.9998711347579956
that O O 0.9999806880950928
of O O 0.9998455047607422
( O O 0.9917810559272766
+ O O 0.9999395608901978
) O O 0.9854689240455627
- O O 0.9571544528007507
propranolol B B 0.9290974140167236
was O O 0.9998551607131958
4 O O 0.9947496056556702
. O O 0.9999924898147583
2 O O 0.9999836683273315
+ O O 0.9999935626983643
/ O O 0.9999713897705078
- O O 0.9999762773513794
1 O O 0.9999947547912598
. O O 0.999997615814209
2 O O 0.9999921321868896
mg O O 0.9999794960021973
/ O O 0.9999796152114868
kg O O 0.9999947547912598
. O O 0.9999784231185913

At O O 0.9997921586036682
the O O 0.9999606609344482
effective O O 0.9997511506080627
dose O O 0.9997507929801941
level O O 0.9999552965164185
of O O 0.9993467926979065
( O O 0.9851714968681335
+ O O 0.9987014532089233
) O O 0.9855985045433044
- O O 0.8933143615722656
propranolol B B 0.974617063999176
there O O 0.9998939037322998
was O O 0.99997878074646
a O O 0.9999911785125732
significant O O 0.9999890327453613
prolongation O O 0.999982476234436
of O O 0.9999866485595703
the O O 0.9999873638153076
PR O O 0.9938110709190369
interval O O 0.999993085861206
of O O 0.9999873638153076
the O O 0.9999924898147583
electrocardiogram O O 0.9999505281448364
. O O 0.9999560117721558

Blockade O O 0.9999253749847412
of O O 0.9999052286148071
arrhythmias O O 0.9999042749404907
with O O 0.999678373336792
both O O 0.6259889006614685
isomers O O 0.9064198136329651
was O O 0.9999680519104004
surmountable O O 0.9999841451644897
by O O 0.9999706745147705
increasing O O 0.9998947381973267
the O O 0.9999674558639526
dose O O 0.9998031258583069
of O O 0.9995546936988831
adrenaline B B 0.9919127225875854
. O O 0.9992656111717224
7 O O 0.9901830554008484
. O O 0.9999731779098511

Both O O 0.9903461337089539
isomers O O 0.925844669342041
of O O 0.9954572916030884
propranolol B B 0.9994750618934631
were O O 0.9998651742935181
also O O 0.999915599822998
capable O O 0.9998296499252319
of O O 0.9999244213104248
reversing O O 0.999925971031189
ventricular O O 0.9999144077301025
tachycardia O O 0.9999622106552124
caused O O 0.9999741315841675
by O O 0.9998916387557983
ouabain B B 0.9987760186195374
in O O 0.9998069405555725
anaesthetized O O 0.9999752044677734
cats O O 0.9999599456787109
and O O 0.9999463558197021
dogs O O 0.9999877214431763
. O O 0.999970555305481

The O O 0.9999853372573853
dose O O 0.9999173879623413
of O O 0.9997839331626892
( O O 0.9644540548324585
- O O 0.9678236842155457
) O O 0.9242081642150879
- O O 0.8685453534126282
propranolol B B 0.8913496136665344
was O O 0.9998310804367065
significantly O O 0.9999860525131226
smaller O O 0.9999799728393555
than O O 0.9999599456787109
that O O 0.9999724626541138
of O O 0.9998313188552856
( O O 0.9966006875038147
+ O O 0.9998396635055542
) O O 0.9814503192901611
- O O 0.9661892652511597
propranolol B B 0.9302093982696533
in O O 0.9995680451393127
both O O 0.9992844462394714
species O O 0.9999572038650513
but O O 0.9999760389328003
much O O 0.999984622001648
higher O O 0.9999486207962036
than O O 0.9999890327453613
that O O 0.9999886751174927
required O O 0.9999867677688599
to O O 0.9999908208847046
produce O O 0.9999908208847046
evidence O O 0.9999758005142212
of O O 0.9999380111694336
beta O O 0.9996188879013062
- O O 0.9990573525428772
blockade O O 0.9999309778213501
. O O 0.9999501705169678
8 O O 0.9992197751998901
. O O 0.999982476234436

The O O 0.9999896287918091
implications O O 0.9999980926513672
of O O 0.9999978542327881
these O O 0.9999953508377075
results O O 0.9999898672103882
are O O 0.999982476234436
discussed O O 0.9999858140945435
. O O 0.9999825954437256

Topotecan B B 0.9988596439361572
in O O 0.9997912049293518
combination O O 0.9999215602874756
with O O 0.9998277425765991
radiotherapy O O 0.9916152358055115
in O O 0.9999524354934692
unresectable O O 0.9996359348297119
glioblastoma O O 0.9988927245140076
: O O 0.9999855756759644
a O O 0.9999891519546509
phase O O 0.9999850988388062
2 O O 0.9973633885383606
study O O 0.9999873638153076
. O O 0.9999715089797974

Improving O O 0.9988516569137573
glioblastoma O O 0.9666349291801453
multiforme O O 0.997645914554596
( O O 0.9997984766960144
GBM O O 0.8425437211990356
) O O 0.9998979568481445
treatment O O 0.9999508857727051
with O O 0.9999346733093262
radio O O 0.8302395939826965
- O O 0.9598989486694336
chemotherapy O O 0.9822126626968384
remains O O 0.9999759197235107
a O O 0.9999864101409912
challenge O O 0.9999891519546509
. O O 0.9999799728393555

Topotecan B B 0.9987540245056152
is O O 0.9994014501571655
an O O 0.9997884631156921
attractive O O 0.9997696280479431
option O O 0.9999319314956665
as O O 0.9999793767929077
it O O 0.9976274371147156
exhibits O O 0.9995958209037781
growth O O 0.99802565574646
inhibition O O 0.9998243451118469
of O O 0.999614953994751
human O O 0.9996960163116455
glioma O O 0.9973611235618591
as O O 0.9999651908874512
well O O 0.9998677968978882
as O O 0.9998770952224731
brain O O 0.9998773336410522
penetration O O 0.9999711513519287
. O O 0.999942421913147

The O O 0.9999957084655762
present O O 0.9999955892562866
study O O 0.9999969005584717
assessed O O 0.9999781847000122
the O O 0.9999852180480957
combination O O 0.9995530247688293
of O O 0.9998118281364441
radiotherapy O O 0.9651402235031128
( O O 0.9998637437820435
60 O O 0.9997946619987488
Gy O O 0.9734926819801331
/ O O 0.9998481273651123
30 O O 0.9999275207519531
fractions O O 0.9999856948852539
/ O O 0.9999667406082153
40 O O 0.9999876022338867
days O O 0.9999949932098389
) O O 0.999957799911499
and O O 0.999134361743927
topotecan B B 0.9995309114456177
( O O 0.9993384480476379
0 O O 0.9999054670333862
. O O 0.9999881982803345
9 O O 0.9998633861541748
mg O O 0.9998775720596313
/ O O 0.9998579025268555
m O O 0.9999649524688721
( O O 0.9996434450149536
2 O O 0.9910994172096252
) O O 0.9992707371711731
/ O O 0.9999179840087891
day O O 0.9999890327453613
on O O 0.9999504089355469
days O O 0.9999840259552002
1 O O 0.9996126294136047
- O O 0.9948953986167908
5 O O 0.9999315738677979
on O O 0.9999810457229614
weeks O O 0.9999922513961792
1 O O 0.9999573230743408
, O O 0.9986585378646851
3 O O 0.9999688863754272
and O O 0.9999580383300781
5 O O 0.9999569654464722
) O O 0.9999736547470093
in O O 0.9999545812606812
50 O O 0.9999874830245972
adults O O 0.9999963045120239
with O O 0.9999823570251465
histologically O O 0.9999918937683105
proven O O 0.9999960660934448
and O O 0.9999873638153076
untreated O O 0.999980092048645
GBM O O 0.9995384216308594
. O O 0.9999653100967407

The O O 0.9999899864196777
incidence O O 0.9999977350234985
of O O 0.9999836683273315
non O O 0.9853773713111877
- O O 0.9996566772460938
hematological O O 0.9996564388275146
toxicities O O 0.9992213249206543
was O O 0.9999587535858154
low O O 0.9999910593032837
and O O 0.9999598264694214
grade O O 0.9999401569366455
3 O O 0.9928561449050903
- O O 0.9951786994934082
4 O O 0.9975417852401733
hematological O O 0.9999061822891235
toxicities O O 0.9993748068809509
were O O 0.9999659061431885
reported O O 0.9999922513961792
in O O 0.9999597072601318
20 O O 0.9998036026954651
patients O O 0.9999933242797852
( O O 0.9999573230743408
mainly O O 0.9998255372047424
lymphopenia O O 0.99983811378479
and O O 0.9998458623886108
neutropenia O O 0.9999262094497681
) O O 0.9999638795852661
. O O 0.9999744892120361

Partial O O 0.9995866417884827
response O O 0.9999840259552002
and O O 0.9998892545700073
stabilization O O 0.999919056892395
rates O O 0.9999819993972778
were O O 0.9999629259109497
2 O O 0.9999668598175049
% O O 0.9999960660934448
and O O 0.9999731779098511
32 O O 0.9999924898147583
% O O 0.999997615814209
, O O 0.9999903440475464
respectively O O 0.9999778270721436
, O O 0.9999899864196777
with O O 0.9999933242797852
an O O 0.9999964237213135
overall O O 0.999992847442627
time O O 0.9999969005584717
to O O 0.9999982118606567
progression O O 0.9999977350234985
of O O 0.9999922513961792
12 O O 0.9999979734420776
weeks O O 0.9999984502792358
. O O 0.9999821186065674

One O O 0.9996451139450073
- O O 0.9999793767929077
year O O 0.9999897480010986
overall O O 0.9999548196792603
survival O O 0.9999080896377563
( O O 0.9998617172241211
OS O O 0.9956234097480774
) O O 0.9999679327011108
rate O O 0.9999802112579346
was O O 0.9999868869781494
42 O O 0.9999986886978149
% O O 0.999998927116394
, O O 0.9999909400939941
with O O 0.9999947547912598
a O O 0.9999927282333374
median O O 0.9999779462814331
OS O O 0.9977743029594421
of O O 0.999971866607666
40 O O 0.9999940395355225
weeks O O 0.9999980926513672
. O O 0.999984622001648

Topotecan B B 0.9991492033004761
in O O 0.9998205304145813
combination O O 0.9999392032623291
with O O 0.9998544454574585
radiotherapy O O 0.9984692931175232
was O O 0.9999622106552124
well O O 0.9999796152114868
tolerated O O 0.9999839067459106
. O O 0.9999765157699585

However O O 0.9999713897705078
, O O 0.9999804496765137
while O O 0.9999611377716064
response O O 0.9999710321426392
and O O 0.999934196472168
stabilization O O 0.9999765157699585
concerned O O 0.9998764991760254
one O O 0.9999712705612183
- O O 0.9999816417694092
third O O 0.9999974966049194
of O O 0.999974250793457
the O O 0.9999786615371704
patients O O 0.9999933242797852
, O O 0.9999891519546509
the O O 0.9999974966049194
study O O 0.9999884366989136
did O O 0.9999858140945435
not O O 0.999987006187439
show O O 0.9999690055847168
increased O O 0.9999685287475586
benefits O O 0.9999892711639404
in O O 0.9999958276748657
terms O O 0.9999969005584717
of O O 0.9999899864196777
survival O O 0.9999861717224121
in O O 0.9999747276306152
patients O O 0.999991774559021
with O O 0.9999839067459106
unresectable O O 0.9999479055404663
GBM O O 0.9814334511756897
. O O 0.9999566078186035

Long O O 0.9912862181663513
- O O 0.9999427795410156
term O O 0.9995740056037903
lithium B B 0.9995902180671692
therapy O O 0.9966990351676941
leading O O 0.9999808073043823
to O O 0.9999697208404541
hyperparathyroidism O O 0.998623251914978
: O O 0.9999847412109375
a O O 0.9999943971633911
case O O 0.9999841451644897
report O O 0.9999970197677612
. O O 0.9999803304672241

PURPOSE O O 0.9998588562011719
: O O 0.9999849796295166
This O O 0.999990701675415
paper O O 0.999994158744812
reviews O O 0.9999709129333496
the O O 0.9999879598617554
effect O O 0.9999450445175171
of O O 0.9999147653579712
chronic O O 0.9981459379196167
lithium B B 0.9997463822364807
therapy O O 0.9981288313865662
on O O 0.9998525381088257
serum O O 0.9943076968193054
calcium B B 0.9986369013786316
level O O 0.9706503748893738
and O O 0.9999281167984009
parathyroid O O 0.9971966743469238
glands O O 0.9999268054962158
, O O 0.99997878074646
its O O 0.9999470710754395
pathogenesis O O 0.9999927282333374
, O O 0.9999545812606812
and O O 0.9999567270278931
treatment O O 0.9999597072601318
options O O 0.9999938011169434
. O O 0.9999849796295166

We O O 0.9999401569366455
examined O O 0.9999918937683105
the O O 0.9999914169311523
case O O 0.9999861717224121
of O O 0.9999854564666748
a O O 0.999969482421875
lithium B B 0.9998277425765991
- O O 0.9988038539886475
treated O O 0.9996910095214844
patient O O 0.9999854564666748
who O O 0.9999682903289795
had O O 0.9999542236328125
recurrent O O 0.9999943971633911
hypercalcemia O O 0.9884560108184814
to O O 0.9999897480010986
better O O 0.9999910593032837
understand O O 0.9999899864196777
the O O 0.9999871253967285
disease O O 0.9999886751174927
process O O 0.9999974966049194
. O O 0.99997878074646

CONCLUSION O O 0.9992042183876038
: O O 0.9997950196266174
Primary O O 0.9996646642684937
hyperparathyroidism O O 0.928156316280365
is O O 0.9999371767044067
a O O 0.9999247789382935
rare O O 0.9999827146530151
but O O 0.9999697208404541
potentially O O 0.9999850988388062
life O O 0.9999499320983887
- O O 0.9999890327453613
threatening O O 0.9999946355819702
side O O 0.999977707862854
effect O O 0.9999866485595703
of O O 0.999859094619751
long O O 0.9992775321006775
- O O 0.9999740123748779
term O O 0.9997312426567078
lithium B B 0.9995726943016052
therapy O O 0.9983400106430054
. O O 0.9999760389328003

Careful O O 0.9992550015449524
patient O O 0.9999659061431885
selection O O 0.999984622001648
and O O 0.9999661445617676
long O O 0.9998276233673096
- O O 0.9999817609786987
term O O 0.9999808073043823
follow O O 0.9999880790710449
- O O 0.9999916553497314
up O O 0.9999880790710449
can O O 0.9999334812164307
reduce O O 0.9999605417251587
morbidity O O 0.999984622001648
. O O 0.9999822378158569

PRACTICAL O O 0.9993923902511597
IMPLICATIONS O O 0.9999921321868896
: O O 0.9999595880508423
As O O 0.9999591112136841
much O O 0.9999747276306152
as O O 0.9999860525131226
15 O O 0.9999858140945435
% O O 0.9999911785125732
of O O 0.9999639987945557
lithium B B 0.9998494386672974
- O O 0.9991078972816467
treated O O 0.9996378421783447
patients O O 0.9999849796295166
become O O 0.9999837875366211
hypercalcemic O O 0.9998937845230103
. O O 0.999948263168335

By O O 0.9999754428863525
routinely O O 0.9999439716339111
monitoring O O 0.9999570846557617
serum O O 0.9962401390075684
calcium B B 0.9975066781044006
levels O O 0.9993017911911011
, O O 0.9999747276306152
healthcare O O 0.9998599290847778
providers O O 0.9999779462814331
can O O 0.9999676942825317
improve O O 0.9999890327453613
the O O 0.9999972581863403
quality O O 0.9999984502792358
of O O 0.9999942779541016
life O O 0.999993085861206
of O O 0.9999939203262329
this O O 0.9999825954437256
patient O O 0.9999774694442749
group O O 0.9999889135360718
. O O 0.9999752044677734

Comparison O O 0.9999594688415527
of O O 0.9998154044151306
laryngeal O B 0.8740721940994263
mask O I 0.973874568939209
with O O 0.9973886609077454
endotracheal O O 0.9996080994606018
tube O O 0.9995744824409485
for O O 0.9999639987945557
anesthesia O O 0.9997000694274902
in O O 0.9999772310256958
endoscopic O O 0.9998462200164795
sinus O O 0.9998824596405029
surgery O O 0.9999810457229614
. O O 0.9999548196792603

BACKGROUND O O 0.9991216063499451
: O O 0.9999940395355225
The O O 0.9999980926513672
purpose O O 0.9999978542327881
of O O 0.9999970197677612
this O O 0.9999943971633911
study O O 0.9999926090240479
was O O 0.9999951124191284
to O O 0.9999960660934448
compare O O 0.9999796152114868
surgical O O 0.9999936819076538
conditions O O 0.9999951124191284
, O O 0.9999936819076538
including O O 0.999991774559021
the O O 0.9999940395355225
amount O O 0.9999891519546509
of O O 0.9999784231185913
intraoperative O O 0.9999879598617554
bleeding O O 0.9998043179512024
as O O 0.99998939037323
well O O 0.999985933303833
as O O 0.9999903440475464
intraoperative O O 0.9999808073043823
blood O O 0.9997623562812805
pressure O O 0.9994080066680908
, O O 0.9999918937683105
during O O 0.9999703168869019
functional O O 0.9998986721038818
endoscopic O O 0.9999630451202393
sinus O O 0.9999614953994751
surgery O O 0.9999865293502808
( O O 0.999886155128479
FESS O O 0.9456163644790649
) O O 0.9999704360961914
using O O 0.9998621940612793
flexible O O 0.9939423203468323
reinforced O O 0.9618750810623169
laryngeal O O 0.9416248202323914
mask O O 0.9601718783378601
airway O O 0.9908690452575684
( O O 0.9997109770774841
FRLMA O O 0.6574365496635437
) O O 0.9998375177383423
versus O O 0.9997895359992981
endotracheal O O 0.9971559047698975
tube O O 0.9999587535858154
( O O 0.999661922454834
ETT O O 0.8680720925331116
) O O 0.9999738931655884
in O O 0.9999334812164307
maintaining O O 0.9978513717651367
controlled O O 0.9999366998672485
hypotension O O 0.9999632835388184
anesthesia O O 0.9990209341049194
induced O O 0.9999890327453613
by O O 0.9999395608901978
propofol B B 0.9991886019706726
- O I 0.7019162178039551
remifentanil B I 0.7459225058555603
total O O 0.9876470565795898
i O O 0.9966892600059509
. O O 0.9999938011169434
v O O 0.9999972581863403
. O O 0.9999815225601196
anesthesia O O 0.9966821074485779
( O O 0.9995885491371155
TIVA O O 0.4749329090118408
) O O 0.9999556541442871
. O O 0.9999749660491943

METHODS O O 0.999874472618103
: O O 0.9999924898147583
Sixty O O 0.999945878982544
normotensive O O 0.999563992023468
American O O 0.999893307685852
Society O O 0.9998074173927307
of O O 0.9994840621948242
Anesthesiologists O O 0.9998515844345093
I O O 0.99688321352005
- O O 0.996098518371582
II O O 0.9955683350563049
adult O O 0.9999924898147583
patients O O 0.9999885559082031
undergoing O O 0.9999099969863892
FESS O O 0.7420225739479065
under O O 0.9971134662628174
controlled O O 0.9997593760490417
hypotension O O 0.9997894167900085
anesthesia O O 0.9998238682746887
caused O O 0.9999520778656006
by O O 0.9998658895492554
propofol B B 0.9991540908813477
- O O 0.5126382112503052
remifentanil B B 0.8946600556373596
- O O 0.7496530413627625
TIVA O B 0.7605590224266052
were O O 0.9998888969421387
randomly O O 0.9999916553497314
assigned O O 0.9999957084655762
into O O 0.9999614953994751
two O O 0.9999938011169434
groups O O 0.999988317489624
: O O 0.9999769926071167
group O O 0.9999788999557495
I O O 0.9999723434448242
, O O 0.999721109867096
FRLMA O O 0.577847421169281
; O O 0.9998347759246826
group O O 0.9999393224716187
II O O 0.9997437596321106
, O O 0.9995179176330566
ETT O O 0.8990896344184875
. O O 0.9999628067016602

Hemorrhage O O 0.9998490810394287
was O O 0.9999701976776123
measured O O 0.9999834299087524
and O O 0.9999872446060181
the O O 0.9999938011169434
visibility O O 0.9999302625656128
of O O 0.9999839067459106
the O O 0.9999908208847046
operative O O 0.999984860420227
field O O 0.999997615814209
was O O 0.9999852180480957
evaluated O O 0.9999974966049194
according O O 0.9999972581863403
to O O 0.9999951124191284
a O O 0.9999932050704956
six O O 0.9999852180480957
- O O 0.9999911785125732
point O O 0.9999963045120239
scale O O 0.9999938011169434
. O O 0.9999752044677734

RESULTS O O 0.9984682202339172
: O O 0.9997065663337708
Controlled O O 0.9998328685760498
hypotension O O 0.9999585151672363
was O O 0.9999613761901855
achieved O O 0.9999785423278809
within O O 0.999976396560669
a O O 0.9999867677688599
shorter O O 0.9999866485595703
period O O 0.9999858140945435
using O O 0.9998650550842285
laryngeal O O 0.9160174131393433
mask O O 0.9926609992980957
using O O 0.9998286962509155
lower O O 0.9998846054077148
rates O O 0.99996018409729
of O O 0.9993334412574768
remifentanil B B 0.9983919262886047
infusion O O 0.9987975358963013
and O O 0.999845027923584
lower O O 0.9998888969421387
total O O 0.999622106552124
dose O O 0.9996321201324463
of O O 0.9976785778999329
remifentanil B B 0.9994727969169617
. O O 0.9999390840530396

CONCLUSION O O 0.9987565279006958
: O O 0.9999747276306152
In O O 0.9999939203262329
summary O O 0.9999868869781494
, O O 0.999981164932251
our O O 0.9999644756317139
results O O 0.9999924898147583
indicate O O 0.9999514818191528
that O O 0.9998596906661987
airway O O 0.9972890615463257
management O O 0.9999494552612305
using O O 0.9997642636299133
FRLMA O O 0.49642038345336914
during O O 0.9997430443763733
controlled O O 0.999968409538269
hypotension O O 0.9998834133148193
anesthesia O O 0.9984081387519836
provided O O 0.9999574422836304
better O O 0.9999368190765381
surgical O O 0.9999942779541016
conditions O O 0.9999951124191284
in O O 0.999993085861206
terms O O 0.9999938011169434
of O O 0.9999932050704956
quality O O 0.9999969005584717
of O O 0.9999856948852539
operative O O 0.9999901056289673
field O O 0.9999980926513672
and O O 0.9999825954437256
blood O O 0.9999865293502808
loss O O 0.9999918937683105
and O O 0.999968409538269
allowed O O 0.9999803304672241
for O O 0.9999749660491943
convenient O O 0.7640185356140137
induced O O 0.9998619556427002
hypotension O O 0.9999703168869019
with O O 0.9999556541442871
low O O 0.9999001026153564
doses O O 0.999850869178772
of O O 0.9984694123268127
remifentanil B B 0.9996060729026794
during O O 0.9995131492614746
TIVA O O 0.6960529088973999
in O O 0.9999016523361206
patients O O 0.9999905824661255
undergoing O O 0.9999232292175293
FESS O O 0.9536383152008057
. O O 0.999935507774353

Nonalcoholic O O 0.9749676585197449
fatty O O 0.9995948672294617
liver O O 0.9948590993881226
disease O O 0.9999783039093018
during O O 0.9996480941772461
valproate B B 0.9989803433418274
therapy O O 0.9988667964935303
. O O 0.9999622106552124

Valproic B B 0.9964863061904907
acid I I 0.9998959302902222
( O O 0.9842156767845154
VPA B B 0.9985528588294983
) O O 0.9986703395843506
is O O 0.999769389629364
effective O O 0.9996182918548584
for O O 0.9999163150787354
the O O 0.9999556541442871
treatment O O 0.9999703168869019
of O O 0.9999740123748779
many O O 0.9998679161071777
types O O 0.9999890327453613
of O O 0.9999788999557495
epilepsy O O 0.9999626874923706
, O O 0.9999300241470337
but O O 0.9999659061431885
its O O 0.9996057152748108
use O O 0.9998338222503662
can O O 0.9999252557754517
be O O 0.9999805688858032
associated O O 0.9999915361404419
with O O 0.9999951124191284
an O O 0.9999961853027344
increase O O 0.999998927116394
in O O 0.9999984502792358
body O O 0.9999969005584717
weight O O 0.9999887943267822
. O O 0.999954104423523

We O O 0.999974250793457
report O O 0.9999943971633911
a O O 0.9999909400939941
case O O 0.9999943971633911
of O O 0.9999734163284302
nonalcoholic O O 0.9118024706840515
fatty O O 0.9902970194816589
liver O O 0.9924970865249634
disease O O 0.9999837875366211
( O O 0.9998443126678467
NAFLD O O 0.5576320886611938
) O O 0.9998342990875244
arising O O 0.9999841451644897
in O O 0.9999936819076538
a O O 0.9999926090240479
child O O 0.9999958276748657
who O O 0.9999674558639526
developed O O 0.999992847442627
obesity O O 0.9941760301589966
during O O 0.999863862991333
VPA B B 0.992037296295166
treatment O O 0.998224675655365
. O O 0.9999812841415405

Laboratory O O 0.9999384880065918
data O O 0.9999822378158569
revealed O O 0.9999634027481079
hyperinsulinemia O O 0.9816516637802124
with O O 0.999903678894043
insulin O O 0.6464473009109497
resistance O O 0.9983949065208435
. O O 0.9999514818191528

After O O 0.9999822378158569
the O O 0.999994158744812
withdrawal O O 0.9999420642852783
of O O 0.9995554089546204
VPA B B 0.9926487803459167
therapy O O 0.9942986965179443
, O O 0.9999768733978271
our O O 0.999980092048645
patient O O 0.9999902248382568
showed O O 0.9999678134918213
a O O 0.9999867677688599
significant O O 0.9999895095825195
weight O O 0.9999854564666748
loss O O 0.9999971389770508
, O O 0.999988317489624
a O O 0.9999924898147583
decrease O O 0.9999984502792358
of O O 0.9999898672103882
body O O 0.9999794960021973
mass O O 0.9856589436531067
index O O 0.9998363256454468
, O O 0.999923825263977
and O O 0.9999457597732544
normalization O O 0.99997878074646
of O O 0.9999641180038452
metabolic O O 0.9996376037597656
and O O 0.999863862991333
endocrine O O 0.9993141889572144
parameters O O 0.9999665021896362
; O O 0.9999562501907349
moreover O O 0.9999865293502808
, O O 0.9999703168869019
ultrasound O O 0.9999537467956543
measurements O O 0.9999841451644897
showed O O 0.9999690055847168
a O O 0.999984622001648
complete O O 0.9999762773513794
normalization O O 0.9999841451644897
. O O 0.9999850988388062

The O O 0.9999932050704956
present O O 0.9999935626983643
case O O 0.9999940395355225
suggests O O 0.9999511241912842
that O O 0.9998258948326111
obesity O O 0.9982346296310425
, O O 0.9999023675918579
hyperinsulinemia O O 0.998358428478241
, O O 0.9998824596405029
insulin O O 0.9864952564239502
resistance O O 0.9999799728393555
, O O 0.9998288154602051
and O O 0.9998672008514404
long O O 0.9997063279151917
- O O 0.9999864101409912
term O O 0.9999744892120361
treatment O O 0.9999867677688599
with O O 0.9995694756507874
VPA B B 0.993290901184082
may O O 0.9994863271713257
be O O 0.9999184608459473
all O O 0.9999277591705322
associated O O 0.9999783039093018
with O O 0.9999632835388184
the O O 0.9999853372573853
development O O 0.999991774559021
of O O 0.9999157190322876
NAFLD O B 0.9897099137306213
; O O 0.9998743534088135
this O O 0.9999523162841797
side O O 0.9999549388885498
effect O O 0.9999923706054688
is O O 0.9999539852142334
reversible O O 0.999896764755249
after O O 0.9996225833892822
VPA B B 0.998262345790863
withdrawal O O 0.9997594952583313
. O O 0.9999743700027466

Carbimazole B B 0.9987660646438599
induced O O 0.9992721676826477
ANCA O O 0.5251252055168152
positive O O 0.9987919926643372
vasculitis O O 0.9999241828918457
. O O 0.999768078327179

Anti B O 0.6389126777648926
- I O 0.980746328830719
thyroid I O 0.7959973216056824
drugs I O 0.9945948719978333
, O O 0.9998438358306885
like O O 0.9995218515396118
carbimazole B B 0.999370276927948
and O O 0.9842357635498047
propylthiouracil B B 0.9916050434112549
( O O 0.9750944375991821
PTU B B 0.9967325925827026
) O O 0.9985003471374512
are O O 0.9998970031738281
commonly O O 0.9999005794525146
prescribed O O 0.9997740387916565
for O O 0.9998667240142822
the O O 0.9999219179153442
treatment O O 0.999968409538269
of O O 0.9999734163284302
hyperthyroidism O O 0.9978006482124329
. O O 0.9998886585235596

One O O 0.9999648332595825
should O O 0.9999701976776123
be O O 0.9999891519546509
aware O O 0.9999773502349854
of O O 0.9999444484710693
the O O 0.9999040365219116
side O O 0.9998664855957031
effects O O 0.999968409538269
of O O 0.999815046787262
antithyroid B O 0.6191111207008362
medications I O 0.9476004242897034
. O O 0.9999377727508545

Antineutrophil O B 0.5574201345443726
cytoplasmic O I 0.5316781401634216
antibody O I 0.9477301836013794
( O O 0.929215669631958
ANCA O O 0.7672010660171509
) O O 0.7095019221305847
- O O 0.7045901417732239
- O O 0.7432647347450256
associated O O 0.9993506073951721
vasculitis O O 0.9999374151229858
is O O 0.9999562501907349
a O O 0.9999481439590454
potentially O O 0.9999892711639404
life O O 0.999946117401123
- O O 0.999988317489624
threatening O O 0.9999934434890747
adverse O O 0.9999245405197144
effect O O 0.999982476234436
of O O 0.9997270703315735
antithyroidmedications B O 0.49235478043556213
. O O 0.9999303817749023

We O O 0.9999732971191406
report O O 0.9999938011169434
a O O 0.9999896287918091
patient O O 0.9999929666519165
with O O 0.9999755620956421
Graves O O 0.999309778213501
' O O 0.9999865293502808
disease O O 0.9999951124191284
who O O 0.9999606609344482
developed O O 0.9999814033508301
ANCA O O 0.6130410432815552
positive O O 0.9583253264427185
carbimazole B B 0.9988002777099609
induced O O 0.9993993043899536
vasculitis O O 0.9999356269836426
. O O 0.9999779462814331

The O O 0.9999818801879883
episode O O 0.9999936819076538
was O O 0.9999781847000122
characterized O O 0.9999940395355225
by O O 0.999982476234436
a O O 0.9999805688858032
vasculitic O O 0.9998682737350464
skin O O 0.9999638795852661
rash O O 0.9999611377716064
associated O O 0.9999628067016602
with O O 0.9999246597290039
large O O 0.9947206974029541
joint O O 0.9999443292617798
arthritis O O 0.999946117401123
, O O 0.9998435974121094
pyrexia O O 0.9970851540565491
and O O 0.9998006224632263
parotiditis O O 0.9997395873069763
but O O 0.9999433755874634
no O O 0.9999597072601318
renal O O 0.9998537302017212
or O O 0.9999352693557739
pulmonary O O 0.9999066591262817
involvement O O 0.9999916553497314
. O O 0.9999773502349854

He O O 0.9999833106994629
was O O 0.9999904632568359
referred O O 0.9999977350234985
to O O 0.9999972581863403
us O O 0.9999978542327881
for O O 0.9999905824661255
neurological O O 0.9999977350234985
evaluation O O 0.9999994039535522
because O O 0.9999971389770508
he O O 0.99998939037323
had O O 0.9999948740005493
difficulty O O 0.999998927116394
in O O 0.9999957084655762
getting O O 0.9999991655349731
up O O 0.9999934434890747
from O O 0.9999701976776123
squatting O O 0.9927329421043396
position O O 0.9999245405197144
and O O 0.9999648332595825
was O O 0.999987006187439
suspected O O 0.9999940395355225
to O O 0.9999736547470093
have O O 0.999942421913147
myositis O O 0.9999836683273315
. O O 0.9999574422836304

Carbimazole B B 0.9990987777709961
and O O 0.9400612115859985
methimazole B B 0.9995880722999573
have O O 0.9998214840888977
a O O 0.9999755620956421
lower O O 0.9999878406524658
incidence O O 0.9999949932098389
of O O 0.9999722242355347
reported O O 0.9999340772628784
ANCA O O 0.8417841196060181
positive O O 0.9990487694740295
side O O 0.9999175071716309
effects O O 0.9999667406082153
than O O 0.9995102882385254
PUT O O 0.6025737524032593
. O O 0.9984855055809021

To O O 0.9999940395355225
the O O 0.9999964237213135
best O O 0.9999955892562866
of O O 0.9999897480010986
our O O 0.9999897480010986
knowledge O O 0.9999940395355225
this O O 0.9999877214431763
is O O 0.999991774559021
the O O 0.9999905824661255
first O O 0.9999934434890747
ANCA O O 0.6234250664710999
positive O O 0.9946959614753723
carbimazole B B 0.9989186525344849
induced O O 0.9990691542625427
vasculitis O O 0.999942421913147
case O O 0.9999805688858032
reported O O 0.9999856948852539
from O O 0.9999492168426514
India O O 0.9998531341552734
. O O 0.999947190284729

Aspirin B B 0.997229278087616
for O O 0.9992270469665527
the O O 0.9999368190765381
primary O O 0.9998244643211365
prevention O O 0.9999500513076782
of O O 0.9999513626098633
cardiovascular O O 0.9999872446060181
events O O 0.9999980926513672
: O O 0.999971866607666
an O O 0.9999951124191284
update O O 0.9999927282333374
of O O 0.9999793767929077
the O O 0.9999936819076538
evidence O O 0.9999966621398926
for O O 0.9999896287918091
the O O 0.9999867677688599
U O O 0.9993866682052612
. O O 0.9999749660491943
S O O 0.9999818801879883
. O O 0.9999850988388062

Preventive O O 0.9961130619049072
Services O O 0.9999010562896729
Task O O 0.9997581839561462
Force O O 0.9999138116836548
. O O 0.9999356269836426

BACKGROUND O O 0.9851614236831665
: O O 0.9998997449874878
Coronary O O 0.9954373240470886
heart O O 0.9999198913574219
disease O O 0.9999710321426392
and O O 0.999666690826416
cerebrovascular O O 0.9922372698783875
disease O O 0.9999704360961914
are O O 0.9999247789382935
leading O O 0.9999912977218628
causes O O 0.9999948740005493
of O O 0.9999926090240479
death O O 0.9999804496765137
in O O 0.9999841451644897
the O O 0.9999793767929077
United O O 0.999152421951294
States O O 0.9999830722808838
. O O 0.9999619722366333

In O O 0.9998825788497925
2002 O O 0.9985439777374268
, O O 0.9999727010726929
the O O 0.9999656677246094
U O O 0.9997840523719788
. O O 0.999985933303833
S O O 0.9999946355819702
. O O 0.9999860525131226

Preventive O O 0.9875489473342896
Services O O 0.999882698059082
Task O O 0.9998658895492554
Force O O 0.9998306035995483
( O O 0.9996039271354675
USPSTF O O 0.8463514447212219
) O O 0.9999608993530273
strongly O O 0.9999713897705078
recommended O O 0.9999934434890747
that O O 0.9999802112579346
clinicians O O 0.9999674558639526
discuss O O 0.999748170375824
aspirin B B 0.9992764592170715
with O O 0.9999053478240967
adults O O 0.9999914169311523
who O O 0.9999895095825195
are O O 0.9999942779541016
at O O 0.9999903440475464
increased O O 0.9999920129776001
risk O O 0.9999978542327881
for O O 0.999988317489624
coronary O O 0.9998965263366699
heart O O 0.999992847442627
disease O O 0.9999959468841553
. O O 0.9999850988388062

PURPOSE O O 0.9998339414596558
: O O 0.9999903440475464
To O O 0.9999926090240479
determine O O 0.9999884366989136
the O O 0.9999839067459106
benefits O O 0.9999903440475464
and O O 0.9999897480010986
harms O O 0.9999902248382568
of O O 0.9999548196792603
taking O O 0.9961705803871155
aspirin B B 0.999339759349823
for O O 0.9995731711387634
the O O 0.999964714050293
primary O O 0.9998718500137329
prevention O O 0.9999759197235107
of O O 0.9999306201934814
myocardial O O 0.9999949932098389
infarctions O O 0.9999837875366211
, O O 0.9999710321426392
strokes O O 0.9999959468841553
, O O 0.9999586343765259
and O O 0.9999449253082275
death O O 0.9999946355819702
. O O 0.9999840259552002

DATA O O 0.9941909909248352
SOURCES O O 0.9999135732650757
: O O 0.9998291730880737
MEDLINE O O 0.968818724155426
and O O 0.9995929598808289
Cochrane O O 0.6062923073768616
Library O O 0.9998461008071899
( O O 0.9998880624771118
search O O 0.9998332262039185
dates O O 0.9999814033508301
, O O 0.9998055100440979
1 O O 0.999176561832428
January O O 0.9982452392578125
2001 O O 0.9967861175537109
to O O 0.9999427795410156
28 O O 0.9999532699584961
August O O 0.9936104416847229
2008 O O 0.9891294240951538
) O O 0.9999583959579468
, O O 0.9999605417251587
recent O O 0.9999817609786987
systematic O O 0.9998663663864136
reviews O O 0.9999867677688599
, O O 0.9999775886535645
reference O O 0.9999828338623047
lists O O 0.9999842643737793
of O O 0.999967098236084
retrieved O O 0.9999234676361084
articles O O 0.9999855756759644
, O O 0.9998905658721924
and O O 0.999964714050293
suggestions O O 0.9999899864196777
from O O 0.9999828338623047
experts O O 0.9999717473983765
. O O 0.999957799911499

STUDY O O 0.9998635053634644
SELECTION O O 0.9999406337738037
: O O 0.9998997449874878
English O O 0.9698970913887024
- O O 0.9999034404754639
language O O 0.9995421171188354
randomized O O 0.9999827146530151
, O O 0.9999575614929199
controlled O O 0.9999356269836426
trials O O 0.9999935626983643
( O O 0.9999094009399414
RCTs O O 0.9926113486289978
) O O 0.9999651908874512
; O O 0.9999390840530396
case O O 0.9999130964279175
- O O 0.9999405145645142
control O O 0.9999712705612183
studies O O 0.9999853372573853
; O O 0.9999673366546631
meta O O 0.9998550415039062
- O O 0.9999747276306152
analyses O O 0.9999620914459229
; O O 0.9999278783798218
and O O 0.9999586343765259
systematic O O 0.999930739402771
reviews O O 0.9999722242355347
of O O 0.9996647834777832
aspirin B B 0.9990021586418152
versus O O 0.9893420934677124
control O O 0.5416395664215088
for O O 0.9970779418945312
the O O 0.9999594688415527
primary O O 0.9997768998146057
prevention O O 0.9995326995849609
of O O 0.9999287128448486
cardiovascular O O 0.9999715089797974
disease O O 0.9999961853027344
( O O 0.999893307685852
CVD O O 0.9747319221496582
) O O 0.9999663829803467
were O O 0.9999836683273315
selected O O 0.9999909400939941
to O O 0.9999942779541016
answer O O 0.999995231628418
the O O 0.9999970197677612
following O O 0.9999955892562866
questions O O 0.9999991655349731
: O O 0.999996542930603
Does O O 0.9990304708480835
aspirin B B 0.9992902278900146
decrease O O 0.9978463649749756
coronary O O 0.9999525547027588
heart O O 0.9999921321868896
events O O 0.9999963045120239
, O O 0.9999821186065674
strokes O O 0.9999961853027344
, O O 0.9999905824661255
death O O 0.9999974966049194
from O O 0.999972939491272
coronary O O 0.9986351132392883
heart O O 0.999737560749054
events O O 0.9999872446060181
or O O 0.9999401569366455
stroke O O 0.9999948740005493
, O O 0.9999581575393677
or O O 0.9999682903289795
all O O 0.9981381893157959
- O O 0.9999613761901855
cause O O 0.9999910593032837
mortality O O 0.9999951124191284
in O O 0.9999712705612183
adults O O 0.9999958276748657
without O O 0.9999879598617554
known O O 0.9999756813049316
CVD O O 0.9887036681175232
? O O 0.9999586343765259

Does O O 0.999170184135437
aspirin B B 0.999433696269989
increase O O 0.9970530271530151
gastrointestinal O O 0.9998199343681335
bleeding O O 0.9999847412109375
or O O 0.9999428987503052
hemorrhagic O O 0.9999518394470215
strokes O O 0.999996542930603
? O O 0.9998927116394043

DATA O O 0.9982287287712097
EXTRACTION O O 0.9999886751174927
: O O 0.9999563694000244
All O O 0.9999493360519409
studies O O 0.999984622001648
were O O 0.9999829530715942
reviewed O O 0.9999967813491821
, O O 0.9999805688858032
abstracted O O 0.999991774559021
, O O 0.9999500513076782
and O O 0.9999657869338989
rated O O 0.9999951124191284
for O O 0.999988317489624
quality O O 0.9999982118606567
by O O 0.9999945163726807
using O O 0.9999759197235107
predefined O O 0.9999687671661377
USPSTF O O 0.9727311730384827
criteria O O 0.9999805688858032
. O O 0.9999818801879883

DATA O O 0.9997778534889221
SYNTHESIS O O 0.9997723698616028
: O O 0.9999247789382935
New O O 0.9999891519546509
evidence O O 0.9999958276748657
from O O 0.9999583959579468
1 O O 0.9997394680976868
good O O 0.999349057674408
- O O 0.999971866607666
quality O O 0.9997172951698303
RCT O O 0.9974426031112671
, O O 0.9999510049819946
1 O O 0.9998268485069275
good O O 0.9982302784919739
- O O 0.9999713897705078
quality O O 0.9999221563339233
meta O O 0.9995656609535217
- O O 0.9999257326126099
analysis O O 0.9989432692527771
, O O 0.9998408555984497
and O O 0.9998904466629028
2 O O 0.9998397827148438
fair O O 0.9998890161514282
- O O 0.9999690055847168
quality O O 0.9999507665634155
subanalyses O O 0.9992571473121643
of O O 0.9998589754104614
RCTs O O 0.9915550351142883
demonstrates O O 0.9999579191207886
that O O 0.9997629523277283
aspirin B B 0.9992974996566772
use O O 0.9994596838951111
reduces O O 0.9999550580978394
the O O 0.999995231628418
number O O 0.9999960660934448
of O O 0.9999886751174927
CVD O O 0.996572732925415
events O O 0.9999926090240479
in O O 0.9999632835388184
patients O O 0.9999938011169434
without O O 0.9999885559082031
known O O 0.9999784231185913
CVD O O 0.9973669648170471
. O O 0.9999585151672363

Men O O 0.9974772334098816
in O O 0.999946117401123
these O O 0.9999231100082397
studies O O 0.999961256980896
experienced O O 0.9999740123748779
fewer O O 0.9999645948410034
myocardial O O 0.9999958276748657
infarctions O O 0.9999740123748779
and O O 0.9999110698699951
women O O 0.9960577487945557
experienced O O 0.9999822378158569
fewer O O 0.9999312162399292
ischemic O O 0.9999867677688599
strokes O O 0.9999938011169434
. O O 0.9999716281890869

Aspirin B B 0.9919512271881104
does O O 0.9997524619102478
not O O 0.9999450445175171
seem O O 0.9999635219573975
to O O 0.9999393224716187
affect O O 0.9998809099197388
CVD O O 0.9804384708404541
mortality O O 0.9999779462814331
or O O 0.999984622001648
all O O 0.9997219443321228
- O O 0.9999651908874512
cause O O 0.9999879598617554
mortality O O 0.9999933242797852
in O O 0.9999542236328125
either O O 0.9999657869338989
men O O 0.9999879598617554
or O O 0.9999755620956421
women O O 0.9999899864196777
. O O 0.9999107122421265

The O O 0.9999468326568604
use O O 0.9998959302902222
of O O 0.9995007514953613
aspirin B B 0.9990672469139099
for O O 0.9989070892333984
primary O O 0.9994930028915405
prevention O O 0.9989332556724548
increases O O 0.9999120235443115
the O O 0.999985933303833
risk O O 0.9999977350234985
for O O 0.9999903440475464
major O O 0.9999921321868896
bleeding O O 0.9999597072601318
events O O 0.9999973773956299
, O O 0.9999856948852539
primarily O O 0.9999051094055176
gastrointestinal O O 0.9999270439147949
bleeding O O 0.9999606609344482
events O O 0.9999959468841553
, O O 0.9999842643737793
in O O 0.9999628067016602
both O O 0.9999563694000244
men O O 0.9999909400939941
and O O 0.9999592304229736
women O O 0.9999878406524658
. O O 0.9999679327011108

Men O O 0.9956710338592529
have O O 0.9999727010726929
an O O 0.999954342842102
increased O O 0.9999659061431885
risk O O 0.9999929666519165
for O O 0.999971866607666
hemorrhagic O O 0.999944806098938
strokes O O 0.9999957084655762
with O O 0.9998133778572083
aspirin B B 0.9992067217826843
use O O 0.9995003938674927
. O O 0.9999444484710693

A O O 0.9999544620513916
new O O 0.9999655485153198
RCT O O 0.9936802387237549
and O O 0.9999352693557739
meta O O 0.9980857372283936
- O O 0.9999463558197021
analysis O O 0.9990144968032837
suggest O O 0.9999712705612183
that O O 0.9999651908874512
the O O 0.9999889135360718
risk O O 0.9999957084655762
for O O 0.9999631643295288
hemorrhagic O O 0.9998985528945923
strokes O O 0.9999889135360718
in O O 0.9999414682388306
women O O 0.9995100498199463
is O O 0.999981164932251
not O O 0.9999964237213135
statistically O O 0.9999884366989136
significantly O O 0.9999929666519165
increased O O 0.9999775886535645
. O O 0.9999672174453735

LIMITATIONS O O 0.9997362494468689
: O O 0.9999802112579346
New O O 0.9999297857284546
evidence O O 0.9999879598617554
on O O 0.9991884827613831
aspirin B B 0.9991669654846191
for O O 0.9997010827064514
the O O 0.99994957447052
primary O O 0.9998350143432617
prevention O O 0.9996989965438843
of O O 0.999966025352478
CVD O O 0.9846625328063965
is O O 0.999944806098938
limited O O 0.9999837875366211
. O O 0.9999814033508301

The O O 0.9999874830245972
dose O O 0.9997267127037048
of O O 0.9979469180107117
aspirin B B 0.9993089437484741
used O O 0.9997685551643372
in O O 0.9997937083244324
the O O 0.9999222755432129
RCTs O O 0.9952392578125
varied O O 0.9999276399612427
, O O 0.9999740123748779
which O O 0.9999794960021973
prevented O O 0.9999922513961792
the O O 0.9999980926513672
estimation O O 0.9999985694885254
of O O 0.999993085861206
the O O 0.9999945163726807
most O O 0.9999922513961792
appropriate O O 0.9999903440475464
dose O O 0.9998987913131714
for O O 0.9999710321426392
primary O O 0.9998955726623535
prevention O O 0.9999884366989136
. O O 0.9999483823776245

Several O O 0.9999570846557617
of O O 0.9999879598617554
the O O 0.9999758005142212
RCTs O O 0.994478702545166
were O O 0.9999703168869019
conducted O O 0.9999865293502808
within O O 0.9998376369476318
populations O O 0.9998083710670471
of O O 0.999951958656311
health O O 0.9962618947029114
professionals O O 0.9999904632568359
, O O 0.9999790191650391
which O O 0.9999717473983765
potentially O O 0.9999923706054688
limits O O 0.9999943971633911
generalizability O O 0.9999947547912598
. O O 0.9999786615371704

CONCLUSION O O 0.9607107043266296
: O O 0.9977912902832031
Aspirin B B 0.9992392063140869
reduces O O 0.9996427297592163
the O O 0.9999611377716064
risk O O 0.9999960660934448
for O O 0.9999818801879883
myocardial O O 0.9999985694885254
infarction O O 0.9999876022338867
in O O 0.9999207258224487
men O O 0.9999747276306152
and O O 0.999886155128479
strokes O O 0.9999653100967407
in O O 0.9998981952667236
women O O 0.9999088048934937
. O O 0.999705970287323

Aspirin B B 0.9741108417510986
use O O 0.9992497563362122
increases O O 0.9998220801353455
the O O 0.9999703168869019
risk O O 0.999996542930603
for O O 0.9999920129776001
serious O O 0.9999912977218628
bleeding O O 0.9999724626541138
events O O 0.9999980926513672
. O O 0.9999384880065918

Reducing O O 0.9992583394050598
harm O O 0.9999699592590332
associated O O 0.9999903440475464
with O O 0.9999014139175415
anticoagulation O O 0.8327047824859619
: O O 0.9995375871658325
practical O O 0.999714195728302
considerations O O 0.9999805688858032
of O O 0.9997228980064392
argatroban B B 0.9967871904373169
therapy O O 0.9996011853218079
in O O 0.9999043941497803
heparin B B 0.987933874130249
- O O 0.9994065761566162
induced O O 0.9999402761459351
thrombocytopenia O O 0.999929666519165
. O O 0.9999690055847168

Argatroban B B 0.9987002611160278
is O O 0.9994614720344543
a O O 0.9974151849746704
hepatically O O 0.936948299407959
metabolized O O 0.9994819760322571
, O O 0.7196292281150818
direct O O 0.693077564239502
thrombin O O 0.5252567529678345
inhibitor O O 0.5238932967185974
used O O 0.9996960163116455
for O O 0.9999468326568604
prophylaxis O O 0.9999244213104248
or O O 0.9999654293060303
treatment O O 0.999977707862854
of O O 0.99996018409729
thrombosis O O 0.9996966123580933
in O O 0.9998878240585327
heparin B B 0.9841225147247314
- O O 0.9980992674827576
induced O O 0.9999582767486572
thrombocytopenia O O 0.999929666519165
( O O 0.9999271631240845
HIT O O 0.9995423555374146
) O O 0.9999749660491943
and O O 0.9999475479125977
for O O 0.9999450445175171
patients O O 0.9999951124191284
with O O 0.9999897480010986
or O O 0.9999839067459106
at O O 0.9999914169311523
risk O O 0.9999991655349731
of O O 0.9999946355819702
HIT O O 0.9997887015342712
undergoing O O 0.9999890327453613
percutaneous O O 0.9999758005142212
coronary O O 0.999568521976471
intervention O O 0.999997615814209
( O O 0.999890923500061
PCI O O 0.9598085880279541
) O O 0.9999778270721436
. O O 0.9998984336853027

The O O 0.9999927282333374
objective O O 0.9999985694885254
of O O 0.9999934434890747
this O O 0.9999890327453613
review O O 0.9999903440475464
is O O 0.9999951124191284
to O O 0.9999960660934448
summarize O O 0.9999798536300659
practical O O 0.9999573230743408
considerations O O 0.9999958276748657
of O O 0.9999279975891113
argatroban B B 0.9984872341156006
therapy O O 0.9995989203453064
in O O 0.9999066591262817
HIT O O 0.9871511459350586
. O O 0.9999597072601318

The O O 0.9995995163917542
US O O 0.9903082251548767
FDA O O 0.8190923929214478
- O O 0.9997501969337463
recommended O O 0.9999203681945801
argatroban B B 0.9992539286613464
dose O O 0.9998776912689209
in O O 0.9999208450317383
HIT O O 0.9749294519424438
is O O 0.9999672174453735
2 O O 0.9999209642410278
microg O O 0.9998157620429993
/ O O 0.9999741315841675
kg O O 0.9999934434890747
/ O O 0.9999825954437256
min O O 0.9999340772628784
( O O 0.9999692440032959
reduced O O 0.9999874830245972
in O O 0.9999687671661377
patients O O 0.9999946355819702
with O O 0.9999866485595703
hepatic O O 0.9999163150787354
impairment O O 0.9999943971633911
and O O 0.9999704360961914
in O O 0.9999780654907227
paediatric O O 0.9999535083770752
patients O O 0.9999935626983643
) O O 0.9999710321426392
, O O 0.9999557733535767
adjusted O O 0.9999765157699585
to O O 0.9999864101409912
achieve O O 0.9998760223388672
activated O O 0.9993274211883545
partial O O 0.9985008239746094
thromboplastin O O 0.9971080422401428
times O O 0.9995877146720886
( O O 0.9999251365661621
aPTTs O O 0.9910410046577454
) O O 0.9999727010726929
1 O O 0.9999545812606812
. O O 0.9999942779541016
5 O O 0.9999837875366211
- O O 0.9996225833892822
3 O O 0.9999650716781616
times O O 0.999980092048645
baseline O O 0.9999828338623047
( O O 0.9999822378158569
not O O 0.999997615814209
> O O 0.9999891519546509
100 O O 0.9999911785125732
seconds O O 0.9999969005584717
) O O 0.9999779462814331
. O O 0.9999808073043823

Contemporary O O 0.9998735189437866
experiences O O 0.9999926090240479
indicate O O 0.9999616146087646
that O O 0.9999614953994751
reduced O O 0.9998383522033691
doses O O 0.999806821346283
are O O 0.9999512434005737
also O O 0.9999774694442749
needed O O 0.9999667406082153
in O O 0.9999533891677856
patients O O 0.9999923706054688
with O O 0.999980092048645
conditions O O 0.9999916553497314
associated O O 0.9999837875366211
with O O 0.9999421834945679
hepatic O O 0.9998437166213989
hypoperfusion O O 0.999751627445221
, O O 0.9999752044677734
e O O 0.9999258518218994
. O O 0.999988317489624
g O O 0.9999792575836182
. O O 0.9999499320983887
heart O O 0.9999914169311523
failure O O 0.9999865293502808
, O O 0.9999831914901733
yet O O 0.998279333114624
are O O 0.9998961687088013
unnecessary O O 0.9997538924217224
for O O 0.9999244213104248
renal O O 0.9999698400497437
dysfunction O O 0.9999936819076538
, O O 0.9999889135360718
adult O O 0.9999951124191284
age O O 0.9999922513961792
, O O 0.9999898672103882
sex O O 0.9999374151229858
, O O 0.9999783039093018
race O O 0.9987208247184753
/ O O 0.9998838901519775
ethnicity O O 0.9080519080162048
or O O 0.9999549388885498
obesity O O 0.9953408241271973
. O O 0.9999704360961914

Argatroban B B 0.9926683902740479
0 O O 0.9984614849090576
. O O 0.9999778270721436
5 O O 0.999910831451416
- O O 0.9974429607391357
1 O O 0.9999538660049438
. O O 0.9999942779541016
2 O O 0.9998573064804077
microg O O 0.9995083808898926
/ O O 0.9998980760574341
kg O O 0.9999924898147583
/ O O 0.9999297857284546
min O O 0.9998800754547119
typically O O 0.9999479055404663
supports O O 0.9999402761459351
therapeutic O O 0.9999685287475586
aPTTs O O 0.9986829161643982
. O O 0.9999666213989258

The O O 0.999951958656311
FDA O B 0.8798815011978149
- O O 0.9990398287773132
recommended O O 0.9999797344207764
dose O O 0.9999470710754395
during O O 0.9998582601547241
PCI O O 0.9611122608184814
is O O 0.9999585151672363
25 O O 0.99997878074646
microg O O 0.9992414712905884
/ O O 0.9999830722808838
kg O O 0.9999932050704956
/ O O 0.9999747276306152
min O O 0.9999812841415405
( O O 0.9999184608459473
350 O O 0.999881386756897
microg O O 0.9994503855705261
/ O O 0.9999687671661377
kg O O 0.9999779462814331
initial O O 0.9983495473861694
bolus O O 0.9999511241912842
) O O 0.999937891960144
, O O 0.9999616146087646
adjusted O O 0.9999828338623047
to O O 0.9999889135360718
achieve O O 0.9999172687530518
activated O O 0.9849287867546082
clotting O O 0.9962975382804871
times O O 0.9998534917831421
( O O 0.9999479055404663
ACTs O O 0.9995554089546204
) O O 0.9999810457229614
of O O 0.9999687671661377
300 O O 0.999984622001648
- O O 0.9998643398284912
450 O O 0.9999902248382568
sec O O 0.9999921321868896
. O O 0.9999667406082153

For O O 0.994551956653595
PCI O O 0.6318877339363098
, O O 0.9998039603233337
argatroban B B 0.9991188645362854
has O O 0.9998961687088013
not O O 0.9999914169311523
been O O 0.999991774559021
investigated O O 0.9999628067016602
in O O 0.9999364614486694
hepatically O O 0.9993510842323303
impaired O O 0.9999802112579346
patients O O 0.99998939037323
; O O 0.9999719858169556
dose O O 0.9998829364776611
adjustment O O 0.9999872446060181
is O O 0.9999841451644897
unnecessary O O 0.9999814033508301
for O O 0.9999678134918213
adult O O 0.9999960660934448
age O O 0.9999964237213135
, O O 0.9999915361404419
sex O O 0.9999979734420776
, O O 0.9999915361404419
race O O 0.9999455213546753
/ O O 0.9999805688858032
ethnicity O O 0.9838135242462158
or O O 0.9999771118164062
obesity O O 0.9966040849685669
, O O 0.9999817609786987
and O O 0.9999756813049316
lesser O O 0.9998743534088135
doses O O 0.9999376535415649
may O O 0.999976396560669
be O O 0.9999876022338867
adequate O O 0.9999531507492065
with O O 0.999936580657959
concurrent O O 0.989048421382904
glycoprotein O O 0.6157721281051636
IIb O O 0.8249000906944275
/ O O 0.9952437281608582
IIIa O O 0.9667637348175049
inhibition O O 0.9992818236351013
. O O 0.9999603033065796

Argatroban B B 0.9974109530448914
prolongs O O 0.9998124241828918
the O O 0.9999747276306152
International O O 0.9988586902618408
Normalized O O 0.9998471736907959
Ratio O O 0.9999494552612305
, O O 0.9999676942825317
and O O 0.9999361038208008
published O O 0.9998773336410522
approaches O O 0.9999942779541016
for O O 0.9999878406524658
monitoring O O 0.9999861717224121
the O O 0.9999812841415405
argatroban B B 0.9989383816719055
- O O 0.9978852868080139
to O O 0.9998874664306641
- O O 0.9994707703590393
warfarin B B 0.9936518669128418
transition O O 0.9998229146003723
should O O 0.9999477863311768
be O O 0.999992847442627
followed O O 0.9999817609786987
. O O 0.9999829530715942

Major O O 0.9999558925628662
bleeding O O 0.9999784231185913
with O O 0.9998236298561096
argatroban B B 0.9971093535423279
is O O 0.9996046423912048
0 O O 0.9999485015869141
- O O 0.9998602867126465
10 O O 0.999995231628418
% O O 0.9999936819076538
in O O 0.9999737739562988
the O O 0.9999889135360718
non O O 0.999750554561615
- O O 0.9998772144317627
interventional O O 0.999995231628418
setting O O 0.9999909400939941
and O O 0.9999511241912842
0 O O 0.9997723698616028
- O O 0.9996531009674072
5 O O 0.9999738931655884
. O O 0.9999929666519165
8 O O 0.9999856948852539
% O O 0.9999904632568359
periprocedurally O O 0.9998955726623535
. O O 0.9999793767929077

Argatroban B B 0.9980146884918213
has O O 0.9996304512023926
no O O 0.9998602867126465
specific O O 0.9998179078102112
antidote O O 0.9556872844696045
, O O 0.9998840093612671
and O O 0.9999359846115112
if O O 0.9999947547912598
excessive O O 0.9999480247497559
anticoagulation O O 0.9446094632148743
occurs O O 0.9999877214431763
, O O 0.9999117851257324
argatroban B B 0.9970593452453613
infusion O O 0.999413251876831
should O O 0.9999641180038452
be O O 0.9999861717224121
stopped O O 0.9997921586036682
or O O 0.9999825954437256
reduced O O 0.9999936819076538
. O O 0.9999384880065918

Improved O O 0.9998935461044312
familiarity O O 0.9999825954437256
of O O 0.9999635219573975
healthcare O O 0.9985992312431335
professionals O O 0.9999936819076538
with O O 0.9998962879180908
argatroban B B 0.9851797819137573
therapy O O 0.998675525188446
in O O 0.9996034502983093
HIT O O 0.9522326588630676
, O O 0.9999817609786987
including O O 0.9999735355377197
in O O 0.9994377493858337
special O O 0.5655261278152466
populations O O 0.999312162399292
and O O 0.9999172687530518
during O O 0.9996104836463928
PCI O O 0.8818217515945435
, O O 0.9999774694442749
may O O 0.9999443292617798
facilitate O O 0.999957799911499
reduction O O 0.9999706745147705
of O O 0.9999452829360962
harm O O 0.9999721050262451
associated O O 0.9999672174453735
with O O 0.9998698234558105
HIT O O 0.9980504512786865
( O O 0.9999713897705078
e O O 0.999871015548706
. O O 0.999987006187439
g O O 0.9999843835830688
. O O 0.9999855756759644
fewer O O 0.9999115467071533
thromboses O O 0.9999281167984009
) O O 0.9999681711196899
or O O 0.9999589920043945
its O O 0.9999179840087891
treatment O O 0.9999605417251587
( O O 0.999976634979248
e O O 0.9999502897262573
. O O 0.9999911785125732
g O O 0.9999910593032837
. O O 0.9999916553497314
fewer O O 0.9999648332595825
argatroban B B 0.9557223320007324
medication O O 0.9987962245941162
errors O O 0.9999696016311646
) O O 0.9999843835830688
. O O 0.9999827146530151

Rhabdomyolysis O O 0.999788224697113
and O O 0.999886155128479
brain O O 0.9999476671218872
ischemic O O 0.9999914169311523
stroke O O 0.9999955892562866
in O O 0.9999706745147705
a O O 0.9999808073043823
heroin B B 0.9832277297973633
- O O 0.9982185959815979
dependent O O 0.9992449283599854
male O O 0.9999878406524658
under O O 0.999384880065918
methadone B B 0.9995797276496887
maintenance O O 0.972334623336792
therapy O O 0.9998667240142822
. O O 0.9999736547470093

OBJECTIVE O O 0.9775861501693726
: O O 0.9999673366546631
There O O 0.9996547698974609
are O O 0.9998798370361328
several O O 0.9998952150344849
complications O O 0.9999734163284302
associated O O 0.999974250793457
with O O 0.999875545501709
heroin O B 0.9885430335998535
abuse O O 0.9979374408721924
, O O 0.9999632835388184
some O O 0.9999265670776367
of O O 0.9997318387031555
which O O 0.9999524354934692
are O O 0.9999076128005981
life O O 0.9999105930328369
- O O 0.9999829530715942
threatening O O 0.9999896287918091
. O O 0.9999614953994751

Methadone B B 0.9990365505218506
may O O 0.9996858835220337
aggravate O O 0.9998781681060791
this O O 0.999969482421875
problem O O 0.999990701675415
. O O 0.9998192191123962

METHOD O O 0.9999662637710571
: O O 0.9999825954437256
A O O 0.9999277591705322
clinical O O 0.9999897480010986
case O O 0.9999932050704956
description O O 0.9999958276748657
. O O 0.9999750852584839

RESULTS O O 0.9998804330825806
: O O 0.9999868869781494
A O O 0.9999947547912598
33 O O 0.9999946355819702
- O O 0.9999879598617554
year O O 0.9999970197677612
- O O 0.9999924898147583
old O O 0.999994158744812
man O O 0.9999918937683105
presented O O 0.9999539852142334
with O O 0.9999703168869019
rhabdomyolysis O O 0.9998605251312256
and O O 0.9999518394470215
cerebral O O 0.9999891519546509
ischemic O O 0.9999978542327881
stroke O O 0.9999972581863403
after O O 0.9997099041938782
intravenous O O 0.9995375871658325
heroin B O 0.7273939251899719
. O O 0.9998672008514404

He O O 0.9997406601905823
had O O 0.9999713897705078
used O O 0.9990259408950806
heroin B B 0.9926411509513855
since O O 0.9994832277297974
age O O 0.9999947547912598
20 O O 0.999971866607666
, O O 0.9999605417251587
and O O 0.9999516010284424
had O O 0.999988317489624
used O O 0.9996722936630249
150 O O 0.9979283809661865
mg O O 0.9974353909492493
methadone B B 0.9995836615562439
daily O O 0.9987146854400635
for O O 0.9999417066574097
6 O O 0.9998617172241211
months O O 0.9999939203262329
. O O 0.9999657869338989

He O O 0.9999691247940063
was O O 0.9999934434890747
found O O 0.9999978542327881
unconsciousness O O 0.9999939203262329
at O O 0.9999768733978271
home O O 0.9999966621398926
and O O 0.9999867677688599
was O O 0.9999881982803345
sent O O 0.9999984502792358
to O O 0.9999982118606567
our O O 0.999991774559021
hospital O O 0.9999977350234985
. O O 0.999977707862854

In O O 0.9997453093528748
the O O 0.9999414682388306
ER O O 0.9994113445281982
, O O 0.999957799911499
his O O 0.9998911619186401
opiate O B 0.9851282238960266
level O O 0.999519944190979
was O O 0.99997878074646
4497 O O 0.9996874332427979
ng O O 0.9989161491394043
/ O O 0.9999599456787109
ml O O 0.9999958276748657
. O O 0.9999728202819824

In O O 0.9998944997787476
the O O 0.999962568283081
ICU O O 0.9901504516601562
, O O 0.9999724626541138
we O O 0.9998513460159302
found O O 0.9999791383743286
rhabdomyolysis O O 0.9997367262840271
, O O 0.9999289512634277
acute O O 0.9998877048492432
renal O O 0.9999778270721436
failure O O 0.9999793767929077
and O O 0.9999091625213623
acute O O 0.999956488609314
respiratory O O 0.9999784231185913
failure O O 0.9999924898147583
. O O 0.9999678134918213

After O O 0.9999768733978271
transfer O O 0.9999940395355225
to O O 0.9999629259109497
an O O 0.9999732971191406
internal O O 0.9987686276435852
ward O O 0.9998595714569092
, O O 0.9999711513519287
we O O 0.9999418258666992
noted O O 0.9999891519546509
aphasia O O 0.9999595880508423
and O O 0.999966025352478
weakness O O 0.9999957084655762
of O O 0.9999858140945435
his O O 0.9999866485595703
left O O 0.9999895095825195
limbs O O 0.9999970197677612
. O O 0.9999748468399048

After O O 0.9997074007987976
MRI O O 0.7716955542564392
, O O 0.9999496936798096
we O O 0.9994932413101196
found O O 0.999987006187439
cerebral O O 0.9999593496322632
ischemic O O 0.9999691247940063
infarction O O 0.9999908208847046
. O O 0.9999682903289795

CONCLUSION O O 0.9817890524864197
: O O 0.9999574422836304
Those O O 0.9998015761375427
using O O 0.9981434345245361
methadone B B 0.9995204210281372
and O O 0.9656528830528259
heroin B B 0.9942070245742798
simultaneously O O 0.982714831829071
may O O 0.9999407529830933
increase O O 0.9999239444732666
risk O O 0.9999966621398926
of O O 0.9999812841415405
rhabdomyolysis O O 0.9999208450317383
and O O 0.999936580657959
ischemic O O 0.9999934434890747
stroke O O 0.9999957084655762
. O O 0.9999715089797974

Patients O O 0.9999628067016602
under O O 0.9994977712631226
methadone B B 0.9995892643928528
maintenance O O 0.9878925681114197
therapy O O 0.999900221824646
should O O 0.9999299049377441
be O O 0.9999861717224121
warned O O 0.9999773502349854
regarding O O 0.9999649524688721
these O O 0.9999423027038574
serious O O 0.9999833106994629
adverse O O 0.9999617338180542
events O O 0.9999983310699463
. O O 0.9999810457229614

Hypotheses O O 0.999575674533844
of O O 0.999875545501709
heroin B B 0.9885270595550537
- O O 0.999530553817749
related O O 0.9999098777770996
rhabdomyolysis O O 0.9999567270278931
and O O 0.999887228012085
stroke O O 0.999988317489624
in O O 0.9999061822891235
heroin B B 0.9395588636398315
abusers O O 0.8549599647521973
are O O 0.9999485015869141
discussed O O 0.9999735355377197
. O O 0.9999816417694092

Increased O O 0.9999040365219116
vulnerability O O 0.9999749660491943
to O O 0.9997791647911072
6 B B 0.8007861971855164
- I I 0.969063401222229
hydroxydopamine I I 0.9995396137237549
lesion O O 0.997701108455658
and O O 0.9999699592590332
reduced O O 0.9999926090240479
development O O 0.9999943971633911
of O O 0.9999719858169556
dyskinesias O O 0.9999958276748657
in O O 0.9999734163284302
mice O O 0.9999920129776001
lacking O O 0.9998725652694702
CB1 O O 0.74256432056427
cannabinoid O O 0.534176230430603
receptors O O 0.9997856020927429
. O O 0.9999371767044067

Motor O O 0.9999407529830933
impairment O O 0.9999943971633911
, O O 0.9999358654022217
dopamine B B 0.9979908466339111
( O O 0.9859945774078369
DA B B 0.9984502792358398
) O O 0.9925678968429565
neuronal O O 0.9998351335525513
activity O O 0.9999197721481323
and O O 0.9998167157173157
proenkephalin B O 0.5219292044639587
( O O 0.9921178221702576
PENK B O 0.8303589820861816
) O O 0.9972681999206543
gene O O 0.9971017241477966
expression O O 0.9999485015869141
in O O 0.999883770942688
the O O 0.9999622106552124
caudate O O 0.9869874715805054
- O O 0.9966428279876709
putamen O O 0.998572826385498
( O O 0.9997345805168152
CPu O O 0.9469804763793945
) O O 0.999931812286377
were O O 0.9999637603759766
measured O O 0.999935507774353
in O O 0.9999196529388428
6 B B 0.5879928469657898
- I I 0.7137708067893982
OHDA I I 0.9977883100509644
- O O 0.997519314289093
lesioned O O 0.9999014139175415
and O O 0.999864935874939
treated O O 0.9995195865631104
( O O 0.9971843361854553
L B B 0.7776091694831848
- I I 0.9302858710289001
DOPA I I 0.9580574035644531
+ I O 0.8516048192977905
benserazide I B 0.9929084777832031
) O O 0.9993960857391357
CB1 O O 0.9496560096740723
KO O O 0.9785705208778381
and O O 0.999916672706604
WT O O 0.9982205033302307
mice O O 0.9999898672103882
. O O 0.9999728202819824

A O O 0.9997144341468811
lesion O O 0.9999617338180542
induced O O 0.9999687671661377
by O O 0.9997515082359314
6 B B 0.966552734375
- I I 0.9970333576202393
OHDA I I 0.999972939491272
produced O O 0.9993886947631836
more O O 0.9999476671218872
severe O O 0.9999818801879883
motor O O 0.9999891519546509
deterioration O O 0.999997615814209
in O O 0.999955415725708
CB1 O O 0.9259896874427795
KO O O 0.9763971567153931
mice O O 0.9999638795852661
accompanied O O 0.999958872795105
by O O 0.9999781847000122
more O O 0.9999511241912842
loss O O 0.999984622001648
of O O 0.9999006986618042
DA B O 0.7144047617912292
neurons O O 0.9997552037239075
and O O 0.9999650716781616
increased O O 0.9999243021011353
PENK B O 0.5726386904716492
gene O O 0.9995642304420471
expression O O 0.9999674558639526
in O O 0.9998756647109985
the O O 0.9999315738677979
CPu O O 0.9700956344604492
. O O 0.9999250173568726

Oxidative O O 0.9571730494499207
/ O O 0.9976717829704285
nitrosative O O 0.5404790043830872
and O O 0.999134361743927
neuroinflammatory O O 0.9999284744262695
parameters O O 0.9999030828475952
were O O 0.9999215602874756
estimated O O 0.9997548460960388
in O O 0.9996743202209473
the O O 0.9997935891151428
CPu O O 0.9454287886619568
and O O 0.9985861778259277
cingulate O O 0.9728753566741943
cortex O O 0.9999727010726929
( O O 0.9991734623908997
Cg O O 0.8059090971946716
) O O 0.9999203681945801
. O O 0.9999521970748901

CB1 O O 0.7108538746833801
KO O O 0.9030460715293884
mice O O 0.9999302625656128
exhibited O O 0.9999371767044067
higher O O 0.9997249245643616
MDA B O 0.7403855323791504
levels O O 0.9997490048408508
and O O 0.999893307685852
iNOS O O 0.8509120345115662
protein O O 0.9986043572425842
expression O O 0.9998897314071655
in O O 0.9996377229690552
the O O 0.9997907280921936
CPu O O 0.8956357836723328
and O O 0.9992056488990784
Cg O O 0.5281445980072021
compared O O 0.9999191761016846
to O O 0.9999794960021973
WT O O 0.9992658495903015
mice O O 0.9999935626983643
. O O 0.9999725818634033

Treatment O O 0.9999493360519409
with O O 0.9998663663864136
L B B 0.8834870457649231
- I I 0.9827357530593872
DOPA I I 0.9996108412742615
+ I O 0.8355004191398621
benserazide I B 0.9983593821525574
( O O 0.9994589686393738
12 O O 0.9999300241470337
weeks O O 0.9999527931213379
) O O 0.9999738931655884
resulted O O 0.9999771118164062
in O O 0.9999920129776001
less O O 0.9999855756759644
severe O O 0.9999861717224121
dyskinesias O O 0.9999977350234985
in O O 0.9998983144760132
CB1 O O 0.9338319897651672
KO O O 0.9589534401893616
than O O 0.9999203681945801
in O O 0.9999197721481323
WT O O 0.9991955161094666
mice O O 0.9999966621398926
. O O 0.9999785423278809

The O O 0.9999794960021973
results O O 0.9999868869781494
revealed O O 0.9999816417694092
that O O 0.9999217987060547
the O O 0.999982476234436
lack O O 0.999830961227417
of O O 0.9995771050453186
cannabinoid O O 0.8205705881118774
CB1 O O 0.445525199174881
receptors O O 0.9575957655906677
increased O O 0.9999074935913086
the O O 0.9999877214431763
severity O O 0.9999926090240479
of O O 0.9999526739120483
motor O O 0.9999884366989136
impairment O O 0.9999972581863403
and O O 0.9999723434448242
DA B O 0.6486636996269226
lesion O O 0.9999431371688843
, O O 0.9999239444732666
and O O 0.9999542236328125
reduced O O 0.999957799911499
L B B 0.9196335077285767
- I I 0.9808890223503113
DOPA I I 0.9995447993278503
- O O 0.9985756874084473
induced O O 0.9999058246612549
dyskinesias O O 0.9999978542327881
. O O 0.9999756813049316

These O O 0.9999794960021973
results O O 0.9999856948852539
suggest O O 0.9999138116836548
that O O 0.9996538162231445
activation O O 0.9993667006492615
of O O 0.9984093308448792
CB1 O O 0.5958614349365234
receptors O O 0.9994795918464661
offers O O 0.9990290403366089
neuroprotection O O 0.9999545812606812
against O O 0.9995085000991821
dopaminergic O B 0.9710496068000793
lesion O O 0.9997681975364685
and O O 0.9999698400497437
the O O 0.9999866485595703
development O O 0.9999920129776001
of O O 0.9999675750732422
L B B 0.9146862030029297
- I I 0.9753594398498535
DOPA I I 0.999747097492218
- O O 0.9986737966537476
induced O O 0.9999308586120605
dyskinesias O O 0.9999980926513672
. O O 0.9999648332595825

Hepatocellular O O 0.9994909763336182
oxidant O O 0.6300804018974304
stress O O 0.9905163645744324
following O O 0.9997043013572693
intestinal O O 0.9999148845672607
ischemia O O 0.9995895028114319
- O O 0.991138756275177
reperfusion O O 0.9939433932304382
injury O O 0.999950647354126
. O O 0.99992835521698

Reperfusion O O 0.9859125018119812
of O O 0.9994828701019287
ischemic O O 0.9999333620071411
intestine O O 0.9995808005332947
results O O 0.9999288320541382
in O O 0.9999717473983765
acute O O 0.9999769926071167
liver O O 0.9996193647384644
dysfunction O O 0.9999966621398926
characterized O O 0.999993085861206
by O O 0.9999743700027466
hepatocellular O O 0.9989494681358337
enzyme O O 0.7416675090789795
release O O 0.9998975992202759
into O O 0.9999077320098877
plasma O O 0.9998598098754883
, O O 0.999914288520813
reduction O O 0.9999886751174927
in O O 0.9999154806137085
bile O O 0.6175298094749451
flow O O 0.9975383281707764
rate O O 0.9996993541717529
, O O 0.9998086094856262
and O O 0.9997701048851013
neutrophil O O 0.9997734427452087
sequestration O O 0.9999598264694214
within O O 0.9999356269836426
the O O 0.9999902248382568
liver O O 0.9996941089630127
. O O 0.9999650716781616

The O O 0.9999661445617676
pathophysiology O O 0.9999679327011108
underlying O O 0.9999760389328003
this O O 0.9999808073043823
acute O O 0.9999707937240601
hepatic O O 0.999924898147583
injury O O 0.9999861717224121
is O O 0.9999399185180664
unknown O O 0.9998927116394043
. O O 0.9999521970748901

This O O 0.9999771118164062
study O O 0.9999854564666748
was O O 0.9999815225601196
undertaken O O 0.9999934434890747
to O O 0.9999923706054688
determine O O 0.9999926090240479
whether O O 0.9999263286590576
oxidants O O 0.7605465054512024
are O O 0.9996825456619263
associated O O 0.9998941421508789
with O O 0.9999583959579468
the O O 0.9999865293502808
hepatic O O 0.9999628067016602
injury O O 0.9999909400939941
and O O 0.9999915361404419
to O O 0.9999949932098389
determine O O 0.9999932050704956
the O O 0.9999898672103882
relative O O 0.9999743700027466
value O O 0.999994158744812
of O O 0.9999816417694092
several O O 0.9998993873596191
indirect O O 0.999990701675415
methods O O 0.999996542930603
of O O 0.999994158744812
assessing O O 0.9998675584793091
oxidant O B 0.8811662197113037
exposure O O 0.9998307228088379
in O O 0.9999778270721436
vivo O O 0.999985933303833
. O O 0.9999628067016602

Rats O O 0.9999688863754272
were O O 0.9999697208404541
subjected O O 0.9999812841415405
to O O 0.9999258518218994
a O O 0.9998412132263184
standardized O O 0.9855162501335144
intestinal O O 0.9998891353607178
ischemia O O 0.9995555281639099
- O O 0.9942253232002258
reperfusion O O 0.998822033405304
injury O O 0.9999507665634155
. O O 0.99996018409729

Hepatic O O 0.9997643828392029
tissue O O 0.9999816417694092
was O O 0.999920129776001
assayed O O 0.9996755123138428
for O O 0.9891026020050049
lipid O O 0.4902789294719696
peroxidation O O 0.6954704523086548
products O O 0.9476470947265625
and O O 0.9980898499488831
oxidized B O 0.6699820160865784
and I O 0.9802666306495667
reduced I O 0.4811546504497528
glutathione I B 0.9161641597747803
. O O 0.9998911619186401

There O O 0.9999231100082397
was O O 0.9999480247497559
no O O 0.9999723434448242
change O O 0.9999938011169434
in O O 0.9999302625656128
hepatic O O 0.9991592168807983
tissue O O 0.9996989965438843
total O O 0.8393436074256897
glutathione B B 0.9428775310516357
following O O 0.9997797608375549
intestinal O O 0.9999278783798218
ischemia O O 0.9998230338096619
- O O 0.9923985600471497
reperfusion O O 0.9933270215988159
injury O O 0.9999611377716064
. O O 0.9999419450759888

Oxidized B O 0.5979138016700745
glutathione I B 0.9008455276489258
( O O 0.9988659620285034
GSSG B O 0.8220949769020081
) O O 0.9994909763336182
increased O O 0.9998012185096741
significantly O O 0.9999772310256958
following O O 0.9999560117721558
30 O O 0.9999860525131226
and O O 0.9999692440032959
60 O O 0.9999942779541016
min O O 0.9999837875366211
of O O 0.9999427795410156
reperfusion O O 0.9908468127250671
. O O 0.9999169111251831

There O O 0.9998743534088135
was O O 0.9999181032180786
no O O 0.999962329864502
increase O O 0.9999749660491943
in O O 0.9999305009841919
any O O 0.9997546076774597
of O O 0.9981552958488464
the O O 0.9996376037597656
products O O 0.9983329176902771
of O O 0.9991514682769775
lipid O O 0.5787575840950012
peroxidation O O 0.8488847613334656
associated O O 0.9999198913574219
with O O 0.999950647354126
this O O 0.999845027923584
injury O O 0.9999748468399048
. O O 0.9998414516448975

An O O 0.9999709129333496
increase O O 0.9999804496765137
in O O 0.9999089241027832
GSSG B O 0.6385953426361084
within O O 0.9995319843292236
hepatic O O 0.9995778203010559
tissue O O 0.9999923706054688
during O O 0.999669075012207
intestinal O O 0.999925971031189
reperfusion O O 0.9997726082801819
suggests O O 0.9998464584350586
exposure O O 0.9999496936798096
of O O 0.9999440908432007
hepatocytes O O 0.9995909333229065
to O O 0.9993177652359009
an O O 0.9960885047912598
oxidant O O 0.6294342875480652
stress O O 0.9041913151741028
. O O 0.9999489784240723

The O O 0.9999876022338867
lack O O 0.999990701675415
of O O 0.9999860525131226
a O O 0.9999822378158569
significant O O 0.9999873638153076
increase O O 0.9999685287475586
in O O 0.9998929500579834
products O O 0.9909268617630005
of O O 0.9930278658866882
lipid O O 0.6393005847930908
peroxidation O O 0.8411940336227417
suggests O O 0.9999408721923828
that O O 0.9999524354934692
the O O 0.9997629523277283
oxidant O O 0.5509263277053833
stress O O 0.9984135627746582
is O O 0.9999268054962158
of O O 0.9999643564224243
insufficient O O 0.9999703168869019
magnitude O O 0.9999560117721558
to O O 0.999974250793457
result O O 0.9999790191650391
in O O 0.9999691247940063
irreversible O O 0.9999516010284424
injury O O 0.9999924898147583
to O O 0.9999572038650513
hepatocyte O O 0.9998362064361572
cell O O 0.9999319314956665
membranes O O 0.9999806880950928
. O O 0.9999450445175171

These O O 0.9999845027923584
data O O 0.9999833106994629
also O O 0.9999841451644897
suggest O O 0.9999669790267944
that O O 0.9999749660491943
the O O 0.9999921321868896
measurement O O 0.9999659061431885
of O O 0.9998190999031067
tissue O O 0.9981181621551514
GSSG B O 0.48139068484306335
may O O 0.9999057054519653
be O O 0.9999737739562988
a O O 0.9999581575393677
more O O 0.9999545812606812
sensitive O O 0.9999788999557495
indicator O O 0.9999619722366333
of O O 0.9999414682388306
oxidant O O 0.8079855442047119
stress O O 0.999797523021698
than O O 0.999925971031189
measurement O O 0.9999364614486694
of O O 0.9995673298835754
products O O 0.9995169639587402
of O O 0.9992507100105286
lipid O O 0.6574947237968445
peroxidation O O 0.898992121219635
. O O 0.99989914894104

Animal O O 0.9998890161514282
model O O 0.9999840259552002
of O O 0.9998819828033447
mania O O 0.9956575632095337
induced O O 0.9999622106552124
by O O 0.9997237324714661
ouabain B B 0.9986452460289001
: O O 0.9998558759689331
Evidence O O 0.9999829530715942
of O O 0.9999209642410278
oxidative O O 0.9938521385192871
stress O O 0.9986580610275269
in O O 0.9993433356285095
submitochondrial O O 0.9253571629524231
particles O O 0.9824497699737549
of O O 0.9998075366020203
the O O 0.9999713897705078
rat O O 0.9999873638153076
brain O O 0.9999860525131226
. O O 0.9999672174453735

The O O 0.9999699592590332
intracerebroventricular O O 0.9997045397758484
( O O 0.9992413520812988
ICV O O 0.9983546137809753
) O O 0.9998985528945923
administration O O 0.9999362230300903
of O O 0.999717652797699
ouabain B B 0.9988114833831787
( O O 0.9994921684265137
a O O 0.8120437860488892
Na B B 0.9630547165870667
( O O 0.904062032699585
+ O O 0.988468587398529
) O O 0.9780148267745972
/ O O 0.9394685626029968
K B B 0.9379597902297974
( O O 0.6947042346000671
+ O O 0.9686613082885742
) O O 0.9449459910392761
- O O 0.9707483053207397
ATPase O O 0.9704495072364807
inhibitor O O 0.9553324580192566
) O O 0.9998113512992859
in O O 0.9996968507766724
rats O O 0.9966117739677429
has O O 0.9999597072601318
been O O 0.9999885559082031
suggested O O 0.999962329864502
to O O 0.9999271631240845
mimic O O 0.9999746084213257
some O O 0.9999723434448242
symptoms O O 0.9999955892562866
of O O 0.9999871253967285
human O O 0.9999184608459473
bipolar O O 0.9934613704681396
mania O O 0.9999740123748779
. O O 0.999957799911499

Clinical O O 0.9999370574951172
studies O O 0.9999887943267822
have O O 0.999983549118042
shown O O 0.9999840259552002
that O O 0.9998998641967773
bipolar O O 0.9507344961166382
disorder O O 0.9999674558639526
may O O 0.9999306201934814
be O O 0.9999505281448364
related O O 0.9999827146530151
to O O 0.9997937083244324
mitochondrial O O 0.9949361085891724
dysfunction O O 0.9999796152114868
. O O 0.9999728202819824

Herein O O 0.9997113347053528
, O O 0.9999468326568604
we O O 0.9999439716339111
investigated O O 0.9999698400497437
the O O 0.9999423027038574
behavioral O O 0.9999691247940063
and O O 0.9999411106109619
biochemical O O 0.9996380805969238
effects O O 0.9999604225158691
induced O O 0.9999850988388062
by O O 0.9999486207962036
the O O 0.9999758005142212
ICV O O 0.9995200634002686
administration O O 0.9999532699584961
of O O 0.9991521835327148
ouabain B B 0.9983057975769043
in O O 0.9997004270553589
rats O O 0.9999790191650391
. O O 0.9999350309371948

To O O 0.9999737739562988
achieve O O 0.9999516010284424
this O O 0.9999822378158569
aim O O 0.9999886751174927
, O O 0.9999842643737793
the O O 0.9999836683273315
effects O O 0.9999834299087524
of O O 0.9999144077301025
ouabain B B 0.9985670447349548
injection O O 0.9997707009315491
immediately O O 0.9999685287475586
after O O 0.9999802112579346
and O O 0.9999741315841675
7 O O 0.9999649524688721
days O O 0.9999945163726807
following O O 0.9999836683273315
a O O 0.9999951124191284
single O O 0.9999547004699707
ICV O O 0.9922072291374207
administration O O 0.9999713897705078
( O O 0.9999786615371704
at O O 0.9999382495880127
concentrations O O 0.9999547004699707
of O O 0.9999812841415405
10 O O 0.999984622001648
( O O 0.9997822642326355
- O O 0.9992246627807617
2 O O 0.9999326467514038
) O O 0.9999502897262573
and O O 0.9999552965164185
10 O O 0.9999669790267944
( O O 0.9995269775390625
- O O 0.9994279742240906
3 O O 0.9999121427536011
) O O 0.9999490976333618
M O O 0.9999972581863403
) O O 0.9999815225601196
on O O 0.9998517036437988
locomotion O O 0.9999536275863647
was O O 0.9999901056289673
measured O O 0.9999942779541016
using O O 0.9999895095825195
the O O 0.9999935626983643
open O O 0.9999163150787354
- O O 0.9999836683273315
field O O 0.9999932050704956
test O O 0.9999971389770508
. O O 0.9999861717224121

Additionally O O 0.9996153116226196
, O O 0.9998194575309753
thiobarbituric B B 0.9808712601661682
acid I I 0.9982807636260986
reactive O O 0.8823587894439697
substances O O 0.6001918911933899
( O O 0.9989525079727173
TBARSs O O 0.7811859250068665
) O O 0.9997827410697937
and O O 0.9997792840003967
superoxide B B 0.9900357127189636
production O O 0.9992508292198181
were O O 0.9999653100967407
measured O O 0.9998902082443237
in O O 0.9992789626121521
submitochondrial O O 0.9562106132507324
particles O O 0.9557628035545349
of O O 0.9993866682052612
the O O 0.9998284578323364
prefrontal O O 0.9946006536483765
cortex O O 0.9999856948852539
, O O 0.9997400641441345
hippocampus O O 0.9989357590675354
, O O 0.9997560381889343
striatum O O 0.9948135614395142
and O O 0.999782145023346
amygdala O O 0.9990768432617188
. O O 0.9999513626098633

Our O O 0.9999665021896362
findings O O 0.9999918937683105
demonstrated O O 0.999988317489624
that O O 0.9998425245285034
ouabain B B 0.9995562434196472
at O O 0.9980948567390442
10 O O 0.9977530837059021
( O O 0.9959491491317749
- O O 0.989342451095581
2 O O 0.9754917621612549
) O O 0.998986542224884
and O O 0.997844934463501
10 O O 0.9972711205482483
( O O 0.9895044565200806
- O O 0.9936671853065491
3 O O 0.9972088932991028
) O O 0.9991863369941711
M O O 0.9993488192558289
induced O O 0.9997861981391907
hyperlocomotion O O 0.9997155070304871
in O O 0.9996836185455322
rats O O 0.9998630285263062
, O O 0.9999456405639648
and O O 0.9999816417694092
this O O 0.9999817609786987
response O O 0.9999814033508301
remained O O 0.9999909400939941
up O O 0.9999942779541016
to O O 0.9999958276748657
7 O O 0.9999887943267822
days O O 0.999997615814209
following O O 0.9999867677688599
a O O 0.9999963045120239
single O O 0.9999816417694092
ICV O O 0.9993181228637695
injection O O 0.9999713897705078
. O O 0.9999793767929077

In O O 0.9999586343765259
addition O O 0.9999768733978271
, O O 0.9999818801879883
we O O 0.9999643564224243
observed O O 0.9999911785125732
that O O 0.9999784231185913
the O O 0.999992847442627
persistent O O 0.9999854564666748
increase O O 0.9999881982803345
in O O 0.9999849796295166
the O O 0.9999796152114868
rat O O 0.9994675517082214
spontaneous O O 0.9999561309814453
locomotion O O 0.9999154806137085
is O O 0.9999465942382812
associated O O 0.9999794960021973
with O O 0.999956488609314
increased O O 0.9998056292533875
TBARS O B 0.862982451915741
levels O O 0.999419093132019
and O O 0.9998753070831299
superoxide B B 0.9717113375663757
generation O O 0.9991344809532166
in O O 0.9975849390029907
submitochondrial O O 0.9756367802619934
particles O O 0.9940603375434875
in O O 0.9996110796928406
the O O 0.9998751878738403
prefrontal O O 0.9910821914672852
cortex O O 0.9999746084213257
, O O 0.9996250867843628
striatum O O 0.9916996955871582
and O O 0.999777615070343
amygdala O O 0.9990861415863037
. O O 0.9999465942382812

In O O 0.9999562501907349
conclusion O O 0.9999681711196899
, O O 0.9998921155929565
ouabain B B 0.998953104019165
- O O 0.9996863603591919
induced O O 0.9999125003814697
mania O O 0.9997562766075134
- O O 0.9999027252197266
like O O 0.9999717473983765
behavior O O 0.9999710321426392
may O O 0.9999687671661377
provide O O 0.9999885559082031
a O O 0.9999886751174927
useful O O 0.9999914169311523
animal O O 0.9999935626983643
model O O 0.9999955892562866
to O O 0.9999892711639404
test O O 0.9999730587005615
the O O 0.9999872446060181
hypothesis O O 0.999945878982544
of O O 0.999919056892395
the O O 0.999950647354126
involvement O O 0.9999580383300781
of O O 0.9997518658638
oxidative O O 0.9350769519805908
stress O O 0.9946331977844238
in O O 0.999927282333374
bipolar O O 0.9947851300239563
disorder O O 0.9999914169311523
. O O 0.9999727010726929

Intraoperative O O 0.9999560117721558
dialysis O O 0.8697044253349304
during O O 0.9999620914459229
liver O O 0.9993841648101807
transplantation O O 0.9999799728393555
with O O 0.9997009038925171
citrate B B 0.9034321904182434
dialysate O O 0.8746829032897949
. O O 0.9998181462287903

Liver O O 0.9608811736106873
transplantation O O 0.9997016787528992
for O O 0.9999243021011353
acutely O O 0.9999393224716187
ill O O 0.9999943971633911
patients O O 0.9999961853027344
with O O 0.9999886751174927
fulminant O O 0.9999635219573975
liver O O 0.9867270588874817
failure O O 0.9999815225601196
carries O O 0.9999637603759766
high O O 0.9999300241470337
intraoperative O O 0.9999884366989136
and O O 0.9999547004699707
immediate O O 0.9999916553497314
postoperative O O 0.9999895095825195
risks O O 0.999997615814209
. O O 0.9999837875366211

These O O 0.9999274015426636
are O O 0.9999464750289917
increased O O 0.9999665021896362
with O O 0.9999929666519165
the O O 0.9999873638153076
presence O O 0.9999808073043823
of O O 0.9999732971191406
concomitant O O 0.9998959302902222
acute O O 0.9979925155639648
kidney O O 0.9998548030853271
injury O O 0.99998939037323
( O O 0.9999613761901855
AKI O O 0.860014021396637
) O O 0.999958872795105
and O O 0.9999614953994751
intraoperative O O 0.9999822378158569
dialysis O O 0.999685525894165
is O O 0.9999740123748779
sometimes O O 0.999983549118042
required O O 0.9999724626541138
to O O 0.999987006187439
allow O O 0.9999818801879883
the O O 0.9999934434890747
transplant O O 0.9999746084213257
to O O 0.9999916553497314
proceed O O 0.9999985694885254
. O O 0.999982476234436

The O O 0.9999219179153442
derangements O O 0.9999803304672241
in O O 0.9999624490737915
the O O 0.9998522996902466
procoagulant O O 0.7808178663253784
and O O 0.9989938139915466
anticoagulant O O 0.5852477550506592
pathways O O 0.9996047616004944
during O O 0.9999167919158936
fulminant O O 0.9999775886535645
liver O O 0.9973260164260864
failure O O 0.9999876022338867
can O O 0.9999253749847412
lead O O 0.9999938011169434
to O O 0.9999896287918091
difficulties O O 0.999996542930603
with O O 0.9999756813049316
anticoagulation O O 0.864522397518158
during O O 0.9997703433036804
dialysis O O 0.9999586343765259
, O O 0.9999871253967285
especially O O 0.9999788999557495
when O O 0.999974250793457
continued O O 0.99997878074646
in O O 0.9999916553497314
the O O 0.999996542930603
operating O O 0.9999932050704956
room O O 0.9999970197677612
. O O 0.9999754428863525

Systemic O O 0.9995773434638977
anticoagulation O O 0.5712237358093262
is O O 0.9999371767044067
unsafe O O 0.9999642372131348
and O O 0.9999513626098633
regional O O 0.9840265512466431
citrate B O 0.8183168768882751
anticoagulation O O 0.5239786505699158
in O O 0.9999196529388428
the O O 0.999985933303833
absence O O 0.9999688863754272
of O O 0.9999769926071167
a O O 0.9999722242355347
functional O O 0.9999867677688599
liver O O 0.999897837638855
carries O O 0.9999696016311646
the O O 0.9999938011169434
risk O O 0.9999954700469971
of O O 0.9999797344207764
citrate B B 0.9739762544631958
toxicity O O 0.9998369216918945
. O O 0.9999829530715942

Citrate B O 0.799161434173584
dialysate O O 0.9736528992652893
, O O 0.9999555349349976
a O O 0.9999730587005615
new O O 0.9999357461929321
dialysate O O 0.9987778067588806
with O O 0.9991853833198547
citric B B 0.9778741002082825
acid I I 0.9999593496322632
can O O 0.9996672868728638
be O O 0.9999902248382568
used O O 0.9999686479568481
for O O 0.9999649524688721
anticoagulation O O 0.9724659323692322
in O O 0.9999723434448242
patients O O 0.9999945163726807
who O O 0.9999954700469971
cannot O O 0.9999957084655762
tolerate O O 0.9998829364776611
heparin B B 0.9976569414138794
or O O 0.9915251135826111
regional O B 0.8974218964576721
citrate B I 0.9856197834014893
. O O 0.9997724890708923

We O O 0.9999910593032837
report O O 0.9999980926513672
a O O 0.9999960660934448
case O O 0.9999977350234985
of O O 0.9999908208847046
a O O 0.9999936819076538
40 O O 0.9999938011169434
- O O 0.9999910593032837
year O O 0.9999972581863403
- O O 0.9999939203262329
old O O 0.9999963045120239
female O O 0.999997615814209
with O O 0.9999438524246216
acetaminophen B B 0.9990239143371582
- O O 0.998842716217041
induced O O 0.9999488592147827
fulminant O O 0.999990701675415
liver O O 0.99882572889328
failure O O 0.9999932050704956
with O O 0.9999644756317139
associated O O 0.9999856948852539
AKI O O 0.9751771092414856
who O O 0.9999568462371826
underwent O O 0.9998382329940796
intraoperative O O 0.9999902248382568
dialytic O O 0.999031662940979
support O O 0.9999849796295166
during O O 0.9999611377716064
liver O O 0.9985499978065491
transplantation O O 0.9999644756317139
anticoagulated O O 0.9979726672172546
with O O 0.9997538924217224
citrate B O 0.6799420118331909
dialysate O O 0.9912999272346497
during O O 0.9999440908432007
the O O 0.9999972581863403
entire O O 0.9999874830245972
procedure O O 0.9999979734420776
. O O 0.9999738931655884

The O O 0.9999836683273315
patient O O 0.999990701675415
tolerated O O 0.9999973773956299
the O O 0.9999984502792358
procedure O O 0.9999971389770508
well O O 0.9999896287918091
without O O 0.9999688863754272
any O O 0.9999823570251465
signs O O 0.9999858140945435
of O O 0.9999434947967529
citrate B B 0.9891975522041321
toxicity O O 0.9993896484375
and O O 0.9999786615371704
maintained O O 0.9999701976776123
adequate O O 0.9998852014541626
anticoagulation O O 0.6741374731063843
for O O 0.9999203681945801
patency O O 0.9998817443847656
of O O 0.9999682903289795
the O O 0.9999861717224121
dialysis O O 0.9997119307518005
circuit O O 0.9999059438705444
. O O 0.9999717473983765

Citrate B B 0.980262041091919
dialysate O O 0.951301634311676
is O O 0.999923825263977
a O O 0.9998818635940552
safe O O 0.9999465942382812
alternative O O 0.999969482421875
for O O 0.9999090433120728
intradialytic O O 0.9999697208404541
support O O 0.9999823570251465
of O O 0.999927282333374
liver O O 0.9839025139808655
transplantation O O 0.9999480247497559
in O O 0.99994957447052
fulminant O O 0.9999802112579346
liver O O 0.9973949193954468
failure O O 0.9999926090240479
. O O 0.9999685287475586

Delirium O O 0.9998070597648621
in O O 0.9999551773071289
a O O 0.9999731779098511
patient O O 0.9999786615371704
with O O 0.9999136924743652
toxic O O 0.9993116855621338
flecainide B B 0.9968757629394531
plasma O O 0.9795122742652893
concentrations O O 0.9904975295066833
: O O 0.9999028444290161
the O O 0.9999713897705078
role O O 0.9999783039093018
of O O 0.9999544620513916
a O O 0.999927282333374
pharmacokinetic O O 0.9880598187446594
drug O O 0.9991456270217896
interaction O O 0.9998152852058411
with O O 0.9997722506523132
paroxetine B B 0.997750461101532
. O O 0.9999189376831055

OBJECTIVE O O 0.9998138546943665
: O O 0.9999942779541016
To O O 0.9999949932098389
describe O O 0.9999940395355225
a O O 0.9999890327453613
case O O 0.9999915361404419
of O O 0.9999451637268066
flecainide B B 0.9995250701904297
- O O 0.9995923638343811
induced O O 0.9999450445175171
delirium O O 0.9999899864196777
associated O O 0.9999539852142334
with O O 0.9999479055404663
a O O 0.9999507665634155
pharmacokinetic O O 0.984679639339447
drug O O 0.9993072748184204
interaction O O 0.9998593330383301
with O O 0.9997228980064392
paroxetine B B 0.9967058300971985
. O O 0.9999164342880249

CASE O O 0.9995959401130676
SUMMARY O O 0.9999961853027344
: O O 0.9999804496765137
A O O 0.999997615814209
69 O O 0.9999967813491821
- O O 0.9999834299087524
year O O 0.9999959468841553
- O O 0.9999923706054688
old O O 0.9999929666519165
white O O 0.9999910593032837
female O O 0.9999945163726807
presented O O 0.9999790191650391
to O O 0.9999978542327881
the O O 0.999998927116394
emergency O O 0.9999951124191284
department O O 0.9999988079071045
with O O 0.9999922513961792
a O O 0.9999955892562866
history O O 0.9999946355819702
of O O 0.999994158744812
confusion O O 0.9999961853027344
and O O 0.9999806880950928
paranoia O O 0.9998955726623535
over O O 0.9999876022338867
the O O 0.9999983310699463
past O O 0.9999970197677612
several O O 0.9999983310699463
days O O 0.9999972581863403
. O O 0.9999840259552002

On O O 0.9999392032623291
admission O O 0.9999864101409912
the O O 0.9999737739562988
patient O O 0.9999865293502808
was O O 0.9999529123306274
taking O O 0.9981552958488464
carvedilol B B 0.9992077946662903
12 O O 0.9022337794303894
mg O O 0.9953262805938721
twice O O 0.9826329946517944
daily O O 0.9996423721313477
, O O 0.9964556694030762
warfarin B B 0.9992629885673523
2 O O 0.8618335127830505
mg O O 0.9975482821464539
/ O O 0.9982859492301941
day O O 0.9987710118293762
, O O 0.9927878975868225
folic B B 0.9929383397102356
acid I I 0.9999772310256958
1 O O 0.8167868256568909
mg O O 0.9897448420524597
/ O O 0.9979491829872131
day O O 0.9985530972480774
, O O 0.9949819445610046
levothyroxine B B 0.9982006549835205
100 O O 0.8173194527626038
microg O O 0.9874500036239624
/ O O 0.9995556473731995
day O O 0.999788224697113
, O O 0.9952645301818848
pantoprazole B B 0.988634467124939
40 O O 0.8730320334434509
mg O O 0.9994370341300964
/ O O 0.9997676014900208
day O O 0.9997267127037048
, O O 0.9933691620826721
paroxetine B B 0.9966392517089844
40 O O 0.8245156407356262
mg O O 0.9993828535079956
/ O O 0.9996516704559326
day O O 0.9996634721755981
, O O 0.9983963370323181
and O O 0.994414210319519
flecainide B B 0.9965574741363525
100 O O 0.6612308025360107
mg O O 0.997633695602417
twice O O 0.9984104633331299
daily O O 0.9998235106468201
. O O 0.9999622106552124

Flecainide B B 0.9992632269859314
had O O 0.9998477697372437
been O O 0.9999608993530273
started O O 0.9998908042907715
2 O O 0.999914288520813
weeks O O 0.9999936819076538
prior O O 0.9999922513961792
for O O 0.9999518394470215
atrial O O 0.9998177886009216
fibrillation O O 0.9999637603759766
. O O 0.9999253749847412

Laboratory O O 0.9998652935028076
test O O 0.9999266862869263
findings O O 0.9999891519546509
on O O 0.9999783039093018
admission O O 0.9999920129776001
were O O 0.9999759197235107
notable O O 0.99998939037323
only O O 0.9999873638153076
for O O 0.9998958110809326
a O O 0.999893069267273
flecainide B B 0.9973318576812744
plasma O O 0.9980329871177673
concentration O O 0.9998708963394165
of O O 0.9999222755432129
1360 O O 0.9999618530273438
microg O O 0.9999809265136719
/ O O 0.999963641166687
L O O 0.9998500347137451
( O O 0.9999713897705078
reference O O 0.9999924898147583
range O O 0.9999910593032837
200 O O 0.9973011612892151
- O O 0.9982788562774658
1000 O O 0.9983612895011902
) O O 0.9999719858169556
. O O 0.9999749660491943

A O O 0.9999229907989502
metabolic O O 0.9993026256561279
drug O O 0.9995243549346924
interaction O O 0.999778687953949
between O O 0.9979671835899353
flecainide B B 0.9987685084342957
and O O 0.9697994589805603
paroxetine B B 0.9966999888420105
, O O 0.9998388290405273
which O O 0.9998612403869629
the O O 0.9999958276748657
patient O O 0.9999926090240479
had O O 0.9999905824661255
been O O 0.999981164932251
taking O O 0.996448278427124
for O O 0.9999287128448486
more O O 0.999983549118042
than O O 0.9999938011169434
5 O O 0.999950647354126
years O O 0.9999722242355347
, O O 0.9999852180480957
was O O 0.9999735355377197
considered O O 0.9999685287475586
. O O 0.9999707937240601

Paroxetine B B 0.997841477394104
was O O 0.9999102354049683
discontinued O O 0.999897837638855
and O O 0.9999741315841675
the O O 0.9999867677688599
dose O O 0.9998666048049927
of O O 0.9993477463722229
flecainide B B 0.9993876218795776
was O O 0.9999251365661621
reduced O O 0.9999942779541016
to O O 0.9999679327011108
50 O O 0.9998503923416138
mg O O 0.9999125003814697
twice O O 0.999738872051239
daily O O 0.9999642372131348
. O O 0.9999598264694214

Her O O 0.9999676942825317
delirium O O 0.9999576807022095
resolved O O 0.9999736547470093
3 O O 0.9998626708984375
days O O 0.9999949932098389
later O O 0.999995231628418
. O O 0.9999819993972778

DISCUSSION O O 0.9997292160987854
: O O 0.9995125532150269
Flecainide B B 0.9995651841163635
and O O 0.9989688396453857
pharmacologically O O 0.9995912909507751
similar O O 0.9997825026512146
agents O O 0.9979262351989746
that O O 0.9997898936271667
interact O O 0.9996492862701416
with O O 0.999757707118988
sodium B B 0.9879146814346313
channels O O 0.9918996095657349
may O O 0.9999499320983887
cause O O 0.9999349117279053
delirium O O 0.999980092048645
in O O 0.999910831451416
susceptible O O 0.8934930562973022
patients O O 0.9999805688858032
. O O 0.9999700784683228

A O O 0.9999537467956543
MEDLINE O O 0.9978049397468567
search O O 0.9998928308486938
( O O 0.9998378753662109
1966 O O 0.9684455990791321
- O O 0.9969410300254822
January O O 0.9204992055892944
2009 O O 0.9481276869773865
) O O 0.9999513626098633
revealed O O 0.9999233484268188
one O O 0.9999810457229614
in O O 0.9998412132263184
vivo O O 0.99997878074646
pharmacokinetic O O 0.999457061290741
study O O 0.9999798536300659
on O O 0.9996578693389893
the O O 0.9999457597732544
interaction O O 0.9998786449432373
between O O 0.9980303645133972
flecainide B B 0.9996985197067261
, O O 0.9980862140655518
a O O 0.9845026135444641
CYP2D6 O O 0.5606169104576111
substrate O O 0.671331524848938
, O O 0.984329104423523
and O O 0.994831383228302
paroxetine B B 0.9985137581825256
, O O 0.9995425939559937
a O O 0.9937925934791565
CYP2D6 O O 0.580190896987915
inhibitor O O 0.8648160099983215
, O O 0.9999376535415649
as O O 0.9999806880950928
well O O 0.9999817609786987
as O O 0.9999866485595703
3 O O 0.9998838901519775
case O O 0.9999936819076538
reports O O 0.9999967813491821
of O O 0.9999616146087646
flecainide B B 0.9997738003730774
- O O 0.9998257756233215
induced O O 0.9999504089355469
delirium O O 0.999982476234436
. O O 0.999954342842102

According O O 0.9999948740005493
to O O 0.9999783039093018
the O O 0.9999524354934692
Naranjo O O 0.5257357358932495
probability O O 0.9976400136947632
scale O O 0.9898960590362549
, O O 0.9996969699859619
flecainide B B 0.9994316697120667
was O O 0.9999243021011353
the O O 0.9999382495880127
probable O O 0.9999703168869019
cause O O 0.999975323677063
of O O 0.9999681711196899
the O O 0.9999876022338867
patient O O 0.9999921321868896
' O O 0.9999948740005493
s O O 0.9999890327453613
delirium O O 0.9999946355819702
; O O 0.9999712705612183
the O O 0.9999802112579346
Horn O O 0.9902200102806091
Drug O O 0.9991291165351868
Interaction O O 0.9998873472213745
Probability O O 0.9986728429794312
Scale O O 0.9838857650756836
indicates O O 0.9998483657836914
a O O 0.9999510049819946
possible O O 0.999862551689148
pharmacokinetic O O 0.9977388381958008
drug O O 0.9975885152816772
interaction O O 0.9998630285263062
between O O 0.999261200428009
flecainide B B 0.9997001886367798
and O O 0.9815117716789246
paroxetine B B 0.9977445602416992
. O O 0.9999545812606812

CONCLUSIONS O O 0.9720367193222046
: O O 0.9998695850372314
Supratherapeutic O O 0.9939047694206238
flecainide B B 0.9992608428001404
plasma O O 0.999178946018219
concentrations O O 0.9990622401237488
may O O 0.9999399185180664
cause O O 0.9999306201934814
delirium O O 0.9999849796295166
. O O 0.9999504089355469

Because O O 0.9996681213378906
toxicity O O 0.9999760389328003
may O O 0.9999816417694092
occur O O 0.9999912977218628
when O O 0.999880313873291
flecainide B B 0.9994322657585144
is O O 0.9998505115509033
prescribed O O 0.9998492002487183
with O O 0.9994462132453918
paroxetine B B 0.9982325434684753
and O O 0.9991880059242249
other O O 0.9997319579124451
potent O O 0.9768257141113281
CYP2D6 O O 0.5224970579147339
inhibitors O O 0.6745142340660095
, O O 0.9999266862869263
flecainide B B 0.9995966553688049
plasma O O 0.9997404217720032
concentrations O O 0.9999334812164307
should O O 0.9999704360961914
be O O 0.9999954700469971
monitored O O 0.9999918937683105
closely O O 0.9999943971633911
with O O 0.999968409538269
commencement O O 0.9887672066688538
of O O 0.9995689988136292
CYP2D6 O O 0.4799685478210449
inhibitors O O 0.5931729674339294
. O O 0.999972939491272

Efficacy O O 0.9993005990982056
of O O 0.9961473941802979
everolimus B B 0.9998087286949158
( O O 0.9814022183418274
RAD001 B B 0.9986717700958252
) O O 0.9994493126869202
in O O 0.9999675750732422
patients O O 0.999993085861206
with O O 0.9999861717224121
advanced O O 0.9999847412109375
NSCLC O O 0.9811928272247314
previously O O 0.9999589920043945
treated O O 0.9999597072601318
with O O 0.9999078512191772
chemotherapy O O 0.9994955062866211
alone O O 0.9998956918716431
or O O 0.9999279975891113
with O O 0.9998107552528381
chemotherapy O O 0.9406452775001526
and O O 0.9984645843505859
EGFR O O 0.888289213180542
inhibitors O O 0.9518224000930786
. O O 0.9999145269393921

BACKGROUND O O 0.9979950189590454
: O O 0.9999767541885376
Treatment O O 0.999962568283081
options O O 0.9999889135360718
are O O 0.9999784231185913
scarce O O 0.99988853931427
in O O 0.9999651908874512
pretreated O O 0.9973243474960327
advanced O O 0.999924898147583
non O O 0.9970898628234863
- O O 0.9996331930160522
small O O 0.9989846348762512
- O O 0.9998506307601929
cell O O 0.9992456436157227
lung O O 0.9990746974945068
cancer O O 0.9980131387710571
( O O 0.999914288520813
NSCLC O O 0.9793540239334106
) O O 0.9998517036437988
patients O O 0.999982476234436
. O O 0.9999510049819946

RAD001 B B 0.9978413581848145
, O O 0.9995213747024536
an O O 0.9984214305877686
oral O O 0.700363039970398
inhibitor O O 0.8028579950332642
of O O 0.9834473133087158
the O O 0.9989325404167175
mammalian O O 0.9971508383750916
target O O 0.998250424861908
of O O 0.9314817786216736
rapamycin B B 0.9828694462776184
( O O 0.9943073391914368
mTOR O O 0.5009672045707703
) O O 0.9995482563972473
, O O 0.999906063079834
has O O 0.9998852014541626
shown O O 0.9999505281448364
phase O O 0.9980771541595459
I O O 0.9906258583068848
efficacy O O 0.9998846054077148
in O O 0.9996885061264038
NSCLC O O 0.8609470129013062
. O O 0.9998961687088013

METHODS O O 0.9996765851974487
: O O 0.9999593496322632
Stage O O 0.9998900890350342
IIIb O O 0.9959749579429626
or O O 0.9988304972648621
IV O O 0.9949579834938049
NSCLC O O 0.9692755937576294
patients O O 0.999889612197876
, O O 0.99998939037323
with O O 0.9999872446060181
two O O 0.9999105930328369
or O O 0.9999924898147583
fewer O O 0.9999821186065674
prior O O 0.9999716281890869
chemotherapy O O 0.9998571872711182
regimens O O 0.9997945427894592
, O O 0.9999794960021973
one O O 0.9964984655380249
platinum B O 0.6614479422569275
based O O 0.5099164843559265
( O O 0.9995504021644592
stratum O O 0.9897778630256653
1 O O 0.9999127388000488
) O O 0.9998573064804077
or O O 0.9998924732208252
both O O 0.9926677346229553
chemotherapy O O 0.9830885529518127
and O O 0.9988466501235962
epidermal O O 0.9415960907936096
growth O O 0.9249016046524048
factor O O 0.9818492531776428
receptor O O 0.9947931170463562
tyrosine B O 0.5940080285072327
kinase O O 0.8869646191596985
inhibitors O O 0.8788596987724304
( O O 0.9997637867927551
stratum O O 0.9863632321357727
2 O O 0.999404788017273
) O O 0.9999637603759766
, O O 0.9999905824661255
received O O 0.999799907207489
RAD001 B B 0.9993385672569275
10 O O 0.9983994364738464
mg O O 0.9999361038208008
/ O O 0.9997434020042419
day O O 0.9999834299087524
until O O 0.9999393224716187
progression O O 0.9999972581863403
or O O 0.9999977350234985
unacceptable O O 0.9997791647911072
toxicity O O 0.9999911785125732
. O O 0.9999847412109375

Primary O O 0.999966025352478
objective O O 0.9999874830245972
was O O 0.9999914169311523
overall O O 0.9999630451202393
response O O 0.9999853372573853
rate O O 0.9999924898147583
( O O 0.9999372959136963
ORR O O 0.9922615885734558
) O O 0.9999830722808838
. O O 0.9999779462814331

Analyses O O 0.9999804496765137
of O O 0.9999319314956665
markers O O 0.9999614953994751
associated O O 0.9999661445617676
with O O 0.999864935874939
the O O 0.9997312426567078
mTOR O O 0.9869858622550964
pathway O O 0.9997099041938782
were O O 0.999987006187439
carried O O 0.9999967813491821
out O O 0.9999974966049194
on O O 0.9999827146530151
archival O O 0.9999929666519165
tumor O O 0.9999986886978149
from O O 0.9999765157699585
a O O 0.9997429251670837
subgroup O O 0.9996975660324097
using O O 0.999975323677063
immunohistochemistry O O 0.9998670816421509
( O O 0.9998039603233337
IHC O O 0.9723013639450073
) O O 0.9999371767044067
and O O 0.9999582767486572
direct O O 0.9998645782470703
mutation O O 0.9999129772186279
sequencing O O 0.9998180270195007
. O O 0.9999822378158569

RESULTS O O 0.9997876286506653
: O O 0.9999555349349976
Eighty O O 0.9551486372947693
- O O 0.9998822212219238
five O O 0.9999890327453613
patients O O 0.9999899864196777
were O O 0.9999780654907227
enrolled O O 0.9999611377716064
, O O 0.9999619722366333
42 O O 0.9999496936798096
in O O 0.9997400641441345
stratum O O 0.8934627175331116
1 O O 0.9974300265312195
and O O 0.9996899366378784
43 O O 0.9998844861984253
in O O 0.9995781779289246
stratum O O 0.8878709077835083
. O O 0.9999514818191528

ORR O O 0.8501008152961731
was O O 0.9999370574951172
4 O O 0.9993212223052979
. O O 0.9999027252197266
7 O O 0.9999849796295166
% O O 0.9999217987060547
( O O 0.9997738003730774
7 O O 0.9996703863143921
. O O 0.9999523162841797
1 O O 0.9999849796295166
% O O 0.9996787309646606
stratum O O 0.9831559658050537
1 O O 0.9967859983444214
; O O 0.999734103679657
2 O O 0.9998941421508789
. O O 0.9999556541442871
3 O O 0.9999046325683594
% O O 0.9993140697479248
stratum O O 0.9269638061523438
2 O O 0.9805497527122498
) O O 0.9998936653137207
. O O 0.9999351501464844

Overall O O 0.9998162388801575
disease O O 0.9999514818191528
control O O 0.9999725818634033
rate O O 0.9998410940170288
was O O 0.9999431371688843
47 O O 0.9999935626983643
. O O 0.9999880790710449
1 O O 0.9999964237213135
% O O 0.9999833106994629
. O O 0.9999628067016602

Median O O 0.9999456405639648
progression O O 0.9993115663528442
- O O 0.999948263168335
free O O 0.9999723434448242
survivals O O 0.9999632835388184
( O O 0.9999442100524902
PFSs O O 0.9990290403366089
) O O 0.9999755620956421
were O O 0.9999873638153076
2 O O 0.9999862909317017
. O O 0.9999942779541016
6 O O 0.9999940395355225
( O O 0.9999529123306274
stratum O O 0.9944289922714233
1 O O 0.9999399185180664
) O O 0.999933123588562
and O O 0.9999572038650513
2 O O 0.9999854564666748
. O O 0.9999946355819702
7 O O 0.9999922513961792
months O O 0.999998927116394
( O O 0.9999583959579468
stratum O O 0.9920092821121216
2 O O 0.9999343156814575
) O O 0.9999731779098511
. O O 0.9999830722808838

Common O O 0.9998403787612915
> O O 0.9998600482940674
or O O 0.9999843835830688
= O O 0.9999443292617798
grade O O 0.9999872446060181
3 O O 0.9998520612716675
events O O 0.9999977350234985
were O O 0.9999905824661255
fatigue O O 0.9999970197677612
, O O 0.9999785423278809
dyspnea O O 0.9999945163726807
, O O 0.9999736547470093
stomatitis O O 0.9987512826919556
, O O 0.9999737739562988
anemia O O 0.9997350573539734
, O O 0.9998574256896973
and O O 0.9999321699142456
thrombocytopenia O O 0.9988062381744385
. O O 0.9999597072601318

Pneumonitis O O 0.998184859752655
, O O 0.9999579191207886
probably O O 0.9989843964576721
or O O 0.9999021291732788
possibly O O 0.9992769360542297
related O O 0.9999634027481079
, O O 0.9999866485595703
mainly O O 0.9998313188552856
grade O O 0.9997475743293762
1 O O 0.9993698000907898
/ O O 0.9998799562454224
2 O O 0.996231734752655
, O O 0.9999783039093018
occurred O O 0.9999797344207764
in O O 0.9999814033508301
25 O O 0.9999337196350098
% O O 0.9999836683273315
. O O 0.9999532699584961

Cox O O 0.6233537197113037
regression O O 0.9988903403282166
analysis O O 0.9999628067016602
of O O 0.9997918009757996
IHC O O 0.9745832085609436
scores O O 0.9997907280921936
found O O 0.9999817609786987
that O O 0.9999464750289917
only O O 0.9987120628356934
phospho O O 0.8155642151832581
AKT O O 0.8058334589004517
( O O 0.9372944235801697
pAKT O O 0.8193536400794983
) O O 0.9957148432731628
was O O 0.9999268054962158
a O O 0.9997649788856506
significant O O 0.9999287128448486
independent O O 0.999936580657959
predictor O O 0.9999735355377197
of O O 0.999987006187439
worse O O 0.9999301433563232
PFS O O 0.9921070337295532
. O O 0.9999368190765381

CONCLUSIONS O O 0.9593894481658936
: O O 0.9991545677185059
RAD001 B B 0.9983271956443787
10 O O 0.998116135597229
mg O O 0.9998979568481445
/ O O 0.9997664093971252
day O O 0.999985933303833
was O O 0.9999772310256958
well O O 0.999970555305481
tolerated O O 0.9999947547912598
, O O 0.9999878406524658
showing O O 0.999976396560669
modest O O 0.9999818801879883
clinical O O 0.9999874830245972
activity O O 0.999992847442627
in O O 0.9999129772186279
pretreated O O 0.9977895021438599
NSCLC O O 0.8976280689239502
. O O 0.9999470710754395

Evaluation O O 0.999922513961792
of O O 0.9988906979560852
RAD001 B B 0.9990721940994263
plus O O 0.9985471367835999
standard O O 0.9998313188552856
therapy O O 0.9999678134918213
for O O 0.9998903274536133
metastatic O O 0.9999821186065674
NSCLC O O 0.9050298929214478
continues O O 0.9982731342315674
. O O 0.9997780919075012

Posttransplant O O 0.9944264888763428
anemia O O 0.9989933371543884
: O O 0.9997952580451965
the O O 0.9998551607131958
role O O 0.9998458623886108
of O O 0.9993876218795776
sirolimus B B 0.9989134073257446
. O O 0.9995673298835754

Posttransplant O O 0.9957413673400879
anemia O O 0.9984025359153748
is O O 0.9999523162841797
a O O 0.9999626874923706
common O O 0.9999370574951172
problem O O 0.9999794960021973
that O O 0.999895453453064
may O O 0.9998914003372192
hinder O O 0.9999724626541138
patients O O 0.9999926090240479
' O O 0.9999966621398926
quality O O 0.9999971389770508
of O O 0.9999910593032837
life O O 0.9999940395355225
. O O 0.9999797344207764

It O O 0.9999691247940063
occurs O O 0.9999914169311523
in O O 0.9999858140945435
12 O O 0.999995231628418
to O O 0.9999961853027344
76 O O 0.9999926090240479
% O O 0.9999964237213135
of O O 0.999976634979248
patients O O 0.999985933303833
, O O 0.9999562501907349
and O O 0.9999721050262451
is O O 0.9999884366989136
most O O 0.9999934434890747
common O O 0.9999935626983643
in O O 0.9999376535415649
the O O 0.9999734163284302
immediate O O 0.99997878074646
posttransplant O O 0.9999278783798218
period O O 0.9999895095825195
. O O 0.9999721050262451

A O O 0.9998912811279297
variety O O 0.999962568283081
of O O 0.9998661279678345
factors O O 0.9999598264694214
have O O 0.9999740123748779
been O O 0.9999914169311523
identified O O 0.9999818801879883
that O O 0.9998829364776611
increase O O 0.999729573726654
the O O 0.9999854564666748
risk O O 0.9999957084655762
of O O 0.9999572038650513
posttransplant O O 0.9987874627113342
anemia O O 0.9999203681945801
, O O 0.9999731779098511
of O O 0.9975125789642334
which O O 0.999946117401123
the O O 0.9999786615371704
level O O 0.999971866607666
of O O 0.9999754428863525
renal O O 0.999718964099884
function O O 0.9999191761016846
is O O 0.9999483823776245
most O O 0.9999493360519409
important O O 0.9999617338180542
. O O 0.9999594688415527

Sirolimus B B 0.9879713654518127
, O O 0.9997342228889465
a O O 0.9951688647270203
mammalian O O 0.9972652196884155
target O O 0.9972743391990662
of O O 0.962181031703949
rapamycin B B 0.9287029504776001
inhibitor O O 0.8428333401679993
, O O 0.9986054301261902
has O O 0.9998955726623535
been O O 0.999970555305481
implicated O O 0.9999030828475952
as O O 0.9999686479568481
playing O O 0.9999504089355469
a O O 0.9999170303344727
special O O 0.9995169639587402
role O O 0.9999686479568481
in O O 0.999948263168335
posttransplant O O 0.9971792697906494
anemia O O 0.999862790107727
. O O 0.9999113082885742

This O O 0.9999574422836304
review O O 0.9999674558639526
considers O O 0.9999352693557739
anemia O O 0.9995355606079102
associated O O 0.9999144077301025
with O O 0.9997560381889343
sirolimus B B 0.9976576566696167
, O O 0.9998055100440979
including O O 0.999916672706604
its O O 0.9999343156814575
presentation O O 0.9999536275863647
, O O 0.9999849796295166
mechanisms O O 0.9999669790267944
, O O 0.9999659061431885
and O O 0.9999650716781616
management O O 0.9999628067016602
. O O 0.9999748468399048

Coronary O O 0.9999504089355469
computerized O O 0.9847581386566162
tomography O O 0.9997300505638123
angiography O O 0.9995142221450806
for O O 0.9999672174453735
rapid O O 0.9999926090240479
discharge O O 0.9999971389770508
of O O 0.9999972581863403
low O O 0.9999217987060547
- O O 0.9999895095825195
risk O O 0.9999953508377075
patients O O 0.9999966621398926
with O O 0.9999905824661255
cocaine B B 0.9922800064086914
- O O 0.9974194765090942
associated O O 0.9999561309814453
chest O O 0.9999901056289673
pain O O 0.9999953508377075
. O O 0.9999076128005981

BACKGROUND O O 0.9998041987419128
: O O 0.9999904632568359
Most O O 0.9999881982803345
patients O O 0.9999957084655762
presenting O O 0.9999816417694092
to O O 0.9999878406524658
emergency O O 0.9999481439590454
departments O O 0.9999983310699463
( O O 0.9998923540115356
EDs O O 0.9960386753082275
) O O 0.9999872446060181
with O O 0.999985933303833
cocaine B B 0.9819077849388123
- O O 0.9962192177772522
associated O O 0.9999682903289795
chest O O 0.9999929666519165
pain O O 0.9999977350234985
are O O 0.9999929666519165
admitted O O 0.9999934434890747
for O O 0.9999892711639404
at O O 0.9999957084655762
least O O 0.9999960660934448
12 O O 0.9999954700469971
hours O O 0.9999951124191284
and O O 0.9999865293502808
receive O O 0.9999798536300659
a O O 0.9999910593032837
" O O 0.9999823570251465
rule O O 0.9995500445365906
out O O 0.9998170733451843
acute O O 0.9994513392448425
coronary O O 0.9998456239700317
syndrome O O 0.999980092048645
" O O 0.9999867677688599
protocol O O 0.9999899864196777
, O O 0.999992847442627
often O O 0.9999810457229614
with O O 0.9999884366989136
noninvasive O O 0.9999393224716187
testing O O 0.999995231628418
prior O O 0.9999982118606567
to O O 0.9999985694885254
discharge O O 0.999996542930603
. O O 0.9999877214431763

In O O 0.9999197721481323
patients O O 0.9999817609786987
without O O 0.9997922778129578
cocaine B B 0.9662426114082336
use O O 0.995650589466095
, O O 0.9999690055847168
coronary O O 0.9947941899299622
computerized O O 0.9868152141571045
tomography O O 0.9974084496498108
angiography O O 0.9757823944091797
( O O 0.9998302459716797
CTA O O 0.9100179076194763
) O O 0.9999712705612183
has O O 0.9999845027923584
been O O 0.99998939037323
shown O O 0.9999818801879883
to O O 0.9999821186065674
be O O 0.9999899864196777
useful O O 0.9999881982803345
for O O 0.9999765157699585
identifying O O 0.9999853372573853
a O O 0.9999912977218628
group O O 0.9999924898147583
of O O 0.9999845027923584
patients O O 0.9999927282333374
at O O 0.9999828338623047
low O O 0.9999898672103882
risk O O 0.999997615814209
for O O 0.9999849796295166
cardiac O O 0.9999775886535645
events O O 0.9999985694885254
who O O 0.999984860420227
can O O 0.9999929666519165
be O O 0.9999980926513672
safely O O 0.999996542930603
discharged O O 0.9999954700469971
. O O 0.9999873638153076

It O O 0.9999854564666748
is O O 0.9999830722808838
unclear O O 0.999982476234436
whether O O 0.9999864101409912
a O O 0.9994744658470154
coronary O O 0.7094597220420837
CTA O O 0.49833858013153076
strategy O O 0.9810879230499268
would O O 0.9999402761459351
be O O 0.9999651908874512
efficacious O O 0.9999561309814453
in O O 0.9998855590820312
cocaine B B 0.9927692413330078
- O O 0.9987109899520874
associated O O 0.9999746084213257
chest O O 0.999993085861206
pain O O 0.999991774559021
, O O 0.9999635219573975
as O O 0.9999794960021973
coronary O O 0.9940140843391418
vasospasm O O 0.9999104738235474
may O O 0.9999263286590576
account O O 0.9999759197235107
for O O 0.9999583959579468
some O O 0.9999785423278809
of O O 0.9999674558639526
the O O 0.9999850988388062
ischemia O O 0.9999979734420776
. O O 0.999966025352478

We O O 0.9999349117279053
studied O O 0.9999878406524658
whether O O 0.9999916553497314
a O O 0.9999876022338867
negative O O 0.9999696016311646
coronary O O 0.9992115497589111
CTA O O 0.9824397563934326
in O O 0.9999436140060425
patients O O 0.9999910593032837
with O O 0.9999659061431885
cocaine B B 0.9898556470870972
- O O 0.9980534315109253
associated O O 0.9999347925186157
chest O O 0.9999853372573853
pain O O 0.9999861717224121
could O O 0.9999752044677734
identify O O 0.9999899864196777
a O O 0.9999732971191406
subset O O 0.9999558925628662
safe O O 0.9999951124191284
for O O 0.9999980926513672
discharge O O 0.9999953508377075
. O O 0.9999868869781494

METHODS O O 0.9997547268867493
: O O 0.999993085861206
We O O 0.9999877214431763
prospectively O O 0.9999918937683105
evaluated O O 0.9999958276748657
the O O 0.9999978542327881
safety O O 0.9999986886978149
of O O 0.9999560117721558
coronary O O 0.9941331744194031
CTA O O 0.888615071773529
for O O 0.9999408721923828
low O O 0.9998793601989746
- O O 0.9999886751174927
risk O O 0.9999966621398926
patients O O 0.9999982118606567
who O O 0.9999935626983643
presented O O 0.9999978542327881
to O O 0.9999946355819702
the O O 0.9999967813491821
ED O O 0.9999761581420898
with O O 0.999993085861206
cocaineassociated O O 0.836881160736084
chest O O 0.9999921321868896
pain O O 0.9999974966049194
( O O 0.9999866485595703
self O O 0.9999774694442749
- O O 0.9999932050704956
reported O O 0.9999985694885254
or O O 0.9999904632568359
positive O O 0.9999909400939941
urine O O 0.9998606443405151
test O O 0.9999679327011108
) O O 0.999983549118042
. O O 0.9999880790710449

Consecutive O O 0.99985671043396
patients O O 0.9999916553497314
received O O 0.9999779462814331
either O O 0.9999861717224121
immediate O O 0.9999681711196899
coronary O O 0.9989765882492065
CTA O O 0.9710761308670044
in O O 0.9999523162841797
the O O 0.999971866607666
ED O O 0.9994707703590393
( O O 0.9999710321426392
without O O 0.9999825954437256
serial O O 0.9824950695037842
markers O O 0.9999110698699951
) O O 0.9999486207962036
or O O 0.9999426603317261
underwent O O 0.9999852180480957
coronary O O 0.9993963241577148
CTA O O 0.9783032536506653
after O O 0.9999359846115112
a O O 0.9999898672103882
brief O O 0.9999911785125732
observation O O 0.9999934434890747
period O O 0.9999911785125732
with O O 0.9999860525131226
serial O O 0.9999687671661377
cardiac O O 0.9956503510475159
marker O O 0.9991909861564636
measurements O O 0.9999878406524658
. O O 0.9999667406082153

Patients O O 0.9999585151672363
with O O 0.9999834299087524
negative O O 0.9999659061431885
coronary O O 0.9997712969779968
CTA O O 0.9825960397720337
( O O 0.9999065399169922
maximal O O 0.9998650550842285
stenosis O O 0.9981114864349365
less O O 0.9999796152114868
than O O 0.9999881982803345
50 O O 0.9999920129776001
% O O 0.9999940395355225
) O O 0.9999644756317139
were O O 0.9999837875366211
discharged O O 0.9999862909317017
. O O 0.9999860525131226

The O O 0.9999749660491943
main O O 0.9999761581420898
outcome O O 0.9999957084655762
was O O 0.9999862909317017
30 O O 0.9999480247497559
- O O 0.9999822378158569
day O O 0.9999923706054688
cardiovascular O O 0.9999920129776001
death O O 0.9999980926513672
or O O 0.999984860420227
myocardial O O 0.9999977350234985
infarction O O 0.9999940395355225
. O O 0.9999701976776123

RESULTS O O 0.9998441934585571
: O O 0.9999659061431885
A O O 0.999983549118042
total O O 0.999987006187439
of O O 0.9999915361404419
59 O O 0.999992847442627
patients O O 0.9999942779541016
with O O 0.999961256980896
cocaine B B 0.9938586354255676
- O O 0.9982319474220276
associated O O 0.9998887777328491
chest O O 0.9999892711639404
pain O O 0.9999920129776001
were O O 0.9999781847000122
evaluated O O 0.9999881982803345
. O O 0.9999648332595825

Patients O O 0.9999310970306396
had O O 0.9999902248382568
a O O 0.9999921321868896
mean O O 0.999996542930603
age O O 0.9998389482498169
of O O 0.9999717473983765
45 O O 0.999998927116394
. O O 0.9999985694885254
6 O O 0.9999973773956299
+ O O 0.9999979734420776
/ O O 0.9999951124191284
- O O 0.9999788999557495
6 O O 0.9999970197677612
. O O 0.9999990463256836
6 O O 0.9999961853027344
yrs O O 0.9975886344909668
and O O 0.9999659061431885
were O O 0.9999922513961792
86 O O 0.9999955892562866
% O O 0.9999853372573853
black O O 0.9990981817245483
, O O 0.999235987663269
66 O O 0.9999926090240479
% O O 0.9999222755432129
male O O 0.9999221563339233
. O O 0.999972939491272

Seventy O O 0.9984055161476135
- O O 0.999968409538269
nine O O 0.9999822378158569
percent O O 0.9999951124191284
had O O 0.9999804496765137
a O O 0.9999903440475464
normal O O 0.9999845027923584
or O O 0.9999817609786987
nonspecific O O 0.9999371767044067
ECG O O 0.9978510141372681
and O O 0.9999281167984009
85 O O 0.9999408721923828
% O O 0.9999938011169434
had O O 0.9999914169311523
a O O 0.999984860420227
TIMI O O 0.9531417489051819
score O O 0.9999569654464722
< O O 0.9999679327011108
2 O O 0.9998190999031067
. O O 0.9999783039093018

Twenty O O 0.9997556805610657
patients O O 0.9999891519546509
received O O 0.9999514818191528
coronary O O 0.9956182241439819
CTA O O 0.5443930625915527
immediately O O 0.9999077320098877
in O O 0.9999619722366333
the O O 0.9999829530715942
ED O O 0.9997828602790833
, O O 0.9999904632568359
18 O O 0.9981200098991394
of O O 0.9999879598617554
whom O O 0.999984622001648
were O O 0.99998939037323
discharged O O 0.9999940395355225
following O O 0.9998584985733032
CTA O O 0.7914367318153381
( O O 0.9986554384231567
90 O O 0.9999908208847046
% O O 0.9999774694442749
) O O 0.9999840259552002
. O O 0.9999778270721436

Thirty O O 0.9561585187911987
- O O 0.9997565150260925
nine O O 0.9981556534767151
received O O 0.9999589920043945
coronary O O 0.9967178702354431
CTA O O 0.8514063358306885
after O O 0.9999610185623169
a O O 0.9999890327453613
brief O O 0.9999929666519165
observation O O 0.9999951124191284
period O O 0.9999899864196777
, O O 0.9999809265136719
with O O 0.9999749660491943
37 O O 0.9998890161514282
discharged O O 0.9999908208847046
home O O 0.9999972581863403
following O O 0.9999154806137085
CTA O O 0.5032579898834229
( O O 0.9997554421424866
95 O O 0.9999849796295166
% O O 0.999988317489624
) O O 0.9999843835830688
. O O 0.9999792575836182

Six O O 0.9998879432678223
patients O O 0.9999905824661255
had O O 0.999980092048645
coronary O O 0.9997231364250183
stenosis O O 0.9994339346885681
> O O 0.9998830556869507
or O O 0.999976396560669
= O O 0.9999876022338867
50 O O 0.9999809265136719
% O O 0.9999954700469971
. O O 0.9999704360961914

During O O 0.9999716281890869
the O O 0.9999953508377075
30 O O 0.999993085861206
- O O 0.9999897480010986
day O O 0.999996542930603
follow O O 0.9999933242797852
- O O 0.9999903440475464
up O O 0.9999932050704956
period O O 0.9999898672103882
, O O 0.9999619722366333
no O O 0.9999200105667114
patients O O 0.9999897480010986
died O O 0.9999926090240479
of O O 0.9999676942825317
a O O 0.9999686479568481
cardiovascular O O 0.9999889135360718
event O O 0.9999983310699463
( O O 0.999915599822998
0 O O 0.9999761581420898
% O O 0.9999555349349976
; O O 0.9997246861457825
95 O O 0.9971309304237366
% O O 0.9990168809890747
CI O O 0.990616500377655
, O O 0.9997001886367798
0 O O 0.99885094165802
- O O 0.9965118765830994
6 O O 0.9998072981834412
. O O 0.9999808073043823
1 O O 0.9999933242797852
% O O 0.999883770942688
) O O 0.999961256980896
and O O 0.9999663829803467
no O O 0.9999128580093384
patient O O 0.9999884366989136
sustained O O 0.9999600648880005
a O O 0.9999697208404541
nonfatal O O 0.981620192527771
myocardial O O 0.9999951124191284
infarction O O 0.9999597072601318
( O O 0.9999446868896484
0 O O 0.9999725818634033
% O O 0.9999858140945435
; O O 0.9999226331710815
95 O O 0.9962109327316284
% O O 0.9993540644645691
CI O O 0.9920463562011719
, O O 0.9997571110725403
0 O O 0.9994361996650696
- O O 0.996737539768219
6 O O 0.9995917677879333
. O O 0.9999803304672241
1 O O 0.99998939037323
% O O 0.9999816417694092
) O O 0.9999576807022095
. O O 0.999974250793457

CONCLUSIONS O O 0.9996505975723267
: O O 0.9999911785125732
Although O O 0.9998830556869507
cocaine B B 0.9969985485076904
- O O 0.9984362721443176
associated O O 0.9998687505722046
myocardial O O 0.9999978542327881
ischemia O O 0.9999912977218628
can O O 0.9998911619186401
result O O 0.9999816417694092
from O O 0.9998449087142944
coronary O O 0.9928202033042908
vasoconstriction O O 0.9996317625045776
, O O 0.9999598264694214
patients O O 0.9999957084655762
with O O 0.9999864101409912
cocaine B B 0.9944091439247131
associated O O 0.9993271827697754
chest O O 0.9999897480010986
pain O O 0.9999963045120239
, O O 0.9999822378158569
a O O 0.9999817609786987
non O O 0.9947409629821777
- O O 0.9998447895050049
ischemic O O 0.999941349029541
ECG O O 0.9997040629386902
, O O 0.9999401569366455
and O O 0.9999666213989258
a O O 0.9999899864196777
TIMI O O 0.9820632934570312
risk O O 0.9998372793197632
score O O 0.999976634979248
< O O 0.9999529123306274
2 O O 0.9998382329940796
may O O 0.999993085861206
be O O 0.9999983310699463
safely O O 0.9999986886978149
discharged O O 0.999998927116394
from O O 0.9999963045120239
the O O 0.9999901056289673
ED O O 0.9999042749404907
after O O 0.9999970197677612
a O O 0.9999963045120239
negative O O 0.9999874830245972
coronary O O 0.9972694516181946
CTA O O 0.9809834361076355
with O O 0.9999874830245972
a O O 0.9999940395355225
low O O 0.9999970197677612
risk O O 0.9999986886978149
of O O 0.9999932050704956
30 O O 0.999980092048645
- O O 0.9999924898147583
day O O 0.9999972581863403
adverse O O 0.999984860420227
events O O 0.9999995231628418
. O O 0.9999905824661255

Bilateral O O 0.9998887777328491
haemorrhagic O O 0.99809330701828
infarction O O 0.9999839067459106
of O O 0.9999183416366577
the O O 0.9999380111694336
globus O O 0.9816129207611084
pallidus O O 0.9970830082893372
after O O 0.9995154142379761
cocaine B B 0.9927162528038025
and O O 0.9100390672683716
alcohol B B 0.9007742404937744
intoxication O O 0.989030659198761
. O O 0.9999394416809082

Cocaine B O 0.8632487058639526
is O O 0.9977800250053406
a O O 0.9993492960929871
risk O O 0.999946117401123
factor O O 0.9999773502349854
for O O 0.9999351501464844
both O O 0.9996180534362793
ischemic O O 0.99997878074646
and O O 0.9998292922973633
haemorrhagic O O 0.9987014532089233
stroke O O 0.9999943971633911
. O O 0.9999486207962036

We O O 0.9999905824661255
present O O 0.9999958276748657
the O O 0.9999971389770508
case O O 0.9999940395355225
of O O 0.9999896287918091
a O O 0.9999929666519165
31 O O 0.9999954700469971
- O O 0.9999896287918091
year O O 0.9999970197677612
- O O 0.999994158744812
old O O 0.9999953508377075
man O O 0.9999960660934448
with O O 0.999958872795105
bilateral O O 0.999703586101532
ischemia O O 0.9999908208847046
of O O 0.9999403953552246
the O O 0.9999783039093018
globus O O 0.9840785264968872
pallidus O O 0.9987218976020813
after O O 0.9997244477272034
excessive O O 0.9992663264274597
alcohol B B 0.9661480188369751
and O O 0.9618350863456726
intranasal O O 0.9887931942939758
cocaine B B 0.9966433048248291
use O O 0.9981471300125122
. O O 0.9999692440032959

Drug O O 0.6776994466781616
- O O 0.9997150301933289
related O O 0.9998637437820435
globus O O 0.9763532876968384
pallidus O O 0.9980738162994385
infarctions O O 0.9999643564224243
are O O 0.9999279975891113
most O O 0.9999512434005737
often O O 0.999948263168335
associated O O 0.9999638795852661
with O O 0.9997649788856506
heroin B O 0.8539665937423706
. O O 0.9997321963310242

Bilateral O O 0.9999326467514038
basal O O 0.9999207258224487
ganglia O O 0.999987006187439
infarcts O O 0.9999779462814331
after O O 0.9996814727783203
the O O 0.9999462366104126
use O O 0.9982914328575134
of O O 0.9787241220474243
cocaine B B 0.9937880635261536
, O O 0.9996662139892578
without O O 0.9999686479568481
concurrent O O 0.999861478805542
heroin B B 0.9548070430755615
use O O 0.9983853101730347
, O O 0.9999775886535645
have O O 0.9999854564666748
never O O 0.9999821186065674
been O O 0.9999939203262329
reported O O 0.9999935626983643
. O O 0.9999765157699585

In O O 0.9999802112579346
our O O 0.9999750852584839
patient O O 0.9999856948852539
, O O 0.9999126195907593
transient O O 0.9999593496322632
cardiac O O 0.9999891519546509
arrhythmia O O 0.9999704360961914
or O O 0.9998230338096619
respiratory O O 0.9999794960021973
dysfunction O O 0.9999967813491821
related O O 0.9999780654907227
to O O 0.999038815498352
cocaine B B 0.9958013892173767
and O O 0.9929741621017456
/ O O 0.9967334270477295
or O O 0.9980512857437134
ethanol B B 0.990763247013092
use O O 0.9975801706314087
were O O 0.9999476671218872
the O O 0.9999737739562988
most O O 0.9999842643737793
likely O O 0.9999765157699585
causes O O 0.9999778270721436
of O O 0.9999679327011108
cerebral O O 0.9999936819076538
hypoperfusion O O 0.9999594688415527
. O O 0.999981164932251

Late O O 0.9999324083328247
fulminant O O 0.999950647354126
posterior O O 0.9980477094650269
reversible O O 0.9999169111251831
encephalopathy O O 0.9999557733535767
syndrome O O 0.9999932050704956
after O O 0.9997935891151428
liver O O 0.9819847941398621
transplant O O 0.9998692274093628
. O O 0.9999582767486572

OBJECTIVES O O 0.9892668724060059
: O O 0.9999383687973022
Posterior O O 0.9998676776885986
leukoencephalopathy O O 0.9999876022338867
due O O 0.9999805688858032
to O O 0.9995713829994202
calcineurin O O 0.8476824760437012
- O O 0.5884643793106079
inhibitor O O 0.8773829340934753
- O O 0.9922184944152832
related O O 0.9999057054519653
neurotoxicity O O 0.9999830722808838
is O O 0.999977707862854
a O O 0.9999821186065674
rare O O 0.9999940395355225
but O O 0.9999889135360718
severe O O 0.9999659061431885
complication O O 0.9999948740005493
that O O 0.9999830722808838
results O O 0.9999945163726807
from O O 0.9998908042907715
treatment O O 0.9999808073043823
with O O 0.9999010562896729
immunosuppressive O O 0.9991397857666016
agents O O 0.9937337040901184
( O O 0.9999457597732544
primarily O O 0.9998103976249695
those O O 0.9999299049377441
administered O O 0.9999213218688965
after O O 0.9999744892120361
a O O 0.9999927282333374
liver O O 0.9999191761016846
or O O 0.9999372959136963
kidney O O 0.9999536275863647
transplant O O 0.9999879598617554
) O O 0.9999819993972778
. O O 0.9999703168869019

The O O 0.999902606010437
pathophysiologic O O 0.9999440908432007
mechanisms O O 0.9999762773513794
of O O 0.9999452829360962
that O O 0.9998144507408142
disorder O O 0.999971866607666
remain O O 0.9999399185180664
unknown O O 0.9999451637268066
. O O 0.9999436140060425

CASE O O 0.9999688863754272
: O O 0.9999958276748657
We O O 0.9999945163726807
report O O 0.9999980926513672
the O O 0.9999984502792358
case O O 0.9999971389770508
of O O 0.9999929666519165
a O O 0.999995231628418
46 O O 0.9999973773956299
- O O 0.9999833106994629
year O O 0.9999967813491821
- O O 0.9999927282333374
old O O 0.9999959468841553
woman O O 0.9999982118606567
who O O 0.999969482421875
received O O 0.999982476234436
a O O 0.9999926090240479
liver O O 0.9979562759399414
transplant O O 0.9999427795410156
in O O 0.9999871253967285
our O O 0.9999901056289673
center O O 0.9999969005584717
as O O 0.9999263286590576
treatment O O 0.999990701675415
for O O 0.9999802112579346
alcoholic O O 0.9478275179862976
cirrhosis O O 0.9957587122917175
and O O 0.9999759197235107
in O O 0.999957799911499
whom O O 0.999982476234436
either O O 0.999948263168335
a O O 0.9999725818634033
fulminant O O 0.9999679327011108
course O O 0.999982476234436
of O O 0.9999663829803467
posterior O O 0.9997643828392029
leukoencephalopathy O O 0.9999722242355347
or O O 0.999875545501709
posterior O O 0.9994109869003296
reversible O O 0.9999513626098633
encephalopathy O O 0.999956488609314
syndrome O O 0.9999903440475464
developed O O 0.9999980926513672
110 O O 0.9999914169311523
days O O 0.9999984502792358
after O O 0.9999886751174927
transplant O O 0.999976396560669
. O O 0.9999836683273315

After O O 0.9999703168869019
an O O 0.999995231628418
initially O O 0.9999938011169434
uneventful O O 0.9999855756759644
course O O 0.9999955892562866
after O O 0.9999752044677734
the O O 0.9999740123748779
transplant O O 0.9999608993530273
, O O 0.9999769926071167
the O O 0.9999948740005493
patient O O 0.9999876022338867
rapidly O O 0.9999915361404419
fell O O 0.9999948740005493
into O O 0.9999773502349854
deep O O 0.9998797178268433
coma O O 0.9999938011169434
. O O 0.9999624490737915

RESULTS O O 0.999697208404541
: O O 0.9998950958251953
Cerebral O O 0.999645471572876
MRI O O 0.9519342184066772
scan O O 0.9997555613517761
showed O O 0.9997501969337463
typical O O 0.9998639822006226
signs O O 0.9999616146087646
of O O 0.999841570854187
enhancement O O 0.9992897510528564
in O O 0.9995436072349548
the O O 0.9998024106025696
pontine O O 0.975047767162323
and O O 0.9986623525619507
posterior O O 0.9998719692230225
regions O O 0.9999666213989258
. O O 0.9999589920043945

Switching O O 0.9999487400054932
the O O 0.9999324083328247
immunosuppressive O O 0.9988064765930176
regimen O O 0.9978925585746765
from O O 0.9995038509368896
tacrolimus B B 0.9996426105499268
to O O 0.9642763137817383
cyclosporine B B 0.9981703758239746
did O O 0.9999459981918335
not O O 0.9999818801879883
improve O O 0.9999908208847046
the O O 0.9999953508377075
clinical O O 0.9999977350234985
situation O O 0.9999994039535522
. O O 0.9999788999557495

The O O 0.9999885559082031
termination O O 0.9999712705612183
of O O 0.9999080896377563
treatment O O 0.9999661445617676
with O O 0.9998785257339478
any O O 0.996855616569519
calcineurin O O 0.5047820210456848
inhibitor O O 0.61456698179245
resulted O O 0.9999243021011353
in O O 0.9999785423278809
a O O 0.9999887943267822
complete O O 0.9999836683273315
resolution O O 0.9999927282333374
of O O 0.999976396560669
that O O 0.9999403953552246
complication O O 0.9999923706054688
. O O 0.9999722242355347

CONCLUSIONS O O 0.96120685338974
: O O 0.9998668432235718
Posterior O O 0.9962149262428284
reversible O O 0.9999445676803589
encephalopathy O O 0.9999434947967529
syndrome O O 0.9999803304672241
after O O 0.9998635053634644
liver O O 0.9511199593544006
transplant O O 0.9998161196708679
is O O 0.9999680519104004
rare O O 0.9999752044677734
. O O 0.9999504089355469

We O O 0.9999567270278931
recommend O O 0.9999783039093018
a O O 0.9999874830245972
complete O O 0.9999476671218872
cessation O O 0.9998897314071655
of O O 0.999853253364563
any O O 0.9984195232391357
calcineurin O O 0.5698348879814148
inhibitor O O 0.5077649354934692
rather O O 0.9999181032180786
than O O 0.9999823570251465
a O O 0.999985933303833
dose O O 0.999736487865448
reduction O O 0.9999879598617554
. O O 0.999866247177124

Prolonged O O 0.999792754650116
hypothermia O O 0.9962322115898132
as O O 0.9999028444290161
a O O 0.9999185800552368
bridge O O 0.9999914169311523
to O O 0.9999326467514038
recovery O O 0.9999896287918091
for O O 0.9999493360519409
cerebral O O 0.9999908208847046
edema O O 0.9999874830245972
and O O 0.9999470710754395
intracranial O O 0.9999791383743286
hypertension O O 0.9998451471328735
associated O O 0.9999648332595825
with O O 0.9999814033508301
fulminant O O 0.9999722242355347
hepatic O O 0.999772846698761
failure O O 0.9999912977218628
. O O 0.9999014139175415

BACKGROUND O O 0.9998476505279541
: O O 0.9999948740005493
To O O 0.9999971389770508
review O O 0.9999953508377075
evidence O O 0.9998144507408142
- O O 0.9999836683273315
based O O 0.9999438524246216
treatment O O 0.9999711513519287
options O O 0.9999847412109375
in O O 0.9999656677246094
patients O O 0.9999945163726807
with O O 0.9999879598617554
cerebral O O 0.9999682903289795
edema O O 0.9999939203262329
complicating O O 0.9999756813049316
fulminant O O 0.9997479319572449
hepatic O O 0.998611330986023
failure O O 0.9999939203262329
( O O 0.9999420642852783
FHF O O 0.9976480603218079
) O O 0.9999673366546631
and O O 0.9999748468399048
discuss O O 0.9999797344207764
the O O 0.9999908208847046
potential O O 0.9999903440475464
applications O O 0.9999949932098389
of O O 0.9998703002929688
hypothermia O O 0.9834263324737549
. O O 0.9999347925186157

METHOD O O 0.9998989105224609
: O O 0.9999927282333374
Case O O 0.9999591112136841
- O O 0.9999938011169434
based O O 0.9999951124191284
observations O O 0.9999963045120239
from O O 0.9999899864196777
a O O 0.999976396560669
medical O O 0.999976634979248
intensive O O 0.9999935626983643
care O O 0.9999858140945435
unit O O 0.999994158744812
( O O 0.9999433755874634
MICU O O 0.9998475313186646
) O O 0.9999810457229614
in O O 0.9999722242355347
a O O 0.9999923706054688
tertiary O O 0.9999648332595825
care O O 0.9999946355819702
facility O O 0.9999953508377075
in O O 0.9999899864196777
a O O 0.9999915361404419
27 O O 0.9999901056289673
- O O 0.9999867677688599
year O O 0.999996542930603
- O O 0.9999953508377075
old O O 0.9999966621398926
female O O 0.9999973773956299
with O O 0.9999481439590454
FHF O O 0.9785194993019104
from O O 0.9905955791473389
acetaminophen B B 0.9974453449249268
and O O 0.9997580647468567
resultant O O 0.999994158744812
cerebral O O 0.9999947547912598
edema O O 0.9999954700469971
. O O 0.9999823570251465

RESULTS O O 0.9995837807655334
: O O 0.99998939037323
Our O O 0.9999759197235107
patient O O 0.9999899864196777
was O O 0.9999804496765137
admitted O O 0.9999847412109375
to O O 0.9999772310256958
the O O 0.9999814033508301
MICU O O 0.9994450211524963
after O O 0.9999862909317017
being O O 0.9999964237213135
found O O 0.9999969005584717
unresponsive O O 0.9999864101409912
with O O 0.999981164932251
presumed O O 0.9997743964195251
toxicity O O 0.9999434947967529
from O O 0.998805046081543
acetaminophen B B 0.9978160858154297
which O O 0.9992103576660156
was O O 0.9999613761901855
ingested O O 0.9998408555984497
over O O 0.9999539852142334
a O O 0.9999847412109375
2 O O 0.999925971031189
- O O 0.9999871253967285
day O O 0.999984622001648
period O O 0.9999860525131226
. O O 0.9999736547470093

The O O 0.9999743700027466
patient O O 0.9999843835830688
had O O 0.9999532699584961
depressed O O 0.9999880790710449
of O O 0.9999877214431763
mental O O 0.9999961853027344
status O O 0.9999876022338867
lasting O O 0.9999555349349976
at O O 0.9999890327453613
least O O 0.9999912977218628
24 O O 0.9999740123748779
h O O 0.9979515671730042
prior O O 0.9999985694885254
to O O 0.9999961853027344
admission O O 0.9999914169311523
. O O 0.999964714050293

Initial O O 0.9999288320541382
evaluation O O 0.9999920129776001
confirmed O O 0.9998704195022583
FHF O O 0.9819127321243286
from O O 0.9970797896385193
acetaminophen B B 0.9990046620368958
and O O 0.9994718432426453
cerebral O O 0.9999884366989136
edema O O 0.9999791383743286
. O O 0.999964714050293

The O O 0.9999839067459106
patient O O 0.9999809265136719
was O O 0.9999512434005737
treated O O 0.9999704360961914
with O O 0.9998900890350342
hyperosmolar O O 0.9499166011810303
therapy O O 0.9997387528419495
, O O 0.9997441172599792
hyperventilation O O 0.9816395044326782
, O O 0.9992777705192566
sedation O O 0.9975873231887817
, O O 0.9995346069335938
and O O 0.9995393753051758
chemical O O 0.9987743496894836
paralysis O O 0.9757959246635437
. O O 0.9998995065689087

Her O O 0.9999686479568481
intracranial O O 0.9999898672103882
pressure O O 0.9999030828475952
remained O O 0.9999752044677734
elevated O O 0.9999860525131226
despite O O 0.9999096393585205
maximal O O 0.999968409538269
medical O O 0.9999853372573853
therapy O O 0.9999840259552002
. O O 0.9999680519104004

We O O 0.999896764755249
then O O 0.9999558925628662
initiated O O 0.9999691247940063
therapeutic O O 0.9998749494552612
hypothermia O O 0.998173713684082
which O O 0.9999243021011353
was O O 0.9999696016311646
continued O O 0.9999680519104004
for O O 0.999981164932251
5 O O 0.9999377727508545
days O O 0.9999926090240479
. O O 0.999982476234436

At O O 0.9997925162315369
re O O 0.9999582767486572
- O O 0.9999465942382812
warming O O 0.9999793767929077
, O O 0.9999833106994629
patient O O 0.9999630451202393
had O O 0.9999872446060181
resolution O O 0.9999927282333374
of O O 0.999988317489624
her O O 0.9999904632568359
cerebral O O 0.9999901056289673
edema O O 0.999984622001648
and O O 0.9999470710754395
intracranial O O 0.9999752044677734
hypertension O O 0.9996614456176758
. O O 0.9999759197235107

At O O 0.9999265670776367
discharge O O 0.999983549118042
, O O 0.9999836683273315
she O O 0.9999847412109375
had O O 0.9999788999557495
complete O O 0.9999624490737915
recovery O O 0.9999918937683105
of O O 0.9999735355377197
neurological O O 0.9999794960021973
and O O 0.9999610185623169
hepatic O O 0.9998420476913452
functions O O 0.9999903440475464
. O O 0.9999872446060181

CONCLUSION O O 0.9994414448738098
: O O 0.9999693632125854
In O O 0.9999688863754272
patients O O 0.9999914169311523
with O O 0.9999709129333496
FHF O O 0.9932679533958435
and O O 0.999904990196228
cerebral O O 0.9999884366989136
edema O O 0.9999947547912598
from O O 0.9998132586479187
acetaminophen B B 0.9979491829872131
overdose O O 0.9966554641723633
, O O 0.9999035596847534
prolonged O O 0.9998722076416016
therapeutic O O 0.999852180480957
hypothermia O O 0.9781866669654846
could O O 0.99994957447052
potentially O O 0.9999741315841675
be O O 0.9999854564666748
used O O 0.9999672174453735
as O O 0.9999728202819824
a O O 0.999936580657959
life O O 0.9998252987861633
saving O O 0.9998258948326111
therapy O O 0.9999728202819824
and O O 0.9999802112579346
a O O 0.9999665021896362
bridge O O 0.9999940395355225
to O O 0.9999721050262451
hepatic O O 0.9997485280036926
and O O 0.9999356269836426
neurological O O 0.9999922513961792
recovery O O 0.9999955892562866
. O O 0.9999839067459106

A O O 0.9999629259109497
clinical O O 0.9999779462814331
trial O O 0.999990701675415
of O O 0.9998472929000854
hypothermia O O 0.9893604516983032
in O O 0.999932050704956
patients O O 0.9999903440475464
with O O 0.9999879598617554
this O O 0.9999661445617676
condition O O 0.9999957084655762
is O O 0.999964714050293
warranted O O 0.999975323677063
. O O 0.9999783039093018

Binasal O O 0.974284827709198
visual O O 0.999942421913147
field O O 0.9999887943267822
defects O O 0.9999954700469971
are O O 0.9999754428863525
not O O 0.9999853372573853
specific O O 0.9999637603759766
to O O 0.9994346499443054
vigabatrin B B 0.9958945512771606
. O O 0.9998979568481445

This O O 0.9999704360961914
study O O 0.9999778270721436
investigated O O 0.9999426603317261
the O O 0.9999731779098511
visual O O 0.9999829530715942
defects O O 0.9999984502792358
associated O O 0.9999873638153076
with O O 0.9998594522476196
the O O 0.9997914433479309
antiepileptic O O 0.7367215156555176
drug O O 0.9490298628807068
vigabatrin B B 0.9720777273178101
( O O 0.9903551340103149
VGB B B 0.9908618927001953
) O O 0.9990781545639038
. O O 0.999940037727356

Two O O 0.9999747276306152
hundred O O 0.9999861717224121
four O O 0.9999920129776001
people O O 0.9999957084655762
with O O 0.9999821186065674
epilepsy O O 0.9999046325683594
were O O 0.9999414682388306
grouped O O 0.9998693466186523
on O O 0.9999691247940063
the O O 0.9999929666519165
basis O O 0.9999788999557495
of O O 0.9998809099197388
antiepileptic O O 0.790799617767334
drug O O 0.9924092292785645
therapy O O 0.999861478805542
( O O 0.9997201561927795
current O O 0.9996898174285889
, O O 0.9995212554931641
previous O O 0.9779682755470276
, O O 0.9995146989822388
or O O 0.9999065399169922
no O O 0.9993684887886047
exposure O O 0.9999610185623169
to O O 0.9984924793243408
VGB B B 0.8449365496635437
) O O 0.999201238155365
. O O 0.999958872795105

Groups O O 0.9999510049819946
were O O 0.9999723434448242
matched O O 0.9999736547470093
with O O 0.9999969005584717
respect O O 0.9999983310699463
to O O 0.9999958276748657
age O O 0.999977707862854
, O O 0.9999908208847046
gender O O 0.9999949932098389
, O O 0.9999648332595825
and O O 0.9999899864196777
seizure O O 0.9999780654907227
frequency O O 0.9999939203262329
. O O 0.9999790191650391

All O O 0.9999761581420898
patients O O 0.999992847442627
underwent O O 0.9999872446060181
objective O O 0.9999858140945435
assessment O O 0.9999971389770508
of O O 0.9999843835830688
electrophysiological O O 0.9999499320983887
function O O 0.9999955892562866
( O O 0.9999152421951294
wide O O 0.9949491024017334
- O O 0.9999325275421143
field O O 0.9999850988388062
multifocal O O 0.988661527633667
electroretinography O O 0.9954975843429565
) O O 0.99994957447052
and O O 0.9999794960021973
conventional O O 0.9999703168869019
visual O O 0.999927282333374
field O O 0.9999879598617554
testing O O 0.9999926090240479
( O O 0.9997705817222595
static O O 0.9998206496238708
perimetry O O 0.999883770942688
) O O 0.9999744892120361
. O O 0.9999783039093018

Bilateral O O 0.9998028874397278
visual O O 0.9999641180038452
field O O 0.9999876022338867
constriction O O 0.9999657869338989
was O O 0.999967098236084
observed O O 0.9999872446060181
in O O 0.9999090433120728
59 O O 0.9999946355819702
% O O 0.9999938011169434
of O O 0.9999823570251465
patients O O 0.9999853372573853
currently O O 0.9998527765274048
taking O O 0.9976517558097839
VGB B B 0.9940693378448486
, O O 0.9997492432594299
43 O O 0.9999768733978271
% O O 0.9999915361404419
of O O 0.9999732971191406
patients O O 0.9999897480010986
who O O 0.999954342842102
previously O O 0.9995675683021545
took O O 0.9988679885864258
VGB B B 0.9870455265045166
, O O 0.9991826415061951
and O O 0.9999397993087769
24 O O 0.9999746084213257
% O O 0.9999926090240479
of O O 0.9999808073043823
patients O O 0.9999892711639404
with O O 0.9999779462814331
no O O 0.9999028444290161
exposure O O 0.999991774559021
to O O 0.9998366832733154
VGB B B 0.9894446730613708
. O O 0.9999022483825684

Assessment O O 0.9999837875366211
of O O 0.9999692440032959
retinal O O 0.9999719858169556
function O O 0.9999889135360718
revealed O O 0.9999489784240723
abnormal O O 0.999956488609314
responses O O 0.9999910593032837
in O O 0.9999040365219116
48 O O 0.999961256980896
% O O 0.9999699592590332
of O O 0.9998940229415894
current O O 0.9996452331542969
VGB B B 0.9036816358566284
users O O 0.9872621893882751
and O O 0.9998513460159302
22 O O 0.9999514818191528
% O O 0.9999672174453735
of O O 0.9998936653137207
prior O O 0.99982088804245
VGB B B 0.8881242275238037
users O O 0.9931811690330505
, O O 0.9999574422836304
but O O 0.999951958656311
in O O 0.9999387264251709
none O O 0.9999864101409912
of O O 0.9999668598175049
the O O 0.9999881982803345
patients O O 0.9999903440475464
without O O 0.999980092048645
previous O O 0.9999641180038452
exposure O O 0.9999885559082031
to O O 0.999822199344635
VGB B B 0.955466628074646
. O O 0.9998911619186401

Bilateral O O 0.9998834133148193
visual O O 0.999946117401123
field O O 0.9999899864196777
abnormalities O O 0.9999945163726807
are O O 0.9999784231185913
common O O 0.9999885559082031
in O O 0.9999247789382935
the O O 0.9999161958694458
treated O O 0.9434260129928589
epilepsy O O 0.9989433884620667
population O O 0.9998764991760254
, O O 0.9999830722808838
irrespective O O 0.9999933242797852
of O O 0.9999430179595947
drug O O 0.9982208609580994
history O O 0.9999369382858276
. O O 0.999970555305481

Assessment O O 0.9999853372573853
by O O 0.9999854564666748
conventional O O 0.999966025352478
static O O 0.9996155500411987
perimetry O O 0.999733030796051
may O O 0.9999604225158691
neither O O 0.9999850988388062
be O O 0.9999834299087524
sufficiently O O 0.9999527931213379
sensitive O O 0.9999825954437256
nor O O 0.9999445676803589
specific O O 0.9999761581420898
to O O 0.9999927282333374
reliably O O 0.9999972581863403
identify O O 0.9999662637710571
retinal O O 0.9997931122779846
toxicity O O 0.9999266862869263
associated O O 0.9999710321426392
with O O 0.9997629523277283
VGB B B 0.9557316899299622
. O O 0.9998956918716431

Smoking O O 0.5560606718063354
of O O 0.8474517464637756
crack B B 0.9584163427352905
cocaine I I 0.9907467365264893
as O O 0.9997836947441101
a O O 0.9996985197067261
risk O O 0.9998317956924438
factor O O 0.9999727010726929
for O O 0.9998210072517395
HIV O O 0.9631355404853821
infection O O 0.9999721050262451
among O O 0.9999098777770996
people O O 0.999987006187439
who O O 0.9998962879180908
use O O 0.9929754734039307
injection O O 0.6443881392478943
drugs O O 0.8825809359550476
. O O 0.9998565912246704

BACKGROUND O O 0.9862470626831055
: O O 0.9999712705612183
Little O O 0.9999855756759644
is O O 0.9999831914901733
known O O 0.9999860525131226
about O O 0.9999675750732422
the O O 0.9999665021896362
possible O O 0.9999178647994995
role O O 0.9999681711196899
that O O 0.9998677968978882
smoking O O 0.5834635496139526
crack B B 0.9015874862670898
cocaine I I 0.9976773858070374
has O O 0.9992293119430542
on O O 0.9998630285263062
the O O 0.9999886751174927
incidence O O 0.9999954700469971
of O O 0.9999721050262451
HIV O O 0.9926828742027283
infection O O 0.9999889135360718
. O O 0.9999358654022217

Given O O 0.9999895095825195
the O O 0.9999933242797852
increasing O O 0.999990701675415
use O O 0.999723494052887
of O O 0.9995211362838745
crack B B 0.9638793468475342
cocaine I I 0.9299497604370117
, O O 0.9994365572929382
we O O 0.999974250793457
sought O O 0.9999969005584717
to O O 0.9999963045120239
examine O O 0.9999967813491821
whether O O 0.9999905824661255
use O O 0.9997898936271667
of O O 0.9984765648841858
this O O 0.9847620725631714
illicit O O 0.7439180612564087
drug O O 0.8903962969779968
has O O 0.9999573230743408
become O O 0.9999899864196777
a O O 0.9999388456344604
risk O O 0.9999620914459229
factor O O 0.9999938011169434
for O O 0.9999254941940308
HIV O O 0.9792405962944031
infection O O 0.999984860420227
. O O 0.999950647354126

METHODS O O 0.9998553991317749
: O O 0.9999831914901733
We O O 0.9999828338623047
included O O 0.9999892711639404
data O O 0.9999822378158569
from O O 0.9999829530715942
people O O 0.999992847442627
participating O O 0.9999939203262329
in O O 0.9999891519546509
the O O 0.9999852180480957
Vancouver O B 0.9660623073577881
Injection O O 0.5507744550704956
Drug O O 0.9107065200805664
Users O O 0.9982129335403442
Study O O 0.9999563694000244
who O O 0.9999451637268066
reported O O 0.9999815225601196
injecting O O 0.9999699592590332
illicit O O 0.9009736776351929
drugs O O 0.993643045425415
at O O 0.9999672174453735
least O O 0.9999878406524658
once O O 0.9999573230743408
in O O 0.999991774559021
the O O 0.9999961853027344
month O O 0.9999986886978149
before O O 0.9999974966049194
enrolment O O 0.9999918937683105
, O O 0.9999834299087524
lived O O 0.9815682768821716
in O O 0.9999094009399414
the O O 0.9999788999557495
greater O O 0.9997976422309875
Vancouver O B 0.9702035784721375
area O O 0.9894528388977051
, O O 0.9999867677688599
were O O 0.9999878406524658
HIV O O 0.6276512145996094
- O O 0.9982395172119141
negative O O 0.9998694658279419
at O O 0.9999754428863525
enrolment O O 0.9999778270721436
and O O 0.9999932050704956
completed O O 0.9999970197677612
at O O 0.9999973773956299
least O O 0.999998927116394
1 O O 0.9999963045120239
follow O O 0.9999955892562866
- O O 0.9999945163726807
up O O 0.9999948740005493
study O O 0.999984622001648
visit O O 0.9999986886978149
. O O 0.9999783039093018

To O O 0.9999922513961792
determine O O 0.9999946355819702
whether O O 0.9999922513961792
the O O 0.999995231628418
risk O O 0.9999963045120239
of O O 0.9999815225601196
HIV O O 0.900262176990509
seroconversion O O 0.9997898936271667
among O O 0.9994983673095703
daily O O 0.9948717951774597
smokers O O 0.6569154262542725
of O O 0.9968048334121704
crack B B 0.8785337805747986
cocaine I I 0.9970502853393555
changed O O 0.9998950958251953
over O O 0.9999969005584717
time O O 0.9999959468841553
, O O 0.9999903440475464
we O O 0.9999867677688599
used O O 0.9999713897705078
Cox O O 0.6313640475273132
proportional O O 0.9993322491645813
hazards O O 0.996917724609375
regression O O 0.9993689656257629
and O O 0.9999854564666748
divided O O 0.9999966621398926
the O O 0.9999972581863403
study O O 0.9999927282333374
into O O 0.999944806098938
3 O O 0.9997004270553589
periods O O 0.9999661445617676
: O O 0.9999581575393677
May O O 0.9997175335884094
1 O O 0.9991753697395325
, O O 0.9992695450782776
1996 O O 0.8437087535858154
- O O 0.983245849609375
Nov O O 0.5874690413475037
. O O 0.9999443292617798

30 O O 0.9699325561523438
, O O 0.9777109026908875
1999 O O 0.5076369643211365
( O O 0.9918713569641113
period O O 0.9992215633392334
1 O O 0.9970073103904724
) O O 0.9991414546966553
, O O 0.9606461524963379
Dec O O 0.8956499099731445
. O O 0.9995537400245667

1 O O 0.8465448617935181
, O O 0.9314646124839783
1999 O O 0.8591837882995605
- O O 0.9665611386299133
Nov O O 0.4772854149341583
. O O 0.9971737861633301

30 O O 0.9890967607498169
, O O 0.998508632183075
2002 O O 0.5070545077323914
( O O 0.9986287355422974
period O O 0.9995458722114563
2 O O 0.9871882200241089
) O O 0.9998037219047546
, O O 0.9962038397789001
and O O 0.9968591928482056
Dec O O 0.8060029745101929
. O O 0.999826967716217

1 O O 0.977172315120697
, O O 0.9851303100585938
2002 O O 0.9669522643089294
- O O 0.9844096899032593
Dec O O 0.9733344316482544
. O O 0.9952667951583862

30 O O 0.9798848628997803
, O O 0.9970607161521912
2005 O O 0.9451813101768494
( O O 0.9997274279594421
period O O 0.9996857643127441
3 O O 0.9985112547874451
) O O 0.9997804760932922
. O O 0.999874472618103

RESULTS O O 0.9998341798782349
: O O 0.9999285936355591
Overall O O 0.9999738931655884
, O O 0.9999814033508301
1048 O O 0.9931226372718811
eligible O O 0.987338662147522
injection O O 0.5166294574737549
drug O O 0.5128297805786133
users O O 0.9977704286575317
were O O 0.9999459981918335
included O O 0.9999752044677734
in O O 0.9999769926071167
our O O 0.9999744892120361
study O O 0.9999727010726929
. O O 0.999961256980896

Of O O 0.9980641007423401
these O O 0.9999089241027832
, O O 0.9996926784515381
137 O O 0.8486496210098267
acquired O O 0.9999549388885498
HIV O O 0.978224515914917
infection O O 0.9999133348464966
during O O 0.9999176263809204
follow O O 0.9999761581420898
- O O 0.9999927282333374
up O O 0.9999946355819702
. O O 0.9999622106552124

The O O 0.9999834299087524
mean O O 0.9999892711639404
proportion O O 0.9999864101409912
of O O 0.9999489784240723
participants O O 0.9999812841415405
who O O 0.9998772144317627
reported O O 0.9999213218688965
daily O O 0.9996021389961243
smoking O B 0.8785043358802795
of O O 0.888999879360199
crack B B 0.9571245312690735
cocaine I I 0.9824736714363098
increased O O 0.9997736811637878
from O O 0.9999856948852539
11 O O 0.9999539852142334
. O O 0.9999899864196777
6 O O 0.9999953508377075
% O O 0.9999788999557495
in O O 0.9999058246612549
period O O 0.9999051094055176
1 O O 0.9999752044677734
to O O 0.9999698400497437
39 O O 0.9999858140945435
. O O 0.9999945163726807
7 O O 0.999997615814209
% O O 0.9999743700027466
in O O 0.9998441934585571
period O O 0.9998059868812561
3 O O 0.9999455213546753
. O O 0.9999728202819824

After O O 0.9999489784240723
adjusting O O 0.9999533891677856
for O O 0.9998206496238708
potential O O 0.9998049139976501
confounders O O 0.9878696799278259
, O O 0.9999586343765259
we O O 0.9999486207962036
found O O 0.9999938011169434
that O O 0.999981164932251
the O O 0.9999960660934448
risk O O 0.9999970197677612
of O O 0.9999809265136719
HIV O O 0.960458517074585
seroconversion O O 0.9999265670776367
among O O 0.999642014503479
participants O O 0.9997181296348572
who O O 0.9996973276138306
were O O 0.9997549653053284
daily O O 0.9836146235466003
smokers O O 0.5398770570755005
of O O 0.9682472944259644
crack B B 0.9115987420082092
cocaine I I 0.9850532412528992
increased O O 0.9996845722198486
over O O 0.9999946355819702
time O O 0.9999856948852539
( O O 0.9999682903289795
period O O 0.9997430443763733
1 O O 0.9997777342796326
: O O 0.998793363571167
hazard O O 0.9961089491844177
ratio O O 0.999697208404541
[ O O 0.895626425743103
HR O O 0.7860943078994751
] O O 0.9994816184043884
1 O O 0.9998378753662109
. O O 0.9999942779541016
03 O O 0.9999955892562866
, O O 0.9999605417251587
95 O O 0.9999004602432251
% O O 0.9999697208404541
confidence O O 0.9998924732208252
interval O O 0.999994158744812
[ O O 0.9480261206626892
CI O O 0.9953458905220032
] O O 0.9999573230743408
0 O O 0.99998939037323
. O O 0.9999933242797852
57 O O 0.9999979734420776
- O O 0.9978783130645752
1 O O 0.9999948740005493
. O O 0.9999943971633911
85 O O 0.9999321699142456
; O O 0.9999444484710693
period O O 0.9998338222503662
2 O O 0.9999531507492065
: O O 0.9997518658638
HR O O 0.8301935195922852
1 O O 0.9999524354934692
. O O 0.9999945163726807
68 O O 0.9999967813491821
, O O 0.9999425411224365
95 O O 0.999693751335144
% O O 0.9999488592147827
CI O O 0.9936635494232178
1 O O 0.9999786615371704
. O O 0.9999873638153076
01 O O 0.9999948740005493
- O O 0.9979771971702576
2 O O 0.9999908208847046
. O O 0.9999948740005493
80 O O 0.9996532201766968
; O O 0.9999356269836426
and O O 0.9999111890792847
period O O 0.9995383024215698
3 O O 0.9996520280838013
: O O 0.9999148845672607
HR O O 0.8319711685180664
2 O O 0.9995027780532837
. O O 0.999993085861206
74 O O 0.9999868869781494
, O O 0.9999282360076904
95 O O 0.9989898800849915
% O O 0.9998385906219482
CI O O 0.9945195317268372
1 O O 0.9999881982803345
. O O 0.9999809265136719
06 O O 0.9999977350234985
- O O 0.9982812404632568
7 O O 0.999948263168335
. O O 0.9999954700469971
11 O O 0.9999959468841553
) O O 0.9999842643737793
. O O 0.9999868869781494

INTERPRETATION O O 0.9736040830612183
: O O 0.999859094619751
Smoking O O 0.7896780967712402
of O O 0.7311436533927917
crack B B 0.9652036428451538
cocaine I I 0.9651092290878296
was O O 0.9997813105583191
found O O 0.9999717473983765
to O O 0.9999263286590576
be O O 0.9999442100524902
an O O 0.9998778104782104
independent O O 0.9998142123222351
risk O O 0.9999662637710571
factor O O 0.9999841451644897
for O O 0.9999281167984009
HIV O O 0.9783626794815063
seroconversion O O 0.999970555305481
among O O 0.9998928308486938
people O O 0.9999830722808838
who O O 0.9998713731765747
were O O 0.9998276233673096
injection O O 0.5604167580604553
drug O O 0.7532505989074707
users O O 0.9988101720809937
. O O 0.9999510049819946

This O O 0.9999732971191406
finding O O 0.9999673366546631
points O O 0.9999383687973022
to O O 0.9999680519104004
the O O 0.999993085861206
urgent O O 0.9999768733978271
need O O 0.9999926090240479
for O O 0.9999836683273315
evidence O O 0.9997294545173645
- O O 0.9999803304672241
based O O 0.9999876022338867
public O O 0.9999730587005615
health O O 0.999954104423523
initiatives O O 0.9999568462371826
targeted O O 0.9999270439147949
at O O 0.9995586276054382
people O O 0.9999849796295166
who O O 0.9999419450759888
smoke O O 0.5882613658905029
crack B B 0.8554728627204895
cocaine I I 0.9995405673980713
. O O 0.9997490048408508

Fluoxetine B B 0.998256266117096
improves O O 0.9982694387435913
the O O 0.9999479055404663
memory O O 0.9999754428863525
deficits O O 0.9999932050704956
caused O O 0.999991774559021
by O O 0.9999333620071411
the O O 0.9999135732650757
chemotherapy O O 0.9998751878738403
agent O O 0.9770426750183105
5 B B 0.9599730372428894
- I I 0.9969947338104248
fluorouracil I I 0.9999898672103882
. O O 0.9987442493438721

Cancer O O 0.9994767308235168
patients O O 0.9999380111694336
who O O 0.9999258518218994
have O O 0.9999872446060181
been O O 0.999985933303833
treated O O 0.9999779462814331
with O O 0.9999552965164185
systemic O O 0.9996280670166016
adjuvant O O 0.9986053109169006
chemotherapy O O 0.9996293783187866
have O O 0.9999468326568604
described O O 0.9999961853027344
experiencing O O 0.9999727010726929
deteriorations O O 0.999996542930603
in O O 0.9999762773513794
cognition O O 0.9990248680114746
. O O 0.9999758005142212

A O O 0.9995512366294861
widely O O 0.9997699856758118
used O O 0.9999068975448608
chemotherapeutic O O 0.9985761642456055
agent O O 0.9888551831245422
, O O 0.9983420372009277
5 B B 0.9849599003791809
- I I 0.9995471835136414
fluorouracil I I 0.999985933303833
( O O 0.9805927276611328
5 B B 0.9914932250976562
- I I 0.9946078062057495
FU I I 0.9999904632568359
) O O 0.9971264004707336
, O O 0.999974250793457
readily O O 0.9999252557754517
crosses O O 0.9999581575393677
the O O 0.9999879598617554
blood O O 0.9935809373855591
- O O 0.9998679161071777
brain O O 0.9999382495880127
barrier O O 0.9999924898147583
and O O 0.999969482421875
so O O 0.9998990297317505
could O O 0.9999344348907471
have O O 0.9999734163284302
a O O 0.999975323677063
direct O O 0.9999721050262451
effect O O 0.999980092048645
on O O 0.9999667406082153
brain O O 0.9999817609786987
function O O 0.9999958276748657
. O O 0.9999669790267944

In O O 0.9999228715896606
particular O O 0.9999023675918579
this O O 0.9971858859062195
anti O O 0.7929548025131226
mitotic O O 0.918994665145874
drug O O 0.990846574306488
could O O 0.9997014403343201
reduce O O 0.9993102550506592
cell O O 0.9999533891677856
proliferation O O 0.9999496936798096
in O O 0.9998488426208496
the O O 0.9999428987503052
neurogenic O O 0.9999476671218872
regions O O 0.9999842643737793
of O O 0.9999721050262451
the O O 0.9999797344207764
adult O O 0.999980092048645
brain O O 0.9999908208847046
. O O 0.9999459981918335

In O O 0.9997177720069885
contrast O O 0.99064701795578
reports O O 0.9999650716781616
indicate O O 0.9998476505279541
that O O 0.9996744394302368
hippocampal O O 0.9819254875183105
dependent O O 0.9991573095321655
neurogenesis O O 0.9999572038650513
and O O 0.9999113082885742
cognition O O 0.9997063279151917
are O O 0.9999161958694458
enhanced O O 0.999935507774353
by O O 0.9997407793998718
the O O 0.9981051683425903
SSRI B O 0.8265613317489624
antidepressant O O 0.47773119807243347
Fluoxetine B B 0.9799376130104065
. O O 0.99994957447052

In O O 0.9999732971191406
this O O 0.9999620914459229
investigation O O 0.9999579191207886
the O O 0.9999463558197021
behavioural O O 0.9999690055847168
effects O O 0.9999629259109497
of O O 0.9999372959136963
chronic O O 0.9997929930686951
( O O 0.9998233914375305
two O O 0.9999936819076538
week O O 0.9999772310256958
) O O 0.9999338388442993
treatment O O 0.9999803304672241
with O O 0.9998443126678467
5 B B 0.8664615750312805
- I I 0.9476295113563538
FU I I 0.9999425411224365
and O O 0.9892755150794983
( O O 0.9993334412574768
three O O 0.9998390674591064
weeks O O 0.999992847442627
) O O 0.9999890327453613
with O O 0.9994372725486755
Fluoxetine B B 0.9992935657501221
either O O 0.9998738765716553
separately O O 0.9997004270553589
or O O 0.9999426603317261
in O O 0.999953031539917
combination O O 0.9998859167098999
with O O 0.9997969269752502
5 B B 0.9422853589057922
- I I 0.908958375453949
FU I I 0.9999063014984131
were O O 0.9998296499252319
tested O O 0.9999654293060303
on O O 0.999944806098938
adult O O 0.9999439716339111
Lister O O 0.9958685636520386
hooded O O 0.997992992401123
rats O O 0.9999622106552124
. O O 0.9999710321426392

Behavioural O O 0.9999045133590698
effects O O 0.999968409538269
were O O 0.9999933242797852
tested O O 0.9999910593032837
using O O 0.9999808073043823
a O O 0.9999755620956421
context O O 0.9977866411209106
dependent O O 0.9998764991760254
conditioned O O 0.999743640422821
emotional O O 0.9893139004707336
response O O 0.9999706745147705
test O O 0.9999885559082031
( O O 0.9998394250869751
CER O O 0.9746033549308777
) O O 0.9999743700027466
which O O 0.9999744892120361
showed O O 0.9999773502349854
that O O 0.9999353885650635
animals O O 0.9999942779541016
treated O O 0.9998327493667603
with O O 0.9997300505638123
5 B B 0.8638629913330078
- I I 0.9296263456344604
FU I I 0.9998733997344971
had O O 0.9995976090431213
a O O 0.9999761581420898
significant O O 0.9999831914901733
reduction O O 0.9999936819076538
in O O 0.9999773502349854
freezing O O 0.999993085861206
time O O 0.9999923706054688
compared O O 0.9999878406524658
to O O 0.9999750852584839
controls O O 0.9999618530273438
. O O 0.9999833106994629

A O O 0.999967098236084
separate O O 0.9999538660049438
group O O 0.9999839067459106
of O O 0.9999785423278809
animals O O 0.9999923706054688
was O O 0.9999710321426392
tested O O 0.9999809265136719
using O O 0.9999216794967651
a O O 0.9998278617858887
hippocampal O O 0.9873769879341125
dependent O O 0.9997357726097107
spatial O O 0.999333918094635
working O O 0.9999462366104126
memory O O 0.999969482421875
test O O 0.9999650716781616
, O O 0.9999188184738159
the O O 0.9999258518218994
object O O 0.9998303651809692
location O O 0.9999345541000366
recognition O O 0.999977707862854
test O O 0.999980092048645
( O O 0.9995336532592773
OLR O O 0.9313392639160156
) O O 0.9999390840530396
. O O 0.9999697208404541

Animals O O 0.9999120235443115
treated O O 0.9998798370361328
only O O 0.9998003840446472
with O O 0.9996724128723145
5 B B 0.8257263898849487
- I I 0.8965906500816345
FU I I 0.9998530149459839
showed O O 0.9996047616004944
significant O O 0.9999725818634033
deficits O O 0.9999947547912598
in O O 0.9999829530715942
their O O 0.999976396560669
ability O O 0.9999903440475464
to O O 0.9999901056289673
carry O O 0.999993085861206
out O O 0.9999886751174927
the O O 0.9999841451644897
OLR O O 0.9945610165596008
task O O 0.9999945163726807
but O O 0.9997265934944153
co O O 0.9859008193016052
administration O O 0.9995974898338318
of O O 0.9992702603340149
Fluoxetine B B 0.999121367931366
improved O O 0.9999039173126221
their O O 0.9999828338623047
performance O O 0.9999963045120239
. O O 0.9999831914901733

5 B B 0.6479063034057617
- I I 0.8368641138076782
FU I I 0.9998506307601929
chemotherapy O O 0.8322498798370361
caused O O 0.999923586845398
a O O 0.9999765157699585
significant O O 0.9999843835830688
reduction O O 0.9999942779541016
in O O 0.9999709129333496
the O O 0.9999817609786987
number O O 0.9999758005142212
of O O 0.9999241828918457
proliferating O O 0.9997321963310242
cells O O 0.999993085861206
in O O 0.9997547268867493
the O O 0.9999091625213623
sub O O 0.9974887371063232
granular O O 0.9981001019477844
zone O O 0.9999679327011108
of O O 0.9999097585678101
the O O 0.9999328851699829
dentate O O 0.9995055198669434
gyrus O O 0.999481737613678
compared O O 0.9999659061431885
to O O 0.9999423027038574
controls O O 0.9998692274093628
. O O 0.9999701976776123

This O O 0.9999254941940308
reduction O O 0.9999629259109497
was O O 0.9999535083770752
eliminated O O 0.9999653100967407
when O O 0.99985671043396
Fluoxetine B B 0.9997016787528992
was O O 0.9999324083328247
co O O 0.9983843564987183
administered O O 0.9998782873153687
with O O 0.9996508359909058
5 B B 0.8516345620155334
- I I 0.965176522731781
FU I I 0.999955415725708
. O O 0.9996949434280396

Fluoxetine B B 0.9985381364822388
on O O 0.9998711347579956
its O O 0.9997949004173279
own O O 0.9999035596847534
had O O 0.9999657869338989
no O O 0.9999690055847168
effect O O 0.9999686479568481
on O O 0.9999250173568726
proliferating O O 0.999653697013855
cell O O 0.9999847412109375
number O O 0.9999692440032959
or O O 0.999977707862854
behaviour O O 0.9998641014099121
. O O 0.9999562501907349

These O O 0.9999762773513794
findings O O 0.9999945163726807
suggest O O 0.9999675750732422
that O O 0.9998133778572083
5 B B 0.9630860686302185
- I I 0.986559271812439
FU I I 0.9999747276306152
can O O 0.9989838004112244
negatively O O 0.9997592568397522
affect O O 0.9997486472129822
both O O 0.9990035891532898
cell O O 0.9997443556785583
proliferation O O 0.9999343156814575
and O O 0.9998189806938171
hippocampal O O 0.9920497536659241
dependent O O 0.9995453953742981
working O O 0.9998328685760498
memory O O 0.9999839067459106
and O O 0.9999771118164062
that O O 0.9999566078186035
these O O 0.999977707862854
deficits O O 0.9999932050704956
can O O 0.9999309778213501
be O O 0.9999903440475464
reversed O O 0.9999823570251465
by O O 0.9999539852142334
the O O 0.9999804496765137
simultaneous O O 0.9998248219490051
administration O O 0.999931812286377
of O O 0.9998990297317505
the O O 0.9996722936630249
antidepressant O O 0.7278030514717102
Fluoxetine B B 0.9888052940368652
. O O 0.9999387264251709

Liver O O 0.7827292680740356
- O O 0.9996054768562317
specific O O 0.9999150037765503
ablation O O 0.9999598264694214
of O O 0.9993075132369995
integrin O O 0.8679471611976624
- O O 0.9755869507789612
linked O O 0.9769294857978821
kinase O O 0.961151123046875
in O O 0.9998973608016968
mice O O 0.9999630451202393
results O O 0.9999226331710815
in O O 0.9999779462814331
enhanced O O 0.9998786449432373
and O O 0.9999624490737915
prolonged O O 0.9998979568481445
cell O O 0.9999681711196899
proliferation O O 0.9999891519546509
and O O 0.9999779462814331
hepatomegaly O O 0.9999792575836182
after O O 0.9998281002044678
phenobarbital B B 0.999515175819397
administration O O 0.9998249411582947
. O O 0.9999804496765137

We O O 0.9999637603759766
have O O 0.9999943971633911
recently O O 0.9999916553497314
demonstrated O O 0.999994158744812
that O O 0.9999505281448364
disruption O O 0.9999586343765259
of O O 0.999821126461029
extracellular O O 0.9974320530891418
matrix O O 0.9997362494468689
( O O 0.9998013377189636
ECM O O 0.995905876159668
) O O 0.9984941482543945
/ O O 0.9984862804412842
integrin O O 0.8388991951942444
signaling O O 0.9998310804367065
via O O 0.9998831748962402
elimination O O 0.9994547963142395
of O O 0.9958873391151428
integrin O O 0.6137306690216064
- O O 0.9284302592277527
linked O O 0.9366441965103149
kinase O O 0.9790924787521362
( O O 0.9980484247207642
ILK O O 0.6547829508781433
) O O 0.9995083808898926
in O O 0.9998107552528381
hepatocytes O O 0.9997817873954773
interferes O O 0.9998601675033569
with O O 0.9998643398284912
signals O O 0.9999046325683594
leading O O 0.9999886751174927
to O O 0.9999866485595703
termination O O 0.9999892711639404
of O O 0.9999653100967407
liver O O 0.9987568855285645
regeneration O O 0.999993085861206
. O O 0.9999744892120361

This O O 0.9999707937240601
study O O 0.9999749660491943
investigates O O 0.9997016787528992
the O O 0.999945878982544
role O O 0.9999295473098755
of O O 0.9968715310096741
ILK O O 0.6108703017234802
in O O 0.9997302889823914
liver O O 0.9991627931594849
enlargement O O 0.9999645948410034
induced O O 0.9999626874923706
by O O 0.999561607837677
phenobarbital B B 0.9991662502288818
( O O 0.9913251399993896
PB B B 0.9953820109367371
) O O 0.9992050528526306
. O O 0.9999575614929199

Wild O O 0.9984747767448425
- O O 0.99992835521698
type O O 0.9999947547912598
( O O 0.9998247027397156
WT O O 0.9963569045066833
) O O 0.9999489784240723
and O O 0.9998151659965515
ILK O O 0.9562000036239624
: O O 0.9998056292533875
liver O O 0.9900487661361694
- O O 0.9996793270111084
/ O O 0.9984347224235535
- O O 0.9998496770858765
mice O O 0.9999948740005493
were O O 0.9999774694442749
given O O 0.9995167255401611
PB B B 0.9980862140655518
( O O 0.9805454015731812
0 O O 0.9992769360542297
. O O 0.9999728202819824
1 O O 0.999911904335022
% O O 0.9955321550369263
in O O 0.9990891218185425
drinking O O 0.9929279685020447
water O O 0.8294572234153748
) O O 0.9998968839645386
for O O 0.9999552965164185
10 O O 0.9999682903289795
days O O 0.9999935626983643
. O O 0.9999829530715942

Livers O O 0.9962692260742188
were O O 0.9999755620956421
harvested O O 0.9999855756759644
on O O 0.9999651908874512
2 O O 0.999062716960907
, O O 0.999930739402771
5 O O 0.9999767541885376
, O O 0.9996219873428345
and O O 0.9999560117721558
10 O O 0.9999723434448242
days O O 0.9999896287918091
during O O 0.9998658895492554
PB B B 0.9976853132247925
administration O O 0.9993576407432556
. O O 0.9999784231185913

In O O 0.9998499155044556
the O O 0.9999282360076904
hepatocyte O O 0.9947105646133423
- O O 0.9984819293022156
specific O O 0.9961830973625183
ILK O O 0.8989589810371399
/ O O 0.9996209144592285
liver O O 0.8772940635681152
- O O 0.9985598921775818
/ O O 0.9960575103759766
- O O 0.998539924621582
mice O O 0.9999901056289673
, O O 0.9999600648880005
the O O 0.9999805688858032
liver O O 0.9978502988815308
: O O 0.9999567270278931
body O O 0.9999715089797974
weight O O 0.9999465942382812
ratio O O 0.9999170303344727
was O O 0.9999524354934692
more O O 0.9999825954437256
than O O 0.9999942779541016
double O O 0.9999935626983643
as O O 0.9999864101409912
compared O O 0.9999847412109375
to O O 0.9999645948410034
0 O O 0.9982419013977051
h O O 0.9999485015869141
at O O 0.9998738765716553
day O O 0.999991774559021
2 O O 0.999948263168335
( O O 0.9999502897262573
2 O O 0.9999630451202393
. O O 0.9999942779541016
5 O O 0.9999778270721436
times O O 0.9999862909317017
) O O 0.9999489784240723
, O O 0.9999622106552124
while O O 0.999962329864502
at O O 0.9999377727508545
days O O 0.9999939203262329
5 O O 0.999990701675415
and O O 0.9999563694000244
10 O O 0.999981164932251
, O O 0.9999642372131348
it O O 0.9999715089797974
was O O 0.9999532699584961
enlarged O O 0.9999874830245972
three O O 0.9999738931655884
times O O 0.9999933242797852
. O O 0.99997878074646

In O O 0.9999294281005859
the O O 0.999946117401123
WT O O 0.9965260624885559
mice O O 0.9999909400939941
, O O 0.9999645948410034
the O O 0.9999879598617554
increase O O 0.99997878074646
was O O 0.9999889135360718
as O O 0.999997615814209
expected O O 0.9999983310699463
from O O 0.999993085861206
previous O O 0.9999521970748901
literature O O 0.9999755620956421
( O O 0.9999501705169678
1 O O 0.9999873638153076
. O O 0.9999967813491821
8 O O 0.9999892711639404
times O O 0.9999922513961792
) O O 0.9999639987945557
and O O 0.9999784231185913
seems O O 0.9999861717224121
to O O 0.9999758005142212
have O O 0.9999942779541016
leveled O O 0.9999940395355225
off O O 0.9999889135360718
after O O 0.9999704360961914
day O O 0.9999861717224121
2 O O 0.999954104423523
. O O 0.999983549118042

There O O 0.9999347925186157
were O O 0.9999706745147705
slightly O O 0.9999839067459106
increased O O 0.9999728202819824
proliferating O O 0.9991165995597839
cell O O 0.9949826002120972
nuclear O O 0.8739228248596191
antigen O O 0.7133692502975464
- O O 0.9961050748825073
positive O O 0.9988700747489929
cells O O 0.9999871253967285
in O O 0.9997548460960388
the O O 0.9997743964195251
ILK O O 0.9706264734268188
/ O O 0.9995664954185486
liver O O 0.9745341539382935
- O O 0.9983313679695129
/ O O 0.9908604621887207
- O O 0.9932042360305786
animals O O 0.9988847374916077
at O O 0.9998652935028076
day O O 0.9999895095825195
2 O O 0.9999643564224243
as O O 0.9999659061431885
compared O O 0.9999878406524658
to O O 0.9999887943267822
WT O O 0.9966002106666565
after O O 0.9998512268066406
PB B B 0.9982106685638428
administration O O 0.9995859265327454
. O O 0.9999728202819824

In O O 0.9998822212219238
the O O 0.9999403953552246
WT O O 0.9904093742370605
animals O O 0.9999842643737793
, O O 0.9999575614929199
the O O 0.9999569654464722
proliferative O O 0.9996516704559326
response O O 0.9999871253967285
had O O 0.9999662637710571
come O O 0.9999974966049194
back O O 0.9999866485595703
to O O 0.9999909400939941
normal O O 0.999969482421875
by O O 0.9999891519546509
days O O 0.9999955892562866
5 O O 0.999995231628418
and O O 0.9999854564666748
10 O O 0.9999936819076538
. O O 0.999987006187439

Hepatocytes O O 0.9994750618934631
of O O 0.9998928308486938
the O O 0.9999058246612549
ILK O O 0.9050100445747375
/ O O 0.9990848302841187
liver O O 0.8478096127510071
- O O 0.9976141452789307
/ O O 0.9933431148529053
- O O 0.9987123012542725
mice O O 0.9999868869781494
continued O O 0.9999697208404541
to O O 0.9999667406082153
proliferate O O 0.9998382329940796
up O O 0.9999432563781738
until O O 0.9999855756759644
day O O 0.9999927282333374
10 O O 0.9999936819076538
. O O 0.9999700784683228

ILK O O 0.8303734064102173
/ O O 0.9866443276405334
liver O O 0.8411081433296204
- O O 0.9991961121559143
/ O O 0.9948742985725403
- O O 0.9996140599250793
mice O O 0.9999849796295166
also O O 0.9999725818634033
showed O O 0.9999505281448364
increased O O 0.9999593496322632
expression O O 0.9999747276306152
of O O 0.9999039173126221
key O O 0.9996154308319092
genes O O 0.9998425245285034
involved O O 0.9999514818191528
in O O 0.9999285936355591
hepatocyte O O 0.9994931221008301
proliferation O O 0.9999697208404541
at O O 0.9999563694000244
different O O 0.999969482421875
time O O 0.9999616146087646
points O O 0.9999926090240479
during O O 0.999893307685852
PB B B 0.9980916380882263
administration O O 0.9995635151863098
. O O 0.999976634979248

In O O 0.9998753070831299
summary O O 0.9999269247055054
, O O 0.9987061023712158
ECM O O 0.7275200486183167
proteins O O 0.8475058674812317
communicate O O 0.9977633953094482
with O O 0.9996538162231445
the O O 0.9998267292976379
signaling O O 0.9947342872619629
machinery O O 0.999953031539917
of O O 0.9999188184738159
dividing O O 0.9993500113487244
cells O O 0.9999581575393677
via O O 0.9992141723632812
ILK O O 0.8026804327964783
to O O 0.9996438026428223
regulate O O 0.9996296167373657
hepatocyte O O 0.9994871616363525
proliferation O O 0.9999706745147705
and O O 0.9999485015869141
termination O O 0.9999760389328003
of O O 0.9999284744262695
the O O 0.9999164342880249
proliferative O O 0.9998249411582947
response O O 0.9999947547912598
. O O 0.9999599456787109

Lack O O 0.9999403953552246
of O O 0.9994091987609863
ILK O O 0.7215044498443604
in O O 0.999665379524231
the O O 0.9998519420623779
hepatocytes O O 0.9992406368255615
imparts O O 0.999846339225769
prolonged O O 0.9998065829277039
proliferative O O 0.9997606873512268
response O O 0.9999666213989258
not O O 0.9999407529830933
only O O 0.9999631643295288
to O O 0.9991517066955566
stimuli O O 0.9996867179870605
related O O 0.9999419450759888
to O O 0.9997342228889465
liver O O 0.9909590482711792
regeneration O O 0.9999818801879883
but O O 0.9999409914016724
also O O 0.9999059438705444
to O O 0.9996451139450073
xenobiotic O O 0.9439523220062256
chemical O O 0.9466040134429932
mitogens O O 0.9755879044532776
, O O 0.9999222755432129
such O O 0.999666690826416
as O O 0.9979998469352722
PB B B 0.9913697242736816
. O O 0.999698281288147

Decreased O O 0.9999004602432251
Expression O O 0.9999179840087891
of O O 0.9958513975143433
Na B B 0.9549134373664856
/ O O 0.9006238579750061
K B O 0.798291027545929
- O O 0.6126001477241516
ATPase O O 0.7663814425468445
, O O 0.998849630355835
NHE3 O O 0.8349860310554504
, O O 0.9985767602920532
NBC1 O O 0.7801191806793213
, O O 0.9974852800369263
AQP1 O O 0.4965132474899292
and O O 0.9982618689537048
OAT O O 0.6500829458236694
in O O 0.9997642636299133
Gentamicin B B 0.999789297580719
- O O 0.9995819926261902
induced O O 0.9999446868896484
Nephropathy O O 0.9999439716339111
. O O 0.9999650716781616

The O O 0.9999911785125732
present O O 0.9999890327453613
study O O 0.9999858140945435
was O O 0.9999910593032837
aimed O O 0.9999969005584717
to O O 0.999996542930603
determine O O 0.999993085861206
whether O O 0.9999785423278809
there O O 0.9998975992202759
is O O 0.9999384880065918
an O O 0.9999346733093262
altered O O 0.9999605417251587
regulation O O 0.9999781847000122
of O O 0.9997478127479553
tubular O O 0.9999035596847534
transporters O O 0.9994677901268005
in O O 0.9998038411140442
gentamicin B B 0.9998623132705688
- O O 0.9996401071548462
induced O O 0.9999212026596069
nephropathy O O 0.9999442100524902
. O O 0.9999760389328003

Sprague O O 0.9995681643486023
- O O 0.9998908042907715
Dawley O O 0.9994797110557556
male O O 0.9999916553497314
rats O O 0.9999966621398926
( O O 0.9999643564224243
200 O O 0.9999133348464966
~ O O 0.9999414682388306
250 O O 0.9999964237213135
g O O 0.999970555305481
) O O 0.9999676942825317
were O O 0.9999909400939941
subcutaneously O O 0.9999675750732422
injected O O 0.9999850988388062
with O O 0.9999115467071533
gentamicin B B 0.9997391104698181
( O O 0.9996113181114197
100 O O 0.999930739402771
mg O O 0.9999688863754272
/ O O 0.9999641180038452
kg O O 0.9999982118606567
per O O 0.9999555349349976
day O O 0.9999963045120239
) O O 0.999970555305481
for O O 0.9999756813049316
7 O O 0.9999791383743286
days O O 0.9999961853027344
, O O 0.9999607801437378
and O O 0.9999873638153076
the O O 0.9999943971633911
expression O O 0.9999831914901733
of O O 0.999828577041626
tubular O O 0.999768078327179
transporters O O 0.9959576725959778
was O O 0.999992847442627
determined O O 0.9999945163726807
by O O 0.9999818801879883
immunoblotting O O 0.9999778270721436
and O O 0.9999572038650513
immunohistochemistry O O 0.999962568283081
. O O 0.9999902248382568

The O O 0.9999388456344604
mRNA O O 0.9678827524185181
and O O 0.9998182654380798
protein O O 0.997557520866394
expression O O 0.999894380569458
of O O 0.9882160425186157
OAT O O 0.8674604296684265
was O O 0.9999531507492065
also O O 0.9999781847000122
determined O O 0.9999556541442871
. O O 0.9999552965164185

Gentamicin B B 0.9996460676193237
- O O 0.9996803998947144
treated O O 0.9998499155044556
rats O O 0.9999628067016602
exhibited O O 0.9999687671661377
significantly O O 0.9999868869781494
decreased O O 0.9999830722808838
creatinine B B 0.9988545179367065
clearance O O 0.9998799562454224
along O O 0.9999759197235107
with O O 0.9999853372573853
increased O O 0.9999768733978271
plasma O O 0.9997785687446594
creatinine B B 0.9982500672340393
levels O O 0.9999220371246338
. O O 0.9999768733978271

Accordingly O O 0.9999306201934814
, O O 0.9999606609344482
the O O 0.9999707937240601
fractional O O 0.9999765157699585
excretion O O 0.999903678894043
of O O 0.9993138313293457
sodium B B 0.9987435936927795
increased O O 0.9998242259025574
. O O 0.9999595880508423

Urine O O 0.9997156262397766
volume O O 0.9995627999305725
was O O 0.9999438524246216
increased O O 0.9999344348907471
, O O 0.9999557733535767
while O O 0.9999011754989624
urine O O 0.9984347224235535
osmolality O O 0.7535983920097351
and O O 0.999639630317688
free O O 0.9596261978149414
water O O 0.9323753714561462
reabsorption O O 0.9998682737350464
were O O 0.9999353885650635
decreased O O 0.9999393224716187
. O O 0.9999481439590454

Immunoblotting O O 0.9999228715896606
and O O 0.9999291896820068
immunohistochemistry O O 0.9998594522476196
revealed O O 0.9999513626098633
decreased O O 0.9999351501464844
expression O O 0.9999566078186035
of O O 0.9960134029388428
Na B B 0.975943922996521
( O O 0.9524579048156738
+ O O 0.9983325600624084
) O O 0.998275637626648
/ O O 0.9322468638420105
K B B 0.9510894417762756
( O O 0.8623954057693481
+ O O 0.992007851600647
) O O 0.9816803932189941
- O O 0.9908656477928162
ATPase O O 0.8592574000358582
, O O 0.9976630210876465
NHE3 O O 0.8578816056251526
, O O 0.9975326061248779
NBC1 O O 0.732041597366333
, O O 0.9951346516609192
and O O 0.9925139546394348
AQP1 O O 0.542804479598999
in O O 0.9993552565574646
the O O 0.9999513626098633
kidney O O 0.9999630451202393
of O O 0.9999403953552246
gentamicin B B 0.9998672008514404
- O O 0.9996922016143799
treated O O 0.9997987151145935
rats O O 0.9999849796295166
. O O 0.9999756813049316

The O O 0.9999362230300903
expression O O 0.9999185800552368
of O O 0.9985835552215576
OAT1 O O 0.9776387810707092
and O O 0.9981253743171692
OAT3 O O 0.9559611678123474
was O O 0.9998962879180908
also O O 0.9999525547027588
decreased O O 0.9999517202377319
. O O 0.9999518394470215

Gentamicin B B 0.9996734857559204
- O O 0.999767005443573
induced O O 0.9998517036437988
nephropathy O O 0.9999758005142212
may O O 0.9999583959579468
at O O 0.9999914169311523
least O O 0.9999933242797852
in O O 0.9999932050704956
part O O 0.9999771118164062
be O O 0.999971866607666
causally O O 0.9999006986618042
related O O 0.999988317489624
with O O 0.999981164932251
a O O 0.9999524354934692
decreased O O 0.9999470710754395
expression O O 0.9999322891235352
of O O 0.9989172220230103
Na B B 0.9852582812309265
( O O 0.9574843049049377
+ O O 0.9995031356811523
) O O 0.9984413981437683
/ O O 0.9727820754051208
K B B 0.9649041295051575
( O O 0.8986123204231262
+ O O 0.9971694350242615
) O O 0.9849976301193237
- O O 0.9883329272270203
ATPase O O 0.9024981260299683
, O O 0.9995482563972473
NHE3 O O 0.8647369146347046
, O O 0.9991915822029114
NBC1 O O 0.8612793684005737
, O O 0.9989871382713318
AQP1 O O 0.5263966917991638
and O O 0.9983118772506714
OAT O O 0.8635911345481873
. O O 0.9999327659606934

Acute O O 0.9999756813049316
renal O O 0.99997878074646
failure O O 0.9999885559082031
after O O 0.999910831451416
high O O 0.9945632815361023
- O O 0.9999542236328125
dose O O 0.9899141788482666
methotrexate B B 0.9994407296180725
therapy O O 0.9984216690063477
in O O 0.9999676942825317
a O O 0.999988317489624
patient O O 0.9999923706054688
with O O 0.9999673366546631
ileostomy O O 0.9999712705612183
. O O 0.9999663829803467

High O O 0.9646220207214355
- O O 0.9995887875556946
dose O O 0.9905418753623962
methotrexate B B 0.9996424913406372
( O O 0.9971387386322021
HD O B 0.8955593109130859
- O O 0.8216632008552551
MTX B B 0.6999388933181763
) O O 0.9986842274665833
is O O 0.9998685121536255
an O O 0.999839186668396
important O O 0.9994496703147888
treatment O O 0.999864935874939
for O O 0.9998522996902466
Burkitt O O 0.9987003803253174
lymphoma O O 0.999983549118042
, O O 0.9999468326568604
but O O 0.9998849630355835
can O O 0.9999226331710815
cause O O 0.999945878982544
hepatic O O 0.9999032020568848
and O O 0.9998751878738403
renal O O 0.9999444484710693
toxicity O O 0.9999865293502808
when O O 0.9999513626098633
its O O 0.9998748302459717
clearance O O 0.9999493360519409
is O O 0.999969482421875
delayed O O 0.9999818801879883
. O O 0.9999268054962158

We O O 0.9999649524688721
report O O 0.9999958276748657
a O O 0.9999955892562866
case O O 0.9999971389770508
of O O 0.9999886751174927
acute O O 0.9999744892120361
renal O O 0.9999878406524658
failure O O 0.999996542930603
after O O 0.9997881054878235
HD O O 0.83009934425354
- O O 0.7573134303092957
MTX B B 0.5504702925682068
therapy O O 0.990351140499115
in O O 0.9999476671218872
a O O 0.9999860525131226
patient O O 0.999991774559021
with O O 0.9999698400497437
ileostomy O O 0.9999864101409912
, O O 0.9999953508377075
The O O 0.9999986886978149
patient O O 0.9999943971633911
was O O 0.9999949932098389
a O O 0.9999926090240479
3 O O 0.9999592304229736
- O O 0.9999874830245972
year O O 0.999996542930603
- O O 0.9999947547912598
old O O 0.9999940395355225
boy O O 0.9999923706054688
who O O 0.9999589920043945
had O O 0.9999884366989136
received O O 0.9999935626983643
a O O 0.9999945163726807
living O O 0.9874696731567383
- O O 0.9998929500579834
related O O 0.9998821020126343
liver O O 0.9988289475440979
transplantation O O 0.9999715089797974
for O O 0.9999779462814331
congenital O O 0.999724805355072
biliary O O 0.9994606375694275
atresia O O 0.9993894100189209
. O O 0.999980092048645

At O O 0.9999816417694092
day O O 0.9999895095825195
833 O O 0.9974416494369507
after O O 0.9999897480010986
the O O 0.9999889135360718
transplantation O O 0.9999451637268066
, O O 0.9999881982803345
he O O 0.9999796152114868
was O O 0.9999867677688599
diagnosed O O 0.9999974966049194
with O O 0.9999579191207886
PTLD O O 0.9917927384376526
( O O 0.9997527003288269
post O O 0.99931800365448
- O O 0.9997218251228333
transplantation O O 0.9999048709869385
lymphoproliferative O O 0.999751627445221
disorder O O 0.9999901056289673
, O O 0.9998045563697815
Burkitt O O 0.991300642490387
- O O 0.9999679327011108
type O O 0.9999042749404907
malignant O O 0.9999953508377075
lymphoma O O 0.9999556541442871
) O O 0.9999741315841675
. O O 0.999984860420227

During O O 0.999881386756897
induction O O 0.9999078512191772
therapy O O 0.9999862909317017
, O O 0.9999728202819824
he O O 0.9999657869338989
suffered O O 0.9996998310089111
ileal O O 0.9999557733535767
perforation O O 0.9999723434448242
and O O 0.9999576807022095
ileostomy O O 0.9999719858169556
was O O 0.9999769926071167
performed O O 0.9999953508377075
. O O 0.9999771118164062

Subsequent O O 0.9995728135108948
HD O O 0.8504323959350586
- O O 0.8311927318572998
MTX B B 0.7636244297027588
therapy O O 0.9988887906074524
caused O O 0.9999555349349976
acute O O 0.9999887943267822
renal O O 0.9999872446060181
failure O O 0.9999957084655762
that O O 0.9999922513961792
required O O 0.999996542930603
continuous O O 0.999981164932251
hemodialysis O O 0.999893307685852
. O O 0.9999712705612183

We O O 0.9999488592147827
supposed O O 0.9999905824661255
that O O 0.9999192953109741
intravascular O O 0.9999514818191528
hypovolemia O O 0.9998365640640259
due O O 0.9999579191207886
to O O 0.999943733215332
substantial O O 0.9999568462371826
drainage O O 0.9999898672103882
from O O 0.9999245405197144
the O O 0.9999904632568359
ileostoma O O 0.9999686479568481
caused O O 0.9999347925186157
acute O O 0.9999821186065674
prerenal O O 0.9948533177375793
failure O O 0.9999805688858032
. O O 0.999963641166687

After O O 0.9999685287475586
recovery O O 0.9999957084655762
of O O 0.9999797344207764
his O O 0.9999833106994629
renal O O 0.9999634027481079
function O O 0.9999905824661255
, O O 0.9999709129333496
we O O 0.9999445676803589
could O O 0.9999876022338867
safely O O 0.9999849796295166
treat O O 0.999985933303833
the O O 0.9999943971633911
patient O O 0.9999916553497314
with O O 0.9998620748519897
HD O O 0.8041021227836609
- O O 0.5986875891685486
MTX B O 0.45331791043281555
therapy O O 0.9992020726203918
by O O 0.9999804496765137
controlling O O 0.9995562434196472
drainage O O 0.9999878406524658
from O O 0.9993922710418701
ileostoma O O 0.9999508857727051
with O O 0.9998912811279297
total O O 0.9935863614082336
parenteral O O 0.9998666048049927
nutrition O O 0.9995736479759216
. O O 0.9999747276306152

Longitudinal O O 0.9996707439422607
association O O 0.9999710321426392
of O O 0.9994950294494629
alcohol B B 0.9787349700927734
use O O 0.9978207349777222
with O O 0.9998661279678345
HIV O O 0.9741607308387756
disease O O 0.9999556541442871
progression O O 0.9999810457229614
and O O 0.9999457597732544
psychological O O 0.9999728202819824
health O O 0.9999936819076538
of O O 0.9999802112579346
women O O 0.9995023012161255
with O O 0.9999217987060547
HIV O O 0.9616098403930664
. O O 0.999914288520813

We O O 0.9999337196350098
evaluated O O 0.9999855756759644
the O O 0.999984622001648
association O O 0.9999903440475464
of O O 0.9997343420982361
alcohol B B 0.9800599813461304
consumption O O 0.9915544390678406
and O O 0.9993995428085327
depression O O 0.9887725710868835
, O O 0.999887228012085
and O O 0.9999535083770752
their O O 0.9978177547454834
effects O O 0.9999409914016724
on O O 0.9999608993530273
HIV O O 0.9861220717430115
disease O O 0.9999822378158569
progression O O 0.9999972581863403
among O O 0.9999486207962036
women O O 0.9999916553497314
with O O 0.9999487400054932
HIV O O 0.9904284477233887
. O O 0.9999532699584961

The O O 0.9999926090240479
study O O 0.9999960660934448
included O O 0.999996542930603
871 O O 0.9997636675834656
women O O 0.9999948740005493
with O O 0.9999538660049438
HIV O O 0.9824383854866028
who O O 0.9999203681945801
were O O 0.9999866485595703
recruited O O 0.999984622001648
from O O 0.9999798536300659
1993 O O 0.9907535314559937
- O O 0.9976310729980469
1995 O O 0.5576083660125732
in O O 0.9997875094413757
four O O 0.999913215637207
US O O 0.999722421169281
cities O O 0.999987006187439
. O O 0.9999673366546631

The O O 0.9999815225601196
participants O O 0.9999905824661255
had O O 0.9999728202819824
physical O O 0.9999896287918091
examination O O 0.9999986886978149
, O O 0.9999908208847046
medical O O 0.9999966621398926
record O O 0.9999983310699463
extraction O O 0.9999959468841553
, O O 0.9999665021896362
and O O 0.9999878406524658
venipuncture O O 0.9999552965164185
, O O 0.9999769926071167
CD4 O O 0.9539898037910461
+ O O 0.999715268611908
T O O 0.9968078136444092
- O O 0.9987457990646362
cell O O 0.9990273714065552
counts O O 0.9974945783615112
determination O O 0.9999737739562988
, O O 0.99998939037323
measurement O O 0.9999936819076538
of O O 0.9999791383743286
depression O O 0.9976730942726135
symptoms O O 0.9999738931655884
( O O 0.9999490976333618
using O O 0.9999790191650391
the O O 0.999987006187439
self O O 0.999896764755249
- O O 0.9999785423278809
report O O 0.9996627569198608
Center O O 0.9989007711410522
for O O 0.9999803304672241
Epidemiological O O 0.9998526573181152
Studies O O 0.9999890327453613
- O O 0.9991938471794128
Depression O O 0.9828712940216064
Scale O O 0.996485710144043
) O O 0.9999669790267944
, O O 0.9999445676803589
and O O 0.9999687671661377
alcohol B B 0.9919703006744385
use O O 0.9996600151062012
assessment O O 0.9999830722808838
at O O 0.9998992681503296
enrollment O O 0.9999381303787231
, O O 0.9999700784683228
and O O 0.999976396560669
semiannually O O 0.9999233484268188
until O O 0.999984622001648
March O O 0.999954104423523
2000 O O 0.9999961853027344
. O O 0.999976634979248

Multilevel O O 0.9976050853729248
random O O 0.9995521903038025
coefficient O O 0.9999817609786987
ordinal O O 0.9997753500938416
models O O 0.9999586343765259
as O O 0.999943733215332
well O O 0.9998438358306885
as O O 0.9999065399169922
multilevel O O 0.992763102054596
models O O 0.999945878982544
with O O 0.9999678134918213
joint O O 0.9993566870689392
responses O O 0.9999969005584717
were O O 0.9999469518661499
used O O 0.9999792575836182
in O O 0.9999786615371704
the O O 0.999987006187439
analysis O O 0.9999920129776001
. O O 0.9999756813049316

There O O 0.999964714050293
was O O 0.9999537467956543
no O O 0.999964714050293
significant O O 0.9999927282333374
association O O 0.9999885559082031
between O O 0.9998210072517395
level O O 0.9998321533203125
of O O 0.9986648559570312
alcohol B B 0.9731350541114807
use O O 0.9989153146743774
and O O 0.9998955726623535
CD4 O O 0.9261063933372498
+ O O 0.9998657703399658
T O O 0.9986612796783447
- O O 0.9989676475524902
cell O O 0.9999061822891235
counts O O 0.9999598264694214
. O O 0.9999617338180542

When O O 0.9999595880508423
participants O O 0.9994232654571533
were O O 0.9999953508377075
stratified O O 0.9999533891677856
by O O 0.9999209642410278
antiretroviral O O 0.6525812149047852
therapy O O 0.7870272397994995
( O O 0.9981655478477478
ART O O 0.8110740780830383
) O O 0.9318352341651917
use O O 0.9998592138290405
, O O 0.9999769926071167
the O O 0.9999947547912598
association O O 0.9999932050704956
between O O 0.9995006322860718
alcohol B B 0.9965050220489502
and O O 0.9993240833282471
CD4 O O 0.8093607425689697
+ O O 0.9998961687088013
T O O 0.9988822340965271
- O O 0.9973166584968567
cell O O 0.9908221960067749
did O O 0.9999901056289673
not O O 0.9999955892562866
reach O O 0.9999855756759644
statistical O O 0.999987006187439
significance O O 0.9999984502792358
. O O 0.999987006187439

The O O 0.999985933303833
association O O 0.9999829530715942
between O O 0.9996213912963867
alcohol B B 0.986416220664978
consumption O O 0.9976838827133179
and O O 0.999800980091095
depression O O 0.999936580657959
was O O 0.9999527931213379
significant O O 0.9999206066131592
( O O 0.9999479055404663
p O O 0.999099850654602
< O O 0.9999592304229736
0 O O 0.9999868869781494
. O O 0.999996542930603
001 O O 0.9995762705802917
) O O 0.9999573230743408
. O O 0.9999788999557495

Depression O B 0.9595857262611389
had O O 0.9997091889381409
a O O 0.9999369382858276
significant O O 0.9999697208404541
negative O O 0.9998636245727539
effect O O 0.9999614953994751
on O O 0.9999212026596069
CD4 O O 0.9204327464103699
+ O O 0.999715268611908
T O O 0.9972819089889526
- O O 0.9989665746688843
cell O O 0.9999302625656128
counts O O 0.9999479055404663
over O O 0.9999110698699951
time O O 0.9999608993530273
regardless O O 0.9998642206192017
of O O 0.9993740916252136
ART O B 0.9082667231559753
use O O 0.9994708895683289
. O O 0.9999449253082275

Our O O 0.9999502897262573
findings O O 0.9999924898147583
suggest O O 0.9999617338180542
that O O 0.9997870326042175
alcohol B B 0.9868462085723877
consumption O O 0.9964475631713867
has O O 0.9999539852142334
a O O 0.9999598264694214
direct O O 0.9999592304229736
association O O 0.9999867677688599
with O O 0.9999679327011108
depression O O 0.9999563694000244
. O O 0.9999568462371826

Moreover O O 0.9997608065605164
, O O 0.9994935989379883
depression O O 0.9991059899330139
is O O 0.9997830986976624
associated O O 0.9999582767486572
with O O 0.9999359846115112
HIV O O 0.9941239953041077
disease O O 0.9999449253082275
progression O O 0.9999812841415405
. O O 0.9999693632125854

Our O O 0.9999675750732422
findings O O 0.9999938011169434
have O O 0.9999741315841675
implications O O 0.9999954700469971
for O O 0.9999841451644897
the O O 0.9999905824661255
provision O O 0.9999198913574219
of O O 0.9998650550842285
alcohol B B 0.9754948616027832
use O O 0.9535257816314697
interventions O O 0.9996715784072876
and O O 0.9998718500137329
psychological O O 0.9999033212661743
resources O O 0.9999294281005859
to O O 0.9999548196792603
improve O O 0.999962568283081
the O O 0.9999905824661255
health O O 0.999994158744812
of O O 0.9999934434890747
women O O 0.999990701675415
with O O 0.9999517202377319
HIV O O 0.9701337814331055
. O O 0.9999500513076782

Chemokine O O 0.7068076729774475
CCL2 O O 0.6376814842224121
and O O 0.9972147345542908
its O O 0.9075984954833984
receptor O O 0.9990606904029846
CCR2 O O 0.5820804238319397
are O O 0.9998526573181152
increased O O 0.9998319149017334
in O O 0.9995545744895935
the O O 0.9999421834945679
hippocampus O O 0.9994874000549316
following O O 0.9998435974121094
pilocarpine B B 0.9999054670333862
- O O 0.9998194575309753
induced O O 0.9999663829803467
status O O 0.9999979734420776
epilepticus O O 0.9999668598175049
. O O 0.9999755620956421

BACKGROUND O O 0.9633055329322815
: O O 0.9996944665908813
Neuroinflammation O O 0.9993650317192078
occurs O O 0.9999046325683594
after O O 0.999896764755249
seizures O O 0.9999494552612305
and O O 0.9999531507492065
is O O 0.9998664855957031
implicated O O 0.9999687671661377
in O O 0.9999608993530273
epileptogenesis O O 0.9999563694000244
. O O 0.999953031539917

CCR2 O O 0.5061679482460022
is O O 0.999705970287323
a O O 0.9941474199295044
chemokine O O 0.7623944878578186
receptor O O 0.9775899052619934
for O O 0.9959673881530762
CCL2 O O 0.7932360172271729
and O O 0.9997479319572449
their O O 0.9958280920982361
interaction O O 0.999506950378418
mediates O O 0.9997672438621521
monocyte O O 0.9997169375419617
infiltration O O 0.9998558759689331
in O O 0.9998695850372314
the O O 0.9999253749847412
neuroinflammatory O O 0.9999600648880005
cascade O O 0.9996246099472046
triggered O O 0.9999805688858032
in O O 0.9999666213989258
different O O 0.999944806098938
brain O O 0.9999839067459106
pathologies O O 0.9999961853027344
. O O 0.9999686479568481

In O O 0.9999685287475586
this O O 0.9999680519104004
work O O 0.999955415725708
CCR2 O O 0.9546153545379639
and O O 0.9992446899414062
CCL2 O O 0.8331212401390076
expression O O 0.9998683929443359
were O O 0.9999445676803589
examined O O 0.9999529123306274
following O O 0.9999641180038452
status O O 0.9999872446060181
epilepticus O O 0.9997612833976746
( O O 0.999920129776001
SE O O 0.9892768859863281
) O O 0.9999282360076904
induced O O 0.9999861717224121
by O O 0.9999392032623291
pilocarpine B B 0.9998354911804199
injection O O 0.9998563528060913
. O O 0.9999812841415405

METHODS O O 0.9949378967285156
: O O 0.9997020363807678
SE O O 0.989014208316803
was O O 0.9999722242355347
induced O O 0.9999905824661255
by O O 0.9999170303344727
pilocarpine B B 0.9996789693832397
injection O O 0.9997262358665466
. O O 0.9999476671218872

Control O O 0.9998416900634766
rats O O 0.999991774559021
were O O 0.9999899864196777
injected O O 0.9999688863754272
with O O 0.9999262094497681
saline O O 0.995649516582489
instead O O 0.9997900128364563
of O O 0.999777615070343
pilocarpine B B 0.999734103679657
. O O 0.9999321699142456

Five O O 0.9999799728393555
days O O 0.999995231628418
after O O 0.9999802112579346
SE O O 0.9977018237113953
, O O 0.9999710321426392
CCR2 O O 0.6400192379951477
staining O O 0.9996421337127686
in O O 0.9990471005439758
neurons O O 0.9999603033065796
and O O 0.9997133612632751
glial O O 0.9970117807388306
cells O O 0.9999834299087524
was O O 0.9999778270721436
examined O O 0.9999750852584839
using O O 0.9999712705612183
imunohistochemical O O 0.9999946355819702
analyses O O 0.9999761581420898
. O O 0.9999901056289673

The O O 0.9999736547470093
number O O 0.999974250793457
of O O 0.9999489784240723
CCR2 O O 0.8186652064323425
positive O O 0.9995895028114319
cells O O 0.9999784231185913
was O O 0.9999849796295166
determined O O 0.9999949932098389
using O O 0.9999734163284302
stereology O O 0.9924927353858948
probes O O 0.9999638795852661
in O O 0.9997991919517517
the O O 0.9999406337738037
hippocampus O O 0.999594509601593
. O O 0.9999462366104126

CCL2 O O 0.6253383159637451
expression O O 0.9998335838317871
in O O 0.9994571805000305
the O O 0.9998781681060791
hippocampus O O 0.998607337474823
was O O 0.9999619722366333
examined O O 0.9999620914459229
by O O 0.9999728202819824
molecular O O 0.9999638795852661
assay O O 0.9999123811721802
. O O 0.9999682903289795

RESULTS O O 0.9996422529220581
: O O 0.9998001456260681
Increased O O 0.9993211030960083
CCR2 O O 0.7810541391372681
was O O 0.9999158382415771
observed O O 0.9999707937240601
in O O 0.999291181564331
the O O 0.9998488426208496
hippocampus O O 0.9993653893470764
after O O 0.9954250454902649
SE O O 0.719337522983551
. O O 0.9966464638710022

Seizures O O 0.99972003698349
also O O 0.9999499320983887
resulted O O 0.9999750852584839
in O O 0.9999734163284302
alterations O O 0.9999872446060181
to O O 0.9999599456787109
the O O 0.9999258518218994
cell O O 0.9999572038650513
types O O 0.9999635219573975
expressing O O 0.9997827410697937
CCR2 O O 0.9064553380012512
. O O 0.9999103546142578

Increased O O 0.9998688697814941
numbers O O 0.9999182224273682
of O O 0.9998424053192139
neurons O O 0.999963641166687
that O O 0.9997532963752747
expressed O O 0.9994415640830994
CCR2 O O 0.6856433153152466
was O O 0.9999336004257202
observed O O 0.9999701976776123
following O O 0.9991505146026611
SE O O 0.5395492911338806
. O O 0.9995569586753845

Microglial O O 0.9965810179710388
cells O O 0.9999409914016724
were O O 0.9999122619628906
more O O 0.9998999834060669
closely O O 0.9999830722808838
apposed O O 0.9998914003372192
to O O 0.9998158812522888
the O O 0.9998966455459595
CCR2 O B 0.9081822633743286
- O O 0.9793846607208252
labeled O O 0.9980307221412659
cells O O 0.9999338388442993
in O O 0.9990873336791992
SE O O 0.8067340850830078
rats O O 0.9429096579551697
. O O 0.9998849630355835

In O O 0.9999339580535889
addition O O 0.9999434947967529
, O O 0.9999488592147827
rats O O 0.999971866607666
that O O 0.99988853931427
experienced O O 0.9988885521888733
SE O O 0.5750981569290161
exhibited O O 0.9963309168815613
CCR2 O O 0.5980809330940247
- O O 0.8257375359535217
labeling O O 0.9952396154403687
in O O 0.9995287656784058
populations O O 0.9899477362632751
of O O 0.999785840511322
hypertrophied O O 0.9472609758377075
astrocytes O O 0.9988054037094116
, O O 0.9999614953994751
especially O O 0.9996365308761597
in O O 0.9994658827781677
CA1 O O 0.984886109828949
and O O 0.9997852444648743
dentate O O 0.9989622831344604
gyrus O O 0.999738872051239
. O O 0.9999469518661499

These O O 0.9989485144615173
CCR2 O O 0.6073803901672363
+ O O 0.9925222992897034
astroctytes O O 0.6123523712158203
were O O 0.9999097585678101
not O O 0.9999538660049438
observed O O 0.9999316930770874
in O O 0.9998012185096741
control O O 0.9994977712631226
rats O O 0.9999760389328003
. O O 0.9999308586120605

Examination O O 0.999970555305481
of O O 0.9986568689346313
CCL2 O O 0.5633899569511414
expression O O 0.9988088607788086
showed O O 0.9999687671661377
that O O 0.9999433755874634
it O O 0.9982190728187561
was O O 0.9999414682388306
elevated O O 0.9997857213020325
in O O 0.9994608759880066
the O O 0.999920129776001
hippocampus O O 0.9997711777687073
following O O 0.9980890154838562
SE O O 0.6163064241409302
. O O 0.9995290040969849

CONCLUSION O O 0.9979645013809204
: O O 0.9999897480010986
The O O 0.9999823570251465
data O O 0.9999845027923584
show O O 0.9999626874923706
that O O 0.9997817873954773
CCR2 O O 0.8371386528015137
and O O 0.998408854007721
CCL2 O O 0.5036567449569702
are O O 0.9998986721038818
up O O 0.9979104399681091
- O O 0.9999666213989258
regulated O O 0.9999408721923828
in O O 0.9995599389076233
the O O 0.9999302625656128
hippocampus O O 0.9997442364692688
after O O 0.9993529915809631
pilocarpine B B 0.9998691082000732
- O O 0.9996882677078247
induced O O 0.999859094619751
SE O O 0.9991463422775269
. O O 0.9998044371604919

Seizures O O 0.9996193647384644
also O O 0.9999450445175171
result O O 0.9999374151229858
in O O 0.9999793767929077
changes O O 0.9999896287918091
to O O 0.9999234676361084
CCR2 O O 0.5022919178009033
receptor O O 0.9990251064300537
expression O O 0.9999176263809204
in O O 0.9995189905166626
neurons O O 0.9999755620956421
and O O 0.9998130202293396
astrocytes O O 0.9998898506164551
. O O 0.9999605417251587

These O O 0.9999114274978638
changes O O 0.9999740123748779
might O O 0.9996415376663208
be O O 0.9998430013656616
involved O O 0.999936580657959
in O O 0.999934196472168
detrimental O O 0.9995788931846619
neuroplasticity O O 0.999971866607666
and O O 0.9999046325683594
neuroinflammatory O O 0.9999382495880127
changes O O 0.9999921321868896
that O O 0.9999816417694092
occur O O 0.999988317489624
following O O 0.9999669790267944
seizures O O 0.9999526739120483
. O O 0.9999504089355469

Metallothionein B B 0.9989006519317627
induction O O 0.9995489716529846
reduces O O 0.9995224475860596
caspase O O 0.8677634000778198
- O O 0.9869956374168396
3 O O 0.988987147808075
activity O O 0.9995531439781189
and O O 0.9997788071632385
TNFalpha O O 0.8040071129798889
levels O O 0.9991068243980408
with O O 0.9999091625213623
preservation O O 0.9999872446060181
of O O 0.9999755620956421
cognitive O O 0.9999408721923828
function O O 0.9999971389770508
and O O 0.9999809265136719
intact O O 0.9999682903289795
hippocampal O O 0.9994877576828003
neurons O O 0.9999902248382568
in O O 0.9999022483825684
carmustine B B 0.99941086769104
- O O 0.9996651411056519
treated O O 0.9998028874397278
rats O O 0.9999889135360718
. O O 0.9999480247497559

Hippocampal O O 0.9938997030258179
integrity O O 0.998056948184967
is O O 0.9998617172241211
essential O O 0.999825656414032
for O O 0.9998051524162292
cognitive O O 0.9999300241470337
functions O O 0.9999914169311523
. O O 0.9999386072158813

On O O 0.9998984336853027
the O O 0.999956488609314
other O O 0.9999467134475708
hand O O 0.9999802112579346
, O O 0.9998683929443359
induction O O 0.9999392032623291
of O O 0.9993816614151001
metallothionein B O 0.5219832062721252
( O O 0.9915907382965088
MT B O 0.5799048542976379
) O O 0.9740954637527466
by O O 0.9985291957855225
ZnSO B B 0.9949799180030823
( I O 0.8869229555130005
4 I O 0.5950928330421448
) I O 0.65091872215271
and O O 0.9998950958251953
its O O 0.999782383441925
role O O 0.9999352693557739
in O O 0.9998470544815063
neuroprotection O O 0.9999816417694092
has O O 0.9999456405639648
been O O 0.9999755620956421
documented O O 0.9999794960021973
. O O 0.9999668598175049

The O O 0.9999899864196777
present O O 0.9999868869781494
study O O 0.9999878406524658
aimed O O 0.9999905824661255
to O O 0.9999942779541016
explore O O 0.9999568462371826
the O O 0.9999704360961914
effect O O 0.9999581575393677
of O O 0.999811589717865
MT B O 0.7794260382652283
induction O O 0.7385964393615723
on O O 0.9987371563911438
carmustine B B 0.9996771812438965
( O O 0.9913617968559265
BCNU B B 0.9976643323898315
) O O 0.9891863465309143
- O O 0.9997463822364807
induced O O 0.9998515844345093
hippocampal O O 0.9987925291061401
cognitive O O 0.999713122844696
dysfunction O O 0.9999974966049194
in O O 0.9999713897705078
rats O O 0.9999934434890747
. O O 0.9999804496765137

A O O 0.9999850988388062
total O O 0.9999899864196777
of O O 0.9999911785125732
60 O O 0.9999969005584717
male O O 0.9999918937683105
Wistar O O 0.9997041821479797
albino O O 0.9968724846839905
rats O O 0.9999935626983643
were O O 0.9999849796295166
randomly O O 0.9999916553497314
divided O O 0.9999929666519165
into O O 0.9999587535858154
four O O 0.9999512434005737
groups O O 0.9999926090240479
( O O 0.9999521970748901
15 O O 0.9999682903289795
/ O O 0.9999293088912964
group O O 0.9999951124191284
) O O 0.9999746084213257
: O O 0.9999899864196777
The O O 0.9999817609786987
control O O 0.9999599456787109
group O O 0.9999786615371704
injected O O 0.9999440908432007
with O O 0.9999501705169678
single O O 0.9998975992202759
doses O O 0.9999508857727051
of O O 0.9999061822891235
normal O O 0.9995115995407104
saline O O 0.9999833106994629
( O O 0.9998868703842163
i O O 0.9995972514152527
. O O 0.9999855756759644
c O O 0.9999812841415405
. O O 0.9999899864196777
v O O 0.9819537401199341
) O O 0.9999583959579468
followed O O 0.9998912811279297
24 O O 0.9999443292617798
h O O 0.9996528625488281
later O O 0.9999638795852661
by O O 0.9997454285621643
BCNU B B 0.9610467553138733
solvent O O 0.995859682559967
( O O 0.999660849571228
i O O 0.988027811050415
. O O 0.9999542236328125
v O O 0.9984143972396851
) O O 0.9999666213989258
. O O 0.9999550580978394

The O O 0.9999877214431763
second O O 0.999990701675415
group O O 0.9999929666519165
administered O O 0.9997825026512146
ZnSO B B 0.9987167119979858
( I O 0.6737564206123352
4 I O 0.7181086540222168
) I O 0.8255716562271118
( O O 0.999381422996521
0 O O 0.9998713731765747
. O O 0.9999897480010986
1 O O 0.9999746084213257
micromol O O 0.9993570446968079
/ O O 0.9999258518218994
10 O O 0.9999762773513794
microl O O 0.9999974966049194
normal O O 0.9999704360961914
saline O O 0.9999921321868896
, O O 0.9999619722366333
i O O 0.9998688697814941
. O O 0.9999898672103882
c O O 0.9999982118606567
. O O 0.9999947547912598
v O O 0.9999639987945557
, O O 0.999984622001648
once O O 0.9997668862342834
) O O 0.9999765157699585
then O O 0.9992126226425171
BCNU B B 0.9648858904838562
solvent O O 0.9991050362586975
( O O 0.9988396763801575
i O O 0.9941349625587463
. O O 0.9999762773513794
v O O 0.9997535347938538
) O O 0.9999765157699585
after O O 0.9999701976776123
24 O O 0.9999934434890747
h O O 0.9999427795410156
. O O 0.9999490976333618

Third O O 0.9995299577713013
group O O 0.9999898672103882
received O O 0.9998207688331604
BCNU B B 0.999411940574646
( O O 0.9978443384170532
20 O O 0.9995710253715515
mg O O 0.9998874664306641
/ O O 0.9999762773513794
kg O O 0.9999951124191284
, O O 0.999903678894043
i O O 0.9989407658576965
. O O 0.9999918937683105
v O O 0.9999656677246094
, O O 0.9999749660491943
once O O 0.989192545413971
) O O 0.9999849796295166
24 O O 0.9999688863754272
h O O 0.9995537400245667
after O O 0.9999417066574097
injection O O 0.9999738931655884
with O O 0.9999837875366211
normal O O 0.999657154083252
saline O O 0.9999916553497314
( O O 0.9998693466186523
i O O 0.999645471572876
. O O 0.9999876022338867
c O O 0.9999943971633911
. O O 0.9999943971633911
v O O 0.9982699155807495
) O O 0.9999768733978271
. O O 0.9999722242355347

Fourth O O 0.9975802898406982
group O O 0.9999880790710449
received O O 0.9999668598175049
a O O 0.9999841451644897
single O O 0.9999537467956543
dose O O 0.9999206066131592
of O O 0.9996647834777832
ZnSO B B 0.9987817406654358
( I O 0.6096577048301697
4 I O 0.8758553266525269
) I O 0.7489285469055176
( O O 0.998250424861908
0 O O 0.9999003410339355
. O O 0.9999908208847046
1 O O 0.9999721050262451
micromol O O 0.9994800686836243
/ O O 0.999923825263977
10 O O 0.9999806880950928
microl O O 0.9999973773956299
normal O O 0.9999510049819946
saline O O 0.9999936819076538
, O O 0.9999548196792603
i O O 0.999871015548706
. O O 0.999993085861206
c O O 0.999997615814209
. O O 0.9999954700469971
v O O 0.9999630451202393
) O O 0.9999785423278809
then O O 0.9980225563049316
BCNU B B 0.9892099499702454
( O O 0.999068558216095
20 O O 0.9999436140060425
mg O O 0.9999393224716187
/ O O 0.9999880790710449
kg O O 0.9999964237213135
, O O 0.9998852014541626
i O O 0.9998196959495544
. O O 0.9999927282333374
v O O 0.9999744892120361
, O O 0.9999748468399048
once O O 0.9981234669685364
) O O 0.9999880790710449
after O O 0.9999701976776123
24 O O 0.9999945163726807
h O O 0.9999464750289917
. O O 0.9999713897705078

The O O 0.9999880790710449
obtained O O 0.9999957084655762
data O O 0.9999867677688599
revealed O O 0.9999778270721436
that O O 0.9998363256454468
BCNU B B 0.999404788017273
administration O O 0.9997814297676086
resulted O O 0.9999499320983887
in O O 0.9999426603317261
deterioration O O 0.9999837875366211
of O O 0.9999328851699829
learning O O 0.9999696016311646
and O O 0.9999340772628784
short O O 0.9997441172599792
- O O 0.9999489784240723
term O O 0.9999780654907227
memory O O 0.9999926090240479
( O O 0.9999008178710938
STM O O 0.9878743290901184
) O O 0.999953031539917
, O O 0.9999884366989136
as O O 0.9999971389770508
measured O O 0.9999978542327881
by O O 0.9999957084655762
using O O 0.9999814033508301
radial O O 0.9999904632568359
arm O O 0.9999980926513672
water O O 0.9999306201934814
maze O O 0.9999861717224121
, O O 0.9999834299087524
accompanied O O 0.9999709129333496
with O O 0.9999719858169556
decreased O O 0.9999628067016602
hippocampal O O 0.9830936193466187
glutathione B B 0.9920209050178528
reductase O O 0.8075374960899353
( O O 0.9994220733642578
GR O O 0.5556085109710693
) O O 0.9982532858848572
activity O O 0.9996724128723145
and O O 0.9999459981918335
reduced O O 0.9999159574508667
glutathione B B 0.9810225367546082
( O O 0.9913753867149353
GSH B B 0.9429949522018433
) O O 0.9908225536346436
content O O 0.9998160004615784
. O O 0.9999710321426392

Also O O 0.9999346733093262
, O O 0.9996196031570435
BCNU B B 0.9981163740158081
administration O O 0.9988998174667358
increased O O 0.999512791633606
serum O O 0.9916033148765564
tumor O O 0.8082788586616516
necrosis O O 0.9334970712661743
factor O O 0.9494583606719971
- O O 0.9596445560455322
alpha O O 0.8998387455940247
( O O 0.9985051155090332
TNFalpha O O 0.5526223182678223
) O O 0.9799916744232178
, O O 0.9979008436203003
hippocampal O O 0.9845884442329407
MT B O 0.4871947467327118
and O O 0.9986147880554199
malondialdehyde B B 0.9951068162918091
( O O 0.9979828596115112
MDA B B 0.9959422945976257
) O O 0.9900739192962646
contents O O 0.9996415376663208
as O O 0.9999734163284302
well O O 0.9999269247055054
as O O 0.9999080896377563
caspase O O 0.8899417519569397
- O O 0.991407036781311
3 O O 0.9931415915489197
activity O O 0.9996896982192993
in O O 0.9999470710754395
addition O O 0.9999490976333618
to O O 0.999955415725708
histological O O 0.999981164932251
alterations O O 0.9999979734420776
. O O 0.9999622106552124

ZnSO B B 0.9772568941116333
( I O 0.6278356313705444
4 I O 0.49834194779396057
) I O 0.7630495429039001
pretreatment O O 0.9827437400817871
counteracted O O 0.9998486042022705
BCNU B B 0.9955885410308838
- O O 0.9988659620285034
induced O O 0.999909520149231
inhibition O O 0.9999575614929199
of O O 0.9998229146003723
GR O O 0.5870699882507324
and O O 0.999861478805542
depletion O O 0.9999395608901978
of O O 0.999302864074707
GSH B B 0.950093686580658
and O O 0.9998948574066162
resulted O O 0.9999876022338867
in O O 0.9999849796295166
significant O O 0.9999773502349854
reduction O O 0.9999847412109375
in O O 0.9999747276306152
the O O 0.99992835521698
levels O O 0.9998817443847656
of O O 0.9990447163581848
MDA B B 0.9832679629325867
and O O 0.9948809146881104
TNFalpha O O 0.693266749382019
as O O 0.9999735355377197
well O O 0.9999632835388184
as O O 0.9999725818634033
the O O 0.9999600648880005
activity O O 0.9999120235443115
of O O 0.9993528723716736
caspase O O 0.9734175801277161
- O O 0.994860053062439
3 O O 0.9931473135948181
. O O 0.9999375343322754

The O O 0.9999593496322632
histological O O 0.9999780654907227
features O O 0.9999955892562866
were O O 0.9999520778656006
improved O O 0.9999864101409912
in O O 0.9995195865631104
hippocampus O O 0.9977763295173645
of O O 0.9999464750289917
rats O O 0.999988317489624
treated O O 0.9999120235443115
with O O 0.9992507100105286
ZnSO B B 0.9975715279579163
( I O 0.7589953541755676
4 I O 0.7107791304588318
) I O 0.8229855895042419
+ O O 0.8328556418418884
BCNU B B 0.9688060879707336
compared O O 0.9998639822006226
to O O 0.999962329864502
only O O 0.9991957545280457
BCNU B B 0.9730579257011414
- O O 0.9965470433235168
treated O O 0.9998292922973633
animals O O 0.9999895095825195
. O O 0.9999772310256958

In O O 0.9999244213104248
conclusion O O 0.9999668598175049
, O O 0.998970627784729
MT B B 0.968230664730072
induction O O 0.7063900232315063
halts O O 0.9846599102020264
BCNU B B 0.9953408241271973
- O O 0.9986878037452698
induced O O 0.9998706579208374
hippocampal O O 0.9966193437576294
toxicity O O 0.9999558925628662
as O O 0.9999486207962036
it O O 0.9996322393417358
prevented O O 0.9993963241577148
GR O O 0.7629972696304321
inhibition O O 0.9973891377449036
and O O 0.9997944235801697
GSH B B 0.9640779495239258
depletion O O 0.9994807839393616
and O O 0.9999023675918579
counteracted O O 0.9997473359107971
the O O 0.9999523162841797
increased O O 0.9998949766159058
levels O O 0.9997690320014954
of O O 0.998846173286438
TNFalpha O O 0.8263099193572998
, O O 0.9806899428367615
MDA B B 0.9814109206199646
and O O 0.9966551065444946
caspase O O 0.907160758972168
- O O 0.9922447800636292
3 O O 0.9898715615272522
activity O O 0.9978768825531006
with O O 0.9999465942382812
subsequent O O 0.9999878406524658
preservation O O 0.9999877214431763
of O O 0.9999557733535767
cognition O O 0.9998447895050049
. O O 0.9999725818634033

Fatal O O 0.9989564418792725
carbamazepine B B 0.9992653727531433
induced O O 0.9997120499610901
fulminant O O 0.999688982963562
eosinophilic O O 0.9968634843826294
( O O 0.9990440011024475
hypersensitivity O O 0.9767730236053467
) O O 0.9999184608459473
myocarditis O O 0.9999929666519165
: O O 0.9999489784240723
emphasis O O 0.9999923706054688
on O O 0.9999186992645264
anatomical O O 0.9999866485595703
and O O 0.9999302625656128
histological O O 0.9999947547912598
characteristics O O 0.9999972581863403
, O O 0.9999829530715942
mechanisms O O 0.9999600648880005
and O O 0.9999822378158569
genetics O O 0.9999861717224121
of O O 0.9999724626541138
drug O O 0.998869001865387
hypersensitivity O O 0.9993512034416199
and O O 0.9999566078186035
differential O O 0.9999781847000122
diagnosis O O 0.9999979734420776
. O O 0.9999834299087524

The O O 0.9999486207962036
most O O 0.9999474287033081
severe O O 0.9999886751174927
adverse O O 0.9999598264694214
reactions O O 0.9999951124191284
to O O 0.999616265296936
carbamazepine B B 0.9990780353546143
have O O 0.99970942735672
been O O 0.9999868869781494
observed O O 0.9999808073043823
in O O 0.9996544122695923
the O O 0.9997718930244446
haemopoietic O O 0.9962782263755798
system O O 0.9998857975006104
, O O 0.9997510313987732
the O O 0.9997957348823547
liver O O 0.9997828602790833
and O O 0.9997609257698059
the O O 0.9998326301574707
cardiovascular O O 0.9999637603759766
system O O 0.9999552965164185
. O O 0.9999501705169678

A O O 0.9996418952941895
frequently O O 0.9997591376304626
fatal O O 0.9999586343765259
, O O 0.9999485015869141
although O O 0.9999772310256958
exceptionally O O 0.9998929500579834
rare O O 0.999972939491272
side O O 0.9999468326568604
effect O O 0.9999834299087524
of O O 0.9998444318771362
carbamazepine B B 0.9993677735328674
is O O 0.9997058510780334
necrotizing O O 0.9998674392700195
eosinophilic O O 0.9958107471466064
( O O 0.9984745383262634
hypersensitivity O O 0.9335853457450867
) O O 0.9999097585678101
myocarditis O O 0.9999954700469971
. O O 0.9999655485153198

We O O 0.9999470710754395
report O O 0.9999932050704956
a O O 0.9999853372573853
case O O 0.9999946355819702
of O O 0.9999738931655884
hypersensitivity O O 0.9940804839134216
myocarditis O O 0.9999963045120239
secondary O O 0.9999746084213257
to O O 0.9997374415397644
administration O O 0.9999006986618042
of O O 0.9990313053131104
carbamazepine B B 0.9990083575248718
. O O 0.9999198913574219

Acute O O 0.9998792409896851
hypersensitivity O O 0.9422256946563721
myocarditis O O 0.9999885559082031
was O O 0.9999839067459106
not O O 0.9999909400939941
suspected O O 0.9999948740005493
clinically O O 0.9999912977218628
, O O 0.9999604225158691
and O O 0.9999810457229614
the O O 0.9999974966049194
diagnosis O O 0.9999969005584717
was O O 0.9999954700469971
made O O 0.9999991655349731
post O O 0.9999850988388062
- O O 0.9997467398643494
mortem O O 0.9999876022338867
. O O 0.9999815225601196

Histology O O 0.9997758269309998
revealed O O 0.999919056892395
diffuse O O 0.9998606443405151
infiltration O O 0.9999221563339233
of O O 0.9999352693557739
the O O 0.9999585151672363
myocardium O O 0.9999969005584717
by O O 0.9997270703315735
eosinophils O O 0.9991375207901001
and O O 0.9997722506523132
lymphocytes O O 0.9994704127311707
with O O 0.9999547004699707
myocyte O O 0.999964714050293
damage O O 0.9999727010726929
. O O 0.9999608993530273

Clinically O O 0.9999363422393799
, O O 0.9999759197235107
death O O 0.9998610019683838
was O O 0.999980092048645
due O O 0.999992847442627
to O O 0.9998799562454224
cardiogenic O O 0.9999829530715942
shock O O 0.9999842643737793
. O O 0.9999722242355347

To O O 0.9999939203262329
best O O 0.9999936819076538
of O O 0.9999933242797852
our O O 0.9999867677688599
knowledge O O 0.9999943971633911
this O O 0.99998939037323
is O O 0.9999915361404419
the O O 0.9999945163726807
second O O 0.9999973773956299
case O O 0.9999966621398926
of O O 0.9999637603759766
fatal O O 0.9995908141136169
carbamazepine B B 0.9987602233886719
induced O O 0.9995566010475159
myocarditis O O 0.999995231628418
reported O O 0.9999853372573853
in O O 0.9999703168869019
English O O 0.9981561303138733
literature O O 0.9999942779541016
. O O 0.9999614953994751

Neuropsychiatric O O 0.9990826845169067
behaviors O O 0.9999052286148071
in O O 0.9998573064804077
the O O 0.9998010993003845
MPTP B O 0.8236016035079956
marmoset O O 0.9823924899101257
model O O 0.9999696016311646
of O O 0.9999074935913086
Parkinson O O 0.9965721368789673
' O O 0.9999862909317017
s O O 0.9999666213989258
disease O O 0.9999867677688599
. O O 0.9999465942382812

OBJECTIVES O O 0.9814440011978149
: O O 0.9999059438705444
Neuropsychiatric O O 0.9997650980949402
symptoms O O 0.9999662637710571
are O O 0.9999699592590332
increasingly O O 0.9999810457229614
recognised O O 0.9999761581420898
as O O 0.9999746084213257
a O O 0.9999799728393555
significant O O 0.9999840259552002
problem O O 0.9999916553497314
in O O 0.9999347925186157
patients O O 0.9999876022338867
with O O 0.9999769926071167
Parkinson O O 0.9950647950172424
' O O 0.9999866485595703
s O O 0.9999319314956665
disease O O 0.9999727010726929
( O O 0.9998691082000732
PD O O 0.9890668392181396
) O O 0.9999700784683228
. O O 0.9999698400497437

These O O 0.9999716281890869
symptoms O O 0.9999935626983643
may O O 0.9999388456344604
be O O 0.9999819993972778
due O O 0.9999843835830688
to O O 0.9999293088912964
' O O 0.999849796295166
sensitisation O O 0.9997749924659729
' O O 0.9999927282333374
following O O 0.9999575614929199
repeated O O 0.9998317956924438
levodopa B B 0.9996052384376526
treatment O O 0.9998351335525513
or O O 0.9999428987503052
a O O 0.9999394416809082
direct O O 0.9999634027481079
effect O O 0.999958872795105
of O O 0.9998432397842407
dopamine B B 0.9995169639587402
on O O 0.9996746778488159
the O O 0.999982476234436
disease O O 0.9999924898147583
state O O 0.9999963045120239
. O O 0.9999843835830688

The O O 0.9997915625572205
levodopa B B 0.9993908405303955
- O O 0.9989830851554871
treated O O 0.9985887408256531
MPTP B B 0.8623995780944824
- O O 0.7904999852180481
lesioned O O 0.9117560386657715
marmoset O B 0.9971643090248108
was O O 0.9998388290405273
used O O 0.9999392032623291
as O O 0.9999712705612183
a O O 0.9999396800994873
model O O 0.9999918937683105
of O O 0.9999610185623169
neuropsychiatric O O 0.9999858140945435
symptoms O O 0.9999903440475464
in O O 0.9999409914016724
PD O O 0.992099940776825
patients O O 0.9999895095825195
. O O 0.9999668598175049

Here O O 0.9999780654907227
we O O 0.9999539852142334
compare O O 0.9999614953994751
the O O 0.9999845027923584
time O O 0.9999597072601318
course O O 0.9999872446060181
of O O 0.9999359846115112
levodopa B B 0.9998688697814941
- O O 0.9997352957725525
induced O O 0.9998476505279541
motor O O 0.9999728202819824
fluctuations O O 0.9999940395355225
and O O 0.9999024868011475
neuropsychiatric O O 0.9999566078186035
- O O 0.9999691247940063
like O O 0.9999926090240479
behaviors O O 0.9999877214431763
to O O 0.999985933303833
determine O O 0.9999958276748657
the O O 0.9999961853027344
relationship O O 0.9999977350234985
between O O 0.9999887943267822
duration O O 0.9999902248382568
of O O 0.9999579191207886
treatment O O 0.999962329864502
and O O 0.999993085861206
onset O O 0.9999978542327881
of O O 0.9999934434890747
symptoms O O 0.9999970197677612
. O O 0.9999665021896362

METHODS O O 0.9970614314079285
: O O 0.9999128580093384
Marmosets O O 0.4932476282119751
were O O 0.9999496936798096
administered O O 0.9997448325157166
1 B B 0.941333532333374
- I I 0.984643816947937
methyl I I 0.9981158971786499
- I I 0.9627034664154053
4 I I 0.9860585331916809
- I I 0.9961997866630554
phenyl I I 0.9986950755119324
- I I 0.9270037412643433
1 I I 0.8737757205963135
, I I 0.9612960815429688
2 I I 0.9900791645050049
, I I 0.975955605506897
3 I I 0.9727585911750793
, I I 0.9768573045730591
6 I I 0.9873092770576477
- I I 0.9826459884643555
tetrahydropyridine I I 0.9998863935470581
( O O 0.998561680316925
2 O O 0.9997637867927551
. O O 0.9999927282333374
0 O O 0.9999680519104004
mg O O 0.9999593496322632
/ O O 0.9999648332595825
kg O O 0.9999927282333374
s O O 0.9999542236328125
. O O 0.9999955892562866
c O O 0.9999979734420776
. O O 0.9999942779541016
) O O 0.9999734163284302
for O O 0.9999563694000244
five O O 0.9999905824661255
days O O 0.999993085861206
, O O 0.9999814033508301
resulting O O 0.9999895095825195
in O O 0.999992847442627
stable O O 0.9999880790710449
parkinsonism O O 0.9996351003646851
. O O 0.9999754428863525

Levodopa B B 0.9993890523910522
( O O 0.9985034465789795
15 O O 0.9993240833282471
mg O O 0.9995385408401489
/ O O 0.9998112320899963
kg O O 0.999982476234436
and O O 0.9988967180252075
benserazide B B 0.996405839920044
, O O 0.9912422895431519
3 O O 0.9876039028167725
. O O 0.9999948740005493
75 O O 0.9997355341911316
mg O O 0.9999533891677856
/ O O 0.9999760389328003
kg O O 0.9999927282333374
) O O 0.9999496936798096
p O O 0.9998694658279419
. O O 0.9999938011169434
o O O 0.9999899864196777
. O O 0.9999556541442871

b O O 0.9999555349349976
. O O 0.9999936819076538
i O O 0.9999966621398926
. O O 0.999995231628418
d O O 0.9999951124191284
, O O 0.999907374382019
was O O 0.9999171495437622
administered O O 0.9999285936355591
for O O 0.9999508857727051
30 O O 0.9999845027923584
days O O 0.9999915361404419
. O O 0.9999167919158936

Animals O O 0.9997926354408264
were O O 0.9999841451644897
evaluated O O 0.9999797344207764
for O O 0.9999443292617798
parkinsonian O O 0.9990397095680237
disability O O 0.999763548374176
, O O 0.9999072551727295
dyskinesia O O 0.9999921321868896
and O O 0.999868631362915
on O O 0.9269348978996277
- O O 0.9996552467346191
time O O 0.9998113512992859
( O O 0.9975020289421082
motor O O 0.999859094619751
fluctuations O O 0.9999700784683228
) O O 0.9999161958694458
and O O 0.9998413324356079
neuropsychiatric O O 0.9999333620071411
- O O 0.9999655485153198
like O O 0.9999911785125732
behaviors O O 0.9999841451644897
on O O 0.9998852014541626
Day O O 0.9999290704727173
0 O O 0.9999336004257202
( O O 0.9999396800994873
prior O O 0.9999834299087524
to O O 0.9994358420372009
levodopa B B 0.9996635913848877
) O O 0.9998074173927307
and O O 0.9999350309371948
on O O 0.999941349029541
Days O O 0.9999885559082031
1 O O 0.9999926090240479
, O O 0.9999241828918457
7 O O 0.999994158744812
, O O 0.9998807907104492
13 O O 0.9999934434890747
, O O 0.9997506737709045
27 O O 0.9999911785125732
and O O 0.9999473094940186
30 O O 0.9999923706054688
of O O 0.9999364614486694
treatment O O 0.9999493360519409
using O O 0.9999624490737915
post O O 0.999562680721283
hoc O O 0.9998698234558105
DVD O O 0.9988836646080017
analysis O O 0.9998705387115479
by O O 0.9999864101409912
a O O 0.9999779462814331
trained O O 0.9997960925102234
rater O O 0.9996755123138428
, O O 0.9999783039093018
blind O O 0.999985933303833
to O O 0.9999948740005493
the O O 0.999994158744812
treatment O O 0.9999654293060303
day O O 0.9999901056289673
. O O 0.9999845027923584

RESULTS O O 0.9999268054962158
: O O 0.9999701976776123
The O O 0.9999749660491943
neuropsychiatric O O 0.9999321699142456
- O O 0.9998689889907837
like O O 0.9999725818634033
behavior O O 0.9999120235443115
rating O O 0.9999096393585205
scale O O 0.9996145963668823
demonstrated O O 0.9999184608459473
high O O 0.999936580657959
interrater O O 0.9999486207962036
reliability O O 0.9999977350234985
between O O 0.9999388456344604
three O O 0.9999104738235474
trained O O 0.999883770942688
raters O O 0.9998947381973267
of O O 0.9999700784683228
differing O O 0.9999855756759644
professional O O 0.9999667406082153
backgrounds O O 0.9999871253967285
. O O 0.9999598264694214

As O O 0.9999594688415527
anticipated O O 0.9999949932098389
, O O 0.9999768733978271
animals O O 0.9994169473648071
exhibited O O 0.9999741315841675
a O O 0.9999823570251465
progressive O O 0.9999881982803345
increase O O 0.999991774559021
in O O 0.9999657869338989
levodopa B B 0.9997807145118713
- O O 0.9998915195465088
induced O O 0.9998772144317627
motor O O 0.9999884366989136
fluctuations O O 0.9999954700469971
, O O 0.9999550580978394
dyskinesia O O 0.9999958276748657
and O O 0.9999309778213501
wearing O O 0.9997525811195374
- O O 0.999953031539917
off O O 0.9998621940612793
, O O 0.9999767541885376
that O O 0.9999669790267944
correlated O O 0.999995231628418
with O O 0.9999945163726807
the O O 0.9999938011169434
duration O O 0.9999845027923584
of O O 0.9999520778656006
levodopa B B 0.999660849571228
therapy O O 0.9998289346694946
. O O 0.9999490976333618

In O O 0.9999303817749023
contrast O O 0.999943733215332
, O O 0.9998664855957031
levodopa B B 0.9996745586395264
- O O 0.999873161315918
induced O O 0.9998869895935059
neuropsychiatric O O 0.9999715089797974
- O O 0.9999693632125854
like O O 0.9999918937683105
behaviors O O 0.9999899864196777
were O O 0.9999632835388184
present O O 0.9999850988388062
on O O 0.999929666519165
Day O O 0.9999881982803345
1 O O 0.9999569654464722
of O O 0.9998934268951416
levodopa B B 0.9998345375061035
treatment O O 0.9998680353164673
and O O 0.9999872446060181
their O O 0.999984622001648
severity O O 0.9999966621398926
did O O 0.9999916553497314
not O O 0.9999954700469971
correlate O O 0.9999966621398926
with O O 0.9999946355819702
duration O O 0.9999909400939941
of O O 0.9999741315841675
treatment O O 0.9999746084213257
. O O 0.9999808073043823

CONCLUSIONS O O 0.9962182641029358
: O O 0.9999959468841553
The O O 0.9999901056289673
data O O 0.9999864101409912
suggest O O 0.9999340772628784
that O O 0.9998897314071655
neuropsychiatric O O 0.999976396560669
disorders O O 0.9999899864196777
in O O 0.9999252557754517
PD O O 0.9613233208656311
are O O 0.9998514652252197
more O O 0.9999327659606934
likely O O 0.9999306201934814
an O O 0.9998750686645508
interaction O O 0.9999574422836304
between O O 0.9995934367179871
levodopa B B 0.9997808337211609
and O O 0.9996840953826904
the O O 0.9999799728393555
disease O O 0.9999861717224121
state O O 0.9999909400939941
than O O 0.9999527931213379
a O O 0.9999334812164307
consequence O O 0.999991774559021
of O O 0.9999387264251709
sensitisation O O 0.9999562501907349
to O O 0.9998195767402649
repeated O O 0.9989556074142456
dopaminergic O B 0.9967920184135437
therapy O O 0.9984299540519714
. O O 0.9999704360961914

Contrast B B 0.9561300277709961
medium I O 0.9931814074516296
nephrotoxicity O O 0.9979433417320251
after O O 0.9995988011360168
renal O O 0.9978275895118713
artery O O 0.9923575520515442
and O O 0.999640941619873
coronary O O 0.9989233613014221
angioplasty O O 0.9893112778663635
. O O 0.9998961687088013

BACKGROUND O O 0.9915379285812378
: O O 0.9998899698257446
Renal O O 0.99985671043396
dysfunction O O 0.9999902248382568
induced O O 0.9999455213546753
by O O 0.9999551773071289
iodinated O B 0.9411001205444336
contrast B I 0.9961742758750916
medium I I 0.9311222434043884
( O O 0.9640073776245117
CM B B 0.9056527018547058
) O O 0.9958981871604919
administration O O 0.999923825263977
can O O 0.9999699592590332
minimize O O 0.9999741315841675
the O O 0.9999958276748657
benefit O O 0.9999969005584717
of O O 0.9999922513961792
the O O 0.9999949932098389
interventional O O 0.9999933242797852
procedure O O 0.9999985694885254
in O O 0.9999864101409912
patients O O 0.999994158744812
undergoing O O 0.9999781847000122
renal O O 0.9999345541000366
angioplasty O O 0.9831915497779846
( O O 0.9998051524162292
PTRA O O 0.9755676984786987
) O O 0.9999749660491943
. O O 0.9999797344207764

PURPOSE O O 0.9999297857284546
: O O 0.9999973773956299
To O O 0.9999940395355225
compare O O 0.9999855756759644
the O O 0.9999758005142212
susceptibility O O 0.9999455213546753
to O O 0.9997815489768982
nephrotoxic O O 0.9987292885780334
effect O O 0.9999363422393799
of O O 0.9995014667510986
CM B B 0.9925565719604492
in O O 0.9997791647911072
patients O O 0.9999908208847046
undergoing O O 0.9999394416809082
PTRA O O 0.6806818842887878
with O O 0.9999277591705322
that O O 0.9999774694442749
of O O 0.9999854564666748
patients O O 0.9999901056289673
submitted O O 0.9999967813491821
to O O 0.9999536275863647
percutaneous O O 0.9999021291732788
coronary O O 0.9993257522583008
intervention O O 0.999995231628418
( O O 0.9998522996902466
PCI O O 0.6724379658699036
) O O 0.9999709129333496
. O O 0.9999802112579346

MATERIAL O O 0.999921441078186
AND O O 0.9999872446060181
METHODS O O 0.999996542930603
: O O 0.9999957084655762
A O O 0.9999916553497314
total O O 0.9999856948852539
of O O 0.9999858140945435
33 O O 0.9999877214431763
patients O O 0.9999905824661255
successfully O O 0.9999653100967407
treated O O 0.9999668598175049
with O O 0.9997761845588684
PTRA O B 0.8659440875053406
( O O 0.9953670501708984
PTRA O O 0.5708742141723633
group O O 0.9978917241096497
, O O 0.9999613761901855
mean O O 0.999991774559021
age O O 0.9999982118606567
70 O O 0.9999984502792358
+ O O 0.9999978542327881
/ O O 0.9999953508377075
- O O 0.9999903440475464
12 O O 0.9999984502792358
years O O 0.9999992847442627
, O O 0.9999785423278809
23 O O 0.9987888932228088
female O O 0.9999091625213623
, O O 0.9999665021896362
basal O O 0.9996336698532104
creatinine B O 0.6824491024017334
1 O O 0.999931812286377
. O O 0.9999951124191284
46 O O 0.9999942779541016
+ O O 0.9999912977218628
/ O O 0.99997878074646
- O O 0.9999731779098511
0 O O 0.9999887943267822
. O O 0.9999884366989136
79 O O 0.9999774694442749
, O O 0.9999706745147705
range O O 0.9999936819076538
0 O O 0.9999918937683105
. O O 0.9999916553497314
7 O O 0.99998939037323
- O O 0.9990222454071045
4 O O 0.9999887943267822
. O O 0.9999959468841553
9 O O 0.9999920129776001
mg O O 0.999991774559021
/ O O 0.9999879598617554
dl O O 0.99998939037323
) O O 0.9999529123306274
were O O 0.9999798536300659
compared O O 0.9999896287918091
with O O 0.9999879598617554
33 O O 0.9999614953994751
patients O O 0.9999881982803345
undergoing O O 0.9999653100967407
successful O O 0.9998664855957031
PCI O O 0.6053979396820068
( O O 0.9989867806434631
PCI O O 0.6623649597167969
group O O 0.9992826581001282
) O O 0.9999216794967651
, O O 0.9999434947967529
matched O O 0.9999500513076782
for O O 0.9999814033508301
basal O O 0.9999157190322876
creatinine B B 0.9854905605316162
( O O 0.9997953772544861
1 O O 0.9999964237213135
. O O 0.9999980926513672
44 O O 0.9999967813491821
+ O O 0.9999933242797852
/ O O 0.999990701675415
- O O 0.9999697208404541
0 O O 0.9999905824661255
. O O 0.9999891519546509
6 O O 0.9999955892562866
, O O 0.9999793767929077
range O O 0.9999911785125732
0 O O 0.9999911785125732
. O O 0.9999932050704956
7 O O 0.9999896287918091
- O O 0.999445378780365
3 O O 0.9999942779541016
. O O 0.9999978542327881
4 O O 0.9999912977218628
mg O O 0.9999933242797852
/ O O 0.9999866485595703
dl O O 0.9999955892562866
) O O 0.9999823570251465
, O O 0.9999819993972778
gender O O 0.9999984502792358
, O O 0.9999699592590332
and O O 0.9999823570251465
age O O 0.9999312162399292
. O O 0.9999799728393555

In O O 0.9997299313545227
both O O 0.9989528656005859
groups O O 0.9999046325683594
postprocedural O O 0.9986959099769592
( O O 0.9998395442962646
48 O O 0.9999780654907227
h O O 0.9954699277877808
) O O 0.999948263168335
serum O O 0.9928365349769592
creatinine B B 0.9987183809280396
was O O 0.9999654293060303
measured O O 0.9999890327453613
. O O 0.9999725818634033

RESULTS O O 0.9997825026512146
: O O 0.9998694658279419
Postprocedural O O 0.9652036428451538
creatinine B B 0.9994269609451294
level O O 0.9995909333229065
decreased O O 0.9999682903289795
nonsignificantly O O 0.9997398257255554
in O O 0.9998733997344971
the O O 0.9998782873153687
PTRA O O 0.8058093190193176
group O O 0.9998968839645386
( O O 0.999942421913147
1 O O 0.9999916553497314
. O O 0.9999940395355225
46 O O 0.9999969005584717
+ O O 0.9999903440475464
/ O O 0.9998928308486938
- O O 0.9998311996459961
0 O O 0.9999781847000122
. O O 0.9999885559082031
8 O O 0.9999748468399048
vs O O 0.9999053478240967
. O O 0.999996542930603
1 O O 0.9999927282333374
. O O 0.9999945163726807
34 O O 0.9999938011169434
+ O O 0.9999905824661255
/ O O 0.999652624130249
- O O 0.9998806715011597
0 O O 0.9999864101409912
. O O 0.9999897480010986
5 O O 0.99998939037323
mg O O 0.9999809265136719
/ O O 0.9999752044677734
dl O O 0.9999920129776001
, O O 0.9999642372131348
P O O 0.9994367957115173
= O O 0.9999650716781616
NS O O 0.9996638298034668
) O O 0.999976396560669
and O O 0.9999462366104126
increased O O 0.9999299049377441
significantly O O 0.9999873638153076
in O O 0.9998998641967773
the O O 0.9998565912246704
PCI O O 0.5984998345375061
group O O 0.9998527765274048
( O O 0.9999586343765259
1 O O 0.9999940395355225
. O O 0.9999951124191284
44 O O 0.9999964237213135
+ O O 0.9999934434890747
/ O O 0.9999462366104126
- O O 0.9999103546142578
0 O O 0.9999864101409912
. O O 0.9999825954437256
6 O O 0.999994158744812
vs O O 0.9999586343765259
. O O 0.9999957084655762
1 O O 0.9999902248382568
. O O 0.9999957084655762
57 O O 0.9999961853027344
+ O O 0.9999936819076538
/ O O 0.9998065829277039
- O O 0.9999524354934692
0 O O 0.9999899864196777
. O O 0.9999891519546509
7 O O 0.9999955892562866
mg O O 0.9999912977218628
/ O O 0.999969482421875
dl O O 0.9999938011169434
, O O 0.999972939491272
P O O 0.9998383522033691
< O O 0.9999778270721436
0 O O 0.999988317489624
. O O 0.9999949932098389
02 O O 0.999976634979248
) O O 0.9999761581420898
. O O 0.9999765157699585

Changes O O 0.9999949932098389
in O O 0.9999898672103882
serum O O 0.9993683695793152
creatinine B B 0.9974797368049622
after O O 0.9997350573539734
intervention O O 0.9999947547912598
( O O 0.9998600482940674
after O O 0.9953328967094421
- O O 0.990445613861084
before O O 0.9951131939888
) O O 0.9999688863754272
were O O 0.9999616146087646
significantly O O 0.9999814033508301
different O O 0.9999922513961792
between O O 0.9997358918190002
the O O 0.9999247789382935
PTRA O O 0.9031668901443481
and O O 0.9994795918464661
PCI O O 0.718903124332428
groups O O 0.999523401260376
( O O 0.999947190284729
- O O 0.9999486207962036
0 O O 0.9999375343322754
. O O 0.9999920129776001
12 O O 0.999992847442627
+ O O 0.999984860420227
/ O O 0.9999114274978638
- O O 0.9999105930328369
0 O O 0.9999616146087646
. O O 0.9999802112579346
5 O O 0.9999829530715942
vs O O 0.9999303817749023
. O O 0.9999969005584717
0 O O 0.9999513626098633
. O O 0.9999959468841553
13 O O 0.9999945163726807
+ O O 0.9999842643737793
/ O O 0.9998075366020203
- O O 0.999929666519165
0 O O 0.9999439716339111
. O O 0.9999947547912598
3 O O 0.9999884366989136
, O O 0.9999696016311646
P O O 0.9998146891593933
= O O 0.9999372959136963
0 O O 0.9999856948852539
. O O 0.9999970197677612
014 O O 0.9999716281890869
) O O 0.9999799728393555
. O O 0.9999860525131226

This O O 0.9999783039093018
difference O O 0.999993085861206
was O O 0.9999516010284424
not O O 0.9999901056289673
related O O 0.9999940395355225
to O O 0.9999837875366211
either O O 0.9999781847000122
a O O 0.9999929666519165
different O O 0.9999933242797852
clinical O O 0.9999954700469971
risk O O 0.9999715089797974
profile O O 0.9999934434890747
or O O 0.9999911785125732
to O O 0.999976396560669
the O O 0.99998939037323
volume O O 0.9998481273651123
of O O 0.9978399276733398
CM B B 0.8850057721138
administered O O 0.9997723698616028
. O O 0.9999454021453857

CONCLUSION O O 0.999736487865448
: O O 0.99989914894104
In O O 0.9999831914901733
this O O 0.9999756813049316
preliminary O O 0.9999877214431763
study O O 0.9999849796295166
patients O O 0.9999679327011108
submitted O O 0.9999759197235107
to O O 0.9888251423835754
PTRA O O 0.6929261684417725
showed O O 0.9998389482498169
a O O 0.9999568462371826
lower O O 0.9999498128890991
susceptibility O O 0.9999798536300659
to O O 0.9998629093170166
renal O O 0.9998806715011597
damage O O 0.9999765157699585
induced O O 0.9999587535858154
by O O 0.9998879432678223
CM B B 0.9428827166557312
administration O O 0.9994045495986938
than O O 0.9999231100082397
PCI O O 0.5036911368370056
patients O O 0.9999357461929321
. O O 0.9999697208404541

The O O 0.9999570846557617
effectiveness O O 0.9999585151672363
of O O 0.998752236366272
PTRA O B 0.9985248446464539
on O O 0.9993224143981934
renal O O 0.9998947381973267
function O O 0.9999644756317139
seems O O 0.9999321699142456
to O O 0.9999562501907349
be O O 0.999956488609314
barely O O 0.9999793767929077
influenced O O 0.9999815225601196
by O O 0.9999059438705444
CM B O 0.8324574828147888
toxicity O O 0.9993686079978943
. O O 0.9999535083770752

Diphenhydramine B B 0.9988670349121094
prevents O O 0.9998190999031067
the O O 0.9999816417694092
haemodynamic O O 0.9998917579650879
changes O O 0.9999939203262329
of O O 0.9996318817138672
cimetidine B B 0.9994526505470276
in O O 0.9997506737709045
ICU O O 0.9758757948875427
patients O O 0.9999713897705078
. O O 0.99980229139328

Cimetidine B B 0.9986742734909058
, O O 0.9997532963752747
a O O 0.9756962656974792
histamine B O 0.6152721643447876
2 O O 0.6001990437507629
( O O 0.8915559649467468
H2 O O 0.6637919545173645
) O O 0.97383713722229
antagonist O O 0.9637941718101501
, O O 0.9998675584793091
produces O O 0.9999277591705322
a O O 0.999971866607666
decrease O O 0.9999927282333374
in O O 0.9999862909317017
arterial O O 0.9998499155044556
pressure O O 0.9999104738235474
due O O 0.9999573230743408
to O O 0.9993748068809509
vasodilatation O O 0.9992621541023254
, O O 0.999969482421875
especially O O 0.9999707937240601
in O O 0.9999613761901855
critically O O 0.9999936819076538
ill O O 0.9999932050704956
patients O O 0.9999938011169434
. O O 0.9999438524246216

This O O 0.9999343156814575
may O O 0.9999090433120728
be O O 0.9999819993972778
because O O 0.9994151592254639
cimetidine B B 0.9993718266487122
acts O O 0.9995469450950623
as O O 0.9998059868812561
a O O 0.9979146122932434
histamine B O 0.48598840832710266
agonist O O 0.6065911054611206
. O O 0.9998860359191895

We O O 0.9999703168869019
, O O 0.9999926090240479
therefore O O 0.9999971389770508
, O O 0.9999853372573853
investigated O O 0.9999717473983765
the O O 0.9999411106109619
effects O O 0.9999545812606812
of O O 0.9998594522476196
the O O 0.9991864562034607
histamine B O 0.7368838787078857
1 O O 0.6875817179679871
( O O 0.7067859172821045
H1 O O 0.7937726378440857
) O O 0.9702165722846985
receptor O O 0.9956907629966736
antagonist O O 0.930465579032898
, O O 0.9878116250038147
diphenhydramine B B 0.9995705485343933
, O O 0.9999275207519531
on O O 0.9999418258666992
the O O 0.9999845027923584
haemodynamic O O 0.9999479055404663
changes O O 0.9999973773956299
observed O O 0.9999954700469971
after O O 0.9999023675918579
cimetidine B B 0.9997749924659729
in O O 0.9995121955871582
ICU O O 0.9775416851043701
patients O O 0.9999792575836182
. O O 0.9999717473983765

Each O O 0.999963641166687
patient O O 0.9999839067459106
was O O 0.9999675750732422
studied O O 0.9999709129333496
on O O 0.9999648332595825
two O O 0.9999908208847046
separate O O 0.9999865293502808
days O O 0.9999880790710449
. O O 0.9999794960021973

In O O 0.9999797344207764
a O O 0.9999949932098389
random O O 0.9999916553497314
fashion O O 0.9999984502792358
, O O 0.9999891519546509
they O O 0.9999934434890747
received O O 0.9998875856399536
cimetidine B B 0.9991284012794495
200 O O 0.619992196559906
mg O O 0.9981497526168823
iv O O 0.9964277148246765
on O O 0.999963641166687
one O O 0.9999850988388062
day O O 0.9999938011169434
, O O 0.9999446868896484
and O O 0.9999587535858154
on O O 0.9999819993972778
the O O 0.9999953508377075
other O O 0.9999842643737793
, O O 0.9999915361404419
a O O 0.9999821186065674
pretreatment O O 0.9999266862869263
of O O 0.999561607837677
diphenhydramine B B 0.9996932744979858
40 O O 0.9966869950294495
mg O O 0.9997524619102478
iv O O 0.9973846077919006
with O O 0.9989744424819946
cimetidine B B 0.9993498921394348
200 O O 0.5145736336708069
mg O O 0.997632622718811
iv O O 0.9965733289718628
. O O 0.9999672174453735

In O O 0.999913215637207
the O O 0.9999591112136841
non O O 0.99785977602005
- O O 0.9993832111358643
pretreatment O O 0.9984098672866821
group O O 0.9999687671661377
, O O 0.9999521970748901
mean O O 0.999987006187439
arterial O O 0.999098539352417
pressure O O 0.9995669722557068
( O O 0.9999080896377563
MAP O O 0.9942312240600586
) O O 0.9999853372573853
decreased O O 0.999980092048645
from O O 0.9999927282333374
107 O O 0.9999603033065796
. O O 0.9999961853027344
4 O O 0.9999836683273315
+ O O 0.9999886751174927
/ O O 0.9999713897705078
- O O 0.999941349029541
8 O O 0.9999188184738159
. O O 0.9999958276748657
4 O O 0.9999839067459106
mmHg O O 0.9999934434890747
to O O 0.9999675750732422
86 O O 0.999976396560669
. O O 0.9999964237213135
7 O O 0.9999972581863403
+ O O 0.9999945163726807
/ O O 0.9999830722808838
- O O 0.9999637603759766
11 O O 0.9999946355819702
. O O 0.9999964237213135
4 O O 0.999981164932251
mmHg O O 0.9999858140945435
( O O 0.9999462366104126
P O O 0.9987640380859375
less O O 0.9999891519546509
than O O 0.999994158744812
0 O O 0.999996542930603
. O O 0.9999978542327881
01 O O 0.9999985694885254
) O O 0.9999793767929077
two O O 0.9999840259552002
minutes O O 0.9999986886978149
after O O 0.9999169111251831
cimetidine B B 0.9996485710144043
. O O 0.9999562501907349

Also O O 0.9999709129333496
, O O 0.9999536275863647
systemic O O 0.9998403787612915
vascular O O 0.999826967716217
resistance O O 0.9999940395355225
( O O 0.999923586845398
SVR O O 0.994621992111206
) O O 0.9999480247497559
decreased O O 0.9999536275863647
during O O 0.999982476234436
the O O 0.9999964237213135
eight O O 0.9999912977218628
- O O 0.9999903440475464
minute O O 0.9999970197677612
observation O O 0.999992847442627
period O O 0.999992847442627
( O O 0.9999719858169556
P O O 0.9995622038841248
less O O 0.9999818801879883
than O O 0.9999897480010986
0 O O 0.9999911785125732
. O O 0.9999954700469971
01 O O 0.999997615814209
) O O 0.9999724626541138
. O O 0.9999748468399048

In O O 0.9998313188552856
contrast O O 0.9990240335464478
, O O 0.9999219179153442
in O O 0.9998865127563477
the O O 0.9999597072601318
pretreatment O O 0.9979888200759888
group O O 0.9999456405639648
, O O 0.9999608993530273
little O O 0.9999754428863525
haemodynamic O O 0.9999794960021973
change O O 0.9999945163726807
was O O 0.999974250793457
seen O O 0.999992847442627
. O O 0.999970555305481

We O O 0.9999536275863647
conclude O O 0.9999693632125854
that O O 0.9999053478240967
an O O 0.9991102814674377
H1 O O 0.7706904411315918
antagonist O O 0.9429121017456055
may O O 0.9998997449874878
be O O 0.9999037981033325
useful O O 0.9998883008956909
in O O 0.9999474287033081
preventing O O 0.9999011754989624
hypotension O O 0.9999748468399048
caused O O 0.9999773502349854
by O O 0.9998860359191895
iv O O 0.9980769157409668
cimetidine B B 0.9980581402778625
, O O 0.9998735189437866
since O O 0.9999682903289795
the O O 0.9999034404754639
vasodilating O O 0.9996283054351807
activity O O 0.999909520149231
of O O 0.9997889399528503
cimetidine B B 0.9989755153656006
is O O 0.9997661709785461
mediated O O 0.999904990196228
, O O 0.9999735355377197
in O O 0.9999758005142212
part O O 0.9999796152114868
, O O 0.9999722242355347
through O O 0.999710738658905
the O O 0.9996113181114197
H1 O O 0.7713184356689453
receptor O O 0.9999325275421143
. O O 0.9999303817749023

Medical O O 0.9999563694000244
and O O 0.999970555305481
psychiatric O O 0.9999793767929077
outcomes O O 0.9999963045120239
for O O 0.9999611377716064
patients O O 0.9999876022338867
transplanted O O 0.9999208450317383
for O O 0.9998589754104614
acetaminophen B B 0.9974510073661804
- O O 0.996740996837616
induced O O 0.9999300241470337
acute O O 0.9999884366989136
liver O O 0.9995492100715637
failure O O 0.999987006187439
: O O 0.9999974966049194
a O O 0.9999933242797852
case O O 0.9999836683273315
- O O 0.9999916553497314
control O O 0.9999953508377075
study O O 0.9999978542327881
. O O 0.9999901056289673

BACKGROUND O O 0.985967218875885
: O O 0.9994744658470154
Acetaminophen B B 0.9985824823379517
- O O 0.9990724325180054
induced O O 0.9999117851257324
hepatotoxicity O O 0.9998805522918701
is O O 0.9999445676803589
the O O 0.9999809265136719
most O O 0.9999862909317017
common O O 0.9999871253967285
cause O O 0.9999842643737793
of O O 0.9999723434448242
acute O O 0.9999686479568481
liver O O 0.9993153810501099
failure O O 0.9999960660934448
( O O 0.9998013377189636
ALF O O 0.9491158723831177
) O O 0.9999411106109619
in O O 0.9998917579650879
the O O 0.9999151229858398
UK O O 0.9948170781135559
. O O 0.9999624490737915

Patients O O 0.9998788833618164
often O O 0.9999358654022217
consume O O 0.9992788434028625
the O O 0.9997894167900085
drug O O 0.9912323355674744
with O O 0.9998953342437744
suicidal O O 0.9992997646331787
intent O O 0.9999350309371948
or O O 0.9999511241912842
with O O 0.9999462366104126
a O O 0.9999710321426392
background O O 0.999982476234436
of O O 0.9999372959136963
substance O O 0.9973037242889404
dependence O O 0.9998843669891357
. O O 0.9999847412109375

AIMS O O 0.9999761581420898
AND O O 0.9999943971633911
METHODS O O 0.9999986886978149
: O O 0.9999966621398926
We O O 0.9999905824661255
compared O O 0.9999879598617554
the O O 0.9999936819076538
severity O O 0.9999958276748657
of O O 0.999987006187439
pretransplant O O 0.9999040365219116
illness O O 0.9999958276748657
, O O 0.9999862909317017
psychiatric O O 0.9999769926071167
co O O 0.9975718855857849
- O O 0.9997689127922058
morbidity O O 0.9999922513961792
, O O 0.9999760389328003
medical O O 0.9999921321868896
and O O 0.9999494552612305
psychosocial O O 0.9999579191207886
outcomes O O 0.9999988079071045
of O O 0.9999805688858032
all O O 0.9999797344207764
patients O O 0.9999947547912598
who O O 0.9999736547470093
had O O 0.9999904632568359
undergone O O 0.9999892711639404
liver O O 0.9980966448783875
transplantation O O 0.9999598264694214
( O O 0.9998613595962524
LT O O 0.9749928116798401
) O O 0.9999713897705078
emergently O O 0.9999836683273315
between O O 0.9998544454574585
1999 O O 0.783314049243927
- O O 0.9913418889045715
2004 O O 0.9647308588027954
for O O 0.999798595905304
acetaminophen B B 0.9969093203544617
- O O 0.9903601408004761
induced O O 0.9993845224380493
ALF O O 0.9467094540596008
( O O 0.9999580383300781
n O O 0.9998369216918945
= O O 0.999943733215332
36 O O 0.9999912977218628
) O O 0.9999841451644897
with O O 0.9999815225601196
age O O 0.9930294156074524
- O O 0.9999620914459229
and O O 0.9999878406524658
sex O O 0.9990426898002625
- O O 0.9999858140945435
matched O O 0.9999881982803345
patients O O 0.9999971389770508
undergoing O O 0.9999822378158569
emergent O O 0.999991774559021
LT O O 0.982823371887207
for O O 0.9999676942825317
non O O 0.8652155995368958
- O O 0.9832216501235962
acetaminophen B B 0.9586430788040161
- O O 0.9954532384872437
induced O O 0.9997172951698303
ALF O O 0.9523653984069824
( O O 0.99996018409729
n O O 0.9997416138648987
= O O 0.9999803304672241
35 O O 0.999976634979248
) O O 0.9999817609786987
and O O 0.9999743700027466
elective O O 0.9999854564666748
LT O O 0.9666078090667725
for O O 0.9999685287475586
chronic O O 0.9999762773513794
liver O O 0.9996060729026794
disease O O 0.9999983310699463
( O O 0.9999313354492188
CLD O O 0.9853498935699463
, O O 0.9999850988388062
n O O 0.9994369149208069
= O O 0.9999693632125854
34 O O 0.9999514818191528
) O O 0.9999876022338867
. O O 0.9999818801879883

RESULTS O O 0.9999399185180664
: O O 0.9998188614845276
Acetaminophen B B 0.9993428587913513
- O O 0.9984312653541565
induced O O 0.9998069405555725
ALF O O 0.9328154921531677
patients O O 0.9999395608901978
undergoing O O 0.9996802806854248
LT O O 0.9361950159072876
had O O 0.9999593496322632
a O O 0.9999836683273315
greater O O 0.9999805688858032
severity O O 0.9999983310699463
of O O 0.9999918937683105
pre O O 0.9999192953109741
- O O 0.9999281167984009
LT O O 0.9748655557632446
illness O O 0.9999961853027344
reflected O O 0.9999916553497314
by O O 0.9999843835830688
higher O O 0.9999063014984131
Acute O O 0.9999536275863647
Physiology O O 0.9999920129776001
and O O 0.9999443292617798
Chronic O O 0.9999181032180786
Health O O 0.999990701675415
Evaluation O O 0.9999909400939941
II O O 0.9960770010948181
scores O O 0.999937891960144
and O O 0.9999873638153076
requirement O O 0.9999916553497314
for O O 0.9999790191650391
organ O O 0.9998993873596191
support O O 0.9999843835830688
compared O O 0.999985933303833
with O O 0.9999872446060181
the O O 0.9999803304672241
other O O 0.9999523162841797
two O O 0.9999467134475708
groups O O 0.9999924898147583
. O O 0.9999754428863525

Twenty O O 0.9997740387916565
( O O 0.9998130202293396
56 O O 0.9999891519546509
% O O 0.99998939037323
) O O 0.9997703433036804
acetaminophen B B 0.9934157133102417
- O O 0.9878794550895691
induced O O 0.9964942336082458
ALF O O 0.5686387419700623
patients O O 0.9995809197425842
had O O 0.9999772310256958
a O O 0.9999945163726807
formal O O 0.9999973773956299
psychiatric O O 0.9999864101409912
diagnosis O O 0.9999985694885254
before O O 0.9999107122421265
LT O O 0.9384978413581848
( O O 0.99989914894104
non O O 0.8298269510269165
- O O 0.978655219078064
acetaminophen B B 0.9629356265068054
- O O 0.9892027974128723
induced O O 0.9977275729179382
ALF O O 0.7398061752319336
= O O 0.9994088411331177
0 O O 0.9998594522476196
/ O O 0.9998173117637634
35 O O 0.9998985528945923
, O O 0.9994875192642212
CLD O O 0.8661490678787231
= O O 0.9994698166847229
2 O O 0.9997687935829163
/ O O 0.9997579455375671
34 O O 0.9998465776443481
; O O 0.9999676942825317
P O O 0.9999068975448608
< O O 0.9999756813049316
0 O O 0.9999892711639404
. O O 0.9999980926513672
01 O O 0.9999901056289673
for O O 0.9999587535858154
all O O 0.9976033568382263
) O O 0.9999698400497437
and O O 0.9999600648880005
nine O O 0.9988013505935669
( O O 0.9999417066574097
25 O O 0.999996542930603
% O O 0.9999946355819702
) O O 0.9999769926071167
had O O 0.9999854564666748
a O O 0.9999947547912598
previous O O 0.9999933242797852
suicide O O 0.9911746978759766
attempt O O 0.9999244213104248
. O O 0.9999624490737915

During O O 0.999950647354126
follow O O 0.9999945163726807
- O O 0.9999929666519165
up O O 0.9999982118606567
( O O 0.9999700784683228
median O O 0.9999945163726807
5 O O 0.9999932050704956
years O O 0.9999966621398926
) O O 0.9999884366989136
, O O 0.9999885559082031
there O O 0.9999862909317017
were O O 0.9999864101409912
no O O 0.999990701675415
significant O O 0.999991774559021
differences O O 0.9999967813491821
in O O 0.9999868869781494
rejection O O 0.9999966621398926
( O O 0.9999456405639648
acute O O 0.9999573230743408
and O O 0.9999171495437622
chronic O O 0.9997915625572205
) O O 0.9999780654907227
, O O 0.9999616146087646
graft O O 0.9999408721923828
failure O O 0.9999949932098389
or O O 0.999963641166687
survival O O 0.9999948740005493
between O O 0.9998422861099243
the O O 0.9999613761901855
groups O O 0.9999741315841675
( O O 0.9997249245643616
acetaminophen B B 0.9936328530311584
- O O 0.990407407283783
induced O O 0.9985501170158386
ALF O O 0.8417352437973022
1 O O 0.9998303651809692
year O O 0.9998377561569214
87 O O 0.999785840511322
% O O 0.9999958276748657
, O O 0.9993952512741089
5 O O 0.9979216456413269
years O O 0.9999719858169556
75 O O 0.9999947547912598
% O O 0.9999961853027344
; O O 0.9998846054077148
non O O 0.862255334854126
- O O 0.9891787767410278
acetaminophen B B 0.9507100582122803
- O O 0.9886736273765564
induced O O 0.9997263550758362
ALF O O 0.944895327091217
88 O O 0.9713195562362671
% O O 0.9999967813491821
, O O 0.9999449253082275
78 O O 0.9999760389328003
% O O 0.9999969005584717
; O O 0.9998762607574463
CLD O O 0.9876866936683655
93 O O 0.9998557567596436
% O O 0.9999970197677612
, O O 0.9996650218963623
82 O O 0.9998644590377808
% O O 0.9999921321868896
: O O 0.9999825954437256
P O O 0.992049515247345
> O O 0.9999700784683228
0 O O 0.999988317489624
. O O 0.999995231628418
6 O O 0.9999629259109497
log O O 0.9668623805046082
rank O O 0.997122585773468
) O O 0.9999791383743286
. O O 0.9999829530715942

Two O O 0.9950225353240967
acetaminophen B B 0.9939233660697937
- O O 0.9972895383834839
induced O O 0.9989638328552246
ALF O O 0.8135808110237122
patients O O 0.9947450160980225
reattempted O O 0.9993540644645691
suicide O O 0.904954195022583
post O O 0.983231782913208
- O O 0.9985112547874451
LT O O 0.8777123093605042
( O O 0.9998083710670471
one O O 0.999976396560669
died O O 0.9999898672103882
8 O O 0.9998961687088013
years O O 0.9999951124191284
post O O 0.9996960163116455
- O O 0.9996544122695923
LT O O 0.9463274478912354
) O O 0.9999402761459351
. O O 0.9999048709869385

CONCLUSIONS O O 0.9988030195236206
: O O 0.9999823570251465
Despite O O 0.9999831914901733
a O O 0.9999874830245972
high O O 0.9999850988388062
prevalence O O 0.999995231628418
of O O 0.9999669790267944
psychiatric O O 0.9996101260185242
disturbance O O 0.9999699592590332
, O O 0.9999500513076782
outcomes O O 0.9999963045120239
for O O 0.9999630451202393
patients O O 0.9999866485595703
transplanted O O 0.9999681711196899
emergently O O 0.9999675750732422
for O O 0.9998502731323242
acetaminophen B B 0.9964606165885925
- O O 0.9974780678749084
induced O O 0.9994495511054993
ALF O O 0.8047223091125488
were O O 0.9999412298202515
comparable O O 0.9999915361404419
to O O 0.9999631643295288
those O O 0.9999771118164062
transplanted O O 0.9999743700027466
for O O 0.9998076558113098
non O O 0.7462894320487976
- O O 0.9771077632904053
acetaminophen B B 0.9454720616340637
- O O 0.9965879917144775
induced O O 0.9993488192558289
ALF O O 0.8476770520210266
and O O 0.9999641180038452
electively O O 0.9999812841415405
for O O 0.9998780488967896
CLD O O 0.824546754360199
. O O 0.9999738931655884

Multidisciplinary O O 0.9995729327201843
approaches O O 0.999971866607666
with O O 0.9999663829803467
long O O 0.9997463822364807
- O O 0.9999797344207764
term O O 0.999980092048645
psychiatric O O 0.9997221827507019
follow O O 0.99998939037323
- O O 0.9999862909317017
up O O 0.9999845027923584
may O O 0.9999511241912842
contribute O O 0.9999904632568359
to O O 0.9999927282333374
low O O 0.9999868869781494
post O O 0.9999494552612305
- O O 0.999894380569458
transplant O O 0.9999808073043823
suicide O O 0.9999392032623291
rates O O 0.9999940395355225
seen O O 0.9999947547912598
and O O 0.9999786615371704
low O O 0.9999775886535645
rates O O 0.999996542930603
of O O 0.999988317489624
graft O O 0.9999349117279053
loss O O 0.9999945163726807
because O O 0.9999699592590332
of O O 0.9998939037322998
non O O 0.9998427629470825
- O O 0.9996358156204224
compliance O O 0.9999771118164062
. O O 0.9999679327011108

Antithrombotic O O 0.4883365333080292
drug O O 0.8834039568901062
use O O 0.999036431312561
, O O 0.9999033212661743
cerebral O O 0.9999438524246216
microbleeds O O 0.999862551689148
, O O 0.9998562335968018
and O O 0.999776303768158
intracerebral O O 0.9999761581420898
hemorrhage O O 0.9999730587005615
: O O 0.9999624490737915
a O O 0.9999891519546509
systematic O O 0.9999867677688599
review O O 0.999992847442627
of O O 0.9999806880950928
published O O 0.9999833106994629
and O O 0.9999734163284302
unpublished O O 0.9999706745147705
studies O O 0.9999898672103882
. O O 0.9999834299087524

BACKGROUND O O 0.9994553923606873
AND O O 0.9999740123748779
PURPOSE O O 0.9998937845230103
: O O 0.9999860525131226
Cerebral O O 0.9982566237449646
microbleeds O O 0.9978651404380798
( O O 0.9997683167457581
MB O O 0.5293081998825073
) O O 0.9986037611961365
are O O 0.9999432563781738
potential O O 0.9999680519104004
risk O O 0.999968409538269
factors O O 0.9999938011169434
for O O 0.9999582767486572
intracerebral O O 0.9999799728393555
hemorrhage O O 0.9999912977218628
( O O 0.9998487234115601
ICH O O 0.9997318387031555
) O O 0.9999693632125854
, O O 0.9999474287033081
but O O 0.9999728202819824
it O O 0.9999924898147583
is O O 0.999982476234436
unclear O O 0.9999873638153076
if O O 0.9999873638153076
they O O 0.9999762773513794
are O O 0.9999706745147705
a O O 0.9999505281448364
contraindication O O 0.9999788999557495
to O O 0.9999477863311768
using O O 0.9994290471076965
antithrombotic O O 0.7179287075996399
drugs O O 0.9957977533340454
. O O 0.9999344348907471

Insights O O 0.9999561309814453
could O O 0.9999840259552002
be O O 0.9999974966049194
gained O O 0.9999991655349731
by O O 0.9999922513961792
pooling O O 0.9999943971633911
data O O 0.9999933242797852
on O O 0.9999464750289917
MB O O 0.7881571054458618
frequency O O 0.999568521976471
stratified O O 0.9999732971191406
by O O 0.9999637603759766
antithrombotic O O 0.7675734162330627
use O O 0.9998797178268433
in O O 0.99996018409729
cohorts O O 0.9998607635498047
with O O 0.9999797344207764
ICH O O 0.9964578747749329
and O O 0.9998165965080261
ischemic O O 0.9998999834060669
stroke O O 0.9999910593032837
( O O 0.9998743534088135
IS O O 0.9977608919143677
) O O 0.9999313354492188
/ O O 0.9998278617858887
transient O O 0.999919056892395
ischemic O O 0.9996086955070496
attack O O 0.9999938011169434
( O O 0.9999392032623291
TIA O O 0.9882354736328125
) O O 0.9999688863754272
. O O 0.9999797344207764

METHODS O O 0.999927282333374
: O O 0.999990701675415
We O O 0.9999774694442749
performed O O 0.9999946355819702
a O O 0.9999943971633911
systematic O O 0.999988317489624
review O O 0.9999948740005493
of O O 0.9999872446060181
published O O 0.9999918937683105
and O O 0.9999735355377197
unpublished O O 0.9999712705612183
data O O 0.9999935626983643
from O O 0.9999842643737793
cohorts O O 0.9996596574783325
with O O 0.9999864101409912
stroke O O 0.9999749660491943
or O O 0.9999122619628906
TIA O O 0.9842005372047424
to O O 0.9999749660491943
compare O O 0.9999676942825317
the O O 0.9999892711639404
presence O O 0.9999723434448242
of O O 0.9998427629470825
MB O O 0.6657106280326843
in O O 0.9986397624015808
: O O 0.9998400211334229
( O O 0.9994934797286987
1 O O 0.999963641166687
) O O 0.9998377561569214
antithrombotic O O 0.6721895933151245
users O O 0.9969155788421631
vs O O 0.9995476603507996
nonantithrombotic O O 0.9940350651741028
users O O 0.9997219443321228
with O O 0.9997883439064026
ICH O O 0.978878378868103
; O O 0.9999446868896484
( O O 0.9998086094856262
2 O O 0.9999748468399048
) O O 0.9999414682388306
antithrombotic O O 0.5099602937698364
users O O 0.9982401132583618
vs O O 0.9994300007820129
nonusers O O 0.9194064140319824
with O O 0.9998575448989868
IS O O 0.9944537281990051
/ O O 0.999134361743927
TIA O O 0.9896152019500732
; O O 0.9999314546585083
and O O 0.9998852014541626
( O O 0.9998688697814941
3 O O 0.9999722242355347
) O O 0.9999696016311646
ICH O O 0.9958412051200867
vs O O 0.9998937845230103
ischemic O O 0.9999897480010986
events O O 0.999996542930603
stratified O O 0.9999873638153076
by O O 0.999946117401123
antithrombotic O O 0.6601908206939697
use O O 0.9991111159324646
. O O 0.9999779462814331

We O O 0.9999512434005737
also O O 0.9999891519546509
analyzed O O 0.9999860525131226
published O O 0.9999887943267822
and O O 0.9999606609344482
unpublished O O 0.9996899366378784
follow O O 0.9999690055847168
- O O 0.9999855756759644
up O O 0.9999933242797852
data O O 0.9999499320983887
to O O 0.9999889135360718
determine O O 0.9999920129776001
the O O 0.9999891519546509
risk O O 0.9999946355819702
of O O 0.9999651908874512
ICH O O 0.9990888833999634
in O O 0.9996942281723022
antithrombotic O O 0.7697868347167969
users O O 0.9987726807594299
with O O 0.9995094537734985
MB O B 0.9887953996658325
. O O 0.9911752939224243

RESULTS O O 0.9999289512634277
: O O 0.9999133348464966
In O O 0.9999661445617676
a O O 0.9999704360961914
pooled O O 0.9999490976333618
analysis O O 0.9999892711639404
of O O 0.9999728202819824
1460 O O 0.9999953508377075
ICH O O 0.9924174547195435
and O O 0.9998993873596191
3817 O O 0.9996404647827148
IS O O 0.9917504191398621
/ O O 0.9981158971786499
TIA O O 0.9938392043113708
, O O 0.9998063445091248
MB O O 0.8754610419273376
were O O 0.9999470710754395
more O O 0.999950647354126
frequent O O 0.9999721050262451
in O O 0.9996294975280762
ICH O O 0.9853406548500061
vs O O 0.999076247215271
IS O O 0.9948701858520508
/ O O 0.9990866184234619
TIA O O 0.9912729859352112
in O O 0.9996891021728516
all O O 0.9996984004974365
treatment O O 0.9998739957809448
groups O O 0.9999734163284302
, O O 0.9999487400054932
but O O 0.9999845027923584
the O O 0.9999823570251465
excess O O 0.9999651908874512
increased O O 0.9999798536300659
from O O 0.9999904632568359
2 O O 0.9998940229415894
. O O 0.9999825954437256
8 O O 0.9999608993530273
( O O 0.9999456405639648
odds O O 0.9995492100715637
ratio O O 0.9999197721481323
; O O 0.999982476234436
range O O 0.9999561309814453
, O O 0.9998928308486938
2 O O 0.999970555305481
. O O 0.9999879598617554
3 O O 0.9999783039093018
- O O 0.9988062381744385
3 O O 0.9999699592590332
. O O 0.999984622001648
5 O O 0.999984622001648
) O O 0.9999737739562988
in O O 0.9997259974479675
nonantithrombotic O O 0.9939345717430115
users O O 0.9985565543174744
to O O 0.9999626874923706
5 O O 0.9999362230300903
. O O 0.9999855756759644
7 O O 0.9999880790710449
( O O 0.9999635219573975
range O O 0.9999608993530273
, O O 0.9999346733093262
3 O O 0.9999710321426392
. O O 0.9999821186065674
4 O O 0.9999198913574219
- O O 0.9994372725486755
9 O O 0.9999755620956421
. O O 0.9999847412109375
7 O O 0.9999688863754272
) O O 0.9999796152114868
in O O 0.9992080330848694
antiplatelet O O 0.5867466926574707
users O O 0.9844927787780762
and O O 0.9999094009399414
8 O O 0.9998223185539246
. O O 0.9999910593032837
0 O O 0.999990701675415
( O O 0.9999669790267944
range O O 0.9999512434005737
, O O 0.999937891960144
3 O O 0.9999741315841675
. O O 0.999984860420227
5 O O 0.9999781847000122
- O O 0.9987123012542725
17 O O 0.99998939037323
. O O 0.9999955892562866
8 O O 0.9999774694442749
) O O 0.99998939037323
in O O 0.999605119228363
warfarin B B 0.9985429048538208
users O O 0.9996744394302368
( O O 0.999860405921936
P O O 0.995120108127594
difference O O 0.9999271631240845
= O O 0.9992944002151489
0 O O 0.999976396560669
. O O 0.9999938011169434
01 O O 0.9999890327453613
) O O 0.9999634027481079
. O O 0.9999792575836182

There O O 0.9999344348907471
was O O 0.9999268054962158
also O O 0.9999783039093018
an O O 0.999976634979248
excess O O 0.9997639060020447
of O O 0.9997943043708801
MB O O 0.669222891330719
in O O 0.9990665316581726
warfarin B B 0.9965236783027649
users O O 0.9985793828964233
vs O O 0.9981243014335632
nonusers O O 0.893551230430603
with O O 0.9997504353523254
ICH O O 0.9778229594230652
( O O 0.9998507499694824
OR O O 0.9918767213821411
, O O 0.9981454610824585
2 O O 0.9999197721481323
. O O 0.9999693632125854
7 O O 0.9999732971191406
; O O 0.9999477863311768
95 O O 0.9999192953109741
% O O 0.9996964931488037
CI O O 0.9928695559501648
, O O 0.9998561143875122
1 O O 0.9999878406524658
. O O 0.999984622001648
6 O O 0.9999884366989136
- O O 0.9958102703094482
4 O O 0.9999759197235107
. O O 0.9999946355819702
4 O O 0.9999815225601196
; O O 0.9999769926071167
P O O 0.9997915625572205
< O O 0.9999697208404541
0 O O 0.999991774559021
. O O 0.9999964237213135
001 O O 0.9998224377632141
) O O 0.9999552965164185
but O O 0.9999324083328247
none O O 0.9999423027038574
in O O 0.9997666478157043
warfarin B B 0.9979760050773621
users O O 0.9997333884239197
with O O 0.9990715980529785
IS O O 0.9678364396095276
/ O O 0.9966457486152649
TIA O O 0.9678395390510559
( O O 0.9998857975006104
OR O O 0.9962067604064941
, O O 0.9992915391921997
1 O O 0.9999783039093018
. O O 0.999993085861206
3 O O 0.9999910593032837
; O O 0.9999582767486572
95 O O 0.9999196529388428
% O O 0.999904990196228
CI O O 0.9939951300621033
, O O 0.9998807907104492
0 O O 0.9999924898147583
. O O 0.9999903440475464
9 O O 0.9999896287918091
- O O 0.9969621300697327
1 O O 0.9999966621398926
. O O 0.9999957084655762
7 O O 0.9999946355819702
; O O 0.9999833106994629
P O O 0.9978869557380676
= O O 0.9999778270721436
0 O O 0.9999895095825195
. O O 0.9999958276748657
33 O O 0.9999977350234985
; O O 0.9999561309814453
P O O 0.9866848587989807
difference O O 0.9997977614402771
= O O 0.9998123049736023
0 O O 0.9999819993972778
. O O 0.9999946355819702
01 O O 0.9999958276748657
) O O 0.9999748468399048
. O O 0.9999738931655884

There O O 0.9999223947525024
was O O 0.9999079704284668
a O O 0.9999545812606812
smaller O O 0.9999754428863525
excess O O 0.9998815059661865
of O O 0.999701201915741
MB O O 0.8668705224990845
in O O 0.9969192743301392
antiplatelet O O 0.6053062677383423
users O O 0.8507114052772522
vs O O 0.9987867474555969
nonusers O O 0.6844292283058167
with O O 0.999595582485199
ICH O O 0.9506388306617737
( O O 0.9998304843902588
OR O O 0.9918683767318726
, O O 0.9966527819633484
1 O O 0.9999386072158813
. O O 0.9999748468399048
7 O O 0.9999796152114868
; O O 0.9999433755874634
95 O O 0.9998416900634766
% O O 0.9996646642684937
CI O O 0.991928219795227
, O O 0.9998725652694702
1 O O 0.9999771118164062
. O O 0.9999715089797974
3 O O 0.9999823570251465
- O O 0.9966094493865967
2 O O 0.9999862909317017
. O O 0.9999934434890747
3 O O 0.999994158744812
; O O 0.9999723434448242
P O O 0.9999443292617798
< O O 0.9999806880950928
0 O O 0.9999905824661255
. O O 0.9999958276748657
001 O O 0.9995761513710022
) O O 0.9999654293060303
, O O 0.9999425411224365
but O O 0.9999301433563232
findings O O 0.9999912977218628
were O O 0.9999723434448242
similar O O 0.9999927282333374
for O O 0.9997288584709167
antiplatelet O O 0.7671153545379639
users O O 0.9640210866928101
with O O 0.9995242357254028
IS O O 0.913173496723175
/ O O 0.9845981597900391
TIA O O 0.974067747592926
( O O 0.9998599290847778
OR O O 0.9967811107635498
, O O 0.9990166425704956
1 O O 0.9999388456344604
. O O 0.9999887943267822
4 O O 0.9999905824661255
; O O 0.9999438524246216
95 O O 0.9999027252197266
% O O 0.9999254941940308
CI O O 0.9935529232025146
, O O 0.9998588562011719
1 O O 0.9999760389328003
. O O 0.9999747276306152
2 O O 0.9999899864196777
- O O 0.9968264102935791
1 O O 0.9999945163726807
. O O 0.9999923706054688
7 O O 0.9999943971633911
; O O 0.9999837875366211
P O O 0.9999855756759644
< O O 0.9999889135360718
0 O O 0.9999945163726807
. O O 0.999996542930603
001 O O 0.999947190284729
; O O 0.9998464584350586
P O O 0.9208337068557739
difference O O 0.9998539686203003
= O O 0.9999098777770996
0 O O 0.9999897480010986
. O O 0.9999948740005493
25 O O 0.9999933242797852
) O O 0.9999697208404541
. O O 0.9999690055847168

In O O 0.9999839067459106
pooled O O 0.9999833106994629
follow O O 0.9999891519546509
- O O 0.9999898672103882
up O O 0.9999943971633911
data O O 0.9999933242797852
for O O 0.999848484992981
768 O O 0.9984666109085083
antithrombotic O O 0.7394351363182068
users O O 0.5066449046134949
, O O 0.9997439980506897
presence O O 0.999981164932251
of O O 0.9998592138290405
MB O O 0.7267330288887024
at O O 0.9998866319656372
baseline O O 0.9999574422836304
was O O 0.999957799911499
associated O O 0.9999912977218628
with O O 0.9999905824661255
a O O 0.9999923706054688
substantially O O 0.9999945163726807
increased O O 0.9999949932098389
risk O O 0.9999983310699463
of O O 0.9999933242797852
subsequent O O 0.9999731779098511
ICH O O 0.9997228980064392
( O O 0.9999384880065918
OR O O 0.9986342787742615
, O O 0.9998650550842285
12 O O 0.9999939203262329
. O O 0.9999936819076538
1 O O 0.9999936819076538
; O O 0.9999749660491943
95 O O 0.9999839067459106
% O O 0.9998369216918945
CI O O 0.9848597645759583
, O O 0.9990149736404419
3 O O 0.9998010993003845
. O O 0.9999755620956421
4 O O 0.9998331069946289
- O O 0.9954268932342529
42 O O 0.9997979998588562
. O O 0.9999936819076538
5 O O 0.9999935626983643
; O O 0.9999780654907227
P O O 0.9999276399612427
< O O 0.9999810457229614
0 O O 0.9999892711639404
. O O 0.9999955892562866
001 O O 0.9997681975364685
) O O 0.9999727010726929
. O O 0.9999817609786987

CONCLUSIONS O O 0.9932409524917603
: O O 0.999984622001648
The O O 0.9999949932098389
excess O O 0.9999815225601196
of O O 0.9998981952667236
MB O B 0.9389854669570923
in O O 0.99793940782547
warfarin B B 0.9987607002258301
users O O 0.999715268611908
with O O 0.9998201727867126
ICH O O 0.9997798800468445
compared O O 0.9999126195907593
to O O 0.9999381303787231
other O O 0.9998645782470703
groups O O 0.9999876022338867
suggests O O 0.9999680519104004
that O O 0.9986937642097473
MB O B 0.9885944128036499
increase O O 0.9967582821846008
the O O 0.999991774559021
risk O O 0.9999973773956299
of O O 0.999975323677063
warfarin B B 0.9985405206680298
- O O 0.9995381832122803
associated O O 0.9999334812164307
ICH O O 0.999927282333374
. O O 0.9999706745147705

Limited O O 0.9999686479568481
prospective O O 0.9999784231185913
data O O 0.9999934434890747
corroborate O O 0.9999771118164062
these O O 0.999992847442627
findings O O 0.9999938011169434
, O O 0.9999692440032959
but O O 0.9999783039093018
larger O O 0.9999656677246094
prospective O O 0.9999847412109375
studies O O 0.9999954700469971
are O O 0.9999935626983643
urgently O O 0.9999886751174927
required O O 0.999995231628418
. O O 0.9999861717224121

Studies O O 0.9999628067016602
of O O 0.9999054670333862
synergy O O 0.999570906162262
between O O 0.9984117746353149
morphine B B 0.999843955039978
and O O 0.99759441614151
a O O 0.9995242357254028
novel O O 0.997134804725647
sodium B B 0.9573151469230652
channel O O 0.907782256603241
blocker O O 0.854856550693512
, O O 0.998856782913208
CNSB002 B B 0.9800215363502502
, O O 0.9998946189880371
in O O 0.9999217987060547
rat O O 0.9999504089355469
models O O 0.9999880790710449
of O O 0.999955415725708
inflammatory O O 0.999822199344635
and O O 0.9998738765716553
neuropathic O O 0.999987006187439
pain O O 0.99993896484375
. O O 0.999975323677063

OBJECTIVE O O 0.9995970129966736
: O O 0.9999899864196777
This O O 0.9999843835830688
study O O 0.9999775886535645
determined O O 0.999914288520813
the O O 0.9999610185623169
antihyperalgesic O O 0.8169119954109192
effect O O 0.9997898936271667
of O O 0.9991583824157715
CNSB002 B B 0.9886416792869568
, O O 0.9993430972099304
a O O 0.9981943964958191
sodium B B 0.9464113712310791
channel O O 0.7132870554924011
blocker O O 0.7209398150444031
with O O 0.9995940327644348
antioxidant O O 0.6828274726867676
properties O O 0.9998514652252197
given O O 0.9998457431793213
alone O O 0.9992886781692505
and O O 0.9999157190322876
in O O 0.9998998641967773
combinations O O 0.9998383522033691
with O O 0.9996892213821411
morphine B B 0.9995818734169006
in O O 0.9998373985290527
rat O O 0.999976396560669
models O O 0.9999936819076538
of O O 0.9999552965164185
inflammatory O O 0.9999030828475952
and O O 0.999868631362915
neuropathic O O 0.9999929666519165
pain O O 0.9999860525131226
. O O 0.9999618530273438

DESIGN O O 0.995804488658905
: O O 0.9999148845672607
Dose O O 0.9993109703063965
response O O 0.9999752044677734
curves O O 0.9999822378158569
for O O 0.9999080896377563
nonsedating O O 0.9981178045272827
doses O O 0.9998525381088257
of O O 0.9978804588317871
morphine B B 0.9997966885566711
and O O 0.9880536198616028
CNSB002 B B 0.9876958131790161
given O O 0.9997822642326355
intraperitoneally O O 0.9999734163284302
alone O O 0.9998874664306641
and O O 0.9998481273651123
together O O 0.9890851378440857
in O O 0.9986051917076111
combinations O O 0.9992159605026245
were O O 0.999972939491272
constructed O O 0.9999401569366455
for O O 0.9999246597290039
antihyperalgesic O O 0.8681589961051941
effect O O 0.9999287128448486
using O O 0.9998119473457336
paw O O 0.9995403289794922
withdrawal O O 0.9999768733978271
from O O 0.9997530579566956
noxious O O 0.9991437196731567
heat O O 0.9722364544868469
in O O 0.9999160766601562
two O O 0.9999532699584961
rat O O 0.9999352693557739
pain O O 0.9998598098754883
models O O 0.9999821186065674
: O O 0.9999377727508545
carrageenan B B 0.9994459748268127
- O O 0.9996881484985352
induced O O 0.9999508857727051
paw O O 0.9996128678321838
inflammation O O 0.9999932050704956
and O O 0.9998489618301392
streptozotocin B B 0.9975506663322449
( O O 0.997093915939331
STZ B B 0.9981052875518799
) O O 0.9691864252090454
- O O 0.9997678399085999
induced O O 0.9999555349349976
diabetic O O 0.9995843768119812
neuropathy O O 0.9999953508377075
. O O 0.9999762773513794

RESULTS O O 0.9998937845230103
: O O 0.9999889135360718
The O O 0.9999943971633911
maximum O O 0.9999716281890869
nonsedating O O 0.9930751323699951
doses O O 0.9999548196792603
were O O 0.9999780654907227
: O O 0.9992222785949707
morphine B B 0.9995731711387634
, O O 0.9981854557991028
3 O O 0.9927480816841125
. O O 0.9999768733978271
2 O O 0.9916783571243286
mg O O 0.9997685551643372
/ O O 0.9998325109481812
kg O O 0.9999920129776001
; O O 0.998955488204956
CNSB002 B O 0.4620431661605835
10 O O 0.9892091155052185
. O O 0.9999938011169434
0 O O 0.9999068975448608
mg O O 0.9999221563339233
/ O O 0.9999716281890869
kg O O 0.9999929666519165
; O O 0.999312162399292
5 O O 0.9999297857284546
. O O 0.9999955892562866
0 O O 0.9999489784240723
mg O O 0.9999761581420898
/ O O 0.9999884366989136
kg O O 0.999944806098938
CNSB002 B O 0.7692133784294128
with O O 0.9967740178108215
morphine B B 0.999392032623291
3 O O 0.9079322218894958
. O O 0.9998846054077148
2 O O 0.9754244089126587
mg O O 0.99967360496521
/ O O 0.9998444318771362
kg O O 0.9999690055847168
in O O 0.9993290901184082
combination O O 0.9980785846710205
. O O 0.9999527931213379

The O O 0.9999812841415405
doses O O 0.9999418258666992
calculated O O 0.9999582767486572
to O O 0.9999637603759766
cause O O 0.9999024868011475
50 O O 0.9999716281890869
% O O 0.999976634979248
reversal O O 0.999955415725708
of O O 0.9998712539672852
hyperalgesia O O 0.9974331259727478
( O O 0.9996379613876343
ED50 O O 0.999903678894043
) O O 0.99993896484375
were O O 0.9999502897262573
7 O O 0.9999397993087769
. O O 0.9999709129333496
54 O O 0.9999904632568359
( O O 0.9998637437820435
1 O O 0.999972939491272
. O O 0.9999746084213257
81 O O 0.9998644590377808
) O O 0.9999513626098633
and O O 0.9998927116394043
4 O O 0.9998708963394165
. O O 0.9999867677688599
83 O O 0.999946117401123
( O O 0.9999392032623291
1 O O 0.9999715089797974
. O O 0.9999876022338867
54 O O 0.9999855756759644
) O O 0.9999779462814331
in O O 0.9999456405639648
the O O 0.9998891353607178
carrageenan B B 0.99671471118927
model O O 0.9998341798782349
and O O 0.9999518394470215
44 O O 0.9999033212661743
. O O 0.9999924898147583
18 O O 0.9999986886978149
( O O 0.9999582767486572
1 O O 0.9999828338623047
. O O 0.999985933303833
37 O O 0.9999935626983643
) O O 0.999970555305481
and O O 0.9999642372131348
9 O O 0.9999479055404663
. O O 0.9999960660934448
14 O O 0.9999982118606567
( O O 0.9999680519104004
1 O O 0.9999862909317017
. O O 0.9999892711639404
24 O O 0.9999959468841553
) O O 0.9999874830245972
in O O 0.9999418258666992
the O O 0.9999334812164307
STZ B B 0.9825606942176819
- O O 0.9979250431060791
induced O O 0.9999159574508667
neuropathy O O 0.9999886751174927
model O O 0.9999901056289673
for O O 0.9988318085670471
CNSB002 B B 0.9292714595794678
and O O 0.9432352781295776
morphine B B 0.9995379447937012
, O O 0.9999138116836548
respectively O O 0.9998806715011597
( O O 0.9998082518577576
mg O O 0.999848484992981
/ O O 0.9999217987060547
kg O O 0.9999953508377075
; O O 0.9998794794082642
mean O O 0.9949612617492676
, O O 0.9935304522514343
SEM O O 0.6723760366439819
) O O 0.9999651908874512
. O O 0.9999666213989258

These O O 0.9999589920043945
values O O 0.9999371767044067
were O O 0.9999686479568481
greater O O 0.9999721050262451
than O O 0.9999920129776001
the O O 0.9999933242797852
maximum O O 0.9999493360519409
nonsedating O O 0.9025730490684509
doses O O 0.9998834133148193
. O O 0.9999498128890991

The O O 0.9999796152114868
ED50 O O 0.9982147216796875
values O O 0.9999407529830933
for O O 0.9996305704116821
morphine B B 0.999818742275238
when O O 0.999948263168335
given O O 0.999958872795105
in O O 0.9999880790710449
combination O O 0.9999483823776245
with O O 0.9997382760047913
CNSB002 B B 0.9481854438781738
( O O 0.9993822574615479
5 O O 0.999840497970581
mg O O 0.9999088048934937
/ O O 0.9998975992202759
kg O O 0.9999898672103882
) O O 0.9999511241912842
were O O 0.9999728202819824
less O O 0.999984860420227
than O O 0.9999947547912598
the O O 0.9999949932098389
maximum O O 0.9999626874923706
nonsedating O O 0.9190093278884888
dose O O 0.9999240636825562
: O O 0.9999692440032959
0 O O 0.9999454021453857
. O O 0.9999837875366211
56 O O 0.9999943971633911
( O O 0.9999122619628906
1 O O 0.9999715089797974
. O O 0.9999922513961792
55 O O 0.9999734163284302
) O O 0.9999765157699585
in O O 0.9999616146087646
the O O 0.9999606609344482
carrageenan B B 0.9757750034332275
model O O 0.9998093247413635
and O O 0.9998980760574341
1 O O 0.999966025352478
. O O 0.9999927282333374
37 O O 0.9999973773956299
( O O 0.999962329864502
1 O O 0.9999904632568359
. O O 0.9999949932098389
23 O O 0.9999963045120239
) O O 0.9999865293502808
in O O 0.9999581575393677
the O O 0.9999469518661499
neuropathy O O 0.9999700784683228
model O O 0.9999858140945435
( O O 0.9997100234031677
mg O O 0.9999769926071167
/ O O 0.9999818801879883
kg O O 0.9999947547912598
; O O 0.9999346733093262
mean O O 0.9997628331184387
, O O 0.9941393136978149
SEM O O 0.9816566109657288
) O O 0.9999719858169556
. O O 0.9999768733978271

The O O 0.9999620914459229
antinociception O O 0.4612184464931488
after O O 0.9996028542518616
morphine B B 0.9996966123580933
( O O 0.9994358420372009
3 O O 0.9974262118339539
. O O 0.9999762773513794
2 O O 0.979596734046936
mg O O 0.9997435212135315
/ O O 0.9996843338012695
kg O O 0.9996525049209595
) O O 0.9999531507492065
was O O 0.999970555305481
increased O O 0.9999203681945801
by O O 0.9998996257781982
co O O 0.8616058230400085
- O O 0.9993304014205933
administration O O 0.9999406337738037
with O O 0.9997833371162415
CNSB002 B O 0.7315455079078674
from O O 0.9998282194137573
28 O O 0.9999579191207886
. O O 0.9999765157699585
0 O O 0.9999880790710449
and O O 0.9998995065689087
31 O O 0.9999775886535645
. O O 0.9999865293502808
7 O O 0.9999957084655762
% O O 0.9999656677246094
to O O 0.9999064207077026
114 O O 0.9978499412536621
. O O 0.999943733215332
6 O O 0.9999215602874756
and O O 0.9998718500137329
56 O O 0.9999727010726929
. O O 0.9999833106994629
9 O O 0.9999949932098389
% O O 0.9999250173568726
reversal O O 0.9999319314956665
of O O 0.9998586177825928
hyperalgesia O O 0.9998348951339722
in O O 0.9995926022529602
the O O 0.9996625185012817
inflammatory O O 0.9993435740470886
and O O 0.9994833469390869
neuropathic O O 0.9999707937240601
models O O 0.9988970756530762
, O O 0.9999740123748779
respectively O O 0.999920129776001
( O O 0.9999607801437378
P O O 0.9998868703842163
< O O 0.9999803304672241
0 O O 0.9999926090240479
. O O 0.9999982118606567
01 O O 0.9999980926513672
; O O 0.9999843835830688
one O O 0.9999921321868896
- O O 0.9999933242797852
way O O 0.9999943971633911
analysis O O 0.9999916553497314
of O O 0.9999921321868896
variance O O 0.9999924898147583
- O O 0.9999833106994629
significantly O O 0.9999971389770508
greater O O 0.9999891519546509
than O O 0.9999860525131226
either O O 0.999645471572876
drug O O 0.9984097480773926
given O O 0.9998682737350464
alone O O 0.9999052286148071
) O O 0.9999717473983765
. O O 0.9999761581420898

CONCLUSIONS O O 0.9982314705848694
: O O 0.9999661445617676
The O O 0.9999804496765137
maximum O O 0.9998594522476196
antihyperalgesic O O 0.9065907597541809
effect O O 0.9998766183853149
achievable O O 0.9999897480010986
with O O 0.9999560117721558
nonsedating O O 0.9982298016548157
doses O O 0.9999121427536011
of O O 0.9987586736679077
morphine B B 0.9996379613876343
may O O 0.9998694658279419
be O O 0.9999713897705078
increased O O 0.999968409538269
significantly O O 0.9999940395355225
when O O 0.9999450445175171
the O O 0.9999712705612183
drug O O 0.9995875954627991
is O O 0.9999697208404541
used O O 0.9999297857284546
in O O 0.9999666213989258
combination O O 0.9999041557312012
with O O 0.9994609951972961
CNSB002 B O 0.7528220415115356
. O O 0.9998462200164795

Heparin B O 0.5068734288215637
- O O 0.9983553290367126
induced O O 0.9998605251312256
thrombocytopenia O O 0.9996503591537476
: O O 0.999956488609314
a O O 0.9999330043792725
practical O O 0.9999715089797974
review O O 0.9999971389770508
. O O 0.9999715089797974

Heparin B O 0.8524795174598694
- O O 0.997776448726654
induced O O 0.9998668432235718
thrombocytopenia O O 0.9988468885421753
( O O 0.9997161030769348
HIT O O 0.9951488375663757
) O O 0.9999599456787109
remains O O 0.9999449253082275
under O O 0.9999228715896606
- O O 0.9999850988388062
recognized O O 0.9999954700469971
despite O O 0.9999467134475708
its O O 0.9999885559082031
potentially O O 0.9999914169311523
devastating O O 0.99998939037323
outcomes O O 0.9999967813491821
. O O 0.9999743700027466

It O O 0.9999537467956543
begins O O 0.9999839067459106
when O O 0.9997966885566711
heparin B B 0.9993201494216919
exposure O O 0.9989261031150818
stimulates O O 0.9996565580368042
the O O 0.9999773502349854
formation O O 0.9999880790710449
of O O 0.999845027923584
heparin B B 0.9010695815086365
- O O 0.9525728225708008
platelet O O 0.9654849171638489
factor O O 0.9950980544090271
4 O O 0.9197733402252197
antibodies O O 0.9997835755348206
, O O 0.9999459981918335
which O O 0.9998618364334106
in O O 0.9999881982803345
turn O O 0.9999769926071167
triggers O O 0.9999066591262817
the O O 0.9999808073043823
release O O 0.9999619722366333
of O O 0.9998310804367065
procoagulant O O 0.8707994818687439
platelet O O 0.9927862286567688
particles O O 0.9999285936355591
. O O 0.9999527931213379

Thrombosis O O 0.9997406601905823
and O O 0.999894380569458
thrombocytopenia O O 0.9968529343605042
that O O 0.9999170303344727
follow O O 0.9991378784179688
comprise O O 0.9999750852584839
the O O 0.9999549388885498
2 O O 0.9996529817581177
hallmark O O 0.9999574422836304
traits O O 0.9997597336769104
of O O 0.9999027252197266
HIT O O 0.9477226734161377
, O O 0.9999253749847412
with O O 0.9999115467071533
the O O 0.9999231100082397
former O O 0.9998787641525269
largely O O 0.9998032450675964
responsible O O 0.9998075366020203
for O O 0.9999306201934814
significant O O 0.9999662637710571
vascular O O 0.9999908208847046
complications O O 0.999996542930603
. O O 0.9999476671218872

The O O 0.9999788999557495
prevalence O O 0.9999738931655884
of O O 0.999923586845398
HIT O O 0.9113520383834839
varies O O 0.9999507665634155
among O O 0.9998934268951416
several O O 0.99986732006073
subgroups O O 0.9995200634002686
, O O 0.9999752044677734
with O O 0.999976634979248
greater O O 0.9999430179595947
incidence O O 0.9999885559082031
in O O 0.9998339414596558
surgical O O 0.9916515946388245
as O O 0.9999359846115112
compared O O 0.9999743700027466
with O O 0.999937891960144
medical O O 0.9999172687530518
populations O O 0.9999768733978271
. O O 0.9999779462814331

HIT O O 0.6004648208618164
must O O 0.9995600581169128
be O O 0.9999243021011353
acknowledged O O 0.9998472929000854
for O O 0.9998865127563477
its O O 0.9998784065246582
intense O O 0.9998438358306885
predilection O O 0.9993749260902405
for O O 0.9998358488082886
thrombosis O O 0.9999309778213501
and O O 0.9999094009399414
suspected O O 0.9999593496322632
whenever O O 0.9997005462646484
thrombosis O O 0.999955415725708
occurs O O 0.9999852180480957
after O O 0.9998482465744019
heparin B B 0.9966669678688049
exposure O O 0.9993908405303955
. O O 0.9999607801437378

Early O O 0.9999005794525146
recognition O O 0.9999837875366211
that O O 0.9998816251754761
incorporates O O 0.9996572732925415
the O O 0.9999485015869141
clinical O O 0.9999781847000122
and O O 0.9999362230300903
serologic O O 0.999975323677063
clues O O 0.9999469518661499
is O O 0.9999730587005615
paramount O O 0.9999676942825317
to O O 0.9999773502349854
timely O O 0.999990701675415
institution O O 0.9999960660934448
of O O 0.9999692440032959
treatment O O 0.9999741315841675
, O O 0.9999685287475586
as O O 0.9999972581863403
its O O 0.9999864101409912
delay O O 0.9999915361404419
may O O 0.9999773502349854
result O O 0.9999933242797852
in O O 0.9999915361404419
catastrophic O O 0.9999891519546509
outcomes O O 0.9999983310699463
. O O 0.9999834299087524

The O O 0.9999591112136841
treatment O O 0.9999561309814453
of O O 0.9999771118164062
HIT O O 0.9164024591445923
mandates O O 0.9998369216918945
an O O 0.9999860525131226
immediate O O 0.999974250793457
cessation O O 0.9999552965164185
of O O 0.9999246597290039
all O O 0.9979744553565979
heparin B B 0.9877852201461792
exposure O O 0.9638584852218628
and O O 0.9999587535858154
the O O 0.9999890327453613
institution O O 0.9999792575836182
of O O 0.9999399185180664
an O O 0.9998797178268433
antithrombotic O O 0.5368306040763855
therapy O O 0.9989355206489563
, O O 0.9999915361404419
most O O 0.9999880790710449
commonly O O 0.9999889135360718
using O O 0.9999063014984131
a O O 0.9998290538787842
direct B O 0.8775378465652466
thrombin I O 0.8267332911491394
inhibitor I O 0.9306324124336243
. O O 0.9999145269393921

Current O O 0.9997867941856384
" O O 0.9998878240585327
diagnostic O O 0.9999768733978271
" O O 0.999985933303833
tests O O 0.9999760389328003
, O O 0.9999772310256958
which O O 0.9999446868896484
primarily O O 0.9999068975448608
include O O 0.9997151494026184
functional O O 0.9997244477272034
and O O 0.9998165965080261
antigenic O O 0.9990986585617065
assays O O 0.999969482421875
, O O 0.9999653100967407
have O O 0.9999328851699829
more O O 0.9999710321426392
of O O 0.9999798536300659
a O O 0.9999760389328003
confirmatory O O 0.9999746084213257
than O O 0.999937891960144
diagnostic O O 0.9999605417251587
role O O 0.9999891519546509
in O O 0.9999783039093018
the O O 0.9999910593032837
management O O 0.9999881982803345
of O O 0.9999773502349854
HIT O O 0.9991727471351624
. O O 0.9999628067016602

Special O O 0.9999464750289917
attention O O 0.9999639987945557
must O O 0.999942421913147
be O O 0.9999916553497314
paid O O 0.9999958276748657
to O O 0.9998694658279419
cardiac O O 0.9998630285263062
patients O O 0.999988317489624
who O O 0.999969482421875
are O O 0.9999779462814331
often O O 0.9999738931655884
exposed O O 0.9999765157699585
to O O 0.999440610408783
heparin B B 0.9904733300209045
multiple O O 0.9993618130683899
times O O 0.9998852014541626
during O O 0.9999384880065918
their O O 0.9999879598617554
course O O 0.9999784231185913
of O O 0.9999619722366333
treatment O O 0.9999793767929077
. O O 0.9999706745147705

Direct B O 0.8127394318580627
thrombin I O 0.8379499316215515
inhibitors I O 0.8108113408088684
are O O 0.9999154806137085
appropriate O O 0.9995743632316589
, O O 0.9999657869338989
evidence O O 0.9995513558387756
- O O 0.9999865293502808
based O O 0.9990940093994141
alternatives O O 0.9999769926071167
to O O 0.999537467956543
heparin B B 0.9975422620773315
in O O 0.9999340772628784
patients O O 0.9999959468841553
with O O 0.999993085861206
a O O 0.9999933242797852
history O O 0.9999896287918091
of O O 0.99968421459198
HIT O O 0.9286908507347107
, O O 0.9999860525131226
who O O 0.9999926090240479
need O O 0.9999954700469971
to O O 0.9999971389770508
undergo O O 0.9999964237213135
percutaneous O O 0.9999940395355225
coronary O O 0.999987006187439
intervention O O 0.9999988079071045
. O O 0.999983549118042

As O O 0.9999617338180542
heparin B B 0.9990799427032471
remains O O 0.9998352527618408
one O O 0.9999270439147949
of O O 0.9999101161956787
the O O 0.9999768733978271
most O O 0.9999735355377197
frequently O O 0.9999598264694214
used O O 0.9997877478599548
medications O O 0.9990200996398926
today O O 0.9999555349349976
with O O 0.9999583959579468
potential O O 0.9999740123748779
for O O 0.9999635219573975
HIT O O 0.9998921155929565
with O O 0.9999682903289795
every O O 0.997072696685791
heparin B B 0.992244303226471
exposure O O 0.9998206496238708
, O O 0.9999761581420898
a O O 0.9999905824661255
close O O 0.9999929666519165
vigilance O O 0.9999961853027344
of O O 0.9999743700027466
platelet O O 0.9997616410255432
counts O O 0.9998441934585571
must O O 0.999962568283081
be O O 0.9999932050704956
practiced O O 0.9999948740005493
whenever O O 0.9998995065689087
heparin B B 0.9961761236190796
is O O 0.9999227523803711
initiated O O 0.9999661445617676
. O O 0.9999768733978271

Abductor O O 0.9811549782752991
paralysis O O 0.9997560381889343
after O O 0.9996427297592163
botox B B 0.9983465671539307
injection O O 0.9973884224891663
for O O 0.9998884201049805
adductor O O 0.9975407123565674
spasmodic O O 0.6670599579811096
dysphonia O O 0.9999071359634399
. O O 0.9999285936355591

OBJECTIVES O O 0.9887031316757202
/ O O 0.9999285936355591
HYPOTHESIS O O 0.9995806813240051
: O O 0.999745786190033
Botulinum O B 0.9957981705665588
toxin O I 0.9961530566215515
( O O 0.8789042234420776
Botox B B 0.9973118305206299
) O O 0.9993352293968201
injections O O 0.9998874664306641
into O O 0.9999634027481079
the O O 0.9999721050262451
thyroarytenoid O O 0.9971579313278198
muscles O O 0.9998390674591064
are O O 0.9999651908874512
the O O 0.9999943971633911
current O O 0.9999953508377075
standard O O 0.9999924898147583
of O O 0.9999901056289673
care O O 0.9999945163726807
for O O 0.9999579191207886
adductor O O 0.9983750581741333
spasmodic O O 0.6135598421096802
dysphonia O O 0.9998815059661865
( O O 0.9998849630355835
ADSD O O 0.9904608130455017
) O O 0.9999772310256958
. O O 0.9999778270721436

Reported O O 0.9999089241027832
adverse O O 0.9998204112052917
effects O O 0.9999662637710571
include O O 0.9999871253967285
a O O 0.9999815225601196
period O O 0.9999867677688599
of O O 0.9999792575836182
breathiness O O 0.9999619722366333
, O O 0.9999730587005615
throat O O 0.9998980760574341
pain O O 0.9999902248382568
, O O 0.9999178647994995
and O O 0.9999611377716064
difficulty O O 0.9999966621398926
with O O 0.999995231628418
swallowing O O 0.9999769926071167
liquids O O 0.9902212619781494
. O O 0.9998911619186401

Here O O 0.9999384880065918
we O O 0.9999314546585083
report O O 0.9999897480010986
multiple O O 0.9999749660491943
cases O O 0.9999868869781494
of O O 0.9999682903289795
bilateral O O 0.9999004602432251
abductor O O 0.9932003617286682
paralysis O O 0.9999134540557861
following O O 0.9997870326042175
Botox B B 0.9975810050964355
injections O O 0.9945849776268005
for O O 0.9996464252471924
ADSD O O 0.799305260181427
, O O 0.9999181032180786
a O O 0.999982476234436
complication O O 0.9999955892562866
previously O O 0.999995231628418
unreported O O 0.9999850988388062
. O O 0.9999687671661377

STUDY O O 0.9999425411224365
DESIGN O O 0.9999953508377075
: O O 0.999992847442627
Retrospective O O 0.999967098236084
case O O 0.9999701976776123
series O O 0.999992847442627
. O O 0.9999902248382568

METHODS O O 0.9996305704116821
: O O 0.9999713897705078
Patients O O 0.9999861717224121
that O O 0.9999476671218872
received O O 0.9999289512634277
Botox B B 0.9959047436714172
injections O O 0.9963711500167847
for O O 0.9999144077301025
spasmodic O O 0.8011046051979065
dysphonia O O 0.9999901056289673
between O O 0.9992042183876038
January O O 0.9866320490837097
2000 O O 0.9735867977142334
and O O 0.9980118274688721
October O O 0.9535925984382629
2009 O O 0.9708144664764404
were O O 0.9999529123306274
evaluated O O 0.9999853372573853
. O O 0.9999676942825317

Patients O O 0.9998189806938171
with O O 0.9998261332511902
ADSD O O 0.908928632736206
were O O 0.9998908042907715
identified O O 0.9999439716339111
. O O 0.9999303817749023

The O O 0.9999803304672241
number O O 0.9999802112579346
of O O 0.9999020099639893
treatments O O 0.9999394416809082
received O O 0.9999780654907227
and O O 0.9999731779098511
adverse O O 0.9999485015869141
effects O O 0.9999878406524658
were O O 0.9999769926071167
noted O O 0.9999890327453613
. O O 0.9999710321426392

For O O 0.9998511075973511
patients O O 0.9999845027923584
with O O 0.999955415725708
bilateral O O 0.9997434020042419
abductor O O 0.995242714881897
paralysis O O 0.9997712969779968
, O O 0.9999786615371704
age O O 0.9999951124191284
, O O 0.9999878406524658
sex O O 0.999996542930603
, O O 0.9999805688858032
paralytic O O 0.9565600752830505
Botox B B 0.9658463001251221
dose O O 0.9665129780769348
, O O 0.999975323677063
prior O O 0.9998893737792969
Botox B B 0.9746273756027222
dose O O 0.9749070405960083
, O O 0.9999297857284546
and O O 0.9999710321426392
course O O 0.9999922513961792
following O O 0.9999785423278809
paralysis O O 0.9997650980949402
were O O 0.9999737739562988
noted O O 0.999992847442627
. O O 0.999976396560669

RESULTS O O 0.9998871088027954
: O O 0.999955415725708
From O O 0.9999806880950928
a O O 0.9999862909317017
database O O 0.9999915361404419
of O O 0.9999667406082153
452 O O 0.9999964237213135
patients O O 0.9999852180480957
receiving O O 0.9992095232009888
Botox B B 0.9881503582000732
, O O 0.9996660947799683
352 O O 0.9999674558639526
patients O O 0.9999816417694092
had O O 0.9999758005142212
been O O 0.9999942779541016
diagnosed O O 0.9999942779541016
with O O 0.9998894929885864
ADSD O O 0.888580322265625
. O O 0.9998762607574463

Of O O 0.9998680353164673
these O O 0.9999911785125732
352 O O 0.9998818635940552
patients O O 0.9999918937683105
, O O 0.9999351501464844
eight O O 0.9999452829360962
patients O O 0.9999812841415405
suffered O O 0.9999510049819946
bilateral O O 0.9996987581253052
abductor O O 0.9865478873252869
paralysis O O 0.9998251795768738
, O O 0.9998880624771118
and O O 0.9999450445175171
two O O 0.9999828338623047
suffered O O 0.9999663829803467
this O O 0.999950647354126
complication O O 0.9999871253967285
twice O O 0.9999814033508301
. O O 0.9999707937240601

All O O 0.9997499585151672
affected O O 0.9999812841415405
patients O O 0.9999868869781494
were O O 0.9999555349349976
females O O 0.9995391368865967
over O O 0.9999947547912598
the O O 0.9999959468841553
age O O 0.9999535083770752
of O O 0.9999943971633911
50 O O 0.9999845027923584
years O O 0.9999494552612305
. O O 0.9999526739120483

Most O O 0.999847412109375
patients O O 0.9999842643737793
had O O 0.9999752044677734
received O O 0.9998161196708679
treatments O O 0.9995729327201843
prior O O 0.9999371767044067
to O O 0.9999313354492188
abductor O O 0.8120326995849609
paralysis O O 0.9990090131759644
and O O 0.9998087286949158
continued O O 0.999935507774353
receiving O O 0.9920806288719177
after O O 0.9993871450424194
paralysis O O 0.9982847571372986
. O O 0.9999586343765259

Seven O O 0.9998822212219238
patients O O 0.9999899864196777
recovered O O 0.9999889135360718
after O O 0.9999783039093018
a O O 0.9999867677688599
brief O O 0.9999932050704956
period O O 0.9999828338623047
of O O 0.9999145269393921
activity O O 0.980666995048523
restrictions O O 0.999954342842102
, O O 0.9999657869338989
and O O 0.999990701675415
one O O 0.9999915361404419
underwent O O 0.9999905824661255
a O O 0.9999878406524658
tracheotomy O O 0.9990046620368958
. O O 0.9999518394470215

The O O 0.999984860420227
incidence O O 0.9999924898147583
of O O 0.9999580383300781
abductor O O 0.9852854609489441
paralysis O O 0.999886155128479
after O O 0.9997337460517883
Botox B B 0.9982877373695374
injection O O 0.999488353729248
for O O 0.9990453124046326
ADSD O B 0.9046638607978821
was O O 0.9998252987861633
0 O O 0.9999746084213257
. O O 0.9999845027923584
34 O O 0.9999958276748657
% O O 0.9999899864196777
. O O 0.9999721050262451

CONCLUSIONS O O 0.9837137460708618
: O O 0.9999427795410156
Bilateral O O 0.9992146492004395
abductor O O 0.995749831199646
paralysis O O 0.9998993873596191
is O O 0.9999713897705078
a O O 0.9999773502349854
rare O O 0.9999823570251465
complication O O 0.9999924898147583
of O O 0.9998243451118469
Botox B B 0.99810791015625
injections O O 0.9827495813369751
for O O 0.999542236328125
ADSD O O 0.7986905574798584
, O O 0.9997451901435852
causing O O 0.9999542236328125
difficulty O O 0.9999966621398926
with O O 0.9999943971633911
breathing O O 0.999969482421875
upon O O 0.9999860525131226
exertion O O 0.9999758005142212
. O O 0.9999737739562988

The O O 0.9999685287475586
likely O O 0.9999257326126099
mechanism O O 0.9999566078186035
of O O 0.9999406337738037
paralysis O O 0.9999370574951172
is O O 0.9998992681503296
diffusion O O 0.9999383687973022
of O O 0.9985852241516113
Botox B O 0.6998302340507507
around O O 0.9994511008262634
the O O 0.999931812286377
muscular O O 0.9999788999557495
process O O 0.9999805688858032
of O O 0.9999033212661743
the O O 0.9999278783798218
arytenoid O O 0.9839617013931274
to O O 0.9998327493667603
the O O 0.9999251365661621
posterior O O 0.9999589920043945
cricoarytenoid O O 0.999609649181366
muscles O O 0.9999728202819824
. O O 0.9999505281448364

The O O 0.9999364614486694
paralysis O O 0.99986732006073
is O O 0.9998725652694702
temporary O O 0.9998561143875122
, O O 0.9999469518661499
and O O 0.9998986721038818
watchful O O 0.9999793767929077
waiting O O 0.9999984502792358
with O O 0.999969482421875
restriction O O 0.9999868869781494
of O O 0.9996429681777954
activity O O 0.9996387958526611
is O O 0.9999722242355347
the O O 0.9999948740005493
recommended O O 0.9999693632125854
management O O 0.9999881982803345
. O O 0.9999798536300659

Mitochondrial O O 0.9898502826690674
impairment O O 0.999950647354126
contributes O O 0.9998841285705566
to O O 0.9998270869255066
cocaine B B 0.9985613226890564
- O O 0.9985300302505493
induced O O 0.9999445676803589
cardiac O O 0.9999929666519165
dysfunction O O 0.9999978542327881
: O O 0.9997598528862
Prevention O O 0.9999028444290161
by O O 0.9998639822006226
the O O 0.99989914894104
targeted O O 0.9997168183326721
antioxidant O O 0.5474650263786316
MitoQ B B 0.9792534112930298
. O O 0.9996993541717529

The O O 0.9999868869781494
goal O O 0.9999973773956299
of O O 0.9999954700469971
this O O 0.9999836683273315
study O O 0.9999744892120361
was O O 0.9999932050704956
to O O 0.9999880790710449
assess O O 0.9999539852142334
mitochondrial O O 0.988617479801178
function O O 0.9999603033065796
and O O 0.9998691082000732
ROS O O 0.6410633325576782
production O O 0.9998557567596436
in O O 0.9999397993087769
an O O 0.9999669790267944
experimental O O 0.9999382495880127
model O O 0.9999922513961792
of O O 0.9999262094497681
cocaine B B 0.9951796531677246
- O O 0.9990148544311523
induced O O 0.99993896484375
cardiac O O 0.999992847442627
dysfunction O O 0.9999954700469971
. O O 0.9999806880950928

We O O 0.9999521970748901
hypothesized O O 0.9999539852142334
that O O 0.9995101690292358
cocaine O B 0.9970682263374329
abuse O O 0.9984381794929504
may O O 0.9999454021453857
lead O O 0.9999902248382568
to O O 0.999955415725708
altered O O 0.9999812841415405
mitochondrial O O 0.9922985434532166
function O O 0.9999610185623169
that O O 0.9999247789382935
in O O 0.9999887943267822
turn O O 0.9999843835830688
may O O 0.9999654293060303
cause O O 0.999977707862854
left O O 0.9999895095825195
ventricular O O 0.9999964237213135
dysfunction O O 0.999996542930603
. O O 0.9999774694442749

Seven O O 0.999975323677063
days O O 0.999982476234436
of O O 0.9998378753662109
cocaine B B 0.998448371887207
administration O O 0.9998099207878113
to O O 0.9999215602874756
rats O O 0.9789354801177979
led O O 0.9999679327011108
to O O 0.9999910593032837
an O O 0.999993085861206
increased O O 0.9999797344207764
oxygen B B 0.98479825258255
consumption O O 0.999904990196228
detected O O 0.9999747276306152
in O O 0.9995095729827881
cardiac O O 0.9994018077850342
fibers O O 0.9995600581169128
, O O 0.9999778270721436
specifically O O 0.9999573230743408
through O O 0.999772846698761
complex O O 0.9992080330848694
I O O 0.9993662238121033
and O O 0.9997187256813049
complex O O 0.9959022402763367
III O O 0.9985860586166382
. O O 0.9999643564224243

ROS O O 0.85760098695755
levels O O 0.9991598129272461
were O O 0.9999344348907471
increased O O 0.9998819828033447
, O O 0.9999594688415527
specifically O O 0.9999605417251587
in O O 0.9997110962867737
interfibrillar O O 0.9916204214096069
mitochondria O O 0.9985962510108948
. O O 0.9999549388885498

In O O 0.9998918771743774
parallel O O 0.9999051094055176
there O O 0.9999376535415649
was O O 0.9999521970748901
a O O 0.9999567270278931
decrease O O 0.9999510049819946
in O O 0.9996594190597534
ATP B O 0.534885585308075
synthesis O O 0.9895336031913757
, O O 0.9999130964279175
whereas O O 0.9999786615371704
no O O 0.9999837875366211
difference O O 0.9999897480010986
was O O 0.9999840259552002
observed O O 0.9999951124191284
in O O 0.9999233484268188
subsarcolemmal O O 0.9952875375747681
mitochondria O O 0.9984222650527954
. O O 0.9999619722366333

This O O 0.9998346567153931
uncoupling O O 0.956977367401123
effect O O 0.999624490737915
on O O 0.9994623064994812
oxidative O O 0.669435441493988
phosphorylation O O 0.566955029964447
was O O 0.9999377727508545
not O O 0.9999514818191528
detectable O O 0.9999858140945435
after O O 0.9995906949043274
short O O 0.9999097585678101
- O O 0.999984860420227
term O O 0.9999468326568604
exposure O O 0.9999579191207886
to O O 0.9981350898742676
cocaine B B 0.9977486729621887
, O O 0.9998149275779724
suggesting O O 0.9998838901519775
that O O 0.9998631477355957
these O O 0.9998995065689087
mitochondrial O O 0.9995713829994202
abnormalities O O 0.9999886751174927
were O O 0.999970555305481
a O O 0.999951958656311
late O O 0.9999186992645264
rather O O 0.9999755620956421
than O O 0.9999792575836182
a O O 0.9999299049377441
primary O O 0.9999600648880005
event O O 0.9999897480010986
in O O 0.9999810457229614
the O O 0.9999802112579346
pathological O O 0.9999902248382568
response O O 0.9999947547912598
to O O 0.9998347759246826
cocaine B B 0.9951993823051453
. O O 0.9998980760574341

MitoQ B B 0.996751070022583
, O O 0.9994877576828003
a O O 0.9989056587219238
mitochondrial O O 0.6434351801872253
- O O 0.9980973601341248
targeted O O 0.9941096305847168
antioxidant O O 0.8035558462142944
, O O 0.9992709755897522
was O O 0.9999467134475708
shown O O 0.9999712705612183
to O O 0.9998818635940552
completely O O 0.9998971223831177
prevent O O 0.9997654557228088
these O O 0.9999315738677979
mitochondrial O O 0.9996663331985474
abnormalities O O 0.9999910593032837
as O O 0.9999783039093018
well O O 0.9999518394470215
as O O 0.9999457597732544
cardiac O O 0.9999872446060181
dysfunction O O 0.9999926090240479
characterized O O 0.9999904632568359
here O O 0.9999964237213135
by O O 0.9999899864196777
a O O 0.9999735355377197
diastolic O O 0.9998656511306763
dysfunction O O 0.999994158744812
studied O O 0.9999808073043823
with O O 0.9999943971633911
a O O 0.9999817609786987
conductance O O 0.9998393058776855
catheter O O 0.9999548196792603
to O O 0.9999885559082031
obtain O O 0.9999933242797852
pressure O O 0.9948220252990723
- O O 0.9988201260566711
volume O O 0.9997466206550598
data O O 0.9999797344207764
. O O 0.999967098236084

Taken O O 0.999982476234436
together O O 0.9999840259552002
, O O 0.9999808073043823
these O O 0.9999810457229614
results O O 0.9999922513961792
extend O O 0.9999676942825317
previous O O 0.9999749660491943
studies O O 0.9999923706054688
and O O 0.9999780654907227
demonstrate O O 0.9999845027923584
that O O 0.9999088048934937
cocaine B B 0.9987496137619019
- O O 0.9996213912963867
induced O O 0.9998924732208252
cardiac O O 0.9999902248382568
dysfunction O O 0.9999969005584717
may O O 0.9999253749847412
be O O 0.9999723434448242
due O O 0.9999834299087524
to O O 0.9999203681945801
a O O 0.9999465942382812
mitochondrial O O 0.9994226694107056
defect O O 0.9999890327453613
. O O 0.9999628067016602

Trimethoprim B B 0.9958136677742004
- O O 0.9989898800849915
induced O O 0.9999005794525146
immune O O 0.9999361038208008
hemolytic O O 0.999420166015625
anemia O O 0.9998130202293396
in O O 0.9999861717224121
a O O 0.9999927282333374
pediatric O O 0.9999865293502808
oncology O O 0.9999626874923706
patient O O 0.9999853372573853
presenting O O 0.9999409914016724
as O O 0.9999953508377075
an O O 0.9999926090240479
acute O O 0.9999711513519287
hemolytic O O 0.9997218251228333
transfusion O O 0.9997105002403259
reaction O O 0.9999929666519165
. O O 0.9999762773513794

A O O 0.9999630451202393
10 O O 0.9999778270721436
- O O 0.9999814033508301
year O O 0.9999923706054688
- O O 0.9999922513961792
old O O 0.9999940395355225
male O O 0.9999938011169434
with O O 0.9999532699584961
acute O O 0.9998904466629028
leukemia O O 0.9999923706054688
presented O O 0.9999607801437378
with O O 0.9999752044677734
post O O 0.9997610449790955
- O O 0.9994693398475647
chemotherapy O O 0.9994889497756958
anemia O O 0.9999220371246338
. O O 0.999972939491272

During O O 0.9996381998062134
red O O 0.9991852641105652
cell O O 0.9844897985458374
transfusion O O 0.9997162222862244
, O O 0.9999643564224243
he O O 0.9999518394470215
developed O O 0.9999669790267944
hemoglobinuria O O 0.9967907071113586
. O O 0.9999581575393677

Transfusion O O 0.9596894383430481
reaction O O 0.9998315572738647
workup O O 0.9999493360519409
was O O 0.9999121427536011
negative O O 0.9994908571243286
. O O 0.9999665021896362

Drug O O 0.7663244605064392
- O O 0.9996836185455322
induced O O 0.9999212026596069
immune O O 0.9999287128448486
hemolytic O O 0.9995917677879333
anemia O O 0.9998699426651001
was O O 0.9999723434448242
suspected O O 0.9999889135360718
because O O 0.9999924898147583
of O O 0.9999544620513916
positive O O 0.9999523162841797
direct O O 0.9945552349090576
antiglobulin O O 0.9790055155754089
test O O 0.9999438524246216
, O O 0.9999613761901855
negative O O 0.9991600513458252
eluate O O 0.9566160440444946
, O O 0.9994099140167236
and O O 0.9996846914291382
microspherocytes O O 0.9787877202033997
on O O 0.9999310970306396
smear O O 0.999588668346405
pre O O 0.999813973903656
- O O 0.9999418258666992
and O O 0.9999251365661621
post O O 0.9997263550758362
- O O 0.999657392501831
transfusion O O 0.999775230884552
. O O 0.9999715089797974

Drug O O 0.9998144507408142
studies O O 0.9999815225601196
using O O 0.9999682903289795
the O O 0.9998999834060669
indirect O O 0.9984868764877319
antiglobulin O O 0.9595367312431335
test O O 0.9997556805610657
were O O 0.9999066591262817
strongly O O 0.9999349117279053
positive O O 0.9999600648880005
with O O 0.9992566704750061
trimethoprim B B 0.9973239898681641
and O O 0.9541236162185669
trimethoprim B B 0.9901678562164307
- I I 0.5692422986030579
sulfamethoxazole I I 0.991676926612854
but O O 0.9992697834968567
negative O O 0.9999487400054932
with O O 0.9996819496154785
sulfamethoxazole B B 0.998310923576355
. O O 0.9999459981918335

The O O 0.9999728202819824
patient O O 0.9999874830245972
recovered O O 0.9999901056289673
after O O 0.999966025352478
discontinuing O O 0.9999737739562988
the O O 0.999754011631012
drug O O 0.9975107908248901
, O O 0.9999752044677734
with O O 0.9999947547912598
no O O 0.9999902248382568
recurrence O O 0.9999967813491821
in O O 0.9999903440475464
2 O O 0.999984622001648
years O O 0.9999960660934448
. O O 0.9999791383743286

Other O O 0.9998164772987366
causes O O 0.9999381303787231
of O O 0.9999430179595947
anemia O O 0.9984726309776306
should O O 0.9999232292175293
be O O 0.9999898672103882
considered O O 0.9999665021896362
in O O 0.9999681711196899
patients O O 0.9999922513961792
with O O 0.9999861717224121
worse O O 0.999932050704956
- O O 0.9999854564666748
than O O 0.9999940395355225
- O O 0.999988317489624
expected O O 0.9999984502792358
anemia O O 0.9996556043624878
after O O 0.9999371767044067
chemotherapy O O 0.9995226860046387
. O O 0.9999785423278809

Furthermore O O 0.9997609257698059
, O O 0.9998857975006104
hemolysis O O 0.9991146922111511
during O O 0.9997962117195129
transfusion O O 0.9997009038925171
is O O 0.9999514818191528
not O O 0.9999443292617798
always O O 0.9999146461486816
a O O 0.9999350309371948
transfusion O O 0.9979346990585327
reaction O O 0.9999872446060181
. O O 0.9999622106552124

Verapamil B B 0.9933487772941589
stimulation O O 0.994635283946991
test O O 0.9999141693115234
in O O 0.9999140501022339
hyperprolactinemia O O 0.9701650738716125
: O O 0.9999427795410156
loss O O 0.9999858140945435
of O O 0.9999614953994751
prolactin O O 0.6670287251472473
response O O 0.9998148083686829
in O O 0.998847246170044
anatomic O O 0.9993683695793152
or O O 0.9997662901878357
functional O O 0.999909520149231
stalk O O 0.9871899485588074
effect O O 0.9998742341995239
. O O 0.9999643564224243

AIM O O 0.9893325567245483
: O O 0.9997007846832275
Verapamil B B 0.9991698265075684
stimulation O O 0.9922314882278442
test O O 0.9997829794883728
was O O 0.9999799728393555
previously O O 0.9999744892120361
investigated O O 0.9999535083770752
as O O 0.999987006187439
a O O 0.9999779462814331
tool O O 0.9999959468841553
for O O 0.999981164932251
differential O O 0.9999830722808838
diagnosis O O 0.9999958276748657
of O O 0.9999759197235107
hyperprolactinemia O O 0.9913649559020996
, O O 0.9999587535858154
but O O 0.999988317489624
with O O 0.9999924898147583
conflicting O O 0.9999966621398926
results O O 0.9999970197677612
. O O 0.9999850988388062

Macroprolactinemia O O 0.995811939239502
was O O 0.9999492168426514
never O O 0.9999574422836304
considered O O 0.9999603033065796
in O O 0.9999806880950928
those O O 0.9999908208847046
previous O O 0.9999769926071167
studies O O 0.999988317489624
. O O 0.9999591112136841

Here O O 0.9999507665634155
, O O 0.999975323677063
we O O 0.9999790191650391
aimed O O 0.9999964237213135
to O O 0.9999948740005493
re O O 0.9999864101409912
- O O 0.999981164932251
investigate O O 0.9999780654907227
the O O 0.9999923706054688
diagnostic O O 0.9999948740005493
value O O 0.9999966621398926
of O O 0.9997392296791077
verapamil B B 0.9995774626731873
in O O 0.9998452663421631
a O O 0.9999558925628662
population O O 0.9999861717224121
who O O 0.9999903440475464
were O O 0.9999908208847046
all O O 0.9999516010284424
screened O O 0.9999901056289673
for O O 0.9999649524688721
macroprolactinemia O O 0.9995189905166626
. O O 0.9999568462371826

Prolactin O O 0.8572207689285278
responses O O 0.9996838569641113
to O O 0.9994133710861206
verapamil B B 0.9992684721946716
in O O 0.9998018145561218
65 O O 0.9999971389770508
female O O 0.999997615814209
patients O O 0.9999967813491821
( O O 0.9999865293502808
age O O 0.9999845027923584
: O O 0.999994158744812
29 O O 0.9999983310699463
. O O 0.9999977350234985
9 O O 0.9999939203262329
+ O O 0.9999959468841553
/ O O 0.9999939203262329
- O O 0.9999786615371704
8 O O 0.9999343156814575
. O O 0.9999983310699463
1 O O 0.9999953508377075
years O O 0.9999958276748657
) O O 0.9999903440475464
with O O 0.9999814033508301
hyperprolactinemia O O 0.9977503418922424
were O O 0.9999825954437256
tested O O 0.9999706745147705
in O O 0.9999839067459106
a O O 0.9999815225601196
descriptive O O 0.9980047345161438
, O O 0.9999644756317139
matched O O 0.999964714050293
case O O 0.9999829530715942
- O O 0.9999793767929077
control O O 0.9999926090240479
study O O 0.9999926090240479
. O O 0.9999804496765137

METHODS O O 0.9995858073234558
: O O 0.9994592070579529
Verapamil B B 0.9991876482963562
80 O O 0.7082841396331787
mg O O 0.9930813908576965
, O O 0.999936580657959
p O O 0.9994391798973083
. O O 0.9999972581863403
o O O 0.9999959468841553
. O O 0.9999910593032837
was O O 0.9999803304672241
administered O O 0.9999489784240723
, O O 0.9999533891677856
and O O 0.9999567270278931
then O O 0.9995597004890442
PRL O O 0.5840399265289307
levels O O 0.9999111890792847
were O O 0.9999798536300659
measured O O 0.9999849796295166
at O O 0.9999706745147705
8th O O 0.9999918937683105
and O O 0.9999898672103882
16th O O 0.9999979734420776
hours O O 0.9999969005584717
, O O 0.9999929666519165
by O O 0.99998939037323
immunometric O O 0.9999480247497559
chemiluminescence O O 0.9767264127731323
. O O 0.9999619722366333

Verapamil B B 0.9993510842323303
responsiveness O O 0.9998471736907959
was O O 0.999984622001648
determined O O 0.9999948740005493
by O O 0.9999923706054688
peak O O 0.9999349117279053
percent O O 0.9999922513961792
change O O 0.999994158744812
in O O 0.9999630451202393
basal O O 0.9994884729385376
prolactin O O 0.7291256785392761
levels O O 0.9998737573623657
( O O 0.9998160004615784
PRL O O 0.9810097813606262
) O O 0.9999362230300903
. O O 0.9999790191650391

RESULTS O O 0.9999524354934692
: O O 0.9995602965354919
Verapamil B B 0.9998443126678467
significantly O O 0.9999104738235474
increased O O 0.9998935461044312
PRL O O 0.6995064616203308
levels O O 0.9997805953025818
in O O 0.999919056892395
healthy O O 0.9996800422668457
controls O O 0.9999922513961792
( O O 0.999931812286377
N O O 0.9985311031341553
. O O 0.9999806880950928
8 O O 0.9999493360519409
, O O 0.9997499585151672
PRL O O 0.9814425110816956
: O O 0.9999158382415771
183 O O 0.9999749660491943
% O O 0.9999823570251465
) O O 0.9999510049819946
, O O 0.9998754262924194
macroprolactinoma O O 0.9990882873535156
( O O 0.9999194145202637
N O O 0.9956824779510498
. O O 0.999913215637207
8 O O 0.9997326731681824
, O O 0.9994966983795166
PRL O O 0.9827614426612854
: O O 0.999946117401123
7 O O 0.9999841451644897
% O O 0.9999724626541138
) O O 0.9999557733535767
, O O 0.9998668432235718
microprolactinoma O O 0.9855683445930481
( O O 0.9999315738677979
N O O 0.9990018010139465
. O O 0.9999792575836182
19 O O 0.9999847412109375
, O O 0.9996091723442078
PRL O O 0.9846524596214294
: O O 0.9999537467956543
21 O O 0.9999810457229614
% O O 0.9999889135360718
) O O 0.9999573230743408
, O O 0.9999619722366333
macroprolactinemia O O 0.9965039491653442
( O O 0.9999628067016602
N O O 0.9990541338920593
. O O 0.9999818801879883
23 O O 0.9999887943267822
, O O 0.9998307228088379
PRL O O 0.9870306849479675
: O O 0.9999622106552124
126 O O 0.9999082088470459
% O O 0.9999924898147583
) O O 0.9999465942382812
, O O 0.9999455213546753
but O O 0.999969482421875
not O O 0.9999350309371948
in O O 0.9998692274093628
pseudoprolactinoma O O 0.95821613073349
( O O 0.9999229907989502
N O O 0.9979838132858276
. O O 0.9999469518661499
8 O O 0.9999264478683472
, O O 0.9998773336410522
PRL O O 0.9801906943321228
: O O 0.9999421834945679
0 O O 0.9999706745147705
. O O 0.9999767541885376
8 O O 0.9999884366989136
% O O 0.9999860525131226
) O O 0.9999594688415527
, O O 0.9999014139175415
and O O 0.9997876286506653
risperidone B B 0.9984803795814514
- O O 0.9996078610420227
induced O O 0.9999140501022339
hyperprolactinemia O O 0.9988068342208862
( O O 0.9999551773071289
N O O 0.9972073435783386
. O O 0.9999370574951172
7 O O 0.9999616146087646
, O O 0.9997139573097229
PRL O O 0.9750463962554932
: O O 0.9999436140060425
3 O O 0.9999024868011475
% O O 0.9999772310256958
) O O 0.999963641166687
. O O 0.9999622106552124

ROC O O 0.9849825501441956
curve O O 0.9929331541061401
analysis O O 0.9999054670333862
revealed O O 0.9999539852142334
that O O 0.9998917579650879
unresponsiveness O O 0.999990701675415
to O O 0.9997357726097107
verapamil B B 0.999576985836029
defined O O 0.9994680285453796
as O O 0.9999432563781738
PRL O O 0.9266496300697327
< O O 0.9999361038208008
7 O O 0.9999909400939941
% O O 0.9999901056289673
, O O 0.9998574256896973
discriminated O O 0.9998378753662109
anatomical O O 0.9998341798782349
or O O 0.9997578263282776
functional O O 0.9998764991760254
stalk O O 0.97006756067276
effect O O 0.999869704246521
( O O 0.9998522996902466
sensitivity O O 0.9999814033508301
: O O 0.9999557733535767
74 O O 0.9999868869781494
% O O 0.9999974966049194
, O O 0.9998464584350586
specificity O O 0.9999791383743286
: O O 0.9999486207962036
73 O O 0.9999969005584717
% O O 0.9999979734420776
, O O 0.999225378036499
AUC O O 0.9362969994544983
: O O 0.9999045133590698
0 O O 0.9999204874038696
. O O 0.9999854564666748
855 O O 0.9868406057357788
+ O O 0.9999680519104004
/ O O 0.9231864809989929
- O O 0.9981352090835571
0 O O 0.9997989535331726
. O O 0.9999939203262329
04 O O 0.99986732006073
, O O 0.9990363121032715
P O O 0.889418363571167
< O O 0.9999614953994751
0 O O 0.9999887943267822
. O O 0.9999967813491821
001 O O 0.9999827146530151
, O O 0.9983680844306946
CI O O 0.9357845187187195
: O O 0.9999467134475708
0 O O 0.9999821186065674
. O O 0.9999902248382568
768 O O 0.9999858140945435
- O O 0.9978304505348206
0 O O 0.9999854564666748
. O O 0.9999881982803345
942 O O 0.9899305105209351
) O O 0.9999701976776123
associated O O 0.9999198913574219
with O O 0.9999603033065796
pseudoprolactinoma O O 0.9400842785835266
or O O 0.9998742341995239
risperidone B B 0.9985769987106323
- O O 0.9997513890266418
induced O O 0.9999545812606812
hyperprolactinemia O O 0.9981721639633179
, O O 0.9999734163284302
respectively O O 0.9998648166656494
. O O 0.9999752044677734

CONCLUSION O O 0.9995692372322083
: O O 0.9996438026428223
Verapamil B B 0.9997848868370056
responsiveness O O 0.9993707537651062
is O O 0.9999657869338989
not O O 0.9999927282333374
a O O 0.9999734163284302
reliable O O 0.9999840259552002
finding O O 0.9999841451644897
for O O 0.9999624490737915
the O O 0.9999947547912598
differential O O 0.9999716281890869
diagnosis O O 0.9999938011169434
of O O 0.9999586343765259
hyperprolactinemia O O 0.9944995641708374
. O O 0.999948263168335

However O O 0.9999141693115234
, O O 0.9998102784156799
verapamil B B 0.999854564666748
unresponsiveness O O 0.9995713829994202
discriminates O O 0.9997937083244324
stalk O O 0.9709216952323914
effect O O 0.9998841285705566
( O O 0.999854326248169
i O O 0.9999260902404785
. O O 0.999962568283081
e O O 0.9999761581420898
. O O 0.9999717473983765
, O O 0.9999020099639893
anatomically O O 0.9999585151672363
or O O 0.9999622106552124
functionally O O 0.9999593496322632
inhibited O O 0.999940037727356
dopaminergic O B 0.9501242637634277
tonus O O 0.9021461009979248
) O O 0.9999722242355347
from O O 0.9996410608291626
other O O 0.9998828172683716
causes O O 0.9999555349349976
of O O 0.9999091625213623
hyperprolactinemia O O 0.9974263310432434
with O O 0.9999206066131592
varying O O 0.9999721050262451
degrees O O 0.9999916553497314
of O O 0.9999661445617676
responsiveness O O 0.9999769926071167
. O O 0.9999604225158691

Blockade O O 0.9999246597290039
of O O 0.9998281002044678
endothelial O O 0.9997147917747498
- O O 0.9992610812187195
mesenchymal O O 0.9996086955070496
transition O O 0.9999892711639404
by O O 0.9998637437820435
a O O 0.9982483386993408
Smad3 O O 0.5229535698890686
inhibitor O O 0.8038763403892517
delays O O 0.9998570680618286
the O O 0.9999740123748779
early O O 0.9999818801879883
development O O 0.9999932050704956
of O O 0.9999765157699585
streptozotocin B B 0.9982262253761292
- O O 0.9994427561759949
induced O O 0.9999603033065796
diabetic O O 0.9999357461929321
nephropathy O O 0.9999902248382568
. O O 0.9999722242355347

OBJECTIVE O O 0.9996378421783447
: O O 0.999992847442627
A O O 0.999991774559021
multicenter O O 0.9998888969421387
, O O 0.9999464750289917
controlled O O 0.9999605417251587
trial O O 0.9999853372573853
showed O O 0.999985933303833
that O O 0.9999417066574097
early O O 0.999890923500061
blockade O O 0.9998530149459839
of O O 0.9995611310005188
the O O 0.9994781613349915
renin O O 0.6622247099876404
- O O 0.9785981774330139
angiotensin B B 0.9300410747528076
system O O 0.9033423662185669
in O O 0.9999284744262695
patients O O 0.9999946355819702
with O O 0.999984622001648
type O O 0.9999905824661255
1 O O 0.999964714050293
diabetes O O 0.9997771382331848
and O O 0.9999572038650513
normoalbuminuria O O 0.969924807548523
did O O 0.9999648332595825
not O O 0.9999293088912964
retard O O 0.9999217987060547
the O O 0.9999899864196777
progression O O 0.9999961853027344
of O O 0.9999830722808838
nephropathy O O 0.9999858140945435
, O O 0.9999788999557495
suggesting O O 0.9999642372131348
that O O 0.9999041557312012
other O O 0.9997697472572327
mechanism O O 0.9998169541358948
( O O 0.9996662139892578
s O O 0.997036337852478
) O O 0.999935507774353
are O O 0.9999380111694336
involved O O 0.9999724626541138
in O O 0.999982476234436
the O O 0.9999837875366211
pathogenesis O O 0.9999942779541016
of O O 0.9999839067459106
early O O 0.9999854564666748
diabetic O O 0.9999399185180664
nephropathy O O 0.9999939203262329
( O O 0.9999563694000244
diabetic O O 0.9998701810836792
nephropathy O O 0.999984860420227
) O O 0.9999797344207764
. O O 0.9999667406082153

We O O 0.9999693632125854
have O O 0.999993085861206
previously O O 0.9999814033508301
demonstrated O O 0.9999904632568359
that O O 0.9998825788497925
endothelial O O 0.9991725087165833
- O O 0.9959462285041809
mesenchymal O O 0.9967367053031921
- O O 0.9943162798881531
transition O O 0.9964287877082825
( O O 0.9979349374771118
EndoMT O O 0.9950077533721924
) O O 0.999764621257782
contributes O O 0.9999175071716309
to O O 0.999971866607666
the O O 0.9999887943267822
early O O 0.9999688863754272
development O O 0.9999853372573853
of O O 0.9999521970748901
renal O O 0.9999592304229736
interstitial O O 0.9998388290405273
fibrosis O O 0.9999953508377075
independently O O 0.9999628067016602
of O O 0.9999573230743408
microalbuminuria O O 0.9930597543716431
in O O 0.9999476671218872
mice O O 0.999985933303833
with O O 0.9999721050262451
streptozotocin B B 0.996272087097168
( O O 0.9947053790092468
STZ B B 0.9977200627326965
) O O 0.9236676096916199
- O O 0.9996672868728638
induced O O 0.9999475479125977
diabetes O O 0.9998216032981873
. O O 0.9999768733978271

In O O 0.9999819993972778
the O O 0.9999955892562866
present O O 0.9999899864196777
study O O 0.9999901056289673
, O O 0.9999450445175171
we O O 0.9999691247940063
hypothesized O O 0.9998065829277039
that O O 0.9998149275779724
blocking O O 0.5549683570861816
EndoMT O O 0.5437768697738647
reduces O O 0.9997100234031677
the O O 0.9999866485595703
early O O 0.999987006187439
development O O 0.9999945163726807
of O O 0.9999780654907227
diabetic O O 0.9998838901519775
nephropathy O O 0.9999674558639526
. O O 0.99992835521698

RESEARCH O O 0.9999681711196899
DESIGN O O 0.9999982118606567
AND O O 0.9999961853027344
METHODS O O 0.9999980926513672
: O O 0.9999802112579346
EndoMT O O 0.8915548920631409
was O O 0.9999703168869019
induced O O 0.9999860525131226
in O O 0.9999611377716064
a O O 0.9999610185623169
mouse O O 0.9999716281890869
pancreatic O O 0.9966403245925903
microvascular O O 0.995741605758667
endothelial O O 0.999881386756897
cell O O 0.9999330043792725
line O O 0.9999701976776123
( O O 0.9997661709785461
MMEC O O 0.9696844220161438
) O O 0.9999127388000488
in O O 0.9999631643295288
the O O 0.999981164932251
presence O O 0.9998500347137451
of O O 0.9998512268066406
advanced O O 0.5428645014762878
glycation O B 0.7095426917076111
end O I 0.955388605594635
products O I 0.9894881248474121
( O O 0.8928968906402588
AGEs O B 0.9025083780288696
) O O 0.9986609220504761
and O O 0.999915599822998
in O O 0.9998972415924072
the O O 0.9999191761016846
endothelial O O 0.9985612034797668
lineage O O 0.9812090396881104
- O O 0.9996451139450073
traceble O O 0.998102605342865
mouse O O 0.9999253749847412
line O O 0.9989797472953796
Tie2 O O 0.9311803579330444
- O O 0.9788128137588501
Cre O O 0.8878674507141113
; O O 0.9971394538879395
Loxp O O 0.5034497380256653
- O O 0.8263344168663025
EGFP O O 0.7178853750228882
by O O 0.9999146461486816
administration O O 0.9999668598175049
of O O 0.9999395608901978
AGEs O O 0.6827022433280945
, O O 0.9999057054519653
with O O 0.9999239444732666
nonglycated O O 0.8178013563156128
mouse O O 0.9902366995811462
albumin O O 0.812073826789856
serving O O 0.999924898147583
as O O 0.999909520149231
a O O 0.999491810798645
control O O 0.9999661445617676
. O O 0.9999675750732422

Phosphorylated O O 0.66424560546875
Smad3 O O 0.6704128384590149
was O O 0.9999078512191772
detected O O 0.9999468326568604
by O O 0.9999561309814453
immunoprecipitation O O 0.9989928603172302
/ O O 0.9998600482940674
Western O O 0.9970261454582214
blotting O O 0.999994158744812
and O O 0.9999723434448242
confocal O O 0.9984875917434692
microscopy O O 0.9999669790267944
. O O 0.9999583959579468

Blocking O O 0.9996590614318848
studies O O 0.9999744892120361
using O O 0.9992490410804749
receptor O O 0.794360339641571
for O O 0.9004496932029724
AGE O O 0.825560986995697
siRNA O O 0.8532432317733765
and O O 0.9994221925735474
a O O 0.9986169338226318
specific O O 0.9834291338920593
inhibitor O O 0.8873828053474426
of O O 0.9790897369384766
Smad3 O O 0.48430851101875305
( O O 0.9955684542655945
SIS3 O O 0.5029336810112
) O O 0.9998323917388916
were O O 0.9999737739562988
performed O O 0.9999842643737793
in O O 0.9998262524604797
MMECs O O 0.9725658297538757
and O O 0.9999092817306519
in O O 0.9999427795410156
STZ B B 0.9830858707427979
- O O 0.9985619187355042
induced O O 0.999932050704956
diabetic O O 0.9999576807022095
nephropathy O O 0.9999916553497314
in O O 0.9999431371688843
Tie2 O O 0.9659721851348877
- O O 0.9947104454040527
Cre O O 0.9523653984069824
; O O 0.9991163611412048
Loxp O O 0.6928655505180359
- O O 0.9565102458000183
EGFP O O 0.9512475728988647
mice O O 0.9999634027481079
. O O 0.9999731779098511

RESULTS O O 0.9998372793197632
: O O 0.9998751878738403
Confocal O O 0.9951848387718201
microscopy O O 0.9999412298202515
and O O 0.999976634979248
real O O 0.9999502897262573
- O O 0.9999849796295166
time O O 0.999970555305481
PCR O O 0.9955535531044006
demonstrated O O 0.9999706745147705
that O O 0.9971296191215515
AGEs O B 0.9425853490829468
induced O O 0.9995664954185486
EndoMT O O 0.9935698509216309
in O O 0.9995914101600647
MMECs O O 0.9754941463470459
and O O 0.9998594522476196
in O O 0.9998019337654114
Tie2 O O 0.9457622170448303
- O O 0.9912934899330139
Cre O O 0.9420753121376038
; O O 0.9976588487625122
Loxp O O 0.6057270765304565
- O O 0.9620739817619324
EGFP O O 0.9004313945770264
mice O O 0.9999425411224365
. O O 0.9999711513519287

Immunoprecipitation O O 0.9995891451835632
/ O O 0.9999220371246338
Western O O 0.9997143149375916
blotting O O 0.9999960660934448
showed O O 0.9999626874923706
that O O 0.9996925592422485
Smad3 O O 0.6829543709754944
was O O 0.9998382329940796
activated O O 0.9994914531707764
by O O 0.9978479146957397
AGEs O B 0.9640806913375854
but O O 0.998640239238739
was O O 0.9998730421066284
inhibited O O 0.9989474415779114
by O O 0.9993597865104675
SIS3 O O 0.7633934020996094
in O O 0.9990866184234619
MMECs O O 0.9933162331581116
and O O 0.9998511075973511
in O O 0.9998207688331604
STZ B B 0.9730892181396484
- O O 0.9986080527305603
induced O O 0.9999445676803589
diabetic O O 0.9999175071716309
nephropathy O O 0.9999606609344482
. O O 0.9999786615371704

Confocal O O 0.9991437196731567
microscopy O O 0.9999465942382812
and O O 0.9999736547470093
real O O 0.9999257326126099
- O O 0.9999862909317017
time O O 0.999971866607666
PCR O O 0.9954706430435181
further O O 0.9999802112579346
demonstrated O O 0.9999879598617554
that O O 0.9996044039726257
SIS3 O O 0.6867570281028748
abrogated O O 0.9997034668922424
EndoMT O O 0.9964454770088196
, O O 0.9999105930328369
reduced O O 0.9999687671661377
renal O O 0.9999452829360962
fibrosis O O 0.9999837875366211
, O O 0.9997754693031311
and O O 0.9997956156730652
retarded O O 0.9999270439147949
progression O O 0.9999957084655762
of O O 0.9999743700027466
nephropathy O O 0.9999395608901978
. O O 0.9999769926071167

CONCLUSIONS O O 0.9803698062896729
: O O 0.9996514320373535
EndoMT O O 0.8792097568511963
is O O 0.9998652935028076
a O O 0.9998583793640137
novel O O 0.9992677569389343
pathway O O 0.9998935461044312
leading O O 0.9999721050262451
to O O 0.999988317489624
early O O 0.9999836683273315
development O O 0.999995231628418
of O O 0.9999871253967285
diabetic O O 0.9999277591705322
nephropathy O O 0.9999874830245972
. O O 0.9999710321426392

Blockade O O 0.9996024966239929
of O O 0.9805474281311035
EndoMT O O 0.8137850761413574
by O O 0.9990060925483704
SIS3 O B 0.8811199069023132
may O O 0.9997208714485168
provide O O 0.9999703168869019
a O O 0.9999747276306152
new O O 0.9999725818634033
strategy O O 0.9999682903289795
to O O 0.9999319314956665
retard O O 0.9999459981918335
the O O 0.9999828338623047
progression O O 0.9999936819076538
of O O 0.9999704360961914
diabetic O O 0.9998829364776611
nephropathy O O 0.9999773502349854
and O O 0.9999731779098511
other O O 0.9999516010284424
diabetes O O 0.9973993301391602
complications O O 0.9999927282333374
. O O 0.999950647354126

Cytostatic O O 0.9959402084350586
and O O 0.9995161294937134
anti O O 0.9477949738502502
- O O 0.9989122152328491
angiogenic O O 0.9991176724433899
effects O O 0.9998499155044556
of O O 0.9968189001083374
temsirolimus B B 0.9991940855979919
in O O 0.9995686411857605
refractory O O 0.9999326467514038
mantle O O 0.9995062351226807
cell O O 0.9996929168701172
lymphoma O O 0.9999222755432129
. O O 0.9998644590377808

Mantle O O 0.9984883069992065
cell O O 0.9996588230133057
lymphoma O O 0.9999454021453857
( O O 0.9997543692588806
MCL O O 0.9903705716133118
) O O 0.9999690055847168
is O O 0.999950647354126
a O O 0.9999643564224243
rare O O 0.9999802112579346
and O O 0.999925971031189
aggressive O O 0.9998878240585327
type O O 0.9999815225601196
of O O 0.9999361038208008
B O O 0.9968229532241821
- O O 0.9997413754463196
cell O O 0.9999301433563232
non O O 0.992892861366272
- O O 0.9992376565933228
Hodgkin O O 0.9989312291145325
' O O 0.9999794960021973
s O O 0.9999697208404541
lymphoma O O 0.9999570846557617
. O O 0.9999548196792603

Patients O O 0.999937891960144
become O O 0.9999948740005493
progressively O O 0.9999939203262329
refractory O O 0.999995231628418
to O O 0.9999477863311768
conventional O O 0.9997401833534241
chemotherapy O O 0.9995416402816772
, O O 0.9998636245727539
and O O 0.9999730587005615
their O O 0.9999805688858032
prognosis O O 0.9999902248382568
is O O 0.9999791383743286
poor O O 0.9999938011169434
. O O 0.9999794960021973

However O O 0.9999411106109619
, O O 0.9999667406082153
a O O 0.9999909400939941
38 O O 0.9999933242797852
% O O 0.9999957084655762
remission O O 0.999974250793457
rate O O 0.9999899864196777
has O O 0.9999864101409912
been O O 0.9999955892562866
recently O O 0.999985933303833
reported O O 0.9999980926513672
in O O 0.9999303817749023
refractory O O 0.9998902082443237
MCL O O 0.998666524887085
treated O O 0.9999547004699707
with O O 0.9996970891952515
temsirolimus B B 0.9991992115974426
, O O 0.9993667006492615
a O O 0.9910365343093872
mTOR O O 0.96886146068573
inhibitor O O 0.9735518097877502
. O O 0.9999386072158813
Here O O 0.999996542930603
we O O 0.9999970197677612
had O O 0.9999986886978149
the O O 0.9999985694885254
opportunity O O 0.9999990463256836
to O O 0.9999980926513672
study O O 0.9999967813491821
a O O 0.9999955892562866
case O O 0.9999964237213135
of O O 0.99998939037323
refractory O O 0.9999017715454102
MCL O O 0.9989375472068787
who O O 0.9999847412109375
had O O 0.9999805688858032
tumor O O 0.9999856948852539
regression O O 0.99997878074646
two O O 0.999992847442627
months O O 0.9999990463256836
after O O 0.9999454021453857
temsirolimus B B 0.9995352029800415
treatment O O 0.9992014765739441
, O O 0.9999699592590332
and O O 0.9999910593032837
a O O 0.9999947547912598
progression O O 0.9999258518218994
- O O 0.9999828338623047
free O O 0.9999971389770508
survival O O 0.9999954700469971
of O O 0.999991774559021
10 O O 0.9999955892562866
months O O 0.9999983310699463
. O O 0.999984622001648

In O O 0.999984622001648
this O O 0.9999690055847168
case O O 0.9999892711639404
, O O 0.9999610185623169
lymph O O 0.9999629259109497
node O O 0.9999821186065674
biopsies O O 0.9999624490737915
were O O 0.9999881982803345
performed O O 0.999996542930603
before O O 0.9999433755874634
and O O 0.9999802112579346
six O O 0.9999939203262329
months O O 0.9999983310699463
after O O 0.9999701976776123
temsirolimus B B 0.9993956089019775
therapy O O 0.9968735575675964
. O O 0.9999842643737793

Comparison O O 0.9999818801879883
of O O 0.9999735355377197
the O O 0.9999828338623047
two O O 0.9999808073043823
biopsies O O 0.9999356269836426
showed O O 0.9999793767929077
that O O 0.9997835755348206
temsirolimus B B 0.9994638562202454
inhibited O O 0.999713122844696
tumor O O 0.9999386072158813
cell O O 0.9999635219573975
proliferation O O 0.999976396560669
through O O 0.999853253364563
cell O O 0.9992353916168213
cycle O O 0.9935877323150635
arrest O O 0.9999325275421143
, O O 0.9999419450759888
but O O 0.999907374382019
did O O 0.9999462366104126
not O O 0.999955415725708
induce O O 0.9999803304672241
any O O 0.999987006187439
change O O 0.9999970197677612
in O O 0.9999924898147583
the O O 0.999991774559021
number O O 0.9999862909317017
of O O 0.9999599456787109
apoptotic O O 0.9996449947357178
tumor O O 0.9999591112136841
cells O O 0.9999951124191284
. O O 0.9999728202819824

Apart O O 0.9997772574424744
from O O 0.9998646974563599
this O O 0.999757707118988
cytostatic O O 0.9975833892822266
effect O O 0.9999306201934814
, O O 0.9990921020507812
temsirolimus B B 0.9996460676193237
had O O 0.9998983144760132
an O O 0.9999282360076904
antiangiogenic O O 0.9950863718986511
effect O O 0.9999303817749023
with O O 0.9999580383300781
decrease O O 0.9999868869781494
of O O 0.9999520778656006
tumor O O 0.9999525547027588
microvessel O O 0.9979845285415649
density O O 0.99998939037323
and O O 0.9999468326568604
of O O 0.9910615086555481
VEGF O O 0.5825373530387878
expression O O 0.9999022483825684
. O O 0.9999297857284546

Moreover O O 0.9998888969421387
, O O 0.9999414682388306
numerous O O 0.9999510049819946
patchy O O 0.9998644590377808
, O O 0.9999427795410156
well O O 0.9011638164520264
- O O 0.9999380111694336
limited O O 0.9999115467071533
fibrotic O O 0.9999434947967529
areas O O 0.9999758005142212
, O O 0.9999758005142212
compatible O O 0.9999876022338867
with O O 0.9999645948410034
post O O 0.9988706707954407
- O O 0.999667763710022
necrotic O O 0.9999817609786987
tissue O O 0.9999939203262329
repair O O 0.9999958276748657
, O O 0.9999822378158569
were O O 0.9999884366989136
found O O 0.9999973773956299
after O O 0.9998918771743774
6 O O 0.9998186230659485
- O O 0.9999585151672363
month O O 0.9999605417251587
temsirolimus B B 0.9989829659461975
therapy O O 0.998448371887207
. O O 0.9999727010726929

Thus O O 0.9999672174453735
, O O 0.9993807077407837
temsirolimus B B 0.999366819858551
reduced O O 0.999887228012085
tumor O O 0.9999698400497437
burden O O 0.9999924898147583
through O O 0.9998250603675842
associated O O 0.9998350143432617
cytostatic O O 0.9986515641212463
and O O 0.9997828602790833
anti O O 0.9547650814056396
- O O 0.9985411167144775
angiogenic O O 0.9990480542182922
effects O O 0.9999206066131592
. O O 0.9999452829360962
This O O 0.9999672174453735
dual O O 0.9976406097412109
effect O O 0.9999450445175171
of O O 0.9998632669448853
temsirolimus B B 0.9994346499443054
on O O 0.9994753003120422
tumor O O 0.9999771118164062
tissue O O 0.9999914169311523
could O O 0.9999138116836548
contribute O O 0.9999704360961914
to O O 0.9999655485153198
its O O 0.9999567270278931
recently O O 0.9999868869781494
reported O O 0.9999916553497314
efficiency O O 0.9999891519546509
in O O 0.9999463558197021
refractory O O 0.9999762773513794
MCL O O 0.9981734752655029
resistant O O 0.9999918937683105
to O O 0.9999550580978394
conventional O O 0.9998303651809692
chemotherapy O O 0.9989166259765625
. O O 0.9999501705169678

Acute O O 0.999944806098938
renal O O 0.9999715089797974
failure O O 0.99997878074646
due O O 0.9999755620956421
to O O 0.9980204105377197
rifampicin B B 0.9906708002090454
. O O 0.9997585415840149

A O O 0.9999721050262451
23 O O 0.9999862909317017
- O O 0.9999818801879883
year O O 0.9999961853027344
- O O 0.9999923706054688
old O O 0.9999921321868896
male O O 0.9999927282333374
patient O O 0.9999831914901733
with O O 0.9999674558639526
bacteriologically O O 0.9999237060546875
proven O O 0.9999926090240479
pulmonary O O 0.9999245405197144
tuberculosis O O 0.999221682548523
was O O 0.9999643564224243
treated O O 0.9999825954437256
with O O 0.9999085664749146
the O O 0.9999593496322632
various O O 0.999887228012085
regimens O O 0.9988351464271545
of O O 0.9980143308639526
antituberculosis O O 0.5690407156944275
drugs O O 0.8891750574111938
for O O 0.9998856782913208
nearly O O 0.9999923706054688
15 O O 0.9999926090240479
months O O 0.9999958276748657
. O O 0.9999703168869019

Rifampicin B B 0.9981551766395569
was O O 0.9998021721839905
administered O O 0.9998977184295654
thrice O O 0.9999470710754395
as O O 0.9999603033065796
one O O 0.9999046325683594
of O O 0.9998346567153931
the O O 0.999980092048645
3 O O 0.9434992074966431
- O O 0.9919519424438477
4 O O 0.9320043921470642
drug O O 0.9924322366714478
regimen O O 0.9765234589576721
and O O 0.999945878982544
each O O 0.9999850988388062
time O O 0.9999889135360718
he O O 0.9999673366546631
developed O O 0.99998939037323
untoward O O 0.9998712539672852
side O O 0.9999759197235107
effects O O 0.9999955892562866
like O O 0.9999911785125732
nausea O O 0.9999953508377075
, O O 0.999976634979248
vomiting O O 0.9999904632568359
and O O 0.999964714050293
fever O O 0.999994158744812
with O O 0.9999759197235107
chills O O 0.9998699426651001
and O O 0.9999728202819824
rigors O O 0.9999963045120239
. O O 0.9999842643737793

The O O 0.9999825954437256
last O O 0.9999969005584717
such O O 0.9999765157699585
episode O O 0.9999936819076538
was O O 0.9999935626983643
of O O 0.9999810457229614
acute O O 0.9999394416809082
renal O O 0.9999730587005615
failure O O 0.9999741315841675
at O O 0.9999185800552368
which O O 0.999983549118042
stage O O 0.9999953508377075
the O O 0.9999938011169434
patient O O 0.9999876022338867
was O O 0.9999812841415405
seen O O 0.9999926090240479
by O O 0.9999926090240479
the O O 0.9999915361404419
authors O O 0.9999986886978149
of O O 0.9999942779541016
this O O 0.9999915361404419
report O O 0.9999918937683105
. O O 0.9999645948410034

The O O 0.9999790191650391
patient O O 0.9999911785125732
, O O 0.9999923706054688
however O O 0.9999918937683105
, O O 0.9999909400939941
made O O 0.9999943971633911
a O O 0.9999951124191284
full O O 0.9999926090240479
recovery O O 0.9999971389770508
. O O 0.9999839067459106

Syncope O O 0.9997722506523132
caused O O 0.999962568283081
by O O 0.9999455213546753
hyperkalemia O O 0.9859299063682556
during O O 0.9998810291290283
use O O 0.9999420642852783
of O O 0.9998018145561218
a O O 0.9997830986976624
combined O O 0.9968994855880737
therapy O O 0.999954342842102
with O O 0.9998569488525391
the O O 0.998450517654419
angiotensin B B 0.9170978665351868
- O O 0.7268686294555664
converting O O 0.7108350396156311
enzyme O O 0.606014609336853
inhibitor O O 0.6963352560997009
and O O 0.909490168094635
spironolactone B B 0.9981922507286072
. O O 0.9997062087059021

A O O 0.9999823570251465
76 O O 0.9999974966049194
year O O 0.9999979734420776
- O O 0.999995231628418
old O O 0.9999963045120239
woman O O 0.9999985694885254
with O O 0.9999728202819824
a O O 0.9999932050704956
history O O 0.9999905824661255
of O O 0.9999215602874756
coronary O O 0.9991718530654907
artery O O 0.9986005425453186
bypass O O 0.9998689889907837
grafting O O 0.9999831914901733
and O O 0.9999581575393677
prior O O 0.9999775886535645
myocardial O O 0.9999980926513672
infarction O O 0.9999802112579346
was O O 0.9999805688858032
transferred O O 0.9999971389770508
to O O 0.9999982118606567
the O O 0.9999990463256836
emergency O O 0.9999967813491821
room O O 0.9999994039535522
with O O 0.9999961853027344
loss O O 0.9999994039535522
of O O 0.999996542930603
consciousness O O 0.9999961853027344
due O O 0.9999935626983643
to O O 0.9999791383743286
marked O O 0.9999707937240601
bradycardia O O 0.9999544620513916
caused O O 0.9999740123748779
by O O 0.9999115467071533
hyperkalemia O O 0.9340277910232544
. O O 0.9999477863311768

The O O 0.9999672174453735
concentration O O 0.9998242259025574
of O O 0.9997437596321106
serum O O 0.9875373244285583
potassium B B 0.9979448914527893
was O O 0.9998683929443359
high O O 0.999858021736145
, O O 0.9999345541000366
and O O 0.9999171495437622
normal O O 0.9999861717224121
sinus O O 0.9999936819076538
rhythm O O 0.999995231628418
was O O 0.9999678134918213
restored O O 0.9999938011169434
after O O 0.9999490976333618
correction O O 0.9999903440475464
of O O 0.9999715089797974
the O O 0.999984622001648
serum O O 0.9949055910110474
potassium B B 0.9985609650611877
level O O 0.9997392296791077
. O O 0.9999687671661377

The O O 0.9999738931655884
cause O O 0.9999747276306152
of O O 0.9999532699584961
hyperkalemia O O 0.9997923970222473
was O O 0.9999513626098633
considered O O 0.9999775886535645
to O O 0.9999316930770874
be O O 0.9999284744262695
several O O 0.999843955039978
doses O O 0.9998020529747009
of O O 0.9980630278587341
spiranolactone B B 0.9993700385093689
, O O 0.9993157386779785
an O O 0.992313802242279
aldosterone B B 0.8682673573493958
antagonist O O 0.6094684600830078
, O O 0.9997665286064148
in O O 0.9999837875366211
addition O O 0.9999836683273315
to O O 0.9999560117721558
the O O 0.9999850988388062
long O O 0.9998757839202881
- O O 0.9999916553497314
term O O 0.9999700784683228
intake O O 0.999822199344635
of O O 0.9939370155334473
ramipril B B 0.9953846335411072
, O O 0.9995279312133789
an O O 0.942799985408783
ACE O O 0.5215395092964172
inhibitor O O 0.6273552775382996
. O O 0.9998983144760132

This O O 0.9999580383300781
case O O 0.9999696016311646
is O O 0.9999533891677856
a O O 0.9999454021453857
good O O 0.9999282360076904
example O O 0.9999706745147705
of O O 0.9998515844345093
electrolyte O O 0.9467642903327942
imbalance O O 0.999922513961792
causing O O 0.9998929500579834
acute O O 0.9999818801879883
life O O 0.9999397993087769
- O O 0.9999879598617554
threatening O O 0.9999957084655762
cardiac O O 0.9999938011169434
events O O 0.9999986886978149
. O O 0.999972939491272

Clinicians O O 0.9996389150619507
should O O 0.9999555349349976
be O O 0.99998939037323
alert O O 0.999993085861206
to O O 0.9999830722808838
the O O 0.9999908208847046
possibility O O 0.9999860525131226
of O O 0.9999452829360962
hyperkalemia O O 0.9840126037597656
, O O 0.9999828338623047
especially O O 0.9999818801879883
in O O 0.9999730587005615
elderly O O 0.9999721050262451
patients O O 0.9999901056289673
using O O 0.999218225479126
ACE O B 0.9911956787109375
/ O O 0.599099338054657
ARB O B 0.8833805918693542
in O O 0.9998177886009216
combination O O 0.9999021291732788
with O O 0.9996465444564819
potassium B B 0.9590914249420166
sparing O O 0.6869257688522339
agents O O 0.9877328872680664
and O O 0.9999806880950928
who O O 0.9999662637710571
have O O 0.9999903440475464
mild O O 0.9999946355819702
renal O O 0.9999704360961914
disturbance O O 0.9999948740005493
. O O 0.9999765157699585

Diffuse O O 0.9999536275863647
skeletal O O 0.999936580657959
pain O O 0.9999510049819946
after O O 0.9998049139976501
administration O O 0.9998675584793091
of O O 0.9972829818725586
alendronate B B 0.9979599714279175
. O O 0.9998691082000732

BACKGROUND O O 0.9831476211547852
: O O 0.9998703002929688
Osteoporosis O O 0.9909114241600037
is O O 0.999875545501709
caused O O 0.9999593496322632
by O O 0.9998834133148193
bone O O 0.8206339478492737
resorption O O 0.9968233108520508
in O O 0.9999356269836426
excess O O 0.998719334602356
of O O 0.9979986548423767
bone O O 0.8064305782318115
formation O O 0.9992408752441406
, O O 0.999805748462677
and O O 0.9991948008537292
bisphosphonates B B 0.9354928135871887
, O O 0.7832979559898376
are O O 0.9939343333244324
used O O 0.9990445971488953
to O O 0.9995768666267395
inhibit O O 0.9996800422668457
bone O O 0.9664813876152039
resorption O O 0.9996926784515381
. O O 0.9999208450317383

Alendronate B B 0.9937261939048767
, O O 0.9997945427894592
a O O 0.9901974201202393
biphosphonate B B 0.912652313709259
, O O 0.9983429908752441
is O O 0.9996067881584167
effective O O 0.9994502663612366
for O O 0.9999158382415771
both O O 0.9998862743377686
the O O 0.9999587535858154
treatment O O 0.9999784231185913
and O O 0.9999761581420898
prevention O O 0.9999818801879883
of O O 0.9999676942825317
osteoporosis O O 0.9997518658638
in O O 0.9999376535415649
postmenopausal O O 0.9998468160629272
women O O 0.9999929666519165
. O O 0.9998955726623535

Side O O 0.9967232346534729
effects O O 0.9999110698699951
are O O 0.9997552037239075
relatively O O 0.9999672174453735
few O O 0.9981696605682373
and O O 0.9998874664306641
prominently O O 0.9906119704246521
gastrointestinal O O 0.999295711517334
. O O 0.9999339580535889

Musculoskeletal O O 0.9980922341346741
pain O O 0.9957394599914551
may O O 0.9999366998672485
be O O 0.9999563694000244
an O O 0.9999299049377441
important O O 0.9998214840888977
side O O 0.9998972415924072
effect O O 0.9999879598617554
in O O 0.9999672174453735
these O O 0.999940037727356
patients O O 0.9999905824661255
. O O 0.9999715089797974

We O O 0.9999831914901733
presented O O 0.999996542930603
a O O 0.9999971389770508
patient O O 0.9999933242797852
admitted O O 0.9999735355377197
to O O 0.9999861717224121
our O O 0.9999915361404419
out O O 0.9999759197235107
- O O 0.9999902248382568
patient O O 0.9999953508377075
clinic O O 0.9999971389770508
with O O 0.999991774559021
diffuse O O 0.9999926090240479
skeletal O O 0.9999178647994995
pain O O 0.9999934434890747
after O O 0.9999535083770752
three O O 0.9992386102676392
consecutive O O 0.9998044371604919
administration O O 0.9999171495437622
of O O 0.9975213408470154
alendronate B B 0.9976939558982849
. O O 0.9998890161514282

CONCLUSION O O 0.9996359348297119
: O O 0.9999709129333496
We O O 0.9996988773345947
conclude O O 0.99996018409729
that O O 0.9999485015869141
patients O O 0.99998939037323
with O O 0.9999749660491943
osteoporosis O O 0.9721947908401489
can O O 0.9998155236244202
report O O 0.9999769926071167
pain O O 0.9997990727424622
, O O 0.999935507774353
and O O 0.9996128678321838
bisphosphonate B B 0.9973879456520081
- O O 0.9989888072013855
related O O 0.9998799562454224
pain O O 0.9998636245727539
should O O 0.9999203681945801
also O O 0.9999712705612183
be O O 0.9999858140945435
considered O O 0.9999804496765137
before O O 0.9999645948410034
ascribing O O 0.9999972581863403
this O O 0.9999926090240479
complaint O O 0.9999980926513672
to O O 0.9998065829277039
osteoporosis O O 0.8244340419769287
. O O 0.9999607801437378

Cerebrospinal O O 0.9656660556793213
fluid O O 0.9994070529937744
penetration O O 0.9993882179260254
of O O 0.9981716871261597
high O O 0.9923821091651917
- O O 0.9999170303344727
dose O O 0.9465274214744568
daptomycin B B 0.9995741248130798
in O O 0.9999216794967651
suspected O O 0.9999046325683594
Staphylococcus O B 0.9710544347763062
aureus O O 0.805536150932312
meningitis O O 0.9994514584541321
. O O 0.9998028874397278

OBJECTIVE O O 0.9999268054962158
: O O 0.9999964237213135
To O O 0.9999977350234985
report O O 0.9999986886978149
a O O 0.9999951124191284
case O O 0.9999945163726807
of O O 0.9999724626541138
methicillin B B 0.9832822680473328
- O O 0.9902361035346985
sensitive O O 0.9582441449165344
Staphylococcus O B 0.9600235223770142
aureus O I 0.9391247630119324
( O O 0.9930461049079895
MSSA O O 0.592497706413269
) O O 0.9998974800109863
bacteremia O O 0.9999803304672241
with O O 0.999955415725708
suspected O O 0.9999183416366577
MSSA O O 0.9309041500091553
meningitis O O 0.9999644756317139
treated O O 0.99994957447052
with O O 0.9997994303703308
high O O 0.998130738735199
- O O 0.9998282194137573
dose O O 0.9899133443832397
daptomycin B B 0.9993171691894531
assessed O O 0.6961131691932678
with O O 0.9999271631240845
concurrent O O 0.9999598264694214
serum O O 0.9996479749679565
and O O 0.9999446868896484
cerebrospinal O O 0.9951313734054565
fluid O O 0.9999687671661377
( O O 0.999923825263977
CSF O O 0.9407708644866943
) O O 0.9999674558639526
concentrations O O 0.9997337460517883
. O O 0.9999655485153198

CASE O O 0.9995984435081482
SUMMARY O O 0.9999953508377075
: O O 0.9999728202819824
A O O 0.9999967813491821
54 O O 0.9999874830245972
- O O 0.9999845027923584
year O O 0.9999966621398926
- O O 0.9999912977218628
old O O 0.9999934434890747
male O O 0.9999939203262329
presented O O 0.9999768733978271
to O O 0.9999974966049194
the O O 0.9999986886978149
emergency O O 0.9999938011169434
department O O 0.9999983310699463
with O O 0.9999823570251465
generalized O O 0.9999792575836182
weakness O O 0.9999985694885254
and O O 0.9999792575836182
presumed O O 0.9999825954437256
health O O 0.9984020590782166
- O O 0.9999517202377319
care O O 0.9989191293716431
- O O 0.9999810457229614
associated O O 0.9999803304672241
pneumonia O O 0.9999901056289673
shown O O 0.9999974966049194
on O O 0.9999982118606567
chest O O 0.9999784231185913
radiograph O O 0.9999573230743408
. O O 0.9999781847000122

Treatment O O 0.999955415725708
was O O 0.9999706745147705
empirically O O 0.9999762773513794
initiated O O 0.9999929666519165
with O O 0.9997809529304504
vancomycin B B 0.9995236396789551
, O O 0.8981514573097229
levofloxacin B B 0.9990218877792358
, O O 0.956393837928772
and O O 0.9969557523727417
piperacillin B B 0.9988971948623657
/ O O 0.8121668100357056
tazobactam B B 0.5399075746536255
. O O 0.9998441934585571

Blood O O 0.9997476935386658
cultures O O 0.9998507499694824
revealed O O 0.9999157190322876
S O O 0.5326755046844482
. O O 0.9993035793304443
aureus O O 0.9882855415344238
susceptible O O 0.9998898506164551
to O O 0.9971265196800232
oxacillin B B 0.9988623857498169
. O O 0.9999005794525146

Empiric O O 0.9999732971191406
antibiotic O O 0.9995669722557068
treatment O O 0.9999717473983765
was O O 0.9999765157699585
narrowed O O 0.9999853372573853
to O O 0.998281717300415
nafcillin B B 0.9995381832122803
on O O 0.999869704246521
day O O 0.9999940395355225
4 O O 0.9999703168869019
. O O 0.9999862909317017

On O O 0.9999759197235107
day O O 0.9999918937683105
8 O O 0.9983457326889038
, O O 0.999994158744812
the O O 0.9999953508377075
patient O O 0.9999895095825195
developed O O 0.9999877214431763
acute O O 0.999983549118042
renal O O 0.9999798536300659
failure O O 0.9999934434890747
( O O 0.999981164932251
serum O O 0.9990739822387695
creatinine B B 0.9942309856414795
1 O O 0.9998594522476196
. O O 0.9999971389770508
9 O O 0.9999960660934448
mg O O 0.9999970197677612
/ O O 0.9999889135360718
dL O O 0.9999979734420776
, O O 0.9999850988388062
increased O O 0.9999959468841553
from O O 0.9999876022338867
1 O O 0.9999754428863525
. O O 0.9999966621398926
2 O O 0.9999912977218628
mg O O 0.9999934434890747
/ O O 0.9999876022338867
dL O O 0.9999905824661255
the O O 0.9999819993972778
previous O O 0.9999940395355225
day O O 0.999997615814209
and O O 0.9999669790267944
0 O O 0.9999827146530151
. O O 0.9999938011169434
8 O O 0.9999929666519165
mg O O 0.9999877214431763
/ O O 0.9999895095825195
dL O O 0.9999884366989136
on O O 0.9999781847000122
admission O O 0.9999926090240479
) O O 0.9999784231185913
. O O 0.9999819993972778

The O O 0.9999897480010986
patient O O 0.9999918937683105
' O O 0.9999943971633911
s O O 0.9999910593032837
Glasgow O O 0.6086774468421936
Coma O O 0.9999880790710449
Score O O 0.9999868869781494
was O O 0.9999724626541138
3 O O 0.9997283816337585
, O O 0.999987006187439
with O O 0.9999867677688599
normal O O 0.9999933242797852
findings O O 0.9999991655349731
shown O O 0.9999991655349731
on O O 0.999996542930603
computed O O 0.9996852874755859
tomography O O 0.9997932314872742
scan O O 0.999972939491272
of O O 0.9999887943267822
the O O 0.999995231628418
head O O 0.9999954700469971
72 O O 0.9999833106994629
hours O O 0.9999929666519165
following O O 0.9999885559082031
an O O 0.9999959468841553
episode O O 0.9999977350234985
of O O 0.9999914169311523
cardiac O O 0.9999591112136841
arrest O O 0.999992847442627
on O O 0.9999837875366211
day O O 0.999995231628418
10 O O 0.9999260902404785
. O O 0.9999815225601196

The O O 0.9999862909317017
patient O O 0.9999866485595703
experienced O O 0.9999771118164062
relapsing O O 0.9999854564666748
MSSA O O 0.5254932641983032
bacteremia O O 0.9998276233673096
on O O 0.9999674558639526
day O O 0.9999948740005493
9 O O 0.9999253749847412
, O O 0.9999749660491943
increasing O O 0.9999639987945557
the O O 0.9999954700469971
suspicion O O 0.9999980926513672
for O O 0.9999831914901733
a O O 0.9999622106552124
central O O 0.9989356398582458
nervous O O 0.9999921321868896
system O O 0.9998225569725037
( O O 0.9993385672569275
CNS O O 0.9249834418296814
) O O 0.9998669624328613
infection O O 0.9999631643295288
. O O 0.9999209642410278

Nafcillin B B 0.9984351992607117
was O O 0.9998331069946289
discontinued O O 0.9997019171714783
and O O 0.9998856782913208
daptomycin B B 0.9990272521972656
9 O O 0.995634138584137
mg O O 0.9998811483383179
/ O O 0.9998997449874878
kg O O 0.9999943971633911
daily O O 0.9999251365661621
was O O 0.9999827146530151
initiated O O 0.9999687671661377
for O O 0.999970555305481
suspected O O 0.9999679327011108
meningitis O O 0.9999157190322876
and O O 0.9999654293060303
was O O 0.9999666213989258
continued O O 0.999946117401123
until O O 0.9999985694885254
the O O 0.9999986886978149
patient O O 0.9999955892562866
' O O 0.9999973773956299
s O O 0.9999990463256836
death O O 0.9999980926513672
on O O 0.9999957084655762
day O O 0.9999980926513672
16 O O 0.9999948740005493
. O O 0.9999830722808838

Daptomycin B B 0.9989344477653503
serum O O 0.9996570348739624
and O O 0.9998393058776855
CSF O O 0.6292803287506104
trough O O 0.9980813264846802
concentrations O O 0.9988670349121094
were O O 0.999972939491272
11 O O 0.9953739047050476
. O O 0.9999940395355225
21 O O 0.999994158744812
ug O O 0.9989213943481445
/ O O 0.9999550580978394
mL O O 0.9999959468841553
and O O 0.9999336004257202
0 O O 0.9999692440032959
. O O 0.999994158744812
52 O O 0.9999960660934448
ug O O 0.9993256330490112
/ O O 0.9999533891677856
mL O O 0.9999936819076538
, O O 0.9999880790710449
respectively O O 0.9999725818634033
, O O 0.9999943971633911
prior O O 0.9999969005584717
to O O 0.9999958276748657
the O O 0.9999964237213135
third O O 0.9999693632125854
dose O O 0.9999731779098511
. O O 0.9999654293060303

Lumbar O O 0.9997019171714783
puncture O O 0.9999368190765381
results O O 0.9999836683273315
were O O 0.9999806880950928
inconclusive O O 0.9999922513961792
and O O 0.9999819993972778
no O O 0.9999865293502808
further O O 0.9999862909317017
blood O O 0.9999412298202515
cultures O O 0.9999587535858154
were O O 0.9999722242355347
positive O O 0.9999785423278809
for O O 0.9990643858909607
MSSA O B 0.8867540955543518
. O O 0.9997922778129578

Creatine B O 0.7387511730194092
kinase O O 0.46161824464797974
levels O O 0.9998824596405029
were O O 0.9999707937240601
normal O O 0.999980092048645
prior O O 0.9999725818634033
to O O 0.9996160268783569
daptomycin B B 0.9997865557670593
therapy O O 0.9998682737350464
and O O 0.9999735355377197
were O O 0.9999850988388062
not O O 0.9999914169311523
reassessed O O 0.9999860525131226
. O O 0.9999706745147705

DISCUSSION O O 0.9724938869476318
: O O 0.9992057681083679
Daptomycin B B 0.9994742274284363
was O O 0.9998470544815063
initiated O O 0.9996498823165894
in O O 0.9999712705612183
our O O 0.9999856948852539
patient O O 0.9999876022338867
secondary O O 0.9999916553497314
to O O 0.9999747276306152
possible O O 0.9999295473098755
nafcillin B B 0.9996137022972107
- O O 0.9996625185012817
induced O O 0.9999492168426514
acute O O 0.9999840259552002
interstitial O O 0.9997655749320984
nephritis O O 0.9999880790710449
and O O 0.999958872795105
relapsing O O 0.9999890327453613
bacteremia O O 0.9999867677688599
. O O 0.9999316930770874

At O O 0.9999144077301025
a O O 0.9999874830245972
dose O O 0.9999649524688721
of O O 0.9999573230743408
9 O O 0.9997356534004211
mg O O 0.999976396560669
/ O O 0.9999085664749146
kg O O 0.9999823570251465
, O O 0.9999593496322632
resultant O O 0.9999827146530151
penetration O O 0.9999650716781616
of O O 0.999882698059082
5 O O 0.9998093247413635
% O O 0.999909520149231
was O O 0.9999606609344482
higher O O 0.9999154806137085
than O O 0.9999943971633911
in O O 0.9999982118606567
previous O O 0.9999938011169434
reports O O 0.9999971389770508
, O O 0.9999865293502808
more O O 0.9999752044677734
consistent O O 0.9999927282333374
with O O 0.9999791383743286
inflamed O O 0.9999024868011475
meninges O O 0.9999030828475952
. O O 0.9999425411224365

CONCLUSIONS O O 0.9992793202400208
: O O 0.9999046325683594
High O O 0.9921256899833679
- O O 0.9997938275337219
dose O O 0.9973704814910889
daptomycin B B 0.999645471572876
may O O 0.9999099969863892
be O O 0.9999860525131226
an O O 0.9999802112579346
alternative O O 0.9999724626541138
option O O 0.9999659061431885
for O O 0.9998714923858643
MSSA O O 0.9532870650291443
bacteremia O O 0.9999850988388062
with O O 0.9999665021896362
or O O 0.9999876022338867
without O O 0.9999842643737793
a O O 0.9999655485153198
CNS O O 0.6815250515937805
source O O 0.9999457597732544
in O O 0.9999661445617676
patients O O 0.9999959468841553
who O O 0.9999926090240479
have O O 0.9999971389770508
failed O O 0.9999946355819702
or O O 0.9999948740005493
cannot O O 0.9999961853027344
tolerate O O 0.9999821186065674
standard O O 0.9999668598175049
therapy O O 0.999983549118042
. O O 0.999983549118042

Further O O 0.999977707862854
clinical O O 0.9999938011169434
evaluation O O 0.9999961853027344
in O O 0.9999843835830688
patients O O 0.9999921321868896
with O O 0.9999815225601196
confirmed O O 0.9998028874397278
meningitis O O 0.9998929500579834
is O O 0.9999873638153076
warranted O O 0.999984860420227
. O O 0.9999853372573853

The O O 0.9999250173568726
role O O 0.9999420642852783
of O O 0.9994663596153259
nitric B B 0.946075439453125
oxide I I 0.9980157613754272
in O O 0.9990807771682739
convulsions O O 0.9998857975006104
induced O O 0.9999901056289673
by O O 0.999828577041626
lindane B B 0.9983882904052734
in O O 0.9998352527618408
rats O O 0.999977707862854
. O O 0.9999452829360962

Lindane B B 0.995730459690094
is O O 0.9208466410636902
an O O 0.9136255979537964
organochloride O B 0.8867049217224121
pesticide O O 0.8244836330413818
and O O 0.7162416577339172
scabicide O B 0.7726100087165833
. O O 0.9982746839523315

It O O 0.9976377487182617
evokes O O 0.9998608827590942
convulsions O O 0.9999388456344604
mainly O O 0.9999369382858276
trough O O 0.9997407793998718
the O O 0.9995700716972351
blockage O O 0.9990574717521667
of O O 0.9897664189338684
GABA B B 0.9606949687004089
( O O 0.9227887392044067
A O O 0.8732610940933228
) O O 0.9299797415733337
receptors O O 0.9990993738174438
. O O 0.9998363256454468

Nitric B B 0.980334997177124
oxide I I 0.9997256398200989
( O O 0.9933271408081055
NO B B 0.9751063585281372
) O O 0.5131037831306458
, O O 0.9987072944641113
gaseous O O 0.7032437324523926
neurotransmitter O O 0.9954699277877808
, O O 0.999311089515686
has O O 0.9999043941497803
contradictor O O 0.9999513626098633
role O O 0.9999853372573853
in O O 0.9999468326568604
epileptogenesis O O 0.999893307685852
due O O 0.9999709129333496
to O O 0.9999016523361206
opposite O O 0.9996559619903564
effects O O 0.9998904466629028
of O O 0.9995662569999695
L B B 0.5775365233421326
- I I 0.9660654664039612
arginine I I 0.9999531507492065
, O O 0.9910063147544861
precursor O O 0.7628710865974426
of O O 0.9993062019348145
NO B O 0.5384891629219055
syntheses O O 0.9131088852882385
( O O 0.9994020462036133
NOS O O 0.7425300478935242
) O O 0.9802818298339844
, O O 0.9962940812110901
and O O 0.998595654964447
L B B 0.5061042308807373
- I I 0.7219477295875549
NAME I I 0.9991955161094666
( O O 0.9868854284286499
NOS O O 0.5845982432365417
inhibitor O O 0.5902955532073975
) O O 0.9999151229858398
observed O O 0.9999445676803589
in O O 0.9999085664749146
different O O 0.9999467134475708
epilepsy O O 0.9998817443847656
models O O 0.9999769926071167
. O O 0.9999594688415527

The O O 0.999990701675415
aim O O 0.9999967813491821
of O O 0.9999935626983643
the O O 0.9999964237213135
current O O 0.9999901056289673
study O O 0.9999909400939941
was O O 0.9999954700469971
to O O 0.9999943971633911
determine O O 0.9999918937683105
the O O 0.9999760389328003
effects O O 0.9999407529830933
of O O 0.9993777275085449
NO B B 0.981086790561676
on O O 0.999295711517334
the O O 0.9999762773513794
behavioral O O 0.9999728202819824
and O O 0.9999692440032959
EEG O O 0.998296320438385
characteristics O O 0.9999864101409912
of O O 0.9999313354492188
lindane B B 0.9970009922981262
- O O 0.9995728135108948
induced O O 0.9999183416366577
epilepsy O O 0.9998986721038818
in O O 0.9999788999557495
male O O 0.999964714050293
Wistar O O 0.9983951449394226
albino O O 0.9937604069709778
rats O O 0.9999890327453613
. O O 0.9999879598617554

The O O 0.9999538660049438
administration O O 0.9999353885650635
of O O 0.999805748462677
L B B 0.9006516337394714
- I I 0.9989508390426636
arginine I I 0.9999797344207764
( O O 0.9977013468742371
600 O O 0.9963255524635315
, O O 0.9983415603637695
800 O O 0.7278891205787659
and O O 0.998957633972168
1000 O O 0.9997324347496033
mg O O 0.999896764755249
/ O O 0.9999861717224121
kg O O 0.9999945163726807
, O O 0.9999270439147949
i O O 0.9994518160820007
. O O 0.9999966621398926
p O O 0.9999977350234985
. O O 0.9999953508377075
) O O 0.9999706745147705
in O O 0.9999157190322876
dose O O 0.9991894364356995
- O O 0.999961256980896
dependent O O 0.9999642372131348
manner O O 0.9999871253967285
significantly O O 0.9999456405639648
increased O O 0.9999622106552124
convulsion O O 0.9999001026153564
incidence O O 0.999985933303833
and O O 0.9999910593032837
severity O O 0.9999967813491821
and O O 0.9999879598617554
shortened O O 0.999963641166687
latency O O 0.9999951124191284
time O O 0.9999971389770508
to O O 0.9999960660934448
first O O 0.9999979734420776
convulsion O O 0.9999252557754517
elicited O O 0.9999959468841553
by O O 0.9999642372131348
lower O O 0.9999421834945679
lindane B B 0.9986409544944763
dose O O 0.9996415376663208
( O O 0.999969482421875
4 O O 0.9997884631156921
mg O O 0.9999321699142456
/ O O 0.9999804496765137
kg O O 0.9999948740005493
, O O 0.9999690055847168
i O O 0.9997352957725525
. O O 0.9999969005584717
p O O 0.9999988079071045
. O O 0.999996542930603
) O O 0.9999845027923584
. O O 0.9999796152114868

On O O 0.9999570846557617
the O O 0.9999866485595703
contrary O O 0.9999867677688599
, O O 0.9999299049377441
pretreatment O O 0.9999649524688721
with O O 0.9998656511306763
L B B 0.7619684338569641
- I I 0.9822966456413269
NAME I I 0.9999505281448364
( O O 0.998645007610321
500 O O 0.9997363686561584
, O O 0.9991921782493591
700 O O 0.9981024861335754
and O O 0.9995480179786682
900 O O 0.9998841285705566
mg O O 0.9999293088912964
/ O O 0.9999862909317017
kg O O 0.9999916553497314
, O O 0.9999666213989258
i O O 0.9994943141937256
. O O 0.9999967813491821
p O O 0.9999978542327881
. O O 0.9999935626983643
) O O 0.9999604225158691
decreased O O 0.9999326467514038
convulsion O O 0.999704897403717
incidence O O 0.9999669790267944
and O O 0.9999899864196777
severity O O 0.9999963045120239
and O O 0.9999914169311523
prolonged O O 0.9999805688858032
latency O O 0.9999970197677612
time O O 0.999997615814209
to O O 0.9999929666519165
convulsion O O 0.9997150301933289
following O O 0.9999710321426392
injection O O 0.9999909400939941
with O O 0.9999767541885376
a O O 0.9999884366989136
convulsive O O 0.9913976192474365
dose O O 0.9997739195823669
of O O 0.995741605758667
lindane B B 0.9973738193511963
( O O 0.9996531009674072
8 O O 0.9991084933280945
mg O O 0.9998862743377686
/ O O 0.9999727010726929
kg O O 0.9999957084655762
, O O 0.9999681711196899
i O O 0.9997187256813049
. O O 0.9999964237213135
p O O 0.9999985694885254
. O O 0.9999958276748657
) O O 0.9999772310256958
. O O 0.9999768733978271

EEG O O 0.9796265959739685
analyses O O 0.9996460676193237
showed O O 0.9999370574951172
increase O O 0.9999808073043823
of O O 0.999968409538269
number O O 0.9999872446060181
and O O 0.9999783039093018
duration O O 0.9999840259552002
of O O 0.9999700784683228
ictal O O 0.9999494552612305
periods O O 0.9999822378158569
in O O 0.9998921155929565
EEG O O 0.9861558079719543
of O O 0.9998511075973511
rats O O 0.9999877214431763
receiving O O 0.9994708895683289
l B B 0.686809778213501
- I I 0.9850516319274902
arginine I I 0.9999345541000366
prior O O 0.9973505735397339
to O O 0.9997959733009338
lindane B B 0.9920273423194885
and O O 0.9999027252197266
decrease O O 0.9999916553497314
of O O 0.9999774694442749
this O O 0.9999810457229614
number O O 0.9999688863754272
in O O 0.9999552965164185
rats O O 0.9999927282333374
pretreated O O 0.9999513626098633
with O O 0.9997648596763611
L B B 0.8710445761680603
- I I 0.9907417297363281
NAME I I 0.999962329864502
. O O 0.9998610019683838

These O O 0.9999781847000122
results O O 0.999985933303833
support O O 0.9999759197235107
the O O 0.9999934434890747
conclusion O O 0.9999731779098511
that O O 0.9998440742492676
NO B B 0.9375574588775635
plays O O 0.9986143112182617
a O O 0.9997875094413757
role O O 0.9997848868370056
of O O 0.9969965219497681
endogenous O O 0.9992141723632812
convulsant O O 0.9600065350532532
in O O 0.9995711445808411
rat O O 0.9999284744262695
model O O 0.999976396560669
of O O 0.9999072551727295
lindane B O 0.7417312860488892
seizures O O 0.9999382495880127
. O O 0.9999452829360962

Severe O O 0.9998414516448975
polyneuropathy O O 0.9999269247055054
and O O 0.999934196472168
motor O O 0.9999802112579346
loss O O 0.9999971389770508
after O O 0.9999027252197266
intrathecal O O 0.9983595013618469
thiotepa B B 0.9989901185035706
combination O O 0.6792754530906677
chemotherapy O O 0.9726990461349487
: O O 0.9999791383743286
description O O 0.9999984502792358
of O O 0.9999899864196777
two O O 0.9999951124191284
cases O O 0.9999933242797852
. O O 0.9999891519546509

Two O O 0.9999790191650391
cases O O 0.9999891519546509
of O O 0.9999634027481079
severe O O 0.9999344348907471
delayed O O 0.9999806880950928
neurologic O O 0.9999946355819702
toxicity O O 0.9999818801879883
related O O 0.9999806880950928
to O O 0.999889612197876
the O O 0.9999673366546631
administration O O 0.9999630451202393
of O O 0.9998834133148193
intrathecal O O 0.9947839379310608
( O O 0.8106682896614075
IT O O 0.571707546710968
) O O 0.650123655796051
combination O O 0.7343355417251587
chemotherapy O O 0.9681569933891296
including O O 0.9977228045463562
thiotepa B B 0.9990721940994263
( O O 0.9819539785385132
TSPA B B 0.9838392734527588
) O O 0.996469259262085
are O O 0.999966025352478
presented O O 0.99998939037323
. O O 0.9999750852584839

Both O O 0.9999282360076904
cases O O 0.999988317489624
developed O O 0.9999840259552002
axonal O O 0.9993240833282471
neuropathy O O 0.9999947547912598
with O O 0.9999672174453735
motor O O 0.9999115467071533
predominance O O 0.9999268054962158
in O O 0.9999594688415527
the O O 0.9999797344207764
lower O O 0.9998705387115479
extremities O O 0.9999825954437256
1 O O 0.9998924732208252
and O O 0.9999922513961792
6 O O 0.999983549118042
months O O 0.9999984502792358
after O O 0.9999264478683472
IT O O 0.9904954433441162
chemotherapy O O 0.9901688098907471
was O O 0.999966025352478
administered O O 0.9999135732650757
. O O 0.9999589920043945

Neurologic O O 0.9998635053634644
toxicities O O 0.9991258978843689
have O O 0.9999040365219116
been O O 0.9999538660049438
described O O 0.9999773502349854
with O O 0.999738872051239
IT O B 0.9796739220619202
- O O 0.8828657269477844
methotrexate B B 0.8896729350090027
, O O 0.9931052327156067
IT O B 0.8881654143333435
- O I 0.7449660897254944
cytosine B I 0.7004445791244507
arabinoside I I 0.9996724128723145
and O O 0.9900597333908081
IT O B 0.9606253504753113
- O O 0.6374257206916809
TSPA B B 0.9453744292259216
. O O 0.9999374151229858

To O O 0.9999901056289673
our O O 0.999985933303833
knowledge O O 0.999993085861206
, O O 0.9999805688858032
however O O 0.9999697208404541
, O O 0.9999574422836304
axonal O O 0.9999221563339233
neuropathy O O 0.9999885559082031
following O O 0.999914288520813
administration O O 0.9999454021453857
of O O 0.9998356103897095
these O O 0.9942185878753662
three O O 0.9677176475524902
agents O O 0.995516836643219
has O O 0.999954104423523
not O O 0.9999861717224121
been O O 0.9999924898147583
previously O O 0.999975323677063
described O O 0.9999908208847046
. O O 0.9999797344207764

In O O 0.9999631643295288
spite O O 0.9999501705169678
of O O 0.9999213218688965
the O O 0.9999768733978271
fact O O 0.999992847442627
that O O 0.999672532081604
TSPA B B 0.9788844585418701
is O O 0.9976959824562073
a O O 0.9987309575080872
useful O O 0.9988172650337219
IT O O 0.7960165739059448
agent O O 0.9614601135253906
, O O 0.9998679161071777
its O O 0.9991739392280579
combination O O 0.9998831748962402
with O O 0.9995301961898804
MTX B B 0.9777408838272095
, O O 0.9452449083328247
ara B B 0.9260590672492981
- I I 0.6917439699172974
C I I 0.9914933443069458
and O O 0.9914979338645935
radiotherapy O O 0.9693332314491272
could O O 0.9999314546585083
cause O O 0.9999724626541138
severe O O 0.9999775886535645
neurotoxicity O O 0.9999942779541016
. O O 0.9999707937240601

This O O 0.9999581575393677
unexpected O O 0.9999583959579468
complication O O 0.9999830722808838
indicates O O 0.9999231100082397
the O O 0.9999881982803345
need O O 0.9999905824661255
for O O 0.999992847442627
further O O 0.9999856948852539
toxicology O O 0.8119087815284729
research O O 0.999974250793457
on O O 0.9996722936630249
IT O O 0.5631335377693176
- O O 0.8203902840614319
TSPA B O 0.5542434453964233
. O O 0.9998331069946289

Effects O O 0.9998171925544739
of O O 0.9975690245628357
cromakalim B B 0.9983096122741699
and O O 0.8518814444541931
pinacidil B B 0.9997790455818176
on O O 0.9997560381889343
large O O 0.9996678829193115
epicardial O O 0.9967183470726013
and O O 0.999815046787262
small O O 0.9998925924301147
coronary O O 0.9994833469390869
arteries O O 0.9997970461845398
in O O 0.9999048709869385
conscious O O 0.999763548374176
dogs O O 0.9999911785125732
. O O 0.9999233484268188

The O O 0.9999686479568481
effects O O 0.999975323677063
of O O 0.999910831451416
i O O 0.9998635053634644
. O O 0.9999902248382568
v O O 0.9999983310699463
. O O 0.9999933242797852
bolus O O 0.9999868869781494
administration O O 0.9999581575393677
of O O 0.9989489912986755
cromakalim B B 0.9993661046028137
( O O 0.9997774958610535
1 O O 0.9993914365768433
- O O 0.9985008239746094
10 O O 0.9999492168426514
micrograms O O 0.9947404265403748
/ O O 0.9999754428863525
kg O O 0.9999914169311523
) O O 0.9999096393585205
and O O 0.9935867786407471
pinacidil B B 0.9998003840446472
( O O 0.9998607635498047
3 O O 0.99460768699646
- O O 0.9987444877624512
100 O O 0.9998862743377686
micrograms O O 0.9976660013198853
/ O O 0.999974250793457
kg O O 0.9999878406524658
) O O 0.9999711513519287
on O O 0.9998843669891357
large O O 0.9993374943733215
( O O 0.999119222164154
circumflex O O 0.9905461072921753
artery O O 0.9977840781211853
) O O 0.9997527003288269
and O O 0.9998266100883484
small O O 0.9999154806137085
coronary O O 0.9996342658996582
arteries O O 0.9998409748077393
and O O 0.9998754262924194
on O O 0.9995236396789551
systemic O O 0.9998452663421631
hemodynamics O O 0.9999738931655884
were O O 0.9999769926071167
investigated O O 0.9999855756759644
in O O 0.9999806880950928
chronically O O 0.9999653100967407
instrumented O O 0.9999958276748657
conscious O O 0.9999254941940308
dogs O O 0.9999979734420776
and O O 0.999991774559021
compared O O 0.9999934434890747
to O O 0.9999151229858398
those O O 0.9999769926071167
of O O 0.9995236396789551
nitroglycerin B B 0.9996235370635986
( O O 0.999478280544281
0 O O 0.9998517036437988
. O O 0.9999889135360718
03 O O 0.9996696710586548
- O O 0.998836100101471
10 O O 0.9999865293502808
micrograms O O 0.999131977558136
/ O O 0.9999849796295166
kg O O 0.9999954700469971
) O O 0.9999769926071167
. O O 0.9999669790267944

Nitroglycerin B B 0.9986839890480042
, O O 0.9997922778129578
up O O 0.9999630451202393
to O O 0.9999924898147583
0 O O 0.9999693632125854
. O O 0.9999926090240479
3 O O 0.999961256980896
micrograms O O 0.9997419714927673
/ O O 0.9999618530273438
kg O O 0.9999932050704956
, O O 0.9998984336853027
selectively O O 0.9996771812438965
increased O O 0.999941349029541
circumflex O O 0.8527140617370605
artery O O 0.9985748529434204
diameter O O 0.9998167157173157
( O O 0.9994698166847229
CxAD O O 0.7120575904846191
) O O 0.9999239444732666
without O O 0.9999486207962036
simultaneously O O 0.999913215637207
affecting O O 0.9999440908432007
any O O 0.999956488609314
other O O 0.9999490976333618
cardiac O O 0.9999773502349854
or O O 0.9999514818191528
systemic O O 0.9999098777770996
hemodynamic O O 0.9999794960021973
parameter O O 0.9999935626983643
. O O 0.9998838901519775

In O O 0.9994398951530457
contrast O O 0.9356843829154968
, O O 0.9989414811134338
cromakalim B B 0.9987075328826904
and O O 0.946803629398346
pinacidil B B 0.9998089671134949
at O O 0.9998753070831299
all O O 0.9998676776885986
doses O O 0.9999674558639526
and O O 0.9996623992919922
nitroglycerin B B 0.999618649482727
at O O 0.999919056892395
doses O O 0.9999750852584839
higher O O 0.9999836683273315
than O O 0.9999954700469971
0 O O 0.9999790191650391
. O O 0.9999951124191284
3 O O 0.9999681711196899
micrograms O O 0.9997836947441101
/ O O 0.9999665021896362
kg O O 0.9999936819076538
simultaneously O O 0.9963995218276978
and O O 0.9999290704727173
dose O O 0.9986754059791565
- O O 0.9999669790267944
dependently O O 0.9999860525131226
increased O O 0.9999128580093384
CxAD O O 0.5892353057861328
, O O 0.999763548374176
coronary O O 0.9734563231468201
blood O O 0.9998218417167664
flow O O 0.9999878406524658
and O O 0.9999628067016602
heart O O 0.9999812841415405
rate O O 0.9999951124191284
and O O 0.9999791383743286
decreased O O 0.9999852180480957
coronary O O 0.9981682300567627
vascular O O 0.9998934268951416
resistance O O 0.9999984502792358
and O O 0.9999661445617676
aortic O O 0.9998185038566589
pressure O O 0.9999551773071289
. O O 0.9999583959579468

Cromakalim B B 0.9993534684181213
was O O 0.9998878240585327
approximately O O 0.9999898672103882
8 O O 0.999954342842102
- O O 0.9999591112136841
to O O 0.9999955892562866
9 O O 0.9999935626983643
. O O 0.9999958276748657
5 O O 0.9999853372573853
- O O 0.9999889135360718
fold O O 0.9999943971633911
more O O 0.999954342842102
potent O O 0.9996825456619263
than O O 0.9987672567367554
pinacidil B B 0.9998419284820557
in O O 0.9997383952140808
increasing O O 0.9986294507980347
CxAD O O 0.664824366569519
. O O 0.9998718500137329

Vasodilation O O 0.9997876286506653
of O O 0.9997392296791077
large O O 0.9997484087944031
and O O 0.9996575117111206
small O O 0.999942421913147
coronary O O 0.9996353387832642
vessels O O 0.9999849796295166
and O O 0.9999104738235474
hypotension O O 0.9999644756317139
induced O O 0.9999330043792725
by O O 0.9998301267623901
cromakalim B B 0.9989780187606812
and O O 0.9533189535140991
pinacidil B B 0.9998306035995483
were O O 0.9999244213104248
not O O 0.9999690055847168
affected O O 0.9999911785125732
by O O 0.9999282360076904
prior O O 0.99985671043396
combined O O 0.997925877571106
beta B O 0.7781312465667725
adrenergic I O 0.9352520108222961
and I O 0.9987932443618774
muscarinic I O 0.8329021334648132
receptors I O 0.9846684336662292
blockade I O 0.9999030828475952
but O O 0.9999433755874634
drug O O 0.9992456436157227
- O O 0.9999328851699829
induced O O 0.9999638795852661
tachycardia O O 0.9999897480010986
was O O 0.9999531507492065
abolished O O 0.9998272061347961
. O O 0.9999719858169556

When O O 0.9998082518577576
circumflex O O 0.9653984904289246
artery O O 0.9999312162399292
blood O O 0.9999109506607056
flow O O 0.9999816417694092
was O O 0.9999701976776123
maintained O O 0.9999514818191528
constant O O 0.999984622001648
, O O 0.9999372959136963
the O O 0.999981164932251
increases O O 0.999963641166687
in O O 0.9997718930244446
CxAD O O 0.6115625500679016
induced O O 0.9998605251312256
by O O 0.9998600482940674
cromakalim B B 0.9989641904830933
( O O 0.9997196793556213
10 O O 0.9998307228088379
micrograms O O 0.9959405660629272
/ O O 0.9999594688415527
kg O O 0.9999915361404419
) O O 0.9998791217803955
, O O 0.9973527193069458
pinacidil B B 0.9998313188552856
( O O 0.9996181726455688
30 O O 0.9999183416366577
micrograms O O 0.9964812994003296
/ O O 0.9999576807022095
kg O O 0.9999897480010986
) O O 0.9998658895492554
and O O 0.9982788562774658
nitroglycerin B B 0.9992111921310425
( O O 0.9998422861099243
10 O O 0.9999043941497803
micrograms O O 0.9993755221366882
/ O O 0.9999756813049316
kg O O 0.9999964237213135
) O O 0.9999614953994751
were O O 0.9999648332595825
reduced O O 0.9999895095825195
by O O 0.9999839067459106
68 O O 0.9997426867485046
+ O O 0.9999955892562866
/ O O 0.9999932050704956
- O O 0.9999674558639526
7 O O 0.9999881982803345
, O O 0.9999587535858154
54 O O 0.9996178150177002
+ O O 0.9999938011169434
/ O O 0.9999792575836182
- O O 0.9999489784240723
9 O O 0.9999616146087646
and O O 0.9999605417251587
1 O O 0.9999490976333618
+ O O 0.9999929666519165
/ O O 0.9999659061431885
- O O 0.9999769926071167
1 O O 0.9999909400939941
% O O 0.9999957084655762
, O O 0.9999903440475464
respectively O O 0.9999781847000122
. O O 0.9999790191650391

Thus O O 0.9999681711196899
, O O 0.9999245405197144
whereas O O 0.9968734383583069
nitroglycerin B B 0.9984164237976074
preferentially O O 0.9995753169059753
and O O 0.9995787739753723
flow O O 0.951200008392334
- O O 0.9985644221305847
independently O O 0.9625020623207092
dilates O O 0.9996222257614136
large O O 0.9999511241912842
coronary O O 0.993854820728302
arteries O O 0.9991999268531799
, O O 0.9991111159324646
cromakalim B B 0.9978166818618774
and O O 0.9615802764892578
pinacidil B B 0.9997938275337219
dilate O O 0.9987271428108215
both O O 0.9999145269393921
large O O 0.99944669008255
and O O 0.9998987913131714
small O O 0.9999618530273438
coronary O O 0.9946619868278503
arteries O O 0.9991679191589355
and O O 0.9999499320983887
this O O 0.9999598264694214
effect O O 0.9999438524246216
is O O 0.9999662637710571
not O O 0.9999490976333618
dependent O O 0.9999741315841675
upon O O 0.9999665021896362
the O O 0.9999486207962036
simultaneous O O 0.9982094764709473
beta O O 0.655354917049408
adrenoceptors O O 0.7875573635101318
- O O 0.999552309513092
mediated O O 0.9999358654022217
rise O O 0.9999935626983643
in O O 0.9999669790267944
myocardial O O 0.9999985694885254
metabolic O O 0.9981203675270081
demand O O 0.9999827146530151
. O O 0.9999589920043945

Finally O O 0.9997954964637756
, O O 0.9998613595962524
two O O 0.9995099306106567
mechanisms O O 0.9997459053993225
at O O 0.9999321699142456
least O O 0.9999692440032959
, O O 0.9998797178268433
direct O O 0.9995524287223816
vasodilation O O 0.9996312856674194
and O O 0.9997130036354065
flow O O 0.9996709823608398
dependency O O 0.999903678894043
, O O 0.9999388456344604
are O O 0.9997945427894592
involved O O 0.999920129776001
in O O 0.9999438524246216
the O O 0.9999334812164307
cromakalim B B 0.9983999133110046
- O O 0.995424211025238
and O O 0.9960685968399048
pinacidil B B 0.9998952150344849
- O O 0.9998353719711304
induced O O 0.99996018409729
increase O O 0.9999892711639404
in O O 0.9999228715896606
CxAD O B 0.9557996392250061
. O O 0.9999101161956787

Mefenamic B B 0.9962371587753296
acid I I 0.9998809099197388
- O O 0.9984690546989441
induced O O 0.99994957447052
neutropenia O O 0.999983549118042
and O O 0.9999713897705078
renal O O 0.9999830722808838
failure O O 0.9999897480010986
in O O 0.9999654293060303
elderly O O 0.9999655485153198
females O O 0.9999969005584717
with O O 0.9999632835388184
hypothyroidism O O 0.9437804818153381
. O O 0.9999582767486572

We O O 0.9999433755874634
report O O 0.9999538660049438
mefenamic B B 0.999396800994873
acid I I 0.9997041821479797
- O O 0.998988926410675
induced O O 0.9999505281448364
non O O 0.9977972507476807
- O O 0.9998390674591064
oliguric O O 0.999710738658905
renal O O 0.9999879598617554
failure O O 0.9999912977218628
and O O 0.9999518394470215
severe O O 0.9999488592147827
neutropenia O O 0.9999829530715942
occurring O O 0.9999808073043823
simultaneously O O 0.99994957447052
in O O 0.9999637603759766
two O O 0.999970555305481
elderly O O 0.9998853206634521
females O O 0.9999618530273438
. O O 0.9999803304672241

The O O 0.9999724626541138
neutropenia O O 0.9999773502349854
was O O 0.9999748468399048
due O O 0.9999845027923584
to O O 0.9998401403427124
maturation O O 0.9998773336410522
arrest O O 0.9998674392700195
of O O 0.9996142387390137
the O O 0.9995094537734985
myeloid O O 0.9998428821563721
series O O 0.9985741376876831
in O O 0.9998664855957031
one O O 0.9999761581420898
patient O O 0.9999861717224121
. O O 0.9999508857727051

Both O O 0.9998573064804077
patients O O 0.9999760389328003
were O O 0.9998503923416138
also O O 0.9997527003288269
hypothyroid O O 0.749445915222168
, O O 0.9998341798782349
but O O 0.9999499320983887
it O O 0.9999895095825195
is O O 0.999984860420227
not O O 0.9999964237213135
clear O O 0.9999915361404419
whether O O 0.9999814033508301
this O O 0.9998486042022705
was O O 0.9999775886535645
a O O 0.999811589717865
predisposing O O 0.9998189806938171
factor O O 0.9999904632568359
to O O 0.9999775886535645
the O O 0.9999924898147583
development O O 0.9999967813491821
of O O 0.9999880790710449
these O O 0.9998973608016968
adverse O O 0.9994385838508606
reactions O O 0.9999916553497314
. O O 0.9999778270721436

However O O 0.9999608993530273
, O O 0.9999756813049316
it O O 0.9999936819076538
would O O 0.9999922513961792
seem O O 0.9999847412109375
prudent O O 0.9999885559082031
not O O 0.9999449253082275
to O O 0.9999363422393799
use O O 0.9994555115699768
mefenamic B B 0.9991577863693237
acid I I 0.9997691512107849
in O O 0.9993466734886169
hypothyroid O O 0.9376024603843689
patients O O 0.9999414682388306
until O O 0.9999361038208008
the O O 0.999987006187439
hypothyroidism O O 0.9879373908042908
has O O 0.9999744892120361
been O O 0.9999849796295166
corrected O O 0.9999675750732422
. O O 0.9999731779098511

Etiology O O 0.9996938705444336
of O O 0.9999442100524902
hypercalcemia O O 0.9994440674781799
in O O 0.9999282360076904
hemodialysis O O 0.9989284873008728
patients O O 0.9999443292617798
on O O 0.9992179870605469
calcium B B 0.9964175224304199
carbonate I I 0.9998831748962402
therapy O O 0.9980077147483826
. O O 0.9999173879623413

Fourteen O O 0.9999604225158691
of O O 0.9999867677688599
39 O O 0.9999889135360718
dialysis O O 0.9998006224632263
patients O O 0.999966025352478
( O O 0.9999674558639526
36 O O 0.9999924898147583
% O O 0.9999959468841553
) O O 0.9999728202819824
became O O 0.9999860525131226
hypercalcemic O O 0.9999512434005737
after O O 0.9998996257781982
switching O O 0.9999445676803589
to O O 0.9994004964828491
calcium B B 0.998233437538147
carbonate I I 0.9999297857284546
as O O 0.9993745684623718
their O O 0.9994763731956482
principal O O 0.7691926956176758
phosphate B B 0.9314899444580078
binder O O 0.6654295325279236
. O O 0.9999517202377319

In O O 0.9999803304672241
order O O 0.9999955892562866
to O O 0.9999954700469971
identify O O 0.999975323677063
risk O O 0.9999338388442993
factors O O 0.9999958276748657
associated O O 0.9999898672103882
with O O 0.99998939037323
the O O 0.9999955892562866
development O O 0.9999966621398926
of O O 0.9999806880950928
hypercalcemia O O 0.9996424913406372
, O O 0.9999547004699707
indirect O O 0.9996994733810425
parameters O O 0.9999537467956543
of O O 0.9998407363891602
intestinal O O 0.9983199238777161
calcium B B 0.9533509016036987
reabsorption O O 0.9239299893379211
and O O 0.9997509121894836
bone O O 0.990326464176178
turnover O O 0.9998676776885986
rate O O 0.9996514320373535
in O O 0.9999295473098755
these O O 0.9999856948852539
14 O O 0.9999691247940063
patients O O 0.9999934434890747
were O O 0.9999685287475586
compared O O 0.999991774559021
with O O 0.9999934434890747
results O O 0.9999923706054688
in O O 0.9999939203262329
14 O O 0.9999756813049316
eucalcemic O O 0.9999282360076904
patients O O 0.9999901056289673
matched O O 0.9999667406082153
for O O 0.9999873638153076
age O O 0.9999864101409912
, O O 0.9999920129776001
sex O O 0.9999974966049194
, O O 0.9999921321868896
length O O 0.9999961853027344
of O O 0.999994158744812
time O O 0.9999909400939941
on O O 0.9999815225601196
dialysis O O 0.999735414981842
, O O 0.9999598264694214
and O O 0.9999819993972778
etiology O O 0.9999856948852539
of O O 0.9999864101409912
renal O O 0.9999597072601318
disease O O 0.9999942779541016
. O O 0.9999758005142212

In O O 0.9999538660049438
addition O O 0.9999432563781738
to O O 0.999956488609314
experiencing O O 0.9998947381973267
hypercalcemic O O 0.9991975426673889
episodes O O 0.9999721050262451
with O O 0.9999629259109497
peak O O 0.9998235106468201
calcium B B 0.9955366849899292
values O O 0.9992269277572632
of O O 0.9999417066574097
2 O O 0.9999477863311768
. O O 0.9999947547912598
7 O O 0.9999901056289673
to O O 0.9999805688858032
3 O O 0.9999719858169556
. O O 0.9999979734420776
8 O O 0.9999500513076782
mmol O O 0.9998760223388672
/ O O 0.9998742341995239
L O O 0.9995352029800415
( O O 0.9999508857727051
10 O O 0.9998217225074768
. O O 0.9999971389770508
7 O O 0.9999439716339111
to O O 0.9999074935913086
15 O O 0.9999992847442627
. O O 0.999998927116394
0 O O 0.9999915361404419
mg O O 0.9999955892562866
/ O O 0.999983549118042
dL O O 0.9999979734420776
) O O 0.9999692440032959
, O O 0.9999725818634033
patients O O 0.9999299049377441
in O O 0.9999126195907593
the O O 0.9999171495437622
hypercalcemic O O 0.9838961362838745
group O O 0.9999146461486816
exhibited O O 0.9999668598175049
a O O 0.9999885559082031
significant O O 0.9999915361404419
increase O O 0.9999948740005493
in O O 0.9999902248382568
the O O 0.999988317489624
mean O O 0.9999680519104004
calcium B B 0.998036801815033
concentration O O 0.9998006224632263
obtained O O 0.9999897480010986
during O O 0.9999797344207764
6 O O 0.9999750852584839
months O O 0.9999990463256836
before O O 0.9999936819076538
the O O 0.9999915361404419
switch O O 0.9999833106994629
, O O 0.9999891519546509
compared O O 0.9999954700469971
with O O 0.9999957084655762
the O O 0.9999942779541016
mean O O 0.9999861717224121
value O O 0.9999876022338867
obtained O O 0.999991774559021
during O O 0.9999856948852539
the O O 0.9999966621398926
7 O O 0.9999949932098389
months O O 0.9999988079071045
of O O 0.9999949932098389
observation O O 0.9999983310699463
after O O 0.9999933242797852
the O O 0.9999884366989136
switch O O 0.9999775886535645
( O O 0.999981164932251
2 O O 0.9999171495437622
. O O 0.9999960660934448
4 O O 0.9999887943267822
+ O O 0.999995231628418
/ O O 0.9999692440032959
- O O 0.9999665021896362
0 O O 0.9999847412109375
. O O 0.9999973773956299
03 O O 0.9999909400939941
to O O 0.9999182224273682
2 O O 0.9999493360519409
. O O 0.9999943971633911
5 O O 0.9999881982803345
+ O O 0.9999932050704956
/ O O 0.9998911619186401
- O O 0.9999158382415771
0 O O 0.999974250793457
. O O 0.9999963045120239
03 O O 0.99997878074646
mmol O O 0.9999924898147583
/ O O 0.9998916387557983
L O O 0.9994742274284363
[ O O 0.9995982050895691
9 O O 0.9997010827064514
. O O 0.9999938011169434
7 O O 0.9999758005142212
+ O O 0.9999850988388062
/ O O 0.9999468326568604
- O O 0.9999654293060303
0 O O 0.9999831914901733
. O O 0.9999901056289673
2 O O 0.9999904632568359
to O O 0.999782145023346
10 O O 0.9998713731765747
. O O 0.9999955892562866
2 O O 0.9999876022338867
+ O O 0.999993085861206
/ O O 0.9998310804367065
- O O 0.9999613761901855
0 O O 0.9999756813049316
. O O 0.9999929666519165
1 O O 0.9999910593032837
mg O O 0.9999946355819702
/ O O 0.9999814033508301
dL O O 0.9999960660934448
] O O 0.9999191761016846
, O O 0.9999808073043823
P O O 0.9999613761901855
= O O 0.9999616146087646
0 O O 0.9999945163726807
. O O 0.9999966621398926
006 O O 0.9999779462814331
) O O 0.9999796152114868
. O O 0.9999836683273315

In O O 0.9999123811721802
contrast O O 0.9999690055847168
, O O 0.9998045563697815
eucalcemic O O 0.9954296350479126
patients O O 0.9999597072601318
exhibited O O 0.9999780654907227
no O O 0.9999746084213257
change O O 0.9999971389770508
in O O 0.9999843835830688
mean O O 0.9999072551727295
calcium B B 0.9960177540779114
values O O 0.999373733997345
over O O 0.9999734163284302
the O O 0.9999940395355225
same O O 0.9999892711639404
time O O 0.999988317489624
period O O 0.9999954700469971
( O O 0.9999455213546753
2 O O 0.9147940874099731
. O O 0.9999362230300903
3 O O 0.9991045594215393
+ O O 0.9999581575393677
/ O O 0.9998140931129456
- O O 0.9998206496238708
0 O O 0.9998507499694824
. O O 0.9999929666519165
05 O O 0.9999319314956665
to O O 0.9999409914016724
2 O O 0.7444506883621216
. O O 0.9999446868896484
3 O O 0.9983185529708862
+ O O 0.9999666213989258
/ O O 0.9992089867591858
- O O 0.999671459197998
0 O O 0.9999444484710693
. O O 0.9999940395355225
05 O O 0.999772846698761
mmol O O 0.9999545812606812
/ O O 0.9997344613075256
L O O 0.9982423782348633
[ O O 0.9998562335968018
9 O O 0.9957914352416992
. O O 0.9999871253967285
2 O O 0.9999076128005981
+ O O 0.9999784231185913
/ O O 0.9999178647994995
- O O 0.9999406337738037
0 O O 0.9999324083328247
. O O 0.9999817609786987
2 O O 0.999984622001648
to O O 0.9998812675476074
9 O O 0.9994297623634338
. O O 0.9999932050704956
2 O O 0.9998419284820557
+ O O 0.9999765157699585
/ O O 0.9998297691345215
- O O 0.9999442100524902
0 O O 0.999964714050293
. O O 0.9999936819076538
2 O O 0.9999831914901733
mg O O 0.9999934434890747
/ O O 0.9999793767929077
dL O O 0.9999895095825195
] O O 0.9998979568481445
) O O 0.999971866607666
. O O 0.9999814033508301

CaCO3 B B 0.9835002422332764
dosage O O 0.9974808096885681
, O O 0.9999668598175049
calculated O O 0.9991612434387207
dietary O O 0.9957851767539978
calcium B B 0.9959458708763123
intake O O 0.9993988275527954
, O O 0.9999408721923828
and O O 0.999968409538269
circulating O O 0.9998003840446472
levels O O 0.9999288320541382
of O O 0.9994801878929138
vitamin B B 0.9107216596603394
D I I 0.9993577599525452
metabolites O O 0.9506524801254272
were O O 0.9999676942825317
similar O O 0.9999856948852539
in O O 0.9999494552612305
both O O 0.9997836947441101
groups O O 0.9999879598617554
. O O 0.9999778270721436

Physical O O 0.9930063486099243
activity O O 0.7650781273841858
index O O 0.9992165565490723
and O O 0.9999510049819946
predialysis O O 0.9998750686645508
serum O O 0.6943599581718445
bicarbonate B B 0.9823863506317139
levels O O 0.9998874664306641
also O O 0.9999852180480957
were O O 0.9999716281890869
similar O O 0.9999842643737793
in O O 0.9999412298202515
both O O 0.9997749924659729
groups O O 0.9999868869781494
. O O 0.9999768733978271

However O O 0.9999239444732666
, O O 0.9999455213546753
there O O 0.9999059438705444
was O O 0.9999449253082275
a O O 0.9999798536300659
significant O O 0.9999756813049316
difference O O 0.9999957084655762
in O O 0.999977707862854
parameters O O 0.9999650716781616
reflecting O O 0.9999697208404541
bone O O 0.9949842691421509
turnover O O 0.9996874332427979
rates O O 0.9995243549346924
between O O 0.9994681477546692
groups O O 0.9999415874481201
. O O 0.9999837875366211
( O O 0.9996802806854248
ABSTRACT O O 0.9999617338180542
TRUNCATED O O 0.9999603033065796
AT O O 0.9999353885650635
250 O O 0.9963604807853699
WORDS O O 0.9999933242797852
) O O 0.9998534917831421

Late O O 0.9994565844535828
- O O 0.9999659061431885
onset O O 0.9999895095825195
scleroderma O O 0.9954625964164734
renal O O 0.9995750784873962
crisis O O 0.9999861717224121
induced O O 0.9999737739562988
by O O 0.9997606873512268
tacrolimus B B 0.9996886253356934
and O O 0.8221185207366943
prednisolone B B 0.9967672824859619
: O O 0.9999223947525024
a O O 0.9999948740005493
case O O 0.9999866485595703
report O O 0.9999953508377075
. O O 0.9999865293502808

Scleroderma O O 0.9932178854942322
renal O O 0.9996485710144043
crisis O O 0.999962329864502
( O O 0.9998502731323242
SRC O O 0.9410526156425476
) O O 0.9999743700027466
is O O 0.9999688863754272
a O O 0.9999797344207764
rare O O 0.9999673366546631
complication O O 0.9999852180480957
of O O 0.9998052716255188
systemic O O 0.794895589351654
sclerosis O O 0.9882227778434753
( O O 0.9998444318771362
SSc O O 0.8141169548034668
) O O 0.9999337196350098
but O O 0.9998639822006226
can O O 0.999966025352478
be O O 0.9999955892562866
severe O O 0.9999918937683105
enough O O 0.9999933242797852
to O O 0.9999953508377075
require O O 0.9999854564666748
temporary O O 0.9999555349349976
or O O 0.9999754428863525
permanent O O 0.9999581575393677
renal O O 0.9999309778213501
replacement O O 0.9979121088981628
therapy O O 0.9999653100967407
. O O 0.9999734163284302

Moderate O O 0.9992940425872803
to O O 0.9998538494110107
high O O 0.9966356158256531
dose O O 0.9901542067527771
corticosteroid B B 0.8450919389724731
use O O 0.9980494976043701
is O O 0.9998383522033691
recognized O O 0.9999289512634277
as O O 0.9999607801437378
a O O 0.9998496770858765
major O O 0.99988853931427
risk O O 0.9999381303787231
factor O O 0.9999899864196777
for O O 0.9999178647994995
SRC O O 0.9843233227729797
. O O 0.9999310970306396

Furthermore O O 0.9996194839477539
, O O 0.9999502897262573
there O O 0.9999607801437378
have O O 0.9999804496765137
been O O 0.9999943971633911
reports O O 0.9999966621398926
of O O 0.9999668598175049
thrombotic O O 0.9995874762535095
microangiopathy O O 0.9998840093612671
precipitated O O 0.9999510049819946
by O O 0.9997746348381042
cyclosporine B B 0.9986742734909058
in O O 0.9996930360794067
patients O O 0.9999854564666748
with O O 0.9999507665634155
SSc O O 0.9167370796203613
. O O 0.999948263168335

In O O 0.9999771118164062
this O O 0.9999759197235107
article O O 0.9999884366989136
, O O 0.9999672174453735
we O O 0.9999643564224243
report O O 0.9999845027923584
a O O 0.9999791383743286
patient O O 0.9999880790710449
with O O 0.999941349029541
SRC O O 0.977735161781311
induced O O 0.9999802112579346
by O O 0.9996115565299988
tacrolimus B B 0.9992087483406067
and O O 0.9878240823745728
corticosteroids B O 0.6357873678207397
. O O 0.9999321699142456

The O O 0.999983549118042
aim O O 0.9999951124191284
of O O 0.9999951124191284
this O O 0.9999834299087524
work O O 0.9999796152114868
is O O 0.9999803304672241
to O O 0.9999847412109375
call O O 0.9999939203262329
attention O O 0.9999901056289673
to O O 0.9999786615371704
the O O 0.9999840259552002
risk O O 0.999992847442627
of O O 0.9999327659606934
tacrolimus B B 0.9997370839118958
use O O 0.9998067021369934
in O O 0.9999563694000244
patients O O 0.9999905824661255
with O O 0.9999723434448242
SSc O O 0.8942009210586548
. O O 0.9999454021453857

Methyldopa B B 0.9994611144065857
- O O 0.9985713958740234
induced O O 0.999834418296814
hemolytic O O 0.9997039437294006
anemia O O 0.9993564486503601
in O O 0.99997878074646
a O O 0.9999946355819702
15 O O 0.9999960660934448
year O O 0.999990701675415
old O O 0.9999862909317017
presenting O O 0.9999736547470093
as O O 0.9999954700469971
near O O 0.9998120665550232
- O O 0.9996829032897949
syncope O O 0.999948263168335
. O O 0.9999768733978271

Methyldopa B B 0.9991446733474731
is O O 0.9992743134498596
an O O 0.9976038336753845
antihypertensive O O 0.4630192220211029
medication O O 0.99611496925354
which O O 0.9998670816421509
is O O 0.9999313354492188
available O O 0.9999251365661621
generically O O 0.9999091625213623
and O O 0.9999825954437256
under O O 0.9998849630355835
the O O 0.9999828338623047
trade O O 0.9986516833305359
name O O 0.9988812804222107
Aldomet B B 0.9903870224952698
that O O 0.9998576641082764
is O O 0.9999710321426392
widely O O 0.9999045133590698
prescribed O O 0.9998515844345093
in O O 0.9999470710754395
the O O 0.9999886751174927
adult O O 0.9999748468399048
population O O 0.9999908208847046
and O O 0.9999802112579346
infrequently O O 0.999847412109375
used O O 0.9999494552612305
in O O 0.9999068975448608
children O O 0.9998774528503418
. O O 0.999874472618103

Methyldopa B B 0.9993651509284973
causes O O 0.9997336268424988
an O O 0.9998223185539246
autoimmune O O 0.9958546757698059
hemolytic O O 0.9997286200523376
anemia O O 0.999045193195343
in O O 0.9999046325683594
a O O 0.9999401569366455
small O O 0.9999916553497314
percentage O O 0.9999872446060181
of O O 0.9999456405639648
patients O O 0.9999854564666748
who O O 0.9999297857284546
take O O 0.9968771934509277
the O O 0.9996021389961243
drug O O 0.9969191551208496
. O O 0.9996274709701538

We O O 0.9999732971191406
report O O 0.999996542930603
a O O 0.9999949932098389
case O O 0.9999942779541016
of O O 0.9999610185623169
methyldopa B B 0.9997017979621887
- O O 0.9986521601676941
induced O O 0.9998039603233337
hemolytic O O 0.9997459053993225
anemia O O 0.9997050166130066
in O O 0.999982476234436
a O O 0.9999954700469971
15 O O 0.9999971389770508
- O O 0.9999880790710449
year O O 0.9999964237213135
- O O 0.9999936819076538
old O O 0.9999947547912598
boy O O 0.9999921321868896
who O O 0.9999806880950928
presented O O 0.9999889135360718
to O O 0.9999978542327881
the O O 0.9999986886978149
emergency O O 0.9999938011169434
department O O 0.999998927116394
with O O 0.9999898672103882
near O O 0.9996856451034546
- O O 0.9998723268508911
syncope O O 0.9999420642852783
. O O 0.9999796152114868

The O O 0.999985933303833
boy O O 0.9999938011169434
had O O 0.9999896287918091
been O O 0.9999843835830688
treated O O 0.999835729598999
with O O 0.9995601773262024
intravenous O O 0.9991676807403564
methyldopa B B 0.9994935989379883
during O O 0.9997575879096985
a O O 0.9999856948852539
trauma O O 0.9999960660934448
admission O O 0.999992847442627
seven O O 0.9999934434890747
weeks O O 0.9999983310699463
prior O O 0.9999992847442627
to O O 0.9999986886978149
presentation O O 0.9999991655349731
. O O 0.9999822378158569

Evaluation O O 0.9999804496765137
revealed O O 0.999969482421875
a O O 0.9999723434448242
hemoglobin O O 0.9966357350349426
of O O 0.999907374382019
three O O 0.9999860525131226
grams O O 0.999985933303833
, O O 0.9999653100967407
3 O O 0.996778666973114
+ O O 0.9999563694000244
Coombs O O 0.9996374845504761
' O O 0.999983549118042
test O O 0.9999825954437256
with O O 0.9997168183326721
polyspecific O O 0.9939481019973755
anti O O 0.9414921998977661
- O O 0.9931695461273193
human O O 0.9797303676605225
globulin O O 0.9706549644470215
and O O 0.9965272545814514
monospecific O O 0.9955936074256897
IgG O O 0.870462954044342
reagents O O 0.9996017813682556
, O O 0.999790608882904
and O O 0.9998255372047424
a O O 0.9988380074501038
warm O O 0.7223128080368042
reacting O O 0.9993841648101807
autoantibody O O 0.9939143061637878
. O O 0.9999481439590454

Transfusion O O 0.9893680214881897
and O O 0.999588668346405
corticosteroid B O 0.8372010588645935
therapy O O 0.9981800317764282
resulted O O 0.9999657869338989
in O O 0.9999879598617554
a O O 0.9999818801879883
complete O O 0.9999884366989136
recovery O O 0.9999953508377075
of O O 0.999988317489624
the O O 0.9999902248382568
patient O O 0.9999862909317017
. O O 0.9999692440032959

Emergency O O 0.969804048538208
physicians O O 0.9999798536300659
treating O O 0.9997901320457458
children O O 0.999848484992981
must O O 0.9999508857727051
be O O 0.9999868869781494
aware O O 0.9999796152114868
of O O 0.9999822378158569
this O O 0.9999529123306274
syndrome O O 0.999982476234436
in O O 0.9999735355377197
order O O 0.999991774559021
to O O 0.9999850988388062
diagnose O O 0.9999960660934448
and O O 0.9999821186065674
treat O O 0.9999278783798218
it O O 0.9999942779541016
correctly O O 0.9999555349349976
. O O 0.9999666213989258

A O O 0.9999687671661377
brief O O 0.9999899864196777
review O O 0.9999885559082031
of O O 0.9999765157699585
autoimmune O O 0.9935104250907898
and O O 0.9997016787528992
drug O O 0.987664520740509
- O O 0.999894380569458
induced O O 0.9999545812606812
hemolytic O O 0.9994680285453796
anemias O O 0.9994072914123535
is O O 0.9999567270278931
provided O O 0.9999896287918091
. O O 0.9999606609344482

The O O 0.999934196472168
risk O O 0.9999799728393555
and O O 0.9999830722808838
associated O O 0.9999761581420898
factors O O 0.9999920129776001
of O O 0.9999619722366333
methamphetamine B B 0.9956855773925781
psychosis O O 0.9997287392616272
in O O 0.9999349117279053
methamphetamine B B 0.9990168809890747
- O O 0.9995121955871582
dependent O O 0.9997329115867615
patients O O 0.9999825954437256
in O O 0.9999164342880249
Malaysia O O 0.9969123601913452
. O O 0.9999730587005615

OBJECTIVE O O 0.9999356269836426
: O O 0.9999978542327881
The O O 0.999997615814209
objective O O 0.9999983310699463
of O O 0.9999938011169434
this O O 0.9999897480010986
study O O 0.9999833106994629
was O O 0.9999948740005493
to O O 0.9999948740005493
determine O O 0.9999935626983643
the O O 0.999993085861206
risk O O 0.9999951124191284
of O O 0.9999618530273438
lifetime O O 0.9985119700431824
and O O 0.9999409914016724
current O O 0.9999198913574219
methamphetamine B B 0.9995604157447815
- O O 0.9997090697288513
induced O O 0.9999425411224365
psychosis O O 0.9999558925628662
in O O 0.999964714050293
patients O O 0.9999953508377075
with O O 0.99997878074646
methamphetamine B B 0.9991839528083801
dependence O O 0.9989438652992249
. O O 0.9999853372573853

The O O 0.9999812841415405
association O O 0.9999814033508301
between O O 0.9998691082000732
psychiatric O O 0.9999327659606934
co O O 0.9925134778022766
- O O 0.9996769428253174
morbidity O O 0.9999653100967407
and O O 0.9997163414955139
methamphetamine B B 0.9995244741439819
- O O 0.9996745586395264
induced O O 0.9999210834503174
psychosis O O 0.9999496936798096
was O O 0.9999632835388184
also O O 0.9999879598617554
studied O O 0.9999451637268066
. O O 0.999968409538269

METHODS O O 0.9999630451202393
: O O 0.9999921321868896
This O O 0.9999961853027344
was O O 0.9999955892562866
a O O 0.999994158744812
cross O O 0.9999710321426392
- O O 0.9999904632568359
sectional O O 0.999997615814209
study O O 0.9999934434890747
conducted O O 0.9999916553497314
concurrently O O 0.9999767541885376
at O O 0.999954104423523
a O O 0.9999645948410034
teaching O O 0.9999516010284424
hospital O O 0.9999898672103882
and O O 0.9999279975891113
a O O 0.9999709129333496
drug O O 0.9993038177490234
rehabilitation O O 0.9999313354492188
center O O 0.9999814033508301
in O O 0.9999716281890869
Malaysia O O 0.999618649482727
. O O 0.999958872795105

Patients O O 0.9999891519546509
with O O 0.9999827146530151
the O O 0.9999929666519165
diagnosis O O 0.9999914169311523
of O O 0.9999480247497559
methamphetamine B B 0.9992037415504456
based O O 0.9986979961395264
on O O 0.9989663362503052
DSM O B 0.9405638575553894
- O I 0.6583667993545532
IV O I 0.9834735989570618
were O O 0.9993948936462402
interviewed O O 0.9999914169311523
using O O 0.9999786615371704
the O O 0.9999938011169434
Mini O O 0.9999481439590454
International O O 0.9999550580978394
Neuropsychiatric O O 0.9999852180480957
Interview O O 0.9999902248382568
( O O 0.9999586343765259
M O O 0.9999598264694214
. O O 0.9999896287918091
I O O 0.9999668598175049
. O O 0.9999936819076538
N O O 0.9999476671218872
. O O 0.9999940395355225
I O O 0.9999171495437622
. O O 0.9999966621398926
) O O 0.9999861717224121
for O O 0.9999407529830933
methamphetamine B B 0.9994787573814392
- O O 0.9996155500411987
induced O O 0.9999046325683594
psychosis O O 0.9999072551727295
and O O 0.9999583959579468
other O O 0.9998352527618408
Axis O O 0.9948544502258301
I O O 0.969528317451477
psychiatric O O 0.9998558759689331
disorders O O 0.9999920129776001
. O O 0.9999755620956421

The O O 0.9999902248382568
information O O 0.9999948740005493
on O O 0.9999754428863525
sociodemographic O O 0.9989873766899109
background O O 0.9999992847442627
and O O 0.9999641180038452
drug O O 0.9822676777839661
use O O 0.9993757605552673
history O O 0.9999606609344482
was O O 0.9999785423278809
obtained O O 0.999996542930603
from O O 0.9999774694442749
interview O O 0.9999456405639648
or O O 0.9999867677688599
medical O O 0.9999971389770508
records O O 0.9999854564666748
. O O 0.9999769926071167

RESULTS O O 0.9999260902404785
: O O 0.9999808073043823
Of O O 0.9999333620071411
292 O O 0.9999973773956299
subjects O O 0.9999915361404419
, O O 0.9999591112136841
47 O O 0.9999947547912598
. O O 0.9999830722808838
9 O O 0.999993085861206
% O O 0.9999920129776001
of O O 0.9999630451202393
the O O 0.9999772310256958
subjects O O 0.9999911785125732
had O O 0.9999728202819824
a O O 0.9999929666519165
past O O 0.9999932050704956
history O O 0.9999948740005493
of O O 0.9999606609344482
psychotic O O 0.9995700716972351
symptoms O O 0.9999877214431763
and O O 0.9999254941940308
13 O O 0.999977707862854
. O O 0.9999783039093018
0 O O 0.999992847442627
% O O 0.9999861717224121
of O O 0.9999634027481079
the O O 0.9999804496765137
patients O O 0.9999889135360718
were O O 0.9999768733978271
having O O 0.999975323677063
current O O 0.99996018409729
psychotic O O 0.9995443224906921
symptoms O O 0.999988317489624
. O O 0.999969482421875

Co O O 0.7937594652175903
- O O 0.9991974234580994
morbid O O 0.9998788833618164
major O O 0.9951836466789246
depressive O O 0.9993921518325806
disorder O O 0.9999635219573975
( O O 0.9999544620513916
OR O O 0.9983429908752441
= O O 0.9999290704727173
7 O O 0.999169111251831
. O O 0.999976396560669
18 O O 0.9999933242797852
, O O 0.9999045133590698
95 O O 0.9913022518157959
CI O O 0.9963668584823608
= O O 0.9995399713516235
2 O O 0.9999722242355347
. O O 0.99992835521698
612 O O 0.9999892711639404
- O O 0.9968677163124084
19 O O 0.9999887943267822
. O O 0.9999747276306152
708 O O 0.9999723434448242
) O O 0.999958872795105
, O O 0.9998505115509033
bipolar O O 0.9579974412918091
disorder O O 0.9999529123306274
( O O 0.999967098236084
OR O O 0.9995468258857727
= O O 0.9999486207962036
13 O O 0.999977707862854
. O O 0.999974250793457
807 O O 0.9993574023246765
, O O 0.9998990297317505
95 O O 0.98370760679245
CI O O 0.9955654740333557
= O O 0.9994947910308838
5 O O 0.9999642372131348
. O O 0.9998784065246582
194 O O 0.9987748265266418
- O O 0.9973313808441162
36 O O 0.9999951124191284
. O O 0.9999914169311523
706 O O 0.9999920129776001
) O O 0.999963641166687
, O O 0.9997641444206238
antisocial O O 0.9403707981109619
personality O O 0.9964284300804138
disorder O O 0.9999068975448608
( O O 0.9999566078186035
OR O O 0.999561607837677
= O O 0.9999802112579346
12 O O 0.9999921321868896
. O O 0.9999866485595703
619 O O 0.9999959468841553
, O O 0.9999204874038696
95 O O 0.9935550093650818
CI O O 0.9982234835624695
= O O 0.9997548460960388
6 O O 0.9999868869781494
. O O 0.9999611377716064
702 O O 0.9999629259109497
- O O 0.9967908263206482
23 O O 0.9999938011169434
. O O 0.9999866485595703
759 O O 0.9999781847000122
) O O 0.9999654293060303
and O O 0.9997931122779846
heavy O O 0.990864098072052
methamphetamine B B 0.9982681274414062
uses O O 0.9984278678894043
were O O 0.9999270439147949
significantly O O 0.9999823570251465
associated O O 0.9999821186065674
with O O 0.99997878074646
lifetime O O 0.9976231455802917
methamphetamine B B 0.9993784427642822
- O O 0.9998791217803955
induced O O 0.9999163150787354
psychosis O O 0.9999793767929077
after O O 0.9999202489852905
adjusted O O 0.9999446868896484
for O O 0.999923825263977
other O O 0.9995816349983215
factors O O 0.9999836683273315
. O O 0.9999747276306152

Major O O 0.994161069393158
depressive O O 0.9993333220481873
disorder O O 0.9999568462371826
( O O 0.9999409914016724
OR O O 0.9994667172431946
= O O 0.9999326467514038
2 O O 0.9999635219573975
. O O 0.9999804496765137
870 O O 0.9999094009399414
, O O 0.9998866319656372
CI O O 0.9922477006912231
= O O 0.9998648166656494
1 O O 0.9999911785125732
. O O 0.9999812841415405
154 O O 0.9999592304229736
- O O 0.9936466217041016
7 O O 0.9994090795516968
. O O 0.99997878074646
142 O O 0.999916672706604
) O O 0.9998908042907715
and O O 0.9997010827064514
antisocial O O 0.9442059397697449
personality O O 0.9937648773193359
disorder O O 0.9997475743293762
( O O 0.9999597072601318
OR O O 0.999357283115387
= O O 0.9999029636383057
3 O O 0.997925877571106
. O O 0.9999809265136719
299 O O 0.9999963045120239
, O O 0.9998501539230347
95 O O 0.9632972478866577
CI O O 0.9965934157371521
= O O 0.9993200302124023
1 O O 0.9999769926071167
. O O 0.9998914003372192
375 O O 0.9998946189880371
- O O 0.9946841597557068
7 O O 0.9999182224273682
. O O 0.9999804496765137
914 O O 0.999550998210907
) O O 0.9999477863311768
were O O 0.999920129776001
the O O 0.9999359846115112
only O O 0.9999105930328369
factors O O 0.9999672174453735
associated O O 0.9999717473983765
with O O 0.999976634979248
current O O 0.9999735355377197
psychosis O O 0.9999634027481079
. O O 0.9999570846557617

CONCLUSION O O 0.9986739158630371
: O O 0.9999343156814575
There O O 0.9999516010284424
was O O 0.9999707937240601
a O O 0.9999783039093018
high O O 0.9999701976776123
risk O O 0.9999966621398926
of O O 0.9999707937240601
psychosis O O 0.999854326248169
in O O 0.9999388456344604
patients O O 0.9999873638153076
with O O 0.9999279975891113
methamphetamine B B 0.9989853501319885
dependence O O 0.9966300129890442
. O O 0.9999639987945557

It O O 0.9999423027038574
was O O 0.9999208450317383
associated O O 0.999966025352478
with O O 0.9999337196350098
co O O 0.9228452444076538
- O O 0.9986398816108704
morbid O O 0.9999650716781616
affective O O 0.9975122213363647
disorder O O 0.9999781847000122
, O O 0.9998941421508789
antisocial O O 0.9706769585609436
personality O O 0.9999500513076782
, O O 0.9994731545448303
and O O 0.9997401833534241
heavy O O 0.9960100650787354
methamphetamine B B 0.9977174997329712
use O O 0.9993610978126526
. O O 0.9999462366104126

It O O 0.9999904632568359
is O O 0.9999834299087524
recommended O O 0.9999939203262329
that O O 0.9999829530715942
all O O 0.9999518394470215
cases O O 0.9999634027481079
of O O 0.9998418092727661
methamphetamine B B 0.9982584118843079
dependence O O 0.993643045425415
should O O 0.9999794960021973
be O O 0.9999946355819702
screened O O 0.9999442100524902
for O O 0.9999408721923828
psychotic O O 0.9998742341995239
symptoms O O 0.9999924898147583
. O O 0.9999805688858032

Cerebellar O O 0.9882069230079651
sensory O O 0.9987255930900574
processing O O 0.999911904335022
alterations O O 0.999942421913147
impact O O 0.9650542736053467
motor O O 0.9989504218101501
cortical O O 0.999523401260376
plasticity O O 0.9999725818634033
in O O 0.9999463558197021
Parkinson O O 0.9934501647949219
' O O 0.9999850988388062
s O O 0.999972939491272
disease O O 0.9999809265136719
: O O 0.9999080896377563
clues O O 0.9997171759605408
from O O 0.9999703168869019
dyskinetic O O 0.9999003410339355
patients O O 0.9999431371688843
. O O 0.9999574422836304

The O O 0.9999517202377319
plasticity O O 0.9998810291290283
of O O 0.9998070597648621
primary O O 0.8683534860610962
motor O O 0.999235987663269
cortex O O 0.9999810457229614
( O O 0.9993093013763428
M1 O O 0.9968618154525757
) O O 0.9999125003814697
in O O 0.9999310970306396
patients O O 0.9999841451644897
with O O 0.999969482421875
Parkinson O O 0.9991483688354492
' O O 0.9999887943267822
s O O 0.9999849796295166
disease O O 0.999993085861206
( O O 0.9997614026069641
PD O O 0.9839986562728882
) O O 0.9999083280563354
and O O 0.9998617172241211
levodopa B B 0.999085545539856
- O O 0.9994871616363525
induced O O 0.9998421669006348
dyskinesias O O 0.9999783039093018
( O O 0.9998315572738647
LIDs O O 0.9976567029953003
) O O 0.9999568462371826
is O O 0.9999542236328125
severely O O 0.9999629259109497
impaired O O 0.9999825954437256
. O O 0.9999804496765137

We O O 0.999977707862854
recently O O 0.9999904632568359
reported O O 0.999997615814209
in O O 0.9999940395355225
young O O 0.999995231628418
healthy O O 0.9999887943267822
subjects O O 0.9999972581863403
that O O 0.9998792409896851
inhibitory O O 0.9957675933837891
cerebellar O O 0.9992178678512573
stimulation O O 0.9998472929000854
enhanced O O 0.9997116923332214
the O O 0.9999469518661499
sensorimotor O O 0.9999935626983643
plasticity O O 0.9999892711639404
of O O 0.9998863935470581
M1 O O 0.9982482194900513
that O O 0.9999485015869141
was O O 0.9999754428863525
induced O O 0.9999866485595703
by O O 0.999885082244873
paired O O 0.9976430535316467
associative O O 0.9994072914123535
stimulation O O 0.9998089671134949
( O O 0.9993963241577148
PAS O O 0.48670846223831177
) O O 0.9997923970222473
. O O 0.9999494552612305

This O O 0.9999732971191406
study O O 0.9999818801879883
demonstrates O O 0.9999523162841797
that O O 0.9999363422393799
the O O 0.9999839067459106
deficient O O 0.9999657869338989
sensorimotor O O 0.9999734163284302
M1 O O 0.9989432692527771
plasticity O O 0.9999618530273438
in O O 0.999924898147583
16 O O 0.999871015548706
patients O O 0.9999926090240479
with O O 0.9998729228973389
LIDs O O 0.7583274245262146
could O O 0.9998719692230225
be O O 0.9999817609786987
reinstated O O 0.9999662637710571
by O O 0.9999655485153198
a O O 0.9999706745147705
single O O 0.999975323677063
session O O 0.9999681711196899
of O O 0.9998824596405029
real O O 0.9958481788635254
inhibitory O O 0.998759388923645
cerebellar O O 0.9994914531707764
stimulation O O 0.9999344348907471
but O O 0.9999712705612183
not O O 0.9999598264694214
sham O O 0.9999425411224365
stimulation O O 0.99996018409729
. O O 0.9999649524688721

This O O 0.9999535083770752
was O O 0.9999551773071289
evident O O 0.9999775886535645
only O O 0.9999610185623169
when O O 0.999864935874939
a O O 0.9993187189102173
sensory O O 0.9990715980529785
component O O 0.9999055862426758
was O O 0.9998908042907715
involved O O 0.9998959302902222
in O O 0.9999151229858398
the O O 0.9999535083770752
induction O O 0.9999864101409912
of O O 0.9999369382858276
plasticity O O 0.9999746084213257
, O O 0.9999635219573975
indicating O O 0.9998171925544739
that O O 0.9996028542518616
cerebellar O O 0.9877312779426575
sensory O O 0.9986843466758728
processing O O 0.9999063014984131
function O O 0.9998816251754761
is O O 0.999828577041626
involved O O 0.9998639822006226
in O O 0.9999502897262573
the O O 0.999974250793457
resurgence O O 0.9999880790710449
of O O 0.9999256134033203
M1 O O 0.994379460811615
plasticity O O 0.9999619722366333
. O O 0.9999744892120361

The O O 0.9999661445617676
benefit O O 0.9999521970748901
of O O 0.9999003410339355
inhibitory O O 0.9970698356628418
cerebellar O O 0.9994415640830994
stimulation O O 0.9998444318771362
on O O 0.9985517859458923
LIDs O O 0.7900906205177307
is O O 0.9999089241027832
known O O 0.9998785257339478
. O O 0.9999549388885498

To O O 0.9999886751174927
explore O O 0.9999887943267822
whether O O 0.9999765157699585
this O O 0.9999747276306152
benefit O O 0.9999794960021973
is O O 0.9999828338623047
linked O O 0.999988317489624
to O O 0.9999730587005615
the O O 0.9999778270721436
restoration O O 0.9999783039093018
of O O 0.9999620914459229
sensorimotor O O 0.9999825954437256
plasticity O O 0.9999808073043823
of O O 0.9998236298561096
M1 O O 0.9970619082450867
, O O 0.9999754428863525
we O O 0.9999781847000122
conducted O O 0.9999967813491821
an O O 0.9999955892562866
additional O O 0.9999891519546509
study O O 0.9999935626983643
looking O O 0.999987006187439
at O O 0.9999581575393677
changes O O 0.9999922513961792
in O O 0.9999488592147827
LIDs O O 0.9885998964309692
and O O 0.9997636675834656
PAS O O 0.7389896512031555
- O O 0.9950262904167175
induced O O 0.9998086094856262
plasticity O O 0.9999657869338989
after O O 0.9999179840087891
10 O O 0.9999003410339355
sessions O O 0.9999897480010986
of O O 0.9998974800109863
either O O 0.9997852444648743
bilateral O O 0.9994308352470398
, O O 0.9996731281280518
real O O 0.9911375045776367
inhibitory O O 0.9994751811027527
cerebellar O O 0.9997982382774353
stimulation O O 0.9999387264251709
or O O 0.9999221563339233
sham O O 0.9999622106552124
stimulation O O 0.9999711513519287
. O O 0.9999287128448486

Only O O 0.9998162388801575
real O O 0.9989249110221863
and O O 0.9999425411224365
not O O 0.9996635913848877
sham O O 0.9997654557228088
stimulation O O 0.9998981952667236
had O O 0.999931812286377
an O O 0.9998841285705566
antidyskinetic O O 0.9696001410484314
effect O O 0.9999203681945801
and O O 0.999932050704956
it O O 0.9999510049819946
was O O 0.9999616146087646
paralleled O O 0.9999920129776001
by O O 0.9999898672103882
a O O 0.9999760389328003
resurgence O O 0.9999947547912598
in O O 0.9999672174453735
the O O 0.9999439716339111
sensorimotor O O 0.9999905824661255
plasticity O O 0.9999833106994629
of O O 0.9999202489852905
M1 O O 0.9985009431838989
. O O 0.999834418296814

These O O 0.99997878074646
results O O 0.9999887943267822
suggest O O 0.9999595880508423
that O O 0.9999037981033325
alterations O O 0.9999910593032837
in O O 0.9999340772628784
cerebellar O O 0.9988402724266052
sensory O O 0.9993502497673035
processing O O 0.9999532699584961
function O O 0.9999750852584839
, O O 0.9999754428863525
occurring O O 0.999981164932251
secondary O O 0.9999836683273315
to O O 0.9998713731765747
abnormal O O 0.9998944997787476
basal O O 0.9997753500938416
ganglia O O 0.9999659061431885
signals O O 0.9999197721481323
reaching O O 0.953741192817688
it O O 0.9997480511665344
, O O 0.9999599456787109
may O O 0.9998520612716675
be O O 0.9998748302459717
an O O 0.9998121857643127
important O O 0.9996838569641113
element O O 0.9999772310256958
contributing O O 0.9999582767486572
to O O 0.9999591112136841
the O O 0.9999688863754272
maladaptive O O 0.9999754428863525
sensorimotor O O 0.9999872446060181
plasticity O O 0.9999855756759644
of O O 0.9995954632759094
M1 O O 0.9945906400680542
and O O 0.9999486207962036
the O O 0.9999874830245972
emergence O O 0.9999921321868896
of O O 0.9999790191650391
abnormal O O 0.9999630451202393
involuntary O O 0.9999476671218872
movements O O 0.9999905824661255
. O O 0.9999418258666992

The O O 0.9999462366104126
long O O 0.9998522996902466
- O O 0.9999886751174927
term O O 0.999972939491272
safety O O 0.9999909400939941
of O O 0.9990957975387573
danazol B B 0.9991426467895508
in O O 0.9998544454574585
women O O 0.999996542930603
with O O 0.9999854564666748
hereditary O O 0.9998185038566589
angioedema O O 0.9978127479553223
. O O 0.9999537467956543

Although O O 0.9999723434448242
the O O 0.9999808073043823
short O O 0.9999128580093384
- O O 0.9999794960021973
term O O 0.999974250793457
safety O O 0.9999912977218628
( O O 0.9999772310256958
less O O 0.9999957084655762
than O O 0.9999938011169434
or O O 0.9999958276748657
equal O O 0.9999977350234985
to O O 0.9999970197677612
6 O O 0.9999945163726807
months O O 0.9999986886978149
) O O 0.9999912977218628
of O O 0.9995064735412598
danazol B B 0.999091625213623
has O O 0.9999051094055176
been O O 0.9999942779541016
established O O 0.9999853372573853
in O O 0.9999431371688843
a O O 0.9999840259552002
variety O O 0.9999909400939941
of O O 0.999943733215332
settings O O 0.999894380569458
, O O 0.9999774694442749
no O O 0.9999946355819702
information O O 0.9999915361404419
exists O O 0.9999886751174927
as O O 0.999998927116394
to O O 0.9999945163726807
its O O 0.9999456405639648
long O O 0.9998908042907715
- O O 0.9999903440475464
term O O 0.999969482421875
safety O O 0.9999904632568359
. O O 0.9999769926071167

We O O 0.9999772310256958
therefore O O 0.9999959468841553
investigated O O 0.9999852180480957
the O O 0.9999898672103882
long O O 0.9997472167015076
- O O 0.9999902248382568
term O O 0.9999905824661255
safety O O 0.9999973773956299
of O O 0.9997149109840393
danazol B B 0.9989848732948303
by O O 0.9999808073043823
performing O O 0.9999979734420776
a O O 0.999997615814209
retrospective O O 0.9999947547912598
chart O O 0.9999974966049194
review O O 0.9999973773956299
of O O 0.9999903440475464
60 O O 0.9999949932098389
female O O 0.9999969005584717
patients O O 0.9999940395355225
with O O 0.9999829530715942
hereditary O O 0.9838825464248657
angioedema O O 0.9986787438392639
treated O O 0.9999717473983765
with O O 0.9997110962867737
danazol B B 0.999233603477478
for O O 0.9998440742492676
a O O 0.9999812841415405
continuous O O 0.9999808073043823
period O O 0.9999935626983643
of O O 0.9999802112579346
6 O O 0.9999696016311646
months O O 0.9999969005584717
or O O 0.9999947547912598
longer O O 0.9999914169311523
. O O 0.9999786615371704

The O O 0.9999880790710449
mean O O 0.9999903440475464
age O O 0.9999865293502808
of O O 0.9999915361404419
the O O 0.9999904632568359
patients O O 0.9999953508377075
was O O 0.9999892711639404
35 O O 0.9999972581863403
. O O 0.9999979734420776
2 O O 0.9999964237213135
years O O 0.999997615814209
and O O 0.999977707862854
the O O 0.9999964237213135
mean O O 0.9999849796295166
duration O O 0.9999910593032837
of O O 0.9999562501907349
therapy O O 0.999969482421875
was O O 0.9999845027923584
59 O O 0.9999985694885254
. O O 0.9999983310699463
7 O O 0.9999973773956299
months O O 0.9999985694885254
. O O 0.9999865293502808

Virtually O O 0.9998970031738281
all O O 0.9999158382415771
patients O O 0.999964714050293
experienced O O 0.9999465942382812
one O O 0.999957799911499
or O O 0.9999817609786987
more O O 0.9999560117721558
adverse O O 0.9998528957366943
reactions O O 0.9999808073043823
. O O 0.99994957447052

Menstrual O O 0.9993388056755066
abnormalities O O 0.9998488426208496
( O O 0.9998815059661865
79 O O 0.9995539784431458
% O O 0.9999918937683105
) O O 0.9999493360519409
, O O 0.9999620914459229
weight O O 0.9999822378158569
gain O O 0.9999839067459106
( O O 0.9999697208404541
60 O O 0.9999964237213135
% O O 0.9999953508377075
) O O 0.9999538660049438
, O O 0.9999517202377319
muscle O O 0.9998644590377808
cramps O O 0.99828040599823
/ O O 0.9997827410697937
myalgias O O 0.9999983310699463
( O O 0.9999289512634277
40 O O 0.9999756813049316
% O O 0.9999749660491943
) O O 0.9999128580093384
, O O 0.9997801184654236
and O O 0.9997511506080627
transaminase O O 0.6720349192619324
elevations O O 0.9947209358215332
( O O 0.9998205304145813
40 O O 0.9999339580535889
% O O 0.999954104423523
) O O 0.9999239444732666
were O O 0.999950647354126
the O O 0.9999716281890869
most O O 0.9999895095825195
common O O 0.999988317489624
adverse O O 0.9999016523361206
reactions O O 0.9999954700469971
. O O 0.9999566078186035

The O O 0.9999518394470215
drug O O 0.9957096576690674
was O O 0.9998925924301147
discontinued O O 0.9998893737792969
due O O 0.9999856948852539
to O O 0.999987006187439
adverse O O 0.9999707937240601
reactions O O 0.9999958276748657
in O O 0.999968409538269
8 O O 0.9993457198143005
patients O O 0.999991774559021
. O O 0.999970555305481

No O O 0.9998518228530884
patient O O 0.9999773502349854
has O O 0.9999706745147705
died O O 0.9999878406524658
or O O 0.9999872446060181
suffered O O 0.999955415725708
any O O 0.9999780654907227
apparent O O 0.9999880790710449
long O O 0.9996718168258667
- O O 0.9999827146530151
term O O 0.9999899864196777
sequelae O O 0.9999916553497314
that O O 0.9999707937240601
were O O 0.9999922513961792
directly O O 0.9999927282333374
attributable O O 0.9999953508377075
to O O 0.9998149275779724
the O O 0.9997338652610779
drug O O 0.9969919919967651
. O O 0.9999146461486816

We O O 0.999942421913147
conclude O O 0.9999806880950928
that O O 0.9999533891677856
, O O 0.9999830722808838
despite O O 0.9999712705612183
a O O 0.9999809265136719
relatively O O 0.9999910593032837
high O O 0.9999896287918091
incidence O O 0.9999958276748657
of O O 0.999967098236084
adverse O O 0.9999278783798218
reactions O O 0.9999961853027344
, O O 0.9997071623802185
danazol B B 0.9993664622306824
has O O 0.9998995065689087
proven O O 0.9999852180480957
to O O 0.9999567270278931
be O O 0.9999587535858154
remarkably O O 0.9999675750732422
safe O O 0.9999432563781738
over O O 0.9999624490737915
the O O 0.9999887943267822
long O O 0.9998683929443359
- O O 0.9999845027923584
term O O 0.9999856948852539
in O O 0.9999783039093018
this O O 0.999983549118042
group O O 0.9999914169311523
of O O 0.9999828338623047
patients O O 0.9999926090240479
. O O 0.9999773502349854

The O O 0.9999289512634277
function O O 0.9999284744262695
of O O 0.9994218349456787
P2X3 O O 0.6022303700447083
receptor O O 0.9788861870765686
and O O 0.9868378043174744
NK1 O O 0.5049598813056946
receptor O O 0.9901556968688965
antagonists O O 0.8323603868484497
on O O 0.9997519850730896
cyclophosphamide B B 0.998992383480072
- O O 0.9995666146278381
induced O O 0.9999409914016724
cystitis O O 0.9966694712638855
in O O 0.9998906850814819
rats O O 0.9998962879180908
. O O 0.9999622106552124

PURPOSE O O 0.9999654293060303
: O O 0.9999966621398926
The O O 0.999997615814209
purpose O O 0.9999974966049194
of O O 0.9999969005584717
the O O 0.9999966621398926
study O O 0.9999878406524658
is O O 0.9999933242797852
to O O 0.9999942779541016
explore O O 0.9999589920043945
the O O 0.9999686479568481
function O O 0.9999544620513916
of O O 0.9996935129165649
P2X3 O O 0.7923694252967834
and O O 0.9861215949058533
NK1 O O 0.49793604016304016
receptors O O 0.965034544467926
antagonists O O 0.8230372667312622
on O O 0.9996963739395142
cyclophosphamide B B 0.9986818432807922
( O O 0.9825448393821716
CYP B B 0.9967543482780457
) O O 0.9673216938972473
- O O 0.9998151659965515
induced O O 0.9999629259109497
cystitis O O 0.9987832903862
in O O 0.9999181032180786
rats O O 0.9999353885650635
. O O 0.9999822378158569

METHODS O O 0.9999487400054932
: O O 0.9999974966049194
Sixty O O 0.99998939037323
female O O 0.9999966621398926
Sprague O O 0.9893177151679993
- O O 0.999360978603363
Dawley O O 0.9979084730148315
( O O 0.9996918439865112
SD O O 0.7790637612342834
) O O 0.9999127388000488
rats O O 0.9999831914901733
were O O 0.9999872446060181
randomly O O 0.9999868869781494
divided O O 0.9999908208847046
into O O 0.9999668598175049
three O O 0.9999103546142578
groups O O 0.9999902248382568
. O O 0.9999808073043823

The O O 0.9999809265136719
rats O O 0.9999957084655762
in O O 0.9999549388885498
the O O 0.9999572038650513
control O O 0.9999502897262573
group O O 0.9999874830245972
were O O 0.999968409538269
intraperitoneally O O 0.9999929666519165
( O O 0.999822199344635
i O O 0.9999597072601318
. O O 0.9999949932098389
p O O 0.9999986886978149
. O O 0.9999985694885254
) O O 0.9999737739562988
injected O O 0.9999873638153076
with O O 0.9999409914016724
0 O O 0.9984291195869446
. O O 0.9999922513961792
9 O O 0.9999454021453857
% O O 0.9998120665550232
saline O O 0.4827437400817871
( O O 0.9998165965080261
4 O O 0.9995174407958984
ml O O 0.9999938011169434
/ O O 0.9999023675918579
kg O O 0.9999845027923584
) O O 0.9999727010726929
; O O 0.9999010562896729
the O O 0.9999940395355225
rats O O 0.9999966621398926
in O O 0.9999619722366333
the O O 0.9999562501907349
model O O 0.9999068975448608
group O O 0.9999732971191406
were O O 0.9999740123748779
i O O 0.9999521970748901
. O O 0.999994158744812
p O O 0.9999973773956299
. O O 0.999994158744812
injected O O 0.9999663829803467
with O O 0.999665379524231
CYP B B 0.9949559569358826
( O O 0.9993414282798767
150 O O 0.9991875290870667
mg O O 0.9999814033508301
/ O O 0.9999688863754272
kg O O 0.9999872446060181
) O O 0.9999783039093018
; O O 0.9999574422836304
and O O 0.9999798536300659
the O O 0.9999901056289673
rats O O 0.9999960660934448
in O O 0.9999576807022095
the O O 0.9999656677246094
intervention O O 0.9994631409645081
group O O 0.9999865293502808
were O O 0.9999710321426392
i O O 0.9999576807022095
. O O 0.9999954700469971
p O O 0.999996542930603
. O O 0.9999954700469971
injected O O 0.9999635219573975
with O O 0.9996566772460938
CYP B B 0.9820866584777832
with O O 0.9995182752609253
subsequently O O 0.8804444670677185
perfusion O O 0.9993636012077332
of O O 0.9997484087944031
bladder O O 0.8619388937950134
with O O 0.9988120794296265
P2X3 O O 0.8357647061347961
and O O 0.9906689524650574
NK1 O O 0.5994896292686462
receptors O O 0.9692524671554565
' O O 0.9931362867355347
antagonists O O 0.9752341508865356
, O O 0.9954279661178589
Suramin B B 0.9851806163787842
and O O 0.9471349716186523
GR B B 0.9282939434051514
82334 I I 0.999845027923584
. O O 0.9998410940170288

Spontaneous O O 0.9997703433036804
pain O O 0.999884843826294
behaviors O O 0.9999727010726929
following O O 0.999904990196228
the O O 0.9999780654907227
administration O O 0.9998579025268555
of O O 0.9996646642684937
CYP B B 0.9946053624153137
were O O 0.9997406601905823
observed O O 0.9999666213989258
. O O 0.9999655485153198

Urodynamic O O 0.9998867511749268
parameters O O 0.9999802112579346
, O O 0.999969482421875
bladder O O 0.9996809959411621
pressure O O 0.9961696267127991
- O O 0.999264657497406
volume O O 0.9987597465515137
curve O O 0.9999381303787231
, O O 0.9999573230743408
maximum O O 0.9998351335525513
voiding O O 0.999984860420227
pressure O O 0.9999570846557617
( O O 0.9999083280563354
MVP O O 0.998664140701294
) O O 0.9999685287475586
, O O 0.9999227523803711
and O O 0.9999337196350098
maximum O O 0.9996947050094604
cystometric O O 0.9923356175422668
capacity O O 0.9999840259552002
( O O 0.9999181032180786
MCC O O 0.9999402761459351
) O O 0.9999769926071167
, O O 0.9999679327011108
were O O 0.9999725818634033
recorded O O 0.9999878406524658
. O O 0.9999643564224243

Pathological O O 0.9998753070831299
changes O O 0.9999946355819702
in O O 0.9999376535415649
bladder O O 0.9950907230377197
tissue O O 0.9999924898147583
were O O 0.9999527931213379
observed O O 0.9999732971191406
. O O 0.9999421834945679

Immunofluorescence O O 0.9994358420372009
was O O 0.9999490976333618
used O O 0.999971866607666
to O O 0.9999775886535645
detect O O 0.9999376535415649
the O O 0.9999111890792847
expression O O 0.9999122619628906
of O O 0.9985003471374512
P2X3 O O 0.8450291752815247
and O O 0.9960259199142456
NK1 O O 0.653008222579956
receptors O O 0.998471200466156
in O O 0.999671459197998
bladder O O 0.9905821084976196
. O O 0.9999316930770874

RESULTS O O 0.9994920492172241
: O O 0.9985867738723755
Cyclophosphamide B B 0.9997066855430603
treatment O O 0.9997026324272156
increased O O 0.9998413324356079
the O O 0.9999877214431763
spontaneous O O 0.9998583793640137
pain O O 0.9996181726455688
behaviors O O 0.9999005794525146
scores O O 0.9999790191650391
. O O 0.9999704360961914

The O O 0.9999885559082031
incidence O O 0.9999949932098389
of O O 0.9999884366989136
bladder O O 0.9999737739562988
instability O O 0.999992847442627
during O O 0.9997981190681458
urine O O 0.9978269934654236
storage O O 0.9998219609260559
period O O 0.9998406171798706
of O O 0.9996377229690552
model O B 0.8938168883323669
group O O 0.9894905686378479
was O O 0.9999358654022217
significantly O O 0.9999761581420898
higher O O 0.9999240636825562
than O O 0.9995889067649841
intervention O O 0.9980214834213257
group O O 0.9998852014541626
( O O 0.9999035596847534
X O O 0.9990022778511047
( O O 0.9976353645324707
2 O O 0.9936195015907288
) O O 0.9997352957725525
= O O 0.9993948936462402
7 O O 0.9998979568481445
. O O 0.9999501705169678
619 O O 0.9999948740005493
, O O 0.9999629259109497
P O O 0.9998038411140442
= O O 0.9999079704284668
0 O O 0.9999884366989136
. O O 0.9999949932098389
007 O O 0.999985933303833
) O O 0.9999388456344604
and O O 0.9993845224380493
control O O 0.999415397644043
group O O 0.9999476671218872
( O O 0.9998806715011597
X O O 0.9992208480834961
( O O 0.9955270886421204
2 O O 0.9900588393211365
) O O 0.9995785355567932
= O O 0.9989050626754761
13 O O 0.9998260140419006
. O O 0.9999737739562988
755 O O 0.999963641166687
, O O 0.9999536275863647
P O O 0.9997829794883728
= O O 0.9999622106552124
0 O O 0.9999904632568359
. O O 0.9999929666519165
000 O O 0.9999969005584717
) O O 0.999966025352478
. O O 0.9999761581420898

MCC O O 0.9306999444961548
in O O 0.9997119307518005
the O O 0.9998354911804199
model O O 0.9996145963668823
group O O 0.9998964071273804
was O O 0.9999446868896484
lower O O 0.999941349029541
than O O 0.999901294708252
the O O 0.9998862743377686
control O O 0.9997525811195374
and O O 0.9998124241828918
intervention O O 0.9996658563613892
groups O O 0.9999016523361206
( O O 0.9999309778213501
P O O 0.9997790455818176
< O O 0.9999498128890991
0 O O 0.9999814033508301
. O O 0.9999953508377075
01 O O 0.9999940395355225
) O O 0.999958872795105
. O O 0.9999737739562988

Histological O O 0.9998694658279419
changes O O 0.999990701675415
evident O O 0.9999527931213379
in O O 0.9997683167457581
model O O 0.9998100399971008
and O O 0.9993168115615845
intervention O O 0.9943576455116272
groups O O 0.9998074173927307
rats O O 0.9999735355377197
' O O 0.9999724626541138
bladder O O 0.9997630715370178
included O O 0.9998130202293396
edema O O 0.9998652935028076
, O O 0.9998007416725159
vasodilation O O 0.998547375202179
, O O 0.9996676445007324
and O O 0.9996758699417114
infiltration O O 0.9996565580368042
of O O 0.9998205304145813
inflammatory O O 0.9998910427093506
cells O O 0.9999942779541016
. O O 0.9999498128890991

In O O 0.999115526676178
model O O 0.9954665899276733
group O O 0.9999313354492188
, O O 0.9999167919158936
the O O 0.9999498128890991
expression O O 0.9999011754989624
of O O 0.9948585033416748
P2X3 O O 0.665427565574646
receptor O O 0.9967177510261536
increased O O 0.9996235370635986
in O O 0.9997372031211853
urothelium O O 0.9999253749847412
and O O 0.9998524188995361
suburothelium O O 0.9989005327224731
, O O 0.9997832179069519
and O O 0.9981726408004761
NK1 O O 0.5058956742286682
receptor O O 0.9975581169128418
increased O O 0.9997114539146423
in O O 0.9995415210723877
suburothelium O O 0.9937700629234314
, O O 0.9999489784240723
while O O 0.9999521970748901
the O O 0.9999561309814453
expression O O 0.9998676776885986
of O O 0.9952118396759033
them O O 0.9922034740447998
in O O 0.9993941783905029
intervention O O 0.9893146753311157
group O O 0.9998455047607422
was O O 0.9999656677246094
lower O O 0.9999476671218872
. O O 0.9999693632125854

CONCLUSIONS O O 0.9908925294876099
: O O 0.999967098236084
In O O 0.9998311996459961
CYP B B 0.9439641237258911
- O O 0.9973189234733582
induced O O 0.9999114274978638
cystitis O O 0.9991945624351501
, O O 0.9999444484710693
the O O 0.9999788999557495
expression O O 0.9999511241912842
of O O 0.9970648884773254
P2X3 O O 0.9789092540740967
and O O 0.9981023669242859
NK1 O O 0.7125098705291748
receptors O O 0.9974164962768555
increased O O 0.999748170375824
in O O 0.9995437264442444
urothelium O O 0.9999403953552246
and O O 0.9999183416366577
/ O O 0.9998464584350586
or O O 0.9999521970748901
suburothelium O O 0.9997838139533997
. O O 0.9999711513519287

Perfusion O O 0.9992850422859192
of O O 0.9995275735855103
bladder O O 0.9599341154098511
with O O 0.9996470212936401
P2X3 O O 0.4972882866859436
and O O 0.9968121647834778
NK1 O O 0.5583757162094116
receptors O O 0.9448941946029663
antagonists O O 0.9015868902206421
ameliorated O O 0.999887228012085
the O O 0.9999843835830688
bladder O O 0.9997710585594177
function O O 0.9999946355819702
. O O 0.9999574422836304

Patient O O 0.999500036239624
tolerance O O 0.99997878074646
study O O 0.999969482421875
of O O 0.9989269375801086
topical O O 0.9979848861694336
chlorhexidine B B 0.9989013671875
diphosphanilate I I 0.9986974596977234
: O O 0.9998635053634644
a O O 0.9999711513519287
new O O 0.9999709129333496
topical O O 0.9999672174453735
agent O O 0.9988992214202881
for O O 0.999747097492218
burns O O 0.8811832666397095
. O O 0.999853253364563

Effective O O 0.9825001358985901
topical O O 0.9998070597648621
antimicrobial O O 0.5053672790527344
agents O O 0.9483734965324402
decrease O O 0.9997182488441467
infection O O 0.9999867677688599
and O O 0.9999819993972778
mortality O O 0.9999961853027344
in O O 0.9999610185623169
burn O O 0.9873817563056946
patients O O 0.9999815225601196
. O O 0.9999475479125977

Chlorhexidine B B 0.9973351359367371
phosphanilate I I 0.9980040192604065
( O O 0.9878195524215698
CHP B B 0.9630337953567505
) O O 0.9676306843757629
, O O 0.9999641180038452
a O O 0.9998914003372192
new O O 0.999875545501709
broad O O 0.9886896014213562
- O O 0.9999605417251587
spectrum O O 0.9950002431869507
antimicrobial O O 0.778806209564209
agent O O 0.9560449719429016
, O O 0.9999517202377319
has O O 0.9999563694000244
been O O 0.9999922513961792
evaluated O O 0.999980092048645
as O O 0.9999490976333618
a O O 0.9999071359634399
topical O O 0.9999822378158569
burn O O 0.9998251795768738
wound O O 0.9999899864196777
dressing O O 0.9999743700027466
in O O 0.9998006224632263
cream O O 0.957531750202179
form O O 0.9999676942825317
, O O 0.9999587535858154
but O O 0.9999774694442749
preliminary O O 0.9999963045120239
clinical O O 0.9999958276748657
trials O O 0.9999978542327881
reported O O 0.9999979734420776
that O O 0.9999853372573853
it O O 0.999981164932251
was O O 0.9999793767929077
painful O O 0.9999829530715942
upon O O 0.9999561309814453
application O O 0.9999898672103882
. O O 0.9999755620956421

This O O 0.9999786615371704
study O O 0.9999722242355347
compared O O 0.9998888969421387
various O O 0.9999188184738159
concentrations O O 0.9960346817970276
of O O 0.9940616488456726
CHP B B 0.9667374491691589
to O O 0.9999328851699829
determine O O 0.9999972581863403
if O O 0.9999972581863403
a O O 0.9999831914901733
tolerable O O 0.9999934434890747
concentration O O 0.9997285008430481
could O O 0.9999822378158569
be O O 0.9999946355819702
identified O O 0.9999895095825195
with O O 0.9999552965164185
retention O O 0.9999608993530273
of O O 0.9998987913131714
antimicrobial O O 0.8515001535415649
efficacy O O 0.9998699426651001
. O O 0.9999443292617798

Twenty O O 0.9988632202148438
- O O 0.9999305009841919
nine O O 0.9999344348907471
burn O O 0.9997661709785461
patients O O 0.9999879598617554
, O O 0.999981164932251
each O O 0.9999603033065796
with O O 0.9999816417694092
two O O 0.9999622106552124
similar O O 0.9999871253967285
burns O O 0.999962329864502
which O O 0.9999407529830933
could O O 0.9999582767486572
be O O 0.9999939203262329
separately O O 0.9999279975891113
treated O O 0.9999591112136841
, O O 0.9999830722808838
were O O 0.9999669790267944
given O O 0.9999802112579346
pairs O O 0.9999430179595947
of O O 0.9997277855873108
treatments O O 0.9999279975891113
at O O 0.9999107122421265
successive O O 0.9998732805252075
12 O O 0.9999680519104004
- O O 0.9999791383743286
h O O 0.9923495054244995
intervals O O 0.9999425411224365
over O O 0.9999605417251587
a O O 0.9999871253967285
3 O O 0.9999270439147949
- O O 0.9999886751174927
day O O 0.9999943971633911
period O O 0.9999933242797852
. O O 0.9999740123748779

One O O 0.999923825263977
burn O O 0.999951958656311
site O O 0.9999911785125732
was O O 0.9999599456787109
treated O O 0.9999761581420898
with O O 0.999744713306427
each O O 0.9989957213401794
of O O 0.9994833469390869
four O O 0.9991142153739929
different O O 0.9994717240333557
CHP B O 0.5336627960205078
concentrations O O 0.8043904304504395
, O O 0.9999599456787109
from O O 0.9999275207519531
0 O O 0.9998908042907715
. O O 0.9999922513961792
25 O O 0.9999785423278809
per O O 0.9999651908874512
cent O O 0.9995297193527222
to O O 0.9997817873954773
2 O O 0.9997569918632507
per O O 0.9999651908874512
cent O O 0.9982830286026001
, O O 0.9990894794464111
their O O 0.9254571199417114
vehicle O O 0.9784741997718811
, O O 0.999861478805542
and O O 0.999568521976471
1 O O 0.9991812109947205
per O O 0.9997934699058533
cent O O 0.9964081645011902
silver B B 0.948148787021637
sulphadiazine I I 0.8717196583747864
( O O 0.9724588394165039
AgSD B B 0.9721370935440063
) O O 0.810834527015686
cream O O 0.9837833046913147
, O O 0.999985933303833
an O O 0.9999450445175171
antimicrobial O O 0.5566269755363464
agent O O 0.9843778014183044
frequently O O 0.9999735355377197
used O O 0.9999405145645142
for O O 0.9999635219573975
topical O O 0.9999831914901733
treatment O O 0.9999852180480957
of O O 0.9999814033508301
burn O O 0.9998805522918701
wounds O O 0.9999971389770508
. O O 0.9999687671661377

The O O 0.9999234676361084
other O O 0.9999091625213623
site O O 0.9999608993530273
was O O 0.9999521970748901
always O O 0.9998823404312134
treated O O 0.9999725818634033
with O O 0.9998194575309753
AgSD B O 0.8440085053443909
cream O O 0.8428382277488708
. O O 0.9999511241912842

There O O 0.9999426603317261
was O O 0.9999122619628906
a O O 0.9999632835388184
direct O O 0.9999744892120361
relationship O O 0.999980092048645
between O O 0.9997290968894958
CHP B O 0.6544218063354492
concentration O O 0.7612371444702148
and O O 0.9998385906219482
patients O O 0.9999773502349854
' O O 0.9999967813491821
ratings O O 0.9999980926513672
of O O 0.9999889135360718
pain O O 0.999947190284729
on O O 0.9999895095825195
an O O 0.9999773502349854
analogue O O 0.9997867941856384
scale O O 0.9999911785125732
. O O 0.9999667406082153

The O O 0.9999090433120728
0 O O 0.9982115030288696
. O O 0.9998990297317505
25 O O 0.9996356964111328
per O O 0.9995561242103577
cent O O 0.9139208197593689
CHP B O 0.7981545925140381
cream O O 0.7033593058586121
was O O 0.9999508857727051
closest O O 0.9998002648353577
to O O 0.999650239944458
AgSD B O 0.7551603317260742
in O O 0.9997418522834778
pain O O 0.9999481439590454
tolerance O O 0.9999607801437378
; O O 0.9999760389328003
however O O 0.9999860525131226
, O O 0.9999833106994629
none O O 0.999984622001648
of O O 0.9999445676803589
the O O 0.9999279975891113
treatments O O 0.9999376535415649
differed O O 0.9999781847000122
statistically O O 0.9999759197235107
from O O 0.9999061822891235
AgSD B O 0.8397273421287537
or O O 0.9999397993087769
from O O 0.9999451637268066
each O O 0.9999690055847168
other O O 0.9999535083770752
. O O 0.9999600648880005

In O O 0.9998570680618286
addition O O 0.9999878406524658
, O O 0.999954342842102
ease O O 0.999980092048645
of O O 0.9999808073043823
application O O 0.9999682903289795
of O O 0.9996300935745239
CHP B O 0.7038049101829529
creams O O 0.5390498042106628
was O O 0.9999327659606934
less O O 0.9999803304672241
satisfactory O O 0.9999912977218628
than O O 0.9999489784240723
that O O 0.999982476234436
of O O 0.999681830406189
AgSD B B 0.933847963809967
. O O 0.9998959302902222

It O O 0.9999896287918091
was O O 0.999990701675415
concluded O O 0.9999929666519165
that O O 0.9999082088470459
formulations O O 0.9993665814399719
at O O 0.9998857975006104
or O O 0.9999743700027466
below O O 0.9999761581420898
0 O O 0.9999253749847412
. O O 0.9999887943267822
5 O O 0.9999581575393677
per O O 0.9999885559082031
cent O O 0.9995881915092468
CHP B O 0.6204053163528442
may O O 0.9999504089355469
prove O O 0.9999868869781494
acceptable O O 0.9999393224716187
for O O 0.9999366998672485
wound O O 0.9999854564666748
care O O 0.9999905824661255
, O O 0.9999687671661377
but O O 0.9999668598175049
the O O 0.9999481439590454
vehicle O O 0.9858407974243164
system O O 0.9999402761459351
needs O O 0.9999226331710815
pharmaceutical O O 0.9997603297233582
improvement O O 0.9999665021896362
to O O 0.9999781847000122
render O O 0.9999854564666748
it O O 0.9999836683273315
more O O 0.9999539852142334
tolerable O O 0.9999949932098389
and O O 0.9999923706054688
easier O O 0.9999850988388062
to O O 0.9999943971633911
use O O 0.9999908208847046
. O O 0.9999736547470093

Acute O O 0.9997872710227966
hepatitis O O 0.9998419284820557
associated O O 0.9999536275863647
with O O 0.9996028542518616
clopidogrel B B 0.9986569881439209
: O O 0.9998806715011597
a O O 0.9999936819076538
case O O 0.9999903440475464
report O O 0.9999978542327881
and O O 0.9999920129776001
review O O 0.9999953508377075
of O O 0.9999943971633911
the O O 0.9999970197677612
literature O O 0.9999957084655762
. O O 0.9999786615371704

Drug O O 0.9570697546005249
- O O 0.9997313618659973
induced O O 0.9998828172683716
hepatotoxicity O O 0.9996984004974365
is O O 0.9999294281005859
a O O 0.9999423027038574
common O O 0.999942421913147
cause O O 0.9999868869781494
of O O 0.9999566078186035
acute O O 0.9999189376831055
hepatitis O O 0.9999078512191772
, O O 0.9999213218688965
and O O 0.9999889135360718
the O O 0.9999946355819702
recognition O O 0.9999947547912598
of O O 0.9999545812606812
the O O 0.9999552965164185
responsible O O 0.9999023675918579
drug O O 0.9988536834716797
may O O 0.9999666213989258
be O O 0.9999958276748657
difficult O O 0.9999951124191284
. O O 0.9999725818634033

We O O 0.999941349029541
describe O O 0.9999819993972778
a O O 0.999977707862854
case O O 0.99998939037323
of O O 0.9999250173568726
clopidogrel B B 0.9991621971130371
- O O 0.999221682548523
related O O 0.999861478805542
acute O O 0.9997667670249939
hepatitis O O 0.9999336004257202
. O O 0.9999754428863525

The O O 0.9999841451644897
diagnosis O O 0.999992847442627
is O O 0.9999874830245972
strongly O O 0.9999951124191284
suggested O O 0.9999973773956299
by O O 0.9999969005584717
an O O 0.9999938011169434
accurate O O 0.999994158744812
medical O O 0.9999971389770508
history O O 0.9999977350234985
and O O 0.9999849796295166
liver O O 0.9993407130241394
biopsy O O 0.999962568283081
. O O 0.9999784231185913

Reports O O 0.99998939037323
about O O 0.9999657869338989
cases O O 0.9999818801879883
of O O 0.9999434947967529
hepatotoxicity O O 0.9998257756233215
due O O 0.999970555305481
to O O 0.9945536851882935
clopidogrel B B 0.9970167875289917
are O O 0.9995773434638977
increasing O O 0.9999799728393555
in O O 0.9999959468841553
the O O 0.9999978542327881
last O O 0.999997615814209
few O O 0.9999984502792358
years O O 0.9999977350234985
, O O 0.9999940395355225
after O O 0.9999206066131592
the O O 0.9999896287918091
increased O O 0.9999756813049316
use O O 0.9998760223388672
of O O 0.9995481371879578
this O O 0.9964774250984192
drug O O 0.9947955012321472
. O O 0.9999445676803589

In O O 0.9999432563781738
conclusion O O 0.9999873638153076
, O O 0.999951958656311
we O O 0.9999611377716064
believe O O 0.9999634027481079
that O O 0.9998552799224854
physicians O O 0.9999843835830688
should O O 0.9999668598175049
carefully O O 0.9999908208847046
consider O O 0.9999825954437256
the O O 0.9999837875366211
risk O O 0.9999954700469971
of O O 0.9999641180038452
drug O O 0.9981802701950073
- O O 0.9998594522476196
induced O O 0.9999758005142212
hepatic O O 0.999977707862854
injury O O 0.9999963045120239
when O O 0.9998413324356079
clopidogrel B B 0.9993261098861694
is O O 0.9999042749404907
prescribed O O 0.9999139308929443
. O O 0.9999582767486572

Bortezomib B B 0.998976469039917
and O O 0.9521769881248474
dexamethasone B B 0.9994161128997803
as O O 0.9998966455459595
salvage O O 0.9989830851554871
therapy O O 0.999954104423523
in O O 0.999971866607666
patients O O 0.9999963045120239
with O O 0.9999904632568359
relapsed O O 0.9999873638153076
/ O O 0.9998797178268433
refractory O O 0.9999843835830688
multiple O O 0.9949542880058289
myeloma O O 0.9999806880950928
: O O 0.999987006187439
analysis O O 0.9999939203262329
of O O 0.9999955892562866
long O O 0.9999299049377441
- O O 0.9999916553497314
term O O 0.9999936819076538
clinical O O 0.999996542930603
outcomes O O 0.9999986886978149
. O O 0.9999901056289673

Bortezomib B B 0.9994478821754456
( O O 0.9807783365249634
bort B B 0.9932354092597961
) O O 0.5123944282531738
- O O 0.7879030704498291
dexamethasone B B 0.5833067893981934
( O O 0.9486861228942871
dex B B 0.9988382458686829
) O O 0.9936445951461792
is O O 0.9999134540557861
an O O 0.999537467956543
effective O O 0.9982594847679138
therapy O O 0.9999440908432007
for O O 0.999906063079834
relapsed O O 0.9998756647109985
/ O O 0.99950110912323
refractory O O 0.999488115310669
( O O 0.9996979236602783
R O O 0.998501181602478
/ O O 0.999909520149231
R O O 0.9992096424102783
) O O 0.9999130964279175
multiple O O 0.9932574033737183
myeloma O O 0.9999912977218628
( O O 0.9998507499694824
MM O O 0.9866982698440552
) O O 0.9999657869338989
. O O 0.9999542236328125

This O O 0.9999909400939941
retrospective O O 0.9999880790710449
study O O 0.9999953508377075
investigated O O 0.9999635219573975
the O O 0.9999747276306152
combination O O 0.9956845045089722
of O O 0.9932594895362854
bort B B 0.9985570311546326
( O O 0.9979044198989868
1 O O 0.9966283440589905
. O O 0.9999312162399292
3 O O 0.9986212253570557
mg O O 0.9997337460517883
/ O O 0.9985128045082092
m O O 0.9995772242546082
( O O 0.999496579170227
2 O O 0.9627779126167297
) O O 0.9945257902145386
on O O 0.999870777130127
days O O 0.9999823570251465
1 O O 0.9999673366546631
, O O 0.9998430013656616
4 O O 0.9999344348907471
, O O 0.9998101592063904
8 O O 0.9977152347564697
, O O 0.9997850060462952
and O O 0.99979168176651
11 O O 0.99993896484375
every O O 0.9999568462371826
3 O O 0.9999741315841675
weeks O O 0.9999942779541016
) O O 0.9998413324356079
and O O 0.9881144165992737
dex B B 0.9993821382522583
( O O 0.9982979893684387
20 O O 0.9987442493438721
mg O O 0.9993298053741455
on O O 0.9999430179595947
the O O 0.9999942779541016
day O O 0.9999909400939941
of O O 0.9999929666519165
and O O 0.9999778270721436
the O O 0.9999964237213135
day O O 0.999990701675415
after O O 0.999963641166687
bort B B 0.9878689646720886
) O O 0.9997314810752869
as O O 0.9999575614929199
salvage O O 0.9992808699607849
treatment O O 0.9999668598175049
in O O 0.9999464750289917
85 O O 0.9999711513519287
patients O O 0.9999971389770508
with O O 0.9999904632568359
R O O 0.9998261332511902
/ O O 0.9999393224716187
R O O 0.9999558925628662
MM O O 0.9999632835388184
after O O 0.999940037727356
prior O O 0.9999825954437256
autologous O O 0.9999653100967407
stem O O 0.9999819993972778
cell O O 0.9999102354049683
transplantation O O 0.9999871253967285
or O O 0.9999594688415527
conventional O O 0.9998602867126465
chemotherapy O O 0.9996604919433594
. O O 0.9999630451202393

The O O 0.9999836683273315
median O O 0.9999803304672241
number O O 0.9999946355819702
of O O 0.9999827146530151
prior O O 0.9999904632568359
lines O O 0.9999780654907227
of O O 0.9997227787971497
therapy O O 0.9999634027481079
was O O 0.9999500513076782
2 O O 0.9999401569366455
. O O 0.9999831914901733

Eighty O O 0.9989598989486694
- O O 0.9999791383743286
seven O O 0.9999898672103882
percent O O 0.9999943971633911
of O O 0.9999847412109375
the O O 0.9999830722808838
patients O O 0.9999914169311523
had O O 0.9999712705612183
received O O 0.9997377991676331
immunomodulatory O O 0.9917848110198975
drugs O O 0.9980490207672119
included O O 0.9998164772987366
in O O 0.9999319314956665
some O O 0.9999208450317383
line O O 0.9998681545257568
of O O 0.99973064661026
therapy O O 0.9999407529830933
before O O 0.9992496371269226
bort B B 0.9496811032295227
- O I 0.883489727973938
dex B I 0.9999817609786987
. O O 0.9997219443321228

The O O 0.9999808073043823
median O O 0.9999744892120361
number O O 0.9999939203262329
of O O 0.9999269247055054
bort B B 0.6176167130470276
- O I 0.5573832392692566
dex B I 0.9976475834846497
cycles O O 0.984767735004425
was O O 0.9999780654907227
6 O O 0.9999687671661377
, O O 0.9999911785125732
up O O 0.9999886751174927
to O O 0.9999942779541016
a O O 0.9999964237213135
maximum O O 0.9999939203262329
of O O 0.9999860525131226
12 O O 0.9999911785125732
cycles O O 0.9999676942825317
. O O 0.9999772310256958

On O O 0.9999924898147583
an O O 0.9999961853027344
intention O O 0.9999973773956299
- O O 0.9999923706054688
to O O 0.9999955892562866
- O O 0.9999933242797852
treat O O 0.9999953508377075
basis O O 0.9999951124191284
, O O 0.9999788999557495
55 O O 0.9999818801879883
% O O 0.999997615814209
of O O 0.9999914169311523
the O O 0.999990701675415
patients O O 0.9999939203262329
achieved O O 0.9999727010726929
at O O 0.9999867677688599
least O O 0.999990701675415
partial O O 0.9999595880508423
response O O 0.999980092048645
, O O 0.9999805688858032
including O O 0.9999686479568481
19 O O 0.999963641166687
% O O 0.9999122619628906
CR O O 0.619574785232544
and O O 0.9998087286949158
35 O O 0.9999642372131348
% O O 0.9999796152114868
achieved O O 0.9999803304672241
at O O 0.9999794960021973
least O O 0.9999942779541016
very O O 0.999992847442627
good O O 0.9999847412109375
partial O O 0.9999492168426514
response O O 0.9999895095825195
. O O 0.9999809265136719

Median O O 0.9999605417251587
durations O O 0.9999617338180542
of O O 0.9999858140945435
response O O 0.999988317489624
, O O 0.9999912977218628
time O O 0.9999961853027344
to O O 0.9999979734420776
next O O 0.9998732805252075
therapy O O 0.9999908208847046
and O O 0.99998939037323
treatment O O 0.9999425411224365
- O O 0.9999868869781494
free O O 0.9999964237213135
interval O O 0.999996542930603
were O O 0.9999747276306152
8 O O 0.999990701675415
, O O 0.999980092048645
11 O O 0.9999785423278809
. O O 0.9999978542327881
2 O O 0.9999932050704956
, O O 0.9999206066131592
and O O 0.9999533891677856
5 O O 0.999981164932251
. O O 0.9999974966049194
1 O O 0.9999954700469971
months O O 0.9999988079071045
, O O 0.9999933242797852
respectively O O 0.9999841451644897
. O O 0.999984622001648

The O O 0.9999709129333496
most O O 0.9999923706054688
relevant O O 0.9999954700469971
adverse O O 0.9999356269836426
event O O 0.999997615814209
was O O 0.9999740123748779
peripheral O O 0.9999480247497559
neuropathy O O 0.9999912977218628
, O O 0.9999819993972778
which O O 0.9999876022338867
occurred O O 0.9999949932098389
in O O 0.9999808073043823
78 O O 0.9999856948852539
% O O 0.9999972581863403
of O O 0.9999827146530151
the O O 0.9999903440475464
patients O O 0.9999939203262329
( O O 0.9999474287033081
grade O O 0.9999184608459473
II O O 0.9874454736709595
, O O 0.9999393224716187
38 O O 0.9999856948852539
% O O 0.9999923706054688
; O O 0.9999107122421265
grade O O 0.9995599389076233
III O O 0.9978151321411133
, O O 0.9999498128890991
21 O O 0.9999901056289673
% O O 0.9999897480010986
) O O 0.9999629259109497
and O O 0.9999780654907227
led O O 0.9999969005584717
to O O 0.9999921321868896
treatment O O 0.9999630451202393
discontinuation O O 0.9999723434448242
in O O 0.999987006187439
6 O O 0.9999357461929321
% O O 0.9999810457229614
. O O 0.9999779462814331

With O O 0.9999759197235107
a O O 0.9999881982803345
median O O 0.9999929666519165
follow O O 0.999997615814209
up O O 0.9999984502792358
of O O 0.99998939037323
22 O O 0.9999948740005493
months O O 0.9999986886978149
, O O 0.999985933303833
median O O 0.9999573230743408
time O O 0.9999971389770508
to O O 0.9999960660934448
progression O O 0.9999929666519165
, O O 0.9999675750732422
progression O O 0.9995998740196228
- O O 0.999943733215332
free O O 0.9999575614929199
survival O O 0.9999901056289673
( O O 0.9999253749847412
PFS O O 0.9943434000015259
) O O 0.9999327659606934
and O O 0.9999223947525024
overall O O 0.9998502731323242
survival O O 0.9999836683273315
( O O 0.9998594522476196
OS O O 0.9940804839134216
) O O 0.9999814033508301
were O O 0.9999837875366211
8 O O 0.9999614953994751
. O O 0.9999967813491821
9 O O 0.9999946355819702
, O O 0.9999504089355469
8 O O 0.9999794960021973
. O O 0.9999971389770508
7 O O 0.9999958276748657
, O O 0.9999393224716187
and O O 0.9999802112579346
22 O O 0.9999895095825195
months O O 0.9999991655349731
, O O 0.999994158744812
respectively O O 0.999988317489624
. O O 0.9999843835830688

Prolonged O O 0.999829888343811
PFS O O 0.9989786148071289
and O O 0.9999196529388428
OS O O 0.958041250705719
were O O 0.999970555305481
observed O O 0.9999884366989136
in O O 0.9999146461486816
patients O O 0.999983549118042
achieving O O 0.998172402381897
CR O O 0.801754355430603
and O O 0.9999685287475586
receiving O O 0.9995276927947998
bort B B 0.9514292478561401
- O I 0.8939967751502991
dex B I 0.9998650550842285
a O O 0.9996322393417358
single O O 0.9999366998672485
line O O 0.9989532232284546
of O O 0.9997342228889465
prior O O 0.9949788451194763
therapy O O 0.9999527931213379
. O O 0.9999748468399048

Bort B B 0.9892029166221619
- O I 0.922266960144043
dex B I 0.9998868703842163
was O O 0.9994852542877197
an O O 0.999853253364563
effective O O 0.9998711347579956
salvage O O 0.9975085258483887
treatment O O 0.999933123588562
for O O 0.9998736381530762
MM O O 0.8331122398376465
patients O O 0.9999810457229614
, O O 0.9999785423278809
particularly O O 0.999983549118042
for O O 0.9999055862426758
those O O 0.9999814033508301
in O O 0.9999634027481079
first O O 0.9999876022338867
relapse O O 0.9999691247940063
. O O 0.9999666213989258

Pubertal O O 0.9992161989212036
exposure O O 0.9999011754989624
to O O 0.9934440851211548
Bisphenol B B 0.9860339760780334
A I I 0.9908820390701294
increases O O 0.998027503490448
anxiety O O 0.868445098400116
- O O 0.9999459981918335
like O O 0.9999847412109375
behavior O O 0.9999740123748779
and O O 0.9999496936798096
decreases O O 0.9997857213020325
acetylcholinesterase O O 0.7495492100715637
activity O O 0.9928047060966492
of O O 0.9995978474617004
hippocampus O O 0.9879164695739746
in O O 0.9999366998672485
adult O O 0.9999916553497314
male O O 0.9999568462371826
mice O O 0.9999903440475464
. O O 0.999797523021698

The O O 0.9999397993087769
negative O O 0.9998685121536255
effects O O 0.9999417066574097
of O O 0.9994176626205444
Bisphenol B B 0.992302417755127
A I I 0.9996737241744995
( O O 0.8490410447120667
BPA B B 0.998625636100769
) O O 0.9972963929176331
on O O 0.9998893737792969
neurodevelopment O O 0.9999936819076538
and O O 0.9999643564224243
behaviors O O 0.999987006187439
have O O 0.999982476234436
been O O 0.9999920129776001
well O O 0.9999755620956421
established O O 0.9999876022338867
. O O 0.9999803304672241

Acetylcholinesterase O B 0.932830274105072
( O O 0.9759885668754578
AChE O O 0.49889421463012695
) O O 0.9991835951805115
is O O 0.9998040795326233
a O O 0.9985257983207703
regulatory O O 0.9952912330627441
enzyme O O 0.9018540382385254
which O O 0.9990284442901611
is O O 0.9997001886367798
involved O O 0.9999347925186157
in O O 0.9999545812606812
anxiety O O 0.8193870782852173
- O O 0.9999321699142456
like O O 0.9999786615371704
behavior O O 0.9999765157699585
. O O 0.9998811483383179

This O O 0.9999756813049316
study O O 0.9999827146530151
investigated O O 0.9999632835388184
behavioral O O 0.9999792575836182
phenotypes O O 0.9999951124191284
and O O 0.9999862909317017
AChE O O 0.9780076146125793
activity O O 0.9999350309371948
in O O 0.9999755620956421
male O O 0.9999774694442749
mice O O 0.9999933242797852
following O O 0.9997920393943787
BPA B B 0.9933172464370728
exposure O O 0.996461808681488
during O O 0.99991774559021
puberty O O 0.999876856803894
. O O 0.9999756813049316

On O O 0.9999866485595703
postnatal O O 0.9999878406524658
day O O 0.9999992847442627
( O O 0.9999150037765503
PND O O 0.9999387264251709
) O O 0.9999877214431763
35 O O 0.9999961853027344
, O O 0.9999819993972778
male O O 0.9999839067459106
mice O O 0.9999969005584717
were O O 0.9999749660491943
exposed O O 0.9999798536300659
to O O 0.9997552037239075
50mg O O 0.9999431371688843
BPA B B 0.9388071298599243
/ O O 0.9976215958595276
kg O O 0.99998939037323
diet O O 0.9987081289291382
per O O 0.999848484992981
day O O 0.9999915361404419
for O O 0.9999520778656006
a O O 0.9999717473983765
period O O 0.9999910593032837
of O O 0.9999792575836182
35 O O 0.9999927282333374
days O O 0.999995231628418
. O O 0.9999796152114868

On O O 0.9999186992645264
PND71 O O 0.9853181838989258
, O O 0.9999650716781616
a O O 0.9999769926071167
behavioral O O 0.9999905824661255
assay O O 0.9999885559082031
was O O 0.9999876022338867
performed O O 0.9999957084655762
using O O 0.9999806880950928
the O O 0.9999752044677734
elevated O O 0.9996936321258545
plus O O 0.9999533891677856
maze O O 0.999984622001648
( O O 0.999955415725708
EPM O O 0.9869809746742249
) O O 0.9999493360519409
and O O 0.9999418258666992
the O O 0.9999700784683228
light O O 0.9999504089355469
/ O O 0.9998816251754761
dark O O 0.9999467134475708
test O O 0.9999713897705078
. O O 0.9999756813049316

In O O 0.9999333620071411
addition O O 0.9999511241912842
, O O 0.9998965263366699
AChE O O 0.8827913403511047
activity O O 0.9995684027671814
was O O 0.9999412298202515
measured O O 0.9999438524246216
in O O 0.99953293800354
the O O 0.9998083710670471
prefrontal O O 0.9918823838233948
cortex O O 0.9999831914901733
, O O 0.999697208404541
hypothalamus O O 0.9784370064735413
, O O 0.9997487664222717
cerebellum O O 0.9970958232879639
and O O 0.9997356534004211
hippocampus O O 0.9977728724479675
. O O 0.9999473094940186

Results O O 0.9999951124191284
from O O 0.9999798536300659
our O O 0.9999395608901978
behavioral O O 0.999964714050293
phenotyping O O 0.9999322891235352
indicated O O 0.9999479055404663
that O O 0.9998123049736023
anxiety O O 0.9784905314445496
- O O 0.999932050704956
like O O 0.9999669790267944
behavior O O 0.9999504089355469
was O O 0.9999557733535767
increased O O 0.9998937845230103
in O O 0.9998781681060791
mice O O 0.9999911785125732
exposed O O 0.9999122619628906
to O O 0.999113142490387
BPA B B 0.9936965107917786
. O O 0.9998985528945923

AChE O O 0.9539826512336731
activity O O 0.9997801184654236
was O O 0.9999397993087769
significantly O O 0.9999728202819824
decreased O O 0.9999827146530151
in O O 0.9997031092643738
the O O 0.9999008178710938
hippocampus O O 0.9987467527389526
of O O 0.9999411106109619
mice O O 0.9999814033508301
with O O 0.9994495511054993
BPA B B 0.9894731640815735
compared O O 0.999733030796051
to O O 0.9998466968536377
control O O 0.9998575448989868
mice O O 0.9999898672103882
, O O 0.9999419450759888
whereas O O 0.9999821186065674
no O O 0.9999775886535645
difference O O 0.9999821186065674
was O O 0.9999805688858032
found O O 0.9999939203262329
in O O 0.9997428059577942
the O O 0.9998863935470581
prefrontal O O 0.9936079978942871
cortex O O 0.9999775886535645
, O O 0.999806821346283
hypothalamus O O 0.9861539602279663
and O O 0.9997445940971375
cerebellum O O 0.9980643391609192
. O O 0.9999492168426514

Our O O 0.9999525547027588
findings O O 0.9999865293502808
showed O O 0.9999691247940063
that O O 0.9998832941055298
pubertal O O 0.9999120235443115
BPA B B 0.9861127734184265
exposure O O 0.9987633228302002
increased O O 0.9996825456619263
anxiety O O 0.7958326935768127
- O O 0.999922513961792
like O O 0.9999812841415405
behavior O O 0.9999712705612183
, O O 0.9999785423278809
which O O 0.9999717473983765
may O O 0.9999181032180786
be O O 0.9999849796295166
associated O O 0.9999822378158569
with O O 0.999969482421875
decreased O O 0.9999194145202637
AChE O O 0.9738413691520691
activity O O 0.9997480511665344
of O O 0.9997305274009705
the O O 0.9999275207519531
hippocampus O O 0.9985623955726624
in O O 0.9999421834945679
adult O O 0.9999871253967285
male O O 0.999930739402771
mice O O 0.9999936819076538
. O O 0.999951958656311

Further O O 0.9999583959579468
studies O O 0.9999847412109375
are O O 0.9999821186065674
necessary O O 0.9999864101409912
to O O 0.9999836683273315
investigate O O 0.999834418296814
the O O 0.9998164772987366
cholinergic O O 0.7556769251823425
signaling O O 0.9993079900741577
of O O 0.9997337460517883
the O O 0.9998737573623657
hippocampus O O 0.9978098273277283
in O O 0.9991303086280823
PBE O B 0.9956539869308472
induced O O 0.9991638660430908
anxiety O O 0.8037093877792358
- O O 0.9999395608901978
like O O 0.9999805688858032
behaviors O O 0.9999489784240723
. O O 0.9999691247940063

Biochemical O O 0.9936237335205078
effects O O 0.9999018907546997
of O O 0.9996076226234436
Solidago O B 0.5198848843574524
virgaurea O I 0.9901267290115356
extract O I 0.9933823347091675
on O O 0.9992249011993408
experimental O O 0.9999586343765259
cardiotoxicity O O 0.9999909400939941
. O O 0.9999523162841797

Cardiovascular O O 0.9991320967674255
diseases O O 0.9999781847000122
( O O 0.9998540878295898
CVDs O O 0.990552544593811
) O O 0.9999412298202515
are O O 0.9999648332595825
the O O 0.9999871253967285
major O O 0.9999699592590332
health O O 0.9999630451202393
problem O O 0.9999936819076538
of O O 0.9999252557754517
advanced O O 0.8390969038009644
as O O 0.9999433755874634
well O O 0.9998722076416016
as O O 0.9999852180480957
developing O O 0.9999850988388062
countries O O 0.9999970197677612
of O O 0.9999759197235107
the O O 0.9999957084655762
world O O 0.9999896287918091
. O O 0.9999797344207764

The O O 0.999990701675415
aim O O 0.9999967813491821
of O O 0.9999949932098389
the O O 0.999996542930603
present O O 0.9999914169311523
study O O 0.9999885559082031
was O O 0.9999958276748657
to O O 0.9999946355819702
investigate O O 0.9999672174453735
the O O 0.9999711513519287
protective O O 0.9998472929000854
effect O O 0.9999603033065796
of O O 0.9997643828392029
the O O 0.984924852848053
Solidago O B 0.46118220686912537
virgaurea O I 0.9708935022354126
extract O I 0.9935100674629211
on O O 0.9960256814956665
isoproterenol B B 0.9995602965354919
- O O 0.999679684638977
induced O O 0.9999265670776367
cardiotoxicity O O 0.999995231628418
in O O 0.9999654293060303
rats O O 0.9999961853027344
. O O 0.9999793767929077

The O O 0.9999817609786987
subcutaneous O O 0.9999022483825684
injection O O 0.9999831914901733
of O O 0.9995637536048889
isoproterenol B B 0.9997268319129944
( O O 0.9996334314346313
30 O O 0.9996253252029419
mg O O 0.9998608827590942
/ O O 0.9999030828475952
kg O O 0.9999746084213257
) O O 0.9999445676803589
into O O 0.9998524188995361
rats O O 0.9409205913543701
twice O O 0.9998759031295776
at O O 0.9999477863311768
an O O 0.9999861717224121
interval O O 0.9999910593032837
of O O 0.9999731779098511
24 O O 0.9999872446060181
h O O 0.9998652935028076
, O O 0.9999767541885376
for O O 0.9999573230743408
two O O 0.9999954700469971
consecutive O O 0.9999939203262329
days O O 0.9999935626983643
, O O 0.9999760389328003
led O O 0.9999834299087524
to O O 0.999990701675415
a O O 0.9999911785125732
significant O O 0.9999898672103882
increase O O 0.9999890327453613
in O O 0.9999692440032959
serum O O 0.9982919096946716
lactate B B 0.992931604385376
dehydrogenase O O 0.7186484932899475
, O O 0.999729335308075
creatine B B 0.9846307635307312
phosphokinase O O 0.5810455679893494
, O O 0.9992480874061584
alanine B B 0.9739904999732971
transaminase O O 0.6304400563240051
, O O 0.998288094997406
aspartate B B 0.9896031022071838
transaminase O O 0.7009837031364441
, O O 0.9919242262840271
and O O 0.9874051213264465
angiotensin B B 0.9498370289802551
- O O 0.5216270089149475
converting O O 0.6221303343772888
enzyme O O 0.561418354511261
activities O O 0.9921063184738159
, O O 0.9998797178268433
total O O 0.7411909103393555
cholesterol B B 0.9157922267913818
, O O 0.9947916865348816
triglycerides B B 0.9382712841033936
, O O 0.9983487129211426
free O O 0.9982847571372986
serum O B 0.8479858040809631
fatty B I 0.8280063271522522
acid I I 0.9897187948226929
, O O 0.9967994689941406
cardiac O O 0.995762825012207
tissue O O 0.9986687898635864
malondialdehyde B B 0.9983739852905273
( O O 0.9985217452049255
MDA B B 0.9437932372093201
) O O 0.9633738994598389
, O O 0.991804838180542
and O O 0.995381236076355
nitric B B 0.9792824387550354
oxide I I 0.996654748916626
levels O O 0.9997530579566956
and O O 0.9999840259552002
a O O 0.999987006187439
significant O O 0.9999932050704956
decrease O O 0.999996542930603
in O O 0.999975323677063
levels O O 0.9997337460517883
of O O 0.9833899140357971
glutathione B B 0.9883528351783752
and O O 0.9941970109939575
superoxide B B 0.9893765449523926
dismutase O O 0.6097158193588257
in O O 0.9997422099113464
cardiac O O 0.999569833278656
tissue O O 0.9999939203262329
as O O 0.9999830722808838
compared O O 0.9999973773956299
to O O 0.999994158744812
the O O 0.9999935626983643
normal O O 0.999778687953949
control O O 0.9999864101409912
group O O 0.9999943971633911
( O O 0.9999755620956421
P O O 0.9998834133148193
< O O 0.9999837875366211
0 O O 0.9999957084655762
. O O 0.9999972581863403
05 O O 0.9999957084655762
) O O 0.9999867677688599
. O O 0.9999719858169556

Pretreatment O O 0.999666690826416
with O O 0.9997368454933167
S O B 0.7645672559738159
. O I 0.5135078430175781
virgaurea O I 0.9770585894584656
extract O I 0.9868360757827759
for O O 0.9989539384841919
5 O O 0.9998984336853027
weeks O O 0.999984622001648
at O O 0.9999535083770752
a O O 0.9999837875366211
dose O O 0.9999865293502808
of O O 0.9999648332595825
250 O O 0.9999009370803833
mg O O 0.9999704360961914
/ O O 0.9999862909317017
kg O O 0.9999936819076538
followed O O 0.9999098777770996
by O O 0.999904990196228
isoproterenol B B 0.9981091022491455
injection O O 0.9997174143791199
significantly O O 0.9999792575836182
prevented O O 0.9999865293502808
the O O 0.9999958276748657
observed O O 0.9999942779541016
alterations O O 0.9999896287918091
. O O 0.9999806880950928

Captopril B B 0.9987081289291382
( O O 0.9995502829551697
50 O O 0.9999624490737915
mg O O 0.999901533126831
/ O O 0.9998995065689087
kg O O 0.9999963045120239
/ O O 0.9998761415481567
day O O 0.9999923706054688
, O O 0.9999326467514038
given O O 0.999901533126831
orally O O 0.9932540059089661
) O O 0.999870777130127
, O O 0.9999291896820068
an O O 0.9961498975753784
inhibitor O O 0.772315263748169
of O O 0.9411064386367798
angiotensin B B 0.908838152885437
- O O 0.6264799237251282
converting O O 0.6251505017280579
enzyme O O 0.5440863370895386
used O O 0.9993847608566284
as O O 0.9999327659606934
a O O 0.9999582767486572
standard O O 0.9998663663864136
cardioprotective O O 0.9999631643295288
drug O O 0.9987455606460571
, O O 0.9999594688415527
was O O 0.9999555349349976
used O O 0.9999520778656006
as O O 0.9999667406082153
a O O 0.9999730587005615
positive O O 0.9993711113929749
control O O 0.9999864101409912
in O O 0.9999877214431763
this O O 0.9999914169311523
study O O 0.9999946355819702
. O O 0.9999734163284302

The O O 0.9999890327453613
data O O 0.9999964237213135
of O O 0.999996542930603
the O O 0.9999959468841553
present O O 0.9999926090240479
study O O 0.9999839067459106
suggest O O 0.9999529123306274
that O O 0.9996696710586548
S O B 0.9420862197875977
. O I 0.7070437669754028
virgaurea O I 0.9963640570640564
extract O I 0.9860765933990479
exerts O O 0.9996945858001709
its O O 0.9998125433921814
protective O O 0.9998587369918823
effect O O 0.9999300241470337
by O O 0.9999494552612305
decreasing O O 0.9994044303894043
MDA B B 0.9970991611480713
level O O 0.9981344938278198
and O O 0.9999228715896606
increasing O O 0.9989545345306396
the O O 0.9999217987060547
antioxidant O O 0.7257132530212402
status O O 0.9999287128448486
in O O 0.999910831451416
isoproterenol B B 0.9976791739463806
- O O 0.9992303848266602
treated O O 0.9997785687446594
rats O O 0.9999918937683105
. O O 0.999962568283081

The O O 0.9999784231185913
study O O 0.9999815225601196
emphasizes O O 0.9998974800109863
the O O 0.9999591112136841
beneficial O O 0.999850869178772
action O O 0.9999442100524902
of O O 0.9993398785591125
S O B 0.8849831223487854
. O I 0.9288089871406555
virgaurea O I 0.9995383024215698
extract O I 0.9958090782165527
as O O 0.9993672966957092
a O O 0.9995061159133911
cardioprotective O O 0.9999805688858032
agent O O 0.9998522996902466
. O O 0.999945878982544

" O O 0.9999457597732544
Real O O 0.9999698400497437
- O O 0.9999890327453613
world O O 0.9999905824661255
" O O 0.9999959468841553
data O O 0.9999934434890747
on O O 0.9999831914901733
the O O 0.9999911785125732
efficacy O O 0.9999889135360718
and O O 0.999983549118042
safety O O 0.9999949932098389
of O O 0.9992830157279968
lenalidomide B B 0.9997218251228333
and O O 0.9242938160896301
dexamethasone B B 0.997282862663269
in O O 0.9998980760574341
patients O O 0.9999954700469971
with O O 0.9999831914901733
relapsed O O 0.9999700784683228
/ O O 0.9998806715011597
refractory O O 0.999974250793457
multiple O O 0.9986054301261902
myeloma O O 0.9999943971633911
who O O 0.9999639987945557
were O O 0.9999845027923584
treated O O 0.9999819993972778
according O O 0.9999961853027344
to O O 0.9999904632568359
the O O 0.9999957084655762
standard O O 0.9999970197677612
clinical O O 0.9999963045120239
practice O O 0.999998927116394
: O O 0.9999934434890747
a O O 0.9999920129776001
study O O 0.9999951124191284
of O O 0.9999886751174927
the O O 0.9999908208847046
Greek O O 0.9359577298164368
Myeloma O O 0.999883770942688
Study O O 0.9999692440032959
Group O O 0.9999802112579346
. O O 0.9999823570251465

Lenalidomide B B 0.9988082647323608
and O O 0.7942983508110046
dexamethasone B B 0.9947924017906189
( O O 0.9990010857582092
RD B B 0.9664580225944519
) O O 0.9970577955245972
is O O 0.9999343156814575
a O O 0.9999580383300781
standard O O 0.9999936819076538
of O O 0.9999865293502808
care O O 0.9999899864196777
for O O 0.9999094009399414
relapsed O O 0.9996373653411865
/ O O 0.9995668530464172
refractory O O 0.9992989301681519
multiple O O 0.983414351940155
myeloma O O 0.9999518394470215
( O O 0.9999334812164307
RRMM O O 0.9948792457580566
) O O 0.9999678134918213
, O O 0.9999622106552124
but O O 0.9999804496765137
there O O 0.9999920129776001
is O O 0.999992847442627
limited O O 0.9999969005584717
published O O 0.9999986886978149
data O O 0.9999945163726807
on O O 0.9999639987945557
its O O 0.9996466636657715
efficacy O O 0.9999665021896362
and O O 0.9999651908874512
safety O O 0.9999809265136719
in O O 0.999841570854187
the O O 0.9999736547470093
" O O 0.9999630451202393
real O O 0.999955415725708
world O O 0.9999910593032837
" O O 0.9999929666519165
( O O 0.9998863935470581
RW O O 0.9865450263023376
) O O 0.9999744892120361
, O O 0.9999887943267822
according O O 0.9999924898147583
to O O 0.999980092048645
the O O 0.9999921321868896
International O O 0.9999864101409912
Society O O 0.9999960660934448
of O O 0.9999040365219116
Pharmacoeconomics O O 0.9994804263114929
and O O 0.9999397993087769
Outcomes O O 0.9974530339241028
Research O O 0.9999678134918213
definition O O 0.9999914169311523
. O O 0.999976634979248

We O O 0.9999303817749023
studied O O 0.9999722242355347
212 O O 0.9996254444122314
RRMM O O 0.9841863512992859
patients O O 0.9999490976333618
who O O 0.9998656511306763
received O O 0.9995749592781067
RD B B 0.94251948595047
in O O 0.8032578229904175
RW O O 0.6179366707801819
. O O 0.9998621940612793

Objective O O 0.9996039271354675
response O O 0.9999847412109375
( O O 0.999916672706604
> O O 0.9862114191055298
PR O O 0.9819387197494507
( O O 0.9997113347053528
partial O O 0.9995229244232178
response O O 0.9999527931213379
) O O 0.9998972415924072
) O O 0.9999186992645264
rate O O 0.9999785423278809
was O O 0.9999736547470093
77 O O 0.9999959468841553
. O O 0.9999934434890747
4 O O 0.9999790191650391
% O O 0.9999961853027344
( O O 0.9996553659439087
complete O O 0.9970003962516785
response O O 0.9999880790710449
( O O 0.9994001388549805
CR O O 0.9397392868995667
) O O 0.9998281002044678
, O O 0.999908447265625
20 O O 0.9999823570251465
. O O 0.9999910593032837
2 O O 0.999974250793457
% O O 0.9999874830245972
) O O 0.9999581575393677
. O O 0.9999755620956421

Median O O 0.9999545812606812
time O O 0.9999947547912598
to O O 0.9999936819076538
first O O 0.999996542930603
and O O 0.9999359846115112
best O O 0.9996985197067261
response O O 0.9999926090240479
was O O 0.9999866485595703
2 O O 0.9999885559082031
and O O 0.9999879598617554
5 O O 0.9999842643737793
months O O 0.9999988079071045
, O O 0.9999932050704956
respectively O O 0.9999827146530151
. O O 0.9999821186065674

Median O O 0.9999679327011108
time O O 0.9999836683273315
to O O 0.9999676942825317
CR O O 0.8658240437507629
when O O 0.999710738658905
RD B B 0.9895893931388855
was O O 0.9996564388275146
given O O 0.9995380640029907
as O O 0.9998916387557983
2nd O O 0.9957899451255798
or O O 0.9995748400688171
> O O 0.9650261998176575
2 O O 0.9533848166465759
( O O 0.9970742464065552
nd O O 0.9432511329650879
) O O 0.9765182137489319
- O O 0.9964757561683655
line O O 0.9686148762702942
treatment O O 0.9998464584350586
at O O 0.9999880790710449
4 O O 0.9999465942382812
and O O 0.9999860525131226
11 O O 0.999974250793457
months O O 0.9999979734420776
, O O 0.999991774559021
respectively O O 0.9999819993972778
. O O 0.9999828338623047

Quality O O 0.9999556541442871
of O O 0.9999852180480957
response O O 0.9999802112579346
was O O 0.9999762773513794
independent O O 0.9999942779541016
of O O 0.9999697208404541
previous O O 0.9999575614929199
lines O O 0.9999680519104004
of O O 0.999305009841919
therapies O O 0.9999628067016602
or O O 0.9999467134475708
previous O O 0.9999192953109741
exposure O O 0.9999867677688599
to O O 0.9989763498306274
thalidomide B B 0.9994040727615356
or O O 0.8965860605239868
bortezomib B B 0.9924392700195312
. O O 0.9999586343765259

Median O O 0.9999535083770752
duration O O 0.9999901056289673
of O O 0.9999887943267822
response O O 0.9999737739562988
was O O 0.999991774559021
34 O O 0.9999940395355225
. O O 0.9999984502792358
4 O O 0.9999951124191284
months O O 0.999998927116394
, O O 0.9999676942825317
and O O 0.9999897480010986
it O O 0.9999936819076538
was O O 0.9999856948852539
higher O O 0.9999880790710449
in O O 0.9999817609786987
patients O O 0.9999959468841553
who O O 0.9999774694442749
received O O 0.9997779726982117
RD B B 0.9800554513931274
until O O 0.967289924621582
progression O O 0.9999818801879883
( O O 0.9999727010726929
not O O 0.9999955892562866
reached O O 0.9999940395355225
versus O O 0.9999939203262329
19 O O 0.99998939037323
months O O 0.9999985694885254
, O O 0.9999797344207764
p O O 0.9999402761459351
< O O 0.9999822378158569
0 O O 0.9999856948852539
. O O 0.9999963045120239
001 O O 0.9993520379066467
) O O 0.9999758005142212
. O O 0.999982476234436

Improvement O O 0.9999698400497437
of O O 0.9999567270278931
humoral O O 0.9999510049819946
immunity O O 0.9999855756759644
occurred O O 0.9999823570251465
in O O 0.9999542236328125
60 O O 0.9999927282333374
% O O 0.9999909400939941
of O O 0.9999417066574097
responders O O 0.9999822378158569
( O O 0.9999159574508667
p O O 0.9999624490737915
< O O 0.9999796152114868
0 O O 0.9999884366989136
. O O 0.9999958276748657
001 O O 0.9999366998672485
) O O 0.9999579191207886
and O O 0.999962568283081
in O O 0.9999685287475586
the O O 0.9999908208847046
majority O O 0.999990701675415
of O O 0.9999685287475586
patients O O 0.9999923706054688
who O O 0.9999784231185913
achieved O O 0.9999837875366211
stable O O 0.9999946355819702
disease O O 0.9999979734420776
. O O 0.9999761581420898

Adverse O O 0.9998626708984375
events O O 0.9999960660934448
were O O 0.9999674558639526
reported O O 0.9999945163726807
in O O 0.9999700784683228
68 O O 0.9999960660934448
. O O 0.99998939037323
9 O O 0.9999949932098389
% O O 0.9999922513961792
of O O 0.9999727010726929
patients O O 0.9999891519546509
( O O 0.9997333884239197
myelosuppression O O 0.9999927282333374
in O O 0.9999715089797974
49 O O 0.9999878406524658
. O O 0.9999896287918091
4 O O 0.9999877214431763
% O O 0.9999864101409912
) O O 0.9999356269836426
and O O 0.9999737739562988
12 O O 0.9999933242797852
. O O 0.9999911785125732
7 O O 0.9999971389770508
% O O 0.9999948740005493
of O O 0.9999849796295166
patients O O 0.9999868869781494
needed O O 0.9998844861984253
hospitalization O O 0.9999487400054932
. O O 0.999966025352478

Peripheral O O 0.9991233944892883
neuropathy O O 0.9999817609786987
was O O 0.999961256980896
observed O O 0.9999806880950928
only O O 0.9999760389328003
in O O 0.9999719858169556
2 O O 0.9999408721923828
. O O 0.9999843835830688
5 O O 0.9999836683273315
% O O 0.9999922513961792
of O O 0.9999769926071167
patients O O 0.9999901056289673
and O O 0.999916672706604
deep O O 0.9926936626434326
vein O O 0.9999831914901733
thrombosis O O 0.9996631145477295
in O O 0.9999570846557617
5 O O 0.9999291896820068
. O O 0.9999868869781494
7 O O 0.9999935626983643
% O O 0.9999927282333374
. O O 0.9999737739562988

Dose O O 0.9989952445030212
reductions O O 0.9999680519104004
were O O 0.9999676942825317
needed O O 0.999957799911499
in O O 0.9999598264694214
31 O O 0.9999731779098511
% O O 0.9999926090240479
of O O 0.9999730587005615
patients O O 0.999988317489624
and O O 0.999927282333374
permanent O O 0.9999645948410034
discontinuation O O 0.9999748468399048
in O O 0.9999740123748779
38 O O 0.9999873638153076
. O O 0.9999901056289673
9 O O 0.9999964237213135
% O O 0.9999943971633911
. O O 0.9999790191650391

Median O O 0.9999873638153076
time O O 0.9999971389770508
to O O 0.9999939203262329
treatment O O 0.9997251629829407
discontinuation O O 0.9999769926071167
was O O 0.9999914169311523
16 O O 0.999997615814209
. O O 0.9999984502792358
8 O O 0.999994158744812
months O O 0.999998927116394
. O O 0.9999904632568359

Performance O O 0.9999061822891235
status O O 0.9999939203262329
( O O 0.999956488609314
PS O O 0.994647204875946
) O O 0.9999910593032837
and O O 0.9999889135360718
initial O O 0.9998968839645386
lenalidomide B B 0.9996429681777954
dose O O 0.9992079138755798
predicted O O 0.9999905824661255
for O O 0.9999963045120239
treatment O O 0.9999687671661377
discontinuation O O 0.9999802112579346
. O O 0.999975323677063

Extra O O 0.8454080820083618
- O O 0.998900294303894
medullary O O 0.9999520778656006
relapses O O 0.9999667406082153
occurred O O 0.999991774559021
in O O 0.9999890327453613
3 O O 0.9999246597290039
. O O 0.9999896287918091
8 O O 0.9999912977218628
% O O 0.9999959468841553
of O O 0.9999860525131226
patients O O 0.9999903440475464
. O O 0.9999638795852661

Our O O 0.9999651908874512
study O O 0.9999841451644897
confirms O O 0.9999672174453735
that O O 0.9997208714485168
RD B B 0.996056079864502
is O O 0.9995684027671814
effective O O 0.9996485710144043
and O O 0.9999831914901733
safe O O 0.9999262094497681
in O O 0.9996684789657593
RRMM O O 0.9750560522079468
in O O 0.9992642998695374
the O O 0.998570442199707
RW O O 0.9872117638587952
; O O 0.9999487400054932
it O O 0.9997431635856628
produces O O 0.9999642372131348
durable O O 0.9999594688415527
responses O O 0.9999878406524658
especially O O 0.9999343156814575
in O O 0.9999551773071289
patients O O 0.9999910593032837
who O O 0.9999781847000122
continue O O 0.9999889135360718
on O O 0.999508261680603
treatment O O 0.9997554421424866
till O O 0.9994176626205444
progression O O 0.9999903440475464
and O O 0.9999624490737915
improves O O 0.999894380569458
humoral O O 0.999982476234436
immunity O O 0.9999903440475464
even O O 0.9999079704284668
in O O 0.9999796152114868
patients O O 0.9999935626983643
with O O 0.999990701675415
stable O O 0.999995231628418
disease O O 0.9999978542327881
. O O 0.9999792575836182

The O O 0.9999604225158691
cytogenetic O O 0.9996343851089478
action O O 0.9998799562454224
of O O 0.9986686706542969
ifosfamide B B 0.9994459748268127
, O O 0.8006559610366821
mesna B B 0.9870184659957886
, O O 0.9301026463508606
and O O 0.9988815188407898
their O O 0.9943594336509705
combination O O 0.9988436698913574
on O O 0.9996960163116455
peripheral O O 0.9999210834503174
rabbit O O 0.9967818260192871
lymphocytes O O 0.9999328851699829
: O O 0.999976634979248
an O O 0.999984622001648
in O O 0.9999396800994873
vivo O O 0.9999922513961792
/ O O 0.9999351501464844
in O O 0.999566376209259
vitro O O 0.9999964237213135
cytogenetic O O 0.9999169111251831
study O O 0.9999943971633911
. O O 0.9999825954437256

Ifosfamide B B 0.999157190322876
( O O 0.9701231122016907
IFO B B 0.9990041851997375
) O O 0.9865341186523438
is O O 0.9993077516555786
an O O 0.8823099136352539
alkylating O B 0.7622641324996948
nitrogen B I 0.9628256559371948
mustard O O 0.9132894277572632
, O O 0.9982896447181702
administrated O O 0.9998453855514526
as O O 0.9999281167984009
an O O 0.9976192116737366
antineoplasmic O O 0.9574865698814392
agent O O 0.9986454844474792
. O O 0.9994763731956482

It O O 0.9998927116394043
is O O 0.999835729598999
characterized O O 0.9999330043792725
by O O 0.9999595880508423
its O O 0.997820258140564
intense O O 0.9995081424713135
urotoxic O O 0.9659590721130371
action O O 0.9997413754463196
, O O 0.9999550580978394
leading O O 0.9999775886535645
to O O 0.999962568283081
hemorrhagic O O 0.9997920393943787
cystitis O O 0.9997164607048035
. O O 0.999921441078186

This O O 0.999907374382019
side O O 0.9999258518218994
effect O O 0.9999803304672241
of O O 0.9991045594215393
IFO B B 0.9993398785591125
raises O O 0.9995812773704529
the O O 0.9999833106994629
requirement O O 0.99998939037323
for O O 0.9999761581420898
the O O 0.9999678134918213
co O O 0.9986082911491394
- O O 0.9999375343322754
administration O O 0.9999417066574097
with O O 0.9999088048934937
sodium B B 0.9933340549468994
2 I I 0.9956088662147522
- I I 0.9976935982704163
sulfanylethanesulfonate I I 0.9998045563697815
( O O 0.9849972724914551
Mesna B B 0.9954975843429565
) O O 0.9995131492614746
aiming O O 0.9998478889465332
to O O 0.9999759197235107
avoid O O 0.9999762773513794
or O O 0.999994158744812
minimize O O 0.9999773502349854
this O O 0.9999376535415649
effect O O 0.9999552965164185
. O O 0.9999114274978638

IFO B B 0.9812899231910706
and O O 0.9884861707687378
Mesna B B 0.927222490310669
were O O 0.9995682835578918
administrated O O 0.9998646974563599
separately O O 0.9965839385986328
on O O 0.9996923208236694
rabbit O O 0.9999761581420898
' O O 0.9999890327453613
s O O 0.9999829530715942
lymphocytes O O 0.999910831451416
in O O 0.9999216794967651
vivo O O 0.9999775886535645
, O O 0.999967098236084
which O O 0.9998806715011597
were O O 0.9999579191207886
later O O 0.9999589920043945
developed O O 0.9999904632568359
in O O 0.9999785423278809
vitro O O 0.9999899864196777
. O O 0.9999781847000122

Cytogenetic O O 0.9997511506080627
markers O O 0.9999761581420898
for O O 0.9998217225074768
sister O O 0.9538046717643738
chromatid O O 0.9896686673164368
exchanges O O 0.9979851245880127
( O O 0.9998557567596436
SCEs O O 0.943971574306488
) O O 0.9999474287033081
, O O 0.9998759031295776
proliferation O O 0.9996452331542969
rate O O 0.9975273013114929
index O O 0.9995476603507996
( O O 0.9997102618217468
PRI O O 0.9978016018867493
) O O 0.9999771118164062
and O O 0.9998705387115479
Mitotic O O 0.9999299049377441
Index O O 0.9998862743377686
were O O 0.9999592304229736
recorded O O 0.9999676942825317
. O O 0.9999607801437378

Mesna B B 0.9827576279640198
' O O 0.9997407793998718
s O O 0.9998202919960022
action O O 0.9997978806495667
, O O 0.9999384880065918
in O O 0.9999561309814453
conjunction O O 0.9999433755874634
with O O 0.9996353387832642
IFO B B 0.9880727529525757
reduces O O 0.9998185038566589
the O O 0.9999886751174927
frequency O O 0.9999933242797852
of O O 0.9999793767929077
SCEs O O 0.9258132576942444
, O O 0.9999691247940063
in O O 0.9999793767929077
comparison O O 0.9999955892562866
with O O 0.9999935626983643
the O O 0.9999873638153076
SCEs O O 0.9608348608016968
recordings O O 0.999988317489624
obtained O O 0.999996542930603
when O O 0.9999339580535889
IFO B B 0.9991945624351501
is O O 0.9998857975006104
administered O O 0.9999209642410278
alone O O 0.9999500513076782
. O O 0.9999579191207886

In O O 0.9999616146087646
addition O O 0.9999555349349976
to O O 0.9999608993530273
this O O 0.9999722242355347
, O O 0.9999823570251465
when O O 0.9999345541000366
high O O 0.9997490048408508
concentrations O O 0.9988896250724792
of O O 0.9983803033828735
Mesna B B 0.9956795573234558
were O O 0.9998182654380798
administered O O 0.9998633861541748
alone O O 0.9996659755706787
significant O O 0.9999315738677979
reductions O O 0.9999674558639526
of O O 0.9998713731765747
the O O 0.9993970394134521
PRI O O 0.8316666483879089
were O O 0.9999752044677734
noted O O 0.9999896287918091
, O O 0.9999598264694214
than O O 0.9999816417694092
with O O 0.9997931122779846
IFO B B 0.998556911945343
acting O O 0.999686598777771
at O O 0.9999616146087646
the O O 0.9999915361404419
same O O 0.9999793767929077
concentration O O 0.9986329674720764
on O O 0.9996092915534973
the O O 0.9999499320983887
lymphocytes O O 0.9998040795326233
. O O 0.9999328851699829

Mesna B B 0.9956389665603638
significantly O O 0.9997722506523132
reduces O O 0.9994671940803528
IFO B B 0.9995474219322205
' O O 0.9999125003814697
s O O 0.9999421834945679
genotoxicity O O 0.9997726082801819
, O O 0.9999475479125977
while O O 0.9999070167541504
when O O 0.9999634027481079
administered O O 0.9999271631240845
in O O 0.9999480247497559
high O O 0.9995214939117432
concentrations O O 0.9998807907104492
it O O 0.9996071457862854
acts O O 0.9998050332069397
in O O 0.999947190284729
an O O 0.9999523162841797
inhibitory O O 0.9980989098548889
fashion O O 0.9999574422836304
on O O 0.9998539686203003
the O O 0.9999576807022095
cytostatic O O 0.9997547268867493
action O O 0.9999761581420898
of O O 0.9999254941940308
the O O 0.9999531507492065
drug O O 0.9989292025566101
. O O 0.9999160766601562

Risk O O 0.9992026686668396
factors O O 0.9999845027923584
and O O 0.9999489784240723
predictors O O 0.9999717473983765
of O O 0.9999580383300781
levodopa B B 0.9997954964637756
- O O 0.9995803236961365
induced O O 0.999863862991333
dyskinesia O O 0.9999977350234985
among O O 0.9999392032623291
multiethnic O O 0.9929735660552979
Malaysians O O 0.9998537302017212
with O O 0.9999617338180542
Parkinson O O 0.9980878233909607
' O O 0.9999881982803345
s O O 0.9999719858169556
disease O O 0.9999914169311523
. O O 0.9999728202819824

Chronic O O 0.9990537762641907
pulsatile O O 0.6988440155982971
levodopa B B 0.9989251494407654
therapy O O 0.9990845918655396
for O O 0.9998891353607178
Parkinson O O 0.9986509680747986
' O O 0.999984860420227
s O O 0.9999731779098511
disease O O 0.9999852180480957
( O O 0.9997499585151672
PD O O 0.9854729771614075
) O O 0.9999394416809082
leads O O 0.9999772310256958
to O O 0.9999935626983643
the O O 0.9999923706054688
development O O 0.9999958276748657
of O O 0.9999843835830688
motor O O 0.9999874830245972
fluctuations O O 0.999995231628418
and O O 0.9999712705612183
dyskinesia O O 0.9999964237213135
. O O 0.9999755620956421

We O O 0.9999580383300781
studied O O 0.9999728202819824
the O O 0.9999876022338867
prevalence O O 0.9999855756759644
and O O 0.9999847412109375
predictors O O 0.9999902248382568
of O O 0.9999568462371826
levodopa B B 0.9998425245285034
- O O 0.9997989535331726
induced O O 0.9998979568481445
dyskinesia O O 0.9999969005584717
among O O 0.999909520149231
multiethnic O O 0.992921769618988
Malaysian O O 0.9997842907905579
patients O O 0.9999818801879883
with O O 0.9999442100524902
PD O O 0.983867883682251
. O O 0.9999442100524902

METHODS O O 0.999915361404419
: O O 0.9999940395355225
This O O 0.9999973773956299
is O O 0.9999951124191284
a O O 0.9999953508377075
cross O O 0.9999819993972778
- O O 0.9999895095825195
sectional O O 0.9999986886978149
study O O 0.9999969005584717
involving O O 0.99998939037323
95 O O 0.9999406337738037
patients O O 0.9999971389770508
with O O 0.9999860525131226
PD O O 0.9942100048065186
on O O 0.9997156262397766
uninterrupted O O 0.993842363357544
levodopa B B 0.9995259046554565
therapy O O 0.9986585378646851
for O O 0.999962568283081
at O O 0.9999921321868896
least O O 0.9999934434890747
6 O O 0.9999525547027588
months O O 0.9999916553497314
. O O 0.9999827146530151

The O O 0.9999672174453735
instrument O O 0.9999791383743286
used O O 0.9999836683273315
was O O 0.9999744892120361
the O O 0.9989227652549744
UPDRS O O 0.7642658948898315
questionnaires O O 0.99964439868927
. O O 0.9998996257781982

The O O 0.9999144077301025
predictors O O 0.9999179840087891
of O O 0.9999570846557617
dyskinesia O O 0.9999972581863403
were O O 0.9999802112579346
determined O O 0.9999924898147583
using O O 0.9999773502349854
multivariate O O 0.9995965361595154
logistic O O 0.9998891353607178
regression O O 0.9999765157699585
analysis O O 0.9999738931655884
. O O 0.9999784231185913

RESULTS O O 0.9999560117721558
: O O 0.9999861717224121
The O O 0.9999945163726807
mean O O 0.9999958276748657
age O O 0.9999790191650391
was O O 0.9999914169311523
65 O O 0.9999994039535522
. O O 0.9999980926513672
6 O O 0.9999966621398926
+ O O 0.9999876022338867
8 O O 0.9999951124191284
. O O 0.9999980926513672
5 O O 0.9999964237213135
years O O 0.9999978542327881
. O O 0.9999896287918091

The O O 0.9999849796295166
mean O O 0.9999886751174927
onset O O 0.9999982118606567
age O O 0.9999934434890747
was O O 0.9999945163726807
58 O O 0.9999995231628418
. O O 0.9999984502792358
5 O O 0.9999972581863403
+ O O 0.9999871253967285
9 O O 0.9999988079071045
. O O 0.9999988079071045
8 O O 0.9999967813491821
years O O 0.9999977350234985
. O O 0.9999886751174927

The O O 0.9999635219573975
median O O 0.9999216794967651
disease O O 0.999984622001648
duration O O 0.9999865293502808
was O O 0.9999862909317017
6 O O 0.9999905824661255
( O O 0.9999352693557739
7 O O 0.9999966621398926
) O O 0.9999895095825195
years O O 0.9999972581863403
. O O 0.9999817609786987

Dyskinesia O O 0.9996212720870972
was O O 0.999932050704956
present O O 0.9999845027923584
in O O 0.9999594688415527
44 O O 0.9999746084213257
% O O 0.9999934434890747
( O O 0.9999659061431885
n O O 0.999927282333374
= O O 0.9999616146087646
42 O O 0.9999465942382812
) O O 0.9999744892120361
with O O 0.9999885559082031
median O O 0.9996923208236694
levodopa B B 0.999546468257904
therapy O O 0.9997361302375793
of O O 0.9999356269836426
3 O O 0.9999115467071533
years O O 0.9999775886535645
. O O 0.9999748468399048

There O O 0.9995635151863098
were O O 0.9998897314071655
64 O O 0.999993085861206
. O O 0.9999798536300659
3 O O 0.9999809265136719
% O O 0.9995050430297852
Chinese O O 0.9773615002632141
, O O 0.9998605251312256
31 O O 0.9999489784240723
% O O 0.9998694658279419
Malays O O 0.9733803272247314
, O O 0.9998891353607178
and O O 0.9996684789657593
3 O O 0.9997485280036926
. O O 0.9999758005142212
7 O O 0.9999837875366211
% O O 0.9998408555984497
Indians O O 0.9680583477020264
and O O 0.9999223947525024
other O O 0.9999222755432129
ethnic O O 0.9829382300376892
groups O O 0.9999353885650635
. O O 0.999956488609314

Eighty O O 0.998725950717926
- O O 0.9999676942825317
one O O 0.9999959468841553
percent O O 0.9999953508377075
of O O 0.999980092048645
patients O O 0.9999872446060181
with O O 0.9999428987503052
dyskinesia O O 0.9999933242797852
had O O 0.9999547004699707
clinical O O 0.9999918937683105
fluctuations O O 0.9999984502792358
. O O 0.9999758005142212

Patients O O 0.9999709129333496
with O O 0.9999452829360962
dyskinesia O O 0.999984860420227
had O O 0.9999196529388428
lower O O 0.9999570846557617
onset O O 0.9999951124191284
age O O 0.9999831914901733
( O O 0.9999667406082153
p O O 0.9999463558197021
< O O 0.9999855756759644
0 O O 0.9999780654907227
. O O 0.999997615814209
001 O O 0.9999545812606812
) O O 0.9999704360961914
, O O 0.9999823570251465
longer O O 0.9999748468399048
duration O O 0.9999592304229736
of O O 0.9996801614761353
levodopa B B 0.9995867609977722
therapy O O 0.9996174573898315
( O O 0.9999679327011108
p O O 0.9995898604393005
< O O 0.9999561309814453
0 O O 0.9999666213989258
. O O 0.999997615814209
001 O O 0.9998540878295898
) O O 0.9999760389328003
, O O 0.9999808073043823
longer O O 0.999911904335022
disease O O 0.9999887943267822
duration O O 0.9999872446060181
( O O 0.9999679327011108
p O O 0.9994507431983948
< O O 0.9999604225158691
0 O O 0.9998785257339478
. O O 0.999997615814209
001 O O 0.9991389513015747
) O O 0.9999806880950928
, O O 0.9999774694442749
higher O O 0.9999510049819946
total O O 0.9995916485786438
daily O O 0.9998893737792969
levodopa B B 0.9997254014015198
dose O O 0.9998118281364441
( O O 0.9999674558639526
p O O 0.9992688298225403
< O O 0.999961256980896
0 O O 0.9999550580978394
. O O 0.9999979734420776
001 O O 0.9988045692443848
) O O 0.9999697208404541
, O O 0.999958872795105
and O O 0.9999786615371704
higher O O 0.9999397993087769
total O O 0.9625280499458313
UPDRS O O 0.9093312621116638
scores O O 0.9999291896820068
( O O 0.9999313354492188
p O O 0.9991942048072815
= O O 0.9999896287918091
0 O O 0.999976634979248
. O O 0.999996542930603
005 O O 0.9996954202651978
) O O 0.9999693632125854
than O O 0.9999778270721436
patients O O 0.9999946355819702
without O O 0.9999839067459106
dyskinesia O O 0.9999912977218628
. O O 0.9999649524688721

The O O 0.9999468326568604
three O O 0.9997449517250061
significant O O 0.9999527931213379
predictors O O 0.99998939037323
of O O 0.9999724626541138
dyskinesia O O 0.9999978542327881
were O O 0.9999306201934814
duration O O 0.9999558925628662
of O O 0.9999241828918457
levodopa B B 0.9996269941329956
therapy O O 0.999771773815155
, O O 0.9999738931655884
onset O O 0.9999957084655762
age O O 0.999996542930603
, O O 0.999972939491272
and O O 0.999977707862854
total O O 0.9997757077217102
daily O O 0.9998862743377686
levodopa B B 0.9995285272598267
dose O O 0.9997918009757996
. O O 0.9999661445617676

CONCLUSIONS O O 0.9977670907974243
: O O 0.9999834299087524
The O O 0.9999860525131226
prevalence O O 0.9999868869781494
of O O 0.9999443292617798
levodopa B B 0.9997310042381287
- O O 0.9997912049293518
induced O O 0.9998646974563599
dyskinesia O O 0.9999947547912598
in O O 0.9999417066574097
our O O 0.9999731779098511
patients O O 0.9999842643737793
was O O 0.9999544620513916
44 O O 0.9999901056289673
% O O 0.9999942779541016
. O O 0.9999803304672241

The O O 0.9999727010726929
most O O 0.999963641166687
significant O O 0.9999862909317017
predictors O O 0.999984860420227
were O O 0.9999629259109497
duration O O 0.9999562501907349
of O O 0.9999141693115234
levodopa B B 0.9996790885925293
therapy O O 0.9997485280036926
, O O 0.9999812841415405
total O O 0.9999279975891113
daily O O 0.9999181032180786
levodopa B B 0.9994850158691406
dose O O 0.9997307658195496
, O O 0.9999105930328369
and O O 0.999954342842102
onset O O 0.999997615814209
age O O 0.9999973773956299
. O O 0.999976396560669

Dose O O 0.9981953501701355
- O O 0.9999406337738037
dependent O O 0.9999330043792725
neurotoxicity O O 0.9999958276748657
of O O 0.9997159838676453
high O O 0.9353564977645874
- O O 0.9994940757751465
dose O O 0.9468774795532227
busulfan B B 0.9997125267982483
in O O 0.9992901086807251
children O O 0.9962590932846069
: O O 0.999991774559021
a O O 0.9999924898147583
clinical O O 0.999992847442627
and O O 0.999984860420227
pharmacological O O 0.9999762773513794
study O O 0.9999948740005493
. O O 0.9999878406524658

Busulfan B B 0.9989818930625916
is O O 0.999559223651886
known O O 0.99988853931427
to O O 0.9998181462287903
be O O 0.9998956918716431
neurotoxic O O 0.9999507665634155
in O O 0.9998713731765747
animals O O 0.9999924898147583
and O O 0.9999111890792847
humans O O 0.999968409538269
, O O 0.9999319314956665
but O O 0.9999426603317261
its O O 0.9998766183853149
acute O O 0.9998346567153931
neurotoxicity O O 0.9999696016311646
remains O O 0.9999793767929077
poorly O O 0.9999918937683105
characterized O O 0.999995231628418
in O O 0.9999567270278931
children O O 0.9998948574066162
. O O 0.9999628067016602

We O O 0.9999898672103882
report O O 0.9999978542327881
here O O 0.9999974966049194
a O O 0.9999971389770508
retrospective O O 0.999991774559021
study O O 0.9999960660934448
of O O 0.9999868869781494
123 O O 0.999988317489624
children O O 0.9999982118606567
( O O 0.9999868869781494
median O O 0.9999890327453613
age O O 0.9999959468841553
, O O 0.9999939203262329
6 O O 0.9999951124191284
. O O 0.9999982118606567
5 O O 0.9999955892562866
years O O 0.9999978542327881
) O O 0.9999889135360718
receiving O O 0.9998420476913452
high O O 0.9980314373970032
- O O 0.9999340772628784
dose O O 0.9909011125564575
busulfan B B 0.999743640422821
in O O 0.9978566765785217
combined O O 0.9961934089660645
chemotherapy O O 0.9995336532592773
before O O 0.9998875856399536
bone O O 0.9999680519104004
marrow O O 0.9999977350234985
transplantation O O 0.999990701675415
for O O 0.999984860420227
malignant O O 0.999992847442627
solid O O 0.9999620914459229
tumors O O 0.9999979734420776
, O O 0.9999741315841675
brain O O 0.9995846152305603
tumors O O 0.9999860525131226
excluded O O 0.9999483823776245
. O O 0.9999667406082153

Busulfan B B 0.9988460540771484
was O O 0.9998867511749268
given O O 0.9999561309814453
p O O 0.9999383687973022
. O O 0.9999978542327881
o O O 0.9999948740005493
. O O 0.9999942779541016
, O O 0.9999747276306152
every O O 0.9999364614486694
6 O O 0.999935507774353
hours O O 0.9999852180480957
for O O 0.999984622001648
16 O O 0.9999681711196899
doses O O 0.9999854564666748
over O O 0.9999880790710449
4 O O 0.9999790191650391
days O O 0.9999961853027344
. O O 0.9999858140945435

Two O O 0.9999662637710571
total O O 0.9999139308929443
doses O O 0.9999668598175049
were O O 0.9999814033508301
consecutively O O 0.9999736547470093
used O O 0.9999829530715942
: O O 0.9999769926071167
16 O O 0.9999246597290039
mg O O 0.9999730587005615
/ O O 0.9999872446060181
kg O O 0.9999969005584717
, O O 0.9999514818191528
then O O 0.9999477863311768
600 O O 0.9999866485595703
mg O O 0.99997878074646
/ O O 0.9999842643737793
m2 O O 0.9999954700469971
. O O 0.9999734163284302

The O O 0.9999799728393555
dose O O 0.999927282333374
calculation O O 0.9999783039093018
on O O 0.999994158744812
the O O 0.9999963045120239
basis O O 0.9999938011169434
of O O 0.9999902248382568
body O O 0.9999884366989136
surface O O 0.9999616146087646
area O O 0.9953976273536682
results O O 0.9999715089797974
in O O 0.9999831914901733
higher O O 0.9998602867126465
doses O O 0.999956488609314
in O O 0.9999639987945557
young O O 0.9999940395355225
children O O 0.9999971389770508
than O O 0.9999752044677734
in O O 0.9999724626541138
older O O 0.9999510049819946
patients O O 0.9999961853027344
( O O 0.9999740123748779
16 O O 0.999935507774353
to O O 0.999984622001648
28 O O 0.9999984502792358
mg O O 0.9999850988388062
/ O O 0.9999873638153076
kg O O 0.9999977350234985
) O O 0.9999686479568481
. O O 0.9999725818634033

Ninety O O 0.8729766607284546
- O O 0.9996672868728638
six O O 0.9999604225158691
patients O O 0.9999951124191284
were O O 0.9999910593032837
not O O 0.9999957084655762
given O O 0.9998536109924316
anticonvulsive O O 0.48446083068847656
prophylaxis O O 0.7856245040893555
; O O 0.9999446868896484
7 O O 0.9999208450317383
( O O 0.9999634027481079
7 O O 0.9999914169311523
. O O 0.9999929666519165
5 O O 0.9999943971633911
% O O 0.9999953508377075
) O O 0.9999828338623047
developed O O 0.9999908208847046
seizures O O 0.999983549118042
during O O 0.9999575614929199
the O O 0.9999934434890747
4 O O 0.9999552965164185
days O O 0.9999959468841553
of O O 0.9999840259552002
the O O 0.9999815225601196
busulfan B B 0.9997739195823669
course O O 0.9996985197067261
or O O 0.9999803304672241
within O O 0.9999915361404419
24 O O 0.9999940395355225
h O O 0.9999876022338867
after O O 0.9999934434890747
the O O 0.999997615814209
last O O 0.9999903440475464
dosing O O 0.9999125003814697
. O O 0.9999696016311646

When O O 0.9999912977218628
the O O 0.9999828338623047
total O O 0.9988117218017578
busulfan B B 0.9996278285980225
dose O O 0.9994045495986938
was O O 0.9999871253967285
taken O O 0.9999924898147583
into O O 0.9999701976776123
account O O 0.9999805688858032
, O O 0.9999667406082153
there O O 0.9999685287475586
was O O 0.9999867677688599
a O O 0.9999915361404419
significant O O 0.9999898672103882
difference O O 0.9999967813491821
in O O 0.9999969005584717
terms O O 0.999990701675415
of O O 0.9999485015869141
neurotoxicity O O 0.9999879598617554
incidence O O 0.9999269247055054
among O O 0.9991455078125
patients O O 0.9999889135360718
under O O 0.999961256980896
16 O O 0.999944806098938
mg O O 0.9999425411224365
/ O O 0.9999504089355469
kg O O 0.9999963045120239
( O O 0.999941349029541
1 O O 0.9999053478240967
of O O 0.9999128580093384
57 O O 0.999963641166687
, O O 0.9999408721923828
1 O O 0.9999712705612183
. O O 0.9999855756759644
7 O O 0.9999918937683105
% O O 0.9999909400939941
) O O 0.9999459981918335
and O O 0.9999088048934937
patients O O 0.9999910593032837
under O O 0.9999774694442749
600 O O 0.9999381303787231
mg O O 0.9999798536300659
/ O O 0.9999924898147583
m2 O O 0.9999918937683105
( O O 0.9999585151672363
6 O O 0.9998517036437988
of O O 0.9999043941497803
39 O O 0.9999600648880005
, O O 0.9999606609344482
15 O O 0.9999969005584717
. O O 0.9999927282333374
4 O O 0.9999897480010986
% O O 0.9999955892562866
) O O 0.9999727010726929
( O O 0.9999467134475708
P O O 0.9993871450424194
less O O 0.9999830722808838
than O O 0.9999935626983643
0 O O 0.9999971389770508
. O O 0.9999972581863403
02 O O 0.9999765157699585
) O O 0.9999638795852661
. O O 0.9999797344207764

Twenty O O 0.9980214834213257
- O O 0.9999462366104126
seven O O 0.9999790191650391
patients O O 0.9999967813491821
were O O 0.9999868869781494
given O O 0.9998470544815063
a O O 0.9999258518218994
600 O O 0.9993653893470764
- O O 0.9999020099639893
mg O O 0.9999659061431885
/ O O 0.9998886585235596
m2 O O 0.9999302625656128
busulfan B B 0.9995637536048889
total O O 0.9808813333511353
dose O O 0.9997158646583557
with O O 0.9999122619628906
continuous O O 0.9998621940612793
i O O 0.9998465776443481
. O O 0.9999912977218628
v O O 0.9999988079071045
. O O 0.9999876022338867
infusion O O 0.9999785423278809
of O O 0.9968637228012085
clonazepam B B 0.999618411064148
; O O 0.9998865127563477
none O O 0.9999854564666748
had O O 0.9999866485595703
any O O 0.9999916553497314
neurological O O 0.9999946355819702
symptoms O O 0.9999969005584717
. O O 0.9999805688858032

Busulfan B B 0.9988970756530762
levels O O 0.9998772144317627
were O O 0.9999922513961792
measured O O 0.999994158744812
by O O 0.999995231628418
a O O 0.9999841451644897
gas O O 0.8149333000183105
chromatographic O O 0.9049232602119446
- O O 0.9948281645774841
mass O O 0.4737938940525055
spectrometry O O 0.8572679758071899
assay O O 0.999794065952301
in O O 0.999840259552002
the O O 0.9999711513519287
plasma O O 0.9999659061431885
and O O 0.9999186992645264
cerebrospinal O O 0.9982435703277588
fluid O O 0.9999632835388184
of O O 0.9999622106552124
9 O O 0.9998137354850769
children O O 0.9999798536300659
without O O 0.9999880790710449
central O O 0.9999644756317139
nervous O O 0.9999971389770508
system O O 0.9999934434890747
disease O O 0.9999986886978149
under O O 0.9996415376663208
600 O O 0.9998869895935059
mg O O 0.9999556541442871
/ O O 0.9999675750732422
m2 O O 0.9999909400939941
busulfan B B 0.999742329120636
with O O 0.9932199120521545
clonazepam B B 0.9994480013847351
: O O 0.9939597845077515
busulfan B B 0.9990501999855042
cerebrospinal O O 0.5154514312744141
fluid O O 0.7037294507026672
: O O 0.9998453855514526
plasma O O 0.9999576807022095
ratio O O 0.9999165534973145
was O O 0.9999736547470093
1 O O 0.9999278783798218
. O O 0.9999932050704956
39 O O 0.999962329864502
. O O 0.9999793767929077

This O O 0.9999785423278809
was O O 0.999961256980896
significantly O O 0.9999880790710449
different O O 0.9999936819076538
( O O 0.9999712705612183
P O O 0.9996492862701416
less O O 0.9999697208404541
than O O 0.999991774559021
0 O O 0.9999904632568359
. O O 0.9999961853027344
02 O O 0.9999862909317017
) O O 0.9999793767929077
from O O 0.9999885559082031
the O O 0.9999939203262329
cerebrospinal O O 0.9992517828941345
fluid O O 0.9899465441703796
: O O 0.9998741149902344
plasma O O 0.9997808337211609
ratio O O 0.9999469518661499
previously O O 0.9999817609786987
defined O O 0.9999938011169434
in O O 0.9999847412109375
children O O 0.9999889135360718
receiving O O 0.999832034111023
a O O 0.9999639987945557
16 O O 0.9995298385620117
- O O 0.9999397993087769
mg O O 0.999961256980896
/ O O 0.9999639987945557
kg O O 0.999996542930603
total O O 0.9998462200164795
dose O O 0.999847412109375
of O O 0.9973052740097046
busulfan B B 0.9996834993362427
. O O 0.9999459981918335

This O O 0.9999581575393677
study O O 0.9999815225601196
shows O O 0.999925971031189
that O O 0.9997624754905701
busulfan B B 0.9997832179069519
neurotoxicity O O 0.9998689889907837
is O O 0.9999083280563354
dose O O 0.9992281198501587
- O O 0.9998736381530762
dependent O O 0.9999200105667114
in O O 0.9998908042907715
children O O 0.9990862607955933
and O O 0.9999481439590454
efficiently O O 0.9989612102508545
prevented O O 0.9999523162841797
by O O 0.9996858835220337
clonazepam B B 0.9992008805274963
. O O 0.9999167919158936

A O O 0.9998884201049805
busulfan B B 0.999638557434082
dose O O 0.999721348285675
calculated O O 0.9999715089797974
on O O 0.9999938011169434
the O O 0.9999971389770508
basis O O 0.9999951124191284
of O O 0.9999864101409912
body O O 0.999983549118042
surface O O 0.999866247177124
area O O 0.9997727274894714
, O O 0.9999810457229614
resulting O O 0.9999854564666748
in O O 0.999995231628418
higher O O 0.9999366998672485
doses O O 0.9999747276306152
in O O 0.9999902248382568
young O O 0.9999977350234985
children O O 0.9999983310699463
, O O 0.9999822378158569
was O O 0.9999629259109497
followed O O 0.9999748468399048
by O O 0.9999693632125854
increased O O 0.999962329864502
neurotoxicity O O 0.9999871253967285
, O O 0.9999891519546509
close O O 0.999993085861206
to O O 0.9999849796295166
neurotoxicity O O 0.9999761581420898
incidence O O 0.9999549388885498
observed O O 0.9999872446060181
in O O 0.9999537467956543
adults O O 0.9999901056289673
. O O 0.999974250793457

Since O O 0.9999911785125732
plasma O O 0.9984806180000305
pharmacokinetic O O 0.9914940595626831
studies O O 0.9999290704727173
showed O O 0.9999487400054932
a O O 0.9999845027923584
faster O O 0.9999542236328125
busulfan B B 0.9997231364250183
clearance O O 0.999882698059082
in O O 0.9999556541442871
children O O 0.9999818801879883
than O O 0.9999769926071167
in O O 0.9999727010726929
adults O O 0.9999946355819702
, O O 0.9999850988388062
this O O 0.9999887943267822
new O O 0.999976396560669
dose O O 0.9997782111167908
may O O 0.9999721050262451
approximate O O 0.9999955892562866
more O O 0.9999940395355225
closely O O 0.999996542930603
the O O 0.9999862909317017
adult O O 0.9999637603759766
systemic O O 0.9998323917388916
exposure O O 0.9999932050704956
obtained O O 0.9999939203262329
after O O 0.9999817609786987
the O O 0.9999957084655762
usual O O 0.999983549118042
16 O O 0.9995131492614746
- O O 0.9999325275421143
mg O O 0.9999343156814575
/ O O 0.9999152421951294
kg O O 0.9999946355819702
total O O 0.9997479319572449
dose O O 0.9999024868011475
, O O 0.9999843835830688
with O O 0.9999690055847168
potential O O 0.9999785423278809
inferences O O 0.999974250793457
in O O 0.9999943971633911
terms O O 0.999981164932251
of O O 0.9998946189880371
anticancer O O 0.9633976817131042
or O O 0.9998155236244202
myeloablative O O 0.9999910593032837
effects O O 0.9999501705169678
. O O 0.999975323677063

The O O 0.9999210834503174
busulfan B B 0.9996194839477539
dose O O 0.9995675683021545
in O O 0.9998743534088135
children O O 0.9998952150344849
and O O 0.9999496936798096
infants O O 0.9999948740005493
undergoing O O 0.9999822378158569
bone O O 0.9999518394470215
marrow O O 0.9999974966049194
transplantation O O 0.9999760389328003
should O O 0.9999716281890869
be O O 0.9999948740005493
reconsidered O O 0.9999926090240479
on O O 0.999997615814209
the O O 0.9999978542327881
basis O O 0.9999983310699463
of O O 0.9999960660934448
pharmacokinetic O O 0.9995511174201965
studies O O 0.9999887943267822
. O O 0.999983549118042

An O O 0.9999692440032959
unexpected O O 0.9999680519104004
diagnosis O O 0.9999964237213135
in O O 0.9999738931655884
a O O 0.9999817609786987
renal O O 0.999858021736145
- O O 0.9966481328010559
transplant O O 0.9985313415527344
patient O O 0.9999598264694214
with O O 0.9999064207077026
proteinuria O O 0.9981435537338257
treated O O 0.9999088048934937
with O O 0.9991907477378845
everolimus B B 0.9997451901435852
: O O 0.9965446591377258
AL O O 0.9578927755355835
amyloidosis O O 0.967070460319519
. O O 0.9999630451202393

Proteinuria O O 0.9994403719902039
is O O 0.9999678134918213
an O O 0.9999902248382568
expected O O 0.9999436140060425
complication O O 0.9999943971633911
in O O 0.9999680519104004
transplant O O 0.9998363256454468
patients O O 0.9999951124191284
treated O O 0.999954104423523
with O O 0.9998207688331604
mammalian O O 0.9961185455322266
target O O 0.8719499707221985
of O O 0.8464903235435486
rapamycin B B 0.9472606778144836
inhibitors O O 0.8760319948196411
( O O 0.9937034249305725
mTOR O O 0.7703841328620911
- O O 0.9511087536811829
i O O 0.5904622077941895
) O O 0.9998973608016968
. O O 0.9999606609344482

However O O 0.9999657869338989
, O O 0.9999756813049316
clinical O O 0.9999957084655762
suspicion O O 0.999997615814209
should O O 0.9999691247940063
always O O 0.9999841451644897
be O O 0.9999959468841553
supported O O 0.999996542930603
by O O 0.9999873638153076
histological O O 0.9999823570251465
evidence O O 0.9999958276748657
in O O 0.9999843835830688
order O O 0.9999934434890747
to O O 0.9999915361404419
investigate O O 0.9999493360519409
potential O O 0.9999278783798218
alternate O O 0.9983161687850952
diagnoses O O 0.9999946355819702
such O O 0.9999555349349976
as O O 0.9999279975891113
acute O O 0.9998794794082642
or O O 0.999887228012085
chronic O O 0.9999085664749146
rejection O O 0.999996542930603
, O O 0.9999353885650635
interstitial O O 0.9959779977798462
fibrosis O O 0.9999923706054688
and O O 0.9998082518577576
tubular O O 0.9999798536300659
atrophy O O 0.9999704360961914
, O O 0.999922513961792
or O O 0.9998546838760376
recurrent O O 0.9999396800994873
or O O 0.9999061822891235
de O O 0.9963564872741699
novo O O 0.9997367262840271
glomerulopathy O O 0.9983311295509338
. O O 0.9999804496765137

In O O 0.9999843835830688
this O O 0.9999773502349854
case O O 0.9999803304672241
we O O 0.9999659061431885
report O O 0.999996542930603
the O O 0.9999945163726807
unexpected O O 0.9999964237213135
diagnosis O O 0.9999977350234985
of O O 0.9999709129333496
amyloidosis O O 0.8644405603408813
in O O 0.9999701976776123
a O O 0.9999902248382568
renal O O 0.9999047517776489
- O O 0.9967179894447327
transplant O O 0.9985536932945251
patient O O 0.9999866485595703
with O O 0.9999589920043945
pre O O 0.9988619089126587
- O O 0.9999009370803833
transplant O O 0.9999769926071167
monoclonal O O 0.9998669624328613
gammapathy O O 0.995502769947052
of O O 0.9999877214431763
undetermined O O 0.9999902248382568
significance O O 0.9999963045120239
who O O 0.9999579191207886
developed O O 0.9999887943267822
proteinuria O O 0.9999066591262817
after O O 0.9998471736907959
conversion O O 0.9999794960021973
from O O 0.9989292025566101
tacrolimus B B 0.9995893836021423
to O O 0.9548619389533997
everolimus B B 0.9997445940971375
. O O 0.9999301433563232

Long O O 0.9988760352134705
- O O 0.9999629259109497
term O O 0.9998698234558105
oral O O 0.9887459874153137
galactose B B 0.9994310736656189
treatment O O 0.9995087385177612
prevents O O 0.9998563528060913
cognitive O O 0.9999876022338867
deficits O O 0.9999959468841553
in O O 0.9999727010726929
male O O 0.9999794960021973
Wistar O O 0.9996192455291748
rats O O 0.9999983310699463
treated O O 0.9999487400054932
intracerebroventricularly O O 0.9999794960021973
with O O 0.9996688365936279
streptozotocin B B 0.9968873858451843
. O O 0.9994891881942749

Basic O O 0.9999146461486816
and O O 0.9999568462371826
clinical O O 0.9999709129333496
research O O 0.9999933242797852
has O O 0.9999754428863525
demonstrated O O 0.9999903440475464
that O O 0.999929666519165
dementia O O 0.999997615814209
of O O 0.9999538660049438
sporadic O O 0.9808589816093445
Alzheimer O O 0.9102247953414917
' O O 0.9999845027923584
s O O 0.9999830722808838
disease O O 0.9999667406082153
( O O 0.9998644590377808
sAD O O 0.8411936163902283
) O O 0.9996871948242188
type O O 0.9999065399169922
is O O 0.9999254941940308
associated O O 0.9999810457229614
with O O 0.9999619722366333
dysfunction O O 0.999984860420227
of O O 0.9999250173568726
the O O 0.9998880624771118
insulin O O 0.6444586515426636
- O O 0.7567315697669983
receptor O O 0.9723607897758484
( O O 0.9983919262886047
IR O O 0.9903061389923096
) O O 0.9997901320457458
system O O 0.9997233748435974
followed O O 0.9998522996902466
by O O 0.9999480247497559
decreased O O 0.9999529123306274
glucose B B 0.9467847943305969
transport O O 0.9998553991317749
via O O 0.9997428059577942
glucose B B 0.9227180480957031
transporter O O 0.9930452704429626
GLUT4 O O 0.518229067325592
and O O 0.9999552965164185
decreased O O 0.9999691247940063
glucose B B 0.9585808515548706
metabolism O O 0.999622106552124
in O O 0.9998027682304382
brain O O 0.9999667406082153
cells O O 0.9999935626983643
. O O 0.9999747276306152

An O O 0.9998272061347961
alternative O O 0.9995322227478027
source O O 0.9998148083686829
of O O 0.9998237490653992
energy O O 0.5229928493499756
is O O 0.9992364645004272
d B B 0.9212597608566284
- I I 0.9948796033859253
galactose I I 0.9956951141357422
( O O 0.998814582824707
the O O 0.9996935129165649
C O B 0.7861689925193787
- O I 0.8875360488891602
4 O I 0.5213541984558105
- O I 0.5120866894721985
epimer O I 0.9772671461105347
of O O 0.7638192176818848
d B B 0.5900071859359741
- I I 0.9344083666801453
glucose I I 0.9999445676803589
) O O 0.9986805319786072
which O O 0.9999477863311768
is O O 0.9999303817749023
transported O O 0.999975323677063
into O O 0.9999492168426514
the O O 0.9999822378158569
brain O O 0.9999878406524658
by O O 0.9998816251754761
insulin O O 0.8274432420730591
- O O 0.9790962934494019
independent O O 0.9905834197998047
GLUT3 O O 0.8322785496711731
transporter O O 0.9860830903053284
where O O 0.9999274015426636
it O O 0.9997895359992981
might O O 0.9998358488082886
be O O 0.9999644756317139
metabolized O O 0.999968409538269
to O O 0.9987335801124573
glucose B B 0.9860958456993103
via O O 0.9997618794441223
the O O 0.9998772144317627
Leloir O B 0.9304910898208618
pathway O O 0.999685525894165
. O O 0.9999537467956543

Exclusively O O 0.9945490956306458
parenteral O O 0.9998906850814819
daily O O 0.9994854927062988
injections O O 0.999915599822998
of O O 0.999226450920105
galactose B B 0.9994173049926758
induce O O 0.9997170567512512
memory O O 0.9999920129776001
deterioration O O 0.9999970197677612
in O O 0.999977707862854
rodents O O 0.9999904632568359
and O O 0.9999557733535767
are O O 0.9999433755874634
used O O 0.9999810457229614
to O O 0.9999809265136719
generate O O 0.9999899864196777
animal O O 0.9999850988388062
aging O O 0.9995120763778687
model O O 0.9999957084655762
, O O 0.9999622106552124
but O O 0.9999673366546631
the O O 0.999984860420227
effects O O 0.9999752044677734
of O O 0.9999525547027588
oral O O 0.9974653720855713
galactose B B 0.9996767044067383
treatment O O 0.9997652173042297
on O O 0.999861478805542
cognitive O O 0.9999711513519287
functions O O 0.9999969005584717
have O O 0.9999936819076538
never O O 0.9999947547912598
been O O 0.999994158744812
tested O O 0.9999852180480957
. O O 0.999975323677063

We O O 0.999982476234436
have O O 0.999993085861206
investigated O O 0.9999847412109375
the O O 0.9999799728393555
effects O O 0.9999880790710449
of O O 0.9999563694000244
continuous O O 0.9998000264167786
daily O O 0.9998387098312378
oral O O 0.9887642860412598
galactose B B 0.9997753500938416
( O O 0.9994714856147766
200 O O 0.9998360872268677
mg O O 0.9998911619186401
/ O O 0.9999586343765259
kg O O 0.9999988079071045
/ O O 0.9999501705169678
day O O 0.9999867677688599
) O O 0.9998911619186401
treatment O O 0.9998193383216858
on O O 0.9998519420623779
cognitive O O 0.999992847442627
deficits O O 0.9999972581863403
in O O 0.9999557733535767
streptozotocin B B 0.9732922315597534
- O O 0.9990956783294678
induced O O 0.9999473094940186
( O O 0.9998874664306641
STZ B O 0.4898691177368164
- O O 0.9910634756088257
icv O O 0.9829320907592773
) O O 0.9999505281448364
rat O O 0.9999905824661255
model O O 0.9999825954437256
of O O 0.9998784065246582
sAD O O 0.9745131134986877
, O O 0.9999861717224121
tested O O 0.9999905824661255
by O O 0.9999887943267822
Morris O O 0.999962329864502
Water O O 0.9967706203460693
Maze O O 0.999980092048645
and O O 0.9999517202377319
Passive O O 0.9999476671218872
Avoidance O O 0.9999946355819702
test O O 0.9999840259552002
, O O 0.9999798536300659
respectively O O 0.9999375343322754
. O O 0.9999867677688599

One O O 0.9999600648880005
month O O 0.9999891519546509
of O O 0.9998770952224731
oral O O 0.9980782270431519
galactose B B 0.9995492100715637
treatment O O 0.9994969367980957
initiated O O 0.9999639987945557
immediately O O 0.9999926090240479
after O O 0.9999876022338867
the O O 0.9999876022338867
STZ B B 0.9628931879997253
- O I 0.5830225348472595
icv O I 0.9372826218605042
administration O O 0.9992049336433411
, O O 0.9999681711196899
successfully O O 0.9999401569366455
prevented O O 0.999977707862854
development O O 0.9999969005584717
of O O 0.9999890327453613
the O O 0.9999877214431763
STZ B B 0.9751541018486023
- O I 0.535359263420105
icv O I 0.9459726214408875
- O O 0.9993649125099182
induced O O 0.9999697208404541
cognitive O O 0.9999961853027344
deficits O O 0.999998927116394
. O O 0.9999794960021973

Beneficial O O 0.9998524188995361
effect O O 0.9999700784683228
of O O 0.9999045133590698
oral O O 0.9988695979118347
galactose B B 0.9992002844810486
was O O 0.9998689889907837
independent O O 0.999972939491272
of O O 0.999991774559021
the O O 0.9999940395355225
rat O O 0.9999978542327881
age O O 0.9999982118606567
and O O 0.9999961853027344
of O O 0.9999680519104004
the O O 0.9999762773513794
galactose B B 0.9986457228660583
dose O O 0.9998699426651001
ranging O O 0.9999889135360718
from O O 0.9999842643737793
100 O O 0.9975800514221191
to O O 0.9999531507492065
300 O O 0.9999897480010986
mg O O 0.9999551773071289
/ O O 0.9999901056289673
kg O O 0.9999988079071045
/ O O 0.9999908208847046
day O O 0.9999971389770508
. O O 0.9999868869781494

Additionally O O 0.9999790191650391
, O O 0.9999250173568726
oral O O 0.9983456134796143
galactose B B 0.9992665648460388
administration O O 0.999900221824646
led O O 0.9999837875366211
to O O 0.9999959468841553
the O O 0.9999966621398926
appearance O O 0.9999971389770508
of O O 0.9999080896377563
galactose B B 0.997395396232605
in O O 0.9998268485069275
the O O 0.9999871253967285
blood O O 0.9999666213989258
. O O 0.9999678134918213

The O O 0.9999901056289673
increase O O 0.9999933242797852
of O O 0.9999114274978638
galactose B B 0.999423623085022
concentration O O 0.9998372793197632
in O O 0.9999265670776367
the O O 0.9999916553497314
cerebrospinal O O 0.9999276399612427
fluid O O 0.9999912977218628
was O O 0.9999741315841675
several O O 0.9999967813491821
times O O 0.9999953508377075
lower O O 0.9999890327453613
after O O 0.9997431635856628
oral O O 0.9984167814254761
than O O 0.9999855756759644
after O O 0.9998134970664978
parenteral O O 0.9999512434005737
administration O O 0.9999815225601196
of O O 0.9999734163284302
the O O 0.9999936819076538
same O O 0.9999855756759644
galactose B B 0.9991217255592346
dose O O 0.9980456829071045
. O O 0.9999768733978271

Oral O O 0.9728853702545166
galactose B B 0.9995237588882446
exposure O O 0.9997046589851379
might O O 0.9999406337738037
have O O 0.9999358654022217
beneficial O O 0.9998725652694702
effects O O 0.9999678134918213
on O O 0.9998779296875
learning O O 0.999987006187439
and O O 0.9999405145645142
memory O O 0.9999866485595703
ability O O 0.9999903440475464
and O O 0.9999738931655884
could O O 0.9999780654907227
be O O 0.9999961853027344
worth O O 0.9999922513961792
investigating O O 0.9999890327453613
for O O 0.9999707937240601
improvement O O 0.9999891519546509
of O O 0.9999542236328125
cognitive O O 0.9999923706054688
deficits O O 0.999997615814209
associated O O 0.999980092048645
with O O 0.9999032020568848
glucose O O 0.6421034932136536
hypometabolism O O 0.99937504529953
in O O 0.9998158812522888
AD O O 0.7485412359237671
. O O 0.9998914003372192

An O O 0.9999663829803467
investigation O O 0.9999914169311523
of O O 0.9999829530715942
the O O 0.9999922513961792
pattern O O 0.9999924898147583
of O O 0.9999843835830688
kidney O O 0.9996976852416992
injury O O 0.9999954700469971
in O O 0.999869704246521
HIV O O 0.550270676612854
- O O 0.9930461049079895
positive O O 0.998871386051178
persons O O 0.9999954700469971
exposed O O 0.9998363256454468
to O O 0.9967058300971985
tenofovir B B 0.9985427856445312
disoproxil I I 0.9888400435447693
fumarate I I 0.991425633430481
: O O 0.9997844099998474
an O O 0.999988317489624
examination O O 0.9999954700469971
of O O 0.99998939037323
a O O 0.9999828338623047
large O O 0.9999266862869263
population O O 0.9999469518661499
database O O 0.9998654127120972
( O O 0.9999103546142578
MHRA O O 0.9969492554664612
database O O 0.9998692274093628
) O O 0.9999750852584839
. O O 0.9999804496765137

The O O 0.9999791383743286
potential O O 0.9999924898147583
for O O 0.9999009370803833
tenofovir B B 0.999821126461029
to O O 0.9998992681503296
cause O O 0.999944806098938
a O O 0.9999685287475586
range O O 0.999887228012085
of O O 0.9999604225158691
kidney O O 0.9993311166763306
syndromes O O 0.9999853372573853
has O O 0.9999798536300659
been O O 0.999994158744812
established O O 0.9999969005584717
from O O 0.9999924898147583
mechanistic O O 0.9999649524688721
and O O 0.9999724626541138
randomised O O 0.9999856948852539
clinical O O 0.99997878074646
trials O O 0.9999895095825195
. O O 0.9999798536300659

However O O 0.9999567270278931
, O O 0.9999938011169434
the O O 0.9999961853027344
exact O O 0.999991774559021
pattern O O 0.9999964237213135
of O O 0.9999827146530151
kidney O O 0.9996618032455444
involvement O O 0.999984622001648
is O O 0.9999802112579346
still O O 0.9999970197677612
uncertain O O 0.9999932050704956
. O O 0.999976396560669

We O O 0.9999713897705078
undertook O O 0.9999946355819702
a O O 0.9999895095825195
descriptive O O 0.9999939203262329
analysis O O 0.9999932050704956
of O O 0.999981164932251
Yellow O O 0.9996234178543091
Card O O 0.9999831914901733
records O O 0.999987006187439
of O O 0.9999493360519409
407 O O 0.9998915195465088
HIV O O 0.928222119808197
- O O 0.9994478821754456
positive O O 0.999704897403717
persons O O 0.999913215637207
taking O O 0.9987051486968994
tenofovir B B 0.9992774128913879
disoproxil I I 0.987163782119751
fumarate I I 0.9993284940719604
( O O 0.9804335236549377
TDF B B 0.9731114506721497
) O O 0.9993707537651062
as O O 0.9999834299087524
part O O 0.9999837875366211
of O O 0.9999628067016602
their O O 0.9999619722366333
antiretroviral O O 0.5498476624488831
therapy O O 0.998301088809967
regimen O O 0.99969482421875
and O O 0.9999017715454102
submitted O O 0.9999477863311768
to O O 0.999845027923584
the O O 0.9999707937240601
Medicines O O 0.9995960593223572
and O O 0.9999309778213501
Healthcare O O 0.998106837272644
Products O O 0.9994964599609375
Regulatory O O 0.9997356534004211
Agency O O 0.9997838139533997
( O O 0.9998883008956909
MHRA O O 0.9920768737792969
) O O 0.9999666213989258
with O O 0.9999263286590576
suspected O O 0.9999586343765259
kidney O O 0.999150276184082
adverse O O 0.9999386072158813
effects O O 0.9999814033508301
. O O 0.9999715089797974

Reports O O 0.9999438524246216
that O O 0.999923825263977
satisfy O O 0.948180079460144
defined O O 0.9999545812606812
criteria O O 0.9999889135360718
were O O 0.99997878074646
classified O O 0.9999884366989136
as O O 0.9999363422393799
acute O O 0.9999603033065796
kidney O O 0.9999432563781738
injury O O 0.9999915361404419
, O O 0.9999017715454102
kidney O O 0.9980961680412292
tubular O O 0.9999867677688599
dysfunction O O 0.9999933242797852
and O O 0.9997630715370178
Fanconi O O 0.9990454316139221
syndrome O O 0.9999537467956543
. O O 0.9999719858169556

Of O O 0.999964714050293
the O O 0.9999924898147583
407 O O 0.9999959468841553
Yellow O O 0.9999678134918213
Card O O 0.9998469352722168
records O O 0.9998154044151306
analysed O O 0.9999699592590332
, O O 0.9999624490737915
106 O O 0.9995971322059631
satisfied O O 0.999977707862854
criteria O O 0.9999974966049194
for O O 0.9999667406082153
TDF B O 0.8551257848739624
- O O 0.998021125793457
related O O 0.9999281167984009
kidney O O 0.9997695088386536
disease O O 0.9999953508377075
, O O 0.9999809265136719
of O O 0.9995474219322205
which O O 0.999977707862854
53 O O 0.9999607801437378
( O O 0.999894380569458
50 O O 0.9999858140945435
% O O 0.9999856948852539
) O O 0.9999333620071411
had O O 0.9999181032180786
features O O 0.9999890327453613
of O O 0.9999345541000366
kidney O O 0.9873611927032471
tubular O O 0.9999839067459106
dysfunction O O 0.9999885559082031
, O O 0.9999678134918213
35 O O 0.9999204874038696
( O O 0.9998946189880371
33 O O 0.9999760389328003
% O O 0.9999803304672241
) O O 0.9999557733535767
were O O 0.9999748468399048
found O O 0.9999834299087524
to O O 0.999962568283081
have O O 0.9999514818191528
features O O 0.9999850988388062
of O O 0.9999316930770874
glomerular O O 0.9971508383750916
dysfunction O O 0.9999691247940063
and O O 0.9999449253082275
18 O O 0.9918680787086487
( O O 0.9998948574066162
17 O O 0.9999972581863403
% O O 0.9999945163726807
) O O 0.9999778270721436
had O O 0.9999456405639648
Fanconi O O 0.9991679191589355
syndrome O O 0.9999735355377197
. O O 0.9999632835388184

The O O 0.9999786615371704
median O O 0.9998419284820557
TDF B O 0.51776123046875
exposure O O 0.9998482465744019
was O O 0.9999674558639526
316 O O 0.9999971389770508
days O O 0.9999916553497314
( O O 0.9999775886535645
interquartile O O 0.9999585151672363
range O O 0.9999946355819702
120 O O 0.9999945163726807
- O O 0.9996283054351807
740 O O 0.999976634979248
) O O 0.9999797344207764
. O O 0.9999772310256958

The O O 0.9999728202819824
incidence O O 0.9999978542327881
of O O 0.9999853372573853
hospitalisation O O 0.9999455213546753
for O O 0.9998648166656494
TDF B O 0.5835936665534973
kidney O O 0.384232759475708
adverse O O 0.9888056516647339
effects O O 0.9998400211334229
was O O 0.9999499320983887
high O O 0.9999681711196899
, O O 0.9999771118164062
particularly O O 0.9999898672103882
amongst O O 0.9999345541000366
patients O O 0.9999877214431763
with O O 0.9999650716781616
features O O 0.9999970197677612
of O O 0.9999748468399048
Fanconi O O 0.998433530330658
syndrome O O 0.9999544620513916
. O O 0.999950647354126

The O O 0.9999821186065674
pattern O O 0.9999815225601196
of O O 0.9999629259109497
kidney O O 0.9968559741973877
syndromes O O 0.999968409538269
in O O 0.9999589920043945
this O O 0.999945878982544
population O O 0.9991363883018494
series O O 0.9999701976776123
mirrors O O 0.9999510049819946
that O O 0.9999862909317017
reported O O 0.9999953508377075
in O O 0.9999922513961792
randomised O O 0.999984860420227
clinical O O 0.9999884366989136
trials O O 0.999988317489624
. O O 0.9999806880950928

Cessation O O 0.9998769760131836
of O O 0.9995993971824646
TDF B B 0.9662562608718872
was O O 0.9998382329940796
associated O O 0.9999829530715942
with O O 0.9999933242797852
complete O O 0.9999756813049316
restoration O O 0.9999948740005493
of O O 0.999981164932251
kidney O O 0.9996885061264038
function O O 0.9999809265136719
in O O 0.9999604225158691
up O O 0.9999926090240479
half O O 0.9999966621398926
of O O 0.9999818801879883
the O O 0.9999861717224121
patients O O 0.9999932050704956
in O O 0.9999921321868896
this O O 0.9999914169311523
report O O 0.9999926090240479
. O O 0.9999717473983765

Incidence O O 0.9999760389328003
of O O 0.999962329864502
postoperative O O 0.9999417066574097
delirium O O 0.9997066855430603
is O O 0.9999433755874634
high O O 0.9999744892120361
even O O 0.9999629259109497
in O O 0.9999759197235107
a O O 0.9999773502349854
population O O 0.999990701675415
without O O 0.9999890327453613
known O O 0.9999629259109497
risk O O 0.9999780654907227
factors O O 0.9999951124191284
. O O 0.9999716281890869

PURPOSE O O 0.9892593622207642
: O O 0.9999498128890991
Postoperative O O 0.9999452829360962
delirium O O 0.9990629553794861
is O O 0.9999630451202393
a O O 0.999969482421875
recognized O O 0.9997965693473816
complication O O 0.9999823570251465
in O O 0.9999160766601562
populations O O 0.9988951086997986
at O O 0.9998031258583069
risk O O 0.9999909400939941
. O O 0.9999544620513916

The O O 0.9999904632568359
aim O O 0.9999969005584717
of O O 0.9999948740005493
this O O 0.9999898672103882
study O O 0.9999865293502808
is O O 0.9999922513961792
to O O 0.9999947547912598
assess O O 0.999985933303833
the O O 0.9999890327453613
prevalence O O 0.9999854564666748
of O O 0.9999784231185913
early O O 0.9999792575836182
postoperative O O 0.9999663829803467
delirium O O 0.9997512698173523
in O O 0.9999594688415527
a O O 0.9999687671661377
population O O 0.9999855756759644
without O O 0.9999861717224121
known O O 0.9999562501907349
risk O O 0.99997878074646
factors O O 0.9999961853027344
admitted O O 0.9999833106994629
to O O 0.999956488609314
the O O 0.9999489784240723
ICU O O 0.9975774884223938
for O O 0.9999654293060303
postoperative O O 0.9999611377716064
monitoring O O 0.9999966621398926
after O O 0.9999886751174927
elective O O 0.9999890327453613
major O O 0.9999769926071167
surgery O O 0.9999980926513672
. O O 0.99997878074646

The O O 0.9999809265136719
secondary O O 0.9999767541885376
outcome O O 0.9999957084655762
investigated O O 0.9999911785125732
is O O 0.9999914169311523
to O O 0.9999926090240479
identify O O 0.9999792575836182
eventual O O 0.9998700618743896
independent O O 0.9999452829360962
risk O O 0.9999821186065674
factors O O 0.9999949932098389
among O O 0.999799907207489
demographic O O 0.9998244643211365
data O O 0.9999773502349854
and O O 0.9998939037322998
anesthetic O O 0.986389696598053
drugs O O 0.9981905817985535
used O O 0.999941349029541
. O O 0.9999582767486572

METHODS O O 0.9999641180038452
: O O 0.9999970197677612
An O O 0.999995231628418
observational O O 0.999990701675415
, O O 0.9999836683273315
prospective O O 0.9999892711639404
study O O 0.9999943971633911
was O O 0.9999927282333374
conducted O O 0.9999973773956299
on O O 0.9999884366989136
a O O 0.999993085861206
consecutive O O 0.9999827146530151
cohort O O 0.9999871253967285
of O O 0.9999908208847046
patients O O 0.9999943971633911
admitted O O 0.9999855756759644
to O O 0.999945878982544
our O O 0.9999518394470215
ICU O O 0.9960185885429382
within O O 0.9999241828918457
and O O 0.9999616146087646
for O O 0.9999628067016602
at O O 0.9999909400939941
least O O 0.9999949932098389
24 O O 0.999984622001648
h O O 0.9998468160629272
after O O 0.9999901056289673
major O O 0.9999783039093018
surgical O O 0.9999938011169434
procedures O O 0.9999970197677612
. O O 0.9999692440032959

Exclusion O O 0.9998822212219238
criteria O O 0.9999868869781494
were O O 0.9999808073043823
any O O 0.9999605417251587
preexisting O O 0.9997710585594177
predisposing O O 0.9998626708984375
factor O O 0.9999847412109375
for O O 0.9999033212661743
delirium O O 0.9999935626983643
or O O 0.9999305009841919
other O O 0.9999186992645264
potentially O O 0.9999169111251831
confounding O O 0.999841570854187
neurological O O 0.9999884366989136
dysfunctions O O 0.9999961853027344
. O O 0.9999682903289795

Patients O O 0.9998735189437866
were O O 0.9999940395355225
assessed O O 0.999992847442627
daily O O 0.9999877214431763
using O O 0.9999668598175049
the O O 0.9999816417694092
confusion O O 0.9998807907104492
assessment O O 0.9999537467956543
method O O 0.9999904632568359
for O O 0.999915599822998
the O O 0.9998869895935059
ICU O O 0.9912673830986023
scale O O 0.9998359680175781
for O O 0.9999531507492065
3 O O 0.9998781681060791
days O O 0.9999960660934448
after O O 0.9999964237213135
the O O 0.9999961853027344
surgical O O 0.9999960660934448
procedure O O 0.9999986886978149
. O O 0.9999856948852539

Early O O 0.9998726844787598
postoperative O O 0.9999243021011353
delirium O O 0.9997630715370178
incidence O O 0.9958849549293518
risk O O 0.9987712502479553
factors O O 0.9999921321868896
were O O 0.9999630451202393
then O O 0.9999854564666748
assessed O O 0.9999886751174927
through O O 0.9999650716781616
three O O 0.9999134540557861
different O O 0.9999850988388062
multiple O O 0.9970741271972656
regression O O 0.9999198913574219
models O O 0.9999901056289673
. O O 0.9999781847000122

RESULTS O O 0.9998742341995239
: O O 0.9999700784683228
According O O 0.9999939203262329
to O O 0.9999784231185913
the O O 0.9999856948852539
confusion O O 0.9999375343322754
assessment O O 0.9999836683273315
method O O 0.9999957084655762
for O O 0.999861478805542
the O O 0.9999208450317383
ICU O O 0.9958240985870361
scale O O 0.9997565150260925
, O O 0.9999756813049316
28 O O 0.9999666213989258
% O O 0.9999964237213135
of O O 0.9999873638153076
patients O O 0.9999891519546509
were O O 0.999976396560669
diagnosed O O 0.999991774559021
with O O 0.9999637603759766
early O O 0.999974250793457
postoperative O O 0.9999747276306152
delirium O O 0.999919056892395
. O O 0.9999774694442749

The O O 0.9999833106994629
use O O 0.9994540810585022
of O O 0.9969578981399536
thiopentone B B 0.9998082518577576
was O O 0.9999148845672607
significantly O O 0.9999831914901733
associated O O 0.9999784231185913
with O O 0.9999871253967285
an O O 0.9999911785125732
eight O O 0.9999816417694092
- O O 0.9999935626983643
fold O O 0.9999959468841553
- O O 0.9999946355819702
higher O O 0.9999939203262329
risk O O 0.9999985694885254
for O O 0.9999853372573853
delirium O O 0.9999935626983643
compared O O 0.9999780654907227
to O O 0.9971055388450623
propofol B B 0.9996514320373535
( O O 0.9996036887168884
57 O O 0.9999840259552002
. O O 0.9999818801879883
1 O O 0.9999891519546509
% O O 0.9999768733978271
vs O O 0.9998568296432495
. O O 0.999992847442627
7 O O 0.9999358654022217
. O O 0.9999901056289673
1 O O 0.999993085861206
% O O 0.9999843835830688
, O O 0.9999507665634155
RR O O 0.9817686080932617
= O O 0.9998026490211487
8 O O 0.9998601675033569
. O O 0.9999923706054688
0 O O 0.9999818801879883
, O O 0.999572217464447
X2 O O 0.9886292219161987
= O O 0.999863862991333
4 O O 0.9996259212493896
. O O 0.9999809265136719
256 O O 0.999946117401123
; O O 0.9999051094055176
df O O 0.7970188856124878
= O O 0.999527096748352
1 O O 0.9998281002044678
; O O 0.9999746084213257
0 O O 0.9999798536300659
. O O 0.9999911785125732
05 O O 0.9999891519546509
< O O 0.9972618818283081
p O O 0.6373720169067383
< O O 0.9999368190765381
0 O O 0.9999881982803345
. O O 0.9999953508377075
02 O O 0.9999871253967285
) O O 0.9999750852584839
. O O 0.999971866607666

CONCLUSION O O 0.9990370273590088
: O O 0.9999294281005859
In O O 0.999980092048645
this O O 0.9999676942825317
study O O 0.999954104423523
early O O 0.99992835521698
postoperative O O 0.9999381303787231
delirium O O 0.9998453855514526
was O O 0.9999674558639526
found O O 0.9999868869781494
to O O 0.9999775886535645
be O O 0.9999910593032837
a O O 0.9999866485595703
very O O 0.9999781847000122
common O O 0.9999862909317017
complication O O 0.9999957084655762
after O O 0.9999467134475708
major O O 0.9999570846557617
surgery O O 0.9999967813491821
, O O 0.9999866485595703
even O O 0.9999576807022095
in O O 0.999968409538269
a O O 0.999968409538269
population O O 0.9999887943267822
without O O 0.999987006187439
known O O 0.9999730587005615
risk O O 0.9999879598617554
factors O O 0.9999967813491821
. O O 0.999976396560669

Thiopentone B B 0.9993081092834473
was O O 0.9998980760574341
independently O O 0.9998569488525391
associated O O 0.9999616146087646
with O O 0.9999697208404541
an O O 0.9999799728393555
increase O O 0.9999873638153076
in O O 0.999990701675415
its O O 0.9999681711196899
relative O O 0.9999583959579468
risk O O 0.9999885559082031
. O O 0.9999573230743408

A O O 0.9999154806137085
single O O 0.9999209642410278
neurotoxic O O 0.9999791383743286
dose O O 0.9996509552001953
of O O 0.9981663823127747
methamphetamine B B 0.9994475245475769
induces O O 0.9997074007987976
a O O 0.9999827146530151
long O O 0.999813973903656
- O O 0.9999843835830688
lasting O O 0.9999867677688599
depressive O O 0.9997267127037048
- O O 0.9999724626541138
like O O 0.9999916553497314
behaviour O O 0.9999884366989136
in O O 0.9999724626541138
mice O O 0.9999845027923584
. O O 0.9999562501907349

Methamphetamine B B 0.9991971850395203
( O O 0.9726636409759521
METH B B 0.998755693435669
) O O 0.9986403584480286
triggers O O 0.9999058246612549
a O O 0.9999420642852783
disruption O O 0.999984860420227
of O O 0.9999336004257202
the O O 0.9999134540557861
monoaminergic O O 0.9872490763664246
system O O 0.9998779296875
and O O 0.9998503923416138
METH B B 0.9992576241493225
abuse O O 0.9994625449180603
leads O O 0.9999619722366333
to O O 0.9999768733978271
negative O O 0.9999308586120605
emotional O O 0.9999314546585083
states O O 0.9999892711639404
including O O 0.9999779462814331
depressive O O 0.9999030828475952
symptoms O O 0.9999855756759644
during O O 0.999914288520813
drug O O 0.9978647828102112
withdrawal O O 0.9998923540115356
. O O 0.9999465942382812

However O O 0.999955415725708
, O O 0.9999803304672241
it O O 0.9999933242797852
is O O 0.9999942779541016
currently O O 0.9999979734420776
unknown O O 0.9999953508377075
if O O 0.999991774559021
the O O 0.9999343156814575
acute O O 0.9998648166656494
toxic O O 0.9995549321174622
dosage O O 0.9998183846473694
of O O 0.9936011433601379
METH B B 0.9989515542984009
also O O 0.9998559951782227
causes O O 0.9998997449874878
a O O 0.9999579191207886
long O O 0.9996248483657837
- O O 0.9999761581420898
lasting O O 0.9999864101409912
depressive O O 0.9999455213546753
phenotype O O 0.9999864101409912
and O O 0.999972939491272
persistent O O 0.9999682903289795
monoaminergic O O 0.9890317320823669
deficits O O 0.9999815225601196
. O O 0.9999035596847534

Thus O O 0.9999845027923584
, O O 0.9999793767929077
we O O 0.9999799728393555
now O O 0.999990701675415
assessed O O 0.9999794960021973
the O O 0.9999568462371826
depressive O O 0.9977502226829529
- O O 0.9999121427536011
like O O 0.9999657869338989
behaviour O O 0.9999786615371704
in O O 0.9999188184738159
mice O O 0.9999940395355225
at O O 0.9999194145202637
early O O 0.999946117401123
and O O 0.9999485015869141
long O O 0.9998792409896851
- O O 0.999988317489624
term O O 0.9999940395355225
periods O O 0.9999918937683105
following O O 0.999970555305481
a O O 0.9999858140945435
single O O 0.9999719858169556
high O O 0.9902961850166321
METH B B 0.9810228943824768
dose O O 0.9981531500816345
( O O 0.9999065399169922
30 O O 0.9998811483383179
mg O O 0.9999192953109741
/ O O 0.9999741315841675
kg O O 0.999995231628418
, O O 0.9999750852584839
i O O 0.9999722242355347
. O O 0.9999970197677612
p O O 0.9999984502792358
. O O 0.9999963045120239
) O O 0.9999827146530151
. O O 0.9999810457229614

METH B B 0.9984966516494751
did O O 0.9999103546142578
not O O 0.9999644756317139
alter O O 0.9999716281890869
the O O 0.9999803304672241
motor O O 0.9999562501907349
function O O 0.999995231628418
and O O 0.9999465942382812
procedural O O 0.9997519850730896
memory O O 0.9999946355819702
of O O 0.9999637603759766
mice O O 0.9754535555839539
as O O 0.9999798536300659
assessed O O 0.9999970197677612
by O O 0.9999916553497314
swimming O O 0.999975323677063
speed O O 0.9999926090240479
and O O 0.9999728202819824
escape O O 0.9999849796295166
latency O O 0.9999979734420776
to O O 0.9999960660934448
find O O 0.9999986886978149
the O O 0.9999984502792358
platform O O 0.999998927116394
in O O 0.9999780654907227
a O O 0.9999791383743286
cued O O 0.9999501705169678
version O O 0.9999948740005493
of O O 0.9999886751174927
the O O 0.9999935626983643
water O O 0.9986415505409241
maze O O 0.9999707937240601
task O O 0.9999933242797852
. O O 0.9999661445617676

However O O 0.9999483823776245
, O O 0.9994231462478638
METH B B 0.9987558126449585
significantly O O 0.9998143315315247
increased O O 0.999893069267273
the O O 0.9999915361404419
immobility O O 0.9999935626983643
time O O 0.9999943971633911
in O O 0.9999774694442749
the O O 0.999984622001648
tail O O 0.9998829364776611
suspension O O 0.9996769428253174
test O O 0.9999685287475586
at O O 0.9999576807022095
3 O O 0.9998968839645386
and O O 0.9999831914901733
49 O O 0.9999926090240479
days O O 0.9999983310699463
post O O 0.999962329864502
- O O 0.9997228980064392
administration O O 0.9999622106552124
. O O 0.9999715089797974

This O O 0.9998682737350464
depressive O O 0.9991703033447266
- O O 0.9999330043792725
like O O 0.9999792575836182
profile O O 0.9999833106994629
induced O O 0.9999500513076782
by O O 0.9997479319572449
METH B B 0.99872225522995
was O O 0.9998899698257446
accompanied O O 0.9999682903289795
by O O 0.9999425411224365
a O O 0.999940037727356
marked O O 0.9999381303787231
depletion O O 0.9999440908432007
of O O 0.9998199343681335
frontostriatal O O 0.9952048063278198
dopaminergic O B 0.9842294454574585
and O O 0.9975295662879944
serotonergic O O 0.5825960040092468
neurotransmission O O 0.9999077320098877
, O O 0.9999874830245972
indicated O O 0.9999911785125732
by O O 0.9999905824661255
a O O 0.9999790191650391
reduction O O 0.9999871253967285
in O O 0.99997878074646
the O O 0.9999470710754395
levels O O 0.9998921155929565
of O O 0.9995554089546204
dopamine B B 0.9991430044174194
, O O 0.9937921166419983
DOPAC B B 0.9982263445854187
and O O 0.9912431240081787
HVA B B 0.8818424940109253
, O O 0.9873437881469727
tyrosine B B 0.9585874080657959
hydroxylase O O 0.5152180790901184
and O O 0.9985439777374268
serotonin B B 0.966559648513794
, O O 0.9999028444290161
observed O O 0.9999850988388062
at O O 0.9999552965164185
both O O 0.9999592304229736
3 O O 0.9998692274093628
and O O 0.9999818801879883
49 O O 0.999993085861206
days O O 0.9999972581863403
post O O 0.9999426603317261
- O O 0.9998214840888977
administration O O 0.9999397993087769
. O O 0.9999269247055054

In O O 0.9999526739120483
parallel O O 0.9999531507492065
, O O 0.9999837875366211
another O O 0.9998977184295654
neurochemical O O 0.999984622001648
feature O O 0.9999938011169434
of O O 0.9999645948410034
depression O O 0.9997779726982117
- O O 0.9981378316879272
- O O 0.9995173215866089
astroglial O O 0.998513400554657
dysfunction O O 0.9999912977218628
- O O 0.9946750402450562
- O O 0.9595013856887817
was O O 0.9999662637710571
unaffected O O 0.9998262524604797
in O O 0.9998137354850769
the O O 0.9999148845672607
cortex O O 0.9999786615371704
and O O 0.9999744892120361
the O O 0.9999780654907227
striatal O O 0.9978681802749634
levels O O 0.9998506307601929
of O O 0.9992631077766418
the O O 0.9996631145477295
astrocytic O O 0.9959385395050049
protein O O 0.9981274008750916
marker O O 0.9996504783630371
, O O 0.9948530793190002
glial O O 0.7374751567840576
fibrillary O O 0.9943035840988159
acidic O O 0.9887892007827759
protein O O 0.9960196614265442
, O O 0.9999715089797974
were O O 0.9999747276306152
only O O 0.9999853372573853
transiently O O 0.999993085861206
increased O O 0.9999680519104004
at O O 0.9999884366989136
3 O O 0.9998550415039062
days O O 0.9999954700469971
. O O 0.9999762773513794

These O O 0.9999769926071167
findings O O 0.9999936819076538
demonstrate O O 0.9999873638153076
for O O 0.9999964237213135
the O O 0.9999929666519165
first O O 0.999990701675415
time O O 0.9999890327453613
that O O 0.999975323677063
a O O 0.9999665021896362
single O O 0.9999351501464844
high O O 0.9994303584098816
dose O O 0.9991045594215393
of O O 0.9951285123825073
METH B B 0.9987648725509644
induces O O 0.9995023012161255
long O O 0.9996312856674194
- O O 0.9999716281890869
lasting O O 0.9999769926071167
depressive O O 0.9997554421424866
- O O 0.9999591112136841
like O O 0.999990701675415
behaviour O O 0.9999905824661255
in O O 0.9998964071273804
mice O O 0.9999357461929321
associated O O 0.9999716281890869
with O O 0.9999628067016602
a O O 0.9999605417251587
persistent O O 0.9999617338180542
disruption O O 0.9999722242355347
of O O 0.9999337196350098
frontostriatal O O 0.9999006986618042
dopaminergic O O 0.7563415169715881
and O O 0.9984027743339539
serotonergic O O 0.7316511869430542
homoeostasis O O 0.9934915900230408
. O O 0.9999606609344482

Linezolid B B 0.999518632888794
- O O 0.9996823072433472
induced O O 0.9999291896820068
optic O O 0.9999357461929321
neuropathy O O 0.9999921321868896
. O O 0.9999502897262573

Many O O 0.9960113763809204
systemic O O 0.9989438652992249
antimicrobials O O 0.4820899963378906
have O O 0.9989492297172546
been O O 0.9999439716339111
implicated O O 0.9992744326591492
to O O 0.9998692274093628
cause O O 0.9998934268951416
ocular O O 0.9998358488082886
adverse O O 0.9999696016311646
effects O O 0.9999892711639404
. O O 0.999957799911499

This O O 0.9999669790267944
is O O 0.9999746084213257
especially O O 0.9999567270278931
relevant O O 0.9999903440475464
in O O 0.9999099969863892
multidrug O O 0.6193752884864807
therapy O O 0.9997320771217346
where O O 0.999962329864502
more O O 0.9997954964637756
than O O 0.9999618530273438
one O O 0.9999152421951294
drug O O 0.9989135265350342
can O O 0.9998807907104492
cause O O 0.9999412298202515
a O O 0.9999748468399048
similar O O 0.9999465942382812
ocular O O 0.9998131394386292
adverse O O 0.9999850988388062
effect O O 0.9999948740005493
. O O 0.9999713897705078

We O O 0.999946117401123
describe O O 0.9999914169311523
a O O 0.9999916553497314
case O O 0.9999971389770508
of O O 0.9999873638153076
progressive O O 0.9999926090240479
loss O O 0.9999985694885254
of O O 0.9999964237213135
vision O O 0.9999973773956299
associated O O 0.9999823570251465
with O O 0.9998109936714172
linezolid B B 0.9997603297233582
therapy O O 0.9995187520980835
. O O 0.9999773502349854

A O O 0.9999865293502808
45 O O 0.9999970197677612
- O O 0.9999909400939941
year O O 0.9999969005584717
- O O 0.9999935626983643
old O O 0.9999929666519165
male O O 0.9999923706054688
patient O O 0.9999808073043823
who O O 0.9999494552612305
was O O 0.9999557733535767
on O O 0.999692440032959
treatment O O 0.9999690055847168
with O O 0.9998749494552612
multiple O O 0.9998331069946289
second O O 0.9998513460159302
- O O 0.9999370574951172
line O O 0.9927145838737488
anti O O 0.7943460941314697
- O O 0.9944210648536682
tuberculous O O 0.9991323351860046
drugs O O 0.997208297252655
including O O 0.9991980195045471
linezolid B B 0.9997829794883728
and O O 0.9205135703086853
ethambutol B B 0.9944126009941101
for O O 0.999580442905426
extensively O O 0.9916824102401733
drug O O 0.9970888495445251
- O O 0.9996945858001709
resistant O O 0.9996843338012695
tuberculosis O O 0.9989649057388306
( O O 0.9995095729827881
XDR O O 0.668864905834198
- O O 0.8944920301437378
TB O O 0.6527903079986572
) O O 0.9996554851531982
presented O O 0.9999831914901733
to O O 0.9999966621398926
us O O 0.9999990463256836
with O O 0.9999918937683105
painless O O 0.9999909400939941
progressive O O 0.9999979734420776
loss O O 0.9999994039535522
of O O 0.9999974966049194
vision O O 0.9999991655349731
in O O 0.9999946355819702
both O O 0.9999657869338989
eyes O O 0.999997615814209
. O O 0.9999840259552002

Color O O 0.9852539896965027
vision O O 0.99997878074646
was O O 0.9999641180038452
defective O O 0.9999922513961792
and O O 0.999950647354126
fundus O O 0.999969482421875
examination O O 0.9999886751174927
revealed O O 0.9999514818191528
optic O O 0.9998983144760132
disc O O 0.9998514652252197
edema O O 0.9999638795852661
in O O 0.999943733215332
both O O 0.9998365640640259
eyes O O 0.9999936819076538
. O O 0.9999700784683228

Ethambutol B B 0.9986805319786072
- O O 0.9998241066932678
induced O O 0.9998956918716431
toxic O O 0.9997109770774841
optic O O 0.9998281002044678
neuropathy O O 0.999992847442627
was O O 0.9999728202819824
suspected O O 0.9999810457229614
and O O 0.9999759197235107
tablet O O 0.9938892126083374
ethambutol B B 0.9973509311676025
was O O 0.9999001026153564
withdrawn O O 0.9996768236160278
. O O 0.9999665021896362

Deterioration O O 0.9999815225601196
of O O 0.9999934434890747
vision O O 0.9999971389770508
occurred O O 0.9999837875366211
despite O O 0.9998089671134949
withdrawal O O 0.9996522665023804
of O O 0.9986910223960876
ethambutol B B 0.9989483952522278
. O O 0.999924898147583

Discontinuation O O 0.9999344348907471
of O O 0.9989476799964905
linezolid B B 0.9997958540916443
resulted O O 0.9998705387115479
in O O 0.9999905824661255
marked O O 0.9999881982803345
improvement O O 0.999997615814209
of O O 0.999992847442627
vision O O 0.9999971389770508
. O O 0.9999542236328125

Our O O 0.9999667406082153
report O O 0.9999945163726807
emphasizes O O 0.9999442100524902
the O O 0.9999958276748657
need O O 0.9999955892562866
for O O 0.9999933242797852
monitoring O O 0.9999932050704956
of O O 0.9999805688858032
visual O O 0.9996664524078369
function O O 0.999996542930603
in O O 0.9999856948852539
patients O O 0.9999943971633911
on O O 0.9999231100082397
long O O 0.9998632669448853
- O O 0.999987006187439
term O O 0.9997921586036682
linezolid B B 0.9997692704200745
treatment O O 0.9996589422225952
. O O 0.9999833106994629

Resuscitation O O 0.9998201727867126
with O O 0.9998834133148193
lipid O B 0.880295991897583
, O O 0.9109389185905457
epinephrine B B 0.950947642326355
, O O 0.9685271382331848
or O O 0.9965613484382629
both O O 0.9126045107841492
in O O 0.9998156428337097
levobupivacaine B B 0.9996017813682556
- O O 0.9998451471328735
induced O O 0.999945878982544
cardiac O O 0.9999542236328125
toxicity O O 0.9999896287918091
in O O 0.999967098236084
newborn O O 0.9999942779541016
piglets O O 0.9999806880950928
. O O 0.9999266862869263

BACKGROUND O O 0.9996119141578674
: O O 0.9999849796295166
The O O 0.9999908208847046
optimal O O 0.9999555349349976
dosing O O 0.999840497970581
regimens O O 0.9986395239830017
of O O 0.9997653365135193
lipid O B 0.9135851263999939
emulsion O O 0.5022532343864441
, O O 0.9867826700210571
epinephrine B B 0.995606005191803
, O O 0.999079704284668
or O O 0.9994871616363525
both O O 0.9978070855140686
are O O 0.9999891519546509
not O O 0.9999986886978149
yet O O 0.9999988079071045
determined O O 0.9999966621398926
in O O 0.9999797344207764
neonates O O 0.9999969005584717
in O O 0.9999698400497437
cases O O 0.9999871253967285
of O O 0.9999817609786987
local O O 0.9976502060890198
anaesthetic O O 0.9628696441650391
systemic O O 0.9990341663360596
toxicity O O 0.9999637603759766
( O O 0.9999241828918457
LAST O O 0.9720761775970459
) O O 0.9999896287918091
. O O 0.9999830722808838

METHODS O O 0.9982630610466003
: O O 0.9999614953994751
Newborn O O 0.9999703168869019
piglets O O 0.999955415725708
received O O 0.9991699457168579
levobupivacaine B B 0.9994088411331177
until O O 0.999845027923584
cardiovascular O O 0.9999946355819702
collapse O O 0.9999986886978149
occurred O O 0.999997615814209
. O O 0.999975323677063

Standard O O 0.9991974234580994
cardiopulmonary O O 0.9999759197235107
resuscitation O O 0.999951958656311
was O O 0.999958872795105
started O O 0.9999754428863525
and O O 0.9999566078186035
electrocardiogram O O 0.9998931884765625
( O O 0.9999496936798096
ECG O O 0.9997443556785583
) O O 0.9999635219573975
was O O 0.9999737739562988
monitored O O 0.9999889135360718
for O O 0.999967098236084
ventricular O O 0.9988999366760254
tachycardia O O 0.9999679327011108
, O O 0.9999274015426636
fibrillation O O 0.9999626874923706
, O O 0.9998360872268677
or O O 0.9988769888877869
QRS O O 0.9792330861091614
prolongation O O 0.9999183416366577
. O O 0.9999570846557617

Piglets O O 0.9985456466674805
were O O 0.9999785423278809
then O O 0.9999960660934448
randomly O O 0.9999911785125732
allocated O O 0.999992847442627
to O O 0.9999563694000244
four O O 0.9999688863754272
groups O O 0.9999834299087524
: O O 0.9999788999557495
control O O 0.9999182224273682
( O O 0.9997852444648743
saline O O 0.9999271631240845
) O O 0.9999377727508545
, O O 0.999875545501709
Intralipid O B 0.8991674184799194
( O O 0.889083981513977
) O O 0.7987139821052551
alone O O 0.9985182881355286
, O O 0.9998037219047546
epinephrine B B 0.9693620204925537
alone O O 0.9983444213867188
, O O 0.999927282333374
or O O 0.9999504089355469
a O O 0.9999855756759644
combination O O 0.9996485710144043
of O O 0.9998356103897095
Intralipd O B 0.959403395652771
plus O O 0.982650101184845
epinephrine B B 0.9454075694084167
. O O 0.9999333620071411

Resuscitation O O 0.9984257221221924
continued O O 0.9999567270278931
for O O 0.9999486207962036
30 O O 0.9999804496765137
min O O 0.9999724626541138
or O O 0.9999814033508301
until O O 0.9999706745147705
there O O 0.9999905824661255
was O O 0.9999926090240479
a O O 0.9999927282333374
return O O 0.9999959468841553
of O O 0.9999817609786987
spontaneous O O 0.9999730587005615
circulation O O 0.9999959468841553
( O O 0.9999234676361084
ROSC O O 0.9985871315002441
) O O 0.9999722242355347
accompanied O O 0.9999591112136841
by O O 0.9999783039093018
a O O 0.9999847412109375
mean O O 0.9999299049377441
arterial O O 0.9991528987884521
pressure O O 0.9999363422393799
at O O 0.999963641166687
or O O 0.9999933242797852
superior O O 0.9999805688858032
to O O 0.9999918937683105
the O O 0.9999938011169434
baseline O O 0.9999626874923706
pressure O O 0.9999691247940063
and O O 0.9999651908874512
normal O O 0.9999927282333374
sinus O O 0.9999946355819702
rhythm O O 0.9999966621398926
for O O 0.9999680519104004
a O O 0.999983549118042
period O O 0.9999915361404419
of O O 0.999984860420227
30 O O 0.9999915361404419
min O O 0.9999855756759644
. O O 0.9999750852584839

RESULTS O O 0.9995205402374268
: O O 0.9997732043266296
ROSC O O 0.9410172700881958
was O O 0.9999558925628662
achieved O O 0.9998877048492432
in O O 0.9998841285705566
only O O 0.9999585151672363
one O O 0.9999560117721558
of O O 0.9999183416366577
the O O 0.9999597072601318
control O O 0.9997870326042175
piglets O O 0.9999631643295288
compared O O 0.9999468326568604
with O O 0.9999334812164307
most O O 0.9999170303344727
of O O 0.9999592304229736
the O O 0.9999622106552124
treated O O 0.999777615070343
piglets O O 0.9999794960021973
. O O 0.9999676942825317

Mortality O O 0.9747090339660645
was O O 0.9999616146087646
not O O 0.9999948740005493
significantly O O 0.999992847442627
different O O 0.9999868869781494
between O O 0.9998099207878113
the O O 0.9999223947525024
three O O 0.9997186064720154
treatment O O 0.9997935891151428
groups O O 0.9999834299087524
, O O 0.9999572038650513
but O O 0.9999613761901855
was O O 0.9999619722366333
significantly O O 0.9999872446060181
lower O O 0.999981164932251
in O O 0.9998539686203003
all O O 0.9998520612716675
the O O 0.9998989105224609
treatment O O 0.9997368454933167
groups O O 0.9999594688415527
compared O O 0.9999796152114868
with O O 0.999880313873291
control O O 0.9997358918190002
. O O 0.999972939491272

The O O 0.9999828338623047
number O O 0.9999889135360718
of O O 0.9999526739120483
ECG O O 0.9889686107635498
abnormalities O O 0.9999572038650513
was O O 0.9999494552612305
zero O O 0.9999899864196777
in O O 0.9998587369918823
the O O 0.9996191263198853
Intralipid O B 0.87546706199646
only O O 0.9971701502799988
group O O 0.9997813105583191
, O O 0.9999556541442871
but O O 0.9999685287475586
14 O O 0.9997096657752991
and O O 0.9999744892120361
17 O O 0.999924898147583
, O O 0.9999908208847046
respectively O O 0.9999831914901733
, O O 0.9999935626983643
in O O 0.9997486472129822
the O O 0.9994252920150757
epinephrine B B 0.8859720826148987
and O O 0.9967010617256165
epinephrine B B 0.9285142421722412
plus O O 0.9854153990745544
lipid O B 0.9325836896896362
groups O O 0.998241662979126
( O O 0.9999687671661377
P O O 0.9999551773071289
< O O 0.9999668598175049
0 O O 0.9999920129776001
. O O 0.999996542930603
05 O O 0.9999921321868896
) O O 0.9999750852584839
. O O 0.9999754428863525

CONCLUSIONS O O 0.989996075630188
: O O 0.9995396137237549
Lipid O O 0.740412175655365
emulsion O O 0.9959134459495544
with O O 0.9998728036880493
or O O 0.9999046325683594
without O O 0.9999222755432129
epinephrine B B 0.9532808065414429
, O O 0.9939752221107483
or O O 0.9998714923858643
epinephrine B B 0.9948245286941528
alone O O 0.9997246861457825
were O O 0.9999562501907349
equally O O 0.9999328851699829
effective O O 0.9999301433563232
in O O 0.9999399185180664
achieving O O 0.9999737739562988
a O O 0.9999858140945435
return O O 0.9999979734420776
to O O 0.999992847442627
spontaneous O O 0.9999904632568359
circulation O O 0.9999943971633911
in O O 0.999962568283081
this O O 0.9999673366546631
model O O 0.9999840259552002
of O O 0.9999505281448364
LAST O O 0.9848039150238037
. O O 0.9999700784683228

Epinephrine B B 0.9891971945762634
alone O O 0.9996393918991089
or O O 0.9999246597290039
in O O 0.9999433755874634
combination O O 0.9998449087142944
with O O 0.9994677901268005
lipid O B 0.95624178647995
was O O 0.9998883008956909
associated O O 0.9999594688415527
with O O 0.9999862909317017
an O O 0.9999861717224121
increased O O 0.9999948740005493
number O O 0.9999945163726807
of O O 0.9999727010726929
ECG O O 0.993200957775116
abnormalities O O 0.9999772310256958
compared O O 0.9999926090240479
with O O 0.9999097585678101
lipid O B 0.8942888975143433
emulsion O O 0.992573618888855
alone O O 0.9999303817749023
. O O 0.9999500513076782

Incidence O O 0.9999861717224121
of O O 0.9999383687973022
heparin B B 0.9939923882484436
- O O 0.9983410835266113
induced O O 0.9999392032623291
thrombocytopenia O O 0.9998766183853149
type O O 0.9997761845588684
II O O 0.9894436597824097
and O O 0.9999117851257324
postoperative O O 0.9999492168426514
recovery O O 0.9999964237213135
of O O 0.9999626874923706
platelet O O 0.9974372386932373
count O O 0.9998509883880615
in O O 0.9999301433563232
liver O O 0.9812589287757874
graft O O 0.9997604489326477
recipients O O 0.9999849796295166
: O O 0.9999961853027344
a O O 0.9999909400939941
retrospective O O 0.9999895095825195
cohort O O 0.9999555349349976
analysis O O 0.9999938011169434
. O O 0.9999886751174927

BACKGROUND O O 0.9966268539428711
: O O 0.9998151659965515
Thrombocytopenia O O 0.9987987279891968
in O O 0.9999419450759888
patients O O 0.999991774559021
with O O 0.9999864101409912
end O O 0.9999681711196899
- O O 0.9999830722808838
stage O O 0.9999896287918091
liver O O 0.9996572732925415
disease O O 0.999997615814209
is O O 0.9999703168869019
a O O 0.9999786615371704
common O O 0.9999572038650513
disorder O O 0.9999966621398926
caused O O 0.9999871253967285
mainly O O 0.9999791383743286
by O O 0.9999239444732666
portal O O 0.9976196885108948
hypertension O O 0.9956983327865601
, O O 0.9999074935913086
low O O 0.9998953342437744
levels O O 0.999840497970581
of O O 0.9902834296226501
thrombopoetin O O 0.5387645959854126
, O O 0.9950796365737915
and O O 0.9996517896652222
endotoxemia O O 0.9365485310554504
. O O 0.9999573230743408

The O O 0.9999833106994629
impact O O 0.999985933303833
of O O 0.9999377727508545
immune O O 0.9882549047470093
- O O 0.9998902082443237
mediated O O 0.9998959302902222
heparin B B 0.9923608899116516
- O O 0.9985484480857849
induced O O 0.9999325275421143
thrombocytopenia O O 0.9996418952941895
type O O 0.9998579025268555
II O O 0.981370747089386
( O O 0.9994432330131531
HIT O O 0.9755216240882874
type O O 0.9997597336769104
II O O 0.9697532653808594
) O O 0.9998712539672852
as O O 0.9999397993087769
a O O 0.9999587535858154
cause O O 0.9999861717224121
of O O 0.9999754428863525
thrombocytopenia O O 0.9998480081558228
after O O 0.9998749494552612
liver O O 0.9979085922241211
transplantation O O 0.9999432563781738
is O O 0.9999842643737793
not O O 0.9999973773956299
yet O O 0.9999980926513672
understood O O 0.999995231628418
, O O 0.9999815225601196
with O O 0.9999905824661255
few O O 0.9999922513961792
literature O O 0.9999829530715942
citations O O 0.9999810457229614
reporting O O 0.9999769926071167
contradictory O O 0.9999948740005493
results O O 0.9999974966049194
. O O 0.9999837875366211

The O O 0.9999903440475464
aim O O 0.999996542930603
of O O 0.9999927282333374
our O O 0.9999816417694092
study O O 0.9999876022338867
was O O 0.9999939203262329
to O O 0.9999929666519165
demonstrate O O 0.9999862909317017
the O O 0.9999938011169434
perioperative O O 0.9999854564666748
course O O 0.9999926090240479
of O O 0.9999573230743408
thrombocytopenia O O 0.9965925812721252
after O O 0.9998947381973267
liver O O 0.9932565689086914
transplantation O O 0.9998843669891357
and O O 0.9999780654907227
determine O O 0.9999881982803345
the O O 0.9999912977218628
occurrence O O 0.9999945163726807
of O O 0.9999724626541138
clinical O O 0.9999483823776245
HIT O O 0.9873040318489075
type O O 0.9998955726623535
II O O 0.9997665286064148
. O O 0.9999788999557495

METHOD O O 0.999934196472168
: O O 0.9999947547912598
We O O 0.9999921321868896
retrospectively O O 0.999992847442627
evaluated O O 0.999996542930603
the O O 0.9999963045120239
medical O O 0.9999978542327881
records O O 0.9999984502792358
of O O 0.9999908208847046
205 O O 0.999988317489624
consecutive O O 0.9999891519546509
adult O O 0.9999958276748657
patients O O 0.9999971389770508
who O O 0.9999755620956421
underwent O O 0.9999921321868896
full O O 0.9998819828033447
- O O 0.9999791383743286
size O O 0.9995519518852234
liver O O 0.9992395639419556
transplantation O O 0.9999804496765137
between O O 0.9992040991783142
January O O 0.9944599866867065
2006 O O 0.9922415018081665
and O O 0.9993113279342651
December O O 0.9959050416946411
2010 O O 0.9994950294494629
due O O 0.9999884366989136
to O O 0.9999895095825195
end O O 0.9999309778213501
- O O 0.9999793767929077
stage O O 0.9999887943267822
or O O 0.9999581575393677
malignant O O 0.9999923706054688
liver O O 0.9987228512763977
disease O O 0.9999973773956299
. O O 0.9999614953994751

Preoperative O O 0.9998506307601929
platelet O O 0.9940512776374817
count O O 0.9998693466186523
, O O 0.999961256980896
postoperative O O 0.9999351501464844
course O O 0.9999833106994629
of O O 0.9997954964637756
platelets O O 0.9718217849731445
, O O 0.9999147653579712
and O O 0.9999641180038452
clinical O O 0.9999772310256958
signs O O 0.999990701675415
of O O 0.9999711513519287
HIT O O 0.5634417533874512
type O O 0.9990565180778503
II O O 0.9778265953063965
were O O 0.9999610185623169
analyzed O O 0.9999488592147827
. O O 0.9999597072601318

RESULTS O O 0.9999479055404663
: O O 0.9999551773071289
A O O 0.9999805688858032
total O O 0.9999828338623047
of O O 0.9999822378158569
155 O O 0.9999417066574097
( O O 0.9999775886535645
75 O O 0.9999967813491821
. O O 0.9999926090240479
6 O O 0.9999951124191284
% O O 0.9999966621398926
) O O 0.9999933242797852
of O O 0.9999895095825195
205 O O 0.9999197721481323
patients O O 0.9999911785125732
had O O 0.9999666213989258
thrombocytopenia O O 0.9998501539230347
before O O 0.9999545812606812
transplantation O O 0.9999665021896362
, O O 0.999974250793457
significantly O O 0.9999682903289795
influenced O O 0.9999871253967285
by O O 0.9999603033065796
Model O O 0.998955488204956
of O O 0.9999525547027588
End O O 0.9999550580978394
- O O 0.9999855756759644
Stage O O 0.9999868869781494
Liver O O 0.9992167949676514
Disease O O 0.9999955892562866
score O O 0.9998088479042053
and O O 0.9999092817306519
liver O O 0.9978232383728027
cirrhosis O O 0.9995982050895691
. O O 0.9999659061431885

The O O 0.9999833106994629
platelet O O 0.9990781545639038
count O O 0.9998857975006104
exceeded O O 0.9999322891235352
100 O O 0.9999349117279053
, O O 0.9999979734420776
000 O O 0.9999964237213135
/ O O 0.9999487400054932
uL O O 0.999642014503479
in O O 0.9999476671218872
most O O 0.9999916553497314
of O O 0.9999843835830688
the O O 0.9999865293502808
patients O O 0.9999918937683105
( O O 0.9999662637710571
n O O 0.9999682903289795
= O O 0.9999465942382812
193 O O 0.9605052471160889
) O O 0.9999773502349854
at O O 0.9999587535858154
a O O 0.9999659061431885
medium O O 0.999941349029541
of O O 0.9999040365219116
7 O O 0.9997405409812927
d O O 0.9999358654022217
. O O 0.999870777130127

Regarding O O 0.9980202913284302
HIT O O 0.9524430632591248
II O O 0.5783654451370239
, O O 0.9998341798782349
there O O 0.9999226331710815
were O O 0.9999713897705078
four O O 0.9999922513961792
( O O 0.9998884201049805
1 O O 0.9999759197235107
. O O 0.9999905824661255
95 O O 0.9999926090240479
% O O 0.9999949932098389
) O O 0.9999507665634155
patients O O 0.999994158744812
with O O 0.9999575614929199
a O O 0.9999724626541138
background O O 0.999987006187439
of O O 0.9999585151672363
HIT O O 0.9951024055480957
type O O 0.999863862991333
II O O 0.9634944796562195
. O O 0.9999539852142334

CONCLUSIONS O O 0.9983716607093811
: O O 0.9999880790710449
The O O 0.999993085861206
incidence O O 0.9999918937683105
of O O 0.9999396800994873
HIT O O 0.9957616925239563
in O O 0.9999462366104126
patients O O 0.9999916553497314
with O O 0.9999845027923584
end O O 0.9999549388885498
- O O 0.9999743700027466
stage O O 0.9999922513961792
hepatic O O 0.9999001026153564
failure O O 0.9999922513961792
is O O 0.9999517202377319
, O O 0.9999960660934448
with O O 0.9999960660934448
about O O 0.9999924898147583
1 O O 0.9999741315841675
. O O 0.9999957084655762
95 O O 0.9999784231185913
% O O 0.9999961853027344
, O O 0.9999861717224121
rare O O 0.9999220371246338
. O O 0.9999653100967407

For O O 0.999861478805542
further O O 0.9999525547027588
reduction O O 0.9999483823776245
of O O 0.9999175071716309
HIT O O 0.6217545866966248
type O O 0.9978808760643005
II O O 0.9845716953277588
, O O 0.9999711513519287
the O O 0.9999849796295166
use O O 0.9999613761901855
of O O 0.9999123811721802
intravenous O O 0.9999344348907471
heparin B B 0.9935146570205688
should O O 0.9983949065208435
be O O 0.9999898672103882
avoided O O 0.9998626708984375
and O O 0.9999337196350098
the O O 0.9999744892120361
prophylactic O O 0.9998922348022461
anticoagulation O O 0.7639119029045105
should O O 0.9999326467514038
be O O 0.9999926090240479
performed O O 0.9999892711639404
with O O 0.9999104738235474
low O O 0.999373733997345
- O O 0.9999558925628662
molecular O O 0.9996767044067383
- O O 0.9999603033065796
weight O O 0.9947872161865234
heparin B B 0.9501992464065552
after O O 0.9997480511665344
normalization O O 0.9999892711639404
of O O 0.9999523162841797
platelet O O 0.999779999256134
count O O 0.9999701976776123
. O O 0.9999520778656006

Takotsubo O B 0.9640524387359619
syndrome O O 0.9988162517547607
( O O 0.9999375343322754
or O O 0.9997519850730896
apical O O 0.9986287355422974
ballooning O O 0.9997773766517639
syndrome O O 0.9999614953994751
) O O 0.9999635219573975
secondary O O 0.9999432563781738
to O O 0.9979121088981628
Zolmitriptan B B 0.9996955394744873
. O O 0.9998944997787476

Takotsubo O B 0.9908257126808167
syndrome O O 0.9990584254264832
( O O 0.9998724460601807
TS O O 0.9444476962089539
) O O 0.9999690055847168
, O O 0.999990701675415
also O O 0.9999880790710449
known O O 0.9999769926071167
as O O 0.9999898672103882
broken O O 0.9998836517333984
heart O O 0.9999815225601196
syndrome O O 0.999990701675415
, O O 0.9999854564666748
is O O 0.9999580383300781
characterized O O 0.9999923706054688
by O O 0.9999690055847168
left O O 0.9998243451118469
ventricle O O 0.9999903440475464
apical O O 0.9967881441116333
ballooning O O 0.9996652603149414
with O O 0.999954104423523
elevated O O 0.9999282360076904
cardiac O O 0.9998770952224731
biomarkers O O 0.9987404942512512
and O O 0.999963641166687
electrocardiographic O O 0.999980092048645
changes O O 0.9999984502792358
suggestive O O 0.9999940395355225
of O O 0.9999841451644897
an O O 0.9999642372131348
acute O O 0.9999514818191528
coronary O O 0.9999513626098633
syndrome O O 0.9999912977218628
( O O 0.9999748468399048
ie O O 0.9999676942825317
, O O 0.9999605417251587
ST O O 0.9917775392532349
- O O 0.9999289512634277
segment O O 0.9999822378158569
elevation O O 0.999988317489624
, O O 0.9999524354934692
T O O 0.9977647066116333
wave O O 0.9999700784683228
inversions O O 0.9999591112136841
, O O 0.9999325275421143
and O O 0.9999725818634033
pathologic O O 0.9999911785125732
Q O O 0.998913049697876
waves O O 0.9999964237213135
) O O 0.9999808073043823
. O O 0.9999641180038452

We O O 0.9999840259552002
report O O 0.9999983310699463
a O O 0.9999972581863403
case O O 0.9999985694885254
of O O 0.9999943971633911
54 O O 0.9999898672103882
- O O 0.9999853372573853
year O O 0.9999972581863403
- O O 0.9999938011169434
old O O 0.9999964237213135
woman O O 0.9999985694885254
with O O 0.9999593496322632
medical O O 0.9999947547912598
history O O 0.9999945163726807
of O O 0.9999607801437378
mitral O O 0.9999122619628906
valve O O 0.9999459981918335
prolapse O O 0.9998161196708679
and O O 0.9999407529830933
migraines O O 0.9999866485595703
, O O 0.9999836683273315
who O O 0.9999738931655884
was O O 0.9999836683273315
admitted O O 0.9999886751174927
to O O 0.9999939203262329
the O O 0.9999983310699463
hospital O O 0.9999973773956299
for O O 0.9999873638153076
substernal O O 0.9997459053993225
chest O O 0.9999943971633911
pain O O 0.9999958276748657
and O O 0.9999771118164062
electrocardiogram O O 0.9999494552612305
demonstrated O O 0.9999680519104004
1 O O 0.9998018145561218
/ O O 0.9999860525131226
2 O O 0.9999840259552002
mm O O 0.9999951124191284
ST O O 0.9850296378135681
- O O 0.9998883008956909
segment O O 0.9999227523803711
elevation O O 0.9999845027923584
in O O 0.9999362230300903
leads O O 0.9999616146087646
II O O 0.9984952211380005
, O O 0.9996142387390137
III O O 0.9987181425094604
, O O 0.9992944002151489
aVF O O 0.9627634286880493
, O O 0.9996191263198853
V5 O O 0.999516487121582
, O O 0.9989041090011597
and O O 0.9995286464691162
V6 O O 0.9995334148406982
and O O 0.9998835325241089
positive O O 0.9997997879981995
troponin O O 0.72161865234375
I O O 0.8964822888374329
. O O 0.9998419284820557

Emergent O O 0.9999306201934814
coronary O O 0.9999417066574097
angiogram O O 0.9999315738677979
revealed O O 0.9999603033065796
normal O O 0.9999614953994751
coronary O O 0.9998877048492432
arteries O O 0.9999042749404907
with O O 0.9999408721923828
moderately O O 0.9999672174453735
reduced O O 0.9999852180480957
left O O 0.9999638795852661
ventricular O O 0.9999953508377075
ejection O O 0.9998726844787598
fraction O O 0.9999940395355225
with O O 0.9999120235443115
wall O O 0.9996966123580933
motion O O 0.999984622001648
abnormalities O O 0.9999864101409912
consistent O O 0.999988317489624
with O O 0.999936580657959
TS O O 0.9750457406044006
. O O 0.9998927116394043

Detailed O O 0.9999562501907349
history O O 0.9999858140945435
obtained O O 0.9999864101409912
retrospectively O O 0.9999805688858032
revealed O O 0.9999904632568359
that O O 0.9999408721923828
the O O 0.999992847442627
patient O O 0.999992847442627
took O O 0.9981628060340881
zolmitriptan B B 0.9997758269309998
sparingly O O 0.9997038245201111
only O O 0.9999197721481323
when O O 0.9999432563781738
she O O 0.9999922513961792
had O O 0.999981164932251
migraines O O 0.9999916553497314
. O O 0.9999585151672363

But O O 0.9999572038650513
before O O 0.9999922513961792
this O O 0.9999932050704956
event O O 0.9999988079071045
, O O 0.9999033212661743
she O O 0.999967098236084
was O O 0.9999510049819946
taking O O 0.9986956715583801
zolmitriptan B B 0.9995933175086975
2 O O 0.9805170893669128
- O O 0.9983934760093689
3 O O 0.9980979561805725
times O O 0.9984448552131653
daily O O 0.9998941421508789
for O O 0.9999498128890991
several O O 0.9999899864196777
days O O 0.9999904632568359
because O O 0.9999877214431763
of O O 0.9999912977218628
a O O 0.9999923706054688
persistent O O 0.9999892711639404
migraine O O 0.999994158744812
headache O O 0.999990701675415
. O O 0.9999560117721558

She O O 0.9999487400054932
otherwise O O 0.9999828338623047
reported O O 0.9999926090240479
that O O 0.9999517202377319
she O O 0.9999803304672241
is O O 0.9999265670776367
quite O O 0.999961256980896
active O O 0.9997982382774353
, O O 0.9999837875366211
rides O O 0.9996768236160278
horses O O 0.990611732006073
, O O 0.9999716281890869
and O O 0.9999833106994629
does O O 0.9999790191650391
show O O 0.9998682737350464
jumping O O 0.9976091384887695
without O O 0.9999896287918091
any O O 0.9999853372573853
limitations O O 0.9999934434890747
in O O 0.9999891519546509
her O O 0.9999799728393555
physical O O 0.999863862991333
activity O O 0.9981576800346375
. O O 0.9999507665634155

There O O 0.999976634979248
was O O 0.9999740123748779
no O O 0.9999827146530151
evidence O O 0.9999856948852539
of O O 0.9999730587005615
any O O 0.9999750852584839
recent O O 0.9999758005142212
stress O O 0.999221920967102
or O O 0.9999254941940308
status O O 0.9998993873596191
migrainosus O O 0.9999908208847046
. O O 0.9999285936355591

Extensive O O 0.9999721050262451
literature O O 0.9999653100967407
search O O 0.999977707862854
revealed O O 0.9999040365219116
multiple O O 0.999954342842102
cases O O 0.9999904632568359
of O O 0.9999634027481079
coronary O O 0.999397873878479
artery O O 0.9997653365135193
vasospasm O O 0.9999459981918335
secondary O O 0.9999089241027832
to O O 0.9969454407691956
zolmitriptan B B 0.9996745586395264
, O O 0.999527096748352
but O O 0.9999271631240845
none O O 0.9999277591705322
of O O 0.9999754428863525
the O O 0.9999843835830688
cases O O 0.999951958656311
were O O 0.9999212026596069
associated O O 0.9999680519104004
with O O 0.9998793601989746
TS O O 0.8877155184745789
. O O 0.9999285936355591

Depression O O 0.9999226331710815
, O O 0.9998196959495544
impulsiveness O O 0.9998478889465332
, O O 0.999854326248169
sleep O O 0.9998817443847656
, O O 0.9992759823799133
and O O 0.9996892213821411
memory O O 0.9999520778656006
in O O 0.9999265670776367
past O O 0.999823272228241
and O O 0.9998051524162292
present O O 0.9994864463806152
polydrug O O 0.5354897379875183
users O O 0.5880815982818604
of O O 0.9237385988235474
3 B B 0.9284420013427734
, I I 0.9451244473457336
4 I I 0.9849787354469299
- I I 0.9967227578163147
methylenedioxymethamphetamine I I 0.9992337226867676
( O O 0.9847683310508728
MDMA B B 0.9894582033157349
, O O 0.5977523326873779
ecstasy B B 0.9920669794082642
) O O 0.9978406429290771
. O O 0.9999284744262695

RATIONALE O O 0.7560333609580994
: O O 0.9941745400428772
Ecstasy B B 0.996529757976532
( O O 0.8060439229011536
3 B B 0.896051824092865
, I I 0.9667015671730042
4 I I 0.9894457459449768
- I I 0.9968366622924805
methylenedioxymethamphetamine I I 0.9993358254432678
, O O 0.9199941754341125
MDMA B B 0.9980137348175049
) O O 0.9992443323135376
is O O 0.9996687173843384
a O O 0.9977396726608276
worldwide O O 0.9459447860717773
recreational O O 0.8078290224075317
drug O O 0.9821761250495911
of O O 0.9883132576942444
abuse O O 0.920383870601654
. O O 0.9998432397842407

Unfortunately O O 0.9999430179595947
, O O 0.9999750852584839
the O O 0.9999912977218628
results O O 0.9999929666519165
from O O 0.9999866485595703
human O O 0.9998599290847778
research O O 0.9999773502349854
investigating O O 0.9998133778572083
its O O 0.9952842593193054
psychological O O 0.9997866749763489
effects O O 0.9999114274978638
have O O 0.9999769926071167
been O O 0.9999932050704956
inconsistent O O 0.9999923706054688
. O O 0.9999788999557495

OBJECTIVES O O 0.9998787641525269
: O O 0.9999902248382568
The O O 0.9999979734420776
present O O 0.999992847442627
study O O 0.9999803304672241
aimed O O 0.9999774694442749
to O O 0.9999868869781494
be O O 0.9999933242797852
the O O 0.9999945163726807
largest O O 0.9999922513961792
to O O 0.9999969005584717
date O O 0.9999988079071045
in O O 0.9999943971633911
sample O O 0.9999914169311523
size O O 0.9999972581863403
and O O 0.999994158744812
5HT O O 0.5172103047370911
- O O 0.9992982149124146
related O O 0.9998874664306641
behaviors O O 0.9999529123306274
; O O 0.9999887943267822
the O O 0.9999963045120239
first O O 0.9999970197677612
to O O 0.9999914169311523
compare O O 0.9999701976776123
present O O 0.9992458820343018
ecstasy B B 0.9856802225112915
users O O 0.9995368719100952
with O O 0.999956488609314
past O O 0.9997463822364807
users O O 0.9998852014541626
after O O 0.9999508857727051
an O O 0.9999842643737793
abstinence O O 0.9999336004257202
of O O 0.9999428987503052
4 O O 0.9995459914207458
or O O 0.9999945163726807
more O O 0.9999815225601196
years O O 0.9999779462814331
, O O 0.9999556541442871
and O O 0.9999699592590332
the O O 0.9999912977218628
first O O 0.9999955892562866
to O O 0.9999948740005493
include O O 0.9999791383743286
robust O O 0.9998149275779724
controls O O 0.9999898672103882
for O O 0.9998146891593933
other O O 0.9998169541358948
recreational O O 0.8783645629882812
substances O O 0.9862159490585327
. O O 0.9999651908874512

METHODS O O 0.9998931884765625
: O O 0.999980092048645
A O O 0.9999790191650391
sample O O 0.9999924898147583
of O O 0.9999701976776123
997 O O 0.999539852142334
participants O O 0.9999523162841797
( O O 0.9999293088912964
52 O O 0.9999920129776001
% O O 0.9999288320541382
male O O 0.9999399185180664
) O O 0.9999498128890991
was O O 0.9999414682388306
recruited O O 0.9999618530273438
to O O 0.9998247027397156
four O O 0.9996380805969238
control O O 0.9996638298034668
groups O O 0.999915599822998
( O O 0.9994657635688782
non O O 0.9024868607521057
- O O 0.9963078498840332
drug O O 0.9148526787757874
( O O 0.9969321489334106
ND O O 0.8600213527679443
) O O 0.999395489692688
, O O 0.9994966983795166
alcohol B B 0.9832120537757874
/ O O 0.8087925910949707
nicotine B B 0.9749256372451782
( O O 0.9831556081771851
AN B B 0.9735530018806458
) O O 0.8122627139091492
, O O 0.9927008152008057
cannabis B B 0.9883335828781128
/ O O 0.789326548576355
alcohol B B 0.9509338736534119
/ O O 0.838118314743042
nicotine B B 0.956243634223938
( O O 0.9778673648834229
CAN B B 0.9587195515632629
) O O 0.5250946879386902
, O O 0.9992936849594116
non O O 0.7875688076019287
- O O 0.9949910044670105
ecstasy B O 0.8735800981521606
polydrug O O 0.7796292304992676
( O O 0.8787091970443726
PD O O 0.48227015137672424
) O O 0.9968416690826416
) O O 0.9999492168426514
, O O 0.9998879432678223
and O O 0.9999336004257202
two O O 0.9994888305664062
ecstasy B O 0.9269334673881531
polydrug O O 0.5505186915397644
groups O O 0.930776059627533
( O O 0.9996077418327332
present O O 0.9997367262840271
( O O 0.9998481273651123
MDMA B O 0.9960839748382568
) O O 0.9999585151672363
and O O 0.999915361404419
past O O 0.9361328482627869
users O O 0.9993690848350525
( O O 0.9997336268424988
EX O O 0.9942850470542908
- O O 0.9997913241386414
MDMA B O 0.9968445301055908
) O O 0.9999667406082153
. O O 0.9999688863754272

Participants O O 0.9999723434448242
completed O O 0.9999288320541382
a O O 0.9999055862426758
drug O O 0.9962823987007141
history O O 0.9998348951339722
questionnaire O O 0.9999747276306152
, O O 0.9997360110282898
Beck O O 0.7323194742202759
Depression O O 0.9872636198997498
Inventory O O 0.9992027878761292
, O O 0.9997536540031433
Barratt O O 0.9837396740913391
Impulsiveness O O 0.9997016787528992
Scale O O 0.9980870485305786
, O O 0.9996991157531738
Pittsburgh O O 0.9534339904785156
Sleep O O 0.9762539863586426
Quality O O 0.9993155002593994
Index O O 0.9979255199432373
, O O 0.9997753500938416
and O O 0.9997153878211975
Wechsler O O 0.9792231321334839
Memory O O 0.9999420642852783
Scale O O 0.9985650181770325
- O O 0.9985318183898926
Revised O O 0.927456259727478
which O O 0.999964714050293
, O O 0.999993085861206
in O O 0.9999946355819702
total O O 0.9999946355819702
, O O 0.9999843835830688
provided O O 0.9999860525131226
13 O O 0.9998999834060669
psychometric O O 0.9999520778656006
measures O O 0.9999957084655762
. O O 0.9999799728393555

RESULTS O O 0.9998651742935181
: O O 0.9999654293060303
While O O 0.9999806880950928
the O O 0.9997172951698303
CAN B O 0.507257342338562
and O O 0.9986065030097961
PD O O 0.7162348628044128
groups O O 0.9995997548103333
tended O O 0.9999798536300659
to O O 0.9999794960021973
record O O 0.9999802112579346
greater O O 0.999847412109375
deficits O O 0.9999926090240479
than O O 0.999950647354126
the O O 0.9999265670776367
non O O 0.989180862903595
- O O 0.9996566772460938
drug O O 0.9941213726997375
controls O O 0.9998701810836792
, O O 0.9999003410339355
the O O 0.9995869994163513
MDMA B O 0.8813643455505371
and O O 0.999242901802063
EX O O 0.9202985763549805
- O O 0.9984477758407593
MDMA B O 0.9278576374053955
groups O O 0.9997747540473938
recorded O O 0.9999407529830933
greater O O 0.9996920824050903
deficits O O 0.999988317489624
than O O 0.9999545812606812
all O O 0.9997063279151917
the O O 0.9995641112327576
control O O 0.9995738863945007
groups O O 0.9999270439147949
on O O 0.9999464750289917
ten O O 0.992613673210144
of O O 0.9999239444732666
the O O 0.9999715089797974
13 O O 0.9998924732208252
psychometric O O 0.9999029636383057
measures O O 0.9999861717224121
. O O 0.9999586343765259

Strikingly O O 0.9970107078552246
, O O 0.9999805688858032
despite O O 0.9999109506607056
prolonged O O 0.9999316930770874
abstinence O O 0.9996370077133179
( O O 0.9999631643295288
mean O O 0.9999878406524658
, O O 0.9999806880950928
4 O O 0.9999808073043823
. O O 0.999996542930603
98 O O 0.9999750852584839
; O O 0.999988317489624
range O O 0.999990701675415
, O O 0.9999847412109375
4 O O 0.999985933303833
- O O 0.9999092817306519
9 O O 0.9999966621398926
years O O 0.9999910593032837
) O O 0.9999681711196899
, O O 0.9999592304229736
past O O 0.9998199343681335
ecstasy B O 0.9227116703987122
users O O 0.9997324347496033
showed O O 0.999984860420227
few O O 0.9999927282333374
signs O O 0.9999964237213135
of O O 0.9999884366989136
recovery O O 0.9999889135360718
. O O 0.9999698400497437

Compared O O 0.999970555305481
with O O 0.9999688863754272
present O O 0.9998569488525391
ecstasy B O 0.6156232953071594
users O O 0.9998325109481812
, O O 0.9999741315841675
the O O 0.9999914169311523
past O O 0.9999145269393921
users O O 0.9998559951782227
showed O O 0.9999698400497437
no O O 0.9999896287918091
change O O 0.9999984502792358
for O O 0.9999533891677856
ten O O 0.9998084902763367
measures O O 0.9999929666519165
, O O 0.9999880790710449
increased O O 0.9999709129333496
impairment O O 0.9999942779541016
for O O 0.9999160766601562
two O O 0.9997571110725403
measures O O 0.9999083280563354
, O O 0.9999182224273682
and O O 0.9999557733535767
improvement O O 0.9999903440475464
on O O 0.9999630451202393
just O O 0.9999629259109497
one O O 0.9999710321426392
measure O O 0.9998096823692322
. O O 0.9999778270721436

CONCLUSIONS O O 0.9979634284973145
: O O 0.9999785423278809
Given O O 0.9999920129776001
this O O 0.9999899864196777
record O O 0.9999969005584717
of O O 0.9999878406524658
impaired O O 0.9999916553497314
memory O O 0.9999960660934448
and O O 0.999971866607666
clinically O O 0.9999842643737793
significant O O 0.9999849796295166
levels O O 0.9999880790710449
of O O 0.9999762773513794
depression O O 0.9999877214431763
, O O 0.9999094009399414
impulsiveness O O 0.999967098236084
, O O 0.9998051524162292
and O O 0.9997838139533997
sleep O O 0.9980838298797607
disturbance O O 0.9999815225601196
, O O 0.9999555349349976
the O O 0.999991774559021
prognosis O O 0.9999884366989136
for O O 0.9999512434005737
the O O 0.9999798536300659
current O O 0.9999711513519287
generation O O 0.9999722242355347
of O O 0.9998583793640137
ecstasy B O 0.6895396113395691
users O O 0.9903006553649902
is O O 0.9999514818191528
a O O 0.9999701976776123
major O O 0.9999897480010986
cause O O 0.999997615814209
for O O 0.9999932050704956
concern O O 0.9999961853027344
. O O 0.9999735355377197

Association O O 0.9999562501907349
of O O 0.9998468160629272
common O O 0.9995174407958984
genetic O O 0.9999145269393921
variants O O 0.9999326467514038
of O O 0.9986534118652344
HOMER1 O O 0.9386000037193298
gene O O 0.9981964230537415
with O O 0.9997840523719788
levodopa B B 0.9994959831237793
adverse O O 0.9994877576828003
effects O O 0.9999488592147827
in O O 0.9999265670776367
Parkinson O O 0.9990847110748291
' O O 0.9999856948852539
s O O 0.9999725818634033
disease O O 0.9999799728393555
patients O O 0.9999659061431885
. O O 0.9999656677246094

Levodopa B B 0.9992913007736206
is O O 0.9989649057388306
the O O 0.9998182654380798
most O O 0.9999673366546631
effective O O 0.9998853206634521
symptomatic O O 0.9995090961456299
therapy O O 0.9996957778930664
for O O 0.9997875094413757
Parkinson O O 0.9987021684646606
' O O 0.9999792575836182
s O O 0.9999841451644897
disease O O 0.9999922513961792
, O O 0.9999343156814575
but O O 0.9999728202819824
its O O 0.9998584985733032
chronic O O 0.9996486902236938
use O O 0.9999374151229858
could O O 0.9999281167984009
lead O O 0.9999849796295166
to O O 0.9999715089797974
chronic O O 0.9999146461486816
adverse O O 0.999971866607666
outcomes O O 0.9999963045120239
, O O 0.9999896287918091
such O O 0.9999916553497314
as O O 0.9999830722808838
motor O O 0.9999886751174927
fluctuations O O 0.9999973773956299
, O O 0.9999550580978394
dyskinesia O O 0.9999959468841553
and O O 0.9999381303787231
visual O O 0.9999779462814331
hallucinations O O 0.9999970197677612
. O O 0.999954104423523

HOMER1 O O 0.8593701720237732
is O O 0.999841570854187
a O O 0.9996216297149658
protein O O 0.9992154836654663
with O O 0.9979075193405151
pivotal O O 0.7634194493293762
function O O 0.9998237490653992
in O O 0.9996403455734253
glutamate B B 0.9281456470489502
transmission O O 0.999264657497406
, O O 0.9999605417251587
which O O 0.999866247177124
has O O 0.9999306201934814
been O O 0.999969482421875
related O O 0.9999911785125732
to O O 0.9999850988388062
the O O 0.9999929666519165
pathogenesis O O 0.9999945163726807
of O O 0.9999808073043823
these O O 0.9999059438705444
complications O O 0.9999864101409912
. O O 0.9999531507492065

This O O 0.9999740123748779
study O O 0.9999834299087524
investigates O O 0.9999328851699829
whether O O 0.999971866607666
polymorphisms O O 0.9997105002403259
in O O 0.9999406337738037
the O O 0.9995285272598267
HOMER1 O O 0.9372878074645996
gene O O 0.9963905215263367
promoter O O 0.9989953637123108
region O O 0.9999092817306519
are O O 0.999944806098938
associated O O 0.9999842643737793
with O O 0.9999897480010986
the O O 0.9999903440475464
occurrence O O 0.9999948740005493
of O O 0.9999785423278809
the O O 0.9999818801879883
chronic O O 0.9999572038650513
complications O O 0.9999959468841553
of O O 0.9998548030853271
levodopa B B 0.9995941519737244
therapy O O 0.9988542795181274
. O O 0.9999762773513794

A O O 0.9999697208404541
total O O 0.9999831914901733
of O O 0.9999809265136719
205 O O 0.9999531507492065
patients O O 0.9999932050704956
with O O 0.9999814033508301
idiopathic O O 0.9999849796295166
Parkinson O O 0.9989877343177795
' O O 0.9999868869781494
s O O 0.999968409538269
disease O O 0.9999902248382568
were O O 0.9999622106552124
investigated O O 0.9999781847000122
. O O 0.9999500513076782

Patients O O 0.9995391368865967
were O O 0.9999779462814331
genotyped O O 0.9999139308929443
for O O 0.9993662238121033
rs4704559 O O 0.6489129066467285
, O O 0.9957190155982971
rs10942891 O O 0.7590651512145996
and O O 0.9987183809280396
rs4704560 O O 0.6470203995704651
by O O 0.9999493360519409
allelic O O 0.9999395608901978
discrimination O O 0.9999897480010986
with O O 0.9999524354934692
Taqman O O 0.5841364860534668
assays O O 0.999630331993103
. O O 0.9999699592590332

The O O 0.9999428987503052
rs4704559 O O 0.6227519512176514
G O O 0.46720167994499207
allele O O 0.9958250522613525
was O O 0.9998990297317505
associated O O 0.9999349117279053
with O O 0.9999643564224243
a O O 0.9999462366104126
lower O O 0.9999096393585205
prevalence O O 0.9999133348464966
of O O 0.9999426603317261
dyskinesia O O 0.9999977350234985
( O O 0.9999434947967529
prevalence O O 0.9987648725509644
ratio O O 0.9999736547470093
( O O 0.9997157454490662
PR O O 0.9975475668907166
) O O 0.9999568462371826
= O O 0.9998910427093506
0 O O 0.9999818801879883
. O O 0.9999852180480957
615 O O 0.9999971389770508
, O O 0.9999685287475586
95 O O 0.9999462366104126
% O O 0.9999758005142212
confidence O O 0.999907374382019
interval O O 0.9999642372131348
( O O 0.9994937181472778
CI O O 0.9982123374938965
) O O 0.9999676942825317
0 O O 0.9999880790710449
. O O 0.9999927282333374
426 O O 0.9999942779541016
- O O 0.9992057681083679
0 O O 0.9999929666519165
. O O 0.9999903440475464
887 O O 0.99892657995224
, O O 0.9999728202819824
P O O 0.9999711513519287
= O O 0.9999716281890869
0 O O 0.9999897480010986
. O O 0.9999923706054688
009 O O 0.9999973773956299
) O O 0.999966025352478
and O O 0.9999366998672485
visual O O 0.9999173879623413
hallucinations O O 0.9999961853027344
( O O 0.9999427795410156
PR O O 0.9898459911346436
= O O 0.9999476671218872
0 O O 0.9999785423278809
. O O 0.9999912977218628
515 O O 0.9999954700469971
, O O 0.9999579191207886
95 O O 0.9998657703399658
% O O 0.9999059438705444
CI O O 0.9951392412185669
0 O O 0.9999496936798096
. O O 0.9999680519104004
295 O O 0.9999808073043823
- O O 0.9989386200904846
0 O O 0.9999772310256958
. O O 0.9999885559082031
899 O O 0.9995214939117432
, O O 0.9999706745147705
P O O 0.9998800754547119
= O O 0.9999436140060425
0 O O 0.9999744892120361
. O O 0.9999903440475464
020 O O 0.9999872446060181
) O O 0.9999626874923706
. O O 0.9999665021896362

Our O O 0.9999685287475586
data O O 0.9999884366989136
suggest O O 0.9999352693557739
that O O 0.9992965459823608
HOMER1 O O 0.757275402545929
rs4704559 O O 0.4547683000564575
G O O 0.4808136224746704
allele O O 0.9892304539680481
has O O 0.9999479055404663
a O O 0.999910831451416
protective O O 0.9998966455459595
role O O 0.9999834299087524
for O O 0.9999302625656128
the O O 0.9999839067459106
development O O 0.9999892711639404
of O O 0.9999345541000366
levodopa B B 0.999686598777771
adverse O O 0.9996674060821533
effects O O 0.9999785423278809
. O O 0.9999555349349976

Crocin B B 0.9980888962745667
improves O O 0.9986924529075623
lipid O O 0.9336764812469482
dysregulation O O 0.9999802112579346
in O O 0.9997285008430481
subacute O O 0.9984466433525085
diazinon B B 0.9985581040382385
exposure O O 0.9996696710586548
through O O 0.9995064735412598
ERK1 O O 0.5837223529815674
/ O O 0.9908682107925415
2 O O 0.9906654357910156
pathway O O 0.9993926286697388
in O O 0.9998621940612793
rat O O 0.9999539852142334
liver O O 0.9992859959602356
. O O 0.9992074370384216

INTRODUCTION O O 0.7126666903495789
: O O 0.9726100564002991
Diazinon B B 0.9982179999351501
Yis O I 0.9997636675834656
one O O 0.9910549521446228
of O O 0.9997408986091614
the O O 0.9999181032180786
most O O 0.9998006224632263
broadly O O 0.9998358488082886
used O O 0.9996011853218079
organophosphorus B B 0.9496759176254272
insecticides O O 0.5362784266471863
in O O 0.9995561242103577
agriculture O O 0.9998564720153809
. O O 0.9997074007987976

It O O 0.9999574422836304
has O O 0.9999537467956543
been O O 0.9999784231185913
shown O O 0.999981164932251
that O O 0.9997442364692688
exposure O O 0.9997149109840393
to O O 0.9939255118370056
diazinon B B 0.9985713958740234
may O O 0.9997926354408264
interfere O O 0.999874472618103
with O O 0.9999507665634155
lipid O O 0.7554070949554443
metabolism O O 0.9998729228973389
. O O 0.9999216794967651

Moreover O O 0.9998224377632141
, O O 0.9999210834503174
the O O 0.9999620914459229
hypolipidemic O O 0.9991266131401062
effect O O 0.9997883439064026
of O O 0.998738706111908
crocin B B 0.9958009123802185
has O O 0.9997555613517761
been O O 0.9999721050262451
established O O 0.999925971031189
. O O 0.9999467134475708

Earlier O O 0.9999092817306519
studies O O 0.9999656677246094
revealed O O 0.9999181032180786
the O O 0.9999469518661499
major O O 0.9999003410339355
role O O 0.9999573230743408
of O O 0.9997079968452454
Extracellular O O 0.9743624925613403
signal O O 0.5318424701690674
- O O 0.8745383024215698
regulated O O 0.8515645861625671
kinase O O 0.8738875389099121
( O O 0.9967173933982849
ERK O O 0.500654399394989
) O O 0.9977856874465942
pathways O O 0.9985159039497375
in O O 0.9999053478240967
low O O 0.9477284550666809
- O O 0.9972108006477356
density O O 0.9596006274223328
lipoprotein O O 0.5581830143928528
receptor O O 0.8671640157699585
( O O 0.9986339211463928
LDLr O O 0.9744043350219727
) O O 0.9993641972541809
expression O O 0.9998735189437866
. O O 0.9999557733535767

The O O 0.9999890327453613
aim O O 0.9999969005584717
of O O 0.9999938011169434
this O O 0.9999872446060181
study O O 0.9999845027923584
was O O 0.9999933242797852
to O O 0.9999895095825195
evaluate O O 0.9999750852584839
changes O O 0.9999909400939941
in O O 0.9999768733978271
the O O 0.9999606609344482
regulation O O 0.9999632835388184
of O O 0.9998574256896973
lipid O O 0.5873450040817261
metabolism O O 0.9980652928352356
, O O 0.9995095729827881
ERK O O 0.5820261836051941
and O O 0.997104823589325
LDLr O O 0.8298734426498413
expression O O 0.9998501539230347
in O O 0.9998353719711304
the O O 0.9999645948410034
liver O O 0.9997410178184509
of O O 0.9999775886535645
rats O O 0.9999909400939941
exposed O O 0.999956488609314
to O O 0.9996417760848999
subacute O O 0.9997723698616028
diazinon B B 0.9990807771682739
. O O 0.9999402761459351

Furthermore O O 0.9999017715454102
ameliorating O O 0.9994204044342041
effect O O 0.9997714161872864
of O O 0.9973745346069336
crocin B B 0.9972776770591736
on O O 0.9991198182106018
diazinon B B 0.9996696710586548
induced O O 0.9998953342437744
disturbed O O 0.9074587821960449
cholesterol B B 0.9923126101493835
homeostasis O O 0.999677300453186
was O O 0.9999748468399048
studied O O 0.9999443292617798
. O O 0.9999740123748779

METHODS O O 0.9992641806602478
: O O 0.999996542930603
24 O O 0.9999814033508301
Rats O O 0.9999947547912598
were O O 0.9999920129776001
divided O O 0.9999948740005493
into O O 0.9999713897705078
4 O O 0.999485969543457
groups O O 0.9999936819076538
and O O 0.9999737739562988
received O O 0.999962568283081
following O O 0.9998449087142944
treatments O O 0.9999841451644897
for O O 0.9999754428863525
4 O O 0.9998410940170288
weeks O O 0.9999984502792358
; O O 0.9999451637268066
Corn O O 0.7465221881866455
oil O O 0.5470566153526306
( O O 0.9989331364631653
control O O 0.880186140537262
) O O 0.999868631362915
, O O 0.9979612827301025
diazinon B B 0.9983008503913879
( O O 0.9993289709091187
15mg O O 0.9998345375061035
/ O O 0.999830961227417
kg O O 0.9999939203262329
per O O 0.9998592138290405
day O O 0.999982476234436
, O O 0.999947190284729
orally O O 0.9970688223838806
) O O 0.9999517202377319
and O O 0.9988566637039185
crocin B B 0.9621334671974182
( O O 0.9989700317382812
12 O O 0.9987611770629883
. O O 0.999961256980896
5 O O 0.9997884631156921
and O O 0.9997707009315491
25mg O O 0.999832034111023
/ O O 0.9999034404754639
kg O O 0.999995231628418
per O O 0.9999381303787231
day O O 0.9999926090240479
, O O 0.999956488609314
intraperitoneally O O 0.9999635219573975
) O O 0.999976634979248
in O O 0.999982476234436
combination O O 0.9999480247497559
with O O 0.9998486042022705
diazinon B B 0.9987232089042664
( O O 0.9996802806854248
15 O O 0.9998873472213745
mg O O 0.9999209642410278
/ O O 0.9999271631240845
kg O O 0.9999935626983643
) O O 0.9999756813049316
. O O 0.9999747276306152

The O O 0.9999748468399048
levels O O 0.9999439716339111
of O O 0.9996556043624878
cholesterol B B 0.9933837056159973
, O O 0.9773842096328735
triglyceride B B 0.9042248725891113
and O O 0.7883782386779785
LDL O O 0.48450326919555664
in O O 0.999806821346283
blood O O 0.9997472167015076
of O O 0.9999221563339233
rats O O 0.9999005794525146
were O O 0.9999772310256958
analyzed O O 0.9999282360076904
. O O 0.9999722242355347

Moreover O O 0.9998024106025696
mRNA O O 0.9633489847183228
levels O O 0.9998823404312134
of O O 0.9981369972229004
LDLr O O 0.8355506658554077
and O O 0.997008740901947
ERK1 O O 0.6947985291481018
/ O O 0.9672197699546814
2 O O 0.980926513671875
as O O 0.9998461008071899
well O O 0.9997451901435852
as O O 0.9999129772186279
protein O O 0.999189555644989
levels O O 0.999866247177124
of O O 0.9988172650337219
total O O 0.884770393371582
and O O 0.9982843995094299
activated O O 0.9631284475326538
forms O O 0.9987013339996338
of O O 0.9964996576309204
ERK1 O O 0.6002802848815918
/ O O 0.932989239692688
2 O O 0.967556357383728
in O O 0.9998000264167786
rat O O 0.9999661445617676
liver O O 0.999424934387207
were O O 0.9999737739562988
evaluated O O 0.9999879598617554
by O O 0.9999860525131226
Western O O 0.9996987581253052
blotting O O 0.9999957084655762
and O O 0.9999803304672241
quantitative O O 0.999771773815155
real O O 0.9997109770774841
time O O 0.996951699256897
polymerase O O 0.9932233095169067
chain O O 0.99397212266922
reaction O O 0.9991262555122375
analysis O O 0.999981164932251
. O O 0.999982476234436

RESULTS O O 0.9994737505912781
: O O 0.9999786615371704
Our O O 0.9998892545700073
data O O 0.9999819993972778
showed O O 0.999966025352478
that O O 0.9999058246612549
subacute O O 0.9998393058776855
exposure O O 0.9997740387916565
to O O 0.991010308265686
diazinon B B 0.9994619488716125
significantly O O 0.9998980760574341
increased O O 0.9997897744178772
concentrations O O 0.9997766613960266
of O O 0.9940412640571594
cholesterol B B 0.9768500328063965
, O O 0.9891296625137329
triglyceride B B 0.9438633322715759
and O O 0.9340094923973083
LDL O O 0.7110801935195923
. O O 0.9996898174285889

Moreover O O 0.9952524900436401
diazinon B B 0.9996935129165649
decreased O O 0.9998138546943665
ERK1 O O 0.5926339626312256
/ O O 0.9671673774719238
2 O O 0.9842547178268433
protein O O 0.999421238899231
phosphorylation O O 0.8749451041221619
and O O 0.9998251795768738
LDLr O O 0.7919520735740662
transcript O O 0.9993292093276978
. O O 0.9997486472129822

Crocin B B 0.9976699948310852
reduced O O 0.999817430973053
inhibition O O 0.9996274709701538
of O O 0.998855471611023
ERK O B 0.9125163555145264
activation O O 0.7318028807640076
and O O 0.9984806180000305
diazinon B B 0.9996706247329712
- O O 0.9994669556617737
induced O O 0.999943733215332
hyperlipemia O O 0.9996160268783569
and O O 0.9999759197235107
increased O O 0.9999545812606812
levels O O 0.9999376535415649
of O O 0.9997034668922424
LDLr O O 0.8473904728889465
transcript O O 0.9972993731498718
. O O 0.9996360540390015

CONCLUSIONS O O 0.9782882928848267
: O O 0.9989066123962402
Crocin B B 0.9965494871139526
may O O 0.9998728036880493
be O O 0.9999445676803589
considered O O 0.9998716115951538
as O O 0.9999594688415527
a O O 0.9997854828834534
novel O O 0.9998569488525391
protective O O 0.9996435642242432
agent O O 0.9995105266571045
in O O 0.9998088479042053
diazinon B B 0.9994938373565674
- O O 0.9991890788078308
induced O O 0.9999536275863647
hyperlipemia O O 0.9872188568115234
through O O 0.9998800754547119
modulating O O 0.9983994364738464
of O O 0.9984515905380249
ERK O O 0.7101001739501953
pathway O O 0.9930863976478577
and O O 0.9999117851257324
increase O O 0.999919056892395
of O O 0.9998072981834412
LDLr O O 0.9654741287231445
expression O O 0.9999486207962036
. O O 0.9999203681945801

GEM B B 0.8131082057952881
- O I 0.882253110408783
P O I 0.9872029423713684
chemotherapy O O 0.720176637172699
is O O 0.9993568062782288
active O O 0.9784185886383057
in O O 0.9998612403869629
the O O 0.999925971031189
treatment O O 0.9999734163284302
of O O 0.9999828338623047
relapsed O O 0.9999765157699585
Hodgkin O O 0.9993271827697754
lymphoma O O 0.9999651908874512
. O O 0.9999223947525024

Hodgkin O O 0.9746272563934326
lymphoma O O 0.9998095631599426
( O O 0.9998214840888977
HL O O 0.906554102897644
) O O 0.9999330043792725
is O O 0.9999202489852905
a O O 0.9999182224273682
relatively O O 0.9998749494552612
chemosensitive O O 0.9919841885566711
malignancy O O 0.9999887943267822
. O O 0.9999580383300781

However O O 0.9999344348907471
, O O 0.9999669790267944
for O O 0.9999430179595947
those O O 0.9999890327453613
who O O 0.9997560381889343
relapse O O 0.999992847442627
, O O 0.999921441078186
high O O 0.9996077418327332
- O O 0.9999655485153198
dose O O 0.9989911913871765
chemotherapy O O 0.9996398687362671
with O O 0.9998639822006226
autologous O O 0.9997085928916931
stem O O 0.9999722242355347
cell O O 0.9999462366104126
transplant O O 0.9999747276306152
is O O 0.9999706745147705
the O O 0.9999845027923584
treatment O O 0.9999905824661255
of O O 0.9999839067459106
choice O O 0.9999884366989136
which O O 0.999930739402771
relies O O 0.999983549118042
on O O 0.9999850988388062
adequate O O 0.9999812841415405
disease O O 0.9999951124191284
control O O 0.9999979734420776
with O O 0.9999693632125854
salvage O O 0.9978905320167542
chemotherapy O O 0.9962538480758667
. O O 0.9999699592590332

Regimens O O 0.989324152469635
commonly O O 0.9998496770858765
used O O 0.9999382495880127
often O O 0.9999758005142212
require O O 0.9999759197235107
inpatient O O 0.9999548196792603
administration O O 0.9999594688415527
and O O 0.9999756813049316
can O O 0.9999715089797974
be O O 0.9999969005584717
difficult O O 0.9999974966049194
to O O 0.9999978542327881
deliver O O 0.9999936819076538
due O O 0.9999856948852539
to O O 0.999941349029541
toxicity O O 0.9999387264251709
. O O 0.999957799911499

Gemcitabine B B 0.9996198415756226
and O O 0.9444013237953186
cisplatin B B 0.9994388222694397
have O O 0.999796450138092
activity O O 0.9998928308486938
in O O 0.9993715882301331
HL O O 0.47789475321769714
, O O 0.9997734427452087
non O O 0.968471109867096
- O O 0.9998366832733154
overlapping O O 0.9933686852455139
toxicity O O 0.9999816417694092
with O O 0.9999159574508667
first O O 0.9999805688858032
- O O 0.9999715089797974
line O O 0.9984435439109802
chemotherapeutics O O 0.9980898499488831
, O O 0.9999431371688843
and O O 0.999963641166687
may O O 0.999963641166687
be O O 0.9999896287918091
delivered O O 0.9999895095825195
in O O 0.9999884366989136
an O O 0.9999940395355225
outpatient O O 0.9999947547912598
setting O O 0.999994158744812
. O O 0.9999793767929077

In O O 0.9999778270721436
this O O 0.9999823570251465
retrospective O O 0.9999786615371704
single O O 0.9998347759246826
- O O 0.9999473094940186
centre O O 0.9994778037071228
analysis O O 0.999993085861206
, O O 0.9999582767486572
patients O O 0.9999904632568359
with O O 0.9999707937240601
relapsed O O 0.9999853372573853
or O O 0.9999457597732544
refractory O O 0.999990701675415
HL O O 0.8463953137397766
treated O O 0.9998419284820557
with O O 0.9995682835578918
gemcitabine B B 0.9994158744812012
1 O O 0.9971430897712708
, O O 0.9999796152114868
000 O O 0.9963877201080322
mg O O 0.9997031092643738
/ O O 0.9994410872459412
m O O 0.999534010887146
( O O 0.9964041709899902
2 O O 0.9703423976898193
) O O 0.9784975051879883
day O O 0.9999074935913086
( O O 0.9977524876594543
D O O 0.9942775368690491
) O O 0.9939460158348083
1 O O 0.9997348189353943
, O O 0.9996103644371033
D8 O O 0.9938429594039917
and O O 0.9996111989021301
D15 O O 0.9936281442642212
; O O 0.998530387878418
methylprednisolone B B 0.9992936849594116
1 O O 0.9806868433952332
, O O 0.9999188184738159
000 O O 0.9534096121788025
mg O O 0.9995021820068359
D1 O O 0.9976708292961121
- O O 0.9918841123580933
5 O O 0.9991068243980408
; O O 0.9991145730018616
and O O 0.9990888833999634
cisplatin B B 0.9971144199371338
100 O O 0.9460048079490662
mg O O 0.9997543692588806
/ O O 0.9997056126594543
m O O 0.9999643564224243
( O O 0.9967225193977356
2 O O 0.8072741627693176
) O O 0.7870720624923706
D15 O O 0.815686821937561
, O O 0.9994329810142517
every O O 0.9998683929443359
28 O O 0.9999793767929077
days O O 0.9999829530715942
( O O 0.9991573095321655
GEM B B 0.8294192552566528
- O I 0.6775095462799072
P O I 0.9778386354446411
) O O 0.9759309887886047
were O O 0.9999850988388062
included O O 0.9999912977218628
. O O 0.9999805688858032

Demographic O O 0.9997027516365051
, O O 0.9999394416809082
survival O O 0.9999372959136963
, O O 0.9998960494995117
response O O 0.9999635219573975
and O O 0.9997597336769104
toxicity O O 0.9998307228088379
data O O 0.9999674558639526
were O O 0.9999327659606934
recorded O O 0.999927282333374
. O O 0.9999606609344482

Forty O O 0.9992187023162842
- O O 0.9999394416809082
one O O 0.999992847442627
eligible O O 0.9999929666519165
patients O O 0.9999963045120239
were O O 0.9999845027923584
identified O O 0.9999947547912598
: O O 0.9999765157699585
median O O 0.9999879598617554
age O O 0.999991774559021
27 O O 0.9999973773956299
. O O 0.9999903440475464

One O O 0.9999953508377075
hundred O O 0.9999616146087646
and O O 0.9999948740005493
twenty O O 0.9988359808921814
- O O 0.9999755620956421
two O O 0.9999711513519287
cycles O O 0.9999418258666992
of O O 0.9997782111167908
GEM B B 0.9988362193107605
- O I 0.9973155856132507
P O I 0.9998313188552856
were O O 0.9958683252334595
administered O O 0.9999490976333618
in O O 0.999977707862854
total O O 0.9999767541885376
( O O 0.9999642372131348
median O O 0.999995231628418
3 O O 0.9999721050262451
cycles O O 0.9999904632568359
; O O 0.9999904632568359
range O O 0.9999604225158691
1 O O 0.9997755885124207
- O O 0.9967111349105835
6 O O 0.9999780654907227
) O O 0.999981164932251
. O O 0.9999833106994629

Twenty O O 0.9999244213104248
of O O 0.9999675750732422
41 O O 0.9999927282333374
( O O 0.9999240636825562
48 O O 0.9999920129776001
% O O 0.9999969005584717
) O O 0.999957799911499
patients O O 0.9999959468841553
received O O 0.9997015595436096
GEM B B 0.997164785861969
- O I 0.9366820454597473
P O I 0.9997597336769104
as O O 0.9980204105377197
second O O 0.9999674558639526
- O O 0.9999662637710571
line O O 0.9978659749031067
treatment O O 0.9999693632125854
and O O 0.999843955039978
11 O O 0.9995321035385132
/ O O 0.9999895095825195
41 O O 0.999994158744812
( O O 0.9999622106552124
27 O O 0.9999935626983643
% O O 0.9999957084655762
) O O 0.9999411106109619
as O O 0.9998365640640259
third O O 0.9989601373672485
- O O 0.9999278783798218
line O O 0.999083399772644
therapy O O 0.9999514818191528
. O O 0.9999842643737793

Overall O O 0.9999268054962158
response O O 0.9999793767929077
rate O O 0.9999953508377075
( O O 0.9999243021011353
ORR O O 0.9986737966537476
) O O 0.99998939037323
to O O 0.9997949004173279
GEM B B 0.9984549283981323
- O I 0.9604335427284241
P O I 0.99937903881073
in O O 0.9990777969360352
the O O 0.9999904632568359
entire O O 0.9999703168869019
cohort O O 0.9999631643295288
was O O 0.9999829530715942
80 O O 0.9999862909317017
% O O 0.9999982118606567
( O O 0.9998856782913208
complete O O 0.9995181560516357
response O O 0.9999927282333374
( O O 0.9999064207077026
CR O O 0.9887579083442688
) O O 0.9999620914459229
37 O O 0.9999918937683105
% O O 0.9999974966049194
, O O 0.9999520778656006
partial O O 0.9999675750732422
response O O 0.9999949932098389
44 O O 0.9999512434005737
% O O 0.9999951124191284
) O O 0.9999822378158569
with O O 0.9999759197235107
14 O O 0.9524011015892029
/ O O 0.9880879521369934
15 O O 0.999294638633728
CR O O 0.7770969867706299
confirmed O O 0.9999421834945679
as O O 0.9999634027481079
a O O 0.9999786615371704
metabolic O O 0.9996799230575562
CR O O 0.924063503742218
on O O 0.9999445676803589
PET O O 0.9695425033569336
and O O 0.9999550580978394
ORR O O 0.9679234027862549
of O O 0.9999611377716064
85 O O 0.9999504089355469
% O O 0.9999943971633911
in O O 0.9999445676803589
the O O 0.9999865293502808
20 O O 0.9999630451202393
second O O 0.9999557733535767
- O O 0.9997664093971252
line O O 0.9838535785675049
patients O O 0.9999343156814575
. O O 0.9999725818634033

The O O 0.9999817609786987
most O O 0.9999877214431763
common O O 0.9999767541885376
grade O O 0.9997772574424744
3 O O 0.9960026144981384
/ O O 0.9994041919708252
4 O O 0.9977889060974121
toxicities O O 0.9997268319129944
were O O 0.9998706579208374
haematological O O 0.9990770816802979
: O O 0.9999455213546753
neutropenia O O 0.9992121458053589
54 O O 0.9999507665634155
% O O 0.9999924898147583
and O O 0.9998611211776733
thrombocytopenia O O 0.9871719479560852
51 O O 0.9999520778656006
% O O 0.9999939203262329
. O O 0.9999737739562988

Median O O 0.999930739402771
follow O O 0.9999936819076538
- O O 0.9999921321868896
up O O 0.9999979734420776
from O O 0.9999914169311523
the O O 0.9999954700469971
start O O 0.9999603033065796
of O O 0.999772846698761
GEM B B 0.9878777265548706
- O I 0.919093132019043
P O I 0.9998874664306641
was O O 0.9992948770523071
4 O O 0.9999873638153076
. O O 0.9999960660934448
5 O O 0.9999923706054688
years O O 0.9999963045120239
. O O 0.9999877214431763

Following O O 0.9995007514953613
GEM B B 0.9921779036521912
- O I 0.9722208380699158
P O I 0.9998944997787476
, O O 0.9990750551223755
5 O O 0.999583899974823
- O O 0.9999761581420898
year O O 0.9999914169311523
progression O O 0.9994189739227295
- O O 0.9999681711196899
free O O 0.9999849796295166
survival O O 0.9999740123748779
was O O 0.9999867677688599
46 O O 0.9999980926513672
% O O 0.9999988079071045
( O O 0.9999450445175171
95 O O 0.9999923706054688
% O O 0.9999624490737915
confidence O O 0.9998482465744019
interval O O 0.9999184608459473
( O O 0.9996483325958252
CI O O 0.9988440275192261
) O O 0.9999638795852661
, O O 0.9998340606689453
30 O O 0.9999816417694092
- O O 0.9997014403343201
62 O O 0.999984622001648
% O O 0.999993085861206
) O O 0.9999682903289795
and O O 0.9999607801437378
5 O O 0.9997898936271667
- O O 0.9999794960021973
year O O 0.9999891519546509
overall O O 0.9999754428863525
survival O O 0.9999852180480957
was O O 0.9999895095825195
59 O O 0.9999990463256836
% O O 0.9999985694885254
( O O 0.9999449253082275
95 O O 0.9997754693031311
% O O 0.9997395873069763
CI O O 0.9942023158073425
, O O 0.9999173879623413
43 O O 0.999991774559021
- O O 0.9996920824050903
74 O O 0.9999175071716309
% O O 0.9999946355819702
) O O 0.9999861717224121
. O O 0.99998939037323

Fourteen O O 0.9998738765716553
of O O 0.9999881982803345
41 O O 0.999992847442627
patients O O 0.9999938011169434
proceeded O O 0.9999936819076538
directly O O 0.9999983310699463
to O O 0.9999947547912598
autologous O O 0.9999821186065674
transplant O O 0.9999818801879883
. O O 0.9999814033508301

GEM B B 0.9969205856323242
- O I 0.9793853759765625
P O I 0.9999486207962036
is O O 0.9051334857940674
a O O 0.9995710253715515
salvage O O 0.9810826778411865
chemotherapy O O 0.9581069946289062
with O O 0.9998862743377686
relatively O O 0.999985933303833
high O O 0.9999332427978516
response O O 0.9999948740005493
rates O O 0.9999960660934448
, O O 0.9999796152114868
leading O O 0.9999940395355225
to O O 0.9999936819076538
successful O O 0.9999794960021973
transplantation O O 0.9999871253967285
in O O 0.9999736547470093
appropriate O O 0.9996557235717773
patients O O 0.999992847442627
, O O 0.9999842643737793
in O O 0.9999467134475708
the O O 0.9999855756759644
treatment O O 0.9999154806137085
of O O 0.9999784231185913
relapsed O O 0.9999878406524658
or O O 0.9999711513519287
refractory O O 0.9999904632568359
HL O O 0.975333571434021
. O O 0.9999403953552246

Basal O O 0.99964439868927
functioning O O 0.9999593496322632
of O O 0.9999020099639893
the O O 0.9999130964279175
hypothalamic O O 0.9161513447761536
- O O 0.9941319823265076
pituitary O O 0.9882881045341492
- O O 0.9968686699867249
adrenal O O 0.8879950642585754
( O O 0.9992550015449524
HPA O O 0.8715755343437195
) O O 0.9995735287666321
axis O O 0.9993756413459778
and O O 0.9999299049377441
psychological O O 0.9998562335968018
distress O O 0.9999785423278809
in O O 0.9997865557670593
recreational O O 0.8323864936828613
ecstasy B O 0.7904877662658691
polydrug O B 0.9584890604019165
users O O 0.6321627497673035
. O O 0.9998775720596313

RATIONALE O O 0.7490605115890503
: O O 0.9933473467826843
Ecstasy B B 0.9983806610107422
( O O 0.9084919691085815
MDMA B B 0.9982359409332275
) O O 0.9731855988502502
is O O 0.9996019005775452
a O O 0.9990192651748657
psychostimulant O O 0.983423113822937
drug O O 0.9965870380401611
which O O 0.9998207688331604
is O O 0.9998706579208374
increasingly O O 0.9999802112579346
associated O O 0.9999774694442749
with O O 0.9999686479568481
psychobiological O O 0.9998941421508789
dysfunction O O 0.9999966621398926
. O O 0.9999587535858154

While O O 0.9999808073043823
some O O 0.9999608993530273
recent O O 0.9999374151229858
studies O O 0.9999724626541138
suggest O O 0.999869704246521
acute O O 0.9999500513076782
changes O O 0.999990701675415
in O O 0.9999557733535767
neuroendocrine O O 0.9998927116394043
function O O 0.9999302625656128
, O O 0.9999188184738159
less O O 0.9999862909317017
is O O 0.9999912977218628
known O O 0.9999920129776001
about O O 0.9999618530273438
long O O 0.9994934797286987
- O O 0.9999821186065674
term O O 0.999972939491272
changes O O 0.9999948740005493
in O O 0.9998948574066162
HPA O O 0.8096686005592346
functionality O O 0.9998377561569214
in O O 0.9994682669639587
recreational O O 0.47896113991737366
users O O 0.9949631690979004
. O O 0.9999430179595947

OBJECTIVES O O 0.9999220371246338
: O O 0.999996542930603
The O O 0.9999985694885254
current O O 0.9999940395355225
study O O 0.9999899864196777
is O O 0.9999939203262329
the O O 0.9999973773956299
first O O 0.9999972581863403
to O O 0.999993085861206
explore O O 0.9999617338180542
the O O 0.9999542236328125
effects O O 0.999962568283081
of O O 0.9998536109924316
ecstasy B B 0.8640918731689453
- O I 0.8253721594810486
polydrug O I 0.9417448043823242
use O O 0.9989417195320129
on O O 0.9998338222503662
psychological O O 0.9991533756256104
distress O O 0.9999947547912598
and O O 0.9999428987503052
basal O O 0.9997922778129578
functioning O O 0.9999799728393555
of O O 0.9999172687530518
the O O 0.9998291730880737
HPA O O 0.9666736125946045
axis O O 0.9997979998588562
through O O 0.9999897480010986
assessing O O 0.999990701675415
the O O 0.9999823570251465
secretion O O 0.9999063014984131
of O O 0.9997982382774353
cortisol B B 0.9334123730659485
across O O 0.9998465776443481
the O O 0.9999866485595703
diurnal O O 0.9999409914016724
period O O 0.9999934434890747
. O O 0.9999797344207764

METHOD O O 0.9997304081916809
: O O 0.9999897480010986
Seventy O O 0.9999897480010986
- O O 0.9999655485153198
six O O 0.9999915361404419
participants O O 0.9999969005584717
( O O 0.9999465942382812
21 O O 0.9999246597290039
nonusers O O 0.9858858585357666
, O O 0.9999234676361084
29 O O 0.9999783039093018
light O O 0.9996331930160522
ecstasy B B 0.926986038684845
- O O 0.5442814230918884
polydrug O O 0.5277120471000671
users O O 0.9989051818847656
, O O 0.9998739957809448
26 O O 0.9996622800827026
heavy O O 0.9902400970458984
ecstasy B B 0.9553569555282593
- O O 0.535431981086731
polydrug O O 0.6129400134086609
users O O 0.9991104006767273
) O O 0.999985933303833
completed O O 0.9999886751174927
a O O 0.9999943971633911
substance O O 0.9862847328186035
use O O 0.9997304081916809
inventory O O 0.9999334812164307
and O O 0.9999881982803345
measures O O 0.9999768733978271
of O O 0.9999896287918091
psychological O O 0.999968409538269
distress O O 0.9999918937683105
at O O 0.9999732971191406
baseline O O 0.9999871253967285
, O O 0.9999691247940063
then O O 0.9999761581420898
two O O 0.9999868869781494
consecutive O O 0.9999877214431763
days O O 0.999990701675415
of O O 0.9999692440032959
cortisol B O 0.8450204133987427
sampling O O 0.9959211349487305
( O O 0.9999558925628662
on O O 0.9999023675918579
awakening O O 0.9999767541885376
, O O 0.999977707862854
30 O O 0.9999772310256958
min O O 0.9999823570251465
post O O 0.9999336004257202
awakening O O 0.9998815059661865
, O O 0.9999849796295166
between O O 0.9999648332595825
1400 O O 0.9999809265136719
and O O 0.9999889135360718
1600 O O 0.9999978542327881
hours O O 0.9999834299087524
and O O 0.9999784231185913
pre O O 0.9995161294937134
bedtime O O 0.9999823570251465
) O O 0.9999810457229614
. O O 0.999982476234436

On O O 0.9999666213989258
day O O 0.9999922513961792
2 O O 0.9999821186065674
, O O 0.9999774694442749
participants O O 0.9999853372573853
also O O 0.9999840259552002
attended O O 0.9999892711639404
the O O 0.9999953508377075
laboratory O O 0.9999958276748657
to O O 0.9999876022338867
complete O O 0.9999821186065674
a O O 0.999962568283081
20 O O 0.9999710321426392
- O O 0.9999877214431763
min O O 0.9999611377716064
multitasking O O 0.9379866719245911
stressor O O 0.9988105297088623
. O O 0.9999665021896362

RESULTS O O 0.9985917210578918
: O O 0.9999328851699829
Both O O 0.8819489479064941
user O O 0.9938039779663086
groups O O 0.9997490048408508
exhibited O O 0.9998773336410522
significantly O O 0.9999654293060303
greater O O 0.9998892545700073
levels O O 0.9999735355377197
of O O 0.9998971223831177
anxiety O O 0.9964272379875183
and O O 0.9997575879096985
depression O O 0.9999809265136719
than O O 0.9998681545257568
nonusers O O 0.9269016981124878
. O O 0.9999536275863647

On O O 0.9999176263809204
day O O 0.999985933303833
1 O O 0.9999828338623047
, O O 0.99996018409729
all O O 0.9999275207519531
participants O O 0.999977707862854
exhibited O O 0.9999181032180786
a O O 0.9999681711196899
typical O O 0.9999592304229736
cortisol B O 0.5066823363304138
profile O O 0.9998431205749512
, O O 0.9999414682388306
though O O 0.9999711513519287
light O O 0.7005565762519836
users O O 0.5163320302963257
had O O 0.9999269247055054
significantly O O 0.999976634979248
elevated O O 0.9999192953109741
levels O O 0.9998998641967773
pre O O 0.9995173215866089
- O O 0.9998114705085754
bed O O 0.9999719858169556
. O O 0.9999768733978271

On O O 0.9999393224716187
day O O 0.9999910593032837
2 O O 0.9999799728393555
, O O 0.999950647354126
heavy O O 0.8025802969932556
users O O 0.6665868759155273
demonstrated O O 0.9999586343765259
elevated O O 0.9998588562011719
levels O O 0.999834418296814
upon O O 0.9999551773071289
awakening O O 0.9999645948410034
and O O 0.9999147653579712
all O O 0.9270815253257751
ecstasy B O 0.5333245992660522
- O O 0.6387220621109009
polydrug O O 0.5265513062477112
users O O 0.995439350605011
demonstrated O O 0.9999730587005615
elevated O O 0.9999222755432129
pre O O 0.9987025260925293
- O O 0.9998834133148193
bed O O 0.999958872795105
levels O O 0.9999321699142456
compared O O 0.9999858140945435
to O O 0.9999619722366333
non O O 0.9738579392433167
- O O 0.9994856119155884
users O O 0.9955989122390747
. O O 0.9999744892120361

Significant O O 0.9998600482940674
between O O 0.996987521648407
group O O 0.9999446868896484
differences O O 0.9999958276748657
were O O 0.9999711513519287
also O O 0.9999816417694092
observed O O 0.9999902248382568
in O O 0.9999735355377197
afternoon O O 0.9485746622085571
cortisol B B 0.9632048606872559
levels O O 0.9997137188911438
and O O 0.999972939491272
in O O 0.9999767541885376
overall O O 0.9994482398033142
cortisol B B 0.9466434717178345
secretion O O 0.9988207221031189
across O O 0.9999682903289795
the O O 0.999994158744812
day O O 0.9999643564224243
. O O 0.9999724626541138

CONCLUSIONS O O 0.9990070462226868
: O O 0.9999716281890869
The O O 0.9999886751174927
increases O O 0.999970555305481
in O O 0.9998894929885864
anxiety O O 0.9950723052024841
and O O 0.9996746778488159
depression O O 0.9999650716781616
are O O 0.999947190284729
in O O 0.9999901056289673
line O O 0.9999963045120239
with O O 0.9999951124191284
previous O O 0.9999833106994629
observations O O 0.9999959468841553
in O O 0.9999427795410156
recreational O O 0.9910344481468201
ecstasy B B 0.8635795712471008
- O I 0.6629874110221863
polydrug O I 0.7870736122131348
users O O 0.9957563281059265
. O O 0.99996018409729

Dysregulated O O 0.9998685121536255
diurnal O O 0.9612578749656677
cortisol B B 0.9508575797080994
may O O 0.9997578263282776
be O O 0.9999539852142334
indicative O O 0.999975323677063
of O O 0.9999592304229736
inappropriate O O 0.9999043941497803
anticipation O O 0.9999750852584839
of O O 0.9997482895851135
forthcoming O O 0.6279264688491821
demands O O 0.9978418350219727
and O O 0.999481737613678
hypersecretion O O 0.9704030156135559
may O O 0.9999271631240845
lead O O 0.9999910593032837
to O O 0.9999873638153076
the O O 0.999995231628418
increased O O 0.9999847412109375
psychological O O 0.9998587369918823
and O O 0.9999685287475586
physical O O 0.9999610185623169
morbidity O O 0.9999960660934448
associated O O 0.9999905824661255
with O O 0.9999340772628784
heavy O O 0.9998593330383301
recreational O O 0.9997215867042542
use O O 0.9993932247161865
of O O 0.9972572922706604
ecstasy B B 0.9964234232902527
. O O 0.9998906850814819

Ifosfamide B B 0.9991544485092163
related O O 0.9995794892311096
encephalopathy O O 0.9998476505279541
: O O 0.999957799911499
the O O 0.9999963045120239
need O O 0.9999980926513672
for O O 0.9999979734420776
a O O 0.9999959468841553
timely O O 0.9999892711639404
EEG O O 0.9945064187049866
evaluation O O 0.9999940395355225
. O O 0.9999829530715942

BACKGROUND O O 0.8255119323730469
: O O 0.9318740367889404
Ifosfamide B B 0.9602967500686646
is O O 0.9978609681129456
an O O 0.9959480166435242
alkylating O B 0.5953532457351685
agent O I 0.9331072568893433
useful O O 0.9889591932296753
in O O 0.9999374151229858
the O O 0.9999347925186157
treatment O O 0.9999469518661499
of O O 0.9999567270278931
a O O 0.9999490976333618
wide O O 0.9999812841415405
range O O 0.9999881982803345
of O O 0.9999687671661377
cancers O O 0.9999798536300659
including O O 0.9998892545700073
sarcomas O O 0.99982088804245
, O O 0.9998912811279297
lymphoma O O 0.9998860359191895
, O O 0.999920129776001
gynecologic O O 0.9994297623634338
and O O 0.9999222755432129
testicular O O 0.9983959794044495
cancers O O 0.9999655485153198
. O O 0.9998924732208252

Encephalopathy O O 0.9990957975387573
has O O 0.9999536275863647
been O O 0.9999902248382568
reported O O 0.9999948740005493
in O O 0.9999725818634033
10 O O 0.9998279809951782
- O O 0.9999164342880249
40 O O 0.9999932050704956
% O O 0.9999910593032837
of O O 0.9999772310256958
patients O O 0.999987006187439
receiving O O 0.9997164607048035
high O O 0.9995214939117432
- O O 0.9999715089797974
dose O O 0.9986585378646851
IV O O 0.9848232269287109
ifosfamide B B 0.9996976852416992
. O O 0.9999343156814575

OBJECTIVE O O 0.9996992349624634
: O O 0.9999923706054688
To O O 0.9999921321868896
highlight O O 0.999967098236084
the O O 0.999984622001648
role O O 0.999983549118042
of O O 0.9999575614929199
electroencephalogram O O 0.9998742341995239
( O O 0.9999319314956665
EEG O O 0.9983423948287964
) O O 0.9999539852142334
in O O 0.9999772310256958
the O O 0.9999943971633911
early O O 0.9999891519546509
detection O O 0.9999945163726807
and O O 0.9999885559082031
management O O 0.9999855756759644
of O O 0.9999591112136841
ifosfamide B B 0.9995928406715393
related O O 0.9995261430740356
encephalopathy O O 0.9996222257614136
. O O 0.9999810457229614

METHODS O O 0.9999184608459473
: O O 0.9999830722808838
Retrospective O O 0.9999852180480957
chart O O 0.9999741315841675
review O O 0.9999967813491821
including O O 0.9999791383743286
clinical O O 0.9999955892562866
data O O 0.9999988079071045
and O O 0.9999805688858032
EEG O O 0.9880742430686951
recordings O O 0.9996883869171143
was O O 0.9999901056289673
done O O 0.9999954700469971
on O O 0.9999619722366333
five O O 0.9999935626983643
patients O O 0.9999966621398926
, O O 0.999987006187439
admitted O O 0.9999861717224121
to O O 0.9997735619544983
MD O O 0.9767826199531555
Anderson O O 0.9996366500854492
Cancer O O 0.9999146461486816
Center O O 0.9999916553497314
between O O 0.9999685287475586
years O O 0.999991774559021
2009 O O 0.9999755620956421
and O O 0.9999667406082153
2012 O O 0.9999942779541016
, O O 0.9999822378158569
who O O 0.9999772310256958
developed O O 0.999988317489624
ifosfamide B B 0.9997703433036804
related O O 0.9997414946556091
acute O O 0.9999749660491943
encephalopathy O O 0.9999110698699951
. O O 0.9999802112579346

RESULTS O O 0.9996007084846497
: O O 0.9999717473983765
All O O 0.9999428987503052
five O O 0.9999923706054688
patients O O 0.9999885559082031
experienced O O 0.9999865293502808
symptoms O O 0.9999958276748657
of O O 0.9999828338623047
encephalopathy O O 0.998785674571991
soon O O 0.999972939491272
after O O 0.999968409538269
( O O 0.9998675584793091
within O O 0.9999936819076538
12 O O 0.9999954700469971
h O O 0.9999010562896729
- O O 0.9997947812080383
2 O O 0.9999618530273438
days O O 0.9999903440475464
) O O 0.9999821186065674
receiving O O 0.9995062351226807
ifosfamide B B 0.9997794032096863
. O O 0.9999262094497681

Two O O 0.9998869895935059
patients O O 0.9999842643737793
developed O O 0.9999802112579346
generalized O O 0.9999053478240967
convulsions O O 0.9994914531707764
while O O 0.999846339225769
one O O 0.9999698400497437
patient O O 0.999990701675415
developed O O 0.9999668598175049
continuous O O 0.9999730587005615
non O O 0.9864657521247864
- O O 0.9990835189819336
convulsive O O 0.9841511249542236
status O O 0.9999927282333374
epilepticus O O 0.9995912909507751
( O O 0.9999508857727051
NCSE O O 0.9895217418670654
) O O 0.999953031539917
that O O 0.9999760389328003
required O O 0.999971866607666
ICU O O 0.9868690371513367
admission O O 0.9999889135360718
and O O 0.9999599456787109
intubation O O 0.9999657869338989
. O O 0.9999624490737915

Initial O O 0.9999432563781738
EEG O O 0.9996440410614014
showed O O 0.9997455477714539
epileptiform O O 0.9989407658576965
discharges O O 0.9999849796295166
in O O 0.999901533126831
three O O 0.9999175071716309
patients O O 0.9999876022338867
; O O 0.9999425411224365
run O O 0.9999475479125977
of O O 0.9997687935829163
triphasic O O 0.999195396900177
waves O O 0.9999929666519165
in O O 0.999958872795105
one O O 0.9999836683273315
patient O O 0.9999868869781494
and O O 0.9998898506164551
moderate O O 0.9997777342796326
degree O O 0.9999610185623169
diffuse O O 0.9999059438705444
generalized O O 0.9999499320983887
slowing O O 0.999994158744812
. O O 0.9999366998672485

Mixed O O 0.9986110925674438
pattern O O 0.9999873638153076
with O O 0.9999556541442871
the O O 0.999976634979248
presence O O 0.9999737739562988
of O O 0.9999655485153198
both O O 0.9995881915092468
sharps O O 0.9997701048851013
and O O 0.9997736811637878
triphasic O O 0.9995393753051758
waves O O 0.9999886751174927
were O O 0.9999548196792603
also O O 0.9999717473983765
noted O O 0.999977707862854
. O O 0.9999514818191528

Repeat O O 0.9999516010284424
EEGs O O 0.9950813055038452
within O O 0.9999637603759766
24 O O 0.9999680519104004
_ O O 0.9999576807022095
h O O 0.9985259175300598
of O O 0.9999874830245972
symptom O O 0.9999474287033081
onset O O 0.9999862909317017
showed O O 0.9999773502349854
marked O O 0.9999909400939941
improvement O O 0.9999967813491821
that O O 0.999976396560669
was O O 0.9999809265136719
correlated O O 0.9999980926513672
with O O 0.9999951124191284
clinical O O 0.9999957084655762
improvement O O 0.9999985694885254
. O O 0.9999849796295166

CONCLUSIONS O O 0.9966257810592651
: O O 0.999956488609314
Severity O O 0.9999649524688721
of O O 0.9999403953552246
ifosfamide B B 0.9996715784072876
related O O 0.9994091987609863
encephalopathy O O 0.9996011853218079
correlates O O 0.9999662637710571
with O O 0.9999864101409912
EEG O O 0.9895707368850708
changes O O 0.9999873638153076
. O O 0.9999791383743286

We O O 0.9999772310256958
suggest O O 0.9999802112579346
a O O 0.9999891519546509
timely O O 0.9999701976776123
EEG O O 0.9931620359420776
evaluation O O 0.9999854564666748
for O O 0.9999819993972778
patients O O 0.9999910593032837
receiving O O 0.9994471669197083
ifosfamide B B 0.9997314810752869
who O O 0.9998996257781982
develop O O 0.9999922513961792
features O O 0.9999979734420776
of O O 0.9999885559082031
encephalopathy O O 0.9998075366020203
. O O 0.9999814033508301

Incidence O O 0.9999715089797974
of O O 0.9999370574951172
contrast B O 0.7433586120605469
- O O 0.9975618124008179
induced O O 0.9999314546585083
nephropathy O O 0.9999043941497803
in O O 0.999911904335022
hospitalised O O 0.9998362064361572
patients O O 0.9999895095825195
with O O 0.9999793767929077
cancer O O 0.9998413324356079
. O O 0.999901294708252

OBJECTIVES O O 0.9998006224632263
: O O 0.9999958276748657
To O O 0.9999926090240479
determine O O 0.999993085861206
the O O 0.999994158744812
frequency O O 0.99998939037323
of O O 0.9999815225601196
and O O 0.9999475479125977
possible O O 0.9999562501907349
factors O O 0.99998939037323
related O O 0.9999916553497314
to O O 0.999953031539917
contrast B O 0.7313303351402283
- O O 0.9930070638656616
induced O O 0.9972400665283203
nephropathy O O 0.9997381567955017
( O O 0.999728262424469
CIN O O 0.8890120387077332
) O O 0.9999713897705078
in O O 0.9999591112136841
hospitalised O O 0.9999456405639648
patients O O 0.9999942779541016
with O O 0.9999836683273315
cancer O O 0.9999357461929321
. O O 0.9999790191650391

METHODS O O 0.9999251365661621
: O O 0.9999942779541016
Ninety O O 0.9999688863754272
adult O O 0.9999948740005493
patients O O 0.9999935626983643
were O O 0.9999867677688599
enrolled O O 0.9999817609786987
. O O 0.9999613761901855

Patients O O 0.9999568462371826
with O O 0.9999436140060425
risk O O 0.9999475479125977
factors O O 0.9999936819076538
for O O 0.9999768733978271
acute O O 0.9999406337738037
renal O O 0.9999864101409912
failure O O 0.9999874830245972
were O O 0.9999586343765259
excluded O O 0.9999700784683228
. O O 0.9999648332595825

Blood O O 0.9997662901878357
samples O O 0.9999675750732422
were O O 0.9999797344207764
examined O O 0.9999927282333374
the O O 0.9999938011169434
day O O 0.999988317489624
before O O 0.9999845027923584
contrast B O 0.987321674823761
- O O 0.9999539852142334
enhanced O O 0.9997251629829407
computed O O 0.999964714050293
tomography O O 0.9999899864196777
( O O 0.9997501969337463
CT O O 0.9829769134521484
) O O 0.9999845027923584
and O O 0.9999314546585083
serially O O 0.9998842477798462
for O O 0.999933123588562
3 O O 0.9998340606689453
days O O 0.9999926090240479
thereafter O O 0.9999872446060181
. O O 0.9999792575836182

CIN O O 0.9581601619720459
was O O 0.9999587535858154
defined O O 0.9999924898147583
as O O 0.9999920129776001
an O O 0.9999970197677612
increase O O 0.999997615814209
in O O 0.9999892711639404
serum O O 0.9986536502838135
creatinine B B 0.9926890730857849
( O O 0.998231828212738
Cr B O 0.8509173393249512
) O O 0.9999799728393555
of O O 0.9999797344207764
0 O O 0.9999876022338867
. O O 0.9999934434890747
5 O O 0.9999932050704956
mg O O 0.9999986886978149
/ O O 0.9999959468841553
dl O O 0.9999990463256836
or O O 0.9999945163726807
more O O 0.9999877214431763
, O O 0.9999837875366211
or O O 0.999987006187439
elevation O O 0.9999955892562866
of O O 0.9999765157699585
Cr B O 0.900885820388794
to O O 0.9999889135360718
25 O O 0.9999922513961792
% O O 0.9999942779541016
over O O 0.9999969005584717
baseline O O 0.9999804496765137
. O O 0.9999828338623047

Relationships O O 0.9999535083770752
between O O 0.9992608428001404
CIN O O 0.6162834763526917
and O O 0.9997683167457581
possible O O 0.999661922454834
risk O O 0.9997394680976868
factors O O 0.9999825954437256
were O O 0.9999475479125977
investigated O O 0.9999516010284424
. O O 0.9999626874923706

RESULTS O O 0.9995728135108948
: O O 0.9991621971130371
CIN O O 0.5782978534698486
was O O 0.9999175071716309
detected O O 0.9998875856399536
in O O 0.9999057054519653
18 O O 0.999136745929718
/ O O 0.9999617338180542
90 O O 0.9995049238204956
( O O 0.9999157190322876
20 O O 0.9999853372573853
% O O 0.999991774559021
) O O 0.9998350143432617
patients O O 0.9999866485595703
. O O 0.9999591112136841

CIN O O 0.7142443060874939
developed O O 0.8098034858703613
in O O 0.9997692704200745
25 O O 0.999890923500061
. O O 0.9999594688415527
5 O O 0.9999631643295288
% O O 0.9999710321426392
patients O O 0.9999881982803345
who O O 0.9999567270278931
underwent O O 0.9999334812164307
chemotherapy O O 0.9995996356010437
and O O 0.9999185800552368
in O O 0.9999486207962036
11 O O 0.9999758005142212
% O O 0.999983549118042
patients O O 0.9999914169311523
who O O 0.9999483823776245
did O O 0.9999908208847046
not O O 0.9999828338623047
( O O 0.999916672706604
P O O 0.9983183145523071
= O O 0.9998830556869507
0 O O 0.999767005443573
. O O 0.9999938011169434
1 O O 0.9999840259552002
) O O 0.9999631643295288
. O O 0.9999653100967407

CIN O O 0.866457462310791
more O O 0.9997077584266663
frequently O O 0.9999710321426392
developed O O 0.9999879598617554
in O O 0.9999469518661499
patients O O 0.999992847442627
who O O 0.9999750852584839
had O O 0.9999887943267822
undergone O O 0.9999873638153076
CT O O 0.9822787046432495
within O O 0.9999836683273315
45 O O 0.9999970197677612
days O O 0.9999988079071045
after O O 0.9999903440475464
the O O 0.9999984502792358
last O O 0.9999897480010986
chemotherapy O O 0.9997875094413757
( O O 0.9999600648880005
P O O 0.9996927976608276
= O O 0.9999274015426636
0 O O 0.9999748468399048
. O O 0.9999967813491821
005 O O 0.9997919201850891
) O O 0.9999567270278931
; O O 0.9999637603759766
it O O 0.9999747276306152
was O O 0.9999672174453735
also O O 0.9999586343765259
an O O 0.9999300241470337
independent O O 0.9998052716255188
risk O O 0.9999749660491943
factor O O 0.9999957084655762
( O O 0.9999722242355347
P O O 0.9996598958969116
= O O 0.999910831451416
0 O O 0.9999691247940063
. O O 0.9999959468841553
017 O O 0.9999853372573853
) O O 0.9999642372131348
. O O 0.9999785423278809

CIN O O 0.9268838763237
was O O 0.9999202489852905
significantly O O 0.9999837875366211
more O O 0.9999443292617798
after O O 0.9998288154602051
treatment O O 0.9999877214431763
with O O 0.9996998310089111
bevacizumab B B 0.973612904548645
/ O I 0.8040924072265625
irinotecan B I 0.9574487805366516
( O O 0.998813271522522
P O O 0.9985798597335815
= O O 0.9998231530189514
0 O O 0.99993896484375
. O O 0.9999887943267822
021 O O 0.9956923127174377
) O O 0.9999589920043945
and O O 0.9999698400497437
in O O 0.9999611377716064
patients O O 0.9999901056289673
with O O 0.9999805688858032
hypertension O O 0.9933575987815857
( O O 0.9999376535415649
P O O 0.998860239982605
= O O 0.999915599822998
0 O O 0.9999408721923828
. O O 0.9999927282333374
044 O O 0.9961122870445251
) O O 0.9999674558639526
. O O 0.99997878074646

CONCLUSIONS O O 0.9908075928688049
: O O 0.9999666213989258
The O O 0.9999839067459106
incidence O O 0.9999829530715942
of O O 0.9998488426208496
CIN O O 0.8767295479774475
after O O 0.9974786639213562
CT O O 0.9287563562393188
in O O 0.9998254179954529
hospitalised O O 0.9992111921310425
oncological O O 0.9993170499801636
patients O O 0.9999804496765137
was O O 0.9999171495437622
20 O O 0.9999688863754272
% O O 0.9999892711639404
. O O 0.9999672174453735

CIN O O 0.5279079675674438
developed O O 0.8512735366821289
4 O O 0.9997122883796692
. O O 0.9999872446060181
5 O O 0.9999657869338989
- O O 0.999988317489624
times O O 0.9999914169311523
more O O 0.9999765157699585
frequently O O 0.9999910593032837
in O O 0.9999650716781616
patients O O 0.9999916553497314
with O O 0.9999853372573853
cancer O O 0.9999828338623047
who O O 0.9999790191650391
had O O 0.9999905824661255
undergone O O 0.9999921321868896
recent O O 0.9999468326568604
chemotherapy O O 0.9991137385368347
. O O 0.9999520778656006

Hypertension O O 0.9976492524147034
and O O 0.999893307685852
the O O 0.9999773502349854
combination O O 0.9988665580749512
of O O 0.9994114637374878
bevacizumab B B 0.9780697822570801
/ O O 0.6152281165122986
irinotecan B B 0.5568413734436035
may O O 0.9993773102760315
be O O 0.9999383687973022
additional O O 0.9999215602874756
risk O O 0.99993896484375
factors O O 0.9999948740005493
for O O 0.9999538660049438
CIN O O 0.9472417235374451
development O O 0.9991530179977417
. O O 0.9999362230300903

KEY O O 0.997168242931366
POINTS O O 0.9999452829360962
: O O 0.9999349117279053
. O O 0.9948561191558838

Contrast B B 0.8720023036003113
- O O 0.9785860776901245
induced O O 0.9997296929359436
nephropathy O O 0.999942421913147
( O O 0.9997996687889099
CIN O O 0.8714256286621094
) O O 0.9999606609344482
is O O 0.999976396560669
a O O 0.9999853372573853
concern O O 0.9999904632568359
for O O 0.9999644756317139
oncological O O 0.9998949766159058
patients O O 0.9999947547912598
undergoing O O 0.9999364614486694
CT O O 0.8911703824996948
. O O 0.9999034404754639

. O O 0.9988042116165161
CIN O O 0.9391704201698303
occurs O O 0.9999390840530396
more O O 0.9999728202819824
often O O 0.9999749660491943
when O O 0.9999343156814575
CT O O 0.9778221249580383
is O O 0.9999808073043823
performed O O 0.9999970197677612
< O O 0.999987006187439
45 O O 0.9999967813491821
days O O 0.9999986886978149
after O O 0.9999876022338867
chemotherapy O O 0.999316930770874
. O O 0.9999735355377197

. O O 0.9997768998146057
Hypertension O O 0.9911094903945923
and O O 0.9998989105224609
treatment O O 0.9999817609786987
with O O 0.9992484450340271
bevacizumab B B 0.9946735501289368
appear O O 0.9995064735412598
to O O 0.9998818635940552
be O O 0.9999381303787231
additional O O 0.9996649026870728
risk O O 0.9999487400054932
factors O O 0.9999929666519165
. O O 0.9999537467956543

Syndrome O O 0.9998947381973267
of O O 0.9998003840446472
inappropriate O O 0.9995352029800415
antidiuretic O O 0.7919291853904724
hormone O O 0.9729344844818115
secretion O O 0.9998136162757874
associated O O 0.9999245405197144
with O O 0.9996034502983093
desvenlafaxine B B 0.9993491768836975
. O O 0.9998602867126465

OBJECTIVE O O 0.9998791217803955
: O O 0.9999970197677612
To O O 0.9999966621398926
report O O 0.9999979734420776
a O O 0.9999924898147583
case O O 0.9999936819076538
of O O 0.9999724626541138
syndrome O O 0.9997348189353943
of O O 0.9998477697372437
inappropriate O O 0.9970844388008118
anti O O 0.9009298086166382
- O O 0.993607759475708
diuretic O O 0.9157472848892212
hormone O O 0.9564743638038635
( O O 0.9989882111549377
SIADH O O 0.8893318772315979
) O O 0.9997510313987732
secretion O O 0.9998451471328735
associated O O 0.999945878982544
with O O 0.9995738863945007
desvenlafaxine B B 0.9993938207626343
. O O 0.9999023675918579

CASE O O 0.9998874664306641
SUMMARY O O 0.9999945163726807
: O O 0.9999712705612183
A O O 0.9999923706054688
57 O O 0.9999967813491821
- O O 0.9999797344207764
year O O 0.9999974966049194
old O O 0.9999915361404419
female O O 0.9999953508377075
with O O 0.9998822212219238
hyponatraemia O O 0.9765098094940186
. O O 0.9999608993530273

Her O O 0.9999169111251831
medications O O 0.9994829893112183
included O O 0.9996198415756226
desvenlafaxine B B 0.9995585083961487
, O O 0.9997223019599915
and O O 0.999876856803894
symptoms O O 0.9999916553497314
included O O 0.9999892711639404
nausea O O 0.9999638795852661
, O O 0.9999605417251587
anxiety O O 0.9993565678596497
and O O 0.999922513961792
confusion O O 0.9999810457229614
. O O 0.9999648332595825

The O O 0.9999914169311523
serum O O 0.9986220598220825
sodium B B 0.9982988238334656
at O O 0.999966025352478
this O O 0.9999960660934448
time O O 0.9999974966049194
was O O 0.9999830722808838
120 O O 0.9999904632568359
mmol O O 0.9999955892562866
/ O O 0.9999593496322632
L O O 0.999327540397644
, O O 0.9999632835388184
serum O O 0.9935585856437683
osmolality O O 0.5494900941848755
was O O 0.9999562501907349
263 O O 0.9999854564666748
mosmol O O 0.9999864101409912
/ O O 0.9999477863311768
kg O O 0.9999926090240479
, O O 0.9999558925628662
urine O O 0.9990965127944946
osmolality O O 0.49017953872680664
410 O O 0.997951328754425
mosmol O O 0.9999924898147583
/ O O 0.9999349117279053
kg O O 0.9999936819076538
and O O 0.9999624490737915
urine O O 0.9997578263282776
sodium B B 0.9802919030189514
63 O O 0.9982141256332397
mmol O O 0.9999970197677612
/ O O 0.9999649524688721
L O O 0.9979245662689209
, O O 0.9999885559082031
consistent O O 0.9999951124191284
with O O 0.9999972581863403
a O O 0.9999929666519165
diagnosis O O 0.999993085861206
of O O 0.9999276399612427
SIADH O O 0.9870259165763855
. O O 0.9999196529388428

Desvenlafaxine B B 0.9987339377403259
was O O 0.9998605251312256
ceased O O 0.9996178150177002
and O O 0.9999575614929199
fluid O O 0.9946265816688538
restriction O O 0.9998526573181152
implemented O O 0.9999473094940186
. O O 0.9999765157699585

After O O 0.999954104423523
4 O O 0.9997245669364929
days O O 0.9999830722808838
the O O 0.9999934434890747
sodium B B 0.9983939528465271
increased O O 0.9999158382415771
to O O 0.9999938011169434
128 O O 0.9970391988754272
mmol O O 0.999948263168335
/ O O 0.9999037981033325
L O O 0.9991710186004639
and O O 0.9999829530715942
fluid O O 0.9961016178131104
restriction O O 0.9999103546142578
was O O 0.9999780654907227
relaxed O O 0.9998915195465088
. O O 0.9999796152114868

During O O 0.999935507774353
her O O 0.9999972581863403
further O O 0.9999946355819702
3 O O 0.9999204874038696
weeks O O 0.9999889135360718
inpatient O O 0.9999890327453613
admission O O 0.999988317489624
the O O 0.9999868869781494
serum O O 0.9996848106384277
sodium B B 0.9990943670272827
ranged O O 0.9999345541000366
from O O 0.9999798536300659
134 O O 0.9994914531707764
to O O 0.9999886751174927
137 O O 0.9999368190765381
mmol O O 0.9999946355819702
/ O O 0.9999293088912964
L O O 0.9998335838317871
during O O 0.9998342990875244
treatment O O 0.9999836683273315
with O O 0.9997536540031433
mirtazapine B B 0.9996538162231445
. O O 0.9999585151672363

DISCUSSION O O 0.7792391777038574
: O O 0.9991952776908875
SIADH O O 0.6204243898391724
has O O 0.9998412132263184
been O O 0.9999593496322632
widely O O 0.9999409914016724
reported O O 0.9999735355377197
with O O 0.9995245933532715
a O O 0.9997777342796326
range O O 0.9922834038734436
of O O 0.9785370826721191
antidepressants O B 0.8561237454414368
. O O 0.9995949864387512

This O O 0.9999833106994629
case O O 0.9999778270721436
report O O 0.9999942779541016
suggests O O 0.9999655485153198
that O O 0.9994680285453796
desvenlafaxine B B 0.999785840511322
might O O 0.9998875856399536
cause O O 0.999906063079834
clinically O O 0.9999833106994629
significant O O 0.9999910593032837
hyponatremia O O 0.9997969269752502
. O O 0.9999324083328247

CONCLUSIONS O O 0.9972136616706848
: O O 0.9999239444732666
Clinicians O O 0.994664192199707
should O O 0.999954104423523
be O O 0.999993085861206
aware O O 0.9999878406524658
of O O 0.9999876022338867
the O O 0.9999873638153076
potential O O 0.9999922513961792
for O O 0.9998108744621277
antidepressants O O 0.8323322534561157
to O O 0.9996401071548462
cause O O 0.9999208450317383
hyponatremia O O 0.9998973608016968
, O O 0.9999436140060425
and O O 0.9999672174453735
take O O 0.9999740123748779
appropriate O O 0.9999799728393555
corrective O O 0.9999700784683228
action O O 0.9999864101409912
where O O 0.9999830722808838
necessary O O 0.9999926090240479
. O O 0.9999759197235107

Oxidative O O 0.997907280921936
stress O O 0.9990445971488953
on O O 0.9997767806053162
cardiotoxicity O O 0.9999886751174927
after O O 0.9997811913490295
treatment O O 0.9999805688858032
with O O 0.9999145269393921
single O O 0.9996951818466187
and O O 0.9997527003288269
multiple O O 0.999848484992981
doses O O 0.9998984336853027
of O O 0.9965331554412842
doxorubicin B B 0.9992903470993042
. O O 0.9997739195823669

The O O 0.9999749660491943
mechanism O O 0.9999657869338989
of O O 0.999929666519165
doxorubicin B B 0.999775230884552
( O O 0.9821250438690186
DOX B B 0.9996755123138428
) O O 0.9527834057807922
- O O 0.9998420476913452
induced O O 0.9999217987060547
cardiotoxicity O O 0.9999954700469971
remains O O 0.9999661445617676
controversial O O 0.999988317489624
. O O 0.99997878074646

Wistar O O 0.9920593500137329
rats O O 0.9999961853027344
( O O 0.9999645948410034
n O O 0.9999122619628906
= O O 0.9999773502349854
66 O O 0.9999910593032837
) O O 0.9999821186065674
received O O 0.9999274015426636
DOX B B 0.9992432594299316
injections O O 0.9994534850120544
intraperitoneally O O 0.9999775886535645
and O O 0.999984622001648
were O O 0.9999945163726807
randomly O O 0.9999974966049194
assigned O O 0.9999967813491821
to O O 0.9999605417251587
2 O O 0.999955415725708
experimental O O 0.9999903440475464
protocols O O 0.9999980926513672
: O O 0.9999909400939941
( O O 0.9999374151229858
1 O O 0.9999959468841553
) O O 0.9999856948852539
rats O O 0.9999964237213135
were O O 0.9999872446060181
killed O O 0.999971866607666
before O O 0.9999651908874512
( O O 0.9974932670593262
- O O 0.9994644522666931
24 O O 0.9989795088768005
h O O 0.9979952573776245
, O O 0.9999462366104126
n O O 0.9981679916381836
= O O 0.9998829364776611
8 O O 0.9984375834465027
) O O 0.9998921155929565
and O O 0.9999285936355591
24 O O 0.9999412298202515
h O O 0.9999066591262817
after O O 0.9999157190322876
( O O 0.9994543194770813
+ O O 0.999970555305481
24 O O 0.9999457597732544
h O O 0.9994176626205444
, O O 0.9999678134918213
n O O 0.9997530579566956
= O O 0.9999864101409912
8 O O 0.9980055689811707
) O O 0.9999665021896362
a O O 0.9999819993972778
single O O 0.9999703168869019
dose O O 0.9999446868896484
of O O 0.9997439980506897
DOX B B 0.9997232556343079
( O O 0.9991244673728943
4 O O 0.9991167187690735
mg O O 0.9999227523803711
/ O O 0.9999955892562866
kg O O 0.9999971389770508
body O O 0.999995231628418
weight O O 0.9990109205245972
) O O 0.9999834299087524
to O O 0.9999866485595703
determine O O 0.9999901056289673
the O O 0.9999866485595703
DOX B B 0.9992281198501587
acute O O 0.9996548891067505
effect O O 0.9999768733978271
and O O 0.9999532699584961
( O O 0.9999312162399292
2 O O 0.9999953508377075
) O O 0.9999856948852539
rats O O 0.9999985694885254
( O O 0.9999849796295166
n O O 0.9999752044677734
= O O 0.9999916553497314
58 O O 0.9999556541442871
) O O 0.9999904632568359
received O O 0.9999830722808838
4 O O 0.9996126294136047
injections O O 0.9999641180038452
of O O 0.9999051094055176
DOX B B 0.998997151851654
( O O 0.9992905855178833
4 O O 0.9996840953826904
mg O O 0.9999412298202515
/ O O 0.9999926090240479
kg O O 0.9999955892562866
body O O 0.9999879598617554
weight O O 0.9999352693557739
/ O O 0.9999527931213379
week O O 0.9999978542327881
) O O 0.9999825954437256
and O O 0.9999743700027466
were O O 0.9999885559082031
killed O O 0.9999821186065674
before O O 0.9999825954437256
the O O 0.9999966621398926
first O O 0.9999949932098389
injection O O 0.9999784231185913
( O O 0.9999358654022217
M0 O O 0.9996476173400879
) O O 0.9999709129333496
and O O 0.9999690055847168
1 O O 0.9999641180038452
week O O 0.9999974966049194
after O O 0.9999868869781494
each O O 0.9999605417251587
injection O O 0.9999675750732422
( O O 0.9998912811279297
M1 O O 0.9996001124382019
, O O 0.999765932559967
M2 O O 0.9997915625572205
, O O 0.9996740818023682
M3 O O 0.9997926354408264
, O O 0.9998764991760254
and O O 0.9998526573181152
M4 O O 0.9994428753852844
) O O 0.9999784231185913
to O O 0.9999743700027466
determine O O 0.9999712705612183
the O O 0.9999748468399048
chronological O O 0.9964087605476379
effects O O 0.9999812841415405
. O O 0.9999808073043823

Animals O O 0.9997685551643372
used O O 0.9999282360076904
at O O 0.9991336464881897
M0 O O 0.99845290184021
( O O 0.999863862991333
n O O 0.9808638095855713
= O O 0.9992921352386475
8 O O 0.9949872493743896
) O O 0.9994984865188599
were O O 0.9999350309371948
also O O 0.9999434947967529
used O O 0.9999527931213379
at O O 0.9998550415039062
moment O O 0.9975429773330688
- O O 0.9998698234558105
24 O O 0.9999899864196777
h O O 0.9999347925186157
of O O 0.9999903440475464
acute O O 0.9999425411224365
study O O 0.9999827146530151
. O O 0.9999656677246094

Cardiac O O 0.9994459748268127
total O O 0.960276186466217
antioxidant O O 0.6382328867912292
performance O O 0.990402340888977
( O O 0.998700737953186
TAP O O 0.9411604404449463
) O O 0.9998490810394287
, O O 0.9997220635414124
DNA O O 0.6454173922538757
damage O O 0.999685525894165
, O O 0.9995738863945007
and O O 0.9986414313316345
morphology O O 0.993453860282898
analyses O O 0.9999001026153564
were O O 0.9999487400054932
carried O O 0.9999707937240601
out O O 0.9999698400497437
at O O 0.9998231530189514
each O O 0.9998586177825928
time O O 0.9999244213104248
point O O 0.9999901056289673
. O O 0.9999635219573975

Single O O 0.9997519850730896
dose O O 0.9996697902679443
of O O 0.9980785846710205
DOX B B 0.9998090863227844
was O O 0.9998703002929688
associated O O 0.9999562501907349
with O O 0.9999692440032959
increased O O 0.9999614953994751
cardiac O O 0.9999316930770874
disarrangement O O 0.9999916553497314
, O O 0.9999462366104126
necrosis O O 0.9999457597732544
, O O 0.9998601675033569
and O O 0.999795138835907
DNA O O 0.8919223546981812
damage O O 0.9999393224716187
( O O 0.9996496438980103
strand O O 0.9946351647377014
breaks O O 0.9937072396278381
( O O 0.998462438583374
SBs O O 0.871427595615387
) O O 0.9994245767593384
and O O 0.9993983507156372
oxidized O O 0.5450919270515442
pyrimidines O B 0.6974651217460632
) O O 0.9997076392173767
and O O 0.9999760389328003
decreased O O 0.9999098777770996
TAP O O 0.5520060062408447
. O O 0.9999697208404541

The O O 0.999983549118042
chronological O O 0.9999001026153564
study O O 0.9999912977218628
showed O O 0.9999103546142578
an O O 0.9999456405639648
effect O O 0.9999791383743286
of O O 0.9998522996902466
a O O 0.7815511226654053
cumulative O O 0.9517146348953247
dose O O 0.9990155696868896
on O O 0.9998315572738647
body O O 0.9999921321868896
weight O O 0.9999929666519165
( O O 0.9999773502349854
R O O 0.9998937845230103
= O O 0.9997597336769104
- O O 0.999987006187439
0 O O 0.9999920129776001
. O O 0.9999935626983643
99 O O 0.9999572038650513
, O O 0.9999722242355347
p O O 0.9999581575393677
= O O 0.9999152421951294
0 O O 0.9999682903289795
. O O 0.9999905824661255
011 O O 0.9999912977218628
) O O 0.999955415725708
, O O 0.9998611211776733
necrosis O O 0.9999158382415771
( O O 0.9999717473983765
R O O 0.9995362758636475
= O O 0.9999440908432007
1 O O 0.9999712705612183
. O O 0.9999963045120239
00 O O 0.9999940395355225
, O O 0.999936580657959
p O O 0.9998403787612915
= O O 0.999950647354126
0 O O 0.9999675750732422
. O O 0.9999908208847046
004 O O 0.9999686479568481
) O O 0.9999421834945679
, O O 0.9998175501823425
TAP O O 0.8327045440673828
( O O 0.9999687671661377
R O O 0.9997757077217102
= O O 0.9999732971191406
0 O O 0.9999748468399048
. O O 0.9999853372573853
95 O O 0.9998977184295654
, O O 0.9999586343765259
p O O 0.9999064207077026
= O O 0.999975323677063
0 O O 0.9999674558639526
. O O 0.9999953508377075
049 O O 0.9998883008956909
) O O 0.9999402761459351
, O O 0.9992006421089172
and O O 0.9987646341323853
DNA O O 0.8612162470817566
SBs O O 0.9983868598937988
( O O 0.9999618530273438
R O O 0.9998599290847778
= O O 0.9998950958251953
- O O 0.9999727010726929
0 O O 0.9999876022338867
. O O 0.9999842643737793
95 O O 0.9999551773071289
, O O 0.9999669790267944
p O O 0.999876856803894
= O O 0.9999707937240601
0 O O 0.9999610185623169
. O O 0.9999936819076538
049 O O 0.9999487400054932
) O O 0.9999681711196899
. O O 0.9999756813049316

DNA O O 0.7870071530342102
SBs O O 0.9846085906028748
damage O O 0.9997196793556213
was O O 0.9998965263366699
negatively O O 0.9929894208908081
associated O O 0.9999752044677734
with O O 0.999774158000946
TAP O O 0.8566758632659912
( O O 0.9999470710754395
R O O 0.9997716546058655
= O O 0.9996167421340942
- O O 0.9999755620956421
0 O O 0.999984622001648
. O O 0.9999847412109375
98 O O 0.9996767044067383
, O O 0.9999818801879883
p O O 0.9999713897705078
= O O 0.9999635219573975
0 O O 0.9999812841415405
. O O 0.9999934434890747
018 O O 0.9999938011169434
) O O 0.9999409914016724
, O O 0.9995228052139282
and O O 0.9995085000991821
necrosis O O 0.9998263716697693
( O O 0.9999693632125854
R O O 0.9997321963310242
= O O 0.9994962215423584
- O O 0.999980092048645
0 O O 0.9999921321868896
. O O 0.9999858140945435
97 O O 0.9999703168869019
, O O 0.9999713897705078
p O O 0.999953031539917
= O O 0.9999580383300781
0 O O 0.9999834299087524
. O O 0.9999935626983643
027 O O 0.9999725818634033
) O O 0.9999542236328125
. O O 0.9999719858169556

Our O O 0.999969482421875
results O O 0.999987006187439
suggest O O 0.9999575614929199
that O O 0.9998642206192017
oxidative O O 0.9987671375274658
damage O O 0.999961256980896
is O O 0.9999040365219116
associated O O 0.9999703168869019
with O O 0.9999510049819946
acute O O 0.999958872795105
cardiotoxicity O O 0.9999955892562866
induced O O 0.9999645948410034
by O O 0.9999264478683472
a O O 0.9999773502349854
single O O 0.9999321699142456
dose O O 0.9996621608734131
of O O 0.9984514713287354
DOX B B 0.9996688365936279
only O O 0.8106644153594971
. O O 0.9999276399612427

Increased O O 0.9997172951698303
resistance O O 0.9999834299087524
to O O 0.9997714161872864
the O O 0.9997941851615906
oxidative O O 0.9024159908294678
stress O O 0.9942197799682617
is O O 0.9999222755432129
plausible O O 0.9934573769569397
for O O 0.9978790283203125
the O O 0.999733030796051
multiple O O 0.999523401260376
dose O O 0.995547890663147
of O O 0.9908724427223206
DOX B B 0.9998045563697815
. O O 0.9998735189437866

Thus O O 0.999946117401123
, O O 0.9999092817306519
different O O 0.999627947807312
mechanisms O O 0.9998352527618408
may O O 0.9998984336853027
be O O 0.9999306201934814
involved O O 0.9999560117721558
in O O 0.9999417066574097
acute O O 0.9996545314788818
toxicity O O 0.9998095631599426
versus O O 0.9999191761016846
chronic O O 0.99959796667099
toxicity O O 0.999889612197876
. O O 0.9999628067016602

Tacrolimus B B 0.9987291693687439
- O O 0.9990442395210266
related O O 0.9999281167984009
seizure O O 0.9999716281890869
after O O 0.9999198913574219
pediatric O O 0.9999849796295166
liver O O 0.9985382556915283
transplantation O O 0.9998936653137207
- O O 0.9999284744262695
- O O 0.9999879598617554
a O O 0.9999979734420776
single O O 0.9999344348907471
- O O 0.9999898672103882
center O O 0.9999945163726807
experience O O 0.9999979734420776
. O O 0.9999871253967285

To O O 0.9999656677246094
identify O O 0.9999785423278809
the O O 0.9999823570251465
risk O O 0.999969482421875
factors O O 0.9999842643737793
for O O 0.9999784231185913
new O O 0.9999521970748901
- O O 0.9999703168869019
onset O O 0.9999915361404419
seizures O O 0.9999556541442871
after O O 0.9997861981391907
pediatric O O 0.9999030828475952
LT O O 0.950171172618866
and O O 0.9999395608901978
to O O 0.999990701675415
assess O O 0.9999886751174927
their O O 0.9999722242355347
clinical O O 0.9999945163726807
implications O O 0.9999991655349731
and O O 0.9999903440475464
long O O 0.9998884201049805
- O O 0.9999865293502808
term O O 0.9999915361404419
prognosis O O 0.9999971389770508
. O O 0.9999819993972778

The O O 0.9999892711639404
clinical O O 0.9999889135360718
and O O 0.9999780654907227
laboratory O O 0.9999736547470093
data O O 0.9999972581863403
of O O 0.9999921321868896
27 O O 0.9999902248382568
consecutive O O 0.9999880790710449
children O O 0.9999951124191284
who O O 0.9999722242355347
underwent O O 0.9999597072601318
LT O O 0.9860379099845886
from O O 0.9997732043266296
January O O 0.9986242055892944
2007 O O 0.9515047669410706
to O O 0.9998587369918823
December O O 0.9993515610694885
2010 O O 0.9997972846031189
in O O 0.999968409538269
our O O 0.9999874830245972
center O O 0.9999963045120239
were O O 0.9999819993972778
analyzed O O 0.9999923706054688
retrospectively O O 0.9999860525131226
. O O 0.9999746084213257

Patients O O 0.9999169111251831
were O O 0.9999483823776245
divided O O 0.9999630451202393
into O O 0.9995729327201843
seizures O O 0.9986364245414734
group O O 0.9998078942298889
and O O 0.9996954202651978
a O O 0.9994149208068848
non O O 0.990492045879364
- O O 0.9997045397758484
seizures O O 0.9987884163856506
group O O 0.9998549222946167
. O O 0.9999656677246094

Pre O O 0.9996271133422852
- O O 0.9999197721481323
operative O O 0.9999808073043823
, O O 0.9999428987503052
intra O O 0.9995797276496887
- O O 0.9999326467514038
operative O O 0.9999902248382568
, O O 0.9998670816421509
and O O 0.9998753070831299
post O O 0.9993218183517456
- O O 0.9999366998672485
operative O O 0.9999860525131226
data O O 0.9999945163726807
were O O 0.999967098236084
collected O O 0.9999884366989136
. O O 0.9999700784683228

Seizures O O 0.9997649788856506
occurred O O 0.9999889135360718
in O O 0.9999825954437256
four O O 0.999984860420227
children O O 0.9999955892562866
, O O 0.9999818801879883
an O O 0.9999840259552002
incidence O O 0.9999954700469971
of O O 0.9999791383743286
14 O O 0.9999946355819702
. O O 0.9999948740005493
8 O O 0.9999915361404419
% O O 0.9999949932098389
. O O 0.9999834299087524

All O O 0.99994957447052
exhibited O O 0.9999796152114868
generalized O O 0.9999594688415527
tonic O O 0.9999806880950928
- O O 0.9994712471961975
clonic O O 0.9996577501296997
seizures O O 0.9999855756759644
within O O 0.9999356269836426
the O O 0.9999920129776001
first O O 0.9999933242797852
two O O 0.9999966621398926
wk O O 0.9986911416053772
after O O 0.9999164342880249
LT O O 0.5166179537773132
. O O 0.9999005794525146

Univariate O O 0.99947589635849
analysis O O 0.9999384880065918
showed O O 0.9999542236328125
that O O 0.9998862743377686
the O O 0.9999561309814453
risk O O 0.9999232292175293
factors O O 0.9999904632568359
associated O O 0.9999860525131226
with O O 0.9999743700027466
seizures O O 0.999976396560669
after O O 0.9997350573539734
pediatric O O 0.9999250173568726
LT O O 0.9659337401390076
included O O 0.999454915523529
gender O O 0.9999746084213257
, O O 0.9999450445175171
pediatric O O 0.999915599822998
end O O 0.9995310306549072
- O O 0.9999130964279175
stage O O 0.9999550580978394
liver O O 0.9986510872840881
disease O O 0.9999904632568359
score O O 0.999924898147583
before O O 0.9998795986175537
surgery O O 0.999996542930603
, O O 0.9999154806137085
Child O O 0.9779134392738342
- O O 0.9963984489440918
Pugh O O 0.9727557897567749
score O O 0.9995530247688293
before O O 0.9998893737792969
surgery O O 0.9999970197677612
, O O 0.9999278783798218
serum O O 0.9950290322303772
total O O 0.6889891624450684
bilirubin B B 0.7704169750213623
after O O 0.9976338148117065
surgery O O 0.9999920129776001
, O O 0.9984038472175598
and O O 0.9983134269714355
trough O O 0.8816860318183899
TAC B B 0.9326267242431641
level O O 0.9328628778457642
. O O 0.9999665021896362

Multivariate O O 0.9980812072753906
analysis O O 0.9996680021286011
showed O O 0.9999576807022095
that O O 0.9996724128723145
trough O O 0.6019302010536194
TAC B B 0.971825122833252
level O O 0.8774399161338806
was O O 0.9998337030410767
the O O 0.999924898147583
only O O 0.9999209642410278
independent O O 0.9999171495437622
risk O O 0.9999328851699829
factor O O 0.9999864101409912
associated O O 0.9999867677688599
with O O 0.9999821186065674
the O O 0.9999895095825195
seizures O O 0.9999866485595703
. O O 0.9999732971191406

All O O 0.9998171925544739
children O O 0.9999915361404419
who O O 0.9999157190322876
experienced O O 0.999956488609314
seizures O O 0.9999001026153564
survived O O 0.9999526739120483
with O O 0.9999816417694092
good O O 0.9999697208404541
graft O O 0.9995928406715393
function O O 0.9999927282333374
and O O 0.9999781847000122
remained O O 0.9999836683273315
seizure O O 0.9998270869255066
- O O 0.9999856948852539
free O O 0.9999889135360718
without O O 0.9998093247413635
anti O O 0.7380027770996094
- O O 0.993827760219574
epileptic O O 0.9935529232025146
drugs O O 0.9991104006767273
over O O 0.9999748468399048
a O O 0.9999904632568359
mean O O 0.999993085861206
follow O O 0.9999945163726807
- O O 0.9999922513961792
up O O 0.9999963045120239
period O O 0.9999943971633911
of O O 0.9999905824661255
33 O O 0.9999983310699463
. O O 0.9999985694885254
7 O O 0.9999967813491821
+ O O 0.9999822378158569
14 O O 0.9999977350234985
. O O 0.9999988079071045
6 O O 0.999997615814209
months O O 0.9999986886978149
. O O 0.9999890327453613

High O O 0.9991928935050964
trough O O 0.8783137798309326
TAC B B 0.975658118724823
level O O 0.9369467496871948
was O O 0.9999278783798218
the O O 0.9998830556869507
predominant O O 0.999748170375824
factor O O 0.999873161315918
that O O 0.9998366832733154
contributed O O 0.9999816417694092
to O O 0.9999797344207764
seizures O O 0.9999805688858032
in O O 0.9999561309814453
the O O 0.9999831914901733
early O O 0.9999643564224243
post O O 0.9999115467071533
- O O 0.9998812675476074
operative O O 0.9999799728393555
period O O 0.9999903440475464
after O O 0.999763548374176
pediatric O O 0.9989043474197388
LT O O 0.9430716037750244
. O O 0.9997439980506897

High O O 0.9962891340255737
PELD O O 0.6506989002227783
and O O 0.9984234571456909
Child O O 0.6206260323524475
- O O 0.8591902852058411
Pugh O O 0.7458456158638
scores O O 0.9892352223396301
before O O 0.9995517134666443
LT O O 0.8244837522506714
and O O 0.9999067783355713
high O O 0.9997065663337708
post O O 0.9990851879119873
- O O 0.9996793270111084
operative O O 0.9999716281890869
serum O O 0.9912508726119995
Tbil O B 0.8911265134811401
may O O 0.9997662901878357
be O O 0.9999090433120728
contributory O O 0.9995193481445312
risk O O 0.9999096393585205
factors O O 0.9999923706054688
for O O 0.9999387264251709
TAC B B 0.9748275876045227
- O O 0.9568873047828674
related O O 0.99991774559021
seizures O O 0.9999723434448242
. O O 0.9999585151672363

The O O 0.9953030347824097
flavonoid B B 0.8989170789718628
apigenin B I 0.716167688369751
delays O O 0.9988420605659485
forgetting O O 0.9992316961288452
of O O 0.9998841285705566
passive O O 0.999657392501831
avoidance O O 0.999906063079834
conditioning O O 0.9999759197235107
in O O 0.9999494552612305
rats O O 0.9999786615371704
. O O 0.9999290704727173

The O O 0.9999904632568359
present O O 0.9999878406524658
experiments O O 0.999993085861206
were O O 0.9999954700469971
performed O O 0.9999957084655762
to O O 0.9999963045120239
study O O 0.9999868869781494
the O O 0.9999881982803345
effect O O 0.9999672174453735
of O O 0.9999066591262817
the O O 0.9982900023460388
flavonoid B B 0.9723731875419617
apigenin B I 0.8540180921554565
( O O 0.9986327290534973
20 O O 0.9997274279594421
mg O O 0.9999494552612305
/ O O 0.9999768733978271
kg O O 0.9999966621398926
intraperitoneally O O 0.9999778270721436
( O O 0.999935507774353
i O O 0.9999650716781616
. O O 0.9999963045120239
p O O 0.9999984502792358
. O O 0.9999977350234985
) O O 0.9999926090240479
, O O 0.9999892711639404
1 O O 0.9999483823776245
h O O 0.9995336532592773
before O O 0.9999804496765137
acquisition O O 0.9999958276748657
) O O 0.99997878074646
, O O 0.9999768733978271
on O O 0.999897837638855
24 O O 0.9999425411224365
h O O 0.9993964433670044
retention O O 0.9989280104637146
performance O O 0.9999712705612183
and O O 0.9999551773071289
forgetting O O 0.9999356269836426
of O O 0.9999849796295166
a O O 0.9999872446060181
step O O 0.999925971031189
- O O 0.9999638795852661
through O O 0.9988958835601807
passive O O 0.9995366334915161
avoidance O O 0.9999721050262451
task O O 0.999988317489624
, O O 0.9999841451644897
in O O 0.9999817609786987
young O O 0.9999943971633911
male O O 0.9999899864196777
Wistar O O 0.9997349381446838
rats O O 0.9999943971633911
. O O 0.9999799728393555

There O O 0.9999738931655884
were O O 0.99997878074646
no O O 0.9999860525131226
differences O O 0.9999940395355225
between O O 0.9997014403343201
saline O O 0.9977055191993713
- O O 0.9992371797561646
and O O 0.9993337988853455
apigenin B B 0.9921091198921204
- O O 0.9994924068450928
treated O O 0.9998394250869751
groups O O 0.9999822378158569
in O O 0.9999598264694214
the O O 0.9999899864196777
24 O O 0.9999747276306152
h O O 0.9982764720916748
retention O O 0.9962483048439026
trial O O 0.9999223947525024
. O O 0.9999589920043945

Furthermore O O 0.9998757839202881
, O O 0.9993599057197571
apigenin B B 0.9984745383262634
did O O 0.9998204112052917
not O O 0.9999041557312012
prevent O O 0.9997994303703308
the O O 0.9999678134918213
amnesia O O 0.9996252059936523
induced O O 0.9999749660491943
by O O 0.9998800754547119
scopolamine B B 0.9997783303260803
( O O 0.9997513890266418
1mg O O 0.9998281002044678
/ O O 0.9999054670333862
kg O O 0.9999949932098389
, O O 0.9999760389328003
i O O 0.9999406337738037
. O O 0.9999957084655762
p O O 0.9999979734420776
. O O 0.9999955892562866
, O O 0.9999872446060181
30 O O 0.9999653100967407
min O O 0.9999849796295166
before O O 0.9999901056289673
the O O 0.9999939203262329
acquisition O O 0.999914288520813
) O O 0.999976396560669
. O O 0.999962568283081

The O O 0.9999719858169556
saline O O 0.9989892840385437
- O O 0.9988436698913574
and O O 0.998018741607666
apigenin B B 0.9882203340530396
- O O 0.9990504384040833
treated O O 0.9997746348381042
rats O O 0.9998282194137573
that O O 0.9999452829360962
did O O 0.9999747276306152
not O O 0.9999794960021973
step O O 0.9999833106994629
through O O 0.9999797344207764
into O O 0.9999579191207886
the O O 0.999972939491272
dark O O 0.9996476173400879
compartment O O 0.9999716281890869
during O O 0.9998984336853027
the O O 0.999970555305481
cut O O 0.9990381002426147
- O O 0.9999698400497437
off O O 0.9985429048538208
time O O 0.9999663829803467
( O O 0.9999223947525024
540 O O 0.9999361038208008
s O O 0.9999750852584839
) O O 0.9999750852584839
were O O 0.9999836683273315
retested O O 0.999993085861206
weekly O O 0.9999923706054688
for O O 0.9999829530715942
up O O 0.9999939203262329
to O O 0.9999960660934448
eight O O 0.9999986886978149
weeks O O 0.9999986886978149
. O O 0.9999858140945435

In O O 0.999836802482605
the O O 0.9998890161514282
saline O O 0.7122315764427185
treated O O 0.9994031190872192
group O O 0.9999545812606812
, O O 0.9999732971191406
the O O 0.9999945163726807
first O O 0.9999966621398926
significant O O 0.9999947547912598
decline O O 0.9999980926513672
in O O 0.9999856948852539
passive O O 0.9973669648170471
avoidance O O 0.9993502497673035
response O O 0.9999475479125977
was O O 0.999988317489624
observed O O 0.9999918937683105
at O O 0.9999912977218628
four O O 0.9999949932098389
weeks O O 0.9999977350234985
, O O 0.9999524354934692
and O O 0.9999474287033081
complete O O 0.9999456405639648
memory O O 0.9999922513961792
loss O O 0.999994158744812
was O O 0.9999874830245972
found O O 0.9999951124191284
five O O 0.9999909400939941
weeks O O 0.9999979734420776
after O O 0.9999887943267822
the O O 0.9999946355819702
acquisition O O 0.9999960660934448
of O O 0.9999915361404419
the O O 0.999992847442627
passive O O 0.9967122077941895
avoidance O O 0.9994412064552307
task O O 0.9999834299087524
. O O 0.9999494552612305

At O O 0.9999762773513794
the O O 0.9999958276748657
end O O 0.999992847442627
of O O 0.9999828338623047
the O O 0.9999874830245972
experimental O O 0.9999830722808838
period O O 0.9999958276748657
, O O 0.9999651908874512
60 O O 0.9999920129776001
% O O 0.9999967813491821
of O O 0.9999845027923584
the O O 0.9999881982803345
animals O O 0.9999932050704956
treated O O 0.9998983144760132
with O O 0.9997658133506775
apigenin B B 0.9622997045516968
still O O 0.9998369216918945
did O O 0.9999892711639404
not O O 0.9999905824661255
step O O 0.9999754428863525
through O O 0.9999532699584961
. O O 0.9999723434448242

These O O 0.999987006187439
data O O 0.9999899864196777
suggest O O 0.9999314546585083
that O O 0.9998149275779724
1 O O 0.9999589920043945
) O O 0.9998080134391785
apigenin B B 0.9975171089172363
delays O O 0.9998457431793213
the O O 0.9999520778656006
long O O 0.9997562766075134
- O O 0.9999821186065674
term O O 0.9999860525131226
forgetting O O 0.999933123588562
but O O 0.999932050704956
did O O 0.9999420642852783
not O O 0.9999008178710938
modulate O O 0.9999595880508423
the O O 0.9999697208404541
24 O O 0.9999622106552124
h O O 0.9996508359909058
retention O O 0.9999879598617554
of O O 0.9999240636825562
fear O O 0.9982808828353882
memory O O 0.9999476671218872
and O O 0.9999078512191772
2 O O 0.999964714050293
) O O 0.9999561309814453
the O O 0.9999822378158569
obtained O O 0.9996988773345947
beneficial O O 0.9999548196792603
effect O O 0.9999794960021973
of O O 0.9996660947799683
apigenin B B 0.9993982315063477
on O O 0.9994809031486511
the O O 0.9998420476913452
passive O O 0.9992625117301941
avoidance O O 0.9998960494995117
conditioning O O 0.9999070167541504
is O O 0.9998784065246582
mediated O O 0.9999452829360962
by O O 0.9997870326042175
mechanisms O O 0.9999421834945679
that O O 0.9999470710754395
do O O 0.9999957084655762
not O O 0.9999778270721436
implicate O O 0.9999916553497314
its O O 0.9993707537651062
action O O 0.9998295307159424
on O O 0.9994994401931763
the O O 0.9997739195823669
muscarinic O O 0.8765386343002319
cholinergic O O 0.6259332299232483
system O O 0.9996652603149414
. O O 0.9999066591262817

Histamine B B 0.9058609008789062
antagonists O O 0.7376351356506348
and O O 0.9991576671600342
d B B 0.8713383078575134
- I I 0.9735022783279419
tubocurarine I I 0.997562050819397
- O O 0.9986760020256042
induced O O 0.9999430179595947
hypotension O O 0.9999628067016602
in O O 0.9999668598175049
cardiac O O 0.9999879598617554
surgical O O 0.9999949932098389
patients O O 0.9999909400939941
. O O 0.9999606609344482

Hemodynamic O O 0.9993745684623718
effects O O 0.9999154806137085
and O O 0.9999123811721802
histamine B O 0.8412337303161621
release O O 0.999159574508667
by O O 0.9999369382858276
bolus O O 0.9999483823776245
injection O O 0.9999775886535645
of O O 0.9999322891235352
0 O O 0.9999127388000488
. O O 0.9999889135360718
35 O O 0.9999877214431763
mg O O 0.9999068975448608
/ O O 0.9999879598617554
kg O O 0.9999922513961792
of O O 0.9978214502334595
d B B 0.5939905047416687
- I I 0.900265097618103
tubocurarine I I 0.9991216063499451
were O O 0.999785840511322
studied O O 0.9999425411224365
in O O 0.999961256980896
24 O O 0.9999516010284424
patients O O 0.9999946355819702
. O O 0.9999819993972778

H1 O O 0.5335345268249512
- O O 0.8941595554351807
and O O 0.9891324639320374
H2 O O 0.7087309956550598
- O O 0.9653347134590149
histamine B O 0.5635324120521545
antagonists O O 0.8052287101745605
or O O 0.9995064735412598
placebo O O 0.9957892298698425
were O O 0.9999626874923706
given O O 0.9999237060546875
before O O 0.9998388290405273
dosing O O 0.9999462366104126
with O O 0.9998502731323242
d B B 0.687149703502655
- I I 0.9038572907447815
tubocurarine I I 0.9969943761825562
in O O 0.9998946189880371
a O O 0.9999970197677612
randomized O O 0.9999943971633911
double O O 0.9999842643737793
- O O 0.9999899864196777
blind O O 0.9999970197677612
fashion O O 0.9999984502792358
to O O 0.9999746084213257
four O O 0.9999607801437378
groups O O 0.9999939203262329
: O O 0.9999855756759644
group O O 0.9999923706054688
1 O O 0.9999716281890869
- O O 0.9981561303138733
- O O 0.9932222366333008
placebo O O 0.9999480247497559
; O O 0.9999183416366577
group O O 0.9999871253967285
2 O O 0.9999181032180786
- O O 0.9981110095977783
- O O 0.9960821270942688
cimetidine B B 0.9971632361412048
, O O 0.9781342148780823
4 O O 0.9976188540458679
mg O O 0.9998804330825806
/ O O 0.9999520778656006
kg O O 0.9999967813491821
, O O 0.9998495578765869
plus O O 0.9998644590377808
placebo O O 0.9998468160629272
; O O 0.9999434947967529
group O O 0.9999821186065674
3 O O 0.9998871088027954
- O O 0.9976575374603271
- O O 0.997124969959259
chlorpheniramine B B 0.9975577592849731
, O O 0.9939144253730774
0 O O 0.9998537302017212
. O O 0.9999958276748657
1 O O 0.9999891519546509
mg O O 0.9999349117279053
/ O O 0.9999736547470093
kg O O 0.999990701675415
, O O 0.9999505281448364
plus O O 0.9998602867126465
placebo O O 0.9998733997344971
; O O 0.9999445676803589
and O O 0.9999502897262573
group O O 0.9999816417694092
4 O O 0.9999209642410278
- O O 0.9978209733963013
- O O 0.9964035749435425
cimetidine B B 0.9980922341346741
plus O O 0.9808639883995056
chlorpheniramine B B 0.9974097609519958
. O O 0.9999649524688721

Histamine B O 0.8571262359619141
release O O 0.9988738894462585
occurred O O 0.9999216794967651
in O O 0.9998754262924194
most O O 0.9999302625656128
patients O O 0.9999876022338867
, O O 0.9999839067459106
the O O 0.999991774559021
highest O O 0.9999538660049438
level O O 0.9999626874923706
2 O O 0.9998164772987366
minutes O O 0.9999960660934448
after O O 0.9999370574951172
d B B 0.6860499382019043
- I I 0.9189143180847168
tubocurarine I I 0.9997627139091492
dosing O O 0.9989827275276184
. O O 0.9999642372131348

Group O O 0.9999366998672485
1 O O 0.9999681711196899
had O O 0.9999480247497559
a O O 0.9999837875366211
moderate O O 0.9999864101409912
negative O O 0.999976396560669
correlation O O 0.9999909400939941
between O O 0.9998774528503418
plasma O O 0.9800587296485901
histamine B B 0.8679486513137817
change O O 0.9995130300521851
and O O 0.9998970031738281
systemic O O 0.9999254941940308
vascular O O 0.9999825954437256
resistance O O 0.9999959468841553
( O O 0.9999507665634155
r O O 0.9995902180671692
= O O 0.9999568462371826
0 O O 0.9999884366989136
. O O 0.9999947547912598
58 O O 0.9999973773956299
; O O 0.9999511241912842
P O O 0.9979104399681091
less O O 0.9999856948852539
than O O 0.9999943971633911
0 O O 0.9999904632568359
. O O 0.9999964237213135
05 O O 0.9999876022338867
) O O 0.9999855756759644
not O O 0.999976634979248
present O O 0.9999843835830688
in O O 0.9999467134475708
group O O 0.9999706745147705
4 O O 0.9998356103897095
. O O 0.9999587535858154

Prior O O 0.9996237754821777
dosing O O 0.9998459815979004
with O O 0.9997875094413757
antagonists O O 0.4566814601421356
partially O O 0.9998420476913452
prevented O O 0.9999502897262573
the O O 0.9999904632568359
fall O O 0.9999964237213135
in O O 0.9999896287918091
systemic O O 0.9999529123306274
vascular O O 0.9999756813049316
resistance O O 0.999994158744812
. O O 0.9999514818191528

These O O 0.9999698400497437
data O O 0.9999823570251465
demonstrate O O 0.9999598264694214
that O O 0.9999315738677979
the O O 0.9999825954437256
hemodynamic O O 0.9999761581420898
changes O O 0.9999966621398926
associated O O 0.9999793767929077
with O O 0.9998618364334106
d B B 0.7369927763938904
- I I 0.9465956091880798
tubocurarine I I 0.9984845519065857
dosing O O 0.9989439845085144
are O O 0.999915361404419
only O O 0.9999731779098511
partially O O 0.999954342842102
explained O O 0.9999749660491943
by O O 0.9996917247772217
histamine B B 0.9395591616630554
release O O 0.998529314994812
. O O 0.9999185800552368

Thus O O 0.9999216794967651
prior O O 0.9995989203453064
dosing O O 0.9997685551643372
with O O 0.9997513890266418
H1 O O 0.5784115791320801
- O O 0.9072136282920837
and O O 0.9895604848861694
H2 O O 0.5449756383895874
- O O 0.9220243692398071
antagonists O O 0.8970516324043274
provides O O 0.9999277591705322
only O O 0.9999817609786987
partial O O 0.9999465942382812
protection O O 0.9999486207962036
. O O 0.9999566078186035

Cholecystokinin B B 0.9947407841682434
- I I 0.726487934589386
octapeptide I I 0.8581207990646362
restored O O 0.9955314993858337
morphine B B 0.9994449019432068
- O O 0.9998595714569092
induced O O 0.9999088048934937
hippocampal O O 0.9976819753646851
long O O 0.9868027567863464
- O O 0.999968409538269
term O O 0.999775230884552
potentiation O O 0.9859703183174133
impairment O O 0.9999347925186157
in O O 0.9999152421951294
rats O O 0.9999665021896362
. O O 0.9999340772628784

Cholecystokinin B B 0.9325923919677734
- I I 0.8001391887664795
octapeptide I I 0.9673232436180115
( O O 0.9819099307060242
CCK B B 0.9181821942329407
- I I 0.8421719074249268
8 I I 0.998034656047821
) O O 0.9843965172767639
, O O 0.9999042749404907
which O O 0.9994290471076965
is O O 0.999904990196228
a O O 0.9994685053825378
typical O O 0.9993459582328796
brain O O 0.8501851558685303
- O O 0.9683831930160522
gut O O 0.8679529428482056
peptide O O 0.8835591077804565
, O O 0.9999184608459473
exerts O O 0.9999572038650513
a O O 0.999968409538269
wide O O 0.9999746084213257
range O O 0.9999772310256958
of O O 0.9999494552612305
biological O O 0.9998370409011841
activities O O 0.9998618364334106
on O O 0.999143123626709
the O O 0.999852180480957
central O O 0.9996577501296997
nervous O O 0.999984860420227
system O O 0.9999831914901733
. O O 0.9999388456344604

We O O 0.9999743700027466
have O O 0.9999966621398926
previously O O 0.9999879598617554
reported O O 0.9999953508377075
that O O 0.9996895790100098
CCK B B 0.9570229053497314
- I I 0.8110670447349548
8 I I 0.9949368238449097
significantly O O 0.9991369843482971
alleviated O O 0.9999096393585205
morphine B B 0.9992844462394714
- O O 0.9999170303344727
induced O O 0.9999473094940186
amnesia O O 0.9999504089355469
and O O 0.9999691247940063
reversed O O 0.9998308420181274
spine O O 0.9991257786750793
density O O 0.9999767541885376
decreases O O 0.9999812841415405
in O O 0.9998739957809448
the O O 0.999893307685852
CA1 O O 0.9859749674797058
region O O 0.9999490976333618
of O O 0.9999138116836548
the O O 0.999954342842102
hippocampus O O 0.9996417760848999
in O O 0.9999232292175293
morphine B B 0.9997078776359558
- O O 0.9998181462287903
treated O O 0.9998227953910828
animals O O 0.9999940395355225
. O O 0.9999797344207764

Here O O 0.9999696016311646
, O O 0.9999788999557495
we O O 0.999971866607666
investigated O O 0.999963641166687
the O O 0.9999576807022095
effects O O 0.9999489784240723
of O O 0.999354898929596
CCK B B 0.9941613078117371
- I I 0.8479785919189453
8 I I 0.9980881810188293
on O O 0.9984778761863708
long O O 0.9645436406135559
- O O 0.9999502897262573
term O O 0.9997790455818176
potentiation O O 0.9942020773887634
( O O 0.9995912909507751
LTP O O 0.9380790591239929
) O O 0.9998939037322998
in O O 0.9997338652610779
the O O 0.9998980760574341
lateral O O 0.9976296424865723
perforant O O 0.9986118078231812
path O O 0.9359159469604492
( O O 0.9991034865379333
LPP O O 0.7444882988929749
) O O 0.989956259727478
- O O 0.9936617612838745
granule O O 0.9925416707992554
cell O O 0.9989345669746399
synapse O O 0.9975426197052002
of O O 0.9997968077659607
rat O O 0.999792754650116
dentate O O 0.9983202815055847
gyrus O O 0.9988123178482056
( O O 0.9998456239700317
DG O O 0.9694255590438843
) O O 0.9999531507492065
in O O 0.9999526739120483
acute O O 0.9988594055175781
saline O O 0.9993281364440918
or O O 0.9996572732925415
morphine B B 0.9995724558830261
- O O 0.9998164772987366
treated O O 0.9998546838760376
rats O O 0.9999885559082031
. O O 0.9999713897705078

Population O O 0.9955346584320068
spikes O O 0.9999903440475464
( O O 0.9998179078102112
PS O O 0.9958731532096863
) O O 0.9999631643295288
, O O 0.9999830722808838
which O O 0.9999485015869141
were O O 0.9999816417694092
evoked O O 0.9999914169311523
by O O 0.9999305009841919
stimulation O O 0.9999338388442993
of O O 0.9998542070388794
the O O 0.9997847676277161
LPP O O 0.9097239375114441
, O O 0.9999619722366333
were O O 0.9999594688415527
recorded O O 0.9999874830245972
in O O 0.9998680353164673
the O O 0.9999138116836548
DG O O 0.8623431921005249
region O O 0.999911904335022
. O O 0.9999531507492065

Acute O O 0.9978558421134949
morphine B B 0.9996993541717529
( O O 0.9995790123939514
30mg O O 0.9992458820343018
/ O O 0.9997726082801819
kg O O 0.999913215637207
, O O 0.9998818635940552
s O O 0.9998981952667236
. O O 0.9999951124191284
c O O 0.9999779462814331
. O O 0.9999897480010986
) O O 0.9998877048492432
treatment O O 0.9998346567153931
significantly O O 0.9999573230743408
attenuated O O 0.9997904896736145
hippocampal O O 0.9996640682220459
LTP O O 0.970388650894165
and O O 0.999748170375824
CCK B B 0.9619099497795105
- I I 0.7822548747062683
8 I I 0.9766753315925598
( O O 0.9668538570404053
1ug O O 0.9961524605751038
, O O 0.9992762207984924
i O O 0.9998650550842285
. O O 0.9999929666519165
c O O 0.9999980926513672
. O O 0.9999961853027344
v O O 0.9999991655349731
. O O 0.9999911785125732
) O O 0.9999358654022217
restored O O 0.999923825263977
the O O 0.9999699592590332
amplitude O O 0.9999189376831055
of O O 0.9997966885566711
PS O O 0.9502573609352112
that O O 0.9999388456344604
was O O 0.9999701976776123
attenuated O O 0.9998893737792969
by O O 0.9999186992645264
morphine B B 0.9998165965080261
injection O O 0.9998975992202759
. O O 0.9999691247940063

Furthermore O O 0.9999457597732544
, O O 0.9998983144760132
microinjection O O 0.9996638298034668
of O O 0.9997307658195496
CCK B B 0.989881694316864
- I I 0.7853530645370483
8 I I 0.9756704568862915
( O O 0.9810168147087097
0 O O 0.9952254295349121
. O O 0.9997949004173279
1 O O 0.9997394680976868
and O O 0.9998170733451843
1ug O O 0.9977602958679199
, O O 0.9998713731765747
i O O 0.9999562501907349
. O O 0.9999938011169434
c O O 0.9999985694885254
. O O 0.9999966621398926
v O O 0.9999991655349731
. O O 0.9999921321868896
) O O 0.9999518394470215
also O O 0.999934196472168
significantly O O 0.9999420642852783
augmented O O 0.9999070167541504
hippocampal O O 0.9996931552886963
LTP O O 0.9652804732322693
in O O 0.9998841285705566
saline O O 0.9991280436515808
- O O 0.9996534585952759
treated O O 0.9998842477798462
( O O 0.9998348951339722
1ml O O 0.9996758699417114
/ O O 0.9999608993530273
kg O O 0.9999951124191284
, O O 0.999954104423523
s O O 0.999991774559021
. O O 0.9999945163726807
c O O 0.9999958276748657
. O O 0.9999904632568359
) O O 0.9999663829803467
rats O O 0.9999935626983643
. O O 0.9999866485595703

Pre O O 0.9959107637405396
- O O 0.9998736381530762
treatment O O 0.9999358654022217
of O O 0.9997962117195129
the O O 0.9997268319129944
CCK2 O O 0.6816719174385071
receptor O O 0.9635202884674072
antagonist O O 0.9401148557662964
L O B 0.8446111679077148
- O I 0.9868987798690796
365 O I 0.9999345541000366
, O I 0.9714727401733398
260 O I 0.9995107650756836
( O O 0.9961972236633301
10ug O O 0.9999022483825684
, O O 0.9990262985229492
i O O 0.9983810186386108
. O O 0.9999946355819702
c O O 0.9999723434448242
. O O 0.9999957084655762
v O O 0.9977602958679199
) O O 0.9998753070831299
reversed O O 0.9999287128448486
the O O 0.9999476671218872
effects O O 0.9999680519104004
of O O 0.9997981190681458
CCK B B 0.9436885714530945
- I I 0.8073015809059143
8 I I 0.9834834337234497
, O O 0.9993927478790283
but O O 0.9999711513519287
the O O 0.9998748302459717
CCK1 O O 0.772795557975769
receptor O O 0.9855006337165833
antagonist O O 0.9826379418373108
L O B 0.8550374507904053
- O I 0.9847862124443054
364 O I 0.9862673282623291
, O I 0.9833517670631409
718 O I 0.9935065507888794
( O O 0.9948859810829163
10ug O O 0.9998307228088379
, O O 0.9993581175804138
i O O 0.9995436072349548
. O O 0.999994158744812
c O O 0.9999678134918213
. O O 0.9999943971633911
v O O 0.9978457689285278
) O O 0.9998717308044434
did O O 0.9999688863754272
not O O 0.9999464750289917
. O O 0.9999415874481201

The O O 0.9999901056289673
present O O 0.9999901056289673
results O O 0.9999947547912598
demonstrate O O 0.9999576807022095
that O O 0.9994639754295349
CCK B B 0.9098694920539856
- I I 0.8122032284736633
8 I I 0.9986617565155029
attenuates O O 0.9964463114738464
the O O 0.9999128580093384
effect O O 0.9999196529388428
of O O 0.9997701048851013
morphine B B 0.9997140765190125
on O O 0.999370276927948
hippocampal O O 0.9868733286857605
LTP O O 0.766970157623291
through O O 0.9984337687492371
CCK2 O B 0.8652040958404541
receptors O O 0.9922990202903748
and O O 0.9999446868896484
suggest O O 0.9997913241386414
an O O 0.9998989105224609
ameliorative O O 0.9999370574951172
function O O 0.9999730587005615
of O O 0.9996833801269531
CCK B B 0.9125245213508606
- I I 0.8262599110603333
8 I I 0.9935021996498108
on O O 0.9983294606208801
morphine B B 0.9997684359550476
- O O 0.9998705387115479
induced O O 0.9999157190322876
memory O O 0.9999927282333374
impairment O O 0.999996542930603
. O O 0.9999737739562988

Glial O O 0.9714274406433105
activation O O 0.9999629259109497
and O O 0.9998257756233215
post O O 0.9948934316635132
- O O 0.9989376664161682
synaptic O O 0.9961678385734558
neurotoxicity O O 0.9999579191207886
: O O 0.999930739402771
the O O 0.9999703168869019
key O O 0.9999619722366333
events O O 0.9999920129776001
in O O 0.9999536275863647
Streptozotocin B B 0.9993473887443542
( O O 0.9803183674812317
ICV O B 0.9296361207962036
) O O 0.9849148988723755
induced O O 0.9998482465744019
memory O O 0.9999921321868896
impairment O O 0.9999970197677612
in O O 0.9999791383743286
rats O O 0.9999884366989136
. O O 0.9999734163284302

In O O 0.999977707862854
the O O 0.9999915361404419
present O O 0.999977707862854
study O O 0.9999634027481079
the O O 0.9999560117721558
role O O 0.999951958656311
of O O 0.9998003840446472
glial O O 0.9885396361351013
activation O O 0.9998916387557983
and O O 0.9996739625930786
post O O 0.9932591915130615
synaptic O O 0.9890680909156799
toxicity O O 0.9998748302459717
in O O 0.9998254179954529
ICV O O 0.71282958984375
Streptozotocin B B 0.9962228536605835
( O O 0.9897749423980713
STZ B B 0.9979077577590942
) O O 0.9816175103187561
induced O O 0.9998518228530884
memory O O 0.9999825954437256
impaired O O 0.9999815225601196
rats O O 0.9999836683273315
was O O 0.9999617338180542
explored O O 0.9999675750732422
. O O 0.9999474287033081

In O O 0.9995865225791931
experiment O O 0.9998975992202759
set O O 0.9999798536300659
up O O 0.9999833106994629
1 O O 0.9996675252914429
: O O 0.9999778270721436
Memory O O 0.9999639987945557
deficit O O 0.9999927282333374
was O O 0.9999864101409912
found O O 0.9999957084655762
in O O 0.9999837875366211
Morris O O 0.9983262419700623
water O O 0.9863777160644531
maze O O 0.999893069267273
test O O 0.9999833106994629
on O O 0.9999839067459106
14 O O 0.999983549118042
- O O 0.9998019337654114
16 O O 0.9999892711639404
days O O 0.9999973773956299
after O O 0.9999103546142578
STZ B B 0.9962297081947327
( O O 0.9339619278907776
ICV O O 0.821201741695404
; O O 0.9959282279014587
3mg O O 0.9951961636543274
/ O O 0.9997138381004333
Kg O O 0.9992672801017761
) O O 0.9983125925064087
administration O O 0.9999160766601562
. O O 0.99997878074646

STZ B B 0.9932571649551392
causes O O 0.999392032623291
increased O O 0.9998514652252197
expression O O 0.9999586343765259
of O O 0.9995245933532715
GFAP O O 0.5505622029304504
, O O 0.9985970854759216
CD11b O O 0.8948994278907776
and O O 0.999496579170227
TNF O O 0.8782554864883423
- O O 0.9769656658172607
a O O 0.7571659684181213
indicating O O 0.9990252256393433
glial O O 0.9936506152153015
activation O O 0.9999685287475586
and O O 0.9998214840888977
neuroinflammation O O 0.9999597072601318
. O O 0.9999110698699951

STZ B B 0.9926776885986328
also O O 0.9996665716171265
significantly O O 0.9999614953994751
increased O O 0.999937891960144
the O O 0.9999600648880005
level O O 0.9999064207077026
of O O 0.9962301850318909
ROS O O 0.5197076797485352
, O O 0.9905691146850586
nitrite B B 0.9597705602645874
, O O 0.7373892664909363
Ca B B 0.9906360507011414
( O O 0.9791617393493652
2 O O 0.9273983240127563
+ O O 0.9968840479850769
) O O 0.9964962601661682
and O O 0.999925971031189
reduced O O 0.9999669790267944
the O O 0.9998874664306641
mitochondrial O O 0.9950630068778992
activity O O 0.9998704195022583
in O O 0.9995042085647583
synaptosomal O O 0.9806733131408691
preparation O O 0.9994961023330688
illustrating O O 0.9998180270195007
free O O 0.8781817555427551
radical O O 0.7273589968681335
generation O O 0.9997040629386902
and O O 0.9997887015342712
excitotoxicity O O 0.9946051239967346
. O O 0.9998611211776733

Increased O O 0.9996882677078247
expression O O 0.9999476671218872
and O O 0.9998865127563477
activity O O 0.9993274211883545
of O O 0.9884538054466248
Caspase O O 0.8897746801376343
- O O 0.985481858253479
3 O O 0.9861680865287781
was O O 0.999958872795105
also O O 0.9999715089797974
observed O O 0.9999790191650391
in O O 0.9996912479400635
STZ B B 0.9989539384841919
treated O O 0.9985778331756592
rat O O 0.9999266862869263
which O O 0.9997740387916565
specify O O 0.9989939332008362
apoptotic O O 0.9996458292007446
cell O O 0.9999512434005737
death O O 0.9999198913574219
in O O 0.9995044469833374
hippocampus O O 0.9978152513504028
and O O 0.9995009899139404
cortex O O 0.9999725818634033
. O O 0.9999568462371826

STZ B B 0.9737271666526794
treatment O O 0.9995205402374268
showed O O 0.9999092817306519
decrease O O 0.9998383522033691
expression O O 0.9999403953552246
of O O 0.9992524981498718
post O O 0.9764769673347473
synaptic O O 0.9902834296226501
markers O O 0.9930838346481323
CaMKIIa O O 0.5343762040138245
and O O 0.9962815642356873
PSD O O 0.911119818687439
- O O 0.9847267866134644
95 O O 0.6711581349372864
, O O 0.9997232556343079
while O O 0.9999252557754517
, O O 0.9997501969337463
expression O O 0.9999244213104248
of O O 0.9984172582626343
pre O O 0.9867831468582153
synaptic O O 0.9984548091888428
markers O O 0.9989635944366455
( O O 0.9956722259521484
synaptophysin O O 0.6479608416557312
and O O 0.9867138266563416
SNAP O O 0.6541081666946411
- O O 0.8959552645683289
25 O O 0.5270875096321106
) O O 0.9998910427093506
remains O O 0.9999456405639648
unaltered O O 0.9999879598617554
indicating O O 0.9997685551643372
selective O O 0.9997158646583557
post O O 0.9985015392303467
synaptic O O 0.9921211004257202
neurotoxicity O O 0.9999841451644897
. O O 0.9999678134918213

Oral O O 0.9996126294136047
treatment O O 0.9999884366989136
with O O 0.9998927116394043
Memantine B B 0.9997679591178894
( O O 0.9995701909065247
10mg O O 0.9995110034942627
/ O O 0.9997982382774353
kg O O 0.9999697208404541
) O O 0.9998064637184143
and O O 0.9985972046852112
Ibuprofen B B 0.991638720035553
( O O 0.9997817873954773
50 O O 0.9999619722366333
mg O O 0.9998730421066284
/ O O 0.9999146461486816
kg O O 0.9999855756759644
) O O 0.9999096393585205
daily O O 0.9997621178627014
for O O 0.9999500513076782
13 O O 0.9999657869338989
days O O 0.9999808073043823
attenuated O O 0.999630331993103
STZ B B 0.9881767630577087
induced O O 0.9981641173362732
glial O O 0.9971075654029846
activation O O 0.9999877214431763
, O O 0.999921441078186
apoptotic O O 0.9998886585235596
cell O O 0.9999748468399048
death O O 0.9999796152114868
and O O 0.9999226331710815
post O O 0.9982396364212036
synaptic O O 0.9904369711875916
neurotoxicity O O 0.9999885559082031
in O O 0.9999444484710693
rat O O 0.9999840259552002
brain O O 0.9999955892562866
. O O 0.9999597072601318

Further O O 0.9999169111251831
, O O 0.9999744892120361
in O O 0.9981270432472229
experiment O O 0.9610238671302795
set O O 0.9999192953109741
up O O 0.999975323677063
2 O O 0.9742801785469055
: O O 0.9999666213989258
where O O 0.999968409538269
memory O O 0.9999017715454102
function O O 0.9999903440475464
was O O 0.9999743700027466
not O O 0.9999849796295166
affected O O 0.9999903440475464
i O O 0.9999830722808838
. O O 0.9999886751174927
e O O 0.9999960660934448
. O O 0.9999953508377075
7 O O 0.9999865293502808
- O O 0.9999759197235107
9 O O 0.999996542930603
days O O 0.9999979734420776
after O O 0.9999651908874512
STZ B B 0.9965672492980957
treatment O O 0.9993829727172852
. O O 0.9999805688858032

The O O 0.9999707937240601
level O O 0.9998531341552734
of O O 0.9937995076179504
GFAP O O 0.5726773738861084
, O O 0.9989662170410156
CD11b O O 0.5812162160873413
, O O 0.9966599941253662
TNF O O 0.7961240410804749
- O O 0.9541215300559998
a O O 0.5910841822624207
, O O 0.9926612377166748
ROS O O 0.686684787273407
and O O 0.9994958639144897
nitrite B B 0.9755886793136597
levels O O 0.999874472618103
were O O 0.9999544620513916
increased O O 0.9999172687530518
. O O 0.9999613761901855

On O O 0.9999622106552124
the O O 0.9999741315841675
other O O 0.9999651908874512
hand O O 0.9999887943267822
, O O 0.9998041987419128
apoptotic O O 0.9868865609169006
marker O O 0.9998020529747009
, O O 0.9997894167900085
synaptic O O 0.9934547543525696
markers O O 0.9997712969779968
, O O 0.9997568726539612
mitochondrial O O 0.9646757245063782
activity O O 0.998963475227356
and O O 0.9943447113037109
Ca B B 0.9749029278755188
( O O 0.9923657774925232
2 O O 0.9838972687721252
+ O O 0.9996553659439087
) O O 0.9908638596534729
levels O O 0.999909520149231
remained O O 0.9999599456787109
unaffected O O 0.999975323677063
. O O 0.9999692440032959

Collective O O 0.9993769526481628
data O O 0.999909520149231
indicates O O 0.9997244477272034
that O O 0.9997535347938538
neuroinflammatory O O 0.999930739402771
process O O 0.9999790191650391
and O O 0.9997408986091614
oxidative O O 0.8744649887084961
stress O O 0.9972445964813232
occurs O O 0.9998805522918701
earlier O O 0.9992895126342773
to O O 0.9995517134666443
apoptosis O O 0.9938002228736877
and O O 0.9999470710754395
does O O 0.9998984336853027
not O O 0.9998821020126343
affect O O 0.9999561309814453
memory O O 0.9999516010284424
function O O 0.9999959468841553
. O O 0.999977707862854

Present O O 0.9999744892120361
study O O 0.999976634979248
clearly O O 0.9999688863754272
suggests O O 0.9998841285705566
that O O 0.9992613196372986
glial O O 0.9703449606895447
activation O O 0.9998955726623535
and O O 0.9995898604393005
post O O 0.9978194236755371
synaptic O O 0.9844165444374084
neurotoxicity O O 0.9999624490737915
are O O 0.9999032020568848
the O O 0.9999555349349976
key O O 0.9996453523635864
factors O O 0.9999715089797974
in O O 0.9998959302902222
STZ B B 0.9973969459533691
induced O O 0.9983898401260376
memory O O 0.9999675750732422
impairment O O 0.9999940395355225
and O O 0.9999504089355469
neuronal O O 0.9999898672103882
cell O O 0.9999880790710449
death O O 0.9999881982803345
. O O 0.9999712705612183

Comparison O O 0.9997957348823547
of O O 0.9992465972900391
effects O O 0.9997993111610413
of O O 0.9993672966957092
isotonic O O 0.6821413040161133
sodium B B 0.9573059678077698
chloride I I 0.9996073842048645
with O O 0.9823874235153198
diltiazem B B 0.9996217489242554
in O O 0.9999232292175293
prevention O O 0.9999626874923706
of O O 0.9999377727508545
contrast B O 0.561052143573761
- O O 0.9997612833976746
induced O O 0.9999730587005615
nephropathy O O 0.999993085861206
. O O 0.9998836517333984

INTRODUCTION O O 0.9996746778488159
AND O O 0.99997878074646
OBJECTIVE O O 0.9999154806137085
: O O 0.9999724626541138
Contrast B O 0.8308632969856262
- O O 0.9902597069740295
induced O O 0.9984303116798401
nephropathy O O 0.9990991353988647
( O O 0.9996451139450073
CIN O O 0.4894653558731079
) O O 0.9992730021476746
significantly O O 0.9999744892120361
increases O O 0.999958872795105
the O O 0.9999945163726807
morbidity O O 0.9999971389770508
and O O 0.9999945163726807
mortality O O 0.9999974966049194
of O O 0.9999865293502808
patients O O 0.9999897480010986
. O O 0.999971866607666

The O O 0.9999899864196777
aim O O 0.999996542930603
of O O 0.999994158744812
this O O 0.9999884366989136
study O O 0.9999840259552002
is O O 0.9999905824661255
to O O 0.999987006187439
investigate O O 0.9999210834503174
and O O 0.9999843835830688
compare O O 0.999951958656311
the O O 0.9999333620071411
protective O O 0.999901533126831
effects O O 0.9999666213989258
of O O 0.9998551607131958
isotonic O O 0.9589350819587708
sodium B B 0.9300398826599121
chloride I I 0.9996827840805054
with O O 0.9960022568702698
sodium B B 0.9960327744483948
bicarbonate I I 0.9975118637084961
infusion O O 0.9975869655609131
and O O 0.999625563621521
isotonic O O 0.978104293346405
sodium B B 0.8174750208854675
chloride I I 0.9993017911911011
infusion O O 0.9984555244445801
with O O 0.9990780353546143
diltiazem B B 0.9998248219490051
, O O 0.9999222755432129
a O O 0.9978199005126953
calcium B B 0.9370517134666443
channel O O 0.9051758050918579
blocker O O 0.9143058657646179
, O O 0.9999110698699951
in O O 0.9998849630355835
preventing O O 0.6912953853607178
CIN O O 0.6488968133926392
. O O 0.999895453453064

MATERIALS O O 0.9999698400497437
AND O O 0.9999942779541016
METHODS O O 0.999998927116394
: O O 0.9999955892562866
Our O O 0.999993085861206
study O O 0.9999918937683105
included O O 0.9999920129776001
patients O O 0.9999955892562866
who O O 0.9999645948410034
were O O 0.999981164932251
administered O O 0.9999244213104248
30 O O 0.9998340606689453
- O O 0.9984651803970337
60 O O 0.9999890327453613
mL O O 0.9999940395355225
of O O 0.9993566870689392
iodinated O B 0.92606520652771
contrast B I 0.9594758152961731
agent O I 0.9974040389060974
for O O 0.9987755417823792
percutaneous O O 0.9999470710754395
coronary O O 0.9997900128364563
angiography O O 0.9991053938865662
( O O 0.9998761415481567
PCAG O O 0.9844234585762024
) O O 0.9999667406082153
, O O 0.9999713897705078
all O O 0.9999725818634033
with O O 0.9999812841415405
creatinine B B 0.8867999911308289
values O O 0.9995749592781067
between O O 0.9999408721923828
1 O O 0.9999628067016602
. O O 0.9999949932098389
1 O O 0.9999963045120239
and O O 0.9999817609786987
3 O O 0.9999065399169922
. O O 0.9999973773956299
1 O O 0.9999974966049194
mg O O 0.9999974966049194
/ O O 0.9999954700469971
dL O O 0.9999985694885254
. O O 0.999974250793457

Patients O O 0.9999114274978638
were O O 0.9999828338623047
divided O O 0.9999889135360718
into O O 0.9999634027481079
three O O 0.9999115467071533
groups O O 0.9999833106994629
and O O 0.9999407529830933
each O O 0.9998403787612915
group O O 0.9999428987503052
had O O 0.9999750852584839
20 O O 0.9999760389328003
patients O O 0.9999936819076538
. O O 0.999977707862854

The O O 0.9999812841415405
first O O 0.9999866485595703
group O O 0.9999939203262329
of O O 0.9999834299087524
patients O O 0.9999723434448242
was O O 0.9999594688415527
administered O O 0.999882698059082
isotonic O B 0.9983744621276855
sodium B I 0.7214289307594299
chloride I I 0.9997746348381042
; O O 0.999769389629364
the O O 0.999993085861206
second O O 0.9999939203262329
group O O 0.9999951124191284
was O O 0.9999880790710449
administered O O 0.999963641166687
a O O 0.9999649524688721
solution O O 0.9999487400054932
that O O 0.9999288320541382
of O O 0.9989049434661865
5 O O 0.9939661622047424
% O O 0.9970241189002991
dextrose B B 0.9901947379112244
and O O 0.9701355695724487
sodium B B 0.9958063364028931
bicarbonate I I 0.9974746108055115
, O O 0.9997462630271912
while O O 0.9999659061431885
the O O 0.9999923706054688
third O O 0.9999369382858276
group O O 0.9999871253967285
was O O 0.999981164932251
administered O O 0.9998897314071655
isotonic O B 0.996577799320221
sodium B I 0.5013061761856079
chloride I I 0.997426450252533
before O O 0.9996528625488281
and O O 0.9999877214431763
after O O 0.9999738931655884
the O O 0.9999886751174927
contrast B O 0.992932915687561
injection O O 0.9999703168869019
. O O 0.9999632835388184

The O O 0.99997878074646
third O O 0.9999749660491943
group O O 0.9999934434890747
received O O 0.9999563694000244
an O O 0.9999812841415405
additional O O 0.9999536275863647
injection O O 0.9999698400497437
of O O 0.9995108842849731
diltiazem B B 0.9996415376663208
the O O 0.9999446868896484
day O O 0.9999855756759644
before O O 0.9999935626983643
and O O 0.9999529123306274
first O O 0.999993085861206
2 O O 0.9999878406524658
days O O 0.9999967813491821
after O O 0.9999909400939941
the O O 0.9999635219573975
contrast B O 0.9620683789253235
injection O O 0.9998927116394043
. O O 0.9999655485153198

All O O 0.9999699592590332
of O O 0.9999849796295166
the O O 0.999992847442627
patients O O 0.9999939203262329
' O O 0.9999920129776001
plasma O O 0.9994871616363525
blood B O 0.9128769636154175
urea I B 0.7236367464065552
nitrogen I I 0.9994838237762451
( O O 0.9956276416778564
BUN B O 0.8060134649276733
) O O 0.9999719858169556
and O O 0.9997239708900452
creatinine B B 0.9985419511795044
levels O O 0.9998817443847656
were O O 0.9999785423278809
measured O O 0.9999872446060181
on O O 0.9999768733978271
the O O 0.9999958276748657
second O O 0.9999978542327881
and O O 0.9999823570251465
seventh O O 0.9999984502792358
day O O 0.9999970197677612
after O O 0.999985933303833
the O O 0.9999920129776001
administration O O 0.9999877214431763
of O O 0.9999792575836182
intravenous O O 0.9999802112579346
contrast B O 0.9236915111541748
material O O 0.9985398054122925
. O O 0.9999587535858154

RESULTS O O 0.9997431635856628
: O O 0.9999730587005615
The O O 0.9999856948852539
basal O O 0.9998056292533875
creatinine B B 0.9955214262008667
levels O O 0.9998375177383423
were O O 0.9999492168426514
similar O O 0.9999778270721436
for O O 0.9998571872711182
all O O 0.9998732805252075
three O O 0.999883770942688
groups O O 0.999976634979248
( O O 0.9999489784240723
p O O 0.9989463686943054
> O O 0.9999798536300659
0 O O 0.9999880790710449
. O O 0.999994158744812
05 O O 0.999990701675415
) O O 0.9999734163284302
. O O 0.999972939491272

Among O O 0.9998044371604919
a O O 0.9999918937683105
total O O 0.9999855756759644
of O O 0.9999892711639404
60 O O 0.9999949932098389
patients O O 0.9999951124191284
included O O 0.9999954700469971
in O O 0.9999864101409912
the O O 0.9999959468841553
study O O 0.9999912977218628
, O O 0.9999709129333496
16 O O 0.9999773502349854
patients O O 0.9999914169311523
developed O O 0.9999903440475464
acute O O 0.999980092048645
renal O O 0.9999911785125732
failure O O 0.9999921321868896
( O O 0.9999598264694214
ARF O O 0.9760715961456299
) O O 0.9999759197235107
on O O 0.9999927282333374
the O O 0.999997615814209
second O O 0.9999988079071045
day O O 0.9999974966049194
after O O 0.9999696016311646
contrast B B 0.9491024613380432
material O O 0.8341459035873413
was O O 0.9999644756317139
injected O O 0.9999582767486572
( O O 0.9999417066574097
26 O O 0.9999196529388428
. O O 0.999988317489624
6 O O 0.9999834299087524
% O O 0.9999923706054688
) O O 0.9999808073043823
. O O 0.9999760389328003

The O O 0.9999905824661255
number O O 0.9999927282333374
of O O 0.9999771118164062
patients O O 0.9999948740005493
who O O 0.9999667406082153
developed O O 0.9999803304672241
ARF O O 0.9997864365577698
on O O 0.9999622106552124
the O O 0.9999945163726807
second O O 0.9999969005584717
day O O 0.9999969005584717
after O O 0.9999696016311646
the O O 0.9999696016311646
injection O O 0.9999463558197021
in O O 0.9998949766159058
the O O 0.9999755620956421
first O O 0.9999328851699829
group O O 0.9999008178710938
was O O 0.99992835521698
five O O 0.9999817609786987
( O O 0.9999262094497681
25 O O 0.9999920129776001
% O O 0.9999929666519165
) O O 0.9998995065689087
, O O 0.9999518394470215
in O O 0.9998904466629028
the O O 0.9999876022338867
second O O 0.9999278783798218
group O O 0.9998883008956909
was O O 0.9999308586120605
six O O 0.9999828338623047
( O O 0.9999340772628784
30 O O 0.9999926090240479
% O O 0.9999912977218628
) O O 0.9999363422393799
and O O 0.9999380111694336
the O O 0.9999697208404541
third O O 0.9994195699691772
group O O 0.9999009370803833
was O O 0.9999215602874756
five O O 0.9999711513519287
( O O 0.9998766183853149
25 O O 0.9999922513961792
% O O 0.9999889135360718
) O O 0.9999549388885498
( O O 0.9999079704284668
p O O 0.9998729228973389
> O O 0.9999874830245972
0 O O 0.9999942779541016
. O O 0.9999972581863403
05 O O 0.9999957084655762
) O O 0.9999771118164062
. O O 0.9999802112579346

CONCLUSION O O 0.9947307109832764
: O O 0.9999439716339111
There O O 0.999966025352478
was O O 0.9999545812606812
no O O 0.9999699592590332
significant O O 0.9999828338623047
difference O O 0.9999843835830688
between O O 0.9990813732147217
isotonic O O 0.9869793653488159
sodium B B 0.6819056868553162
chloride I I 0.9995841383934021
, O O 0.9805868864059448
sodium B B 0.9916327595710754
bicarbonate I I 0.9917382597923279
and O O 0.9968767166137695
isotonic O O 0.9860911965370178
sodium B B 0.7010360956192017
chloride I I 0.9987506866455078
with O O 0.9984073042869568
diltiazem B B 0.9995666146278381
application O O 0.9999579191207886
in O O 0.9999592304229736
prevention O O 0.9999129772186279
of O O 0.9998332262039185
CIN O O 0.6767210364341736
. O O 0.9997573494911194

Neurocognitive O O 0.9993046522140503
and O O 0.9997912049293518
neuroradiologic O O 0.9999592304229736
central O O 0.998985230922699
nervous O O 0.9999693632125854
system O O 0.9999278783798218
late O O 0.9997439980506897
effects O O 0.9999862909317017
in O O 0.9999579191207886
children O O 0.9999911785125732
treated O O 0.9999425411224365
on O O 0.9992820620536804
Pediatric O O 0.999728262424469
Oncology O O 0.9997926354408264
Group O O 0.9912263751029968
( O O 0.995712399482727
POG O O 0.8905134201049805
) O O 0.9901527762413025
P9605 O B 0.8879448175430298
( O O 0.998468816280365
standard O O 0.9996707439422607
risk O O 0.9990366697311401
) O O 0.9993544220924377
and O O 0.9895198345184326
P9201 O O 0.7205610871315002
( O O 0.999175488948822
lesser O O 0.9990798234939575
risk O O 0.9994472861289978
) O O 0.9993591904640198
acute O O 0.9979400038719177
lymphoblastic O O 0.9998884201049805
leukemia O O 0.9999780654907227
protocols O O 0.9989485144615173
( O O 0.9981669187545776
ACCL0131 O O 0.7579507231712341
) O O 0.9993587136268616
: O O 0.9996539354324341
a O O 0.5056354403495789
methotrexate B B 0.9566417932510376
consequence O O 0.9990841150283813
? O O 0.9990307092666626

A O O 0.9998990297317505
report O O 0.9999963045120239
from O O 0.9999891519546509
the O O 0.9999915361404419
Children O O 0.999967098236084
' O O 0.9999938011169434
s O O 0.9999891519546509
Oncology O O 0.9999439716339111
Group O O 0.9999856948852539
. O O 0.9999438524246216

Concerns O O 0.9999957084655762
about O O 0.9999576807022095
long O O 0.9992356300354004
- O O 0.9999804496765137
term O O 0.9999284744262695
methotrexate B B 0.9993670582771301
( O O 0.9554252624511719
MTX B B 0.9986140727996826
) O O 0.9989939332008362
neurotoxicity O O 0.999958872795105
in O O 0.9999442100524902
the O O 0.9999592304229736
1990s O O 0.9972050786018372
led O O 0.9999966621398926
to O O 0.9999921321868896
modifications O O 0.9999964237213135
in O O 0.9999785423278809
intrathecal O O 0.9998468160629272
( O O 0.965313732624054
IT O B 0.92287278175354
) O O 0.8020312190055847
therapy O O 0.9999128580093384
, O O 0.9999377727508545
leucovorin O B 0.9988288283348083
rescue O O 0.9986373782157898
, O O 0.9998238682746887
and O O 0.9999270439147949
frequency O O 0.9999856948852539
of O O 0.9999809265136719
systemic O O 0.9995802044868469
MTX B B 0.99818354845047
administration O O 0.9997449517250061
in O O 0.9999827146530151
children O O 0.9999971389770508
with O O 0.9999934434890747
acute O O 0.9999216794967651
lymphoblastic O O 0.9999829530715942
leukemia O O 0.9999966621398926
. O O 0.9999805688858032

In O O 0.9999784231185913
this O O 0.9999816417694092
study O O 0.9999884366989136
, O O 0.9999513626098633
neurocognitive O O 0.9999723434448242
outcomes O O 0.9999884366989136
and O O 0.9999488592147827
neuroradiologic O O 0.9999788999557495
evidence O O 0.9999908208847046
of O O 0.9999817609786987
leukoencephalopathy O O 0.9999665021896362
were O O 0.9999662637710571
compared O O 0.9999479055404663
in O O 0.9999566078186035
children O O 0.9999955892562866
treated O O 0.9999374151229858
with O O 0.9999004602432251
intense O O 0.9993810653686523
central O O 0.9979686141014099
nervous O O 0.9999510049819946
system O O 0.9991883635520935
( O O 0.9968850016593933
CNS O O 0.7093775868415833
) O O 0.9958989024162292
- O O 0.9998968839645386
directed O O 0.9994126558303833
therapy O O 0.999966025352478
( O O 0.9997058510780334
P9605 O O 0.9074038863182068
) O O 0.9999650716781616
versus O O 0.9999605417251587
those O O 0.9999892711639404
receiving O O 0.9999417066574097
fewer O O 0.9998341798782349
CNS O O 0.5578003525733948
- O O 0.9996540546417236
directed O O 0.9997215867042542
treatment O O 0.9999566078186035
days O O 0.9999796152114868
during O O 0.9998908042907715
intensive O O 0.9999089241027832
consolidation O O 0.9999912977218628
( O O 0.9999566078186035
P9201 O O 0.9898537993431091
) O O 0.9999701976776123
. O O 0.9999765157699585

A O O 0.9999881982803345
total O O 0.9999946355819702
of O O 0.9999933242797852
66 O O 0.9999972581863403
children O O 0.9999971389770508
from O O 0.9999669790267944
16 O O 0.9996436834335327
Pediatric O O 0.999987006187439
Oncology O O 0.9999773502349854
Group O O 0.9997672438621521
institutions O O 0.9997844099998474
with O O 0.9999805688858032
" O O 0.9999736547470093
standard O O 0.9995591044425964
- O O 0.9999700784683228
risk O O 0.9999713897705078
" O O 0.9999884366989136
acute O O 0.9995251893997192
lymphoblastic O O 0.999962568283081
leukemia O O 0.9999942779541016
, O O 0.9999897480010986
1 O O 0.9999949932098389
. O O 0.9999974966049194
00 O O 0.99977046251297
to O O 0.9999850988388062
9 O O 0.9999979734420776
. O O 0.9999986886978149
99 O O 0.9999973773956299
years O O 0.9999994039535522
at O O 0.999996542930603
diagnosis O O 0.999998927116394
, O O 0.9999899864196777
without O O 0.9999898672103882
evidence O O 0.9999939203262329
of O O 0.9999783039093018
CNS O O 0.9706354141235352
leukemia O O 0.9999860525131226
at O O 0.999969482421875
diagnosis O O 0.9999980926513672
were O O 0.9999836683273315
enrolled O O 0.9999920129776001
on O O 0.9997054934501648
ACCL0131 O O 0.5717839598655701
: O O 0.9994807839393616
28 O O 0.9998924732208252
from O O 0.9992921352386475
P9201 O O 0.9813476800918579
and O O 0.9998745918273926
38 O O 0.9998272061347961
from O O 0.9995429515838623
P9605 O O 0.9803791046142578
. O O 0.9999492168426514

Magnetic O O 0.9998133778572083
resonance O O 0.9999747276306152
imaging O O 0.9999384880065918
scans O O 0.9999557733535767
and O O 0.9999703168869019
standard O O 0.99996018409729
neuropsychological O O 0.9999903440475464
tests O O 0.9999949932098389
were O O 0.9999707937240601
performed O O 0.9999946355819702
> O O 0.9999816417694092
2 O O 0.999996542930603
. O O 0.9999990463256836
6 O O 0.9999966621398926
years O O 0.9999990463256836
after O O 0.9999982118606567
the O O 0.9999982118606567
end O O 0.9999935626983643
of O O 0.999955415725708
treatment O O 0.9999862909317017
. O O 0.9999818801879883

Significantly O O 0.9999865293502808
more O O 0.9999486207962036
P9605 O O 0.9542262554168701
patients O O 0.9999512434005737
developed O O 0.999980092048645
leukoencephalopathy O O 0.999958872795105
compared O O 0.999963641166687
with O O 0.9999799728393555
P9201 O O 0.9881356954574585
patients O O 0.9999545812606812
( O O 0.999941349029541
68 O O 0.9999915361404419
% O O 0.9999959468841553
, O O 0.9999364614486694
95 O O 0.9998822212219238
% O O 0.9998857975006104
confidence O O 0.9995738863945007
interval O O 0.9998059868812561
49 O O 0.9999831914901733
% O O 0.9999759197235107
- O O 0.9985686540603638
83 O O 0.9988683462142944
% O O 0.9999914169311523
vs O O 0.9999518394470215
. O O 0.9999940395355225
22 O O 0.9999938011169434
% O O 0.9999912977218628
, O O 0.9999380111694336
95 O O 0.9990046620368958
% O O 0.9997894167900085
confidence O O 0.9996108412742615
interval O O 0.9998242259025574
5 O O 0.9999717473983765
% O O 0.9999096393585205
- O O 0.9996343851089478
44 O O 0.9999818801879883
% O O 0.9999938011169434
; O O 0.9999758005142212
P O O 0.9999127388000488
= O O 0.9999041557312012
0 O O 0.9999831914901733
. O O 0.9999963045120239
001 O O 0.9997716546058655
) O O 0.9999780654907227
identified O O 0.9999802112579346
as O O 0.9999876022338867
late O O 0.9999942779541016
as O O 0.9999932050704956
7 O O 0.9999922513961792
. O O 0.9999972581863403
7 O O 0.9999972581863403
years O O 0.9999991655349731
after O O 0.9999973773956299
the O O 0.9999984502792358
end O O 0.9999954700469971
of O O 0.999941349029541
treatment O O 0.9999724626541138
. O O 0.9999555349349976

Overall O O 0.9999445676803589
, O O 0.9999775886535645
40 O O 0.9999812841415405
% O O 0.9999974966049194
of O O 0.9999908208847046
patients O O 0.9999915361404419
scored O O 0.999992847442627
< O O 0.9999736547470093
85 O O 0.9981017708778381
on O O 0.9999262094497681
either O O 0.9996775388717651
Verbal O O 0.9998712539672852
or O O 0.9998887777328491
Performance O O 0.977931022644043
IQ O O 0.9481925964355469
. O O 0.9999258518218994

Children O O 0.9999220371246338
on O O 0.9998847246170044
both O O 0.9997987151145935
studies O O 0.9999651908874512
had O O 0.9999446868896484
significant O O 0.9999730587005615
attention O O 0.9999204874038696
problems O O 0.9999901056289673
, O O 0.9999525547027588
but O O 0.9999639987945557
P9605 O O 0.9385281801223755
children O O 0.9999634027481079
scored O O 0.9999762773513794
below O O 0.999983549118042
average O O 0.9999926090240479
on O O 0.9999289512634277
more O O 0.999700665473938
neurocognitive O O 0.9999773502349854
measures O O 0.9999771118164062
than O O 0.9999566078186035
those O O 0.9999837875366211
treated O O 0.9999568462371826
on O O 0.9999203681945801
P9201 O O 0.9530220627784729
( O O 0.9999409914016724
82 O O 0.9999077320098877
% O O 0.9999971389770508
, O O 0.9999629259109497
14 O O 0.9999873638153076
/ O O 0.9999014139175415
17 O O 0.9999197721481323
measures O O 0.9999749660491943
vs O O 0.9998370409011841
. O O 0.9999889135360718
24 O O 0.999976396560669
% O O 0.999991774559021
, O O 0.9999599456787109
4 O O 0.9997708201408386
/ O O 0.9999059438705444
17 O O 0.9998770952224731
measures O O 0.999980092048645
) O O 0.9999722242355347
. O O 0.9999834299087524

This O O 0.9999704360961914
supports O O 0.9999368190765381
ongoing O O 0.9999790191650391
concerns O O 0.9999902248382568
about O O 0.9999310970306396
intensive O O 0.9980732202529907
MTX B B 0.996142566204071
exposure O O 0.9982547163963318
as O O 0.9999415874481201
a O O 0.9998365640640259
major O O 0.9997641444206238
contributor O O 0.9999805688858032
to O O 0.9998852014541626
CNS O O 0.5151348114013672
late O O 0.8860278725624084
effects O O 0.9999021291732788
. O O 0.9999589920043945

Tranexamic B B 0.9976276755332947
acid I I 0.999731719493866
overdosage O O 0.943359911441803
- O O 0.9990598559379578
induced O O 0.9999581575393677
generalized O O 0.9999680519104004
seizure O O 0.9999887943267822
in O O 0.9999375343322754
renal O O 0.9998213648796082
failure O O 0.999962329864502
. O O 0.9999246597290039

We O O 0.9999884366989136
report O O 0.9999972581863403
a O O 0.9999954700469971
45 O O 0.9999982118606567
- O O 0.9999918937683105
year O O 0.9999977350234985
- O O 0.9999936819076538
old O O 0.999995231628418
lady O O 0.9999982118606567
with O O 0.9999685287475586
chronic O O 0.9996373653411865
kidney O O 0.9994819760322571
disease O O 0.9999953508377075
stage O O 0.9999872446060181
4 O O 0.9975515007972717
due O O 0.9999611377716064
to O O 0.9996201992034912
chronic O O 0.9958066940307617
tubulointerstial O O 0.9999762773513794
disease O O 0.9999905824661255
. O O 0.9999712705612183

She O O 0.9999735355377197
was O O 0.9999754428863525
admitted O O 0.9999847412109375
to O O 0.9999938011169434
our O O 0.999983549118042
center O O 0.9999978542327881
for O O 0.9999762773513794
severe O O 0.9999408721923828
anemia O O 0.999371349811554
due O O 0.9999712705612183
to O O 0.9997027516365051
menorrhagia O O 0.9693146347999573
and O O 0.9999560117721558
deterioration O O 0.999995231628418
of O O 0.999971866607666
renal O O 0.9999616146087646
function O O 0.9999847412109375
. O O 0.99997878074646

She O O 0.999945878982544
was O O 0.9999517202377319
infused O O 0.9999607801437378
three O O 0.9999316930770874
units O O 0.9999867677688599
of O O 0.9998910427093506
packed O O 0.9933098554611206
cells O O 0.9999840259552002
during O O 0.9999042749404907
a O O 0.9999830722808838
session O O 0.9999953508377075
of O O 0.9999679327011108
hemodialysis O O 0.9997743964195251
. O O 0.9999293088912964

Tranexamic B B 0.997563362121582
acid I I 0.9999204874038696
( O O 0.9377919435501099
TNA B B 0.983467161655426
) O O 0.9919766783714294
1 O O 0.999723494052887
g O O 0.9992942810058594
8 O B 0.8713207244873047
- O I 0.8617942929267883
hourly O I 0.9644320607185364
was O O 0.999445378780365
administered O O 0.9999575614929199
to O O 0.9999555349349976
her O O 0.9999901056289673
to O O 0.9999459981918335
control O O 0.9998289346694946
bleeding O O 0.9998482465744019
per O O 0.9999316930770874
vaginum O O 0.9624171853065491
. O O 0.99994957447052

Two O O 0.9999804496765137
hours O O 0.9999939203262329
after O O 0.9999769926071167
the O O 0.9999688863754272
sixth O O 0.9990894794464111
dose O O 0.9994382262229919
of O O 0.998043417930603
TNA B B 0.991910994052887
, O O 0.9999037981033325
she O O 0.999984860420227
had O O 0.9999921321868896
an O O 0.9999966621398926
episode O O 0.9999974966049194
of O O 0.9999909400939941
generalized O O 0.9999738931655884
tonic O O 0.9999897480010986
clonic O O 0.9999815225601196
convulsions O O 0.9998989105224609
. O O 0.9999741315841675

TNA B B 0.9770113825798035
was O O 0.9996829032897949
discontinued O O 0.9993929862976074
. O O 0.9998201727867126

Investigations O O 0.9999700784683228
of O O 0.9999861717224121
the O O 0.9999856948852539
patient O O 0.9999774694442749
revealed O O 0.9999294281005859
no O O 0.9999148845672607
biochemical O O 0.9979549646377563
or O O 0.9998308420181274
structural O O 0.999961256980896
central O O 0.9998394250869751
nervous O O 0.9999879598617554
system O O 0.99997878074646
abnormalities O O 0.9999806880950928
that O O 0.9999570846557617
could O O 0.9999425411224365
have O O 0.9999951124191284
provoked O O 0.9999849796295166
the O O 0.9999886751174927
convulsions O O 0.9999758005142212
. O O 0.9999650716781616

She O O 0.9999779462814331
did O O 0.9999804496765137
not O O 0.9999912977218628
require O O 0.9999639987945557
any O O 0.9999802112579346
further O O 0.9999837875366211
dialytic O O 0.9992218017578125
support O O 0.9999784231185913
. O O 0.9999678134918213

She O O 0.9999681711196899
had O O 0.999985933303833
no O O 0.9999939203262329
further O O 0.999993085861206
episodes O O 0.9999977350234985
of O O 0.9999897480010986
convulsion O O 0.9998428821563721
till O O 0.9994372725486755
dis O O 0.9998668432235718
- O O 0.9998778104782104
charge O O 0.9999867677688599
and O O 0.999981164932251
during O O 0.9999592304229736
the O O 0.9999978542327881
two O O 0.9999964237213135
months O O 0.9999985694885254
of O O 0.9999955892562866
follow O O 0.9999936819076538
- O O 0.999992847442627
up O O 0.9999959468841553
. O O 0.9999822378158569

Thus O O 0.9999644756317139
, O O 0.9999260902404785
the O O 0.9999686479568481
precipitating O O 0.9999743700027466
cause O O 0.9999914169311523
of O O 0.9999867677688599
convulsions O O 0.9997618794441223
was O O 0.9999475479125977
believed O O 0.9999756813049316
to O O 0.9999370574951172
be O O 0.9999148845672607
an O O 0.9998511075973511
overdose O O 0.9998525381088257
of O O 0.990313708782196
TNA B B 0.9683957099914551
. O O 0.9998888969421387

Pre O O 0.9859946966171265
- O O 0.9998641014099121
treatment O O 0.9999631643295288
of O O 0.9999302625656128
bupivacaine B B 0.9994713664054871
- O O 0.9997338652610779
induced O O 0.9999432563781738
cardiovascular O O 0.9999839067459106
depression O O 0.9999958276748657
using O O 0.999822199344635
different O O 0.9998781681060791
lipid O O 0.7302538156509399
formulations O O 0.9890198111534119
of O O 0.9963967204093933
propofol B B 0.999021053314209
. O O 0.9996079802513123

BACKGROUND O O 0.9522596001625061
: O O 0.9998879432678223
Pre O O 0.9925605654716492
- O O 0.999862790107727
treatment O O 0.9999691247940063
with O O 0.9998384714126587
lipid O O 0.6822609901428223
emulsions O O 0.519669771194458
has O O 0.9999300241470337
been O O 0.9999891519546509
shown O O 0.9999853372573853
to O O 0.9999370574951172
increase O O 0.9995160102844238
lethal O O 0.9924848675727844
doses O O 0.9998915195465088
of O O 0.9993672966957092
bupivacaine B B 0.9991412162780762
, O O 0.999546468257904
and O O 0.9999208450317383
the O O 0.9996092915534973
lipid O O 0.532610297203064
content O O 0.9643081426620483
of O O 0.9974799752235413
propofol B B 0.9998098015785217
may O O 0.9998970031738281
alleviate O O 0.9995585083961487
bupivacaine B B 0.9994675517082214
- O O 0.9998846054077148
induced O O 0.9999440908432007
cardiotoxicity O O 0.9999977350234985
. O O 0.9999809265136719

The O O 0.99998939037323
aim O O 0.9999959468841553
of O O 0.9999943971633911
this O O 0.9999896287918091
study O O 0.9999854564666748
is O O 0.9999914169311523
to O O 0.9999879598617554
investigate O O 0.9999161958694458
the O O 0.9999213218688965
effects O O 0.999897837638855
of O O 0.9995930790901184
propofol B B 0.9998733997344971
in O O 0.997314989566803
intralipid O O 0.8912748098373413
or O O 0.9938549399375916
medialipid O O 0.7941004633903503
emulsions O O 0.997381865978241
on O O 0.999751627445221
bupivacaine B B 0.9997922778129578
- O O 0.9998251795768738
induced O O 0.9999401569366455
cardiotoxicity O O 0.9999955892562866
. O O 0.9999784231185913

METHODS O O 0.9991284012794495
: O O 0.9999904632568359
Rats O O 0.9999880790710449
were O O 0.9999879598617554
anaesthetised O O 0.9999909400939941
with O O 0.9998981952667236
ketamine B B 0.9992421865463257
and O O 0.999497652053833
were O O 0.9999910593032837
given O O 0.9999161958694458
0 O O 0.9999368190765381
. O O 0.9999840259552002
5 O O 0.9999830722808838
mg O O 0.9999772310256958
/ O O 0.9999874830245972
kg O O 0.9999948740005493
/ O O 0.9999704360961914
min O O 0.9999227523803711
propofol B B 0.9993284940719604
in O O 0.9903815388679504
intralipid O O 0.9918394088745117
( O O 0.9998674392700195
Group O O 0.9997112154960632
P O O 0.9992934465408325
) O O 0.9998544454574585
, O O 0.9997231364250183
propofol B B 0.9961521029472351
in O O 0.8503942489624023
medialipid O O 0.7791301012039185
( O O 0.9993201494216919
Group O O 0.9999281167984009
L O O 0.9991027116775513
) O O 0.9998587369918823
, O O 0.9994258880615234
or O O 0.9977800250053406
saline O O 0.9998080134391785
( O O 0.999890923500061
Group O O 0.9998595714569092
C O O 0.9951353669166565
) O O 0.9999759197235107
over O O 0.9999674558639526
20 O O 0.999987006187439
min O O 0.9999872446060181
. O O 0.9999696016311646

Thereafter O O 0.9999772310256958
, O O 0.9999555349349976
2 O O 0.9998804330825806
mg O O 0.999963641166687
/ O O 0.9999831914901733
kg O O 0.9999934434890747
/ O O 0.9999537467956543
min O O 0.9998698234558105
bupivacaine B B 0.9997910857200623
0 O O 0.979478120803833
. O O 0.9999269247055054
5 O O 0.9998717308044434
% O O 0.9986679553985596
was O O 0.9999314546585083
infused O O 0.9998893737792969
. O O 0.9999678134918213

We O O 0.9999140501022339
recorded O O 0.9999756813049316
time O O 0.9999881982803345
to O O 0.999991774559021
first O O 0.9999794960021973
dysrhythmia O O 0.9999934434890747
occurrence O O 0.999914288520813
, O O 0.9999833106994629
respective O O 0.9999443292617798
times O O 0.9999939203262329
to O O 0.9999721050262451
25 O O 0.9999573230743408
% O O 0.9999881982803345
and O O 0.9999411106109619
50 O O 0.9999881982803345
% O O 0.9999886751174927
reduction O O 0.9999912977218628
of O O 0.9999586343765259
the O O 0.9999839067459106
heart O O 0.9999891519546509
rate O O 0.9999929666519165
( O O 0.9999501705169678
HR O O 0.992145836353302
) O O 0.9999831914901733
and O O 0.9999449253082275
mean O O 0.999974250793457
arterial O O 0.9982402324676514
pressure O O 0.999944806098938
, O O 0.9999675750732422
and O O 0.9999809265136719
time O O 0.9999901056289673
to O O 0.9999862909317017
asystole O O 0.9999029636383057
and O O 0.9999711513519287
total O O 0.9999074935913086
amount O O 0.99986732006073
of O O 0.9990414977073669
bupivacaine B B 0.9995551705360413
consumption O O 0.9997537732124329
. O O 0.9999675750732422

Blood O O 0.9997950196266174
and O O 0.9998621940612793
tissue O O 0.9999735355377197
samples O O 0.9999809265136719
were O O 0.9999690055847168
collected O O 0.9999903440475464
following O O 0.9999505281448364
asystole O O 0.9999247789382935
. O O 0.9999680519104004

RESULTS O O 0.9999052286148071
: O O 0.9999773502349854
The O O 0.9999932050704956
time O O 0.9999876022338867
to O O 0.9999947547912598
first O O 0.9999898672103882
dysrhythmia O O 0.9999922513961792
occurrence O O 0.9999600648880005
, O O 0.9999774694442749
time O O 0.9999849796295166
to O O 0.9999877214431763
25 O O 0.9999544620513916
% O O 0.9999831914901733
and O O 0.9997478127479553
50 O O 0.9999831914901733
% O O 0.9999830722808838
reductions O O 0.999975323677063
in O O 0.9999380111694336
HR O O 0.9597580432891846
, O O 0.9999399185180664
and O O 0.9999657869338989
time O O 0.9999887943267822
to O O 0.9999884366989136
asystole O O 0.9999481439590454
were O O 0.9999779462814331
longer O O 0.9999724626541138
in O O 0.9998117089271545
Group O O 0.9990324974060059
P O O 0.826209545135498
than O O 0.9999501705169678
the O O 0.9999678134918213
other O O 0.9998770952224731
groups O O 0.999962329864502
. O O 0.9999626874923706

The O O 0.9999898672103882
cumulative O O 0.9963942170143127
bupivacaine B B 0.9993093013763428
dose O O 0.9993928670883179
given O O 0.9999464750289917
at O O 0.9999650716781616
those O O 0.9999867677688599
time O O 0.999980092048645
points O O 0.9999940395355225
was O O 0.9999616146087646
higher O O 0.9997761845588684
in O O 0.9998444318771362
Group O O 0.9998154044151306
P O O 0.9920180439949036
. O O 0.9999618530273438
Plasma O O 0.9952722191810608
bupivacaine B B 0.9991912245750427
levels O O 0.9998430013656616
were O O 0.999976634979248
significantly O O 0.9999828338623047
lower O O 0.999976634979248
in O O 0.9999172687530518
Group O O 0.9998987913131714
P O O 0.9921748042106628
than O O 0.9999910593032837
in O O 0.9999668598175049
Group O O 0.9999667406082153
C O O 0.9990290403366089
. O O 0.999903678894043
Bupivacaine B B 0.998115062713623
levels O O 0.9997982382774353
in O O 0.9997715353965759
the O O 0.9999445676803589
brain O O 0.9999774694442749
and O O 0.9998652935028076
heart O O 0.999961256980896
were O O 0.9999598264694214
significantly O O 0.9999679327011108
lower O O 0.9999560117721558
in O O 0.9998241066932678
Group O O 0.9999412298202515
P O O 0.9965550899505615
and O O 0.9998749494552612
Group O O 0.9998526573181152
L O O 0.9971344470977783
than O O 0.9999898672103882
in O O 0.999954342842102
Group O O 0.9999567270278931
C O O 0.9978094696998596
. O O 0.9999746084213257

CONCLUSION O O 0.9995954632759094
: O O 0.9999773502349854
We O O 0.9999719858169556
conclude O O 0.9999686479568481
that O O 0.9998719692230225
pre O O 0.9996023774147034
- O O 0.9998593330383301
treatment O O 0.9999780654907227
with O O 0.9998900890350342
propofol B B 0.9994657635688782
in O O 0.9884669780731201
intralipid O O 0.6354218125343323
, O O 0.9999076128005981
compared O O 0.9999700784683228
with O O 0.9998185038566589
propofol B B 0.9984879493713379
in O O 0.9014487266540527
medialipid O B 0.8876338005065918
or O O 0.9959406852722168
saline O O 0.9998618364334106
, O O 0.999955415725708
delayed O O 0.9999679327011108
the O O 0.999993085861206
onset O O 0.9999920129776001
of O O 0.9999631643295288
bupivacaine B B 0.9993748068809509
- O O 0.9998121857643127
induced O O 0.9998947381973267
cardiotoxic O O 0.9999938011169434
effects O O 0.9999840259552002
as O O 0.9999885559082031
well O O 0.9999873638153076
as O O 0.9999905824661255
reduced O O 0.9999958276748657
plasma O O 0.9998142123222351
bupivacaine B B 0.9996737241744995
levels O O 0.9999306201934814
. O O 0.9999473094940186

Further O O 0.9999626874923706
studies O O 0.999985933303833
are O O 0.9999898672103882
needed O O 0.9999891519546509
to O O 0.9999842643737793
explore O O 0.9997187256813049
tissue O O 0.9954837560653687
bupivacaine B B 0.9991569519042969
levels O O 0.9991711378097534
of O O 0.9945934414863586
propofol B B 0.9995338916778564
in O O 0.9907855987548828
medialipid O O 0.8308591842651367
and O O 0.99982088804245
adapt O O 0.999994158744812
these O O 0.9999942779541016
results O O 0.9999803304672241
to O O 0.9999908208847046
clinical O O 0.9999881982803345
practice O O 0.9999970197677612
. O O 0.9999812841415405

Drug O O 0.9935503005981445
- O O 0.9998451471328735
Induced O O 0.9999706745147705
Acute O O 0.9999879598617554
Liver O O 0.998963475227356
Injury O O 0.9999926090240479
Within O O 0.9999803304672241
12 O O 0.9999938011169434
Hours O O 0.999994158744812
After O O 0.9999420642852783
Fluvastatin B B 0.9995903372764587
Therapy O O 0.999721109867096
. O O 0.9999731779098511

Although O O 0.9998286962509155
statins B B 0.9920880198478699
are O O 0.9990293979644775
generally O O 0.9999339580535889
well O O 0.9995608925819397
- O O 0.9999761581420898
tolerated O O 0.9998944997787476
drugs O O 0.9963992834091187
, O O 0.9999126195907593
recent O O 0.9999841451644897
cases O O 0.9999967813491821
of O O 0.9999823570251465
drug O O 0.9976609945297241
- O O 0.9999310970306396
induced O O 0.9999852180480957
liver O O 0.9985259175300598
injury O O 0.9999964237213135
associated O O 0.9999843835830688
with O O 0.9999154806137085
their O O 0.9962674975395203
use O O 0.9995075464248657
have O O 0.9999688863754272
been O O 0.999984622001648
reported O O 0.9999911785125732
. O O 0.9999688863754272

A O O 0.999984622001648
52 O O 0.9999959468841553
- O O 0.9999901056289673
year O O 0.9999973773956299
- O O 0.9999949932098389
old O O 0.9999933242797852
Chinese O O 0.9963215589523315
man O O 0.999994158744812
reported O O 0.9999779462814331
with O O 0.9999829530715942
liver O O 0.9993981122970581
damage O O 0.9999955892562866
, O O 0.9999877214431763
which O O 0.999996542930603
appeared O O 0.999998927116394
12 O O 0.9999804496765137
hours O O 0.9999967813491821
after O O 0.9999884366989136
beginning O O 0.9999343156814575
treatment O O 0.9999523162841797
with O O 0.9987412095069885
fluvastatin B B 0.9985176920890808
. O O 0.999897837638855

Patient O O 0.9999120235443115
presented O O 0.9999773502349854
with O O 0.9999868869781494
complaints O O 0.999996542930603
of O O 0.9999938011169434
increasing O O 0.9999904632568359
nausea O O 0.9998495578765869
, O O 0.9999752044677734
anorexia O O 0.9944003224372864
, O O 0.9999208450317383
and O O 0.999976396560669
upper O O 0.9999080896377563
abdominal O O 0.9999864101409912
pain O O 0.9999903440475464
. O O 0.999976634979248

His O O 0.9999549388885498
laboratory O O 0.9998975992202759
values O O 0.9998725652694702
showed O O 0.9999414682388306
elevated O O 0.9993365406990051
creatine B B 0.9884867668151855
kinase O O 0.4931011497974396
and O O 0.9993718266487122
transaminases O O 0.6326677203178406
. O O 0.9999246597290039

Testing O O 0.9999421834945679
for O O 0.9992849230766296
autoantibodies O O 0.9908106327056885
was O O 0.9999333620071411
also O O 0.999968409538269
negative O O 0.9999121427536011
. O O 0.9999585151672363

The O O 0.9999759197235107
liver O O 0.9972631931304932
biochemistries O O 0.9987634420394897
eventually O O 0.9999144077301025
normalized O O 0.9999548196792603
within O O 0.9999828338623047
3 O O 0.9998552799224854
weeks O O 0.9999974966049194
of O O 0.9999874830245972
stopping O O 0.9998266100883484
the O O 0.9997335076332092
fluvastatin B B 0.9985275268554688
. O O 0.9999289512634277

Therefore O O 0.9999680519104004
, O O 0.9999778270721436
when O O 0.9999889135360718
prescribing O O 0.9999231100082397
statins O B 0.9879807829856873
, O O 0.9997768998146057
the O O 0.9999834299087524
possibility O O 0.9999737739562988
of O O 0.999943733215332
hepatic O O 0.9999337196350098
damage O O 0.9999760389328003
should O O 0.9999606609344482
be O O 0.9999936819076538
taken O O 0.9999896287918091
into O O 0.999971866607666
account O O 0.9999810457229614
. O O 0.9999644756317139

Fluconazole B B 0.9994630217552185
associated O O 0.9998119473457336
agranulocytosis O O 0.9989645481109619
and O O 0.9999569654464722
thrombocytopenia O O 0.9997512698173523
. O O 0.9998694658279419

CASE O O 0.9997557997703552
: O O 0.9999821186065674
We O O 0.9999678134918213
describe O O 0.9999923706054688
a O O 0.9999880790710449
second O O 0.9999959468841553
case O O 0.9999934434890747
of O O 0.9999444484710693
fluconazole B B 0.9997467398643494
associated O O 0.9997095465660095
agranulocytosis O O 0.9991233944892883
with O O 0.9999549388885498
thrombocytopenia O O 0.9997310042381287
and O O 0.9999508857727051
recovery O O 0.9999966621398926
upon O O 0.9999843835830688
discontinuation O O 0.9999830722808838
of O O 0.9999511241912842
therapy O O 0.9999561309814453
. O O 0.9999759197235107

The O O 0.99998939037323
patient O O 0.9999880790710449
began O O 0.9999966621398926
to O O 0.9999897480010986
have O O 0.9999926090240479
changes O O 0.9999980926513672
in O O 0.9999878406524658
white O O 0.9999960660934448
blood O O 0.9999815225601196
cells O O 0.9999959468841553
and O O 0.9999312162399292
platelets O O 0.9995248317718506
within O O 0.9999675750732422
48 O O 0.9999926090240479
h O O 0.9999691247940063
of O O 0.9999244213104248
administration O O 0.9999463558197021
of O O 0.9991149306297302
fluconazole B B 0.9996622800827026
and O O 0.9999097585678101
began O O 0.9999955892562866
to O O 0.9999915361404419
recover O O 0.9999964237213135
with O O 0.9999903440475464
48 O O 0.999995231628418
h O O 0.9999192953109741
of O O 0.9999722242355347
discontinuation O O 0.9999690055847168
. O O 0.9999709129333496

This O O 0.9999618530273438
case O O 0.9999773502349854
highlights O O 0.9999557733535767
that O O 0.9998779296875
drug O O 0.9980341792106628
- O O 0.9998887777328491
induced O O 0.9999445676803589
blood O O 0.9992584586143494
dyscrasias O O 0.9999926090240479
can O O 0.9998821020126343
occur O O 0.9999772310256958
unexpectedly O O 0.9999016523361206
as O O 0.9999854564666748
a O O 0.9999818801879883
result O O 0.9999774694442749
of O O 0.9998164772987366
treatment O O 0.9999748468399048
with O O 0.9998685121536255
a O O 0.999974250793457
commonly O O 0.9999027252197266
used O O 0.9999189376831055
drug O O 0.9991160035133362
thought O O 0.9999551773071289
to O O 0.999976396560669
be O O 0.9999747276306152
" O O 0.9999616146087646
safe O O 0.9995301961898804
" O O 0.9999901056289673
. O O 0.9999699592590332

CONCLUSION O O 0.9999197721481323
: O O 0.9999728202819824
According O O 0.9999960660934448
to O O 0.9999468326568604
Naranjo O O 0.8101895451545715
' O O 0.9998934268951416
s O O 0.9999852180480957
algorithm O O 0.9999634027481079
the O O 0.9999878406524658
likelihood O O 0.9999960660934448
that O O 0.9999818801879883
our O O 0.9999780654907227
patient O O 0.9999865293502808
' O O 0.9999924898147583
s O O 0.9999843835830688
agranulocytosis O O 0.9989163875579834
and O O 0.999932050704956
thrombocytopenia O O 0.9997912049293518
occurred O O 0.9999901056289673
as O O 0.9999889135360718
a O O 0.9999911785125732
result O O 0.9999759197235107
of O O 0.9997109770774841
therapy O O 0.9999594688415527
with O O 0.9991305470466614
fluconazole B B 0.999235987663269
is O O 0.9992302656173706
probable O O 0.9989022016525269
, O O 0.9999814033508301
with O O 0.9999837875366211
a O O 0.9999862909317017
total O O 0.9999877214431763
of O O 0.9999880790710449
six O O 0.9999903440475464
points O O 0.9999939203262329
. O O 0.9999821186065674

We O O 0.9999679327011108
feel O O 0.9999839067459106
that O O 0.9999721050262451
the O O 0.999994158744812
weight O O 0.9999972581863403
of O O 0.9999958276748657
the O O 0.9999936819076538
overall O O 0.9999904632568359
evidence O O 0.9999856948852539
of O O 0.9999809265136719
this O O 0.9999673366546631
evidence O O 0.9999611377716064
is O O 0.999955415725708
strong O O 0.9999690055847168
. O O 0.9999710321426392

In O O 0.9999556541442871
particular O O 0.9999781847000122
the O O 0.9999864101409912
temporal O O 0.9999864101409912
relationship O O 0.9999943971633911
of O O 0.9999421834945679
bone O O 0.9999250173568726
marrow O O 0.9999974966049194
suppression O O 0.9999864101409912
to O O 0.9998736381530762
the O O 0.9999866485595703
initiation O O 0.9999072551727295
of O O 0.9988675117492676
fluconazole B B 0.9993380904197693
and O O 0.9998589754104614
the O O 0.9999877214431763
abatement O O 0.9999818801879883
of O O 0.9999855756759644
symptoms O O 0.9999967813491821
that O O 0.9999841451644897
rapidly O O 0.9999932050704956
reversed O O 0.9999973773956299
immediately O O 0.999997615814209
following O O 0.999977707862854
discontinuation O O 0.9999703168869019
. O O 0.9999828338623047

Two O O 0.9998754262924194
- O O 0.9999837875366211
dimensional O O 0.9999847412109375
speckle O O 0.9910888671875
tracking O O 0.9999542236328125
echocardiography O O 0.999893307685852
combined O O 0.9999831914901733
with O O 0.9999740123748779
high O O 0.9941312670707703
- O O 0.9999603033065796
sensitive O O 0.9998219609260559
cardiac O O 0.9996089339256287
troponin O B 0.8824701905250549
T O I 0.986234188079834
in O O 0.9995836615562439
early O O 0.9999911785125732
detection O O 0.9999964237213135
and O O 0.9999938011169434
prediction O O 0.9999958276748657
of O O 0.9999897480010986
cardiotoxicity O O 0.9999934434890747
during O O 0.9999265670776367
epirubicine B B 0.9941996335983276
- O O 0.999405026435852
based O O 0.9979856014251709
chemotherapy O O 0.9995768666267395
. O O 0.9999690055847168

AIMS O O 0.9997569918632507
: O O 0.9999939203262329
To O O 0.9999891519546509
investigate O O 0.99997878074646
whether O O 0.9999816417694092
alterations O O 0.9999738931655884
of O O 0.9999387264251709
myocardial O O 0.9999970197677612
strain O O 0.9999667406082153
and O O 0.9998067021369934
high O O 0.9859426617622375
- O O 0.9999078512191772
sensitive O O 0.9980338215827942
cardiac O O 0.9994497895240784
troponin O O 0.69319748878479
T O O 0.8635668158531189
( O O 0.980463445186615
cTnT O O 0.8016093969345093
) O O 0.9998524188995361
could O O 0.9999531507492065
predict O O 0.9999935626983643
future O O 0.9999899864196777
cardiac O O 0.9999904632568359
dysfunction O O 0.9999980926513672
in O O 0.9999841451644897
patients O O 0.9999938011169434
after O O 0.999923586845398
epirubicin B B 0.9930330514907837
exposure O O 0.999672532081604
. O O 0.999981164932251

METHODS O O 0.999774158000946
: O O 0.999988317489624
Seventy O O 0.9998719692230225
- O O 0.9999539852142334
five O O 0.9999920129776001
patients O O 0.9999961853027344
with O O 0.9999886751174927
non O O 0.9991268515586853
- O O 0.9995697140693665
Hodgkin O O 0.999350368976593
lymphoma O O 0.9999434947967529
treated O O 0.999879002571106
with O O 0.9992750287055969
epirubicin B B 0.9728719592094421
were O O 0.9996790885925293
studied O O 0.9999691247940063
. O O 0.9999591112136841

Blood O O 0.9997771382331848
collection O O 0.9999363422393799
and O O 0.999983549118042
echocardiography O O 0.9998811483383179
were O O 0.9999758005142212
performed O O 0.9999943971633911
at O O 0.9999858140945435
baseline O O 0.999990701675415
, O O 0.9999932050704956
1 O O 0.9999663829803467
day O O 0.9999960660934448
after O O 0.9999927282333374
the O O 0.9999979734420776
third O O 0.9999374151229858
cycle O O 0.9999768733978271
, O O 0.999954104423523
and O O 0.999961256980896
1 O O 0.9999661445617676
day O O 0.999996542930603
after O O 0.9999936819076538
completion O O 0.9999960660934448
of O O 0.9999531507492065
chemotherapy O O 0.9997835755348206
. O O 0.9999697208404541

Patients O O 0.9997729659080505
were O O 0.9999910593032837
studied O O 0.9999880790710449
using O O 0.9999711513519287
echocardiography O O 0.9995737671852112
during O O 0.9999189376831055
follow O O 0.9999839067459106
- O O 0.9999935626983643
up O O 0.9999963045120239
. O O 0.9999827146530151

Global O O 0.9998352527618408
longitudinal O O 0.9999810457229614
( O O 0.9998950958251953
GLS O O 0.9986642599105835
) O O 0.9998941421508789
, O O 0.9998754262924194
circumferential O O 0.995954155921936
( O O 0.9997884631156921
GCS O O 0.9889199137687683
) O O 0.9999001026153564
, O O 0.9996885061264038
and O O 0.9998675584793091
radial O O 0.9993942975997925
strain O O 0.9999946355819702
( O O 0.9998518228530884
GRS O O 0.968319296836853
) O O 0.9999816417694092
were O O 0.999991774559021
calculated O O 0.9999960660934448
using O O 0.9999703168869019
speckle O O 0.996632993221283
tracking O O 0.9999511241912842
echocardiography O O 0.9999169111251831
. O O 0.999974250793457

Left O O 0.9998005032539368
ventricular O O 0.9999903440475464
ejection O O 0.999862551689148
fraction O O 0.9999861717224121
was O O 0.999983549118042
analysed O O 0.9999583959579468
by O O 0.999988317489624
real O O 0.9999432563781738
- O O 0.9999905824661255
time O O 0.9999878406524658
3D O O 0.9872046709060669
echocardiography O O 0.9999041557312012
. O O 0.9999493360519409

Cardiotoxicity O O 0.9999765157699585
was O O 0.9999639987945557
defined O O 0.9999890327453613
as O O 0.9999891519546509
a O O 0.9999887943267822
reduction O O 0.9999901056289673
of O O 0.9999524354934692
the O O 0.9999289512634277
LVEF O O 0.9340025186538696
of O O 0.9999115467071533
> O O 0.9999771118164062
5 O O 0.9999825954437256
% O O 0.99998939037323
to O O 0.9999452829360962
< O O 0.9999885559082031
55 O O 0.9999761581420898
% O O 0.9999912977218628
with O O 0.9999746084213257
symptoms O O 0.9999951124191284
of O O 0.9999862909317017
heart O O 0.9999645948410034
failure O O 0.9999873638153076
or O O 0.9999692440032959
an O O 0.9999784231185913
asymptomatic O O 0.9999935626983643
reduction O O 0.9999895095825195
of O O 0.9999583959579468
the O O 0.9999312162399292
LVEF O O 0.9270370602607727
of O O 0.9999338388442993
> O O 0.9999808073043823
10 O O 0.9999932050704956
% O O 0.9999892711639404
to O O 0.9999703168869019
< O O 0.9999911785125732
55 O O 0.9999904632568359
% O O 0.9999954700469971
. O O 0.9999693632125854

RESULTS O O 0.9997177720069885
: O O 0.999983549118042
Fourteen O O 0.999993085861206
patients O O 0.9999935626983643
( O O 0.9999756813049316
18 O O 0.999983549118042
. O O 0.9999927282333374
67 O O 0.9999762773513794
% O O 0.9999896287918091
) O O 0.9999502897262573
developed O O 0.9999836683273315
cardiotoxicity O O 0.9999910593032837
after O O 0.9998218417167664
treatment O O 0.9999743700027466
. O O 0.999964714050293

GLS O O 0.8123578429222107
( O O 0.9997071623802185
- O O 0.9998223185539246
18 O O 0.9998617172241211
. O O 0.9999856948852539
48 O O 0.9999884366989136
+ O O 0.999920129776001
1 O O 0.9999817609786987
. O O 0.9999797344207764
72 O O 0.9999762773513794
% O O 0.9999896287918091
vs O O 0.9998772144317627
. O O 0.9999568462371826
- O O 0.9998849630355835
15 O O 0.9999972581863403
. O O 0.9999909400939941
96 O O 0.999932050704956
+ O O 0.9999178647994995
1 O O 0.9999866485595703
. O O 0.9999752044677734
6 O O 0.999993085861206
% O O 0.9999943971633911
) O O 0.9999332427978516
, O O 0.9987396597862244
GCS O O 0.5959435105323792
( O O 0.9995982050895691
- O O 0.9997243285179138
20 O O 0.999956488609314
. O O 0.9999814033508301
93 O O 0.9999748468399048
+ O O 0.9999252557754517
2 O O 0.9999586343765259
. O O 0.9999784231185913
86 O O 0.9999655485153198
% O O 0.9999926090240479
vs O O 0.9998902082443237
. O O 0.9998679161071777
- O O 0.9998044371604919
19 O O 0.9999645948410034
. O O 0.9999911785125732
20 O O 0.999980092048645
+ O O 0.9999104738235474
3 O O 0.9996750354766846
. O O 0.9999898672103882
21 O O 0.9999914169311523
% O O 0.9999933242797852
) O O 0.9999241828918457
, O O 0.9994832277297974
and O O 0.9675197601318359
GRS O O 0.5794306993484497
( O O 0.9999055862426758
39 O O 0.9999785423278809
. O O 0.9999871253967285
23 O O 0.9999924898147583
+ O O 0.9998743534088135
6 O O 0.9999872446060181
. O O 0.9999938011169434
44 O O 0.9999929666519165
% O O 0.9999945163726807
vs O O 0.9999573230743408
. O O 0.9999871253967285
34 O O 0.9999592304229736
. O O 0.9999836683273315
98 O O 0.9999587535858154
+ O O 0.9999127388000488
6 O O 0.9999858140945435
. O O 0.9999806880950928
2 O O 0.9999850988388062
% O O 0.9999908208847046
) O O 0.9999326467514038
were O O 0.9999542236328125
markedly O O 0.9999817609786987
reduced O O 0.9999926090240479
and O O 0.999957799911499
cTnT O O 0.955669641494751
was O O 0.9999555349349976
elevated O O 0.9999679327011108
from O O 0.9999765157699585
0 O O 0.9999606609344482
. O O 0.9999897480010986
0010 O O 0.9768253564834595
+ O O 0.9991488456726074
0 O O 0.9995600581169128
. O O 0.9999836683273315
0020 O O 0.9746764302253723
to O O 0.9998975992202759
0 O O 0.9999326467514038
. O O 0.99998939037323
0073 O O 0.9741763472557068
+ O O 0.9990853071212769
0 O O 0.9964702129364014
. O O 0.9999833106994629
0038 O O 0.9071540832519531
ng O O 0.9996665716171265
/ O O 0.9999582767486572
mL O O 0.9999983310699463
( O O 0.9999579191207886
P O O 0.993362545967102
all O O 0.999993085861206
< O O 0.9999134540557861
0 O O 0.9999843835830688
. O O 0.9999958276748657
01 O O 0.9999927282333374
) O O 0.9999709129333496
at O O 0.9999445676803589
the O O 0.9999954700469971
completion O O 0.9999951124191284
of O O 0.9999493360519409
chemotherapy O O 0.9976165294647217
compared O O 0.9999613761901855
with O O 0.999995231628418
baseline O O 0.9999781847000122
values O O 0.9999855756759644
. O O 0.9999396800994873

A O O 0.9999362230300903
> O O 0.9999709129333496
15 O O 0.9999918937683105
. O O 0.999987006187439
9 O O 0.9999934434890747
% O O 0.999992847442627
decrease O O 0.9999939203262329
in O O 0.9998869895935059
GLS O O 0.7168112993240356
[ O O 0.999687910079956
sensitivity O O 0.9999754428863525
, O O 0.9999529123306274
86 O O 0.9999752044677734
% O O 0.9999946355819702
; O O 0.9999309778213501
specificity O O 0.9999198913574219
, O O 0.9999004602432251
75 O O 0.9999969005584717
% O O 0.999995231628418
; O O 0.9999648332595825
area O O 0.9961282014846802
under O O 0.9997512698173523
the O O 0.9999649524688721
curve O O 0.9999791383743286
( O O 0.9998548030853271
AUC O O 0.9990425705909729
) O O 0.9999375343322754
= O O 0.9990969896316528
0 O O 0.9999833106994629
. O O 0.9999884366989136
815 O O 0.9993246793746948
; O O 0.9999666213989258
P O O 0.9999688863754272
= O O 0.9999514818191528
0 O O 0.9999650716781616
. O O 0.9999943971633911
001 O O 0.9994816184043884
] O O 0.9999469518661499
and O O 0.9999542236328125
a O O 0.9999760389328003
> O O 0.9999527931213379
0 O O 0.9999843835830688
. O O 0.9999939203262329
004 O O 0.99998939037323
ng O O 0.9999271631240845
/ O O 0.9999758005142212
mL O O 0.9999983310699463
elevation O O 0.9999889135360718
in O O 0.9996291399002075
cTnT O O 0.9127427339553833
( O O 0.9996784925460815
sensitivity O O 0.9999778270721436
, O O 0.9999585151672363
79 O O 0.9999227523803711
% O O 0.9999958276748657
; O O 0.9999340772628784
specificity O O 0.999932050704956
, O O 0.9999510049819946
64 O O 0.9999942779541016
% O O 0.9999947547912598
; O O 0.9997747540473938
AUC O O 0.9816283583641052
= O O 0.9996949434280396
0 O O 0.9999794960021973
. O O 0.9999772310256958
757 O O 0.9999697208404541
; O O 0.9999637603759766
P O O 0.9998993873596191
= O O 0.9998869895935059
0 O O 0.9999545812606812
. O O 0.9999927282333374
005 O O 0.9998337030410767
) O O 0.9999831914901733
from O O 0.999991774559021
baseline O O 0.9999910593032837
to O O 0.9999853372573853
the O O 0.9999967813491821
third O O 0.9999864101409912
cycle O O 0.9999855756759644
of O O 0.9998576641082764
chemotherapy O O 0.9946069121360779
predicted O O 0.9996784925460815
later O O 0.9999130964279175
cardiotoxicity O O 0.9999959468841553
. O O 0.999955415725708

The O O 0.9999799728393555
decrease O O 0.9999892711639404
in O O 0.9998283386230469
GLS O O 0.5483760833740234
remained O O 0.9999083280563354
the O O 0.9999575614929199
only O O 0.9998980760574341
independent O O 0.9999407529830933
predictor O O 0.9999680519104004
of O O 0.9999665021896362
cardiotoxicity O O 0.9999942779541016
( O O 0.9999581575393677
P O O 0.9994148015975952
= O O 0.9999557733535767
0 O O 0.9999908208847046
. O O 0.9999966621398926
000 O O 0.9999901056289673
) O O 0.9999686479568481
. O O 0.9999698400497437

CONCLUSIONS O O 0.9908673763275146
: O O 0.9996007084846497
GLS O O 0.5500721335411072
combined O O 0.9999116659164429
with O O 0.999790370464325
cTnT O O 0.7288314700126648
may O O 0.999941349029541
provide O O 0.9999922513961792
a O O 0.999992847442627
reliable O O 0.9999940395355225
and O O 0.9999879598617554
non O O 0.9999744892120361
- O O 0.9999783039093018
invasive O O 0.9999973773956299
method O O 0.9999969005584717
to O O 0.9999954700469971
predict O O 0.9999945163726807
cardiac O O 0.9999904632568359
dysfunction O O 0.9999977350234985
in O O 0.9999873638153076
patients O O 0.9999926090240479
receiving O O 0.9998589754104614
anthracycline B B 0.9963614344596863
- O O 0.9972642660140991
based O O 0.9962924122810364
chemotherapy O O 0.999607503414154
. O O 0.9999792575836182

Prevention O O 0.9998176693916321
of O O 0.9998860359191895
etomidate B B 0.9994480013847351
- O O 0.9994426369667053
induced O O 0.9999334812164307
myoclonus O O 0.9999978542327881
: O O 0.999962568283081
which O O 0.9999514818191528
is O O 0.9999500513076782
superior O O 0.9919874668121338
: O O 0.9995291233062744
Fentanyl B B 0.998902440071106
, O O 0.9642558097839355
midazolam B B 0.9997583031654358
, O O 0.9477822184562683
or O O 0.9998804330825806
a O O 0.9999384880065918
combination O O 0.9996722936630249
? O O 0.9997705817222595

A O O 0.9999752044677734
Retrospective O O 0.9999630451202393
comparative O O 0.9999667406082153
study O O 0.9999876022338867
. O O 0.9999810457229614

BACKGROUND O O 0.9991006851196289
: O O 0.9999868869781494
In O O 0.999995231628418
this O O 0.999991774559021
retrospective O O 0.9999840259552002
comparative O O 0.9999908208847046
study O O 0.9999908208847046
, O O 0.999975323677063
we O O 0.9999806880950928
aimed O O 0.9999961853027344
to O O 0.9999932050704956
compare O O 0.9998840093612671
the O O 0.9999585151672363
effectiveness O O 0.9999123811721802
of O O 0.9996083378791809
fentanyl B B 0.9997419714927673
, O O 0.9467638731002808
midazolam B B 0.9997624754905701
, O O 0.9858048558235168
and O O 0.9997349381446838
a O O 0.9999371767044067
combination O O 0.9990630745887756
of O O 0.9995855689048767
fentanyl B B 0.9997325539588928
and O O 0.973998486995697
midazolam B B 0.9998308420181274
to O O 0.9999266862869263
prevent O O 0.9998515844345093
etomidate B B 0.9996145963668823
- O O 0.9998133778572083
induced O O 0.9999414682388306
myoclonus O O 0.9999982118606567
. O O 0.9999406337738037

MATERIAL O O 0.9999909400939941
AND O O 0.9999966621398926
METHODS O O 0.9999979734420776
: O O 0.999993085861206
This O O 0.999995231628418
study O O 0.9999932050704956
was O O 0.9999954700469971
performed O O 0.9999977350234985
based O O 0.999996542930603
on O O 0.9999891519546509
anesthesia O O 0.9999567270278931
records O O 0.9999791383743286
. O O 0.9999772310256958

Depending O O 0.9999969005584717
on O O 0.9999761581420898
the O O 0.9999619722366333
drugs O O 0.9969897270202637
that O O 0.9999803304672241
would O O 0.999994158744812
be O O 0.9999972581863403
given O O 0.999945878982544
before O O 0.999984622001648
the O O 0.9999954700469971
induction O O 0.9999974966049194
of O O 0.9999810457229614
anesthesia O O 0.999994158744812
with O O 0.9998493194580078
etomidate B B 0.9989179372787476
, O O 0.9998964071273804
the O O 0.9999935626983643
patients O O 0.999996542930603
were O O 0.9999884366989136
separated O O 0.9999957084655762
into O O 0.999970555305481
4 O O 0.9995858073234558
groups O O 0.9999880790710449
: O O 0.9999279975891113
no O O 0.9997100234031677
pretreatment O O 0.9991762042045593
( O O 0.9999165534973145
Group O O 0.9993302822113037
NP O O 0.9156541228294373
) O O 0.9999496936798096
, O O 0.9998007416725159
fentanyl B B 0.9995859265327454
1 O O 0.997688889503479
ug O O 0.7928505539894104
. O O 0.9999912977218628
kg O O 0.9991366267204285
- O O 0.9984261989593506
1 O O 0.9998356103897095
( O O 0.9999468326568604
Group O O 0.9998965263366699
F O O 0.9996738433837891
) O O 0.9999709129333496
, O O 0.9996706247329712
midazolam B B 0.9998522996902466
0 O O 0.962541401386261
. O O 0.9999909400939941
03 O O 0.9998160004615784
mg O O 0.9999791383743286
. O O 0.9999918937683105
kg O O 0.9999774694442749
- O O 0.9993509650230408
1 O O 0.9999392032623291
( O O 0.9999301433563232
Group O O 0.9991044402122498
M O O 0.9982753992080688
) O O 0.9999734163284302
, O O 0.9999173879623413
and O O 0.9994454979896545
midazolam B B 0.9997844099998474
0 O O 0.9940404295921326
. O O 0.999997615814209
015 O O 0.9999866485595703
mg O O 0.9999892711639404
. O O 0.999991774559021
kg O O 0.9999581575393677
- O O 0.9994019269943237
1 O O 0.9995917677879333
+ O O 0.9940866231918335
fentanyl B B 0.9995262622833252
0 O O 0.9981024861335754
. O O 0.999995231628418
5 O O 0.9999817609786987
ug O O 0.9901463389396667
. O O 0.9999929666519165
kg O O 0.9994943141937256
- O O 0.9993941783905029
1 O O 0.9999521970748901
( O O 0.9999525547027588
Group O O 0.9993361830711365
FM O O 0.8668142557144165
) O O 0.9999792575836182
. O O 0.9999822378158569

Patients O O 0.999954104423523
who O O 0.9999819993972778
received O O 0.9999819993972778
the O O 0.9999934434890747
same O O 0.999972939491272
anesthetic O O 0.9998762607574463
procedure O O 0.9999860525131226
were O O 0.999967098236084
selected O O 0.9999775886535645
: O O 0.9999926090240479
2 O O 0.9999685287475586
minutes O O 0.9999972581863403
after O O 0.999987006187439
intravenous O O 0.9999911785125732
injections O O 0.9999604225158691
of O O 0.9998867511749268
the O O 0.9999194145202637
pretreatment O O 0.9979021549224854
drugs O O 0.9978846907615662
, O O 0.9999204874038696
anesthesia O O 0.9999151229858398
is O O 0.9999715089797974
induced O O 0.999997615814209
with O O 0.9999558925628662
0 O O 0.9998249411582947
. O O 0.9999790191650391
3 O O 0.9998282194137573
mg O O 0.9997770190238953
. O O 0.9990739822387695
kg O O 0.8625010848045349
- O O 0.9882082343101501
1 O O 0.9957979321479797
etomidate B B 0.9983972907066345
injected O O 0.999864935874939
intravenously O O 0.999976634979248
over O O 0.9999762773513794
a O O 0.9999924898147583
period O O 0.9999963045120239
of O O 0.9999927282333374
20 O O 0.9999910593032837
- O O 0.999985933303833
30 O O 0.9999967813491821
seconds O O 0.9999961853027344
. O O 0.9999761581420898

Myoclonic O O 0.9999691247940063
movements O O 0.9999879598617554
are O O 0.9999212026596069
evaluated O O 0.9999767541885376
, O O 0.9999778270721436
which O O 0.9999595880508423
were O O 0.9999910593032837
observed O O 0.9999877214431763
and O O 0.9999788999557495
graded O O 0.999995231628418
according O O 0.9999940395355225
to O O 0.9999812841415405
clinical O O 0.99998939037323
severity O O 0.9999977350234985
during O O 0.9999847412109375
the O O 0.9999960660934448
2 O O 0.9999620914459229
minutes O O 0.9999974966049194
after O O 0.9999630451202393
etomidate B B 0.9996834993362427
injection O O 0.9998824596405029
. O O 0.9999798536300659

The O O 0.9999799728393555
severity O O 0.9999969005584717
of O O 0.9999868869781494
pain O O 0.9999828338623047
due O O 0.9999849796295166
to O O 0.9997755885124207
etomidate B B 0.9993582367897034
injection O O 0.999758780002594
, O O 0.9999717473983765
mean O O 0.9999668598175049
arterial O O 0.9993178844451904
pressure O O 0.9996243715286255
, O O 0.9999644756317139
heart O O 0.9999737739562988
rate O O 0.9999784231185913
, O O 0.9999294281005859
and O O 0.9998646974563599
adverse O O 0.9998738765716553
effects O O 0.9999827146530151
were O O 0.9999767541885376
also O O 0.9999858140945435
evaluated O O 0.9999889135360718
. O O 0.9999774694442749

RESULTS O O 0.9995673298835754
: O O 0.9988142251968384
Study O O 0.9999344348907471
results O O 0.9999713897705078
showed O O 0.9999572038650513
that O O 0.9996564388275146
myoclonus O O 0.9999667406082153
incidence O O 0.9997859597206116
was O O 0.9999040365219116
85 O O 0.9998587369918823
% O O 0.999987006187439
, O O 0.9998974800109863
40 O O 0.9999769926071167
% O O 0.9999876022338867
, O O 0.9998452663421631
70 O O 0.9999856948852539
% O O 0.9999897480010986
, O O 0.9997708201408386
and O O 0.9999033212661743
25 O O 0.9999701976776123
% O O 0.9999738931655884
in O O 0.9997872710227966
Group O O 0.9990355968475342
NP O O 0.9737623333930969
, O O 0.9998681545257568
Group O O 0.9995786547660828
F O O 0.9989185333251953
, O O 0.9998517036437988
Group O O 0.9997443556785583
M O O 0.9999711513519287
, O O 0.9998725652694702
and O O 0.9997473359107971
Group O O 0.9978963136672974
FM O O 0.9873857498168945
, O O 0.9999523162841797
respectively O O 0.9998739957809448
, O O 0.999923586845398
and O O 0.9998706579208374
were O O 0.9999005794525146
significantly O O 0.999980092048645
lower O O 0.9999748468399048
in O O 0.9996577501296997
Group O O 0.9990068078041077
F O O 0.9988620281219482
and O O 0.9998329877853394
Group O O 0.9953655004501343
FM O O 0.9781631827354431
. O O 0.9999563694000244

CONCLUSIONS O O 0.9960441589355469
: O O 0.9999918937683105
We O O 0.9998972415924072
conclude O O 0.9999480247497559
that O O 0.999893069267273
pretreatment O O 0.9999257326126099
with O O 0.9999148845672607
fentanyl B B 0.9997449517250061
or O O 0.9993370175361633
combination O O 0.9901808500289917
of O O 0.9996316432952881
fentanyl B B 0.9997240900993347
and O O 0.9812860488891602
midazolam B B 0.9998883008956909
was O O 0.9999210834503174
effective O O 0.9999077320098877
in O O 0.9999634027481079
preventing O O 0.9999383687973022
etomidate B B 0.9997629523277283
- O O 0.9997532963752747
induced O O 0.9999405145645142
myoclonus O O 0.999998927116394
. O O 0.9999666213989258

Convulsant O O 0.9987097978591919
effect O O 0.9998606443405151
of O O 0.9986498951911926
lindane B B 0.9984188079833984
and O O 0.9995884299278259
regional O O 0.9997757077217102
brain O O 0.999932050704956
concentration O O 0.9927765130996704
of O O 0.9966323971748352
GABA B B 0.999005138874054
and O O 0.9548714756965637
dopamine B B 0.9992978572845459
. O O 0.9999045133590698

Lindane B B 0.9964579939842224
( O O 0.9037132263183594
gamma B B 0.9575724005699158
- I I 0.9910035133361816
hexachlorocyclohexane I I 0.9998902082443237
) O O 0.9912914037704468
is O O 0.9997201561927795
an O O 0.9939494132995605
organochlorine O B 0.9496435523033142
insecticide O O 0.650331437587738
with O O 0.9995743632316589
known O O 0.9998254179954529
neurotoxic O O 0.9999803304672241
effects O O 0.9999381303787231
. O O 0.9998248219490051

Its O O 0.9997759461402893
mechanism O O 0.9999713897705078
of O O 0.9999468326568604
action O O 0.9997033476829529
is O O 0.9999327659606934
not O O 0.9999957084655762
well O O 0.999991774559021
understood O O 0.9999954700469971
although O O 0.9999362230300903
it O O 0.999983549118042
has O O 0.999972939491272
been O O 0.9999933242797852
proposed O O 0.9999810457229614
that O O 0.9987372756004333
lindane B B 0.9994933605194092
acts O O 0.999683141708374
as O O 0.9998974800109863
a O O 0.9994105100631714
non O O 0.9653325080871582
- O O 0.9992914199829102
competitive O O 0.9605878591537476
antagonist O O 0.9541356563568115
at O O 0.9990630745887756
the O O 0.9992421865463257
gamma B B 0.7589281797409058
- I I 0.873374342918396
aminobutyric I I 0.9987483024597168
acid I I 0.9995099306106567
( O O 0.9053660035133362
GABA B B 0.9711271524429321
) O O 0.9173527359962463
- O O 0.9973777532577515
A O O 0.9646489024162292
receptor O O 0.9999065399169922
. O O 0.9999222755432129

We O O 0.9999572038650513
studied O O 0.9999724626541138
the O O 0.9999687671661377
effect O O 0.9999289512634277
of O O 0.9975433349609375
lindane B B 0.9995365142822266
( O O 0.9996374845504761
150 O O 0.9992175102233887
mg O O 0.9998492002487183
/ O O 0.9998621940612793
kg O O 0.9999812841415405
) O O 0.99994957447052
on O O 0.9998502731323242
the O O 0.9999544620513916
GABAergic O B 0.9328897595405579
and O O 0.9994149208068848
dopaminergic O O 0.8384905457496643
systems O O 0.9998490810394287
by O O 0.9999943971633911
measuring O O 0.999990701675415
the O O 0.999976396560669
concentration O O 0.9999252557754517
of O O 0.9997004270553589
GABA B B 0.997102677822113
, O O 0.9792270064353943
dopamine B B 0.9918081164360046
and O O 0.9994977712631226
its O O 0.9889512658119202
metabolites O O 0.9998212456703186
in O O 0.9998182654380798
7 O O 0.9835504293441772
brain O O 0.9999771118164062
areas O O 0.9999651908874512
at O O 0.9999767541885376
the O O 0.9999957084655762
onset O O 0.9999969005584717
of O O 0.9999904632568359
seizures O O 0.999988317489624
. O O 0.9999754428863525

All O O 0.9999161958694458
animals O O 0.9999947547912598
suffered O O 0.9999849796295166
tonic O O 0.9999614953994751
convulsions O O 0.9999815225601196
at O O 0.9999525547027588
18 O O 0.9964267611503601
. O O 0.9999864101409912
3 O O 0.9999637603759766
+ O O 0.9999871253967285
/ O O 0.9998973608016968
- O O 0.9999493360519409
1 O O 0.9999912977218628
. O O 0.9999954700469971
4 O O 0.9999902248382568
min O O 0.9999860525131226
after O O 0.9999195337295532
lindane B B 0.9989824891090393
administration O O 0.9998341798782349
. O O 0.999968409538269

The O O 0.9999769926071167
concentration O O 0.999705970287323
of O O 0.991479754447937
GABA B B 0.9959926009178162
was O O 0.9999313354492188
only O O 0.9999921321868896
slightly O O 0.9999903440475464
but O O 0.999987006187439
significantly O O 0.99998939037323
decreased O O 0.9999655485153198
in O O 0.9996547698974609
the O O 0.9998641014099121
colliculi O O 0.9917621612548828
without O O 0.9998588562011719
modifications O O 0.9999707937240601
in O O 0.9998223185539246
the O O 0.9999585151672363
other O O 0.9998774528503418
areas O O 0.9999288320541382
. O O 0.9999643564224243

The O O 0.9999771118164062
concentration O O 0.999414324760437
of O O 0.9972224235534668
dopamine B B 0.9995226860046387
was O O 0.9999517202377319
increased O O 0.9999009370803833
in O O 0.9997007846832275
the O O 0.9999253749847412
mesencephalon O O 0.9985373020172119
and O O 0.9998729228973389
that O O 0.9998171925544739
of O O 0.9993020296096802
its O O 0.9928043484687805
metabolite O O 0.9989804625511169
DOPAC B B 0.999434769153595
was O O 0.9999635219573975
also O O 0.99997878074646
increased O O 0.9998447895050049
in O O 0.999754011631012
the O O 0.9999324083328247
mesencephalon O O 0.9966390132904053
and O O 0.999777615070343
the O O 0.9998843669891357
striatum O O 0.9961974620819092
. O O 0.9999339580535889

Cholestatic O O 0.9981105327606201
presentation O O 0.9999525547027588
of O O 0.9994701743125916
yellow O B 0.6425624489784241
phosphorus B I 0.9932945370674133
poisoning O O 0.9129140973091125
. O O 0.9996762275695801

Yellow O O 0.9511345028877258
phosphorus B B 0.5928986668586731
, O O 0.9996945858001709
a O O 0.9991452693939209
component O O 0.9982815980911255
of O O 0.9932616353034973
certain O O 0.9981221556663513
pesticide O O 0.727222740650177
pastes O O 0.8550513982772827
and O O 0.9784106016159058
fireworks O O 0.7410748600959778
, O O 0.9992915391921997
is O O 0.9998490810394287
well O O 0.999853253364563
known O O 0.9999010562896729
to O O 0.9998685121536255
cause O O 0.9998706579208374
hepatotoxicity O O 0.9999263286590576
. O O 0.9999526739120483

Poisoning O O 0.9957733750343323
with O O 0.9979864358901978
yellow O B 0.8871467113494873
phosphorus B I 0.9725202918052673
classically O O 0.9991853833198547
manifests O O 0.9999649524688721
with O O 0.9999822378158569
acute O O 0.99983811378479
hepatitis O O 0.9996976852416992
leading O O 0.9999814033508301
to O O 0.9999904632568359
acute O O 0.999987006187439
liver O O 0.9999268054962158
failure O O 0.9999959468841553
which O O 0.9999874830245972
may O O 0.999990701675415
need O O 0.9999897480010986
liver O O 0.9994555115699768
transplantation O O 0.9999837875366211
. O O 0.9999876022338867

We O O 0.9999842643737793
present O O 0.9999945163726807
a O O 0.9999942779541016
case O O 0.9999963045120239
of O O 0.9999668598175049
yellow O B 0.830509603023529
phosphorus B I 0.9982536435127258
poisoning O O 0.9756495952606201
in O O 0.9999853372573853
which O O 0.9999727010726929
a O O 0.9999879598617554
patient O O 0.9999889135360718
presented O O 0.9999690055847168
with O O 0.999970555305481
florid O O 0.9997050166130066
clinical O O 0.9999964237213135
features O O 0.9999988079071045
of O O 0.999976396560669
cholestasis O O 0.962519645690918
highlighting O O 0.9999159574508667
the O O 0.9999926090240479
fact O O 0.9999921321868896
that O O 0.9999849796295166
cholestasis O O 0.9837930798530579
can O O 0.9999284744262695
rarely O O 0.9999798536300659
be O O 0.9999799728393555
a O O 0.9999630451202393
presenting O O 0.999984860420227
feature O O 0.9999936819076538
of O O 0.9999538660049438
yellow O B 0.9307233691215515
phosphorus B I 0.9944232106208801
hepatotoxicity O O 0.9990422129631042
. O O 0.9999749660491943

Vasovagal O O 0.9998995065689087
syncope O O 0.9999357461929321
and O O 0.9999535083770752
severe O O 0.9999818801879883
bradycardia O O 0.999984860420227
following O O 0.9998412132263184
intranasal O O 0.9999513626098633
dexmedetomidine B B 0.9990968704223633
for O O 0.9996378421783447
pediatric O O 0.9942230582237244
procedural O O 0.9987228512763977
sedation O O 0.9993101358413696
. O O 0.9999605417251587

We O O 0.9999608993530273
report O O 0.9999892711639404
syncope O O 0.9999958276748657
and O O 0.9999892711639404
bradycardia O O 0.999984622001648
in O O 0.9999891519546509
an O O 0.9999958276748657
11 O O 0.9999699592590332
- O O 0.9999890327453613
year O O 0.9999963045120239
- O O 0.9999947547912598
old O O 0.9999970197677612
girl O O 0.9999983310699463
following O O 0.999893307685852
administration O O 0.9999001026153564
of O O 0.9997779726982117
intranasal O O 0.9992558360099792
dexmedetomidine B B 0.9990058541297913
for O O 0.9989049434661865
sedation O O 0.9946735501289368
for O O 0.9999665021896362
a O O 0.999981164932251
voiding O O 0.99997878074646
cystourethrogram O O 0.9992809891700745
. O O 0.999972939491272

Following O O 0.9999691247940063
successful O O 0.9999711513519287
completion O O 0.9999656677246094
of O O 0.9998307228088379
VCUG O O 0.6103770136833191
and O O 0.9998407363891602
a O O 0.9999797344207764
60 O O 0.9999880790710449
- O O 0.9999895095825195
min O O 0.999970555305481
recovery O O 0.9999904632568359
period O O 0.9999858140945435
, O O 0.9999797344207764
the O O 0.9999945163726807
patient O O 0.9999934434890747
' O O 0.9999953508377075
s O O 0.9999960660934448
level O O 0.9999978542327881
of O O 0.9999927282333374
consciousness O O 0.999963641166687
and O O 0.9999818801879883
vital O O 0.9999886751174927
signs O O 0.9999847412109375
returned O O 0.9999847412109375
to O O 0.9999897480010986
presedation O O 0.993225634098053
levels O O 0.9999736547470093
. O O 0.9999810457229614

Upon O O 0.9999539852142334
leaving O O 0.9999717473983765
the O O 0.9999550580978394
sedation O O 0.9990172386169434
area O O 0.9998100399971008
, O O 0.9999703168869019
the O O 0.999994158744812
patient O O 0.9999890327453613
collapsed O O 0.9999648332595825
, O O 0.999976634979248
with O O 0.9999854564666748
no O O 0.9999798536300659
apparent O O 0.9999892711639404
inciting O O 0.9999867677688599
event O O 0.9999966621398926
. O O 0.9999747276306152

The O O 0.9999876022338867
patient O O 0.9999916553497314
quickly O O 0.9999878406524658
regained O O 0.9999949932098389
consciousness O O 0.9999973773956299
and O O 0.9999828338623047
no O O 0.9999881982803345
injury O O 0.9999963045120239
occurred O O 0.9999951124191284
. O O 0.9999749660491943

The O O 0.9999841451644897
primary O O 0.9999600648880005
abnormality O O 0.9999961853027344
found O O 0.9999884366989136
was O O 0.9999719858169556
persistent O O 0.9999697208404541
bradycardia O O 0.9999409914016724
, O O 0.9999552965164185
and O O 0.9999849796295166
she O O 0.999992847442627
was O O 0.9999895095825195
admitted O O 0.9999929666519165
to O O 0.9999959468841553
the O O 0.9999978542327881
hospital O O 0.999994158744812
for O O 0.9999854564666748
telemetric O O 0.9999725818634033
observation O O 0.9999960660934448
. O O 0.9999815225601196

The O O 0.9999825954437256
bradycardia O O 0.9999864101409912
lasted O O 0.999962329864502
~ O O 0.9999899864196777
2 O O 0.9999619722366333
h O O 0.9963511228561401
, O O 0.9999412298202515
and O O 0.9999696016311646
further O O 0.9999868869781494
cardiac O O 0.999976396560669
workup O O 0.9999921321868896
revealed O O 0.9999762773513794
no O O 0.9999878406524658
underlying O O 0.9999865293502808
abnormality O O 0.9999927282333374
. O O 0.9999692440032959

Unanticipated O O 0.9998169541358948
and O O 0.9999650716781616
previously O O 0.9999871253967285
unreported O O 0.9999865293502808
outcomes O O 0.9999881982803345
may O O 0.9999622106552124
be O O 0.9999903440475464
witnessed O O 0.9999958276748657
as O O 0.9999752044677734
we O O 0.9999731779098511
expand O O 0.9999368190765381
the O O 0.9999791383743286
use O O 0.9999657869338989
of O O 0.9999185800552368
certain O O 0.9997339844703674
sedatives O O 0.6001031994819641
to O O 0.9999330043792725
alternative O O 0.9999678134918213
routes O O 0.9999784231185913
of O O 0.9999608993530273
administration O O 0.9999459981918335
. O O 0.9999626874923706

Paradoxical O O 0.9998685121536255
severe O O 0.9999102354049683
agitation O O 0.9998613595962524
induced O O 0.9999359846115112
by O O 0.9998407363891602
add O O 0.8301093578338623
- O O 0.999467670917511
on O O 0.9959983825683594
high O O 0.9946411848068237
- O O 0.9999064207077026
doses O O 0.9948908090591431
quetiapine B B 0.9993463158607483
in O O 0.9995367527008057
schizo O O 0.9350353479385376
- O O 0.9993374943733215
affective O O 0.9955626726150513
disorder O O 0.9999802112579346
. O O 0.999964714050293

We O O 0.99998939037323
report O O 0.9999977350234985
the O O 0.9999978542327881
case O O 0.999995231628418
of O O 0.9999901056289673
a O O 0.9999911785125732
35 O O 0.9999960660934448
- O O 0.9999856948852539
year O O 0.9999947547912598
- O O 0.9999916553497314
old O O 0.9999932050704956
patient O O 0.999991774559021
suffering O O 0.9999539852142334
from O O 0.999962329864502
schizo O O 0.9931394457817078
- O O 0.9996752738952637
affective O O 0.9974890947341919
disorder O O 0.9999908208847046
since O O 0.9999817609786987
the O O 0.9999982118606567
age O O 0.999997615814209
of O O 0.9999961853027344
19 O O 0.9999960660934448
years O O 0.9999953508377075
, O O 0.9999833106994629
treated O O 0.9999531507492065
by O O 0.9999200105667114
a O O 0.9999431371688843
combination O O 0.9928523898124695
of O O 0.9995212554931641
first O O 0.9997560381889343
- O O 0.9998342990875244
generation O O 0.9926685094833374
antipsychotics O O 0.6820782423019409
, O O 0.9700007438659668
zuclopenthixol B B 0.9995318651199341
( O O 0.9964244961738586
100 O O 0.9942139983177185
mg O O 0.9996032118797302
/ O O 0.9995383024215698
day O O 0.9973663687705994
) O O 0.9997370839118958
and O O 0.9969011545181274
lithium B B 0.9996949434280396
( O O 0.9987767338752747
1200 O O 0.9968076944351196
mg O O 0.999687671661377
/ O O 0.9996858835220337
day O O 0.9964503049850464
) O O 0.9998985528945923
( O O 0.9999521970748901
serum O O 0.9989151954650879
lithium B B 0.999086856842041
= O O 0.9971044659614563
0 O O 0.9999641180038452
. O O 0.999995231628418
85 O O 0.9993516802787781
mEq O O 0.9999593496322632
/ O O 0.9999370574951172
l O O 0.9990023970603943
) O O 0.9999773502349854
. O O 0.9999731779098511

This O O 0.9999440908432007
patient O O 0.9999819993972778
had O O 0.9999321699142456
no O O 0.9998583793640137
associated O O 0.9999425411224365
personality O O 0.9995224475860596
disorder O O 0.999910831451416
( O O 0.9999451637268066
particularly O O 0.9999680519104004
no O O 0.9978572726249695
antisocial O O 0.9857949018478394
disorder O O 0.9997689127922058
) O O 0.9998817443847656
and O O 0.999930739402771
no O O 0.9995822310447693
substance O O 0.9891181588172913
abuse O O 0.9992401599884033
disorder O O 0.9999407529830933
. O O 0.999945878982544

Within O O 0.9999823570251465
the O O 0.9999973773956299
48 O O 0.9999949932098389
h O O 0.9999748468399048
following O O 0.9999843835830688
the O O 0.9999934434890747
gradual O O 0.9999842643737793
introduction O O 0.999976396560669
of O O 0.9992716908454895
quetiapine B B 0.9993207454681396
( O O 0.9997658133506775
up O O 0.9999794960021973
to O O 0.9999909400939941
600 O O 0.9998549222946167
mg O O 0.9999405145645142
/ O O 0.9998345375061035
day O O 0.9999710321426392
) O O 0.9999678134918213
, O O 0.9999803304672241
the O O 0.9999955892562866
patient O O 0.9999915361404419
presented O O 0.9999744892120361
severe O O 0.9999706745147705
agitation O O 0.9999696016311646
without O O 0.9999761581420898
an O O 0.9999698400497437
environmental O O 0.9971844553947449
explanation O O 0.9999899864196777
, O O 0.9999785423278809
contrasting O O 0.9999895095825195
with O O 0.9999953508377075
the O O 0.9999980926513672
absence O O 0.9999957084655762
of O O 0.9999945163726807
a O O 0.9999927282333374
history O O 0.9999903440475464
of O O 0.9999603033065796
aggressiveness O O 0.9981308579444885
or O O 0.9999542236328125
personality O O 0.9999183416366577
disorder O O 0.9999897480010986
. O O 0.99994957447052

The O O 0.9999715089797974
diagnoses O O 0.9999858140945435
of O O 0.999916672706604
manic O O 0.9998281002044678
shift O O 0.9999823570251465
and O O 0.9998157620429993
akathisia O O 0.9993031024932861
were O O 0.9999299049377441
dismissed O O 0.9997848868370056
. O O 0.9999454021453857

The O O 0.999852180480957
withdrawal O O 0.9999642372131348
and O O 0.999970555305481
the O O 0.9999955892562866
gradual O O 0.9999898672103882
reintroduction O O 0.999985933303833
of O O 0.9986082911491394
quetiapine B B 0.9979788661003113
2 O O 0.9995681643486023
weeks O O 0.9999972581863403
later O O 0.9999943971633911
, O O 0.9999856948852539
which O O 0.9999666213989258
led O O 0.9999938011169434
to O O 0.9999909400939941
another O O 0.9999929666519165
severe O O 0.999992847442627
agitation O O 0.9999639987945557
, O O 0.9999840259552002
enabled O O 0.9999879598617554
us O O 0.9999892711639404
to O O 0.99997878074646
attribute O O 0.9999662637710571
the O O 0.9999920129776001
agitation O O 0.9998565912246704
specifically O O 0.9999783039093018
to O O 0.9990377426147461
quetiapine B B 0.9985085129737854
. O O 0.9998568296432495

Antioxidant O O 0.7034059762954712
effects O O 0.9965813755989075
of O O 0.9976122379302979
bovine O B 0.9682535529136658
lactoferrin O I 0.9927830696105957
on O O 0.9964869022369385
dexamethasone B B 0.9996695518493652
- O O 0.9997127652168274
induced O O 0.9999346733093262
hypertension O O 0.9994595646858215
in O O 0.9999290704727173
rat O O 0.9997450709342957
. O O 0.9997979998588562

Dexamethasone B B 0.999264657497406
- O O 0.6861990690231323
( O O 0.8911097645759583
Dex B B 0.9964951872825623
- O O 0.9234460592269897
) O O 0.7227006554603577
induced O O 0.9998443126678467
hypertension O O 0.9998201727867126
is O O 0.9999126195907593
associated O O 0.9999831914901733
with O O 0.9999656677246094
enhanced O O 0.9998987913131714
oxidative O O 0.9543814063072205
stress O O 0.9994776844978333
. O O 0.9999698400497437

Lactoferrin O B 0.9957183003425598
( O O 0.9902262687683105
LF O O 0.7310934066772461
) O O 0.9970648884773254
is O O 0.9997172951698303
an O O 0.9790674448013306
iron B O 0.8445078730583191
- O O 0.9546904563903809
binding O O 0.9753163456916809
glycoprotein O O 0.5833295583724976
with O O 0.999474823474884
antihypertensive O O 0.7987754344940186
properties O O 0.9998918771743774
. O O 0.9997894167900085

In O O 0.9999793767929077
this O O 0.9999680519104004
study O O 0.9999788999557495
, O O 0.9999430179595947
we O O 0.999941349029541
investigated O O 0.9999662637710571
the O O 0.9999562501907349
effect O O 0.9999648332595825
of O O 0.9999396800994873
chronic O O 0.9996086955070496
administration O O 0.9997829794883728
of O O 0.9974440336227417
LF O B 0.9680938720703125
on O O 0.9990954399108887
oxidative O O 0.978107750415802
stress O O 0.9996024966239929
and O O 0.9999105930328369
hypertension O O 0.9992430210113525
upon O O 0.9997808337211609
Dex B B 0.999544084072113
administration O O 0.9998196959495544
. O O 0.9998946189880371

Male O O 0.999961256980896
Wistar O O 0.9997262358665466
rats O O 0.9999858140945435
were O O 0.9999860525131226
treated O O 0.9999855756759644
by O O 0.9992885589599609
Dex B B 0.9996044039726257
( O O 0.9959949254989624
30 O O 0.9999465942382812
u O O 0.9997702240943909
g O O 0.9998751878738403
/ O O 0.9999830722808838
kg O O 0.9999985694885254
/ O O 0.999961256980896
day O O 0.9999959468841553
subcutaneously O O 0.9999417066574097
) O O 0.9999103546142578
or O O 0.9991081357002258
saline O O 0.9992233514785767
for O O 0.9999582767486572
14 O O 0.9999911785125732
days O O 0.9999955892562866
. O O 0.9999881982803345

Oral O O 0.9976676106452942
bovine O B 0.9802323579788208
LF O O 0.861735463142395
( O O 0.9883803129196167
30 O O 0.9947742819786072
, O O 0.9886884093284607
100 O O 0.9725727438926697
, O O 0.9942430853843689
300 O O 0.9999200105667114
mg O O 0.9999792575836182
/ O O 0.9999536275863647
kg O O 0.9999945163726807
) O O 0.9999014139175415
was O O 0.9999659061431885
given O O 0.9999547004699707
from O O 0.9999724626541138
day O O 0.9999979734420776
8 O O 0.9999281167984009
to O O 0.9999958276748657
14 O O 0.9999977350234985
in O O 0.9999922513961792
a O O 0.9999873638153076
reversal O O 0.9999786615371704
study O O 0.9999949932098389
. O O 0.9999818801879883

In O O 0.9999567270278931
a O O 0.99993896484375
prevention O O 0.999931812286377
study O O 0.9999828338623047
, O O 0.9999680519104004
rats O O 0.9980113506317139
received O O 0.9999433755874634
4 O O 0.9995108842849731
days O O 0.9999617338180542
of O O 0.9997768998146057
LF O O 0.8485002517700195
treatment O O 0.9985758066177368
followed O O 0.9997308850288391
by O O 0.9993847608566284
Dex B B 0.9971035122871399
and O O 0.9983330368995667
continued O O 0.9998583793640137
during O O 0.9999692440032959
the O O 0.9999932050704956
test O O 0.9999880790710449
period O O 0.999993085861206
. O O 0.9999741315841675

Systolic O O 0.9998465776443481
blood O O 0.9997631907463074
pressure O O 0.9995866417884827
( O O 0.9998902082443237
SBP O O 0.9566688537597656
) O O 0.9999666213989258
was O O 0.9999854564666748
measured O O 0.9999963045120239
using O O 0.9999709129333496
tail O O 0.9885602593421936
- O O 0.9991063475608826
cuff O O 0.9981259703636169
method O O 0.9999841451644897
. O O 0.9999783039093018

Thymus O O 0.9361448884010315
weight O O 0.9939842820167542
was O O 0.9999431371688843
used O O 0.999962568283081
as O O 0.9999812841415405
a O O 0.999955415725708
marker O O 0.9999550580978394
of O O 0.9998862743377686
glucocorticoid O B 0.8804940581321716
activity O O 0.993273138999939
. O O 0.9999464750289917

Plasma O O 0.9888261556625366
hydrogen B B 0.9738967418670654
peroxide I I 0.9735909104347229
( O O 0.9870399832725525
H2O2 B B 0.9549546241760254
) O O 0.995571494102478
concentration O O 0.9996331930160522
and O O 0.9999289512634277
ferric O B 0.9062483310699463
reducing O O 0.7616848945617676
antioxidant O O 0.7209493517875671
power O O 0.6973901391029358
( O O 0.998881995677948
FRAP O O 0.4764234125614166
) O O 0.999924898147583
value O O 0.9996888637542725
were O O 0.9999421834945679
determined O O 0.9999618530273438
. O O 0.9999229907989502

Dexamethasone B B 0.999439537525177
significantly O O 0.9999285936355591
increased O O 0.9999228715896606
SBP O O 0.7357279062271118
and O O 0.9999097585678101
plasma O O 0.9358466863632202
H2O2 B B 0.8662401437759399
level O O 0.9941226840019226
and O O 0.9999748468399048
decreased O O 0.9999873638153076
thymus O O 0.9989882111549377
and O O 0.9999605417251587
body O O 0.9999920129776001
weights O O 0.9999854564666748
. O O 0.9999390840530396

LF O O 0.7198346853256226
lowered O O 0.9781147837638855
( O O 0.999491810798645
P O O 0.9976677298545837
< O O 0.9999514818191528
0 O O 0.9999603033065796
. O O 0.9999903440475464
01 O O 0.9999918937683105
) O O 0.9997654557228088
and O O 0.9998034834861755
dose O O 0.9979396462440491
dependently O O 0.9998729228973389
prevented O O 0.9998364448547363
( O O 0.999840497970581
P O O 0.9993913173675537
< O O 0.9999661445617676
0 O O 0.9999402761459351
. O O 0.9999908208847046
001 O O 0.999804675579071
) O O 0.9961956739425659
Dex B B 0.9994575381278992
- O O 0.9993690848350525
induced O O 0.9999387264251709
hypertension O O 0.9997357726097107
. O O 0.999964714050293

LF O B 0.8917016386985779
prevented O O 0.9979435801506042
body O O 0.9999661445617676
weight O O 0.9917749166488647
loss O O 0.9999837875366211
and O O 0.9998378753662109
significantly O O 0.9999452829360962
reduced O O 0.9999760389328003
the O O 0.9999665021896362
elevated O O 0.9998857975006104
plasma O O 0.997668445110321
H2O2 B O 0.8250130414962769
and O O 0.999795138835907
increased O O 0.9997853636741638
FRAP O O 0.6825934648513794
values O O 0.999924898147583
. O O 0.9998704195022583

Chronic O O 0.9993495345115662
administration O O 0.9998210072517395
of O O 0.9994581341743469
LF O B 0.9523158073425293
strongly O O 0.9996827840805054
reduced O O 0.9999645948410034
the O O 0.9999494552612305
blood O O 0.9993940591812134
pressure O O 0.9998599290847778
and O O 0.9999316930770874
production O O 0.9999275207519531
of O O 0.9888280630111694
ROS O O 0.7419787049293518
and O O 0.9999136924743652
improved O O 0.9998694658279419
antioxidant O O 0.49139806628227234
capacity O O 0.9993124008178711
in O O 0.9996228218078613
Dex B B 0.9994720816612244
- O O 0.9985419511795044
induced O O 0.9999336004257202
hypertension O O 0.9989006519317627
, O O 0.9999762773513794
suggesting O O 0.9999022483825684
the O O 0.9999654293060303
role O O 0.9999514818191528
of O O 0.999727189540863
inhibition O O 0.9982851147651672
of O O 0.9992109537124634
oxidative O O 0.9162403345108032
stress O O 0.9936898946762085
as O O 0.9999526739120483
another O O 0.9998679161071777
mechanism O O 0.9999462366104126
of O O 0.999836802482605
antihypertensive O O 0.6936365365982056
action O O 0.9997239708900452
of O O 0.9976025223731995
LF O B 0.9764567613601685
. O O 0.9998998641967773

The O O 0.9999567270278931
association O O 0.999984860420227
between O O 0.9998051524162292
tranexamic B B 0.9982584118843079
acid I I 0.9998297691345215
and O O 0.9990969896316528
convulsive O O 0.9994682669639587
seizures O O 0.9999895095825195
after O O 0.9999508857727051
cardiac O O 0.9999382495880127
surgery O O 0.9999938011169434
: O O 0.9999924898147583
a O O 0.9999896287918091
multivariate O O 0.9972911477088928
analysis O O 0.9999487400054932
in O O 0.9999743700027466
11 O O 0.999993085861206
529 O O 0.9999938011169434
patients O O 0.9999955892562866
. O O 0.9999843835830688

Because O O 0.9999951124191284
of O O 0.9999898672103882
a O O 0.9999943971633911
lack O O 0.9999969005584717
of O O 0.9999954700469971
contemporary O O 0.9999840259552002
data O O 0.999992847442627
regarding O O 0.9999254941940308
seizures O O 0.9998371601104736
after O O 0.9998620748519897
cardiac O O 0.9999825954437256
surgery O O 0.9999963045120239
, O O 0.9999830722808838
we O O 0.9999902248382568
undertook O O 0.9999953508377075
a O O 0.9999972581863403
retrospective O O 0.9999945163726807
analysis O O 0.999997615814209
of O O 0.9999899864196777
prospectively O O 0.9999933242797852
collected O O 0.9999954700469971
data O O 0.9999957084655762
from O O 0.9999881982803345
11 O O 0.9999839067459106
529 O O 0.9999898672103882
patients O O 0.9999947547912598
in O O 0.9999547004699707
whom O O 0.9999635219573975
cardiopulmonary O O 0.9999594688415527
bypass O O 0.9998170733451843
was O O 0.9999474287033081
used O O 0.9999620914459229
from O O 0.9999175071716309
January O O 0.9982831478118896
2004 O O 0.9922490119934082
to O O 0.9998229146003723
December O O 0.9989354014396667
2010 O O 0.9999101161956787
. O O 0.999977707862854

A O O 0.9999179840087891
convulsive O O 0.9989495873451233
seizure O O 0.9999902248382568
was O O 0.9999737739562988
defined O O 0.9999924898147583
as O O 0.9999920129776001
a O O 0.9999874830245972
transient O O 0.9999678134918213
episode O O 0.999981164932251
of O O 0.9999337196350098
disturbed O O 0.9860851764678955
brain O O 0.9999599456787109
function O O 0.9999901056289673
characterised O O 0.9999805688858032
by O O 0.9999738931655884
abnormal O O 0.9999617338180542
involuntary O O 0.9999244213104248
motor O O 0.9999814033508301
movements O O 0.9999955892562866
. O O 0.9999750852584839

Multivariate O O 0.9981498718261719
regression O O 0.9995601773262024
analysis O O 0.9999700784683228
was O O 0.9999716281890869
performed O O 0.9999855756759644
to O O 0.9999825954437256
identify O O 0.9999691247940063
independent O O 0.9997455477714539
predictors O O 0.9999263286590576
of O O 0.9999570846557617
postoperative O O 0.999907374382019
seizures O O 0.9999451637268066
. O O 0.9999752044677734

A O O 0.999946117401123
total O O 0.9999760389328003
of O O 0.9999860525131226
100 O O 0.9999657869338989
( O O 0.9999589920043945
0 O O 0.9999748468399048
. O O 0.9999762773513794
9 O O 0.9999936819076538
% O O 0.9999935626983643
) O O 0.9999146461486816
patients O O 0.9999936819076538
developed O O 0.9999849796295166
postoperative O O 0.9999629259109497
convulsive O O 0.9985232949256897
seizures O O 0.9999712705612183
. O O 0.9999641180038452

Generalised O O 0.9955714344978333
and O O 0.9991810917854309
focal O O 0.9997580647468567
seizures O O 0.9999567270278931
were O O 0.9999386072158813
identified O O 0.9999731779098511
in O O 0.9998623132705688
68 O O 0.9999039173126221
and O O 0.9999560117721558
32 O O 0.9999758005142212
patients O O 0.9999929666519165
, O O 0.9999831914901733
respectively O O 0.9999639987945557
. O O 0.9999614953994751

The O O 0.999977707862854
median O O 0.9999762773513794
( O O 0.9998231530189514
IQR O O 0.995039165019989
[ O O 0.9989431500434875
range O O 0.9982878565788269
] O O 0.9999707937240601
) O O 0.9999748468399048
time O O 0.9999922513961792
after O O 0.9999872446060181
surgery O O 0.9999960660934448
when O O 0.9999938011169434
the O O 0.9999951124191284
seizure O O 0.9999902248382568
occurred O O 0.9999983310699463
was O O 0.9999816417694092
7 O O 0.9999970197677612
( O O 0.9999494552612305
6 O O 0.9999864101409912
- O O 0.99962317943573
12 O O 0.9999829530715942
[ O O 0.9997174143791199
1 O O 0.9998086094856262
- O O 0.9969879984855652
216 O O 0.9788114428520203
] O O 0.9998425245285034
) O O 0.999937891960144
h O O 0.9999401569366455
and O O 0.9999618530273438
8 O O 0.9999681711196899
( O O 0.9999572038650513
6 O O 0.9999414682388306
- O O 0.9996340274810791
11 O O 0.9999783039093018
[ O O 0.9997137188911438
4 O O 0.9987215399742126
- O O 0.9964432120323181
18 O O 0.9874892830848694
] O O 0.9999384880065918
) O O 0.9999716281890869
h O O 0.9998736381530762
, O O 0.9999842643737793
respectively O O 0.9999815225601196
. O O 0.9999780654907227

Epileptiform O O 0.9903772473335266
findings O O 0.9999940395355225
on O O 0.999990701675415
electroencephalography O O 0.9999637603759766
were O O 0.9999681711196899
seen O O 0.9999886751174927
in O O 0.9999333620071411
19 O O 0.9999213218688965
patients O O 0.9999924898147583
. O O 0.9999711513519287

Independent O O 0.9989990592002869
predictors O O 0.9999555349349976
of O O 0.9999746084213257
postoperative O O 0.9999438524246216
seizures O O 0.9999295473098755
included O O 0.9999635219573975
age O O 0.9999669790267944
, O O 0.9999823570251465
female O O 0.9999817609786987
sex O O 0.9999946355819702
, O O 0.9999639987945557
redo O O 0.9999935626983643
cardiac O O 0.9999747276306152
surgery O O 0.9999926090240479
, O O 0.9998106360435486
calcification O O 0.9729090929031372
of O O 0.9997730851173401
ascending O O 0.9992327690124512
aorta O O 0.9951812624931335
, O O 0.9999531507492065
congestive O O 0.9769669771194458
heart O O 0.9999773502349854
failure O O 0.9999762773513794
, O O 0.9997188448905945
deep O O 0.9987301230430603
hypothermic O O 0.9960148334503174
circulatory O O 0.9986201524734497
arrest O O 0.9999849796295166
, O O 0.9994319081306458
duration O O 0.9998605251312256
of O O 0.9998626708984375
aortic O O 0.5848674178123474
cross O O 0.9938621520996094
- O O 0.9981480836868286
clamp O O 0.9884690642356873
and O O 0.9992596507072449
tranexamic B B 0.9891078472137451
acid I I 0.9994853734970093
. O O 0.9998533725738525

When O O 0.9999791383743286
tested O O 0.9999872446060181
in O O 0.9999802112579346
a O O 0.9999784231185913
multivariate O O 0.9991130232810974
regression O O 0.9999685287475586
analysis O O 0.9999711513519287
, O O 0.9997751116752625
tranexamic B B 0.9984191656112671
acid I I 0.999110758304596
was O O 0.999738872051239
a O O 0.9999070167541504
strong O O 0.9998939037322998
independent O O 0.9999552965164185
predictor O O 0.9999603033065796
of O O 0.9999809265136719
seizures O O 0.9999898672103882
( O O 0.9999622106552124
OR O O 0.999727189540863
14 O O 0.9999631643295288
. O O 0.9999881982803345
3 O O 0.9999616146087646
, O O 0.9999494552612305
95 O O 0.9999731779098511
% O O 0.9998986721038818
CI O O 0.9954466223716736
5 O O 0.9999531507492065
. O O 0.9999797344207764
5 O O 0.9999771118164062
- O O 0.9973684549331665
36 O O 0.999993085861206
. O O 0.9999932050704956
7 O O 0.9999932050704956
; O O 0.9999780654907227
p O O 0.9996044039726257
< O O 0.9999747276306152
0 O O 0.9999903440475464
. O O 0.9999961853027344
001 O O 0.9998724460601807
) O O 0.9999769926071167
. O O 0.9999768733978271

Patients O O 0.9999808073043823
with O O 0.9999676942825317
convulsive O O 0.9856117963790894
seizures O O 0.9999009370803833
had O O 0.9999576807022095
2 O O 0.9999668598175049
. O O 0.9999924898147583
5 O O 0.999971866607666
times O O 0.999992847442627
higher O O 0.9999849796295166
in O O 0.999911904335022
- O O 0.9999758005142212
hospital O O 0.9999953508377075
mortality O O 0.9999961853027344
rates O O 0.9999901056289673
and O O 0.9999902248382568
twice O O 0.9999951124191284
the O O 0.9999977350234985
length O O 0.9999933242797852
of O O 0.9999898672103882
hospital O O 0.9999865293502808
stay O O 0.9999945163726807
compared O O 0.9999834299087524
with O O 0.999990701675415
patients O O 0.9999932050704956
without O O 0.9999743700027466
convulsive O O 0.9977814555168152
seizures O O 0.9999710321426392
. O O 0.9999641180038452

Mean O O 0.9999496936798096
( O O 0.9998501539230347
IQR O O 0.9966931343078613
[ O O 0.9998723268508911
range O O 0.9997518658638
] O O 0.9999880790710449
) O O 0.9999808073043823
length O O 0.9999934434890747
of O O 0.9999858140945435
stay O O 0.9999871253967285
in O O 0.9999788999557495
the O O 0.9999910593032837
intensive O O 0.9999758005142212
care O O 0.9999971389770508
unit O O 0.9999979734420776
was O O 0.9999839067459106
115 O O 0.999996542930603
( O O 0.9999608993530273
49 O O 0.9999947547912598
- O O 0.9997838139533997
228 O O 0.9997816681861877
[ O O 0.9997836947441101
32 O O 0.9999555349349976
- O O 0.9988532066345215
481 O O 0.9967606663703918
] O O 0.9999545812606812
) O O 0.9999444484710693
h O O 0.9995958209037781
in O O 0.9999667406082153
patients O O 0.9999923706054688
with O O 0.9999632835388184
convulsive O O 0.9985613226890564
seizures O O 0.9999721050262451
compared O O 0.999970555305481
with O O 0.9999902248382568
26 O O 0.9999818801879883
( O O 0.9999382495880127
22 O O 0.9999904632568359
- O O 0.9997857213020325
69 O O 0.9998478889465332
[ O O 0.9998214840888977
14 O O 0.9999915361404419
- O O 0.9994522929191589
1080 O O 0.9969022870063782
] O O 0.999975323677063
) O O 0.9999730587005615
h O O 0.9993953704833984
in O O 0.9999353885650635
patients O O 0.9999897480010986
without O O 0.999985933303833
seizures O O 0.9999685287475586
( O O 0.999961256980896
p O O 0.9998255372047424
< O O 0.9999912977218628
0 O O 0.9999951124191284
. O O 0.9999978542327881
001 O O 0.9998867511749268
) O O 0.9999759197235107
. O O 0.9999831914901733

Convulsive O O 0.9886950850486755
seizures O O 0.999846339225769
are O O 0.9999547004699707
a O O 0.9999680519104004
serious O O 0.9999862909317017
postoperative O O 0.9999494552612305
complication O O 0.999985933303833
after O O 0.9999371767044067
cardiac O O 0.9998840093612671
surgery O O 0.9999918937683105
. O O 0.9999657869338989

As O O 0.9999721050262451
tranexamic B B 0.9964908957481384
acid I I 0.9992788434028625
is O O 0.998961329460144
the O O 0.99992835521698
only O O 0.9998062252998352
modifiable O O 0.9998608827590942
factor O O 0.9999804496765137
, O O 0.9999407529830933
its O O 0.9998371601104736
administration O O 0.9999221563339233
, O O 0.9999938011169434
particularly O O 0.9999880790710449
in O O 0.9999752044677734
doses O O 0.9999674558639526
exceeding O O 0.9999827146530151
80 O O 0.9996612071990967
mg O O 0.9999743700027466
. O O 0.9999734163284302
kg O O 0.9999933242797852
( O O 0.9994440674781799
- O O 0.9923312664031982
1 O O 0.9826247096061707
) O O 0.9998339414596558
, O O 0.9999896287918091
should O O 0.9999773502349854
be O O 0.9999963045120239
weighed O O 0.9999902248382568
against O O 0.9999575614929199
the O O 0.999993085861206
risk O O 0.9999971389770508
of O O 0.999985933303833
postoperative O O 0.9999353885650635
seizures O O 0.9999891519546509
. O O 0.9999822378158569

Dysfunctional O O 0.9998511075973511
overnight O O 0.9953306913375854
memory O O 0.9998961687088013
consolidation O O 0.9999523162841797
in O O 0.9997797608375549
ecstasy B B 0.9183948040008545
users O O 0.9912636280059814
. O O 0.9999390840530396

Sleep O O 0.9895305633544922
plays O O 0.99985671043396
an O O 0.9999295473098755
important O O 0.999786913394928
role O O 0.999901533126831
in O O 0.9999021291732788
the O O 0.999953031539917
consolidation O O 0.9999537467956543
and O O 0.9999175071716309
integration O O 0.9999784231185913
of O O 0.999915361404419
memory O O 0.9999587535858154
in O O 0.9998733997344971
a O O 0.9999346733093262
process O O 0.9999620914459229
called O O 0.9999791383743286
overnight O O 0.9971289038658142
memory O O 0.999937891960144
consolidation O O 0.99997878074646
. O O 0.9999841451644897

Previous O O 0.9999258518218994
studies O O 0.999971866607666
indicate O O 0.9999505281448364
that O O 0.9998961687088013
ecstasy B B 0.939937949180603
users O O 0.97359699010849
have O O 0.9999147653579712
marked O O 0.9999645948410034
and O O 0.9999730587005615
persistent O O 0.9999802112579346
neurocognitive O O 0.9999843835830688
and O O 0.9999490976333618
sleep O O 0.9915125966072083
- O O 0.999971866607666
related O O 0.9999892711639404
impairments O O 0.999997615814209
. O O 0.9999674558639526

We O O 0.9999740123748779
extend O O 0.999995231628418
past O O 0.9999905824661255
research O O 0.9999973773956299
by O O 0.9999957084655762
examining O O 0.999967098236084
overnight O O 0.9993089437484741
memory O O 0.9999797344207764
consolidation O O 0.9999904632568359
among O O 0.9999279975891113
regular O O 0.9686388373374939
ecstasy B B 0.931147575378418
users O O 0.9994648098945618
( O O 0.999971866607666
n O O 0.9998635053634644
= O O 0.9999544620513916
12 O O 0.999991774559021
) O O 0.9999315738677979
and O O 0.9999150037765503
drug O O 0.9948558807373047
naive O O 0.9998756647109985
healthy O O 0.999958872795105
controls O O 0.9999949932098389
( O O 0.9999768733978271
n O O 0.9999657869338989
= O O 0.9999788999557495
26 O O 0.9999860525131226
) O O 0.9999698400497437
. O O 0.9999847412109375

Memory O O 0.999825656414032
recall O O 0.9999934434890747
of O O 0.9999663829803467
word O O 0.999969482421875
pairs O O 0.9997263550758362
was O O 0.999964714050293
evaluated O O 0.9999792575836182
before O O 0.9998308420181274
and O O 0.9999721050262451
after O O 0.9999403953552246
a O O 0.9999849796295166
period O O 0.9999607801437378
of O O 0.9999688863754272
sleep O O 0.9997203946113586
, O O 0.9999721050262451
with O O 0.9999436140060425
and O O 0.9999796152114868
without O O 0.9999736547470093
interference O O 0.999976634979248
prior O O 0.9999973773956299
to O O 0.9999973773956299
testing O O 0.9999970197677612
. O O 0.9999749660491943

In O O 0.9999552965164185
addition O O 0.9999717473983765
, O O 0.9999741315841675
we O O 0.999876856803894
assessed O O 0.9999592304229736
neurocognitive O O 0.9999703168869019
performances O O 0.9999850988388062
across O O 0.9997027516365051
tasks O O 0.9998927116394043
of O O 0.9999297857284546
learning O O 0.9999725818634033
, O O 0.9999250173568726
memory O O 0.999971866607666
and O O 0.9999208450317383
executive O O 0.9988319277763367
functioning O O 0.999992847442627
. O O 0.9999748468399048

Ecstasy B O 0.7527092099189758
users O O 0.998018741607666
demonstrated O O 0.9998132586479187
impaired O O 0.9998698234558105
overnight O O 0.9881182312965393
memory O O 0.9999682903289795
consolidation O O 0.9999732971191406
, O O 0.9999808073043823
a O O 0.9999845027923584
finding O O 0.999995231628418
that O O 0.9999809265136719
was O O 0.9999687671661377
more O O 0.9999761581420898
pronounced O O 0.9999942779541016
following O O 0.9999064207077026
associative O O 0.9994402527809143
interference O O 0.9999529123306274
. O O 0.9999692440032959

Additionally O O 0.9999314546585083
, O O 0.9998257756233215
ecstasy B B 0.8945446014404297
users O O 0.9973841309547424
demonstrated O O 0.9998934268951416
impairments O O 0.9999796152114868
on O O 0.9999220371246338
tasks O O 0.9999327659606934
recruiting O O 0.9946263432502747
frontostriatal O O 0.9998906850814819
and O O 0.99945467710495
hippocampal O O 0.9961121678352356
neural O O 0.9998947381973267
circuitry O O 0.9999053478240967
, O O 0.9999611377716064
in O O 0.9999293088912964
the O O 0.9999321699142456
domains O O 0.9999086856842041
of O O 0.9997962117195129
proactive O O 0.9892149567604065
interference O O 0.9988460540771484
memory O O 0.9999330043792725
, O O 0.9998231530189514
long O O 0.9983267188072205
- O O 0.9999717473983765
term O O 0.9999710321426392
memory O O 0.9999736547470093
, O O 0.9998094439506531
encoding O O 0.9999480247497559
, O O 0.9998883008956909
working O O 0.9998255372047424
memory O O 0.9999911785125732
and O O 0.9998934268951416
complex O O 0.9998492002487183
planning O O 0.9999898672103882
. O O 0.999954342842102

We O O 0.999971866607666
suggest O O 0.9999679327011108
that O O 0.9999122619628906
ecstasy B B 0.9586545825004578
- O O 0.9989957213401794
associated O O 0.9997578263282776
dysfunction O O 0.9999669790267944
in O O 0.9997864365577698
fronto O O 0.999985933303833
- O O 0.9998701810836792
temporal O O 0.9998824596405029
circuitry O O 0.9998249411582947
may O O 0.9999114274978638
underlie O O 0.9999700784683228
overnight O O 0.9990931749343872
consolidation O O 0.9992849230766296
memory O O 0.9999254941940308
impairments O O 0.9999955892562866
in O O 0.9998571872711182
regular O O 0.9888577461242676
ecstasy B B 0.9361845850944519
users O O 0.9994515776634216
. O O 0.9999409914016724

Normoammonemic O O 0.9846433401107788
encephalopathy O O 0.9999450445175171
: O O 0.9999300241470337
solely O O 0.982819139957428
valproate B B 0.9992761015892029
induced O O 0.9996931552886963
or O O 0.9998875856399536
multiple O O 0.9898779392242432
mechanisms O O 0.9998289346694946
? O O 0.9998857975006104

A O O 0.9999841451644897
77 O O 0.9999940395355225
- O O 0.9999887943267822
year O O 0.9999974966049194
- O O 0.9999949932098389
old O O 0.999996542930603
woman O O 0.999997615814209
presented O O 0.999970555305481
with O O 0.9999814033508301
subacute O O 0.9999556541442871
onset O O 0.9999938011169434
progressive O O 0.9999958276748657
confusion O O 0.9999938011169434
, O O 0.9999736547470093
aggression O O 0.999510645866394
, O O 0.9999812841415405
auditory O O 0.9999873638153076
hallucinations O O 0.9999974966049194
and O O 0.9999263286590576
delusions O O 0.9999673366546631
. O O 0.9999771118164062

In O O 0.9999799728393555
the O O 0.9999960660934448
preceding O O 0.9999971389770508
months O O 0.9999978542327881
, O O 0.9999898672103882
the O O 0.9999946355819702
patient O O 0.9999922513961792
had O O 0.9999934434890747
a O O 0.999994158744812
number O O 0.9999982118606567
of O O 0.9999881982803345
admissions O O 0.9999908208847046
with O O 0.999988317489624
transient O O 0.9999948740005493
unilateral O O 0.999995231628418
hemiparesis O O 0.9999884366989136
with O O 0.9999818801879883
facial O O 0.9999938011169434
droop O O 0.9999891519546509
, O O 0.9999663829803467
and O O 0.9999761581420898
had O O 0.9999915361404419
been O O 0.9999933242797852
started O O 0.9999703168869019
on O O 0.996800422668457
valproate B B 0.9994184970855713
for O O 0.9998076558113098
presumed O O 0.999961256980896
hemiplegic O O 0.9995009899139404
migraine O O 0.9999971389770508
. O O 0.9999690055847168

Valproate B B 0.9990542531013489
was O O 0.9998100399971008
withdrawn O O 0.9997015595436096
soon O O 0.999976396560669
after O O 0.9999957084655762
admission O O 0.9999935626983643
and O O 0.9999793767929077
her O O 0.9999876022338867
cognitive O O 0.9999926090240479
abilities O O 0.999997615814209
have O O 0.9999953508377075
gradually O O 0.9999958276748657
improved O O 0.9999954700469971
over O O 0.9999948740005493
3 O O 0.9999353885650635
months O O 0.9999988079071045
of O O 0.9999947547912598
follow O O 0.9999908208847046
- O O 0.999992847442627
up O O 0.9999974966049194
. O O 0.9999849796295166

Valproate B B 0.9985645413398743
levels O O 0.9994660019874573
taken O O 0.9999775886535645
prior O O 0.9999971389770508
to O O 0.9999922513961792
withdrawal O O 0.999086856842041
were O O 0.9999462366104126
subtherapeutic O O 0.9999377727508545
and O O 0.9999737739562988
the O O 0.9999936819076538
patient O O 0.9999918937683105
was O O 0.9999843835830688
normoammonaemic O O 0.9999263286590576
. O O 0.9999719858169556

EEG O O 0.9778644442558289
undertaken O O 0.9998389482498169
during O O 0.9999055862426758
inpatient O O 0.9999822378158569
stay O O 0.9999784231185913
showed O O 0.9999381303787231
changes O O 0.9999959468841553
consistent O O 0.9999946355819702
with O O 0.9999779462814331
encephalopathy O O 0.9995978474617004
, O O 0.9999260902404785
and O O 0.9999403953552246
low O O 0.9984599351882935
titre O O 0.9711703062057495
N B B 0.7898752093315125
- I I 0.9057841897010803
methyl I I 0.9982193112373352
- I I 0.9005323052406311
D I I 0.9752143025398254
- I I 0.9705610871315002
aspartate I I 0.9996956586837769
( O O 0.9554545283317566
NMDA B B 0.9989575147628784
) O O 0.7642735838890076
receptor O O 0.9836181998252869
antibodies O O 0.9998779296875
were O O 0.9999679327011108
present O O 0.9999719858169556
in O O 0.9999642372131348
this O O 0.999980092048645
patient O O 0.9999856948852539
. O O 0.9999786615371704

The O O 0.999974250793457
possible O O 0.9999425411224365
aetiologies O O 0.999982476234436
of O O 0.9999321699142456
valproate B B 0.9997637867927551
- O O 0.9993531107902527
induced O O 0.99988853931427
encephalopathy O O 0.9999628067016602
and O O 0.9997953772544861
NMDA B B 0.999737560749054
receptor O O 0.6296498775482178
- O O 0.9978262782096863
associated O O 0.9998623132705688
encephalitis O O 0.9997556805610657
present O O 0.9999852180480957
a O O 0.9999866485595703
diagnostic O O 0.999996542930603
dilemma O O 0.9999963045120239
. O O 0.999984622001648

We O O 0.9999085664749146
present O O 0.9999567270278931
a O O 0.9999045133590698
putative O O 0.9998352527618408
combinatorial O O 0.995014488697052
hypothesis O O 0.9997853636741638
to O O 0.9999562501907349
explain O O 0.9999725818634033
this O O 0.9999769926071167
patient O O 0.999988317489624
' O O 0.9999911785125732
s O O 0.9999940395355225
symptoms O O 0.9999963045120239
. O O 0.9999665021896362

Cerebellar O O 0.9972277283668518
and O O 0.9997237324714661
oculomotor O O 0.9994301199913025
dysfunction O O 0.9999755620956421
induced O O 0.9999608993530273
by O O 0.9999498128890991
rapid O O 0.9999524354934692
infusion O O 0.9999761581420898
of O O 0.9811068773269653
pethidine B B 0.9998877048492432
. O O 0.9999116659164429

Pethidine B B 0.99952232837677
is O O 0.9968531727790833
an O O 0.9839329719543457
opioid O B 0.8847669363021851
that O O 0.9929203391075134
gains O O 0.9998345375061035
its O O 0.9999053478240967
popularity O O 0.9997829794883728
for O O 0.9998618364334106
the O O 0.9999134540557861
effective O O 0.9997699856758118
pain O O 0.9999158382415771
control O O 0.9999566078186035
through O O 0.9998514652252197
acting O O 0.9993890523910522
on O O 0.9983505010604858
the O O 0.9992871880531311
opioid O O 0.5373804569244385
- O O 0.9684434533119202
receptors O O 0.9989175796508789
. O O 0.9998658895492554

However O O 0.9998800754547119
, O O 0.9998706579208374
rapid O O 0.9998711347579956
pain O O 0.9997815489768982
relief O O 0.9996180534362793
sometimes O O 0.9999666213989258
brings O O 0.9999812841415405
about O O 0.9999823570251465
unfavourable O O 0.9999387264251709
side O O 0.9999603033065796
effects O O 0.9999922513961792
that O O 0.9999555349349976
largely O O 0.9999507665634155
limit O O 0.9999915361404419
its O O 0.9999834299087524
clinical O O 0.9999926090240479
utility O O 0.9999970197677612
. O O 0.9999775886535645

Common O O 0.9985230565071106
side O O 0.9998366832733154
effects O O 0.9999486207962036
include O O 0.999935507774353
nausea O O 0.9998749494552612
, O O 0.9999463558197021
vomiting O O 0.9998875856399536
and O O 0.999836802482605
hypotension O O 0.9998722076416016
. O O 0.9998270869255066

In O O 0.9997106194496155
patients O O 0.9999840259552002
with O O 0.9999780654907227
impaired O O 0.9999791383743286
renal O O 0.9998763799667358
and O O 0.9999194145202637
liver O O 0.9974222183227539
function O O 0.9999872446060181
, O O 0.9999316930770874
and O O 0.9999651908874512
those O O 0.9999864101409912
who O O 0.9999871253967285
need O O 0.999972939491272
long O O 0.9999551773071289
- O O 0.9999904632568359
term O O 0.9999841451644897
pain O O 0.9998351335525513
control O O 0.9999549388885498
, O O 0.999600350856781
pethidine B B 0.9997708201408386
may O O 0.9999021291732788
cause O O 0.9998252987861633
excitatory O O 0.9974610805511475
central O O 0.9902750253677368
nervous O O 0.9999748468399048
system O O 0.9998763799667358
( O O 0.9990744590759277
CNS O O 0.899756908416748
) O O 0.999850869178772
effects O O 0.9999183416366577
through O O 0.9997406601905823
its O O 0.9997130036354065
neurotoxic O O 0.9999264478683472
metabolite O O 0.9994664788246155
, O O 0.9993492960929871
norpethidine B B 0.9975513815879822
, O O 0.9999127388000488
resulting O O 0.99997878074646
in O O 0.9999639987945557
irritability O O 0.9999724626541138
and O O 0.9999496936798096
seizure O O 0.9999849796295166
attack O O 0.9999966621398926
. O O 0.9999669790267944

On O O 0.9999626874923706
the O O 0.9999861717224121
contrary O O 0.9999740123748779
, O O 0.9999752044677734
though O O 0.9999954700469971
not O O 0.9999933242797852
clinically O O 0.9999939203262329
apparent O O 0.9999969005584717
, O O 0.9996500015258789
pethidine B B 0.999925971031189
potentially O O 0.9999014139175415
causes O O 0.9998390674591064
inhibitory O O 0.9860138893127441
impacts O O 0.9998241066932678
on O O 0.999539852142334
the O O 0.9989402890205383
CNS O O 0.730360746383667
and O O 0.9999474287033081
impairs O O 0.9999772310256958
normal O O 0.999923825263977
cerebellar O O 0.9997335076332092
and O O 0.9995608925819397
oculomotor O O 0.9994070529937744
function O O 0.9999792575836182
in O O 0.9999487400054932
the O O 0.9999723434448242
short O O 0.9999547004699707
term O O 0.9999908208847046
. O O 0.999969482421875

In O O 0.9999885559082031
this O O 0.9999878406524658
case O O 0.9999750852584839
report O O 0.9999967813491821
, O O 0.9999432563781738
we O O 0.9998892545700073
highlight O O 0.9994082450866699
opioid O B 0.991890549659729
' O O 0.9997490048408508
s O O 0.9992449283599854
inhibitory O O 0.9328145384788513
side O O 0.9997850060462952
effects O O 0.9999349117279053
on O O 0.9997534155845642
the O O 0.9999637603759766
cerebellar O O 0.9998379945755005
structure O O 0.9999908208847046
that O O 0.9998863935470581
causes O O 0.9999104738235474
dysmetria O O 0.9999986886978149
, O O 0.9999651908874512
dysarthria O O 0.9999978542327881
, O O 0.9999816417694092
reduced O O 0.9999904632568359
smooth O O 0.9999626874923706
pursuit O O 0.9999935626983643
gain O O 0.9999855756759644
and O O 0.9999626874923706
decreased O O 0.9999840259552002
saccadic O O 0.999996542930603
velocity O O 0.9999974966049194
. O O 0.9999605417251587

Baboon O O 0.9975408315658569
syndrome O O 0.9999761581420898
induced O O 0.99997878074646
by O O 0.9995386600494385
ketoconazole B B 0.9989810585975647
. O O 0.9997350573539734

A O O 0.9999680519104004
27 O O 0.9999924898147583
- O O 0.9999864101409912
year O O 0.9999963045120239
- O O 0.9999934434890747
old O O 0.9999942779541016
male O O 0.9999908208847046
patient O O 0.9999552965164185
presented O O 0.9999746084213257
with O O 0.9999901056289673
a O O 0.9999921321868896
maculopapular O O 0.9999890327453613
eruption O O 0.9999929666519165
on O O 0.9999681711196899
the O O 0.9999716281890869
flexural O O 0.9853604435920715
areas O O 0.9999675750732422
and O O 0.9999580383300781
buttocks O O 0.9999672174453735
after O O 0.9998825788497925
using O O 0.9995511174201965
oral O O 0.9787036776542664
ketoconazole B B 0.9993065595626831
. O O 0.999929666519165

The O O 0.9999910593032837
patient O O 0.9999902248382568
was O O 0.9999756813049316
diagnosed O O 0.9999959468841553
with O O 0.9999791383743286
drug O O 0.9941871166229248
- O O 0.9999157190322876
induced O O 0.999948263168335
baboon O O 0.9999039173126221
syndrome O O 0.9999923706054688
based O O 0.9999959468841553
on O O 0.9999977350234985
his O O 0.9999942779541016
history O O 0.9999959468841553
, O O 0.9999916553497314
which O O 0.999991774559021
included O O 0.9999855756759644
prior O O 0.9999072551727295
sensitivity O O 0.9999938011169434
to O O 0.9995854496955872
topical O O 0.9998921155929565
ketoconazole B B 0.9987809062004089
, O O 0.9998966455459595
a O O 0.9999877214431763
physical O O 0.999984860420227
examination O O 0.9999980926513672
, O O 0.9999511241912842
and O O 0.9999860525131226
histopathological O O 0.9999839067459106
findings O O 0.9999966621398926
. O O 0.9999805688858032

Baboon O O 0.9713578820228577
syndrome O O 0.999958872795105
is O O 0.9999724626541138
a O O 0.9999849796295166
drug O O 0.9973209500312805
- O O 0.9994376301765442
or O O 0.9801692366600037
contact O O 0.5730696320533752
allergen O O 0.4446406960487366
- O O 0.9995423555374146
related O O 0.9999147653579712
maculopapular O O 0.9999873638153076
eruption O O 0.9999934434890747
that O O 0.9999681711196899
typically O O 0.9999537467956543
involves O O 0.9999637603759766
the O O 0.9999434947967529
flexural O O 0.9938517808914185
and O O 0.99972003698349
gluteal O O 0.9967832565307617
areas O O 0.9999353885650635
. O O 0.9999644756317139

To O O 0.9999935626983643
the O O 0.9999967813491821
best O O 0.9999963045120239
of O O 0.999988317489624
our O O 0.9999886751174927
knowledge O O 0.9999933242797852
, O O 0.9999819993972778
this O O 0.9999910593032837
is O O 0.9999942779541016
the O O 0.9999946355819702
first O O 0.9999961853027344
reported O O 0.9999953508377075
case O O 0.9999954700469971
of O O 0.9999430179595947
ketoconazole B B 0.9995487332344055
- O O 0.9993414282798767
induced O O 0.999932050704956
baboon O O 0.999891996383667
syndrome O O 0.999983549118042
in O O 0.9999598264694214
the O O 0.9999856948852539
English O O 0.9995589852333069
literature O O 0.9999921321868896
. O O 0.9999791383743286

A O O 0.9999699592590332
Case O O 0.9999971389770508
of O O 0.999988317489624
Sudden O O 0.999992847442627
Cardiac O O 0.999994158744812
Death O O 0.999997615814209
due O O 0.9999865293502808
to O O 0.9993568062782288
Pilsicainide B B 0.9992455244064331
- O O 0.9978049397468567
Induced O O 0.9998972415924072
Torsades O O 0.9998449087142944
de O O 0.9999198913574219
Pointes O O 0.9996567964553833
. O O 0.9999618530273438

An O O 0.9999749660491943
84 O O 0.9997320771217346
- O O 0.9999818801879883
year O O 0.9999959468841553
- O O 0.9999908208847046
old O O 0.9999880790710449
male O O 0.9999958276748657
received O O 0.9995579123497009
oral O O 0.9175035357475281
pilsicainide B B 0.9995672106742859
, O O 0.9994862079620361
a O O 0.9931687116622925
pure O O 0.7656812071800232
sodium B B 0.9460737705230713
channel O O 0.672347366809845
blocker O O 0.5824770927429199
with O O 0.9998948574066162
slow O O 0.9998894929885864
recovery O O 0.999961256980896
kinetics O O 0.999948263168335
, O O 0.9999744892120361
to O O 0.9999202489852905
convert O O 0.9999804496765137
his O O 0.9999912977218628
paroxysmal O O 0.9999784231185913
atrial O O 0.9941456317901611
fibrillation O O 0.9999673366546631
to O O 0.9999794960021973
a O O 0.9999842643737793
sinus O O 0.9999879598617554
rhythm O O 0.9999891519546509
; O O 0.9999892711639404
the O O 0.9999961853027344
patient O O 0.9999938011169434
developed O O 0.9999977350234985
sudden O O 0.9999961853027344
cardiac O O 0.9999947547912598
death O O 0.9999983310699463
two O O 0.999997615814209
days O O 0.999998927116394
later O O 0.9999978542327881
. O O 0.9999829530715942

The O O 0.9999885559082031
Holter O O 0.9987120628356934
electrocardiogram O O 0.9999493360519409
, O O 0.9999834299087524
which O O 0.9999825954437256
was O O 0.9999716281890869
worn O O 0.9999951124191284
by O O 0.9999779462814331
chance O O 0.9971156120300293
, O O 0.9999855756759644
revealed O O 0.9999231100082397
torsade O O 0.9999383687973022
de O O 0.9999839067459106
pointes O O 0.99979168176651
with O O 0.9999707937240601
gradually O O 0.9999688863754272
prolonged O O 0.9999799728393555
QT O O 0.982521116733551
intervals O O 0.999983549118042
. O O 0.999971866607666

This O O 0.9923096895217896
drug O O 0.9936246871948242
is O O 0.9998757839202881
rapidly O O 0.9999586343765259
absorbed O O 0.999957799911499
from O O 0.9998865127563477
the O O 0.9999591112136841
gastrointestinal O O 0.9994902610778809
tract O O 0.9999845027923584
, O O 0.9999096393585205
and O O 0.9999343156814575
most O O 0.9999651908874512
of O O 0.9999014139175415
it O O 0.9990069270133972
is O O 0.999942421913147
excreted O O 0.9999570846557617
from O O 0.9998408555984497
the O O 0.99994957447052
kidney O O 0.9998301267623901
. O O 0.9998732805252075

Although O O 0.9999779462814331
the O O 0.9999901056289673
patient O O 0.9999915361404419
' O O 0.9999923706054688
s O O 0.9999836683273315
renal O O 0.9999760389328003
function O O 0.9999854564666748
was O O 0.9999680519104004
not O O 0.9999880790710449
highly O O 0.9999784231185913
impaired O O 0.9999955892562866
and O O 0.9999887943267822
the O O 0.9999865293502808
dose O O 0.9998487234115601
of O O 0.9992560744285583
pilsicainide B B 0.9993095397949219
was O O 0.9998946189880371
low O O 0.9999516010284424
, O O 0.9999680519104004
the O O 0.9999693632125854
plasma O O 0.9994528889656067
concentration O O 0.9990319013595581
of O O 0.9982176423072815
pilsicainide B B 0.9995008707046509
may O O 0.9998574256896973
have O O 0.9999904632568359
been O O 0.9999788999557495
high O O 0.9993999004364014
, O O 0.9999697208404541
which O O 0.9998881816864014
can O O 0.999810516834259
produce O O 0.9999537467956543
torsades O O 0.9994695782661438
de O O 0.9999475479125977
pointes O O 0.999715268611908
in O O 0.9998644590377808
the O O 0.9995170831680298
octogenarian O O 0.9836612343788147
. O O 0.999951958656311

Although O O 0.9999715089797974
the O O 0.9999803304672241
oral O O 0.999518871307373
administration O O 0.9999290704727173
of O O 0.9995236396789551
class O O 0.5224590301513672
IC O O 0.3954911231994629
drugs O O 0.8796472549438477
, O O 0.999913215637207
including O O 0.9984672665596008
pilsicainide B B 0.9982299208641052
, O O 0.9998412132263184
is O O 0.9999663829803467
effective O O 0.9998373985290527
to O O 0.9998646974563599
terminate O O 0.999794065952301
atrial O O 0.9950973391532898
fibrillation O O 0.999806821346283
, O O 0.9999743700027466
careful O O 0.9999880790710449
consideration O O 0.9999948740005493
must O O 0.9999822378158569
be O O 0.9999972581863403
taken O O 0.9999983310699463
before O O 0.9999955892562866
giving O O 0.9999338388442993
these O O 0.9988123178482056
drugs O O 0.9975749850273132
to O O 0.9994021654129028
octogenarians O O 0.46455153822898865
. O O 0.9998770952224731

All B O 0.9608132839202881
- I O 0.9950858950614929
trans I O 0.912328839302063
retinoic I B 0.9482579827308655
acid I I 0.9998712539672852
- O O 0.9961232542991638
induced O O 0.9999046325683594
inflammatory O O 0.9999220371246338
myositis O O 0.9999939203262329
in O O 0.9999781847000122
a O O 0.9999856948852539
patient O O 0.9999935626983643
with O O 0.9999839067459106
acute O O 0.9999803304672241
promyelocytic O O 0.9995594620704651
leukemia O O 0.9999961853027344
. O O 0.9999699592590332

All B B 0.8997045755386353
- I I 0.96478670835495
trans I I 0.5117093920707703
retinoic I I 0.9673535227775574
acid I I 0.9999417066574097
( O O 0.9768227338790894
ATRA B B 0.9992628693580627
) O O 0.9982253909111023
, O O 0.9999692440032959
a O O 0.9998294115066528
component O O 0.9999450445175171
of O O 0.9998927116394043
standard O O 0.999744713306427
therapy O O 0.9999303817749023
for O O 0.99996018409729
acute O O 0.9993762373924255
promyelocytic O O 0.9988394379615784
leukemia O O 0.9999850988388062
( O O 0.9999405145645142
APL O O 0.9028462171554565
) O O 0.9999645948410034
, O O 0.9999728202819824
is O O 0.9998831748962402
associated O O 0.9999630451202393
with O O 0.9999724626541138
potentially O O 0.9999698400497437
serious O O 0.9999837875366211
but O O 0.9999629259109497
treatable O O 0.9999822378158569
adverse O O 0.999934196472168
effects O O 0.9999840259552002
involving O O 0.9999759197235107
numerous O O 0.999924898147583
organ O O 0.9998319149017334
systems O O 0.9999716281890869
, O O 0.9999786615371704
including O O 0.9999861717224121
rare O O 0.999977707862854
skeletal O O 0.9998495578765869
muscle O O 0.999971866607666
involvement O O 0.9999902248382568
. O O 0.9999814033508301

Only O O 0.9999781847000122
a O O 0.999975323677063
handful O O 0.9999951124191284
of O O 0.9999663829803467
cases O O 0.999990701675415
of O O 0.9999533891677856
ATRA B B 0.9954016208648682
- O O 0.7776241898536682
induced O O 0.999681830406189
myositis O O 0.9999916553497314
in O O 0.9998354911804199
children O O 0.999630331993103
have O O 0.9999624490737915
been O O 0.9999806880950928
reported O O 0.999974250793457
, O O 0.9999327659606934
and O O 0.9999847412109375
none O O 0.9999500513076782
in O O 0.9999638795852661
the O O 0.9999864101409912
radiology O O 0.9999052286148071
literature O O 0.9999860525131226
. O O 0.9999656677246094

We O O 0.9999896287918091
present O O 0.9999966621398926
such O O 0.9999955892562866
a O O 0.9999982118606567
case O O 0.9999971389770508
in O O 0.9999884366989136
a O O 0.9999921321868896
15 O O 0.9999953508377075
- O O 0.999984860420227
year O O 0.9999942779541016
- O O 0.9999912977218628
old O O 0.9999960660934448
boy O O 0.9999972581863403
with O O 0.9999498128890991
APL O O 0.9859697818756104
, O O 0.9999241828918457
where O O 0.9997536540031433
recognition O O 0.9999866485595703
of O O 0.9998340606689453
imaging O O 0.9998757839202881
findings O O 0.9999876022338867
played O O 0.9999654293060303
a O O 0.9999672174453735
crucial O O 0.999983549118042
role O O 0.9999722242355347
in O O 0.9999746084213257
making O O 0.9999954700469971
the O O 0.9999983310699463
diagnosis O O 0.9999973773956299
and O O 0.9999853372573853
facilitated O O 0.9999467134475708
prompt O O 0.999947190284729
, O O 0.999993085861206
effective O O 0.9999246597290039
treatment O O 0.9999790191650391
. O O 0.9999829530715942

Tolerability O O 0.9998356103897095
of O O 0.9988338351249695
lomustine B B 0.9995197057723999
in O O 0.9998641014099121
combination O O 0.9999079704284668
with O O 0.9992615580558777
cyclophosphamide B B 0.9989954829216003
in O O 0.9999339580535889
dogs O O 0.9999428987503052
with O O 0.9999881982803345
lymphoma O O 0.9999428987503052
. O O 0.9999198913574219

This O O 0.9999827146530151
retrospective O O 0.9999665021896362
study O O 0.999992847442627
describes O O 0.9999451637268066
toxicity O O 0.9999582767486572
associated O O 0.9999845027923584
with O O 0.999890923500061
a O O 0.9999276399612427
protocol O O 0.9997983574867249
of O O 0.9974378347396851
lomustine B B 0.9995019435882568
( O O 0.9970548152923584
CCNU B B 0.9875814914703369
) O O 0.9963293671607971
and O O 0.9931032657623291
cyclophosphamide B B 0.9988478422164917
( O O 0.9987038373947144
CTX B B 0.9675607085227966
) O O 0.9991152882575989
in O O 0.9999542236328125
dogs O O 0.9999923706054688
with O O 0.9999831914901733
lymphoma O O 0.9999548196792603
. O O 0.9999744892120361

CCNU B B 0.9981833100318909
was O O 0.9998503923416138
administered O O 0.999864935874939
per O O 0.7400375008583069
os O O 0.7695059180259705
( O O 0.9914454221725464
PO O O 0.9988256096839905
) O O 0.9998959302902222
at O O 0.9999483823776245
a O O 0.9999864101409912
targeted O O 0.9999488592147827
dosage O O 0.9999825954437256
of O O 0.9999747276306152
60 O O 0.9999947547912598
mg O O 0.9999551773071289
/ O O 0.9999520778656006
m O O 0.9999920129776001
( O O 0.9997840523719788
2 O O 0.9918394088745117
) O O 0.9992741942405701
body O O 0.9999732971191406
surface O O 0.9999203681945801
area O O 0.9999246597290039
on O O 0.9999527931213379
day O O 0.9999933242797852
0 O O 0.9999921321868896
, O O 0.9996485710144043
CTX B B 0.9555728435516357
was O O 0.9999178647994995
administered O O 0.9997369647026062
PO O O 0.9741266369819641
at O O 0.9999717473983765
a O O 0.9999877214431763
targeted O O 0.9999217987060547
dosage O O 0.9999802112579346
of O O 0.9999688863754272
250 O O 0.9999023675918579
mg O O 0.9998286962509155
/ O O 0.9997332692146301
m O O 0.9999814033508301
( O O 0.99945467710495
2 O O 0.9624376893043518
) O O 0.997377872467041
divided O O 0.9999665021896362
over O O 0.9999896287918091
days O O 0.9999973773956299
0 O O 0.9999923706054688
through O O 0.9999769926071167
4 O O 0.9999942779541016
, O O 0.999962568283081
and O O 0.9999706745147705
all O O 0.9999847412109375
dogs O O 0.9999881982803345
received O O 0.9999344348907471
prophylactic O O 0.9999375343322754
antibiotics O O 0.9987555742263794
. O O 0.9999760389328003

Ninety O O 0.6546955704689026
treatments O O 0.9999088048934937
were O O 0.9999728202819824
given O O 0.999962568283081
to O O 0.9999414682388306
the O O 0.9999855756759644
57 O O 0.9999196529388428
dogs O O 0.9999977350234985
included O O 0.9999946355819702
in O O 0.9999911785125732
the O O 0.9999969005584717
study O O 0.9999946355819702
. O O 0.9999635219573975

Neutropenia O O 0.9990346431732178
was O O 0.9999290704727173
the O O 0.9999673366546631
principal O O 0.9998173117637634
toxic O O 0.9996953010559082
effect O O 0.9999802112579346
, O O 0.9999256134033203
and O O 0.9999818801879883
the O O 0.9999934434890747
overall O O 0.999972939491272
frequency O O 0.9999974966049194
of O O 0.9999868869781494
grade O O 0.9999752044677734
4 O O 0.9990787506103516
neutropenia O O 0.9999886751174927
after O O 0.9998841285705566
the O O 0.9999897480010986
first O O 0.9999910593032837
treatment O O 0.9999833106994629
of O O 0.9987585544586182
CCNU B B 0.99069744348526
/ O O 0.7156630158424377
CTX B B 0.9278690218925476
was O O 0.9998291730880737
30 O O 0.9999920129776001
% O O 0.9999984502792358
( O O 0.9999752044677734
95 O O 0.9999964237213135
% O O 0.9999955892562866
confidence O O 0.9999974966049194
interval O O 0.9999890327453613
, O O 0.9999618530273438
19 O O 0.999858021736145
- O O 0.9993915557861328
43 O O 0.9999933242797852
% O O 0.9999957084655762
) O O 0.9999819993972778
. O O 0.9999828338623047

The O O 0.9999909400939941
mean O O 0.9999948740005493
body O O 0.9999963045120239
weight O O 0.9999980926513672
of O O 0.9999679327011108
dogs O O 0.9999940395355225
with O O 0.9999254941940308
grade O O 0.9999169111251831
4 O O 0.9945231676101685
neutropenia O O 0.9999781847000122
( O O 0.9999806880950928
19 O O 0.9999972581863403
. O O 0.9999979734420776
7 O O 0.9999942779541016
kg O O 0.9999954700469971
+ O O 0.999954104423523
13 O O 0.999996542930603
. O O 0.9999973773956299
4 O O 0.9999897480010986
kg O O 0.9999938011169434
) O O 0.9999825954437256
was O O 0.9999831914901733
significantly O O 0.999995231628418
less O O 0.9999946355819702
than O O 0.9999960660934448
the O O 0.9999966621398926
mean O O 0.9999932050704956
body O O 0.9999963045120239
weight O O 0.9999974966049194
of O O 0.9999808073043823
dogs O O 0.9999947547912598
that O O 0.9999661445617676
did O O 0.9999803304672241
not O O 0.9999929666519165
develop O O 0.9999808073043823
grade O O 0.9999581575393677
4 O O 0.9976468682289124
neutropenia O O 0.9999825954437256
( O O 0.9999620914459229
31 O O 0.9999969005584717
. O O 0.9999972581863403
7 O O 0.9999960660934448
kg O O 0.9999960660934448
+ O O 0.9999521970748901
12 O O 0.9999971389770508
. O O 0.999997615814209
4 O O 0.9999932050704956
kg O O 0.9999960660934448
; O O 0.9999738931655884
P O O 0.9999819993972778
= O O 0.9999639987945557
. O O 0.9999980926513672
005 O O 0.9999451637268066
) O O 0.9999834299087524
. O O 0.9999799728393555

One O O 0.9998447895050049
dog O O 0.9999532699584961
( O O 0.9999374151229858
3 O O 0.9999328851699829
% O O 0.9999724626541138
) O O 0.9999567270278931
developed O O 0.999953031539917
hematologic O O 0.9999473094940186
changes O O 0.9999971389770508
suggestive O O 0.9999879598617554
of O O 0.9999560117721558
hepatotoxicity O O 0.9996460676193237
. O O 0.9999256134033203

No O O 0.8427942991256714
dogs O O 0.9993391633033752
had O O 0.9999192953109741
evidence O O 0.9999611377716064
of O O 0.9999464750289917
either O O 0.999742329120636
renal O O 0.9955599308013916
toxicity O O 0.9998660087585449
or O O 0.999868631362915
hemorrhagic O O 0.9997658133506775
cystitis O O 0.9963012933731079
. O O 0.999931812286377

Adverse O O 0.9993708729743958
gastrointestinal O O 0.9989532232284546
effects O O 0.9999517202377319
were O O 0.9999499320983887
uncommon O O 0.9997021555900574
. O O 0.9999157190322876

On O O 0.9999946355819702
the O O 0.9999964237213135
basis O O 0.9999979734420776
of O O 0.9999960660934448
the O O 0.9999946355819702
findings O O 0.999997615814209
reported O O 0.9999988079071045
herein O O 0.9999679327011108
, O O 0.999984622001648
a O O 0.9999768733978271
dose O O 0.9999450445175171
of O O 0.9999345541000366
60 O O 0.9999794960021973
mg O O 0.9999532699584961
/ O O 0.9999499320983887
m O O 0.9999911785125732
( O O 0.999703586101532
2 O O 0.998052716255188
) O O 0.9994553923606873
of O O 0.9890095591545105
CCNU B B 0.9705448150634766
combined O O 0.9995017051696777
with O O 0.9998103976249695
250 O O 0.9998936653137207
mg O O 0.9998641014099121
/ O O 0.9998282194137573
m O O 0.9999604225158691
( O O 0.9998718500137329
2 O O 0.9973599314689636
) O O 0.999803364276886
of O O 0.9973063468933105
CTX B B 0.9519972801208496
( O O 0.9989681243896484
divided O O 0.9999178647994995
over O O 0.9999858140945435
5 O O 0.9999616146087646
days O O 0.9999769926071167
) O O 0.9999547004699707
q O O 0.9998804330825806
4 O O 0.99996018409729
wk O O 0.9998118281364441
is O O 0.9999794960021973
tolerable O O 0.999995231628418
in O O 0.9999353885650635
tumor O O 0.9997979998588562
- O O 0.9999605417251587
bearing O O 0.9999839067459106
dogs O O 0.9999603033065796
. O O 0.9999815225601196

Nelarabine B B 0.9961155652999878
neurotoxicity O O 0.9993405938148499
with O O 0.9999465942382812
concurrent O O 0.9999184608459473
intrathecal O O 0.998164713382721
chemotherapy O O 0.9990800619125366
: O O 0.99997878074646
Case O O 0.9999955892562866
report O O 0.9999979734420776
and O O 0.9999912977218628
review O O 0.9999949932098389
of O O 0.9999966621398926
literature O O 0.9999940395355225
. O O 0.9999843835830688

Severe O O 0.9999276399612427
nelarabine B B 0.9992507100105286
neurotoxicity O O 0.9998264908790588
in O O 0.9999637603759766
a O O 0.9999850988388062
patient O O 0.9999934434890747
who O O 0.9999799728393555
received O O 0.9999628067016602
concurrent O O 0.9996821880340576
intrathecal O O 0.9922897219657898
( O O 0.9868673086166382
IT O O 0.6723197102546692
) O O 0.9482880234718323
chemotherapy O O 0.993866503238678
is O O 0.9999707937240601
reported O O 0.9999902248382568
. O O 0.9999877214431763

A O O 0.9999769926071167
37 O O 0.9999891519546509
- O O 0.9999843835830688
year O O 0.9999964237213135
- O O 0.9999927282333374
old O O 0.9999912977218628
Caucasian O O 0.9994816184043884
woman O O 0.9999946355819702
with O O 0.9999523162841797
a O O 0.9999830722808838
history O O 0.9999864101409912
of O O 0.9999680519104004
T O O 0.9962334036827087
- O O 0.9996770620346069
cell O O 0.9989725351333618
lymphoblastic O O 0.9998323917388916
lymphoma O O 0.9999382495880127
was O O 0.9999436140060425
admitted O O 0.9999556541442871
for O O 0.9999802112579346
relapsed O O 0.9999758005142212
disease O O 0.9999915361404419
. O O 0.9999749660491943

She O O 0.9999523162841797
was O O 0.9999740123748779
originally O O 0.9999902248382568
treated O O 0.9999855756759644
with O O 0.9999711513519287
induction O O 0.9999719858169556
chemotherapy O O 0.999428927898407
followed O O 0.9999037981033325
by O O 0.9999781847000122
an O O 0.9999880790710449
autologous O O 0.9999704360961914
transplant O O 0.9999921321868896
. O O 0.9999722242355347

She O O 0.999966025352478
developed O O 0.9999939203262329
relapsed O O 0.9999886751174927
disease O O 0.9999946355819702
10 O O 0.9999657869338989
months O O 0.9999980926513672
later O O 0.9999964237213135
with O O 0.9999819993972778
leukemic O O 0.9999562501907349
involvement O O 0.9999942779541016
. O O 0.9999654293060303

She O O 0.9999535083770752
was O O 0.999953031539917
re O O 0.999983549118042
- O O 0.999954104423523
induced O O 0.9999947547912598
with O O 0.9997681975364685
nelarabine B B 0.9995073080062866
1500 O O 0.9994345307350159
mg O O 0.9998879432678223
/ O O 0.9996380805969238
m O O 0.9999644756317139
( O O 0.9989913105964661
2 O O 0.9559811949729919
) O O 0.9968720078468323
on O O 0.9999319314956665
days O O 0.9999880790710449
1 O O 0.9999923706054688
, O O 0.9999446868896484
3 O O 0.9999923706054688
, O O 0.9999626874923706
and O O 0.9999853372573853
5 O O 0.9999923706054688
with O O 0.9999332427978516
1 O O 0.9997496008872986
dose O O 0.9998971223831177
of O O 0.9992561936378479
IT O O 0.5136040449142456
cytarabine B B 0.9920502305030823
100 O O 0.9608209729194641
mg O O 0.9996671676635742
on O O 0.9999203681945801
day O O 0.9999713897705078
2 O O 0.9993652701377869
as O O 0.9999009370803833
central O O 0.9983820915222168
nervous O O 0.9999803304672241
system O O 0.9999064207077026
( O O 0.9995094537734985
CNS O O 0.9305120706558228
) O O 0.9998866319656372
prophylaxis O O 0.9995182752609253
. O O 0.999980092048645

At O O 0.9999561309814453
the O O 0.9999970197677612
time O O 0.9999946355819702
of O O 0.9999904632568359
treatment O O 0.999994158744812
, O O 0.9999557733535767
she O O 0.9999792575836182
was O O 0.9999569654464722
on O O 0.9995748400688171
continuous O O 0.9952952265739441
renal O O 0.7212105989456177
replacement O O 0.9254412651062012
therapy O O 0.9998958110809326
due O O 0.9999730587005615
to O O 0.999919056892395
sequelae O O 0.9999340772628784
of O O 0.9999239444732666
tumor O O 0.9916614294052124
lysis O O 0.9967479705810547
syndrome O O 0.9998338222503662
( O O 0.9999170303344727
TLS O O 0.9695232510566711
) O O 0.9999562501907349
. O O 0.9999561309814453

She O O 0.9999455213546753
tolerated O O 0.9999756813049316
therapy O O 0.9999837875366211
well O O 0.9999841451644897
, O O 0.9999881982803345
entered O O 0.9999667406082153
a O O 0.9999810457229614
complete O O 0.9998499155044556
remission O O 0.9999881982803345
, O O 0.99996018409729
and O O 0.9999691247940063
recovered O O 0.9999816417694092
her O O 0.9999808073043823
renal O O 0.9999325275421143
function O O 0.9999877214431763
. O O 0.9999678134918213

She O O 0.9999833106994629
received O O 0.9999526739120483
a O O 0.9999903440475464
second O O 0.9999957084655762
cycle O O 0.9999532699584961
of O O 0.9996597766876221
nelarabine B B 0.9995765089988708
without O O 0.9994010925292969
additional O O 0.9991324543952942
IT O O 0.9718115329742432
prophylaxis O O 0.9996840953826904
one O O 0.9999879598617554
month O O 0.9999991655349731
later O O 0.9999963045120239
. O O 0.9999805688858032

A O O 0.9999897480010986
week O O 0.9999992847442627
after O O 0.9999949932098389
this O O 0.9999828338623047
second O O 0.9999746084213257
cycle O O 0.99943608045578
, O O 0.9999839067459106
she O O 0.9999842643737793
noted O O 0.9999924898147583
numbness O O 0.9999845027923584
in O O 0.9999921321868896
her O O 0.9999864101409912
lower O O 0.9998038411140442
extremities O O 0.9999876022338867
. O O 0.9999843835830688

Predominantly O O 0.9951459765434265
sensory O O 0.9995822310447693
, O O 0.9999583959579468
though O O 0.9999301433563232
also O O 0.9993191957473755
motor O O 0.9996631145477295
and O O 0.99964439868927
autonomic O O 0.962091863155365
, O O 0.9999445676803589
peripheral O O 0.9999525547027588
neuropathy O O 0.999990701675415
started O O 0.9999912977218628
in O O 0.9999656677246094
her O O 0.9999752044677734
feet O O 0.9999821186065674
, O O 0.9999603033065796
ascended O O 0.9998641014099121
proximally O O 0.9999648332595825
to O O 0.9999412298202515
the O O 0.9999784231185913
mid O O 0.9999662637710571
- O O 0.9996883869171143
thoracic O O 0.9997463822364807
region O O 0.9999839067459106
, O O 0.9999426603317261
and O O 0.9999449253082275
eventually O O 0.9999490976333618
included O O 0.9999690055847168
her O O 0.9999791383743286
distal O O 0.9999243021011353
upper O O 0.9992902278900146
extremities O O 0.9999874830245972
. O O 0.9999717473983765

A O O 0.9999862909317017
magnetic O O 0.9999836683273315
resonance O O 0.9999890327453613
imaging O O 0.9999901056289673
( O O 0.9999527931213379
MRI O O 0.9982990622520447
) O O 0.9999873638153076
of O O 0.9999874830245972
her O O 0.9999879598617554
spine O O 0.9999674558639526
demonstrated O O 0.9999579191207886
changes O O 0.9999980926513672
from O O 0.999984860420227
C2 O O 0.9990549683570862
to O O 0.9999064207077026
C6 O O 0.9993470311164856
consistent O O 0.9999713897705078
with O O 0.9999649524688721
subacute O O 0.9998714923858643
combined O O 0.9938371777534485
degeneration O O 0.9999817609786987
. O O 0.9999632835388184

Nelarabine B B 0.999203622341156
was O O 0.9998886585235596
felt O O 0.9999330043792725
to O O 0.9997612833976746
be O O 0.9997795224189758
the O O 0.9998729228973389
cause O O 0.9999712705612183
of O O 0.9999887943267822
her O O 0.9999657869338989
symptoms O O 0.999996542930603
. O O 0.9999692440032959

Her O O 0.999980092048645
neuropathy O O 0.9999921321868896
stabilized O O 0.9999901056289673
and O O 0.9999960660934448
showed O O 0.999996542930603
slight O O 0.9999982118606567
improvement O O 0.999998927116394
and O O 0.9999949932098389
ultimately O O 0.9999940395355225
received O O 0.9999969005584717
an O O 0.9999954700469971
unrelated O O 0.9999886751174927
, O O 0.9999374151229858
reduced O O 0.9998829364776611
- O O 0.9999386072158813
intensity O O 0.999134361743927
allogeneic O O 0.9999861717224121
transplant O O 0.9999662637710571
while O O 0.9999376535415649
in O O 0.999964714050293
complete O O 0.9999668598175049
remission O O 0.999996542930603
, O O 0.999974250793457
but O O 0.9999759197235107
relapsed O O 0.9999946355819702
disease O O 0.9999973773956299
10 O O 0.9999814033508301
weeks O O 0.9999990463256836
later O O 0.9999978542327881
. O O 0.9999858140945435

She O O 0.9999511241912842
is O O 0.9999552965164185
currently O O 0.9999772310256958
being O O 0.9999909400939941
treated O O 0.9999856948852539
with O O 0.9999772310256958
best O O 0.9996421337127686
supportive O O 0.9997417330741882
care O O 0.9999682903289795
. O O 0.9999724626541138

To O O 0.9999901056289673
our O O 0.9999895095825195
knowledge O O 0.9999942779541016
, O O 0.9999854564666748
this O O 0.9999945163726807
is O O 0.9999946355819702
the O O 0.9999942779541016
first O O 0.9999927282333374
published O O 0.9999935626983643
case O O 0.9999873638153076
report O O 0.9999964237213135
of O O 0.9999368190765381
severe O O 0.9998883008956909
neurotoxicity O O 0.9999829530715942
caused O O 0.9999790191650391
by O O 0.9998341798782349
nelarabine B B 0.9992138147354126
in O O 0.9998233914375305
a O O 0.9999884366989136
patient O O 0.9999922513961792
who O O 0.9999687671661377
received O O 0.999946117401123
concurrent O O 0.9962059259414673
IT O O 0.5895435214042664
chemotherapy O O 0.9960696697235107
. O O 0.9999467134475708

Valproate B B 0.9989821314811707
- O O 0.9994624257087708
induced O O 0.9999051094055176
hyperammonemic O O 0.9991740584373474
encephalopathy O O 0.9999556541442871
in O O 0.9999774694442749
a O O 0.9999819993972778
renal O O 0.999795138835907
transplanted O O 0.9999433755874634
patient O O 0.9999923706054688
. O O 0.9999626874923706

Neurological O O 0.9997761845588684
complications O O 0.9999912977218628
after O O 0.9999420642852783
renal O O 0.9987139701843262
transplantation O O 0.999650239944458
constitute O O 0.9999220371246338
an O O 0.9999527931213379
important O O 0.9999639987945557
cause O O 0.9999890327453613
of O O 0.9999797344207764
morbidity O O 0.9999957084655762
and O O 0.9999947547912598
mortality O O 0.999996542930603
. O O 0.999988317489624

Their O O 0.9999570846557617
differential O O 0.9999226331710815
diagnosis O O 0.9999908208847046
is O O 0.9999814033508301
difficult O O 0.9999945163726807
and O O 0.9999881982803345
essential O O 0.9999734163284302
for O O 0.9999881982803345
subsequent O O 0.9999839067459106
patient O O 0.9999922513961792
' O O 0.9999942779541016
s O O 0.9999929666519165
management O O 0.9999891519546509
. O O 0.9999750852584839

Valproate B B 0.9989660978317261
- O O 0.999855637550354
induced O O 0.9999462366104126
hyperammonemic O O 0.999503493309021
encephalopathy O O 0.9999668598175049
is O O 0.9999732971191406
an O O 0.9999791383743286
uncommon O O 0.9999828338623047
but O O 0.9999802112579346
serious O O 0.999969482421875
effect O O 0.9999864101409912
of O O 0.9998300075531006
valproate B B 0.9996108412742615
treatment O O 0.9998088479042053
. O O 0.9999803304672241

Here O O 0.999985933303833
, O O 0.9999929666519165
we O O 0.9999916553497314
describe O O 0.9999980926513672
the O O 0.999997615814209
case O O 0.999996542930603
of O O 0.9999918937683105
a O O 0.9999934434890747
15 O O 0.9999966621398926
- O O 0.9999879598617554
year O O 0.999996542930603
- O O 0.9999935626983643
old O O 0.9999951124191284
girl O O 0.9999986886978149
who O O 0.9999622106552124
was O O 0.9999703168869019
on O O 0.9996089339256287
a O O 0.9999724626541138
long O O 0.9998500347137451
- O O 0.99998939037323
term O O 0.9999821186065674
therapy O O 0.9999853372573853
with O O 0.9994889497756958
valproate B B 0.9994006156921387
due O O 0.9998883008956909
to O O 0.9999598264694214
epilepsy O O 0.9998573064804077
and O O 0.9999469518661499
revealed O O 0.9999754428863525
impaired O O 0.9999880790710449
consciousness O O 0.999996542930603
with O O 0.9999817609786987
hyperammonemia O O 0.9954982995986938
12 O O 0.9999773502349854
days O O 0.9999974966049194
after O O 0.9999797344207764
renal O O 0.9996374845504761
transplantation O O 0.9999308586120605
. O O 0.9999765157699585

After O O 0.9998999834060669
withdraw O O 0.9980345368385315
of O O 0.9982779026031494
valproate B B 0.9992406368255615
, O O 0.999846339225769
patients O O 0.999984860420227
' O O 0.9999935626983643
symptoms O O 0.9999951124191284
resolved O O 0.9999865293502808
within O O 0.9999934434890747
24 O O 0.9999837875366211
h O O 0.9999173879623413
. O O 0.9999788999557495

Clinicians O O 0.9998317956924438
should O O 0.9999572038650513
increase O O 0.9999741315841675
their O O 0.999984622001648
awareness O O 0.9999939203262329
for O O 0.9999755620956421
potential O O 0.9999650716781616
complication O O 0.9999805688858032
of O O 0.9992693066596985
valproate B B 0.999535322189331
, O O 0.9998804330825806
especially O O 0.9999549388885498
in O O 0.9999622106552124
transplanted O O 0.9998824596405029
patients O O 0.99998939037323
. O O 0.9999734163284302

Necrotising O O 0.9999711513519287
fasciitis O O 0.9999779462814331
after O O 0.9998264908790588
bortezomib B B 0.9989173412322998
and O O 0.9838780164718628
dexamethasone B B 0.9993807077407837
- O O 0.9991233944892883
containing O O 0.9977425336837769
regimen O O 0.9981344938278198
in O O 0.9999703168869019
an O O 0.9999884366989136
elderly O O 0.9999821186065674
patient O O 0.999993085861206
of O O 0.9999146461486816
Waldenstrom O O 0.9808496832847595
macroglobulinaemia O O 0.9950506091117859
. O O 0.9999680519104004

Bortezomib B B 0.9995157718658447
and O O 0.9982624650001526
high O O 0.998794436454773
- O O 0.9999669790267944
dose O O 0.9987745881080627
dexamethasone B B 0.99957674741745
- O O 0.9992085099220276
containing O O 0.9987121820449829
regimens O O 0.9996664524078369
are O O 0.9999614953994751
considered O O 0.9999864101409912
to O O 0.9999814033508301
be O O 0.9999946355819702
generally O O 0.9999877214431763
tolerable O O 0.9999951124191284
with O O 0.9999914169311523
few O O 0.9999474287033081
severe O O 0.9999586343765259
bacterial O O 0.9999450445175171
infections O O 0.9999812841415405
in O O 0.9999678134918213
patients O O 0.999992847442627
with O O 0.9999788999557495
B O O 0.9650751352310181
- O O 0.9992467164993286
cell O O 0.9970141649246216
malignancies O O 0.9999938011169434
. O O 0.9999812841415405

However O O 0.9999628067016602
, O O 0.9999899864196777
information O O 0.9999885559082031
is O O 0.9999855756759644
limited O O 0.9999979734420776
concerning O O 0.9999910593032837
the O O 0.9999973773956299
safety O O 0.9999983310699463
of O O 0.9999862909317017
the O O 0.9999558925628662
regimen O O 0.9914578795433044
in O O 0.9999632835388184
elderly O O 0.9998713731765747
patients O O 0.9999924898147583
. O O 0.9999728202819824

We O O 0.9999850988388062
report O O 0.9999966621398926
a O O 0.9999943971633911
case O O 0.9999972581863403
of O O 0.9999873638153076
a O O 0.9999905824661255
76 O O 0.9999932050704956
- O O 0.9999847412109375
year O O 0.9999938011169434
- O O 0.999991774559021
old O O 0.9999932050704956
man O O 0.9999957084655762
with O O 0.9999477863311768
Waldenstrom O O 0.9825634360313416
macroglobulinaemia O O 0.9945149421691895
who O O 0.9999322891235352
suffered O O 0.9999591112136841
necrotising O O 0.9999384880065918
fasciitis O O 0.9999098777770996
without O O 0.9999058246612549
neutropenia O O 0.9999923706054688
after O O 0.9998226761817932
the O O 0.999942421913147
combination O O 0.998645007610321
treatment O O 0.9999446868896484
with O O 0.9997462630271912
bortezomib B B 0.997694194316864
, O O 0.9664808511734009
high O O 0.9975252747535706
- O O 0.9999195337295532
dose O O 0.9949544072151184
dexamethasone B B 0.9986531734466553
and O O 0.958490788936615
rituximab O B 0.4978995621204376
. O O 0.9998526573181152

Despite O O 0.999953031539917
immediate O O 0.999934196472168
intravenous O O 0.9998509883880615
antimicrobial O O 0.8059436678886414
therapy O O 0.9998511075973511
, O O 0.999947190284729
he O O 0.9999532699584961
succumbed O O 0.9999845027923584
23 O O 0.9999780654907227
h O O 0.9992534518241882
after O O 0.999994158744812
the O O 0.9999812841415405
onset O O 0.9999964237213135
. O O 0.9999847412109375

Physicians O O 0.9998142123222351
should O O 0.9999555349349976
recognise O O 0.9999731779098511
the O O 0.999984860420227
possibility O O 0.9999850988388062
of O O 0.9999693632125854
fatal O O 0.9999510049819946
bacterial O O 0.9999614953994751
infections O O 0.999990701675415
related O O 0.9999806880950928
to O O 0.9982060194015503
bortezomib B B 0.9995312690734863
plus O O 0.9890845417976379
high O O 0.997393012046814
- O O 0.9999327659606934
dose O O 0.9938523769378662
dexamethasone B B 0.9987719655036926
in O O 0.9998119473457336
elderly O O 0.9998570680618286
patients O O 0.9999926090240479
, O O 0.999970555305481
and O O 0.9999918937683105
we O O 0.9999908208847046
believe O O 0.9999936819076538
this O O 0.9999958276748657
case O O 0.9999924898147583
warrants O O 0.999980092048645
further O O 0.9999963045120239
investigation O O 0.9999966621398926
. O O 0.9999849796295166

An O O 0.9999397993087769
integrated O O 0.9999139308929443
characterization O O 0.999988317489624
of O O 0.9999508857727051
serological O O 0.9999226331710815
, O O 0.9998857975006104
pathological O O 0.9999593496322632
, O O 0.9998311996459961
and O O 0.999808132648468
functional O O 0.9999773502349854
events O O 0.9999971389770508
in O O 0.999929666519165
doxorubicin B B 0.9997407793998718
- O O 0.9996486902236938
induced O O 0.9999393224716187
cardiotoxicity O O 0.9999932050704956
. O O 0.9999779462814331

Many O O 0.9978125095367432
efficacious O O 0.9996834993362427
cancer O O 0.9842748045921326
treatments O O 0.9998366832733154
cause O O 0.9998810291290283
significant O O 0.9999736547470093
cardiac O O 0.9999886751174927
morbidity O O 0.9999938011169434
, O O 0.9999659061431885
yet O O 0.9999033212661743
biomarkers O O 0.9997608065605164
or O O 0.9999098777770996
functional O O 0.9999566078186035
indices O O 0.999966025352478
of O O 0.9999707937240601
early O O 0.9997124075889587
damage O O 0.9999885559082031
, O O 0.9999762773513794
which O O 0.9999850988388062
would O O 0.9999754428863525
allow O O 0.999962329864502
monitoring O O 0.9999932050704956
and O O 0.9999738931655884
intervention O O 0.9999916553497314
, O O 0.999984622001648
are O O 0.9999750852584839
lacking O O 0.999970555305481
. O O 0.9999710321426392

In O O 0.9999867677688599
this O O 0.99997878074646
study O O 0.9999936819076538
, O O 0.9999788999557495
we O O 0.999981164932251
have O O 0.9999957084655762
utilized O O 0.9999850988388062
a O O 0.9999842643737793
rat O O 0.9999867677688599
model O O 0.9999961853027344
of O O 0.9999703168869019
progressive O O 0.9998517036437988
doxorubicin B B 0.9991480112075806
( O O 0.9833338856697083
DOX B B 0.999714195728302
) O O 0.9539911150932312
- O O 0.9998165965080261
induced O O 0.9999711513519287
cardiomyopathy O O 0.9999954700469971
, O O 0.9999850988388062
applying O O 0.9999821186065674
multiple O O 0.9999358654022217
approaches O O 0.9999927282333374
, O O 0.9999898672103882
including O O 0.9999562501907349
cardiac O O 0.9998948574066162
magnetic O O 0.998980700969696
resonance O O 0.9999121427536011
imaging O O 0.9999903440475464
( O O 0.999929666519165
MRI O O 0.9969695210456848
) O O 0.999975323677063
, O O 0.9999898672103882
to O O 0.9999874830245972
provide O O 0.9999954700469971
the O O 0.9999903440475464
most O O 0.9999902248382568
comprehensive O O 0.999988317489624
characterization O O 0.9999977350234985
to O O 0.9999979734420776
date O O 0.9999984502792358
of O O 0.9999756813049316
the O O 0.9999872446060181
timecourse O O 0.9999529123306274
of O O 0.9999731779098511
serological O O 0.9999278783798218
, O O 0.9999204874038696
pathological O O 0.9999690055847168
, O O 0.9998576641082764
and O O 0.9999055862426758
functional O O 0.9999790191650391
events O O 0.999997615814209
underlying O O 0.9999847412109375
this O O 0.9998599290847778
toxicity O O 0.9999738931655884
. O O 0.9999603033065796

Hannover O O 0.9364988803863525
Wistar O O 0.9972564578056335
rats O O 0.9997947812080383
were O O 0.9999809265136719
dosed O O 0.9998962879180908
with O O 0.9999057054519653
1 O O 0.999813973903656
. O O 0.9999840259552002
25 O O 0.9999736547470093
mg O O 0.9998784065246582
/ O O 0.999975323677063
kg O O 0.9997226595878601
DOX B B 0.9995540976524353
weekly O I 0.9970570802688599
for O O 0.9997512698173523
8 O O 0.9998805522918701
weeks O O 0.9999963045120239
followed O O 0.9999499320983887
by O O 0.9999853372573853
a O O 0.9999845027923584
4 O O 0.999909520149231
week O O 0.999990701675415
off O O 0.9947035908699036
- O O 0.9998315572738647
dosing O O 0.9965686798095703
" O O 0.9999260902404785
recovery O O 0.9999837875366211
" O O 0.9999901056289673
period O O 0.9999781847000122
. O O 0.9999837875366211

Electron O O 0.9999605417251587
microscopy O O 0.9999735355377197
of O O 0.9999841451644897
the O O 0.9999873638153076
myocardium O O 0.9999946355819702
revealed O O 0.9998934268951416
subcellular O O 0.9934279322624207
degeneration O O 0.9999738931655884
and O O 0.9999080896377563
marked O O 0.9999533891677856
mitochondrial O O 0.9993512034416199
changes O O 0.9999970197677612
after O O 0.999962329864502
a O O 0.9999727010726929
single O O 0.9998657703399658
dose O O 0.999150276184082
. O O 0.9999098777770996

Histopathological O O 0.9999697208404541
analysis O O 0.9999958276748657
revealed O O 0.9999434947967529
progressive O O 0.9999897480010986
cardiomyocyte O O 0.9999923706054688
degeneration O O 0.9999924898147583
, O O 0.9999409914016724
hypertrophy O O 0.9987163543701172
/ O O 0.9998670816421509
cytomegaly O O 0.999779999256134
, O O 0.9997530579566956
and O O 0.9999322891235352
extensive O O 0.9998043179512024
vacuolation O O 0.9999738931655884
after O O 0.9999254941940308
two O O 0.9995393753051758
doses O O 0.9998263716697693
. O O 0.9999456405639648

Extensive O O 0.999695897102356
replacement O O 0.9982550740242004
fibrosis O O 0.999974250793457
( O O 0.9999641180038452
quantified O O 0.9997016787528992
by O O 0.9999561309814453
Sirius O O 0.8587111234664917
red O O 0.9928503036499023
staining O O 0.9998806715011597
) O O 0.9999493360519409
developed O O 0.9999908208847046
during O O 0.9999487400054932
the O O 0.999984622001648
off O O 0.9962390661239624
- O O 0.9998379945755005
dosing O O 0.9989283680915833
period O O 0.9999710321426392
. O O 0.9999617338180542

Functional O O 0.9998997449874878
indices O O 0.9999003410339355
assessed O O 0.9999767541885376
by O O 0.9999545812606812
cardiac O O 0.9997071623802185
MRI O O 0.9976370334625244
( O O 0.9999512434005737
including O O 0.9999516010284424
left O O 0.9998326301574707
ventricular O O 0.9999783039093018
ejection O O 0.9980731010437012
fraction O O 0.9999926090240479
( O O 0.9999183416366577
LVEF O O 0.979899525642395
) O O 0.9999246597290039
, O O 0.9999217987060547
cardiac O O 0.999202311038971
output O O 0.9999938011169434
, O O 0.9997974038124084
and O O 0.9998083710670471
E O O 0.9862850904464722
/ O O 0.9997838139533997
A O O 0.9875108003616333
ratio O O 0.9999047517776489
) O O 0.9999680519104004
declined O O 0.9999902248382568
progressively O O 0.9999958276748657
, O O 0.9999951124191284
reaching O O 0.9999872446060181
statistical O O 0.9999850988388062
significance O O 0.9999982118606567
after O O 0.9999499320983887
two O O 0.9997573494911194
doses O O 0.9997128844261169
and O O 0.9999945163726807
culminating O O 0.9999833106994629
in O O 0.9999765157699585
" O O 0.9999489784240723
clinical O O 0.9999605417251587
" O O 0.9999854564666748
LV O O 0.9863319396972656
dysfunction O O 0.9999959468841553
by O O 0.9999902248382568
12 O O 0.9999959468841553
weeks O O 0.9999972581863403
. O O 0.9999873638153076

Significant O O 0.999976634979248
increases O O 0.9999830722808838
in O O 0.99997878074646
peak O O 0.9995017051696777
myocardial O O 0.9999939203262329
contrast O O 0.9116557836532593
enhancement O O 0.9998816251754761
and O O 0.9999314546585083
serological O O 0.9996227025985718
cardiac O O 0.9874460697174072
troponin O O 0.7329283952713013
I O O 0.7292690277099609
( O O 0.9983401298522949
cTnI O O 0.9353274703025818
) O O 0.9998873472213745
emerged O O 0.9999490976333618
after O O 0.9999196529388428
eight O O 0.9895361661911011
doses O O 0.9998237490653992
, O O 0.9999603033065796
importantly O O 0.9999161958694458
preceding O O 0.9999932050704956
the O O 0.999984622001648
LVEF O O 0.7841065526008606
decline O O 0.9999604225158691
to O O 0.9999905824661255
< O O 0.9999858140945435
50 O O 0.9999960660934448
% O O 0.9999945163726807
. O O 0.9999752044677734

Troponin O B 0.852920413017273
I O I 0.9481870532035828
levels O O 0.9986440539360046
positively O O 0.9998652935028076
correlated O O 0.9999923706054688
with O O 0.9999808073043823
delayed O O 0.9998877048492432
and O O 0.9997846484184265
peak O O 0.9945430755615234
gadolinium B B 0.9956607222557068
contrast O O 0.9107788801193237
enhancement O O 0.9999440908432007
, O O 0.9999556541442871
histopathological O O 0.9999855756759644
grading O O 0.9992647767066956
, O O 0.9999344348907471
and O O 0.9999159574508667
diastolic O O 0.9998118281364441
dysfunction O O 0.9999891519546509
. O O 0.999966025352478

In O O 0.9999107122421265
summary O O 0.999981164932251
, O O 0.9999076128005981
subcellular O O 0.9914745092391968
cardiomyocyte O O 0.9999798536300659
degeneration O O 0.9999783039093018
was O O 0.9999798536300659
the O O 0.9999905824661255
earliest O O 0.9999929666519165
marker O O 0.999996542930603
, O O 0.9999697208404541
followed O O 0.9999696016311646
by O O 0.9999688863754272
progressive O O 0.9999845027923584
functional O O 0.9999884366989136
decline O O 0.9999971389770508
and O O 0.9999651908874512
histopathological O O 0.9999668598175049
manifestations O O 0.9999904632568359
. O O 0.9999748468399048

Myocardial O O 0.9999111890792847
contrast O O 0.8906552791595459
enhancement O O 0.9999222755432129
and O O 0.9999281167984009
elevations O O 0.9999531507492065
in O O 0.9998331069946289
cTnI O O 0.9246203303337097
occurred O O 0.9999616146087646
later O O 0.9999822378158569
. O O 0.9999617338180542

However O O 0.9999411106109619
, O O 0.999921441078186
all O O 0.9993651509284973
indices O O 0.999146580696106
predated O O 0.9996159076690674
" O O 0.9998842477798462
clinical O O 0.9999798536300659
" O O 0.9999581575393677
LV O O 0.9743753671646118
dysfunction O O 0.999983549118042
and O O 0.9999629259109497
thus O O 0.9999589920043945
warrant O O 0.99993896484375
further O O 0.9999898672103882
evaluation O O 0.9999897480010986
as O O 0.9999608993530273
predictive O O 0.9999810457229614
biomarkers O O 0.9994152784347534
. O O 0.999956488609314

Intradermal O O 0.9996424913406372
glutamate B B 0.9987616539001465
and O O 0.9499512314796448
capsaicin B B 0.9904792904853821
injections O O 0.9995028972625732
: O O 0.9999339580535889
intra O O 0.9998648166656494
- O O 0.9999583959579468
and O O 0.999944806098938
interindividual O O 0.9980720281600952
variability O O 0.9999929666519165
of O O 0.9999628067016602
provoked O O 0.9990838766098022
hyperalgesia O O 0.9996272325515747
and O O 0.9998922348022461
allodynia O O 0.9999768733978271
. O O 0.9999324083328247

Intradermal O O 0.9999803304672241
injections O O 0.9999648332595825
of O O 0.9997095465660095
glutamate B B 0.9982826709747314
and O O 0.9519182443618774
capsaicin B B 0.9968434572219849
are O O 0.9998860359191895
attractive O O 0.9999418258666992
to O O 0.9999892711639404
use O O 0.9999843835830688
in O O 0.9999738931655884
human O O 0.9999352693557739
experimental O O 0.9999567270278931
pain O O 0.9998264908790588
models O O 0.9999879598617554
because O O 0.9999667406082153
hyperalgesia O O 0.9992629885673523
and O O 0.9998058676719666
allodynia O O 0.9989674091339111
mimic O O 0.9999269247055054
isolated O O 0.99886155128479
aspects O O 0.9999935626983643
of O O 0.9999858140945435
clinical O O 0.9999635219573975
pain O O 0.9998201727867126
disorders O O 0.999994158744812
. O O 0.9999654293060303

The O O 0.9999901056289673
aim O O 0.999996542930603
of O O 0.9999949932098389
the O O 0.9999967813491821
present O O 0.9999927282333374
study O O 0.9999924898147583
was O O 0.999994158744812
to O O 0.9999942779541016
investigate O O 0.9999737739562988
the O O 0.9999862909317017
reproducibility O O 0.9999973773956299
of O O 0.9999806880950928
these O O 0.9998817443847656
models O O 0.99998939037323
. O O 0.9999825954437256

Twenty O O 0.9997844099998474
healthy O O 0.9999912977218628
male O O 0.9999915361404419
volunteers O O 0.9999958276748657
( O O 0.9999783039093018
mean O O 0.9999972581863403
age O O 0.9999932050704956
24 O O 0.9999990463256836
years O O 0.9999980926513672
; O O 0.999994158744812
range O O 0.9999946355819702
18 O O 0.9999938011169434
- O O 0.9998615980148315
38 O O 0.9999966621398926
years O O 0.9999959468841553
) O O 0.9999799728393555
received O O 0.9999731779098511
intradermal O O 0.9999947547912598
injections O O 0.9999812841415405
of O O 0.999472439289093
glutamate B B 0.9980940222740173
and O O 0.7864054441452026
capsaicin B B 0.9948239326477051
in O O 0.999680757522583
the O O 0.9999748468399048
volar O O 0.9999874830245972
forearm O O 0.9999927282333374
. O O 0.9999784231185913

Magnitudes O O 0.9997361302375793
of O O 0.9999459981918335
secondary O O 0.9995237588882446
pinprick O O 0.6334398984909058
hyperalgesia O O 0.9997979998588562
and O O 0.9998562335968018
brush O O 0.48151689767837524
- O O 0.9997468590736389
evoked O O 0.9999790191650391
allodynia O O 0.9999904632568359
were O O 0.9999650716781616
investigated O O 0.9999754428863525
using O O 0.999954104423523
von O O 0.7352979779243469
Frey O O 0.8099943995475769
filaments O O 0.9970883727073669
( O O 0.9995995163917542
gauges O O 0.9828099012374878
10 O O 0.9978588223457336
, O O 0.9990456700325012
15 O O 0.9999476671218872
, O O 0.9980148077011108
60 O O 0.9986427426338196
and O O 0.9983880519866943
100 O O 0.996509850025177
g O O 0.98808753490448
) O O 0.9999690055847168
and O O 0.9997710585594177
brush O O 0.6274210810661316
strokes O O 0.9861782789230347
. O O 0.9999591112136841

Areas O O 0.9998732805252075
of O O 0.9999260902404785
secondary O O 0.9996625185012817
hyperalgesia O O 0.9995418787002563
and O O 0.9997579455375671
allodynia O O 0.9999290704727173
were O O 0.9999443292617798
quantified O O 0.9999021291732788
immediately O O 0.9999675750732422
after O O 0.9999643564224243
injection O O 0.9999476671218872
and O O 0.9999406337738037
after O O 0.9999046325683594
15 O O 0.999983549118042
, O O 0.9999390840530396
30 O O 0.9999853372573853
and O O 0.9999426603317261
60 O O 0.9999791383743286
min O O 0.999951958656311
. O O 0.9999351501464844

Two O O 0.9999713897705078
identical O O 0.9999810457229614
experiments O O 0.9999886751174927
separated O O 0.9999691247940063
by O O 0.999983549118042
at O O 0.9999884366989136
least O O 0.9999935626983643
7 O O 0.9999486207962036
days O O 0.9999895095825195
were O O 0.999988317489624
performed O O 0.9999924898147583
. O O 0.999971866607666

Reproducibility O O 0.9999825954437256
across O O 0.9998972415924072
and O O 0.9997649788856506
within O O 0.9966974258422852
volunteers O O 0.9978493452072144
( O O 0.9998478889465332
inter O O 0.9997590184211731
- O O 0.9999592304229736
and O O 0.9999098777770996
intra O O 0.9999574422836304
- O O 0.9999692440032959
individual O O 0.9999843835830688
variation O O 0.9999983310699463
, O O 0.9999896287918091
respectively O O 0.9999781847000122
) O O 0.9999793767929077
was O O 0.9999815225601196
assessed O O 0.9999938011169434
using O O 0.9999632835388184
intraclass O O 0.9999165534973145
correlation O O 0.9999752044677734
coefficient O O 0.9999855756759644
( O O 0.9999604225158691
ICC O O 0.9998470544815063
) O O 0.9999644756317139
and O O 0.9999508857727051
coefficient O O 0.9999206066131592
of O O 0.999948263168335
variation O O 0.9999963045120239
( O O 0.9998711347579956
CV O O 0.9978967905044556
) O O 0.9999817609786987
. O O 0.9999812841415405

Secondary O O 0.999291181564331
pinprick O O 0.9158769845962524
hyperalgesia O O 0.9999030828475952
was O O 0.9999568462371826
observed O O 0.9999725818634033
as O O 0.9999748468399048
a O O 0.9999886751174927
marked O O 0.99997878074646
increase O O 0.9999743700027466
in O O 0.9999765157699585
the O O 0.9999750852584839
visual O O 0.9995719790458679
analogue O O 0.9999535083770752
scale O O 0.9992220401763916
( O O 0.9996232986450195
VAS O O 0.9925220608711243
) O O 0.9998670816421509
response O O 0.9999408721923828
to O O 0.9996304512023926
von O O 0.5631012916564941
Frey O O 0.4199748635292053
gauges O O 0.9298348426818848
60 O O 0.984860360622406
and O O 0.9984157085418701
100 O O 0.9912617206573486
g O O 0.9952778816223145
( O O 0.9999420642852783
P O O 0.9999762773513794
< O O 0.9999710321426392
0 O O 0.9999895095825195
. O O 0.9999960660934448
001 O O 0.9999569654464722
) O O 0.9999774694442749
after O O 0.9999052286148071
glutamate B B 0.999390721321106
injection O O 0.9999319314956665
. O O 0.9999700784683228

For O O 0.9969906806945801
capsaicin B B 0.9990590214729309
, O O 0.9998379945755005
secondary O O 0.9997201561927795
pinprick O O 0.5961014628410339
hyperalgesia O O 0.9998339414596558
was O O 0.9999663829803467
detected O O 0.9999921321868896
with O O 0.9996675252914429
all O O 0.9992620348930359
von O O 0.9831860065460205
Frey O O 0.6114524602890015
gauges O O 0.7624976634979248
( O O 0.9999064207077026
P O O 0.9996820688247681
< O O 0.9999353885650635
0 O O 0.9999834299087524
. O O 0.9999960660934448
001 O O 0.9999241828918457
) O O 0.9999614953994751
. O O 0.9999668598175049

Glutamate B B 0.997373104095459
evoked O O 0.9985463619232178
reproducible O O 0.9999294281005859
VAS O O 0.9987298846244812
response O O 0.9999405145645142
to O O 0.9997512698173523
all O O 0.999534010887146
von O O 0.9626843333244324
Frey O O 0.9840898513793945
gauges O O 0.9949624538421631
( O O 0.9999277591705322
ICC O O 0.9987077713012695
> O O 0.9997865557670593
0 O O 0.9998458623886108
. O O 0.9999828338623047
60 O O 0.9999916553497314
) O O 0.9999442100524902
and O O 0.9992303848266602
brush O O 0.49555808305740356
strokes O O 0.9997273087501526
( O O 0.9999383687973022
ICC O O 0.9998070597648621
> O O 0.9998879432678223
0 O O 0.9998906850814819
. O O 0.9999785423278809
83 O O 0.999830961227417
) O O 0.9999412298202515
. O O 0.999958872795105

Capsaicin B B 0.9929688572883606
injection O O 0.999792754650116
was O O 0.9999547004699707
reproducible O O 0.9999812841415405
for O O 0.9998618364334106
secondary O O 0.9995415210723877
hyperalgesia O O 0.9997062087059021
( O O 0.9999444484710693
ICC O O 0.9967818260192871
> O O 0.9991350769996643
0 O O 0.9981347322463989
. O O 0.9999748468399048
70 O O 0.9999425411224365
) O O 0.9999470710754395
and O O 0.9998606443405151
allodynia O O 0.9999525547027588
( O O 0.9999266862869263
ICC O O 0.9972731471061707
> O O 0.9994764924049377
0 O O 0.9994327425956726
. O O 0.9999778270721436
71 O O 0.9999561309814453
) O O 0.9999536275863647
. O O 0.9999752044677734

Intra O O 0.999914288520813
- O O 0.9999502897262573
individual O O 0.9999622106552124
variability O O 0.9999929666519165
was O O 0.9999557733535767
generally O O 0.9999799728393555
lower O O 0.9999793767929077
for O O 0.9998942613601685
the O O 0.9998667240142822
VAS O O 0.9981479644775391
response O O 0.999922513961792
to O O 0.9993807077407837
von O O 0.6381337642669678
Frey O O 0.8118958473205566
and O O 0.9726038575172424
brush O O 0.7869678735733032
compared O O 0.9998261332511902
with O O 0.9999194145202637
areas O O 0.9999361038208008
of O O 0.9999390840530396
secondary O O 0.9997300505638123
hyperalgesia O O 0.9996428489685059
and O O 0.9998729228973389
allodynia O O 0.999790608882904
. O O 0.9999432563781738

In O O 0.9999274015426636
conclusion O O 0.9999363422393799
, O O 0.9995087385177612
glutamate B B 0.9995285272598267
and O O 0.9707435965538025
capsaicin B B 0.9990648627281189
yield O O 0.9994159936904907
reproducible O O 0.999919056892395
hyperalgesic O O 0.9997791647911072
and O O 0.9998028874397278
allodynic O O 0.999727189540863
responses O O 0.999967098236084
, O O 0.999944806098938
and O O 0.9999756813049316
the O O 0.9999964237213135
present O O 0.9999926090240479
model O O 0.9999949932098389
is O O 0.9999825954437256
well O O 0.9999642372131348
suited O O 0.9999945163726807
for O O 0.9999701976776123
basic O O 0.9999854564666748
research O O 0.9999963045120239
, O O 0.9999799728393555
as O O 0.9999750852584839
well O O 0.9999792575836182
as O O 0.9999884366989136
for O O 0.9999792575836182
assessing O O 0.9999792575836182
the O O 0.9999762773513794
modulation O O 0.9999760389328003
of O O 0.9999710321426392
central O O 0.9999407529830933
phenomena O O 0.9999953508377075
. O O 0.9999707937240601

Ocular O O 0.7886442542076111
- O O 0.9997881054878235
specific O O 0.9936507344245911
ER O O 0.688740074634552
stress O O 0.9770025014877319
reduction O O 0.9489309191703796
rescues O O 0.9995366334915161
glaucoma O O 0.9966467022895813
in O O 0.9998175501823425
murine O O 0.8593170046806335
glucocorticoid O B 0.8881974220275879
- O O 0.9992656111717224
induced O O 0.9999572038650513
glaucoma O O 0.9983508586883545
. O O 0.9999275207519531

Administration O O 0.9997633099555969
of O O 0.9991776347160339
glucocorticoids O B 0.961311936378479
induces O O 0.9994742274284363
ocular O O 0.9999053478240967
hypertension O O 0.9998712539672852
in O O 0.9999192953109741
some O O 0.999916672706604
patients O O 0.9999780654907227
. O O 0.9999476671218872

If O O 0.9999089241027832
untreated O O 0.9998610019683838
, O O 0.9999568462371826
these O O 0.9999608993530273
patients O O 0.9999792575836182
can O O 0.999962329864502
develop O O 0.9999901056289673
a O O 0.9999645948410034
secondary O O 0.9999082088470459
glaucoma O O 0.9997566342353821
that O O 0.999923825263977
resembles O O 0.9999723434448242
primary O O 0.9997557997703552
open O O 0.9950254559516907
- O O 0.9999202489852905
angle O O 0.9809685945510864
glaucoma O O 0.9969147443771362
( O O 0.9997105002403259
POAG O O 0.9861770272254944
) O O 0.9999450445175171
. O O 0.9999693632125854

The O O 0.9999849796295166
underlying O O 0.9999631643295288
pathology O O 0.9999858140945435
of O O 0.9999592304229736
glucocorticoid O B 0.9984464049339294
- O O 0.9988000392913818
induced O O 0.9999384880065918
glaucoma O O 0.9986775517463684
is O O 0.999969482421875
not O O 0.9999954700469971
fully O O 0.999995231628418
understood O O 0.9999954700469971
, O O 0.9999781847000122
due O O 0.9999905824661255
in O O 0.9999911785125732
part O O 0.9999953508377075
to O O 0.9999921321868896
lack O O 0.9999985694885254
of O O 0.9999974966049194
an O O 0.9999970197677612
appropriate O O 0.9999934434890747
animal O O 0.9999922513961792
model O O 0.9999964237213135
. O O 0.9999828338623047

Here O O 0.999969482421875
, O O 0.9999815225601196
we O O 0.999977707862854
developed O O 0.9999881982803345
a O O 0.9999879598617554
murine O O 0.9999830722808838
model O O 0.999993085861206
of O O 0.9999361038208008
glucocorticoid O B 0.9957127571105957
- O O 0.9989686012268066
induced O O 0.9999281167984009
glaucoma O O 0.9997307658195496
that O O 0.9999369382858276
exhibits O O 0.9997636675834656
glaucoma O O 0.9912403225898743
features O O 0.9999793767929077
that O O 0.9999748468399048
are O O 0.9999890327453613
observed O O 0.9999908208847046
in O O 0.9999593496322632
patients O O 0.999931812286377
. O O 0.999946117401123

Treatment O O 0.9999415874481201
of O O 0.9999852180480957
WT O O 0.9943456053733826
mice O O 0.9999480247497559
with O O 0.9999051094055176
topical O O 0.9998931884765625
ocular O O 0.9855964183807373
0 O O 0.9973616003990173
. O O 0.9999786615371704
1 O O 0.9999374151229858
% O O 0.9931180477142334
dexamethasone B B 0.9985969662666321
led O O 0.9999361038208008
to O O 0.9999866485595703
elevation O O 0.9999743700027466
of O O 0.9999686479568481
intraocular O O 0.9999452829360962
pressure O O 0.9993403553962708
( O O 0.9998072981834412
IOP O O 0.9952803254127502
) O O 0.999945878982544
, O O 0.9999568462371826
functional O O 0.9999778270721436
and O O 0.9999680519104004
structural O O 0.9999880790710449
loss O O 0.9999966621398926
of O O 0.999955415725708
retinal O O 0.9998708963394165
ganglion O O 0.9991782307624817
cells O O 0.9999948740005493
, O O 0.9999306201934814
and O O 0.9999368190765381
axonal O O 0.9999409914016724
degeneration O O 0.9999970197677612
, O O 0.999988317489624
resembling O O 0.99988853931427
glucocorticoid O B 0.9931907057762146
- O O 0.9992682337760925
induced O O 0.9999444484710693
glaucoma O O 0.9997976422309875
in O O 0.9999749660491943
human O O 0.9994183778762817
patients O O 0.9999889135360718
. O O 0.9999808073043823

Furthermore O O 0.9998888969421387
, O O 0.9998434782028198
dexamethasone B B 0.9997263550758362
- O O 0.9998455047607422
induced O O 0.9998798370361328
ocular O O 0.9999786615371704
hypertension O O 0.9999409914016724
was O O 0.9999480247497559
associated O O 0.9999853372573853
with O O 0.9999655485153198
chronic O O 0.9998389482498169
ER O O 0.9982171654701233
stress O O 0.9986894726753235
of O O 0.9998770952224731
the O O 0.9999626874923706
trabecular O O 0.9953473210334778
meshwork O O 0.999581515789032
( O O 0.9995689988136292
TM O O 0.6770399212837219
) O O 0.9999216794967651
. O O 0.9999537467956543

Similar O O 0.9999701976776123
to O O 0.9999793767929077
patients O O 0.9999833106994629
, O O 0.9999414682388306
withdrawal O O 0.9994763731956482
of O O 0.9993270635604858
dexamethasone B B 0.9995406866073608
treatment O O 0.998304009437561
reduced O O 0.9998984336853027
elevated O O 0.9997748732566833
IOP O O 0.7032603025436401
and O O 0.9997404217720032
ER O O 0.5096143484115601
stress O O 0.9955503940582275
in O O 0.9999817609786987
this O O 0.9999854564666748
animal O O 0.9999911785125732
model O O 0.9999957084655762
. O O 0.9999821186065674

Dexamethasone B B 0.9982908368110657
induced O O 0.9995896220207214
the O O 0.9998657703399658
transcriptional O O 0.9981217980384827
factor O O 0.995731770992279
CHOP O O 0.7876943945884705
, O O 0.9999707937240601
a O O 0.9999390840530396
marker O O 0.9999747276306152
for O O 0.9999641180038452
chronic O O 0.9998099207878113
ER O O 0.9663727283477783
stress O O 0.9997313618659973
, O O 0.9999734163284302
in O O 0.9996594190597534
the O O 0.9999010562896729
anterior O O 0.9994392991065979
segment O O 0.9999682903289795
tissues O O 0.9999833106994629
, O O 0.9999263286590576
and O O 0.9997166991233826
Chop O O 0.4748833477497101
deletion O O 0.9991274476051331
reduced O O 0.9998688697814941
ER O O 0.6165918707847595
stress O O 0.9996441602706909
in O O 0.9998346567153931
these O O 0.9998207688331604
tissues O O 0.999972939491272
and O O 0.9999696016311646
prevented O O 0.9999254941940308
dexamethasone B B 0.9998672008514404
- O O 0.9998726844787598
induced O O 0.9999505281448364
ocular O O 0.9999897480010986
hypertension O O 0.9999864101409912
. O O 0.9999604225158691

Furthermore O O 0.9998993873596191
, O O 0.9997453093528748
reduction O O 0.9995040893554688
of O O 0.9720450639724731
ER O O 0.5493959188461304
stress O O 0.728695273399353
in O O 0.9989131689071655
the O O 0.9993821382522583
TM O O 0.5854317545890808
with O O 0.9995983242988586
sodium B B 0.9871057271957397
4 I I 0.9946712851524353
- I I 0.9995898604393005
phenylbutyrate I I 0.9999326467514038
prevented O O 0.9992040991783142
dexamethasone B B 0.9997766613960266
- O O 0.9998931884765625
induced O O 0.9999524354934692
ocular O O 0.9999756813049316
hypertension O O 0.9999740123748779
in O O 0.9999599456787109
WT O O 0.9991344809532166
mice O O 0.999996542930603
. O O 0.9999756813049316

Our O O 0.9999696016311646
data O O 0.9999924898147583
indicate O O 0.9999245405197144
that O O 0.9997337460517883
ER O B 0.9386793971061707
stress O O 0.9198542237281799
contributes O O 0.9992107152938843
to O O 0.999823272228241
glucocorticoid O B 0.99664306640625
- O O 0.9996005892753601
induced O O 0.9999531507492065
ocular O O 0.9999867677688599
hypertension O O 0.9999736547470093
and O O 0.9999778270721436
suggest O O 0.9999673366546631
that O O 0.9999425411224365
reducing O O 0.9996997117996216
ER O B 0.9471697807312012
stress O O 0.9706875681877136
has O O 0.9999597072601318
potential O O 0.9999899864196777
as O O 0.9999889135360718
a O O 0.9999879598617554
therapeutic O O 0.9999710321426392
strategy O O 0.9999933242797852
for O O 0.9999619722366333
treating O O 0.9999370574951172
glucocorticoid O B 0.9941160678863525
- O O 0.999573290348053
induced O O 0.9999642372131348
glaucoma O O 0.9998817443847656
. O O 0.9999603033065796

Effects O O 0.9997579455375671
of O O 0.9983348250389099
ginsenosides B B 0.9899517893791199
on O O 0.9993076324462891
opioid O B 0.9654259085655212
- O O 0.999484658241272
induced O O 0.9999086856842041
hyperalgesia O O 0.9999085664749146
in O O 0.9998950958251953
mice O O 0.9999589920043945
. O O 0.9999117851257324

Opioid O B 0.9638722538948059
- O O 0.9988020658493042
induced O O 0.9999158382415771
hyperalgesia O O 0.9992057681083679
( O O 0.9999150037765503
OIH O O 0.975802481174469
) O O 0.9999619722366333
is O O 0.999945878982544
characterized O O 0.9999773502349854
by O O 0.9999443292617798
nociceptive O O 0.9680191278457642
sensitization O O 0.9986830353736877
caused O O 0.9999449253082275
by O O 0.9999613761901855
the O O 0.9999904632568359
cessation O O 0.99997878074646
of O O 0.9999784231185913
chronic O O 0.9997584223747253
opioid O B 0.9549641013145447
use O O 0.999636173248291
. O O 0.9998453855514526

OIH O B 0.9674057960510254
can O O 0.9989988207817078
limit O O 0.999966025352478
the O O 0.9999871253967285
clinical O O 0.9999852180480957
use O O 0.9999816417694092
of O O 0.9998880624771118
opioid O O 0.7204427719116211
analgesics O O 0.9057552814483643
and O O 0.9999618530273438
complicate O O 0.9999598264694214
withdrawal O O 0.9999912977218628
from O O 0.9998997449874878
opioid O O 0.6294489502906799
addiction O O 0.927824079990387
. O O 0.9999293088912964

In O O 0.999976634979248
this O O 0.9999754428863525
study O O 0.999980092048645
, O O 0.9999433755874634
we O O 0.9999337196350098
investigated O O 0.9999363422393799
the O O 0.9998835325241089
effects O O 0.9999101161956787
of O O 0.9988208413124084
Re B B 0.948491096496582
, I O 0.8210486173629761
Rg1 I O 0.610144853591919
, I O 0.9035223722457886
and I O 0.986232340335846
Rb1 I O 0.5592862963676453
ginsenosides I O 0.6731573343276978
, O O 0.9971177577972412
the O O 0.9996747970581055
bioactive O O 0.9549840688705444
components O O 0.9950188398361206
of O O 0.9965496063232422
ginseng O O 0.7394257187843323
, O O 0.9995057582855225
on O O 0.9996774196624756
OIH O O 0.9712284803390503
. O O 0.9999439716339111

OIH O O 0.9267533421516418
was O O 0.9999836683273315
achieved O O 0.999975323677063
in O O 0.9999595880508423
mice O O 0.9998859167098999
after O O 0.9999351501464844
subcutaneous O O 0.9998062252998352
administration O O 0.9999576807022095
of O O 0.9998829364776611
morphine B B 0.9996938705444336
for O O 0.9998477697372437
7 O O 0.9999735355377197
consecutive O O 0.9999804496765137
days O O 0.9999877214431763
three O O 0.999969482421875
times O O 0.9999054670333862
per O O 0.9999922513961792
day O O 0.9999946355819702
. O O 0.9999865293502808

During O O 0.9997401833534241
withdrawal O O 0.9999536275863647
( O O 0.9999643564224243
days O O 0.999990701675415
8 O O 0.9999767541885376
and O O 0.9999891519546509
9 O O 0.9999864101409912
) O O 0.9999840259552002
, O O 0.9999762773513794
these O O 0.9995852112770081
mice O O 0.9463139772415161
were O O 0.9999402761459351
administered O O 0.9995868802070618
Re B B 0.9567654132843018
, O O 0.6455299854278564
Rg1 B B 0.9041975736618042
, O O 0.7853911519050598
or O O 0.9878966808319092
Rb1 B B 0.9553396105766296
intragastrically O O 0.9998891353607178
two O O 0.9999767541885376
times O O 0.9999642372131348
per O O 0.9999879598617554
day O O 0.9999957084655762
. O O 0.9999849796295166

On O O 0.9999715089797974
the O O 0.9999918937683105
test O O 0.999990701675415
day O O 0.9999972581863403
( O O 0.9999386072158813
day O O 0.9999970197677612
10 O O 0.9999887943267822
) O O 0.9999874830245972
, O O 0.999985933303833
mice O O 0.9999946355819702
were O O 0.9999960660934448
subjected O O 0.9999929666519165
to O O 0.9999816417694092
the O O 0.9999655485153198
thermal O O 0.9987615346908569
sensitivity O O 0.9999557733535767
test O O 0.9999823570251465
and O O 0.9999562501907349
the O O 0.9999585151672363
acetic B B 0.976232647895813
acid I I 0.9996510744094849
- O O 0.9978070855140686
induced O O 0.9999432563781738
writhing O O 0.9999097585678101
test O O 0.9999864101409912
. O O 0.9999867677688599

Re B B 0.9379797577857971
( O O 0.9989633560180664
300 O O 0.9998056292533875
mg O O 0.9999626874923706
/ O O 0.9999321699142456
kg O O 0.9999376535415649
) O O 0.99970942735672
inhibited O O 0.9998674392700195
OIH O O 0.8559418320655823
in O O 0.9999300241470337
both O O 0.9999139308929443
the O O 0.999975323677063
thermal O O 0.9995633959770203
sensitivity O O 0.9999639987945557
test O O 0.9999791383743286
and O O 0.9999566078186035
the O O 0.9999676942825317
acetic B B 0.986292839050293
acid I I 0.9997934699058533
- O O 0.9989257454872131
induced O O 0.9999667406082153
writhing O O 0.9999781847000122
test O O 0.9999843835830688
. O O 0.9999253749847412

However O O 0.9999480247497559
, O O 0.9997822642326355
the O O 0.9997890591621399
Rg1 B O 0.4980669617652893
and I O 0.994734525680542
Rb1 I O 0.550983726978302
ginsenosides I O 0.6992653608322144
failed O O 0.9997057318687439
to O O 0.9999773502349854
prevent O O 0.999762237071991
OIH O O 0.8629093766212463
in O O 0.9999332427978516
either O O 0.9998711347579956
test O O 0.9999548196792603
. O O 0.9999618530273438

Furthermore O O 0.9997747540473938
, O O 0.9994120597839355
Rg1 B O 0.6642515063285828
showed O O 0.9997947812080383
a O O 0.9999339580535889
tendency O O 0.9999767541885376
to O O 0.9999216794967651
aggravate O O 0.9999189376831055
OIH O O 0.9651767611503601
in O O 0.9999123811721802
the O O 0.9999446868896484
acetic B B 0.9811229109764099
acid I I 0.999519944190979
- O O 0.99871826171875
induced O O 0.9999251365661621
writhing O O 0.9999643564224243
test O O 0.9999681711196899
. O O 0.9999649524688721

Our O O 0.9999421834945679
data O O 0.9999803304672241
suggested O O 0.9999706745147705
that O O 0.9998145699501038
the O O 0.9986249208450317
ginsenoside B B 0.9858801960945129
Re I O 0.8714113235473633
, O O 0.9998376369476318
but O O 0.9998650550842285
not O O 0.9994200468063354
Rg1 B O 0.5711981058120728
or O O 0.9962643980979919
Rb1 B O 0.7524076700210571
, O O 0.9995471835136414
may O O 0.9999064207077026
contribute O O 0.9999232292175293
toward O O 0.9999326467514038
reversal O O 0.9999023675918579
of O O 0.9999169111251831
OIH O O 0.7716745734214783
. O O 0.9998917579650879

A O O 0.9999314546585083
comparison O O 0.9999752044677734
of O O 0.9999591112136841
severe O O 0.9999583959579468
hemodynamic O O 0.9999632835388184
disturbances O O 0.9999876022338867
between O O 0.9964641332626343
dexmedetomidine B B 0.9996440410614014
and O O 0.9755396842956543
propofol B B 0.9997779726982117
for O O 0.999739944934845
sedation O O 0.9993300437927246
in O O 0.9999511241912842
neurocritical O O 0.9999935626983643
care O O 0.9999849796295166
patients O O 0.999991774559021
. O O 0.9999756813049316

OBJECTIVE O O 0.9192230701446533
: O O 0.9982982277870178
Dexmedetomidine B B 0.9992401599884033
and O O 0.9735609292984009
propofol B B 0.9997255206108093
are O O 0.999846339225769
commonly O O 0.9999289512634277
used O O 0.9998514652252197
sedatives O O 0.6348346471786499
in O O 0.9998503923416138
neurocritical O O 0.9999923706054688
care O O 0.9999915361404419
as O O 0.9999802112579346
they O O 0.9998534917831421
allow O O 0.9999685287475586
for O O 0.9999885559082031
frequent O O 0.9999911785125732
neurologic O O 0.9999938011169434
examinations O O 0.9999979734420776
. O O 0.9999692440032959

However O O 0.9998158812522888
, O O 0.9999361038208008
both O O 0.9957383871078491
agents O O 0.9933193922042847
are O O 0.9997609257698059
associated O O 0.9999716281890869
with O O 0.9999765157699585
significant O O 0.9999724626541138
hemodynamic O O 0.9998984336853027
side O O 0.9999606609344482
effects O O 0.9999897480010986
. O O 0.9999555349349976

The O O 0.9999903440475464
primary O O 0.9999922513961792
objective O O 0.9999982118606567
of O O 0.9999933242797852
this O O 0.9999914169311523
study O O 0.9999866485595703
is O O 0.9999904632568359
to O O 0.9999942779541016
compare O O 0.9999583959579468
the O O 0.9999773502349854
prevalence O O 0.9999145269393921
of O O 0.9999656677246094
severe O O 0.9998700618743896
hemodynamic O O 0.9998878240585327
effects O O 0.9999552965164185
in O O 0.9999470710754395
neurocritical O O 0.9999939203262329
care O O 0.9999878406524658
patients O O 0.9999767541885376
receiving O O 0.999749481678009
dexmedetomidine B B 0.9995937943458557
and O O 0.9888888001441956
propofol B B 0.9997397065162659
. O O 0.9999548196792603

DESIGN O O 0.9999899864196777
: O O 0.9999954700469971
Multicenter O O 0.9999369382858276
, O O 0.9999910593032837
retrospective O O 0.9999853372573853
, O O 0.9999862909317017
propensity O O 0.999640941619873
- O O 0.9998838901519775
matched O O 0.9995446801185608
cohort O O 0.999980092048645
study O O 0.9999910593032837
. O O 0.9999879598617554

SETTING O O 0.9999164342880249
: O O 0.9999732971191406
Neurocritical O O 0.999958872795105
care O O 0.9999891519546509
units O O 0.9999912977218628
at O O 0.9999651908874512
two O O 0.9999877214431763
academic O O 0.9999762773513794
medical O O 0.9999982118606567
centers O O 0.9999974966049194
with O O 0.9999825954437256
dedicated O O 0.9999630451202393
neurocritical O O 0.9999909400939941
care O O 0.9999749660491943
teams O O 0.9999850988388062
and O O 0.9999544620513916
board O O 0.9997929930686951
- O O 0.9999818801879883
certified O O 0.9999128580093384
neurointensivists O O 0.9999682903289795
. O O 0.99997878074646

PATIENTS O O 0.9998936653137207
: O O 0.9999735355377197
Neurocritical O O 0.9999709129333496
care O O 0.9999823570251465
patients O O 0.9999842643737793
admitted O O 0.9999732971191406
between O O 0.9993035793304443
July O O 0.9540504813194275
2009 O O 0.9865434765815735
and O O 0.9991098046302795
September O O 0.8848377466201782
2012 O O 0.973215639591217
were O O 0.9999529123306274
evaluated O O 0.9999874830245972
and O O 0.9999617338180542
then O O 0.9999719858169556
matched O O 0.9999734163284302
1 O O 0.9991963505744934
: O O 0.9999384880065918
1 O O 0.9999369382858276
based O O 0.9999864101409912
on O O 0.9999727010726929
propensity O O 0.9997265934944153
scoring O O 0.998224675655365
of O O 0.9999798536300659
baseline O O 0.9999512434005737
characteristics O O 0.9999842643737793
. O O 0.9999803304672241

INTERVENTIONS O O 0.9985644221305847
: O O 0.9999475479125977
Continuous O O 0.9997851252555847
sedation O O 0.9997051358222961
with O O 0.9998824596405029
dexmedetomidine B B 0.9990283250808716
or O O 0.9805296659469604
propofol B B 0.9990413784980774
. O O 0.9999029636383057

MEASUREMENTS O O 0.9995846152305603
AND O O 0.9999686479568481
MAIN O O 0.9999790191650391
RESULTS O O 0.9999839067459106
: O O 0.9999427795410156
A O O 0.9999797344207764
total O O 0.9999840259552002
of O O 0.9999861717224121
342 O O 0.9999686479568481
patients O O 0.9999896287918091
( O O 0.999582827091217
105 O O 0.9462133646011353
dexmedetomidine B B 0.9985013008117676
and O O 0.9950742125511169
237 O O 0.9724982976913452
propofol B B 0.998633086681366
) O O 0.9996792078018188
were O O 0.9999783039093018
included O O 0.9999945163726807
in O O 0.9999829530715942
the O O 0.9999929666519165
analysis O O 0.9999910593032837
, O O 0.9999808073043823
with O O 0.9999943971633911
190 O O 0.9994811415672302
matched O O 0.9999936819076538
( O O 0.9999862909317017
95 O O 0.9983237385749817
in O O 0.9999847412109375
each O O 0.9999645948410034
group O O 0.9999672174453735
) O O 0.9999701976776123
by O O 0.9999516010284424
propensity O O 0.9991992115974426
score O O 0.998823344707489
. O O 0.9999649524688721

The O O 0.9999827146530151
primary O O 0.9999881982803345
outcome O O 0.9999972581863403
of O O 0.9999908208847046
this O O 0.999985933303833
study O O 0.999991774559021
was O O 0.9999866485595703
a O O 0.9999759197235107
composite O O 0.9999740123748779
of O O 0.9999698400497437
severe O O 0.9999759197235107
hypotension O O 0.9999710321426392
( O O 0.9999611377716064
mean O O 0.9999935626983643
arterial O O 0.9999657869338989
pressure O O 0.999982476234436
< O O 0.9999808073043823
60 O O 0.9999979734420776
mm O O 0.9999978542327881
Hg O O 0.6765883564949036
) O O 0.9999666213989258
and O O 0.9999136924743652
bradycardia O O 0.9999854564666748
( O O 0.9999744892120361
heart O O 0.9999926090240479
rate O O 0.9999974966049194
< O O 0.9999879598617554
50 O O 0.9999948740005493
beats O O 0.9999991655349731
/ O O 0.9999921321868896
min O O 0.9999951124191284
) O O 0.9999817609786987
during O O 0.9999337196350098
sedative O O 0.6058430075645447
infusion O O 0.9997536540031433
. O O 0.9999575614929199

No O O 0.9999792575836182
difference O O 0.9999947547912598
in O O 0.999987006187439
the O O 0.9999873638153076
primary O O 0.9999707937240601
composite O O 0.9999803304672241
outcome O O 0.9999910593032837
in O O 0.9998435974121094
both O O 0.9999401569366455
the O O 0.9999842643737793
unmatched O O 0.9992806315422058
( O O 0.9999330043792725
30 O O 0.9999804496765137
% O O 0.9999945163726807
vs O O 0.9999321699142456
30 O O 0.9999802112579346
% O O 0.9999935626983643
, O O 0.9999692440032959
p O O 0.9998621940612793
= O O 0.9999476671218872
0 O O 0.999985933303833
. O O 0.9999916553497314
94 O O 0.9996020197868347
) O O 0.9999042749404907
or O O 0.9998393058776855
matched O O 0.9999091625213623
cohorts O O 0.9999369382858276
( O O 0.9999431371688843
28 O O 0.9999862909317017
% O O 0.999994158744812
vs O O 0.9999476671218872
34 O O 0.9999772310256958
% O O 0.9999947547912598
, O O 0.9999651908874512
p O O 0.9998980760574341
= O O 0.9999651908874512
0 O O 0.9999649524688721
. O O 0.9999949932098389
35 O O 0.9999960660934448
) O O 0.9999775886535645
could O O 0.9999872446060181
be O O 0.999995231628418
found O O 0.9999958276748657
. O O 0.9999767541885376

When O O 0.9999715089797974
analyzed O O 0.9999911785125732
separately O O 0.9999737739562988
, O O 0.9999799728393555
no O O 0.9999790191650391
differences O O 0.9999939203262329
could O O 0.9999876022338867
be O O 0.9999980926513672
found O O 0.9999972581863403
in O O 0.9999858140945435
the O O 0.9999872446060181
prevalence O O 0.9999603033065796
of O O 0.9999748468399048
severe O O 0.9999775886535645
hypotension O O 0.9999649524688721
or O O 0.9999182224273682
bradycardia O O 0.9999877214431763
in O O 0.9999418258666992
either O O 0.9999558925628662
the O O 0.9999798536300659
unmatched O O 0.998583197593689
or O O 0.9998569488525391
matched O O 0.9998880624771118
cohorts O O 0.9998918771743774
. O O 0.9999688863754272

CONCLUSIONS O O 0.995383083820343
: O O 0.9999339580535889
Severe O O 0.9999532699584961
hypotension O O 0.9999712705612183
and O O 0.9998999834060669
bradycardia O O 0.9999805688858032
occur O O 0.9999871253967285
at O O 0.9999823570251465
similar O O 0.99994957447052
prevalence O O 0.9999887943267822
in O O 0.9999675750732422
neurocritical O O 0.9999920129776001
care O O 0.9999902248382568
patients O O 0.9999927282333374
who O O 0.9999761581420898
receive O O 0.9997963309288025
dexmedetomidine B B 0.999382495880127
or O O 0.9961501359939575
propofol B B 0.9994950294494629
. O O 0.9999203681945801

Providers O O 0.9998737573623657
should O O 0.9999833106994629
similarly O O 0.9999933242797852
consider O O 0.9999867677688599
the O O 0.9999892711639404
likelihood O O 0.999991774559021
of O O 0.999968409538269
hypotension O O 0.999954104423523
or O O 0.9999686479568481
bradycardia O O 0.9999934434890747
before O O 0.9999698400497437
starting O O 0.9997684359550476
either O O 0.997829258441925
sedative O O 0.5355655550956726
. O O 0.9999068975448608

Hydroxytyrosol B B 0.9956718683242798
ameliorates O O 0.9992703795433044
oxidative O O 0.9863503575325012
stress O O 0.9995412826538086
and O O 0.9999091625213623
mitochondrial O O 0.9997304081916809
dysfunction O O 0.9999933242797852
in O O 0.9995662569999695
doxorubicin B B 0.9997122883796692
- O O 0.9995937943458557
induced O O 0.9999138116836548
cardiotoxicity O O 0.999993085861206
in O O 0.9999288320541382
rats O O 0.9999923706054688
with O O 0.9999896287918091
breast O O 0.9991199374198914
cancer O O 0.9999685287475586
. O O 0.9995403289794922

Oxidative O O 0.9823544025421143
stress O O 0.9432487487792969
is O O 0.9998176693916321
involved O O 0.9999417066574097
in O O 0.9999233484268188
several O O 0.9998685121536255
processes O O 0.9999878406524658
including O O 0.9999603033065796
cancer O O 0.9999867677688599
, O O 0.9999730587005615
aging O O 0.9996137022972107
and O O 0.9999581575393677
cardiovascular O O 0.999968409538269
disease O O 0.9999953508377075
, O O 0.9999542236328125
and O O 0.9999566078186035
has O O 0.9999614953994751
been O O 0.9999923706054688
shown O O 0.9999878406524658
to O O 0.9998331069946289
potentiate O O 0.9994398951530457
the O O 0.999921441078186
therapeutic O O 0.9999120235443115
effect O O 0.9999685287475586
of O O 0.9998552799224854
drugs O O 0.9995328187942505
such O O 0.9999021291732788
as O O 0.9994295239448547
doxorubicin B B 0.9993852376937866
. O O 0.9998815059661865

Doxorubicin B B 0.9993341565132141
causes O O 0.9997773766517639
significant O O 0.9999537467956543
cardiotoxicity O O 0.9999966621398926
characterized O O 0.9999657869338989
by O O 0.9999620914459229
marked O O 0.9999654293060303
increases O O 0.9999523162841797
in O O 0.9999103546142578
oxidative O O 0.9519505500793457
stress O O 0.9911940693855286
and O O 0.9998807907104492
mitochondrial O O 0.9997519850730896
dysfunction O O 0.9999908208847046
. O O 0.9998706579208374

Herein O O 0.9992724061012268
, O O 0.9999556541442871
we O O 0.9999346733093262
investigate O O 0.9999580383300781
whether O O 0.9999581575393677
doxorubicin B B 0.9998518228530884
- O O 0.9998127818107605
associated O O 0.9998961687088013
chronic O O 0.9999392032623291
cardiac O O 0.9999568462371826
toxicity O O 0.9999914169311523
can O O 0.9999765157699585
be O O 0.9999955892562866
ameliorated O O 0.9999911785125732
with O O 0.9998548030853271
the O O 0.9992074370384216
antioxidant O O 0.6732501983642578
hydroxytyrosol B B 0.9770947098731995
in O O 0.9999054670333862
rats O O 0.999982476234436
with O O 0.9999929666519165
breast O O 0.9998031258583069
cancer O O 0.999980092048645
. O O 0.9999758005142212

Thirty O O 0.9992591738700867
- O O 0.9999679327011108
six O O 0.9999947547912598
rats O O 0.9999951124191284
bearing O O 0.9999860525131226
breast O O 0.9981549382209778
tumors O O 0.99998939037323
induced O O 0.9999886751174927
chemically O O 0.9999223947525024
were O O 0.9999816417694092
divided O O 0.9999912977218628
into O O 0.9999610185623169
4 O O 0.9991137385368347
groups O O 0.999982476234436
: O O 0.9997137188911438
control O O 0.9994138479232788
, O O 0.9995304346084595
hydroxytyrosol B B 0.9901767373085022
( O O 0.9977079629898071
0 O O 0.9996496438980103
. O O 0.9999828338623047
5mg O O 0.9998995065689087
/ O O 0.9997130036354065
kg O O 0.9999078512191772
, O O 0.9998948574066162
5days O O 0.9928170442581177
/ O O 0.9999395608901978
week O O 0.9999972581863403
) O O 0.9999346733093262
, O O 0.9991724491119385
doxorubicin B B 0.9997629523277283
( O O 0.9997726082801819
1mg O O 0.9998477697372437
/ O O 0.9999299049377441
kg O O 0.9999967813491821
/ O O 0.9999558925628662
week O O 0.9999979734420776
) O O 0.9999599456787109
, O O 0.9997615218162537
and O O 0.9994553923606873
doxorubicin B B 0.999789297580719
plus O O 0.9932265877723694
hydroxytyrosol B B 0.9952318072319031
. O O 0.9999637603759766

Cardiac O O 0.9962195754051208
disturbances O O 0.9999667406082153
at O O 0.9999657869338989
the O O 0.9999270439147949
cellular O O 0.9999148845672607
and O O 0.9999338388442993
mitochondrial O O 0.9997124075889587
level O O 0.9999687671661377
, O O 0.999890923500061
mitochondrial O O 0.9845996499061584
electron O O 0.6343877911567688
transport O O 0.9305430054664612
chain O O 0.9368100762367249
complexes O O 0.9618991613388062
I O O 0.917828381061554
- O O 0.9674785733222961
IV O O 0.5828115940093994
and O O 0.9959076642990112
apoptosis O O 0.47022226452827454
- O O 0.9497125744819641
inducing O O 0.9878984093666077
factor O O 0.98245769739151
, O O 0.9968022108078003
and O O 0.9970471262931824
oxidative O O 0.7685967683792114
stress O O 0.932415783405304
markers O O 0.9996259212493896
have O O 0.999940037727356
been O O 0.9999489784240723
analyzed O O 0.9998576641082764
. O O 0.9999510049819946

Hydroxytyrosol B B 0.9985958933830261
improved O O 0.9999020099639893
the O O 0.9999864101409912
cardiac O O 0.9999701976776123
disturbances O O 0.9999974966049194
enhanced O O 0.9999840259552002
by O O 0.9994328618049622
doxorubicin B B 0.9997707009315491
by O O 0.9998955726623535
significantly O O 0.9999481439590454
reducing O O 0.9999455213546753
the O O 0.9999240636825562
percentage O O 0.9999605417251587
of O O 0.9999576807022095
altered O O 0.9999394416809082
mitochondria O O 0.9992071986198425
and O O 0.9998986721038818
oxidative O O 0.9522917866706848
damage O O 0.9999690055847168
. O O 0.9992020726203918

These O O 0.9999831914901733
results O O 0.9999774694442749
suggest O O 0.9997441172599792
that O O 0.9917348623275757
hydroxytyrosol B B 0.9980047345161438
improve O O 0.9842754006385803
the O O 0.9998921155929565
mitochondrial O O 0.9996380805969238
electron O O 0.9479699730873108
transport O O 0.9998661279678345
chain O O 0.9999566078186035
. O O 0.9999170303344727

This O O 0.9999630451202393
study O O 0.9999687671661377
demonstrates O O 0.9999288320541382
that O O 0.9955423474311829
hydroxytyrosol B B 0.9970316886901855
protect O O 0.747996985912323
rat O O 0.93720942735672
heart O O 0.9998884201049805
damage O O 0.999981164932251
provoked O O 0.9999525547027588
by O O 0.9995701909065247
doxorubicin B B 0.9997947812080383
decreasing O O 0.9983440637588501
oxidative O O 0.9487078785896301
damage O O 0.999962568283081
and O O 0.9999366998672485
mitochondrial O O 0.9998769760131836
alterations O O 0.9999960660934448
. O O 0.9999631643295288

Amiodarone B B 0.9992535710334778
- O O 0.9992775321006775
induced O O 0.9998866319656372
myxoedema O O 0.9999488592147827
coma O O 0.9999880790710449
. O O 0.9999097585678101

A O O 0.9999865293502808
62 O O 0.9999970197677612
- O O 0.9999850988388062
year O O 0.9999966621398926
- O O 0.9999916553497314
old O O 0.9999946355819702
man O O 0.9999961853027344
was O O 0.9999781847000122
found O O 0.9999954700469971
to O O 0.9999815225601196
have O O 0.9999775886535645
bradycardia O O 0.9999583959579468
, O O 0.999976634979248
hypothermia O O 0.9999442100524902
and O O 0.9999668598175049
respiratory O O 0.9999864101409912
failure O O 0.9999988079071045
3 O O 0.9999120235443115
weeks O O 0.9999988079071045
after O O 0.9999892711639404
initiation O O 0.9999754428863525
of O O 0.9996490478515625
amiodarone B B 0.9998307228088379
therapy O O 0.9963357448577881
for O O 0.9999401569366455
atrial O O 0.9921197891235352
fibrillation O O 0.999931812286377
. O O 0.999961256980896

Thyroid O O 0.7019889950752258
- O O 0.9537610411643982
stimulating O O 0.8690840601921082
hormone O O 0.8065537810325623
was O O 0.9999440908432007
found O O 0.999980092048645
to O O 0.9999380111694336
be O O 0.9998829364776611
168 O O 0.9995775818824768
uIU O O 0.9997586607933044
/ O O 0.999901294708252
mL O O 0.9999963045120239
( O O 0.9999089241027832
nl O O 0.9999673366546631
. O O 0.9999867677688599
0 O O 0.9999639987945557
. O O 0.9999840259552002
3 O O 0.9999619722366333
- O O 0.9986911416053772
5 O O 0.9999418258666992
uIU O O 0.9973620772361755
/ O O 0.9999349117279053
mL O O 0.9999974966049194
) O O 0.9999396800994873
and O O 0.9998682737350464
free O O 0.5524157881736755
thyroxine B B 0.5684622526168823
( O O 0.9812414646148682
FT4 O O 0.9170822501182556
) O O 0.9999219179153442
was O O 0.999984860420227
< O O 0.9999886751174927
0 O O 0.9999889135360718
. O O 0.9999971389770508
2 O O 0.9999914169311523
ng O O 0.9996533393859863
/ O O 0.9999871253967285
dL O O 0.999996542930603
( O O 0.9999473094940186
nl O O 0.9999663829803467
. O O 0.9999880790710449
0 O O 0.999992847442627
. O O 0.9999936819076538
8 O O 0.999970555305481
- O O 0.9986971020698547
1 O O 0.9999980926513672
. O O 0.9999978542327881
8 O O 0.9999539852142334
ng O O 0.9983764886856079
/ O O 0.9999880790710449
dL O O 0.9999948740005493
) O O 0.9999681711196899
. O O 0.9999743700027466

He O O 0.9999809265136719
received O O 0.9998561143875122
intravenous O O 0.9999830722808838
fluids O O 0.9997108578681946
, O O 0.9997327923774719
vasopressor O O 0.957502007484436
therapy O O 0.9998255372047424
and O O 0.9998151659965515
stress O O 0.9990845918655396
dose O O 0.9809772372245789
steroids B B 0.9926291704177856
; O O 0.9998570680618286
he O O 0.9999768733978271
was O O 0.9999752044677734
intubated O O 0.9999841451644897
and O O 0.99998939037323
admitted O O 0.9999945163726807
to O O 0.9999940395355225
the O O 0.9999963045120239
intensive O O 0.9999831914901733
care O O 0.9999972581863403
unit O O 0.9999982118606567
. O O 0.9999802112579346

He O O 0.9999653100967407
received O O 0.999915599822998
500 O O 0.9999604225158691
ug O O 0.9947941899299622
of O O 0.9998732805252075
intravenous O O 0.9987414479255676
levothyroxine B B 0.9993688464164734
in O O 0.9996455907821655
the O O 0.9999804496765137
first O O 0.9999939203262329
18 O O 0.9999908208847046
h O O 0.9995771050453186
of O O 0.9999701976776123
therapy O O 0.9999876022338867
, O O 0.9999343156814575
and O O 0.9998550415039062
150 O O 0.9994737505912781
ug O O 0.9525901675224304
intravenous O O 0.9998835325241089
daily O O 0.9999161958694458
thereafter O O 0.999987006187439
. O O 0.9999736547470093

Haemodynamic O O 0.9998717308044434
improvement O O 0.999987006187439
, O O 0.9999785423278809
along O O 0.9999833106994629
with O O 0.9999785423278809
complete O O 0.9999675750732422
recovery O O 0.9999954700469971
of O O 0.9999873638153076
mental O O 0.9999963045120239
status O O 0.999994158744812
, O O 0.9999881982803345
occurred O O 0.9999862909317017
after O O 0.9999771118164062
48 O O 0.9999853372573853
h O O 0.9995032548904419
. O O 0.9998785257339478

Twelve O O 0.9999685287475586
hours O O 0.999992847442627
after O O 0.9999959468841553
the O O 0.9999958276748657
initiation O O 0.9999920129776001
of O O 0.999955415725708
therapy O O 0.9999362230300903
, O O 0.9997113347053528
FT4 O O 0.7883012890815735
was O O 0.9999638795852661
0 O O 0.9999575614929199
. O O 0.9999904632568359
96 O O 0.9995940327644348
ng O O 0.9997593760490417
/ O O 0.9999651908874512
dL O O 0.9999750852584839
. O O 0.9999700784683228

The O O 0.9999867677688599
patient O O 0.999983549118042
was O O 0.9999743700027466
maintained O O 0.9999443292617798
on O O 0.998751163482666
levothyroxine B B 0.999170184135437
175 O I 0.946381688117981
( O O 0.9949888586997986
g O O 0.8350140452384949
POorally O O 0.9984745383262634
daily O O 0.9999531507492065
. O O 0.9999840259552002

A O O 0.9999638795852661
thyroid O O 0.9632710218429565
ultrasound O O 0.9997990727424622
showed O O 0.9999123811721802
diffuse O O 0.9999221563339233
heterogeneity O O 0.999990701675415
. O O 0.9999760389328003

The O O 0.9999725818634033
24 O O 0.9999035596847534
hour O O 0.9998786449432373
excretion O O 0.9992258548736572
of O O 0.9945390820503235
iodine B B 0.9988603591918945
was O O 0.9999202489852905
3657 O O 0.9974972605705261
( O O 0.9997108578681946
mcg O O 0.9998949766159058
( O O 0.998769223690033
25 O O 0.9658219814300537
- O O 0.9828494191169739
756 O O 0.5603142976760864
( O O 0.9810088872909546
mcg O O 0.9986577033996582
) O O 0.9999321699142456
. O O 0.999962329864502

The O O 0.9999616146087646
only O O 0.9999899864196777
two O O 0.999988317489624
cases O O 0.9999932050704956
of O O 0.9999556541442871
amiodarone B B 0.9997878670692444
- O O 0.9992923736572266
induced O O 0.9999144077301025
myxoedema O O 0.999893069267273
coma O O 0.9998855590820312
in O O 0.9999861717224121
the O O 0.9999933242797852
literature O O 0.9999727010726929
report O O 0.999971866607666
patient O O 0.9999176263809204
death O O 0.999971866607666
despite O O 0.9999213218688965
supportive O O 0.9998108744621277
therapy O O 0.9999760389328003
and O O 0.9997977614402771
thyroid O O 0.800834596157074
hormone O O 0.6814785003662109
replacement O O 0.9782630801200867
. O O 0.9999678134918213

This O O 0.9999711513519287
case O O 0.9999850988388062
represents O O 0.9999632835388184
the O O 0.9999873638153076
most O O 0.9999861717224121
thoroughly O O 0.9999887943267822
investigated O O 0.9999908208847046
case O O 0.9999867677688599
of O O 0.9999281167984009
amiodarone B B 0.9998114705085754
- O O 0.9995391368865967
induced O O 0.9999122619628906
myxoedema O O 0.9999468326568604
coma O O 0.9999443292617798
with O O 0.9999904632568359
a O O 0.9999905824661255
history O O 0.9999891519546509
significant O O 0.999990701675415
for O O 0.9999603033065796
subclinical O O 0.9999651908874512
thyroid O O 0.9909692406654358
disease O O 0.9999901056289673
. O O 0.9999784231185913

Use O O 0.9998675584793091
of O O 0.9990849494934082
argatroban B B 0.9976750016212463
and O O 0.9987651109695435
catheter O O 0.993895947933197
- O O 0.9999537467956543
directed O O 0.9999350309371948
thrombolysis O O 0.9934984445571899
with O O 0.99968421459198
alteplase O B 0.9827898740768433
in O O 0.999945878982544
an O O 0.9999635219573975
oncology O O 0.999971866607666
patient O O 0.9999816417694092
with O O 0.999970555305481
heparin B B 0.9918826222419739
- O O 0.9990636706352234
induced O O 0.9999710321426392
thrombocytopenia O O 0.9999005794525146
with O O 0.9999767541885376
thrombosis O O 0.9987144470214844
. O O 0.9998859167098999

PURPOSE O O 0.9999284744262695
: O O 0.9999945163726807
The O O 0.999992847442627
case O O 0.9999898672103882
of O O 0.99997878074646
an O O 0.9999662637710571
oncology O O 0.9999738931655884
patient O O 0.9999868869781494
who O O 0.9999638795852661
developed O O 0.9999731779098511
heparin B B 0.9926339983940125
- O O 0.9984246492385864
induced O O 0.999922513961792
thrombocytopenia O O 0.9998278617858887
with O O 0.9999438524246216
thrombosis O O 0.9976945519447327
( O O 0.9996562004089355
HITT O O 0.9874250292778015
) O O 0.9999289512634277
and O O 0.999946117401123
was O O 0.9999666213989258
treated O O 0.999966025352478
with O O 0.9998483657836914
argatroban B B 0.9965511560440063
plus O O 0.9978673458099365
catheter O O 0.9945166707038879
- O O 0.9999383687973022
directed O O 0.9997029900550842
thrombolysis O O 0.9945383667945862
( O O 0.9997676014900208
CDT O O 0.8491926789283752
) O O 0.9999608993530273
with O O 0.9994542002677917
alteplase O B 0.9514474868774414
is O O 0.9997627139091492
presented O O 0.9999828338623047
. O O 0.9999765157699585

SUMMARY O O 0.9999778270721436
: O O 0.9999881982803345
A O O 0.999994158744812
63 O O 0.9999984502792358
- O O 0.9999855756759644
year O O 0.9999954700469971
- O O 0.9999923706054688
old O O 0.9999922513961792
Caucasian O O 0.9994301199913025
man O O 0.9999955892562866
with O O 0.9999269247055054
renal O O 0.9995957016944885
amyloidosis O O 0.8877061009407043
undergoing O O 0.9999403953552246
peripheral O O 0.9999918937683105
blood O O 0.9999589920043945
stem O O 0.9999090433120728
cell O O 0.9995304346084595
collection O O 0.9999806880950928
for O O 0.9999899864196777
an O O 0.9999901056289673
autologous O O 0.9999188184738159
stem O O 0.9999773502349854
cell O O 0.9999353885650635
transplant O O 0.999976634979248
developed O O 0.9999668598175049
extensive O O 0.9999843835830688
bilateral O O 0.9999713897705078
upper O O 0.9984499216079712
- O O 0.9998388290405273
extremity O O 0.9998438358306885
deep O O 0.990397572517395
venous O O 0.999994158744812
thrombosis O O 0.9999338388442993
( O O 0.9999469518661499
DVT O O 0.9995429515838623
) O O 0.9999717473983765
and O O 0.9999589920043945
pulmonary O O 0.9998893737792969
embolism O O 0.9999961853027344
secondary O O 0.9999867677688599
to O O 0.9998875856399536
heparin B B 0.9973205924034119
- O O 0.9991201758384705
induced O O 0.999956488609314
thrombocytopenia O O 0.9998756647109985
. O O 0.9999759197235107

A O O 0.999962329864502
continuous O O 0.9998557567596436
i O O 0.9995947480201721
. O O 0.9999885559082031
v O O 0.9999980926513672
. O O 0.9999860525131226
infusion O O 0.9999653100967407
of O O 0.9981934428215027
argatroban B B 0.9925877451896667
was O O 0.9998137354850769
initiated O O 0.9999656677246094
, O O 0.9999537467956543
and O O 0.9999905824661255
the O O 0.9999974966049194
patient O O 0.9999960660934448
was O O 0.9999892711639404
managed O O 0.9999963045120239
on O O 0.999996542930603
the O O 0.9999980926513672
general O O 0.9999938011169434
medical O O 0.9999985694885254
floor O O 0.9999979734420776
. O O 0.999983549118042

After O O 0.9999743700027466
one O O 0.9999946355819702
week O O 0.9999953508377075
of O O 0.9999463558197021
therapy O O 0.999943733215332
, O O 0.9999891519546509
he O O 0.999983549118042
was O O 0.999984622001648
transferred O O 0.9999966621398926
to O O 0.9999957084655762
the O O 0.9999959468841553
intensive O O 0.999984860420227
care O O 0.9999979734420776
unit O O 0.9999978542327881
with O O 0.9999924898147583
cardiopulmonary O O 0.9999967813491821
compromise O O 0.9999946355819702
related O O 0.9999923706054688
to O O 0.9998776912689209
superior O O 0.9966030120849609
vena O O 0.9992695450782776
cava O O 0.9898836016654968
( O O 0.9996654987335205
SVC O O 0.984043538570404
) O O 0.999886155128479
syndrome O O 0.9999394416809082
. O O 0.9999775886535645

A O O 0.999972939491272
percutaneous O O 0.9999558925628662
mechanical O O 0.9999619722366333
thrombectomy O O 0.9989117383956909
and O O 0.9997730851173401
CDT O O 0.7005412578582764
with O O 0.998435914516449
alteplase O B 0.9729605317115784
were O O 0.9994575381278992
attempted O O 0.9999860525131226
, O O 0.9999605417251587
but O O 0.9999897480010986
the O O 0.9999984502792358
procedure O O 0.9999967813491821
was O O 0.9999914169311523
aborted O O 0.9999974966049194
due O O 0.9999948740005493
to O O 0.9999879598617554
epistaxis O O 0.9999758005142212
. O O 0.9999707937240601

The O O 0.999974250793457
epistaxis O O 0.999983549118042
resolved O O 0.9999732971191406
the O O 0.9999916553497314
next O O 0.9999970197677612
day O O 0.9999951124191284
, O O 0.9999651908874512
and O O 0.9999880790710449
the O O 0.9999955892562866
patient O O 0.9999915361404419
was O O 0.9999735355377197
restarted O O 0.9999411106109619
on O O 0.9986904263496399
argatroban B B 0.9967077970504761
. O O 0.999927282333374

A O O 0.9999754428863525
second O O 0.9999911785125732
percutaneous O O 0.999976634979248
mechanical O O 0.9996471405029297
thrombectomy O O 0.9978232383728027
was O O 0.9999828338623047
performed O O 0.9999892711639404
six O O 0.9999958276748657
days O O 0.9999984502792358
later O O 0.9999970197677612
and O O 0.9999805688858032
resulted O O 0.9999908208847046
in O O 0.9999843835830688
partial O O 0.9999576807022095
revascularization O O 0.999976396560669
of O O 0.9999510049819946
the O O 0.9999656677246094
SVC O O 0.7616902589797974
and O O 0.9995538592338562
central O O 0.9999234676361084
veins O O 0.9999938011169434
. O O 0.9999717473983765

Postthrombectomy O O 0.8157787322998047
continuous O O 0.9598777890205383
CDT O O 0.7131441831588745
with O O 0.9988105297088623
alteplase O B 0.9326056838035583
was O O 0.9997779726982117
commenced O O 0.9999213218688965
while O O 0.9995912909507751
argatroban B B 0.9986612796783447
was O O 0.9999361038208008
withheld O O 0.9999841451644897
, O O 0.9999552965164185
and O O 0.9999814033508301
complete O O 0.9999586343765259
patency O O 0.9999793767929077
of O O 0.9999655485153198
the O O 0.9999821186065674
SVC O O 0.8612948656082153
and O O 0.999636173248291
central O O 0.9999721050262451
veins O O 0.9999966621398926
was O O 0.9999887943267822
achieved O O 0.9999967813491821
after O O 0.9999892711639404
three O O 0.9999921321868896
days O O 0.9999969005584717
of O O 0.999977707862854
therapy O O 0.9999629259109497
. O O 0.9999809265136719

Alteplase O O 0.861198365688324
was O O 0.999518871307373
discontinued O O 0.9995735287666321
, O O 0.9999414682388306
and O O 0.999968409538269
the O O 0.9999957084655762
patient O O 0.9999940395355225
was O O 0.9999750852584839
reinitiated O O 0.9999834299087524
on O O 0.9995241165161133
argatroban B B 0.9936216473579407
; O O 0.9998979568481445
ultimately O O 0.9999945163726807
, O O 0.9999884366989136
he O O 0.9999758005142212
was O O 0.9999829530715942
transitioned O O 0.9999860525131226
to O O 0.9993670582771301
warfarin B B 0.9991264939308167
for O O 0.9999159574508667
long O O 0.9999486207962036
- O O 0.9999921321868896
term O O 0.9999887943267822
anticoagulation O O 0.9872915744781494
. O O 0.9999778270721436

Although O O 0.9999251365661621
the O O 0.9999932050704956
patient O O 0.9999909400939941
recovered O O 0.9999878406524658
, O O 0.9999821186065674
he O O 0.9999650716781616
experienced O O 0.9999734163284302
permanent O O 0.9999740123748779
vision O O 0.9999972581863403
and O O 0.9999839067459106
hearing O O 0.9999861717224121
loss O O 0.9999927282333374
, O O 0.9999665021896362
as O O 0.9999817609786987
well O O 0.9999799728393555
as O O 0.9999850988388062
end O O 0.9999728202819824
- O O 0.9999827146530151
stage O O 0.9999908208847046
renal O O 0.9999855756759644
disease O O 0.9999923706054688
. O O 0.9999771118164062

CONCLUSION O O 0.9999078512191772
: O O 0.999987006187439
A O O 0.9999922513961792
63 O O 0.9999984502792358
- O O 0.9999866485595703
year O O 0.9999949932098389
- O O 0.9999911785125732
old O O 0.9999922513961792
man O O 0.9999923706054688
with O O 0.9999257326126099
renal O O 0.9998652935028076
amyloidosis O O 0.7371295094490051
and O O 0.9999395608901978
SVC O O 0.9805213212966919
syndrome O O 0.9999526739120483
secondary O O 0.9999716281890869
to O O 0.9981315732002258
HITT O O 0.8181296586990356
was O O 0.9999464750289917
successfully O O 0.9999557733535767
treated O O 0.9999617338180542
with O O 0.9996521472930908
argatroban B B 0.9983721375465393
and O O 0.9991554021835327
CDT O O 0.6329063773155212
with O O 0.9979374408721924
alteplase O B 0.9879334568977356
. O O 0.9999004602432251

Effects O O 0.9998422861099243
of O O 0.9991204142570496
dehydroepiandrosterone B B 0.978859543800354
in O O 0.9993845224380493
amphetamine B B 0.9935983419418335
- O O 0.9991648197174072
induced O O 0.9996925592422485
schizophrenia O O 0.9862272143363953
models O O 0.9999544620513916
in O O 0.9999831914901733
mice O O 0.9999629259109497
. O O 0.9999181032180786

OBJECTIVE O O 0.9999667406082153
: O O 0.9999963045120239
To O O 0.9999959468841553
examine O O 0.9999722242355347
the O O 0.99994957447052
effects O O 0.9998356103897095
of O O 0.9984631538391113
dehydroepiandrosterone B B 0.9947471022605896
( O O 0.959775984287262
DHEA B B 0.9993659853935242
) O O 0.9996280670166016
on O O 0.999880313873291
animal O O 0.9999709129333496
models O O 0.9999936819076538
of O O 0.9999572038650513
schizophrenia O O 0.9891196489334106
. O O 0.9999761581420898

METHODS O O 0.9997525811195374
: O O 0.9999934434890747
Seventy O O 0.999427318572998
Swiss O O 0.9969307780265808
albino O O 0.9996931552886963
female O O 0.9999942779541016
mice O O 0.999996542930603
( O O 0.9999876022338867
25 O O 0.9999936819076538
- O O 0.9988632202148438
35 O O 0.9999938011169434
g O O 0.9999387264251709
) O O 0.9999736547470093
were O O 0.999987006187439
divided O O 0.9999908208847046
into O O 0.9999617338180542
4 O O 0.9993686079978943
groups O O 0.9999747276306152
: O O 0.9999017715454102
amphetamine B B 0.9938027858734131
- O O 0.9879448413848877
free O O 0.9988429546356201
( O O 0.9995889067649841
control O O 0.9989157915115356
) O O 0.9997372031211853
, O O 0.999629020690918
amphetamine B B 0.9960194230079651
, O O 0.9830687046051025
50 O O 0.9848825335502625
, O O 0.9994839429855347
and O O 0.9997283816337585
100 O O 0.9987725615501404
mg O O 0.999957799911499
/ O O 0.9999414682388306
kg O O 0.9999884366989136
DHEA B O 0.995914876461029
. O O 0.9999732971191406

The O O 0.9962843656539917
DHEA B B 0.9918739199638367
was O O 0.9998892545700073
administered O O 0.999947190284729
intraperitoneally O O 0.9999867677688599
( O O 0.9999431371688843
ip O O 0.9980176687240601
) O O 0.9999827146530151
for O O 0.9999730587005615
5 O O 0.999954342842102
days O O 0.9999949932098389
. O O 0.9999809265136719

Amphetamine B B 0.9986644983291626
( O O 0.9996253252029419
3 O O 0.9978225231170654
mg O O 0.9998296499252319
/ O O 0.9999427795410156
kg O O 0.9999622106552124
ip O O 0.7281870245933533
) O O 0.9998983144760132
induced O O 0.9998936653137207
hyper O O 0.9992747902870178
locomotion O O 0.9974844455718994
, O O 0.9994193315505981
apomorphine B B 0.9978856444358826
( O O 0.9990703463554382
1 O O 0.9998944997787476
. O O 0.9999878406524658
5 O O 0.9999573230743408
mg O O 0.999842643737793
/ O O 0.9999392032623291
kg O O 0.9999880790710449
subcutaneously O O 0.9998388290405273
[ O O 0.998075008392334
sc O O 0.6054445505142212
] O O 0.9992437362670898
) O O 0.9998290538787842
induced O O 0.9998455047607422
climbing O O 0.9981704950332642
, O O 0.9995837807655334
and O O 0.999046266078949
haloperidol B B 0.999372661113739
( O O 0.9995622038841248
1 O O 0.9999048709869385
. O O 0.9999912977218628
5 O O 0.9999688863754272
mg O O 0.9998747110366821
/ O O 0.9999728202819824
kg O O 0.9999676942825317
sc O O 0.711080014705658
) O O 0.9993341565132141
induced O O 0.9997754693031311
catalepsy O O 0.9993367791175842
tests O O 0.9999392032623291
were O O 0.999976396560669
used O O 0.9999904632568359
as O O 0.9999889135360718
animal O O 0.9999932050704956
models O O 0.9999977350234985
of O O 0.9999806880950928
schizophrenia O O 0.9951918125152588
. O O 0.9999791383743286

The O O 0.9999896287918091
study O O 0.9999879598617554
was O O 0.9999892711639404
conducted O O 0.9999942779541016
at O O 0.999941349029541
the O O 0.999977707862854
Animal O O 0.9999817609786987
Experiment O O 0.9999812841415405
Laboratories O O 0.9999918937683105
, O O 0.9999488592147827
Department O O 0.9999604225158691
of O O 0.9996408224105835
Pharmacology O O 0.9976932406425476
, O O 0.9999246597290039
Medical O O 0.999984860420227
School O O 0.9999939203262329
, O O 0.9999146461486816
Eskisehir O O 0.9821073412895203
Osmangazi O O 0.9703066945075989
University O O 0.999919056892395
, O O 0.9991784691810608
Eskisehir O O 0.968995988368988
, O O 0.9998717308044434
Turkey O O 0.9999706745147705
between O O 0.999864935874939
March O O 0.9997082352638245
and O O 0.9999487400054932
May O O 0.9997479319572449
2012 O O 0.9999806880950928
. O O 0.9999697208404541

Statistical O O 0.999922513961792
analysis O O 0.9999945163726807
was O O 0.9999783039093018
carried O O 0.9999914169311523
out O O 0.9999933242797852
using O O 0.999886155128479
Kruskal O O 0.9514265656471252
- O O 0.9998134970664978
Wallis O O 0.9911596179008484
test O O 0.9999285936355591
for O O 0.9998825788497925
hyper O O 0.9970755577087402
locomotion O O 0.9998652935028076
, O O 0.9998250603675842
and O O 0.9997653365135193
one O O 0.9992468357086182
- O O 0.9999405145645142
way O O 0.9997701048851013
ANOVA O O 0.9820038676261902
for O O 0.9995273351669312
climbing O O 0.9990403056144714
and O O 0.9996861219406128
catalepsy O O 0.9998418092727661
tests O O 0.999963641166687
. O O 0.9999688863754272

RESULTS O O 0.9997387528419495
: O O 0.9999628067016602
In O O 0.9999589920043945
the O O 0.9999619722366333
amphetamine B B 0.9982398748397827
- O O 0.999396800994873
induced O O 0.9998451471328735
locomotion O O 0.9996813535690308
test O O 0.9999542236328125
, O O 0.9999080896377563
there O O 0.9999239444732666
were O O 0.999970555305481
significant O O 0.9999817609786987
increases O O 0.999985933303833
in O O 0.9999867677688599
all O O 0.9992181062698364
movements O O 0.9999924898147583
compared O O 0.9999867677688599
with O O 0.999991774559021
the O O 0.999977707862854
amphetamine B B 0.9984676241874695
- O O 0.9994940757751465
free O O 0.9991395473480225
group O O 0.9999542236328125
. O O 0.9999668598175049

Both O O 0.9900925755500793
DHEA B O 0.4969542622566223
50 O O 0.9998175501823425
mg O O 0.9999420642852783
/ O O 0.9999891519546509
kg O O 0.9999911785125732
( O O 0.9999681711196899
p O O 0.9999492168426514
< O O 0.9999804496765137
0 O O 0.9999891519546509
. O O 0.9999954700469971
05 O O 0.9999922513961792
) O O 0.9999654293060303
, O O 0.9994778037071228
and O O 0.9991238713264465
100 O O 0.9986352324485779
mg O O 0.9999200105667114
/ O O 0.9999779462814331
kg O O 0.999974250793457
( O O 0.9999403953552246
p O O 0.9997437596321106
< O O 0.9999631643295288
0 O O 0.999985933303833
. O O 0.9999942779541016
01 O O 0.9999948740005493
) O O 0.9999556541442871
significantly O O 0.9999645948410034
decreased O O 0.9999806880950928
all O O 0.9999606609344482
movements O O 0.9999958276748657
compared O O 0.9999892711639404
with O O 0.9999915361404419
the O O 0.9999644756317139
amphetamine B B 0.9984097480773926
- O O 0.9997356534004211
induced O O 0.999895453453064
locomotion O O 0.9993826150894165
group O O 0.9998914003372192
. O O 0.999962329864502

There O O 0.9999700784683228
was O O 0.9999639987945557
a O O 0.9999815225601196
significant O O 0.9999674558639526
difference O O 0.9999915361404419
between O O 0.9997088313102722
groups O O 0.999983549118042
in O O 0.99996018409729
the O O 0.9999375343322754
haloperidol B B 0.9996497631072998
- O O 0.9995139837265015
induced O O 0.9998258948326111
catalepsy O O 0.9999756813049316
test O O 0.9999772310256958
( O O 0.9999665021896362
p O O 0.999921441078186
< O O 0.9999361038208008
0 O O 0.9999858140945435
. O O 0.9999939203262329
05 O O 0.9999855756759644
) O O 0.9999681711196899
. O O 0.999962329864502

There O O 0.9999710321426392
was O O 0.9999736547470093
no O O 0.9999812841415405
significant O O 0.9999908208847046
difference O O 0.9999926090240479
between O O 0.999815046787262
groups O O 0.9999862909317017
in O O 0.999994158744812
terms O O 0.999996542930603
of O O 0.9999833106994629
total O O 0.9998558759689331
climbing O O 0.9999713897705078
time O O 0.9999865293502808
in O O 0.9999246597290039
the O O 0.9999558925628662
apomorphine B B 0.9972015619277954
- O O 0.9988071918487549
induced O O 0.99988853931427
climbing O O 0.9999369382858276
test O O 0.9999881982803345
( O O 0.9999511241912842
p O O 0.9994907379150391
> O O 0.9999760389328003
0 O O 0.9999873638153076
. O O 0.9999921321868896
05 O O 0.9999880790710449
) O O 0.9999710321426392
. O O 0.9999645948410034

CONCLUSION O O 0.9996596574783325
: O O 0.9999743700027466
We O O 0.9999068975448608
observed O O 0.9999794960021973
that O O 0.9989483952522278
DHEA B B 0.9978389143943787
reduced O O 0.9996479749679565
locomotor O O 0.9998495578765869
activity O O 0.9999485015869141
and O O 0.999886155128479
increased O O 0.9998503923416138
catalepsy O O 0.9996743202209473
at O O 0.9997535347938538
both O O 0.9995995163917542
doses O O 0.9997555613517761
, O O 0.9999401569366455
while O O 0.9999701976776123
it O O 0.997931957244873
had O O 0.9999531507492065
no O O 0.9999614953994751
effect O O 0.9999772310256958
on O O 0.9999473094940186
climbing O O 0.9999591112136841
behavior O O 0.9999920129776001
. O O 0.9999583959579468

We O O 0.9999531507492065
suggest O O 0.9999241828918457
that O O 0.971293032169342
DHEA B B 0.9987460374832153
displays O O 0.9989026784896851
typical O O 0.9991045594215393
neuroleptic O O 0.9988868832588196
- O O 0.9997734427452087
like O O 0.9996362924575806
effects O O 0.9998571872711182
, O O 0.9999432563781738
and O O 0.9999228715896606
may O O 0.9999403953552246
be O O 0.9999767541885376
used O O 0.9998525381088257
in O O 0.9999542236328125
the O O 0.9999790191650391
treatment O O 0.9999681711196899
of O O 0.9999595880508423
schizophrenia O O 0.9985558390617371
. O O 0.9998773336410522

Availability O O 0.999980092048645
of O O 0.9999642372131348
human O O 0.9946845173835754
induced O O 0.9997839331626892
pluripotent O O 0.9993343949317932
stem O O 0.9999324083328247
cell O O 0.999347984790802
- O O 0.9998747110366821
derived O O 0.9999862909317017
cardiomyocytes O O 0.9999727010726929
in O O 0.9999738931655884
assessment O O 0.9999945163726807
of O O 0.9999697208404541
drug O O 0.9997283816337585
potential O O 0.9999483823776245
for O O 0.9999402761459351
QT O O 0.9835281372070312
prolongation O O 0.9998639822006226
. O O 0.9999650716781616

Field O O 0.9994413256645203
potential O O 0.9999908208847046
duration O O 0.999976396560669
( O O 0.9999525547027588
FPD O O 0.9993300437927246
) O O 0.999987006187439
in O O 0.9999803304672241
human O O 0.8484873175621033
- O O 0.9992320537567139
induced O O 0.999006450176239
pluripotent O O 0.9994149208068848
stem O O 0.9999371767044067
cell O O 0.9982041120529175
- O O 0.9999233484268188
derived O O 0.9999740123748779
cardiomyocytes O O 0.9998469352722168
( O O 0.999940037727356
hiPS O O 0.9909153580665588
- O O 0.9997592568397522
CMs O O 0.9998733997344971
) O O 0.9999715089797974
, O O 0.9999856948852539
which O O 0.9999516010284424
can O O 0.99981290102005
express O O 0.999956488609314
QT O O 0.9577851295471191
interval O O 0.9999550580978394
in O O 0.9999927282333374
an O O 0.9999786615371704
electrocardiogram O O 0.9999707937240601
, O O 0.9999866485595703
is O O 0.9999815225601196
reported O O 0.9999964237213135
to O O 0.999982476234436
be O O 0.9999924898147583
a O O 0.9999814033508301
useful O O 0.9999860525131226
tool O O 0.9999947547912598
to O O 0.9999890327453613
predict O O 0.9998774528503418
K B B 0.9646371603012085
( O O 0.5257159471511841
+ O O 0.9605507850646973
) O O 0.9866511821746826
channel O O 0.9964317083358765
and O O 0.998856782913208
Ca B B 0.9666220545768738
( O O 0.9557874202728271
2 O O 0.9877383708953857
+ O O 0.9980517625808716
) O O 0.9868757724761963
channel O O 0.9967549443244934
blocker O O 0.9890946745872498
effects O O 0.9999345541000366
on O O 0.9999421834945679
QT O O 0.9780585765838623
interval O O 0.9999843835830688
. O O 0.9999892711639404

However O O 0.9999630451202393
, O O 0.9999855756759644
there O O 0.9999872446060181
is O O 0.9999880790710449
no O O 0.9999899864196777
report O O 0.9999977350234985
showing O O 0.9999730587005615
that O O 0.9999833106994629
this O O 0.9999822378158569
technique O O 0.9999924898147583
can O O 0.9999754428863525
be O O 0.9999927282333374
used O O 0.9999929666519165
to O O 0.9999865293502808
predict O O 0.9999258518218994
multichannel O O 0.9107844233512878
blocker O O 0.8664762377738953
potential O O 0.9999377727508545
for O O 0.9999483823776245
QT O O 0.9662015438079834
prolongation O O 0.9999094009399414
. O O 0.9999607801437378

The O O 0.9999898672103882
aim O O 0.9999949932098389
of O O 0.9999946355819702
this O O 0.9999880790710449
study O O 0.9999899864196777
is O O 0.9999871253967285
to O O 0.9999816417694092
show O O 0.9999444484710693
that O O 0.9998435974121094
FPD O O 0.9869480133056641
from O O 0.9991045594215393
MEA O O 0.7010458111763
( O O 0.9992056488990784
Multielectrode O O 0.9609861969947815
array O O 0.9941582679748535
) O O 0.9998689889907837
of O O 0.9997683167457581
hiPS O O 0.9221577644348145
- O O 0.9987607002258301
CMs O O 0.9988607168197632
can O O 0.9999284744262695
detect O O 0.9998313188552856
QT O O 0.9562926888465881
prolongation O O 0.9998900890350342
induced O O 0.9999738931655884
by O O 0.999896764755249
multichannel O O 0.9679692983627319
blockers O O 0.9653231501579285
. O O 0.9999542236328125

hiPS O O 0.525740385055542
- O O 0.8316565155982971
CMs O O 0.9008496403694153
were O O 0.9994433522224426
seeded O O 0.9997597336769104
onto O O 0.998823344707489
MEA O O 0.6198582649230957
and O O 0.9998860359191895
FPD O O 0.9004005789756775
was O O 0.9999780654907227
measured O O 0.9999806880950928
for O O 0.9999555349349976
2min O O 0.9999029636383057
every O O 0.9998670816421509
10min O O 0.9999871253967285
for O O 0.9999796152114868
30min O O 0.9999880790710449
after O O 0.9999346733093262
drug O O 0.9990899562835693
exposure O O 0.9999470710754395
for O O 0.9996069073677063
the O O 0.9999827146530151
vehicle O O 0.9998692274093628
and O O 0.9999322891235352
each O O 0.9999300241470337
drug O O 0.9960391521453857
concentration O O 0.9994860887527466
. O O 0.9999663829803467

IKr O O 0.54410320520401
and O O 0.9846993088722229
IKs O O 0.505326509475708
blockers O O 0.7331633567810059
concentration O O 0.9885703921318054
- O O 0.9997548460960388
dependently O O 0.99991774559021
prolonged O O 0.9999017715454102
corrected O O 0.999854564666748
FPD O O 0.9727542996406555
( O O 0.9995902180671692
FPDc O O 0.9566227793693542
) O O 0.9999086856842041
, O O 0.9995198249816895
whereas O O 0.7391135096549988
Ca B B 0.9774250984191895
( O O 0.9945841431617737
2 O O 0.9661604762077332
+ O O 0.9983678460121155
) O O 0.8646314144134521
channel O O 0.7698612213134766
blockers O O 0.7996091842651367
concentration O O 0.9950122237205505
- O O 0.9998979568481445
dependently O O 0.9999431371688843
shortened O O 0.9998874664306641
FPDc O O 0.9800060987472534
. O O 0.9999557733535767

Also O O 0.9992326498031616
, O O 0.9992271661758423
the O O 0.9993090629577637
multichannel O O 0.7659468650817871
blockers O O 0.4904857575893402
Amiodarone B B 0.9986781477928162
, O O 0.9668060541152954
Paroxetine B B 0.9981929659843445
, O O 0.9600803256034851
Terfenadine B B 0.9983172416687012
and O O 0.9880820512771606
Citalopram B B 0.9993020296096802
prolonged O O 0.999708354473114
FPDc O O 0.6958307027816772
in O O 0.9999765157699585
a O O 0.9999651908874512
concentration O O 0.9855210185050964
dependent O O 0.9999070167541504
manner O O 0.9999803304672241
. O O 0.999974250793457

Finally O O 0.9973478317260742
, O O 0.999622106552124
the O O 0.9990767240524292
IKr O O 0.5910099744796753
blockers O O 0.7453218698501587
, O O 0.9980487823486328
Terfenadine B B 0.9993513226509094
and O O 0.9926798343658447
Citalopram B B 0.999154806137085
, O O 0.9998877048492432
which O O 0.9998816251754761
are O O 0.9999321699142456
reported O O 0.9999799728393555
to O O 0.9999606609344482
cause O O 0.999925971031189
Torsade O O 0.9998615980148315
de O O 0.9999721050262451
Pointes O O 0.9999704360961914
( O O 0.9999368190765381
TdP O O 0.9967984557151794
) O O 0.9999711513519287
in O O 0.9999901056289673
clinical O O 0.9999890327453613
practice O O 0.9999951124191284
, O O 0.9999749660491943
produced O O 0.9996985197067261
early O O 0.999601423740387
afterdepolarization O O 0.9841375946998596
( O O 0.9999102354049683
EAD O O 0.9989751577377319
) O O 0.9999631643295288
. O O 0.9999614953994751

hiPS O O 0.5499424934387207
- O O 0.9491220116615295
CMs O O 0.9560225009918213
using O O 0.9999475479125977
MEA O O 0.9893961548805237
system O O 0.9998199343681335
and O O 0.9998617172241211
FPDc O O 0.8589239716529846
can O O 0.9998966455459595
predict O O 0.9999797344207764
the O O 0.9999866485595703
effects O O 0.9999635219573975
of O O 0.9999334812164307
drug O O 0.9992148876190186
candidates O O 0.991391658782959
on O O 0.9998950958251953
QT O O 0.9809684157371521
interval O O 0.9999760389328003
. O O 0.99997878074646

This O O 0.999963641166687
study O O 0.9999676942825317
also O O 0.9999768733978271
shows O O 0.9999464750289917
that O O 0.999962568283081
this O O 0.9999257326126099
assay O O 0.9987265467643738
can O O 0.9999270439147949
help O O 0.999955415725708
detect O O 0.999830961227417
EAD O O 0.9755545258522034
for O O 0.9989283680915833
drugs O O 0.9994004964828491
with O O 0.9997907280921936
TdP O O 0.622918426990509
potential O O 0.9981982111930847
. O O 0.99993896484375

Dermal O O 0.9987284541130066
developmental O O 0.9998317956924438
toxicity O O 0.999901533126831
of O O 0.9987056255340576
N O B 0.7776735424995422
- O I 0.9863567352294922
phenylimide O I 0.999627947807312
herbicides O O 0.7861982583999634
in O O 0.9996650218963623
rats O O 0.9997689127922058
. O O 0.9998894929885864

BACKGROUND O O 0.894810140132904
: O O 0.9988812804222107
S B B 0.8321390151977539
- I I 0.9879400730133057
53482 I I 0.9998708963394165
and O O 0.9498496055603027
S B B 0.7880701422691345
- I I 0.8858713507652283
23121 I I 0.9996591806411743
are O O 0.9736731648445129
N O B 0.8018448352813721
- O I 0.996542751789093
phenylimide O I 0.999805748462677
herbicides O O 0.7445843815803528
and O O 0.9995799660682678
produced O O 0.999869704246521
embryolethality O O 0.9999691247940063
, O O 0.9999334812164307
teratogenicity O O 0.9999810457229614
( O O 0.9999760389328003
mainly O O 0.9997237324714661
ventricular O O 0.999669075012207
septal O O 0.9971332550048828
defects O O 0.9999938011169434
and O O 0.999910831451416
wavy O O 0.9999344348907471
ribs O O 0.9999740123748779
) O O 0.9999793767929077
, O O 0.9999439716339111
and O O 0.9999645948410034
growth O O 0.9999911785125732
retardation O O 0.9999984502792358
in O O 0.9999873638153076
rats O O 0.9999932050704956
in O O 0.9999799728393555
conventional O O 0.9999772310256958
oral O O 0.9584556221961975
developmental O O 0.9999616146087646
toxicity O O 0.9995324611663818
studies O O 0.9999653100967407
. O O 0.9999133348464966

Our O O 0.999991774559021
objective O O 0.9999984502792358
in O O 0.9999954700469971
this O O 0.9999861717224121
study O O 0.9999794960021973
was O O 0.9999947547912598
to O O 0.9999922513961792
investigate O O 0.9999802112579346
whether O O 0.9999815225601196
the O O 0.9981862902641296
compounds O O 0.9808682799339294
induce O O 0.9998679161071777
developmental O O 0.9998732805252075
toxicity O O 0.9999672174453735
via O O 0.9999512434005737
the O O 0.999951958656311
dermal O O 0.9999784231185913
route O O 0.999985933303833
, O O 0.9999876022338867
which O O 0.9999680519104004
is O O 0.9999798536300659
more O O 0.99991774559021
relevant O O 0.9999934434890747
to O O 0.9999452829360962
occupational O O 0.9997674822807312
exposure O O 0.999953031539917
, O O 0.9999856948852539
hence O O 0.9999854564666748
better O O 0.9999855756759644
addressing O O 0.9999949932098389
human O O 0.9999891519546509
health O O 0.9999946355819702
risks O O 0.9999955892562866
. O O 0.9999816417694092

METHODS O O 0.9985401630401611
: O O 0.9998272061347961
S B B 0.9702621698379517
- I I 0.9931564927101135
53482 I I 0.9999213218688965
was O O 0.9994997978210449
administered O O 0.9999419450759888
dermally O O 0.9999293088912964
to O O 0.9999634027481079
rats O O 0.9997393488883972
at O O 0.9998764991760254
30 O O 0.9999895095825195
, O O 0.9998356103897095
100 O O 0.9993324875831604
, O O 0.9997557997703552
and O O 0.9995993971824646
300 O O 0.9999878406524658
mg O O 0.9999798536300659
/ O O 0.9999866485595703
kg O O 0.9999903440475464
during O O 0.9999501705169678
organogenesis O O 0.9999866485595703
, O O 0.9999402761459351
and O O 0.9995751976966858
S B B 0.9199309349060059
- I I 0.9438871145248413
23121 I I 0.9999078512191772
was O O 0.999698281288147
administered O O 0.9999328851699829
at O O 0.9999017715454102
200 O O 0.999392032623291
, O O 0.9995310306549072
400 O O 0.9981671571731567
, O O 0.9996761083602905
and O O 0.9995649456977844
800 O O 0.9994899034500122
mg O O 0.9999853372573853
/ O O 0.9999895095825195
kg O O 0.9999949932098389
( O O 0.9999812841415405
the O O 0.9999954700469971
maximum O O 0.9999608993530273
applicable O O 0.9997668862342834
dose O O 0.9998989105224609
level O O 0.9999675750732422
) O O 0.9999725818634033
. O O 0.9999744892120361

Fetuses O O 0.9999592304229736
were O O 0.999995231628418
obtained O O 0.9999992847442627
by O O 0.9999986886978149
a O O 0.9999969005584717
Cesarean O O 0.9998655319213867
section O O 0.9999790191650391
and O O 0.9999703168869019
examined O O 0.9999926090240479
for O O 0.9999589920043945
external O O 0.9993566870689392
, O O 0.9999145269393921
visceral O O 0.9926786422729492
, O O 0.9998227953910828
and O O 0.9997983574867249
skeletal O O 0.9999064207077026
alterations O O 0.9999954700469971
. O O 0.9999651908874512

RESULTS O O 0.9996776580810547
: O O 0.9998335838317871
Dermal O O 0.9995829463005066
exposure O O 0.9999657869338989
of O O 0.9999797344207764
rats O O 0.9999802112579346
to O O 0.9987841248512268
S B B 0.945192813873291
- I I 0.992425799369812
53482 I I 0.9999276399612427
at O O 0.998570442199707
300 O O 0.9999017715454102
mg O O 0.9999668598175049
/ O O 0.9999798536300659
kg O O 0.9999927282333374
produced O O 0.9999582767486572
patterns O O 0.9999828338623047
of O O 0.9999668598175049
developmental O O 0.998305082321167
toxicity O O 0.9999592304229736
similar O O 0.9999927282333374
to O O 0.9999889135360718
those O O 0.9999923706054688
resulting O O 0.9999936819076538
from O O 0.9999223947525024
oral O O 0.9940983057022095
exposure O O 0.9999626874923706
. O O 0.9999693632125854

Toxicity O O 0.9999006986618042
included O O 0.9999533891677856
embryolethality O O 0.9999655485153198
, O O 0.9999136924743652
teratogenicity O O 0.9999399185180664
, O O 0.999776303768158
and O O 0.9999024868011475
growth O O 0.9999278783798218
retardation O O 0.9999877214431763
. O O 0.9999498128890991

Dermal O O 0.9992538094520569
administration O O 0.999964714050293
of O O 0.9998544454574585
S B B 0.9476383328437805
- I I 0.9901126623153687
23121 I I 0.9998427629470825
at O O 0.9994043111801147
800 O O 0.9991244673728943
mg O O 0.9999845027923584
/ O O 0.9999840259552002
kg O O 0.9999960660934448
resulted O O 0.9999780654907227
in O O 0.9999934434890747
an O O 0.9999938011169434
increased O O 0.9999905824661255
incidence O O 0.9999982118606567
of O O 0.9999868869781494
embryonic O O 0.999997615814209
death O O 0.9999980926513672
and O O 0.9999698400497437
ventricular O O 0.999846339225769
septal O O 0.9989907145500183
defect O O 0.9999972581863403
, O O 0.999968409538269
but O O 0.9999761581420898
retarded O O 0.9999922513961792
fetal O O 0.9999985694885254
growth O O 0.9999978542327881
was O O 0.9999892711639404
not O O 0.9999855756759644
observed O O 0.9999935626983643
as O O 0.9999860525131226
it O O 0.9999984502792358
was O O 0.9999923706054688
following O O 0.9999372959136963
oral O O 0.9991174340248108
exposure O O 0.9999878406524658
to O O 0.9998302459716797
S B B 0.9658468961715698
- I I 0.9952070116996765
23121 I I 0.999880313873291
. O O 0.999835729598999

CONCLUSIONS O O 0.9954519867897034
: O O 0.9999780654907227
Based O O 0.9999990463256836
on O O 0.9999947547912598
the O O 0.9999967813491821
results O O 0.9999963045120239
, O O 0.9997619986534119
S B B 0.8504331707954407
- I I 0.9626373648643494
53482 I I 0.9998030066490173
and O O 0.9778508543968201
S B B 0.7998150587081909
- I I 0.8545022010803223
23121 I I 0.9995664954185486
were O O 0.9994018077850342
teratogenic O O 0.9998925924301147
when O O 0.9999812841415405
administered O O 0.999956488609314
dermally O O 0.9999027252197266
to O O 0.9999722242355347
pregnant O O 0.9999898672103882
rats O O 0.999997615814209
as O O 0.9999504089355469
were O O 0.9999812841415405
the O O 0.9992222785949707
compounds O O 0.9661849141120911
administered O O 0.9998680353164673
orally O O 0.9992695450782776
. O O 0.999962329864502

Thus O O 0.9999635219573975
, O O 0.9999701976776123
investigation O O 0.9999843835830688
of O O 0.9999593496322632
the O O 0.9999613761901855
mechanism O O 0.9999699592590332
and O O 0.999981164932251
its O O 0.9999892711639404
human O O 0.9998352527618408
relevancy O O 0.9999978542327881
become O O 0.9999902248382568
more O O 0.9999918937683105
important O O 0.9999940395355225
. O O 0.9999719858169556

Rates O O 0.9998310804367065
of O O 0.9999481439590454
Renal O O 0.9966435432434082
Toxicity O O 0.9999572038650513
in O O 0.9999227523803711
Cancer O O 0.9996089339256287
Patients O O 0.9999659061431885
Receiving O O 0.9994267225265503
Cisplatin B B 0.999630331993103
With O O 0.9963698387145996
and O O 0.9999309778213501
Without O O 0.9996455907821655
Mannitol B B 0.999112069606781
. O O 0.9998840093612671

BACKGROUND O O 0.9714785814285278
: O O 0.9984989166259766
Cisplatin B B 0.9995573163032532
is O O 0.9991377592086792
a O O 0.9985496401786804
widely O O 0.9964300990104675
used O O 0.9996540546417236
antineoplastic O O 0.7079086899757385
. O O 0.998654842376709

One O O 0.9999759197235107
of O O 0.9999290704727173
the O O 0.9999827146530151
major O O 0.9999909400939941
complications O O 0.999993085861206
of O O 0.9998487234115601
cisplatin B B 0.9997434020042419
use O O 0.9996414184570312
is O O 0.9999449253082275
dose O O 0.9996201992034912
- O O 0.9999607801437378
limiting O O 0.9999573230743408
nephrotoxicity O O 0.999953031539917
. O O 0.9999730587005615

There O O 0.999876856803894
are O O 0.9997968077659607
many O O 0.9998031258583069
strategies O O 0.999954104423523
to O O 0.999954104423523
prevent O O 0.9998511075973511
this O O 0.999618649482727
toxicity O O 0.9998993873596191
, O O 0.9999712705612183
including O O 0.9998925924301147
the O O 0.9999572038650513
use O O 0.9999321699142456
of O O 0.9994158744812012
mannitol B B 0.9994524121284485
as O O 0.9996616840362549
a O O 0.9994561076164246
nephroprotectant O O 0.9825625419616699
in O O 0.9999508857727051
combination O O 0.9999171495437622
with O O 0.9998384714126587
hydration O O 0.9913206696510315
. O O 0.9999120235443115

OBJECTIVE O O 0.9997933506965637
: O O 0.9999916553497314
We O O 0.9999805688858032
aimed O O 0.9999957084655762
to O O 0.9999958276748657
evaluate O O 0.9999833106994629
the O O 0.9999788999557495
rates O O 0.9999773502349854
of O O 0.9999346733093262
cisplatin B B 0.9996030926704407
- O O 0.9995391368865967
induced O O 0.9999260902404785
nephrotoxicity O O 0.9999619722366333
in O O 0.9999241828918457
cancer O O 0.9999651908874512
patients O O 0.9999902248382568
receiving O O 0.9998500347137451
single O O 0.9920457601547241
- O O 0.9985641837120056
agent O O 0.5420016050338745
cisplatin B B 0.9954710006713867
with O O 0.9981585144996643
and O O 0.9999517202377319
without O O 0.9998669624328613
mannitol B B 0.9991727471351624
. O O 0.9999420642852783

METHODS O O 0.9999556541442871
: O O 0.9999842643737793
This O O 0.9999911785125732
single O O 0.9999362230300903
- O O 0.9999756813049316
center O O 0.9999918937683105
retrospective O O 0.9999758005142212
analysis O O 0.9999904632568359
was O O 0.9999891519546509
a O O 0.9999821186065674
quasi O O 0.9999698400497437
experiment O O 0.9999819993972778
created O O 0.9999945163726807
by O O 0.9999774694442749
the O O 0.9999649524688721
national O O 0.9987695813179016
mannitol B B 0.9987875819206238
shortage O O 0.9958353042602539
. O O 0.9999650716781616

Data O O 0.9999657869338989
were O O 0.9999899864196777
collected O O 0.9999943971633911
on O O 0.9999023675918579
adult O O 0.9997904896736145
cancer O O 0.9999771118164062
patients O O 0.9999785423278809
receiving O O 0.9998815059661865
single O O 0.9927281141281128
- O O 0.9988480806350708
agent O O 0.613167941570282
cisplatin B B 0.9970390796661377
as O O 0.9999103546142578
an O O 0.9999960660934448
outpatient O O 0.9999949932098389
from O O 0.9998170733451843
January O O 0.988473117351532
2011 O O 0.9721846580505371
to O O 0.9985920786857605
September O O 0.9077485799789429
2012 O O 0.9028056263923645
. O O 0.9999412298202515

The O O 0.9999727010726929
primary O O 0.9999819993972778
outcome O O 0.9999953508377075
was O O 0.9999839067459106
acute O O 0.999966025352478
kidney O O 0.9999568462371826
injury O O 0.9999922513961792
( O O 0.9999301433563232
AKI O O 0.9279454350471497
) O O 0.9999587535858154
. O O 0.9999816417694092

RESULTS O O 0.9999027252197266
: O O 0.9999309778213501
We O O 0.9999847412109375
evaluated O O 0.9999947547912598
143 O O 0.9999759197235107
patients O O 0.9999969005584717
who O O 0.9999727010726929
received O O 0.9997382760047913
single O O 0.9892503023147583
- O O 0.9986141920089722
agent O O 0.5838825106620789
cisplatin B B 0.9979531764984131
; O O 0.9999022483825684
97 O O 0.9999474287033081
. O O 0.9999955892562866
2 O O 0.9999948740005493
% O O 0.9999964237213135
of O O 0.9999876022338867
patients O O 0.9999927282333374
had O O 0.9999655485153198
head O O 0.9998986721038818
and O O 0.9997139573097229
neck O O 0.9995489716529846
cancer O O 0.9998430013656616
as O O 0.9999724626541138
their O O 0.9999929666519165
primary O O 0.9999862909317017
malignancy O O 0.9999953508377075
. O O 0.9999761581420898

Patients O O 0.9999774694442749
who O O 0.9999663829803467
did O O 0.9999953508377075
not O O 0.9999605417251587
receive O O 0.9996390342712402
mannitol B B 0.9989699125289917
were O O 0.9999129772186279
more O O 0.9999630451202393
likely O O 0.9999946355819702
to O O 0.9999911785125732
develop O O 0.9999918937683105
nephrotoxicity O O 0.9998992681503296
: O O 0.9999642372131348
odds O O 0.9994556307792664
ratio O O 0.9998599290847778
[ O O 0.9998094439506531
OR O O 0.9997001886367798
] O O 0.9999561309814453
= O O 0.9993464350700378
2 O O 0.9999395608901978
. O O 0.9999927282333374
646 O O 0.9999960660934448
( O O 0.9999276399612427
95 O O 0.9999631643295288
% O O 0.9989277720451355
CI O O 0.9952396154403687
= O O 0.9979569911956787
1 O O 0.9999793767929077
. O O 0.9999957084655762
008 O O 0.9999892711639404
, O O 0.9976287484169006
6 O O 0.9998878240585327
. O O 0.9999920129776001
944 O O 0.9672778844833374
; O O 0.9999386072158813
P O O 0.9987665414810181
= O O 0.9998849630355835
0 O O 0.999992847442627
. O O 0.9999973773956299
048 O O 0.999971866607666
) O O 0.9999765157699585
. O O 0.9999847412109375

Patients O O 0.9999837875366211
who O O 0.9999595880508423
received O O 0.9998892545700073
the O O 0.9999139308929443
100 O O 0.9948064684867859
mg O O 0.9995808005332947
/ O O 0.984211266040802
m O O 0.977873682975769
( O O 0.9909502863883972
2 O O 0.9171251654624939
) O O 0.9752805233001709
dosing O O 0.999276340007782
and O O 0.9999207258224487
patients O O 0.9999845027923584
who O O 0.9999700784683228
had O O 0.999987006187439
a O O 0.9999852180480957
history O O 0.9999884366989136
of O O 0.9998944997787476
hypertension O O 0.9745377898216248
also O O 0.9999673366546631
had O O 0.9999635219573975
a O O 0.9999858140945435
higher O O 0.9999814033508301
likelihood O O 0.9999986886978149
of O O 0.9999927282333374
developing O O 0.9999711513519287
nephrotoxicity O O 0.9999051094055176
: O O 0.999976634979248
OR O O 0.9997566342353821
= O O 0.9999459981918335
11 O O 0.9999208450317383
. O O 0.9999880790710449
494 O O 0.9999932050704956
( O O 0.9999550580978394
95 O O 0.9999594688415527
% O O 0.9998704195022583
CI O O 0.997884213924408
= O O 0.9998382329940796
4 O O 0.9999067783355713
. O O 0.9999725818634033
149 O O 0.9999788999557495
, O O 0.9980252981185913
32 O O 0.999985933303833
. O O 0.999991774559021
258 O O 0.9999868869781494
; O O 0.9999746084213257
P O O 0.9999239444732666
< O O 0.9999856948852539
0 O O 0.9999934434890747
. O O 0.9999942779541016
0001 O O 0.9999785423278809
) O O 0.9999686479568481
and O O 0.9999428987503052
OR O O 0.9993488192558289
= O O 0.9999637603759766
3 O O 0.9999376535415649
. O O 0.9999836683273315
219 O O 0.9999945163726807
( O O 0.9999529123306274
95 O O 0.999941349029541
% O O 0.9999231100082397
CI O O 0.9976087808609009
= O O 0.9999130964279175
1 O O 0.9999922513961792
. O O 0.9999133348464966
228 O O 0.9999817609786987
, O O 0.9986045956611633
8 O O 0.9996161460876465
. O O 0.9999873638153076
439 O O 0.9999908208847046
; O O 0.9999834299087524
P O O 0.9995775818824768
= O O 0.9999603033065796
0 O O 0.9999920129776001
. O O 0.9999967813491821
017 O O 0.9999951124191284
) O O 0.9999780654907227
, O O 0.999980092048645
respectively O O 0.9999568462371826
. O O 0.9999841451644897

CONCLUSIONS O O 0.9974840879440308
: O O 0.999988317489624
When O O 0.9999920129776001
limited O O 0.9999898672103882
quantities O O 0.9999260902404785
of O O 0.9996015429496765
mannitol B B 0.9991851449012756
are O O 0.9999178647994995
available O O 0.9999773502349854
, O O 0.9999678134918213
it O O 0.9999332427978516
should O O 0.9999606609344482
preferentially O O 0.9999765157699585
be O O 0.999990701675415
given O O 0.999970555305481
to O O 0.9999440908432007
patients O O 0.999990701675415
at O O 0.9999786615371704
particularly O O 0.9999860525131226
high O O 0.999982476234436
risk O O 0.9999964237213135
of O O 0.9999721050262451
nephrotoxicity O O 0.9997733235359192
. O O 0.9999700784683228

Our O O 0.9999521970748901
analysis O O 0.9999921321868896
suggests O O 0.9999517202377319
that O O 0.9999526739120483
those O O 0.9999681711196899
patients O O 0.9999923706054688
receiving O O 0.9997897744178772
the O O 0.9999762773513794
dosing O O 0.9999303817749023
schedule O O 0.9999589920043945
of O O 0.999727189540863
100 O O 0.9980973601341248
mg O O 0.999803364276886
/ O O 0.997188150882721
m O O 0.980851948261261
( O O 0.994114100933075
2 O O 0.9659817814826965
) O O 0.9724377989768982
cisplatin B B 0.9984244108200073
every O O 0.9993453621864319
3 O O 0.9999197721481323
weeks O O 0.9999932050704956
and O O 0.9999639987945557
those O O 0.9999814033508301
with O O 0.9999686479568481
hypertension O O 0.9874498844146729
are O O 0.9999711513519287
at O O 0.9999765157699585
the O O 0.9999902248382568
greatest O O 0.9999871253967285
risk O O 0.9999963045120239
of O O 0.9999653100967407
nephrotoxicity O O 0.9999047517776489
and O O 0.9999843835830688
would O O 0.9999897480010986
benefit O O 0.9999957084655762
from O O 0.9999819993972778
the O O 0.9999933242797852
addition O O 0.9999680519104004
of O O 0.9993864297866821
mannitol B B 0.9994811415672302
. O O 0.9999207258224487

Metformin B B 0.9989257454872131
protects O O 0.9993582367897034
against O O 0.9983773231506348
seizures O O 0.9999755620956421
, O O 0.9999268054962158
learning O O 0.9999656677246094
and O O 0.9999063014984131
memory O O 0.9999834299087524
impairments O O 0.9999929666519165
and O O 0.9999008178710938
oxidative O O 0.9241206049919128
damage O O 0.9999845027923584
induced O O 0.9999749660491943
by O O 0.9999151229858398
pentylenetetrazole B B 0.9957516193389893
- O O 0.9994766116142273
induced O O 0.9998074173927307
kindling O O 0.9997215867042542
in O O 0.9999158382415771
mice O O 0.9999685287475586
. O O 0.9998915195465088

Cognitive O O 0.9998365640640259
impairment O O 0.9999889135360718
, O O 0.9999864101409912
the O O 0.9999904632568359
most O O 0.9999507665634155
common O O 0.9999686479568481
and O O 0.9999630451202393
severe O O 0.999718964099884
comorbidity O O 0.9999387264251709
of O O 0.9999467134475708
epilepsy O O 0.9996987581253052
, O O 0.9999295473098755
greatly O O 0.9999821186065674
diminishes O O 0.9999922513961792
the O O 0.9999924898147583
quality O O 0.9999982118606567
of O O 0.9999853372573853
life O O 0.9999914169311523
. O O 0.999975323677063

However O O 0.9999282360076904
, O O 0.999880313873291
current O O 0.9993681311607361
therapeutic O O 0.9994138479232788
interventions O O 0.9999204874038696
for O O 0.9994174242019653
epilepsy O O 0.9986963868141174
can O O 0.9998898506164551
also O O 0.9999510049819946
cause O O 0.9999616146087646
untoward O O 0.9999507665634155
cognitive O O 0.9999924898147583
effects O O 0.9999948740005493
. O O 0.9999697208404541

Thus O O 0.9999643564224243
, O O 0.9999622106552124
there O O 0.9999548196792603
is O O 0.9999732971191406
an O O 0.9999868869781494
urgent O O 0.9999810457229614
need O O 0.9999932050704956
for O O 0.9999710321426392
new O O 0.9999582767486572
kinds O O 0.9998321533203125
of O O 0.9994070529937744
agents O O 0.9984095692634583
targeting O O 0.9994945526123047
both O O 0.9996942281723022
seizures O O 0.9999704360961914
and O O 0.999893069267273
cognition O O 0.9995020627975464
deficits O O 0.9999814033508301
. O O 0.9999219179153442

Oxidative O O 0.9099697470664978
stress O O 0.9627447724342346
is O O 0.9998613595962524
considered O O 0.9999593496322632
to O O 0.9999253749847412
play O O 0.9999347925186157
an O O 0.9999240636825562
important O O 0.9999226331710815
role O O 0.9999661445617676
in O O 0.999923586845398
epileptogenesis O O 0.999923586845398
and O O 0.9999748468399048
cognitive O O 0.9999940395355225
deficits O O 0.9999980926513672
, O O 0.9999020099639893
and O O 0.9992458820343018
antioxidants O O 0.7500857710838318
have O O 0.9993103742599487
a O O 0.9998425245285034
putative O O 0.9999456405639648
antiepileptic O O 0.6754753589630127
potential O O 0.9998906850814819
. O O 0.9999167919158936

Metformin B B 0.9982605576515198
, O O 0.9998798370361328
the O O 0.9998214840888977
most O O 0.9997345805168152
commonly O O 0.9999417066574097
prescribed O O 0.9998224377632141
antidiabetic O O 0.4557924270629883
oral O O 0.536545991897583
drug O O 0.9665690064430237
, O O 0.9998829364776611
has O O 0.9990311861038208
antioxidant O O 0.6215715408325195
properties O O 0.9992169141769409
. O O 0.9997742772102356

This O O 0.9999784231185913
study O O 0.9999809265136719
was O O 0.9999847412109375
designed O O 0.9999947547912598
to O O 0.9999903440475464
evaluate O O 0.9999473094940186
the O O 0.9999470710754395
ameliorative O O 0.9998332262039185
effects O O 0.9999371767044067
of O O 0.9994164705276489
metformin B B 0.9996997117996216
on O O 0.9996442794799805
seizures O O 0.9999860525131226
, O O 0.9999336004257202
cognitive O O 0.9999948740005493
impairment O O 0.9999978542327881
and O O 0.9999501705169678
brain O O 0.9998985528945923
oxidative O O 0.6696596145629883
stress O O 0.811927080154419
markers O O 0.9999271631240845
observed O O 0.9999858140945435
in O O 0.9999275207519531
pentylenetetrazole B B 0.9979326725006104
- O O 0.9995772242546082
induced O O 0.999893307685852
kindling O O 0.999861478805542
animals O O 0.9999890327453613
. O O 0.9999805688858032

Male O O 0.9998071789741516
C57BL O O 0.9985036849975586
/ O O 0.9996598958969116
6 O O 0.9993971586227417
mice O O 0.9998776912689209
were O O 0.9999767541885376
administered O O 0.9999755620956421
with O O 0.999966025352478
subconvulsive O O 0.9997490048408508
dose O O 0.99940025806427
of O O 0.9930857419967651
pentylenetetrazole B B 0.9969995021820068
( O O 0.9979972243309021
37 O O 0.9997580647468567
mg O O 0.9999593496322632
/ O O 0.9999868869781494
kg O O 0.9999961853027344
, O O 0.9999635219573975
i O O 0.9999005794525146
. O O 0.9999961853027344
p O O 0.9999977350234985
. O O 0.9999960660934448
) O O 0.9999881982803345
every O O 0.9999598264694214
other O O 0.9999943971633911
day O O 0.999984622001648
for O O 0.9999673366546631
14 O O 0.9998661279678345
injections O O 0.9999686479568481
. O O 0.9999815225601196

Metformin B B 0.9981744289398193
was O O 0.9999288320541382
injected O O 0.9999785423278809
intraperitoneally O O 0.9999866485595703
in O O 0.9998712539672852
dose O O 0.9999799728393555
of O O 0.9999737739562988
200mg O O 0.9977743029594421
/ O O 0.9999552965164185
kg O O 0.9999891519546509
along O O 0.9998903274536133
with O O 0.9997866749763489
alternate O O 0.962450385093689
- O O 0.9999544620513916
day O O 0.999778687953949
PTZ B O 0.7315210700035095
. O O 0.9998388290405273

We O O 0.9999257326126099
found O O 0.9999834299087524
that O O 0.998848557472229
metformin B B 0.999605119228363
suppressed O O 0.9987624883651733
the O O 0.9999227523803711
progression O O 0.9999755620956421
of O O 0.999705970287323
kindling O O 0.9820882678031921
, O O 0.9997555613517761
ameliorated O O 0.9994797110557556
the O O 0.9999755620956421
cognitive O O 0.9999934434890747
impairment O O 0.9999977350234985
and O O 0.999981164932251
decreased O O 0.9999648332595825
brain O O 0.9999439716339111
oxidative O O 0.6856220364570618
stress O O 0.9989814162254333
. O O 0.9999516010284424

Thus O O 0.9999921321868896
the O O 0.9999969005584717
present O O 0.9999916553497314
study O O 0.9999803304672241
concluded O O 0.9999681711196899
that O O 0.9997394680976868
metformin B B 0.9997541308403015
may O O 0.9999080896377563
be O O 0.999932050704956
a O O 0.9998500347137451
potential O O 0.999925971031189
agent O O 0.9998121857643127
for O O 0.9997879862785339
the O O 0.9999570846557617
treatment O O 0.999955415725708
of O O 0.9999210834503174
epilepsy O O 0.9998716115951538
as O O 0.9999741315841675
well O O 0.9999604225158691
as O O 0.9999655485153198
a O O 0.9998621940612793
protective O O 0.9998689889907837
medicine O O 0.9999438524246216
against O O 0.9996852874755859
cognitive O O 0.9999886751174927
impairment O O 0.9999899864196777
induced O O 0.9999767541885376
by O O 0.9999558925628662
seizures O O 0.9999599456787109
. O O 0.9999531507492065

P53 O O 0.7582823038101196
inhibition O O 0.982296884059906
exacerbates O O 0.9999107122421265
late O O 0.9998592138290405
- O O 0.99994957447052
stage O O 0.9999275207519531
anthracycline B B 0.9971417784690857
cardiotoxicity O O 0.999363124370575
. O O 0.9998925924301147

AIMS O O 0.9633329510688782
: O O 0.9971833825111389
Doxorubicin B B 0.9996161460876465
( O O 0.9785339832305908
DOX B B 0.9996612071990967
) O O 0.9991462230682373
is O O 0.9998708963394165
an O O 0.9991681575775146
effective O O 0.9993689656257629
anti O O 0.9515514969825745
- O O 0.998172402381897
cancer O O 0.9989332556724548
therapeutic O O 0.998666524887085
, O O 0.999907374382019
but O O 0.9999181032180786
is O O 0.9998306035995483
associated O O 0.9999681711196899
with O O 0.9999653100967407
both O O 0.9998339414596558
acute O O 0.9998804330825806
and O O 0.9999053478240967
late O O 0.9998821020126343
- O O 0.9999772310256958
stage O O 0.9999939203262329
cardiotoxicity O O 0.9999951124191284
. O O 0.9999425411224365

Children O O 0.9991623163223267
are O O 0.9998984336853027
particularly O O 0.9997716546058655
sensitive O O 0.9999253749847412
to O O 0.9998412132263184
DOX B B 0.9993196725845337
- O O 0.998865008354187
induced O O 0.9999284744262695
heart O O 0.9999302625656128
failure O O 0.9999231100082397
. O O 0.9999618530273438

Here O O 0.9999673366546631
, O O 0.9999783039093018
the O O 0.9999632835388184
impact O O 0.9999772310256958
of O O 0.9997610449790955
p53 O O 0.711558997631073
inhibition O O 0.9970932006835938
on O O 0.9995576739311218
acute O O 0.9998052716255188
vs O O 0.9998258948326111
. O O 0.9999417066574097
late O O 0.999821126461029
- O O 0.9999518394470215
stage O O 0.9999587535858154
DOX B B 0.895824134349823
cardiotoxicity O O 0.9999148845672607
was O O 0.9999767541885376
examined O O 0.9999794960021973
in O O 0.9999676942825317
a O O 0.999914288520813
juvenile O O 0.9884548187255859
model O O 0.9999918937683105
. O O 0.9999762773513794

METHODS O O 0.9999635219573975
AND O O 0.9999947547912598
RESULTS O O 0.9999873638153076
: O O 0.9999569654464722
Two O O 0.9999924898147583
- O O 0.9999834299087524
week O O 0.9999949932098389
- O O 0.9999920129776001
old O O 0.9999797344207764
MHC O O 0.992760181427002
- O O 0.9989870190620422
CB7 O O 0.9188359975814819
mice O O 0.9999790191650391
( O O 0.9999786615371704
which O O 0.9998782873153687
express O O 0.9998342990875244
dominant O O 0.905071496963501
- O O 0.9906783103942871
interfering O O 0.9873672723770142
p53 O O 0.9907258152961731
in O O 0.9997403025627136
cardiomyocytes O O 0.9999654293060303
) O O 0.999936580657959
and O O 0.9999610185623169
their O O 0.9999855756759644
non O O 0.9776631593704224
- O O 0.9996634721755981
transgenic O O 0.9946944117546082
( O O 0.9997424483299255
NON O O 0.9869310259819031
- O O 0.9997285008430481
TXG O O 0.9896811842918396
) O O 0.9998846054077148
littermates O O 0.9999085664749146
received O O 0.9999691247940063
weekly O O 0.9998445510864258
DOX B B 0.9964495897293091
injections O O 0.9992741942405701
for O O 0.9999827146530151
5 O O 0.9999758005142212
weeks O O 0.9999988079071045
( O O 0.9999593496322632
25 O O 0.9999617338180542
mg O O 0.9999117851257324
/ O O 0.9999662637710571
kg O O 0.9999958276748657
cumulative O O 0.9996665716171265
dose O O 0.9998669624328613
) O O 0.9999725818634033
. O O 0.9999806880950928

One O O 0.9999909400939941
week O O 0.999998927116394
after O O 0.9999873638153076
the O O 0.9999949932098389
last O O 0.9998694658279419
DOX B B 0.9989770650863647
treatment O O 0.9978132247924805
( O O 0.9999418258666992
acute O O 0.9999760389328003
stage O O 0.9999955892562866
) O O 0.9999862909317017
, O O 0.9999750852584839
MHC O O 0.9879438877105713
- O O 0.9976683259010315
CB7 O O 0.6668781042098999
mice O O 0.99994957447052
exhibited O O 0.9999644756317139
improved O O 0.9999788999557495
cardiac O O 0.9999889135360718
function O O 0.9999973773956299
and O O 0.9999854564666748
lower O O 0.9999507665634155
levels O O 0.9999802112579346
of O O 0.9999649524688721
cardiomyocyte O O 0.99997878074646
apoptosis O O 0.9964812994003296
when O O 0.9999839067459106
compared O O 0.9999951124191284
with O O 0.9999934434890747
the O O 0.9999922513961792
NON O O 0.9965366125106812
- O O 0.9998093247413635
TXG O O 0.9648754596710205
mice O O 0.9999891519546509
. O O 0.999981164932251

Surprisingly O O 0.9999523162841797
, O O 0.9999873638153076
by O O 0.9999938011169434
13 O O 0.999994158744812
weeks O O 0.9999991655349731
following O O 0.9999836683273315
the O O 0.9999974966049194
last O O 0.9999327659606934
DOX B B 0.9970219731330872
treatment O O 0.9977487921714783
( O O 0.9999542236328125
late O O 0.9999668598175049
stage O O 0.999990701675415
) O O 0.9999865293502808
, O O 0.9999620914459229
MHC O O 0.9911734461784363
- O O 0.9957455992698669
CB7 O O 0.8497186899185181
exhibited O O 0.9999388456344604
a O O 0.9999878406524658
progressive O O 0.9999890327453613
decrease O O 0.9999946355819702
in O O 0.9999831914901733
cardiac O O 0.999984622001648
function O O 0.9999971389770508
and O O 0.9999825954437256
higher O O 0.9999315738677979
rates O O 0.9999873638153076
of O O 0.9999762773513794
cardiomyocyte O O 0.9999802112579346
apoptosis O O 0.9991514682769775
when O O 0.9999819993972778
compared O O 0.9999934434890747
with O O 0.9999898672103882
NON O O 0.9979099631309509
- O O 0.9997950196266174
TXG O O 0.9883997440338135
mice O O 0.9999901056289673
. O O 0.9999802112579346

p53 O O 0.7614696621894836
inhibition O O 0.9987323880195618
blocked O O 0.9991325736045837
transient O O 0.999953031539917
DOX B B 0.9991245865821838
- O O 0.9991183876991272
induced O O 0.9999158382415771
STAT3 O O 0.9242874383926392
activation O O 0.9998877048492432
in O O 0.9999556541442871
MHC O O 0.9861504435539246
- O O 0.9976994395256042
CB7 O O 0.7061387896537781
mice O O 0.9999364614486694
, O O 0.9999687671661377
which O O 0.9999688863754272
was O O 0.9999542236328125
associated O O 0.999981164932251
with O O 0.9999593496322632
enhanced O O 0.9999215602874756
induction O O 0.9999512434005737
of O O 0.9998687505722046
the O O 0.999509334564209
DNA O O 0.963745653629303
repair O O 0.9991868138313293
proteins O O 0.9966331124305725
Ku70 O O 0.7039585709571838
and O O 0.9981677532196045
Ku80 O O 0.5989279747009277
. O O 0.9999333620071411

Mice O O 0.999988317489624
with O O 0.9999035596847534
cardiomyocyte O O 0.9998773336410522
- O O 0.9997604489326477
restricted O O 0.9997343420982361
deletion O O 0.9998733997344971
of O O 0.996819257736206
STAT3 O O 0.8509454131126404
exhibited O O 0.9999158382415771
worse O O 0.9999196529388428
cardiac O O 0.9999926090240479
function O O 0.9999979734420776
, O O 0.9999881982803345
higher O O 0.9999139308929443
levels O O 0.9999780654907227
of O O 0.9999634027481079
cardiomyocyte O O 0.9999485015869141
apoptosis O O 0.9957230091094971
, O O 0.9999406337738037
and O O 0.9999781847000122
a O O 0.9999657869338989
greater O O 0.99981290102005
induction O O 0.9999510049819946
of O O 0.9997355341911316
Ku70 O O 0.6872588396072388
and O O 0.9954667091369629
Ku80 O O 0.8253008723258972
in O O 0.9998524188995361
response O O 0.9999734163284302
to O O 0.9997032284736633
DOX B B 0.9998729228973389
treatment O O 0.9995920062065125
during O O 0.9999206066131592
the O O 0.9999732971191406
acute O O 0.9999667406082153
stage O O 0.9999934434890747
when O O 0.999984622001648
compared O O 0.9999866485595703
with O O 0.9999635219573975
control O O 0.9998915195465088
animals O O 0.9999901056289673
. O O 0.9999767541885376

CONCLUSION O O 0.9999545812606812
: O O 0.9999814033508301
These O O 0.999993085861206
data O O 0.999985933303833
support O O 0.999955415725708
a O O 0.9998576641082764
model O O 0.999981164932251
wherein O O 0.9996275901794434
a O O 0.9995654225349426
p53 O O 0.5654467344284058
- O O 0.9986168146133423
dependent O O 0.9997196793556213
cardioprotective O O 0.9999872446060181
pathway O O 0.999897837638855
, O O 0.999942421913147
mediated O O 0.9999356269836426
via O O 0.9997376799583435
STAT3 O O 0.6826651692390442
activation O O 0.9983106851577759
, O O 0.9998641014099121
mitigates O O 0.9999436140060425
DOX B B 0.9995579123497009
- O O 0.9995474219322205
induced O O 0.9999734163284302
myocardial O O 0.9999990463256836
stress O O 0.9999877214431763
during O O 0.9999407529830933
drug O O 0.9998526573181152
delivery O O 0.9999501705169678
. O O 0.9999690055847168

Furthermore O O 0.9999513626098633
, O O 0.999984622001648
these O O 0.9999840259552002
data O O 0.9999891519546509
suggest O O 0.9999326467514038
an O O 0.9999521970748901
explanation O O 0.9999847412109375
as O O 0.9999969005584717
to O O 0.9999939203262329
how O O 0.9998838901519775
p53 O O 0.796574056148529
inhibition O O 0.9993939399719238
can O O 0.9999181032180786
result O O 0.9999675750732422
in O O 0.9999123811721802
cardioprotection O O 0.9999840259552002
during O O 0.9997121691703796
drug O O 0.9979352951049805
treatment O O 0.9999390840530396
and O O 0.9999431371688843
, O O 0.9999860525131226
paradoxically O O 0.9999793767929077
, O O 0.999983549118042
enhanced O O 0.9999666213989258
cardiotoxicity O O 0.9999881982803345
long O O 0.9999479055404663
after O O 0.999980092048645
the O O 0.9999890327453613
cessation O O 0.99998939037323
of O O 0.9999566078186035
drug O O 0.9976771473884583
treatment O O 0.999891996383667
. O O 0.999966025352478

Metronidazole B B 0.9946938157081604
- O O 0.9995263814926147
induced O O 0.9999508857727051
encephalopathy O O 0.9999425411224365
: O O 0.9999731779098511
an O O 0.9999794960021973
uncommon O O 0.9999783039093018
scenario O O 0.9999926090240479
. O O 0.9999785423278809

Metronidazole B B 0.9975749850273132
can O O 0.9997950196266174
produce O O 0.9999263286590576
neurological O O 0.9999924898147583
complications O O 0.9999966621398926
although O O 0.9999551773071289
it O O 0.9999862909317017
is O O 0.9999749660491943
not O O 0.9999915361404419
a O O 0.9999762773513794
common O O 0.9999867677688599
scenario O O 0.9999945163726807
. O O 0.9999551773071289

We O O 0.9999885559082031
present O O 0.999993085861206
a O O 0.999992847442627
case O O 0.9999953508377075
where O O 0.9999754428863525
a O O 0.9999819993972778
patient O O 0.9999897480010986
developed O O 0.9999890327453613
features O O 0.9999960660934448
of O O 0.9999836683273315
encephalopathy O O 0.9999027252197266
following O O 0.9999182224273682
prolonged O O 0.9998844861984253
metronidazole B B 0.9989959597587585
intake O O 0.9995712637901306
. O O 0.9999783039093018

Magnetic O O 0.9999006986618042
resonance O O 0.9999324083328247
imaging O O 0.9999786615371704
( O O 0.9998660087585449
MRI O O 0.995142936706543
) O O 0.999944806098938
brain O O 0.9999767541885376
showed O O 0.9998886585235596
abnormal O O 0.9999598264694214
signal O O 0.9998835325241089
intensity O O 0.9999780654907227
involving O O 0.9999008178710938
both O O 0.9990371465682983
dentate O O 0.9833351373672485
nuclei O O 0.9999731779098511
of O O 0.9996337890625
cerebellum O O 0.9926692247390747
and O O 0.999863862991333
splenium O O 0.9949427247047424
of O O 0.9994431138038635
corpus O O 0.9999018907546997
callosum O O 0.9999991655349731
. O O 0.9999423027038574

The O O 0.9999891519546509
diagnosis O O 0.9999938011169434
of O O 0.9999426603317261
metronidazole B B 0.9994427561759949
toxicity O O 0.9998451471328735
was O O 0.9999896287918091
made O O 0.9999977350234985
by O O 0.9999954700469971
the O O 0.9999918937683105
MRI O O 0.9784559607505798
findings O O 0.9999920129776001
and O O 0.9999781847000122
supported O O 0.9999970197677612
clinically O O 0.9999915361404419
. O O 0.9999871253967285

Aconitine B B 0.9972336888313293
- O O 0.9918493032455444
induced O O 0.999565064907074
Ca2 B B 0.9969498515129089
+ O O 0.9306604266166687
overload O O 0.9981076717376709
causes O O 0.9999369382858276
arrhythmia O O 0.9999936819076538
and O O 0.9999754428863525
triggers O O 0.9998874664306641
apoptosis O O 0.9995748400688171
through O O 0.9997046589851379
p38 O O 0.9519358277320862
MAPK O O 0.8991912007331848
signaling O O 0.9902100563049316
pathway O O 0.9987045526504517
in O O 0.9997784495353699
rats O O 0.9996474981307983
. O O 0.9999486207962036

Aconitine B B 0.9937154650688171
is O O 0.9987118244171143
a O O 0.9988824725151062
major O O 0.9918627738952637
bioactive O O 0.930462121963501
diterpenoid O O 0.5488767623901367
alkaloid O O 0.4594065248966217
with O O 0.999817430973053
high O O 0.9937784075737
content O O 0.9998133778572083
derived O O 0.9998760223388672
from O O 0.9961084723472595
herbal O O 0.9857586622238159
aconitum O B 0.8931254148483276
plants O O 0.8291247487068176
. O O 0.9997091889381409

Emerging O O 0.999964714050293
evidence O O 0.9999842643737793
indicates O O 0.9998824596405029
that O O 0.9994833469390869
voltage O O 0.8575754761695862
- O O 0.9996082186698914
dependent O O 0.9961972236633301
Na B B 0.9886709451675415
( O O 0.840793251991272
+ O O 0.9985020160675049
) O O 0.9949610233306885
channels O O 0.9997552037239075
have O O 0.9998971223831177
pivotal O O 0.9986306428909302
roles O O 0.9999568462371826
in O O 0.9999370574951172
the O O 0.999950647354126
cardiotoxicity O O 0.9999914169311523
of O O 0.9995941519737244
aconitine B B 0.9231793880462646
. O O 0.9998937845230103

However O O 0.9999315738677979
, O O 0.9999616146087646
no O O 0.9999712705612183
reports O O 0.9999866485595703
are O O 0.9999862909317017
available O O 0.9999954700469971
on O O 0.9999202489852905
the O O 0.9999567270278931
role O O 0.99993896484375
of O O 0.9805552363395691
Ca B B 0.9960500597953796
( O O 0.970527172088623
2 O O 0.7556926012039185
+ O O 0.9648833274841309
) O O 0.9693177938461304
in O O 0.9997265934944153
aconitine B O 0.8433486819267273
poisoning O O 0.995780348777771
. O O 0.9999374151229858

In O O 0.9999785423278809
this O O 0.9999755620956421
study O O 0.9999840259552002
, O O 0.999953031539917
we O O 0.9999517202377319
explored O O 0.9999653100967407
the O O 0.9999799728393555
importance O O 0.9999769926071167
of O O 0.9998970031738281
pathological O O 0.9999618530273438
Ca B B 0.9260982275009155
( O O 0.9967260360717773
2 O O 0.9798566699028015
+ O O 0.9996938705444336
) O O 0.9927672147750854
signaling O O 0.9993035793304443
in O O 0.9996795654296875
aconitine B O 0.7176116108894348
poisoning O O 0.9982972741127014
in O O 0.9999144077301025
vitro O O 0.9999754428863525
and O O 0.9999370574951172
in O O 0.9999016523361206
vivo O O 0.999962329864502
. O O 0.9999231100082397

We O O 0.9999637603759766
found O O 0.9999910593032837
that O O 0.9998118281364441
Ca B B 0.9928690791130066
( O O 0.9523693323135376
2 O O 0.855934202671051
+ O O 0.9987460374832153
) O O 0.7274497151374817
overload O O 0.9652897119522095
lead O O 0.9999382495880127
to O O 0.9999526739120483
accelerated O O 0.9999847412109375
beating O O 0.9999953508377075
rhythm O O 0.9999978542327881
in O O 0.999925971031189
adult O O 0.9999746084213257
rat O O 0.9999464750289917
ventricular O O 0.9999688863754272
myocytes O O 0.9999690055847168
and O O 0.9999454021453857
caused O O 0.9999778270721436
arrhythmia O O 0.9999915361404419
in O O 0.9999444484710693
conscious O O 0.9999737739562988
freely O O 0.9999852180480957
moving O O 0.9999946355819702
rats O O 0.9999912977218628
. O O 0.999967098236084

To O O 0.9999886751174927
investigate O O 0.9999191761016846
effects O O 0.999895453453064
of O O 0.997892439365387
aconitine B B 0.9982600808143616
on O O 0.9994122982025146
myocardial O O 0.9999982118606567
injury O O 0.9999902248382568
, O O 0.9999828338623047
we O O 0.9999779462814331
performed O O 0.9999825954437256
cytotoxicity O O 0.9965441823005676
assay O O 0.9997356534004211
in O O 0.9998788833618164
neonatal O O 0.999994158744812
rat O O 0.9999643564224243
ventricular O O 0.9996944665908813
myocytes O O 0.9999419450759888
( O O 0.9999467134475708
NRVMs O O 0.9721906185150146
) O O 0.9999613761901855
, O O 0.9999692440032959
as O O 0.9999865293502808
well O O 0.999983549118042
as O O 0.9999918937683105
measured O O 0.9998121857643127
lactate B B 0.993595540523529
dehydrogenase O O 0.5586611032485962
level O O 0.999699592590332
in O O 0.999923586845398
the O O 0.9999301433563232
culture O O 0.9998972415924072
medium O O 0.9999696016311646
of O O 0.9996874332427979
NRVMs O O 0.8869590759277344
and O O 0.9999686479568481
activities O O 0.999521017074585
of O O 0.9999542236328125
serum O O 0.9977450370788574
cardiac O O 0.4946019947528839
enzymes O O 0.7999453544616699
in O O 0.9998237490653992
rats O O 0.9995586276054382
. O O 0.999923586845398

The O O 0.9999860525131226
results O O 0.9999916553497314
showed O O 0.9999837875366211
that O O 0.9997972846031189
aconitine B B 0.9988710284233093
resulted O O 0.9999074935913086
in O O 0.9999517202377319
myocardial O O 0.9999980926513672
injury O O 0.999994158744812
and O O 0.9999750852584839
reduced O O 0.9999672174453735
NRVMs O O 0.9539567232131958
viability O O 0.9999532699584961
dose O O 0.9984003901481628
- O O 0.9999756813049316
dependently O O 0.9999727010726929
. O O 0.9999843835830688

To O O 0.9999679327011108
confirm O O 0.9999316930770874
the O O 0.9998829364776611
pro O O 0.951128363609314
- O O 0.9973880648612976
apoptotic O O 0.9992254972457886
effects O O 0.9998929500579834
, O O 0.9999521970748901
we O O 0.9999454021453857
performed O O 0.9999815225601196
flow O O 0.9999481439590454
cytometric O O 0.999942421913147
detection O O 0.9999920129776001
, O O 0.9999810457229614
cardiac O O 0.9999598264694214
histology O O 0.9999862909317017
, O O 0.9999693632125854
transmission O O 0.9999879598617554
electron O O 0.9995456337928772
microscopy O O 0.9999572038650513
and O O 0.9999711513519287
terminal O B 0.6818511486053467
deoxynucleotidyl O I 0.6922341585159302
transferase O O 0.8732062578201294
- O O 0.9204955101013184
mediated O O 0.9950008988380432
dUTP B O 0.4983378052711487
- O O 0.7043747305870056
biotin B O 0.5373311042785645
nick O O 0.7903695106506348
end O O 0.5929391980171204
labeling O O 0.9897423982620239
assay O O 0.999924898147583
. O O 0.9999862909317017

The O O 0.9999803304672241
results O O 0.9999816417694092
showed O O 0.9999778270721436
that O O 0.9998005032539368
aconitine B B 0.9955689311027527
stimulated O O 0.9983862638473511
apoptosis O O 0.998231828212738
time O O 0.9970788955688477
- O O 0.9999617338180542
dependently O O 0.9999798536300659
. O O 0.999983549118042

The O O 0.9999750852584839
expression O O 0.999830961227417
analysis O O 0.9999650716781616
of O O 0.9995385408401489
Ca B O 0.8459822535514832
( O O 0.7664989233016968
2 O O 0.8162354826927185
+ O O 0.9320025444030762
) O O 0.9335945248603821
handling O O 0.9798760414123535
proteins O O 0.9982957243919373
demonstrated O O 0.9999212026596069
that O O 0.9996756315231323
aconitine B B 0.9715409278869629
promoted O O 0.9994021654129028
Ca B B 0.9037071466445923
( O O 0.8725787401199341
2 O O 0.8534479141235352
+ O O 0.9733542203903198
) O O 0.9799543023109436
overload O O 0.999122679233551
through O O 0.9998362064361572
the O O 0.9997585415840149
expression O O 0.9941105246543884
regulation O O 0.9999257326126099
of O O 0.9996541738510132
Ca B O 0.7686973214149475
( O O 0.8736918568611145
2 O O 0.9040269255638123
+ O O 0.9563899040222168
) O O 0.9078736305236816
handling O O 0.9903603792190552
proteins O O 0.9995885491371155
. O O 0.9999387264251709

The O O 0.9999399185180664
expression O O 0.999934196472168
analysis O O 0.9999494552612305
of O O 0.9991299510002136
apoptosis O O 0.8871585726737976
- O O 0.9990758895874023
related O O 0.9988644123077393
proteins O O 0.9984388947486877
revealed O O 0.9999233484268188
that O O 0.9995635151863098
pro O O 0.9739382266998291
- O O 0.9983605742454529
apoptotic O O 0.9956186413764954
protein O O 0.9989703893661499
expression O O 0.9998856782913208
was O O 0.999927282333374
upregulated O O 0.9839193224906921
, O O 0.9998019337654114
and O O 0.9994208812713623
anti O O 0.9189773201942444
- O O 0.9989616870880127
apoptotic O O 0.9638718962669373
protein O O 0.9868773221969604
BCL O O 0.9239285588264465
- O O 0.9947762489318848
2 O O 0.9926308393478394
expression O O 0.9999271631240845
was O O 0.9999592304229736
downregulated O O 0.9998574256896973
. O O 0.9999711513519287

Furthermore O O 0.9997103810310364
, O O 0.9999555349349976
increased O O 0.9998778104782104
phosphorylation O O 0.9526218771934509
of O O 0.998927652835846
MAPK O O 0.4879567623138428
family O O 0.9024125933647156
members O O 0.9992454051971436
, O O 0.9999465942382812
especially O O 0.9995354413986206
the O O 0.9998908042907715
P O O 0.7982932329177856
- O O 0.9248034358024597
P38 O O 0.8563549518585205
/ O O 0.9955084323883057
P38 O O 0.9649267196655273
ratio O O 0.9963790774345398
was O O 0.9999502897262573
found O O 0.9999723434448242
in O O 0.9997926354408264
cardiac O O 0.9992844462394714
tissues O O 0.9999905824661255
. O O 0.9999576807022095

Hence O O 0.9999717473983765
, O O 0.9999668598175049
our O O 0.9998432397842407
results O O 0.9999901056289673
suggest O O 0.9999333620071411
that O O 0.99907386302948
aconitine B B 0.9949959516525269
significantly O O 0.9995918869972229
aggravates O O 0.9998759031295776
Ca B B 0.9887451529502869
( O O 0.9844334125518799
2 O O 0.953070878982544
+ O O 0.9991834759712219
) O O 0.972446084022522
overload O O 0.9988701939582825
and O O 0.9999690055847168
causes O O 0.9999091625213623
arrhythmia O O 0.9999889135360718
and O O 0.9999628067016602
finally O O 0.9997547268867493
promotes O O 0.9998722076416016
apoptotic O O 0.9987044334411621
development O O 0.9999847412109375
via O O 0.9999450445175171
phosphorylation O O 0.911491870880127
of O O 0.9987983703613281
P38 O O 0.943495512008667
mitogen O O 0.9417937994003296
- O O 0.9975196719169617
activated O O 0.9881101846694946
protein O O 0.9971743822097778
kinase O O 0.9958353042602539
. O O 0.9999409914016724

Chronic O O 0.9990664124488831
treatment O O 0.9999104738235474
with O O 0.9992935657501221
metformin B B 0.9994051456451416
suppresses O O 0.996222734451294
toll O O 0.953072726726532
- O O 0.9985236525535583
like O O 0.9952120780944824
receptor O O 0.999426007270813
4 O O 0.9786771535873413
signaling O O 0.9998347759246826
and O O 0.9999270439147949
attenuates O O 0.9996521472930908
left O O 0.999988317489624
ventricular O O 0.9999969005584717
dysfunction O O 0.9999945163726807
following O O 0.9999494552612305
myocardial O O 0.9999955892562866
infarction O O 0.9999885559082031
. O O 0.9998157620429993

Acute O O 0.9989790916442871
treatment O O 0.9999344348907471
with O O 0.9992378950119019
metformin B B 0.9997802376747131
has O O 0.9995470643043518
a O O 0.9999456405639648
protective O O 0.9997808337211609
effect O O 0.9999598264694214
in O O 0.9999483823776245
myocardial O O 0.9999980926513672
infarction O O 0.9999936819076538
by O O 0.9999183416366577
suppression O O 0.9998359680175781
of O O 0.9996390342712402
inflammatory O O 0.9995194673538208
responses O O 0.9999847412109375
due O O 0.9999310970306396
to O O 0.9984424710273743
activation O O 0.999110996723175
of O O 0.9986225366592407
AMP B O 0.5788173675537109
- O O 0.725176990032196
activated O O 0.8200799822807312
protein O O 0.9559032320976257
kinase O O 0.9880474805831909
( O O 0.9993563294410706
AMPK O O 0.7450449466705322
) O O 0.9997747540473938
. O O 0.9999151229858398

In O O 0.9999842643737793
the O O 0.9999934434890747
present O O 0.9999856948852539
study O O 0.9999905824661255
, O O 0.9999556541442871
the O O 0.9999704360961914
effect O O 0.9999744892120361
of O O 0.9999479055404663
chronic O O 0.9996942281723022
pre O O 0.9970337152481079
- O O 0.999876856803894
treatment O O 0.9999681711196899
with O O 0.999569833278656
metformin B B 0.999539852142334
on O O 0.9995681643486023
cardiac O O 0.999977707862854
dysfunction O O 0.9999938011169434
and O O 0.9999090433120728
toll O O 0.9684169888496399
- O O 0.9983319640159607
like O O 0.9923122525215149
receptor O O 0.998884379863739
4 O O 0.9849766492843628
( O O 0.9991076588630676
TLR4 O O 0.9846499562263489
) O O 0.9995631575584412
activities O O 0.9994538426399231
following O O 0.9999336004257202
myocardial O O 0.9999967813491821
infarction O O 0.9999923706054688
and O O 0.9999430179595947
their O O 0.9999157190322876
relation O O 0.9999911785125732
with O O 0.9998210072517395
AMPK O B 0.946025550365448
were O O 0.999804675579071
assessed O O 0.9999744892120361
. O O 0.9999605417251587

Male O O 0.9999724626541138
Wistar O O 0.9997220635414124
rats O O 0.9999943971633911
were O O 0.9999873638153076
randomly O O 0.9999949932098389
assigned O O 0.9999959468841553
to O O 0.9999631643295288
one O O 0.9999849796295166
of O O 0.9999626874923706
5 O O 0.999947190284729
groups O O 0.9999872446060181
( O O 0.9999637603759766
n O O 0.9999513626098633
= O O 0.9999834299087524
6 O O 0.9999896287918091
) O O 0.9999736547470093
: O O 0.9999738931655884
normal O O 0.9997889399528503
control O O 0.9999858140945435
and O O 0.9996604919433594
groups O O 0.998997151851654
were O O 0.9999663829803467
injected O O 0.9993687272071838
isoproterenol B B 0.9989840388298035
after O O 0.9997791647911072
chronic O O 0.999835729598999
pre O O 0.9999182224273682
- O O 0.9999743700027466
treatment O O 0.9999808073043823
with O O 0.999931812286377
0 O O 0.9942627549171448
, O O 0.9997207522392273
25 O O 0.9996352195739746
, O O 0.9987491369247437
50 O O 0.9991273283958435
, O O 0.9994206428527832
or O O 0.999889612197876
100mg O O 0.999423623085022
/ O O 0.9999113082885742
kg O O 0.9999964237213135
of O O 0.9994408488273621
metformin B B 0.9992916584014893
twice O O 0.9930272698402405
daily O O 0.9999823570251465
for O O 0.9999717473983765
14 O O 0.9999940395355225
days O O 0.9999963045120239
. O O 0.9999887943267822

Isoproterenol B B 0.9991135001182556
( O O 0.9996979236602783
100mg O O 0.9956269264221191
/ O O 0.9995020627975464
kg O O 0.9999680519104004
) O O 0.9999319314956665
was O O 0.9999724626541138
injected O O 0.9999747276306152
subcutaneously O O 0.9999594688415527
on O O 0.9999829530715942
the O O 0.9999971389770508
13th O O 0.9999972581863403
and O O 0.9999887943267822
14th O O 0.9999978542327881
days O O 0.9999953508377075
to O O 0.9999755620956421
induce O O 0.9999927282333374
acute O O 0.9999901056289673
myocardial O O 0.9999980926513672
infarction O O 0.9999908208847046
. O O 0.9999735355377197

Isoproterenol B B 0.9994639754295349
alone O O 0.9996016621589661
decreased O O 0.9999295473098755
left O O 0.9999914169311523
ventricular O O 0.9999963045120239
systolic O O 0.9946309328079224
pressure O O 0.9999126195907593
and O O 0.9998952150344849
myocardial O O 0.9999955892562866
contractility O O 0.9999711513519287
indexed O O 0.999762237071991
as O O 0.9998800754547119
LVdp O O 0.7135273218154907
/ O O 0.9977735877037048
dtmax O O 0.9820818305015564
and O O 0.9997240900993347
LVdp O O 0.6439275741577148
/ O O 0.9969711303710938
dtmin O O 0.9415525197982788
. O O 0.9999126195907593

The O O 0.9999710321426392
left O O 0.9999591112136841
ventricular O O 0.9999920129776001
dysfunction O O 0.9999898672103882
was O O 0.9999686479568481
significantly O O 0.999980092048645
lower O O 0.9999847412109375
in O O 0.9998794794082642
the O O 0.9999667406082153
groups O O 0.9999651908874512
treated O O 0.9999665021896362
with O O 0.9998977184295654
25 O O 0.9937840700149536
and O O 0.9995984435081482
50mg O O 0.9999529123306274
/ O O 0.9999445676803589
kg O O 0.9999942779541016
of O O 0.9990590214729309
metformin B B 0.9992464780807495
. O O 0.9999581575393677

Metfromin O B 0.9848588109016418
markedly O O 0.9996040463447571
lowered O O 0.9920393228530884
isoproterenol B B 0.9997226595878601
- O O 0.999897837638855
induced O O 0.9999274015426636
elevation O O 0.9999849796295166
in O O 0.9999902248382568
the O O 0.9999803304672241
levels O O 0.9999433755874634
of O O 0.9995206594467163
TLR4 O O 0.8754962682723999
mRNA O O 0.9865951538085938
, O O 0.9996328353881836
myeloid O O 0.999619722366333
differentiation O O 0.996006190776825
protein O O 0.9953715205192566
88 O O 0.7791314125061035
( O O 0.9997674822807312
MyD88 O O 0.998543381690979
) O O 0.999846339225769
, O O 0.999158501625061
tumor O O 0.8929557204246521
necrosis O O 0.9819419980049133
factor O O 0.9867231249809265
- O O 0.9881801605224609
alpha O O 0.9344326853752136
( O O 0.9995390176773071
TNF O O 0.8847240805625916
- O O 0.9866949319839478
a O O 0.5847153067588806
) O O 0.9959198236465454
, O O 0.9982109069824219
and O O 0.998984158039093
interleukin O O 0.981264591217041
6 O O 0.9845263957977295
( O O 0.9992498755455017
IL O O 0.9854861497879028
- O O 0.9976117610931396
6 O O 0.9844123721122742
) O O 0.9999524354934692
in O O 0.9998726844787598
the O O 0.9999607801437378
heart O O 0.9996163845062256
tissues O O 0.9999912977218628
. O O 0.9999655485153198

Similar O O 0.9999120235443115
changes O O 0.9999938011169434
were O O 0.9999767541885376
also O O 0.9999821186065674
seen O O 0.9999960660934448
in O O 0.999982476234436
the O O 0.9999575614929199
serum O O 0.9993153810501099
levels O O 0.9998562335968018
of O O 0.9964498281478882
TNF O O 0.7640281915664673
- O O 0.9366934895515442
a O O 0.5172640085220337
and O O 0.998997151851654
IL O O 0.9108242988586426
- O O 0.9871273040771484
6 O O 0.977642297744751
. O O 0.9999349117279053

However O O 0.9999487400054932
, O O 0.9999144077301025
the O O 0.9999790191650391
lower O O 0.9999611377716064
doses O O 0.9999821186065674
of O O 0.9999645948410034
25 O O 0.9982149600982666
and O O 0.9988150596618652
50mg O O 0.9997016787528992
/ O O 0.9999117851257324
kg O O 0.9999762773513794
were O O 0.9999736547470093
more O O 0.9999328851699829
effective O O 0.9999717473983765
than O O 0.9997997879981995
100mg O O 0.9989107847213745
/ O O 0.9998200535774231
kg O O 0.9999905824661255
. O O 0.9999701976776123

Phosphorylated O O 0.5190428495407104
AMPKa O O 0.5020849108695984
( O O 0.998324453830719
p O O 0.8464292883872986
- O O 0.9522773027420044
AMPK O O 0.727182924747467
) O O 0.9997881054878235
in O O 0.9997977614402771
the O O 0.999944806098938
myocardium O O 0.9999963045120239
was O O 0.9999738931655884
significantly O O 0.9999842643737793
elevated O O 0.9999595880508423
by O O 0.9999271631240845
25mg O O 0.9999415874481201
/ O O 0.9999680519104004
kg O O 0.9999094009399414
of O O 0.9974709749221802
metformin B B 0.9994482398033142
, O O 0.9998774528503418
slightly O O 0.9999853372573853
by O O 0.9999768733978271
50mg O O 0.9998892545700073
/ O O 0.9999624490737915
kg O O 0.999955415725708
, O O 0.9999804496765137
but O O 0.9999831914901733
not O O 0.9999819993972778
by O O 0.9999443292617798
100mg O O 0.9987608194351196
/ O O 0.9998719692230225
kg O O 0.9998328685760498
. O O 0.9999769926071167

Chronic O O 0.9989731311798096
pre O O 0.9981499910354614
- O O 0.999874472618103
treatment O O 0.9999353885650635
with O O 0.9993219375610352
metformin B B 0.999617338180542
reduces O O 0.9995378255844116
post O O 0.9991555213928223
- O O 0.9994897842407227
myocardial O O 0.9999964237213135
infarction O O 0.9999651908874512
cardiac O O 0.9999837875366211
dysfunction O O 0.9999954700469971
and O O 0.9999145269393921
suppresses O O 0.9955102205276489
inflammatory O O 0.9995648264884949
responses O O 0.9999856948852539
, O O 0.9999786615371704
possibly O O 0.9999544620513916
through O O 0.9998636245727539
inhibition O O 0.9993820190429688
of O O 0.9992697834968567
TLR4 O O 0.9151106476783752
activities O O 0.9990667700767517
. O O 0.9998651742935181

This O O 0.9996916055679321
mechanism O O 0.9992606043815613
can O O 0.9996756315231323
be O O 0.9999250173568726
considered O O 0.9997413754463196
as O O 0.9999059438705444
a O O 0.9995918869972229
target O O 0.9997201561927795
to O O 0.999810516834259
protect O O 0.9993367791175842
infarcted O O 0.9998906850814819
myocardium O O 0.9999912977218628
. O O 0.9998756647109985

Unusual O O 0.9993340373039246
complications O O 0.999980092048645
of O O 0.9998421669006348
antithyroid O O 0.5234850645065308
drug O O 0.9279613494873047
therapy O O 0.9990631937980652
: O O 0.9999682903289795
four O O 0.9999333620071411
case O O 0.9999698400497437
reports O O 0.9999947547912598
and O O 0.9999786615371704
review O O 0.9999908208847046
of O O 0.999993085861206
literature O O 0.999991774559021
. O O 0.9999758005142212

Two O O 0.9999655485153198
cases O O 0.9999892711639404
of O O 0.9998980760574341
propylthiouracil B B 0.9989035129547119
- O O 0.9982151985168457
associated O O 0.9996334314346313
acute O O 0.9992338418960571
hepatitis O O 0.9999663829803467
, O O 0.9999415874481201
one O O 0.9999884366989136
case O O 0.9999918937683105
of O O 0.9999197721481323
fatal O O 0.9975854158401489
methimazole B B 0.9991762042045593
- O O 0.9983651041984558
associated O O 0.9994775652885437
hepatocellular O O 0.9989569187164307
necrosis O O 0.9999797344207764
and O O 0.9999501705169678
one O O 0.9999696016311646
case O O 0.9999923706054688
of O O 0.9999141693115234
propylthiouracil B B 0.9991563558578491
- O O 0.9986949563026428
associated O O 0.9997115731239319
lupus O O 0.9988577365875244
- O O 0.9999710321426392
like O O 0.9999896287918091
syndrome O O 0.9999921321868896
are O O 0.999962329864502
described O O 0.9999899864196777
. O O 0.9999594688415527

The O O 0.9999868869781494
literature O O 0.9999947547912598
related O O 0.9999918937683105
to O O 0.999758780002594
antithyroid O O 0.5352522134780884
drug O O 0.901222825050354
side O O 0.9998425245285034
effects O O 0.9999780654907227
and O O 0.9999585151672363
the O O 0.9999828338623047
mechanisms O O 0.9999936819076538
for O O 0.9999899864196777
their O O 0.9999767541885376
occurrence O O 0.9999957084655762
are O O 0.9999792575836182
reviewed O O 0.9999916553497314
and O O 0.9999964237213135
the O O 0.9999825954437256
efficacy O O 0.9999668598175049
and O O 0.9999734163284302
complications O O 0.9999943971633911
of O O 0.9998865127563477
thyroidectomy O B 0.9020282030105591
and O O 0.8660889863967896
radioiodine O B 0.9994462132453918
compared O O 0.9998548030853271
to O O 0.9998261332511902
those O O 0.9999630451202393
of O O 0.9995688796043396
antithyroid O O 0.4858758747577667
drugs O O 0.9813806414604187
. O O 0.999937891960144

It O O 0.9999884366989136
is O O 0.9999699592590332
concluded O O 0.9999550580978394
that O O 0.9996224641799927
in O O 0.9999475479125977
most O O 0.999976634979248
circumstances O O 0.999925971031189
131I O B 0.9723582863807678
is O O 0.9995586276054382
the O O 0.999942421913147
therapy O O 0.9998829364776611
of O O 0.9999693632125854
choice O O 0.999964714050293
for O O 0.9998769760131836
hyperthyroidism O O 0.9941070079803467
. O O 0.9999431371688843

Neuroleptic O O 0.9997544884681702
malignant O O 0.9999922513961792
syndrome O O 0.99998939037323
induced O O 0.999976634979248
by O O 0.9999314546585083
combination O O 0.9615064263343811
therapy O O 0.9996849298477173
with O O 0.9995833039283752
tetrabenazine B B 0.9978014826774597
and O O 0.7643479108810425
tiapride B B 0.9966433048248291
in O O 0.9998855590820312
a O O 0.9999881982803345
Japanese O O 0.9748755097389221
patient O O 0.9999734163284302
with O O 0.9999711513519287
Huntington O O 0.9974396228790283
' O O 0.9999896287918091
s O O 0.9999935626983643
disease O O 0.9999858140945435
at O O 0.9999819993972778
the O O 0.9999939203262329
terminal O O 0.9999955892562866
stage O O 0.999997615814209
of O O 0.9999765157699585
recurrent O O 0.99997878074646
breast O O 0.9996170997619629
cancer O O 0.9999597072601318
. O O 0.9999734163284302

We O O 0.9999895095825195
herein O O 0.9999939203262329
describe O O 0.9999978542327881
the O O 0.9999970197677612
case O O 0.999996542930603
of O O 0.9999892711639404
an O O 0.9999947547912598
81 O O 0.9999781847000122
- O O 0.9999887943267822
year O O 0.9999955892562866
- O O 0.999992847442627
old O O 0.9999904632568359
Japanese O O 0.9912070631980896
woman O O 0.9999903440475464
with O O 0.9999442100524902
neuroleptic O O 0.999983549118042
malignant O O 0.9999974966049194
syndrome O O 0.9999961853027344
that O O 0.9999881982803345
occurred O O 0.9999983310699463
36 O O 0.9999961853027344
days O O 0.9999984502792358
after O O 0.9999887943267822
the O O 0.9999923706054688
initiation O O 0.9999741315841675
of O O 0.9999090433120728
combination O O 0.9637351632118225
therapy O O 0.9998052716255188
with O O 0.9995031356811523
tiapride B B 0.9993890523910522
( O O 0.9972584247589111
75 O O 0.9971445202827454
mg O O 0.9993882179260254
/ O O 0.9994699358940125
day O O 0.9976252913475037
) O O 0.9994029998779297
and O O 0.9859011769294739
tetrabenazine B B 0.9978111386299133
( O O 0.9990743398666382
12 O O 0.9997851252555847
. O O 0.9999750852584839
5 O O 0.9999231100082397
mg O O 0.999727189540863
/ O O 0.9998294115066528
day O O 0.998989999294281
) O O 0.9999492168426514
for O O 0.9998735189437866
Huntington O O 0.9984625577926636
' O O 0.9999885559082031
s O O 0.9999933242797852
disease O O 0.9999926090240479
. O O 0.9999740123748779

The O O 0.9999765157699585
patient O O 0.9999814033508301
had O O 0.9999719858169556
been O O 0.9999887943267822
treated O O 0.9998866319656372
with O O 0.9993380904197693
tiapride B B 0.9994983673095703
or O O 0.8935858607292175
tetrabenazine B B 0.9964398741722107
alone O O 0.9994695782661438
without O O 0.9999871253967285
any O O 0.9999850988388062
adverse O O 0.9999724626541138
effects O O 0.9999878406524658
before O O 0.9999866485595703
the O O 0.9999953508377075
administration O O 0.9999843835830688
of O O 0.9999762773513794
the O O 0.9999642372131348
combination O O 0.9924526810646057
therapy O O 0.9997496008872986
. O O 0.9999686479568481

She O O 0.9999661445617676
also O O 0.9999744892120361
had O O 0.9999850988388062
advanced O O 0.9999940395355225
breast O O 0.9985767602920532
cancer O O 0.9999568462371826
when O O 0.9999834299087524
the O O 0.9999300241470337
combination O O 0.9197463989257812
therapy O O 0.998916745185852
was O O 0.9999580383300781
initiated O O 0.9999761581420898
. O O 0.9999656677246094

To O O 0.9999914169311523
the O O 0.9999942779541016
best O O 0.9999945163726807
of O O 0.9999842643737793
our O O 0.9999833106994629
knowledge O O 0.9999905824661255
, O O 0.9999738931655884
the O O 0.9999927282333374
occurrence O O 0.9999948740005493
of O O 0.9999713897705078
neuroleptic O O 0.9999529123306274
malignant O O 0.9999963045120239
syndrome O O 0.9999904632568359
due O O 0.9999759197235107
to O O 0.9995484948158264
combination O O 0.9818595051765442
therapy O O 0.9998142123222351
with O O 0.9995322227478027
tetrabenazine B B 0.9982628226280212
and O O 0.8319012522697449
tiapride B B 0.9984133243560791
has O O 0.999897837638855
not O O 0.999993085861206
been O O 0.9999969005584717
previously O O 0.9999873638153076
reported O O 0.9999957084655762
. O O 0.9999840259552002

Tetrabenazine B B 0.9989799857139587
should O O 0.9997305274009705
be O O 0.9999858140945435
administered O O 0.9999254941940308
very O O 0.999987006187439
carefully O O 0.9999901056289673
in O O 0.999966025352478
combination O O 0.9999030828475952
with O O 0.9997640252113342
other O O 0.9997664093971252
neuroleptic B O 0.9992524981498718
drugs I O 0.9972048401832581
, O O 0.9999783039093018
particularly O O 0.9999847412109375
in O O 0.9999711513519287
patients O O 0.9999946355819702
with O O 0.9999936819076538
a O O 0.9999951124191284
worsening O O 0.9999951124191284
general O O 0.9999948740005493
condition O O 0.9999988079071045
. O O 0.9999722242355347

A O O 0.9900612831115723
metoprolol B B 0.999625563621521
- O O 0.5099507570266724
terbinafine B B 0.7404463291168213
combination O O 0.9639047980308533
induced O O 0.9999387264251709
bradycardia O O 0.9999867677688599
. O O 0.9999430179595947

To O O 0.9999730587005615
report O O 0.9999896287918091
a O O 0.9999760389328003
sinus O O 0.9999850988388062
bradycardia O O 0.9999769926071167
induced O O 0.9999591112136841
by O O 0.9997888207435608
metoprolol B B 0.9998364448547363
and O O 0.9895918965339661
terbinafine B B 0.9587802290916443
drug O O 0.9052293300628662
- O O 0.9993758797645569
drug O O 0.9976235032081604
interaction O O 0.9999598264694214
and O O 0.999947190284729
its O O 0.9999527931213379
management O O 0.9999494552612305
. O O 0.9999728202819824

A O O 0.9999823570251465
63 O O 0.9999983310699463
year O O 0.9999970197677612
- O O 0.9999945163726807
old O O 0.999995231628418
Caucasian O O 0.9999024868011475
man O O 0.9999923706054688
on O O 0.9993255138397217
metoprolol B B 0.9996089339256287
200 O O 0.5920896530151367
mg O O 0.9911937117576599
/ O O 0.9996291399002075
day O O 0.9995163679122925
for O O 0.9999593496322632
stable O O 0.9999858140945435
coronary O O 0.9997989535331726
artery O O 0.9999735355377197
disease O O 0.9999954700469971
was O O 0.9999810457229614
prescribed O O 0.9999535083770752
a O O 0.9999803304672241
90 O O 0.9999371767044067
- O O 0.9999889135360718
day O O 0.9999916553497314
course O O 0.9999440908432007
of O O 0.9996752738952637
oral O O 0.9180409908294678
terbinafine B B 0.9934665560722351
250 O O 0.9277506470680237
mg O O 0.9994939565658569
/ O O 0.9993883371353149
day O O 0.9996010661125183
for O O 0.9999297857284546
onychomycosis O O 0.9998388290405273
. O O 0.9999697208404541

On O O 0.9999898672103882
the O O 0.9999984502792358
49th O O 0.9999668598175049
day O O 0.9999864101409912
of O O 0.9994811415672302
terbinafine B B 0.9985670447349548
therapy O O 0.998925507068634
, O O 0.9999903440475464
he O O 0.9999872446060181
was O O 0.9999927282333374
brought O O 0.9999991655349731
to O O 0.9999985694885254
the O O 0.9999990463256836
emergency O O 0.9999972581863403
room O O 0.9999992847442627
for O O 0.999993085861206
a O O 0.9999938011169434
decrease O O 0.9999988079071045
of O O 0.9999922513961792
his O O 0.9999892711639404
global O O 0.9999440908432007
health O O 0.9999666213989258
status O O 0.9999942779541016
, O O 0.9999744892120361
confusion O O 0.9999958276748657
and O O 0.9999691247940063
falls O O 0.9999959468841553
. O O 0.9999829530715942

The O O 0.9999901056289673
electrocardiogram O O 0.9999622106552124
revealed O O 0.9999620914459229
a O O 0.9999651908874512
37 O O 0.9999927282333374
beats O O 0.9999971389770508
/ O O 0.9999866485595703
min O O 0.9999904632568359
sinus O O 0.9999004602432251
bradycardia O O 0.9999200105667114
. O O 0.9999685287475586

A O O 0.9999539852142334
score O O 0.9999817609786987
of O O 0.9999629259109497
7 O O 0.999946117401123
on O O 0.9999861717224121
the O O 0.9999407529830933
Naranjo O O 0.7476895451545715
adverse O O 0.9833443760871887
drug O O 0.9983437061309814
reaction O O 0.9999896287918091
probability O O 0.9998094439506531
scale O O 0.9965619444847107
indicates O O 0.999920129776001
a O O 0.9999768733978271
probable O O 0.9999747276306152
relationship O O 0.9999878406524658
between O O 0.999897837638855
the O O 0.9999927282333374
patient O O 0.9999935626983643
' O O 0.999994158744812
s O O 0.9999834299087524
sinus O O 0.9999806880950928
bradycardia O O 0.9999561309814453
and O O 0.9999197721481323
the O O 0.9999493360519409
drug O O 0.9993805885314941
interaction O O 0.9999028444290161
between O O 0.9973968267440796
metoprolol B B 0.9997461438179016
and O O 0.8681930303573608
terbinafine B B 0.9626471400260925
. O O 0.9999545812606812

The O O 0.9999827146530151
heart O O 0.9999911785125732
rate O O 0.9999877214431763
ameliorated O O 0.9999849796295166
first O O 0.9999979734420776
with O O 0.9999719858169556
a O O 0.9999898672103882
decrease O O 0.9999939203262329
in O O 0.9999867677688599
the O O 0.999962329864502
dose O O 0.9997841715812683
of O O 0.996785044670105
metoprolol B B 0.9997422099113464
. O O 0.9999308586120605

It O O 0.9994730353355408
was O O 0.999945878982544
subsequently O O 0.9999923706054688
changed O O 0.9999009370803833
to O O 0.9966417551040649
bisoprolol B B 0.9980694651603699
and O O 0.9999262094497681
the O O 0.9999942779541016
heart O O 0.9999908208847046
rate O O 0.9999734163284302
remained O O 0.9999805688858032
normal O O 0.9999936819076538
. O O 0.9999786615371704

By O O 0.9994179010391235
inhibiting O O 0.9989941716194153
the O O 0.9978894591331482
cytochrome O O 0.6244823336601257
P450 O O 0.668764054775238
2D6 O O 0.6454631090164185
, O O 0.9988089799880981
terbinafine B B 0.9995498061180115
had O O 0.9999500513076782
decreased O O 0.9999375343322754
metoprolol B B 0.9997634291648865
' O O 0.9999527931213379
s O O 0.9999544620513916
clearance O O 0.999966025352478
, O O 0.999970555305481
leading O O 0.9999831914901733
in O O 0.9999383687973022
metoprolol B B 0.9998002648353577
accumulation O O 0.999908447265625
which O O 0.9999890327453613
has O O 0.9999696016311646
resulted O O 0.999996542930603
in O O 0.9999878406524658
clinically O O 0.9999916553497314
significant O O 0.9999966621398926
sinus O O 0.9999953508377075
bradycardia O O 0.9999966621398926
. O O 0.9999696016311646

Optochiasmatic O O 0.996586799621582
and O O 0.9998363256454468
peripheral O O 0.999788224697113
neuropathy O O 0.9999775886535645
due O O 0.9999725818634033
to O O 0.9996628761291504
ethambutol B B 0.9993621706962585
overtreatment O O 0.9979015588760376
. O O 0.9999563694000244

Ethambutol B B 0.9984021782875061
is O O 0.9995524287223816
known O O 0.9996912479400635
to O O 0.999908447265625
cause O O 0.9997537732124329
optic O O 0.9993889331817627
neuropathy O O 0.9999868869781494
and O O 0.9998795986175537
, O O 0.9999614953994751
more O O 0.9999761581420898
rarely O O 0.9999961853027344
, O O 0.9999579191207886
axonal O O 0.9986984729766846
polyneuropathy O O 0.99993896484375
. O O 0.999900221824646

We O O 0.9999666213989258
characterize O O 0.9999901056289673
the O O 0.999993085861206
clinical O O 0.9999868869781494
, O O 0.9999634027481079
neurophysiological O O 0.9999862909317017
, O O 0.999931812286377
and O O 0.9999599456787109
neuroimaging O O 0.9999934434890747
findings O O 0.9999973773956299
in O O 0.9999831914901733
a O O 0.9999880790710449
72 O O 0.9999982118606567
- O O 0.9999862909317017
year O O 0.9999959468841553
- O O 0.9999929666519165
old O O 0.9999951124191284
man O O 0.9999964237213135
who O O 0.9999511241912842
developed O O 0.9999858140945435
visual O O 0.999995231628418
loss O O 0.9999986886978149
and O O 0.9999760389328003
paresthesias O O 0.9999197721481323
after O O 0.9999504089355469
11 O O 0.9999873638153076
weeks O O 0.9999953508377075
of O O 0.9999523162841797
exposure O O 0.9999873638153076
to O O 0.9995680451393127
a O O 0.9999681711196899
supratherapeutic O O 0.9999037981033325
dose O O 0.9984179735183716
of O O 0.990628182888031
ethambutol B B 0.99868243932724
. O O 0.9999057054519653

This O O 0.9999560117721558
case O O 0.9999345541000366
demonstrates O O 0.9998675584793091
the O O 0.9999381303787231
selective O O 0.9993576407432556
vulnerability O O 0.9999510049819946
of O O 0.9998592138290405
the O O 0.9999117851257324
anterior O O 0.9995498061180115
visual O O 0.999433696269989
pathways O O 0.9999854564666748
and O O 0.9997748732566833
peripheral O O 0.9998787641525269
nerves O O 0.9999924898147583
to O O 0.9995806813240051
ethambutol B B 0.9994608759880066
toxicity O O 0.9984482526779175
. O O 0.9999576807022095

Testosterone B B 0.9979149699211121
ameliorates O O 0.9955803751945496
streptozotocin B B 0.9980887770652771
- O O 0.999762237071991
induced O O 0.9999109506607056
memory O O 0.9999924898147583
impairment O O 0.9999970197677612
in O O 0.999962568283081
male O O 0.9999321699142456
rats O O 0.9999833106994629
. O O 0.9980906844139099

AIM O O 0.9999731779098511
: O O 0.9999942779541016
To O O 0.9999921321868896
study O O 0.9999575614929199
the O O 0.9999551773071289
effects O O 0.9998712539672852
of O O 0.999237060546875
testosterone B B 0.9991679191589355
on O O 0.9990010857582092
streptozotocin B B 0.9985976815223694
( O O 0.9964810609817505
STZ B B 0.9992656111717224
) O O 0.9923020601272583
- O O 0.9997575879096985
induced O O 0.9998999834060669
memory O O 0.9999905824661255
impairment O O 0.9999953508377075
in O O 0.9999778270721436
male O O 0.9999681711196899
rats O O 0.9999943971633911
. O O 0.999977707862854

METHODS O O 0.9997262358665466
: O O 0.9999896287918091
Adult O O 0.9999951124191284
male O O 0.9999909400939941
Wistar O O 0.9995799660682678
rats O O 0.9999921321868896
were O O 0.9999719858169556
intracerebroventricularly O O 0.9999630451202393
( O O 0.9994115829467773
icv O O 0.9864283204078674
) O O 0.9999395608901978
infused O O 0.9998958110809326
with O O 0.9995201826095581
STZ B B 0.9939365983009338
( O O 0.9991124272346497
750 O O 0.9997466206550598
ug O O 0.9557873010635376
) O O 0.9999123811721802
on O O 0.9998244643211365
d O O 0.9975245594978333
1 O O 0.999987006187439
and O O 0.9999598264694214
d O O 0.999225378036499
3 O O 0.9999798536300659
, O O 0.9999481439590454
and O O 0.9999685287475586
a O O 0.99997878074646
passive O O 0.9999220371246338
avoidance O O 0.9999679327011108
task O O 0.9999567270278931
was O O 0.9999809265136719
assessed O O 0.9999948740005493
2 O O 0.9999809265136719
weeks O O 0.9999991655349731
after O O 0.9999909400939941
the O O 0.9999967813491821
first O O 0.9999954700469971
injection O O 0.9999817609786987
of O O 0.9998630285263062
STZ B B 0.9931419491767883
. O O 0.9998832941055298

Castration O O 0.9920564293861389
surgery O O 0.9999698400497437
was O O 0.9999876022338867
performed O O 0.9999847412109375
in O O 0.9999822378158569
another O O 0.9999885559082031
group O O 0.9999879598617554
of O O 0.9999669790267944
rats O O 0.9997784495353699
, O O 0.9999537467956543
and O O 0.9999852180480957
the O O 0.9999697208404541
passive O O 0.9989374279975891
avoidance O O 0.9996132254600525
task O O 0.9999467134475708
was O O 0.9999855756759644
assessed O O 0.9999909400939941
4 O O 0.9999172687530518
weeks O O 0.9999984502792358
after O O 0.9999961853027344
the O O 0.9999963045120239
operation O O 0.9999923706054688
. O O 0.9999793767929077

Testosterone B B 0.9931803941726685
( O O 0.9988452196121216
1 O O 0.9992018342018127
mg O O 0.999782383441925
. O O 0.9999855756759644
kg O O 0.9999849796295166
( O O 0.9939913153648376
- O O 0.9957883954048157
1 O O 0.9989853501319885
) O O 0.9999088048934937
. O O 0.9999845027923584
d O O 0.9999229907989502
( O O 0.9997559189796448
- O O 0.9997120499610901
1 O O 0.9999827146530151
) O O 0.9999920129776001
, O O 0.9996150732040405
sc O O 0.8151460289955139
) O O 0.9977558255195618
, O O 0.9997695088386536
the O O 0.9997192025184631
androgen B O 0.7429113984107971
receptor O O 0.9854528307914734
antagonist O O 0.9706816077232361
flutamide B B 0.9996165037155151
( O O 0.9987996816635132
10 O O 0.9982901215553284
mg O O 0.9999529123306274
. O O 0.9999924898147583
kg O O 0.9999955892562866
( O O 0.9977791905403137
- O O 0.996410071849823
1 O O 0.9993126392364502
) O O 0.9999322891235352
. O O 0.9999879598617554
d O O 0.9999228715896606
( O O 0.9996498823165894
- O O 0.9994636178016663
1 O O 0.9999901056289673
) O O 0.9999920129776001
, O O 0.9995019435882568
ip O O 0.9923587441444397
) O O 0.9999793767929077
, O O 0.9998617172241211
the O O 0.9992820620536804
estrogen B O 0.7085207104682922
receptor O O 0.8992178440093994
antagonist O O 0.8688024878501892
tamoxifen B B 0.9998010993003845
( O O 0.9990524649620056
1 O O 0.9999023675918579
mg O O 0.9999706745147705
. O O 0.999991774559021
kg O O 0.9999934434890747
( O O 0.9977754950523376
- O O 0.9969730377197266
1 O O 0.9993816614151001
) O O 0.9999332427978516
. O O 0.9999923706054688
d O O 0.9999831914901733
( O O 0.9998441934585571
- O O 0.9998233914375305
1 O O 0.9999740123748779
) O O 0.9999953508377075
, O O 0.9999129772186279
ip O O 0.9944341778755188
) O O 0.9999555349349976
or O O 0.9997312426567078
the O O 0.9984378218650818
aromatase O O 0.6363747715950012
inhibitor O O 0.8302013874053955
letrozole B B 0.9962220191955566
( O O 0.9996517896652222
4 O O 0.9994096755981445
mg O O 0.9999622106552124
. O O 0.9999923706054688
kg O O 0.9999904632568359
( O O 0.9966880679130554
- O O 0.9966815114021301
1 O O 0.9995734095573425
) O O 0.9999449253082275
. O O 0.9999916553497314
d O O 0.9999849796295166
( O O 0.9998723268508911
- O O 0.9998533725738525
1 O O 0.9999932050704956
) O O 0.9999955892562866
, O O 0.9999616146087646
ip O O 0.9955214262008667
) O O 0.9999867677688599
were O O 0.9999772310256958
administered O O 0.9999614953994751
for O O 0.9999877214431763
6 O O 0.9999809265136719
d O O 0.9999933242797852
after O O 0.9999884366989136
the O O 0.9999959468841553
first O O 0.9999940395355225
injection O O 0.999976634979248
of O O 0.9997050166130066
STZ B B 0.9947127103805542
. O O 0.9983012080192566

RESULTS O O 0.9996386766433716
: O O 0.9995461106300354
STZ B B 0.9965921640396118
administration O O 0.990138053894043
and O O 0.9993220567703247
castration O O 0.6037481427192688
markedly O O 0.9997890591621399
decreased O O 0.999936580657959
both O O 0.9998517036437988
STL1 O O 0.9077044725418091
( O O 0.9998753070831299
the O O 0.9999699592590332
short O O 0.9991725087165833
memory O O 0.9999916553497314
) O O 0.9999113082885742
and O O 0.9998955726623535
STL2 O O 0.771631121635437
( O O 0.9998238682746887
the O O 0.9999521970748901
long O O 0.9985051155090332
memory O O 0.9999854564666748
) O O 0.9999607801437378
in O O 0.9999188184738159
passive O O 0.9968587160110474
avoidance O O 0.9999265670776367
tests O O 0.9999719858169556
. O O 0.999962329864502

Testosterone B B 0.9955423474311829
replacement O O 0.9983776807785034
almost O O 0.9996820688247681
restored O O 0.9998376369476318
the O O 0.9999517202377319
STL1 O O 0.9084624648094177
and O O 0.9998093247413635
STL2 O O 0.8316539525985718
in O O 0.9998974800109863
castrated O O 0.9999724626541138
rats O O 0.9999923706054688
, O O 0.9999440908432007
and O O 0.9998522996902466
significantly O O 0.9999593496322632
prolonged O O 0.9999029636383057
the O O 0.9999463558197021
STL1 O O 0.9298771619796753
and O O 0.9998836517333984
STL2 O O 0.8740437030792236
in O O 0.9998804330825806
STZ B B 0.9909231066703796
- O O 0.9964738488197327
treated O O 0.9997938275337219
rats O O 0.9999910593032837
. O O 0.9999710321426392

Administration O O 0.9998844861984253
of O O 0.9995889067649841
flutamide B B 0.9995158910751343
, O O 0.9713767766952515
letrozole B B 0.9991047978401184
or O O 0.9954833984375
tamoxifen B B 0.9990968704223633
significantly O O 0.9999370574951172
impaired O O 0.9999655485153198
the O O 0.9999656677246094
memory O O 0.9999881982803345
in O O 0.9998630285263062
intact O O 0.9994171857833862
rats O O 0.9999715089797974
, O O 0.9999557733535767
and O O 0.9999371767044067
significantly O O 0.9999120235443115
attenuated O O 0.9924963712692261
the O O 0.9994333386421204
testosterone B B 0.9964640736579895
replacement O O 0.958819568157196
in O O 0.9999302625656128
improving O O 0.9980408549308777
STZ B B 0.9617342948913574
- O O 0.9978085160255432
and O O 0.9994897842407227
castration O O 0.9794730544090271
- O O 0.9997666478157043
induced O O 0.9999362230300903
memory O O 0.9999781847000122
impairment O O 0.9999954700469971
. O O 0.9999687671661377

CONCLUSION O O 0.9892717599868774
: O O 0.9989840388298035
Testosterone B B 0.9991554021835327
administration O O 0.9998014569282532
ameliorates O O 0.9998685121536255
STZ B B 0.9278424978256226
- O O 0.9973838925361633
and O O 0.9992584586143494
castration O O 0.9939828515052795
- O O 0.9998107552528381
induced O O 0.9999419450759888
memory O O 0.9999939203262329
impairment O O 0.9999977350234985
in O O 0.9999822378158569
male O O 0.9999604225158691
Wistar O O 0.9995689988136292
rats O O 0.9999929666519165
. O O 0.9999651908874512

Behavioral O O 0.9999645948410034
and O O 0.9999371767044067
neurochemical O O 0.9999849796295166
studies O O 0.9999897480010986
in O O 0.999966025352478
mice O O 0.9999903440475464
pretreated O O 0.9999443292617798
with O O 0.999229907989502
garcinielliptone B B 0.998222291469574
FC I I 0.9474560022354126
in O O 0.9990177154541016
pilocarpine B B 0.9998102784156799
- O O 0.9998457431793213
induced O O 0.9999496936798096
seizures O O 0.9999825954437256
. O O 0.9999784231185913

Garcinielliptone B B 0.8316963911056519
FC I I 0.9744283556938171
( O O 0.8209843635559082
GFC B O 0.8304762244224548
) O O 0.9469873309135437
isolated O O 0.9969571828842163
from O O 0.9986181259155273
hexanic O B 0.6375141143798828
fraction O I 0.9835494756698608
seed O I 0.9553171992301941
extract O I 0.9963997602462769
of O O 0.7738462090492249
species O O 0.5665162205696106
Platonia O O 0.5289965867996216
insignis O O 0.979790449142456
Mart O O 0.9941551089286804
. O O 0.9991599321365356

It O B 0.9640716314315796
is O O 0.9503939151763916
widely O O 0.9995114803314209
used O O 0.999356210231781
in O O 0.9997079968452454
folk O O 0.9634265303611755
medicine O O 0.999795138835907
to O O 0.9995823502540588
treat O O 0.9994021654129028
skin O O 0.9998482465744019
diseases O O 0.9999895095825195
in O O 0.9999382495880127
both O O 0.9999046325683594
humans O O 0.999992847442627
and O O 0.999914288520813
animals O O 0.9999829530715942
as O O 0.9999538660049438
well O O 0.9997815489768982
as O O 0.9994969367980957
the O O 0.9765213131904602
seed O O 0.9374315142631531
decoction O O 0.6957529783248901
has O O 0.9998279809951782
been O O 0.9999492168426514
used O O 0.999239444732666
to O O 0.9997664093971252
treat O O 0.9978640675544739
diarrheas O O 0.9987855553627014
and O O 0.9998965263366699
inflammatory O O 0.9999661445617676
diseases O O 0.9999935626983643
. O O 0.9998666048049927

However O O 0.9999469518661499
, O O 0.9999788999557495
there O O 0.9999798536300659
is O O 0.9999791383743286
no O O 0.9999765157699585
research O O 0.9999896287918091
on O O 0.9996216297149658
GFC B B 0.9871726036071777
effects O O 0.9995482563972473
in O O 0.9997671246528625
the O O 0.9999178647994995
central O O 0.9998531341552734
nervous O O 0.9999827146530151
system O O 0.9999871253967285
of O O 0.9999710321426392
rodents O O 0.9999594688415527
. O O 0.9999357461929321

The O O 0.9999923706054688
present O O 0.9999923706054688
study O O 0.9999889135360718
aimed O O 0.9999921321868896
to O O 0.9999939203262329
evaluate O O 0.9999793767929077
the O O 0.999536395072937
GFC B B 0.9882910847663879
effects O O 0.9994010925292969
at O O 0.999797523021698
doses O O 0.9999756813049316
of O O 0.9999533891677856
25 O O 0.9998103976249695
, O O 0.9995266199111938
50 O O 0.999872088432312
or O O 0.9996789693832397
75 O O 0.9997702240943909
mg O O 0.9999498128890991
/ O O 0.9999909400939941
kg O O 0.9999935626983643
on O O 0.9997718930244446
seizure O O 0.9998863935470581
parameters O O 0.9999799728393555
to O O 0.9999899864196777
determine O O 0.9999761581420898
their O O 0.9926689863204956
anticonvulsant O O 0.7186458706855774
activity O O 0.9995887875556946
and O O 0.9999586343765259
its O O 0.9997629523277283
effects O O 0.9999537467956543
on O O 0.9998238682746887
amino B B 0.7013447880744934
acid I I 0.9995433688163757
( O O 0.8756259083747864
r B B 0.7529041171073914
- I I 0.9791096448898315
aminobutyric I I 0.9995459914207458
acid I I 0.9999369382858276
( O O 0.9623850584030151
GABA B B 0.9967376589775085
) O O 0.8719480037689209
, O O 0.9929336309432983
glutamine B B 0.9947867393493652
, O O 0.9289078116416931
aspartate B B 0.9870033860206604
and O O 0.9825350046157837
glutathione B B 0.9933072924613953
) O O 0.9996821880340576
levels O O 0.9999198913574219
as O O 0.9999758005142212
well O O 0.9999772310256958
as O O 0.9999793767929077
on O O 0.9997789263725281
acetylcholinesterase O B 0.9321728944778442
( O O 0.9712966084480286
AChE O O 0.520893931388855
) O O 0.9974427223205566
activity O O 0.9992604851722717
in O O 0.9998658895492554
mice O O 0.7734444737434387
hippocampus O O 0.9983602166175842
after O O 0.9998849630355835
seizures O O 0.9999696016311646
. O O 0.9999735355377197

GFC B B 0.9850024580955505
produced O O 0.9997245669364929
an O O 0.9999723434448242
increased O O 0.9999842643737793
latency O O 0.999997615814209
to O O 0.9999970197677612
first O O 0.9999985694885254
seizure O O 0.9999946355819702
, O O 0.999991774559021
at O O 0.9999115467071533
doses O O 0.99991774559021
25mg O O 0.9998910427093506
/ O O 0.9999758005142212
kg O O 0.9999935626983643
( O O 0.9999597072601318
20 O O 0.9999188184738159
. O O 0.9999958276748657
12 O O 0.999997615814209
+ O O 0.9999419450759888
2 O O 0.9997909665107727
. O O 0.9999958276748657
20 O O 0.9999953508377075
min O O 0.9999957084655762
) O O 0.999968409538269
, O O 0.9998383522033691
50mg O O 0.999936580657959
/ O O 0.9999638795852661
kg O O 0.9999901056289673
( O O 0.9999682903289795
20 O O 0.9999791383743286
. O O 0.9999949932098389
95 O O 0.9998476505279541
+ O O 0.9999549388885498
2 O O 0.9998573064804077
. O O 0.9999964237213135
21 O O 0.9999973773956299
min O O 0.9999959468841553
) O O 0.9999743700027466
or O O 0.9999070167541504
75 O O 0.9998911619186401
mg O O 0.9999700784683228
/ O O 0.9999895095825195
kg O O 0.9999861717224121
( O O 0.9999651908874512
23 O O 0.9999836683273315
. O O 0.9999971389770508
43 O O 0.9999886751174927
+ O O 0.9999606609344482
1 O O 0.9999966621398926
. O O 0.9999934434890747
99 O O 0.9999680519104004
min O O 0.9999940395355225
) O O 0.9999709129333496
when O O 0.9999901056289673
compared O O 0.9999902248382568
with O O 0.9999686479568481
seized O O 0.9327241778373718
mice O O 0.9999812841415405
. O O 0.9999603033065796

In O O 0.9999499320983887
addition O O 0.9999619722366333
, O O 0.9998818635940552
GABA B B 0.9843305945396423
content O O 0.9997081160545349
of O O 0.9998828172683716
mice O O 0.9998483657836914
hippocampus O O 0.9939711093902588
treated O O 0.99977046251297
with O O 0.9996193647384644
GFC75 O B 0.9869303703308105
plus O O 0.9275434017181396
P400 O B 0.9254787564277649
showed O O 0.9998108744621277
an O O 0.9999836683273315
increase O O 0.9999843835830688
of O O 0.9999476671218872
46 O O 0.9999871253967285
. O O 0.9999872446060181
90 O O 0.9999750852584839
% O O 0.999987006187439
when O O 0.9999924898147583
compared O O 0.999993085861206
with O O 0.9999891519546509
seized O O 0.9910178184509277
mice O O 0.9999910593032837
. O O 0.999961256980896

In O O 0.9995891451835632
aspartate B B 0.9934000968933105
, O O 0.9886414408683777
glutamine B B 0.9942928552627563
and O O 0.9959795475006104
glutamate B B 0.9920640587806702
levels O O 0.9997350573539734
detected O O 0.999942421913147
a O O 0.9999769926071167
decrease O O 0.9999908208847046
of O O 0.999931812286377
5 O O 0.9999353885650635
. O O 0.999982476234436
21 O O 0.9999972581863403
% O O 0.9999798536300659
, O O 0.9999232292175293
13 O O 0.9999868869781494
. O O 0.9999852180480957
55 O O 0.9999792575836182
% O O 0.9999871253967285
and O O 0.9999009370803833
21 O O 0.9999597072601318
. O O 0.9999830722808838
80 O O 0.9999829530715942
% O O 0.9999723434448242
, O O 0.9999861717224121
respectively O O 0.9999699592590332
in O O 0.9999101161956787
mice O O 0.999656081199646
hippocampus O O 0.9971866011619568
treated O O 0.9997602105140686
with O O 0.9994658827781677
GFC75 O B 0.9941813349723816
plus O O 0.9340384602546692
P400 O B 0.9711474776268005
when O O 0.9999040365219116
compared O O 0.9999827146530151
with O O 0.9999817609786987
seized O O 0.9835441708564758
mice O O 0.9999860525131226
. O O 0.9999374151229858

Hippocampus O O 0.9878031611442566
mice O O 0.9999511241912842
treated O O 0.9996894598007202
with O O 0.999548614025116
GFC75 O B 0.9923117756843567
plus O O 0.896466851234436
P400 O B 0.9633924961090088
showed O O 0.9997542500495911
an O O 0.9999682903289795
increase O O 0.9999756813049316
in O O 0.9999604225158691
AChE O O 0.8375369310379028
activity O O 0.9998410940170288
( O O 0.999968409538269
63 O O 0.9999926090240479
. O O 0.9999808073043823
30 O O 0.9999969005584717
% O O 0.999983549118042
) O O 0.9999600648880005
when O O 0.9999867677688599
compared O O 0.9999876022338867
with O O 0.9999839067459106
seized O O 0.7363088726997375
mice O O 0.9999837875366211
. O O 0.9999639987945557

The O O 0.9999747276306152
results O O 0.9999866485595703
indicate O O 0.9999449253082275
that O O 0.9994412064552307
GFC B B 0.997556209564209
can O O 0.9995827078819275
exert O O 0.9998719692230225
anticonvulsant O O 0.7943146824836731
activity O O 0.9996004700660706
and O O 0.9999173879623413
reduce O O 0.9999256134033203
the O O 0.9999736547470093
frequency O O 0.9999908208847046
of O O 0.9999790191650391
installation O O 0.9999293088912964
of O O 0.9999183416366577
pilocarpine B B 0.9998499155044556
- O O 0.9997983574867249
induced O O 0.9999383687973022
status O O 0.9999940395355225
epilepticus O O 0.9998984336853027
, O O 0.9999841451644897
as O O 0.9999949932098389
demonstrated O O 0.999996542930603
by O O 0.9999938011169434
increase O O 0.9999936819076538
in O O 0.9999878406524658
latency O O 0.9999974966049194
to O O 0.999995231628418
first O O 0.9999972581863403
seizure O O 0.9999904632568359
and O O 0.9999852180480957
decrease O O 0.9999898672103882
in O O 0.9999841451644897
mortality O O 0.9999756813049316
rate O O 0.9999927282333374
of O O 0.9998780488967896
animals O O 0.9994600415229797
. O O 0.9999690055847168

In O O 0.999948263168335
conclusion O O 0.9999850988388062
, O O 0.9999650716781616
our O O 0.999971866607666
data O O 0.999991774559021
suggest O O 0.9999562501907349
that O O 0.9993501305580139
GFC B B 0.9941210150718689
may O O 0.9994940757751465
influence O O 0.9982258677482605
in O O 0.9992610812187195
epileptogenesis O O 0.999638557434082
and O O 0.9998430013656616
promote O O 0.9962949156761169
anticonvulsant O O 0.7009172439575195
actions O O 0.9997838139533997
in O O 0.9993239641189575
pilocarpine B B 0.9995691180229187
model O O 0.9994003772735596
by O O 0.9999246597290039
modulating O O 0.9994865655899048
the O O 0.9998418092727661
GABA B B 0.9785390496253967
and O O 0.9852622151374817
glutamate B B 0.9907139539718628
contents O O 0.9991855025291443
and O O 0.9999085664749146
of O O 0.9623203277587891
AChE O O 0.652048647403717
activity O O 0.9987019300460815
in O O 0.9995914101600647
seized O B 0.9345269203186035
mice O O 0.5345403552055359
hippocampus O O 0.9988735318183899
. O O 0.999944806098938

This O O 0.9863889813423157
compound O O 0.8811336159706116
may O O 0.9999024868011475
be O O 0.9999196529388428
useful O O 0.9998490810394287
to O O 0.9994065761566162
produce O O 0.9998225569725037
neuronal O O 0.9999651908874512
protection O O 0.999921441078186
and O O 0.9999611377716064
it O O 0.9968608617782593
can O O 0.999927282333374
be O O 0.9999843835830688
considered O O 0.9999556541442871
as O O 0.9999167919158936
an O O 0.9985390901565552
anticonvulsant O O 0.6849886775016785
agent O O 0.987572193145752
. O O 0.9994925260543823

Standard O O 0.999954342842102
operating O O 0.9999926090240479
procedures O O 0.9999973773956299
for O O 0.9998818635940552
antibiotic O O 0.7409477233886719
therapy O O 0.9997758269309998
and O O 0.9999740123748779
the O O 0.9999942779541016
occurrence O O 0.9999969005584717
of O O 0.9999920129776001
acute O O 0.9999122619628906
kidney O O 0.9998568296432495
injury O O 0.9999927282333374
: O O 0.9999902248382568
a O O 0.9999942779541016
prospective O O 0.9999961853027344
, O O 0.9999936819076538
clinical O O 0.9999959468841553
, O O 0.9999929666519165
non O O 0.9998950958251953
- O O 0.9999067783355713
interventional O O 0.9999947547912598
, O O 0.9999833106994629
observational O O 0.9999961853027344
study O O 0.9999953508377075
. O O 0.9999861717224121

INTRODUCTION O O 0.9976478219032288
: O O 0.9999120235443115
Acute O O 0.9998241066932678
kidney O O 0.9996129870414734
injury O O 0.999984860420227
( O O 0.9998377561569214
AKI O O 0.7548606991767883
) O O 0.9999402761459351
occurs O O 0.999984622001648
in O O 0.9999874830245972
7 O O 0.9999840259552002
% O O 0.9999969005584717
of O O 0.9999855756759644
hospitalized O O 0.9999610185623169
and O O 0.9999157190322876
66 O O 0.9999845027923584
% O O 0.9999933242797852
of O O 0.9999669790267944
Intensive O O 0.9999653100967407
Care O O 0.9999864101409912
Unit O O 0.9999891519546509
( O O 0.9998655319213867
ICU O O 0.9994434714317322
) O O 0.9999583959579468
patients O O 0.9999940395355225
. O O 0.9999675750732422

It O O 0.9996570348739624
increases O O 0.999711811542511
mortality O O 0.9999947547912598
, O O 0.9999805688858032
hospital O O 0.9999547004699707
length O O 0.9999901056289673
of O O 0.9999839067459106
stay O O 0.9999909400939941
, O O 0.9999617338180542
and O O 0.9999750852584839
costs O O 0.9999839067459106
. O O 0.9999516010284424

The O O 0.9999926090240479
aim O O 0.9999971389770508
of O O 0.9999940395355225
this O O 0.9999909400939941
study O O 0.9999933242797852
was O O 0.9999949932098389
to O O 0.9999957084655762
investigate O O 0.9999922513961792
, O O 0.9999939203262329
whether O O 0.9999948740005493
there O O 0.9999804496765137
is O O 0.9999843835830688
an O O 0.9999902248382568
association O O 0.999994158744812
between O O 0.9998968839645386
adherence O O 0.9999666213989258
to O O 0.999724805355072
guidelines O O 0.9999545812606812
( O O 0.9995274543762207
standard O O 0.999915599822998
operating O O 0.9999932050704956
procedures O O 0.9999967813491821
( O O 0.9998719692230225
SOP O O 0.9602210521697998
) O O 0.9998164772987366
) O O 0.9999644756317139
for O O 0.9993646740913391
potentially O O 0.9993972778320312
nephrotoxic O O 0.984478235244751
antibiotics O O 0.9178297519683838
and O O 0.9999507665634155
the O O 0.9999932050704956
occurrence O O 0.999995231628418
of O O 0.9999819993972778
AKI O O 0.9997982382774353
. O O 0.9999608993530273

METHODS O O 0.9999710321426392
: O O 0.9999940395355225
This O O 0.9999942779541016
study O O 0.9999914169311523
was O O 0.999992847442627
carried O O 0.9999955892562866
out O O 0.9999961853027344
as O O 0.9999914169311523
a O O 0.9999926090240479
prospective O O 0.9999951124191284
, O O 0.9999903440475464
clinical O O 0.999994158744812
, O O 0.9999909400939941
non O O 0.9998525381088257
- O O 0.9999014139175415
interventional O O 0.9999946355819702
, O O 0.9999823570251465
observational O O 0.9999943971633911
study O O 0.9999939203262329
. O O 0.9999738931655884

Data O O 0.9996993541717529
collection O O 0.9999879598617554
was O O 0.9999808073043823
performed O O 0.9999884366989136
over O O 0.9999790191650391
a O O 0.9999935626983643
total O O 0.9999891519546509
of O O 0.9999911785125732
170 O O 0.9999945163726807
days O O 0.9999939203262329
in O O 0.9999488592147827
three O O 0.9946565628051758
ICUs O O 0.95531165599823
at O O 0.9991160035133362
Charite O O 0.9860036969184875
- O O 0.9991794228553772
Universitaetsmedizin O O 0.9970628619194031
Berlin O O 0.9993035793304443
. O O 0.9999558925628662

A O O 0.9999806880950928
total O O 0.9999935626983643
of O O 0.9999885559082031
675 O O 0.9999916553497314
patients O O 0.9999964237213135
were O O 0.9999897480010986
included O O 0.9999963045120239
; O O 0.9999829530715942
163 O O 0.9998722076416016
of O O 0.9999799728393555
these O O 0.9999886751174927
had O O 0.9999363422393799
therapy O O 0.9999737739562988
with O O 0.9998313188552856
vancomycin B B 0.9994254112243652
, O O 0.5588690638542175
gentamicin B B 0.9973946809768677
, O O 0.8658888339996338
or O O 0.9902158975601196
tobramycin B B 0.9977017045021057
; O O 0.997989296913147
were O O 0.9999902248382568
> O O 0.999924898147583
18 O O 0.9997753500938416
years O O 0.9999573230743408
; O O 0.9999915361404419
and O O 0.9999765157699585
treated O O 0.9999783039093018
in O O 0.9997900128364563
the O O 0.9998726844787598
ICU O O 0.9854609370231628
for O O 0.9999490976333618
> O O 0.9998985528945923
24 O O 0.9999804496765137
hours O O 0.9999845027923584
. O O 0.9999788999557495

Patients O O 0.9999570846557617
with O O 0.9999774694442749
an O O 0.9999226331710815
adherence O O 0.9978748559951782
to O O 0.998358428478241
SOP O B 0.965821385383606
> O O 0.993347704410553
70 O O 0.9999719858169556
% O O 0.9999383687973022
were O O 0.9999669790267944
classified O O 0.9999905824661255
into O O 0.9998948574066162
the O O 0.9999401569366455
high O O 0.9922451376914978
adherence O O 0.9884070754051208
group O O 0.9997958540916443
( O O 0.9984428286552429
HAG O O 0.6515030264854431
) O O 0.9997649788856506
and O O 0.999923825263977
patients O O 0.9999855756759644
with O O 0.9999886751174927
an O O 0.9999467134475708
adherence O O 0.9967315196990967
of O O 0.9999555349349976
< O O 0.999988317489624
70 O O 0.9999947547912598
% O O 0.9999881982803345
into O O 0.9999011754989624
the O O 0.9999638795852661
low O O 0.9998676776885986
adherence O O 0.9900540113449097
group O O 0.9998241066932678
( O O 0.9980323910713196
LAG O O 0.7912610769271851
) O O 0.9999421834945679
. O O 0.9999707937240601

AKI O O 0.8950691819190979
was O O 0.9999380111694336
defined O O 0.999972939491272
according O O 0.9999886751174927
to O O 0.9999513626098633
RIFLE O O 0.8603821992874146
criteria O O 0.9999736547470093
. O O 0.9999634027481079

Adherence O O 0.9941989183425903
to O O 0.9993811845779419
SOPs O B 0.919234037399292
was O O 0.9998223185539246
evaluated O O 0.9999855756759644
by O O 0.9999865293502808
retrospective O O 0.9999465942382812
expert O O 0.9999862909317017
audit O O 0.9999630451202393
. O O 0.9999746084213257

Development O O 0.9999687671661377
of O O 0.9999711513519287
AKI O O 0.9739606380462646
was O O 0.9999693632125854
compared O O 0.9999794960021973
between O O 0.9995394945144653
groups O O 0.9999741315841675
with O O 0.999981164932251
exact O O 0.9991644620895386
Chi2 O O 0.9849123954772949
- O O 0.9992227554321289
test O O 0.9999014139175415
and O O 0.9999706745147705
multivariate O O 0.998754620552063
logistic O O 0.99974125623703
regression O O 0.9998194575309753
analysis O O 0.9999468326568604
( O O 0.9999598264694214
two O O 0.999980092048645
- O O 0.9999701976776123
sided O O 0.9999922513961792
P O O 0.9989677667617798
< O O 0.9999417066574097
0 O O 0.999991774559021
. O O 0.9999963045120239
05 O O 0.9999901056289673
) O O 0.9999713897705078
. O O 0.9999780654907227

RESULTS O O 0.9998911619186401
: O O 0.9996046423912048
LAG O O 0.5101532936096191
consisted O O 0.9998437166213989
of O O 0.9998985528945923
75 O O 0.999233603477478
patients O O 0.9999868869781494
( O O 0.9999222755432129
46 O O 0.9999886751174927
% O O 0.9999877214431763
) O O 0.9998886585235596
versus O O 0.9998486042022705
88 O O 0.9459662437438965
HAG O O 0.8116756081581116
patients O O 0.9999086856842041
( O O 0.9999468326568604
54 O O 0.9999867677688599
% O O 0.9999933242797852
) O O 0.9999454021453857
. O O 0.9999659061431885

AKI O O 0.6414434313774109
occurred O O 0.999842643737793
significantly O O 0.9999821186065674
more O O 0.9999802112579346
often O O 0.9999778270721436
in O O 0.9984042048454285
LAG O O 0.6582699418067932
with O O 0.999861478805542
36 O O 0.9999295473098755
% O O 0.9999790191650391
versus O O 0.999947190284729
21 O O 0.9999781847000122
% O O 0.9999896287918091
in O O 0.9976657629013062
HAG O B 0.9577187895774841
( O O 0.9998127818107605
P O O 0.9999769926071167
= O O 0.9999804496765137
0 O O 0.9999942779541016
. O O 0.9999978542327881
035 O O 0.9997405409812927
) O O 0.9999668598175049
. O O 0.9999599456787109

Basic O O 0.9935646653175354
characteristics O O 0.9999911785125732
were O O 0.999945878982544
comparable O O 0.99996018409729
, O O 0.9999668598175049
except O O 0.9999755620956421
an O O 0.9999728202819824
increased O O 0.9999703168869019
rate O O 0.999984860420227
of O O 0.9999485015869141
soft O O 0.9997416138648987
tissue O O 0.999982476234436
infections O O 0.9999336004257202
in O O 0.9924374222755432
LAG O B 0.8841299414634705
. O O 0.9988344311714172

Multivariate O O 0.9979773163795471
analysis O O 0.9998906850814819
revealed O O 0.9999545812606812
an O O 0.9999731779098511
odds O O 0.9999281167984009
ratio O O 0.9999920129776001
of O O 0.9999363422393799
2 O O 0.9999586343765259
. O O 0.9999909400939941
5 O O 0.9999682903289795
- O O 0.9999570846557617
fold O O 0.9999964237213135
for O O 0.999893069267273
LAG O O 0.736548900604248
to O O 0.9999691247940063
develop O O 0.9999886751174927
AKI O O 0.9979094862937927
compared O O 0.9999545812606812
with O O 0.9990041851997375
HAG O B 0.921713650226593
( O O 0.999735414981842
95 O O 0.9999903440475464
% O O 0.9999884366989136
confidence O O 0.9999951124191284
interval O O 0.9999967813491821
1 O O 0.999994158744812
. O O 0.999992847442627
195 O O 0.99998939037323
to O O 0.9998719692230225
5 O O 0.9999765157699585
. O O 0.9999980926513672
124 O O 0.9999885559082031
, O O 0.9999755620956421
P O O 0.9996905326843262
= O O 0.9999305009841919
0 O O 0.9999904632568359
. O O 0.9999974966049194
039 O O 0.9999916553497314
) O O 0.9999773502349854
. O O 0.9999793767929077

CONCLUSION O O 0.9996054768562317
: O O 0.9999386072158813
Low O O 0.9999806880950928
adherence O O 0.999940037727356
to O O 0.999052107334137
SOPs O O 0.7693148255348206
for O O 0.9363340139389038
potentially O O 0.998894989490509
nephrotoxic O O 0.901199460029602
antibiotics O O 0.8304545879364014
was O O 0.9999185800552368
associated O O 0.9999762773513794
with O O 0.9999887943267822
a O O 0.9999853372573853
higher O O 0.9999794960021973
occurrence O O 0.9999927282333374
of O O 0.999970555305481
AKI O O 0.9912359714508057
. O O 0.9999325275421143

TRIAL O O 0.9996671676635742
REGISTRATION O O 0.9997016787528992
: O O 0.9999159574508667
Current O O 0.9998823404312134
Controlled O O 0.9999349117279053
Trials O O 0.9995597004890442
ISRCTN54598675 O B 0.9605920314788818
. O O 0.999895453453064

Registered O O 0.9924517273902893
17 O O 0.9851561784744263
August O O 0.9874821901321411
2007 O O 0.875468909740448
. O O 0.9993902444839478

Rhabdomyolysis O O 0.9996896982192993
in O O 0.9999580383300781
a O O 0.9999731779098511
hepatitis O O 0.8285558819770813
C O O 0.4830940365791321
virus O O 0.857672929763794
infected O O 0.9966985583305359
patient O O 0.9999815225601196
treated O O 0.9998716115951538
with O O 0.9988493919372559
telaprevir B B 0.9969491362571716
and O O 0.9300137758255005
simvastatin B B 0.9965224266052246
. O O 0.9998915195465088

A O O 0.9999773502349854
46 O O 0.999996542930603
- O O 0.9999845027923584
year O O 0.9999973773956299
old O O 0.999994158744812
man O O 0.9999958276748657
with O O 0.9999704360961914
a O O 0.9999889135360718
chronic O O 0.9994977712631226
hepatitis O O 0.9894788861274719
C O O 0.9517578482627869
virus O O 0.9725003242492676
infection O O 0.9999698400497437
received O O 0.9998846054077148
triple O O 0.9891453981399536
therapy O O 0.9998155236244202
with O O 0.9997336268424988
ribavirin B B 0.998301088809967
, O O 0.6800278425216675
pegylated B B 0.9748327136039734
interferon I I 0.9817306995391846
and O O 0.5514625310897827
telaprevir B B 0.823134183883667
. O O 0.9999423027038574

The O O 0.99997878074646
patient O O 0.9999879598617554
also O O 0.9998196959495544
received O O 0.9993701577186584
simvastatin B B 0.9986428618431091
. O O 0.9998503923416138

One O O 0.9999884366989136
month O O 0.9999992847442627
after O O 0.9999979734420776
starting O O 0.9999525547027588
the O O 0.9999494552612305
antiviral O O 0.5598016977310181
therapy O O 0.9278509616851807
, O O 0.9999910593032837
the O O 0.9999963045120239
patient O O 0.9999920129776001
was O O 0.999988317489624
admitted O O 0.999994158744812
to O O 0.9999963045120239
the O O 0.9999972581863403
hospital O O 0.9999960660934448
because O O 0.9999971389770508
he O O 0.9999892711639404
developed O O 0.9999831914901733
rhabdomyolysis O O 0.9999642372131348
. O O 0.9999663829803467

At O O 0.9997802376747131
admission O O 0.9998478889465332
simvastatin B B 0.9997503161430359
and O O 0.998826801776886
all O O 0.9996850490570068
antiviral O O 0.6478947997093201
drugs O O 0.9488829374313354
were O O 0.9999240636825562
discontinued O O 0.9998149275779724
because O O 0.9999711513519287
toxicity O O 0.9999867677688599
due O O 0.9999902248382568
to O O 0.9999418258666992
a O O 0.9999847412109375
drug O O 0.9965200424194336
- O O 0.9997395873069763
drug O O 0.9988701939582825
interaction O O 0.9999574422836304
was O O 0.9999860525131226
suspected O O 0.9999899864196777
. O O 0.9999712705612183

The O O 0.9999827146530151
creatine B B 0.9595871567726135
kinase O O 0.4415629804134369
peaked O O 0.9999072551727295
at O O 0.9999024868011475
62 O O 0.999887228012085
, O O 0.9999855756759644
246 O O 0.9999022483825684
IU O O 0.9995859265327454
/ O O 0.9998551607131958
L O O 0.997595489025116
and O O 0.9999773502349854
the O O 0.9999969005584717
patient O O 0.9999911785125732
was O O 0.9999790191650391
treated O O 0.9999668598175049
with O O 0.999925971031189
intravenous O O 0.9999692440032959
normal O O 0.9944103360176086
saline O O 0.9997965693473816
. O O 0.9999396800994873

The O O 0.9999741315841675
patient O O 0.9999837875366211
' O O 0.9999884366989136
s O O 0.9999784231185913
renal O O 0.9999083280563354
function O O 0.9999716281890869
remained O O 0.9999723434448242
unaffected O O 0.9999805688858032
. O O 0.9999755620956421

Fourteen O O 0.9999914169311523
days O O 0.9999974966049194
after O O 0.9999961853027344
hospitalization O O 0.9999799728393555
, O O 0.9999426603317261
creatine B B 0.9844403266906738
kinase O O 0.5952185392379761
level O O 0.9919062852859497
had O O 0.9999829530715942
returned O O 0.9999691247940063
to O O 0.9999862909317017
230 O O 0.9998961687088013
IU O O 0.9999518394470215
/ O O 0.9998778104782104
L O O 0.9980980753898621
and O O 0.9999904632568359
the O O 0.9999984502792358
patient O O 0.9999938011169434
was O O 0.9999940395355225
discharged O O 0.9999947547912598
. O O 0.9999895095825195

Telaprevir B B 0.996181845664978
was O O 0.9998486042022705
considered O O 0.9998894929885864
the O O 0.9999082088470459
probable O O 0.9999587535858154
causative O O 0.9999189376831055
agent O O 0.9999172687530518
of O O 0.999911904335022
an O O 0.9998496770858765
interaction O O 0.9999426603317261
with O O 0.9995213747024536
simvastatin B B 0.9976685643196106
according O O 0.9999359846115112
to O O 0.999984860420227
the O O 0.9999854564666748
Drug O O 0.999239444732666
Interaction O O 0.9998375177383423
Probability O O 0.9997124075889587
Scale O O 0.999484658241272
. O O 0.9999550580978394

The O O 0.9999003410339355
interaction O O 0.9998903274536133
is O O 0.9998236298561096
due O O 0.9999450445175171
to O O 0.999402642250061
inhibition O O 0.9994421601295471
of O O 0.9996545314788818
CYP3A4 O O 0.7564394474029541
- O O 0.9962931275367737
mediated O O 0.9998026490211487
simvastatin B B 0.9948298335075378
clearance O O 0.9996861219406128
. O O 0.9999468326568604

Simvastatin B B 0.9990994930267334
plasma O O 0.997515082359314
concentration O O 0.9998679161071777
increased O O 0.9999662637710571
30 O O 0.9999744892120361
times O O 0.9999891519546509
in O O 0.9999810457229614
this O O 0.9999797344207764
patient O O 0.9999910593032837
and O O 0.9999290704727173
statin B B 0.9929376244544983
induced O O 0.9996178150177002
muscle O O 0.9880980849266052
toxicity O O 0.9999731779098511
is O O 0.9999116659164429
related O O 0.9999935626983643
to O O 0.9999599456787109
the O O 0.9999772310256958
concentration O O 0.9997585415840149
of O O 0.9998718500137329
the O O 0.9998238682746887
statin B B 0.9918721318244934
in O O 0.9993637204170227
blood O O 0.9994708895683289
. O O 0.999957799911499

In O O 0.9999459981918335
conclusion O O 0.9999712705612183
, O O 0.9999732971191406
with O O 0.9999783039093018
this O O 0.9999632835388184
case O O 0.9999886751174927
we O O 0.9999350309371948
illustrate O O 0.9999649524688721
that O O 0.9997629523277283
telaprevir B B 0.9992330074310303
as O O 0.9997038245201111
well O O 0.9994926452636719
as O O 0.9994578957557678
statins B B 0.9284926652908325
are O O 0.999749481678009
susceptible O O 0.9999364614486694
to O O 0.9999173879623413
clinical O O 0.9999693632125854
relevant O O 0.9999920129776001
drug O O 0.9985777139663696
- O O 0.9998403787612915
drug O O 0.9996308088302612
interactions O O 0.9999750852584839
. O O 0.9999754428863525

Combination O O 0.9978687763214111
of O O 0.994023859500885
bortezomib B B 0.9993270635604858
, O O 0.7741867899894714
thalidomide B B 0.9968750476837158
, O O 0.917108416557312
and O O 0.9839292764663696
dexamethasone B B 0.9988885521888733
( O O 0.9939471483230591
VTD O B 0.9925600290298462
) O O 0.9965214729309082
as O O 0.9999630451202393
a O O 0.9999154806137085
consolidation O O 0.9998390674591064
therapy O O 0.999948263168335
after O O 0.9999608993530273
autologous O O 0.999915599822998
stem O O 0.9999858140945435
cell O O 0.9999191761016846
transplantation O O 0.9999805688858032
for O O 0.9999830722808838
symptomatic O O 0.9999767541885376
multiple O O 0.9958452582359314
myeloma O O 0.9999940395355225
in O O 0.9999568462371826
Japanese O O 0.9898988604545593
patients O O 0.9999356269836426
. O O 0.9999383687973022

Consolidation O O 0.9987673759460449
therapy O O 0.999901294708252
for O O 0.9999322891235352
patients O O 0.9999899864196777
with O O 0.9999856948852539
multiple O O 0.9874727725982666
myeloma O O 0.9999780654907227
( O O 0.999861478805542
MM O O 0.9856038093566895
) O O 0.9998156428337097
has O O 0.999977707862854
been O O 0.9999939203262329
widely O O 0.9999845027923584
adopted O O 0.9999939203262329
to O O 0.9999674558639526
improve O O 0.999961256980896
treatment O O 0.9999680519104004
response O O 0.9999978542327881
following O O 0.9999812841415405
autologous O O 0.9999181032180786
stem O O 0.9999569654464722
cell O O 0.9999228715896606
transplantation O O 0.9999659061431885
. O O 0.9999815225601196

In O O 0.9999816417694092
this O O 0.9999830722808838
study O O 0.9999932050704956
, O O 0.9999802112579346
we O O 0.9999854564666748
retrospectively O O 0.9999914169311523
analyzed O O 0.9999926090240479
the O O 0.9999881982803345
safety O O 0.9999936819076538
and O O 0.9999855756759644
efficacy O O 0.9999942779541016
of O O 0.9999309778213501
combination O O 0.9970380067825317
regimen O O 0.9957899451255798
of O O 0.9894893765449524
bortezomib B B 0.9987441301345825
, O O 0.8051908016204834
thalidomide B B 0.996366024017334
, O O 0.9666829705238342
and O O 0.9928008317947388
dexamethasone B B 0.9991550445556641
( O O 0.9959560036659241
VTD O B 0.9879142642021179
) O O 0.9985302686691284
as O O 0.9998816251754761
consolidation O O 0.999528169631958
therapy O O 0.9999243021011353
in O O 0.9999419450759888
24 O O 0.9999042749404907
Japanese O O 0.9855459928512573
patients O O 0.9999669790267944
with O O 0.9999868869781494
newly O O 0.999994158744812
diagnosed O O 0.9999947547912598
MM O O 0.9992424249649048
. O O 0.9999816417694092

VTD O O 0.8593530058860779
consisted O O 0.9999221563339233
of O O 0.9985723495483398
bortezomib B B 0.9995562434196472
at O O 0.9996553659439087
a O O 0.9999788999557495
dose O O 0.9999767541885376
of O O 0.999910831451416
1 O O 0.9999438524246216
. O O 0.9999954700469971
3 O O 0.9994608759880066
mg O O 0.9999827146530151
/ O O 0.999377429485321
m O O 0.9999933242797852
( O O 0.9997933506965637
2 O O 0.9054583311080933
) O O 0.9848617315292358
and O O 0.9987101554870605
dexamethasone B B 0.9996380805969238
at O O 0.9999160766601562
a O O 0.9999905824661255
dose O O 0.9999855756759644
of O O 0.9999792575836182
40 O O 0.9999525547027588
mg O O 0.9999748468399048
/ O O 0.9999804496765137
day O O 0.9999821186065674
on O O 0.9999525547027588
days O O 0.999993085861206
1 O O 0.9999768733978271
, O O 0.9999176263809204
8 O O 0.9991292357444763
, O O 0.9998921155929565
15 O O 0.9999960660934448
, O O 0.9999346733093262
and O O 0.9999560117721558
22 O O 0.9999881982803345
of O O 0.9999878406524658
a O O 0.9999924898147583
35 O O 0.9999912977218628
- O O 0.9999886751174927
day O O 0.9999874830245972
cycle O O 0.9999544620513916
, O O 0.9999867677688599
with O O 0.9999312162399292
daily O O 0.9998348951339722
oral O O 0.9934166669845581
thalidomide B B 0.9995392560958862
at O O 0.9999375343322754
a O O 0.9999867677688599
dose O O 0.9999868869781494
of O O 0.9999735355377197
100 O O 0.9989963173866272
mg O O 0.9999904632568359
/ O O 0.9999794960021973
day O O 0.99998939037323
. O O 0.9999618530273438

Grade O O 0.9995885491371155
3 O O 0.9928528666496277
- O O 0.9955145716667175
4 O O 0.9922419786453247
neutropenia O O 0.9999514818191528
and O O 0.999935507774353
thrombocytopenia O O 0.9992231130599976
were O O 0.9999691247940063
documented O O 0.9999910593032837
in O O 0.9999450445175171
four O O 0.9999815225601196
and O O 0.9999675750732422
three O O 0.9999895095825195
patients O O 0.9999934434890747
( O O 0.999962568283081
17 O O 0.9999964237213135
and O O 0.9999642372131348
13 O O 0.9999949932098389
% O O 0.9999970197677612
) O O 0.9999771118164062
, O O 0.99997878074646
respectively O O 0.9999732971191406
, O O 0.999970555305481
but O O 0.9999593496322632
drug O O 0.9997777342796326
dose O O 0.9997859597206116
reduction O O 0.999967098236084
due O O 0.99998939037323
to O O 0.9999551773071289
cytopenia O O 0.9954714775085449
was O O 0.9999674558639526
not O O 0.9999699592590332
required O O 0.999967098236084
in O O 0.9999582767486572
any O O 0.9999709129333496
case O O 0.9999866485595703
. O O 0.9999736547470093

Peripheral O O 0.9993364214897156
neuropathy O O 0.9999823570251465
was O O 0.9999223947525024
common O O 0.9999167919158936
( O O 0.9999651908874512
63 O O 0.9999957084655762
% O O 0.9999959468841553
) O O 0.9999518394470215
, O O 0.9999475479125977
but O O 0.9999829530715942
severe O O 0.9999362230300903
grade O O 0.9999688863754272
3 O O 0.9897243976593018
- O O 0.9965741634368896
4 O O 0.9975044131278992
peripheral O O 0.9998008608818054
neuropathy O O 0.9999854564666748
was O O 0.999968409538269
not O O 0.9999910593032837
observed O O 0.9999881982803345
. O O 0.9999605417251587

Very O O 0.9998993873596191
good O O 0.9999661445617676
partial O O 0.9999643564224243
response O O 0.9999884366989136
or O O 0.9999127388000488
better O O 0.9990837574005127
response O O 0.9999877214431763
( O O 0.9997788071632385
> O O 0.9923509955406189
VGPR O O 0.46977564692497253
) O O 0.9998026490211487
rates O O 0.9999827146530151
before O O 0.9999511241912842
and O O 0.9999645948410034
after O O 0.9999598264694214
consolidation O O 0.9986391663551331
therapy O O 0.999930739402771
were O O 0.9999653100967407
54 O O 0.9999971389770508
and O O 0.999981164932251
79 O O 0.9999850988388062
% O O 0.9999982118606567
, O O 0.9999891519546509
respectively O O 0.9999771118164062
. O O 0.9999803304672241

Patients O O 0.9998742341995239
had O O 0.9999772310256958
a O O 0.9999842643737793
significant O O 0.9999885559082031
probability O O 0.9999986886978149
of O O 0.9999932050704956
improving O O 0.9999916553497314
from O O 0.9999747276306152
< O O 0.9874796271324158
VGPR O O 0.6961607336997986
before O O 0.9986431002616882
consolidation O O 0.995231568813324
therapy O O 0.9999163150787354
to O O 0.9999480247497559
> O O 0.9933857321739197
VGPR O O 0.5382139086723328
after O O 0.9991214871406555
consolidation O O 0.98919278383255
therapy O O 0.999954104423523
( O O 0.9999645948410034
p O O 0.9998109936714172
= O O 0.9999629259109497
0 O O 0.9999914169311523
. O O 0.9999973773956299
041 O O 0.9978818297386169
) O O 0.9999599456787109
. O O 0.9999768733978271

The O O 0.9998587369918823
VTD O B 0.9688223004341125
regimen O O 0.5517815351486206
may O O 0.9999176263809204
be O O 0.9999806880950928
safe O O 0.9999611377716064
and O O 0.9999823570251465
effective O O 0.9998440742492676
as O O 0.999946117401123
a O O 0.9996107220649719
consolidation O O 0.9980436563491821
therapy O O 0.9998717308044434
in O O 0.9999402761459351
the O O 0.9999728202819824
treatment O O 0.9999345541000366
of O O 0.9999747276306152
MM O O 0.976992130279541
in O O 0.999710738658905
Japanese O O 0.9909124374389648
population O O 0.9999160766601562
. O O 0.999935507774353

Conversion O O 0.9998175501823425
to O O 0.9916812777519226
sirolimus B B 0.9994069337844849
ameliorates O O 0.998110294342041
cyclosporine B B 0.9993658661842346
- O O 0.9994778037071228
induced O O 0.9999489784240723
nephropathy O O 0.9999860525131226
in O O 0.9999868869781494
the O O 0.9999827146530151
rat O O 0.9999901056289673
: O O 0.9999818801879883
focus O O 0.9999675750732422
on O O 0.9999042749404907
serum O O 0.998695433139801
, O O 0.9999333620071411
urine O O 0.9986979961395264
, O O 0.9995133876800537
gene O O 0.534886360168457
, O O 0.969894528388977
and O O 0.9978456497192383
protein O O 0.990122377872467
renal O O 0.9938676953315735
expression O O 0.9910362958908081
biomarkers O O 0.9991006851196289
. O O 0.9999668598175049

Protocols O O 0.9998615980148315
of O O 0.9994157552719116
conversion O O 0.9999370574951172
from O O 0.9993646740913391
cyclosporin B B 0.9970073103904724
A I I 0.999915599822998
( O O 0.9849575757980347
CsA B B 0.9834045767784119
) O O 0.9739534854888916
to O O 0.9978266358375549
sirolimus B B 0.9987801909446716
( O O 0.9984643459320068
SRL B B 0.990683913230896
) O O 0.9972499012947083
have O O 0.999968409538269
been O O 0.9999821186065674
widely O O 0.9999552965164185
used O O 0.9999240636825562
in O O 0.9999096393585205
immunotherapy O O 0.9999123811721802
after O O 0.9999765157699585
transplantation O O 0.9999771118164062
to O O 0.9999405145645142
prevent O O 0.9999359846115112
CsA B B 0.9819886088371277
- O O 0.9992852807044983
induced O O 0.9999550580978394
nephropathy O O 0.9999889135360718
, O O 0.9999586343765259
but O O 0.9999722242355347
the O O 0.9999898672103882
molecular O O 0.9999887943267822
mechanisms O O 0.9999916553497314
underlying O O 0.9999651908874512
these O O 0.999923825263977
protocols O O 0.999966025352478
remain O O 0.9999750852584839
nuclear O O 0.9997703433036804
. O O 0.9999765157699585

This O O 0.9999815225601196
study O O 0.9999790191650391
aimed O O 0.9999806880950928
to O O 0.9999887943267822
identify O O 0.9999744892120361
the O O 0.999977707862854
molecular O O 0.9999779462814331
pathways O O 0.99997878074646
and O O 0.9999681711196899
putative O O 0.9999681711196899
biomarkers O O 0.9999303817749023
of O O 0.9999585151672363
CsA B O 0.5958875417709351
- O O 0.999337375164032
to O O 0.9985285997390747
- O O 0.9980425834655762
SRL B O 0.48670676350593567
conversion O O 0.9999121427536011
in O O 0.9999721050262451
a O O 0.9999744892120361
rat O O 0.9999738931655884
model O O 0.9999903440475464
. O O 0.9999781847000122

Four O O 0.9996035695075989
animal O O 0.9998565912246704
groups O O 0.9999504089355469
( O O 0.9999514818191528
n O O 0.9998772144317627
= O O 0.9999699592590332
6 O O 0.9999706745147705
) O O 0.9999669790267944
were O O 0.9999829530715942
tested O O 0.9999749660491943
during O O 0.9999581575393677
9 O O 0.9998952150344849
weeks O O 0.9999966621398926
: O O 0.9999401569366455
control O O 0.9996538162231445
, O O 0.9998281002044678
CsA B O 0.7266502976417542
, O O 0.9995136260986328
SRL B O 0.5934372544288635
, O O 0.9995649456977844
and O O 0.9988607168197632
conversion O O 0.9978339076042175
( O O 0.9997677206993103
CsA B O 0.6713212132453918
for O O 0.9995672106742859
3 O O 0.9999052286148071
weeks O O 0.9999935626983643
followed O O 0.9999557733535767
by O O 0.9998689889907837
SRL B O 0.6172178983688354
for O O 0.9997389912605286
6 O O 0.9999419450759888
weeks O O 0.9999960660934448
) O O 0.9999774694442749
. O O 0.9999825954437256

Classical O O 0.9972189664840698
and O O 0.9999072551727295
emergent O O 0.9998756647109985
serum O O 0.9994575381278992
, O O 0.9999091625213623
urinary O O 0.9998103976249695
, O O 0.9997133612632751
and O O 0.9997747540473938
kidney O O 0.9998306035995483
tissue O O 0.9999573230743408
( O O 0.9997101426124573
gene O O 0.9985264539718628
and O O 0.9998462200164795
protein O O 0.9996215105056763
expression O O 0.9998588562011719
) O O 0.9995197057723999
markers O O 0.9999675750732422
were O O 0.9999692440032959
assessed O O 0.9999746084213257
. O O 0.9999657869338989

Renal O O 0.998927652835846
lesions O O 0.9999749660491943
were O O 0.99996018409729
analyzed O O 0.9999668598175049
in O O 0.9995371103286743
hematoxylin B O 0.9672885537147522
and O O 0.9967250227928162
eosin B O 0.8679136633872986
, O O 0.9998016953468323
periodic O O 0.9862457513809204
acid O O 0.9856429696083069
- O O 0.9940125346183777
Schiff O O 0.9789949059486389
, O O 0.9972556233406067
and O O 0.9986987113952637
Masson O O 0.9974712133407593
' O O 0.9999772310256958
s O O 0.9966842532157898
trichrome O O 0.9117476344108582
stains O O 0.999686598777771
. O O 0.9999595880508423

SRL B B 0.9952967762947083
- O O 0.9726769328117371
treated O O 0.9986157417297363
rats O O 0.9998403787612915
presented O O 0.9998900890350342
proteinuria O O 0.9957971572875977
and O O 0.9995672106742859
NGAL O O 0.9574917554855347
( O O 0.9997839331626892
serum O O 0.9992364645004272
and O O 0.9998965263366699
urinary O O 0.9999183416366577
) O O 0.9999232292175293
as O O 0.9999709129333496
the O O 0.9999862909317017
best O O 0.9998682737350464
markers O O 0.9999945163726807
of O O 0.9999837875366211
renal O O 0.999966025352478
impairment O O 0.9999903440475464
. O O 0.9999781847000122

Short O O 0.5957619547843933
CsA B O 0.6912189722061157
treatment O O 0.9981219172477722
presented O O 0.9999145269393921
slight O O 0.9999337196350098
or O O 0.9999908208847046
even O O 0.9999892711639404
absent O O 0.9999774694442749
kidney O O 0.9995684027671814
lesions O O 0.9999940395355225
and O O 0.9998916387557983
TGF O O 0.7301113605499268
- O O 0.9766201972961426
b O O 0.937583863735199
, O O 0.9984021782875061
NF O O 0.8597601056098938
- O O 0.9756465554237366
kb O O 0.46511104702949524
, O O 0.991113007068634
mTOR O O 0.930957555770874
, O O 0.9970948696136475
PCNA O O 0.8031167387962341
, O O 0.9980397820472717
TP53 O O 0.8504295349121094
, O O 0.9974835515022278
KIM O O 0.9584354162216187
- O O 0.9972965121269226
1 O O 0.9935503005981445
, O O 0.9868899583816528
and O O 0.9870794415473938
CTGF O O 0.5539056658744812
as O O 0.9997629523277283
relevant O O 0.9998555183410645
gene O O 0.9959396123886108
and O O 0.9998685121536255
protein O O 0.9998482465744019
changes O O 0.9999668598175049
. O O 0.9999610185623169

Prolonged O O 0.9611747860908508
CsA B B 0.9300456643104553
exposure O O 0.9297196269035339
aggravated O O 0.9995259046554565
renal O O 0.9999680519104004
damage O O 0.9999923706054688
, O O 0.9999792575836182
without O O 0.999990701675415
clear O O 0.9999841451644897
changes O O 0.9999953508377075
on O O 0.9999876022338867
the O O 0.9999438524246216
traditional O O 0.8705609440803528
markers O O 0.9999650716781616
, O O 0.9999486207962036
but O O 0.999976396560669
with O O 0.9999773502349854
changes O O 0.9999843835830688
in O O 0.9999432563781738
serums O O 0.9889755249023438
TGF O O 0.6729007363319397
- O O 0.9272443652153015
b O O 0.8205328583717346
and O O 0.9991400241851807
IL O O 0.9788557887077332
- O O 0.9953336119651794
7 O O 0.9699528217315674
, O O 0.9997732043266296
TBARs O O 0.7293453812599182
clearance O O 0.9979223608970642
, O O 0.9992338418960571
and O O 0.9970760345458984
kidney O O 0.9995075464248657
TGF O O 0.5595479607582092
- O O 0.8801893591880798
b O O 0.7358623147010803
and O O 0.9974964261054993
mTOR O O 0.9063898324966431
. O O 0.9998843669891357

Conversion O O 0.9999740123748779
to O O 0.9981098175048828
SRL B B 0.9678662419319153
prevented O O 0.9979324340820312
CsA B B 0.9633079767227173
- O O 0.9969520568847656
induced O O 0.9998279809951782
renal O O 0.9998688697814941
damage O O 0.9999549388885498
evolution O O 0.9999635219573975
( O O 0.99989914894104
absent O O 0.9997718930244446
/ O O 0.9999498128890991
mild O O 0.9999629259109497
grade O O 0.9999442100524902
lesions O O 0.9999774694442749
) O O 0.9999332427978516
, O O 0.999954342842102
while O O 0.999889612197876
NGAL O O 0.8029696345329285
( O O 0.9995433688163757
serum O O 0.9998124241828918
versus O O 0.9999285936355591
urine O O 0.9997178912162781
) O O 0.9999589920043945
seems O O 0.9999536275863647
to O O 0.9999496936798096
be O O 0.9999731779098511
a O O 0.9999363422393799
feasible O O 0.99979168176651
biomarker O O 0.9999493360519409
of O O 0.9999312162399292
CsA B B 0.8970067501068115
replacement O O 0.9996355772018433
to O O 0.9985774755477905
SRL B B 0.8978869915008545
. O O 0.9998998641967773

Kinin O O 0.7673934698104858
B2 O O 0.8476554751396179
receptor O O 0.9987937211990356
deletion O O 0.9995682835578918
and O O 0.9996827840805054
blockage O O 0.990050196647644
ameliorates O O 0.9997712969779968
cisplatin B B 0.9996325969696045
- O O 0.9997178912162781
induced O O 0.9999513626098633
acute O O 0.9999825954437256
renal O O 0.9999902248382568
injury O O 0.9999974966049194
. O O 0.9999514818191528

Cisplatin B B 0.9980937838554382
treatment O O 0.9974372386932373
has O O 0.9998757839202881
been O O 0.9999675750732422
adopted O O 0.9990297555923462
in O O 0.9997627139091492
some O O 0.9997119307518005
chemotherapies O O 0.9988468885421753
; O O 0.9999302625656128
however O O 0.9999425411224365
, O O 0.9998899698257446
this O O 0.9982810020446777
drug O O 0.9980294108390808
can O O 0.9998300075531006
induce O O 0.9999691247940063
acute O O 0.9999595880508423
kidney O O 0.9999727010726929
injury O O 0.9999959468841553
due O O 0.9999754428863525
its O O 0.9999572038650513
ability O O 0.9999685287475586
to O O 0.9999297857284546
negatively O O 0.9988422989845276
affect O O 0.9999525547027588
renal O O 0.9999624490737915
function O O 0.9999850988388062
, O O 0.9999556541442871
augment O O 0.996607780456543
serum O O 0.9993199110031128
levels O O 0.999927282333374
of O O 0.9997569918632507
creatinine B B 0.9952398538589478
and O O 0.9307915568351746
urea B B 0.9330211281776428
, O O 0.9996423721313477
increase O O 0.9998314380645752
the O O 0.9999586343765259
acute O O 0.9948328733444214
tubular O O 0.9999933242797852
necrosis O O 0.9999514818191528
score O O 0.9998021721839905
and O O 0.99982088804245
up O O 0.9314920902252197
- O O 0.9999282360076904
regulate O O 0.9984169006347656
cytokines O O 0.974403977394104
( O O 0.9998177886009216
e O O 0.9963977336883545
. O O 0.99996018409729
g O O 0.999924898147583
. O O 0.9999600648880005
, O O 0.9947004318237305
IL O O 0.9642403721809387
- O O 0.9924319982528687
1b O O 0.976951539516449
and O O 0.9977442026138306
TNF O O 0.8549375534057617
- O O 0.9653677940368652
a O O 0.546855092048645
) O O 0.9999263286590576
. O O 0.9999427795410156

The O O 0.9979530572891235
kinin O O 0.8408867716789246
B2 O O 0.7195839881896973
receptor O O 0.9969667792320251
has O O 0.999818742275238
been O O 0.999864935874939
associated O O 0.9998955726623535
with O O 0.9998966455459595
the O O 0.9998842477798462
inflammation O O 0.9995781779289246
process O O 0.9999765157699585
, O O 0.9999465942382812
as O O 0.9999613761901855
well O O 0.9999181032180786
as O O 0.9999600648880005
the O O 0.9999347925186157
regulation O O 0.9999511241912842
of O O 0.9998723268508911
cytokine O O 0.9476679563522339
expression O O 0.9998847246170044
, O O 0.9999074935913086
and O O 0.9999167919158936
its O O 0.9996488094329834
deletion O O 0.9998630285263062
resulted O O 0.9999773502349854
in O O 0.9999877214431763
an O O 0.9999836683273315
improvement O O 0.9999934434890747
in O O 0.9999892711639404
the O O 0.9999878406524658
diabetic O O 0.9999182224273682
nephropathy O O 0.9999899864196777
status O O 0.9999948740005493
. O O 0.9999775886535645

To O O 0.9999861717224121
examine O O 0.9999505281448364
the O O 0.9999672174453735
role O O 0.9999752044677734
of O O 0.9999088048934937
the O O 0.9997625946998596
kinin O O 0.5376170873641968
B2 O O 0.5258995294570923
receptor O O 0.9979187846183777
in O O 0.9999120235443115
cisplatin B B 0.9996498823165894
- O O 0.9997410178184509
induced O O 0.9999673366546631
acute O O 0.9999886751174927
kidney O O 0.9999744892120361
injury O O 0.9999982118606567
, O O 0.999972939491272
kinin O O 0.5073608756065369
B2 O O 0.6528455018997192
receptor O O 0.9985494017601013
knockout O O 0.999832034111023
mice O O 0.9999933242797852
were O O 0.999980092048645
challenged O O 0.9999864101409912
with O O 0.9997372031211853
cisplatin B B 0.9994168281555176
. O O 0.9998977184295654

Additionally O O 0.9999567270278931
, O O 0.9999382495880127
WT O O 0.9907227158546448
mice O O 0.9999954700469971
were O O 0.9999771118164062
treated O O 0.9999592304229736
with O O 0.9998714923858643
a O O 0.9983363747596741
B2 O O 0.5507978200912476
receptor O O 0.9953857064247131
antagonist O O 0.9772922992706299
after O O 0.9997163414955139
cisplatin B B 0.9987726807594299
administration O O 0.9998328685760498
. O O 0.9999741315841675

B2 O O 0.5027374029159546
receptor O O 0.9386690258979797
- O O 0.9978118538856506
deficient O O 0.9995800852775574
mice O O 0.9999834299087524
were O O 0.9999732971191406
less O O 0.9999573230743408
sensitive O O 0.9999812841415405
to O O 0.9998769760131836
this O O 0.9963638186454773
drug O O 0.9983072280883789
than O O 0.9999444484710693
the O O 0.9999778270721436
WT O O 0.9931332468986511
mice O O 0.9999896287918091
, O O 0.9999886751174927
as O O 0.999996542930603
shown O O 0.9999984502792358
by O O 0.9999959468841553
reduced O O 0.9999970197677612
weight O O 0.9999942779541016
loss O O 0.9999988079071045
, O O 0.9999828338623047
better O O 0.9998654127120972
preservation O O 0.9999949932098389
of O O 0.9999779462814331
kidney O O 0.9999027252197266
function O O 0.9999881982803345
, O O 0.9999755620956421
down O O 0.9987568855285645
regulation O O 0.9999892711639404
of O O 0.9998915195465088
inflammatory O O 0.9994912147521973
cytokines O O 0.9954482913017273
and O O 0.9999306201934814
less O O 0.9999444484710693
acute O O 0.9996649026870728
tubular O O 0.9999921321868896
necrosis O O 0.9999964237213135
. O O 0.9999834299087524

Moreover O O 0.9999308586120605
, O O 0.9997798800468445
treatment O O 0.9999485015869141
with O O 0.9998939037322998
the O O 0.9986990690231323
kinin O O 0.6772152781486511
B2 O O 0.748353123664856
receptor O O 0.9816029667854309
antagonist O O 0.9564009308815002
effectively O O 0.9998780488967896
reduced O O 0.9999483823776245
the O O 0.9999674558639526
levels O O 0.9999645948410034
of O O 0.9999499320983887
serum O O 0.9974150657653809
creatinine B B 0.9989594221115112
and O O 0.999643087387085
blood O O 0.8502065539360046
urea B B 0.9150406718254089
after O O 0.9983141422271729
cisplatin B B 0.9997513890266418
administration O O 0.9999048709869385
. O O 0.9999697208404541

Thus O O 0.9999812841415405
, O O 0.9999774694442749
our O O 0.9999622106552124
data O O 0.9999905824661255
suggest O O 0.9999027252197266
that O O 0.9997853636741638
the O O 0.9986302852630615
kinin O O 0.7776058316230774
B2 O O 0.7396479845046997
receptor O O 0.9989786148071289
is O O 0.9998586177825928
involved O O 0.9999054670333862
in O O 0.9998899698257446
cisplatin B B 0.9997727274894714
- O O 0.9996583461761475
induced O O 0.9999470710754395
acute O O 0.9999879598617554
kidney O O 0.9999516010284424
injury O O 0.9999964237213135
by O O 0.9999384880065918
mediating O O 0.9995200634002686
the O O 0.9999508857727051
necrotic O O 0.999972939491272
process O O 0.9999909400939941
and O O 0.9999430179595947
the O O 0.9999001026153564
expression O O 0.9999120235443115
of O O 0.9995550513267517
inflammatory O O 0.996253252029419
cytokines O O 0.987776517868042
, O O 0.9999605417251587
thus O O 0.9999617338180542
resulting O O 0.9999837875366211
in O O 0.9999822378158569
declined O O 0.9990641474723816
renal O O 0.9999834299087524
function O O 0.9999940395355225
. O O 0.9999839067459106

These O O 0.999982476234436
results O O 0.999971866607666
highlight O O 0.9883290529251099
the O O 0.9925065636634827
kinin O O 0.5650022625923157
B2 O O 0.5929387211799622
receptor O O 0.9861926436424255
antagonist O O 0.8908517956733704
treatment O O 0.999525785446167
in O O 0.9997583031654358
amelioration O O 0.9999330043792725
of O O 0.9998667240142822
nephrotoxicity O O 0.9999657869338989
induced O O 0.999977707862854
by O O 0.999893307685852
cisplatin B B 0.9994481205940247
therapy O O 0.9991790652275085
. O O 0.9999375343322754

Safety O O 0.9999417066574097
and O O 0.9999799728393555
efficacy O O 0.9999767541885376
of O O 0.998641312122345
fluocinolone B B 0.9995146989822388
acetonide I I 0.9988104104995728
intravitreal O O 0.9255284667015076
implant O O 0.9264957308769226
( O O 0.9995458722114563
0 O O 0.9991602897644043
. O O 0.9999308586120605
59 O O 0.9891632795333862
mg O O 0.9988252520561218
) O O 0.9999071359634399
in O O 0.9999135732650757
birdshot O O 0.7548890113830566
retinochoroidopathy O O 0.972690224647522
. O O 0.9999046325683594

PURPOSE O O 0.9999700784683228
: O O 0.9999980926513672
To O O 0.9999985694885254
report O O 0.9999980926513672
the O O 0.9999942779541016
treatment O O 0.9999803304672241
outcomes O O 0.999996542930603
of O O 0.9998321533203125
the O O 0.9984477758407593
fluocinolone B B 0.9992793202400208
acetonide I I 0.998005211353302
intravitreal O O 0.9589129686355591
implant O O 0.9989770650863647
( O O 0.999639630317688
0 O O 0.9982883334159851
. O O 0.9999076128005981
59 O O 0.9625237584114075
mg O O 0.9973540306091309
) O O 0.9999579191207886
in O O 0.9999507665634155
patients O O 0.9999934434890747
with O O 0.9999704360961914
birdshot O O 0.9957310557365417
retinochoroidopathy O O 0.997986912727356
whose O O 0.999972939491272
disease O O 0.9999960660934448
is O O 0.9999837875366211
refractory O O 0.9999943971633911
or O O 0.9999898672103882
intolerant O O 0.9999953508377075
to O O 0.9999620914459229
conventional O O 0.99977046251297
immunomodulatory O O 0.998648464679718
therapy O O 0.9999589920043945
. O O 0.9999830722808838

METHODS O O 0.9999531507492065
: O O 0.9999942779541016
A O O 0.9999939203262329
retrospective O O 0.9999750852584839
case O O 0.9999871253967285
series O O 0.9999933242797852
involving O O 0.999976396560669
11 O O 0.9997755885124207
birdshot O O 0.9991419315338135
retinochoroidopathy O O 0.9982324242591858
patients O O 0.999967098236084
( O O 0.9999016523361206
11 O O 0.9998753070831299
eyes O O 0.9999949932098389
) O O 0.9999724626541138
. O O 0.9999796152114868

Eleven O O 0.9999463558197021
patients O O 0.9999927282333374
( O O 0.9999793767929077
11 O O 0.9999895095825195
eyes O O 0.999997615814209
) O O 0.9999845027923584
underwent O O 0.999991774559021
surgery O O 0.9999973773956299
for O O 0.9998829364776611
fluocinolone B B 0.9994029998779297
acetonide I I 0.997612476348877
implant O O 0.997936487197876
( O O 0.9996801614761353
0 O O 0.9984806180000305
. O O 0.9999063014984131
59 O O 0.98160719871521
mg O O 0.9990711212158203
) O O 0.9999393224716187
. O O 0.9999570846557617

Treatment O O 0.9998013377189636
outcomes O O 0.9999926090240479
of O O 0.9999622106552124
interest O O 0.999908447265625
were O O 0.9999796152114868
noted O O 0.9999929666519165
at O O 0.9999747276306152
baseline O O 0.9999856948852539
, O O 0.9999946355819702
before O O 0.9998273849487305
fluocinolone B B 0.9994834661483765
acetonide I I 0.9986421465873718
implant O O 0.9986162185668945
, O O 0.999970555305481
and O O 0.999931812286377
then O O 0.9999785423278809
at O O 0.9999599456787109
6 O O 0.9999711513519287
months O O 0.9999985694885254
, O O 0.9999713897705078
1 O O 0.9999792575836182
year O O 0.9999939203262329
, O O 0.9999513626098633
2 O O 0.9999724626541138
years O O 0.9999934434890747
, O O 0.9999451637268066
3 O O 0.9999394416809082
years O O 0.9999891519546509
, O O 0.999976634979248
and O O 0.999950647354126
beyond O O 0.9999837875366211
3 O O 0.9999752044677734
years O O 0.9999924898147583
. O O 0.9999841451644897

Disease O O 0.9989519119262695
activity O O 0.9991728663444519
markers O O 0.9999598264694214
, O O 0.9999674558639526
including O O 0.9999213218688965
signs O O 0.9999666213989258
of O O 0.9999663829803467
ocular O O 0.9998393058776855
inflammation O O 0.9999903440475464
, O O 0.9999567270278931
evidence O O 0.9999822378158569
of O O 0.9999735355377197
retinal O O 0.9999474287033081
vasculitis O O 0.9999206066131592
, O O 0.9999477863311768
Swedish O O 0.6894035935401917
interactive O O 0.9974254965782166
threshold O O 0.9989719390869141
algorithm O O 0.9766197800636292
- O O 0.9946526288986206
short O O 0.9874204993247986
wavelength O O 0.999784529209137
automated O O 0.9976130723953247
perimetry O O 0.9979981780052185
Humphrey O O 0.9271923899650574
visual O O 0.9998588562011719
field O O 0.9999889135360718
analysis O O 0.9998082518577576
, O O 0.9999476671218872
electroretinographic O O 0.9943445920944214
parameters O O 0.9999672174453735
, O O 0.9998931884765625
and O O 0.9999208450317383
optical O O 0.9997422099113464
coherence O O 0.9974608421325684
tomography O O 0.9996182918548584
were O O 0.9999738931655884
recorded O O 0.9999905824661255
. O O 0.9999696016311646

Data O O 0.999962568283081
on O O 0.9998846054077148
occurrence O O 0.9999948740005493
of O O 0.999977707862854
cataract O O 0.9999092817306519
and O O 0.9998863935470581
raised O O 0.9999692440032959
intraocular O O 0.9996811151504517
pressure O O 0.9966121315956116
were O O 0.999963641166687
collected O O 0.999954342842102
in O O 0.9998794794082642
all O O 0.9998763799667358
eyes O O 0.9999921321868896
. O O 0.9999595880508423

RESULTS O O 0.9998334646224976
: O O 0.9998944997787476
Intraocular O O 0.9995400905609131
inflammation O O 0.9999481439590454
was O O 0.9999523162841797
present O O 0.9999769926071167
in O O 0.9999399185180664
54 O O 0.9999395608901978
. O O 0.999975323677063
5 O O 0.9999740123748779
, O O 0.999897837638855
9 O O 0.9998548030853271
. O O 0.9999854564666748
9 O O 0.9999583959579468
, O O 0.9997557997703552
11 O O 0.9999045133590698
. O O 0.9999831914901733
1 O O 0.999991774559021
, O O 0.9996813535690308
and O O 0.9998152852058411
0 O O 0.9999732971191406
% O O 0.9999920129776001
of O O 0.999976396560669
patients O O 0.9999896287918091
at O O 0.9999570846557617
baseline O O 0.9999896287918091
, O O 0.9999884366989136
6 O O 0.9999637603759766
months O O 0.9999980926513672
, O O 0.9999649524688721
1 O O 0.9999810457229614
year O O 0.9999932050704956
, O O 0.9999454021453857
2 O O 0.9999687671661377
years O O 0.9999892711639404
, O O 0.99988853931427
3 O O 0.9999207258224487
years O O 0.9999812841415405
, O O 0.999945878982544
and O O 0.999901294708252
beyond O O 0.9999896287918091
3 O O 0.9999827146530151
years O O 0.9999972581863403
after O O 0.9999953508377075
receiving O O 0.9999899864196777
the O O 0.999984860420227
implant O O 0.9999793767929077
, O O 0.9999752044677734
respectively O O 0.9999054670333862
. O O 0.9999711513519287

Active O O 0.9998646974563599
vasculitis O O 0.9999079704284668
was O O 0.9999724626541138
noted O O 0.9999926090240479
in O O 0.9999761581420898
36 O O 0.9999853372573853
. O O 0.99998939037323
3 O O 0.9999879598617554
% O O 0.9999819993972778
patients O O 0.9999929666519165
at O O 0.9999780654907227
baseline O O 0.999985933303833
and O O 0.9999654293060303
0 O O 0.9999656677246094
% O O 0.9999946355819702
at O O 0.9999860525131226
3 O O 0.9999462366104126
years O O 0.9999973773956299
of O O 0.9999953508377075
follow O O 0.9999934434890747
- O O 0.9999933242797852
up O O 0.9999964237213135
. O O 0.9999797344207764

More O O 0.9998738765716553
than O O 0.9999876022338867
20 O O 0.9999904632568359
% O O 0.9999885559082031
( O O 0.9999432563781738
47 O O 0.9998917579650879
. O O 0.9999939203262329
61 O O 0.9998387098312378
- O O 0.9968275427818298
67 O O 0.9999840259552002
. O O 0.9999934434890747
2 O O 0.9999877214431763
% O O 0.9999946355819702
) O O 0.9999421834945679
reduction O O 0.9999958276748657
in O O 0.9999903440475464
central O O 0.9999275207519531
retinal O O 0.9999885559082031
thickness O O 0.999995231628418
was O O 0.9999861717224121
noted O O 0.9999935626983643
in O O 0.9999328851699829
all O O 0.9999499320983887
patients O O 0.999992847442627
with O O 0.9999710321426392
cystoid O O 0.9994176626205444
macular O O 0.9999943971633911
edema O O 0.9999927282333374
at O O 0.999974250793457
6 O O 0.9999314546585083
months O O 0.9999983310699463
, O O 0.99997878074646
1 O O 0.9999799728393555
year O O 0.9999954700469971
, O O 0.999964714050293
2 O O 0.9999804496765137
years O O 0.9999945163726807
, O O 0.9999610185623169
and O O 0.9999392032623291
3 O O 0.999954104423523
years O O 0.9999964237213135
postimplant O O 0.9999672174453735
. O O 0.9999605417251587

At O O 0.9999384880065918
baseline O O 0.9999812841415405
, O O 0.999970555305481
54 O O 0.9999555349349976
. O O 0.9999741315841675
5 O O 0.9999902248382568
% O O 0.9999873638153076
patients O O 0.9999853372573853
were O O 0.9999681711196899
on O O 0.9980629086494446
immunomodulatory O O 0.9965764880180359
agents O O 0.997495174407959
. O O 0.9999425411224365

This O O 0.9999394416809082
percentage O O 0.9998601675033569
decreased O O 0.9999867677688599
to O O 0.999976396560669
45 O O 0.999977707862854
. O O 0.9999896287918091
45 O O 0.9999958276748657
, O O 0.999933123588562
44 O O 0.9999912977218628
. O O 0.9999920129776001
4 O O 0.9999890327453613
, O O 0.999887228012085
and O O 0.999934196472168
14 O O 0.9999899864196777
. O O 0.9999895095825195
28 O O 0.9999971389770508
% O O 0.9999860525131226
at O O 0.9999634027481079
1 O O 0.9999784231185913
year O O 0.9999957084655762
, O O 0.9999560117721558
2 O O 0.9999809265136719
years O O 0.9999921321868896
, O O 0.9999563694000244
and O O 0.999943733215332
3 O O 0.9999492168426514
years O O 0.9999953508377075
postimplant O O 0.9999732971191406
, O O 0.999984860420227
respectively O O 0.9999736547470093
. O O 0.9999710321426392

Adverse O O 0.9998337030410767
events O O 0.9999970197677612
included O O 0.9999877214431763
increased O O 0.9999622106552124
intraocular O O 0.9997617602348328
pressure O O 0.9970199465751648
( O O 0.9999376535415649
54 O O 0.9999550580978394
. O O 0.9999910593032837
5 O O 0.9999938011169434
% O O 0.9999945163726807
) O O 0.9999313354492188
and O O 0.9998791217803955
cataract O O 0.9999032020568848
formation O O 0.9999574422836304
( O O 0.9999313354492188
100 O O 0.9999756813049316
% O O 0.9999938011169434
) O O 0.999954104423523
. O O 0.9999673366546631

CONCLUSION O O 0.9995385408401489
: O O 0.9999911785125732
The O O 0.9999958276748657
data O O 0.9999943971633911
suggest O O 0.9999656677246094
that O O 0.9996558427810669
fluocinolone B B 0.9995379447937012
acetonide I I 0.9971201419830322
implant O O 0.7179304957389832
( O O 0.9993085861206055
0 O O 0.9983250498771667
. O O 0.9999274015426636
59 O O 0.9883329272270203
mg O O 0.9992231130599976
) O O 0.9998652935028076
helps O O 0.9998806715011597
to O O 0.9998925924301147
control O O 0.9997053742408752
inflammation O O 0.9999593496322632
in O O 0.9998927116394043
otherwise O O 0.9934282898902893
treatment O O 0.996654748916626
- O O 0.9999542236328125
refractory O O 0.999968409538269
cases O O 0.999982476234436
of O O 0.9999626874923706
birdshot O O 0.9893598556518555
retinochoroidopathy O O 0.9984330534934998
. O O 0.999966025352478

It O O 0.9986653327941895
is O O 0.9996480941772461
associated O O 0.9999332427978516
with O O 0.9999504089355469
significant O O 0.9999393224716187
side O O 0.9999110698699951
effects O O 0.9999806880950928
of O O 0.9999289512634277
cataract O O 0.9996412992477417
and O O 0.9998865127563477
ocular O O 0.9997931122779846
hypertension O O 0.9973762035369873
requiring O O 0.9999086856842041
treatment O O 0.999961256980896
. O O 0.9999454021453857

Optimal O O 0.9988048076629639
precurarizing O O 0.9981940388679504
dose O O 0.9993615746498108
of O O 0.9973884224891663
rocuronium B B 0.9995205402374268
to O O 0.9998664855957031
decrease O O 0.9999042749404907
fasciculation O O 0.9999632835388184
and O O 0.9999585151672363
myalgia O O 0.9999984502792358
following O O 0.9998241066932678
succinylcholine B B 0.999609649181366
administration O O 0.9998878240585327
. O O 0.9999206066131592

BACKGROUND O O 0.5892932415008545
: O O 0.997235119342804
Succinylcholine B B 0.9994764924049377
commonly O O 0.9996284246444702
produces O O 0.9998670816421509
frequent O O 0.9998453855514526
adverse O O 0.9998437166213989
effects O O 0.9999616146087646
, O O 0.9999703168869019
including O O 0.9999479055404663
muscle O O 0.9999498128890991
fasciculation O O 0.999984622001648
and O O 0.9999306201934814
myalgia O O 0.9999972581863403
. O O 0.9998906850814819

The O O 0.9999938011169434
current O O 0.9999904632568359
study O O 0.9999884366989136
identified O O 0.9999833106994629
the O O 0.9999874830245972
optimal O O 0.9999165534973145
dose O O 0.9998534917831421
of O O 0.9993984699249268
rocuronium B B 0.9986097812652588
to O O 0.9998821020126343
prevent O O 0.999860405921936
succinylcholine B B 0.9993657469749451
- O O 0.9997542500495911
induced O O 0.9999442100524902
fasciculation O O 0.9999877214431763
and O O 0.9999284744262695
myalgia O O 0.9999980926513672
and O O 0.999976396560669
evaluated O O 0.9999748468399048
the O O 0.999966025352478
influence O O 0.9999629259109497
of O O 0.9998030066490173
rocuronium B B 0.9992566704750061
on O O 0.9998144507408142
the O O 0.9999855756759644
speed O O 0.9999885559082031
of O O 0.9999881982803345
onset O O 0.9999914169311523
produced O O 0.9999973773956299
by O O 0.9998728036880493
succinylcholine B B 0.9995836615562439
. O O 0.9999032020568848

METHODS O O 0.9999701976776123
: O O 0.999993085861206
This O O 0.9999939203262329
randomized O O 0.9999880790710449
, O O 0.9999821186065674
double O O 0.9999246597290039
- O O 0.9999754428863525
blinded O O 0.999991774559021
study O O 0.9999935626983643
was O O 0.9999853372573853
conducted O O 0.9999971389770508
in O O 0.9999885559082031
100 O O 0.999972939491272
patients O O 0.9999960660934448
randomly O O 0.9999929666519165
allocated O O 0.999995231628418
into O O 0.9999707937240601
five O O 0.9999756813049316
groups O O 0.9999954700469971
of O O 0.999987006187439
20 O O 0.9999786615371704
patients O O 0.9999896287918091
each O O 0.9999492168426514
. O O 0.9999768733978271

Patients O O 0.9999617338180542
were O O 0.9999918937683105
randomized O O 0.9999940395355225
to O O 0.999922513961792
receive O O 0.9997730851173401
0 O O 0.9987449645996094
. O O 0.9998712539672852
02 O O 0.9998242259025574
, O O 0.998216450214386
0 O O 0.9977834820747375
. O O 0.9999040365219116
03 O O 0.9997721314430237
, O O 0.998315691947937
0 O O 0.9978298544883728
. O O 0.9999203681945801
04 O O 0.9996567964553833
, O O 0.99824059009552
0 O O 0.9979634284973145
. O O 0.9999490976333618
05 O O 0.999925971031189
and O O 0.9993025064468384
0 O O 0.9997609257698059
. O O 0.9999904632568359
06 O O 0.9999890327453613
mg O O 0.9999284744262695
/ O O 0.999876856803894
kg O O 0.9998365640640259
rocuronium B B 0.999496579170227
as O O 0.9999198913574219
a O O 0.9999752044677734
precurarizing O O 0.9999680519104004
dose O O 0.999932050704956
. O O 0.9999666213989258

Neuromuscular O O 0.999972939491272
monitoring O O 0.9999953508377075
after O O 0.9999691247940063
each O O 0.9999078512191772
precurarizing O O 0.9964364767074585
dose O O 0.9989246726036072
was O O 0.9999784231185913
recorded O O 0.9999966621398926
from O O 0.9999743700027466
the O O 0.9999773502349854
adductor O O 0.9997391104698181
pollicis O O 0.999176561832428
muscle O O 0.9999562501907349
using O O 0.9999597072601318
acceleromyography O O 0.9999406337738037
with O O 0.9999631643295288
train O O 0.9999104738235474
- O O 0.999985933303833
of O O 0.9964196681976318
- O O 0.999958872795105
four O O 0.999277651309967
stimulation O O 0.9999630451202393
of O O 0.9999208450317383
the O O 0.9999836683273315
ulnar O O 0.9998706579208374
nerve O O 0.9999908208847046
. O O 0.9999747276306152

All O O 0.9999788999557495
patients O O 0.9999951124191284
received O O 0.9998530149459839
succinylcholine B B 0.9996744394302368
1 O O 0.9994584918022156
. O O 0.9999799728393555
5 O O 0.9999004602432251
mg O O 0.9999058246612549
/ O O 0.9998266100883484
kg O O 0.9999895095825195
at O O 0.9999769926071167
2 O O 0.9999674558639526
minutes O O 0.9999979734420776
after O O 0.9999923706054688
the O O 0.9999896287918091
precurarization O O 0.99989914894104
, O O 0.9999651908874512
and O O 0.9999597072601318
were O O 0.99998939037323
assessed O O 0.9999943971633911
the O O 0.99998939037323
incidence O O 0.9999852180480957
and O O 0.999984622001648
severity O O 0.999987006187439
of O O 0.9999759197235107
fasciculations O O 0.99996018409729
, O O 0.9999656677246094
while O O 0.9997380375862122
myalgia O O 0.9999964237213135
was O O 0.999975323677063
assessed O O 0.9999909400939941
at O O 0.9999791383743286
24 O O 0.9999890327453613
hours O O 0.999997615814209
after O O 0.9999957084655762
surgery O O 0.9999967813491821
. O O 0.999983549118042

RESULTS O O 0.9998424053192139
: O O 0.9999855756759644
The O O 0.9999912977218628
incidence O O 0.999981164932251
and O O 0.9999732971191406
severity O O 0.9999799728393555
of O O 0.9999532699584961
visible O O 0.9157031178474426
muscle O O 0.9998416900634766
fasciculation O O 0.9999408721923828
was O O 0.9999613761901855
significantly O O 0.9999902248382568
less O O 0.9999943971633911
with O O 0.9999861717224121
increasing O O 0.9999862909317017
the O O 0.9999902248382568
amount O O 0.9998888969421387
of O O 0.9998879432678223
precurarizing O O 0.9988935589790344
dose O O 0.9988025426864624
of O O 0.9946171641349792
rocuronium B B 0.9994655251502991
( O O 0.9996829032897949
P O O 0.9997794032096863
< O O 0.9999611377716064
0 O O 0.9999873638153076
. O O 0.9999960660934448
001 O O 0.9998979568481445
) O O 0.9999715089797974
. O O 0.999961256980896

Those O O 0.9999167919158936
of O O 0.9999597072601318
myalgia O O 0.9999949932098389
tend O O 0.9999864101409912
to O O 0.9999858140945435
decrease O O 0.9999933242797852
according O O 0.9999963045120239
to O O 0.9999648332595825
increasing O O 0.9999648332595825
the O O 0.9999915361404419
amount O O 0.9999223947525024
of O O 0.9998865127563477
precurarizing O O 0.9997250437736511
dose O O 0.9990885257720947
of O O 0.9976492524147034
rocuronium B B 0.9987505674362183
, O O 0.999765932559967
but O O 0.999977707862854
there O O 0.9999879598617554
was O O 0.9999880790710449
no O O 0.9999842643737793
significance O O 0.9999972581863403
( O O 0.9999704360961914
P O O 0.9990837574005127
= O O 0.9999445676803589
0 O O 0.9999920129776001
. O O 0.9999953508377075
072 O O 0.9999189376831055
) O O 0.9999701976776123
. O O 0.9999786615371704

The O O 0.9999773502349854
onset O O 0.9999804496765137
time O O 0.9999878406524658
of O O 0.9998205304145813
succinylcholine B B 0.9997413754463196
was O O 0.9999396800994873
significantly O O 0.9999932050704956
longer O O 0.9999889135360718
with O O 0.9999827146530151
increasing O O 0.9999849796295166
the O O 0.9999912977218628
amount O O 0.9999163150787354
of O O 0.999890923500061
precurarizing O O 0.998946487903595
dose O O 0.9987586736679077
of O O 0.9946876764297485
rocuronium B B 0.9993568062782288
( O O 0.999811589717865
P O O 0.9999334812164307
< O O 0.9999678134918213
0 O O 0.9999884366989136
. O O 0.9999967813491821
001 O O 0.9998419284820557
) O O 0.9999716281890869
. O O 0.9999611377716064

CONCLUSIONS O O 0.9990822076797485
: O O 0.999954104423523
Precurarization O O 0.978157103061676
with O O 0.9999176263809204
0 O O 0.999698281288147
. O O 0.9999842643737793
04 O O 0.9998183846473694
mg O O 0.999923825263977
/ O O 0.9999736547470093
kg O O 0.9998186230659485
rocuronium B B 0.999087929725647
was O O 0.9999442100524902
the O O 0.999985933303833
optimal O O 0.9999409914016724
dose O O 0.9999599456787109
considering O O 0.9999874830245972
the O O 0.9999959468841553
reduction O O 0.9999945163726807
in O O 0.9999879598617554
the O O 0.9999926090240479
incidence O O 0.9999922513961792
and O O 0.9999814033508301
severity O O 0.9999940395355225
of O O 0.999963641166687
fasciculation O O 0.999945878982544
and O O 0.9998929500579834
myalgia O O 0.9999979734420776
with O O 0.9999723434448242
acceptable O O 0.9998859167098999
onset O O 0.9999940395355225
time O O 0.9999926090240479
, O O 0.9999511241912842
and O O 0.999987006187439
the O O 0.9999943971633911
safe O O 0.9999852180480957
and O O 0.9999922513961792
effective O O 0.9999668598175049
precurarization O O 0.9999388456344604
. O O 0.9999786615371704

Absence O O 0.9994308352470398
of O O 0.999010443687439
PKC O B 0.8547089695930481
- O I 0.7701715230941772
alpha O I 0.9996092915534973
attenuates O O 0.9941425919532776
lithium B B 0.999883770942688
- O O 0.9998267292976379
induced O O 0.9999474287033081
nephrogenic O O 0.9999620914459229
diabetes O O 0.9999209642410278
insipidus O O 0.9999418258666992
. O O 0.9999405145645142

Lithium B B 0.9994111061096191
, O O 0.9998282194137573
an O O 0.9974309802055359
effective O O 0.802073061466217
antipsychotic O O 0.7959654927253723
, O O 0.9989681243896484
induces O O 0.9999210834503174
nephrogenic O O 0.9982744455337524
diabetes O O 0.9997811913490295
insipidus O O 0.9999418258666992
( O O 0.9999518394470215
NDI O O 0.9877903461456299
) O O 0.9999474287033081
in O O 0.999927282333374
40 O O 0.9999170303344727
% O O 0.9999891519546509
of O O 0.9999524354934692
patients O O 0.9999864101409912
. O O 0.9998992681503296

The O O 0.9999804496765137
decreased O O 0.9999890327453613
capacity O O 0.9999901056289673
to O O 0.9999587535858154
concentrate O O 0.9998632669448853
urine O O 0.9939121007919312
is O O 0.9999401569366455
likely O O 0.9999303817749023
due O O 0.999974250793457
to O O 0.9997958540916443
lithium B B 0.9998866319656372
acutely O O 0.999804675579071
disrupting O O 0.9998917579650879
the O O 0.9993044137954712
cAMP B O 0.6508868932723999
pathway O O 0.9998379945755005
and O O 0.999886155128479
chronically O O 0.9998176693916321
reducing O O 0.999703586101532
urea B B 0.9743080139160156
transporter O O 0.9926741719245911
( O O 0.9995110034942627
UT O O 0.7394618391990662
- O O 0.9794166088104248
A1 O O 0.4890344738960266
) O O 0.9990732669830322
and O O 0.999560534954071
water O O 0.6299843192100525
channel O O 0.9980893731117249
( O O 0.9993274211883545
AQP2 O O 0.509239912033081
) O O 0.998174786567688
expression O O 0.9993948936462402
in O O 0.9998195767402649
the O O 0.9999301433563232
inner O O 0.9971339702606201
medulla O O 0.9999760389328003
. O O 0.9999654293060303

Targeting O O 0.9990515112876892
an O O 0.9997100234031677
alternative O O 0.9978629946708679
signaling O O 0.9985849857330322
pathway O O 0.9993606209754944
, O O 0.9999368190765381
such O O 0.999849796295166
as O O 0.9997089505195618
PKC O O 0.8489425778388977
- O O 0.993036687374115
mediated O O 0.999660849571228
signaling O O 0.9995869994163513
, O O 0.9999663829803467
may O O 0.9999479055404663
be O O 0.999976396560669
an O O 0.9999597072601318
effective O O 0.9999547004699707
method O O 0.9999892711639404
of O O 0.999976396560669
treating O O 0.9998661279678345
lithium B B 0.9998078942298889
- O O 0.9997095465660095
induced O O 0.9998939037322998
polyuria O O 0.9999537467956543
. O O 0.9999690055847168

PKC O O 0.7857464551925659
- O O 0.9800242781639099
alpha O O 0.9610267281532288
null O O 0.999643087387085
mice O O 0.9999877214431763
( O O 0.9997929930686951
PKCa O O 0.9390292167663574
KO O O 0.9479315280914307
) O O 0.9999105930328369
and O O 0.9998973608016968
strain O O 0.9973936080932617
- O O 0.999953031539917
matched O O 0.9999284744262695
wild O O 0.9998956918716431
type O O 0.999996542930603
( O O 0.9998599290847778
WT O O 0.9975009560585022
) O O 0.9999723434448242
controls O O 0.9999903440475464
were O O 0.9999717473983765
treated O O 0.9999676942825317
with O O 0.9997003078460693
lithium B B 0.9998470544815063
for O O 0.9998456239700317
0 O O 0.9996206760406494
, O O 0.9999319314956665
3 O O 0.9994385838508606
or O O 0.9999587535858154
5 O O 0.9999388456344604
days O O 0.9999862909317017
. O O 0.9999773502349854

WT O O 0.7417802810668945
mice O O 0.9999593496322632
had O O 0.999976396560669
increased O O 0.9999850988388062
urine O O 0.9998261332511902
output O O 0.9999905824661255
and O O 0.9999722242355347
lowered O O 0.9999747276306152
urine O O 0.9995551705360413
osmolality O O 0.7655518651008606
after O O 0.9998548030853271
3 O O 0.9995940327644348
and O O 0.9999796152114868
5 O O 0.9999558925628662
days O O 0.9999924898147583
of O O 0.9999241828918457
treatment O O 0.9999597072601318
whereas O O 0.9994565844535828
PKCa O O 0.6196611523628235
KO O B 0.9140896201133728
mice O O 0.9993221759796143
had O O 0.9999804496765137
no O O 0.9999929666519165
change O O 0.9999983310699463
in O O 0.9999909400939941
urine O O 0.9998086094856262
output O O 0.9999879598617554
or O O 0.9999833106994629
concentration O O 0.9999773502349854
. O O 0.999975323677063

Western O O 0.9991162419319153
blot O O 0.9999938011169434
analysis O O 0.9999747276306152
revealed O O 0.999975323677063
that O O 0.9997413754463196
AQP2 O O 0.5563677549362183
expression O O 0.9999040365219116
in O O 0.9996795654296875
medullary O O 0.9995786547660828
tissues O O 0.9999803304672241
was O O 0.9999510049819946
lowered O O 0.9999468326568604
after O O 0.9999431371688843
3 O O 0.9994827508926392
and O O 0.9999802112579346
5 O O 0.9998658895492554
days O O 0.9999879598617554
in O O 0.9999687671661377
WT O O 0.9941243529319763
mice O O 0.9999939203262329
; O O 0.9999682903289795
however O O 0.9999808073043823
, O O 0.9999703168869019
AQP2 O O 0.64710932970047
was O O 0.9999309778213501
unchanged O O 0.9999637603759766
in O O 0.9997139573097229
PKCa O O 0.8958019018173218
KO O O 0.7639697194099426
. O O 0.999944806098938

Similar O O 0.9999376535415649
results O O 0.9999837875366211
were O O 0.999985933303833
observed O O 0.9999938011169434
with O O 0.9998292922973633
UT O O 0.7952168583869934
- O O 0.9540452361106873
A1 O O 0.6532701253890991
expression O O 0.9991815686225891
. O O 0.9999576807022095

Animals O O 0.9999126195907593
were O O 0.9999871253967285
also O O 0.9999583959579468
treated O O 0.9999347925186157
with O O 0.9994173049926758
lithium B B 0.9997592568397522
for O O 0.9996052384376526
6 O O 0.9995504021644592
weeks O O 0.9999837875366211
. O O 0.9999673366546631

Lithium B B 0.9993661046028137
- O O 0.9978412389755249
treated O O 0.999782383441925
WT O O 0.9891176819801331
mice O O 0.9999926090240479
had O O 0.9999852180480957
19 O O 0.9999681711196899
- O O 0.9999929666519165
fold O O 0.9999982118606567
increased O O 0.9999862909317017
urine O O 0.9999508857727051
output O O 0.9999914169311523
whereas O O 0.9980599284172058
treated O O 0.9985474944114685
PKCa O O 0.9482331275939941
KO O B 0.9635434150695801
animals O O 0.9985277652740479
had O O 0.9999861717224121
a O O 0.9999880790710449
4 O O 0.9999566078186035
- O O 0.999993085861206
fold O O 0.9999977350234985
increase O O 0.9999905824661255
in O O 0.9999781847000122
output O O 0.9999926090240479
. O O 0.9999786615371704

AQP2 O O 0.6411709189414978
and O O 0.9995102882385254
UT O O 0.9128754734992981
- O O 0.991314709186554
A1 O O 0.9239738583564758
expression O O 0.9999121427536011
was O O 0.9999470710754395
lowered O O 0.9999653100967407
in O O 0.9999113082885742
6 O O 0.9992095232009888
week O O 0.9999321699142456
lithium B B 0.9998764991760254
- O O 0.9994301199913025
treated O O 0.9997081160545349
WT O O 0.9983996748924255
animals O O 0.9998358488082886
whereas O O 0.9999352693557739
in O O 0.9999098777770996
treated O O 0.9994632601737976
PKCa O O 0.7159587740898132
KO O O 0.7441913485527039
mice O O 0.9999774694442749
, O O 0.9999569654464722
AQP2 O O 0.5548210740089417
was O O 0.999962568283081
only O O 0.9999675750732422
reduced O O 0.9999853372573853
by O O 0.9999730587005615
2 O O 0.9998598098754883
- O O 0.9999735355377197
fold O O 0.9999955892562866
and O O 0.9999665021896362
UT O O 0.9518807530403137
- O O 0.9952352643013
A1 O O 0.9598402976989746
expression O O 0.9999650716781616
was O O 0.9999868869781494
unaffected O O 0.9999847412109375
. O O 0.9999865293502808

Urinary O O 0.9992491602897644
sodium B B 0.998999297618866
, O O 0.9985228180885315
potassium B B 0.9989665746688843
and O O 0.9992849230766296
calcium B B 0.9985369443893433
were O O 0.999933123588562
elevated O O 0.9999486207962036
in O O 0.999828577041626
lithium B B 0.9997894167900085
- O O 0.9990178346633911
fed O O 0.9995916485786438
WT O O 0.995975911617279
but O O 0.9999527931213379
not O O 0.9998466968536377
in O O 0.9998358488082886
lithium B B 0.9993100166320801
- O O 0.9987680315971375
fed O O 0.9985541701316833
PKCa O O 0.568337082862854
KO O B 0.9432116150856018
mice O O 0.9643504619598389
. O O 0.9999680519104004

Our O O 0.999976634979248
data O O 0.9999934434890747
show O O 0.9999161958694458
that O O 0.9998225569725037
ablation O O 0.9999457597732544
of O O 0.9975075721740723
PKCa O O 0.5586086511611938
preserves O O 0.9719666838645935
AQP2 O O 0.5228884220123291
and O O 0.9980607628822327
UT O O 0.8616681098937988
- O O 0.9819714426994324
A1 O O 0.842199981212616
protein O O 0.9997170567512512
expression O O 0.9999477863311768
and O O 0.9999136924743652
localization O O 0.999811589717865
in O O 0.9998654127120972
lithium B B 0.9998371601104736
- O O 0.9995667338371277
induced O O 0.9998660087585449
NDI O O 0.9348010420799255
, O O 0.9999070167541504
and O O 0.999882698059082
prevents O O 0.9999336004257202
the O O 0.9999896287918091
development O O 0.999995231628418
of O O 0.9999804496765137
the O O 0.9999860525131226
severe O O 0.9999805688858032
polyuria O O 0.9999781847000122
associated O O 0.999987006187439
with O O 0.9998998641967773
lithium B B 0.9997578263282776
therapy O O 0.9995569586753845
. O O 0.9999716281890869

Is O O 0.9999785423278809
Dysguesia O O 0.9999861717224121
Going O O 0.9999337196350098
to O O 0.9999828338623047
be O O 0.999991774559021
a O O 0.9999794960021973
Rare O O 0.9999589920043945
or O O 0.9999769926071167
a O O 0.999971866607666
Common O O 0.9999310970306396
Side O O 0.9999589920043945
- O O 0.9999734163284302
effect O O 0.9999927282333374
of O O 0.9998596906661987
Amlodipine B B 0.9994816184043884
? O O 0.999955415725708

A O O 0.9998980760574341
very O O 0.999981164932251
rare O O 0.999971866607666
side O O 0.9999222755432129
- O O 0.9999561309814453
effect O O 0.999985933303833
of O O 0.999835729598999
amlodipine B B 0.9996533393859863
is O O 0.9997106194496155
dysguesia O O 0.999982476234436
. O O 0.9999282360076904

A O O 0.9999585151672363
review O O 0.999982476234436
of O O 0.9999755620956421
the O O 0.999983549118042
literature O O 0.9999616146087646
produced O O 0.9999908208847046
only O O 0.9999927282333374
one O O 0.9999959468841553
case O O 0.9999771118164062
. O O 0.9999513626098633

We O O 0.9999825954437256
report O O 0.999997615814209
a O O 0.9999949932098389
case O O 0.999997615814209
about O O 0.9999971389770508
a O O 0.9999935626983643
female O O 0.9999966621398926
with O O 0.999852180480957
essential O O 0.9976781010627747
hypertension O O 0.9836803674697876
on O O 0.9996548891067505
drug O O 0.9995393753051758
treatment O O 0.9999185800552368
with O O 0.9990453124046326
amlodipine B B 0.9993048906326294
developed O O 0.9998788833618164
loss O O 0.9999974966049194
of O O 0.999982476234436
taste O O 0.9983977675437927
sensation O O 0.9999873638153076
. O O 0.9999748468399048

Condition O O 0.9999574422836304
moderately O O 0.9999867677688599
improved O O 0.999995231628418
on O O 0.9998810291290283
stoppage O O 0.9998559951782227
of O O 0.9998602867126465
the O O 0.9997269511222839
drug O O 0.998307466506958
for O O 0.9999052286148071
25 O O 0.9999346733093262
days O O 0.9999737739562988
. O O 0.9999754428863525

We O O 0.9999053478240967
conclude O O 0.9997527003288269
that O O 0.9983857870101929
amlodipine B B 0.9997895359992981
can O O 0.9998475313186646
cause O O 0.9998838901519775
dysguesia O O 0.999992847442627
. O O 0.9999246597290039

Here O O 0.9999561309814453
, O O 0.9999730587005615
we O O 0.9999697208404541
describe O O 0.999994158744812
the O O 0.9999966621398926
clinical O O 0.9999940395355225
presentation O O 0.9999966621398926
and O O 0.9999662637710571
review O O 0.9999878406524658
the O O 0.9999955892562866
relevant O O 0.9999959468841553
literature O O 0.9999947547912598
on O O 0.9998432397842407
amlodipine B B 0.9997710585594177
and O O 0.9994714856147766
dysguesia O O 0.998580813407898
. O O 0.9999384880065918

Rhabdomyolysis O O 0.9992119073867798
in O O 0.9999282360076904
association O O 0.9999805688858032
with O O 0.9998301267623901
simvastatin B B 0.9987348914146423
and O O 0.9991090893745422
dosage O O 0.9999043941497803
increment O O 0.9999265670776367
in O O 0.9949581027030945
clarithromycin B B 0.9991567134857178
. O O 0.9999074935913086

Clarithromycin B B 0.9992550015449524
is O O 0.9991439580917358
the O O 0.9991419315338135
most O O 0.9986252784729004
documented O O 0.9988467693328857
cytochrome O O 0.46910685300827026
P450 O O 0.8420158624649048
3A4 O O 0.5679130554199219
( O O 0.9944065809249878
CYP3A4 O O 0.656087338924408
) O O 0.968421459197998
inhibitor O O 0.9176523685455322
to O O 0.9998495578765869
cause O O 0.9999288320541382
an O O 0.999962568283081
adverse O O 0.9998602867126465
interaction O O 0.999968409538269
with O O 0.9997958540916443
simvastatin B B 0.9981434345245361
. O O 0.9998300075531006

This O O 0.9999750852584839
particular O O 0.9999901056289673
case O O 0.9999877214431763
is O O 0.9999567270278931
of O O 0.9999477863311768
interest O O 0.9999902248382568
as O O 0.9999815225601196
rhabdomyolysis O O 0.999950647354126
only O O 0.9999536275863647
occurred O O 0.9999914169311523
after O O 0.9999595880508423
an O O 0.9999916553497314
increase O O 0.9999886751174927
in O O 0.9999847412109375
the O O 0.9999690055847168
dose O O 0.9997727274894714
of O O 0.9965117573738098
clarithromycin B B 0.9987432360649109
. O O 0.9999243021011353

The O O 0.999981164932251
patient O O 0.9999797344207764
developed O O 0.9999507665634155
raised O O 0.997818112373352
cardiac O O 0.9980266690254211
biomarkers O O 0.9984279870986938
without O O 0.999930739402771
any O O 0.9999650716781616
obvious O O 0.9999685287475586
cardiac O O 0.9999511241912842
issues O O 0.9999948740005493
, O O 0.9999818801879883
a O O 0.9999791383743286
phenomenon O O 0.9999946355819702
that O O 0.9999716281890869
has O O 0.9999814033508301
been O O 0.9999876022338867
linked O O 0.9999874830245972
to O O 0.9998669624328613
rhabdomyolysis O O 0.9998340606689453
previously O O 0.9999352693557739
. O O 0.9999648332595825

To O O 0.999970555305481
date O O 0.9999887943267822
, O O 0.9999555349349976
there O O 0.9999639987945557
has O O 0.9999700784683228
been O O 0.999994158744812
no O O 0.9999650716781616
reported O O 0.9999881982803345
effect O O 0.999975323677063
of O O 0.9997996687889099
rhabdomyolysis O O 0.7139403223991394
on O O 0.9997445940971375
the O O 0.9999662637710571
structure O O 0.9999911785125732
and O O 0.999972939491272
function O O 0.9999818801879883
of O O 0.999945878982544
cardiac O O 0.9996360540390015
muscle O O 0.9999402761459351
. O O 0.9999673366546631

Clinicians O O 0.9991005659103394
need O O 0.9999852180480957
to O O 0.9999903440475464
be O O 0.9999942779541016
aware O O 0.9999876022338867
of O O 0.999954104423523
prescribing O O 0.999749481678009
concomitant O O 0.976487398147583
medications O O 0.9989854693412781
that O O 0.999876856803894
increase O O 0.9998778104782104
the O O 0.9999918937683105
risk O O 0.999997615814209
of O O 0.9999779462814331
myopathy O O 0.9999939203262329
or O O 0.9998511075973511
inhibit O O 0.999292254447937
the O O 0.9996296167373657
CYP3A4 O O 0.7062469720840454
enzyme O O 0.9986224174499512
. O O 0.9999598264694214

Our O O 0.9999778270721436
case O O 0.9999855756759644
suggests O O 0.9999501705169678
that O O 0.9998145699501038
troponin O O 0.8556398749351501
elevation O O 0.9988934397697449
could O O 0.9997519850730896
be O O 0.9998847246170044
associated O O 0.9999536275863647
with O O 0.9998321533203125
statin B B 0.9930408000946045
induced O O 0.9991642236709595
rhabdomyolysis O O 0.9999164342880249
, O O 0.9999758005142212
which O O 0.9999898672103882
may O O 0.9999808073043823
warrant O O 0.9999903440475464
further O O 0.9999961853027344
studies O O 0.9999955892562866
. O O 0.999980092048645

Characterization O O 0.9999657869338989
of O O 0.9999289512634277
a O O 0.9999208450317383
novel O O 0.9994809031486511
BCHE O O 0.5107258558273315
" O O 0.9987854361534119
silent O O 0.9984633922576904
" O O 0.9999604225158691
allele O O 0.9997605681419373
: O O 0.9996084570884705
point O O 0.996124804019928
mutation O O 0.9990487694740295
( O O 0.9976574182510376
p O O 0.9252154231071472
. O O 0.9989194869995117
Val204Asp O O 0.8033757209777832
) O O 0.9998236298561096
causes O O 0.9999285936355591
loss O O 0.999994158744812
of O O 0.9999796152114868
activity O O 0.9998138546943665
and O O 0.9999791383743286
prolonged O O 0.9999845027923584
apnea O O 0.9998747110366821
with O O 0.9994561076164246
suxamethonium B B 0.9989038705825806
. O O 0.9997722506523132

Butyrylcholinesterase O O 0.48472604155540466
deficiency O O 0.9997945427894592
is O O 0.9999762773513794
characterized O O 0.9999955892562866
by O O 0.9999911785125732
prolonged O O 0.9999887943267822
apnea O O 0.9999159574508667
after O O 0.999921441078186
the O O 0.9999823570251465
use O O 0.9999439716339111
of O O 0.9999055862426758
muscle O O 0.9968666434288025
relaxants O O 0.9740304946899414
( O O 0.9993528723716736
suxamethonium B B 0.9981174468994141
or O O 0.9826543927192688
mivacurium B B 0.9981642365455627
) O O 0.9998345375061035
in O O 0.9999643564224243
patients O O 0.9999927282333374
who O O 0.9999735355377197
have O O 0.9999721050262451
mutations O O 0.9999904632568359
in O O 0.9999629259109497
the O O 0.9999381303787231
BCHE O O 0.8399868011474609
gene O O 0.999904990196228
. O O 0.9999518394470215

Here O O 0.9999837875366211
, O O 0.9999822378158569
we O O 0.9999741315841675
report O O 0.9999966621398926
a O O 0.9999949932098389
case O O 0.9999955892562866
of O O 0.999984622001648
prolonged O O 0.9999656677246094
neuromuscular O O 0.9999954700469971
block O O 0.9999977350234985
after O O 0.9998962879180908
administration O O 0.9999243021011353
of O O 0.9993894100189209
suxamethonium B B 0.9994370341300964
leading O O 0.9998403787612915
to O O 0.9999910593032837
the O O 0.9999967813491821
discovery O O 0.9999949932098389
of O O 0.9999769926071167
a O O 0.999958872795105
novel O O 0.9998965263366699
BCHE O O 0.9869459271430969
variant O O 0.9999595880508423
( O O 0.9997033476829529
c O O 0.9162977933883667
. O O 0.9963447451591492
695T O O 0.9089977741241455
> O O 0.9311785697937012
A O O 0.8304603695869446
, O O 0.9784599542617798
p O O 0.900140106678009
. O O 0.9968900084495544
Val204Asp O O 0.9675275683403015
) O O 0.9999631643295288
. O O 0.9999706745147705

Inhibition O O 0.9933217167854309
studies O O 0.9998863935470581
, O O 0.9999428987503052
kinetic O O 0.9998193383216858
analysis O O 0.9999953508377075
and O O 0.9999620914459229
molecular O O 0.9999740123748779
dynamics O O 0.9999477863311768
were O O 0.9999610185623169
undertaken O O 0.9999879598617554
to O O 0.9999914169311523
understand O O 0.9999933242797852
how O O 0.9999734163284302
this O O 0.999563992023468
mutation O O 0.9999276399612427
disrupts O O 0.9999223947525024
the O O 0.9999502897262573
catalytic O O 0.9933239817619324
triad O O 0.9992796778678894
and O O 0.9999605417251587
determines O O 0.9999654293060303
a O O 0.9999725818634033
" O O 0.9999459981918335
silent O O 0.9999773502349854
" O O 0.999987006187439
phenotype O O 0.9999943971633911
. O O 0.9999616146087646

Low O O 0.9997356534004211
activity O O 0.9996434450149536
of O O 0.9997807145118713
patient O O 0.8937670588493347
plasma O O 0.9614620208740234
butyrylcholinesterase O B 0.8909157514572144
with O O 0.9976209998130798
butyrylthiocholine B B 0.9797088503837585
( O O 0.9978947043418884
BTC B B 0.8599750995635986
) O O 0.9932373762130737
and O O 0.9950503706932068
benzoylcholine B B 0.9959245920181274
, O O 0.9997161030769348
and O O 0.999797523021698
values O O 0.9994722008705139
of O O 0.9968714118003845
dibucaine B B 0.9985640645027161
and O O 0.9777581095695496
fluoride B B 0.999776303768158
numbers O O 0.9969430565834045
fit O O 0.9999878406524658
with O O 0.999970555305481
heterozygous O O 0.9998534917831421
atypical O O 0.9986819624900818
silent O O 0.999903678894043
genotype O O 0.9998635053634644
. O O 0.9999443292617798

Electrophoretic O O 0.9991735816001892
analysis O O 0.9999796152114868
of O O 0.9998800754547119
plasma O O 0.9796671867370605
BChE O O 0.9518803954124451
of O O 0.9997298121452332
the O O 0.999976396560669
proband O O 0.9999349117279053
and O O 0.9998579025268555
his O O 0.9999426603317261
mother O O 0.9999927282333374
showed O O 0.9999738931655884
that O O 0.9999154806137085
patient O O 0.9997746348381042
has O O 0.9998675584793091
a O O 0.9999779462814331
reduced O O 0.9999850988388062
amount O O 0.9999431371688843
of O O 0.9998040795326233
tetrameric O O 0.9704590439796448
enzyme O O 0.9253286123275757
in O O 0.9997676014900208
plasma O O 0.9998732805252075
and O O 0.9999544620513916
that O O 0.9999188184738159
minor O O 0.9995521903038025
fast O O 0.9957011342048645
- O O 0.999937891960144
moving O O 0.9999237060546875
BChE O O 0.9497383832931519
components O O 0.9999020099639893
: O O 0.9982911944389343
monomer O O 0.9598535895347595
, O O 0.994561493396759
dimer O O 0.9837325215339661
, O O 0.9986987113952637
and O O 0.9987226128578186
monomer O O 0.9450252056121826
- O O 0.9963586926460266
albumin O O 0.9563688039779663
conjugate O O 0.9882206916809082
are O O 0.9999421834945679
missing O O 0.9997872710227966
. O O 0.9999617338180542

Kinetic O O 0.999398946762085
analysis O O 0.9999622106552124
showed O O 0.9999490976333618
that O O 0.9997598528862
the O O 0.9993027448654175
p O O 0.7303775548934937
. O O 0.9772909283638
Val204Asp O O 0.7487398982048035
/ O O 0.9959553480148315
p O O 0.6858131885528564
. O O 0.9202534556388855
Asp70Gly O O 0.8286071419715881
- O O 0.6529647707939148
p O O 0.37875592708587646
. O O 0.8373427987098694
Ala539Thr O O 0.6147624850273132
BChE O O 0.721734881401062
displays O O 0.9997488856315613
a O O 0.9998911619186401
pure O O 0.9986763596534729
Michaelian O O 0.9999396800994873
behavior O O 0.999956488609314
with O O 0.9997171759605408
BTC B O 0.5356793403625488
as O O 0.9997217059135437
the O O 0.999764621257782
substrate O O 0.9999374151229858
. O O 0.9999443292617798

Both O O 0.9989385008811951
catalytic O O 0.9934989213943481
parameters O O 0.9999369382858276
Km O O 0.9582273960113525
= O O 0.9995397329330444
265 O O 0.9829828143119812
uM O O 0.9999394416809082
for O O 0.9972694516181946
BTC B O 0.6149004697799683
, O O 0.9999206066131592
two O O 0.9999854564666748
times O O 0.9999927282333374
higher O O 0.9998352527618408
than O O 0.9999707937240601
that O O 0.9999489784240723
of O O 0.9999277591705322
the O O 0.9999043941497803
atypical O O 0.9959845542907715
enzyme O O 0.988301694393158
, O O 0.9998266100883484
and O O 0.9998914003372192
a O O 0.9999514818191528
low O O 0.9998099207878113
Vmax O O 0.6077255010604858
are O O 0.9999111890792847
consistent O O 0.9999853372573853
with O O 0.9999901056289673
the O O 0.9999898672103882
absence O O 0.9999289512634277
of O O 0.9998681545257568
activity O O 0.9952827095985413
against O O 0.9986768364906311
suxamethonium B B 0.9991638660430908
. O O 0.9998212456703186

Molecular O O 0.9999643564224243
dynamic O O 0.9998021721839905
( O O 0.9997597336769104
MD O O 0.9983441829681396
) O O 0.9999352693557739
simulations O O 0.9999316930770874
showed O O 0.9999698400497437
that O O 0.9999480247497559
the O O 0.9999790191650391
overall O O 0.9999028444290161
effect O O 0.9999806880950928
of O O 0.9999314546585083
the O O 0.9999369382858276
mutation O O 0.9993058443069458
p O O 0.5713063478469849
. O O 0.9669249653816223
Val204Asp O O 0.712914228439331
is O O 0.9998558759689331
disruption O O 0.9999489784240723
of O O 0.9997913241386414
hydrogen B O 0.7445421814918518
bonding O O 0.9986068606376648
between O O 0.9984966516494751
Gln223 O B 0.9586431384086609
and O O 0.9856599569320679
Glu441 O B 0.9523442387580872
, O O 0.9996929168701172
leading O O 0.9997186064720154
Ser198 O O 0.8306053280830383
and O O 0.99379962682724
His438 O O 0.6675791144371033
to O O 0.9998800754547119
move O O 0.9999872446060181
away O O 0.9999237060546875
from O O 0.9999732971191406
each O O 0.9999356269836426
other O O 0.9999303817749023
with O O 0.9999533891677856
subsequent O O 0.9999833106994629
disruption O O 0.9999715089797974
of O O 0.9999527931213379
the O O 0.9999319314956665
catalytic O O 0.9969465136528015
triad O O 0.9989181756973267
functionality O O 0.999976634979248
regardless O O 0.9999351501464844
of O O 0.9999769926071167
the O O 0.999987006187439
type O O 0.9999459981918335
of O O 0.9988707900047302
substrate O O 0.9956472516059875
. O O 0.9999517202377319

MD O O 0.5627069473266602
also O O 0.9999605417251587
showed O O 0.9999583959579468
that O O 0.9999303817749023
the O O 0.9998248219490051
enzyme O O 0.9622405171394348
volume O O 0.9916714429855347
is O O 0.9997857213020325
increased O O 0.9995163679122925
, O O 0.9999616146087646
suggesting O O 0.9999452829360962
a O O 0.9999455213546753
pre O O 0.9978300929069519
- O O 0.9998252987861633
denaturation O O 0.99968421459198
state O O 0.9999796152114868
. O O 0.9999661445617676

This O O 0.9999569654464722
fits O O 0.99998939037323
with O O 0.9999843835830688
the O O 0.9999858140945435
reduced O O 0.9999650716781616
concentration O O 0.9998329877853394
of O O 0.999546468257904
p O O 0.5049594640731812
. O O 0.8097612857818604
Ala204Asp O O 0.383347749710083
/ O O 0.97736656665802
p O O 0.6027876138687134
. O O 0.6591014266014099
Asp70Gly O O 0.7249961495399475
- O O 0.6392368078231812
p O O 0.4202362596988678
. O O 0.6374892592430115
Ala539Thr O O 0.5206141471862793
tetrameric O O 0.8341200947761536
enzyme O O 0.9784664511680603
in O O 0.9998828172683716
the O O 0.9999533891677856
plasma O O 0.999920129776001
and O O 0.9999673366546631
non O O 0.9999309778213501
- O O 0.99997878074646
detectable O O 0.9999954700469971
fast O O 0.9944410920143127
moving O O 0.9843631386756897
- O O 0.9947112798690796
bands O O 0.999920129776001
on O O 0.9999808073043823
electrophoresis O O 0.9999732971191406
gels O O 0.9999887943267822
. O O 0.9999740123748779

Delayed O O 0.9999473094940186
anemia O O 0.9997879862785339
after O O 0.9999121427536011
treatment O O 0.9999697208404541
with O O 0.9997147917747498
injectable O O 0.9997400641441345
artesunate B B 0.9937798380851746
in O O 0.9982615113258362
the O O 0.9996610879898071
Democratic O O 0.9349226951599121
Republic O O 0.9901338219642639
of O O 0.9967145919799805
the O O 0.9989799857139587
Congo O O 0.9320718050003052
: O O 0.999980092048645
a O O 0.9999661445617676
manageable O O 0.999970555305481
issue O O 0.9999939203262329
. O O 0.9999765157699585

Cases O O 0.9999786615371704
of O O 0.9999696016311646
delayed O O 0.999945878982544
hemolytic O O 0.9995730519294739
anemia O O 0.9998082518577576
have O O 0.9999741315841675
been O O 0.9999877214431763
described O O 0.9999945163726807
after O O 0.9998160004615784
treatment O O 0.9999710321426392
with O O 0.9997974038124084
injectable O O 0.9991446733474731
artesunate B B 0.9975234866142273
, O O 0.9998867511749268
the O O 0.999983549118042
current O O 0.9999637603759766
World O O 0.99798583984375
Health O O 0.9902247786521912
Organization O O 0.9999195337295532
( O O 0.9999309778213501
WHO O O 0.9933444261550903
) O O 0.9966116547584534
- O O 0.9999325275421143
recommended O O 0.9999091625213623
first O O 0.9998329877853394
- O O 0.999904990196228
line O O 0.9981716871261597
drug O O 0.9979392886161804
for O O 0.9999111890792847
the O O 0.9999819993972778
treatment O O 0.999980092048645
of O O 0.9999865293502808
severe O O 0.999970555305481
malaria O O 0.9999829530715942
. O O 0.999974250793457

A O O 0.999969482421875
total O O 0.9999924898147583
of O O 0.9999881982803345
350 O O 0.999985933303833
patients O O 0.9999970197677612
( O O 0.9999765157699585
215 O O 0.9999866485595703
[ O O 0.9999223947525024
61 O O 0.9999954700469971
. O O 0.9999918937683105
4 O O 0.9999821186065674
% O O 0.9999715089797974
] O O 0.9999774694442749
< O O 0.9999898672103882
5 O O 0.9999955892562866
years O O 0.9999978542327881
of O O 0.9999971389770508
age O O 0.9999929666519165
and O O 0.9999483823776245
135 O O 0.9995794892311096
[ O O 0.9999465942382812
38 O O 0.9999958276748657
. O O 0.9999909400939941
6 O O 0.9999916553497314
% O O 0.9999798536300659
] O O 0.9999631643295288
> O O 0.9999886751174927
5 O O 0.9999938011169434
years O O 0.9999973773956299
of O O 0.999996542930603
age O O 0.999950647354126
) O O 0.9999693632125854
were O O 0.9999837875366211
followed O O 0.9999873638153076
- O O 0.9999845027923584
up O O 0.9999955892562866
after O O 0.9999083280563354
treatment O O 0.999961256980896
with O O 0.9998125433921814
injectable O O 0.9992520213127136
artesunate B B 0.9976832866668701
for O O 0.99947589635849
severe O O 0.9998183846473694
malaria O O 0.9994719624519348
in O O 0.9998030066490173
hospitals O O 0.9999648332595825
and O O 0.9999457597732544
health O O 0.9999855756759644
centers O O 0.9999977350234985
of O O 0.9999872446060181
the O O 0.9999902248382568
Democratic O O 0.9993744492530823
Republic O O 0.9999969005584717
of O O 0.9992985725402832
the O O 0.9998912811279297
Congo O O 0.910526692867279
. O O 0.99996018409729

Complete O O 0.9998941421508789
series O O 0.999970555305481
of O O 0.9999644756317139
hemoglobin O O 0.9665730595588684
( O O 0.9980282187461853
Hb O O 0.5831718444824219
) O O 0.9997324347496033
measurements O O 0.9999545812606812
were O O 0.9999697208404541
available O O 0.9999899864196777
for O O 0.9999432563781738
201 O O 0.9995545744895935
patients O O 0.9999884366989136
. O O 0.9999638795852661

A O O 0.9999617338180542
decrease O O 0.9999946355819702
in O O 0.9999841451644897
Hb O O 0.7356048226356506
levels O O 0.9996179342269897
between O O 0.9998427629470825
2 O O 0.9999005794525146
and O O 0.999976634979248
5 O O 0.9999827146530151
g O O 0.9999945163726807
/ O O 0.9999927282333374
dL O O 0.9999969005584717
was O O 0.9999805688858032
detected O O 0.9999938011169434
in O O 0.999971866607666
23 O O 0.9999972581863403
( O O 0.9999732971191406
11 O O 0.9999954700469971
. O O 0.9999947547912598
4 O O 0.9999904632568359
% O O 0.9999954700469971
) O O 0.9999613761901855
patients O O 0.9999967813491821
during O O 0.9999595880508423
the O O 0.9999936819076538
follow O O 0.9999837875366211
- O O 0.999991774559021
up O O 0.9999940395355225
period O O 0.9999953508377075
. O O 0.9999724626541138

For O O 0.9999346733093262
five O O 0.9999470710754395
patients O O 0.9999934434890747
, O O 0.9999746084213257
Hb O O 0.7413917183876038
levels O O 0.9994144439697266
decreased O O 0.9999681711196899
below O O 0.9999845027923584
5 O O 0.9999822378158569
g O O 0.9999790191650391
/ O O 0.9999923706054688
dL O O 0.9999940395355225
during O O 0.9999792575836182
at O O 0.9999961853027344
least O O 0.9999980926513672
one O O 0.9999984502792358
follow O O 0.9999908208847046
- O O 0.9999940395355225
up O O 0.999995231628418
visit O O 0.9999971389770508
. O O 0.9999687671661377

All O O 0.9999479055404663
cases O O 0.9999887943267822
of O O 0.9999704360961914
delayed O O 0.9998869895935059
anemia O O 0.9993036985397339
were O O 0.9999711513519287
clinically O O 0.9999886751174927
manageable O O 0.9999884366989136
and O O 0.9999793767929077
resolved O O 0.9999936819076538
within O O 0.9999927282333374
one O O 0.9999953508377075
month O O 0.9999971389770508
. O O 0.9999821186065674

Regulation O O 0.9987714886665344
of O O 0.998198926448822
signal O O 0.9360738396644592
transducer O O 0.9907487034797668
and O O 0.984499454498291
activator O O 0.9527202844619751
of O O 0.987726628780365
transcription O O 0.9973722696304321
3 O O 0.9814738631248474
and O O 0.9994639754295349
apoptotic O O 0.9946836829185486
pathways O O 0.9998626708984375
by O O 0.9995667338371277
betaine B B 0.9273403882980347
attenuates O O 0.9944530129432678
isoproterenol B B 0.9997753500938416
- O O 0.9998025298118591
induced O O 0.9999517202377319
acute O O 0.9999881982803345
myocardial O O 0.9999988079071045
injury O O 0.999997615814209
in O O 0.999956488609314
rats O O 0.9999780654907227
. O O 0.9999663829803467

The O O 0.9999916553497314
present O O 0.9999889135360718
study O O 0.9999868869781494
was O O 0.9999898672103882
designed O O 0.9999964237213135
to O O 0.9999943971633911
investigate O O 0.9999359846115112
the O O 0.9999457597732544
cardioprotective O O 0.9999825954437256
effects O O 0.999932050704956
of O O 0.9992520213127136
betaine B B 0.9731929302215576
on O O 0.9990599751472473
acute O O 0.9999536275863647
myocardial O O 0.9999974966049194
ischemia O O 0.9999879598617554
induced O O 0.9999817609786987
experimentally O O 0.9999827146530151
in O O 0.9999656677246094
rats O O 0.9999785423278809
focusing O O 0.9999550580978394
on O O 0.9983574748039246
regulation O O 0.9997363686561584
of O O 0.9992172718048096
signal O O 0.9584119319915771
transducer O O 0.9870445132255554
and O O 0.9729591012001038
activator O O 0.9694945812225342
of O O 0.9843446612358093
transcription O O 0.9952930808067322
3 O O 0.9879536628723145
( O O 0.9995920062065125
STAT3 O O 0.9141004085540771
) O O 0.999664306640625
and O O 0.9996795654296875
apoptotic O O 0.9974578022956848
pathways O O 0.9999097585678101
as O O 0.999964714050293
the O O 0.9999810457229614
potential O O 0.9999853372573853
mechanism O O 0.9999918937683105
underlying O O 0.9999814033508301
the O O 0.9999828338623047
drug O O 0.9995774626731873
effect O O 0.9999675750732422
. O O 0.9999707937240601

Male O O 0.9999597072601318
Sprague O O 0.9999076128005981
Dawley O O 0.999992847442627
rats O O 0.999995231628418
were O O 0.9999750852584839
treated O O 0.9999754428863525
with O O 0.9996496438980103
betaine B B 0.9466137290000916
( O O 0.9968319535255432
100 O O 0.9956199526786804
, O O 0.9983217120170593
200 O O 0.9114479422569275
, O O 0.9972284436225891
and O O 0.9988804459571838
400 O O 0.9983977675437927
mg O O 0.9998981952667236
/ O O 0.9999622106552124
kg O O 0.999992847442627
) O O 0.9999582767486572
orally O O 0.9988104104995728
for O O 0.9999352693557739
40 O O 0.9999628067016602
days O O 0.9999935626983643
. O O 0.9999792575836182

Acute O O 0.999954104423523
myocardial O O 0.9999980926513672
ischemic O O 0.9999933242797852
injury O O 0.9999948740005493
was O O 0.9999802112579346
induced O O 0.9999934434890747
in O O 0.9999841451644897
rats O O 0.9999759197235107
by O O 0.9999527931213379
subcutaneous O O 0.9999321699142456
injection O O 0.9999839067459106
of O O 0.9996838569641113
isoproterenol B B 0.9992772936820984
( O O 0.9994454979896545
85 O O 0.9970980882644653
mg O O 0.9998595714569092
/ O O 0.9998573064804077
kg O O 0.999984860420227
) O O 0.9999375343322754
, O O 0.9999556541442871
for O O 0.9999513626098633
two O O 0.9999910593032837
consecutive O O 0.9999924898147583
days O O 0.9999955892562866
. O O 0.9999819993972778

Serum O O 0.9988827109336853
cardiac O O 0.9965841770172119
marker O O 0.9818004369735718
enzyme O O 0.9708890914916992
, O O 0.9998778104782104
histopathological O O 0.9999573230743408
variables O O 0.999988317489624
and O O 0.9999499320983887
expression O O 0.9999414682388306
of O O 0.9982770681381226
protein O O 0.9990977048873901
levels O O 0.9998049139976501
were O O 0.9999454021453857
analyzed O O 0.9999243021011353
. O O 0.9999452829360962

Oral O O 0.9997292160987854
administration O O 0.999954104423523
of O O 0.9995548129081726
betaine B B 0.9891920685768127
( O O 0.999294638633728
200 O O 0.9978187084197998
and O O 0.9993973970413208
400 O O 0.9974305033683777
mg O O 0.9998672008514404
/ O O 0.9999227523803711
kg O O 0.9999916553497314
) O O 0.9999014139175415
significantly O O 0.9999663829803467
reduced O O 0.9999735355377197
the O O 0.9999802112579346
level O O 0.9999648332595825
of O O 0.999695897102356
cardiac O O 0.9671754837036133
marker O O 0.9375609159469604
enzyme O O 0.45204344391822815
in O O 0.9997594952583313
the O O 0.9999291896820068
serum O O 0.9992401599884033
and O O 0.9999403953552246
prevented O O 0.9999386072158813
left O O 0.9999839067459106
ventricular O O 0.9999948740005493
remodeling O O 0.999990701675415
. O O 0.9999560117721558

Western O O 0.9940676689147949
blot O O 0.9999916553497314
analysis O O 0.9999492168426514
showed O O 0.9999724626541138
that O O 0.9997480511665344
isoproterenol B B 0.999629020690918
- O O 0.9995181560516357
induced O O 0.999847412109375
phosphorylation O O 0.9902114272117615
of O O 0.994312047958374
STAT3 O O 0.6826978921890259
was O O 0.9999297857284546
maintained O O 0.9998409748077393
or O O 0.9999130964279175
further O O 0.9999468326568604
enhanced O O 0.9999837875366211
by O O 0.9999226331710815
betaine B B 0.9170438051223755
treatment O O 0.9996861219406128
in O O 0.9995214939117432
myocardium O O 0.9999958276748657
. O O 0.9999637603759766

Furthermore O O 0.9999210834503174
, O O 0.9993417859077454
betaine B B 0.9939749836921692
( O O 0.996826171875
200 O O 0.9969322681427002
and O O 0.9989833235740662
400 O O 0.9982612729072571
mg O O 0.9997970461845398
/ O O 0.9998805522918701
kg O O 0.9999767541885376
) O O 0.9995442032814026
treatment O O 0.999786913394928
increased O O 0.9997591376304626
the O O 0.9999731779098511
ventricular O O 0.9998652935028076
expression O O 0.9997062087059021
of O O 0.9962528944015503
Bcl O O 0.7141013741493225
- O O 0.9809991121292114
2 O O 0.9312162399291992
and O O 0.9998981952667236
reduced O O 0.9999749660491943
the O O 0.9999697208404541
level O O 0.9999374151229858
of O O 0.9996925592422485
Bax O O 0.8382729291915894
, O O 0.9999176263809204
therefore O O 0.9999781847000122
causing O O 0.999981164932251
a O O 0.9999918937683105
significant O O 0.9999927282333374
increase O O 0.9999849796295166
in O O 0.9999871253967285
the O O 0.9999881982803345
ratio O O 0.9999600648880005
of O O 0.9999125003814697
Bcl O O 0.687961220741272
- O O 0.9824999570846558
2 O O 0.9858506321907043
/ O O 0.9993929862976074
Bax O O 0.5669681429862976
. O O 0.9999727010726929

The O O 0.9999520778656006
protective O O 0.9998595714569092
role O O 0.9999574422836304
of O O 0.9995467066764832
betaine B B 0.9042567610740662
on O O 0.9987049102783203
myocardial O O 0.9999959468841553
damage O O 0.9999819993972778
was O O 0.999962568283081
further O O 0.9999743700027466
confirmed O O 0.9999749660491943
by O O 0.9999935626983643
histopathological O O 0.9999827146530151
examination O O 0.9999971389770508
. O O 0.9999732971191406

In O O 0.9999285936355591
summary O O 0.9999790191650391
, O O 0.9999467134475708
our O O 0.9999158382415771
results O O 0.9999874830245972
showed O O 0.9999502897262573
that O O 0.9994353652000427
betaine B B 0.992155909538269
pretreatment O O 0.9986245632171631
attenuated O O 0.999448835849762
isoproterenol B B 0.9997177720069885
- O O 0.9997474551200867
induced O O 0.9999281167984009
acute O O 0.9999828338623047
myocardial O O 0.9999977350234985
ischemia O O 0.999987006187439
via O O 0.9998823404312134
the O O 0.9997261166572571
regulation O O 0.9998956918716431
of O O 0.9995195865631104
STAT3 O O 0.8299023509025574
and O O 0.9994877576828003
apoptotic O O 0.9960189461708069
pathways O O 0.9998927116394043
. O O 0.999924898147583

Quetiapine B B 0.9980798959732056
- O O 0.9996333122253418
induced O O 0.9999420642852783
neutropenia O O 0.9999897480010986
in O O 0.999974250793457
a O O 0.9999862909317017
bipolar O O 0.9632226824760437
patient O O 0.999969482421875
with O O 0.9999560117721558
hepatocellular O O 0.9994882345199585
carcinoma O O 0.999854326248169
. O O 0.9999525547027588

OBJECTIVE O O 0.9873401522636414
: O O 0.9980554580688477
Quetiapine B B 0.9995484948158264
is O O 0.9982879757881165
a O O 0.9960481524467468
dibenzothiazepine O B 0.9725964069366455
derivative O O 0.6402757167816162
, O O 0.9998037219047546
similar O O 0.9999407529830933
to O O 0.9968302845954895
clozapine B B 0.9993859529495239
, O O 0.9998766183853149
which O O 0.999879002571106
has O O 0.9999558925628662
the O O 0.9999866485595703
highest O O 0.999975323677063
risk O O 0.9999932050704956
of O O 0.9999878406524658
causing O O 0.9999451637268066
blood O O 0.9995982050895691
dyscrasias O O 0.9999954700469971
, O O 0.999984860420227
especially O O 0.9999266862869263
neutropenia O O 0.9999819993972778
. O O 0.9998853206634521

There O O 0.9999661445617676
are O O 0.9999648332595825
some O O 0.9999755620956421
case O O 0.9999479055404663
reports O O 0.999996542930603
about O O 0.9998749494552612
this O O 0.9999076128005981
side O O 0.9999399185180664
effect O O 0.9999663829803467
of O O 0.9988734126091003
quetiapine B B 0.9989578723907471
, O O 0.999650239944458
but O O 0.9999136924743652
possible O O 0.9997114539146423
risk O O 0.9999185800552368
factors O O 0.9999970197677612
are O O 0.9999843835830688
seldom O O 0.9999929666519165
discussed O O 0.9999934434890747
and O O 0.9999774694442749
identified O O 0.9999854564666748
. O O 0.9999624490737915

A O O 0.9999644756317139
case O O 0.999992847442627
of O O 0.9999659061431885
a O O 0.9999823570251465
patient O O 0.9999881982803345
with O O 0.9999662637710571
hepatocellular O O 0.9995224475860596
carcinoma O O 0.9998742341995239
that O O 0.9999403953552246
developed O O 0.9999773502349854
neutropenia O O 0.9999909400939941
after O O 0.9998047947883606
treatment O O 0.9999426603317261
with O O 0.9979331493377686
quetiapine B B 0.9985198378562927
is O O 0.9998903274536133
described O O 0.9999918937683105
here O O 0.9999920129776001
. O O 0.9999847412109375

CASE O O 0.9998637437820435
REPORT O O 0.9999974966049194
: O O 0.9999691247940063
A O O 0.9999943971633911
62 O O 0.9999978542327881
- O O 0.9999806880950928
year O O 0.9999896287918091
- O O 0.999988317489624
old O O 0.9999449253082275
Taiwanese O O 0.9921493530273438
widow O O 0.999876856803894
with O O 0.9999126195907593
bipolar O O 0.9785741567611694
disorder O O 0.9999576807022095
was O O 0.9999816417694092
diagnosed O O 0.9999979734420776
with O O 0.9999904632568359
hepatocellular O O 0.9996837377548218
carcinoma O O 0.999915599822998
at O O 0.9999842643737793
age O O 0.9999911785125732
60 O O 0.9999254941940308
. O O 0.9999836683273315

She O O 0.9999681711196899
developed O O 0.9999873638153076
leucopenia O O 0.9997305274009705
after O O 0.9999245405197144
being O O 0.9999688863754272
treated O O 0.9999444484710693
with O O 0.9991747736930847
quetiapine B B 0.9984807372093201
. O O 0.9999173879623413

After O O 0.9999353885650635
quetiapine B B 0.9989686012268066
was O O 0.9999042749404907
discontinued O O 0.9999294281005859
, O O 0.9999809265136719
her O O 0.9999912977218628
white O O 0.9999960660934448
blood O O 0.9999915361404419
cell O O 0.9999856948852539
count O O 0.9999545812606812
returned O O 0.9999899864196777
to O O 0.9999957084655762
normal O O 0.9999949932098389
. O O 0.9999852180480957

CONCLUSIONS O O 0.9989759922027588
: O O 0.9999768733978271
Although O O 0.9999716281890869
neutropenia O O 0.9999412298202515
is O O 0.9999692440032959
not O O 0.999967098236084
a O O 0.9999666213989258
common O O 0.9999631643295288
side O O 0.9999580383300781
effect O O 0.9999854564666748
of O O 0.999872088432312
quetiapine B B 0.998976469039917
, O O 0.9997627139091492
physicians O O 0.9999936819076538
should O O 0.9999830722808838
be O O 0.9999973773956299
cautious O O 0.9999957084655762
about O O 0.9999958276748657
its O O 0.9999679327011108
presentation O O 0.9999958276748657
and O O 0.9999960660934448
associated O O 0.9999830722808838
risk O O 0.9999723434448242
factors O O 0.9999986886978149
. O O 0.9999788999557495

Hepatic O O 0.9995046854019165
dysfunction O O 0.9999744892120361
may O O 0.9999382495880127
be O O 0.9999654293060303
one O O 0.9999746084213257
of O O 0.9999527931213379
the O O 0.9999873638153076
possible O O 0.9999338388442993
risk O O 0.9999759197235107
factors O O 0.9999971389770508
, O O 0.9999445676803589
and O O 0.9999170303344727
concomitant O O 0.9999772310256958
fever O O 0.9999264478683472
may O O 0.9999662637710571
be O O 0.9999749660491943
a O O 0.9999544620513916
diagnostic O O 0.9999922513961792
marker O O 0.999996542930603
for O O 0.9999730587005615
adverse O O 0.9999302625656128
reaction O O 0.9999920129776001
to O O 0.9995699524879456
quetiapine B B 0.9986032843589783
. O O 0.9999480247497559

Lateral O O 0.9998247027397156
antebrachial O O 0.9996776580810547
cutaneous O O 0.999913215637207
neuropathy O O 0.9999854564666748
after O O 0.9996263980865479
steroid B B 0.9943473935127258
injection O O 0.9985563158988953
at O O 0.9994615912437439
lateral O O 0.997412383556366
epicondyle O O 0.9988503456115723
. O O 0.9999408721923828

BACKGROUND O O 0.9995717406272888
AND O O 0.9999902248382568
OBJECTIVES O O 0.9999477863311768
: O O 0.9999932050704956
This O O 0.9999970197677612
report O O 0.9999971389770508
aimed O O 0.9999957084655762
to O O 0.9999988079071045
present O O 0.9999977350234985
a O O 0.9999964237213135
case O O 0.999996542930603
of O O 0.9999899864196777
lateral O O 0.9996103644371033
antebrachial O O 0.9995906949043274
cutaneous O O 0.9993185997009277
neuropathy O O 0.9999840259552002
( O O 0.99993896484375
LACNP O O 0.993067741394043
) O O 0.9999834299087524
that O O 0.999975323677063
occurred O O 0.9999973773956299
after O O 0.9999338388442993
a O O 0.9999146461486816
steroid B B 0.9331154227256775
injection O O 0.9954900145530701
in O O 0.9999382495880127
the O O 0.9999783039093018
lateral O O 0.9974678754806519
epicondyle O O 0.9985169768333435
to O O 0.9999001026153564
treat O O 0.999901533126831
lateral O O 0.9972689747810364
epicondylitis O O 0.9982481002807617
in O O 0.9999780654907227
a O O 0.9999953508377075
40 O O 0.999994158744812
- O O 0.9999905824661255
year O O 0.9999979734420776
- O O 0.9999942779541016
old O O 0.9999949932098389
woman O O 0.9999980926513672
. O O 0.9999803304672241

MATERIAL O O 0.9997552037239075
AND O O 0.9999911785125732
METHOD O O 0.9999828338623047
: O O 0.9999886751174927
A O O 0.9999953508377075
40 O O 0.9999922513961792
- O O 0.9999865293502808
year O O 0.9999969005584717
- O O 0.999988317489624
old O O 0.9999927282333374
woman O O 0.9999953508377075
presented O O 0.9999741315841675
with O O 0.9999874830245972
decreased O O 0.9999927282333374
sensation O O 0.9999984502792358
and O O 0.9999861717224121
paresthesia O O 0.9999904632568359
over O O 0.9999872446060181
her O O 0.9999943971633911
right O O 0.9999933242797852
lateral O O 0.9998652935028076
forearm O O 0.999987006187439
; O O 0.9999899864196777
the O O 0.9999969005584717
paresthesia O O 0.9999818801879883
had O O 0.9999920129776001
occurred O O 0.9999983310699463
after O O 0.9999426603317261
a O O 0.9999572038650513
steroid B B 0.9393937587738037
injection O O 0.9946402907371521
in O O 0.9999454021453857
the O O 0.9999864101409912
right O O 0.9999498128890991
lateral O O 0.9989742040634155
epicondyle O O 0.9992139339447021
3 O O 0.9997602105140686
months O O 0.9999961853027344
before O O 0.9999963045120239
. O O 0.9999856948852539

Her O O 0.9998923540115356
sensation O O 0.9999914169311523
of O O 0.9999333620071411
light O O 0.9998588562011719
touch O O 0.9999879598617554
and O O 0.9997311234474182
pain O O 0.9996616840362549
was O O 0.9999302625656128
diminished O O 0.9999886751174927
over O O 0.9999494552612305
the O O 0.9999850988388062
lateral O O 0.9998998641967773
side O O 0.999997615814209
of O O 0.9999741315841675
the O O 0.9999933242797852
right O O 0.9999779462814331
forearm O O 0.9999915361404419
and O O 0.9999154806137085
wrist O O 0.9999300241470337
area O O 0.9999700784683228
. O O 0.9999654293060303

RESULTS O O 0.9998915195465088
: O O 0.9999580383300781
The O O 0.9999762773513794
sensory O O 0.9998685121536255
action O O 0.9998594522476196
potential O O 0.9999731779098511
amplitude O O 0.999872088432312
of O O 0.9998695850372314
the O O 0.9999266862869263
right O O 0.9999229907989502
lateral O O 0.9998892545700073
antebrachial O O 0.9993822574615479
cutaneous O O 0.9998204112052917
nerve O O 0.9998131394386292
( O O 0.9987452030181885
LACN O O 0.9534082412719727
) O O 0.9998797178268433
( O O 0.9999009370803833
6 O O 0.9998639822006226
. O O 0.9999513626098633
2 O O 0.9996902942657471
uV O O 0.9878050088882446
) O O 0.9999353885650635
was O O 0.9999526739120483
lower O O 0.999871015548706
than O O 0.9999639987945557
that O O 0.9999721050262451
of O O 0.9999650716781616
the O O 0.9999879598617554
left O O 0.9999641180038452
( O O 0.9999747276306152
13 O O 0.9999830722808838
. O O 0.9999887943267822
1 O O 0.9999737739562988
uV O O 0.9924029111862183
) O O 0.9999666213989258
. O O 0.9999648332595825

The O O 0.9999847412109375
difference O O 0.9999948740005493
of O O 0.9999843835830688
amplitude O O 0.9999887943267822
between O O 0.9998444318771362
both O O 0.9998266100883484
sides O O 0.9999827146530151
was O O 0.9999496936798096
significant O O 0.9999767541885376
because O O 0.9999902248382568
there O O 0.9999525547027588
was O O 0.9999748468399048
more O O 0.9999772310256958
than O O 0.9999938011169434
a O O 0.9999836683273315
50 O O 0.9999858140945435
% O O 0.9999938011169434
reduction O O 0.9999910593032837
. O O 0.9999628067016602

She O O 0.9999784231185913
was O O 0.9999674558639526
diagnosed O O 0.9999924898147583
with O O 0.9999734163284302
right O O 0.9997401833534241
LACNP O O 0.9934318661689758
( O O 0.9999085664749146
mainly O O 0.9996881484985352
axonal O O 0.9993494153022766
involvement O O 0.9999831914901733
) O O 0.999964714050293
on O O 0.9999971389770508
the O O 0.9999978542327881
basis O O 0.9999982118606567
of O O 0.9999940395355225
the O O 0.9999960660934448
clinical O O 0.9999910593032837
manifestation O O 0.9999971389770508
and O O 0.9999955892562866
the O O 0.9999964237213135
electrodiagnostic O O 0.9996647834777832
findings O O 0.9999972581863403
. O O 0.9999788999557495

Her O O 0.9999454021453857
symptoms O O 0.9999923706054688
improved O O 0.9999904632568359
through O O 0.9999158382415771
physical O O 0.9996362924575806
therapy O O 0.9999752044677734
but O O 0.9999724626541138
persisted O O 0.9999934434890747
to O O 0.999995231628418
some O O 0.9999951124191284
degree O O 0.9999949932098389
. O O 0.9999815225601196

CONCLUSION O O 0.9999333620071411
: O O 0.9999743700027466
This O O 0.999991774559021
report O O 0.9999943971633911
describes O O 0.9999920129776001
the O O 0.999997615814209
case O O 0.9999959468841553
of O O 0.9999879598617554
a O O 0.9999901056289673
woman O O 0.9999957084655762
with O O 0.9998903274536133
LACNP O O 0.9669734835624695
that O O 0.9999456405639648
developed O O 0.9999959468841553
after O O 0.9999499320983887
a O O 0.9999384880065918
steroid B B 0.9421663284301758
injection O O 0.985512912273407
for O O 0.9999033212661743
the O O 0.9999841451644897
treatment O O 0.9999752044677734
of O O 0.9999850988388062
lateral O O 0.9996156692504883
epicondylitis O O 0.9994459748268127
. O O 0.9999567270278931

An O O 0.9999808073043823
electrodiagnostic O O 0.9997300505638123
study O O 0.9999901056289673
, O O 0.999984860420227
including O O 0.9999712705612183
a O O 0.999966025352478
nerve O O 0.9995993971824646
conduction O O 0.9999716281890869
study O O 0.999985933303833
of O O 0.9999570846557617
the O O 0.9999756813049316
LACN O O 0.9964905381202698
, O O 0.9999828338623047
was O O 0.99997878074646
helpful O O 0.9999936819076538
to O O 0.9999923706054688
diagnose O O 0.9999961853027344
right O O 0.999643087387085
LACNP O O 0.9916762113571167
and O O 0.9999786615371704
to O O 0.9999938011169434
find O O 0.9999951124191284
the O O 0.9999955892562866
passage O O 0.9999974966049194
of O O 0.9999831914901733
the O O 0.9999834299087524
LACN O O 0.971369743347168
on O O 0.9999301433563232
the O O 0.9999847412109375
lateral O O 0.9997128844261169
epicondyle O O 0.9993330836296082
. O O 0.9999427795410156

Curcumin B B 0.9978813529014587
prevents O O 0.5586137175559998
maleate B B 0.9957953691482544
- O O 0.9979497790336609
induced O O 0.9999138116836548
nephrotoxicity O O 0.999702513217926
: O O 0.9999492168426514
relation O O 0.9999891519546509
to O O 0.9998644590377808
hemodynamic O O 0.9999662637710571
alterations O O 0.9999942779541016
, O O 0.9998601675033569
oxidative O O 0.946147620677948
stress O O 0.9996901750564575
, O O 0.9997463822364807
mitochondrial O O 0.859576940536499
oxygen B B 0.9329376816749573
consumption O O 0.9989757537841797
and O O 0.999816358089447
activity O O 0.9945597052574158
of O O 0.9975122213363647
respiratory O O 0.960175633430481
complex O O 0.9775539040565491
I O O 0.8463913798332214
. O O 0.9998856782913208

The O O 0.9999853372573853
potential O O 0.9999678134918213
protective O O 0.9999288320541382
effect O O 0.9999804496765137
of O O 0.9999064207077026
the O O 0.9999001026153564
dietary O O 0.9990039467811584
antioxidant O O 0.7647323608398438
curcumin B B 0.5086185932159424
( O O 0.9987931251525879
120 O O 0.9988584518432617
mg O O 0.9999301433563232
/ O O 0.9999630451202393
Kg O O 0.9999983310699463
/ O O 0.9999364614486694
day O O 0.9999927282333374
for O O 0.9999723434448242
6 O O 0.9999140501022339
days O O 0.9999861717224121
) O O 0.9999731779098511
against O O 0.9998076558113098
the O O 0.999962568283081
renal O O 0.9999581575393677
injury O O 0.9999938011169434
induced O O 0.9999892711639404
by O O 0.9998443126678467
maleate B B 0.9811861515045166
was O O 0.9997841715812683
evaluated O O 0.9999877214431763
. O O 0.9999706745147705

Tubular O O 0.9998799562454224
proteinuria O O 0.9916623830795288
and O O 0.9999079704284668
oxidative O O 0.9526289105415344
stress O O 0.9993323683738708
were O O 0.99997878074646
induced O O 0.9999889135360718
by O O 0.9999666213989258
a O O 0.999984622001648
single O O 0.9999518394470215
injection O O 0.9999762773513794
of O O 0.9990509152412415
maleate B B 0.999041736125946
( O O 0.9996998310089111
400 O O 0.9990536570549011
mg O O 0.9998825788497925
/ O O 0.9999233484268188
kg O O 0.999984622001648
) O O 0.999937891960144
in O O 0.9998619556427002
rats O O 0.9995242357254028
. O O 0.9999721050262451

Maleate B B 0.9904662370681763
- O O 0.9990432858467102
induced O O 0.9999157190322876
renal O O 0.9999823570251465
injury O O 0.9999909400939941
included O O 0.9999701976776123
increase O O 0.9999716281890869
in O O 0.9999494552612305
renal O O 0.9999673366546631
vascular O O 0.9999045133590698
resistance O O 0.999998927116394
and O O 0.999974250793457
in O O 0.999961256980896
the O O 0.9999644756317139
urinary O O 0.999982476234436
excretion O O 0.9999809265136719
of O O 0.9995802044868469
total O O 0.9379517436027527
protein O O 0.997936487197876
, O O 0.9972781538963318
glucose B B 0.9917044639587402
, O O 0.8552523851394653
sodium B B 0.9873208999633789
, O O 0.993989109992981
neutrophil O O 0.8564574718475342
gelatinase O O 0.9147432446479797
- O O 0.9859587550163269
associated O O 0.9795472025871277
lipocalin O O 0.6558558940887451
( O O 0.9953140020370483
NGAL O O 0.6238082051277161
) O O 0.9911068081855774
and O O 0.9960075616836548
N O B 0.47861430048942566
- O I 0.6944558620452881
acetyl O I 0.996690034866333
b O I 0.8990061283111572
- O I 0.9317275881767273
D O I 0.994743824005127
- O I 0.9228248596191406
glucosaminidase O I 0.9970104694366455
( O O 0.9939694404602051
NAG O B 0.9939050078392029
) O O 0.9997901320457458
, O O 0.9999645948410034
upregulation O O 0.9936622381210327
of O O 0.9940341114997864
kidney O O 0.9532280564308167
injury O O 0.9792696833610535
molecule O O 0.9710902571678162
( O O 0.7996717691421509
KIM O O 0.7862828969955444
) O O 0.975356936454773
- O O 0.9843260645866394
1 O O 0.9637401103973389
, O O 0.9999392032623291
decrease O O 0.9999970197677612
in O O 0.9999833106994629
renal O O 0.9999734163284302
blood O O 0.9998243451118469
flow O O 0.9999945163726807
and O O 0.9998000264167786
claudin O O 0.7540727853775024
- O O 0.5180059671401978
2 O O 0.8411684632301331
expression O O 0.9958957433700562
besides O O 0.9960344433784485
of O O 0.9988653659820557
necrosis O O 0.9998216032981873
and O O 0.9998880624771118
apoptosis O O 0.999303936958313
of O O 0.9997770190238953
tubular O O 0.9999911785125732
cells O O 0.9999949932098389
on O O 0.999958872795105
24 O O 0.9998860359191895
h O O 0.9890468716621399
. O O 0.9996147155761719

Oxidative O O 0.9977115392684937
stress O O 0.9998842477798462
was O O 0.9999690055847168
determined O O 0.9999871253967285
by O O 0.9999935626983643
measuring O O 0.999925971031189
the O O 0.9999226331710815
oxidation O O 0.7661389708518982
of O O 0.9992392063140869
lipids O O 0.7474570274353027
and O O 0.9889587163925171
proteins O O 0.9950704574584961
and O O 0.9999692440032959
diminution O O 0.9998856782913208
in O O 0.9998817443847656
renal O O 0.998796820640564
Nrf2 O O 0.7032938599586487
levels O O 0.9996711015701294
. O O 0.9999405145645142

Studies O O 0.9999872446060181
were O O 0.9999923706054688
also O O 0.9999878406524658
conducted O O 0.9999977350234985
in O O 0.9999334812164307
renal O O 0.9998313188552856
epithelial O O 0.9994387030601501
LLC O O 0.9877743124961853
- O O 0.9945335388183594
PK1 O O 0.9241397976875305
cells O O 0.9998078942298889
and O O 0.9998654127120972
in O O 0.9998737573623657
mitochondria O O 0.9951021671295166
isolated O O 0.9999245405197144
from O O 0.9999402761459351
kidneys O O 0.9999377727508545
of O O 0.999958872795105
all O O 0.999942421913147
the O O 0.9999778270721436
experimental O O 0.9999152421951294
groups O O 0.9999904632568359
. O O 0.9999758005142212

Maleate B B 0.9967508316040039
induced O O 0.9994155168533325
cell O O 0.9999098777770996
damage O O 0.9999899864196777
and O O 0.999923825263977
reactive O O 0.8848833441734314
oxygen B B 0.8600104451179504
species O O 0.7592040300369263
( O O 0.9984982013702393
ROS O O 0.8161607384681702
) O O 0.9982611536979675
production O O 0.9998536109924316
in O O 0.9997116923332214
LLC O O 0.9553892612457275
- O O 0.988972008228302
PK1 O O 0.8878674507141113
cells O O 0.9998960494995117
in O O 0.9998427629470825
culture O O 0.9999324083328247
. O O 0.9998852014541626

In O O 0.9999380111694336
addition O O 0.9999510049819946
, O O 0.9995260238647461
maleate B B 0.9997476935386658
treatment O O 0.999344527721405
reduced O O 0.9998931884765625
oxygen B B 0.9887318015098572
consumption O O 0.9998680353164673
in O O 0.999767005443573
ADP B B 0.9432392716407776
- O O 0.9181762337684631
stimulated O O 0.9891632795333862
mitochondria O O 0.9994997978210449
and O O 0.999974250793457
diminished O O 0.9999876022338867
respiratory O O 0.9984965324401855
control O O 0.9999693632125854
index O O 0.9999868869781494
when O O 0.9998761415481567
using O O 0.9997103810310364
malate B B 0.999620795249939
/ O O 0.6066379547119141
glutamate B B 0.9891117215156555
as O O 0.9981483221054077
substrate O O 0.9988662004470825
. O O 0.9999494552612305

The O O 0.9998847246170044
activities O O 0.9990921020507812
of O O 0.9993199110031128
both O O 0.9961859583854675
complex O O 0.7785781621932983
I O O 0.6793125867843628
and O O 0.9963343143463135
aconitase O O 0.5774056911468506
were O O 0.9998201727867126
also O O 0.9999634027481079
diminished O O 0.9999717473983765
. O O 0.9999444484710693

All O O 0.9999159574508667
the O O 0.9999760389328003
above O O 0.9991170763969421
- O O 0.999975323677063
described O O 0.9999879598617554
alterations O O 0.9999862909317017
were O O 0.9998723268508911
prevented O O 0.999920129776001
by O O 0.9996721744537354
curcumin B B 0.9981751441955566
. O O 0.9998468160629272

It O O 0.9999867677688599
is O O 0.9999560117721558
concluded O O 0.9999518394470215
that O O 0.9992536902427673
curcumin B B 0.9991357922554016
is O O 0.9998844861984253
able O O 0.9998667240142822
to O O 0.9998852014541626
attenuate O O 0.9996610879898071
in O O 0.9998993873596191
vivo O O 0.9992875456809998
maleate B B 0.9989175796508789
- O O 0.9992730021476746
induced O O 0.9999021291732788
nephropathy O O 0.9999196529388428
and O O 0.9999344348907471
in O O 0.9997797608375549
vitro O O 0.9999830722808838
cell O O 0.9999358654022217
damage O O 0.9999934434890747
. O O 0.9999663829803467

The O O 0.9999570846557617
in O O 0.9997785687446594
vivo O O 0.9999738931655884
protection O O 0.999943733215332
was O O 0.9999158382415771
associated O O 0.9999814033508301
to O O 0.9999325275421143
the O O 0.9999549388885498
prevention O O 0.9999285936355591
of O O 0.999897837638855
oxidative O O 0.9989230036735535
stress O O 0.9999045133590698
and O O 0.9999300241470337
preservation O O 0.9999674558639526
of O O 0.9998997449874878
mitochondrial O O 0.9944753050804138
oxygen B B 0.9182535409927368
consumption O O 0.9995939135551453
and O O 0.999873161315918
activity O O 0.9961101412773132
of O O 0.9959362745285034
respiratory O O 0.9558172821998596
complex O O 0.9452092051506042
I O O 0.7325647473335266
, O O 0.9997270703315735
and O O 0.9998524188995361
the O O 0.9999361038208008
in O O 0.9997705817222595
vitro O O 0.9999791383743286
protection O O 0.9998378753662109
was O O 0.9999403953552246
associated O O 0.9999736547470093
to O O 0.9999475479125977
the O O 0.9999667406082153
prevention O O 0.9998983144760132
of O O 0.9997653365135193
ROS O O 0.8389983177185059
production O O 0.9999315738677979
. O O 0.9999582767486572

Anticonvulsant O O 0.7491256594657898
actions O O 0.9989557266235352
of O O 0.9968616962432861
MK B B 0.9984851479530334
- I I 0.9616488218307495
801 I I 0.999970555305481
on O O 0.998252809047699
the O O 0.9999161958694458
lithium B B 0.9997482895851135
- O O 0.8188074827194214
pilocarpine B B 0.9529466032981873
model O O 0.9999053478240967
of O O 0.9999231100082397
status O O 0.999992847442627
epilepticus O O 0.9998824596405029
in O O 0.9999529123306274
rats O O 0.9999861717224121
. O O 0.9998918771743774

MK B B 0.9961658716201782
- I I 0.9005629420280457
801 I I 0.9998862743377686
, O O 0.999422550201416
a O O 0.9995409250259399
noncompetitive O O 0.9248048663139343
N B B 0.786435067653656
- I I 0.9338636994361877
methyl I I 0.9973340034484863
- I I 0.860407829284668
D I I 0.9690663814544678
- I I 0.9760273098945618
aspartate I I 0.9997817873954773
( O O 0.9245556592941284
NMDA B B 0.9997134804725647
) O O 0.9009328484535217
receptor O O 0.9896448850631714
antagonist O O 0.7763977646827698
, O O 0.9999538660049438
was O O 0.9999597072601318
tested O O 0.9999459981918335
for O O 0.9999021291732788
anticonvulsant O O 0.846733570098877
effects O O 0.9998389482498169
in O O 0.9999262094497681
rats O O 0.999985933303833
using O O 0.9999427795410156
two O O 0.9998990297317505
seizure O O 0.999927282333374
models O O 0.9999783039093018
, O O 0.99994957447052
coadministration O O 0.9920978546142578
of O O 0.9993671774864197
lithium B B 0.9999271631240845
and O O 0.9648255109786987
pilocarpine B B 0.9995694756507874
and O O 0.9994875192642212
administration O O 0.999975323677063
of O O 0.9999599456787109
a O O 0.999988317489624
high O O 0.9998894929885864
dose O O 0.999901533126831
of O O 0.9989925026893616
pilocarpine B B 0.999875545501709
alone O O 0.9996728897094727
. O O 0.9999550580978394

Three O O 0.9999629259109497
major O O 0.9999959468841553
results O O 0.9999939203262329
are O O 0.9999810457229614
reported O O 0.999993085861206
. O O 0.9999630451202393

First O O 0.9999814033508301
, O O 0.9999200105667114
pretreatment O O 0.9999173879623413
with O O 0.9997754693031311
MK B B 0.9975634813308716
- I I 0.8900744318962097
801 I I 0.999869704246521
produced O O 0.9994673132896423
an O O 0.9998471736907959
effective O O 0.9997339844703674
and O O 0.9998811483383179
dose O O 0.9977018237113953
- O O 0.999967098236084
dependent O O 0.9999849796295166
anticonvulsant O O 0.9306528568267822
action O O 0.9998879432678223
with O O 0.9998793601989746
the O O 0.9998635053634644
lithium B B 0.999778687953949
- O O 0.8716884255409241
pilocarpine B B 0.982519268989563
model O O 0.9998152852058411
but O O 0.9999778270721436
not O O 0.9999673366546631
with O O 0.9999668598175049
rats O O 0.9999853372573853
treated O O 0.9999819993972778
with O O 0.9998917579650879
pilocarpine B B 0.9997612833976746
alone O O 0.999771773815155
, O O 0.9999744892120361
suggesting O O 0.9999629259109497
that O O 0.999944806098938
different O O 0.9999173879623413
biochemical O O 0.9986963868141174
mechanisms O O 0.9998738765716553
control O O 0.9998865127563477
seizures O O 0.9999793767929077
in O O 0.9998395442962646
these O O 0.9999418258666992
two O O 0.9999185800552368
models O O 0.999967098236084
. O O 0.9999699592590332

Second O O 0.9999616146087646
, O O 0.9999761581420898
the O O 0.9999366998672485
anticonvulsant O O 0.908054530620575
effect O O 0.9998043179512024
of O O 0.9993273019790649
MK B B 0.9993852376937866
- I I 0.9811045527458191
801 I I 0.9999667406082153
in O O 0.9909393787384033
the O O 0.9998143315315247
lithium B B 0.9998418092727661
- O O 0.7157964706420898
pilocarpine B B 0.9605885148048401
model O O 0.9994847774505615
only O O 0.9999693632125854
occurred O O 0.9999459981918335
after O O 0.9999595880508423
initial O O 0.999990701675415
periods O O 0.9999891519546509
of O O 0.9999700784683228
seizure O O 0.9999845027923584
activity O O 0.9999957084655762
. O O 0.9999743700027466

This O O 0.9999847412109375
observation O O 0.9999923706054688
is O O 0.9999790191650391
suggested O O 0.9999945163726807
to O O 0.9999918937683105
be O O 0.9999924898147583
an O O 0.9999889135360718
in O O 0.9999287128448486
vivo O O 0.9999854564666748
demonstration O O 0.9999921321868896
of O O 0.9999817609786987
the O O 0.9999922513961792
conclusion O O 0.9999932050704956
derived O O 0.9999983310699463
from O O 0.999977707862854
in O O 0.9999136924743652
vitro O O 0.9999912977218628
experiments O O 0.9999885559082031
that O O 0.9999102354049683
MK B B 0.9957761168479919
- I I 0.7792348861694336
801 I I 0.9994847774505615
binding O O 0.999180018901825
requires O O 0.9998782873153687
agonist O O 0.7090254426002502
- O O 0.9995680451393127
induced O O 0.9999477863311768
opening O O 0.9999492168426514
of O O 0.9999231100082397
the O O 0.9999123811721802
channel O O 0.9998284578323364
sites O O 0.999714195728302
of O O 0.9998356103897095
the O O 0.9994608759880066
NMDA B B 0.9984152317047119
receptor O O 0.9996565580368042
. O O 0.9999619722366333

Third O O 0.9998664855957031
, O O 0.9999827146530151
although O O 0.9999760389328003
it O O 0.9999583959579468
is O O 0.999947190284729
relatively O O 0.9999542236328125
easy O O 0.9998573064804077
to O O 0.9999563694000244
block O O 0.9995631575584412
seizures O O 0.9999426603317261
induced O O 0.99997878074646
by O O 0.9998471736907959
lithium B B 0.9999135732650757
and O O 0.9934360980987549
pilocarpine B B 0.999606192111969
by O O 0.9997765421867371
administration O O 0.9999487400054932
of O O 0.9998273253440857
anticonvulsants O O 0.500931441783905
prior O O 0.9995436072349548
to O O 0.9997612833976746
pilocarpine B B 0.9996787309646606
, O O 0.9998410940170288
it O O 0.999963641166687
is O O 0.9999593496322632
more O O 0.9999507665634155
difficult O O 0.9999817609786987
to O O 0.9999548196792603
terminate O O 0.9999243021011353
ongoing O O 0.9999337196350098
status O O 0.9999831914901733
epilepticus O O 0.9998843669891357
and O O 0.9999533891677856
block O O 0.9998779296875
the O O 0.9999581575393677
lethality O O 0.9999867677688599
of O O 0.9999548196792603
the O O 0.9999781847000122
seizures O O 0.9999245405197144
. O O 0.9999765157699585

Administration O O 0.9998888969421387
of O O 0.9996125102043152
MK B B 0.9949253797531128
- I I 0.9133434295654297
801 I I 0.9999054670333862
30 O O 0.9956464171409607
or O O 0.9999924898147583
60 O O 0.9999927282333374
min O O 0.9999779462814331
after O O 0.999967098236084
pilocarpine B B 0.9997754693031311
, O O 0.9999525547027588
i O O 0.9999803304672241
. O O 0.9999932050704956
e O O 0.999993085861206
. O O 0.9999885559082031
, O O 0.9999879598617554
during O O 0.9999631643295288
status O O 0.9999936819076538
epilepticus O O 0.9999682903289795
, O O 0.9999558925628662
gradually O O 0.9998956918716431
reduced O O 0.9999476671218872
electrical O O 0.9999815225601196
and O O 0.9998904466629028
behavioral O O 0.9999488592147827
seizure O O 0.9999709129333496
activity O O 0.9999929666519165
and O O 0.9999549388885498
greatly O O 0.9999773502349854
enhanced O O 0.9999793767929077
the O O 0.999980092048645
survival O O 0.9999890327453613
rate O O 0.9999926090240479
. O O 0.9999786615371704

These O O 0.999976396560669
results O O 0.9999829530715942
suggest O O 0.9999306201934814
that O O 0.9997432827949524
activation O O 0.9985905289649963
of O O 0.9927948117256165
NMDA B B 0.9984833598136902
receptors O O 0.9991212487220764
plays O O 0.9999524354934692
an O O 0.9999539852142334
important O O 0.9998817443847656
role O O 0.9999735355377197
in O O 0.9999496936798096
status O O 0.999966025352478
epilepticus O O 0.9999834299087524
and O O 0.999950647354126
brain O O 0.9999854564666748
damage O O 0.9999963045120239
in O O 0.999922513961792
the O O 0.9999071359634399
lithium B B 0.9998481273651123
- O O 0.8301661610603333
pilocarpine B B 0.9646575450897217
model O O 0.9999139308929443
. O O 0.9999655485153198

This O O 0.9999668598175049
was O O 0.9999585151672363
further O O 0.9999839067459106
supported O O 0.9999934434890747
by O O 0.9999923706054688
results O O 0.9999887943267822
showing O O 0.9999891519546509
that O O 0.9998859167098999
nonconvulsive O O 0.993010938167572
doses O O 0.9996932744979858
of O O 0.9978004097938538
NMDA B B 0.9998171925544739
and O O 0.8467885255813599
pilocarpine B B 0.999690055847168
were O O 0.9996367692947388
synergistic O O 0.9954468607902527
, O O 0.9999681711196899
resulting O O 0.9999773502349854
in O O 0.9999650716781616
status O O 0.9999885559082031
epilepticus O O 0.9999831914901733
and O O 0.9999710321426392
subsequent O O 0.9999881982803345
mortality O O 0.9999911785125732
. O O 0.9999783039093018

Continuous O O 0.9977142810821533
infusion O O 0.9997254014015198
tobramycin B B 0.9997450709342957
combined O O 0.9984557628631592
with O O 0.9981774091720581
carbenicillin B B 0.99943608045578
for O O 0.9998788833618164
infections O O 0.9999686479568481
in O O 0.9999492168426514
cancer O O 0.9998944997787476
patients O O 0.9999854564666748
. O O 0.9997953772544861

The O O 0.9999357461929321
cure O O 0.999981164932251
rate O O 0.9999905824661255
of O O 0.9998884201049805
infections O O 0.9998691082000732
in O O 0.9999254941940308
cancer O O 0.9997989535331726
patients O O 0.9999775886535645
is O O 0.9999377727508545
adversely O O 0.9999558925628662
affected O O 0.9999827146530151
by O O 0.9998639822006226
neutropenia O O 0.9999167919158936
( O O 0.9999626874923706
less O O 0.9999966621398926
than O O 0.999996542930603
1 O O 0.999995231628418
, O O 0.9999983310699463
000 O O 0.9999878406524658
/ O O 0.9999803304672241
mm3 O O 0.9999958276748657
) O O 0.9999761581420898
. O O 0.9999725818634033

In O O 0.9998832941055298
particular O O 0.9999730587005615
, O O 0.9999688863754272
patients O O 0.9999901056289673
with O O 0.9999794960021973
severe O O 0.999964714050293
neutropenia O O 0.9999856948852539
( O O 0.9999724626541138
less O O 0.9999960660934448
than O O 0.9999947547912598
100 O O 0.999923825263977
/ O O 0.9999879598617554
mm3 O O 0.999992847442627
) O O 0.9999749660491943
have O O 0.9999864101409912
shown O O 0.9999966621398926
a O O 0.9999927282333374
poor O O 0.9999946355819702
response O O 0.9999966621398926
to O O 0.9999232292175293
antibiotics O O 0.992949366569519
. O O 0.9999769926071167

To O O 0.9998862743377686
overcome O O 0.9999278783798218
the O O 0.999974250793457
adverse O O 0.9999432563781738
effects O O 0.9999785423278809
of O O 0.9999587535858154
neutropenia O O 0.999990701675415
, O O 0.9998217225074768
tobramycin B B 0.9995788931846619
was O O 0.9998076558113098
given O O 0.9999185800552368
by O O 0.9999351501464844
continuous O O 0.9998314380645752
infusion O O 0.9999313354492188
and O O 0.9999864101409912
combined O O 0.9999144077301025
with O O 0.9998223185539246
intermittent O O 0.9990610480308533
carbenicillin B B 0.9988791346549988
. O O 0.9999226331710815

Tobramycin B B 0.9990118741989136
was O O 0.9996916055679321
given O O 0.9999260902404785
to O O 0.999972939491272
a O O 0.9999878406524658
total O O 0.9999382495880127
daily O O 0.9999847412109375
dose O O 0.999982476234436
of O O 0.9999788999557495
300 O O 0.9999737739562988
mg O O 0.9999881982803345
/ O O 0.999977707862854
m2 O O 0.999993085861206
and O O 0.9994739890098572
carbenicillin B B 0.9996132254600525
was O O 0.9998757839202881
given O O 0.9999309778213501
at O O 0.9999632835388184
a O O 0.9999877214431763
dose O O 0.9999692440032959
of O O 0.9999690055847168
5 O O 0.999852180480957
gm O O 0.9927889704704285
every O O 0.9999518394470215
four O O 0.9999574422836304
hours O O 0.9999912977218628
. O O 0.9999502897262573

There O O 0.9999494552612305
were O O 0.9999791383743286
125 O O 0.9999786615371704
infectious O O 0.9999872446060181
episodes O O 0.9999935626983643
in O O 0.9999089241027832
116 O O 0.8729407787322998
cancer O O 0.9999719858169556
patients O O 0.9999727010726929
receiving O O 0.9998013377189636
myelosuppressive O O 0.9999518394470215
chemotherapy O O 0.9989989399909973
. O O 0.9999425411224365

The O O 0.9999523162841797
overall O O 0.999914288520813
cure O O 0.9999780654907227
rate O O 0.9999771118164062
was O O 0.9999710321426392
70 O O 0.9999946355819702
% O O 0.9999957084655762
. O O 0.9999704360961914

Pneumonia O O 0.9997684359550476
was O O 0.999955415725708
the O O 0.9999847412109375
most O O 0.9999874830245972
common O O 0.9999815225601196
infection O O 0.9999845027923584
and O O 0.9999608993530273
61 O O 0.9999933242797852
% O O 0.9999982118606567
of O O 0.9999815225601196
59 O O 0.9999434947967529
episodes O O 0.9999921321868896
were O O 0.9999622106552124
cured O O 0.9992660880088806
. O O 0.9999685287475586

Gram O O 0.8399226069450378
- O O 0.993486762046814
negative O O 0.9851025342941284
bacilli O O 0.6573385000228882
were O O 0.9998286962509155
the O O 0.9999121427536011
most O O 0.9999481439590454
common O O 0.9999154806137085
causative O O 0.9999102354049683
organisms O O 0.9999464750289917
and O O 0.9999504089355469
69 O O 0.9999923706054688
% O O 0.9999963045120239
of O O 0.9999678134918213
these O O 0.9998694658279419
infections O O 0.9999721050262451
were O O 0.9999606609344482
cured O O 0.9992818236351013
. O O 0.9999634027481079

The O O 0.9999459981918335
most O O 0.9999772310256958
common O O 0.9999316930770874
pathogen O O 0.9999856948852539
was O O 0.9998688697814941
Klebsiella O O 0.850484311580658
pneumoniae O O 0.9749184846878052
and O O 0.9999512434005737
this O O 0.999823272228241
, O O 0.9999877214431763
together O O 0.9999773502349854
with O O 0.9998562335968018
Escherichia O O 0.9986579418182373
coli O O 0.9997081160545349
and O O 0.9997395873069763
Pseudomonas O O 0.8170246481895447
aeruginosa O O 0.957737386226654
, O O 0.9999641180038452
accounted O O 0.9999775886535645
for O O 0.9999819993972778
74 O O 0.9999866485595703
% O O 0.9999977350234985
of O O 0.9999772310256958
all O O 0.9999558925628662
gram O O 0.9986312985420227
- O O 0.9997461438179016
negative O O 0.9965830445289612
bacillary O O 0.9993494153022766
infections O O 0.9999772310256958
. O O 0.9999794960021973

Response O O 0.9999452829360962
was O O 0.9999648332595825
not O O 0.9999761581420898
influenced O O 0.9999903440475464
by O O 0.9999754428863525
the O O 0.9999853372573853
initial O O 0.9999775886535645
neutrophil O O 0.9998972415924072
count O O 0.9998490810394287
, O O 0.9999719858169556
with O O 0.9999821186065674
a O O 0.9999879598617554
62 O O 0.9999908208847046
% O O 0.9999881982803345
cure O O 0.9999470710754395
rate O O 0.9999760389328003
for O O 0.9999263286590576
39 O O 0.9997804760932922
episodes O O 0.9999921321868896
associated O O 0.9999643564224243
with O O 0.9999771118164062
severe O O 0.9999657869338989
neutropenia O O 0.9999547004699707
. O O 0.9999724626541138

However O O 0.9999160766601562
, O O 0.9999312162399292
failure O O 0.9999939203262329
of O O 0.9999657869338989
the O O 0.9999580383300781
neutrophil O O 0.9999240636825562
count O O 0.9999352693557739
to O O 0.9999312162399292
increase O O 0.9992052912712097
during O O 0.9996542930603027
therapy O O 0.9999583959579468
adversely O O 0.9999439716339111
affected O O 0.9999901056289673
response O O 0.9999880790710449
. O O 0.9999736547470093

Azotemia O O 0.7504101395606995
was O O 0.9999251365661621
the O O 0.9999586343765259
major O O 0.9999074935913086
side O O 0.9999092817306519
effect O O 0.9999772310256958
recognized O O 0.999964714050293
, O O 0.9999345541000366
and O O 0.999981164932251
it O O 0.9999895095825195
occurred O O 0.9999874830245972
in O O 0.9999884366989136
11 O O 0.9999814033508301
% O O 0.9999979734420776
of O O 0.9999804496765137
episodes O O 0.9999895095825195
. O O 0.999963641166687

Major O O 0.9997732043266296
azotemia O O 0.9960107803344727
( O O 0.9999418258666992
serum O O 0.9981694221496582
creatinine B B 0.9954959154129028
greater O O 0.9996743202209473
than O O 0.9999939203262329
2 O O 0.9999740123748779
. O O 0.9999979734420776
5 O O 0.9999927282333374
mg O O 0.9999960660934448
/ O O 0.9999878406524658
dl O O 0.9999961853027344
or O O 0.9998952150344849
BUN O O 0.545129656791687
greater O O 0.9999384880065918
than O O 0.9999934434890747
50 O O 0.999992847442627
mg O O 0.9999936819076538
/ O O 0.9999877214431763
dl O O 0.9999942779541016
) O O 0.9999592304229736
occurred O O 0.9999858140945435
in O O 0.9999911785125732
only O O 0.9999942779541016
2 O O 0.9999887943267822
% O O 0.9999886751174927
. O O 0.9999669790267944

Azotemia O O 0.9981889128684998
was O O 0.9999382495880127
not O O 0.9999542236328125
related O O 0.9999886751174927
to O O 0.9999172687530518
duration O O 0.9999703168869019
of O O 0.9999475479125977
therapy O O 0.9999425411224365
or O O 0.9999622106552124
serum O O 0.9974657297134399
tobramycin B B 0.9989683628082275
concentration O O 0.9958183169364929
. O O 0.9999655485153198

This O O 0.9999315738677979
antibiotic O O 0.934097170829773
regimen O O 0.9930495023727417
showed O O 0.9998931884765625
both O O 0.9998700618743896
therapeutic O O 0.9999275207519531
efficacy O O 0.9999794960021973
and O O 0.9999680519104004
acceptable O O 0.9997226595878601
renal O O 0.9998892545700073
toxicity O O 0.9999796152114868
for O O 0.9999619722366333
these O O 0.9999626874923706
patients O O 0.9999861717224121
. O O 0.9999696016311646

Incidence O O 0.9999793767929077
of O O 0.9999414682388306
solid O O 0.9997766613960266
tumours O O 0.9999942779541016
among O O 0.9995286464691162
pesticide O O 0.5928760766983032
applicators O O 0.9865888953208923
exposed O O 0.9999241828918457
to O O 0.9994494318962097
the O O 0.9997305274009705
organophosphate B B 0.9522019624710083
insecticide O O 0.6505797505378723
diazinon B B 0.9969305396080017
in O O 0.9997509121894836
the O O 0.9999463558197021
Agricultural O O 0.999901533126831
Health O O 0.9999703168869019
Study O O 0.9999814033508301
: O O 0.9999847412109375
an O O 0.9999911785125732
updated O O 0.9999938011169434
analysis O O 0.9999945163726807
. O O 0.9999895095825195

OBJECTIVE O O 0.9956403970718384
: O O 0.9986248016357422
Diazinon B B 0.9992233514785767
, O O 0.9998422861099243
a O O 0.9995885491371155
common O O 0.9907113909721375
organophosphate B B 0.9643815159797668
insecticide O O 0.6008756756782532
with O O 0.9990909099578857
genotoxic O O 0.9996531009674072
properties O O 0.9999697208404541
, O O 0.9999624490737915
was O O 0.9999731779098511
previously O O 0.9999321699142456
associated O O 0.9999833106994629
with O O 0.9999903440475464
lung O O 0.9997307658195496
cancer O O 0.9999788999557495
in O O 0.9999574422836304
the O O 0.9999834299087524
Agricultural O O 0.9982983469963074
Health O O 0.9991406202316284
Study O O 0.9999912977218628
( O O 0.9998763799667358
AHS O O 0.9973756074905396
) O O 0.9999662637710571
cohort O O 0.9999326467514038
, O O 0.9999644756317139
but O O 0.9999679327011108
few O O 0.9999903440475464
other O O 0.9999827146530151
epidemiological O O 0.9999834299087524
studies O O 0.9999948740005493
have O O 0.9999876022338867
examined O O 0.9999725818634033
diazinon B B 0.999599277973175
- O O 0.9998223185539246
associated O O 0.9999586343765259
cancer O O 0.9999808073043823
risk O O 0.9999963045120239
. O O 0.9999798536300659

We O O 0.9999063014984131
used O O 0.999950647354126
updated O O 0.9185477495193481
diazinon B B 0.9982748031616211
exposure O O 0.9985482096672058
and O O 0.9999125003814697
cancer O O 0.9999028444290161
incidence O O 0.9999649524688721
information O O 0.9998606443405151
to O O 0.9999755620956421
evaluate O O 0.9999698400497437
solid O O 0.9996964931488037
tumour O O 0.9999920129776001
risk O O 0.9999899864196777
in O O 0.9999537467956543
the O O 0.9993457198143005
AHS O O 0.9047462344169617
. O O 0.9999706745147705

METHODS O O 0.9999268054962158
: O O 0.9998974800109863
Male O O 0.8961599469184875
pesticide O O 0.4548161029815674
applicators O O 0.9544861912727356
in O O 0.9987494945526123
Iowa O O 0.9667072296142578
and O O 0.9990496039390564
North O O 0.7723634243011475
Carolina O O 0.4325736165046692
reported O O 0.999911904335022
lifetime O O 0.6411210298538208
diazinon B B 0.9917506575584412
use O O 0.9996359348297119
at O O 0.9998719692230225
enrolment O O 0.9999632835388184
( O O 0.9999383687973022
1993 O O 0.9952711462974548
- O O 0.9987179040908813
1997 O O 0.9721547961235046
) O O 0.9999271631240845
and O O 0.9999665021896362
follow O O 0.9999301433563232
- O O 0.9999860525131226
up O O 0.9999926090240479
( O O 0.9999723434448242
1998 O O 0.998110294342041
- O O 0.99908447265625
2005 O O 0.9998648166656494
) O O 0.9999779462814331
; O O 0.9999693632125854
cancer O O 0.9998960494995117
incidence O O 0.9999910593032837
was O O 0.9999850988388062
assessed O O 0.9999959468841553
through O O 0.9999909400939941
2010 O O 0.9999958276748657
( O O 0.9999366998672485
North O O 0.9688532948493958
Carolina O O 0.752576470375061
) O O 0.9998879432678223
/ O O 0.9999794960021973
2011 O O 0.999991774559021
( O O 0.9997479319572449
Iowa O O 0.9864418506622314
) O O 0.9999666213989258
. O O 0.9999790191650391

Among O O 0.9909349083900452
applicators O O 0.999854564666748
with O O 0.9999237060546875
usage O O 0.9996770620346069
information O O 0.9999712705612183
sufficient O O 0.9999630451202393
to O O 0.999987006187439
evaluate O O 0.9999827146530151
exposure O O 0.9945698380470276
- O O 0.9998335838317871
response O O 0.9999574422836304
patterns O O 0.9999899864196777
, O O 0.999980092048645
we O O 0.999976634979248
used O O 0.9999805688858032
Poisson O O 0.9916538596153259
regression O O 0.999186098575592
to O O 0.9999867677688599
estimate O O 0.9999725818634033
adjusted O O 0.9997134804725647
rate O O 0.9997115731239319
ratios O O 0.9999545812606812
( O O 0.9999182224273682
RRs O O 0.9982423782348633
) O O 0.9999768733978271
and O O 0.9999667406082153
95 O O 0.9945535659790039
% O O 0.9988256096839905
CI O O 0.9775395393371582
for O O 0.9998786449432373
cancer O O 0.9999587535858154
sites O O 0.999987006187439
with O O 0.999991774559021
> O O 0.999950647354126
10 O O 0.9999713897705078
exposed O O 0.9999217987060547
cases O O 0.9999924898147583
for O O 0.9997723698616028
both O O 0.9997382760047913
lifetime O O 0.9880141615867615
( O O 0.9986770749092102
LT O O 0.9782769083976746
) O O 0.9996693134307861
exposure O O 0.9998058676719666
days O O 0.9999812841415405
and O O 0.999897837638855
intensity O O 0.9967189431190491
- O O 0.9999042749404907
weighted O O 0.999745786190033
( O O 0.9996960163116455
IW O O 0.9985122084617615
) O O 0.9999046325683594
lifetime O O 0.9990366697311401
exposure O O 0.9996128678321838
days O O 0.999985933303833
( O O 0.9999680519104004
accounting O O 0.9999613761901855
for O O 0.9997054934501648
factors O O 0.999961256980896
impacting O O 0.9999852180480957
exposure O O 0.999903678894043
) O O 0.9999722242355347
. O O 0.9999748468399048

RESULTS O O 0.9998981952667236
: O O 0.9999463558197021
We O O 0.9999558925628662
observed O O 0.999981164932251
elevated O O 0.999902606010437
lung O O 0.9990173578262329
cancer O O 0.9989540576934814
risks O O 0.9999819993972778
( O O 0.999976634979248
N O O 0.9998658895492554
= O O 0.9999663829803467
283 O O 0.9999866485595703
) O O 0.9999430179595947
among O O 0.9233641028404236
applicators O O 0.999698281288147
with O O 0.9999027252197266
the O O 0.9999697208404541
greatest O O 0.9999568462371826
number O O 0.9999362230300903
of O O 0.999596893787384
LT O O 0.919592559337616
( O O 0.9998231530189514
RR O O 0.989474356174469
= O O 0.9987697005271912
1 O O 0.999957799911499
. O O 0.9999865293502808
60 O O 0.9999948740005493
; O O 0.9999573230743408
95 O O 0.9997267127037048
% O O 0.9996869564056396
CI O O 0.9936093091964722
1 O O 0.9999823570251465
. O O 0.999962568283081
11 O O 0.9999953508377075
to O O 0.9966669678688049
2 O O 0.9999246597290039
. O O 0.9999923706054688
31 O O 0.9999935626983643
; O O 0.9999115467071533
Ptrend O O 0.9815607070922852
= O O 0.9984839558601379
0 O O 0.9999856948852539
. O O 0.999995231628418
02 O O 0.9999815225601196
) O O 0.9999312162399292
and O O 0.9998723268508911
IW O O 0.8082455396652222
days O O 0.9999880790710449
of O O 0.9997562766075134
diazinon B B 0.9990708827972412
use O O 0.999815046787262
( O O 0.9999567270278931
RR O O 0.9913169145584106
= O O 0.9999396800994873
1 O O 0.9999954700469971
. O O 0.9999977350234985
41 O O 0.9999977350234985
; O O 0.999981164932251
95 O O 0.9998890161514282
% O O 0.9998787641525269
CI O O 0.9945308566093445
0 O O 0.9999946355819702
. O O 0.9999918937683105
98 O O 0.9997264742851257
to O O 0.9979404807090759
2 O O 0.9998761415481567
. O O 0.9999957084655762
04 O O 0.9999885559082031
; O O 0.9999501705169678
Ptrend O O 0.9675109386444092
= O O 0.9993801116943359
0 O O 0.9999940395355225
. O O 0.9999966621398926
08 O O 0.9999920129776001
) O O 0.9999784231185913
. O O 0.9999784231185913

Kidney O O 0.9676312208175659
cancer O O 0.9992141723632812
( O O 0.9999301433563232
N O O 0.9998070597648621
= O O 0.9999052286148071
94 O O 0.914882481098175
) O O 0.9999207258224487
risks O O 0.9998652935028076
were O O 0.999980092048645
non O O 0.9998669624328613
- O O 0.9999808073043823
significantly O O 0.9999945163726807
elevated O O 0.9998063445091248
( O O 0.9999063014984131
RRLT O O 0.9666450023651123
days O O 0.9911695718765259
= O O 0.9987849593162537
1 O O 0.9999818801879883
. O O 0.9999885559082031
77 O O 0.9999860525131226
; O O 0.9999181032180786
95 O O 0.9937100410461426
% O O 0.9993817806243896
CI O O 0.9852288365364075
0 O O 0.9999842643737793
. O O 0.9999860525131226
90 O O 0.9999501705169678
to O O 0.9988246560096741
3 O O 0.9999687671661377
. O O 0.999995231628418
51 O O 0.9999740123748779
; O O 0.9996874332427979
Ptrend O O 0.9519674777984619
= O O 0.9940577745437622
0 O O 0.9999762773513794
. O O 0.9999945163726807
09 O O 0.9999924898147583
; O O 0.9996374845504761
RRIW O O 0.9250639081001282
days O O 0.9998936653137207
1 O O 0.9999668598175049
. O O 0.9999921321868896
37 O O 0.9999940395355225
; O O 0.9999372959136963
95 O O 0.995415449142456
% O O 0.9995198249816895
CI O O 0.9865708947181702
0 O O 0.9999881982803345
. O O 0.9999881982803345
64 O O 0.9999959468841553
to O O 0.9992547631263733
2 O O 0.9999885559082031
. O O 0.9999881982803345
92 O O 0.9986155033111572
; O O 0.999830961227417
Ptrend O O 0.938244104385376
= O O 0.9995681643486023
0 O O 0.9999825954437256
. O O 0.9999939203262329
50 O O 0.9999881982803345
) O O 0.9999711513519287
, O O 0.9999599456787109
as O O 0.9999866485595703
were O O 0.9999604225158691
risks O O 0.9798335433006287
for O O 0.9998308420181274
aggressive O O 0.9997146725654602
prostate O O 0.9990092515945435
cancer O O 0.9998867511749268
( O O 0.9999741315841675
N O O 0.9999488592147827
= O O 0.9999798536300659
656 O O 0.9999351501464844
) O O 0.9999721050262451
. O O 0.9999759197235107

CONCLUSIONS O O 0.9999473094940186
: O O 0.9999816417694092
Our O O 0.9999830722808838
updated O O 0.9999912977218628
evaluation O O 0.9999005794525146
of O O 0.9947192668914795
diazinon B B 0.9995916485786438
provides O O 0.9998950958251953
additional O O 0.999974250793457
evidence O O 0.9999723434448242
of O O 0.9999765157699585
an O O 0.9999459981918335
association O O 0.9999885559082031
with O O 0.9999866485595703
lung O O 0.999591052532196
cancer O O 0.99982750415802
risk O O 0.9999860525131226
. O O 0.9999834299087524

Newly O O 0.9998503923416138
identified O O 0.9999591112136841
links O O 0.9998780488967896
to O O 0.9998202919960022
kidney O O 0.9428490400314331
cancer O O 0.9993376135826111
and O O 0.9999035596847534
associations O O 0.99998939037323
with O O 0.9999793767929077
aggressive O O 0.9997673630714417
prostate O O 0.9935635328292847
cancer O O 0.999884843826294
require O O 0.9999737739562988
further O O 0.9999918937683105
evaluation O O 0.9999929666519165
. O O 0.9999784231185913

Associations O O 0.9998382329940796
of O O 0.9921735525131226
Ozone B B 0.9982945322990417
and O O 0.9144564270973206
PM2 O B 0.9029187560081482
. O O 0.571628212928772
5 O O 0.4899579882621765
Concentrations O O 0.6247606873512268
With O O 0.9996410608291626
Parkinson O O 0.9970213770866394
' O O 0.9999876022338867
s O O 0.9999847412109375
Disease O O 0.9999876022338867
Among O O 0.9999181032180786
Participants O O 0.9999908208847046
in O O 0.999980092048645
the O O 0.999983549118042
Agricultural O O 0.9993997812271118
Health O O 0.9999750852584839
Study O O 0.999984860420227
. O O 0.999971866607666

OBJECTIVE O O 0.9992086291313171
: O O 0.9999865293502808
This O O 0.9999881982803345
study O O 0.9999828338623047
describes O O 0.9999535083770752
associations O O 0.9999455213546753
of O O 0.9912192225456238
ozone B B 0.986764132976532
and O O 0.9197553992271423
fine O O 0.9145657420158386
particulate B O 0.9904663562774658
matter I O 0.9060261249542236
with O O 0.9998879432678223
Parkinson O O 0.9994538426399231
' O O 0.999990701675415
s O O 0.9999938011169434
disease O O 0.9999961853027344
observed O O 0.9999741315841675
among O O 0.9998670816421509
farmers O O 0.9998351335525513
in O O 0.9998106360435486
North O O 0.9552373886108398
Carolina O O 0.9952037334442139
and O O 0.9993688464164734
Iowa O O 0.9908733367919922
. O O 0.9998927116394043

METHODS O O 0.999792754650116
: O O 0.9999892711639404
We O O 0.9999669790267944
used O O 0.9999703168869019
logistic O O 0.9999301433563232
regression O O 0.99988853931427
to O O 0.9999862909317017
determine O O 0.9999923706054688
the O O 0.999995231628418
associations O O 0.9999953508377075
of O O 0.9999103546142578
these O O 0.8032656311988831
pollutants O O 0.8802377581596375
with O O 0.9999533891677856
self O O 0.9999768733978271
- O O 0.9999916553497314
reported O O 0.9999982118606567
, O O 0.999980092048645
doctor O O 0.9998421669006348
- O O 0.999985933303833
diagnosed O O 0.9999938011169434
Parkinson O O 0.995375394821167
' O O 0.9999871253967285
s O O 0.9999589920043945
disease O O 0.9999899864196777
. O O 0.9999724626541138

Daily O O 0.9998292922973633
predicted O O 0.9999204874038696
pollutant O O 0.9962634444236755
concentrations O O 0.999555766582489
were O O 0.9999661445617676
used O O 0.9999833106994629
to O O 0.9999890327453613
derive O O 0.9999926090240479
surrogates O O 0.9999899864196777
of O O 0.9999866485595703
long O O 0.9998102784156799
- O O 0.999988317489624
term O O 0.9999862909317017
exposure O O 0.9999842643737793
and O O 0.9999830722808838
link O O 0.9999781847000122
them O O 0.9999890327453613
to O O 0.9999922513961792
study O O 0.9999817609786987
participants O O 0.9999984502792358
' O O 0.9999967813491821
geocoded O O 0.9999877214431763
addresses O O 0.9999953508377075
. O O 0.9999815225601196

RESULTS O O 0.9998045563697815
: O O 0.999909520149231
We O O 0.9999462366104126
observed O O 0.9999661445617676
positive O O 0.9998427629470825
associations O O 0.9999743700027466
of O O 0.9999468326568604
Parkinson O O 0.9964732527732849
' O O 0.999980092048645
s O O 0.9999722242355347
disease O O 0.9999858140945435
with O O 0.9995064735412598
ozone B B 0.9932827949523926
( O O 0.9997029900550842
odds O O 0.9998138546943665
ratio O O 0.9999872446060181
= O O 0.9999390840530396
1 O O 0.9999903440475464
. O O 0.9999964237213135
39 O O 0.9999982118606567
; O O 0.9999758005142212
95 O O 0.9999074935913086
% O O 0.9998654127120972
CI O O 0.9956041574478149
: O O 0.9999598264694214
0 O O 0.9999943971633911
. O O 0.999992847442627
98 O O 0.9998486042022705
to O O 0.9982695579528809
1 O O 0.9999948740005493
. O O 0.9999967813491821
98 O O 0.9989148378372192
) O O 0.9999074935913086
and O O 0.998763918876648
fine O O 0.8929228186607361
particulate B O 0.9843071699142456
matter I O 0.9814597368240356
( O O 0.9999229907989502
odds O O 0.9989399313926697
ratio O O 0.9999780654907227
= O O 0.9998494386672974
1 O O 0.9999874830245972
. O O 0.9999947547912598
34 O O 0.9999957084655762
; O O 0.9999595880508423
95 O O 0.9997181296348572
% O O 0.9998757839202881
CI O O 0.996747612953186
: O O 0.9999613761901855
0 O O 0.9999934434890747
. O O 0.9999926090240479
93 O O 0.999985933303833
to O O 0.9984833598136902
1 O O 0.999988317489624
. O O 0.9999892711639404
93 O O 0.999248206615448
) O O 0.9999592304229736
in O O 0.9997702240943909
North O O 0.635897159576416
Carolina O O 0.9881073832511902
but O O 0.9999144077301025
not O O 0.999884843826294
in O O 0.9994587302207947
Iowa O O 0.980643630027771
. O O 0.9999277591705322

CONCLUSIONS O O 0.9999221563339233
: O O 0.9999881982803345
The O O 0.9999940395355225
plausibility O O 0.9999959468841553
of O O 0.9999779462814331
an O O 0.9999333620071411
effect O O 0.9999556541442871
of O O 0.9999330043792725
ambient O O 0.9981226325035095
concentrations O O 0.997840404510498
of O O 0.9987762570381165
these O O 0.9163739681243896
pollutants O O 0.9280189275741577
on O O 0.9998008608818054
Parkinson O O 0.998019814491272
' O O 0.9999805688858032
s O O 0.9999929666519165
disease O O 0.9999904632568359
risk O O 0.9999790191650391
is O O 0.9999679327011108
supported O O 0.9999923706054688
by O O 0.9999912977218628
experimental O O 0.9999731779098511
data O O 0.9999947547912598
demonstrating O O 0.9999673366546631
damage O O 0.9999871253967285
to O O 0.9998925924301147
dopaminergic O O 0.5517225861549377
neurons O O 0.9999619722366333
at O O 0.9995157718658447
relevant O O 0.9996089339256287
concentrations O O 0.9993071556091309
. O O 0.9999619722366333

Additional O O 0.9999561309814453
studies O O 0.9999896287918091
are O O 0.9999855756759644
needed O O 0.9999853372573853
to O O 0.9999899864196777
address O O 0.9999555349349976
uncertainties O O 0.9999905824661255
related O O 0.999991774559021
to O O 0.9997739195823669
confounding O O 0.9976581335067749
and O O 0.9999762773513794
to O O 0.9999864101409912
examine O O 0.999933123588562
temporal O O 0.999775230884552
aspects O O 0.9999954700469971
of O O 0.9999842643737793
the O O 0.9999867677688599
associations O O 0.9999885559082031
we O O 0.9999951124191284
observed O O 0.9999959468841553
. O O 0.9999693632125854

Low O O 0.9989196062088013
functional O O 0.999840497970581
programming O O 0.9997237324714661
of O O 0.9994947910308838
renal O O 0.9987082481384277
AT2R O O 0.9288209080696106
mediates O O 0.9994851350784302
the O O 0.999980092048645
developmental O O 0.9999935626983643
origin O O 0.9999978542327881
of O O 0.9999730587005615
glomerulosclerosis O O 0.9991911053657532
in O O 0.9999485015869141
adult O O 0.9999799728393555
offspring O O 0.9999955892562866
induced O O 0.999990701675415
by O O 0.9999268054962158
prenatal O O 0.9999850988388062
caffeine B B 0.9990693926811218
exposure O O 0.9981948733329773
. O O 0.9999606609344482

UNASSIGNED O O 0.9994913339614868
: O O 0.9999912977218628
Our O O 0.9999951124191284
previous O O 0.9999828338623047
study O O 0.9999936819076538
has O O 0.9999737739562988
indicated O O 0.999975323677063
that O O 0.9998999834060669
prenatal O O 0.9999818801879883
caffeine B B 0.9990025162696838
exposure O O 0.9962762594223022
( O O 0.9995180368423462
PCE O B 0.9794954657554626
) O O 0.9987552165985107
could O O 0.9999363422393799
induce O O 0.9999644756317139
intrauterine O O 0.9999569654464722
growth O O 0.9906994700431824
retardation O O 0.9999756813049316
( O O 0.9999545812606812
IUGR O O 0.998214602470398
) O O 0.9999758005142212
of O O 0.9999392032623291
offspring O O 0.9995114803314209
. O O 0.999975323677063

Recent O O 0.999942421913147
research O O 0.999983549118042
suggested O O 0.9999847412109375
that O O 0.9993865489959717
IUGR O B 0.948183536529541
is O O 0.9988536834716797
a O O 0.9991840720176697
risk O O 0.9998109936714172
factor O O 0.999974250793457
for O O 0.9998685121536255
glomerulosclerosis O O 0.999721348285675
. O O 0.9999399185180664

However O O 0.999945878982544
, O O 0.9999815225601196
whether O O 0.9998905658721924
PCE O B 0.9964637160301208
could O O 0.9996693134307861
induce O O 0.9998834133148193
glomerulosclerosis O O 0.9991098046302795
and O O 0.9999216794967651
its O O 0.9999779462814331
underlying O O 0.999977707862854
mechanisms O O 0.9999778270721436
remain O O 0.9999903440475464
unknown O O 0.9999809265136719
. O O 0.9999721050262451

This O O 0.9999730587005615
study O O 0.9999746084213257
aimed O O 0.9999819993972778
to O O 0.9999814033508301
demonstrate O O 0.9999388456344604
the O O 0.9999628067016602
induction O O 0.9999942779541016
to O O 0.9999721050262451
glomerulosclerosis O O 0.9979730248451233
in O O 0.9999276399612427
adult O O 0.999981164932251
offspring O O 0.9999971389770508
by O O 0.9997667670249939
PCE O O 0.5272470712661743
and O O 0.9997206330299377
its O O 0.9997413754463196
intrauterine O O 0.9990891218185425
programming O O 0.9997921586036682
mechanisms O O 0.9999300241470337
. O O 0.9999643564224243

A O O 0.9999514818191528
rat O O 0.9999697208404541
model O O 0.9999905824661255
of O O 0.9997374415397644
IUGR O O 0.9660248160362244
was O O 0.9999606609344482
established O O 0.9999841451644897
by O O 0.9999419450759888
PCE O O 0.7505101561546326
, O O 0.999906063079834
male O O 0.9999719858169556
fetuses O O 0.9999963045120239
and O O 0.9999254941940308
adult O O 0.9999591112136841
offspring O O 0.9999916553497314
at O O 0.9999927282333374
the O O 0.9999978542327881
age O O 0.9999985694885254
of O O 0.9999966621398926
postnatal O O 0.9999938011169434
week O O 0.9999996423721313
24 O O 0.9999955892562866
were O O 0.99998939037323
euthanized O O 0.9999958276748657
. O O 0.9999841451644897

The O O 0.999977707862854
results O O 0.9999874830245972
revealed O O 0.9999774694442749
that O O 0.999925971031189
the O O 0.999962329864502
adult O O 0.999940037727356
offspring O O 0.9759530425071716
kidneys O O 0.9998306035995483
in O O 0.9997753500938416
the O O 0.999477207660675
PCE O O 0.5022991299629211
group O O 0.9996103644371033
exhibited O O 0.9996104836463928
glomerulosclerosis O O 0.9982681274414062
as O O 0.9999669790267944
well O O 0.9999245405197144
as O O 0.9999351501464844
interstitial O O 0.9972776770591736
fibrosis O O 0.999984860420227
, O O 0.9999786615371704
accompanied O O 0.9999837875366211
by O O 0.9999853372573853
elevated O O 0.9999754428863525
levels O O 0.9999727010726929
of O O 0.999955415725708
serum O O 0.9954937696456909
creatinine B B 0.9955182671546936
and O O 0.9994707703590393
urine O O 0.9997968077659607
protein O O 0.9917934536933899
. O O 0.9999512434005737

Renal O O 0.9954829216003418
angiotensin B B 0.8658376932144165
II I I 0.9355107545852661
receptor O O 0.7354264259338379
type O O 0.5354403853416443
2 O O 0.8311046957969666
( O O 0.8918991684913635
AT2R O O 0.855792224407196
) O O 0.9996494054794312
gene O O 0.9992061257362366
expression O O 0.9999181032180786
in O O 0.999840497970581
adult O O 0.999736487865448
offspring O O 0.9936802387237549
was O O 0.9999425411224365
reduced O O 0.999974250793457
by O O 0.9995055198669434
PCE O B 0.9723353981971741
, O O 0.999316930770874
whereas O O 0.9998934268951416
the O O 0.999966025352478
renal O O 0.9976779818534851
angiotensin B B 0.8612707257270813
II I O 0.8478670716285706
receptor O O 0.5799936056137085
type O O 0.7341071963310242
1a O O 0.7666950225830078
( O O 0.9745352268218994
AT1aR O O 0.9091811180114746
) O O 0.9923858642578125
/ O O 0.9992107152938843
AT2R O O 0.6664945483207703
expression O O 0.99969482421875
ratio O O 0.9994818568229675
was O O 0.9999409914016724
increased O O 0.9998713731765747
. O O 0.9999620914459229

The O O 0.9999840259552002
fetal O O 0.9999909400939941
kidneys O O 0.9997697472572327
in O O 0.9998229146003723
the O O 0.9997953772544861
PCE O O 0.93864506483078
group O O 0.9998815059661865
displayed O O 0.9999233484268188
an O O 0.9999781847000122
enlarged O O 0.9999477863311768
Bowman O O 0.9994440674781799
' O O 0.9999921321868896
s O O 0.9999924898147583
space O O 0.9999775886535645
and O O 0.9999682903289795
a O O 0.99996018409729
shrunken O O 0.9999425411224365
glomerular O O 0.996522068977356
tuft O O 0.9994390606880188
, O O 0.999982476234436
accompanied O O 0.9999774694442749
by O O 0.9999797344207764
a O O 0.9999775886535645
reduced O O 0.9999876022338867
cortex O O 0.9999809265136719
width O O 0.999995231628418
and O O 0.9999744892120361
an O O 0.999982476234436
increase O O 0.9999854564666748
in O O 0.9999749660491943
the O O 0.9999614953994751
nephrogenic O O 0.999542236328125
zone O O 0.9999351501464844
/ O O 0.9998264908790588
cortical O O 0.9986830353736877
zone O O 0.9999624490737915
ratio O O 0.9999749660491943
. O O 0.9999748468399048

Observation O O 0.9999843835830688
by O O 0.9999903440475464
electronic O O 0.9999440908432007
microscope O O 0.9999791383743286
revealed O O 0.9999284744262695
structural O O 0.9999485015869141
damage O O 0.9999945163726807
of O O 0.9998644590377808
podocytes O O 0.9984442591667175
; O O 0.9999539852142334
the O O 0.999983549118042
reduced O O 0.999963641166687
expression O O 0.9999287128448486
level O O 0.9999319314956665
of O O 0.9989192485809326
podocyte O O 0.9970782995223999
marker O O 0.9994460940361023
genes O O 0.9984877109527588
, O O 0.9995929598808289
nephrin O O 0.8947790265083313
and O O 0.9985176920890808
podocin O O 0.9756219387054443
, O O 0.9999531507492065
was O O 0.9999823570251465
also O O 0.9999910593032837
detected O O 0.999993085861206
by O O 0.9999881982803345
q O O 0.9817491769790649
- O O 0.9977582693099976
PCR O O 0.9815015196800232
. O O 0.9999644756317139

Moreover O O 0.9999010562896729
, O O 0.9996639490127563
AT2R O O 0.7741714715957642
gene O O 0.9966704249382019
and O O 0.9997656941413879
protein O O 0.9975263476371765
expressions O O 0.9998769760131836
in O O 0.9998748302459717
fetal O O 0.9999946355819702
kidneys O O 0.9997356534004211
were O O 0.9999154806137085
inhibited O O 0.9997506737709045
by O O 0.9995631575584412
PCE O B 0.9933694005012512
, O O 0.999560534954071
associated O O 0.9999505281448364
with O O 0.999953031539917
the O O 0.9999228715896606
repression O O 0.9999518394470215
of O O 0.9999300241470337
the O O 0.9999150037765503
gene O O 0.9995515942573547
expression O O 0.9999343156814575
of O O 0.9985975623130798
glial O O 0.787144124507904
- O O 0.978076159954071
cell O O 0.9727131128311157
- O O 0.9926998019218445
line O O 0.9872428178787231
- O O 0.998066246509552
derived O O 0.9842153191566467
neurotrophic O O 0.9600787162780762
factor O O 0.9848579168319702
( O O 0.9988429546356201
GDNF O O 0.8048127889633179
) O O 0.9508413076400757
/ O O 0.9944702386856079
tyrosine B O 0.5276486873626709
kinase O O 0.6906958818435669
receptor O O 0.9824346899986267
( O O 0.9976649284362793
c O O 0.9220730066299438
- O O 0.9792323708534241
Ret O O 0.7673710584640503
) O O 0.994200587272644
signaling O O 0.9982976317405701
pathway O O 0.9991945624351501
. O O 0.9999645948410034

These O O 0.9999724626541138
results O O 0.9999854564666748
demonstrated O O 0.9999568462371826
that O O 0.999768078327179
PCE O B 0.9982490539550781
could O O 0.9997286200523376
induce O O 0.9998879432678223
dysplasia O O 0.999970555305481
of O O 0.9999222755432129
fetal O O 0.9999963045120239
kidneys O O 0.999760091304779
as O O 0.9999624490737915
well O O 0.9999144077301025
as O O 0.9999001026153564
glomerulosclerosis O O 0.9993952512741089
of O O 0.9998794794082642
adult O O 0.999226450920105
offspring O O 0.9961613416671753
, O O 0.9999172687530518
and O O 0.9999129772186279
the O O 0.9999561309814453
low O O 0.9997140765190125
functional O O 0.9999107122421265
programming O O 0.9997847676277161
of O O 0.9992212057113647
renal O O 0.986365556716919
AT2R O O 0.8466667532920837
might O O 0.9995230436325073
mediate O O 0.9998257756233215
the O O 0.9999814033508301
developmental O O 0.9999936819076538
origin O O 0.9999984502792358
of O O 0.9999852180480957
adult O O 0.9999514818191528
glomerulosclerosis O O 0.9999034404754639
. O O 0.9999812841415405

1 B B 0.8541869521141052
, I I 0.976410448551178
3 I I 0.7840920686721802
- I I 0.9969895482063293
Butadiene I I 0.9982661604881287
, O O 0.8072257041931152
CML O B 0.9977904558181763
and O O 0.9994298815727234
the O O 0.9999450445175171
t O O 0.9768301248550415
( O O 0.9943646192550659
9 O O 0.9889758825302124
: O O 0.9979420304298401
22 O O 0.8718149662017822
) O O 0.9918578267097473
translocation O O 0.9999042749404907
: O O 0.9999719858169556
A O O 0.9980151653289795
reality O O 0.9999662637710571
check O O 0.9999709129333496
. O O 0.999976396560669

UNASSIGNED O O 0.9991405010223389
: O O 0.9999600648880005
Epidemiological O O 0.9996024966239929
studies O O 0.9999747276306152
of O O 0.9970279335975647
1 B B 0.9018511176109314
, I I 0.9827548861503601
3 I I 0.971723735332489
- I I 0.9954095482826233
butadiene I I 0.9991868138313293
have O O 0.9895630478858948
suggest O O 0.9999632835388184
that O O 0.9997538924217224
exposures O O 0.9999270439147949
to O O 0.999881386756897
humans O O 0.6838801503181458
are O O 0.9994736313819885
associated O O 0.9999629259109497
with O O 0.9999823570251465
chronic O O 0.9993470311164856
myeloid O O 0.9999943971633911
leukemia O O 0.9999922513961792
( O O 0.9999558925628662
CML O O 0.9998331069946289
) O O 0.9999707937240601
. O O 0.9999657869338989

CML O B 0.9734252691268921
has O O 0.9995715022087097
a O O 0.9999513626098633
well O O 0.9998290538787842
- O O 0.9999938011169434
documented O O 0.9999922513961792
association O O 0.9999899864196777
with O O 0.9998155236244202
ionizing O O 0.5683795809745789
radiation O O 0.7908146977424622
, O O 0.9997063279151917
but O O 0.9999408721923828
reports O O 0.999995231628418
of O O 0.999983549118042
associations O O 0.999985933303833
with O O 0.9998601675033569
chemical O O 0.9980213642120361
exposures O O 0.9998869895935059
have O O 0.9999828338623047
been O O 0.9999924898147583
questioned O O 0.9999924898147583
. O O 0.999975323677063

Ionizing O O 0.858569324016571
radiation O O 0.8218980431556702
is O O 0.9994705319404602
capable O O 0.9999138116836548
of O O 0.9998906850814819
inducing O O 0.9999374151229858
the O O 0.9999719858169556
requisite O O 0.9925768971443176
CML O O 0.9179691076278687
- O O 0.9994327425956726
associated O O 0.9997331500053406
t O O 0.9888736009597778
( O O 0.9960588216781616
9 O O 0.9941269159317017
: O O 0.9982130527496338
22 O O 0.9305435419082642
) O O 0.9892132878303528
translocation O O 0.9999444484710693
( O O 0.9996606111526489
Philadelphia O O 0.9410607218742371
chromosome O O 0.9951270818710327
) O O 0.9999583959579468
in O O 0.9998352527618408
appropriate O O 0.9984103441238403
cells O O 0.9999914169311523
in O O 0.9999589920043945
vitro O O 0.9999920129776001
but O O 0.999948263168335
, O O 0.999993085861206
thus O O 0.9999980926513672
far O O 0.9999923706054688
, O O 0.9999791383743286
chemicals O O 0.9997649788856506
have O O 0.9999936819076538
not O O 0.9999868869781494
shown O O 0.9999709129333496
this O O 0.9999709129333496
capacity O O 0.9999744892120361
. O O 0.9999679327011108

We O O 0.9999399185180664
have O O 0.999993085861206
proposed O O 0.9999902248382568
that O O 0.9998854398727417
1 B B 0.9597018361091614
, I I 0.9877194166183472
3 I I 0.9798457026481628
- I I 0.9920250177383423
butadiene I I 0.9990691542625427
metabolites O O 0.7999742031097412
be O O 0.999975323677063
so O O 0.9999638795852661
tested O O 0.999957799911499
as O O 0.9999864101409912
a O O 0.9999661445617676
reality O O 0.999982476234436
check O O 0.9999945163726807
on O O 0.9999924898147583
the O O 0.9999936819076538
epidemiological O O 0.9999899864196777
reports O O 0.9999983310699463
. O O 0.9999723434448242

In O O 0.9999808073043823
order O O 0.9999895095825195
to O O 0.9999926090240479
conduct O O 0.9999929666519165
reliable O O 0.999994158744812
testing O O 0.9999957084655762
in O O 0.9999829530715942
this O O 0.9999850988388062
regard O O 0.9999785423278809
, O O 0.999958872795105
it O O 0.9999784231185913
is O O 0.9999628067016602
essential O O 0.9999880790710449
that O O 0.9999945163726807
a O O 0.999977707862854
positive O O 0.9998890161514282
control O O 0.999992847442627
for O O 0.9973700046539307
induction O O 0.9988025426864624
be O O 0.9999762773513794
available O O 0.9999815225601196
. O O 0.9999721050262451

We O O 0.9997103810310364
have O O 0.999992847442627
used O O 0.9999432563781738
ionizing O O 0.7990851402282715
radiation O O 0.8896365165710449
to O O 0.9998742341995239
develop O O 0.9999871253967285
such O O 0.999935507774353
a O O 0.9999594688415527
control O O 0.9999606609344482
. O O 0.999956488609314

Results O O 0.9999927282333374
described O O 0.999997615814209
here O O 0.9999850988388062
demonstrate O O 0.9999817609786987
that O O 0.9999527931213379
this O O 0.9766001105308533
agent O O 0.9894430637359619
does O O 0.9999512434005737
in O O 0.9999822378158569
fact O O 0.9999395608901978
induce O O 0.9999085664749146
pathogenic O O 0.9999699592590332
t O O 0.9870692491531372
( O O 0.9980202913284302
9 O O 0.9940181970596313
: O O 0.9987937211990356
22 O O 0.9605096578598022
) O O 0.9950017333030701
translocations O O 0.9998539686203003
in O O 0.999963641166687
a O O 0.9999560117721558
human O O 0.99973064661026
myeloid O O 0.999995231628418
cell O O 0.9999880790710449
line O O 0.9999840259552002
in O O 0.9999275207519531
vitro O O 0.9999853372573853
, O O 0.9999465942382812
but O O 0.999901294708252
does O O 0.9999643564224243
so O O 0.9999629259109497
at O O 0.9999232292175293
low O O 0.9999532699584961
frequencies O O 0.9999898672103882
. O O 0.9999727010726929

Conditions O O 0.9998984336853027
that O O 0.9999821186065674
will O O 0.99998939037323
be O O 0.9999946355819702
required O O 0.9999724626541138
for O O 0.9999822378158569
studies O O 0.9999374151229858
of O O 0.9996784925460815
1 B B 0.982714831829071
, I I 0.9946227073669434
3 I I 0.9789998531341553
- I I 0.9977255463600159
butadiene I I 0.9996700286865234
are O O 0.9998185038566589
discussed O O 0.9999877214431763
. O O 0.9999827146530151

Cancer O O 0.793913722038269
incidence O O 0.9999195337295532
and O O 0.9998283386230469
metolachlor B B 0.9998370409011841
use O O 0.9997144341468811
in O O 0.9999423027038574
the O O 0.999951958656311
Agricultural O O 0.9990552067756653
Health O O 0.999932050704956
Study O O 0.9999855756759644
: O O 0.9999815225601196
An O O 0.9999127388000488
update O O 0.9999513626098633
. O O 0.999976396560669

UNASSIGNED O O 0.9930106997489929
: O O 0.9980792999267578
Metolachlor B B 0.9996558427810669
, O O 0.9998773336410522
a O O 0.9992921352386475
widely O O 0.9851741194725037
used O O 0.9992712140083313
herbicide O O 0.5430540442466736
, O O 0.9997608065605164
is O O 0.9998717308044434
classified O O 0.9999420642852783
as O O 0.9998526573181152
a O O 0.9995021820068359
Group O O 0.914660632610321
C O O 0.8498687148094177
carcinogen O O 0.9950689077377319
by O O 0.9999619722366333
the O O 0.9999758005142212
U O O 0.9993942975997925
. O O 0.9999781847000122
S O O 0.9999922513961792
. O O 0.9999450445175171

Environmental O O 0.9687235355377197
Protection O O 0.9814914464950562
Agency O O 0.99985671043396
based O O 0.9999432563781738
on O O 0.9999094009399414
increased O O 0.9999562501907349
liver O O 0.9987485408782959
neoplasms O O 0.9999445676803589
in O O 0.9999157190322876
female O O 0.9993027448654175
rats O O 0.9999854564666748
. O O 0.999723494052887

Epidemiologic O O 0.9998164772987366
studies O O 0.9999871253967285
of O O 0.9999325275421143
the O O 0.9999305009841919
health O O 0.9997681975364685
effects O O 0.9999707937240601
of O O 0.9995343685150146
metolachlor B B 0.9996178150177002
have O O 0.9998641014099121
been O O 0.9999918937683105
limited O O 0.9999926090240479
. O O 0.9999744892120361

The O O 0.999990701675415
Agricultural O O 0.999764621257782
Health O O 0.999970555305481
Study O O 0.9999901056289673
( O O 0.9999680519104004
AHS O O 0.9637179970741272
) O O 0.9999959468841553
is O O 0.9999938011169434
a O O 0.999995231628418
prospective O O 0.9999929666519165
cohort O O 0.9999622106552124
study O O 0.9999920129776001
including O O 0.9999639987945557
licensed O O 0.9996408224105835
private O O 0.9968774318695068
and O O 0.9992327690124512
commercial O O 0.9995148181915283
pesticide O O 0.5447096228599548
applicators O O 0.9983528852462769
in O O 0.999629020690918
Iowa O O 0.9644034504890442
and O O 0.9994662404060364
North O O 0.7745405435562134
Carolina O O 0.9579949378967285
enrolled O O 0.9999754428863525
1993 O O 0.9847871661186218
- O O 0.9983869791030884
1997 O O 0.865294873714447
. O O 0.9999804496765137

We O O 0.9999563694000244
evaluated O O 0.9999909400939941
cancer O O 0.99951171875
incidence O O 0.999996542930603
through O O 0.9999924898147583
2010 O O 0.9999983310699463
/ O O 0.9999786615371704
2011 O O 0.9999967813491821
( O O 0.9999387264251709
NC O O 0.9866651296615601
/ O O 0.9981279969215393
IA O O 0.9957805871963501
) O O 0.9999593496322632
for O O 0.9997901320457458
49 O O 0.9999628067016602
, O O 0.9999871253967285
616 O O 0.9999932050704956
applicators O O 0.9999005794525146
, O O 0.999966025352478
53 O O 0.9999926090240479
% O O 0.9999969005584717
of O O 0.9999910593032837
whom O O 0.999982476234436
reported O O 0.9999853372573853
ever O O 0.9998255372047424
using O O 0.9988177418708801
metolachlor B B 0.9997158646583557
. O O 0.9999212026596069

We O O 0.999968409538269
used O O 0.9999700784683228
Poisson O O 0.9891313314437866
regression O O 0.9997259974479675
to O O 0.9999802112579346
evaluate O O 0.9999854564666748
relations O O 0.999995231628418
between O O 0.9999330043792725
two O O 0.9999268054962158
metrics O O 0.999943733215332
of O O 0.9998984336853027
metolachlor B B 0.9995611310005188
use O O 0.9995548129081726
( O O 0.9999241828918457
lifetime O O 0.996791660785675
days O O 0.999987006187439
, O O 0.9999226331710815
intensity O O 0.997260570526123
- O O 0.9999698400497437
weighted O O 0.9998464584350586
lifetime O O 0.9974647760391235
days O O 0.9999911785125732
) O O 0.9999610185623169
and O O 0.9999638795852661
cancer O O 0.9999688863754272
incidence O O 0.9999948740005493
. O O 0.9999822378158569

We O O 0.9999567270278931
saw O O 0.999995231628418
no O O 0.9999867677688599
association O O 0.9999898672103882
between O O 0.9996211528778076
metolachlor B B 0.9998119473457336
use O O 0.9994926452636719
and O O 0.9999274015426636
incidence O O 0.9999963045120239
of O O 0.9999812841415405
all O O 0.9997531771659851
cancers O O 0.9999809265136719
combined O O 0.9999692440032959
( O O 0.9999569654464722
n O O 0.9999572038650513
= O O 0.9999538660049438
5 O O 0.9999332427978516
, O O 0.9999778270721436
701 O O 0.9997912049293518
with O O 0.9999723434448242
a O O 0.9999799728393555
5 O O 0.9999277591705322
- O O 0.9999839067459106
year O O 0.9999852180480957
lag O O 0.9982221722602844
) O O 0.9999673366546631
or O O 0.9999369382858276
most O O 0.9997934699058533
site O O 0.9995802044868469
- O O 0.9999551773071289
specific O O 0.9999768733978271
cancers O O 0.9999430179595947
. O O 0.9999698400497437

For O O 0.9995501637458801
liver O O 0.9532340168952942
cancer O O 0.9988815188407898
, O O 0.99996018409729
in O O 0.9999402761459351
analyses O O 0.9963129162788391
restricted O O 0.9999246597290039
to O O 0.999653697013855
exposed O O 0.997448742389679
workers O O 0.999916672706604
, O O 0.999948263168335
elevations O O 0.9998040795326233
observed O O 0.9999626874923706
at O O 0.999909520149231
higher O O 0.9999419450759888
categories O O 0.9999901056289673
of O O 0.9999148845672607
use O O 0.9996554851531982
were O O 0.9999679327011108
not O O 0.9999890327453613
statistically O O 0.9999834299087524
significant O O 0.9999901056289673
. O O 0.9999744892120361

However O O 0.9999645948410034
, O O 0.9999465942382812
trends O O 0.9999785423278809
for O O 0.9999256134033203
both O O 0.999622106552124
lifetime O O 0.9978563189506531
and O O 0.999815046787262
intensity O O 0.9979991316795349
- O O 0.99997878074646
weighted O O 0.9999812841415405
lifetime O O 0.999853253364563
days O O 0.9999802112579346
of O O 0.9998414516448975
metolachor B B 0.9996284246444702
use O O 0.9994841814041138
were O O 0.9999607801437378
positive O O 0.9999639987945557
and O O 0.9999908208847046
statistically O O 0.9999873638153076
significant O O 0.999992847442627
with O O 0.9999927282333374
an O O 0.9999840259552002
unexposed O O 0.9997121691703796
reference O O 0.9999735355377197
group O O 0.9999741315841675
. O O 0.9999769926071167

A O O 0.9999474287033081
similar O O 0.9999639987945557
pattern O O 0.9999924898147583
was O O 0.999983549118042
observed O O 0.9999915361404419
for O O 0.9998058676719666
follicular O O 0.999115526676178
cell O O 0.999721109867096
lymphoma O O 0.9998428821563721
, O O 0.9999309778213501
but O O 0.9999107122421265
no O O 0.9999213218688965
other O O 0.9998947381973267
lymphoma O O 0.9996527433395386
subtypes O O 0.9992581009864807
. O O 0.9999673366546631

An O O 0.9999874830245972
earlier O O 0.9999847412109375
suggestion O O 0.9999953508377075
of O O 0.9999719858169556
increased O O 0.9999756813049316
lung O O 0.99925297498703
cancer O O 0.999503493309021
risk O O 0.9999967813491821
at O O 0.9999351501464844
high O O 0.9997791647911072
levels O O 0.9998593330383301
of O O 0.9955610036849976
metolachlor B B 0.999800980091095
use O O 0.9852985143661499
in O O 0.9999481439590454
this O O 0.9999734163284302
cohort O O 0.9999003410339355
was O O 0.9999731779098511
not O O 0.9999905824661255
confirmed O O 0.999993085861206
in O O 0.9999818801879883
this O O 0.9999722242355347
update O O 0.9997566342353821
. O O 0.9999830722808838

This O O 0.9999901056289673
suggestion O O 0.999987006187439
of O O 0.9999644756317139
an O O 0.9999656677246094
association O O 0.9999862909317017
between O O 0.9996930360794067
metolachlor B B 0.9998229146003723
and O O 0.9990386962890625
liver O O 0.9904745221138
cancer O O 0.9999430179595947
among O O 0.9981903433799744
pesticide O O 0.7471131682395935
applicators O O 0.9955565333366394
is O O 0.9999699592590332
a O O 0.999974250793457
novel O O 0.9999938011169434
finding O O 0.9999929666519165
and O O 0.9999814033508301
echoes O O 0.9999680519104004
observation O O 0.9999949932098389
of O O 0.9999861717224121
increased O O 0.9999635219573975
liver O O 0.9922767281532288
neoplasms O O 0.9999359846115112
in O O 0.9999758005142212
some O O 0.9999818801879883
animal O O 0.9999806880950928
studies O O 0.9999819993972778
. O O 0.9999686479568481

However O O 0.999963641166687
, O O 0.9999760389328003
our O O 0.9999871253967285
findings O O 0.9999945163726807
for O O 0.9999626874923706
both O O 0.9998980760574341
liver O O 0.9812304973602295
cancer O O 0.9999589920043945
and O O 0.9998206496238708
follicular O O 0.999336302280426
cell O O 0.9996615648269653
lymphoma O O 0.9999537467956543
warrant O O 0.999923825263977
follow O O 0.9999678134918213
- O O 0.9999867677688599
up O O 0.999991774559021
to O O 0.9999910593032837
better O O 0.9999806880950928
differentiate O O 0.9999396800994873
effects O O 0.9999074935913086
of O O 0.9993521571159363
metolachlor B B 0.9997751116752625
use O O 0.9486087560653687
from O O 0.9996191263198853
other O O 0.9994090795516968
factors O O 0.9999470710754395
. O O 0.9999682903289795

Mechanisms O O 0.9998972415924072
Underlying O O 0.9999727010726929
Latent O O 0.9999514818191528
Disease O O 0.9999953508377075
Risk O O 0.9999905824661255
Associated O O 0.9999758005142212
with O O 0.9999228715896606
Early O O 0.9999258518218994
- O O 0.9998993873596191
Life O O 0.9998716115951538
Arsenic B B 0.9978010058403015
Exposure O O 0.9992339611053467
: O O 0.9999376535415649
Current O O 0.9999866485595703
Research O O 0.9999855756759644
Trends O O 0.9999964237213135
and O O 0.9999829530715942
Scientific O O 0.9999948740005493
Gaps O O 0.9999964237213135
. O O 0.9999778270721436

BACKGROUND O O 0.9986914992332458
: O O 0.9999864101409912
Millions O O 0.999984622001648
of O O 0.9999716281890869
individuals O O 0.9999881982803345
worldwide O O 0.9999805688858032
, O O 0.9999840259552002
particularly O O 0.9999727010726929
those O O 0.9999760389328003
living O O 0.9999895095825195
in O O 0.9999760389328003
rural O O 0.9999793767929077
and O O 0.9999527931213379
developing O O 0.9999812841415405
areas O O 0.9999884366989136
, O O 0.9999685287475586
are O O 0.9999501705169678
exposed O O 0.9999639987945557
to O O 0.9999222755432129
harmful O O 0.999858021736145
levels O O 0.9996625185012817
of O O 0.9970462918281555
inorganic B B 0.9240840673446655
arsenic I I 0.9665554165840149
( O O 0.946191132068634
iAs B B 0.9378356337547302
) O O 0.992615818977356
in O O 0.9997077584266663
their O O 0.9999545812606812
drinking O O 0.9997465014457703
water O O 0.9960806965827942
. O O 0.9999459981918335

Inorganic B O 0.8153325915336609
As I B 0.8950875997543335
exposure O O 0.9975206255912781
during O O 0.9998270869255066
key O O 0.9996452331542969
developmental O O 0.999988317489624
periods O O 0.9999903440475464
is O O 0.9999139308929443
associated O O 0.9999721050262451
with O O 0.9999808073043823
a O O 0.9999595880508423
variety O O 0.9999860525131226
of O O 0.999954342842102
adverse O O 0.9999536275863647
health O O 0.999969482421875
effects O O 0.9999898672103882
including O O 0.9999715089797974
those O O 0.999982476234436
that O O 0.9999833106994629
are O O 0.9999915361404419
evident O O 0.9999920129776001
in O O 0.9999854564666748
adulthood O O 0.9999736547470093
. O O 0.9999686479568481

There O O 0.999975323677063
is O O 0.9999774694442749
considerable O O 0.9999874830245972
interest O O 0.999992847442627
in O O 0.9999910593032837
identifying O O 0.9999709129333496
the O O 0.9999690055847168
molecular O O 0.9999727010726929
mechanisms O O 0.9999721050262451
that O O 0.9999744892120361
relate O O 0.9999356269836426
early O O 0.9995928406715393
- O O 0.9998482465744019
life O O 0.99928218126297
iAs B O 0.901029109954834
exposure O O 0.9997878670692444
to O O 0.9999547004699707
the O O 0.999987006187439
development O O 0.9999951124191284
of O O 0.9999724626541138
these O O 0.9998747110366821
latent O O 0.9997850060462952
diseases O O 0.9999963045120239
, O O 0.999980092048645
particularly O O 0.9999768733978271
in O O 0.9999649524688721
relationship O O 0.9999892711639404
to O O 0.9999737739562988
cancer O O 0.9999855756759644
. O O 0.9999638795852661

OBJECTIVES O O 0.9996592998504639
: O O 0.9999864101409912
This O O 0.9999842643737793
work O O 0.9999884366989136
summarizes O O 0.9999207258224487
research O O 0.9999910593032837
on O O 0.999947190284729
the O O 0.999969482421875
molecular O O 0.9999674558639526
mechanisms O O 0.9999886751174927
that O O 0.9999841451644897
underlie O O 0.9999866485595703
the O O 0.9999955892562866
increased O O 0.9999920129776001
risk O O 0.9999983310699463
of O O 0.9999852180480957
cancer O O 0.9999507665634155
development O O 0.9999964237213135
in O O 0.9999626874923706
adulthood O O 0.9999666213989258
that O O 0.9999809265136719
is O O 0.9999920129776001
associated O O 0.9999878406524658
with O O 0.9998637437820435
early O O 0.9994112253189087
- O O 0.9995080232620239
life O O 0.996542751789093
iAs B B 0.9832746386528015
exposure O O 0.993804931640625
. O O 0.9999734163284302

DISCUSSION O O 0.9966530203819275
: O O 0.9991183876991272
Epigenetic O O 0.9971417784690857
reprogramming O O 0.9996418952941895
that O O 0.9997941851615906
imparts O O 0.999968409538269
functional O O 0.9999586343765259
changes O O 0.9999970197677612
in O O 0.9999773502349854
gene O O 0.9997639060020447
expression O O 0.9999905824661255
, O O 0.9998962879180908
the O O 0.9999481439590454
development O O 0.9999873638153076
of O O 0.9999556541442871
cancer O O 0.9997144341468811
stem O O 0.9999752044677734
cells O O 0.9999958276748657
, O O 0.9995423555374146
and O O 0.999711811542511
immunomodulation O O 0.9983201622962952
are O O 0.9999330043792725
plausible O O 0.9994717240333557
underlying O O 0.9999693632125854
mechanisms O O 0.9999517202377319
by O O 0.9999518394470215
which O O 0.9999581575393677
early O O 0.9972144961357117
- O O 0.9998295307159424
life O O 0.9983875751495361
iAs B B 0.8702268004417419
exposure O O 0.6084074974060059
elicits O O 0.9999368190765381
latent O O 0.9999610185623169
carcinogenic O O 0.9999309778213501
effects O O 0.9999821186065674
. O O 0.9999644756317139

CONCLUSIONS O O 0.9794401526451111
: O O 0.9999310970306396
Evidence O O 0.9999468326568604
is O O 0.9999605417251587
mounting O O 0.9999271631240845
that O O 0.9999333620071411
relates O O 0.9994762539863586
early O O 0.9986263513565063
- O O 0.9998041987419128
life O O 0.9970364570617676
iAs B B 0.9189677834510803
exposure O O 0.9462924599647522
and O O 0.9999045133590698
cancer O O 0.9998687505722046
development O O 0.9999934434890747
later O O 0.9999839067459106
in O O 0.9999959468841553
life O O 0.9999955892562866
. O O 0.9999707937240601

Future O O 0.9999676942825317
research O O 0.999995231628418
should O O 0.9999812841415405
include O O 0.9999761581420898
animal O O 0.9999918937683105
studies O O 0.999991774559021
that O O 0.9999631643295288
address O O 0.9992871880531311
mechanistic O O 0.9999266862869263
hypotheses O O 0.9998972415924072
and O O 0.9999575614929199
studies O O 0.9999868869781494
of O O 0.9999831914901733
human O O 0.9999560117721558
populations O O 0.9999918937683105
that O O 0.9999690055847168
integrate O O 0.9978896975517273
early O O 0.9997743964195251
- O O 0.999927282333374
life O O 0.9999560117721558
exposure O O 0.9999426603317261
, O O 0.9999542236328125
molecular O O 0.9999768733978271
alterations O O 0.999990701675415
, O O 0.999834418296814
and O O 0.9999121427536011
latent O O 0.9999573230743408
disease O O 0.9999912977218628
outcomes O O 0.9999828338623047
. O O 0.999980092048645

Nifedipine B B 0.9995326995849609
induced O O 0.9998651742935181
bradycardia O O 0.9999723434448242
in O O 0.99996018409729
a O O 0.9999752044677734
patient O O 0.9999855756759644
with O O 0.9999570846557617
autonomic O O 0.9538037776947021
neuropathy O O 0.9999841451644897
. O O 0.9999392032623291

An O O 0.9999873638153076
80 O O 0.9999829530715942
year O O 0.9999984502792358
old O O 0.9999947547912598
diabetic O O 0.9998801946640015
male O O 0.9999934434890747
with O O 0.9999363422393799
evidence O O 0.9999866485595703
of O O 0.9999580383300781
peripheral O O 0.9987092018127441
and O O 0.9995806813240051
autonomic O O 0.9002297520637512
neuropathy O O 0.9999761581420898
was O O 0.9999310970306396
admitted O O 0.999967098236084
with O O 0.9999874830245972
chest O O 0.9999934434890747
pain O O 0.9999940395355225
. O O 0.999983549118042

He O O 0.9999675750732422
was O O 0.9999675750732422
found O O 0.9999942779541016
to O O 0.9999754428863525
have O O 0.9999775886535645
atrial O O 0.9998918771743774
flutter O O 0.9999966621398926
at O O 0.999976634979248
a O O 0.9999874830245972
ventricular O O 0.9999891519546509
rate O O 0.9999922513961792
of O O 0.9999313354492188
70 O O 0.9999910593032837
/ O O 0.9999711513519287
min O O 0.9999830722808838
which O O 0.9999477863311768
slowed O O 0.9999895095825195
down O O 0.9999819993972778
to O O 0.9999817609786987
30 O O 0.9999836683273315
- O O 0.9997503161430359
40 O O 0.9999963045120239
/ O O 0.9999877214431763
min O O 0.9999754428863525
when O O 0.9965924620628357
nifedipine B B 0.9997797608375549
( O O 0.9983044862747192
60 O O 0.9990921020507812
mg O O 0.9963300824165344
) O O 0.9996008276939392
in O O 0.9996240139007568
3 O O 0.9976269602775574
divided O O 0.9998101592063904
doses O O 0.9998921155929565
, O O 0.9999624490737915
during O O 0.9999575614929199
which O O 0.9999381303787231
he O O 0.999976396560669
was O O 0.9999665021896362
paced O O 0.9999891519546509
at O O 0.9999839067459106
a O O 0.9999816417694092
rate O O 0.9999904632568359
of O O 0.9999202489852905
70 O O 0.999984622001648
/ O O 0.9999666213989258
min O O 0.999910831451416
. O O 0.9999527931213379

This O O 0.9999804496765137
is O O 0.9999828338623047
inconsistent O O 0.9999938011169434
with O O 0.9999947547912598
the O O 0.9999909400939941
well O O 0.9999200105667114
- O O 0.9999892711639404
established O O 0.9999903440475464
finding O O 0.9999916553497314
that O O 0.9999184608459473
nifedipine B B 0.9997662901878357
induces O O 0.9997557997703552
tachycardia O O 0.999983549118042
in O O 0.9997695088386536
normally O O 0.9994035959243774
innervated O O 0.9997010231018066
hearts O O 0.9999747276306152
. O O 0.9999750852584839

However O O 0.9999080896377563
, O O 0.9999308586120605
in O O 0.9999034404754639
hearts O O 0.9975403547286987
deprived O O 0.9992824196815491
of O O 0.9995192289352417
compensatory O O 0.9975842237472534
sympathetic O O 0.9744046926498413
drive O O 0.9999427795410156
, O O 0.9999477863311768
it O O 0.9999097585678101
may O O 0.999962329864502
lead O O 0.9999942779541016
to O O 0.9999797344207764
bradycardia O O 0.9999884366989136
. O O 0.9999704360961914

The O O 0.9998167157173157
effect O O 0.9998379945755005
of O O 0.9994415640830994
haloperidol B B 0.9997462630271912
in O O 0.9993202686309814
cocaine B B 0.9955886602401733
and O O 0.9948965907096863
amphetamine B B 0.9846311211585999
intoxication O O 0.999630331993103
. O O 0.999944806098938

The O O 0.9999629259109497
effectiveness O O 0.9999589920043945
of O O 0.9998002648353577
haloperidol B B 0.9998238682746887
pretreatment O O 0.9986729621887207
in O O 0.9999449253082275
preventing O O 0.999846339225769
the O O 0.9999572038650513
toxic O O 0.9998263716697693
effects O O 0.9999439716339111
of O O 0.999921441078186
high O O 0.9997729659080505
doses O O 0.9997751116752625
of O O 0.9988189339637756
amphetamine B B 0.9971219897270203
and O O 0.9080139398574829
cocaine B B 0.9960804581642151
was O O 0.9999133348464966
studied O O 0.9999563694000244
in O O 0.9999474287033081
rats O O 0.9999860525131226
. O O 0.9999722242355347

In O O 0.9999576807022095
this O O 0.9999642372131348
model O O 0.9999955892562866
, O O 0.9998642206192017
toxic O O 0.999832272529602
effects O O 0.9999599456787109
were O O 0.9999679327011108
induced O O 0.9999864101409912
by O O 0.9999170303344727
intraperitoneal O O 0.999961256980896
( O O 0.9997534155845642
i O O 0.999942421913147
. O O 0.9999949932098389
p O O 0.9999986886978149
. O O 0.9999959468841553
) O O 0.9999616146087646
injection O O 0.9999579191207886
of O O 0.9997255206108093
amphetamine B B 0.997337281703949
75 O O 0.8085542321205139
mg O O 0.9995397329330444
/ O O 0.9999648332595825
kg O O 0.9999904632568359
( O O 0.9999489784240723
100 O O 0.9999583959579468
% O O 0.9999897480010986
death O O 0.9999711513519287
rate O O 0.9998610019683838
) O O 0.9999046325683594
or O O 0.9947443008422852
cocaine B B 0.9932764768600464
70 O O 0.5748966336250305
mg O O 0.9936489462852478
/ O O 0.9999170303344727
kg O O 0.9999916553497314
( O O 0.9999517202377319
82 O O 0.9999486207962036
% O O 0.9999903440475464
death O O 0.9999865293502808
rate O O 0.9999415874481201
) O O 0.9999575614929199
. O O 0.9999719858169556

Haloperidol B B 0.9991623163223267
failed O O 0.9996340274810791
to O O 0.9999666213989258
prevent O O 0.999523401260376
amphetamine B B 0.9977319240570068
- O O 0.9998605251312256
induced O O 0.999934196472168
seizures O O 0.9999825954437256
, O O 0.9999376535415649
but O O 0.9976651668548584
did O O 0.9999258518218994
lower O O 0.9999561309814453
the O O 0.9999864101409912
mortality O O 0.9999475479125977
rate O O 0.9999817609786987
at O O 0.9999425411224365
most O O 0.9999666213989258
doses O O 0.9999310970306396
tested O O 0.9999830722808838
. O O 0.9999357461929321

Haloperidol B B 0.9992184638977051
decreased O O 0.9999130964279175
the O O 0.9999828338623047
incidence O O 0.9999954700469971
of O O 0.9999643564224243
cocaine B B 0.9958542585372925
- O O 0.9993888139724731
induced O O 0.9999427795410156
seizures O O 0.9999856948852539
at O O 0.9997864365577698
the O O 0.9999041557312012
two O O 0.999969482421875
highest O O 0.999863862991333
doses O O 0.9997989535331726
, O O 0.9999344348907471
but O O 0.9999610185623169
the O O 0.9999856948852539
lowering O O 0.9999879598617554
of O O 0.9999810457229614
the O O 0.9999592304229736
mortality O O 0.9999176263809204
rate O O 0.9999749660491943
did O O 0.9999856948852539
not O O 0.9999954700469971
reach O O 0.9999834299087524
statistical O O 0.999985933303833
significance O O 0.9999977350234985
at O O 0.9999527931213379
any O O 0.9999669790267944
dose O O 0.9999204874038696
. O O 0.999940037727356

These O O 0.9999852180480957
data O O 0.9999923706054688
suggest O O 0.9998759031295776
a O O 0.9999454021453857
protective O O 0.9998156428337097
role O O 0.9999724626541138
for O O 0.9998121857643127
the O O 0.9993973970413208
central O O 0.9795762300491333
dopamine B B 0.9882721304893494
blocker O O 0.7351715564727783
haloperidol B B 0.9979630708694458
against O O 0.9998056292533875
death O O 0.9999954700469971
from O O 0.9998793601989746
high O O 0.9959516525268555
- O O 0.9998689889907837
dose O O 0.9854737520217896
amphetamine B B 0.9978380799293518
exposure O O 0.99977046251297
without O O 0.9999674558639526
reducing O O 0.999974250793457
the O O 0.9999918937683105
incidence O O 0.9999973773956299
of O O 0.9999845027923584
seizures O O 0.9999878406524658
. O O 0.9999265670776367

In O O 0.9999406337738037
contrast O O 0.9999672174453735
, O O 0.999206006526947
haloperidol B B 0.9998370409011841
demonstrated O O 0.9999207258224487
an O O 0.9999397993087769
ability O O 0.9999061822891235
to O O 0.9999421834945679
reduce O O 0.9997171759605408
cocaine B B 0.9979532957077026
- O O 0.9996684789657593
induced O O 0.999923586845398
seizures O O 0.9999772310256958
without O O 0.9999498128890991
significantly O O 0.9999817609786987
reducing O O 0.9998905658721924
mortality O O 0.9992504715919495
. O O 0.9999594688415527

Autoradiographic O O 0.9958815574645996
evidence O O 0.9999784231185913
of O O 0.9998664855957031
estrogen B B 0.944420337677002
binding O O 0.976884663105011
sites O O 0.9995669722557068
in O O 0.999861478805542
nuclei O O 0.9997918009757996
of O O 0.9999024868011475
diethylstilbesterol B B 0.9929234981536865
induced O O 0.9990204572677612
hamster O O 0.9964110255241394
renal O O 0.999431312084198
carcinomas O O 0.9997879862785339
. O O 0.9999507665634155

Estrogen B B 0.8965455293655396
binding O O 0.9559256434440613
sites O O 0.9997163414955139
were O O 0.9999722242355347
demonstrated O O 0.9999818801879883
by O O 0.9999892711639404
autoradiography O O 0.9967777132987976
in O O 0.9999375343322754
one O O 0.9999570846557617
transplantable O O 0.9997230172157288
and O O 0.9998573064804077
five O O 0.9998748302459717
primary O O 0.9999700784683228
diethylstilbesterol B B 0.9729096293449402
induced O O 0.9981788396835327
renal O O 0.9999254941940308
carcinomas O O 0.9999464750289917
in O O 0.9999806880950928
three O O 0.9999139308929443
hamsters O O 0.9975454211235046
. O O 0.9999741315841675

Radiolabelling O O 0.5166507363319397
, O O 0.9999796152114868
following O O 0.9999610185623169
the O O 0.9999902248382568
in O O 0.9999542236328125
vivo O O 0.9999916553497314
injection O O 0.9999648332595825
of O O 0.9996767044067383
3H O B 0.9008268713951111
- O I 0.8878721594810486
17 O I 0.9971697926521301
beta O I 0.9942445158958435
estradiol B I 0.9994532465934753
, O O 0.9996826648712158
was O O 0.9999810457229614
increased O O 0.9999278783798218
only O O 0.9999607801437378
over O O 0.9999269247055054
the O O 0.9999829530715942
nuclei O O 0.9999685287475586
of O O 0.999976396560669
tumor O O 0.9999768733978271
cells O O 0.999992847442627
; O O 0.9999688863754272
stereologic O O 0.9999402761459351
analysis O O 0.9999935626983643
revealed O O 0.9999725818634033
a O O 0.9999778270721436
4 O O 0.9999414682388306
. O O 0.9999903440475464
5 O O 0.9999778270721436
- O O 0.9999732971191406
to O O 0.9999939203262329
6 O O 0.9999796152114868
. O O 0.9999951124191284
7 O O 0.9999897480010986
- O O 0.9999904632568359
times O O 0.9999951124191284
higher O O 0.9999784231185913
concentration O O 0.9999740123748779
of O O 0.9998530149459839
reduced O O 0.9974318146705627
silver B O 0.6498448252677917
grains O O 0.999077320098877
over O O 0.9992842078208923
nuclei O O 0.9997926354408264
than O O 0.9998962879180908
cytoplasm O O 0.99992835521698
of O O 0.9999282360076904
these O O 0.9999710321426392
cells O O 0.9999934434890747
. O O 0.9999765157699585

Despite O O 0.9998712539672852
rapid O O 0.9999603033065796
tubular O O 0.9999819993972778
excretion O O 0.9999650716781616
of O O 0.9985703229904175
estradiol B B 0.968784511089325
which O O 0.999850869178772
peaked O O 0.9999549388885498
in O O 0.999987006187439
less O O 0.9999947547912598
than O O 0.999995231628418
1 O O 0.9999597072601318
h O O 0.9996013045310974
, O O 0.9999485015869141
the O O 0.9999719858169556
normal O O 0.995721697807312
cells O O 0.9999922513961792
did O O 0.9999665021896362
not O O 0.9999814033508301
appear O O 0.9999665021896362
to O O 0.9999678134918213
bind O O 0.9998284578323364
the O O 0.9997456669807434
ligand O O 0.8660410642623901
. O O 0.999923586845398

This O O 0.9999914169311523
is O O 0.9999948740005493
the O O 0.9999947547912598
first O O 0.9999961853027344
published O O 0.9999970197677612
report O O 0.9999951124191284
documenting O O 0.9998449087142944
the O O 0.9999842643737793
preferential O O 0.9999451637268066
in O O 0.9999468326568604
vivo O O 0.9999719858169556
binding O O 0.9999501705169678
of O O 0.9998441934585571
estrogen B B 0.9787498116493225
to O O 0.9995633959770203
nuclei O O 0.9998912811279297
of O O 0.9998846054077148
cells O O 0.9999855756759644
in O O 0.9999470710754395
estrogen B B 0.9518032073974609
induced O O 0.9964325428009033
hamster O O 0.9966306090354919
renal O O 0.9996535778045654
carcinomas O O 0.9998481273651123
. O O 0.9999768733978271

Bradycardia O O 0.9978888630867004
due O O 0.9999639987945557
to O O 0.9852046966552734
biperiden B B 0.938099205493927
. O O 0.9993816614151001

In O O 0.9999572038650513
a O O 0.999991774559021
38 O O 0.9999958276748657
- O O 0.9999841451644897
year O O 0.9999955892562866
- O O 0.9999935626983643
old O O 0.9999946355819702
male O O 0.9999942779541016
patient O O 0.9999703168869019
suffering O O 0.9999735355377197
from O O 0.9999885559082031
a O O 0.9999865293502808
severe O O 0.9999781847000122
postzosteric O O 0.9960481524467468
trigeminal O O 0.9995551705360413
neuralgia O O 0.9999964237213135
, O O 0.9999394416809082
intravenous O O 0.999963641166687
application O O 0.9999653100967407
of O O 0.9989805817604065
10 O O 0.9986013770103455
mg O O 0.9957413673400879
biperiden B O 0.9175387620925903
lactate I B 0.8526224493980408
led O O 0.9999191761016846
to O O 0.9999868869781494
a O O 0.9999935626983643
long O O 0.9999022483825684
- O O 0.9999897480010986
lasting O O 0.9999861717224121
paradoxical O O 0.9997797608375549
reaction O O 0.9999969005584717
characterized O O 0.9999914169311523
by O O 0.9999873638153076
considerable O O 0.9999469518661499
bradycardia O O 0.9999779462814331
, O O 0.9999613761901855
dysarthria O O 0.999997615814209
, O O 0.9999452829360962
and O O 0.9999518394470215
dysphagia O O 0.999982476234436
. O O 0.9999580383300781

The O O 0.9999802112579346
heart O O 0.999993085861206
rate O O 0.9999780654907227
was O O 0.999967098236084
back O O 0.9999912977218628
to O O 0.9999895095825195
normal O O 0.9999946355819702
within O O 0.9999889135360718
12 O O 0.999995231628418
hours O O 0.9999918937683105
upon O O 0.9999711513519287
administration O O 0.9999221563339233
of O O 0.9996418952941895
orciprenaline B B 0.9993171691894531
under O O 0.999782145023346
cardiac O O 0.9999862909317017
monitoring O O 0.9999867677688599
in O O 0.9999791383743286
an O O 0.9999896287918091
intensive O O 0.9999915361404419
care O O 0.9999970197677612
unit O O 0.9999970197677612
. O O 0.9999778270721436

Bradycardia O O 0.9999114274978638
induced O O 0.999974250793457
by O O 0.9998682737350464
biperiden B B 0.9973264932632446
is O O 0.9999172687530518
attributed O O 0.9999909400939941
to O O 0.9999228715896606
the O O 0.9999904632568359
speed O O 0.9999924898147583
of O O 0.9999758005142212
injection O O 0.9999542236328125
and O O 0.9999654293060303
to O O 0.9997783303260803
a O O 0.9999170303344727
dose O O 0.9990099668502808
- O O 0.9999594688415527
related O O 0.99997878074646
dual O O 0.9985527396202087
effect O O 0.9999357461929321
of O O 0.9998181462287903
atropine B B 0.9981176853179932
- O O 0.9984058737754822
like O O 0.9976382255554199
drugs O O 0.9980742931365967
on O O 0.9995630383491516
muscarine B O 0.9719142317771912
receptors O O 0.9998893737792969
. O O 0.9999600648880005

Deliberate O O 0.9998278617858887
hypotension O O 0.9998949766159058
induced O O 0.9999676942825317
by O O 0.9998737573623657
labetalol B B 0.9994853734970093
with O O 0.9906706809997559
halothane B B 0.9957094192504883
, O O 0.8346142768859863
enflurane B B 0.9809285998344421
or O O 0.9823529124259949
isoflurane B B 0.9997158646583557
for O O 0.9996914863586426
middle O O 0.9998677968978882
- O O 0.9985910058021545
ear O O 0.9999538660049438
surgery O O 0.9999959468841553
. O O 0.9998847246170044

The O O 0.9999880790710449
feasibility O O 0.9999964237213135
of O O 0.9999786615371704
using O O 0.9998941421508789
labetalol B B 0.9998077750205994
, O O 0.9998639822006226
an O O 0.9980533123016357
alpha O O 0.9511186480522156
- O O 0.9923925399780273
and O O 0.9962659478187561
beta O O 0.9769570827484131
- O O 0.994821310043335
adrenergic O O 0.9838727116584778
blocking O O 0.9789084196090698
agent O O 0.9898432493209839
, O O 0.9999456405639648
as O O 0.9998871088027954
a O O 0.9998921155929565
hypotensive O O 0.9962154030799866
agent O O 0.998978853225708
in O O 0.9999531507492065
combination O O 0.9999366998672485
with O O 0.9997246861457825
inhalation O O 0.9992038607597351
anaesthetics O O 0.7063612341880798
( O O 0.9989796280860901
halothane B B 0.9974499344825745
, O O 0.7061708569526672
enflurane B B 0.9809242486953735
or O O 0.9964554309844971
isoflurane B B 0.9994046688079834
) O O 0.9999021291732788
was O O 0.9999744892120361
studied O O 0.9999896287918091
in O O 0.9999823570251465
23 O O 0.9999847412109375
adult O O 0.9999959468841553
patients O O 0.9999978542327881
undergoing O O 0.999993085861206
middle O O 0.9999082088470459
- O O 0.9997677206993103
ear O O 0.9999324083328247
surgery O O 0.999998927116394
. O O 0.9999798536300659

The O O 0.9999890327453613
mean O O 0.9999940395355225
arterial O O 0.9999346733093262
pressure O O 0.9999685287475586
was O O 0.9999531507492065
decreased O O 0.999987006187439
from O O 0.9999881982803345
86 O O 0.999976634979248
+ O O 0.9999880790710449
/ O O 0.9999794960021973
- O O 0.9999445676803589
5 O O 0.9999151229858398
( O O 0.9999089241027832
s O O 0.9995276927947998
. O O 0.9999879598617554
e O O 0.9999861717224121
. O O 0.9999830722808838
mean O O 0.9999980926513672
) O O 0.9999139308929443
mmHg O O 0.9999905824661255
to O O 0.999948263168335
52 O O 0.9999655485153198
+ O O 0.9999830722808838
/ O O 0.99996018409729
- O O 0.9999591112136841
1 O O 0.9999282360076904
mmHg O O 0.9999771118164062
( O O 0.999900221824646
11 O O 0.9999657869338989
. O O 0.9999939203262329
5 O O 0.9999830722808838
+ O O 0.9999865293502808
/ O O 0.9999728202819824
- O O 0.9999574422836304
0 O O 0.9999858140945435
. O O 0.9999767541885376
7 O O 0.9999916553497314
to O O 0.9999532699584961
6 O O 0.9999600648880005
. O O 0.999992847442627
9 O O 0.9999892711639404
+ O O 0.9999946355819702
/ O O 0.999886155128479
- O O 0.9999614953994751
0 O O 0.9999853372573853
. O O 0.9999942779541016
1 O O 0.9999774694442749
kPa O O 0.6980769634246826
) O O 0.9999485015869141
for O O 0.9999468326568604
98 O O 0.9998623132705688
+ O O 0.999990701675415
/ O O 0.999935507774353
- O O 0.9999338388442993
10 O O 0.999966025352478
min O O 0.9999668598175049
in O O 0.9998975992202759
the O O 0.9996346235275269
halothane B O 0.6840646266937256
( O O 0.9983134269714355
H B O 0.7929940223693848
) O O 0.9980857372283936
group O O 0.999931812286377
, O O 0.9999752044677734
from O O 0.9999767541885376
79 O O 0.9999916553497314
+ O O 0.9999877214431763
/ O O 0.9999600648880005
- O O 0.999850869178772
5 O O 0.9999305009841919
to O O 0.9999315738677979
53 O O 0.9999911785125732
+ O O 0.9999872446060181
/ O O 0.9999511241912842
- O O 0.9999567270278931
1 O O 0.9999250173568726
mmHg O O 0.9999752044677734
( O O 0.9998948574066162
10 O O 0.9999823570251465
. O O 0.999994158744812
5 O O 0.9999849796295166
+ O O 0.9999814033508301
/ O O 0.9999291896820068
- O O 0.9999635219573975
0 O O 0.9999868869781494
. O O 0.9999804496765137
7 O O 0.9999909400939941
to O O 0.9999581575393677
7 O O 0.9999960660934448
. O O 0.9999954700469971
1 O O 0.9999886751174927
+ O O 0.9999889135360718
/ O O 0.9997320771217346
- O O 0.9999451637268066
0 O O 0.999990701675415
. O O 0.9999891519546509
1 O O 0.9999794960021973
kPa O O 0.519966185092926
) O O 0.9999637603759766
for O O 0.999967098236084
129 O O 0.999993085861206
+ O O 0.9999880790710449
/ O O 0.9999333620071411
- O O 0.9999552965164185
11 O O 0.9999629259109497
min O O 0.9999737739562988
in O O 0.9997959733009338
the O O 0.9995958209037781
enflurane B O 0.8181840777397156
( O O 0.9983260035514832
E B O 0.997549831867218
) O O 0.9997685551643372
group O O 0.999925971031189
, O O 0.9999690055847168
and O O 0.9999562501907349
from O O 0.9999816417694092
80 O O 0.9999262094497681
+ O O 0.9999858140945435
/ O O 0.999953031539917
- O O 0.9999151229858398
4 O O 0.9998601675033569
to O O 0.9999110698699951
49 O O 0.9999834299087524
+ O O 0.9999793767929077
/ O O 0.9997115731239319
- O O 0.9999533891677856
1 O O 0.9999059438705444
mmHg O O 0.9998574256896973
( O O 0.9999148845672607
10 O O 0.9999591112136841
. O O 0.9999947547912598
7 O O 0.9999924898147583
+ O O 0.9999864101409912
/ O O 0.9999610185623169
- O O 0.9999562501907349
0 O O 0.9999871253967285
. O O 0.9999786615371704
5 O O 0.9999845027923584
to O O 0.9999542236328125
6 O O 0.9999630451202393
. O O 0.9999904632568359
5 O O 0.9999837875366211
+ O O 0.9999783039093018
/ O O 0.9996122717857361
- O O 0.9999337196350098
0 O O 0.9999730587005615
. O O 0.9999876022338867
1 O O 0.99996018409729
kPa O O 0.4856030344963074
) O O 0.999962568283081
for O O 0.9999551773071289
135 O O 0.9999904632568359
+ O O 0.9999923706054688
/ O O 0.9999641180038452
- O O 0.9999561309814453
15 O O 0.9999912977218628
min O O 0.9999728202819824
in O O 0.9998292922973633
the O O 0.9997109770774841
isoflurane B B 0.9686046242713928
( O O 0.9984488487243652
I B O 0.9998445510864258
) O O 0.9998062252998352
group O O 0.9999521970748901
. O O 0.9999721050262451

The O O 0.9999771118164062
mean O O 0.9996592998504639
H B B 0.8963429927825928
concentration O O 0.9517900347709656
during O O 0.9996731281280518
hypotension O O 0.9999568462371826
in O O 0.9995008707046509
the O O 0.9996542930603027
inspiratory O O 0.9994495511054993
gas O O 0.9989136457443237
was O O 0.9999510049819946
0 O O 0.9999581575393677
. O O 0.9999897480010986
7 O O 0.9999933242797852
+ O O 0.9999867677688599
/ O O 0.9999219179153442
- O O 0.9999078512191772
0 O O 0.9999841451644897
. O O 0.999990701675415
1 O O 0.9999759197235107
vol O O 0.9730843305587769
% O O 0.9999157190322876
, O O 0.9999394416809082
the O O 0.9999691247940063
mean O O 0.9992510676383972
E B O 0.6693757176399231
concentration O O 0.9996557235717773
1 O O 0.9999696016311646
. O O 0.9999880790710449
6 O O 0.9999879598617554
+ O O 0.9999892711639404
/ O O 0.9999189376831055
- O O 0.9999419450759888
0 O O 0.9999908208847046
. O O 0.9999902248382568
2 O O 0.9999802112579346
vol O O 0.9525588750839233
% O O 0.9999110698699951
, O O 0.9999347925186157
and O O 0.9998807907104492
the O O 0.999970555305481
mean O O 0.9986196756362915
I B O 0.6990417242050171
concentration O O 0.9998162388801575
1 O O 0.9999866485595703
. O O 0.999993085861206
0 O O 0.9999943971633911
+ O O 0.9999942779541016
/ O O 0.9999552965164185
- O O 0.9999542236328125
0 O O 0.999991774559021
. O O 0.9999880790710449
1 O O 0.9999819993972778
vol O O 0.9896984696388245
% O O 0.9999759197235107
. O O 0.9999569654464722

In O O 0.999934196472168
addition O O 0.9999817609786987
, O O 0.9999618530273438
the O O 0.9999903440475464
patients O O 0.9999760389328003
received O O 0.9990339279174805
fentanyl B B 0.9998220801353455
and O O 0.9874842762947083
d B B 0.5530421733856201
- I I 0.8447886109352112
tubocurarine I I 0.9995768666267395
. O O 0.9997503161430359

The O O 0.9999909400939941
initial O O 0.9999608993530273
dose O O 0.9998329877853394
of O O 0.99853515625
labetalol B B 0.9996917247772217
for O O 0.9996001124382019
lowering O O 0.9996618032455444
blood O O 0.9998289346694946
pressure O O 0.9995966553688049
was O O 0.9999653100967407
similar O O 0.9999934434890747
, O O 0.9999868869781494
0 O O 0.9999619722366333
. O O 0.9999918937683105
52 O O 0.999954104423523
- O O 0.9978604912757874
0 O O 0.9999915361404419
. O O 0.9999982118606567
59 O O 0.9999964237213135
mg O O 0.9999629259109497
/ O O 0.9999722242355347
kg O O 0.9999977350234985
, O O 0.9999890327453613
in O O 0.999913215637207
all O O 0.9999258518218994
the O O 0.9999674558639526
groups O O 0.9999868869781494
. O O 0.9999810457229614

During O O 0.9997572302818298
hypotension O O 0.9999523162841797
, O O 0.9999580383300781
the O O 0.999990701675415
heart O O 0.9999862909317017
rate O O 0.9999808073043823
was O O 0.999962329864502
stable O O 0.9999840259552002
without O O 0.9999699592590332
tachy O O 0.9999397993087769
- O O 0.9997144341468811
or O O 0.9999690055847168
bradycardia O O 0.9999561309814453
. O O 0.9999697208404541

The O O 0.9999855756759644
operating O O 0.9999873638153076
conditions O O 0.999997615814209
regarding O O 0.9999699592590332
bleeding O O 0.9988130331039429
were O O 0.9999808073043823
estimated O O 0.9999881982803345
in O O 0.9999957084655762
a O O 0.9999909400939941
double O O 0.9999361038208008
- O O 0.9999852180480957
blind O O 0.9999948740005493
manner O O 0.9999963045120239
, O O 0.9999749660491943
and O O 0.9999920129776001
did O O 0.9999947547912598
not O O 0.9999961853027344
differ O O 0.9999970197677612
significantly O O 0.9999940395355225
between O O 0.9998832941055298
the O O 0.9999796152114868
groups O O 0.9999918937683105
. O O 0.9999790191650391

During O O 0.9997062087059021
hypotension O O 0.9996757507324219
, O O 0.9999583959579468
the O O 0.9999874830245972
serum O O 0.9942471981048584
creatinine B B 0.9982770681381226
concentration O O 0.999638557434082
rose O O 0.9999815225601196
significantly O O 0.9999912977218628
in O O 0.9998668432235718
all O O 0.9997660517692566
groups O O 0.9999815225601196
from O O 0.9999885559082031
the O O 0.999992847442627
values O O 0.9999932050704956
before O O 0.999964714050293
hypotension O O 0.999757707118988
and O O 0.9999653100967407
returned O O 0.999984860420227
postoperatively O O 0.9999758005142212
to O O 0.999990701675415
the O O 0.9999949932098389
initial O O 0.9999672174453735
level O O 0.999985933303833
in O O 0.99982750415802
the O O 0.9999531507492065
other O O 0.9999078512191772
groups O O 0.9999788999557495
, O O 0.9999831914901733
except O O 0.9999654293060303
the O O 0.9998503923416138
isoflurane B B 0.9991582632064819
group O O 0.9997625946998596
. O O 0.9999710321426392

After O O 0.999834418296814
hypotension O O 0.9999096393585205
there O O 0.9998981952667236
was O O 0.9999712705612183
no O O 0.9999699592590332
rebound O O 0.9999918937683105
phenomenon O O 0.9999985694885254
in O O 0.9999831914901733
either O O 0.9999505281448364
blood O O 0.9997658133506775
pressure O O 0.9998831748962402
or O O 0.9999586343765259
heart O O 0.999985933303833
rate O O 0.9999854564666748
. O O 0.9999527931213379

These O O 0.9999836683273315
results O O 0.9999864101409912
indicate O O 0.9999631643295288
that O O 0.9997544884681702
labetalol B B 0.9996951818466187
induces O O 0.9997379183769226
easily O O 0.9997568726539612
adjustable O O 0.999987006187439
hypotension O O 0.999966025352478
without O O 0.999887228012085
compensatory O O 0.9998511075973511
tachycardia O O 0.9999604225158691
and O O 0.9998997449874878
rebound O O 0.9999536275863647
hypertension O O 0.9997624754905701
. O O 0.99996018409729

Convulsion O O 0.9999135732650757
following O O 0.9998658895492554
intravenous O O 0.99880051612854
fluorescein B B 0.9889531135559082
angiography O O 0.998126208782196
. O O 0.9998326301574707

Tonic O O 0.9999381303787231
- O O 0.9991822838783264
clonic O O 0.9998171925544739
seizures O O 0.9999935626983643
followed O O 0.9993532299995422
intravenous O O 0.9992198944091797
fluorescein B B 0.998813271522522
injection O O 0.9977285265922546
for O O 0.9999685287475586
fundus O O 0.9980886578559875
angiography O O 0.9999102354049683
in O O 0.9999817609786987
a O O 0.999994158744812
47 O O 0.999996542930603
- O O 0.9999912977218628
year O O 0.9999977350234985
- O O 0.9999957084655762
old O O 0.9999954700469971
male O O 0.999995231628418
. O O 0.9999634027481079

Despite O O 0.9965503215789795
precautions O O 0.9985962510108948
this O O 0.9999732971191406
adverse O O 0.9998961687088013
reaction O O 0.999995231628418
recurred O O 0.9999881982803345
on O O 0.9999113082885742
re O O 0.9999305009841919
- O O 0.9998992681503296
exposure O O 0.9999967813491821
to O O 0.9996525049209595
intravenous O O 0.9995136260986328
fluorescein B B 0.9928701519966125
. O O 0.9998464584350586

Pharmacology O O 0.7004846930503845
of O O 0.8109474182128906
ACC B B 0.9874807000160217
- I I 0.9956684112548828
9653 I I 0.9999778270721436
( O O 0.8998929858207703
phenytoin B B 0.9954227805137634
prodrug O O 0.6727957725524902
) O O 0.9995214939117432
. O O 0.9984492063522339

ACC B B 0.9364475011825562
- I I 0.9848774671554565
9653 I I 0.9999547004699707
, O O 0.9962840676307678
the O O 0.994788646697998
disodium B B 0.8820792436599731
phosphate I I 0.8827027678489685
ester I I 0.9664181470870972
of O O 0.6142187118530273
3 B B 0.8543131947517395
- I I 0.9962343573570251
hydroxymethyl I I 0.9976505637168884
- I I 0.9843854308128357
5 I I 0.9500212669372559
, I I 0.995345413684845
5 I I 0.9743510484695435
- I I 0.9980752468109131
diphenylhydantoin I I 0.9994128942489624
, O O 0.9621016979217529
is O O 0.9998112320899963
a O O 0.998261034488678
prodrug O O 0.793400228023529
of O O 0.9927351474761963
phenytoin B B 0.9987757802009583
with O O 0.9998226761817932
advantageous O O 0.9998571872711182
physicochemical O O 0.9999722242355347
properties O O 0.999987006187439
. O O 0.9998689889907837

ACC B B 0.8773200511932373
- I I 0.9303116202354431
9653 I I 0.9998774528503418
is O O 0.9994391798973083
rapidly O O 0.9999606609344482
converted O O 0.999942421913147
enzymatically O O 0.9994522929191589
to O O 0.999311089515686
phenytoin B B 0.999640703201294
in O O 0.999893069267273
vivo O O 0.9999737739562988
. O O 0.9999425411224365

ACC B B 0.9861100912094116
- I I 0.995895266532898
9653 I I 0.9999396800994873
and O O 0.9832859635353088
phenytoin B B 0.9995653033256531
sodium I I 0.994158148765564
have O O 0.9996222257614136
equivalent O O 0.9994226694107056
anticonvulsant O O 0.991860568523407
activity O O 0.9998503923416138
against O O 0.9998236298561096
seizures O O 0.99998939037323
induced O O 0.9999885559082031
by O O 0.9999655485153198
maximal O O 0.9999483823776245
electroshock O O 0.9880384206771851
( O O 0.9997573494911194
MES O O 0.9915657043457031
) O O 0.999980092048645
in O O 0.9999287128448486
mice O O 0.9999842643737793
following O O 0.9999603033065796
i O O 0.9998863935470581
. O O 0.999990701675415
p O O 0.9999967813491821
. O O 0.9999885559082031
, O O 0.9999080896377563
oral O O 0.9987766146659851
, O O 0.999845027923584
or O O 0.9998806715011597
i O O 0.9996610879898071
. O O 0.9999934434890747
v O O 0.9999986886978149
. O O 0.9999887943267822
administration O O 0.999963641166687
. O O 0.9999662637710571

The O O 0.999976634979248
ED50 O O 0.9974272847175598
doses O O 0.9999489784240723
were O O 0.9999749660491943
16 O O 0.9999260902404785
mg O O 0.9999661445617676
/ O O 0.9999877214431763
kg O O 0.9999899864196777
for O O 0.9995749592781067
i O O 0.9976557493209839
. O O 0.9999725818634033
v O O 0.9985079169273376
. O O 0.9997922778129578
ACC B B 0.5977240204811096
- I I 0.8814600706100464
9653 I I 0.9998953342437744
and O O 0.997330904006958
8 O O 0.999302864074707
mg O O 0.9999442100524902
/ O O 0.9999901056289673
kg O O 0.9999922513961792
for O O 0.9996812343597412
i O O 0.9970520734786987
. O O 0.9999678134918213
v O O 0.9995866417884827
. O O 0.9986987113952637
phenytoin B B 0.9997252821922302
sodium I I 0.9504549503326416
. O O 0.9998353719711304

ACC B B 0.988246500492096
- I I 0.9922744631767273
9653 I I 0.9999583959579468
and O O 0.9727665781974792
phenytoin B B 0.9996434450149536
sodium I I 0.9981770515441895
have O O 0.9996747970581055
similar O O 0.999901533126831
antiarrhythmic O O 0.973783016204834
activity O O 0.9998891353607178
against O O 0.9996992349624634
ouabain B B 0.9986944794654846
- O O 0.9997888207435608
induced O O 0.9999620914459229
ventricular O O 0.9999840259552002
tachycardia O O 0.9999679327011108
in O O 0.9999665021896362
anesthetized O O 0.9999909400939941
dogs O O 0.9999953508377075
. O O 0.9999408721923828

The O O 0.9999856948852539
total O O 0.9999111890792847
doses O O 0.9999310970306396
of O O 0.9994760155677795
ACC B B 0.9963489770889282
- I I 0.9773101806640625
9653 I I 0.9998252987861633
or O O 0.9877267479896545
phenytoin B B 0.9997394680976868
sodium I O 0.9992745518684387
necessary O O 0.9999769926071167
to O O 0.999990701675415
convert O O 0.9999934434890747
the O O 0.999994158744812
arrhythmia O O 0.9999829530715942
to O O 0.9999935626983643
a O O 0.9999958276748657
normal O O 0.9999971389770508
sinus O O 0.9999974966049194
rhythm O O 0.9999964237213135
were O O 0.9999717473983765
24 O O 0.9997822642326355
+ O O 0.9999903440475464
/ O O 0.9999737739562988
- O O 0.9998835325241089
6 O O 0.9999434947967529
and O O 0.999934196472168
14 O O 0.9999871253967285
+ O O 0.9999945163726807
/ O O 0.9999735355377197
- O O 0.9999562501907349
3 O O 0.9999681711196899
mg O O 0.9999749660491943
/ O O 0.9999507665634155
kg O O 0.9999966621398926
, O O 0.9999892711639404
respectively O O 0.9999738931655884
. O O 0.9999837875366211

Only O O 0.9966983199119568
phenytoin B B 0.999288022518158
sodium I I 0.9993313550949097
displayed O O 0.9996993541717529
in O O 0.999650239944458
vitro O O 0.9999923706054688
antiarrhythmic O O 0.9752713441848755
activity O O 0.9998658895492554
against O O 0.999622106552124
strophanthidin B B 0.9886055588722229
- O O 0.9993945360183716
induced O O 0.999944806098938
arrhythmias O O 0.9999070167541504
in O O 0.9998658895492554
guinea O O 0.99993896484375
pig O O 0.9999861717224121
right O O 0.9998904466629028
atria O O 0.9999885559082031
. O O 0.9999520778656006

In O O 0.9999237060546875
anesthetized O O 0.9999955892562866
dogs O O 0.9999936819076538
, O O 0.9999693632125854
a O O 0.9999866485595703
high O O 0.9997140765190125
dose O O 0.9998181462287903
of O O 0.9993051290512085
ACC B B 0.994669497013092
- I I 0.9952455163002014
9653 I I 0.9999414682388306
( O O 0.9984627962112427
31 O O 0.999984860420227
mg O O 0.9999781847000122
/ O O 0.9999744892120361
kg O O 0.9999840259552002
) O O 0.99994957447052
was O O 0.9999830722808838
infused O O 0.9999580383300781
over O O 0.9999638795852661
15 O O 0.9999936819076538
, O O 0.9999631643295288
20 O O 0.9999841451644897
, O O 0.9999083280563354
and O O 0.9999557733535767
30 O O 0.9999879598617554
min O O 0.9999817609786987
and O O 0.9999852180480957
the O O 0.9999940395355225
responses O O 0.9999964237213135
were O O 0.9999977350234985
compared O O 0.9999957084655762
to O O 0.9999312162399292
an O O 0.9999843835830688
equimolar O O 0.9999886751174927
dose O O 0.9999018907546997
of O O 0.9993220567703247
phenytoin B B 0.9998131394386292
sodium I I 0.9931875467300415
( O O 0.9997206330299377
21 O O 0.9999827146530151
mg O O 0.9999842643737793
/ O O 0.9999823570251465
kg O O 0.999996542930603
) O O 0.9999765157699585
. O O 0.9999750852584839

The O O 0.9997634291648865
ACC B B 0.9459749460220337
- I I 0.9608727097511292
9653 I I 0.9997332692146301
and O O 0.9680688381195068
phenytoin B B 0.9994895458221436
sodium I I 0.9612911343574524
treatments O O 0.9996496438980103
produced O O 0.999977707862854
similar O O 0.9999898672103882
marked O O 0.9999886751174927
reductions O O 0.9999959468841553
in O O 0.999984860420227
diastolic O O 0.999969482421875
blood O O 0.9999262094497681
pressure O O 0.9999566078186035
and O O 0.9999289512634277
contractile O O 0.9999586343765259
force O O 0.9999737739562988
( O O 0.9998859167098999
LVdP O O 0.9568250775337219
/ O O 0.9997252821922302
dt O O 0.989982545375824
) O O 0.999968409538269
. O O 0.9999737739562988

The O O 0.9999687671661377
maximum O O 0.9999101161956787
effects O O 0.9999850988388062
of O O 0.9999369382858276
each O O 0.9997907280921936
treatment O O 0.9998674392700195
occurred O O 0.9999699592590332
at O O 0.999944806098938
the O O 0.9999856948852539
time O O 0.999975323677063
of O O 0.9999687671661377
maximum O O 0.9998791217803955
phenytoin B B 0.9995115995407104
sodium I O 0.8029466271400452
levels O O 0.9998080134391785
. O O 0.9999725818634033

Acute O O 0.9998170733451843
toxicity O O 0.9999372959136963
studies O O 0.9999805688858032
of O O 0.9982837438583374
ACC B B 0.9940497875213623
- I I 0.9962562322616577
9653 I I 0.9999716281890869
and O O 0.8956307768821716
phenytoin B B 0.9988813996315002
sodium I I 0.9965788722038269
were O O 0.9997132420539856
carried O O 0.9999924898147583
out O O 0.9999924898147583
in O O 0.999940037727356
mice O O 0.9999978542327881
, O O 0.999943733215332
rats O O 0.9999957084655762
, O O 0.9999659061431885
rabbits O O 0.9999953508377075
, O O 0.999969482421875
and O O 0.9999020099639893
dogs O O 0.999992847442627
by O O 0.9999624490737915
i O O 0.9998549222946167
. O O 0.99998939037323
v O O 0.9999984502792358
. O O 0.9999929666519165
, O O 0.9999243021011353
i O O 0.9997956156730652
. O O 0.9999860525131226
m O O 0.999997615814209
. O O 0.999991774559021
, O O 0.9998847246170044
and O O 0.9998575448989868
i O O 0.9989054203033447
. O O 0.9999802112579346
p O O 0.999995231628418
. O O 0.9999920129776001
routes O O 0.9999909400939941
of O O 0.9999605417251587
administration O O 0.9999490976333618
. O O 0.9999687671661377

The O O 0.9999847412109375
systemic O O 0.9999043941497803
toxic O O 0.9998840093612671
signs O O 0.9999946355819702
of O O 0.9997639060020447
both O O 0.9969045519828796
agents O O 0.9953527450561523
were O O 0.999915599822998
similar O O 0.9999853372573853
and O O 0.9999948740005493
occurred O O 0.9999881982803345
at O O 0.9999576807022095
approximately O O 0.9999794960021973
equivalent O O 0.9999706745147705
doses O O 0.9999749660491943
. O O 0.9999698400497437

Importantly O O 0.9999244213104248
, O O 0.9999409914016724
the O O 0.9999617338180542
local O O 0.999742329120636
irritation O O 0.9999326467514038
of O O 0.9978951215744019
ACC B B 0.6958585381507874
- I I 0.8824060559272766
9653 I I 0.999889612197876
was O O 0.9995893836021423
markedly O O 0.9999881982803345
less O O 0.9999594688415527
than O O 0.999424934387207
phenytoin B B 0.9994582533836365
sodium I O 0.7621259093284607
following O O 0.9999058246612549
i O O 0.9994266033172607
. O O 0.9999970197677612
m O O 0.9999988079071045
. O O 0.9999823570251465
administration O O 0.9999657869338989
. O O 0.9999805688858032
( O O 0.9998576641082764
ABSTRACT O O 0.9999176263809204
TRUNCATED O O 0.9999666213989258
AT O O 0.9999370574951172
250 O O 0.9970479607582092
WORDS O O 0.9999951124191284
) O O 0.999930739402771

Tachyphylaxis O O 0.9995980858802795
to O O 0.9998440742492676
systemic O O 0.9979599714279175
but O O 0.9999793767929077
not O O 0.9999521970748901
to O O 0.9997739195823669
airway O O 0.9975101947784424
responses O O 0.9999662637710571
during O O 0.9999165534973145
prolonged O O 0.9999334812164307
therapy O O 0.999992847442627
with O O 0.9999208450317383
high O O 0.99955815076828
dose O O 0.9980791807174683
inhaled O O 0.9986781477928162
salbutamol B B 0.9991746544837952
in O O 0.9996863603591919
asthmatics O O 0.9996976852416992
. O O 0.999941349029541

High O O 0.9997716546058655
doses O O 0.9998873472213745
of O O 0.9998193383216858
inhaled O O 0.9990078806877136
salbutamol B B 0.9996247291564941
produce O O 0.9996871948242188
substantial O O 0.9999793767929077
improvements O O 0.9999867677688599
in O O 0.9999597072601318
airway O O 0.999569833278656
response O O 0.9999861717224121
in O O 0.9999527931213379
patients O O 0.9999921321868896
with O O 0.9999624490737915
asthma O O 0.9988297820091248
, O O 0.9999558925628662
and O O 0.9999498128890991
are O O 0.9999390840530396
associated O O 0.9999717473983765
with O O 0.9999507665634155
dose O O 0.9956835508346558
- O O 0.9999523162841797
dependent O O 0.9999740123748779
systemic O O 0.9997469782829285
beta O O 0.9637107849121094
- O O 0.99172043800354
adrenoceptor O O 0.9745838642120361
responses O O 0.9998760223388672
. O O 0.9999687671661377

The O O 0.9999916553497314
purpose O O 0.999996542930603
of O O 0.9999964237213135
the O O 0.9999977350234985
present O O 0.9999942779541016
study O O 0.9999905824661255
was O O 0.9999935626983643
to O O 0.9999938011169434
investigate O O 0.999980092048645
whether O O 0.9999557733535767
tachyphylaxis O O 0.9999207258224487
occurs O O 0.9999698400497437
during O O 0.9999157190322876
prolonged O O 0.9999252557754517
treatment O O 0.9999836683273315
with O O 0.999886155128479
high O O 0.9996123909950256
dose O O 0.9988510608673096
inhaled O O 0.9925855994224548
salbutamol B B 0.999545156955719
. O O 0.9999350309371948

Twelve O O 0.9994742274284363
asthmatic O O 0.9998488426208496
patients O O 0.9999854564666748
( O O 0.9999464750289917
FEV1 O O 0.9964150190353394
, O O 0.9999465942382812
81 O O 0.999592125415802
+ O O 0.9999866485595703
/ O O 0.9999866485595703
- O O 0.9999710321426392
4 O O 0.9999843835830688
% O O 0.999995231628418
predicted O O 0.9999401569366455
) O O 0.9999643564224243
, O O 0.9999909400939941
requiring O O 0.999893069267273
only O O 0.9999321699142456
occasional O O 0.9996829032897949
inhaled O O 0.9903269410133362
beta O O 0.917805552482605
- O O 0.9795355200767517
agonists O O 0.9563429355621338
as O O 0.9999475479125977
their O O 0.999958872795105
sole O O 0.9993640780448914
therapy O O 0.9999334812164307
, O O 0.9999865293502808
were O O 0.9999887943267822
given O O 0.9999828338623047
a O O 0.9999904632568359
14 O O 0.9999918937683105
- O O 0.9999873638153076
day O O 0.9999905824661255
treatment O O 0.9999890327453613
with O O 0.9999147653579712
high O O 0.9985159039497375
dose O O 0.9989635944366455
inhaled O O 0.9837806224822998
salbutamol B B 0.9995201826095581
( O O 0.9690285921096802
HDS O B 0.9413212537765503
) O O 0.998932421207428
, O O 0.9994487166404724
4 O O 0.9993826150894165
, O O 0.9999961853027344
000 O O 0.999876856803894
micrograms O O 0.9977194666862488
daily O O 0.9998388290405273
, O O 0.9998795986175537
low O O 0.999549925327301
dose O O 0.9988786578178406
inhaled O O 0.9734222292900085
salbutamol B B 0.9991436004638672
( O O 0.9688341617584229
LDS O B 0.870025634765625
) O O 0.9985609650611877
, O O 0.9991918206214905
800 O O 0.9978780746459961
micrograms O O 0.9962702989578247
daily O O 0.9997867941856384
, O O 0.9997630715370178
or O O 0.9997218251228333
placebo O O 0.9997164607048035
( O O 0.9991388320922852
PI O O 0.9247928261756897
) O O 0.9999486207962036
by O O 0.9998853206634521
metered O O 0.9996970891952515
- O O 0.9997991919517517
dose O O 0.9885127544403076
inhaler O O 0.9957528114318848
in O O 0.9999864101409912
a O O 0.999995231628418
double O O 0.9999794960021973
- O O 0.9999880790710449
blind O O 0.9999963045120239
, O O 0.9999874830245972
randomized O O 0.999992847442627
crossover O O 0.999972939491272
design O O 0.9999970197677612
. O O 0.9999843835830688

During O O 0.9999449253082275
the O O 0.9999891519546509
14 O O 0.9999867677688599
- O O 0.9999796152114868
day O O 0.9999860525131226
run O O 0.9994025230407715
- O O 0.9999246597290039
in O O 0.9998397827148438
and O O 0.9999574422836304
during O O 0.999828577041626
washout O O 0.9998113512992859
periods O O 0.9999899864196777
, O O 0.9998787641525269
inhaled O O 0.9989816546440125
beta O O 0.9617378115653992
- O O 0.9871518611907959
agonists O O 0.9671811461448669
were O O 0.9999299049377441
withheld O O 0.9999840259552002
and O O 0.9999079704284668
ipratropium B B 0.9982708692550659
bromide I I 0.9990053772926331
was O O 0.9998156428337097
substituted O O 0.9998223185539246
for O O 0.9999822378158569
rescue O O 0.9998807907104492
purposes O O 0.9999912977218628
. O O 0.9999798536300659

At O O 0.9999768733978271
the O O 0.9999960660934448
end O O 0.9999949932098389
of O O 0.9999793767929077
each O O 0.9999790191650391
14 O O 0.9999876022338867
- O O 0.9999693632125854
day O O 0.9999693632125854
treatment O O 0.9999668598175049
, O O 0.9999815225601196
a O O 0.9999897480010986
dose O O 0.9940059185028076
- O O 0.9999520778656006
response O O 0.9999880790710449
curve O O 0.9999901056289673
( O O 0.9998965263366699
DRC O O 0.9982989430427551
) O O 0.9999841451644897
was O O 0.9999842643737793
performed O O 0.999995231628418
, O O 0.9999431371688843
and O O 0.9999542236328125
airway O O 0.9983652234077454
( O O 0.9996657371520996
FEV1 O O 0.9568639397621155
, O O 0.9977220892906189
FEF25 O O 0.8903162479400635
- O O 0.9651902914047241
75 O O 0.7241891622543335
) O O 0.9996160268783569
chronotropic O O 0.9834643602371216
( O O 0.9994063377380371
HR O O 0.8275461196899414
) O O 0.9998741149902344
, O O 0.9997974038124084
tremor O O 0.9994398951530457
, O O 0.9997913241386414
and O O 0.999423623085022
metabolic O O 0.9995934367179871
( O O 0.999588668346405
K B O 0.8098840117454529
, O O 0.8708635568618774
Glu B O 0.7856594920158386
) O O 0.9996213912963867
responses O O 0.9999830722808838
were O O 0.99997878074646
measured O O 0.9999861717224121
at O O 0.999832034111023
each O O 0.9999537467956543
step O O 0.9999916553497314
( O O 0.9999727010726929
from O O 0.9999912977218628
100 O O 0.9972553849220276
to O O 0.9999666213989258
4 O O 0.9999825954437256
, O O 0.9999985694885254
000 O O 0.999994158744812
micrograms O O 0.9999020099639893
) O O 0.9999759197235107
. O O 0.9999651908874512

Treatment O O 0.9993802309036255
had O O 0.9999382495880127
no O O 0.9999721050262451
significant O O 0.9999866485595703
effect O O 0.9999765157699585
on O O 0.9999876022338867
baseline O O 0.9999829530715942
values O O 0.9999886751174927
. O O 0.9999675750732422

There O O 0.9999462366104126
were O O 0.9999488592147827
dose O O 0.9986283779144287
- O O 0.9999643564224243
dependent O O 0.9999828338623047
increases O O 0.9999734163284302
in O O 0.9999145269393921
FEV1 O O 0.8293766975402832
and O O 0.9996830224990845
FEF25 O B 0.6725314259529114
- O I 0.6402745246887207
75 O I 0.9900571703910828
( O O 0.9993706345558167
p O O 0.9998499155044556
less O O 0.9999850988388062
than O O 0.9999960660934448
0 O O 0.999993085861206
. O O 0.999997615814209
001 O O 0.9999866485595703
) O O 0.999956488609314
, O O 0.9999420642852783
and O O 0.9999716281890869
pretreatment O O 0.9998605251312256
with O O 0.9997299313545227
HDS O B 0.9083700776100159
did O O 0.9998722076416016
not O O 0.9999542236328125
displace O O 0.9999854564666748
the O O 0.9999499320983887
DRC O O 0.8560763001441956
to O O 0.999976634979248
the O O 0.9999836683273315
right O O 0.999968409538269
. O O 0.9999732971191406

DRC O O 0.909981906414032
for O O 0.9907738566398621
HR O O 0.7959864139556885
( O O 0.999562680721283
p O O 0.9945407509803772
less O O 0.9999551773071289
than O O 0.999994158744812
0 O O 0.9999817609786987
. O O 0.9999960660934448
001 O O 0.9999529123306274
) O O 0.9998559951782227
, O O 0.9962221384048462
K B B 0.9389731884002686
( O O 0.9994080066680908
p O O 0.9986279010772705
less O O 0.9999654293060303
than O O 0.9999959468841553
0 O O 0.9999699592590332
. O O 0.9999972581863403
001 O O 0.9997701048851013
) O O 0.9998384714126587
, O O 0.9842910766601562
and O O 0.9896773099899292
Glu B O 0.831054151058197
( O O 0.9994280934333801
p O O 0.9927912950515747
less O O 0.9999701976776123
than O O 0.999994158744812
0 O O 0.9999794960021973
. O O 0.9999963045120239
005 O O 0.9995980858802795
) O O 0.999937891960144
were O O 0.9999516010284424
attenuated O O 0.9996819496154785
after O O 0.9997608065605164
treatment O O 0.9999440908432007
with O O 0.9993984699249268
HDS O B 0.9881910085678101
compared O O 0.9998456239700317
with O O 0.9996651411056519
PI O O 0.6477357745170593
. O O 0.9998886585235596

There O O 0.9999252557754517
were O O 0.9999465942382812
also O O 0.9999737739562988
differences O O 0.9999935626983643
between O O 0.9995187520980835
HDS O O 0.583052933216095
and O O 0.9995405673980713
LDS O O 0.7586671113967896
for O O 0.9988746047019958
HR O O 0.47516173124313354
( O O 0.999893069267273
p O O 0.9991992115974426
less O O 0.999976634979248
than O O 0.9999897480010986
0 O O 0.9999819993972778
. O O 0.9999951124191284
001 O O 0.9999858140945435
) O O 0.9997759461402893
and O O 0.9979573488235474
Glu B O 0.6035479307174683
( O O 0.999813973903656
p O O 0.9976007342338562
less O O 0.9999767541885376
than O O 0.9999865293502808
0 O O 0.9999790191650391
. O O 0.9999874830245972
05 O O 0.999981164932251
) O O 0.9998639822006226
responses O O 0.9998984336853027
. O O 0.9999630451202393

Frequency O O 0.9999866485595703
and O O 0.9999767541885376
severity O O 0.9999957084655762
of O O 0.999984622001648
subjective O O 0.9999349117279053
adverse O O 0.9998399019241333
effects O O 0.9999798536300659
were O O 0.9999431371688843
also O O 0.999976396560669
reduced O O 0.99998939037323
after O O 0.9991711378097534
HDS O O 0.6801917552947998
: O O 0.9991123080253601
tremor O O 0.9995869994163513
( O O 0.9999483823776245
p O O 0.9968787431716919
less O O 0.9999703168869019
than O O 0.9999933242797852
0 O O 0.9999839067459106
. O O 0.9999960660934448
001 O O 0.9999730587005615
) O O 0.9999485015869141
, O O 0.9998182654380798
palpitations O O 0.9999614953994751
( O O 0.9999626874923706
p O O 0.9959518909454346
less O O 0.9999494552612305
than O O 0.9999946355819702
0 O O 0.9999451637268066
. O O 0.9999971389770508
001 O O 0.9987699389457703
) O O 0.9999374151229858
. O O 0.9999758005142212
( O O 0.9983834028244019
ABSTRACT O O 0.999596893787384
TRUNCATED O O 0.9999412298202515
AT O O 0.9995259046554565
250 O O 0.9931995272636414
WORDS O O 0.999993085861206
) O O 0.9998641014099121

Phenytoin B B 0.9978578686714172
induced O O 0.9997256398200989
fatal O O 0.9996963739395142
hepatic O O 0.9999593496322632
injury O O 0.999984622001648
. O O 0.9996877908706665

A O O 0.9999797344207764
61 O O 0.9999977350234985
year O O 0.9999971389770508
old O O 0.9999909400939941
female O O 0.9999967813491821
developed O O 0.9999600648880005
fatal O O 0.9999606609344482
hepatic O O 0.9999722242355347
failure O O 0.9999922513961792
after O O 0.9997982382774353
phenytoin B B 0.9994648098945618
administration O O 0.9997534155845642
. O O 0.9999617338180542

A O O 0.9998987913131714
typical O O 0.9999508857727051
multisystem O O 0.9995293617248535
clinical O O 0.9997920393943787
pattern O O 0.9999839067459106
precedes O O 0.999954104423523
the O O 0.9999827146530151
manifestations O O 0.9999892711639404
of O O 0.9999755620956421
hepatic O O 0.999944806098938
injury O O 0.9999896287918091
. O O 0.9999691247940063

The O O 0.9999628067016602
hematologic O O 0.9999125003814697
, O O 0.99988853931427
biochemical O O 0.9996024966239929
and O O 0.9997453093528748
pathologic O O 0.9999783039093018
features O O 0.9999943971633911
indicate O O 0.9998536109924316
a O O 0.9998915195465088
mixed O O 0.9997528195381165
hepatocellular O O 0.9999181032180786
damage O O 0.9999879598617554
due O O 0.9999426603317261
to O O 0.999717652797699
drug O O 0.9980023503303528
hypersensitivity O O 0.9977865219116211
. O O 0.9999536275863647

In O O 0.9999662637710571
a O O 0.9999810457229614
patient O O 0.9999850988388062
receiving O O 0.9994144439697266
phenytoin B B 0.9990788698196411
who O O 0.9998375177383423
presents O O 0.999947190284729
a O O 0.9999891519546509
viral O O 0.9997439980506897
- O O 0.9999655485153198
like O O 0.9999890327453613
illness O O 0.9999947547912598
, O O 0.9999905824661255
early O O 0.9999885559082031
recognition O O 0.9999964237213135
and O O 0.9999818801879883
discontinuation O O 0.9999847412109375
of O O 0.9999631643295288
the O O 0.9999715089797974
drug O O 0.9994751811027527
are O O 0.9999796152114868
mandatory O O 0.9999430179595947
. O O 0.9999862909317017

Treatment O O 0.9998906850814819
of O O 0.999891996383667
lethal O O 0.9989187717437744
pertussis B O 0.9917135238647461
vaccine I O 0.9983035326004028
reaction O O 0.999988317489624
with O O 0.999303936958313
histamine B O 0.7841182947158813
H1 O O 0.7336251139640808
antagonists O O 0.5940013527870178
. O O 0.9980587363243103

We O O 0.999953031539917
studied O O 0.9999767541885376
mortality O O 0.9999951124191284
after O O 0.9998476505279541
pertussis O O 0.8039042353630066
immunization O O 0.9709387421607971
in O O 0.9999425411224365
the O O 0.9999914169311523
mouse O O 0.9999957084655762
. O O 0.9999672174453735

Without O O 0.999906063079834
treatment O O 0.9999765157699585
, O O 0.9999808073043823
73 O O 0.9999585151672363
of O O 0.9999822378158569
92 O O 0.9998562335968018
animals O O 0.9999364614486694
( O O 0.9999619722366333
80 O O 0.9999921321868896
% O O 0.9999964237213135
) O O 0.9999876022338867
died O O 0.9999985694885254
after O O 0.9999524354934692
injection O O 0.9999490976333618
of O O 0.9997214674949646
bovine O B 0.821433424949646
serum O I 0.9012922048568726
albumin O I 0.9933599829673767
( O O 0.9781588315963745
BSA O B 0.9456908702850342
) O O 0.9993913173675537
on O O 0.9999704360961914
day O O 0.9999970197677612
+ O O 0.9993984699249268
7 O O 0.9994958639144897
of O O 0.9997667670249939
pertussis O O 0.6815103888511658
immunization O O 0.9976814985275269
. O O 0.9999408721923828

After O O 0.9999583959579468
pretreatment O O 0.9998892545700073
with O O 0.9999028444290161
3 O O 0.9938440322875977
mg O O 0.9985947012901306
of O O 0.9945710301399231
cyproheptadine B B 0.9979502558708191
, O O 0.98459792137146
2 O O 0.9973046779632568
mg O O 0.9950059056282043
mianserin B B 0.9993577599525452
, O O 0.9482499957084656
or O O 0.9992790818214417
2 O O 0.9956355690956116
mg O O 0.994491696357727
chlorpheniramine B B 0.9989558458328247
, O O 0.9998443126678467
only O O 0.999991774559021
5 O O 0.9999834299087524
of O O 0.9999834299087524
105 O O 0.9998795986175537
animals O O 0.9999356269836426
( O O 0.9999569654464722
5 O O 0.9999792575836182
% O O 0.999992847442627
) O O 0.9999786615371704
died O O 0.9999955892562866
after O O 0.9999841451644897
receiving O O 0.9997429251670837
BSA O B 0.9913261532783508
on O O 0.9997640252113342
day O O 0.9999837875366211
+ O O 0.9997218251228333
7 O O 0.999699592590332
( O O 0.9999632835388184
p O O 0.9994555115699768
less O O 0.9999932050704956
than O O 0.9999969005584717
0 O O 0.9999960660934448
. O O 0.9999983310699463
001 O O 0.9999678134918213
) O O 0.9999761581420898
. O O 0.9999829530715942

Blockade O O 0.9987039566040039
of O O 0.9971354007720947
histamine B O 0.8306120038032532
H1 O O 0.7699769735336304
receptors O O 0.906714141368866
may O O 0.999908447265625
reduce O O 0.9999426603317261
mortality O O 0.9999973773956299
in O O 0.9999700784683228
pertussis O O 0.8035734295845032
immunization O O 0.911126434803009
- O O 0.9999022483825684
induced O O 0.999976634979248
encephalopathy O O 0.999968409538269
in O O 0.9999827146530151
mice O O 0.9999939203262329
. O O 0.999933123588562

Support O O 0.9625323414802551
for O O 0.9714716076850891
adrenaline B B 0.9771471619606018
- O O 0.8195695877075195
hypertension O O 0.8806653022766113
hypothesis O O 0.9702337384223938
: O O 0.9996607303619385
18 O O 0.9995923638343811
hour O O 0.9999194145202637
pressor O O 0.999208390712738
effect O O 0.9999451637268066
after O O 0.9996644258499146
6 O O 0.9996334314346313
hours O O 0.9996927976608276
adrenaline B B 0.9950523972511292
infusion O O 0.9950306415557861
. O O 0.9998940229415894

In O O 0.9999496936798096
a O O 0.9999352693557739
double O O 0.9998169541358948
blind O O 0.999985933303833
, O O 0.9999617338180542
crossover O O 0.9910733103752136
study O O 0.9999468326568604
6 O O 0.9999152421951294
h O O 0.9698002338409424
infusions O O 0.9997187256813049
of O O 0.999569833278656
adrenaline B B 0.9895521998405457
( O O 0.9984108209609985
15 O O 0.9999765157699585
ng O O 0.9977464079856873
/ O O 0.9999786615371704
kg O O 0.9999872446060181
/ O O 0.9999697208404541
min O O 0.999526858329773
; O O 0.9999583959579468
1 O O 0.9995488524436951
ng O O 0.9727947115898132
= O O 0.999303936958313
5 O O 0.9988341927528381
. O O 0.9999890327453613
458 O O 0.999895453453064
pmol O O 0.9999222755432129
) O O 0.9996095299720764
, O O 0.9977697134017944
noradrenaline B B 0.9988621473312378
( O O 0.9996141195297241
30 O O 0.9999487400054932
ng O O 0.997230589389801
/ O O 0.9999682903289795
kg O O 0.9999758005142212
/ O O 0.9999573230743408
min O O 0.9997914433479309
; O O 0.9999529123306274
1 O O 0.9993725419044495
ng O O 0.9766616225242615
= O O 0.9996415376663208
5 O O 0.9907147884368896
. O O 0.9998207688331604
911 O O 0.9917843341827393
pmol O O 0.999792754650116
) O O 0.9999101161956787
, O O 0.999774158000946
and O O 0.9996850490570068
a O O 0.9999521970748901
5 O O 0.997991681098938
% O O 0.9994045495986938
dextrose B B 0.9851827025413513
solution O O 0.9992421865463257
( O O 0.9999537467956543
5 O O 0.9998929500579834
. O O 0.9999959468841553
4 O O 0.9996511936187744
ml O O 0.9999947547912598
/ O O 0.9999572038650513
h O O 0.9914228320121765
) O O 0.9999656677246094
, O O 0.9999667406082153
were O O 0.9999741315841675
given O O 0.999967098236084
to O O 0.9999649524688721
ten O O 0.9999960660934448
healthy O O 0.9999953508377075
volunteers O O 0.9999984502792358
in O O 0.9999830722808838
random O O 0.9999927282333374
order O O 0.9999971389770508
2 O O 0.99998939037323
weeks O O 0.9999988079071045
apart O O 0.9999949932098389
. O O 0.9999775886535645

By O O 0.99998939037323
means O O 0.9999916553497314
of O O 0.9999840259552002
intra O O 0.9999803304672241
- O O 0.9999399185180664
arterial O O 0.9999814033508301
ambulatory O O 0.9999923706054688
monitoring O O 0.9999921321868896
the O O 0.9999734163284302
haemodynamic O O 0.9992916584014893
effects O O 0.9999734163284302
were O O 0.9999709129333496
followed O O 0.999984860420227
for O O 0.999975323677063
18 O O 0.999915599822998
h O O 0.999869704246521
after O O 0.9999881982803345
the O O 0.9998970031738281
infusions O O 0.9982942938804626
were O O 0.9999740123748779
stopped O O 0.9998445510864258
. O O 0.9999663829803467

Adrenaline B B 0.9665358066558838
, O O 0.9895692467689514
but O O 0.9998366832733154
not O O 0.9987784028053284
noradrenaline B B 0.9977717995643616
, O O 0.9996744394302368
caused O O 0.9999555349349976
a O O 0.9999758005142212
delayed O O 0.9999822378158569
and O O 0.9999878406524658
protracted O O 0.9999500513076782
pressor O O 0.9999876022338867
effect O O 0.9999783039093018
. O O 0.9999686479568481

Over O O 0.9999040365219116
the O O 0.9999836683273315
total O O 0.9999675750732422
postinfusion O O 0.9999099969863892
period O O 0.9999606609344482
systolic O O 0.9942939877510071
and O O 0.9999195337295532
diastolic O O 0.9998711347579956
arterial O O 0.9994514584541321
pressure O O 0.9998890161514282
were O O 0.9999580383300781
6 O O 0.9997954964637756
( O O 0.9996216297149658
SEM O O 0.9429182410240173
2 O O 0.9545212984085083
) O O 0.9997865557670593
% O O 0.9999903440475464
and O O 0.9999496936798096
7 O O 0.9998152852058411
( O O 0.9998161196708679
2 O O 0.9999275207519531
) O O 0.9998977184295654
% O O 0.9999939203262329
, O O 0.9999892711639404
respectively O O 0.9999853372573853
, O O 0.999987006187439
higher O O 0.999880313873291
than O O 0.9999892711639404
after O O 0.9996111989021301
dextrose B B 0.9977924823760986
infusion O O 0.9994624257087708
( O O 0.9999022483825684
ANOVA O O 0.7024358510971069
, O O 0.9994915723800659
p O O 0.9901543855667114
less O O 0.999967098236084
than O O 0.9999909400939941
0 O O 0.999992847442627
. O O 0.9999974966049194
001 O O 0.9999138116836548
) O O 0.999958872795105
. O O 0.9999706745147705

Thus O O 0.9999668598175049
, O O 0.9997449517250061
" O O 0.9994753003120422
stress O O 0.9991273283958435
" O O 0.999970555305481
levels O O 0.9993727803230286
of O O 0.9977389574050903
adrenaline B B 0.9982428550720215
( O O 0.9992658495903015
230 O O 0.9981531500816345
pg O O 0.999098539352417
/ O O 0.9998762607574463
ml O O 0.9999915361404419
) O O 0.9998142123222351
for O O 0.999816358089447
6 O O 0.9993694424629211
h O O 0.9907373785972595
cause O O 0.9999191761016846
a O O 0.9999605417251587
delayed O O 0.9999661445617676
and O O 0.9999850988388062
protracted O O 0.9999450445175171
pressor O O 0.9999505281448364
effect O O 0.9999699592590332
. O O 0.9999719858169556

These O O 0.9999747276306152
findings O O 0.9999886751174927
are O O 0.9999608993530273
strong O O 0.9999525547027588
support O O 0.9999921321868896
for O O 0.9999217987060547
the O O 0.9998966455459595
adrenaline B O 0.577406644821167
- O O 0.9305669665336609
hypertension O O 0.8119343519210815
hypothesis O O 0.9997438788414001
in O O 0.9999408721923828
man O O 0.999957799911499
. O O 0.999946117401123

Effect O O 0.9998539686203003
of O O 0.9994712471961975
alkylxanthines B B 0.995836615562439
on O O 0.999527096748352
gentamicin B B 0.999889612197876
- O O 0.9998379945755005
induced O O 0.9999641180038452
acute O O 0.9999877214431763
renal O O 0.9999953508377075
failure O O 0.9999910593032837
in O O 0.9999688863754272
the O O 0.9999829530715942
rat O O 0.9999837875366211
. O O 0.9999586343765259

Adenosine B B 0.9685442447662354
antagonists O O 0.548107385635376
have O O 0.9998550415039062
been O O 0.9999582767486572
previously O O 0.9998747110366821
shown O O 0.9999711513519287
to O O 0.9999393224716187
be O O 0.999958872795105
of O O 0.9998716115951538
benefit O O 0.9999473094940186
in O O 0.9999037981033325
some O O 0.9997557997703552
ischaemic O O 0.9999315738677979
and O O 0.999567449092865
nephrotoxic O O 0.9993341565132141
models O O 0.9999704360961914
of O O 0.9999663829803467
acute O O 0.9999352693557739
renal O O 0.9999963045120239
failure O O 0.9999908208847046
( O O 0.9998681545257568
ARF O O 0.6360536217689514
) O O 0.9999402761459351
. O O 0.9999607801437378

In O O 0.9999866485595703
the O O 0.9999960660934448
present O O 0.9999905824661255
study O O 0.9999898672103882
, O O 0.9999666213989258
the O O 0.9999678134918213
effects O O 0.999953031539917
of O O 0.999882698059082
three O O 0.9816777110099792
alkylxanthines B B 0.960904061794281
with O O 0.999277651309967
different O O 0.999962568283081
potencies O O 0.9964646100997925
as O O 0.9994899034500122
adenosine B B 0.9372159838676453
antagonists O I 0.5120769143104553
8 B I 0.5863847732543945
- I I 0.9834228754043579
phenyltheophylline I I 0.9998205304145813
, O O 0.8992893695831299
theophylline B B 0.9994792342185974
and O O 0.9754451513290405
enprofylline B B 0.9913848638534546
, O O 0.9994538426399231
were O O 0.9999823570251465
examined O O 0.9999704360961914
in O O 0.9999620914459229
rats O O 0.9999934434890747
developing O O 0.9999793767929077
acute O O 0.9999845027923584
renal O O 0.9999969005584717
failure O O 0.9999977350234985
after O O 0.9999439716339111
4 O O 0.9994138479232788
daily O O 0.9999680519104004
injections O O 0.9999825954437256
of O O 0.9997007846832275
gentamicin B B 0.9998753070831299
( O O 0.9997597336769104
200 O O 0.9998955726623535
mg O O 0.9999357461929321
kg O O 0.9955061674118042
- O O 0.9982618689537048
1 O O 0.9992836117744446
) O O 0.9999785423278809
. O O 0.9999737739562988

Renal O O 0.9998757839202881
function O O 0.9999879598617554
was O O 0.9999743700027466
assessed O O 0.9999890327453613
by O O 0.9999831914901733
biochemical O O 0.9996775388717651
( O O 0.9999055862426758
plasma O O 0.9960306286811829
urea B B 0.9916797280311584
and O O 0.998803973197937
creatinine B B 0.9968066215515137
) O O 0.9998688697814941
, O O 0.9999610185623169
functional O O 0.9999692440032959
( O O 0.9996492862701416
urine O O 0.9996597766876221
analysis O O 0.9996047616004944
and O O 0.9999592304229736
[ O O 0.623171329498291
3H O O 0.5316290855407715
] O O 0.7984486818313599
inulin O O 0.6867576837539673
and O O 0.9191857576370239
[ O O 0.47394341230392456
14C O O 0.5545444488525391
] O O 0.9526274800300598
p B B 0.5949922800064087
- I I 0.8824605345726013
aminohippuric I I 0.9994402527809143
acid I I 0.9998884201049805
clearances O O 0.5187447667121887
) O O 0.9999123811721802
and O O 0.9999326467514038
morphological O O 0.9998511075973511
( O O 0.9998688697814941
degree O O 0.9999874830245972
of O O 0.9999585151672363
necrosis O O 0.9999204874038696
) O O 0.9999220371246338
indices O O 0.9999469518661499
. O O 0.9999843835830688

The O O 0.9999656677246094
various O O 0.999883770942688
drug O O 0.9994527697563171
treatments O O 0.999860405921936
produced O O 0.9999566078186035
improvements O O 0.9999865293502808
in O O 0.9999785423278809
some O O 0.9999749660491943
, O O 0.9999815225601196
but O O 0.9999924898147583
not O O 0.9999926090240479
all O O 0.9999536275863647
, O O 0.9999799728393555
measurements O O 0.9999892711639404
of O O 0.9999643564224243
renal O O 0.9999347925186157
function O O 0.9999830722808838
. O O 0.9999697208404541

However O O 0.9999209642410278
, O O 0.9999116659164429
any O O 0.9999879598617554
improvement O O 0.9999912977218628
produced O O 0.9999977350234985
by O O 0.999907374382019
drug O O 0.9996250867843628
treatment O O 0.999913215637207
was O O 0.9999463558197021
largely O O 0.9999709129333496
a O O 0.9999735355377197
result O O 0.9999653100967407
of O O 0.9999343156814575
a O O 0.9999375343322754
beneficial O O 0.9999032020568848
effect O O 0.9999752044677734
exerted O O 0.9999873638153076
by O O 0.9999097585678101
its O O 0.9995879530906677
vehicle O O 0.9992269277572632
( O O 0.9990935325622559
polyethylene B B 0.9738487005233765
glycol I I 0.9746823906898499
and O O 0.8541714549064636
NaOH B B 0.9916538596153259
) O O 0.9998711347579956
. O O 0.9999586343765259

The O O 0.9999892711639404
lack O O 0.99998939037323
of O O 0.9999819993972778
any O O 0.9999682903289795
consistent O O 0.9999829530715942
protective O O 0.9998972415924072
effect O O 0.9999713897705078
noted O O 0.9999940395355225
with O O 0.9998966455459595
the O O 0.9996501207351685
alkylxanthines B B 0.9849335551261902
tested O O 0.9985874891281128
in O O 0.9999825954437256
the O O 0.9999964237213135
present O O 0.9999910593032837
study O O 0.9999799728393555
indicates O O 0.9999172687530518
that O O 0.9996639490127563
adenosine B B 0.9981928467750549
plays O O 0.9998795986175537
little O O 0.9999589920043945
, O O 0.9999707937240601
if O O 0.999994158744812
any O O 0.9999876022338867
, O O 0.9999724626541138
pathophysiological O O 0.9998935461044312
role O O 0.9999650716781616
in O O 0.9998928308486938
gentamicin B B 0.9998630285263062
- O O 0.9997325539588928
induced O O 0.9999434947967529
ARF O O 0.9975932240486145
. O O 0.9999138116836548

Adverse O O 0.9986036419868469
ocular O O 0.9994189739227295
reactions O O 0.9999833106994629
possibly O O 0.9999254941940308
associated O O 0.9999463558197021
with O O 0.9994460940361023
isotretinoin B B 0.999398946762085
. O O 0.9994869232177734

A O O 0.9999476671218872
total O O 0.9999719858169556
of O O 0.9999798536300659
261 O O 0.9997683167457581
adverse O O 0.9999102354049683
ocular O O 0.9998792409896851
reactions O O 0.9999959468841553
occurred O O 0.9999819993972778
in O O 0.9999531507492065
237 O O 0.9994408488273621
patients O O 0.9999897480010986
who O O 0.9999276399612427
received O O 0.999284565448761
isotretinoin B B 0.9996665716171265
, O O 0.9998883008956909
a O O 0.9999382495880127
commonly O O 0.9999016523361206
used O O 0.9998456239700317
drug O O 0.9986659288406372
in O O 0.9999415874481201
the O O 0.9999663829803467
treatment O O 0.9999731779098511
of O O 0.9999833106994629
severe O O 0.9999899864196777
cystic O O 0.9993914365768433
acne O O 0.9955106973648071
. O O 0.9999520778656006

Blepharoconjunctivitis O O 0.9930393099784851
, O O 0.9998706579208374
subjective O O 0.9999853372573853
complaints O O 0.9999972581863403
of O O 0.9999880790710449
dry O O 0.9999951124191284
eyes O O 0.999998927116394
, O O 0.9999679327011108
blurred O O 0.9999948740005493
vision O O 0.9999994039535522
, O O 0.999916672706604
contact O O 0.7759486436843872
lens O O 0.9917964935302734
intolerance O O 0.9999525547027588
, O O 0.9993853569030762
and O O 0.9993686079978943
photodermatitis O O 0.9563581943511963
are O O 0.9997022747993469
reversible O O 0.9970099925994873
side O O 0.9998810291290283
effects O O 0.9999728202819824
. O O 0.9999152421951294

More O O 0.9996412992477417
serious O O 0.9999299049377441
ocular O O 0.9997175335884094
adverse O O 0.9998706579208374
reactions O O 0.999992847442627
include O O 0.9999558925628662
papilledema O O 0.9964295029640198
, O O 0.9999321699142456
pseudotumor O O 0.9868499040603638
cerebri O O 0.9977645874023438
, O O 0.9998883008956909
and O O 0.9997097849845886
white O O 0.9993516802787781
or O O 0.9992352724075317
gray O O 0.9926171898841858
subepithelial O O 0.9984252452850342
corneal O O 0.999957799911499
opacities O O 0.9999722242355347
; O O 0.9999643564224243
all O O 0.9999431371688843
of O O 0.9999468326568604
these O O 0.9999847412109375
are O O 0.9999563694000244
reversible O O 0.9999784231185913
if O O 0.999723494052887
the O O 0.999799907207489
drug O O 0.9972743391990662
is O O 0.9999467134475708
discontinued O O 0.9999192953109741
. O O 0.9999289512634277

Reported O O 0.9998140931129456
cases O O 0.9999840259552002
of O O 0.9999591112136841
decreased O O 0.9999473094940186
dark O O 0.9964501857757568
adaptation O O 0.9999850988388062
are O O 0.9999605417251587
under O O 0.9999521970748901
investigation O O 0.9999749660491943
. O O 0.9999563694000244

Isotretinoin B B 0.9992062449455261
is O O 0.9995872378349304
contraindicated O O 0.9979575872421265
in O O 0.9999796152114868
pregnancy O O 0.9999977350234985
because O O 0.9999845027923584
of O O 0.9999915361404419
the O O 0.9999970197677612
many O O 0.9999550580978394
reported O O 0.9999939203262329
congenital O O 0.9999123811721802
abnormalities O O 0.9999984502792358
after O O 0.9999165534973145
maternal O O 0.9987335801124573
use O O 0.9998243451118469
( O O 0.9999654293060303
including O O 0.9999663829803467
microphthalmos O O 0.9994633793830872
, O O 0.9999533891677856
orbital O O 0.9996010661125183
hypertelorism O O 0.9984173774719238
, O O 0.9998762607574463
and O O 0.9998266100883484
optic O O 0.9997400641441345
nerve O O 0.999940037727356
hypoplasia O O 0.999711811542511
) O O 0.9999798536300659
. O O 0.9999632835388184

Procaterol B B 0.9940097332000732
and O O 0.9439525604248047
terbutaline B B 0.9991112351417542
in O O 0.999714195728302
bronchial O O 0.9931005239486694
asthma O O 0.783835232257843
. O O 0.9992683529853821

A O O 0.9999730587005615
double O O 0.9999605417251587
- O O 0.9999793767929077
blind O O 0.9999955892562866
, O O 0.9999786615371704
placebo O O 0.9998237490653992
- O O 0.9999170303344727
controlled O O 0.9999574422836304
, O O 0.9999686479568481
cross O O 0.9995554089546204
- O O 0.9999712705612183
over O O 0.9999678134918213
study O O 0.9999911785125732
. O O 0.999972939491272

Procaterol B B 0.9749124646186829
, O O 0.9998902082443237
a O O 0.999754011631012
new O O 0.9992577433586121
beta O O 0.9644856452941895
- O O 0.9909865260124207
2 O O 0.9797012805938721
adrenoceptor O O 0.9343394637107849
stimulant O O 0.9488372802734375
, O O 0.9999396800994873
was O O 0.9999581575393677
studied O O 0.9999451637268066
in O O 0.9999886751174927
a O O 0.9999752044677734
double O O 0.9998552799224854
- O O 0.9999593496322632
blind O O 0.9999886751174927
, O O 0.999957799911499
placebo O O 0.9998700618743896
- O O 0.9998921155929565
controlled O O 0.999910831451416
, O O 0.9999481439590454
cross O O 0.9952211976051331
- O O 0.9999529123306274
over O O 0.9997343420982361
trial O O 0.9999529123306274
in O O 0.9999778270721436
patients O O 0.9999922513961792
with O O 0.9999880790710449
bronchial O O 0.9987636804580688
asthma O O 0.9989301562309265
. O O 0.9999597072601318

Oral O O 0.9980767965316772
procaterol B B 0.9917311072349548
50 O O 0.939806342124939
micrograms O O 0.9969125986099243
b O O 0.9994990825653076
. O O 0.9999948740005493
d O O 0.9999958276748657
. O O 0.9999897480010986
, O O 0.9982006549835205
procaterol B B 0.940274715423584
100 O O 0.8208563923835754
micrograms O O 0.9913149476051331
b O O 0.9990782737731934
. O O 0.9999959468841553
d O O 0.9999959468841553
. O O 0.9999878406524658
, O O 0.9994106292724609
and O O 0.9974877834320068
terbutaline B B 0.9990124702453613
5 O O 0.9987815022468567
mg O O 0.9998829364776611
t O O 0.9999159574508667
. O O 0.9999951124191284
i O O 0.999998927116394
. O O 0.9999972581863403
d O O 0.9999984502792358
. O O 0.9999855756759644
, O O 0.9999655485153198
were O O 0.999971866607666
compared O O 0.999945878982544
when O O 0.9999589920043945
given O O 0.9999158382415771
randomly O O 0.9996254444122314
in O O 0.999945878982544
1 O O 0.9999097585678101
- O O 0.9999871253967285
week O O 0.9999809265136719
treatment O O 0.9999451637268066
periods O O 0.9999557733535767
. O O 0.999977707862854

The O O 0.9999629259109497
best O O 0.9999364614486694
clinical O O 0.9999582767486572
effect O O 0.9999716281890869
was O O 0.9999817609786987
found O O 0.9999970197677612
with O O 0.9997510313987732
terbutaline B B 0.999748170375824
. O O 0.9999421834945679

Both O O 0.9998125433921814
anti O O 0.7777014970779419
- O O 0.9977201819419861
asthmatic O O 0.9996028542518616
and O O 0.9992220401763916
tremorgenic O O 0.9972833395004272
effects O O 0.9998761415481567
of O O 0.999428927898407
procaterol B B 0.9968420267105103
were O O 0.9997488856315613
dose O O 0.999295711517334
- O O 0.9999154806137085
related O O 0.9999650716781616
. O O 0.9999665021896362

Procaterol B B 0.9945774078369141
appeared O O 0.999658465385437
effective O O 0.9991722106933594
in O O 0.9998924732208252
the O O 0.9998950958251953
doses O O 0.9997450709342957
tested O O 0.9999619722366333
, O O 0.9999392032623291
and O O 0.9999632835388184
a O O 0.9999746084213257
twice O O 0.9999005794525146
daily O O 0.9999521970748901
regimen O O 0.9998555183410645
would O O 0.9999719858169556
appear O O 0.9999922513961792
to O O 0.9999865293502808
be O O 0.9999934434890747
suitable O O 0.9999852180480957
with O O 0.9999699592590332
this O O 0.9993494153022766
drug O O 0.9989755153656006
. O O 0.9999436140060425

Subacute O O 0.9996298551559448
effects O O 0.9999406337738037
of O O 0.9991808533668518
propranolol B B 0.9996703863143921
and O O 0.9244166612625122
B O B 0.9949067234992981
24 O I 0.9726572036743164
/ O I 0.9696003794670105
76 O I 0.9979689717292786
on O O 0.9993220567703247
isoproterenol B B 0.9993876218795776
- O O 0.9996527433395386
induced O O 0.9999258518218994
rat O O 0.9999023675918579
heart O O 0.9999920129776001
hypertrophy O O 0.9998195767402649
in O O 0.9999576807022095
correlation O O 0.999991774559021
with O O 0.9999703168869019
blood O O 0.9998558759689331
pressure O O 0.9993886947631836
. O O 0.9999184608459473

We O O 0.9999675750732422
compared O O 0.9998650550842285
the O O 0.9997738003730774
potential O O 0.999444305896759
beta O O 0.944858968257904
- O O 0.9777374267578125
receptor O O 0.9896865487098694
blocker O O 0.9502552151679993
, O O 0.9988565444946289
B O B 0.9792410731315613
24 O I 0.983863115310669
/ O I 0.9022606015205383
76 O I 0.9603990316390991
i O O 0.970570981502533
. O O 0.9999170303344727
e O O 0.9998786449432373
. O O 0.999190628528595
1 O B 0.6517804861068726
- O I 0.9177754521369934
( O I 0.9938720464706421
2 O I 0.9794981479644775
, O I 0.9954631924629211
4 O I 0.9909975528717041
- O I 0.9922422170639038
dichlorophenoxy O I 0.9980085492134094
) O I 0.7686207890510559
- O I 0.8184128999710083
3 O I 0.9351800680160522
[ O I 0.9807917475700378
2 O I 0.9882434606552124
- O I 0.981228768825531
3 O I 0.9910160303115845
, O I 0.9919298887252808
4 O I 0.9927258491516113
- O I 0.9968993663787842
dimethoxyphenyl O I 0.9997535347938538
) O I 0.9785312414169312
ethanolamino O I 0.9767826199531555
] O I 0.8662571310997009
- O I 0.9684193134307861
prop O I 0.9988970756530762
an O I 0.9677924513816833
- O I 0.9540704488754272
2 O I 0.9928850531578064
- O I 0.9659576416015625
ol O I 0.9985376596450806
, O O 0.9998227953910828
which O O 0.9999563694000244
is O O 0.9998944997787476
characterized O O 0.9999434947967529
by O O 0.9997512698173523
beta O O 0.9725006818771362
1 O O 0.9831085801124573
- O O 0.9924342632293701
adrenoceptor O O 0.9715704321861267
blocking O O 0.9980422258377075
and O O 0.9994333386421204
beta O O 0.970216691493988
2 O O 0.9804689288139343
- O O 0.9944268465042114
adrenoceptor O O 0.9703724980354309
stimulating O O 0.9892265200614929
properties O O 0.9999196529388428
with O O 0.9995594620704651
propranolol B B 0.9996224641799927
. O O 0.9999576807022095

The O O 0.9999872446060181
studies O O 0.9999938011169434
were O O 0.9999957084655762
performed O O 0.9999947547912598
using O O 0.999974250793457
an O O 0.9999825954437256
experimental O O 0.9999568462371826
model O O 0.9999939203262329
of O O 0.9998993873596191
isoproterenol B B 0.9940197467803955
- O O 0.9988541603088379
induced O O 0.9999290704727173
heart O O 0.9999856948852539
hypertrophy O O 0.9992401599884033
in O O 0.999970555305481
rats O O 0.9999890327453613
. O O 0.9999784231185913

A O O 0.999951958656311
correlation O O 0.9999897480010986
of O O 0.9999639987945557
the O O 0.9999761581420898
blood O O 0.9986531734466553
pressure O O 0.9864659905433655
was O O 0.9999620914459229
neither O O 0.9999895095825195
found O O 0.9999889135360718
in O O 0.9999414682388306
the O O 0.9999545812606812
development O O 0.9999661445617676
nor O O 0.9999887943267822
in O O 0.9999603033065796
the O O 0.9999864101409912
attempt O O 0.9999845027923584
to O O 0.9999750852584839
suppress O O 0.9999390840530396
the O O 0.999982476234436
development O O 0.9999963045120239
of O O 0.9999837875366211
heart O O 0.9999618530273438
hypertrophy O O 0.9998522996902466
with O O 0.9998164772987366
the O O 0.9997414946556091
two O O 0.9963172674179077
beta O O 0.6923187971115112
- O O 0.8934968709945679
receptor O O 0.9132938981056213
blockers O O 0.842409610748291
. O O 0.9999490976333618

Both O O 0.9985166192054749
beta O O 0.5741514563560486
- O O 0.9021264910697937
blockers O O 0.5677013993263245
influenced O O 0.9997766613960266
the O O 0.9999819993972778
development O O 0.9999955892562866
of O O 0.9999723434448242
hypertrophy O O 0.9995819926261902
to O O 0.9999912977218628
a O O 0.9999758005142212
different O O 0.9999440908432007
, O O 0.9999818801879883
but O O 0.9999891519546509
not O O 0.9999920129776001
reproducible O O 0.9999957084655762
extent O O 0.9999927282333374
. O O 0.9999439716339111

It O O 0.9999604225158691
was O O 0.999957799911499
possible O O 0.9999532699584961
to O O 0.9998679161071777
suppress O O 0.9997045397758484
the O O 0.9999583959579468
increased O O 0.999790608882904
ornithine B B 0.9138119220733643
decarboxylase O O 0.5461533665657043
activity O O 0.9987879395484924
with O O 0.9999189376831055
both O O 0.9985758066177368
beta O O 0.5544663667678833
- O O 0.7647501826286316
blockers O O 0.6377947926521301
in O O 0.9997909665107727
hypertrophied O O 0.9965696334838867
hearts O O 0.9999802112579346
, O O 0.9999374151229858
but O O 0.9999499320983887
there O O 0.9999563694000244
was O O 0.9999570846557617
no O O 0.9999393224716187
effect O O 0.999969482421875
on O O 0.9999246597290039
the O O 0.9999853372573853
heart O O 0.9999457597732544
mass O O 0.9999833106994629
. O O 0.999969482421875

Neither O O 0.9998013377189636
propranolol B B 0.9996137022972107
nor O O 0.992070734500885
B O B 0.996222972869873
24 O I 0.9734276533126831
/ O I 0.9850784540176392
76 O I 0.9992361068725586
could O O 0.9997661709785461
stop O O 0.9999524354934692
the O O 0.9999908208847046
changes O O 0.9999960660934448
in O O 0.9999861717224121
the O O 0.9999790191650391
characteristic O O 0.9998762607574463
myosin O O 0.9988042116165161
isoenzyme O O 0.9968748092651367
pattern O O 0.9999220371246338
of O O 0.9999608993530273
the O O 0.9999711513519287
hypertrophied O O 0.9873523712158203
rat O O 0.9999872446060181
heart O O 0.9999825954437256
. O O 0.99994957447052

Thus O O 0.9999723434448242
, O O 0.9999420642852783
the O O 0.9999558925628662
investigations O O 0.9999130964279175
did O O 0.9999760389328003
not O O 0.9999850988388062
provide O O 0.9999808073043823
any O O 0.9999843835830688
evidence O O 0.9999747276306152
that O O 0.9997755885124207
the O O 0.9985889792442322
beta O O 0.9031415581703186
- O O 0.9796823859214783
receptor O O 0.9865182042121887
blockers O O 0.8658592700958252
propranolol B B 0.9994908571243286
and O O 0.9744203090667725
B O B 0.9938602447509766
24 O I 0.9846076369285583
/ O I 0.9785587787628174
76 O I 0.9982555508613586
have O O 0.9995224475860596
the O O 0.9999688863754272
potency O O 0.9998536109924316
to O O 0.9999669790267944
prevent O O 0.9996351003646851
isoproterenol B B 0.9971740245819092
from O O 0.9997710585594177
producing O O 0.9998854398727417
heart O O 0.9999884366989136
hypertrophy O O 0.9998565912246704
. O O 0.9999487400054932

Increased O O 0.999358594417572
anxiogenic O O 0.9575438499450684
effects O O 0.9997363686561584
of O O 0.9979274272918701
caffeine B B 0.998994767665863
in O O 0.9992800354957581
panic O O 0.9894954562187195
disorders O O 0.9999666213989258
. O O 0.9997761845588684

The O O 0.9999772310256958
effects O O 0.9999868869781494
of O O 0.9999383687973022
oral O O 0.99957674741745
administration O O 0.9999682903289795
of O O 0.9986104965209961
caffeine B B 0.9998636245727539
( O O 0.999767005443573
10 O O 0.9994025230407715
mg O O 0.9997429251670837
/ O O 0.999880313873291
kg O O 0.9999626874923706
) O O 0.9999518394470215
on O O 0.9998592138290405
behavioral O O 0.9999829530715942
ratings O O 0.9999840259552002
, O O 0.99996018409729
somatic O O 0.9998906850814819
symptoms O O 0.9999960660934448
, O O 0.9999855756759644
blood O O 0.9996755123138428
pressure O O 0.9982267022132874
and O O 0.9999722242355347
plasma O O 0.9998562335968018
levels O O 0.9998787641525269
of O O 0.9975987076759338
3 B B 0.803093671798706
- I I 0.9917674660682678
methoxy I I 0.9988428354263306
- I I 0.9553301930427551
4 I I 0.9873567819595337
- I I 0.9919456839561462
hydroxyphenethyleneglycol I I 0.9981491565704346
( O O 0.9947118759155273
MHPG B O 0.8578498363494873
) O O 0.9969608187675476
and O O 0.9975478053092957
cortisol B B 0.981340229511261
were O O 0.9999209642410278
determined O O 0.999980092048645
in O O 0.9999656677246094
17 O O 0.9999935626983643
healthy O O 0.9999758005142212
subjects O O 0.9999959468841553
and O O 0.9999768733978271
21 O O 0.9999674558639526
patients O O 0.9999960660934448
meeting O O 0.9999620914459229
DSM O O 0.9833691716194153
- O O 0.9993451237678528
III O O 0.9970738887786865
criteria O O 0.9999904632568359
for O O 0.9999687671661377
agoraphobia O O 0.9867008328437805
with O O 0.999963641166687
panic O O 0.9997367262840271
attacks O O 0.9999918937683105
or O O 0.9999616146087646
panic O O 0.9995666146278381
disorder O O 0.9999921321868896
. O O 0.9999756813049316

Caffeine B B 0.9992572665214539
produced O O 0.9998461008071899
significantly O O 0.9999772310256958
greater O O 0.9999569654464722
increases O O 0.9999886751174927
in O O 0.9999732971191406
subject O O 0.7000822424888611
- O O 0.99991774559021
rated O O 0.9999494552612305
anxiety O O 0.9999783039093018
, O O 0.9999039173126221
nervousness O O 0.9999911785125732
, O O 0.9999107122421265
fear O O 0.9999921321868896
, O O 0.9999483823776245
nausea O O 0.9999823570251465
, O O 0.9999161958694458
palpitations O O 0.9999827146530151
, O O 0.9999185800552368
restlessness O O 0.9999920129776001
, O O 0.9999146461486816
and O O 0.9998059868812561
tremors O O 0.9998929500579834
in O O 0.9998760223388672
the O O 0.9999383687973022
patients O O 0.999954104423523
compared O O 0.9999845027923584
with O O 0.9999915361404419
healthy O O 0.9998923540115356
subjects O O 0.9999929666519165
. O O 0.9999459981918335

In O O 0.9997841715812683
the O O 0.9999710321426392
patients O O 0.99997878074646
, O O 0.9999803304672241
but O O 0.9999910593032837
not O O 0.9999881982803345
the O O 0.9999903440475464
healthy O O 0.9999399185180664
subjects O O 0.9999922513961792
, O O 0.9999440908432007
these O O 0.9999642372131348
symptoms O O 0.9999908208847046
were O O 0.9999306201934814
significantly O O 0.9999620914459229
correlated O O 0.9999940395355225
with O O 0.9999758005142212
plasma O O 0.9995023012161255
caffeine B B 0.9989261031150818
levels O O 0.999850869178772
. O O 0.9999871253967285

Seventy O O 0.9996997117996216
- O O 0.9999850988388062
one O O 0.9999961853027344
percent O O 0.9999936819076538
of O O 0.9999886751174927
the O O 0.9999823570251465
patients O O 0.9999942779541016
reported O O 0.999988317489624
that O O 0.9999634027481079
the O O 0.9999773502349854
behavioral O O 0.9999637603759766
effects O O 0.9999563694000244
of O O 0.999790608882904
caffeine B B 0.9996026158332825
were O O 0.9998767375946045
similar O O 0.999988317489624
to O O 0.9999719858169556
those O O 0.9999890327453613
experienced O O 0.9999885559082031
during O O 0.999945878982544
panic O O 0.9994638562202454
attacks O O 0.999988317489624
. O O 0.9999665021896362

Caffeine B B 0.9990991353988647
did O O 0.9999042749404907
not O O 0.9999585151672363
alter O O 0.9999512434005737
plasma O O 0.9997844099998474
MHPG B B 0.9251645803451538
levels O O 0.999810516834259
in O O 0.9999005794525146
either O O 0.9999526739120483
the O O 0.9999830722808838
healthy O O 0.9999260902404785
subjects O O 0.9999918937683105
or O O 0.9999388456344604
patients O O 0.9999784231185913
. O O 0.9999129772186279

Caffeine B B 0.9989443421363831
increased O O 0.999875545501709
plasma O O 0.9996652603149414
cortisol B B 0.976952075958252
levels O O 0.9998568296432495
equally O O 0.9999126195907593
in O O 0.9998601675033569
the O O 0.9999629259109497
patient O O 0.9999526739120483
and O O 0.9999306201934814
healthy O O 0.9988498687744141
groups O O 0.9999756813049316
. O O 0.9998329877853394

Because O O 0.9992116689682007
caffeine B B 0.9997478127479553
is O O 0.9988570213317871
an O O 0.9940510392189026
adenosine B B 0.9900934100151062
receptor O O 0.9584043025970459
antagonist O O 0.9074400067329407
, O O 0.9999737739562988
these O O 0.9999842643737793
results O O 0.9999912977218628
suggest O O 0.9999701976776123
that O O 0.9999661445617676
some O O 0.9999431371688843
panic O O 0.9792938828468323
disorder O O 0.9998767375946045
patients O O 0.9999459981918335
may O O 0.999953031539917
have O O 0.9999300241470337
abnormalities O O 0.9999806880950928
in O O 0.9999486207962036
neuronal O O 0.9999773502349854
systems O O 0.9999778270721436
involving O O 0.9997696280479431
adenosine B B 0.9920907020568848
. O O 0.9999196529388428

Patients O O 0.9999701976776123
with O O 0.9999645948410034
anxiety O O 0.9853687882423401
disorders O O 0.9999830722808838
may O O 0.9999750852584839
benefit O O 0.9999911785125732
by O O 0.9999876022338867
avoiding O O 0.9997739195823669
caffeine B B 0.9965792298316956
- O O 0.9987267851829529
containing O O 0.9965872764587402
foods O O 0.9998466968536377
and O O 0.9999377727508545
beverages O O 0.9976766705513
. O O 0.9999792575836182

Comparison O O 0.999945878982544
of O O 0.9997774958610535
the O O 0.999927282333374
effect O O 0.9998804330825806
of O O 0.9987521171569824
oxitropium B B 0.9995715022087097
bromide I I 0.9987021684646606
and O O 0.9976951479911804
of O O 0.9996740818023682
slow O O 0.9919335246086121
- O O 0.9998534917831421
release O O 0.9766626358032227
theophylline B B 0.9997335076332092
on O O 0.9997408986091614
nocturnal O O 0.9970479607582092
asthma O O 0.9848929643630981
. O O 0.9999362230300903

The O O 0.9999802112579346
effects O O 0.9999667406082153
of O O 0.9998878240585327
a O O 0.9999362230300903
new O O 0.9999399185180664
inhaled O O 0.9976680874824524
antimuscarinic O O 0.6092330813407898
drug O O 0.9763901233673096
, O O 0.9949232935905457
oxitropium B B 0.9988595247268677
bromide I I 0.9995237588882446
, O O 0.9992274045944214
and O O 0.9998464584350586
of O O 0.9998502731323242
a O O 0.9997633099555969
slow O O 0.9905661940574646
- O O 0.9997877478599548
release O O 0.978871762752533
theophylline B B 0.9994503855705261
preparation O O 0.6932845115661621
upon O O 0.9998568296432495
nocturnal O O 0.9994701743125916
asthma O O 0.9995606541633606
were O O 0.9999825954437256
compared O O 0.9999872446060181
in O O 0.9999932050704956
a O O 0.9999845027923584
placebo O O 0.9998807907104492
- O O 0.9999701976776123
controlled O O 0.9999634027481079
double O O 0.9999610185623169
- O O 0.9999854564666748
blind O O 0.9999964237213135
study O O 0.9999948740005493
. O O 0.9999843835830688

Two O O 0.9999271631240845
samples O O 0.9999803304672241
were O O 0.9999654293060303
studied O O 0.9999821186065674
: O O 0.9999872446060181
12 O O 0.9999865293502808
patients O O 0.9999935626983643
received O O 0.9998284578323364
oxitropium B B 0.9991587400436401
at O O 0.9995970129966736
600 O O 0.9989521503448486
micrograms O O 0.994001567363739
( O O 0.9998950958251953
6 O O 0.9991242289543152
subjects O O 0.9783120155334473
) O O 0.9999290704727173
or O O 0.999819815158844
at O O 0.9999370574951172
400 O O 0.9992340803146362
micrograms O O 0.998149037361145
t O O 0.9999680519104004
. O O 0.9999929666519165
i O O 0.9999982118606567
. O O 0.9999959468841553
d O O 0.9999979734420776
. O O 0.999963641166687

( O O 0.9997087121009827
6 O O 0.9998278617858887
subjects O O 0.9989204406738281
) O O 0.9999666213989258
whereas O O 0.9999897480010986
11 O O 0.9990731477737427
received O O 0.9997460246086121
theophylline B B 0.9998238682746887
at O O 0.9995602965354919
300 O O 0.9997647404670715
mg O O 0.9999128580093384
b O O 0.9999682903289795
. O O 0.9999945163726807
i O O 0.9999974966049194
. O O 0.9999958276748657
d O O 0.9999973773956299
. O O 0.9999686479568481

Morning O O 0.9927756786346436
dipping O O 0.9990556836128235
, O O 0.9999964237213135
assessed O O 0.9999958276748657
by O O 0.9999966621398926
the O O 0.9999978542327881
fall O O 0.9999985694885254
in O O 0.9999881982803345
peak O O 0.993687093257904
flow O O 0.9999575614929199
overnight O O 0.9998395442962646
, O O 0.9999793767929077
was O O 0.9999673366546631
significantly O O 0.9999814033508301
reduced O O 0.9999877214431763
in O O 0.9997870326042175
the O O 0.9999591112136841
periods O O 0.9999592304229736
when O O 0.9999582767486572
either O O 0.9998065829277039
active O O 0.999517560005188
drug O O 0.9986249208450317
was O O 0.999951958656311
taken O O 0.999767005443573
, O O 0.9999487400054932
whereas O O 0.9999788999557495
no O O 0.9999876022338867
difference O O 0.9999920129776001
was O O 0.9999843835830688
noticed O O 0.9999972581863403
during O O 0.999937891960144
the O O 0.9999667406082153
placebo O O 0.9997100234031677
administration O O 0.9999254941940308
. O O 0.999980092048645

No O O 0.9999744892120361
significant O O 0.9999923706054688
difference O O 0.999996542930603
was O O 0.9999876022338867
noticed O O 0.9999978542327881
between O O 0.999908447265625
results O O 0.999992847442627
obtained O O 0.9999978542327881
with O O 0.9999059438705444
either O O 0.9998362064361572
active O O 0.998725950717926
drug O O 0.9992759823799133
, O O 0.9999120235443115
as O O 0.9999673366546631
well O O 0.9998960494995117
as O O 0.9999467134475708
with O O 0.9999045133590698
either O O 0.9996315240859985
dosage O O 0.9997490048408508
of O O 0.9942522644996643
oxitropium B B 0.9985074400901794
. O O 0.9999330043792725

No O O 0.9996763467788696
subject O O 0.9999703168869019
reported O O 0.9999058246612549
side O O 0.999869704246521
effects O O 0.9999758005142212
of O O 0.999265730381012
oxitropium B B 0.9993984699249268
, O O 0.9998700618743896
as O O 0.999976634979248
compared O O 0.9999845027923584
to O O 0.9999730587005615
three O O 0.9999589920043945
subjects O O 0.9999949932098389
reporting O O 0.999948263168335
nausea O O 0.9999929666519165
, O O 0.9999780654907227
vomiting O O 0.999963641166687
and O O 0.9999642372131348
tremors O O 0.9999847412109375
after O O 0.9996680021286011
theophylline B B 0.9997610449790955
. O O 0.9999583959579468

Oxitropium B B 0.9993701577186584
proves O O 0.9998263716697693
to O O 0.9999415874481201
be O O 0.999958872795105
a O O 0.9999200105667114
valuable O O 0.9999784231185913
alternative O O 0.9998842477798462
to O O 0.9994239807128906
theophylline B B 0.9998334646224976
in O O 0.999747097492218
nocturnal O O 0.9856857061386108
asthma O O 0.988993227481842
, O O 0.9999771118164062
since O O 0.9999929666519165
it O O 0.9994895458221436
is O O 0.9999356269836426
equally O O 0.9998788833618164
potent O O 0.9996709823608398
, O O 0.9999810457229614
safer O O 0.9999403953552246
and O O 0.9999918937683105
does O O 0.9999899864196777
not O O 0.9999966621398926
require O O 0.9999896287918091
the O O 0.9999964237213135
titration O O 0.9999966621398926
of O O 0.9999812841415405
dosage O O 0.999953031539917
. O O 0.9999479055404663

Penicillin B B 0.9779880046844482
anaphylaxis O O 0.5906599760055542
. O O 0.9931827187538147

A O O 0.9999711513519287
case O O 0.9999932050704956
of O O 0.9999696016311646
oral O O 0.7979732155799866
penicillin B B 0.9779890179634094
anaphylaxis O O 0.9683800935745239
is O O 0.9999736547470093
described O O 0.9999865293502808
, O O 0.9999494552612305
and O O 0.9999608993530273
the O O 0.9999871253967285
terminology O O 0.9999940395355225
, O O 0.999980092048645
occurrence O O 0.9999954700469971
, O O 0.9999806880950928
clinical O O 0.9999803304672241
manifestations O O 0.9999951124191284
, O O 0.9999810457229614
pathogenesis O O 0.9999890327453613
, O O 0.9999862909317017
prevention O O 0.9999725818634033
, O O 0.9999610185623169
and O O 0.9999759197235107
treatment O O 0.9999616146087646
of O O 0.9999650716781616
anaphylaxis O O 0.9977574944496155
are O O 0.9999760389328003
reviewed O O 0.9999949932098389
. O O 0.9999793767929077

Emergency O O 0.9988299012184143
physicians O O 0.9999926090240479
should O O 0.9999667406082153
be O O 0.9999942779541016
aware O O 0.9999850988388062
of O O 0.9999581575393677
oral O O 0.9302628636360168
penicillin B B 0.9969375133514404
anaphylaxis O O 0.9892519116401672
in O O 0.9999674558639526
order O O 0.9999903440475464
to O O 0.9999843835830688
prevent O O 0.9999724626541138
its O O 0.9999908208847046
occurrence O O 0.9999943971633911
by O O 0.999985933303833
prescribing O O 0.9999021291732788
the O O 0.9999788999557495
antibiotic O O 0.9666163325309753
judiciously O O 0.9999613761901855
and O O 0.9999841451644897
knowledgeably O O 0.9999755620956421
and O O 0.9999796152114868
to O O 0.9999840259552002
offer O O 0.9999783039093018
optimal O O 0.9998893737792969
medical O O 0.9999902248382568
therapy O O 0.9999916553497314
once O O 0.9999923706054688
this O O 0.9999856948852539
life O O 0.9999122619628906
- O O 0.999987006187439
threatening O O 0.9999934434890747
reaction O O 0.9999955892562866
has O O 0.9999905824661255
begun O O 0.9999983310699463
. O O 0.9999816417694092

Reversible O O 0.9977446794509888
valproic B B 0.9933956265449524
acid I I 0.9999567270278931
- O O 0.9952848553657532
induced O O 0.9999443292617798
dementia O O 0.9999983310699463
: O O 0.9999856948852539
a O O 0.9999955892562866
case O O 0.9999877214431763
report O O 0.9999945163726807
. O O 0.9999833106994629

Reversible O O 0.9991639852523804
valproic B B 0.9921619296073914
acid I I 0.9999504089355469
- O O 0.9970044493675232
induced O O 0.9999517202377319
dementia O O 0.999998927116394
was O O 0.9999872446060181
documented O O 0.9999949932098389
in O O 0.9999853372573853
a O O 0.9999898672103882
21 O O 0.9999904632568359
- O O 0.9999841451644897
year O O 0.9999951124191284
- O O 0.9999923706054688
old O O 0.9999947547912598
man O O 0.9999967813491821
with O O 0.9999698400497437
epilepsy O O 0.9997476935386658
who O O 0.9999537467956543
had O O 0.9999809265136719
a O O 0.9999918937683105
3 O O 0.9999231100082397
- O O 0.9999890327453613
year O O 0.9999967813491821
history O O 0.9999946355819702
of O O 0.9999885559082031
insidious O O 0.9999290704727173
progressive O O 0.999993085861206
decline O O 0.9999967813491821
in O O 0.9999819993972778
global O O 0.9997472167015076
cognitive O O 0.9999903440475464
abilities O O 0.9999964237213135
documented O O 0.9999852180480957
by O O 0.9999921321868896
serial O O 0.9999840259552002
neuropsychological O O 0.9999959468841553
studies O O 0.9999959468841553
. O O 0.9999825954437256

Repeat O O 0.9999918937683105
neuropsychological O O 0.9999953508377075
testing O O 0.9999982118606567
7 O O 0.9999839067459106
weeks O O 0.9999990463256836
after O O 0.9999922513961792
discontinuation O O 0.9999864101409912
of O O 0.9999316930770874
the O O 0.9999212026596069
drug O O 0.99769526720047
revealed O O 0.9999653100967407
dramatic O O 0.9999765157699585
improvement O O 0.9999923706054688
in O O 0.9999508857727051
IQ O O 0.9760577082633972
, O O 0.9998762607574463
memory O O 0.999984622001648
, O O 0.9999533891677856
naming O O 0.9999960660934448
, O O 0.9999207258224487
and O O 0.9999610185623169
other O O 0.9999369382858276
tasks O O 0.9999929666519165
commensurate O O 0.9999847412109375
with O O 0.9999873638153076
clinical O O 0.999994158744812
recovery O O 0.9999984502792358
in O O 0.9999920129776001
his O O 0.9999836683273315
intellectual O O 0.9997594952583313
capacity O O 0.9999954700469971
. O O 0.9999825954437256

Possible O O 0.99985671043396
pathophysiological O O 0.9999403953552246
mechanisms O O 0.9999440908432007
which O O 0.9999053478240967
may O O 0.9997583031654358
have O O 0.9999878406524658
been O O 0.9999711513519287
operative O O 0.9999321699142456
in O O 0.9999871253967285
this O O 0.9999792575836182
case O O 0.9999722242355347
include O O 0.999920129776001
: O O 0.9998579025268555
a O O 0.9996044039726257
direct O O 0.9998888969421387
central O O 0.9996545314788818
nervous O O 0.9999861717224121
system O O 0.9999212026596069
( O O 0.9989153146743774
CNS O O 0.8868799209594727
) O O 0.9998196959495544
toxic O O 0.9996656179428101
effect O O 0.9999687671661377
of O O 0.9997625946998596
valproic B B 0.9975970387458801
acid I I 0.9999520778656006
; O O 0.9994020462036133
a O O 0.9998849630355835
paradoxical O O 0.999883770942688
epileptogenic O O 0.999935507774353
effect O O 0.9999918937683105
secondary O O 0.9999887943267822
to O O 0.9996071457862854
the O O 0.9998133778572083
drug O O 0.9988206028938293
; O O 0.9998551607131958
and O O 0.9997836947441101
an O O 0.9997979998588562
indirect O O 0.9989983439445496
CNS O O 0.5978857278823853
toxic O O 0.9969260096549988
effect O O 0.9999608993530273
mediated O O 0.9999675750732422
through O O 0.9998929500579834
valproic B B 0.9994614720344543
acid I I 0.9999485015869141
- O O 0.9990405440330505
induced O O 0.9999184608459473
hyperammonemia O O 0.9438984990119934
. O O 0.9999604225158691

Reversal O O 0.9998263716697693
of O O 0.9998910427093506
scopolamine B B 0.9994533658027649
- O O 0.9998005032539368
induced O O 0.9999324083328247
amnesia O O 0.9999067783355713
of O O 0.9998279809951782
passive O O 0.9984456896781921
avoidance O O 0.9999551773071289
by O O 0.9994121789932251
pre O O 0.9990002512931824
- O O 0.999826967716217
and O O 0.9996898174285889
post O O 0.9988430738449097
- O O 0.9998908042907715
training O O 0.9842811822891235
naloxone B B 0.99974125623703
. O O 0.9997907280921936

In O O 0.9999698400497437
a O O 0.9999752044677734
series O O 0.999994158744812
of O O 0.9999812841415405
five O O 0.9999874830245972
experiments O O 0.9999885559082031
, O O 0.9999562501907349
the O O 0.9999696016311646
modulating O O 0.9998406171798706
role O O 0.9999673366546631
of O O 0.9996789693832397
naloxone B B 0.9998431205749512
on O O 0.999699592590332
a O O 0.9999215602874756
scopolamine B B 0.9989308714866638
- O O 0.9995344877243042
induced O O 0.9999159574508667
retention O O 0.9999631643295288
deficit O O 0.9999887943267822
in O O 0.9999558925628662
a O O 0.9999264478683472
passive O O 0.9988916516304016
avoidance O O 0.9999575614929199
paradigm O O 0.9999525547027588
was O O 0.9999877214431763
investigated O O 0.999985933303833
in O O 0.9999669790267944
mice O O 0.9999651908874512
. O O 0.9999831914901733

Scopolamine B B 0.9994189739227295
, O O 0.9992910623550415
but O O 0.9997789263725281
not O O 0.9995691180229187
methyl B B 0.9968882203102112
scopolamine I I 0.9435556530952454
( O O 0.9984806180000305
1 O O 0.9990535378456116
and O O 0.9998145699501038
3 O O 0.9997416138648987
mg O O 0.9999294281005859
/ O O 0.9999350309371948
kg O O 0.999995231628418
) O O 0.99986732006073
, O O 0.999931812286377
induced O O 0.9999567270278931
an O O 0.9999734163284302
amnesia O O 0.999916672706604
as O O 0.9999881982803345
measured O O 0.9999943971633911
by O O 0.9999856948852539
latency O O 0.9999852180480957
and O O 0.9999669790267944
duration O O 0.9999682903289795
parameters O O 0.9999951124191284
. O O 0.9999740123748779

Naloxone B B 0.9991208910942078
( O O 0.9994248151779175
0 O O 0.9988334774971008
. O O 0.9999727010726929
3 O O 0.9991406202316284
, O O 0.9986457228660583
1 O O 0.9985734224319458
, O O 0.9980382323265076
3 O O 0.9946714043617249
, O O 0.9989413619041443
and O O 0.9993401169776917
10 O O 0.9997871518135071
mg O O 0.9998866319656372
/ O O 0.9999114274978638
kg O O 0.999882698059082
) O O 0.9998651742935181
injected O O 0.999859094619751
prior O O 0.999988317489624
to O O 0.9999842643737793
training O O 0.9998388290405273
attenuated O O 0.9999423027038574
the O O 0.999974250793457
retention O O 0.9999258518218994
deficit O O 0.999983549118042
with O O 0.9999874830245972
a O O 0.9999898672103882
peak O O 0.9999593496322632
of O O 0.999805748462677
activity O O 0.9971262812614441
at O O 0.9999761581420898
3 O O 0.9996606111526489
mg O O 0.9999754428863525
/ O O 0.9999868869781494
kg O O 0.9999959468841553
. O O 0.9999663829803467

The O O 0.999954104423523
effect O O 0.9999463558197021
of O O 0.9998379945755005
naloxone B B 0.9997530579566956
could O O 0.9998397827148438
be O O 0.9999760389328003
antagonized O O 0.9999446868896484
with O O 0.9997729659080505
morphine B B 0.9998231530189514
( O O 0.9994888305664062
1 O O 0.9986594915390015
, O O 0.9994858503341675
3 O O 0.9977681636810303
, O O 0.9996575117111206
and O O 0.999916672706604
10 O O 0.9999006986618042
mg O O 0.9998648166656494
/ O O 0.9999251365661621
kg O O 0.9999829530715942
) O O 0.9999681711196899
, O O 0.9999781847000122
demonstrating O O 0.9999555349349976
the O O 0.9999809265136719
opioid O O 0.9652513861656189
specificity O O 0.9998780488967896
of O O 0.9999531507492065
the O O 0.9999674558639526
naloxone B B 0.9997649788856506
effect O O 0.9998290538787842
. O O 0.9999576807022095

Post O O 0.9996922016143799
- O O 0.9999206066131592
training O O 0.9994089603424072
administration O O 0.9999557733535767
of O O 0.9994255304336548
naloxone B B 0.9998160004615784
( O O 0.9997947812080383
3 O O 0.9998743534088135
mg O O 0.9999340772628784
/ O O 0.9999505281448364
kg O O 0.9999945163726807
) O O 0.9999629259109497
as O O 0.9999794960021973
a O O 0.9999856948852539
single O O 0.9999527931213379
or O O 0.9999401569366455
as O O 0.9999874830245972
a O O 0.9999890327453613
split O O 0.9999016523361206
dose O O 0.9998835325241089
also O O 0.9999358654022217
attenuated O O 0.9997000694274902
the O O 0.9999829530715942
scopolamine B B 0.9993407130241394
- O O 0.9998316764831543
induced O O 0.9999417066574097
amnesia O O 0.9999616146087646
. O O 0.9999573230743408

Control O O 0.9996845722198486
experiments O O 0.9999808073043823
indicated O O 0.9999423027038574
that O O 0.9999233484268188
neither O O 0.9999264478683472
an O O 0.9998233914375305
increase O O 0.9999306201934814
in O O 0.9999078512191772
pain O O 0.9979670643806458
sensitivity O O 0.9999268054962158
( O O 0.9996504783630371
pre O O 0.9982319474220276
- O O 0.9998264908790588
training O O 0.9970320463180542
naloxone B B 0.9997450709342957
) O O 0.9992266893386841
nor O O 0.9999110698699951
an O O 0.999727189540863
induced O O 0.9998039603233337
aversive O O 0.9992187023162842
state O O 0.9999713897705078
( O O 0.9997761845588684
post O O 0.9992103576660156
- O O 0.9998584985733032
training O O 0.9990474581718445
naloxone B B 0.9997960925102234
) O O 0.9998443126678467
appear O O 0.9999053478240967
to O O 0.9998834133148193
be O O 0.9999217987060547
responsible O O 0.9999492168426514
for O O 0.9999009370803833
the O O 0.9999603033065796
influence O O 0.999957799911499
of O O 0.999784529209137
naloxone B B 0.9998500347137451
on O O 0.9997640252113342
the O O 0.9999805688858032
scopolamine B B 0.9997652173042297
- O O 0.999810516834259
induced O O 0.9999276399612427
retention O O 0.9999908208847046
deficit O O 0.9999929666519165
. O O 0.9999563694000244

These O O 0.9999727010726929
results O O 0.9999845027923584
extend O O 0.9999666213989258
previous O O 0.9999617338180542
findings O O 0.9999915361404419
implicating O O 0.9999881982803345
a O O 0.9996768236160278
cholinergic O O 0.5991731286048889
- O O 0.9817444682121277
opioid O O 0.573763906955719
interaction O O 0.999742329120636
in O O 0.9998034834861755
memory O O 0.99994957447052
processes O O 0.9999873638153076
. O O 0.9999696016311646

A O O 0.9999583959579468
possible O O 0.9998264908790588
mechanism O O 0.9999459981918335
for O O 0.9999282360076904
this O O 0.999906063079834
interaction O O 0.9999358654022217
involving O O 0.9997840523719788
the O O 0.9998488426208496
septo O O 0.9899643063545227
- O O 0.9994950294494629
hippocampal O O 0.9981864094734192
cholinergic O O 0.707754909992218
pathway O O 0.9998733997344971
is O O 0.9999475479125977
discussed O O 0.9999711513519287
. O O 0.9999713897705078

Electron O O 0.9998633861541748
microscopic O O 0.9999569654464722
investigations O O 0.9999905824661255
of O O 0.999970555305481
the O O 0.9999581575393677
cyclophosphamide B B 0.9988227486610413
- O O 0.9993477463722229
induced O O 0.999924898147583
lesions O O 0.9999887943267822
of O O 0.9999432563781738
the O O 0.999976396560669
urinary O O 0.999970555305481
bladder O O 0.9999464750289917
of O O 0.9998791217803955
the O O 0.9999597072601318
rat O O 0.9998114705085754
and O O 0.9999517202377319
their O O 0.9999169111251831
prevention O O 0.9998897314071655
by O O 0.9997331500053406
mesna B B 0.9127689599990845
. O O 0.9997075200080872

Fully O O 0.9993880987167358
developed O O 0.9999563694000244
cyclophosphamide B B 0.9987063407897949
- O O 0.9991511106491089
induced O O 0.9998990297317505
cystitis O O 0.9997082352638245
is O O 0.9999630451202393
characterized O O 0.9999897480010986
by O O 0.9999736547470093
nearly O O 0.9999656677246094
complete O O 0.9999581575393677
detachment O O 0.9999908208847046
of O O 0.999977707862854
the O O 0.9999822378158569
urothelium O O 0.9999295473098755
, O O 0.9999401569366455
severe O O 0.9999487400054932
submucosal O O 0.9989676475524902
edema O O 0.999987006187439
owing O O 0.9999750852584839
to O O 0.9962908029556274
damage O O 0.9999850988388062
to O O 0.9999252557754517
the O O 0.9999642372131348
microvascular O O 0.999311089515686
bed O O 0.9999812841415405
and O O 0.9998811483383179
focal O O 0.9999065399169922
muscle O O 0.9998941421508789
necroses O O 0.9999897480010986
. O O 0.9999823570251465

The O O 0.9999685287475586
initial O O 0.999984622001648
response O O 0.9999897480010986
to O O 0.9999517202377319
the O O 0.9999518394470215
primary O O 0.9998072981834412
attack O O 0.9999630451202393
by O O 0.9997588992118835
the O O 0.9984377026557922
cyclophosphamide B B 0.9958129525184631
metabolites O O 0.979097306728363
seems O O 0.9999594688415527
to O O 0.9999469518661499
be O O 0.9999681711196899
fragmentation O O 0.9999864101409912
of O O 0.9999148845672607
the O O 0.9999250173568726
luminal B O 0.9405068159103394
membrane O O 0.9999488592147827
. O O 0.999964714050293

This O O 0.9985877275466919
damages O O 0.9998633861541748
the O O 0.9998753070831299
cellular O O 0.99989914894104
barrier O O 0.9999855756759644
against O O 0.9996320009231567
the O O 0.9998834133148193
hypertonic O O 0.9848052859306335
urine O O 0.9663996696472168
. O O 0.9998151659965515

Subsequent O O 0.9999308586120605
breaks O O 0.9999879598617554
in O O 0.9999176263809204
the O O 0.9999351501464844
lateral O O 0.999438464641571
cell O O 0.9999524354934692
membranes O O 0.9999754428863525
of O O 0.9998658895492554
the O O 0.9998231530189514
superficial O O 0.9993957281112671
cells O O 0.999984622001648
and O O 0.999825656414032
in O O 0.9998435974121094
all O O 0.9996955394744873
the O O 0.9999219179153442
plasma O O 0.9998852014541626
membranes O O 0.9999637603759766
of O O 0.9998431205749512
the O O 0.999806821346283
intermediate O O 0.9981497526168823
and O O 0.9998010993003845
basal O O 0.999345600605011
cells O O 0.9999799728393555
, O O 0.9997159838676453
intercellular O O 0.9768224954605103
and O O 0.9993137121200562
intracellular O O 0.9995953440666199
edema O O 0.9999282360076904
and O O 0.9998045563697815
disintegration O O 0.9998853206634521
of O O 0.9998395442962646
the O O 0.9998914003372192
desmosomes O O 0.9603143334388733
and O O 0.9996252059936523
hemidesmosomes O O 0.9818804264068604
lead O O 0.9999580383300781
to O O 0.9999847412109375
progressive O O 0.9999799728393555
degeneration O O 0.9999743700027466
and O O 0.9999622106552124
detachment O O 0.9999864101409912
of O O 0.9999685287475586
the O O 0.9999572038650513
epithelial O O 0.9999372959136963
cells O O 0.9999860525131226
with O O 0.999962329864502
exposure O O 0.9999722242355347
and O O 0.9999611377716064
splitting O O 0.9999799728393555
of O O 0.9999595880508423
the O O 0.9999622106552124
basal O O 0.9999165534973145
membrane O O 0.9999692440032959
. O O 0.9999589920043945

The O O 0.9999685287475586
morphological O O 0.9999892711639404
changes O O 0.9999972581863403
of O O 0.999910831451416
the O O 0.9999445676803589
endothelial O O 0.9999527931213379
cells O O 0.9999829530715942
, O O 0.9999809265136719
which O O 0.9999845027923584
become O O 0.9999933242797852
more O O 0.9999850988388062
pronounced O O 0.9999862909317017
in O O 0.999984622001648
the O O 0.9999933242797852
later O O 0.9999881982803345
stages O O 0.9999960660934448
of O O 0.9999889135360718
the O O 0.9999920129776001
experiment O O 0.9999815225601196
, O O 0.9999423027038574
the O O 0.9999681711196899
involvement O O 0.9999642372131348
of O O 0.9998323917388916
blood O O 0.9996024966239929
vessels O O 0.9999809265136719
regardless O O 0.9998428821563721
of O O 0.9999687671661377
their O O 0.9998346567153931
diameter O O 0.9999690055847168
and O O 0.9999735355377197
the O O 0.999985933303833
location O O 0.9986733198165894
- O O 0.9999194145202637
dependent O O 0.9999924898147583
extent O O 0.999984622001648
of O O 0.9999833106994629
the O O 0.9999743700027466
damage O O 0.999984622001648
indicate O O 0.9998923540115356
a O O 0.9999141693115234
direct O O 0.9999620914459229
type O O 0.9999892711639404
of O O 0.9999488592147827
damage O O 0.9999884366989136
which O O 0.9998915195465088
is O O 0.9999558925628662
preceded O O 0.9999744892120361
by O O 0.999954104423523
a O O 0.9999196529388428
mediator O O 0.9476591944694519
- O O 0.9995170831680298
induced O O 0.9999744892120361
increase O O 0.9999808073043823
in O O 0.9999371767044067
permeability O O 0.9998750686645508
, O O 0.999982476234436
the O O 0.9999758005142212
morphological O O 0.9999891519546509
correlate O O 0.9999490976333618
of O O 0.9999490976333618
which O O 0.9999303817749023
is O O 0.9999645948410034
the O O 0.9999878406524658
formation O O 0.9999953508377075
of O O 0.9999592304229736
gaps O O 0.9998281002044678
in O O 0.9999589920043945
the O O 0.9999550580978394
interendothelial O O 0.9988126754760742
cell O O 0.9999221563339233
connections O O 0.9995928406715393
on O O 0.9997716546058655
the O O 0.9998730421066284
venules O O 0.999222993850708
. O O 0.9999464750289917

These O O 0.9999040365219116
changes O O 0.9999759197235107
can O O 0.9983676075935364
be O O 0.9999011754989624
effectively O O 0.999870777130127
prevented O O 0.9999768733978271
by O O 0.9994930028915405
mesna B B 0.862551212310791
. O O 0.9995602965354919

The O O 0.9999794960021973
only O O 0.9999841451644897
sign O O 0.9999935626983643
of O O 0.9999896287918091
a O O 0.9999707937240601
possible O O 0.9999595880508423
involvement O O 0.9999849796295166
is O O 0.9999921321868896
the O O 0.9999955892562866
increase O O 0.9999926090240479
in O O 0.9999817609786987
the O O 0.9999831914901733
number O O 0.9999748468399048
of O O 0.9999402761459351
specific O O 0.9756801128387451
granules O O 0.9983627200126648
with O O 0.999930739402771
a O O 0.9999517202377319
presumed O O 0.999902606010437
lysosomal O O 0.9965421557426453
function O O 0.9999361038208008
in O O 0.999846339225769
the O O 0.9999183416366577
superficial O O 0.9994400143623352
cells O O 0.9999912977218628
. O O 0.9999499320983887

Increase O O 0.9999707937240601
in O O 0.9999750852584839
intragastric O O 0.9999810457229614
pressure O O 0.9999740123748779
during O O 0.9997311234474182
suxamethonium B B 0.9997051358222961
- O O 0.999647855758667
induced O O 0.9999068975448608
muscle O O 0.9998039603233337
fasciculations O O 0.9999812841415405
in O O 0.999679446220398
children O O 0.7317447066307068
: O O 0.9996185302734375
inhibition O O 0.9955434203147888
by O O 0.9997734427452087
alfentanil B B 0.9995740056037903
. O O 0.9998089671134949

Changes O O 0.9999932050704956
in O O 0.9999921321868896
intragastric O O 0.9999947547912598
pressure O O 0.9999921321868896
after O O 0.9999634027481079
the O O 0.9999912977218628
administration O O 0.9999489784240723
of O O 0.9997836947441101
suxamethonium B B 0.9987019300460815
1 O O 0.9960625767707825
. O O 0.9999706745147705
5 O O 0.9999203681945801
mg O O 0.9997974038124084
kg O O 0.8872923254966736
- O O 0.987675666809082
1 O O 0.9992260932922363
i O O 0.9997478127479553
. O O 0.999996542930603
v O O 0.9999994039535522
. O O 0.9999920129776001
were O O 0.9999912977218628
studied O O 0.9999915361404419
in O O 0.9999834299087524
32 O O 0.9999825954437256
children O O 0.9999967813491821
( O O 0.999990701675415
mean O O 0.9999986886978149
age O O 0.999998927116394
6 O O 0.9999982118606567
. O O 0.9999986886978149
9 O O 0.9999973773956299
yr O O 0.9983653426170349
) O O 0.999990701675415
pretreated O O 0.9999762773513794
with O O 0.999923586845398
either O O 0.9998379945755005
physiological O O 0.9170804023742676
saline O O 0.9996088147163391
or O O 0.9989559650421143
alfentanil B B 0.9995253086090088
50 O O 0.9996566772460938
micrograms O O 0.9998908042907715
kg O O 0.9987803101539612
- O O 0.998023509979248
1 O O 0.9996848106384277
. O O 0.9999711513519287

Anaesthesia O O 0.9998488426208496
was O O 0.9999765157699585
induced O O 0.9999957084655762
with O O 0.9998365640640259
thiopentone B B 0.9997155070304871
5 O O 0.9989827275276184
mg O O 0.9998406171798706
kg O O 0.9834238290786743
- O O 0.995818555355072
1 O O 0.9981390237808228
. O O 0.999976634979248

The O O 0.9999805688858032
incidence O O 0.9999672174453735
and O O 0.9999698400497437
intensity O O 0.9999654293060303
of O O 0.9999580383300781
muscle O O 0.9998376369476318
fasciculations O O 0.9999642372131348
caused O O 0.9999567270278931
by O O 0.9998612403869629
suxamethonium B B 0.9991351962089539
were O O 0.9998860359191895
significantly O O 0.9999769926071167
greater O O 0.999927282333374
in O O 0.9998168349266052
the O O 0.9997009038925171
control O O 0.9651340246200562
than O O 0.9999793767929077
in O O 0.9997958540916443
the O O 0.9997500777244568
alfentanil B B 0.9994649291038513
group O O 0.9998267292976379
. O O 0.9999651908874512

The O O 0.9999812841415405
intragastric O O 0.9999748468399048
pressure O O 0.9999644756317139
during O O 0.999618649482727
muscle O O 0.9989222288131714
fasciculations O O 0.9999425411224365
was O O 0.9999376535415649
significantly O O 0.9999790191650391
higher O O 0.9999394416809082
in O O 0.9998936653137207
the O O 0.9998226761817932
control O O 0.9993777275085449
group O O 0.9999539852142334
( O O 0.9999719858169556
16 O O 0.9999804496765137
+ O O 0.9999796152114868
/ O O 0.9999881982803345
- O O 0.9999597072601318
0 O O 0.9999771118164062
. O O 0.9999866485595703
7 O O 0.9999896287918091
( O O 0.9998076558113098
SEM O O 0.9981750249862671
) O O 0.9999603033065796
cm O O 0.9999165534973145
H2O B O 0.9330336451530457
) O O 0.9999595880508423
than O O 0.9999804496765137
in O O 0.9998070597648621
the O O 0.9998258948326111
alfentanil B B 0.9984201192855835
group O O 0.9998453855514526
( O O 0.9999709129333496
7 O O 0.9999821186065674
. O O 0.9999926090240479
7 O O 0.9999936819076538
+ O O 0.99998939037323
/ O O 0.9999942779541016
- O O 0.999975323677063
1 O O 0.999984860420227
. O O 0.9999853372573853
5 O O 0.9999886751174927
( O O 0.999830961227417
SEM O O 0.9994833469390869
) O O 0.9999661445617676
cm O O 0.9999605417251587
H2O B O 0.9354560971260071
) O O 0.9999716281890869
. O O 0.999971866607666

The O O 0.9999872446060181
increase O O 0.9999961853027344
in O O 0.9999818801879883
intragastric O O 0.9999752044677734
pressure O O 0.999975323677063
was O O 0.9999407529830933
directly O O 0.999975323677063
related O O 0.9999921321868896
to O O 0.9999459981918335
the O O 0.9999796152114868
intensity O O 0.9999520778656006
of O O 0.9999196529388428
muscle O O 0.9996564388275146
fasciculations O O 0.9998965263366699
( O O 0.999849796295166
regression O O 0.9989344477653503
line O O 0.9991413354873657
: O O 0.9999336004257202
y O O 0.9638940691947937
= O O 0.9996032118797302
0 O O 0.9997730851173401
. O O 0.9999643564224243
5 O O 0.9999105930328369
+ O O 0.9994844198226929
4 O O 0.967699408531189
. O O 0.9999638795852661
78x O O 0.7308099865913391
with O O 0.999944806098938
r O O 0.9761571288108826
of O O 0.999941349029541
0 O O 0.9999537467956543
. O O 0.9999909400939941
78 O O 0.9999089241027832
) O O 0.9999666213989258
. O O 0.9999752044677734

It O O 0.9999908208847046
is O O 0.9999710321426392
concluded O O 0.9999819993972778
that O O 0.9999256134033203
intragastric O O 0.9999518394470215
pressure O O 0.9997112154960632
increases O O 0.9998385906219482
significantly O O 0.9999819993972778
during O O 0.9997511506080627
muscle O O 0.9995439648628235
fasciculations O O 0.9999792575836182
caused O O 0.9999614953994751
by O O 0.9998297691345215
suxamethonium B B 0.9989355206489563
in O O 0.999777615070343
healthy O O 0.9998911619186401
children O O 0.9999914169311523
. O O 0.9999690055847168

Alfentanil B B 0.998880922794342
50 O O 0.9992795586585999
micrograms O O 0.9996812343597412
kg O O 0.9369849562644958
- O O 0.9833675622940063
1 O O 0.9857392907142639
effectively O O 0.9996895790100098
inhibits O O 0.9999455213546753
the O O 0.9999624490737915
incidence O O 0.9999828338623047
and O O 0.9999486207962036
intensity O O 0.9999728202819824
of O O 0.9998989105224609
suxamethonium B B 0.9996845722198486
- O O 0.9998190999031067
induced O O 0.999909520149231
muscle O O 0.9999105930328369
fasciculations O O 0.9999797344207764
; O O 0.9999653100967407
moreover O O 0.9999878406524658
, O O 0.9999202489852905
intragastric O O 0.9994320273399353
pressure O O 0.999737560749054
remains O O 0.9999555349349976
at O O 0.9999606609344482
its O O 0.9999688863754272
control O O 0.9999755620956421
value O O 0.9999926090240479
. O O 0.9999712705612183

Acute O O 0.9893662333488464
insulin O B 0.9434248208999634
treatment O O 0.9996448755264282
normalizes O O 0.9998925924301147
the O O 0.9999666213989258
resistance O O 0.9999951124191284
to O O 0.9999351501464844
the O O 0.9999544620513916
cardiotoxic O O 0.9999940395355225
effect O O 0.9999301433563232
of O O 0.9997939467430115
isoproterenol B B 0.9990831613540649
in O O 0.9995566010475159
streptozotocin B B 0.9404900670051575
diabetic O O 0.932894229888916
rats O O 0.9999486207962036
. O O 0.9999467134475708

A O O 0.9998977184295654
morphometric O O 0.9999611377716064
study O O 0.9999767541885376
of O O 0.9999097585678101
isoproterenol B B 0.9976035952568054
induced O O 0.9993090629577637
myocardial O O 0.9999954700469971
fibrosis O O 0.9999823570251465
. O O 0.9999438524246216

The O O 0.9999748468399048
acute O O 0.999886155128479
effect O O 0.9999790191650391
of O O 0.9998626708984375
insulin O B 0.9574295282363892
treatment O O 0.999392032623291
on O O 0.9996623992919922
the O O 0.9999583959579468
earlier O O 0.9999585151672363
reported O O 0.9999865293502808
protective O O 0.9999372959136963
effect O O 0.9999743700027466
of O O 0.9997790455818176
streptozotocin B B 0.9949004054069519
diabetes O O 0.5708836913108826
against O O 0.9994980096817017
the O O 0.9999585151672363
cardiotoxic O O 0.9999963045120239
effect O O 0.9999725818634033
of O O 0.9999319314956665
high O O 0.9996265172958374
doses O O 0.9998451471328735
of O O 0.9957751631736755
isoproterenol B B 0.9974889755249023
( O O 0.9949348568916321
ISO B B 0.9969456791877747
) O O 0.9915100336074829
was O O 0.9999724626541138
investigated O O 0.9999724626541138
in O O 0.9999477863311768
rats O O 0.9999121427536011
. O O 0.9999731779098511

Thirty O O 0.999943733215332
to O O 0.9999988079071045
135 O O 0.9999922513961792
min O O 0.9999964237213135
after O O 0.9999915361404419
the O O 0.9999940395355225
injection O O 0.999974250793457
of O O 0.9998878240585327
crystalline O B 0.8810917735099792
insulin O I 0.6587057113647461
, O O 0.9987491369247437
ISO B B 0.9980812072753906
was O O 0.9998788833618164
given O O 0.999956488609314
subcutaneously O O 0.999954342842102
and O O 0.999988317489624
when O O 0.9999914169311523
ISO B B 0.9949342608451843
induced O O 0.9962449669837952
fibrosis O O 0.9999464750289917
in O O 0.9999196529388428
the O O 0.9999841451644897
myocardium O O 0.999997615814209
was O O 0.9999880790710449
morphometrically O O 0.9999936819076538
analyzed O O 0.9999891519546509
7 O O 0.9999747276306152
days O O 0.9999977350234985
later O O 0.9999971389770508
, O O 0.9999886751174927
a O O 0.9999905824661255
highly O O 0.9999643564224243
significant O O 0.9999880790710449
correlation O O 0.9999963045120239
( O O 0.9999675750732422
r O O 0.9992461204528809
= O O 0.9999637603759766
0 O O 0.9999891519546509
. O O 0.9999938011169434
83 O O 0.9999747276306152
, O O 0.9999704360961914
2 O O 0.9839747548103333
p O O 0.9987320303916931
= O O 0.9998621940612793
0 O O 0.999988317489624
. O O 0.9999973773956299
006 O O 0.9999673366546631
) O O 0.9999861717224121
to O O 0.9999896287918091
the O O 0.9999971389770508
slope O O 0.9999948740005493
of O O 0.9999951124191284
the O O 0.9999982118606567
fall O O 0.9999992847442627
in O O 0.999993085861206
blood O O 0.9998000264167786
glucose B O 0.818228542804718
after O O 0.999863862991333
insulin O B 0.9781660437583923
treatment O O 0.9998030066490173
appeared O O 0.9999890327453613
. O O 0.9999724626541138

The O O 0.9999619722366333
myocardial O O 0.9999904632568359
content O O 0.9997311234474182
of O O 0.9990078806877136
catecholamines B B 0.8704569339752197
was O O 0.9998592138290405
estimated O O 0.9998607635498047
in O O 0.9998925924301147
these O O 0.9999785423278809
8 O O 0.9979386925697327
day O O 0.9999693632125854
diabetic O O 0.9975812435150146
rats O O 0.9999830722808838
. O O 0.9999605417251587

The O O 0.9999550580978394
norepinephrine B B 0.9987285733222961
content O O 0.999700665473938
was O O 0.9999547004699707
significantly O O 0.9999779462814331
increased O O 0.999821126461029
while O O 0.9995397329330444
epinephrine B B 0.9964599013328552
remained O O 0.9998992681503296
unchanged O O 0.9999767541885376
. O O 0.9999604225158691

An O O 0.9998390674591064
enhanced O O 0.9996659755706787
sympathetic O O 0.9954634308815002
nervous O O 0.9998483657836914
system O O 0.9999063014984131
activity O O 0.9997221827507019
with O O 0.9998891353607178
a O O 0.999861478805542
consequent O O 0.9995550513267517
down O O 0.9993316531181335
regulation O O 0.9999736547470093
of O O 0.999811589717865
the O O 0.9997802376747131
myocardial O O 0.9999402761459351
beta O O 0.9479261636734009
- O O 0.9843127131462097
adrenergic O O 0.946699321269989
receptors O O 0.9998677968978882
could O O 0.9999182224273682
, O O 0.9999817609786987
therefore O O 0.9999829530715942
, O O 0.9999841451644897
explain O O 0.9999483823776245
this O O 0.9999003410339355
catecholamine B B 0.9898563623428345
resistance O O 0.9997424483299255
. O O 0.9999096393585205

The O O 0.9999852180480957
rapid O O 0.9999889135360718
reversion O O 0.9999954700469971
after O O 0.9998897314071655
insulin O B 0.9693515300750732
treatment O O 0.9995085000991821
excludes O O 0.9999523162841797
the O O 0.9999924898147583
possibility O O 0.9999798536300659
that O O 0.999841570854187
streptozotocin B B 0.9996116757392883
in O O 0.9999303817749023
itself O O 0.9999533891677856
causes O O 0.9999407529830933
the O O 0.9999872446060181
ISO B O 0.9961234927177429
resistance O O 0.9999797344207764
and O O 0.9999834299087524
points O O 0.9999804496765137
towards O O 0.9999363422393799
a O O 0.9999344348907471
direct O O 0.9998815059661865
insulin O B 0.8878908157348633
effect O O 0.9997983574867249
on O O 0.9998847246170044
myocardial O O 0.9999469518661499
catecholamine B B 0.9746456146240234
sensitivity O O 0.9997090697288513
in O O 0.999937891960144
diabetic O O 0.9990288019180298
rats O O 0.9999676942825317
. O O 0.9999568462371826

The O O 0.999982476234436
phenomenon O O 0.9999938011169434
described O O 0.9999890327453613
might O O 0.9999364614486694
elucidate O O 0.9998728036880493
pathogenetic O O 0.9999533891677856
mechanisms O O 0.9999794960021973
behind O O 0.9999231100082397
toxic O O 0.9998704195022583
myocardial O O 0.9999963045120239
cell O O 0.9999533891677856
degeneration O O 0.9999862909317017
and O O 0.9999713897705078
may O O 0.9999562501907349
possibly O O 0.9999818801879883
have O O 0.9999566078186035
relevance O O 0.9999927282333374
for O O 0.9999524354934692
acute O O 0.999962329864502
cardiovascular O O 0.9999874830245972
complications O O 0.9999951124191284
in O O 0.9999758005142212
diabetic O O 0.9993057250976562
patients O O 0.9999744892120361
. O O 0.9999663829803467

Differential O O 0.9960594177246094
effects O O 0.99980229139328
of O O 0.9995021820068359
non O O 0.6301926374435425
- O O 0.9684090614318848
steroidal O O 0.6361894607543945
anti O O 0.3628494441509247
- O O 0.9366666674613953
inflammatory O O 0.9762231111526489
drugs O O 0.9956344962120056
on O O 0.9992386102676392
seizures O O 0.9999644756317139
produced O O 0.99998939037323
by O O 0.9998124241828918
pilocarpine B B 0.9997147917747498
in O O 0.999815046787262
rats O O 0.999955415725708
. O O 0.9999216794967651

The O O 0.9998069405555725
muscarinic O O 0.5877244472503662
cholinergic O O 0.4861234724521637
agonist O O 0.3980403542518616
pilocarpine B B 0.9994531273841858
induces O O 0.9997369647026062
in O O 0.9965803027153015
rats O O 0.9681158661842346
seizures O O 0.9999786615371704
and O O 0.999933123588562
status O O 0.9999878406524658
epilepticus O O 0.9999879598617554
followed O O 0.9999220371246338
by O O 0.9999656677246094
widespread O O 0.999901533126831
damage O O 0.9999948740005493
to O O 0.9999767541885376
the O O 0.9999749660491943
forebrain O O 0.9999536275863647
. O O 0.9999508857727051

The O O 0.9999903440475464
present O O 0.9999899864196777
study O O 0.9999822378158569
was O O 0.9999864101409912
designed O O 0.9999964237213135
to O O 0.9999910593032837
investigate O O 0.9999297857284546
the O O 0.999925971031189
effect O O 0.9999382495880127
of O O 0.9994614720344543
5 O O 0.9276614785194397
non O O 0.6779566407203674
- O O 0.9775290489196777
steroidal O O 0.5852209329605103
anti O O 0.3990044891834259
- O O 0.942493736743927
inflammatory O O 0.9955281615257263
drugs O O 0.9968792200088501
, O O 0.999417781829834
sodium B B 0.994595468044281
salicylate I I 0.9424123167991638
, O O 0.6221184730529785
phenylbutazone B B 0.9949674010276794
, O O 0.8349108099937439
indomethacin B B 0.9774113893508911
, O O 0.7861270308494568
ibuprofen B B 0.8338330388069153
and O O 0.9799321293830872
mefenamic B B 0.9981718063354492
acid I I 0.9999265670776367
, O O 0.9995293617248535
on O O 0.9998297691345215
seizures O O 0.9999817609786987
produced O O 0.9999946355819702
by O O 0.9998561143875122
pilocarpine B B 0.9998288154602051
. O O 0.9999408721923828

Pretreatment O O 0.999426007270813
of O O 0.9999473094940186
rats O O 0.9335967898368835
with O O 0.999864935874939
sodium B B 0.9931939840316772
salicylate I I 0.9132791757583618
, O O 0.9874933362007141
ED50 O B 0.8890401721000671
103 O O 0.6983844637870789
mg O O 0.9990379810333252
/ O O 0.999975323677063
kg O O 0.9999920129776001
( O O 0.9998052716255188
60 O O 0.999537467956543
- O O 0.995963454246521
174 O O 0.7444964647293091
) O O 0.9934176206588745
, O O 0.9987083673477173
and O O 0.9977376461029053
phenylbutazone B B 0.9993159770965576
, O O 0.9992408752441406
59 O O 0.9999045133590698
mg O O 0.9999685287475586
/ O O 0.9999759197235107
kg O O 0.9999942779541016
( O O 0.9999133348464966
50 O O 0.9996325969696045
- O O 0.9970294237136841
70 O O 0.9900959730148315
) O O 0.9998792409896851
converted O O 0.9999719858169556
the O O 0.999901294708252
non O O 0.9676072597503662
- O O 0.9995256662368774
convulsant O O 0.9952446818351746
dose O O 0.999601423740387
of O O 0.9961317777633667
pilocarpine B B 0.9998378753662109
, O O 0.9992583394050598
200 O O 0.9929547905921936
mg O O 0.9998611211776733
/ O O 0.9999754428863525
kg O O 0.999987006187439
, O O 0.9999854564666748
to O O 0.9999656677246094
a O O 0.9999431371688843
convulsant O O 0.9885914921760559
one O O 0.9999774694442749
. O O 0.9998699426651001

Indomethacin B B 0.9994555115699768
, O O 0.9992629885673523
1 O O 0.9982317090034485
- O O 0.995772659778595
10 O O 0.9999692440032959
mg O O 0.9998866319656372
/ O O 0.9999713897705078
kg O O 0.9999861717224121
, O O 0.9998158812522888
and O O 0.9986555576324463
ibuprofen B B 0.9938353300094604
, O O 0.999714195728302
10 O O 0.9993003606796265
- O O 0.9979610443115234
100 O O 0.9996441602706909
mg O O 0.9998359680175781
/ O O 0.9999493360519409
kg O O 0.999971866607666
, O O 0.9999575614929199
failed O O 0.999971866607666
to O O 0.999967098236084
modulate O O 0.9999661445617676
seizures O O 0.9999891519546509
produced O O 0.9999916553497314
by O O 0.9998648166656494
pilocarpine B B 0.9997639060020447
. O O 0.9999425411224365

Mefenamic B B 0.997806966304779
acid I I 0.9998836517333984
, O O 0.9956446886062622
26 O O 0.9977898597717285
( O O 0.9955436587333679
22 O O 0.9680473208427429
- O O 0.9456474781036377
30 O O 0.9651090502738953
) O O 0.9993773102760315
mg O O 0.999889612197876
/ O O 0.9998164772987366
kg O O 0.99996018409729
, O O 0.9998230338096619
prevented O O 0.9999173879623413
seizures O O 0.9999839067459106
and O O 0.9999589920043945
protected O O 0.9999669790267944
rats O O 0.9999377727508545
from O O 0.9998090863227844
seizure O O 0.9956455826759338
- O O 0.999945878982544
related O O 0.9999805688858032
brain O O 0.9999895095825195
damage O O 0.999997615814209
induced O O 0.9999898672103882
by O O 0.9998390674591064
pilocarpine B B 0.9998335838317871
, O O 0.998392641544342
380 O O 0.9956990480422974
mg O O 0.9998262524604797
/ O O 0.9997053742408752
kg O O 0.9999860525131226
. O O 0.9998249411582947

These O O 0.999980092048645
results O O 0.9999855756759644
indicate O O 0.9999431371688843
that O O 0.999860405921936
non O O 0.8530786633491516
- O O 0.9929578304290771
steroidal O O 0.6904677152633667
anti O O 0.38342785835266113
- O O 0.9093632698059082
inflammatory O O 0.9697586297988892
drugs O O 0.9982622265815735
differentially O O 0.9980779886245728
modulate O O 0.9999669790267944
the O O 0.999976634979248
threshold O O 0.9999940395355225
for O O 0.9999656677246094
pilocarpine B B 0.999895453453064
- O O 0.9998700618743896
induced O O 0.9999223947525024
seizures O O 0.9999860525131226
. O O 0.9999715089797974

Acute O O 0.9999507665634155
neurologic O O 0.9999940395355225
dysfunction O O 0.999997615814209
after O O 0.9998462200164795
high O O 0.9953775405883789
- O O 0.9999465942382812
dose O O 0.9861353635787964
etoposide B B 0.9994792342185974
therapy O O 0.9965183734893799
for O O 0.9998891353607178
malignant O O 0.9999932050704956
glioma O O 0.9867318272590637
. O O 0.9999638795852661

Etoposide B B 0.9986072182655334
( O O 0.9503863453865051
VP B B 0.9925448298454285
- I I 0.9659964442253113
16 I I 0.9989782571792603
- I I 0.9831957221031189
213 I I 0.999970555305481
) O O 0.9637464284896851
has O O 0.9998769760131836
been O O 0.999967098236084
used O O 0.9998220801353455
in O O 0.999954342842102
the O O 0.9999514818191528
treatment O O 0.9999734163284302
of O O 0.9999806880950928
many O O 0.9999262094497681
solid O O 0.999954342842102
tumors O O 0.9999960660934448
and O O 0.9999396800994873
hematologic O O 0.9999724626541138
malignancies O O 0.9999969005584717
. O O 0.9999507665634155

When O O 0.9999332427978516
used O O 0.999953031539917
in O O 0.9999456405639648
high O O 0.9998818635940552
doses O O 0.9999622106552124
and O O 0.9999740123748779
in O O 0.9999678134918213
conjunction O O 0.9999661445617676
with O O 0.9999563694000244
autologous O O 0.9999145269393921
bone O O 0.9999551773071289
marrow O O 0.9999985694885254
transplantation O O 0.9999837875366211
, O O 0.9999547004699707
this O O 0.9862247705459595
agent O O 0.9932056665420532
has O O 0.9998049139976501
activity O O 0.9999186992645264
against O O 0.9998021721839905
several O O 0.9999033212661743
treatment O O 0.9988112449645996
- O O 0.9999591112136841
resistant O O 0.999879002571106
cancers O O 0.9999736547470093
including O O 0.9998892545700073
malignant O O 0.9999818801879883
glioma O O 0.9980042576789856
. O O 0.9999343156814575

In O O 0.9999258518218994
six O O 0.9999964237213135
of O O 0.9999744892120361
eight O O 0.9999961853027344
patients O O 0.9999935626983643
( O O 0.9999632835388184
75 O O 0.9999946355819702
% O O 0.9999960660934448
) O O 0.9999752044677734
who O O 0.9999639987945557
we O O 0.9998666048049927
treated O O 0.9999229907989502
for O O 0.9999315738677979
recurrent O O 0.9999667406082153
or O O 0.9998779296875
resistant O O 0.9999654293060303
glioma O O 0.9896219968795776
, O O 0.9999569654464722
sudden O O 0.9999676942825317
severe O O 0.9999904632568359
neurologic O O 0.9999971389770508
deterioration O O 0.9999984502792358
occurred O O 0.9999966621398926
. O O 0.9999796152114868

This O O 0.9999812841415405
developed O O 0.9999967813491821
a O O 0.9999924898147583
median O O 0.9999933242797852
of O O 0.9999924898147583
9 O O 0.9999924898147583
days O O 0.9999979734420776
after O O 0.9999887943267822
initiation O O 0.9999830722808838
of O O 0.9999494552612305
high O O 0.9994138479232788
- O O 0.9999666213989258
dose O O 0.9982011318206787
etoposide B B 0.9994708895683289
therapy O O 0.9993842840194702
. O O 0.9999715089797974

Significant O O 0.9998117089271545
clinical O O 0.9999877214431763
manifestations O O 0.9999945163726807
have O O 0.9999876022338867
included O O 0.9999774694442749
confusion O O 0.9999945163726807
, O O 0.9999372959136963
papilledema O O 0.9993757605552673
, O O 0.9998989105224609
somnolence O O 0.9999805688858032
, O O 0.9999234676361084
exacerbation O O 0.9999604225158691
of O O 0.9998787641525269
motor O O 0.9999630451202393
deficits O O 0.9999945163726807
, O O 0.9998857975006104
and O O 0.999940037727356
sharp O O 0.9999706745147705
increase O O 0.9999967813491821
in O O 0.9999765157699585
seizure O O 0.9999727010726929
activity O O 0.9999938011169434
. O O 0.9999676942825317

These O O 0.9999369382858276
abnormalities O O 0.999984860420227
resolved O O 0.999984622001648
rapidly O O 0.9999971389770508
after O O 0.9999676942825317
initiation O O 0.9999781847000122
of O O 0.9999475479125977
high O O 0.9993898868560791
- O O 0.9999773502349854
dose O O 0.9970449805259705
intravenous O O 0.9993351101875305
dexamethasone B B 0.998609185218811
therapy O O 0.9972406625747681
. O O 0.9999725818634033

In O O 0.9999116659164429
all O O 0.999897837638855
patients O O 0.9999934434890747
, O O 0.9999833106994629
computerized O O 0.9982438087463379
tomographic O O 0.9970153570175171
( O O 0.9995133876800537
CT O O 0.9651740789413452
) O O 0.9999722242355347
brain O O 0.9999657869338989
scans O O 0.9998781681060791
demonstrated O O 0.9999659061431885
stability O O 0.9999974966049194
in O O 0.999988317489624
tumor O O 0.9999808073043823
size O O 0.9999966621398926
and O O 0.9999767541885376
peritumor O O 0.9996312856674194
edema O O 0.9999808073043823
when O O 0.9999860525131226
compared O O 0.9999967813491821
with O O 0.9999921321868896
pretransplant O O 0.9996383190155029
scans O O 0.9999322891235352
. O O 0.9999781847000122

This O O 0.9999305009841919
complication O O 0.999990701675415
appears O O 0.9999449253082275
to O O 0.9999278783798218
represent O O 0.9999516010284424
a O O 0.9999754428863525
significant O O 0.9999898672103882
new O O 0.9999891519546509
toxicity O O 0.9999748468399048
of O O 0.9997921586036682
high O O 0.995318591594696
- O O 0.9999207258224487
dose O O 0.9827514290809631
etoposide B B 0.9993997812271118
therapy O O 0.996192216873169
for O O 0.999757707118988
malignant O O 0.9999890327453613
glioma O O 0.9983497858047485
. O O 0.9999498128890991

Progressive O O 0.9998739957809448
bile O O 0.9982650876045227
duct O O 0.9998288154602051
injury O O 0.9999905824661255
after O O 0.9997298121452332
thiabendazole B B 0.9989877343177795
administration O O 0.9997684359550476
. O O 0.9999542236328125

A O O 0.9999828338623047
27 O O 0.9999939203262329
- O O 0.9999821186065674
yr O O 0.997143566608429
- O O 0.9999817609786987
old O O 0.9999845027923584
man O O 0.999992847442627
developed O O 0.9999867677688599
jaundice O O 0.9998854398727417
2 O O 0.9999020099639893
wk O O 0.9966950416564941
after O O 0.9998528957366943
exposure O O 0.9999165534973145
to O O 0.9910392165184021
thiabendazole B B 0.9975863695144653
. O O 0.9998685121536255

Cholestasis O O 0.9981478452682495
persisted O O 0.9999624490737915
for O O 0.9999682903289795
3 O O 0.999894380569458
yr O O 0.9886038303375244
, O O 0.9999805688858032
at O O 0.9999748468399048
which O O 0.9999947547912598
time O O 0.9999935626983643
a O O 0.9999946355819702
liver O O 0.9995244741439819
transplant O O 0.9999772310256958
was O O 0.9999855756759644
performed O O 0.9999972581863403
. O O 0.9999765157699585

Two O O 0.9999368190765381
liver O O 0.9991641044616699
biopsy O O 0.9999426603317261
specimens O O 0.9999828338623047
and O O 0.9998874664306641
the O O 0.9999758005142212
hepatectomy O O 0.9969640374183655
specimen O O 0.9999809265136719
were O O 0.9999521970748901
remarkable O O 0.9999735355377197
for O O 0.9999544620513916
almost O O 0.9999569654464722
complete O O 0.9999037981033325
disappearance O O 0.9997957348823547
of O O 0.9999349117279053
interlobular O O 0.9981110095977783
bile O O 0.991390585899353
ducts O O 0.9999557733535767
. O O 0.9999552965164185

Prominent O O 0.9814187288284302
fibrosis O O 0.9999052286148071
and O O 0.9992600083351135
hepatocellular O O 0.9977774024009705
regeneration O O 0.9977706670761108
were O O 0.9999122619628906
also O O 0.9999338388442993
present O O 0.9999587535858154
; O O 0.9999407529830933
however O O 0.9999682903289795
, O O 0.9999825954437256
the O O 0.9999628067016602
lobular O O 0.9993963241577148
architecture O O 0.9999905824661255
was O O 0.9999434947967529
preserved O O 0.9999791383743286
. O O 0.9999618530273438

This O O 0.9999706745147705
case O O 0.9999749660491943
represents O O 0.9999386072158813
an O O 0.9999734163284302
example O O 0.9999574422836304
of O O 0.9999306201934814
" O O 0.9999226331710815
idiosyncratic O O 0.9999741315841675
" O O 0.9999570846557617
drug O O 0.9965400695800781
- O O 0.999830961227417
induced O O 0.9999508857727051
liver O O 0.998863935470581
damage O O 0.9999880790710449
in O O 0.9999618530273438
which O O 0.9998917579650879
the O O 0.9999666213989258
primary O O 0.9998842477798462
target O O 0.9999330043792725
of O O 0.9999328851699829
injury O O 0.999972939491272
is O O 0.9998365640640259
the O O 0.9999308586120605
bile O O 0.9852948188781738
duct O O 0.9999762773513794
. O O 0.9999603033065796

An O O 0.9999082088470459
autoimmune O O 0.9902604222297668
pathogenesis O O 0.9999350309371948
of O O 0.9998960494995117
the O O 0.999966025352478
bile O O 0.9834038615226746
duct O O 0.9998496770858765
destruction O O 0.9998158812522888
is O O 0.9999353885650635
suggested O O 0.9998743534088135
. O O 0.9999483823776245

Differential O O 0.9988440275192261
effects O O 0.9999148845672607
of O O 0.9996578693389893
1 B B 0.9442465305328369
, I I 0.939793050289154
4 I I 0.9796608686447144
- I I 0.9894395470619202
dihydropyridine I I 0.9985276460647583
calcium B O 0.5402041077613831
channel I O 0.9192797541618347
blockers I O 0.8793635964393616
: O O 0.9999217987060547
therapeutic O O 0.9998654127120972
implications O O 0.9999953508377075
. O O 0.9999816417694092

Increasing O O 0.9999767541885376
recognition O O 0.9999939203262329
of O O 0.9999698400497437
the O O 0.9999822378158569
importance O O 0.9999161958694458
of O O 0.9997861981391907
calcium B B 0.994134247303009
in O O 0.9996404647827148
the O O 0.9999788999557495
pathogenesis O O 0.9999923706054688
of O O 0.9999668598175049
cardiovascular O O 0.9999650716781616
disease O O 0.9999903440475464
has O O 0.9999583959579468
stimulated O O 0.9999860525131226
research O O 0.9999942779541016
into O O 0.9999713897705078
the O O 0.9999595880508423
use O O 0.999947190284729
of O O 0.9996507167816162
calcium B B 0.9455217123031616
channel I O 0.9650235176086426
blocking I O 0.9441471695899963
agents I O 0.9782513380050659
for O O 0.9998760223388672
treatment O O 0.9999401569366455
of O O 0.999954342842102
a O O 0.9999635219573975
variety O O 0.9999879598617554
of O O 0.9999570846557617
cardiovascular O O 0.9999386072158813
diseases O O 0.9999855756759644
. O O 0.9999666213989258

The O O 0.9999386072158813
favorable O O 0.9999724626541138
efficacy O O 0.9999755620956421
and O O 0.9999537467956543
tolerability O O 0.9999920129776001
profiles O O 0.9999924898147583
of O O 0.9998250603675842
these O O 0.978855550289154
agents O O 0.9852370619773865
make O O 0.9998981952667236
them O O 0.9999194145202637
attractive O O 0.9999029636383057
therapeutic O O 0.9999587535858154
modalities O O 0.9999731779098511
. O O 0.9999632835388184

Clinical O O 0.999901533126831
applications O O 0.9999836683273315
of O O 0.9997722506523132
calcium B B 0.9648956656455994
channel I O 0.844708263874054
blockers I O 0.7420766949653625
parallel O O 0.9998526573181152
their O O 0.9995694756507874
tissue O O 0.9984839558601379
selectivity O O 0.9997630715370178
. O O 0.9999744892120361

In O O 0.9999363422393799
contrast O O 0.9999459981918335
to O O 0.9992218017578125
verapamil B B 0.9998538494110107
and O O 0.9752492308616638
diltiazem B B 0.9995995163917542
, O O 0.9999111890792847
which O O 0.9999411106109619
are O O 0.9999134540557861
roughly O O 0.999963641166687
equipotent O O 0.9998970031738281
in O O 0.9999889135360718
their O O 0.9999508857727051
actions O O 0.9999210834503174
on O O 0.9996633529663086
the O O 0.9999120235443115
heart O O 0.999968409538269
and O O 0.9998408555984497
vascular O O 0.9995577931404114
smooth O O 0.9995121955871582
muscle O O 0.9999622106552124
, O O 0.9998743534088135
the O O 0.9981406927108765
dihydropyridine B B 0.9796051979064941
calcium B O 0.36157894134521484
channel I O 0.9721447825431824
blockers I O 0.954254150390625
are O O 0.9999394416809082
a O O 0.9999483823776245
group O O 0.9962211847305298
of O O 0.9994220733642578
potent O O 0.9498545527458191
peripheral O O 0.8745416402816772
vasodilator O O 0.5013834834098816
agents O O 0.8838542699813843
that O O 0.9996674060821533
exert O O 0.9999502897262573
minimal O O 0.9999747276306152
electrophysiologic O O 0.9999649524688721
effects O O 0.9999579191207886
on O O 0.9998816251754761
cardiac O O 0.9997401833534241
nodal O O 0.9999746084213257
or O O 0.9999058246612549
conduction O O 0.9999852180480957
tissue O O 0.9999836683273315
. O O 0.9999593496322632

As O O 0.9998900890350342
the O O 0.9997114539146423
first O O 0.9989458918571472
dihydropyridine B B 0.9909427762031555
available O O 0.9995926022529602
for O O 0.9999704360961914
use O O 0.9998962879180908
in O O 0.999895453453064
the O O 0.9998857975006104
United O O 0.9950199127197266
States O O 0.9999456405639648
, O O 0.9991244673728943
nifedipine B B 0.99982088804245
controls O O 0.9996986389160156
angina O O 0.9947368502616882
and O O 0.9998915195465088
hypertension O O 0.8056137561798096
with O O 0.9999308586120605
minimal O O 0.9999752044677734
depression O O 0.9999946355819702
of O O 0.9999595880508423
cardiac O O 0.9999743700027466
function O O 0.9999927282333374
. O O 0.9999169111251831

Additional O O 0.9980467557907104
members O O 0.9998076558113098
of O O 0.9997046589851379
this O O 0.9997438788414001
group O O 0.9789172410964966
of O O 0.9882068037986755
calcium B B 0.9640284180641174
channel I O 0.8090842962265015
blockers I O 0.6931178569793701
have O O 0.9998443126678467
been O O 0.9999651908874512
studied O O 0.9997988343238831
for O O 0.9998687505722046
a O O 0.999968409538269
variety O O 0.9999873638153076
of O O 0.999946117401123
indications O O 0.9998916387557983
for O O 0.999961256980896
which O O 0.9999821186065674
they O O 0.9995457530021667
may O O 0.9999616146087646
offer O O 0.9999712705612183
advantages O O 0.9999545812606812
over O O 0.9999874830245972
current O O 0.9994131326675415
therapy O O 0.999962329864502
. O O 0.999948263168335

Once O O 0.9999096393585205
or O O 0.9999704360961914
twice O O 0.9999574422836304
daily O O 0.9999661445617676
dosage O O 0.9999428987503052
possible O O 0.999972939491272
with O O 0.9997714161872864
nitrendipine B B 0.9980935454368591
and O O 0.9667483568191528
nisoldipine B B 0.9968716502189636
offers O O 0.9999103546142578
a O O 0.999985933303833
convenient O O 0.9999794960021973
administration O O 0.9999573230743408
schedule O O 0.9999815225601196
, O O 0.9999874830245972
which O O 0.9999881982803345
encourages O O 0.9998602867126465
patient O O 0.9999473094940186
compliance O O 0.9999834299087524
in O O 0.9999791383743286
long O O 0.9999220371246338
- O O 0.9999892711639404
term O O 0.9999845027923584
therapy O O 0.999987006187439
of O O 0.9999425411224365
hypertension O O 0.9244325757026672
. O O 0.9999600648880005

The O O 0.9999181032180786
coronary O O 0.9762272834777832
vasodilating O O 0.9800063967704773
properties O O 0.999913215637207
of O O 0.9991037249565125
nisoldipine B B 0.9984979629516602
have O O 0.9991157650947571
led O O 0.9999943971633911
to O O 0.9999841451644897
the O O 0.9999949932098389
investigation O O 0.9999897480010986
of O O 0.9998636245727539
this O O 0.99700528383255
agent O O 0.9796985387802124
for O O 0.9999078512191772
use O O 0.9999420642852783
in O O 0.9999198913574219
angina O O 0.9997995495796204
. O O 0.9999510049819946

Selectivity O O 0.9983267188072205
for O O 0.999309778213501
the O O 0.9999014139175415
cerebrovascular O O 0.998859167098999
bed O O 0.9999942779541016
makes O O 0.9999247789382935
nimodipine B B 0.9996532201766968
potentially O O 0.9999200105667114
useful O O 0.9999560117721558
in O O 0.9999659061431885
the O O 0.9999643564224243
treatment O O 0.9999717473983765
of O O 0.9999581575393677
subarachnoid O O 0.9999805688858032
hemorrhage O O 0.9999942779541016
, O O 0.9999488592147827
migraine O O 0.9999840259552002
headache O O 0.9999802112579346
, O O 0.9999550580978394
dementia O O 0.9999971389770508
, O O 0.9998493194580078
and O O 0.9998286962509155
stroke O O 0.999992847442627
. O O 0.9999027252197266

In O O 0.9999312162399292
general O O 0.9999836683273315
, O O 0.9999481439590454
the O O 0.9990426898002625
dihydropyridine B B 0.9837902188301086
calcium B O 0.47515419125556946
channel I O 0.922278881072998
blockers I O 0.9095725417137146
are O O 0.9999308586120605
usually O O 0.9999781847000122
well O O 0.9999462366104126
tolerated O O 0.9999855756759644
, O O 0.9999876022338867
with O O 0.9999737739562988
headache O O 0.9999909400939941
, O O 0.9999163150787354
facial O O 0.9997873902320862
flushing O O 0.9999674558639526
, O O 0.9999386072158813
palpitations O O 0.9999926090240479
, O O 0.9999262094497681
edema O O 0.9999921321868896
, O O 0.9999481439590454
nausea O O 0.9999854564666748
, O O 0.9999644756317139
anorexia O O 0.9983106851577759
, O O 0.999832272529602
and O O 0.9997593760490417
dizziness O O 0.9999105930328369
being O O 0.9999698400497437
the O O 0.9999912977218628
more O O 0.9999884366989136
common O O 0.9999829530715942
adverse O O 0.9999779462814331
effects O O 0.9999911785125732
. O O 0.9999715089797974

The O O 0.999901294708252
enhancement O O 0.9998065829277039
of O O 0.9998055100440979
aminonucleoside B O 0.4595801532268524
nephrosis O O 0.9952491521835327
by O O 0.9998341798782349
the O O 0.9999704360961914
co O O 0.990435779094696
- O O 0.9998635053634644
administration O O 0.9999110698699951
of O O 0.9997363686561584
protamine O O 0.8418133854866028
. O O 0.999755322933197

An O O 0.9999780654907227
experimental O O 0.9998806715011597
model O O 0.9999933242797852
of O O 0.9999488592147827
focal O O 0.9996011853218079
segmental O O 0.9998716115951538
glomerular O O 0.9804564714431763
sclerosis O O 0.9994727969169617
( O O 0.9999555349349976
FSGS O O 0.999546229839325
) O O 0.999969482421875
was O O 0.9999818801879883
developed O O 0.999995231628418
in O O 0.9999805688858032
rats O O 0.9999489784240723
by O O 0.9999775886535645
the O O 0.9999812841415405
combined O O 0.9993910789489746
administration O O 0.999927282333374
of O O 0.9997727274894714
puromycin B B 0.9993019104003906
- I I 0.6301261186599731
aminonucleoside I I 0.994491457939148
( O O 0.9925000071525574
AMNS B B 0.9521368145942688
) O O 0.9981327652931213
and O O 0.9993013143539429
protamine B B 0.9369089007377625
sulfate I I 0.9147685766220093
( O O 0.9954965114593506
PS B B 0.9636193513870239
) O O 0.9997251629829407
. O O 0.9999678134918213

Male O O 0.9999829530715942
Sprague O O 0.9993448853492737
- O O 0.9996122717857361
Dawley O O 0.9993539452552795
rats O O 0.9999719858169556
, O O 0.9999806880950928
uninephrectomized O O 0.9791222214698792
three O O 0.9999814033508301
weeks O O 0.9999973773956299
before O O 0.9999978542327881
, O O 0.9999889135360718
received O O 0.999970555305481
daily O O 0.9997788071632385
injections O O 0.9999439716339111
of O O 0.9998983144760132
subcutaneous O O 0.999525785446167
AMNS B B 0.9761762022972107
( O O 0.9982503056526184
1 O O 0.9997866749763489
mg O O 0.9995965361595154
/ O O 0.9999324083328247
100 O O 0.9991631507873535
g O O 0.999985933303833
body O O 0.9998499155044556
wt O O 0.9774767756462097
) O O 0.9999127388000488
and O O 0.9992656111717224
intravenous O O 0.9999376535415649
PS B B 0.9937412142753601
( O O 0.9993667006492615
2 O O 0.9989113807678223
separated O O 0.9999337196350098
doses O O 0.9999796152114868
of O O 0.9998613595962524
2 O O 0.9934831261634827
. O O 0.9999953508377075
5 O O 0.9999295473098755
mg O O 0.9998328685760498
/ O O 0.9999262094497681
100 O O 0.9995143413543701
g O O 0.9999881982803345
body O O 0.9995542168617249
wt O O 0.9900462031364441
) O O 0.99996018409729
for O O 0.999976634979248
four O O 0.9999946355819702
days O O 0.9999969005584717
. O O 0.9999837875366211

The O O 0.9999760389328003
series O O 0.9999560117721558
of O O 0.999932050704956
injections O O 0.999822199344635
were O O 0.9999836683273315
repeated O O 0.9999855756759644
another O O 0.9999876022338867
three O O 0.9999817609786987
times O O 0.999987006187439
at O O 0.9999768733978271
10 O O 0.9999517202377319
day O O 0.9999948740005493
intervals O O 0.9999947547912598
. O O 0.9999738931655884

The O O 0.9999862909317017
animals O O 0.9999951124191284
were O O 0.9999914169311523
sacrificed O O 0.9999909400939941
on O O 0.9999690055847168
days O O 0.9999916553497314
24 O O 0.9999927282333374
, O O 0.9998792409896851
52 O O 0.999896764755249
, O O 0.9998387098312378
and O O 0.9998481273651123
80 O O 0.9933695793151855
. O O 0.9999796152114868

They O O 0.9999629259109497
developed O O 0.9999676942825317
nephrotic O O 0.9998171925544739
syndrome O O 0.9999436140060425
and O O 0.9999244213104248
finally O O 0.9998281002044678
renal O O 0.9999591112136841
failure O O 0.9999768733978271
. O O 0.9999597072601318

The O O 0.9999821186065674
time O O 0.9998358488082886
- O O 0.9999831914901733
course O O 0.9999916553497314
curve O O 0.9999245405197144
of O O 0.9997530579566956
creatinine B B 0.9969720840454102
clearance O O 0.9988977909088135
dropped O O 0.999974250793457
and O O 0.99998939037323
showed O O 0.9999666213989258
significant O O 0.9999855756759644
difference O O 0.9999954700469971
( O O 0.9999810457229614
P O O 0.9993706345558167
less O O 0.9999773502349854
than O O 0.9999946355819702
0 O O 0.9999923706054688
. O O 0.9999970197677612
01 O O 0.999997615814209
) O O 0.999984622001648
from O O 0.999930739402771
that O O 0.9999805688858032
of O O 0.9999512434005737
each O O 0.9997403025627136
control O O 0.9997857213020325
group O O 0.9998358488082886
, O O 0.9999737739562988
such O O 0.999849796295166
as O O 0.9998712539672852
, O O 0.9956048727035522
AMNS B O 0.7784573435783386
alone O O 0.9973913431167603
, O O 0.9991046786308289
PS B O 0.8159492611885071
alone O O 0.5690978765487671
or O O 0.9986543655395508
saline O O 0.9986635446548462
injected O O 0.9997920393943787
. O O 0.9999706745147705

Their O O 0.9998064637184143
glomeruli O O 0.9995641112327576
showed O O 0.9999264478683472
changes O O 0.9999903440475464
of O O 0.9999779462814331
progressive O O 0.9998906850814819
FSGS O O 0.9877891540527344
. O O 0.9999309778213501

The O O 0.9999854564666748
ultrastructural O O 0.9994356036186218
studies O O 0.9999922513961792
in O O 0.9999674558639526
the O O 0.9999854564666748
initial O O 0.9999868869781494
stage O O 0.9999943971633911
revealed O O 0.9999517202377319
significant O O 0.9999756813049316
lack O O 0.9999611377716064
of O O 0.9999405145645142
particles O O 0.9947742819786072
of O O 0.9992996454238892
perfused O O 0.9814754724502563
ruthenium B O 0.7005677819252014
red O O 0.6572700142860413
on O O 0.998957633972168
the O O 0.999936580657959
lamina O O 0.9952316880226135
rara O O 0.9985902905464172
externa O O 0.9997549653053284
and O O 0.9999336004257202
marked O O 0.9999825954437256
changes O O 0.9999967813491821
in O O 0.9999792575836182
epithelial O O 0.9999151229858398
cell O O 0.9999814033508301
cytoplasm O O 0.9999182224273682
. O O 0.9999746084213257

Therefore O O 0.9999762773513794
, O O 0.9999778270721436
it O O 0.9999924898147583
is O O 0.999984860420227
suggested O O 0.9999890327453613
that O O 0.9998045563697815
the O O 0.9999697208404541
administration O O 0.9998124241828918
of O O 0.9992203712463379
PS B B 0.9499915838241577
enhances O O 0.9989349246025085
the O O 0.9999693632125854
toxicity O O 0.9999436140060425
of O O 0.9993917942047119
AMNS B B 0.9020677804946899
on O O 0.998224675655365
the O O 0.9998162388801575
glomerulus O O 0.9979167580604553
and O O 0.9999421834945679
readily O O 0.9999129772186279
produces O O 0.9999575614929199
progressive O O 0.9999393224716187
FSGS O O 0.9648839831352234
in O O 0.9998183846473694
rats O O 0.999848484992981
resulting O O 0.9999877214431763
in O O 0.9999872446060181
the O O 0.9999910593032837
end O O 0.9999830722808838
- O O 0.999987006187439
stage O O 0.9999927282333374
renal O O 0.9999843835830688
disease O O 0.9999959468841553
. O O 0.9999731779098511

Theophylline B B 0.9992560744285583
neurotoxicity O O 0.9996761083602905
in O O 0.9998549222946167
pregnant O O 0.9998420476913452
rats O O 0.9999886751174927
. O O 0.9997811913490295

The O O 0.9999898672103882
purpose O O 0.9999969005584717
of O O 0.9999951124191284
this O O 0.999992847442627
investigation O O 0.9999953508377075
was O O 0.9999949932098389
to O O 0.9999961853027344
determine O O 0.999996542930603
whether O O 0.9999876022338867
the O O 0.9999762773513794
neurotoxicity O O 0.9999926090240479
of O O 0.9981756210327148
theophylline B B 0.999647855758667
is O O 0.9999421834945679
altered O O 0.9999710321426392
in O O 0.9999120235443115
advanced O O 0.9998176693916321
pregnancy O O 0.999993085861206
. O O 0.9999668598175049

Sprague O O 0.9996045231819153
- O O 0.9997952580451965
Dawley O O 0.9998226761817932
rats O O 0.9999932050704956
that O O 0.9999884366989136
were O O 0.999987006187439
20 O O 0.9999775886535645
days O O 0.9999942779541016
pregnant O O 0.9999935626983643
and O O 0.9998936653137207
nonpregnant O O 0.9934077262878418
rats O O 0.9999972581863403
of O O 0.9999947547912598
the O O 0.9999969005584717
same O O 0.9999964237213135
age O O 0.9999954700469971
and O O 0.9999555349349976
strain O O 0.9998515844345093
received O O 0.9998739957809448
infusions O O 0.9998394250869751
of O O 0.9989718198776245
aminophylline B B 0.999723494052887
until O O 0.9998507499694824
onset O O 0.9999966621398926
of O O 0.9999828338623047
maximal O O 0.9999797344207764
seizures O O 0.9999927282333374
which O O 0.9999880790710449
occurred O O 0.9999961853027344
after O O 0.9999908208847046
28 O O 0.9999946355819702
and O O 0.999976634979248
30 O O 0.9999873638153076
minutes O O 0.9999959468841553
respectively O O 0.9999752044677734
. O O 0.9999731779098511

Theophylline B B 0.9989053010940552
concentrations O O 0.9997596144676208
at O O 0.9998902082443237
this O O 0.9999279975891113
endpoint O O 0.9998972415924072
in O O 0.9995222091674805
serum O O 0.9996788501739502
( O O 0.9990854263305664
total O O 0.9541433453559875
) O O 0.9998227953910828
and O O 0.999334990978241
CSF O O 0.5804503560066223
were O O 0.999931812286377
similar O O 0.9999794960021973
but O O 0.9999651908874512
serum O O 0.9435309171676636
( O O 0.9962403774261475
free O O 0.9872857928276062
) O O 0.9991266131401062
and O O 0.9998250603675842
brain O O 0.9998892545700073
concentrations O O 0.9998794794082642
were O O 0.9999692440032959
slightly O O 0.9999891519546509
different O O 0.9999879598617554
in O O 0.9999407529830933
pregnant O O 0.9999502897262573
rats O O 0.999995231628418
. O O 0.9999717473983765

Theophylline B B 0.9979454874992371
serum O O 0.899598240852356
protein O O 0.9407638907432556
binding O O 0.9998258948326111
determined O O 0.9999682903289795
by O O 0.9999821186065674
equilibrium O O 0.9964566826820374
dialysis O O 0.999846339225769
was O O 0.9999570846557617
lower O O 0.9999282360076904
in O O 0.9999332427978516
pregnant O O 0.9999744892120361
rats O O 0.999996542930603
. O O 0.9999608993530273

Fetal O O 0.6493610143661499
serum O O 0.6343035697937012
concentrations O O 0.9963638186454773
at O O 0.9999641180038452
onset O O 0.9999946355819702
of O O 0.9999700784683228
seizures O O 0.9998936653137207
in O O 0.9999321699142456
the O O 0.9999825954437256
mother O O 0.9999837875366211
were O O 0.9999525547027588
similar O O 0.9999799728393555
to O O 0.9998600482940674
maternal O O 0.9998369216918945
brain O O 0.9991391897201538
and O O 0.9991078972816467
CSF O O 0.7869090437889099
concentrations O O 0.9979720711708069
and O O 0.9999539852142334
correlated O O 0.999972939491272
significantly O O 0.9999887943267822
with O O 0.9999769926071167
the O O 0.999962568283081
former O O 0.9999573230743408
. O O 0.9999740123748779

It O O 0.9999911785125732
is O O 0.9999547004699707
concluded O O 0.9999741315841675
that O O 0.9998421669006348
advanced O O 0.9996886253356934
pregnancy O O 0.9994839429855347
has O O 0.9999157190322876
a O O 0.9999566078186035
negligible O O 0.9999455213546753
effect O O 0.9999666213989258
on O O 0.9999408721923828
the O O 0.999954104423523
neurotoxic O O 0.9999936819076538
response O O 0.9999858140945435
to O O 0.9995822310447693
theophylline B B 0.9998359680175781
in O O 0.999788224697113
rats O O 0.9996135830879211
. O O 0.9999607801437378

Hyperkalemia O O 0.998880922794342
induced O O 0.9999319314956665
by O O 0.9997969269752502
indomethacin B B 0.9990267753601074
and O O 0.9035531282424927
naproxen B B 0.9416856169700623
and O O 0.9995599389076233
reversed O O 0.9999641180038452
by O O 0.9996981620788574
fludrocortisone B B 0.9991219639778137
. O O 0.9998834133148193

We O O 0.9999370574951172
have O O 0.9999902248382568
described O O 0.9999922513961792
a O O 0.9999845027923584
patient O O 0.9999932050704956
with O O 0.9999618530273438
severe O O 0.9999741315841675
rheumatoid O O 0.9999603033065796
arthritis O O 0.9999557733535767
and O O 0.9999465942382812
a O O 0.9999783039093018
history O O 0.9999722242355347
of O O 0.9998965263366699
mefenamic B B 0.9844220876693726
acid I I 0.9963938593864441
nephropathy O O 0.9657971858978271
in O O 0.9999651908874512
whom O O 0.9998825788497925
hyperkalemia O O 0.9536306262016296
and O O 0.9999110698699951
inappropriate O O 0.9990212917327881
hypoaldosteronism O O 0.9096530079841614
were O O 0.9999361038208008
caused O O 0.9999792575836182
by O O 0.9997091889381409
both O O 0.9876317381858826
indomethacin B B 0.9975702166557312
and O O 0.7548108696937561
naproxen B B 0.9223612546920776
, O O 0.9997957348823547
without O O 0.9999785423278809
major O O 0.9999955892562866
decline O O 0.9999985694885254
in O O 0.9999881982803345
renal O O 0.9999819993972778
function O O 0.9999920129776001
. O O 0.9999797344207764

It O O 0.9999852180480957
is O O 0.9999343156814575
likely O O 0.9998735189437866
that O O 0.9997425675392151
preexisting O O 0.9984499216079712
renal O O 0.9995686411857605
disease O O 0.9999862909317017
predisposed O O 0.99989914894104
this O O 0.9999839067459106
patient O O 0.999982476234436
to O O 0.9997720122337341
type O O 0.9984132051467896
IV O O 0.991087019443512
renal O O 0.9988114833831787
tubular O O 0.9999754428863525
acidosis O O 0.6556218266487122
with O O 0.999387264251709
prostaglandin B O 0.5822561383247375
synthetase O O 0.6497954726219177
inhibitors O O 0.6018155217170715
. O O 0.9998680353164673

Because O O 0.9999862909317017
he O O 0.9999836683273315
was O O 0.9999878406524658
unable O O 0.9999977350234985
to O O 0.9999921321868896
discontinue O O 0.9999129772186279
nonsteroidal O O 0.593941330909729
anti O O 0.49136415123939514
- O O 0.8835217356681824
inflammatory O O 0.9816603660583496
drug O O 0.9922798871994019
therapy O O 0.9995637536048889
, O O 0.9996356964111328
fludrocortisone B B 0.9986981153488159
was O O 0.9997158646583557
added O O 0.9998873472213745
, O O 0.9999767541885376
correcting O O 0.9999403953552246
the O O 0.9999916553497314
hyperkalemia O O 0.9986811280250549
and O O 0.9999710321426392
allowing O O 0.9993552565574646
indomethacin B B 0.9990484118461609
therapy O O 0.9970285296440125
to O O 0.9999892711639404
be O O 0.9999959468841553
continued O O 0.9999518394470215
safely O O 0.9999947547912598
. O O 0.9999819993972778

Hypotension O O 0.9997989535331726
as O O 0.9999605417251587
a O O 0.9999867677688599
manifestation O O 0.999991774559021
of O O 0.9999505281448364
cardiotoxicity O O 0.9999779462814331
in O O 0.9999624490737915
three O O 0.999975323677063
patients O O 0.9999904632568359
receiving O O 0.9995473027229309
cisplatin B B 0.99944669008255
and O O 0.9490298628807068
5 B B 0.9537105560302734
- I I 0.9943519830703735
fluorouracil I I 0.9999911785125732
. O O 0.9995232820510864

Cardiac O O 0.9999289512634277
symptoms O O 0.9999949932098389
, O O 0.9999924898147583
including O O 0.9999867677688599
hypotension O O 0.9999866485595703
, O O 0.9999910593032837
developed O O 0.9999970197677612
in O O 0.9999761581420898
three O O 0.9999839067459106
patients O O 0.9999947547912598
with O O 0.9999887943267822
advanced O O 0.9999927282333374
colorectal O O 0.9997496008872986
carcinoma O O 0.9998482465744019
while O O 0.9999085664749146
being O O 0.9999761581420898
treated O O 0.9999569654464722
with O O 0.9993404746055603
cisplatin B B 0.9994887113571167
( O O 0.9780132174491882
CDDP B B 0.9942412376403809
) O O 0.9644467234611511
and O O 0.9926751255989075
5 B B 0.9137371778488159
- I I 0.9948831796646118
fluorouracil I I 0.9999932050704956
( O O 0.9845547080039978
5 B B 0.9698128700256348
- I I 0.9917588829994202
FU I I 0.9999884366989136
) O O 0.9955947995185852
. O O 0.9999732971191406

In O O 0.9999438524246216
two O O 0.9999901056289673
patients O O 0.9999946355819702
, O O 0.999929666519165
hypotension O O 0.9999383687973022
was O O 0.9999257326126099
associated O O 0.9999830722808838
with O O 0.9999740123748779
severe O O 0.9999655485153198
left O O 0.999982476234436
ventricular O O 0.999994158744812
dysfunction O O 0.9999942779541016
. O O 0.9999815225601196

All O O 0.9999639987945557
three O O 0.9999889135360718
patients O O 0.9999902248382568
required O O 0.999961256980896
therapy O O 0.9997174143791199
discontinuation O O 0.999927282333374
. O O 0.9999583959579468

Cardiac O O 0.9898216724395752
enzymes O O 0.9164304733276367
remained O O 0.9999572038650513
normal O O 0.9999717473983765
despite O O 0.9999444484710693
transient O O 0.9999864101409912
electrocardiographic O O 0.9999809265136719
( O O 0.9998989105224609
EKG O O 0.996946394443512
) O O 0.9999086856842041
changes O O 0.9999974966049194
. O O 0.9999672174453735

The O O 0.9999877214431763
presentation O O 0.9999895095825195
and O O 0.9999896287918091
cardiac O O 0.9999926090240479
evaluation O O 0.9999977350234985
( O O 0.9999599456787109
hemodynamic O O 0.9999668598175049
, O O 0.9999731779098511
echocardiographic O O 0.9996147155761719
, O O 0.99983811378479
and O O 0.9998395442962646
scintigraphic O O 0.989216685295105
) O O 0.9999896287918091
of O O 0.9999879598617554
these O O 0.9999767541885376
patients O O 0.9999922513961792
suggest O O 0.9999682903289795
new O O 0.9999829530715942
manifestations O O 0.9999877214431763
of O O 0.999913215637207
5 B B 0.494596928358078
- I I 0.5621364712715149
FU I I 0.9931619167327881
cardiotoxicity O O 0.9998437166213989
that O O 0.9999430179595947
may O O 0.9999359846115112
be O O 0.9999819993972778
influenced O O 0.9999717473983765
by O O 0.9996732473373413
CDDP B B 0.8670257925987244
. O O 0.9997919201850891

The O O 0.9999645948410034
possible O O 0.9998311996459961
pathophysiologic O O 0.9999469518661499
mechanisms O O 0.9999618530273438
are O O 0.9999545812606812
discussed O O 0.999971866607666
. O O 0.9999743700027466

Fatal O O 0.9996641874313354
aplastic O O 0.9933264255523682
anemia O O 0.9997953772544861
in O O 0.9999707937240601
a O O 0.9999514818191528
patient O O 0.9999774694442749
treated O O 0.9998421669006348
with O O 0.9980456829071045
carbamazepine B B 0.9993699193000793
. O O 0.9998431205749512

A O O 0.9999669790267944
case O O 0.9999953508377075
of O O 0.9999746084213257
fatal O O 0.9999492168426514
aplastic O O 0.9962653517723083
anemia O O 0.9999098777770996
due O O 0.9999659061431885
to O O 0.9975246787071228
carbamazepine B B 0.9987462759017944
treatment O O 0.9986721277236938
in O O 0.9998764991760254
an O O 0.9999282360076904
epileptic O O 0.9995787739753723
woman O O 0.9999872446060181
is O O 0.9999659061431885
reported O O 0.9999938011169434
. O O 0.9999775886535645

Despite O O 0.999968409538269
concerns O O 0.9999974966049194
of O O 0.9999853372573853
fatal O O 0.9999663829803467
bone O O 0.9999316930770874
marrow O O 0.9999973773956299
toxicity O O 0.9999815225601196
due O O 0.9999654293060303
to O O 0.9979994893074036
carbamazepine B B 0.9988372921943665
, O O 0.9997784495353699
this O O 0.9999920129776001
is O O 0.9999910593032837
only O O 0.9999932050704956
the O O 0.999993085861206
fourth O O 0.9999895095825195
documented O O 0.999990701675415
and O O 0.9999768733978271
published O O 0.9999779462814331
report O O 0.9999927282333374
. O O 0.9999696016311646

Carbamazepine B B 0.9988777041435242
is O O 0.9998295307159424
a O O 0.9998899698257446
safe O O 0.9999364614486694
drug O O 0.9996157884597778
, O O 0.9999319314956665
but O O 0.9999746084213257
physicians O O 0.999994158744812
and O O 0.9999713897705078
patients O O 0.9999896287918091
should O O 0.9999785423278809
be O O 0.9999960660934448
aware O O 0.9999916553497314
of O O 0.9999780654907227
the O O 0.9999819993972778
exceedingly O O 0.9999794960021973
rare O O 0.9999926090240479
but O O 0.9999773502349854
potentially O O 0.9999836683273315
fatal O O 0.9999810457229614
side O O 0.999972939491272
effects O O 0.999991774559021
, O O 0.9999901056289673
better O O 0.9999701976776123
prevented O O 0.9999940395355225
by O O 0.9999881982803345
clinical O O 0.9999861717224121
than O O 0.9999955892562866
by O O 0.9999858140945435
laboratory O O 0.9999942779541016
monitoring O O 0.9999970197677612
. O O 0.9999737739562988

Participation O O 0.9997820258140564
of O O 0.999825656414032
a O O 0.9985176920890808
bulbospinal O O 0.9905757904052734
serotonergic O O 0.7242147326469421
pathway O O 0.9983008503913879
in O O 0.9997871518135071
the O O 0.9999704360961914
rat O O 0.9999188184738159
brain O O 0.9999847412109375
in O O 0.9998226761817932
clonidine B B 0.9998319149017334
- O O 0.9998213648796082
induced O O 0.9999170303344727
hypotension O O 0.9999321699142456
and O O 0.9999574422836304
bradycardia O O 0.9999735355377197
. O O 0.9999496936798096

The O O 0.9999740123748779
effects O O 0.9999854564666748
of O O 0.999931812286377
microinjection O O 0.9968451261520386
of O O 0.9987357258796692
clonidine B B 0.9998025298118591
( O O 0.9996559619903564
1 O O 0.999570906162262
- O O 0.9981070756912231
10 O O 0.9999791383743286
micrograms O O 0.9997336268424988
in O O 0.9999648332595825
1 O O 0.9999481439590454
microliter O O 0.99970942735672
) O O 0.9999641180038452
into O O 0.9999421834945679
a O O 0.9999724626541138
region O O 0.9999716281890869
adjacent O O 0.9999860525131226
to O O 0.999983549118042
the O O 0.9999788999557495
ventrolateral O O 0.9999586343765259
surface O O 0.9999899864196777
of O O 0.999943733215332
the O O 0.9999710321426392
medulla O O 0.9997530579566956
oblongata O O 0.9996408224105835
on O O 0.9998254179954529
cardiovascular O O 0.9999839067459106
function O O 0.9999964237213135
were O O 0.9999889135360718
assessed O O 0.9999897480010986
in O O 0.9999762773513794
urethane B B 0.9960476756095886
- O O 0.9987292885780334
anesthetized O O 0.9999151229858398
rats O O 0.9999895095825195
. O O 0.9999754428863525

Intramedullary O O 0.9999673366546631
administration O O 0.999962568283081
of O O 0.9994522929191589
clonidine B B 0.9998101592063904
, O O 0.9999102354049683
but O O 0.9998732805252075
not O O 0.9998555183410645
saline O O 0.9898590445518494
vehicle O O 0.9960015416145325
, O O 0.9999690055847168
caused O O 0.9999730587005615
a O O 0.9999858140945435
dose O O 0.9996790885925293
- O O 0.9999822378158569
dependent O O 0.9999909400939941
decrease O O 0.9999959468841553
in O O 0.9999868869781494
both O O 0.9999425411224365
the O O 0.9999873638153076
mean O O 0.9999734163284302
arterial O O 0.9996776580810547
pressure O O 0.9999550580978394
and O O 0.9999746084213257
the O O 0.9999861717224121
heart O O 0.9999921321868896
rate O O 0.9999933242797852
. O O 0.999958872795105

The O O 0.9999446868896484
clonidine B B 0.9997323155403137
- O O 0.9999151229858398
induced O O 0.9999322891235352
hypotension O O 0.9999814033508301
was O O 0.9999556541442871
antagonized O O 0.9999476671218872
by O O 0.9999188184738159
prior O O 0.9999767541885376
spinal O O 0.9999256134033203
transection O O 0.9999910593032837
, O O 0.999956488609314
but O O 0.9999799728393555
not O O 0.9999521970748901
bilateral O O 0.9994887113571167
vagotomy O O 0.9978467226028442
. O O 0.9999608993530273

On O O 0.9999778270721436
the O O 0.9999867677688599
other O O 0.9999834299087524
hand O O 0.9999942779541016
, O O 0.9999470710754395
the O O 0.9999740123748779
clonidine B B 0.9997677206993103
- O O 0.9999144077301025
induced O O 0.9999164342880249
bradycardia O O 0.9999890327453613
was O O 0.9999649524688721
antagonized O O 0.9999769926071167
by O O 0.9999431371688843
prior O O 0.9999665021896362
bilateral O O 0.9996013045310974
vagotomy O O 0.8736482262611389
, O O 0.9999403953552246
but O O 0.9999650716781616
not O O 0.9999301433563232
spinal O O 0.9997772574424744
transection O O 0.999985933303833
. O O 0.9999675750732422

Furthermore O O 0.9998706579208374
, O O 0.9998154044151306
selective O O 0.9997175335884094
destruction O O 0.9998086094856262
of O O 0.9997993111610413
the O O 0.9998712539672852
spinal O O 0.9983929991722107
5 B O 0.5708778500556946
- I O 0.7450621128082275
HT I O 0.9020615816116333
nerves O O 0.9793925881385803
, O O 0.9999890327453613
produced O O 0.9999885559082031
by O O 0.999943733215332
bilateral O O 0.9999043941497803
spinal O O 0.9999395608901978
injection O O 0.9999701976776123
of O O 0.9992289543151855
5 B B 0.9555065631866455
, I I 0.9653435945510864
7 I I 0.9857355952262878
- I I 0.9902029037475586
dihydroxytryptamine I I 0.9984211921691895
, O O 0.999735414981842
reduced O O 0.9999605417251587
the O O 0.999984622001648
magnitude O O 0.999921441078186
of O O 0.999945878982544
the O O 0.9999048709869385
vasodepressor O B 0.9680787920951843
or O O 0.9998617172241211
the O O 0.9999732971191406
bradycardiac O O 0.9996267557144165
responses O O 0.9999929666519165
to O O 0.9998866319656372
clonidine B B 0.9998713731765747
microinjected O O 0.9995433688163757
into O O 0.9999433755874634
the O O 0.9999738931655884
area O O 0.9999592304229736
near O O 0.9999871253967285
the O O 0.9999798536300659
ventrolateral O O 0.9999182224273682
surface O O 0.999992847442627
of O O 0.9999600648880005
the O O 0.9999687671661377
medulla O O 0.9999152421951294
oblongata O O 0.9990959167480469
in O O 0.999840497970581
rats O O 0.9946706891059875
. O O 0.9999481439590454

The O O 0.9999819993972778
data O O 0.9999799728393555
indicate O O 0.9998708963394165
that O O 0.9998304843902588
a O O 0.9974931478500366
bulbospinal O O 0.9717983603477478
serotonergic O O 0.7697740197181702
pathway O O 0.9994238615036011
is O O 0.9998297691345215
involved O O 0.999925971031189
in O O 0.9999535083770752
development O O 0.9999895095825195
of O O 0.9999269247055054
clonidine B B 0.9997178912162781
- O O 0.9998020529747009
induced O O 0.9999175071716309
hypotension O O 0.9999685287475586
and O O 0.9999706745147705
bradycardia O O 0.9999932050704956
. O O 0.9999697208404541

The O O 0.999699592590332
induced O O 0.9999295473098755
hypotension O O 0.9999783039093018
is O O 0.9998992681503296
brought O O 0.9999889135360718
about O O 0.9999856948852539
by O O 0.9999397993087769
a O O 0.9999305009841919
decrease O O 0.9999569654464722
in O O 0.9998679161071777
sympathetic O O 0.9971734285354614
efferent O O 0.9966402053833008
activity O O 0.9999206066131592
, O O 0.9998824596405029
whereas O O 0.9999343156814575
the O O 0.9999797344207764
induced O O 0.9999572038650513
bradycardia O O 0.9999879598617554
was O O 0.9999470710754395
due O O 0.9999853372573853
to O O 0.9999198913574219
an O O 0.999936580657959
increase O O 0.9999303817749023
in O O 0.9998512268066406
vagal O O 0.9934452772140503
efferent O O 0.9939872026443481
activity O O 0.9998815059661865
. O O 0.9999450445175171

Hypertension O O 0.997281551361084
in O O 0.9997825026512146
neuroblastoma O O 0.9993636012077332
induced O O 0.9999581575393677
by O O 0.9995436072349548
imipramine B B 0.9988251328468323
. O O 0.9997206330299377

Hypertension O O 0.9969252943992615
is O O 0.9999524354934692
a O O 0.9999724626541138
well O O 0.9998482465744019
- O O 0.9999847412109375
known O O 0.9999754428863525
finding O O 0.9999880790710449
in O O 0.9999282360076904
some O O 0.9999508857727051
patients O O 0.9999852180480957
with O O 0.9999653100967407
neuroblastoma O O 0.9999294281005859
. O O 0.9999415874481201

However O O 0.9999459981918335
, O O 0.9999655485153198
it O O 0.9999754428863525
has O O 0.9999649524688721
not O O 0.9999915361404419
previously O O 0.9999799728393555
been O O 0.9999936819076538
described O O 0.9999927282333374
in O O 0.99997878074646
association O O 0.9999856948852539
with O O 0.9999403953552246
the O O 0.9999768733978271
use O O 0.9998986721038818
of O O 0.9988560676574707
Imipramine B B 0.9995185136795044
. O O 0.9999191761016846

We O O 0.9999767541885376
report O O 0.9999969005584717
the O O 0.9999955892562866
occurrence O O 0.9999963045120239
of O O 0.9999880790710449
severe O O 0.9999669790267944
hypertension O O 0.9998376369476318
( O O 0.9999533891677856
blood O O 0.9999407529830933
pressure O O 0.9999133348464966
190 O O 0.9997842907905579
/ O O 0.9999885559082031
160 O O 0.9987308382987976
) O O 0.9999837875366211
in O O 0.9999613761901855
a O O 0.9999904632568359
4 O O 0.9998537302017212
- O O 0.9999867677688599
year O O 0.9999951124191284
- O O 0.9999940395355225
old O O 0.9999921321868896
girl O O 0.9999984502792358
with O O 0.999972939491272
neuroblastoma O O 0.9998921155929565
who O O 0.9999384880065918
was O O 0.9999641180038452
given O O 0.9994710087776184
Imipramine B B 0.9994857311248779
to O O 0.9995278120040894
control O O 0.9999189376831055
a O O 0.9999450445175171
behavior O O 0.9994596838951111
disorder O O 0.9999921321868896
. O O 0.9999693632125854

It O O 0.999984622001648
was O O 0.9999828338623047
determined O O 0.9999961853027344
later O O 0.999993085861206
that O O 0.9999607801437378
this O O 0.9999867677688599
patient O O 0.9999809265136719
' O O 0.9999879598617554
s O O 0.9999808073043823
tumor O O 0.9999793767929077
was O O 0.9999655485153198
recurring O O 0.9999831914901733
at O O 0.9999881982803345
the O O 0.9999953508377075
time O O 0.9999954700469971
of O O 0.9999896287918091
her O O 0.9999849796295166
hypertensive O O 0.999416708946228
episode O O 0.9999841451644897
. O O 0.9999649524688721

Since O O 0.9999880790710449
she O O 0.9999865293502808
had O O 0.9999879598617554
no O O 0.99998939037323
blood O O 0.9998041987419128
pressure O O 0.9934729933738708
elevation O O 0.9999685287475586
at O O 0.9999394416809082
initial O O 0.9999927282333374
diagnosis O O 0.9999972581863403
and O O 0.9999624490737915
none O O 0.9999473094940186
following O O 0.9999613761901855
discontinuation O O 0.9999872446060181
of O O 0.9997636675834656
the O O 0.9983618855476379
Imipramine B B 0.9995204210281372
( O O 0.9999140501022339
when O O 0.9999806880950928
she O O 0.9999876022338867
was O O 0.9999821186065674
in O O 0.9999428987503052
florid O O 0.9940694570541382
relapse O O 0.9999669790267944
) O O 0.9999737739562988
, O O 0.9999717473983765
we O O 0.9999703168869019
believe O O 0.9998258948326111
that O O 0.9998674392700195
this O O 0.99928879737854
drug O O 0.9986642599105835
rather O O 0.9999493360519409
than O O 0.9999583959579468
her O O 0.999883770942688
underlying O O 0.999946117401123
disease O O 0.9999841451644897
alone O O 0.9999302625656128
caused O O 0.9999535083770752
her O O 0.9999878406524658
hypertension O O 0.9999176263809204
. O O 0.9999692440032959

The O O 0.9999464750289917
mechanism O O 0.9999847412109375
for O O 0.9999736547470093
this O O 0.9999426603317261
reaction O O 0.9999783039093018
is O O 0.9999065399169922
believed O O 0.9999711513519287
to O O 0.9999127388000488
be O O 0.9999339580535889
increased O O 0.9999299049377441
levels O O 0.9998186230659485
of O O 0.9994729161262512
vasoactive O O 0.9879108667373657
catecholamines B B 0.8814985156059265
due O O 0.9997091889381409
to O O 0.9996603727340698
interference O O 0.9998918771743774
of O O 0.9997381567955017
their O O 0.9994165897369385
physiologic O O 0.9995111227035522
inactivation O O 0.9999010562896729
by O O 0.999776303768158
Imipramine B B 0.9997485280036926
. O O 0.9999390840530396

From O O 0.9999912977218628
this O O 0.9999947547912598
experience O O 0.9999988079071045
, O O 0.9999719858169556
we O O 0.9999727010726929
urge O O 0.9999703168869019
extreme O O 0.9999750852584839
caution O O 0.9999949932098389
in O O 0.9999861717224121
the O O 0.9999896287918091
use O O 0.9999440908432007
of O O 0.9998055100440979
tricyclic O B 0.9195676445960999
antidepressants O O 0.621392548084259
in O O 0.999516487121582
children O O 0.9999964237213135
with O O 0.9999855756759644
active O O 0.999945878982544
neuroblastoma O O 0.9999326467514038
. O O 0.9999730587005615

Rechallenge O O 0.9998422861099243
of O O 0.9999735355377197
patients O O 0.9999884366989136
who O O 0.9999723434448242
developed O O 0.9999916553497314
oral O O 0.9956515431404114
candidiasis O O 0.9122504591941833
or O O 0.9999783039093018
hoarseness O O 0.9999977350234985
with O O 0.9991231560707092
beclomethasone B B 0.9990181922912598
dipropionate I I 0.9985355138778687
. O O 0.9992254972457886

Of O O 0.9999616146087646
158 O O 0.9999842643737793
asthmatic O O 0.9998942613601685
patients O O 0.9999834299087524
who O O 0.9999618530273438
were O O 0.9999833106994629
placed O O 0.9999880790710449
on O O 0.9997794032096863
inhaled O O 0.9948615431785583
beclomethasone B B 0.9994530081748962
, O O 0.9997796416282654
15 O O 0.9999771118164062
( O O 0.9999759197235107
9 O O 0.999990701675415
. O O 0.9999923706054688
5 O O 0.9999946355819702
% O O 0.9999933242797852
) O O 0.9999834299087524
developed O O 0.9999932050704956
either O O 0.9999585151672363
hoarseness O O 0.9999960660934448
( O O 0.9999663829803467
8 O O 0.9982380867004395
) O O 0.9999499320983887
, O O 0.9999785423278809
oral O O 0.9984118938446045
thrush O O 0.9998047947883606
( O O 0.9999569654464722
6 O O 0.999901294708252
) O O 0.9999262094497681
, O O 0.99992835521698
or O O 0.9999402761459351
both O O 0.9986573457717896
( O O 0.9999760389328003
1 O O 0.9999856948852539
) O O 0.9999855756759644
. O O 0.9999790191650391

When O O 0.9999886751174927
their O O 0.9998828172683716
adverse O O 0.9999074935913086
reactions O O 0.9999921321868896
subsided O O 0.9999524354934692
, O O 0.9999673366546631
seven O O 0.999984860420227
of O O 0.9999878406524658
these O O 0.9999942779541016
15 O O 0.999992847442627
patients O O 0.9999949932098389
were O O 0.9999864101409912
rechallenged O O 0.9999967813491821
with O O 0.9998244643211365
inhaled O O 0.9919258952140808
beclomethasone B B 0.9995548129081726
. O O 0.9999457597732544

These O O 0.9999616146087646
included O O 0.9999812841415405
five O O 0.9999626874923706
cases O O 0.99998939037323
who O O 0.9999340772628784
developed O O 0.9999685287475586
hoarseness O O 0.9999760389328003
and O O 0.999910831451416
three O O 0.9999583959579468
who O O 0.9999632835388184
developed O O 0.999961256980896
Candidiasis O O 0.9073644280433655
. O O 0.99996018409729

One O O 0.9998996257781982
patient O O 0.999982476234436
had O O 0.9996206760406494
both O O 0.9957062602043152
. O O 0.9998512268066406

Oral O O 0.9920578598976135
thrush O O 0.9974429607391357
did O O 0.9999759197235107
not O O 0.9999790191650391
recur O O 0.9999889135360718
, O O 0.9999544620513916
but O O 0.9999812841415405
60 O O 0.9999921321868896
% O O 0.9999978542327881
( O O 0.9999657869338989
3 O O 0.999964714050293
/ O O 0.9999650716781616
5 O O 0.9999872446060181
) O O 0.9999760389328003
of O O 0.9999854564666748
patients O O 0.9999927282333374
with O O 0.9999728202819824
hoarseness O O 0.9999637603759766
had O O 0.9999707937240601
recurrence O O 0.9999939203262329
. O O 0.9999798536300659

We O O 0.9999573230743408
conclude O O 0.9999808073043823
that O O 0.9999743700027466
patients O O 0.9999881982803345
may O O 0.9999812841415405
be O O 0.9999958276748657
restarted O O 0.9999585151672363
on O O 0.9997840523719788
inhaled O O 0.9856327772140503
beclomethasone B B 0.9996442794799805
when O O 0.9999285936355591
clinically O O 0.9999972581863403
indicated O O 0.9999979734420776
; O O 0.9999769926071167
however O O 0.9999898672103882
, O O 0.9999916553497314
because O O 0.9999943971633911
of O O 0.9999903440475464
the O O 0.999996542930603
high O O 0.9999747276306152
recurrence O O 0.9999980926513672
rate O O 0.9999982118606567
, O O 0.9999759197235107
patients O O 0.9999922513961792
who O O 0.9999831914901733
develop O O 0.999992847442627
hoarseness O O 0.9999769926071167
should O O 0.9999785423278809
not O O 0.9999815225601196
be O O 0.9999923706054688
re O O 0.9999806880950928
- O O 0.9999665021896362
challenged O O 0.9999878406524658
. O O 0.9999804496765137

Concomitant O O 0.9999240636825562
use O O 0.9999493360519409
of O O 0.9998699426651001
oral O O 0.9957337975502014
prednisone B B 0.9971996545791626
and O O 0.9970676302909851
topical O O 0.999961256980896
beclomethasone B B 0.9997128844261169
may O O 0.999915361404419
increase O O 0.9999690055847168
the O O 0.9999921321868896
risk O O 0.9999982118606567
of O O 0.9999971389770508
developing O O 0.9999948740005493
hoarseness O O 0.9999936819076538
or O O 0.9999756813049316
candidiasis O O 0.9947807192802429
. O O 0.9999567270278931

Cyclophosphamide B B 0.9952800273895264
cardiotoxicity O O 0.9998779296875
: O O 0.9999494552612305
an O O 0.9999313354492188
analysis O O 0.9932971596717834
of O O 0.999667763710022
dosing O O 0.9994412064552307
as O O 0.9999454021453857
a O O 0.9999269247055054
risk O O 0.9999797344207764
factor O O 0.9999961853027344
. O O 0.999944806098938

Patients O O 0.9999778270721436
who O O 0.9999756813049316
undergo O O 0.9999867677688599
bone O O 0.999916672706604
marrow O O 0.9999982118606567
transplantation O O 0.9999772310256958
are O O 0.999964714050293
generally O O 0.9999576807022095
immunosuppressed O O 0.9999377727508545
with O O 0.9999090433120728
a O O 0.9999593496322632
dose O O 0.9994866847991943
of O O 0.9988226294517517
cyclophosphamide B B 0.9986120462417603
( O O 0.9922120571136475
CYA B B 0.9990665316581726
) O O 0.9997746348381042
which O O 0.9999707937240601
is O O 0.9999748468399048
usually O O 0.9999752044677734
calculated O O 0.9999912977218628
based O O 0.9999972581863403
on O O 0.9999973773956299
the O O 0.9999982118606567
patient O O 0.9999970197677612
' O O 0.9999970197677612
s O O 0.9999980926513672
weight O O 0.9999845027923584
. O O 0.9999791383743286

At O O 0.9997813105583191
these O O 0.9999465942382812
high O O 0.9998990297317505
doses O O 0.9997519850730896
of O O 0.9991113543510437
CYA B B 0.9894513487815857
, O O 0.9998664855957031
serious O O 0.9999573230743408
cardiotoxicity O O 0.9999889135360718
may O O 0.9999740123748779
occur O O 0.9999881982803345
, O O 0.9999533891677856
but O O 0.9999651908874512
definitive O O 0.9999457597732544
risk O O 0.9999556541442871
factors O O 0.9999945163726807
for O O 0.9999845027923584
the O O 0.9999905824661255
development O O 0.9999947547912598
of O O 0.9999864101409912
such O O 0.9999284744262695
cardiotoxicity O O 0.9999822378158569
have O O 0.9999892711639404
not O O 0.9999969005584717
been O O 0.9999971389770508
described O O 0.9999966621398926
. O O 0.99998939037323

Since O O 0.9999804496765137
chemotherapeutic O O 0.9958915710449219
agent O O 0.9893414974212646
toxicity O O 0.9999343156814575
generally O O 0.9999234676361084
correlates O O 0.9999831914901733
with O O 0.999968409538269
dose O O 0.999455988407135
per O O 0.9999474287033081
body O O 0.9999179840087891
surface O O 0.9998669624328613
area O O 0.9949150085449219
, O O 0.9999841451644897
we O O 0.9999914169311523
retrospectively O O 0.9999933242797852
calculated O O 0.9999969005584717
the O O 0.9999895095825195
dose O O 0.9997419714927673
of O O 0.998121440410614
CYA B B 0.9839391708374023
in O O 0.9998260140419006
patients O O 0.9999936819076538
transplanted O O 0.9999873638153076
at O O 0.9999833106994629
our O O 0.9999921321868896
institution O O 0.9999972581863403
to O O 0.9999935626983643
determine O O 0.9999974966049194
whether O O 0.9999923706054688
the O O 0.999995231628418
incidence O O 0.999993085861206
of O O 0.999945878982544
CYA B B 0.9891419410705566
cardiotoxicity O O 0.9999322891235352
correlated O O 0.999993085861206
with O O 0.9999918937683105
the O O 0.9999903440475464
dose O O 0.9998995065689087
per O O 0.9999516010284424
body O O 0.9998406171798706
surface O O 0.9999037981033325
area O O 0.9976252913475037
. O O 0.9999754428863525

Eighty O O 0.9998669624328613
patients O O 0.9999949932098389
who O O 0.9999802112579346
were O O 0.9999954700469971
to O O 0.9999960660934448
receive O O 0.9998542070388794
CYA B B 0.9977871179580688
50 O O 0.9841655492782593
mg O O 0.9999053478240967
/ O O 0.9999768733978271
kg O O 0.9999980926513672
/ O O 0.9999638795852661
d O O 0.9999746084213257
for O O 0.9999779462814331
four O O 0.999988317489624
days O O 0.999996542930603
as O O 0.9999891519546509
preparation O O 0.9999991655349731
for O O 0.999991774559021
marrow O O 0.9999945163726807
grafting O O 0.9999783039093018
underwent O O 0.9999901056289673
a O O 0.9999929666519165
total O O 0.9999967813491821
of O O 0.9999903440475464
84 O O 0.9997050166130066
transplants O O 0.9999927282333374
for O O 0.9999817609786987
aplastic O O 0.9983423948287964
anemia O O 0.9999524354934692
, O O 0.9999784231185913
Wiskott O O 0.9995577931404114
- O O 0.999363124370575
Aldrich O O 0.9363463521003723
syndrome O O 0.9999575614929199
, O O 0.9999240636825562
or O O 0.999941349029541
severe O O 0.9999711513519287
combined O O 0.9993442893028259
immunodeficiency O O 0.9999879598617554
syndrome O O 0.99998939037323
. O O 0.9999821186065674

Fourteen O O 0.9998980760574341
of O O 0.99997878074646
84 O O 0.9999663829803467
( O O 0.9999576807022095
17 O O 0.9999957084655762
% O O 0.9999949932098389
) O O 0.9999537467956543
patients O O 0.9999940395355225
had O O 0.9999852180480957
symptoms O O 0.9999980926513672
and O O 0.9999955892562866
signs O O 0.9999977350234985
consistent O O 0.9999949932098389
with O O 0.9999589920043945
CYA B B 0.9222267866134644
cardiotoxicity O O 0.9998672008514404
within O O 0.9999827146530151
ten O O 0.9999984502792358
days O O 0.999997615814209
of O O 0.9999833106994629
receiving O O 0.9999514818191528
1 O O 0.9999445676803589
to O O 0.9999942779541016
4 O O 0.9997435212135315
doses O O 0.9999207258224487
of O O 0.9992585778236389
CYA B B 0.9927858710289001
. O O 0.9999431371688843

Six O O 0.999883770942688
of O O 0.9999825954437256
the O O 0.9999924898147583
14 O O 0.999995231628418
patients O O 0.9999958276748657
died O O 0.9999943971633911
with O O 0.9999879598617554
congestive O O 0.9753002524375916
heart O O 0.9999628067016602
failure O O 0.9998053908348083
. O O 0.9999526739120483

The O O 0.9999788999557495
dose O O 0.9999366998672485
of O O 0.9998868703842163
CYA B B 0.9943475127220154
per O O 0.9998935461044312
body O O 0.999985933303833
surface O O 0.9999876022338867
area O O 0.9999699592590332
was O O 0.9999747276306152
calculated O O 0.9999880790710449
for O O 0.9998687505722046
all O O 0.9999374151229858
patients O O 0.9999942779541016
and O O 0.9999781847000122
the O O 0.9999946355819702
patients O O 0.9999946355819702
were O O 0.9999923706054688
divided O O 0.9999959468841553
into O O 0.999966025352478
two O O 0.999988317489624
groups O O 0.9999899864196777
based O O 0.999997615814209
on O O 0.9999920129776001
daily O O 0.9998952150344849
CYA B B 0.9923319816589355
dose O O 0.9999245405197144
: O O 0.9999750852584839
Group O O 0.9999790191650391
1 O O 0.9999479055404663
, O O 0.9997785687446594
CYA B O 0.696588397026062
less O O 0.9998064637184143
than O O 0.9999912977218628
or O O 0.9999977350234985
equal O O 0.999997615814209
to O O 0.9999947547912598
1 O O 0.9999909400939941
. O O 0.999998927116394
55 O O 0.9977649450302124
g O O 0.9999264478683472
/ O O 0.9999797344207764
m2 O O 0.9999829530715942
/ O O 0.9999496936798096
d O O 0.999983549118042
; O O 0.9999239444732666
Group O O 0.9999620914459229
2 O O 0.9998550415039062
, O O 0.9997510313987732
CYA B O 0.47723761200904846
greater O O 0.9999657869338989
than O O 0.9999954700469971
1 O O 0.9999961853027344
. O O 0.999998927116394
55 O O 0.9983229041099548
g O O 0.9999632835388184
/ O O 0.9999926090240479
m2 O O 0.9999896287918091
/ O O 0.9999841451644897
d O O 0.9999970197677612
. O O 0.9999808073043823

Cardiotoxicity O O 0.9999711513519287
that O O 0.9999483823776245
was O O 0.9999591112136841
thought O O 0.9999773502349854
to O O 0.9999548196792603
be O O 0.9999641180038452
related O O 0.9999730587005615
to O O 0.9986788630485535
CYA B B 0.8982135057449341
occurred O O 0.9991374015808105
in O O 0.999934196472168
1 O O 0.9999542236328125
/ O O 0.9999812841415405
32 O O 0.9999874830245972
( O O 0.9999245405197144
3 O O 0.9999512434005737
% O O 0.9999903440475464
) O O 0.9999719858169556
of O O 0.9999608993530273
patients O O 0.9999945163726807
in O O 0.9999210834503174
Group O O 0.9997562766075134
1 O O 0.9998537302017212
and O O 0.9998356103897095
in O O 0.9999299049377441
13 O O 0.9999110698699951
/ O O 0.9999818801879883
52 O O 0.9999916553497314
( O O 0.9999212026596069
25 O O 0.9999920129776001
% O O 0.9999924898147583
) O O 0.9999659061431885
patients O O 0.9999932050704956
in O O 0.9998915195465088
Group O O 0.9997484087944031
2 O O 0.999423623085022
( O O 0.9998571872711182
P O O 0.9958767890930176
less O O 0.9999903440475464
than O O 0.9999932050704956
0 O O 0.9999964237213135
. O O 0.9999977350234985
025 O O 0.9997972846031189
) O O 0.9999449253082275
. O O 0.9999531507492065

Congestive O O 0.9977701902389526
heart O O 0.9999626874923706
failure O O 0.9999085664749146
caused O O 0.9999547004699707
or O O 0.9999778270721436
contributed O O 0.9999959468841553
to O O 0.9999921321868896
death O O 0.999994158744812
in O O 0.9999814033508301
0 O O 0.9999759197235107
/ O O 0.9999855756759644
32 O O 0.9999889135360718
patients O O 0.9999957084655762
in O O 0.9998952150344849
Group O O 0.9997534155845642
1 O O 0.9998863935470581
v O O 0.9997438788414001
6 O O 0.9999527931213379
/ O O 0.9999738931655884
52 O O 0.9999854564666748
( O O 0.9999631643295288
12 O O 0.9999959468841553
% O O 0.999997615814209
) O O 0.9999943971633911
of O O 0.9999635219573975
patients O O 0.9999942779541016
in O O 0.9999039173126221
Group O O 0.9997389912605286
2 O O 0.9990962743759155
( O O 0.9999098777770996
P O O 0.9990799427032471
less O O 0.999984622001648
than O O 0.9999949932098389
0 O O 0.9999951124191284
. O O 0.9999984502792358
25 O O 0.9999946355819702
) O O 0.9999234676361084
. O O 0.9999490976333618

There O O 0.9999682903289795
was O O 0.9999655485153198
no O O 0.9999854564666748
difference O O 0.9999961853027344
in O O 0.9999948740005493
the O O 0.9999922513961792
rate O O 0.9999929666519165
of O O 0.9999701976776123
engraftment O O 0.9999631643295288
of O O 0.999836802482605
evaluable O O 0.999901533126831
patients O O 0.9988228678703308
in O O 0.9997466206550598
the O O 0.9998704195022583
two O O 0.9999004602432251
groups O O 0.9999701976776123
( O O 0.9999434947967529
P O O 0.9706467986106873
greater O O 0.9999542236328125
than O O 0.9999891519546509
0 O O 0.9999797344207764
. O O 0.9999866485595703
5 O O 0.9999741315841675
) O O 0.9999600648880005
. O O 0.9999599456787109

We O O 0.9999748468399048
conclude O O 0.9999686479568481
that O O 0.9999451637268066
the O O 0.9999794960021973
CYA B O 0.5703635811805725
cardiotoxicity O O 0.999925971031189
correlates O O 0.9999849796295166
with O O 0.9999197721481323
CYA B B 0.9885388016700745
dosage O O 0.9994396567344666
as O O 0.9999904632568359
calculated O O 0.9999953508377075
by O O 0.9999798536300659
body O O 0.999970555305481
surface O O 0.9991052746772766
area O O 0.9977056384086609
, O O 0.9999756813049316
and O O 0.9999910593032837
that O O 0.9999889135360718
patients O O 0.9999942779541016
with O O 0.9999867677688599
aplastic O O 0.9950048327445984
anemia O O 0.9997971653938293
and O O 0.9999010562896729
immunodeficiencies O O 0.9999566078186035
can O O 0.9999815225601196
be O O 0.9999957084655762
effectively O O 0.9999728202819824
prepared O O 0.9999948740005493
for O O 0.9999709129333496
bone O O 0.999958872795105
marrow O O 0.9999986886978149
grafting O O 0.9999904632568359
at O O 0.9998881816864014
a O O 0.9999600648880005
CYA B B 0.8927338719367981
dose O O 0.9994553923606873
of O O 0.9999370574951172
1 O O 0.9998512268066406
. O O 0.9999974966049194
55 O O 0.9987093210220337
g O O 0.9998661279678345
/ O O 0.9999821186065674
m2 O O 0.9999966621398926
/ O O 0.9999558925628662
d O O 0.999995231628418
for O O 0.9999754428863525
four O O 0.9999895095825195
days O O 0.9999963045120239
with O O 0.9999861717224121
a O O 0.9999918937683105
lower O O 0.9999938011169434
incidence O O 0.9999979734420776
of O O 0.9999812841415405
cardiotoxicity O O 0.9999938011169434
than O O 0.9999557733535767
patients O O 0.999993085861206
whose O O 0.9999604225158691
CYA B B 0.9382766485214233
dosage O O 0.9994063377380371
is O O 0.9999860525131226
calculated O O 0.9999924898147583
based O O 0.9999943971633911
on O O 0.9999809265136719
weight O O 0.9999836683273315
. O O 0.9999786615371704

This O O 0.9999793767929077
study O O 0.9999791383743286
reaffirms O O 0.9999936819076538
the O O 0.9999910593032837
principle O O 0.9999781847000122
that O O 0.9999487400054932
drug O O 0.9992194175720215
toxicity O O 0.9999520778656006
correlates O O 0.9999699592590332
with O O 0.9999580383300781
dose O O 0.9998569488525391
per O O 0.9999209642410278
body O O 0.9999778270721436
surface O O 0.9999885559082031
area O O 0.9999828338623047
. O O 0.9999747276306152

Studies O O 0.9996347427368164
of O O 0.9997346997261047
risk O O 0.9926145076751709
factors O O 0.9999426603317261
for O O 0.9998925924301147
aminoglycoside B B 0.9683443307876587
nephrotoxicity O O 0.6733663082122803
. O O 0.9999481439590454

The O O 0.9999622106552124
epidemiology O O 0.9999704360961914
of O O 0.9999247789382935
aminoglycoside B B 0.997265100479126
- O O 0.9993401169776917
induced O O 0.999895453453064
nephrotoxicity O O 0.9999115467071533
is O O 0.9999642372131348
not O O 0.9999940395355225
fully O O 0.9999935626983643
understood O O 0.9999911785125732
. O O 0.9999686479568481

Experimental O O 0.9998961687088013
studies O O 0.9999880790710449
in O O 0.9999779462814331
healthy O O 0.9999181032180786
human O O 0.9999915361404419
volunteers O O 0.9999954700469971
indicate O O 0.9996410608291626
aminoglycosides B B 0.9904566407203674
cause O O 0.9993396401405334
proximal O O 0.999736487865448
tubular O O 0.9999843835830688
damage O O 0.9999924898147583
in O O 0.999941349029541
most O O 0.9998972415924072
patients O O 0.9999878406524658
, O O 0.9999599456787109
but O O 0.9999079704284668
rarely O O 0.999932050704956
, O O 0.9999852180480957
if O O 0.9999897480010986
ever O O 0.9999876022338867
, O O 0.9999765157699585
cause O O 0.9998832941055298
glomerular O O 0.9993327260017395
or O O 0.9998883008956909
tubular O O 0.9999842643737793
dysfunction O O 0.9999959468841553
. O O 0.9999785423278809

Clinical O O 0.9999686479568481
trials O O 0.9999747276306152
of O O 0.9996071457862854
aminoglycosides B B 0.9720277190208435
in O O 0.9995972514152527
seriously O O 0.9966108202934265
ill O O 0.9999715089797974
patients O O 0.9999866485595703
indicate O O 0.9999551773071289
that O O 0.9999701976776123
the O O 0.9999912977218628
relative O O 0.999976634979248
risk O O 0.9999986886978149
for O O 0.9999948740005493
developing O O 0.9999948740005493
acute O O 0.9999912977218628
renal O O 0.9999946355819702
failure O O 0.999996542930603
during O O 0.9998295307159424
therapy O O 0.999967098236084
ranges O O 0.9999654293060303
from O O 0.9999667406082153
8 O O 0.9991047978401184
to O O 0.9999371767044067
10 O O 0.9999881982803345
and O O 0.9999719858169556
that O O 0.9999783039093018
the O O 0.9999891519546509
attributable O O 0.9999769926071167
risk O O 0.999994158744812
is O O 0.9999808073043823
70 O O 0.9999966621398926
% O O 0.9999960660934448
to O O 0.9999891519546509
80 O O 0.9999914169311523
% O O 0.9999945163726807
. O O 0.9999804496765137

Further O O 0.9999934434890747
analysis O O 0.999997615814209
of O O 0.9999891519546509
these O O 0.9999847412109375
data O O 0.9999901056289673
suggests O O 0.9999579191207886
that O O 0.9999498128890991
the O O 0.9999916553497314
duration O O 0.9999423027038574
of O O 0.9999215602874756
therapy O O 0.9998507499694824
, O O 0.9999436140060425
plasma O O 0.9330248236656189
aminoglycoside B B 0.8810036182403564
levels O O 0.9940062761306763
, O O 0.9999604225158691
liver O O 0.9998254179954529
disease O O 0.9999977350234985
, O O 0.9999754428863525
advanced O O 0.9999986886978149
age O O 0.9999852180480957
, O O 0.9999672174453735
high O O 0.9999322891235352
initial O O 0.9999904632568359
estimated O O 0.9981379508972168
creatinine B B 0.9947899580001831
clearance O O 0.9994407296180725
and O O 0.9998083710670471
, O O 0.9999786615371704
possibly O O 0.9999774694442749
, O O 0.9999657869338989
female O O 0.999775230884552
gender O O 0.9981315732002258
all O O 0.9999697208404541
increase O O 0.9999185800552368
the O O 0.9999932050704956
risk O O 0.9999964237213135
for O O 0.9999750852584839
nephrotoxicity O O 0.9999492168426514
. O O 0.999981164932251

Other O O 0.9995843768119812
causes O O 0.9999138116836548
of O O 0.9999399185180664
acute O O 0.9999604225158691
renal O O 0.9999856948852539
failure O O 0.9999783039093018
, O O 0.9999659061431885
such O O 0.9998599290847778
as O O 0.9997952580451965
shock O O 0.9988676309585571
, O O 0.9999711513519287
appear O O 0.9999266862869263
to O O 0.9998593330383301
have O O 0.9998487234115601
an O O 0.9998461008071899
additive O O 0.9995743632316589
effect O O 0.9999595880508423
. O O 0.9999526739120483

Predictive O O 0.998613715171814
models O O 0.9999809265136719
have O O 0.9999781847000122
been O O 0.9999892711639404
developed O O 0.9999927282333374
from O O 0.9997032284736633
these O O 0.9994920492172241
analyses O O 0.9998795986175537
that O O 0.9999613761901855
should O O 0.9999390840530396
be O O 0.9999939203262329
useful O O 0.999984860420227
for O O 0.9999865293502808
identifying O O 0.9999885559082031
patients O O 0.9999942779541016
at O O 0.9999872446060181
high O O 0.9999806880950928
risk O O 0.9999966621398926
. O O 0.9999761581420898

These O O 0.9998742341995239
models O O 0.9999829530715942
may O O 0.999964714050293
also O O 0.9999812841415405
be O O 0.9999885559082031
useful O O 0.9999831914901733
in O O 0.9999909400939941
developing O O 0.9999935626983643
insights O O 0.9999964237213135
into O O 0.9999884366989136
the O O 0.9999802112579346
pathophysiology O O 0.9999785423278809
of O O 0.9999479055404663
aminoglycoside B B 0.996539831161499
- O O 0.9997292160987854
induced O O 0.9999244213104248
nephrotoxicity O O 0.9999092817306519
. O O 0.9999828338623047

Central O O 0.9987252354621887
action O O 0.9998806715011597
of O O 0.9995023012161255
narcotic O O 0.8347827196121216
analgesics O O 0.9068557620048523
. O O 0.9997839331626892

Part O O 0.9762054085731506
IV O O 0.9902237057685852
. O O 0.9997884631156921

Noradrenergic O O 0.49389442801475525
influences O O 0.9993270635604858
on O O 0.9998581409454346
the O O 0.9999450445175171
activity O O 0.9997956156730652
of O O 0.9996553659439087
analgesics O O 0.9769750833511353
in O O 0.9995026588439941
rats O O 0.999275267124176
. O O 0.9999465942382812

The O O 0.9999289512634277
effect O O 0.9999140501022339
of O O 0.9996768236160278
clonidine B B 0.9997593760490417
, O O 0.8139829635620117
naphazoline B B 0.9921591281890869
and O O 0.9528347849845886
xylometazoline B B 0.9990224838256836
on O O 0.999778687953949
analgesia O O 0.9999761581420898
induced O O 0.999975323677063
by O O 0.9998599290847778
morphine B B 0.9995891451835632
, O O 0.9489421844482422
codeine B B 0.9889538288116455
, O O 0.8837741017341614
fentanyl B B 0.9929577112197876
and O O 0.9840795397758484
pentazocine B B 0.9940980672836304
, O O 0.9997840523719788
and O O 0.9997730851173401
on O O 0.9646387100219727
cataleptic O O 0.9852654337882996
effect O O 0.999866247177124
of O O 0.9997913241386414
morphine B B 0.9997441172599792
, O O 0.9219575524330139
codine B B 0.9996410608291626
and O O 0.951560914516449
fentanyl B B 0.9988059997558594
was O O 0.9999468326568604
studied O O 0.9999533891677856
in O O 0.9998786449432373
rats O O 0.9998983144760132
. O O 0.9999645948410034

The O O 0.9999697208404541
biochemical O O 0.9993976354598999
assays O O 0.9998999834060669
on O O 0.9999064207077026
the O O 0.9999279975891113
influence O O 0.9999395608901978
of O O 0.9997734427452087
four O O 0.9550308585166931
analgesics O O 0.9663455486297607
on O O 0.9998103976249695
the O O 0.9999209642410278
brain O O 0.9997618794441223
concentration O O 0.999889612197876
and O O 0.9999386072158813
turnover O O 0.9997939467430115
of O O 0.9978952407836914
noradrenaline B B 0.9988000392913818
( O O 0.9977808594703674
NA B B 0.9992949962615967
) O O 0.9996196031570435
were O O 0.9999755620956421
also O O 0.9999868869781494
performed O O 0.9999861717224121
. O O 0.9999731779098511

It O O 0.9999885559082031
was O O 0.999985933303833
found O O 0.9999946355819702
that O O 0.9997237324714661
three O O 0.9930156469345093
drugs O O 0.9940937161445618
stimulating O O 0.996340811252594
central O O 0.6387658715248108
NA B B 0.9001835584640503
receptors O O 0.9977444410324097
failed O O 0.999958872795105
to O O 0.9999579191207886
affect O O 0.9998641014099121
the O O 0.9999618530273438
analgesic O O 0.9999103546142578
ED50 O O 0.9999854564666748
of O O 0.999660849571228
all O O 0.9966018199920654
antinociceptive O O 0.5261181592941284
agents O O 0.801176130771637
and O O 0.9997832179069519
they O O 0.9950241446495056
enhanced O O 0.9994576573371887
catalepsy O O 0.9998518228530884
induced O O 0.9999508857727051
by O O 0.9998371601104736
morphine B B 0.9998165965080261
and O O 0.9792891144752502
fentanyl B B 0.9996579885482788
. O O 0.999946117401123

Codeine B B 0.9453839063644409
catalepsy O O 0.998555600643158
was O O 0.9999237060546875
increased O O 0.9999063014984131
by O O 0.9990069270133972
clonidine B B 0.9997866749763489
and O O 0.9998477697372437
decreased O O 0.9999295473098755
by O O 0.999670147895813
naphazoline B B 0.9995386600494385
and O O 0.988105058670044
xylometazoline B B 0.9991905093193054
. O O 0.9999581575393677

The O O 0.9999604225158691
brain O O 0.9999085664749146
concentration O O 0.9999330043792725
of O O 0.9980693459510803
NA B B 0.971453070640564
was O O 0.9999077320098877
not O O 0.9999755620956421
changed O O 0.9999788999557495
by O O 0.9997879862785339
morphine B B 0.9998564720153809
and O O 0.9927753210067749
fentanyl B B 0.9995834231376648
, O O 0.9998668432235718
but O O 0.9998997449874878
one O O 0.9997597336769104
of O O 0.9998196959495544
the O O 0.9999706745147705
doses O O 0.9997352957725525
of O O 0.99777752161026
codeine B B 0.9988974332809448
( O O 0.9992350339889526
45 O O 0.9986805319786072
mg O O 0.9998377561569214
/ O O 0.9998190999031067
kg O O 0.9998797178268433
) O O 0.999950647354126
slightly O O 0.999972939491272
enhanced O O 0.9999401569366455
it O O 0.999992847442627
. O O 0.9999696016311646

Pentazocine B B 0.9993089437484741
dose O O 0.9997300505638123
- O O 0.9999574422836304
dependently O O 0.9999680519104004
decreased O O 0.9999496936798096
the O O 0.9999852180480957
brain O O 0.9999347925186157
level O O 0.999913215637207
of O O 0.9986212253570557
NA B B 0.9962844848632812
. O O 0.999715268611908

The O O 0.999981164932251
rate O O 0.9999712705612183
of O O 0.9999247789382935
NA B B 0.9811944365501404
turnover O O 0.9656949639320374
was O O 0.9999783039093018
not O O 0.9999839067459106
altered O O 0.9999933242797852
by O O 0.9998531341552734
analgesics O O 0.9993041753768921
except O O 0.9999270439147949
for O O 0.9999052286148071
the O O 0.9999678134918213
higher O O 0.9999445676803589
dose O O 0.9998019337654114
of O O 0.9984654188156128
fentanyl B B 0.9997859597206116
( O O 0.9995436072349548
0 O O 0.9998648166656494
. O O 0.999994158744812
2 O O 0.9998888969421387
mg O O 0.9999117851257324
/ O O 0.9999260902404785
kg O O 0.9999839067459106
) O O 0.9999788999557495
following O O 0.9999837875366211
which O O 0.9999881982803345
the O O 0.9999926090240479
disappearance O O 0.9999860525131226
of O O 0.9996727705001831
NA B B 0.9972388744354248
from O O 0.9996078610420227
the O O 0.9999762773513794
brain O O 0.9999864101409912
was O O 0.9999803304672241
diminished O O 0.9999862909317017
. O O 0.9999724626541138

The O O 0.9999872446060181
results O O 0.9999923706054688
are O O 0.999991774559021
discussed O O 0.9999969005584717
in O O 0.9999955892562866
the O O 0.9999964237213135
light O O 0.9999935626983643
of O O 0.9999926090240479
various O O 0.9999793767929077
and O O 0.9999781847000122
non O O 0.9999339580535889
- O O 0.9999691247940063
uniform O O 0.9999977350234985
data O O 0.9999955892562866
from O O 0.9999808073043823
the O O 0.9999897480010986
literature O O 0.9999791383743286
. O O 0.9999650716781616

It O O 0.9999865293502808
is O O 0.9999628067016602
suggested O O 0.9999703168869019
that O O 0.9998419284820557
in O O 0.9991931319236755
rats O O 0.9973102807998657
the O O 0.996791660785675
brain O O 0.9915157556533813
NA B O 0.7982041835784912
plays O O 0.9996140599250793
a O O 0.999929666519165
less O O 0.9999425411224365
important O O 0.9994863271713257
function O O 0.9998912811279297
than O O 0.9998700618743896
the O O 0.9995935559272766
other O O 0.9986257553100586
monoamines B O 0.9162144064903259
in O O 0.9998109936714172
the O O 0.9998759031295776
behavioural O O 0.9999138116836548
activity O O 0.9998830556869507
of O O 0.9996040463447571
potent O O 0.9456339478492737
analgesics O O 0.9695746898651123
. O O 0.9998952150344849

Flurothyl B O 0.716558039188385
seizure O O 0.9996129870414734
thresholds O O 0.9999613761901855
in O O 0.9999525547027588
mice O O 0.9999946355819702
treated O O 0.9999583959579468
neonatally O O 0.9999988079071045
with O O 0.9999566078186035
a O O 0.999976634979248
single O O 0.9999302625656128
injection O O 0.9999728202819824
of O O 0.9998133778572083
monosodium B B 0.969508707523346
glutamate I I 0.9624934792518616
( O O 0.9956619143486023
MSG B B 0.8901036381721497
) O O 0.9997835755348206
: O O 0.9999752044677734
evaluation O O 0.9999963045120239
of O O 0.9999889135360718
experimental O O 0.9999759197235107
parameters O O 0.9999984502792358
in O O 0.9999788999557495
flurothyl B B 0.9368550777435303
seizure O O 0.9997251629829407
testing O O 0.99998939037323
. O O 0.9999831914901733

Monosodium B B 0.9967058300971985
glutamate I I 0.9962285757064819
( O O 0.9890861511230469
MSG B B 0.9936217665672302
) O O 0.9988969564437866
administration O O 0.9999195337295532
to O O 0.9999393224716187
neonatal O O 0.9999985694885254
rodents O O 0.9999687671661377
produces O O 0.999942421913147
convulsions O O 0.999948263168335
and O O 0.9999786615371704
results O O 0.9999769926071167
in O O 0.9999924898147583
numerous O O 0.9999690055847168
biochemical O O 0.9996483325958252
and O O 0.9999614953994751
behavioral O O 0.9999916553497314
deficits O O 0.9999969005584717
. O O 0.9999746084213257

These O O 0.9999758005142212
studies O O 0.9999911785125732
were O O 0.9999856948852539
undertaken O O 0.9999955892562866
to O O 0.9999949932098389
determine O O 0.9999969005584717
if O O 0.9999704360961914
neonatal O O 0.9999964237213135
administration O O 0.9999425411224365
of O O 0.9997726082801819
MSG B B 0.9966561794281006
produced O O 0.9997995495796204
permanent O O 0.9999723434448242
alterations O O 0.999996542930603
in O O 0.9999701976776123
seizure O O 0.999957799911499
susceptibility O O 0.9999711513519287
, O O 0.9999719858169556
since O O 0.9999938011169434
previous O O 0.9999682903289795
investigations O O 0.9999932050704956
were O O 0.9999908208847046
inconclusive O O 0.999991774559021
. O O 0.9999876022338867

A O O 0.999914288520813
flurothyl B B 0.9909968376159668
ether B I 0.9997383952140808
seizure O O 0.9874227046966553
screening O O 0.9999580383300781
technique O O 0.9999908208847046
was O O 0.9999843835830688
used O O 0.999990701675415
to O O 0.9999933242797852
evaluate O O 0.9999871253967285
seizure O O 0.9999626874923706
susceptibility O O 0.9999830722808838
in O O 0.9999781847000122
adult O O 0.9999929666519165
mice O O 0.9999990463256836
that O O 0.9999910593032837
received O O 0.9999748468399048
neonatal O O 0.9999974966049194
injections O O 0.9999721050262451
of O O 0.9998612403869629
MSG B B 0.9921964406967163
( O O 0.9819289445877075
4 O O 0.9924106597900391
mg O O 0.9998262524604797
/ O O 0.9996695518493652
g O O 0.9993696808815002
and O O 0.9996981620788574
1 O O 0.9994919300079346
mg O O 0.9992751479148865
/ O O 0.9995507597923279
g O O 0.9988523721694946
) O O 0.9999676942825317
. O O 0.9999796152114868

MSG B B 0.9940686225891113
treatment O O 0.9997194409370422
resulted O O 0.9999587535858154
in O O 0.9999821186065674
significant O O 0.9999762773513794
reductions O O 0.999992847442627
in O O 0.9999773502349854
whole O O 0.9996269941329956
brain O O 0.9999827146530151
weight O O 0.9982255101203918
but O O 0.9999650716781616
did O O 0.999975323677063
not O O 0.9999892711639404
alter O O 0.9999825954437256
seizure O O 0.9999808073043823
threshold O O 0.9999966621398926
. O O 0.999975323677063

A O O 0.9992522597312927
naloxone B B 0.9996848106384277
( O O 0.999377965927124
5 O O 0.9999581575393677
mg O O 0.999941349029541
/ O O 0.9998478889465332
kg O O 0.9999911785125732
) O O 0.9998074173927307
challenge O O 0.9997723698616028
was O O 0.9999632835388184
also O O 0.9999551773071289
ineffective O O 0.9999152421951294
in O O 0.9999512434005737
altering O O 0.9999574422836304
the O O 0.999981164932251
seizure O O 0.9999804496765137
thresholds O O 0.9999904632568359
of O O 0.9999445676803589
either O O 0.9950085878372192
control O O 0.9951848387718201
of O O 0.9998679161071777
MSG B B 0.9970952272415161
- O O 0.9991493225097656
treated O O 0.9998819828033447
mice O O 0.9999953508377075
. O O 0.9999630451202393

Flurothyl B B 0.9967689514160156
ether B I 0.9994556307792664
produced O O 0.9993045330047607
hypothermia O O 0.9999330043792725
which O O 0.9999704360961914
was O O 0.9999730587005615
correlated O O 0.9999978542327881
with O O 0.999990701675415
the O O 0.9999951124191284
duration O O 0.9999890327453613
of O O 0.9999464750289917
flurothyl B B 0.9987642765045166
exposure O O 0.9997096657752991
; O O 0.9999655485153198
however O O 0.9999897480010986
, O O 0.9999895095825195
the O O 0.9999918937683105
relationship O O 0.9999921321868896
of O O 0.999969482421875
hypothermia O O 0.9999531507492065
to O O 0.9998923540115356
seizure O O 0.9999774694442749
induction O O 0.9999940395355225
was O O 0.9999756813049316
unclear O O 0.9999624490737915
. O O 0.9999814033508301

Flurothyl B B 0.9911153316497803
seizure O O 0.9993706345558167
testing O O 0.9999518394470215
proved O O 0.9999614953994751
to O O 0.999970555305481
be O O 0.9999845027923584
a O O 0.9999724626541138
rapid O O 0.9999912977218628
and O O 0.9999783039093018
reliable O O 0.9999936819076538
technique O O 0.9999966621398926
with O O 0.9999798536300659
which O O 0.9999938011169434
to O O 0.9999933242797852
evaluate O O 0.9999866485595703
seizure O O 0.9999159574508667
susceptibility O O 0.9999545812606812
. O O 0.9999668598175049

Susceptibility O O 0.9999161958694458
to O O 0.9999328851699829
seizures O O 0.999961256980896
produced O O 0.9999890327453613
by O O 0.9998370409011841
pilocarpine B B 0.9998729228973389
in O O 0.9997428059577942
rats O O 0.9999418258666992
after O O 0.9999314546585083
microinjection O O 0.9994557499885559
of O O 0.9998754262924194
isoniazid B B 0.9997798800468445
or O O 0.9920352101325989
gamma B B 0.9450988173484802
- I I 0.9537255167961121
vinyl I I 0.9988822340965271
- I I 0.9404994249343872
GABA I I 0.9992369413375854
into O O 0.9996211528778076
the O O 0.9999793767929077
substantia O O 0.9995038509368896
nigra O O 0.9999247789382935
. O O 0.9999467134475708

Pilocarpine B B 0.9994801878929138
, O O 0.9999632835388184
given O O 0.9999415874481201
intraperitoneally O O 0.9999878406524658
to O O 0.9999440908432007
rats O O 0.9996005892753601
, O O 0.9999716281890869
reproduces O O 0.9998422861099243
the O O 0.9999794960021973
neuropathological O O 0.9999921321868896
sequelae O O 0.9999932050704956
of O O 0.9999595880508423
temporal O O 0.9985176920890808
lobe O O 0.9997734427452087
epilepsy O O 0.9982624650001526
and O O 0.9999668598175049
provides O O 0.999970555305481
a O O 0.9999914169311523
relevant O O 0.9999912977218628
animal O O 0.9999926090240479
model O O 0.9999966621398926
for O O 0.9999786615371704
studying O O 0.9999316930770874
mechanisms O O 0.9999508857727051
of O O 0.9999308586120605
buildup O O 0.9999233484268188
of O O 0.9997484087944031
convulsive O O 0.9916845560073853
activity O O 0.9999146461486816
and O O 0.9997677206993103
pathways O O 0.9997510313987732
operative O O 0.9991365075111389
in O O 0.9999715089797974
the O O 0.9999656677246094
generalization O O 0.999832034111023
and O O 0.9999302625656128
propagation O O 0.9999895095825195
of O O 0.9999467134475708
seizures O O 0.9999468326568604
within O O 0.9999421834945679
the O O 0.9999663829803467
forebrain O O 0.999847412109375
. O O 0.9999321699142456

In O O 0.9999834299087524
the O O 0.9999946355819702
present O O 0.9999861717224121
study O O 0.999976634979248
, O O 0.9999558925628662
the O O 0.9999639987945557
effects O O 0.9999611377716064
of O O 0.9999440908432007
manipulating O O 0.999958872795105
the O O 0.9998817443847656
activity O O 0.9991428852081299
of O O 0.9997290968894958
the O O 0.9996811151504517
gamma B B 0.9145603179931641
- I I 0.9588981866836548
aminobutyric I I 0.9997871518135071
acid I I 0.9998021721839905
( O O 0.951962947845459
GABA B B 0.9978050589561462
) O O 0.9986100196838379
- O O 0.9997628331184387
mediated O O 0.999813973903656
synaptic O O 0.9963923096656799
inhibition O O 0.9995293617248535
within O O 0.999835729598999
the O O 0.9999549388885498
substantia O O 0.998817503452301
nigra O O 0.9998975992202759
on O O 0.9998080134391785
seizures O O 0.9999867677688599
produced O O 0.9999926090240479
by O O 0.9998741149902344
pilocarpine B B 0.999896764755249
in O O 0.9998219609260559
rats O O 0.999863862991333
, O O 0.9999572038650513
were O O 0.9999806880950928
investigated O O 0.9999796152114868
. O O 0.9999507665634155

In O O 0.999871015548706
animals O O 0.9999929666519165
pretreated O O 0.9999645948410034
with O O 0.999932050704956
microinjections O O 0.9888659119606018
of O O 0.9990208148956299
isoniazid B B 0.999836802482605
, O O 0.9988045692443848
150 O O 0.9997972846031189
micrograms O O 0.9998350143432617
, O O 0.9995172023773193
an O O 0.9920991659164429
inhibitor O O 0.9267838597297668
of O O 0.9879624247550964
activity O O 0.9692419767379761
of O O 0.9893791079521179
the O O 0.9974855184555054
GABA B B 0.9506930112838745
- O O 0.8402266502380371
synthesizing O O 0.9702621698379517
enzyme O O 0.9894713163375854
, O O 0.9959961175918579
L B B 0.5149742364883423
- I I 0.6696715354919434
glutamic I I 0.9846737384796143
acid I I 0.9982137680053711
decarboxylase O O 0.7715638875961304
, O O 0.9997543692588806
into O O 0.9998088479042053
the O O 0.9999545812606812
substantia O O 0.9976204037666321
nigra O O 0.9991220831871033
pars O O 0.9998801946640015
reticulata O O 0.9990350008010864
( O O 0.9997451901435852
SNR O O 0.8227511048316956
) O O 0.9999097585678101
, O O 0.999962568283081
bilaterally O O 0.999927282333374
, O O 0.9998946189880371
non O O 0.9891669750213623
- O O 0.9997308850288391
convulsant O O 0.9684810638427734
doses O O 0.9997742772102356
of O O 0.9977645874023438
pilocarpine B B 0.999711811542511
, O O 0.9991437196731567
100 O O 0.9926764965057373
and O O 0.9995335340499878
200 O O 0.9959522485733032
mg O O 0.9999116659164429
/ O O 0.9999537467956543
kg O O 0.9999731779098511
, O O 0.999977707862854
resulted O O 0.9999805688858032
in O O 0.9999898672103882
severe O O 0.9999431371688843
motor O O 0.9992187023162842
limbic O O 0.9996095299720764
seizures O O 0.999988317489624
and O O 0.9999749660491943
status O O 0.9999945163726807
epilepticus O O 0.9999940395355225
. O O 0.9999775886535645

Electroencephalographic O O 0.9998853206634521
and O O 0.999964714050293
behavioral O O 0.9999912977218628
monitoring O O 0.9999927282333374
revealed O O 0.9999551773071289
a O O 0.9999709129333496
profound O O 0.9999713897705078
reduction O O 0.9999874830245972
of O O 0.9999653100967407
the O O 0.9999712705612183
threshold O O 0.9999927282333374
for O O 0.9999487400054932
pilocarpine B B 0.9998921155929565
- O O 0.9998045563697815
induced O O 0.9999442100524902
convulsions O O 0.9999605417251587
. O O 0.9999786615371704

Morphological O O 0.9998689889907837
analysis O O 0.9999943971633911
of O O 0.9999581575393677
frontal O O 0.9997034668922424
forebrain O O 0.9999289512634277
sections O O 0.9999881982803345
with O O 0.9999886751174927
light O O 0.9999758005142212
microscopy O O 0.9999836683273315
revealed O O 0.9998890161514282
seizure O O 0.9972777962684631
- O O 0.999906063079834
related O O 0.9999619722366333
damage O O 0.999985933303833
to O O 0.9998631477355957
the O O 0.999909520149231
hippocampal O O 0.9970274567604065
formation O O 0.9999834299087524
, O O 0.9997947812080383
thalamus O O 0.9993410706520081
, O O 0.9998100399971008
amygdala O O 0.9994468092918396
, O O 0.999771773815155
olfactory O O 0.9962837100028992
cortex O O 0.9999730587005615
, O O 0.9998559951782227
substantia O O 0.9952358603477478
nigra O O 0.9991827607154846
and O O 0.9997408986091614
neocortex O O 0.9954953193664551
, O O 0.9999738931655884
which O O 0.9999641180038452
is O O 0.9999693632125854
typically O O 0.9999650716781616
observed O O 0.999984860420227
with O O 0.9998321533203125
pilocarpine B B 0.9999099969863892
in O O 0.9999003410339355
doses O O 0.9999579191207886
exceeding O O 0.999967098236084
350 O O 0.9994602799415588
mg O O 0.9999500513076782
/ O O 0.9999443292617798
kg O O 0.9999912977218628
. O O 0.9999576807022095

Bilateral O O 0.9996463060379028
intrastriatal O O 0.9999449253082275
injections O O 0.9999222755432129
of O O 0.9986124038696289
isoniazid B B 0.9997232556343079
did O O 0.999906063079834
not O O 0.9998693466186523
augment O O 0.9967336654663086
seizures O O 0.9999865293502808
produced O O 0.9999927282333374
by O O 0.9998700618743896
pilocarpine B B 0.9998434782028198
, O O 0.9986673593521118
200 O O 0.9983832836151123
mg O O 0.9996163845062256
/ O O 0.999763548374176
kg O O 0.9999828338623047
. O O 0.9996869564056396

Application O O 0.9999513626098633
of O O 0.9998794794082642
an O O 0.9996538162231445
irreversible O O 0.9841299057006836
inhibitor O O 0.907612144947052
of O O 0.9293924570083618
GABA B B 0.9916723370552063
transaminase O O 0.9411971569061279
, O O 0.9989703893661499
gamma B B 0.9741417169570923
- I I 0.975540816783905
vinyl I I 0.9994767308235168
- I I 0.9798514246940613
GABA I I 0.9944294691085815
( O O 0.7236964702606201
D B B 0.9831615686416626
, I I 0.8686222434043884
L I I 0.912743330001831
- I I 0.9780601859092712
4 I I 0.9976226687431335
- I I 0.9866878390312195
amino I I 0.9982763528823853
- I I 0.9760878086090088
hex I I 0.9996805191040039
- I I 0.9890698194503784
5 I I 0.9846602082252502
- I I 0.9930163621902466
enoic I I 0.9998914003372192
acid I I 0.9999682903289795
) O O 0.9979910850524902
, O O 0.9999618530273438
5 O O 0.9998631477355957
micrograms O O 0.9999226331710815
, O O 0.9999915361404419
into O O 0.9999066591262817
the O O 0.9999313354492188
SNR O O 0.7475770115852356
, O O 0.9999747276306152
bilaterally O O 0.9999542236328125
, O O 0.9999896287918091
suppressed O O 0.9999719858169556
the O O 0.999994158744812
appearance O O 0.9999926090240479
of O O 0.9999730587005615
electrographic O O 0.9998112320899963
and O O 0.9999035596847534
behavioral O O 0.999958872795105
seizures O O 0.9999905824661255
produced O O 0.9999935626983643
by O O 0.999815046787262
pilocarpine B B 0.9998923540115356
, O O 0.9996682405471802
380 O O 0.9985809326171875
mg O O 0.9998227953910828
/ O O 0.9997586607933044
kg O O 0.9999873638153076
. O O 0.9993077516555786

This O O 0.9998466968536377
treatment O O 0.9999160766601562
was O O 0.9999724626541138
also O O 0.999935507774353
sufficient O O 0.9999368190765381
to O O 0.9999510049819946
protect O O 0.999967098236084
animals O O 0.9999933242797852
from O O 0.999942421913147
the O O 0.9999912977218628
occurrence O O 0.9999949932098389
of O O 0.9999706745147705
brain O O 0.9999790191650391
damage O O 0.999994158744812
. O O 0.9999505281448364

Microinjections O O 0.998767614364624
of O O 0.999858021736145
gamma B B 0.881300151348114
- I I 0.9595719575881958
vinyl I I 0.9984858632087708
- I I 0.9292169213294983
GABA I I 0.9984090924263
, O O 0.9868113398551941
5 O O 0.9998052716255188
micrograms O O 0.9993616938591003
, O O 0.9999890327453613
into O O 0.9999300241470337
the O O 0.9999812841415405
dorsal O O 0.9994778037071228
striatum O O 0.9991344809532166
, O O 0.9999781847000122
bilaterally O O 0.9999370574951172
, O O 0.9999874830245972
failed O O 0.999984622001648
to O O 0.9999855756759644
prevent O O 0.999971866607666
the O O 0.999990701675415
development O O 0.9999974966049194
of O O 0.9999841451644897
convulsions O O 0.9999191761016846
produced O O 0.9999932050704956
by O O 0.9999151229858398
pilocarpine B B 0.999868631362915
, O O 0.9994237422943115
380 O O 0.9985879063606262
mg O O 0.9998714923858643
/ O O 0.9996596574783325
kg O O 0.9999831914901733
. O O 0.9998555183410645

The O O 0.9999746084213257
results O O 0.9999876022338867
demonstrate O O 0.9999737739562988
that O O 0.9999033212661743
the O O 0.9999161958694458
threshold O O 0.9999871253967285
for O O 0.9999533891677856
pilocarpine B B 0.9998972415924072
- O O 0.9998418092727661
induced O O 0.9999450445175171
seizures O O 0.9999850988388062
in O O 0.9999663829803467
rats O O 0.9999310970306396
is O O 0.9999188184738159
subjected O O 0.9998546838760376
to O O 0.9996592998504639
the O O 0.9998723268508911
regulation O O 0.9998989105224609
of O O 0.9997839331626892
the O O 0.9997517466545105
GABA B B 0.9817600846290588
- O O 0.9981905817985535
mediated O O 0.9997257590293884
synaptic O O 0.9948233366012573
inhibition O O 0.9996583461761475
within O O 0.9998531341552734
the O O 0.9999642372131348
substantia O O 0.9993945360183716
nigra O O 0.9999244213104248
. O O 0.999946117401123

Human O O 0.5556082725524902
and O O 0.9985585808753967
canine O O 0.9712051749229431
ventricular O O 0.8123593926429749
vasoactive O O 0.4635612964630127
intestinal O O 0.6739274859428406
polypeptide O O 0.5712812542915344
: O O 0.9986829161643982
decrease O O 0.9994505047798157
with O O 0.9999817609786987
heart O O 0.9999438524246216
failure O O 0.9999858140945435
. O O 0.9999226331710815

Vasoactive O O 0.7721763253211975
intestinal O O 0.7473090887069702
polypeptide O O 0.7933891415596008
( O O 0.9553775787353516
VIP O B 0.9179204702377319
) O O 0.9914596080780029
is O O 0.9997674822807312
a O O 0.998042106628418
systemic O O 0.9909074306488037
and O O 0.9980199337005615
coronary O O 0.9238429665565491
vasodilator O O 0.6617493629455566
that O O 0.9995585083961487
may O O 0.9999285936355591
have O O 0.9999160766601562
positive O O 0.9988935589790344
inotropic O O 0.9997993111610413
properties O O 0.9999563694000244
. O O 0.9999189376831055

Myocardial O O 0.9997665286064148
levels O O 0.999724805355072
of O O 0.9951501488685608
VIP O O 0.7445120811462402
were O O 0.9998883008956909
assayed O O 0.9997231364250183
before O O 0.9999181032180786
and O O 0.9999611377716064
after O O 0.9999558925628662
the O O 0.9999936819076538
development O O 0.9999973773956299
of O O 0.9999889135360718
heart O O 0.9999911785125732
failure O O 0.9999949932098389
in O O 0.9999600648880005
two O O 0.9999778270721436
canine O O 0.9999531507492065
models O O 0.9999905824661255
. O O 0.999966025352478

In O O 0.9999136924743652
the O O 0.9999916553497314
first O O 0.9999949932098389
, O O 0.9999474287033081
cobalt B O 0.9456983208656311
cardiomyopathy O O 0.9999788999557495
was O O 0.999955415725708
induced O O 0.9999855756759644
in O O 0.9999735355377197
eight O O 0.9999685287475586
dogs O O 0.9999973773956299
; O O 0.9999309778213501
VIP O O 0.5498473048210144
( O O 0.9992938041687012
by O O 0.9999831914901733
radioimmunoassay O O 0.9867260456085205
) O O 0.9999386072158813
decreased O O 0.9999607801437378
from O O 0.9999641180038452
35 O O 0.9998459815979004
+ O O 0.9999792575836182
/ O O 0.9999123811721802
- O O 0.9997522234916687
11 O O 0.9981570839881897
pg O O 0.9976221919059753
/ O O 0.9999079704284668
mg O O 0.9999055862426758
protein O O 0.9998770952224731
( O O 0.9999399185180664
mean O O 0.9998489618301392
+ O O 0.9999916553497314
/ O O 0.9999617338180542
- O O 0.9999395608901978
SD O O 0.9987323880195618
) O O 0.9999587535858154
to O O 0.9999542236328125
5 O O 0.9998231530189514
+ O O 0.9999854564666748
/ O O 0.9999328851699829
- O O 0.9998921155929565
4 O O 0.9999097585678101
pg O O 0.997867226600647
/ O O 0.9999459981918335
mg O O 0.9998830556869507
protein O O 0.9999346733093262
( O O 0.9999097585678101
P O O 0.997955322265625
less O O 0.999993085861206
than O O 0.9999948740005493
0 O O 0.9999945163726807
. O O 0.9999959468841553
05 O O 0.9999954700469971
) O O 0.999955415725708
. O O 0.9999723434448242

In O O 0.9999486207962036
six O O 0.9999856948852539
dogs O O 0.9999804496765137
with O O 0.9999679327011108
doxorubicin B B 0.9996981620788574
- O O 0.9997809529304504
induced O O 0.9999736547470093
heart O O 0.9999957084655762
failure O O 0.9999942779541016
, O O 0.9998764991760254
VIP O B 0.8713061213493347
decreased O O 0.9833124279975891
from O O 0.9999599456787109
31 O O 0.9998064637184143
+ O O 0.9999704360961914
/ O O 0.9997114539146423
- O O 0.9994186162948608
7 O O 0.9936237335205078
to O O 0.9999525547027588
11 O O 0.9999134540557861
+ O O 0.9999817609786987
/ O O 0.9998615980148315
- O O 0.9998953342437744
4 O O 0.9999251365661621
pg O O 0.9970213770866394
/ O O 0.9999402761459351
mg O O 0.999950647354126
protein O O 0.999840497970581
( O O 0.9999370574951172
P O O 0.9989972710609436
less O O 0.9999899864196777
than O O 0.9999953508377075
0 O O 0.9999946355819702
. O O 0.9999969005584717
05 O O 0.9999910593032837
) O O 0.9999703168869019
. O O 0.9999707937240601

In O O 0.9999685287475586
addition O O 0.9999830722808838
, O O 0.9998611211776733
VIP O O 0.9375014305114746
content O O 0.9996211528778076
of O O 0.9995642304420471
left O O 0.9987353682518005
ventricular O O 0.9999425411224365
muscle O O 0.9956426620483398
of O O 0.9996492862701416
resected O O 0.9999840259552002
failing O O 0.9999747276306152
hearts O O 0.9999649524688721
in O O 0.9999330043792725
10 O O 0.9999480247497559
patients O O 0.9999926090240479
receiving O O 0.9999533891677856
a O O 0.9999716281890869
heart O O 0.9998975992202759
transplant O O 0.9999688863754272
was O O 0.9999727010726929
compared O O 0.9999620914459229
with O O 0.9999399185180664
the O O 0.9998925924301147
papillary O O 0.9884448051452637
muscles O O 0.9998950958251953
in O O 0.9999514818191528
14 O O 0.9999890327453613
patients O O 0.999995231628418
( O O 0.9999685287475586
five O O 0.9999948740005493
with O O 0.9999856948852539
rheumatic O O 0.999895453453064
disease O O 0.9999915361404419
, O O 0.9999657869338989
nine O O 0.9999147653579712
with O O 0.9999743700027466
myxomatous O O 0.9999233484268188
degeneration O O 0.9999511241912842
) O O 0.9999736547470093
receiving O O 0.9994076490402222
mitral O O 0.9991760849952698
valve O O 0.9979081153869629
prostheses O O 0.9993995428085327
. O O 0.999964714050293

The O O 0.9999760389328003
lowest O O 0.9999094009399414
myocardial O O 0.9999861717224121
VIP O O 0.7497579455375671
concentration O O 0.999643087387085
was O O 0.9999319314956665
found O O 0.9999184608459473
in O O 0.999840259552002
the O O 0.9999368190765381
hearts O O 0.9998214840888977
of O O 0.9999637603759766
patients O O 0.9999916553497314
with O O 0.999983549118042
coronary O O 0.9998488426208496
disease O O 0.9999959468841553
( O O 0.9999561309814453
one O O 0.9999845027923584
patient O O 0.9999914169311523
receiving O O 0.9998999834060669
a O O 0.999177873134613
transplant O O 0.9991664886474609
and O O 0.9999091625213623
three O O 0.9992560744285583
receiving O O 0.9997292160987854
mitral O O 0.9997240900993347
prostheses O O 0.9990573525428772
) O O 0.9999630451202393
( O O 0.9998801946640015
6 O O 0.9963902831077576
. O O 0.9999585151672363
3 O O 0.9998437166213989
+ O O 0.9999749660491943
/ O O 0.9998098015785217
- O O 0.9998946189880371
1 O O 0.9999872446060181
. O O 0.9999887943267822
9 O O 0.9999626874923706
pg O O 0.9938411712646484
/ O O 0.9999198913574219
mg O O 0.9999593496322632
protein O O 0.9997839331626892
) O O 0.9999502897262573
. O O 0.9999626874923706

The O O 0.999981164932251
other O O 0.9999902248382568
patients O O 0.9999936819076538
undergoing O O 0.9999822378158569
transplantation O O 0.9998291730880737
had O O 0.9999628067016602
an O O 0.9999889135360718
average O O 0.9999674558639526
ejection O O 0.9999594688415527
fraction O O 0.9999967813491821
of O O 0.9999710321426392
17 O O 0.9999984502792358
% O O 0.9999978542327881
+ O O 0.9999897480010986
/ O O 0.9997120499610901
- O O 0.9999687671661377
6 O O 0.999990701675415
% O O 0.999997615814209
and O O 0.999972939491272
a O O 0.9999703168869019
VIP O O 0.7441887259483337
level O O 0.9992098808288574
of O O 0.9998237490653992
8 O O 0.9540194272994995
. O O 0.9999756813049316
8 O O 0.9999047517776489
+ O O 0.9999841451644897
/ O O 0.9994515776634216
- O O 0.9998146891593933
3 O O 0.9999604225158691
. O O 0.9999922513961792
9 O O 0.9999523162841797
pg O O 0.9976527094841003
/ O O 0.9999449253082275
mg O O 0.9999713897705078
protein O O 0.9995779395103455
. O O 0.9999587535858154

The O O 0.9999728202819824
hearts O O 0.9999836683273315
without O O 0.9999678134918213
coronary O O 0.9983071088790894
artery O O 0.9991670846939087
disease O O 0.9999788999557495
( O O 0.9999548196792603
average O O 0.9999507665634155
ejection O O 0.9999748468399048
fraction O O 0.9999970197677612
of O O 0.999957799911499
this O O 0.9999452829360962
group O O 0.9994163513183594
62 O O 0.9999979734420776
% O O 0.9999963045120239
+ O O 0.9999899864196777
/ O O 0.9997492432594299
- O O 0.9999629259109497
10 O O 0.9999936819076538
% O O 0.999993085861206
) O O 0.999966025352478
had O O 0.9999532699584961
a O O 0.9999339580535889
VIP O O 0.8313242793083191
concentration O O 0.9969323873519897
of O O 0.9997699856758118
14 O O 0.9979566335678101
. O O 0.9999839067459106
1 O O 0.9999713897705078
+ O O 0.9999887943267822
/ O O 0.9993101358413696
- O O 0.9995766282081604
7 O O 0.9999593496322632
. O O 0.9999948740005493
9 O O 0.9999707937240601
pg O O 0.9982445240020752
/ O O 0.9999529123306274
mg O O 0.999970555305481
protein O O 0.9991143345832825
, O O 0.9999374151229858
and O O 0.9999704360961914
this O O 0.9999604225158691
was O O 0.9999691247940063
greater O O 0.9999581575393677
than O O 0.9999862909317017
in O O 0.9999028444290161
hearts O O 0.9999395608901978
of O O 0.9999548196792603
the O O 0.9999920129776001
patients O O 0.9999945163726807
with O O 0.9999606609344482
coronary O O 0.9992688298225403
disease O O 0.999992847442627
and O O 0.9999288320541382
the O O 0.999988317489624
hearts O O 0.9999434947967529
of O O 0.9999735355377197
patients O O 0.9999932050704956
receiving O O 0.9999847412109375
a O O 0.9998815059661865
transplant O O 0.9999808073043823
( O O 0.9999569654464722
P O O 0.9997182488441467
less O O 0.9999891519546509
than O O 0.9999953508377075
0 O O 0.9999957084655762
. O O 0.9999966621398926
05 O O 0.999996542930603
) O O 0.9999685287475586
. O O 0.9999666213989258

Myocardial O O 0.9655327200889587
catecholamines B B 0.92982017993927
were O O 0.9998859167098999
also O O 0.9999785423278809
determined O O 0.9999511241912842
in O O 0.9999127388000488
14 O O 0.9983119964599609
subjects O O 0.9999837875366211
; O O 0.999977707862854
a O O 0.9999872446060181
weak O O 0.9999845027923584
correlation O O 0.9999915361404419
( O O 0.9999711513519287
r O O 0.9996808767318726
= O O 0.9999510049819946
0 O O 0.9999825954437256
. O O 0.9999924898147583
57 O O 0.9999970197677612
, O O 0.9999605417251587
P O O 0.9999053478240967
less O O 0.9999926090240479
than O O 0.9999960660934448
0 O O 0.9999932050704956
. O O 0.9999942779541016
05 O O 0.9999940395355225
) O O 0.9999873638153076
between O O 0.999795138835907
the O O 0.9998987913131714
tissue O O 0.999871015548706
concentrations O O 0.9982495903968811
of O O 0.9965094923973083
VIP O B 0.9843035340309143
and O O 0.9837656617164612
norepinephrine B B 0.9971550703048706
was O O 0.9999390840530396
noted O O 0.9999912977218628
. O O 0.999977707862854
( O O 0.9998488426208496
ABSTRACT O O 0.9999169111251831
TRUNCATED O O 0.9999719858169556
AT O O 0.9999634027481079
250 O O 0.9968231916427612
WORDS O O 0.9999955892562866
) O O 0.9999133348464966

Non O O 0.999927282333374
- O O 0.9999797344207764
invasive O O 0.9999960660934448
detection O O 0.9999982118606567
of O O 0.9999954700469971
coronary O O 0.9999257326126099
artery O O 0.9999241828918457
disease O O 0.9999971389770508
by O O 0.9999932050704956
body O O 0.9999721050262451
surface O O 0.999992847442627
electrocardiographic O O 0.999915599822998
mapping O O 0.9999964237213135
after O O 0.9999325275421143
dipyridamole B B 0.9996194839477539
infusion O O 0.9997044205665588
. O O 0.99997878074646

Electrocardiographic O O 0.9999356269836426
changes O O 0.9999979734420776
after O O 0.999942421913147
dipyridamole B B 0.9998306035995483
infusion O O 0.9997032284736633
( O O 0.9999436140060425
0 O O 0.999790608882904
. O O 0.9999939203262329
568 O O 0.999974250793457
mg O O 0.9999561309814453
/ O O 0.9999743700027466
kg O O 0.9999961853027344
/ O O 0.9999369382858276
4 O O 0.9998831748962402
min O O 0.9998459815979004
) O O 0.9999732971191406
were O O 0.9999856948852539
studied O O 0.999990701675415
in O O 0.9999797344207764
41 O O 0.9999788999557495
patients O O 0.9999963045120239
with O O 0.9999802112579346
coronary O O 0.9997705817222595
artery O O 0.99980229139328
disease O O 0.9999936819076538
and O O 0.9999756813049316
compared O O 0.9999858140945435
with O O 0.999987006187439
those O O 0.9999914169311523
after O O 0.999913215637207
submaximal O O 0.999626874923706
treadmill O O 0.9999696016311646
exercise O O 0.9998911619186401
by O O 0.999985933303833
use O O 0.9999953508377075
of O O 0.9999939203262329
the O O 0.9999914169311523
body O O 0.9999450445175171
surface O O 0.9998328685760498
mapping O O 0.9999932050704956
technique O O 0.9999896287918091
. O O 0.9999775886535645

Patients O O 0.9999301433563232
were O O 0.9999833106994629
divided O O 0.9999918937683105
into O O 0.9999707937240601
three O O 0.9999560117721558
groups O O 0.9999915361404419
; O O 0.99998939037323
19 O O 0.9999699592590332
patients O O 0.9999920129776001
without O O 0.9999771118164062
myocardial O O 0.9999970197677612
infarction O O 0.99996018409729
( O O 0.9997574687004089
non O O 0.9538809061050415
- O O 0.9959010481834412
MI O O 0.992258608341217
group O O 0.9999629259109497
) O O 0.9998974800109863
, O O 0.9999661445617676
14 O O 0.9999760389328003
with O O 0.9999582767486572
anterior O O 0.9988613128662109
infarction O O 0.9999401569366455
( O O 0.999675989151001
ANT O O 0.9545407295227051
- O O 0.9933184385299683
MI O O 0.9923805594444275
) O O 0.9998974800109863
and O O 0.9998931884765625
eight O O 0.9997327923774719
with O O 0.9999538660049438
inferior O O 0.9998805522918701
infarction O O 0.9998600482940674
( O O 0.9994151592254639
INF O O 0.9454489350318909
- O O 0.9957724213600159
MI O O 0.9908047914505005
) O O 0.9999407529830933
. O O 0.9999663829803467

Eighty O O 0.7150530219078064
- O O 0.9996927976608276
seven O O 0.9999572038650513
unipolar O O 0.9945958256721497
electrocardiograms O O 0.9998992681503296
( O O 0.9999383687973022
ECGs O O 0.9997019171714783
) O O 0.9999442100524902
distributed O O 0.999942421913147
over O O 0.9999572038650513
the O O 0.9999845027923584
entire O O 0.9999576807022095
thoracic O O 0.9999103546142578
surface O O 0.9999912977218628
were O O 0.9999699592590332
simultaneously O O 0.9999761581420898
recorded O O 0.9999939203262329
. O O 0.999970555305481

After O O 0.9987584352493286
dipyridamole B B 0.999447762966156
, O O 0.9998308420181274
ischemic O O 0.999958872795105
ST O O 0.9857182502746582
- O O 0.999776303768158
segment O O 0.9999798536300659
depression O O 0.9999945163726807
( O O 0.9999713897705078
0 O O 0.999982476234436
. O O 0.9999929666519165
05 O O 0.99998939037323
mV O O 0.9999686479568481
or O O 0.9999840259552002
more O O 0.9999338388442993
) O O 0.9999597072601318
was O O 0.9999676942825317
observed O O 0.9999879598617554
in O O 0.9998642206192017
84 O O 0.9999529123306274
% O O 0.9999901056289673
of O O 0.9999667406082153
the O O 0.9999375343322754
non O O 0.8612388968467712
- O O 0.9896112680435181
MI O O 0.9725537896156311
group O O 0.9999440908432007
, O O 0.999942421913147
29 O O 0.9999865293502808
% O O 0.9999914169311523
of O O 0.9999667406082153
the O O 0.9999047517776489
ANT O O 0.8788617253303528
- O O 0.9882760643959045
MI O O 0.9811995029449463
group O O 0.9999516010284424
, O O 0.9999440908432007
63 O O 0.9999945163726807
% O O 0.9999915361404419
of O O 0.9999639987945557
the O O 0.9999041557312012
INF O O 0.9160479307174683
- O O 0.9961259961128235
MI O O 0.9854716658592224
group O O 0.9999418258666992
and O O 0.9998979568481445
61 O O 0.9999921321868896
% O O 0.9999896287918091
of O O 0.999968409538269
the O O 0.9999830722808838
total O O 0.9991468191146851
population O O 0.9999908208847046
. O O 0.9999697208404541

Exercise O O 0.5696475505828857
- O O 0.9996778964996338
induced O O 0.9999358654022217
ST O O 0.9980106949806213
depression O O 0.999968409538269
was O O 0.9999573230743408
observed O O 0.9999799728393555
in O O 0.9998906850814819
84 O O 0.9999682903289795
% O O 0.999990701675415
of O O 0.9999655485153198
the O O 0.9999511241912842
non O O 0.8860822319984436
- O O 0.9927181005477905
MI O O 0.964646577835083
group O O 0.9999551773071289
, O O 0.9999500513076782
43 O O 0.9999915361404419
% O O 0.9999923706054688
of O O 0.9999672174453735
the O O 0.9999076128005981
ANT O O 0.8734004497528076
- O O 0.9897054433822632
MI O O 0.9825807213783264
group O O 0.9999523162841797
, O O 0.999953031539917
38 O O 0.9999860525131226
% O O 0.9999903440475464
of O O 0.9999624490737915
the O O 0.9998989105224609
INF O O 0.8927621841430664
- O O 0.9963405132293701
MI O O 0.9832767248153687
group O O 0.9999334812164307
and O O 0.999915599822998
61 O O 0.9999905824661255
% O O 0.9999905824661255
of O O 0.9999562501907349
the O O 0.9999758005142212
total O O 0.9995549321174622
. O O 0.9999713897705078

For O O 0.999913215637207
individual O O 0.9998699426651001
patients O O 0.9999926090240479
, O O 0.9999752044677734
there O O 0.9999849796295166
were O O 0.9999873638153076
no O O 0.9999927282333374
obvious O O 0.9999916553497314
differences O O 0.9999966621398926
between O O 0.9999568462371826
the O O 0.9999892711639404
body O O 0.9999688863754272
surface O O 0.9999876022338867
distribution O O 0.9999865293502808
of O O 0.9999591112136841
ST O O 0.9859711527824402
depression O O 0.9998524188995361
in O O 0.9999122619628906
both O O 0.9999362230300903
tests O O 0.9999856948852539
. O O 0.9999736547470093

The O O 0.9999884366989136
increase O O 0.9999855756759644
in O O 0.9999628067016602
pressure O O 0.9948510527610779
rate O O 0.9982907176017761
product O O 0.9999568462371826
after O O 0.9994122982025146
dipyridamole B B 0.9994489550590515
was O O 0.9999418258666992
significantly O O 0.9999911785125732
less O O 0.9999847412109375
than O O 0.9999862909317017
that O O 0.9999861717224121
during O O 0.9999328851699829
the O O 0.999993085861206
treadmill O O 0.9999825954437256
exercise O O 0.9999791383743286
. O O 0.9999669790267944

The O O 0.9999849796295166
data O O 0.9999929666519165
suggest O O 0.9999600648880005
that O O 0.9999430179595947
the O O 0.999951958656311
dipyridamole B B 0.9996154308319092
- O O 0.9997308850288391
induced O O 0.999915599822998
myocardial O O 0.9999990463256836
ischemia O O 0.9999964237213135
is O O 0.9998692274093628
caused O O 0.9999828338623047
by O O 0.9999561309814453
the O O 0.9999781847000122
inhomogenous O O 0.9999539852142334
distribution O O 0.9999856948852539
of O O 0.9999575614929199
myocardial O O 0.9999949932098389
blood O O 0.998634397983551
flow O O 0.999969482421875
. O O 0.999962329864502

We O O 0.9999771118164062
conclude O O 0.9999728202819824
that O O 0.9999707937240601
the O O 0.99996018409729
dipyridamole B B 0.9977774024009705
ECG O O 0.666256844997406
test O O 0.9992396831512451
is O O 0.9999738931655884
as O O 0.9999755620956421
useful O O 0.9999868869781494
as O O 0.9999890327453613
the O O 0.9999767541885376
exercise O O 0.9988792538642883
ECG O O 0.9843659400939941
test O O 0.9999312162399292
for O O 0.9999724626541138
the O O 0.9999960660934448
assessment O O 0.9999973773956299
of O O 0.9999879598617554
coronary O O 0.999929666519165
artery O O 0.9999487400054932
disease O O 0.9999935626983643
. O O 0.9999657869338989

Bradycardia O O 0.9999665021896362
after O O 0.9998825788497925
high O O 0.9988911747932434
- O O 0.9999674558639526
dose O O 0.99506676197052
intravenous O O 0.9991082549095154
methylprednisolone B B 0.9990031123161316
therapy O O 0.9988685846328735
. O O 0.9999598264694214

In O O 0.9999760389328003
5 O O 0.9999488592147827
consecutive O O 0.9999837875366211
patients O O 0.9999973773956299
with O O 0.9999856948852539
rheumatoid O O 0.999924898147583
arthritis O O 0.9999291896820068
who O O 0.9999774694442749
received O O 0.9999535083770752
intravenous O O 0.9999716281890869
high O O 0.9863859415054321
- O O 0.9999573230743408
dose O O 0.9853999018669128
methylprednisolone B B 0.999160647392273
( O O 0.961076021194458
MP B B 0.9978329539299011
) O O 0.7357263565063477
therapy O O 0.9996408224105835
( O O 0.9999114274978638
1 O O 0.9999361038208008
g O O 0.9973379969596863
daily O O 0.9999359846115112
for O O 0.9999809265136719
2 O O 0.9999704360961914
or O O 0.9999879598617554
3 O O 0.9999693632125854
consecutive O O 0.9999862909317017
days O O 0.9999909400939941
) O O 0.9999754428863525
, O O 0.9999891519546509
a O O 0.9999957084655762
decline O O 0.9999978542327881
in O O 0.999992847442627
pulse O O 0.9999806880950928
rate O O 0.9999923706054688
was O O 0.9999884366989136
observed O O 0.9999954700469971
, O O 0.9999948740005493
most O O 0.9999972581863403
pronounced O O 0.9999972581863403
on O O 0.9999865293502808
day O O 0.9999951124191284
4 O O 0.999988317489624
. O O 0.9999881982803345

In O O 0.9999715089797974
one O O 0.9999940395355225
of O O 0.9999781847000122
the O O 0.9999896287918091
5 O O 0.99988853931427
patients O O 0.9999924898147583
the O O 0.999988317489624
bradycardia O O 0.9999788999557495
was O O 0.9999595880508423
associated O O 0.9999914169311523
with O O 0.9999898672103882
complaints O O 0.9999972581863403
of O O 0.9999886751174927
substernal O O 0.9903276562690735
pressure O O 0.9998568296432495
. O O 0.9999676942825317

Reversal O O 0.999704897403717
to O O 0.9999843835830688
normal O O 0.9999867677688599
heart O O 0.9999918937683105
rate O O 0.9999814033508301
was O O 0.9999885559082031
found O O 0.9999887943267822
on O O 0.9999817609786987
day O O 0.9999924898147583
7 O O 0.9999873638153076
. O O 0.9999836683273315

Electrocardiographic O O 0.9997621178627014
registrations O O 0.9999696016311646
showed O O 0.9999505281448364
sinus O O 0.9999322891235352
bradycardia O O 0.999971866607666
in O O 0.9999274015426636
all O O 0.9999443292617798
cases O O 0.9999833106994629
. O O 0.9999687671661377

No O O 0.999941349029541
significant O O 0.9999871253967285
changes O O 0.9999960660934448
in O O 0.9999862909317017
plasma O O 0.9998267292976379
concentrations O O 0.9998512268066406
of O O 0.9993442893028259
electrolytes O O 0.9113874435424805
were O O 0.9999632835388184
found O O 0.9999849796295166
. O O 0.999945878982544

Careful O O 0.9999662637710571
observation O O 0.9999924898147583
of O O 0.9999860525131226
patients O O 0.9999854564666748
receiving O O 0.999702513217926
high O O 0.9987584352493286
- O O 0.9999617338180542
dose O O 0.9899515509605408
MP B B 0.9945616126060486
is O O 0.9999182224273682
recommended O O 0.9999853372573853
. O O 0.9999802112579346

High O O 0.998134195804596
- O O 0.9998724460601807
dose O O 0.9911501407623291
MP B B 0.9990864992141724
may O O 0.9998657703399658
be O O 0.9999840259552002
contraindicated O O 0.9998148083686829
in O O 0.9999866485595703
patients O O 0.9999939203262329
with O O 0.999991774559021
known O O 0.9999909400939941
heart O O 0.9999939203262329
disease O O 0.9999984502792358
. O O 0.9999583959579468

Two O O 0.9999480247497559
cases O O 0.9999910593032837
of O O 0.9999655485153198
downbeat O O 0.9981688261032104
nystagmus O O 0.9999755620956421
and O O 0.9998051524162292
oscillopsia O O 0.9987810254096985
associated O O 0.9999357461929321
with O O 0.9993701577186584
carbamazepine B B 0.9994781613349915
. O O 0.9998811483383179

Downbeat O O 0.9980549812316895
nystagmus O O 0.9999368190765381
is O O 0.9999510049819946
often O O 0.9999536275863647
associated O O 0.9999712705612183
with O O 0.9999344348907471
structural O O 0.9998596906661987
lesions O O 0.9999974966049194
at O O 0.9999574422836304
the O O 0.9999687671661377
craniocervical O O 0.9998763799667358
junction O O 0.9999872446060181
, O O 0.9999462366104126
but O O 0.9998051524162292
has O O 0.9999786615371704
occasionally O O 0.9999914169311523
been O O 0.9999904632568359
reported O O 0.9999872446060181
as O O 0.9999803304672241
a O O 0.9999650716781616
manifestation O O 0.9999866485595703
of O O 0.9999254941940308
metabolic O O 0.9994814991950989
imbalance O O 0.9999819993972778
or O O 0.9999098777770996
drug O O 0.9982686042785645
intoxication O O 0.9998842477798462
. O O 0.9999500513076782

We O O 0.9998899698257446
recorded O O 0.999984622001648
the O O 0.9999872446060181
eye O O 0.9999829530715942
movements O O 0.9999942779541016
of O O 0.9999436140060425
two O O 0.9999823570251465
patients O O 0.9999897480010986
with O O 0.9999514818191528
reversible O O 0.999881386756897
downbeat O O 0.9987881779670715
nystagmus O O 0.9999873638153076
related O O 0.9999887943267822
to O O 0.9997703433036804
carbamazepine B B 0.9994248151779175
therapy O O 0.9996258020401001
. O O 0.9999634027481079

The O O 0.9999833106994629
nystagmus O O 0.9999946355819702
of O O 0.9999573230743408
both O O 0.9999223947525024
patients O O 0.9999698400497437
resolved O O 0.999975323677063
after O O 0.999945878982544
reduction O O 0.9999773502349854
of O O 0.9999463558197021
the O O 0.9999717473983765
serum O O 0.9979789853096008
carbamazepine B B 0.9992735981941223
levels O O 0.9996640682220459
. O O 0.9999662637710571

Neuroradiologic O O 0.9999823570251465
investigations O O 0.9999940395355225
including O O 0.9999662637710571
magnetic O O 0.9998294115066528
resonance O O 0.9999659061431885
imaging O O 0.9999688863754272
scans O O 0.9999215602874756
in O O 0.9999687671661377
both O O 0.9999477863311768
patients O O 0.9999932050704956
showed O O 0.9999717473983765
no O O 0.9999878406524658
evidence O O 0.9999936819076538
of O O 0.999985933303833
intracranial O O 0.9999903440475464
abnormality O O 0.9999977350234985
. O O 0.9999713897705078

In O O 0.9998916387557983
patients O O 0.9999829530715942
with O O 0.9999699592590332
downbeat O O 0.996966540813446
nystagmus O O 0.9999806880950928
who O O 0.9999738931655884
are O O 0.9999743700027466
taking O O 0.9995404481887817
anticonvulsant O O 0.748184084892273
medications O O 0.9946860074996948
, O O 0.9999691247940063
consideration O O 0.9999936819076538
should O O 0.999976396560669
be O O 0.9999984502792358
given O O 0.999998927116394
to O O 0.9999254941940308
reduction O O 0.9999842643737793
in O O 0.9999501705169678
dose O O 0.9997934699058533
before O O 0.9999936819076538
further O O 0.9999970197677612
investigation O O 0.9999969005584717
is O O 0.9999945163726807
undertaken O O 0.9999978542327881
. O O 0.9999812841415405

Improvement O O 0.9999619722366333
by O O 0.9996216297149658
denopamine B B 0.9997654557228088
( O O 0.9961729645729065
TA B B 0.8838403820991516
- I I 0.9720494747161865
064 I I 0.9999810457229614
) O O 0.9988000392913818
of O O 0.9997443556785583
pentobarbital B B 0.9995751976966858
- O O 0.9999059438705444
induced O O 0.9999737739562988
cardiac O O 0.9999936819076538
failure O O 0.9999933242797852
in O O 0.9998595714569092
the O O 0.9998438358306885
dog O O 0.7937985062599182
heart O O 0.9868770837783813
- O O 0.999161958694458
lung O O 0.9977071285247803
preparation O O 0.9999552965164185
. O O 0.9999129772186279

The O O 0.9999649524688721
efficacy O O 0.9999678134918213
of O O 0.9991108775138855
denopamine B B 0.9998385906219482
, O O 0.9998494386672974
an O O 0.9997456669807434
orally O O 0.9564527273178101
active O O 0.9859041571617126
beta O O 0.9440959692001343
1 O O 0.976760745048523
- O O 0.9868376851081848
adrenoceptor O O 0.9447425603866577
agonist O O 0.916958212852478
, O O 0.9999459981918335
in O O 0.9999226331710815
improving O O 0.9999589920043945
cardiac O O 0.9999920129776001
failure O O 0.9999971389770508
was O O 0.9999728202819824
assessed O O 0.9999786615371704
in O O 0.9999278783798218
dog O O 0.9697431325912476
heart O O 0.9900931715965271
- O O 0.9996092915534973
lung O O 0.9981107711791992
preparations O O 0.9999798536300659
. O O 0.9999591112136841

Cardiac O O 0.9995680451393127
functions O O 0.9999934434890747
depressed O O 0.9999821186065674
by O O 0.9998519420623779
pentobarbital B B 0.999772846698761
( O O 0.9983969330787659
118 O O 0.8327187299728394
+ O O 0.9999887943267822
/ O O 0.9999169111251831
- O O 0.9996850490570068
28 O O 0.9999815225601196
mg O O 0.9996222257614136
; O O 0.9999430179595947
mean O O 0.9999785423278809
value O O 0.9999818801879883
+ O O 0.9999896287918091
/ O O 0.9999781847000122
- O O 0.9999542236328125
SD O O 0.9923058152198792
) O O 0.9999552965164185
such O O 0.9999761581420898
that O O 0.999941349029541
cardiac O O 0.9999127388000488
output O O 0.99998939037323
and O O 0.9999572038650513
maximum O O 0.9999325275421143
rate O O 0.9999810457229614
of O O 0.9999592304229736
rise O O 0.9998576641082764
of O O 0.999829888343811
left O O 0.9999744892120361
ventricular O O 0.9999934434890747
pressure O O 0.9999034404754639
( O O 0.9998618364334106
LV O O 0.9408516883850098
dP O O 0.9920026063919067
/ O O 0.9993615746498108
dt O O 0.9893506169319153
max O O 0.9996342658996582
) O O 0.9999525547027588
had O O 0.9999556541442871
been O O 0.9999855756759644
reduced O O 0.9999874830245972
by O O 0.9999761581420898
about O O 0.9999957084655762
35 O O 0.9999920129776001
% O O 0.9999951124191284
and O O 0.999967098236084
26 O O 0.999984860420227
% O O 0.9999948740005493
of O O 0.9999651908874512
the O O 0.9999779462814331
respective O O 0.9998278617858887
controls O O 0.9999610185623169
were O O 0.9999854564666748
improved O O 0.9999873638153076
by O O 0.9996943473815918
denopamine B B 0.9998915195465088
( O O 0.9998340606689453
10 O O 0.9972659349441528
- O O 0.9931160807609558
300 O O 0.9995512366294861
micrograms O O 0.9994468092918396
) O O 0.9999239444732666
in O O 0.9999793767929077
a O O 0.9999756813049316
dose O O 0.9996392726898193
- O O 0.9999693632125854
dependent O O 0.9999724626541138
manner O O 0.9999918937683105
. O O 0.9999698400497437

With O O 0.9998233914375305
100 O O 0.9983226656913757
micrograms O O 0.9991554021835327
denopamine B B 0.9993516802787781
, O O 0.9999256134033203
almost O O 0.9999765157699585
complete O O 0.9999711513519287
restoration O O 0.9999936819076538
of O O 0.9999860525131226
cardiac O O 0.9999264478683472
performance O O 0.9999972581863403
was O O 0.999985933303833
attained O O 0.9999957084655762
, O O 0.9999890327453613
associated O O 0.9999915361404419
with O O 0.9999918937683105
a O O 0.9999935626983643
slight O O 0.9999974966049194
increase O O 0.999996542930603
in O O 0.9999926090240479
heart O O 0.9999924898147583
rate O O 0.9999958276748657
. O O 0.99997878074646

No O O 0.9998718500137329
arrhythmias O O 0.9999847412109375
were O O 0.9999815225601196
induced O O 0.9999959468841553
by O O 0.9998944997787476
these O O 0.9998353719711304
doses O O 0.9997275471687317
of O O 0.997607946395874
denopamine B B 0.999765932559967
. O O 0.9999291896820068

The O O 0.9999828338623047
results O O 0.9999896287918091
warrant O O 0.9999740123748779
clinical O O 0.9999808073043823
trials O O 0.9999865293502808
of O O 0.9983660578727722
denopamine B B 0.9998217225074768
in O O 0.9998840093612671
the O O 0.999982476234436
treatment O O 0.9999798536300659
of O O 0.9999784231185913
cardiac O O 0.9999914169311523
failure O O 0.9999966621398926
. O O 0.9999836683273315

Clonazepam B B 0.9993107318878174
monotherapy O O 0.9969719648361206
for O O 0.9998261332511902
epilepsy O O 0.999556839466095
in O O 0.9998655319213867
childhood O O 0.9999805688858032
. O O 0.9966381788253784

Sixty O O 0.9992794394493103
patients O O 0.9999927282333374
( O O 0.9999676942825317
age O O 0.9999550580978394
- O O 0.999987006187439
range O O 0.9999803304672241
one O O 0.9999979734420776
month O O 0.9999983310699463
to O O 0.9999823570251465
14 O O 0.9999972581863403
years O O 0.9999951124191284
) O O 0.9999716281890869
with O O 0.9999538660049438
other O O 0.9999358654022217
types O O 0.9999886751174927
of O O 0.9999775886535645
epilepsy O O 0.999970555305481
than O O 0.999958872795105
infantile O O 0.9998844861984253
spasms O O 0.9984800219535828
were O O 0.9999626874923706
treated O O 0.9999450445175171
with O O 0.9994072914123535
clonazepam B B 0.9994791150093079
. O O 0.999891996383667

Disappearance O O 0.9998887777328491
of O O 0.9998691082000732
seizures O O 0.9998937845230103
and O O 0.9998263716697693
normalization O O 0.9999358654022217
of O O 0.9999008178710938
abnormal O O 0.9999147653579712
EEG O O 0.9936502575874329
with O O 0.9999176263809204
disappearance O O 0.9999411106109619
of O O 0.9998248219490051
seizures O O 0.9997908473014832
were O O 0.9999063014984131
recognized O O 0.9999701976776123
in O O 0.9999415874481201
77 O O 0.9999732971191406
% O O 0.99997878074646
and O O 0.9999501705169678
50 O O 0.9999810457229614
% O O 0.9999793767929077
, O O 0.9999750852584839
respectively O O 0.9999691247940063
. O O 0.9999566078186035

Seizures O O 0.9992411136627197
disappeared O O 0.9999591112136841
in O O 0.9999663829803467
71 O O 0.9999963045120239
% O O 0.9999921321868896
of O O 0.9999560117721558
the O O 0.9999580383300781
patients O O 0.999985933303833
with O O 0.999923586845398
generalized O O 0.9996470212936401
seizures O O 0.9999501705169678
and O O 0.9999421834945679
89 O O 0.9999016523361206
% O O 0.9999938011169434
of O O 0.9999178647994995
partial O O 0.9997989535331726
seizures O O 0.9999675750732422
. O O 0.9999663829803467

Improvement O O 0.9999635219573975
of O O 0.999958872795105
abnormal O O 0.9999643564224243
EEG O O 0.9972984194755554
was O O 0.9999685287475586
noticed O O 0.9999898672103882
in O O 0.9998225569725037
76 O O 0.9999790191650391
% O O 0.9999847412109375
of O O 0.9998970031738281
diffuse O O 0.9997549653053284
paroxysms O O 0.9999008178710938
and O O 0.9998680353164673
in O O 0.9999206066131592
67 O O 0.9999877214431763
% O O 0.9999887943267822
of O O 0.9998553991317749
focal O O 0.9998691082000732
paroxysms O O 0.9999324083328247
. O O 0.9999629259109497

In O O 0.9998874664306641
excellent O O 0.9973913431167603
cases O O 0.999962329864502
, O O 0.9999622106552124
mean O O 0.9999103546142578
effective O O 0.9996930360794067
dosages O O 0.9999403953552246
were O O 0.9999736547470093
0 O O 0.9999165534973145
. O O 0.9999909400939941
086 O O 0.9986122846603394
+ O O 0.9999836683273315
/ O O 0.9998499155044556
- O O 0.9998031258583069
0 O O 0.9999321699142456
. O O 0.999997615814209
021 O O 0.9992063641548157
mg O O 0.9999825954437256
/ O O 0.9999872446060181
kg O O 0.9999983310699463
/ O O 0.9999829530715942
day O O 0.9999940395355225
in O O 0.9999830722808838
infants O O 0.9999953508377075
and O O 0.999946117401123
0 O O 0.9999140501022339
. O O 0.9999929666519165
057 O O 0.9997261166572571
+ O O 0.99997878074646
/ O O 0.9993599057197571
- O O 0.9997782111167908
0 O O 0.9999089241027832
. O O 0.9999969005584717
022 O O 0.999742329120636
mg O O 0.9999791383743286
/ O O 0.9999887943267822
kg O O 0.9999979734420776
/ O O 0.9999827146530151
day O O 0.9999932050704956
in O O 0.9999504089355469
schoolchildren O O 0.9999334812164307
, O O 0.9999806880950928
this O O 0.9999932050704956
difference O O 0.999990701675415
was O O 0.9999831914901733
statistically O O 0.9999860525131226
significant O O 0.9999947547912598
( O O 0.999976396560669
p O O 0.9996341466903687
less O O 0.9999916553497314
than O O 0.9999948740005493
0 O O 0.9999940395355225
. O O 0.9999967813491821
005 O O 0.9999904632568359
) O O 0.9999779462814331
. O O 0.9999831914901733

The O O 0.9999510049819946
incidence O O 0.9999939203262329
of O O 0.9999594688415527
side O O 0.9998903274536133
effects O O 0.9999831914901733
such O O 0.9999582767486572
as O O 0.9999586343765259
drowsiness O O 0.9999802112579346
and O O 0.9998737573623657
ataxia O O 0.9999028444290161
was O O 0.9999490976333618
only O O 0.9999874830245972
5 O O 0.99997878074646
% O O 0.9999955892562866
. O O 0.9999624490737915

Postmarketing O O 0.9994199275970459
study O O 0.9999696016311646
of O O 0.996878981590271
timolol B B 0.9987797141075134
- O I 0.7102500796318054
hydrochlorothiazide B I 0.9354524612426758
antihypertensive O O 0.8212911486625671
therapy O O 0.9970569610595703
. O O 0.9999344348907471

A O O 0.9999778270721436
postmarketing O O 0.9980800151824951
surveillance O O 0.9999839067459106
study O O 0.9999903440475464
was O O 0.9999712705612183
conducted O O 0.9999974966049194
to O O 0.9999889135360718
determine O O 0.9999908208847046
the O O 0.9999896287918091
safety O O 0.9999886751174927
and O O 0.9999858140945435
efficacy O O 0.999992847442627
of O O 0.9999387264251709
a O O 0.9999011754989624
fixed O O 0.9970477223396301
- O O 0.9993066787719727
ratio O O 0.9979478716850281
combination O O 0.9983602166175842
containing O O 0.9994321465492249
10 O O 0.9990860223770142
mg O O 0.9973284006118774
of O O 0.9946006536483765
timolol B B 0.9982335567474365
maleate I I 0.9974188804626465
and O O 0.9850243330001831
25 O O 0.9997956156730652
mg O O 0.9990231990814209
of O O 0.9964338541030884
hydrochlorothiazide B B 0.9981808662414551
, O O 0.9998530149459839
administered O O 0.999913215637207
twice O O 0.9998805522918701
daily O O 0.9999619722366333
for O O 0.9999735355377197
one O O 0.9999918937683105
month O O 0.9999972581863403
to O O 0.9999173879623413
hypertensive O O 0.9972319006919861
patients O O 0.9999369382858276
. O O 0.9999626874923706

Data O O 0.9999581575393677
on O O 0.9999712705612183
9 O O 0.9999922513961792
, O O 0.9999974966049194
037 O O 0.9999951124191284
patients O O 0.9999953508377075
were O O 0.9999836683273315
collected O O 0.9999926090240479
by O O 0.9999865293502808
1 O O 0.9999897480010986
, O O 0.9999963045120239
455 O O 0.9999926090240479
participating O O 0.9999880790710449
physicians O O 0.9999958276748657
. O O 0.9999690055847168

Mean O O 0.9999206066131592
systolic O O 0.9982136487960815
blood O O 0.9999532699584961
pressure O O 0.9997877478599548
decreased O O 0.9999697208404541
25 O O 0.9999792575836182
mmHg O O 0.9999972581863403
and O O 0.9999407529830933
mean O O 0.9999622106552124
diastolic O O 0.9999207258224487
blood O O 0.9999126195907593
pressure O O 0.9998422861099243
declined O O 0.999984622001648
15 O O 0.9999936819076538
mmHg O O 0.9999974966049194
after O O 0.9998621940612793
one O O 0.9999966621398926
month O O 0.9999960660934448
of O O 0.9998749494552612
timolol B B 0.9994520545005798
- O I 0.7158166766166687
hydrochlorothiazide B I 0.9547131657600403
therapy O O 0.9996069073677063
( O O 0.99997878074646
P O O 0.9985772371292114
less O O 0.9999850988388062
than O O 0.9999921321868896
0 O O 0.9999946355819702
. O O 0.999997615814209
01 O O 0.9999972581863403
, O O 0.9999744892120361
both O O 0.9999165534973145
comparisons O O 0.9998968839645386
) O O 0.9999637603759766
. O O 0.9999678134918213

Age O O 0.9994088411331177
, O O 0.9998897314071655
race O O 0.9939008951187134
, O O 0.9999239444732666
and O O 0.9998347759246826
sex O O 0.9992916584014893
appeared O O 0.9999643564224243
to O O 0.9999372959136963
have O O 0.9999598264694214
no O O 0.9999240636825562
influence O O 0.9999778270721436
on O O 0.9999773502349854
the O O 0.999985933303833
decrease O O 0.9999949932098389
in O O 0.9999833106994629
blood O O 0.9997445940971375
pressure O O 0.9988207221031189
. O O 0.9999556541442871

The O O 0.9999676942825317
antihypertensive O O 0.5394216179847717
effect O O 0.9997668862342834
of O O 0.9998732805252075
the O O 0.9993878602981567
drug O O 0.9966323971748352
was O O 0.9999175071716309
greater O O 0.9998424053192139
in O O 0.999919056892395
patients O O 0.9999916553497314
with O O 0.9999752044677734
more O O 0.9999728202819824
severe O O 0.9999866485595703
hypertension O O 0.998967170715332
. O O 0.9999566078186035

Overall O O 0.9999277591705322
, O O 0.9999843835830688
1 O O 0.9999940395355225
, O O 0.9999954700469971
453 O O 0.9999939203262329
patients O O 0.999992847442627
experienced O O 0.9999737739562988
a O O 0.9999891519546509
total O O 0.9999911785125732
of O O 0.9999923706054688
2 O O 0.9999889135360718
, O O 0.9999970197677612
658 O O 0.9999959468841553
adverse O O 0.9999957084655762
events O O 0.9999986886978149
, O O 0.999985933303833
the O O 0.999993085861206
most O O 0.9999924898147583
common O O 0.9999771118164062
being O O 0.9999803304672241
fatigue O O 0.9999922513961792
, O O 0.9999659061431885
dizziness O O 0.9999812841415405
, O O 0.9998905658721924
and O O 0.9999278783798218
weakness O O 0.9999969005584717
. O O 0.999967098236084

Treatment O O 0.999817430973053
in O O 0.9999771118164062
590 O O 0.9999666213989258
patients O O 0.999990701675415
was O O 0.9999126195907593
discontinued O O 0.9999620914459229
because O O 0.9999923706054688
of O O 0.9999616146087646
adverse O O 0.999972939491272
events O O 0.9999966621398926
. O O 0.9999715089797974

Salicylate B B 0.9796183109283447
nephropathy O O 0.9990028738975525
in O O 0.9998946189880371
the O O 0.9999208450317383
Gunn O O 0.685880720615387
rat O O 0.9999756813049316
: O O 0.9998915195465088
potential O O 0.9999418258666992
role O O 0.9999315738677979
of O O 0.9993649125099182
prostaglandins B O 0.50105881690979
. O O 0.9998433589935303

We O O 0.9999278783798218
examined O O 0.9999696016311646
the O O 0.9999767541885376
potential O O 0.9999740123748779
role O O 0.9999704360961914
of O O 0.9996272325515747
prostaglandins B O 0.5264560580253601
in O O 0.9998626708984375
the O O 0.9999804496765137
development O O 0.9999897480010986
of O O 0.9999567270278931
analgesic O O 0.9983552098274231
nephropathy O O 0.9999648332595825
in O O 0.9999126195907593
the O O 0.9999191761016846
Gunn O O 0.6318325996398926
strain O O 0.9999545812606812
of O O 0.9999409914016724
rat O O 0.9999492168426514
. O O 0.9999593496322632

The O O 0.9999533891677856
homozygous O O 0.9994673132896423
Gunn O O 0.6962261199951172
rats O O 0.9993103742599487
have O O 0.9998650550842285
unconjugated O O 0.9912769794464111
hyperbilirubinemia O O 0.9979822635650635
due O O 0.9999783039093018
to O O 0.9999337196350098
the O O 0.9999855756759644
absence O O 0.9997664093971252
of O O 0.9994603991508484
glucuronyl B B 0.9586526155471802
transferase O O 0.7266234159469604
, O O 0.9997891783714294
leading O O 0.9999864101409912
to O O 0.999985933303833
marked O O 0.9999139308929443
bilirubin B B 0.9803942441940308
deposition O O 0.9997560381889343
in O O 0.9998050332069397
renal O O 0.9998359680175781
medulla O O 0.9999114274978638
and O O 0.9996629953384399
papilla O O 0.9972977042198181
. O O 0.9999387264251709

These O O 0.9998794794082642
rats O O 0.9999691247940063
are O O 0.9999514818191528
also O O 0.9999734163284302
highly O O 0.9999526739120483
susceptible O O 0.9999871253967285
to O O 0.9999837875366211
develop O O 0.9999874830245972
papillary O O 0.9988698363304138
necrosis O O 0.9999933242797852
with O O 0.9999072551727295
analgesic O O 0.9862019419670105
administration O O 0.9998490810394287
. O O 0.9999576807022095

We O O 0.9999494552612305
used O O 0.9999607801437378
homozygous O O 0.995582640171051
( O O 0.9994576573371887
jj O O 0.9860466122627258
) O O 0.9998902082443237
and O O 0.9999130964279175
phenotypically O O 0.9999887943267822
normal O O 0.9999715089797974
heterozygous O O 0.9989566802978516
( O O 0.9988574981689453
jJ O O 0.9789866805076599
) O O 0.999869704246521
animals O O 0.9999948740005493
. O O 0.999976634979248

Four O O 0.9999246597290039
groups O O 0.9999947547912598
of O O 0.9999831914901733
rats O O 0.9999877214431763
( O O 0.9999572038650513
n O O 0.999937891960144
= O O 0.9999799728393555
7 O O 0.9999827146530151
) O O 0.9999643564224243
were O O 0.9999672174453735
studied O O 0.9999518394470215
: O O 0.9999427795410156
jj O O 0.975333571434021
and O O 0.9993715882301331
jJ O O 0.8604143261909485
rats O O 0.9999839067459106
treated O O 0.9999567270278931
either O O 0.999969482421875
with O O 0.9998843669891357
aspirin B B 0.9993663430213928
300 O O 0.9629772901535034
mg O O 0.9998741149902344
/ O O 0.9999125003814697
kg O O 0.9999932050704956
every O O 0.9999492168426514
other O O 0.9999909400939941
day O O 0.9999865293502808
or O O 0.9999675750732422
sham O O 0.9976087808609009
- O O 0.9998971223831177
treated O O 0.9999586343765259
. O O 0.9999847412109375

After O O 0.999954342842102
one O O 0.9999891519546509
week O O 0.9999926090240479
, O O 0.9999599456787109
slices O O 0.9998216032981873
of O O 0.9998891353607178
cortex O O 0.999742329120636
, O O 0.9993098974227905
outer O O 0.9975191354751587
and O O 0.9980109333992004
inner O O 0.9995324611663818
medulla O O 0.9998080134391785
from O O 0.9999454021453857
one O O 0.9999659061431885
kidney O O 0.9999390840530396
were O O 0.9999628067016602
incubated O O 0.9999649524688721
in O O 0.9981365203857422
buffer O O 0.9615875482559204
and O O 0.9999359846115112
prostaglandin B O 0.5435563921928406
synthesis O O 0.9964115023612976
was O O 0.9999760389328003
determined O O 0.9999700784683228
by O O 0.9999792575836182
radioimmunoassay O O 0.9793913960456848
. O O 0.9999746084213257

The O O 0.9999592304229736
other O O 0.9999147653579712
kidney O O 0.999911904335022
was O O 0.9999712705612183
examined O O 0.9999822378158569
histologically O O 0.9999827146530151
. O O 0.9999673366546631

A O O 0.9999117851257324
marked O O 0.9999572038650513
corticomedullary O O 0.9994571805000305
gradient O O 0.9998695850372314
of O O 0.9973846077919006
prostaglandin B O 0.5061972737312317
synthesis O O 0.7145808935165405
was O O 0.9999197721481323
observed O O 0.9999799728393555
in O O 0.9995087385177612
all O O 0.9992668032646179
groups O O 0.9999016523361206
. O O 0.9999207258224487

PGE2 B O 0.5603288412094116
synthesis O O 0.7775841951370239
was O O 0.9999183416366577
significantly O O 0.9999616146087646
higher O O 0.9998464584350586
in O O 0.9993977546691895
outer O O 0.9988743662834167
medulla O O 0.9996265172958374
, O O 0.9999569654464722
but O O 0.9999661445617676
not O O 0.999927282333374
cortex O O 0.9999128580093384
or O O 0.9999358654022217
inner O O 0.9997395873069763
medulla O O 0.9997026324272156
, O O 0.9999788999557495
of O O 0.9985941052436829
jj O O 0.7174071669578552
( O O 0.9998807907104492
38 O O 0.9993165731430054
+ O O 0.9999798536300659
/ O O 0.9999853372573853
- O O 0.9999451637268066
6 O O 0.9999358654022217
ng O O 0.9950044751167297
/ O O 0.9999212026596069
mg O O 0.9978190660476685
prot O O 0.9299740791320801
) O O 0.9999034404754639
than O O 0.9994722008705139
jJ O O 0.6411904096603394
rats O O 0.9919387698173523
( O O 0.9999091625213623
15 O O 0.9999803304672241
+ O O 0.9999867677688599
/ O O 0.9999905824661255
- O O 0.9999130964279175
3 O O 0.9999037981033325
) O O 0.9999208450317383
( O O 0.9999634027481079
p O O 0.9989988207817078
less O O 0.999980092048645
than O O 0.9999912977218628
0 O O 0.9999920129776001
. O O 0.9999973773956299
01 O O 0.9999947547912598
) O O 0.9999628067016602
. O O 0.9999732971191406

Aspirin B B 0.9992451667785645
treatment O O 0.9997273087501526
reduced O O 0.9998979568481445
PGE2 B O 0.611595094203949
synthesis O O 0.9962132573127747
in O O 0.9995254278182983
all O O 0.9992986917495728
regions O O 0.9999443292617798
, O O 0.9999475479125977
but O O 0.9999551773071289
outer O O 0.9036467671394348
medullary O O 0.9990615248680115
PGE2 B O 0.7811467051506042
remained O O 0.9999494552612305
higher O O 0.9999287128448486
in O O 0.9994747042655945
jj O O 0.9245927333831787
( O O 0.9999638795852661
18 O O 0.9959481358528137
+ O O 0.9999758005142212
/ O O 0.9999721050262451
- O O 0.999875545501709
3 O O 0.99967360496521
) O O 0.9998989105224609
than O O 0.9997170567512512
jJ O O 0.9050226807594299
rats O O 0.9929870963096619
( O O 0.9999375343322754
9 O O 0.9999418258666992
+ O O 0.9999839067459106
/ O O 0.9999645948410034
- O O 0.9998644590377808
2 O O 0.9999538660049438
) O O 0.9999202489852905
( O O 0.9999517202377319
p O O 0.9995570778846741
less O O 0.9999911785125732
than O O 0.999993085861206
0 O O 0.9999945163726807
. O O 0.9999961853027344
05 O O 0.9999939203262329
) O O 0.9999656677246094
. O O 0.9999784231185913

PGF2 B O 0.6574161648750305
alpha I O 0.9452458620071411
was O O 0.9999043941497803
also O O 0.9999498128890991
significantly O O 0.9999388456344604
higher O O 0.9997707009315491
in O O 0.9992603659629822
the O O 0.9996449947357178
outer O O 0.9834834337234497
medulla O O 0.9999306201934814
of O O 0.9991538524627686
jj O O 0.9676370620727539
rats O O 0.9995365142822266
with O O 0.9998137354850769
and O O 0.9999885559082031
without O O 0.9999122619628906
aspirin B B 0.9986894726753235
administration O O 0.9998989105224609
( O O 0.999961256980896
p O O 0.9995132684707642
less O O 0.9999850988388062
than O O 0.9999897480010986
0 O O 0.9999889135360718
. O O 0.9999935626983643
05 O O 0.999987006187439
) O O 0.9999693632125854
. O O 0.9999687671661377

The O O 0.9999748468399048
changes O O 0.9999854564666748
in O O 0.9999172687530518
renal O O 0.9723062515258789
prostaglandin B O 0.520267128944397
synthesis O O 0.8875561952590942
were O O 0.9998791217803955
accompanied O O 0.9999738931655884
by O O 0.9999688863754272
evidence O O 0.9999810457229614
of O O 0.9999648332595825
renal O O 0.9999688863754272
damage O O 0.9999920129776001
in O O 0.9996864795684814
aspirin B B 0.9990485310554504
- O O 0.998695433139801
treated O O 0.9997130036354065
jj O O 0.9334078431129456
but O O 0.999901533126831
not O O 0.9992212057113647
jJ O O 0.9441278576850891
rats O O 0.9997172951698303
as O O 0.9999938011169434
evidenced O O 0.9999967813491821
by O O 0.9999955892562866
: O O 0.9999828338623047
increased O O 0.9999909400939941
incidence O O 0.9999969005584717
and O O 0.9999918937683105
severity O O 0.9999963045120239
of O O 0.999983549118042
hematuria O O 0.9999594688415527
( O O 0.9999580383300781
p O O 0.9926027655601501
less O O 0.999950647354126
than O O 0.9999935626983643
0 O O 0.9999923706054688
. O O 0.9999958276748657
01 O O 0.9999971389770508
) O O 0.9999781847000122
; O O 0.9999914169311523
increased O O 0.9999901056289673
serum O O 0.9918652176856995
creatinine B B 0.9975882768630981
( O O 0.9997513890266418
p O O 0.979744553565979
less O O 0.9999808073043823
than O O 0.9999966621398926
0 O O 0.9999929666519165
. O O 0.9999971389770508
05 O O 0.9999947547912598
) O O 0.999972939491272
; O O 0.9999691247940063
and O O 0.9999834299087524
increase O O 0.9999943971633911
in O O 0.9999849796295166
outer O O 0.6618210673332214
medullary O O 0.9990447163581848
histopathologic O O 0.9999439716339111
lesions O O 0.9999936819076538
( O O 0.9999685287475586
p O O 0.9966267347335815
less O O 0.9999858140945435
than O O 0.9999960660934448
0 O O 0.9999943971633911
. O O 0.9999969005584717
005 O O 0.9999951124191284
compared O O 0.9999927282333374
to O O 0.9999735355377197
either O O 0.9999312162399292
sham O O 0.9966220855712891
- O O 0.9999303817749023
treated O O 0.9998413324356079
jj O O 0.9899017810821533
or O O 0.9999221563339233
aspirin B B 0.9986754059791565
- O O 0.998204231262207
treated O O 0.999495267868042
jJ O O 0.9652984738349915
) O O 0.9999765157699585
. O O 0.9999748468399048

These O O 0.9999823570251465
results O O 0.9999910593032837
suggest O O 0.9999582767486572
that O O 0.9998626708984375
enhanced O O 0.9990843534469604
prostaglandin B O 0.7092575430870056
synthesis O O 0.9872647523880005
contributes O O 0.9998878240585327
to O O 0.9998880624771118
maintenance O O 0.9999732971191406
of O O 0.9999580383300781
renal O O 0.9999547004699707
function O O 0.9999879598617554
and O O 0.9999896287918091
morphological O O 0.9999949932098389
integrity O O 0.9999988079071045
, O O 0.9999545812606812
and O O 0.9999765157699585
that O O 0.9999659061431885
inhibition O O 0.9998652935028076
of O O 0.9995574355125427
prostaglandin B O 0.7044074535369873
synthesis O O 0.9783518314361572
may O O 0.9999464750289917
lead O O 0.999981164932251
to O O 0.9999589920043945
pathological O O 0.9999829530715942
renal O O 0.9999395608901978
medullary O O 0.9999203681945801
lesions O O 0.9999971389770508
and O O 0.9999608993530273
deterioration O O 0.9999880790710449
of O O 0.9999736547470093
renal O O 0.9999566078186035
function O O 0.9999858140945435
. O O 0.9999713897705078

Prophylactic O O 0.9923904538154602
lidocaine B B 0.9997870326042175
in O O 0.9999535083770752
the O O 0.9999833106994629
early O O 0.9999823570251465
phase O O 0.9999946355819702
of O O 0.9999896287918091
suspected O O 0.9999793767929077
myocardial O O 0.9999973773956299
infarction O O 0.9999901056289673
. O O 0.9996738433837891

Four O O 0.9999607801437378
hundred O O 0.9999923706054688
two O O 0.9999969005584717
patients O O 0.9999964237213135
with O O 0.999988317489624
suspected O O 0.9999860525131226
myocardial O O 0.9999980926513672
infarction O O 0.9999915361404419
seen O O 0.999994158744812
within O O 0.9999954700469971
6 O O 0.999991774559021
hours O O 0.9999974966049194
of O O 0.9999963045120239
the O O 0.9999977350234985
onset O O 0.9999979734420776
of O O 0.999994158744812
symptoms O O 0.9999978542327881
entered O O 0.9999387264251709
a O O 0.9999847412109375
double O O 0.99994957447052
- O O 0.9999798536300659
blind O O 0.9999901056289673
randomized O O 0.9999934434890747
trial O O 0.9999861717224121
of O O 0.9996799230575562
lidocaine B B 0.9996587038040161
vs O O 0.9971250891685486
placebo O O 0.9999721050262451
. O O 0.999966025352478

During O O 0.9999544620513916
the O O 0.9999945163726807
1 O O 0.9999661445617676
hour O O 0.9999915361404419
after O O 0.9999589920043945
administration O O 0.9999516010284424
of O O 0.9999749660491943
the O O 0.999804675579071
drug O O 0.9994767308235168
the O O 0.9999804496765137
incidence O O 0.9999958276748657
of O O 0.9999779462814331
ventricular O O 0.9997063279151917
fibrillation O O 0.9999912977218628
or O O 0.9999282360076904
sustained O O 0.9999271631240845
ventricular O O 0.9992461204528809
tachycardia O O 0.9999192953109741
among O O 0.9998672008514404
the O O 0.9999806880950928
204 O O 0.9997250437736511
patients O O 0.9999942779541016
with O O 0.9999847412109375
acute O O 0.9999558925628662
myocardial O O 0.9999967813491821
infarction O O 0.9999657869338989
was O O 0.9999575614929199
low O O 0.9999933242797852
, O O 0.9999542236328125
1 O O 0.999957799911499
. O O 0.9999858140945435
5 O O 0.9999948740005493
% O O 0.9999963045120239
. O O 0.9999812841415405

Lidocaine B B 0.9993578791618347
, O O 0.999946117401123
given O O 0.9999538660049438
in O O 0.9999773502349854
a O O 0.9999840259552002
300 O O 0.9992187023162842
mg O O 0.9997460246086121
dose O O 0.9998511075973511
intramuscularly O O 0.9999783039093018
followed O O 0.9999299049377441
by O O 0.9999361038208008
100 O O 0.999075174331665
mg O O 0.9999003410339355
intravenously O O 0.9999492168426514
, O O 0.9999555349349976
did O O 0.9999345541000366
not O O 0.9999381303787231
prevent O O 0.9998759031295776
sustained O O 0.9998389482498169
ventricular O O 0.9999551773071289
tachycardia O O 0.999934196472168
, O O 0.9999767541885376
although O O 0.99997878074646
there O O 0.9999850988388062
was O O 0.9999880790710449
a O O 0.9999942779541016
significant O O 0.999992847442627
reduction O O 0.9999969005584717
in O O 0.9999905824661255
the O O 0.9999939203262329
number O O 0.9999899864196777
of O O 0.9999786615371704
patients O O 0.9999948740005493
with O O 0.999977707862854
warning O O 0.9993714690208435
arrhythmias O O 0.9999833106994629
between O O 0.9999648332595825
15 O O 0.9999970197677612
and O O 0.9999885559082031
45 O O 0.9999957084655762
minutes O O 0.999997615814209
after O O 0.9999797344207764
the O O 0.9999895095825195
administration O O 0.9999737739562988
of O O 0.9998828172683716
lidocaine B B 0.999775230884552
( O O 0.999855637550354
p O O 0.99989914894104
less O O 0.9999903440475464
than O O 0.9999955892562866
0 O O 0.9999940395355225
. O O 0.9999953508377075
05 O O 0.9999963045120239
) O O 0.9999752044677734
. O O 0.9999679327011108

The O O 0.9999831914901733
average O O 0.9998902082443237
plasma O O 0.9714480042457581
lidocaine B B 0.9995697140693665
level O O 0.9998620748519897
10 O O 0.9999140501022339
minutes O O 0.9999943971633911
after O O 0.9999750852584839
administration O O 0.999947190284729
for O O 0.9999426603317261
patients O O 0.9999932050704956
without O O 0.9999903440475464
a O O 0.999988317489624
myocardial O O 0.9999978542327881
infarction O O 0.999944806098938
was O O 0.9999701976776123
significantly O O 0.9999852180480957
higher O O 0.9999009370803833
than O O 0.9999827146530151
that O O 0.9999830722808838
for O O 0.9999557733535767
patients O O 0.9999899864196777
with O O 0.9999837875366211
an O O 0.9999864101409912
acute O O 0.9998632669448853
infarction O O 0.9999935626983643
. O O 0.9999724626541138

The O O 0.9999806880950928
mean O O 0.9999709129333496
plasma O O 0.9996188879013062
lidocaine B B 0.9997637867927551
level O O 0.9998171925544739
of O O 0.999942421913147
patients O O 0.9999849796295166
on O O 0.9996053576469421
beta O O 0.9653360247612
- O O 0.9982470273971558
blocking O O 0.9834566712379456
agents O O 0.992046594619751
was O O 0.9999619722366333
no O O 0.9999908208847046
different O O 0.99997878074646
from O O 0.9999749660491943
that O O 0.9999866485595703
in O O 0.9999630451202393
patients O O 0.9999920129776001
not O O 0.9999762773513794
on O O 0.9996383190155029
beta O O 0.99261873960495
blocking O O 0.9802830815315247
agents O O 0.9912834167480469
. O O 0.9999544620513916

During O O 0.9999055862426758
the O O 0.9999921321868896
1 O O 0.9998886585235596
- O O 0.9999836683273315
hour O O 0.999967098236084
study O O 0.999969482421875
period O O 0.9999703168869019
, O O 0.9999719858169556
the O O 0.9999923706054688
incidence O O 0.9999939203262329
of O O 0.999974250793457
central O O 0.999846339225769
nervous O O 0.9999912977218628
system O O 0.9999520778656006
side O O 0.9999507665634155
effects O O 0.9999873638153076
was O O 0.9999618530273438
significantly O O 0.9999847412109375
greater O O 0.9999662637710571
in O O 0.9997813105583191
the O O 0.999846339225769
lidocaine B B 0.9998149275779724
group O O 0.9998278617858887
, O O 0.999974250793457
hypotension O O 0.9999774694442749
occurred O O 0.9999837875366211
in O O 0.9999548196792603
11 O O 0.9999488592147827
patients O O 0.9999963045120239
, O O 0.9999943971633911
nine O O 0.9999921321868896
of O O 0.9999788999557495
whom O O 0.9999593496322632
had O O 0.9999735355377197
received O O 0.9998681545257568
lidocaine B B 0.9995362758636475
, O O 0.9995788931846619
and O O 0.9999691247940063
four O O 0.9999758005142212
patients O O 0.9999935626983643
died O O 0.9999970197677612
from O O 0.9999659061431885
asystole O O 0.9999772310256958
, O O 0.999992847442627
three O O 0.9999347925186157
of O O 0.9999662637710571
whom O O 0.9998378753662109
had O O 0.9999604225158691
had O O 0.9995974898338318
lidocaine B B 0.9996249675750732
. O O 0.999937891960144

We O O 0.9999663829803467
cannot O O 0.999977707862854
advocate O O 0.9977293610572815
the O O 0.9999591112136841
administration O O 0.9999241828918457
of O O 0.9997356534004211
lidocaine B B 0.9998124241828918
prophylactically O O 0.9998687505722046
in O O 0.9999637603759766
the O O 0.9999877214431763
early O O 0.9999663829803467
hours O O 0.9999953508377075
of O O 0.9999855756759644
suspected O O 0.9999749660491943
myocardial O O 0.9999966621398926
infarction O O 0.9999854564666748
. O O 0.999940037727356

Evidence O O 0.9999305009841919
for O O 0.9997755885124207
a O O 0.9996953010559082
cholinergic O O 0.5662491321563721
role O O 0.9998435974121094
in O O 0.9998914003372192
haloperidol B B 0.9997692704200745
- O O 0.9997811913490295
induced O O 0.9999364614486694
catalepsy O O 0.9999957084655762
. O O 0.9999383687973022

Experiments O O 0.9999738931655884
in O O 0.9999682903289795
mice O O 0.9999797344207764
tested O O 0.999933123588562
previous O O 0.9999649524688721
evidence O O 0.9999606609344482
that O O 0.9998102784156799
activation O O 0.9996811151504517
of O O 0.9994508624076843
cholinergic O O 0.8900055885314941
systems O O 0.9994707703590393
promotes O O 0.999727189540863
catalepsy O O 0.9999089241027832
and O O 0.9999586343765259
that O O 0.9999576807022095
cholinergic O O 0.6655938625335693
mechanisms O O 0.9998114705085754
need O O 0.9999418258666992
to O O 0.9999682903289795
be O O 0.9999572038650513
intact O O 0.9998805522918701
for O O 0.9999285936355591
full O O 0.9998985528945923
expression O O 0.9999779462814331
of O O 0.9999098777770996
neuroleptic B O 0.999534010887146
- O O 0.9994916915893555
induced O O 0.9999045133590698
catalepsy O O 0.9999686479568481
. O O 0.9999667406082153

Large O O 0.999810516834259
doses O O 0.9997684359550476
of O O 0.9997692704200745
the O O 0.9995114803314209
cholinomimetic O O 0.5651501417160034
, O O 0.9784874320030212
pilocarpine B B 0.9997332692146301
, O O 0.9998960494995117
could O O 0.9999492168426514
induce O O 0.9999545812606812
catalepsy O O 0.9999727010726929
when O O 0.9998915195465088
peripheral O O 0.9996742010116577
cholinergic O O 0.4885900914669037
receptors O O 0.9998912811279297
were O O 0.9999600648880005
blocked O O 0.9998713731765747
. O O 0.9999397993087769

Low O O 0.9997598528862
doses O O 0.9998227953910828
of O O 0.9981155395507812
pilocarpine B B 0.9997816681861877
caused O O 0.9998793601989746
a O O 0.9999438524246216
pronounced O O 0.9999268054962158
enhancement O O 0.9999697208404541
of O O 0.9999239444732666
the O O 0.9999544620513916
catalepsy O O 0.999929666519165
that O O 0.9999520778656006
was O O 0.9999693632125854
induced O O 0.9999868869781494
by O O 0.999907374382019
the O O 0.9998013377189636
dopaminergic O B 0.8951985239982605
blocker O O 0.7973743081092834
, O O 0.9139958024024963
haloperidol B B 0.9996949434280396
. O O 0.9999477863311768

A O O 0.9965511560440063
muscarinic O O 0.5649415254592896
receptor O O 0.8419593572616577
blocker O O 0.6948594450950623
, O O 0.9884246587753296
atropine B B 0.9997026324272156
, O O 0.9990357160568237
disrupted O O 0.994225800037384
haloperidol B B 0.99973064661026
- O O 0.9998241066932678
induced O O 0.999954104423523
catalepsy O O 0.9999868869781494
. O O 0.9998879432678223

Intracranial O O 0.9999651908874512
injection O O 0.999971866607666
of O O 0.9997583031654358
an O O 0.9987255930900574
acetylcholine B B 0.8831104636192322
- O O 0.6454067826271057
synthesis O O 0.7707446813583374
inhibitor O O 0.6941881775856018
, O O 0.9905787110328674
hemicholinium B B 0.9961429238319397
, O O 0.9992882609367371
prevented O O 0.9998840093612671
the O O 0.9999779462814331
catalepsy O O 0.9999573230743408
that O O 0.9999827146530151
is O O 0.9999856948852539
usually O O 0.9999791383743286
induced O O 0.9999877214431763
by O O 0.999842643737793
haloperidol B B 0.9997318387031555
. O O 0.9999032020568848

These O O 0.9999752044677734
findings O O 0.9999936819076538
suggest O O 0.9999377727508545
the O O 0.99998939037323
hypothesis O O 0.9999707937240601
that O O 0.9998937845230103
the O O 0.999963641166687
catalepsy O O 0.9999703168869019
that O O 0.999894380569458
is O O 0.9999347925186157
produced O O 0.9999791383743286
by O O 0.999638557434082
neuroleptics B O 0.9995101690292358
such O O 0.9997760653495789
as O O 0.999313473701477
haloperidol B B 0.9994245767593384
is O O 0.9997641444206238
actually O O 0.9999327659606934
mediated O O 0.9999527931213379
by O O 0.9997287392616272
intrinsic O O 0.9997279047966003
central O O 0.9993146657943726
cholinergic O O 0.841700553894043
systems O O 0.9998800754547119
. O O 0.9999363422393799

Alternatively O O 0.9999021291732788
, O O 0.9997547268867493
activation O O 0.9998044371604919
of O O 0.9997918009757996
central O O 0.9992258548736572
cholinergic O O 0.690129280090332
systems O O 0.999339759349823
could O O 0.9997581839561462
promote O O 0.9998385906219482
catalepsy O O 0.9999521970748901
by O O 0.999821126461029
suppression O O 0.9997192025184631
of O O 0.9996100068092346
dopaminergic O O 0.7183313965797424
systems O O 0.9990772008895874
. O O 0.9999203681945801

Cardiovascular O O 0.9999006986618042
dysfunction O O 0.9999873638153076
and O O 0.9999665021896362
hypersensitivity O O 0.9998974800109863
to O O 0.9996469020843506
sodium B B 0.9968066215515137
pentobarbital I I 0.9988523721694946
induced O O 0.9997703433036804
by O O 0.999955415725708
chronic O O 0.9998354911804199
barium B B 0.9995110034942627
chloride I I 0.9999058246612549
ingestion O O 0.9982116222381592
. O O 0.9999649524688721

Barium B B 0.9375799894332886
- O O 0.9985674619674683
supplemented O O 0.9993793964385986
Long O O 0.7013433575630188
- O O 0.9883114695549011
Evans O O 0.7446721196174622
hooded O O 0.9827280640602112
rats O O 0.999427318572998
were O O 0.9999414682388306
characterized O O 0.9999737739562988
by O O 0.9999799728393555
a O O 0.9999740123748779
persistent O O 0.9999792575836182
hypertension O O 0.9998940229415894
that O O 0.9999814033508301
was O O 0.9999862909317017
evident O O 0.9999927282333374
after O O 0.9999160766601562
1 O O 0.9999700784683228
month O O 0.9999940395355225
of O O 0.9999011754989624
barium B B 0.8768846392631531
( O O 0.9679612517356873
100 O O 0.9992952346801758
micrograms O O 0.9995338916778564
/ O O 0.99988853931427
ml O O 0.9999964237213135
mineral O O 0.9399694800376892
fortified O O 0.5215248465538025
water O O 0.8203004598617554
) O O 0.9967905879020691
treatment O O 0.999957799911499
. O O 0.9999816417694092

Analysis O O 0.9999804496765137
of O O 0.9999502897262573
in O O 0.9998449087142944
vivo O O 0.9999854564666748
myocardial O O 0.9999964237213135
excitability O O 0.9999276399612427
, O O 0.9999173879623413
contractility O O 0.9999681711196899
, O O 0.9998657703399658
and O O 0.9998931884765625
metabolic O O 0.9995946288108826
characteristics O O 0.9999887943267822
at O O 0.9999842643737793
16 O O 0.9999746084213257
months O O 0.9999898672103882
revealed O O 0.9999407529830933
other O O 0.9997411370277405
significant O O 0.9999474287033081
barium B B 0.9972066283226013
- O O 0.9987519979476929
induced O O 0.9999027252197266
disturbances O O 0.999970555305481
within O O 0.9999637603759766
the O O 0.999975323677063
cardiovascular O O 0.9999738931655884
system O O 0.9999855756759644
. O O 0.9999712705612183

The O O 0.9999744892120361
most O O 0.9999809265136719
distinctive O O 0.9999836683273315
aspect O O 0.9999903440475464
of O O 0.9999617338180542
the O O 0.9999485015869141
barium B B 0.9876194000244141
effect O O 0.9995212554931641
was O O 0.9999620914459229
a O O 0.9999487400054932
demonstrated O O 0.9999265670776367
hypersensitivity O O 0.9997528195381165
of O O 0.99992835521698
the O O 0.9999574422836304
cardiovascular O O 0.9999518394470215
system O O 0.9999867677688599
to O O 0.9995414018630981
sodium B B 0.9615680575370789
pentobarbital I I 0.6331251263618469
. O O 0.9998420476913452

Under O O 0.9998517036437988
barbiturate B B 0.997291624546051
anesthesia O O 0.9999426603317261
, O O 0.9999488592147827
virtually O O 0.9999630451202393
all O O 0.9999443292617798
of O O 0.9999090433120728
the O O 0.9999641180038452
myocardial O O 0.9999899864196777
contractile O O 0.9999459981918335
indices O O 0.9998841285705566
were O O 0.9999388456344604
depressed O O 0.9999709129333496
significantly O O 0.9999843835830688
in O O 0.9998739957809448
barium B B 0.9979854822158813
- O O 0.999372661113739
exposed O O 0.999874472618103
rats O O 0.9999903440475464
relative O O 0.9999750852584839
to O O 0.9999366998672485
the O O 0.9999722242355347
corresponding O O 0.9999127388000488
control O O 0.7414618730545044
- O O 0.9998704195022583
fed O O 0.9998557567596436
rats O O 0.9999895095825195
. O O 0.9999847412109375

The O O 0.9999889135360718
lack O O 0.9999920129776001
of O O 0.999982476234436
a O O 0.999990701675415
similar O O 0.9999716281890869
response O O 0.999993085861206
to O O 0.9996870756149292
ketamine B B 0.9998310804367065
and O O 0.9899805188179016
xylazine B B 0.9995726943016052
anesthesia O O 0.9997888207435608
revealed O O 0.999991774559021
that O O 0.9999798536300659
the O O 0.9999886751174927
cardiovascular O O 0.9999948740005493
actions O O 0.9999909400939941
of O O 0.9999179840087891
sodium B B 0.99345463514328
pentobarbital I I 0.9758515357971191
in O O 0.9995315074920654
barium B B 0.9995600581169128
- O O 0.9992664456367493
treated O O 0.9998983144760132
rats O O 0.9999947547912598
were O O 0.9999463558197021
linked O O 0.9998107552528381
specifically O O 0.9999841451644897
to O O 0.9999034404754639
this O O 0.9997710585594177
anesthetic O O 0.9992054104804993
, O O 0.9999616146087646
and O O 0.9999924898147583
were O O 0.9999861717224121
not O O 0.9999901056289673
representative O O 0.9999891519546509
of O O 0.9999604225158691
a O O 0.9999692440032959
generalized O O 0.9999072551727295
anesthetic O O 0.9997950196266174
response O O 0.9999755620956421
. O O 0.9999706745147705

Other O O 0.9998687505722046
myocardial O O 0.9999934434890747
pathophysiologic O O 0.9998962879180908
and O O 0.9998759031295776
metabolic O O 0.9999005794525146
changes O O 0.9999933242797852
induced O O 0.9999665021896362
by O O 0.9999005794525146
barium B B 0.8660894632339478
were O O 0.9997547268867493
manifest O O 0.9999099969863892
, O O 0.9999880790710449
irrespective O O 0.9999949932098389
of O O 0.9999760389328003
the O O 0.9999551773071289
anesthetic O O 0.9995238780975342
employed O O 0.9999297857284546
. O O 0.9999517202377319

The O O 0.9999197721481323
contractile O O 0.9997920393943787
element O O 0.9986334443092346
shortening O O 0.9999041557312012
velocity O O 0.9999332427978516
of O O 0.9996335506439209
the O O 0.9999042749404907
cardiac O O 0.9976016879081726
muscle O O 0.9996970891952515
fibers O O 0.9999803304672241
was O O 0.9999494552612305
significantly O O 0.9999810457229614
slower O O 0.9999699592590332
in O O 0.9998109936714172
both O O 0.9997749924659729
groups O O 0.9999569654464722
of O O 0.9998981952667236
barium B B 0.9945178627967834
- O O 0.9986157417297363
treated O O 0.9996819496154785
rats O O 0.9941437840461731
relative O O 0.9999483823776245
to O O 0.9998705387115479
the O O 0.9999457597732544
control O O 0.9998409748077393
groups O O 0.9999853372573853
, O O 0.9999891519546509
irrespective O O 0.9999964237213135
of O O 0.9999867677688599
the O O 0.9999828338623047
anesthetic O O 0.998565137386322
regimen O O 0.9978954792022705
. O O 0.9999585151672363

Similarly O O 0.9998019337654114
, O O 0.9999550580978394
significant O O 0.9999310970306396
disturbances O O 0.9999707937240601
in O O 0.9999725818634033
myocardial O O 0.999994158744812
energy O O 0.7199832797050476
metabolism O O 0.99922776222229
were O O 0.999954342842102
detected O O 0.9999845027923584
in O O 0.9998030066490173
the O O 0.9999067783355713
barium B B 0.9948078989982605
- O O 0.9990376234054565
exposed O O 0.999649167060852
rats O O 0.9998584985733032
which O O 0.9999637603759766
were O O 0.9999324083328247
consistent O O 0.99998939037323
with O O 0.9999819993972778
the O O 0.9999771118164062
reduced O O 0.9999567270278931
contractile O O 0.9999556541442871
element O O 0.9984273910522461
shortening O O 0.9999614953994751
velocity O O 0.9999477863311768
. O O 0.999964714050293

In O O 0.9999207258224487
addition O O 0.9999547004699707
, O O 0.9999529123306274
the O O 0.9999583959579468
excitability O O 0.999906063079834
of O O 0.9998733997344971
the O O 0.999937891960144
cardiac O O 0.9996364116668701
conduction O O 0.9999570846557617
system O O 0.9999282360076904
was O O 0.9999017715454102
depressed O O 0.9999687671661377
preferentially O O 0.99992835521698
in O O 0.9997732043266296
the O O 0.9999147653579712
atrioventricular O O 0.9997326731681824
nodal O O 0.9999209642410278
region O O 0.9999781847000122
of O O 0.9999485015869141
hearts O O 0.9999768733978271
from O O 0.9999158382415771
barium B B 0.8657418489456177
- O O 0.9943647384643555
exposed O O 0.9998399019241333
rats O O 0.9999047517776489
. O O 0.9999586343765259

Overall O O 0.999876856803894
, O O 0.9999693632125854
the O O 0.9999874830245972
altered O O 0.9999662637710571
cardiac O O 0.9999258518218994
contractility O O 0.9999822378158569
and O O 0.9998297691345215
excitability O O 0.9996615648269653
characteristics O O 0.9999653100967407
, O O 0.9999762773513794
the O O 0.9999873638153076
myocardial O O 0.9999948740005493
metabolic O O 0.9978833794593811
disturbances O O 0.9999852180480957
, O O 0.9998897314071655
and O O 0.9999301433563232
the O O 0.9999792575836182
hypersensitivity O O 0.9997904896736145
of O O 0.999908447265625
the O O 0.9999212026596069
cardiovascular O O 0.9999544620513916
system O O 0.9999806880950928
to O O 0.9993370175361633
sodium B O 0.7237495183944702
pentobarbital I B 0.8562318682670593
suggest O O 0.9997021555900574
the O O 0.9999727010726929
existence O O 0.9999799728393555
of O O 0.9999707937240601
a O O 0.9999593496322632
heretofore O O 0.9999442100524902
undescribed O O 0.9998500347137451
cardiomyopathic O O 0.9999961853027344
disorder O O 0.9999974966049194
induced O O 0.9999866485595703
by O O 0.9999356269836426
chronic O O 0.9997238516807556
barium B B 0.9981720447540283
exposure O O 0.9986442923545837
. O O 0.9999724626541138

These O O 0.9999833106994629
experimental O O 0.9999891519546509
findings O O 0.9999978542327881
represent O O 0.9999836683273315
the O O 0.9999912977218628
first O O 0.9999957084655762
indication O O 0.9999920129776001
that O O 0.9999433755874634
life O O 0.9999290704727173
- O O 0.9999794960021973
long O O 0.9992474317550659
barium B B 0.9972896575927734
ingestion O O 0.9982362985610962
may O O 0.9999525547027588
have O O 0.9999531507492065
significant O O 0.9999765157699585
adverse O O 0.9999284744262695
effects O O 0.9999772310256958
on O O 0.9999473094940186
the O O 0.9999783039093018
mammalian O O 0.9999861717224121
cardiovascular O O 0.9999594688415527
system O O 0.9999886751174927
. O O 0.999974250793457

Propranolol B B 0.9995051622390747
antagonism O O 0.9987591505050659
of O O 0.9993183612823486
phenylpropanolamine B B 0.9994182586669922
- O O 0.9992228746414185
induced O O 0.9999301433563232
hypertension O O 0.9979779124259949
. O O 0.9992102384567261

Phenylpropanolamine B B 0.999221920967102
( O O 0.826192319393158
PPA B B 0.9993314743041992
) O O 0.9902909398078918
overdose O O 0.9995388984680176
can O O 0.9997432827949524
cause O O 0.9999608993530273
severe O O 0.9999386072158813
hypertension O O 0.9994544386863708
, O O 0.999942421913147
intracerebral O O 0.9999730587005615
hemorrhage O O 0.9999858140945435
, O O 0.9999123811721802
and O O 0.9999440908432007
death O O 0.9999839067459106
. O O 0.9999611377716064

We O O 0.9999221563339233
studied O O 0.9999531507492065
the O O 0.9999731779098511
efficacy O O 0.9999788999557495
and O O 0.9999868869781494
safety O O 0.9999938011169434
of O O 0.9986293315887451
propranolol B B 0.999863862991333
in O O 0.9998252987861633
the O O 0.9999680519104004
treatment O O 0.9999669790267944
of O O 0.9999181032180786
PPA B B 0.9987298846244812
- O O 0.9981195330619812
induced O O 0.9999368190765381
hypertension O O 0.9985865354537964
. O O 0.9999747276306152

Subjects O O 0.9996901750564575
received O O 0.9997264742851257
propranolol B B 0.999776303768158
either O O 0.9998698234558105
by O O 0.9999393224716187
mouth O O 0.9999288320541382
for O O 0.9999743700027466
48 O O 0.9999847412109375
hours O O 0.9999899864196777
before O O 0.9998536109924316
PPA B O 0.7294578552246094
or O O 0.9997500777244568
as O O 0.9999845027923584
a O O 0.999988317489624
rapid O O 0.9999618530273438
intravenous O O 0.9999849796295166
infusion O O 0.9999648332595825
after O O 0.9998701810836792
PPA B B 0.8574673533439636
. O O 0.9998946189880371

PPA B B 0.9965358972549438
, O O 0.9537551999092102
75 O O 0.9945263266563416
mg O O 0.9942290782928467
alone O O 0.6495019793510437
, O O 0.9998250603675842
increased O O 0.9999599456787109
blood O O 0.9998164772987366
pressure O O 0.9996358156204224
( O O 0.9999626874923706
31 O O 0.9999945163726807
+ O O 0.9999934434890747
/ O O 0.9999926090240479
- O O 0.999976396560669
14 O O 0.9999979734420776
mm O O 0.9999979734420776
Hg O O 0.9004266858100891
systolic O O 0.9998787641525269
, O O 0.9999604225158691
20 O O 0.9999775886535645
+ O O 0.999991774559021
/ O O 0.9999904632568359
- O O 0.9999608993530273
5 O O 0.999980092048645
mm O O 0.9999951124191284
Hg O O 0.8393632173538208
diastolic O O 0.9995507597923279
) O O 0.9999569654464722
, O O 0.9993176460266113
and O O 0.9980067610740662
propranolol B B 0.9997590184211731
pretreatment O O 0.9976678490638733
antagonized O O 0.9998371601104736
this O O 0.9999891519546509
increase O O 0.9999935626983643
( O O 0.9999785423278809
12 O O 0.9999972581863403
+ O O 0.9999924898147583
/ O O 0.9999916553497314
- O O 0.9999756813049316
10 O O 0.9999896287918091
mm O O 0.9999977350234985
Hg O O 0.9761471152305603
systolic O O 0.9999229907989502
, O O 0.9999725818634033
10 O O 0.9999886751174927
+ O O 0.9999922513961792
/ O O 0.9999874830245972
- O O 0.9999635219573975
7 O O 0.9999898672103882
mm O O 0.9999963045120239
Hg O O 0.9321114420890808
diastolic O O 0.9999598264694214
) O O 0.9999748468399048
. O O 0.9999727010726929

Intravenous O O 0.9983925223350525
propranolol B B 0.9994136095046997
after O O 0.9991996884346008
PPA B B 0.9927001595497131
also O O 0.9999029636383057
decreased O O 0.999981164932251
blood O O 0.9998018145561218
pressure O O 0.9995015859603882
. O O 0.9998289346694946

Left O O 0.9999551773071289
ventricular O O 0.9999911785125732
function O O 0.9999914169311523
( O O 0.9999834299087524
assessed O O 0.9999977350234985
by O O 0.9999945163726807
echocardiography O O 0.9999465942382812
) O O 0.9999746084213257
showed O O 0.9999831914901733
that O O 0.9979079961776733
PPA B B 0.9949280023574829
increased O O 0.9999018907546997
the O O 0.9999275207519531
stroke O O 0.9999356269836426
volume O O 0.9999892711639404
30 O O 0.9999673366546631
% O O 0.9999964237213135
( O O 0.9999734163284302
from O O 0.9999891519546509
62 O O 0.9999903440475464
. O O 0.9999939203262329
5 O O 0.9999805688858032
+ O O 0.9999750852584839
/ O O 0.9999206066131592
- O O 0.9997599720954895
20 O O 0.9998557567596436
. O O 0.9999940395355225
9 O O 0.9999924898147583
to O O 0.9999775886535645
80 O O 0.9998753070831299
. O O 0.9999977350234985
8 O O 0.9999637603759766
+ O O 0.9999912977218628
/ O O 0.9998918771743774
- O O 0.9999420642852783
22 O O 0.9999845027923584
. O O 0.9999971389770508
4 O O 0.9999687671661377
ml O O 0.999996542930603
) O O 0.9999779462814331
, O O 0.9999748468399048
the O O 0.9999797344207764
ejection O O 0.9997336268424988
fraction O O 0.9999966621398926
9 O O 0.9999696016311646
% O O 0.9999973773956299
( O O 0.999985933303833
from O O 0.9999936819076538
64 O O 0.9999973773956299
% O O 0.9999897480010986
+ O O 0.9999685287475586
/ O O 0.9996784925460815
- O O 0.9999152421951294
10 O O 0.999985933303833
% O O 0.9999912977218628
to O O 0.9999607801437378
70 O O 0.9999953508377075
% O O 0.9999912977218628
+ O O 0.999976396560669
/ O O 0.9996881484985352
- O O 0.999953031539917
7 O O 0.9999781847000122
% O O 0.9999933242797852
) O O 0.9999833106994629
, O O 0.9999570846557617
and O O 0.9999394416809082
cardiac O O 0.9996756315231323
output O O 0.9999960660934448
14 O O 0.9999924898147583
% O O 0.9999979734420776
( O O 0.9999817609786987
from O O 0.999993085861206
3 O O 0.9998037219047546
. O O 0.9999947547912598
6 O O 0.9999673366546631
+ O O 0.9999830722808838
/ O O 0.9999158382415771
- O O 0.9999349117279053
0 O O 0.9999910593032837
. O O 0.9999936819076538
6 O O 0.9999960660934448
to O O 0.9999595880508423
4 O O 0.999907374382019
. O O 0.9999970197677612
1 O O 0.999993085861206
+ O O 0.9999810457229614
/ O O 0.9997759461402893
- O O 0.9999067783355713
1 O O 0.9999934434890747
. O O 0.9999954700469971
0 O O 0.9999938011169434
L O O 0.9999936819076538
/ O O 0.999990701675415
min O O 0.9999953508377075
) O O 0.9999841451644897
. O O 0.9999709129333496

Intravenous O O 0.9996452331542969
propranolol B B 0.9995225667953491
reversed O O 0.9998931884765625
these O O 0.9999635219573975
effects O O 0.9999793767929077
. O O 0.9999566078186035

Systemic O O 0.999566376209259
vascular O O 0.9998375177383423
resistance O O 0.9999845027923584
was O O 0.9999703168869019
increased O O 0.9999744892120361
by O O 0.9995976090431213
PPA B B 0.9972034692764282
28 O O 0.9971780776977539
% O O 0.999976634979248
( O O 0.999947190284729
from O O 0.9999638795852661
1710 O O 0.9959256649017334
+ O O 0.9999645948410034
/ O O 0.9998242259025574
- O O 0.9998000264167786
200 O O 0.9893761873245239
to O O 0.9999310970306396
2190 O O 0.9999693632125854
+ O O 0.9999628067016602
/ O O 0.9991674423217773
- O O 0.9999264478683472
700 O O 0.9997819066047668
dyne O O 0.9999871253967285
X O O 0.9994450211524963
sec O O 0.99979168176651
/ O O 0.9999592304229736
cm5 O O 0.9999721050262451
) O O 0.9999567270278931
and O O 0.9999260902404785
was O O 0.9999594688415527
further O O 0.9999802112579346
increased O O 0.9999819993972778
by O O 0.9999033212661743
propranolol B B 0.9998351335525513
22 O O 0.9970267415046692
% O O 0.9999490976333618
( O O 0.9999504089355469
to O O 0.9999858140945435
2660 O O 0.9999805688858032
+ O O 0.9999747276306152
/ O O 0.9997405409812927
- O O 0.9999467134475708
1200 O O 0.9999767541885376
dyne O O 0.9999984502792358
X O O 0.9995086193084717
sec O O 0.9998694658279419
/ O O 0.9999687671661377
cm5 O O 0.9999860525131226
) O O 0.9999707937240601
. O O 0.999976396560669

We O O 0.9999581575393677
conclude O O 0.999970555305481
that O O 0.9995935559272766
PPA B B 0.998477041721344
increases O O 0.9994516968727112
blood O O 0.9999014139175415
pressure O O 0.9999212026596069
by O O 0.9999562501907349
increasing O O 0.9995577931404114
systemic O O 0.9999009370803833
vascular O O 0.9999872446060181
resistance O O 0.9999978542327881
and O O 0.9999600648880005
cardiac O O 0.9998111128807068
output O O 0.9999825954437256
, O O 0.9999568462371826
and O O 0.9999593496322632
that O O 0.999847412109375
propranolol B B 0.9997527003288269
antagonizes O O 0.9997352957725525
this O O 0.9999865293502808
increase O O 0.9999375343322754
by O O 0.9999685287475586
reversing O O 0.9999624490737915
the O O 0.9999585151672363
effect O O 0.9999512434005737
of O O 0.9998698234558105
PPA B B 0.9988324046134949
on O O 0.9995765089988708
cardiac O O 0.9990440011024475
output O O 0.9999300241470337
. O O 0.9999383687973022

That O O 0.9998418092727661
propranolol B B 0.9993709921836853
antagonizes O O 0.9999022483825684
the O O 0.9998811483383179
pressor O O 0.9998496770858765
effect O O 0.9998871088027954
of O O 0.9995736479759216
PPA B B 0.999201238155365
is O O 0.9999374151229858
in O O 0.9999855756759644
contrast O O 0.9999830722808838
to O O 0.9996194839477539
the O O 0.9998728036880493
interaction O O 0.999895453453064
in O O 0.9999518394470215
which O O 0.9997970461845398
propranolol B B 0.9992691874504089
enhances O O 0.9944553971290588
the O O 0.9999468326568604
pressor O O 0.9998646974563599
effect O O 0.9999455213546753
of O O 0.9998522996902466
norepinephrine B B 0.9979788661003113
. O O 0.9999134540557861

This O O 0.9999336004257202
is O O 0.9999487400054932
probably O O 0.9999217987060547
because O O 0.999782383441925
PPA B B 0.9978548884391785
has O O 0.999272882938385
less O O 0.9998151659965515
beta O O 0.985612690448761
2 O O 0.9855507612228394
activity O O 0.9979028701782227
than O O 0.9984573125839233
does O O 0.9983193278312683
norepinephrine B B 0.9985892176628113
. O O 0.9999123811721802

Mesangial O O 0.9987841248512268
function O O 0.9999314546585083
and O O 0.9999293088912964
glomerular O O 0.9845458269119263
sclerosis O O 0.9987804293632507
in O O 0.999921441078186
rats O O 0.9999431371688843
with O O 0.9998892545700073
aminonucleoside B O 0.7203594446182251
nephrosis O O 0.9726141095161438
. O O 0.9999592304229736

The O O 0.9999821186065674
possible O O 0.9999760389328003
relationship O O 0.9999872446060181
between O O 0.9999188184738159
mesangial O O 0.999794065952301
dysfunction O O 0.9999759197235107
and O O 0.999935507774353
development O O 0.9999902248382568
of O O 0.9999727010726929
glomerular O O 0.9985591769218445
sclerosis O O 0.9998575448989868
was O O 0.9999674558639526
studied O O 0.9999798536300659
in O O 0.9999322891235352
the O O 0.9999090433120728
puromycin B B 0.9965464472770691
aminonucleoside I I 0.998160183429718
( O O 0.9882737398147583
PAN B O 0.49612778425216675
) O O 0.9991672039031982
model O O 0.999976396560669
. O O 0.9999725818634033

Five O O 0.9999605417251587
male O O 0.9999886751174927
Wistar O O 0.9997606873512268
rats O O 0.999987006187439
received O O 0.9999309778213501
repeated O O 0.9999215602874756
subcutaneous O O 0.9998568296432495
PAN B B 0.9769995212554932
injections O O 0.9958673715591431
; O O 0.9999593496322632
five O O 0.9998219609260559
controls O O 0.9999918937683105
received O O 0.9998916387557983
saline O O 0.9992756247520447
only O O 0.9998045563697815
. O O 0.9999731779098511

After O O 0.9999644756317139
4 O O 0.9998868703842163
weeks O O 0.9999865293502808
the O O 0.9999693632125854
PAN B O 0.5955528020858765
rats O O 0.9942090511322021
were O O 0.9999523162841797
severely O O 0.9999042749404907
proteinuric O O 0.9998025298118591
( O O 0.9998704195022583
190 O O 0.9499157071113586
+ O O 0.9999692440032959
/ O O 0.9996851682662964
- O O 0.999360978603363
80 O O 0.9791088104248047
mg O O 0.9999102354049683
/ O O 0.9999560117721558
24 O O 0.9999144077301025
hr O O 0.9928594827651978
) O O 0.9999518394470215
, O O 0.9999309778213501
and O O 0.9999697208404541
all O O 0.9999403953552246
rats O O 0.9999890327453613
were O O 0.9999860525131226
given O O 0.9998194575309753
colloidal O B 0.9924127459526062
carbon B I 0.999893307685852
( O O 0.9420228600502014
CC O B 0.551473081111908
) O O 0.9897783398628235
intravenously O O 0.9999656677246094
. O O 0.9999828338623047

At O O 0.9999336004257202
5 O O 0.9997658133506775
months O O 0.9999887943267822
glomerular O O 0.99774169921875
sclerosis O O 0.9996793270111084
was O O 0.9999834299087524
found O O 0.9999932050704956
in O O 0.9999550580978394
7 O O 0.9999226331710815
. O O 0.999976396560669
6 O O 0.9999834299087524
+ O O 0.9999858140945435
/ O O 0.9999721050262451
- O O 0.9999409914016724
3 O O 0.9999678134918213
. O O 0.9999706745147705
4 O O 0.9999827146530151
% O O 0.9999827146530151
of O O 0.9999217987060547
the O O 0.9999426603317261
glomeruli O O 0.9988932013511658
of O O 0.9996447563171387
PAN B O 0.49638283252716064
rats O O 0.6858559250831604
; O O 0.9999147653579712
glomeruli O O 0.9993765950202942
of O O 0.9993890523910522
the O O 0.9998175501823425
controls O O 0.9677676558494568
were O O 0.9999731779098511
normal O O 0.9999798536300659
. O O 0.9999841451644897

Glomeruli O O 0.9947485327720642
of O O 0.9992069602012634
PAN B O 0.5256754755973816
rats O O 0.5485630035400391
contained O O 0.9997511506080627
significantly O O 0.9999599456787109
more O O 0.9997498393058777
CC O O 0.6971172094345093
than O O 0.9998593330383301
glomeruli O O 0.9976391792297363
of O O 0.999815046787262
controls O O 0.9995155334472656
. O O 0.9999223947525024

Glomeruli O O 0.9977333545684814
with O O 0.999631404876709
sclerosis O O 0.9830427765846252
contained O O 0.9998699426651001
significantly O O 0.9999682903289795
more O O 0.9997097849845886
CC O O 0.7273091077804565
than O O 0.999907374382019
non O O 0.9911648631095886
- O O 0.9996857643127441
sclerotic O O 0.9981564879417419
glomeruli O O 0.9993795156478882
in O O 0.9999197721481323
the O O 0.9999891519546509
same O O 0.9999253749847412
kidneys O O 0.99993896484375
. O O 0.9999548196792603

CC O B 0.9644855260848999
was O O 0.9995811581611633
preferentially O O 0.9999630451202393
localized O O 0.9999630451202393
within O O 0.9999256134033203
the O O 0.9999442100524902
sclerotic O O 0.9997003078460693
areas O O 0.9999703168869019
of O O 0.9999356269836426
the O O 0.9999336004257202
affected O O 0.9998406171798706
glomeruli O O 0.9992893934249878
. O O 0.9999563694000244

Since O O 0.9999707937240601
mesangial O O 0.9908772110939026
CC O B 0.9647276401519775
clearance O O 0.9994696974754333
from O O 0.9998290538787842
the O O 0.9999382495880127
mesangium O O 0.9974405765533447
did O O 0.9999809265136719
not O O 0.9999834299087524
change O O 0.9999876022338867
during O O 0.9998121857643127
chronic O O 0.9986451268196106
PAN B B 0.9863685965538025
treatment O O 0.999011754989624
, O O 0.9999712705612183
we O O 0.9999796152114868
conclude O O 0.9999780654907227
that O O 0.9999510049819946
this O O 0.9999529123306274
preferential O O 0.9998511075973511
CC O B 0.9903544187545776
localization O O 0.9999103546142578
within O O 0.9998738765716553
the O O 0.9999711513519287
lesions O O 0.9999797344207764
is O O 0.9999455213546753
caused O O 0.9999856948852539
by O O 0.999971866607666
an O O 0.9999732971191406
increased O O 0.9999566078186035
CC O B 0.9910110235214233
uptake O O 0.9989604949951172
shortly O O 0.9999558925628662
after O O 0.9999345541000366
injection O O 0.9999018907546997
in O O 0.9998432397842407
apparent O O 0.9993628859519958
vulnerable O O 0.999643087387085
areas O O 0.9999418258666992
where O O 0.9999028444290161
sclerosis O O 0.9991081357002258
will O O 0.9999587535858154
develop O O 0.9999934434890747
subsequently O O 0.9999924898147583
. O O 0.9999790191650391

Cluster O O 0.9957183003425598
analysis O O 0.9999756813049316
showed O O 0.9998985528945923
a O O 0.9999440908432007
random O O 0.9999550580978394
distribution O O 0.9999905824661255
of O O 0.9999527931213379
lesions O O 0.9999730587005615
in O O 0.9998383522033691
the O O 0.9998359680175781
PAN B O 0.8517925143241882
glomeruli O O 0.9340298771858215
in O O 0.9999585151672363
concordance O O 0.999988317489624
with O O 0.999982476234436
the O O 0.9999840259552002
random O O 0.9999254941940308
localization O O 0.9999825954437256
of O O 0.9999558925628662
mesangial O O 0.9997745156288147
areas O O 0.9999375343322754
with O O 0.9999690055847168
dysfunction O O 0.9999617338180542
in O O 0.9999374151229858
this O O 0.9999178647994995
model O O 0.9999737739562988
. O O 0.9999716281890869

Similar O O 0.9999572038650513
to O O 0.9998902082443237
the O O 0.9999397993087769
remnant O O 0.9996644258499146
kidney O O 0.9998546838760376
model O O 0.9999738931655884
in O O 0.9997171759605408
PAN B O 0.8338100910186768
nephrosis O O 0.9764442443847656
the O O 0.9999831914901733
development O O 0.9999884366989136
of O O 0.999958872795105
glomerular O O 0.9924237728118896
sclerosis O O 0.9997250437736511
may O O 0.9999209642410278
be O O 0.9999673366546631
related O O 0.9999836683273315
to O O 0.999868631362915
" O O 0.9999061822891235
mesangial O O 0.9935279488563538
overloading O O 0.9991693496704102
. O O 0.9999785423278809
" O O 0.9999821186065674

Relationship O O 0.999954104423523
between O O 0.999344527721405
nicotine B B 0.9974082112312317
- O O 0.9994620680809021
induced O O 0.9998704195022583
seizures O O 0.9999505281448364
and O O 0.9997817873954773
hippocampal O O 0.9903993010520935
nicotinic O B 0.8699232339859009
receptors O O 0.9955034852027893
. O O 0.9999605417251587

A O O 0.9999157190322876
controversy O O 0.9999868869781494
has O O 0.9999778270721436
existed O O 0.9999967813491821
for O O 0.999976396560669
several O O 0.9999904632568359
years O O 0.9999861717224121
concerning O O 0.9999847412109375
the O O 0.9999898672103882
physiological O O 0.9999661445617676
relevance O O 0.9999967813491821
of O O 0.9999723434448242
the O O 0.9999274015426636
nicotinic O O 0.8236845135688782
receptor O O 0.9996217489242554
measured O O 0.9999498128890991
by O O 0.9999196529388428
alpha O B 0.4674718677997589
- O I 0.5711299180984497
bungarotoxin O I 0.9722669124603271
binding O O 0.9992685914039612
. O O 0.9999616146087646

Using O O 0.9999639987945557
mice O O 0.9999948740005493
derived O O 0.9999942779541016
from O O 0.9999865293502808
a O O 0.9999780654907227
classical O O 0.9998714923858643
F2 O O 0.9976352453231812
and O O 0.9998681545257568
backcross O O 0.9995970129966736
genetic O O 0.9999798536300659
design O O 0.9999929666519165
, O O 0.999975323677063
a O O 0.9999819993972778
relationship O O 0.9999879598617554
between O O 0.9998273253440857
nicotine B B 0.9980567097663879
- O O 0.9988935589790344
induced O O 0.9999215602874756
seizures O O 0.9999721050262451
and O O 0.9997463822364807
alpha O B 0.7269416451454163
- O I 0.7403797507286072
bungarotoxin O I 0.9940211176872253
nicotinic O O 0.4202936291694641
receptor O O 0.9881129860877991
concentration O O 0.9986175298690796
was O O 0.9999896287918091
found O O 0.9999958276748657
. O O 0.999980092048645

Mice O O 0.9999732971191406
sensitive O O 0.9999183416366577
to O O 0.9998125433921814
the O O 0.9998736381530762
convulsant O O 0.9939180612564087
effects O O 0.9997788071632385
of O O 0.9998393058776855
nicotine B B 0.9987150430679321
had O O 0.9998337030410767
greater O O 0.9997968077659607
alpha O B 0.8354663252830505
- O I 0.9062853455543518
bungarotoxin O I 0.9992713332176208
binding O O 0.9986112117767334
in O O 0.9998171925544739
the O O 0.9999516010284424
hippocampus O O 0.9968833327293396
than O O 0.9999010562896729
seizure O O 0.9988003969192505
insensitive O O 0.9998598098754883
mice O O 0.9999936819076538
. O O 0.9999699592590332

The O O 0.999845027923584
binding O O 0.9996869564056396
sites O O 0.9999039173126221
from O O 0.9998786449432373
seizure O O 0.972241222858429
sensitive O O 0.9998065829277039
and O O 0.9995225667953491
resistant O O 0.9999692440032959
mice O O 0.9999730587005615
were O O 0.9999006986618042
equally O O 0.9998655319213867
affected O O 0.9999631643295288
by O O 0.9998980760574341
treatment O O 0.9999651908874512
with O O 0.9998699426651001
dithiothreitol B B 0.9977080821990967
, O O 0.9890806674957275
trypsin O B 0.9754893779754639
or O O 0.9960283041000366
heat O O 0.864932656288147
. O O 0.9998977184295654

Thus O O 0.9999823570251465
it O O 0.999983549118042
appears O O 0.9999492168426514
that O O 0.9999575614929199
the O O 0.9999898672103882
difference O O 0.9999841451644897
between O O 0.9997302889823914
seizure O O 0.9961163997650146
sensitive O O 0.9997096657752991
and O O 0.9996563196182251
insensitive O O 0.9995573163032532
animals O O 0.999954104423523
may O O 0.9999014139175415
be O O 0.9999618530273438
due O O 0.9999861717224121
to O O 0.9999574422836304
a O O 0.999966025352478
difference O O 0.9999823570251465
in O O 0.9999297857284546
hippocampal O O 0.9951270818710327
nicotinic O B 0.8990352749824524
receptor O O 0.9864164590835571
concentration O O 0.9997989535331726
as O O 0.9999856948852539
measured O O 0.9999945163726807
with O O 0.9999508857727051
alpha O B 0.7796167135238647
- O I 0.8501510620117188
bungarotoxin O I 0.999298095703125
binding O O 0.9991887211799622
. O O 0.9999648332595825

The O O 0.9998750686645508
role O O 0.9999363422393799
of O O 0.9997815489768982
p B B 0.9596312642097473
- I I 0.9973773956298828
aminophenol I I 0.9999490976333618
in O O 0.9986728429794312
acetaminophen B B 0.999197781085968
- O O 0.9994140863418579
induced O O 0.9999462366104126
nephrotoxicity O O 0.9999711513519287
: O O 0.9998306035995483
effect O O 0.9999027252197266
of O O 0.9993384480476379
bis B B 0.9329375624656677
( I O 0.7156668305397034
p I B 0.7073429822921753
- I I 0.9767430424690247
nitrophenyl I I 0.9987269043922424
) I I 0.7657278776168823
phosphate I I 0.9973288774490356
on O O 0.9979584217071533
acetaminophen B B 0.9993888139724731
and O O 0.9987707734107971
p B B 0.9641613960266113
- I I 0.9908297061920166
aminophenol I I 0.9997965693473816
nephrotoxicity O O 0.9975058436393738
and O O 0.99996018409729
metabolism O O 0.9999593496322632
in O O 0.9998608827590942
Fischer O O 0.9793598651885986
344 O O 0.9999370574951172
rats O O 0.99986732006073
. O O 0.9999017715454102

Acetaminophen B B 0.9980979561805725
( O O 0.8875970840454102
APAP B B 0.9885821342468262
) O O 0.9959924817085266
produces O O 0.9998252987861633
proximal O O 0.9997544884681702
tubular O O 0.999993085861206
necrosis O O 0.999981164932251
in O O 0.9995924830436707
Fischer O O 0.9734573364257812
344 O O 0.9959360361099243
( O O 0.9985684156417847
F344 O O 0.9782969951629639
) O O 0.9997720122337341
rats O O 0.9995187520980835
. O O 0.9996757507324219

Recently O O 0.9999624490737915
, O O 0.9996392726898193
p B B 0.9447172284126282
- I I 0.9982245564460754
aminophenol I I 0.9999266862869263
( O O 0.9606887102127075
PAP B B 0.977141797542572
) O O 0.9669773578643799
, O O 0.9999579191207886
a O O 0.99985671043396
known O O 0.9996356964111328
potent O O 0.9137328863143921
nephrotoxicant O O 0.9863855242729187
, O O 0.9999470710754395
was O O 0.9999722242355347
identified O O 0.9999210834503174
as O O 0.99992835521698
a O O 0.9998401403427124
metabolite O O 0.9992764592170715
of O O 0.9990814924240112
APAP B B 0.9377437233924866
in O O 0.999657154083252
F344 O O 0.9939951300621033
rats O O 0.9999322891235352
. O O 0.9999563694000244

The O O 0.9999876022338867
purpose O O 0.9999964237213135
of O O 0.9999953508377075
this O O 0.9999878406524658
study O O 0.9999840259552002
was O O 0.9999914169311523
to O O 0.9999934434890747
determine O O 0.9999942779541016
if O O 0.9999191761016846
PAP B O 0.8596522808074951
formation O O 0.9998236298561096
is O O 0.999969482421875
a O O 0.9999291896820068
requisite O O 0.99997878074646
step O O 0.9999901056289673
in O O 0.9999538660049438
APAP B B 0.9939881563186646
- O O 0.9994356036186218
induced O O 0.9998860359191895
nephrotoxicity O O 0.9998927116394043
. O O 0.9999746084213257

Therefore O O 0.999977707862854
, O O 0.9999474287033081
the O O 0.9999433755874634
effect O O 0.9999260902404785
of O O 0.9996806383132935
bis B B 0.9496447443962097
( I I 0.7903220653533936
p I I 0.5042396783828735
- I I 0.8944076299667358
nitrophenyl I I 0.9963330030441284
) I I 0.8939715623855591
phosphate I I 0.9985248446464539
( O O 0.950374186038971
BNPP B B 0.9910147786140442
) O O 0.997209370136261
, O O 0.9997527003288269
an O O 0.9835178852081299
acylamidase O O 0.7111677527427673
inhibitor O O 0.5744624137878418
, O O 0.9997792840003967
on O O 0.9996383190155029
APAP B B 0.9786521792411804
and O O 0.9993926286697388
PAP B B 0.9044926762580872
nephrotoxicity O O 0.9994090795516968
and O O 0.9999202489852905
metabolism O O 0.9999608993530273
was O O 0.999966025352478
determined O O 0.9999767541885376
. O O 0.9999734163284302

BNPP B O 0.7817649245262146
( O O 0.9993752837181091
1 O O 0.9998170733451843
to O O 0.9999790191650391
8 O O 0.999944806098938
mM O O 0.9999891519546509
) O O 0.9998507499694824
reduced O O 0.999874472618103
APAP B B 0.9742403626441956
deacetylation O O 0.986417293548584
and O O 0.9997629523277283
covalent O O 0.5417290329933167
binding O O 0.9999078512191772
in O O 0.9997343420982361
F344 O O 0.9327009916305542
renal O O 0.9977995753288269
cortical O O 0.9896829128265381
homogenates O O 0.9939348101615906
in O O 0.9999798536300659
a O O 0.9999626874923706
concentration O O 0.8986791968345642
- O O 0.9998952150344849
dependent O O 0.9999496936798096
manner O O 0.9999865293502808
. O O 0.9999363422393799

Pretreatment O O 0.9997896552085876
of O O 0.9999667406082153
animals O O 0.9995563626289368
with O O 0.9997606873512268
BNPP B B 0.9048636555671692
prior O O 0.999739944934845
to O O 0.9999549388885498
APAP B B 0.9800621867179871
or O O 0.9930771589279175
PAP B B 0.959346354007721
administration O O 0.9998511075973511
resulted O O 0.9999772310256958
in O O 0.9999880790710449
marked O O 0.9999746084213257
reduction O O 0.9999876022338867
of O O 0.9999260902404785
APAP B B 0.993335485458374
( O O 0.9993894100189209
900 O O 0.9995875954627991
mg O O 0.999922513961792
/ O O 0.9999366998672485
kg O O 0.9999922513961792
) O O 0.9997707009315491
nephrotoxicity O O 0.9999231100082397
but O O 0.9999690055847168
not O O 0.9997603297233582
PAP B B 0.919913649559021
nephrotoxicity O O 0.9994631409645081
. O O 0.999976634979248

This O O 0.9999743700027466
result O O 0.9999873638153076
was O O 0.9999337196350098
not O O 0.9999479055404663
due O O 0.9999847412109375
to O O 0.9999344348907471
altered O O 0.9999679327011108
disposition O O 0.9999643564224243
of O O 0.9998393058776855
either O O 0.9985669255256653
APAP B B 0.9474749565124512
or O O 0.9992239475250244
acetylated O O 0.7835105061531067
metabolites O O 0.9750533103942871
in O O 0.9997053742408752
plasma O O 0.9997647404670715
or O O 0.999816358089447
renal O O 0.9997333884239197
cortical O O 0.9878652691841125
and O O 0.9997324347496033
hepatic O O 0.9994304776191711
tissue O O 0.9999874830245972
. O O 0.9999533891677856

Rather O O 0.9998651742935181
, O O 0.9992826581001282
BNPP B B 0.9828260540962219
pretreatment O O 0.9974367022514343
reduced O O 0.9999516010284424
the O O 0.9999884366989136
fraction O O 0.9999877214431763
of O O 0.9993473887443542
APAP B B 0.9826778769493103
excreted O O 0.9998941421508789
as O O 0.9546278715133667
PAP B O 0.5006362199783325
by O O 0.9999332427978516
64 O O 0.9999942779541016
and O O 0.9999747276306152
75 O O 0.9999940395355225
% O O 0.9999934434890747
after O O 0.9998964071273804
APAP B B 0.9533902406692505
doses O O 0.9996895790100098
of O O 0.9998942613601685
750 O O 0.9943218231201172
and O O 0.9997548460960388
900 O O 0.9998726844787598
mg O O 0.9999805688858032
/ O O 0.9999831914901733
kg O O 0.9999963045120239
. O O 0.9999555349349976

BNPP B B 0.9549680948257446
did O O 0.9998685121536255
not O O 0.9999760389328003
alter O O 0.9999656677246094
the O O 0.9999821186065674
excretion O O 0.999777615070343
of O O 0.9995855689048767
APAP B B 0.948514997959137
or O O 0.9996019005775452
any O O 0.9999152421951294
of O O 0.9997850060462952
its O O 0.9990947246551514
non O O 0.7935145497322083
- O O 0.9971262812614441
deacetylated O O 0.9753525257110596
metabolites O O 0.9991200566291809
nor O O 0.9999392032623291
did O O 0.9999479055404663
BNPP B B 0.9556530714035034
alter O O 0.9997307658195496
excretion O O 0.9999135732650757
of O O 0.9984474778175354
PAP B B 0.8648476600646973
or O O 0.9995520710945129
its O O 0.7781147956848145
metabolites O O 0.997323751449585
after O O 0.999810516834259
PAP B B 0.9944280385971069
doses O O 0.9997496008872986
of O O 0.999901533126831
150 O O 0.9976626634597778
and O O 0.999745786190033
300 O O 0.9999240636825562
mg O O 0.9999854564666748
/ O O 0.9999653100967407
kg O O 0.9999967813491821
. O O 0.9999375343322754

Therefore O O 0.9999511241912842
, O O 0.9999215602874756
the O O 0.9999672174453735
BNPP B B 0.9945275187492371
- O O 0.9991839528083801
induced O O 0.9999045133590698
reduction O O 0.999988317489624
in O O 0.9999167919158936
APAP B B 0.993259072303772
- O O 0.9994924068450928
induced O O 0.9999301433563232
nephrotoxicity O O 0.999970555305481
appears O O 0.9999070167541504
to O O 0.9998589754104614
be O O 0.9999505281448364
due O O 0.999969482421875
to O O 0.9997723698616028
inhibition O O 0.9997401833534241
of O O 0.999528169631958
APAP B B 0.9164803624153137
deacetylation O O 0.8006963133811951
. O O 0.9999479055404663

It O O 0.999987006187439
is O O 0.9999638795852661
concluded O O 0.9999340772628784
that O O 0.9995765089988708
PAP B O 0.7608193159103394
formation O O 0.997912585735321
, O O 0.9999415874481201
in O O 0.9998754262924194
vivo O O 0.999921441078186
, O O 0.999955415725708
accounts O O 0.9996001124382019
, O O 0.9999827146530151
at O O 0.9999834299087524
least O O 0.9999904632568359
in O O 0.9999692440032959
part O O 0.9999760389328003
, O O 0.9999680519104004
for O O 0.9987552165985107
APAP B B 0.9767758846282959
- O O 0.9992121458053589
induced O O 0.99988853931427
renal O O 0.9999427795410156
tubular O O 0.9999830722808838
necrosis O O 0.9999909400939941
. O O 0.9999716281890869

Morphine B B 0.9940084218978882
- O O 0.9985343217849731
induced O O 0.9999139308929443
seizures O O 0.9999659061431885
in O O 0.9999849796295166
newborn O O 0.9999988079071045
infants O O 0.9999988079071045
. O O 0.9999279975891113

Two O O 0.9999450445175171
neonates O O 0.9999580383300781
suffered O O 0.9999802112579346
from O O 0.9999725818634033
generalized O O 0.9997468590736389
seizures O O 0.9999772310256958
during O O 0.9999573230743408
the O O 0.999984860420227
course O O 0.999955415725708
of O O 0.9998795986175537
intravenous O O 0.9991558790206909
morphine B B 0.9993164539337158
sulfate I I 0.9969527721405029
for O O 0.9995136260986328
post O O 0.9998573064804077
- O O 0.999924898147583
operative O O 0.9999915361404419
analgesia O O 0.9988718628883362
. O O 0.9999779462814331

They O O 0.9999852180480957
received O O 0.9995543360710144
morphine B B 0.999862790107727
in O O 0.9997335076332092
doses O O 0.9999618530273438
of O O 0.9999592304229736
32 O O 0.9999666213989258
micrograms O O 0.9989836812019348
/ O O 0.9999867677688599
kg O O 0.999997615814209
/ O O 0.9999847412109375
hr O O 0.9878009557723999
and O O 0.9997712969779968
40 O O 0.9999438524246216
micrograms O O 0.9988241791725159
/ O O 0.9999872446060181
kg O O 0.9999945163726807
/ O O 0.999955415725708
hr O O 0.9670323133468628
larger O O 0.9997656941413879
than O O 0.9999793767929077
a O O 0.9999871253967285
group O O 0.999995231628418
of O O 0.9999841451644897
10 O O 0.9999819993972778
neonates O O 0.9999977350234985
who O O 0.9999752044677734
received O O 0.9999762773513794
6 O O 0.9981202483177185
- O O 0.9966921806335449
24 O O 0.9999279975891113
micrograms O O 0.998980700969696
/ O O 0.9999876022338867
kg O O 0.9999970197677612
/ O O 0.9999234676361084
hr O O 0.979013979434967
and O O 0.9999788999557495
had O O 0.9999927282333374
no O O 0.9999916553497314
seizures O O 0.9999932050704956
. O O 0.9999823570251465

Plasma O O 0.9994242191314697
concentrations O O 0.9971912503242493
of O O 0.9950366616249084
morphine B B 0.9996015429496765
in O O 0.9996846914291382
these O O 0.9999932050704956
neonates O O 0.9999961853027344
was O O 0.9998941421508789
excessive O O 0.9171409606933594
( O O 0.9997286200523376
60 O O 0.9998052716255188
and O O 0.9998753070831299
90 O O 0.9996809959411621
mg O O 0.9999110698699951
/ O O 0.9999619722366333
ml O O 0.9999967813491821
) O O 0.9999351501464844
. O O 0.999972939491272

Other O O 0.9994801878929138
known O O 0.9999158382415771
reasons O O 0.9999189376831055
for O O 0.9999384880065918
seizures O O 0.9999481439590454
were O O 0.9999717473983765
ruled O O 0.9999619722366333
out O O 0.9999774694442749
and O O 0.9999773502349854
the O O 0.9999934434890747
convulsions O O 0.999976634979248
stopped O O 0.9999921321868896
a O O 0.9999872446060181
few O O 0.9999945163726807
hours O O 0.9999959468841553
after O O 0.9999226331710815
cessation O O 0.999832272529602
of O O 0.9984228610992432
morphine B B 0.9992908239364624
and O O 0.9998788833618164
did O O 0.9999955892562866
not O O 0.9999951124191284
reoccur O O 0.9999896287918091
in O O 0.9999749660491943
the O O 0.9999940395355225
subsequent O O 0.999997615814209
8 O O 0.9999555349349976
months O O 0.9999988079071045
. O O 0.9999885559082031

It O O 0.9999929666519165
is O O 0.9999911785125732
suggested O O 0.9999966621398926
that O O 0.9999265670776367
post O O 0.9997108578681946
- O O 0.999828577041626
operative O O 0.9999755620956421
intravenous O O 0.9844374656677246
morphine B B 0.9996129870414734
should O O 0.9998270869255066
not O O 0.9999804496765137
exceed O O 0.9999687671661377
20 O O 0.9999487400054932
micrograms O O 0.9998239874839783
/ O O 0.999977707862854
kg O O 0.9999972581863403
/ O O 0.9999855756759644
ml O O 0.9999988079071045
in O O 0.9999651908874512
neonates O O 0.9999969005584717
. O O 0.9999765157699585

Indomethacin B B 0.9960753321647644
induced O O 0.9998509883880615
hypotension O O 0.9999707937240601
in O O 0.9999343156814575
sodium B B 0.9102018475532532
and O O 0.9991604089736938
volume O O 0.9988250136375427
depleted O O 0.9997699856758118
rats O O 0.9999854564666748
. O O 0.9998934268951416

After O O 0.9999734163284302
a O O 0.9999920129776001
single O O 0.9999775886535645
oral O O 0.9997170567512512
dose O O 0.9999065399169922
of O O 0.9998646974563599
4 O O 0.9980446100234985
mg O O 0.9999417066574097
/ O O 0.9999346733093262
kg O O 0.9998878240585327
indomethacin B B 0.9991999268531799
( O O 0.9955946803092957
IDM B B 0.9965247511863708
) O O 0.9997392296791077
to O O 0.9998805522918701
sodium B B 0.9551786184310913
and O O 0.9997747540473938
volume O O 0.9261234998703003
depleted O O 0.9992591738700867
rats O O 0.8926235437393188
plasma O O 0.7825884819030762
renin O O 0.8854631781578064
activity O O 0.9942358136177063
( O O 0.9995607733726501
PRA O O 0.9726995825767517
) O O 0.9999561309814453
and O O 0.9999134540557861
systolic O O 0.9997991919517517
blood O O 0.9999536275863647
pressure O O 0.9995201826095581
fell O O 0.9999774694442749
significantly O O 0.9999955892562866
within O O 0.9999949932098389
four O O 0.9999934434890747
hours O O 0.9999961853027344
. O O 0.9999831914901733

In O O 0.9964219331741333
sodium B B 0.995998740196228
repleted O O 0.9799739122390747
animals O O 0.995210587978363
indomethacin B B 0.9995229244232178
did O O 0.9999504089355469
not O O 0.9999815225601196
change O O 0.9999865293502808
systolic O O 0.9998915195465088
blood O O 0.9998558759689331
pressure O O 0.9999394416809082
( O O 0.9998482465744019
BP O O 0.9577070474624634
) O O 0.999948263168335
although O O 0.999946117401123
plasma O O 0.9474619030952454
renin O O 0.8863999247550964
activity O O 0.9993502497673035
was O O 0.9999639987945557
decreased O O 0.9999710321426392
. O O 0.999880313873291

Thus O O 0.9999805688858032
, O O 0.9993352293968201
indomethacin B B 0.9996232986450195
by O O 0.9997281432151794
inhibition O O 0.9990525841712952
of O O 0.9932835102081299
prostaglandin B O 0.5824334621429443
synthesis O O 0.6433354020118713
may O O 0.9998818635940552
diminish O O 0.9999443292617798
the O O 0.9999041557312012
blood O O 0.999187171459198
pressure O O 0.9964499473571777
maintaining O O 0.9994542002677917
effect O O 0.9998979568481445
of O O 0.9997757077217102
the O O 0.9987930059432983
stimulated O O 0.9233434796333313
renin O O 0.5204875469207764
- O O 0.9495793581008911
angiotensin B B 0.9258571267127991
system O O 0.9552491307258606
in O O 0.9993342757225037
sodium B O 0.8391733169555664
and O O 0.9990094900131226
volume O O 0.9992445707321167
depletion O O 0.999916672706604
. O O 0.9999350309371948

On O O 0.9997711777687073
the O O 0.999880313873291
antiarrhythmic O O 0.9092885851860046
activity O O 0.9997476935386658
of O O 0.9989357590675354
one O O 0.9956954717636108
N O B 0.8241596817970276
- O I 0.9390804767608643
substituted O I 0.9998989105224609
piperazine B I 0.7855186462402344
derivative O O 0.6677383780479431
of O O 0.7836815714836121
trans B B 0.8499109148979187
- I I 0.9805174469947815
2 I I 0.9993069171905518
- I I 0.9942654967308044
amino I I 0.9996166229248047
- I I 0.988459050655365
3 I I 0.9215506911277771
- I I 0.9912603497505188
hydroxy I I 0.9961108565330505
- I I 0.9429545998573303
1 I I 0.9115456342697144
, I I 0.9754635691642761
2 I I 0.9840270280838013
, I I 0.9869383573532104
3 I I 0.9529436826705933
, I I 0.9903261065483093
4 I I 0.9928458333015442
- I I 0.9965652823448181
tetrahydroanaphthalene I I 0.99996018409729
. O O 0.9996858835220337

The O O 0.9999370574951172
antiarrhythmic O O 0.9425345063209534
activity O O 0.9998382329940796
of O O 0.9997739195823669
the O O 0.9991852641105652
compound O O 0.9839904308319092
N B B 0.7980936765670776
- I I 0.980061948299408
( I I 0.9897225499153137
trans I I 0.7829278707504272
- I I 0.9768673181533813
3 I I 0.9581974148750305
- I I 0.9878766536712646
hydroxy I I 0.9885554909706116
- I I 0.8855997323989868
1 I I 0.8647100925445557
, I I 0.9629197120666504
2 I I 0.9890216588973999
, I I 0.9879512190818787
3 I I 0.9733148217201233
, I I 0.9921616911888123
4 I I 0.9936071634292603
- I I 0.9952402114868164
tetrahydro I I 0.9997290968894958
- I I 0.9849927425384521
2 I I 0.9979305267333984
- I I 0.9977415800094604
naphthyl I I 0.9999423027038574
) I I 0.6646663546562195
- I I 0.7145959138870239
N I I 0.5493278503417969
- I I 0.9661828279495239
( I I 0.9884202480316162
3 I I 0.8908402323722839
- I I 0.9840248227119446
oxo I I 0.998399555683136
- I I 0.9784262776374817
3 I I 0.9757781028747559
- I I 0.9935358762741089
phenyl I I 0.9992619156837463
- I I 0.9923442006111145
2 I I 0.9951508045196533
- I I 0.9944133162498474
methylpropyl I I 0.9999175071716309
) I I 0.8534731864929199
- I I 0.995380163192749
piperazine I I 0.9982783794403076
hydrochloride I I 0.9842148423194885
, O O 0.999863862991333
referred O O 0.9999788999557495
to O O 0.9999858140945435
as O O 0.9999009370803833
P11 B O 0.6763095259666443
, O O 0.9999822378158569
is O O 0.9999666213989258
studied O O 0.9999483823776245
on O O 0.99992835521698
anaesthesized O O 0.999962568283081
cats O O 0.9999072551727295
and O O 0.9999521970748901
Wistar O O 0.9990352392196655
albino O O 0.9994562268257141
rats O O 0.9999949932098389
, O O 0.9999834299087524
as O O 0.9999697208404541
well O O 0.9999651908874512
as O O 0.9999825954437256
on O O 0.9999194145202637
non O O 0.999647855758667
- O O 0.9998852014541626
anaesthesized O O 0.9997510313987732
rabbits O O 0.9999786615371704
. O O 0.9999604225158691

Four O O 0.9996423721313477
types O O 0.9999390840530396
of O O 0.9998874664306641
experimental O O 0.9997842907905579
arrhythmia O O 0.9994298815727234
are O O 0.9998632669448853
used O O 0.9998809099197388
- O O 0.999626636505127
- O O 0.995087206363678
with O O 0.9995699524879456
BaCl2 B B 0.996507465839386
, O O 0.9978552460670471
with O O 0.9994902610778809
chloroform B B 0.9943678975105286
- O I 0.673499584197998
adrenaline B I 0.9961095452308655
, O O 0.9920939803123474
with O O 0.999715268611908
strophantine B B 0.9898132681846619
G I O 0.6639091968536377
and O O 0.9991859793663025
with O O 0.9996980428695679
aconitine B B 0.9872462749481201
. O O 0.9999425411224365

The O O 0.9999483823776245
compound O B 0.7126749157905579
P11 B I 0.991101861000061
is O O 0.9996033310890198
introduced O O 0.9999821186065674
in O O 0.9999644756317139
doses O O 0.999976634979248
of O O 0.9999710321426392
0 O O 0.9997556805610657
. O O 0.999993085861206
25 O O 0.9999754428863525
and O O 0.9998664855957031
0 O O 0.9999802112579346
. O O 0.9999972581863403
50 O O 0.9999948740005493
mg O O 0.9999816417694092
/ O O 0.999992847442627
kg O O 0.999995231628418
intravenously O O 0.9999743700027466
and O O 0.9999407529830933
10 O O 0.9999696016311646
mg O O 0.9999545812606812
/ O O 0.9999939203262329
kg O O 0.999996542930603
orally O O 0.9996825456619263
. O O 0.9999698400497437

The O O 0.9994068145751953
compound O O 0.9976872205734253
manifests O O 0.9997685551643372
antiarrhythmic O O 0.9284201860427856
activity O O 0.9997262358665466
in O O 0.9996106028556824
all O O 0.9998132586479187
models O O 0.9999793767929077
of O O 0.9999223947525024
experimental O O 0.9999535083770752
arrhythmia O O 0.9997878670692444
used O O 0.99997878074646
, O O 0.9999688863754272
causing O O 0.9999115467071533
greatest O O 0.999579131603241
inhibition O O 0.99986732006073
on O O 0.9998490810394287
the O O 0.9999563694000244
arrhythmia O O 0.9999750852584839
induced O O 0.9999822378158569
by O O 0.999788224697113
chloroform B B 0.9974061846733093
- O I 0.7623178362846375
adrenaline B I 0.9997829794883728
( O O 0.9994508624076843
in O O 0.9999581575393677
90 O O 0.9998750686645508
per O O 0.9999957084655762
cent O O 0.9999933242797852
) O O 0.9999282360076904
and O O 0.9997814297676086
with O O 0.9998331069946289
BaCl2 B B 0.9990155696868896
( O O 0.99974125623703
in O O 0.9999473094940186
84 O O 0.9998278617858887
per O O 0.999995231628418
cent O O 0.9999874830245972
) O O 0.9999394416809082
. O O 0.9999431371688843

The O O 0.9999769926071167
results O O 0.9999828338623047
obtained O O 0.9999955892562866
are O O 0.9999222755432129
associated O O 0.999976634979248
with O O 0.9999246597290039
the O O 0.9998795986175537
beta O O 0.9043028354644775
- O O 0.9689807891845703
adrenoblocking O O 0.9635795950889587
and O O 0.9998817443847656
with O O 0.9999305009841919
the O O 0.999945878982544
membrane O O 0.9758396148681641
- O O 0.9996240139007568
stabilizing O O 0.99933260679245
action O O 0.9999489784240723
of O O 0.9998650550842285
the O O 0.999099612236023
compound O O 0.9952698349952698
. O O 0.9999439716339111

Recurrent O O 0.9998866319656372
subarachnoid O O 0.9999815225601196
hemorrhage O O 0.9999912977218628
associated O O 0.9999758005142212
with O O 0.9997492432594299
aminocaproic B B 0.9896711707115173
acid I I 0.9998669624328613
therapy O O 0.9981695413589478
and O O 0.9999651908874512
acute O O 0.9999241828918457
renal O O 0.9999802112579346
artery O O 0.999854326248169
thrombosis O O 0.9999163150787354
. O O 0.9999529123306274

Case O O 0.9997151494026184
report O O 0.9999834299087524
. O O 0.9998818635940552

Epsilon B B 0.852447509765625
aminocaproic I I 0.9878062605857849
acid I I 0.9999027252197266
( O O 0.9729250073432922
EACA B B 0.9918485879898071
) O O 0.9960973858833313
has O O 0.9998525381088257
been O O 0.9999446868896484
used O O 0.9998231530189514
to O O 0.9998626708984375
prevent O O 0.9998928308486938
rebleeding O O 0.9999433755874634
in O O 0.9998997449874878
patients O O 0.9999873638153076
with O O 0.9999810457229614
subarachnoid O O 0.9996212720870972
hemorrhage O O 0.9999545812606812
( O O 0.9998643398284912
SAH O O 0.6805988550186157
) O O 0.9999146461486816
. O O 0.9997976422309875

Although O O 0.9999552965164185
this O O 0.9964324235916138
agent O O 0.9221064448356628
does O O 0.9998466968536377
decrease O O 0.9999431371688843
the O O 0.9999885559082031
frequency O O 0.9999971389770508
of O O 0.99998939037323
rebleeding O O 0.9999778270721436
, O O 0.9999115467071533
several O O 0.9999779462814331
reports O O 0.9999916553497314
have O O 0.9999853372573853
described O O 0.9999656677246094
thrombotic O O 0.9999535083770752
complications O O 0.9999960660934448
of O O 0.9998514652252197
EACA B B 0.9700245261192322
therapy O O 0.9978123903274536
. O O 0.9999336004257202

These O O 0.9998610019683838
complications O O 0.9999858140945435
have O O 0.9999688863754272
included O O 0.999962329864502
clinical O O 0.9999774694442749
deterioration O O 0.999997615814209
and O O 0.999970555305481
intracranial O O 0.9999505281448364
vascular O O 0.999981164932251
thrombosis O O 0.9999806880950928
in O O 0.9999462366104126
patients O O 0.9999854564666748
with O O 0.9998898506164551
SAH O O 0.6536872982978821
, O O 0.9984232187271118
arteriolar O O 0.9800941348075867
and O O 0.9992252588272095
capillary O O 0.9962455630302429
fibrin O O 0.9487834572792053
thrombi O O 0.9995794892311096
in O O 0.9999188184738159
patients O O 0.9999828338623047
with O O 0.9999661445617676
fibrinolytic O O 0.9683969616889954
syndromes O O 0.9999167919158936
treated O O 0.9999401569366455
with O O 0.9994844198226929
EACA B B 0.9799157381057739
, O O 0.9968926310539246
or O O 0.999839186668396
other O O 0.9996805191040039
thromboembolic O O 0.9990221261978149
phenomena O O 0.9999818801879883
. O O 0.9999501705169678

Since O O 0.9999878406524658
intravascular O O 0.9998099207878113
fibrin O O 0.9953979849815369
thrombi O O 0.9996349811553955
are O O 0.9999549388885498
often O O 0.9999655485153198
observed O O 0.9999719858169556
in O O 0.9999197721481323
patients O O 0.9999858140945435
with O O 0.9999599456787109
fibrinolytic O O 0.9894481897354126
disorders O O 0.9999758005142212
, O O 0.9998866319656372
EACA B O 0.5467492938041687
should O O 0.9997822642326355
not O O 0.9999549388885498
be O O 0.9999730587005615
implicated O O 0.9999395608901978
in O O 0.9999499320983887
the O O 0.9999774694442749
pathogenesis O O 0.9999953508377075
of O O 0.9999752044677734
fibrin O O 0.9944735169410706
thrombi O O 0.9998925924301147
in O O 0.9999206066131592
patients O O 0.9999891519546509
with O O 0.9999746084213257
disseminated O O 0.999962329864502
intravascular O O 0.9999363422393799
coagulation O O 0.9746112823486328
or O O 0.9999222755432129
other O O 0.9997969269752502
" O O 0.9996896982192993
consumption O O 0.9556424021720886
coagulopathies O O 0.9941293001174927
. O O 0.9999845027923584
" O O 0.9999945163726807
This O O 0.9999897480010986
report O O 0.9999850988388062
describes O O 0.9999388456344604
subtotal O O 0.9757703542709351
infarction O O 0.9999817609786987
of O O 0.9999499320983887
the O O 0.9999773502349854
kidney O O 0.9999548196792603
due O O 0.9999611377716064
to O O 0.9996098875999451
thrombosis O O 0.9997734427452087
of O O 0.999901533126831
a O O 0.9999794960021973
normal O O 0.9999535083770752
renal O O 0.9999817609786987
artery O O 0.9999758005142212
. O O 0.9999434947967529

This O O 0.9999071359634399
occlusion O O 0.9999591112136841
occurred O O 0.9999874830245972
after O O 0.9998822212219238
EACA B B 0.9524902105331421
therapy O O 0.9985148310661316
in O O 0.9999396800994873
a O O 0.9999809265136719
patient O O 0.9999909400939941
with O O 0.9999444484710693
SAH O O 0.6819643378257751
and O O 0.9999526739120483
histopathological O O 0.9999918937683105
documentation O O 0.9999935626983643
of O O 0.9999868869781494
recurrent O O 0.9999868869781494
SAH O O 0.4964739680290222
. O O 0.999921441078186

The O O 0.999976634979248
corresponding O O 0.9999896287918091
clinical O O 0.9999935626983643
event O O 0.9999977350234985
was O O 0.9999632835388184
characterized O O 0.9999896287918091
by O O 0.9999613761901855
marked O O 0.9999326467514038
hypertension O O 0.9991934895515442
and O O 0.9998955726623535
abrupt O O 0.9999806880950928
neurological O O 0.9999946355819702
deterioration O O 0.9999974966049194
. O O 0.9999579191207886

Effect O O 0.9995710253715515
of O O 0.9964478015899658
vincristine B B 0.9981688261032104
sulfate I I 0.9988823533058167
on O O 0.9990930557250977
Pseudomonas O O 0.8074952363967896
infections O O 0.9999293088912964
in O O 0.9998888969421387
monkeys O O 0.9772356152534485
. O O 0.9998551607131958

In O O 0.9998488426208496
rhesus O O 0.9968396425247192
monkeys O O 0.9637520909309387
, O O 0.9998360872268677
intravenous O O 0.9999537467956543
challenge O O 0.9999498128890991
with O O 0.9998723268508911
0 O O 0.997748076915741
. O O 0.9999268054962158
6 O O 0.9994113445281982
x O O 0.9882271885871887
10 O O 0.9953226447105408
( O O 0.9989451766014099
10 O O 0.9989762306213379
) O O 0.9946802258491516
to O O 0.997147262096405
2 O O 0.9993649125099182
. O O 0.9999614953994751
2 O O 0.9987713694572449
x O O 0.9901204109191895
10 O O 0.9868484139442444
( O O 0.9977415800094604
10 O O 0.9972233772277832
) O O 0.9980280995368958
Pseudomonas O O 0.9391112923622131
aeruginosa O O 0.9097388386726379
organisms O O 0.999665379524231
caused O O 0.9999794960021973
acute O O 0.9999943971633911
illness O O 0.9999994039535522
of O O 0.9999830722808838
4 O O 0.9999655485153198
to O O 0.9999949932098389
5 O O 0.9999891519546509
days O O 0.9999967813491821
' O O 0.9999978542327881
duration O O 0.9999942779541016
with O O 0.9999834299087524
spontaneous O O 0.9999905824661255
recovery O O 0.9999980926513672
in O O 0.999976396560669
13 O O 0.9999510049819946
of O O 0.999948263168335
15 O O 0.9999895095825195
monkeys O O 0.9999141693115234
; O O 0.9999920129776001
blood O O 0.9999765157699585
cultures O O 0.999985933303833
became O O 0.9999933242797852
negative O O 0.9999920129776001
3 O O 0.9999439716339111
to O O 0.9999977350234985
17 O O 0.9999982118606567
days O O 0.9999984502792358
after O O 0.9999727010726929
challenge O O 0.9999709129333496
. O O 0.9999833106994629

Leukocytosis O O 0.9989616870880127
was O O 0.9999171495437622
observed O O 0.9999728202819824
in O O 0.9997610449790955
all O O 0.99968421459198
monkeys O O 0.9999622106552124
. O O 0.9999312162399292

Intravenous O O 0.9999668598175049
or O O 0.9998762607574463
intratracheal O O 0.9999583959579468
inoculation O O 0.9999849796295166
of O O 0.999848484992981
2 O O 0.9994274377822876
. O O 0.9999914169311523
0 O O 0.9999144077301025
to O O 0.9999915361404419
2 O O 0.999956488609314
. O O 0.9999946355819702
5 O O 0.999991774559021
mg O O 0.9999271631240845
of O O 0.9975965619087219
vincristine B B 0.9945799112319946
sulfate I I 0.9978255033493042
was O O 0.9997873902320862
followed O O 0.9999768733978271
by O O 0.9999898672103882
leukopenia O O 0.9999654293060303
in O O 0.9999837875366211
4 O O 0.9999786615371704
to O O 0.9999982118606567
5 O O 0.9999924898147583
days O O 0.9999947547912598
. O O 0.9999805688858032

Intravenous O O 0.9999679327011108
inoculation O O 0.9999758005142212
of O O 0.999859094619751
4 O O 0.9646307826042175
. O O 0.9997784495353699
2 O O 0.9978690147399902
x O O 0.9901785850524902
10 O O 0.9967742562294006
( O O 0.9993104934692383
10 O O 0.9993656277656555
) O O 0.9934746623039246
to O O 0.9980822801589966
7 O O 0.9995274543762207
. O O 0.9999557733535767
8 O O 0.9958702921867371
x O O 0.9968746900558472
10 O O 0.9964317083358765
( O O 0.9995253086090088
10 O O 0.9981866478919983
) O O 0.9974474906921387
pyocin O O 0.5202073454856873
type O O 0.9886071085929871
6 O O 0.9753904938697815
Pseudomonas O O 0.8386945724487305
organisms O O 0.9993224143981934
in O O 0.9998347759246826
monkeys O O 0.9996600151062012
given O O 0.99958735704422
vincristine B B 0.998711109161377
sulfate I I 0.9982763528823853
4 O O 0.9990059733390808
days O O 0.9999762773513794
previously O O 0.9999778270721436
resulted O O 0.9999909400939941
in O O 0.9999921321868896
fatal O O 0.9999102354049683
infection O O 0.9999946355819702
in O O 0.9999725818634033
11 O O 0.9999696016311646
of O O 0.9999752044677734
14 O O 0.9999942779541016
monkeys O O 0.9999954700469971
, O O 0.9999626874923706
whereas O O 0.9999830722808838
none O O 0.9999853372573853
of O O 0.9999312162399292
four O O 0.9999712705612183
receiving O O 0.9994924068450928
Pseudomonas O O 0.5668237805366516
alone O O 0.9994810223579407
died O O 0.9999866485595703
. O O 0.9999675750732422

These O O 0.9999756813049316
studies O O 0.9999890327453613
suggest O O 0.9999547004699707
that O O 0.999921441078186
an O O 0.9998356103897095
antimetabolite O O 0.7642260193824768
- O O 0.9976320266723633
induced O O 0.9998095631599426
leukopenia O O 0.999919056892395
predisposes O O 0.9999533891677856
to O O 0.9999641180038452
severe O O 0.9999567270278931
Pseudomonas O O 0.8515430092811584
sepsis O O 0.9998780488967896
and O O 0.9999805688858032
that O O 0.9999798536300659
such O O 0.9998583793640137
monkeys O O 0.9996185302734375
may O O 0.9999679327011108
serve O O 0.9999727010726929
as O O 0.999974250793457
a O O 0.9999682903289795
biological O O 0.9999831914901733
model O O 0.9999969005584717
for O O 0.999981164932251
study O O 0.999987006187439
of O O 0.9999810457229614
comparative O O 0.9999099969863892
efficacy O O 0.9999611377716064
of O O 0.9998257756233215
antimicrobial O O 0.7380328178405762
agents O O 0.9986326098442078
. O O 0.9999634027481079

Modification O O 0.999840259552002
by O O 0.9996073842048645
propranolol B B 0.999396800994873
of O O 0.9980813264846802
cardiovascular O O 0.9999287128448486
effects O O 0.9999555349349976
of O O 0.9993658661842346
induced O O 0.9999498128890991
hypoglycaemia O O 0.9988598823547363
. O O 0.9997441172599792

The O O 0.9999531507492065
cardiovascular O O 0.9999634027481079
effects O O 0.9999759197235107
of O O 0.9998984336853027
hypoglycaemia O O 0.9917743802070618
, O O 0.9999549388885498
with O O 0.9998482465744019
and O O 0.9999185800552368
without O O 0.9999208450317383
beta O O 0.9918736815452576
- O O 0.9978906512260437
blockade O O 0.9948299527168274
, O O 0.9999805688858032
were O O 0.9999669790267944
compared O O 0.9999507665634155
in O O 0.9999699592590332
fourteen O O 0.9998722076416016
healthy O O 0.9999860525131226
men O O 0.9999966621398926
. O O 0.9999629259109497

Eight O O 0.9998645782470703
received O O 0.9997469782829285
insulin O B 0.9752199649810791
alone O O 0.9993577599525452
, O O 0.9999184608459473
and O O 0.9998395442962646
eight O O 0.9901518225669861
, O O 0.9999899864196777
including O O 0.9999836683273315
two O O 0.9999638795852661
of O O 0.9999855756759644
the O O 0.9999951124191284
original O O 0.9999765157699585
insulin O O 0.6643797159194946
- O O 0.9963195323944092
only O O 0.9992017149925232
group O O 0.999563992023468
, O O 0.999982476234436
were O O 0.9999890327453613
given O O 0.9996715784072876
propranolol B B 0.9992161989212036
and O O 0.9706595540046692
insulin O B 0.9851554036140442
. O O 0.9999308586120605

In O O 0.9996397495269775
the O O 0.9997478127479553
insulin O O 0.609967827796936
- O O 0.9786737561225891
group O O 0.9936895370483398
the O O 0.9999728202819824
period O O 0.999940037727356
of O O 0.9999114274978638
hypoglycaemia O O 0.999718964099884
was O O 0.9999386072158813
associated O O 0.9999828338623047
with O O 0.9999756813049316
an O O 0.9999864101409912
increase O O 0.999992847442627
in O O 0.9999798536300659
heart O O 0.9999200105667114
- O O 0.9994664788246155
rate O O 0.9999815225601196
and O O 0.999977707862854
a O O 0.9999892711639404
fall O O 0.9999971389770508
in O O 0.9999736547470093
diastolic O O 0.9998860359191895
blood O O 0.9925206899642944
- O O 0.993685781955719
pressure O O 0.9996827840805054
. O O 0.9999701976776123

In O O 0.9994268417358398
the O O 0.9996538162231445
propranolol B B 0.9995693564414978
- O O 0.8361164331436157
insulin O B 0.7903907895088196
group O O 0.9998527765274048
there O O 0.9999713897705078
was O O 0.9999876022338867
a O O 0.999994158744812
significant O O 0.9999953508377075
fall O O 0.9999988079071045
in O O 0.99998939037323
heart O O 0.9999401569366455
- O O 0.9998315572738647
rate O O 0.9999748468399048
in O O 0.9998542070388794
most O O 0.9989651441574097
subjects O O 0.9983254075050354
and O O 0.9999823570251465
an O O 0.999990701675415
increase O O 0.9999942779541016
in O O 0.9999624490737915
diastolic O O 0.9999003410339355
pressure O O 0.9999603033065796
. O O 0.9999645948410034

Typical O O 0.9978429079055786
S O O 0.9583816528320312
- O O 0.9965893030166626
T O O 0.9944491386413574
/ O O 0.9993389248847961
T O O 0.9989421963691711
changes O O 0.9999628067016602
occurred O O 0.9999485015869141
in O O 0.9997127652168274
the O O 0.999474823474884
insulin O O 0.8503495454788208
- O O 0.9746753573417664
group O O 0.9996092915534973
but O O 0.9999133348464966
in O O 0.9997642636299133
none O O 0.9997718930244446
of O O 0.999908447265625
the O O 0.9995923638343811
propranolol B B 0.9993833303451538
- O O 0.8132301568984985
insulin O O 0.6315609812736511
group O O 0.9976396560668945
. O O 0.9999662637710571

Hypertension O O 0.976851761341095
in O O 0.9996951818466187
diabetics O O 0.983252763748169
prone O O 0.9999245405197144
to O O 0.999859094619751
hypoglycaemia O O 0.9858238697052002
attacks O O 0.9999548196792603
should O O 0.9999552965164185
not O O 0.9999599456787109
be O O 0.9999932050704956
treated O O 0.9999650716781616
with O O 0.999907374382019
beta O O 0.9333192110061646
- O O 0.9964626431465149
blockers O O 0.9736567735671997
because O O 0.9999792575836182
these O O 0.9991846680641174
drugs O O 0.9979677796363831
may O O 0.9999619722366333
cause O O 0.9999716281890869
a O O 0.9999874830245972
sharp O O 0.9999942779541016
rise O O 0.9999971389770508
in O O 0.9999866485595703
blood O O 0.997307300567627
- O O 0.9898170232772827
pressure O O 0.9994907379150391
in O O 0.9999450445175171
such O O 0.9999741315841675
patients O O 0.9999911785125732
. O O 0.9999654293060303

Long O O 0.9678239226341248
- O O 0.9999157190322876
term O O 0.9995325803756714
propranolol B B 0.9991456270217896
therapy O O 0.9773725867271423
in O O 0.9999610185623169
pregnancy O O 0.9999945163726807
: O O 0.9999508857727051
maternal O O 0.9999802112579346
and O O 0.9999731779098511
fetal O O 0.9999932050704956
outcome O O 0.9999940395355225
. O O 0.9999605417251587

Propranolol B B 0.999126136302948
, O O 0.9998495578765869
a O O 0.9972748160362244
beta O O 0.9462896585464478
- O O 0.9852896332740784
adrenergic O O 0.9719751477241516
blocking O O 0.9493566155433655
agent O O 0.9618169665336609
, O O 0.9999170303344727
has O O 0.9999260902404785
found O O 0.9999958276748657
an O O 0.9999614953994751
important O O 0.9999654293060303
position O O 0.999987006187439
in O O 0.9999727010726929
the O O 0.9999929666519165
practice O O 0.9999884366989136
of O O 0.9999819993972778
medicine O O 0.9999922513961792
. O O 0.999958872795105

Its O O 0.9401489496231079
use O O 0.999757707118988
in O O 0.9999046325683594
pregnancy O O 0.9999939203262329
, O O 0.9999665021896362
however O O 0.9999611377716064
, O O 0.9999477863311768
is O O 0.999976396560669
an O O 0.9999914169311523
open O O 0.9999908208847046
question O O 0.9999982118606567
as O O 0.9999914169311523
a O O 0.9999803304672241
number O O 0.9999798536300659
of O O 0.9999042749404907
detrimental O O 0.9998183846473694
side O O 0.9999212026596069
effects O O 0.9999706745147705
have O O 0.9999748468399048
been O O 0.9999788999557495
reported O O 0.9999864101409912
in O O 0.9999488592147827
the O O 0.9999573230743408
fetus O O 0.9999896287918091
and O O 0.9998369216918945
neonate O O 0.9999794960021973
. O O 0.9999674558639526

Ten O O 0.9998996257781982
patients O O 0.9999920129776001
and O O 0.9999839067459106
12 O O 0.99998939037323
pregnancies O O 0.9999990463256836
are O O 0.9999921321868896
reported O O 0.9999972581863403
where O O 0.999672532081604
chronic O O 0.9964809417724609
propranolol B B 0.9994382262229919
has O O 0.9993613362312317
been O O 0.9999384880065918
administered O O 0.9997721314430237
. O O 0.9999537467956543

Five O O 0.9999034404754639
patients O O 0.9999923706054688
with O O 0.9999854564666748
serial O O 0.9999847412109375
pregnancies O O 0.9999985694885254
with O O 0.9998921155929565
and O O 0.9999661445617676
without O O 0.9999251365661621
propranolol B B 0.999264657497406
therapy O O 0.9983091354370117
are O O 0.9999710321426392
also O O 0.9999914169311523
examined O O 0.9999874830245972
. O O 0.9999790191650391

Maternal O O 0.9997764229774475
, O O 0.9998189806938171
fetal O O 0.9999370574951172
, O O 0.9998739957809448
and O O 0.9998877048492432
neonatal O O 0.999996542930603
complications O O 0.9999938011169434
are O O 0.9999585151672363
examined O O 0.999946117401123
. O O 0.9999604225158691

An O O 0.9999773502349854
attempt O O 0.9999916553497314
is O O 0.9999828338623047
made O O 0.9999982118606567
to O O 0.9999949932098389
differentiate O O 0.9998635053634644
drug O O 0.9965787529945374
- O O 0.999688982963562
related O O 0.9999504089355469
complications O O 0.99998939037323
from O O 0.9997627139091492
maternal O O 0.9999802112579346
disease O O 0.9993389248847961
- O O 0.969660222530365
- O O 0.9699527025222778
related O O 0.9999274015426636
complications O O 0.9999972581863403
. O O 0.9999837875366211

We O O 0.9999649524688721
conclude O O 0.999975323677063
that O O 0.9999600648880005
previously O O 0.9999792575836182
reported O O 0.9999947547912598
hypoglycemia O O 0.9999533891677856
, O O 0.9999521970748901
hyperbilirubinemia O O 0.9988756775856018
, O O 0.9999477863311768
polycythemia O O 0.9999144077301025
, O O 0.9999581575393677
neonatal O O 0.9999954700469971
apnea O O 0.9964696168899536
, O O 0.9999243021011353
and O O 0.9998908042907715
bradycardia O O 0.9999610185623169
are O O 0.9999500513076782
not O O 0.9999643564224243
invariable O O 0.9984338879585266
and O O 0.999976634979248
cannot O O 0.9999896287918091
be O O 0.9999964237213135
statistically O O 0.9999927282333374
correlated O O 0.9999970197677612
with O O 0.999967098236084
chronic O O 0.9995797276496887
propranolol B B 0.9995574355125427
therapy O O 0.9997972846031189
. O O 0.9999682903289795

Growth O O 0.9957833290100098
retardation O O 0.9999161958694458
, O O 0.999988317489624
however O O 0.9999600648880005
, O O 0.9999665021896362
appears O O 0.9999507665634155
to O O 0.9999176263809204
be O O 0.9999501705169678
significant O O 0.9999722242355347
in O O 0.9999794960021973
both O O 0.9999645948410034
of O O 0.9999849796295166
our O O 0.9999716281890869
series O O 0.9999673366546631
. O O 0.9999819993972778

Central O O 0.9878135919570923
excitatory O O 0.9962305426597595
actions O O 0.9998669624328613
of O O 0.9992619156837463
flurazepam B B 0.9989207983016968
. O O 0.9998069405555725

Toxic O O 0.9995627999305725
actions O O 0.9998644590377808
of O O 0.9992238283157349
flurazepam B B 0.9985036849975586
( O O 0.9829742908477783
FZP B B 0.9981776475906372
) O O 0.99901282787323
were O O 0.9999668598175049
studied O O 0.9999288320541382
in O O 0.9999195337295532
cats O O 0.9999587535858154
, O O 0.9999372959136963
mice O O 0.999992847442627
and O O 0.9999204874038696
rats O O 0.9999887943267822
. O O 0.999963641166687

High O O 0.9991613626480103
doses O O 0.9993864297866821
caused O O 0.9998924732208252
an O O 0.9999072551727295
apparent O O 0.9999185800552368
central O O 0.9995334148406982
excitation O O 0.9998393058776855
, O O 0.9999765157699585
most O O 0.99997878074646
clearly O O 0.9999779462814331
seen O O 0.9999867677688599
as O O 0.999943733215332
clonic O O 0.9995654225349426
convulsions O O 0.9999792575836182
, O O 0.9999816417694092
superimposed O O 0.9997621178627014
on O O 0.9998610019683838
general O O 0.9997770190238953
depression O O 0.9999918937683105
. O O 0.9999618530273438

Following O O 0.999953031539917
a O O 0.9999874830245972
lethal O O 0.9997865557670593
dose O O 0.9996819496154785
, O O 0.9998672008514404
death O O 0.9999603033065796
was O O 0.9999434947967529
always O O 0.9999336004257202
associated O O 0.9999774694442749
with O O 0.9999563694000244
convulsions O O 0.9998611211776733
. O O 0.9999552965164185

Comparing O O 0.9999430179595947
the O O 0.9999520778656006
relative O O 0.9997641444206238
sensitivity O O 0.9999775886535645
to O O 0.999840259552002
central O O 0.9995638728141785
depression O O 0.9999856948852539
and O O 0.9993895292282104
excitation O O 0.9861815571784973
revealed O O 0.9999500513076782
that O O 0.9999396800994873
rats O O 0.9999901056289673
were O O 0.9999804496765137
least O O 0.9999841451644897
likely O O 0.999984860420227
to O O 0.9999697208404541
have O O 0.9999642372131348
convulsions O O 0.9999599456787109
at O O 0.9996656179428101
doses O O 0.9998751878738403
that O O 0.9999371767044067
did O O 0.9999749660491943
not O O 0.9999734163284302
first O O 0.9999792575836182
cause O O 0.9999786615371704
loss O O 0.9999980926513672
of O O 0.9999938011169434
consciousness O O 0.9999973773956299
, O O 0.9999626874923706
while O O 0.999947190284729
cats O O 0.8781373500823975
most O O 0.9999550580978394
clearly O O 0.9999706745147705
showed O O 0.9998339414596558
marked O O 0.9999130964279175
central O O 0.9983587861061096
excitatory O O 0.9978995323181152
actions O O 0.9999433755874634
. O O 0.999958872795105

Signs O O 0.9999666213989258
of O O 0.9999117851257324
FZP B O 0.7844894528388977
toxocity O O 0.9983545541763306
in O O 0.9997716546058655
cats O O 0.6625201106071472
included O O 0.9999449253082275
excessive O O 0.9990867376327515
salivation O O 0.9931640028953552
, O O 0.9999099969863892
extreme O O 0.9996802806854248
apprehensive O O 0.9998458623886108
behavior O O 0.9999831914901733
, O O 0.9998683929443359
retching O O 0.9998708963394165
, O O 0.9999091625213623
muscle O O 0.9999419450759888
tremors O O 0.9999370574951172
and O O 0.9997956156730652
convulsions O O 0.9998408555984497
. O O 0.9999536275863647

An O O 0.9999362230300903
interaction O O 0.9999111890792847
between O O 0.9995415210723877
FZP B B 0.9953859448432922
and O O 0.9976255297660828
pentylenetetrazol B B 0.9919866323471069
( O O 0.9985960125923157
PTZ B B 0.9859267473220825
) O O 0.999833345413208
was O O 0.9999828338623047
shown O O 0.999984860420227
by O O 0.9999823570251465
pretreating O O 0.9999635219573975
mice O O 0.9999959468841553
with O O 0.9996058344841003
FZP B B 0.9918122291564941
before O O 0.9989175796508789
PTZ B B 0.9934592247009277
challenge O O 0.9997382760047913
. O O 0.9999743700027466

As O O 0.9999618530273438
a O O 0.9999579191207886
function O O 0.9999722242355347
of O O 0.9982354640960693
dose O O 0.985370397567749
, O O 0.999468982219696
FZP B B 0.9935210347175598
first O O 0.9836169481277466
protected O O 0.9999502897262573
against O O 0.9998867511749268
convulsions O O 0.9999047517776489
and O O 0.999956488609314
death O O 0.9999895095825195
. O O 0.9999560117721558

At O O 0.9999340772628784
higher O O 0.9999446868896484
doses O O 0.9999029636383057
, O O 0.9999697208404541
however O O 0.999976396560669
, O O 0.9999734163284302
convulsions O O 0.9999337196350098
again O O 0.9999850988388062
emerged O O 0.9999948740005493
. O O 0.9999780654907227

These O O 0.9999337196350098
doses O O 0.9997261166572571
of O O 0.9990150928497314
FZP B B 0.9985073208808899
were O O 0.9997174143791199
lower O O 0.9998781681060791
than O O 0.9999451637268066
those O O 0.999840259552002
that O O 0.999942421913147
would O O 0.9999598264694214
alone O O 0.9999475479125977
cause O O 0.9999631643295288
convulsions O O 0.9999799728393555
. O O 0.9999375343322754

These O O 0.9999843835830688
results O O 0.9999845027923584
may O O 0.9999595880508423
be O O 0.999990701675415
relevant O O 0.9999946355819702
to O O 0.9999889135360718
the O O 0.9999929666519165
use O O 0.9999527931213379
of O O 0.9998151659965515
FZP B B 0.9936268329620361
in O O 0.9997413754463196
clinical O O 0.9999786615371704
situations O O 0.9999862909317017
in O O 0.999922513961792
which O O 0.9999696016311646
there O O 0.9999517202377319
is O O 0.9999698400497437
increased O O 0.9999418258666992
neural O O 0.9999737739562988
excitability O O 0.9999825954437256
, O O 0.9999796152114868
such O O 0.9999573230743408
as O O 0.9999277591705322
epilepsy O O 0.9997022747993469
or O O 0.9999014139175415
sedative O O 0.6303286552429199
- O O 0.993645191192627
hypnotic O O 0.8196834921836853
drug O O 0.9941200613975525
withdrawal O O 0.9998812675476074
. O O 0.9999622106552124

Use O O 0.999496340751648
of O O 0.9950646758079529
propranolol B B 0.9997209906578064
in O O 0.9997772574424744
the O O 0.9998968839645386
treatment O O 0.999969482421875
of O O 0.9999773502349854
idiopathic O O 0.9999969005584717
orthostatic O O 0.9993853569030762
hypotension O O 0.9999575614929199
. O O 0.9990002512931824

Five O O 0.9993237257003784
patients O O 0.9999815225601196
with O O 0.9999593496322632
idiopathic O O 0.9999899864196777
orthostatic O O 0.9990288019180298
hypotension O O 0.9999550580978394
who O O 0.9999067783355713
had O O 0.9999057054519653
physiologic O O 0.9998225569725037
and O O 0.9998942613601685
biochemical O O 0.999701201915741
evidence O O 0.9999895095825195
of O O 0.9999642372131348
severe O O 0.9997338652610779
autonomic O O 0.9940231442451477
dysfunction O O 0.9999899864196777
were O O 0.9999673366546631
included O O 0.9999926090240479
in O O 0.9999854564666748
the O O 0.9999922513961792
study O O 0.9999914169311523
. O O 0.9999737739562988

They O O 0.9999427795410156
all O O 0.9998846054077148
exhibited O O 0.9999407529830933
markedly O O 0.9999682903289795
reduced O O 0.999969482421875
plasma O O 0.9939435124397278
catecholamines B B 0.979292631149292
and O O 0.9993058443069458
plasma O O 0.8331075310707092
renin O O 0.9099270105361938
activity O O 0.9997699856758118
in O O 0.9999396800994873
both O O 0.9999290704727173
recumbent O O 0.9999936819076538
and O O 0.9999442100524902
upright O O 0.9999831914901733
positions O O 0.9999905824661255
and O O 0.9999665021896362
had O O 0.9999349117279053
marked O O 0.9999794960021973
hypersensitivity O O 0.9995744824409485
to O O 0.999847412109375
the O O 0.9999325275421143
pressor O O 0.99850994348526
effects O O 0.999871015548706
of O O 0.9999278783798218
infused O O 0.9998780488967896
norepinephrine B B 0.9994354844093323
. O O 0.99994957447052

Treatment O O 0.9999561309814453
with O O 0.9997484087944031
propanolol B B 0.9996476173400879
administered O O 0.9998476505279541
intravenously O O 0.9999727010726929
( O O 0.999883770942688
1 O O 0.999273955821991
- O O 0.9947939515113831
5 O O 0.9999334812164307
mg O O 0.9998113512992859
) O O 0.9999287128448486
produced O O 0.9999415874481201
increases O O 0.9999949932098389
in O O 0.9999926090240479
supine O O 0.9999916553497314
and O O 0.9999487400054932
upright O O 0.9999803304672241
blood O O 0.9999779462814331
pressure O O 0.9999018907546997
in O O 0.999901294708252
4 O O 0.9996827840805054
of O O 0.9999382495880127
the O O 0.9999845027923584
5 O O 0.9997194409370422
individuals O O 0.999701201915741
with O O 0.9999727010726929
rises O O 0.9999969005584717
ranging O O 0.9999940395355225
from O O 0.9999827146530151
11 O O 0.9998428821563721
/ O O 0.9999722242355347
6 O O 0.9999610185623169
to O O 0.9999364614486694
22 O O 0.9999537467956543
/ O O 0.9999744892120361
11 O O 0.9998600482940674
mmHg O O 0.9999737739562988
. O O 0.999966025352478

Chronic O O 0.999561607837677
oral O O 0.9994057416915894
administration O O 0.9999713897705078
of O O 0.9988048076629639
propranolol B B 0.9996956586837769
( O O 0.9995321035385132
40 O O 0.9993932247161865
- O O 0.9964860677719116
160 O O 0.9816915392875671
mg O O 0.9999369382858276
/ O O 0.9998964071273804
day O O 0.9998993873596191
) O O 0.9998337030410767
also O O 0.9999662637710571
elevated O O 0.9999494552612305
the O O 0.9999899864196777
blood O O 0.9999483823776245
pressures O O 0.9999723434448242
of O O 0.9996292591094971
these O O 0.9995787739753723
individuals O O 0.9922589659690857
with O O 0.9999666213989258
increases O O 0.9999891519546509
in O O 0.999992847442627
the O O 0.9999946355819702
order O O 0.9999947547912598
of O O 0.9999803304672241
20 O O 0.9998877048492432
- O O 0.9985694885253906
35 O O 0.9999713897705078
/ O O 0.9999454021453857
15 O O 0.9999945163726807
- O O 0.9992656111717224
25 O O 0.9999896287918091
mmg O O 0.999824583530426
being O O 0.9999816417694092
observed O O 0.999990701675415
. O O 0.9999654293060303

In O O 0.9999430179595947
1 O O 0.9996434450149536
patient O O 0.9999898672103882
, O O 0.9999246597290039
marked O O 0.9998987913131714
hypertension O O 0.9990704655647278
was O O 0.9999542236328125
induced O O 0.9999822378158569
by O O 0.9997597336769104
propranolol B B 0.9996945858001709
and O O 0.9998658895492554
the O O 0.999963641166687
drug O O 0.9997785687446594
had O O 0.9999804496765137
to O O 0.9999921321868896
be O O 0.9999854564666748
withdrawn O O 0.9998940229415894
. O O 0.9999608993530273

It O O 0.999660849571228
otherwise O O 0.9999381303787231
was O O 0.9999781847000122
well O O 0.9999862909317017
tolerated O O 0.9999854564666748
and O O 0.99997878074646
no O O 0.9999793767929077
important O O 0.9999344348907471
side O O 0.9999477863311768
effects O O 0.9999841451644897
were O O 0.9999834299087524
observed O O 0.9999923706054688
. O O 0.9999655485153198

Treatment O O 0.9994972944259644
has O O 0.9999569654464722
been O O 0.9999905824661255
continued O O 0.9999326467514038
in O O 0.9998660087585449
3 O O 0.7835953831672668
individuals O O 0.9930012226104736
for O O 0.9999277591705322
6 O O 0.9998936653137207
- O O 0.9993020296096802
13 O O 0.9999842643737793
months O O 0.999996542930603
with O O 0.9999890327453613
persistence O O 0.9999855756759644
of O O 0.9999861717224121
the O O 0.9999723434448242
pressor O O 0.9941636919975281
effect O O 0.9998958110809326
, O O 0.9999527931213379
although O O 0.9999810457229614
there O O 0.9999839067459106
appears O O 0.999984622001648
to O O 0.999988317489624
have O O 0.9999969005584717
been O O 0.9999970197677612
some O O 0.9999946355819702
decrease O O 0.9999969005584717
in O O 0.9999951124191284
the O O 0.9999949932098389
degree O O 0.9999951124191284
of O O 0.9999902248382568
response O O 0.9999924898147583
with O O 0.999994158744812
time O O 0.9999783039093018
. O O 0.9999610185623169

Hemodynamic O O 0.9999477863311768
measurements O O 0.9999910593032837
in O O 0.9999678134918213
1 O O 0.9986032843589783
of O O 0.9999747276306152
the O O 0.9999905824661255
patients O O 0.9999891519546509
demonstrated O O 0.9999656677246094
an O O 0.9999850988388062
increase O O 0.999993085861206
in O O 0.9999802112579346
total O O 0.9995253086090088
peripheral O O 0.9979404807090759
resistance O O 0.999994158744812
and O O 0.9999737739562988
essentially O O 0.9999899864196777
no O O 0.9999914169311523
change O O 0.9999980926513672
in O O 0.9999873638153076
cardiac O O 0.9998276233673096
output O O 0.9999921321868896
following O O 0.998958945274353
propranolol B B 0.9998037219047546
therapy O O 0.9998687505722046
. O O 0.9999700784683228

The O O 0.9999862909317017
studies O O 0.999992847442627
suggest O O 0.9999784231185913
that O O 0.9998776912689209
propranolol B B 0.9998341798782349
is O O 0.999861478805542
a O O 0.999907374382019
useful O O 0.9998990297317505
drug O O 0.9997860789299011
in O O 0.9999666213989258
selected O O 0.9999638795852661
patients O O 0.9999920129776001
with O O 0.9999861717224121
severe O O 0.9999830722808838
idiopathic O O 0.9999986886978149
orthostatic O O 0.9997981190681458
hypotension O O 0.9999823570251465
. O O 0.999962329864502

Total O O 0.9999088048934937
intravenous O O 0.999988317489624
anesthesia O O 0.9999459981918335
with O O 0.9998570680618286
etomidate B B 0.9980961680412292
. O O 0.9998321533203125

III O O 0.9896111488342285
. O O 0.9998800754547119

Some O O 0.9998918771743774
observations O O 0.9999839067459106
in O O 0.9999598264694214
adults O O 0.9999881982803345
. O O 0.9999357461929321

An O O 0.9999746084213257
investigation O O 0.9999957084655762
was O O 0.9999912977218628
undertaken O O 0.9999982118606567
to O O 0.9999977350234985
determine O O 0.9999946355819702
the O O 0.9999829530715942
dosage O O 0.9998018145561218
of O O 0.9969491362571716
etomidate B B 0.9995583891868591
required O O 0.9998761415481567
to O O 0.9999731779098511
maintain O O 0.9999351501464844
sleep O O 0.9991359114646912
in O O 0.9999481439590454
adults O O 0.9999868869781494
undergoing O O 0.9999890327453613
surgery O O 0.9999971389770508
under O O 0.9999860525131226
regional O O 0.9999793767929077
local O O 0.9999396800994873
anesthesia O O 0.9999097585678101
. O O 0.9999632835388184

Premedication O O 0.9960720539093018
of O O 0.9988086223602295
diazepam B B 0.9997183680534363
10 O O 0.9919394850730896
mg O O 0.998871386051178
and O O 0.9962866306304932
atropine B B 0.9996495246887207
0 O O 0.9938430786132812
. O O 0.9999915361404419
5 O O 0.9999505281448364
mg O O 0.999263346195221
was O O 0.9999468326568604
given O O 0.9999144077301025
, O O 0.9999556541442871
and O O 0.9999653100967407
sleep O O 0.9999642372131348
was O O 0.9999674558639526
induced O O 0.9999971389770508
and O O 0.9999918937683105
maintained O O 0.999996542930603
by O O 0.9999825954437256
intermittent O O 0.9999536275863647
intravenous O O 0.9999901056289673
injections O O 0.9999788999557495
of O O 0.9997257590293884
etomidate B B 0.9992948770523071
0 O O 0.9970632195472717
. O O 0.999987006187439
1 O O 0.9999773502349854
/ O O 0.9994626641273499
mg O O 0.9999382495880127
/ O O 0.9995262622833252
kg O O 0.9997991919517517
, O O 0.9999847412109375
given O O 0.9999628067016602
whenever O O 0.9999955892562866
the O O 0.9999972581863403
patient O O 0.9999938011169434
would O O 0.9999873638153076
open O O 0.9999966621398926
his O O 0.9999935626983643
eyes O O 0.9999974966049194
on O O 0.9999735355377197
request O O 0.9999839067459106
. O O 0.9999827146530151

A O O 0.9999792575836182
mean O O 0.9999700784683228
overall O O 0.9998782873153687
dose O O 0.9999082088470459
of O O 0.9996999502182007
etomidate B B 0.9993094205856323
17 O O 0.9867397546768188
. O O 0.9999815225601196
4 O O 0.9987315535545349
microgram O O 0.9999115467071533
/ O O 0.9999924898147583
kg O O 0.9999973773956299
/ O O 0.999984860420227
min O O 0.9999366998672485
. O O 0.9999871253967285
was O O 0.9999810457229614
required O O 0.9999512434005737
to O O 0.999976396560669
maintain O O 0.9999526739120483
sleep O O 0.9998683929443359
, O O 0.9999799728393555
but O O 0.9999785423278809
great O O 0.9999791383743286
individual O O 0.9999748468399048
variation O O 0.9999986886978149
occurred O O 0.9999954700469971
, O O 0.9999947547912598
with O O 0.9999964237213135
older O O 0.9999924898147583
patients O O 0.9999967813491821
requiring O O 0.9999614953994751
less O O 0.9999692440032959
drug O O 0.9992826581001282
. O O 0.9999653100967407

The O O 0.9999819993972778
investigation O O 0.9999481439590454
was O O 0.9999785423278809
discontinued O O 0.9999855756759644
after O O 0.999991774559021
18 O O 0.9999443292617798
patients O O 0.9999945163726807
because O O 0.999997615814209
of O O 0.9999910593032837
the O O 0.9999958276748657
frequency O O 0.9999932050704956
and O O 0.9999861717224121
intensity O O 0.9999932050704956
of O O 0.9999737739562988
side O O 0.999863862991333
- O O 0.9999256134033203
effects O O 0.9999731779098511
, O O 0.9999845027923584
particularly O O 0.9997311234474182
pain O O 0.9998801946640015
and O O 0.999863862991333
myoclonia O O 0.9999977350234985
, O O 0.9999896287918091
which O O 0.9999657869338989
caused O O 0.999980092048645
the O O 0.9999899864196777
technique O O 0.9999860525131226
to O O 0.99998939037323
be O O 0.99998939037323
abandoned O O 0.9999769926071167
in O O 0.9999809265136719
two O O 0.9999926090240479
cases O O 0.9999934434890747
. O O 0.9999688863754272

It O O 0.9999901056289673
is O O 0.999984860420227
considered O O 0.9999971389770508
unlikely O O 0.9999935626983643
that O O 0.9999305009841919
etomidate B B 0.9996771812438965
will O O 0.9999264478683472
prove O O 0.9999842643737793
to O O 0.9999538660049438
be O O 0.9999473094940186
the O O 0.9999533891677856
hypnotic O O 0.9925538897514343
of O O 0.9999504089355469
choice O O 0.9999582767486572
for O O 0.9999139308929443
a O O 0.9999208450317383
totally O O 0.9997738003730774
intravenous O O 0.9999232292175293
anesthetic O O 0.9980279803276062
technique O O 0.999969482421875
in O O 0.9998716115951538
adults O O 0.9998096823692322
because O O 0.9999903440475464
of O O 0.9999915361404419
the O O 0.9999967813491821
high O O 0.9999921321868896
incidence O O 0.9999972581863403
of O O 0.9999845027923584
myoclonia O O 0.999998927116394
after O O 0.9999517202377319
prolonged O O 0.9996528625488281
administration O O 0.9999535083770752
. O O 0.9999599456787109

In O O 0.9999439716339111
several O O 0.9999568462371826
patients O O 0.9999797344207764
uncontrollable O O 0.9999597072601318
muscle O O 0.9998594522476196
movements O O 0.9999942779541016
persisted O O 0.9999711513519287
for O O 0.9999731779098511
many O O 0.9999887943267822
minutes O O 0.9999972581863403
after O O 0.9999873638153076
complete O O 0.999988317489624
recovery O O 0.999997615814209
of O O 0.9999884366989136
consciousness O O 0.9999959468841553
. O O 0.9999731779098511

Evidence O O 0.9999251365661621
for O O 0.9990547299385071
cardiac O O 0.9967966675758362
beta O O 0.9234620928764343
2 O O 0.9498459100723267
- O O 0.9789363145828247
adrenoceptors O O 0.9659700989723206
in O O 0.9998041987419128
man O O 0.9997525811195374
. O O 0.9998952150344849

We O O 0.9999794960021973
compared O O 0.9999692440032959
the O O 0.9999690055847168
effects O O 0.9999717473983765
of O O 0.9999120235443115
single O O 0.9998598098754883
doses O O 0.9999103546142578
of O O 0.9998352527618408
50 O O 0.9999210834503174
mg O O 0.9968780279159546
atenolol B B 0.9996825456619263
( O O 0.9987027645111084
cardioselective O O 0.9999139308929443
) O O 0.9997027516365051
, O O 0.9981885552406311
40 O O 0.999768078327179
mg O O 0.998090922832489
propranolol B B 0.9997145533561707
( O O 0.9995009899139404
nonselective O O 0.9565743803977966
) O O 0.9998351335525513
, O O 0.9988576173782349
and O O 0.9973388314247131
placebo O O 0.8192211985588074
on O O 0.9997139573097229
both O O 0.9993311166763306
exercise O O 0.6018024682998657
- O O 0.9996045231819153
and O O 0.9996949434280396
isoproterenol B B 0.9981805086135864
- O O 0.9997957348823547
induced O O 0.9999415874481201
tachycardia O O 0.9999909400939941
in O O 0.9999847412109375
two O O 0.9999940395355225
experiments O O 0.9999924898147583
involving O O 0.9999916553497314
nine O O 0.9999948740005493
normal O O 0.9999806880950928
subjects O O 0.9999973773956299
. O O 0.9999837875366211

Maximal O O 0.9999667406082153
exercise O O 0.9999659061431885
heart O O 0.9999818801879883
rate O O 0.9999748468399048
was O O 0.9999483823776245
reduced O O 0.9999947547912598
from O O 0.9999852180480957
187 O O 0.9999699592590332
+ O O 0.9999862909317017
/ O O 0.9999936819076538
- O O 0.9999635219573975
4 O O 0.9999727010726929
( O O 0.9998414516448975
SEM O O 0.9930886626243591
) O O 0.9999731779098511
after O O 0.9994661211967468
placebo O O 0.9779759049415588
to O O 0.9999667406082153
146 O O 0.9999833106994629
+ O O 0.9999935626983643
/ O O 0.9999947547912598
- O O 0.9999604225158691
7 O O 0.9999806880950928
bpm O O 0.9988338351249695
after O O 0.9994493126869202
atenolol B B 0.9995974898338318
and O O 0.999729335308075
138 O O 0.9998053908348083
+ O O 0.9999924898147583
/ O O 0.9999945163726807
- O O 0.9999711513519287
6 O O 0.9999874830245972
bpm O O 0.9978785514831543
after O O 0.9994264841079712
propranolol B B 0.9995598196983337
, O O 0.9998437166213989
but O O 0.9999771118164062
there O O 0.9999918937683105
were O O 0.9999915361404419
no O O 0.9999899864196777
differences O O 0.9999958276748657
between O O 0.999819815158844
the O O 0.9999462366104126
drugs O O 0.9998950958251953
. O O 0.9999642372131348

The O O 0.999911904335022
effects O O 0.9999082088470459
on O O 0.9999122619628906
isoproterenol B B 0.9980054497718811
tachycardia O O 0.999687910079956
were O O 0.9999752044677734
determined O O 0.9999641180038452
before O O 0.9996706247329712
and O O 0.9999338388442993
after O O 0.9998440742492676
atropine B B 0.9998000264167786
( O O 0.9997610449790955
0 O O 0.9999508857727051
. O O 0.9999943971633911
04 O O 0.9998304843902588
mg O O 0.9999288320541382
/ O O 0.9999545812606812
kg O O 0.9999831914901733
IV O O 0.98411625623703
) O O 0.9999606609344482
. O O 0.9999607801437378

Isoproterenol B B 0.9986311793327332
sensitivity O O 0.9870004653930664
was O O 0.9999638795852661
determined O O 0.999991774559021
as O O 0.9999788999557495
the O O 0.9999815225601196
intravenous O O 0.999945878982544
dose O O 0.9995306730270386
that O O 0.9998151659965515
increased O O 0.9998806715011597
heart O O 0.9999814033508301
rate O O 0.9999903440475464
by O O 0.9999929666519165
25 O O 0.9999765157699585
bpm O O 0.9996216297149658
( O O 0.9997777342796326
CD25 O O 0.5088329911231995
) O O 0.9998630285263062
and O O 0.999977707862854
this O O 0.9999821186065674
was O O 0.9999790191650391
increased O O 0.9999877214431763
from O O 0.9999879598617554
1 O O 0.9999701976776123
. O O 0.999991774559021
8 O O 0.9997733235359192
+ O O 0.9999904632568359
/ O O 0.9999616146087646
- O O 0.9999330043792725
0 O O 0.9999929666519165
. O O 0.9999935626983643
3 O O 0.9999781847000122
micrograms O O 0.9998316764831543
after O O 0.9993859529495239
placebo O O 0.7295896410942078
to O O 0.9998924732208252
38 O O 0.9999599456787109
. O O 0.9999879598617554
9 O O 0.9999905824661255
+ O O 0.9999935626983643
/ O O 0.9999799728393555
- O O 0.9999397993087769
8 O O 0.9995748400688171
. O O 0.9999942779541016
3 O O 0.9999879598617554
micrograms O O 0.9999526739120483
after O O 0.9989325404167175
propranolol B B 0.9993829727172852
and O O 0.9998613595962524
8 O O 0.9989057779312134
. O O 0.9999924898147583
3 O O 0.9999884366989136
+ O O 0.999994158744812
/ O O 0.9999771118164062
- O O 0.9999558925628662
1 O O 0.9999909400939941
. O O 0.9999849796295166
7 O O 0.9999914169311523
micrograms O O 0.9999337196350098
after O O 0.9980558156967163
atenolol B B 0.9993361830711365
. O O 0.999946117401123

The O O 0.9999771118164062
difference O O 0.9999938011169434
in O O 0.9999898672103882
the O O 0.9999629259109497
effects O O 0.9999535083770752
of O O 0.9998342990875244
the O O 0.9992641806602478
two O O 0.9992247819900513
was O O 0.9999141693115234
significant O O 0.999962568283081
. O O 0.9999693632125854

After O O 0.9959399700164795
atropine B B 0.9997270703315735
the O O 0.9998500347137451
CD25 O O 0.8731856346130371
was O O 0.9999535083770752
unchanged O O 0.999988317489624
after O O 0.9996058344841003
placebo O O 0.9828869700431824
( O O 0.9999098777770996
2 O O 0.9999600648880005
. O O 0.9999932050704956
3 O O 0.9999778270721436
+ O O 0.9999904632568359
/ O O 0.9999850988388062
- O O 0.9999203681945801
0 O O 0.9999902248382568
. O O 0.9999948740005493
3 O O 0.9999654293060303
micrograms O O 0.9980483055114746
) O O 0.9998588562011719
and O O 0.9983344674110413
atenolol B B 0.9994396567344666
( O O 0.999563992023468
7 O O 0.9999676942825317
. O O 0.9999951124191284
7 O O 0.9999954700469971
+ O O 0.9999918937683105
/ O O 0.9999814033508301
- O O 0.9999072551727295
1 O O 0.9999915361404419
. O O 0.999988317489624
3 O O 0.9999747276306152
micrograms O O 0.9992520213127136
) O O 0.9999597072601318
; O O 0.9999715089797974
it O O 0.999954104423523
was O O 0.9999486207962036
reduced O O 0.9999943971633911
after O O 0.9991996884346008
propranolol B B 0.9995587468147278
( O O 0.9997749924659729
24 O O 0.9999216794967651
. O O 0.9999943971633911
8 O O 0.9999858140945435
+ O O 0.9999897480010986
/ O O 0.999987006187439
- O O 0.9999432563781738
5 O O 0.9999892711639404
. O O 0.9999957084655762
0 O O 0.9999874830245972
micrograms O O 0.9998389482498169
) O O 0.9999593496322632
, O O 0.9999613761901855
but O O 0.9999648332595825
remained O O 0.9999861717224121
different O O 0.9999890327453613
from O O 0.9996306896209717
atenolol B B 0.9986009001731873
. O O 0.9999639987945557

This O O 0.999950647354126
change O O 0.999992847442627
with O O 0.9997624754905701
propranolol B B 0.9997959733009338
sensitivity O O 0.9993137121200562
was O O 0.9999539852142334
calculated O O 0.9999663829803467
as O O 0.9999810457229614
the O O 0.9999904632568359
apparent O O 0.9999830722808838
Ka O O 0.9994083642959595
, O O 0.9999545812606812
this O O 0.9999715089797974
was O O 0.9999700784683228
unchanged O O 0.9999872446060181
by O O 0.9981818199157715
atropine B B 0.9997373223304749
( O O 0.9996747970581055
11 O O 0.9996426105499268
. O O 0.9999721050262451
7 O O 0.9999788999557495
+ O O 0.9999804496765137
/ O O 0.9998881816864014
- O O 0.9997352957725525
2 O O 0.9997403025627136
. O O 0.9999793767929077
1 O O 0.9999897480010986
and O O 0.9998658895492554
10 O O 0.9999394416809082
. O O 0.9999940395355225
1 O O 0.9999918937683105
+ O O 0.9999831914901733
/ O O 0.9999500513076782
- O O 0.9999521970748901
2 O O 0.999981164932251
. O O 0.9999852180480957
5 O O 0.9999711513519287
ml O O 0.9999876022338867
/ O O 0.9992658495903015
ng O O 0.9989643096923828
) O O 0.9999667406082153
. O O 0.9999616146087646

These O O 0.9999830722808838
data O O 0.9999934434890747
are O O 0.9999597072601318
consistent O O 0.9999868869781494
with O O 0.999990701675415
the O O 0.9999901056289673
hypothesis O O 0.9999740123748779
that O O 0.9999417066574097
exercise O O 0.8642646670341492
- O O 0.9996533393859863
induced O O 0.9999831914901733
tachycardia O O 0.9999977350234985
results O O 0.9999688863754272
largely O O 0.9999780654907227
from O O 0.9996893405914307
beta O O 0.9750663638114929
1 O O 0.977997362613678
- O O 0.993760883808136
receptor O O 0.9996788501739502
activation O O 0.999745786190033
that O O 0.9998347759246826
is O O 0.999882698059082
blocked O O 0.9993289709091187
by O O 0.9997854828834534
both O O 0.9987797141075134
cardioselective O O 0.9990429282188416
and O O 0.9995255470275879
nonselective O O 0.9557828903198242
drugs O O 0.9988277554512024
, O O 0.9999127388000488
whereas O O 0.9977269768714905
isoproterenol B B 0.9991331696510315
activates O O 0.9982642531394958
both O O 0.9994974136352539
beta O O 0.9916286468505859
1 O O 0.9891510009765625
- O O 0.9988625049591064
and O O 0.9994449019432068
beta O O 0.9889528751373291
2 O O 0.9833050966262817
- O O 0.9988996982574463
receptors O O 0.9999372959136963
so O O 0.9999675750732422
that O O 0.9999783039093018
after O O 0.9998342990875244
cardioselective O O 0.9971640706062317
blockade O O 0.999913215637207
there O O 0.9997161030769348
remains O O 0.9999363422393799
a O O 0.9998835325241089
beta O O 0.985945999622345
2 O O 0.9786148071289062
- O O 0.9986993074417114
component O O 0.999708354473114
that O O 0.999943733215332
can O O 0.9997811913490295
be O O 0.9999876022338867
blocked O O 0.9998146891593933
with O O 0.9998890161514282
a O O 0.9998847246170044
nonselective O O 0.9514985084533691
drug O O 0.9990854263305664
. O O 0.9999196529388428

While O O 0.9999406337738037
there O O 0.9989480376243591
appear O O 0.9998525381088257
to O O 0.9998037219047546
be O O 0.9994773268699646
beta O O 0.9309105277061462
2 O O 0.937663733959198
- O O 0.9660584330558777
receptors O O 0.9933823347091675
in O O 0.9996607303619385
the O O 0.9999549388885498
human O O 0.9999779462814331
heart O O 0.999951958656311
, O O 0.9999125003814697
their O O 0.9998701810836792
physiologic O O 0.9999241828918457
or O O 0.999893307685852
pathologic O O 0.9999674558639526
roles O O 0.9999878406524658
remain O O 0.9999922513961792
to O O 0.999992847442627
be O O 0.9999954700469971
defined O O 0.9999963045120239
. O O 0.9999709129333496

Hormones O O 0.7156050801277161
and O O 0.9988850951194763
risk O O 0.9999836683273315
of O O 0.9999691247940063
breast O O 0.9968505501747131
cancer O O 0.9996378421783447
. O O 0.9999161958694458

This O O 0.9999840259552002
paper O O 0.9999951124191284
reports O O 0.9999897480010986
the O O 0.9999970197677612
results O O 0.999996542930603
of O O 0.9999923706054688
a O O 0.9999932050704956
study O O 0.9999932050704956
of O O 0.9999850988388062
50 O O 0.9999696016311646
menopausal O O 0.9989814162254333
women O O 0.9999912977218628
receiving O O 0.9995397329330444
hormonal O O 0.5023127794265747
replacement O O 0.6226246953010559
therapy O O 0.9918513894081116
. O O 0.9999361038208008

The O O 0.9999613761901855
majority O O 0.9999881982803345
( O O 0.9999486207962036
29 O O 0.9999486207962036
) O O 0.9999688863754272
had O O 0.9999825954437256
surgical O O 0.9999901056289673
menopause O O 0.9943060278892517
; O O 0.9999822378158569
their O O 0.9999967813491821
mean O O 0.9999957084655762
age O O 0.9999656677246094
was O O 0.999995231628418
45 O O 0.9999990463256836
. O O 0.9999986886978149
7 O O 0.9999984502792358
years O O 0.9999984502792358
. O O 0.9999886751174927

It O O 0.9999871253967285
was O O 0.999984622001648
hypothesized O O 0.9999619722366333
that O O 0.9998483657836914
progestins B O 0.8193874955177307
could O O 0.9997654557228088
equilibrate O O 0.9999679327011108
the O O 0.9999417066574097
effects O O 0.9999527931213379
of O O 0.9999101161956787
the O O 0.9997736811637878
estrogenic O B 0.851769208908081
stimulation O O 0.8848425149917603
on O O 0.9997255206108093
the O O 0.9999209642410278
mammary O O 0.9988648891448975
and O O 0.9994766116142273
endometrial O O 0.9995585083961487
target O O 0.9997740387916565
tissues O O 0.9999921321868896
of O O 0.9999792575836182
women O O 0.9999957084655762
on O O 0.9998118281364441
hormonal O O 0.4826453626155853
replacement O O 0.5977626442909241
therapy O O 0.997597873210907
. O O 0.9999643564224243

The O O 0.9999779462814331
treatment O O 0.9999690055847168
schedule O O 0.9999916553497314
consisted O O 0.9999892711639404
of O O 0.9998279809951782
conjugated B B 0.7200793623924255
estrogens I I 0.9010153412818909
( O O 0.8108426332473755
Premarin B O 0.8152776956558228
) O O 0.993818461894989
1 O O 0.9992996454238892
. O O 0.9999771118164062
25 O O 0.9997643828392029
mg O O 0.9998579025268555
/ O O 0.9994860887527466
day O O 0.9999754428863525
for O O 0.99996018409729
21 O O 0.9999781847000122
days O O 0.9999904632568359
and O O 0.9996761083602905
Medroxyprogesterone B B 0.9967303276062012
acetate I I 0.9990696310997009
10 O O 0.9931936860084534
mg O O 0.9998873472213745
/ O O 0.9998493194580078
day O O 0.9999754428863525
for O O 0.9999734163284302
10 O O 0.9999765157699585
days O O 0.9999889135360718
in O O 0.999984622001648
each O O 0.9999845027923584
month O O 0.9999970197677612
. O O 0.9999831914901733

The O O 0.9999569654464722
mean O O 0.9999616146087646
treatment O O 0.999914288520813
period O O 0.9999704360961914
was O O 0.9999836683273315
18 O O 0.9999922513961792
months O O 0.9999967813491821
. O O 0.9999732971191406

During O O 0.9999414682388306
the O O 0.9999946355819702
follow O O 0.9999902248382568
- O O 0.9999918937683105
up O O 0.9999949932098389
period O O 0.9999936819076538
, O O 0.9999644756317139
attention O O 0.9999796152114868
was O O 0.9999798536300659
paid O O 0.9999972581863403
to O O 0.9999088048934937
breast O O 0.9930121302604675
modifications O O 0.9998437166213989
as O O 0.9999755620956421
evidenced O O 0.9999926090240479
by O O 0.9999915361404419
symptomatology O O 0.9999488592147827
, O O 0.9999899864196777
physical O O 0.9999886751174927
examination O O 0.9999986886978149
, O O 0.9999566078186035
and O O 0.9999827146530151
plate O O 0.9838738441467285
thermography O O 0.9998193383216858
. O O 0.9999715089797974

Mastodynia O O 0.9981843829154968
was O O 0.9999597072601318
reported O O 0.9999912977218628
by O O 0.9999804496765137
21 O O 0.9995899796485901
patients O O 0.999992847442627
, O O 0.9999617338180542
and O O 0.9999784231185913
physical O O 0.9999873638153076
examination O O 0.9999979734420776
revealed O O 0.9999862909317017
a O O 0.9999934434890747
light O O 0.9999957084655762
increase O O 0.9999988079071045
in O O 0.9999837875366211
breast O O 0.9994916915893555
firmness O O 0.9999862909317017
in O O 0.9999659061431885
12 O O 0.9999854564666748
women O O 0.9999324083328247
and O O 0.9999605417251587
a O O 0.9999843835830688
moderate O O 0.9999809265136719
increase O O 0.9999978542327881
in O O 0.999985933303833
breast O O 0.9991004467010498
nodularity O O 0.9999934434890747
in O O 0.9999443292617798
2 O O 0.9998346567153931
women O O 0.9999488592147827
. O O 0.9999762773513794

Themography O O 0.9999473094940186
confirmed O O 0.9999631643295288
the O O 0.9999860525131226
existence O O 0.9999877214431763
of O O 0.9999691247940063
an O O 0.9999392032623291
excessive O O 0.9996203184127808
breast O O 0.9068979024887085
stimulation O O 0.9979228377342224
in O O 0.999881386756897
1 O O 0.99970942735672
women O O 0.9999942779541016
who O O 0.999941349029541
complained O O 0.9999858140945435
of O O 0.9999637603759766
moderate O O 0.9999573230743408
mastodynia O O 0.9993926286697388
and O O 0.9999183416366577
in O O 0.9999358654022217
5 O O 0.9999536275863647
of O O 0.9999701976776123
the O O 0.9999926090240479
7 O O 0.9999479055404663
women O O 0.9999955892562866
who O O 0.9999494552612305
complained O O 0.9999821186065674
of O O 0.9999656677246094
severe O O 0.9999566078186035
mastodynia O O 0.9997723698616028
. O O 0.9999618530273438

Normalization O O 0.9981787204742432
was O O 0.9999699592590332
obtained O O 0.99998939037323
by O O 0.9999544620513916
halving O O 0.999751627445221
the O O 0.9997819066047668
estrogen B B 0.9576396346092224
dose O O 0.9974216222763062
. O O 0.9999072551727295

These O O 0.9999910593032837
results O O 0.9999947547912598
suggest O O 0.9999874830245972
that O O 0.9999557733535767
hormonal O O 0.6237165927886963
replacement O O 0.5581468939781189
therapy O O 0.9995959401130676
can O O 0.9999680519104004
be O O 0.9999939203262329
safely O O 0.9999818801879883
prescribed O O 0.9999836683273315
if O O 0.9999892711639404
the O O 0.9999958276748657
following O O 0.9999904632568359
criteria O O 0.999997615814209
are O O 0.9999923706054688
satisfied O O 0.9999803304672241
: O O 0.9999895095825195
1 O O 0.9999895095825195
) O O 0.9999927282333374
preliminary O O 0.9999953508377075
evaluation O O 0.9999986886978149
of O O 0.999995231628418
patients O O 0.9999935626983643
from O O 0.9999936819076538
a O O 0.9999899864196777
clinical O O 0.9999921321868896
, O O 0.9999854564666748
metabolic O O 0.9999521970748901
, O O 0.9999790191650391
cytologic O O 0.9996360540390015
, O O 0.9999338388442993
and O O 0.9999645948410034
mammographic O O 0.9999842643737793
perspective O O 0.9999852180480957
; O O 0.9999885559082031
2 O O 0.9999951124191284
) O O 0.9999713897705078
cyclic O O 0.7944943904876709
treatment O O 0.9988158941268921
schedule O O 0.9999452829360962
, O O 0.9999921321868896
with O O 0.9999797344207764
a O O 0.9999778270721436
progestative O O 0.9669034481048584
phase O O 0.9999339580535889
of O O 0.999927282333374
10 O O 0.9999536275863647
days O O 0.9999783039093018
; O O 0.9999427795410156
and O O 0.9999719858169556
3 O O 0.9999905824661255
) O O 0.9999908208847046
periodic O O 0.9999877214431763
complete O O 0.9999961853027344
follow O O 0.9999972581863403
- O O 0.9999948740005493
up O O 0.9999984502792358
, O O 0.9999940395355225
with O O 0.999990701675415
accurate O O 0.9999899864196777
thermographic O O 0.9997121691703796
evaluation O O 0.9999885559082031
of O O 0.9999815225601196
the O O 0.9999910593032837
breast O O 0.9996515512466431
target O O 0.9998844861984253
tissues O O 0.9999948740005493
. O O 0.9999850988388062

Early O O 0.9998045563697815
infections O O 0.9999914169311523
in O O 0.9999572038650513
kidney O O 0.9998007416725159
, O O 0.9999282360076904
heart O O 0.9999220371246338
, O O 0.9998213648796082
and O O 0.9999032020568848
liver O O 0.9993763566017151
transplant O O 0.9999115467071533
recipients O O 0.9999830722808838
on O O 0.9971858859062195
cyclosporine B B 0.9989871382713318
. O O 0.9997835755348206

Eighty O O 0.9931440353393555
- O O 0.9999573230743408
one O O 0.9999805688858032
renal O O 0.9997047781944275
, O O 0.9999098777770996
seventeen O O 0.9995724558830261
heart O O 0.9999370574951172
, O O 0.9999209642410278
and O O 0.9999171495437622
twenty O O 0.998308539390564
- O O 0.9998792409896851
four O O 0.9999827146530151
liver O O 0.9988221526145935
transplant O O 0.9998797178268433
patients O O 0.9999896287918091
were O O 0.9999686479568481
followed O O 0.9999734163284302
for O O 0.9999455213546753
infection O O 0.9999740123748779
. O O 0.9999616146087646

Seventeen O O 0.999108612537384
renal O O 0.9998394250869751
patients O O 0.9999901056289673
received O O 0.999896764755249
azathioprine B B 0.9996812343597412
( O O 0.9884636998176575
Aza B B 0.9994606375694275
) O O 0.9755109548568726
and O O 0.9957531690597534
prednisone B B 0.998659610748291
as O O 0.9999645948410034
part O O 0.9999924898147583
of O O 0.999988317489624
a O O 0.9999921321868896
randomized O O 0.9999942779541016
trial O O 0.9999924898147583
of O O 0.9999569654464722
immunosuppression O O 0.9999066591262817
with O O 0.9999752044677734
21 O O 0.9901610612869263
cyclosporine B B 0.9976771473884583
- O O 0.998389720916748
and O O 0.9764199256896973
- O O 0.9913474917411804
prednisone B B 0.9787315130233765
- O O 0.9995821118354797
treated O O 0.9999289512634277
renal O O 0.9999828338623047
transplant O O 0.9999722242355347
patients O O 0.9999964237213135
. O O 0.99997878074646

All O O 0.9997455477714539
others O O 0.9999847412109375
received O O 0.9993398785591125
cyclosporine B B 0.999620795249939
and O O 0.9624525308609009
prednisone B B 0.9975870847702026
. O O 0.9999258518218994

The O O 0.9999634027481079
randomized O O 0.9998911619186401
Aza B B 0.9917442202568054
patients O O 0.9957205653190613
had O O 0.9999676942825317
more O O 0.9999010562896729
overall O O 0.9940552711486816
infections O O 0.9999744892120361
( O O 0.9999581575393677
P O O 0.9967913031578064
less O O 0.9999752044677734
than O O 0.9999920129776001
0 O O 0.9999877214431763
. O O 0.9999946355819702
05 O O 0.9999892711639404
) O O 0.9999542236328125
and O O 0.999958872795105
more O O 0.9998903274536133
nonviral O O 0.900673508644104
infections O O 0.9999464750289917
( O O 0.9999392032623291
P O O 0.9936978220939636
less O O 0.9999709129333496
than O O 0.999990701675415
0 O O 0.9999617338180542
. O O 0.9999932050704956
02 O O 0.9999760389328003
) O O 0.9999439716339111
than O O 0.9999653100967407
the O O 0.9999691247940063
randomized O O 0.9999352693557739
cyclosporine B B 0.9988604784011841
patients O O 0.9996920824050903
. O O 0.9999688863754272

Heart O O 0.9974762797355652
and O O 0.9998899698257446
liver O O 0.9995142221450806
patients O O 0.9999456405639648
had O O 0.999963641166687
more O O 0.9996587038040161
infections O O 0.9999620914459229
than O O 0.9997742772102356
cyclosporine B B 0.999104917049408
renal O O 0.9959191679954529
patients O O 0.9999430179595947
but O O 0.9999746084213257
fewer O O 0.9999727010726929
infections O O 0.9999721050262451
than O O 0.9999539852142334
the O O 0.9999145269393921
Aza B B 0.9238505363464355
renal O O 0.9724239110946655
patients O O 0.9999358654022217
. O O 0.9999738931655884

There O O 0.9999167919158936
were O O 0.9999548196792603
no O O 0.9998643398284912
infectious O O 0.999962568283081
deaths O O 0.99998939037323
in O O 0.9999179840087891
renal O O 0.9995442032814026
transplant O O 0.9996201992034912
patients O O 0.9999856948852539
on O O 0.9982473850250244
cyclosporine B B 0.999535083770752
or O O 0.8818422555923462
Aza B B 0.9965873956680298
, O O 0.999589741230011
but O O 0.9988170862197876
infection O O 0.9997742772102356
played O O 0.999974250793457
a O O 0.999955415725708
major O O 0.9999717473983765
role O O 0.9999840259552002
in O O 0.9999653100967407
3 O O 0.9995765089988708
out O O 0.999975323677063
of O O 0.9999827146530151
6 O O 0.9999834299087524
cardiac O O 0.9999772310256958
transplant O O 0.9999524354934692
deaths O O 0.9999885559082031
and O O 0.9999529123306274
in O O 0.9999668598175049
8 O O 0.999836802482605
out O O 0.9999921321868896
of O O 0.9999855756759644
9 O O 0.9999816417694092
liver O O 0.998867392539978
transplant O O 0.9998939037322998
deaths O O 0.9999872446060181
. O O 0.9999740123748779

Renal O O 0.9872209429740906
patients O O 0.9999715089797974
on O O 0.9979026317596436
cyclosporine B B 0.999281108379364
had O O 0.9999256134033203
the O O 0.9999910593032837
fewest O O 0.9999953508377075
bacteremias O O 0.9999188184738159
. O O 0.9999459981918335

Analysis O O 0.9999439716339111
of O O 0.9999693632125854
site O O 0.9999854564666748
of O O 0.9999485015869141
infection O O 0.9999756813049316
showed O O 0.9999600648880005
a O O 0.9999375343322754
preponderance O O 0.9990711212158203
of O O 0.999872088432312
abdominal O O 0.9999197721481323
infections O O 0.9999594688415527
in O O 0.9999011754989624
liver O O 0.9980754852294922
patients O O 0.9999737739562988
, O O 0.9999492168426514
intrathoracic O O 0.9998950958251953
infections O O 0.9999141693115234
in O O 0.9999409914016724
heart O O 0.9998461008071899
patients O O 0.9999842643737793
, O O 0.9998536109924316
and O O 0.9998430013656616
urinary O O 0.999885082244873
tract O O 0.999924898147583
infections O O 0.9999164342880249
in O O 0.9998888969421387
renal O O 0.9997798800468445
patients O O 0.9999758005142212
. O O 0.9999748468399048

Pulmonary O O 0.9989991784095764
infections O O 0.9999761581420898
were O O 0.9999686479568481
less O O 0.9999887943267822
common O O 0.9999905824661255
in O O 0.9998362064361572
cyclosporine B B 0.9996150732040405
- O O 0.9992749094963074
treated O O 0.999674916267395
renal O O 0.9998971223831177
patients O O 0.9999711513519287
than O O 0.9999628067016602
in O O 0.9999039173126221
Aza B B 0.9965512752532959
- O O 0.9974557757377625
treated O O 0.9998983144760132
patients O O 0.999980092048645
( O O 0.9999620914459229
P O O 0.9992243051528931
less O O 0.9999938011169434
than O O 0.999994158744812
0 O O 0.9999959468841553
. O O 0.9999978542327881
05 O O 0.9999953508377075
) O O 0.9999731779098511
. O O 0.9999852180480957

Aza B O 0.7753999829292297
patients O O 0.999768078327179
had O O 0.9999673366546631
significantly O O 0.9999798536300659
more O O 0.9999563694000244
staphylococcal O O 0.5364043712615967
infections O O 0.999950647354126
than O O 0.999940037727356
all O O 0.9998719692230225
other O O 0.9999160766601562
transplant O O 0.9998589754104614
groups O O 0.9999861717224121
( O O 0.9999507665634155
P O O 0.999648928642273
less O O 0.9999908208847046
than O O 0.9999948740005493
0 O O 0.9999946355819702
. O O 0.9999978542327881
005 O O 0.9999909400939941
) O O 0.9999469518661499
, O O 0.999875545501709
and O O 0.9999372959136963
systemic O O 0.9997819066047668
fungal O O 0.999442994594574
infections O O 0.999972939491272
occurred O O 0.9999843835830688
only O O 0.9999696016311646
in O O 0.9999475479125977
the O O 0.99996018409729
liver O O 0.984966516494751
transplant O O 0.9996539354324341
group O O 0.9999439716339111
. O O 0.9999631643295288

Cytomegalovirus O B 0.8906534314155579
( O O 0.9448374509811401
CMV O O 0.678989589214325
) O O 0.9961347579956055
shedding O O 0.9999067783355713
or O O 0.9999279975891113
serological O O 0.9999610185623169
rises O O 0.9999967813491821
in O O 0.999950647354126
antibody O O 0.998275637626648
titer O O 0.9998836517333984
, O O 0.9999381303787231
or O O 0.9998974800109863
both O O 0.9999397993087769
occurred O O 0.9999911785125732
in O O 0.9999680519104004
78 O O 0.9999955892562866
% O O 0.9999901056289673
of O O 0.9999406337738037
cyclosporine B B 0.9985178112983704
patients O O 0.9997316002845764
and O O 0.9999188184738159
76 O O 0.99998939037323
% O O 0.9999921321868896
of O O 0.9999548196792603
Aza B O 0.6565693616867065
patients O O 0.9998863935470581
. O O 0.9999618530273438

Of O O 0.9995680451393127
the O O 0.999932050704956
cyclosporine B B 0.9984061121940613
patients O O 0.9992420673370361
, O O 0.9999396800994873
15 O O 0.9999622106552124
% O O 0.9999855756759644
had O O 0.9999896287918091
symptoms O O 0.9999971389770508
related O O 0.9999957084655762
to O O 0.9999186992645264
CMV O O 0.912193775177002
infection O O 0.9999186992645264
. O O 0.999948263168335

Serological O O 0.999931812286377
evidence O O 0.9999871253967285
for O O 0.9998648166656494
Epstein O O 0.7939239740371704
Barr O O 0.4972062408924103
Virus O O 0.6222537159919739
infection O O 0.9996906518936157
was O O 0.999966025352478
found O O 0.9999864101409912
in O O 0.999974250793457
20 O O 0.9999755620956421
% O O 0.9999958276748657
of O O 0.9999891519546509
65 O O 0.9999529123306274
cyclosporine B B 0.9952479004859924
patients O O 0.9993056058883667
studied O O 0.9999409914016724
. O O 0.9999628067016602

Three O O 0.9996172189712524
had O O 0.9999656677246094
associated O O 0.9999799728393555
symptoms O O 0.9999967813491821
, O O 0.9999632835388184
and O O 0.9999793767929077
one O O 0.999976634979248
developed O O 0.9999943971633911
a O O 0.9999828338623047
lymphoma O O 0.9999500513076782
. O O 0.9999510049819946

Structure O O 0.8431980609893799
- O O 0.9992524981498718
activity O O 0.9998235106468201
and O O 0.9998809099197388
dose O O 0.9981164932250977
- O O 0.9998959302902222
effect O O 0.9999785423278809
relationships O O 0.9999899864196777
of O O 0.9999203681945801
the O O 0.9998863935470581
antagonism O O 0.992387056350708
of O O 0.9996534585952759
picrotoxin B B 0.9985987544059753
- O O 0.999363362789154
induced O O 0.9999032020568848
seizures O O 0.9999741315841675
by O O 0.9995567202568054
cholecystokinin B B 0.901830792427063
, O O 0.970832884311676
fragments O O 0.7144380211830139
and O O 0.9928877949714661
analogues O O 0.9909029603004456
of O O 0.9912250638008118
cholecystokinin B B 0.9764328598976135
in O O 0.999734103679657
mice O O 0.999951958656311
. O O 0.9999585151672363

Intraperitoneal O O 0.9999539852142334
administration O O 0.999922513961792
of O O 0.9997020363807678
cholecystokinin B B 0.9090096950531006
octapeptide I I 0.9391312003135681
sulphate O I 0.9122722744941711
ester O I 0.9965856075286865
( O O 0.9975873231887817
CCK B B 0.8674440979957581
- I I 0.8413780927658081
8 I I 0.9766077995300293
- O I 0.9140837788581848
SE O I 0.9965522289276123
) O O 0.9907351732254028
and O O 0.9990435242652893
nonsulphated O O 0.5963646173477173
cholecystokinin B B 0.9410459995269775
octapeptide I I 0.9814845323562622
( O O 0.9980734586715698
CCK B B 0.966817319393158
- I I 0.7705081701278687
8 I I 0.966008722782135
- O I 0.8089848160743713
NS O I 0.9914746284484863
) O O 0.9989257454872131
enhanced O O 0.9999457597732544
the O O 0.9999927282333374
latency O O 0.9999961853027344
of O O 0.9999791383743286
seizures O O 0.9999873638153076
induced O O 0.9999961853027344
by O O 0.9999145269393921
picrotoxin B B 0.9991455078125
in O O 0.9997846484184265
mice O O 0.9999805688858032
. O O 0.9999575614929199

Experiments O O 0.9999831914901733
with O O 0.9998886585235596
N O O 0.7926494479179382
- O O 0.9613485336303711
and O O 0.9889967441558838
C O O 0.5500513315200806
- O O 0.9752893447875977
terminal O O 0.9313514232635498
fragments O O 0.9872143268585205
revealed O O 0.9999767541885376
that O O 0.9998863935470581
the O O 0.9995906949043274
C O O 0.7877205014228821
- O O 0.9805286526679993
terminal O O 0.8903597593307495
tetrapeptide O O 0.6164078712463379
( O O 0.995466947555542
CCK O B 0.5704166889190674
- O I 0.5692356824874878
5 O I 0.6482213139533997
- O I 0.8398160934448242
8 O I 0.9985174536705017
) O O 0.9910885095596313
was O O 0.9999253749847412
the O O 0.9998284578323364
active O O 0.9983963370323181
centre O O 0.9991509914398193
of O O 0.9996803998947144
the O O 0.9994720816612244
CCK O B 0.91275554895401
octapeptide O O 0.8101706504821777
molecule O O 0.9978736639022827
. O O 0.9999622106552124

The O O 0.9998841285705566
analogues O O 0.9972760081291199
CCK B B 0.8528689742088318
- I I 0.6718786358833313
8 I I 0.9289689064025879
- O I 0.904026448726654
SE O I 0.987793505191803
and O O 0.9887555241584778
CCK B O 0.48010995984077454
- I O 0.8972009420394897
8 I O 0.7579861879348755
- O O 0.9413086175918579
NS O O 0.7429066896438599
( O O 0.9997733235359192
dose O O 0.9999344348907471
range O O 0.9999274015426636
0 O O 0.9997707009315491
. O O 0.9999901056289673
2 O O 0.9998964071273804
- O O 0.9979845285415649
6 O O 0.9999667406082153
. O O 0.9999942779541016
4 O O 0.9991164803504944
mumol O O 0.9639477729797363
/ O O 0.9998230338096619
kg O O 0.9999666213989258
) O O 0.9997608065605164
and O O 0.9993150234222412
caerulein B B 0.974205493927002
dose O O 0.9997294545173645
range O O 0.9998131394386292
0 O O 0.9995195865631104
. O O 0.9999716281890869
1 O O 0.999950647354126
- O O 0.9983750581741333
0 O O 0.9999914169311523
. O O 0.999996542930603
8 O O 0.9999794960021973
mumol O O 0.9635594487190247
/ O O 0.9998179078102112
kg O O 0.9999829530715942
) O O 0.9994611144065857
showed O O 0.9999589920043945
bell O O 0.9998629093170166
- O O 0.9999945163726807
shaped O O 0.9999946355819702
dose O O 0.9996283054351807
- O O 0.999964714050293
effect O O 0.9999840259552002
curves O O 0.9999667406082153
, O O 0.9999852180480957
with O O 0.9999748468399048
the O O 0.9999862909317017
greatest O O 0.9999774694442749
maximum O O 0.999749481678009
inhibition O O 0.9999390840530396
for O O 0.9997850060462952
CCK B O 0.7086642980575562
- I O 0.7002267837524414
8 I O 0.5716145634651184
- O O 0.7270311117172241
NS O O 0.7988682389259338
. O O 0.9999380111694336

The O O 0.9997788071632385
peptide O O 0.6076522469520569
CCK O B 0.9956483244895935
- O I 0.8646588325500488
5 O I 0.9042890071868896
- O I 0.9368253946304321
8 O I 0.9996039271354675
had O O 0.9990346431732178
weak O O 0.9997623562812805
anticonvulsant O O 0.7708476185798645
activity O O 0.9996823072433472
in O O 0.9999773502349854
comparison O O 0.9999598264694214
to O O 0.999394416809082
the O O 0.998869001865387
octapeptides O O 0.69808429479599
, O O 0.9951181411743164
3 O O 0.9760342240333557
. O O 0.9998718500137329
2 O O 0.9962408542633057
mumol O O 0.9740867614746094
/ O O 0.9988076686859131
kg O O 0.9995220899581909
and O O 0.9998570680618286
larger O O 0.9998886585235596
doses O O 0.999869704246521
of O O 0.9998880624771118
the O O 0.9999469518661499
reference O O 0.9989239573478699
drug O O 0.9983731508255005
, O O 0.9937410950660706
diazepam B B 0.9997352957725525
, O O 0.9999041557312012
totally O O 0.9999576807022095
prevented O O 0.9999210834503174
picrotoxin B B 0.9937911629676819
- O O 0.9996678829193115
induced O O 0.9999505281448364
seizures O O 0.9999815225601196
and O O 0.9999306201934814
mortality O O 0.999919056892395
. O O 0.9999595880508423

The O O 0.9999496936798096
maximum O O 0.999743640422821
effect O O 0.9999150037765503
of O O 0.9993584752082825
the O O 0.9996060729026794
peptides O O 0.8791224956512451
tested O O 0.9997422099113464
was O O 0.9999243021011353
less O O 0.999958872795105
than O O 0.9998947381973267
that O O 0.9999679327011108
of O O 0.9994692206382751
diazepam B B 0.9997891783714294
. O O 0.9999290704727173

Experiments O O 0.9999878406524658
with O O 0.9998202919960022
analogues O O 0.9404445290565491
and O O 0.9990807771682739
derivatives O O 0.8425027132034302
of O O 0.9968999624252319
CCK O B 0.8914194107055664
- O I 0.7968538403511047
5 O I 0.8080282211303711
- O I 0.8338326811790466
8 O I 0.9966444969177246
demonstrated O O 0.9998446702957153
that O O 0.999924898147583
the O O 0.9999364614486694
effectiveness O O 0.9999362230300903
of O O 0.999861478805542
the O O 0.9998170733451843
beta O O 0.6096370220184326
- O O 0.6414843201637268
alanyl O O 0.5565990805625916
derivatives O O 0.5561378002166748
of O O 0.9974583983421326
CCK O B 0.9452913403511047
- O I 0.7797439694404602
5 O I 0.785010814666748
- O I 0.8137609958648682
8 O I 0.9935165643692017
were O O 0.9991633892059326
enhanced O O 0.9999021291732788
and O O 0.999981164932251
that O O 0.999945878982544
they O O 0.9999254941940308
were O O 0.9999442100524902
equipotent O O 0.9997829794883728
with O O 0.9996744394302368
CCK B B 0.8900031447410583
- I I 0.7678515911102295
8 I I 0.946895956993103
- O I 0.8528228998184204
SE O I 0.9962280988693237
. O O 0.9996607303619385

Of O O 0.9999212026596069
the O O 0.9998206496238708
CCK O O 0.7894688844680786
- O O 0.9745837450027466
2 O O 0.8375548720359802
- O O 0.8921429514884949
8 O O 0.6000557541847229
analogues O O 0.6251311302185059
, O O 0.9982946515083313
Ser O O 0.5039002299308777
( O O 0.9773470759391785
SO3H O O 0.7467361092567444
) O O 0.9927605390548706
7 O O 0.9574167728424072
- O O 0.9846172332763672
Ac O O 0.6589062809944153
- O O 0.9382054805755615
CCK O B 0.47140899300575256
- O I 0.9089212417602539
2 O I 0.6065040826797485
- O I 0.7813197374343872
8 O I 0.8546377420425415
- O I 0.7036302089691162
SE O I 0.9491368532180786
and O O 0.9940339922904968
Thr O O 0.5753629207611084
( O O 0.9742361903190613
SO3H O O 0.6192180514335632
) O O 0.9944717884063721
7 O O 0.8687314391136169
- O O 0.9576076865196228
Ac O O 0.47499385476112366
- O O 0.7953807711601257
CCK O O 0.5573394298553467
- O O 0.921795666217804
2 O O 0.8263182640075684
- O O 0.9260077476501465
8 O O 0.4996434152126312
- O O 0.8395634889602661
SE O O 0.5609557628631592
and O O 0.999321460723877
Hyp O O 0.7348207831382751
( O O 0.8366199135780334
SO3H O O 0.5116184949874878
) O O 0.8054207563400269
- O O 0.9146754145622253
Ac O O 0.4154414236545563
- O O 0.80202317237854
CCK O B 0.47061702609062195
- O I 0.9267569184303284
2 O I 0.5591926574707031
- O I 0.7183252573013306
8 O I 0.8686649799346924
- O I 0.6118813753128052
SE O I 0.9422667622566223
were O O 0.999455988407135
slightly O O 0.9999767541885376
more O O 0.9999443292617798
active O O 0.9999253749847412
than O O 0.9997952580451965
CCK B O 0.5579318404197693
- I O 0.8734612464904785
8 I O 0.6402386426925659
- O O 0.830461859703064
SE O O 0.824103832244873
. O O 0.9998819828033447

Vasopressin B B 0.9833588004112244
as O O 0.9998956918716431
a O O 0.9996893405914307
possible O O 0.9997593760490417
contributor O O 0.9999631643295288
to O O 0.9998056292533875
hypertension O O 0.9994478821754456
. O O 0.9997568726539612

The O O 0.9999710321426392
role O O 0.9999349117279053
of O O 0.9996685981750488
vasopressin B B 0.9963744282722473
as O O 0.9992716908454895
a O O 0.9976430535316467
pressor O O 0.9994927644729614
agent O O 0.9972807168960571
to O O 0.9998527765274048
the O O 0.999966025352478
hypertensive O O 0.9987282156944275
process O O 0.9999773502349854
was O O 0.9999231100082397
examined O O 0.9999550580978394
. O O 0.9999490976333618

Vasopressin B B 0.9208191633224487
plays O O 0.9984233379364014
a O O 0.999778687953949
major O O 0.9999082088470459
role O O 0.999884843826294
in O O 0.9998918771743774
the O O 0.9999550580978394
pathogenesis O O 0.9999821186065674
of O O 0.9999346733093262
DOCA B B 0.9994258880615234
- O I 0.854299783706665
salt O I 0.9774707555770874
hypertension O O 0.9991334080696106
, O O 0.9999637603759766
since O O 0.9999942779541016
the O O 0.9999901056289673
elevation O O 0.9999926090240479
of O O 0.9999604225158691
blood O O 0.9997093081474304
pressure O O 0.9990572333335876
was O O 0.9999715089797974
not O O 0.9999594688415527
substantial O O 0.9999896287918091
in O O 0.9998917579650879
the O O 0.9999760389328003
rats O O 0.9999359846115112
with O O 0.9999183416366577
lithium B B 0.9999133348464966
- O O 0.9992823004722595
treated O O 0.9998619556427002
diabetes O O 0.9999605417251587
insipidus O O 0.9999837875366211
after O O 0.9997264742851257
DOCA B B 0.9989851117134094
- O I 0.6579609513282776
salt O I 0.9934479594230652
treatment O O 0.9993151426315308
. O O 0.9999704360961914

Administration O O 0.9999172687530518
of O O 0.9996463060379028
DDAVP B B 0.999377429485321
which O O 0.9997583031654358
has O O 0.9995156526565552
antidiuretic O O 0.472029447555542
action O O 0.9991258978843689
but O O 0.9998763799667358
minimal O O 0.9998443126678467
vasopressor O O 0.9860458970069885
effect O O 0.9998915195465088
failed O O 0.9999489784240723
to O O 0.9999775886535645
increase O O 0.9999581575393677
blood O O 0.9998980760574341
pressure O O 0.9996787309646606
to O O 0.9999879598617554
the O O 0.999993085861206
levels O O 0.9999921321868896
observed O O 0.9999940395355225
after O O 0.9999282360076904
administration O O 0.9999204874038696
of O O 0.9995762705802917
AVP O B 0.9578996896743774
. O O 0.9998682737350464

Furthermore O O 0.9999443292617798
, O O 0.9999274015426636
the O O 0.9997852444648743
pressor O O 0.9989284873008728
action O O 0.9994102716445923
of O O 0.9992697834968567
vasopressin B B 0.9952409267425537
appears O O 0.9995150566101074
to O O 0.9997950196266174
be O O 0.9998584985733032
important O O 0.9997901320457458
in O O 0.9999561309814453
the O O 0.999976396560669
development O O 0.9999905824661255
of O O 0.999974250793457
this O O 0.9999734163284302
model O O 0.9999943971633911
of O O 0.9999490976333618
hypertension O O 0.9995750784873962
, O O 0.9999531507492065
since O O 0.9999785423278809
the O O 0.9999691247940063
enhanced O O 0.9998354911804199
pressor O O 0.9998806715011597
responsiveness O O 0.9999719858169556
to O O 0.9996142387390137
the O O 0.9971758127212524
hormone O O 0.9615921974182129
was O O 0.9999518394470215
observed O O 0.9999699592590332
in O O 0.9998704195022583
the O O 0.9999620914459229
initial O O 0.9999841451644897
stage O O 0.9999902248382568
of O O 0.9999576807022095
hypertension O O 0.9996567964553833
. O O 0.9999752044677734

Increased O O 0.999833345413208
secretion O O 0.9997510313987732
of O O 0.9990621209144592
vasopressin B B 0.9761012196540833
from O O 0.9957091808319092
neurohypophysis O O 0.999468982219696
also O O 0.9999182224273682
promotes O O 0.9995146989822388
the O O 0.9999233484268188
function O O 0.9998843669891357
of O O 0.9990195035934448
the O O 0.871356189250946
hormone O O 0.7571157217025757
as O O 0.9999189376831055
a O O 0.9997413754463196
pathogenetic O O 0.9999418258666992
factor O O 0.9999861717224121
in O O 0.9999407529830933
hypertension O O 0.9995226860046387
. O O 0.9999427795410156

An O O 0.9999545812606812
unproportional O O 0.9996180534362793
release O O 0.9999614953994751
of O O 0.9998109936714172
vasopressin B B 0.9869008660316467
compared O O 0.9996781349182129
to O O 0.9997732043266296
plasma O O 0.9985895752906799
osmolality O O 0.70603346824646
may O O 0.9998660087585449
be O O 0.9999144077301025
induced O O 0.9999772310256958
by O O 0.9999595880508423
the O O 0.9999814033508301
absence O O 0.9999409914016724
of O O 0.9999512434005737
an O O 0.9998021721839905
adjusting O O 0.9301500916481018
control O O 0.9998002648353577
of O O 0.9991663694381714
angiotensin B B 0.9520606398582458
II O O 0.5919508337974548
forming O O 0.9141029119491577
and O O 0.9994581341743469
receptor O O 0.9995081424713135
binding O O 0.9997245669364929
capacity O O 0.99983811378479
for O O 0.9998733997344971
sodium B B 0.9959278702735901
balance O O 0.9986862540245056
in O O 0.9998406171798706
the O O 0.9999624490737915
brain O O 0.9999873638153076
. O O 0.999951958656311

However O O 0.9999488592147827
, O O 0.9999594688415527
the O O 0.9999691247940063
role O O 0.9999399185180664
of O O 0.9997304081916809
vasopressin B B 0.9788018465042114
remains O O 0.999756395816803
to O O 0.9999762773513794
be O O 0.9999891519546509
determined O O 0.9999788999557495
in O O 0.9999058246612549
human O O 0.9997867941856384
essential O O 0.999583899974823
hypertension O O 0.9985517859458923
. O O 0.999936580657959

Toxic O O 0.9995494484901428
hepatitis O O 0.9993236064910889
induced O O 0.9999477863311768
by O O 0.9997171759605408
disulfiram B B 0.9830922484397888
in O O 0.999626636505127
a O O 0.9999643564224243
non O O 0.9709084033966064
- O O 0.9988202452659607
alcoholic O O 0.9733390808105469
. O O 0.9998677968978882

A O O 0.9999167919158936
reversible O O 0.999843955039978
toxic O O 0.9998167157173157
liver O O 0.990777850151062
damage O O 0.9999778270721436
was O O 0.9999591112136841
observed O O 0.9999850988388062
in O O 0.999945878982544
a O O 0.999961256980896
non O O 0.9777243733406067
- O O 0.9991825222969055
alcoholic O O 0.8733834028244019
woman O O 0.9999938011169434
treated O O 0.9998588562011719
with O O 0.9990955591201782
disulfiram B B 0.9939951300621033
. O O 0.9999152421951294

The O O 0.9999450445175171
causative O O 0.9999361038208008
relationship O O 0.9999183416366577
was O O 0.9999462366104126
proven O O 0.9999749660491943
by O O 0.9999368190765381
challenge O O 0.9999366998672485
. O O 0.9999598264694214

Atrial O O 0.9993282556533813
thrombosis O O 0.9999182224273682
involving O O 0.9999687671661377
the O O 0.9999279975891113
heart O O 0.9996272325515747
of O O 0.9898081421852112
F O O 0.981403112411499
- O O 0.9745814800262451
344 O O 0.7556966543197632
rats O O 0.9802554845809937
ingesting O O 0.9991783499717712
quinacrine B B 0.9930221438407898
hydrochloride I I 0.9962925314903259
. O O 0.9987455606460571

Quinacrine B B 0.9960165619850159
hydrochloride I I 0.9903136491775513
is O O 0.9947428703308105
toxic O O 0.9950377345085144
for O O 0.9992595314979553
the O O 0.9995691180229187
heart O O 0.9873133301734924
of O O 0.9926930665969849
F O O 0.980472981929779
- O O 0.9718517065048218
344 O O 0.6296661496162415
rats O O 0.8119210004806519
. O O 0.9993471503257751

Rats O O 0.99977046251297
treated O O 0.9999058246612549
with O O 0.9998297691345215
500 O O 0.9967710375785828
ppm O O 0.9693288803100586
quinacrine B B 0.9939985275268555
hydrochloride I I 0.9873621463775635
in O O 0.9902780652046204
the O O 0.9998077750205994
diet O O 0.9993259906768799
all O O 0.9999475479125977
developed O O 0.9999916553497314
a O O 0.9999837875366211
high O O 0.9999656677246094
incidence O O 0.999997615814209
of O O 0.999983549118042
left O O 0.9999861717224121
atrial O O 0.999968409538269
thrombosis O O 0.9999077320098877
. O O 0.9999638795852661

The O O 0.9999563694000244
lesion O O 0.999984622001648
was O O 0.9999418258666992
associated O O 0.9999803304672241
with O O 0.9999709129333496
cardiac O O 0.999941349029541
hypertrophy O O 0.9990333318710327
and O O 0.9998809099197388
dilatation O O 0.9998902082443237
and O O 0.9999246597290039
focal O O 0.9999617338180542
myocardial O O 0.9999982118606567
degeneration O O 0.9999932050704956
. O O 0.9999616146087646

Rats O O 0.9996516704559326
died O O 0.9999881982803345
from O O 0.9998020529747009
cardiac O O 0.9997918009757996
hypertrophy O O 0.9981027245521545
with O O 0.9999712705612183
severe O O 0.9999570846557617
acute O O 0.9999181032180786
and O O 0.9998985528945923
chronic O O 0.9999277591705322
congestion O O 0.9999876022338867
of O O 0.9999600648880005
the O O 0.9999836683273315
lungs O O 0.9999719858169556
, O O 0.9999191761016846
liver O O 0.9998112320899963
, O O 0.9998658895492554
and O O 0.9998786449432373
other O O 0.9998990297317505
organs O O 0.9999821186065674
. O O 0.999834418296814

Seventy O O 0.9998996257781982
percent O O 0.9999982118606567
of O O 0.9999892711639404
rats O O 0.9999946355819702
given O O 0.9998179078102112
250 O O 0.9965698719024658
ppm O O 0.9685728549957275
quinacrine B B 0.9971191883087158
hydrochloride I I 0.9903038144111633
and O O 0.9950745701789856
1 O O 0.9999701976776123
, O O 0.9999973773956299
000 O O 0.9996625185012817
ppm O O 0.9776204228401184
sodium B B 0.9911969900131226
nitrite I I 0.9480873942375183
simultaneously O O 0.8501301407814026
in O O 0.9999294281005859
the O O 0.999974250793457
diet O O 0.9998830556869507
had O O 0.9999680519104004
thrombosis O O 0.9998406171798706
of O O 0.9999332427978516
the O O 0.9999864101409912
atria O O 0.9996548891067505
of O O 0.9998303651809692
the O O 0.9999868869781494
heart O O 0.9999648332595825
, O O 0.9999614953994751
while O O 0.99996018409729
untreated O O 0.9997847676277161
control O O 0.9999536275863647
rats O O 0.9999898672103882
in O O 0.9999533891677856
this O O 0.9999871253967285
laboratory O O 0.9999903440475464
did O O 0.9999852180480957
not O O 0.9999853372573853
have O O 0.9999591112136841
atrial O O 0.9987133741378784
thrombosis O O 0.9997952580451965
. O O 0.9999699592590332

Sodium B B 0.9950447082519531
nitrite I I 0.9254739880561829
in O O 0.9995782971382141
combination O O 0.9997920393943787
with O O 0.9995632767677307
quinacrine B B 0.997099757194519
hydrochloride I I 0.9885256886482239
appeared O O 0.9997870326042175
to O O 0.999951958656311
have O O 0.9999744892120361
no O O 0.9999785423278809
additional O O 0.9999696016311646
effect O O 0.9999639987945557
. O O 0.9999498128890991

Alternating O O 0.9998242259025574
sinus O O 0.999976634979248
rhythm O O 0.9999799728393555
and O O 0.9998980760574341
intermittent O O 0.9997788071632385
sinoatrial O O 0.9996711015701294
block O O 0.9999784231185913
induced O O 0.9999500513076782
by O O 0.9997757077217102
propranolol B B 0.9997484087944031
. O O 0.9999287128448486

Alternating O O 0.9993495345115662
sinus O O 0.9999866485595703
rhythm O O 0.9999935626983643
and O O 0.9999312162399292
intermittent O O 0.999039351940155
sinoatrial O O 0.9990750551223755
( O O 0.9991338849067688
S O O 0.9748924970626831
- O O 0.9980542659759521
A O O 0.9579124450683594
) O O 0.9997859597206116
block O O 0.999985933303833
was O O 0.9999788999557495
observed O O 0.9999910593032837
in O O 0.9999613761901855
a O O 0.999991774559021
57 O O 0.9999970197677612
- O O 0.99998939037323
year O O 0.999997615814209
- O O 0.9999947547912598
old O O 0.9999947547912598
woman O O 0.9999979734420776
, O O 0.9999738931655884
under O O 0.999800980091095
treatment O O 0.9999786615371704
for O O 0.9999502897262573
angina O O 0.999445378780365
with O O 0.99981290102005
80 O O 0.9980037808418274
mg O O 0.9980170726776123
propranolol B B 0.9993711113929749
daily O O 0.997492790222168
. O O 0.9999656677246094

The O O 0.9999862909317017
electrocardiogram O O 0.9999500513076782
showed O O 0.999941349029541
alternation O O 0.9999213218688965
of O O 0.999919056892395
long O O 0.9993067979812622
and O O 0.99979168176651
short O O 0.9999558925628662
P O O 0.9805439114570618
- O O 0.9955117106437683
P O O 0.9828066825866699
intervals O O 0.9999819993972778
and O O 0.999925971031189
occasional O O 0.9998695850372314
pauses O O 0.9999809265136719
. O O 0.9999686479568481

These O O 0.9998195767402649
pauses O O 0.9999740123748779
were O O 0.9999572038650513
always O O 0.9999339580535889
preceded O O 0.9999797344207764
by O O 0.9999618530273438
the O O 0.9999736547470093
short O O 0.999982476234436
P O O 0.9538176655769348
- O O 0.9956845045089722
P O O 0.9878950119018555
intervals O O 0.9999822378158569
and O O 0.9999260902404785
were O O 0.9999760389328003
usually O O 0.9999815225601196
followed O O 0.9999732971191406
by O O 0.9999688863754272
one O O 0.9999563694000244
or O O 0.999980092048645
two O O 0.9999842643737793
P O O 0.9773461818695068
- O O 0.9964163303375244
P O O 0.9948564767837524
intervals O O 0.9999865293502808
of O O 0.9999661445617676
0 O O 0.9999890327453613
. O O 0.9999942779541016
92 O O 0.9995390176773071
- O O 0.9965680837631226
0 O O 0.9999886751174927
. O O 0.9999922513961792
95 O O 0.9998810291290283
s O O 0.9999544620513916
representing O O 0.9999778270721436
the O O 0.9999716281890869
basic O O 0.9999032020568848
sinus O O 0.9999827146530151
cycle O O 0.9999890327453613
. O O 0.9999620914459229

Following O O 0.9999492168426514
these O O 0.999981164932251
basic O O 0.9990463852882385
sinus O O 0.9999412298202515
cycles O O 0.9999061822891235
, O O 0.9999706745147705
alternating O O 0.999919056892395
rhythm O O 0.9999712705612183
started O O 0.9999912977218628
with O O 0.9999918937683105
the O O 0.9999915361404419
longer O O 0.9999282360076904
P O O 0.993433952331543
- O O 0.9996052384376526
P O O 0.9867448210716248
interval O O 0.9999769926071167
. O O 0.9999809265136719

The O O 0.9999711513519287
long O O 0.9996291399002075
P O O 0.992283284664154
- O O 0.9968326687812805
P O O 0.981748640537262
intervals O O 0.9999772310256958
ranged O O 0.9999654293060303
between O O 0.9999616146087646
1 O O 0.9999922513961792
. O O 0.9999977350234985
04 O O 0.9999963045120239
- O O 0.9982328414916992
1 O O 0.9999957084655762
. O O 0.9999980926513672
12 O O 0.9999988079071045
s O O 0.9999755620956421
and O O 0.9999549388885498
the O O 0.9999839067459106
short O O 0.9999686479568481
P O O 0.9883108139038086
- O O 0.9961976408958435
P O O 0.9826975464820862
intervals O O 0.9999796152114868
between O O 0.9998624324798584
0 O O 0.9999783039093018
. O O 0.9999947547912598
80 O O 0.9999825954437256
- O O 0.9963845014572144
0 O O 0.9999816417694092
. O O 0.9999910593032837
84 O O 0.9999743700027466
s O O 0.999919056892395
, O O 0.9999816417694092
respectively O O 0.9999616146087646
. O O 0.9999700784683228

The O O 0.9999791383743286
duration O O 0.9999876022338867
of O O 0.9999769926071167
the O O 0.999981164932251
pauses O O 0.9999892711639404
were O O 0.999970555305481
equal O O 0.9999908208847046
or O O 0.9999954700469971
almost O O 0.9999943971633911
equal O O 0.9999935626983643
to O O 0.9999649524688721
one O O 0.9999473094940186
short O O 0.9998047947883606
plus O O 0.9999704360961914
one O O 0.9999512434005737
long O O 0.9995172023773193
P O O 0.9732003211975098
- O O 0.9974461793899536
P O O 0.9812544584274292
interval O O 0.999977707862854
or O O 0.9999402761459351
to O O 0.9999617338180542
twice O O 0.9999072551727295
the O O 0.9999842643737793
basic O O 0.9979891777038574
sinus O O 0.999975323677063
cycle O O 0.9999774694442749
. O O 0.9999703168869019

In O O 0.9999178647994995
one O O 0.9999867677688599
recording O O 0.9999912977218628
a O O 0.999984860420227
short O O 0.9999910593032837
period O O 0.9999880790710449
of O O 0.9999743700027466
regular O O 0.9999759197235107
sinus O O 0.9999911785125732
rhythm O O 0.9999873638153076
with O O 0.9999703168869019
intermittent O O 0.9998806715011597
2 O O 0.9963905215263367
/ O O 0.9998410940170288
1 O O 0.9998260140419006
S O O 0.9916050434112549
- O O 0.9975242018699646
A O O 0.9689441919326782
block O O 0.9999774694442749
was O O 0.9999810457229614
observed O O 0.9999856948852539
. O O 0.9999681711196899

This O O 0.9999586343765259
short O O 0.999983549118042
period O O 0.9999774694442749
of O O 0.9999607801437378
sinus O O 0.9999802112579346
rhythm O O 0.9999771118164062
was O O 0.999953031539917
interrupted O O 0.9999853372573853
by O O 0.999950647354126
sudden O O 0.999962568283081
prolongation O O 0.9999672174453735
of O O 0.9999616146087646
the O O 0.9999665021896362
P O O 0.9944990873336792
- O O 0.9988679885864258
P O O 0.9878981709480286
interval O O 0.9999933242797852
starting O O 0.9999346733093262
the O O 0.9999393224716187
alternative O O 0.9872447848320007
rhythm O O 0.9999731779098511
. O O 0.9999499320983887

There O O 0.9999744892120361
were O O 0.9999731779098511
small O O 0.9999938011169434
changes O O 0.9999966621398926
in O O 0.9999921321868896
the O O 0.9999936819076538
shape O O 0.9999936819076538
of O O 0.9999731779098511
the O O 0.9999489784240723
P O O 0.9946030974388123
waves O O 0.9999886751174927
and O O 0.9999181032180786
P O O 0.9732667803764343
- O O 0.997000515460968
R O O 0.9468193054199219
intervals O O 0.9999871253967285
. O O 0.9999580383300781

S O O 0.7311499118804932
- O O 0.933192789554596
A O O 0.5677536725997925
conduction O O 0.9999352693557739
through O O 0.9999163150787354
two O O 0.9998267292976379
pathways O O 0.9999784231185913
, O O 0.9999827146530151
the O O 0.9999936819076538
first O O 0.9999785423278809
with O O 0.9999276399612427
2 O O 0.9967324733734131
/ O O 0.9998937845230103
1 O O 0.9990876913070679
block O O 0.9999701976776123
the O O 0.9997431635856628
second O O 0.9999433755874634
having O O 0.9998501539230347
0 O O 0.999968409538269
. O O 0.9999922513961792
12 O O 0.9999971389770508
- O O 0.9987792372703552
0 O O 0.9999499320983887
. O O 0.9999932050704956
14 O O 0.9999958276748657
s O O 0.9999710321426392
longer O O 0.9999629259109497
conduction O O 0.9999864101409912
time O O 0.999993085861206
and O O 0.9999427795410156
with O O 0.9999324083328247
occasional O O 0.999941349029541
2 O O 0.9973191618919373
/ O O 0.9998118281364441
1 O O 0.9984440207481384
block O O 0.9999759197235107
was O O 0.9999760389328003
proposed O O 0.999962329864502
for O O 0.9999696016311646
the O O 0.99998939037323
explanation O O 0.999992847442627
of O O 0.9999771118164062
the O O 0.9999932050704956
alternating O O 0.9999499320983887
P O O 0.9814255237579346
- O O 0.9991722106933594
P O O 0.9846276640892029
interval O O 0.999995231628418
and O O 0.9999830722808838
other O O 0.9999816417694092
electrocardiographic O O 0.9999785423278809
features O O 0.9999982118606567
seen O O 0.9999954700469971
. O O 0.9999432563781738

Atropine B B 0.9989126920700073
1 O O 0.9921684861183167
mg O O 0.9990442395210266
given O O 0.9998999834060669
intravenously O O 0.9999427795410156
resulted O O 0.9999679327011108
in O O 0.9999805688858032
shortening O O 0.9999926090240479
of O O 0.999970555305481
all O O 0.9998482465744019
P O O 0.9918637275695801
- O O 0.9970110654830933
P O O 0.988063395023346
intervals O O 0.9999904632568359
without O O 0.9999630451202393
changing O O 0.9999948740005493
the O O 0.9999971389770508
rhythm O O 0.9999943971633911
. O O 0.9999613761901855

The O O 0.9999879598617554
abnormal O O 0.9999966621398926
rhythm O O 0.9999959468841553
disappeared O O 0.9999926090240479
with O O 0.9999781847000122
the O O 0.9999825954437256
withdrawal O O 0.9998327493667603
of O O 0.9989563226699829
propranolol B B 0.9995457530021667
and O O 0.9999632835388184
when O O 0.9999890327453613
the O O 0.9999347925186157
drug O O 0.9994631409645081
was O O 0.9999645948410034
restarted O O 0.9999285936355591
a O O 0.9999420642852783
2 O O 0.995924711227417
/ O O 0.9998786449432373
1 O O 0.9998712539672852
S O O 0.9913328289985657
- O O 0.9974000453948975
A O O 0.9956740736961365
block O O 0.9999799728393555
was O O 0.9999880790710449
seen O O 0.9999963045120239
. O O 0.9999724626541138

This O O 0.9999568462371826
was O O 0.9999604225158691
accepted O O 0.9999880790710449
as O O 0.9999885559082031
evidence O O 0.9999681711196899
for O O 0.9997780919075012
propranolol B B 0.9996542930603027
being O O 0.9998844861984253
the O O 0.9999706745147705
cause O O 0.9999649524688721
of O O 0.9999614953994751
this O O 0.9998512268066406
conduction O O 0.9999719858169556
disorder O O 0.9999973773956299
. O O 0.9999489784240723

Antitumor O O 0.9831482172012329
effect O O 0.9999425411224365
, O O 0.9999028444290161
cardiotoxicity O O 0.9999886751174927
, O O 0.9998679161071777
and O O 0.9998656511306763
nephrotoxicity O O 0.9997988343238831
of O O 0.9973125457763672
doxorubicin B B 0.9997132420539856
in O O 0.9997171759605408
the O O 0.9997026324272156
IgM O O 0.9762682914733887
solid O O 0.9896265268325806
immunocytoma O O 0.9970122575759888
- O O 0.9997357726097107
bearing O O 0.9962181448936462
LOU O O 0.9533669352531433
/ O O 0.9971330165863037
M O O 0.9732308983802795
/ O O 0.9960609078407288
WSL O O 0.9843558669090271
rat O O 0.999377429485321
. O O 0.9998307228088379

Antitumor O O 0.9901997447013855
activity O O 0.9999151229858398
, O O 0.9999290704727173
cardiotoxicity O O 0.9999871253967285
, O O 0.9998264908790588
and O O 0.9998894929885864
nephrotoxicity O O 0.9999057054519653
induced O O 0.9999713897705078
by O O 0.9998663663864136
doxorubicin B B 0.9994812607765198
were O O 0.9998846054077148
studied O O 0.999955415725708
in O O 0.999940037727356
LOU O O 0.9629985094070435
/ O O 0.998826801776886
M O O 0.9986017346382141
/ O O 0.9992504715919495
WSL O O 0.9864826798439026
inbred O O 0.9992172718048096
rats O O 0.9999834299087524
each O O 0.999859094619751
bearing O O 0.9999561309814453
a O O 0.9999762773513794
transplantable O O 0.9999622106552124
solid O O 0.9997617602348328
IgM O O 0.9950500130653381
immunocytoma O O 0.9998773336410522
. O O 0.999954342842102

Animals O O 0.9999548196792603
with O O 0.9999905824661255
a O O 0.9999673366546631
tumor O O 0.9999947547912598
( O O 0.9999500513076782
diameter O O 0.999991774559021
, O O 0.9999744892120361
15 O O 0.9999833106994629
. O O 0.9999959468841553
8 O O 0.9999743700027466
+ O O 0.9999945163726807
/ O O 0.9999643564224243
- O O 0.9998960494995117
3 O O 0.9999755620956421
. O O 0.9999949932098389
3 O O 0.9999779462814331
mm O O 0.9999973773956299
) O O 0.9999759197235107
were O O 0.9999898672103882
treated O O 0.9999902248382568
with O O 0.9999479055404663
iv O O 0.9988530874252319
injections O O 0.9999604225158691
of O O 0.9989504814147949
doxorubicin B B 0.999563992023468
on O O 0.999832034111023
5 O O 0.9999566078186035
consecutive O O 0.9999921321868896
days O O 0.9999964237213135
, O O 0.9999829530715942
followed O O 0.9999701976776123
by O O 0.9999768733978271
1 O O 0.9997580647468567
weekly O O 0.9999440908432007
injection O O 0.9999356269836426
for O O 0.9999802112579346
7 O O 0.9999791383743286
weeks O O 0.9999984502792358
( O O 0.9999771118164062
dose O O 0.9999737739562988
range O O 0.9999791383743286
, O O 0.9999814033508301
0 O O 0.9999804496765137
. O O 0.9999936819076538
015 O O 0.9999589920043945
- O O 0.9988723397254944
4 O O 0.9999057054519653
. O O 0.9999979734420776
0 O O 0.9999816417694092
mg O O 0.9999871253967285
/ O O 0.9999886751174927
kg O O 0.9999984502792358
body O O 0.9999831914901733
wt O O 0.9995577931404114
) O O 0.999984860420227
. O O 0.9999849796295166

Tumor O O 0.9999191761016846
regression O O 0.999976396560669
was O O 0.999985933303833
observed O O 0.9999902248382568
with O O 0.999754011631012
0 O O 0.9998194575309753
. O O 0.9999744892120361
5 O O 0.9999489784240723
mg O O 0.9979355335235596
doxorubicin B B 0.9996968507766724
/ O O 0.9964575171470642
kg O O 0.9842993021011353
. O O 0.9999555349349976

Complete O O 0.999848484992981
disappearance O O 0.9999911785125732
of O O 0.9999892711639404
the O O 0.999993085861206
tumor O O 0.9999924898147583
was O O 0.9999786615371704
induced O O 0.9999946355819702
with O O 0.9999152421951294
1 O O 0.9997947812080383
. O O 0.9999841451644897
0 O O 0.9996378421783447
mg O O 0.9989878535270691
doxorubicin B B 0.9995784163475037
/ O O 0.997286319732666
kg O O 0.999014139175415
. O O 0.9999626874923706

Histologic O O 0.9999276399612427
evidence O O 0.9999797344207764
of O O 0.9999428987503052
cardiotoxicity O O 0.9999845027923584
scored O O 0.9993401169776917
as O O 0.9997722506523132
grade O O 0.9980968832969666
III O O 0.9901776909828186
was O O 0.9999821186065674
only O O 0.9999717473983765
observed O O 0.9999864101409912
at O O 0.9999454021453857
a O O 0.9999892711639404
dose O O 0.9999485015869141
of O O 0.9998838901519775
1 O O 0.9999557733535767
. O O 0.9999902248382568
0 O O 0.9998596906661987
mg O O 0.9993888139724731
doxorubicin B B 0.9997382760047913
/ O O 0.9990434050559998
kg O O 0.9998916387557983
. O O 0.9999561309814453

Light O O 0.9997208714485168
microscopic O O 0.999923586845398
evidence O O 0.9999727010726929
of O O 0.9999290704727173
renal O O 0.999607264995575
damage O O 0.9999876022338867
was O O 0.9999669790267944
seen O O 0.999985933303833
above O O 0.9996261596679688
a O O 0.9999830722808838
dose O O 0.9999269247055054
of O O 0.9998672008514404
0 O O 0.9999654293060303
. O O 0.9999856948852539
5 O O 0.9999566078186035
mg O O 0.9992596507072449
doxorubicin B B 0.9997158646583557
/ O O 0.9984662532806396
kg O O 0.996978759765625
, O O 0.9999808073043823
which O O 0.9999526739120483
resulted O O 0.9999781847000122
in O O 0.9999644756317139
albuminuria O O 0.9994196891784668
and O O 0.9999790191650391
very O O 0.999995231628418
low O O 0.9999908208847046
serum O O 0.9986063838005066
albumin O B 0.9687405228614807
levels O O 0.999897837638855
. O O 0.9999744892120361

In O O 0.9998961687088013
the O O 0.999987006187439
group O O 0.9999954700469971
that O O 0.9999858140945435
received O O 0.9999358654022217
1 O O 0.9999521970748901
. O O 0.9999874830245972
0 O O 0.9996429681777954
mg O O 0.9990783929824829
doxorubicin B B 0.9997367262840271
/ O O 0.9866883158683777
kg O O 0.9745182394981384
, O O 0.999983549118042
the O O 0.9999954700469971
serum O O 0.997740626335144
albumin O B 0.9706742763519287
level O O 0.9997368454933167
decreased O O 0.9999817609786987
from O O 0.9999837875366211
33 O O 0.9999291896820068
. O O 0.999987006187439
6 O O 0.9999672174453735
+ O O 0.9999850988388062
/ O O 0.9998514652252197
- O O 0.9996510744094849
4 O O 0.9993853569030762
. O O 0.999995231628418
1 O O 0.9999951124191284
to O O 0.9999732971191406
1 O O 0.9999721050262451
. O O 0.9999943971633911
5 O O 0.9999762773513794
+ O O 0.9999862909317017
/ O O 0.9998745918273926
- O O 0.9998925924301147
0 O O 0.9999901056289673
. O O 0.9999938011169434
5 O O 0.9999895095825195
g O O 0.9999872446060181
/ O O 0.9999842643737793
liter O O 0.9999982118606567
. O O 0.9999775886535645

Ascites O O 0.999575674533844
and O O 0.9997672438621521
hydrothorax O O 0.9996101260185242
were O O 0.999954104423523
observed O O 0.9999858140945435
simultaneously O O 0.999915361404419
. O O 0.9999516010284424

The O O 0.9999891519546509
same O O 0.9999841451644897
experiments O O 0.9999940395355225
were O O 0.9999946355819702
performed O O 0.9999954700469971
with O O 0.9999837875366211
non O O 0.9996558427810669
- O O 0.9999126195907593
tumor O O 0.999737560749054
- O O 0.9999464750289917
bearing O O 0.9999744892120361
rats O O 0.9999790191650391
, O O 0.999982476234436
in O O 0.9999819993972778
which O O 0.999984860420227
no O O 0.9999880790710449
major O O 0.9999938011169434
differences O O 0.9999977350234985
were O O 0.9999920129776001
observed O O 0.9999943971633911
. O O 0.9999803304672241

In O O 0.999893307685852
conclusion O O 0.999945878982544
, O O 0.9997013211250305
antitumor O O 0.9504556059837341
activity O O 0.9997674822807312
, O O 0.9997754693031311
cardiotoxicity O O 0.9999585151672363
, O O 0.9995762705802917
and O O 0.9994099140167236
nephrotoxicity O O 0.9991902709007263
were O O 0.9999290704727173
studied O O 0.9998742341995239
simultaneously O O 0.9999059438705444
in O O 0.9998693466186523
the O O 0.9999580383300781
same O O 0.9999068975448608
LOU O O 0.9814748764038086
/ O O 0.9987738728523254
M O O 0.9961296319961548
/ O O 0.9985888600349426
WSL O O 0.9751664400100708
rat O O 0.9999607801437378
. O O 0.9999489784240723

Albuminuria O O 0.789601743221283
due O O 0.9999141693115234
to O O 0.9998489618301392
renal O O 0.9998949766159058
damage O O 0.9999725818634033
led O O 0.9999767541885376
to O O 0.9999886751174927
extremely O O 0.9999856948852539
low O O 0.9999914169311523
serum O O 0.9994192123413086
albumin O B 0.8868146538734436
levels O O 0.9998083710670471
, O O 0.9999786615371704
so O O 0.9999274015426636
ascites O O 0.9997422099113464
and O O 0.9999278783798218
hydrothorax O O 0.9998021721839905
were O O 0.9999818801879883
not O O 0.9999876022338867
necessarily O O 0.9999896287918091
a O O 0.9999719858169556
consequence O O 0.9999934434890747
of O O 0.999975323677063
the O O 0.999990701675415
observed O O 0.9999905824661255
cardiomyopathy O O 0.9999938011169434
. O O 0.9999758005142212

Intraoperative O O 0.999927282333374
bradycardia O O 0.9991557598114014
and O O 0.999954342842102
hypotension O O 0.9999608993530273
associated O O 0.9999771118164062
with O O 0.9994933605194092
timolol B B 0.9994394183158875
and O O 0.9476988911628723
pilocarpine B B 0.9986264705657959
eye O O 0.999316930770874
drops O O 0.9429378509521484
. O O 0.9999591112136841

A O O 0.9999793767929077
69 O O 0.9999967813491821
- O O 0.9999803304672241
yr O O 0.9973024129867554
- O O 0.999987006187439
old O O 0.9999939203262329
man O O 0.9999948740005493
, O O 0.9999884366989136
who O O 0.9999768733978271
was O O 0.9999648332595825
concurrently O O 0.9999489784240723
being O O 0.9999644756317139
treated O O 0.9999176263809204
with O O 0.9986149072647095
pilocarpine B B 0.9995309114456177
nitrate I I 0.9843809604644775
and O O 0.9369402527809143
timolol B B 0.9964174032211304
maleate I O 0.9188298583030701
eye O O 0.9960185885429382
drops O O 0.9466454982757568
, O O 0.999992847442627
developed O O 0.9999971389770508
a O O 0.999991774559021
bradycardia O O 0.9999799728393555
and O O 0.9999849796295166
became O O 0.9999963045120239
hypotensive O O 0.9999517202377319
during O O 0.9995738863945007
halothane B B 0.9102767705917358
anaesthesia O O 0.9997970461845398
. O O 0.9999662637710571

Both O O 0.9971217513084412
timolol B B 0.9995208978652954
and O O 0.9769529104232788
pilocarpine B B 0.999579131603241
were O O 0.9999643564224243
subsequently O O 0.9999854564666748
identified O O 0.9998444318771362
in O O 0.999954342842102
a O O 0.9999806880950928
24 O O 0.9999334812164307
- O O 0.9999791383743286
h O O 0.9971099495887756
collection O O 0.9999816417694092
of O O 0.9999700784683228
urine O O 0.9997225403785706
. O O 0.9999486207962036

Timolol B B 0.999395489692688
( O O 0.9978943467140198
but O O 0.9997310042381287
not O O 0.998887836933136
pilocarpine B B 0.9996115565299988
) O O 0.9997065663337708
was O O 0.9999834299087524
detected O O 0.999980092048645
in O O 0.9999454021453857
a O O 0.999975323677063
sample O O 0.9999943971633911
of O O 0.9999643564224243
plasma O O 0.9990609288215637
removed O O 0.9999697208404541
during O O 0.9999701976776123
surgery O O 0.9999974966049194
; O O 0.9999850988388062
the O O 0.9999860525131226
plasma O O 0.9976062774658203
concentration O O 0.9991050362586975
of O O 0.999642014503479
timolol B B 0.9996839761734009
( O O 0.9998131394386292
2 O O 0.9998098015785217
. O O 0.9999890327453613
6 O O 0.9999778270721436
ng O O 0.9999030828475952
ml O O 0.9999221563339233
- O O 0.9960789084434509
1 O O 0.9898483157157898
) O O 0.9999747276306152
was O O 0.999962568283081
consistent O O 0.9999831914901733
with O O 0.9999372959136963
partial O O 0.9996466636657715
beta O O 0.9719508290290833
- O O 0.9921038150787354
adrenoceptor O O 0.9695437550544739
blockade O O 0.9996415376663208
. O O 0.9999532699584961

It O O 0.9999815225601196
is O O 0.9999597072601318
postulated O O 0.9999586343765259
that O O 0.9999195337295532
this O O 0.9999080896377563
action O O 0.9998908042907715
may O O 0.9998288154602051
have O O 0.9999898672103882
been O O 0.9999756813049316
enhanced O O 0.9999239444732666
during O O 0.9995535016059875
halothane B B 0.9735061526298523
anaesthesia O O 0.9993535876274109
with O O 0.9999551773071289
resultant O O 0.9999943971633911
bradycardia O O 0.9999821186065674
and O O 0.9999746084213257
hypotension O O 0.9999831914901733
. O O 0.999962329864502

Pilocarpine B B 0.9993195533752441
may O O 0.9997405409812927
have O O 0.9998574256896973
had O O 0.9999520778656006
a O O 0.9998486042022705
contributory O O 0.999481737613678
effect O O 0.9999219179153442
. O O 0.9998037219047546

Succinylcholine B B 0.9548362493515015
apnoea O O 0.9943639039993286
: O O 0.9999125003814697
attempted O O 0.9998569488525391
reversal O O 0.9998422861099243
with O O 0.9997020363807678
anticholinesterases O O 0.705941915512085
. O O 0.9997745156288147

Anticholinesterases O O 0.6758682727813721
were O O 0.999658465385437
administered O O 0.9997300505638123
in O O 0.9999802112579346
an O O 0.9999915361404419
attempt O O 0.9999940395355225
to O O 0.9999853372573853
antagonize O O 0.9998507499694824
prolonged O O 0.9998599290847778
neuromuscular O O 0.9999876022338867
blockade O O 0.9999904632568359
following O O 0.9999624490737915
the O O 0.9999889135360718
administration O O 0.9999457597732544
of O O 0.9996342658996582
succinylcholine B B 0.9994980096817017
in O O 0.9999288320541382
a O O 0.9999943971633911
patient O O 0.9999971389770508
later O O 0.9999961853027344
found O O 0.999996542930603
to O O 0.999985933303833
be O O 0.9999673366546631
homozygous O O 0.9995009899139404
for O O 0.9991948008537292
atypical O O 0.992547333240509
plasma O O 0.8565970659255981
cholinesterase O B 0.851353108882904
. O O 0.9998600482940674

Edrophonium B B 0.9990936517715454
10 O O 0.995570719242096
mg O O 0.9960414171218872
, O O 0.9999227523803711
given O O 0.9999635219573975
74 O O 0.9998599290847778
min O O 0.99997878074646
after O O 0.9998736381530762
succinylcholine B B 0.999352753162384
, O O 0.9998743534088135
when O O 0.9999797344207764
train O O 0.9992406368255615
- O O 0.9999662637710571
of O O 0.9938257932662964
- O O 0.9999150037765503
four O O 0.9990293979644775
stimulation O O 0.9999731779098511
was O O 0.999975323677063
characteristic O O 0.9999866485595703
of O O 0.9999511241912842
phase O O 0.9999139308929443
II O O 0.9966674447059631
block O O 0.9999817609786987
, O O 0.9996508359909058
produced O O 0.9999270439147949
partial O O 0.9997891783714294
antagonism O O 0.999225378036499
which O O 0.9999561309814453
was O O 0.9999681711196899
not O O 0.9999878406524658
sustained O O 0.9999667406082153
. O O 0.999958872795105

Repeated O O 0.9998992681503296
doses O O 0.9998883008956909
of O O 0.9993892908096313
edrophonium B B 0.9997504353523254
to O O 0.9994755387306213
70 O O 0.9985185265541077
mg O O 0.9987143278121948
and O O 0.9987188577651978
neostigmine B B 0.998992383480072
to O O 0.9998030066490173
2 O O 0.9965631365776062
. O O 0.9999352693557739
5 O O 0.9996867179870605
mg O O 0.9996066689491272
did O O 0.9999409914016724
not O O 0.9999479055404663
antagonize O O 0.9996757507324219
or O O 0.999943733215332
augment O O 0.9998486042022705
the O O 0.9999613761901855
block O O 0.9999806880950928
. O O 0.9999527931213379

Spontaneous O O 0.9999765157699585
respiration O O 0.9999575614929199
recommenced O O 0.9999723434448242
200 O O 0.9999700784683228
min O O 0.9999877214431763
after O O 0.9999184608459473
succinylcholine B B 0.9997860789299011
administration O O 0.9999134540557861
. O O 0.9999704360961914

It O O 0.999985933303833
is O O 0.9999381303787231
concluded O O 0.9999662637710571
that O O 0.9995743632316589
anticholinesterases O O 0.7417059540748596
are O O 0.9992732405662537
only O O 0.9999489784240723
partially O O 0.999873161315918
effective O O 0.9995620846748352
in O O 0.9998263716697693
restoring O O 0.9998507499694824
neuromuscular O O 0.9999921321868896
function O O 0.9999902248382568
in O O 0.9997310042381287
succinylcholine B B 0.9773568511009216
apnoea O O 0.9612444043159485
despite O O 0.9996535778045654
muscle O O 0.9998704195022583
twitch O O 0.9999383687973022
activity O O 0.9999744892120361
typical O O 0.9999727010726929
of O O 0.9999344348907471
phase O O 0.9997753500938416
II O O 0.992558479309082
block O O 0.9999192953109741
. O O 0.9999160766601562

Effect O O 0.99969482421875
of O O 0.9965956807136536
doxorubicin B B 0.9997698664665222
on O O 0.9992368221282959
[ B B 0.6249991059303284
omega I I 0.8115940690040588
- I I 0.8941711783409119
I I I 0.9967273473739624
- I I 0.9612955451011658
131 I I 0.9996132254600525
] I I 0.6706265807151794
heptadecanoic I I 0.49724772572517395
acid I I 0.9999346733093262
myocardial O O 0.9956402778625488
scintigraphy O O 0.9868593215942383
and O O 0.99997878074646
echocardiography O O 0.9998717308044434
in O O 0.9999432563781738
dogs O O 0.9992294311523438
. O O 0.9999388456344604

The O O 0.9999668598175049
effects O O 0.999981164932251
of O O 0.999962329864502
serial O O 0.9998918771743774
treatment O O 0.9999822378158569
with O O 0.9996554851531982
doxorubicin B B 0.9997599720954895
on O O 0.9997150301933289
dynamic O O 0.9998613595962524
myocardial O O 0.9999973773956299
scintigraphy O O 0.9934198260307312
with O O 0.9996931552886963
[ B B 0.6187130212783813
omega I I 0.7070873379707336
- I I 0.8133708834648132
I I I 0.9735637903213501
- I I 0.971281886100769
131 I I 0.9995026588439941
] I I 0.6673404574394226
heptadecanoic I I 0.6808726787567139
acid I I 0.9999407529830933
( O O 0.9857811331748962
I B B 0.7690976858139038
- I I 0.8063722252845764
131 I I 0.979069173336029
HA I I 0.9803923964500427
) O O 0.9989925026893616
, O O 0.9999641180038452
and O O 0.9999172687530518
on O O 0.9997100234031677
global O O 0.9998055100440979
left O O 0.9999191761016846
- O O 0.9998158812522888
ventricular O O 0.9999936819076538
function O O 0.9999911785125732
determined O O 0.9999942779541016
echocardiographically O O 0.9999595880508423
, O O 0.9999880790710449
were O O 0.9999914169311523
studied O O 0.9999871253967285
in O O 0.9999833106994629
a O O 0.999984622001648
group O O 0.999995231628418
of O O 0.9999890327453613
nine O O 0.9999901056289673
mongrel O O 0.9939073920249939
dogs O O 0.999932050704956
. O O 0.9999560117721558

Total O O 0.9854127764701843
extractable O O 0.9921924471855164
myocardial O O 0.9993316531181335
lipid O O 0.5548139810562134
was O O 0.9999431371688843
compared O O 0.9999178647994995
postmortem O O 0.9999440908432007
between O O 0.9997501969337463
a O O 0.9999643564224243
group O O 0.9999898672103882
of O O 0.9998948574066162
control O O 0.9997918009757996
dogs O O 0.9999922513961792
and O O 0.9997894167900085
doxorubicin B B 0.9996297359466553
- O O 0.9993439316749573
treated O O 0.9998519420623779
dogs O O 0.9999971389770508
. O O 0.9999741315841675

A O O 0.9999767541885376
significant O O 0.9999858140945435
and O O 0.9999828338623047
then O O 0.9999833106994629
progressive O O 0.9999847412109375
fall O O 0.9999970197677612
in O O 0.999988317489624
global O O 0.9998430013656616
LV O O 0.97153240442276
function O O 0.9999903440475464
was O O 0.9999864101409912
observed O O 0.999997615814209
at O O 0.9999059438705444
a O O 0.9999847412109375
cumulative O O 0.9992831349372864
doxorubicin B B 0.9995397329330444
dose O O 0.9998472929000854
of O O 0.9999275207519531
4 O O 0.9993853569030762
mg O O 0.9999213218688965
/ O O 0.9998464584350586
kg O O 0.9999961853027344
. O O 0.999970555305481

A O O 0.9999701976776123
significant O O 0.9999830722808838
increase O O 0.9999754428863525
in O O 0.9999654293060303
the O O 0.9999691247940063
myocardial O O 0.999995231628418
t1 O O 0.9982836246490479
/ O O 0.9999352693557739
2 O O 0.999521017074585
of O O 0.9990463852882385
the O O 0.9997566342353821
I B B 0.542486846446991
- I I 0.5893734097480774
131 I I 0.9995580315589905
HA I O 0.6999866366386414
was O O 0.9999858140945435
observed O O 0.9999946355819702
only O O 0.9999829530715942
at O O 0.9999270439147949
a O O 0.9999914169311523
higher O O 0.9999855756759644
cumulative O O 0.9998176693916321
dose O O 0.9999785423278809
, O O 0.9999741315841675
10 O O 0.999968409538269
mg O O 0.9999620914459229
/ O O 0.9999825954437256
kg O O 0.9999939203262329
. O O 0.9999277591705322

No O O 0.999947190284729
significant O O 0.9999909400939941
alteration O O 0.9999970197677612
in O O 0.9999799728393555
total O O 0.9714563488960266
extractable O O 0.97785884141922
myocardial O O 0.9997712969779968
lipids O O 0.6214128732681274
was O O 0.9999723434448242
observed O O 0.9999854564666748
between O O 0.9996119141578674
control O O 0.9993253946304321
dogs O O 0.9998109936714172
and O O 0.9999406337738037
those O O 0.9999508857727051
treated O O 0.9999251365661621
with O O 0.9993956089019775
doxorubicin B B 0.9997026324272156
. O O 0.9999445676803589

Our O O 0.9999566078186035
findings O O 0.9999949932098389
suggest O O 0.9999589920043945
that O O 0.9999133348464966
the O O 0.9999604225158691
changes O O 0.9999961853027344
leading O O 0.9999935626983643
to O O 0.9999812841415405
an O O 0.9999771118164062
alteration O O 0.9999958276748657
of O O 0.9999734163284302
myocardial O O 0.999997615814209
dynamic O O 0.9999558925628662
imaging O O 0.9999897480010986
with O O 0.9997261166572571
I B B 0.5690916180610657
- I I 0.6649507284164429
131 I I 0.999832272529602
HA I O 0.7039512395858765
are O O 0.999721348285675
not O O 0.9998138546943665
the O O 0.9998281002044678
initiating O O 0.9998874664306641
factor O O 0.9999904632568359
in O O 0.9999079704284668
doxorubicin B B 0.9998390674591064
cardiotoxicity O O 0.9999551773071289
. O O 0.9999626874923706

Hemodynamics O O 0.9995324611663818
and O O 0.9998575448989868
myocardial O O 0.9999924898147583
metabolism O O 0.9998489618301392
under O O 0.9997878670692444
deliberate O O 0.997848391532898
hypotension O O 0.9998705387115479
. O O 0.9999421834945679

An O O 0.9999359846115112
experimental O O 0.9999569654464722
study O O 0.9999923706054688
in O O 0.9999796152114868
dogs O O 0.999976634979248
. O O 0.9999673366546631

Coronary O O 0.9996013045310974
blood O O 0.9998617172241211
flow O O 0.9999934434890747
, O O 0.9999432563781738
cardiac O O 0.9999521970748901
work O O 0.9999971389770508
and O O 0.9999265670776367
metabolism O O 0.9998785257339478
were O O 0.9999632835388184
studied O O 0.9999493360519409
in O O 0.9999048709869385
dogs O O 0.9999669790267944
under O O 0.9992959499359131
sodium B B 0.9893776774406433
nitroprusside I I 0.9807413220405579
( O O 0.9934343099594116
SNP B B 0.9904175400733948
) O O 0.9747999906539917
and O O 0.9919305443763733
trimetaphan B B 0.9985730648040771
( O O 0.9977197051048279
TMP B B 0.9921798706054688
) O O 0.9993845224380493
deliberate O O 0.9995813965797424
hypotension O O 0.9999300241470337
( O O 0.9999716281890869
20 O O 0.9999661445617676
% O O 0.9999958276748657
and O O 0.9999775886535645
40 O O 0.9999855756759644
% O O 0.9999974966049194
mean O O 0.999972939491272
pressure O O 0.9999523162841797
decrease O O 0.9999963045120239
from O O 0.999997615814209
baseline O O 0.9999896287918091
) O O 0.9999790191650391
. O O 0.9999699592590332

Regarding O O 0.9999682903289795
the O O 0.999945878982544
effects O O 0.999977707862854
of O O 0.9999186992645264
drug O O 0.9981938004493713
- O O 0.999798595905304
induced O O 0.9999487400054932
hypotension O O 0.9999006986618042
on O O 0.999845027923584
coronary O O 0.9998965263366699
blood O O 0.9998308420181274
flow O O 0.999990701675415
, O O 0.9999270439147949
aortic O O 0.9979454874992371
and O O 0.9993938207626343
coronary O O 0.9939203262329102
sinus O O 0.9986308217048645
metabolic O O 0.9536377787590027
data O O 0.9999655485153198
( O O 0.9995684027671814
pH O O 0.8811531662940979
, O O 0.994511604309082
pO2 O O 0.7486720085144043
, O O 0.9359216690063477
pCO2 O O 0.7250565886497498
) O O 0.9998043179512024
we O O 0.9999759197235107
could O O 0.9999887943267822
confirm O O 0.9999966621398926
that O O 0.9999251365661621
nitroprusside B B 0.9997155070304871
hypotension O O 0.9993788003921509
could O O 0.9999815225601196
be O O 0.9999910593032837
safely O O 0.9999767541885376
used O O 0.9999852180480957
to O O 0.9999339580535889
30 O O 0.9999892711639404
% O O 0.9999886751174927
mean O O 0.9999810457229614
blood O O 0.9994713664054871
pressure O O 0.9980413913726807
decrease O O 0.999985933303833
from O O 0.9993839263916016
control O O 0.9999781847000122
, O O 0.999204695224762
trimetaphan B B 0.9998059868812561
hypotension O O 0.9989163875579834
to O O 0.9999634027481079
20 O O 0.9999855756759644
% O O 0.9999911785125732
mean O O 0.9999881982803345
blood O O 0.9993332028388977
pressure O O 0.9970071911811829
decrease O O 0.999911904335022
. O O 0.9999765157699585

Cardiac O O 0.9987622499465942
work O O 0.9998840093612671
was O O 0.9999008178710938
significantly O O 0.9999395608901978
reduced O O 0.9999817609786987
during O O 0.9996192455291748
SNP B B 0.893801748752594
hypotension O O 0.9993127584457397
. O O 0.999953031539917

Myocardial O O 0.9998629093170166
O2 B B 0.8895187377929688
consumption O O 0.9992383718490601
and O O 0.999858021736145
O2 B B 0.9553142786026001
availability O O 0.9996411800384521
were O O 0.9999397993087769
directly O O 0.9999585151672363
dependent O O 0.9999784231185913
on O O 0.9999431371688843
the O O 0.9999792575836182
coronary O O 0.9997844099998474
perfusion O O 0.9997009038925171
. O O 0.9999629259109497

Careful O O 0.9996991157531738
invasive O O 0.9999909400939941
monitoring O O 0.9999948740005493
of O O 0.9999878406524658
the O O 0.9999780654907227
blood O O 0.9995661377906799
pressure O O 0.9991152882575989
, O O 0.9999357461929321
blood O O 0.9974766373634338
gases O B 0.9159826040267944
and O O 0.9998750686645508
of O O 0.999962568283081
the O O 0.9999380111694336
ECG O O 0.9749448895454407
ST O O 0.919243574142456
- O O 0.994208812713623
T O O 0.9889603853225708
segment O O 0.999920129776001
is O O 0.9999744892120361
mandatory O O 0.9999849796295166
. O O 0.9999839067459106

Evidence O O 0.999954104423523
for O O 0.9997400641441345
a O O 0.9995602965354919
selective O O 0.9992899894714355
brain O O 0.9997832179069519
noradrenergic O O 0.6444584131240845
involvement O O 0.9998282194137573
in O O 0.9998831748962402
the O O 0.999919056892395
locomotor O O 0.9989629983901978
stimulant O O 0.9940789937973022
effects O O 0.9998728036880493
of O O 0.9998395442962646
amphetamine B B 0.9994146823883057
in O O 0.9998252987861633
the O O 0.9999865293502808
rat O O 0.9999792575836182
. O O 0.9999576807022095

Male O O 0.9998201727867126
rats O O 0.9999948740005493
received O O 0.9999446868896484
the O O 0.9999194145202637
noradrenaline B B 0.9745208024978638
neurotoxin O O 0.5062521696090698
DSP4 B B 0.9866700768470764
( O O 0.9993870258331299
50 O O 0.9999388456344604
mg O O 0.9998890161514282
/ O O 0.9998836517333984
kg O O 0.9999895095825195
) O O 0.9999727010726929
7 O O 0.999911904335022
days O O 0.9999938011169434
prior O O 0.9999971389770508
to O O 0.9999788999557495
injection O O 0.9999701976776123
of O O 0.9997627139091492
D B B 0.9669926166534424
- I I 0.9939604997634888
amphetamine I I 0.9995267391204834
( O O 0.9990561604499817
10 O O 0.9966607093811035
or O O 0.9999594688415527
40 O O 0.999914288520813
mumol O O 0.9991303086280823
/ O O 0.999901294708252
kg O O 0.9999936819076538
i O O 0.999859094619751
. O O 0.9999964237213135
p O O 0.999998927116394
. O O 0.9999964237213135
) O O 0.9999837875366211
. O O 0.9999781847000122

The O O 0.999962329864502
hyperactivity O O 0.9998846054077148
induced O O 0.9999463558197021
by O O 0.9998774528503418
D B B 0.9679485559463501
- I I 0.9836931824684143
amphetamine I I 0.9986879229545593
( O O 0.9985272884368896
10 O O 0.9993738532066345
mumol O O 0.9984484910964966
/ O O 0.9998214840888977
kg O O 0.999991774559021
) O O 0.9999676942825317
was O O 0.9999657869338989
significantly O O 0.9999814033508301
reduced O O 0.9999915361404419
by O O 0.9998399019241333
DSP4 B B 0.9600245356559753
pretreatment O O 0.9990673661231995
. O O 0.9999688863754272

However O O 0.9999371767044067
, O O 0.9999244213104248
the O O 0.9999722242355347
increased O O 0.9999266862869263
rearings O O 0.9999591112136841
and O O 0.9999113082885742
the O O 0.9999650716781616
amphetamine B B 0.998140811920166
- O O 0.9998878240585327
induced O O 0.9999237060546875
stereotypies O O 0.9997580647468567
were O O 0.9999561309814453
not O O 0.9999532699584961
blocked O O 0.9999536275863647
by O O 0.9999004602432251
pretreatment O O 0.9997784495353699
with O O 0.9998121857643127
DSP4 B B 0.9595146775245667
. O O 0.9997671246528625

The O O 0.9999325275421143
reduction O O 0.9998654127120972
of O O 0.9997077584266663
amphetamine B B 0.9956012964248657
hyperactivity O O 0.9981774091720581
induced O O 0.9999167919158936
by O O 0.9997463822364807
DSP4 B B 0.9633786678314209
was O O 0.9997485280036926
blocked O O 0.9998077750205994
by O O 0.999852180480957
pretreatment O O 0.9997857213020325
with O O 0.999929666519165
the O O 0.9995926022529602
noradrenaline B B 0.9608892202377319
- O O 0.9531117081642151
uptake O O 0.9559356570243835
blocking O O 0.8954994082450867
agent O O 0.9763675332069397
, O O 0.9915596842765808
desipramine B B 0.9998937845230103
, O O 0.9999231100082397
which O O 0.9999241828918457
prevents O O 0.9996336698532104
the O O 0.9999587535858154
neurotoxic O O 0.9999880790710449
action O O 0.9999780654907227
of O O 0.999841570854187
DSP4 B B 0.9860782623291016
. O O 0.9998784065246582

The O O 0.9999892711639404
present O O 0.9999909400939941
results O O 0.999991774559021
suggest O O 0.9998468160629272
a O O 0.9997707009315491
selective O O 0.9995782971382141
involvement O O 0.9999229907989502
of O O 0.9996371269226074
central O O 0.9991556406021118
noradrenergic O O 0.7071699500083923
neurones O O 0.9998304843902588
in O O 0.9998254179954529
the O O 0.9999003410339355
locomotor O O 0.9993298053741455
stimulant O O 0.9939655661582947
effect O O 0.9998961687088013
of O O 0.9998434782028198
amphetamine B B 0.9993891716003418
in O O 0.9998413324356079
the O O 0.9999852180480957
rat O O 0.9999856948852539
. O O 0.9999598264694214

Accelerated O O 0.9998630285263062
junctional O O 0.9999821186065674
rhythms O O 0.999994158744812
during O O 0.9998389482498169
oral O O 0.9963915944099426
verapamil B B 0.9992984533309937
therapy O O 0.9998378753662109
. O O 0.9999721050262451

This O O 0.999984860420227
study O O 0.9999805688858032
examined O O 0.9999752044677734
the O O 0.9999837875366211
frequency O O 0.999994158744812
of O O 0.9999679327011108
atrioventricular O O 0.9907799363136292
( O O 0.9988195300102234
AV O O 0.9846848249435425
) O O 0.9997758269309998
dissociation O O 0.9999786615371704
and O O 0.9998589754104614
accelerated O O 0.9998544454574585
junctional O O 0.9999884366989136
rhythms O O 0.9999948740005493
in O O 0.9999333620071411
59 O O 0.999945878982544
patients O O 0.9999898672103882
receiving O O 0.9998183846473694
oral O O 0.9866678714752197
verapamil B B 0.9992640614509583
. O O 0.9999414682388306

Accelerated O O 0.9986756443977356
junctional O O 0.9999617338180542
rhythms O O 0.9999923706054688
and O O 0.9998887777328491
AV O O 0.9702463150024414
dissociation O O 0.9999604225158691
were O O 0.999953031539917
frequent O O 0.9998866319656372
in O O 0.9999008178710938
patients O O 0.9999898672103882
with O O 0.9999651908874512
supraventricular O O 0.9999685287475586
tachyarrhythmias O O 0.9999518394470215
, O O 0.9999634027481079
particularly O O 0.9998281002044678
AV O O 0.9336676597595215
nodal O O 0.9999828338623047
reentry O O 0.9999796152114868
. O O 0.9999701976776123

Verapamil B B 0.9991106390953064
administration O O 0.9998949766159058
to O O 0.9999574422836304
these O O 0.9999783039093018
patients O O 0.9999880790710449
led O O 0.9999759197235107
to O O 0.9999901056289673
an O O 0.999995231628418
asymptomatic O O 0.999997615814209
increase O O 0.9999966621398926
in O O 0.9999878406524658
activity O O 0.9999920129776001
of O O 0.9999730587005615
these O O 0.9999698400497437
junctional O O 0.9999544620513916
pacemakers O O 0.9992509484291077
. O O 0.9999697208404541

In O O 0.9998828172683716
patients O O 0.999985933303833
with O O 0.9999761581420898
various O O 0.9999681711196899
chest O O 0.9999645948410034
pain O O 0.999854326248169
syndromes O O 0.9999539852142334
, O O 0.999642014503479
verapamil B B 0.9998072981834412
neither O O 0.9998908042907715
increased O O 0.9999390840530396
the O O 0.9999918937683105
frequency O O 0.9999963045120239
of O O 0.9999823570251465
junctional O O 0.9999551773071289
rhythms O O 0.9999904632568359
nor O O 0.9999544620513916
suppressed O O 0.9999246597290039
their O O 0.999886155128479
role O O 0.9999481439590454
as O O 0.9999308586120605
escape O O 0.999527096748352
rhythms O O 0.9999877214431763
under O O 0.9999709129333496
physiologically O O 0.9999825954437256
appropriate O O 0.9999926090240479
circumstances O O 0.9999942779541016
. O O 0.9999774694442749

Interstrain O O 0.9775790572166443
variation O O 0.9999932050704956
in O O 0.9999797344207764
acute O O 0.9998621940612793
toxic O O 0.9983004927635193
response O O 0.9999637603759766
to O O 0.9995203018188477
caffeine B B 0.9995409250259399
among O O 0.999512791633606
inbred O O 0.99988853931427
mice O O 0.9999914169311523
. O O 0.9999457597732544

Acute O O 0.9997562766075134
toxic O O 0.999158501625061
dosage O O 0.9990938901901245
- O O 0.9997952580451965
dependent O O 0.9999128580093384
behavioral O O 0.9999682903289795
effects O O 0.9999517202377319
of O O 0.9998356103897095
caffeine B B 0.9995675683021545
were O O 0.9998726844787598
compared O O 0.9999094009399414
in O O 0.9999489784240723
adult O O 0.999990701675415
males O O 0.9999972581863403
from O O 0.9999819993972778
seven O O 0.9998786449432373
inbred O O 0.9999219179153442
mouse O O 0.9999943971633911
strains O O 0.999991774559021
( O O 0.9999287128448486
A O O 0.9433260560035706
/ O O 0.9988093376159668
J O O 0.9991932511329651
, O O 0.9996981620788574
BALB O O 0.98527991771698
/ O O 0.9993688464164734
cJ O O 0.9767870306968689
, O O 0.9995817542076111
CBA O O 0.8761349320411682
/ O O 0.9993971586227417
J O O 0.9992640614509583
, O O 0.999363124370575
C3H O O 0.9887630939483643
/ O O 0.9988963603973389
HeJ O O 0.991216778755188
, O O 0.9994956254959106
C57BL O O 0.9848745465278625
/ O O 0.9989888072013855
6J O O 0.9905633926391602
, O O 0.9989694356918335
DBA O O 0.9470618367195129
/ O O 0.9992393255233765
2J O O 0.9837892651557922
, O O 0.9978277087211609
SWR O O 0.7576204538345337
/ O O 0.9980813264846802
J O O 0.9972226619720459
) O O 0.9999681711196899
. O O 0.9999669790267944

C57BL O O 0.9952479004859924
/ O O 0.9998607635498047
6J O O 0.996669352054596
, O O 0.9999752044677734
chosen O O 0.9999761581420898
as O O 0.9999626874923706
a O O 0.999976396560669
" O O 0.9999508857727051
prototypic O O 0.9997863173484802
" O O 0.9999843835830688
mouse O O 0.9999970197677612
strain O O 0.9999959468841553
, O O 0.9999867677688599
was O O 0.999984622001648
used O O 0.9999918937683105
to O O 0.9999909400939941
determine O O 0.9999896287918091
behavioral O O 0.999991774559021
responses O O 0.999996542930603
to O O 0.9999443292617798
a O O 0.9999890327453613
broad O O 0.9999743700027466
range O O 0.9999402761459351
( O O 0.9998830556869507
5 O O 0.9995864033699036
- O O 0.9993195533752441
500 O O 0.9999732971191406
mg O O 0.9999524354934692
/ O O 0.9999921321868896
kg O O 0.9999985694885254
) O O 0.9999746084213257
of O O 0.9958329796791077
caffeine B B 0.9995593428611755
doses O O 0.9997058510780334
. O O 0.9999831914901733

Five O O 0.998788058757782
phenotypic O O 0.9999661445617676
characteristics O O 0.999997615814209
- O O 0.999733030796051
- O O 0.9995487332344055
locomotor O O 0.9997509121894836
activity O O 0.9999752044677734
, O O 0.9999423027038574
righting O O 0.9997038245201111
ability O O 0.9999920129776001
, O O 0.9999330043792725
clonic O O 0.9986764788627625
seizure O O 0.9999392032623291
induction O O 0.999984860420227
, O O 0.9999502897262573
stress O O 0.9969919919967651
- O O 0.9999064207077026
induced O O 0.9999762773513794
lethality O O 0.9999957084655762
, O O 0.9999555349349976
death O O 0.9999964237213135
without O O 0.9999806880950928
external O O 0.9997671246528625
stress O O 0.9998045563697815
- O O 0.9910043478012085
- O O 0.9954839944839478
were O O 0.9999964237213135
scored O O 0.9999959468841553
at O O 0.9999722242355347
various O O 0.9999557733535767
caffeine B B 0.9995086193084717
doses O O 0.9996273517608643
in O O 0.999961256980896
drug O O 0.9967010617256165
- O O 0.9998823404312134
naive O O 0.9999580383300781
animals O O 0.9999960660934448
under O O 0.9999349117279053
empirically O O 0.9999574422836304
optimized O O 0.9999740123748779
, O O 0.9999878406524658
rigidly O O 0.9996851682662964
constant O O 0.9999899864196777
experimental O O 0.9999949932098389
conditions O O 0.9999957084655762
. O O 0.9999855756759644

Mice O O 0.9999827146530151
( O O 0.9999740123748779
n O O 0.9999730587005615
= O O 0.999984860420227
12 O O 0.9999939203262329
for O O 0.9999480247497559
each O O 0.9999527931213379
point O O 0.9999879598617554
) O O 0.9999759197235107
received O O 0.9999881982803345
single O O 0.9999114274978638
IP O O 0.9867908358573914
injections O O 0.9999809265136719
of O O 0.9999585151672363
a O O 0.9999783039093018
fixed O O 0.9999661445617676
volume O O 0.9999542236328125
/ O O 0.9999821186065674
g O O 0.9999964237213135
body O O 0.9999972581863403
weight O O 0.9999991655349731
of O O 0.9998395442962646
physiological O O 0.9605912566184998
saline O O 0.9997225403785706
carrier O O 0.9963343143463135
with O O 0.9998865127563477
or O O 0.9999614953994751
without O O 0.9998570680618286
caffeine B B 0.9996645450592041
in O O 0.9999374151229858
doses O O 0.9999903440475464
ranging O O 0.9999934434890747
from O O 0.9999896287918091
125 O O 0.9959516525268555
- O O 0.9993791580200195
500 O O 0.9999731779098511
mg O O 0.9999752044677734
/ O O 0.9999885559082031
kg O O 0.9999977350234985
. O O 0.9999797344207764

Loss O O 0.9999822378158569
of O O 0.9999750852584839
righting O O 0.9997864365577698
ability O O 0.9999860525131226
was O O 0.9999617338180542
scored O O 0.9999827146530151
at O O 0.9999690055847168
1 O O 0.9999473094940186
, O O 0.9999333620071411
3 O O 0.9999492168426514
, O O 0.9999107122421265
5 O O 0.9999678134918213
min O O 0.9999781847000122
post O O 0.9997541308403015
dosing O O 0.9990346431732178
and O O 0.9998643398284912
at O O 0.999956488609314
5 O O 0.9999088048934937
min O O 0.999970555305481
intervals O O 0.9999804496765137
thereafter O O 0.9999651908874512
for O O 0.9999501705169678
20 O O 0.9999871253967285
min O O 0.9999860525131226
. O O 0.9999728202819824

In O O 0.9999682903289795
the O O 0.9999864101409912
same O O 0.9999648332595825
animals O O 0.9999165534973145
the O O 0.9999916553497314
occurrence O O 0.9999943971633911
of O O 0.9999721050262451
clonic O O 0.9994574189186096
seizures O O 0.9999855756759644
was O O 0.9999755620956421
scored O O 0.9999922513961792
as O O 0.9999927282333374
to O O 0.999985933303833
time O O 0.9999922513961792
of O O 0.999990701675415
onset O O 0.9999949932098389
and O O 0.9999831914901733
severity O O 0.9999969005584717
for O O 0.999987006187439
20 O O 0.9999903440475464
min O O 0.9999969005584717
after O O 0.9999816417694092
drug O O 0.9992160797119141
administration O O 0.9999494552612305
. O O 0.9999891519546509

When O O 0.9999842643737793
these O O 0.9999611377716064
proceeded O O 0.9999963045120239
to O O 0.9999873638153076
tonic O O 0.9999719858169556
seizures O O 0.9999890327453613
, O O 0.9999535083770752
death O O 0.9999861717224121
occurred O O 0.9999973773956299
in O O 0.999994158744812
less O O 0.9999980926513672
than O O 0.9999970197677612
20 O O 0.9999949932098389
min O O 0.9999927282333374
. O O 0.9999860525131226

Animals O O 0.999984622001648
surviving O O 0.9999823570251465
for O O 0.9999549388885498
20 O O 0.9999731779098511
min O O 0.9999752044677734
were O O 0.9999914169311523
immediately O O 0.9999754428863525
stressed O O 0.9999865293502808
by O O 0.9999912977218628
a O O 0.9999886751174927
swim O O 0.9999722242355347
test O O 0.9999960660934448
in O O 0.9999767541885376
25 O O 0.9999939203262329
degrees O O 0.9999903440475464
C O O 0.7783530950546265
water O O 0.9949964284896851
, O O 0.999937891960144
and O O 0.9998581409454346
death O O 0.7063090801239014
- O O 0.9996364116668701
producing O O 0.9997765421867371
tonic O O 0.9997891783714294
seizures O O 0.9999841451644897
were O O 0.9999861717224121
scored O O 0.9999814033508301
for O O 0.9999674558639526
2 O O 0.9999547004699707
min O O 0.9999876022338867
. O O 0.999981164932251

In O O 0.999919056892395
other O O 0.9998366832733154
animals O O 0.9999758005142212
locomotor O O 0.999725878238678
activity O O 0.9999463558197021
was O O 0.9999600648880005
measured O O 0.9999877214431763
15 O O 0.9999701976776123
or O O 0.9999817609786987
60 O O 0.9999945163726807
min O O 0.9999880790710449
after O O 0.9999560117721558
caffeine B B 0.9996973276138306
administration O O 0.9998346567153931
. O O 0.9999833106994629

By O O 0.9999397993087769
any O O 0.9999555349349976
single O O 0.9999409914016724
behavioral O O 0.9999842643737793
criterion O O 0.9999947547912598
or O O 0.9999701976776123
a O O 0.9999723434448242
combination O O 0.9998456239700317
of O O 0.9999366998672485
these O O 0.9999210834503174
criteria O O 0.9999738931655884
, O O 0.9999383687973022
marked O O 0.9999663829803467
differences O O 0.9999951124191284
in O O 0.999981164932251
response O O 0.9999895095825195
to O O 0.9999274015426636
toxic O O 0.9994074106216431
caffeine B B 0.9990862607955933
doses O O 0.9994636178016663
were O O 0.9999829530715942
observed O O 0.999991774559021
between O O 0.9997653365135193
strains O O 0.9982884526252747
. O O 0.9999656677246094

These O O 0.999984622001648
results O O 0.9999946355819702
indicate O O 0.9999744892120361
that O O 0.9999724626541138
behavioral O O 0.9999688863754272
toxicity O O 0.9998435974121094
testing O O 0.9999909400939941
of O O 0.9998738765716553
alkylxanthines B B 0.9807737469673157
in O O 0.9996395111083984
a O O 0.9999626874923706
single O O 0.9999748468399048
mouse O O 0.9999934434890747
strain O O 0.9999953508377075
may O O 0.9999802112579346
be O O 0.9999915361404419
misleading O O 0.9999873638153076
and O O 0.999976396560669
suggest O O 0.9999605417251587
that O O 0.9999139308929443
toxic O O 0.9995298385620117
responses O O 0.999964714050293
of O O 0.9999058246612549
the O O 0.9999431371688843
central O O 0.9995713829994202
nervous O O 0.9999843835830688
system O O 0.999984622001648
to O O 0.9998359680175781
this O O 0.9999632835388184
class O O 0.9940702319145203
of O O 0.9972423315048218
compounds O O 0.9716669917106628
are O O 0.9999405145645142
genetically O O 0.9999614953994751
influenced O O 0.9999901056289673
in O O 0.9999083280563354
mammals O O 0.9999250173568726
. O O 0.9999706745147705

Treatment O O 0.9999079704284668
of O O 0.9999489784240723
ovarian O O 0.9965288043022156
cancer O O 0.999927282333374
with O O 0.9998573064804077
a O O 0.999798595905304
combination O O 0.9819629192352295
of O O 0.9950516819953918
cis B B 0.9947342872619629
- I I 0.9588986039161682
platinum I I 0.9999297857284546
, O O 0.5557959675788879
adriamycin B B 0.99519944190979
, O O 0.7914726138114929
cyclophosphamide B B 0.996996283531189
and O O 0.9287240505218506
hexamethylmelamine B B 0.9940967559814453
. O O 0.9996008276939392

During O O 0.9999510049819946
the O O 0.9999927282333374
last O O 0.9999959468841553
2 O O 0.9999837875366211
1 O O 0.9998842477798462
/ O O 0.9999916553497314
2 O O 0.9999756813049316
years O O 0.9999920129776001
, O O 0.9999840259552002
38 O O 0.9999818801879883
patients O O 0.9999964237213135
with O O 0.9999865293502808
ovarian O O 0.9993571639060974
cancer O O 0.9999630451202393
were O O 0.9999794960021973
treated O O 0.9999834299087524
with O O 0.9999386072158813
a O O 0.9999539852142334
combination O O 0.9888266324996948
of O O 0.9985847473144531
cisplatinum B B 0.9995334148406982
( O O 0.9887362122535706
CPDD B B 0.9827106595039368
) O O 0.9568390846252441
, O O 0.9981071949005127
50 O O 0.9998791217803955
mg O O 0.999871015548706
/ O O 0.9996286630630493
m2 O O 0.9999426603317261
, O O 0.9964499473571777
adriamycin B B 0.999293327331543
, O O 0.9588582515716553
30 O O 0.999763548374176
mg O O 0.9999017715454102
/ O O 0.9998039603233337
m2 O O 0.9999715089797974
, O O 0.9950639605522156
cyclophosphamide B B 0.9990754127502441
, O O 0.9966039657592773
300 O O 0.999789297580719
mg O O 0.999934196472168
/ O O 0.9998539686203003
m2 O O 0.999993085861206
, O O 0.9999774694442749
on O O 0.9999173879623413
day O O 0.9999949932098389
1 O O 0.999987006187439
; O O 0.9999152421951294
and O O 0.9996222257614136
hexamethylmelamine B B 0.9987805485725403
( O O 0.9946849346160889
HMM B B 0.9766359925270081
) O O 0.9919490814208984
, O O 0.9999332427978516
6 O O 0.999839186668396
mg O O 0.9999634027481079
/ O O 0.9999839067459106
kg O O 0.9999946355819702
daily O O 0.9999679327011108
, O O 0.9999836683273315
for O O 0.9999740123748779
14 O O 0.9999955892562866
days O O 0.9999949932098389
. O O 0.9999868869781494

Each O O 0.9998136162757874
course O O 0.9997716546058655
was O O 0.9999819993972778
repeated O O 0.9999783039093018
monthly O O 0.9999886751174927
. O O 0.9999806880950928

2 O O 0.9995146989822388
patients O O 0.9999812841415405
had O O 0.9999363422393799
stage O O 0.9999591112136841
II O O 0.9994843006134033
, O O 0.9999260902404785
14 O O 0.9999444484710693
stage O O 0.9999288320541382
III O O 0.9981555342674255
and O O 0.9995424747467041
22 O O 0.9993630051612854
stage O O 0.9999090433120728
IV O O 0.9994924068450928
disease O O 0.9999877214431763
. O O 0.99996018409729

14 O O 0.999957799911499
of O O 0.999985933303833
the O O 0.9999920129776001
38 O O 0.9999943971633911
patients O O 0.9999943971633911
were O O 0.9999580383300781
previously O O 0.9999517202377319
treated O O 0.9999672174453735
with O O 0.999901294708252
chemotherapy O O 0.9993244409561157
, O O 0.9999758005142212
1 O O 0.9997928738594055
with O O 0.9998669624328613
radiation O O 0.999796450138092
, O O 0.9999792575836182
6 O O 0.9999324083328247
with O O 0.999901533126831
both O O 0.9996275901794434
chemotherapy O O 0.9688416719436646
and O O 0.9996672868728638
radiation O O 0.9989110231399536
, O O 0.9999076128005981
and O O 0.999964714050293
17 O O 0.9999372959136963
did O O 0.9999954700469971
not O O 0.9999936819076538
have O O 0.9999829530715942
any O O 0.999924898147583
treatment O O 0.999975323677063
before O O 0.9994558691978455
CPDD B O 0.7214919328689575
combination O O 0.9982926249504089
. O O 0.9999551773071289

31 O O 0.9998375177383423
of O O 0.9999616146087646
the O O 0.9999865293502808
38 O O 0.9999864101409912
cases O O 0.9997639060020447
( O O 0.9999567270278931
81 O O 0.9999661445617676
. O O 0.9999808073043823
5 O O 0.9999942779541016
% O O 0.9999896287918091
) O O 0.9999542236328125
demonstrated O O 0.9999547004699707
objective O O 0.999840259552002
responses O O 0.9999915361404419
lasting O O 0.9999877214431763
for O O 0.9999942779541016
2 O O 0.9999845027923584
months O O 0.9999983310699463
or O O 0.9999953508377075
more O O 0.9999908208847046
. O O 0.999984622001648

These O O 0.9998365640640259
responses O O 0.9999402761459351
were O O 0.9999470710754395
partial O O 0.9999502897262573
in O O 0.9999778270721436
19 O O 0.9996693134307861
and O O 0.9999340772628784
complete O O 0.9997603297233582
in O O 0.999975323677063
12 O O 0.9999929666519165
cases O O 0.9999912977218628
. O O 0.9999719858169556

Hematologic O O 0.9984511137008667
toxicity O O 0.9998800754547119
was O O 0.9999281167984009
moderate O O 0.9999535083770752
and O O 0.9999920129776001
with O O 0.9999645948410034
reversible O O 0.9998155236244202
anemia O O 0.9971543550491333
developing O O 0.9999861717224121
in O O 0.9999595880508423
71 O O 0.9999957084655762
% O O 0.999996542930603
of O O 0.9999785423278809
patients O O 0.9999876022338867
. O O 0.9999734163284302

Gastrointestinal O O 0.9861136078834534
side O O 0.9998010993003845
effects O O 0.9999339580535889
from O O 0.9994385838508606
CPDD B B 0.890605628490448
were O O 0.9992544054985046
universal O O 0.9288478493690491
. O O 0.9999114274978638

HMM B O 0.8434278964996338
gastrointestinal O O 0.977846622467041
toxicity O O 0.9999359846115112
necessitated O O 0.9999892711639404
discontinuation O O 0.9999821186065674
of O O 0.9998583793640137
the O O 0.9978623986244202
drug O O 0.9959053993225098
in O O 0.9999552965164185
5 O O 0.9997568726539612
patients O O 0.9999914169311523
. O O 0.9999735355377197

Severe O O 0.999769389629364
nephrotoxicity O O 0.9996939897537231
was O O 0.9999251365661621
observed O O 0.9999550580978394
in O O 0.9998828172683716
2 O O 0.9995978474617004
patients O O 0.9999856948852539
but O O 0.9998282194137573
was O O 0.9998364448547363
reversible O O 0.9998199343681335
. O O 0.9999698400497437

There O O 0.9999494552612305
were O O 0.9999885559082031
no O O 0.9999817609786987
drug O O 0.9814172387123108
- O O 0.9999198913574219
related O O 0.9999771118164062
deaths O O 0.9999886751174927
. O O 0.99996018409729

Nontraumatic O O 0.9945387244224548
dissecting O O 0.9998584985733032
aneurysm O O 0.9998916387557983
of O O 0.9999139308929443
the O O 0.9999467134475708
basilar O O 0.9984205961227417
artery O O 0.9999388456344604
. O O 0.9998668432235718

A O O 0.9999723434448242
case O O 0.9999887943267822
of O O 0.9999778270721436
nontraumatic O O 0.9890674948692322
dissecting O O 0.9999382495880127
aneurysm O O 0.9999755620956421
of O O 0.9998853206634521
the O O 0.9999585151672363
basilar O O 0.999016523361206
artery O O 0.9999464750289917
in O O 0.9999408721923828
association O O 0.9999550580978394
with O O 0.9997957348823547
hypertension O O 0.9523212909698486
, O O 0.9961845278739929
smoke O B 0.9269272089004517
, O O 0.6836372017860413
and O O 0.9723798036575317
oral B B 0.6654697060585022
contraceptives I I 0.9903332591056824
is O O 0.9991652965545654
reported O O 0.9999953508377075
in O O 0.9999749660491943
a O O 0.9999864101409912
young O O 0.9999977350234985
female O O 0.9999963045120239
patient O O 0.9999880790710449
with O O 0.9999637603759766
a O O 0.9999717473983765
locked O O 0.9832348823547363
- O O 0.9999473094940186
in O O 0.9994723200798035
syndrome O O 0.9999666213989258
. O O 0.9999730587005615

A O O 0.9999631643295288
method O O 0.999996542930603
for O O 0.9999936819076538
the O O 0.9999942779541016
measurement O O 0.9999947547912598
of O O 0.9999624490737915
tremor O O 0.9999099969863892
, O O 0.9999589920043945
and O O 0.9999884366989136
a O O 0.9999943971633911
comparison O O 0.9999816417694092
of O O 0.9999439716339111
the O O 0.9999274015426636
effects O O 0.999948263168335
of O O 0.9998512268066406
tocolytic O O 0.6296713352203369
beta O O 0.5924693942070007
- O O 0.8782536387443542
mimetics O O 0.5700391530990601
. O O 0.9999309778213501

A O O 0.9999638795852661
method O O 0.9999901056289673
permitting O O 0.9999462366104126
measurement O O 0.9999845027923584
of O O 0.9999462366104126
finger O O 0.9999467134475708
tremor O O 0.999893307685852
as O O 0.999947190284729
a O O 0.9999725818634033
displacement O O 0.9995361566543579
- O O 0.9999493360519409
time O O 0.9999905824661255
curve O O 0.9999810457229614
is O O 0.9999840259552002
described O O 0.9999922513961792
, O O 0.9999946355819702
using O O 0.99997878074646
a O O 0.9999865293502808
test O O 0.9999750852584839
system O O 0.9999953508377075
with O O 0.9999885559082031
simple O O 0.999906063079834
amplitude O O 0.9998441934585571
calibration O O 0.9999673366546631
. O O 0.9999696016311646

The O O 0.9999877214431763
coordinates O O 0.9999958276748657
of O O 0.999985933303833
the O O 0.9999784231185913
inversion O O 0.9999526739120483
points O O 0.9999945163726807
of O O 0.9999768733978271
the O O 0.999971866607666
displacement O O 0.99886155128479
- O O 0.9999420642852783
time O O 0.9999159574508667
curves O O 0.9999345541000366
were O O 0.9999839067459106
transferred O O 0.9999971389770508
through O O 0.9999934434890747
graphical O O 0.9998964071273804
input O O 0.9999895095825195
equipment O O 0.9999964237213135
to O O 0.9999585151672363
punched O O 0.8724930286407471
tape O O 0.9999805688858032
. O O 0.9999446868896484

By O O 0.9999802112579346
means O O 0.9999864101409912
of O O 0.9999873638153076
a O O 0.9999762773513794
computer O O 0.9999581575393677
program O O 0.9999855756759644
, O O 0.9999561309814453
periods O O 0.9999648332595825
and O O 0.9999409914016724
amplitudes O O 0.9999167919158936
of O O 0.9999353885650635
tremor O O 0.9991361498832703
oscillations O O 0.9998904466629028
were O O 0.999976634979248
calculated O O 0.9999842643737793
and O O 0.9999884366989136
classified O O 0.9999120235443115
. O O 0.9999821186065674

The O O 0.999976634979248
event O O 0.9999779462814331
frequency O O 0.9999922513961792
for O O 0.9998618364334106
each O O 0.9998103976249695
class O O 0.9999254941940308
of O O 0.9999408721923828
periods O O 0.9999551773071289
and O O 0.9998874664306641
amplitudes O O 0.9997013211250305
was O O 0.9999747276306152
determined O O 0.9999864101409912
. O O 0.9999781847000122

The O O 0.9999761581420898
actions O O 0.9997064471244812
of O O 0.9997135996818542
fenoterol B B 0.9987040758132935
- I O 0.5047021508216858
hydrobromide I B 0.5057849884033203
, O O 0.9557603001594543
ritodrin B B 0.9648718237876892
- I I 0.6480543613433838
HCl I I 0.8958244919776917
and O O 0.9833868145942688
placebo O O 0.852815568447113
given O O 0.9999293088912964
to O O 0.9999525547027588
10 O O 0.9999276399612427
healthy O O 0.9999920129776001
subjects O O 0.9999983310699463
by O O 0.9999586343765259
intravenous O O 0.9999822378158569
infusion O O 0.9999788999557495
in O O 0.999984860420227
a O O 0.9999866485595703
double O O 0.9999587535858154
- O O 0.9999767541885376
blind O O 0.999993085861206
crossover O O 0.9999933242797852
study O O 0.999982476234436
were O O 0.999984622001648
tested O O 0.9999833106994629
by O O 0.9999916553497314
this O O 0.9999892711639404
method O O 0.999996542930603
. O O 0.9999790191650391

At O O 0.9998823404312134
therapeutic O O 0.9999607801437378
doses O O 0.9999547004699707
both O O 0.9975347518920898
substances O O 0.9859372973442078
raised O O 0.9999004602432251
the O O 0.9999809265136719
mean O O 0.9999613761901855
tremor O O 0.9999371767044067
amplitude O O 0.9999814033508301
to O O 0.9999861717224121
about O O 0.999995231628418
three O O 0.9999942779541016
times O O 0.9999892711639404
the O O 0.999980092048645
control O O 0.9999080896377563
level O O 0.9999874830245972
. O O 0.9999731779098511

At O O 0.9999760389328003
the O O 0.9999942779541016
same O O 0.9999887943267822
time O O 0.9999959468841553
, O O 0.9999794960021973
the O O 0.9999865293502808
mean O O 0.9999802112579346
period O O 0.9999881982803345
within O O 0.9998984336853027
each O O 0.9998490810394287
class O O 0.9998760223388672
of O O 0.9998914003372192
amplitudes O O 0.9992662072181702
shortened O O 0.999976396560669
by O O 0.9999948740005493
10 O O 0.9999905824661255
- O O 0.9999223947525024
- O O 0.9998363256454468
20 O O 0.9999933242797852
ms O O 0.9999963045120239
, O O 0.9999516010284424
whereas O O 0.9999817609786987
the O O 0.9999656677246094
mean O O 0.9999208450317383
periods O O 0.9999767541885376
calculated O O 0.9999897480010986
from O O 0.9999333620071411
all O O 0.9987442493438721
oscillations O O 0.9995131492614746
together O O 0.9998098015785217
did O O 0.9999805688858032
not O O 0.999990701675415
change O O 0.9999946355819702
significantly O O 0.9999936819076538
. O O 0.9999734163284302

After O O 0.9999767541885376
the O O 0.9999945163726807
end O O 0.999982476234436
of O O 0.9998530149459839
fenoterol B B 0.9985950589179993
- I I 0.6679688692092896
hydrobromide I I 0.8397387266159058
infusion O O 0.9978737831115723
, O O 0.9999382495880127
tremor O O 0.9996953010559082
amplitudes O O 0.9998502731323242
decreased O O 0.999977707862854
significantly O O 0.9999910593032837
faster O O 0.9999923706054688
than O O 0.999983549118042
those O O 0.9999921321868896
following O O 0.9998723268508911
ritodrin B B 0.9956021308898926
- I I 0.7367817163467407
HCl I I 0.7979162335395813
infusion O O 0.998984158039093
. O O 0.9999790191650391

Propylthiouracil B B 0.9988976716995239
- O O 0.9996628761291504
induced O O 0.9998910427093506
hepatic O O 0.9999470710754395
damage O O 0.9999802112579346
. O O 0.9999262094497681

Two O O 0.9999374151229858
cases O O 0.9999874830245972
of O O 0.9999203681945801
propylthiouracil B B 0.9991245865821838
- O O 0.9995937943458557
induced O O 0.9999181032180786
liver O O 0.9990994930267334
damage O O 0.9999902248382568
have O O 0.9999663829803467
been O O 0.9999842643737793
observed O O 0.9999793767929077
. O O 0.9999717473983765

The O O 0.9999793767929077
first O O 0.9999954700469971
case O O 0.9999948740005493
is O O 0.9999749660491943
of O O 0.999962329864502
an O O 0.9999558925628662
acute O O 0.9999765157699585
type O O 0.999987006187439
of O O 0.9999462366104126
damage O O 0.9999798536300659
, O O 0.9999890327453613
proven O O 0.9999974966049194
by O O 0.999990701675415
rechallenge O O 0.9999822378158569
; O O 0.9999319314956665
the O O 0.9999918937683105
second O O 0.9999953508377075
presents O O 0.9999804496765137
a O O 0.9999681711196899
clinical O O 0.9999914169311523
and O O 0.9999817609786987
histologic O O 0.9999902248382568
picture O O 0.9999959468841553
resembling O O 0.9999889135360718
chronic O O 0.9998902082443237
active O O 0.9997654557228088
hepatitis O O 0.9996252059936523
, O O 0.9999760389328003
with O O 0.9999707937240601
spontaneous O O 0.9999721050262451
remission O O 0.9999905824661255
. O O 0.9999774694442749

Studies O O 0.9997578263282776
on O O 0.9994727969169617
the O O 0.9999619722366333
bradycardia O O 0.9999300241470337
induced O O 0.9999583959579468
by O O 0.9994124174118042
bepridil B B 0.9987456798553467
. O O 0.9998737573623657

Bepridil B B 0.9970802664756775
, O O 0.9998689889907837
a O O 0.999832272529602
novel O O 0.9997456669807434
active O O 0.9902346134185791
compound O O 0.988736093044281
for O O 0.9995494484901428
prophylactic O O 0.9997151494026184
treatment O O 0.999937891960144
of O O 0.9999359846115112
anginal O O 0.9999604225158691
attacks O O 0.9999969005584717
, O O 0.9999569654464722
induced O O 0.999936580657959
persistent O O 0.9999804496765137
bradycardia O O 0.9999878406524658
and O O 0.9999462366104126
a O O 0.999954342842102
non O O 0.9992091059684753
- O O 0.9999611377716064
specific O O 0.9999793767929077
anti O O 0.9715636968612671
- O O 0.9995003938674927
tachycardial O O 0.9999421834945679
effect O O 0.9999440908432007
, O O 0.99997878074646
the O O 0.99998939037323
mechanisms O O 0.9999834299087524
of O O 0.9999650716781616
which O O 0.9999463558197021
were O O 0.999985933303833
investigated O O 0.9999899864196777
in O O 0.9999659061431885
vitro O O 0.9999868869781494
and O O 0.9999616146087646
in O O 0.9999462366104126
vivo O O 0.9999902248382568
. O O 0.9999665021896362

In O O 0.9997438788414001
vitro O O 0.999990701675415
perfusion O O 0.998946487903595
of O O 0.9931161999702454
bepridil B B 0.9992091059684753
in O O 0.9997867941856384
the O O 0.9998661279678345
life O O 0.998506486415863
- O O 0.9998433589935303
support O O 0.9992165565490723
medium O O 0.9998636245727539
for O O 0.9997692704200745
isolated O O 0.999901294708252
sino O O 0.9995892643928528
- O O 0.9995008707046509
atrial O O 0.9995749592781067
tissue O O 0.999993085861206
from O O 0.9999439716339111
rabbit O O 0.9896687865257263
heart O O 0.9999814033508301
, O O 0.9998548030853271
caused O O 0.9999351501464844
a O O 0.9999815225601196
reduction O O 0.9999924898147583
in O O 0.9999785423278809
action O O 0.9993784427642822
potential O O 0.9999903440475464
( O O 0.9997990727424622
AP O O 0.7323424816131592
) O O 0.9980146884918213
spike O O 0.9999814033508301
frequency O O 0.9999966621398926
( O O 0.9999675750732422
recorded O O 0.9999943971633911
by O O 0.9999440908432007
KCl B O 0.7783844470977783
microelectrodes O O 0.9648791551589966
) O O 0.9999724626541138
starting O O 0.9999457597732544
at O O 0.9999524354934692
doses O O 0.9999582767486572
of O O 0.999940037727356
5 O O 0.9997562766075134
X O O 0.999845027923584
10 O O 0.9999879598617554
( O O 0.9988767504692078
- O O 0.9986359477043152
6 O O 0.999964714050293
) O O 0.9999210834503174
M O O 0.9999524354934692
. O O 0.9998351335525513

This O O 0.9999312162399292
effect O O 0.9999549388885498
was O O 0.999942421913147
dose O O 0.9998517036437988
- O O 0.9999516010284424
dependent O O 0.9999805688858032
up O O 0.9999884366989136
to O O 0.9999814033508301
concentrations O O 0.9998748302459717
of O O 0.9999579191207886
5 O O 0.9998764991760254
X O O 0.9999712705612183
10 O O 0.9999903440475464
( O O 0.9996907711029053
- O O 0.9997755885124207
5 O O 0.9999867677688599
) O O 0.99993896484375
M O O 0.999984860420227
, O O 0.9999796152114868
whereupon O O 0.9997417330741882
blockade O O 0.9998550415039062
of O O 0.9998800754547119
sinus O O 0.9999535083770752
activity O O 0.999984622001648
set O O 0.9999427795410156
in O O 0.9999830722808838
. O O 0.999964714050293

Bepridil B B 0.9966386556625366
at O O 0.9999045133590698
a O O 0.9999865293502808
dose O O 0.9999643564224243
of O O 0.9999165534973145
5 O O 0.9993190765380859
X O O 0.9989228844642639
10 O O 0.9999047517776489
( O O 0.998488187789917
- O O 0.9957838654518127
6 O O 0.9996128678321838
) O O 0.9997203946113586
M O O 0.9999444484710693
, O O 0.9997915625572205
induced O O 0.9998539686203003
a O O 0.9999805688858032
concomitant O O 0.9999650716781616
reduction O O 0.9999904632568359
in O O 0.9999130964279175
AP O O 0.6416844725608826
amplitude O O 0.9980400204658508
( O O 0.9999486207962036
falling O O 0.9999948740005493
from O O 0.9999773502349854
71 O O 0.9999957084655762
+ O O 0.9999884366989136
/ O O 0.999981164932251
- O O 0.9998711347579956
8 O O 0.9995269775390625
mV O O 0.9998804330825806
to O O 0.9999754428863525
47 O O 0.9999918937683105
+ O O 0.9999872446060181
/ O O 0.9999644756317139
- O O 0.9998262524604797
6 O O 0.9998968839645386
mV O O 0.9995086193084717
) O O 0.9999526739120483
, O O 0.9999256134033203
maximum O O 0.998889148235321
systolic O O 0.9994151592254639
depolarization O O 0.9998512268066406
velocity O O 0.9999810457229614
( O O 0.9998483657836914
phase O O 0.9999744892120361
0 O O 0.9999716281890869
) O O 0.9999710321426392
which O O 0.9999721050262451
fell O O 0.9999873638153076
from O O 0.9999861717224121
1 O O 0.9999877214431763
. O O 0.9999920129776001
85 O O 0.9999076128005981
+ O O 0.999993085861206
/ O O 0.9999804496765137
- O O 0.9999479055404663
0 O O 0.9999797344207764
. O O 0.9999938011169434
35 O O 0.9999910593032837
V O O 0.9999955892562866
/ O O 0.9999839067459106
s O O 0.9999822378158569
to O O 0.9999760389328003
0 O O 0.9999822378158569
. O O 0.9999933242797852
84 O O 0.9999322891235352
+ O O 0.999995231628418
/ O O 0.9998633861541748
- O O 0.999900221824646
0 O O 0.9999786615371704
. O O 0.9999966621398926
28 O O 0.9999967813491821
V O O 0.9999915361404419
/ O O 0.9999531507492065
s O O 0.9999912977218628
, O O 0.9999810457229614
together O O 0.9999748468399048
with O O 0.99996018409729
maximum O O 0.9972960352897644
diastolic O O 0.9999475479125977
depolarization O O 0.9996084570884705
velocity O O 0.9999555349349976
( O O 0.9999294281005859
phase O O 0.9999600648880005
4 O O 0.9999769926071167
) O O 0.9999744892120361
which O O 0.999968409538269
fell O O 0.9999909400939941
from O O 0.9999872446060181
38 O O 0.999990701675415
+ O O 0.999988317489624
/ O O 0.9999829530715942
- O O 0.999962329864502
3 O O 0.9999359846115112
mV O O 0.9999738931655884
/ O O 0.9999579191207886
s O O 0.9999605417251587
to O O 0.9999829530715942
24 O O 0.9999809265136719
+ O O 0.9999895095825195
/ O O 0.999972939491272
- O O 0.999934196472168
5 O O 0.9999659061431885
mV O O 0.999988317489624
/ O O 0.9999649524688721
s O O 0.9999790191650391
. O O 0.999976396560669

In O O 0.99994957447052
vivo O O 0.999995231628418
injection O O 0.9999767541885376
of O O 0.9988553524017334
bepridil B B 0.9989199638366699
at O O 0.9998476505279541
a O O 0.9999935626983643
dose O O 0.999982476234436
of O O 0.999972939491272
5 O O 0.9999663829803467
mg O O 0.9999887943267822
/ O O 0.9999920129776001
kg O O 0.9999972581863403
( O O 0.9999452829360962
i O O 0.9999580383300781
. O O 0.999997615814209
v O O 0.9999992847442627
. O O 0.9999969005584717
) O O 0.9999765157699585
into O O 0.9999433755874634
6 O O 0.9997135996818542
anaesthetized O O 0.9999784231185913
dogs O O 0.9999324083328247
which O O 0.9999616146087646
had O O 0.9999902248382568
undergone O O 0.9999785423278809
ablation O O 0.9999583959579468
of O O 0.9997056126594543
all O O 0.9987505674362183
the O O 0.9999210834503174
extrinsic O O 0.9995922446250916
cardiac O O 0.9795834422111511
afferent O O 0.9903760552406311
nerve O O 0.9973537921905518
supply O O 0.9993894100189209
, O O 0.9999749660491943
together O O 0.9999816417694092
with O O 0.9999771118164062
a O O 0.9999799728393555
bilateral O O 0.9997805953025818
medullo O O 0.9987558126449585
- O O 0.9985260367393494
adrenalectomy O O 0.9910338521003723
, O O 0.9999736547470093
caused O O 0.9999706745147705
a O O 0.9999929666519165
marked O O 0.999991774559021
reduction O O 0.9999984502792358
in O O 0.9999897480010986
heart O O 0.9999946355819702
rate O O 0.9999970197677612
which O O 0.9999781847000122
fell O O 0.9999980926513672
from O O 0.9999912977218628
98 O O 0.9997175335884094
. O O 0.9999961853027344
7 O O 0.9999885559082031
+ O O 0.9999920129776001
/ O O 0.9999881982803345
- O O 0.999954104423523
4 O O 0.9999843835830688
. O O 0.9999970197677612
2 O O 0.9999880790710449
beats O O 0.9999972581863403
/ O O 0.9999897480010986
min O O 0.9999935626983643
to O O 0.999976634979248
76 O O 0.9999915361404419
+ O O 0.999992847442627
/ O O 0.9999850988388062
- O O 0.9999170303344727
5 O O 0.9999892711639404
. O O 0.999996542930603
3 O O 0.9999891519546509
beats O O 0.9999977350234985
/ O O 0.9999879598617554
min O O 0.9999769926071167
sustained O O 0.9999630451202393
for O O 0.9999384880065918
more O O 0.9999924898147583
than O O 0.9999963045120239
45 O O 0.9999936819076538
min O O 0.9999942779541016
. O O 0.999976634979248

It O O 0.9999849796295166
is O O 0.9999264478683472
concluded O O 0.9998260140419006
that O O 0.9982966780662537
bepridil B B 0.9995155334472656
reduces O O 0.9996707439422607
heart O O 0.9997966885566711
rate O O 0.9999022483825684
by O O 0.9998565912246704
acting O O 0.9997901320457458
directly O O 0.9999362230300903
on O O 0.9997585415840149
the O O 0.9999314546585083
sinus O O 0.9998873472213745
node O O 0.9997640252113342
. O O 0.9999052286148071

This O O 0.999883770942688
effect O O 0.9999659061431885
, O O 0.9999759197235107
which O O 0.9999566078186035
results O O 0.9999682903289795
in O O 0.9999798536300659
a O O 0.999958872795105
flattening O O 0.9999645948410034
of O O 0.9999372959136963
the O O 0.9998881816864014
phase O O 0.9999134540557861
0 O O 0.9994127750396729
and O O 0.9994207620620728
phase O O 0.9996302127838135
4 O O 0.9993089437484741
slope O O 0.9996927976608276
, O O 0.9999819993972778
together O O 0.9999767541885376
with O O 0.9999759197235107
a O O 0.9999793767929077
longer O O 0.9999427795410156
AP O O 0.6811590790748596
duration O O 0.9999465942382812
, O O 0.9999815225601196
may O O 0.9999129772186279
be O O 0.9999597072601318
due O O 0.9999812841415405
to O O 0.999890923500061
an O O 0.9999692440032959
increase O O 0.9999836683273315
in O O 0.999971866607666
the O O 0.9999512434005737
time O O 0.999911904335022
constants O O 0.9999675750732422
of O O 0.9998704195022583
slow O O 0.99958735704422
inward O O 0.9984514713287354
ionic O O 0.9919304251670837
currents O O 0.9999165534973145
( O O 0.9999631643295288
already O O 0.9999604225158691
demonstrated O O 0.9999916553497314
elsewhere O O 0.9999891519546509
) O O 0.9999698400497437
, O O 0.9999575614929199
but O O 0.9999411106109619
also O O 0.9999563694000244
to O O 0.999946117401123
an O O 0.9999674558639526
increased O O 0.9999476671218872
time O O 0.999901533126831
constant O O 0.9999721050262451
for O O 0.9999082088470459
deactivation O O 0.9998252987861633
of O O 0.9997323155403137
the O O 0.9998980760574341
outward O O 0.9987336993217468
potassium B B 0.8765268921852112
current O O 0.9996585845947266
( O O 0.9997792840003967
Ip O O 0.9762202501296997
) O O 0.9999557733535767
. O O 0.9999524354934692

Hepatitis O O 0.9995957016944885
and O O 0.9998794794082642
renal O O 0.9999206066131592
tubular O O 0.9999767541885376
acidosis O O 0.45888128876686096
after O O 0.9996209144592285
anesthesia O O 0.9999322891235352
with O O 0.9994981288909912
methoxyflurane B B 0.9990383386611938
. O O 0.9999115467071533

A O O 0.999985933303833
69 O O 0.9999954700469971
- O O 0.9999879598617554
year O O 0.9999970197677612
- O O 0.9999939203262329
old O O 0.9999939203262329
man O O 0.9999958276748657
operated O O 0.9999710321426392
for O O 0.9999655485153198
acute O O 0.9999442100524902
cholecystitis O O 0.9975861310958862
under O O 0.9996379613876343
methoxyflurane B B 0.9995877146720886
anesthesia O O 0.9996570348739624
developed O O 0.999981164932251
postoperatively O O 0.999984622001648
a O O 0.9999693632125854
hepatic O O 0.9995231628417969
insufficiency O O 0.999942421913147
syndrome O O 0.999972939491272
and O O 0.9999414682388306
renal O O 0.9998962879180908
tubular O O 0.9999898672103882
acidosis O O 0.8012990951538086
. O O 0.9999710321426392

Massive O O 0.9999507665634155
bleeding O O 0.9993639588356018
appeared O O 0.9999827146530151
during O O 0.9999047517776489
surgery O O 0.9999969005584717
which O O 0.999932050704956
lasted O O 0.9999852180480957
for O O 0.9999924898147583
six O O 0.9999908208847046
hours O O 0.9999896287918091
. O O 0.999963641166687

Postoperative O O 0.9997439980506897
evolution O O 0.999988317489624
under O O 0.999715268611908
supportive O O 0.9978092312812805
therapy O O 0.9999794960021973
was O O 0.9999470710754395
favourable O O 0.9991602897644043
. O O 0.9999701976776123

Complete O O 0.9997641444206238
recovery O O 0.9999874830245972
was O O 0.9999886751174927
confirmed O O 0.9999879598617554
by O O 0.9999945163726807
repeated O O 0.9999693632125854
controls O O 0.9999309778213501
performed O O 0.9999847412109375
over O O 0.999984622001648
a O O 0.9999904632568359
period O O 0.999994158744812
of O O 0.9999825954437256
one O O 0.9999948740005493
year O O 0.9999972581863403
after O O 0.9999932050704956
surgery O O 0.9999955892562866
. O O 0.9999812841415405

Pituitary O O 0.9934908747673035
response O O 0.9998630285263062
to O O 0.9991598129272461
luteinizing O O 0.4807782769203186
hormone O O 0.645634114742279
- O O 0.8790428042411804
releasing O O 0.8169761896133423
hormone O O 0.5191657543182373
during O O 0.9992775321006775
haloperidol B B 0.9997264742851257
- O O 0.9996929168701172
induced O O 0.9999432563781738
hyperprolactinemia O O 0.9998570680618286
. O O 0.9999480247497559

The O O 0.999981164932251
effects O O 0.9999760389328003
of O O 0.9999381303787231
a O O 0.9999505281448364
6 O O 0.9997263550758362
- O O 0.9999772310256958
hour O O 0.9999338388442993
infusion O O 0.999885082244873
with O O 0.9995779395103455
haloperidol B B 0.999722421169281
on O O 0.9997543692588806
serum O O 0.9995185136795044
prolactin O O 0.8715411424636841
and O O 0.9986479878425598
luteinizing O O 0.7976359724998474
hormone O O 0.8438506722450256
( O O 0.9973553419113159
LH O O 0.7885127067565918
) O O 0.9998916387557983
levels O O 0.9998947381973267
was O O 0.999980092048645
studied O O 0.9999741315841675
in O O 0.9999829530715942
a O O 0.9999796152114868
group O O 0.9999929666519165
of O O 0.9999881982803345
male O O 0.9999604225158691
subjects O O 0.9999967813491821
. O O 0.9999771118164062

Five O O 0.9999762773513794
hours O O 0.9999923706054688
after O O 0.9999933242797852
starting O O 0.99996018409729
the O O 0.999954104423523
infusions O O 0.9998063445091248
, O O 0.9999744892120361
a O O 0.9999878406524658
study O O 0.9999890327453613
of O O 0.9999676942825317
the O O 0.9999393224716187
pituitary O O 0.9997194409370422
responses O O 0.9999363422393799
to O O 0.9990901947021484
LH O O 0.4753304421901703
- O O 0.7927942276000977
releasing O O 0.6961320042610168
hormone O O 0.5583271384239197
( O O 0.999107301235199
LH O O 0.8033258318901062
- O O 0.9543002843856812
RH O O 0.7595070600509644
) O O 0.9999475479125977
was O O 0.9999791383743286
carried O O 0.9999953508377075
out O O 0.9999899864196777
. O O 0.9999691247940063

Control O O 0.9998898506164551
patients O O 0.9999923706054688
received O O 0.9998925924301147
infusions O O 0.9999052286148071
of O O 0.9998354911804199
0 O O 0.9973143935203552
. O O 0.999957799911499
9 O O 0.9993281364440918
% O O 0.9990513920783997
NaCl B B 0.9978036284446716
solution O O 0.9930945634841919
. O O 0.9999374151229858

During O O 0.9999508857727051
the O O 0.999985933303833
course O O 0.9999715089797974
of O O 0.9998288154602051
haloperidol B B 0.9998039603233337
infusions O O 0.9997535347938538
, O O 0.999932050704956
significant O O 0.999920129776001
hyperprolactinemia O O 0.9992652535438538
was O O 0.9999539852142334
found O O 0.9999830722808838
, O O 0.9999740123748779
together O O 0.9999747276306152
with O O 0.9999527931213379
an O O 0.999941349029541
abolished O O 0.9747540950775146
pituitary O O 0.9978491067886353
response O O 0.9998980760574341
to O O 0.9995189905166626
LH O O 0.6935023069381714
- O O 0.8760335445404053
RH O O 0.857090413570404
, O O 0.9995508790016174
as O O 0.9999690055847168
compared O O 0.9999785423278809
with O O 0.9999643564224243
responses O O 0.9998770952224731
of O O 0.9999040365219116
control O O 0.9996185302734375
subjects O O 0.9998993873596191
. O O 0.9999653100967407

Antirifampicin O O 0.6469731330871582
antibodies O O 0.99160236120224
in O O 0.9999090433120728
acute O O 0.99989914894104
rifampicin B B 0.9922311902046204
- O O 0.9993821382522583
associated O O 0.9999473094940186
renal O O 0.9999845027923584
failure O O 0.9999899864196777
. O O 0.999951958656311

5 O O 0.999823272228241
patients O O 0.9999927282333374
with O O 0.999969482421875
acute O O 0.9999523162841797
renal O O 0.9999901056289673
failure O O 0.9999924898147583
( O O 0.9999663829803467
3 O O 0.9981568455696106
with O O 0.9999760389328003
thrombopenia O O 0.9981346130371094
and O O 0.9999039173126221
hemolysis O O 0.9998364448547363
) O O 0.9999756813049316
induced O O 0.9999793767929077
by O O 0.9999399185180664
the O O 0.9999758005142212
reintroduction O O 0.9999313354492188
of O O 0.9967997074127197
rifampicin B B 0.9692766666412354
are O O 0.9996811151504517
described O O 0.9999855756759644
. O O 0.999976634979248

No O O 0.9999620914459229
correlation O O 0.9999953508377075
was O O 0.9999829530715942
found O O 0.999997615814209
between O O 0.9998537302017212
the O O 0.9999892711639404
severity O O 0.9999960660934448
of O O 0.9999853372573853
clinical O O 0.9999933242797852
manifestations O O 0.9999974966049194
and O O 0.9999884366989136
the O O 0.9999816417694092
total O O 0.9996205568313599
dose O O 0.9988889098167419
taken O O 0.9999595880508423
by O O 0.999976396560669
the O O 0.999984860420227
patients O O 0.9999799728393555
. O O 0.9999514818191528

In O O 0.9998496770858765
all O O 0.9999749660491943
but O O 0.9999812841415405
1 O O 0.9998444318771362
patient O O 0.9999898672103882
, O O 0.9996936321258545
antirifampicin O O 0.6876707673072815
antibodies O O 0.9997591376304626
were O O 0.9998811483383179
detected O O 0.9998801946640015
. O O 0.9999606609344482

Antibodies O O 0.9999276399612427
suggested O O 0.9999675750732422
to O O 0.999909520149231
be O O 0.9999139308929443
of O O 0.9998772144317627
the O O 0.9997079968452454
IgM O O 0.982973575592041
class O O 0.999169111251831
were O O 0.9999308586120605
detected O O 0.9999346733093262
in O O 0.9998924732208252
all O O 0.9999420642852783
3 O O 0.9998983144760132
patients O O 0.9999914169311523
with O O 0.9999830722808838
hematological O O 0.9998602867126465
disorders O O 0.9999963045120239
. O O 0.9999643564224243

The O O 0.999984860420227
pattern O O 0.999977707862854
of O O 0.9999409914016724
non O O 0.9996731281280518
- O O 0.9999414682388306
specific O O 0.9999710321426392
acute O O 0.9984482526779175
tubular O O 0.9999890327453613
necrosis O O 0.9999858140945435
found O O 0.9999821186065674
in O O 0.9999088048934937
the O O 0.999984860420227
2 O O 0.9998549222946167
biopsied O O 0.9999771118164062
patients O O 0.9999785423278809
, O O 0.9999759197235107
indistinguishable O O 0.99998939037323
from O O 0.9999746084213257
that O O 0.9999762773513794
of O O 0.9999697208404541
ischemic O O 0.9999860525131226
origin O O 0.9999892711639404
, O O 0.9999804496765137
raised O O 0.9999552965164185
the O O 0.9999904632568359
possibility O O 0.999980092048645
of O O 0.9999529123306274
a O O 0.9998207688331604
vascular O O 0.9850505590438843
- O O 0.9998811483383179
mediated O O 0.9999505281448364
damage O O 0.9999899864196777
. O O 0.9999419450759888

In O O 0.9999593496322632
3 O O 0.9981352090835571
patients O O 0.9999839067459106
, O O 0.9999744892120361
the O O 0.9999940395355225
possibility O O 0.9999748468399048
of O O 0.9999332427978516
a O O 0.9998666048049927
triggering O O 0.9999548196792603
immunoallergic O O 0.9994292855262756
mechanism O O 0.9999639987945557
is O O 0.9999651908874512
discussed O O 0.9999880790710449
. O O 0.9999769926071167

Cardiovascular O O 0.9997300505638123
effects O O 0.9999783039093018
of O O 0.9998984336853027
hypotension O O 0.999744713306427
induced O O 0.999940037727356
by O O 0.9998107552528381
adenosine B B 0.9993174076080322
triphosphate I I 0.9942155480384827
and O O 0.9606046676635742
sodium B B 0.9921360015869141
nitroprusside I I 0.995970606803894
on O O 0.9996435642242432
dogs O O 0.9999804496765137
with O O 0.9999873638153076
denervated O O 0.9995707869529724
hearts O O 0.9999663829803467
. O O 0.999955415725708

Adenosine B B 0.9985705614089966
triphosphate I I 0.9930891394615173
( O O 0.9821560978889465
ATP B B 0.9956100583076477
) O O 0.9877868294715881
and O O 0.9988898634910583
sodium B B 0.987788736820221
nitroprusside I I 0.9962731599807739
( O O 0.9929295182228088
SNP B B 0.9957774877548218
) O O 0.997124969959259
are O O 0.999897837638855
administered O O 0.9999128580093384
to O O 0.9998558759689331
patients O O 0.999303936958313
to O O 0.9999395608901978
induce O O 0.999977707862854
and O O 0.9999209642410278
control O O 0.9999284744262695
hypotension O O 0.9999620914459229
during O O 0.9999667406082153
anesthesia O O 0.999994158744812
. O O 0.9999403953552246

SNP B B 0.9883232712745667
is O O 0.999470055103302
authorized O O 0.9991884827613831
for O O 0.9999434947967529
clinical O O 0.9999725818634033
use O O 0.9999785423278809
in O O 0.9998422861099243
USA O O 0.9960834980010986
and O O 0.9998258948326111
UK O O 0.8768616914749146
, O O 0.999933123588562
and O O 0.9997016787528992
ATP B B 0.994556188583374
is O O 0.9999091625213623
clinically O O 0.999953031539917
used O O 0.9999611377716064
in O O 0.9999194145202637
other O O 0.9999616146087646
countries O O 0.999969482421875
such O O 0.9999854564666748
as O O 0.9999816417694092
Japan O O 0.9333499670028687
. O O 0.9999343156814575

We O O 0.9999619722366333
investigated O O 0.9999895095825195
how O O 0.9999821186065674
these O O 0.996290922164917
two O O 0.9918431639671326
drugs O O 0.975009024143219
act O O 0.9997714161872864
on O O 0.9997832179069519
the O O 0.9999785423278809
cardiovascular O O 0.9999741315841675
systems O O 0.9999961853027344
of O O 0.9999891519546509
20 O O 0.9998288154602051
dogs O O 0.9999973773956299
whose O O 0.9999909400939941
hearts O O 0.9999234676361084
had O O 0.9999814033508301
been O O 0.9999768733978271
denervated O O 0.9998248219490051
by O O 0.9999371767044067
a O O 0.9999710321426392
procedure O O 0.9999855756759644
we O O 0.9999872446060181
had O O 0.9999957084655762
devised O O 0.9999902248382568
. O O 0.9999725818634033

ATP B B 0.9942129254341125
( O O 0.9991689920425415
10 O O 0.9998661279678345
dogs O O 0.9999754428863525
) O O 0.999859094619751
or O O 0.9909155964851379
SNP B B 0.9773339629173279
( O O 0.9984440207481384
10 O O 0.9996868371963501
dogs O O 0.9999513626098633
) O O 0.9999245405197144
was O O 0.9999345541000366
administered O O 0.9999231100082397
to O O 0.9999258518218994
reduce O O 0.9999865293502808
mean O O 0.9999909400939941
arterial O O 0.9999580383300781
pressure O O 0.9999598264694214
by O O 0.9999866485595703
30 O O 0.9999905824661255
% O O 0.9999958276748657
to O O 0.9999902248382568
70 O O 0.999996542930603
% O O 0.9999977350234985
of O O 0.9999274015426636
control O O 0.9999840259552002
. O O 0.9999711513519287

Before O O 0.9999163150787354
, O O 0.9999366998672485
during O O 0.999909520149231
and O O 0.9999412298202515
after O O 0.9998440742492676
induced O O 0.9999557733535767
hypotension O O 0.9999583959579468
, O O 0.9999746084213257
we O O 0.9999232292175293
measured O O 0.9999709129333496
major O O 0.9998142123222351
cardiovascular O O 0.9999796152114868
parameters O O 0.9999920129776001
. O O 0.9999735355377197

Hypotension O O 0.9998648166656494
induced O O 0.9999493360519409
by O O 0.9998723268508911
ATP B B 0.9949930310249329
was O O 0.9999067783355713
accompanied O O 0.9999868869781494
by O O 0.9999783039093018
significant O O 0.9999886751174927
decreases O O 0.9999980926513672
in O O 0.9999817609786987
mean O O 0.9999942779541016
pulmonary O O 0.999987006187439
arterial O O 0.9999699592590332
pressure O O 0.9999562501907349
( O O 0.9999716281890869
p O O 0.9973426461219788
less O O 0.999961256980896
than O O 0.9999966621398926
0 O O 0.9999929666519165
. O O 0.9999970197677612
001 O O 0.9999854564666748
) O O 0.9999725818634033
, O O 0.9999566078186035
central O O 0.9999884366989136
venous O O 0.9999969005584717
pressure O O 0.9999127388000488
( O O 0.9999572038650513
p O O 0.9983333945274353
less O O 0.9999716281890869
than O O 0.9999970197677612
0 O O 0.9999927282333374
. O O 0.9999979734420776
001 O O 0.9999772310256958
) O O 0.9999697208404541
, O O 0.9999312162399292
left O O 0.9999258518218994
ventricular O O 0.9999885559082031
end O O 0.9989351630210876
- O O 0.9992371797561646
diastolic O O 0.9999363422393799
pressure O O 0.999901294708252
( O O 0.9999504089355469
p O O 0.9979166388511658
less O O 0.9999805688858032
than O O 0.9999963045120239
0 O O 0.9999957084655762
. O O 0.9999977350234985
001 O O 0.9999809265136719
) O O 0.9999662637710571
, O O 0.9999403953552246
total O O 0.9978834986686707
peripheral O O 0.99689781665802
resistance O O 0.999990701675415
( O O 0.9999549388885498
p O O 0.9983069896697998
less O O 0.9999877214431763
than O O 0.9999979734420776
0 O O 0.999996542930603
. O O 0.9999982118606567
001 O O 0.999976634979248
) O O 0.9999550580978394
, O O 0.9996722936630249
rate O O 0.9808045029640198
pressure O O 0.9889113903045654
product O O 0.9992498755455017
( O O 0.9999098777770996
p O O 0.9989895224571228
less O O 0.9999877214431763
than O O 0.9999973773956299
0 O O 0.9999945163726807
. O O 0.9999974966049194
001 O O 0.9999808073043823
) O O 0.9999690055847168
, O O 0.9999479055404663
total O O 0.9862275719642639
body O O 0.9998511075973511
oxygen B B 0.95393967628479
consumption O O 0.9998053908348083
( O O 0.9999500513076782
p O O 0.9957823753356934
less O O 0.9999881982803345
than O O 0.9999966621398926
0 O O 0.9999938011169434
. O O 0.999996542930603
05 O O 0.9999959468841553
) O O 0.9999748468399048
, O O 0.9998464584350586
and O O 0.9998195767402649
heart O O 0.9999077320098877
rate O O 0.9999690055847168
( O O 0.9999622106552124
p O O 0.9962764382362366
less O O 0.9999877214431763
than O O 0.9999973773956299
0 O O 0.9999915361404419
. O O 0.9999979734420776
001 O O 0.9999310970306396
) O O 0.9999700784683228
; O O 0.9999731779098511
all O O 0.9999885559082031
these O O 0.9998844861984253
variables O O 0.9997761845588684
returned O O 0.999983549118042
normal O O 0.999991774559021
within O O 0.9999934434890747
30 O O 0.9999918937683105
min O O 0.9999957084655762
after O O 0.9999589920043945
ATP B B 0.9973022937774658
was O O 0.9999128580093384
stopped O O 0.9998001456260681
. O O 0.9999599456787109

Cardiac O O 0.9963099360466003
output O O 0.9999406337738037
did O O 0.9999747276306152
not O O 0.9999868869781494
change O O 0.9999889135360718
. O O 0.9999700784683228

During O O 0.9998979568481445
hypotension O O 0.9999393224716187
produced O O 0.9999476671218872
by O O 0.999625563621521
SNP B O 0.7186728119850159
similar O O 0.9799839854240417
decreases O O 0.9999157190322876
were O O 0.9999731779098511
observed O O 0.9999967813491821
in O O 0.9999706745147705
mean O O 0.9999911785125732
pulmonary O O 0.9999805688858032
arterial O O 0.9999276399612427
pressure O O 0.9998867511749268
( O O 0.9999580383300781
p O O 0.9985606074333191
less O O 0.9999700784683228
than O O 0.999993085861206
0 O O 0.9999855756759644
. O O 0.9999963045120239
01 O O 0.9999922513961792
) O O 0.9999717473983765
, O O 0.9999327659606934
central O O 0.9999806880950928
venous O O 0.9999756813049316
pressure O O 0.9998877048492432
( O O 0.9999456405639648
p O O 0.9993240833282471
less O O 0.9999802112579346
than O O 0.9999960660934448
0 O O 0.9999916553497314
. O O 0.9999974966049194
001 O O 0.999988317489624
) O O 0.9999749660491943
, O O 0.9999213218688965
left O O 0.9999325275421143
ventricular O O 0.9999902248382568
end O O 0.9993298053741455
- O O 0.9994900226593018
diastolic O O 0.9999645948410034
pressure O O 0.9998993873596191
( O O 0.999943733215332
p O O 0.9970652461051941
less O O 0.9999809265136719
than O O 0.9999966621398926
0 O O 0.999995231628418
. O O 0.9999969005584717
01 O O 0.9999967813491821
) O O 0.9999748468399048
, O O 0.999921441078186
total O O 0.9985265731811523
peripheral O O 0.9970045685768127
resistance O O 0.9999914169311523
( O O 0.9999518394470215
p O O 0.9988138675689697
less O O 0.9999841451644897
than O O 0.999997615814209
0 O O 0.9999958276748657
. O O 0.999997615814209
001 O O 0.9999891519546509
) O O 0.9999674558639526
, O O 0.9996730089187622
rate O O 0.9619308114051819
pressure O O 0.9787728786468506
product O O 0.999129593372345
( O O 0.9998677968978882
p O O 0.9967315196990967
less O O 0.9999829530715942
than O O 0.9999969005584717
0 O O 0.9999899864196777
. O O 0.9999970197677612
001 O O 0.9999769926071167
) O O 0.9999701976776123
, O O 0.999893069267273
and O O 0.9995203018188477
oxygen B B 0.9819929599761963
content O O 0.9993533492088318
difference O O 0.9999831914901733
between O O 0.9997126460075378
arterial O O 0.9995168447494507
and O O 0.9998756647109985
mixed O O 0.9965493679046631
venous O O 0.9999792575836182
blood O O 0.9999549388885498
( O O 0.9999501705169678
p O O 0.9949319958686829
less O O 0.9999867677688599
than O O 0.9999961853027344
0 O O 0.9999918937683105
. O O 0.9999971389770508
05 O O 0.9999899864196777
) O O 0.9999747276306152
, O O 0.9999740123748779
while O O 0.9998714923858643
heart O O 0.9999669790267944
rate O O 0.9999454021453857
( O O 0.9999600648880005
p O O 0.9989675283432007
less O O 0.9999828338623047
than O O 0.999996542930603
0 O O 0.9999847412109375
. O O 0.9999978542327881
001 O O 0.9999707937240601
) O O 0.9999727010726929
and O O 0.9999426603317261
cardiac O O 0.9999675750732422
output O O 0.9999933242797852
( O O 0.9999496936798096
p O O 0.9988835453987122
less O O 0.9999922513961792
than O O 0.9999969005584717
0 O O 0.9999902248382568
. O O 0.9999971389770508
05 O O 0.9999874830245972
) O O 0.9999737739562988
were O O 0.999957799911499
increased O O 0.9999570846557617
. O O 0.9999585151672363

Recoveries O O 0.9998772144317627
of O O 0.9999485015869141
heart O O 0.9999618530273438
rate O O 0.9999756813049316
and O O 0.9999287128448486
left O O 0.9999792575836182
ventricular O O 0.9999939203262329
end O O 0.9990472197532654
- O O 0.9970447421073914
diastolic O O 0.9999767541885376
pressure O O 0.9999361038208008
were O O 0.9999648332595825
not O O 0.9999886751174927
shown O O 0.9999897480010986
within O O 0.9999805688858032
60 O O 0.9999955892562866
min O O 0.9999955892562866
after O O 0.9999322891235352
SNP B B 0.9882879853248596
had O O 0.9998395442962646
been O O 0.9999693632125854
stopped O O 0.9979888200759888
. O O 0.9999521970748901

Both O O 0.9861006140708923
ATP B B 0.9677861928939819
and O O 0.9865229725837708
SNP B B 0.9503766894340515
should O O 0.999138593673706
act O O 0.9991450309753418
on O O 0.9994227886199951
the O O 0.9999104738235474
pacemaker O O 0.999330997467041
tissue O O 0.9998831748962402
of O O 0.9999222755432129
the O O 0.999945878982544
heart O O 0.9999754428863525
. O O 0.9999299049377441

Comparative O O 0.9993854761123657
study O O 0.9998471736907959
: O O 0.9952744245529175
Endografine B B 0.999182403087616
( O O 0.9146164655685425
diatrizoate B B 0.9946141839027405
) O O 0.9876776337623596
, O O 0.9957228899002075
Vasurix B B 0.974090039730072
polyvidone I I 0.9558488726615906
( O O 0.9031102061271667
acetrizoate B B 0.8656399846076965
) O O 0.9883472323417664
, O O 0.9967806339263916
Dimer B B 0.5604101419448853
- I I 0.6258017420768738
X I I 0.9965937733650208
( O O 0.8632310032844543
iocarmate B B 0.9896876215934753
) O O 0.9924214482307434
and O O 0.9980202913284302
Hexabrix B B 0.9940760135650635
( O O 0.9924641847610474
ioxaglate B B 0.9971056580543518
) O O 0.9996285438537598
in O O 0.9999581575393677
hysterosalpingography O O 0.9936138987541199
. O O 0.9998762607574463

Side O O 0.9998934268951416
effects O O 0.9999676942825317
of O O 0.9998316764831543
hysterosalpingography O O 0.6097983121871948
with O O 0.9876812696456909
Dimer B B 0.5647781491279602
- I I 0.7255465984344482
X I I 0.9923158884048462
, O O 0.5850998759269714
Hexabrix B B 0.9097387194633484
, O O 0.8968008756637573
Vasurix B B 0.9731491804122925
polyvidone I I 0.9743260145187378
and O O 0.9244937896728516
Endografine B B 0.9939544796943665
in O O 0.9999160766601562
142 O O 0.9999927282333374
consecutive O O 0.9999904632568359
patients O O 0.999996542930603
, O O 0.9999834299087524
receiving O O 0.9998321533203125
one O O 0.9990413784980774
of O O 0.9995649456977844
the O O 0.9998689889907837
four O O 0.9986579418182373
tested O O 0.9993494153022766
media O O 0.9945355653762817
were O O 0.9999874830245972
evaluated O O 0.9999948740005493
from O O 0.9999934434890747
replies O O 0.9999959468841553
to O O 0.9999932050704956
postal O O 0.9998929500579834
questionnaires O O 0.999995231628418
. O O 0.9999749660491943

The O O 0.9995715022087097
Dimer B B 0.48861411213874817
- I I 0.7681945562362671
X I I 0.9658073782920837
group O O 0.9796344637870789
had O O 0.9999803304672241
a O O 0.999988317489624
higher O O 0.9999847412109375
incidence O O 0.9999978542327881
of O O 0.9999858140945435
nausea O O 0.9999486207962036
and O O 0.9999643564224243
dizziness O O 0.9999788999557495
. O O 0.9999579191207886

The O O 0.9998743534088135
Endografine B B 0.999261200428009
group O O 0.9995779395103455
had O O 0.9999780654907227
a O O 0.9999884366989136
higher O O 0.999983549118042
incidence O O 0.9999979734420776
of O O 0.9999924898147583
abdominal O O 0.9999740123748779
pain O O 0.999985933303833
. O O 0.9999661445617676

These O O 0.9999600648880005
differences O O 0.9999927282333374
occur O O 0.9999892711639404
especially O O 0.9999731779098511
in O O 0.9999840259552002
the O O 0.9999923706054688
age O O 0.9999855756759644
groups O O 0.9999967813491821
under O O 0.9999973773956299
30 O O 0.9999912977218628
years O O 0.9999947547912598
. O O 0.9999703168869019

Hexabrix B B 0.9970065951347351
and O O 0.9950790405273438
Vasurix B B 0.9675045609474182
polyvidone I I 0.947472095489502
are O O 0.9994969367980957
considered O O 0.9999481439590454
the O O 0.9999654293060303
best O O 0.9997602105140686
contrast B O 0.9962052702903748
media I O 0.9989261031150818
for O O 0.9998869895935059
hysterosalpingography O O 0.9952443242073059
and O O 0.9999403953552246
perhaps O O 0.9999740123748779
because O O 0.9999899864196777
of O O 0.9999746084213257
its O O 0.99982088804245
low O O 0.9997110962867737
toxicity O O 0.9999116659164429
Hexabrix B B 0.9995369911193848
should O O 0.9996860027313232
be O O 0.99998939037323
preferred O O 0.9999498128890991
. O O 0.9999518394470215

Post O O 0.998833954334259
- O O 0.9951444268226624
suxamethonium B B 0.9907025098800659
pains O O 0.9993176460266113
in O O 0.9999518394470215
Nigerian O O 0.9192845225334167
surgical O O 0.9999592304229736
patients O O 0.9999772310256958
. O O 0.999966025352478

Contrary O O 0.9999761581420898
to O O 0.9999929666519165
an O O 0.9999963045120239
earlier O O 0.9999685287475586
report O O 0.9999970197677612
by O O 0.9999775886535645
Coxon O O 0.9076981544494629
, O O 0.9998917579650879
scoline B O 0.9941707253456116
pain O O 0.999852180480957
occurs O O 0.9999758005142212
in O O 0.9998394250869751
African O O 0.9497228860855103
negroes O O 0.9995891451835632
. O O 0.9999501705169678

Its O O 0.9999678134918213
incidence O O 0.9999864101409912
was O O 0.9999923706054688
determined O O 0.9999935626983643
in O O 0.9999934434890747
a O O 0.9999903440475464
prospective O O 0.9999874830245972
study O O 0.999990701675415
involving O O 0.9999761581420898
a O O 0.9999823570251465
total O O 0.9999840259552002
of O O 0.9999861717224121
100 O O 0.99993896484375
Nigerian O O 0.9807766079902649
patients O O 0.9999743700027466
( O O 0.999951958656311
50 O O 0.9999618530273438
out O O 0.9994204044342041
- O O 0.99989914894104
patients O O 0.9999780654907227
and O O 0.9998990297317505
50 O O 0.9999009370803833
in O O 0.9984739422798157
- O O 0.999881386756897
patients O O 0.9999716281890869
) O O 0.9999570846557617
. O O 0.9999703168869019

About O O 0.999984622001648
62 O O 0.9999971389770508
% O O 0.999997615814209
of O O 0.9999923706054688
the O O 0.9999910593032837
out O O 0.9996460676193237
- O O 0.9999679327011108
patients O O 0.9999854564666748
developed O O 0.9999837875366211
scoline B O 0.9924081563949585
pain O O 0.999910831451416
as O O 0.9999681711196899
compared O O 0.9999822378158569
with O O 0.9999898672103882
about O O 0.9999922513961792
26 O O 0.9999873638153076
% O O 0.9999974966049194
among O O 0.9999825954437256
the O O 0.9999880790710449
in O O 0.9994578957557678
- O O 0.9999547004699707
patients O O 0.9999862909317017
. O O 0.9999785423278809

The O O 0.9999662637710571
abolition O O 0.9997772574424744
of O O 0.9997864365577698
muscle O O 0.9996935129165649
fasciculations O O 0.9997528195381165
( O O 0.999879002571106
by O O 0.9999076128005981
0 O O 0.9999117851257324
. O O 0.9999905824661255
075mg O O 0.9999759197235107
/ O O 0.9999357461929321
kg O O 0.9999748468399048
dose O O 0.9996718168258667
of O O 0.9979612827301025
Fazadinium B B 0.9992129802703857
) O O 0.9997220635414124
did O O 0.9999696016311646
not O O 0.9999548196792603
influence O O 0.9999897480010986
the O O 0.9999960660934448
occurrence O O 0.9999979734420776
of O O 0.9999927282333374
scoline B O 0.9252373576164246
pain O O 0.9999681711196899
. O O 0.9999591112136841

Neither O O 0.9999490976333618
the O O 0.9999796152114868
type O O 0.999935507774353
of O O 0.9999189376831055
induction O O 0.9583936929702759
agent O O 0.9975354671478271
( O O 0.9993191957473755
Althesin B B 0.9913630485534668
or O O 0.9840960502624512
Thiopentone B B 0.9956764578819275
) O O 0.9997091889381409
nor O O 0.9999755620956421
the O O 0.9999850988388062
salt O O 0.999346911907196
preparation O O 0.9994578957557678
of O O 0.9983805418014526
suxamethonium B B 0.9984675049781799
used O O 0.9998959302902222
( O O 0.9991146922111511
chloride B B 0.9947994947433472
or O O 0.9107575416564941
bromide B B 0.9936901330947876
) O O 0.9997532963752747
, O O 0.999956488609314
affected O O 0.9999721050262451
the O O 0.9999927282333374
incidence O O 0.9999966621398926
of O O 0.9999910593032837
scoline B O 0.6731806993484497
pain O O 0.9999138116836548
. O O 0.9999569654464722

Invasive O O 0.9999536275863647
carcinoma O O 0.999950647354126
of O O 0.9999759197235107
the O O 0.9999792575836182
renal O O 0.999937891960144
pelvis O O 0.9999217987060547
following O O 0.9996187686920166
cyclophosphamide B B 0.9985154271125793
therapy O O 0.9953941106796265
for O O 0.999931812286377
nonmalignant O O 0.9940639138221741
disease O O 0.9999942779541016
. O O 0.9998838901519775

A O O 0.999977707862854
47 O O 0.9999973773956299
- O O 0.9999853372573853
year O O 0.9999966621398926
- O O 0.9999938011169434
old O O 0.9999914169311523
woman O O 0.9999972581863403
with O O 0.9999396800994873
right O O 0.9999864101409912
hydroureteronephrosis O O 0.9979436993598938
due O O 0.9999809265136719
to O O 0.9982719421386719
ureterovesical O O 0.9974697828292847
junction O O 0.9966394901275635
obstruction O O 0.9998654127120972
had O O 0.999948263168335
gross O O 0.9999352693557739
hematuria O O 0.9990829229354858
after O O 0.9999493360519409
being O O 0.999974250793457
treated O O 0.9999451637268066
for O O 0.999947190284729
five O O 0.9999921321868896
years O O 0.9999871253967285
wtih O O 0.9810566306114197
cyclophosphamide B B 0.9982954859733582
for O O 0.9990629553794861
cerebral O O 0.9999499320983887
vasculitis O O 0.9999412298202515
. O O 0.9999710321426392

A O O 0.9999667406082153
right O O 0.9999843835830688
nephroureterectomy O O 0.9999428987503052
was O O 0.9999595880508423
required O O 0.9999839067459106
for O O 0.9998941421508789
control O O 0.9999672174453735
of O O 0.9999668598175049
bleeding O O 0.9997113347053528
. O O 0.9999535083770752

The O O 0.9999648332595825
pathology O O 0.9999880790710449
specimen O O 0.9999912977218628
contained O O 0.9999024868011475
clinically O O 0.9998422861099243
occult O O 0.9986811280250549
invasive O O 0.9999092817306519
carcinoma O O 0.9998193383216858
of O O 0.999954104423523
the O O 0.9999762773513794
renal O O 0.9999561309814453
pelvis O O 0.9999151229858398
. O O 0.999967098236084

Although O O 0.9999676942825317
the O O 0.9999802112579346
ability O O 0.9999841451644897
of O O 0.9990273714065552
cyclophosphamide B B 0.999402642250061
to O O 0.9998393058776855
cause O O 0.9998966455459595
hemorrhagic O O 0.9998787641525269
cystitis O O 0.999790370464325
and O O 0.9999186992645264
urine O O 0.9999192953109741
cytologic O O 0.9996931552886963
abnormalities O O 0.9999939203262329
indistinguishable O O 0.9999849796295166
from O O 0.9998325109481812
high O O 0.9981464147567749
grade O O 0.9997866749763489
carcinoma O O 0.9998685121536255
is O O 0.9999772310256958
well O O 0.99996018409729
known O O 0.9999873638153076
, O O 0.9999706745147705
it O O 0.9999927282333374
is O O 0.9999921321868896
less O O 0.999997615814209
widely O O 0.9999970197677612
appreciated O O 0.9999992847442627
that O O 0.9999443292617798
it O O 0.9999555349349976
is O O 0.9999310970306396
also O O 0.9999521970748901
associated O O 0.9999890327453613
with O O 0.999969482421875
carcinoma O O 0.999854326248169
of O O 0.999945878982544
the O O 0.9999890327453613
urinary O O 0.999991774559021
tract O O 0.9999876022338867
. O O 0.9999827146530151

Twenty O O 0.9870730638504028
carcinomas O O 0.9997168183326721
of O O 0.9999275207519531
the O O 0.999880313873291
urinary O O 0.999777615070343
bladder O O 0.9992352724075317
and O O 0.9998898506164551
one O O 0.9998319149017334
carcinoma O O 0.9996696710586548
of O O 0.9997840523719788
the O O 0.9998070597648621
prostate O O 0.9981251358985901
have O O 0.9999499320983887
been O O 0.999967098236084
reported O O 0.9999895095825195
in O O 0.9999696016311646
association O O 0.9999821186065674
with O O 0.9998418092727661
its O O 0.7035641670227051
use O O 0.9982017278671265
. O O 0.9999457597732544

The O O 0.9999939203262329
present O O 0.9999947547912598
case O O 0.9999895095825195
is O O 0.999982476234436
the O O 0.9999912977218628
first O O 0.9999923706054688
carcinoma O O 0.9999234676361084
of O O 0.999929666519165
the O O 0.9999769926071167
renal O O 0.9999518394470215
pelvis O O 0.9998588562011719
reported O O 0.9999836683273315
in O O 0.9999774694442749
association O O 0.9999853372573853
with O O 0.9998038411140442
cyclophosphamide B B 0.9989608526229858
treatment O O 0.9991716146469116
. O O 0.9999721050262451

It O O 0.9999698400497437
is O O 0.9999767541885376
the O O 0.9999864101409912
third O O 0.9998400211334229
urinary O O 0.9999274015426636
tract O O 0.9997232556343079
cancer O O 0.9980114698410034
reported O O 0.9999799728393555
in O O 0.9999798536300659
association O O 0.99997878074646
with O O 0.9998181462287903
cyclophosphamide B B 0.9988538026809692
treatment O O 0.9990636706352234
for O O 0.9998836517333984
nonmalignant O O 0.9923353791236877
disease O O 0.9999947547912598
. O O 0.9999693632125854

The O O 0.999987006187439
association O O 0.9999922513961792
of O O 0.999988317489624
the O O 0.9999903440475464
tumor O O 0.9999911785125732
with O O 0.9998774528503418
preexisting O O 0.9997426867485046
hydroureteronephrosis O O 0.9986124038696289
suggests O O 0.9997995495796204
that O O 0.9889492988586426
stasis O O 0.8366660475730896
prolonged O O 0.7401676774024963
and O O 0.9994868040084839
intensified O O 0.9172813892364502
exposure O O 0.9999525547027588
of O O 0.9998904466629028
upper O O 0.9961467981338501
urinary O O 0.9999078512191772
tract O O 0.9998763799667358
epithelium O O 0.9980329871177673
to O O 0.9984893798828125
cyclophosphamide B B 0.998960018157959
. O O 0.9999161958694458

Patients O O 0.9999736547470093
who O O 0.9999682903289795
are O O 0.9999819993972778
candidates O O 0.9999403953552246
for O O 0.9999312162399292
long O O 0.9996572732925415
- O O 0.9999850988388062
term O O 0.9999202489852905
cyclophosphamide B B 0.9988036155700684
treatment O O 0.9996234178543091
should O O 0.9999761581420898
be O O 0.9999958276748657
routinely O O 0.9999966621398926
evaluated O O 0.9999954700469971
for O O 0.999974250793457
obstructive O O 0.9997406601905823
uropathy O O 0.9999853372573853
. O O 0.9999836683273315

Medial O O 0.9992569088935852
changes O O 0.9999905824661255
in O O 0.9999682903289795
arterial O O 0.9998427629470825
spasm O O 0.8512511253356934
induced O O 0.9999492168426514
by O O 0.999690055847168
L B B 0.8574409484863281
- I I 0.9865887761116028
norepinephrine I I 0.9998573064804077
. O O 0.9996102452278137

In O O 0.9998834133148193
normal O O 0.9989848732948303
rats O O 0.9996084570884705
, O O 0.9999583959579468
the O O 0.9999457597732544
media O O 0.9999231100082397
of O O 0.9999504089355469
small O O 0.9999165534973145
arteries O O 0.9998283386230469
( O O 0.9999432563781738
0 O O 0.9999419450759888
. O O 0.9999808073043823
4 O O 0.9999452829360962
- O O 0.9977107048034668
- O O 0.9977080821990967
0 O O 0.9999716281890869
. O O 0.9999839067459106
2 O O 0.9999814033508301
mm O O 0.9999942779541016
in O O 0.9999867677688599
diameter O O 0.9999459981918335
) O O 0.9999349117279053
previously O O 0.999891996383667
was O O 0.9999641180038452
shown O O 0.9999806880950928
to O O 0.9999207258224487
contain O O 0.9998965263366699
intracellular O O 0.9993745684623718
vacuoles O O 0.9999583959579468
, O O 0.9999756813049316
identified O O 0.9999828338623047
ultrastructurally O O 0.9998077750205994
as O O 0.9999704360961914
herniations O O 0.9999699592590332
of O O 0.9999139308929443
one O O 0.9999408721923828
smooth O O 0.9991092085838318
muscle O O 0.9999312162399292
cell O O 0.9999521970748901
into O O 0.9998342990875244
another O O 0.9998677968978882
. O O 0.9999438524246216

The O O 0.9999847412109375
hypothesis O O 0.9999781847000122
that O O 0.9999548196792603
intense O O 0.9987829327583313
vasoconstriction O O 0.9987898468971252
would O O 0.999879002571106
increase O O 0.999767005443573
the O O 0.9999855756759644
number O O 0.9999815225601196
of O O 0.9999634027481079
such O O 0.9997170567512512
vacuoles O O 0.9999498128890991
has O O 0.9999533891677856
been O O 0.9999865293502808
tested O O 0.999948263168335
. O O 0.9999618530273438

In O O 0.9994285702705383
the O O 0.9998844861984253
media O O 0.9998273253440857
of O O 0.9998898506164551
the O O 0.9999430179595947
saphenous O O 0.9995217323303223
artery O O 0.9999128580093384
and O O 0.9996520280838013
its O O 0.9998581409454346
distal O O 0.9999655485153198
branch O O 0.9999878406524658
, O O 0.9998806715011597
vasoconstriction O O 0.9999334812164307
induced O O 0.9999175071716309
by O O 0.9998743534088135
L B B 0.6640679836273193
- I I 0.9411627650260925
norepinephrine I I 0.9997949004173279
produced O O 0.9996309280395508
many O O 0.9999655485153198
cell O O 0.9999476671218872
- O O 0.9999871253967285
to O O 0.9999203681945801
- O O 0.9999818801879883
cell O O 0.9999901056289673
hernias O O 0.9999912977218628
within O O 0.9999921321868896
15 O O 0.9999877214431763
minutes O O 0.9999960660934448
. O O 0.9999710321426392

At O O 0.9999210834503174
1 O O 0.999946117401123
day O O 0.9999933242797852
their O O 0.9999791383743286
number O O 0.9999399185180664
was O O 0.9999746084213257
reduced O O 0.9999911785125732
to O O 0.9999821186065674
about O O 0.9999967813491821
1 O O 0.9999867677688599
/ O O 0.9999918937683105
10 O O 0.9999961853027344
of O O 0.9999880790710449
the O O 0.9999971389770508
original O O 0.999992847442627
number O O 0.9999707937240601
. O O 0.9999767541885376

By O O 0.9999606609344482
7 O O 0.999729573726654
days O O 0.999976396560669
the O O 0.9999692440032959
vessel O O 0.9999862909317017
was O O 0.9999750852584839
almost O O 0.9999834299087524
restored O O 0.9999920129776001
to O O 0.9999904632568359
normal O O 0.999984860420227
. O O 0.9999842643737793

Triple O O 0.7141284346580505
stimulation O O 0.9992979764938354
over O O 0.9999227523803711
1 O O 0.9999071359634399
day O O 0.9999521970748901
induced O O 0.9999585151672363
more O O 0.9999830722808838
severe O O 0.9999856948852539
changes O O 0.9999934434890747
in O O 0.9999816417694092
the O O 0.9999707937240601
media O O 0.9999561309814453
. O O 0.9999732971191406

These O O 0.9999654293060303
findings O O 0.9999861717224121
suggest O O 0.999908447265625
that O O 0.9998452663421631
smooth O O 0.9981400966644287
muscle O O 0.9999457597732544
cells O O 0.9999271631240845
are O O 0.9998400211334229
susceptible O O 0.9999659061431885
to O O 0.9998414516448975
damage O O 0.9999476671218872
in O O 0.9999291896820068
the O O 0.9999480247497559
course O O 0.9996675252914429
of O O 0.9998725652694702
their O O 0.9994839429855347
specific O O 0.9995322227478027
function O O 0.9999604225158691
. O O 0.9999412298202515

The O O 0.9999853372573853
experimental O O 0.9999914169311523
data O O 0.9999980926513672
are O O 0.9999877214431763
discussed O O 0.9999933242797852
in O O 0.9999880790710449
relation O O 0.9999865293502808
to O O 0.9999629259109497
medial O O 0.9996938705444336
changes O O 0.9999927282333374
observed O O 0.9999905824661255
in O O 0.9999599456787109
other O O 0.9999517202377319
instances O O 0.9999862909317017
of O O 0.9999531507492065
arterial O O 0.9998005032539368
spasm O O 0.9947669506072998
. O O 0.9999632835388184

Endothelial O O 0.999869704246521
changes O O 0.9999877214431763
that O O 0.9999582767486572
developed O O 0.9999873638153076
in O O 0.9999333620071411
the O O 0.9999890327453613
same O O 0.9999518394470215
experimental O O 0.9999607801437378
model O O 0.9999927282333374
were O O 0.9999868869781494
described O O 0.9999939203262329
in O O 0.9999960660934448
a O O 0.9999972581863403
previous O O 0.9999951124191284
paper O O 0.9999985694885254
. O O 0.9999704360961914

Bilateral O O 0.9999266862869263
retinal O O 0.9999539852142334
artery O O 0.9951660633087158
and O O 0.9997813105583191
choriocapillaris O O 0.9993809461593628
occlusion O O 0.9999889135360718
following O O 0.9999539852142334
the O O 0.9999890327453613
injection O O 0.9999573230743408
of O O 0.999806821346283
long O O 0.9611856341362
- O O 0.9995976090431213
acting O O 0.9678948521614075
corticosteroid B O 0.6106852889060974
suspensions O O 0.7189154624938965
in O O 0.999890923500061
combination O O 0.9998915195465088
with O O 0.9998010993003845
other O O 0.9995941519737244
drugs O O 0.9970031380653381
: O O 0.9998230338096619
I O O 0.9256547093391418
. O O 0.9998276233673096

Clinical O O 0.999950647354126
studies O O 0.9999881982803345
. O O 0.9999785423278809

Two O O 0.9999653100967407
well O O 0.9997907280921936
- O O 0.9999809265136719
documented O O 0.9999920129776001
cases O O 0.9999904632568359
of O O 0.9999707937240601
bilateral O O 0.9998658895492554
retinal O O 0.9998514652252197
artery O O 0.994174063205719
and O O 0.9996161460876465
choriocapillaris O O 0.9993709921836853
occlusions O O 0.9999470710754395
with O O 0.9999111890792847
blindness O O 0.9999940395355225
following O O 0.9998874664306641
head O O 0.9999819993972778
and O O 0.9997261166572571
neck O O 0.9999849796295166
soft O O 0.9986701011657715
- O O 0.9999517202377319
tissue O O 0.999992847442627
injection O O 0.9999830722808838
with O O 0.9996616840362549
methylprednisolone B B 0.9989481568336487
acetate I I 0.9997170567512512
in O O 0.9993335604667664
combination O O 0.9998384714126587
with O O 0.9997867941856384
lidocaine B B 0.9996451139450073
, O O 0.9597485065460205
epinephrine B B 0.9343476891517639
, O O 0.951198399066925
or O O 0.9945916533470154
penicillin B B 0.9939600229263306
are O O 0.9998010993003845
reported O O 0.9999884366989136
. O O 0.9999665021896362

One O O 0.9999552965164185
case O O 0.9999558925628662
had O O 0.9999344348907471
only O O 0.9999679327011108
a O O 0.9999773502349854
unilateral O O 0.9999058246612549
injection O O 0.9999457597732544
. O O 0.9999034404754639

The O O 0.9999796152114868
acute O O 0.9999263286590576
observations O O 0.9999642372131348
included O O 0.9999716281890869
hazy O O 0.9999547004699707
sensorium O O 0.9999988079071045
, O O 0.9999512434005737
superior O O 0.9999854564666748
gaze O O 0.9999901056289673
palsy O O 0.9999654293060303
, O O 0.9999489784240723
pupillary O O 0.999990701675415
abnormalities O O 0.9999954700469971
, O O 0.9999055862426758
and O O 0.9999133348464966
conjunctival O O 0.9864438772201538
hemorrhages O O 0.9999401569366455
with O O 0.9999251365661621
edema O O 0.9998242259025574
. O O 0.9999513626098633

Follow O O 0.9989494681358337
- O O 0.9999821186065674
up O O 0.9999904632568359
changes O O 0.9999963045120239
showed O O 0.9999583959579468
marked O O 0.999969482421875
visual O O 0.9999901056289673
loss O O 0.9999971389770508
, O O 0.9999727010726929
constricted O O 0.9999550580978394
visual O O 0.9999855756759644
fields O O 0.9999970197677612
, O O 0.9999641180038452
optic O O 0.9999532699584961
nerve O O 0.9999639987945557
pallor O O 0.9999881982803345
, O O 0.9998377561569214
vascular O O 0.999337375164032
attenuation O O 0.9997028708457947
, O O 0.9996174573898315
and O O 0.999722421169281
chorioretinal O O 0.9996318817138672
atrophy O O 0.999482274055481
. O O 0.9999650716781616

The O O 0.9999884366989136
literature O O 0.999980092048645
is O O 0.9999785423278809
reviewed O O 0.9999935626983643
, O O 0.9999550580978394
and O O 0.999974250793457
possible O O 0.9998817443847656
causes O O 0.999983549118042
are O O 0.9999854564666748
discussed O O 0.9999862909317017
. O O 0.9999842643737793

Abnormalities O O 0.9999656677246094
of O O 0.9999557733535767
the O O 0.999958872795105
pupil O O 0.9999762773513794
and O O 0.9998669624328613
visual O O 0.9930069446563721
- O O 0.9998247027397156
evoked O O 0.9997410178184509
potential O O 0.9999955892562866
in O O 0.9997833371162415
quinine B O 0.9221275448799133
amblyopia O O 0.7485540509223938
. O O 0.9999045133590698

Total O O 0.998676598072052
blindness O O 0.9999938011169434
with O O 0.9999802112579346
a O O 0.9999852180480957
transient O O 0.9999785423278809
tonic O O 0.9999632835388184
pupillary O O 0.9999879598617554
response O O 0.9999880790710449
, O O 0.9999101161956787
denervation O O 0.807697594165802
supersensitivity O O 0.6081426739692688
, O O 0.9998201727867126
and O O 0.9999544620513916
abnormal O O 0.9999804496765137
visual O O 0.9984719157218933
- O O 0.9998679161071777
evoked O O 0.9998407363891602
potentials O O 0.9999973773956299
developed O O 0.9999973773956299
in O O 0.9999889135360718
a O O 0.9999924898147583
54 O O 0.9999780654907227
- O O 0.9999897480010986
year O O 0.9999967813491821
- O O 0.9999943971633911
old O O 0.9999948740005493
man O O 0.9999966621398926
after O O 0.9999644756317139
the O O 0.9999847412109375
use O O 0.9998218417167664
of O O 0.9991787075996399
quinine B B 0.9964736104011536
sulfate I I 0.9962168335914612
for O O 0.9981441497802734
leg O O 0.9914582371711731
cramps O O 0.9943185448646545
. O O 0.9999717473983765

He O O 0.9999215602874756
later O O 0.9998396635055542
recovered O O 0.9999411106109619
normal O O 0.9999696016311646
visual O O 0.9999758005142212
acuity O O 0.9999822378158569
. O O 0.9999606609344482

A O O 0.9999252557754517
transient O O 0.9999768733978271
tonic O O 0.9999563694000244
pupillary O O 0.9999878406524658
response O O 0.9999827146530151
, O O 0.9998737573623657
denervation O O 0.6721457242965698
supersensitivity O O 0.7629820704460144
, O O 0.9998714923858643
and O O 0.9999295473098755
abnormal O O 0.9999812841415405
visual O O 0.9958821535110474
- O O 0.9998902082443237
evoked O O 0.9999220371246338
potentials O O 0.9999966621398926
in O O 0.9997085928916931
quinine B B 0.9979962706565857
toxicity O O 0.989391028881073
, O O 0.9999881982803345
to O O 0.9999955892562866
our O O 0.9999958276748657
knowledge O O 0.9999947547912598
, O O 0.9999897480010986
have O O 0.9999867677688599
not O O 0.999992847442627
been O O 0.999995231628418
previously O O 0.9999812841415405
reported O O 0.9999954700469971
. O O 0.9999721050262451

Suxamethonium B B 0.9991908669471741
- O O 0.9994421601295471
induced O O 0.9999262094497681
jaw O O 0.9999521970748901
stiffness O O 0.9999775886535645
and O O 0.9999701976776123
myalgia O O 0.9999985694885254
associated O O 0.9999804496765137
with O O 0.9999120235443115
atypical O O 0.9343348741531372
cholinesterase O O 0.4857008755207062
: O O 0.9999520778656006
case O O 0.9999881982803345
report O O 0.9999934434890747
. O O 0.9999849796295166

An O O 0.9999910593032837
11 O O 0.9999771118164062
- O O 0.9999909400939941
year O O 0.9999970197677612
- O O 0.9999960660934448
old O O 0.999996542930603
boy O O 0.9999845027923584
was O O 0.9999758005142212
given O O 0.999488115310669
halothane B B 0.9993314743041992
, O O 0.9530584812164307
nitrous B B 0.9965798258781433
oxide I I 0.9999217987060547
and O O 0.9779796600341797
oxygen B B 0.9973888993263245
, O O 0.9844310879707336
pancuronium B B 0.9985835552215576
0 O O 0.9403467774391174
. O O 0.9999456405639648
4 O O 0.9984086155891418
mg O O 0.9985986351966858
and O O 0.9980570673942566
suxamethonium B B 0.9981155395507812
100 O O 0.8838557004928589
mg O O 0.9967693090438843
for O O 0.9999676942825317
induction O O 0.9999984502792358
of O O 0.9999815225601196
anaesthesia O O 0.9997016787528992
. O O 0.9999306201934814

In O O 0.9999704360961914
response O O 0.9999833106994629
to O O 0.999968409538269
this O O 0.9999790191650391
a O O 0.999985933303833
marked O O 0.9999815225601196
jaw O O 0.9999340772628784
stiffness O O 0.9999699592590332
occurred O O 0.9999924898147583
which O O 0.999966025352478
lasted O O 0.9999926090240479
for O O 0.9999945163726807
two O O 0.9999959468841553
minutes O O 0.9999960660934448
and O O 0.9999872446060181
the O O 0.9999849796295166
anaesthesia O O 0.9999475479125977
were O O 0.9999539852142334
terminated O O 0.9999750852584839
. O O 0.9999754428863525

Four O O 0.9999667406082153
hours O O 0.9999904632568359
of O O 0.9999880790710449
apnoea O O 0.9993987083435059
ensued O O 0.9999785423278809
and O O 0.9999842643737793
he O O 0.9999803304672241
suffered O O 0.9999880790710449
generalized O O 0.9999663829803467
severe O O 0.9999666213989258
myalgia O O 0.9999988079071045
lasting O O 0.9999896287918091
for O O 0.9999935626983643
one O O 0.9999964237213135
week O O 0.9999970197677612
. O O 0.999984860420227

He O O 0.9999380111694336
was O O 0.9999493360519409
found O O 0.9999840259552002
to O O 0.9998680353164673
have O O 0.9996377229690552
atypical O O 0.9922029972076416
plasma O O 0.9502133727073669
cholinesterase O O 0.7342112064361572
with O O 0.9998791217803955
a O O 0.9999624490737915
dibucaine B B 0.9884575009346008
number O O 0.98974609375
of O O 0.9999246597290039
12 O O 0.9840876460075378
, O O 0.9999653100967407
indicating O O 0.9995162487030029
homozygocity O O 0.9994031190872192
. O O 0.9999638795852661

This O O 0.9999759197235107
was O O 0.9999799728393555
verified O O 0.9999885559082031
by O O 0.9999890327453613
study O O 0.9999128580093384
of O O 0.9999818801879883
the O O 0.9999897480010986
family O O 0.9999853372573853
. O O 0.9999674558639526

The O O 0.9999850988388062
case O O 0.999991774559021
shows O O 0.9999760389328003
that O O 0.9999444484710693
prolonged O O 0.9999109506607056
jaw O O 0.9997828602790833
rigidity O O 0.9999936819076538
and O O 0.9999232292175293
myalgia O O 0.9999960660934448
may O O 0.9999676942825317
occur O O 0.9999959468841553
after O O 0.9995788931846619
suxamethonium B B 0.9989651441574097
in O O 0.9998101592063904
patients O O 0.9999879598617554
with O O 0.9999583959579468
atypical O O 0.9951044321060181
cholinesterase O O 0.4664892852306366
despite O O 0.9995006322860718
pretreatment O O 0.9999215602874756
with O O 0.9997559189796448
pancuronium B B 0.9966920614242554
. O O 0.9999524354934692

Indomethacin B B 0.9978942275047302
- O O 0.9967010617256165
induced O O 0.9998595714569092
hyperkalemia O O 0.9813204407691956
in O O 0.99996018409729
three O O 0.9999754428863525
patients O O 0.9999927282333374
with O O 0.9999747276306152
gouty O O 0.9997771382331848
arthritis O O 0.9998399019241333
. O O 0.9999418258666992

We O O 0.9999687671661377
describe O O 0.9999868869781494
three O O 0.9999779462814331
patients O O 0.999992847442627
in O O 0.9999240636825562
whom O O 0.999940037727356
severe O O 0.9999289512634277
, O O 0.9999731779098511
life O O 0.999923825263977
- O O 0.9999884366989136
threatening O O 0.9999896287918091
hyperkalemia O O 0.9485344290733337
and O O 0.999927282333374
renal O O 0.999961256980896
insufficiency O O 0.9999902248382568
developed O O 0.9999932050704956
after O O 0.9999159574508667
treatment O O 0.9999692440032959
of O O 0.9999721050262451
acute O O 0.9999665021896362
gouty O O 0.9999579191207886
arthritis O O 0.9999467134475708
with O O 0.9997203946113586
indomethacin B B 0.9979111552238464
. O O 0.9999058246612549

This O O 0.9999034404754639
complication O O 0.9999796152114868
may O O 0.9999094009399414
result O O 0.9999655485153198
from O O 0.9999059438705444
an O O 0.9998788833618164
inhibition O O 0.9996587038040161
of O O 0.9996800422668457
prostaglandin B O 0.5620435476303101
synthesis O O 0.9963176250457764
and O O 0.999916672706604
consequent O O 0.9995480179786682
hyporeninemic O O 0.9941154718399048
hypoaidosteronism O O 0.9995983242988586
. O O 0.9999403953552246

Careful O O 0.9998248219490051
attention O O 0.9999793767929077
to O O 0.999847412109375
renal O O 0.9998457431793213
function O O 0.9999748468399048
and O O 0.99993896484375
potassium B B 0.9927880167961121
balance O O 0.9986056685447693
in O O 0.9999576807022095
patients O O 0.9999871253967285
receiving O O 0.9997684359550476
indomethacin B B 0.9991618394851685
or O O 0.9984716773033142
other O O 0.9997103810310364
nonsteroidal O O 0.5926902890205383
anti O O 0.5228606462478638
- O O 0.9343336224555969
inflammatory O O 0.9651743173599243
agents O O 0.9751253128051758
, O O 0.9999817609786987
particularly O O 0.9999843835830688
in O O 0.9999830722808838
those O O 0.9999864101409912
patients O O 0.9999936819076538
with O O 0.9999858140945435
diabetes O O 0.9998812675476074
mellitus O O 0.9999985694885254
or O O 0.9999620914459229
preexisting O O 0.9990712404251099
renal O O 0.9999402761459351
disease O O 0.9999921321868896
, O O 0.9999845027923584
will O O 0.9999656677246094
help O O 0.9999438524246216
prevent O O 0.9999761581420898
this O O 0.999985933303833
potentially O O 0.9999922513961792
serious O O 0.9999963045120239
complication O O 0.9999961853027344
. O O 0.9999881982803345

Etomidate B B 0.9995423555374146
: O O 0.9999001026153564
a O O 0.9999291896820068
foreshortened O O 0.9999217987060547
clinical O O 0.9999674558639526
trial O O 0.9999829530715942
. O O 0.9999009370803833

A O O 0.9999668598175049
clinical O O 0.9999837875366211
evaluation O O 0.9999891519546509
of O O 0.9990861415863037
etomidate B B 0.9995343685150146
for O O 0.9999067783355713
outpatient O O 0.9999730587005615
cystoscopy O O 0.9995903372764587
was O O 0.9999817609786987
embarked O O 0.9999822378158569
upon O O 0.9999972581863403
. O O 0.9999761581420898

Unpremedicated O O 0.9334112405776978
patients O O 0.9999938011169434
were O O 0.9999874830245972
given O O 0.9990102052688599
fentanyl B B 0.999833345413208
1 O O 0.9993017911911011
microgram O O 0.999769389629364
/ O O 0.9999748468399048
kg O O 0.9999794960021973
followed O O 0.999840259552002
by O O 0.9991931319236755
etomidate B B 0.9992157220840454
0 O O 0.9949795603752136
. O O 0.9999856948852539
3 O O 0.9996324777603149
mg O O 0.999810516834259
/ O O 0.999834418296814
kg O O 0.9999510049819946
. O O 0.9999039173126221

Anaesthesia O O 0.9985418319702148
was O O 0.9999531507492065
maintained O O 0.9999761581420898
with O O 0.9999208450317383
intermittent O O 0.9971857666969299
etomidate B B 0.9990407824516296
in O O 0.9975135326385498
2 O O 0.991634726524353
- O O 0.9962263107299805
4 O O 0.9972176551818848
mg O O 0.9984719157218933
doses O O 0.9996476173400879
. O O 0.9999655485153198

Patients O O 0.9999164342880249
were O O 0.9999964237213135
interviewed O O 0.9999843835830688
personally O O 0.9999940395355225
later O O 0.9999788999557495
the O O 0.9999972581863403
same O O 0.9999943971633911
day O O 0.9999953508377075
, O O 0.9999678134918213
and O O 0.9999749660491943
by O O 0.9999825954437256
questionnaire O O 0.9999499320983887
three O O 0.9999874830245972
to O O 0.999997615814209
four O O 0.9999984502792358
weeks O O 0.9999988079071045
later O O 0.9999973773956299
. O O 0.9999837875366211

The O O 0.9999651908874512
trial O O 0.9999188184738159
was O O 0.9999815225601196
discontinued O O 0.9999892711639404
after O O 0.9999912977218628
20 O O 0.9999523162841797
cases O O 0.9999878406524658
because O O 0.9999946355819702
of O O 0.9999922513961792
an O O 0.9999955892562866
unacceptable O O 0.9999887943267822
incidence O O 0.9999979734420776
of O O 0.9999711513519287
side O O 0.9999668598175049
effects O O 0.9999890327453613
. O O 0.9999723434448242

Venous O O 0.9998401403427124
pain O O 0.9999234676361084
occurred O O 0.9999886751174927
in O O 0.9999786615371704
68 O O 0.9999922513961792
% O O 0.9999963045120239
of O O 0.9999668598175049
patients O O 0.999970555305481
and O O 0.9998694658279419
50 O O 0.9999792575836182
% O O 0.999992847442627
had O O 0.9999756813049316
redness O O 0.9999994039535522
, O O 0.9999767541885376
pain O O 0.9991025924682617
or O O 0.9999635219573975
swelling O O 0.9999960660934448
related O O 0.9999948740005493
to O O 0.9999737739562988
the O O 0.9999897480010986
injection O O 0.9999146461486816
site O O 0.9999746084213257
, O O 0.9999895095825195
in O O 0.9999806880950928
some O O 0.9999910593032837
cases O O 0.9999816417694092
lasting O O 0.999991774559021
up O O 0.9999932050704956
to O O 0.9999935626983643
three O O 0.9999973773956299
weeks O O 0.9999986886978149
after O O 0.999977707862854
anaesthesia O O 0.9999737739562988
. O O 0.9999667406082153

Skeletal O O 0.9885830879211426
movements O O 0.9999731779098511
occurred O O 0.9999866485595703
in O O 0.9999793767929077
50 O O 0.9999873638153076
% O O 0.9999955892562866
of O O 0.9999784231185913
patients O O 0.9999915361404419
; O O 0.9999709129333496
30 O O 0.9999587535858154
% O O 0.9999914169311523
experienced O O 0.9999737739562988
respiratory O O 0.9999752044677734
upset O O 0.9999916553497314
, O O 0.9999823570251465
one O O 0.999984622001648
sufficiently O O 0.9999731779098511
severe O O 0.9999686479568481
to O O 0.9999945163726807
necessitate O O 0.9999953508377075
abandoning O O 0.9998372793197632
the O O 0.9999866485595703
technique O O 0.9999915361404419
. O O 0.9999673366546631

Nausea O O 0.9998480081558228
and O O 0.9999585151672363
vomiting O O 0.9998917579650879
occurred O O 0.9999773502349854
in O O 0.9999746084213257
40 O O 0.9999312162399292
% O O 0.9999855756759644
and O O 0.9998064637184143
25 O O 0.9999682903289795
% O O 0.9999845027923584
had O O 0.9998664855957031
disturbing O O 0.9300227165222168
emergence O O 0.9955739974975586
psychoses O O 0.9996155500411987
. O O 0.9999475479125977

Levodopa B B 0.9989922642707825
- O O 0.9997337460517883
induced O O 0.999818742275238
dyskinesias O O 0.9999954700469971
are O O 0.9999245405197144
improved O O 0.9999746084213257
by O O 0.9992571473121643
fluoxetine B B 0.99962317943573
. O O 0.9999406337738037

We O O 0.9999591112136841
evaluated O O 0.9999890327453613
the O O 0.9999881982803345
severity O O 0.9999880790710449
of O O 0.999964714050293
motor O O 0.9999715089797974
disability O O 0.999966025352478
and O O 0.9999170303344727
dyskinesias O O 0.9999922513961792
in O O 0.9999476671218872
seven O O 0.9971007704734802
levodopa B B 0.9991344809532166
- O O 0.9991670846939087
responsive O O 0.9993206262588501
patients O O 0.9999905824661255
with O O 0.9999740123748779
Parkinson O O 0.9994791150093079
' O O 0.9999898672103882
s O O 0.9999926090240479
disease O O 0.9999973773956299
after O O 0.9999338388442993
an O O 0.9999840259552002
acute O O 0.9999668598175049
challenge O O 0.9999918937683105
with O O 0.9998536109924316
the O O 0.9998501539230347
mixed O O 0.8128535747528076
dopamine B B 0.9524090886116028
agonist O O 0.7978662848472595
, O O 0.9768539071083069
apomorphine B B 0.9981538653373718
, O O 0.9998782873153687
before O O 0.9999204874038696
and O O 0.999984622001648
after O O 0.9999700784683228
the O O 0.9999939203262329
administration O O 0.9999725818634033
of O O 0.9997745156288147
fluoxetine B B 0.9997486472129822
( O O 0.9997484087944031
20 O O 0.9997820258140564
mg O O 0.9998600482940674
twice O O 0.9999231100082397
per O O 0.9999790191650391
day O O 0.9999921321868896
) O O 0.9999722242355347
for O O 0.9999701976776123
11 O O 0.999925971031189
+ O O 0.9999949932098389
/ O O 0.9999649524688721
- O O 0.9999581575393677
1 O O 0.9999924898147583
days O O 0.9999902248382568
. O O 0.9999840259552002

After O O 0.9998107552528381
fluoxetine B B 0.9995809197425842
treatment O O 0.9999023675918579
, O O 0.9999667406082153
there O O 0.9999743700027466
was O O 0.9999874830245972
a O O 0.9999951124191284
significant O O 0.9999954700469971
47 O O 0.9999982118606567
% O O 0.9999979734420776
improvement O O 0.9999971389770508
( O O 0.9999794960021973
p O O 0.9999922513961792
< O O 0.9999895095825195
0 O O 0.9999939203262329
. O O 0.9999963045120239
05 O O 0.9999971389770508
) O O 0.9999877214431763
of O O 0.9999512434005737
apomorphine B B 0.9935467839241028
- O O 0.9997745156288147
induced O O 0.9998496770858765
dyskinesias O O 0.9999969005584717
without O O 0.9999574422836304
modification O O 0.999985933303833
of O O 0.999951958656311
parkinsonian O O 0.9985507130622864
motor O O 0.9999264478683472
disability O O 0.9999841451644897
. O O 0.9999709129333496

The O O 0.9999499320983887
dyskinesias O O 0.9999861717224121
were O O 0.9999382495880127
reduced O O 0.9999722242355347
predominantly O O 0.9999145269393921
in O O 0.999492883682251
the O O 0.9999268054962158
lower O O 0.9999113082885742
limbs O O 0.9999899864196777
during O O 0.9996999502182007
the O O 0.9999196529388428
onset O O 0.9999527931213379
and O O 0.9999322891235352
disappearance O O 0.9999624490737915
of O O 0.9999043941497803
dystonic O O 0.9999871253967285
dyskinesias O O 0.9999853372573853
( O O 0.9998894929885864
onset O O 0.9997773766517639
- O O 0.9999585151672363
and O O 0.9999504089355469
end O O 0.9999613761901855
- O O 0.9999775886535645
of O O 0.9962570667266846
- O O 0.9999604225158691
dose O O 0.9991307854652405
dyskinesias O O 0.9999855756759644
) O O 0.9999526739120483
and O O 0.9998307228088379
in O O 0.9997889399528503
the O O 0.999941349029541
upper O O 0.9989376664161682
limbs O O 0.999988317489624
during O O 0.9998462200164795
choreic O O 0.9904984831809998
mid O O 0.9998699426651001
- O O 0.9998865127563477
dose O O 0.9988340735435486
dyskinesias O O 0.9999786615371704
. O O 0.9999593496322632

The O O 0.9999839067459106
results O O 0.9999904632568359
suggest O O 0.999977707862854
that O O 0.999889612197876
increased O O 0.9998946189880371
brain O O 0.999797523021698
serotoninergic O O 0.49170681834220886
transmission O O 0.9999319314956665
with O O 0.9995711445808411
fluoxetine B B 0.9998201727867126
may O O 0.9998408555984497
reduce O O 0.9993365406990051
levodopa B B 0.9997976422309875
- O O 0.9995266199111938
or O O 0.9989027976989746
dopamine B B 0.9977720379829407
agonist O O 0.6278640627861023
- O O 0.9998507499694824
induced O O 0.9999103546142578
dyskinesias O O 0.9999957084655762
without O O 0.9999439716339111
aggravating O O 0.9999312162399292
parkinsonian O O 0.9996612071990967
motor O O 0.9999502897262573
disability O O 0.9999877214431763
. O O 0.999971866607666

A O O 0.9999537467956543
large O O 0.9999741315841675
population O O 0.9999467134475708
- O O 0.9999872446060181
based O O 0.9999951124191284
follow O O 0.9999817609786987
- O O 0.9999916553497314
up O O 0.9999891519546509
study O O 0.999976634979248
of O O 0.9991476535797119
trimethoprim B B 0.996654748916626
- I I 0.7330820560455322
sulfamethoxazole I I 0.9388814568519592
, O O 0.9235522150993347
trimethoprim B B 0.9937094449996948
, O O 0.9496740698814392
and O O 0.9804431796073914
cephalexin B B 0.9986640214920044
for O O 0.9999022483825684
uncommon O O 0.9992350339889526
serious O O 0.9999531507492065
drug O O 0.9992635846138
toxicity O O 0.9999459981918335
. O O 0.9999672174453735

We O O 0.9999692440032959
conducted O O 0.9999966621398926
a O O 0.9999942779541016
population O O 0.9998952150344849
- O O 0.9999885559082031
based O O 0.9999959468841553
45 O O 0.9999943971633911
- O O 0.9999910593032837
day O O 0.9999964237213135
follow O O 0.9999904632568359
- O O 0.9999921321868896
up O O 0.9999927282333374
study O O 0.9999916553497314
of O O 0.9999784231185913
232 O O 0.9998937845230103
, O O 0.9999947547912598
390 O O 0.9999479055404663
people O O 0.9999953508377075
who O O 0.999858021736145
were O O 0.9999313354492188
prescribed O O 0.9995880722999573
trimethoprim B B 0.9907950758934021
- I I 0.8174054622650146
sulfamethoxazole I I 0.9915088415145874
( O O 0.984176516532898
TMP B B 0.9180911183357239
- I I 0.7359333038330078
SMZ I I 0.9599031209945679
) O O 0.9921666383743286
, O O 0.9999372959136963
266 O O 0.9998655319213867
, O O 0.9999790191650391
951 O O 0.9042187333106995
prescribed O O 0.9997084736824036
trimethoprim B B 0.9986779093742371
alone O O 0.9970601201057434
, O O 0.9999418258666992
and O O 0.9998472929000854
196 O O 0.9771909713745117
, O O 0.999992847442627
397 O O 0.9999231100082397
prescribed O O 0.9995042085647583
cephalexin B B 0.9983330368995667
, O O 0.9997207522392273
to O O 0.9999942779541016
estimate O O 0.9998732805252075
the O O 0.9999860525131226
risk O O 0.9999967813491821
of O O 0.9999878406524658
serious O O 0.9999477863311768
liver O O 0.999614953994751
, O O 0.999964714050293
blood O O 0.9958661794662476
, O O 0.9999569654464722
skin O O 0.999638557434082
, O O 0.999836802482605
and O O 0.9998008608818054
renal O O 0.9999659061431885
disorders O O 0.9999966621398926
resulting O O 0.9999903440475464
in O O 0.9999876022338867
referral O O 0.9999947547912598
or O O 0.9999912977218628
hospitalization O O 0.9999958276748657
associated O O 0.9999963045120239
with O O 0.9997772574424744
these O O 0.997628390789032
drugs O O 0.9921119213104248
. O O 0.999907374382019

The O O 0.999988317489624
results O O 0.9999938011169434
were O O 0.9999945163726807
based O O 0.9999982118606567
on O O 0.9999910593032837
information O O 0.9999886751174927
recorded O O 0.9999828338623047
on O O 0.9999685287475586
office O O 0.9999653100967407
computers O O 0.9999959468841553
by O O 0.9999759197235107
selected O O 0.9998459815979004
general O O 0.9996352195739746
practitioners O O 0.9999814033508301
in O O 0.9999399185180664
the O O 0.9999619722366333
United O O 0.996240496635437
Kingdom O O 0.9999903440475464
, O O 0.9999829530715942
together O O 0.9999769926071167
with O O 0.9999896287918091
a O O 0.9999895095825195
review O O 0.999990701675415
of O O 0.9999798536300659
clinical O O 0.999988317489624
records O O 0.9999910593032837
. O O 0.9999722242355347

The O O 0.9999864101409912
risk O O 0.9999977350234985
of O O 0.9999839067459106
clinically O O 0.9999783039093018
important O O 0.999984622001648
idiopathic O O 0.9999970197677612
liver O O 0.9988711476325989
disease O O 0.9999983310699463
was O O 0.9999587535858154
similar O O 0.999983549118042
for O O 0.9997434020042419
persons O O 0.9985906481742859
prescribed O O 0.9994980096817017
TMP B B 0.9547134637832642
- I I 0.8772707581520081
SMZ I I 0.9897312521934509
( O O 0.9935169219970703
5 O O 0.995925784111023
. O O 0.999841570854187
2 O O 0.9983893632888794
/ O O 0.9993640780448914
100 O O 0.9983507394790649
, O O 0.9999899864196777
000 O O 0.9937431216239929
) O O 0.999815046787262
and O O 0.9997894167900085
those O O 0.9999716281890869
prescribed O O 0.9998352527618408
trimethoprim B B 0.9984140396118164
alone O O 0.9992701411247253
( O O 0.9999517202377319
3 O O 0.99769127368927
. O O 0.9999819993972778
8 O O 0.9996260404586792
/ O O 0.9998701810836792
100 O O 0.9987309575080872
, O O 0.9999940395355225
000 O O 0.9971000552177429
) O O 0.9999650716781616
. O O 0.9999768733978271

The O O 0.9999799728393555
risk O O 0.9999852180480957
for O O 0.9999170303344727
those O O 0.999967098236084
prescribed O O 0.9994780421257019
cephalexin B B 0.9991899132728577
was O O 0.9998894929885864
somewhat O O 0.9999966621398926
lower O O 0.9999924898147583
( O O 0.9999784231185913
2 O O 0.9999598264694214
. O O 0.9999933242797852
0 O O 0.9999850988388062
/ O O 0.9999873638153076
100 O O 0.9999954700469971
, O O 0.9999988079071045
000 O O 0.9999920129776001
) O O 0.9999752044677734
. O O 0.9999761581420898

Only O O 0.9999650716781616
five O O 0.9999831914901733
patients O O 0.9999896287918091
experienced O O 0.9999768733978271
blood O O 0.9993700385093689
disorders O O 0.9999728202819824
, O O 0.9999650716781616
one O O 0.9999499320983887
of O O 0.9999430179595947
whom O O 0.9999712705612183
was O O 0.9999158382415771
exposed O O 0.9998424053192139
to O O 0.9987438321113586
TMP B B 0.8141170144081116
- I I 0.6122856140136719
SMZ I I 0.9643632173538208
; O O 0.9988523721694946
of O O 0.9999525547027588
seven O O 0.9999949932098389
with O O 0.9999620914459229
erythema O O 0.9999715089797974
multiforme O O 0.9968229532241821
and O O 0.9999402761459351
Stevens O O 0.9546976089477539
- O O 0.9959096908569336
Johnson O O 0.9947025179862976
syndrome O O 0.9999634027481079
, O O 0.9999356269836426
four O O 0.9997358918190002
were O O 0.9999319314956665
exposed O O 0.9999322891235352
to O O 0.9996254444122314
TMP B O 0.8348226547241211
- I O 0.6545407176017761
SMZ I O 0.9082788228988647
. O O 0.9995125532150269

The O O 0.9999884366989136
one O O 0.9999980926513672
case O O 0.9999939203262329
of O O 0.9999432563781738
toxic O O 0.9975613355636597
epidermal O O 0.9928485155105591
necrolysis O O 0.9999719858169556
occurred O O 0.9999872446060181
in O O 0.999958872795105
a O O 0.9999613761901855
patient O O 0.9999865293502808
who O O 0.9999189376831055
took O O 0.9967935681343079
cephalexin B B 0.9979327917098999
. O O 0.9999129772186279

Finally O O 0.9999356269836426
, O O 0.9999642372131348
only O O 0.9999827146530151
five O O 0.9999798536300659
cases O O 0.9999923706054688
of O O 0.999969482421875
acute O O 0.9999301433563232
parenchymal O O 0.9999691247940063
renal O O 0.9999628067016602
disease O O 0.9999964237213135
occurred O O 0.9999896287918091
, O O 0.9999731779098511
none O O 0.9999792575836182
likely O O 0.9999756813049316
to O O 0.9999576807022095
be O O 0.9999837875366211
caused O O 0.9999916553497314
by O O 0.9998804330825806
a O O 0.9996073842048645
study O O 0.9700246453285217
drug O O 0.9975207448005676
. O O 0.9999057054519653

We O O 0.9999310970306396
conclude O O 0.999972939491272
that O O 0.9999655485153198
the O O 0.999982476234436
risk O O 0.999987006187439
of O O 0.9999700784683228
the O O 0.9999284744262695
serious O O 0.999890923500061
diseases O O 0.9999822378158569
studied O O 0.999971866607666
is O O 0.9999227523803711
small O O 0.9999902248382568
for O O 0.9988771080970764
the O O 0.9983249306678772
three O O 0.9611489176750183
agents O O 0.9861230850219727
, O O 0.9999072551727295
and O O 0.9999713897705078
compares O O 0.9999915361404419
reasonably O O 0.999996542930603
with O O 0.9999865293502808
the O O 0.9999854564666748
risk O O 0.9999856948852539
for O O 0.999832272529602
many O O 0.9999133348464966
other O O 0.99960857629776
antibiotics O O 0.9133625030517578
. O O 0.9999319314956665

Clinical O O 0.9999319314956665
safety O O 0.9999715089797974
of O O 0.9989776611328125
lidocaine B B 0.9998399019241333
in O O 0.9999368190765381
patients O O 0.9999932050704956
with O O 0.9999780654907227
cocaine B B 0.9904795289039612
- O O 0.998024582862854
associated O O 0.9997348189353943
myocardial O O 0.9999978542327881
infarction O O 0.9999910593032837
. O O 0.9999779462814331

STUDY O O 0.9999573230743408
OBJECTIVE O O 0.9999905824661255
: O O 0.9999948740005493
To O O 0.9999929666519165
evaluate O O 0.9999867677688599
the O O 0.9999932050704956
safety O O 0.9999911785125732
of O O 0.9988653659820557
lidocaine B B 0.9998456239700317
in O O 0.9999061822891235
the O O 0.999991774559021
setting O O 0.9999760389328003
of O O 0.9999353885650635
cocaine B B 0.9959008097648621
- O O 0.9986088871955872
induced O O 0.9999231100082397
myocardial O O 0.9999978542327881
infarction O O 0.9999589920043945
( O O 0.9999450445175171
MI O O 0.9954620003700256
) O O 0.9999866485595703
. O O 0.9999876022338867

DESIGN O O 0.9999938011169434
: O O 0.9999977350234985
A O O 0.9999954700469971
retrospective O O 0.9999872446060181
, O O 0.999990701675415
multicenter O O 0.9999439716339111
study O O 0.9999927282333374
. O O 0.9999885559082031

SETTING O O 0.9998868703842163
: O O 0.9999722242355347
Twenty O O 0.9998947381973267
- O O 0.9999533891677856
nine O O 0.9999725818634033
university O O 0.9984625577926636
, O O 0.9999485015869141
university O O 0.9967556595802307
- O O 0.9999451637268066
affiliated O O 0.9988781809806824
, O O 0.9998571872711182
or O O 0.9998323917388916
community O O 0.9998233914375305
hospitals O O 0.9999874830245972
during O O 0.9999446868896484
a O O 0.9999854564666748
6 O O 0.9999487400054932
- O O 0.9999865293502808
year O O 0.9999953508377075
period O O 0.9999948740005493
( O O 0.9999717473983765
total O O 0.9999904632568359
of O O 0.9999868869781494
117 O O 0.9999926090240479
cumulative O O 0.9999592304229736
hospital O O 0.9999735355377197
- O O 0.999981164932251
years O O 0.9999918937683105
) O O 0.9999785423278809
. O O 0.999984622001648

PARTICIPANTS O O 0.9995424747467041
: O O 0.9999750852584839
Patients O O 0.999985933303833
with O O 0.9999382495880127
cocaine B B 0.9978013634681702
- O O 0.9963319897651672
associated O O 0.9989247918128967
MI O O 0.9922852516174316
who O O 0.9999418258666992
received O O 0.9994304776191711
lidocaine B B 0.9998331069946289
in O O 0.9998717308044434
the O O 0.9999961853027344
emergency O O 0.9999818801879883
department O O 0.9999979734420776
. O O 0.999983549118042

RESULTS O O 0.9997174143791199
: O O 0.9999868869781494
Of O O 0.9999829530715942
29 O O 0.9999850988388062
patients O O 0.9999897480010986
who O O 0.9999597072601318
received O O 0.9995487332344055
lidocaine B B 0.9998180270195007
in O O 0.9998762607574463
the O O 0.9999916553497314
setting O O 0.9999761581420898
of O O 0.9998695850372314
cocaine B B 0.9964522123336792
- O O 0.9979816675186157
associated O O 0.9997377991676331
MI O O 0.9996021389961243
, O O 0.9999790191650391
no O O 0.9999923706054688
patient O O 0.999991774559021
died O O 0.9999868869781494
; O O 0.999995231628418
exhibited O O 0.9998328685760498
bradydysrhythmias O O 0.9999586343765259
, O O 0.9999613761901855
ventricular O O 0.9998708963394165
tachycardia O O 0.9999620914459229
, O O 0.9998327493667603
or O O 0.9998993873596191
ventricular O O 0.9990142583847046
fibrillation O O 0.999992847442627
; O O 0.9999724626541138
or O O 0.9999805688858032
experienced O O 0.9999904632568359
seizures O O 0.999995231628418
after O O 0.99996018409729
administration O O 0.9999582767486572
of O O 0.999828577041626
lidocaine B B 0.99982088804245
( O O 0.9997511506080627
95 O O 0.9999767541885376
% O O 0.999984860420227
confidence O O 0.9997418522834778
interval O O 0.9999632835388184
, O O 0.999969482421875
0 O O 0.9999791383743286
% O O 0.99998939037323
to O O 0.999880313873291
11 O O 0.9999933242797852
% O O 0.9999892711639404
) O O 0.9999704360961914
. O O 0.9999849796295166

CONCLUSION O O 0.9997418522834778
: O O 0.9999240636825562
Despite O O 0.9999867677688599
theoretical O O 0.9999809265136719
concerns O O 0.9999926090240479
that O O 0.9999284744262695
lidocaine B B 0.9997991919517517
may O O 0.999871015548706
enhance O O 0.9996196031570435
cocaine B B 0.9934294819831848
toxicity O O 0.9998641014099121
, O O 0.9999417066574097
the O O 0.999992847442627
use O O 0.9999516010284424
of O O 0.9997785687446594
lidocaine B B 0.9997249245643616
in O O 0.9998645782470703
patients O O 0.9999943971633911
with O O 0.9999736547470093
cocaine B B 0.997535228729248
- O O 0.9992308616638184
associated O O 0.9998308420181274
MI O O 0.999444305896759
was O O 0.9999532699584961
not O O 0.9999576807022095
associated O O 0.9999744892120361
with O O 0.9999700784683228
significant O O 0.9999732971191406
cardiovascular O O 0.9999792575836182
or O O 0.999943733215332
central O O 0.9999535083770752
nervous O O 0.9999967813491821
system O O 0.9999911785125732
toxicity O O 0.9999759197235107
. O O 0.9999792575836182

Experimental O O 0.9985623955726624
progressive O O 0.9999343156814575
muscular O O 0.9999867677688599
dystrophy O O 0.9999816417694092
and O O 0.9999567270278931
its O O 0.9999854564666748
treatment O O 0.9999721050262451
with O O 0.9998878240585327
high O O 0.9989463686943054
doses O O 0.9981184005737305
anabolizing O O 0.5989230871200562
agents O O 0.9315462112426758
. O O 0.9997979998588562

We O O 0.9999812841415405
are O O 0.9999963045120239
still O O 0.9999984502792358
a O O 0.9999953508377075
long O O 0.9999957084655762
way O O 0.9999972581863403
from O O 0.9999980926513672
discovering O O 0.9999914169311523
an O O 0.9999887943267822
unequivocal O O 0.9999790191650391
pathogenetic O O 0.9999909400939941
interpretation O O 0.9999948740005493
of O O 0.9999474287033081
progressive O O 0.9999501705169678
muscular O O 0.9999840259552002
dystrophy O O 0.9999909400939941
in O O 0.9999428987503052
man O O 0.9999842643737793
. O O 0.9999595880508423

Noteworthy O O 0.999932050704956
efforts O O 0.9999943971633911
have O O 0.9999920129776001
been O O 0.9999964237213135
made O O 0.9999986886978149
in O O 0.9999918937683105
the O O 0.9999916553497314
experimental O O 0.9999887943267822
field O O 0.9999979734420776
; O O 0.999980092048645
a O O 0.9999667406082153
recessive O O 0.9997748732566833
autosomic O O 0.9996861219406128
form O O 0.9999959468841553
found O O 0.9999712705612183
in O O 0.9999853372573853
the O O 0.9999943971633911
mouse O O 0.9999938011169434
seems O O 0.9999643564224243
to O O 0.9999420642852783
bear O O 0.9999876022338867
the O O 0.9999947547912598
closest O O 0.9999961853027344
resemblance O O 0.9999977350234985
to O O 0.9999926090240479
the O O 0.9999927282333374
human O O 0.9999669790267944
form O O 0.9999957084655762
from O O 0.9999934434890747
the O O 0.9999880790710449
genetic O O 0.999988317489624
point O O 0.9999819993972778
of O O 0.9999822378158569
view O O 0.9999920129776001
. O O 0.9999696016311646

Myopathy O O 0.999904990196228
due O O 0.9999784231185913
to O O 0.9998760223388672
lack O O 0.9998266100883484
of O O 0.9986745119094849
vitamin B B 0.5462451577186584
E I I 0.9997089505195618
and O O 0.9988033771514893
myopathy O O 0.9999922513961792
induced O O 0.9999771118164062
by O O 0.9998706579208374
certain O O 0.9958251714706421
viruses O O 0.9992064833641052
have O O 0.9999808073043823
much O O 0.9999938011169434
in O O 0.9999910593032837
common O O 0.9999866485595703
anatomically O O 0.9999864101409912
and O O 0.9999831914901733
pathologically O O 0.9999897480010986
with O O 0.9999890327453613
the O O 0.9999829530715942
human O O 0.9998146891593933
form O O 0.9999892711639404
. O O 0.9999673366546631

The O O 0.9997243285179138
authors O O 0.548557460308075
induced O O 0.999858021736145
myodystrophy O O 0.9999779462814331
in O O 0.9999909400939941
the O O 0.9999909400939941
rat O O 0.9999936819076538
by O O 0.999951958656311
giving O O 0.9999232292175293
it O O 0.9999561309814453
a O O 0.9998823404312134
diet O O 0.9990966320037842
lacking O O 0.9995445609092712
in O O 0.9892732501029968
vitamin B B 0.6610277891159058
E I I 0.9997884631156921
. O O 0.9996601343154907

The O O 0.9999397993087769
pharmacological O O 0.9987046718597412
characteristics O O 0.9999220371246338
of O O 0.9984524250030518
vitamin B B 0.796002984046936
E I I 0.9999109506607056
and O O 0.9986296892166138
the O O 0.9999501705169678
degenerative O O 0.9999731779098511
changes O O 0.9999951124191284
brought O O 0.9999960660934448
about O O 0.9999954700469971
by O O 0.9998987913131714
its O O 0.9763839840888977
deficiency O O 0.9998325109481812
, O O 0.9999867677688599
especially O O 0.9999758005142212
in O O 0.9999375343322754
the O O 0.9999727010726929
muscles O O 0.9999561309814453
, O O 0.9999884366989136
are O O 0.9999638795852661
illustrated O O 0.999956488609314
. O O 0.9999622106552124

It O O 0.9999804496765137
is O O 0.9999730587005615
thus O O 0.9999896287918091
confirmed O O 0.9999887943267822
that O O 0.9999749660491943
the O O 0.999988317489624
histological O O 0.9999691247940063
characteristics O O 0.9999903440475464
of O O 0.999961256980896
myopathic O O 0.9999786615371704
rat O O 0.9995111227035522
muscle O O 0.9998378753662109
induced O O 0.999970555305481
experimentally O O 0.9999560117721558
are O O 0.9999548196792603
extraordinarily O O 0.9999693632125854
similar O O 0.9999936819076538
to O O 0.9999758005142212
those O O 0.9999709129333496
of O O 0.9999637603759766
human O O 0.9998908042907715
myopathy O O 0.9999902248382568
as O O 0.9999867677688599
confirmed O O 0.9999955892562866
during O O 0.9999890327453613
biopsies O O 0.9998302459716797
performed O O 0.9999911785125732
at O O 0.9999727010726929
the O O 0.9999936819076538
Orthopaedic O O 0.9999545812606812
Traumatological O O 0.9999964237213135
Centre O O 0.9999972581863403
, O O 0.9999216794967651
Florence O O 0.9916540384292603
. O O 0.9999674558639526

The O O 0.9999833106994629
encouraging O O 0.9999865293502808
results O O 0.9999966621398926
obtained O O 0.9999982118606567
in O O 0.9999411106109619
various O O 0.9997650980949402
authoratative O O 0.9080337882041931
departments O O 0.9956690073013306
in O O 0.9998514652252197
myopathic O O 0.9999631643295288
patients O O 0.9999904632568359
by O O 0.9999574422836304
using O O 0.9998164772987366
anabolizing O O 0.476650595664978
steroids B B 0.8836138844490051
have O O 0.9991306662559509
encouraged O O 0.999984622001648
the O O 0.9999932050704956
authors O O 0.999996542930603
to O O 0.9999891519546509
investigate O O 0.9999734163284302
the O O 0.9999687671661377
beneficial O O 0.9999566078186035
effects O O 0.9999769926071167
of O O 0.9998753070831299
one O O 0.9978107810020447
anabolizing O O 0.6330322027206421
agent O O 0.9168460965156555
( O O 0.9984108209609985
Dianabol B B 0.989458441734314
, O O 0.8570748567581177
CIBA B B 0.971331000328064
) O O 0.9997377991676331
at O O 0.9999281167984009
high O O 0.9999082088470459
doses O O 0.999896764755249
in O O 0.9999470710754395
rats O O 0.9999817609786987
rendered O O 0.9999687671661377
myopathic O O 0.9999853372573853
by O O 0.9999597072601318
a O O 0.9999628067016602
diet O O 0.9995272159576416
deficient O O 0.9999828338623047
in O O 0.9966020584106445
vitamin B B 0.6162949800491333
E I I 0.9998181462287903
. O O 0.9996870756149292

In O O 0.9999743700027466
this O O 0.9999868869781494
way O O 0.9999912977218628
they O O 0.9999933242797852
obtained O O 0.9999963045120239
appreciable O O 0.9999949932098389
changes O O 0.9999994039535522
in O O 0.9999979734420776
body O O 0.9999974966049194
weight O O 0.9999966621398926
( O O 0.9999713897705078
increased O O 0.9999963045120239
from O O 0.9999908208847046
50 O O 0.9999970197677612
to O O 0.9999841451644897
70 O O 0.9999961853027344
g O O 0.9999982118606567
after O O 0.9999656677246094
forty O O 0.9999949932098389
days O O 0.9999960660934448
at O O 0.9999653100967407
a O O 0.999992847442627
dose O O 0.999950647354126
of O O 0.9999207258224487
5 O O 0.9997245669364929
mg O O 0.9999301433563232
per O O 0.9999741315841675
day O O 0.9999938011169434
of O O 0.9992154836654663
anabolizing O O 0.5306682586669922
agent O O 0.7886414527893066
) O O 0.9998112320899963
, O O 0.9999674558639526
but O O 0.9999872446060181
most O O 0.9999918937683105
of O O 0.9999879598617554
all O O 0.9999793767929077
they O O 0.9999970197677612
found O O 0.9999611377716064
histological O O 0.9999575614929199
changes O O 0.9999964237213135
due O O 0.999984860420227
to O O 0.9998939037322998
" O O 0.9999276399612427
regenerative O O 0.9992408752441406
" O O 0.999977707862854
changes O O 0.9999943971633911
in O O 0.9999449253082275
the O O 0.9999687671661377
muscle O O 0.9999434947967529
tissue O O 0.999994158744812
, O O 0.9999793767929077
which O O 0.9999260902404785
however O O 0.9998422861099243
maintained O O 0.999936580657959
its O O 0.9999202489852905
myopathic O O 0.9999951124191284
characteristics O O 0.99998939037323
in O O 0.9998706579208374
the O O 0.9999405145645142
control O O 0.9993435740470886
animals O O 0.9999918937683105
that O O 0.9999840259552002
were O O 0.999995231628418
not O O 0.9999939203262329
treated O O 0.9999849796295166
with O O 0.9999529123306274
the O O 0.9999289512634277
anabolizing O O 0.6176134347915649
agent O O 0.8123329281806946
. O O 0.9999747276306152

The O O 0.9999841451644897
authors O O 0.9999967813491821
conclude O O 0.9999945163726807
by O O 0.9999865293502808
affirming O O 0.9984874725341797
the O O 0.9999915361404419
undoubted O O 0.9999821186065674
efficacy O O 0.9999936819076538
of O O 0.9999098777770996
the O O 0.9995474219322205
anabolizing O O 0.5895819664001465
steroids B B 0.9712581634521484
in O O 0.999535083770752
experimental O O 0.9998666048049927
myopathic O O 0.9999943971633911
disease O O 0.9999933242797852
, O O 0.9999783039093018
but O O 0.999977707862854
they O O 0.9999903440475464
have O O 0.9999877214431763
reservations O O 0.9999927282333374
as O O 0.9999992847442627
to O O 0.9999961853027344
the O O 0.9999970197677612
transfer O O 0.9999988079071045
of O O 0.9999988079071045
the O O 0.9999977350234985
results O O 0.9999905824661255
into O O 0.9999899864196777
the O O 0.9999836683273315
human O O 0.9999673366546631
field O O 0.9999947547912598
, O O 0.9999945163726807
where O O 0.9999864101409912
high O O 0.9998278617858887
dosage O O 0.9999563694000244
cannot O O 0.9999744892120361
be O O 0.999994158744812
carried O O 0.9999959468841553
out O O 0.9999901056289673
continuously O O 0.999982476234436
because O O 0.9999935626983643
of O O 0.9999780654907227
the O O 0.9999839067459106
effects O O 0.9999761581420898
of O O 0.9999570846557617
the O O 0.9999667406082153
drug O O 0.9988166093826294
on O O 0.999414324760437
virility O O 0.9937228560447693
; O O 0.9999890327453613
because O O 0.9999936819076538
the O O 0.999964714050293
tissue O O 0.9999738931655884
injury O O 0.9999933242797852
too O O 0.9999377727508545
often O O 0.999984622001648
occurs O O 0.9999899864196777
at O O 0.999969482421875
an O O 0.9999505281448364
irreversible O O 0.999984860420227
stage O O 0.9999939203262329
vis O O 0.9990384578704834
- O O 0.9997449517250061
a O O 0.9945657253265381
- O O 0.9995313882827759
vis O O 0.991121768951416
the O O 0.9999598264694214
" O O 0.9999649524688721
regeneration O O 0.9999960660934448
" O O 0.999995231628418
of O O 0.9999504089355469
the O O 0.9999721050262451
muscle O O 0.9999628067016602
tissue O O 0.999994158744812
; O O 0.9999737739562988
and O O 0.9999780654907227
finally O O 0.9999912977218628
because O O 0.9999914169311523
the O O 0.9998680353164673
dystrophic O O 0.9995442032814026
injurious O O 0.9997648596763611
agent O O 0.9998846054077148
is O O 0.9998856782913208
certainly O O 0.9999207258224487
not O O 0.9999551773071289
the O O 0.9987673759460449
lack O O 0.9955893754959106
of O O 0.9917784333229065
vitamin B B 0.770535409450531
E I I 0.9997774958610535
but O O 0.9954494833946228
something O O 0.9999849796295166
as O O 0.9999971389770508
yet O O 0.999998927116394
unknown O O 0.9999659061431885
. O O 0.999984622001648

Paclitaxel B B 0.9995198249816895
3 O O 0.9942811727523804
- O O 0.9998514652252197
hour O O 0.9896780252456665
infusion O O 0.9998403787612915
given O O 0.9999405145645142
alone O O 0.9998444318771362
and O O 0.9999830722808838
combined O O 0.9999649524688721
with O O 0.9996404647827148
carboplatin B B 0.9998034834861755
: O O 0.9999480247497559
preliminary O O 0.9999994039535522
results O O 0.9999991655349731
of O O 0.9999951124191284
dose O O 0.999743640422821
- O O 0.9999281167984009
escalation O O 0.9998424053192139
trials O O 0.9999921321868896
. O O 0.999984860420227

Paclitaxel B B 0.9997280240058899
( O O 0.9866355061531067
Taxol B B 0.999203622341156
; O O 0.9012336730957031
Bristol O B 0.7102084159851074
- O I 0.6109358072280884
Myers O I 0.9686505794525146
Squibb O O 0.8144789934158325
Company O O 0.7148237228393555
, O O 0.6213310360908508
Princeton O O 0.6873580813407898
, O O 0.9151730537414551
NJ O O 0.8131840825080872
) O O 0.9991214871406555
by O O 0.9999337196350098
3 O O 0.998814582824707
- O O 0.9999624490737915
hour O O 0.9992252588272095
infusion O O 0.9999239444732666
was O O 0.9999799728393555
combined O O 0.9999700784683228
with O O 0.9996665716171265
carboplatin B B 0.9997536540031433
in O O 0.9998970031738281
a O O 0.9999830722808838
phase O O 0.9999688863754272
I O O 0.9998207688331604
/ O O 0.9998548030853271
II O O 0.9999629259109497
study O O 0.9999878406524658
directed O O 0.9999959468841553
to O O 0.9999827146530151
patients O O 0.9999963045120239
with O O 0.9999946355819702
non O O 0.999363362789154
- O O 0.9999028444290161
small O O 0.9997957348823547
cell O O 0.9999359846115112
lung O O 0.9997430443763733
cancer O O 0.9999736547470093
. O O 0.999976634979248

Carboplatin B B 0.9993452429771423
was O O 0.9998364448547363
given O O 0.9999687671661377
at O O 0.9999665021896362
a O O 0.9999855756759644
fixed O O 0.9999791383743286
target O O 0.9999767541885376
area O O 0.9999716281890869
under O O 0.9999957084655762
the O O 0.9999808073043823
concentration O O 0.9990442395210266
- O O 0.9999532699584961
time O O 0.9999755620956421
curve O O 0.9999722242355347
of O O 0.999958872795105
6 O O 0.999799907207489
. O O 0.999995231628418
0 O O 0.9999803304672241
by O O 0.9999361038208008
the O O 0.9998781681060791
Calvert O O 0.6863845586776733
formula O O 0.9846141338348389
, O O 0.9999393224716187
whereas O O 0.9994907379150391
paclitaxel B B 0.9998836517333984
was O O 0.9999427795410156
escalated O O 0.9999642372131348
in O O 0.9999643564224243
patient O O 0.9999514818191528
cohorts O O 0.9998494386672974
from O O 0.9999886751174927
150 O O 0.9999632835388184
mg O O 0.9999649524688721
/ O O 0.9999450445175171
m2 O O 0.9999948740005493
( O O 0.9999316930770874
dose O O 0.9997808337211609
level O O 0.9999480247497559
I O O 0.9912418127059937
) O O 0.9999747276306152
to O O 0.9999594688415527
175 O O 0.9998598098754883
, O O 0.9998434782028198
200 O O 0.9745937585830688
, O O 0.9996140599250793
225 O O 0.9966975450515747
, O O 0.9998800754547119
and O O 0.999854326248169
250 O O 0.9999572038650513
mg O O 0.9999891519546509
/ O O 0.999990701675415
m2 O O 0.9999963045120239
. O O 0.9999680519104004

The O O 0.9999799728393555
225 O O 0.9994001388549805
mg O O 0.9999067783355713
/ O O 0.9997738003730774
m2 O O 0.9999884366989136
level O O 0.999869704246521
was O O 0.9999514818191528
expanded O O 0.9993492960929871
for O O 0.999972939491272
the O O 0.9999961853027344
phase O O 0.9999735355377197
II O O 0.9998331069946289
study O O 0.999992847442627
since O O 0.9999836683273315
the O O 0.9999979734420776
highest O O 0.9999884366989136
level O O 0.9999799728393555
achieved O O 0.999966025352478
( O O 0.9999827146530151
250 O O 0.9999656677246094
mg O O 0.9999562501907349
/ O O 0.9999667406082153
m2 O O 0.9999910593032837
) O O 0.9999698400497437
required O O 0.9999665021896362
modification O O 0.9999914169311523
because O O 0.9999905824661255
of O O 0.9999816417694092
nonhematologic O O 0.9927109479904175
toxicities O O 0.9997225403785706
( O O 0.9998879432678223
arthralgia O O 0.9997996687889099
and O O 0.9999173879623413
sensory O O 0.9998960494995117
neuropathy O O 0.9999929666519165
) O O 0.9999765157699585
. O O 0.999969482421875

Therapeutic O O 0.9997441172599792
effects O O 0.9999856948852539
were O O 0.9999805688858032
noted O O 0.9999924898147583
at O O 0.999933123588562
all O O 0.9998992681503296
dose O O 0.9992109537124634
levels O O 0.9999622106552124
, O O 0.9999799728393555
with O O 0.9999904632568359
objective O O 0.999964714050293
responses O O 0.9999932050704956
in O O 0.9999502897262573
17 O O 0.999718964099884
( O O 0.9999306201934814
two O O 0.9999634027481079
complete O O 0.9998608827590942
and O O 0.9999281167984009
15 O O 0.999894380569458
partial O O 0.999950647354126
regressions O O 0.9999711513519287
) O O 0.9999804496765137
of O O 0.9999760389328003
41 O O 0.999993085861206
previously O O 0.99997878074646
untreated O O 0.9999765157699585
patients O O 0.9999954700469971
. O O 0.9999778270721436

Toxicities O O 0.9998553991317749
were O O 0.9999717473983765
compared O O 0.9999839067459106
with O O 0.9999929666519165
a O O 0.9999920129776001
cohort O O 0.9999727010726929
of O O 0.9999902248382568
patients O O 0.9999947547912598
in O O 0.9999788999557495
a O O 0.9999890327453613
phase O O 0.9999744892120361
I O O 0.9978826642036438
trial O O 0.9999686479568481
of O O 0.9974598288536072
paclitaxel B B 0.9998431205749512
alone O O 0.9982819557189941
at O O 0.9999516010284424
identical O O 0.9999457597732544
dose O O 0.9998568296432495
levels O O 0.9999849796295166
. O O 0.9999768733978271

Carboplatin B B 0.9987516403198242
did O O 0.9999297857284546
not O O 0.9999417066574097
appear O O 0.9999706745147705
to O O 0.9999099969863892
add O O 0.9999698400497437
to O O 0.9999593496322632
the O O 0.9999904632568359
hematologic O O 0.9999880790710449
toxicities O O 0.9999760389328003
observed O O 0.9999947547912598
, O O 0.9999617338180542
and O O 0.9999740123748779
the O O 0.9997934699058533
paclitaxel B B 0.9998353719711304
/ O O 0.7700271010398865
carboplatin B B 0.9991579055786133
combination O O 0.966513991355896
could O O 0.9999599456787109
be O O 0.9999884366989136
dosed O O 0.9999417066574097
every O O 0.9999632835388184
3 O O 0.9999600648880005
weeks O O 0.9999978542327881
. O O 0.9999840259552002

The O O 0.9999161958694458
dose O O 0.9992882609367371
- O O 0.9999550580978394
dependent O O 0.9999746084213257
effect O O 0.9999637603759766
of O O 0.9993927478790283
misoprostol B B 0.9998219609260559
on O O 0.9996121525764465
indomethacin B B 0.9994214773178101
- O O 0.9997921586036682
induced O O 0.9999376535415649
renal O O 0.999990701675415
dysfunction O O 0.9999978542327881
in O O 0.9999467134475708
well O O 0.9970934391021729
compensated O O 0.9998600482940674
cirrhosis O O 0.9975119829177856
. O O 0.9999605417251587

Misoprostol B B 0.9994031190872192
( O O 0.9990639090538025
200 O O 0.9980323910713196
micrograms O O 0.9987057447433472
) O O 0.9997733235359192
has O O 0.9998564720153809
been O O 0.9999818801879883
shown O O 0.9999653100967407
to O O 0.999881386756897
acutely O O 0.9998099207878113
counteract O O 0.9998840093612671
the O O 0.999947190284729
indomethacin B B 0.9988998174667358
- O O 0.9996694326400757
induced O O 0.9999325275421143
renal O O 0.9999866485595703
dysfunction O O 0.999996542930603
in O O 0.9999234676361084
well O O 0.9965071082115173
compensated O O 0.9999607801437378
cirrhotic O O 0.9996094107627869
patients O O 0.9999858140945435
. O O 0.9999746084213257

The O O 0.9999914169311523
aim O O 0.9999969005584717
of O O 0.9999949932098389
this O O 0.9999916553497314
study O O 0.9999908208847046
was O O 0.9999957084655762
to O O 0.9999961853027344
determine O O 0.9999963045120239
if O O 0.9999878406524658
the O O 0.9999905824661255
prophylactic O O 0.9999507665634155
value O O 0.9999849796295166
of O O 0.9995657801628113
misoprostol B B 0.9996950626373291
was O O 0.9999152421951294
dose O O 0.9997040629386902
- O O 0.999940037727356
dependent O O 0.9999713897705078
. O O 0.9999814033508301

Parameters O O 0.9999479055404663
of O O 0.9999536275863647
renal O O 0.9999397993087769
hemodynamics O O 0.9999196529388428
and O O 0.9999325275421143
tubular O O 0.9999768733978271
sodium B B 0.9845635890960693
and O O 0.9928597807884216
water O B 0.8994824886322021
handling O O 0.998474657535553
were O O 0.9999769926071167
assessed O O 0.9999914169311523
by O O 0.9999587535858154
clearance O O 0.9995653033256531
techniques O O 0.9999921321868896
in O O 0.9999762773513794
26 O O 0.9999630451202393
well O O 0.9990509152412415
compensated O O 0.9998950958251953
cirrhotic O O 0.9995775818824768
patients O O 0.9999949932098389
before O O 0.9999358654022217
and O O 0.9999866485595703
after O O 0.9999637603759766
an O O 0.9999809265136719
oral O O 0.9997389912605286
combination O O 0.9971893429756165
of O O 0.9996516704559326
50 O O 0.9994992017745972
mg O O 0.9994064569473267
of O O 0.9938150644302368
indomethacin B B 0.999043881893158
and O O 0.9927263259887695
various O O 0.9999676942825317
doses O O 0.9999175071716309
of O O 0.9978926777839661
misoprostol B B 0.999466598033905
. O O 0.999924898147583

The O O 0.9999321699142456
200 O O 0.9981215596199036
- O O 0.999202311038971
micrograms O O 0.997184693813324
dose O O 0.9993492960929871
was O O 0.9999445676803589
able O O 0.9999523162841797
to O O 0.9999356269836426
totally O O 0.9999029636383057
abolish O O 0.9999827146530151
the O O 0.9999434947967529
deleterious O O 0.9999303817749023
renal O O 0.9998949766159058
effects O O 0.9999606609344482
of O O 0.9997829794883728
indomethacin B B 0.9994254112243652
, O O 0.999832272529602
whereas O O 0.999976634979248
the O O 0.9999299049377441
800 O O 0.989487886428833
- O O 0.9995115995407104
micrograms O O 0.9982333183288574
dose O O 0.999605119228363
resulted O O 0.9999709129333496
in O O 0.9999680519104004
significant O O 0.9999799728393555
worsening O O 0.9999910593032837
of O O 0.9999796152114868
renal O O 0.9999827146530151
hemodynamics O O 0.9999772310256958
and O O 0.9999761581420898
sodium B B 0.993802011013031
retention O O 0.9998617172241211
. O O 0.999976396560669

These O O 0.9999680519104004
changes O O 0.9999866485595703
were O O 0.9999723434448242
maximal O O 0.9999020099639893
in O O 0.999964714050293
the O O 0.9999681711196899
hour O O 0.9999209642410278
immediately O O 0.999981164932251
after O O 0.9999123811721802
medications O O 0.9996376037597656
and O O 0.9999539852142334
slowly O O 0.999992847442627
returned O O 0.9999958276748657
toward O O 0.9999942779541016
base O O 0.9999514818191528
- O O 0.999982476234436
line O O 0.9999740123748779
levels O O 0.9999879598617554
thereafter O O 0.9999855756759644
. O O 0.9999827146530151

These O O 0.9999817609786987
results O O 0.9999878406524658
suggest O O 0.9999643564224243
that O O 0.9999333620071411
the O O 0.9999666213989258
renal O O 0.999903678894043
protective O O 0.9994297623634338
effects O O 0.9999496936798096
of O O 0.9997462630271912
misoprostol B B 0.9994978904724121
is O O 0.9998272061347961
dose O O 0.9993821382522583
- O O 0.9998773336410522
dependent O O 0.9999785423278809
. O O 0.999976634979248

However O O 0.9999785423278809
, O O 0.9999897480010986
until O O 0.9999740123748779
this O O 0.9999872446060181
apparent O O 0.9999896287918091
ability O O 0.9999786615371704
of O O 0.9998486042022705
200 O O 0.9986464381217957
micrograms O O 0.9997010231018066
of O O 0.9953591227531433
misoprostol B B 0.9996399879455566
to O O 0.9997653365135193
prevent O O 0.9994219541549683
the O O 0.9999717473983765
adverse O O 0.9999556541442871
effects O O 0.9999710321426392
of O O 0.9998748302459717
indomethacin B B 0.9987792372703552
on O O 0.9995749592781067
renal O O 0.9999592304229736
function O O 0.9999867677688599
is O O 0.9999905824661255
confirmed O O 0.9999955892562866
with O O 0.9999752044677734
chronic O O 0.9999550580978394
frequent O O 0.9998835325241089
dosing O O 0.9999165534973145
, O O 0.999987006187439
it O O 0.9999972581863403
would O O 0.9999957084655762
be O O 0.9999977350234985
prudent O O 0.9999957084655762
to O O 0.9999902248382568
avoid O O 0.9998327493667603
nonsteroidal O O 0.6195890307426453
anti O O 0.4235706031322479
- O O 0.8895915150642395
inflammatory O O 0.977724552154541
therapy O O 0.9998409748077393
in O O 0.9999712705612183
patients O O 0.9999960660934448
with O O 0.9999874830245972
cirrhosis O O 0.9989053010940552
. O O 0.9999779462814331

Increased O O 0.9999792575836182
frequency O O 0.9999972581863403
and O O 0.9999899864196777
severity O O 0.9999963045120239
of O O 0.9999837875366211
angio O O 0.9996323585510254
- O O 0.9983270764350891
oedema O O 0.9945108890533447
related O O 0.9999940395355225
to O O 0.9999074935913086
long O O 0.9998730421066284
- O O 0.9999886751174927
term O O 0.9999752044677734
therapy O O 0.9999903440475464
with O O 0.9998425245285034
angiotensin B B 0.9828020930290222
- I O 0.6968005895614624
converting I O 0.7143682241439819
enzyme I O 0.6916864514350891
inhibitor I O 0.891133725643158
in O O 0.9988349080085754
two O O 0.9999815225601196
patients O O 0.9999926090240479
. O O 0.9999650716781616

Adverse O O 0.9995328187942505
reactions O O 0.9999841451644897
to O O 0.9993218183517456
drugs O O 0.9972146153450012
are O O 0.9998840093612671
well O O 0.9998483657836914
recognized O O 0.9999691247940063
as O O 0.999962568283081
a O O 0.9999344348907471
cause O O 0.9999722242355347
of O O 0.9999668598175049
acute O O 0.9999830722808838
or O O 0.9999494552612305
chronic O O 0.9999842643737793
urticaria O O 0.999988317489624
, O O 0.9999330043792725
and O O 0.9999099969863892
angio O O 0.9995824694633484
- O O 0.9992396831512451
oedema O O 0.9970651268959045
. O O 0.9999557733535767

Angiotensin B B 0.9129257202148438
- I I 0.7248803973197937
converting I I 0.8116339445114136
enzyme I I 0.8758198618888855
( I I 0.6834400296211243
ACE I I 0.5159617066383362
) I I 0.8252626061439514
inhibitors I I 0.9370342493057251
, O O 0.996994137763977
used O O 0.9995118379592896
to O O 0.9996801614761353
treat O O 0.9996803998947144
hypertension O O 0.992741048336029
and O O 0.9999094009399414
congestive O O 0.9961507320404053
heart O O 0.9999936819076538
failure O O 0.9999862909317017
, O O 0.9999774694442749
were O O 0.9999481439590454
introduced O O 0.9999159574508667
in O O 0.9997873902320862
Europe O O 0.991574227809906
in O O 0.9999895095825195
the O O 0.9999959468841553
middle O O 0.9999977350234985
of O O 0.9999934434890747
the O O 0.9999973773956299
eighties O O 0.9999821186065674
, O O 0.9999696016311646
and O O 0.9999884366989136
the O O 0.9999933242797852
use O O 0.9999774694442749
of O O 0.9998503923416138
these O O 0.9993736147880554
drugs O O 0.9958964586257935
has O O 0.9999735355377197
increased O O 0.9999833106994629
progressively O O 0.9999964237213135
. O O 0.9999779462814331

Soon O O 0.9999865293502808
after O O 0.9999817609786987
the O O 0.9999918937683105
introduction O O 0.999976634979248
of O O 0.9998210072517395
ACE B O 0.6325095295906067
inhibitors I O 0.9233526587486267
, O O 0.9990799427032471
acute O O 0.9999771118164062
bouts O O 0.9999921321868896
of O O 0.9999806880950928
angio O O 0.9997642636299133
- O O 0.9992815852165222
oedema O O 0.9947580695152283
were O O 0.9999839067459106
reported O O 0.9999970197677612
in O O 0.9999873638153076
association O O 0.9999814033508301
with O O 0.9999305009841919
the O O 0.9999788999557495
use O O 0.9998879432678223
of O O 0.999738872051239
these O O 0.9959185719490051
drugs O O 0.9921643733978271
. O O 0.9999475479125977

We O O 0.9999580383300781
wish O O 0.9999905824661255
to O O 0.9999886751174927
draw O O 0.9999939203262329
attention O O 0.9999890327453613
to O O 0.9999841451644897
the O O 0.9999889135360718
possibility O O 0.9999903440475464
of O O 0.9999852180480957
adverse O O 0.9999524354934692
reactions O O 0.9999927282333374
to O O 0.999832272529602
ACE B O 0.6616595387458801
inhibitors I O 0.8347527980804443
after O O 0.9989315867424011
long O O 0.9998024106025696
- O O 0.9999879598617554
term O O 0.9999600648880005
use O O 0.9999501705169678
and O O 0.9999878406524658
in O O 0.9999690055847168
patients O O 0.999991774559021
with O O 0.9999790191650391
pre O O 0.9984495639801025
- O O 0.999984622001648
existing O O 0.9999936819076538
angio O O 0.9995923638343811
- O O 0.9994301199913025
oedema O O 0.9967917799949646
. O O 0.9999697208404541

Myoclonus O O 0.9999502897262573
associated O O 0.999984622001648
with O O 0.9998441934585571
lorazepam B B 0.9994800686836243
therapy O O 0.9994180202484131
in O O 0.9999651908874512
very O O 0.9999896287918091
- O O 0.9999608993530273
low O O 0.9999945163726807
- O O 0.9999905824661255
birth O O 0.9999983310699463
- O O 0.999996542930603
weight O O 0.9999902248382568
infants O O 0.9999988079071045
. O O 0.999954104423523

Lorazepam B B 0.9980846643447876
is O O 0.9997473359107971
being O O 0.9999861717224121
used O O 0.9999175071716309
with O O 0.9999799728393555
increasing O O 0.9999809265136719
frequency O O 0.9999302625656128
as O O 0.9999212026596069
a O O 0.9978892207145691
sedative O O 0.8906096816062927
in O O 0.9997811913490295
the O O 0.9999892711639404
newborn O O 0.999997615814209
and O O 0.9999825954437256
the O O 0.9999959468841553
young O O 0.9999984502792358
infant O O 0.999998927116394
. O O 0.9998273849487305

Concern O O 0.9999759197235107
has O O 0.9999915361404419
been O O 0.9999974966049194
raised O O 0.9999984502792358
with O O 0.9999959468841553
regard O O 0.999997615814209
to O O 0.9999855756759644
the O O 0.9999948740005493
safety O O 0.9999873638153076
of O O 0.9992668032646179
lorazepam B B 0.9994822144508362
in O O 0.999874472618103
this O O 0.999994158744812
age O O 0.9999910593032837
group O O 0.9999955892562866
, O O 0.9999885559082031
especially O O 0.9999866485595703
in O O 0.9999825954437256
very O O 0.9999669790267944
- O O 0.9999436140060425
low O O 0.9999548196792603
- O O 0.9999445676803589
birth O O 0.9999966621398926
- O O 0.999987006187439
weight O O 0.9999890327453613
( O O 0.9998356103897095
VLBW O O 0.9796271324157715
; O O 0.9999707937240601
< O O 0.9999967813491821
1 O O 0.9999986886978149
, O O 0.9999973773956299
500 O O 0.9999974966049194
g O O 0.999994158744812
) O O 0.9999752044677734
infants O O 0.9999992847442627
. O O 0.9999847412109375

Three O O 0.9999865293502808
young O O 0.9999979734420776
infants O O 0.9999991655349731
, O O 0.9999947547912598
all O O 0.9999803304672241
of O O 0.9999833106994629
birth O O 0.9999964237213135
weight O O 0.999994158744812
< O O 0.9999579191207886
1 O O 0.9999983310699463
, O O 0.9999994039535522
500 O O 0.9999990463256836
g O O 0.9999974966049194
, O O 0.9999874830245972
experienced O O 0.999972939491272
myoclonus O O 0.9999992847442627
following O O 0.9999617338180542
the O O 0.9999783039093018
intravenous O O 0.9999836683273315
administration O O 0.9999525547027588
of O O 0.9982753992080688
lorazepam B B 0.9993730187416077
. O O 0.9999099969863892

The O O 0.9999754428863525
potential O O 0.9999562501907349
neurotoxic O O 0.9999878406524658
effects O O 0.999975323677063
of O O 0.9999091625213623
the O O 0.9998939037322998
drug O O 0.9980742931365967
( O O 0.9999041557312012
and O O 0.9998687505722046
its O O 0.9995410442352295
vehicle O O 0.9997661709785461
) O O 0.9999622106552124
in O O 0.9998003840446472
this O O 0.999890923500061
population O O 0.9990817308425903
are O O 0.9999544620513916
discussed O O 0.9999644756317139
. O O 0.9999761581420898

Injectable O O 0.9995321035385132
lorazepam B B 0.9995162487030029
should O O 0.9997426867485046
be O O 0.9999940395355225
used O O 0.9999819993972778
with O O 0.9999853372573853
caution O O 0.9999840259552002
in O O 0.9998661279678345
VLBW O O 0.9473308324813843
infants O O 0.9999375343322754
. O O 0.9999511241912842

Transvenous O O 0.9998370409011841
right O O 0.9999732971191406
ventricular O O 0.9999613761901855
pacing O O 0.9998513460159302
during O O 0.999919056892395
cardiopulmonary O O 0.9999884366989136
resuscitation O O 0.9999836683273315
of O O 0.9999760389328003
pediatric O O 0.9999958276748657
patients O O 0.9999954700469971
with O O 0.9999877214431763
acute O O 0.9999685287475586
cardiomyopathy O O 0.9999880790710449
. O O 0.9998778104782104

We O O 0.999987006187439
describe O O 0.9999929666519165
the O O 0.9999477863311768
cardiopulmonary O O 0.9999361038208008
resuscitation O O 0.9995019435882568
efforts O O 0.9999337196350098
on O O 0.9998899698257446
five O O 0.9999915361404419
patients O O 0.999995231628418
who O O 0.9999701976776123
presented O O 0.9999926090240479
in O O 0.9999881982803345
acute O O 0.999988317489624
circulatory O O 0.999874472618103
failure O O 0.9999974966049194
from O O 0.9999563694000244
myocardial O O 0.9999964237213135
dysfunction O O 0.999983549118042
. O O 0.9999775886535645

Three O O 0.9999053478240967
patients O O 0.999990701675415
had O O 0.9999555349349976
acute O O 0.9999068975448608
viral O O 0.9999724626541138
myocarditis O O 0.999997615814209
, O O 0.9999585151672363
one O O 0.9999499320983887
had O O 0.9999525547027588
a O O 0.9999041557312012
carbamazepine B B 0.9986656904220581
- O O 0.9997223019599915
induced O O 0.9999499320983887
acute O O 0.999941349029541
eosinophilic O O 0.9961889386177063
myocarditis O O 0.9999970197677612
, O O 0.9998816251754761
and O O 0.9999290704727173
one O O 0.9998089671134949
had O O 0.9999440908432007
cardiac O O 0.9991199374198914
hemosiderosis O O 0.9550286531448364
resulting O O 0.99997878074646
in O O 0.9999849796295166
acute O O 0.999985933303833
cardiogenic O O 0.9999969005584717
shock O O 0.9999945163726807
. O O 0.9999779462814331

All O O 0.9999576807022095
patients O O 0.9999877214431763
were O O 0.9999880790710449
continuously O O 0.9999856948852539
monitored O O 0.9999943971633911
with O O 0.9999831914901733
central O O 0.999945878982544
venous O O 0.9999788999557495
and O O 0.9998660087585449
arterial O O 0.996953010559082
catheters O O 0.9999305009841919
in O O 0.999976634979248
addition O O 0.9999830722808838
to O O 0.9999836683273315
routine O O 0.9999828338623047
noninvasive O O 0.9999136924743652
monitoring O O 0.9999946355819702
. O O 0.9999815225601196

An O O 0.9999592304229736
introducer O O 0.9999780654907227
sheath O O 0.9999809265136719
, O O 0.9999208450317383
a O O 0.9997391104698181
pacemaker O O 0.993811845779419
, O O 0.9997428059577942
and O O 0.999883770942688
sterile O O 0.9993958473205566
pacing O O 0.9999793767929077
wires O O 0.9999767541885376
were O O 0.9999405145645142
made O O 0.9999960660934448
readily O O 0.9999948740005493
available O O 0.9999899864196777
for O O 0.9999575614929199
the O O 0.9999856948852539
patients O O 0.999972939491272
, O O 0.99997878074646
should O O 0.9999955892562866
the O O 0.9999929666519165
need O O 0.9999943971633911
arise O O 0.9999977350234985
to O O 0.9999725818634033
terminate O O 0.9998173117637634
resistant O O 0.9980900883674622
cardiac O O 0.9999518394470215
dysrhythmias O O 0.9999946355819702
. O O 0.9999618530273438

All O O 0.9999184608459473
patients O O 0.9999854564666748
developed O O 0.9999847412109375
cardiocirculatory O O 0.9999934434890747
arrest O O 0.9999926090240479
associated O O 0.9999864101409912
with O O 0.9999773502349854
extreme O O 0.9999632835388184
hypotension O O 0.9999525547027588
and O O 0.9999345541000366
dysrhythmias O O 0.9999938011169434
within O O 0.999970555305481
the O O 0.999991774559021
first O O 0.9999953508377075
48 O O 0.9999963045120239
hours O O 0.9999940395355225
of O O 0.999984622001648
their O O 0.9999935626983643
admission O O 0.9999911785125732
to O O 0.9999747276306152
the O O 0.9999898672103882
pediatric O O 0.9999897480010986
intensive O O 0.9999828338623047
care O O 0.9999895095825195
unit O O 0.9999951124191284
( O O 0.9997954964637756
PICU O O 0.9955045580863953
) O O 0.9999558925628662
. O O 0.9999624490737915

Right O O 0.9998329877853394
ventricular O O 0.9999359846115112
pacemaker O O 0.9989137649536133
wires O O 0.9999104738235474
were O O 0.9999215602874756
inserted O O 0.9999700784683228
in O O 0.9997907280921936
all O O 0.9992533326148987
of O O 0.9996943473815918
them O O 0.9997710585594177
during O O 0.9998550415039062
cardiopulmonary O O 0.9999730587005615
resuscitation O O 0.9999878406524658
( O O 0.9997105002403259
CPR O O 0.8756072521209717
) O O 0.9999266862869263
. O O 0.9999538660049438

In O O 0.9999434947967529
four O O 0.9999810457229614
patients O O 0.9999953508377075
, O O 0.9999285936355591
cardiac O O 0.9989650249481201
pacing O O 0.9975419044494629
was O O 0.9999364614486694
used O O 0.9999619722366333
, O O 0.9999741315841675
resulting O O 0.9999880790710449
in O O 0.9999828338623047
a O O 0.9999854564666748
temporary O O 0.9999510049819946
captured O O 0.999755322933197
rhythm O O 0.9999884366989136
and O O 0.9999632835388184
restoration O O 0.999988317489624
of O O 0.999976634979248
their O O 0.9999514818191528
cardiac O O 0.9998664855957031
output O O 0.9999784231185913
. O O 0.9999656677246094

These O O 0.9999604225158691
patients O O 0.9999889135360718
had O O 0.9999879598617554
a O O 0.9999879598617554
second O O 0.9999963045120239
event O O 0.9999978542327881
of O O 0.9999722242355347
cardiac O O 0.9999094009399414
arrest O O 0.9999909400939941
, O O 0.9999860525131226
resulting O O 0.9999912977218628
in O O 0.9999911785125732
death O O 0.9999938011169434
, O O 0.9999963045120239
within O O 0.9999957084655762
10 O O 0.9999938011169434
to O O 0.9999969005584717
60 O O 0.9999967813491821
minutes O O 0.9999978542327881
. O O 0.9999798536300659

In O O 0.9999624490737915
one O O 0.9999922513961792
patient O O 0.9999959468841553
, O O 0.999940037727356
cardiac O O 0.9993067979812622
pacing O O 0.9981968998908997
was O O 0.9999585151672363
not O O 0.9999628067016602
used O O 0.9999717473983765
, O O 0.9999552965164185
because O O 0.9999943971633911
he O O 0.9999834299087524
converted O O 0.999991774559021
to O O 0.9999922513961792
normal O O 0.9999921321868896
sinus O O 0.9999938011169434
rhythm O O 0.9999954700469971
by O O 0.9999768733978271
electrical O O 0.9999821186065674
defibrillation O O 0.9999858140945435
within O O 0.9999788999557495
three O O 0.9999946355819702
minutes O O 0.999997615814209
of O O 0.9999915361404419
initiating O O 0.9999949932098389
CPR O O 0.703521728515625
. O O 0.9999245405197144

We O O 0.9999696016311646
conclude O O 0.9999850988388062
that O O 0.9998841285705566
cardiac O O 0.998224675655365
pacing O O 0.9502884745597839
during O O 0.9998623132705688
resuscitative O O 0.9999603033065796
efforts O O 0.9999608993530273
in O O 0.9999121427536011
pediatric O O 0.9999825954437256
patients O O 0.9999912977218628
suffering O O 0.9999905824661255
from O O 0.9999792575836182
acute O O 0.9999290704727173
myocardial O O 0.9999973773956299
dysfunction O O 0.999990701675415
may O O 0.9999656677246094
not O O 0.9999674558639526
have O O 0.9999406337738037
long O O 0.9998248219490051
- O O 0.9999865293502808
term O O 0.9999866485595703
value O O 0.9999849796295166
in O O 0.9999918937683105
and O O 0.9999880790710449
of O O 0.999982476234436
itself O O 0.9999885559082031
; O O 0.999980092048645
however O O 0.9999812841415405
, O O 0.999985933303833
if O O 0.9999773502349854
temporary O O 0.9999849796295166
hemodynamic O O 0.9999921321868896
stability O O 0.9999943971633911
is O O 0.9999901056289673
achieved O O 0.9999945163726807
by O O 0.9999877214431763
this O O 0.9999885559082031
procedure O O 0.9999953508377075
, O O 0.9999771118164062
it O O 0.9999840259552002
may O O 0.9999701976776123
provide O O 0.9999858140945435
additional O O 0.9999920129776001
time O O 0.9999825954437256
needed O O 0.9999958276748657
to O O 0.9999853372573853
institute O O 0.9987896084785461
other O O 0.9999343156814575
therapeutic O O 0.9999716281890869
modalities O O 0.9999868869781494
. O O 0.999977707862854

Efficacy O O 0.9999552965164185
and O O 0.9999842643737793
safety O O 0.9999946355819702
of O O 0.9992019534111023
granisetron B B 0.9999010562896729
, O O 0.9997968077659607
a O O 0.9989621639251709
selective O O 0.9900662899017334
5 B B 0.5989751219749451
- I I 0.7631511688232422
hydroxytryptamine I I 0.9788433313369751
- O O 0.7284966707229614
3 O O 0.6536989808082581
receptor O O 0.7948687076568604
antagonist O O 0.8480127453804016
, O O 0.9999644756317139
in O O 0.9999700784683228
the O O 0.999972939491272
prevention O O 0.9999517202377319
of O O 0.99994957447052
nausea O O 0.9999880790710449
and O O 0.9999761581420898
vomiting O O 0.9999781847000122
induced O O 0.9999858140945435
by O O 0.9999467134475708
high O O 0.9994924068450928
- O O 0.9999572038650513
dose O O 0.9958999752998352
cisplatin B B 0.9985839128494263
. O O 0.9997419714927673

PURPOSE O O 0.9999630451202393
: O O 0.9999961853027344
To O O 0.9999964237213135
assess O O 0.9999891519546509
the O O 0.9999792575836182
antiemetic O O 0.8408986330032349
effects O O 0.9998953342437744
and O O 0.9999806880950928
safety O O 0.9999892711639404
profile O O 0.9999963045120239
of O O 0.9999086856842041
four O O 0.998354971408844
different O O 0.999956488609314
doses O O 0.9997193217277527
of O O 0.996878981590271
granisetron B B 0.9998044371604919
( O O 0.9846640229225159
Kytril B B 0.998171329498291
; O O 0.9547088742256165
SmithKline O O 0.7445665001869202
Beecham O O 0.5846393704414368
Pharmaceuticals O O 0.6517053842544556
, O O 0.7897849082946777
Philadelphia O O 0.5975061655044556
, O O 0.6985422372817993
PA O B 0.9302577972412109
) O O 0.9998904466629028
when O O 0.999971866607666
administered O O 0.9999769926071167
as O O 0.9999885559082031
a O O 0.9999840259552002
single O O 0.9999715089797974
intravenous O O 0.9999839067459106
( O O 0.9999244213104248
IV O O 0.9999730587005615
) O O 0.9999735355377197
dose O O 0.9999556541442871
for O O 0.9999746084213257
prophylaxis O O 0.999981164932251
of O O 0.9999679327011108
cisplatin B B 0.9992720484733582
- O O 0.9997655749320984
induced O O 0.9999691247940063
nausea O O 0.9999957084655762
and O O 0.9999881982803345
vomiting O O 0.9999949932098389
. O O 0.9999885559082031

PATIENTS O O 0.9999605417251587
AND O O 0.9999871253967285
METHODS O O 0.9999916553497314
: O O 0.9999969005584717
One O O 0.9999988079071045
hundred O O 0.9999977350234985
eighty O O 0.9998825788497925
- O O 0.9999746084213257
four O O 0.9999880790710449
chemotherapy O O 0.998684823513031
- O O 0.9999681711196899
naive O O 0.9997759461402893
patients O O 0.9999948740005493
receiving O O 0.9999035596847534
high O O 0.9989810585975647
- O O 0.9999626874923706
dose O O 0.9893905520439148
cisplatin B B 0.9992961883544922
( O O 0.9992703795433044
81 O O 0.9974502921104431
to O O 0.999967098236084
120 O O 0.999976634979248
mg O O 0.9999966621398926
/ O O 0.9999878406524658
m2 O O 0.9999980926513672
) O O 0.9999765157699585
were O O 0.9999891519546509
randomized O O 0.9999980926513672
to O O 0.9999850988388062
receive O O 0.9999735355377197
one O O 0.9999865293502808
of O O 0.9999786615371704
four O O 0.9993618130683899
granisetron B B 0.999594509601593
doses O O 0.9996892213821411
( O O 0.999890923500061
5 O O 0.9997500777244568
, O O 0.9989351630210876
10 O O 0.9995597004890442
, O O 0.9974048733711243
20 O O 0.9994875192642212
, O O 0.9995996356010437
or O O 0.9999271631240845
40 O O 0.9999241828918457
micrograms O O 0.999914288520813
/ O O 0.9999474287033081
kg O O 0.9999958276748657
) O O 0.9999855756759644
administered O O 0.9999661445617676
before O O 0.9999672174453735
chemotherapy O O 0.9996746778488159
. O O 0.999975323677063

Patients O O 0.9999226331710815
were O O 0.9999954700469971
observed O O 0.9999929666519165
on O O 0.9999940395355225
an O O 0.9999960660934448
inpatient O O 0.9999836683273315
basis O O 0.9999947547912598
for O O 0.9999841451644897
18 O O 0.9999916553497314
to O O 0.9999984502792358
24 O O 0.9999974966049194
hours O O 0.9999860525131226
, O O 0.9999791383743286
and O O 0.9999843835830688
vital O O 0.9999878406524658
signs O O 0.9999951124191284
, O O 0.9999933242797852
nausea O O 0.9999889135360718
, O O 0.9999704360961914
vomiting O O 0.9999700784683228
, O O 0.9999607801437378
retching O O 0.9999828338623047
, O O 0.9999580383300781
and O O 0.9999381303787231
appetite O O 0.9988419413566589
were O O 0.9999833106994629
assessed O O 0.9999942779541016
. O O 0.9999823570251465

Safety O O 0.9999643564224243
analyses O O 0.9999911785125732
included O O 0.9999617338180542
incidence O O 0.9999874830245972
of O O 0.9999785423278809
adverse O O 0.9999675750732422
experiences O O 0.9999984502792358
and O O 0.9999504089355469
laboratory O O 0.9999767541885376
parameter O O 0.9999979734420776
changes O O 0.9999967813491821
. O O 0.9999707937240601

RESULTS O O 0.999943733215332
: O O 0.9999897480010986
After O O 0.9998993873596191
granisetron B B 0.9998412132263184
doses O O 0.9998759031295776
of O O 0.9998947381973267
5 O O 0.9995817542076111
, O O 0.9968315958976746
10 O O 0.9979974627494812
, O O 0.9963617920875549
20 O O 0.9944618344306946
, O O 0.9989513158798218
and O O 0.9996110796928406
40 O O 0.9999179840087891
micrograms O O 0.9998975992202759
/ O O 0.9999035596847534
kg O O 0.9999929666519165
, O O 0.9999719858169556
a O O 0.9999535083770752
major O O 0.9999679327011108
response O O 0.9999934434890747
( O O 0.9999386072158813
< O O 0.9999696016311646
or O O 0.9999691247940063
= O O 0.9999771118164062
two O O 0.9999890327453613
vomiting O O 0.9999748468399048
or O O 0.9998977184295654
retching O O 0.9999388456344604
episodes O O 0.9999918937683105
, O O 0.9999628067016602
and O O 0.9999585151672363
no O O 0.9992276430130005
antiemetic O O 0.9317848086357117
rescue O O 0.9998961687088013
) O O 0.9999711513519287
was O O 0.9999703168869019
recorded O O 0.9999901056289673
in O O 0.9998916387557983
23 O O 0.9999923706054688
% O O 0.9999836683273315
, O O 0.9999392032623291
57 O O 0.9999942779541016
% O O 0.9999887943267822
, O O 0.9999289512634277
58 O O 0.9999896287918091
% O O 0.9999902248382568
, O O 0.9999101161956787
and O O 0.999894380569458
60 O O 0.9999880790710449
% O O 0.9999879598617554
of O O 0.9999749660491943
patients O O 0.99998939037323
, O O 0.9999864101409912
respectively O O 0.9999712705612183
, O O 0.9999735355377197
and O O 0.9999305009841919
a O O 0.9999518394470215
complete O O 0.9999308586120605
response O O 0.9999935626983643
( O O 0.9999347925186157
no O O 0.9999287128448486
vomiting O O 0.9999812841415405
or O O 0.999919056892395
retching O O 0.9999876022338867
, O O 0.9999685287475586
and O O 0.9999567270278931
no O O 0.999845027923584
antiemetic O O 0.832648754119873
rescue O O 0.9998899698257446
) O O 0.9999780654907227
in O O 0.9998948574066162
18 O O 0.9999899864196777
% O O 0.9999897480010986
, O O 0.9999687671661377
41 O O 0.999984622001648
% O O 0.9999891519546509
, O O 0.9999351501464844
40 O O 0.9999321699142456
% O O 0.9999866485595703
, O O 0.9999194145202637
and O O 0.9998999834060669
47 O O 0.9999911785125732
% O O 0.9999929666519165
of O O 0.999967098236084
patients O O 0.9999909400939941
, O O 0.9999850988388062
respectively O O 0.9999747276306152
. O O 0.9999816417694092

There O O 0.9999725818634033
was O O 0.9999899864196777
a O O 0.9999946355819702
statistically O O 0.9999889135360718
longer O O 0.9999915361404419
time O O 0.9999961853027344
to O O 0.9999964237213135
first O O 0.9999982118606567
episode O O 0.9999961853027344
of O O 0.9999845027923584
nausea O O 0.9998916387557983
( O O 0.9999738931655884
P O O 0.9998331069946289
= O O 0.9999536275863647
. O O 0.9999980926513672
0015 O O 0.9999706745147705
) O O 0.9999767541885376
and O O 0.9999593496322632
vomiting O O 0.9999591112136841
( O O 0.9999748468399048
P O O 0.9997946619987488
= O O 0.9999295473098755
. O O 0.9999982118606567
0001 O O 0.9998654127120972
) O O 0.9999699592590332
, O O 0.9999631643295288
and O O 0.9999785423278809
fewer O O 0.9999531507492065
patients O O 0.9999969005584717
were O O 0.999994158744812
administered O O 0.9999474287033081
additional O O 0.9998217225074768
antiemetic O O 0.5711846351623535
medication O O 0.9936010241508484
in O O 0.9997561573982239
the O O 0.9999135732650757
10 O O 0.9998045563697815
- O O 0.99981290102005
micrograms O O 0.9974306225776672
/ O O 0.999911904335022
kg O O 0.999934196472168
dosing O O 0.999718964099884
groups O O 0.9997619986534119
than O O 0.9999761581420898
in O O 0.9999165534973145
the O O 0.9999644756317139
5 O O 0.9998631477355957
- O O 0.9998432397842407
micrograms O O 0.9984161853790283
/ O O 0.9999415874481201
kg O O 0.9999229907989502
dosing O O 0.9994032382965088
group O O 0.9999381303787231
. O O 0.9999731779098511

As O O 0.9999551773071289
granisetron B B 0.9997187256813049
dose O O 0.9995276927947998
increased O O 0.9999747276306152
, O O 0.9999539852142334
appetite O O 0.6260064840316772
return O O 0.9999828338623047
increased O O 0.9999490976333618
( O O 0.9999681711196899
P O O 0.9997809529304504
= O O 0.9999865293502808
. O O 0.9999980926513672
040 O O 0.9999401569366455
) O O 0.999968409538269
. O O 0.9999817609786987

Headache O O 0.9998434782028198
was O O 0.9999420642852783
the O O 0.9999700784683228
most O O 0.9999772310256958
frequently O O 0.9999842643737793
reported O O 0.9999936819076538
adverse O O 0.9999567270278931
event O O 0.999997615814209
( O O 0.999951958656311
20 O O 0.9999914169311523
% O O 0.9999911785125732
) O O 0.9999619722366333
. O O 0.9999715089797974

CONCLUSION O O 0.9996132254600525
: O O 0.9999748468399048
A O O 0.999958872795105
single O O 0.9998711347579956
10 O O 0.9991377592086792
- O O 0.9978552460670471
, O O 0.9990454316139221
20 O O 0.9990942478179932
- O O 0.9988970756530762
, O O 0.9995086193084717
or O O 0.9999021291732788
40 O O 0.9999009370803833
- O O 0.9999536275863647
micrograms O O 0.9999549388885498
/ O O 0.9999366998672485
kg O O 0.9999964237213135
dose O O 0.9998044371604919
of O O 0.9966332316398621
granisetron B B 0.9997894167900085
was O O 0.9998998641967773
effective O O 0.999868631362915
in O O 0.9999423027038574
controlling O O 0.999864935874939
vomiting O O 0.9997151494026184
in O O 0.9999417066574097
57 O O 0.9999933242797852
% O O 0.999994158744812
to O O 0.999994158744812
60 O O 0.9999978542327881
% O O 0.9999945163726807
of O O 0.9999834299087524
patients O O 0.9999969005584717
who O O 0.9999812841415405
received O O 0.999702513217926
cisplatin B B 0.9997538924217224
at O O 0.9998502731323242
doses O O 0.9999809265136719
greater O O 0.999995231628418
than O O 0.9999973773956299
81 O O 0.9996368885040283
mg O O 0.9999945163726807
/ O O 0.9999691247940063
m2 O O 0.9999974966049194
and O O 0.9999247789382935
totally O O 0.9999099969863892
prevented O O 0.9999332427978516
vomiting O O 0.9998716115951538
in O O 0.9999361038208008
40 O O 0.9999865293502808
% O O 0.999992847442627
to O O 0.9999933242797852
47 O O 0.9999973773956299
% O O 0.9999949932098389
of O O 0.9999786615371704
patients O O 0.9999943971633911
. O O 0.9999738931655884

There O O 0.9999788999557495
were O O 0.9999891519546509
no O O 0.999993085861206
statistically O O 0.9999803304672241
significant O O 0.9999932050704956
differences O O 0.9999954700469971
in O O 0.9999934434890747
efficacy O O 0.9999918937683105
between O O 0.9995219707489014
the O O 0.9999510049819946
10 O O 0.9999470710754395
- O O 0.9998292922973633
micrograms O O 0.9990847110748291
/ O O 0.9999701976776123
kg O O 0.9999932050704956
dose O O 0.9998661279678345
and O O 0.9996896982192993
the O O 0.9999555349349976
20 O O 0.9998181462287903
- O O 0.9997965693473816
and O O 0.9995715022087097
40 O O 0.9998844861984253
- O O 0.9998995065689087
micrograms O O 0.9992992877960205
/ O O 0.9999537467956543
kg O O 0.999990701675415
doses O O 0.9999165534973145
. O O 0.999967098236084

Granisetron B B 0.9996925592422485
was O O 0.9998990297317505
well O O 0.9999494552612305
tolerated O O 0.9999794960021973
at O O 0.9999562501907349
all O O 0.999896764755249
doses O O 0.9999465942382812
. O O 0.9999686479568481

Adverse O O 0.9985266923904419
interaction O O 0.9995923638343811
between O O 0.9968135952949524
clonidine B B 0.9995291233062744
and O O 0.981421947479248
verapamil B B 0.9992583394050598
. O O 0.9998399019241333

OBJECTIVE O O 0.9997774958610535
: O O 0.9999958276748657
To O O 0.9999966621398926
report O O 0.9999966621398926
two O O 0.9999880790710449
cases O O 0.9999910593032837
of O O 0.9999755620956421
a O O 0.9999693632125854
possible O O 0.9999368190765381
adverse O O 0.9997619986534119
interaction O O 0.9999055862426758
between O O 0.9966922998428345
clonidine B B 0.9996582269668579
and O O 0.8767893314361572
verapamil B B 0.9966025352478027
resulting O O 0.9999464750289917
in O O 0.9999256134033203
atrioventricular O O 0.9992159605026245
( O O 0.9988118410110474
AV O O 0.9949681162834167
) O O 0.9997926354408264
block O O 0.9999805688858032
in O O 0.9999628067016602
both O O 0.9999077320098877
patients O O 0.9999901056289673
and O O 0.9999665021896362
severe O O 0.9999791383743286
hypotension O O 0.9999772310256958
in O O 0.9999620914459229
one O O 0.9999904632568359
patient O O 0.9999947547912598
. O O 0.9999686479568481

CASE O O 0.9976966977119446
SUMMARIES O O 0.9998962879180908
: O O 0.9999383687973022
A O O 0.9999850988388062
54 O O 0.9999899864196777
- O O 0.9999818801879883
year O O 0.9999942779541016
- O O 0.9999905824661255
old O O 0.9999904632568359
woman O O 0.9999957084655762
with O O 0.9999239444732666
hyperaldosteronism O O 0.9139862656593323
was O O 0.9999407529830933
treated O O 0.9999645948410034
with O O 0.998953104019165
verapamil B B 0.9987071752548218
480 O O 0.797256588935852
mg O O 0.9991235136985779
/ O O 0.9991335272789001
d O O 0.9958515167236328
and O O 0.9965337514877319
spironolactone B B 0.9982693195343018
100 O O 0.7966492772102356
mg O O 0.9986360669136047
/ O O 0.9985373020172119
d O O 0.9947206974029541
. O O 0.9999357461929321

After O O 0.999993085861206
the O O 0.9999936819076538
addition O O 0.9999819993972778
of O O 0.9999628067016602
a O O 0.9999861717224121
minimal O O 0.9999525547027588
dose O O 0.9997979998588562
of O O 0.9972136616706848
clonidine B B 0.9995961785316467
( O O 0.9986968636512756
0 O O 0.9997887015342712
. O O 0.9999947547912598
15 O O 0.9999758005142212
mg O O 0.9996554851531982
bid O O 0.9943388104438782
) O O 0.9999480247497559
, O O 0.9999665021896362
she O O 0.9999862909317017
developed O O 0.9999754428863525
complete O O 0.9999502897262573
AV O O 0.9997426867485046
block O O 0.9999935626983643
and O O 0.9999630451202393
severe O O 0.9999823570251465
hypotension O O 0.9999794960021973
, O O 0.9999773502349854
which O O 0.9999812841415405
resolved O O 0.9999897480010986
upon O O 0.9999784231185913
cessation O O 0.999988317489624
of O O 0.9999655485153198
all O O 0.9990649819374084
medications O O 0.9991495609283447
. O O 0.9999556541442871

A O O 0.9999781847000122
65 O O 0.9999961853027344
- O O 0.999988317489624
year O O 0.9999970197677612
- O O 0.9999946355819702
old O O 0.999994158744812
woman O O 0.9999973773956299
was O O 0.9999545812606812
treated O O 0.9999701976776123
with O O 0.999541163444519
extended O O 0.989437460899353
- O O 0.9996870756149292
release O O 0.9951158761978149
verapamil B B 0.9988671541213989
240 O O 0.990833580493927
mg O O 0.9999537467956543
/ O O 0.9997108578681946
d O O 0.9999035596847534
. O O 0.9998127818107605

After O O 0.9999871253967285
the O O 0.9999871253967285
addition O O 0.9999287128448486
of O O 0.9988219141960144
clonidine B B 0.9998008608818054
0 O O 0.9671147465705872
. O O 0.9999759197235107
15 O O 0.9998742341995239
mg O O 0.997869610786438
bid O O 0.9971339702606201
she O O 0.9999679327011108
developed O O 0.9999821186065674
complete O O 0.9999775886535645
AV O O 0.9999271631240845
block O O 0.999996542930603
, O O 0.9999805688858032
which O O 0.9999865293502808
resolved O O 0.9999926090240479
after O O 0.9999743700027466
all O O 0.9966946840286255
therapy O O 0.9998704195022583
was O O 0.9999765157699585
stopped O O 0.99988853931427
. O O 0.9999721050262451

DISCUSSION O O 0.9982263445854187
: O O 0.9999319314956665
An O O 0.9999386072158813
adverse O O 0.9997003078460693
interaction O O 0.9999096393585205
between O O 0.9988521337509155
clonidine B B 0.9996836185455322
and O O 0.9829933643341064
verapamil B B 0.9993834495544434
has O O 0.999943733215332
not O O 0.9999779462814331
been O O 0.9999889135360718
reported O O 0.9999827146530151
previously O O 0.9999725818634033
. O O 0.9999758005142212

We O O 0.9999432563781738
describe O O 0.9999855756759644
two O O 0.999985933303833
such O O 0.9999548196792603
cases O O 0.999977707862854
and O O 0.9999576807022095
discuss O O 0.9999170303344727
the O O 0.9999710321426392
various O O 0.9999210834503174
mechanisms O O 0.9999594688415527
that O O 0.9999721050262451
might O O 0.9999680519104004
cause O O 0.9999834299087524
such O O 0.999975323677063
an O O 0.9999887943267822
interaction O O 0.9999904632568359
. O O 0.9999721050262451

Clinicians O O 0.9997201561927795
should O O 0.999936580657959
be O O 0.9999908208847046
acquainted O O 0.9999699592590332
with O O 0.9999855756759644
this O O 0.99996018409729
possibly O O 0.999901294708252
fatal O O 0.9999294281005859
interaction O O 0.9999173879623413
between O O 0.9987695813179016
two O O 0.9996564388275146
commonly O O 0.9996894598007202
used O O 0.9997631907463074
antihypertensive O O 0.5225251913070679
drugs O O 0.9592616558074951
. O O 0.9999451637268066

CONCLUSIONS O O 0.9982584118843079
: O O 0.999983549118042
Caution O O 0.9999278783798218
is O O 0.9999866485595703
recommended O O 0.9999887943267822
in O O 0.9999773502349854
combining O O 0.9899966716766357
clonidine B B 0.9996886253356934
and O O 0.9653130173683167
verapamil B B 0.9995443224906921
therapy O O 0.9998679161071777
, O O 0.9999841451644897
even O O 0.9999649524688721
in O O 0.9999821186065674
patients O O 0.9999927282333374
who O O 0.9999873638153076
do O O 0.9999948740005493
not O O 0.9999889135360718
have O O 0.9999784231185913
sinus O O 0.9998400211334229
or O O 0.9998637437820435
AV O O 0.995634138584137
node O O 0.9999878406524658
dysfunction O O 0.999990701675415
. O O 0.9999748468399048

The O O 0.9997128844261169
two O O 0.9979056119918823
drugs O O 0.9943643808364868
may O O 0.9998540878295898
act O O 0.9997547268867493
synergistically O O 0.9996886253356934
on O O 0.9993845224380493
both O O 0.9997320771217346
the O O 0.9998611211776733
AV O O 0.9873529672622681
node O O 0.9999189376831055
and O O 0.9998059868812561
the O O 0.9999306201934814
peripheral O O 0.9999393224716187
circulation O O 0.9999814033508301
. O O 0.9999269247055054

Pharmacological O O 0.9999376535415649
studies O O 0.9999949932098389
on O O 0.9999104738235474
a O O 0.9999250173568726
new O O 0.9995458722114563
dihydrothienopyridine B B 0.9876704216003418
calcium I O 0.8018022179603577
antagonist O O 0.5538378357887268
, O O 0.9994787573814392
S B B 0.9329881072044373
- I I 0.9156416654586792
312 I I 0.9959864020347595
- I O 0.6315313577651978
d I O 0.8805431723594666
. O O 0.9996825456619263

5th O O 0.9729088544845581
communication O O 0.9992915391921997
: O O 0.998039186000824
anticonvulsant O O 0.7301602363586426
effects O O 0.9756528735160828
in O O 0.9999207258224487
mice O O 0.9999003410339355
. O O 0.9998630285263062

S B B 0.5856583118438721
- I I 0.5739816427230835
312 I I 0.9884562492370605
, O O 0.948061466217041
S B B 0.6888841986656189
- I I 0.6312656402587891
312 I I 0.9864051938056946
- I O 0.5985792279243469
d I O 0.6466012597084045
, O O 0.9989810585975647
but O O 0.9998806715011597
not O O 0.9991577863693237
S B O 0.5110520124435425
- I O 0.7511863112449646
312 I O 0.929027259349823
- I O 0.712119460105896
l I O 0.7229370474815369
, O O 0.7074897289276123
L O O 0.5158804655075073
- O O 0.8421937227249146
type O O 0.9342758655548096
calcium B B 0.9383450746536255
channel O O 0.7525783777236938
antagonists O O 0.658438503742218
, O O 0.9997510313987732
showed O O 0.999625563621521
anticonvulsant O O 0.502400815486908
effects O O 0.9994476437568665
on O O 0.9998619556427002
the O O 0.9999573230743408
audiogenic O O 0.9993440508842468
tonic O O 0.9999762773513794
convulsions O O 0.9997186064720154
in O O 0.999809205532074
DBA O O 0.9645076990127563
/ O O 0.9995612502098083
2 O O 0.9938312768936157
mice O O 0.9999589920043945
; O O 0.9999818801879883
and O O 0.9999876022338867
their O O 0.9999676942825317
ED50 O O 0.999125063419342
values O O 0.9999521970748901
were O O 0.9999841451644897
18 O O 0.9999960660934448
. O O 0.999997615814209
4 O O 0.9999865293502808
( O O 0.9999576807022095
12 O O 0.9999988079071045
. O O 0.9999967813491821
8 O O 0.9985332489013672
- O O 0.9988825917243958
27 O O 0.9999980926513672
. O O 0.9999979734420776
1 O O 0.999996542930603
) O O 0.9999703168869019
mg O O 0.9999943971633911
/ O O 0.999996542930603
kg O O 0.9999984502792358
, O O 0.9999034404754639
p O O 0.9964410662651062
. O O 0.999995231628418
o O O 0.9999650716781616
. O O 0.9999922513961792
and O O 0.999972939491272
15 O O 0.9999994039535522
. O O 0.9999984502792358
0 O O 0.9999942779541016
( O O 0.9999732971191406
10 O O 0.9999986886978149
. O O 0.9999982118606567
2 O O 0.999738872051239
- O O 0.9994949102401733
23 O O 0.9999984502792358
. O O 0.9999985694885254
7 O O 0.999991774559021
) O O 0.9999842643737793
mg O O 0.9999960660934448
/ O O 0.9999958276748657
kg O O 0.9999979734420776
, O O 0.9999736547470093
p O O 0.9978220462799072
. O O 0.9999961853027344
o O O 0.9999713897705078
. O O 0.999995231628418
, O O 0.9999926090240479
respectively O O 0.9999901056289673
, O O 0.9999918937683105
while O O 0.9999618530273438
that O O 0.9999876022338867
of O O 0.9991474151611328
flunarizine B B 0.999168872833252
was O O 0.9999539852142334
34 O O 0.9999785423278809
. O O 0.9999961853027344
0 O O 0.9999943971633911
( O O 0.9999676942825317
26 O O 0.9999880790710449
. O O 0.9999920129776001
0 O O 0.9999116659164429
- O O 0.9994841814041138
44 O O 0.9999899864196777
. O O 0.9999971389770508
8 O O 0.9999877214431763
) O O 0.9999752044677734
mg O O 0.9999922513961792
/ O O 0.9999935626983643
kg O O 0.9999979734420776
, O O 0.9999217987060547
p O O 0.9974333643913269
. O O 0.9999948740005493
o O O 0.999981164932251
. O O 0.9999533891677856

Although O O 0.999897837638855
moderate O O 0.9996644258499146
anticonvulsant O O 0.8947660326957703
effects O O 0.9999096393585205
of O O 0.9997939467430115
S B B 0.9071598649024963
- I I 0.9182586073875427
312 I I 0.9977734684944153
- I I 0.5112165808677673
d I I 0.9814819097518921
in O O 0.9987271428108215
higher O O 0.9997671246528625
doses O O 0.9999161958694458
were O O 0.9999805688858032
observed O O 0.9999899864196777
against O O 0.9998114705085754
the O O 0.9999586343765259
clonic O O 0.9996597766876221
convulsions O O 0.9998838901519775
induced O O 0.9999840259552002
by O O 0.9998816251754761
pentylenetetrazole B B 0.9991395473480225
( O O 0.9997946619987488
85 O O 0.9998310804367065
mg O O 0.9999748468399048
/ O O 0.9999895095825195
kg O O 0.9999980926513672
, O O 0.9999600648880005
s O O 0.9996602535247803
. O O 0.9999967813491821
c O O 0.9999659061431885
. O O 0.9999940395355225
) O O 0.9999451637268066
or O O 0.9980886578559875
bemegride B B 0.9983787536621094
( O O 0.999830961227417
40 O O 0.9997923970222473
mg O O 0.9999737739562988
/ O O 0.9999910593032837
kg O O 0.9999979734420776
, O O 0.9999382495880127
s O O 0.9981648325920105
. O O 0.9999936819076538
c O O 0.9999643564224243
. O O 0.9999910593032837
) O O 0.9999748468399048
, O O 0.9999545812606812
no O O 0.999907374382019
effects O O 0.9999881982803345
were O O 0.9999790191650391
observed O O 0.9999940395355225
in O O 0.9999605417251587
convulsions O O 0.9993183612823486
induced O O 0.9999792575836182
by O O 0.9998294115066528
N B B 0.8366009593009949
- I I 0.9632493257522583
methyl I I 0.999806821346283
- I I 0.9604699611663818
D I I 0.9937732815742493
- I I 0.987399697303772
aspartate I I 0.999800980091095
, O O 0.9651806354522705
picrotoxin B B 0.9924589991569519
, O O 0.9931952953338623
or O O 0.9995682835578918
electroshock O O 0.5339579582214355
in O O 0.9989778995513916
Slc O O 0.8362799286842346
: O O 0.801219642162323
ddY O O 0.6957013010978699
mice O O 0.9997671246528625
. O O 0.9999430179595947

S B B 0.9318325519561768
- I I 0.9038724303245544
312 I I 0.9766006469726562
- I I 0.7502368688583374
d I I 0.9780093431472778
may O O 0.9996359348297119
be O O 0.9999666213989258
useful O O 0.9999464750289917
in O O 0.9999592304229736
the O O 0.9999611377716064
therapy O O 0.9999457597732544
of O O 0.999956488609314
certain O O 0.9999542236328125
types O O 0.999983549118042
of O O 0.9999747276306152
human O O 0.9999234676361084
epilepsy O O 0.9999098777770996
. O O 0.9999581575393677

Transmural O O 0.9999353885650635
myocardial O O 0.9999923706054688
infarction O O 0.9999754428863525
with O O 0.9979748129844666
sumatriptan B B 0.999607503414154
. O O 0.9985678195953369

For O O 0.998002827167511
sumatriptan B B 0.9998403787612915
, O O 0.9998277425765991
tightness O O 0.9999548196792603
in O O 0.9999936819076538
the O O 0.9999961853027344
chest O O 0.9999852180480957
caused O O 0.9999908208847046
by O O 0.999977707862854
an O O 0.99998939037323
unknown O O 0.999962329864502
mechanism O O 0.9999920129776001
has O O 0.9999867677688599
been O O 0.9999971389770508
reported O O 0.9999983310699463
in O O 0.9999916553497314
3 O O 0.9997935891151428
- O O 0.9999220371246338
5 O O 0.9999828338623047
% O O 0.9999943971633911
of O O 0.9999704360961914
users O O 0.9988540410995483
. O O 0.9999566078186035

We O O 0.9999898672103882
describe O O 0.9999971389770508
a O O 0.9999958276748657
47 O O 0.9999984502792358
- O O 0.9999892711639404
year O O 0.9999973773956299
- O O 0.9999942779541016
old O O 0.9999966621398926
woman O O 0.9999978542327881
with O O 0.9999738931655884
an O O 0.9999942779541016
acute O O 0.9999878406524658
myocardial O O 0.9999988079071045
infarction O O 0.9999943971633911
after O O 0.9999185800552368
administration O O 0.9998927116394043
of O O 0.9978293776512146
sumatriptan B B 0.9996570348739624
6 O O 0.9504086375236511
mg O O 0.9957713484764099
subcutaneously O O 0.999868631362915
for O O 0.9999158382415771
cluster O O 0.999202311038971
headache O O 0.9999891519546509
. O O 0.9999771118164062

The O O 0.9999805688858032
patient O O 0.9999871253967285
had O O 0.999963641166687
no O O 0.9999817609786987
history O O 0.999984622001648
of O O 0.9999533891677856
underlying O O 0.9999157190322876
ischaemic O O 0.9999880790710449
heart O O 0.9999946355819702
disease O O 0.9999969005584717
or O O 0.9999308586120605
Prinzmetal O O 0.9862123727798462
' O O 0.9999815225601196
s O O 0.9999830722808838
angina O O 0.9999682903289795
. O O 0.9999480247497559

She O O 0.9999181032180786
recovered O O 0.9999650716781616
without O O 0.9999868869781494
complications O O 0.9999936819076538
. O O 0.9999741315841675

Flumazenil B B 0.9992712140083313
induces O O 0.9998169541358948
seizures O O 0.9999836683273315
and O O 0.9999097585678101
death O O 0.9999693632125854
in O O 0.999708354473114
mixed O O 0.9722312092781067
cocaine B B 0.9955541491508484
- O O 0.5846347808837891
diazepam B B 0.8842182755470276
intoxications O O 0.9995929598808289
. O O 0.9999125003814697

STUDY O O 0.9977928400039673
HYPOTHESIS O O 0.9997714161872864
: O O 0.999940037727356
Administration O O 0.9998811483383179
of O O 0.9997885823249817
the O O 0.9992141723632812
benzodiazepine B B 0.9709506630897522
antagonist O O 0.7298049330711365
flumazenil B B 0.9986598491668701
may O O 0.9999293088912964
unmask O O 0.9996849298477173
seizures O O 0.9999810457229614
in O O 0.9998723268508911
mixed O O 0.9960581064224243
cocaine B B 0.9959567189216614
- O O 0.6397110819816589
benzodiazepine B B 0.9374153017997742
intoxication O O 0.9994128942489624
. O O 0.9999711513519287

DESIGN O O 0.9993159770965576
: O O 0.9999650716781616
Male O O 0.9999809265136719
Sprague O O 0.9986147880554199
- O O 0.9996626377105713
Dawley O O 0.9997045397758484
rats O O 0.9999970197677612
received O O 0.9998928308486938
100 O O 0.9998323917388916
mg O O 0.9999339580535889
/ O O 0.9999856948852539
kg O O 0.9999414682388306
cocaine B B 0.9932976365089417
IP O O 0.7060589790344238
alone O O 0.9982956051826477
, O O 0.9998756647109985
5 O O 0.9998897314071655
mg O O 0.9999516010284424
/ O O 0.9999818801879883
kg O O 0.9996575117111206
diazepam B B 0.9995524287223816
alone O O 0.9967992305755615
, O O 0.999603807926178
or O O 0.9998158812522888
a O O 0.9999699592590332
combination O O 0.9958689212799072
of O O 0.9992979764938354
diazepam B B 0.9996131062507629
and O O 0.978417694568634
cocaine B B 0.9971219897270203
. O O 0.999910831451416

Three O O 0.9999816417694092
minutes O O 0.9999978542327881
later O O 0.9999959468841553
, O O 0.9999717473983765
groups O O 0.9999499320983887
were O O 0.9999939203262329
challenged O O 0.999985933303833
with O O 0.9998955726623535
vehicle O O 0.6698513031005859
or O O 0.9900581240653992
flumazenil B B 0.999566376209259
5 O O 0.9985501170158386
or O O 0.9999614953994751
10 O O 0.9999637603759766
mg O O 0.9999613761901855
/ O O 0.9999712705612183
kg O O 0.9999915361404419
IP O O 0.9224554896354675
. O O 0.9999713897705078

Animal O O 0.9995086193084717
behavior O O 0.9999901056289673
, O O 0.9999337196350098
seizures O O 0.9999721050262451
( O O 0.9999386072158813
time O O 0.9999773502349854
to O O 0.9999891519546509
and O O 0.9999071359634399
incidence O O 0.9999854564666748
) O O 0.9999457597732544
, O O 0.9999709129333496
death O O 0.9999864101409912
( O O 0.9999691247940063
time O O 0.9999833106994629
to O O 0.9999911785125732
and O O 0.9999516010284424
incidence O O 0.9999910593032837
) O O 0.9999607801437378
, O O 0.9999134540557861
and O O 0.9999030828475952
cortical O O 0.9983274340629578
EEG O O 0.9989098310470581
tracings O O 0.9999675750732422
were O O 0.9999524354934692
recorded O O 0.9999772310256958
. O O 0.9999580383300781

INTERVENTIONS O O 0.9990450739860535
: O O 0.9998387098312378
Administration O O 0.9999164342880249
of O O 0.9991180300712585
flumazenil B B 0.9996058344841003
to O O 0.9999160766601562
animals O O 0.8126451969146729
after O O 0.9999727010726929
they O O 0.9999947547912598
had O O 0.999992847442627
received O O 0.9999396800994873
a O O 0.9999730587005615
combination O O 0.9933911561965942
dose O O 0.9992778897285461
of O O 0.9985722303390503
cocaine B B 0.9975885152816772
and O O 0.8858187794685364
diazepam B B 0.9993663430213928
. O O 0.9996657371520996

RESULTS O O 0.9996349811553955
: O O 0.9999169111251831
In O O 0.9999489784240723
group O O 0.9999861717224121
1 O O 0.9999736547470093
, O O 0.9999001026153564
animals O O 0.9999901056289673
received O O 0.9994775652885437
cocaine B B 0.9988007545471191
followed O O 0.9989803433418274
by O O 0.9996466636657715
vehicle O O 0.9940776824951172
. O O 0.9999125003814697

This O O 0.9994334578514099
resulted O O 0.9999631643295288
in O O 0.9999873638153076
100 O O 0.9998987913131714
% O O 0.9999843835830688
developing O O 0.9999769926071167
seizures O O 0.9999715089797974
and O O 0.9999700784683228
death O O 0.9999860525131226
. O O 0.9999591112136841

Group O O 0.9998993873596191
2 O O 0.9998652935028076
received O O 0.9997075200080872
diazepam B B 0.9998302459716797
alone O O 0.9997673630714417
followed O O 0.9997664093971252
by O O 0.9996811151504517
vehicle O O 0.9934131503105164
. O O 0.9999411106109619

Animals O O 0.9998260140419006
became O O 0.9999858140945435
somnolent O O 0.9999251365661621
and O O 0.9999476671218872
none O O 0.9835531711578369
died O O 0.9997952580451965
. O O 0.9999767541885376

Group O O 0.9996053576469421
3 O O 0.9998288154602051
received O O 0.9996216297149658
diazepam B B 0.9997751116752625
followed O O 0.9988433122634888
by O O 0.9996570348739624
5 O O 0.9998534917831421
mg O O 0.9999040365219116
/ O O 0.9999281167984009
kg O O 0.9996920824050903
flumazenil B B 0.9995463490486145
. O O 0.9999397993087769

Animals O O 0.9998199343681335
became O O 0.9999825954437256
somnolent O O 0.9999812841415405
after O O 0.9992278814315796
diazepam B B 0.9996458292007446
and O O 0.9997370839118958
then O O 0.9997022747993469
active O O 0.9999662637710571
after O O 0.9997535347938538
flumazenil B B 0.9995854496955872
administration O O 0.9998748302459717
. O O 0.9999591112136841

In O O 0.9998724460601807
group O O 0.9999802112579346
4 O O 0.9996911287307739
, O O 0.9999328851699829
a O O 0.9999195337295532
combination O O 0.9961515069007874
of O O 0.9992615580558777
cocaine B B 0.9986171722412109
and O O 0.9854309558868408
diazepam B B 0.9995951056480408
was O O 0.9998685121536255
administered O O 0.999901294708252
simultaneously O O 0.9997261166572571
. O O 0.9999758005142212

This O O 0.9998332262039185
resulted O O 0.9999717473983765
in O O 0.9999876022338867
no O O 0.9999632835388184
overt O O 0.999966025352478
or O O 0.9998949766159058
EEG O O 0.9806484580039978
- O O 0.9998395442962646
detectable O O 0.9999839067459106
seizures O O 0.9999741315841675
and O O 0.9999866485595703
a O O 0.9999920129776001
50 O O 0.9999954700469971
% O O 0.9999980926513672
incidence O O 0.999998927116394
of O O 0.9999959468841553
death O O 0.9999942779541016
. O O 0.9999616146087646

Group O O 0.9999245405197144
5 O O 0.9999585151672363
received O O 0.9997796416282654
a O O 0.9999632835388184
similar O O 0.9999420642852783
combination O O 0.9951257109642029
of O O 0.9986820816993713
cocaine B B 0.9984978437423706
and O O 0.9759719967842102
diazepam B B 0.9996261596679688
, O O 0.9997525811195374
followed O O 0.9999116659164429
later O O 0.9999825954437256
by O O 0.9998377561569214
5 O O 0.999884843826294
mg O O 0.999911904335022
/ O O 0.9999138116836548
kg O O 0.999679446220398
flumazenil B B 0.9994712471961975
. O O 0.9999517202377319

This O O 0.9998656511306763
resulted O O 0.9999698400497437
in O O 0.9999867677688599
an O O 0.9999895095825195
increased O O 0.9999852180480957
incidence O O 0.9999957084655762
of O O 0.9999724626541138
seizures O O 0.9999740123748779
, O O 0.9999775886535645
90 O O 0.9999268054962158
% O O 0.9999964237213135
( O O 0.9999462366104126
P O O 0.9975190162658691
< O O 0.9999182224273682
. O O 0.9999966621398926
01 O O 0.9999806880950928
) O O 0.9999444484710693
, O O 0.9999096393585205
and O O 0.9998462200164795
death O O 0.9999834299087524
, O O 0.9999812841415405
100 O O 0.999953031539917
% O O 0.9999959468841553
( O O 0.9999412298202515
P O O 0.9933688044548035
< O O 0.9999805688858032
or O O 0.9999936819076538
= O O 0.9999752044677734
. O O 0.9999970197677612
01 O O 0.9999569654464722
) O O 0.9999586343765259
, O O 0.9999850988388062
compared O O 0.9999910593032837
with O O 0.9999914169311523
group O O 0.9999915361404419
4 O O 0.999762237071991
. O O 0.9999656677246094

Group O O 0.9997345805168152
6 O O 0.9997780919075012
received O O 0.9995830655097961
cocaine B B 0.9990365505218506
and O O 0.9887800216674805
diazepam B B 0.999637246131897
followed O O 0.9991248250007629
by O O 0.9997926354408264
10 O O 0.9998751878738403
mg O O 0.9999045133590698
/ O O 0.9999470710754395
kg O O 0.9996168613433838
flumazenil B B 0.999605119228363
. O O 0.9999387264251709

This O O 0.99983811378479
also O O 0.9999574422836304
resulted O O 0.9999799728393555
in O O 0.9999896287918091
an O O 0.9999884366989136
increased O O 0.9999889135360718
incidence O O 0.9999963045120239
of O O 0.9999737739562988
seizures O O 0.9999721050262451
, O O 0.999975323677063
90 O O 0.9997691512107849
% O O 0.9999964237213135
( O O 0.9999446868896484
P O O 0.9987114667892456
< O O 0.9999874830245972
or O O 0.9999642372131348
= O O 0.9999785423278809
. O O 0.9999967813491821
01 O O 0.9999972581863403
) O O 0.9999635219573975
, O O 0.9999140501022339
and O O 0.999832272529602
death O O 0.9999837875366211
, O O 0.9999828338623047
90 O O 0.9998160004615784
% O O 0.9999969005584717
( O O 0.9999535083770752
P O O 0.9993153810501099
< O O 0.9999914169311523
or O O 0.9999868869781494
= O O 0.9999759197235107
. O O 0.9999971389770508
05 O O 0.999995231628418
) O O 0.9999680519104004
, O O 0.9999867677688599
compared O O 0.9999912977218628
with O O 0.9999898672103882
group O O 0.99998939037323
4 O O 0.9996814727783203
. O O 0.9999678134918213

CONCLUSION O O 0.937328577041626
: O O 0.9987646341323853
Flumazenil B B 0.9996699094772339
can O O 0.9997120499610901
unmask O O 0.9982581734657288
seizures O O 0.999968409538269
and O O 0.999969482421875
increase O O 0.9999306201934814
the O O 0.9999972581863403
incidence O O 0.9999990463256836
of O O 0.9999953508377075
death O O 0.999994158744812
in O O 0.9999322891235352
a O O 0.9998759031295776
model O O 0.999967098236084
of O O 0.999934196472168
combined O O 0.9969465136528015
cocaine B B 0.9949935078620911
- O O 0.6270138025283813
diazepam B B 0.9082179665565491
intoxications O O 0.9998339414596558
. O O 0.9999539852142334

Mechanisms O O 0.9997254014015198
for O O 0.9996108412742615
protective O O 0.9993509650230408
effects O O 0.9999210834503174
of O O 0.9996404647827148
free O O 0.756171464920044
radical O O 0.6690651774406433
scavengers O O 0.4409039616584778
on O O 0.9994856119155884
gentamicin B B 0.9997639060020447
- O O 0.9997643828392029
mediated O O 0.9999364614486694
nephropathy O O 0.9999794960021973
in O O 0.9999265670776367
rats O O 0.9999669790267944
. O O 0.9999605417251587

Studies O O 0.9999760389328003
were O O 0.9999874830245972
performed O O 0.999995231628418
to O O 0.9999918937683105
examine O O 0.9999681711196899
the O O 0.9999680519104004
mechanisms O O 0.9999685287475586
for O O 0.9999535083770752
the O O 0.9999282360076904
protective O O 0.9997155070304871
effects O O 0.9999431371688843
of O O 0.9998173117637634
free O O 0.7582758665084839
radical O B 0.8216012716293335
scavengers O O 0.5352666974067688
on O O 0.9993129968643188
gentamicin B B 0.999504566192627
( O O 0.9924966096878052
GM B B 0.9982682466506958
) O O 0.8456283807754517
- O O 0.9998537302017212
mediated O O 0.999936580657959
nephropathy O O 0.9999606609344482
. O O 0.999977707862854

Administration O O 0.9999619722366333
of O O 0.9997873902320862
GM B B 0.9959986209869385
at O O 0.9995583891868591
40 O O 0.9997264742851257
mg O O 0.9999818801879883
/ O O 0.9999780654907227
kg O O 0.9999845027923584
sc O O 0.4987497627735138
for O O 0.9999512434005737
13 O O 0.9999866485595703
days O O 0.9999912977218628
to O O 0.9999606609344482
rats O O 0.9677028656005859
induced O O 0.9999730587005615
a O O 0.9999898672103882
significant O O 0.9999858140945435
reduction O O 0.9999927282333374
in O O 0.999975323677063
renal O O 0.9999791383743286
blood O O 0.9995200634002686
flow O O 0.99998939037323
( O O 0.9997060894966125
RBF O O 0.9878332614898682
) O O 0.9999233484268188
and O O 0.9999066591262817
inulin O O 0.606991171836853
clearance O O 0.9997782111167908
( O O 0.9992890357971191
CIn O O 0.9337140917778015
) O O 0.9999641180038452
as O O 0.9999827146530151
well O O 0.9999637603759766
as O O 0.9999693632125854
marked O O 0.9999537467956543
tubular O O 0.999994158744812
damage O O 0.9999966621398926
. O O 0.9999752044677734

A O O 0.9998860359191895
significant O O 0.9999644756317139
reduction O O 0.9999914169311523
in O O 0.9999208450317383
urinary O O 0.9237028360366821
guanosine B B 0.9955839514732361
3 I I 0.5236474871635437
' I I 0.8570587038993835
, I I 0.8888751268386841
5 I I 0.896807074546814
' I I 0.9774238467216492
- I I 0.9298096895217896
cyclic I I 0.9829445481300354
monophosphate I I 0.9980337023735046
( O O 0.9834229946136475
cGMP B B 0.9544203877449036
) O O 0.9909464120864868
excretion O O 0.9998863935470581
and O O 0.999940037727356
a O O 0.9999608993530273
significant O O 0.9999678134918213
increase O O 0.9999557733535767
in O O 0.9998723268508911
renal O O 0.9986417889595032
cortical O O 0.8582760095596313
renin O O 0.871484100818634
and O O 0.9988179802894592
endothelin O O 0.5153441429138184
- O O 0.8306643962860107
1 O O 0.9261869788169861
contents O O 0.9864072203636169
were O O 0.9999575614929199
also O O 0.9999762773513794
observed O O 0.9999822378158569
in O O 0.9997685551643372
GM B B 0.9791669249534607
- O O 0.9939337372779846
mediated O O 0.9998729228973389
nephropathy O O 0.9998940229415894
. O O 0.9999357461929321

Superoxide B B 0.9844586849212646
dismutase O O 0.6202189922332764
( O O 0.9953511953353882
SOD O B 0.9536543488502502
) O O 0.9899395108222961
or O O 0.9989699125289917
dimethylthiourea B B 0.9920841455459595
( O O 0.99783855676651
DMTU B B 0.9948574304580688
) O O 0.999096155166626
significantly O O 0.9999637603759766
lessened O O 0.9999562501907349
the O O 0.9999454021453857
GM B B 0.9985367059707642
- O O 0.9978454113006592
induced O O 0.9999401569366455
decrement O O 0.9999929666519165
in O O 0.9998568296432495
CIn O O 0.6759404540061951
. O O 0.9997976422309875

The O O 0.999962329864502
SOD O B 0.9974429607391357
- O O 0.9960598349571228
induced O O 0.9999107122421265
increase O O 0.9999842643737793
in O O 0.9999548196792603
glomerular O O 0.9968340992927551
filtration O O 0.9998419284820557
rate O O 0.9999536275863647
was O O 0.9999428987503052
associated O O 0.9999828338623047
with O O 0.9999606609344482
a O O 0.9999802112579346
marked O O 0.9999862909317017
improvement O O 0.9999929666519165
in O O 0.9999343156814575
RBF O O 0.990358293056488
, O O 0.9999557733535767
an O O 0.9999802112579346
increase O O 0.9999874830245972
in O O 0.9999380111694336
urinary O O 0.9985212683677673
cGMP B B 0.926342248916626
excretion O O 0.9985465407371521
, O O 0.9998897314071655
and O O 0.9999451637268066
a O O 0.9999691247940063
decrease O O 0.9999812841415405
in O O 0.9998873472213745
renal O O 0.9713245034217834
renin O O 0.522818922996521
and O O 0.9985985159873962
endothelin O O 0.6859411597251892
- O O 0.9340806007385254
1 O O 0.9561445713043213
content O O 0.9996155500411987
. O O 0.9999536275863647

SOD O B 0.9795921444892883
did O O 0.9997089505195618
not O O 0.9998962879180908
attenuate O O 0.9997215867042542
the O O 0.9999610185623169
tubular O O 0.9999655485153198
damage O O 0.9999871253967285
. O O 0.9998854398727417

In O O 0.99992835521698
contrast O O 0.9995633959770203
, O O 0.9985896944999695
DMTU B B 0.9976819753646851
significantly O O 0.9997541308403015
reduced O O 0.9999176263809204
the O O 0.9999524354934692
tubular O O 0.9999922513961792
damage O O 0.9999922513961792
and O O 0.9999465942382812
lipid O O 0.7883068323135376
peroxidation O O 0.9795827865600586
, O O 0.9999300241470337
but O O 0.9999614953994751
it O O 0.9994596838951111
did O O 0.9999277591705322
not O O 0.9999563694000244
affect O O 0.99994957447052
renal O O 0.9999427795410156
hemodynamics O O 0.999945878982544
and O O 0.9999724626541138
vasoactive O O 0.9993378520011902
substances O O 0.9998328685760498
. O O 0.9999276399612427

Neither O O 0.9995680451393127
SOD O B 0.953933835029602
nor O O 0.9960350394248962
DMTU B B 0.9752424955368042
affected O O 0.9998315572738647
the O O 0.9999725818634033
renal O O 0.9996662139892578
cortical O O 0.9931557774543762
GM B B 0.951331377029419
content O O 0.9952964186668396
in O O 0.9998811483383179
GM B B 0.9979242086410522
- O O 0.9924067854881287
treated O O 0.9997743964195251
rats O O 0.9999864101409912
. O O 0.9999755620956421

These O O 0.9999810457229614
results O O 0.9999884366989136
suggest O O 0.9999158382415771
that O O 0.9998047947883606
1 O O 0.9999804496765137
) O O 0.9999111890792847
both O O 0.9974283576011658
SOD O B 0.9796981811523438
and O O 0.9245173335075378
DMTU B B 0.9851850271224976
have O O 0.9990574717521667
protective O O 0.9994208812713623
effects O O 0.999961256980896
on O O 0.9996793270111084
GM B B 0.9910998940467834
- O O 0.9953919649124146
mediated O O 0.9999094009399414
nephropathy O O 0.9999819993972778
, O O 0.9999251365661621
2 O O 0.9999743700027466
) O O 0.9999692440032959
the O O 0.9999686479568481
mechanisms O O 0.9999829530715942
for O O 0.9999791383743286
the O O 0.9999758005142212
protective O O 0.9997846484184265
effects O O 0.9999628067016602
differ O O 0.9950957894325256
for O O 0.9433191418647766
SOD O B 0.9011921882629395
and O O 0.9896082282066345
DMTU B B 0.9402816295623779
, O O 0.9991707801818848
and O O 0.9997944235801697
3 O O 0.9997972846031189
) O O 0.9999128580093384
superoxide B B 0.9830864667892456
anions O O 0.6239652633666992
play O O 0.9997264742851257
a O O 0.9998726844787598
critical O O 0.9999094009399414
role O O 0.9999189376831055
in O O 0.9998714923858643
GM B B 0.9975394010543823
- O O 0.9940475225448608
induced O O 0.999890923500061
renal O O 0.999946117401123
vasoconstriction O O 0.9999772310256958
. O O 0.9999693632125854

Cephalothin B B 0.9912126660346985
- O O 0.9955283999443054
induced O O 0.9996414184570312
immune O O 0.9996008276939392
hemolytic O O 0.9991499185562134
anemia O O 0.9995427131652832
. O O 0.9999188184738159

A O O 0.9999563694000244
patient O O 0.9999843835830688
with O O 0.9999454021453857
renal O O 0.9997867941856384
disease O O 0.9999841451644897
developed O O 0.9999747276306152
Coombs O O 0.9816873669624329
- O O 0.9999077320098877
positive O O 0.999854564666748
hemolytic O O 0.9998496770858765
anemia O O 0.9997178912162781
while O O 0.9998661279678345
receiving O O 0.999519944190979
cephalothin B B 0.9990574717521667
therapy O O 0.9994045495986938
. O O 0.9999721050262451

An O O 0.99970942735672
anti O O 0.8618684411048889
- O O 0.9663287401199341
cephalothin B O 0.7573058605194092
IgG O O 0.8806846737861633
antibody O O 0.7636058330535889
was O O 0.9999327659606934
detected O O 0.9999614953994751
in O O 0.9998834133148193
the O O 0.9999898672103882
patient O O 0.9999918937683105
' O O 0.9999936819076538
s O O 0.9999830722808838
serum O O 0.9999232292175293
and O O 0.999934196472168
in O O 0.9998379945755005
the O O 0.9999374151229858
eluates O O 0.9862022995948792
from O O 0.99988853931427
her O O 0.9999644756317139
erythrocytes O O 0.9999645948410034
. O O 0.9999344348907471

In O O 0.9999274015426636
addition O O 0.9999573230743408
, O O 0.9999316930770874
nonimmunologic O O 0.9992828965187073
binding O O 0.9999476671218872
of O O 0.999903678894043
normal O O 0.9906696081161499
and O O 0.9998835325241089
patient O O 0.9996553659439087
' O O 0.9999924898147583
s O O 0.9999881982803345
serum O O 0.9992423057556152
proteins O O 0.9996629953384399
to O O 0.9998778104782104
her O O 0.9999854564666748
own O O 0.9991675615310669
and O O 0.9989526271820068
cephalothin B B 0.9715175628662109
- O O 0.9880814552307129
coated O O 0.9972177743911743
normal O O 0.9996036887168884
red O O 0.9999963045120239
cells O O 0.999987006187439
was O O 0.9999696016311646
demonstrated O O 0.999982476234436
. O O 0.9999637603759766

Skin O O 0.9997907280921936
tests O O 0.9999884366989136
and O O 0.9999672174453735
in O O 0.9984595775604248
vitro O O 0.9999897480010986
lymphocyte O O 0.9990832805633545
stimulation O O 0.9999250173568726
revealed O O 0.9999886751174927
that O O 0.9999654293060303
the O O 0.99998939037323
patient O O 0.9999866485595703
was O O 0.9999048709869385
sensitized O O 0.9998701810836792
to O O 0.9970095157623291
cephalothin B B 0.9994773268699646
and O O 0.9994367957115173
also O O 0.9998121857643127
to O O 0.9983684420585632
ampicillin B B 0.9993910789489746
. O O 0.9999362230300903

Careful O O 0.9998692274093628
investigation O O 0.9999750852584839
of O O 0.9999486207962036
drug O O 0.9941188097000122
- O O 0.9998248219490051
induced O O 0.9998927116394043
hemolytic O O 0.9988283514976501
anemias O O 0.9995505213737488
reveals O O 0.999947190284729
the O O 0.9999889135360718
complexity O O 0.9999927282333374
of O O 0.999971866607666
the O O 0.9999183416366577
immune O O 0.9998300075531006
mechanisms O O 0.9999582767486572
involved O O 0.9999872446060181
. O O 0.999962568283081

Assessment O O 0.9999626874923706
of O O 0.9999246597290039
cardiomyocyte O O 0.999967098236084
DNA O O 0.9909167885780334
synthesis O O 0.9999537467956543
during O O 0.9991775155067444
hypertrophy O O 0.9969786405563354
in O O 0.9999780654907227
adult O O 0.999988317489624
mice O O 0.9999924898147583
. O O 0.9999662637710571

The O O 0.9999735355377197
ability O O 0.9999598264694214
of O O 0.9999125003814697
cardiomyocytes O O 0.999970555305481
to O O 0.9998624324798584
synthesize O O 0.9991815686225891
DNA O O 0.8296162486076355
in O O 0.999736487865448
response O O 0.9999638795852661
to O O 0.9999493360519409
experimentally O O 0.999974250793457
induced O O 0.999991774559021
cardiac O O 0.9999799728393555
hypertrophy O O 0.9992629885673523
was O O 0.9999828338623047
assessed O O 0.999988317489624
in O O 0.9999874830245972
adult O O 0.9999904632568359
mice O O 0.9999942779541016
. O O 0.9999786615371704

Isoproterenol B B 0.999099612236023
delivered O O 0.9997397065162659
by O O 0.9999425411224365
osmotic O O 0.9444149136543274
minipump O O 0.9821527600288391
implantation O O 0.9999871253967285
in O O 0.9999511241912842
adult O O 0.9999791383743286
C3Heb O O 0.9976357221603394
/ O O 0.9990063309669495
FeJ O O 0.9951766729354858
mice O O 0.9999727010726929
resulted O O 0.9999772310256958
in O O 0.9999920129776001
a O O 0.9999914169311523
46 O O 0.9999979734420776
% O O 0.9999979734420776
increase O O 0.9999963045120239
in O O 0.9999910593032837
heart O O 0.9999827146530151
weight O O 0.9999920129776001
and O O 0.9999775886535645
a O O 0.9999853372573853
19 O O 0.9999904632568359
. O O 0.9999935626983643
3 O O 0.9999905824661255
% O O 0.9999960660934448
increase O O 0.9999908208847046
in O O 0.9999802112579346
cardiomyocyte O O 0.999985933303833
area O O 0.9998457431793213
. O O 0.9999676942825317

No O O 0.9997337460517883
DNA O O 0.9917860627174377
synthesis O O 0.9997480511665344
, O O 0.9999865293502808
as O O 0.9999939203262329
assessed O O 0.9999953508377075
by O O 0.9999856948852539
autoradiographic O O 0.9993374943733215
analysis O O 0.9999858140945435
of O O 0.9999639987945557
isolated O O 0.999924898147583
cardiomyocytes O O 0.9999862909317017
, O O 0.9999704360961914
was O O 0.9999561309814453
observed O O 0.9999761581420898
in O O 0.999756395816803
control O O 0.9941694736480713
or O O 0.9998471736907959
hypertrophic O O 0.9988889098167419
hearts O O 0.9999916553497314
. O O 0.9999616146087646

A O O 0.999983549118042
survey O O 0.9999970197677612
of O O 0.9999743700027466
15 O O 0.9999693632125854
independent O O 0.9999768733978271
inbred O O 0.9999480247497559
strains O O 0.9999972581863403
of O O 0.9999831914901733
mice O O 0.9999829530715942
revealed O O 0.9999674558639526
that O O 0.9997221827507019
ventricular O O 0.9981038570404053
cardiomyocyte O O 0.9999358654022217
nuclear O O 0.9999452829360962
number O O 0.9999840259552002
ranged O O 0.9999696016311646
from O O 0.9999706745147705
3 O O 0.9998102784156799
to O O 0.9999672174453735
13 O O 0.9999969005584717
% O O 0.9999779462814331
mononucleate O O 0.9988805651664734
, O O 0.999964714050293
suggesting O O 0.9999561309814453
that O O 0.999909520149231
cardiomyocyte O O 0.9999551773071289
terminal O O 0.9998574256896973
differentiation O O 0.999984860420227
is O O 0.9999810457229614
influenced O O 0.9999810457229614
directly O O 0.999972939491272
or O O 0.9999630451202393
indirectly O O 0.9999812841415405
by O O 0.9999700784683228
genetic O O 0.999981164932251
background O O 0.9999959468841553
. O O 0.9999773502349854

To O O 0.9999828338623047
determine O O 0.9999909400939941
whether O O 0.9999781847000122
the O O 0.9999617338180542
capacity O O 0.9999556541442871
for O O 0.9999319314956665
reactive O O 0.7289496660232544
DNA O O 0.5885975956916809
synthesis O O 0.9989826083183289
was O O 0.9999675750732422
also O O 0.9999707937240601
subject O O 0.9999692440032959
to O O 0.9998917579650879
genetic O O 0.9999572038650513
regulation O O 0.9999960660934448
, O O 0.9999758005142212
cardiac O O 0.9999574422836304
hypertrophy O O 0.9952707886695862
was O O 0.9999679327011108
induced O O 0.9999887943267822
in O O 0.9999315738677979
the O O 0.999974250793457
strains O O 0.9999904632568359
of O O 0.9999791383743286
mice O O 0.9999865293502808
comprising O O 0.9999641180038452
the O O 0.9999810457229614
extremes O O 0.9996433258056641
of O O 0.9999837875366211
the O O 0.9999881982803345
nuclear O O 0.9999512434005737
number O O 0.9997416138648987
survey O O 0.9999650716781616
. O O 0.9999648332595825

These O O 0.9999761581420898
data O O 0.9999700784683228
indicate O O 0.9998974800109863
that O O 0.9997484087944031
adult O O 0.9913204312324524
mouse O O 0.8832520842552185
atrial O O 0.9986590147018433
and O O 0.999286949634552
ventricular O O 0.9995086193084717
cardiomyocytes O O 0.9999428987503052
do O O 0.9998446702957153
not O O 0.9998044371604919
synthesize O O 0.9996366500854492
DNA O O 0.8008228540420532
in O O 0.9997844099998474
response O O 0.9999381303787231
to O O 0.9998761415481567
isoproterenol B B 0.9994682669639587
- O O 0.999640703201294
induced O O 0.9999551773071289
cardiac O O 0.9999892711639404
hypertrophy O O 0.9991875290870667
. O O 0.9999706745147705

Central O O 0.9959290623664856
cardiovascular O O 0.9998600482940674
effects O O 0.9999635219573975
of O O 0.9996606111526489
AVP B B 0.8905103802680969
and O O 0.9629964232444763
ANP O B 0.8845129013061523
in O O 0.9996575117111206
normotensive O O 0.9999123811721802
and O O 0.9998664855957031
spontaneously O O 0.9998965263366699
hypertensive O O 0.9994478821754456
rats O O 0.9999890327453613
. O O 0.9999563694000244

The O O 0.9999921321868896
purpose O O 0.9999967813491821
of O O 0.9999960660934448
the O O 0.9999971389770508
present O O 0.9999938011169434
study O O 0.9999923706054688
was O O 0.9999964237213135
to O O 0.9999957084655762
compare O O 0.9999265670776367
influence O O 0.9998800754547119
of O O 0.9997574687004089
central O O 0.9916481971740723
arginine B B 0.961793065071106
vasopressin I I 0.8747360706329346
( O O 0.9856778979301453
AVP B B 0.934442400932312
) O O 0.9964962601661682
and O O 0.9989207983016968
of O O 0.9941680431365967
atrial O O 0.4902956187725067
natriuretic O O 0.5409148335456848
peptide O O 0.5414354801177979
( O O 0.9975287318229675
ANP O B 0.934887170791626
) O O 0.9993060827255249
on O O 0.9998804330825806
control O O 0.9999872446060181
of O O 0.9999797344207764
arterial O O 0.9998873472213745
blood O O 0.9995890259742737
pressure O O 0.9993927478790283
( O O 0.9998401403427124
MAP O O 0.9988603591918945
) O O 0.9999772310256958
and O O 0.999962329864502
heart O O 0.9999892711639404
rate O O 0.9999958276748657
( O O 0.9999634027481079
HR O O 0.9769966006278992
) O O 0.9999899864196777
in O O 0.9999295473098755
normotensive O O 0.9998764991760254
( O O 0.9998501539230347
WKY O O 0.9978296160697937
) O O 0.9999457597732544
and O O 0.9999111890792847
spontaneously O O 0.9999427795410156
hypertensive O O 0.9996322393417358
( O O 0.9998177886009216
SHR O O 0.9953937530517578
) O O 0.9999450445175171
rats O O 0.9999567270278931
. O O 0.9999697208404541

Three O O 0.9999758005142212
series O O 0.9999864101409912
of O O 0.9999687671661377
experiments O O 0.9994094371795654
were O O 0.9999834299087524
performed O O 0.9999921321868896
on O O 0.9999542236328125
30 O O 0.9996387958526611
WKY O O 0.9924669861793518
and O O 0.9999098777770996
30 O O 0.9896073937416077
SHR O O 0.9554715156555176
, O O 0.9999699592590332
chronically O O 0.9999057054519653
instrumented O O 0.9999887943267822
with O O 0.9999809265136719
guide O O 0.9999794960021973
tubes O O 0.9999107122421265
in O O 0.999954342842102
the O O 0.9999717473983765
lateral O O 0.9994699358940125
ventricle O O 0.9999886751174927
( O O 0.9998012185096741
LV O O 0.9827046990394592
) O O 0.999966025352478
and O O 0.9998955726623535
arterial O O 0.9995989203453064
and O O 0.9998636245727539
venous O O 0.9999234676361084
catheters O O 0.9999655485153198
. O O 0.9999712705612183

MAP O O 0.9285573959350586
and O O 0.9999337196350098
HR O O 0.8165094256401062
were O O 0.9999666213989258
monitored O O 0.9999866485595703
before O O 0.9999703168869019
and O O 0.9999898672103882
after O O 0.9999600648880005
i O O 0.9999388456344604
. O O 0.9999932050704956
v O O 0.9999986886978149
. O O 0.9999933242797852
injections O O 0.9999666213989258
of O O 0.9999576807022095
either O O 0.999736487865448
vehicle O O 0.9994237422943115
or O O 0.9998047947883606
1 O O 0.9886393547058105
, O O 0.9970285296440125
10 O O 0.9998108744621277
and O O 0.9997990727424622
50 O O 0.9999775886535645
ng O O 0.9961977601051331
of O O 0.9989516735076904
AVP B B 0.8655053973197937
and O O 0.9955742359161377
25 O O 0.9990654587745667
, O O 0.9979853630065918
125 O O 0.9414982199668884
and O O 0.9993719458580017
500 O O 0.9999443292617798
ng O O 0.9977188110351562
of O O 0.993986964225769
ANP O B 0.919848620891571
. O O 0.9995033740997314

Sensitivity O O 0.9999440908432007
of O O 0.999803364276886
cardiac O O 0.9991318583488464
component O O 0.9999277591705322
of O O 0.9987760186195374
baroreflex O O 0.754036545753479
( O O 0.9994851350784302
CCB O O 0.9211457371711731
) O O 0.9999312162399292
, O O 0.9999762773513794
expressed O O 0.9999896287918091
as O O 0.9999918937683105
a O O 0.9999884366989136
slope O O 0.999977707862854
of O O 0.9999864101409912
the O O 0.9999898672103882
regression O O 0.9999545812606812
line O O 0.9999899864196777
was O O 0.9999806880950928
determined O O 0.9999936819076538
from O O 0.9999833106994629
relationships O O 0.9999891519546509
between O O 0.9998453855514526
systolic O O 0.9984464049339294
arterial O O 0.9944097399711609
pressure O O 0.9999033212661743
( O O 0.9991123080253601
SAP O O 0.5115180015563965
) O O 0.9996707439422607
and O O 0.9997065663337708
HR O O 0.477862149477005
period O O 0.9815289974212646
( O O 0.998795747756958
HRp O O 0.633307695388794
) O O 0.9999425411224365
during O O 0.9998034834861755
phenylephrine B B 0.9997281432151794
( O O 0.9981622099876404
Phe B B 0.9953409433364868
) O O 0.9857184290885925
- O O 0.999824583530426
induced O O 0.9999475479125977
hypertension O O 0.9999568462371826
and O O 0.9998588562011719
sodium B B 0.9974796175956726
nitroprusside I I 0.9981443881988525
( O O 0.994057297706604
SN B B 0.9993082284927368
) O O 0.9854159951210022
- O O 0.99992835521698
induced O O 0.9999642372131348
hypotension O O 0.9999768733978271
. O O 0.9999734163284302

CCB O O 0.6733237504959106
was O O 0.9999538660049438
measured O O 0.9999685287475586
before O O 0.9999191761016846
and O O 0.9999711513519287
after O O 0.9999352693557739
administration O O 0.9999371767044067
of O O 0.9998822212219238
either O O 0.99909508228302
vehicle O O 0.7481069564819336
, O O 0.9989479184150696
AVP B B 0.9042067527770996
, O O 0.8411457538604736
ANP O B 0.9020552039146423
, O O 0.9654874801635742
or O O 0.9994956254959106
both O O 0.9987371563911438
peptides O O 0.9560059309005737
together O O 0.9996652603149414
. O O 0.9999645948410034

Increases O O 0.9999191761016846
of O O 0.9993650317192078
MAP O O 0.8103282451629639
occurred O O 0.9999872446060181
after O O 0.9999077320098877
LV O O 0.6744797825813293
administration O O 0.9997363686561584
of O O 0.9998742341995239
1 O O 0.9959020018577576
, O O 0.9985162615776062
10 O O 0.998995840549469
and O O 0.999582827091217
50 O O 0.9997631907463074
ng O O 0.9972720742225647
of O O 0.996364951133728
AVP B B 0.8783711791038513
in O O 0.9971528053283691
WKY O O 0.9663708209991455
and O O 0.9998250603675842
of O O 0.9995519518852234
10 O O 0.9864361882209778
and O O 0.9993191957473755
50 O O 0.9992223978042603
ng O O 0.9666596055030823
in O O 0.998576283454895
SHR O O 0.6646248698234558
. O O 0.9999481439590454

ANP O B 0.9934881925582886
did O O 0.9998353719711304
not O O 0.999942421913147
cause O O 0.9999622106552124
significant O O 0.9999831914901733
changes O O 0.9999966621398926
in O O 0.9999778270721436
MAP O O 0.9998819828033447
in O O 0.9998550415039062
both O O 0.999545156955719
strains O O 0.9999690055847168
as O O 0.999972939491272
compared O O 0.9999850988388062
to O O 0.9996925592422485
vehicle O O 0.9851657152175903
, O O 0.9999294281005859
but O O 0.9999126195907593
it O O 0.9990692734718323
abolished O O 0.9404405951499939
AVP B B 0.9645049571990967
- O O 0.9968680739402771
induced O O 0.9998965263366699
MAP O O 0.9999591112136841
increase O O 0.9999665021896362
in O O 0.9998505115509033
WKY O O 0.9911824464797974
and O O 0.9998050332069397
SHR O O 0.9465968608856201
. O O 0.9999315738677979

CCB O O 0.7605201601982117
was O O 0.99981290102005
reduced O O 0.9999696016311646
in O O 0.9998897314071655
WKY O O 0.9636669158935547
and O O 0.9996734857559204
SHR O O 0.875271201133728
after O O 0.9994578957557678
LV O O 0.8044386506080627
administration O O 0.9994637370109558
of O O 0.9992659687995911
AVP B B 0.9698017835617065
during O O 0.9995729327201843
SN B B 0.9931233525276184
- O O 0.9969046711921692
induced O O 0.9999756813049316
hypotension O O 0.9999728202819824
. O O 0.9999743700027466

In O O 0.9996558427810669
SHR O O 0.929542064666748
but O O 0.9999566078186035
not O O 0.9999219179153442
in O O 0.9998562335968018
WKY O O 0.9340716600418091
administration O O 0.9998008608818054
of O O 0.9991753697395325
ANP O B 0.9538661241531372
, O O 0.9528703093528748
AVP B B 0.9205157160758972
and O O 0.9959010481834412
ANP O B 0.9565043449401855
+ O O 0.9893520474433899
AVP B B 0.8975118398666382
decreased O O 0.9997063279151917
CCB O O 0.8641629815101624
during O O 0.9993715882301331
Phe B B 0.99828040599823
- O O 0.994599461555481
induced O O 0.9999288320541382
MAP O O 0.9979639053344727
elevation O O 0.9999624490737915
. O O 0.9999572038650513

The O O 0.999988317489624
results O O 0.9999929666519165
indicate O O 0.9999401569366455
that O O 0.9998493194580078
centrally O O 0.9997052550315857
applied O O 0.9994592070579529
AVP B B 0.9771356582641602
and O O 0.8671323657035828
ANP O B 0.9589150547981262
exert O O 0.999764621257782
differential O O 0.999605119228363
effects O O 0.9999493360519409
on O O 0.9999021291732788
blood O O 0.997745931148529
pressure O O 0.9932395219802856
and O O 0.9995620846748352
baroreflex O O 0.9686973094940186
control O O 0.9999353885650635
of O O 0.9999262094497681
heart O O 0.9999380111694336
rate O O 0.999976634979248
in O O 0.9996770620346069
WKY O O 0.9865297079086304
and O O 0.9996180534362793
SHR O O 0.9413893818855286
and O O 0.9999345541000366
suggest O O 0.9997245669364929
interaction O O 0.9999445676803589
of O O 0.999496340751648
these O O 0.9787296652793884
two O O 0.9916782379150391
peptides O O 0.8917217254638672
in O O 0.9998761415481567
blood O O 0.9928805828094482
pressure O O 0.975404679775238
regulation O O 0.9999381303787231
at O O 0.9999189376831055
the O O 0.9999006986618042
level O O 0.9999477863311768
of O O 0.999890923500061
central O O 0.9998822212219238
nervous O O 0.9999890327453613
system O O 0.9999862909317017
. O O 0.9999613761901855

Cutaneous O O 0.9993427395820618
exposure O O 0.999933123588562
to O O 0.9979070425033569
warfarin B B 0.9993628859519958
- O O 0.9927712082862854
like O O 0.9854824542999268
anticoagulant O O 0.7425757646560669
causing O O 0.9998008608818054
an O O 0.9999833106994629
intracerebral O O 0.999995231628418
hemorrhage O O 0.9999881982803345
: O O 0.9999908208847046
a O O 0.9999929666519165
case O O 0.9999855756759644
report O O 0.9999947547912598
. O O 0.9999711513519287

A O O 0.9999411106109619
case O O 0.9999833106994629
of O O 0.9999693632125854
intercerebral O O 0.9982883334159851
hematoma O O 0.9999716281890869
due O O 0.9999603033065796
to O O 0.9995549321174622
warfarin B B 0.9995694756507874
- O O 0.9992678761482239
induced O O 0.9999173879623413
coagulopathy O O 0.969860851764679
is O O 0.9999369382858276
presented O O 0.9999866485595703
. O O 0.9999712705612183

The O O 0.9999946355819702
39 O O 0.9999929666519165
- O O 0.9999889135360718
year O O 0.9999964237213135
- O O 0.9999936819076538
old O O 0.999993085861206
woman O O 0.9999939203262329
had O O 0.9999643564224243
spread O O 0.9999043941497803
a O O 0.9997574687004089
warfarin B B 0.9993013143539429
- O O 0.9982218146324158
type O O 0.998381495475769
rat O O 0.7305879592895508
poison O O 0.629086434841156
around O O 0.9997723698616028
her O O 0.9999864101409912
house O O 0.9999921321868896
weekly O O 0.9999511241912842
using O O 0.9999431371688843
her O O 0.9999862909317017
bare O O 0.9999556541442871
hands O O 0.9999377727508545
, O O 0.9999738931655884
with O O 0.9999755620956421
no O O 0.9999504089355469
washing O O 0.9997954964637756
post O O 0.9920584559440613
application O O 0.9999685287475586
. O O 0.999970555305481

Percutaneous O O 0.9999061822891235
absorption O O 0.9998878240585327
of O O 0.9995537400245667
warfarin B B 0.9995355606079102
causing O O 0.9996765851974487
coagulopathy O O 0.9976281523704529
, O O 0.9999755620956421
reported O O 0.9999953508377075
three O O 0.999956488609314
times O O 0.9999889135360718
in O O 0.9999943971633911
the O O 0.9999982118606567
past O O 0.9999949932098389
, O O 0.9999922513961792
is O O 0.999976396560669
a O O 0.9999774694442749
significant O O 0.9999938011169434
risk O O 0.999995231628418
if O O 0.9999750852584839
protective O O 0.9981318116188049
measures O O 0.9998458623886108
, O O 0.9999808073043823
such O O 0.9999605417251587
as O O 0.9999126195907593
gloves O O 0.6133097410202026
, O O 0.9997212290763855
are O O 0.9999691247940063
not O O 0.9999665021896362
used O O 0.9999485015869141
. O O 0.9998759031295776

An O O 0.9999295473098755
adverse O O 0.9995644688606262
drug O O 0.9994205236434937
interaction O O 0.9999088048934937
with O O 0.9994889497756958
piroxicam B B 0.9993301630020142
, O O 0.9997480511665344
which O O 0.9993661046028137
she O O 0.9999634027481079
took O O 0.9990113973617554
occasionally O O 0.9996309280395508
, O O 0.9999384880065918
may O O 0.9999252557754517
have O O 0.9999829530715942
exacerbated O O 0.9999659061431885
the O O 0.9999905824661255
coagulopathy O O 0.9994040727615356
. O O 0.9999573230743408

Pediatric O O 0.9998468160629272
heart O O 0.9998741149902344
transplantation O O 0.9999793767929077
without O O 0.9999393224716187
chronic O O 0.9997872710227966
maintenance O O 0.9932658672332764
steroids B B 0.9861857891082764
. O O 0.9998401403427124

From O O 0.9999244213104248
1986 O O 0.9981983304023743
to O O 0.9999334812164307
February O O 0.9999423027038574
1993 O O 0.9999585151672363
, O O 0.9999830722808838
40 O O 0.9999815225601196
children O O 0.9999947547912598
aged O O 0.9999905824661255
2 O O 0.999984622001648
months O O 0.999997615814209
to O O 0.9999898672103882
18 O O 0.9999961853027344
years O O 0.9999973773956299
( O O 0.9999831914901733
average O O 0.9999945163726807
age O O 0.9999958276748657
10 O O 0.9999971389770508
. O O 0.9999982118606567
4 O O 0.9999943971633911
+ O O 0.9999958276748657
/ O O 0.9999939203262329
- O O 0.9999810457229614
5 O O 0.9999982118606567
. O O 0.9999986886978149
8 O O 0.9999958276748657
years O O 0.9999984502792358
) O O 0.9999879598617554
underwent O O 0.9999895095825195
heart O O 0.9999680519104004
transplantation O O 0.9999594688415527
. O O 0.9999773502349854

Indications O O 0.9999793767929077
for O O 0.9999884366989136
transplantation O O 0.9999542236328125
were O O 0.9999672174453735
idiopathic O O 0.9999955892562866
cardiomyopathy O O 0.9999955892562866
( O O 0.9999589920043945
52 O O 0.9999864101409912
% O O 0.9999860525131226
) O O 0.9999741315841675
, O O 0.9999747276306152
congenital O O 0.9938127994537354
heart O O 0.9999942779541016
disease O O 0.9999979734420776
( O O 0.9999552965164185
35 O O 0.9999914169311523
% O O 0.9999830722808838
) O O 0.9999570846557617
with O O 0.9999358654022217
and O O 0.999962329864502
without O O 0.9999840259552002
prior O O 0.9999368190765381
repair O O 0.9999959468841553
( O O 0.9999620914459229
71 O O 0.9999918937683105
% O O 0.9999966621398926
and O O 0.9999752044677734
29 O O 0.9999926090240479
% O O 0.9999939203262329
, O O 0.999991774559021
respectively O O 0.99998939037323
) O O 0.9999650716781616
, O O 0.9999682903289795
hypertrophic O O 0.9795467257499695
cardiomyopathy O O 0.9999901056289673
( O O 0.9999563694000244
5 O O 0.9999669790267944
% O O 0.9999830722808838
) O O 0.9999630451202393
, O O 0.999962329864502
valvular O O 0.9997795224189758
heart O O 0.9999871253967285
disease O O 0.9999951124191284
( O O 0.9999644756317139
3 O O 0.9998561143875122
% O O 0.999954104423523
) O O 0.999945878982544
, O O 0.9998098015785217
and O O 0.9996055960655212
doxorubicin B B 0.9993379712104797
cardiomyopathy O O 0.9996817111968994
( O O 0.9999467134475708
5 O O 0.9999328851699829
% O O 0.9999604225158691
) O O 0.9999712705612183
. O O 0.9999785423278809

Patients O O 0.9998757839202881
were O O 0.9999746084213257
managed O O 0.9999865293502808
with O O 0.9996751546859741
cyclosporine B B 0.999482274055481
and O O 0.9557002186775208
azathioprine B B 0.9980582594871521
. O O 0.9999251365661621

No O O 0.9998875856399536
prophylaxis O O 0.999906063079834
with O O 0.9998219609260559
antilymphocyte O O 0.5911312103271484
globulin O O 0.7197147011756897
was O O 0.9994762539863586
used O O 0.999909520149231
. O O 0.9999053478240967

Steroids B O 0.5644335746765137
were O O 0.9999188184738159
given O O 0.999901294708252
to O O 0.9999568462371826
39 O O 0.9999805688858032
% O O 0.9999945163726807
of O O 0.9999839067459106
patients O O 0.9999886751174927
for O O 0.9998774528503418
refractory O O 0.9999727010726929
rejection O O 0.9999959468841553
, O O 0.9999513626098633
but O O 0.9999254941940308
weaning O O 0.9999755620956421
was O O 0.9999834299087524
always O O 0.9999651908874512
attempted O O 0.9999731779098511
and O O 0.9999932050704956
generally O O 0.9999954700469971
successful O O 0.9999886751174927
( O O 0.9999877214431763
64 O O 0.9999985694885254
% O O 0.9999982118606567
) O O 0.9999833106994629
. O O 0.9999827146530151

Five O O 0.9999593496322632
patients O O 0.9999938011169434
( O O 0.9999732971191406
14 O O 0.9999963045120239
% O O 0.9999923706054688
) O O 0.9999743700027466
received O O 0.999904990196228
maintenance O O 0.9991363883018494
steroids B B 0.9865795969963074
. O O 0.9999088048934937

Four O O 0.999674916267395
patients O O 0.9999794960021973
died O O 0.9999442100524902
in O O 0.9999569654464722
the O O 0.9999876022338867
perioperative O O 0.9998229146003723
period O O 0.9999774694442749
and O O 0.9998890161514282
one O O 0.9999722242355347
died O O 0.9999589920043945
4 O O 0.9998186230659485
months O O 0.9999979734420776
later O O 0.9999958276748657
. O O 0.9999773502349854

There O O 0.9999185800552368
have O O 0.999984622001648
been O O 0.9999890327453613
no O O 0.9998743534088135
deaths O O 0.9997535347938538
related O O 0.999976634979248
to O O 0.9992251396179199
rejection O O 0.99993896484375
or O O 0.999810516834259
infection O O 0.9999196529388428
. O O 0.9999401569366455

Average O O 0.9999048709869385
follow O O 0.9999856948852539
- O O 0.999993085861206
up O O 0.9999954700469971
was O O 0.9999947547912598
36 O O 0.999997615814209
+ O O 0.9999955892562866
/ O O 0.9999887943267822
- O O 0.9999843835830688
19 O O 0.9999228715896606
months O O 0.9999985694885254
( O O 0.9999644756317139
range O O 0.999991774559021
1 O O 0.999992847442627
to O O 0.9999904632568359
65 O O 0.9999904632568359
months O O 0.9999985694885254
) O O 0.9999837875366211
. O O 0.999987006187439

Cumulative O O 0.999910831451416
survival O O 0.999921441078186
is O O 0.9999815225601196
88 O O 0.9999648332595825
% O O 0.9999985694885254
at O O 0.999991774559021
5 O O 0.9999536275863647
years O O 0.9999927282333374
. O O 0.9999778270721436

In O O 0.9999703168869019
patients O O 0.9999986886978149
less O O 0.9999983310699463
than O O 0.999998927116394
7 O O 0.9999983310699463
years O O 0.9999994039535522
of O O 0.9999992847442627
age O O 0.9999971389770508
, O O 0.999962329864502
rejection O O 0.999935507774353
was O O 0.999976634979248
monitored O O 0.9999788999557495
noninvasively O O 0.9999700784683228
. O O 0.9999850988388062

In O O 0.9999418258666992
the O O 0.9999927282333374
first O O 0.9999954700469971
postoperative O O 0.999980092048645
month O O 0.9999966621398926
, O O 0.9999792575836182
89 O O 0.9997864365577698
% O O 0.9999967813491821
of O O 0.9999885559082031
patients O O 0.999990701675415
were O O 0.9999641180038452
treated O O 0.9999618530273438
for O O 0.9999346733093262
rejection O O 0.9999386072158813
. O O 0.999970555305481

Freedom O O 0.999768078327179
from O O 0.9999428987503052
serious O O 0.9995830655097961
infections O O 0.9999707937240601
was O O 0.9999573230743408
83 O O 0.9999468326568604
% O O 0.9999942779541016
at O O 0.9999814033508301
1 O O 0.9999732971191406
month O O 0.9999979734420776
and O O 0.999967098236084
65 O O 0.9999959468841553
% O O 0.9999953508377075
at O O 0.9999755620956421
1 O O 0.9999756813049316
year O O 0.9999966621398926
. O O 0.9999796152114868

Cytomegalovirus O O 0.8307820558547974
infections O O 0.9998072981834412
were O O 0.9999828338623047
treated O O 0.9999730587005615
successfully O O 0.9999804496765137
with O O 0.9996609687805176
ganciclovir B B 0.99960857629776
in O O 0.9996657371520996
11 O O 0.999852180480957
patients O O 0.9999946355819702
. O O 0.9999781847000122

No O O 0.9998334646224976
impairment O O 0.9999974966049194
of O O 0.9999897480010986
growth O O 0.9999693632125854
was O O 0.9999847412109375
observed O O 0.9999924898147583
in O O 0.9999350309371948
children O O 0.9999958276748657
who O O 0.9999552965164185
underwent O O 0.999972939491272
transplantation O O 0.9995724558830261
compared O O 0.999972939491272
with O O 0.9999862909317017
a O O 0.9999585151672363
control O O 0.9999146461486816
population O O 0.9999935626983643
. O O 0.9999775886535645

Twenty O O 0.9812953472137451
- O O 0.9998747110366821
one O O 0.9999467134475708
patients O O 0.9999904632568359
( O O 0.9999558925628662
60 O O 0.999996542930603
% O O 0.9999951124191284
) O O 0.9999701976776123
have O O 0.9999874830245972
undergone O O 0.9999938011169434
annual O O 0.9998806715011597
catheterizations O O 0.9999796152114868
and O O 0.9999510049819946
no O O 0.9999842643737793
sign O O 0.9999842643737793
of O O 0.9999642372131348
graft O O 0.9992160797119141
atherosclerosis O O 0.9998388290405273
has O O 0.9999873638153076
been O O 0.999996542930603
observed O O 0.9999954700469971
. O O 0.9999707937240601

Seizures O O 0.9996901750564575
occurred O O 0.9999836683273315
in O O 0.9999613761901855
five O O 0.9999970197677612
patients O O 0.9999947547912598
( O O 0.9999452829360962
14 O O 0.9999966621398926
% O O 0.9999945163726807
) O O 0.9999336004257202
and O O 0.9998373985290527
hypertension O O 0.6758750677108765
was O O 0.9998959302902222
treated O O 0.999771773815155
in O O 0.9999362230300903
10 O O 0.9999041557312012
patients O O 0.9999932050704956
( O O 0.9999575614929199
28 O O 0.9999945163726807
% O O 0.9999880790710449
) O O 0.9999439716339111
. O O 0.9999762773513794

No O O 0.9999078512191772
patient O O 0.9999864101409912
was O O 0.9999356269836426
disabled O O 0.9999542236328125
and O O 0.999940037727356
no O O 0.9999622106552124
lymphoproliferative O O 0.9996870756149292
disorder O O 0.9999922513961792
was O O 0.9999645948410034
observed O O 0.9999862909317017
. O O 0.9999905824661255
( O O 0.9994078874588013
ABSTRACT O O 0.9999603033065796
TRUNCATED O O 0.999955415725708
AT O O 0.9997599720954895
250 O O 0.9931840300559998
WORDS O O 0.9999819993972778
) O O 0.9999202489852905

Delirium O O 0.9991815686225891
during O O 0.9996813535690308
fluoxetine B B 0.9994957447052002
treatment O O 0.9998149275779724
. O O 0.9999339580535889

A O O 0.9991351962089539
case O O 0.9998360872268677
report O O 0.999976634979248
. O O 0.999750554561615

The O O 0.9999748468399048
correlation O O 0.999990701675415
between O O 0.9998725652694702
high O O 0.9997734427452087
serum O O 0.9987624883651733
tricyclic O B 0.9460354447364807
antidepressant O O 0.6879749894142151
concentrations O O 0.9911001324653625
and O O 0.9999207258224487
central O O 0.9998953342437744
nervous O O 0.9999877214431763
system O O 0.9999574422836304
side O O 0.9999414682388306
effects O O 0.9999858140945435
has O O 0.999958872795105
been O O 0.9999918937683105
well O O 0.9999871253967285
established O O 0.9999916553497314
. O O 0.9999786615371704

Only O O 0.9999829530715942
a O O 0.9999873638153076
few O O 0.9999938011169434
reports O O 0.9999933242797852
exist O O 0.99998939037323
, O O 0.9999794960021973
however O O 0.9999786615371704
, O O 0.9999901056289673
on O O 0.9999347925186157
the O O 0.9999858140945435
relationship O O 0.9999921321868896
between O O 0.9999264478683472
the O O 0.9999641180038452
serum O O 0.9993391633033752
concentrations O O 0.998964786529541
of O O 0.9987998008728027
selective O O 0.5367984771728516
serotonin B B 0.7940104007720947
reuptake O I 0.8342387676239014
inhibitors O I 0.9479386806488037
( O O 0.9824635982513428
SSRIs O B 0.9534000158309937
) O O 0.9992788434028625
and O O 0.9998959302902222
their O O 0.9991416931152344
toxic O O 0.999541163444519
effects O O 0.9999531507492065
. O O 0.9999687671661377

In O O 0.9998997449874878
some O O 0.9998878240585327
cases O O 0.9999527931213379
, O O 0.9999009370803833
a O O 0.9999475479125977
high O O 0.999800980091095
serum O O 0.9993300437927246
concentration O O 0.9992281198501587
of O O 0.9974188804626465
citalopram B B 0.9992875456809998
( O O 0.99970942735672
> O O 0.9998990297317505
600 O O 0.9998952150344849
nmol O O 0.999922513961792
/ O O 0.9997661709785461
L O O 0.9934497475624084
) O O 0.9999432563781738
in O O 0.9999176263809204
elderly O O 0.9995478987693787
patients O O 0.9999855756759644
has O O 0.9999349117279053
been O O 0.9999775886535645
associated O O 0.9999855756759644
with O O 0.9999852180480957
increased O O 0.999987006187439
somnolence O O 0.999982476234436
and O O 0.9999524354934692
movement O O 0.9999951124191284
difficulties O O 0.9999967813491821
. O O 0.9999772310256958

Widespread O O 0.9882394075393677
cognitive O O 0.999903678894043
disorders O O 0.9999842643737793
, O O 0.9999693632125854
such O O 0.9999386072158813
as O O 0.9999063014984131
delirium O O 0.9996891021728516
, O O 0.9999675750732422
have O O 0.9999593496322632
not O O 0.9999747276306152
been O O 0.9999860525131226
previously O O 0.9999029636383057
linked O O 0.9999887943267822
with O O 0.9999778270721436
high O O 0.9999228715896606
blood O O 0.9998216032981873
levels O O 0.9999313354492188
of O O 0.997884213924408
SSRIs O B 0.9323529601097107
. O O 0.9998642206192017

In O O 0.9999905824661255
this O O 0.9999889135360718
report O O 0.9999971389770508
, O O 0.9999780654907227
we O O 0.9999649524688721
describe O O 0.9999904632568359
a O O 0.9999847412109375
patient O O 0.9999884366989136
with O O 0.9999352693557739
acute O O 0.999966025352478
hyperkinetic O O 0.999339759349823
delirium O O 0.9999576807022095
connected O O 0.9998912811279297
with O O 0.9999402761459351
a O O 0.9999535083770752
high O O 0.9997609257698059
serum O O 0.9990695118904114
total O O 0.5588805675506592
fluoxetine B B 0.897727370262146
( O O 0.991493821144104
fluoxetine B B 0.9989911913871765
plus O O 0.976782500743866
desmethylfluoxetine B B 0.9933928847312927
) O O 0.9979091286659241
concentration O O 0.9997949004173279
. O O 0.9999814033508301

Pulmonary O O 0.9999499320983887
edema O O 0.9999935626983643
and O O 0.9999783039093018
shock O O 0.9999957084655762
after O O 0.9999098777770996
high O O 0.9983707070350647
- O O 0.9999513626098633
dose O O 0.9960708618164062
aracytine B B 0.98271644115448
- I I 0.8024854063987732
C I I 0.9960333704948425
for O O 0.9873093962669373
lymphoma O O 0.9999243021011353
; O O 0.9999475479125977
possible O O 0.999810516834259
role O O 0.999934196472168
of O O 0.9982967972755432
TNF O B 0.5826131701469421
- O I 0.6354519128799438
alpha O I 0.9648993015289307
and O O 0.7971220016479492
PAF O B 0.8810780048370361
. O O 0.9998458623886108

Four O O 0.9999904632568359
out O O 0.9999922513961792
of O O 0.9999920129776001
23 O O 0.999996542930603
consecutive O O 0.9999890327453613
patients O O 0.9999951124191284
treated O O 0.9999585151672363
with O O 0.9998794794082642
high O O 0.9983478784561157
- O O 0.9999573230743408
dose O O 0.9975314140319824
Ara B B 0.990996241569519
- I I 0.6934528946876526
C I I 0.9959762692451477
for O O 0.9929934144020081
lymphomas O O 0.9999315738677979
in O O 0.9999749660491943
our O O 0.9999819993972778
institution O O 0.9999909400939941
developed O O 0.9999909400939941
a O O 0.9999912977218628
strikingly O O 0.9999837875366211
similar O O 0.9999935626983643
syndrome O O 0.9999959468841553
during O O 0.9999713897705078
the O O 0.9999417066574097
perfusion O O 0.9994567036628723
. O O 0.9999805688858032

It O O 0.9999746084213257
was O O 0.9999731779098511
characterized O O 0.9999945163726807
by O O 0.9999916553497314
the O O 0.9999953508377075
onset O O 0.9999973773956299
of O O 0.9999901056289673
fever O O 0.9999816417694092
, O O 0.9999778270721436
diarrhea O O 0.9999710321426392
, O O 0.9999516010284424
shock O O 0.9999918937683105
, O O 0.9999768733978271
pulmonary O O 0.9999784231185913
edema O O 0.9999898672103882
, O O 0.9999748468399048
acute O O 0.9999809265136719
renal O O 0.9999978542327881
failure O O 0.9999955892562866
, O O 0.9999607801437378
metabolic O O 0.9701805710792542
acidosis O O 0.9932988882064819
, O O 0.9999539852142334
weight O O 0.9999877214431763
gain O O 0.9999929666519165
and O O 0.9999475479125977
leukocytosis O O 0.9998965263366699
. O O 0.9999706745147705

Thorough O O 0.9997404217720032
bacteriological O O 0.999751627445221
screening O O 0.9999839067459106
failed O O 0.9999761581420898
to O O 0.9999867677688599
provide O O 0.999977707862854
evidence O O 0.9999693632125854
of O O 0.9999395608901978
infection O O 0.999963641166687
. O O 0.9999510049819946

Sequential O O 0.9999176263809204
biological O O 0.9999479055404663
assays O O 0.9998894929885864
of O O 0.9997909665107727
IL O O 0.9806950092315674
- O O 0.9967310428619385
1 O O 0.9983508586883545
, O O 0.9986205101013184
IL O O 0.9827028512954712
- O O 0.9957466721534729
2 O O 0.9976528286933899
, O O 0.997805655002594
TNF O O 0.8559143543243408
and O O 0.9963266253471375
PAF O O 0.7575791478157043
were O O 0.999966025352478
performed O O 0.9999896287918091
during O O 0.9998824596405029
Ara B B 0.9379081130027771
- I I 0.6480429768562317
C I I 0.9890785813331604
infusion O O 0.9992823004722595
to O O 0.999963641166687
ten O O 0.99998939037323
patients O O 0.9999972581863403
, O O 0.9999923706054688
including O O 0.9999918937683105
the O O 0.9999927282333374
four O O 0.9999902248382568
who O O 0.9999908208847046
developed O O 0.9999926090240479
the O O 0.9999933242797852
syndrome O O 0.999994158744812
. O O 0.999975323677063

TNF O O 0.6578696966171265
and O O 0.9757025837898254
PAF O O 0.5887745022773743
activity O O 0.9371152520179749
was O O 0.9999384880065918
found O O 0.9999330043792725
in O O 0.9998633861541748
the O O 0.9999637603759766
serum O O 0.9998902082443237
of O O 0.9999524354934692
respectively O O 0.999894380569458
two O O 0.999984622001648
and O O 0.9999514818191528
four O O 0.9999868869781494
of O O 0.9999880790710449
the O O 0.9999942779541016
cases O O 0.9999909400939941
, O O 0.999966025352478
but O O 0.9999743700027466
not O O 0.9999752044677734
in O O 0.9999313354492188
the O O 0.9999905824661255
six O O 0.9999115467071533
controls O O 0.99998939037323
. O O 0.9999632835388184

As O O 0.999941349029541
TNF O O 0.7993513941764832
and O O 0.9951743483543396
PAF O O 0.7370530962944031
are O O 0.9996150732040405
thought O O 0.9998997449874878
to O O 0.9999001026153564
be O O 0.9999204874038696
involved O O 0.9999542236328125
in O O 0.9999853372573853
the O O 0.9999923706054688
development O O 0.9999932050704956
of O O 0.9999864101409912
septic O O 0.9999927282333374
shock O O 0.9999947547912598
and O O 0.9999853372573853
adult O O 0.999872088432312
respiratory O O 0.9999960660934448
distress O O 0.9999967813491821
syndrome O O 0.9999971389770508
, O O 0.9999668598175049
we O O 0.9999715089797974
hypothesize O O 0.9998041987419128
that O O 0.9999212026596069
high O O 0.9996341466903687
- O O 0.999936580657959
dose O O 0.9986567497253418
Ara B B 0.9924209713935852
- I I 0.8283807039260864
C I I 0.9997442364692688
may O O 0.9995884299278259
be O O 0.999974250793457
associated O O 0.9999673366546631
with O O 0.9999105930328369
cytokine O O 0.9955442547798157
release O O 0.9999237060546875
. O O 0.9999802112579346

Protective O O 0.9995711445808411
effect O O 0.9998742341995239
of O O 0.9976786971092224
clentiazem B B 0.9995680451393127
against O O 0.9986791014671326
epinephrine B B 0.9970698356628418
- O O 0.9998021721839905
induced O O 0.999956488609314
cardiac O O 0.9999898672103882
injury O O 0.9999970197677612
in O O 0.9999768733978271
rats O O 0.9999858140945435
. O O 0.9999269247055054

We O O 0.9999617338180542
investigated O O 0.9999710321426392
the O O 0.9999665021896362
effects O O 0.9999535083770752
of O O 0.9986541271209717
clentiazem B B 0.9998520612716675
, O O 0.9996565580368042
a O O 0.9989781379699707
1 B B 0.7604787945747375
, I I 0.8858012557029724
5 I I 0.9153321385383606
- I I 0.9717857241630554
benzothiazepine I I 0.999617338180542
calcium B I 0.9270837306976318
antagonist O O 0.7490264773368835
, O O 0.9999182224273682
on O O 0.9998700618743896
epinephrine B B 0.9975461363792419
- O O 0.9998617172241211
induced O O 0.9999628067016602
cardiomyopathy O O 0.9999969005584717
in O O 0.9999630451202393
rats O O 0.9999773502349854
. O O 0.9999815225601196

With O O 0.9999222755432129
2 O O 0.9996113181114197
- O O 0.9999421834945679
week O O 0.9999754428863525
chronic O O 0.9970223307609558
epinephrine B B 0.9924070239067078
infusion O O 0.9993889331817627
, O O 0.999981164932251
16 O O 0.9998747110366821
of O O 0.9999744892120361
30 O O 0.9999805688858032
rats O O 0.9998685121536255
died O O 0.9999940395355225
within O O 0.9999938011169434
4 O O 0.9999480247497559
days O O 0.9999969005584717
, O O 0.9999614953994751
and O O 0.999981164932251
severe O O 0.9998905658721924
ischemic O O 0.9999665021896362
lesions O O 0.999996542930603
and O O 0.9999237060546875
fibrosis O O 0.9999737739562988
of O O 0.9999469518661499
the O O 0.9999836683273315
left O O 0.9999778270721436
ventricles O O 0.999991774559021
were O O 0.9999819993972778
observed O O 0.9999949932098389
. O O 0.9999808073043823

In O O 0.9998385906219482
epinephrine B B 0.9973076581954956
- O O 0.9998421669006348
treated O O 0.9997257590293884
rats O O 0.9997560381889343
, O O 0.9999006986618042
left O O 0.9998769760131836
atrial O O 0.9998887777328491
and O O 0.9997029900550842
left O O 0.9998375177383423
ventricular O O 0.999984860420227
papillary O O 0.9961819648742676
muscle O O 0.9993935823440552
contractile O O 0.9996374845504761
responses O O 0.9999649524688721
to O O 0.9998006224632263
isoproterenol B B 0.9991004467010498
were O O 0.9998339414596558
reduced O O 0.9999669790267944
, O O 0.9999585151672363
but O O 0.9999090433120728
responses O O 0.9999674558639526
to O O 0.9997881054878235
calcium B B 0.9959666728973389
were O O 0.9999114274978638
normal O O 0.9999568462371826
or O O 0.9999921321868896
enhanced O O 0.9999873638153076
compared O O 0.9999924898147583
to O O 0.999969482421875
controls O O 0.9999498128890991
. O O 0.9999822378158569

Left O O 0.9967095851898193
ventricular O O 0.9996782541275024
alpha O O 0.9303277134895325
and O O 0.9988009929656982
beta O O 0.9825542569160461
adrenoceptor O O 0.9442068934440613
densities O O 0.9994528889656067
were O O 0.9999080896377563
also O O 0.9999324083328247
reduced O O 0.9999762773513794
compared O O 0.9999823570251465
to O O 0.9999197721481323
controls O O 0.999904990196228
. O O 0.999964714050293

Treatment O O 0.9999082088470459
with O O 0.9994410872459412
clentiazem B B 0.9996966123580933
prevented O O 0.9997650980949402
epinephrine B B 0.9968384504318237
- O O 0.9999159574508667
induced O O 0.9999713897705078
death O O 0.9999902248382568
( O O 0.9999620914459229
P O O 0.9999765157699585
< O O 0.999991774559021
. O O 0.9999957084655762
05 O O 0.9999933242797852
) O O 0.9999408721923828
, O O 0.9999251365661621
and O O 0.9998611211776733
attenuated O O 0.998866081237793
the O O 0.9997870326042175
ventricular O O 0.9998762607574463
ischemic O O 0.9999392032623291
lesions O O 0.99998939037323
and O O 0.9998832941055298
fibrosis O O 0.9999852180480957
, O O 0.9999703168869019
in O O 0.9999850988388062
a O O 0.9999734163284302
dose O O 0.9990732669830322
- O O 0.9999680519104004
dependent O O 0.9999619722366333
manner O O 0.9999873638153076
. O O 0.9999687671661377

Left O O 0.9994333386421204
atrial O O 0.99982088804245
and O O 0.999460756778717
left O O 0.9997021555900574
ventricular O O 0.9999680519104004
papillary O O 0.9889864921569824
muscle O O 0.9987875819206238
contractile O O 0.9996150732040405
responses O O 0.9999549388885498
to O O 0.9997174143791199
isoproterenol B B 0.9992720484733582
were O O 0.9998598098754883
reduced O O 0.9999842643737793
compared O O 0.9999858140945435
to O O 0.9999679327011108
controls O O 0.9999759197235107
in O O 0.9999172687530518
groups O O 0.9999812841415405
treated O O 0.9999589920043945
with O O 0.9998883008956909
clentiazem B B 0.9994779229164124
alone O O 0.9994644522666931
, O O 0.9999431371688843
but O O 0.9998855590820312
combined O O 0.9999363422393799
with O O 0.9997990727424622
epinephrine B B 0.9958416819572449
, O O 0.9986175298690796
clentiazem B B 0.9997305274009705
restored O O 0.9998395442962646
left O O 0.9999053478240967
atrial O O 0.9999682903289795
responses O O 0.9999725818634033
and O O 0.9999504089355469
enhanced O O 0.9998143315315247
left O O 0.9998444318771362
ventricular O O 0.9999910593032837
papillary O O 0.9974185228347778
responses O O 0.999984860420227
to O O 0.9997205138206482
isoproterenol B B 0.9994608759880066
. O O 0.9999477863311768

On O O 0.9999080896377563
the O O 0.999961256980896
other O O 0.999923586845398
hand O O 0.9998852014541626
clentiazem B B 0.9998295307159424
did O O 0.9999082088470459
not O O 0.9999313354492188
prevent O O 0.9996762275695801
epinephrine B B 0.9987890124320984
- O O 0.9998559951782227
induced O O 0.9999336004257202
down O O 0.9997103810310364
- O O 0.9999631643295288
regulation O O 0.9999836683273315
of O O 0.9997749924659729
alpha O O 0.983249306678772
and O O 0.9992051720619202
beta O O 0.9928303360939026
adrenoceptors O O 0.9425933957099915
. O O 0.9998524188995361

Interestingly O O 0.9993451237678528
, O O 0.9993842840194702
clentiazem B B 0.9997918009757996
, O O 0.9999278783798218
infused O O 0.9999226331710815
alone O O 0.9995884299278259
, O O 0.9999651908874512
resulted O O 0.9999716281890869
in O O 0.9999810457229614
decreased O O 0.9998983144760132
adrenergic O O 0.8860666155815125
receptor O O 0.9887399077415466
densities O O 0.9996365308761597
in O O 0.9998062252998352
the O O 0.9999722242355347
left O O 0.9999529123306274
ventricle O O 0.9999839067459106
. O O 0.9999682903289795

Clentiazem B B 0.9987194538116455
also O O 0.9998065829277039
did O O 0.9999345541000366
not O O 0.9999254941940308
prevent O O 0.999702513217926
the O O 0.9999676942825317
enhanced O O 0.9999256134033203
responses O O 0.9999829530715942
to O O 0.999795138835907
calcium B B 0.9981136322021484
seen O O 0.9999449253082275
in O O 0.9999278783798218
the O O 0.999953031539917
epinephrine B B 0.9442087411880493
- O O 0.9997175335884094
treated O O 0.9998763799667358
animals O O 0.9999895095825195
, O O 0.9999788999557495
although O O 0.9999620914459229
the O O 0.9999803304672241
high O O 0.9997596144676208
dose O O 0.9996577501296997
of O O 0.9990056157112122
clentiazem B B 0.999470055103302
partially O O 0.9997935891151428
attenuated O O 0.9998801946640015
the O O 0.9999719858169556
maximal O O 0.9999407529830933
response O O 0.9999872446060181
to O O 0.999772846698761
calcium B B 0.9990560412406921
compared O O 0.9998459815979004
to O O 0.9999179840087891
epinephrine B B 0.9726452231407166
- O O 0.9996261596679688
treated O O 0.9998849630355835
animals O O 0.9999858140945435
. O O 0.9999710321426392

In O O 0.999921441078186
conclusion O O 0.9999653100967407
, O O 0.9992592930793762
clentiazem B B 0.9998395442962646
attenuated O O 0.999381422996521
epinephrine B B 0.9982481002807617
- O O 0.9998617172241211
induced O O 0.9999443292617798
cardiac O O 0.9999920129776001
injury O O 0.9999967813491821
, O O 0.9999788999557495
possibly O O 0.9999401569366455
through O O 0.9999114274978638
its O O 0.9994344115257263
effect O O 0.9998921155929565
on O O 0.9996918439865112
the O O 0.9975709319114685
adrenergic O O 0.9010616540908813
pathway O O 0.9999029636383057
. O O 0.9999502897262573

Kaliuretic O O 0.994358479976654
effect O O 0.9998214840888977
of O O 0.9993599057197571
L B B 0.9143374562263489
- I I 0.9777340292930603
dopa I I 0.9995172023773193
treatment O O 0.9953758716583252
in O O 0.9999213218688965
parkinsonian O O 0.9978402853012085
patients O O 0.9999474287033081
. O O 0.9999352693557739

Hypokalemia O O 0.9993100166320801
, O O 0.9999662637710571
sometimes O O 0.9999610185623169
severe O O 0.9999377727508545
, O O 0.9999836683273315
was O O 0.9999685287475586
observed O O 0.9999793767929077
in O O 0.9998890161514282
some O O 0.9999455213546753
L B B 0.8598952889442444
- I I 0.9532420039176941
dopa I I 0.9989448189735413
- O O 0.9956997632980347
treated O O 0.9995083808898926
parkinsonian O O 0.997837483882904
patients O O 0.9999444484710693
. O O 0.9999631643295288

The O O 0.9999741315841675
influence O O 0.9999502897262573
of O O 0.9991543292999268
L B B 0.987594723701477
- I I 0.9979789853096008
dopa I I 0.9998465776443481
on O O 0.999382495880127
the O O 0.9999743700027466
renal O O 0.9999792575836182
excretion O O 0.9999574422836304
of O O 0.9981920123100281
potassium B B 0.9988497495651245
was O O 0.9999368190765381
studied O O 0.9999773502349854
in O O 0.9999412298202515
3 O O 0.9995655417442322
patients O O 0.9999878406524658
with O O 0.9999568462371826
hypokalemia O O 0.9847418069839478
and O O 0.9999178647994995
in O O 0.9999568462371826
5 O O 0.9998334646224976
normokalemic O O 0.9996248483657837
patients O O 0.9999867677688599
by O O 0.9999923706054688
determination O O 0.9999953508377075
of O O 0.9999783039093018
renal O O 0.9999576807022095
plasma O O 0.9959843158721924
flow O O 0.9999333620071411
, O O 0.9999557733535767
glomerular O O 0.9965800642967224
filtration O O 0.9999251365661621
rate O O 0.9999696016311646
, O O 0.9999690055847168
plasma O O 0.9981550574302673
concentration O O 0.9995161294937134
of O O 0.9960285425186157
potassium B B 0.997820258140564
and O O 0.9376447796821594
sodium B B 0.9967045187950134
as O O 0.9999644756317139
well O O 0.9999672174453735
as O O 0.999962329864502
urinary O O 0.9999843835830688
excretion O O 0.9999452829360962
of O O 0.9983341097831726
potassium B B 0.9979046583175659
, O O 0.8317623138427734
sodium B B 0.993838369846344
and O O 0.9687291979789734
aldosterone B B 0.9845726490020752
. O O 0.9998020529747009

L B B 0.9060625433921814
- I I 0.9856712222099304
Dopa I I 0.9984776377677917
intake O O 0.8120886087417603
was O O 0.9999469518661499
found O O 0.9999788999557495
to O O 0.999936580657959
cause O O 0.9999150037765503
an O O 0.9999794960021973
increased O O 0.9999567270278931
excretion O O 0.9999681711196899
of O O 0.9983762502670288
potassium B B 0.9989535808563232
, O O 0.9998165965080261
and O O 0.9998524188995361
sometimes O O 0.9999207258224487
also O O 0.9999074935913086
of O O 0.9943296313285828
sodium B B 0.9916388392448425
, O O 0.9999383687973022
in O O 0.9999209642410278
the O O 0.9999635219573975
hypokalemic O O 0.9989351630210876
but O O 0.9999492168426514
not O O 0.9998750686645508
in O O 0.9999337196350098
the O O 0.9999651908874512
normokalemic O O 0.9995239973068237
patients O O 0.9999774694442749
. O O 0.9999741315841675

This O O 0.9998621940612793
effect O O 0.9998948574066162
on O O 0.9998687505722046
the O O 0.9999769926071167
renal O O 0.9999417066574097
function O O 0.9999697208404541
could O O 0.9998987913131714
be O O 0.9999644756317139
prohibited O O 0.9999493360519409
by O O 0.9999347925186157
the O O 0.9999781847000122
administration O O 0.9999498128890991
of O O 0.9999337196350098
a O O 0.9998583793640137
peripheral O O 0.9951022863388062
dopa O B 0.9907275438308716
decarbodylase O O 0.620018720626831
inhibitor O O 0.6427263617515564
. O O 0.9998564720153809

It O O 0.9999854564666748
is O O 0.9999891519546509
not O O 0.9999974966049194
known O O 0.9999933242797852
why O O 0.9999696016311646
this O O 0.9999129772186279
effect O O 0.9999585151672363
occurred O O 0.9999926090240479
in O O 0.9999322891235352
some O O 0.9999517202377319
individuals O O 0.99997878074646
but O O 0.9999819993972778
not O O 0.9999774694442749
in O O 0.999972939491272
others O O 0.9999350309371948
, O O 0.9999524354934692
but O O 0.9999603033065796
our O O 0.9999761581420898
results O O 0.9999904632568359
indicate O O 0.9998729228973389
a O O 0.9999688863754272
correlation O O 0.9999927282333374
between O O 0.9995788931846619
aldosterone B B 0.9820178747177124
production O O 0.9993890523910522
and O O 0.9998507499694824
this O O 0.9998615980148315
renal O O 0.9996765851974487
effect O O 0.9999319314956665
of O O 0.9994142055511475
L B B 0.9687405228614807
- I I 0.9958440661430359
dopa I I 0.9998774528503418
. O O 0.9998044371604919

Cocaine B B 0.9848499298095703
induced O O 0.9990240335464478
myocardial O O 0.9999933242797852
ischemia O O 0.9999083280563354
. O O 0.9997815489768982

We O O 0.9999406337738037
report O O 0.9999920129776001
a O O 0.9999836683273315
case O O 0.9999899864196777
of O O 0.9999567270278931
myocardial O O 0.9999955892562866
ischemia O O 0.9999568462371826
induced O O 0.9999411106109619
by O O 0.9996153116226196
cocaine B B 0.9969646334648132
. O O 0.9999105930328369

The O O 0.9998939037322998
ischemia O O 0.9999896287918091
probably O O 0.9999430179595947
induced O O 0.9999724626541138
by O O 0.9999428987503052
coronary O O 0.9934893846511841
artery O O 0.9980812072753906
spasm O O 0.9784958958625793
was O O 0.9998996257781982
reversed O O 0.999868631362915
by O O 0.9997050166130066
nitroglycerin B B 0.9971731901168823
and O O 0.9969610571861267
calcium B B 0.9242965579032898
blocking O O 0.7462378740310669
agents O O 0.7475935816764832
. O O 0.9999421834945679

Doxorubicin B B 0.9994897842407227
- O O 0.9997243285179138
induced O O 0.9999366998672485
cardiotoxicity O O 0.9999945163726807
monitored O O 0.9999887943267822
by O O 0.9999874830245972
ECG O O 0.9971858859062195
in O O 0.9999141693115234
freely O O 0.9999856948852539
moving O O 0.9999967813491821
mice O O 0.999992847442627
. O O 0.9999568462371826

A O O 0.9999366998672485
new O O 0.999963641166687
model O O 0.9999860525131226
to O O 0.9999740123748779
test O O 0.9999563694000244
potential O O 0.99980229139328
protectors O O 0.9512866139411926
. O O 0.9999595880508423

In O O 0.9999438524246216
laboratory O O 0.9999892711639404
animals O O 0.9999970197677612
, O O 0.999967098236084
histology O O 0.9998986721038818
is O O 0.9999810457229614
most O O 0.999992847442627
commonly O O 0.9999918937683105
used O O 0.9999932050704956
to O O 0.999994158744812
study O O 0.9999713897705078
doxorubicin B B 0.9997304081916809
- O O 0.9998156428337097
induced O O 0.9999442100524902
cardiotoxicity O O 0.9999948740005493
. O O 0.9999868869781494

However O O 0.999943733215332
, O O 0.9999693632125854
for O O 0.9999727010726929
monitoring O O 0.9999945163726807
during O O 0.9999502897262573
treatment O O 0.9999616146087646
, O O 0.9999825954437256
large O O 0.9999843835830688
numbers O O 0.9999940395355225
of O O 0.9999932050704956
animals O O 0.9999953508377075
are O O 0.9999843835830688
needed O O 0.9999874830245972
. O O 0.9999798536300659

Recently O O 0.999990701675415
we O O 0.9999897480010986
developed O O 0.9999969005584717
a O O 0.999996542930603
new O O 0.999995231628418
method O O 0.9999972581863403
to O O 0.9999953508377075
measure O O 0.9999929666519165
ECG O O 0.9808647036552429
values O O 0.9999065399169922
in O O 0.9999028444290161
freely O O 0.9999852180480957
moving O O 0.9999958276748657
mice O O 0.9999532699584961
by O O 0.9999926090240479
telemetry O O 0.999967098236084
. O O 0.9999798536300659

With O O 0.999920129776001
this O O 0.9999527931213379
model O O 0.9999939203262329
we O O 0.9999403953552246
investigated O O 0.9999798536300659
the O O 0.9999862909317017
effect O O 0.9999825954437256
of O O 0.9999485015869141
chronic O O 0.9995542168617249
doxorubicin B B 0.9997116923332214
administration O O 0.9998941421508789
on O O 0.9998706579208374
the O O 0.9999686479568481
ECG O O 0.9993084669113159
of O O 0.9999476671218872
freely O O 0.9999617338180542
moving O O 0.9999916553497314
BALB O O 0.9992814660072327
/ O O 0.9991519451141357
c O O 0.9960540533065796
mice O O 0.9999934434890747
and O O 0.9999728202819824
the O O 0.9999784231185913
efficacy O O 0.9999854564666748
of O O 0.9996111989021301
ICRF B B 0.8666556477546692
- I I 0.8332162499427795
187 I I 0.9996956586837769
as O O 0.9996907711029053
a O O 0.9998704195022583
protective O O 0.9998804330825806
agent O O 0.999948263168335
. O O 0.9999668598175049

The O O 0.9999916553497314
ST O O 0.996171772480011
interval O O 0.999995231628418
significantly O O 0.9999856948852539
widened O O 0.9999896287918091
from O O 0.9999880790710449
15 O O 0.9999910593032837
. O O 0.9999951124191284
0 O O 0.9999927282333374
+ O O 0.9999940395355225
/ O O 0.9999915361404419
- O O 0.9999467134475708
1 O O 0.999990701675415
. O O 0.9999904632568359
5 O O 0.9999940395355225
to O O 0.9999825954437256
56 O O 0.9999936819076538
. O O 0.9999969005584717
8 O O 0.9999932050704956
+ O O 0.9999942779541016
/ O O 0.9999850988388062
- O O 0.9999715089797974
11 O O 0.9999592304229736
. O O 0.999991774559021
8 O O 0.9999794960021973
ms O O 0.9999905824661255
in O O 0.999977707862854
week O O 0.9999949932098389
10 O O 0.9998626708984375
( O O 0.9999226331710815
7 O O 0.9998906850814819
weekly O O 0.9999868869781494
doses O O 0.9999814033508301
of O O 0.9998520612716675
4 O O 0.9977005124092102
mg O O 0.9997956156730652
/ O O 0.9997084736824036
kg O O 0.9993765950202942
doxorubicin B B 0.9995148181915283
given O O 0.9997469782829285
i O O 0.9998857975006104
. O O 0.9999943971633911
v O O 0.9999985694885254
. O O 0.9999933242797852
plus O O 0.999963641166687
3 O O 0.9999597072601318
weeks O O 0.999997615814209
of O O 0.999988317489624
observation O O 0.9999938011169434
) O O 0.9999755620956421
. O O 0.9999843835830688

The O O 0.999975323677063
ECG O O 0.9964746832847595
of O O 0.9997397065162659
the O O 0.9998534917831421
control O O 0.9981400966644287
animals O O 0.9995099306106567
did O O 0.9999740123748779
not O O 0.9999867677688599
change O O 0.9999749660491943
during O O 0.9999724626541138
the O O 0.9999955892562866
entire O O 0.9999830722808838
study O O 0.9999940395355225
. O O 0.9999681711196899

After O O 0.9999299049377441
sacrifice O O 0.9999915361404419
the O O 0.9999836683273315
hearts O O 0.9999508857727051
of O O 0.9999039173126221
doxorubicin B B 0.9998290538787842
- O O 0.9993625283241272
treated O O 0.9997783303260803
animals O O 0.9999877214431763
were O O 0.9999516010284424
enlarged O O 0.9999611377716064
and O O 0.9999831914901733
the O O 0.9999725818634033
atria O O 0.9998466968536377
were O O 0.9999691247940063
hypertrophic O O 0.9990498423576355
. O O 0.9999808073043823

As O O 0.999990701675415
this O O 0.9999727010726929
schedule O O 0.9988999366760254
exerted O O 0.9999744892120361
more O O 0.9998751878738403
toxicity O O 0.9999767541885376
than O O 0.9999895095825195
needed O O 0.9999927282333374
to O O 0.999984622001648
investigate O O 0.9980058073997498
protective O O 0.9949422478675842
agents O O 0.9992344379425049
, O O 0.9999581575393677
the O O 0.9999854564666748
protection O O 0.9999788999557495
of O O 0.9997871518135071
ICRF B B 0.4901278614997864
- I I 0.836395263671875
187 I I 0.9399885535240173
was O O 0.9997286200523376
determined O O 0.9999969005584717
using O O 0.9999794960021973
a O O 0.9999927282333374
dose O O 0.9998593330383301
schedule O O 0.9999598264694214
with O O 0.9999881982803345
lower O O 0.9999498128890991
general O O 0.9994707703590393
toxicity O O 0.999990701675415
( O O 0.999944806098938
6 O O 0.9999474287033081
weekly O O 0.9999901056289673
doses O O 0.9999827146530151
of O O 0.9999310970306396
4 O O 0.9978256821632385
mg O O 0.9999240636825562
/ O O 0.9999624490737915
kg O O 0.999824583530426
doxorubicin B B 0.9995874762535095
given O O 0.9998452663421631
i O O 0.9999593496322632
. O O 0.9999969005584717
v O O 0.9999990463256836
. O O 0.9999945163726807
plus O O 0.9999816417694092
2 O O 0.9999916553497314
weeks O O 0.9999982118606567
of O O 0.9999924898147583
observation O O 0.9999959468841553
) O O 0.999984622001648
. O O 0.999984860420227

On O O 0.9999430179595947
this O O 0.9999793767929077
schedule O O 0.999962329864502
, O O 0.9999732971191406
the O O 0.9999945163726807
animals O O 0.9999974966049194
' O O 0.9999947547912598
hearts O O 0.9999867677688599
appeared O O 0.9999890327453613
normal O O 0.9999957084655762
after O O 0.9999556541442871
sacrifice O O 0.9999828338623047
and O O 0.99958735704422
ICRF B B 0.8945807218551636
- I I 0.7197557091712952
187 I I 0.9998300075531006
( O O 0.9969642758369446
50 O O 0.9999290704727173
mg O O 0.9999470710754395
/ O O 0.9999744892120361
kg O O 0.9999929666519165
given O O 0.9998780488967896
i O O 0.9999130964279175
. O O 0.9999960660934448
p O O 0.9999977350234985
. O O 0.9999964237213135
1 O O 0.9999783039093018
h O O 0.997616171836853
before O O 0.9998193383216858
doxorubicin B B 0.9992536902427673
) O O 0.9996315240859985
provided O O 0.9999680519104004
almost O O 0.9999868869781494
full O O 0.9999793767929077
protection O O 0.9999971389770508
. O O 0.9999867677688599

These O O 0.9999799728393555
data O O 0.9999920129776001
were O O 0.9999843835830688
confirmed O O 0.9999867677688599
by O O 0.9999899864196777
histology O O 0.9998061060905457
. O O 0.9999712705612183

The O O 0.9999839067459106
results O O 0.9999905824661255
indicate O O 0.9999493360519409
that O O 0.9999681711196899
this O O 0.9999872446060181
new O O 0.9999796152114868
model O O 0.9999898672103882
is O O 0.999961256980896
very O O 0.9999387264251709
sensitive O O 0.9999730587005615
and O O 0.9999704360961914
enables O O 0.999940037727356
monitoring O O 0.9999890327453613
of O O 0.9999852180480957
the O O 0.9999910593032837
development O O 0.9999936819076538
of O O 0.9999734163284302
cardiotoxicity O O 0.9999939203262329
with O O 0.9999903440475464
time O O 0.999985933303833
. O O 0.9999771118164062

These O O 0.9999746084213257
findings O O 0.9999963045120239
result O O 0.9999849796295166
in O O 0.9999898672103882
a O O 0.9999886751174927
model O O 0.999994158744812
that O O 0.9999744892120361
allows O O 0.9999607801437378
the O O 0.9999904632568359
testing O O 0.9999808073043823
of O O 0.9998527765274048
protectors O O 0.954931914806366
against O O 0.9993269443511963
doxorubicin B B 0.9996875524520874
- O O 0.9997565150260925
induced O O 0.9999356269836426
cardiotoxicity O O 0.9999911785125732
as O O 0.9999890327453613
demonstrated O O 0.9999918937683105
by O O 0.9999902248382568
the O O 0.9999706745147705
protection O O 0.9999494552612305
provided O O 0.9999680519104004
by O O 0.9997698664665222
ICRF B B 0.5849780440330505
- I I 0.6190544366836548
187 I I 0.9979400038719177
. O O 0.9998043179512024

Epinephrine B B 0.9310144782066345
dysrhythmogenicity O O 0.999783456325531
is O O 0.9999197721481323
not O O 0.9999078512191772
enhanced O O 0.9999369382858276
by O O 0.9998842477798462
subtoxic O O 0.9973812699317932
bupivacaine B B 0.9997358918190002
in O O 0.9997549653053284
dogs O O 0.9997127652168274
. O O 0.9999294281005859

Since O O 0.999845027923584
bupivacaine B B 0.9996621608734131
and O O 0.9950730204582214
epinephrine B B 0.9980898499488831
may O O 0.9999080896377563
both O O 0.9999289512634277
precipitate O O 0.999893307685852
dysrhythmias O O 0.9999963045120239
, O O 0.9999289512634277
circulating O O 0.991346538066864
bupivacaine B B 0.9997219443321228
during O O 0.9996452331542969
regional O O 0.9999610185623169
anesthesia O O 0.9999701976776123
could O O 0.9999388456344604
potentiate O O 0.9998886585235596
dysrhythmogenic O O 0.9999916553497314
effects O O 0.9999659061431885
of O O 0.999813973903656
epinephrine B B 0.9907269477844238
. O O 0.9999070167541504

We O O 0.999977707862854
therefore O O 0.9999967813491821
examined O O 0.9999935626983643
whether O O 0.9999841451644897
bupivacaine B B 0.9997004270553589
alters O O 0.9999477863311768
the O O 0.9999903440475464
dysrhythmogenicity O O 0.9999978542327881
of O O 0.9999752044677734
subsequent O O 0.9999686479568481
administration O O 0.9999583959579468
of O O 0.9995549321174622
epinephrine B B 0.9982120990753174
in O O 0.9997815489768982
conscious O O 0.9999781847000122
, O O 0.9999886751174927
healthy O O 0.9999840259552002
dogs O O 0.9999969005584717
and O O 0.9999706745147705
in O O 0.9999657869338989
anesthetized O O 0.9999756813049316
dogs O O 0.9999954700469971
with O O 0.9999810457229614
myocardial O O 0.9999972581863403
infarction O O 0.9999815225601196
. O O 0.9999706745147705

Forty O O 0.993179202079773
- O O 0.999879002571106
one O O 0.9999926090240479
conscious O O 0.9999926090240479
dogs O O 0.999997615814209
received O O 0.9998868703842163
10 O O 0.9999105930328369
micrograms O O 0.9997730851173401
. O O 0.999955415725708
kg O O 0.995075523853302
- O O 0.987130343914032
1 O O 0.9904149770736694
. O O 0.9971305727958679
min O O 0.8800813555717468
- O O 0.9898113012313843
1 O O 0.9972039461135864
epinephrine B B 0.9958121180534363
. O O 0.9999107122421265

Seventeen O O 0.9236579537391663
animals O O 0.9999827146530151
responded O O 0.9999659061431885
with O O 0.9999797344207764
ventricular O O 0.9979343414306641
tachycardia O O 0.9997394680976868
( O O 0.9998505115509033
VT O O 0.9640529155731201
) O O 0.9999381303787231
within O O 0.9999700784683228
3 O O 0.9999579191207886
min O O 0.9999796152114868
. O O 0.9999724626541138

After O O 0.9999426603317261
3 O O 0.9999104738235474
h O O 0.9999246597290039
, O O 0.9999724626541138
these O O 0.9998101592063904
responders O O 0.9998743534088135
randomly O O 0.9999746084213257
received O O 0.9999535083770752
1 O O 0.9999403953552246
or O O 0.9999841451644897
2 O O 0.999953031539917
mg O O 0.9999709129333496
/ O O 0.9999858140945435
kg O O 0.9999006986618042
bupivacaine B B 0.9995855689048767
or O O 0.9980872273445129
saline O O 0.9997368454933167
over O O 0.999941349029541
5 O O 0.9999510049819946
min O O 0.9999884366989136
, O O 0.9999786615371704
followed O O 0.9999630451202393
by O O 0.9999278783798218
10 O O 0.9999290704727173
micrograms O O 0.9999535083770752
. O O 0.9993545413017273
kg O O 0.8404964804649353
- O O 0.9169949889183044
1 O O 0.9558894038200378
. O O 0.9955644607543945
min O O 0.8603017330169678
- O O 0.9863731861114502
1 O O 0.9976493716239929
epinephrine B B 0.9955365657806396
. O O 0.9999384880065918

In O O 0.9986600875854492
the O O 0.9990884065628052
bupivacaine B B 0.9983086585998535
groups O O 0.998350977897644
, O O 0.9998160004615784
epinephrine B B 0.9993072748184204
caused O O 0.9999246597290039
fewer O O 0.9998717308044434
prodysrhythmic O O 0.9941589832305908
effects O O 0.9999589920043945
than O O 0.9999779462814331
without O O 0.999764621257782
bupivacaine B B 0.9992074370384216
. O O 0.999922513961792

VT O O 0.6559345722198486
appeared O O 0.9999343156814575
in O O 0.9998763799667358
fewer O O 0.997379720211029
dogs O O 0.9983343482017517
and O O 0.9999756813049316
at O O 0.9999920129776001
a O O 0.9999963045120239
later O O 0.9999915361404419
time O O 0.9999972581863403
, O O 0.9999724626541138
and O O 0.9999890327453613
there O O 0.9999752044677734
were O O 0.9999825954437256
more O O 0.9999428987503052
sinoatrial O O 0.9994389414787292
beats O O 0.9999942779541016
and O O 0.9999517202377319
less O O 0.9999279975891113
ectopies O O 0.9999579191207886
. O O 0.9999634027481079

Epinephrine B B 0.9969437718391418
shortened O O 0.9998027682304382
QT O O 0.8841421604156494
less O O 0.9999024868011475
after O O 0.9997712969779968
bupivacaine B B 0.9998171925544739
than O O 0.999925971031189
in O O 0.9998409748077393
control O O 0.9998365640640259
animals O O 0.9999945163726807
. O O 0.9999529123306274

One O O 0.9999853372573853
day O O 0.9999970197677612
after O O 0.9999948740005493
experimental O O 0.9998847246170044
myocardial O O 0.9999978542327881
infarction O O 0.999995231628418
, O O 0.999962329864502
six O O 0.9999918937683105
additional O O 0.9999850988388062
halothane B B 0.9977025389671326
- O O 0.9992213249206543
anesthetized O O 0.9997829794883728
dogs O O 0.9999940395355225
received O O 0.9998961687088013
4 O O 0.9996323585510254
micrograms O O 0.999626874923706
. O O 0.9996809959411621
kg O O 0.827031672000885
- O O 0.9299662709236145
1 O O 0.9613447785377502
. O O 0.9978381991386414
min O O 0.9526930451393127
- O O 0.9944836497306824
1 O O 0.9946833252906799
epinephrine B B 0.9948158860206604
until O O 0.999723494052887
VT O O 0.923333466053009
appeared O O 0.9999871253967285
. O O 0.9999680519104004

After O O 0.9999630451202393
45 O O 0.9999953508377075
min O O 0.9999943971633911
, O O 0.9999691247940063
1 O O 0.9999076128005981
mg O O 0.9999665021896362
/ O O 0.9999749660491943
kg O O 0.9998809099197388
bupivacaine B B 0.9996447563171387
was O O 0.9999098777770996
injected O O 0.9999382495880127
over O O 0.9999547004699707
5 O O 0.9999724626541138
min O O 0.9999877214431763
, O O 0.9999775886535645
again O O 0.9999678134918213
followed O O 0.9999529123306274
by O O 0.9999159574508667
4 O O 0.9998067021369934
micrograms O O 0.9999469518661499
. O O 0.9988709092140198
kg O O 0.5993543863296509
- O O 0.8191789388656616
1 O O 0.8850400447845459
. O O 0.9724128842353821
min O O 0.8178395628929138
- O O 0.9813913106918335
1 O O 0.995900571346283
epinephrine B B 0.9906120896339417
. O O 0.9999126195907593

In O O 0.9998083710670471
these O O 0.9999599456787109
dogs O O 0.9999849796295166
, O O 0.9998925924301147
the O O 0.9999713897705078
prodysrhythmic O O 0.9988497495651245
response O O 0.9999783039093018
to O O 0.9998018145561218
epinephrine B B 0.9987491369247437
was O O 0.9998353719711304
also O O 0.9999432563781738
mitigated O O 0.9999512434005737
by O O 0.9998040795326233
preceding O O 0.9737105369567871
bupivacaine B B 0.9997130036354065
. O O 0.9999535083770752

Bupivacaine B B 0.9994630217552185
antagonizes O O 0.9995577931404114
epinephrine B B 0.989476203918457
dysrhythmogenicity O O 0.9999287128448486
in O O 0.9998914003372192
conscious O O 0.9999651908874512
dogs O O 0.9999938011169434
susceptible O O 0.9998923540115356
to O O 0.9996811151504517
VT O O 0.6881688237190247
and O O 0.9998980760574341
in O O 0.9999262094497681
anesthetized O O 0.9999767541885376
dogs O O 0.9999923706054688
with O O 0.9999597072601318
spontaneous O O 0.9999587535858154
postinfarct O O 0.9984962940216064
dysrhythmias O O 0.9999958276748657
. O O 0.9998241066932678

There O O 0.9999774694442749
is O O 0.9999611377716064
no O O 0.9999834299087524
evidence O O 0.9999775886535645
that O O 0.9999024868011475
systemic O O 0.9996732473373413
subtoxic O O 0.9900028705596924
bupivacaine B B 0.9995145797729492
administration O O 0.9998910427093506
enhances O O 0.9996745586395264
the O O 0.999977707862854
dysrhythmogenicity O O 0.9999971389770508
of O O 0.9998955726623535
subsequent O O 0.9981062412261963
epinephrine B B 0.9963182210922241
. O O 0.9999231100082397

Milk O O 0.43325504660606384
- O O 0.7219462990760803
alkali O O 0.5300254225730896
syndrome O O 0.9991248250007629
induced O O 0.9999593496322632
by O O 0.9991880059242249
1 B B 0.7816082239151001
, I I 0.8736300468444824
25 I I 0.9736985564231873
( I I 0.9042578935623169
OH I I 0.9771566987037659
) I I 0.9562551975250244
2D I I 0.9994636178016663
in O O 0.9996101260185242
a O O 0.9999868869781494
patient O O 0.9999887943267822
with O O 0.9999606609344482
hypoparathyroidism O O 0.9913604855537415
. O O 0.999955415725708

Milk O O 0.5241008400917053
- O O 0.860538899898529
alkali O O 0.4327794015407562
syndrome O O 0.9997262358665466
was O O 0.9999865293502808
first O O 0.9999971389770508
described O O 0.9999958276748657
70 O O 0.9999934434890747
years O O 0.9999916553497314
ago O O 0.9999880790710449
in O O 0.9999818801879883
the O O 0.9999926090240479
context O O 0.9999781847000122
of O O 0.9998364448547363
the O O 0.9999351501464844
treatment O O 0.9999557733535767
of O O 0.9999747276306152
peptic O O 0.999884843826294
ulcer O O 0.9998606443405151
disease O O 0.9999873638153076
with O O 0.9997978806495667
large O O 0.9999072551727295
amounts O O 0.9990971088409424
of O O 0.9916451573371887
calcium B B 0.9872851967811584
and O O 0.5279747247695923
alkali B O 0.6447005867958069
. O O 0.9998435974121094

Although O O 0.9999855756759644
with O O 0.9999316930770874
current O O 0.9988656044006348
ulcer O O 0.9799981713294983
therapy O O 0.9998220801353455
( O O 0.998771607875824
H O O 0.4808276295661926
- O O 0.749187171459198
2 O O 0.556233823299408
blockers O O 0.7097634673118591
, O O 0.794599175453186
omeprazole B B 0.9871286153793335
, O O 0.8586737513542175
and O O 0.9738019108772278
sucralfate B B 0.9969332218170166
) O O 0.9991869330406189
, O O 0.9999706745147705
the O O 0.9999927282333374
frequency O O 0.9999959468841553
of O O 0.9999788999557495
milk O O 0.556789219379425
- O O 0.9206220507621765
alkali O O 0.8458287119865417
syndrome O O 0.999894380569458
has O O 0.9999711513519287
decreased O O 0.9999953508377075
significantly O O 0.9999936819076538
, O O 0.9999653100967407
the O O 0.999976634979248
classic O O 0.9999549388885498
triad O O 0.9999804496765137
of O O 0.9999600648880005
hypercalcemia O O 0.9993808269500732
, O O 0.9998741149902344
alkalosis O O 0.8714634776115417
, O O 0.9998584985733032
and O O 0.9998593330383301
renal O O 0.9999599456787109
impairment O O 0.9999865293502808
remains O O 0.999977707862854
the O O 0.9999938011169434
hallmark O O 0.9999891519546509
of O O 0.9999904632568359
the O O 0.9999887943267822
syndrome O O 0.9999902248382568
. O O 0.9999665021896362

Milk O O 0.6217443346977234
- O O 0.5548990964889526
alkali O O 0.4547575116157532
syndrome O O 0.9989655017852783
can O O 0.9999176263809204
present O O 0.999946117401123
serious O O 0.9999643564224243
and O O 0.9999650716781616
occasionally O O 0.999956488609314
life O O 0.999934196472168
- O O 0.9999850988388062
threatening O O 0.9999932050704956
illness O O 0.9999935626983643
unless O O 0.999946117401123
diagnosed O O 0.9999970197677612
and O O 0.9999876022338867
treated O O 0.9999681711196899
appropriately O O 0.9999821186065674
. O O 0.9999653100967407

This O O 0.9999791383743286
article O O 0.9999831914901733
presents O O 0.999969482421875
a O O 0.9999852180480957
patient O O 0.9999902248382568
with O O 0.9999403953552246
hypoparathyroidism O O 0.9941527247428894
who O O 0.9999492168426514
was O O 0.9999663829803467
treated O O 0.9999525547027588
with O O 0.9995206594467163
calcium B B 0.9973856806755066
carbonate I I 0.9998499155044556
and O O 0.8528670072555542
calcitriol B B 0.9985237717628479
resulting O O 0.9998238682746887
in O O 0.9999927282333374
two O O 0.9999938011169434
admissions O O 0.9999949932098389
to O O 0.999991774559021
the O O 0.9999966621398926
hospital O O 0.9999939203262329
for O O 0.9999780654907227
milk O O 0.5868141651153564
- O O 0.8840975761413574
alkali O O 0.7780389785766602
syndrome O O 0.9997370839118958
. O O 0.9999655485153198

The O O 0.9999903440475464
patient O O 0.99998939037323
was O O 0.9999814033508301
successfully O O 0.9999837875366211
treated O O 0.999969482421875
with O O 0.999797523021698
intravenous O O 0.9995120763778687
pamidronate B B 0.9998047947883606
on O O 0.9997921586036682
his O O 0.9999884366989136
first O O 0.9999951124191284
admission O O 0.9999939203262329
and O O 0.9999603033065796
with O O 0.9997523427009583
hydrocortisone B B 0.9961940050125122
on O O 0.9996991157531738
the O O 0.9999943971633911
second O O 0.9999932050704956
. O O 0.9999892711639404

This O O 0.9999504089355469
illustrates O O 0.999545156955719
intravenous O O 0.9928101301193237
pamidronate B B 0.9997723698616028
as O O 0.9998759031295776
a O O 0.9999417066574097
valuable O O 0.9999856948852539
therapeutic O O 0.9999712705612183
tool O O 0.9999921321868896
when O O 0.9999743700027466
milk O O 0.5541645884513855
- O O 0.7220152616500854
alkali O O 0.6169498562812805
syndrome O O 0.9995890259742737
presents O O 0.9999818801879883
as O O 0.9999908208847046
hypercalcemic O O 0.9999082088470459
emergency O O 0.9999796152114868
. O O 0.999976634979248

Famotidine B B 0.9977545142173767
- O O 0.999174177646637
associated O O 0.9998575448989868
delirium O O 0.9999567270278931
. O O 0.9999145269393921

A O O 0.99993896484375
series O O 0.9999934434890747
of O O 0.9999755620956421
six O O 0.9999933242797852
cases O O 0.9999812841415405
. O O 0.9999662637710571

Famotidine B B 0.9994521737098694
is O O 0.9997207522392273
a O O 0.9984579086303711
histamine O O 0.7610260248184204
H2 O O 0.5023956298828125
- O O 0.8211038708686829
receptor O O 0.9459803104400635
antagonist O O 0.917262613773346
used O O 0.9998979568481445
in O O 0.9999008178710938
inpatient O O 0.9999315738677979
settings O O 0.9999879598617554
for O O 0.9999268054962158
prevention O O 0.9999725818634033
of O O 0.9999760389328003
stress O O 0.9993507266044617
ulcers O O 0.99997878074646
and O O 0.9999438524246216
is O O 0.9999496936798096
showing O O 0.9999943971633911
increasing O O 0.9999589920043945
popularity O O 0.9999644756317139
because O O 0.999987006187439
of O O 0.9999853372573853
its O O 0.9999802112579346
low O O 0.9999850988388062
cost O O 0.9999881982803345
. O O 0.9999094009399414

Although O O 0.9999728202819824
all O O 0.9997550845146179
of O O 0.9998303651809692
the O O 0.9999276399612427
currently O O 0.9999370574951172
available O O 0.9996780157089233
H2 O O 0.5533761382102966
- O O 0.6988157033920288
receptor O O 0.9290168881416321
antagonists O O 0.8653512001037598
have O O 0.9999415874481201
shown O O 0.9999439716339111
the O O 0.9999765157699585
propensity O O 0.9999613761901855
to O O 0.9999690055847168
cause O O 0.9999376535415649
delirium O O 0.9999896287918091
, O O 0.9999039173126221
only O O 0.999971866607666
two O O 0.9999885559082031
previously O O 0.9999569654464722
reported O O 0.999995231628418
cases O O 0.9999853372573853
have O O 0.9999805688858032
been O O 0.9999852180480957
associated O O 0.9999620914459229
with O O 0.9994165897369385
famotidine B B 0.9990329742431641
. O O 0.9999139308929443

The O O 0.9999815225601196
authors O O 0.9999964237213135
report O O 0.9999961853027344
on O O 0.9999593496322632
six O O 0.9999920129776001
cases O O 0.9999942779541016
of O O 0.9999549388885498
famotidine B B 0.9985230565071106
- O O 0.9996824264526367
associated O O 0.9999040365219116
delirium O O 0.9999843835830688
in O O 0.999941349029541
hospitalized O O 0.9999567270278931
patients O O 0.9999911785125732
who O O 0.9999618530273438
cleared O O 0.9999910593032837
completely O O 0.9999948740005493
upon O O 0.9999765157699585
removal O O 0.9999845027923584
of O O 0.9997385144233704
famotidine B B 0.9982535243034363
. O O 0.9999419450759888

The O O 0.9999803304672241
pharmacokinetics O O 0.9998310804367065
of O O 0.999692440032959
famotidine B B 0.9993823766708374
are O O 0.999755322933197
reviewed O O 0.9999382495880127
, O O 0.9999864101409912
with O O 0.9999778270721436
no O O 0.9999877214431763
change O O 0.9999977350234985
in O O 0.9999926090240479
its O O 0.99974125623703
metabolism O O 0.9999527931213379
in O O 0.9998359680175781
the O O 0.9999432563781738
elderly O O 0.9972399473190308
population O O 0.9999867677688599
seen O O 0.9999818801879883
. O O 0.9999709129333496

The O O 0.9999899864196777
implications O O 0.9999958276748657
of O O 0.9999806880950928
using O O 0.9996435642242432
famotidine B B 0.9991395473480225
in O O 0.999809205532074
elderly O O 0.9995030164718628
persons O O 0.9999973773956299
are O O 0.9999831914901733
discussed O O 0.9999878406524658
. O O 0.9999853372573853

Encephalopathy O O 0.9996740818023682
during O O 0.9998148083686829
amitriptyline B B 0.9999063014984131
therapy O O 0.9996758699417114
: O O 0.9999517202377319
are O O 0.9997549653053284
neuroleptic O O 0.9997190833091736
malignant O O 0.9999864101409912
syndrome O O 0.9999380111694336
and O O 0.9996471405029297
serotonin O B 0.8642087578773499
syndrome O O 0.6678603291511536
spectrum O O 0.9852622151374817
disorders O O 0.9999184608459473
? O O 0.9999082088470459

This O O 0.9999693632125854
report O O 0.9999889135360718
describes O O 0.9999494552612305
a O O 0.9999802112579346
case O O 0.9999891519546509
of O O 0.9999651908874512
encephalopathy O O 0.9997377991676331
developed O O 0.9999926090240479
in O O 0.9999892711639404
the O O 0.9999915361404419
course O O 0.9999655485153198
of O O 0.999809205532074
amitriptyline B B 0.9999032020568848
therapy O O 0.9996340274810791
, O O 0.9999676942825317
during O O 0.9998841285705566
a O O 0.9999480247497559
remission O O 0.9999793767929077
of O O 0.9999243021011353
unipolar O O 0.9849470853805542
depression O O 0.9999700784683228
. O O 0.9999598264694214

This O O 0.9999731779098511
patient O O 0.9999775886535645
could O O 0.9998558759689331
have O O 0.9999912977218628
been O O 0.9999831914901733
diagnosed O O 0.9999817609786987
as O O 0.9999275207519531
having O O 0.9999306201934814
either O O 0.999705970287323
neuroleptic O O 0.9998229146003723
malignant O O 0.9999872446060181
syndrome O O 0.9999520778656006
( O O 0.999894380569458
NMS O O 0.9967098236083984
) O O 0.9999314546585083
or O O 0.9996490478515625
serotonin O B 0.8484935164451599
syndrome O O 0.9406934976577759
( O O 0.999565064907074
SS O O 0.5123519897460938
) O O 0.9998654127120972
. O O 0.9999603033065796

The O O 0.9999666213989258
major O O 0.9999526739120483
determinant O O 0.9999619722366333
of O O 0.9999746084213257
the O O 0.9999895095825195
symptoms O O 0.9999939203262329
may O O 0.9997163414955139
have O O 0.9999744892120361
been O O 0.9997640252113342
dopamine B B 0.9974508881568909
/ O O 0.9756008386611938
serotonin B B 0.9872297644615173
imbalance O O 0.9995604157447815
in O O 0.9998457431793213
the O O 0.999966025352478
central O O 0.9999386072158813
nervous O O 0.9999892711639404
system O O 0.9999831914901733
. O O 0.9999634027481079

The O O 0.9999796152114868
NMS O O 0.9701560139656067
- O O 0.9999587535858154
like O O 0.9999728202819824
encephalopathy O O 0.9999880790710449
that O O 0.9999940395355225
develops O O 0.9999959468841553
in O O 0.9999912977218628
association O O 0.9999879598617554
with O O 0.9999297857284546
the O O 0.9999788999557495
use O O 0.9998657703399658
of O O 0.9996989965438843
antidepressants O O 0.7073166966438293
indicates O O 0.9996166229248047
that O O 0.9995866417884827
NMS O O 0.9538161754608154
and O O 0.9995286464691162
SS O O 0.7041098475456238
are O O 0.9998493194580078
spectrum O O 0.9724757671356201
disorders O O 0.999962329864502
induced O O 0.999963641166687
by O O 0.9998096823692322
drugs O O 0.9990737438201904
with O O 0.9997938275337219
both O O 0.9995231628417969
antidopaminergic O O 0.48334982991218567
and O O 0.9979234933853149
serotonergic O O 0.7938418984413147
effects O O 0.9991974234580994
. O O 0.9999542236328125

Genetic O O 0.9998997449874878
separation O O 0.9999585151672363
of O O 0.9998499155044556
tumor O O 0.9999390840530396
growth O O 0.9998430013656616
and O O 0.9998664855957031
hemorrhagic O O 0.9994568228721619
phenotypes O O 0.9999828338623047
in O O 0.9999566078186035
an O O 0.9999293088912964
estrogen B B 0.9669966697692871
- O O 0.9968955516815186
induced O O 0.9998487234115601
tumor O O 0.9999897480010986
. O O 0.9999538660049438

Chronic O O 0.9998175501823425
administration O O 0.999897837638855
of O O 0.9998279809951782
estrogen B B 0.9745190143585205
to O O 0.9995310306549072
the O O 0.9996440410614014
Fischer O O 0.9383937120437622
344 O O 0.9946165680885315
( O O 0.9965978264808655
F344 O O 0.9681720733642578
) O O 0.9991699457168579
rat O O 0.9992514252662659
induces O O 0.999924898147583
growth O O 0.9999831914901733
of O O 0.9999825954437256
large O O 0.9999649524688721
, O O 0.9999440908432007
hemorrhagic O O 0.9999313354492188
pituitary O O 0.9997398257255554
tumors O O 0.9999912977218628
. O O 0.9999585151672363

Ten O O 0.9999830722808838
weeks O O 0.9999908208847046
of O O 0.9998465776443481
diethylstilbestrol B B 0.9988532066345215
( O O 0.9783323407173157
DES B B 0.9787623286247253
) O O 0.9856545329093933
treatment O O 0.9998964071273804
caused O O 0.9999706745147705
female O O 0.9999830722808838
F344 O O 0.9947638511657715
rat O O 0.9999364614486694
pituitaries O O 0.9991174340248108
to O O 0.9999665021896362
grow O O 0.999955415725708
to O O 0.9999868869781494
an O O 0.9999929666519165
average O O 0.9999657869338989
of O O 0.9999628067016602
109 O O 0.999763548374176
. O O 0.9999849796295166
2 O O 0.9999892711639404
+ O O 0.9999886751174927
/ O O 0.999972939491272
- O O 0.9999340772628784
6 O O 0.9999803304672241
. O O 0.9999912977218628
3 O O 0.999958872795105
mg O O 0.9999722242355347
( O O 0.9999711513519287
mean O O 0.9999706745147705
+ O O 0.9999934434890747
/ O O 0.9999923706054688
- O O 0.9999935626983643
SE O O 0.9997738003730774
) O O 0.9999747276306152
versus O O 0.9999818801879883
11 O O 0.9999769926071167
. O O 0.9999967813491821
3 O O 0.9999895095825195
+ O O 0.9999945163726807
/ O O 0.9999889135360718
- O O 0.999963641166687
1 O O 0.9999939203262329
. O O 0.9999940395355225
4 O O 0.9999849796295166
mg O O 0.9999805688858032
for O O 0.9999680519104004
untreated O O 0.9998849630355835
rats O O 0.999988317489624
, O O 0.9999842643737793
and O O 0.9999961853027344
to O O 0.9999947547912598
become O O 0.9999954700469971
highly O O 0.999970555305481
hemorrhagic O O 0.9999688863754272
. O O 0.9999825954437256

The O O 0.9999836683273315
same O O 0.9999552965164185
DES B O 0.48294389247894287
treatment O O 0.9995751976966858
produced O O 0.9999663829803467
no O O 0.9999687671661377
significant O O 0.9999926090240479
growth O O 0.9999736547470093
( O O 0.9999527931213379
8 O O 0.9004490971565247
. O O 0.999945878982544
9 O O 0.9999886751174927
+ O O 0.9999884366989136
/ O O 0.9999891519546509
- O O 0.9999744892120361
0 O O 0.9999871253967285
. O O 0.999982476234436
5 O O 0.9999855756759644
mg O O 0.9999277591705322
for O O 0.9999181032180786
treated O O 0.99992835521698
females O O 0.9999557733535767
versus O O 0.9999700784683228
8 O O 0.9989646673202515
. O O 0.9999914169311523
7 O O 0.9999938011169434
+ O O 0.9999920129776001
/ O O 0.9999911785125732
- O O 0.9999701976776123
1 O O 0.9999823570251465
. O O 0.9999914169311523
1 O O 0.9999948740005493
for O O 0.9999712705612183
untreated O O 0.9998364448547363
females O O 0.999907374382019
) O O 0.9999595880508423
or O O 0.9999728202819824
morphological O O 0.9999947547912598
changes O O 0.999997615814209
in O O 0.9999423027038574
Brown O O 0.9680559039115906
Norway O O 0.9534990191459656
( O O 0.997710108757019
BN O O 0.8484092354774475
) O O 0.9976551532745361
rat O O 0.993344783782959
pituitaries O O 0.9997171759605408
. O O 0.9999561309814453

An O O 0.9997584223747253
F1 O O 0.9898264408111572
hybrid O O 0.9939416646957397
of O O 0.9984879493713379
F344 O O 0.9824298620223999
and O O 0.9978698492050171
BN O O 0.6214451193809509
exhibited O O 0.9998910427093506
significant O O 0.9999562501907349
pituitary O O 0.9997557997703552
growth O O 0.9999579191207886
after O O 0.999937891960144
10 O O 0.9999798536300659
weeks O O 0.9999942779541016
of O O 0.9999161958694458
DES B O 0.7125957012176514
treatment O O 0.9996077418327332
with O O 0.9999879598617554
an O O 0.9999936819076538
average O O 0.9999322891235352
mass O O 0.9999887943267822
of O O 0.9999561309814453
26 O O 0.9999860525131226
. O O 0.9999934434890747
3 O O 0.9999914169311523
+ O O 0.9999912977218628
/ O O 0.9999607801437378
- O O 0.9999662637710571
0 O O 0.999987006187439
. O O 0.9999923706054688
7 O O 0.9999936819076538
mg O O 0.999992847442627
compared O O 0.9999809265136719
with O O 0.999994158744812
8 O O 0.9998883008956909
. O O 0.9999939203262329
6 O O 0.9999938011169434
+ O O 0.9999921321868896
/ O O 0.9999685287475586
- O O 0.9999712705612183
0 O O 0.9999895095825195
. O O 0.9999873638153076
9 O O 0.9999927282333374
mg O O 0.9999791383743286
for O O 0.9999653100967407
untreated O O 0.9999359846115112
rats O O 0.999871015548706
. O O 0.9999761581420898

Surprisingly O O 0.9998918771743774
, O O 0.9999436140060425
the O O 0.999887228012085
F1 O O 0.9876506924629211
hybrid O O 0.9992826581001282
tumors O O 0.9999725818634033
were O O 0.9999330043792725
not O O 0.9998914003372192
hemorrhagic O O 0.9997546076774597
and O O 0.9999641180038452
had O O 0.9999294281005859
hemoglobin O O 0.5840896368026733
content O O 0.9991359114646912
and O O 0.9999179840087891
outward O O 0.9999563694000244
appearance O O 0.9999978542327881
identical O O 0.9999868869781494
to O O 0.9999858140945435
that O O 0.9999910593032837
of O O 0.9999523162841797
BN O O 0.8592444658279419
. O O 0.9999407529830933

Expression O O 0.9999055862426758
of O O 0.9999682903289795
both O O 0.9995108842849731
growth O O 0.9998692274093628
and O O 0.9999128580093384
morphological O O 0.9999951124191284
changes O O 0.999995231628418
is O O 0.9999125003814697
due O O 0.9999575614929199
to O O 0.9998109936714172
multiple O O 0.9993457198143005
genes O O 0.9996335506439209
. O O 0.9999250173568726

However O O 0.999945878982544
, O O 0.9999700784683228
while O O 0.9999250173568726
DES B B 0.9173198342323303
- O O 0.9914104342460632
induced O O 0.9998390674591064
pituitary O O 0.999301552772522
growth O O 0.9994139671325684
exhibited O O 0.9997656941413879
quantitative O O 0.9987909197807312
, O O 0.9999210834503174
additive O O 0.9996397495269775
inheritance O O 0.9999856948852539
, O O 0.9999047517776489
the O O 0.9999048709869385
hemorrhagic O O 0.9982720613479614
phenotype O O 0.9999513626098633
exhibited O O 0.9997095465660095
recessive O O 0.9998346567153931
, O O 0.9998971223831177
epistatic O O 0.999848484992981
inheritance O O 0.9999878406524658
. O O 0.9999701976776123

Only O O 0.999963641166687
5 O O 0.9999436140060425
of O O 0.9999159574508667
the O O 0.9999628067016602
160 O O 0.9924576282501221
F2 O O 0.997636079788208
pituitaries O O 0.9983205199241638
exhibited O O 0.9998069405555725
the O O 0.9999635219573975
hemorrhagic O O 0.9997842907905579
phenotype O O 0.9999648332595825
; O O 0.999876856803894
36 O O 0.9999788999557495
of O O 0.9999550580978394
the O O 0.9999744892120361
160 O O 0.9980146884918213
F2 O O 0.9978975057601929
pituitaries O O 0.9994552731513977
were O O 0.9999163150787354
in O O 0.9999152421951294
the O O 0.9999570846557617
F344 O O 0.9994444251060486
range O O 0.9998310804367065
of O O 0.9998643398284912
mass O O 0.9998090863227844
, O O 0.9999459981918335
but O O 0.9999678134918213
31 O O 0.9980996251106262
of O O 0.9999105930328369
these O O 0.9999239444732666
were O O 0.9999048709869385
not O O 0.9999312162399292
hemorrhagic O O 0.9994668364524841
, O O 0.9999681711196899
indicating O O 0.9999622106552124
that O O 0.9999635219573975
the O O 0.999985933303833
hemorrhagic O O 0.999969482421875
phenotype O O 0.999983549118042
is O O 0.9999741315841675
not O O 0.9999887943267822
merely O O 0.9999904632568359
a O O 0.999971866607666
consequence O O 0.9999880790710449
of O O 0.9999160766601562
extensive O O 0.9997116923332214
growth O O 0.9998296499252319
. O O 0.9999771118164062

The O O 0.9998552799224854
hemorrhagic O O 0.9990184307098389
F2 O O 0.9875075221061707
pituitaries O O 0.9969863295555115
were O O 0.9998278617858887
all O O 0.9998716115951538
among O O 0.9999350309371948
the O O 0.9999605417251587
most O O 0.9998897314071655
massive O O 0.9974194765090942
, O O 0.9999511241912842
indicating O O 0.9998549222946167
that O O 0.9996464252471924
some O O 0.9994673132896423
of O O 0.999017596244812
the O O 0.999323844909668
genes O O 0.9978749752044678
regulate O O 0.9998379945755005
both O O 0.9997976422309875
phenotypes O O 0.999981164932251
. O O 0.9999325275421143

Increased O O 0.9999198913574219
expression O O 0.9999310970306396
of O O 0.9996902942657471
neuronal O O 0.9988129138946533
nitric B B 0.9471547603607178
oxide I I 0.948081910610199
synthase O O 0.5192709565162659
in O O 0.9995357990264893
bladder O O 0.7985879778862
afferent O O 0.9832344055175781
pathways O O 0.999887228012085
following O O 0.9999139308929443
chronic O O 0.9998784065246582
bladder O O 0.8716781735420227
irritation O O 0.9994877576828003
. O O 0.9999415874481201

Immunocytochemical O O 0.9998295307159424
techniques O O 0.9999847412109375
were O O 0.9999769926071167
used O O 0.9999822378158569
to O O 0.9999889135360718
examine O O 0.9999717473983765
alterations O O 0.9999932050704956
in O O 0.9999810457229614
the O O 0.9999724626541138
expression O O 0.9999608993530273
of O O 0.9993929862976074
neuronal O O 0.996846616268158
nitric B B 0.8562341928482056
oxide I I 0.9351113438606262
synthase O O 0.6613624095916748
( O O 0.9980060458183289
NOS O O 0.6488751769065857
) O O 0.9993522763252258
in O O 0.9994589686393738
bladder O O 0.9961491823196411
pathways O O 0.9999343156814575
following O O 0.99991774559021
acute O O 0.9999673366546631
and O O 0.9998964071273804
chronic O O 0.9999501705169678
irritation O O 0.9999773502349854
of O O 0.9999585151672363
the O O 0.9999905824661255
urinary O O 0.9999655485153198
tract O O 0.9999878406524658
of O O 0.9999700784683228
the O O 0.9999829530715942
rat O O 0.9999760389328003
. O O 0.9999675750732422

Chemical O O 0.9970833659172058
cystitis O O 0.9994332194328308
was O O 0.9999693632125854
induced O O 0.9999909400939941
by O O 0.9998515844345093
cyclophosphamide B B 0.9987443685531616
( O O 0.9846684336662292
CYP B B 0.9954487681388855
) O O 0.9788751006126404
which O O 0.9998847246170044
is O O 0.9994966983795166
metabolized O O 0.9997878670692444
to O O 0.995369017124176
acrolein B B 0.9866909980773926
, O O 0.9998680353164673
an O O 0.9959030747413635
irritant O O 0.991701066493988
eliminated O O 0.8643423318862915
in O O 0.9997840523719788
the O O 0.999961256980896
urine O O 0.9993717074394226
. O O 0.9999328851699829

Injection O O 0.9999260902404785
of O O 0.9991756081581116
CYP B B 0.9984599351882935
( O O 0.9980194568634033
n O O 0.8685646057128906
= O O 0.9765658378601074
10 O O 0.9937788844108582
, O O 0.9998935461044312
75 O O 0.9996975660324097
mg O O 0.9999371767044067
/ O O 0.9999773502349854
kg O O 0.999992847442627
, O O 0.9999344348907471
i O O 0.9999747276306152
. O O 0.9999972581863403
p O O 0.9999983310699463
. O O 0.9999963045120239
) O O 0.9999692440032959
2 O O 0.999936580657959
hours O O 0.9999942779541016
prior O O 0.9999951124191284
to O O 0.9999682903289795
perfusion O O 0.9992958307266235
( O O 0.9999160766601562
acute O O 0.9998428821563721
treatment O O 0.9999948740005493
) O O 0.9999808073043823
of O O 0.9999297857284546
the O O 0.9999494552612305
animals O O 0.9420244693756104
increased O O 0.9997323155403137
Fos O B 0.9228489995002747
- O O 0.6036239862442017
immunoreactivity O O 0.9945175051689148
( O O 0.999601423740387
IR O O 0.9590767621994019
) O O 0.9999604225158691
in O O 0.9993972778320312
neurons O O 0.9992740750312805
in O O 0.9996165037155151
the O O 0.9998601675033569
dorsal O O 0.9993818998336792
commissure O O 0.9989957213401794
, O O 0.999581515789032
dorsal O O 0.9996763467788696
horn O O 0.9999548196792603
, O O 0.9994506239891052
and O O 0.9984089732170105
autonomic O O 0.8591086268424988
regions O O 0.999908447265625
of O O 0.9997734427452087
spinal O O 0.989700198173523
segments O O 0.9999758005142212
( O O 0.9998995065689087
L1 O O 0.9988309741020203
- O O 0.9979630708694458
L2 O O 0.9979965090751648
and O O 0.9999089241027832
L6 O O 0.9982821941375732
- O O 0.9966666102409363
S1 O O 0.9959606528282166
) O O 0.9999651908874512
which O O 0.9998537302017212
receive O O 0.9999115467071533
afferent O O 0.9989803433418274
inputs O O 0.9999728202819824
from O O 0.9999545812606812
the O O 0.9999712705612183
bladder O O 0.9998453855514526
, O O 0.9999419450759888
urethra O O 0.9990571141242981
, O O 0.9998475313186646
and O O 0.9998030066490173
ureter O O 0.9888266324996948
. O O 0.9999258518218994

Fos O B 0.9344934821128845
- O I 0.6681596040725708
IR O I 0.993220329284668
in O O 0.9993391633033752
the O O 0.9999929666519165
spinal O O 0.9999849796295166
cord O O 0.9999972581863403
was O O 0.9999812841415405
not O O 0.9999954700469971
changed O O 0.9999966621398926
in O O 0.9999547004699707
rats O O 0.999955415725708
receiving O O 0.9999243021011353
chronic O O 0.9992082715034485
CYP B B 0.9958844780921936
treatment O O 0.9990454316139221
( O O 0.999906063079834
n O O 0.958471417427063
= O O 0.9971964359283447
15 O O 0.9997908473014832
, O O 0.9998207688331604
75 O O 0.9997525811195374
mg O O 0.9998821020126343
/ O O 0.9999736547470093
kg O O 0.9999949932098389
, O O 0.9999648332595825
i O O 0.9998893737792969
. O O 0.9999961853027344
p O O 0.9999984502792358
. O O 0.9999974966049194
, O O 0.999990701675415
every O O 0.9999597072601318
3rd O O 0.9999469518661499
day O O 0.9999912977218628
for O O 0.9999855756759644
2 O O 0.9999808073043823
weeks O O 0.9999979734420776
) O O 0.9999847412109375
. O O 0.9999871253967285

In O O 0.9998443126678467
control O O 0.9998677968978882
animals O O 0.9999896287918091
and O O 0.9999109506607056
in O O 0.9999438524246216
animals O O 0.99998939037323
treated O O 0.9999390840530396
acutely O O 0.9999493360519409
with O O 0.9996861219406128
CYP B B 0.9902780652046204
, O O 0.9998044371604919
only O O 0.9999748468399048
small O O 0.9999903440475464
numbers O O 0.9999877214431763
of O O 0.9999419450759888
NOS O O 0.9044213891029358
- O O 0.9938188195228577
IR O O 0.9820289611816406
cells O O 0.9999850988388062
( O O 0.9999380111694336
0 O O 0.9999512434005737
. O O 0.9999717473983765
5 O O 0.99994957447052
- O O 0.9991264939308167
0 O O 0.9999573230743408
. O O 0.999963641166687
7 O O 0.9999775886535645
cell O O 0.999946117401123
profiles O O 0.9996861219406128
/ O O 0.9999352693557739
sections O O 0.999994158744812
) O O 0.9999425411224365
were O O 0.9999802112579346
detected O O 0.9999924898147583
in O O 0.9997537732124329
the O O 0.9999344348907471
L6 O O 0.9925782084465027
- O O 0.9976415634155273
S1 O O 0.9970314502716064
dorsal O O 0.999958872795105
root O O 0.9996896982192993
ganglia O O 0.9999428987503052
( O O 0.9998051524162292
DRG O O 0.9932456612586975
) O O 0.9999525547027588
. O O 0.9999758005142212

Chronic O O 0.9924399852752686
CYP B B 0.9970431923866272
administration O O 0.9975649118423462
significantly O O 0.9999045133590698
( O O 0.9998940229415894
P O O 0.9957754015922546
< O O 0.9999778270721436
or O O 0.9999958276748657
= O O 0.9999873638153076
. O O 0.9999982118606567
002 O O 0.99953293800354
) O O 0.9998843669891357
increased O O 0.999982476234436
bladder O O 0.9993491768836975
weight O O 0.9998376369476318
by O O 0.9999961853027344
60 O O 0.9999983310699463
% O O 0.9999980926513672
and O O 0.9999778270721436
increased O O 0.999984622001648
( O O 0.999953031539917
7 O O 0.9999586343765259
- O O 0.9998464584350586
to O O 0.9999834299087524
11 O O 0.9999665021896362
- O O 0.9999794960021973
fold O O 0.9999908208847046
) O O 0.9999790191650391
the O O 0.9999946355819702
numbers O O 0.9999797344207764
of O O 0.9999485015869141
NOS O B 0.8775854110717773
- O O 0.9138320088386536
immunoreactive O O 0.9982908368110657
( O O 0.9990801811218262
IR O O 0.977809727191925
) O O 0.9997991919517517
afferent O O 0.9975885152816772
neurons O O 0.9999587535858154
in O O 0.9998408555984497
the O O 0.9999290704727173
L6 O O 0.994874894618988
- O O 0.9970093965530396
S1 O O 0.9968934059143066
DRG O O 0.9967702627182007
. O O 0.9999510049819946

A O O 0.9999704360961914
small O O 0.9999914169311523
increase O O 0.9999809265136719
( O O 0.9999569654464722
1 O O 0.9999583959579468
. O O 0.9999887943267822
5 O O 0.9999479055404663
- O O 0.999977707862854
fold O O 0.9999954700469971
) O O 0.9999760389328003
also O O 0.9999845027923584
occurred O O 0.9999932050704956
in O O 0.9999226331710815
the O O 0.9999120235443115
L1 O O 0.9961243271827698
DRG O O 0.9908620119094849
, O O 0.999913215637207
but O O 0.9999641180038452
no O O 0.9999747276306152
change O O 0.9999916553497314
was O O 0.9999792575836182
detected O O 0.9999963045120239
in O O 0.9998319149017334
the O O 0.9998829364776611
L2 O O 0.9942599534988403
and O O 0.9996539354324341
L5 O O 0.9968684315681458
DRG O O 0.9944855570793152
. O O 0.9999371767044067

Bladder O O 0.9975165128707886
afferent O O 0.9950470924377441
cells O O 0.9999662637710571
in O O 0.9998186230659485
the O O 0.9998899698257446
L6 O O 0.9958385229110718
- O O 0.9940416216850281
S1 O O 0.991041362285614
DRG O O 0.9914577603340149
labeled O O 0.9999548196792603
by O O 0.9998286962509155
Fluorogold O B 0.9577303528785706
( O O 0.9994100332260132
40 O O 0.999687671661377
microliters O O 0.997622549533844
) O O 0.9998620748519897
injected O O 0.9999314546585083
into O O 0.9999369382858276
the O O 0.9999748468399048
bladder O O 0.9985924363136292
wall O O 0.9999696016311646
did O O 0.9999769926071167
not O O 0.999954342842102
exhibit O O 0.9999268054962158
NOS O O 0.9250919222831726
- O O 0.9985729455947876
IR O O 0.97854083776474
in O O 0.9996784925460815
control O O 0.9994631409645081
animals O O 0.9999648332595825
; O O 0.9999665021896362
however O O 0.9999747276306152
, O O 0.9999843835830688
following O O 0.9999716281890869
chronic O O 0.9993795156478882
CYP B B 0.9952730536460876
administration O O 0.9998431205749512
, O O 0.9999411106109619
a O O 0.9998875856399536
significant O O 0.9999496936798096
percentage O O 0.9999773502349854
of O O 0.99993896484375
bladder O O 0.9983088970184326
afferent O O 0.9926536083221436
neurons O O 0.9999637603759766
were O O 0.9998855590820312
NOS O O 0.903512716293335
- O O 0.9961642026901245
IR O O 0.9841184616088867
: O O 0.9994747042655945
L6 O O 0.9896827936172485
( O O 0.9999430179595947
19 O O 0.9999508857727051
. O O 0.999980092048645
8 O O 0.999974250793457
+ O O 0.9999747276306152
/ O O 0.9999678134918213
- O O 0.9999345541000366
4 O O 0.9999475479125977
. O O 0.999958872795105
6 O O 0.9999890327453613
% O O 0.9999793767929077
) O O 0.9999001026153564
and O O 0.9995943903923035
S1 O O 0.9824509024620056
( O O 0.9999538660049438
25 O O 0.9999622106552124
. O O 0.9999852180480957
3 O O 0.9999876022338867
+ O O 0.9999797344207764
/ O O 0.999943733215332
- O O 0.9999550580978394
2 O O 0.9999897480010986
. O O 0.9999569654464722
9 O O 0.9999932050704956
% O O 0.999985933303833
) O O 0.9999527931213379
. O O 0.9999755620956421

These O O 0.9999821186065674
results O O 0.9999914169311523
indicate O O 0.9999130964279175
that O O 0.9998558759689331
neuronal O O 0.9999706745147705
gene O O 0.9991028308868408
expression O O 0.9999661445617676
in O O 0.9998414516448975
visceral O O 0.9954894185066223
sensory O O 0.9986664056777954
pathways O O 0.9999665021896362
can O O 0.999880313873291
be O O 0.9999774694442749
upregulated O O 0.9991419315338135
by O O 0.9999136924743652
chemical O O 0.9979117512702942
irritation O O 0.9995384216308594
of O O 0.9991925358772278
afferent O O 0.8883814215660095
receptors O O 0.9999243021011353
in O O 0.9999127388000488
the O O 0.9999749660491943
urinary O O 0.9998881816864014
tract O O 0.9999738931655884
and O O 0.9999243021011353
/ O O 0.9999363422393799
or O O 0.9999858140945435
that O O 0.999951958656311
pathological O O 0.9999808073043823
changes O O 0.9999969005584717
in O O 0.999971866607666
the O O 0.999981164932251
urinary O O 0.9992882609367371
tract O O 0.9999732971191406
can O O 0.9998942613601685
initiate O O 0.9997219443321228
chemical O O 0.9941703081130981
signals O O 0.9998369216918945
that O O 0.9999068975448608
alter O O 0.9999611377716064
the O O 0.9999624490737915
chemical O O 0.9995359182357788
properties O O 0.9999768733978271
of O O 0.9998998641967773
visceral O O 0.9940245747566223
afferent O O 0.939245879650116
neurons O O 0.999909520149231
. O O 0.9999661445617676

Effects O O 0.9999035596847534
of O O 0.9997084736824036
a O O 0.9998264908790588
new O O 0.9994031190872192
calcium B B 0.9559575915336609
antagonist O O 0.7380990982055664
, O O 0.9887141585350037
CD B B 0.9977895021438599
- I I 0.9481056928634644
832 I I 0.9999715089797974
, O O 0.9996728897094727
on O O 0.9998154044151306
isoproterenol B B 0.9993232488632202
- O O 0.9998193383216858
induced O O 0.999924898147583
myocardial O O 0.9999985694885254
ischemia O O 0.9999921321868896
in O O 0.9999682903289795
dogs O O 0.999990701675415
with O O 0.9999840259552002
partial O O 0.9999747276306152
coronary O O 0.9999382495880127
stenosis O O 0.9998325109481812
. O O 0.9999610185623169

Effects O O 0.9999216794967651
of O O 0.9993894100189209
CD B B 0.9951735138893127
- I I 0.9386389851570129
832 I I 0.9999551773071289
on O O 0.9889398217201233
isoproterenol B B 0.9990429282188416
( O O 0.9970980882644653
ISO B B 0.9982511401176453
) O O 0.8575268387794495
- O O 0.9997158646583557
induced O O 0.9999440908432007
myocardial O O 0.9999984502792358
ischemia O O 0.9999936819076538
were O O 0.9999746084213257
studied O O 0.999971866607666
in O O 0.9999306201934814
dogs O O 0.9999746084213257
with O O 0.999972939491272
partial O O 0.9999486207962036
coronary O O 0.999584972858429
stenosis O O 0.9993108510971069
of O O 0.99985671043396
the O O 0.9999780654907227
left O O 0.9999560117721558
circumflex O O 0.9942335486412048
coronary O O 0.9984152317047119
artery O O 0.9992259740829468
and O O 0.9999531507492065
findings O O 0.9999949932098389
were O O 0.9999901056289673
compared O O 0.9999960660934448
with O O 0.9999918937683105
those O O 0.9999946355819702
for O O 0.9987975358963013
nifedipine B B 0.9997647404670715
or O O 0.9787693023681641
diltiazem B B 0.9994608759880066
. O O 0.9999628067016602

In O O 0.9999572038650513
the O O 0.9999805688858032
presence O O 0.9999741315841675
of O O 0.9999657869338989
coronary O O 0.9990631937980652
artery O O 0.9987560510635376
stenosis O O 0.9994021654129028
, O O 0.999864935874939
3 O O 0.9909023642539978
- O O 0.9999570846557617
min O O 0.9997319579124451
periods O O 0.9999585151672363
of O O 0.9999020099639893
intracoronary O O 0.9993875026702881
ISO B B 0.9900541305541992
infusion O O 0.9529454112052917
( O O 0.9998736381530762
10 O O 0.9999662637710571
ng O O 0.9999275207519531
/ O O 0.9999849796295166
kg O O 0.9999884366989136
/ O O 0.9999406337738037
min O O 0.9997710585594177
) O O 0.9999616146087646
increased O O 0.999929666519165
heart O O 0.999988317489624
rate O O 0.9999916553497314
and O O 0.9999017715454102
maximal O O 0.9999797344207764
rate O O 0.9999839067459106
of O O 0.9997069239616394
left O O 0.9999713897705078
ventricular O O 0.9999936819076538
pressure O O 0.9997677206993103
rise O O 0.9999079704284668
, O O 0.9999836683273315
which O O 0.9999707937240601
resulted O O 0.99998939037323
in O O 0.9999905824661255
a O O 0.999990701675415
decrease O O 0.9999899864196777
in O O 0.9999771118164062
percentage O O 0.5400210618972778
segmental O O 0.9999866485595703
shortening O O 0.9999934434890747
and O O 0.999966025352478
ST O O 0.9955488443374634
- O O 0.9999644756317139
segment O O 0.999990701675415
elevation O O 0.9999948740005493
of O O 0.9999955892562866
the O O 0.9999969005584717
epicardial O O 0.9999933242797852
electrocardiogram O O 0.9999566078186035
. O O 0.9999734163284302

After O O 0.9999890327453613
the O O 0.9999850988388062
control O O 0.9997435212135315
ISO B O 0.7023423314094543
infusion O O 0.9992251396179199
with O O 0.9998745918273926
stenosis O O 0.9986856579780579
was O O 0.9999791383743286
performed O O 0.9999847412109375
, O O 0.999890923500061
equihypotensive O O 0.987078070640564
doses O O 0.9998130202293396
of O O 0.9986931681632996
CD B B 0.9966176152229309
- I I 0.9384174942970276
832 I I 0.9998760223388672
( O O 0.988856852054596
3 O O 0.9218974709510803
and O O 0.9996625185012817
10 O O 0.999941349029541
micrograms O O 0.9977360963821411
/ O O 0.9999756813049316
kg O O 0.9999957084655762
/ O O 0.9999798536300659
min O O 0.9999597072601318
, O O 0.9999775886535645
n O O 0.9976010918617249
= O O 0.9995144605636597
7 O O 0.9998831748962402
) O O 0.9996706247329712
, O O 0.9993289709091187
nifedipine B B 0.9997385144233704
( O O 0.9995846152305603
1 O O 0.9996623992919922
and O O 0.9997944235801697
3 O O 0.9997456669807434
micrograms O O 0.9982172846794128
/ O O 0.9999700784683228
kg O O 0.9999969005584717
/ O O 0.9999786615371704
min O O 0.9999579191207886
, O O 0.9999762773513794
n O O 0.9992897510528564
= O O 0.9999556541442871
9 O O 0.9999845027923584
) O O 0.9998921155929565
or O O 0.9977020621299744
diltiazem B B 0.999603807926178
( O O 0.9995809197425842
10 O O 0.9995224475860596
and O O 0.9997981190681458
30 O O 0.9999936819076538
micrograms O O 0.9995318651199341
/ O O 0.9999785423278809
kg O O 0.9999946355819702
/ O O 0.9999830722808838
min O O 0.9999858140945435
, O O 0.9999794960021973
n O O 0.9989331364631653
= O O 0.9998811483383179
7 O O 0.9999738931655884
) O O 0.9999825954437256
were O O 0.9999822378158569
infused O O 0.9999629259109497
5 O O 0.9999021291732788
min O O 0.9999783039093018
before O O 0.9999873638153076
and O O 0.9999728202819824
during O O 0.9999816417694092
the O O 0.9999942779541016
second O O 0.9999926090240479
and O O 0.9999582767486572
third O O 0.999937891960144
ISO B O 0.5601772665977478
infusion O O 0.9997225403785706
. O O 0.9999749660491943

Both O O 0.9871201515197754
CD B B 0.9476913809776306
- I I 0.9204518795013428
832 I I 0.9998655319213867
and O O 0.9965268969535828
diltiazem B B 0.9998016953468323
, O O 0.9998341798782349
but O O 0.9998985528945923
not O O 0.9999086856842041
nifedipine B B 0.999811589717865
, O O 0.9999698400497437
significantly O O 0.9999767541885376
reduced O O 0.9999825954437256
the O O 0.9999933242797852
increase O O 0.9999969005584717
in O O 0.9999905824661255
heart O O 0.9999924898147583
rate O O 0.9999933242797852
induced O O 0.9999911785125732
by O O 0.9999558925628662
ISO B B 0.9989864230155945
infusion O O 0.9873194694519043
. O O 0.9999487400054932

In O O 0.9999681711196899
contrast O O 0.9999463558197021
to O O 0.9992430210113525
nifedipine B B 0.9996577501296997
, O O 0.9996126294136047
CD B B 0.9914793968200684
- I I 0.8685803413391113
832 I I 0.9998645782470703
( O O 0.9985522627830505
10 O O 0.9999401569366455
micrograms O O 0.9996403455734253
/ O O 0.999969482421875
kg O O 0.9999942779541016
/ O O 0.9999643564224243
min O O 0.9997596144676208
) O O 0.9998083710670471
prevented O O 0.9999489784240723
the O O 0.9999963045120239
decrease O O 0.9999953508377075
in O O 0.9999861717224121
percentage O O 0.5945753455162048
segmental O O 0.9999910593032837
shortening O O 0.9999945163726807
from O O 0.9999899864196777
32 O O 0.9999920129776001
+ O O 0.999990701675415
/ O O 0.9999831914901733
- O O 0.9999638795852661
12 O O 0.9999920129776001
% O O 0.999995231628418
to O O 0.9999881982803345
115 O O 0.9999799728393555
+ O O 0.9999938011169434
/ O O 0.9999921321868896
- O O 0.9999843835830688
26 O O 0.9999933242797852
% O O 0.9999978542327881
of O O 0.9999918937683105
the O O 0.9999876022338867
control O O 0.9999881982803345
value O O 0.9999967813491821
( O O 0.9999771118164062
P O O 0.9999674558639526
< O O 0.9999871253967285
. O O 0.9999980926513672
01 O O 0.9999973773956299
) O O 0.9999814033508301
and O O 0.9999629259109497
ST O O 0.9797061085700989
- O O 0.9998568296432495
segment O O 0.9999842643737793
elevation O O 0.999995231628418
from O O 0.9999961853027344
5 O O 0.999873161315918
. O O 0.9999958276748657
6 O O 0.9999843835830688
+ O O 0.9999948740005493
/ O O 0.9999815225601196
- O O 0.9999755620956421
1 O O 0.9999877214431763
. O O 0.9999868869781494
0 O O 0.9999908208847046
mV O O 0.9999732971191406
to O O 0.9999799728393555
1 O O 0.9999662637710571
. O O 0.9999946355819702
6 O O 0.999984622001648
+ O O 0.9999932050704956
/ O O 0.9999182224273682
- O O 0.9999430179595947
1 O O 0.9999834299087524
. O O 0.999985933303833
3 O O 0.9999784231185913
mV O O 0.9999159574508667
( O O 0.9999774694442749
P O O 0.9999629259109497
< O O 0.9999819993972778
. O O 0.9999983310699463
01 O O 0.9999955892562866
) O O 0.9999856948852539
at O O 0.9999889135360718
3 O O 0.9999560117721558
min O O 0.999992847442627
after O O 0.999915599822998
ISO B B 0.9875920414924622
infusion O O 0.998602569103241
with O O 0.9999480247497559
stenosis O O 0.9906531572341919
. O O 0.9999634027481079

Diltiazem B B 0.9993038177490234
( O O 0.9997003078460693
30 O O 0.9999798536300659
micrograms O O 0.9997726082801819
/ O O 0.9999715089797974
kg O O 0.9999961853027344
/ O O 0.9999724626541138
min O O 0.9998390674591064
) O O 0.9997746348381042
also O O 0.9999158382415771
prevented O O 0.9999202489852905
the O O 0.9999939203262329
decrease O O 0.9999939203262329
in O O 0.9999840259552002
percentage O O 0.5173454284667969
segmental O O 0.9999881982803345
shortening O O 0.999992847442627
from O O 0.9999850988388062
34 O O 0.9999631643295288
+ O O 0.9999885559082031
/ O O 0.999972939491272
- O O 0.9999339580535889
14 O O 0.9999873638153076
% O O 0.9999948740005493
to O O 0.9999839067459106
63 O O 0.9999953508377075
+ O O 0.9999932050704956
/ O O 0.9999916553497314
- O O 0.9999792575836182
18 O O 0.9999927282333374
% O O 0.9999974966049194
of O O 0.9999901056289673
the O O 0.9999791383743286
control O O 0.999982476234436
value O O 0.9999939203262329
( O O 0.9999746084213257
P O O 0.9999679327011108
< O O 0.9999921321868896
. O O 0.9999967813491821
05 O O 0.9999953508377075
) O O 0.9999715089797974
and O O 0.9999470710754395
ST O O 0.9833968281745911
- O O 0.9998272061347961
segment O O 0.9999788999557495
elevation O O 0.9999933242797852
from O O 0.9999939203262329
4 O O 0.9995449185371399
. O O 0.9999934434890747
7 O O 0.9999649524688721
+ O O 0.9999895095825195
/ O O 0.9999144077301025
- O O 0.9999639987945557
0 O O 0.9999799728393555
. O O 0.9999699592590332
7 O O 0.9999783039093018
mV O O 0.9999699592590332
to O O 0.9999769926071167
2 O O 0.9999508857727051
. O O 0.9999940395355225
1 O O 0.9999929666519165
+ O O 0.9999895095825195
/ O O 0.999902606010437
- O O 0.9999504089355469
0 O O 0.9999786615371704
. O O 0.9999732971191406
7 O O 0.9999884366989136
mV O O 0.9999136924743652
( O O 0.9999682903289795
P O O 0.9999150037765503
< O O 0.9999855756759644
. O O 0.9999973773956299
01 O O 0.9999985694885254
) O O 0.9999819993972778
at O O 0.9999854564666748
3 O O 0.9999425411224365
min O O 0.9999951124191284
after O O 0.9999288320541382
ISO B B 0.9469459652900696
infusion O O 0.9984947443008423
with O O 0.9999020099639893
stenosis O O 0.9540174007415771
. O O 0.9999634027481079

These O O 0.9999856948852539
data O O 0.9999914169311523
show O O 0.9999040365219116
that O O 0.999700665473938
CD B B 0.9968421459197998
- I I 0.9285759329795837
832 I I 0.9999488592147827
improves O O 0.9986987113952637
myocardial O O 0.9999988079071045
ischemia O O 0.9999958276748657
during O O 0.9996669292449951
ISO B O 0.8624355792999268
infusion O O 0.9992033839225769
with O O 0.9998125433921814
stenosis O O 0.9966037273406982
and O O 0.9999591112136841
suggest O O 0.999951958656311
that O O 0.9998573064804077
the O O 0.9997523427009583
negative O O 0.9954174757003784
chronotropic O O 0.9544880390167236
property O O 0.9998290538787842
of O O 0.9997697472572327
CD B B 0.9977685213088989
- I I 0.9182242751121521
832 I I 0.9999244213104248
plays O O 0.9988170862197876
a O O 0.9998207688331604
major O O 0.9999321699142456
role O O 0.999908447265625
in O O 0.9999372959136963
the O O 0.9999523162841797
beneficial O O 0.9998786449432373
effects O O 0.9999803304672241
of O O 0.9997277855873108
CD B B 0.9975554347038269
- I I 0.9366313219070435
832 I I 0.9999527931213379
. O O 0.99974125623703

The O O 0.9999502897262573
effect O O 0.999929666519165
of O O 0.999581515789032
recombinant O O 0.9694650173187256
human O O 0.9432717561721802
insulin O O 0.6247122287750244
- O O 0.9118369221687317
like O O 0.9428350329399109
growth O O 0.896323561668396
factor O O 0.8893023133277893
- O O 0.9537501931190491
I O O 0.7563716173171997
on O O 0.9993531107902527
chronic O O 0.9994589686393738
puromycin B B 0.9979119896888733
aminonucleoside I I 0.9909164309501648
nephropathy O O 0.996436357498169
in O O 0.9999183416366577
rats O O 0.9999419450759888
. O O 0.9999607801437378

We O O 0.9999464750289917
recently O O 0.9999818801879883
demonstrated O O 0.9999901056289673
that O O 0.9998986721038818
recombinant O O 0.9977067708969116
hGH O B 0.9718238711357117
exacerbates O O 0.9997093081474304
renal O O 0.999953031539917
functional O O 0.9999785423278809
and O O 0.9999721050262451
structural O O 0.9999858140945435
injury O O 0.9999964237213135
in O O 0.9999086856842041
chronic O O 0.9980249404907227
puromycin B B 0.9963802695274353
aminonucleoside I I 0.9985966086387634
( O O 0.9660308361053467
PAN B O 0.6378545761108398
) O O 0.913191556930542
nephropathy O O 0.9997299313545227
, O O 0.9999808073043823
an O O 0.9999653100967407
experimental O O 0.9999183416366577
model O O 0.9999932050704956
of O O 0.9999473094940186
glomerular O O 0.998382568359375
disease O O 0.9999911785125732
. O O 0.9999732971191406

Therefore O O 0.9999850988388062
, O O 0.9999822378158569
we O O 0.9999819993972778
examined O O 0.9999947547912598
whether O O 0.9999872446060181
recombinant O O 0.9767508506774902
human O O 0.9453116059303284
( O O 0.974398136138916
rh O O 0.9785413146018982
) O O 0.9915947318077087
IGF O O 0.7309046983718872
- O O 0.9163236618041992
I O O 0.8012583255767822
is O O 0.9998571872711182
a O O 0.9999868869781494
safer O O 0.9999641180038452
alternative O O 0.9999818801879883
for O O 0.9999557733535767
the O O 0.9999867677688599
treatment O O 0.9999617338180542
of O O 0.9999734163284302
growth O O 0.9972686767578125
failure O O 0.9999927282333374
in O O 0.999950647354126
rats O O 0.9999911785125732
with O O 0.9999810457229614
chronic O O 0.9998728036880493
PAN B O 0.8783575296401978
nephropathy O O 0.9999300241470337
. O O 0.999976634979248

The O O 0.9999470710754395
glomerulopathy O O 0.9992198944091797
was O O 0.9999533891677856
induced O O 0.9999902248382568
by O O 0.9999327659606934
seven O O 0.9999799728393555
serial O O 0.999908447265625
injections O O 0.9999459981918335
of O O 0.9997069239616394
PAN B B 0.9932693839073181
over O O 0.9995478987693787
12 O O 0.9999867677688599
wk O O 0.999896764755249
. O O 0.9999804496765137

Experimental O O 0.9998927116394043
animals O O 0.9999980926513672
( O O 0.9999610185623169
n O O 0.9998632669448853
= O O 0.9999792575836182
6 O O 0.9999783039093018
) O O 0.9999535083770752
received O O 0.9995079040527344
rhIGF O B 0.8216220140457153
- O I 0.6845842599868774
I O I 0.9579633474349976
, O O 0.8853995203971863
400 O O 0.998011589050293
micrograms O O 0.9995244741439819
/ O O 0.99950110912323
d O O 0.9960556030273438
, O O 0.9997108578681946
whereas O O 0.931833028793335
control O O 0.9999616146087646
rats O O 0.9999967813491821
( O O 0.9999563694000244
n O O 0.9998501539230347
= O O 0.9999772310256958
6 O O 0.9999692440032959
) O O 0.9999562501907349
received O O 0.9998680353164673
the O O 0.9999816417694092
vehicle O O 0.9998875856399536
. O O 0.9999480247497559

rhIGF O B 0.5848884582519531
- O I 0.5593287348747253
I O I 0.997479259967804
improved O O 0.9997289776802063
weight O O 0.9999269247055054
gain O O 0.9999977350234985
by O O 0.9999970197677612
14 O O 0.999998927116394
% O O 0.9999967813491821
( O O 0.9999655485153198
p O O 0.9998995065689087
< O O 0.9999924898147583
0 O O 0.9999961853027344
. O O 0.9999983310699463
05 O O 0.9999966621398926
) O O 0.999980092048645
, O O 0.9999861717224121
without O O 0.9999892711639404
altering O O 0.9998615980148315
hematocrit O O 0.9998225569725037
or O O 0.9999697208404541
blood O O 0.9997604489326477
pressure O O 0.9998979568481445
in O O 0.9999518394470215
rats O O 0.9999505281448364
with O O 0.9999817609786987
renal O O 0.9999723434448242
disease O O 0.9999901056289673
. O O 0.9999619722366333

Urinary O O 0.995469331741333
protein O O 0.7480176687240601
excretion O O 0.9998471736907959
was O O 0.9999628067016602
unaltered O O 0.9999707937240601
by O O 0.9999121427536011
rhIGF O B 0.8572379946708679
- O I 0.7093276977539062
I O I 0.9729358553886414
treatment O O 0.9987937211990356
in O O 0.9999619722366333
rats O O 0.9999911785125732
with O O 0.9999833106994629
chronic O O 0.9998773336410522
PAN B O 0.8136746287345886
nephropathy O O 0.9998631477355957
. O O 0.999972939491272

After O O 0.9998996257781982
12 O O 0.9999814033508301
wk O O 0.9996106028556824
, O O 0.9999618530273438
the O O 0.9999575614929199
inulin O O 0.4658418893814087
clearance O O 0.9998096823692322
was O O 0.9999394416809082
higher O O 0.9997933506965637
in O O 0.999765932559967
rhIGF O O 0.5420086979866028
- O O 0.8906799554824829
I O O 0.56680828332901
- O O 0.9984174966812134
treated O O 0.9997705817222595
rats O O 0.999977707862854
, O O 0.9999624490737915
0 O O 0.9993688464164734
. O O 0.9999703168869019
48 O O 0.9999865293502808
+ O O 0.9999685287475586
/ O O 0.9996730089187622
- O O 0.9996172189712524
0 O O 0.999254047870636
. O O 0.999993085861206
08 O O 0.9999843835830688
versus O O 0.9999521970748901
0 O O 0.9998379945755005
. O O 0.9999797344207764
24 O O 0.999984622001648
+ O O 0.9999731779098511
/ O O 0.9996927976608276
- O O 0.9998868703842163
0 O O 0.9999548196792603
. O O 0.9999926090240479
06 O O 0.9999947547912598
mL O O 0.999991774559021
/ O O 0.9999827146530151
min O O 0.9999825954437256
/ O O 0.9999901056289673
100 O O 0.9999963045120239
g O O 0.9999995231628418
of O O 0.9999990463256836
body O O 0.9999969005584717
weight O O 0.9999774694442749
in O O 0.999930739402771
untreated O O 0.9997681975364685
PAN B O 0.7553952932357788
nephropathy O O 0.997776210308075
animals O O 0.999690055847168
, O O 0.9999570846557617
p O O 0.9996896982192993
< O O 0.9999417066574097
0 O O 0.9999822378158569
. O O 0.999993085861206
05 O O 0.9999904632568359
. O O 0.9999804496765137

The O O 0.9999823570251465
improvement O O 0.999995231628418
in O O 0.9999507665634155
GFR O O 0.61463862657547
was O O 0.9999091625213623
not O O 0.9999691247940063
associated O O 0.9999735355377197
with O O 0.9999175071716309
enhanced O O 0.9998346567153931
glomerular O O 0.9991689920425415
hypertrophy O O 0.9998608827590942
or O O 0.9999171495437622
increased O O 0.9999514818191528
segmental O O 0.999923586845398
glomerulosclerosis O O 0.9924138188362122
, O O 0.999855637550354
tubulointerstitial O O 0.9999873638153076
injury O O 0.9999915361404419
, O O 0.9997650980949402
or O O 0.999504566192627
renal O O 0.996771514415741
cortical O O 0.5998758673667908
malondialdehyde B O 0.8420333862304688
content O O 0.9993271827697754
. O O 0.9999607801437378

In O O 0.9999270439147949
rats O O 0.9999831914901733
with O O 0.999954342842102
PAN B O 0.6707004308700562
nephropathy O O 0.9998427629470825
, O O 0.9999136924743652
administration O O 0.9998977184295654
of O O 0.9997851252555847
rhIGF O B 0.5021772980690002
- O I 0.6157104969024658
I O I 0.971065878868103
increased O O 0.9982157945632935
IGF O O 0.6836701035499573
- O O 0.9433882236480713
I O O 0.8367337584495544
and O O 0.9995501637458801
GH O O 0.7940487265586853
receptor O O 0.9992945194244385
gene O O 0.9998942613601685
expression O O 0.9999752044677734
, O O 0.9999735355377197
without O O 0.9999679327011108
altering O O 0.999987006187439
the O O 0.9999927282333374
steady O O 0.9999585151672363
state O O 0.9999790191650391
level O O 0.9999628067016602
of O O 0.9997957348823547
IGF O O 0.5688754916191101
- O O 0.6675788760185242
I O O 0.7899355888366699
receptor O O 0.998674750328064
mRNA O O 0.98099285364151
. O O 0.9999653100967407

In O O 0.999671220779419
normal O O 0.9992390871047974
rats O O 0.9999839067459106
with O O 0.9999665021896362
intact O O 0.9999361038208008
kidneys O O 0.9999127388000488
, O O 0.999727189540863
rhIGF O B 0.7238730192184448
- O I 0.5735937356948853
I O I 0.9731171131134033
administration O O 0.99772709608078
( O O 0.9999122619628906
n O O 0.9952402114868164
= O O 0.9996275901794434
4 O O 0.9984198808670044
) O O 0.9998750686645508
did O O 0.9999756813049316
not O O 0.999994158744812
alter O O 0.9999908208847046
weight O O 0.9999945163726807
gain O O 0.9999986886978149
, O O 0.9999874830245972
blood O O 0.9998519420623779
pressure O O 0.9999362230300903
, O O 0.9999737739562988
proteinuria O O 0.9999582767486572
, O O 0.9999427795410156
GFR O O 0.7370226979255676
, O O 0.9998130202293396
glomerular O O 0.9914408922195435
planar O O 0.9999384880065918
area O O 0.999755322933197
, O O 0.9999511241912842
renal O O 0.9984009861946106
cortical O O 0.9444018602371216
malondialdehyde B O 0.6072848439216614
content O O 0.9996299743652344
, O O 0.9999064207077026
or O O 0.9998226761817932
glomerular O O 0.90216064453125
or O O 0.9997871518135071
tubulointerstitial O O 0.9999815225601196
damage O O 0.9999908208847046
, O O 0.9999868869781494
compared O O 0.9999924898147583
with O O 0.9999920129776001
untreated O O 0.9995250701904297
animals O O 0.999980092048645
( O O 0.9999576807022095
n O O 0.9998242259025574
= O O 0.99997878074646
4 O O 0.9999343156814575
) O O 0.9999618530273438
. O O 0.9999725818634033

rhIGF O B 0.9155707955360413
- O I 0.7365009188652039
I O I 0.96196049451828
treatment O O 0.9990857839584351
reduced O O 0.9999641180038452
the O O 0.9999693632125854
steady O O 0.9999438524246216
state O O 0.9999610185623169
renal O O 0.9979372024536133
IGF O O 0.9486676454544067
- O O 0.980089545249939
I O O 0.958442747592926
mRNA O O 0.9622480273246765
level O O 0.9998599290847778
but O O 0.9999126195907593
did O O 0.9999510049819946
not O O 0.999953031539917
modify O O 0.9999558925628662
gene O O 0.9998694658279419
expression O O 0.9999603033065796
of O O 0.9998487234115601
the O O 0.9997950196266174
IGF O O 0.9674989581108093
- O O 0.9898226261138916
I O O 0.9809911251068115
or O O 0.9988086223602295
GH O O 0.502858579158783
receptors O O 0.9997538924217224
. O O 0.9999184608459473

We O O 0.999980092048645
conclude O O 0.9999790191650391
that O O 0.9999387264251709
: O O 0.9999098777770996
1 O O 0.9999693632125854
) O O 0.9999574422836304
administration O O 0.999904990196228
of O O 0.9998407363891602
rhIGF O O 0.4720819890499115
- O O 0.762211263179779
I O O 0.9237014055252075
improves O O 0.9991827607154846
growth O O 0.9999185800552368
and O O 0.9999662637710571
GFR O O 0.7433767318725586
in O O 0.9999237060546875
rats O O 0.9999908208847046
with O O 0.999976396560669
chronic O O 0.9997856020927429
PAN B O 0.8301949501037598
nephropathy O O 0.9997110962867737
and O O 0.9998884201049805
2 O O 0.9999740123748779
) O O 0.9999804496765137
unlike O O 0.9994140863418579
rhGH O O 0.8483196496963501
, O O 0.9998487234115601
long O O 0.9996974468231201
- O O 0.9999771118164062
term O O 0.9999570846557617
use O O 0.9999525547027588
of O O 0.9997585415840149
rhIGF O B 0.6341187357902527
- O I 0.5254766345024109
I O I 0.9759865403175354
does O O 0.9995977282524109
not O O 0.9999408721923828
worsen O O 0.9996767044067383
renal O O 0.9999629259109497
functional O O 0.9999862909317017
and O O 0.9999642372131348
structural O O 0.9999799728393555
injury O O 0.9999960660934448
in O O 0.9999634027481079
this O O 0.9999173879623413
disease O O 0.9999538660049438
model O O 0.9999905824661255
. O O 0.9999765157699585

Nefiracetam B B 0.9991078972816467
( O O 0.9904849529266357
DM B B 0.9958937168121338
- I I 0.9737812280654907
9384 I I 0.9999840259552002
) O O 0.9930406808853149
reverses O O 0.999703586101532
apomorphine B B 0.9985973238945007
- O O 0.9998822212219238
induced O O 0.9999099969863892
amnesia O O 0.9999309778213501
of O O 0.999824583530426
a O O 0.9991587400436401
passive O O 0.9951474070549011
avoidance O O 0.9999620914459229
response O O 0.999932050704956
: O O 0.9998286962509155
delayed O O 0.9999657869338989
emergence O O 0.9999923706054688
of O O 0.9999678134918213
the O O 0.999930739402771
memory O O 0.9998743534088135
retention O O 0.9998548030853271
effects O O 0.9999597072601318
. O O 0.9999692440032959

Nefiracetam B B 0.9987753033638
is O O 0.9986586570739746
a O O 0.998022198677063
novel O O 0.9697432518005371
pyrrolidone B B 0.9891806244850159
derivative O O 0.8022485971450806
which O O 0.9992415904998779
attenuates O O 0.9958667755126953
scopolamine B B 0.9992955923080444
- O O 0.9997825026512146
induced O O 0.9998992681503296
learning O O 0.9999709129333496
and O O 0.9998981952667236
post O O 0.9969462752342224
- O O 0.9998195767402649
training O O 0.999954342842102
consolidation O O 0.9997672438621521
deficits O O 0.9999872446060181
. O O 0.9999336004257202

Given O O 0.9999889135360718
that O O 0.9998836517333984
apomorphine B B 0.9994291663169861
inhibits O O 0.9993991851806641
passive O O 0.9336944818496704
avoidance O O 0.999803364276886
retention O O 0.9998162388801575
when O O 0.9999449253082275
given O O 0.9998995065689087
during O O 0.9999310970306396
training O O 0.9999936819076538
or O O 0.9999750852584839
in O O 0.9999157190322876
a O O 0.9999499320983887
defined O O 0.9998917579650879
10 O O 0.9999538660049438
- O O 0.9999581575393677
12h O O 0.9999206066131592
post O O 0.9996179342269897
- O O 0.9998672008514404
training O O 0.999993085861206
period O O 0.9999644756317139
, O O 0.9999678134918213
we O O 0.9999607801437378
evaluated O O 0.9999850988388062
the O O 0.9999849796295166
ability O O 0.9999873638153076
of O O 0.9974925518035889
nefiracetam B B 0.9996546506881714
to O O 0.9998688697814941
attenuate O O 0.9997400641441345
amnesia O O 0.9993822574615479
induced O O 0.9999620914459229
by O O 0.999916672706604
dopaminergic O B 0.9897957444190979
agonism O O 0.6487762928009033
. O O 0.9998742341995239

A O O 0.999945878982544
step O O 0.9998224377632141
- O O 0.9999427795410156
down O O 0.9999417066574097
passive O O 0.9990822076797485
avoidance O O 0.9999511241912842
paradigm O O 0.9999536275863647
was O O 0.9999756813049316
employed O O 0.9999834299087524
and O O 0.9998849630355835
nefiracetam B B 0.9994934797286987
( O O 0.9997901320457458
3 O O 0.9990777969360352
mg O O 0.9998648166656494
/ O O 0.9999696016311646
kg O O 0.9999853372573853
) O O 0.9996665716171265
and O O 0.9942703247070312
apomorphine B B 0.9966607093811035
( O O 0.9998151659965515
0 O O 0.9999737739562988
. O O 0.9999949932098389
5 O O 0.9999817609786987
mg O O 0.9998601675033569
/ O O 0.9999032020568848
kg O O 0.9999793767929077
) O O 0.9999098777770996
were O O 0.9999697208404541
given O O 0.9999262094497681
alone O O 0.9998200535774231
or O O 0.9999513626098633
in O O 0.9999361038208008
combination O O 0.9998088479042053
during O O 0.999900221824646
training O O 0.9999953508377075
and O O 0.99998939037323
at O O 0.999937891960144
the O O 0.9999954700469971
10 O O 0.9999881982803345
- O O 0.9999812841415405
12h O O 0.9999914169311523
post O O 0.9999220371246338
- O O 0.9999252557754517
training O O 0.9999946355819702
period O O 0.9999673366546631
of O O 0.9999914169311523
consolidation O O 0.9999191761016846
. O O 0.9999808073043823

Co O O 0.9945521950721741
- O O 0.9998138546943665
administration O O 0.9998360872268677
of O O 0.9995889067649841
nefiracetam B B 0.9991975426673889
and O O 0.992508590221405
apomorphine B B 0.9954034090042114
during O O 0.9995899796485901
training O O 0.9992814660072327
or O O 0.9999855756759644
10h O O 0.9995753169059753
thereafter O O 0.9999539852142334
produced O O 0.9999687671661377
no O O 0.999969482421875
significant O O 0.9999902248382568
anti O O 0.9928534626960754
- O O 0.9993368983268738
amnesic O O 0.9987485408782959
effect O O 0.9999485015869141
. O O 0.9999710321426392

However O O 0.9999544620513916
, O O 0.9998360872268677
administration O O 0.9998806715011597
of O O 0.9994423985481262
nefiracetam B B 0.9992014765739441
during O O 0.9993502497673035
training O O 0.9999829530715942
completely O O 0.9999680519104004
reversed O O 0.9999254941940308
the O O 0.999985933303833
amnesia O O 0.9998481273651123
induced O O 0.9999901056289673
by O O 0.999914288520813
apomorphine B B 0.998694121837616
at O O 0.9998749494552612
the O O 0.9999910593032837
10h O O 0.9999228715896606
post O O 0.9998983144760132
- O O 0.9999151229858398
training O O 0.9999936819076538
time O O 0.9999833106994629
and O O 0.9999639987945557
the O O 0.9999908208847046
converse O O 0.9997013211250305
was O O 0.9999874830245972
also O O 0.9999856948852539
true O O 0.9999604225158691
. O O 0.9999876022338867

These O O 0.9998869895935059
effects O O 0.9999567270278931
were O O 0.9998806715011597
not O O 0.9999122619628906
mediated O O 0.9999723434448242
by O O 0.9999244213104248
a O O 0.9998805522918701
dopaminergic O O 0.7973101735115051
mechanism O O 0.9998999834060669
as O O 0.9998911619186401
nefiracetam B B 0.9998482465744019
, O O 0.9999462366104126
at O O 0.9999359846115112
millimolar O O 0.9972004890441895
concentrations O O 0.9998701810836792
, O O 0.9999606609344482
failed O O 0.9999512434005737
to O O 0.9999419450759888
displace O O 0.9998310804367065
either O O 0.9997703433036804
[ O O 0.877614438533783
3H O O 0.8391926288604736
] O O 0.9958525896072388
SCH B B 0.9193212389945984
23390 I O 0.8501926064491272
or O O 0.9986445307731628
[ O O 0.753777027130127
3H O O 0.7724043130874634
] O O 0.9840114712715149
spiperone B B 0.964572012424469
binding O O 0.9997393488883972
from O O 0.999632716178894
D1 O O 0.9819058179855347
or O O 0.9997730851173401
D2 O O 0.9731448888778687
dopamine B O 0.7396150827407837
receptor O O 0.9983184337615967
subtypes O O 0.999556839466095
, O O 0.9999716281890869
respectively O O 0.9997912049293518
. O O 0.9999610185623169

It O O 0.999991774559021
is O O 0.9999738931655884
suggested O O 0.9999792575836182
that O O 0.9996359348297119
nefiracetam B B 0.999579131603241
augments O O 0.9924147725105286
molecular O O 0.9999634027481079
processes O O 0.9999735355377197
in O O 0.9999316930770874
the O O 0.9999659061431885
early O O 0.9999560117721558
stages O O 0.9999914169311523
of O O 0.9999755620956421
events O O 0.9999856948852539
which O O 0.999976396560669
ultimately O O 0.9999768733978271
lead O O 0.9999874830245972
to O O 0.9999792575836182
consolidation O O 0.9999847412109375
of O O 0.9999701976776123
memory O O 0.9999932050704956
. O O 0.9999725818634033

Phenytoin B B 0.9547252058982849
encephalopathy O O 0.9895619750022888
as O O 0.9998735189437866
probable O O 0.999955415725708
idiosyncratic O O 0.9999866485595703
reaction O O 0.9999918937683105
: O O 0.9999827146530151
case O O 0.9999831914901733
report O O 0.9999934434890747
. O O 0.9999775886535645

A O O 0.9999558925628662
case O O 0.9999828338623047
of O O 0.9999294281005859
phenytoin B B 0.9979555606842041
( O O 0.9890413880348206
DPH B B 0.9892920255661011
) O O 0.9993690848350525
encephalopathy O O 0.9997406601905823
with O O 0.9999213218688965
increasing O O 0.9999614953994751
seizures O O 0.9999845027923584
and O O 0.9998916387557983
EEG O O 0.9807156324386597
and O O 0.9998995065689087
mental O O 0.9999947547912598
changes O O 0.9999973773956299
is O O 0.999980092048645
described O O 0.9999948740005493
. O O 0.9999843835830688

Despite O O 0.9999313354492188
adequate O O 0.9999783039093018
oral O O 0.9998537302017212
dosage O O 0.9999767541885376
of O O 0.9987677335739136
DPH B B 0.9976845979690552
( O O 0.9991482496261597
5 O O 0.9998855590820312
mg O O 0.9998981952667236
/ O O 0.9999747276306152
kg O O 0.9999982118606567
/ O O 0.9998247027397156
daily O O 0.999170184135437
) O O 0.9999706745147705
the O O 0.9999895095825195
plasma O O 0.9999351501464844
level O O 0.9999570846557617
was O O 0.9999759197235107
very O O 0.9999951124191284
low O O 0.999993085861206
( O O 0.9999805688858032
2 O O 0.9999505281448364
. O O 0.999995231628418
8 O O 0.999985933303833
microgramg O O 0.9999605417251587
/ O O 0.9999780654907227
ml O O 0.9999984502792358
) O O 0.9999762773513794
. O O 0.9999812841415405

The O O 0.9999566078186035
encephalopathy O O 0.9999303817749023
was O O 0.9999194145202637
probably O O 0.9999077320098877
an O O 0.9999188184738159
idiosyncratic O O 0.9999905824661255
and O O 0.9999892711639404
not O O 0.9998899698257446
toxic O O 0.9990808963775635
or O O 0.9996922016143799
allergic O O 0.9947622418403625
reaction O O 0.9999849796295166
. O O 0.9999579191207886

In O O 0.9999788999557495
fact O O 0.9999690055847168
the O O 0.9999547004699707
concentration O O 0.9995515942573547
of O O 0.9995892643928528
free O O 0.8886906504631042
DPH B B 0.9902030229568481
was O O 0.9999145269393921
normal O O 0.9997068047523499
, O O 0.9999641180038452
the O O 0.9999929666519165
patient O O 0.9999921321868896
presented O O 0.9999830722808838
a O O 0.9999845027923584
retarded O O 0.9999158382415771
morbilliform O O 0.999728262424469
rash O O 0.9999934434890747
during O O 0.9996839761734009
DPH B B 0.99334716796875
treatment O O 0.9998279809951782
, O O 0.9999805688858032
the O O 0.9998490810394287
protidogram O O 0.9624037146568298
was O O 0.9999631643295288
normal O O 0.999929666519165
, O O 0.999941349029541
and O O 0.9999610185623169
an O O 0.9998657703399658
intradermic O O 0.9999082088470459
DPH B B 0.9950035214424133
injection O O 0.9998339414596558
had O O 0.9999783039093018
no O O 0.9999854564666748
local O O 0.9999773502349854
effect O O 0.9999877214431763
. O O 0.9999804496765137

The O O 0.9999854564666748
authors O O 0.9999984502792358
conclude O O 0.9999850988388062
that O O 0.9999673366546631
in O O 0.9999642372131348
a O O 0.9999818801879883
patient O O 0.9999760389328003
starting O O 0.9996448755264282
DPH B B 0.9907936453819275
treatment O O 0.9993020296096802
an O O 0.9999749660491943
unexpected O O 0.9999829530715942
increase O O 0.9999914169311523
in O O 0.999980092048645
seizures O O 0.9999884366989136
, O O 0.9999897480010986
with O O 0.9999701976776123
EEG O O 0.9668301343917847
and O O 0.9998193383216858
mental O O 0.999991774559021
changes O O 0.9999963045120239
occurring O O 0.9999784231185913
simultaneously O O 0.9999390840530396
, O O 0.999981164932251
should O O 0.9999759197235107
alert O O 0.9999873638153076
the O O 0.999990701675415
physician O O 0.9999946355819702
to O O 0.9999808073043823
the O O 0.9999943971633911
possible O O 0.9999947547912598
need O O 0.9999972581863403
for O O 0.999982476234436
eliminating O O 0.9998569488525391
DPH B B 0.9943395256996155
from O O 0.9994275569915771
the O O 0.9999816417694092
therapeutic O O 0.9998860359191895
regimen O O 0.9996727705001831
, O O 0.999976634979248
even O O 0.9999676942825317
if O O 0.9999905824661255
plasma O O 0.9998941421508789
concentrations O O 0.9999334812164307
are O O 0.9999809265136719
low O O 0.9999840259552002
. O O 0.9999780654907227

Prevention O O 0.9999457597732544
and O O 0.9999381303787231
treatment O O 0.9999594688415527
of O O 0.9999790191650391
endometrial O O 0.9998496770858765
disease O O 0.999987006187439
in O O 0.9999202489852905
climacteric O O 0.9296280145645142
women O O 0.999968409538269
receiving O O 0.9992175102233887
oestrogen B B 0.9553998112678528
therapy O O 0.984459638595581
. O O 0.9998180270195007

The O O 0.9999535083770752
treatment O O 0.9998257756233215
regimens O O 0.9949163198471069
are O O 0.9999674558639526
described O O 0.9999896287918091
in O O 0.999957799911499
74 O O 0.9999693632125854
patients O O 0.999993085861206
with O O 0.9999815225601196
endometrial O O 0.9997835755348206
disease O O 0.9999852180480957
among O O 0.9998685121536255
850 O O 0.9993023872375488
climacteric O O 0.9816965460777283
women O O 0.9999794960021973
receiving O O 0.9992544054985046
oestrogen B B 0.8962365388870239
therapy O O 0.9839063882827759
. O O 0.9999481439590454

Cystic O O 0.9980277419090271
hyperplasia O O 0.9978662133216858
was O O 0.9999452829360962
associated O O 0.9999812841415405
with O O 0.999903678894043
unopposed O O 0.8615353107452393
oestrogen B B 0.9333409667015076
therapy O O 0.997613787651062
without O O 0.9989525079727173
progestagen B O 0.519751787185669
. O O 0.9998927116394043

Two O O 0.9999667406082153
courses O O 0.9999485015869141
of O O 0.9999241828918457
21 O O 0.9996261596679688
days O O 0.9999468326568604
of O O 0.9997262358665466
5 O O 0.9987932443618774
mg O O 0.994716227054596
norethisterone B B 0.9987974166870117
daily O O 0.9989008903503418
caused O O 0.9999499320983887
reversion O O 0.9999890327453613
to O O 0.9999920129776001
normal O O 0.999976396560669
in O O 0.9999542236328125
all O O 0.9999728202819824
57 O O 0.999985933303833
cases O O 0.9999916553497314
of O O 0.9999406337738037
cystic O O 0.9961340427398682
hyperplasia O O 0.9950700998306274
and O O 0.9999583959579468
6 O O 0.9998948574066162
of O O 0.9999628067016602
the O O 0.9999933242797852
8 O O 0.9998276233673096
cases O O 0.9999868869781494
of O O 0.9999585151672363
atypical O O 0.9991459846496582
hyperplasia O O 0.9951604008674622
. O O 0.9999644756317139

4 O O 0.9997814297676086
cases O O 0.9999934434890747
of O O 0.9999798536300659
endometrial O O 0.9997462630271912
carcinoma O O 0.9996411800384521
referred O O 0.9999873638153076
from O O 0.9999895095825195
elsewhere O O 0.9999734163284302
demonstrated O O 0.9999510049819946
the O O 0.9999895095825195
problems O O 0.99997878074646
of O O 0.9999535083770752
inappropriate O O 0.9997382760047913
and O O 0.9999120235443115
unsupervised O O 0.9999831914901733
unopposed O O 0.9828178882598877
oestrogen B B 0.9026310443878174
therapy O O 0.9971849322319031
and O O 0.9999613761901855
the O O 0.9999916553497314
difficulty O O 0.9999980926513672
in O O 0.9999972581863403
distinguishing O O 0.9999480247497559
severe O O 0.9991183876991272
hyperplasia O O 0.9801034331321716
from O O 0.9997982382774353
malignancy O O 0.9999879598617554
. O O 0.9999654293060303

Cyclical O O 0.8539548516273499
low O O 0.9974315762519836
- O O 0.9997952580451965
dose O O 0.9903720617294312
oestrogen B B 0.943547785282135
therapy O O 0.9973167777061462
with O O 0.9998440742492676
7 O O 0.9997487664222717
- O O 0.9969140291213989
- O O 0.998071014881134
13 O O 0.999991774559021
days O O 0.9999799728393555
of O O 0.9956226944923401
progestagen B B 0.8970144391059875
does O O 0.9997004270553589
not O O 0.9999663829803467
seem O O 0.9999828338623047
to O O 0.9999583959579468
increase O O 0.9999402761459351
the O O 0.9999836683273315
risk O O 0.9999973773956299
of O O 0.9999889135360718
endometrial O O 0.999885082244873
hyperplasia O O 0.9997382760047913
or O O 0.9999488592147827
carcinoma O O 0.9999642372131348
. O O 0.9998792409896851

Effects O O 0.9999040365219116
of O O 0.9998931884765625
exercise O O 0.997452437877655
on O O 0.9998300075531006
the O O 0.9999573230743408
severity O O 0.9999833106994629
of O O 0.9998831748962402
isoproterenol B B 0.9987807869911194
- O O 0.9993388056755066
induced O O 0.9999178647994995
myocardial O O 0.9999977350234985
infarction O O 0.9999886751174927
. O O 0.9999330043792725

The O O 0.9999656677246094
effect O O 0.9999606609344482
of O O 0.999894380569458
exercise O O 0.9993461966514587
on O O 0.9998292922973633
the O O 0.9999805688858032
severity O O 0.9999843835830688
of O O 0.9998950958251953
isoproterenol B B 0.9990503191947937
- O O 0.9994444251060486
induced O O 0.9999346733093262
myocardial O O 0.9999978542327881
infarction O O 0.999995231628418
was O O 0.9999728202819824
studied O O 0.9999603033065796
in O O 0.9999769926071167
male O O 0.9999678134918213
rats O O 0.9999942779541016
. O O 0.999962568283081

Ninety O O 0.9986838698387146
- O O 0.9999196529388428
three O O 0.9999486207962036
rats O O 0.9999955892562866
were O O 0.9999938011169434
randomly O O 0.9999892711639404
divided O O 0.9999935626983643
into O O 0.9999581575393677
three O O 0.9999417066574097
groups O O 0.9999914169311523
. O O 0.9999822378158569

The O O 0.999619722366333
exercise O O 0.6386609673500061
- O O 0.8612846732139587
isoproterenol B B 0.8274219632148743
( O O 0.9792181253433228
E O O 0.8780797719955444
- O O 0.975311815738678
1 O O 0.9762925505638123
) O O 0.9993135929107666
and O O 0.9994075298309326
exercise O O 0.9227738976478577
control O O 0.9941410422325134
( O O 0.9984971284866333
EC O O 0.8543294668197632
) O O 0.9998388290405273
groups O O 0.9999226331710815
exercised O O 0.9999830722808838
daily O O 0.9999775886535645
for O O 0.9999831914901733
thirty O O 0.9999954700469971
days O O 0.9999961853027344
on O O 0.9999830722808838
a O O 0.9999915361404419
treadmill O O 0.9999459981918335
at O O 0.9999651908874512
1 O O 0.9999736547470093
mph O O 0.9999983310699463
, O O 0.999882698059082
2 O O 0.9999146461486816
% O O 0.9998037219047546
grade O O 0.997334361076355
while O O 0.9998451471328735
animals O O 0.9971705079078674
of O O 0.9998052716255188
the O O 0.9998236298561096
sedentary O O 0.7252295613288879
- O O 0.9282118678092957
isoproterenol B B 0.9258349537849426
( O O 0.9846121668815613
S O B 0.7332519888877869
- O I 0.585168719291687
I O I 0.9596089720726013
) O O 0.9515855312347412
group O O 0.999821126461029
remained O O 0.9998774528503418
sedentary O O 0.9945348501205444
. O O 0.9999629259109497

Eight O O 0.9994138479232788
animals O O 0.9999940395355225
were O O 0.9999773502349854
assigned O O 0.9999784231185913
to O O 0.9998966455459595
the O O 0.9998620748519897
sedentary O O 0.9627320766448975
control O O 0.9998466968536377
( O O 0.9994124174118042
SC O O 0.7811489105224609
) O O 0.9998010993003845
group O O 0.9999480247497559
which O O 0.999876856803894
remained O O 0.9999675750732422
sedentary O O 0.9981256127357483
throughout O O 0.9999401569366455
the O O 0.9999876022338867
experimental O O 0.9999723434448242
period O O 0.999993085861206
. O O 0.9999760389328003

Forty O O 0.9999616146087646
- O O 0.9999836683273315
eight O O 0.9999536275863647
hours O O 0.999992847442627
after O O 0.9999948740005493
the O O 0.999993085861206
final O O 0.9999897480010986
exercise O O 0.9999716281890869
period O O 0.9999464750289917
, O O 0.9998781681060791
S O O 0.9136117696762085
- O O 0.9951695799827576
I O O 0.9981753826141357
and O O 0.9997496008872986
E O O 0.9896078705787659
- O O 0.9993532299995422
I O O 0.9941650032997131
animals O O 0.9999725818634033
received O O 0.9999804496765137
a O O 0.999992847442627
single O O 0.9999743700027466
subcutaneous O O 0.9999352693557739
injection O O 0.9999878406524658
of O O 0.9998456239700317
isoproterenol B B 0.999330997467041
( O O 0.9998481273651123
250 O O 0.9999232292175293
mg O O 0.9999657869338989
/ O O 0.9999881982803345
kg O O 0.9999977350234985
body O O 0.9999920129776001
weight O O 0.9989247918128967
) O O 0.9999704360961914
. O O 0.9999750852584839

Animals O O 0.9999872446060181
of O O 0.999951958656311
the O O 0.9998407363891602
S O O 0.7068747282028198
- O O 0.9716107249259949
I O O 0.9642723202705383
group O O 0.9998070597648621
exhibited O O 0.999920129776001
significantly O O 0.9999784231185913
( O O 0.9999779462814331
Pp O O 0.999987006187439
less O O 0.9999903440475464
than O O 0.9999899864196777
0 O O 0.9999936819076538
. O O 0.9999954700469971
05 O O 0.9999963045120239
) O O 0.9999622106552124
greater O O 0.9999440908432007
mortality O O 0.999995231628418
from O O 0.9998500347137451
the O O 0.9998706579208374
effects O O 0.9998630285263062
of O O 0.9997742772102356
isoproterenol B B 0.9993891716003418
than O O 0.9997629523277283
animals O O 0.9999732971191406
of O O 0.9999488592147827
the O O 0.9999202489852905
E O O 0.905947208404541
- O O 0.9989816546440125
I O O 0.9868599772453308
group O O 0.9999254941940308
. O O 0.9999669790267944

Serum O O 0.9975712895393372
CPK O O 0.80971759557724
activity O O 0.9983127117156982
for O O 0.9991969466209412
E O O 0.7886772751808167
- O O 0.9857628345489502
I O O 0.9661747217178345
animals O O 0.9998496770858765
was O O 0.9999250173568726
significantly O O 0.9999825954437256
( O O 0.9999557733535767
p O O 0.9991959929466248
less O O 0.9999808073043823
than O O 0.9999910593032837
0 O O 0.9999909400939941
. O O 0.9999951124191284
05 O O 0.9999909400939941
) O O 0.9999656677246094
greater O O 0.9998093247413635
than O O 0.9999721050262451
for O O 0.9997808337211609
animals O O 0.999915599822998
in O O 0.9998518228530884
the O O 0.9998587369918823
S O O 0.881406307220459
- O O 0.9900325536727905
I O O 0.9925642609596252
and O O 0.9992803931236267
EC O O 0.792201042175293
groups O O 0.9999198913574219
twenty O O 0.999957799911499
hours O O 0.999993085861206
following O O 0.9999608993530273
isoproterenol B B 0.9996374845504761
injection O O 0.9998716115951538
. O O 0.9999727010726929

No O O 0.9999545812606812
statistically O O 0.9999511241912842
significant O O 0.9999873638153076
differences O O 0.9999923706054688
were O O 0.9999901056289673
observed O O 0.9999953508377075
between O O 0.9998038411140442
the O O 0.9999538660049438
two O O 0.9999339580535889
isoproterenol B B 0.9991552829742432
treated O O 0.9991298317909241
groups O O 0.999968409538269
for O O 0.9999432563781738
severity O O 0.9999963045120239
of O O 0.9999860525131226
the O O 0.9999562501907349
induced O O 0.999976634979248
lesions O O 0.999997615814209
, O O 0.9999819993972778
changes O O 0.9999980926513672
in O O 0.9999908208847046
heart O O 0.9999810457229614
weight O O 0.9999873638153076
, O O 0.9999154806137085
or O O 0.9999268054962158
heart O O 0.998900294303894
weight O O 0.9988868832588196
to O O 0.9999809265136719
body O O 0.9999886751174927
weight O O 0.9998403787612915
ratios O O 0.9999854564666748
. O O 0.9999722242355347

The O O 0.9999793767929077
results O O 0.9999871253967285
indicated O O 0.9999794960021973
that O O 0.9997023940086365
exercise O O 0.6992290616035461
reduced O O 0.9998455047607422
the O O 0.9999463558197021
mortality O O 0.999988317489624
associated O O 0.9999803304672241
with O O 0.9998960494995117
the O O 0.9999064207077026
effects O O 0.9999022483825684
of O O 0.9999388456344604
large O O 0.999785840511322
dosages O O 0.9998705387115479
of O O 0.9973112344741821
isoproterenol B B 0.9982659220695496
but O O 0.999454915523529
had O O 0.9999440908432007
little O O 0.9999922513961792
on O O 0.9999359846115112
the O O 0.9999910593032837
severity O O 0.9999963045120239
of O O 0.9999885559082031
the O O 0.9999908208847046
infarction O O 0.9999912977218628
. O O 0.9999696016311646

Human O O 0.8476195931434631
corticotropin B O 0.8198739886283875
- O O 0.5985156893730164
releasing O O 0.6415203809738159
hormone O O 0.7989870309829712
and O O 0.972842276096344
thyrotropin B O 0.7382845878601074
- O O 0.7435832023620605
releasing O O 0.7956411242485046
hormone O O 0.7126384973526001
modulate O O 0.9998849630355835
the O O 0.9999728202819824
hypercapnic O O 0.9992398023605347
ventilatory O O 0.9999371767044067
response O O 0.9999767541885376
in O O 0.9999127388000488
humans O O 0.9997743964195251
. O O 0.9999353885650635

Human O O 0.9346287250518799
corticotropin B O 0.7192667126655579
- O O 0.5162484645843506
releasing O O 0.5751679539680481
hormone O O 0.6877598166465759
( O O 0.9959897398948669
hCRH O O 0.4964565336704254
) O O 0.9898157119750977
and O O 0.9971043467521667
thyrotropin B O 0.4997938573360443
- O O 0.7938213348388672
releasing O O 0.8163481950759888
hormone O O 0.7922350764274597
( O O 0.9936509728431702
TRH O O 0.45653048157691956
) O O 0.9989455342292786
are O O 0.9998774528503418
known O O 0.9997963309288025
to O O 0.9997474551200867
stimulate O O 0.9984997510910034
ventilation O O 0.9965523481369019
after O O 0.9998646974563599
i O O 0.9998865127563477
. O O 0.9999946355819702
v O O 0.9999967813491821
. O O 0.9999862909317017
administration O O 0.999963641166687
in O O 0.9999732971191406
humans O O 0.9999741315841675
. O O 0.9999593496322632

In O O 0.9999850988388062
a O O 0.9999755620956421
placebo O O 0.9994333386421204
- O O 0.9997264742851257
controlled O O 0.9999336004257202
, O O 0.9999499320983887
single O O 0.9998582601547241
- O O 0.9999518394470215
blind O O 0.9999895095825195
study O O 0.9999788999557495
we O O 0.9999774694442749
aimed O O 0.999995231628418
to O O 0.9999967813491821
clarify O O 0.9999897480010986
if O O 0.9999673366546631
both O O 0.9921818971633911
peptides O O 0.8669807314872742
act O O 0.9994139671325684
by O O 0.9999152421951294
altering O O 0.999869704246521
central O O 0.9996483325958252
chemosensitivity O O 0.9553361535072327
. O O 0.9999620914459229

Two O O 0.9999531507492065
subsequent O O 0.9999772310256958
CO2 B O 0.8122603893280029
- O O 0.5388966202735901
rebreathing O O 0.7783908843994141
tests O O 0.9999144077301025
were O O 0.9999768733978271
performed O O 0.9999858140945435
in O O 0.9999818801879883
healthy O O 0.9999855756759644
young O O 0.9999972581863403
volunteers O O 0.9999983310699463
. O O 0.9999730587005615

During O O 0.9999535083770752
the O O 0.9999957084655762
first O O 0.9999959468841553
test O O 0.9999874830245972
0 O O 0.998803973197937
. O O 0.9999687671661377
9 O O 0.9985736608505249
% O O 0.9987351298332214
NaCl B B 0.9983701109886169
was O O 0.999900221824646
given O O 0.9999417066574097
i O O 0.9998573064804077
. O O 0.999996542930603
v O O 0.9999798536300659
. O O 0.9999945163726807
; O O 0.9999854564666748
during O O 0.9999650716781616
the O O 0.9999980926513672
second O O 0.9999974966049194
test O O 0.9999874830245972
200 O O 0.9997870326042175
micrograms O O 0.9997739195823669
of O O 0.9993528723716736
hCRH O B 0.8508310317993164
( O O 0.9988579750061035
n O O 0.9956279993057251
= O O 0.9998395442962646
12 O O 0.9999843835830688
) O O 0.9998151659965515
or O O 0.9998200535774231
400 O O 0.9996899366378784
micrograms O O 0.999198853969574
of O O 0.9982073307037354
TRH O O 0.7718528509140015
( O O 0.9990528225898743
n O O 0.9924185276031494
= O O 0.9998536109924316
6 O O 0.9999687671661377
) O O 0.9999085664749146
was O O 0.9999759197235107
administered O O 0.9999179840087891
i O O 0.9998111128807068
. O O 0.9999936819076538
v O O 0.9999861717224121
. O O 0.9999899864196777
Nine O O 0.9819682240486145
subjects O O 0.9999697208404541
received O O 0.999961256980896
0 O O 0.9999752044677734
. O O 0.9999960660934448
9 O O 0.9999175071716309
% O O 0.9998123049736023
NaCl B B 0.9959383010864258
i O O 0.9993079900741577
. O O 0.9999951124191284
v O O 0.9999607801437378
. O O 0.9999936819076538
during O O 0.9999274015426636
both O O 0.9990155696868896
rebreathing O O 0.9994427561759949
manoeuvres O O 0.9999921321868896
. O O 0.9999686479568481

The O O 0.9999639987945557
CO2 B O 0.8615782260894775
- O O 0.9991126656532288
response O O 0.9999533891677856
curves O O 0.999937891960144
for O O 0.999854564666748
the O O 0.9999634027481079
two O O 0.999972939491272
tests O O 0.9999761581420898
were O O 0.9999654293060303
compared O O 0.9999876022338867
within O O 0.9999691247940063
the O O 0.9999946355819702
same O O 0.999980092048645
subject O O 0.9999954700469971
. O O 0.9999643564224243

In O O 0.9997977614402771
the O O 0.9997988343238831
hCRH O B 0.8959969282150269
group O O 0.9990842342376709
a O O 0.9999682903289795
marked O O 0.9999685287475586
parallel O O 0.9998449087142944
shift O O 0.9999966621398926
of O O 0.999985933303833
the O O 0.9998272061347961
CO2 B O 0.8503186106681824
- O O 0.995962917804718
response O O 0.9996964931488037
curve O O 0.9998481273651123
to O O 0.9999818801879883
the O O 0.9999908208847046
left O O 0.9999328851699829
was O O 0.9999812841415405
observed O O 0.999992847442627
after O O 0.9993302822113037
hCRH O O 0.8232022523880005
( O O 0.9996262788772583
P O O 0.9998663663864136
< O O 0.9999474287033081
0 O O 0.9999873638153076
. O O 0.9999969005584717
01 O O 0.9999948740005493
) O O 0.9999699592590332
. O O 0.9999755620956421

The O O 0.9999886751174927
same O O 0.9999301433563232
effect O O 0.9999793767929077
occurred O O 0.999992847442627
following O O 0.9997681975364685
TRH O O 0.6802693009376526
but O O 0.9998074173927307
was O O 0.9999821186065674
less O O 0.9999895095825195
striking O O 0.999993085861206
( O O 0.9999611377716064
P O O 0.999893307685852
= O O 0.9999499320983887
0 O O 0.9999872446060181
. O O 0.9999935626983643
05 O O 0.9999895095825195
) O O 0.9999585151672363
. O O 0.9999651908874512

hCRH O B 0.9624491930007935
and O O 0.981732189655304
TRH O B 0.938007116317749
caused O O 0.9995725750923157
a O O 0.9999152421951294
reduction O O 0.9999716281890869
in O O 0.9999496936798096
the O O 0.9998666048049927
CO2 B O 0.6749268770217896
threshold O O 0.9995255470275879
. O O 0.9999306201934814

The O O 0.9999444484710693
CO2 B O 0.5684829354286194
- O O 0.9894891381263733
response O O 0.9998657703399658
curves O O 0.9998974800109863
in O O 0.9998049139976501
the O O 0.9999071359634399
control O O 0.9996565580368042
group O O 0.999962329864502
were O O 0.9999606609344482
nearly O O 0.9999886751174927
identical O O 0.9999884366989136
. O O 0.9999786615371704

The O O 0.9999808073043823
results O O 0.9999881982803345
indicate O O 0.9999133348464966
an O O 0.9999561309814453
additive O O 0.9995379447937012
effect O O 0.9999408721923828
of O O 0.9996391534805298
both O O 0.9907572865486145
releasing O O 0.6151250600814819
hormones O O 0.5039458870887756
on O O 0.9995324611663818
the O O 0.9999675750732422
hypercapnic O O 0.9998602867126465
ventilatory O O 0.9999637603759766
response O O 0.9999845027923584
in O O 0.9999490976333618
humans O O 0.9998446702957153
, O O 0.9999810457229614
presumably O O 0.9999713897705078
independent O O 0.9999566078186035
of O O 0.9999347925186157
central O O 0.9997029900550842
chemosensitivity O O 0.6333058476448059
. O O 0.9999604225158691

Lamivudine B B 0.999382495880127
is O O 0.9996944665908813
effective O O 0.9993324875831604
in O O 0.9999204874038696
suppressing O O 0.9997236132621765
hepatitis O O 0.9774588942527771
B O O 0.9580816030502319
virus O O 0.9986214637756348
DNA O O 0.9998289346694946
in O O 0.9998080134391785
Chinese O O 0.9766769409179688
hepatitis B O 0.617651104927063
B I O 0.5763452649116516
surface I O 0.6944062113761902
antigen I O 0.8637627363204956
carriers O O 0.9987003803253174
: O O 0.9999780654907227
a O O 0.9999700784683228
placebo O O 0.9999133348464966
- O O 0.9999539852142334
controlled O O 0.999972939491272
trial O O 0.999987006187439
. O O 0.9999599456787109

Lamivudine B B 0.9991896748542786
is O O 0.9987432360649109
a O O 0.9973616003990173
novel O B 0.9336400032043457
2 B I 0.9388039708137512
' I I 0.7567828297615051
, I I 0.5495994091033936
3 I I 0.5496528744697571
' I I 0.8798919916152954
- I I 0.9705438017845154
dideoxy I I 0.9318345189094543
cytosine I I 0.9115966558456421
analogue O O 0.6357972621917725
that O O 0.9996716976165771
has O O 0.9999004602432251
potent O O 0.9992784857749939
inhibitory O O 0.9972867965698242
effects O O 0.9999103546142578
on O O 0.9998718500137329
hepatitis O O 0.9677524566650391
B O O 0.944719672203064
virus O O 0.9985896944999695
replication O O 0.999972939491272
in O O 0.9999456405639648
vitro O O 0.9999927282333374
and O O 0.9998990297317505
in O O 0.9998753070831299
vivo O O 0.9999918937683105
. O O 0.9999202489852905

We O O 0.9999648332595825
performed O O 0.9999935626983643
a O O 0.9999946355819702
single O O 0.9998584985733032
- O O 0.9999649524688721
blind O O 0.9999936819076538
, O O 0.9999524354934692
placebo O O 0.9996746778488159
- O O 0.9999262094497681
controlled O O 0.9999192953109741
study O O 0.9999847412109375
to O O 0.9999898672103882
assess O O 0.9999891519546509
its O O 0.9999450445175171
effectiveness O O 0.9999549388885498
and O O 0.9999833106994629
safety O O 0.9999954700469971
in O O 0.9999178647994995
Chinese O O 0.9624258875846863
hepatitis B B 0.6368081569671631
B I I 0.509438157081604
surface I I 0.5770936608314514
antigen I I 0.927259087562561
( O O 0.7870455980300903
HBsAg B O 0.5823745727539062
) O O 0.9969184398651123
carriers O O 0.9998654127120972
. O O 0.9999734163284302

Forty O O 0.9599144458770752
- O O 0.9998899698257446
two O O 0.9998831748962402
Chinese O O 0.9930169582366943
HBsAg B O 0.9721933007240295
carriers O O 0.998842716217041
were O O 0.999992847442627
randomized O O 0.9999953508377075
to O O 0.999984622001648
receive O O 0.999931812286377
placebo O O 0.9999033212661743
( O O 0.9999257326126099
6 O O 0.9999465942382812
patients O O 0.9999823570251465
) O O 0.9999783039093018
or O O 0.9997349381446838
lamivudine B B 0.9991611242294312
orally O O 0.9995881915092468
in O O 0.999943733215332
dosages O O 0.9999624490737915
of O O 0.9999772310256958
25 O O 0.9999603033065796
mg O O 0.9999268054962158
, O O 0.9998971223831177
100 O O 0.9997299313545227
mg O O 0.9999028444290161
, O O 0.999713122844696
or O O 0.9999150037765503
300 O O 0.9998645782470703
mg O O 0.999864935874939
daily O O 0.9999486207962036
( O O 0.9999654293060303
12 O O 0.9999903440475464
patients O O 0.9999934434890747
for O O 0.9999668598175049
each O O 0.999974250793457
dosage O O 0.9999107122421265
) O O 0.9999806880950928
. O O 0.9999850988388062

The O O 0.9999393224716187
drug O O 0.998188316822052
was O O 0.9999221563339233
given O O 0.9999029636383057
for O O 0.9999376535415649
4 O O 0.9998247027397156
weeks O O 0.999990701675415
. O O 0.9999669790267944

The O O 0.9999823570251465
patients O O 0.9999868869781494
were O O 0.9999903440475464
closely O O 0.9999942779541016
monitored O O 0.9999939203262329
clinically O O 0.9999915361404419
, O O 0.9999934434890747
biochemically O O 0.9999405145645142
, O O 0.9999686479568481
and O O 0.9999711513519287
serologically O O 0.9999581575393677
up O O 0.9999806880950928
to O O 0.9999963045120239
4 O O 0.9999841451644897
weeks O O 0.9999992847442627
after O O 0.9999864101409912
drug O O 0.9995525479316711
treatment O O 0.9999500513076782
. O O 0.999987006187439

All O O 0.9999748468399048
36 O O 0.9999854564666748
patients O O 0.9999858140945435
receiving O O 0.9991951584815979
lamivudine B B 0.9995575547218323
had O O 0.9999023675918579
a O O 0.9999905824661255
decrease O O 0.9999943971633911
in O O 0.9999756813049316
hepatitis O O 0.9721020460128784
B O O 0.9616380333900452
virus O O 0.9458087682723999
( O O 0.9982435703277588
HBV O O 0.6566735506057739
) O O 0.997058629989624
DNA O O 0.992049515247345
values O O 0.99993896484375
of O O 0.9999538660049438
> O O 0.9999114274978638
90 O O 0.9998810291290283
% O O 0.9999960660934448
( O O 0.9999136924743652
P O O 0.99864262342453
< O O 0.9999721050262451
. O O 0.9999977350234985
001 O O 0.9983526468276978
compared O O 0.9999911785125732
with O O 0.9998487234115601
placebo O O 0.9998784065246582
) O O 0.9999428987503052
. O O 0.9999618530273438

Although O O 0.9999754428863525
25 O O 0.9998906850814819
mg O O 0.9996452331542969
of O O 0.9984800219535828
lamivudine B B 0.9992583394050598
was O O 0.9998021721839905
slightly O O 0.99998939037323
less O O 0.999980092048645
effective O O 0.9999630451202393
than O O 0.9999105930328369
100 O O 0.9995068311691284
mg O O 0.9998852014541626
( O O 0.9999282360076904
P O O 0.9992017149925232
= O O 0.9998111128807068
. O O 0.9999963045120239
011 O O 0.9999797344207764
) O O 0.9999678134918213
and O O 0.9997760653495789
300 O O 0.9997847676277161
mg O O 0.9997606873512268
( O O 0.9998762607574463
P O O 0.996756374835968
= O O 0.9997852444648743
. O O 0.9999957084655762
005 O O 0.999951958656311
) O O 0.9999328851699829
, O O 0.999906063079834
it O O 0.9989331364631653
still O O 0.9999384880065918
induced O O 0.9999299049377441
94 O O 0.9999755620956421
% O O 0.9999868869781494
suppression O O 0.9999843835830688
of O O 0.9998970031738281
HBV O O 0.8282268643379211
DNA O O 0.9956531524658203
after O O 0.9999302625656128
the O O 0.9999969005584717
fourth O O 0.9999980926513672
week O O 0.9999967813491821
of O O 0.9999672174453735
therapy O O 0.9999727010726929
. O O 0.9999668598175049

HBV O O 0.6579744815826416
DNA O O 0.950093686580658
values O O 0.9998750686645508
returned O O 0.9999827146530151
to O O 0.9999903440475464
pretreatment O O 0.9985992312431335
levels O O 0.9999821186065674
within O O 0.9999853372573853
4 O O 0.9999712705612183
weeks O O 0.9999986886978149
of O O 0.9999884366989136
cessation O O 0.9999891519546509
of O O 0.999971866607666
therapy O O 0.9999649524688721
. O O 0.9999798536300659

There O O 0.9999629259109497
was O O 0.9999783039093018
no O O 0.9999898672103882
change O O 0.9999986886978149
in O O 0.999995231628418
the O O 0.9999781847000122
hepatitis O B 0.74132239818573
B O I 0.5465121269226074
e O I 0.9345335960388184
antigen O I 0.9953833222389221
status O O 0.9993569254875183
or O O 0.9999942779541016
in O O 0.9991772770881653
aminotransferase O O 0.6291202902793884
levels O O 0.9998965263366699
. O O 0.9999645948410034

No O O 0.9999250173568726
serious O O 0.99998939037323
adverse O O 0.9999613761901855
events O O 0.999996542930603
were O O 0.9999860525131226
observed O O 0.9999902248382568
. O O 0.9999555349349976

In O O 0.9999631643295288
conclusion O O 0.9999887943267822
, O O 0.9999220371246338
a O O 0.9999600648880005
4 O O 0.9998716115951538
- O O 0.9999715089797974
week O O 0.9999876022338867
course O O 0.999873161315918
of O O 0.9991067051887512
lamivudine B B 0.9996880292892456
was O O 0.999895453453064
safe O O 0.9999816417694092
and O O 0.9999810457229614
effective O O 0.9998912811279297
in O O 0.9998947381973267
suppression O O 0.999881386756897
of O O 0.9998961687088013
HBV O O 0.847985565662384
DNA O O 0.9990713596343994
in O O 0.9997169375419617
Chinese O O 0.9917541742324829
HBsAg B O 0.9123181700706482
carriers O O 0.9976205229759216
. O O 0.9999699592590332

The O O 0.9998712539672852
suppression O O 0.9998730421066284
was O O 0.999902606010437
> O O 0.9998739957809448
90 O O 0.9997969269752502
% O O 0.9999804496765137
but O O 0.9999312162399292
reversible O O 0.9997895359992981
. O O 0.9999487400054932

Studies O O 0.9999866485595703
with O O 0.9999542236328125
long O O 0.9997156262397766
- O O 0.9999794960021973
term O O 0.9999046325683594
lamivudine B B 0.9994592070579529
administration O O 0.999861478805542
should O O 0.9999728202819824
be O O 0.9999929666519165
performed O O 0.9999945163726807
to O O 0.9999945163726807
determine O O 0.9999969005584717
if O O 0.9999934434890747
prolonged O O 0.9998487234115601
suppression O O 0.999954342842102
of O O 0.9998835325241089
HBV O O 0.6635253429412842
DNA O O 0.963735044002533
can O O 0.9999730587005615
be O O 0.9999927282333374
achieved O O 0.9999783039093018
. O O 0.9999839067459106

Population O O 0.9998162388801575
- O O 0.9999884366989136
based O O 0.9999902248382568
study O O 0.9999871253967285
of O O 0.9999576807022095
risk O O 0.9999880790710449
of O O 0.9999637603759766
venous O O 0.9998769760131836
thromboembolism O O 0.9999516010284424
associated O O 0.9999696016311646
with O O 0.9998481273651123
various O O 0.9980189800262451
oral B B 0.5448950529098511
contraceptives I I 0.9986862540245056
. O O 0.9997925162315369

BACKGROUND O O 0.9974576830863953
: O O 0.9999504089355469
Four O O 0.9997355341911316
studies O O 0.99997878074646
published O O 0.9999927282333374
since O O 0.9999840259552002
December O O 0.9710789322853088
, O O 0.9999819993972778
1995 O O 0.9972922205924988
, O O 0.9999871253967285
reported O O 0.9999891519546509
that O O 0.9999878406524658
the O O 0.9999945163726807
incidence O O 0.9999954700469971
of O O 0.9999747276306152
venous O O 0.9992384910583496
thromboembolism O O 0.999152660369873
( O O 0.9998262524604797
VTE O O 0.9357345700263977
) O O 0.9999516010284424
was O O 0.9999802112579346
higher O O 0.9999785423278809
in O O 0.9998947381973267
women O O 0.9999926090240479
who O O 0.9998965263366699
used O O 0.9997264742851257
oral B B 0.5383208990097046
contraceptives I I 0.9987192153930664
( O O 0.9945645332336426
OCs B O 0.5843457579612732
) O O 0.9998493194580078
containing O O 0.9994422793388367
the O O 0.9986721277236938
third O O 0.9728355407714844
- O O 0.9998631477355957
generation O O 0.9796231389045715
progestagens B O 0.6178709864616394
gestodene B B 0.9942933320999146
or O O 0.8752574324607849
desogestrel B B 0.9997076392173767
than O O 0.999875545501709
in O O 0.9999090433120728
users O O 0.999693751335144
of O O 0.999729573726654
OCs B O 0.5861003398895264
containing O O 0.9986584186553955
second O O 0.9969270825386047
- O O 0.999893307685852
generation O O 0.9762635231018066
progestagens B O 0.830212414264679
. O O 0.9998983144760132

However O O 0.9999210834503174
, O O 0.9999275207519531
confounding O O 0.9999376535415649
and O O 0.9999359846115112
bias O O 0.9999932050704956
in O O 0.9999852180480957
the O O 0.9999948740005493
design O O 0.9999961853027344
of O O 0.9999862909317017
these O O 0.9999635219573975
studies O O 0.9999740123748779
may O O 0.9999648332595825
have O O 0.9999895095825195
affected O O 0.9999946355819702
the O O 0.999997615814209
findings O O 0.9999949932098389
. O O 0.999984622001648

The O O 0.9999887943267822
aim O O 0.9999966621398926
of O O 0.9999921321868896
our O O 0.9999698400497437
study O O 0.9999847412109375
was O O 0.9999926090240479
to O O 0.9999901056289673
re O O 0.9999868869781494
- O O 0.9999746084213257
examine O O 0.999991774559021
the O O 0.9999909400939941
association O O 0.999991774559021
between O O 0.9998461008071899
risk O O 0.9999514818191528
of O O 0.9997121691703796
VTE O O 0.4635523855686188
and O O 0.9965324401855469
OC B B 0.8775135278701782
use O O 0.9977349042892456
with O O 0.9999653100967407
a O O 0.9999868869781494
different O O 0.9999872446060181
study O O 0.9999728202819824
design O O 0.999994158744812
and O O 0.9999874830245972
analysis O O 0.9999792575836182
to O O 0.9999829530715942
avoid O O 0.9999462366104126
some O O 0.9999775886535645
of O O 0.9999823570251465
the O O 0.9999896287918091
bias O O 0.9999961853027344
and O O 0.99997878074646
confounding O O 0.9999560117721558
of O O 0.999987006187439
the O O 0.9999936819076538
earlier O O 0.9998570680618286
studies O O 0.9999815225601196
. O O 0.9999630451202393

METHODS O O 0.9999685287475586
: O O 0.9999747276306152
We O O 0.9999780654907227
used O O 0.9999878406524658
computer O O 0.9999711513519287
records O O 0.9999958276748657
of O O 0.9999876022338867
patients O O 0.9999924898147583
from O O 0.9999469518661499
143 O O 0.9993883371353149
general O O 0.9998761415481567
practices O O 0.9999831914901733
in O O 0.9999587535858154
the O O 0.9999785423278809
UK O O 0.9996460676193237
. O O 0.9999611377716064

The O O 0.9999943971633911
study O O 0.9999974966049194
was O O 0.9999986886978149
based O O 0.999998927116394
on O O 0.9999914169311523
the O O 0.9999959468841553
medical O O 0.9999967813491821
records O O 0.9999961853027344
of O O 0.9999877214431763
about O O 0.999990701675415
540 O O 0.9999949932098389
, O O 0.999998927116394
000 O O 0.9999908208847046
women O O 0.9999961853027344
born O O 0.9999904632568359
between O O 0.9999549388885498
1941 O O 0.9999912977218628
and O O 0.9999617338180542
1981 O O 0.9999383687973022
. O O 0.9999643564224243

All O O 0.9999583959579468
women O O 0.9999966621398926
who O O 0.9999293088912964
had O O 0.9999798536300659
a O O 0.9999945163726807
recorded O O 0.999996542930603
diagnosis O O 0.9999969005584717
of O O 0.9999713897705078
deep O O 0.998872697353363
- O O 0.9998302459716797
vein O O 0.9999469518661499
thrombosis O O 0.9999773502349854
, O O 0.999953031539917
venous O O 0.9999746084213257
thrombosis O O 0.9999754428863525
not O O 0.9999942779541016
otherwise O O 0.9999834299087524
specified O O 0.9999927282333374
, O O 0.9999542236328125
or O O 0.9999445676803589
pulmonary O O 0.9999152421951294
embolus O O 0.9999847412109375
during O O 0.9999657869338989
the O O 0.999994158744812
study O O 0.9999908208847046
period O O 0.9999972581863403
, O O 0.9999663829803467
and O O 0.9999804496765137
who O O 0.9999704360961914
had O O 0.9999961853027344
been O O 0.9999910593032837
treated O O 0.9999752044677734
with O O 0.9999327659606934
an O O 0.995880126953125
anticoagulant O O 0.5759766697883606
were O O 0.9999345541000366
identified O O 0.9999699592590332
as O O 0.9999595880508423
potential O O 0.999988317489624
cases O O 0.9999849796295166
of O O 0.9999668598175049
VTE O O 0.989832878112793
. O O 0.999942421913147

We O O 0.999954342842102
did O O 0.9999903440475464
a O O 0.9999815225601196
cohort O O 0.9994922876358032
analysis O O 0.9999841451644897
to O O 0.9999850988388062
estimate O O 0.9999386072158813
and O O 0.999988317489624
compare O O 0.9999780654907227
incidence O O 0.9999899864196777
of O O 0.9999405145645142
VTE O O 0.9224474430084229
in O O 0.9996896982192993
users O O 0.7599236369132996
of O O 0.996607780456543
the O O 0.9997534155845642
main O O 0.9961716532707214
OC B O 0.9326584339141846
preparations O O 0.986889123916626
, O O 0.9999440908432007
and O O 0.9999721050262451
a O O 0.9999880790710449
nested O O 0.9999898672103882
case O O 0.9999748468399048
- O O 0.9999828338623047
control O O 0.9999876022338867
study O O 0.9999911785125732
to O O 0.9999898672103882
calculate O O 0.9999827146530151
the O O 0.9999903440475464
odds O O 0.9999139308929443
ratios O O 0.9999935626983643
of O O 0.9999388456344604
VTE O O 0.9339448809623718
associated O O 0.9999485015869141
with O O 0.9999356269836426
use O O 0.9999150037765503
of O O 0.9998959302902222
different O O 0.999958872795105
types O O 0.9999592304229736
of O O 0.9886828064918518
OC B O 0.6432766318321228
, O O 0.9993708729743958
after O O 0.9999133348464966
adjustment O O 0.9999862909317017
for O O 0.9999556541442871
potential O O 0.9999790191650391
confounding O O 0.9997407793998718
factors O O 0.999988317489624
. O O 0.9999839067459106

In O O 0.9999830722808838
the O O 0.9999935626983643
case O O 0.999974250793457
- O O 0.9999821186065674
control O O 0.9999884366989136
study O O 0.9999929666519165
, O O 0.9999626874923706
we O O 0.9999508857727051
matched O O 0.9999871253967285
cases O O 0.999994158744812
to O O 0.9999536275863647
controls O O 0.9999961853027344
by O O 0.9999879598617554
exact O O 0.9999942779541016
year O O 0.9999990463256836
of O O 0.9999990463256836
birth O O 0.9999977350234985
, O O 0.9999901056289673
practice O O 0.9999910593032837
, O O 0.9999691247940063
and O O 0.9999892711639404
current O O 0.9999701976776123
use O O 0.9999172687530518
of O O 0.9995852112770081
OCs B O 0.49485501646995544
. O O 0.9999593496322632

We O O 0.9999507665634155
used O O 0.9999579191207886
a O O 0.9999614953994751
multiple O O 0.9992125034332275
logistic O O 0.999900221824646
regression O O 0.9999557733535767
model O O 0.9999874830245972
that O O 0.9999340772628784
included O O 0.9999524354934692
body O O 0.9998857975006104
- O O 0.9978654980659485
mass O O 0.9813011884689331
index O O 0.9999294281005859
, O O 0.9999775886535645
number O O 0.9999970197677612
of O O 0.9999949932098389
cycles O O 0.9999699592590332
, O O 0.9999868869781494
change O O 0.9999985694885254
in O O 0.9999932050704956
type O O 0.9998476505279541
of O O 0.9950749278068542
OC B O 0.6445180177688599
prescribed O O 0.7435661554336548
within O O 0.999925971031189
3 O O 0.9999276399612427
months O O 0.9999984502792358
of O O 0.9999964237213135
the O O 0.9999985694885254
event O O 0.9999991655349731
, O O 0.9999868869781494
previous O O 0.9999945163726807
pregnancy O O 0.9999818801879883
, O O 0.9999130964279175
and O O 0.9999721050262451
concurrent O O 0.9999755620956421
disease O O 0.9999959468841553
. O O 0.9999774694442749

FINDINGS O O 0.9999715089797974
: O O 0.9999902248382568
85 O O 0.9999476671218872
women O O 0.9999896287918091
met O O 0.9999845027923584
the O O 0.9999966621398926
inclusion O O 0.9999945163726807
criteria O O 0.9999943971633911
for O O 0.9998571872711182
VTE O O 0.7210589647293091
, O O 0.9999467134475708
two O O 0.9999747276306152
of O O 0.9999697208404541
whom O O 0.9999748468399048
were O O 0.999840497970581
users O O 0.9736365079879761
of O O 0.9736014008522034
progestagen B O 0.7708349227905273
- O O 0.9663315415382385
only O O 0.957708477973938
OCs B O 0.8553642630577087
. O O 0.9999438524246216

Of O O 0.9999094009399414
the O O 0.9999833106994629
83 O O 0.999971866607666
cases O O 0.9999762773513794
of O O 0.9999184608459473
VTE O O 0.700206995010376
associated O O 0.9999161958694458
with O O 0.9999368190765381
use O O 0.9993409514427185
of O O 0.9972720742225647
combined O O 0.5707201957702637
OCs B O 0.5925841927528381
, O O 0.999872088432312
43 O O 0.9999302625656128
were O O 0.9999532699584961
recorded O O 0.9999804496765137
as O O 0.9999480247497559
deep O O 0.9987764954566956
- O O 0.9997320771217346
vein O O 0.9999663829803467
thrombosis O O 0.9999234676361084
, O O 0.9999443292617798
35 O O 0.9999775886535645
as O O 0.999963641166687
pulmonary O O 0.9998867511749268
thrombosis O O 0.9998912811279297
, O O 0.9999514818191528
and O O 0.999927282333374
five O O 0.9999868869781494
as O O 0.9999418258666992
venous O O 0.9999760389328003
thrombosis O O 0.9999709129333496
not O O 0.999992847442627
otherwise O O 0.999984622001648
specified O O 0.99998939037323
. O O 0.9999785423278809

The O O 0.9999839067459106
crude O O 0.9999840259552002
rate O O 0.9999840259552002
of O O 0.9999179840087891
VTE O O 0.8264269828796387
per O O 0.9999740123748779
10 O O 0.9999959468841553
, O O 0.9999988079071045
000 O O 0.9999967813491821
woman O O 0.9999934434890747
- O O 0.9999892711639404
years O O 0.9999920129776001
was O O 0.9999717473983765
4 O O 0.9997629523277283
. O O 0.9999921321868896
10 O O 0.9999970197677612
in O O 0.999940037727356
current O O 0.9999428987503052
users O O 0.9996715784072876
of O O 0.9990242719650269
any O O 0.7657583951950073
OC B O 0.49924391508102417
, O O 0.9997730851173401
3 O O 0.9991018772125244
. O O 0.9999886751174927
10 O O 0.9999957084655762
in O O 0.9998538494110107
users O O 0.9997990727424622
of O O 0.9989181756973267
second O O 0.9945181012153625
- O O 0.9998061060905457
generation O O 0.9701814651489258
OCs B O 0.5387048125267029
, O O 0.9990459084510803
and O O 0.999884843826294
4 O O 0.9997298121452332
. O O 0.999990701675415
96 O O 0.9999808073043823
in O O 0.9998375177383423
users O O 0.9996860027313232
of O O 0.9986364245414734
third O O 0.9883421063423157
- O O 0.9997510313987732
generation O O 0.9769342541694641
preparations O O 0.9803026914596558
. O O 0.9999436140060425

After O O 0.9999611377716064
adjustment O O 0.9999947547912598
for O O 0.9999626874923706
age O O 0.9995388984680176
, O O 0.9999657869338989
the O O 0.9999827146530151
rate O O 0.9997525811195374
ratio O O 0.999958872795105
of O O 0.9997767806053162
VTE O O 0.723699152469635
in O O 0.9991853833198547
users O O 0.9866536259651184
of O O 0.9996597766876221
third O O 0.9808564186096191
- O O 0.9995594620704651
generation O O 0.9788165092468262
relative O O 0.9998934268951416
to O O 0.9996150732040405
second O O 0.998920202255249
- O O 0.999915599822998
generation O O 0.9902475476264954
OCs B O 0.6641614437103271
was O O 0.9999582767486572
1 O O 0.9998774528503418
. O O 0.9999806880950928
68 O O 0.9999935626983643
( O O 0.9999542236328125
95 O O 0.9999923706054688
% O O 0.999848484992981
CI O O 0.9964210987091064
1 O O 0.9999818801879883
. O O 0.9999473094940186
04 O O 0.9999958276748657
- O O 0.9982950091362
2 O O 0.9999889135360718
. O O 0.9999938011169434
75 O O 0.9999662637710571
) O O 0.9999735355377197
. O O 0.9999796152114868

Logistic O O 0.9997779726982117
regression O O 0.9998716115951538
showed O O 0.9999545812606812
no O O 0.9999732971191406
significant O O 0.999994158744812
difference O O 0.9999943971633911
in O O 0.9999929666519165
the O O 0.9999914169311523
risk O O 0.9999887943267822
of O O 0.9999468326568604
VTE O O 0.8563523888587952
between O O 0.9992942810058594
users O O 0.9945065379142761
of O O 0.9991104006767273
third O O 0.9317194819450378
- O O 0.9994852542877197
generation O O 0.96509850025177
and O O 0.999291181564331
second O O 0.9912996888160706
- O O 0.9997138381004333
generation O O 0.9696782231330872
OCs B O 0.5606551766395569
. O O 0.9999284744262695

Among O O 0.9987819790840149
users O O 0.9996805191040039
of O O 0.9993199110031128
third O O 0.917019784450531
- O O 0.9995494484901428
generation O O 0.967103898525238
progestagens B O 0.5517629981040955
, O O 0.9998878240585327
the O O 0.999980092048645
risk O O 0.9999805688858032
of O O 0.9999066591262817
VTE O O 0.6414890289306641
was O O 0.9999517202377319
higher O O 0.9999667406082153
in O O 0.9998767375946045
users O O 0.9997418522834778
of O O 0.9994070529937744
desogestrel B B 0.9984217882156372
with O O 0.9951136708259583
20 O O 0.9977237582206726
g O O 0.9768626689910889
ethinyloestradiol B B 0.9404626488685608
than O O 0.9997919201850891
in O O 0.9998677968978882
users O O 0.9997063279151917
of O O 0.9991958737373352
gestodene B B 0.9989105463027954
or O O 0.989004909992218
desogestrel B B 0.998557984828949
with O O 0.9963271021842957
30 O O 0.999717652797699
g O O 0.987007200717926
ethinyloestradiol B B 0.9548964500427246
. O O 0.9999037981033325

With O O 0.9999027252197266
all O O 0.9993526339530945
second O O 0.9889783263206482
- O O 0.9991457462310791
generation O O 0.9532947540283203
OCs B O 0.6755357980728149
as O O 0.9997425675392151
the O O 0.9999814033508301
reference O O 0.999991774559021
, O O 0.9999614953994751
the O O 0.9999639987945557
odds O O 0.9999098777770996
ratios O O 0.9999821186065674
for O O 0.999683141708374
VTE O O 0.6661751866340637
were O O 0.9999339580535889
3 O O 0.9999703168869019
. O O 0.9999877214431763
49 O O 0.9999860525131226
( O O 0.9999008178710938
1 O O 0.9999942779541016
. O O 0.9999916553497314
21 O O 0.9999915361404419
- O O 0.9982628226280212
10 O O 0.9999837875366211
. O O 0.9999970197677612
12 O O 0.9999953508377075
) O O 0.9999688863754272
for O O 0.9980252981185913
desogestrel B B 0.9998148083686829
plus O O 0.9956138134002686
20 O O 0.9987882971763611
g O O 0.99420565366745
ethinyloestradiol B B 0.9919690489768982
and O O 0.9995638728141785
1 O O 0.9999485015869141
. O O 0.9999927282333374
18 O O 0.9999966621398926
( O O 0.999945878982544
0 O O 0.9999927282333374
. O O 0.999991774559021
66 O O 0.9999967813491821
- O O 0.9983574748039246
2 O O 0.9999648332595825
. O O 0.9999971389770508
17 O O 0.9999953508377075
) O O 0.9999754428863525
for O O 0.9994081258773804
the O O 0.9997721314430237
other O O 0.9991956353187561
third O O 0.9280438423156738
- O O 0.9994856119155884
generation O O 0.9675837755203247
progestagens B O 0.5608088970184326
. O O 0.9999134540557861

INTERPRETATION O O 0.9999496936798096
: O O 0.999990701675415
The O O 0.9999964237213135
previously O O 0.9999881982803345
reported O O 0.9999939203262329
increase O O 0.9999924898147583
in O O 0.9999829530715942
odds O O 0.999832034111023
ratio O O 0.9999818801879883
associated O O 0.9999779462814331
with O O 0.9998379945755005
third O O 0.9100613594055176
- O O 0.9987064599990845
generation O O 0.958536684513092
OCs B O 0.5287242531776428
when O O 0.9999151229858398
compared O O 0.9999816417694092
with O O 0.9998700618743896
second O O 0.9973297119140625
- O O 0.9998065829277039
generation O O 0.9656021595001221
products O O 0.9970108270645142
is O O 0.9999206066131592
likely O O 0.9998865127563477
to O O 0.9997612833976746
have O O 0.9999927282333374
been O O 0.9999830722808838
the O O 0.9999891519546509
result O O 0.999963641166687
of O O 0.9999455213546753
residual O O 0.9999427795410156
confounding O O 0.9999080896377563
by O O 0.9999719858169556
age O O 0.9983865022659302
. O O 0.9999607801437378

The O O 0.9999935626983643
increased O O 0.9999814033508301
odds O O 0.9999079704284668
ratio O O 0.9999902248382568
associated O O 0.9999827146530151
with O O 0.9999287128448486
products O O 0.9999037981033325
containing O O 0.9998317956924438
20 O O 0.9978563189506531
micrograms O O 0.9948280453681946
ethinyloestradiol B B 0.9934961795806885
and O O 0.8433097004890442
desogestrel B B 0.9993858337402344
compared O O 0.9999136924743652
with O O 0.9999337196350098
the O O 0.9999580383300781
30 O O 0.9997801184654236
micrograms O O 0.9989135265350342
product O O 0.9995645880699158
is O O 0.9999643564224243
biologically O O 0.9999760389328003
implausible O O 0.9999986886978149
, O O 0.9999682903289795
and O O 0.9999773502349854
is O O 0.9999860525131226
likely O O 0.9999775886535645
to O O 0.9999723434448242
be O O 0.9999872446060181
the O O 0.9999936819076538
result O O 0.9999674558639526
of O O 0.9999169111251831
preferential O O 0.9998326301574707
prescribing O O 0.9994657635688782
and O O 0.9999105930328369
, O O 0.9999885559082031
thus O O 0.9999959468841553
, O O 0.9999803304672241
confounding O O 0.9999170303344727
. O O 0.9999794960021973

MK B B 0.9913092851638794
- I I 0.9386394023895264
801 I I 0.9999035596847534
augments O O 0.8832796216011047
pilocarpine B B 0.9997568726539612
- O O 0.9998983144760132
induced O O 0.9999334812164307
electrographic O O 0.9999657869338989
seizure O O 0.9999840259552002
but O O 0.999788224697113
protects O O 0.9996472597122192
against O O 0.9997250437736511
brain O O 0.9999759197235107
damage O O 0.9999949932098389
in O O 0.9999481439590454
rats O O 0.9999768733978271
. O O 0.9997302889823914

1 O O 0.9998971223831177
. O O 0.9998472929000854

The O O 0.9999815225601196
authors O O 0.9999974966049194
examined O O 0.9999624490737915
the O O 0.9999110698699951
anticonvulsant O O 0.9180386066436768
effects O O 0.9997450709342957
of O O 0.9988844990730286
MK B B 0.9994463324546814
- I I 0.9810996651649475
801 I I 0.9999737739562988
on O O 0.998943030834198
the O O 0.9999496936798096
pilocarpine B B 0.9998083710670471
- O O 0.9999148845672607
induced O O 0.999924898147583
seizure O O 0.9999867677688599
model O O 0.9999957084655762
. O O 0.9999762773513794

Intraperitoneal O O 0.9999170303344727
injection O O 0.999958872795105
of O O 0.998982846736908
pilocarpine B B 0.9997746348381042
( O O 0.9995993971824646
400 O O 0.9991456270217896
mg O O 0.9998865127563477
/ O O 0.9996428489685059
kg O O 0.9999679327011108
) O O 0.9998985528945923
induced O O 0.9999778270721436
tonic O O 0.9999947547912598
and O O 0.9999210834503174
clonic O O 0.9998679161071777
seizure O O 0.9999899864196777
. O O 0.9998273253440857

Scopolamine B B 0.9994685053825378
( O O 0.9997068047523499
10 O O 0.9986885190010071
mg O O 0.9996871948242188
/ O O 0.999924898147583
kg O O 0.9999809265136719
) O O 0.9997875094413757
and O O 0.9974556565284729
pentobarbital B B 0.9992874264717102
( O O 0.9997971653938293
5 O O 0.9999105930328369
mg O O 0.9997853636741638
/ O O 0.9999305009841919
kg O O 0.9999676942825317
) O O 0.9998846054077148
prevented O O 0.9999585151672363
development O O 0.9999973773956299
of O O 0.9999674558639526
pilocarpine B B 0.9998216032981873
- O O 0.9998456239700317
induced O O 0.9999567270278931
behavioral O O 0.9999867677688599
seizure O O 0.9999935626983643
but O O 0.9999351501464844
MK B B 0.998235821723938
- I I 0.9336033463478088
801 I I 0.9999699592590332
( O O 0.9973610043525696
0 O O 0.9999125003814697
. O O 0.9999898672103882
5 O O 0.9999595880508423
mg O O 0.9995036125183105
/ O O 0.9998164772987366
kg O O 0.9999421834945679
) O O 0.9996833801269531
did O O 0.9999643564224243
not O O 0.9999412298202515
. O O 0.9999492168426514

2 O O 0.9993448853492737
. O O 0.9999009370803833

An O O 0.9999595880508423
electrical O O 0.9999423027038574
seizure O O 0.9999724626541138
measured O O 0.9999653100967407
with O O 0.9999308586120605
hippocampal O O 0.9837522506713867
EEG O O 0.9980463981628418
appeared O O 0.9999302625656128
in O O 0.9998281002044678
the O O 0.9998855590820312
pilocarpine B B 0.9998921155929565
- O O 0.9997236132621765
treated O O 0.9998327493667603
group O O 0.9999772310256958
. O O 0.9999672174453735

Scopolamine B B 0.999390721321106
and O O 0.9782757759094238
pentobarbital B B 0.9995841383934021
blocked O O 0.9999068975448608
the O O 0.9999350309371948
pilocarpine B B 0.9997629523277283
- O O 0.9999183416366577
induced O O 0.9999717473983765
electrographic O O 0.999809205532074
seizure O O 0.9999890327453613
, O O 0.9929234981536865
MK B B 0.9968656897544861
- I I 0.9101342558860779
801 I I 0.9998891353607178
treatment O O 0.9948955178260803
augmented O O 0.9999338388442993
the O O 0.999968409538269
electrographic O O 0.9997410178184509
seizure O O 0.9999881982803345
induced O O 0.9999911785125732
by O O 0.9998713731765747
pilocarpine B B 0.9998880624771118
. O O 0.9998900890350342

3 O O 0.9850600361824036
. O O 0.9998869895935059

Brain O O 0.9993497729301453
damage O O 0.999976396560669
was O O 0.9999783039093018
assessed O O 0.9999864101409912
by O O 0.999990701675415
examining O O 0.9999738931655884
the O O 0.9999399185180664
hippocampus O O 0.9968652129173279
microscopically O O 0.9998676776885986
. O O 0.9999693632125854

Pilocarpine B B 0.9994175434112549
produced O O 0.9998010993003845
neuronal O O 0.9996416568756104
death O O 0.9984357953071594
in O O 0.9996374845504761
the O O 0.9998700618743896
hippocampus O O 0.9991182684898376
, O O 0.999934196472168
which O O 0.9997677206993103
showed O O 0.9998263716697693
pyknotic O O 0.9352115392684937
changes O O 0.9999721050262451
. O O 0.9999265670776367

Pentobarbital B B 0.9988858103752136
, O O 0.9600368142127991
scopolamine B B 0.9996451139450073
and O O 0.992100179195404
MK B B 0.9976348876953125
- I I 0.9371722340583801
801 I I 0.9999790191650391
protected O O 0.9990664124488831
the O O 0.9999716281890869
brain O O 0.9999555349349976
damage O O 0.9999842643737793
by O O 0.9996649026870728
pilocarpine B B 0.999904990196228
, O O 0.9998633861541748
though O O 0.9999669790267944
in O O 0.9998706579208374
the O O 0.9999401569366455
MK B B 0.9980605244636536
- I I 0.9196481108665466
801 I I 0.9999688863754272
- O O 0.9888831973075867
treated O O 0.9998501539230347
group O O 0.9999512434005737
, O O 0.9999505281448364
the O O 0.9999315738677979
pyramidal O O 0.9999217987060547
cells O O 0.9999818801879883
of O O 0.9984291195869446
hippocampus O O 0.9917938113212585
appeared O O 0.9999431371688843
darker O O 0.9998863935470581
than O O 0.9999864101409912
normal O O 0.9998290538787842
. O O 0.9999685287475586

In O O 0.9997449517250061
all O O 0.9984118938446045
treatments O O 0.9996477365493774
, O O 0.9998329877853394
granule O O 0.9969786405563354
cells O O 0.999974250793457
of O O 0.9998200535774231
the O O 0.9999454021453857
dentate O O 0.998956561088562
gyrus O O 0.9993743300437927
were O O 0.999945878982544
not O O 0.9999637603759766
affected O O 0.9999803304672241
. O O 0.9999512434005737

4 O O 0.9273311495780945
. O O 0.9998733997344971

These O O 0.9999790191650391
results O O 0.9999847412109375
indicate O O 0.9998968839645386
that O O 0.9998658895492554
status O O 0.9999914169311523
epilepticus O O 0.9999921321868896
induced O O 0.9999810457229614
by O O 0.9997455477714539
pilocarpine B B 0.9998138546943665
is O O 0.9997463822364807
initiated O O 0.9999808073043823
by O O 0.9997242093086243
cholinergic O O 0.7489498257637024
overstimulation O O 0.9986763596534729
and O O 0.9998537302017212
propagated O O 0.999835729598999
by O O 0.9997588992118835
glutamatergic O O 0.6450740098953247
transmission O O 0.9999399185180664
, O O 0.9999790191650391
the O O 0.9999704360961914
elevation O O 0.9997772574424744
of O O 0.9998058676719666
which O O 0.9998416900634766
may O O 0.9998669624328613
cause O O 0.9999573230743408
brain O O 0.999988317489624
damage O O 0.9999949932098389
through O O 0.9999344348907471
an O O 0.9999147653579712
excitatory O O 0.9945255517959595
NMDA B B 0.9996781349182129
receptor O O 0.9448263645172119
- O O 0.9997515082359314
mediated O O 0.9999076128005981
mechanism O O 0.9999709129333496
. O O 0.9999649524688721

Paclitaxel B B 0.9992833733558655
, O O 0.8784880042076111
5 B B 0.9317728877067566
- I I 0.9955969452857971
fluorouracil I I 0.9999924898147583
, O O 0.745583713054657
and O O 0.9714635610580444
folinic B B 0.9958897233009338
acid I I 0.9999490976333618
in O O 0.9996121525764465
metastatic O O 0.9999916553497314
breast O O 0.9998942613601685
cancer O O 0.9999572038650513
: O O 0.9999278783798218
BRE O O 0.735679030418396
- O O 0.8678223490715027
26 O O 0.6983588337898254
, O O 0.9996691942214966
a O O 0.9999732971191406
phase O O 0.9999696016311646
II O O 0.997921884059906
trial O O 0.9999719858169556
. O O 0.9999825954437256

5 B B 0.9183934926986694
- I I 0.9961400628089905
Fluorouracil I I 0.9999872446060181
plus O O 0.9840350151062012
folinic B B 0.9966641068458557
acid I I 0.9999219179153442
and O O 0.923599362373352
paclitaxel B B 0.9992601275444031
( O O 0.9922756552696228
Taxol B B 0.9989832043647766
; O O 0.9425396919250488
Bristol O B 0.7100344896316528
- O I 0.5239323377609253
Myers O I 0.9437475800514221
Squibb O O 0.7266798615455627
Company O O 0.6259635090827942
, O O 0.7932137250900269
Princeton O O 0.5759177803993225
, O O 0.9001961350440979
NJ O O 0.785223126411438
) O O 0.998508632183075
are O O 0.9998881816864014
effective O O 0.9996535778045654
salvage O O 0.9937072396278381
therapies O O 0.9998600482940674
for O O 0.9999443292617798
metastatic O O 0.9999922513961792
breast O O 0.9998637437820435
cancer O O 0.9999368190765381
patients O O 0.9999868869781494
. O O 0.9999645948410034

Paclitaxel B B 0.9993472695350647
and O O 0.9450242519378662
5 B B 0.9742409586906433
- I I 0.9964757561683655
fluorouracil I I 0.9999810457229614
have O O 0.9990708827972412
additive O O 0.9989689588546753
cytotoxicity O O 0.9999128580093384
in O O 0.9998925924301147
MCF O O 0.9950761198997498
- O O 0.9983692765235901
7 O O 0.9935309290885925
cell O O 0.9999651908874512
lines O O 0.9999815225601196
. O O 0.9999228715896606

We O O 0.9999661445617676
performed O O 0.9999887943267822
a O O 0.9999884366989136
phase O O 0.9999637603759766
II O O 0.9999068975448608
trial O O 0.9999878406524658
of O O 0.9998387098312378
paclitaxel B B 0.9997237324714661
175 O O 0.9656224846839905
mg O O 0.9999781847000122
/ O O 0.9999097585678101
m2 O O 0.9999903440475464
over O O 0.9999710321426392
3 O O 0.9996509552001953
hours O O 0.9999727010726929
on O O 0.9999017715454102
day O O 0.9999381303787231
I O O 0.99967360496521
followed O O 0.9999574422836304
by O O 0.9997172951698303
folinic B B 0.9968191385269165
acid I I 0.9997816681861877
300 O O 0.7921922206878662
mg O O 0.998785674571991
over O O 0.9999599456787109
1 O O 0.9999748468399048
hour O O 0.9999626874923706
before O O 0.9995622038841248
5 B B 0.9369262456893921
- I I 0.9963480830192566
fluorouracil I I 0.9999884366989136
350 O O 0.6669013500213623
mg O O 0.9888349175453186
/ O O 0.9998117089271545
m2 O O 0.9999909400939941
on O O 0.9999545812606812
days O O 0.9999866485595703
1 O O 0.9999734163284302
to O O 0.9999433755874634
3 O O 0.9999371767044067
every O O 0.9999545812606812
28 O O 0.999991774559021
days O O 0.9999957084655762
( O O 0.9999076128005981
TFL O O 0.827977180480957
) O O 0.9999765157699585
in O O 0.9999703168869019
women O O 0.9999972581863403
with O O 0.9999918937683105
metastatic O O 0.9999954700469971
breast O O 0.9998764991760254
cancer O O 0.9999803304672241
. O O 0.9999841451644897

Analysis O O 0.9999305009841919
is O O 0.9999924898147583
reported O O 0.9999979734420776
on O O 0.9999958276748657
37 O O 0.9999948740005493
patients O O 0.9999972581863403
with O O 0.9999912977218628
a O O 0.9999969005584717
minimum O O 0.9999972581863403
of O O 0.9999908208847046
6 O O 0.9999814033508301
months O O 0.9999966621398926
follow O O 0.9999926090240479
- O O 0.9999903440475464
up O O 0.9999985694885254
who O O 0.9999740123748779
received O O 0.9999732971191406
a O O 0.999996542930603
total O O 0.9999951124191284
of O O 0.9999942779541016
192 O O 0.9999958276748657
cycles O O 0.9999822378158569
of O O 0.9997782111167908
TFL O B 0.9917476177215576
: O O 0.9989286065101624
nine O O 0.9999905824661255
cycles O O 0.9999871253967285
( O O 0.9999321699142456
5 O O 0.9999881982803345
% O O 0.9998020529747009
) O O 0.9999145269393921
were O O 0.9999830722808838
associated O O 0.9999920129776001
with O O 0.9999830722808838
grade O O 0.9999896287918091
3 O O 0.9993293285369873
/ O O 0.9998205304145813
4 O O 0.9990247488021851
neutropenia O O 0.9999898672103882
requiring O O 0.999962568283081
hospitalization O O 0.9999823570251465
; O O 0.9999738931655884
seven O O 0.9999492168426514
( O O 0.9998430013656616
4 O O 0.9999812841415405
% O O 0.9999891519546509
) O O 0.9999490976333618
cycles O O 0.9999749660491943
in O O 0.9999771118164062
two O O 0.9999946355819702
patients O O 0.9999891519546509
required O O 0.9998084902763367
granulocyte B O 0.5764736533164978
colony I O 0.6069427728652954
- I O 0.9161829948425293
stimulating I O 0.9463757872581482
factor I O 0.8850914239883423
due O O 0.9999755620956421
to O O 0.9999681711196899
neutropenia O O 0.9999901056289673
; O O 0.9999856948852539
no O O 0.9999866485595703
patient O O 0.9999914169311523
required O O 0.9999207258224487
platelet O O 0.9990386962890625
transfusions O O 0.9999310970306396
. O O 0.9999738931655884

Grade O O 0.9915298223495483
3 O O 0.9886056780815125
/ O O 0.9908464550971985
4 O O 0.9931275844573975
nonhematologic O O 0.8640053272247314
toxicities O O 0.9876025319099426
were O O 0.9998883008956909
uncommon O O 0.9986081719398499
. O O 0.9999321699142456

Among O O 0.9998409748077393
the O O 0.9999876022338867
34 O O 0.9999752044677734
patients O O 0.9999945163726807
evaluable O O 0.9999780654907227
for O O 0.9999772310256958
response O O 0.9999605417251587
, O O 0.9999337196350098
there O O 0.9999421834945679
were O O 0.9999754428863525
three O O 0.9999772310256958
complete O O 0.9998190999031067
responses O O 0.999988317489624
( O O 0.9999557733535767
9 O O 0.9999806880950928
% O O 0.999988317489624
) O O 0.9999510049819946
and O O 0.9999562501907349
18 O O 0.9995263814926147
partial O O 0.9999091625213623
responses O O 0.9999823570251465
( O O 0.9999358654022217
53 O O 0.9999860525131226
% O O 0.9999927282333374
) O O 0.9999724626541138
for O O 0.999947190284729
an O O 0.9999819993972778
overall O O 0.9999735355377197
response O O 0.9999878406524658
rate O O 0.9999955892562866
of O O 0.9999765157699585
62 O O 0.9999985694885254
% O O 0.9999983310699463
. O O 0.9999819993972778

Of O O 0.9999043941497803
the O O 0.9999924898147583
19 O O 0.9999828338623047
evaluable O O 0.9999769926071167
patients O O 0.999996542930603
with O O 0.9999791383743286
prior O O 0.999915599822998
doxorubicin B B 0.9992320537567139
exposure O O 0.9998573064804077
, O O 0.999962329864502
11 O O 0.9999505281448364
( O O 0.9999644756317139
58 O O 0.9999942779541016
% O O 0.9999960660934448
) O O 0.9999622106552124
responded O O 0.9999899864196777
compared O O 0.9999799728393555
with O O 0.9999903440475464
nine O O 0.999970555305481
of O O 0.9999793767929077
15 O O 0.9999967813491821
( O O 0.9999548196792603
60 O O 0.9999971389770508
% O O 0.9999973773956299
) O O 0.9999746084213257
without O O 0.9999309778213501
prior O O 0.9999016523361206
doxorubicin B B 0.9988756775856018
. O O 0.9999560117721558

Plasma O O 0.9991318583488464
paclitaxel B B 0.9997108578681946
concentrations O O 0.9994296431541443
were O O 0.9999915361404419
measured O O 0.9999876022338867
at O O 0.999974250793457
the O O 0.9999971389770508
completion O O 0.9999948740005493
of O O 0.9999438524246216
paclitaxel B B 0.9998664855957031
infusion O O 0.9998527765274048
and O O 0.9999874830245972
at O O 0.9999674558639526
24 O O 0.9999831914901733
hours O O 0.9999920129776001
in O O 0.9999759197235107
19 O O 0.9999655485153198
patients O O 0.9999963045120239
. O O 0.9999853372573853

TFL O B 0.9744076132774353
is O O 0.9988285899162292
an O O 0.9998345375061035
active O O 0.9994996786117554
, O O 0.9999676942825317
well O O 0.9998843669891357
- O O 0.9999885559082031
tolerated O O 0.9999778270721436
regimen O O 0.9695613384246826
in O O 0.9999470710754395
metastatic O O 0.9999899864196777
breast O O 0.9993628859519958
cancer O O 0.9999773502349854
. O O 0.9999610185623169

Efficacy O O 0.995745837688446
and O O 0.9999403953552246
proarrhythmia O O 0.9995885491371155
with O O 0.9999071359634399
the O O 0.9999583959579468
use O O 0.9998458623886108
of O O 0.9979945421218872
d B B 0.9341610074043274
, I I 0.8186015486717224
l I I 0.9562285542488098
- I I 0.9860580563545227
sotalol I I 0.9907174706459045
for O O 0.9996354579925537
sustained O O 0.9998751878738403
ventricular O O 0.9999654293060303
tachyarrhythmias O O 0.9999203681945801
. O O 0.9999247789382935

This O O 0.9999772310256958
study O O 0.9999827146530151
prospectively O O 0.9999878406524658
evaluated O O 0.9999831914901733
the O O 0.9999908208847046
clinical O O 0.9999926090240479
efficacy O O 0.9999988079071045
, O O 0.9999947547912598
the O O 0.9999953508377075
incidence O O 0.9999969005584717
of O O 0.9999871253967285
torsades O O 0.9997982382774353
de O O 0.9999709129333496
pointes O O 0.999930739402771
, O O 0.9999353885650635
and O O 0.9999591112136841
the O O 0.9999831914901733
presumable O O 0.9995218515396118
risk O O 0.9999580383300781
factors O O 0.9999958276748657
for O O 0.9999775886535645
torsades O O 0.9994444251060486
de O O 0.9999727010726929
pointes O O 0.9999675750732422
in O O 0.9999287128448486
patients O O 0.9999908208847046
treated O O 0.9999701976776123
with O O 0.9995213747024536
d B B 0.9056816101074219
, I I 0.8437350392341614
l I I 0.9655243754386902
- I I 0.9896894693374634
sotalol I I 0.9961679577827454
for O O 0.9991751313209534
sustained O O 0.9999099969863892
ventricular O O 0.9999839067459106
tachyarrhythmias O O 0.9999711513519287
. O O 0.9999756813049316

Eighty O O 0.9918208122253418
- O O 0.9999688863754272
one O O 0.9999926090240479
consecutive O O 0.9999828338623047
patients O O 0.999994158744812
( O O 0.9999704360961914
54 O O 0.9999521970748901
with O O 0.9999740123748779
coronary O O 0.9993846416473389
artery O O 0.9997313618659973
disease O O 0.9999933242797852
, O O 0.9999299049377441
and O O 0.9999632835388184
20 O O 0.9999762773513794
with O O 0.9999818801879883
dilated O O 0.9999436140060425
cardiomyopathy O O 0.9999926090240479
) O O 0.99997878074646
with O O 0.9999598264694214
inducible O O 0.9999459981918335
sustained O O 0.9998941421508789
ventricular O O 0.9999254941940308
tachycardia O O 0.9999592304229736
or O O 0.999923586845398
ventricular O O 0.9995152950286865
fibrillation O O 0.9999864101409912
received O O 0.9998944997787476
oral O O 0.9491442441940308
d B B 0.9868979454040527
, I I 0.5786266922950745
l I I 0.6737779974937439
- I I 0.9915362596511841
sotalol I I 0.9989513158798218
to O O 0.9996669292449951
prevent O O 0.9999517202377319
induction O O 0.9999969005584717
of O O 0.9999855756759644
the O O 0.9999910593032837
ventricular O O 0.9999722242355347
tachyarrhythmia O O 0.9999837875366211
. O O 0.9999734163284302

During O O 0.9998704195022583
oral O O 0.9979808926582336
loading O O 0.9999586343765259
with O O 0.9995269775390625
d B B 0.9640397429466248
, I I 0.7202067971229553
l I I 0.6812674403190613
- I I 0.9358063340187073
sotalol I I 0.7982735633850098
, O O 0.9997884631156921
continuous O O 0.9999860525131226
electrocardiographic O O 0.9999912977218628
( O O 0.9999632835388184
ECG O O 0.9998412132263184
) O O 0.9999760389328003
monitoring O O 0.9999960660934448
was O O 0.9999881982803345
performed O O 0.9999970197677612
. O O 0.9999791383743286

Those O O 0.9999592304229736
patients O O 0.9999849796295166
in O O 0.9999092817306519
whom O O 0.9996757507324219
d B B 0.9463783502578735
, I I 0.8259546756744385
l I I 0.7983201742172241
- I I 0.9928474426269531
sotalol I I 0.9606620073318481
prevented O O 0.9984185695648193
induction O O 0.9999862909317017
of O O 0.9999666213989258
ventricular O O 0.999692440032959
tachycardia O O 0.9999794960021973
or O O 0.9999439716339111
ventricular O O 0.999167799949646
fibrillation O O 0.9999901056289673
were O O 0.9999867677688599
discharged O O 0.9999947547912598
with O O 0.9999661445617676
the O O 0.9998506307601929
drug O O 0.999126136302948
and O O 0.999985933303833
followed O O 0.9999971389770508
up O O 0.9999978542327881
on O O 0.9999974966049194
an O O 0.9999973773956299
outpatient O O 0.9999960660934448
basis O O 0.9999960660934448
for O O 0.9999963045120239
21 O O 0.9999749660491943
+ O O 0.9999967813491821
/ O O 0.9999860525131226
- O O 0.9999845027923584
18 O O 0.9999343156814575
months O O 0.9999984502792358
. O O 0.9999935626983643

Induction O O 0.9999507665634155
of O O 0.9999678134918213
the O O 0.9999843835830688
ventricular O O 0.9999706745147705
tachyarrhythmia O O 0.999942421913147
was O O 0.9999510049819946
prevented O O 0.9999884366989136
by O O 0.9999008178710938
oral O O 0.9980554580688477
d B B 0.986553966999054
, I I 0.9424404501914978
l I I 0.95606529712677
- I I 0.9913895726203918
sotalol I I 0.9952355027198792
in O O 0.9995978474617004
35 O O 0.9999657869338989
( O O 0.999907374382019
43 O O 0.999980092048645
% O O 0.9999871253967285
) O O 0.9999282360076904
patients O O 0.9999942779541016
; O O 0.9999196529388428
the O O 0.9999852180480957
ventricular O O 0.9999831914901733
tachyarrhythmia O O 0.999953031539917
remained O O 0.9998311996459961
inducible O O 0.9980060458183289
in O O 0.9999314546585083
40 O O 0.999946117401123
( O O 0.9998960494995117
49 O O 0.9999916553497314
% O O 0.9999933242797852
) O O 0.9999489784240723
patients O O 0.9999939203262329
; O O 0.9999480247497559
and O O 0.9999579191207886
two O O 0.9999953508377075
( O O 0.9998200535774231
2 O O 0.999981164932251
. O O 0.999981164932251
5 O O 0.9999899864196777
% O O 0.9999946355819702
) O O 0.9999736547470093
patients O O 0.9999963045120239
did O O 0.9999969005584717
not O O 0.9999971389770508
tolerate O O 0.9999699592590332
even O O 0.9999743700027466
40 O O 0.9998502731323242
mg O O 0.9999637603759766
of O O 0.9995027780532837
d B B 0.874937891960144
, I I 0.9060106873512268
l I I 0.8904480338096619
- I I 0.9883291721343994
sotalol I I 0.9887325763702393
once O O 0.9972730278968811
daily O O 0.9999732971191406
. O O 0.9999827146530151

Four O O 0.9999518394470215
( O O 0.9998388290405273
5 O O 0.9999699592590332
% O O 0.999995231628418
) O O 0.9999494552612305
patients O O 0.9999935626983643
had O O 0.9999923706054688
from O O 0.9999432563781738
torsades O O 0.9998363256454468
de O O 0.9999574422836304
pointes O O 0.9998008608818054
during O O 0.9999092817306519
the O O 0.9999802112579346
initial O O 0.9999905824661255
oral O O 0.9995853304862976
treatment O O 0.9999872446060181
with O O 0.9996442794799805
d B B 0.9231082797050476
, I I 0.898262619972229
l I I 0.991353452205658
- I I 0.9942876696586609
sotalol I I 0.992049515247345
. O O 0.9998430013656616

Neither O O 0.9999241828918457
ECG O O 0.99481201171875
[ O O 0.9996442794799805
sinus O O 0.999570906162262
- O O 0.9961159229278564
cycle O O 0.9983676075935364
length O O 0.999955415725708
( O O 0.9994269609451294
SCL O O 0.961081862449646
) O O 0.9998937845230103
, O O 0.9999079704284668
QT O O 0.9866677522659302
or O O 0.9999566078186035
QTc O O 0.9805777072906494
interval O O 0.9999850988388062
, O O 0.9999028444290161
or O O 0.9999048709869385
U O O 0.9585378170013428
wave O O 0.9993290901184082
] O O 0.9998986721038818
nor O O 0.9999583959579468
clinical O O 0.9999799728393555
parameters O O 0.9999933242797852
identified O O 0.9999731779098511
patients O O 0.9999912977218628
at O O 0.9999383687973022
risk O O 0.9999959468841553
for O O 0.9999743700027466
torsades O O 0.9999525547027588
de O O 0.9999856948852539
pointes O O 0.999874472618103
. O O 0.9999730587005615

However O O 0.9999810457229614
, O O 0.9999656677246094
the O O 0.9999641180038452
oral O O 0.9994505047798157
dose O O 0.9998399019241333
of O O 0.9993597865104675
d B B 0.9428799748420715
, I I 0.6297863125801086
l I I 0.9387697577476501
- I I 0.9924134612083435
sotalol I I 0.985772430896759
was O O 0.9998045563697815
significantly O O 0.9999910593032837
lower O O 0.9999605417251587
in O O 0.9999289512634277
patients O O 0.9999967813491821
with O O 0.9999890327453613
torsades O O 0.9999508857727051
de O O 0.9999849796295166
pointes O O 0.9996476173400879
( O O 0.9999476671218872
200 O O 0.9995056390762329
+ O O 0.9999648332595825
/ O O 0.9994175434112549
- O O 0.9996979236602783
46 O O 0.9995878338813782
vs O O 0.9999340772628784
. O O 0.9999972581863403
328 O O 0.9999858140945435
+ O O 0.999992847442627
/ O O 0.9996880292892456
- O O 0.9998968839645386
53 O O 0.9999585151672363
mg O O 0.9999834299087524
/ O O 0.9999772310256958
day O O 0.9999958276748657
; O O 0.9999841451644897
p O O 0.9999574422836304
= O O 0.9999494552612305
0 O O 0.9999879598617554
. O O 0.9999973773956299
0017 O O 0.9998515844345093
) O O 0.9999798536300659
. O O 0.9999793767929077

Risk O O 0.999204695224762
factors O O 0.9999955892562866
associated O O 0.9999898672103882
with O O 0.9999873638153076
the O O 0.9999934434890747
development O O 0.999996542930603
of O O 0.9999884366989136
torsades O O 0.9999676942825317
de O O 0.9999825954437256
pointes O O 0.9998064637184143
were O O 0.9999779462814331
the O O 0.9999966621398926
appearance O O 0.9999963045120239
of O O 0.9999799728393555
an O O 0.9990249872207642
U O O 0.9836680293083191
wave O O 0.9999595880508423
( O O 0.999945878982544
p O O 0.9993878602981567
= O O 0.9996848106384277
0 O O 0.9999833106994629
. O O 0.9999966621398926
049 O O 0.9998359680175781
) O O 0.9999657869338989
, O O 0.9999856948852539
female O O 0.999946117401123
gender O O 0.9998364448547363
( O O 0.9999780654907227
p O O 0.9996253252029419
= O O 0.999382495880127
0 O O 0.9999562501907349
. O O 0.999995231628418
015 O O 0.9999068975448608
) O O 0.9999489784240723
, O O 0.9999221563339233
and O O 0.9999717473983765
significant O O 0.9999802112579346
dose O O 0.998350977897644
- O O 0.9999827146530151
corrected O O 0.9999911785125732
changes O O 0.9999977350234985
of O O 0.9999734163284302
SCL O O 0.989246666431427
, O O 0.9999070167541504
QT O O 0.9771415591239929
interval O O 0.9999818801879883
, O O 0.9986900687217712
and O O 0.9998931884765625
QTc O O 0.9225887656211853
interval O O 0.9999696016311646
( O O 0.999975323677063
p O O 0.9998001456260681
< O O 0.9999856948852539
0 O O 0.9999920129776001
. O O 0.9999971389770508
05 O O 0.9999948740005493
) O O 0.9999717473983765
. O O 0.9999793767929077

During O O 0.9999605417251587
follow O O 0.9999932050704956
- O O 0.9999918937683105
up O O 0.9999967813491821
, O O 0.9999849796295166
seven O O 0.9999783039093018
( O O 0.9998724460601807
20 O O 0.9999933242797852
% O O 0.9999946355819702
) O O 0.9999635219573975
patients O O 0.9999915361404419
had O O 0.9999865293502808
a O O 0.9999891519546509
nonfatal O O 0.9971081614494324
ventricular O O 0.99831223487854
tachycardia O O 0.9981410503387451
recurrence O O 0.9999823570251465
, O O 0.999924898147583
and O O 0.9999512434005737
two O O 0.9999957084655762
( O O 0.9997208714485168
6 O O 0.9999829530715942
% O O 0.999993085861206
) O O 0.9999507665634155
patients O O 0.9999879598617554
died O O 0.9999850988388062
suddenly O O 0.9999881982803345
. O O 0.9999847412109375

One O O 0.9999634027481079
female O O 0.9999881982803345
patient O O 0.9999775886535645
with O O 0.9998853206634521
stable O O 0.999980092048645
cardiac O O 0.999985933303833
disease O O 0.999997615814209
had O O 0.9999526739120483
recurrent O O 0.9999963045120239
torsades O O 0.9999417066574097
de O O 0.9999455213546753
pointes O O 0.9993786811828613
after O O 0.999903678894043
2 O O 0.9999450445175171
years O O 0.9999921321868896
of O O 0.9999604225158691
successful O O 0.9999042749404907
treatment O O 0.999984622001648
with O O 0.9997184872627258
d B B 0.7300269603729248
, I I 0.7350562214851379
l I I 0.9420310854911804
- I I 0.9886528849601746
sotalol I I 0.9947946667671204
. O O 0.9997962117195129

Torsades O O 0.999622106552124
de O O 0.9999572038650513
pointes O O 0.999009370803833
occurred O O 0.9999837875366211
early O O 0.9999872446060181
during O O 0.9999521970748901
treatment O O 0.9999746084213257
even O O 0.9999243021011353
with O O 0.9999345541000366
low O O 0.9999610185623169
doses O O 0.9999021291732788
of O O 0.9994649291038513
oral O O 0.961205005645752
d B B 0.9857324957847595
, I I 0.6468175649642944
l I I 0.9598625302314758
- I I 0.994312047958374
sotalol I I 0.9978310465812683
. O O 0.9998449087142944

Pronounced O O 0.999871015548706
changes O O 0.9999969005584717
in O O 0.9999910593032837
the O O 0.999958872795105
surface O O 0.983626663684845
ECG O O 0.9955841898918152
( O O 0.9998588562011719
cycle O O 0.9975378513336182
length O O 0.9999880790710449
, O O 0.9999545812606812
QT O O 0.9427926540374756
, O O 0.9998488426208496
and O O 0.9999041557312012
QTc O O 0.8577097654342651
) O O 0.9999659061431885
in O O 0.9999905824661255
relation O O 0.9999970197677612
to O O 0.9999605417251587
the O O 0.9999839067459106
dose O O 0.9997434020042419
of O O 0.9997884631156921
oral O O 0.8183301091194153
d B B 0.9969764947891235
, I O 0.9198282957077026
l I B 0.8399920463562012
- I I 0.9880311489105225
sotalol I I 0.9832648634910583
might O O 0.9996751546859741
identify O O 0.9999796152114868
a O O 0.9999892711639404
subgroup O O 0.9999793767929077
of O O 0.9999868869781494
patients O O 0.9999915361404419
with O O 0.999982476234436
an O O 0.999990701675415
increased O O 0.999990701675415
risk O O 0.9999971389770508
for O O 0.9999866485595703
torsades O O 0.9999510049819946
de O O 0.9999910593032837
pointes O O 0.9998002648353577
. O O 0.9999680519104004

Other O O 0.9982155561447144
ECG O O 0.9006320834159851
parameters O O 0.9999082088470459
before O O 0.9999544620513916
the O O 0.9999899864196777
application O O 0.9999468326568604
of O O 0.9983699917793274
d B B 0.9938374161720276
, I O 0.754806399345398
l I O 0.44327396154403687
- I O 0.9187541007995605
sotalol I B 0.6130788326263428
did O O 0.999944806098938
not O O 0.9999808073043823
identify O O 0.9999792575836182
patients O O 0.9999936819076538
at O O 0.9999818801879883
increased O O 0.9999920129776001
risk O O 0.9999973773956299
for O O 0.999984860420227
torsades O O 0.9999620914459229
de O O 0.9999889135360718
pointes O O 0.9999265670776367
. O O 0.9999587535858154

Recurrence O O 0.9999275207519531
rates O O 0.9999912977218628
of O O 0.9999498128890991
ventricular O O 0.9998867511749268
tachyarrhythmias O O 0.9999397993087769
are O O 0.9999393224716187
high O O 0.9999402761459351
despite O O 0.9998992681503296
complete O O 0.999714195728302
suppression O O 0.9999748468399048
of O O 0.999948263168335
the O O 0.9999806880950928
arrhythmia O O 0.9999442100524902
during O O 0.9997814297676086
programmed O O 0.9992868304252625
stimulation O O 0.9999395608901978
. O O 0.9999581575393677

Therefore O O 0.9999057054519653
programmed O O 0.9998241066932678
electrical O O 0.9998775720596313
stimulation O O 0.999883770942688
in O O 0.9999266862869263
the O O 0.9999681711196899
case O O 0.9998979568481445
of O O 0.9993245601654053
d B B 0.8839898109436035
, I O 0.82813960313797
l I O 0.8378809094429016
- I O 0.9621828198432922
sotalol I B 0.611575186252594
seems O O 0.9997686743736267
to O O 0.9999698400497437
be O O 0.999976634979248
of O O 0.9999386072158813
limited O O 0.9999890327453613
prognostic O O 0.9999903440475464
value O O 0.9999903440475464
. O O 0.9999662637710571

Chronic O O 0.9997987151145935
hyperprolactinemia O O 0.9500995874404907
and O O 0.999840497970581
changes O O 0.999980092048645
in O O 0.9999443292617798
dopamine B B 0.9936023354530334
neurons O O 0.9996782541275024
. O O 0.9999088048934937

The O O 0.9993665814399719
tuberoinfundibular O O 0.9966354966163635
dopaminergic O B 0.8983627557754517
( O O 0.9324896335601807
TIDA O O 0.8116912245750427
) O O 0.9962133765220642
system O O 0.9961431622505188
is O O 0.9996305704116821
known O O 0.9994176626205444
to O O 0.9979627132415771
inhibit O O 0.9988774657249451
prolactin O O 0.45739126205444336
( O O 0.9861577749252319
PRL O O 0.6959470510482788
) O O 0.9735124707221985
secretion O O 0.9992772936820984
. O O 0.9998373985290527

In O O 0.9999436140060425
young O O 0.9999887943267822
animals O O 0.9999961853027344
this O O 0.9998935461044312
system O O 0.9998983144760132
responds O O 0.9999182224273682
to O O 0.9999481439590454
acute O O 0.9999412298202515
elevations O O 0.9998859167098999
in O O 0.9999191761016846
serum O O 0.9585016369819641
PRL O O 0.7162665724754333
by O O 0.9998377561569214
increasing O O 0.9993600249290466
its O O 0.998730480670929
activity O O 0.9993765950202942
. O O 0.9999580383300781

However O O 0.9999301433563232
, O O 0.9999409914016724
this O O 0.9997379183769226
responsiveness O O 0.999889612197876
is O O 0.9999496936798096
lost O O 0.9999805688858032
in O O 0.9999619722366333
aging O O 0.9999825954437256
rats O O 0.9999945163726807
with O O 0.9999735355377197
chronically O O 0.9999825954437256
high O O 0.99996018409729
serum O O 0.9985622763633728
PRL O O 0.845876157283783
levels O O 0.9992783665657043
. O O 0.9999685287475586

The O O 0.9999886751174927
purpose O O 0.9999954700469971
of O O 0.999995231628418
this O O 0.9999878406524658
study O O 0.9999731779098511
was O O 0.9999948740005493
to O O 0.9999837875366211
induce O O 0.9999746084213257
hyperprolactinemia O O 0.9892033934593201
in O O 0.9999402761459351
rats O O 0.9999868869781494
for O O 0.9999170303344727
extended O O 0.9999674558639526
periods O O 0.9999833106994629
of O O 0.9999828338623047
time O O 0.9999749660491943
and O O 0.9999810457229614
examine O O 0.9999374151229858
its O O 0.9989240765571594
effects O O 0.9998489618301392
on O O 0.9998231530189514
dopaminergic O O 0.7706447243690491
systems O O 0.9997503161430359
in O O 0.9998018145561218
the O O 0.9999685287475586
brain O O 0.9999885559082031
. O O 0.9999697208404541

Hyperprolactinemia O O 0.9985602498054504
was O O 0.999945878982544
induced O O 0.9999860525131226
by O O 0.9999234676361084
treatment O O 0.999977707862854
with O O 0.9998722076416016
haloperidol B B 0.9998495578765869
, O O 0.9990824460983276
a O O 0.9985522627830505
dopamine B B 0.9973924160003662
receptor O O 0.960595428943634
antagonist O O 0.9552027583122253
, O O 0.9998080134391785
and O O 0.9998748302459717
Palkovits O O 0.6506666541099548
' O O 0.9998832941055298
microdissection O O 0.9972547888755798
technique O O 0.9999794960021973
in O O 0.9999916553497314
combination O O 0.999987006187439
with O O 0.9999771118164062
high O O 0.9775381684303284
- O O 0.9999616146087646
performance O O 0.9863671660423279
liquid O O 0.7808424234390259
chromatography O O 0.8879579305648804
was O O 0.9999542236328125
used O O 0.9999799728393555
to O O 0.9999879598617554
measure O O 0.9999828338623047
neurotransmitter O O 0.9998574256896973
concentrations O O 0.9995753169059753
in O O 0.9998352527618408
several O O 0.9999853372573853
areas O O 0.9999744892120361
of O O 0.9999549388885498
the O O 0.999984622001648
brain O O 0.9999867677688599
. O O 0.999945878982544

After O O 0.9999685287475586
6 O O 0.999931812286377
months O O 0.9999940395355225
of O O 0.9999781847000122
hyperprolactinemia O O 0.9990774393081665
, O O 0.9998878240585327
dopamine B B 0.9994075298309326
( O O 0.989870011806488
DA B B 0.9959549903869629
) O O 0.9240624904632568
concentrations O O 0.9993366599082947
in O O 0.9999017715454102
the O O 0.9999592304229736
median O O 0.9758771657943726
eminence O O 0.9933834671974182
( O O 0.9995181560516357
ME O O 0.7886120080947876
) O O 0.9997095465660095
increased O O 0.9999793767929077
by O O 0.9999972581863403
84 O O 0.9999488592147827
% O O 0.9999969005584717
over O O 0.9999899864196777
the O O 0.9999691247940063
control O O 0.9999346733093262
group O O 0.9999910593032837
. O O 0.9999812841415405

Nine O O 0.9998089671134949
months O O 0.9999749660491943
of O O 0.9998730421066284
hyperprolactinemia O O 0.9549674391746521
produced O O 0.9999241828918457
a O O 0.9999735355377197
50 O O 0.9999898672103882
% O O 0.9999940395355225
increase O O 0.9999735355377197
in O O 0.9999629259109497
DA B B 0.9027413725852966
concentrations O O 0.9996271133422852
in O O 0.9995942711830139
the O O 0.9997299313545227
ME O O 0.6930526494979858
over O O 0.9996708631515503
the O O 0.9998855590820312
control O O 0.9992105960845947
group O O 0.9999682903289795
. O O 0.9999607801437378

However O O 0.9999654293060303
, O O 0.9999700784683228
DA B O 0.9954168796539307
response O O 0.9999855756759644
was O O 0.9999823570251465
lost O O 0.9999951124191284
if O O 0.9999604225158691
a O O 0.9999651908874512
9 O O 0.9999465942382812
- O O 0.9999794960021973
month O O 0.9999936819076538
long O O 0.9999504089355469
haloperidol B B 0.9997187256813049
- O O 0.9997742772102356
induced O O 0.9999516010284424
hyperprolactinemia O O 0.9996168613433838
was O O 0.9999775886535645
followed O O 0.9999674558639526
by O O 0.9999730587005615
a O O 0.9999730587005615
1 O O 0.99983811378479
1 O O 0.9998350143432617
/ O O 0.9999891519546509
2 O O 0.9999662637710571
month O O 0.999990701675415
- O O 0.9999889135360718
long O O 0.9999877214431763
extremely O O 0.9999873638153076
high O O 0.9999830722808838
increase O O 0.9999862909317017
in O O 0.9999707937240601
serum O O 0.9982452392578125
PRL O B 0.8879448175430298
levels O O 0.9995296001434326
produced O O 0.9999768733978271
by O O 0.99994957447052
implantation O O 0.9999955892562866
of O O 0.999933123588562
MMQ O O 0.9417372941970825
cells O O 0.9999536275863647
under O O 0.999950647354126
the O O 0.999988317489624
kidney O O 0.9999017715454102
capsule O O 0.9999922513961792
. O O 0.9999748468399048

There O O 0.9999396800994873
was O O 0.999954104423523
no O O 0.9999798536300659
change O O 0.9999945163726807
in O O 0.9999840259552002
the O O 0.9999667406082153
levels O O 0.9998464584350586
of O O 0.9983799457550049
DA B B 0.9979249238967896
, O O 0.9856153726577759
norepinephrine B B 0.9993963241577148
( O O 0.9987687468528748
NE B B 0.9990411400794983
) O O 0.9832837581634521
, O O 0.9984825253486633
serotonin B B 0.9954473376274109
( O O 0.9975382089614868
5 B B 0.6580600738525391
- I I 0.7557855248451233
HT I I 0.9973843693733215
) O O 0.9915136694908142
, O O 0.9984531402587891
or O O 0.9998132586479187
their O O 0.8408665060997009
metabolites O O 0.9997887015342712
in O O 0.9997575879096985
the O O 0.9998922348022461
arcuate O O 0.9993133544921875
nucleus O O 0.9999892711639404
( O O 0.9998413324356079
AN O O 0.845241129398346
) O O 0.9998196959495544
, O O 0.9998844861984253
medial O O 0.9998021721839905
preoptic O O 0.9979643821716309
area O O 0.9996637105941772
( O O 0.9998194575309753
MPA O O 0.9892100691795349
) O O 0.9999431371688843
, O O 0.9998012185096741
caudate O O 0.9808063507080078
putamen O O 0.9975751042366028
( O O 0.9996185302734375
CP O O 0.9533657431602478
) O O 0.9999281167984009
, O O 0.9998793601989746
substantia O O 0.9981521964073181
nigra O O 0.9997373223304749
( O O 0.9997897744178772
SN O O 0.8070439100265503
) O O 0.9997953772544861
, O O 0.999116837978363
and O O 0.9979661703109741
zona O O 0.48619139194488525
incerta O O 0.5023927092552185
( O O 0.9988101720809937
ZI O O 0.9079893827438354
) O O 0.9999697208404541
, O O 0.9999630451202393
except O O 0.9999867677688599
for O O 0.999990701675415
a O O 0.9999910593032837
decrease O O 0.9999957084655762
in O O 0.9999425411224365
5 B B 0.7513588666915894
- I I 0.9221281409263611
hydroxyindoleacetic I I 0.9965007305145264
acid I I 0.9999257326126099
( O O 0.9976542592048645
5 B B 0.8172862529754639
- I I 0.8674805164337158
HIAA I I 0.9993900060653687
) O O 0.9992771744728088
in O O 0.9999392032623291
the O O 0.9997228980064392
AN O O 0.9976977705955505
after O O 0.9999357461929321
6 O O 0.9998111128807068
- O O 0.999966025352478
months O O 0.9999954700469971
of O O 0.9999592304229736
hyperprolactinemia O O 0.9900432825088501
and O O 0.9999653100967407
an O O 0.9999879598617554
increase O O 0.999991774559021
in O O 0.9999110698699951
DA B B 0.9843713641166687
concentrations O O 0.9998064637184143
in O O 0.9998729228973389
the O O 0.9998435974121094
AN O O 0.9979429841041565
after O O 0.9999219179153442
9 O O 0.999671220779419
- O O 0.9999685287475586
months O O 0.9999957084655762
of O O 0.9999589920043945
hyperprolactinemia O O 0.9844403266906738
. O O 0.9999527931213379

These O O 0.9999681711196899
results O O 0.9999849796295166
demonstrate O O 0.9999662637710571
that O O 0.9997841715812683
hyperprolactinemia O O 0.9052903056144714
specifically O O 0.9998188614845276
affects O O 0.9996752738952637
TIDA O O 0.5630120635032654
neurons O O 0.986604630947113
and O O 0.9999350309371948
these O O 0.999872088432312
effects O O 0.999903678894043
vary O O 0.9999651908874512
, O O 0.9999842643737793
depending O O 0.9999876022338867
on O O 0.9999750852584839
the O O 0.9999866485595703
duration O O 0.9999802112579346
and O O 0.999981164932251
intensity O O 0.9999810457229614
of O O 0.9999420642852783
hyperprolactinemia O O 0.9810217618942261
. O O 0.9999395608901978

The O O 0.9999796152114868
age O O 0.999077320098877
- O O 0.9999665021896362
related O O 0.9999918937683105
decrease O O 0.9999891519546509
in O O 0.9999510049819946
hypothalamic O O 0.9972516894340515
dopamine B B 0.998069703578949
function O O 0.9998818635940552
may O O 0.9999070167541504
be O O 0.9999033212661743
associated O O 0.9999710321426392
with O O 0.9999024868011475
increases O O 0.9999368190765381
in O O 0.999904990196228
PRL O O 0.8149918913841248
secretion O O 0.9981082677841187
. O O 0.9999536275863647

Treatment O O 0.8104556798934937
- O O 0.9996863603591919
related O O 0.9999760389328003
disseminated O O 0.9999876022338867
necrotizing O O 0.9999884366989136
leukoencephalopathy O O 0.9999903440475464
with O O 0.9999827146530151
characteristic O O 0.9999804496765137
contrast O O 0.9826077818870544
enhancement O O 0.9998903274536133
of O O 0.9998866319656372
the O O 0.9999520778656006
white O O 0.999990701675415
matter O O 0.9999974966049194
. O O 0.9999531507492065

This O O 0.9999912977218628
report O O 0.9999957084655762
describes O O 0.999967098236084
unique O O 0.9920470714569092
contrast O O 0.9756599068641663
enhancement O O 0.9999085664749146
of O O 0.9998962879180908
the O O 0.9999390840530396
white O O 0.9999792575836182
matter O O 0.9999973773956299
on O O 0.9999555349349976
T1 O O 0.9896652102470398
- O O 0.9999586343765259
weighted O O 0.9997970461845398
magnetic O O 0.9999064207077026
resonance O O 0.9999183416366577
images O O 0.9999740123748779
of O O 0.99993896484375
two O O 0.9999873638153076
patients O O 0.999993085861206
with O O 0.9999756813049316
disseminated O O 0.999923825263977
necrotizing O O 0.9999669790267944
leukoencephalopathy O O 0.9999948740005493
, O O 0.9999792575836182
which O O 0.9999830722808838
developed O O 0.9999979734420776
from O O 0.9999706745147705
acute O O 0.9998958110809326
lymphoblastic O O 0.9999585151672363
leukemia O O 0.9999922513961792
treated O O 0.999954342842102
with O O 0.9997997879981995
high O O 0.9969546794891357
- O O 0.9999411106109619
dose O O 0.9920497536659241
methotrexate B B 0.9993864297866821
. O O 0.9999277591705322

In O O 0.9998981952667236
both O O 0.9998975992202759
patients O O 0.999991774559021
, O O 0.9999707937240601
the O O 0.9999804496765137
enhancement O O 0.999799907207489
was O O 0.9999594688415527
more O O 0.9999721050262451
pronounced O O 0.9999901056289673
near O O 0.9998785257339478
the O O 0.9999783039093018
base O O 0.9999933242797852
of O O 0.9999810457229614
the O O 0.999984860420227
brain O O 0.9999802112579346
than O O 0.9999526739120483
at O O 0.9999327659606934
the O O 0.9999817609786987
vertex O O 0.9999972581863403
. O O 0.9999768733978271

Necropsy O O 0.9999716281890869
of O O 0.9999878406524658
the O O 0.9999896287918091
first O O 0.9999955892562866
case O O 0.9999810457229614
revealed O O 0.999953031539917
loss O O 0.9999879598617554
of O O 0.9999223947525024
myelination O O 0.9999492168426514
and O O 0.9997931122779846
necrosis O O 0.9998761415481567
of O O 0.9998914003372192
the O O 0.9999499320983887
white O O 0.9999897480010986
matter O O 0.9999974966049194
. O O 0.9999645948410034

Possible O O 0.9995735287666321
mechanisms O O 0.9998886585235596
causing O O 0.9999550580978394
such O O 0.9999282360076904
a O O 0.9999685287475586
leukoencephalopathy O O 0.9999682903289795
are O O 0.9999328851699829
discussed O O 0.9999574422836304
. O O 0.9999686479568481

Thrombotic O O 0.9998564720153809
complications O O 0.9999933242797852
in O O 0.9999392032623291
acute O O 0.9998490810394287
promyelocytic O O 0.9975506663322449
leukemia O O 0.9999892711639404
during O O 0.9995941519737244
all B B 0.6720264554023743
- I I 0.7930678129196167
trans I I 0.5106824636459351
- I I 0.5608147382736206
retinoic I I 0.9981908202171326
acid I I 0.9999083280563354
therapy O O 0.9955516457557678
. O O 0.9999545812606812

A O O 0.999966025352478
case O O 0.9999901056289673
of O O 0.9999744892120361
acute O O 0.999880313873291
renal O O 0.9999839067459106
failure O O 0.9999895095825195
, O O 0.9999905824661255
due O O 0.9999940395355225
to O O 0.9999487400054932
occlusion O O 0.9999130964279175
of O O 0.9999322891235352
renal O O 0.9997255206108093
vessels O O 0.9999918937683105
in O O 0.9999366998672485
a O O 0.9999792575836182
patient O O 0.9999885559082031
with O O 0.9999401569366455
acute O O 0.999230146408081
promyelocytic O O 0.9958049058914185
leukemia O O 0.9999570846557617
( O O 0.9998944997787476
APL O O 0.8064320087432861
) O O 0.999944806098938
treated O O 0.9998816251754761
with O O 0.9997472167015076
all B B 0.48712584376335144
- I I 0.49642515182495117
trans I I 0.8924728035926819
- I I 0.9120376110076904
retinoic I I 0.9993886947631836
acid I I 0.9999399185180664
( O O 0.9656265377998352
ATRA B B 0.9981789588928223
) O O 0.9876503348350525
and O O 0.9969462752342224
tranexamic B B 0.9889065027236938
acid I I 0.9990105628967285
has O O 0.9997181296348572
been O O 0.9999867677688599
described O O 0.9999905824661255
recently O O 0.9999880790710449
. O O 0.9999827146530151

We O O 0.9999524354934692
report O O 0.9999945163726807
a O O 0.999992847442627
case O O 0.9999945163726807
of O O 0.9999856948852539
acute O O 0.9999629259109497
renal O O 0.9999668598175049
failure O O 0.9999890327453613
in O O 0.9999545812606812
an O O 0.9999264478683472
APL O O 0.7106620073318481
patient O O 0.9998599290847778
treated O O 0.9998903274536133
with O O 0.9988698363304138
ATRA B B 0.9996956586837769
alone O O 0.99724280834198
. O O 0.9999656677246094

This O O 0.9999711513519287
case O O 0.9999817609786987
further O O 0.9999796152114868
supports O O 0.9999711513519287
the O O 0.9999897480010986
concern O O 0.9999914169311523
about O O 0.999966025352478
thromboembolic O O 0.9998127818107605
complications O O 0.9999967813491821
associated O O 0.9999843835830688
with O O 0.9997925162315369
ATRA B B 0.9992467164993286
therapy O O 0.9984253644943237
in O O 0.9999021291732788
APL O O 0.8442615270614624
patients O O 0.9999183416366577
. O O 0.9999667406082153

The O O 0.9999912977218628
patients O O 0.9999960660934448
, O O 0.9999970197677612
a O O 0.9999902248382568
43 O O 0.9999974966049194
- O O 0.9999886751174927
year O O 0.9999973773956299
- O O 0.9999949932098389
old O O 0.9999910593032837
man O O 0.9999924898147583
, O O 0.9999634027481079
presented O O 0.9999474287033081
all O O 0.9999834299087524
the O O 0.9999940395355225
signs O O 0.999987006187439
and O O 0.9999909400939941
symptoms O O 0.9999973773956299
of O O 0.9999802112579346
APL O O 0.872017502784729
and O O 0.9999537467956543
was O O 0.9999423027038574
included O O 0.9999879598617554
in O O 0.9999662637710571
a O O 0.9999617338180542
treatment O O 0.9999375343322754
protocol O O 0.9999899864196777
with O O 0.9994563460350037
ATRA B B 0.999417781829834
. O O 0.9968652129173279

After O O 0.9999593496322632
10 O O 0.9999592304229736
days O O 0.9999947547912598
of O O 0.9999454021453857
treatment O O 0.9999449253082275
, O O 0.9999852180480957
he O O 0.9999783039093018
developed O O 0.9999805688858032
acute O O 0.999971866607666
renal O O 0.9999326467514038
failure O O 0.9999895095825195
that O O 0.9999653100967407
was O O 0.9999641180038452
completely O O 0.9998061060905457
reversible O O 0.9999463558197021
after O O 0.9999202489852905
complete O O 0.999954104423523
remission O O 0.9999903440475464
of O O 0.9995627999305725
APL O O 0.7134042978286743
was O O 0.9998910427093506
achieved O O 0.9999765157699585
and O O 0.9999786615371704
therapy O O 0.9999716281890869
discontinued O O 0.9999518394470215
. O O 0.9999772310256958

We O O 0.9999537467956543
conclude O O 0.999954104423523
that O O 0.9997450709342957
ATRA B B 0.999724805355072
is O O 0.9998592138290405
a O O 0.999922513961792
valid O O 0.9999431371688843
therapeutic O O 0.999883770942688
choice O O 0.9999297857284546
for O O 0.9998959302902222
patients O O 0.9999878406524658
with O O 0.9999762773513794
APL O O 0.8515951037406921
, O O 0.9999498128890991
although O O 0.9999884366989136
the O O 0.9999575614929199
procoagulant O O 0.9719973206520081
tendency O O 0.9998880624771118
is O O 0.9999628067016602
not O O 0.999994158744812
completely O O 0.9999774694442749
corrected O O 0.9999788999557495
. O O 0.9999642372131348

Thrombotic O O 0.9998078942298889
events O O 0.9999903440475464
, O O 0.9999734163284302
however O O 0.9999114274978638
, O O 0.9999864101409912
could O O 0.9999054670333862
be O O 0.9999830722808838
avoided O O 0.9999755620956421
by O O 0.9999839067459106
using O O 0.9999452829360962
low O O 0.999855637550354
- O O 0.9999704360961914
dose O O 0.9988665580749512
heparin B B 0.9896971583366394
. O O 0.9997727274894714

Pupillary O O 0.999842643737793
changes O O 0.9999935626983643
associated O O 0.9999624490737915
with O O 0.9999711513519287
the O O 0.9999904632568359
development O O 0.9999940395355225
of O O 0.9999505281448364
stimulant O B 0.8719262480735779
- O O 0.994564414024353
induced O O 0.9999293088912964
mania O O 0.9997157454490662
: O O 0.9999920129776001
a O O 0.9999959468841553
case O O 0.9999877214431763
report O O 0.9999966621398926
. O O 0.9999823570251465

A O O 0.9999885559082031
30 O O 0.9999873638153076
- O O 0.9999889135360718
year O O 0.9999951124191284
- O O 0.9999946355819702
old O O 0.9999929666519165
cocaine B B 0.9960607886314392
- O O 0.9944491386413574
dependent O O 0.9986775517463684
man O O 0.9999877214431763
who O O 0.9999423027038574
was O O 0.9999592304229736
a O O 0.9999697208404541
subject O O 0.9999977350234985
in O O 0.9999818801879883
a O O 0.9999864101409912
study O O 0.9999676942825317
evaluating O O 0.9999568462371826
the O O 0.9999003410339355
anticraving O O 0.9737871885299683
efficacy O O 0.9999266862869263
of O O 0.9991521835327148
the O O 0.9974212646484375
stimulant O O 0.5761322975158691
medication O O 0.9428552985191345
diethylpropion B B 0.9993810653686523
( O O 0.8722677826881409
DEP B B 0.9952142238616943
) O O 0.9976542592048645
became O O 0.999953031539917
manic O O 0.9999306201934814
during O O 0.9999769926071167
his O O 0.9999904632568359
second O O 0.9999988079071045
week O O 0.9999973773956299
on O O 0.999622106552124
the O O 0.9999473094940186
study O O 0.9986675977706909
drug O O 0.9990003705024719
. O O 0.9999322891235352

Pupillometric O O 0.9999275207519531
changes O O 0.9999942779541016
while O O 0.9998512268066406
on O O 0.9964216947555542
DEP B B 0.9672880172729492
, O O 0.9998815059661865
especially O O 0.9999271631240845
changes O O 0.999994158744812
in O O 0.9999788999557495
the O O 0.9999724626541138
total O O 0.9992806315422058
power O O 0.9999891519546509
of O O 0.9999339580535889
pupillary O O 0.9999758005142212
oscillation O O 0.9997963309288025
, O O 0.999972939491272
were O O 0.9999618530273438
dramatically O O 0.9999935626983643
different O O 0.9999879598617554
than O O 0.9999849796295166
those O O 0.999990701675415
observed O O 0.9999908208847046
in O O 0.9999432563781738
the O O 0.9999899864196777
eight O O 0.9999587535858154
other O O 0.999985933303833
study O O 0.9999822378158569
subjects O O 0.999996542930603
who O O 0.9999629259109497
did O O 0.9999872446060181
not O O 0.99998939037323
become O O 0.9999871253967285
manic O O 0.999984622001648
. O O 0.9999678134918213

The O O 0.9999847412109375
large O O 0.9999834299087524
changes O O 0.9999914169311523
in O O 0.9999837875366211
total O O 0.9982419013977051
power O O 0.9999779462814331
of O O 0.9998482465744019
pupillary O O 0.9999809265136719
oscillation O O 0.9993501305580139
occurred O O 0.9999810457229614
a O O 0.9999877214431763
few O O 0.9999910593032837
days O O 0.999991774559021
before O O 0.9999876022338867
the O O 0.9999908208847046
patient O O 0.9999860525131226
became O O 0.9999793767929077
fully O O 0.9999767541885376
manic O O 0.9999872446060181
. O O 0.9999617338180542

Such O O 0.9998965263366699
medication O O 0.9991055130958557
- O O 0.9999468326568604
associated O O 0.9999314546585083
changes O O 0.9999940395355225
in O O 0.9999852180480957
the O O 0.9999679327011108
total O O 0.9989486336708069
power O O 0.999984860420227
of O O 0.9998961687088013
pupillary O O 0.9999622106552124
oscillation O O 0.9996017813682556
might O O 0.9999572038650513
be O O 0.999991774559021
of O O 0.9999749660491943
utility O O 0.9999926090240479
in O O 0.9999902248382568
identifying O O 0.9999850988388062
persons O O 0.9999955892562866
at O O 0.999961256980896
risk O O 0.9999939203262329
for O O 0.9999449253082275
manic O O 0.9997811913490295
- O O 0.9999611377716064
like O O 0.9999790191650391
adverse O O 0.9999444484710693
effects O O 0.9999945163726807
during O O 0.9998912811279297
the O O 0.9999568462371826
medical O O 0.9999758005142212
use O O 0.999941349029541
of O O 0.9997633099555969
psychomotor O O 0.9959024786949158
stimulants O O 0.9159258604049683
or O O 0.9994338154792786
sympathomimetic O O 0.993988037109375
agents O O 0.9964685440063477
. O O 0.9999587535858154

Fetal O O 0.9993141889572144
risks O O 0.9999823570251465
due O O 0.9999885559082031
to O O 0.9993807077407837
warfarin B B 0.9992882609367371
therapy O O 0.9963300824165344
during O O 0.9999496936798096
pregnancy O O 0.9999974966049194
. O O 0.9999634027481079

Two O O 0.9967717528343201
mothers O O 0.9998586177825928
with O O 0.9999626874923706
heart O O 0.996016800403595
valve O O 0.9999401569366455
prosthesis O O 0.9998921155929565
were O O 0.9999593496322632
treated O O 0.9999390840530396
with O O 0.9994400143623352
warfarin B B 0.9985041618347168
during O O 0.9993255138397217
pregnancy O O 0.9999961853027344
. O O 0.9999676942825317

In O O 0.9999849796295166
the O O 0.9999973773956299
first O O 0.9999974966049194
case O O 0.9999946355819702
a O O 0.9999957084655762
caesarean O O 0.9995459914207458
section O O 0.999981164932251
was O O 0.9999877214431763
done O O 0.9999980926513672
one O O 0.9999943971633911
week O O 0.9999991655349731
after O O 0.9999665021896362
replacement O O 0.9997724890708923
of O O 0.9990139007568359
warfarin B B 0.9984618425369263
with O O 0.988004207611084
heparin B B 0.9962078332901001
. O O 0.999935507774353

The O O 0.9999887943267822
baby O O 0.9999959468841553
died O O 0.999983549118042
of O O 0.9998276233673096
cerebral O O 0.9999661445617676
and O O 0.999916672706604
pulmonary O O 0.9999396800994873
hemorrhage O O 0.9999179840087891
. O O 0.999948263168335

The O O 0.9999873638153076
second O O 0.9999967813491821
mother O O 0.9999969005584717
had O O 0.9999963045120239
a O O 0.9999945163726807
male O O 0.9999947547912598
infant O O 0.999997615814209
by O O 0.9999821186065674
caesarean O O 0.9980328679084778
section O O 0.9995966553688049
. O O 0.9999659061431885

The O O 0.9999923706054688
baby O O 0.9999967813491821
showed O O 0.9999454021453857
warfarin B B 0.9997100234031677
- O O 0.9995120763778687
induced O O 0.9999580383300781
embryopathy O O 0.9999897480010986
with O O 0.999976634979248
nasal O O 0.999630331993103
hypoplasia O O 0.9988148212432861
and O O 0.9999266862869263
stippled O O 0.9499459862709045
epiphyses O O 0.9907943606376648
( O O 0.9998077750205994
chondrodysplasia O O 0.9954987168312073
punctata O O 0.9981414079666138
) O O 0.9999597072601318
. O O 0.999977707862854

Nasal O O 0.9997426867485046
hypoplasia O O 0.9995077848434448
with O O 0.9999397993087769
or O O 0.9999581575393677
without O O 0.9999608993530273
stippled O O 0.9557462930679321
epiphyses O O 0.9941654205322266
has O O 0.9999872446060181
now O O 0.999995231628418
been O O 0.9999964237213135
reported O O 0.9999958276748657
in O O 0.9999722242355347
11 O O 0.9999657869338989
infants O O 0.9999986886978149
born O O 0.9999955892562866
to O O 0.9998044371604919
mothers O O 0.9999752044677734
treated O O 0.9999105930328369
with O O 0.9992308616638184
warfarin B B 0.9987105131149292
during O O 0.999573290348053
the O O 0.9999945163726807
first O O 0.9999977350234985
trimester O O 0.9999974966049194
, O O 0.9999746084213257
and O O 0.9999850988388062
a O O 0.9999946355819702
causal O O 0.9999940395355225
association O O 0.9999970197677612
is O O 0.9999901056289673
probable O O 0.9999929666519165
. O O 0.9999880790710449

In O O 0.9999878406524658
view O O 0.9999948740005493
of O O 0.9999861717224121
the O O 0.9999880790710449
risks O O 0.9999926090240479
to O O 0.9999709129333496
both O O 0.9999068975448608
mother O O 0.9999940395355225
and O O 0.999944806098938
fetus O O 0.9999947547912598
in O O 0.9999622106552124
women O O 0.9999970197677612
with O O 0.9999818801879883
prosthetic O O 0.9998842477798462
cardiac O O 0.9997426867485046
valves O O 0.9999816417694092
it O O 0.9999886751174927
is O O 0.9999853372573853
recommended O O 0.9999972581863403
that O O 0.9999746084213257
therapeutic O O 0.9999327659606934
abortion O O 0.9216539859771729
be O O 0.999977707862854
advised O O 0.9999717473983765
as O O 0.9999686479568481
the O O 0.999984860420227
first O O 0.9999877214431763
alternative O O 0.9999904632568359
. O O 0.9999806880950928

The O O 0.9994413256645203
negative O O 0.9998726844787598
mucosal O O 0.9998793601989746
potential O O 0.9999514818191528
: O O 0.9996497631072998
separating O O 0.9928633570671082
central O O 0.9995231628417969
and O O 0.9997156262397766
peripheral O O 0.9998055100440979
effects O O 0.999930739402771
of O O 0.9997757077217102
NSAIDs O O 0.8073257803916931
in O O 0.9995656609535217
man O O 0.999913215637207
. O O 0.9999251365661621

OBJECTIVE O O 0.9999395608901978
: O O 0.9999967813491821
We O O 0.9999868869781494
wanted O O 0.9999972581863403
to O O 0.9999969005584717
test O O 0.9999945163726807
whether O O 0.9999884366989136
assessment O O 0.99997878074646
of O O 0.9999493360519409
both O O 0.9998881816864014
a O O 0.999903678894043
central O O 0.9998849630355835
pain O O 0.9874308109283447
- O O 0.9998800754547119
related O O 0.9998944997787476
signal O O 0.9999626874923706
( O O 0.999750554561615
chemo O O 0.9565821886062622
- O O 0.9973704814910889
somatosensory O O 0.9780141115188599
evoked O O 0.9993802309036255
potential O O 0.9999967813491821
, O O 0.9999339580535889
CSSEP O O 0.8788498044013977
) O O 0.9999346733093262
and O O 0.9998835325241089
a O O 0.9998769760131836
concomitantly O O 0.9999223947525024
recorded O O 0.9999650716781616
peripheral O O 0.9998732805252075
signal O O 0.9999678134918213
( O O 0.9998965263366699
negative O O 0.9997221827507019
mucosal O O 0.9999381303787231
potential O O 0.9999964237213135
, O O 0.9999128580093384
NMP O O 0.9620817303657532
) O O 0.9999713897705078
allows O O 0.9999698400497437
for O O 0.999982476234436
separation O O 0.9999833106994629
of O O 0.9999464750289917
central O O 0.9995724558830261
and O O 0.9998145699501038
peripheral O O 0.999839186668396
effects O O 0.9999818801879883
of O O 0.9996846914291382
NSAIDs O O 0.7786140441894531
. O O 0.999925971031189

For O O 0.9999386072158813
this O O 0.999975323677063
purpose O O 0.999991774559021
, O O 0.9999558925628662
experimental O O 0.999948263168335
conditions O O 0.9999915361404419
were O O 0.9999862909317017
created O O 0.9999948740005493
in O O 0.9999526739120483
which O O 0.9999558925628662
NSAIDs O O 0.7911372184753418
had O O 0.9999396800994873
previously O O 0.9999263286590576
been O O 0.9999837875366211
observed O O 0.9999799728393555
to O O 0.9999594688415527
produce O O 0.9999654293060303
effects O O 0.9999592304229736
on O O 0.9999258518218994
phasic O O 0.997565746307373
and O O 0.9997815489768982
tonic O O 0.9999481439590454
pain O O 0.999976634979248
by O O 0.9998849630355835
either O O 0.9998817443847656
central O O 0.999889612197876
or O O 0.9998959302902222
peripheral O O 0.9998188614845276
mechanisms O O 0.9999067783355713
. O O 0.9999794960021973

METHODS O O 0.9999841451644897
: O O 0.9999946355819702
According O O 0.9999986886978149
to O O 0.9999949932098389
a O O 0.9999945163726807
double O O 0.9999600648880005
- O O 0.9999716281890869
blind O O 0.9999953508377075
, O O 0.9999716281890869
randomised O O 0.9999905824661255
, O O 0.9999659061431885
controlled O O 0.9999806880950928
, O O 0.9999889135360718
threefold O O 0.999950647354126
cross O O 0.9999867677688599
- O O 0.9999827146530151
over O O 0.9999626874923706
design O O 0.9999934434890747
, O O 0.9999852180480957
18 O O 0.9999936819076538
healthy O O 0.9999942779541016
subjects O O 0.9999970197677612
( O O 0.9999746084213257
11 O O 0.9999027252197266
males O O 0.9999476671218872
, O O 0.999954104423523
7 O O 0.9999121427536011
females O O 0.9999657869338989
; O O 0.9999923706054688
mean O O 0.9999972581863403
age O O 0.9999984502792358
26 O O 0.9999979734420776
years O O 0.9999992847442627
) O O 0.9999891519546509
received O O 0.9999768733978271
either O O 0.9999417066574097
placebo O O 0.9998722076416016
, O O 0.9997518658638
400 O O 0.9975094795227051
mg O O 0.9996592998504639
ibuprofen B B 0.9392254948616028
, O O 0.9937061667442322
or O O 0.9997656941413879
800 O O 0.991658627986908
mg O O 0.9998213648796082
ibuprofen B B 0.9434195160865784
. O O 0.9998970031738281

Phasic O O 0.9989339709281921
pain O O 0.9999572038650513
was O O 0.9999535083770752
applied O O 0.9999772310256958
by O O 0.9999804496765137
means O O 0.9999901056289673
of O O 0.9999613761901855
short O O 0.9998774528503418
pulses O O 0.9994274377822876
of O O 0.9907165169715881
CO2 B B 0.9357073307037354
to O O 0.9994609951972961
the O O 0.9999860525131226
nasal O O 0.9999721050262451
mucosa O O 0.9999967813491821
( O O 0.9999215602874756
stimulus O O 0.9999498128890991
duration O O 0.9999867677688599
500 O O 0.9999797344207764
ms O O 0.9999974966049194
, O O 0.9999802112579346
interval O O 0.9999974966049194
approximately O O 0.9999977350234985
60 O O 0.9999946355819702
s O O 0.9999810457229614
) O O 0.9999853372573853
, O O 0.9999548196792603
and O O 0.9998793601989746
tonic O O 0.9999321699142456
pain O O 0.9999467134475708
was O O 0.999964714050293
induced O O 0.9999904632568359
in O O 0.999909520149231
the O O 0.9999823570251465
nasal O O 0.9999380111694336
cavity O O 0.999996542930603
by O O 0.9999867677688599
means O O 0.9999867677688599
of O O 0.9999788999557495
dry O O 0.9999533891677856
air O O 0.9998086094856262
of O O 0.999915361404419
controlled O O 0.9999351501464844
temperature O O 0.9999810457229614
, O O 0.9999620914459229
humidity O O 0.9997881054878235
and O O 0.9999539852142334
flow O O 0.9998583793640137
rate O O 0.9999457597732544
( O O 0.9999707937240601
22 O O 0.9999755620956421
degrees O O 0.9999855756759644
C O O 0.9966704249382019
, O O 0.9999513626098633
0 O O 0.9999682903289795
% O O 0.9999315738677979
relative O O 0.9997912049293518
humidity O O 0.9417484402656555
, O O 0.999921441078186
145 O O 0.9999833106994629
ml O O 0.9999985694885254
. O O 0.9999873638153076
s O O 0.997794508934021
- O O 0.9983775615692139
1 O O 0.9997257590293884
) O O 0.9999788999557495
. O O 0.9999754428863525

Both O O 0.9996009469032288
CSSEPs O O 0.8299509286880493
as O O 0.9997076392173767
central O O 0.9998188614845276
and O O 0.9995260238647461
NMPs O O 0.6221835017204285
as O O 0.9997221827507019
peripheral O O 0.9996731281280518
correlates O O 0.9999521970748901
of O O 0.9999634027481079
pain O O 0.9999184608459473
were O O 0.9999606609344482
obtained O O 0.9999781847000122
in O O 0.9999740123748779
response O O 0.999982476234436
to O O 0.999944806098938
the O O 0.9999306201934814
CO2 B B 0.8804560303688049
stimuli O O 0.9995317459106445
. O O 0.9999622106552124

Additionally O O 0.9999691247940063
, O O 0.9999667406082153
the O O 0.9999703168869019
subjects O O 0.9999901056289673
rated O O 0.9999911785125732
the O O 0.9999872446060181
intensity O O 0.9999868869781494
of O O 0.9999797344207764
both O O 0.9997215867042542
phasic O O 0.9964019060134888
and O O 0.9997708201408386
tonic O O 0.9999269247055054
pain O O 0.9999504089355469
by O O 0.9999855756759644
means O O 0.9999959468841553
of O O 0.9999916553497314
visual O O 0.9999755620956421
analogue O O 0.9999926090240479
scales O O 0.9999420642852783
. O O 0.9999638795852661

RESULTS O O 0.9999300241470337
: O O 0.9999473094940186
As O O 0.999997615814209
described O O 0.9999982118606567
earlier O O 0.999996542930603
, O O 0.9999469518661499
administration O O 0.9999508857727051
of O O 0.999729335308075
ibuprofen B B 0.9901115298271179
was O O 0.9998898506164551
followed O O 0.9999713897705078
by O O 0.9999620914459229
a O O 0.9999756813049316
decrease O O 0.9999933242797852
in O O 0.9999855756759644
tonic O O 0.9999877214431763
pain O O 0.999990701675415
but O O 0.9998561143875122
- O O 0.9999830722808838
relative O O 0.9999945163726807
to O O 0.9999171495437622
placebo O O 0.999915361404419
- O O 0.9999761581420898
an O O 0.9999856948852539
increase O O 0.9999822378158569
in O O 0.9999626874923706
correlates O O 0.9996683597564697
of O O 0.9999561309814453
phasic O O 0.9992040991783142
pain O O 0.9999784231185913
, O O 0.9999876022338867
indicating O O 0.9998661279678345
a O O 0.9999333620071411
specific O O 0.9999337196350098
effect O O 0.9999740123748779
of O O 0.9998449087142944
ibuprofen B B 0.9862136244773865
on O O 0.999347984790802
the O O 0.9999706745147705
interaction O O 0.9999868869781494
between O O 0.999826967716217
the O O 0.999920129776001
pain O O 0.9993477463722229
stimuli O O 0.9999293088912964
under O O 0.999895453453064
these O O 0.999925971031189
special O O 0.9998304843902588
experimental O O 0.9999898672103882
conditions O O 0.99998939037323
. O O 0.9999725818634033

Based O O 0.999992847442627
on O O 0.9999896287918091
the O O 0.9999932050704956
similar O O 0.9999496936798096
behaviour O O 0.9999796152114868
of O O 0.9994483590126038
CSSEP O O 0.6924680471420288
and O O 0.9920627474784851
NMP O O 0.7150972485542297
, O O 0.9998661279678345
it O O 0.9999877214431763
was O O 0.9999676942825317
concluded O O 0.999983549118042
that O O 0.9999303817749023
the O O 0.9999043941497803
pharmacological O O 0.9996175765991211
process O O 0.9999483823776245
underlying O O 0.9999673366546631
this O O 0.9999680519104004
phenomenon O O 0.9999942779541016
was O O 0.9999076128005981
localised O O 0.9999346733093262
in O O 0.9998449087142944
the O O 0.9998655319213867
periphery O O 0.9999698400497437
. O O 0.9999655485153198

By O O 0.9999874830245972
means O O 0.9999943971633911
of O O 0.9999936819076538
the O O 0.9999916553497314
simultaneous O O 0.9999665021896362
recording O O 0.9999878406524658
of O O 0.9999206066131592
interrelated O O 0.9992722868919373
peripheral O O 0.9997803568840027
and O O 0.9997462630271912
central O O 0.9998317956924438
electrophysiologic O O 0.9999258518218994
correlates O O 0.9999573230743408
of O O 0.9998612403869629
nociception O O 0.962572455406189
, O O 0.999962568283081
it O O 0.999990701675415
was O O 0.9999827146530151
possible O O 0.9999947547912598
to O O 0.9999916553497314
separate O O 0.9996957778930664
central O O 0.9997530579566956
and O O 0.9998154044151306
peripheral O O 0.9997832179069519
effects O O 0.9999758005142212
of O O 0.9994753003120422
an O O 0.8949469327926636
NSAID O O 0.7873592376708984
. O O 0.9998766183853149

The O O 0.9999819993972778
major O O 0.999988317489624
advantage O O 0.9999898672103882
of O O 0.9999710321426392
this O O 0.9999465942382812
pain O O 0.9998086094856262
model O O 0.9999810457229614
is O O 0.9999885559082031
the O O 0.9999959468841553
possibility O O 0.9999979734420776
of O O 0.9999939203262329
obtaining O O 0.9999785423278809
peripheral O O 0.9999531507492065
pain O O 0.992764413356781
- O O 0.9998918771743774
related O O 0.9999490976333618
activity O O 0.9999814033508301
directly O O 0.9999951124191284
using O O 0.9999610185623169
a O O 0.9999845027923584
non O O 0.9999226331710815
- O O 0.9999707937240601
invasive O O 0.999967098236084
technique O O 0.9999947547912598
in O O 0.9999445676803589
humans O O 0.9970537424087524
. O O 0.9999667406082153

Effect O O 0.9997373223304749
of O O 0.9980553388595581
D B B 0.8738369941711426
- I I 0.967316210269928
Glucarates I I 0.9994563460350037
on O O 0.9989564418792725
basic O O 0.9991512298583984
antibiotic O O 0.5911580920219421
- O O 0.9997742772102356
induced O O 0.9999533891677856
renal O O 0.9999812841415405
damage O O 0.9999960660934448
in O O 0.9999415874481201
rats O O 0.9999738931655884
. O O 0.9999239444732666

Dehydrated O O 0.9990975856781006
rats O O 0.999671459197998
regularly O O 0.9999606609344482
develop O O 0.9999892711639404
acute O O 0.9999889135360718
renal O O 0.9999901056289673
failure O O 0.999996542930603
following O O 0.999962568283081
single O O 0.9997667670249939
injection O O 0.9999477863311768
of O O 0.9997594952583313
aminoglycoside B B 0.949324905872345
antibiotics O O 0.5965802669525146
combined O O 0.9995538592338562
with O O 0.9994493126869202
dextran O B 0.9987490177154541
or O O 0.9984017014503479
of O O 0.9983590245246887
antibiotics O O 0.8359535932540894
only O O 0.9996269941329956
. O O 0.9999692440032959

Oral O O 0.9995470643043518
administration O O 0.9999420642852783
of O O 0.9993425011634827
2 B B 0.9536333084106445
, I I 0.9940797090530396
5 I I 0.9732587933540344
- I I 0.9940800070762634
di I I 0.9892120361328125
- I I 0.9763500094413757
O I I 0.984622061252594
- I I 0.9891588091850281
acetyl I I 0.9992233514785767
- I I 0.9580358862876892
D I I 0.9948866963386536
- I I 0.9885405898094177
glucaro I I 0.9996299743652344
- I I 0.9866036176681519
1 I I 0.8979166150093079
, I I 0.9800570011138916
4 I I 0.9903566241264343
- I I 0.9824665784835815
6 I I 0.9953759908676147
, I I 0.995537519454956
3 I I 0.9757966995239258
- I I 0.994979202747345
dilactone I I 0.9989093542098999
protected O O 0.9725937843322754
rats O O 0.9767218828201294
against O O 0.9993355870246887
renal O O 0.9999147653579712
failure O O 0.999987006187439
induced O O 0.9999662637710571
by O O 0.9998809099197388
kanamycin B B 0.9993844032287598
- O I 0.897663414478302
dextran O I 0.9996359348297119
. O O 0.9991177916526794

The O O 0.9998125433921814
protective O O 0.9989596605300903
effect O O 0.9998428821563721
was O O 0.9998981952667236
prevalent O O 0.9999196529388428
among O O 0.9935256242752075
D B B 0.5363410115242004
- I I 0.7874584794044495
glucarates I I 0.9956507086753845
, O O 0.9978797435760498
and O O 0.9998462200164795
also O O 0.9999008178710938
to O O 0.9996713399887085
other O O 0.9872300028800964
saccharic B B 0.7746739387512207
acid I I 0.9981645941734314
, O O 0.7510334849357605
hexauronic B B 0.8524048328399658
acids I I 0.997326135635376
and O O 0.968485951423645
hexaaldonic B B 0.8616890907287598
acids I I 0.9975213408470154
, O O 0.9995463490486145
although O O 0.9999918937683105
to O O 0.9999855756759644
a O O 0.9999805688858032
lesser O O 0.9999617338180542
degree O O 0.9999836683273315
, O O 0.9999873638153076
but O O 0.9999887943267822
not O O 0.9999732971191406
to O O 0.9996389150619507
a O O 0.6654802560806274
hexaaldose O O 0.7014776468276978
, O O 0.994297206401825
sugar B O 0.5897965431213379
alcohols I O 0.6677418351173401
, O O 0.9805582165718079
substances O O 0.9920541048049927
inthe O O 0.9993076324462891
TCA B O 0.8908250331878662
cycle O O 0.9759387969970703
and O O 0.9998593330383301
other O O 0.9993311166763306
acidic O O 0.900175929069519
compounds O O 0.9923237562179565
. O O 0.9999380111694336

D B B 0.7575784921646118
- I I 0.9416298866271973
Glucarates I I 0.9990655779838562
were O O 0.9989731311798096
effective O O 0.9995195865631104
against O O 0.9991284012794495
renal O O 0.9999269247055054
damage O O 0.9999891519546509
induced O O 0.9999589920043945
by O O 0.99982750415802
peptide O O 0.6699251532554626
antibiotics O O 0.555446445941925
as O O 0.9999345541000366
well O O 0.9998756647109985
as O O 0.9998949766159058
various O O 0.9989110231399536
aminoglycoside B B 0.8341817259788513
antibitocis O O 0.6096813678741455
. O O 0.99985671043396

Dose O O 0.7936903238296509
- O O 0.9996650218963623
responses O O 0.999975323677063
were O O 0.9999439716339111
observed O O 0.9999867677688599
in O O 0.999914288520813
the O O 0.999886155128479
protective O O 0.9978649020195007
effect O O 0.9998844861984253
of O O 0.9991014003753662
D B B 0.8491055965423584
- I I 0.9678537249565125
Glucarates I I 0.9991447925567627
. O O 0.9997410178184509

With O O 0.9998990297317505
a O O 0.9975778460502625
D B B 0.5493507981300354
- I I 0.7969246506690979
glucarate I I 0.9986698627471924
of O O 0.9993504881858826
a O O 0.9999796152114868
fixed O O 0.9999785423278809
size O O 0.9999963045120239
of O O 0.9999042749404907
dose O O 0.9988211989402771
, O O 0.9999638795852661
approximately O O 0.9999920129776001
the O O 0.999995231628418
same O O 0.9999724626541138
degree O O 0.9999881982803345
of O O 0.9999803304672241
protection O O 0.9999794960021973
was O O 0.9999841451644897
obtained O O 0.9999923706054688
against O O 0.9997287392616272
renal O O 0.9999496936798096
damages O O 0.9999375343322754
induced O O 0.9999798536300659
by O O 0.9999397993087769
different O O 0.9999402761459351
basic O O 0.9860213398933411
antibiotics O O 0.9703242182731628
despite O O 0.9999557733535767
large O O 0.9999909400939941
disparities O O 0.9999984502792358
in O O 0.999995231628418
administration O O 0.9999457597732544
doses O O 0.9999805688858032
of O O 0.9999301433563232
different O O 0.9998583793640137
antibiotics O O 0.8848021030426025
. O O 0.9999003410339355

D B B 0.8797444701194763
- I I 0.9834596514701843
Glucarates I I 0.9973645806312561
had O O 0.9995810389518738
the O O 0.9999562501907349
ability O O 0.9999659061431885
to O O 0.9999607801437378
prevent O O 0.9998431205749512
renal O O 0.9996902942657471
damage O O 0.999987006187439
but O O 0.9999728202819824
not O O 0.9999860525131226
to O O 0.9999816417694092
cure O O 0.9999639987945557
it O O 0.9999856948852539
. O O 0.99989914894104

Rats O O 0.9983171224594116
excreted O O 0.9998929500579834
acidic O O 0.9911285638809204
urine O O 0.9589818120002747
when O O 0.9994997978210449
they O O 0.9996366500854492
were O O 0.9999322891235352
spared O O 0.9998173117637634
from O O 0.9997610449790955
renal O O 0.999218225479126
lesions O O 0.9999932050704956
by O O 0.9998339414596558
monosaccharides B O 0.5048887729644775
. O O 0.9998019337654114

The O O 0.9999254941940308
reduction O O 0.9995917677879333
effect O O 0.9999024868011475
of O O 0.9994496703147888
D B B 0.8433408737182617
- I I 0.9555091857910156
glucarates I I 0.9994338154792786
against O O 0.9961851239204407
nephrotoxicity O O 0.9998039603233337
of O O 0.9991351962089539
basic O O 0.9814223051071167
antibiotics O O 0.9231874346733093
was O O 0.9999610185623169
discussed O O 0.9999662637710571
. O O 0.9999690055847168

Acute O O 0.999935507774353
severe O O 0.9999140501022339
depression O O 0.9999860525131226
following O O 0.9998975992202759
peri O O 0.9998502731323242
- O O 0.9999164342880249
operative O O 0.9999666213989258
ondansetron B B 0.9997621178627014
. O O 0.9999309778213501

A O O 0.9999825954437256
41 O O 0.9999936819076538
- O O 0.9999877214431763
year O O 0.9999974966049194
- O O 0.9999949932098389
old O O 0.9999916553497314
woman O O 0.9999969005584717
with O O 0.9999523162841797
a O O 0.9999852180480957
strong O O 0.9999834299087524
history O O 0.999991774559021
of O O 0.9999706745147705
postoperative O O 0.999862551689148
nausea O O 0.9999841451644897
and O O 0.9999550580978394
vomiting O O 0.9998955726623535
presented O O 0.9999790191650391
for O O 0.9999724626541138
abdominal O O 0.9999597072601318
hysterectomy O O 0.9977286458015442
3 O O 0.9998899698257446
months O O 0.9999985694885254
after O O 0.9999884366989136
a O O 0.9999837875366211
previous O O 0.9999046325683594
anaesthetic O O 0.9996080994606018
where O O 0.9984729886054993
ondansetron B B 0.9998270869255066
prophylaxis O O 0.553870439529419
had O O 0.9999657869338989
been O O 0.9999679327011108
used O O 0.9997754693031311
. O O 0.9999542236328125

She O O 0.9999343156814575
had O O 0.9999665021896362
developed O O 0.9999878406524658
a O O 0.99996018409729
severe O O 0.9999713897705078
acute O O 0.9999639987945557
major O O 0.9984195232391357
depression O O 0.9965620636940002
disorder O O 0.9999849796295166
almost O O 0.9999755620956421
immediately O O 0.9999929666519165
thereafter O O 0.9999936819076538
, O O 0.9999760389328003
possibly O O 0.9999735355377197
related O O 0.9999885559082031
to O O 0.999832272529602
the O O 0.9999436140060425
use O O 0.9998379945755005
of O O 0.9998196959495544
a O O 0.9988579750061035
serotonin B O 0.8126407265663147
antagonist O O 0.6248645782470703
. O O 0.9998806715011597

Nine O O 0.9999715089797974
years O O 0.999992847442627
before O O 0.9999942779541016
she O O 0.9999831914901733
had O O 0.9999871253967285
experienced O O 0.999991774559021
a O O 0.9999864101409912
self O O 0.9997385144233704
- O O 0.9999830722808838
limited O O 0.999976634979248
puerperal O O 0.9801802635192871
depressive O O 0.9966701865196228
episode O O 0.9999533891677856
. O O 0.999950647354126

Anaesthesia O O 0.9995984435081482
with O O 0.999937891960144
a O O 0.9998815059661865
propofol B B 0.9989431500434875
infusion O O 0.997621476650238
and O O 0.9999425411224365
avoidance O O 0.9995844960212708
of O O 0.9996167421340942
serotonin B O 0.8353341817855835
antagonists O O 0.5722509026527405
provided O O 0.9999234676361084
a O O 0.9999872446060181
nausea O O 0.9745668768882751
- O O 0.9999735355377197
free O O 0.9999747276306152
postoperative O O 0.9999855756759644
course O O 0.999994158744812
without O O 0.999969482421875
exacerbation O O 0.9999850988388062
of O O 0.9999741315841675
the O O 0.9999713897705078
depression O O 0.9996142387390137
disorder O O 0.9999933242797852
. O O 0.9999716281890869

Hypertensive O O 0.9984070658683777
response O O 0.9999207258224487
during O O 0.9998619556427002
dobutamine B B 0.9994366765022278
stress O O 0.9996199607849121
echocardiography O O 0.9999383687973022
. O O 0.9999533891677856

Among O O 0.9995762705802917
3 O O 0.988444447517395
, O O 0.9988517761230469
129 O O 0.9924793243408203
dobutamine B B 0.9960994720458984
stress O O 0.9994426369667053
echocardiographic O O 0.9998476505279541
studies O O 0.9999780654907227
, O O 0.9999666213989258
a O O 0.999964714050293
hypertensive O O 0.999627947807312
response O O 0.9999868869781494
, O O 0.9999912977218628
defined O O 0.9999891519546509
as O O 0.9999799728393555
systolic O O 0.999524712562561
blood O O 0.9999184608459473
pressure O O 0.9999344348907471
( O O 0.9998934268951416
BP O O 0.9727204442024231
) O O 0.9999678134918213
> O O 0.9999641180038452
or O O 0.9999898672103882
= O O 0.9999960660934448
220 O O 0.999998927116394
mm O O 0.9999977350234985
Hg O O 0.7101340889930725
and O O 0.9999344348907471
/ O O 0.9999768733978271
or O O 0.9999808073043823
diastolic O O 0.999864935874939
BP O O 0.9167406558990479
> O O 0.9999560117721558
or O O 0.999993085861206
= O O 0.9999942779541016
110 O O 0.9999967813491821
mm O O 0.9999980926513672
Hg O O 0.9346405267715454
, O O 0.9999885559082031
occurred O O 0.9999932050704956
in O O 0.9999885559082031
30 O O 0.9999754428863525
patients O O 0.9999954700469971
( O O 0.9999772310256958
1 O O 0.999988317489624
% O O 0.9999957084655762
) O O 0.9999735355377197
. O O 0.9999673366546631

Patients O O 0.9999666213989258
with O O 0.9999340772628784
this O O 0.9998185038566589
response O O 0.9999630451202393
more O O 0.9999340772628784
often O O 0.9999798536300659
had O O 0.9999855756759644
a O O 0.9999735355377197
history O O 0.9999895095825195
of O O 0.9999479055404663
hypertension O O 0.9982576966285706
and O O 0.9999788999557495
had O O 0.999984860420227
higher O O 0.9999129772186279
resting O O 0.9999761581420898
systolic O O 0.9977732300758362
and O O 0.9998952150344849
diastolic O O 0.9997866749763489
BP O O 0.9532846212387085
before O O 0.9997546076774597
dobutamine B B 0.9998637437820435
infusion O O 0.999828577041626
. O O 0.9999644756317139

Continuously O O 0.9869502186775208
nebulized O O 0.8025426864624023
albuterol B B 0.9911932349205017
in O O 0.9998570680618286
severe O O 0.9998610019683838
exacerbations O O 0.9999690055847168
of O O 0.9999417066574097
asthma O O 0.9905101656913757
in O O 0.9999114274978638
adults O O 0.9999682903289795
: O O 0.999991774559021
a O O 0.9999920129776001
case O O 0.999967098236084
- O O 0.9999918937683105
controlled O O 0.9999954700469971
study O O 0.9999963045120239
. O O 0.99998939037323

A O O 0.9999698400497437
retrospective O O 0.9999834299087524
, O O 0.9999722242355347
case O O 0.9998354911804199
- O O 0.9999752044677734
controlled O O 0.9999921321868896
analysis O O 0.9999910593032837
comparing O O 0.9999521970748901
patients O O 0.9999871253967285
admitted O O 0.9999665021896362
to O O 0.9999606609344482
a O O 0.9999823570251465
medical O O 0.9999914169311523
intensive O O 0.9999961853027344
care O O 0.9999969005584717
unit O O 0.999997615814209
with O O 0.9999833106994629
severe O O 0.9999489784240723
exacerbations O O 0.9999852180480957
of O O 0.9999679327011108
asthma O O 0.9914538860321045
who O O 0.9999486207962036
received O O 0.9999159574508667
continuously O O 0.9994722008705139
nebulized O O 0.6158709526062012
albuterol B B 0.9856287240982056
( O O 0.9953064322471619
CNA O O 0.6102302074432373
) O O 0.9981794357299805
versus O O 0.9996771812438965
intermittent O O 0.9991463422775269
albuterol B B 0.9899097681045532
( O O 0.9974417686462402
INA O B 0.9860143661499023
) O O 0.9990035891532898
treatments O O 0.9999009370803833
is O O 0.9999794960021973
reported O O 0.9999959468841553
. O O 0.9999871253967285

Forty O O 0.9992480874061584
matched O O 0.9999642372131348
pairs O O 0.9999752044677734
of O O 0.9999752044677734
patients O O 0.9999880790710449
with O O 0.9999771118164062
asthma O O 0.995345413684845
are O O 0.9999433755874634
compared O O 0.9999569654464722
. O O 0.9999649524688721

CNA O B 0.929770290851593
was O O 0.9998452663421631
administered O O 0.9998831748962402
for O O 0.9999523162841797
a O O 0.9999796152114868
mean O O 0.999968409538269
of O O 0.9999804496765137
11 O O 0.9999758005142212
+ O O 0.9999945163726807
/ O O 0.9999918937683105
- O O 0.9999736547470093
10 O O 0.9999902248382568
hr O O 0.9962499737739563
. O O 0.9999673366546631

The O O 0.9999772310256958
incidence O O 0.9999954700469971
of O O 0.9999762773513794
cardiac O O 0.9999765157699585
dysrhythmias O O 0.9999963045120239
was O O 0.9999589920043945
similar O O 0.9999830722808838
between O O 0.9997643828392029
groups O O 0.9999788999557495
. O O 0.9999750852584839

Symptomatic O O 0.9999512434005737
hypokalemia O O 0.9998916387557983
did O O 0.9999579191207886
not O O 0.9999712705612183
occur O O 0.9999926090240479
. O O 0.9999552965164185

CNA O O 0.6393243670463562
patients O O 0.9998863935470581
had O O 0.9999767541885376
higher O O 0.9999779462814331
heart O O 0.9999852180480957
rates O O 0.9999912977218628
during O O 0.9997144341468811
treatment O O 0.9999434947967529
, O O 0.9999762773513794
which O O 0.9999682903289795
may O O 0.9999333620071411
reflect O O 0.9999797344207764
severity O O 0.9999898672103882
of O O 0.9999681711196899
illness O O 0.9999910593032837
. O O 0.9999737739562988

The O O 0.9999852180480957
incidence O O 0.9999963045120239
of O O 0.9999711513519287
intubation O O 0.9999735355377197
was O O 0.9999716281890869
similar O O 0.9999897480010986
. O O 0.9999719858169556

We O O 0.9999558925628662
conclude O O 0.999908447265625
that O O 0.9996089339256287
CNA O O 0.6983166337013245
and O O 0.9983152151107788
INA O O 0.5260921120643616
demonstrated O O 0.9998427629470825
similar O O 0.9998939037322998
profiles O O 0.9999669790267944
with O O 0.999990701675415
regard O O 0.9999964237213135
to O O 0.9999847412109375
safety O O 0.9999957084655762
, O O 0.9999866485595703
morbidity O O 0.9999967813491821
, O O 0.9999604225158691
and O O 0.9999841451644897
mortality O O 0.9999949932098389
. O O 0.9999634027481079

Paraplegia O O 0.99928218126297
following O O 0.9995537400245667
intrathecal O O 0.9744542837142944
methotrexate B B 0.999728262424469
: O O 0.9999324083328247
report O O 0.9999990463256836
of O O 0.9999934434890747
a O O 0.9999954700469971
case O O 0.999984860420227
and O O 0.9999880790710449
review O O 0.9999947547912598
of O O 0.999994158744812
the O O 0.9999966621398926
literature O O 0.9999921321868896
. O O 0.9999651908874512

A O O 0.9999456405639648
patient O O 0.9999806880950928
who O O 0.9999217987060547
developed O O 0.9999814033508301
paraplegia O O 0.9997594952583313
following O O 0.9999440908432007
the O O 0.9999715089797974
intrathecal O O 0.9999696016311646
instillation O O 0.9999791383743286
of O O 0.9927392601966858
methotrexate B B 0.9996738433837891
is O O 0.9998348951339722
discribed O O 0.9999589920043945
. O O 0.9999809265136719

The O O 0.9999747276306152
ten O O 0.9999887943267822
previously O O 0.9999716281890869
reported O O 0.99998939037323
cases O O 0.999985933303833
of O O 0.9999586343765259
this O O 0.9999681711196899
unusual O O 0.9999374151229858
complication O O 0.9999876022338867
are O O 0.9999240636825562
reviewed O O 0.9999852180480957
. O O 0.9999639987945557

The O O 0.9999698400497437
following O O 0.9999157190322876
factors O O 0.9999675750732422
appear O O 0.9999414682388306
to O O 0.9999362230300903
predispose O O 0.9996739625930786
to O O 0.9999895095825195
the O O 0.9999905824661255
development O O 0.9999957084655762
of O O 0.9999837875366211
this O O 0.9999275207519531
complication O O 0.9999912977218628
: O O 0.9999477863311768
abnormal O O 0.9999663829803467
cerebrospinal O O 0.9998180270195007
dynamics O O 0.9999874830245972
related O O 0.9999666213989258
to O O 0.9999346733093262
the O O 0.999987006187439
presence O O 0.9999628067016602
of O O 0.9999256134033203
central O O 0.9998365640640259
nervous O O 0.9999948740005493
system O O 0.9999631643295288
leukemia O O 0.9999815225601196
, O O 0.9997313618659973
and O O 0.9995377063751221
epidural O O 0.9980800151824951
cerebrospinal O O 0.9693076014518738
leakage O O 0.9999839067459106
; O O 0.9999538660049438
elevated O O 0.9999306201934814
cerebrospinal O O 0.4649760127067566
fluid O O 0.9840766787528992
methothexate B B 0.9996969699859619
concentration O O 0.9998170733451843
related O O 0.9999914169311523
to O O 0.9999845027923584
abnormal O O 0.9999890327453613
cerebrospinal O O 0.9993714690208435
fluid O O 0.9999434947967529
dynamics O O 0.9999854564666748
and O O 0.9999948740005493
to O O 0.9999878406524658
inappropriately O O 0.999958872795105
high O O 0.99989914894104
methotrexate B B 0.9995081424713135
doses O O 0.9999245405197144
based O O 0.9999951124191284
on O O 0.9999891519546509
body O O 0.9999638795852661
surface O O 0.9998086094856262
area O O 0.988224983215332
calculations O O 0.9999662637710571
in O O 0.99997878074646
older O O 0.9999469518661499
children O O 0.9999980926513672
and O O 0.9999346733093262
adults O O 0.9999953508377075
; O O 0.9999672174453735
the O O 0.999984622001648
presence O O 0.9999628067016602
of O O 0.9998629093170166
neurotoxic O O 0.9998952150344849
preservatives O O 0.9425296187400818
in O O 0.9996938705444336
commercially O O 0.9989523887634277
available O O 0.9998642206192017
methotrexate B B 0.9992520213127136
preparations O O 0.9948948621749878
and O O 0.9990271329879761
diluents O O 0.9912954568862915
; O O 0.9999085664749146
and O O 0.99993896484375
the O O 0.9999767541885376
use O O 0.9999641180038452
of O O 0.9998623132705688
methotrexate B B 0.9991538524627686
diluents O O 0.880673348903656
of O O 0.999509334564209
unphysiologic O O 0.9496322870254517
pH O O 0.8489199876785278
, O O 0.9991695880889893
ionic O O 0.8714175820350647
content O O 0.9994183778762817
and O O 0.999704897403717
osmolarity O O 0.7273889183998108
. O O 0.9999146461486816

The O O 0.999962568283081
role O O 0.9999706745147705
of O O 0.9998169541358948
methotrexate B B 0.998979389667511
contaminants O I 0.9314747452735901
, O O 0.9982095956802368
local O O 0.9957274198532104
folate O B 0.9768936038017273
deficiency O O 0.9984082579612732
, O O 0.99916672706604
and O O 0.9994472861289978
cranial O O 0.9991276860237122
irradiation O O 0.9990746974945068
in O O 0.9999548196792603
the O O 0.9999876022338867
pathogenesis O O 0.9999935626983643
of O O 0.9999816417694092
intrathecal O O 0.9999412298202515
methotrexate B B 0.9997498393058777
toxicity O O 0.9998117089271545
is O O 0.9999678134918213
unclear O O 0.9999215602874756
. O O 0.9999794960021973

The O O 0.9999849796295166
incidence O O 0.9999880790710449
of O O 0.9999665021896362
neurotoxicity O O 0.9999791383743286
may O O 0.9999512434005737
be O O 0.999984860420227
reduced O O 0.9999839067459106
by O O 0.9999740123748779
employing O O 0.9996734857559204
lower O O 0.999932050704956
doses O O 0.9998965263366699
of O O 0.998748779296875
methotrexate B B 0.9996386766433716
in O O 0.9998294115066528
the O O 0.9999755620956421
presence O O 0.9999538660049438
of O O 0.999937891960144
central O O 0.9998908042907715
nervous O O 0.9999951124191284
system O O 0.9999673366546631
leukemia O O 0.9999740123748779
, O O 0.9999747276306152
in O O 0.9999775886535645
older O O 0.9999839067459106
children O O 0.9999980926513672
and O O 0.9999693632125854
adults O O 0.9999932050704956
, O O 0.9999685287475586
and O O 0.9999560117721558
in O O 0.9999667406082153
the O O 0.999983549118042
presence O O 0.9999672174453735
of O O 0.9999732971191406
epidural O O 0.9993698000907898
leakage O O 0.9999754428863525
. O O 0.9999762773513794

Only O O 0.9995273351669312
preservative O O 0.5049559473991394
- O O 0.9469301700592041
free O O 0.8676292300224304
methotrexate B B 0.9964178800582886
in O O 0.9978387951850891
Elliott O O 0.7652713060379028
' O O 0.9999685287475586
s O O 0.9999444484710693
B O O 0.8959218859672546
Solution O O 0.9920084476470947
at O O 0.9999256134033203
a O O 0.9999837875366211
concentration O O 0.9998900890350342
of O O 0.9999613761901855
not O O 0.9999947547912598
more O O 0.9999879598617554
than O O 0.9999946355819702
1 O O 0.9999755620956421
mg O O 0.9999879598617554
/ O O 0.9999722242355347
ml O O 0.9999958276748657
should O O 0.9999533891677856
be O O 0.9999867677688599
used O O 0.9999785423278809
for O O 0.9999711513519287
intrathecal O O 0.9999895095825195
administration O O 0.99997878074646
. O O 0.999970555305481

Periodic O O 0.9999579191207886
monitoring O O 0.9999904632568359
of O O 0.9999639987945557
cerebruspinal O O 0.9923804998397827
fluid O O 0.9984801411628723
methotrexate B B 0.9996626377105713
levels O O 0.9996084570884705
may O O 0.9999562501907349
be O O 0.9999823570251465
predictive O O 0.9999884366989136
of O O 0.9999911785125732
the O O 0.9999932050704956
development O O 0.9999958276748657
of O O 0.9999874830245972
serious O O 0.9999231100082397
neurotoxicity O O 0.9999860525131226
. O O 0.9999737739562988

Hyperosmolar O O 0.998024582862854
nonketotic O O 0.6139845252037048
coma O O 0.9983205199241638
precipitated O O 0.9999194145202637
by O O 0.9997949004173279
lithium B B 0.9999091625213623
- O O 0.9991886019706726
induced O O 0.999886155128479
nephrogenic O O 0.9997159838676453
diabetes O O 0.9995321035385132
insipidus O O 0.9999138116836548
. O O 0.9999294281005859

A O O 0.9999865293502808
45 O O 0.999996542930603
- O O 0.9999889135360718
year O O 0.9999957084655762
- O O 0.999993085861206
old O O 0.9999947547912598
man O O 0.9999955892562866
, O O 0.9999878406524658
with O O 0.9999721050262451
a O O 0.9999896287918091
10 O O 0.9999496936798096
- O O 0.9999849796295166
year O O 0.9999914169311523
history O O 0.9999876022338867
of O O 0.9999741315841675
manic O O 0.9996974468231201
depression O O 0.9999126195907593
treated O O 0.9998980760574341
with O O 0.9994385838508606
lithium B B 0.9996752738952637
, O O 0.9998514652252197
was O O 0.9999756813049316
admitted O O 0.9999816417694092
with O O 0.9999866485595703
hyperosmolar O O 0.9986391663551331
, O O 0.9997699856758118
nonketotic O O 0.8320477604866028
coma O O 0.9999319314956665
. O O 0.9999743700027466

He O O 0.9999086856842041
gave O O 0.9999222755432129
a O O 0.9999643564224243
five O O 0.9999885559082031
- O O 0.9999918937683105
year O O 0.9999954700469971
history O O 0.9999886751174927
of O O 0.9999617338180542
polyuria O O 0.9997499585151672
and O O 0.9999314546585083
polydipsia O O 0.9997374415397644
, O O 0.9999744892120361
during O O 0.9998663663864136
which O O 0.9999812841415405
time O O 0.9999228715896606
urinalysis O O 0.9990805387496948
had O O 0.9999849796295166
been O O 0.9999915361404419
negative O O 0.9999487400054932
for O O 0.9963666200637817
glucose B B 0.9584687948226929
. O O 0.9998784065246582

After O O 0.9999191761016846
recovery O O 0.9999960660934448
from O O 0.9999586343765259
hyperglycaemia O O 0.9988335967063904
, O O 0.9999551773071289
he O O 0.9999748468399048
remained O O 0.9999139308929443
polyuric O O 0.9998493194580078
despite O O 0.9998806715011597
normal O O 0.9999504089355469
blood O O 0.9988417029380798
glucose B B 0.9668827652931213
concentrations O O 0.9997288584709167
; O O 0.999954342842102
water O O 0.5471583008766174
deprivation O O 0.9701757431030273
testing O O 0.9999405145645142
indicated O O 0.9998805522918701
nephrogenic O O 0.9996625185012817
diabetes O O 0.9992851614952087
insipidus O O 0.9998589754104614
, O O 0.9999806880950928
likely O O 0.9999589920043945
to O O 0.9999294281005859
be O O 0.999904990196228
lithium B B 0.9998457431793213
- O O 0.9993171691894531
induced O O 0.9998263716697693
. O O 0.9999731779098511

We O O 0.9999418258666992
hypothesize O O 0.9998061060905457
that O O 0.999931812286377
when O O 0.9999872446060181
this O O 0.9999895095825195
man O O 0.9999953508377075
developed O O 0.9999898672103882
type O O 0.9999908208847046
2 O O 0.9996662139892578
diabetes O O 0.9992276430130005
, O O 0.9996770620346069
chronic O O 0.9997445940971375
polyuria O O 0.9875784516334534
due O O 0.9999675750732422
to O O 0.9994785189628601
nephrogenic O O 0.988959789276123
diabetes O O 0.9915505647659302
insipidus O O 0.999439537525177
was O O 0.9999396800994873
sufficient O O 0.9997695088386536
to O O 0.9999436140060425
precipitate O O 0.9999094009399414
hyperosmolar O O 0.9999446868896484
dehydration O O 0.9999179840087891
. O O 0.9999603033065796

Effects O O 0.9999269247055054
of O O 0.999847412109375
the O O 0.9999046325683594
intracoronary O O 0.9996929168701172
infusion O O 0.9998034834861755
of O O 0.9336718916893005
cocaine B B 0.9985623955726624
on O O 0.9997753500938416
left O O 0.9999592304229736
ventricular O O 0.9999922513961792
systolic O O 0.9896035194396973
and O O 0.9998538494110107
diastolic O O 0.9998588562011719
function O O 0.9999842643737793
in O O 0.9995473027229309
humans O O 0.8233854174613953
. O O 0.9999511241912842

BACKGROUND O O 0.9803974628448486
: O O 0.9999457597732544
In O O 0.9992837309837341
dogs O O 0.9961555600166321
, O O 0.9998804330825806
a O O 0.9999774694442749
large O O 0.9999775886535645
amount O O 0.999808132648468
of O O 0.9993983507156372
intravenous O O 0.9984027743339539
cocaine B B 0.9882771372795105
causes O O 0.9997792840003967
a O O 0.9999818801879883
profound O O 0.9999750852584839
deterioration O O 0.9999933242797852
of O O 0.9999586343765259
left O O 0.9999185800552368
ventricular O O 0.9999886751174927
( O O 0.9996236562728882
LV O O 0.990839421749115
) O O 0.9999136924743652
systolic O O 0.9995286464691162
function O O 0.9999853372573853
and O O 0.9999699592590332
an O O 0.9999791383743286
increase O O 0.9999788999557495
in O O 0.9999489784240723
LV O O 0.9335522055625916
end O O 0.999729573726654
- O O 0.9991638660430908
diastolic O O 0.9999417066574097
pressure O O 0.9999539852142334
. O O 0.9999669790267944

This O O 0.9999812841415405
study O O 0.9999881982803345
was O O 0.9999794960021973
done O O 0.9999945163726807
to O O 0.9999853372573853
assess O O 0.9999750852584839
the O O 0.9999688863754272
influence O O 0.9999699592590332
of O O 0.9999327659606934
a O O 0.9999608993530273
high O O 0.9997051358222961
intracoronary O O 0.9990720748901367
cocaine B B 0.9971987009048462
concentration O O 0.9990136623382568
on O O 0.9997894167900085
LV O O 0.8641801476478577
systolic O O 0.9992238283157349
and O O 0.9998742341995239
diastolic O O 0.9998980760574341
function O O 0.9999910593032837
in O O 0.9999282360076904
humans O O 0.9938820600509644
. O O 0.9999575614929199

METHODS O O 0.9997889399528503
AND O O 0.999993085861206
RESULTS O O 0.9999902248382568
: O O 0.999956488609314
In O O 0.999996542930603
20 O O 0.9999936819076538
patients O O 0.9999984502792358
( O O 0.9999719858169556
14 O O 0.9999722242355347
men O O 0.9999806880950928
and O O 0.9999783039093018
6 O O 0.9997518658638
women O O 0.9998782873153687
aged O O 0.9999954700469971
39 O O 0.9999959468841553
to O O 0.9999879598617554
72 O O 0.9999921321868896
years O O 0.9999371767044067
) O O 0.9999847412109375
referred O O 0.9999945163726807
for O O 0.9999955892562866
cardiac O O 0.9999970197677612
catheterization O O 0.999997615814209
for O O 0.9999886751174927
the O O 0.9999977350234985
evaluation O O 0.9999982118606567
of O O 0.9999920129776001
chest O O 0.9999955892562866
pain O O 0.9999979734420776
, O O 0.9999910593032837
we O O 0.9999887943267822
measured O O 0.9999905824661255
heart O O 0.9999940395355225
rate O O 0.9999970197677612
, O O 0.9999783039093018
systemic O O 0.9999427795410156
arterial O O 0.9999159574508667
pressure O O 0.999786913394928
, O O 0.9999535083770752
LV O O 0.9190641045570374
pressure O O 0.9999065399169922
and O O 0.9999328851699829
its O O 0.9999375343322754
first O O 0.9999679327011108
derivative O O 0.9998444318771362
( O O 0.9999148845672607
dP O O 0.9989769458770752
/ O O 0.9998983144760132
dt O O 0.9982865452766418
) O O 0.9999831914901733
, O O 0.9999635219573975
and O O 0.9999425411224365
LV O O 0.9092616438865662
volumes O O 0.9997710585594177
and O O 0.999948263168335
ejection O O 0.999879002571106
fraction O O 0.9999939203262329
before O O 0.9998618364334106
and O O 0.9999653100967407
during O O 0.9999734163284302
the O O 0.9999966621398926
final O O 0.9999972581863403
2 O O 0.9999905824661255
to O O 0.9999983310699463
3 O O 0.9999926090240479
minutes O O 0.9999977350234985
of O O 0.9999514818191528
a O O 0.9999809265136719
15 O O 0.999988317489624
- O O 0.9999902248382568
minute O O 0.999993085861206
intracoronary O O 0.9999867677688599
infusion O O 0.999985933303833
of O O 0.9980683922767639
saline O O 0.9794701933860779
( O O 0.9999297857284546
n O O 0.9828899502754211
= O O 0.999397873878479
10 O O 0.9999666213989258
, O O 0.999957799911499
control O O 0.9981133937835693
subjects O O 0.9981979727745056
) O O 0.9999178647994995
or O O 0.9960209727287292
cocaine B B 0.9875091910362244
hydrochloride I I 0.9769026041030884
1 O O 0.9992177486419678
mg O O 0.9998315572738647
/ O O 0.9994977712631226
min O O 0.9974008798599243
( O O 0.9999752044677734
n O O 0.9970184564590454
= O O 0.9999086856842041
10 O O 0.9997212290763855
) O O 0.9999747276306152
. O O 0.9999762773513794

No O O 0.9990447163581848
variable O O 0.9999908208847046
changed O O 0.9999129772186279
with O O 0.9999266862869263
saline O O 0.9997555613517761
. O O 0.9998140931129456

With O O 0.9996676445007324
cocaine B B 0.9971987009048462
, O O 0.9998914003372192
the O O 0.9999841451644897
drug O O 0.9975401163101196
concentration O O 0.9992071986198425
in O O 0.9998800754547119
blood O O 0.9999246597290039
obtained O O 0.9999749660491943
from O O 0.999962568283081
the O O 0.9999874830245972
coronary O O 0.9997687935829163
sinus O O 0.9999573230743408
was O O 0.9999707937240601
3 O O 0.9994640946388245
. O O 0.9999890327453613
0 O O 0.999987006187439
+ O O 0.9999909400939941
/ O O 0.9999843835830688
- O O 0.9999532699584961
0 O O 0.9999904632568359
. O O 0.9999899864196777
4 O O 0.9999865293502808
( O O 0.9999123811721802
mean O O 0.9998698234558105
+ O O 0.9999872446060181
/ O O 0.9999688863754272
- O O 0.9999765157699585
SD O O 0.9991359114646912
) O O 0.9999728202819824
mg O O 0.9999823570251465
/ O O 0.999982476234436
L O O 0.9999589920043945
, O O 0.9999802112579346
similar O O 0.9999921321868896
in O O 0.9999978542327881
magnitude O O 0.9999915361404419
to O O 0.9999871253967285
the O O 0.9999912977218628
blood O O 0.9988308548927307
cocaine B B 0.9974586367607117
concentration O O 0.989629328250885
reported O O 0.9999792575836182
in O O 0.9999366998672485
abusers O O 0.9945275187492371
dying O O 0.9997705817222595
of O O 0.9998242259025574
cocaine B B 0.984527587890625
intoxication O O 0.998565137386322
. O O 0.9999369382858276

Cocaine B O 0.6734593510627747
induced O O 0.9999122619628906
no O O 0.9999743700027466
significant O O 0.9999953508377075
change O O 0.9999978542327881
in O O 0.9999741315841675
heart O O 0.9999892711639404
rate O O 0.9999912977218628
, O O 0.9999529123306274
LV O O 0.9337791800498962
dP O O 0.9964060187339783
/ O O 0.9986788630485535
dt O O 0.992770254611969
( O O 0.9998270869255066
positive O O 0.9999685287475586
or O O 0.9998409748077393
negative O O 0.9999489784240723
) O O 0.9999402761459351
, O O 0.9999128580093384
or O O 0.9998124241828918
LV O O 0.8663055300712585
end O O 0.9990918636322021
- O O 0.9989147186279297
diastolic O O 0.9999240636825562
volume O O 0.9998007416725159
, O O 0.9999535083770752
but O O 0.9998676776885986
it O O 0.9998227953910828
caused O O 0.9999121427536011
an O O 0.9999688863754272
increase O O 0.9999861717224121
in O O 0.9999419450759888
systolic O O 0.9990014433860779
and O O 0.9997019171714783
mean O O 0.9999281167984009
arterial O O 0.9999802112579346
pressures O O 0.9999274015426636
, O O 0.9999265670776367
LV O O 0.9821339249610901
end O O 0.9995916485786438
- O O 0.9996082186698914
diastolic O O 0.9998830556869507
pressure O O 0.9998868703842163
, O O 0.9998922348022461
and O O 0.9997621178627014
LV O O 0.936281681060791
end O O 0.9978958368301392
- O O 0.9988570213317871
systolic O O 0.9994528889656067
volume O O 0.9998766183853149
, O O 0.9999681711196899
as O O 0.9999772310256958
well O O 0.9999802112579346
as O O 0.9999831914901733
a O O 0.9999806880950928
decrease O O 0.9999951124191284
in O O 0.9999504089355469
LV O O 0.9034522175788879
ejection O O 0.9999827146530151
fraction O O 0.9999972581863403
. O O 0.9999624490737915

CONCLUSIONS O O 0.9963209629058838
: O O 0.9999657869338989
In O O 0.9999426603317261
humans O O 0.9999164342880249
, O O 0.9999357461929321
the O O 0.9999727010726929
intracoronary O O 0.9999130964279175
infusion O O 0.9998750686645508
of O O 0.99695885181427
cocaine B B 0.9982426166534424
sufficient O O 0.998802900314331
in O O 0.9999465942382812
amount O O 0.9998315572738647
to O O 0.9999418258666992
achieve O O 0.9999358654022217
a O O 0.9999901056289673
high O O 0.999784529209137
drug O O 0.9979726672172546
concentration O O 0.9999141693115234
in O O 0.9998156428337097
coronary O O 0.9992091059684753
sinus O O 0.999936580657959
blood O O 0.999357283115387
causes O O 0.9999459981918335
a O O 0.9999837875366211
deterioration O O 0.9999926090240479
of O O 0.9999489784240723
LV O O 0.8074383735656738
systolic O O 0.9978024363517761
and O O 0.9997157454490662
diastolic O O 0.9998390674591064
performance O O 0.9999499320983887
. O O 0.9999586343765259

Ascending O O 0.999582827091217
dose O O 0.9994151592254639
tolerance O O 0.9999430179595947
study O O 0.9999798536300659
of O O 0.9997826218605042
intramuscular O O 0.9998797178268433
carbetocin B B 0.9994035959243774
administered O O 0.9999246597290039
after O O 0.999982476234436
normal O O 0.9999926090240479
vaginal O O 0.9999192953109741
birth O O 0.9999986886978149
. O O 0.9999549388885498

OBJECTIVE O O 0.9998972415924072
: O O 0.9999970197677612
To O O 0.999997615814209
determine O O 0.9999971389770508
the O O 0.9999916553497314
maximum O O 0.9999686479568481
tolerated O O 0.9999842643737793
dose O O 0.9999628067016602
( O O 0.9999067783355713
MTD O O 0.9730377197265625
) O O 0.9999819993972778
of O O 0.9993628859519958
carbetocin B B 0.9995185136795044
( O O 0.9997040629386902
a O O 0.9999215602874756
long O O 0.9909987449645996
- O O 0.999900221824646
acting O O 0.988827109336853
synthetic O O 0.9597460031509399
analogue O O 0.9915050864219666
of O O 0.997934103012085
oxytocin B B 0.9798588752746582
) O O 0.9997150301933289
, O O 0.9999815225601196
when O O 0.9999805688858032
administered O O 0.9999605417251587
immediately O O 0.9999949932098389
after O O 0.9999957084655762
vaginal O O 0.9999991655349731
delivery O O 0.999998927116394
at O O 0.9999768733978271
term O O 0.9999994039535522
. O O 0.9999891519546509

MATERIALS O O 0.9999512434005737
AND O O 0.9999969005584717
METHODS O O 0.9999979734420776
: O O 0.9999350309371948
Carbetocin B B 0.9993640780448914
was O O 0.9998822212219238
given O O 0.9999202489852905
as O O 0.9999529123306274
an O O 0.9999010562896729
intramuscular O O 0.9999788999557495
injection O O 0.999969482421875
immediately O O 0.9999890327453613
after O O 0.9999985694885254
the O O 0.9999991655349731
birth O O 0.9999988079071045
of O O 0.9999978542327881
the O O 0.9999988079071045
infant O O 0.9999985694885254
in O O 0.9999710321426392
45 O O 0.9999945163726807
healthy O O 0.999991774559021
women O O 0.9999983310699463
with O O 0.9999854564666748
normal O O 0.9999946355819702
singleton O O 0.9999368190765381
pregnancies O O 0.999998927116394
who O O 0.9999881982803345
delivered O O 0.9999986886978149
vaginally O O 0.9999979734420776
at O O 0.9999803304672241
term O O 0.9999992847442627
. O O 0.9999825954437256

Dosage O O 0.9997504353523254
groups O O 0.9999337196350098
of O O 0.9998810291290283
15 O O 0.9999755620956421
, O O 0.9999158382415771
30 O O 0.9999858140945435
, O O 0.9995087385177612
50 O O 0.9999891519546509
, O O 0.9993732571601868
75 O O 0.9997628331184387
, O O 0.9992049336433411
100 O O 0.9999500513076782
, O O 0.9983880519866943
125 O O 0.999891996383667
, O O 0.9982301592826843
150 O O 0.9998934268951416
, O O 0.9983566403388977
175 O O 0.9988771080970764
or O O 0.9997128844261169
200 O O 0.9985194802284241
microg O O 0.9998581409454346
carbetocin B B 0.9977356195449829
were O O 0.9998553991317749
assigned O O 0.9999871253967285
to O O 0.9999058246612549
blocks O O 0.9984128475189209
of O O 0.9999455213546753
three O O 0.9999618530273438
women O O 0.9999871253967285
according O O 0.9999943971633911
to O O 0.9999946355819702
the O O 0.9999938011169434
continual O O 0.9991199374198914
reassessment O O 0.9999943971633911
method O O 0.9999979734420776
( O O 0.9999521970748901
CRM O O 0.9899498224258423
) O O 0.9999862909317017
. O O 0.9999769926071167

RESULTS O O 0.9996292591094971
: O O 0.9999485015869141
All O O 0.9990472197532654
dosage O O 0.9996850490570068
groups O O 0.9998563528060913
consisted O O 0.9999401569366455
of O O 0.9991212487220764
three O O 0.9871883988380432
women O O 0.9759702682495117
, O O 0.9999598264694214
except O O 0.999924898147583
those O O 0.99994957447052
with O O 0.9997768998146057
100 O O 0.9845653176307678
microg O O 0.9899263381958008
( O O 0.9999004602432251
n O O 0.9993403553962708
= O O 0.9997616410255432
6 O O 0.9998703002929688
) O O 0.9998421669006348
and O O 0.9988206028938293
200 O O 0.9931437969207764
microg O O 0.9953573346138
( O O 0.9999232292175293
n O O 0.9993259906768799
= O O 0.9998624324798584
18 O O 0.9967569708824158
) O O 0.9999310970306396
. O O 0.9999688863754272

Recorded O O 0.999462902545929
were O O 0.9999408721923828
dose O O 0.9989996552467346
- O O 0.9999566078186035
limiting O O 0.9999188184738159
adverse O O 0.999847412109375
events O O 0.9999985694885254
: O O 0.9999622106552124
hyper O O 0.9996669292449951
- O O 0.9998706579208374
or O O 0.999868631362915
hypotension O O 0.9997634291648865
( O O 0.9999065399169922
three O O 0.999839186668396
) O O 0.9999222755432129
, O O 0.9999673366546631
severe O O 0.9999812841415405
abdominal O O 0.9999929666519165
pain O O 0.9999946355819702
( O O 0.9999442100524902
0 O O 0.9994797110557556
) O O 0.9999202489852905
, O O 0.9998979568481445
vomiting O O 0.9993452429771423
( O O 0.9999412298202515
0 O O 0.9977465271949768
) O O 0.999922513961792
and O O 0.9999672174453735
retained O O 0.9999922513961792
placenta O O 0.9999967813491821
( O O 0.9998470544815063
four O O 0.9958951473236084
) O O 0.9999465942382812
. O O 0.9999661445617676

Serious O O 0.9999074935913086
adverse O O 0.9999533891677856
events O O 0.9999982118606567
occurred O O 0.9999898672103882
in O O 0.9999598264694214
seven O O 0.999968409538269
women O O 0.9999792575836182
: O O 0.9999837875366211
six O O 0.9999886751174927
cases O O 0.9999935626983643
with O O 0.9999819993972778
blood O O 0.9999644756317139
loss O O 0.9999947547912598
> O O 0.9999445676803589
or O O 0.9999954700469971
= O O 0.9999945163726807
1000 O O 0.9999982118606567
ml O O 0.9999985694885254
, O O 0.9999775886535645
four O O 0.9999873638153076
cases O O 0.9999909400939941
of O O 0.9999186992645264
manual O O 0.999906063079834
placenta O O 0.9999618530273438
removal O O 0.9999443292617798
, O O 0.9999644756317139
five O O 0.9999849796295166
cases O O 0.9999892711639404
of O O 0.9999140501022339
additional O O 0.9979786276817322
oxytocics O B 0.9877244234085083
administration O O 0.9988862872123718
and O O 0.9999282360076904
five O O 0.9999310970306396
cases O O 0.9999891519546509
of O O 0.9998965263366699
blood O O 0.998724639415741
transfusion O O 0.999828577041626
. O O 0.9999481439590454

Maximum O O 0.9999567270278931
blood O O 0.9999761581420898
loss O O 0.9999912977218628
was O O 0.9999637603759766
greatest O O 0.999985933303833
at O O 0.9997748732566833
the O O 0.9999350309371948
upper O O 0.9995248317718506
and O O 0.999850869178772
lower O O 0.9998763799667358
dose O O 0.9988646507263184
levels O O 0.9999284744262695
, O O 0.9999502897262573
and O O 0.9999732971191406
lowest O O 0.9999932050704956
in O O 0.9999532699584961
the O O 0.9999816417694092
70 O O 0.9991355538368225
- O O 0.9980369210243225
125 O O 0.9349548816680908
microg O O 0.9814334511756897
dose O O 0.9997261166572571
range O O 0.9999337196350098
. O O 0.9999699592590332

Four O O 0.9999785423278809
out O O 0.9999873638153076
of O O 0.9999839067459106
six O O 0.9999966621398926
cases O O 0.9999938011169434
with O O 0.999984860420227
blood O O 0.9999803304672241
loss O O 0.9999966621398926
> O O 0.9999510049819946
or O O 0.9999929666519165
= O O 0.9999947547912598
1000 O O 0.9999977350234985
ml O O 0.9999971389770508
occurred O O 0.9999727010726929
in O O 0.9999014139175415
the O O 0.9998753070831299
200 O O 0.9660494327545166
microg O O 0.9557756781578064
group O O 0.9998397827148438
. O O 0.9999486207962036

The O O 0.9999759197235107
majority O O 0.999987006187439
of O O 0.9999769926071167
additional O O 0.9999306201934814
administration O O 0.9999655485153198
of O O 0.999822199344635
oxytocics O B 0.9975256323814392
( O O 0.99947589635849
4 O O 0.999600350856781
/ O O 0.999869704246521
5 O O 0.9999363422393799
) O O 0.9999347925186157
and O O 0.9997043013572693
blood O O 0.9998658895492554
transfusion O O 0.9999580383300781
( O O 0.9999713897705078
3 O O 0.9998506307601929
/ O O 0.9999096393585205
5 O O 0.9999587535858154
) O O 0.9999779462814331
occurred O O 0.999991774559021
in O O 0.9999357461929321
the O O 0.9999152421951294
dose O O 0.9996261596679688
groups O O 0.9999445676803589
of O O 0.9999018907546997
200 O O 0.9926954507827759
microg O O 0.8461278676986694
. O O 0.9999479055404663

All O O 0.9993162155151367
retained O O 0.9999532699584961
placentae O O 0.9998444318771362
were O O 0.9999114274978638
found O O 0.9999454021453857
in O O 0.999874472618103
the O O 0.9999353885650635
group O O 0.999858021736145
of O O 0.9999436140060425
200 O O 0.9984814524650574
microg O O 0.9996962547302246
. O O 0.9999042749404907

CONCLUSION O O 0.9957568049430847
: O O 0.9999539852142334
The O O 0.9999703168869019
MTD O O 0.517392635345459
was O O 0.9998859167098999
calculated O O 0.9999725818634033
to O O 0.9999618530273438
be O O 0.9999634027481079
at O O 0.9998816251754761
200 O O 0.9991552829742432
microg O O 0.9995793700218201
carbetocin B B 0.9946152567863464
. O O 0.9997883439064026

Heparin B O 0.985550045967102
- O O 0.9994679093360901
induced O O 0.9999327659606934
thrombocytopenia O O 0.9998893737792969
, O O 0.9999300241470337
paradoxical O O 0.9998947381973267
thromboembolism O O 0.9999669790267944
, O O 0.9998595714569092
and O O 0.9998916387557983
other O O 0.9999511241912842
side O O 0.9999791383743286
effects O O 0.9999918937683105
of O O 0.9998899698257446
heparin B B 0.9986332058906555
therapy O O 0.9987488985061646
. O O 0.9999194145202637

Although O O 0.99997878074646
several O O 0.9998175501823425
new O O 0.9998664855957031
anticoagulant O O 0.4839043617248535
drugs O O 0.9303115606307983
are O O 0.9999258518218994
in O O 0.9999687671661377
development O O 0.9999819993972778
, O O 0.9997451901435852
heparin B B 0.9928703904151917
remains O O 0.9997724890708923
the O O 0.9999662637710571
drug O O 0.9999340772628784
of O O 0.9999723434448242
choice O O 0.9999395608901978
for O O 0.9999635219573975
most O O 0.9998993873596191
anticoagulation O O 0.8872487545013428
needs O O 0.9999362230300903
. O O 0.9999728202819824

The O O 0.9999574422836304
clinical O O 0.9999717473983765
effects O O 0.9999892711639404
of O O 0.9998334646224976
heparin B B 0.9958299994468689
are O O 0.9995453953742981
meritorious O O 0.9999810457229614
, O O 0.999954342842102
but O O 0.9995622038841248
side O O 0.9998602867126465
effects O O 0.9999661445617676
do O O 0.9999552965164185
exist O O 0.9999853372573853
. O O 0.9999754428863525

Important O O 0.9998565912246704
untoward O O 0.999948263168335
effects O O 0.9999884366989136
of O O 0.9998854398727417
heparin B B 0.9992685914039612
therapy O O 0.9993890523910522
including O O 0.9998950958251953
heparin B B 0.9983722567558289
- O O 0.9992534518241882
induced O O 0.9999442100524902
thrombocytopenia O O 0.9998062252998352
, O O 0.9999374151229858
heparin B B 0.9974730610847473
- O O 0.9992187023162842
associated O O 0.9998637437820435
osteoporosis O O 0.9983518123626709
, O O 0.9999547004699707
eosinophilia O O 0.9995924830436707
, O O 0.9999572038650513
skin O O 0.999962568283081
reactions O O 0.9999983310699463
, O O 0.9999366998672485
allergic O O 0.9994840621948242
reactions O O 0.9999829530715942
other O O 0.9999386072158813
than O O 0.9999750852584839
thrombocytopenia O O 0.9930495023727417
and O O 0.9998162388801575
alopecia O O 0.9692409634590149
will O O 0.9999604225158691
be O O 0.999983549118042
discussed O O 0.9999855756759644
in O O 0.9999904632568359
this O O 0.999984860420227
article O O 0.9999948740005493
. O O 0.9999794960021973

Nonopaque O O 0.5199812650680542
crystal O O 0.6358049511909485
deposition O O 0.9972767233848572
causing O O 0.9999022483825684
ureteric O O 0.9998965263366699
obstruction O O 0.9999501705169678
in O O 0.99993896484375
patients O O 0.9999891519546509
with O O 0.9999362230300903
HIV O O 0.9086092710494995
undergoing O O 0.9986087679862976
indinavir B B 0.9989826083183289
therapy O O 0.9981406927108765
. O O 0.9999582767486572

OBJECTIVE O O 0.9998873472213745
: O O 0.9999924898147583
We O O 0.9999873638153076
describe O O 0.9999939203262329
the O O 0.9999840259552002
unique O O 0.9993029832839966
CT O O 0.9966917037963867
features O O 0.9999957084655762
of O O 0.9999850988388062
ureteric O O 0.9999616146087646
calculi O O 0.9998087286949158
in O O 0.9999639987945557
six O O 0.9998388290405273
HIV O O 0.507641613483429
- O O 0.997870922088623
infected O O 0.9998996257781982
patients O O 0.999985933303833
receiving O O 0.9993677735328674
indinavir B B 0.9995651841163635
, O O 0.9998705387115479
the O O 0.9999722242355347
most O O 0.9985339641571045
commonly O O 0.9998807907104492
used O O 0.9997374415397644
HIV O O 0.5822790861129761
protease O O 0.922313392162323
inhibitor O O 0.8973492383956909
, O O 0.9999619722366333
which O O 0.9999523162841797
is O O 0.999937891960144
associated O O 0.9999911785125732
with O O 0.9999947547912598
an O O 0.9999957084655762
increased O O 0.9999972581863403
incidence O O 0.9999988079071045
of O O 0.9999921321868896
urolithiasis O O 0.9999808073043823
. O O 0.9999843835830688

CONCLUSION O O 0.9995641112327576
: O O 0.9998941421508789
Ureteric O O 0.9993053674697876
obstruction O O 0.9998788833618164
caused O O 0.9999445676803589
by O O 0.9998495578765869
precipitated O O 0.9930018782615662
indinavir B B 0.996616542339325
crystals O O 0.5922721028327942
may O O 0.9999480247497559
be O O 0.9999973773956299
difficult O O 0.9999972581863403
to O O 0.9999980926513672
diagnose O O 0.9999982118606567
with O O 0.9999959468841553
unenhanced O O 0.9998726844787598
CT O O 0.9522459506988525
. O O 0.9999643564224243

The O O 0.9999362230300903
calculi O O 0.9998084902763367
are O O 0.9998921155929565
not O O 0.9999483823776245
opaque O O 0.9995996356010437
, O O 0.9999034404754639
and O O 0.999942421913147
secondary O O 0.9999332427978516
signs O O 0.9999696016311646
of O O 0.9999616146087646
obstruction O O 0.9996284246444702
may O O 0.9999517202377319
be O O 0.9999872446060181
absent O O 0.999977707862854
or O O 0.9999765157699585
minimal O O 0.9999873638153076
and O O 0.9999651908874512
should O O 0.9999810457229614
be O O 0.9999974966049194
sought O O 0.9999933242797852
carefully O O 0.9999964237213135
. O O 0.9999778270721436

Images O O 0.999964714050293
may O O 0.9999778270721436
need O O 0.9999967813491821
to O O 0.999997615814209
be O O 0.999998927116394
obtained O O 0.9999983310699463
using O O 0.9999171495437622
i O O 0.9986459612846375
. O O 0.9999858140945435
v O O 0.9999924898147583
. O O 0.9999921321868896
contrast O O 0.991759717464447
material O O 0.9999395608901978
to O O 0.9999792575836182
enable O O 0.9999289512634277
diagnosis O O 0.9999958276748657
of O O 0.9999865293502808
ureteric O O 0.9999066591262817
stones O O 0.9999834299087524
or O O 0.9999527931213379
obstruction O O 0.9999270439147949
in O O 0.999975323677063
patients O O 0.9999945163726807
with O O 0.9999810457229614
HIV O O 0.9760068655014038
infection O O 0.9999661445617676
who O O 0.9999754428863525
receive O O 0.9999041557312012
indinavir B B 0.9979633092880249
therapy O O 0.9981309771537781
. O O 0.9999796152114868

Ischemic O O 0.999042809009552
colitis O O 0.9991546869277954
and O O 0.9992578625679016
sumatriptan B B 0.999849796295166
use O O 0.9992417097091675
. O O 0.9998440742492676

Sumatriptan B B 0.9994718432426453
succinate I I 0.9959004521369934
, O O 0.9995774626731873
a O O 0.9592510461807251
serotonin B B 0.886645495891571
- O O 0.5993318557739258
1 O O 0.5394108295440674
( O O 0.7531981468200684
5 B B 0.5393907427787781
- I I 0.8230941295623779
hydroxytryptamine I I 0.9860365390777588
- O O 0.8736412525177002
1 O O 0.9222250580787659
) O O 0.8997313380241394
receptor O O 0.5753549337387085
agonist O O 0.5034250617027283
, O O 0.999636173248291
is O O 0.9997889399528503
an O O 0.9976798892021179
antimigraine O O 0.47953328490257263
drug O O 0.9926503300666809
that O O 0.999871015548706
is O O 0.9998575448989868
reported O O 0.9999047517776489
to O O 0.999897837638855
act O O 0.9997324347496033
by O O 0.9997950196266174
selectively O O 0.9992497563362122
constricting O O 0.9976818561553955
intracranial O O 0.9999667406082153
arteries O O 0.9999191761016846
. O O 0.9999179840087891

Recently O O 0.9999520778656006
, O O 0.9998912811279297
vasopressor O O 0.9986036419868469
responses O O 0.9998513460159302
that O O 0.9999035596847534
are O O 0.9999368190765381
distinct O O 0.9998854398727417
from O O 0.9999561309814453
the O O 0.999934196472168
cranial O O 0.9995242357254028
circulation O O 0.999904990196228
have O O 0.9999558925628662
been O O 0.9999768733978271
demonstrated O O 0.9999853372573853
to O O 0.9998657703399658
occur O O 0.9999302625656128
in O O 0.9995133876800537
the O O 0.9997963309288025
systemic O O 0.9985426664352417
, O O 0.9996298551559448
pulmonary O O 0.9985223412513733
, O O 0.9995937943458557
and O O 0.998813271522522
coronary O O 0.9968668818473816
circulations O O 0.99991774559021
. O O 0.9999574422836304

Cases O O 0.9994750618934631
have O O 0.9999672174453735
been O O 0.9999712705612183
published O O 0.9997469782829285
of O O 0.9999337196350098
coronary O O 0.9995412826538086
vasospasm O O 0.9999767541885376
, O O 0.9999018907546997
myocardial O O 0.9999940395355225
ischemia O O 0.9999916553497314
, O O 0.9997671246528625
and O O 0.999795138835907
myocardial O O 0.9999895095825195
infarction O O 0.9999833106994629
occurring O O 0.9999456405639648
after O O 0.9997631907463074
sumatriptan B B 0.9998600482940674
use O O 0.999409556388855
. O O 0.9999407529830933

We O O 0.9999555349349976
report O O 0.9999932050704956
on O O 0.9999624490737915
the O O 0.9999933242797852
development O O 0.9999973773956299
of O O 0.9999850988388062
8 O O 0.9997751116752625
serious O O 0.9999898672103882
cases O O 0.9999933242797852
of O O 0.9999552965164185
ischemic O O 0.9999245405197144
colitis O O 0.9995399713516235
in O O 0.9999244213104248
patients O O 0.9999872446060181
with O O 0.9999659061431885
migraine O O 0.999956488609314
treated O O 0.9999107122421265
with O O 0.9991725087165833
sumatriptan B B 0.9997379183769226
. O O 0.9999384880065918

Pallidotomy O O 0.9956693649291992
with O O 0.9998248219490051
the O O 0.9993457198143005
gamma O B 0.6640014052391052
knife O I 0.9943564534187317
: O O 0.9991770386695862
a O O 0.9997816681861877
positive O O 0.9999692440032959
experience O O 0.9999873638153076
. O O 0.9998966455459595

51 O O 0.9999721050262451
patients O O 0.9999957084655762
with O O 0.9999840259552002
medically O O 0.9999829530715942
refractory O O 0.9999951124191284
Parkinson O O 0.9984456896781921
' O O 0.9999914169311523
s O O 0.9999771118164062
disease O O 0.9999954700469971
underwent O O 0.999962329864502
stereotactic O O 0.9994316697120667
posteromedial O O 0.9998369216918945
pallidotomy O O 0.997685432434082
between O O 0.9983204007148743
August O O 0.6539121270179749
1993 O O 0.660737156867981
and O O 0.9947704672813416
February O O 0.9707106947898865
1997 O O 0.9603519439697266
for O O 0.9999386072158813
treatment O O 0.999985933303833
of O O 0.9999864101409912
bradykinesia O O 0.9999758005142212
, O O 0.9999614953994751
rigidity O O 0.9999969005584717
, O O 0.9999289512634277
and O O 0.9999250173568726
L B B 0.8860482573509216
- I I 0.983758807182312
DOPA I I 0.9998917579650879
- O O 0.9983357787132263
induced O O 0.999948263168335
dyskinesias O O 0.9999978542327881
. O O 0.9999752044677734

In O O 0.9999567270278931
29 O O 0.9999734163284302
patients O O 0.9999947547912598
, O O 0.9999779462814331
the O O 0.9999791383743286
pallidotomies O O 0.9990856647491455
were O O 0.999976634979248
performed O O 0.9999897480010986
with O O 0.9999581575393677
the O O 0.9999070167541504
Leksell O O 0.634761393070221
Gamma O O 0.8246663808822632
Knife O O 0.6171953082084656
and O O 0.9997745156288147
in O O 0.9999339580535889
22 O O 0.999018669128418
they O O 0.9999762773513794
were O O 0.9999817609786987
performed O O 0.9999885559082031
with O O 0.9999815225601196
the O O 0.9999841451644897
standard O O 0.9999690055847168
radiofrequency O O 0.6775233745574951
( O O 0.9994188547134399
RF O O 0.8497119545936584
) O O 0.9999308586120605
method O O 0.99998939037323
. O O 0.9999796152114868

Clinical O O 0.9999676942825317
assessment O O 0.999995231628418
as O O 0.9999769926071167
well O O 0.9999790191650391
as O O 0.9999872446060181
blinded O O 0.9999774694442749
ratings O O 0.999996542930603
of O O 0.9999855756759644
Unified O O 0.9914291501045227
Parkinson O O 0.991558313369751
' O O 0.9999858140945435
s O O 0.999969482421875
Disease O O 0.9999707937240601
Rating O O 0.999887228012085
Scale O O 0.996650755405426
( O O 0.9997816681861877
UPDRS O O 0.9768481254577637
) O O 0.9999469518661499
scores O O 0.9997631907463074
were O O 0.9999828338623047
carried O O 0.9999927282333374
out O O 0.9999897480010986
pre O O 0.9999178647994995
- O O 0.9999611377716064
and O O 0.9999228715896606
postoperatively O O 0.9999204874038696
. O O 0.9999781847000122

Mean O O 0.9999382495880127
follow O O 0.9999889135360718
- O O 0.9999910593032837
up O O 0.9999929666519165
time O O 0.999990701675415
is O O 0.9999916553497314
20 O O 0.9999979734420776
. O O 0.999998927116394
6 O O 0.9999978542327881
months O O 0.9999990463256836
( O O 0.9999837875366211
range O O 0.999992847442627
6 O O 0.9999834299087524
- O O 0.9982036352157593
48 O O 0.9996514320373535
) O O 0.9999903440475464
and O O 0.9999808073043823
all O O 0.9999827146530151
except O O 0.9999724626541138
4 O O 0.9986782670021057
patients O O 0.9999879598617554
have O O 0.9999897480010986
been O O 0.9999932050704956
followed O O 0.9999845027923584
more O O 0.999980092048645
than O O 0.9999949932098389
one O O 0.999995231628418
year O O 0.9999920129776001
. O O 0.9999858140945435

85 O O 0.9998409748077393
percent O O 0.9999969005584717
of O O 0.9999778270721436
patients O O 0.9999885559082031
with O O 0.999966025352478
dyskinesias O O 0.9999933242797852
were O O 0.9999254941940308
relieved O O 0.99997878074646
of O O 0.999975323677063
symptoms O O 0.9999943971633911
, O O 0.9999822378158569
regardless O O 0.9999864101409912
of O O 0.999994158744812
whether O O 0.9999912977218628
the O O 0.999987006187439
pallidotomies O O 0.9981744289398193
were O O 0.9999874830245972
performed O O 0.9999940395355225
with O O 0.9999759197235107
the O O 0.9999302625656128
Gamma O O 0.7827656269073486
Knife O O 0.7038488984107971
or O O 0.9993199110031128
radiofrequency O O 0.4786510169506073
methods O O 0.9990942478179932
. O O 0.9999730587005615

About O O 0.9999756813049316
2 O O 0.9999825954437256
/ O O 0.9999889135360718
3 O O 0.999984622001648
of O O 0.9999881982803345
the O O 0.9999855756759644
patients O O 0.9999940395355225
in O O 0.999822199344635
both O O 0.9993590712547302
Gamma O O 0.530051589012146
Knife O O 0.9137330055236816
and O O 0.9598705172538757
radiofrequency O O 0.7093520760536194
groups O O 0.9976220726966858
showed O O 0.9999465942382812
improvements O O 0.9999899864196777
in O O 0.999967098236084
bradykinesia O O 0.9996805191040039
and O O 0.999842643737793
rigidity O O 0.9999470710754395
, O O 0.9999678134918213
although O O 0.9999825954437256
when O O 0.9999774694442749
considered O O 0.9999731779098511
as O O 0.9999650716781616
a O O 0.9998296499252319
group O O 0.9999864101409912
neither O O 0.9998834133148193
the O O 0.9999266862869263
Gamma O O 0.6432108879089355
Knife O O 0.804328203201294
nor O O 0.9981420040130615
the O O 0.9998165965080261
radiofrequency O O 0.7726525068283081
group O O 0.9953905344009399
showed O O 0.9999579191207886
statistically O O 0.999955415725708
significant O O 0.9999918937683105
improvements O O 0.9999935626983643
in O O 0.9999785423278809
UPDRS O O 0.9761743545532227
scores O O 0.9999717473983765
. O O 0.9999769926071167

One O O 0.9999734163284302
patient O O 0.9999934434890747
in O O 0.9998495578765869
the O O 0.9998699426651001
Gamma O O 0.7078995108604431
Knife O O 0.841167688369751
group O O 0.9986215829849243
( O O 0.9998337030410767
3 O O 0.9994847774505615
. O O 0.9999568462371826
4 O O 0.9999322891235352
% O O 0.9998548030853271
) O O 0.9999498128890991
developed O O 0.9999821186065674
a O O 0.9999874830245972
homonymous O O 0.9968159794807434
hemianopsia O O 0.9998883008956909
9 O O 0.9999107122421265
months O O 0.9999979734420776
following O O 0.9999690055847168
treatment O O 0.9999891519546509
and O O 0.9999432563781738
5 O O 0.9997095465660095
patients O O 0.9999935626983643
( O O 0.9999182224273682
27 O O 0.9999918937683105
. O O 0.9999897480010986
7 O O 0.9999933242797852
% O O 0.9999765157699585
) O O 0.9999494552612305
in O O 0.9999057054519653
the O O 0.9998698234558105
radiofrequency O O 0.5248841643333435
group O O 0.9997479319572449
became O O 0.9999963045120239
transiently O O 0.999996542930603
confused O O 0.9999963045120239
postoperatively O O 0.9999680519104004
. O O 0.9999794960021973

No O O 0.9999456405639648
other O O 0.9999674558639526
complications O O 0.9999949932098389
were O O 0.9999845027923584
seen O O 0.999992847442627
. O O 0.9999616146087646

Gamma O B 0.6687785387039185
Knife O I 0.9880175590515137
pallidotomy O I 0.8805994391441345
is O O 0.9980429410934448
as O O 0.9999562501907349
effective O O 0.9997090697288513
as O O 0.9997517466545105
radiofrequency O O 0.7704926133155823
pallidotomy O O 0.4841325879096985
in O O 0.9999150037765503
controlling O O 0.9999465942382812
certain O O 0.9996488094329834
of O O 0.9999425411224365
the O O 0.9999483823776245
symptoms O O 0.9999947547912598
of O O 0.999971866607666
Parkinson O O 0.9970449805259705
' O O 0.9999796152114868
s O O 0.9999696016311646
disease O O 0.9999862909317017
. O O 0.9999334812164307

It O O 0.999948263168335
may O O 0.9999498128890991
be O O 0.999975323677063
the O O 0.9999847412109375
only O O 0.9999617338180542
practical O O 0.9999239444732666
technique O O 0.9999874830245972
available O O 0.9999527931213379
in O O 0.9999608993530273
certain O O 0.9999579191207886
patients O O 0.9999911785125732
, O O 0.999991774559021
such O O 0.9999858140945435
as O O 0.9999790191650391
those O O 0.999984622001648
who O O 0.9999635219573975
take O O 0.9995983242988586
anticoagulants O O 0.5497905611991882
, O O 0.9998766183853149
have O O 0.9999492168426514
bleeding O O 0.9997115731239319
diatheses O O 0.9999487400054932
or O O 0.9999504089355469
serious O O 0.999968409538269
systemic O O 0.9999529123306274
medical O O 0.9999946355819702
illnesses O O 0.9999963045120239
. O O 0.9999648332595825

It O O 0.9993446469306946
is O O 0.9999037981033325
a O O 0.999929666519165
viable O O 0.9998185038566589
option O O 0.9999456405639648
for O O 0.9998922348022461
other O O 0.9999228715896606
patients O O 0.9999814033508301
as O O 0.9999699592590332
well O O 0.9998946189880371
. O O 0.9999606609344482

Centrally O O 0.9979658126831055
mediated O O 0.9998859167098999
cardiovascular O O 0.9999608993530273
effects O O 0.9999754428863525
of O O 0.9999005794525146
intracisternal O O 0.9999085664749146
application O O 0.999970555305481
of O O 0.9980781078338623
carbachol B B 0.9996819496154785
in O O 0.9999105930328369
anesthetized O O 0.9999903440475464
rats O O 0.9999967813491821
. O O 0.9999663829803467

The O O 0.9999798536300659
pressor O O 0.9998737573623657
response O O 0.9999752044677734
to O O 0.9999094009399414
the O O 0.9999771118164062
intracisternal O O 0.9999346733093262
( O O 0.9998410940170288
i O O 0.9998726844787598
. O O 0.9999945163726807
c O O 0.9999986886978149
. O O 0.9999967813491821
) O O 0.9999673366546631
injection O O 0.9999483823776245
of O O 0.999448835849762
carbachol B B 0.999830961227417
( O O 0.9995936751365662
1 O O 0.9981689453125
mug O O 0.9442158341407776
) O O 0.9999544620513916
in O O 0.9999408721923828
anesthetized O O 0.9999909400939941
rats O O 0.999993085861206
was O O 0.9999575614929199
analyzed O O 0.9997918009757996
. O O 0.9999732971191406

This O O 0.9999371767044067
response O O 0.9999693632125854
was O O 0.9999507665634155
significantly O O 0.999988317489624
reduced O O 0.9999954700469971
by O O 0.999934196472168
the O O 0.9999819993972778
intravenous O O 0.9999771118164062
( O O 0.9997028708457947
i O O 0.9999231100082397
. O O 0.9999895095825195
v O O 0.9999988079071045
. O O 0.9999971389770508
) O O 0.9999650716781616
injection O O 0.9999638795852661
of O O 0.999110996723175
guanethidine B B 0.9997636675834656
( O O 0.9988516569137573
5 O O 0.999850869178772
mg O O 0.9981300234794617
) O O 0.9998631477355957
, O O 0.9953305721282959
hexamethonium B B 0.9975736737251282
( O O 0.9947243332862854
10 O O 0.9984825253486633
mg O O 0.9984277486801147
) O O 0.999569833278656
or O O 0.9929196238517761
phentolamine B B 0.9980917572975159
( O O 0.9985645413398743
5 O O 0.99980229139328
mg O O 0.9990102052688599
) O O 0.9998958110809326
, O O 0.9999284744262695
and O O 0.9999657869338989
conversely O O 0.9999256134033203
, O O 0.999985933303833
potentiated O O 0.9999356269836426
by O O 0.9999070167541504
i O O 0.9994822144508362
. O O 0.9999749660491943
v O O 0.9999949932098389
. O O 0.9998284578323364
desmethylimipramine B B 0.9991480112075806
( O O 0.9992927312850952
0 O O 0.9994229078292847
. O O 0.9999716281890869
3 O O 0.9990344047546387
mg O O 0.9980553388595581
) O O 0.9999165534973145
, O O 0.9999645948410034
while O O 0.9998522996902466
propranolol B B 0.9994924068450928
( O O 0.9989976286888123
0 O O 0.9999239444732666
. O O 0.9999896287918091
5 O O 0.9999896287918091
mg O O 0.9996688365936279
) O O 0.9998366832733154
i O O 0.9987512826919556
. O O 0.9999864101409912
v O O 0.9999258518218994
. O O 0.999977707862854
selectively O O 0.9995811581611633
inhibited O O 0.9999239444732666
the O O 0.9999806880950928
enlargement O O 0.9999873638153076
of O O 0.9999486207962036
pulse O O 0.9999097585678101
pressure O O 0.9999710321426392
and O O 0.9999688863754272
the O O 0.9999858140945435
tachycardia O O 0.9999967813491821
following O O 0.9999343156814575
i O O 0.9992839694023132
. O O 0.999985933303833
c O O 0.9999411106109619
. O O 0.9998070597648621
carbachol B B 0.9997525811195374
( O O 0.9995108842849731
1 O O 0.997439980506897
mug O O 0.9437450170516968
) O O 0.9999192953109741
. O O 0.9999613761901855

On O O 0.9999812841415405
the O O 0.9999804496765137
other O O 0.9999854564666748
hand O O 0.9999935626983643
, O O 0.9999608993530273
the O O 0.9999645948410034
pressor O O 0.9998476505279541
response O O 0.9999697208404541
to O O 0.999901533126831
i O O 0.9995834231376648
. O O 0.9999668598175049
c O O 0.999823272228241
. O O 0.9968760013580322
carbachol B B 0.9998049139976501
( O O 0.9992772936820984
1 O O 0.9991486072540283
mug O O 0.8933224678039551
) O O 0.9998806715011597
was O O 0.9999371767044067
almost O O 0.9999711513519287
completely O O 0.9999696016311646
blocked O O 0.9999762773513794
by O O 0.9997761845588684
i O O 0.9998829364776611
. O O 0.9999773502349854
c O O 0.9997053742408752
. O O 0.9989792704582214
atropine B B 0.9998088479042053
( O O 0.9992431402206421
3 O O 0.9969120025634766
mug O O 0.9475148916244507
) O O 0.9994774460792542
or O O 0.9960421323776245
hexamethonium B B 0.9993083477020264
( O O 0.9994240999221802
500 O O 0.9995261430740356
mug O O 0.9992951154708862
) O O 0.9999136924743652
, O O 0.999950647354126
and O O 0.9999545812606812
significantly O O 0.9999790191650391
reduced O O 0.9999921321868896
by O O 0.9998958110809326
i O O 0.9996894598007202
. O O 0.9999860525131226
c O O 0.9998852014541626
. O O 0.9984956979751587
chlorpromazine B B 0.9994450211524963
( O O 0.9997538924217224
50 O O 0.997654378414154
mug O O 0.9894746541976929
) O O 0.9998956918716431
but O O 0.9999457597732544
significantly O O 0.9999713897705078
potentiated O O 0.9999769926071167
by O O 0.9998787641525269
i O O 0.9993658661842346
. O O 0.9999839067459106
c O O 0.9998447895050049
. O O 0.9990571141242981
desmethylimipramine B B 0.9992916584014893
( O O 0.9996610879898071
30 O O 0.9987689852714539
mug O O 0.9890062808990479
) O O 0.9999120235443115
. O O 0.9999595880508423

The O O 0.9999841451644897
pressor O O 0.999798595905304
response O O 0.9999499320983887
to O O 0.9997979998588562
i O O 0.995389461517334
. O O 0.9999721050262451
c O O 0.9999943971633911
. O O 0.9990031123161316
carbachol B B 0.9997701048851013
( O O 0.9982208609580994
1 O O 0.9860982894897461
mug O O 0.9570941925048828
) O O 0.9998776912689209
remained O O 0.9999721050262451
unchanged O O 0.9999885559082031
after O O 0.9998438358306885
sectioning O O 0.9999344348907471
of O O 0.9999228715896606
the O O 0.9999769926071167
bilateral O O 0.9999234676361084
cervical O O 0.993020236492157
vagal O O 0.9505707025527954
nerves O O 0.999891996383667
but O O 0.9999600648880005
disappeared O O 0.9999722242355347
after O O 0.9998420476913452
sectioning O O 0.9999854564666748
of O O 0.999968409538269
the O O 0.9999815225601196
spinal O O 0.9999865293502808
cord O O 0.9999973773956299
( O O 0.9999386072158813
C7 O O 0.9993689656257629
- O O 0.9969841837882996
C8 O O 0.9983826875686646
) O O 0.9999750852584839
. O O 0.9999721050262451

From O O 0.9999866485595703
the O O 0.9999921321868896
above O O 0.999994158744812
result O O 0.9999847412109375
it O O 0.9999871253967285
is O O 0.9999737739562988
suggested O O 0.9999854564666748
that O O 0.9999336004257202
the O O 0.9999397993087769
pressor O O 0.9999206066131592
response O O 0.9999533891677856
to O O 0.9991706609725952
i O O 0.9992163181304932
. O O 0.9999809265136719
c O O 0.9999817609786987
. O O 0.9997844099998474
carbachol B B 0.9991447925567627
ortral O O 0.9985482096672058
and O O 0.9995573163032532
peripheral O O 0.9859920144081116
adrenergic O O 0.7228856086730957
mechanisms O O 0.9997925162315369
, O O 0.9998897314071655
and O O 0.9996727705001831
that O O 0.9998867511749268
the O O 0.9995580315589905
sympathetic O O 0.9944177865982056
trunk O O 0.9998651742935181
is O O 0.9999479055404663
the O O 0.9999450445175171
main O O 0.9997203946113586
pathway O O 0.9999760389328003
. O O 0.9999544620513916

Neuroleptic O O 0.9988783001899719
malignant O O 0.999988317489624
syndrome O O 0.9999537467956543
and O O 0.9984797835350037
methylphenidate B B 0.9995648264884949
. O O 0.9997376799583435

A O O 0.9999767541885376
1 O O 0.9999407529830933
- O O 0.9999840259552002
year O O 0.9999951124191284
- O O 0.9999942779541016
old O O 0.9999942779541016
female O O 0.9999942779541016
presented O O 0.9999446868896484
with O O 0.9999727010726929
neuroleptic O O 0.9999891519546509
malignant O O 0.9999967813491821
syndrome O O 0.999995231628418
probably O O 0.9999862909317017
caused O O 0.9999864101409912
by O O 0.9996633529663086
methylphenidate B B 0.9992747902870178
. O O 0.9998964071273804

She O O 0.9999552965164185
had O O 0.9999209642410278
defects O O 0.9999761581420898
in O O 0.9999369382858276
the O O 0.9999419450759888
supratentorial O O 0.9998900890350342
brain O O 0.9999793767929077
including O O 0.9998093247413635
the O O 0.9998979568481445
basal O O 0.9989826083183289
ganglia O O 0.999985933303833
and O O 0.9997733235359192
the O O 0.999832034111023
striatum O O 0.9916390776634216
( O O 0.9998670816421509
multicystic O O 0.9752354621887207
encephalomalacia O O 0.999384880065918
) O O 0.9999678134918213
due O O 0.9999637603759766
to O O 0.9998012185096741
severe O O 0.9999288320541382
perinatal O O 0.9998576641082764
hypoxic O O 0.9618390202522278
- O O 0.9952528476715088
ischemic O O 0.9990090131759644
encephalopathy O O 0.9998179078102112
, O O 0.9999657869338989
which O O 0.9999617338180542
was O O 0.999967098236084
considered O O 0.9999839067459106
to O O 0.9999674558639526
be O O 0.999945878982544
a O O 0.9998431205749512
possible O O 0.9997473359107971
predisposing O O 0.9998261332511902
factor O O 0.999985933303833
causing O O 0.9999066591262817
neuroleptic O O 0.9999903440475464
malignant O O 0.9999971389770508
syndrome O O 0.9999957084655762
. O O 0.9999740123748779

A O O 0.999512791633606
dopaminergic O O 0.7675727009773254
blockade O O 0.9754005670547485
mechanism O O 0.999433696269989
generally O O 0.9996721744537354
is O O 0.9999192953109741
accepted O O 0.9999200105667114
as O O 0.9999819993972778
the O O 0.9999756813049316
pathogenesis O O 0.9999841451644897
of O O 0.9999666213989258
this O O 0.9999303817749023
syndrome O O 0.9999915361404419
. O O 0.9999587535858154

However O O 0.9999550580978394
, O O 0.9996318817138672
methylphenidate B B 0.9997989535331726
is O O 0.9994391798973083
a O O 0.9983593821525574
dopamine B B 0.9784483909606934
agonist O O 0.8304946422576904
via O O 0.9996705055236816
the O O 0.9999345541000366
inhibition O O 0.9997462630271912
of O O 0.9996236562728882
uptake O O 0.9945138692855835
of O O 0.9982607960700989
dopamine B B 0.9990904331207275
, O O 0.9998621940612793
and O O 0.9999418258666992
therefore O O 0.9998764991760254
dopaminergic O O 0.48090848326683044
systems O O 0.9992402791976929
in O O 0.9994089603424072
the O O 0.9998780488967896
brainstem O O 0.9998644590377808
( O O 0.9999516010284424
mainly O O 0.9997584223747253
the O O 0.9999123811721802
midbrain O O 0.9984205961227417
) O O 0.9999127388000488
and O O 0.9996919631958008
the O O 0.9999076128005981
spinal O O 0.9999829530715942
cord O O 0.9999899864196777
were O O 0.9999632835388184
unlikely O O 0.999972939491272
to O O 0.9999779462814331
participate O O 0.9999922513961792
in O O 0.9999872446060181
the O O 0.9999920129776001
onset O O 0.9999958276748657
of O O 0.9999865293502808
this O O 0.9999759197235107
syndrome O O 0.9999938011169434
. O O 0.999966025352478

A O O 0.9999164342880249
relative O O 0.9998648166656494
gamma B B 0.8373762369155884
- I I 0.8628810048103333
aminobutyric I I 0.9967758059501648
acid I I 0.9992951154708862
- O O 0.9426994323730469
ergic O O 0.9047849774360657
deficiency O O 0.9999542236328125
might O O 0.9999423027038574
occur O O 0.9999783039093018
because O O 0.999758780002594
diazepam B B 0.9998123049736023
, O O 0.9998844861984253
a O O 0.9992634654045105
gamma B B 0.806722104549408
- I I 0.8342583775520325
aminobutyric I I 0.9940474033355713
acid I I 0.9993383288383484
- O O 0.8491893410682678
mimetic O O 0.9529329538345337
agent O O 0.9975429773330688
, O O 0.9999668598175049
was O O 0.9999492168426514
strikingly O O 0.9998894929885864
effective O O 0.999810516834259
. O O 0.9999558925628662

This O O 0.9999881982803345
is O O 0.9999946355819702
the O O 0.9999921321868896
first O O 0.9999957084655762
reported O O 0.9999954700469971
patient O O 0.9999935626983643
with O O 0.9999675750732422
neuroleptic O O 0.9999773502349854
malignant O O 0.9999960660934448
syndrome O O 0.9999940395355225
probably O O 0.9999773502349854
caused O O 0.9999856948852539
by O O 0.9997535347938538
methylphenidate B B 0.9993308782577515
. O O 0.9999219179153442

Differential O O 0.9995089769363403
effects O O 0.9999170303344727
of O O 0.9990134239196777
17alpha B B 0.9882532954216003
- I I 0.7627458572387695
ethinylestradiol I I 0.9816292524337769
on O O 0.9987253546714783
the O O 0.9998874664306641
neutral O O 0.9865147471427917
and O O 0.999716579914093
acidic O O 0.965703010559082
pathways O O 0.9999620914459229
of O O 0.9998781681060791
bile B B 0.6970854997634888
salt I I 0.9885911345481873
synthesis O O 0.9847895503044128
in O O 0.9999387264251709
the O O 0.9999866485595703
rat O O 0.9999700784683228
. O O 0.9999547004699707

Effects O O 0.9999140501022339
of O O 0.9995362758636475
17alpha B B 0.9921073317527771
- I I 0.8219055533409119
ethinylestradiol I I 0.9962524771690369
( O O 0.9743350744247437
EE B B 0.9986520409584045
) O O 0.9995142221450806
on O O 0.9998805522918701
the O O 0.9999172687530518
neutral O O 0.9732751846313477
and O O 0.9997677206993103
acidic O O 0.9520815014839172
biosynthetic O O 0.9486885666847229
pathways O O 0.9999717473983765
of O O 0.9999122619628906
bile B B 0.4771612286567688
salt I I 0.9612596035003662
( O O 0.9842166900634766
BS B O 0.6225345730781555
) O O 0.9961446523666382
synthesis O O 0.9994968175888062
were O O 0.9999686479568481
evaluated O O 0.999981164932251
in O O 0.9999586343765259
rats O O 0.9999943971633911
with O O 0.9999703168869019
an O O 0.9999852180480957
intact O O 0.9999594688415527
enterohepatic O O 0.9994426369667053
circulation O O 0.9999805688858032
and O O 0.9999632835388184
in O O 0.9999525547027588
rats O O 0.9999934434890747
with O O 0.9999661445617676
long O O 0.9994390606880188
- O O 0.9999794960021973
term O O 0.9998981952667236
bile O O 0.47936558723449707
diversion O O 0.8807462453842163
to O O 0.9992445707321167
induce O O 0.9998800754547119
BS B O 0.5677483677864075
synthesis O O 0.9997881054878235
. O O 0.9999442100524902

For O O 0.999818742275238
this O O 0.9999551773071289
purpose O O 0.9999687671661377
, O O 0.9999665021896362
bile B O 0.975045382976532
salt I O 0.8420100808143616
pool O O 0.9996508359909058
composition O O 0.9999570846557617
, O O 0.9999529123306274
synthesis O O 0.9999666213989258
of O O 0.9999212026596069
individual O O 0.9981390237808228
BS B O 0.7724517583847046
in O O 0.9998550415039062
vivo O O 0.9999854564666748
, O O 0.999948263168335
hepatic O O 0.9998403787612915
activities O O 0.9998389482498169
, O O 0.999932050704956
and O O 0.9998891353607178
expression O O 0.9908620119094849
levels O O 0.9998676776885986
of O O 0.9983962178230286
cholesterol B B 0.9500842094421387
7alpha O O 0.6491448879241943
- O O 0.522050142288208
hydroxylase O O 0.5842045545578003
( O O 0.9989008903503418
CYP7A O O 0.6451060771942139
) O O 0.99905925989151
, O O 0.9963704347610474
and O O 0.9877514839172363
sterol B O 0.8395687937736511
27 O O 0.5776162147521973
- O O 0.49657490849494934
hydroxylase O O 0.6548369526863098
( O O 0.998848557472229
CYP27 O O 0.6431922316551208
) O O 0.9998875856399536
, O O 0.9999704360961914
as O O 0.9999409914016724
well O O 0.9999141693115234
as O O 0.9999654293060303
of O O 0.9996707439422607
other O O 0.9997785687446594
enzymes O O 0.991401731967926
involved O O 0.9999481439590454
in O O 0.9999377727508545
BS B O 0.5102806091308594
synthesis O O 0.9996649026870728
, O O 0.9999779462814331
were O O 0.9999798536300659
analyzed O O 0.9999674558639526
in O O 0.9999444484710693
rats O O 0.9999933242797852
treated O O 0.999975323677063
with O O 0.999812662601471
EE B B 0.9984502792358398
( O O 0.9994865655899048
5 O O 0.9998941421508789
mg O O 0.999958872795105
/ O O 0.9999918937683105
kg O O 0.9999963045120239
, O O 0.9999710321426392
3 O O 0.9998555183410645
days O O 0.9999808073043823
) O O 0.9999730587005615
or O O 0.9997203946113586
its O O 0.9610111713409424
vehicle O O 0.99988853931427
. O O 0.9999642372131348

BS B O 0.5359245538711548
pool O O 0.9994223117828369
size O O 0.9999701976776123
was O O 0.9999457597732544
decreased O O 0.9999752044677734
by O O 0.9999841451644897
27 O O 0.9999858140945435
% O O 0.9999957084655762
but O O 0.9999322891235352
total O O 0.9970439076423645
BS B O 0.7969062924385071
synthesis O O 0.9946740865707397
was O O 0.9999630451202393
not O O 0.9999681711196899
affected O O 0.9999741315841675
by O O 0.9998195767402649
EE B B 0.9504917860031128
in O O 0.9995806813240051
intact O O 0.9997724890708923
rats O O 0.9999626874923706
. O O 0.999957799911499

Synthesis O O 0.9876370429992676
of O O 0.9947904348373413
cholate B B 0.9562399387359619
was O O 0.9998946189880371
reduced O O 0.9999656677246094
by O O 0.999976634979248
68 O O 0.9998990297317505
% O O 0.9999849796295166
in O O 0.9997277855873108
EE B B 0.9975741505622864
- O O 0.9983769655227661
treated O O 0.9997707009315491
rats O O 0.9998183846473694
, O O 0.9999576807022095
while O O 0.9999457597732544
that O O 0.9998884201049805
of O O 0.9991996884346008
chenodeoxycholate B B 0.9860430955886841
was O O 0.9999475479125977
increased O O 0.9999634027481079
by O O 0.99998939037323
60 O O 0.9999948740005493
% O O 0.9999885559082031
. O O 0.999981164932251

The O O 0.999901294708252
recently O O 0.9999475479125977
identified O O 0.9998551607131958
Delta22 O O 0.6679040789604187
- O O 0.8475623726844788
isomer O O 0.9045146107673645
of O O 0.9918975830078125
beta O B 0.474563866853714
- O I 0.8639968633651733
muricholate O I 0.999261200428009
contributed O O 0.9996776580810547
for O O 0.9999521970748901
5 O O 0.9998729228973389
. O O 0.9999390840530396
4 O O 0.9999825954437256
% O O 0.9999845027923584
and O O 0.9999430179595947
18 O O 0.9999349117279053
. O O 0.999985933303833
3 O O 0.9999908208847046
% O O 0.9999879598617554
( O O 0.9999732971191406
P O O 0.9999845027923584
< O O 0.9999834299087524
0 O O 0.9999959468841553
. O O 0.9999984502792358
01 O O 0.9999973773956299
) O O 0.9999837875366211
to O O 0.9999232292175293
the O O 0.9999291896820068
pool O O 0.9998908042907715
in O O 0.9998076558113098
control O O 0.9984292387962341
and O O 0.9998822212219238
EE B B 0.9927392601966858
- O O 0.9969634413719177
treated O O 0.9998757839202881
rats O O 0.9999880790710449
, O O 0.9999767541885376
respectively O O 0.9999431371688843
, O O 0.9999691247940063
but O O 0.9999679327011108
could O O 0.9999798536300659
not O O 0.9999901056289673
be O O 0.9999866485595703
detected O O 0.9999864101409912
in O O 0.9998067021369934
bile O O 0.9906929135322571
after O O 0.9998726844787598
exhaustion O O 0.9999622106552124
of O O 0.999915599822998
the O O 0.9999531507492065
pool O O 0.9995928406715393
. O O 0.9999412298202515

A O O 0.999921441078186
clear O O 0.9999377727508545
reduction O O 0.9999630451202393
of O O 0.9998661279678345
BS B O 0.751919686794281
synthesis O O 0.9962833523750305
was O O 0.9999750852584839
found O O 0.9999864101409912
in O O 0.9996457099914551
bile O O 0.9291292428970337
- O O 0.9944656491279602
diverted O O 0.8703885078430176
rats O O 0.999887228012085
treated O O 0.9997699856758118
with O O 0.9990065693855286
EE B B 0.9893383979797363
, O O 0.9997808337211609
yet O O 0.9999350309371948
biliary O O 0.9982374906539917
BS B O 0.9149366617202759
composition O O 0.9998156428337097
was O O 0.9999728202819824
only O O 0.9999903440475464
minimally O O 0.9999935626983643
affected O O 0.9999897480010986
. O O 0.9999740123748779

Activity O O 0.998730480670929
of O O 0.9972625970840454
CYP7A O O 0.5994805693626404
was O O 0.999880313873291
decreased O O 0.9999003410339355
by O O 0.9987284541130066
EE B B 0.9430627226829529
in O O 0.9992181062698364
both O O 0.9993906021118164
intact O O 0.9997066855430603
and O O 0.9997850060462952
bile O O 0.8617600202560425
- O O 0.9987672567367554
diverted O O 0.9856281280517578
rats O O 0.9998599290847778
, O O 0.9999213218688965
whereas O O 0.9999562501907349
the O O 0.9999338388442993
activity O O 0.9994539618492126
of O O 0.999546468257904
the O O 0.9995719790458679
CYP27 O O 0.4934525191783905
was O O 0.9999345541000366
not O O 0.9999517202377319
affected O O 0.9999740123748779
. O O 0.9999518394470215

Hepatic O O 0.9987448453903198
mRNA O O 0.5916956067085266
levels O O 0.9996936321258545
of O O 0.9946632385253906
CYP7A O O 0.5038967132568359
were O O 0.9998929500579834
significantly O O 0.9999430179595947
reduced O O 0.999984860420227
by O O 0.9997513890266418
EE B O 0.7532739043235779
in O O 0.9995430707931519
bile O O 0.476934552192688
- O O 0.9611741304397583
diverted O O 0.89865642786026
rats O O 0.9999299049377441
only O O 0.999876856803894
; O O 0.9999202489852905
CYP27 O O 0.6346419453620911
mRNA O O 0.5370884537696838
levels O O 0.9998598098754883
were O O 0.999946117401123
not O O 0.9999498128890991
affected O O 0.9999828338623047
by O O 0.9997764229774475
EE B O 0.8105713725090027
. O O 0.9997954964637756

In O O 0.999847412109375
addition O O 0.9999171495437622
, O O 0.9996434450149536
mRNA O O 0.782662034034729
levels O O 0.9997863173484802
of O O 0.9983494281768799
sterol B B 0.8750012516975403
12alpha O O 0.8782943487167358
- O O 0.7668524384498596
hydroxylase O O 0.9067028164863586
and O O 0.9840489625930786
lithocholate O B 0.9361547827720642
6beta O O 0.5679544806480408
- O O 0.5611593723297119
hydroxylase O O 0.7282659411430359
were O O 0.9998927116394043
increased O O 0.9998183846473694
by O O 0.9994901418685913
bile O O 0.7734324336051941
diversion O O 0.7299774885177612
and O O 0.9997233748435974
suppressed O O 0.9996156692504883
by O O 0.9989443421363831
EE B B 0.9782344698905945
. O O 0.9998997449874878

This O O 0.9999606609344482
study O O 0.9999785423278809
shows O O 0.9999371767044067
that O O 0.9998966455459595
17alpha B B 0.9952527284622192
- I I 0.8768531680107117
ethinylestradiol I I 0.9990803003311157
( O O 0.8962810635566711
EE B B 0.9989959597587585
) O O 0.9847870469093323
- O O 0.9998875856399536
induced O O 0.9999690055847168
intrahepatic O O 0.9999912977218628
cholestasis O O 0.9374794960021973
in O O 0.9999356269836426
rats O O 0.9961138963699341
is O O 0.9999151229858398
associated O O 0.9999752044677734
with O O 0.999848484992981
selective O O 0.9988147020339966
inhibition O O 0.999826967716217
of O O 0.9998327493667603
the O O 0.9997386336326599
neutral O O 0.9755187034606934
pathway O O 0.9998961687088013
of O O 0.9990758895874023
bile B B 0.4863619804382324
salt I I 0.9709032773971558
( O O 0.9732972979545593
BS B O 0.5441117882728577
) O O 0.995242714881897
synthesis O O 0.9993487000465393
. O O 0.9999518394470215

Simultaneous O O 0.9992849230766296
impairment O O 0.9998782873153687
of O O 0.9997583031654358
other O O 0.9992363452911377
enzymes O O 0.9862717390060425
in O O 0.9995560050010681
the O O 0.9997079968452454
BS B O 0.7152047157287598
biosynthetic O O 0.9156913161277771
pathways O O 0.9997358918190002
may O O 0.9998292922973633
contribute O O 0.9999285936355591
to O O 0.9998924732208252
overall O O 0.9998276233673096
effects O O 0.9999614953994751
of O O 0.9992807507514954
EE B B 0.9646530151367188
on O O 0.99750816822052
BS B O 0.7131710052490234
synthesis O O 0.9994487166404724
. O O 0.9999682903289795

Glibenclamide B B 0.9992324113845825
- O O 0.999762237071991
sensitive O O 0.9998250603675842
hypotension O O 0.999923586845398
produced O O 0.9999569654464722
by O O 0.9998317956924438
helodermin B B 0.9950886368751526
assessed O O 0.991460919380188
in O O 0.9999125003814697
the O O 0.9999736547470093
rat O O 0.9999716281890869
. O O 0.9999350309371948

The O O 0.9999607801437378
effects O O 0.9999649524688721
of O O 0.999496579170227
helodermin B B 0.99882572889328
, O O 0.9997261166572571
a O O 0.9995139837265015
basic O O 0.9734262824058533
35 O O 0.918753981590271
- O O 0.9670871496200562
amino B O 0.6470903158187866
acid I O 0.9167712330818176
peptide O O 0.8731821775436401
isolated O O 0.5848488211631775
from O O 0.7774223685264587
the O O 0.992933988571167
venom O O 0.9778009057044983
of O O 0.9996154308319092
a O O 0.9957491159439087
lizard O O 0.9378488659858704
salivary O O 0.9975691437721252
gland O O 0.9892645478248596
, O O 0.9999488592147827
on O O 0.9998667240142822
arterial O O 0.9999781847000122
blood O O 0.9999637603759766
pressure O O 0.9997227787971497
and O O 0.9999725818634033
heart O O 0.9999895095825195
rate O O 0.9999915361404419
were O O 0.9999637603759766
examined O O 0.9999804496765137
in O O 0.9999409914016724
the O O 0.9999769926071167
rat O O 0.9999871253967285
, O O 0.9999769926071167
focusing O O 0.9999836683273315
on O O 0.9999758005142212
the O O 0.9999898672103882
possibility O O 0.9999877214431763
that O O 0.9999217987060547
activation O O 0.9996610879898071
of O O 0.9988270401954651
ATP B B 0.946803629398346
sensitive O O 0.9500076174736023
K B B 0.9272019863128662
+ O O 0.9335997104644775
( O O 0.9923285841941833
K B B 0.9242674708366394
( O O 0.6875145435333252
ATP B O 0.4397752285003662
) O O 0.9713266491889954
) O O 0.9938503503799438
channels O O 0.999058187007904
is O O 0.9999452829360962
involved O O 0.9999456405639648
in O O 0.9999603033065796
the O O 0.9999526739120483
responses O O 0.9999774694442749
. O O 0.9999041557312012

The O O 0.9999915361404419
results O O 0.9999850988388062
were O O 0.9999939203262329
also O O 0.9999936819076538
compared O O 0.9999933242797852
with O O 0.9999715089797974
those O O 0.9999897480010986
of O O 0.9998393058776855
vasoactive O O 0.7390850186347961
intestinal O O 0.9153253436088562
polypeptide O O 0.7721572518348694
( O O 0.9977982044219971
VIP O B 0.898185670375824
) O O 0.9995322227478027
. O O 0.9999704360961914

Helodermin B B 0.9987488985061646
produced O O 0.9998888969421387
hypotension O O 0.999947190284729
in O O 0.9999750852584839
a O O 0.999955415725708
dose O O 0.9993663430213928
- O O 0.9999451637268066
dependent O O 0.9999585151672363
manner O O 0.9999812841415405
with O O 0.9999587535858154
approximately O O 0.9999809265136719
similar O O 0.9999194145202637
potency O O 0.9997527003288269
and O O 0.9999750852584839
duration O O 0.9999788999557495
to O O 0.9991415739059448
VIP O B 0.9931010007858276
. O O 0.9995704293251038

Hypotension O O 0.9998026490211487
induced O O 0.9999399185180664
by O O 0.999788224697113
both O O 0.8297812342643738
peptides O O 0.7430467009544373
was O O 0.9999191761016846
significantly O O 0.9999650716781616
attenuated O O 0.9998757839202881
by O O 0.9996805191040039
glibenclamide B B 0.9998927116394043
, O O 0.9998992681503296
which O O 0.9998946189880371
abolished O O 0.9997590184211731
a O O 0.9998661279678345
levcromakalim B B 0.9907989501953125
- O O 0.999146580696106
produced O O 0.9998888969421387
decrease O O 0.9999918937683105
in O O 0.9999918937683105
arterial O O 0.9999706745147705
blood O O 0.9999586343765259
pressure O O 0.9999173879623413
. O O 0.9999639987945557

Oxyhemoglobin O B 0.9990735054016113
did O O 0.999891996383667
not O O 0.9999185800552368
affect O O 0.9997746348381042
helodermin B B 0.9984390139579773
- O O 0.9997339844703674
induced O O 0.9999492168426514
hypotension O O 0.9999651908874512
, O O 0.9999614953994751
whereas O O 0.9999551773071289
it O O 0.9997166991233826
shortened O O 0.9999617338180542
the O O 0.9999758005142212
duration O O 0.9999830722808838
of O O 0.9999223947525024
acetylcholine B B 0.9959839582443237
( O O 0.9956609606742859
ACh B B 0.9936304688453674
) O O 0.962631106376648
- O O 0.9997451901435852
produced O O 0.9999088048934937
hypotension O O 0.999955415725708
. O O 0.9999653100967407

These O O 0.9999773502349854
findings O O 0.9999933242797852
suggest O O 0.9999459981918335
that O O 0.999815046787262
helodermin B B 0.9993483424186707
- O O 0.9997264742851257
produced O O 0.9999232292175293
hypotension O O 0.9999697208404541
is O O 0.9999125003814697
partly O O 0.9999047517776489
attributable O O 0.9999828338623047
to O O 0.9996517896652222
the O O 0.9997172951698303
activation O O 0.9996309280395508
of O O 0.9995965361595154
glibenclamide B B 0.9971179962158203
- O O 0.9994389414787292
sensitive O O 0.9880752563476562
K B B 0.8686343431472778
+ O O 0.8335167169570923
channels O O 0.9985163807868958
( O O 0.9997405409812927
K B B 0.9298335909843445
( O O 0.770463228225708
ATP B O 0.6240067481994629
) O O 0.9912648797035217
channels O O 0.9975922107696533
) O O 0.9999395608901978
, O O 0.9999673366546631
which O O 0.9998980760574341
presumably O O 0.9991745352745056
exist O O 0.9990371465682983
on O O 0.9998492002487183
arterial O O 0.9998205304145813
smooth O O 0.9998000264167786
muscle O O 0.9999639987945557
cells O O 0.9999867677688599
. O O 0.9999514818191528

EDRF O O 0.7819908857345581
( O O 0.9712948203086853
endothelium O O 0.9845120906829834
- O O 0.9978387951850891
derived O O 0.9895594120025635
relaxing O O 0.9317745566368103
factor O O 0.9252640604972839
) O O 0.9948911666870117
/ O O 0.9966040849685669
nitric B B 0.9400895237922668
oxide I I 0.9922404289245605
does O O 0.9995777010917664
not O O 0.9999489784240723
seem O O 0.9999732971191406
to O O 0.9999333620071411
play O O 0.9998921155929565
an O O 0.9999374151229858
important O O 0.9999265670776367
role O O 0.9999197721481323
in O O 0.999923825263977
the O O 0.9998877048492432
peptide O B 0.9888962507247925
- O O 0.9985400438308716
produced O O 0.9999328851699829
hypotension O O 0.9999489784240723
. O O 0.9999505281448364

Long O O 0.9989340901374817
- O O 0.9999852180480957
term O O 0.9999370574951172
efficacy O O 0.9999790191650391
and O O 0.999987006187439
adverse O O 0.9999856948852539
event O O 0.9999984502792358
of O O 0.9996426105499268
nifedipine B B 0.9996480941772461
sustained O O 0.9913144707679749
- O O 0.9997835755348206
release O O 0.9970738887786865
tablets O O 0.9914034008979797
for O O 0.9993506073951721
cyclosporin B B 0.9965218305587769
A I I 0.9974908828735352
- O O 0.9882603883743286
induced O O 0.9999544620513916
hypertension O O 0.9990867376327515
in O O 0.9999755620956421
patients O O 0.9999933242797852
with O O 0.9999828338623047
psoriasis O O 0.9999252557754517
. O O 0.9999722242355347

Thirteen O O 0.9993187189102173
psoriatic O O 0.9997652173042297
patients O O 0.9999845027923584
with O O 0.9999343156814575
hypertension O O 0.997494101524353
during O O 0.9999301433563232
the O O 0.9999828338623047
course O O 0.9999566078186035
of O O 0.999816358089447
cyclosporin B B 0.9990940093994141
A I I 0.9727856516838074
therapy O O 0.8046977519989014
were O O 0.9999562501907349
treated O O 0.9999744892120361
for O O 0.9999643564224243
25 O O 0.9999544620513916
months O O 0.9999969005584717
with O O 0.9999362230300903
a O O 0.9998277425765991
calcium B B 0.9524167776107788
channel O O 0.8917763233184814
blocker O O 0.9307481646537781
, O O 0.9985914826393127
sustained O O 0.9914685487747192
- O O 0.999584972858429
release O O 0.9909862279891968
nifedipine B B 0.9996910095214844
, O O 0.9996366500854492
to O O 0.9999886751174927
study O O 0.9999380111694336
the O O 0.999988317489624
clinical O O 0.9999619722366333
antihypertensive O O 0.7661298513412476
effects O O 0.999929666519165
and O O 0.9999794960021973
adverse O O 0.9999872446060181
events O O 0.9999986886978149
during O O 0.9999829530715942
treatment O O 0.9999890327453613
with O O 0.999948263168335
both O O 0.9973276853561401
drugs O O 0.9979762434959412
. O O 0.9999630451202393

Seven O O 0.9999610185623169
of O O 0.9999837875366211
the O O 0.9999880790710449
13 O O 0.9999932050704956
patients O O 0.9999916553497314
had O O 0.9999785423278809
exhibited O O 0.9999921321868896
a O O 0.9999881982803345
subclinical O O 0.9999784231185913
hypertensive O O 0.9998637437820435
state O O 0.9999839067459106
before O O 0.9997919201850891
cyclosporin B B 0.9990724325180054
A I I 0.9955043196678162
therapy O O 0.9959575533866882
. O O 0.9999666213989258

Both O O 0.999869704246521
systolic O O 0.9986287355422974
and O O 0.9998164772987366
diastolic O O 0.9999097585678101
blood O O 0.9994569420814514
pressures O O 0.9999024868011475
of O O 0.9999229907989502
these O O 0.9999715089797974
13 O O 0.9999616146087646
patients O O 0.9999905824661255
were O O 0.999953031539917
decreased O O 0.9999852180480957
significantly O O 0.9999942779541016
after O O 0.9999560117721558
4 O O 0.999725878238678
weeks O O 0.9999946355819702
of O O 0.9998403787612915
nifedipine B B 0.9998254179954529
therapy O O 0.9998747110366821
, O O 0.9999748468399048
and O O 0.9999679327011108
blood O O 0.9997381567955017
pressure O O 0.9967389702796936
was O O 0.9999767541885376
maintained O O 0.9999761581420898
within O O 0.9999812841415405
the O O 0.9999933242797852
normal O O 0.9999934434890747
range O O 0.9999958276748657
thereafter O O 0.9999949932098389
for O O 0.9999730587005615
25 O O 0.9999679327011108
months O O 0.9999983310699463
. O O 0.9999873638153076

The O O 0.9999862909317017
adverse O O 0.9999747276306152
events O O 0.9999985694885254
during O O 0.9999617338180542
combined O O 0.9968344569206238
therapy O O 0.9999666213989258
with O O 0.9996222257614136
cyclosporin B B 0.9990134239196777
A I I 0.999869704246521
and O O 0.7063152194023132
nifedipine B B 0.998307466506958
included O O 0.9999685287475586
an O O 0.9999970197677612
increase O O 0.9999960660934448
in O O 0.9999799728393555
blood B B 0.8561818599700928
urea I I 0.7427017688751221
nitrogen I I 0.9996466636657715
levels O O 0.9997078776359558
in O O 0.9999862909317017
9 O O 0.9999500513076782
of O O 0.9999814033508301
the O O 0.9999891519546509
13 O O 0.999991774559021
patients O O 0.9999947547912598
and O O 0.999970555305481
development O O 0.9999973773956299
of O O 0.999984622001648
gingival O O 0.9695172309875488
hyperplasia O O 0.9967795014381409
in O O 0.9999796152114868
2 O O 0.9999871253967285
of O O 0.9999775886535645
the O O 0.9999881982803345
13 O O 0.9999878406524658
patients O O 0.9999945163726807
. O O 0.9999748468399048

Our O O 0.9999672174453735
findings O O 0.9999935626983643
indicate O O 0.9999418258666992
that O O 0.9998729228973389
sustained O O 0.9924088716506958
- O O 0.9995120763778687
release O O 0.9860012531280518
nifedipine B B 0.9997784495353699
is O O 0.9999169111251831
useful O O 0.9999481439590454
for O O 0.9999215602874756
hypertensive O O 0.9938583970069885
psoriatic O O 0.9999604225158691
patients O O 0.9999878406524658
under O O 0.9999220371246338
long O O 0.9998406171798706
- O O 0.9999905824661255
term O O 0.9999765157699585
treatment O O 0.999984622001648
with O O 0.9997203946113586
cyclosporin B B 0.997251570224762
A I I 0.999762237071991
, O O 0.9994136095046997
but O O 0.999956488609314
that O O 0.9999779462814331
these O O 0.9999728202819824
patients O O 0.9999780654907227
should O O 0.9999550580978394
be O O 0.9999953508377075
monitored O O 0.9999868869781494
for O O 0.9999734163284302
gingival O O 0.9788569211959839
hyperplasia O O 0.9992520213127136
. O O 0.9999762773513794

